Modul 4 A - ROS1 positives ROS1-Inhibitor- naives NSCLC

Inhalt

Anhang 4G – Teil 1 409
Angaben zum Pooling der Daten aus STARTRK-2 und STARTRK-1, ALKA-372-001 und STARTRK-NG 409
Studiendesign und -methodik nach TREND 411
Studiendesign und -methodik für Studie ALKA-372-001 411
Studiendesign und -methodik für Studie STARTRK-1 430
Studiendesign und -methodik für Studie STARTRK-NG 451
Ergänzende Evidenz 470
Daten der STARTRK-2 470
Charakterisierung der Studienpopulation, Patientenverteilung und beteiligte Zentren 470
Endpunkte 666
Wirksamkeit 666
Patientenberichtete Endpunkte 757
Anhang 4G – Teil 2 9011
Verträglichkeit 9011
ROS1 SE 9011
Gesamt SE 16930
Sensititvitätsanalysen 28579
Anhang 4G – Teil 3 28636
Daten der gepoolten Analysen 28636
Charakterisierung der Studienpopulation, Patientenverteilung und beteiligte Zentren .. 28636
Endpunkte 28694
Wirksamkeit 28694
Verträglichkeit 28708
Sensititvitätsanalysen 30028

Teil 1 befindet sich in dieser Datei. Die Teile 2 und 3 befinden sich in separaten Dateien.

Anhang 4G – Teil 1

Angaben zum Pooling der Daten aus STARTRK-2 und STARTRK-1, ALKA-372-001 und STARTRK-NG

Das vorliegende Dossier basiert auf der einarmigen Studie STARTRK-2. Neben der STARTRK-2 wurden noch drei weitere Studien im Anwendungsgebiet ROS1+ ROS1-Inhibitor-naiven NSCLC durchgeführt (STARTRK-1, ALKA-372-001 und STARTRK-NG). Die ALKA-372-001 sowie STARTRK-1 waren Phase I/Ib-Dosiseskalationsstudien. In der Studie STARTRK-NG wurde die Wirksamkeit und Verträglichkeit von Entrectinib bei pädiatrischen Patienten untersucht.

Gepoolte Efficacy Evaluable Population

Für die gepoolte Efficacy Evaluable Population wurden alle Patienten aus STARTRK-1 und ALKA-372-001, die eine Dosierung von 600 mg/m^2 (Zulassungsdosierung) oder höher erhalten haben, mit den Patienten aus STARTRK-2 gepoolt und analysiert**.** Aufgrund des einarmigen Studiendesigns und des damit einhergehenden fehlenden Behandlungseffektes, wurde der Faktor „Studie“ bei der Auswertung nicht berücksichtigt.

Da die drei zugrundeliegenden Studien übereinstimmenden Prüfplänen folgten, wird von homogenen Studienpopulationen ausgegangen.

Es wurden alle patientenrelevanten Endpunkte, vorausgesetzt sie wurden in allen drei Studien erhoben, mit denselben statistischen Modellen wie unter Abschnitt 4.2.5.2 beschrieben auf Basis individueller Patientendaten metaanalytisch zusammengefasst.

Die präsentierten Ergebnisse basieren auf den drei einarmigen Studien (STARTRK-1, STARTRK-2 und ALKA-372-001), denen ein in den wesentlichen Punkten übereinstimmender Prüfplan zugrunde lag.

Gepoolte Safety Evaluable Population

Für die gepoolte Safety Evaluable Population wurden zusätzlich pädiatrische Patienten aus der Studie STARTRK-NG eingeschlossen. Analysen zur Verträglichkeit von Entrectinib wurden für folgende Populationen durchgeführt:

NTRK-Adult: Patienten mit NTRKf+ NTRK-Inhibitor-naiven soliden Tumoren aus den Studien STARTRK-1, STARTRK-2 und ALKA-372-001, die mindestens eine Gabe Entrectinib erhielten. Alle Patienten in dieser Analysepopulation haben ein Alter von 18 Jahren oder älter.

ROS1 NSCLC-Adult: Alle ROS1+ NSCLC Patienten aus den Studien STARTRK-1, STARTRK-2 und ALKA-372-001, die mindestens eine Gabe Entrectinib erhielten. Alle Patienten in dieser Analysepopulation haben ein Alter von 18 Jahren oder älter.

Other-Adult: Alle Patienten aus den Studien STARTRK-1, STARTRK-2 und ALKA-372-001, die mit ROS1+ non-NSCLC, ALK+ Tumoren oder ohne Gen-Fusion identifiziert wurden

und mindestens eine Gabe Entrectinib erhielten. Alle Patienten in dieser Analysepopulation haben ein Alter von 18 Jahren oder älter.

Total-Adult: Alle Patienten aus den Populationen NTRK-Adult, ROS1 NSCLC-Adult und Other-Adult.

Pediatric: Alle Patienten aus der Studie STARTRK-NG, die mindestens eine Gabe Entrectinib erhielten.

Total: Die Gesamt Safety Evaluable Population bestehend aus allen Patienten aus den Populationen Total-Adult und Pediatric.

Die Ergebnisse sind auf den Versorgungskontext übertragbar (siehe 4.3.2.3.2.1). Dies gilt für alle Endpunkte.

Studiendesign und -methodik nach TREND

Studiendesign und -methodik für Studie ALKA-372-001

Tabelle 4-90 (Anhang): Studiendesign und -methodik für Studie ALKA-372-001

Item[a]	**Charakteristikum**	**Studieninformation**
Studienziel		
2	Wissenschaftlicher Hintergrund und Erläuterung der Rationale	Die anaplastische Lymphomkinase (ALK) ist eine Rezeptortyrosin-Kinase (RTK), deren physiologische Expression hauptsächlich auf neuronale Zellen während der Entwicklung beschränkt ist. Eine Überaktivierung der Kinase durch Mutation wurde ursprünglich beim anaplastischen großzelligen Lymphom (ALCL) beobachtet. Gentische Aberrationen unter Involvierung des ALK-Gens wurden auch bei einer Untergruppe von Patienten mit nicht-kleinzelligem Lungenkarzinom (NSCLC), bei familiären und sporadischen Neuroblastomen, bei inflammatorischen myofibroblastischen Tumoren (IMTs) und bei anderen Krebsarten (systemische Histiozytose, inflammatorischer Brustkrebs (IBC), Glioblastom und undifferenzierter anaplastischer Schilddrüsenkrebs) festgestellt (Protokoll). Entrectinib ist ein oral bioverfügbarer potenter niedermolekularer ATP-kompetitiver Inhibitor der Kinaseaktivität der ALK und zählt zu den Indazolen. Entrectinib weist eine Kreuzreaktivität mit Rezeptoren der TRK-Familie (TRKA/B/C) sowie mit ROS1 auf. Die Inhibition erfolgt bereits im niedrigen nanomolaren Bereich (Protokoll). Entrectinib zeigt eine starke antitumorale Aktivität in ALK-abhängigen Tumorzelllinien und in Xenograftmodellen von ALK-getriebenem ALCL und NSCLC. In präklinischen Experimenten hatte Entrectinib ein akzeptables Sicherheitsprofil. Entrectinib kann die Blut-Hirnschranke passieren (Protokoll). Die Studie ALKA-372-001 ist eine Phase I-Studie, in der die Sicherheit, Pharmakokinetik und Antitumoraktivität von Entrectinib bei Patienten mit fortgeschrittenen/metastasierten soliden TRKA/B/C-, ROS1- oder ALK-positiven Tumoren untersucht wurde.
Methoden		
3	Probanden / Patienten	
3a	• Eignungskriterien für Studienteilnehmer, einschließlich der Kriterien auf verschiedenen	**Einschlusskriterien:**

Item[a]	**Charakteristikum**	**Studieninformation**
	Ebenen des Rekrutierungsplans / Plan zur Stichprobennahme (Sampling Plan) (z. B. Städte, Kliniken, Patienten) • Rekrutierungsmethode (z. B. Überweisung, Selbstauswahl) einschließlich der Methode zur Stichprobennahme (Sampling Method), falls ein systematischer Plan zur Stichprobennahme verwendet wurde • Vorgehensweise bei der Rekrutierung • Setting der Datenerhebung und Orte, an denen die Daten erhoben wurden	1. Unterzeichnete und datierte Einverständniserklärung; 2. Histologisch oder zytologisch gesicherte Diagnose eines fortgeschrittenen oder metastasierten soliden Tumors, welcher eine genetische Veränderung von TRKA/B/C-, ROS1- oder ALK aufweist und für dessen Behandlung keine effektive Standardtherapie verfügbar ist, diese als unpassend betrachtet wird oder abgelehnt wird; 3. Tumorgewebe zur Analyse muss vorhanden sein; 4. Vorangehende Krebstherapien sind erlaubt, mit Ausnahme von TRK-, ROS1- oder ALK- (gilt nur für nicht-NSCLC Patienten) Inhibitoren bei Patienten mit den oben genannten molekularen Veränderungen. Zum Zeitpunkt des Behandlungsbeginns müssen mindestens vier Wochen seit der letzten Krebstherapie vergangen sein bzw. fünf Halbwertszeiten, wenn keinerlei Toxizität aufgetreten ist (bei Nitrosoharnstoffen, Mitomycin C oder liposomalem Doxorubicin sechs Wochen); 5. Vorangegangene Radiandereapie ist erlaubt, wenn sichergestellt ist, dass nicht mehr als 25% der Knochenmarkreserven bestrahlt wurden; 6. Patienten mit einer kontrollierten, asymptomatischen ZNS-Beteiligung können in die Studie eingeschlossen werden. Die Verwendung von Medikamenten zur Anfalls-Prophylaxe sind erlaubt, solange die Patienten nicht-enzyminduzierende Antiepileptika (non-EIAEDs) erhalten. Patienten, die keine Steroide benötigen oder Steroide in einer stabilen Dosierung (≤ 4 mg/Tag Dexamethason oder Äquivalent) für mindestens zwei Wochen benötigen, sind geeignet; 7. Auflösung von allen akuten toxischen Effekten (mit Ausnahme von Alopezie) vorangegangener Krebstherapien, d.h. NCI CTC (Version 4.03) Grad ≤ 1 oder Rückgang der Laborwerte zu den in

		Einschlusskriterium 11 definierten Werten zu Baseline; 8. ECOG Performance Status ≤ 2; 9. Alter ≥18 Jahre; 10. Lebenserwartung von mindestens drei Monaten; 11. Die Laborwerte zu Baseline müssen folgende Kriterien erfüllen: - Absolute Neutrophilenzahl ≥ 1.500/mm^3 (≥ 1,5 × 10^9/L) - Thrombozyten ≥ 100.000/mm^3 (≥ 100 × 10^9/L) - Hämoglobin > 9,0 g/dL - Serumkreatinin ≤ 1,5 × ULN oder Kreatinin Clearance > 60 mL/min - Gesamtbilirubin im Serum ≤ 1,5 × ULN - AST/ALT ≤ 2,5 × ULN (≤ 5 × ULN bei Lebermetastasen) - ALP ≤ 2,5 × ULN (≤ 5 × ULN bei Leber- und/oder Knochenmetastasen) - Amylase und Lipase unterhalb des ULN - Bei Frauen im gebärfähigen Alter ein negativer Schwangerschaftstest innerhalb von sieben Tagen vor Behandlungsbeginn; 12. Vereinbarung bei zeugungs- bzw. gebärfähigen Frauen oder Männern, über die gesamte Studiendauer und 90 Tage nach Beendigung der Studienbehandlung mindestens zwei effektive Verhütungsmethoden anzuwenden (hormonelle Verhütungsmethode, Barrieremethode zur Verhütung oder Abstinenz) 13. Fähigkeit, Kapseln oder Tabletten zu schlucken ohne diese zu öffnen oder zu zerkleinern; 14. Bereitschaft, geplante Visiten, Behandlungsplan, Laboruntersuchungen und andere Untersuchungen durchführen zu lassen. **Ausschlusskriterien:** Patienten, die folgende Ausschlusskriterien erfüllen, konnten nicht in die ALKA-372-001 eingeschlossen werden: 1. Aktuelle Teilnahme an einer weiteren klinischen Studie; 2. Eine derzeit aktive weitere maligne Erkrankung, ausgenommen adäquat behandelte Basalzell- oder Plattenepithelkarzinome und/oder kegelförmig biopsiertes Carcinoma in situ der Cervix uteri und/oder oberflächlicher Blasenkrebs. Patienten mit jeglicher anderen

		Krebserkrankung müssen seit fünf oder mehr Jahren erkrankungsfrei sein; 3. Große chirurgische Eingriffe, ausgenommen diagnostische Operationen, innerhalb der letzten vier Wochen vor Behandlungsbeginn; 4. Mindestens eine der folgenden Erkrankungen innerhalb der letzten sechs Monate: Myokardinfarkt, instabile Angina pectoris, Koronararterien-Bypass/peripherer arterieller Bypass, symptomatische Herzinsuffizienz, cerebrovaskulärer Infarkt oder transiente ischämische Attacke, Lungenembolie oder tiefe Venentrombose; 5. Krankengeschichte eines verlängerten QTc-Intervalls (wiederholtes Auftreten von QTc Intervall > 450 Millisekunden); 6. Krankengeschichte mit weiteren Risikofaktoren für Torsade de pointes (Herzinsuffizienz, Hypokaliämie, familiäres Auftreten eines Long-QT-Syndroms); 7. Schwangere oder stillende Frauen; 8. Bekannte aktive Infektionen (bakteriell, durch Pilze oder viral inkl. HIV-Infektion); 9. Aktive gastrointestinale Erkrankungen (z.B. Morbus Crohn, Colitis ulcerosa oder Kurzdarmsyndrom) oder andere Malabsorptionssyndrome, welche die Absorption von Medikamenten beeinflussen würden; 10. Dokumentiertes gastrointestinales Ulkus; 11. Bekannte interstitielle Lungenerkrankung oder interstitielle Fibrose; 12. Andere schwerwiegende akute oder chronische medizinische oder psychiatrische Zustände oder Abweichungen in Laborparametern, die das Risiko einer Studienteilnahme oder das Risiko der Einnahme der Studienmedikation erhöhen oder die Beurteilunge der Studiendaten beeinflussen könnten und welche nach Ansicht des Prüfarztes den Patienten als ungeeignet für die Studie einstufen würden oder welche laut Prüfarzt und/oder Sponsor die Studienziele gefährden würden. **Rekrutierung:** Nach dem Unterschreiben der Einverständniserklärung wurde der Patient mit einer Screening-Nummer registriert. Diese Nummer wurde zentral vom Sponsor zugewiesen. Nach Beendigung der Screening-Untersuchungen wurde dem Patienten, falls er geeignet war, eine Patientennummer zugewiesen, die er für die gesamte Studiendauer behielt. Für die Zuweisung der

Item[a]	**Charakteristikum**	**Studieninformation**
		Patienten auf ein Dosierungsschema und dem entsprechenden Dosierungslevel war der Sponsor verantwortlich. Die Rekrutierung erfolgte in den Studienzentren auf Basis der festgelegten Ein- und Ausschlusskriterien. **Datenerhebung und Orte, an denen die Daten erhoben wurden** Die Studie fand in 2 Zentren in Italien statt.
4	Intervention	
4a	Details der vorgesehenen Interventionen für jede Studiensituation, wie und wann sie verabreicht wurden, und zwar einschließlich: • Inhalt: was wurde gegeben? • Verabreichungsmethode: wie wurde der Inhalt gegeben? • Verabreichungseinheit: wie wurden die Patienten während der Verabreichung eingeteilt? • Verabreicher: wer verabreichte die Intervention? • Umfeld: wo wurde die Intervention verabreicht? • Expositionsmenge und -dauer: wie viele Sitzungen oder Episoden oder Ereignisse sollten verabreicht werden? Wie lange sollten sie dauern? • Zeitspanne: wie lange sollte die Verabreichung der Intervention bei jeder Einheit dauern? • Aktivitäten zur Erhöhung der Compliance oder Adhärenz (z. B. Anreize)	**Studiendauer**: Einschluss des ersten Patienten: 26.10.2012 Zum Datenschnitt vom 31.05.2018 lagen die Daten der Patienten vor, die bis 30.11.2017 in ALKA-372-001 eingeschlossen wurden. Der letzte Patient wurde am 20.03.2018 eingeschlossen. **Arzneimittelverabreichung und Zeitspanne der Verabreichung** Entrectinib wurde als 50 mg, 100 mg und 200 mg Kapseln vom Sponsor zur Verfügung gestellt. Die Anzahl der benötigten Kapseln wurde vom Prüfarzt je Behandlungszyklus abgezählt. Der Patient bekam die Medikation ausschließlich für den aktuellen Behandlungszyklus und erst nachdem sichergestellt wurde, dass er das Behandlungsschema vollständig verstanden hatte. Die Studienmedikation wurde von den Patienten selbst zu Hause eingenommen. Alle Patienten führten ein Tagebuch, in welchem die Entrectinib-Dosierungen dokumentiert wurden. Hier waren auch Informationen zur Verabreichung der Studienmedikation sowie Anweisungen für den Fall, dass Medikamente unbeabsichtigt verschüttet wurde, hinterlegt. Adäquate Dokumentation von Empfang, Verbrauch, Rückgabe, Verlust oder anderer Verwendung der Studienmedikation musste gewährleistet sein. Ein spezielles Formular des Sponsors zur Dokumentation der Prüfmedikation oder die elektronische Dokumentation der Apotheke am Studienzentrum konnten hierfür verwendet werden. Informationen zur Bereitstellung und Verwendung der Studienmedikation an jeden einzelnen Patienten wurde bereitgestellt, vom Prüfarzt (oder dem Apotheker bzw. dem Beauftragten zur

		Verteilunge der Studienmedikation) unterschrieben und vom Monitor gesammelt. Am Ende der Studie wurde auf Anweisung des Sponsors die Medikation vor Ort vernichtet. Hier wurden entsprechende Standardprozeduren der teilnehmenden Institutionen angewendet oder die Medikation wurde zu einem Medikationsdepot zur Vernichtung weitergeleitet. Alternativ konnte alle unverbrauchte Studienmedikation nach entsprechender Verifikation durch den Monitor an den Sponsor zurückgeschickt werden. Die Vernichtung und/oder der Rückversand der Studienmedikation wurde entsprechend dokumentiert. **Dosierungspläne** Für die ALKA-372-001 wurden drei unterschiedliche Dosierungspläne untersucht. <u>Dosierungsplan A:</u> Für drei Wochen nimmt der Patient 4 Tage Entrectinib in der individuellen Dosierung, gefolgt von einer dreitägigen Pause. Nach drei Wochen folgt eine 7-tägige Pause, die den vierwöchigen Behandlungszyklus abschließt. Startdosis ist 100 mg/m2 KOF/Tag, die Einnahme erfolgt nüchtern ein- oder zweimal täglich. <u>Dosierungsplan B:</u> Für vier Wochen nimmt der Patient täglich Entrectinib in der individuellen Dosierung. Startdosis 200 mg/m2 KOF/Tag, die Einnahme erfolgt nach einer Mahlzeit ein oder zweimal täglich. <u>Dosierungsplan C:</u> Für vier Wochen nimmt der Patient 4 Tage Entrectinib in der individuellen Dosierung, gefolgt von einer dreitägigen Pause. Startdosis ist 400 mg/m2 KOF/Tag, die Einnahme erfolgt nach einer Mahlzeit ein- oder zweimal täglich. **Dosiseskalation** Die initiale Dosiseskalation von Dosierungsplan A beinhaltete ein beschleunigtes Titriationsdesign, bei dem eine 100%-Dosiseskalation je Kohorte vorgesehen war. Diese schnelle Eskalationsphase wurde eingeführt, um die Anzahl der Patienten mit einem niedrigen Medikationslevel und damit einer niedrigeren Wahrscheinlichkeit auf einen Behandlung-Nutzen zu reduzieren. Dies wurde fortgeführt, bis bei einem Patienten im ersten Behandlungszyklus eine medikationsbezogene DLT oder bei zwei Patienten in jeglicher Dosierung eine

		medikationsbezogene Non-DLT mit CTCAE Grad ≥ 2 während des ersten Behandlungszyklus auftrat. Neben den genannten Toxizitäten folgte die Dosiseskalation einem modifizierten Fibonacci-Schema (50, 40 or 33% Schritte). Nachdem jede Kohorte die Behandlung abgeschlossen hatte, wurden die verfügbaren Daten zu Sicherheit und Pharmakokinetik geprüft und die Dosiseskalation zwischen Prüfarzt und Sponsor beschlossen. In beiden Eskalationsphasen begannen mindestens drei Patienten in jedem Dosislevel. • Wenn bei 0/3 Patienten im ersten Behandlungszyklus keine DLT auftraten, startete die nächste Kohorte ein Dosislevel höher • Wenn bei 1/3 Patienten im ersten Behandlungszyklus DLT auftraten, starten weitere drei Patienten mit diesem Dosislevel; wenn bei 1/6 Patienten im ersten Behandlungszyklus DLT auftraten, startete die nächste Kohorte ein Dosislevel höher • Wenn bei ≥2/3 oder ≥2/6 Patienten im ersten Behandlungszyklus DLT auftraten, galt die MTD als erreicht. Zur Definition der MTD wurden drei weitere Patienten auf das vorangegangene Dosislevel oder sechs Patienten auf ein mittleres Dosislevel gesetzt. Nur ein Dosislevel pro Dosierungsplan war für den Einschluss zur gleichen Zeit geöffnet. Es war geplant, dass die ersten zwei Patienten jeder Kohorte mit einem Abstand von zwei Wochen starten. Sollten beim ersten Patienten im Rahmen des ersten Behandlungszyklus keine DLT auftreten, konnte der dritte Patient jederzeit eingeschlossen werden. Sind beim ersten Patienten DLT aufgetreten, konnte der dritte Patient erst starten, wenn beim zweiten Patienten kein DLT im ersten Behandlungszyklus aufgetreten sind. Wenn eine Kohorte um drei weitere Patienten ergänzt wurde, begannen diese ihre Behandlung nach dem gleichen Schema. Der dritte oder sechste Patient jeder Kohorte musste für einen Behandlungszyklus beobachtet werden, bevor weitere Patienten auf eine höhere Dosis gesetzt werden konnten. Wenn ein Patient weniger als 75% des ersten Behandlungszyklus abgeschlossen hat, musste ein weiterer Patient auf dem gleichen Dosislevel eingeschlossen werden. **Compliance**

Item[a]	**Charakteristikum**	**Studieninformation**
		Verwendete Studienmedikation, die Anzahl der Behandlungszyklen, aktuelle und gesamt verbrauchte Dosis, Dosismodifikationen, Dosierungsverzögerungen und Dosisunterbrechungen sowie alle Abweichungen zur geplanten Einnahme wurden über den Zeitraum der Studie dokumentiert und zusammengefasst.
5	Zielsetzungen	
5a	• Spezifische Studienziele und Hypothesen	**Primäres Studienziel** Bestimmung der dosis-limitierenden Toxizität (DLT) im ersten Behandlungszyklus und der maximal verträglichen Dosis (MTD) von Entrectinib in einer oralen Formulierung in verschiedenen Behandlungsschemata bei Patienten mit fortgeschrittenen/metastasierten soliden Tumoren mit TrkA, TrkB, TrkC-, ROS1- oder ALK-Genumlagerung anhand der: • DLTs im ersten Behandlungszyklus • MTD **Sekundäre Studienziele** Die Definition des Sicherheits-Profils von Entrectinib charakterisiert durch Typ, Schweregrad (nach NCI CTCAE Version 4.03), Timing und der Kausalität von Studienbehandlung und UE/abnormer Laborparameter im ersten und folgenden Behandlungszyklen. Die Evaluation der Pharmakokinetik von Entrectinib im Plasma, definiert durch die Plasmakonzentration von Entrectinib zu unterschiedlichen Zeitpunkten nach Dosierung und der zugehörigen Bewertung von C_{max}, t_{max}, $t_{1/2,z}$, AUC_{daily} und $AUC_{tlast.}$ Die Dokumentation der Anti-Tumor-Aktivität von Entrectinib anhand des objektiven Tumoransprechens gemäß der RECIST v1.1. **Hypothesen** Da es sich um eine Phase I Studie (First in human) handelt, wurden keine Hypothesen generiert.
6	Zielkriterien	

Item[a]	**Charakteristikum**	**Studieninformation**
6a	• Klar definierte primäre und sekundäre Wirksamkeitsmessgrößen • Methoden zur Datenerhebung und Methoden zur Verbesserung der Qualität von Messungen • Informationen über validierte Instrumente wie z. B. psychometrische und biometrische Eigenschaften von Selbsterhebungsinstrumenten	**Analyse der primären Wirksamkeits-Endpunkte** **Dosis-limitierende Toxizität (DLT) im ersten Behandlungszyklus und maximal verträgliche Dosis (MTD)** Alle Toxizitäten wurden nach der NCI CTCAE Version 4.03 bewertet. Im Rahmen dieser Studie war eine DLT definiert als eines der nachfolgend aufgeführten Ereignisse, für die ein Zusammenhang mit Entrectinib nicht vollständig ausgeschlossen werden kann: • Hemotologische Toxizität o Neutropenie Grad 4, die länger als 7 Tage anhält o Febrile Neutropenie o Neutropenische Infektion ≥ Grad 3 o Thrombozytopenie Grad 4 o Thrombozytopenie Grad 3, die länger als 7 Tage andauert oder mit einer Blutung ≥ Grad 2 zusammenhängt • Übelkeit/Übergeben o Nausea ≥ Grad 3 trotz optimierter antiemetischer Therapie • Diarrhoe o Diarrhoe ≥ Grad 3 trotz optimierter Behandlung des Ereignisses • ZNS-Toxizität o ≥ Grad 2, die der Studienmedikation zugerechnet werden kann und eine Veränderung von mindestens 2 CTCAE-Graden seit Studienbeginn • Andere nicht-hämatologische Toxizitäten o Toxizitäten ≥ Grad 3, die der Studienmedikation zugerechnet werden können und eine Veränderung von mindestens 2 CTCAE-Graden seit Studienbeginn o Asymptomatische Laborveränderungen (mit Ausnahme der Leber- und Nierenwerte) die erfolgreich supplementiert werden konnten, wurden nicht als DLT gewertet; eine asymptomatische Grad 4 Lipase/Amylase wurde als DLT gewertet • Keine vollständige Genesung von dem Ereignis (mit Ausnahme Alopezie) o Keine vollständige Erholung von Toxizitäten auf ein Level von ≤ Grad 1 oder auf Werte zu Studienbeginn (wenn ein Grad von 2 zu

		Studienbeginn erlaubt war) nach einer Verzögerung des nächsten Behandlungszyklus um maximal 14 Tage o Für die Dosispläne A, B und C ein Nicht-beenden des ersten Behandlungszyklus aufgrund von Toxizitäten mit Entrectinib-Bezug mit mind. 75% der geplanten Dosen Wenn eine DLT allein auf einem Laborwert basierte, musste mindestens ein wiederholter Wert innerhalb von 24h erhoben werden um die DLT zu bestätigen. MTD ist definiert als das Dosislevel, bei welchem 0/6 oder 1/6 Patienten im ersten Behandlungszyklus eine DLT und 2/3 oder 2/6 Patienten unter der nächsthöheren Dosierung ebenfalls eine DLT erfahren. Wenn eine Dosierung als sicher bewertet wurde, wurden weitere Patienten eingeschlossen (insgesamt 15 Patienten, inkl. der bereits behandelten) und ihre Verträglichkeitsprofile wurden für die Definition der MTD evaluiert. Die MTD war die höchste Dosis, bei der weniger als 33% der Patienten im Rahmen des ersten Behandlungszyklus DLTs erfuhren. Diese Dosis konnte ebenso die RP2D für die weitere Studie sein. Jeder Dosisplan konnte eine andere RP2D haben. **Analyse der sekundären Wirksamkeits-Endpunkte** **Objektives Ansprechen des Tumors** **Erhebung des Tumorstatus** Vor Behandlungsstart war ein CT des gesamten Körpers sowie des Gehirns verpflichtend, mit Ausnahme von Glioblastoma-Patienten: hier war nur ein MRT des Gehirn**s** akzeptiert. Mit dem sechsten Protokoll-Amendment mussten alle bildgebenden Tumorbewertungen (CT oder MRT) des Thorax und des Abdomen innerhalb von vier Wochen vor Behandlungsbeginn erfolgen. Durch die Häufigkeit von Hirnmetastasen wurde für Patienten mit NSCLC im Rahmen des Screenings ein Gehirn-Scan erstellt. Bei Patienten mit Knochenmetastasen war ein Knochenscan innerhalb von vier Wochen vor Behandlungsbeginn erforderlich. Während der Behandlung wurde die Tumorbewertung zu jedem geraden Zyklus durchgeführt (d.h. am Ende von Zyklus 2, 4, 6 etc.) oder wenn eine klinische Verschlechterung festgestellt wurde und bei Beendigung der Behandlung (sofern mehr als 4 Wochen seit der letzten Bildgebung

		vergangen sind). Mit dem sechsten Protokoll-Amendment wurde der Bewertungszeitpunkt auf das Ende von Zyklus 1 und anschließend alle 8 Wochen festgelegt. Für Patienten mit 12 oder mehr Zyklen war eine Bildgebung nur noch alle 12 Wochen erforderlich. Alle Scans wurden vor Ort eingelesen und das Tumoransprechen nach RECIST v1.1 evaluiert. CT-Scans waren die bevorzugte Methode zur Messung von Läsionen, aber auch MRT wurde akzeptiert (mit Ausnahme bei Lungen-Läsionen). Die jeweilige Methode und Technik zur Bewertung wurde über den gesamten Studienzeitraum beibehalten. Bildgestützte Bewertung war gegenüber der klinischen Bewertung die bevorzugte Methode, um den Antitumor Effekt der Behandlung zu messen. Für Patienten mit einer Tumoransprache (Gesamtansprechen oder partielles Ansprechen) erfolgte die Bestätigung des Ansprechens nach nicht weniger als vier Wochen, nachdem die Kriterien des Tumoransprechens zum ersten Mal erreicht wurden. Darauffolgend wurde die nächste onkologische Bewertung am Ende jedes zweiten Zyklus zur Bestätigung wiederholt. Bei Patienten, die die Studie aus anderen Gründen als Progression beendet haben, wurde das Tumoransprechen zum Absetzen der Medikation wiederholt. Für diese Patienten erfolgte eine reguläre Tumorbewertung alle 8 Wochen im Rahmen des Follow-Up bis zur Progression oder bis eine neue Antitumor-Therapie begonnen wurde. Alle Patientenakten und Scans wurden zur Source-Verifizierung bereitgestellt. **Unabhängiges Bewertungsgremium (BICR):** Mit dem achten Protokoll-Amendment wurde die Möglichkeit einer unabhängigen Bewertung aller Scans auf Anfrage eingerichtet. Die Scans wurden an ein unabhängiges Labor für Bildgebung übermittelt. Dort fand die unabhängige Überprüfung des Tumoransprechens und der Krankheitsprogression während der Studie statt. **Evaluationskriterien für das Ansprechen bei soliden Tumoren** Für die Messung und Definition der Tumorveränderung wurden standardmäßig die Kriterien nach RECIST v1.1 verwendet. Zu Studienbeginn wurden die

Tumorläsionen vom Prüfarzt als messbar oder nicht messbar kategorisiert.

Maximal wurden insgesamt 5 messbare Läsionen (maximal 2 Läsionen pro Organ) als Zielläsionen bewertet und waren so repräsentativ für alle betroffenen Organe. Diese Zielläsionen wurden zu Studienbeginn identifiziert und zu jedem festgelegten Zeitpunkt gemessen und dokumentiert.

Alle anderen Läsionen wurden als Nicht-Zielläsionen zu Studienbeginn festgelegt und dokumentiert. Hier waren keine Messungen sondern nur eine Bewertung als „vorhanden“, „abwesend“ oder, in seltenen Fällen, „eindeutige Progression“ notwendig.

Waren Ziel- und Nicht-Zielläsionen vorhanden, so wurde die individuelle Bewertung separat dokumentiert. Die Gesamtbewertung des Ansprechens beinhaltete alle in der Tabelle aufgeführten Parameter:

Zielläsion	**Nicht-Zielläsion**	**Neue Läsionen**	**Gesamt-ansprechen**
CR	CR	Nein	CR
CR	Kein CR oder PD	Nein	PR
CR	Nicht evaluiert	Nein	PR
PR	Keine PD oder nicht alle evaluiert	Nein	PR
SD	Keine PD oder nicht alle evaluiert	Nein	SD
Nicht alle evaluiert	Keine PD	Nein	NE
PD	Jedes Ansprechen	Ja oder Nein	PD
Jedes Ansprechen	PD	Ja oder Nein	PD
Jedes Ansprechen	Jedes Ansprechen	Ja	PD

CR: totales Ansprechen; PD: Krankheitsprogression; PR: partielles Ansprechen; SD: stabile Erkrankung; NE: nicht bewertbar;

Um den Status eines PR oder CR zu erhalten, musste die Veränderung der Tumormessung bei Patienten mit einem Ansprechen nach mehr als vier Wochen nach den ersten Zeichen des Ansprechens durch eine weitere Bildgebung und Messung bestätigt werden.

Im Falle einer stabilen Erkrankung mussten die SD-Kriterien mindestens einmal nach Studieneinschluss innerhalb von mindestens acht Wochen erfüllt sein.

Hinweis:

Die Dauer des Ansprechens (DOR), Dauer der stabilen Erkrankung (SD), progressionsfreies Überleben und

Item[a]	**Charakteristikum**	**Studieninformation**
		Gesamtüberleben waren keine Wirksamkeitsendpunkte dieser Studie. Individuelle Evaluationen und zusammenfassende Auswertungen für behandelte und analysierbare Patienten waren als explorative Analysen geplant. **Bestes Gesamtansprechen** Bestes Gesamtansprechen (BOR, best overall response) ist das beste Gesamtansprechen, das zwischen Behandlungsbeginn bis zum Behandlungsende dokumentiert wurde. Das BOR eines jeden Patienten hängt ab von den Veränderungen der Zielläsionen und Nicht-Zielläsionen sowie vom Auftreten neuer Läsionen. Im Falle einer stabilen Erkrankung mussten die SD-Kriterien nach mindestens 8 Wochen nach Studieneintritt erfüllt worden sein. Die genauen Kriterien für die Bewertung finden sich im Studienbericht der ALKA-372-001 Seite 40. Eine allgemeine Verschlechterung des Gesundheitszustands, die einen Abbruch der Behandlung erforderlich machte, jedoch ohne Hinweis auf eine Krankheitsprogression, wurde als „systematische Verschlechterung“ bewertet. Auch nach Beendigung der Behandlung sollte alles versucht werden, eine mögliche objektive Progression zu dokumentieren. Eine systematische Verschlechterung war keine Beschreibung eines objektiven Ansprechens, aber ein Grund zum Beenden der Therapie. Das objektive Ansprechen dieser Patienten wurde über die Bewertung der Zielläsionen und Nicht-Zielläsionen bestimmt. **Analyse der Sicherheitsendpunkte** **Unerwünschte Ereignisse** Für jeden Patienten wurden UE dokumentiert. Die Beobachtung von UE begann mit der ersten Einnahme von Entrectinib und wurde fortgesetzt bis zum telefonischen Follow-Up-Kontakt 30 Tage nach der letzten Einnahme von Entrectinib. Alle UE, die bei der Behandlung auftraten, wurden nach NCI CTCAE v4.03 eingestuft und mit dem Medical Dictionary for Regulatory Activities (MedDRA Version 17.0) kodiert. Weitere Endpunkte umfassen Elektrokardiogramme, Pharmakokinetik, Pharmakodynamik und Tumormarker.

Item[a]	**Charakteristikum**	**Studieninformation**
7	Fallzahl	
7a	• Wie wurden die Fallzahlen bestimmt?	Es wurde eine gesamte Patientenzahl von etwa N=70 vorauskalkuliert. Da im Studiendesign für die Identifikation der MTD sequentielle Dosis-Eskalations-Stufen vorgesehen waren, konnte die Anzahl von eingeschlossenen und behandelten Patienten von der vorausberechneten Anzahl abweichen. Relevant hierfür war die beobachtete Toxizität und der darauf resultierende Einfluss auf die Kohortengröße und die Anzahl untersuchter Dosislevel.
7b	• Falls notwendig, Beschreibung von Zwischenanalysen und Kriterien für einen vorzeitigen Studienabbruch	Es wurden keine Zwischenanalysen vorab geplant. **Kriterien für einen vorzeitigen Studienabbruch:** - Progression zu jeglichem Zeitpunkt, außer es gibt angemessene Evidenz für einen klinischen Benefit, der das Fortführen der Behandlung begründet (in Rücksprache mit dem Sponsor - Nicht vertretbare Toxizitäten - Veränderung des medizinischen Status des Patienten (inkl. Schwangerschaft), so dass der Prüfarzt/Sponsor eine Beeinträchtigung der Sicherheit des Patienten befürchtet oder ein Beenden der Behandlung im besten Sinne des Patienten ist. - Rücknahme der Einverständniserklärung - Der Patient weigert sich, die Studienbehandlung fortzuführen - Fehlende Compliance des Patienten mit den Anforderungen aus dem Studienprotokoll - Der Patient ist nicht mehr erreichbar (Lost-to-Follow-up)
8	Zuweisungsmethode • Zuweisungseinheit (die Einheit, die der Studienbedingung zugewiesen wird, wie z. B. Person, Gruppe, Gemeinde) • Methode der Zuweisung von Einheiten zu Studienbedingungen, einschließlich Details über etwaige Restriktion (z. B. Blockbildung, Stratifikation, Minimierung) • Einbeziehung von Aspekten, um potenzielle Verzerrung durch Nichtrandomisierung zu minimieren (z. B. Matching)	**Zuweisung** Nicht zutreffend. Die Studie ist nicht randomisiert.
9	Verblindung	
9a	• Waren a) die Probanden / Patienten und / oder b) diejenigen, die die Intervention / Behandlung durchführten, und / oder c) diejenigen, die die Zielgrößen beurteilten, verblindet oder nicht	**Verblindung** Nicht zutreffend. Einarmige Phase I-Studie

Item[a]	**Charakteristikum**	**Studieninformation**
	verblindet, wie wurde die Verblindung vorgenommen?	
10	Analyseeinheit • Bezeichnung der kleinsten Einheit, die analysiert wird, um Wirkungen der Intervention zu beurteilen (z. B. Person, Gruppe, Gemeinde) • Wenn sich die Analyseneinheit von der Zuweisungseinheit unterscheidet, ist die verwendete Analysenmethode anzugeben, die dies berücksichtigt (z. B. Adjustierung der Standardfehlerschätzungen um den Designeffekt oder durch Verwendung einer Multilevel-Analyse)	Die Analysen wurden für jeden vorab festgelegten Dosierungsplan (A, B und C) durchgeführt.
11	Statistische Methoden	
11a	• Statistische Methoden zur Bewertung der primären und sekundären Zielkriterien einschließlich komplexer Methoden für korrelierte Daten	**Grundsätzliche statistische Methoden** Für alle Variablen wurden zusammenfassende Tabellen nach Dosierungsplan, Dosierungsansatz, zugewiesenem Dosierungslevel und Studienabschnitt/Visite mittels deskriptiver Statistik dargestellt. Stetige Variablen wurden mittels N, Mittelwert, Standardabweichung, Median, Minimum und Maximum dargestellt. Für alle kategorialen Variablen wurden absolute und relative Werte jeder Kategorie dargestellt. Die Häufigkeit fehlender Werte wurde nur dargestellt, wenn diese >0 für mindestens eine Behandlungsgruppe waren. Es wurden keine formalen Signifikanztests für die primäre Analyse durchgeführt. Für ausgewählte Wirksamkeitsparameter wurden 95%-Konfidenzintervalle berechnet. UE und Laborparameter wurden nach NCI CTCAE (Version 4.03) erfasst und mithilfe des Medical Dictionary for Regulatory Activities (MedDRA; version 15.1) kodiert. Die Antitumoraktivität von Entrectinib wurde über das vom Prüfarzt bestimmte objektive Ansprechen nach RECIST v1.1 bewertet. Vorangegangene Medikamente und Begleitmedikation wurde nach der WHO-DRL vom März 2014 kodiert. **Analyse der Wirksamkeitsendpunkte** Das objektive Tumoransprechen war ein sekundärer Endpunkt dieser Studie. Das Tumoransprechen basiert auf der standardmäßigen Bewertung des Prüfarztes von Zielläsionen, Nicht-Zielläsionen und

Item[a]	**Charakteristikum**	**Studieninformation**
		neuer Läsionen über die Kriterien von RECIST v1.1. Die Objektive Ansprechrate und die Rate des besten Ansprechens wurde für behandelte und auswertbare Patienten berechnet. Die Summe der Durchmesser der Zielläsionen, die prozentuale Veränderung seit Studienbeginn und seit der niedrigsten vorangegangenen Summe (d.h. des Nadirs) wurden berechnet. Zur graphischen Darstellung der besten prozentualen Veränderung der Durchmesser-Summe von Zielläsionen seit Studienbeginn wurden für jeden behandelten und auswertbaren Patienten Wasserfall-Plots erstellt. **Time-to-Event-Analysen** Dauer SD, PFS und OS: Berechnung vom ersten Tag der Einnahme von Entrectinib bis zum Datum des entsprechenden Events in Monaten. **DOR** wurde für alle Patienten mit einem Ansprechen (CR oder PR) berechnet als Zeit vom ersten Ansprechens bis zum Progress oder Tod in Monaten. Patienten, die nicht während der Studie verstarben, wurden für den Endpunkt **OS** zu dem Datum, an dem sie wissentlich noch am Leben waren, zensiert. Für andere Endpunkte wurden Patienten, bei denen nicht das entsprechende Ereignis aufgetreten ist, zum Zeitpunkt ihrer letzten Tumorbewertung zensiert. Patienten ohne Tumorbewertung nach der ersten Einnahme von Entrectinib wurden zu Tag 1 zensiert. Alle Time-to-Event Endpunkte wurden mithilfe der Kaplan-Meier-Methode analysiert und die zugehörigen Kaplan-Meier-Kurven für DOR, PFS und OS für behandelte und auswertbare Patienten erstellt. Wenn die Möglichkeit bestand, wurde die mediane Überlebenszeit zusammen mit den 25%- und 75%-Perzentilen, sowie dem 95%-KI dargestellt. Zusätzlich wurden die absoluten und relativen Häufigkeiten der Patienten mit Ereignis oder der zensierten Patienten dargestellt.
11b	• Verwendete statistische Methoden für zusätzliche Analysen, wie z. B. Subgruppenanalysen und adjustierte Analysen • Methoden zur Imputation fehlender Daten • Falls verwendet: Verwendete statistische Software oder Programme	Subgruppenanalysen waren nicht geplant. **Fehlende Daten** • Wenn im Rahmen der Erhebung demographischer und krankheitsbezogener Daten die Angabe auf eine JA/NEIN Frage fehlte, wurde die Antwort auf Ja gesetzt, wenn auf dem entsprechenden Formular

Item[a]	**Charakteristikum**	**Studieninformation**
		mindestens ein Hinweis auf das Vorliegen der entsprechenden Daten vermerkt war. • Wurde ein Labortest zu einem Zyklus mit fehlender Behandlung oder fehlendem Datum berichtet, so wurde dieser dem letzten Zyklus mit valider Behandlung und Datum zugeteilt.
Resultate		
12	Patientenfluss	
12a	• Patientenfluss durch jede Studienphase: Rekrutierung, Zuweisung, Allokation und Interventionsexposition, Nachbeobachtung, Analyse (Diagramm siehe unten)	
12b	• Rekrutierung: die Anzahl der Teilnehmer, die auf ihre Eignung gescreent werden, sich als geeignet oder nicht geeignet erweisen, nicht in die Studie aufgenommen und in die Studie aufgenommen werden • Zuweisung: die Anzahl der Teilnehmer, die einer Studienbedingung zugewiesen wurden • Allokation und Interventionsexposition: die Anzahl der Teilnehmer, die jeder Studienbedingung zugewiesen werden, und die Anzahl der Teilnehmer, die jede Intervention erhielten • Nachbeobachtung: die Anzahl der Teilnehmer, die das Follow-up abschlossen oder das Follow-up nicht abschlossen (lost to follow-up), aufgeschlüsselt nach Studienbedingungen • Analyse: die Anzahl der Teilnehmer, die in die Hauptanalyse einbezogen oder ausgeschlossen wurden, aufgeschlüsselt nach Studienbedingungen • Beschreibung von Abweichungen vom Prüfplan der Studie unter Angabe von Gründen	Zwischen 10.10.2012 und 30.11.2017 wurden 141 Patienten gescreent, um an ALKA-372-001 teilzunehmen; davon wurden 58 Patienten eingeschlossen. Somit wurden 83 Patienten nicht in die Studie aufgenommen. Die Gründe hierfür waren wie folgt: - Fehlende klinische Eignung (z.B. Hirnmetastasen, abnormale Laborwerte, klinische Verschlechterung) N=14 - Fehlende Eignung aufgrund der molekularen Analyse N=67 - Entschluss des Patienten N=1 - Keine Informationen vorhanden N=1 Von den 58 eingeschlossenen Patienten erhielten 57 Patienten mindestens eine Dosis Entrectinib. In der Studie wurden drei unterschiedliche Dosierungspläne untersucht. Zunächst war geplant, nur Dosierungsplan A zu prüfen, mit dem Protokoll-Amendment Nr. 3 vom 05. Dezember 2013 wurden die Dosierungspläne B und C ergänzt. Mit der Initiierung von Amendment 3 wurden keine weiteren Patienten in den Dosierungsplan A eingeschlossen. Da für einen Patienten eine höhere Dosierung analog zu Dosierungsschema A aufgrund des erwarteten klinischen Nutzens durch den Prüfarzt als sinnvoll erachtet wurde, wurde dieser Patient in den Dosierungsplan C mit einer Dosis von 400 mg/m2 KOF eingeschlossen. Die Patienten wurden in zwei verschiedenen Zentren in Italien rekrutiert. Von den 57 Patienten, die mit Entrectinib behandelt wurden, wurden 19 nach Dosierungsplan A behandelt, 32 nach

Item[a]	**Charakteristikum**	**Studieninformation**
		Dosierungsplan B und 6 nach Dosierungsplan C. Zum Clincal cut-off date (31. Mai 2018) wurden 2 von 58 Patienten (3,4 %) weiterhin mit Entrectinib behandelt.
13	Aufnahme / Rekrutierung	
13a	• Nähere Angaben über den Zeitraum der Studienaufnahme der Probanden / Patienten und der Nachbeobachtung	Die Ergebnisse des Interimsdatenschnitts vom 31.05.2018 beinhalten die Daten vom 26.10.2012 (first patient enrolled) bis zum CCOD am 31.05.2018 für Patienten, die bis zum 30.11.2017 eingeschlossen wurden. **Nachbeobachtung** Es war ein regulärer Follow-Up bis 28 Tage nach Behandlungsende vorgesehen. Bestimmte Ereignisse sollten auch über diesen Zeitraum hinaus beobachtet werden: • Alle SUE mit den Outcomes „not recovered“ oder „unknown“ zum Ende des Berichtszeitraums. • Alle UE, für die ein Kausalzusammenhang mit Entrectinib dokumentiert wurde mit den Outcomes „not recovered“ oder „unknown“ zum Ende des Berichtszeitraums. Diese Ereignisse sollten bis zum endgültigen Auflösen weiterverfolgt werden bzw. bis der Prüfarzt die Ereignisse als „chonisch“ oder „stabil“ bewertet. Weiter sollte jede unerwartete schwerwiegende Nebenwirkung und jeder Todesfall auch nach dem Berichtszeitraum an den Sponsor weitergeleitet werden, wenn dieses/dieser möglicherweise im Zusammenhang mit Entrectinib steht.
13b	• Informationen, warum die Studie endete oder beendet wurde	Die Studie läuft noch
a: nach TREND 2004.		

Stellen Sie für jede Studie den Patientenfluss in einem Flow-Chart gemäß CONSORT dar.



Abbildung 4-68 Patientenfluss der ALKA-372-001 (Datenschnitt NDA)

Studiendesign und -methodik für Studie STARTRK-1

Tabelle 4-91 (Anhang): Studiendesign und -methodik für Studie STARTRK-1

Item[a]	**Charakteristikum**	**Studieninformation**
Studienziel		
2	Wissenschaftlicher Hintergrund und Erläuterung der Rationale	Entrectinib ist ein oral bioverfügbarer Inhibitor der Tropomyosin-Rezeptor-Kinasen TRKA (codiert durch das NTRK1), TRKB (codiert durch das NTRK2), TRKC (codiert durch das NTRK3), des ROS Protoonkogen-Tyrosinproteinkinase 1 (ROS1, codiert durch das Gen ROS1) und der anaplastischen Lymphomkinase (ALK, codiert durch das Gen ALK) mit IC_{50}-Werten im niedrigen nanomolaren Bereich. Molekulare Veränderungen dieser Zielstrukturen finden sich bei verschiedenen Tumorarten, darunter nicht-kleinzelliges Lungenkarzinom (NSCLC), Dickdarmkrebs (CRC), papilläres Schilddrüsenkarzinom, Bauchspeicheldrüsenkrebs und Neuroblastom. Genetische Veränderungen können durch Next Generation Sequencing (NGS), quantitative Polymerase-Kettenreaktion (qPCR), Fluoreszenz-in-Situ-Hybridisierung (FISH) und/oder Immunhistochemie (IHC) nachgewiesen werden (Protokoll). Die Erstanwendung am Menschen von Entrectinib fand im Rahmen der Studie ALKA-372-001 mit Durchführung in Italien statt. STARTK-1 ist eine Phase I-Studie, in der die Sicherheit und Wirksamkeit von Entrectinib bei erwachsenen Patienten mit einem lokal fortgeschrittenen oder metastasierten soliden Tumor untersucht wird. Die Studie wurde in zwei Abschnitten durchgeführt. Im Dosiseskalations-Abschnitt sollten die dosis-limitierenden Toxizität (DLT) im ersten Behandlungszyklus, die maximal verträgliche Dosis (MTD) und/oder eine biologisch effektive und empfohlene Phase II-Dosierung (RP2D) bestimmt werden. In diesem Abschnitt wurden vorzugsweise Patienten mit soliden Tumoren, die molekulare Veränderungen in NTRK1/2/3, ROS1 oder ALK aufwiesen, eingeschlossen. Dies war allerdings kein Einschlusskriterium. Im Dosisexpansions-Abschnitt sollte die Antitumoraktivität von Entrectinib bei Patienten, die RP2D erhalten, weiter untersucht werden. In diesem Abschnitt mussten die Patienten bestimmte molekulare Veränderungen in NTRK1/2/3, ROS1 oder ALK haben, die entweder lokal oder zentral identifiziert wurden (Protokoll).

Item[a]	**Charakteristikum**	**Studieninformation**
Methoden		
3	Probanden / Patienten	
3a	• Eignungskriterien für Studienteilnehmer, einschließlich der Kriterien auf verschiedenen Ebenen des Rekrutierungsplans / Plan zur Stichprobennahme (Sampling Plan) (z. B. Städte, Kliniken, Patienten) • Rekrutierungsmethode (z. B. Überweisung, Selbstauswahl) einschließlich der Methode zur Stichprobennahme (Sampling Method), falls ein systematischer Plan zur Stichprobennahme verwendet wurde • Vorgehensweise bei der Rekrutierung • Setting der Datenerhebung und Orte, an denen die Daten erhoben wurden	**Einschlusskriterien:** 1. Bereitschaft und Fähigkeit, eine vom „Institutional Review Board“ (IRB)/von der unabhängigen Ethikkommission genehmigte schriftliche Einverständniserklärung abzugeben. 2. Histologisch oder zytologisch gesicherte Diagnose eines rezidivierten oder refraktären lokal fortgeschrittenen oder metastasierten soliden Tumors, für den keine alternative effektive Standradtherapie verfügbar ist oder der für eine Standardtherapie als nicht geeignet oder intolerant betrachtet wird. **Dosiseskalations-Abschnitt**: Der Fokus liegt auf dem Einschluss von Patienten mit soliden Tumoren, die eine molekulare NTRK1/2/3-, ROS1- oder ALK-Veränderung aufweisen; dies ist jedoch kein Einschlusskriterium. **Dosisexpansions-Abschnitt**: Patienten mit lokal fortgeschrittenen oder metastasierten soliden Tumoren, die folgende molekulare Veränderungen aufweisen: • NTRK-Genumlagerung (Fusionen), die vorher mit anderen TRK Inhibitoren behandelt wurden; • ALK-Genumlagerung mit 1198 Resistenz-SNP • ALK^{ATI} • NTRK/ROS/ALK Überexpression > 6 (via RNA) • Aktivierende Spleißvarianten • Andere molekulare Veränderungen, die aufgrund ihrer biologischen Rationale und nach Diskussion mit dem Sponsor interessant sind. Anmerkung: Wenn bei einer Untergruppe von 6 Patienten mit der gleichen molekularen Veränderung kein Ansprechen erkennbar ist, ist diese molekulare Veränderung nicht länger von klinischem Interesse und der Einschluss in diese Kategorie wird beendet. 3. Analysierbares Tumorgewebe wird für den Dosiseskalations-Abschnitt nicht benötigt, ist aber im Dosisexpansions-Abschnitt gewünscht (falls klinisch möglich). Nur nicht-ZNS-Läsionen können erneut biopsiert werden. Sie dürfen nur ein

		minimales Risiko für den Patienten darstellen (z. B. perkutane Biopsie). 4. Vorhandensein messbarer Tumorläsion/en nach RECIST-Kriterien (Version 1.1, v1.1) 5. Vorangehende Krebstherapien sind erlaubt, einschließlich Crizotinib, Ceritinib und Arzneimittel in der klinischen Erprobung. Zum Behandlungsbeginn müssen vorangehende zytotoxische Chemotherapien seit mindestens 2 bis 4 Wochen beendet sein (mind. 6 Wochen bei Nitrosoharnstoff, Mitomycin C und liposomalem Doxorubicin). Bei fehlender Toxizität müssen 7 Tage nach Abschluss einer nicht-zytotoxischen Chemotherapie vergangen sein. Mindestens 4 Wochen müssen nach Abschluss einer Antikörper-gerichteten Therapie vergangen sein. 6. Nach einer vorhergehender Strahlentherapie müssen mindestens 14 Tage vergangen sein. Zwischen einer Gesamtbestrahlung des Gehirns und dem Beginn der Therapie mit Entrectinib müssen ebenfalls mindestens 14 Tage liegen. Eine stereotaktische Radiochirurgie muss mindestens 7 Tage zurückliegen. 7. Patienten mit asymptomatischer, kontrollierter ZNS-Beteiligung können in die Studie eingeschlossen werden. Die Gabe einer Anfallsprophylaxe/Antikonvulsiva-Therapie ist erlaubt, sofern die Patienten keine Enzym-induzierenden Antiepileptika (nicht-EIAEDs) einnehmen. Bei Patienten, die mit Enzym-induzierenden Antiepileptika (EIAEDs) vorbehandelt sind, müssen diese mindestens 2 Wochen vor Beginn der Therapie mit Entrectinib abgesetzt werden. Wenn Patienten eine anti-konvulsive Therapie benötigen, kann ein CYP3A4 nicht-Enzym-induzierendes Antiepileptikum wie Levetiracetam, Valproinsäure, Gabapentin, Topiramat oder Lacosamid verwendet werden. Erlaubte Antiepilektika sind dem Studienprotokoll zu entnehmen. Moderate Induktoren von CYP3A, CYP3A4 oder CYP3A4/5, wie Dexamethason oder andere Glukokortikoide, können nach Ermessen des Prüfarztes verwendet werden. Die Dosis einer benötigten Kortikosteroidtherapie muss zwei Wochen vor Beginn der Therapie mit Entrectinib stabil oder reduziert (≤ 8 mg/Tag Dexamethason oder Äquivalent) worden sein. 8. Auflösung von allen akuten toxischen Effekten (mit Ausnahme von Alopezie) vorangegangener Krebstherapien, d.h. NCI CTC (Version 4.03) Grad ≤ 1 oder Rückgang der Laborwerte zu den in

		Einschlusskriterium 11 definierten Werten zu Baseline; 9. ECOG Performance Status ≤ 2 10. Erwachsene Patienten (Alter ≥18 Jahre) 11. Lebenserwartung von mindestens drei Monaten; 12 Die Laborwerte zu Baseline müssen folgende Kriterien erfüllen: - Absolute Neutrophilenzahl ≥ 1.500/mm^3 (≥ 1,5 × 10^9/L) - Thrombozyten ≥ 100.000/mm^3 (≥ 100 × 10^9/L) - Hämoglobin > 9,0 g/dL (Transfusionen sind erlaubt) - Serumkreatinin innerhalb normaler Werte - Kreatinin Clearance > 40 mL/min - Gesamtbilirubin im Serum ≤ 1,5 × ULN - AST/ALT ≤ 2,5 × ULN (≤ 5 × ULN bei Lebermetastasen) - ALP ≤ 2.5 × ULN (≤ 5 × ULN bei Leber- und/oder Knochenmetastasen) - Normale Calcium-, Magnesium- und Kalium-Werte oder ≤ CTCAE Grad 1, mit oder ohne Supplementierung - Bei Frauen im gebärfähigen Alter ein negativer Schwangerschaftstest innerhalb von sieben Tagen vor Behandlungsbeginn 13. Frauen im gebärfähigen Alter müssen beim Screening einen negativen Serum-Schwangerschaftstest nachweisen, dürfen nicht stillen oder während der Studie schwanger werden. Frauen im gebärfähigen Alter müssen der Vereinbarung zustimmen, vor Studienbeginn, über die gesamte Studiendauer und 90 Tage nach Beendigung der Studienbehandlung mindestens zwei effektive Verhütungsmethoden anzuwenden (hormonelle Verhütungsmethoden, Barrieremethode zur Verhütung oder Abstinenz). Männer mit Partnerinnen im gebärfähigen Alter haben Vorsicht zu tragen, von Screening bis 90 Tage nach Beendigung der Studienbehandlung kein Kind zu zeugen und entsprechende Verhütungsmethoden (Barrieremethode zur Verhütung, Vasektomie oder Abstinenz) anzuwenden. 14. Fähigkeit, Kapseln mit Entrectinib zu schlucken ohne diese zu öffnen oder zu zerkleinern. 15. Bereitschaft, geplante Visiten, Behandlungsplan, Laboruntersuchungen und andere Untersuchungen durchführen zu lassen. **Ausschlusskriterien:**

		Patienten, die folgende Ausschlusskriterien erfüllen, werden aus STARTRK-1 ausgeschlossen: 1. Aktuelle Teilnahme an einer weiteren klinischen Studie. 2. Vorherige Behandlung mit Entrectinib. 3. Vorherige Krebserkrankung, die eine Behandlung innerhalb der letzten 3 Jahre erforderte (mit Ausnahme von Plattenepithel- oder Basalzellkarzinoma der Haut sowie jedes andere Carcinoma in situ, das vollständig entfernt wurde). 4. Unvollständige Genesung von einer vorangegangenen Operation. 5. Eine der folgenden Erkrankungen während der letzten 6 Monate: Myokardinfarkt, instabile Angina pectoris, Koronararterien-Bypass/peripherer arterieller Bypass, symptomatische Herzinsuffizienz, cerebrovaskulärer Infarkt oder transiente ischämische Attacke, Schlaganfall, symptomatische Bradykardie oder unkontrollierte Arrhythmien mit der Indikation zur medikamentösen Intervention. 6. Krankengeschichte eines nicht pharmakologisch induzierten verlängerten QTc-Intervalls (wiederholtes Auftreten von QTc-Intervall > 450 Millisekunden); 7. Krankengeschichte mit weiteren Risikofaktoren für Torsade de pointes (z.B. Long-QT-Syndrom in der Familiengeschichte). 8. Periphere Neuropathie ≥ Grad 2. 9. Bekannte aktive Infektionen (bakteriell, durch Pilze oder viral inkl. HIV-Infektion); 10. Gastrointestinale Erkrankungen (z.B. Morbus Crohn, Colitis ulcerosa, Kurzdarmsyndrom) oder andere Malabsorptionsstörungen, welche die Absorption von Entrectinib beeinflussen würden. 11. Bekannte interstitielle Lungenerkrankungen, interstitielle Fibrose oder Krankengeschichte einer Tyrosinkinase-Inhibitor-induzierten Pneumonitis. 12. Andere schwerwiegende akute oder chronische medizinische oder psychiatrische Zustände oder Abweichungen in Laborparametern, die das Risiko einer Studienteilnahme oder das Risiko der Einnahme der Studienmedikation erhöhen oder die Beurteilunge der Studiendaten beeinflussen könnten, und welche nach Ansicht des Prüfarztes den Patienten als ungeeignet für die Studie einstufen würden oder welche laut Prüfarzt und/oder Sponsor die Studienziele gefährden würden.

Item[a]	**Charakteristikum**	**Studieninformation**
		Rekrutierung: Sobald die Eignung des Patienten bestätigt wurde, kann der Patient in die Studie eingeschlossen werden. Der Prüfarzt füllt ein Antragsformular zum Studieneinschluss mit allen erforderlichen Informationen aus und übermittelt dieses an den Sponsor. Die Unterschrift des Prüfarztes auf dem Antragsformular zum Studieneinschluss bestätigt, dass der Patienten alle Auswahlkriterien erfüllt und für die Studie geeignet ist. Die Bestätigung für den Studieneinschluss wird dem Prüfarzt innerhalb eines Arbeitstages zugesandt. Nach dem Erhalt dieser Bestätigung, muss die Behandlung innerhalb von 1-3 Tagen initiiert werden. Der Sponsor ist verantwortlich für die Zuweisung des Patienten zur jeweiligen Dosisstufe. Die Studie umfasst zwei Abschnitte: Dosiseskalation und Dosisexpansion. **Datenerhebung und Orte, an denen die Daten erhoben wurden** Die Studie fand bis zum aktuellen Datenschnitt (31.05.2018) in 11 Zentren in 3 Ländern weltweit statt (Spanien, Südkorea, USA).
4	Intervention	
4a	Details der vorgesehenen Interventionen für jede Studiensituation, wie und wann sie verabreicht wurden, und zwar einschließlich: • Inhalt: was wurde gegeben? • Verabreichungsmethode: wie wurde der Inhalt gegeben? • Verabreichungseinheit: wie wurden die Patienten während der Verabreichung eingeteilt? • Verabreicher: wer verabreichte die Intervention? • Umfeld: wo wurde die Intervention verabreicht? • Expositionsmenge und -dauer: wie viele Sitzungen oder Episoden oder Ereignisse sollten verabreicht werden? Wie lange sollten sie dauern? • Zeitspanne: wie lange sollte die Verabreichung der Intervention bei jeder Einheit dauern? • Aktivitäten zur Erhöhung der Compliance oder Adhärenz (z. B. Anreize)	**Studiendauer:** Einschluss des ersten Patienten: 30.07.2014 Zum Datenschnitt vom 31.05.2018 lagen die Daten der Patienten vor, die bis zum 30.11.2017 in die STARTRK-1 eingeschlossen wurden. Bis zum 30.11.2017 wurden noch keine Patienten im Dosisexpansions-Abschnitt eingeschlossen. Die Studie rekrutiert weiter. **Arzneimittelverabreichung und Zeitspanne der Verabreichung** Entrectinib wird in zwei Formulierungen (F1 und F2A) für diese Studie verwendet. Die erste Formulierung (F1) umfasst Kapseln à 50 mg, 100 mg und 200 mg. Die zweite Formulierung (F2A) umfasst Kapseln à 200 mg. Dosiseskalations-Abschnitt: Im Dosiseskalations-Abschnitt wird die entsprechende Menge an Entrectinib in Abhängigkeit von der Körperoberfläche des einzelnen Patienten oder als Fixdosis oral

		verabreicht. Entrectinib wird von den Patienten selbst zu Hause eingenommen. Die Behandlungszyklen jeder Dosierungskohorte sind 28 Tage (Patienten, die zwischen der Protokollversion 2 (26.03.2014) und 4 (08.10.2014) eingeschlossen wurden, hatten einen ersten Behandlungszyklus von 42 Tagen, jeder folgende Behandlungszyklus betrug 28 Tage). Die Dosiseskalation wird fortgeführt bis die Dosis-limitierende Toxizität (DLT) bei 2 von 3 oder 2 von 6 Patienten im ersten Behandlungszyklus beobachtet wurde. Beim Auftreten der DLT bei 2 von 3 Patienten wird der Studieneinschluss in die Kohorte gestoppt. Die DLT wurde definiert als Auftreten eines UE innerhalb des ersten Behandlungszyklus, welches die vorher festgelegten Kriterien von Interesse erfüllt, einen bestimmten Schweregrad hat (im Allgemeinen ≥ Grad 3) und für das ein kausaler Zusammenhang mit Entrectinib nicht ausgeschlossen werden kann. Wenn der Patient sich nicht innerhalb von 28 Tagen nach Auftreten des UE von diesem erholen kann, sind die Kriterien für eine DLT ebenfalls erfüllt. Die Einstufung der DLTs erfolgte gemäß den NCI CTCAE-Kriterien (v4.03). Im Rahmen der Dosiseskalation wurde ein 3+3 Einschlussschema angewendet. Die Startdosis beträgt 100 mg/m2 KOF, einmal täglich. Die Einnahme erfolgt innerhalb von 60 Minuten nach einer Mahlzeit. Die Dosiseskalation begann mit einer beschleunigten Phase, in der die Dosis bei aufeinanderfolgenden Kohorten solange verdoppelt wurde, bis bei einem Patienten eine DLT im ersten Zyklus beobachtet wurde, oder bei 2 Patienten im ersten Zyklus UE auftraten, die zumindest möglicherweise mit Entrectinib in Zusammenhang standen, jedoch nicht als DLTs angesehen wurden. Sobald dieser vorgegebene Toxizitätsgrad erreicht wurde, sollte die Eskalation dem modifizierten Fibonacci-Schema folgen (50%-, 40%-, 33%-Steigerungen). Die maximal verträgliche Dosis (MTD) ist die Dosis, bei der eine DLT während des ersten Behandlungszyklus auftritt bei 0 von 6 oder 1 von 6 Patienten und bei mindestens 2/3 oder 2/6 Patienten in der nächsthöheren Dosisstufe. Eine Dosisreduktion ist bei medikamentenbedingten Toxizitäten zulässig. Alle Dosisreduktionen basieren auf der schwersten Toxizität, die für das mit der

Item[a]	**Charakteristikum**	**Studieninformation**
		Prüfsubstanz in Zusammenhang stehende Ereignis beobachtet wurde. Bei Toxizitäten, die möglicherweise mit Entrectinib in Zusammenhang stehen und die nicht leicht zu behandeln sind und die für den Patienten nicht tolerierbar sind, oder bei UE, die nach Einschätzung des Prüfarztes nicht akzeptabel sind, wird die Behandlung mit der Studienmedikation unterbrochen, bis der Schweregrad des UEs ≤1 ist. Wenn die Studienmedikation unterbrochen wird, sollte bei Wiederaufnahme der Studienmedikation eine Dosisreduktion erfolgen. Eine intraindividuelle Dosisreduktion um eine Dosisstufe und, falls erforderlich, zwei Dosisstufen ist je nach Art und Schwere der Toxizität zulässig. Patienten, bei denen aufgrund der behandlungsbedingten Toxizität mehr als 2 Reduktionen erforderlich sind, können von der Teilnahme an der Studie ausgeschlossen werden. Die Behandlung mit Entrectinib wird für maximal 28 Tage unterbrochen, um eine ausreichende Erholung von jeglicher Toxizität zu ermöglichen, wenn der Patient nach Einschätzung des Prüfarztes noch immer einen klinischen Nutzen hat. Die Bestimmung der RP2D erfolgt auf der Grundlage der verfügbaren Daten zur Sicherheit, Verträglichkeit, PK und PD aus den verschiedenen geprüften Dosisstufen und Schemata. Dosisexpansions-Abschnitt: Alle Patienten im Dosisexpansions-Abschnitt dieser Studie erhalten Entrectinib in der RP2D. Die RP2D wurde als Fixdosis von 600 mg einmal täglich über 28 aufeinander folgende Tage in sich wiederholenden 4-wöchigen Zyklen festgelegt. Wie für den Dosiseskalations-Abschnitt beschrieben, sind Dosisreduktionen im Dosisexpansions-Abschnitt zulässig. **Compliance** Patienten im Dosiseskalations-Abschnitt dokumentieren die tägliche Dosierung in einem papierbasierten Patiententagebuch. Zu jeder Visite bringen die Patienten das Tagebuch zum Studienzentrum mit, wo die Compliance beurteilt wird. Darüber hinaus wurden die Patienten aufgefordert, bei jeder Visite nicht benutze Studienmedikation zurückzugeben. Patienten im Dosisexpansions-Abschnitt sollen bei der Dokumentation der täglichen Dosierung und Compliance wie im Dosiseskalations-Abschnitt vorgehen.

Item[a]	**Charakteristikum**	**Studieninformation**
5	Zielsetzungen	
5a	• Spezifische Studienziele und Hypothesen	**Primäre Studienziele** <u>Dosiseskalations-Abschnitt:</u> Bestimmung der dosis-limitierenden Toxizität (DLT) im ersten Behandlungszyklus, der maximal verträglichen Dosis (MTD) und einer biologisch effektiven und empfohlenen Phase II-Dosierung (RP2D) von Entrectinib in einer oralen Formulierung. • DLTs im ersten Behandlungszyklus • MTD • RP2D <u>Dosisexpansions-Abschnitt:</u> Beurteilunge der Wirksamkeit von Entrectinib anhand der Objektiven Ansprechrate (ORR, objective response rate) definiert als der Anteil aller Patienten mit einem vollständigen (CR) oder partiellen Ansprechen (PR). **Sekundäre Studienziele** <u>Dosiseskalations-Abschnitt:</u> • Erfassung des Sicherheitsprofils von Entrectinib. • Pharmakokinetik von Entrectinib (und seinen potenziellen Metaboliten) im Blutplasma • Erfassung der Antitumor-Aktivität von Entrectinib • Erfassung von Untersuchungsmethoden zum Erkennen von molekularen Veränderungen und die Identifikation von angemessenen analytischen Schwellen-werten und anderen relevanten Biomarker-Parametern, mit denen sich die Antitumor-Aktivität von Entrectinib vorhersagen lässt • Erfassung der Pharmakodynamik von Entrectinib in molekularen Zielen des Tumors und Surrogat-Gewebe <u>Dosisexpansions-Abschnitt:</u> • Erfassung des PFS • OS • Krankheitskontrollrate (Disease Control Rate) • Erfassung der Dauer des Ansprechens (DOR, Duration of response) • Erfassung des intrakraniellen Tumoransprechens bei Patienten mit einer ZNS-Beteiligung • Erfassung des Sicherheitsprofils von Entrectinib. • Erfassung von Untersuchungsmethoden zum Erkennen von molekularen

Item[a]	**Charakteristikum**	**Studieninformation**
		Veränderungen und die Identifikation von angemessenen analytischen Schwellen-werten und anderen relevanten Biomarker-Parametern, mit denen sich die Antitumor-Aktivität von Entrectinib vorhersagen lässt • Erfassung der Pharmakodynamik von Entrectinib in molekularen Zielen des Tumors und Surrogat-Gewebe • Pharmakokinetik von Entrectinib (und seinen potenziellen Metaboliten) im Blutplasma **Hypothesen** Für diese Phase I-Studie wurden keine Hypothesen generiert.
6	Zielkriterien	
6a	• Klar definierte primäre und sekundäre Wirksamkeitsmessgrößen • Methoden zur Datenerhebung und Methoden zur Verbesserung der Qualität von Messungen • Informationen über validierte Instrumente wie z. B. psychometrische und biometrische Eigenschaften von Selbsterhebungsinstrumenten	**Dosislimitierende Toxizität (DLT)** Der primäre Endpunkt ist die DLT im Zyklus 1. Basierend auf der DLT werden die MTD und RP2D hergeleitet. Zur Klassifizierung der DLTs werden die NCI CTCAE v4.03 herangezogen. Eine DLT ist dadurch definiert, dass eines der im Studienprotokoll (S. 12, Table. Dose Limiting Toxicity) aufgeführten Ereignisse innerhalb des ersten Zyklus auftritt und ein kausaler Zusammenhang mit Entrectinib nicht ausgeschlossen werden kann. Für die Auswertung der DLT werden alle Patienten herangezogen, bei denen nach der Einnahme von mindestens einer Dosis Entrectinib eine DLT aufgetreten ist oder bei denen nach mindestens 80% der für den ersten Zyklus geplanten Dosen Entrectinib keine DLT aufgetreten ist. Patienten, die keines dieser Kriterien erfüllen und die Studie vor der vollständigen Erfassung von DLTs beendet haben, werden ersetzt, außer es gibt bereits drei auswertbare Patienten ohne DLTs. **Maximal tolerierte Dosis (MTD)** Die MTD ist definiert als das Dosislevel, bei welchem 0/6 oder 1/6 Patienten im ersten Behandlungszyklus eine DLT und 2/3 oder 2/6 Patienten unter der nächsthöheren Dosierung ebenfalls eine DLT erfahren. Die MTD ist damit die höchste Dosis, bei der weniger als 33% der Patienten im Rahmen des ersten Behandlungszyklus DLTs erfuhren. **Empfohlene Dosis für Phase II (RP2D)** Die RP2D basiert auf allen verfügbaren Daten zu Sicherheit, Toleranz, Pharmakokinetik und Pharmakodynamik

		aller Dosislevel und Dosispläne, die getestet wurden. **Erhebung sekundärer Endpunkte** • Erfassung des Sicherheitsprofils von Entrectinib. Dieses ist charakterisiert durch die Art der UE, Schweregrad nach NCI CTCAE v4.03, Zeitraum und Zusammenhang mit der Studienmedikation, sowie durch EKG und Laborauffälligkeiten im ersten und den folgenden Zyklen. • Pharmakokinetik von Entrectinib (und seinen potenziellen Metaboliten) im Blutplasma gemessen mithilfe der Parameter C_{max}, t_{max}, $t_{1/2}$, AUC_{daily} und AUC_{last} • Das objektive Tumoransprechen wird via RECIST v1.1 bewertet und ist definiert als der Anteil der Patienten mit bestätigtem komplettem Ansprechen (CR, complete response) oder partiellem Ansprechen (PR, partial response) nach RECIST v1.1. Ein bestätigtes Ansprechen ist definiert als Ansprechen, das auf wiederholten Bildgebungen über ≥ 4 Wochen nach der initialen Dokumentation anhält. • PFS ist definiert als die Zeit zwischen erster Dosis Entrectinib bis zu einer Progression oder Tod jeglicher Ursache. Die genauen Zensierungsregeln dieses Endpunkts sind im SAP dargestellt. • OS ist definiert als die Zeit von der ersten Dosis Entrectinib bis zum Datum des Todes aufgrund jeglicher Ursache. Patienten, die im Laufe der Studie nicht versterben, werden zum letzten bekannten Zeitpunkt ihres Lebens zensiert. Zusätzliche Zensierungsregeln werden im SAP dargestellt. • Klinische Benefitrate (CBR, Clinical Benefit Rate) ist der Anteil Patienten, die eines der folgenden Kriterien erfüllen: CR oder PR, Stabile Erkrankung (SD, stable disease) für mindestens 6 Monate (±14 Tage) nach der ersten Dosis Entrectinib, erhoben via RECIST v1.1. • Dauer des Ansprechens (DOR, duration of response) wird nur für Responder gemessen vom Zeitpunkt des ersten objektiven Ansprechens (CR oder PR) bis zur ersten dokumentierten Progression des Tumors oder Datum des Todes durch Progression. Dieser Endpunkt wird nur bei Patienten mit einem Ansprechen erhoben. Die genauen Zensierungsregeln dieses Endpunkts sind im SAP dargestellt. **Erhebung des Tumorstatus**

		Die Bildgebung umfasst einen CT- oder MRT-Scan von Thorax und Abdomen und muss innerhalb von 30 Tagen vor der ersten Einnahme von Entrectinib erfolgen. Aufgrund des häufigen Auftretens von Hirnmetastasen ist bei allen NSCLC-Patienten im Rahmen des Screening eine Bildgebung des Gehirns durchzuführen. Der Tumorstatus wird zu folgenden Zeitpunkten erhoben: Screening, Ende von Zyklus 1, anschließend alle 8 Wochen (d.h. am Ende von Zyklus 3, 5, 7 etc. oder wann immer eine klinische Verschlechterung festgestellt wird) und bei Beendigung der Behandlung (sofern mehr als 4 Wochen seit der letzten Bildgebung vergangen sind). Für jede Bildgebung ist ein Zeitfenster von bis zu 7 Tagen gegeben. Abweichend von den Protokollvorgaben kann jederzeit nach Ermessen des Prüfarztes eine Bildgebung erfolgen. Die zu Beginn gewählte Methode der Bildgebung soll über den gesamten Studienzeitraum beibehalten werden. Bei Patienten mit einem CR oder PR muss die Bestätigung dieses Ansprechens nach mehr als vier Wochen nach dem ersten Feststellen eines Ansprechens erfolgen. Nach der Bestätigung des Ansprechens sind radiologische Bewertungen zum Ende jedes zweiten Zyklus durchzuführen. Patienten mit einer stabilen Erkrankung müssen die Kriterien für ein SD mindestens acht Wochen nach der ersten Einnahme von Entrectinib erfüllen. Das Tumoransprechen soll zum Ende der Behandlung mit Entrectinib noch einmal erfasst werden, sofern mehr als 4 Wochen seit der letzten Bildgebung vergangen sind. Wenn ein Patient die Studie aus einem anderen Grund als Progression abgebrochen hat, soll das Zentrum versuchen, eine Einwilligung des Patienten für ein Fortsetzen der Tumorbewertung alle 8 Wochen einzuholen. Diese sollte bis zur Progression oder dem Start einer neuen Behandlung fortgeführt werden. **Kriterien zur Bewertung des Tumoransprechens** Die Bewertung und Messungen der Tumore erfolgt nach den „Response Evaluation Criteria in Solid Tumors“ (RECIST) in der Version 1.1. Diese publizierten Regeln definieren die Entwicklung von Tumoren bei Krebspatienten im Rahmen einer Behandlung (Ansprechen, Stabilisierung, Progress). RECIST wird als Standardmethode für die Tumormessung und eine objektive Bewertung von Änderungen in der Tumorgröße in klinischen Studien mit

		erwachsenen Krebspatienten verwendet (Eisenhauer 2019). Das Tumoransprechen basiert in der STARTRK-1 auf der Bewertung des Prüfarztes von Zielläsionen, nicht-Zielläsionen und neuen Läsionen gemäß den Kriterien aus Tabelle 1 (für messbare Läsionen) und Tabelle 2 (für nicht-messbare Läsionen) der Publikation zu RECIST v1.1 (Eisenhauer 2019). Die Bestätigung eines CR oder PR erfolgt analog zu den Kriterien aus Tabelle 3 derselben Publikation (Eisenhauer 2019). Es ist nicht mehr als eine fehlende Messung des initialen Ansprechens und der Bestätigung des Ansprechens erlaubt. Bei Patienten, die nicht die Kriterien für ein CR oder PR erreichen, jedoch die Kriterien für eine stabile Erkrankung (SD) mindestens einmal nach 35 oder mehr Tagen nach Start der Behandlung erreichen, wird als bestes Gesamtansprechen SD erfasst. Sind die Kriterien für eine SD erfüllt und ist die minimal erforderliche Zeitdauer nicht erreicht, hängt das Gesamtansprechen des Patienten von den nachfolgenden Bewertungen ab. Gibt es keine nachfolgenden Bewertungen, so ist das beste Ansprechen nicht bewertbar. Auswertbare Patienten ohne valide Bewertungen des Tumoransprechens nach Studienbeginn werden als Non-Responder erfasst. Für Zielläsionen wird die Summe der Durchmesser sowie deren prozentuale Veränderung seit Studienbeginn und seit dem niedrigsten gemessenen Durchmesser berechnet. **Unabhängiges Bewertungsgremium (BICR):** Alle Scans werden an ein unabhängiges Labor für Bildgebung übermittelt. Dort findet die unabhängige Überprüfung des Tumoransprechens und der Krankheitsprogression statt. **Bewertung der Sicherheit und Verträglichkeit** **Unerwünschte Ereignisse (UE)** Von jedem Patienten werden die Daten zu UE gesammelt. Die Fragestellung an den Patienten sollte neutral erfolgen (z.B. Hat sich seit Ihrem letzten Besuch Ihr Gesundheitszustand verändert?). Die Beobachtung von UE startet mit der ersten Einnahme von Entrectinib und wird bis zum telefonischen Follow-Up 30 Tage nach der letzten Einnahme von Entrectinib fortgeführt.

		Alle UE werden bewertet nach Art des UEs, Schweregrad nach NCI CTCAE v4.03, Zeitraum und Zusammenhang mit der Studienmedikation, sowie durch EKG und Laborauffälligkeiten im ersten und den folgenden Zyklen **Klinische Laborergebnisse** Normbereiche werden verwendet, um Werte außerhalb des Normbereichs zu identifizieren. Abweichende Laborergebnisse werden gemäß NCI CTCAE v4.0 bewertet. Es werden beschreibende Statistiken für den jeweils schlechtesten Wert (Häufigkeiten und Prozent auf Basis von Patienten, nicht Ereignissen) nach NCI-CTCAE-Grad für folgende Parameter dargestellt: • Prävalenz der hämatologischen, biochemischen und Gerinnungstoxizität; Dabei wird der letzte verfügbare Wert vor Beginn der Studienmedikation herangezogen. • Inzidenzrate der behandlungsbezogenen der hämatologischen, biochemischen und Gerinnungstoxizität; Patienten mit Beobachtungen nach Beginn der Studienmedikation, die im Einnahmezeitraum der Studienmedikation Toxizitäten berichtet haben. • Veränderung des schlechtesten Grads von hämatologischen, biochemischen und Gerinnungstoxizitäten seit Studienbeginn (Schlechtester Grad unter Studienmedikation abzüglich Wert zu Studienbeginn). • Inzidenzraten behandlungsbezogener niedriger oder erhöhter Laborabweichungen. Zusätzlich werden zusammenfassende Statistiken für Laborwerte und Veränderungen seit Studienbeginn je Visite gezeigt. Für die Darstellung der Veränderung seit Studienbeginn in Kategorien werden, basierend auf Labor Normwerten, Shift-Tabellen gezeigt. Die Inzidenzraten von Toxizitäten mit NCI-CTCAE Grad 3 und 4 werden zusammenfassend je Zyklus für folgende Werte dargestellt: Hämoglobin, Leukozytenzahl, absolute Neutrophilenzahl, absolute Lymphozyten, Thrombozyten und weitere biochemische und Gerinnungsparameter (mit NCI-CTCAE-Grad). Für diese Auswertungen basieren die prozentualen Werte jeweils auf den im Zyklus behandelten Patienten. **„Time to Event“ -Analysen**

Item[a]	**Charakteristikum**	**Studieninformation**
		Für PFS, OS und DOR werden der Median und die 25% und 75% Percentile unter Verwendung der Kaplan-Meier-Methode geschätzt. Die zugehörigen 95% -KI werden je Dosislevel und für die gesamte Analysepopulation dargestellt. Für jeden „Time to Event"-Endpunkt wird die entsprechende Kaplan-Meier-Kurve für das gesamte Analyseset erstellt. **Analyse kategorialer Daten** Kategoriale Endpunkte dieser Studie sind das objektive Tumoransprechen, die objektive Ansprechrate (ORR) und die CBR. Alle kategorialen Daten werden zusammenfassend dargestellt als absolute und relative Häufigkeiten. Als Nenner zur Berechnung der Ansprechraten werden alle Patienten des jeweiligen Analysesets verwendet. Weitere Endpunkte umfassen Elektrokardiogramme, Pharmakokinetik, Pharmakodynamik und Tumormarker.
7	Fallzahl	
7a	• Wie wurden die Fallzahlen bestimmt?	Der **Dosiseskalations-Abschnitt** der Studie ist als Phase I-Studie mit Sicherheit und Verträglichkeit als primäre Zielparameter konzipiert. Es wurde keine Berechnung zur statistischen Power durchgeführt. Für den **Dosisexpansions-Abschnitt** wurden in etwa 50 Patienten angestrebt. Die Dosisexpansion stellt einen nach Signalen suchenden, exploratorischen Studienteil dar, in welchem Patienten eingeschlossen werden mit verschiedenen molekularen Veränderungen in einem der folgenden Gene: NTRK1, NTRK2, NTRK3, ROS1, ALK, NGF, BDNF, NTF3, NTF4 und NGFR. Für jeden einzelnen Typ molekularer Veränderungen werden die Patienten nach einem „Simon's two-stage" (minimax) Design eingeschlossen: In der ersten Stufe werden 6 Patienten eingeschlossen. Wenn kein objektives Ansprechen bei diesen 6 Patienten erkennbar ist, wird diese spezielle molekulare Veränderung nicht weiterverfolgt. Wenn mindestens ein objektives Ansprechen bei den 6 Patienten beobachtet wurde, wird diese Gruppe auf insgesamt 14 Patienten erweitert. Wenn bei diesen 14 Patienten bei mindestens 5 Patienten ein objektives Ansprechen beobachtet wird, ist eine weitere Untersuchung von Entrectinib bei dieser Gruppe gerechtfertigt.

Item[a]	**Charakteristikum**	**Studieninformation**
		Diese Regelung ergibt eine Power von 90%, mit einem einseitigen Alpha von 0,046 die Nullhypothese (Responserate <15%) im Vergleich zu einer alternativen Hypothese (>50%) abzulehnen.
7b	• Falls notwendig, Beschreibung von Zwischenanalysen und Kriterien für einen vorzeitigen Studienabbruch	**Zwischenanalysen** Es waren keine formalen Zwischenanalysen vorab geplant. Der aktuelle CSR zeigt jedoch einen Datenschnitt vor Studienende. Diese Daten wurden im Rahmen einer integrierten Analyse von Entrectinib zur Unterstützung der Zulassung verwendet. **Kriterien für einen vorzeitigen Studienabbruch** Studienabbruch durch den Patienten zu jedem beliebigen Zeitpunkt durch: • Widerruf der Einverständniserklärung • Progression der Erkrankung • Nicht akzeptable Toxizitäten durch Entrectinib • Unerwünschtes Ereignis • Lost-to-Follow-Up • Schwangerschaft • Fehlende Compliance bei der Einnahme der Studienmedikation oder den Studienabläufen. • Protokollverletzungen • Andere Stellt der Prüfarzt im Laufe der Studie fest, dass die sichere Teilnahme eines Patienten an der Studie durch eine Änderung seines medizinischen Status, die nicht mit dem Protokollanforderungen konform ist (z.B. Ein-/Ausschlusskritierien, Schwangerschaft), nicht länger möglich ist, so muss dieser Patient die Studienbehandlung beenden. Eine vorzeitige Beendigung der Studie kann durch Behörden, IRB/IEC, Sicherheitsprobleme oder durch eine Entscheidung des Sponsors erfolgen.
8	Zuweisungsmethode • Zuweisungseinheit (die Einheit, die der Studienbedingung zugewiesen wird, wie z. B. Person, Gruppe, Gemeinde) • Methode der Zuweisung von Einheiten zu Studienbedingungen, einschließlich Details über etwaige Restriktion (z. B. Blockbildung, Stratifikation, Minimierung) • Einbeziehung von Aspekten, um potenzielle Verzerrung durch Nichtrandomisierung zu minimieren (z. B. Matching)	**Zuweisung** Nicht zutreffend. Es handelt sich um eine einarmige Phase I-Studie.
9	Verblindung	
9a	• Waren a) die Probanden / Patienten und / oder b) diejenigen, die die Intervention / Behandlung durchführten, und / oder c) diejenigen, die die Zielgrößen beurteilten, verblindet oder nicht	**Verblindung** Nicht zutreffend. Es handelt sich um ein offenes Studiendesign.

Item[a]	**Charakteristikum**	**Studieninformation**
	verblindet, wie wurde die Verblindung vorgenommen?	
10	Analyseeinheit • Bezeichnung der kleinsten Einheit, die analysiert wird, um Wirkungen der Intervention zu beurteilen (z. B. Person, Gruppe, Gemeinde) • Wenn sich die Analyseneinheit von der Zuweisungseinheit unterscheidet, ist die verwendete Analysenmethode anzugeben, die dies berücksichtigt (z. B. Adjustierung der Standardfehlerschätzungen um den Designeffekt oder durch Verwendung einer Multilevel-Analyse)	Die Analysen wurden für jede getestete Dosierung und Formulierung (100 mg/m2 KOF [F1], 200 mg/m2 KOF [F1], 400 mg/m2 KOF [F1], 800 mg [F1], 600-800 mg [BSA F1], 600 mg [F1], 600 mg [F2A]) durchgeführt.
11	Statistische Methoden	
11a	• Statistische Methoden zur Bewertung der primären und sekundären Zielkriterien einschließlich komplexer Methoden für korrelierte Daten	**Grundsätzliche statistische Annahmen** Alle Variablen werden je Dosierung mithilfe deskriptiver Statistik dargestellt. Für metrische Daten werden Anzahl, Anzahl fehlender Werte, Mittelwert, Standardabweichung, Minimum, Quartile, Median und Maximum berechnet. Für kategoriale Daten werden Häufigkeitstabellen erstellt mit den absoluten und relativen Werten jeder Kategorie. Zur Berechnung von Prozenten wird die Patientenzahl des jeweils angewendeten Analysesets als Nenner verwendet. Wenn es mindestens einen fehlenden Wert in der jeweiligen Behandlungsgruppe gibt, wird die Kategorie „Missing“ gezeigt. Der Baseline-Wert ist definiert als der letzte beobachtete Wert vor Beginn der Studienbehandlung. Allgemein (falls nicht anders im Protokoll definiert) werden Werte, die an Tag 1 im Zyklus 1 erhoben wurden als „vor Beginn der Studienbehandlung“ betrachtet. Zeitspannen (in Tagen) werden als „Enddatum – Startdatum + 1“ berechnet. Solang nicht anders definiert werden alle Zeitspannen von Baseline-Daten, Patientenhistorie und Wirksamkeitsdaten in Monaten angegeben. Um Zeitspannen von Tagen auf Monate umzurechnen, wird die Anzahl der Tage durch 30,4375 geteilt. In dieser Studie wird kein formaler Test auf Signifikanz durchgeführt. Für ausgewählte Wirksamkeitsparameter (z.B. Objektive Ansprechrate) werden, wenn möglich, 95%-KI berechnet.
11b	• Verwendete statistische Methoden für zusätzliche Analysen, wie z. B. Subgruppenanalysen und adjustierte Analysen • Methoden zur Imputation fehlender Daten • Falls verwendet: Verwendete statistische Software oder Programme	Für die STRTRK-1 waren keine Subgruppenanalysen geplant. **Fehlende Daten**

Item[a]	**Charakteristikum**	**Studieninformation**
		Soweit nicht anders vermerkt, werden fehlende Daten nicht imputiert, außer für teilweise fehlende Datumsangaben. Unvollständige Datumsangaben für UE und Begleitmedikation werden wie folgt gehandhabt: • Wenn das Startdatum vollständig fehlt oder der Beginn im gleichen Jahr ist (wenn nur das Startjahr verfügbar ist) oder der Beginn des UE im gleichen Monat oder Jahr (falls der Tag fehlt) des Behandlungsstarts liegt, wird das Startdatum des UEs durch Start der Behandlung und Abklingdatum des UEs ersetzt, je nachdem welches den früheren Zeitpunkt darstellt. • In allen anderen Fällen wird ein fehlender Tag oder Monate mit einer 1 ersetzt. • Unvollständige Enddaten werden durch den letzten Tag des Monats ersetzt (falls nur der Tag fehlt), solange das Enddatum nicht später als der Todeszeitpunkt des Patienten ist. In diesem Fall wird der Todeszeitpunkt als Enddatum imputiert. • In allen anderen Fällen wird das Enddatum nicht imputiert. Unvollständige oder fehlende Datumsangaben zur Studienbehandlung werden wie folgt gehandhabt: • Wenn das Startdatum vollständig fehlt wurde angenommen, dass die erste Einnahme von Entrectinib zum Datum der ersten messbaren PK-Konzentration erfolgte. Wenn keine Daten zur PK-Konzentration verfügbar sind, wird das Entsorgungsdatum der Studienmedikation als Startdatum von Entrectinib verwendet. • Wenn das Enddatum der Behandlung fehlt oder unvollständig ist, wird das Enddatum des eCRFs zum Behandlungsende verwendet. Ist hier kein vollständiges Datum dokumentiert, wurde das Enddatum über das letzte Entsorgungsdatum und der letzten PK-Konzentration hergeleitet. Für die Imputation von fehlenden Angaben des Starts von Folgetherapien / Krankheitsverläufen wird der 15. des Monats eingesetzt, falls Jahr und Monat angegeben sind. In allen anderen Fällen von fehlenden oder unvollständigen Daten wird nicht imputiert, sofern nicht anders angegeben.
Resultate		

Item[a]	**Charakteristikum**	**Studieninformation**
12	Patientenfluss	
12a	• Patientenfluss durch jede Studienphase: Rekrutierung, Zuweisung, Allokation und Interventionsexposition, Nachbeobachtung, Analyse (Diagramm siehe unten)	
12b	• Rekrutierung: die Anzahl der Teilnehmer, die auf ihre Eignung gescreent werden, sich als geeignet oder nicht geeignet erweisen, nicht in die Studie aufgenommen und in die Studie aufgenommen werden • Zuweisung: die Anzahl der Teilnehmer, die einer Studienbedingung zugewiesen wurden • Allokation und Interventionsexposition: die Anzahl der Teilnehmer, die jeder Studienbedingung zugewiesen werden, und die Anzahl der Teilnehmer, die jede Intervention erhielten • Nachbeobachtung: die Anzahl der Teilnehmer, die das Follow-up abschlossen oder das Follow-up nicht abschlossen (lost to follow-up), aufgeschlüsselt nach Studienbedingungen • Analyse: die Anzahl der Teilnehmer, die in die Hauptanalyse einbezogen oder ausgeschlossen wurden, aufgeschlüsselt nach Studienbedingungen • Beschreibung von Abweichungen vom Prüfplan der Studie unter Angabe von Gründen	Es wurden 93 Patienten gescreent, um an der STARTRK-1 teilzunehmen. Während der Screeningphase wurden 17 Patienten als nicht geeignet identifiziert. 76 Patienten wurden eingeschlossen und mit Entrectinib behandelt (erhielten mindestens eine Dosis). Alle Patienten, die in die Dosis-Gruppen 100, 200, und 400 mg/m2 KOF, 800 mg und 600-800 mg (nach BSA) eingeschlossen wurden, brachen die Studienbehandlung ab. In den Gruppen 600 mg [F1] und 600 mg [F2A] brachen 85,0% bzw. 95,5% die Einnahme der Studienmedikation ab. Der Großteil der Patienten (63,2%) beendete die Studienmedikation aufgrund einer Progression der Erkrankung. Weitere Gründe waren: UE, Tod, Entscheidung des Patienten und klinische Progression oder die Entscheidung des Arztes. Grund für den Abbruch der Studie war bei einem Großteil der Patienten der Beginn einer neuen Anti-Neoplastischen Therapie (34,2%), Tod (22,4%) oder Abbruch auf Wunsch des Patienten (25,0%). Die Patienten wurden in 11 verschiedenen Zentren in 3 verschiedenen Ländern rekrutiert (Südkorea, Spanien, USA). Von den 76 Patienten, die mit Entrectinib im Rahmen des Dosiseskalations-Abschnitts behandelt wurden, wurden 5 in die 100 mg/m2 KOF [F1]-Population, 5 in die 200 mg/m2 KOF [F1]-Population, 10 in die 400 mg/m2 KOF [F1]-Population, 9 in die 800 mg [F1]]-Population, 5 in die 600-800 mg [BSA F1]]-Population, 22 in die 600 mg [F1]]-Population und 20 in die 600 mg [F2A]]-Population eingeschlossen. Zum Clincal cut-off date (31.05.2018) erhielten insgesamt 4 Patienten die Studienmedikation (600 mg [F1]: n=1; 600 mg [F2A]: n=3).
13	Aufnahme / Rekrutierung	
13a	• Nähere Angaben über den Zeitraum der Studienaufnahme der Probanden / Patienten und der Nachbeobachtung	Die Ergebnisse des Interimsdatenschnitts vom 31.05.2018 beinhalten die Daten vom 16.11.2015 (first patient enrolled) bis zum Datenschnitt am 31.05.2018 für Patienten, die bis zum 30.11.2017 eingeschlossen wurden.

Item[a]	**Charakteristikum**	**Studieninformation**
		Nachbeobachtung Die Zentren sollen jeden Patienten etwa 30 Tage nach der letzten Einnahme von Entrectinib telefonisch kontaktieren. Ziel dieses Safety-Follow-up ist die Nachverfolgung von bestehenden UE sowie die Erfassung neuer behandlungsbezogener UE, neuer Medikationen oder Änderungen der bestehenden Medikation seit der letzten Erhebung. Alle neuen Informationen aus diesem Follow-up-Telefonat müssen im CRF entsprechend dokumentiert werden. Zusätzlich soll jeder Patient nach Studienabbruch in einem dreimonatigen Rhythmus bis zum Tod, Loss-to-Follow-Up, Start einer neuen Krebstherapie oder Rücknahme der Einverständniserklärung telefonisch kontaktiert werden, um Progression und Überlebensstatus zu erfassen.
13b	• Informationen, warum die Studie endete oder beendet wurde	Nicht zu treffend. Studie läuft.
a: nach TREND 2004.		

Stellen Sie für jede Studie den Patientenfluss in einem Flow-Chart gemäß CONSORT dar.



Abbildung 4-69 Patientenfluss der STARTRK-1 Dosiseskalations-Abschnitt (Datenschnitt NDA)

Studiendesign und -methodik für Studie STARTRK-NG

Tabelle 4-92 (Anhang): Studiendesign und -methodik für Studie STARTRK-NG

Item[a]	**Charakteristikum**	**Studieninformation**
Studienziel		
2	Wissenschaftlicher Hintergrund und Erläuterung der Rationale	Aktivierte Rezeptortyrosin-Kinasen (RTKs) wie die Rezeptoren der TRK-Familie (TRKA [codiert durch das Gen NTRK1], TRKB [codiert durch das Gen NTRK2] und TRKC [codiert durch das Gen NTRK3]) spielen eine zentrale Rolle bei der Entstehung vieler Tumore im Kindes- und Erwachsenenalter. TRKB wird zusammen mit seinem Liganden „Gehirn-Derived Neurotrophic Factor“ (BDNF) exprimiert. Dieser autokrine Signalweg führt zu Invasion, Angiogenese und Arzneimittelresistenz. Mutationen in oder Translokationen mit TRK-Genen wurden beim Neuroblastomen nicht gefunden. Jedoch besteht bei 50-60 % der Hochrisiko-Neuroblastome eine autokrine Aktivierung des TRKB/BDNF-Signalwegs, was diesen zu einem der attraktivsten Ziele für biologische Tumortherapiestrategien macht. Das Blockieren von TRKB führt zu Apoptose und einer erhöhten Empfindlichkeit gegenüber Chemotherapie. Darüber hinaus weisen viele weitere Krebserkrankungen bei Kindern und Erwachsenen, einschließlich Medulloblastome, gliale Tumore und Sarkome, Fusionen (Umlagerungen) oder eine aberrante Expression der NTRK-Gene auf. TRKB scheint ein besonders vielversprechender Ansatzpunkt in der Krebstherapie zu sein, da dieser Rezeptor bei Tumoren besonders häufig aktiviert ist. Jedoch kann sich von Tumortyp zu Tumortyp unterscheiden, welche Mitglieder der TRK-Familie jeweils aktiviert sind. Daher wäre ein pan-TRK-Inhibitor, d.h. ein Inhibitor aller Mitglieder der TRK-Familie, für viele unterschiedliche Krebserkrankungen bei Kindern und Erwachsenen von Nutzen (Protokoll). Entrectinib ist ein potenter Inhibitor von TRKA, TRKB, TRKC, ROS1 (codiert durch das Gen ROS1) und ALK (codiert durch das Gen ALK). Die Studie STARTK-NG ist eine fünfteilige Dosiseskalationsstudie mit pädiatrischen Patienten mit rezidivierten oder refraktären soliden Tumoren und primären ZNS-Tumoren mit oder ohne TRK-, ROS1- oder ALK-Fusionen (Protokoll).
Methoden		
3	Probanden / Patienten	
3a	• Eignungskriterien für Studienteilnehmer, einschließlich der Kriterien auf verschiedenen Ebenen des Rekrutierungsplans / Plan zur Stichprobennahme (Sampling Plan) (z. B. Städte, Kliniken, Patienten) • Rekrutierungsmethode (z. B. Überweisung, Selbstauswahl) einschließlich der Methode zur Stichprobennahme (Sampling	**Einschlusskriterien:** Jeder Patient muss alle der folgenden Einschlusskriterien erfüllen, um für die Studienteilnahme zugelassen zu werden: 1. Schriftliche Einwilligungserklärung: Eine unterschriebene Einwilligungserklärung und/oder Zustimmung zur Studienteilnahme wird gemäß den institutionellen Richtlinien eingeholt 2. Fähigkeit, Kapseln zu schlucken *Hinweis: In Phase Ib können Patienten ≥ 2 Jahre und < 22 Jahre, die keine Kapseln schlucken können, sowie*

	Method), falls ein systematischer Plan zur Stichprobennahme verwendet wurde • Vorgehensweise bei der Rekrutierung • Setting der Datenerhebung und Orte, an denen die Daten erhoben wurden	*alle Patienten, die ansonsten alle anderen Zulassungskriterien erfüllen, nach Absprache mit dem Sponsor in Teil E aufgenommen werden, in dem Entrectinib über alternative Dosierungstechniken verabreicht wird* 3. Körperoberfläche (BSA, body surface area): Die Patienten in den Teilen A, B, C und D müssen zum Zeitpunkt der Studienaufnahme eine Körperoberfläche von ≥ 0,45 m2 KOF haben 4. Krankheitsstatus: Teil A und D: Patienten müssen eine messbare oder auswertbare Krankheit, wie in Anlage 5 definiert [RECIST v1.1, Protokoll], haben Teil B: Patienten müssen messbare oder auswertbare Krankheiten, wie in Anlage 6 definiert [RANO, Protokoll], haben Teil C: Patienten müssen eine messbare oder auswertbare Krankheit haben, wie in Anlage 5 definiert [RECIST v1.1 ± Curie Scale, Protokoll] Teil E: Patienten müssen eine messbare oder auswertbare Krankheit haben und werden gemäß Tumortyp, wie in Anhang 5 [RECIST v1.1 ± Curie Scale, Protokoll] oder Anhang 6 [RANO, Protokoll] definiert, bewertet 5. Tumortyp (Nachweis der Molekülveränderungen durch ein „Clinical Laboratory Improvement Amendments“ (CLIA)-zertifiziertes oder gleichwertig akkreditiertes diagnostisches Labor): **Teil A:** Rezidivierte oder refraktäre extrakranielle solide Tumore **Teil A (Expansion):** Rezidivierte oder refraktäre extrakranielle solide Tumore, die keine Neuroblastome sind, mit NTRK1/2/3-, ROS1- oder ALK-Molekülveränderungen, die keine Genfusionen sind **Teil B:** Rezidivierte oder refraktäre primäre Gehirntumore mit NTRK1/2/3-, ROS1- oder ALK-Molekülveränderungen, einschließlich Genfusionen; Genfusionen sind definiert als diejenigen Molekülveränderungen, die zur Expression eines Fusionsproteins mit einer funktionellen TRKA/B/C-, ROS1- oder ALK-Kinase-Domäne führen, ohne dass gleichzeitig eine zweite Treibermutation (z. B. EGFR, KRAS) vorliegt, bestimmt durch eine beliebige Nukleinsäure-basierte diagnostische Testmethode, z. B. NGS, Sanger, RT-PCR, NanoString, EdgeSeq. **Teil C:** Rezidivierte oder refraktäre Neuroblastome **Teil D**: Rezidivierte oder refraktäre extrakranielle solide Tumore, die keine Neuroblastome sind, mit NTRK1/2/3-, ROS1- oder ALK-Genfusionen; Genfusionen sind definiert als diejenigen Molekülveränderungen, die zur Expression eines Fusionsproteins mit einer funktionellen TRKA/B/C-, ROS1- oder ALK-Kinase-Domäne führen, ohne dass gleichzeitig eine zweite Treibermutation (z. B. EGFR, KRAS) vorliegt, bestimmt durch eine beliebige Nukleinsäure-basierte diagnostische Testmethode, z. B. NGS, Sanger, RT-PCR, NanoString, EdgeSeq. **Teil E**: Jeder Patient, der für die Teile A (Expansion), B, C oder D geeignet ist (Alter ≥ 2 Jahre und < 22 Jahre)

		und keine Kapseln schlucken kann, sowie alle Patienten < 2 Jahre. 6. Histologische/molekulare Diagnostik der Malignität bei Erstdiagnose oder zum Zeitpunkt des Rezidivs 7. Archiviertes Tumorgewebe, das bei Erstdiagnose oder vorzugsweise zum Zeitpunkt des Rezidivs entnommen wurde 8. Alter: männlich oder weiblich ≥ 2 Jahre und < 22 Jahre; Patienten < 2 Jahre können in Teil E aufgenommen werden (alternative Dosierungstechniken) 9. Leistungsstatus: Lansky- oder Karnofsky-Score ≥ 60 % und voraussichtliche verbleibende Lebensdauer von mindestens 4 Wochen *Hinweis: Neurologische Defizite bei Patienten mit ZNS-Tumoren müssen mindestens 7 Tage vor Einschluss in die Studie relativ stabil gewesen sein. Patienten, die aufgrund von Lähmungen nicht gehen können, aber im Rollstuhl sitzen, werden zum Zweck der Leistungsbewertung als gehfähig betrachtet.* 10. Vorangehende Therapie: Rezidivierter oder refraktärer Tumor nach einer kurativen Erstlinientherapie, oder fehlende Verfügbarkeit anderer potenziell kurativer Therapiemöglichkeiten. Die Patienten müssen sich vor der Aufnahme in die Studie von den akuten toxischen Wirkungen aller vorheriger Chemotherapien, Immuntherapien oder Strahlentherapien erholt haben. a. <u>Zytotoxische Chemotherapie oder andere Krebsmedikamente, die bekanntermaßen myelosuppressiv wirken:</u> • ≥ 21 Tage nach der letzten Gabe einer zytotoxischen oder myelosuppressiven Chemotherapie (42 Tage, falls vorher Nitrosoharnstoffe verabreicht wurde). b. <u>Krebsmedikamente, ohne bekannte myelosuppressive Wirkung (z. B. nicht mit einer reduzierten Thrombozytenzahl oder reduzierten absoluten Zahl neutrophiler Granulozyten (ANC, absolute neutrophil count) assoziiert):</u> • ≥ 7 Tage nach der letzten Gabe des Medikaments. c. <u>Antikörper</u>: • ≥ 21 Tage nach der letzten Gabe. d. <u>Hämatopoetische Wachstumsfaktoren</u>: • ≥ 14 Tage nach der letzten Gabe eines langwirksamen Wachstumsfaktors (z. B. Neulasta) oder 7 Tage nach der letzten Gabe eines kurzwirksamen Wachstumsfaktors. e. <u>Stammzellinfusionen (mit oder ohne Ganzkörperbestrahlung (TBI, total body irradiation):</u> • Allogene (nicht-autologe) Knochenmark- oder Stammzelltransplantation oder jegliche Stammzellinfusion einschließlich Spenderlymphozyteninfusion (donor lymphocyte infusion, DLI) oder Boost-Infusion: ≥ 84 Tage nach der Infusion und kein Nachweis

von Spender-gegen-Wirt-Krankheit (graft-versus-host-disease, GVHD).

- Autologe Stammzellinfusion einschließlich Boost-Infusion: ≥ 42 Tage.

f. Zelltherapie: ≥ 42 Tage nach Abschluss einer beliebigen Art von Zelltherapie (z. B. modifizierte T-Zellen, NK-Zellen, dendritische Zellen usw.)

g. XRT/perkutane Bestrahlung: ≥ 14 Tage nach lokaler XRT (kleiner Port); ≥ 150 Tage nach TBI, kraniospinaler XRT oder bei Bestrahlung ≥ 50 % des Beckens; ≥ 42 Tage, wenn andere starke Bestrahlung des Knochenmarks.

h. Radiandereapeutika (z. B. radiomarkierter Antikörper, 131I-MIBG): ≥ 42 Tage nach systemisch verabreichten Radiandereapeutika.

11. Organfunktion

Adäquate Knochenmarkfunktion:

Teil A (alle), B (alle), C (unbekannt oder ohne dokumentierte Tumorinfiltration des Knochenmarks bei der Aufnahme) und D (alle):

- ANC ≥ 1.000/µl;
- Thrombozytenzahl ≥ 75.000/µl (ohne Transfusion);
- Hämoglobin ≥ 8 g/dl („Common Toxicity Criteria Adverse Event" (CTCAE)-Term Anämie, Transfusion zulässig)

Teil C (mit dokumentierter Tumorinfiltration des Knochenmarks bei der Aufnahme)

- ANC ≥ 750/µl;
- Keine bekannte Unverträglichkeit von Thrombozyten-Transfusionen
- Hämoglobin ≥ 8 g/dl (CTCAE-Term Anämie, Transfusion zulässig)

Adäquate Leberfunktion:

- ALT < 3 × obere Normwertgrenze (ULN, upper limit of normal; ULN für Protokoll: 45 U/l);
- Bilirubin < 1,5 × ULN

Adäquate Nierenfunktion:

- Serumkreatinin normal für Alter und Geschlecht:

Alter (in Jahren)	Maximum Serumkreatinin (mg/dl)	
	männlich	weiblich
2 bis < 6	0,8	0,8
6 bis < 10	1,0	1,0
10 bis < 13	1,2	1,2
13 bis < 16	1,5	1,4
> 16	1,7	1,4

Die Grenzwerte für Kreatinin in dieser Tabelle wurden von der Schwartz-Formel zur Schätzung der GFR abgeleitet [Schwartz GJ. J Pediatr 106:522-6, 1985

		utilizing child length and stature data published by the Centers for Disease Control and Prevention (CDC).] Adäquate Herzfunktion: • EKG mit QTc ≤ 480 ms Adäquate neurologische Funktion: • Periphere motorische oder sensorische Neuropathie Grad ≤ 2, sofern kein Zusammenhang mit dem Tumor oder voroperativen Eingriffen besteht 12. Frauen im gebärfähigen Alter müssen innerhalb von 14 Tagen vor der ersten Entrectinib-Dosis einen negativen Serum-Schwangerschaftstest nachweisen und dürfen während der Studienteilnahme weder stillen noch beabsichtigen, schwanger zu werden. Frauen und Männer mit Partnern im gebärfähigen Alter müssen zustimmen, während der Studie eine Schwangerschaft zu vermeiden. Darüber hinaus müssen sie der Verwendung von mindestens zwei wirksamen Verhütungsmethoden (hormonelle Methode, Barrieremethode zur Empfängnisverhütung oder Abstinenz) vor Eintritt in die Studie, für die Dauer der Studie und in den 90 Tagen nach dem Ende der Behandlung mit der Studienmedikation zustimmen. 13. Bereitschaft und Fähigkeit, geplante Visiten, Behandlungsplan, Laboruntersuchungen und andere Untersuchungsverfahren einzuhalten bzw. durchführen zu lassen **Ausschlusskriterien:** Patienten, die folgende Einschlusskriterien erfüllen, werden aus STARTRK-NG ausgeschlossen: 1. Aktuelle Teilnahme an einer weiteren klinischen Studie 2. Bekanntes angeborenes Long-QT-Syndrom 3. Bekannte aktive Infektionen (Bakterien, Pilze oder Viren) 4. Erhalt von Enzym-induzierenden Antiepileptika (EIAEDs) während der letzten 14 Tage (siehe Abschnitt 6.1.7.2, Tabelle 6, Protokoll) 5. Alle Patienten der Phase Ib: Vortherapie mit einem zugelassenen oder in der klinischen Prüfung befindlichen TRK-, ROS1- oder ALK-Inhibitor 6. Nur Teil C: Patienten mit Neuroblastom ausschließlicher Erkrankung des Knochenmarkraums 7. Unvollständige Genesung von den akuten Auswirkungen einer Operation vor der Behandlung 8. Aktive gastrointestinale Krankheit (z. B. Morbus Crohn, Colitis Ulcerosa oder Kurzdarm-Syndrom) oder andere Malabsorptionssyndrome, die die Arzneimittelresorption beeinflussen könnten 9. Andere schwerwiegende akute oder chronische medizinische oder psychiatrische Zustände oder Abweichungen in Laborparametern, die das Risiko einer Studienteilnahme oder das Risiko der Einnahme der Studienmedikation erhöhen oder die Beurteilunge der Studiendaten beeinflussen könnten und welche nach Ansicht des Prüfarztes den Patienten als ungeeignet für

		die Studie einstufen würden oder welche laut Prüfarzt und/oder Sponsor die Studienziele gefährden würden. **Rekrutierung:** Screening: Es gibt einen Screening-Zeitraum von bis zu 14 Tagen, um die Eignung der Patienten anhand der definierten Einschluss- und Ausschlusskriterien der Studie zu bewerten. Folgendes muss vor der Aufnahme der Patienten in die Studie abgeschlossen sein: • Die zustimmende Bewertung durch das „Institutional Review Board“ (IRB)/die unabhängige Ethikkommission muss vor der Aufnahme der Patienten eingeholt werden • Die Einverständniserklärung muss vor der Aufnahme eingeholt werden • Die Beurteilunge des Krankheitsstatus zu Baseline muss innerhalb von 14 Tagen vor der Aufnahme erfolgen • Untersuchungen, die im Rahmen der Standardversorgung vor der Einwilligungserklärung durchgeführt wurden UND die obigen Anforderungen erfüllen, können für das Screening herangezogen werden und müssen nicht wiederholt werden. • Der verantwortliche Prüfarzt muss die ausgefüllte Checkliste zur Eignung des Patienten unterschreiben und datieren • Die Dosierung wird zum Zeitpunkt der Aufnahme zugewiesen. • Die Patienten müssen mit der Therapie gemäß Protokoll innerhalb von 5 Kalendertagen nach der Aufnahme beginnen. **Datenerhebung und Orte, an denen die Daten erhoben wurden** Die Studie findet in 8 Zentren in den USA statt
4	Intervention	
4a	Details der vorgesehenen Interventionen für jede Studiensituation, wie und wann sie verabreicht wurden, und zwar einschließlich: • Inhalt: was wurde gegeben? • Verabreichungsmethode: wie wurde der Inhalt gegeben? • Verabreichungseinheit: wie wurden die Patienten während der Verabreichung eingeteilt? • Verabreicher: wer verabreichte die Intervention? • Umfeld: wo wurde die Intervention verabreicht? • Expositionsmenge und -dauer: wie viele Sitzungen oder Episoden oder Ereignisse sollten verabreicht werden? Wie lange sollten sie dauern?	**Studiendauer** Einschluss des ersten Patienten: 02.05.2016 Zum Datenschnitt vom 31.05.2018 lagen die Daten der Patienten vor, die bis zum 30.11.2017 in STARTRK-NG Phase I/II eingeschlossen wurden. Die Studie rekrutiert weiter. **Studiendesign** Es handelt sich um eine fünfteilige, multizentrische, offene Phase I/II-Dosiseskalationsstudie mit pädiatrischen Patienten mit rezidivierten oder refraktären extrakraniellen soliden Tumoren (Phase I; Teil A), mit zusätzlichen Expansions-Kohorten (Phase Ib) bei Patienten mit primärem Gehirntumoren mit NTRK1/2/3-, ROS1- oder ALK- Molekülveränderungen (Teil B), Neuroblastomen (Teil C) und anderen extrakraniellen soliden Tumoren, die keine Neuroblastome sind, mit NTRK1/2/3-, ROS1- oder ALK- Genfusionen (Teil D).

	• Zeitspanne: wie lange sollte die Verabreichung der Intervention bei jeder Einheit dauern? • Aktivitäten zur Erhöhung der Compliance oder Adhärenz (z. B. Anreize)	Darüber hinaus werden in einer explorativen Kohorte (Teil E) Patienten eingeschlossen, die ansonsten geeignet sind, aber keine Kapseln schlucken können. **Arzneimittelverabreichung und Zeitspanne der Verabreichung** **Phase I Teil A** (Dosiseskalation) bestimmt die maximal verträgliche Dosis (MTD, maximum tolerated dose) oder die empfohlene Phase 2 Dosis (RP2D, recommended phase 2 dose), die Pharmakokinetik (PK) und das Sicherheitsprofil von Entrectinib bei Kindern und Jugendlichen mit rezidivierten oder refraktären extrakraniellen soliden Tumoren. Entrectinib wird einmal täglich in wiederholten 4-Wochen-Zyklen oral mit der Nahrung verabreicht. Die Anfangsdosis in Teil A beträgt 250 mg/m2 KOF (ca. 63 % des auf der Körperoberfläche (BSA) basierenden RP2D-Wertes für Erwachsene von 400 mg/m2 KOF) in einer kontinuierlichen Dosierung. Es werden bis zu vier Dosisstufen bewertet. Bei einzelnen Teilnehmern sind bis zu 2 Dosisreduktionen aufgrund behandlungsassoziierte Toxizität zulässig. Während der Dosissteigerung wird ein „3 + 3“ Rekrutierungsschema durchgeführt. Die RP2D wird aus der dosislimitierenden Toxizität (DLT, dose-limiting toxicity) ermittelt, die aus klinischen Beobachtungen und Laborbemessungen im ersten Behandlungszyklus (28 Tage) stammt. Die Patienten können hinsichtlich des primären Endpunkts in Teil A bewertet werden, wenn sie das Arzneimittel aufgrund von Toxizität während Zyklus 1 abbrechen oder zu irgendeinem Zeitpunkt während Zyklus 1 DLT auftritt. Patienten, bei denen keine DLT auftritt, gelten als auswertbar hinsichtlich Toxizität, wenn sie mindestens 75 % der verordneten Dosis während Zyklus 1 (≥ 21 von 28 Dosen) erhalten haben. Patienten, die die Behandlung mit Entrectinib aufgrund einer progressiven Erkrankung (PD, progressive disease) oder aus anderen Gründen, die nicht mit der Toxizität zusammenhängen, absetzen, werden ersetzt, wenn sie im Zyklus 1 nicht 75 % der verordneten Dosis erhalten haben. Die Patienten erhalten zusätzliche Zyklen von Entrectinib, vorausgesetzt die Toxizität aus dem vorherigen Zyklus kann auf Grad ≤ 2 heruntergestuft werden und es gibt keinen Hinweis auf eine Krankheitsprogression. Die RP2D basiert auf einer Gesamtbeurteilunge von Entrectinib aus Teil A. Diese Beurteilunge umfasst das Sicherheitsprofil, das PK-Profil und alle klinischen Nachweise für die Wirksamkeit. Die RP2D kann basierend auf dieser Beurteilunge als kleiner oder gleich der MTD bestimmt werden. Darüber hinaus kann die RP2D auch vor der Festlegung einer MTD bestimmt werden, wenn eine angemessene Exposition oder klinische Nachweisen einer Aktivität in hinreichend gezeigt werden können. Die MTD ist definiert als das Dosisniveau unmittelbar unter dem Dosisniveau, bei dem bei ≥ 2 Patienten aus einer Kohorte von 3 bis 6 Patienten eine DLT auftritt. Bis zu 9 Patienten zwischen ≥ 2 und < 22 Jahren werden mit

		der MTD behandelt, darunter mindestens 3 von 9 Patienten < 12 Jahre und mindestens 3 von 9 Patienten ab 12 Jahren. Bei Kohorten, bei denen 3 oder mehr Patienten mindestens 75 % der verordneten Dosis erhalten, gilt die MTD als überschritten, wenn bei > 33 % der Patienten bei einer bestimmten Dosis eine DLT während der ersten 28 Tage der Arzneimittelgabe auftritt (Zyklus 1). Dosissteigerungen beim gleichen Patienten sind nur nach Festlegung der RP2D zulässig. Bei einzelnen Patienten, die eine Dosierung unterhalb der festgelegten RP2D erhalten, kann je nach Verträglichkeit alle zwei Zyklen die Dosierung um eine Dosisstufe bis Erreichen der RP2D eskaliert werden. Toxizität und DLT nach Zyklus 1 (Dosis bei Einschluss in die Studie) werden erfasst und bei der Bestimmung der RP2D berücksichtigt, aber nicht zur Bestimmung der MTD verwendet. Wenn der RP2D festgelegt ist, können sich Patienten, die über der RP2D behandelt werden, dafür entscheiden, ihre Dosis auf die RP2D zu deeskalieren, oder sie können die Dosisstufe beibehalten, wenn für sie die Behandlung verträglich ist. **Während der Phase Ib wird mit den Teilen B, C, D und E gleichzeitig begonnen, nachdem die RP2D in Teil A bestimmt wurde.** Die Patienten in den Teilen B, C und D erhalten Entrectinib mit der in Teil A bestimmten RP2D. Darüber hinaus werden weiterhin in Teil A (Expansion) Patienten aufgenommen mit rezidivierten oder refraktären extrakraniellen soliden Tumoren, die keine Neuroblastome sind, mit NTRK1/2/3-, ROS1- oder ALK-Molekülveränderungen, die keine Genfusionen sind und sich somit nicht für Teil D eignen. In **Teil B (Primäre Gehirntumore-Expansionskohorte)** wird die intrakranielle Tumorantwort (nach RANO; Anhang 6, Protokoll) bei Kindern und Jugendlichen mit rezidivierten oder refraktären primären ZNS-Tumoren mit NTRK1/2/3-, ROS1- oder ALK-Molekülveränderungen einschließlich Genfusionen untersucht. In **Teil C (Neuroblastom-Expansionskohorte)** wird die Tumorantwort (objektive Ansprechrate) bei Kindern und Jugendlichen mit rezidiviertem oder refraktärem Neuroblastom untersucht. In **Teil D (Genfusion-Expansionskohorte)** wird die Tumorantwort bei Kindern und Jugendlichen mit rezidivierten oder refraktären extrakraniellen soliden Tumoren, die keine Neuroblastome sind, mit NTRK1/2/3-, ROS1- oder ALK-Genfusionen untersucht. **Teil E (Explorative Kohorte):** Eine zusätzliche Kohorte ermöglicht die Aufnahme von Patienten im Alter von ≥ 2 Jahren und < 22 Jahren, die keine Kapseln schlucken können, sowie von allen Patienten < 2 Jahren, die ansonsten alle anderen Eignungskriterien für Teil A (Expansion) erfüllen. Patienten, die für die Teile B, C oder D in Frage kämen, können nach Absprache mit dem Sponsor aufgenommen werden. Die Patienten erhalten den Inhalt von Entrectinib-Kapseln entweder oral vermischt mit flüssiger oder weicher Nahrung (ihrem Alter entsprechend) oder durch enterale Ernährung. Alle

		Patienten in Teil E werden zunächst mit einer Dosisstufe behandelt, die um eine Stufe kleiner ist als die in Teil A festgelegte pädiatrische RP2D-Dosis (Dosisdeeskalation). Während des Zyklus 1 wird überwacht, ob eine DLT bei den Patienten auftritt. Abhängig von der aus den PK-Analysen ermittelten Exposition kann die tägliche Dosis für diese Patienten auf die pädiatrische RP2D eskaliert werden. **Compliance** Vor jedem Zyklus werden die Patienten gebeten, nicht benötigte Studienmedikation zurückzugeben. Die Anzahl übrig gebliebener Kapseln wird dokumentiert und die Patiententagebücher bei jeder klinischen Visite überprüft. Nicht-therapietreue Patienten können aus der Studie ausgeschlossen werden. Fehlende Therapietreue ist dabei definiert als eine Rate < 75 % der verschriebenen Dosis pro Zyklus (< 21 von 28 Dosierungen) bei Ausbleiben einer DLT.
5	Zielsetzungen	
5a	• Spezifische Studienziele und Hypothesen	**Primäres Studienziel** Bestimmung der maximal verträglichen Dosis (MTD) oder der empfohlenen Phase 2 Dosis (RP2D) von Entrectinib bei pädiatrischen Patienten (Kindern und Jugendlichen) mit rezidivierten der refraktären soliden Tumoren (Phase I, Teil A). **Sekundäre Studienziele** 1. Beschreibung des Sicherheitsprofils von Entrectinib anhand von unerwünschten Ereignissen (UE), Schweregrad, Zeitpunkt und Zusammenhang mit Entrectinib-Behandlung, sowie Auffälligkeiten beim Elektrokardiogramm (EKG) und Labor im ersten und nachfolgenden Behandlungszyklus 2. Charakterisierung der Pharmakokinetik (PK) von Entrectinib im Plasma 3. Bestimmung der objektiven Ansprechrate (ORR, objective response rate), der Dauer des Ansprechens (DOR, duration of response), der Zeit bis zum Ansprechen (TTR, time to response), der klinischen Benefitrate (CBR, clinical benefit rate) und des progressionsfreien Überlebens (PFS, progression free survival) bei allen Patienten in den Teilen A (Expansion), C und D, die Entrectinib mit RP2D erhalten, ermittelt durch RECIST v1.1 und gegebenenfalls Curie-Skala 4. Bestimmung von intrakraniellem Tumoransprechen, ZNS-PFS (CNS-PFS, CNS progression free survival) bei Patienten mit messbarer ZNS-Beteiligung in den Teilen B und D, die Entrectinib mit RP2D erhalten, via „Response Assessment in Neuro-Oncology“ (RANO)-Kriterien oder „Response Assessment in Neuro-Oncology Gehirn Metastases“ (RANO-BM)-Kriterien **Explorative Studienziele** 1. Identifikation molekularer Veränderungen der Gene, die für TRKA, TRKB, TRKC oder deren verwandte Liganden oder Co-Rezeptoren (NGF, BDNF, Neurotrophin 1/2/3, p75), ROS1 oder ALK codieren, im

		Tumorgewebe bei Beginn der Therapie (bei Rezidiv, falls vorhanden, jedoch bei Diagnose, wenn kein Rezidivtumor vorhanden ist) und zum Zeitpunkt der Progression. 2. Durchführung eines In-vitro-Bioassays mit dem Plasma der Patienten vor und 4 Stunden nach Verabreichung der ersten Dosis und im Kumulationsgleichgewicht, sowie Beurteilunge der Hemmung der TRKB-Autophosphorylierung als Antwort auf den Liganden von SY5Y-TRKB-Zellen 3. Bestimmung potenzieller zielabhängiger (TRKB) und/oder unabhängiger Mechanismen (Downstream-Effektoren) der Arzneimittelresistenz bei Patienten mit Neuroblastom, die Anzeichen für ein Fortschreiten der Erkrankung aufweisen und sich einer Biopsie unterzogen haben oder sich während der Studie einer Biopsie unterziehen können 4. Ermittlunge von möglichen Unterschieden hinsichtlich der klinisch-pathologischen Präsentation und hinsichtlich des Ansprechens auf Entrectinib zwischen den verschiedenen Tumortypen mit NTRK1/2/3-, ROS1- und ALK-Genfusionen
6	Zielkriterien	
6a	• Klar definierte primäre und sekundäre Wirksamkeitsmessgrößen • Methoden zur Datenerhebung und Methoden zur Verbesserung der Qualität von Messungen • Informationen über validierte Instrumente wie z. B. psychometrische und biometrische Eigenschaften von Selbsterhebungsinstrumenten	**Erhebung des Tumorstatus** Teile A und E: Der Tumorstatus wird zu folgenden Zeitpunkten erhoben: • Screening • Am Ende von Zyklus 2, 4 und 6 • Alle 3 Zyklen × 2 (d. h. nach den Zyklen 9 und 12) • Alle 4 Zyklen × 3 (d. h. nach den Zyklen 16, 20 und 24) • Danach alle 6 Zyklen Teile B, C und D: Der Tumorstatus wird beim Screening und danach alle 8 Wochen erhoben, beginnend mit dem Ende von Zyklus 2. Die Erhebung des Tumorstatus kann Magnetresonanztomographie (MRT)- oder Computertomographie (CT)-Scans, MIBG, +/- Knochenmarkaspirate und Biopsien umfassen, abhängig von den geeigneten Bildgebungsmodalitäten für die primäre Malignität. **Unabhängiges Bewertungsgremium (BICR, Blinded Independent Central Review):** Alle Scans werden an ein unabhängiges Labor für Bildgebung übermittelt. Dort findet die unabhängige Überprüfung des Tumoransprechens und der Krankheitsprogression während der Studie gemäß der „Imaging Review Charter" statt. **Erhebung und Analyse des primären Endpunkts** **Dosislimitierende Toxizität (DLT)** DLTs wurden während des ersten Behandlungszyklus (d.h. 28 Tage) evaluiert; die RP2D war abhängig von den DLT, die im Rahmen der Beobachtung von klinischen

		und Laborparametern auftraten. DLT ist definiert als der absolute und relative Anteil von Patienten in Phase I (Teil A, Dosissteigerung), die im Rahmen des ersten Behandlungszyklus mindestens ein DLT erfahren haben. **Analyse des primären Endpunkts** **Objektives Ansprechen (ORR, objective response rate)** ORR bewertet durch das BICR via RECIST v1.1 ist der primäre Endpunkt der Studie. Die Analyse wird in jedem Basket durchgeführt, der eine Patientenpopulation mit soliden Tumoren enthält, die NTRK1/2/3-, ROS1-, oder ALK-Genumlagerungen aufweisen. ORR ist definiert als der Anteil der Patienten mit bestätigtem kompletten Ansprechen (CR, complete response) oder partiellem Ansprechen (PR, partial response). Ein bestätigtes Ansprechen ist definiert als Ansprechen, das auf wiederholten Bildgebungen über ≥ 4 Wochen nach der initialen Dokumentation anhält. Patienten mit einem solchen bestätigten objektiven Ansprechen (CR oder PR) werden "Responder" genannt. Non-Responder werden wie folgt definiert: • Patienten ohne bestätigtes objektives Ansprechen • Patienten ohne Erhebung des post-Baseline-Tumorstatus • Patienten, die mindestens eine Dosis Entrectinib erhalten haben, aber die Behandlung aufgrund jeglichen Grundes abbrachen, bevor eine Erhebung des Ansprechens nach Baseline durchgeführt werden konnte ORR wird dargestellt als der Anteil von Respondern inklusive des zugehörigen 2-seitigen 95 % Clopper-Pearson-Konfidenzintervalls (KI). **Analyse der sekundären Endpunkte** **Klinische Benefitrate (CBR, Clinical Benefit Rate)** ist der Anteil Patienten, die eines der folgenden Kriterien erfüllen: CR oder PR **Stabile Erkrankung (SD, stable disease)** für mindestens 6 Monate nach der ersten Dosis Entrectinib, erhoben via RECIST v1.1. **Dauer des Ansprechens (DOR, duration of response)** wird nur für Responder gemessen vom Zeitpunkt des ersten objektiven Ansprechens (CR oder PR) bis zur ersten dokumentierten radiologischen Progression gemäß RECIST v1.1 oder Datum des Todes, je nachdem was zuerst eintritt. DOR wird zensiert am Tag der letzten Erhebung des Tumorstatus vor dem Beginn einer Folgetherapie bei Patienten ohne Progression, die 30 Tage nach letzter Dosis der Studienmedikation am Leben sind. **Zeit bis zum Ansprechen (Time to Response, TTR):** TTR ist definiert als die Zeit von der ersten Entrectinib-Dosis bis zur Dokumentation des ersten objektiven Ansprechens (entweder CR oder PR), bewertet mit RECIST v1.1. Bei Patienten, bei denen kein Ansprechen erzielt wird, wird das Datum der letzten Tumorbewertung

		nach Studienbeginn oder der Tod als Zensurdatum verwendet. **Progressionsfreies Überleben (Progression-Free Survival, PFS)** ist definiert als die Zeit zwischen erster Dosis Entrectinib bis zum ersten radiologischen Nachweis einer Progression oder Tod durch jegliche Ursache, je nachdem was zuerst eintritt. PFS-Daten von Patienten ohne Progression oder Tod werden zum Datum der letzten Erhebung des Tumorstatus zensiert (oder, sofern kein Tumorstatus nach der Baseline-Visite erhoben wurde, zum Datum der ersten Dosis der Studienmedikation). Zur Schätzung des mittleren PFS wird die Kaplan-Meier-Methode verwendet. **Gesamtüberleben (OS, Overall Survival):** OS ist definiert als die Zeit von der ersten Entrectinib-Dosis bis zum Todesdatum aus jeglichem Grund. Patienten, die zum Zeitpunkt der Analyse am Leben waren, werden an dem letzten bekannten Datum, an dem sie am Leben waren, zensiert. Zusätzliche Zensierungsregeln werden im SAP dargestellt. ORR und CBR werden mithilfe deskriptiver Statistiken zusammengefasst. DOR und TTR werden für einzelne Patienten aufgelistet, die ein objektives Ansprechen erzielt hatten. In Phase Ib der Studie umfassen die für Teil A (Erweiterung), C und D geplanten Analysen der sekundären Wirksamkeitsendpunkte ORR, DOR, TTR, CBR und PFS. Die für die Teile B und D (Patienten mit messbarer primärer oder sekundärer ZNS-Erkrankung zu Studienbeginn) geplanten Wirksamkeitsendpunktanalysen umfassen: intrakranielle Tumoransprechrate und ZNS-PFS. Für alle Teile ist eine OS-Analyse geplant. Weitere Informationen finden sich in Abschnitt 12.4 des Studienprotokolls. **Pharmakokinetische Analyse (PK)** PK-Analysen basieren auf der auswertbaren PK-Population. PK-Daten für Entrectinib und seinen aktiven Hauptmetaboliten M5 werden von PK-auswertbaren Patienten gesammelt. Die folgenden PK-Parameter für Entrectinib und M5-Metaboliten werden direkt aus den Plasmakonzentrations- / Zeitprofilen für jeden Patienten bezogen oder gegebenenfalls mithilfe der Non-Compartmental Analysis (NCA) geschätzt: • C_{max}: Maximal beobachtete Plasmakonzentration • T_{max}: Zeit bis zur maximal beobachteten Plasmakonzentration • T_{last}: Zeit bis zur letzten messbaren Plasmakonzentration • AUC_{last}: Fläche unter der Plasmakonzentrations-Zeit-Kurve (AUC) vom Zeitpunkt 0 bis zum letzten Zeitpunkt mit messbarer Plasmakonzentration • AUC_{0-24}: Fläche unter der Plasma-Konzentrations-Zeit-Kurve vom Zeitpunkt 0 bis 24 Stunden nach der Verabreichung

		• AUC_{0-6}: Fläche unter der Plasmakonzentrations-Zeit-Kurve vom Zeitpunkt 0 bis 6 Stunden nach der Verabreichung • C_{trough}: Durch Plasma-Talspiegel-Konzentration (Trough plasma) vor der Dosierung (pre-Dosis) PK-Parameter werden durch Standard-NCA-Methoden unter Verwendung von Phoenix WinNonlin v.6.4 (Pharsight Corporation) bestimmt. Die tatsächlichen Probenzeiten werden für alle Analysen verwendet. Nennzeiten werden verwendet, um den Mittelwert zu melden. Konzentrationen, die als unter der Bestimmungsgrenze angegeben werden, werden auf Null gesetzt, wenn sie vor der ersten nachweisbaren Konzentration auftreten, andernfalls werden sie als "fehlend" eingestuft. Die AUC wird unter Verwendung der linear-linearen Trapezregel (linear-linear trapezoidal rule) und der tatsächlichen Probeentnahmezeiten (mit Ausnahme der auf Null gesetzten Vordosis) berechnet. Die PK-Parameter und Plasmakonzentrationen von Entrectinib und M5 zu jedem nominalen Zeitpunkt werden in Auflistungen dargestellt und mittels deskriptiver Statistiken zusammengefasst einschließlich Mittelwert, Standardabweichung (SD), Minimum, Median, Maximum, Variationskoeffizient (CV), geometrische Mittelwerte und CV des geometrischen Mittels. **Biomarker-Analyse** Ab Phase I wird, sofern verfügbar, der Genfusionsstatus in den Tumorproben für jeden Patienten aufgelistet und innerhalb der Grundmerkmale der Erkrankung zusammengefasst. Zum Zeitpunkt der Primäranalyse werden keine zusätzlichen Biomarker-Analysen durchgeführt. **Sicherheitsanalyse** Der primäre Endpunkt sind DLTs bei Kindern, Jugendlichen und jungen erwachsenen Patienten mit rezidivierten oder refraktären soliden Tumoren. Die DLTs werden während des ersten Zyklus (d. H. 28 Tage) bewertet. Die RP2D wird aus der DLT bestimmt, die aus klinischen Beobachtungen und Laborbeobachtungen im ersten Behandlungszyklus abgeleitet wurde. Zu den sekundären Sicherheitsendpunkten für diese Studie gehören UE (einschließlich SUE), Todesfälle, Laborparameter, Vitalzeichenmessungen, EKG und andere anwendbare Sicherheitsparameter. **Dosislimitierende Toxizität** Die Anzahl und der Anteil der Patienten in Phase I (Teil A, Dosissteigerung), bei denen im ersten Zyklus mindestens eine DLT auftritt, wird zusammengefasst. **Unerwünschte Ereignisse (UE)** Alle während des Berichtszeitraums gemeldeten UE (ab dem Zeitpunkt, zu dem der Patient die erste Entrectinib-Dosis eingenommen hat bis 30 Tage nach der letzten Entrectinib-Dosis) werden als behandlungsassoziierte unerwünschte Ereignisse (treatment-emergent AEs, TEAEs) eingestuft.

		Zur Kodierung der UE wird Version 19.0 des Medical Dictionary for Regulatory Activities (MedDRA) verwendet. Der Schweregrad der UE wird anhand des NCI-CTCAE, v.4.03, eingestuft. Die periphere motorische und sensorische Neuropathie wird nach den pädiatrischen Einstufungskriterien (pediatric specific grading criteria) eingestuft. UE, die nicht speziell im NCI-CTCAE aufgeführt sind, werden gemäß der in Abschnitt 9.1.5 des Protokolls angegebenen Bewertungsskala bewertet. Der Zusammenhang einer UE mit Prüfpräparat wird vom Prüfer gemäß den im Protokoll aufgeführten Kriterien bewertet. UE werden nach Ausmaß (seriousness), Schweregrad (severity) und Zusammenhang zur Studienbehandlung erfasst. Ebenso erfasst werden UE, die zum Tod führen, UE, die zum Absetzen des Studienmedikaments führen und UE, die zu Dosisanpassung führen. Die UE-Daten werden anhand von MedDRA preferred terms (PT) in Häufigkeitstabellen dargestellt. Für jede Dosisstufe und für Gesamtheit der Patienten werden die Inzidenzraten von Nebenwirkungen nach System Organ Class (SOC) und PT dargestellt. **Todesfälle** Todesfälle aufgrund der Krankheitsprogression werden nicht als SUE angesehen. Der Tod wird als Outcome und nicht als bestimmtes Ereignis angesehen. Das Ereignis oder der Zustand, der das tödliche Outcome verursacht oder dazu beigetragen hat, wird als UE erhoben. Die Häufigkeit der Todesfälle wird nach Dosis und nach dem Zeitraum seit Absetzen der Behandlung zusammengefasst. **Labordaten** Labortestergebnisse werden konvertiert und in standardisierten Einheiten angegeben. Normbereiche werden verwendet, um Werte zu identifizieren, die niedrig, normal oder hoch waren, und die Laborergebnisse für Hämatologie und Chemie werden ebenfalls gemäß NCI-CTCAE v.4.03 eingestuft. Für jeden im NCI-CTCAE-System enthaltenen Laborparameter wird die Inzidenz von Anomalien durch den schlechtesten CTCAE-Grad zusammengefasst, der für jeden Patienten während des Behandlungszeitraums erreicht wird. Änderungen des Schweregrads im Vergleich zum Ausgangswert werden bewertet und in Shift-Tabellen dargestellt. **Elektrokardiogramme** Während der Studie werden EKG-Parameter wie ventrikuläre Frequenz und Standard-EKG-Intervalle PR, QT und QRS gemessen. Die QTc werden nach der Formel von Fridericia oder Bazett bestimmt. Der maximale post-Baseline QTc-Anstieg nach Kategorie wird in einer Shift-Tabelle dargestellt. **Vitalfunktionen** Abnormitäten der Vitalfunktionen (Temperatur, Blutdruck [systolisch und diastolisch], Atemfrequenz, Herzfrequenz) nach Studienbeginn werden erfasst. **Sonstige Sicherheitsanalysen**

		Gewicht und Body-Mass-Index Die maximale Gewichtszunahme oder -abnahme nach Studienbeginn wird nach NCI-CTCAE v.4.03 eingestuft und entsprechend dargestellt. Die Veränderung vom Baseline- BMI bis zum maximalen post-Baseline-Wert wird dargestellt. **Karnofsky/Lansky Performance Score** Die Veränderung des Baseline-Karnofsky/Lansky performance scores zum maximalen post-Baseline -Wert wird ebenfalls dargestellt. **Entrectinib Exposition** Die Entrectinib-Exposition, die Therapietreue (treatment compliance) und die Dosisanpassungen werden nach Dosisstufen zusammengefasst und in folgenden Parametern dargestellt: • Behandlungsdauer (Tage) • Anzahl der versäumten Dosen • Die kumulative Gesamtdosis (mg) • Dosisintensität (mg / Tag), definiert als kumulative Dosis geteilt durch die Anzahl der geplanten Tage in den abgeschlossenen Behandlungszyklen • Relative Dosisintensität (%), definiert als Dosisintensität geteilt durch die geplante Tagesdosis und ausgedrückt als Prozentsatz Die Anzahl der Probanden mit mindestens einer Dosisanpassung wird stratifiziert nach Gründen dargestellt. **Demografie und Grunderkrankung** Demografische und andere Basismerkmale werden nach Dosisgruppen und für alle Patienten zusammengefasst. **Anamnese** Begleiterkrankungen, die zum Zeitpunkt der Einwilligung nach Aufklärung und vor der ersten Entrectinib-Dosis bestehen, werden mit der MedDRA-Version 19.0 kodiert und nach SOC und PT dargestellt. **Vorangegangene und nachfolgende Krebstherapien** Frühere Krebstherapien / Medikamente werden unter Verwendung des Drug Dictionary der Weltgesundheitsorganisation (WHO), Version 01MAR2016, kodiert und nach Anatomic Therapeutic Chemical (ATC) -2nd Level und PT dargestellt. Frühere Operationen werden mit MedDRA Version 19.0 codiert und nach SOC und PT dargestellt. **Frühere und begleitende Therapien und Medikamente** Medikamente und Therapien werden mit dem WHO Drug Dictionary, Version 01MAR2016, kodiert und nach ATC-2.Stufe und PT dargestellt.
7	Fallzahl	
7a	• Wie wurden die Fallzahlen bestimmt?	**Phase I (Teil A)** Die Stichprobengröße in Teil A (Dosissteigerung) basiert auf den Anforderungen für das 3 + 3-Design von ungefähr 6-30 Probanden. **Für Teil B (Primäre Gehirntumore; Genfusionen) und Teil D (Nicht-Neuroblastom-extrakranielle solide**

		Tumore mit NTRK1/2/3-, ROS1- oder ALK-Genfusionen) Für die Teile B (Genfusionen) und D werden die Probanden in einem 2-stufigen sequenziellen Test eingeschlossen, um festzustellen, ob Entrectinib eine ausreichende Antikrebsaktivität aufweist und um die weitere Entwicklung für spezifische Patientenpopulationen mit verschieden Tumortyp- und Genfusionskombinationen zu rechtfertigen. Für jeden Basket wird eine wahre Ansprechrate von ≤ 20 % als unzureichend angenommen, um die Studie fortzuführen. Während eine wahre Ansprechrate von ≥ 40 % als ausreichend betrachtet wird. Auf Basis sequenziellen Testens mit einer mindestens 80%igen Power und einseitigem Alpha von 0,025 wird die erste Testphase pro Basket gestartet. Hier werden 13 Patienten pro Basket eingeschlossen. Ab dem 4. Patienten mit Ansprechen gilt die erste Testphase und der Basket als erfolgreich. Falls es zu weniger als 4 Patienten mit Ansprechen in der ersten Phase kommt, wird die Rekrutierung in diesem Basket geschlossen. Bei Erfolg der ersten Phase werden 49 weitere Patienten eingeschlossen. • Wenn in einem Basket der 14. Patient mit Ansprechen beobachtet wird, gilt in diesem Basket der primäre Endpunkt als erreicht (eine Ansprechrate von ≤ 20 % als widerlegt) • Falls alle 49 Patienten eingeschlossen werden und 13 Wochen nach Tag 1 Zyklus 1 weniger als 14 Patienten ein Ansprechen zeigen, gilt der primäre Endpunkt als nicht erreicht Bei einer wahren Ansprechrate von 20 % liegt die Wahrscheinlichkeit, die Rekrutierung bereits in der ersten Phase zu stoppen, bei 75 %. Gleichzeitig liegt die Wahrscheinlichkeit, die Rekrutierung bei einer wahren Ansprechrate von 40 % in der ersten Phase zu stoppen, bei 17 %. **Teil C** Das Simon's two-stage design wird angewendet, um ein Wirksamkeitssignal zu identifizieren. Stufe 1 - Einschreibung von 13 bewertbaren Patienten. Wenn es keine Patienten mit Ansprechen gibt, wird die Rekrutierung für Teil C gestoppt, da keine Beweise für die Wirksamkeit vorliegen. Wenn es einen oder mehrere Patienten mit Ansprechen gibt, kann die Rekrutierung mit Stufe 2 fortgesetzt werden. Stufe 2 – Einschreibung von 7 zusätzlichen Patienten für insgesamt 20 auswertbare Probanden. Bei 2 oder weniger Patienten mit Ansprechen zeigt sich keine ausreichende Evidenz für die Wirksamkeit. Bei 3 oder mehr Patienten mit Ansprechen gibt es ausreichende Evidenz für die Wirksamkeit, um eine weitere Studie zu rechtfertigen. Dieses Design hat eine 90%ige Power (alpha = 0.074), um die Nullhypothese, einer Responserate < 5 % im Vergleich zur alternativen Hypothese mit einer Responserate > 25 % abzulehnen. Die erwartete Stichprobengröße beträgt 14.82 und die

		Wahrscheinlichkeit einer vorzeitigen Beendigung beträgt 0.599. **Teil A (Expansion), Teil B (Nicht-Genfusionen), Teil E** Diese Kohorten werden explorativ ausgewertet und können hinsichtlich ihrer Wirksamkeit nicht beurteilt werden. Sie tragen hauptsächlich zur Beurteilunge von Sicherheit und PK bei. **Explorations- / Korrelationsstudien** **Plasma-Hemmungstest:** Die prozentuale Änderung der TRKB-Phosphorylierung bei jeder Dosisstufe (vom Vordosiszyklus 1 Tag 1 bis 4 Stunden nach der Dosis 1 [C_{max}]; vom Vordosiszyklus 1 Tag 1 bis zum Vordosiszyklus 1 Tag 15) [Steady State]) wird mittels deskriptiver Statistik (Quartile / Bereich) zusammengefasst und die mittlere / mittlere prozentuale Änderung der TRKB-Phosphorylierung grafisch dargestellt. Die Menge an TRKB-Phosphorylierung bei jeder Dosisstufe im Steady-State wird ebenfalls mittels deskriptiver Statistiken dargestellt.
7b	• Falls notwendig, Beschreibung von Zwischenanalysen und Kriterien für einen vorzeitigen Studienabbruch	
8	Zuweisungsmethode • Zuweisungseinheit (die Einheit, die der Studienbedingung zugewiesen wird, wie z. B. Person, Gruppe, Gemeinde) • Methode der Zuweisung von Einheiten zu Studienbedingungen, einschließlich Details über etwaige Restriktion (z. B. Blockbildung, Stratifikation, Minimierung) • Einbeziehung von Aspekten, um potenzielle Verzerrung durch Nichtrandomisierung zu minimieren (z. B. Matching)	**Zuweisung** Nichtzutreffend aufgrund des Studiendesigns
9	Verblindung	
9a	• Waren a) die Probanden / Patienten und / oder b) diejenigen, die die Intervention / Behandlung durchführten, und / oder c) diejenigen, die die Zielgrößen beurteilten, verblindet oder nicht verblindet, wie wurde die Verblindung vorgenommen?	**Verblindung** Nicht zutreffend: offene Studie
10	Analyseeinheit • Bezeichnung der kleinsten Einheit, die analysiert wird, um Wirkungen der Intervention zu beurteilen (z. B. Person, Gruppe, Gemeinde) • Wenn sich die Analyseneinheit von der Zuweisungseinheit unterscheidet, ist die verwendete Analysenmethode anzugeben, die dies berücksichtigt (z. B. Adjustierung der Standardfehlerschätzungen um den	

	Designeffekt oder durch Verwendung einer Multilevel-Analyse)	
11	Statistische Methoden	
11a	• Statistische Methoden zur Bewertung der primären und sekundären Zielkriterien einschließlich komplexer Methoden für korrelierte Daten	Es war kein formaler statistischer Hypothesentest für Phase I (Teil A) geplant. Wirksamkeits-, PK- und Sicherheitsdaten wurden unter Verwendung deskriptiver Statistiken zusammengefasst. Für Time-to-Event Analysen sind Kaplan-Meier Analysen geplant.
11b	• Verwendete statistische Methoden für zusätzliche Analysen, wie z. B. Subgruppenanalysen und adjustierte Analysen • Methoden zur Imputation fehlender Daten • Falls verwendet: Verwendete statistische Software oder Programme	
Resultate		
12	Patientenfluss	
12a	• Patientenfluss durch jede Studienphase: Rekrutierung, Zuweisung, Allokation und Interventionsexposition, Nachbeobachtung, Analyse (Diagramm siehe unten)	
12b	• Rekrutierung: die Anzahl der Teilnehmer, die auf ihre Eignung gescreent werden, sich als geeignet oder nicht geeignet erweisen, nicht in die Studie aufgenommen und in die Studie aufgenommen werden • Zuweisung: die Anzahl der Teilnehmer, die einer Studienbedingung zugewiesen wurden • Allokation und Interventionsexposition: die Anzahl der Teilnehmer, die jeder Studienbedingung zugewiesen werden, und die Anzahl der Teilnehmer, die jede Intervention erhielten • Nachbeobachtung: die Anzahl der Teilnehmer, die das Follow-up abschlossen oder das Follow-up nicht abschlossen (lost to follow-up), aufgeschlüsselt nach Studienbedingungen • Analyse: die Anzahl der Teilnehmer, die in die Hauptanalyse einbezogen oder ausgeschlossen wurden, aufgeschlüsselt nach Studienbedingungen • Beschreibung von Abweichungen vom Prüfplan der Studie unter Angabe von Gründen	Insgesamt 17 Patienten wurden während des Phase I-Teils der Studie zwischen 02.05.2016 und 30.11.2017 gescreent, ein Patient brach das Screening ab. Der Grund für die Beendigung des Screenings war der Widerruf der Einwilligung (Hinweis: Die Daten für den Abbruch des Screenings wurden nicht validiert). Insgesamt 16 Patienten wurden an acht Standorten in den USA in den Phase I-Teil (Dosissteigerung) der Studie eingeschlossen. Die Anzahl der Patienten, die bei jeder Dosisstufe eingeschlossen wurden, war wie folgt: drei Patienten mit 250 mg/m²; drei Patienten mit 400 mg/m2 KOF; sieben Patienten mit 550 mg/m2 KOF; und drei Patienten mit 750 mg/m2 KOF. Zum Zeitpunkt des klinischen Datenschnitts (31.05.2018) wurden insgesamt sieben Patienten (43,8 %) aus der Studie ausgeschlossen. Drei Patienten (18,8 %) blieben in der Studienbehandlung und fünf Patienten (31,3 %) befanden sich im survival follow-up. Der häufigste Grund für die Beendigung der Studie war der Tod, der für fünf Patienten (31,3 %) berichtet wurde, die zuvor eine Progression der Krankheit aufwiesen. Bei einem dieser Patienten spiegelte sich der Studienabbruch aufgrund eines Todesfalls zum Zeitpunkt des klinischen Datenschnitts nicht in der klinischen Datenbank wider. Die anderen drei Patienten (18,8 %) brachen die Studie aus „anderen“ Gründen ab, im Speziellen: „Patient begann mit einer anderen Chemotherapie“, „Patient begann mit einer Strahlentherapie“ und „Patient begann mit einer neuen Behandlung“. Diese drei Patienten hatten die Behandlung aufgrund von Krankheitsprogression bereits vor Beendigung der Studie abgebrochen.

		Insgesamt 13 Patienten (81,3 %) hatten die medikamentöse Behandlung der Studie abgebrochen. Der häufigste Grund für den Abbruch der Behandlung war Krankheitsprogression, berichtet bei 12 Patienten (75%). Der andere Patient brach die Behandlung aufgrund eines Widerrufs der Einwilligung ab.
13	Aufnahme / Rekrutierung	
13a	• Nähere Angaben über den Zeitraum der Studienaufnahme der Probanden / Patienten und der Nachbeobachtung	Die Ergebnisse des klinischen Datenschnitts vom 31.05.2018 beinhalten die Daten vom 02.05.2017 (first patient enrolled) bis zum 31.05.2018 für Patienten, die bis zum 30.11.2017 (Enrollment cut-off) eingeschlossen wurden. Nachbeobachtung Patienten, die die Behandlung abbrachen werden in die Überlebens-Nachbeobachtungsphase eingeschlossen und verbleiben bis zum Tod in der Studie, loss to follow up oder Entzug der Einverständniserklärung (Infored Consent), je nach dem was zuerst eintritt.
13b	• Informationen, warum die Studie endete oder beendet wurde	Es handelt sich um eine laufende Studie.
a: nach TREND 2004.		



Abbildung 4-70: Flussdiagramm STARTRK-NG (Datenschnitt NDA)

Ergänzende Evidenz

Daten der STARTRK-2

Charakterisierung der Studienpopulation, Patientenverteilung und beteiligte Zentren

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
Sex	
n	37
Male	14 (37.8%)
Female	23 (62.2%)
Age (years)	
n	37
Mean (SD)	53.3 (11.5)
Median	53
Q1, Q3	46.0, 61.0
Min, Max	28, 73
Age category	
n	37
< 65	29 (78.4%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_REE.xls
06DEC2019 20:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
>= 65	8 (21.6%)
Region	
AM	12 (32.4%)
AS	15 (40.5%)
n	37
Europe (EU)	10 (27.0%)
Race	
n	37
White	20 (54.1%)
Asian	14 (37.8%)
Black or African American	3 (8.1%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_REE.xls
06DEC2019 20:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
Ethnicity	
n	37
Hispanic or Latino	2 (5.4%)
Not Hispanic or Latino	35 (94.6%)
Baseline Weight (kg)	
n	37
Mean (SD)	73.79 (16.40)
Median	71,6
Q1, Q3	63.50, 82.40
Min, Max	44.9, 115.9

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_REE.xls
06DEC2019 20:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
Baseline BMI (kg/m2)	
n	37
Mean (SD)	26.77 (4.98)
Median	25,65
Q1, Q3	23.32, 30.31
Min, Max	17.8, 39.2
Does Patient Have a History of Smoking?	
n	37
Yes	18 (48.6%)
No	19 (51.4%)
Smoking History	

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_REE.xls
06DEC2019 20:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
n	18
Current Smoker	1 (5.6%)
Former Smoker	17 (94.4%)
Baseline ECOG Performance Status	
n	37
0	15 (40.5%)
1	17 (45.9%)
2	5 (13.5%)
BICR Confirmed Measurable Disease at Baseline	
n	37
Measurable	35 (94.6%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_REE.xls
06DEC2019 20:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
Non-Measurable	2 (5.4%)
Have Received at least One Dose of Entrectinib	
n	37
Yes	37 (100.0%)
Patients with BICR Confirmed Measurable Disease at Baseline & Patients who Have Received at least One Dose of Entrectinib	
n	37
Yes & Yes	35 (94.6%)
No & Yes	2 (5.4%)
Tumor Entities/Types (HIGH LEVEL TERM; LOW LEVEL TERM)	
n	37
THORACIC; NSCLC	37 (100.0%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_REE.xls
06DEC2019 20:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
CNS Metastases by BICR	
n	37
Yes	17 (45.9%)
No	20 (54.1%)
CNS Metastases by Investigator	
n	37
Yes	18 (48.6%)
No	19 (51.4%)
Primary Brain Tumors	
n	37

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_REE.xls
06DEC2019 20:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
No	37 (100.0%)
Patients with CNS Metastases by Investigator & Patients with Primary Brain Tumors	
n	37
Yes & No	18 (48.6%)
No & No	19 (51.4%)
Prior Treatment in Patients with Metastases	
n	23
Chemotherapy	15 (65.2%)
Chemotherapy & Immunotherapy	1 (4.3%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	1 (4.3%)
Chemotherapy & Immunotherapy & Targeted therapy	2 (8.7%)

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
Chemotherapy & Monoclonal antibody	1 (4.3%)
Chemotherapy & Targeted therapy	2 (8.7%)
Targeted therapy	1 (4.3%)
CNS Metastases Treatment	
n	12
Chemotherapy	9 (75.0%)
Chemotherapy & Immunotherapy	1 (8.3%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	1 (8.3%)
Chemotherapy & Immunotherapy & Targeted therapy	1 (8.3%)
Measurable/Non-Measurable Lesions at Baseline (IRC)	
n	37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
Measurable	35 (94.6%)
Non-Measurable	2 (5.4%)
Histologic Type	
n	37
Adenocarcinoma	35 (94.6%)
Bronchioloalveolar carcinoma	1 (2.7%)
Carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements	1 (2.7%)
Initial Stage of Disease	
n	37
IB	2 (5.4%)
IIB	1 (2.7%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_REE.xls
06DEC2019 20:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
IIIA	5 (13.5%)
IIIB	3 (8.1%)
IIIC	1 (2.7%)
IV	24 (64.9%)
Unknown	1 (2.7%)
Prior Brain Radiation in Patients with CNS Metastases at Baseline	
n	37
Yes	13 (35.1%)
No	5 (13.5%)
No CNS Metastases at Baseline	19 (51.4%)
Extent of Disease at Baseline	
n	37

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_REE.xls
06DEC2019 20:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
locally advanced	1 (2.7%)
metastatic	36 (97.3%)
Sites of Metastases	
n	36
Bone & Brain	2 (5.6%)
Bone & Brain & Liver & Lung & Lymph Node	1 (2.8%)
Bone & Brain & Liver & Lung & Lymph Node & Other	1 (2.8%)
Bone & Brain & Liver & Lymph Node	1 (2.8%)
Bone & Brain & Liver & Lymph Node & Other	1 (2.8%)
Bone & Brain & Lung & Lymph Node	1 (2.8%)
Bone & Brain & Lung & Other	1 (2.8%)
Bone & Brain & Lymph Node & Other	1 (2.8%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_REE.xls
06DEC2019 20:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
Bone & Liver & Lung	1 (2.8%)
Bone & Liver & Lung & Lymph Node	1 (2.8%)
Bone & Liver & Lung & Lymph Node & Other	1 (2.8%)
Bone & Lung	1 (2.8%)
Bone & Lung & Lymph Node	1 (2.8%)
Bone & Lung & Lymph Node & Other	1 (2.8%)
Bone & Lymph Node	1 (2.8%)
Brain & Liver & Lung & Lymph Node	1 (2.8%)
Brain & Lung	2 (5.6%)
Brain & Lung & Lymph Node & Other	3 (8.3%)
Brain & Lymph Node	2 (5.6%)
Brain & Lymph Node & Other	1 (2.8%)
Lung	2 (5.6%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_REE.xls
06DEC2019 20:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
Lung & Lymph Node	5 (13.9%)
Lymph Node	4 (11.1%)
Prior Anti-cancer Therapies (systemic, radiation or surgery)	
n	37
Yes	34 (91.9%)
No	3 (8.1%)
Number of Prior Anti-cancer Therapies	
n	37
0	3 (8.1%)
1	3 (8.1%)
2	9 (24.3%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_REE.xls
06DEC2019 20:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
3	8 (21.6%)
4	2 (5.4%)
5	4 (10.8%)
6	4 (10.8%)
7	2 (5.4%)
9	1 (2.7%)
19	1 (2.7%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_REE.xls
06DEC2019 20:15

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
Sex	
n	105
Male	45 (42.9%)
Female	60 (57.1%)
Age (years)	
n	105
Mean (SD)	54.1 (13.2)
Median	54
Q1, Q3	46.0, 64.0
Min, Max	15, 86
Age category	
n	105
< 65	79 (75.2%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
>= 65	26 (24.8%)
Region	
AM	30 (28.6%)
AS	47 (44.8%)
n	105
Europe (EU)	28 (26.7%)
Race	
n	105
White	48 (45.7%)
Asian	45 (42.9%)
Black or African American	7 (6.7%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
Not Reported	4 (3.8%)
Missing	1 (1.0%)
Ethnicity	
n	105
Hispanic or Latino	2 (1.9%)
Not Hispanic or Latino	98 (93.3%)
Not Reported	2 (1.9%)
Unknown	2 (1.9%)
Missing	1 (1.0%)
Baseline Weight (kg)	
n	105

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
Mean (SD)	67.70 (15.66)
Median	67,5
Q1, Q3	58.05, 75.40
Min, Max	38.5, 115.9
Baseline BMI (kg/m2)	
n	105
Mean (SD)	24.84 (4.93)
Median	23,88
Q1, Q3	21.87, 27.22
Min, Max	15.5, 44.1
Does Patient Have a History of Smoking?	

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
n	105
Yes	46 (43.8%)
No	59 (56.2%)
Smoking History	
n	46
Current Smoker	4 (8.7%)
Former Smoker	42 (91.3%)
Baseline ECOG Performance Status	
n	105
0	40 (38.1%)
1	51 (48.6%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
2	12 (11.4%)
3	1 (1.0%)
4	1 (1.0%)
BICR Confirmed Measurable Disease at Baseline	
n	105
Measurable	92 (87.6%)
Non-Measurable	13 (12.4%)
Have Received at least One Dose of Entrectinib	
n	105
Yes	105 (100.0%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
Patients with BICR Confirmed Measurable Disease at Baseline & Patients who Have Received at least One Dose of Entrectinib	
n	105
Yes & Yes	92 (87.6%)
No & Yes	13 (12.4%)
Tumor Entities/Types (HIGH LEVEL TERM; LOW LEVEL TERM)	
n	105
THORACIC; NSCLC	105 (100.0%)
CNS Metastases by BICR	
n	105
Yes	47 (44.8%)
No	58 (55.2%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
CNS Metastases by Investigator	
n	105
Yes	53 (50.5%)
No	52 (49.5%)
Primary Brain Tumors	
n	105
No	105 (100.0%)
Patients with CNS Metastases by Investigator & Patients with Primary Brain Tumors	
n	105
Yes & No	53 (50.5%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
No & No	52 (49.5%)
Prior Treatment in Patients with Metastases	
n	64
Chemotherapy	28 (43.8%)
Chemotherapy & Immunotherapy	7 (10.9%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	2 (3.1%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy & Other	1 (1.6%)
Chemotherapy & Immunotherapy & Targeted therapy	3 (4.7%)
Chemotherapy & Monoclonal antibody	4 (6.3%)
Chemotherapy & Monoclonal antibody & Targeted therapy	3 (4.7%)
Chemotherapy & Targeted therapy	7 (10.9%)
Immunotherapy & Targeted therapy	1 (1.6%)

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
Targeted therapy	8 (12.5%)
CNS Metastases Treatment	
n	33
Chemotherapy	13 (39.4%)
Chemotherapy & Immunotherapy	3 (9.1%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	1 (3.0%)
Chemotherapy & Immunotherapy & Targeted therapy	2 (6.1%)
Chemotherapy & Monoclonal antibody	1 (3.0%)
Chemotherapy & Monoclonal antibody & Targeted therapy	3 (9.1%)
Chemotherapy & Targeted therapy	2 (6.1%)
Immunotherapy & Targeted therapy	1 (3.0%)
Targeted therapy	7 (21.2%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
Measurable/Non-Measurable Lesions at Baseline (IRC)	
n	105
Measurable	92 (87.6%)
Non-Measurable	13 (12.4%)
Histologic Type	
n	105
Adenocarcinoma	102 (97.1%)
Bronchioloalveolar carcinoma	1 (1.0%)
Carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements	2 (1.9%)
Initial Stage of Disease	

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
n	105
IA	3 (2.9%)
IB	5 (4.8%)
IIA	2 (1.9%)
IIB	1 (1.0%)
IIIA	8 (7.6%)
IIIB	7 (6.7%)
IIIC	1 (1.0%)
IV	77 (73.3%)
Unknown	1 (1.0%)
Prior Brain Radiation in Patients with CNS Metastases at Baseline	
n	105

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
Yes	33 (31.4%)
No	20 (19.0%)
No CNS Metastases at Baseline	52 (49.5%)
Extent of Disease at Baseline	
n	105
locally advanced	4 (3.8%)
metastatic	101 (96.2%)
Sites of Metastases	
n	101
Bone & Brain	5 (5.0%)
Bone & Brain & Liver & Lung	1 (1.0%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
Bone & Brain & Liver & Lung & Lymph Node	1 (1.0%)
Bone & Brain & Liver & Lung & Lymph Node & Other	1 (1.0%)
Bone & Brain & Liver & Lymph Node	3 (3.0%)
Bone & Brain & Liver & Lymph Node & Other	1 (1.0%)
Bone & Brain & Lung	4 (4.0%)
Bone & Brain & Lung & Lymph Node	2 (2.0%)
Bone & Brain & Lung & Lymph Node & Other	1 (1.0%)
Bone & Brain & Lung & Other	1 (1.0%)
Bone & Brain & Lymph Node & Other	1 (1.0%)
Bone & Brain & Other	1 (1.0%)
Bone & Liver	1 (1.0%)
Bone & Liver & Lung	1 (1.0%)
Bone & Liver & Lung & Lymph Node	2 (2.0%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
Bone & Liver & Lung & Lymph Node & Other	3 (3.0%)
Bone & Lung	2 (2.0%)
Bone & Lung & Lymph Node	2 (2.0%)
Bone & Lung & Lymph Node & Other	2 (2.0%)
Bone & Lymph Node	4 (4.0%)
Bone & Lymph Node & Other	2 (2.0%)
Bone & Lymph Node & Skin & Other	1 (1.0%)
Brain	4 (4.0%)
Brain & Liver	1 (1.0%)
Brain & Liver & Lung & Lymph Node	1 (1.0%)
Brain & Liver & Lung & Lymph Node & Other	2 (2.0%)
Brain & Lung	3 (3.0%)
Brain & Lung & Lymph Node	3 (3.0%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
Brain & Lung & Lymph Node & Other	5 (5.0%)
Brain & Lymph Node	7 (6.9%)
Brain & Lymph Node & Other	4 (4.0%)
Brain & Other	1 (1.0%)
Liver & Lung & Lymph Node	1 (1.0%)
Liver & Lymph Node	2 (2.0%)
Lung	3 (3.0%)
Lung & Lymph Node	9 (8.9%)
Lymph Node	8 (7.9%)
Lymph Node & Other	4 (4.0%)
Other	1 (1.0%)
Prior Anti-cancer Therapies (systemic, radiation or surgery)	

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
n	105
Yes	90 (85.7%)
No	15 (14.3%)
Number of Prior Anti-cancer Therapies	
n	105
0	15 (14.3%)
1	10 (9.5%)
2	16 (15.2%)
3	20 (19.0%)
4	8 (7.6%)
5	13 (12.4%)
6	6 (5.7%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
7	7 (6.7%)
8	2 (1.9%)
9	2 (1.9%)
11	1 (1.0%)
13	2 (1.9%)
18	2 (1.9%)
19	1 (1.0%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SEROS1.xls
06DEC2019 20:30

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
Sex	
n	206
Male	89 (43.2%)
Female	117 (56.8%)
Age (years)	
n	206
Mean (SD)	54.2 (14.0)
Median	55,5
Q1, Q3	46.0, 65.0
Min, Max	15, 86
Age category	
n	206
< 65	149 (72.3%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
>= 65	57 (27.7%)
Region	
AM	97 (47.1%)
AS	64 (31.1%)
n	206
Europe (EU)	45 (21.8%)
Race	
n	206
White	114 (55.3%)
Asian	66 (32.0%)
Black or African American	9 (4.4%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
Not Reported	16 (7.8%)
Missing	1 (0.5%)
Ethnicity	
n	206
Hispanic or Latino	7 (3.4%)
Not Hispanic or Latino	183 (88.8%)
Not Reported	7 (3.4%)
Unknown	8 (3.9%)
Missing	1 (0.5%)
Baseline Weight (kg)	
n	206

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
Mean (SD)	69.47 (17.86)
Median	69,5
Q1, Q3	57.66, 80.90
Min, Max	31.6, 130.2
Baseline BMI (kg/m2)	
n	205
Mean (SD)	24.89 (5.28)
Median	24,26
Q1, Q3	21.57, 27.44
Min, Max	12.3, 44.1
Does Patient Have a History of Smoking?	

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
n	206
Yes	84 (40.8%)
No	122 (59.2%)
Smoking History	
n	84
Current Smoker	13 (15.5%)
Former Smoker	71 (84.5%)
Baseline ECOG Performance Status	
n	206
0	84 (40.8%)
1	97 (47.1%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
2	21 (10.2%)
3	3 (1.5%)
4	1 (0.5%)
BICR Confirmed Measurable Disease at Baseline	
n	206
Measurable	179 (86.9%)
Non-Measurable	27 (13.1%)
Have Received at least One Dose of Entrectinib	
n	206
Yes	206 (100.0%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
Patients with BICR Confirmed Measurable Disease at Baseline & Patients who Have Received at least One Dose of Entrectinib	
n	206
Yes & Yes	179 (86.9%)
No & Yes	27 (13.1%)
Tumor Entities/Types (HIGH LEVEL TERM; LOW LEVEL TERM)	
n	205
BREAST; BREAST (NON-SECRETORY)	2 (1.0%)
BREAST; BREAST (SECRETORY)	3 (1.5%)
GI - CRC; CRC	6 (2.9%)
GI - NON-CRC; APPENDICEAL	1 (0.5%)
GI - NON-CRC; CHOLANGIOCARCINOMA	1 (0.5%)
GI - NON-CRC; GASTRIC CANCER	1 (0.5%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
GI - NON-CRC; GASTROESOPHAGEAL JUNCTION CANCER	1 (0.5%)
GI - NON-CRC; PANCREATIC	5 (2.4%)
GYNECOLOGICAL; ENDOMETRIOID	1 (0.5%)
GYNECOLOGICAL; OVARIAN	2 (1.0%)
GYNECOLOGICAL; UTERINE	1 (0.5%)
HEAD AND NECK; MASC	10 (4.9%)
HEAD AND NECK; PAPILLARY THYROID	5 (2.4%)
HEAD AND NECK; THYROID - OTHER	2 (1.0%)
NEUROENDOCRINE; NEUROENDOCRINE	3 (1.5%)
NHL; ALCL	1 (0.5%)
PRIMARY BRAIN TUMORS; GLIOMA	8 (3.9%)
PRIMARY BRAIN TUMORS; GLIONEURONAL	1 (0.5%)
SARCOMA; CERVICAL ADENOSARCOMA	1 (0.5%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
SARCOMA; DEDIFFERENTIATED CHONDROSARCOMA	1 (0.5%)
SARCOMA; ENDOMETRIAL STROMAL SARCOMA	3 (1.5%)
SARCOMA; EWINGS SARCOMA	1 (0.5%)
SARCOMA; FOLLICULAR DENDRITIC CELL SARCOMA	1 (0.5%)
SARCOMA; GIST	1 (0.5%)
SARCOMA; INFLAMMATORY MYOFIBROBLASTIC TUMOR	2 (1.0%)
SARCOMA; LEIOMYOSARCOMA	3 (1.5%)
SARCOMA; MPNST	1 (0.5%)
SARCOMA; OSTEOSARCOMA	1 (0.5%)
SARCOMA; SARCOMA (NOS)	9 (4.4%)
SARCOMA; SARCOMA OTHER	1 (0.5%)
SARCOMA; SYNOVIAL SARCOMA	1 (0.5%)
THORACIC; MESOTHELIOMA	1 (0.5%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
THORACIC; NSCLC	124 (60.5%)
CNS Metastases by BICR	
n	206
Yes	67 (32.5%)
No	139 (67.5%)
CNS Metastases by Investigator	
n	206
Yes	80 (38.8%)
No	126 (61.2%)
Primary Brain Tumors	

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
n	206
Yes	9 (4.4%)
No	197 (95.6%)
Patients with CNS Metastases by Investigator & Patients with Primary Brain Tumors	
n	206
Yes & Yes	1 (0.5%)
Yes & No	79 (38.3%)
No & Yes	8 (3.9%)
No & No	118 (57.3%)
Prior Treatment in Patients with Metastases	
n	128

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
Chemotherapy	49 (38.3%)
Chemotherapy & Hormonal therapy	2 (1.6%)
Chemotherapy & Hormonal therapy & Targeted therapy	2 (1.6%)
Chemotherapy & Immunotherapy	13 (10.2%)
Chemotherapy & Immunotherapy & Monoclonal antibody	1 (0.8%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	2 (1.6%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy & Other	2 (1.6%)
Chemotherapy & Immunotherapy & Targeted therapy	7 (5.5%)
Chemotherapy & Monoclonal antibody	13 (10.2%)
Chemotherapy & Monoclonal antibody & Targeted therapy	4 (3.1%)
Chemotherapy & Targeted therapy	16 (12.5%)
Immunotherapy & Targeted therapy	1 (0.8%)
Targeted therapy	16 (12.5%)

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
CNS Metastases Treatment	
n	53
Chemotherapy	15 (28.3%)
Chemotherapy & Hormonal therapy & Targeted therapy	1 (1.9%)
Chemotherapy & Immunotherapy	6 (11.3%)
Chemotherapy & Immunotherapy & Monoclonal antibody	1 (1.9%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	1 (1.9%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy & Other	1 (1.9%)
Chemotherapy & Immunotherapy & Targeted therapy	3 (5.7%)
Chemotherapy & Monoclonal antibody	1 (1.9%)
Chemotherapy & Monoclonal antibody & Targeted therapy	3 (5.7%)
Chemotherapy & Targeted therapy	6 (11.3%)

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
Immunotherapy & Targeted therapy	1 (1.9%)
Targeted therapy	14 (26.4%)
Measurable/Non-Measurable Lesions at Baseline (IRC)	
n	206
Measurable	179 (86.9%)
Non-Measurable	27 (13.1%)
Histologic Type	
n	206
Adenocarcinoma	140 (68.0%)
Bronchioloalveolar carcinoma	1 (0.5%)
Carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements	4 (1.9%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
Neuroendocrine	3 (1.5%)
Spindle cell	8 (3.9%)
Squamous-cell carcinoma	3 (1.5%)
Unclassified carcinoma/Undifferentiated carcinoma	4 (1.9%)
Other	41 (19.9%)
Not Applicable	1 (0.5%)
Unknown	1 (0.5%)
Initial Stage of Disease	
n	206
0	1 (0.5%)
IA	9 (4.4%)
IB	7 (3.4%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
IIA	8 (3.9%)
IIB	7 (3.4%)
IIIA	19 (9.2%)
IIIB	15 (7.3%)
IIIC	3 (1.5%)
IV	128 (62.1%)
Unknown	9 (4.4%)
Prior Brain Radiation in Patients with CNS Metastases at Baseline	
n	206
Yes	56 (27.2%)
No	24 (11.7%)
No CNS Metastases at Baseline	126 (61.2%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
Extent of Disease at Baseline	
n	206
locally advanced	13 (6.3%)
metastatic	192 (93.2%)
Missing	1 (0.5%)
Sites of Metastases	
n	192
Bone	1 (0.5%)
Bone & Brain	6 (3.1%)
Bone & Brain & Liver & Lung	4 (2.1%)
Bone & Brain & Liver & Lung & Lymph Node	1 (0.5%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
Bone & Brain & Liver & Lung & Lymph Node & Other	1 (0.5%)
Bone & Brain & Liver & Lymph Node	3 (1.6%)
Bone & Brain & Liver & Lymph Node & Other	3 (1.6%)
Bone & Brain & Lung	4 (2.1%)
Bone & Brain & Lung & Lymph Node	3 (1.6%)
Bone & Brain & Lung & Lymph Node & Other	2 (1.0%)
Bone & Brain & Lung & Other	2 (1.0%)
Bone & Brain & Lymph Node	1 (0.5%)
Bone & Brain & Lymph Node & Other	2 (1.0%)
Bone & Brain & Other	1 (0.5%)
Bone & Brain & Skin & Other	1 (0.5%)
Bone & Liver	1 (0.5%)
Bone & Liver & Lung	3 (1.6%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
Bone & Liver & Lung & Lymph Node	3 (1.6%)
Bone & Liver & Lung & Lymph Node & Other	4 (2.1%)
Bone & Liver & Lung & Lymph Node & Skin	1 (0.5%)
Bone & Liver & Lung & Other	1 (0.5%)
Bone & Liver & Lymph Node	2 (1.0%)
Bone & Lung	3 (1.6%)
Bone & Lung & Lymph Node	2 (1.0%)
Bone & Lung & Lymph Node & Other	3 (1.6%)
Bone & Lung & Other	1 (0.5%)
Bone & Lymph Node	6 (3.1%)
Bone & Lymph Node & Other	2 (1.0%)
Bone & Lymph Node & Skin & Other	1 (0.5%)
Brain	8 (4.2%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
Brain & Liver	1 (0.5%)
Brain & Liver & Lung & Lymph Node	3 (1.6%)
Brain & Liver & Lung & Lymph Node & Other	2 (1.0%)
Brain & Liver & Lung & Lymph Node & Skin & Other	1 (0.5%)
Brain & Lung	5 (2.6%)
Brain & Lung & Lymph Node	3 (1.6%)
Brain & Lung & Lymph Node & Other	6 (3.1%)
Brain & Lymph Node	7 (3.6%)
Brain & Lymph Node & Other	7 (3.6%)
Brain & Lymph Node & Skin	1 (0.5%)
Brain & Lymph Node & Skin & Other	1 (0.5%)
Brain & Other	1 (0.5%)
Liver	5 (2.6%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
Liver & Lung	3 (1.6%)
Liver & Lung & Lymph Node	6 (3.1%)
Liver & Lymph Node	4 (2.1%)
Liver & Lymph Node & Other	1 (0.5%)
Liver & Other	1 (0.5%)
Lung	13 (6.8%)
Lung & Lymph Node	13 (6.8%)
Lung & Lymph Node & Other	5 (2.6%)
Lung & Other	3 (1.6%)
Lung & Skin	1 (0.5%)
Lymph Node	13 (6.8%)
Lymph Node & Other	5 (2.6%)
Other	5 (2.6%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
Prior Anti-cancer Therapies (systemic, radiation or surgery)	
n	206
Yes	191 (92.7%)
No	15 (7.3%)
Number of Prior Anti-cancer Therapies	
n	206
0	15 (7.3%)
1	14 (6.8%)
2	23 (11.2%)
3	33 (16.0%)
4	19 (9.2%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
5	29 (14.1%)
6	17 (8.3%)
7	15 (7.3%)
8	8 (3.9%)
9	5 (2.4%)
10	3 (1.5%)
11	7 (3.4%)
12	3 (1.5%)
13	3 (1.5%)
14	1 (0.5%)
15	2 (1.0%)
16	1 (0.5%)
18	4 (1.9%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
19	1 (0.5%)
20	2 (1.0%)
27	1 (0.5%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dm_NDA_SE.xls
06DEC2019 21:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Sex	
n	78
Male	29 (37.2%)
Female	49 (62.8%)
Age (years)	
n	78
Mean (SD)	53.3 (12.3)
Median	53
Q1, Q3	44.0, 62.0
Min, Max	28, 86
Age category	
n	78
< 65	62 (79.5%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
>= 65	16 (20.5%)
Region	
n	78
America (AM)	22 (28.2%)
Europe (EU)	17 (21.8%)
Asia (AS)	39 (50.0%)
Race	
n	78
White	35 (44.9%)
Asian	36 (46.2%)
Black or African American	5 (6.4%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Not Reported	2 (2.6%)
Ethnicity	
n	78
Hispanic or Latino	2 (2.6%)
Not Hispanic or Latino	74 (94.9%)
Unknown	2 (2.6%)
Baseline Weight (kg)	
n	78
Mean (SD)	68.58 (16.07)
Median	67,95
Q1, Q3	59.00, 78.35

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Min, Max	38.5, 115.9
Baseline BMI (kg/m2)	
n	78
Mean (SD)	25.22 (5.07)
Median	24,03
Q1, Q3	22.23, 27.39
Min, Max	15.5, 44.1
Does Patient Have a History of Smoking?	
n	78
Yes	34 (43.6%)
No	44 (56.4%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Smoking History	
n	34
Current Smoker	3 (8.8%)
Former Smoker	31 (91.2%)
Baseline ECOG Performance Status	
n	78
0	30 (38.5%)
1	38 (48.7%)
2	10 (12.8%)
BICR Confirmed Measurable Disease at Baseline	

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
n	78
Measurable	74 (94.9%)
Non-Measurable	4 (5.1%)
Have Received at least One Dose of Entrectinib	
n	78
Yes	78 (100.0%)
Patients with BICR Confirmed Measurable Disease at Baseline & Patients who Have Received at least One Dose of Entrectinib	
n	78
Yes & Yes	74 (94.9%)
No & Yes	4 (5.1%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Tumor Entities/Types (HIGH LEVEL TERM; LOW LEVEL TERM)	
n	78
THORACIC; NSCLC	78 (100.0%)
CNS Metastases by BICR	
n	78
Yes	31 (39.7%)
No	47 (60.3%)
CNS Metastases by Investigator	
n	78
Yes	35 (44.9%)
No	43 (55.1%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Primary Brain Tumors	
n	78
No	78 (100.0%)
Patients with CNS Metastases by Investigator & Patients with Primary Brain Tumors	
n	78
Yes & No	35 (44.9%)
No & No	43 (55.1%)
Prior Treatment in Patients with Metastases	
n	56
Chemotherapy	30 (53.6%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Chemotherapy & Immunotherapy	8 (14.3%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	1 (1.8%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy & Other	1 (1.8%)
Chemotherapy & Immunotherapy & Targeted therapy	3 (5.4%)
Chemotherapy & Monoclonal antibody	6 (10.7%)
Chemotherapy & Targeted therapy	4 (7.1%)
Hormonal therapy	1 (1.8%)
Monoclonal antibody	1 (1.8%)
Targeted therapy	1 (1.8%)
CNS Metastases Treatment	
n	23
Chemotherapy	14 (60.9%)

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Chemotherapy & Immunotherapy	4 (17.4%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	1 (4.3%)
Chemotherapy & Immunotherapy & Targeted therapy	2 (8.7%)
Chemotherapy & Monoclonal antibody	1 (4.3%)
Monoclonal antibody	1 (4.3%)
Measurable/Non-Measurable Lesions at Baseline (IRC)	
n	78
Measurable	74 (94.9%)
Non-Measurable	4 (5.1%)
Histologic Type	
n	78

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Adenocarcinoma	76 (97.4%)
Bronchioloalveolar carcinoma	1 (1.3%)
Carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements	1 (1.3%)
Initial Stage of Disease	
n	78
IA	2 (2.6%)
IB	3 (3.8%)
IIA	1 (1.3%)
IIB	1 (1.3%)
IIIA	8 (10.3%)
IIIB	4 (5.1%)
IIIC	1 (1.3%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
IV	57 (73.1%)
Unknown	1 (1.3%)
Prior Brain Radiation in Patients with CNS Metastases at Baseline	
n	78
Yes	21 (26.9%)
No	14 (17.9%)
No CNS Metastases at Baseline	43 (55.1%)
Extent of Disease at Baseline	
n	78
Locally Advanced	1 (1.3%)
Metastatic Disease	77 (98.7%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Sites of Metastases	
n	77
Bone & Brain	2 (2.6%)
Bone & Brain & Liver & Lung	1 (1.3%)
Bone & Brain & Liver & Lung & Lymph Node	1 (1.3%)
Bone & Brain & Liver & Lung & Lymph Node & Other	1 (1.3%)
Bone & Brain & Liver & Lymph Node	3 (3.9%)
Bone & Brain & Liver & Lymph Node & Other	1 (1.3%)
Bone & Brain & Lung	1 (1.3%)
Bone & Brain & Lung & Lymph Node	2 (2.6%)
Bone & Brain & Lung & Lymph Node & Other	1 (1.3%)
Bone & Brain & Lung & Other	1 (1.3%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Bone & Brain & Lymph Node & Other	1 (1.3%)
Bone & Liver	1 (1.3%)
Bone & Liver & Lung	1 (1.3%)
Bone & Liver & Lung & Lymph Node	2 (2.6%)
Bone & Liver & Lung & Lymph Node & Other	2 (2.6%)
Bone & Lung	2 (2.6%)
Bone & Lung & Lymph Node	1 (1.3%)
Bone & Lung & Lymph Node & Other	2 (2.6%)
Bone & Lymph Node	4 (5.2%)
Bone & Lymph Node & Other	2 (2.6%)
Bone & Lymph Node & Skin & Other	1 (1.3%)
Brain	1 (1.3%)
Brain & Liver & Lung & Lymph Node	1 (1.3%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Brain & Liver & Lung & Lymph Node & Other	2 (2.6%)
Brain & Lung	2 (2.6%)
Brain & Lung & Lymph Node	1 (1.3%)
Brain & Lung & Lymph Node & Other	3 (3.9%)
Brain & Lymph Node	6 (7.8%)
Brain & Lymph Node & Other	3 (3.9%)
Brain & Other	1 (1.3%)
Liver & Lung & Lymph Node	1 (1.3%)
Liver & Lymph Node	1 (1.3%)
Lung	3 (3.9%)
Lung & Lymph Node	8 (10.4%)
Lymph Node	7 (9.1%)
Lymph Node & Other	3 (3.9%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Other	1 (1.3%)
Prior Anti-cancer Therapies (systemic, radiation or surgery)	
n	78
Yes	69 (88.5%)
No	9 (11.5%)
Number of Prior Anti-cancer Therapies	
n	78
0	9 (11.5%)
1	7 (9.0%)
2	13 (16.7%)
3	18 (23.1%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
4	7 (9.0%)
5	11 (14.1%)
6	4 (5.1%)
7	4 (5.1%)
9	2 (2.6%)
11	1 (1.3%)
13	1 (1.3%)
19	1 (1.3%)
Prior Systemic Anti-cancer Therapies	
n	78
Yes	47 (60.3%)
No	31 (39.7%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)
Number of Prior Systemic Anti-cancer Therapies	
n	78
0	31 (39.7%)
1	3 (3.8%)
2	21 (26.9%)
3	12 (15.4%)
4	4 (5.1%)
5	2 (2.6%)
7	1 (1.3%)
9	2 (2.6%)
10	1 (1.3%)
17	1 (1.3%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=78)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_REE.xls
22JUN2020 13:23

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
Sex	
n	180
Male	72 (40.0%)
Female	108 (60.0%)
Age (years)	
n	180
Mean (SD)	54.7 (13.3)
Median	54
Q1, Q3	46.0, 65.0
Min, Max	15, 86
Age category	
n	180
< 65	133 (73.9%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
>= 65	47 (26.1%)
Region	
n	180
America (AM)	52 (28.9%)
Europe (EU)	46 (25.6%)
Asia (AS)	82 (45.6%)
Race	
n	180
White	76 (42.2%)
Asian	80 (44.4%)
Black or African American	10 (5.6%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
Other	3 (1.7%)
Not Reported	10 (5.6%)
Missing	1 (0.6%)
Ethnicity	
n	180
Hispanic or Latino	4 (2.2%)
Not Hispanic or Latino	164 (91.1%)
Not Reported	4 (2.2%)
Unknown	6 (3.3%)
Missing	2 (1.1%)
Baseline Weight (kg)	

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
n	180
Mean (SD)	68.24 (16.17)
Median	66,7
Q1, Q3	56.05, 78.18
Min, Max	38.5, 115.9
Baseline BMI (kg/m2)	
n	180
Mean (SD)	25.10 (4.95)
Median	24,2
Q1, Q3	21.90, 27.38
Min, Max	15.5, 45.7

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
Does Patient Have a History of Smoking?	
n	180
Yes	70 (38.9%)
No	110 (61.1%)
Smoking History	
n	70
Current Smoker	7 (10.0%)
Former Smoker	63 (90.0%)
Baseline ECOG Performance Status	
n	180
0	76 (42.2%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
1	84 (46.7%)
2	18 (10.0%)
3	1 (0.6%)
4	1 (0.6%)
BICR Confirmed Measurable Disease at Baseline	
n	180
Measurable	157 (87.2%)
Non-Measurable	23 (12.8%)
Have Received at least One Dose of Entrectinib	
n	180
Yes	180 (100.0%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
	180
Patients with BICR Confirmed Measurable Disease at Baseline & Patients who Have Received	at least One Dose of
Entrectinib	
n	180
Yes & Yes	157 (87.2%)
No & Yes	23 (12.8%)
Tumor Entities/Types (HIGH LEVEL TERM; LOW LEVEL TERM)	
n	150
THORACIC; NSCLC	150 (100.0%)
CNS Metastases by BICR	
n	180
Yes	63 (35.0%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
No	117 (65.0%)
CNS Metastases by Investigator	
n	180
Yes	71 (39.4%)
No	109 (60.6%)
Primary Brain Tumors	
n	180
No	180 (100.0%)
Patients with CNS Metastases by Investigator & Patients with Primary Brain Tumors	
n	180

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
Yes & No	71 (39.4%)
No & No	109 (60.6%)
Prior Treatment in Patients with Metastases	
n	127
Chemotherapy	64 (50.4%)
Chemotherapy & Immunotherapy	16 (12.6%)
Chemotherapy & Immunotherapy & Monoclonal antibody	3 (2.4%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	2 (1.6%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy & Other	1 (0.8%)
Chemotherapy & Immunotherapy & Targeted therapy	3 (2.4%)
Chemotherapy & Monoclonal antibody	9 (7.1%)
Chemotherapy & Monoclonal antibody & Targeted therapy	4 (3.1%)

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
Chemotherapy & Targeted therapy	10 (7.9%)
Hormonal therapy	1 (0.8%)
Immunotherapy	1 (0.8%)
Immunotherapy & Targeted therapy	1 (0.8%)
Monoclonal antibody	1 (0.8%)
Targeted therapy	11 (8.7%)
CNS Metastases Treatment	
n	54
Chemotherapy	23 (42.6%)
Chemotherapy & Immunotherapy	5 (9.3%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	1 (1.9%)
Chemotherapy & Immunotherapy & Targeted therapy	2 (3.7%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
Chemotherapy & Monoclonal antibody	2 (3.7%)
Chemotherapy & Monoclonal antibody & Targeted therapy	4 (7.4%)
Chemotherapy & Targeted therapy	4 (7.4%)
Immunotherapy	1 (1.9%)
Immunotherapy & Targeted therapy	1 (1.9%)
Monoclonal antibody	1 (1.9%)
Targeted therapy	10 (18.5%)
Measurable/Non-Measurable Lesions at Baseline (IRC)	
n	180
Measurable	157 (87.2%)
Non-Measurable	23 (12.8%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
Histologic Type	
n	180
Adenocarcinoma	176 (97.8%)
Bronchioloalveolar carcinoma	1 (0.6%)
Carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements	2 (1.1%)
Missing	1 (0.6%)
Initial Stage of Disease	
n	180
IA	4 (2.2%)
IB	5 (2.8%)
IIA	4 (2.2%)
IIB	5 (2.8%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
IIIA	12 (6.7%)
IIIB	12 (6.7%)
IIIC	2 (1.1%)
IV	134 (74.4%)
Unknown	2 (1.1%)
Prior Brain Radiation in Patients with CNS Metastases at Baseline	
n	180
Yes	43 (23.9%)
No	28 (15.6%)
No CNS Metastases at Baseline	109 (60.6%)
Extent of Disease at Baseline	

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
n	180
Locally Advanced	7 (3.9%)
Metastatic Disease	173 (96.1%)
Sites of Metastases	
n	173
Bone	1 (0.6%)
Bone & Brain	6 (3.5%)
Bone & Brain & Liver & Lung	1 (0.6%)
Bone & Brain & Liver & Lung & Lymph Node	1 (0.6%)
Bone & Brain & Liver & Lung & Lymph Node & Other	2 (1.2%)
Bone & Brain & Liver & Lymph Node	3 (1.7%)
Bone & Brain & Liver & Lymph Node & Other	1 (0.6%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
Bone & Brain & Lung	4 (2.3%)
Bone & Brain & Lung & Lymph Node	3 (1.7%)
Bone & Brain & Lung & Lymph Node & Other	1 (0.6%)
Bone & Brain & Lung & Other	1 (0.6%)
Bone & Brain & Lymph Node	4 (2.3%)
Bone & Brain & Lymph Node & Other	3 (1.7%)
Bone & Brain & Other	1 (0.6%)
Bone & Liver	1 (0.6%)
Bone & Liver & Lung	3 (1.7%)
Bone & Liver & Lung & Lymph Node	3 (1.7%)
Bone & Liver & Lung & Lymph Node & Other	3 (1.7%)
Bone & Liver & Lymph Node & Other	1 (0.6%)
Bone & Lung	4 (2.3%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
Bone & Lung & Lymph Node	5 (2.9%)
Bone & Lung & Lymph Node & Other	3 (1.7%)
Bone & Lymph Node	10 (5.8%)
Bone & Lymph Node & Other	3 (1.7%)
Bone & Lymph Node & Skin & Other	1 (0.6%)
Bone & Other	1 (0.6%)
Brain	5 (2.9%)
Brain & Liver	1 (0.6%)
Brain & Liver & Lung	1 (0.6%)
Brain & Liver & Lung & Lymph Node	1 (0.6%)
Brain & Liver & Lung & Lymph Node & Other	2 (1.2%)
Brain & Liver & Other	1 (0.6%)
Brain & Lung	4 (2.3%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
Brain & Lung & Lymph Node	4 (2.3%)
Brain & Lung & Lymph Node & Other	5 (2.9%)
Brain & Lymph Node	10 (5.8%)
Brain & Lymph Node & Other	5 (2.9%)
Brain & Other	1 (0.6%)
Liver	2 (1.2%)
Liver & Lung & Lymph Node	1 (0.6%)
Liver & Lymph Node	2 (1.2%)
Lung	7 (4.0%)
Lung & Lymph Node	12 (6.9%)
Lung & Lymph Node & Other	6 (3.5%)
Lung & Other	3 (1.7%)
Lymph Node	13 (7.5%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
Lymph Node & Other	9 (5.2%)
Other	8 (4.6%)
Prior Anti-cancer Therapies (systemic, radiation or surgery)	
n	180
Yes	154 (85.6%)
No	26 (14.4%)
Number of Prior Anti-cancer Therapies	
n	180
0	26 (14.4%)
1	23 (12.8%)
2	28 (15.6%)
3	30 (16.7%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
4	19 (10.6%)
5	19 (10.6%)
6	10 (5.6%)
7	8 (4.4%)
8	4 (2.2%)
9	3 (1.7%)
10	1 (0.6%)
11	2 (1.1%)
13	3 (1.7%)
18	2 (1.1%)
19	2 (1.1%)
Prior Systemic Anti-cancer Therapies	

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
n	180
Yes	108 (60.0%)
No	72 (40.0%)
Number of Prior Systemic Anti-cancer Therapies	
n	180
0	72 (40.0%)
1	13 (7.2%)
2	42 (23.3%)
3	25 (13.9%)
4	8 (4.4%)
5	5 (2.8%)
6	2 (1.1%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=180)
7	3 (1.7%)
8	1 (0.6%)
9	2 (1.1%)
10	1 (0.6%)
11	2 (1.1%)
12	1 (0.6%)
16	1 (0.6%)
17	2 (1.1%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SEROS1.xls
22JUN2020 13:31

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Sex	
n	332
Male	145 (43.7%)
Female	187 (56.3%)
Age (years)	
n	332
Mean (SD)	54.2 (14.4)
Median	55
Q1, Q3	45.0, 65.5
Min, Max	15, 88
Age category	
n	332
< 65	240 (72.3%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
>= 65	92 (27.7%)
Region	
n	332
America (AM)	142 (42.8%)
Europe (EU)	77 (23.2%)
Asia (AS)	113 (34.0%)
Race	
n	332
White	167 (50.3%)
Asian	117 (35.2%)
Black or African American	15 (4.5%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Other	3 (0.9%)
Not Reported	29 (8.7%)
Missing	1 (0.3%)
Ethnicity	
n	332
Hispanic or Latino	10 (3.0%)
Not Hispanic or Latino	295 (88.9%)
Not Reported	13 (3.9%)
Unknown	12 (3.6%)
Missing	2 (0.6%)
Baseline Weight (kg)	

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
n	332
Mean (SD)	69.14 (17.40)
Median	67,55
Q1, Q3	57.00, 80.00
Min, Max	31.6, 130.2
Baseline BMI (kg/m2)	
n	331
Mean (SD)	24.87 (5.13)
Median	24,22
Q1, Q3	21.57, 27.39
Min, Max	12.3, 45.7

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Does Patient Have a History of Smoking?	
n	332
Yes	128 (38.6%)
No	202 (60.8%)
Missing	2 (0.6%)
Smoking History	
n	128
Current Smoker	21 (16.4%)
Former Smoker	107 (83.6%)
Baseline ECOG Performance Status	
n	332

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
0	139 (41.9%)
1	155 (46.7%)
2	34 (10.2%)
3	3 (0.9%)
4	1 (0.3%)
BICR Confirmed Measurable Disease at Baseline	
n	332
Measurable	290 (87.3%)
Non-Measurable	42 (12.7%)
Have Received at least One Dose of Entrectinib	
n	332

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Yes	332 (100.0%)
Patients with BICR Confirmed Measurable Disease at Baseline & Patients who Have Received at least One Dose of Entrectinib	
n	332
Yes & Yes	290 (87.3%)
No & Yes	42 (12.7%)
Tumor Entities/Types (HIGH LEVEL TERM; LOW LEVEL TERM)	
n	284
BREAST; BREAST (NON-SECRETORY)	3 (1.1%)
BREAST; BREAST (SECRETORY)	4 (1.4%)
CUP; CUP	1 (0.4%)
GI - CRC; CRC	9 (3.2%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
GI - NON-CRC; APPENDICEAL	1 (0.4%)
GI - NON-CRC; CHOLANGIOCARCINOMA	1 (0.4%)
GI - NON-CRC; GASTRIC CANCER	1 (0.4%)
GI - NON-CRC; GASTROESOPHAGEAL JUNCTION CANCER	1 (0.4%)
GI - NON-CRC; PANCREATIC	5 (1.8%)
GI; NON-CRC GI (NOS)	2 (0.7%)
GYNECOLOGICAL; ENDOMETRIOID	1 (0.4%)
GYNECOLOGICAL; OVARIAN	2 (0.7%)
GYNECOLOGICAL; UTERINE	1 (0.4%)
HEAD AND NECK; MASC	18 (6.3%)
HEAD AND NECK; PAPILLARY THYROID	7 (2.5%)
HEAD AND NECK; THYROID - OTHER	3 (1.1%)
NEUROBLASTOMA; NEURBLASTOMA	1 (0.4%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
NEUROENDOCRINE; NEUROENDOCRINE	5 (1.8%)
NHL; ALCL	1 (0.4%)
PRIMARY BRAIN TUMORS; GLIOMA	11 (3.9%)
PRIMARY BRAIN TUMORS; GLIONEURONAL	1 (0.4%)
SARCOMA; CERVICAL ADENOSARCOMA	1 (0.4%)
SARCOMA; DEDIFFERENTIATED CHONDROSARCOMA	1 (0.4%)
SARCOMA; ENDOMETRIAL STROMAL SARCOMA	3 (1.1%)
SARCOMA; EWINGS SARCOMA	1 (0.4%)
SARCOMA; FOLLICULAR DENDRITIC CELL SARCOMA	1 (0.4%)
SARCOMA; GIST	2 (0.7%)
SARCOMA; INFLAMMATORY MYOFIBROBLASTIC TUMOR	3 (1.1%)
SARCOMA; LEIOMYOSARCOMA	3 (1.1%)
SARCOMA; MPNST	1 (0.4%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
SARCOMA; OSTEOSARCOMA	1 (0.4%)
SARCOMA; SARCOMA (NOS)	10 (3.5%)
SARCOMA; SARCOMA OTHER	2 (0.7%)
SARCOMA; SYNOVIAL SARCOMA	1 (0.4%)
SARCOMA; UNDIFFERENITATED PLEOMORPHIC SARCOMA	1 (0.4%)
THORACIC; MESOTHELIOMA	1 (0.4%)
THORACIC; NSCLC	173 (60.9%)
CNS Metastases by BICR	
n	332
Yes	91 (27.4%)
No	241 (72.6%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
CNS Metastases by Investigator	
n	332
Yes	108 (32.5%)
No	224 (67.5%)
Primary Brain Tumors	
n	332
Yes	12 (3.6%)
No	320 (96.4%)
Patients with CNS Metastases by Investigator & Patients with Primary Brain Tumors	
n	332
Yes & Yes	2 (0.6%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Yes & No	106 (31.9%)
No & Yes	10 (3.0%)
No & No	214 (64.5%)
Prior Treatment in Patients with Metastases	
n	242
Chemotherapy	113 (46.7%)
Chemotherapy & Hormonal therapy	5 (2.1%)
Chemotherapy & Hormonal therapy & Monoclonal antibody & Targeted therapy	1 (0.4%)
Chemotherapy & Hormonal therapy & Targeted therapy	2 (0.8%)
Chemotherapy & Immunotherapy	24 (9.9%)
Chemotherapy & Immunotherapy & Monoclonal antibody	4 (1.7%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	3 (1.2%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy & Other	2 (0.8%)
Chemotherapy & Immunotherapy & Targeted therapy	7 (2.9%)
Chemotherapy & Monoclonal antibody	19 (7.9%)
Chemotherapy & Monoclonal antibody & Targeted therapy	7 (2.9%)
Chemotherapy & Other	1 (0.4%)
Chemotherapy & Targeted therapy	24 (9.9%)
Hormonal therapy	1 (0.4%)
Immunotherapy	1 (0.4%)
Immunotherapy & Targeted therapy	1 (0.4%)
Monoclonal antibody	1 (0.4%)
Other	2 (0.8%)
Targeted therapy	24 (9.9%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
CNS Metastases Treatment	
n	90
Chemotherapy	34 (37.8%)
Chemotherapy & Hormonal therapy & Monoclonal antibody & Targeted therapy	1 (1.1%)
Chemotherapy & Hormonal therapy & Targeted therapy	1 (1.1%)
Chemotherapy & Immunotherapy	9 (10.0%)
Chemotherapy & Immunotherapy & Monoclonal antibody	1 (1.1%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	2 (2.2%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy & Other	1 (1.1%)
Chemotherapy & Immunotherapy & Targeted therapy	3 (3.3%)
Chemotherapy & Monoclonal antibody	2 (2.2%)
Chemotherapy & Monoclonal antibody & Targeted therapy	4 (4.4%)
Chemotherapy & Targeted therapy	11 (12.2%)

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Immunotherapy	1 (1.1%)
Immunotherapy & Targeted therapy	1 (1.1%)
Monoclonal antibody	1 (1.1%)
Targeted therapy	18 (20.0%)
Measurable/Non-Measurable Lesions at Baseline (IRC)	
n	332
Measurable	290 (87.3%)
Non-Measurable	42 (12.7%)
Histologic Type	
n	332
Adenocarcinoma	232 (69.9%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Bronchioloalveolar carcinoma	1 (0.3%)
Carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements	5 (1.5%)
Neuroendocrine	6 (1.8%)
Spindle cell	10 (3.0%)
Squamous-cell carcinoma	3 (0.9%)
Unclassified carcinoma/Undifferentiated carcinoma	5 (1.5%)
Other	64 (19.3%)
Not Applicable	4 (1.2%)
Unknown	1 (0.3%)
Missing	1 (0.3%)
Initial Stage of Disease	
n	332

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
0	3 (0.9%)
IA	12 (3.6%)
IB	9 (2.7%)
IIA	17 (5.1%)
IIB	15 (4.5%)
IIIA	29 (8.7%)
IIIB	22 (6.6%)
IIIC	4 (1.2%)
IV	206 (62.0%)
Unknown	15 (4.5%)
Prior Brain Radiation in Patients with CNS Metastases at Baseline	
n	332

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Yes	74 (22.3%)
No	34 (10.2%)
No CNS Metastases at Baseline	224 (67.5%)
Extent of Disease at Baseline	
n	332
Locally Advanced	22 (6.6%)
Metastatic Disease	309 (93.1%)
Unknown	1 (0.3%)
Sites of Metastases	
n	309
Bone	2 (0.6%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Bone & Brain	6 (1.9%)
Bone & Brain & Liver & Lung	5 (1.6%)
Bone & Brain & Liver & Lung & Lymph Node	1 (0.3%)
Bone & Brain & Liver & Lung & Lymph Node & Other	3 (1.0%)
Bone & Brain & Liver & Lymph Node	4 (1.3%)
Bone & Brain & Liver & Lymph Node & Other	3 (1.0%)
Bone & Brain & Lung	4 (1.3%)
Bone & Brain & Lung & Lymph Node	4 (1.3%)
Bone & Brain & Lung & Lymph Node & Other	3 (1.0%)
Bone & Brain & Lung & Other	3 (1.0%)
Bone & Brain & Lymph Node	5 (1.6%)
Bone & Brain & Lymph Node & Other	4 (1.3%)
Bone & Brain & Other	1 (0.3%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Bone & Brain & Skin & Other	1 (0.3%)
Bone & Liver	1 (0.3%)
Bone & Liver & Lung	6 (1.9%)
Bone & Liver & Lung & Lymph Node	5 (1.6%)
Bone & Liver & Lung & Lymph Node & Other	5 (1.6%)
Bone & Liver & Lung & Lymph Node & Skin	1 (0.3%)
Bone & Liver & Lung & Other	1 (0.3%)
Bone & Liver & Lymph Node	2 (0.6%)
Bone & Liver & Lymph Node & Other	1 (0.3%)
Bone & Lung	6 (1.9%)
Bone & Lung & Lymph Node	5 (1.6%)
Bone & Lung & Lymph Node & Other	4 (1.3%)
Bone & Lung & Other	1 (0.3%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Bone & Lymph Node	12 (3.9%)
Bone & Lymph Node & Other	3 (1.0%)
Bone & Lymph Node & Skin & Other	1 (0.3%)
Bone & Other	1 (0.3%)
Brain	10 (3.2%)
Brain & Liver	1 (0.3%)
Brain & Liver & Lung	1 (0.3%)
Brain & Liver & Lung & Lymph Node	3 (1.0%)
Brain & Liver & Lung & Lymph Node & Other	2 (0.6%)
Brain & Liver & Lung & Lymph Node & Skin & Other	1 (0.3%)
Brain & Liver & Other	2 (0.6%)
Brain & Lung	6 (1.9%)
Brain & Lung & Lymph Node	4 (1.3%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Brain & Lung & Lymph Node & Other	7 (2.3%)
Brain & Lung & Other	2 (0.6%)
Brain & Lymph Node	11 (3.6%)
Brain & Lymph Node & Other	8 (2.6%)
Brain & Lymph Node & Skin	1 (0.3%)
Brain & Lymph Node & Skin & Other	1 (0.3%)
Brain & Other	1 (0.3%)
Liver	10 (3.2%)
Liver & Lung	4 (1.3%)
Liver & Lung & Lymph Node	8 (2.6%)
Liver & Lung & Other	1 (0.3%)
Liver & Lymph Node	4 (1.3%)
Liver & Lymph Node & Other	1 (0.3%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Liver & Other	3 (1.0%)
Lung	26 (8.4%)
Lung & Lymph Node	21 (6.8%)
Lung & Lymph Node & Other	11 (3.6%)
Lung & Lymph Node & Skin & Other	1 (0.3%)
Lung & Other	7 (2.3%)
Lung & Skin	1 (0.3%)
Lymph Node	19 (6.1%)
Lymph Node & Other	12 (3.9%)
Other	15 (4.9%)
Prior Anti-cancer Therapies (systemic, radiation or surgery)	
n	332

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
Yes	306 (92.2%)
No	26 (7.8%)
Number of Prior Anti-cancer Therapies	
n	332
0	26 (7.8%)
1	34 (10.2%)
2	40 (12.0%)
3	53 (16.0%)
4	30 (9.0%)
5	42 (12.7%)
6	22 (6.6%)
7	19 (5.7%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
8	15 (4.5%)
9	8 (2.4%)
10	7 (2.1%)
11	9 (2.7%)
12	5 (1.5%)
13	4 (1.2%)
14	3 (0.9%)
15	1 (0.3%)
16	2 (0.6%)
17	1 (0.3%)
18	4 (1.2%)
19	2 (0.6%)
20	2 (0.6%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
21	1 (0.3%)
27	2 (0.6%)
Prior Systemic Anti-cancer Therapies	
n	332
Yes	205 (61.7%)
No	127 (38.3%)
Number of Prior Systemic Anti-cancer Therapies	
n	332
0	127 (38.3%)
1	31 (9.3%)
2	66 (19.9%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)
3	34 (10.2%)
4	30 (9.0%)
5	13 (3.9%)
6	7 (2.1%)
7	6 (1.8%)
8	4 (1.2%)
9	3 (0.9%)
10	2 (0.6%)
11	4 (1.2%)
12	1 (0.3%)
15	1 (0.3%)
16	1 (0.3%)
17	2 (0.6%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=332)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D180_SE.xls
08JUL2020 7:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Sex	
n	145
Male	52 (35.9%)
Female	93 (64.1%)
Age (years)	
n	145
Mean (SD)	54.8 (12.6)
Median	54
Q1, Q3	46.0, 64.0
Min, Max	20, 86
Age category	
n	145
< 65	109 (75.2%)
>= 65	36 (24.8%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D194_REE.xls
24JUN2020 13:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Region	
n	145
America (AM)	40 (27.6%)
Europe (EU)	34 (23.4%)
Asia (AS)	71 (49.0%)
Race	
n	145
White	60 (41.4%)
Asian	68 (46.9%)
Black or African American	7 (4.8%)
Other	2 (1.4%)
Not Reported	8 (5.5%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D194_REE.xls
24JUN2020 13:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Ethnicity	
n	145
Hispanic or Latino	4 (2.8%)
Not Hispanic or Latino	132 (91.0%)
Not Reported	2 (1.4%)
Unknown	6 (4.1%)
Missing	1 (0.7%)
Baseline Weight (kg)	
n	145
Mean (SD)	68.68 (16.54)
Median	67
Q1, Q3	57.00, 78.50

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D194_REE.xls
24JUN2020 13:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Min, Max	38.5, 115.9
Baseline BMI (kg/m2)	
n	145
Mean (SD)	25.38 (5.04)
Median	24,35
Q1, Q3	22.23, 27.62
Min, Max	15.5, 45.7
Does Patient Have a History of Smoking?	
n	145
Yes	56 (38.6%)
No	89 (61.4%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D194_REE.xls
24JUN2020 13:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Smoking History	
n	56
Current Smoker	6 (10.7%)
Former Smoker	50 (89.3%)
Baseline ECOG Performance Status	
n	145
0	61 (42.1%)
1	69 (47.6%)
2	15 (10.3%)
BICR Confirmed Measurable Disease at Baseline	
n	145
Measurable	135 (93.1%)

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Non-Measurable	10 (6.9%)
Have Received at least One Dose of Entrectinib	
n	145
Yes	145 (100.0%)
Entrectinib	
n	145
Yes & Yes	135 (93.1%)
No & Yes	10 (6.9%)
Tumor Entities/Types (HIGH LEVEL TERM; LOW LEVEL TERM)	
n	116
THORACIC; NSCLC	116 (100.0%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D194_REE.xls
24JUN2020 13:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
CNS Metastases by BICR	
n	145
Yes	42 (29.0%)
No	103 (71.0%)
CNS Metastases by Investigator	
n	145
Yes	48 (33.1%)
No	97 (66.9%)
Primary Brain Tumors	
n	145
No	145 (100.0%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D194_REE.xls
24JUN2020 13:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)

Patients with CNS Metastases by Investigator & Patients with Primary Brain Tumors	
n	145
Yes & No	48 (33.1%)
No & No	97 (66.9%)
Prior Treatment in Patients with Metastases	
n	99
Chemotherapy	58 (58.6%)
Chemotherapy & Immunotherapy	15 (15.2%)
Chemotherapy & Immunotherapy & Monoclonal antibody	3 (3.0%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	1 (1.0%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy & Other	1 (1.0%)
Chemotherapy & Immunotherapy & Targeted therapy	3 (3.0%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D194_REE.xls
24JUN2020 13:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Chemotherapy & Monoclonal antibody	9 (9.1%)
Chemotherapy & Targeted therapy	5 (5.1%)
Hormonal therapy	1 (1.0%)
Immunotherapy	1 (1.0%)
Monoclonal antibody	1 (1.0%)
Targeted therapy	1 (1.0%)
CNS Metastases Treatment	
n	32
Chemotherapy	20 (62.5%)
Chemotherapy & Immunotherapy	5 (15.6%)
Chemotherapy & Immunotherapy & Monoclonal antibody & Targeted therapy	1 (3.1%)
Chemotherapy & Immunotherapy & Targeted therapy	2 (6.3%)
Chemotherapy & Monoclonal antibody	2 (6.3%)

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Immunotherapy	1 (3.1%)
Monoclonal antibody	1 (3.1%)
Measurable/Non-Measurable Lesions at Baseline (IRC)	
n	145
Measurable	135 (93.1%)
Non-Measurable	10 (6.9%)
Histologic Type	
n	145
Adenocarcinoma	142 (97.9%)
Bronchioloalveolar carcinoma	1 (0.7%)
Carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements	1 (0.7%)
Missing	1 (0.7%)

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Initial Stage of Disease	
n	145
IA	3 (2.1%)
IB	3 (2.1%)
IIA	3 (2.1%)
IIB	5 (3.4%)
IIIA	11 (7.6%)
IIIB	8 (5.5%)
IIIC	2 (1.4%)
IV	108 (74.5%)
Unknown	2 (1.4%)
Prior Brain Radiation in Patients with CNS Metastases at Baseline	

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
n	145
Yes	27 (18.6%)
No	21 (14.5%)
No CNS Metastases at Baseline	97 (66.9%)
Extent of Disease at Baseline	
n	145
Locally Advanced	3 (2.1%)
Metastatic Disease	142 (97.9%)
Sites of Metastases	
n	142
Bone	1 (0.7%)
Bone & Brain	2 (1.4%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D194_REE.xls
24JUN2020 13:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Bone & Brain & Liver & Lung	1 (0.7%)
Bone & Brain & Liver & Lung & Lymph Node	1 (0.7%)
Bone & Brain & Liver & Lung & Lymph Node & Other	2 (1.4%)
Bone & Brain & Liver & Lymph Node	3 (2.1%)
Bone & Brain & Liver & Lymph Node & Other	1 (0.7%)
Bone & Brain & Lung	1 (0.7%)
Bone & Brain & Lung & Lymph Node	3 (2.1%)
Bone & Brain & Lung & Lymph Node & Other	1 (0.7%)
Bone & Brain & Lung & Other	1 (0.7%)
Bone & Brain & Lymph Node	3 (2.1%)
Bone & Brain & Lymph Node & Other	2 (1.4%)
Bone & Liver	1 (0.7%)
Bone & Liver & Lung	3 (2.1%)
Bone & Liver & Lung & Lymph Node	3 (2.1%)

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Bone & Liver & Lung & Lymph Node & Other	2 (1.4%)
Bone & Liver & Lymph Node & Other	1 (0.7%)
Bone & Lung	4 (2.8%)
Bone & Lung & Lymph Node	4 (2.8%)
Bone & Lung & Lymph Node & Other	2 (1.4%)
Bone & Lymph Node	9 (6.3%)
Bone & Lymph Node & Other	3 (2.1%)
Bone & Lymph Node & Skin & Other	1 (0.7%)
Bone & Other	1 (0.7%)
Brain	2 (1.4%)
Brain & Liver & Lung & Lymph Node	1 (0.7%)
Brain & Liver & Lung & Lymph Node & Other	2 (1.4%)
Brain & Liver & Other	1 (0.7%)
Brain & Lung	2 (1.4%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D194_REE.xls
24JUN2020 13:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Brain & Lung & Lymph Node	2 (1.4%)
Brain & Lung & Lymph Node & Other	3 (2.1%)
Brain & Lymph Node	9 (6.3%)
Brain & Lymph Node & Other	4 (2.8%)
Brain & Other	1 (0.7%)
Liver	2 (1.4%)
Liver & Lung & Lymph Node	1 (0.7%)
Liver & Lymph Node	1 (0.7%)
Lung	7 (4.9%)
Lung & Lymph Node	11 (7.7%)
Lung & Lymph Node & Other	6 (4.2%)
Lung & Other	3 (2.1%)
Lymph Node	12 (8.5%)
Lymph Node & Other	8 (5.6%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D194_REE.xls
24JUN2020 13:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Other	8 (5.6%)
Prior Anti-cancer Therapies (systemic, radiation or surgery)	
n	145
Yes	123 (84.8%)
No	22 (15.2%)
Number of Prior Anti-cancer Therapies	
n	145
0	22 (15.2%)
1	18 (12.4%)
2	23 (15.9%)
3	27 (18.6%)
4	15 (10.3%)

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
5	17 (11.7%)
6	7 (4.8%)
7	5 (3.4%)
8	1 (0.7%)
9	3 (2.1%)
10	1 (0.7%)
11	2 (1.4%)
13	2 (1.4%)
19	2 (1.4%)
Prior Systemic Anti-cancer Therapies	
n	145
Yes	83 (57.2%)
No	62 (42.8%)

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
Number of Prior Systemic Anti-cancer Therapies	
n	145
0	62 (42.8%)
1	4 (2.8%)
2	37 (25.5%)
3	22 (15.2%)
4	5 (3.4%)
5	4 (2.8%)
6	1 (0.7%)
7	3 (2.1%)
8	1 (0.7%)
9	2 (1.4%)
10	1 (0.7%)

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Demographics and Baseline Characteristics per arm

	RXDX-101 600 mg/day (N=145)
11	1 (0.7%)
17	2 (1.4%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dm_D194_REE.xls
24JUN2020 13:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

Status	RXDX-101 600 mg/day (N=37)
Patients enrolled	37 (100.0%)
Patients who received at least 1 dose	37 (100.0%)
Ongoing patients	18 (48.6%)
Discontinued treatment	19 (51.4%)
Reason for treatment discontinuation	
Adverse Event	3 (15.8%)
Informed Consent Withdrawn	2 (10.5%)
Progressive Disease	14 (73.7%)
Discontinued study	14 (37.8%)
Reason for study discontinuation	

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_disp_NDA_REE.
09SEP2019 13:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

Status	RXDX-101 600 mg/day (N=37)
Patients enrolled	37 (100.0%)
Death	8 (57.1%)
Informed Consent Withdrawn	6 (42.9%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_disp_NDA_REE.
09SEP2019 13:11

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

Status	RXDX-101 600 mg/day (N=105)
Patients enrolled	105 (100.0%)
Patients who received at least 1 dose	105 (100.0%)
Ongoing patients	53 (50.5%)
Discontinued treatment	52 (49.5%)
Reason for treatment discontinuation	
Adverse Event	10 (19.2%)
Informed Consent Withdrawn	4 (7.7%)
Other	1 (1.9%)
Progressive Disease	37 (71.2%)
Discontinued study	34 (32.4%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_disp_NDA_SEROS1
09SEP2019 13:17

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

Status	RXDX-101 600 mg/day (N=105)
Patients enrolled	105 (100.0%)
Reason for study discontinuation	
Death	23 (67.6%)
Informed Consent Withdrawn	9 (26.5%)
Lost To Follow-Up	1 (2.9%)
Not Applicable	1 (2.9%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_disp_NDA_SEROS1
09SEP2019 13:17

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

Status	RXDX-101 600 mg/day (N=206)
Patients enrolled	206 (100.0%)
Patients who received at least 1 dose	206 (100.0%)
Ongoing patients	87 (42.2%)
Discontinued treatment	119 (57.8%)
Reason for treatment discontinuation	
Adverse Event	22 (18.5%)
Informed Consent Withdrawn	8 (6.7%)
Non-Compliance	1 (0.8%)
Other	1 (0.8%)
Progressive Disease	87 (73.1%)
Discontinued study	80 (38.8%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_disp_NDA_SE.xls
09SEP2019 13:20

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

Status	RXDX-101 600 mg/day (N=206)
Patients enrolled	206 (100.0%)
Reason for study discontinuation	
Death	57 (71.3%)
Informed Consent Withdrawn	20 (25.0%)
Lost To Follow-Up	2 (2.5%)
Not Applicable	1 (1.3%)

Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_disp_NDA_SE.xls
09SEP2019 13:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

Status	RXDX-101 600 mg/day (N=78)
Patients enrolled	78 (100.0%)
Patients who received at least 1 dose	78 (100.0%)
Ongoing patients	27 (34.6%)
Discontinued treatment	51 (65.4%)
Reason for treatment discontinuation	
Adverse Event	8 (15.7%)
Informed Consent Withdrawn	3 (5.9%)
Other	1 (2.0%)
Progressive Disease	39 (76.5%)

Enrollment cut-off: 30NOV2017, Clinical cut-off:

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782
/data_analysis/ACE_D180/prod/output/oth_disp_D18
27NOV2019 12:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

Status	RXDX-101 600 mg/day (N=78)
Patients enrolled	78 (100.0%)
Discontinued study	34 (43.6%)
Reason for study discontinuation	
Death	23 (67.6%)
Informed Consent Withdrawn	10 (29.4%)
Other	1 (2.9%)

Enrollment cut-off: 30NOV2017, Clinical cut-off:

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782
/data_analysis/ACE_D180/prod/output/oth_disp_D18
27NOV2019 12:29

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

Status	RXDX-101 600 mg/day (N=180)
Patients enrolled	180 (100.0%)
Patients who received at least 1 dose	180 (100.0%)
Ongoing patients	73 (40.6%)
Discontinued treatment	107 (59.4%)
Reason for treatment discontinuation	
Adverse Event	15 (14.0%)
Informed Consent Withdrawn	7 (6.5%)
Other	3 (2.8%)
Progressive Disease	82 (76.6%)

Enrollment cut-off: 31OCT2018, Clinical cut-off:

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_disp_D180_
27NOV2019 12:31

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

Status	RXDX-101 600 mg/day (N=180)
Patients enrolled	180 (100.0%)
Discontinued study	72 (40.0%)
Reason for study discontinuation	
Death	50 (69.4%)
Informed Consent Withdrawn	18 (25.0%)
Lost To Follow-Up	2 (2.8%)
Other	2 (2.8%)

Enrollment cut-off: 31OCT2018, Clinical cut-off:

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_disp_D180_
27NOV2019 12:31

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm

Status	RXDX-101 600 mg/day (N=332)
Patients enrolled	332 (100.0%)
Patients who received at least 1 dose	332 (100.0%)
Ongoing patients	123 (37.0%)
Discontinued treatment	209 (63.0%)
Reason for treatment discontinuation	
Adverse Event	36 (17.2%)
Informed Consent Withdrawn	12 (5.7%)
Non-Compliance	1 (0.5%)
Other	6 (2.9%)
Progressive Disease	154 (73.7%)

Enrollment cut-off: 31OCT2018, Clinical cut-off:

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_disp_D180_
08JUL2020 7:19

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm

Status	RXDX-101 600 mg/day (N=332)
Patients enrolled	332 (100.0%)
Discontinued study	145 (43.7%)
Reason for study discontinuation	
Death	109 (75.2%)
Informed Consent Withdrawn	31 (21.4%)
Lost To Follow-Up	3 (2.1%)
Other	2 (1.4%)

Enrollment cut-off: 31OCT2018, Clinical cut-off:

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_disp_D180_
08JUL2020 7:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm

Status	RXDX-101 600 mg/day (N=145)
Patients enrolled	145 (100.0%)
Patients who received at least 1 dose	145 (100.0%)
Ongoing patients	62 (42.8%)
Discontinued treatment	83 (57.2%)
Reason for treatment discontinuation	
Adverse Event	12 (14.5%)
Informed Consent Withdrawn	6 (7.2%)
Other	3 (3.6%)
Progressive Disease	62 (74.7%)
Discontinued study	55 (37.9%)

Enrollment cut-off: 31OCT2018, Clinical cut-off:

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_disp_D194_REE.
24JUN2020 13:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Disposition of Patients per arm

Status	RXDX-101 600 mg/day (N=145)
Patients enrolled	145 (100.0%)
Reason for study discontinuation	
Death	36 (65.5%)
Informed Consent Withdrawn	15 (27.3%)
Lost To Follow-Up	2 (3.6%)
Other	2 (3.6%)

Enrollment cut-off: 31OCT2018, Clinical cut-off:

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_disp_D194_REE.
24JUN2020 13:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Patients who Died Including
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=37)
All Deaths	8 (21.6%)
Progressive Disease	8 (100.0%)

Clinical cut-off: 31MAY2018

root/clinical_studies/RO7102122/CDT30222/GO40782/data_

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dth_NDA_REE.xls
09SEP2019 13:23

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Patients who Died Including
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=105)
All Deaths	24 (22.9%)
Progressive Disease	22 (91.7%)
Other: Cardiogenic shock	1 (4.2%)
Other: Pneumonia	1 (4.2%)

Clinical cut-off: 31MAY2018

root/clinical_studies/RO7102122/CDT30222/GO40782/data_analys

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analys
is/ACE_NDA/prod/output/oth_dth_NDA_SEROS1.xls
09SEP2019 13:28

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Patients who Died Including Primary Reason
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=206)
All Deaths	62 (30.1%)
Progressive Disease	53 (85.5%)
Other: Acute respiratory failure	1 (1.6%)
Other: Cardio-respiratory arrest	1 (1.6%)
Other: Cardiogenic shock	1 (1.6%)
Other: Completed suicide	1 (1.6%)
Other: Pneumonia	2 (3.2%)
Other: Sepsis	1 (1.6%)
Other: Unknown. no death certificate available. cause of death is unknown.	1 (1.6%)
Unknown	1 (1.6%)

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/oth_dth.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_dth_NDA_SE.xls
09SEP2019 13:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Patients who Died Including Primary
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=78)
All Deaths	24 (30.8%)
Progressive Disease	22 (91.7%)
Other: Pneumonia	1 (4.2%)
Other: Progressive disease	1 (4.2%)

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/A

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dth_D180_REE.xls
27NOV2019 12:33

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Patients who Died Including Primary
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	RXDX-101 600 mg/day (N=180)
All Deaths	51 (28.3%)
Progressive Disease	47 (92.2%)
Other: Cardiogenic shock	1 (2.0%)
Other: Pneumonia	1 (2.0%)
Other: Progressive disease	1 (2.0%)
Other: Pulmonary embolism	1 (2.0%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/AC

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/AC
E_D180/prod/output/oth_dth_D180_SEROS1.xls
27NOV2019 12:34

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Patients who Died Including Primary Reason

	RXDX-101 600 mg/day (N=332)
All Deaths	114 (34.3%)
Progressive Disease	101 (87.8%)
Other: Acute respiratory failure	1 (0.9%)
Other: Cardiac arrest	1 (0.9%)
Other: Cardio-respiratory arrest	1 (0.9%)
Other: Cardiogenic shock	1 (0.9%)
Other: Completed suicide	1 (0.9%)
Other: Pneumonia	2 (1.7%)
Other: Progressive disease	1 (0.9%)
Other: Pulmonary embolism	1 (0.9%)
Other: Sepsis	1 (0.9%)
Other: Unknown. no death certificate available. cause of death is unknown.	1 (0.9%)
Unknown	3 (2.6%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dth_D180_SE.xls
08JUL2020 7:32

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Patients who Died Including Primary Reason

	RXDX-101 600 mg/day (N=332)
All Deaths	114 (34.3%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_dth_D180_SE.xls
08JUL2020 7:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Patients who Died Including Primary

	RXDX-101 600 mg/day (N=145)
All Deaths	37 (25.5%)
Progressive Disease	34 (91.9%)
Other: Pneumonia	1 (2.7%)
Other: Progressive disease	1 (2.7%)
Other: Pulmonary embolism	1 (2.7%)

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis
/ACE_D180/prod/output/oth_dth_D194_REE.xls
24JUN2020 13:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				**Country**				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	24	100	37	100	9	100	37	100	3	100	37	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 31MAY2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_center_NDA_REE.xls
09SEP2019 12:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	24	100	37	100	9	100	37	100	3	100	37	100
With <10												

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 31MAY2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_center_NDA_REE.xls
09SEP2019 12:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	24	100	37	100	9	100	37	100	3	100	37	100
With >=10												

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 31MAY2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_center_NDA_REE.xls
09SEP2019 12:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				**Country**				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	24	100	37	100	9	100	37	100	3	100	37	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 31MAY2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_center_NDA_REE.xls
09SEP2019 12:46

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				**Country**				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	46	100	105	100	15	100	105	100	3	100	105	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 31MAY2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_center_NDA_SEROS1.xls
09SEP2019 12:49

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	46	100	105	100	15	100	105	100	3	100	105	100
With <10												

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 31MAY2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_center_NDA_SEROS1.xls
09SEP2019 12:49

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	46	100	105	100	15	100	105	100	3	100	105	100
With >=10												

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 31MAY2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_center_NDA_SEROS1.xls
09SEP2019 12:49

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				**Country**				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	46	100	105	100	15	100	105	100	3	100	105	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 31MAY2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_center_NDA_SEROS1.xls
09SEP2019 12:49

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				**Country**				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	84	100	206	100	15	100	206	100	3	100	206	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 31MAY2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_center_NDA_SE.xls
09SEP2019 12:50

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	84	100	206	100	15	100	206	100	3	100	206	100
With <10												

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 31MAY2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_center_NDA_SE.xls
09SEP2019 12:50

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	84	100	206	100	15	100	206	100	3	100	206	100
With >=10												

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 31MAY2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_center_NDA_SE.xls
09SEP2019 12:50

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				**Country**				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	84	100	206	100	15	100	206	100	3	100	206	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 31MAY2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/oth_center_NDA_SE.xls
09SEP2019 12:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	36	100	78	100	12	100	78	100	3	100	78	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)
[7]: % of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D180_REE.xls
27NOV2019 12:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	36	100	78	100	12	100	78	100	3	100	78	100
With <10 Patients per arm [1]	36	100	78	100	10	83.3	43	55.1	0	0	0	0

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)
[7]: % of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D180_REE.xls
27NOV2019 12:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	36	100	78	100	12	100	78	100	3	100	78	100
With >=10 Patients per arm [2]	0	0	0	0	2	16.7	35	44.9	3	100	78	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)
[7]: % of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D180_REE.xls
27NOV2019 12:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	36	100	78	100	12	100	78	100	3	100	78	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)
[7]: % of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D180_REE.xls
27NOV2019 12:20

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	65	100	180	100	15	100	180	100	3	100	180	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)
[7]: % of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm
Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D180_SEROS1.xls
27NOV2019 12:21

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	65	100	180	100	15	100	180	100	3	100	180	100
With <10 Patients per arm [1]	64	98.5	168	93.3	9	60	46	25.6	0	0	0	0

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)
[7]: % of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm
Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D180_SEROS1.xls
27NOV2019 12:21

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	65	100	180	100	15	100	180	100	3	100	180	100
With >=10 Patients per arm [2]	1	1.5	12	6.7	6	40	134	74.4	3	100	180	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)
[7]: % of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm
Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D180_SEROS1.xls
27NOV2019 12:21

POPULATION: Safety-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	65	100	180	100	15	100	180	100	3	100	180	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)
[7]: % of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm
Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D180_SEROS1.xls
27NOV2019 12:21

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				**Country**				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	99	100	332	100	15	100	332	100	3	100	332	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)
[7]: % of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm
Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D180_SE.xls
08JUL2020 07:07

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	99	100	332	100	15	100	332	100	3	100	332	100
With <10 Patients per arm [1]	95	96	281	84.6	4	26.7	22	6.6	0	0	0	0

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)
[7]: % of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm
Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D180_SE.xls
08JUL2020 07:07

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				**Country**				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	99	100	332	100	15	100	332	100	3	100	332	100
With >=10 Patients per arm [2]	4	4	51	15.4	11	73.3	310	93.4	3	100	332	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)
[7]: % of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm
Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D180_SE.xls
08JUL2020 07:07

POPULATION: Safety-Evaluable Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				**Country**				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	99	100	332	100	15	100	332	100	3	100	332	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm)
[7]: % of randomized patients compared to overall number of randomized patients (e.g. % of randomized patients in centers with <10 patients per arm
Enrollment cut-off: 31OCT2018, Clinical cut-off: 31OCT2018
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D180_SE.xls
08JUL2020 07:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				**Country**				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	53	100	152	100	13	100	152	100	3	100	152	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 01MAY2019
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D194_REE.xls
24JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				Country				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	53	100	152	100	13	100	152	100	3	100	152	100
With <10												

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 01MAY2019
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D194_REE.xls
24JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				**Country**				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	53	100	152	100	13	100	152	100	3	100	152	100
With >=10												

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)

Clinical cut-off: 01MAY2019
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D194_REE.xls
24JUN2020 13:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Number of Centers/Countries/Geographical regions with <10, >=10 patients per arm
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

	Center				**Country**				Geographical region [3]			
Category	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]	n [4]	% [5]	n of patients randomized [6]	% randomized patients [7]
Overall	53	100	152	100	13	100	152	100	3	100	152	100

[1]: ' <10 patients category' if at least one treatment arm has <10 patients. [2]: ' >=10 patients ' category if all treatment arms have >=10 patients.
[3]: Geographical regions: Asia, Europe, America
[4]: Number of centers
[5]: % of centers compared to overall number of centers
[6]: Number of patients randomized in the corresponding category (e.g. Number of patients randomized in centers with <10 pts per arm) compared to overall number of randomized patients)
Clinical cut-off: 01MAY2019
Program: SAS v9.4 $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/oth_center.sas

Output: $root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/oth_center_D194_REE.xls
24JUN2020 13:23

POPULATION: Efficacy-Evaluable
ROS1 Population

ENDPOINT: All patients
MODEL: --
STUDY: STARTRK-2
Median follow-up time in Days

	RXDX-101 600 mg/day (N=145)
Follow-up time	
n	145
Mean (SD)	419.43 (232.59)
Median	378
Q1, Q3	252.00, 601.00
Min, Max	2.0, 986.0

off: 01MAY2019

-
root/clinical_studies/RO7102122/CDT30222/GO40
Output:
root/clinical_studies/RO7102122/CDT30222/GO40
782/data_analysis/ACE_D180/prod/output/oth_fu
t_D194_REE.xls
13JUL2020 20:11

Endpunkte

Wirksamkeit

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	8	21,6	29	78,4	15,11	6,87	NE	NE	NE	NE
Sex	Male	14	37,8	3	21,4	11	78,6	NE	5,09	NE	NE	NE	NE
	Female	23	62,2	5	21,7	18	78,3	NE	6,87	NE	NE	NE	NE
Age	18-64	29	78,4	7	24,1	22	75,9	15,11	6,87	NE	NE	NE	NE
	65-74	8	21,6	1	12,5	7	87,5	NE	5,09	NE	NE	NE	NE
Race	White	20	54,1	5	25,0	15	75,0	10,55	5,09	NE	NE	NE	NE
	Other	17	45,9	3	17,6	14	82,4	15,11	7,69	NE	NE	15,11	NE
Region	America (AM)	12	32,4	1	8,3	11	91,7	NE	NE	NE	NE	NE	NE
	Europe (EU)	10	27,0	3	30,0	7	70,0	6,87	1,45	NE	NE	6,87	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_OS_SG.xls
07SEP2019 16:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	4	26,7	11	73,3	7,69	5,09	NE	NE	7,69	NE
ECOG Performance Status	0	15	40,5			15	100,0	NE	NE	NE	NE	NE	NE
	1	17	45,9	6	35,3	11	64,7	7,69	1,81	NE	NE	10,55	NE
	2	5	13,5	2	40,0	3	60,0	5,32	3,78	NE	NE	3,78	NE
Number of Prior Anticancer Therapies	None	14	37,8	1	7,1	13	92,9	NE	NE	NE	NE	NE	NE
	1	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
	2 or More	21	56,8	7	33,3	14	66,7	6,87	3,78	NE	NE	10,55	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_OS_SG.xls
07SEP2019 16:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	1	7,1	13	92,9	NE	NE	NE	NE	NE	NE
	Previously Treated	23	62,2	7	30,4	16	69,6	10,55	3,78	NE	NE	10,55	NE
Molecular Testing Results	Local	12	32,4	2	16,7	10	83,3	NE	10,55	NE	NE	NE	NE
	Central	25	67,6	6	24,0	19	76,0	7,69	3,78	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_OS_SG.xls
07SEP2019 16:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	8	22,9	27	77,1	15,11	6,87	NE	NE	NE	NE
	No	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8	2	50,0	2	50,0	1,81	1,81	NE	7,69	1,81	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_OS_SG.xls
07SEP2019 16:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	6	18,2	27	81,8	NE	10,55	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_OS_SG.xls
07SEP2019 16:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	24	30,8	54	69,2	16,07	7,66	30,75	30,75	28,32	NE
Sex	Male	29	37,2	10	34,5	19	65,5	14,82	5,09	NE	25,56	16,07	NE
	Female	49	62,8	14	28,6	35	71,4	21,19	6,87	30,75	30,75	28,32	NE
Age	18-64	62	79,5	19	30,6	43	69,4	15,74	7,66	NE	NE	25,56	NE
	65-74	14	17,9	5	35,7	9	64,3	21,19	2,92	NE	30,75	21,19	NE
	>=75	2	2,6			2	100,0	NE	NE	NE	NE	NE	NE
Race	White	35	44,9	11	31,4	24	68,6	16,13	5,09	NE	NE	25,56	NE
	Other	43	55,1	13	30,2	30	69,8	15,74	4,24	30,75	30,75	28,32	NE
Region	America (AM)	22	28,2	4	18,2	18	81,8	30,75	16,13	NE	30,75	30,75	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_OS_SG.xls
27NOV2019 12:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	7	41,2	10	58,8	14,82	1,81	NE	25,56	14,82	NE
	Asia (AS)	39	50,0	13	33,3	26	66,7	15,11	4,01	NE	28,32	16,07	NE
ECOG Performance Status	0	30	38,5	5	16,7	25	83,3	25,56	21,19	NE	NE	NE	NE
	1	38	48,7	12	31,6	26	68,4	14,82	7,66	NE	NE	28,32	NE
	2	10	12,8	7	70,0	3	30,0	2,92	0,10	6,87	4,01	2,92	30,75
Number of Prior Anticancer Therapies	None	31	39,7	4	12,9	27	87,1	NE	16,13	NE	NE	NE	NE
	1	3	3,8	2	66,7	1	33,3	7,66	7,66	30,75	30,75	7,66	30,75

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_OS_SG.xls
27NOV2019 12:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	18	40,9	26	59,1	6,87	3,78	21,19	25,56	16,07	NE
Prior Treatment	Naïve	31	39,7	4	12,9	27	87,1	NE	16,13	NE	NE	NE	NE
	Previously Treated	47	60,3	20	42,6	27	57,4	7,66	3,78	21,19	25,56	16,07	30,75
Molecular Testing Results	Local	35	44,9	11	31,4	24	68,6	15,74	3,25	30,75	30,75	NE	NE
	Central	43	55,1	13	30,2	30	69,8	16,07	6,87	NE	28,32	25,56	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_OS_SG.xls
27NOV2019 12:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	22	29,7	52	70,3	16,07	7,66	NE	NE	25,56	NE
	No	4	5,1	2	50,0	2	50,0	15,43	0,10	30,75	30,75	0,10	30,75
Investigator Measurable CNS Disease	Yes	8	10,3	3	37,5	5	62,5	1,81	1,41	NE	NE	1,81	NE
	No	70	89,7	21	30,0	49	70,0	16,13	10,55	30,75	30,75	28,32	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_OS_SG.xls
27NOV2019 12:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_OS_SG.xls
27NOV2019 12:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	37	25,5	108	74,5	15,74	11,63	28,32	30,75	28,32	NE
Sex	Male	52	35,9	15	28,8	37	71,2	14,82	7,72	NE	25,56	16,07	NE
	Female	93	64,1	22	23,7	71	76,3	16,13	10,55	30,75	30,75	28,32	NE
Age	18-64	109	75,2	30	27,5	79	72,5	14,82	10,55	28,32	NE	25,56	NE
	65-74	29	20,0	7	24,1	22	75,9	21,19	7,66	NE	30,75	21,19	NE
	>=75	7	4,8			7	100,0	NE	NE	NE	NE	NE	NE
Race	White	60	41,4	18	30,0	42	70,0	11,79	7,72	NE	NE	25,56	NE
	Other	85	58,6	19	22,4	66	77,6	15,74	13,04	30,75	30,75	28,32	NE
Region	America (AM)	40	27,6	7	17,5	33	82,5	30,75	11,79	NE	30,75	30,75	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_OS_SG.xls
24JUN2020 13:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	9	26,5	25	73,5	21,19	7,66	NE	25,56	21,19	NE
	Asia (AS)	71	49,0	21	29,6	50	70,4	11,63	7,69	NE	28,32	16,07	NE
ECOG Performance Status	0	61	42,1	7	11,5	54	88,5	25,56	21,19	NE	NE	NE	NE
	1	69	47,6	20	29,0	49	71,0	11,79	8,41	NE	28,32	16,07	NE
	2	15	10,3	10	66,7	5	33,3	2,92	0,10	7,66	6,87	2,92	30,75
Number of Prior Anticancer Therapies	None	62	42,8	12	19,4	50	80,6	NE	11,79	NE	NE	NE	NE
	1	4	2,8	2	50,0	2	50,0	7,66	7,66	30,75	30,75	7,66	30,75

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_OS_SG.xls
24JUN2020 13:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	79	54,5	23	29,1	56	70,9	15,11	7,92	28,32	25,56	21,19	NE
Prior Treatment	Naïve	62	42,8	12	19,4	50	80,6	NE	11,79	NE	NE	NE	NE
	Previously Treated	83	57,2	25	30,1	58	69,9	15,11	7,92	25,56	28,32	21,19	30,75
Molecular Testing Results	Local	75	51,7	18	24,0	57	76,0	15,74	10,55	30,75	30,75	NE	NE
	Central	70	48,3	19	27,1	51	72,9	16,07	7,92	NE	28,32	25,56	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_OS_SG.xls
24JUN2020 13:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	34	25,2	101	74,8	15,74	11,63	28,32	NE	25,56	NE
	No	10	6,9	3	30,0	7	70,0	30,75	0,07	30,75	30,75	NE	NE
Investigator Measurable CNS Disease	Yes	11	7,6	4	36,4	7	63,6	1,81	0,07	NE	NE	1,81	NE
	No	134	92,4	33	24,6	101	75,4	15,74	11,63	28,32	30,75	28,32	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_OS_SG.xls
24JUN2020 13:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Overall Survival

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_OS_SG.xls
24JUN2020 13:07

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: Overall Survival
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	33	32	30	26	26	24	21	11	9	3	1	1	NE
Patients censored														
RXDX-101 600 mg/day	0	2	2	3	5	5	6	9	18	20	26	28	28	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_OS_SG1.pdf
12SEP2019 8:18

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: Overall Survival
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	70	63	57	55	54	41	27	18	8	4	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	2	4	7	8	8	17	31	39	48	51	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_OS_SG1.pdf
27NOV2019 11:37

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: Overall Survival
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	136	124	98	74	58	41	27	18	8	4	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	2	7	26	44	58	71	85	93	102	105	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_OS_SG1.pdf
24JUN2020 15:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Objective Response Rate by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
All	n/a	37	100,0	28	75,7	59,9	86,6
Sex	Male	14	37,8	11	78,6	52,4	92,4
	Female	23	62,2	17	73,9	53,5	87,5
Age	18-64	29	78,4	23	79,3	61,6	90,2
	65-74	8	21,6	5	62,5	30,6	86,3
Race	White	20	54,1	15	75,0	53,1	88,8
	Other	17	45,9	13	76,5	52,7	90,4
Region	America (AM)	12	32,4	10	83,3	55,2	95,3
	Europe (EU)	10	27,0	7	70,0	39,7	89,2
	Asia (AS)	15	40,5	11	73,3	48,0	89,1
ECOG Performance Status	0	15	40,5	15	100,0	79,6	100,0
	1	17	45,9	11	64,7	41,3	82,7

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Objective Response Rate by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
	2	5	13,5	2	40,0	11,8	76,9
Number of Prior Anticancer Therapies	None	14	37,8	12	85,7	60,1	96,0
	1	2	5,4	1	50,0	9,5	90,5
	2 or More	21	56,8	15	71,4	50,0	86,2
Prior Treatment	Naïve	14	37,8	12	85,7	60,1	96,0
	Previously Treated	23	62,2	16	69,6	49,1	84,4
Molecular Testing Results	Local	12	32,4	9	75,0	46,8	91,1
	Central	25	67,6	19	76,0	56,6	88,5
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	28	80,0	64,1	90,0

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Objective Response Rate by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
	No	2	5,4	0	0,0	0,0	65,8
Investigator Measurable CNS Disease	Yes	4	10,8	2	50,0	15,0	85,0
	No	33	89,2	26	78,8	62,2	89,3

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Objective Response Rate by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
All	n/a	78	100,0	56	71,8	61,0	80,6
Sex	Male	29	37,2	21	72,4	54,3	85,3
	Female	49	62,8	35	71,4	57,6	82,2
Age	18-64	62	79,5	46	74,2	62,1	83,4
	65-74	14	17,9	8	57,1	32,6	78,6
	>=75	2	2,6	2	100,0	34,2	100,0
Race	White	35	44,9	24	68,6	52,0	81,4
	Other	43	55,1	32	74,4	59,8	85,1

95% CI based on Wilson Scores.
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D180_REE_ORR BIRC_SG.xls
25NOV2019 14:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Objective Response Rate by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
Region	America (AM)	22	28,2	16	72,7	51,8	86,8
	Europe (EU)	17	21,8	12	70,6	46,9	86,7
	Asia (AS)	39	50,0	28	71,8	56,2	83,5
ECOG Performance Status	0	30	38,5	27	90,0	74,4	96,5
	1	38	48,7	25	65,8	49,9	78,8
	2	10	12,8	4	40,0	16,8	68,7
Number of Prior Anticancer Therapies	None	31	39,7	26	83,9	67,4	92,9

95% CI based on Wilson Scores.
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D180_REE_ORR BIRC_SG.xls
25NOV2019 14:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Objective Response Rate by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
	1	3	3,8	1	33,3	6,1	79,2
	2 or More	44	56,4	29	65,9	51,1	78,1
Prior Treatment	Naïve	31	39,7	26	83,9	67,4	92,9
	Previously Treated	47	60,3	30	63,8	49,5	76,0
Molecular Testing Results	Local	35	44,9	25	71,4	54,9	83,7
	Central	43	55,1	31	72,1	57,3	83,3

95% CI based on Wilson Scores.
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D180_REE_ORR BIRC_SG.xls
25NOV2019 14:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Objective Response Rate by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	55	74,3	63,3	82,9
	No	4	5,1	1	25,0	4,6	69,9
Investigator Measurable CNS Disease	Yes	8	10,3	4	50,0	21,5	78,5
	No	70	89,7	52	74,3	63,0	83,1

95% CI based on Wilson Scores.
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D180_REE_ORR BIRC_SG.xls
25NOV2019 14:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Objective Response Rate by IRF per RECIST v1.1

MODEL: --

STUDY: STARTRK-2

Dichotomous analysis (efficacy)

		RXDX-101 600 mg/day (N=145)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
All	n/a	145	100,0	95	65,5	57,5	72,8
Sex	Male	52	35,9	36	69,2	55,7	80,1
	Female	93	64,1	59	63,4	53,3	72,5
Age	18-64	109	75,2	74	67,9	58,6	75,9
	65-74	29	20,0	17	58,6	40,7	74,5
	>=75	7	4,8	4	57,1	25,0	84,2
Race	White	60	41,4	35	58,3	45,7	69,9

95% CI based on Wilson Scores.
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_resp.sas
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D194_REE_ORRBIRC_SG.xls
24JUN2020 12:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Objective Response Rate by IRF per RECIST v1.1

MODEL: --

STUDY: STARTRK-2

Dichotomous analysis (efficacy)

		RXDX-101 600 mg/day (N=145)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
	Other	85	58,6	60	70,6	60,2	79,2
Region	America (AM)	40	27,6	26	65,0	49,5	77,9
	Europe (EU)	34	23,4	23	67,6	50,8	80,9
	Asia (AS)	71	49,0	46	64,8	53,2	74,9
ECOG Performance Status	0	61	42,1	50	82,0	70,5	89,6
	1	69	47,6	38	55,1	43,4	66,2
	2	15	10,3	7	46,7	24,8	69,9

95% CI based on Wilson Scores.
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_resp.sas
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D194_REE_ORRBIRC_SG.xls
24JUN2020 12:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Objective Response Rate by IRF per RECIST v1.1

MODEL: --

STUDY: STARTRK-2

Dichotomous analysis (efficacy)

		RXDX-101 600 mg/day (N=145)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
Number of Prior Anticancer Therapies	None	62	42,8	44	71,0	58,7	80,8
	1	4	2,8	2	50,0	15,0	85,0
	2 or More	79	54,5	49	62,0	51,0	71,9
Prior Treatment	Naïve	62	42,8	44	71,0	58,7	80,8
	Previously Treated	83	57,2	51	61,4	50,7	71,2
Molecular Testing Results	Local	75	51,7	50	66,7	55,4	76,3
	Central	70	48,3	45	64,3	52,6	74,5

95% CI based on Wilson Scores.
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_resp.sas
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D194_REE_ORRBIRC_SG.xls
24JUN2020 12:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Objective Response Rate by IRF per RECIST v1.1

MODEL: --

STUDY: STARTRK-2

Dichotomous analysis (efficacy)

		RXDX-101 600 mg/day (N=145)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	93	68,9	60,6	76,1
	No	10	6,9	2	20,0	5,7	51,0
Investigator Measurable CNS Disease	Yes	11	7,6	6	54,5	28,0	78,7
	No	134	92,4	89	66,4	58,1	73,9

95% CI based on Wilson Scores.
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_resp.sas
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D194_REE_ORRBIRC_SG.xls
24JUN2020 12:37

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Intracranial Objective Response Rate by IRF per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=17)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
All	n/a	17	100,0	9	52,9	31,0	73,8
Sex	Male	6	35,3	4	66,7	30,0	90,3
	Female	11	64,7	5	45,5	21,3	72,0
Age	18-64	12	70,6	7	58,3	32,0	80,7
	65-74	5	29,4	2	40,0	11,8	76,9
Race	White	7	41,2	4	57,1	25,0	84,2
	Other	10	58,8	5	50,0	23,7	76,3
Region	America (AM)	4	23,5	3	75,0	30,1	95,4
	Europe (EU)	3	17,6	1	33,3	6,1	79,2
	Asia (AS)	10	58,8	5	50,0	23,7	76,3
ECOG Performance Status	0	4	23,5	3	75,0	30,1	95,4
	1	10	58,8	5	50,0	23,7	76,3

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Intracranial Objective Response Rate by IRF per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=17)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
	2	3	17,6	1	33,3	6,1	79,2
Number of Prior Anticancer Therapies	None	5	29,4	4	80,0	37,6	96,4
	2 or More	12	70,6	5	41,7	19,3	68,0
Prior Treatment	Naïve	5	29,4	4	80,0	37,6	96,4
	Previously Treated	12	70,6	5	41,7	19,3	68,0
Molecular Testing Results	Local	3	17,6	3	100,0	43,9	100,0
	Central	14	82,4	6	42,9	21,4	67,4
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	17	100,0	9	52,9	31,0	73,8

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Intracranial Objective Response Rate by IRF per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=17)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
Investigator Measurable CNS Disease	Yes	4	23,5	2	50,0	15,0	85,0
	No	13	76,5	7	53,8	29,1	76,8

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Intracranial Objective Response Rate by IRF per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=31)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
All	n/a	31	100,0	15	48,4	32,0	65,2
Sex	Male	12	38,7	5	41,7	19,3	68,0
	Female	19	61,3	10	52,6	31,7	72,7
Age	18-64	25	80,6	12	48,0	30,0	66,5
	65-74	6	19,4	3	50,0	18,8	81,2
Race	White	12	38,7	6	50,0	25,4	74,6
	Other	19	61,3	9	47,4	27,3	68,3

95% CI based on Wilson Scores.
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D180_REE_CNS_ORRCNS_SG.xls
25NOV2019 14:14

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Intracranial Objective Response Rate by IRF per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=31)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
Region	America (AM)	10	32,3	6	60,0	31,3	83,2
	Europe (EU)	4	12,9	2	50,0	15,0	85,0
	Asia (AS)	17	54,8	7	41,2	21,6	64,0
ECOG Performance Status	0	8	25,8	4	50,0	21,5	78,5
	1	18	58,1	9	50,0	29,0	71,0
	2	5	16,1	2	40,0	11,8	76,9
Number of Prior Anticancer Therapies	None	15	48,4	9	60,0	35,7	80,2
	2 or More	16	51,6	6	37,5	18,5	61,4

95% CI based on Wilson Scores.
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D180_REE_CNS_ORRCNS_SG.xls
25NOV2019 14:14

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Intracranial Objective Response Rate by IRF per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=31)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
Prior Treatment	Naïve	15	48,4	9	60,0	35,7	80,2
	Previously Treated	16	51,6	6	37,5	18,5	61,4
Molecular Testing Results	Local	12	38,7	7	58,3	32,0	80,7
	Central	19	61,3	8	42,1	23,1	63,7
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	31	100,0	15	48,4	32,0	65,2

95% CI based on Wilson Scores.
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D180_REE_CNS_ORRCNS_SG.xls
25NOV2019 14:14

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Intracranial Objective Response Rate by IRF per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Dichotomous analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=31)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
Investigator Measurable CNS Disease	Yes	8	25,8	4	50,0	21,5	78,5
	No	23	74,2	11	47,8	29,2	67,0

95% CI based on Wilson Scores.
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D180_REE_CNS_ORRCNS_SG.xls
25NOV2019 14:14

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Intracranial Objective Response Rate by IRF per CNS RECIST

MODEL: --

STUDY: STARTRK-2

Dichotomous analysis (efficacy)

		RXDX-101 600 mg/day (N=43)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
All	n/a	43	100,0	22	51,2	36,8	65,4
Sex	Male	15	34,9	6	40,0	19,8	64,3
	Female	28	65,1	16	57,1	39,1	73,5
Age	18-64	33	76,7	17	51,5	35,2	67,5
	65-74	8	18,6	4	50,0	21,5	78,5
	>=75	2	4,7	1	50,0	9,5	90,5
Race	White	18	41,9	11	61,1	38,6	79,7

95% CI based on Wilson Scores.
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_resp.sas
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D194_REE_CNS_ORR CNS_SG.xls
24JUN2020 12:49

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Intracranial Objective Response Rate by IRF per CNS RECIST

MODEL: --

STUDY: STARTRK-2

Dichotomous analysis (efficacy)

		RXDX-101 600 mg/day (N=43)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
	Other	25	58,1	11	44,0	26,7	62,9
Region	America (AM)	18	41,9	11	61,1	38,6	79,7
	Europe (EU)	6	14,0	4	66,7	30,0	90,3
	Asia (AS)	19	44,2	7	36,8	19,1	59,0
ECOG Performance Status	0	12	27,9	6	50,0	25,4	74,6
	1	25	58,1	13	52,0	33,5	70,0
	2	6	14,0	3	50,0	18,8	81,2

95% CI based on Wilson Scores.
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_resp.sas
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D194_REE_CNS_ORR CNS_SG.xls
24JUN2020 12:49

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Intracranial Objective Response Rate by IRF per CNS RECIST

MODEL: --

STUDY: STARTRK-2

Dichotomous analysis (efficacy)

		RXDX-101 600 mg/day (N=43)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
Number of Prior Anticancer Therapies	None	19	44,2	12	63,2	41,0	80,9
	2 or More	24	55,8	10	41,7	24,5	61,2
Prior Treatment	Naïve	19	44,2	12	63,2	41,0	80,9
	Previously Treated	24	55,8	10	41,7	24,5	61,2
Molecular Testing Results	Local	21	48,8	13	61,9	40,9	79,2
	Central	22	51,2	9	40,9	23,3	61,3

95% CI based on Wilson Scores.
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_resp.sas
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D194_REE_CNS_ORR CNS_SG.xls
24JUN2020 12:49

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Intracranial Objective Response Rate by IRF per CNS RECIST

MODEL: --

STUDY: STARTRK-2

Dichotomous analysis (efficacy)

		RXDX-101 600 mg/day (N=43)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL) (Wilson)	95% CI (UL) (Wilson)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	42	97,7	22	52,4	37,7	66,6
	No	1	2,3	0	0,0	0,0	79,3
Investigator Measurable CNS Disease	Yes	10	23,3	6	60,0	31,3	83,2
	No	33	76,7	16	48,5	32,5	64,8

95% CI based on Wilson Scores.
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_resp.sas
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_resp_D194_REE_CNS_ORR CNS_SG.xls
24JUN2020 12:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	28	100,0	12	42,9	16	57,1	6,77	3,71	12,65	NE	9,20	NE
Sex	Male	11	39,3	4	36,4	7	63,6	6,77	3,58	NE	NE	6,77	NE
	Female	17	60,7	8	47,1	9	52,9	5,59	3,55	12,65	12,65	9,20	NE
Age	18-64	23	82,1	11	47,8	12	52,2	5,59	3,58	12,65	12,65	6,77	NE
	65-74	5	17,9	1	20,0	4	80,0	9,20	9,20	NE	NE	9,20	NE
Race	White	15	53,6	5	33,3	10	66,7	9,20	5,59	NE	NE	11,37	NE
	Other	13	46,4	7	53,8	6	46,2	3,71	3,58	9,46	9,46	3,71	NE
Region	America (AM)	10	35,7	3	30,0	7	70,0	9,46	5,59	NE	NE	9,13	NE
	Europe (EU)	7	25,0	2	28,6	5	71,4	9,20	3,55	NE	NE	9,20	NE
	Asia (AS)	11	39,3	7	63,6	4	36,4	3,71	2,40	11,37	11,37	3,71	12,65
ECOG Performance Status	0	15	53,6	4	26,7	11	73,3	9,46	9,13	NE	NE	9,46	NE
	1	11	39,3	6	54,5	5	45,5	5,59	3,58	12,65	11,37	5,59	NE

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2	2	7,1	2	100,0			2,40	2,40	3,55	2,97	2,40	3,55
Number of Prior Anticancer Therapies	None	12	42,9	4	33,3	8	66,7	9,13	3,55	NE	NE	9,13	NE
	1	1	3,6			1	100,0	NE	NE	NE	NE	NE	NE
	2 or More	15	53,6	8	53,3	7	46,7	5,55	3,58	12,65	11,37	5,55	NE
Prior Treatment	Naïve	12	42,9	4	33,3	8	66,7	9,13	3,55	NE	NE	9,13	NE
	Previously Treated	16	57,1	8	50,0	8	50,0	5,55	3,58	12,65	12,65	5,59	NE
Molecular Testing Results	Local	9	32,1	6	66,7	3	33,3	5,59	3,58	9,20	9,20	5,59	NE
	Central	19	67,9	6	31,6	13	68,4	11,37	3,55	NE	NE	11,37	NE

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	28	100,0	12	42,9	16	57,1	6,77	3,71	12,65	NE	9,20	NE
Investigator Measurable CNS Disease	Yes	2	7,1	1	50,0	1	50,0	6,77	6,77	NE	NE	6,77	NE
	No	26	92,9	11	42,3	15	57,7	9,13	3,58	12,65	NE	9,20	NE

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	56	100,0	29	51,8	27	48,2	9,13	5,55	12,65	14,88	11,37	NE
Sex	Male	21	37,5	14	66,7	7	33,3	9,07	3,71	13,93	14,59	9,13	14,88
	Female	35	62,5	15	42,9	20	57,1	9,46	5,52	20,21	20,50	11,37	NE
Age	18-64	46	82,1	24	52,2	22	47,8	6,77	5,45	12,65	16,53	11,07	NE
	65-74	8	14,3	3	37,5	5	62,5	9,20	9,07	NE	NE	9,20	NE
	>=75	2	3,6	2	100,0			9,59	9,59	14,78	12,19	9,59	14,78
Race	White	24	42,9	12	50,0	12	50,0	10,14	5,59	16,53	20,50	11,37	NE
	Other	32	57,1	17	53,1	15	46,9	6,77	3,61	12,65	14,59	9,20	NE
Region	America (AM)	16	28,6	6	37,5	10	62,5	9,13	5,59	NE	NE	9,46	NE
	Europe (EU)	12	21,4	7	58,3	5	41,7	12,50	9,20	20,50	17,69	13,93	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_DORBIRC_5G.xls
25NOV2019 14:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	28	50,0	16	57,1	12	42,9	5,55	3,61	11,37	12,65	9,07	NE
ECOG Performance Status	0	27	48,2	11	40,7	16	59,3	9,20	5,62	NE	NE	14,59	NE
	1	25	44,6	14	56,0	11	44,0	9,20	5,55	13,93	14,78	9,59	NE
	2	4	7,1	4	100,0			2,78	2,40	3,55	3,35	2,40	20,21
Number of Prior Anticancer Therapies	None	26	46,4	13	50,0	13	50,0	9,17	5,52	13,93	15,56	9,46	NE
	1	1	1,8			1	100,0	NE	NE	NE	NE	NE	NE
	2 or More	29	51,8	16	55,2	13	44,8	9,07	3,71	14,78	14,88	11,37	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_DORBIRC_5G.xls
25NOV2019 14:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	26	46,4	13	50,0	13	50,0	9,17	5,52	13,93	15,56	9,46	NE
	Previously Treated	30	53,6	16	53,3	14	46,7	9,07	3,71	14,85	14,88	11,37	NE
Molecular Testing Results	Local	25	44,6	13	52,0	12	48,0	7,38	5,45	14,85	16,53	9,20	NE
	Central	31	55,4	16	51,6	15	48,4	9,20	3,71	13,93	14,88	11,07	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_DORBIRC_5G.xls
25NOV2019 14:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	55	98,2	29	52,7	26	47,3	9,13	5,55	12,65	14,88	11,37	NE
	No	1	1,8			1	100,0	NE	NE	NE	NE	NE	NE
Investigator Measurable CNS Disease	Yes	4	7,1	2	50,0	2	50,0	11,65	6,77	NE	16,53	6,77	NE
	No	52	92,9	27	51,9	25	48,1	9,13	5,52	11,37	14,85	11,07	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_DORBIRC_5G.xls
25NOV2019 14:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_DORBIRC_5G.xls
25NOV2019 14:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	95	100,0	41	43,2	54	56,8	8,94	5,62	9,59	14,88	11,37	NE
Sex	Male	36	37,9	18	50,0	18	50,0	9,07	5,36	13,93	14,59	9,20	NE
	Female	59	62,1	23	39,0	36	61,0	8,94	5,59	11,37	20,21	10,97	NE
Age	18-64	74	77,9	33	44,6	41	55,4	8,71	5,59	10,97	14,88	11,07	NE
	65-74	17	17,9	6	35,3	11	64,7	9,07	5,36	NE	14,59	9,07	NE
	>=75	4	4,2	2	50,0	2	50,0	9,59	9,59	14,78	14,78	9,59	14,78
Race	White	35	36,8	17	48,6	18	51,4	9,13	5,62	14,78	16,53	11,07	NE
	Other	60	63,2	24	40,0	36	60,0	8,71	5,45	9,59	14,59	9,49	NE
Region	America (AM)	26	27,4	9	34,6	17	65,4	9,13	5,59	NE	NE	9,46	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_DORBIRC_SG.xls
24JUN2020 12:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Duration of Response by IRF per RECIST v1.1

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	23	24,2	10	43,5	13	56,5	11,07	7,49	14,88	20,50	13,93	NE
	Asia (AS)	46	48,4	22	47,8	24	52,2	6,87	5,13	9,59	12,65	9,20	20,21
ECOG Performance Status	0	50	52,6	13	26,0	37	74,0	14,59	9,07	NE	NE	14,88	NE
	1	38	40,0	21	55,3	17	44,7	7,49	5,59	10,97	11,37	9,49	20,50
	2	7	7,4	7	100,0			3,15	2,40	6,87	5,13	3,15	8,94
Number of Prior Anticancer Therapies	None	44	46,3	19	43,2	25	56,8	7,49	5,52	10,97	14,59	9,46	NE
	1	2	2,1	1	50,0	1	50,0	5,59	5,59	NE	NE	5,59	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_DORBIRC_SG.xls
24JUN2020 12:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Duration of Response by IRF per RECIST v1.1

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	49	51,6	21	42,9	28	57,1	9,07	5,55	14,78	14,88	11,37	NE
Prior Treatment	Naïve	44	46,3	19	43,2	25	56,8	7,49	5,52	10,97	14,59	9,46	NE
	Previously Treated	51	53,7	22	43,1	29	56,9	8,94	5,59	14,78	14,88	11,37	NE
Molecular Testing Results	Local	50	52,6	21	42,0	29	58,0	8,71	5,59	10,97	14,85	9,46	NE
	Central	45	47,4	20	44,4	25	55,6	9,07	5,52	12,65	14,88	11,37	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_DORBIRC_SG.xls
24JUN2020 12:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	93	97,9	41	44,1	52	55,9	8,94	5,59	9,59	14,88	11,07	NE
	No	2	2,1			2	100,0	NE	NE	NE	NE	NE	NE
Investigator Measurable CNS Disease	Yes	6	6,3	3	50,0	3	50,0	8,94	6,77	NE	16,53	8,94	NE
	No	89	93,7	38	42,7	51	57,3	8,71	5,59	10,97	14,85	11,07	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_DORBIRC_SG.xls
24JUN2020 12:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_DORBIRC_SG.xls
24JUN2020 12:42

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	28	27	22	20	18	15	10	5	3	1	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	1	2	2	3	3	7	11	13	15	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_DORBIRC_SG1.pdf
10SEP2019 13:52

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	56	53	42	41	32	22	15	7	3	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	2	3	3	4	8	14	20	24	26	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_DORBIRC_SG1.pdf
26NOV2019 8:05

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: Duration of Response by IRF per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	95	91	65	57	37	22	15	7	3	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	3	14	16	26	35	41	47	51	53	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_DORBIRC_SG1.pdf
24JUN2020 17:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	17	45,9	20	54,1	4,63	2,96	12,22	15,74	8,31	NE
Sex	Male	14	37,8	6	42,9	8	57,1	4,63	2,96	NE	NE	4,63	NE
	Female	23	62,2	11	47,8	12	52,2	8,08	2,79	13,63	15,74	8,31	NE
Age	18-64	29	78,4	14	48,3	15	51,7	4,63	3,78	12,22	15,74	8,08	NE
	65-74	8	21,6	3	37,5	5	62,5	2,96	0,43	NE	NE	2,96	NE
Race	White	20	54,1	9	45,0	11	55,0	6,39	2,79	NE	NE	8,31	NE
	Other	17	45,9	8	47,1	9	52,9	4,63	3,78	15,74	13,63	4,63	NE
Region	America (AM)	12	32,4	3	25,0	9	75,0	15,74	8,31	NE	NE	15,74	NE
	Europe (EU)	10	27,0	5	50,0	5	50,0	2,79	1,45	NE	NE	2,79	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_PFSRAD1_SG.xls
07SEP2019 16:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	9	60,0	6	40,0	4,47	2,96	8,08	8,08	4,47	NE
ECOG Performance Status	0	15	40,5	4	26,7	11	73,3	15,74	9,99	NE	NE	15,74	NE
	1	17	45,9	9	52,9	8	47,1	6,08	1,81	12,22	12,22	7,69	NE
	2	5	13,5	4	80,0	1	20,0	1,61	0,43	3,78	3,29	0,43	4,47
Number of Prior Anticancer Therapies	None	14	37,8	4	28,6	10	71,4	15,74	7,69	NE	NE	15,74	NE
	1	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
	2 or More	21	56,8	13	61,9	8	38,1	3,37	1,81	8,31	8,31	3,78	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_PFSRAD1_SG.xls
07SEP2019 16:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	4	28,6	10	71,4	15,74	7,69	NE	NE	15,74	NE
	Previously Treated	23	62,2	13	56,5	10	43,5	3,78	1,81	8,31	10,15	4,47	NE
Molecular Testing Results	Local	12	32,4	6	50,0	6	50,0	8,31	4,47	15,74	15,74	8,31	NE
	Central	25	67,6	11	44,0	14	56,0	4,12	1,81	13,63	NE	4,63	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_PFSRAD1_SG.xls
07SEP2019 16:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	17	48,6	18	51,4	4,63	2,96	10,15	15,74	8,31	NE
	No	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8	2	50,0	2	50,0	1,81	1,81	NE	7,69	1,81	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_PFSRAD1_SG.xls
07SEP2019 16:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	15	45,5	18	54,5	4,63	3,78	13,63	15,74	9,99	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_PFSRAD1_SG.xls
07SEP2019 16:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	46	59,0	32	41,0	4,63	2,96	8,31	15,70	9,99	21,13
Sex	Male	29	37,2	21	72,4	8	27,6	3,71	1,45	9,92	9,95	4,63	15,70
	Female	49	62,8	25	51,0	24	49,0	6,34	4,01	13,63	21,09	11,93	30,75
Age	18-64	62	79,5	36	58,1	26	41,9	4,50	3,78	8,31	15,70	8,31	21,39
	65-74	14	17,9	8	57,1	6	42,9	2,96	0,43	30,75	15,47	2,96	30,75
	>=75	2	2,6	2	100,0			11,93	11,93	19,19	15,56	11,93	19,19
Race	White	35	44,9	21	60,0	14	40,0	4,47	2,69	11,99	17,45	8,31	NE
	Other	43	55,1	25	58,1	18	41,9	4,63	4,01	9,92	14,82	8,08	30,75
Region	America (AM)	22	28,2	11	50,0	11	50,0	8,31	4,63	21,09	30,75	9,99	30,75

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_PFSRAD1_SG.xls
25NOV2019 14:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	11	64,7	6	35,3	4,47	1,45	15,70	15,70	4,47	NE
	Asia (AS)	39	50,0	24	61,5	15	38,5	4,24	2,92	8,08	11,93	4,63	21,13
ECOG Performance Status	0	30	38,5	12	40,0	18	60,0	10,15	6,41	NE	NE	15,70	NE
	1	38	48,7	24	63,2	14	36,8	4,50	2,69	9,92	12,22	8,08	21,09
	2	10	12,8	10	100,0			1,41	0,10	3,78	3,35	1,41	4,47
Number of Prior Anticancer Therapies	None	31	39,7	17	54,8	14	45,2	7,69	4,50	14,82	15,74	9,99	NE
	1	3	3,8	2	66,7	1	33,3	0,95	0,95	30,75	30,75	0,95	30,75

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_PFSRAD1_SG.xls
25NOV2019 14:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	27	61,4	17	38,6	3,78	2,10	8,08	12,22	6,41	21,13
Prior Treatment	Naïve	31	39,7	17	54,8	14	45,2	7,69	4,50	14,82	15,74	9,99	NE
	Previously Treated	47	60,3	29	61,7	18	38,3	3,78	1,81	8,08	13,63	6,41	21,39
Molecular Testing Results	Local	35	44,9	21	60,0	14	40,0	6,41	2,69	15,47	17,45	8,31	30,75
	Central	43	55,1	25	58,1	18	41,9	4,50	2,96	9,92	13,63	7,69	21,39

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_PFSRAD1_SG.xls
25NOV2019 14:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	44	59,5	30	40,5	4,63	3,78	8,31	15,47	9,92	21,09
	No	4	5,1	2	50,0	2	50,0	15,43	0,10	30,75	30,75	0,10	30,75
Investigator Measurable CNS Disease	Yes	8	10,3	5	62,5	3	37,5	1,81	1,41	17,45	7,69	1,81	NE
	No	70	89,7	41	58,6	29	41,4	4,63	4,01	9,92	15,70	10,15	21,39

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_PFSRAD1_SG.xls
25NOV2019 14:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_PFSRAD1_SG.xls
25NOV2019 14:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	74	51,0	71	49,0	6,24	4,24	8,31	13,63	10,15	19,19
Sex	Male	52	35,9	29	55,8	23	44,2	5,16	2,92	9,92	11,04	8,18	15,74
	Female	93	64,1	45	48,4	48	51,6	6,37	4,01	9,56	15,74	10,15	21,39
Age	18-64	109	75,2	57	52,3	52	47,7	5,55	4,47	8,34	13,63	9,95	21,09
	65-74	29	20,0	14	48,3	15	51,7	5,19	2,79	10,15	15,47	7,66	30,75
	>=75	7	4,8	3	42,9	4	57,1	11,93	2,96	19,19	19,19	11,93	19,19
Race	White	60	41,4	35	58,3	25	41,7	4,60	2,92	8,41	11,99	8,41	21,09
	Other	85	58,6	39	45,9	46	54,1	6,41	4,47	9,92	15,47	10,38	30,75
Region	America (AM)	40	27,6	20	50,0	20	50,0	8,18	6,24	11,79	15,74	9,95	30,75

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_PFSRAD1_SG.xls
24JUN2020 13:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	17	50,0	17	50,0	4,47	1,87	11,99	15,70	10,15	21,39
	Asia (AS)	71	49,0	37	52,1	34	47,9	4,24	2,92	7,72	11,93	8,08	21,13
ECOG Performance Status	0	61	42,1	16	26,2	45	73,8	15,47	9,92	NE	NE	15,74	NE
	1	69	47,6	43	62,3	26	37,7	4,50	2,79	8,08	10,38	8,31	13,63
	2	15	10,3	15	100,0			1,41	0,10	3,78	3,78	2,79	7,66
Number of Prior Anticancer Therapies	None	62	42,8	31	50,0	31	50,0	7,66	4,63	9,99	14,82	9,95	NE
	1	4	2,8	3	75,0	1	25,0	3,66	0,95	30,75	18,56	0,95	30,75

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_PFSRAD1_SG.xls
24JUN2020 13:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	79	54,5	40	50,6	39	49,4	4,47	2,96	9,23	13,63	9,56	21,13
Prior Treatment	Naïve	62	42,8	31	50,0	31	50,0	7,66	4,63	9,99	14,82	9,95	NE
	Previously Treated	83	57,2	43	51,8	40	48,2	4,47	2,96	8,34	13,63	9,56	21,13
Molecular Testing Results	Local	75	51,7	36	48,0	39	52,0	7,66	5,16	9,99	15,47	9,99	21,13
	Central	70	48,3	38	54,3	32	45,7	4,24	2,79	8,18	12,22	8,41	21,39

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_PFSRAD1_SG.xls
24JUN2020 13:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	71	52,6	64	47,4	6,24	4,47	8,31	13,63	9,99	17,45
	No	10	6,9	3	30,0	7	70,0	15,43	0,07	30,75	30,75	0,10	30,75
Investigator Measurable CNS Disease	Yes	11	7,6	7	63,6	4	36,4	1,81	0,07	9,86	8,77	1,81	NE
	No	134	92,4	67	50,0	67	50,0	6,37	4,47	8,41	14,82	10,38	21,09

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_PFSRAD1_SG.xls
24JUN2020 13:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per RECIST v1.1

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_PFSRAD1_SG.xls
24JUN2020 13:03

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	32	29	25	24	21	19	8	6	1	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	2	2	3	3	3	4	13	14	19	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_PFSRAD1_SG1.pdf
10SEP2019 15:35

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	64	53	47	40	35	24	17	9	4	1	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	1	4	4	5	7	13	19	24	29	32	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_PFSRAD1_SG1.pdf
27NOV2019 9:53

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: Progression-free Survival by BICR per RECIST v1.1
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	118	100	75	51	38	24	17	9	4	1	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	5	11	23	34	43	52	58	63	68	71	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_PFSRAD1_SG1.pdf
24JUN2020 15:05

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=17)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	17	100,0	10	58,8	7	41,2	2,87	1,81	7,69	7,69	2,96	NE
Sex	Male	6	35,3	2	33,3	4	66,7	7,69	2,96	NE	NE	2,96	NE
	Female	11	64,7	8	72,7	3	27,3	2,63	0,43	6,67	6,67	2,63	NE
Age	18-64	12	70,6	7	58,3	5	41,7	2,79	1,81	8,31	8,31	2,79	NE
	65-74	5	29,4	3	60,0	2	40,0	2,96	0,43	NE	6,67	0,43	NE
Race	White	7	41,2	4	57,1	3	42,9	2,79	1,81	NE	8,31	2,79	NE
	Other	10	58,8	6	60,0	4	40,0	3,78	0,43	7,69	7,69	3,78	13,63
Region	America (AM)	4	23,5	2	50,0	2	50,0	7,49	6,67	NE	NE	6,67	NE
	Europe (EU)	3	17,6	2	66,7	1	33,3	1,81	1,81	NE	2,79	1,81	NE
	Asia (AS)	10	58,8	6	60,0	4	40,0	2,96	0,43	13,63	7,69	2,96	NE
ECOG Performance Status	0	4	23,5	1	25,0	3	75,0	NE	6,67	NE	NE	6,67	NE
	1	10	58,8	6	60,0	4	40,0	2,96	1,81	8,31	8,31	2,96	NE

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=17)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2	3	17,6	3	100,0			0,43	0,43	3,78	2,79	0,43	3,78
Number of Prior Anticancer Therapies	None	5	29,4	2	40,0	3	60,0	7,69	6,67	NE	NE	6,67	NE
	2 or More	12	70,6	8	66,7	4	33,3	2,63	0,43	3,78	3,78	2,63	13,63
Prior Treatment	Naïve	5	29,4	2	40,0	3	60,0	7,69	6,67	NE	NE	6,67	NE
	Previously Treated	12	70,6	8	66,7	4	33,3	2,63	0,43	3,78	3,78	2,63	13,63
Molecular Testing Results	Local	3	17,6	1	33,3	2	66,7	8,31	8,31	NE	NE	8,31	NE
	Central	14	82,4	9	64,3	5	35,7	2,79	1,81	6,67	6,67	2,79	NE

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=17)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	17	100,0	10	58,8	7	41,2	2,87	1,81	7,69	7,69	2,96	NE
Investigator Measurable CNS Disease	Yes	4	23,5	2	50,0	2	50,0	1,81	1,81	NE	7,69	1,81	NE
	No	13	76,5	8	61,5	5	38,5	2,96	2,63	8,31	8,31	2,96	NE

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=31)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	31	100,0	22	71,0	9	29,0	2,79	1,41	6,67	8,31	3,78	16,13
Sex	Male	12	38,7	7	58,3	5	41,7	2,69	0,89	7,69	7,69	2,69	NE
	Female	19	61,3	15	78,9	4	21,1	2,79	1,81	8,31	11,99	3,78	16,13
Age	18-64	25	80,6	18	72,0	7	28,0	2,74	1,41	8,31	11,99	3,78	16,13
	65-74	6	19,4	4	66,7	2	33,3	2,96	0,43	6,67	6,44	2,96	NE
Race	White	12	38,7	9	75,0	3	25,0	2,87	2,69	13,80	11,99	2,96	24,80
	Other	19	61,3	13	68,4	6	31,6	2,63	0,79	6,67	6,67	3,78	17,38
Region	America (AM)	10	32,3	8	80,0	2	20,0	6,21	2,69	16,13	12,22	6,21	24,80
	Europe (EU)	4	12,9	3	75,0	1	25,0	2,30	1,81	11,99	7,39	1,81	11,99

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_CNS_PFSCNS_SG.xls
25NOV2019 14:16

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=31)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	17	54,8	11	64,7	6	35,3	2,02	0,79	7,69	7,69	2,63	15,74
ECOG Performance Status	0	8	25,8	5	62,5	3	37,5	6,44	0,79	16,13	15,74	6,21	NE
	1	18	58,1	13	72,2	5	27,8	2,96	1,81	8,31	8,31	2,96	17,38
	2	5	16,1	4	80,0	1	20,0	1,41	0,43	3,78	2,79	0,43	NE
Number of Prior Anticancer Therapies	None	15	48,4	10	66,7	5	33,3	6,21	2,69	16,13	16,13	6,21	24,80
	2 or More	16	51,6	12	75,0	4	25,0	1,81	0,79	3,78	3,78	2,63	13,63

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_CNS_PFSCNS_SG.xls
25NOV2019 14:16

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=31)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	15	48,4	10	66,7	5	33,3	6,21	2,69	16,13	16,13	6,21	24,80
	Previously Treated	16	51,6	12	75,0	4	25,0	1,81	0,79	3,78	3,78	2,63	13,63
Molecular Testing Results	Local	12	38,7	8	66,7	4	33,3	4,45	1,41	15,74	13,80	6,21	NE
	Central	19	61,3	14	73,7	5	26,3	2,79	0,89	6,67	6,67	2,96	16,13

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_CNS_PFSCNS_SG.xls
25NOV2019 14:16

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=31)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	31	100,0	22	71,0	9	29,0	2,79	1,41	6,67	8,31	3,78	16,13
Investigator Measurable CNS Disease	Yes	8	25,8	6	75,0	2	25,0	1,81	1,41	13,80	7,69	1,81	17,38

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_CNS_PFSCNS_SG.xls
25NOV2019 14:16

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per CNS RECIST
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=31)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	23	74,2	16	69,6	7	30,4	2,96	0,89	8,31	8,31	4,63	16,13

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_CNS_PFSCNS_SG.xls
25NOV2019 14:16

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per CNS RECIST

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=43)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	43	100,0	28	65,1	15	34,9	3,78	2,63	7,92	8,80	6,67	15,74
Sex	Male	15	34,9	9	60,0	6	40,0	2,96	1,41	7,69	7,69	2,96	NE
	Female	28	65,1	19	67,9	9	32,1	3,78	2,63	8,80	11,99	6,67	16,13
Age	18-64	33	76,7	23	69,7	10	30,3	3,29	2,63	8,31	11,99	6,37	15,74
	65-74	8	18,6	5	62,5	3	37,5	4,58	0,43	7,92	6,67	2,96	NE
	>=75	2	4,7			2	100,0	NE	NE	NE	NE	NE	NE
Race	White	18	41,9	12	66,7	6	33,3	8,02	2,69	13,63	13,63	8,31	24,80
	Other	25	58,1	16	64,0	9	36,0	3,20	0,89	6,67	7,69	4,63	15,74
Region	America (AM)	18	41,9	11	61,1	7	38,9	6,67	4,63	13,63	13,63	6,67	24,80

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_CNS_PFSCNS_SG.xls
24JUN2020 12:54

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per CNS RECIST

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=43)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	6	14,0	4	66,7	2	33,3	2,79	1,81	11,99	8,02	2,79	NE
	Asia (AS)	19	44,2	13	68,4	6	31,6	2,63	0,79	7,69	7,69	2,63	15,74
ECOG Performance Status	0	12	27,9	6	50,0	6	50,0	6,37	6,21	16,13	15,74	6,37	NE
	1	25	58,1	17	68,0	8	32,0	3,79	2,63	8,80	10,40	7,69	13,80
	2	6	14,0	5	83,3	1	16,7	1,41	0,43	3,78	3,29	1,41	8,02
Number of Prior Anticancer Therapies	None	19	44,2	12	63,2	7	36,8	6,21	2,69	13,80	13,80	6,67	24,80
	2 or More	24	55,8	16	66,7	8	33,3	2,79	0,89	8,02	8,02	3,78	13,63

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_CNS_PFSCNS_SG.xls
24JUN2020 12:54

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per CNS RECIST

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=43)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	19	44,2	12	63,2	7	36,8	6,21	2,69	13,80	13,80	6,67	24,80
	Previously Treated	24	55,8	16	66,7	8	33,3	2,79	0,89	8,02	8,02	3,78	13,63
Molecular Testing Results	Local	21	48,8	12	57,1	9	42,9	6,37	2,69	13,63	13,63	8,02	17,38
	Central	22	51,2	16	72,7	6	27,3	2,79	1,81	6,67	7,69	2,96	16,13

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_CNS_PFSCNS_SG.xls
24JUN2020 12:54

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per CNS RECIST

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=43)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	42	97,7	27	64,3	15	35,7	3,78	2,63	7,92	8,80	6,67	15,74
	No	1	2,3	1	100,0			6,37	NE	NE	6,37	NE	NE
Investigator Measurable CNS Disease	Yes	10	23,3	7	70,0	3	30,0	2,69	1,41	13,80	8,02	2,69	17,38

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_CNS_PFSCNS_SG.xls
24JUN2020 12:54

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population

ENDPOINT: Progression-free Survival by BICR per CNS RECIST

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=43)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	76,7	21	63,6	12	36,4	4,63	2,63	8,31	8,80	6,37	16,13

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_CNS_PFSCNS_SG.xls
24JUN2020 12:54

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population
ENDPOINT: Progression-free Survival by BICR per CNS RECIST
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	17	14	10	9	7	6	5	NE	NE	NE	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	1	1	2	2	2	3	NE	NE	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_CNS_PFSCNS_SG1.pdf
10SEP2019 14:35

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population
ENDPOINT: Progression-free Survival by BICR per CNS RECIST
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	31	21	17	13	12	9	6	4	2	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	1	3	3	3	4	4	6	8	NE	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_CNS_PFSCNS_SG1.pdf
26NOV2019 8:30

POPULATION: CNS at Baseline, Efficacy-Evaluable ROS1 Population
ENDPOINT: Progression-free Survival by BICR per CNS RECIST
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	43	32	26	17	14	9	6	4	2	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	1	5	6	8	10	10	12	14	NE	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_CNS_PFSCNS_SG1.pdf
24JUN2020 14:32

Patientenberichtete Endpunkte

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	68,94	21,79
Cycle 2 Day 1	All	33	89,2	29	87,9	71,14	23,11
Cycle 3 Day 1	All	32	86,5	28	87,5	76,75	15,33
Cycle 4 Day 1	All	32	86,5	26	81,3	77,19	17,88
Cycle 5 Day 1	All	31	83,8	29	93,5	77,55	15,06
Cycle 6 Day 1	All	31	83,8	26	83,9	79,00	14,13
Cycle 7 Day 1	All	30	81,1	26	86,7	76,65	16,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	76,96	17,05
Cycle 9 Day 1	All	25	67,6	25	100,0	79,88	14,40
Cycle 10 Day 1	All	25	67,6	24	96,0	78,21	13,05
Cycle 11 Day 1	All	24	64,9	24	100,0	80,75	11,78
Cycle 12 Day 1	All	24	64,9	21	87,5	78,29	14,53
Cycle 13 Day 1	All	22	59,5	21	95,5	79,48	14,63
Cycle 14 Day 1	All	22	59,5	22	100,0	78,45	17,73
Cycle 15 Day 1	All	22	59,5	21	95,5	79,10	17,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	75,53	17,79
Cycle 17 Day 1	All	18	48,6	14	77,8	77,29	19,02
Cycle 18 Day 1	All	15	40,5	8	53,3	75,13	19,29
Cycle 19 Day 1	All	13	35,1	8	61,5	72,50	17,22
Cycle 20 Day 1	All	9	24,3	9	100,0	71,67	18,79
Cycle 21 Day 1	All	7	18,9	4	57,1	63,50	26,06
Cycle 22 Day 1	All	7	18,9	2	28,6	62,00	46,67
Cycle 23 Day 1	All	4	10,8	1	25,0	90,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	91,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	62,20	18,97
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	70,00	25,28
	Female	23	100,0	21	91,3	68,29	19,96
Cycle 2 Day 1	Male	13	92,9	13	100,0	77,23	17,53
	Female	20	87,0	16	80,0	66,19	26,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	81,42	13,55
	Female	20	87,0	16	80,0	73,25	16,05
Cycle 4 Day 1	Male	12	85,7	10	83,3	83,80	15,32
	Female	20	87,0	16	80,0	73,06	18,56
Cycle 5 Day 1	Male	12	85,7	11	91,7	79,45	17,24
	Female	19	82,6	18	94,7	76,39	13,96
Cycle 6 Day 1	Male	12	85,7	11	91,7	81,64	16,03
	Female	19	82,6	15	78,9	77,07	12,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	77,73	21,13
	Female	19	82,6	15	78,9	75,87	13,48
Cycle 8 Day 1	Male	10	71,4	9	90,0	77,67	22,34
	Female	18	78,3	16	88,9	76,56	14,08
Cycle 9 Day 1	Male	8	57,1	8	100,0	85,00	11,92
	Female	17	73,9	17	100,0	77,47	15,15
Cycle 10 Day 1	Male	8	57,1	8	100,0	85,13	12,61
	Female	17	73,9	16	94,1	74,75	12,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	85,25	11,96
	Female	16	69,6	16	100,0	78,50	11,40
Cycle 12 Day 1	Male	8	57,1	8	100,0	84,13	13,64
	Female	16	69,6	13	81,3	74,69	14,37
Cycle 13 Day 1	Male	8	57,1	8	100,0	86,88	11,19
	Female	14	60,9	13	92,9	74,92	14,99
Cycle 14 Day 1	Male	8	57,1	8	100,0	82,00	18,62
	Female	14	60,9	14	100,0	76,43	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	84,13	15,51
	Female	14	60,9	13	92,9	76,00	18,00
Cycle 16 Day 1	Male	8	57,1	5	62,5	81,60	12,93
	Female	13	56,5	10	76,9	72,50	19,68
Cycle 17 Day 1	Male	6	42,9	2	33,3	81,50	12,02
	Female	12	52,2	12	100,0	76,58	20,26
Cycle 18 Day 1	Male	3	21,4	2	66,7	82,50	13,44
	Female	12	52,2	6	50,0	72,67	21,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	82,00	11,31
	Female	11	47,8	6	54,5	69,33	18,48
Cycle 20 Day 1	Male	2	14,3	2	100,0	75,00	7,07
	Female	7	30,4	7	100,0	70,71	21,40
Cycle 21 Day 1	Male	1	7,1	1	100,0	75,00	-
	Female	6	26,1	3	50,0	59,67	30,50
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	62,00	46,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	90,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	91,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	49,50	28,99
	Female	7	30,4	3	42,9	70,67	5,51
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	68,59	21,77
	65-74	8	100,0	7	87,5	70,29	23,54
Cycle 2 Day 1	18-64	27	93,1	24	88,9	69,17	24,24
	65-74	6	75,0	5	83,3	80,60	14,99
Cycle 3 Day 1	18-64	26	89,7	24	92,3	74,79	15,38
	65-74	6	75,0	4	66,7	88,50	9,26
Cycle 4 Day 1	18-64	26	89,7	22	84,6	75,50	18,64
	65-74	6	75,0	4	66,7	86,50	9,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	77,39	14,14
	65-74	6	75,0	6	100,0	78,17	19,75
Cycle 6 Day 1	18-64	25	86,2	21	84,0	77,57	14,64
	65-74	6	75,0	5	83,3	85,00	11,00
Cycle 7 Day 1	18-64	25	86,2	22	88,0	74,64	17,27
	65-74	5	62,5	4	80,0	87,75	7,85
Cycle 8 Day 1	18-64	23	79,3	20	87,0	75,25	18,39
	65-74	5	62,5	5	100,0	83,80	8,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	80,75	12,43
	65-74	5	62,5	5	100,0	76,40	22,14
Cycle 10 Day 1	18-64	20	69,0	19	95,0	78,79	10,43
	65-74	5	62,5	5	100,0	76,00	21,94
Cycle 11 Day 1	18-64	19	65,5	19	100,0	80,74	10,97
	65-74	5	62,5	5	100,0	80,80	16,02
Cycle 12 Day 1	18-64	19	65,5	17	89,5	77,53	14,97
	65-74	5	62,5	4	80,0	81,50	13,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	80,38	12,23
	65-74	5	62,5	5	100,0	76,60	22,27
Cycle 14 Day 1	18-64	17	58,6	17	100,0	77,29	18,87
	65-74	5	62,5	5	100,0	82,40	14,15
Cycle 15 Day 1	18-64	17	58,6	16	94,1	77,19	18,82
	65-74	5	62,5	5	100,0	85,20	9,20
Cycle 16 Day 1	18-64	17	58,6	13	76,5	74,23	18,84
	65-74	4	50,0	2	50,0	84,00	2,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	75,08	19,73
	65-74	3	37,5	2	66,7	90,50	3,54
Cycle 18 Day 1	18-64	13	44,8	8	61,5	75,13	19,29
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	71,57	18,38
	65-74	2	25,0	1	50,0	79,00	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	71,38	20,07
	65-74	1	12,5	1	100,0	74,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	63,50	26,06
Cycle 22 Day 1	18-64	7	24,1	2	28,6	62,00	46,67
Cycle 23 Day 1	18-64	4	13,8	1	25,0	90,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	91,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	58,67	25,93
	65-74	6	75,0	2	33,3	67,50	0,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	67,29	23,42
	Other	17	100,0	17	100,0	70,59	20,61
Cycle 2 Day 1	White	19	95,0	16	84,2	70,31	25,83
	Other	14	82,4	13	92,9	72,15	20,25
Cycle 3 Day 1	White	18	90,0	15	83,3	75,40	13,34
	Other	14	82,4	13	92,9	78,31	17,77
Cycle 4 Day 1	White	18	90,0	14	77,8	80,36	13,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	12	85,7	73,50	22,26
Cycle 5 Day 1	White	18	90,0	17	94,4	79,00	14,42
	Other	13	76,5	12	92,3	75,50	16,34
Cycle 6 Day 1	White	18	90,0	13	72,2	81,15	13,28
	Other	13	76,5	13	100,0	76,85	15,15
Cycle 7 Day 1	White	17	85,0	14	82,4	81,64	13,47
	Other	13	76,5	12	92,3	70,83	18,87
Cycle 8 Day 1	White	17	85,0	14	82,4	80,21	13,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	72,82	20,71
Cycle 9 Day 1	White	16	80,0	16	100,0	81,38	15,22
	Other	9	52,9	9	100,0	77,22	13,24
Cycle 10 Day 1	White	16	80,0	15	93,8	78,00	14,45
	Other	9	52,9	9	100,0	78,56	11,13
Cycle 11 Day 1	White	16	80,0	16	100,0	82,63	10,31
	Other	8	47,1	8	100,0	77,00	14,28
Cycle 12 Day 1	White	16	80,0	13	81,3	78,15	15,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	78,50	13,40
Cycle 13 Day 1	White	14	70,0	13	92,9	78,31	16,57
	Other	8	47,1	8	100,0	81,38	11,59
Cycle 14 Day 1	White	14	70,0	14	100,0	78,00	18,17
	Other	8	47,1	8	100,0	79,25	18,12
Cycle 15 Day 1	White	14	70,0	13	92,9	81,46	15,99
	Other	8	47,1	8	100,0	75,25	19,41
Cycle 16 Day 1	White	14	70,0	9	64,3	77,22	20,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	73,00	13,91
Cycle 17 Day 1	White	13	65,0	10	76,9	78,90	20,84
	Other	5	29,4	4	80,0	73,25	15,31
Cycle 18 Day 1	White	11	55,0	4	36,4	74,75	25,02
	Other	4	23,5	4	100,0	75,50	15,55
Cycle 19 Day 1	White	9	45,0	5	55,6	75,60	21,59
	Other	4	23,5	3	75,0	67,33	6,43
Cycle 20 Day 1	White	5	25,0	5	100,0	68,60	22,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	75,50	14,75
Cycle 21 Day 1	White	3	15,0	2	66,7	52,00	32,53
	Other	4	23,5	2	50,0	75,00	21,21
Cycle 22 Day 1	White	3	15,0	1	33,3	29,00	-
	Other	4	23,5	1	25,0	95,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	90,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	91,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	71,67	4,73
	Other	9	52,9	2	22,2	48,00	26,87
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	76,42	23,33
	Europe (EU)	10	100,0	8	80,0	58,13	25,07
	Asia (AS)	15	100,0	14	93,3	68,71	16,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	80,56	19,29
	Europe (EU)	9	90,0	8	88,9	63,63	30,06
	Asia (AS)	13	86,7	12	92,3	69,08	19,89
Cycle 3 Day 1	America (AM)	11	91,7	10	90,9	81,10	16,00
	Europe (EU)	8	80,0	5	62,5	70,40	11,87
	Asia (AS)	13	86,7	13	100,0	75,85	16,00
Cycle 4 Day 1	America (AM)	11	91,7	9	81,8	84,89	13,04
	Europe (EU)	8	80,0	4	50,0	77,00	13,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	71,92	20,81
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	84,91	11,79
	Europe (EU)	8	80,0	7	87,5	75,86	16,29
	Asia (AS)	12	80,0	11	91,7	71,27	15,23
Cycle 6 Day 1	America (AM)	11	91,7	9	81,8	89,56	7,67
	Europe (EU)	8	80,0	6	75,0	74,00	11,68
	Asia (AS)	12	80,0	11	91,7	73,09	15,18
Cycle 7 Day 1	America (AM)	11	91,7	9	81,8	87,78	11,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	75,14	13,20
	Asia (AS)	11	73,3	10	90,9	67,70	17,99
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	86,30	11,85
	Europe (EU)	8	80,0	6	75,0	71,33	11,31
	Asia (AS)	9	60,0	9	100,0	70,33	21,25
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	84,09	12,28
	Europe (EU)	7	70,0	7	100,0	75,86	17,51
	Asia (AS)	7	46,7	7	100,0	77,29	14,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	82,30	12,28
	Europe (EU)	7	70,0	7	100,0	70,00	13,98
	Asia (AS)	7	46,7	7	100,0	80,57	10,86
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	84,64	12,72
	Europe (EU)	7	70,0	7	100,0	77,14	10,32
	Asia (AS)	6	40,0	6	100,0	77,83	11,20
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	82,40	18,06
	Europe (EU)	7	70,0	5	71,4	69,40	6,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	78,83	10,70
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	87,50	11,68
	Europe (EU)	6	60,0	5	83,3	66,20	15,24
	Asia (AS)	6	40,0	6	100,0	77,17	10,65
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	83,60	20,92
	Europe (EU)	6	60,0	6	100,0	68,83	14,44
	Asia (AS)	6	40,0	6	100,0	79,50	12,58
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	85,60	17,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	74,40	14,57
	Asia (AS)	6	40,0	6	100,0	72,17	17,42
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	82,86	17,58
	Europe (EU)	6	60,0	2	33,3	73,00	18,38
	Asia (AS)	6	40,0	6	100,0	67,83	17,29
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	73,33	25,69
	Europe (EU)	4	40,0	3	75,0	89,33	3,21
	Asia (AS)	5	33,3	5	100,0	74,80	14,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	78,20	23,00
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	70,00	13,45
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	74,75	24,84
	Europe (EU)	3	30,0	1	33,3	79,00	-
	Asia (AS)	4	26,7	3	75,0	67,33	6,43
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	71,80	24,72
	Europe (EU)	1	10,0	1	100,0	74,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	70,67	13,65
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	64,67	31,79
	Asia (AS)	3	20,0	1	33,3	60,00	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	62,00	46,67
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	90,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	91,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	71,33	5,13
	Europe (EU)	2	20,0	1	50,0	68,00	-
	Asia (AS)	7	46,7	1	14,3	29,00	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	83,08	12,82
	1	17	100,0	17	100,0	65,18	22,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	47,80	17,58
Cycle 2 Day 1	0	15	100,0	12	80,0	83,42	12,58
	1	15	88,2	14	93,3	67,07	18,20
	2	3	60,0	3	100,0	41,00	45,51
Cycle 3 Day 1	0	15	100,0	12	80,0	81,42	14,78
	1	14	82,4	13	92,9	77,08	12,91
	2	3	60,0	3	100,0	56,67	15,28
Cycle 4 Day 1	0	15	100,0	12	80,0	81,25	15,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	77,58	16,26
	2	3	60,0	2	66,7	50,50	28,99
Cycle 5 Day 1	0	15	100,0	15	100,0	80,87	14,96
	1	14	82,4	12	85,7	74,67	13,61
	2	2	40,0	2	100,0	70,00	28,28
Cycle 6 Day 1	0	15	100,0	14	93,3	83,93	12,80
	1	14	82,4	11	78,6	73,55	14,54
	2	2	40,0	1	50,0	70,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	81,36	16,18
	1	13	76,5	10	76,9	69,40	16,89
	2	2	40,0	2	100,0	80,00	14,14
Cycle 8 Day 1	0	15	100,0	13	86,7	79,54	18,64
	1	11	64,7	10	90,9	75,70	15,34
	2	2	40,0	2	100,0	66,50	19,09
Cycle 9 Day 1	0	14	93,3	14	100,0	79,36	15,80
	1	10	58,8	10	100,0	80,10	13,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	85,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	79,71	15,11
	1	10	58,8	9	90,0	76,22	10,41
	2	1	20,0	1	100,0	75,00	-
Cycle 11 Day 1	0	14	93,3	14	100,0	82,07	12,49
	1	9	52,9	9	100,0	77,67	11,00
	2	1	20,0	1	100,0	90,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	79,75	17,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	77,13	10,70
	2	1	20,0	1	100,0	70,00	-
Cycle 13 Day 1	0	14	93,3	13	92,9	79,77	17,25
	1	8	47,1	8	100,0	79,00	10,06
Cycle 14 Day 1	0	14	93,3	14	100,0	79,29	19,05
	1	8	47,1	8	100,0	77,00	16,27
Cycle 15 Day 1	0	14	93,3	14	100,0	82,64	16,26
	1	8	47,1	7	87,5	72,00	17,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	76,25	21,88
	1	8	47,1	7	87,5	74,71	13,36
Cycle 17 Day 1	0	12	80,0	8	66,7	77,38	22,19
	1	6	35,3	6	100,0	77,17	15,85
Cycle 18 Day 1	0	9	60,0	4	44,4	74,25	24,53
	1	6	35,3	4	66,7	76,00	16,27
Cycle 19 Day 1	0	8	53,3	4	50,0	70,75	21,56
	1	5	29,4	4	80,0	74,25	14,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	68,80	22,96
	1	4	23,5	4	100,0	75,25	14,43
Cycle 21 Day 1	0	3	20,0	3	100,0	64,67	31,79
	1	4	23,5	1	25,0	60,00	-
Cycle 22 Day 1	0	3	20,0	2	66,7	62,00	46,67
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	90,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	91,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	68,33	1,53
	1	7	41,2	2	28,6	53,00	33,94
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	77,38	19,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	60,00	42,43
	2 or More	21	100,0	19	90,5	64,11	20,79
Cycle 2 Day 1	None	14	100,0	12	85,7	80,58	17,69
	1	1	50,0	1	100,0	90,00	-
	2 or More	18	85,7	16	88,9	62,88	24,49
Cycle 3 Day 1	None	14	100,0	12	85,7	82,08	12,02
	1	1	50,0	1	100,0	90,00	-
	2 or More	17	81,0	15	88,2	71,60	16,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	10	71,4	82,10	18,05
	1	1	50,0	1	100,0	90,00	-
	2 or More	17	81,0	15	88,2	73,07	17,72
Cycle 5 Day 1	None	14	100,0	14	100,0	83,64	11,81
	1	1	50,0	1	100,0	90,00	-
	2 or More	16	76,2	14	87,5	70,57	15,64
Cycle 6 Day 1	None	14	100,0	12	85,7	87,33	8,28
	1	1	50,0	1	100,0	91,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	13	81,3	70,38	13,84
Cycle 7 Day 1	None	14	100,0	12	85,7	84,83	10,51
	1	1	50,0	1	100,0	90,00	-
	2 or More	15	71,4	13	86,7	68,08	17,97
Cycle 8 Day 1	None	14	100,0	13	92,9	81,46	15,34
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	72,08	18,09
Cycle 9 Day 1	None	13	92,9	13	100,0	83,00	10,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	90,00	-
	2 or More	11	52,4	11	100,0	75,27	17,65
Cycle 10 Day 1	None	13	92,9	12	92,3	80,42	10,71
	1	1	50,0	1	100,0	93,00	-
	2 or More	11	52,4	11	100,0	74,45	14,90
Cycle 11 Day 1	None	13	92,9	13	100,0	84,15	11,56
	1	1	50,0	1	100,0	90,00	-
	2 or More	10	47,6	10	100,0	75,40	10,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	83,08	11,41
	1	1	50,0	1	100,0	87,00	-
	2 or More	10	47,6	8	80,0	70,00	16,43
Cycle 13 Day 1	None	12	85,7	11	91,7	83,91	11,93
	1	1	50,0	1	100,0	96,00	-
	2 or More	9	42,9	9	100,0	72,22	15,39
Cycle 14 Day 1	None	12	85,7	12	100,0	83,33	14,30
	1	1	50,0	1	100,0	91,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	70,56	20,45
Cycle 15 Day 1	None	12	85,7	12	100,0	84,00	15,05
	1	1	50,0	1	100,0	89,00	-
	2 or More	9	42,9	8	88,9	70,50	18,62
Cycle 16 Day 1	None	11	78,6	8	72,7	75,63	20,16
	1	1	50,0	1	100,0	90,00	-
	2 or More	9	42,9	6	66,7	73,00	16,37
Cycle 17 Day 1	None	10	71,4	7	70,0	78,43	12,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	90,00	-
	2 or More	7	33,3	6	85,7	73,83	26,75
Cycle 18 Day 1	None	8	57,1	4	50,0	86,00	9,49
	1	1	50,0	1	100,0	92,00	-
	2 or More	6	28,6	3	50,0	55,00	13,45
Cycle 19 Day 1	None	7	50,0	3	42,9	79,67	13,43
	1	1	50,0	1	100,0	90,00	-
	2 or More	5	23,8	4	80,0	62,75	17,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	82,25	9,32
	1	1	50,0	1	100,0	80,00	-
	2 or More	4	19,0	4	100,0	59,00	21,65
Cycle 21 Day 1	None	4	28,6	2	50,0	82,50	10,61
	2 or More	3	14,3	2	66,7	44,50	21,92
Cycle 22 Day 1	None	4	28,6	1	25,0	95,00	-
	2 or More	3	14,3	1	33,3	29,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	90,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	91,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	67,00	-
	1	2	100,0	1	50,0	70,00	-
	2 or More	9	42,9	3	33,3	58,00	25,51
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	77,38	19,47
	Previously Treated	23	100,0	21	91,3	63,71	21,92
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	80,58	17,69
	Previously Treated	19	82,6	17	89,5	64,47	24,60
Cycle 3 Day 1	Naïve	14	100,0	12	85,7	82,08	12,02
	Previously Treated	18	78,3	16	88,9	72,75	16,64
Cycle 4 Day 1	Naïve	14	100,0	10	71,4	82,10	18,05
	Previously Treated	18	78,3	16	88,9	74,13	17,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	83,64	11,81
	Previously Treated	17	73,9	15	88,2	71,87	15,89
Cycle 6 Day 1	Naïve	14	100,0	12	85,7	87,33	8,28
	Previously Treated	17	73,9	14	82,4	71,86	14,39
Cycle 7 Day 1	Naïve	14	100,0	12	85,7	84,83	10,51
	Previously Treated	16	69,6	14	87,5	69,64	18,24
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	81,46	15,34
	Previously Treated	14	60,9	12	85,7	72,08	18,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	83,00	10,79
	Previously Treated	12	52,2	12	100,0	76,50	17,35
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	80,42	10,71
	Previously Treated	12	52,2	12	100,0	76,00	15,18
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	84,15	11,56
	Previously Treated	11	47,8	11	100,0	76,73	11,23
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	83,08	11,41
	Previously Treated	11	47,8	9	81,8	71,89	16,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	83,91	11,93
	Previously Treated	10	43,5	10	100,0	74,60	16,34
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	83,33	14,30
	Previously Treated	10	43,5	10	100,0	72,60	20,33
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	84,00	15,05
	Previously Treated	10	43,5	9	90,0	72,56	18,48
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	75,63	20,16
	Previously Treated	10	43,5	7	70,0	75,43	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	78,43	12,12
	Previously Treated	8	34,8	7	87,5	76,14	25,18
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	86,00	9,49
	Previously Treated	7	30,4	4	57,1	64,25	21,52
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	79,67	13,43
	Previously Treated	6	26,1	5	83,3	68,20	19,16
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	82,25	9,32
	Previously Treated	5	21,7	5	100,0	63,20	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	82,50	10,61
	Previously Treated	3	13,0	2	66,7	44,50	21,92
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	95,00	-
	Previously Treated	3	13,0	1	33,3	29,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	90,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	91,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	67,00	-
	Previously Treated	11	47,8	4	36,4	61,00	21,68
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	76,83	23,44
	Central	25	100,0	22	88,0	64,64	20,08
Cycle 2 Day 1	Local	11	91,7	11	100,0	77,73	19,91
	Central	22	88,0	18	81,8	67,11	24,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	10	90,9	86,70	11,19
	Central	21	84,0	18	85,7	71,22	14,70
Cycle 4 Day 1	Local	11	91,7	9	81,8	85,11	17,84
	Central	21	84,0	17	81,0	73,00	16,92
Cycle 5 Day 1	Local	11	91,7	10	90,9	86,20	10,39
	Central	20	80,0	19	95,0	73,00	15,34
Cycle 6 Day 1	Local	11	91,7	11	100,0	84,91	12,36
	Central	20	80,0	15	75,0	74,67	14,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	82,73	16,62
	Central	19	76,0	15	78,9	72,20	15,96
Cycle 8 Day 1	Local	10	83,3	10	100,0	86,10	15,75
	Central	18	72,0	15	83,3	70,87	15,46
Cycle 9 Day 1	Local	10	83,3	10	100,0	81,30	17,81
	Central	15	60,0	15	100,0	78,93	12,21
Cycle 10 Day 1	Local	10	83,3	9	90,0	80,44	17,47
	Central	15	60,0	15	100,0	76,87	10,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	86,44	10,37
	Central	15	60,0	15	100,0	77,33	11,54
Cycle 12 Day 1	Local	9	75,0	8	88,9	88,75	8,58
	Central	15	60,0	13	86,7	71,85	13,82
Cycle 13 Day 1	Local	8	66,7	8	100,0	82,88	19,47
	Central	14	56,0	13	92,9	77,38	11,10
Cycle 14 Day 1	Local	8	66,7	8	100,0	87,13	11,93
	Central	14	56,0	14	100,0	73,50	18,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	85,50	16,36
	Central	14	56,0	13	92,9	75,15	17,06
Cycle 16 Day 1	Local	8	66,7	6	75,0	84,50	12,69
	Central	13	52,0	9	69,2	69,56	18,78
Cycle 17 Day 1	Local	8	66,7	5	62,5	80,60	14,17
	Central	10	40,0	9	90,0	75,44	21,84
Cycle 18 Day 1	Local	6	50,0	4	66,7	86,00	9,49
	Central	9	36,0	4	44,4	64,25	21,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	79,50	10,97
	Central	8	32,0	4	50,0	65,50	21,00
Cycle 20 Day 1	Local	5	41,7	5	100,0	80,60	8,88
	Central	4	16,0	4	100,0	60,50	23,19
Cycle 21 Day 1	Local	4	33,3	2	50,0	82,50	10,61
	Central	3	12,0	2	66,7	44,50	21,92
Cycle 22 Day 1	Local	4	33,3	1	25,0	95,00	-
	Central	3	12,0	1	33,3	29,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	90,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	91,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	72,50	6,36
	Central	8	32,0	3	37,5	55,33	22,85
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	69,50	21,02
	No	2	100,0	2	100,0	60,00	42,43
Cycle 2 Day 1	Yes	32	91,4	28	87,5	72,25	22,73
	No	1	50,0	1	100,0	40,00	-
Cycle 3 Day 1	Yes	31	88,6	27	87,1	76,63	15,60
	No	1	50,0	1	100,0	80,00	-
Cycle 4 Day 1	Yes	31	88,6	25	80,6	78,68	16,52
	No	1	50,0	1	100,0	40,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	77,82	15,27
	No	1	50,0	1	100,0	70,00	-
Cycle 6 Day 1	Yes	30	85,7	25	83,3	78,96	14,42
	No	1	50,0	1	100,0	80,00	-
Cycle 7 Day 1	Yes	29	82,9	25	86,2	76,92	17,06
	No	1	50,0	1	100,0	70,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	78,29	16,03
	No	1	50,0	1	100,0	45,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	80,29	14,56
	No	1	50,0	1	100,0	70,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	78,13	13,33
	No	1	50,0	1	100,0	80,00	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	81,00	11,98
	No	1	50,0	1	100,0	75,00	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	78,20	14,90
	No	1	50,0	1	100,0	80,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	79,95	14,84
	No	1	50,0	1	100,0	70,00	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	78,38	18,16
	No	1	50,0	1	100,0	80,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	80,55	16,24
	No	1	50,0	1	100,0	50,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	76,64	17,92
	No	1	50,0	1	100,0	60,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	78,62	19,11
	No	1	50,0	1	100,0	60,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	73,71	20,39
	No	1	50,0	1	100,0	85,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	72,86	18,57
	No	1	50,0	1	100,0	70,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	70,63	19,81
	No	1	50,0	1	100,0	80,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	63,50	26,06
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	62,00	46,67
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	90,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	91,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	62,20	18,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	56,33	10,97
	No	33	100,0	31	93,9	70,16	22,29
Cycle 2 Day 1	Yes	2	50,0	1	50,0	90,00	-
	No	31	93,9	28	90,3	70,46	23,24
Cycle 3 Day 1	Yes	2	50,0	2	100,0	82,00	4,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	26	86,7	76,35	15,83
Cycle 4 Day 1	Yes	2	50,0	2	100,0	79,50	14,85
	No	30	90,9	24	80,0	77,00	18,37
Cycle 5 Day 1	Yes	2	50,0	2	100,0	77,50	10,61
	No	29	87,9	27	93,1	77,56	15,49
Cycle 6 Day 1	Yes	2	50,0	2	100,0	86,50	4,95
	No	29	87,9	24	82,8	78,38	14,52
Cycle 7 Day 1	Yes	2	50,0	2	100,0	85,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	24	85,7	75,96	17,29
Cycle 8 Day 1	Yes	2	50,0	2	100,0	74,50	6,36
	No	26	78,8	23	88,5	77,17	17,73
Cycle 9 Day 1	Yes	1	25,0	1	100,0	73,00	-
	No	24	72,7	24	100,0	80,17	14,63
Cycle 10 Day 1	Yes	1	25,0	1	100,0	80,00	-
	No	24	72,7	23	95,8	78,13	13,33
Cycle 11 Day 1	Yes	1	25,0	1	100,0	77,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	80,91	12,02
Cycle 12 Day 1	Yes	1	25,0	1	100,0	80,00	-
	No	23	69,7	20	87,0	78,20	14,90
Cycle 13 Day 1	Yes	1	25,0	1	100,0	64,00	-
	No	21	63,6	20	95,2	80,25	14,56
Cycle 14 Day 1	Yes	1	25,0	1	100,0	74,00	-
	No	21	63,6	21	100,0	78,67	18,14
Cycle 15 Day 1	Yes	1	25,0	1	100,0	79,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	79,10	17,62
Cycle 16 Day 1	Yes	1	25,0	1	100,0	39,00	-
	No	20	60,6	14	70,0	78,14	15,20
Cycle 17 Day 1	Yes	1	25,0	1	100,0	77,00	-
	No	17	51,5	13	76,5	77,31	19,80
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	75,13	19,29
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	72,50	17,22
Cycle 20 Day 1	No	9	27,3	9	100,0	71,67	18,79
Cycle 21 Day 1	No	7	21,2	4	57,1	63,50	26,06
Cycle 22 Day 1	No	7	21,2	2	28,6	62,00	46,67
Cycle 23 Day 1	No	4	12,1	1	25,0	90,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	91,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	29,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	70,50	4,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_VAS_SG.xls
07SEP2019 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	65,69	19,29
Cycle 2 Day 1	All	72	92,3	65	90,3	69,94	20,24
Cycle 3 Day 1	All	68	87,2	61	89,7	74,56	17,44
Cycle 4 Day 1	All	67	85,9	59	88,1	75,47	15,41
Cycle 5 Day 1	All	65	83,3	63	96,9	77,79	14,42
Cycle 6 Day 1	All	63	80,8	57	90,5	77,44	15,09
Cycle 7 Day 1	All	60	76,9	56	93,3	76,36	16,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	56	71,8	52	92,9	77,81	16,27
Cycle 9 Day 1	All	51	65,4	51	100,0	79,82	13,60
Cycle 10 Day 1	All	51	65,4	49	96,1	77,71	13,31
Cycle 11 Day 1	All	50	64,1	49	98,0	78,55	14,58
Cycle 12 Day 1	All	49	62,8	45	91,8	78,02	15,35
Cycle 13 Day 1	All	46	59,0	45	97,8	79,44	14,26
Cycle 14 Day 1	All	45	57,7	44	97,8	78,61	16,36
Cycle 15 Day 1	All	44	56,4	44	100,0	78,05	16,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	41	52,6	39	95,1	78,51	15,84
Cycle 17 Day 1	All	39	50,0	39	100,0	78,79	16,05
Cycle 18 Day 1	All	38	48,7	35	92,1	77,69	15,69
Cycle 19 Day 1	All	36	46,2	33	91,7	77,85	16,22
Cycle 20 Day 1	All	36	46,2	32	88,9	78,13	15,80
Cycle 21 Day 1	All	29	37,2	26	89,7	76,81	15,18
Cycle 22 Day 1	All	29	37,2	25	86,2	75,52	20,19
Cycle 23 Day 1	All	21	26,9	18	85,7	78,44	17,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	25,6	18	90,0	78,94	14,57
Cycle 25 Day 1	All	15	19,2	13	86,7	78,23	13,50
Cycle 26 Day 1	All	14	17,9	12	85,7	77,67	14,49
Cycle 27 Day 1	All	11	14,1	8	72,7	71,00	22,87
Cycle 28 Day 1	All	10	12,8	9	90,0	65,11	28,30
Cycle 29 Day 1	All	9	11,5	7	77,8	70,00	17,79
Cycle 30 Day 1	All	7	9,0	5	71,4	69,60	16,98
Cycle 31 Day 1	All	7	9,0	5	71,4	70,60	14,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	7,7	5	83,3	67,00	24,45
Cycle 33 Day 1	All	2	2,6	2	100,0	81,50	12,02
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	27	69,2	63,52	18,59
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	64,59	19,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	49	100,0	49	100,0	66,35	19,50
Cycle 2 Day 1	Male	27	93,1	26	96,3	71,38	17,64
	Female	45	91,8	39	86,7	68,97	21,98
Cycle 3 Day 1	Male	25	86,2	23	92,0	76,17	14,21
	Female	43	87,8	38	88,4	73,58	19,25
Cycle 4 Day 1	Male	25	86,2	23	92,0	76,39	14,59
	Female	42	85,7	36	85,7	74,89	16,09
Cycle 5 Day 1	Male	25	86,2	24	96,0	76,92	16,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	40	81,6	39	97,5	78,33	13,36
Cycle 6 Day 1	Male	25	86,2	23	92,0	76,52	16,69
	Female	38	77,6	34	89,5	78,06	14,12
Cycle 7 Day 1	Male	23	79,3	23	100,0	74,52	20,37
	Female	37	75,5	33	89,2	77,64	14,39
Cycle 8 Day 1	Male	21	72,4	19	90,5	77,32	19,15
	Female	35	71,4	33	94,3	78,09	14,67
Cycle 9 Day 1	Male	18	62,1	18	100,0	82,94	12,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	78,12	14,28
Cycle 10 Day 1	Male	18	62,1	17	94,4	79,82	15,24
	Female	33	67,3	32	97,0	76,59	12,27
Cycle 11 Day 1	Male	18	62,1	17	94,4	81,00	15,78
	Female	32	65,3	32	100,0	77,25	13,98
Cycle 12 Day 1	Male	17	58,6	17	100,0	80,12	15,80
	Female	32	65,3	28	87,5	76,75	15,22
Cycle 13 Day 1	Male	17	58,6	17	100,0	83,76	11,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	29	59,2	28	96,6	76,82	15,51
Cycle 14 Day 1	Male	17	58,6	16	94,1	80,13	16,70
	Female	28	57,1	28	100,0	77,75	16,41
Cycle 15 Day 1	Male	16	55,2	16	100,0	79,31	16,95
	Female	28	57,1	28	100,0	77,32	17,01
Cycle 16 Day 1	Male	14	48,3	14	100,0	82,57	11,65
	Female	27	55,1	25	92,6	76,24	17,58
Cycle 17 Day 1	Male	12	41,4	12	100,0	82,33	12,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	27	100,0	77,22	17,41
Cycle 18 Day 1	Male	11	37,9	10	90,9	82,40	13,76
	Female	27	55,1	25	92,6	75,80	16,27
Cycle 19 Day 1	Male	10	34,5	10	100,0	82,30	14,48
	Female	26	53,1	23	88,5	75,91	16,85
Cycle 20 Day 1	Male	10	34,5	9	90,0	82,89	12,75
	Female	26	53,1	23	88,5	76,26	16,73
Cycle 21 Day 1	Male	8	27,6	8	100,0	82,38	12,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	42,9	18	85,7	74,33	16,00
Cycle 22 Day 1	Male	8	27,6	6	75,0	83,50	15,87
	Female	21	42,9	19	90,5	73,00	21,11
Cycle 23 Day 1	Male	5	17,2	4	80,0	87,25	9,74
	Female	16	32,7	14	87,5	75,93	19,05
Cycle 24 Day 1	Male	5	17,2	4	80,0	84,25	12,39
	Female	15	30,6	14	93,3	77,43	15,20
Cycle 25 Day 1	Male	3	10,3	2	66,7	81,00	18,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	24,5	11	91,7	77,73	13,53
Cycle 26 Day 1	Male	3	10,3	2	66,7	84,50	12,02
	Female	11	22,4	10	90,9	76,30	15,10
Cycle 27 Day 1	Male	3	10,3	2	66,7	83,50	17,68
	Female	8	16,3	6	75,0	66,83	24,21
Cycle 28 Day 1	Male	2	6,9	2	100,0	76,50	23,33
	Female	8	16,3	7	87,5	61,86	30,36
Cycle 29 Day 1	Male	1	3,4	1	100,0	74,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	16,3	6	75,0	69,33	19,39
Cycle 30 Day 1	Male	1	3,4	1	100,0	68,00	-
	Female	6	12,2	4	66,7	70,00	19,58
Cycle 31 Day 1	Male	1	3,4	1	100,0	67,00	-
	Female	6	12,2	4	66,7	71,50	17,14
Cycle 32 Day 1	Male	1	3,4	1	100,0	60,00	-
	Female	5	10,2	4	80,0	68,75	27,87
Cycle 33 Day 1	Male	1	3,4	1	100,0	73,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	2,0	1	100,0	90,00	-
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	14	77,8	62,00	21,16
	Female	21	42,9	13	61,9	65,15	16,07
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	65,71	19,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	64,43	21,85
	>=75	2	100,0	2	100,0	74,00	8,49
Cycle 2 Day 1	18-64	59	95,2	53	89,8	70,36	20,17
	65-74	11	78,6	10	90,9	66,80	23,39
	>=75	2	100,0	2	100,0	74,50	0,71
Cycle 3 Day 1	18-64	56	90,3	51	91,1	73,57	17,88
	65-74	10	71,4	8	80,0	78,50	14,11
	>=75	2	100,0	2	100,0	84,00	22,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	55	88,7	49	89,1	75,67	16,00
	65-74	10	71,4	8	80,0	76,25	13,84
	>=75	2	100,0	2	100,0	67,50	3,54
Cycle 5 Day 1	18-64	53	85,5	52	98,1	78,29	13,77
	65-74	10	71,4	10	100,0	73,00	16,62
	>=75	2	100,0	1	50,0	100,00	-
Cycle 6 Day 1	18-64	51	82,3	46	90,2	78,20	15,23
	65-74	10	71,4	9	90,0	78,11	11,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	57,00	16,97
Cycle 7 Day 1	18-64	49	79,0	46	93,9	76,72	17,32
	65-74	9	64,3	8	88,9	78,50	11,50
	>=75	2	100,0	2	100,0	59,50	28,99
Cycle 8 Day 1	18-64	45	72,6	41	91,1	78,98	16,58
	65-74	9	64,3	9	100,0	76,44	11,16
	>=75	2	100,0	2	100,0	60,00	28,28
Cycle 9 Day 1	18-64	40	64,5	40	100,0	81,68	12,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	73,89	16,65
	>=75	2	100,0	2	100,0	69,50	0,71
Cycle 10 Day 1	18-64	40	64,5	39	97,5	78,67	12,70
	65-74	9	64,3	9	100,0	73,33	16,42
	>=75	2	100,0	1	50,0	80,00	-
Cycle 11 Day 1	18-64	39	62,9	39	100,0	79,13	15,25
	65-74	9	64,3	9	100,0	77,00	12,50
	>=75	2	100,0	1	50,0	70,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	38	61,3	35	92,1	79,23	15,23
	65-74	9	64,3	8	88,9	78,00	11,36
	>=75	2	100,0	2	100,0	57,00	25,46
Cycle 13 Day 1	18-64	35	56,5	34	97,1	81,44	13,27
	65-74	9	64,3	9	100,0	75,00	17,28
	>=75	2	100,0	2	100,0	65,50	6,36
Cycle 14 Day 1	18-64	35	56,5	35	100,0	78,89	17,19
	65-74	9	64,3	8	88,9	79,38	13,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	63,00	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	77,97	17,92
	65-74	8	57,1	8	100,0	80,75	10,82
	>=75	1	50,0	1	100,0	59,00	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	78,78	16,30
	65-74	7	50,0	6	85,7	80,33	13,41
	>=75	1	50,0	1	100,0	59,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	77,94	16,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	6	42,9	6	100,0	84,83	13,67
	>=75	1	50,0	1	100,0	70,00	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	78,52	15,79
	65-74	6	42,9	5	83,3	76,20	16,41
	>=75	1	50,0	1	100,0	61,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	77,64	16,63
	65-74	5	35,7	4	80,0	81,50	16,50
	>=75	1	50,0	1	100,0	69,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	78,92	16,27
	65-74	5	35,7	5	100,0	77,20	14,46
	>=75	1	50,0	1	100,0	62,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	77,48	15,20
	65-74	4	28,6	4	100,0	74,00	19,10
	>=75	1	50,0	1	100,0	74,00	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	78,10	17,20
	65-74	4	28,6	4	100,0	65,50	34,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	64,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	76,44	17,88
	65-74	2	14,3	2	100,0	94,50	4,95
Cycle 24 Day 1	18-64	18	29,0	16	88,9	77,06	14,26
	65-74	2	14,3	2	100,0	94,00	7,07
Cycle 25 Day 1	18-64	14	22,6	12	85,7	77,42	13,76
	65-74	1	7,1	1	100,0	88,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	77,67	14,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	71,00	22,87
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	65,11	28,30
	65-74	1	7,1	0	0,0	-	-
Cycle 29 Day 1	18-64	8	12,9	7	87,5	70,00	17,79
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	69,60	16,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	70,60	14,98
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	61,50	24,41
	65-74	1	7,1	1	100,0	89,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	73,00	-
	65-74	1	7,1	1	100,0	90,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	19	70,4	60,37	19,83
	65-74	10	71,4	7	70,0	71,14	14,54
	>=75	2	100,0	1	50,0	70,00	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	64,06	21,21
	Other	43	100,0	43	100,0	67,02	17,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	33	94,3	29	87,9	70,72	22,55
	Other	39	90,7	36	92,3	69,31	18,48
Cycle 3 Day 1	White	31	88,6	26	83,9	76,54	13,28
	Other	37	86,0	35	94,6	73,09	20,05
Cycle 4 Day 1	White	31	88,6	25	80,6	78,92	13,37
	Other	36	83,7	34	94,4	72,94	16,49
Cycle 5 Day 1	White	31	88,6	29	93,5	79,14	14,69
	Other	34	79,1	34	100,0	76,65	14,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	30	85,7	25	83,3	79,48	15,43
	Other	33	76,7	32	97,0	75,84	14,86
Cycle 7 Day 1	White	29	82,9	26	89,7	78,85	17,13
	Other	31	72,1	30	96,8	74,20	16,87
Cycle 8 Day 1	White	28	80,0	24	85,7	79,46	15,42
	Other	28	65,1	28	100,0	76,39	17,11
Cycle 9 Day 1	White	26	74,3	26	100,0	81,08	14,76
	Other	25	58,1	25	100,0	78,52	12,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	24	92,3	77,21	15,89
	Other	25	58,1	25	100,0	78,20	10,56
Cycle 11 Day 1	White	26	74,3	25	96,2	80,32	14,42
	Other	24	55,8	24	100,0	76,71	14,82
Cycle 12 Day 1	White	26	74,3	22	84,6	76,91	17,09
	Other	23	53,5	23	100,0	79,09	13,79
Cycle 13 Day 1	White	24	68,6	23	95,8	79,48	14,85
	Other	22	51,2	22	100,0	79,41	13,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	24	68,6	24	100,0	78,21	17,20
	Other	21	48,8	20	95,2	79,10	15,73
Cycle 15 Day 1	White	24	68,6	24	100,0	77,92	17,00
	Other	20	46,5	20	100,0	78,20	17,03
Cycle 16 Day 1	White	22	62,9	20	90,9	78,90	16,21
	Other	19	44,2	19	100,0	78,11	15,88
Cycle 17 Day 1	White	22	62,9	22	100,0	78,32	17,19
	Other	17	39,5	17	100,0	79,41	14,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	21	60,0	18	85,7	77,50	16,36
	Other	17	39,5	17	100,0	77,88	15,45
Cycle 19 Day 1	White	20	57,1	20	100,0	78,45	16,18
	Other	16	37,2	13	81,3	76,92	16,88
Cycle 20 Day 1	White	20	57,1	17	85,0	78,24	15,75
	Other	16	37,2	15	93,8	78,00	16,41
Cycle 21 Day 1	White	16	45,7	14	87,5	75,00	17,11
	Other	13	30,2	12	92,3	78,92	13,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	45,7	13	81,3	77,85	18,81
	Other	13	30,2	12	92,3	73,00	22,14
Cycle 23 Day 1	White	12	34,3	10	83,3	73,90	20,73
	Other	9	20,9	8	88,9	84,13	12,37
Cycle 24 Day 1	White	11	31,4	10	90,9	76,40	13,48
	Other	9	20,9	8	88,9	82,13	16,16
Cycle 25 Day 1	White	10	28,6	8	80,0	76,88	13,75
	Other	5	11,6	5	100,0	80,40	14,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	28,6	8	80,0	79,75	13,02
	Other	4	9,3	4	100,0	73,50	18,41
Cycle 27 Day 1	White	8	22,9	5	62,5	73,80	27,82
	Other	3	7,0	3	100,0	66,33	15,18
Cycle 28 Day 1	White	7	20,0	6	85,7	81,17	13,67
	Other	3	7,0	3	100,0	33,00	20,42
Cycle 29 Day 1	White	6	17,1	4	66,7	77,00	13,64
	Other	3	7,0	3	100,0	60,67	21,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	11,4	2	50,0	81,50	19,09
	Other	3	7,0	3	100,0	61,67	12,58
Cycle 31 Day 1	White	4	11,4	2	50,0	78,50	16,26
	Other	3	7,0	3	100,0	65,33	14,57
Cycle 32 Day 1	White	4	11,4	3	75,0	81,67	19,09
	Other	2	4,7	2	100,0	45,00	7,07
Cycle 33 Day 1	White	2	5,7	2	100,0	81,50	12,02
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-
End Of Treatment	White	15	42,9	12	80,0	64,92	18,00
	Other	24	55,8	15	62,5	62,40	19,60
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	69,32	25,10
	Europe (EU)	17	100,0	17	100,0	60,88	19,87
	Asia (AS)	39	100,0	39	100,0	65,74	14,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	77,12	20,85
	Europe (EU)	16	94,1	13	81,3	66,46	25,80
	Asia (AS)	36	92,3	35	97,2	67,74	17,22
Cycle 3 Day 1	America (AM)	20	90,9	17	85,0	74,35	23,86
	Europe (EU)	15	88,2	11	73,3	73,18	12,90
	Asia (AS)	33	84,6	33	100,0	75,12	15,25
Cycle 4 Day 1	America (AM)	20	90,9	17	85,0	82,76	14,59
	Europe (EU)	15	88,2	11	73,3	73,55	11,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	32	82,1	31	96,9	72,16	16,06
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	82,85	14,65
	Europe (EU)	15	88,2	13	86,7	76,54	14,05
	Asia (AS)	30	76,9	30	100,0	74,97	13,99
Cycle 6 Day 1	America (AM)	20	90,9	18	90,0	86,00	14,50
	Europe (EU)	14	82,4	12	85,7	74,17	11,46
	Asia (AS)	29	74,4	27	93,1	73,19	14,92
Cycle 7 Day 1	America (AM)	19	86,4	17	89,5	84,76	15,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	14	82,4	13	92,9	72,77	15,71
	Asia (AS)	27	69,2	26	96,3	72,65	17,06
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	85,06	12,71
	Europe (EU)	14	82,4	11	78,6	71,45	15,81
	Asia (AS)	24	61,5	24	100,0	75,58	17,39
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	82,50	12,37
	Europe (EU)	12	70,6	12	100,0	77,83	16,04
	Asia (AS)	21	53,8	21	100,0	78,67	13,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	80,59	14,87
	Europe (EU)	12	70,6	11	91,7	71,82	14,12
	Asia (AS)	21	53,8	21	100,0	78,48	11,02
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	82,89	15,98
	Europe (EU)	12	70,6	11	91,7	75,82	11,15
	Asia (AS)	20	51,3	20	100,0	76,15	14,65
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	83,76	15,51
	Europe (EU)	12	70,6	9	75,0	66,33	13,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	19	48,7	19	100,0	78,42	13,68
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	87,71	10,32
	Europe (EU)	11	64,7	10	90,9	70,70	14,54
	Asia (AS)	18	46,2	18	100,0	76,50	13,84
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	84,12	18,49
	Europe (EU)	11	64,7	11	100,0	71,18	13,98
	Asia (AS)	17	43,6	16	94,1	77,88	14,05
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	83,88	17,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	64,7	11	100,0	72,00	13,54
	Asia (AS)	16	41,0	16	100,0	76,00	16,66
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	86,64	13,23
	Europe (EU)	11	64,7	9	81,8	74,44	12,18
	Asia (AS)	16	41,0	16	100,0	73,69	17,57
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	82,57	19,25
	Europe (EU)	10	58,8	10	100,0	76,70	14,07
	Asia (AS)	15	38,5	15	100,0	76,67	14,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	84,00	15,34
	Europe (EU)	9	52,9	6	66,7	73,33	16,66
	Asia (AS)	15	38,5	15	100,0	73,53	14,62
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	84,46	16,26
	Europe (EU)	9	52,9	9	100,0	75,22	15,83
	Asia (AS)	14	35,9	11	78,6	72,18	15,03
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	82,85	17,96
	Europe (EU)	9	52,9	6	66,7	77,33	9,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	73,77	15,47
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	81,40	20,67
	Europe (EU)	7	41,2	6	85,7	74,67	9,99
	Asia (AS)	11	28,2	10	90,9	73,50	10,92
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	83,40	21,53
	Europe (EU)	7	41,2	5	71,4	78,60	12,44
	Asia (AS)	11	28,2	10	90,9	66,10	19,54
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	79,56	22,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	29,4	3	60,0	82,67	15,31
	Asia (AS)	7	17,9	6	85,7	74,67	12,13
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	83,38	14,86
	Europe (EU)	5	29,4	4	80,0	80,50	12,04
	Asia (AS)	7	17,9	6	85,7	72,00	15,32
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	81,71	15,56
	Europe (EU)	4	23,5	2	50,0	79,00	12,73
	Asia (AS)	4	10,3	4	100,0	71,75	10,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	80,50	14,49
	Europe (EU)	4	23,5	2	50,0	84,50	13,44
	Asia (AS)	4	10,3	4	100,0	70,00	15,30
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	73,50	32,11
	Europe (EU)	3	17,6	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	68,50	13,13
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	78,50	15,33
	Europe (EU)	2	11,8	1	50,0	95,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	44,25	28,00
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	79,33	15,70
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	63,00	17,78
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	81,50	19,09
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	61,67	12,58
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	78,50	16,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	65,33	14,57
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	78,00	25,46
	Europe (EU)	1	5,9	1	100,0	89,00	-
	Asia (AS)	3	7,7	2	66,7	45,00	7,07
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	73,00	-
	Europe (EU)	1	5,9	1	100,0	90,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	72,18	19,52
	Europe (EU)	6	35,3	3	50,0	56,33	10,12
	Asia (AS)	21	53,8	13	61,9	57,85	17,25
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	74,33	15,23
	1	38	100,0	38	100,0	63,45	19,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	10	100,0	10	100,0	48,30	16,53
Cycle 2 Day 1	0	30	100,0	27	90,0	76,33	18,71
	1	36	94,7	32	88,9	68,22	16,55
	2	6	60,0	6	100,0	50,33	31,99
Cycle 3 Day 1	0	29	96,7	25	86,2	78,88	13,90
	1	34	89,5	31	91,2	73,35	19,16
	2	5	50,0	5	100,0	60,40	16,46
Cycle 4 Day 1	0	29	96,7	23	79,3	79,17	15,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	74,94	13,97
	2	5	50,0	4	80,0	58,50	19,84
Cycle 5 Day 1	0	29	96,7	29	100,0	80,41	14,67
	1	33	86,8	31	93,9	76,03	13,68
	2	3	30,0	3	100,0	70,67	20,03
Cycle 6 Day 1	0	29	96,7	28	96,6	82,29	13,02
	1	31	81,6	27	87,1	72,74	16,24
	2	3	30,0	2	66,7	73,00	4,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	29	96,7	28	96,6	79,96	16,20
	1	28	73,7	25	89,3	71,88	17,90
	2	3	30,0	3	100,0	80,00	10,00
Cycle 8 Day 1	0	28	93,3	26	92,9	78,85	17,79
	1	25	65,8	23	92,0	77,13	14,77
	2	3	30,0	3	100,0	74,00	18,73
Cycle 9 Day 1	0	26	86,7	26	100,0	78,92	15,05
	1	23	60,5	23	100,0	80,48	12,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	2	20,0	2	100,0	84,00	1,41
Cycle 10 Day 1	0	26	86,7	26	100,0	78,15	13,94
	1	23	60,5	21	91,3	77,19	13,45
	2	2	20,0	2	100,0	77,50	3,54
Cycle 11 Day 1	0	26	86,7	26	100,0	79,85	14,24
	1	22	57,9	21	95,5	76,10	15,47
	2	2	20,0	2	100,0	87,50	3,54
Cycle 12 Day 1	0	25	83,3	22	88,0	78,32	17,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	21	95,5	77,90	14,27
	2	2	20,0	2	100,0	76,00	8,49
Cycle 13 Day 1	0	25	83,3	24	96,0	79,08	17,01
	1	20	52,6	20	100,0	79,60	10,89
	2	1	10,0	1	100,0	85,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	79,29	18,15
	1	19	50,0	19	100,0	77,37	14,61
	2	1	10,0	1	100,0	86,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	24	80,0	24	100,0	79,92	17,09
	1	19	50,0	19	100,0	75,16	16,83
	2	1	10,0	1	100,0	88,00	-
Cycle 16 Day 1	0	22	73,3	20	90,9	78,15	18,84
	1	18	47,4	18	100,0	78,39	12,61
	2	1	10,0	1	100,0	88,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	78,57	19,03
	1	17	44,7	17	100,0	78,59	12,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	87,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	78,11	18,21
	1	16	42,1	16	100,0	76,44	13,05
	2	1	10,0	1	100,0	90,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	78,26	19,08
	1	15	39,5	13	86,7	77,23	12,44
	2	1	10,0	1	100,0	78,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	77,18	19,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	39,5	14	93,3	79,36	12,09
	2	1	10,0	1	100,0	77,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	77,50	19,65
	1	13	34,2	11	84,6	75,27	8,13
	2	1	10,0	1	100,0	84,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	79,83	20,37
	1	13	34,2	12	92,3	70,08	20,14
	2	1	10,0	1	100,0	89,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	78,89	22,02
	1	9	23,7	8	88,9	76,75	14,18
	2	1	10,0	1	100,0	88,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	81,78	13,35
	1	9	23,7	8	88,9	74,38	16,14
	2	1	10,0	1	100,0	90,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	81,00	13,07
	1	7	18,4	7	100,0	75,86	14,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	26,7	6	75,0	83,17	10,36
	1	6	15,8	6	100,0	72,17	16,79
Cycle 27 Day 1	0	6	20,0	3	50,0	80,67	13,43
	1	5	13,2	5	100,0	65,20	26,70
Cycle 28 Day 1	0	5	16,7	4	80,0	81,50	16,22
	1	5	13,2	5	100,0	52,00	30,36
Cycle 29 Day 1	0	4	13,3	2	50,0	72,00	2,83
	1	5	13,2	5	100,0	69,20	21,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	10,0	1	33,3	68,00	-
	1	4	10,5	4	100,0	70,00	19,58
Cycle 31 Day 1	0	3	10,0	1	33,3	67,00	-
	1	4	10,5	4	100,0	71,50	17,14
Cycle 32 Day 1	0	3	10,0	2	66,7	74,50	20,51
	1	3	7,9	3	100,0	62,00	29,87
Cycle 33 Day 1	0	2	6,7	2	100,0	81,50	12,02
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	73,00	15,14
	1	20	52,6	11	55,0	53,73	18,38
	2	4	40,0	2	50,0	51,00	1,41
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	69,58	19,19
	1	3	100,0	3	100,0	60,33	30,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	44	100,0	44	100,0	63,32	18,68
Cycle 2 Day 1	None	30	96,8	27	90,0	74,11	18,62
	1	2	66,7	1	50,0	90,00	-
	2 or More	40	90,9	37	92,5	66,35	20,99
Cycle 3 Day 1	None	30	96,8	26	86,7	77,27	20,11
	1	2	66,7	1	50,0	90,00	-
	2 or More	36	81,8	34	94,4	72,03	15,07
Cycle 4 Day 1	None	30	96,8	26	86,7	76,62	16,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	83,00	9,90
	2 or More	35	79,5	31	88,6	74,03	14,52
Cycle 5 Day 1	None	30	96,8	30	100,0	80,30	13,64
	1	2	66,7	2	100,0	83,00	9,90
	2 or More	33	75,0	31	93,9	75,03	15,19
Cycle 6 Day 1	None	29	93,5	26	89,7	81,58	15,47
	1	2	66,7	2	100,0	82,00	12,73
	2 or More	32	72,7	29	90,6	73,41	14,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	27	87,1	25	92,6	80,84	15,38
	1	2	66,7	2	100,0	82,50	10,61
	2 or More	31	70,5	29	93,5	72,07	17,91
Cycle 8 Day 1	None	26	83,9	25	96,2	80,20	15,33
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	75,59	17,08
Cycle 9 Day 1	None	25	80,6	25	100,0	81,48	12,72
	1	1	33,3	1	100,0	90,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	77,76	14,56
Cycle 10 Day 1	None	25	80,6	24	96,0	79,08	13,87
	1	1	33,3	1	100,0	93,00	-
	2 or More	25	56,8	24	96,0	75,71	12,68
Cycle 11 Day 1	None	25	80,6	25	100,0	80,28	16,34
	1	1	33,3	1	100,0	90,00	-
	2 or More	24	54,5	23	95,8	76,17	12,53
Cycle 12 Day 1	None	25	80,6	24	96,0	81,29	13,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	87,00	-
	2 or More	23	52,3	20	87,0	73,65	16,66
Cycle 13 Day 1	None	24	77,4	23	95,8	82,48	13,66
	1	1	33,3	1	100,0	96,00	-
	2 or More	21	47,7	21	100,0	75,33	14,14
Cycle 14 Day 1	None	23	74,2	23	100,0	81,43	15,43
	1	1	33,3	1	100,0	91,00	-
	2 or More	21	47,7	20	95,2	74,75	17,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	23	74,2	23	100,0	80,39	17,46
	1	1	33,3	1	100,0	89,00	-
	2 or More	20	45,5	20	100,0	74,80	16,21
Cycle 16 Day 1	None	20	64,5	19	95,0	80,79	17,94
	1	1	33,3	1	100,0	90,00	-
	2 or More	20	45,5	19	95,0	75,63	13,66
Cycle 17 Day 1	None	19	61,3	19	100,0	81,84	13,66
	1	1	33,3	1	100,0	90,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	19	43,2	19	100,0	75,16	18,07
Cycle 18 Day 1	None	18	58,1	17	94,4	82,71	12,75
	1	1	33,3	1	100,0	92,00	-
	2 or More	19	43,2	17	89,5	71,82	16,87
Cycle 19 Day 1	None	17	54,8	17	100,0	83,53	14,41
	1	1	33,3	1	100,0	90,00	-
	2 or More	18	40,9	15	83,3	70,60	16,05
Cycle 20 Day 1	None	17	54,8	16	94,1	82,44	14,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	80,00	-
	2 or More	18	40,9	15	83,3	73,40	16,56
Cycle 21 Day 1	None	15	48,4	13	86,7	82,54	11,58
	2 or More	14	31,8	13	92,9	71,08	16,59
Cycle 22 Day 1	None	15	48,4	13	86,7	85,08	12,00
	2 or More	14	31,8	12	85,7	65,17	22,53
Cycle 23 Day 1	None	10	32,3	9	90,0	83,89	14,70
	2 or More	11	25,0	9	81,8	73,00	19,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	32,3	10	100,0	83,80	14,20
	2 or More	10	22,7	8	80,0	72,88	13,45
Cycle 25 Day 1	None	9	29,0	8	88,9	82,13	14,46
	2 or More	6	13,6	5	83,3	72,00	10,10
Cycle 26 Day 1	None	8	25,8	8	100,0	83,50	12,48
	2 or More	6	13,6	4	66,7	66,00	11,58
Cycle 27 Day 1	None	7	22,6	6	85,7	74,83	25,01
	2 or More	4	9,1	2	50,0	59,50	13,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	22,6	7	100,0	75,29	19,95
	2 or More	3	6,8	2	66,7	29,50	27,58
Cycle 29 Day 1	None	6	19,4	5	83,3	69,60	20,33
	2 or More	3	6,8	2	66,7	71,00	15,56
Cycle 30 Day 1	None	4	12,9	3	75,0	74,33	18,34
	2 or More	3	6,8	2	66,7	62,50	17,68
Cycle 31 Day 1	None	4	12,9	3	75,0	75,67	12,50
	2 or More	3	6,8	2	66,7	63,00	19,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	65,33	28,38
	2 or More	2	4,5	2	100,0	69,50	27,58
Cycle 33 Day 1	None	1	3,2	1	100,0	73,00	-
	2 or More	1	2,3	1	100,0	90,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	11	84,6	70,09	20,00
	1	2	66,7	1	50,0	70,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	54,5	15	62,5	58,27	17,02
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	69,58	19,19
	Previously Treated	47	100,0	47	100,0	63,13	19,13
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	74,11	18,62
	Previously Treated	42	89,4	38	90,5	66,97	21,05
Cycle 3 Day 1	Naïve	30	96,8	26	86,7	77,27	20,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	38	80,9	35	92,1	72,54	15,15
Cycle 4 Day 1	Naïve	30	96,8	26	86,7	76,62	16,90
	Previously Treated	37	78,7	33	89,2	74,58	14,34
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	80,30	13,64
	Previously Treated	35	74,5	33	94,3	75,52	14,94
Cycle 6 Day 1	Naïve	29	93,5	26	89,7	81,58	15,47
	Previously Treated	34	72,3	31	91,2	73,97	14,07
Cycle 7 Day 1	Naïve	27	87,1	25	92,6	80,84	15,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	33	70,2	31	93,9	72,74	17,61
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	80,20	15,33
	Previously Treated	30	63,8	27	90,0	75,59	17,08
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	81,48	12,72
	Previously Treated	26	55,3	26	100,0	78,23	14,47
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	79,08	13,87
	Previously Treated	26	55,3	25	96,2	76,40	12,89
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	80,28	16,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	53,2	24	96,0	76,75	12,58
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	81,29	13,79
	Previously Treated	24	51,1	21	87,5	74,29	16,50
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	82,48	13,66
	Previously Treated	22	46,8	22	100,0	76,27	14,49
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	81,43	15,43
	Previously Treated	22	46,8	21	95,5	75,52	17,17
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	80,39	17,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	21	100,0	75,48	16,10
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	80,79	17,94
	Previously Treated	21	44,7	20	95,2	76,35	13,68
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	81,84	13,66
	Previously Treated	20	42,6	20	100,0	75,90	17,90
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	82,71	12,75
	Previously Treated	20	42,6	18	90,0	72,94	17,04
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	83,53	14,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	40,4	16	84,2	71,81	16,25
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	82,44	14,76
	Previously Treated	19	40,4	16	84,2	73,81	16,08
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	82,54	11,58
	Previously Treated	14	29,8	13	92,9	71,08	16,59
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	85,08	12,00
	Previously Treated	14	29,8	12	85,7	65,17	22,53
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	83,89	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	73,00	19,81
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	83,80	14,20
	Previously Treated	10	21,3	8	80,0	72,88	13,45
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	82,13	14,46
	Previously Treated	6	12,8	5	83,3	72,00	10,10
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	83,50	12,48
	Previously Treated	6	12,8	4	66,7	66,00	11,58
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	74,83	25,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	8,5	2	50,0	59,50	13,44
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	75,29	19,95
	Previously Treated	3	6,4	2	66,7	29,50	27,58
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	69,60	20,33
	Previously Treated	3	6,4	2	66,7	71,00	15,56
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	74,33	18,34
	Previously Treated	3	6,4	2	66,7	62,50	17,68
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	75,67	12,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	63,00	19,80
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	65,33	28,38
	Previously Treated	2	4,3	2	100,0	69,50	27,58
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	73,00	-
	Previously Treated	1	2,1	1	100,0	90,00	-
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	11	84,6	70,09	20,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	16	61,5	59,00	16,70
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	67,74	21,89
	Central	43	100,0	43	100,0	64,02	16,98
Cycle 2 Day 1	Local	32	91,4	31	96,9	74,26	18,50
	Central	40	93,0	34	85,0	66,00	21,21
Cycle 3 Day 1	Local	29	82,9	26	89,7	79,77	13,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	39	90,7	35	89,7	70,69	19,18
Cycle 4 Day 1	Local	28	80,0	24	85,7	80,79	15,97
	Central	39	90,7	35	89,7	71,83	14,11
Cycle 5 Day 1	Local	27	77,1	27	100,0	82,37	13,85
	Central	38	88,4	36	94,7	74,36	14,06
Cycle 6 Day 1	Local	27	77,1	27	100,0	81,78	14,84
	Central	36	83,7	30	83,3	73,53	14,45
Cycle 7 Day 1	Local	27	77,1	27	100,0	81,89	16,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	33	76,7	29	87,9	71,21	16,42
Cycle 8 Day 1	Local	26	74,3	26	100,0	83,69	14,01
	Central	30	69,8	26	86,7	71,92	16,48
Cycle 9 Day 1	Local	25	71,4	25	100,0	81,16	14,48
	Central	26	60,5	26	100,0	78,54	12,85
Cycle 10 Day 1	Local	25	71,4	24	96,0	78,83	15,67
	Central	26	60,5	25	96,2	76,64	10,79
Cycle 11 Day 1	Local	24	68,6	24	100,0	82,25	14,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	26	60,5	25	96,2	75,00	13,63
Cycle 12 Day 1	Local	23	65,7	22	95,7	84,86	12,24
	Central	26	60,5	23	88,5	71,48	15,39
Cycle 13 Day 1	Local	22	62,9	22	100,0	83,45	14,55
	Central	24	55,8	23	95,8	75,61	13,16
Cycle 14 Day 1	Local	22	62,9	22	100,0	83,77	14,01
	Central	23	53,5	22	95,7	73,45	17,21
Cycle 15 Day 1	Local	22	62,9	22	100,0	82,50	16,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	73,59	16,15
Cycle 16 Day 1	Local	20	57,1	20	100,0	84,95	11,73
	Central	21	48,8	19	90,5	71,74	17,04
Cycle 17 Day 1	Local	20	57,1	20	100,0	83,85	13,34
	Central	19	44,2	19	100,0	73,47	17,26
Cycle 18 Day 1	Local	20	57,1	19	95,0	84,16	12,69
	Central	18	41,9	16	88,9	70,00	15,77
Cycle 19 Day 1	Local	19	54,3	17	89,5	81,82	14,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	39,5	16	94,1	73,63	17,53
Cycle 20 Day 1	Local	19	54,3	17	89,5	85,82	9,66
	Central	17	39,5	15	88,2	69,40	17,11
Cycle 21 Day 1	Local	14	40,0	12	85,7	84,42	10,04
	Central	15	34,9	14	93,3	70,29	16,09
Cycle 22 Day 1	Local	14	40,0	12	85,7	81,17	22,59
	Central	15	34,9	13	86,7	70,31	16,92
Cycle 23 Day 1	Local	11	31,4	10	90,9	87,90	7,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	23,3	8	80,0	66,63	20,27
Cycle 24 Day 1	Local	11	31,4	10	90,9	85,60	10,98
	Central	9	20,9	8	88,9	70,63	14,78
Cycle 25 Day 1	Local	7	20,0	7	100,0	85,43	11,91
	Central	8	18,6	6	75,0	69,83	10,48
Cycle 26 Day 1	Local	6	17,1	6	100,0	84,83	9,95
	Central	8	18,6	6	75,0	70,50	15,48
Cycle 27 Day 1	Local	4	11,4	4	100,0	86,25	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	16,3	4	57,1	55,75	20,77
Cycle 28 Day 1	Local	4	11,4	4	100,0	70,50	25,09
	Central	6	14,0	5	83,3	60,80	32,83
Cycle 29 Day 1	Local	3	8,6	3	100,0	70,33	28,68
	Central	6	14,0	4	66,7	69,75	9,18
Cycle 30 Day 1	Local	3	8,6	3	100,0	74,33	18,34
	Central	4	9,3	2	50,0	62,50	17,68
Cycle 31 Day 1	Local	3	8,6	3	100,0	75,67	12,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	9,3	2	50,0	63,00	19,80
Cycle 32 Day 1	Local	3	8,6	3	100,0	65,33	28,38
	Central	3	7,0	2	66,7	69,50	27,58
Cycle 33 Day 1	Local	1	2,9	1	100,0	73,00	-
	Central	1	2,3	1	100,0	90,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	67,21	18,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	21	48,8	13	61,9	59,54	18,66
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	66,41	18,38
	No	4	100,0	4	100,0	52,50	33,04
Cycle 2 Day 1	Yes	70	94,6	63	90,0	71,21	19,15
	No	2	50,0	2	100,0	30,00	14,14
Cycle 3 Day 1	Yes	66	89,2	59	89,4	74,71	17,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	70,00	14,14
Cycle 4 Day 1	Yes	65	87,8	57	87,7	76,37	14,78
	No	2	50,0	2	100,0	50,00	14,14
Cycle 5 Day 1	Yes	63	85,1	61	96,8	78,21	14,44
	No	2	50,0	2	100,0	65,00	7,07
Cycle 6 Day 1	Yes	61	82,4	55	90,2	77,71	15,17
	No	2	50,0	2	100,0	70,00	14,14
Cycle 7 Day 1	Yes	58	78,4	54	93,1	76,69	17,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	67,50	3,54
Cycle 8 Day 1	Yes	54	73,0	50	92,6	78,82	15,68
	No	2	50,0	2	100,0	52,50	10,61
Cycle 9 Day 1	Yes	49	66,2	49	100,0	80,43	13,49
	No	2	50,0	2	100,0	65,00	7,07
Cycle 10 Day 1	Yes	49	66,2	47	95,9	77,94	13,46
	No	2	50,0	2	100,0	72,50	10,61
Cycle 11 Day 1	Yes	48	64,9	47	97,9	78,81	14,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	72,50	3,54
Cycle 12 Day 1	Yes	47	63,5	43	91,5	78,28	15,58
	No	2	50,0	2	100,0	72,50	10,61
Cycle 13 Day 1	Yes	44	59,5	43	97,7	80,12	14,19
	No	2	50,0	2	100,0	65,00	7,07
Cycle 14 Day 1	Yes	43	58,1	42	97,7	78,90	16,62
	No	2	50,0	2	100,0	72,50	10,61
Cycle 15 Day 1	Yes	42	56,8	42	100,0	79,02	16,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	57,50	10,61
Cycle 16 Day 1	Yes	39	52,7	37	94,9	79,51	15,65
	No	2	50,0	2	100,0	60,00	0,00
Cycle 17 Day 1	Yes	37	50,0	37	100,0	79,81	15,85
	No	2	50,0	2	100,0	60,00	0,00
Cycle 18 Day 1	Yes	36	48,6	33	91,7	78,15	15,61
	No	2	50,0	2	100,0	70,00	21,21
Cycle 19 Day 1	Yes	34	45,9	32	94,1	78,09	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	1	50,0	70,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	78,67	15,97
	No	2	50,0	2	100,0	70,00	14,14
Cycle 21 Day 1	Yes	27	36,5	24	88,9	78,00	15,05
	No	2	50,0	2	100,0	62,50	10,61
Cycle 22 Day 1	Yes	27	36,5	23	85,2	76,65	20,67
	No	2	50,0	2	100,0	62,50	3,54
Cycle 23 Day 1	Yes	20	27,0	17	85,0	78,06	18,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	85,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	78,59	14,94
	No	1	25,0	1	100,0	85,00	-
Cycle 25 Day 1	Yes	14	18,9	12	85,7	77,67	13,94
	No	1	25,0	1	100,0	85,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	77,00	15,00
	No	1	25,0	1	100,0	85,00	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	69,71	24,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	80,00	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	68,25	28,53
	No	1	25,0	1	100,0	40,00	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	75,00	13,02
	No	1	25,0	1	100,0	40,00	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	72,00	18,60
	No	1	25,0	1	100,0	60,00	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	70,75	17,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	70,00	-
Cycle 32 Day 1	Yes	5	6,8	4	80,0	73,75	22,22
	No	1	25,0	1	100,0	40,00	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	81,50	12,02
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	27	71,1	63,52	18,59
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	65,00	18,60
	No	70	100,0	70	100,0	65,77	19,50
Cycle 2 Day 1	Yes	5	62,5	5	100,0	79,80	21,06
	No	67	95,7	60	89,6	69,12	20,14
Cycle 3 Day 1	Yes	5	62,5	4	80,0	82,75	11,32
	No	63	90,0	57	90,5	73,98	17,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	5	62,5	5	100,0	83,20	17,74
	No	62	88,6	54	87,1	74,76	15,17
Cycle 5 Day 1	Yes	5	62,5	5	100,0	74,40	18,13
	No	60	85,7	58	96,7	78,09	14,21
Cycle 6 Day 1	Yes	5	62,5	5	100,0	80,40	24,86
	No	58	82,9	52	89,7	77,15	14,16
Cycle 7 Day 1	Yes	5	62,5	5	100,0	79,60	22,69
	No	55	78,6	51	92,7	76,04	16,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	5	62,5	5	100,0	80,00	12,96
	No	51	72,9	47	92,2	77,57	16,68
Cycle 9 Day 1	Yes	4	50,0	4	100,0	77,50	18,16
	No	47	67,1	47	100,0	80,02	13,38
Cycle 10 Day 1	Yes	4	50,0	4	100,0	76,25	27,00
	No	47	67,1	45	95,7	77,84	11,97
Cycle 11 Day 1	Yes	4	50,0	4	100,0	75,00	27,95
	No	46	65,7	45	97,8	78,87	13,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	4	50,0	4	100,0	82,50	16,66
	No	45	64,3	41	91,1	77,59	15,37
Cycle 13 Day 1	Yes	4	50,0	4	100,0	81,50	16,94
	No	42	60,0	41	97,6	79,24	14,20
Cycle 14 Day 1	Yes	4	50,0	4	100,0	78,00	20,98
	No	41	58,6	40	97,6	78,68	16,17
Cycle 15 Day 1	Yes	4	50,0	4	100,0	77,00	27,14
	No	40	57,1	40	100,0	78,15	15,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	37,5	3	100,0	77,00	32,91
	No	38	54,3	36	94,7	78,64	14,51
Cycle 17 Day 1	Yes	3	37,5	3	100,0	89,33	10,69
	No	36	51,4	36	100,0	77,92	16,22
Cycle 18 Day 1	Yes	3	37,5	3	100,0	88,00	10,44
	No	35	50,0	32	91,4	76,72	15,87
Cycle 19 Day 1	Yes	3	37,5	3	100,0	88,33	10,79
	No	33	47,1	30	90,9	76,80	16,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	37,5	3	100,0	86,67	15,31
	No	33	47,1	29	87,9	77,24	15,84
Cycle 21 Day 1	Yes	2	25,0	2	100,0	75,50	13,44
	No	27	38,6	24	88,9	76,92	15,58
Cycle 22 Day 1	Yes	2	25,0	2	100,0	83,50	19,09
	No	27	38,6	23	85,2	74,83	20,54
Cycle 23 Day 1	Yes	2	25,0	2	100,0	78,00	25,46
	No	19	27,1	16	84,2	78,50	17,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	25,0	2	100,0	77,50	24,75
	No	18	25,7	16	88,9	79,13	14,13
Cycle 25 Day 1	Yes	2	25,0	2	100,0	79,50	13,44
	No	13	18,6	11	84,6	78,00	14,15
Cycle 26 Day 1	Yes	1	12,5	1	100,0	76,00	-
	No	13	18,6	11	84,6	77,82	15,18
Cycle 27 Day 1	Yes	1	12,5	1	100,0	75,00	-
	No	10	14,3	7	70,0	70,43	24,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	78,00	-
	No	9	12,9	8	88,9	63,50	29,81
Cycle 29 Day 1	Yes	1	12,5	1	100,0	70,00	-
	No	8	11,4	6	75,0	70,00	19,48
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	69,60	16,98
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	70,60	14,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	67,00	24,45
Cycle 33 Day 1	No	2	2,9	2	100,0	81,50	12,02
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	32,50	4,95
	No	37	52,9	25	67,6	66,00	16,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_VAS_SG.xls
28NOV2019 11:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	64,91	20,55
Cycle 2 Day 1	All	136	93,8	125	91,9	70,45	19,43
Cycle 3 Day 1	All	131	90,3	114	87,0	72,71	16,57
Cycle 4 Day 1	All	128	88,3	115	89,8	73,04	15,57
Cycle 5 Day 1	All	124	85,5	116	93,5	75,43	15,10
Cycle 6 Day 1	All	121	83,4	109	90,1	75,64	15,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	104	92,0	74,98	16,55
Cycle 8 Day 1	All	106	73,1	96	90,6	75,89	15,91
Cycle 9 Day 1	All	98	67,6	96	98,0	77,05	14,73
Cycle 10 Day 1	All	89	61,4	85	95,5	75,05	14,77
Cycle 11 Day 1	All	80	55,2	76	95,0	76,99	15,34
Cycle 12 Day 1	All	76	52,4	69	90,8	76,70	15,22
Cycle 13 Day 1	All	66	45,5	61	92,4	77,44	16,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	77,30	16,38
Cycle 15 Day 1	All	57	39,3	54	94,7	78,46	16,07
Cycle 16 Day 1	All	50	34,5	47	94,0	77,85	15,75
Cycle 17 Day 1	All	45	31,0	44	97,8	77,25	16,86
Cycle 18 Day 1	All	41	28,3	37	90,2	77,57	15,29
Cycle 19 Day 1	All	36	24,8	33	91,7	77,85	16,22
Cycle 20 Day 1	All	36	24,8	32	88,9	78,13	15,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	76,81	15,18
Cycle 22 Day 1	All	29	20,0	25	86,2	75,52	20,19
Cycle 23 Day 1	All	21	14,5	18	85,7	78,44	17,83
Cycle 24 Day 1	All	20	13,8	18	90,0	78,94	14,57
Cycle 25 Day 1	All	15	10,3	13	86,7	78,23	13,50
Cycle 26 Day 1	All	14	9,7	12	85,7	77,67	14,49
Cycle 27 Day 1	All	11	7,6	8	72,7	71,00	22,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	65,11	28,30
Cycle 29 Day 1	All	9	6,2	7	77,8	70,00	17,79
Cycle 30 Day 1	All	7	4,8	5	71,4	69,60	16,98
Cycle 31 Day 1	All	7	4,8	5	71,4	70,60	14,98
Cycle 32 Day 1	All	6	4,1	5	83,3	67,00	24,45
Cycle 33 Day 1	All	2	1,4	2	100,0	81,50	12,02
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	43	67,2	59,93	19,95
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	66,69	20,08
	Female	93	100,0	91	97,8	63,91	20,85
Cycle 2 Day 1	Male	50	96,2	47	94,0	70,40	19,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	78	90,7	70,47	19,41
Cycle 3 Day 1	Male	47	90,4	42	89,4	74,38	15,52
	Female	84	90,3	72	85,7	71,74	17,18
Cycle 4 Day 1	Male	46	88,5	43	93,5	74,42	16,25
	Female	82	88,2	72	87,8	72,22	15,20
Cycle 5 Day 1	Male	45	86,5	42	93,3	76,48	16,06
	Female	79	84,9	74	93,7	74,84	14,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	76,17	16,66
	Female	76	81,7	68	89,5	75,32	14,94
Cycle 7 Day 1	Male	40	76,9	39	97,5	74,21	18,80
	Female	73	78,5	65	89,0	75,45	15,18
Cycle 8 Day 1	Male	37	71,2	34	91,9	77,91	15,64
	Female	69	74,2	62	89,9	74,77	16,07
Cycle 9 Day 1	Male	33	63,5	33	100,0	81,55	11,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	74,70	15,75
Cycle 10 Day 1	Male	30	57,7	29	96,7	77,45	14,16
	Female	59	63,4	56	94,9	73,80	15,05
Cycle 11 Day 1	Male	29	55,8	27	93,1	79,00	13,81
	Female	51	54,8	49	96,1	75,88	16,15
Cycle 12 Day 1	Male	27	51,9	26	96,3	78,46	14,06
	Female	49	52,7	43	87,8	75,63	15,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	78,13	16,18
	Female	41	44,1	38	92,7	77,03	16,93
Cycle 14 Day 1	Male	23	44,2	21	91,3	77,14	15,92
	Female	37	39,8	36	97,3	77,39	16,86
Cycle 15 Day 1	Male	21	40,4	20	95,2	77,10	16,05
	Female	36	38,7	34	94,4	79,26	16,26
Cycle 16 Day 1	Male	16	30,8	16	100,0	81,00	12,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	76,23	17,24
Cycle 17 Day 1	Male	13	25,0	13	100,0	80,23	14,11
	Female	32	34,4	31	96,9	76,00	17,96
Cycle 18 Day 1	Male	12	23,1	11	91,7	81,36	13,50
	Female	29	31,2	26	89,7	75,96	15,97
Cycle 19 Day 1	Male	10	19,2	10	100,0	82,30	14,48
	Female	26	28,0	23	88,5	75,91	16,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	82,89	12,75
	Female	26	28,0	23	88,5	76,26	16,73
Cycle 21 Day 1	Male	8	15,4	8	100,0	82,38	12,26
	Female	21	22,6	18	85,7	74,33	16,00
Cycle 22 Day 1	Male	8	15,4	6	75,0	83,50	15,87
	Female	21	22,6	19	90,5	73,00	21,11
Cycle 23 Day 1	Male	5	9,6	4	80,0	87,25	9,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	75,93	19,05
Cycle 24 Day 1	Male	5	9,6	4	80,0	84,25	12,39
	Female	15	16,1	14	93,3	77,43	15,20
Cycle 25 Day 1	Male	3	5,8	2	66,7	81,00	18,38
	Female	12	12,9	11	91,7	77,73	13,53
Cycle 26 Day 1	Male	3	5,8	2	66,7	84,50	12,02
	Female	11	11,8	10	90,9	76,30	15,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	83,50	17,68
	Female	8	8,6	6	75,0	66,83	24,21
Cycle 28 Day 1	Male	2	3,8	2	100,0	76,50	23,33
	Female	8	8,6	7	87,5	61,86	30,36
Cycle 29 Day 1	Male	1	1,9	1	100,0	74,00	-
	Female	8	8,6	6	75,0	69,33	19,39
Cycle 30 Day 1	Male	1	1,9	1	100,0	68,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	70,00	19,58
Cycle 31 Day 1	Male	1	1,9	1	100,0	67,00	-
	Female	6	6,5	4	66,7	71,50	17,14
Cycle 32 Day 1	Male	1	1,9	1	100,0	60,00	-
	Female	5	5,4	4	80,0	68,75	27,87
Cycle 33 Day 1	Male	1	1,9	1	100,0	73,00	-
	Female	1	1,1	1	100,0	90,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	20	74,1	57,45	20,09
	Female	37	39,8	23	62,2	62,09	20,03
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	64,83	19,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	63,90	24,80
	>=75	7	100,0	7	100,0	70,29	15,53
Cycle 2 Day 1	18-64	103	94,5	93	90,3	71,02	20,03
	65-74	26	89,7	25	96,2	67,20	19,26
	>=75	7	100,0	7	100,0	74,43	9,98
Cycle 3 Day 1	18-64	99	90,8	86	86,9	72,37	16,60
	65-74	25	86,2	22	88,0	73,50	17,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	6	85,7	74,67	17,01
Cycle 4 Day 1	18-64	98	89,9	88	89,8	73,56	16,35
	65-74	23	79,3	20	87,0	72,00	13,51
	>=75	7	100,0	7	100,0	69,57	11,27
Cycle 5 Day 1	18-64	95	87,2	89	93,7	75,47	15,03
	65-74	22	75,9	22	100,0	74,55	15,94
	>=75	7	100,0	5	71,4	78,60	15,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	81	88,0	76,91	15,37
	65-74	22	75,9	21	95,5	74,76	13,87
	>=75	7	100,0	7	100,0	63,57	18,95
Cycle 7 Day 1	18-64	86	78,9	79	91,9	75,48	17,22
	65-74	20	69,0	19	95,0	74,53	12,84
	>=75	7	100,0	6	85,7	69,83	19,65
Cycle 8 Day 1	18-64	80	73,4	71	88,8	77,45	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	72,00	13,75
	>=75	7	100,0	6	85,7	69,67	16,74
Cycle 9 Day 1	18-64	74	67,9	73	98,6	79,25	14,27
	65-74	18	62,1	18	100,0	68,89	15,64
	>=75	6	85,7	5	83,3	74,40	7,09
Cycle 10 Day 1	18-64	69	63,3	66	95,7	76,02	14,70
	65-74	15	51,7	15	100,0	70,53	15,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	4	80,0	76,00	11,46
Cycle 11 Day 1	18-64	61	56,0	59	96,7	77,68	16,40
	65-74	15	51,7	14	93,3	73,79	11,61
	>=75	4	57,1	3	75,0	78,33	7,64
Cycle 12 Day 1	18-64	57	52,3	51	89,5	77,94	15,06
	65-74	15	51,7	14	93,3	73,43	13,80
	>=75	4	57,1	4	100,0	72,25	23,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	79,13	16,37
	65-74	13	44,8	11	84,6	70,91	17,97
	>=75	4	57,1	4	100,0	76,00	12,68
Cycle 14 Day 1	18-64	45	41,3	44	97,8	77,70	17,27
	65-74	13	44,8	11	84,6	75,91	13,55
	>=75	2	28,6	2	100,0	76,00	18,38
Cycle 15 Day 1	18-64	43	39,4	41	95,3	79,05	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	77,27	11,90
	>=75	2	28,6	2	100,0	73,00	19,80
Cycle 16 Day 1	18-64	38	34,9	36	94,7	78,14	16,65
	65-74	10	34,5	9	90,0	77,78	12,55
	>=75	2	28,6	2	100,0	73,00	19,80
Cycle 17 Day 1	18-64	36	33,0	35	97,2	76,86	17,48
	65-74	8	27,6	8	100,0	79,88	15,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	70,00	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	78,57	15,52
	65-74	7	24,1	6	85,7	75,33	14,83
	>=75	1	14,3	1	100,0	61,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	77,64	16,63
	65-74	5	17,2	4	80,0	81,50	16,50
	>=75	1	14,3	1	100,0	69,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	78,92	16,27
	65-74	5	17,2	5	100,0	77,20	14,46
	>=75	1	14,3	1	100,0	62,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	77,48	15,20
	65-74	4	13,8	4	100,0	74,00	19,10
	>=75	1	14,3	1	100,0	74,00	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	78,10	17,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	65,50	34,15
	>=75	1	14,3	1	100,0	64,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	76,44	17,88
	65-74	2	6,9	2	100,0	94,50	4,95
Cycle 24 Day 1	18-64	18	16,5	16	88,9	77,06	14,26
	65-74	2	6,9	2	100,0	94,00	7,07
Cycle 25 Day 1	18-64	14	12,8	12	85,7	77,42	13,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	88,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	77,67	14,49
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	71,00	22,87
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	65,11	28,30
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	70,00	17,79
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	69,60	16,98
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	70,60	14,98
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	61,50	24,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	89,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	73,00	-
	65-74	1	3,4	1	100,0	90,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	33	73,3	57,73	21,04
	65-74	15	51,7	8	53,3	69,13	14,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	59,50	14,85
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	62,38	21,56
	Other	85	100,0	84	98,8	66,65	19,75
Cycle 2 Day 1	White	57	95,0	51	89,5	70,57	19,39
	Other	79	92,9	74	93,7	70,36	19,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	43	79,6	72,88	14,58
	Other	77	90,6	71	92,2	72,61	17,77
Cycle 4 Day 1	White	53	88,3	44	83,0	73,32	14,08
	Other	75	88,2	71	94,7	72,87	16,52
Cycle 5 Day 1	White	52	86,7	47	90,4	76,26	14,47
	Other	72	84,7	69	95,8	74,87	15,59
Cycle 6 Day 1	White	50	83,3	41	82,0	75,24	16,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	75,88	14,74
Cycle 7 Day 1	White	47	78,3	40	85,1	76,40	15,99
	Other	66	77,6	64	97,0	74,09	16,96
Cycle 8 Day 1	White	45	75,0	38	84,4	76,53	14,52
	Other	61	71,8	58	95,1	75,47	16,86
Cycle 9 Day 1	White	42	70,0	41	97,6	77,68	14,95
	Other	56	65,9	55	98,2	76,58	14,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	38	92,7	74,55	15,53
	Other	48	56,5	47	97,9	75,45	14,28
Cycle 11 Day 1	White	37	61,7	35	94,6	77,54	15,90
	Other	43	50,6	41	95,3	76,51	15,03
Cycle 12 Day 1	White	37	61,7	33	89,2	75,09	16,59
	Other	39	45,9	36	92,3	78,17	13,92
Cycle 13 Day 1	White	32	53,3	30	93,8	76,57	16,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	31	91,2	78,29	16,92
Cycle 14 Day 1	White	31	51,7	30	96,8	76,60	16,97
	Other	29	34,1	27	93,1	78,07	15,99
Cycle 15 Day 1	White	30	50,0	28	93,3	77,39	16,83
	Other	27	31,8	26	96,3	79,62	15,45
Cycle 16 Day 1	White	26	43,3	24	92,3	77,46	16,53
	Other	24	28,2	23	95,8	78,26	15,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	76,17	17,98
	Other	21	24,7	20	95,2	78,55	15,77
Cycle 18 Day 1	White	22	36,7	19	86,4	77,16	15,97
	Other	19	22,4	18	94,7	78,00	15,00
Cycle 19 Day 1	White	20	33,3	20	100,0	78,45	16,18
	Other	16	18,8	13	81,3	76,92	16,88
Cycle 20 Day 1	White	20	33,3	17	85,0	78,24	15,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	78,00	16,41
Cycle 21 Day 1	White	16	26,7	14	87,5	75,00	17,11
	Other	13	15,3	12	92,3	78,92	13,00
Cycle 22 Day 1	White	16	26,7	13	81,3	77,85	18,81
	Other	13	15,3	12	92,3	73,00	22,14
Cycle 23 Day 1	White	12	20,0	10	83,3	73,90	20,73
	Other	9	10,6	8	88,9	84,13	12,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	76,40	13,48
	Other	9	10,6	8	88,9	82,13	16,16
Cycle 25 Day 1	White	10	16,7	8	80,0	76,88	13,75
	Other	5	5,9	5	100,0	80,40	14,36
Cycle 26 Day 1	White	10	16,7	8	80,0	79,75	13,02
	Other	4	4,7	4	100,0	73,50	18,41
Cycle 27 Day 1	White	8	13,3	5	62,5	73,80	27,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	66,33	15,18
Cycle 28 Day 1	White	7	11,7	6	85,7	81,17	13,67
	Other	3	3,5	3	100,0	33,00	20,42
Cycle 29 Day 1	White	6	10,0	4	66,7	77,00	13,64
	Other	3	3,5	3	100,0	60,67	21,01
Cycle 30 Day 1	White	4	6,7	2	50,0	81,50	19,09
	Other	3	3,5	3	100,0	61,67	12,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	78,50	16,26
	Other	3	3,5	3	100,0	65,33	14,57
Cycle 32 Day 1	White	4	6,7	3	75,0	81,67	19,09
	Other	2	2,4	2	100,0	45,00	7,07
Cycle 33 Day 1	White	2	3,3	2	100,0	81,50	12,02
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	62,00	18,91
	Other	39	45,9	26	66,7	58,58	20,86
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	69,15	22,88
	Europe (EU)	34	100,0	31	91,2	59,71	20,37
	Asia (AS)	71	100,0	71	100,0	64,79	18,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	33	86,8	76,61	17,61
	Europe (EU)	32	94,1	27	84,4	66,30	24,62
	Asia (AS)	66	93,0	65	98,5	69,05	17,36
Cycle 3 Day 1	America (AM)	37	92,5	30	81,1	72,57	20,78
	Europe (EU)	31	91,2	21	67,7	69,95	14,64
	Asia (AS)	63	88,7	63	100,0	73,70	15,03
Cycle 4 Day 1	America (AM)	37	92,5	31	83,8	76,42	17,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	24	80,0	70,08	11,18
	Asia (AS)	61	85,9	60	98,4	72,48	15,83
Cycle 5 Day 1	America (AM)	37	92,5	34	91,9	78,24	17,52
	Europe (EU)	30	88,2	25	83,3	74,44	12,60
	Asia (AS)	57	80,3	57	100,0	74,19	14,57
Cycle 6 Day 1	America (AM)	37	92,5	33	89,2	80,64	17,56
	Europe (EU)	28	82,4	24	85,7	73,21	14,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	73,60	14,32
Cycle 7 Day 1	America (AM)	35	87,5	30	85,7	81,37	18,08
	Europe (EU)	28	82,4	25	89,3	70,68	14,76
	Asia (AS)	50	70,4	49	98,0	73,27	15,60
Cycle 8 Day 1	America (AM)	31	77,5	26	83,9	84,73	12,88
	Europe (EU)	28	82,4	23	82,1	71,83	13,31
	Asia (AS)	47	66,2	47	100,0	72,98	16,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	82,96	12,70
	Europe (EU)	26	76,5	25	96,2	74,60	14,47
	Asia (AS)	43	60,6	43	100,0	74,63	15,30
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	80,63	14,48
	Europe (EU)	25	73,5	24	96,0	69,08	13,70
	Asia (AS)	37	52,1	37	100,0	75,30	14,51
Cycle 11 Day 1	America (AM)	24	60,0	22	91,7	82,27	17,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	21	91,3	75,14	12,48
	Asia (AS)	33	46,5	33	100,0	74,64	15,31
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	84,09	15,63
	Europe (EU)	23	67,6	18	78,3	67,67	12,07
	Asia (AS)	29	40,8	28	96,6	76,43	13,83
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	86,95	11,27
	Europe (EU)	18	52,9	14	77,8	66,21	17,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	75,36	15,80
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	83,81	17,97
	Europe (EU)	17	50,0	16	94,1	70,81	12,13
	Asia (AS)	21	29,6	20	95,2	75,65	15,80
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	85,50	16,93
	Europe (EU)	15	44,1	14	93,3	71,50	12,73
	Asia (AS)	20	28,2	20	100,0	76,30	15,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	85,00	15,02
	Europe (EU)	14	41,2	11	78,6	75,27	11,06
	Asia (AS)	19	26,8	19	100,0	72,95	16,95
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	81,38	20,06
	Europe (EU)	13	38,2	12	92,3	74,75	14,18
	Asia (AS)	16	22,5	16	100,0	75,00	15,39
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	84,00	15,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	73,00	15,23
	Asia (AS)	16	22,5	16	100,0	73,94	14,22
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	84,46	16,26
	Europe (EU)	9	26,5	9	100,0	75,22	15,83
	Asia (AS)	14	19,7	11	78,6	72,18	15,03
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	82,85	17,96
	Europe (EU)	9	26,5	6	66,7	77,33	9,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	73,77	15,47
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	81,40	20,67
	Europe (EU)	7	20,6	6	85,7	74,67	9,99
	Asia (AS)	11	15,5	10	90,9	73,50	10,92
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	83,40	21,53
	Europe (EU)	7	20,6	5	71,4	78,60	12,44
	Asia (AS)	11	15,5	10	90,9	66,10	19,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	79,56	22,50
	Europe (EU)	5	14,7	3	60,0	82,67	15,31
	Asia (AS)	7	9,9	6	85,7	74,67	12,13
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	83,38	14,86
	Europe (EU)	5	14,7	4	80,0	80,50	12,04
	Asia (AS)	7	9,9	6	85,7	72,00	15,32
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	81,71	15,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	79,00	12,73
	Asia (AS)	4	5,6	4	100,0	71,75	10,28
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	80,50	14,49
	Europe (EU)	4	11,8	2	50,0	84,50	13,44
	Asia (AS)	4	5,6	4	100,0	70,00	15,30
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	73,50	32,11
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	68,50	13,13
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	78,50	15,33
	Europe (EU)	2	5,9	1	50,0	95,00	-
	Asia (AS)	4	5,6	4	100,0	44,25	28,00
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	79,33	15,70
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	63,00	17,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	81,50	19,09
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	61,67	12,58
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	78,50	16,26
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	65,33	14,57
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	78,00	25,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	89,00	-
	Asia (AS)	3	4,2	2	66,7	45,00	7,07
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	73,00	-
	Europe (EU)	1	2,9	1	100,0	90,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	64,29	22,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	4	40,0	57,25	8,46
	Asia (AS)	34	47,9	22	64,7	57,05	19,40
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	73,53	16,23
	1	69	100,0	67	97,1	61,46	21,31
	2	15	100,0	15	100,0	45,80	15,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	55	93,2	74,91	19,08
	1	67	97,1	60	89,6	68,07	17,48
	2	10	66,7	10	100,0	60,20	27,14
Cycle 3 Day 1	0	57	93,4	48	84,2	76,75	15,11
	1	65	94,2	57	87,7	70,74	17,25
	2	9	60,0	9	100,0	63,67	15,35
Cycle 4 Day 1	0	57	93,4	49	86,0	75,37	17,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	72,28	13,60
	2	9	60,0	8	88,9	64,38	16,38
Cycle 5 Day 1	0	56	91,8	52	92,9	77,87	16,87
	1	62	89,9	58	93,5	73,98	13,27
	2	6	40,0	6	100,0	68,33	13,65
Cycle 6 Day 1	0	56	91,8	53	94,6	79,23	15,34
	1	59	85,5	52	88,1	72,52	15,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	4	66,7	68,75	7,09
Cycle 7 Day 1	0	54	88,5	51	94,4	78,67	16,59
	1	54	78,3	48	88,9	71,04	16,32
	2	5	33,3	5	100,0	75,20	11,19
Cycle 8 Day 1	0	52	85,2	48	92,3	79,10	15,95
	1	49	71,0	43	87,8	72,98	15,55
	2	5	33,3	5	100,0	70,00	14,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	79,06	14,09
	1	44	63,8	43	97,7	75,07	15,55
	2	4	26,7	4	100,0	73,75	13,00
Cycle 10 Day 1	0	46	75,4	46	100,0	76,85	14,29
	1	40	58,0	36	90,0	72,75	15,81
	2	3	20,0	3	100,0	75,00	5,00
Cycle 11 Day 1	0	43	70,5	40	93,0	78,40	14,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	33	97,1	74,85	16,67
	2	3	20,0	3	100,0	81,67	10,41
Cycle 12 Day 1	0	42	68,9	36	85,7	78,08	15,61
	1	31	44,9	30	96,8	75,63	15,27
	2	3	20,0	3	100,0	70,67	11,02
Cycle 13 Day 1	0	38	62,3	34	89,5	76,82	18,41
	1	27	39,1	26	96,3	77,96	14,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	85,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	77,41	17,17
	1	24	34,8	24	100,0	76,79	15,89
	2	1	6,7	1	100,0	86,00	-
Cycle 15 Day 1	0	33	54,1	30	90,9	79,10	16,31
	1	23	33,3	23	100,0	77,22	16,28
	2	1	6,7	1	100,0	88,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	77,24	18,36
	1	21	30,4	21	100,0	78,10	12,65
	2	1	6,7	1	100,0	88,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	78,30	19,18
	1	20	29,0	20	100,0	75,55	14,42
	2	1	6,7	1	100,0	87,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	77,74	17,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	76,65	12,66
	2	1	6,7	1	100,0	90,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	78,26	19,08
	1	15	21,7	13	86,7	77,23	12,44
	2	1	6,7	1	100,0	78,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	77,18	19,04
	1	15	21,7	14	93,3	79,36	12,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	77,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	77,50	19,65
	1	13	18,8	11	84,6	75,27	8,13
	2	1	6,7	1	100,0	84,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	79,83	20,37
	1	13	18,8	12	92,3	70,08	20,14
	2	1	6,7	1	100,0	89,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	78,89	22,02
	1	9	13,0	8	88,9	76,75	14,18
	2	1	6,7	1	100,0	88,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	81,78	13,35
	1	9	13,0	8	88,9	74,38	16,14
	2	1	6,7	1	100,0	90,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	81,00	13,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	75,86	14,42
Cycle 26 Day 1	0	8	13,1	6	75,0	83,17	10,36
	1	6	8,7	6	100,0	72,17	16,79
Cycle 27 Day 1	0	6	9,8	3	50,0	80,67	13,43
	1	5	7,2	5	100,0	65,20	26,70
Cycle 28 Day 1	0	5	8,2	4	80,0	81,50	16,22
	1	5	7,2	5	100,0	52,00	30,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	72,00	2,83
	1	5	7,2	5	100,0	69,20	21,67
Cycle 30 Day 1	0	3	4,9	1	33,3	68,00	-
	1	4	5,8	4	100,0	70,00	19,58
Cycle 31 Day 1	0	3	4,9	1	33,3	67,00	-
	1	4	5,8	4	100,0	71,50	17,14
Cycle 32 Day 1	0	3	4,9	2	66,7	74,50	20,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	62,00	29,87
Cycle 33 Day 1	0	2	3,3	2	100,0	81,50	12,02
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	67,29	19,69
	1	34	49,3	19	55,9	52,74	19,28
	2	7	46,7	3	42,9	54,00	5,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	63,95	22,21
	1	4	100,0	4	100,0	62,75	24,97
	2 or More	79	100,0	78	98,7	65,76	19,21
Cycle 2 Day 1	None	60	96,8	54	90,0	71,94	19,08
	1	3	75,0	2	66,7	84,00	8,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	68,88	19,85
Cycle 3 Day 1	None	59	95,2	51	86,4	73,69	17,84
	1	3	75,0	2	66,7	80,00	14,14
	2 or More	69	87,3	61	88,4	71,66	15,65
Cycle 4 Day 1	None	59	95,2	53	89,8	72,51	15,36
	1	3	75,0	2	66,7	83,00	9,90
	2 or More	66	83,5	60	90,9	73,18	15,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	55	94,8	77,64	13,36
	1	3	75,0	3	100,0	81,67	7,37
	2 or More	63	79,7	58	92,1	73,02	16,62
Cycle 6 Day 1	None	57	91,9	50	87,7	77,56	15,52
	1	3	75,0	3	100,0	84,67	10,12
	2 or More	61	77,2	56	91,8	73,45	15,58
Cycle 7 Day 1	None	52	83,9	48	92,3	76,75	15,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	85,00	8,66
	2 or More	58	73,4	53	91,4	72,81	17,31
Cycle 8 Day 1	None	50	80,6	45	90,0	77,20	15,06
	1	3	75,0	1	33,3	87,00	-
	2 or More	53	67,1	50	94,3	74,48	16,76
Cycle 9 Day 1	None	48	77,4	47	97,9	77,17	14,92
	1	1	25,0	1	100,0	90,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	76,67	14,72
Cycle 10 Day 1	None	43	69,4	41	95,3	76,32	14,22
	1	1	25,0	1	100,0	93,00	-
	2 or More	45	57,0	43	95,6	73,42	15,22
Cycle 11 Day 1	None	37	59,7	34	91,9	79,76	14,97
	1	1	25,0	1	100,0	90,00	-
	2 or More	42	53,2	41	97,6	74,37	15,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	80,41	13,74
	1	1	25,0	1	100,0	87,00	-
	2 or More	38	48,1	34	89,5	72,68	15,94
Cycle 13 Day 1	None	34	54,8	29	85,3	79,69	17,14
	1	1	25,0	1	100,0	96,00	-
	2 or More	31	39,2	31	100,0	74,74	15,74
Cycle 14 Day 1	None	31	50,0	29	93,5	79,72	15,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	91,00	-
	2 or More	28	35,4	27	96,4	74,19	17,52
Cycle 15 Day 1	None	30	48,4	28	93,3	79,93	16,90
	1	1	25,0	1	100,0	89,00	-
	2 or More	26	32,9	25	96,2	76,40	15,41
Cycle 16 Day 1	None	25	40,3	23	92,0	80,17	16,96
	1	1	25,0	1	100,0	90,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	75,00	14,49
Cycle 17 Day 1	None	23	37,1	22	95,7	80,95	14,33
	1	1	25,0	1	100,0	90,00	-
	2 or More	21	26,6	21	100,0	72,76	18,74
Cycle 18 Day 1	None	20	32,3	18	90,0	82,06	12,67
	1	1	25,0	1	100,0	92,00	-
	2 or More	20	25,3	18	90,0	72,28	16,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	83,53	14,41
	1	1	25,0	1	100,0	90,00	-
	2 or More	18	22,8	15	83,3	70,60	16,05
Cycle 20 Day 1	None	17	27,4	16	94,1	82,44	14,76
	1	1	25,0	1	100,0	80,00	-
	2 or More	18	22,8	15	83,3	73,40	16,56
Cycle 21 Day 1	None	15	24,2	13	86,7	82,54	11,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	71,08	16,59
Cycle 22 Day 1	None	15	24,2	13	86,7	85,08	12,00
	2 or More	14	17,7	12	85,7	65,17	22,53
Cycle 23 Day 1	None	10	16,1	9	90,0	83,89	14,70
	2 or More	11	13,9	9	81,8	73,00	19,81
Cycle 24 Day 1	None	10	16,1	10	100,0	83,80	14,20
	2 or More	10	12,7	8	80,0	72,88	13,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	82,13	14,46
	2 or More	6	7,6	5	83,3	72,00	10,10
Cycle 26 Day 1	None	8	12,9	8	100,0	83,50	12,48
	2 or More	6	7,6	4	66,7	66,00	11,58
Cycle 27 Day 1	None	7	11,3	6	85,7	74,83	25,01
	2 or More	4	5,1	2	50,0	59,50	13,44
Cycle 28 Day 1	None	7	11,3	7	100,0	75,29	19,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	29,50	27,58
Cycle 29 Day 1	None	6	9,7	5	83,3	69,60	20,33
	2 or More	3	3,8	2	66,7	71,00	15,56
Cycle 30 Day 1	None	4	6,5	3	75,0	74,33	18,34
	2 or More	3	3,8	2	66,7	62,50	17,68
Cycle 31 Day 1	None	4	6,5	3	75,0	75,67	12,50
	2 or More	3	3,8	2	66,7	63,00	19,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	65,33	28,38
	2 or More	2	2,5	2	100,0	69,50	27,58
Cycle 33 Day 1	None	1	1,6	1	100,0	73,00	-
	2 or More	1	1,3	1	100,0	90,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	18	81,8	60,67	21,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	70,00	-
	2 or More	39	49,4	24	61,5	58,96	19,78
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	63,95	22,21
	Previously Treated	83	100,0	82	98,8	65,61	19,35
Cycle 2 Day 1	Naïve	60	96,8	54	90,0	71,94	19,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	69,31	19,75
Cycle 3 Day 1	Naïve	59	95,2	51	86,4	73,69	17,84
	Previously Treated	72	86,7	63	87,5	71,92	15,57
Cycle 4 Day 1	Naïve	59	95,2	53	89,8	72,51	15,36
	Previously Treated	69	83,1	62	89,9	73,50	15,86
Cycle 5 Day 1	Naïve	58	93,5	55	94,8	77,64	13,36
	Previously Treated	66	79,5	61	92,4	73,44	16,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	50	87,7	77,56	15,52
	Previously Treated	64	77,1	59	92,2	74,02	15,49
Cycle 7 Day 1	Naïve	52	83,9	48	92,3	76,75	15,83
	Previously Treated	61	73,5	56	91,8	73,46	17,14
Cycle 8 Day 1	Naïve	50	80,6	45	90,0	77,20	15,06
	Previously Treated	56	67,5	51	91,1	74,73	16,68
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	77,17	14,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	76,94	14,69
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	76,32	14,22
	Previously Treated	46	55,4	44	95,7	73,86	15,33
Cycle 11 Day 1	Naïve	37	59,7	34	91,9	79,76	14,97
	Previously Treated	43	51,8	42	97,7	74,74	15,44
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	80,41	13,74
	Previously Treated	39	47,0	35	89,7	73,09	15,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	29	85,3	79,69	17,14
	Previously Treated	32	38,6	32	100,0	75,41	15,93
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	79,72	15,15
	Previously Treated	29	34,9	28	96,6	74,79	17,48
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	79,93	16,90
	Previously Treated	27	32,5	26	96,3	76,88	15,30
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	80,17	16,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	75,63	14,50
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	80,95	14,33
	Previously Treated	22	26,5	22	100,0	73,55	18,66
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	82,06	12,67
	Previously Treated	21	25,3	19	90,5	73,32	16,64
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	83,53	14,41
	Previously Treated	19	22,9	16	84,2	71,81	16,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	82,44	14,76
	Previously Treated	19	22,9	16	84,2	73,81	16,08
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	82,54	11,58
	Previously Treated	14	16,9	13	92,9	71,08	16,59
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	85,08	12,00
	Previously Treated	14	16,9	12	85,7	65,17	22,53
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	83,89	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	73,00	19,81
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	83,80	14,20
	Previously Treated	10	12,0	8	80,0	72,88	13,45
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	82,13	14,46
	Previously Treated	6	7,2	5	83,3	72,00	10,10
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	83,50	12,48
	Previously Treated	6	7,2	4	66,7	66,00	11,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	74,83	25,01
	Previously Treated	4	4,8	2	50,0	59,50	13,44
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	75,29	19,95
	Previously Treated	3	3,6	2	66,7	29,50	27,58
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	69,60	20,33
	Previously Treated	3	3,6	2	66,7	71,00	15,56
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	74,33	18,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	62,50	17,68
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	75,67	12,50
	Previously Treated	3	3,6	2	66,7	63,00	19,80
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	65,33	28,38
	Previously Treated	2	2,4	2	100,0	69,50	27,58
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	73,00	-
	Previously Treated	1	1,2	1	100,0	90,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	18	81,8	60,67	21,13
	Previously Treated	42	50,6	25	59,5	59,40	19,49
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	63,37	22,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	66,63	18,53
Cycle 2 Day 1	Local	71	94,7	68	95,8	71,90	18,76
	Central	65	92,9	57	87,7	68,72	20,22
Cycle 3 Day 1	Local	67	89,3	59	88,1	73,71	15,59
	Central	64	91,4	55	85,9	71,64	17,64
Cycle 4 Day 1	Local	65	86,7	58	89,2	73,52	16,92
	Central	63	90,0	57	90,5	72,56	14,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	58	92,1	75,83	16,47
	Central	61	87,1	58	95,1	75,03	13,72
Cycle 6 Day 1	Local	63	84,0	61	96,8	77,36	16,52
	Central	58	82,9	48	82,8	73,46	14,04
Cycle 7 Day 1	Local	61	81,3	58	95,1	77,76	16,29
	Central	52	74,3	46	88,5	71,48	16,38
Cycle 8 Day 1	Local	57	76,0	54	94,7	78,72	15,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	72,24	15,24
Cycle 9 Day 1	Local	54	72,0	53	98,1	78,49	14,41
	Central	44	62,9	43	97,7	75,28	15,09
Cycle 10 Day 1	Local	48	64,0	46	95,8	75,09	15,97
	Central	41	58,6	39	95,1	75,00	13,42
Cycle 11 Day 1	Local	40	53,3	38	95,0	77,92	16,51
	Central	40	57,1	38	95,0	76,05	14,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	82,55	13,49
	Central	40	57,1	36	90,0	71,33	14,89
Cycle 13 Day 1	Local	30	40,0	29	96,7	82,86	14,01
	Central	36	51,4	32	88,9	72,53	17,28
Cycle 14 Day 1	Local	27	36,0	27	100,0	83,07	14,51
	Central	33	47,1	30	90,9	72,10	16,44
Cycle 15 Day 1	Local	26	34,7	25	96,2	83,84	16,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	73,83	14,79
Cycle 16 Day 1	Local	24	32,0	24	100,0	84,08	13,01
	Central	26	37,1	23	88,5	71,35	15,96
Cycle 17 Day 1	Local	22	29,3	22	100,0	82,86	14,88
	Central	23	32,9	22	95,7	71,64	17,16
Cycle 18 Day 1	Local	20	26,7	19	95,0	84,16	12,69
	Central	21	30,0	18	85,7	70,61	15,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	81,82	14,26
	Central	17	24,3	16	94,1	73,63	17,53
Cycle 20 Day 1	Local	19	25,3	17	89,5	85,82	9,66
	Central	17	24,3	15	88,2	69,40	17,11
Cycle 21 Day 1	Local	14	18,7	12	85,7	84,42	10,04
	Central	15	21,4	14	93,3	70,29	16,09
Cycle 22 Day 1	Local	14	18,7	12	85,7	81,17	22,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	70,31	16,92
Cycle 23 Day 1	Local	11	14,7	10	90,9	87,90	7,56
	Central	10	14,3	8	80,0	66,63	20,27
Cycle 24 Day 1	Local	11	14,7	10	90,9	85,60	10,98
	Central	9	12,9	8	88,9	70,63	14,78
Cycle 25 Day 1	Local	7	9,3	7	100,0	85,43	11,91
	Central	8	11,4	6	75,0	69,83	10,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	84,83	9,95
	Central	8	11,4	6	75,0	70,50	15,48
Cycle 27 Day 1	Local	4	5,3	4	100,0	86,25	12,97
	Central	7	10,0	4	57,1	55,75	20,77
Cycle 28 Day 1	Local	4	5,3	4	100,0	70,50	25,09
	Central	6	8,6	5	83,3	60,80	32,83
Cycle 29 Day 1	Local	3	4,0	3	100,0	70,33	28,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	69,75	9,18
Cycle 30 Day 1	Local	3	4,0	3	100,0	74,33	18,34
	Central	4	5,7	2	50,0	62,50	17,68
Cycle 31 Day 1	Local	3	4,0	3	100,0	75,67	12,50
	Central	4	5,7	2	50,0	63,00	19,80
Cycle 32 Day 1	Local	3	4,0	3	100,0	65,33	28,38
	Central	3	4,3	2	66,7	69,50	27,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	73,00	-
	Central	1	1,4	1	100,0	90,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	61,46	20,16
	Central	32	45,7	19	59,4	58,00	20,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	65,87	19,92
	No	10	100,0	10	100,0	52,20	25,39
Cycle 2 Day 1	Yes	129	95,6	118	91,5	71,27	19,01
	No	7	70,0	7	100,0	56,57	22,71
Cycle 3 Day 1	Yes	124	91,9	108	87,1	73,42	16,49
	No	7	70,0	6	85,7	60,00	13,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	108	89,3	74,27	14,81
	No	7	70,0	7	100,0	54,14	15,76
Cycle 5 Day 1	Yes	117	86,7	110	94,0	76,15	14,68
	No	7	70,0	6	85,7	62,17	17,90
Cycle 6 Day 1	Yes	114	84,4	102	89,5	76,48	14,90
	No	7	70,0	7	100,0	63,43	20,48
Cycle 7 Day 1	Yes	106	78,5	97	91,5	76,05	16,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	60,14	16,41
Cycle 8 Day 1	Yes	100	74,1	90	90,0	76,67	15,79
	No	6	60,0	6	100,0	64,17	13,93
Cycle 9 Day 1	Yes	92	68,1	90	97,8	77,38	14,85
	No	6	60,0	6	100,0	72,17	12,80
Cycle 10 Day 1	Yes	83	61,5	79	95,2	75,16	15,09
	No	6	60,0	6	100,0	73,50	10,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	72	94,7	77,17	15,65
	No	4	40,0	4	100,0	73,75	8,54
Cycle 12 Day 1	Yes	72	53,3	65	90,3	76,95	15,43
	No	4	40,0	4	100,0	72,50	11,90
Cycle 13 Day 1	Yes	64	47,4	59	92,2	77,86	16,61
	No	2	20,0	2	100,0	65,00	7,07
Cycle 14 Day 1	Yes	58	43,0	55	94,8	77,47	16,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	72,50	10,61
Cycle 15 Day 1	Yes	55	40,7	52	94,5	79,27	15,75
	No	2	20,0	2	100,0	57,50	10,61
Cycle 16 Day 1	Yes	48	35,6	45	93,8	78,64	15,62
	No	2	20,0	2	100,0	60,00	0,00
Cycle 17 Day 1	Yes	43	31,9	42	97,7	78,07	16,82
	No	2	20,0	2	100,0	60,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	78,00	15,19
	No	2	20,0	2	100,0	70,00	21,21
Cycle 19 Day 1	Yes	34	25,2	32	94,1	78,09	16,41
	No	2	20,0	1	50,0	70,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	78,67	15,97
	No	2	20,0	2	100,0	70,00	14,14
Cycle 21 Day 1	Yes	27	20,0	24	88,9	78,00	15,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	62,50	10,61
Cycle 22 Day 1	Yes	27	20,0	23	85,2	76,65	20,67
	No	2	20,0	2	100,0	62,50	3,54
Cycle 23 Day 1	Yes	20	14,8	17	85,0	78,06	18,30
	No	1	10,0	1	100,0	85,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	78,59	14,94
	No	1	10,0	1	100,0	85,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	77,67	13,94
	No	1	10,0	1	100,0	85,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	77,00	15,00
	No	1	10,0	1	100,0	85,00	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	69,71	24,38
	No	1	10,0	1	100,0	80,00	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	68,25	28,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	40,00	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	75,00	13,02
	No	1	10,0	1	100,0	40,00	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	72,00	18,60
	No	1	10,0	1	100,0	60,00	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	70,75	17,29
	No	1	10,0	1	100,0	70,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	73,75	22,22
	No	1	10,0	1	100,0	40,00	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	81,50	12,02
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	42	67,7	60,74	19,47
	No	2	20,0	1	50,0	26,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	60,82	19,43
	No	134	100,0	131	97,8	65,25	20,67
Cycle 2 Day 1	Yes	7	63,6	7	100,0	73,43	21,59
	No	129	96,3	118	91,5	70,27	19,38
Cycle 3 Day 1	Yes	7	63,6	6	85,7	76,00	14,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	108	87,1	72,53	16,72
Cycle 4 Day 1	Yes	7	63,6	7	100,0	79,86	16,32
	No	121	90,3	108	89,3	72,60	15,49
Cycle 5 Day 1	Yes	7	63,6	7	100,0	70,57	17,00
	No	117	87,3	109	93,2	75,74	15,00
Cycle 6 Day 1	Yes	7	63,6	7	100,0	74,43	22,71
	No	114	85,1	102	89,5	75,73	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	73,14	21,63
	No	106	79,1	97	91,5	75,11	16,26
Cycle 8 Day 1	Yes	7	63,6	7	100,0	75,57	13,39
	No	99	73,9	89	89,9	75,91	16,15
Cycle 9 Day 1	Yes	6	54,5	6	100,0	72,00	17,40
	No	92	68,7	90	97,8	77,39	14,58
Cycle 10 Day 1	Yes	6	54,5	6	100,0	69,33	25,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	79	95,2	75,48	13,83
Cycle 11 Day 1	Yes	6	54,5	6	100,0	68,67	25,37
	No	74	55,2	70	94,6	77,70	14,23
Cycle 12 Day 1	Yes	6	54,5	6	100,0	74,50	17,92
	No	70	52,2	63	90,0	76,90	15,08
Cycle 13 Day 1	Yes	5	45,5	5	100,0	74,60	21,29
	No	61	45,5	56	91,8	77,70	16,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	76,40	18,51
	No	55	41,0	52	94,5	77,38	16,36
Cycle 15 Day 1	Yes	4	36,4	4	100,0	77,00	27,14
	No	53	39,6	50	94,3	78,58	15,29
Cycle 16 Day 1	Yes	3	27,3	3	100,0	77,00	32,91
	No	47	35,1	44	93,6	77,91	14,66
Cycle 17 Day 1	Yes	3	27,3	3	100,0	89,33	10,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	76,37	16,97
Cycle 18 Day 1	Yes	3	27,3	3	100,0	88,00	10,44
	No	38	28,4	34	89,5	76,65	15,42
Cycle 19 Day 1	Yes	3	27,3	3	100,0	88,33	10,79
	No	33	24,6	30	90,9	76,80	16,42
Cycle 20 Day 1	Yes	3	27,3	3	100,0	86,67	15,31
	No	33	24,6	29	87,9	77,24	15,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	75,50	13,44
	No	27	20,1	24	88,9	76,92	15,58
Cycle 22 Day 1	Yes	2	18,2	2	100,0	83,50	19,09
	No	27	20,1	23	85,2	74,83	20,54
Cycle 23 Day 1	Yes	2	18,2	2	100,0	78,00	25,46
	No	19	14,2	16	84,2	78,50	17,80
Cycle 24 Day 1	Yes	2	18,2	2	100,0	77,50	24,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	79,13	14,13
Cycle 25 Day 1	Yes	2	18,2	2	100,0	79,50	13,44
	No	13	9,7	11	84,6	78,00	14,15
Cycle 26 Day 1	Yes	1	9,1	1	100,0	76,00	-
	No	13	9,7	11	84,6	77,82	15,18
Cycle 27 Day 1	Yes	1	9,1	1	100,0	75,00	-
	No	10	7,5	7	70,0	70,43	24,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	78,00	-
	No	9	6,7	8	88,9	63,50	29,81
Cycle 29 Day 1	Yes	1	9,1	1	100,0	70,00	-
	No	8	6,0	6	75,0	70,00	19,48
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	69,60	16,98
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	70,60	14,98
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	67,00	24,45
Cycle 33 Day 1	No	2	1,5	2	100,0	81,50	12,02
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	41,67	16,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	40	65,6	61,30	19,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_VAS_SG.xls
24JUN2020 21:16

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_VAS.p
10SEP2019 21:25

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_VAS.
28NOV2019 14:03

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EQ-5D VAS
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.:
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_VAS.
25JUN2020 0:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	19	51,4	18	48,6	1,87	0,95	4,63	11,93	4,37	17,54
Sex	Male	14	37,8	8	57,1	6	42,9	4,37	0,95	11,93	11,93	4,37	NE
	Female	23	62,2	11	47,8	12	52,2	1,02	0,95	7,36	7,36	1,05	NE
Age	18-64	29	78,4	14	48,3	15	51,7	0,99	0,95	11,93	15,61	1,87	NE
	65-74	8	21,6	5	62,5	3	37,5	3,91	3,75	4,63	4,50	3,91	7,36
Race	White	20	54,1	7	35,0	13	65,0	4,63	1,05	NE	17,54	7,36	NE
	Other	17	45,9	12	70,6	5	29,4	0,95	0,95	3,91	3,91	0,95	11,93
Region	America (AM)	12	32,4	6	50,0	6	50,0	1,87	0,92	17,54	17,54	1,87	NE
	Europe (EU)	10	27,0	3	30,0	7	70,0	9,64	1,05	NE	NE	7,36	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_VAS7_SG.xls
29OCT2019 13:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	10	66,7	5	33,3	0,95	0,95	4,63	4,63	0,95	15,61
ECOG Performance Status	0	15	40,5	8	53,3	7	46,7	3,91	1,87	17,54	17,54	4,63	NE
	1	17	45,9	9	52,9	8	47,1	0,95	0,92	11,93	11,93	0,95	NE
	2	5	13,5	2	40,0	3	60,0	0,95	0,95	NE	1,05	0,95	NE
Number of Prior Anticancer Therapies	None	14	37,8	6	42,9	8	57,1	3,75	0,95	NE	NE	3,75	NE
	1	2	5,4	1	50,0	1	50,0	17,54	NE	NE	17,54	NE	NE
	2 or More	21	56,8	12	57,1	9	42,9	1,05	0,95	4,63	6,41	1,87	15,61

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_VAS7_SG.xls
29OCT2019 13:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	6	42,9	8	57,1	3,75	0,95	NE	NE	3,75	NE
	Previously Treated	23	62,2	13	56,5	10	43,5	1,05	0,95	6,41	6,41	1,87	17,54
Molecular Testing Results	Local	12	32,4	5	41,7	7	58,3	0,99	0,95	NE	NE	0,99	NE
	Central	25	67,6	14	56,0	11	44,0	1,87	0,95	6,41	6,41	3,91	17,54

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_VAS7_SG.xls
29OCT2019 13:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	18	51,4	17	48,6	3,75	0,95	6,41	11,93	4,37	17,54
	No	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_VAS7_SG.xls
29OCT2019 13:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	0,85	0,85	NE	NE	0,85	NE
	No	33	89,2	18	54,5	15	45,5	1,87	0,95	4,63	7,36	3,91	17,54

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_VAS7_SG.xls
29OCT2019 13:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	41	52,6	37	47,4	2,69	0,99	4,57	11,93	4,63	20,27
Sex	Male	29	37,2	16	55,2	13	44,8	4,57	0,95	6,41	11,93	4,63	22,11
	Female	49	62,8	25	51,0	24	49,0	1,87	0,95	3,78	7,36	2,79	NE
Age	18-64	62	79,5	30	48,4	32	51,6	2,14	0,99	5,55	15,61	5,55	NE
	65-74	14	17,9	9	64,3	5	35,7	2,79	0,92	4,37	4,37	2,79	5,55
	>=75	2	2,6	2	100,0			2,79	2,79	5,55	4,17	2,79	5,55
Race	White	35	44,9	16	45,7	19	54,3	4,57	2,69	14,72	20,27	7,36	NE
	Other	43	55,1	25	58,1	18	41,9	0,99	0,95	3,75	4,63	2,79	15,61
Region	America (AM)	22	28,2	13	59,1	9	40,9	2,91	0,99	14,72	14,72	3,75	22,11

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_VAS7_SG.xls
28NOV2019 10:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	7	41,2	10	58,8	2,73	1,05	NE	NE	5,55	NE
	Asia (AS)	39	50,0	21	53,8	18	46,2	1,56	0,95	4,63	5,55	4,37	NE
ECOG Performance Status	0	30	38,5	19	63,3	11	36,7	3,75	0,99	6,41	13,96	4,63	22,11
	1	38	48,7	19	50,0	19	50,0	2,73	0,95	4,63	11,93	4,37	NE
	2	10	12,8	3	30,0	7	70,0	0,95	0,92	NE	1,05	0,95	NE
Number of Prior Anticancer Therapies	None	31	39,7	18	58,1	13	41,9	2,79	0,99	4,63	11,93	3,78	22,11
	1	3	3,8	1	33,3	2	66,7	17,54	NE	NE	17,54	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_VAS7_SG.xls
28NOV2019 10:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	22	50,0	22	50,0	1,05	0,95	4,63	6,41	4,37	NE
Prior Treatment	Naïve	31	39,7	18	58,1	13	41,9	2,79	0,99	4,63	11,93	3,78	22,11
	Previously Treated	47	60,3	23	48,9	24	51,1	1,87	0,95	5,55	7,36	4,63	NE
Molecular Testing Results	Local	35	44,9	16	45,7	19	54,3	2,14	0,95	7,36	20,27	3,75	NE
	Central	43	55,1	25	58,1	18	41,9	2,73	0,95	4,63	5,55	4,63	15,61

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_VAS7_SG.xls
28NOV2019 10:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	39	52,7	35	47,3	2,79	1,05	4,63	11,93	4,63	20,27
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	0,95	0,94	0,92	0,95
Investigator Measurable CNS Disease	Yes	8	10,3	4	50,0	4	50,0	3,78	0,85	13,96	9,26	3,78	NE
	No	70	89,7	37	52,9	33	47,1	2,69	0,99	4,63	11,93	4,63	22,11

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_VAS7_SG.xls
28NOV2019 10:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_VAS7_SG.xls
28NOV2019 10:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	69	47,6	76	52,4	2,79	1,87	3,91	11,93	6,41	17,54
Sex	Male	52	35,9	30	57,7	22	42,3	2,89	1,02	4,63	6,54	4,63	20,27
	Female	93	64,1	39	41,9	54	58,1	2,73	0,99	4,63	14,72	7,36	NE
Age	18-64	109	75,2	49	45,0	60	55,0	2,73	1,05	5,55	14,82	9,23	22,11
	65-74	29	20,0	16	55,2	13	44,8	2,79	0,99	3,91	4,37	2,89	7,36
	>=75	7	4,8	4	57,1	3	42,9	2,79	0,95	NE	5,55	2,79	NE
Race	White	60	41,4	25	41,7	35	58,3	4,37	2,69	13,96	17,54	13,96	NE
	Other	85	58,6	44	51,8	41	48,2	1,87	0,95	3,75	7,46	3,91	15,61
Region	America (AM)	40	27,6	21	52,5	19	47,5	2,76	1,87	4,63	14,82	3,78	22,11

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_VAS7_SG.xls
24JUN2020 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	12	35,3	22	64,7	3,71	2,69	NE	NE	6,54	NE
	Asia (AS)	71	49,0	36	50,7	35	49,3	2,14	0,95	4,63	7,46	4,63	15,61
ECOG Performance Status	0	61	42,1	35	57,4	26	42,6	2,79	1,02	4,63	8,41	4,63	20,27
	1	69	47,6	31	44,9	38	55,1	2,79	0,99	4,63	11,93	4,63	NE
	2	15	10,3	3	20,0	12	80,0	1,05	0,92	NE	NE	1,05	NE
Number of Prior Anticancer Therapies	None	62	42,8	29	46,8	33	53,2	3,68	2,69	4,63	13,96	5,09	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_VAS7_SG.xls
24JUN2020 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	1	25,0	3	75,0	17,54	NE	NE	17,54	NE	NE
	2 or More	79	54,5	39	49,4	40	50,6	1,81	0,95	4,37	8,41	4,63	15,61
Prior Treatment	Naïve	62	42,8	29	46,8	33	53,2	3,68	2,69	4,63	13,96	5,09	NE
	Previously Treated	83	57,2	40	48,2	43	51,8	1,81	0,95	4,63	9,23	5,55	17,54
Molecular Testing Results	Local	75	51,7	30	40,0	45	60,0	2,79	0,99	9,23	20,27	9,23	NE
	Central	70	48,3	39	55,7	31	44,3	2,79	1,05	4,63	6,41	4,63	13,96

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_VAS7_SG.xls
24JUN2020 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	65	48,1	70	51,9	2,79	1,87	4,57	11,93	6,41	17,54
	No	10	6,9	4	40,0	6	60,0	0,95	0,92	NE	2,76	0,95	NE
Investigator Measurable CNS Disease	Yes	11	7,6	5	45,5	6	54,5	2,37	0,85	13,96	9,26	0,95	NE
	No	134	92,4	64	47,8	70	52,2	2,79	1,87	4,37	11,93	6,41	20,27

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_VAS7_SG.xls
24JUN2020 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 7

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_VAS7_SG.xls
24JUN2020 20:21

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EQ-5D VAS, MID 7
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	24	22	18	15	14	11	7	3	1	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	4	4	5	6	7	9	13	16	17	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_VAS7_SG1.pdf
29OCT2019 14:45

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EQ-5D VAS, MID 7
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	152	92	68	44	26	20	13	9	3	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	16	25	44	59	62	67	70	75	77	NE	NE	NE

Clinical cut-off: 31OCT2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_VAS7_SG1.pdf
29OCT2019 14:49

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EQ-5D VAS, MID 7
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	91	68	44	26	20	13	9	3	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	15	23	42	57	60	65	68	73	75	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_VAS7_SG1.pdf
25JUN2020 0:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	17	45,9	20	54,1	1,87	0,95	7,36	15,61	5,55	17,54
Sex	Male	14	37,8	6	42,9	8	57,1	6,41	0,95	17,54	17,54	6,41	NE
	Female	23	62,2	11	47,8	12	52,2	1,02	0,95	7,36	7,36	1,05	NE
Age	18-64	29	78,4	14	48,3	15	51,7	0,99	0,95	11,93	15,61	1,87	NE
	65-74	8	21,6	3	37,5	5	62,5	5,55	3,91	NE	7,36	5,55	NE
Race	White	20	54,1	6	30,0	14	70,0	7,36	1,05	NE	17,54	17,54	NE
	Other	17	45,9	11	64,7	6	35,3	0,95	0,95	5,55	5,55	0,95	15,61
Region	America (AM)	12	32,4	5	41,7	7	58,3	1,87	0,92	NE	17,54	1,87	NE
	Europe (EU)	10	27,0	3	30,0	7	70,0	9,64	1,05	NE	NE	7,36	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_VAS10_SG.xls
29OCT2019 13:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	9	60,0	6	40,0	0,95	0,95	5,55	5,55	0,95	15,61
ECOG Performance Status	0	15	40,5	7	46,7	8	53,3	5,55	1,87	17,54	17,54	6,41	NE
	1	17	45,9	8	47,1	9	52,9	0,95	0,92	15,61	11,93	0,95	NE
	2	5	13,5	2	40,0	3	60,0	0,95	0,95	NE	1,05	0,95	NE
Number of Prior Anticancer Therapies	None	14	37,8	5	35,7	9	64,3	3,91	0,95	NE	NE	3,91	NE
	1	2	5,4	1	50,0	1	50,0	17,54	NE	NE	17,54	NE	NE
	2 or More	21	56,8	11	52,4	10	47,6	1,05	0,95	6,41	6,41	1,87	15,61

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_VAS10_SG.xls
29OCT2019 13:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	5	35,7	9	64,3	3,91	0,95	NE	NE	3,91	NE
	Previously Treated	23	62,2	12	52,2	11	47,8	1,05	0,95	6,41	7,36	1,87	17,54
Molecular Testing Results	Local	12	32,4	4	33,3	8	66,7	0,99	0,95	NE	NE	0,99	NE
	Central	25	67,6	13	52,0	12	48,0	1,87	0,95	6,41	11,93	3,91	17,54

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_VAS10_SG.xls
29OCT2019 13:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	16	45,7	19	54,3	3,91	0,95	11,93	15,61	5,55	NE
	No	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_VAS10_SG.xls
29OCT2019 13:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	0,85	0,85	NE	NE	0,85	NE
	No	33	89,2	16	48,5	17	51,5	1,87	0,95	7,36	15,61	4,63	17,54

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_VAS10_SG.xls
29OCT2019 13:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	36	46,2	42	53,8	2,79	0,99	5,55	16,56	6,41	NE
Sex	Male	29	37,2	13	44,8	16	55,2	5,55	1,87	11,93	17,54	6,41	NE
	Female	49	62,8	23	46,9	26	53,1	1,87	0,95	5,55	15,61	3,91	NE
Age	18-64	62	79,5	27	43,5	35	56,5	2,14	0,99	11,93	17,54	11,93	NE
	65-74	14	17,9	7	50,0	7	50,0	3,91	0,92	8,28	7,36	3,91	NE
	>=75	2	2,6	2	100,0			2,79	2,79	5,55	4,17	2,79	5,55
Race	White	35	44,9	12	34,3	23	65,7	7,36	4,57	24,87	24,87	16,56	NE
	Other	43	55,1	24	55,8	19	44,2	0,99	0,95	3,91	5,55	2,79	16,56
Region	America (AM)	22	28,2	11	50,0	11	50,0	2,92	0,99	17,54	17,54	3,78	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_VAS10_SG.xls
28NOV2019 10:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	5	29,4	12	70,6	7,36	1,87	NE	NE	7,36	NE
	Asia (AS)	39	50,0	20	51,3	19	48,7	1,56	0,95	5,55	8,28	4,63	NE
ECOG Performance Status	0	30	38,5	16	53,3	14	46,7	5,55	0,99	13,96	16,56	6,41	NE
	1	38	48,7	17	44,7	21	55,3	2,79	0,95	11,93	15,61	4,63	NE
	2	10	12,8	3	30,0	7	70,0	0,95	0,92	NE	1,05	0,95	NE
Number of Prior Anticancer Therapies	None	31	39,7	14	45,2	17	54,8	3,91	0,99	13,96	24,87	4,63	NE
	1	3	3,8	1	33,3	2	66,7	17,54	NE	NE	17,54	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_VAS10_SG.xls
28NOV2019 10:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	21	47,7	23	52,3	1,87	0,95	6,41	8,28	5,55	NE
Prior Treatment	Naïve	31	39,7	14	45,2	17	54,8	3,91	0,99	13,96	24,87	4,63	NE
	Previously Treated	47	60,3	22	46,8	25	53,2	1,87	0,95	6,41	15,61	5,55	NE
Molecular Testing Results	Local	35	44,9	14	40,0	21	60,0	2,14	0,95	16,56	24,87	4,57	NE
	Central	43	55,1	22	51,2	21	48,8	3,91	1,05	5,55	11,93	5,55	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_VAS10_SG.xls
28NOV2019 10:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	34	45,9	40	54,1	3,91	1,87	6,41	16,56	7,36	NE
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	0,95	0,94	0,92	0,95
Investigator Measurable CNS Disease	Yes	8	10,3	4	50,0	4	50,0	3,78	0,85	13,96	9,26	3,78	NE
	No	70	89,7	32	45,7	38	54,3	2,79	0,99	6,41	16,56	6,41	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_VAS10_SG.xls
28NOV2019 10:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_VAS10_SG.xls
28NOV2019 10:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	61	42,1	84	57,9	2,86	1,87	5,09	16,56	8,41	NE
Sex	Male	52	35,9	27	51,9	25	48,1	3,68	1,87	5,55	8,41	5,55	24,87
	Female	93	64,1	34	36,6	59	63,4	2,79	0,99	7,46	16,56	13,96	NE
Age	18-64	109	75,2	43	39,4	66	60,6	2,86	1,81	7,46	17,54	11,93	NE
	65-74	29	20,0	14	48,3	15	51,7	3,71	0,99	5,55	7,36	3,91	NE
	>=75	7	4,8	4	57,1	3	42,9	2,79	0,95	NE	5,55	2,79	NE
Race	White	60	41,4	20	33,3	40	66,7	5,55	2,89	17,54	24,87	16,56	NE
	Other	85	58,6	41	48,2	44	51,8	2,07	0,95	3,91	8,41	5,09	16,56
Region	America (AM)	40	27,6	17	42,5	23	57,5	2,79	1,87	16,56	17,54	4,57	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_VAS10_SG.xls
24JUN2020 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	10	29,4	24	70,6	6,54	2,79	NE	NE	11,93	NE
	Asia (AS)	71	49,0	34	47,9	37	52,1	2,14	0,95	5,09	8,41	5,55	16,56
ECOG Performance Status	0	61	42,1	32	52,5	29	47,5	2,86	1,87	5,55	11,10	5,55	24,87
	1	69	47,6	26	37,7	43	62,3	3,71	0,99	11,93	16,56	11,93	NE
	2	15	10,3	3	20,0	12	80,0	1,05	0,92	NE	NE	1,05	NE
Number of Prior Anticancer Therapies	None	62	42,8	24	38,7	38	61,3	3,91	2,79	11,93	24,87	11,93	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_VAS10_SG.xls
24JUN2020 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	1	25,0	3	75,0	17,54	NE	NE	17,54	NE	NE
	2 or More	79	54,5	36	45,6	43	54,4	1,87	0,99	5,55	11,10	5,55	NE
Prior Treatment	Naïve	62	42,8	24	38,7	38	61,3	3,91	2,79	11,93	24,87	11,93	NE
	Previously Treated	83	57,2	37	44,6	46	55,4	1,87	0,99	5,55	11,10	6,41	17,54
Molecular Testing Results	Local	75	51,7	26	34,7	49	65,3	2,79	0,99	16,56	24,87	16,56	NE
	Central	70	48,3	35	50,0	35	50,0	3,68	1,87	5,55	8,28	5,55	17,54

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_VAS10_SG.xls
24JUN2020 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	57	42,2	78	57,8	3,68	1,87	5,55	16,56	8,41	NE
	No	10	6,9	4	40,0	6	60,0	0,95	0,92	NE	2,79	0,95	NE
Investigator Measurable CNS Disease	Yes	11	7,6	5	45,5	6	54,5	2,37	0,85	13,96	9,26	0,95	NE
	No	134	92,4	56	41,8	78	58,2	2,86	1,87	5,55	16,56	8,41	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_VAS10_SG.xls
24JUN2020 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_VAS10_SG.xls
24JUN2020 20:19

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	24	23	19	16	15	12	7	3	1	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	4	4	6	7	8	10	15	18	19	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_VAS10_SG1.pdf
29OCT2019 14:06

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	152	97	73	48	30	24	15	10	4	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	16	28	47	63	68	73	78	84	86	NE	NE	NE

Clinical cut-off: 31OCT2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_VAS10_SG1.pdf
29OCT2019 14:39

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EQ-5D VAS, MID 10
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	95	73	48	30	24	15	10	4	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	15	25	44	60	65	70	75	81	83	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_VAS10_SG1.pdf
24JUN2020 23:54

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	33,33	33,83
Cycle 2 Day 1	All	33	89,2	29	87,9	12,64	22,56
Cycle 3 Day 1	All	32	86,5	30	93,8	10,00	23,41
Cycle 4 Day 1	All	32	86,5	28	87,5	8,33	17,27
Cycle 5 Day 1	All	31	83,8	29	93,5	2,30	8,60
Cycle 6 Day 1	All	31	83,8	29	93,5	5,75	15,61
Cycle 7 Day 1	All	30	81,1	27	90,0	4,94	12,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	10,67	20,91
Cycle 9 Day 1	All	25	67,6	25	100,0	4,00	14,66
Cycle 10 Day 1	All	25	67,6	24	96,0	4,17	11,26
Cycle 11 Day 1	All	24	64,9	24	100,0	1,39	6,80
Cycle 12 Day 1	All	24	64,9	21	87,5	3,17	10,03
Cycle 13 Day 1	All	22	59,5	21	95,5	6,35	17,06
Cycle 14 Day 1	All	22	59,5	22	100,0	6,06	16,70
Cycle 15 Day 1	All	22	59,5	21	95,5	3,17	10,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	11,11	16,27
Cycle 17 Day 1	All	18	48,6	14	77,8	14,29	28,39
Cycle 18 Day 1	All	15	40,5	8	53,3	0,00	0,00
Cycle 19 Day 1	All	13	35,1	8	61,5	0,00	0,00
Cycle 20 Day 1	All	9	24,3	9	100,0	0,00	0,00
Cycle 21 Day 1	All	7	18,9	4	57,1	0,00	0,00
Cycle 22 Day 1	All	7	18,9	2	28,6	50,00	70,71
Cycle 23 Day 1	All	4	10,8	1	25,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	0,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	26,67	27,89
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	41,03	36,40
	Female	23	100,0	21	91,3	28,57	32,12
Cycle 2 Day 1	Male	13	92,9	12	92,3	5,56	12,97
	Female	20	87,0	17	85,0	17,65	26,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	5,56	12,97
	Female	20	87,0	18	90,0	12,96	28,33
Cycle 4 Day 1	Male	12	85,7	11	91,7	3,03	10,05
	Female	20	87,0	17	85,0	11,76	20,21
Cycle 5 Day 1	Male	12	85,7	11	91,7	0,00	0,00
	Female	19	82,6	18	94,7	3,70	10,78
Cycle 6 Day 1	Male	12	85,7	11	91,7	6,06	13,48
	Female	19	82,6	18	94,7	5,56	17,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	9,09	15,57
	Female	19	82,6	16	84,2	2,08	8,33
Cycle 8 Day 1	Male	10	71,4	9	90,0	14,81	29,40
	Female	18	78,3	16	88,9	8,33	14,91
Cycle 9 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	17	73,9	17	100,0	5,88	17,62
Cycle 10 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	17	73,9	16	94,1	4,17	11,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	16	69,6	16	100,0	2,08	8,33
Cycle 12 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	16	69,6	13	81,3	5,13	12,52
Cycle 13 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	14	60,9	13	92,9	10,26	21,01
Cycle 14 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	14	60,9	14	100,0	9,52	20,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	14	60,9	13	92,9	5,13	12,52
Cycle 16 Day 1	Male	8	57,1	5	62,5	0,00	0,00
	Female	13	56,5	10	76,9	16,67	17,57
Cycle 17 Day 1	Male	6	42,9	2	33,3	0,00	0,00
	Female	12	52,2	12	100,0	16,67	30,15
Cycle 18 Day 1	Male	3	21,4	2	66,7	0,00	0,00
	Female	12	52,2	6	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	11	47,8	6	54,5	0,00	0,00
Cycle 20 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	7	30,4	7	100,0	0,00	0,00
Cycle 21 Day 1	Male	1	7,1	1	100,0	0,00	-
	Female	6	26,1	3	50,0	0,00	0,00
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	50,00	70,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	0,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	0,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	50,00	23,57
	Female	7	30,4	3	42,9	11,11	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	33,33	34,59
	65-74	8	100,0	7	87,5	33,33	33,33
Cycle 2 Day 1	18-64	27	93,1	24	88,9	12,50	23,70
	65-74	6	75,0	5	83,3	13,33	18,26
Cycle 3 Day 1	18-64	26	89,7	24	92,3	9,72	23,01
	65-74	6	75,0	6	100,0	11,11	27,22
Cycle 4 Day 1	18-64	26	89,7	23	88,5	10,14	18,63
	65-74	6	75,0	5	83,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	1,45	6,95
	65-74	6	75,0	6	100,0	5,56	13,61
Cycle 6 Day 1	18-64	25	86,2	24	96,0	4,17	11,26
	65-74	6	75,0	5	83,3	13,33	29,81
Cycle 7 Day 1	18-64	25	86,2	23	92,0	5,80	12,92
	65-74	5	62,5	4	80,0	0,00	0,00
Cycle 8 Day 1	18-64	23	79,3	20	87,0	11,67	22,36
	65-74	5	62,5	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	1,67	7,45
	65-74	5	62,5	5	100,0	13,33	29,81
Cycle 10 Day 1	18-64	20	69,0	19	95,0	3,51	10,51
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 11 Day 1	18-64	19	65,5	19	100,0	1,75	7,65
	65-74	5	62,5	5	100,0	0,00	0,00
Cycle 12 Day 1	18-64	19	65,5	17	89,5	3,92	11,07
	65-74	5	62,5	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	4,17	11,39
	65-74	5	62,5	5	100,0	13,33	29,81
Cycle 14 Day 1	18-64	17	58,6	17	100,0	3,92	11,07
	65-74	5	62,5	5	100,0	13,33	29,81
Cycle 15 Day 1	18-64	17	58,6	16	94,1	2,08	8,33
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 16 Day 1	18-64	17	58,6	13	76,5	10,26	16,01
	65-74	4	50,0	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	16,67	30,15
	65-74	3	37,5	2	66,7	0,00	0,00
Cycle 18 Day 1	18-64	13	44,8	8	61,5	0,00	0,00
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	0,00	0,00
	65-74	2	25,0	1	50,0	0,00	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	0,00	0,00
	65-74	1	12,5	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	0,00	0,00
Cycle 22 Day 1	18-64	7	24,1	2	28,6	50,00	70,71
Cycle 23 Day 1	18-64	4	13,8	1	25,0	0,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	0,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	33,33	33,33
	65-74	6	75,0	2	33,3	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	35,29	43,25
	Other	17	100,0	17	100,0	31,37	21,96
Cycle 2 Day 1	White	19	95,0	16	84,2	14,58	24,25
	Other	14	82,4	13	92,9	10,26	21,01
Cycle 3 Day 1	White	18	90,0	16	88,9	16,67	29,81
	Other	14	82,4	14	100,0	2,38	8,91
Cycle 4 Day 1	White	18	90,0	15	83,3	8,89	15,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	7,69	19,97
Cycle 5 Day 1	White	18	90,0	17	94,4	3,92	11,07
	Other	13	76,5	12	92,3	0,00	0,00
Cycle 6 Day 1	White	18	90,0	16	88,9	8,33	19,25
	Other	13	76,5	13	100,0	2,56	9,25
Cycle 7 Day 1	White	17	85,0	15	88,2	2,22	8,61
	Other	13	76,5	12	92,3	8,33	15,08
Cycle 8 Day 1	White	17	85,0	14	82,4	9,52	15,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	12,12	26,97
Cycle 9 Day 1	White	16	80,0	16	100,0	6,25	18,13
	Other	9	52,9	9	100,0	0,00	0,00
Cycle 10 Day 1	White	16	80,0	15	93,8	6,67	13,80
	Other	9	52,9	9	100,0	0,00	0,00
Cycle 11 Day 1	White	16	80,0	16	100,0	2,08	8,33
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 12 Day 1	White	16	80,0	13	81,3	2,56	9,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	4,17	11,79
Cycle 13 Day 1	White	14	70,0	13	92,9	10,26	21,01
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 14 Day 1	White	14	70,0	14	100,0	9,52	20,37
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 15 Day 1	White	14	70,0	13	92,9	5,13	12,52
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 16 Day 1	White	14	70,0	9	64,3	14,81	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	5,56	13,61
Cycle 17 Day 1	White	13	65,0	10	76,9	16,67	32,39
	Other	5	29,4	4	80,0	8,33	16,67
Cycle 18 Day 1	White	11	55,0	4	36,4	0,00	0,00
	Other	4	23,5	4	100,0	0,00	0,00
Cycle 19 Day 1	White	9	45,0	5	55,6	0,00	0,00
	Other	4	23,5	3	75,0	0,00	0,00
Cycle 20 Day 1	White	5	25,0	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	0,00	0,00
Cycle 21 Day 1	White	3	15,0	2	66,7	0,00	0,00
	Other	4	23,5	2	50,0	0,00	0,00
Cycle 22 Day 1	White	3	15,0	1	33,3	100,00	-
	Other	4	23,5	1	25,0	0,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	0,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	11,11	19,25
	Other	9	52,9	2	22,2	50,00	23,57
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	19,44	30,01
	Europe (EU)	10	100,0	8	80,0	41,67	42,72
	Asia (AS)	15	100,0	14	93,3	40,48	29,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	7,41	14,70
	Europe (EU)	9	90,0	8	88,9	12,50	24,80
	Asia (AS)	13	86,7	12	92,3	16,67	26,59
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	3,03	10,05
	Europe (EU)	8	80,0	6	75,0	33,33	42,16
	Asia (AS)	13	86,7	13	100,0	5,13	12,52
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	6,06	13,48
	Europe (EU)	8	80,0	4	50,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	10,26	21,01
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	0,00	0,00
	Europe (EU)	8	80,0	7	87,5	9,52	16,27
	Asia (AS)	12	80,0	11	91,7	0,00	0,00
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	3,03	10,05
	Europe (EU)	8	80,0	7	87,5	14,29	26,23
	Asia (AS)	12	80,0	11	91,7	3,03	10,05
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	4,76	12,60
	Asia (AS)	11	73,3	10	90,9	10,00	16,10
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	3,33	10,54
	Europe (EU)	8	80,0	6	75,0	5,56	13,61
	Asia (AS)	9	60,0	9	100,0	22,22	28,87
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	3,03	10,05
	Europe (EU)	7	70,0	7	100,0	9,52	25,20
	Asia (AS)	7	46,7	7	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	3,33	10,54
	Europe (EU)	7	70,0	7	100,0	9,52	16,27
	Asia (AS)	7	46,7	7	100,0	0,00	0,00
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	3,03	10,05
	Europe (EU)	7	70,0	7	100,0	0,00	0,00
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	6,67	14,05
	Europe (EU)	7	70,0	5	71,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	6,67	14,05
	Europe (EU)	6	60,0	5	83,3	13,33	29,81
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	6,67	14,05
	Europe (EU)	6	60,0	6	100,0	11,11	27,22
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	3,33	10,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	6,67	14,91
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	4,76	12,60
	Europe (EU)	6	60,0	2	33,3	16,67	23,57
	Asia (AS)	6	40,0	6	100,0	16,67	18,26
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	22,22	40,37
	Europe (EU)	4	40,0	3	75,0	0,00	0,00
	Asia (AS)	5	33,3	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	0,00	0,00
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	0,00	0,00
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	0,00	0,00
	Europe (EU)	3	30,0	1	33,3	0,00	-
	Asia (AS)	4	26,7	3	75,0	0,00	0,00
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	0,00	0,00
	Europe (EU)	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	0,00	0,00
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	0,00	0,00
	Asia (AS)	3	20,0	1	33,3	0,00	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	50,00	70,71
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	0,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	22,22	19,25
	Europe (EU)	2	20,0	1	50,0	0,00	-
	Asia (AS)	7	46,7	1	14,3	66,67	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	11,11	16,41
	1	17	100,0	17	100,0	50,98	35,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	26,67	27,89
Cycle 2 Day 1	0	15	100,0	12	80,0	2,78	9,62
	1	15	88,2	14	93,3	16,67	25,32
	2	3	60,0	3	100,0	33,33	33,33
Cycle 3 Day 1	0	15	100,0	14	93,3	11,90	21,11
	1	14	82,4	13	92,9	0,00	0,00
	2	3	60,0	3	100,0	44,44	50,92
Cycle 4 Day 1	0	15	100,0	14	93,3	4,76	12,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	5,56	12,97
	2	3	60,0	2	66,7	50,00	23,57
Cycle 5 Day 1	0	15	100,0	15	100,0	2,22	8,61
	1	14	82,4	12	85,7	0,00	0,00
	2	2	40,0	2	100,0	16,67	23,57
Cycle 6 Day 1	0	15	100,0	15	100,0	6,67	18,69
	1	14	82,4	12	85,7	5,56	12,97
	2	2	40,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	4,76	12,10
	1	13	76,5	11	84,6	6,06	13,48
	2	2	40,0	2	100,0	0,00	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	10,26	21,01
	1	11	64,7	10	90,9	13,33	23,31
	2	2	40,0	2	100,0	0,00	0,00
Cycle 9 Day 1	0	14	93,3	14	100,0	4,76	17,82
	1	10	58,8	10	100,0	3,33	10,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	0,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	4,76	12,10
	1	10	58,8	9	90,0	3,70	11,11
	2	1	20,0	1	100,0	0,00	-
Cycle 11 Day 1	0	14	93,3	14	100,0	0,00	0,00
	1	9	52,9	9	100,0	3,70	11,11
	2	1	20,0	1	100,0	0,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	2,78	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	4,17	11,79
	2	1	20,0	1	100,0	0,00	-
Cycle 13 Day 1	0	14	93,3	13	92,9	7,69	19,97
	1	8	47,1	8	100,0	4,17	11,79
Cycle 14 Day 1	0	14	93,3	14	100,0	7,14	19,30
	1	8	47,1	8	100,0	4,17	11,79
Cycle 15 Day 1	0	14	93,3	14	100,0	2,38	8,91
	1	8	47,1	7	87,5	4,76	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	8,33	15,43
	1	8	47,1	7	87,5	14,29	17,82
Cycle 17 Day 1	0	12	80,0	8	66,7	12,50	35,36
	1	6	35,3	6	100,0	16,67	18,26
Cycle 18 Day 1	0	9	60,0	4	44,4	0,00	0,00
	1	6	35,3	4	66,7	0,00	0,00
Cycle 19 Day 1	0	8	53,3	4	50,0	0,00	0,00
	1	5	29,4	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	0,00	0,00
	1	4	23,5	4	100,0	0,00	0,00
Cycle 21 Day 1	0	3	20,0	3	100,0	0,00	0,00
	1	4	23,5	1	25,0	0,00	-
Cycle 22 Day 1	0	3	20,0	2	66,7	50,00	70,71
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	0,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	22,22	19,25
	1	7	41,2	2	28,6	33,33	47,14
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	15,38	22,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	16,67	23,57
	2 or More	21	100,0	19	90,5	47,37	35,69
Cycle 2 Day 1	None	14	100,0	12	85,7	5,56	12,97
	1	1	50,0	1	100,0	0,00	-
	2 or More	18	85,7	16	88,9	18,75	27,13
Cycle 3 Day 1	None	14	100,0	13	92,9	5,13	12,52
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	16	94,1	14,58	29,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	5,56	12,97
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	11,11	20,57
Cycle 5 Day 1	None	14	100,0	14	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	4,76	12,10
Cycle 6 Day 1	None	14	100,0	14	100,0	2,38	8,91
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	9,52	20,37
Cycle 7 Day 1	None	14	100,0	13	92,9	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	15	71,4	13	86,7	10,26	16,01
Cycle 8 Day 1	None	14	100,0	13	92,9	10,26	21,01
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	11,11	21,71
Cycle 9 Day 1	None	13	92,9	13	100,0	2,56	9,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	6,06	20,10
Cycle 10 Day 1	None	13	92,9	12	92,3	2,78	9,62
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	6,06	13,48
Cycle 11 Day 1	None	13	92,9	13	100,0	2,56	9,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	10	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	5,56	12,97
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	8	80,0	0,00	0,00
Cycle 13 Day 1	None	12	85,7	11	91,7	3,03	10,05
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	11,11	23,57
Cycle 14 Day 1	None	12	85,7	12	100,0	2,78	9,62
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	11,11	23,57
Cycle 15 Day 1	None	12	85,7	12	100,0	2,78	9,62
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	8	88,9	4,17	11,79
Cycle 16 Day 1	None	11	78,6	8	72,7	8,33	15,43
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	16,67	18,26
Cycle 17 Day 1	None	10	71,4	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	7	33,3	6	85,7	22,22	40,37
Cycle 18 Day 1	None	8	57,1	4	50,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	6	28,6	3	50,0	0,00	0,00
Cycle 19 Day 1	None	7	50,0	3	42,9	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	5	23,8	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	4	19,0	4	100,0	0,00	0,00
Cycle 21 Day 1	None	4	28,6	2	50,0	0,00	0,00
	2 or More	3	14,3	2	66,7	0,00	0,00
Cycle 22 Day 1	None	4	28,6	1	25,0	0,00	-
	2 or More	3	14,3	1	33,3	100,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	33,33	-
	1	2	100,0	1	50,0	33,33	-
	2 or More	9	42,9	3	33,3	22,22	38,49
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	15,38	22,01
	Previously Treated	23	100,0	21	91,3	44,44	35,49
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	5,56	12,97
	Previously Treated	19	82,6	17	89,5	17,65	26,66
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	5,13	12,52
	Previously Treated	18	78,3	17	94,4	13,73	29,01
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	5,56	12,97
	Previously Treated	18	78,3	16	88,9	10,42	20,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	0,00	0,00
	Previously Treated	17	73,9	15	88,2	4,44	11,73
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	2,38	8,91
	Previously Treated	17	73,9	15	88,2	8,89	19,79
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	0,00	0,00
	Previously Treated	16	69,6	14	87,5	9,52	15,63
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	10,26	21,01
	Previously Treated	14	60,9	12	85,7	11,11	21,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	2,56	9,25
	Previously Treated	12	52,2	12	100,0	5,56	19,25
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	2,78	9,62
	Previously Treated	12	52,2	12	100,0	5,56	12,97
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	2,56	9,25
	Previously Treated	11	47,8	11	100,0	0,00	0,00
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	5,56	12,97
	Previously Treated	11	47,8	9	81,8	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	3,03	10,05
	Previously Treated	10	43,5	10	100,0	10,00	22,50
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	2,78	9,62
	Previously Treated	10	43,5	10	100,0	10,00	22,50
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	2,78	9,62
	Previously Treated	10	43,5	9	90,0	3,70	11,11
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	8,33	15,43
	Previously Treated	10	43,5	7	70,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	9,52	16,27
	Previously Treated	8	34,8	7	87,5	19,05	37,80
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	0,00	0,00
	Previously Treated	7	30,4	4	57,1	0,00	0,00
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	0,00	0,00
	Previously Treated	6	26,1	5	83,3	0,00	0,00
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	0,00	0,00
	Previously Treated	5	21,7	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	0,00	0,00
	Previously Treated	3	13,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	0,00	-
	Previously Treated	3	13,0	1	33,3	100,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	11	47,8	4	36,4	25,00	31,91
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	25,00	32,18
	Central	25	100,0	22	88,0	37,88	34,57
Cycle 2 Day 1	Local	11	91,7	10	90,9	0,00	0,00
	Central	22	88,0	19	86,4	19,30	25,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	9,09	21,56
	Central	21	84,0	19	90,5	10,53	24,98
Cycle 4 Day 1	Local	11	91,7	10	90,9	3,33	10,54
	Central	21	84,0	18	85,7	11,11	19,80
Cycle 5 Day 1	Local	11	91,7	10	90,9	3,33	10,54
	Central	20	80,0	19	95,0	1,75	7,65
Cycle 6 Day 1	Local	11	91,7	11	100,0	9,09	21,56
	Central	20	80,0	18	90,0	3,70	10,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	3,03	10,05
	Central	19	76,0	16	84,2	6,25	13,44
Cycle 8 Day 1	Local	10	83,3	10	100,0	3,33	10,54
	Central	18	72,0	15	83,3	15,56	24,77
Cycle 9 Day 1	Local	10	83,3	10	100,0	6,67	21,08
	Central	15	60,0	15	100,0	2,22	8,61
Cycle 10 Day 1	Local	10	83,3	9	90,0	3,70	11,11
	Central	15	60,0	15	100,0	4,44	11,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	0,00	0,00
	Central	15	60,0	15	100,0	2,22	8,61
Cycle 12 Day 1	Local	9	75,0	8	88,9	4,17	11,79
	Central	15	60,0	13	86,7	2,56	9,25
Cycle 13 Day 1	Local	8	66,7	8	100,0	8,33	23,57
	Central	14	56,0	13	92,9	5,13	12,52
Cycle 14 Day 1	Local	8	66,7	8	100,0	8,33	23,57
	Central	14	56,0	14	100,0	4,76	12,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	4,17	11,79
	Central	14	56,0	13	92,9	2,56	9,25
Cycle 16 Day 1	Local	8	66,7	6	75,0	5,56	13,61
	Central	13	52,0	9	69,2	14,81	17,57
Cycle 17 Day 1	Local	8	66,7	5	62,5	6,67	14,91
	Central	10	40,0	9	90,0	18,52	33,79
Cycle 18 Day 1	Local	6	50,0	4	66,7	0,00	0,00
	Central	9	36,0	4	44,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	0,00	0,00
	Central	8	32,0	4	50,0	0,00	0,00
Cycle 20 Day 1	Local	5	41,7	5	100,0	0,00	0,00
	Central	4	16,0	4	100,0	0,00	0,00
Cycle 21 Day 1	Local	4	33,3	2	50,0	0,00	0,00
	Central	3	12,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Local	4	33,3	1	25,0	0,00	-
	Central	3	12,0	1	33,3	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	0,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	0,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	0,00	0,00
	Central	8	32,0	3	37,5	44,44	19,25
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	34,38	34,38
	No	2	100,0	2	100,0	16,67	23,57
Cycle 2 Day 1	Yes	32	91,4	28	87,5	13,10	22,84
	No	1	50,0	1	100,0	0,00	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	10,34	23,74
	No	1	50,0	1	100,0	0,00	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	8,64	17,52
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	2,38	8,74
	No	1	50,0	1	100,0	0,00	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	5,95	15,85
	No	1	50,0	1	100,0	0,00	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	5,13	12,26
	No	1	50,0	1	100,0	0,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	11,11	21,23
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	4,17	14,95
	No	1	50,0	1	100,0	0,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	4,35	11,48
	No	1	50,0	1	100,0	0,00	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	1,45	6,95
	No	1	50,0	1	100,0	0,00	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	3,33	10,26
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	6,67	17,44
	No	1	50,0	1	100,0	0,00	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	6,35	17,06
	No	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	3,33	10,26
	No	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	11,90	16,57
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	12,82	28,99
	No	1	50,0	1	100,0	33,33	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	0,00	0,00
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	0,00	0,00
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	50,00	70,71
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	0,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	0,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	26,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	55,56	19,25
	No	33	100,0	31	93,9	31,18	34,36
Cycle 2 Day 1	Yes	2	50,0	1	50,0	0,00	-
	No	31	93,9	28	90,3	13,10	22,84
Cycle 3 Day 1	Yes	2	50,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	9,52	23,76
Cycle 4 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	30	90,9	26	86,7	7,69	17,15
Cycle 5 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	27	93,1	2,47	8,90
Cycle 6 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	27	93,1	6,17	16,11
Cycle 7 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	5,33	12,47
Cycle 8 Day 1	Yes	2	50,0	2	100,0	50,00	23,57
	No	26	78,8	23	88,5	7,25	17,28
Cycle 9 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	24	100,0	4,17	14,95
Cycle 10 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	23	95,8	4,35	11,48
Cycle 11 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	1,45	6,95
Cycle 12 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	23	69,7	20	87,0	3,33	10,26
Cycle 13 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	20	95,2	6,67	17,44
Cycle 14 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	21	100,0	6,35	17,06
Cycle 15 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	3,33	10,26
Cycle 16 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	20	60,6	14	70,0	9,52	15,63
Cycle 17 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	17	51,5	13	76,5	15,38	29,24
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	0,00	0,00
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	0,00	0,00
Cycle 20 Day 1	No	9	27,3	9	100,0	0,00	0,00
Cycle 21 Day 1	No	7	21,2	4	57,1	0,00	0,00
Cycle 22 Day 1	No	7	21,2	2	28,6	50,00	70,71
Cycle 23 Day 1	No	4	12,1	1	25,0	0,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	0,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30AP_SG.xls
07SEP2019 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	81,86	19,83
Cycle 2 Day 1	All	33	89,2	29	87,9	77,01	21,09
Cycle 3 Day 1	All	32	86,5	30	93,8	71,67	23,63
Cycle 4 Day 1	All	32	86,5	28	87,5	80,95	19,62
Cycle 5 Day 1	All	31	83,8	29	93,5	77,01	21,55
Cycle 6 Day 1	All	31	83,8	29	93,5	74,71	15,82
Cycle 7 Day 1	All	30	81,1	27	90,0	75,31	20,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	74,00	24,57
Cycle 9 Day 1	All	25	67,6	25	100,0	80,67	19,65
Cycle 10 Day 1	All	25	67,6	24	96,0	81,25	21,03
Cycle 11 Day 1	All	24	64,9	24	100,0	79,86	20,84
Cycle 12 Day 1	All	24	64,9	21	87,5	73,81	20,80
Cycle 13 Day 1	All	22	59,5	21	95,5	76,19	23,90
Cycle 14 Day 1	All	22	59,5	22	100,0	75,76	23,42
Cycle 15 Day 1	All	22	59,5	21	95,5	73,02	26,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	76,67	20,70
Cycle 17 Day 1	All	18	48,6	14	77,8	78,57	18,98
Cycle 18 Day 1	All	15	40,5	8	53,3	70,83	21,36
Cycle 19 Day 1	All	13	35,1	8	61,5	56,25	33,26
Cycle 20 Day 1	All	9	24,3	9	100,0	68,52	29,40
Cycle 21 Day 1	All	7	18,9	4	57,1	58,33	21,52
Cycle 22 Day 1	All	7	18,9	2	28,6	58,33	35,36
Cycle 23 Day 1	All	4	10,8	1	25,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	83,33	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	70,00	32,06
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	80,77	28,74
	Female	23	100,0	21	91,3	82,54	12,33
Cycle 2 Day 1	Male	13	92,9	12	92,3	79,17	22,61
	Female	20	87,0	17	85,0	75,49	20,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	80,56	23,39
	Female	20	87,0	18	90,0	65,74	22,49
Cycle 4 Day 1	Male	12	85,7	11	91,7	89,39	13,48
	Female	20	87,0	17	85,0	75,49	21,34
Cycle 5 Day 1	Male	12	85,7	11	91,7	81,82	18,94
	Female	19	82,6	18	94,7	74,07	23,02
Cycle 6 Day 1	Male	12	85,7	11	91,7	81,82	11,68
	Female	19	82,6	18	94,7	70,37	16,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	81,82	11,68
	Female	19	82,6	16	84,2	70,83	23,96
Cycle 8 Day 1	Male	10	71,4	9	90,0	74,07	27,78
	Female	18	78,3	16	88,9	73,96	23,55
Cycle 9 Day 1	Male	8	57,1	8	100,0	87,50	17,25
	Female	17	73,9	17	100,0	77,45	20,36
Cycle 10 Day 1	Male	8	57,1	8	100,0	81,25	24,30
	Female	17	73,9	16	94,1	81,25	20,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	83,33	25,20
	Female	16	69,6	16	100,0	78,13	18,97
Cycle 12 Day 1	Male	8	57,1	8	100,0	81,25	16,52
	Female	16	69,6	13	81,3	69,23	22,41
Cycle 13 Day 1	Male	8	57,1	8	100,0	87,50	19,42
	Female	14	60,9	13	92,9	69,23	24,39
Cycle 14 Day 1	Male	8	57,1	8	100,0	79,17	23,15
	Female	14	60,9	14	100,0	73,81	24,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	81,25	18,77
	Female	14	60,9	13	92,9	67,95	30,02
Cycle 16 Day 1	Male	8	57,1	5	62,5	80,00	21,73
	Female	13	56,5	10	76,9	75,00	21,15
Cycle 17 Day 1	Male	6	42,9	2	33,3	83,33	23,57
	Female	12	52,2	12	100,0	77,78	19,25
Cycle 18 Day 1	Male	3	21,4	2	66,7	66,67	47,14
	Female	12	52,2	6	50,0	72,22	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	58,33	35,36
	Female	11	47,8	6	54,5	55,56	36,00
Cycle 20 Day 1	Male	2	14,3	2	100,0	66,67	47,14
	Female	7	30,4	7	100,0	69,05	27,94
Cycle 21 Day 1	Male	1	7,1	1	100,0	33,33	-
	Female	6	26,1	3	50,0	66,67	16,67
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	58,33	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	83,33	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	83,33	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	50,00	47,14
	Female	7	30,4	3	42,9	83,33	16,67
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	83,95	20,40
	65-74	8	100,0	7	87,5	73,81	16,27
Cycle 2 Day 1	18-64	27	93,1	24	88,9	78,47	19,95
	65-74	6	75,0	5	83,3	70,00	27,39
Cycle 3 Day 1	18-64	26	89,7	24	92,3	73,61	22,48
	65-74	6	75,0	6	100,0	63,89	28,71
Cycle 4 Day 1	18-64	26	89,7	23	88,5	81,16	20,90
	65-74	6	75,0	5	83,3	80,00	13,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	78,26	21,58
	65-74	6	75,0	6	100,0	72,22	22,77
Cycle 6 Day 1	18-64	25	86,2	24	96,0	75,69	15,53
	65-74	6	75,0	5	83,3	70,00	18,26
Cycle 7 Day 1	18-64	25	86,2	23	92,0	75,36	21,24
	65-74	5	62,5	4	80,0	75,00	16,67
Cycle 8 Day 1	18-64	23	79,3	20	87,0	73,33	26,16
	65-74	5	62,5	5	100,0	76,67	19,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	82,50	18,32
	65-74	5	62,5	5	100,0	73,33	25,28
Cycle 10 Day 1	18-64	20	69,0	19	95,0	81,58	22,84
	65-74	5	62,5	5	100,0	80,00	13,94
Cycle 11 Day 1	18-64	19	65,5	19	100,0	78,07	21,55
	65-74	5	62,5	5	100,0	86,67	18,26
Cycle 12 Day 1	18-64	19	65,5	17	89,5	73,53	22,87
	65-74	5	62,5	4	80,0	75,00	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	78,13	21,70
	65-74	5	62,5	5	100,0	70,00	32,06
Cycle 14 Day 1	18-64	17	58,6	17	100,0	74,51	25,08
	65-74	5	62,5	5	100,0	80,00	18,26
Cycle 15 Day 1	18-64	17	58,6	16	94,1	71,88	27,02
	65-74	5	62,5	5	100,0	76,67	27,89
Cycle 16 Day 1	18-64	17	58,6	13	76,5	75,64	21,10
	65-74	4	50,0	2	50,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	77,78	20,52
	65-74	3	37,5	2	66,7	83,33	0,00
Cycle 18 Day 1	18-64	13	44,8	8	61,5	70,83	21,36
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	57,14	35,82
	65-74	2	25,0	1	50,0	50,00	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	68,75	31,42
	65-74	1	12,5	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	58,33	21,52
Cycle 22 Day 1	18-64	7	24,1	2	28,6	58,33	35,36
Cycle 23 Day 1	18-64	4	13,8	1	25,0	83,33	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	83,33	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	66,67	44,10
	65-74	6	75,0	2	33,3	75,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	85,29	14,29
	Other	17	100,0	17	100,0	78,43	24,13
Cycle 2 Day 1	White	19	95,0	16	84,2	76,04	21,92
	Other	14	82,4	13	92,9	78,21	20,84
Cycle 3 Day 1	White	18	90,0	16	88,9	67,71	23,94
	Other	14	82,4	14	100,0	76,19	23,31
Cycle 4 Day 1	White	18	90,0	15	83,3	82,22	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	79,49	22,72
Cycle 5 Day 1	White	18	90,0	17	94,4	74,51	22,91
	Other	13	76,5	12	92,3	80,56	19,89
Cycle 6 Day 1	White	18	90,0	16	88,9	77,08	15,96
	Other	13	76,5	13	100,0	71,79	15,79
Cycle 7 Day 1	White	17	85,0	15	88,2	75,56	18,76
	Other	13	76,5	12	92,3	75,00	23,03
Cycle 8 Day 1	White	17	85,0	14	82,4	80,95	18,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	65,15	29,30
Cycle 9 Day 1	White	16	80,0	16	100,0	81,25	21,84
	Other	9	52,9	9	100,0	79,63	16,20
Cycle 10 Day 1	White	16	80,0	15	93,8	83,33	21,82
	Other	9	52,9	9	100,0	77,78	20,41
Cycle 11 Day 1	White	16	80,0	16	100,0	83,33	21,08
	Other	8	47,1	8	100,0	72,92	19,80
Cycle 12 Day 1	White	16	80,0	13	81,3	76,92	18,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	68,75	24,30
Cycle 13 Day 1	White	14	70,0	13	92,9	79,49	24,68
	Other	8	47,1	8	100,0	70,83	23,15
Cycle 14 Day 1	White	14	70,0	14	100,0	76,19	24,21
	Other	8	47,1	8	100,0	75,00	23,57
Cycle 15 Day 1	White	14	70,0	13	92,9	73,08	23,11
	Other	8	47,1	8	100,0	72,92	33,26
Cycle 16 Day 1	White	14	70,0	9	64,3	79,63	16,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	72,22	27,22
Cycle 17 Day 1	White	13	65,0	10	76,9	80,00	15,32
	Other	5	29,4	4	80,0	75,00	28,87
Cycle 18 Day 1	White	11	55,0	4	36,4	75,00	28,87
	Other	4	23,5	4	100,0	66,67	13,61
Cycle 19 Day 1	White	9	45,0	5	55,6	63,33	21,73
	Other	4	23,5	3	75,0	44,44	50,92
Cycle 20 Day 1	White	5	25,0	5	100,0	73,33	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	62,50	34,36
Cycle 21 Day 1	White	3	15,0	2	66,7	50,00	23,57
	Other	4	23,5	2	50,0	66,67	23,57
Cycle 22 Day 1	White	3	15,0	1	33,3	33,33	-
	Other	4	23,5	1	25,0	83,33	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	83,33	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	83,33	16,67
	Other	9	52,9	2	22,2	50,00	47,14
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	83,33	15,89
	Europe (EU)	10	100,0	8	80,0	89,58	8,63
	Asia (AS)	15	100,0	14	93,3	76,19	25,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	70,37	24,69
	Europe (EU)	9	90,0	8	88,9	83,33	15,43
	Asia (AS)	13	86,7	12	92,3	77,78	21,71
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	71,21	25,92
	Europe (EU)	8	80,0	6	75,0	72,22	20,18
	Asia (AS)	13	86,7	13	100,0	71,79	24,89
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	81,82	18,94
	Europe (EU)	8	80,0	4	50,0	91,67	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	76,92	22,09
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	75,76	21,56
	Europe (EU)	8	80,0	7	87,5	76,19	25,20
	Asia (AS)	12	80,0	11	91,7	78,79	21,20
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	80,30	14,56
	Europe (EU)	8	80,0	7	87,5	71,43	18,54
	Asia (AS)	12	80,0	11	91,7	71,21	15,08
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	85,00	14,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	71,43	12,60
	Asia (AS)	11	73,3	10	90,9	68,33	26,59
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	83,33	13,61
	Europe (EU)	8	80,0	6	75,0	75,00	17,48
	Asia (AS)	9	60,0	9	100,0	62,96	34,13
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	80,30	17,98
	Europe (EU)	7	70,0	7	100,0	80,95	24,40
	Asia (AS)	7	46,7	7	100,0	80,95	20,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	83,33	22,22
	Europe (EU)	7	70,0	7	100,0	80,95	15,00
	Asia (AS)	7	46,7	7	100,0	78,57	26,73
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	83,33	22,36
	Europe (EU)	7	70,0	7	100,0	83,33	16,67
	Asia (AS)	6	40,0	6	100,0	69,44	22,15
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	78,33	15,81
	Europe (EU)	7	70,0	5	71,4	70,00	13,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	69,44	32,35
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	81,67	18,34
	Europe (EU)	6	60,0	5	83,3	70,00	32,06
	Asia (AS)	6	40,0	6	100,0	72,22	27,22
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	78,33	19,33
	Europe (EU)	6	60,0	6	100,0	77,78	20,18
	Asia (AS)	6	40,0	6	100,0	69,44	34,02
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	81,67	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	70,00	24,72
	Asia (AS)	6	40,0	6	100,0	61,11	38,97
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	83,33	16,67
	Europe (EU)	6	60,0	2	33,3	66,67	0,00
	Asia (AS)	6	40,0	6	100,0	72,22	27,22
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	75,00	17,48
	Europe (EU)	4	40,0	3	75,0	88,89	9,62
	Asia (AS)	5	33,3	5	100,0	76,67	25,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	73,33	25,28
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	66,67	16,67
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	66,67	23,57
	Europe (EU)	3	30,0	1	33,3	50,00	-
	Asia (AS)	4	26,7	3	75,0	44,44	50,92
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	76,67	27,89
	Europe (EU)	1	10,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	55,56	38,49
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	61,11	25,46
	Asia (AS)	3	20,0	1	33,3	50,00	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	58,33	35,36
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	83,33	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	88,89	9,62
	Europe (EU)	2	20,0	1	50,0	66,67	-
	Asia (AS)	7	46,7	1	14,3	16,67	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	90,28	13,22
	1	17	100,0	17	100,0	76,47	24,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	80,00	7,45
Cycle 2 Day 1	0	15	100,0	12	80,0	77,78	24,96
	1	15	88,2	14	93,3	73,81	19,30
	2	3	60,0	3	100,0	88,89	9,62
Cycle 3 Day 1	0	15	100,0	14	93,3	75,00	24,24
	1	14	82,4	13	92,9	67,95	25,88
	2	3	60,0	3	100,0	72,22	9,62
Cycle 4 Day 1	0	15	100,0	14	93,3	84,52	16,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	79,17	18,97
	2	3	60,0	2	66,7	66,67	47,14
Cycle 5 Day 1	0	15	100,0	15	100,0	75,56	24,29
	1	14	82,4	12	85,7	77,78	19,25
	2	2	40,0	2	100,0	83,33	23,57
Cycle 6 Day 1	0	15	100,0	15	100,0	78,89	14,73
	1	14	82,4	12	85,7	69,44	13,91
	2	2	40,0	2	100,0	75,00	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	77,38	20,26
	1	13	76,5	11	84,6	72,73	22,70
	2	2	40,0	2	100,0	75,00	11,79
Cycle 8 Day 1	0	15	100,0	13	86,7	76,92	18,68
	1	11	64,7	10	90,9	68,33	31,87
	2	2	40,0	2	100,0	83,33	23,57
Cycle 9 Day 1	0	14	93,3	14	100,0	80,95	20,52
	1	10	58,8	10	100,0	78,33	19,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	100,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	79,76	20,86
	1	10	58,8	9	90,0	81,48	22,74
	2	1	20,0	1	100,0	100,00	-
Cycle 11 Day 1	0	14	93,3	14	100,0	82,14	23,08
	1	9	52,9	9	100,0	74,07	16,90
	2	1	20,0	1	100,0	100,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	76,39	16,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	72,92	26,63
	2	1	20,0	1	100,0	50,00	-
Cycle 13 Day 1	0	14	93,3	13	92,9	79,49	25,60
	1	8	47,1	8	100,0	70,83	21,36
Cycle 14 Day 1	0	14	93,3	14	100,0	76,19	23,31
	1	8	47,1	8	100,0	75,00	25,20
Cycle 15 Day 1	0	14	93,3	14	100,0	77,38	24,11
	1	8	47,1	7	87,5	64,29	31,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	81,25	18,77
	1	8	47,1	7	87,5	71,43	23,00
Cycle 17 Day 1	0	12	80,0	8	66,7	81,25	16,52
	1	6	35,3	6	100,0	75,00	22,97
Cycle 18 Day 1	0	9	60,0	4	44,4	70,83	28,46
	1	6	35,3	4	66,7	70,83	15,96
Cycle 19 Day 1	0	8	53,3	4	50,0	58,33	21,52
	1	5	29,4	4	80,0	54,17	45,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	70,00	24,72
	1	4	23,5	4	100,0	66,67	38,49
Cycle 21 Day 1	0	3	20,0	3	100,0	61,11	25,46
	1	4	23,5	1	25,0	50,00	-
Cycle 22 Day 1	0	3	20,0	2	66,7	58,33	35,36
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	83,33	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	83,33	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	77,78	9,62
	1	7	41,2	2	28,6	58,33	58,93
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	84,62	14,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	83,33	23,57
	2 or More	21	100,0	19	90,5	79,82	23,29
Cycle 2 Day 1	None	14	100,0	12	85,7	73,61	24,06
	1	1	50,0	1	100,0	100,00	-
	2 or More	18	85,7	16	88,9	78,13	18,97
Cycle 3 Day 1	None	14	100,0	13	92,9	70,51	28,18
	1	1	50,0	1	100,0	100,00	-
	2 or More	17	81,0	16	94,1	70,83	19,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	83,33	18,80
	1	1	50,0	1	100,0	100,00	-
	2 or More	17	81,0	15	88,2	77,78	20,57
Cycle 5 Day 1	None	14	100,0	14	100,0	80,95	21,54
	1	1	50,0	1	100,0	83,33	-
	2 or More	16	76,2	14	87,5	72,62	22,27
Cycle 6 Day 1	None	14	100,0	14	100,0	78,57	16,57
	1	1	50,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	70,24	14,88
Cycle 7 Day 1	None	14	100,0	13	92,9	76,92	25,04
	1	1	50,0	1	100,0	83,33	-
	2 or More	15	71,4	13	86,7	73,08	16,01
Cycle 8 Day 1	None	14	100,0	13	92,9	69,23	27,93
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	79,17	20,26
Cycle 9 Day 1	None	13	92,9	13	100,0	79,49	18,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	83,33	-
	2 or More	11	52,4	11	100,0	81,82	22,92
Cycle 10 Day 1	None	13	92,9	12	92,3	76,39	20,67
	1	1	50,0	1	100,0	100,00	-
	2 or More	11	52,4	11	100,0	84,85	21,67
Cycle 11 Day 1	None	13	92,9	13	100,0	75,64	23,19
	1	1	50,0	1	100,0	100,00	-
	2 or More	10	47,6	10	100,0	83,33	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	66,67	23,57
	1	1	50,0	1	100,0	83,33	-
	2 or More	10	47,6	8	80,0	83,33	12,60
Cycle 13 Day 1	None	12	85,7	11	91,7	71,21	19,85
	1	1	50,0	1	100,0	100,00	-
	2 or More	9	42,9	9	100,0	79,63	28,60
Cycle 14 Day 1	None	12	85,7	12	100,0	72,22	25,95
	1	1	50,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	79,63	21,70
Cycle 15 Day 1	None	12	85,7	12	100,0	69,44	30,01
	1	1	50,0	1	100,0	83,33	-
	2 or More	9	42,9	8	88,9	77,08	23,46
Cycle 16 Day 1	None	11	78,6	8	72,7	72,92	17,68
	1	1	50,0	1	100,0	83,33	-
	2 or More	9	42,9	6	66,7	80,56	26,70
Cycle 17 Day 1	None	10	71,4	7	70,0	80,95	11,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	100,00	-
	2 or More	7	33,3	6	85,7	72,22	25,09
Cycle 18 Day 1	None	8	57,1	4	50,0	62,50	20,97
	1	1	50,0	1	100,0	100,00	-
	2 or More	6	28,6	3	50,0	72,22	19,25
Cycle 19 Day 1	None	7	50,0	3	42,9	38,89	41,94
	1	1	50,0	1	100,0	83,33	-
	2 or More	5	23,8	4	80,0	62,50	28,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	62,50	34,36
	1	1	50,0	1	100,0	100,00	-
	2 or More	4	19,0	4	100,0	66,67	27,22
Cycle 21 Day 1	None	4	28,6	2	50,0	58,33	35,36
	2 or More	3	14,3	2	66,7	58,33	11,79
Cycle 22 Day 1	None	4	28,6	1	25,0	83,33	-
	2 or More	3	14,3	1	33,3	33,33	-
Cycle 23 Day 1	None	2	14,3	1	50,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	83,33	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	83,33	-
	1	2	100,0	1	50,0	83,33	-
	2 or More	9	42,9	3	33,3	61,11	41,94
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	84,62	14,37
	Previously Treated	23	100,0	21	91,3	80,16	22,74
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	73,61	24,06
	Previously Treated	19	82,6	17	89,5	79,41	19,12
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	70,51	28,18
	Previously Treated	18	78,3	17	94,4	72,55	20,36
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	83,33	18,80
	Previously Treated	18	78,3	16	88,9	79,17	20,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	80,95	21,54
	Previously Treated	17	73,9	15	88,2	73,33	21,64
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	78,57	16,57
	Previously Treated	17	73,9	15	88,2	71,11	14,73
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	76,92	25,04
	Previously Treated	16	69,6	14	87,5	73,81	15,63
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	69,23	27,93
	Previously Treated	14	60,9	12	85,7	79,17	20,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	79,49	18,20
	Previously Treated	12	52,2	12	100,0	81,94	21,86
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	76,39	20,67
	Previously Treated	12	52,2	12	100,0	86,11	21,12
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	75,64	23,19
	Previously Treated	11	47,8	11	100,0	84,85	17,41
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	66,67	23,57
	Previously Treated	11	47,8	9	81,8	83,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	71,21	19,85
	Previously Treated	10	43,5	10	100,0	81,67	27,72
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	72,22	25,95
	Previously Treated	10	43,5	10	100,0	80,00	20,49
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	69,44	30,01
	Previously Treated	10	43,5	9	90,0	77,78	22,05
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	72,92	17,68
	Previously Treated	10	43,5	7	70,0	80,95	24,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	80,95	11,50
	Previously Treated	8	34,8	7	87,5	76,19	25,20
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	62,50	20,97
	Previously Treated	7	30,4	4	57,1	79,17	20,97
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	38,89	41,94
	Previously Treated	6	26,1	5	83,3	66,67	26,35
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	62,50	34,36
	Previously Treated	5	21,7	5	100,0	73,33	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	58,33	35,36
	Previously Treated	3	13,0	2	66,7	58,33	11,79
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	83,33	-
	Previously Treated	3	13,0	1	33,3	33,33	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	83,33	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	83,33	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	83,33	-
	Previously Treated	11	47,8	4	36,4	66,67	36,00
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	75,00	27,06
	Central	25	100,0	22	88,0	85,61	13,89
Cycle 2 Day 1	Local	11	91,7	10	90,9	68,33	22,84
	Central	22	88,0	19	86,4	81,58	19,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	69,70	28,69
	Central	21	84,0	19	90,5	72,81	20,94
Cycle 4 Day 1	Local	11	91,7	10	90,9	85,00	18,34
	Central	21	84,0	18	85,7	78,70	20,46
Cycle 5 Day 1	Local	11	91,7	10	90,9	76,67	26,29
	Central	20	80,0	19	95,0	77,19	19,41
Cycle 6 Day 1	Local	11	91,7	11	100,0	75,76	17,26
	Central	20	80,0	18	90,0	74,07	15,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	77,27	25,03
	Central	19	76,0	16	84,2	73,96	17,18
Cycle 8 Day 1	Local	10	83,3	10	100,0	76,67	26,29
	Central	18	72,0	15	83,3	72,22	24,12
Cycle 9 Day 1	Local	10	83,3	10	100,0	78,33	22,29
	Central	15	60,0	15	100,0	82,22	18,33
Cycle 10 Day 1	Local	10	83,3	9	90,0	81,48	21,15
	Central	15	60,0	15	100,0	81,11	21,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	77,78	25,00
	Central	15	60,0	15	100,0	81,11	18,76
Cycle 12 Day 1	Local	9	75,0	8	88,9	70,83	27,82
	Central	15	60,0	13	86,7	75,64	16,12
Cycle 13 Day 1	Local	8	66,7	8	100,0	64,58	30,13
	Central	14	56,0	13	92,9	83,33	16,67
Cycle 14 Day 1	Local	8	66,7	8	100,0	68,75	27,37
	Central	14	56,0	14	100,0	79,76	20,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	66,67	35,63
	Central	14	56,0	13	92,9	76,92	19,88
Cycle 16 Day 1	Local	8	66,7	6	75,0	72,22	20,18
	Central	13	52,0	9	69,2	79,63	21,70
Cycle 17 Day 1	Local	8	66,7	5	62,5	76,67	9,13
	Central	10	40,0	9	90,0	79,63	23,24
Cycle 18 Day 1	Local	6	50,0	4	66,7	62,50	20,97
	Central	9	36,0	4	44,4	79,17	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	41,67	34,69
	Central	8	32,0	4	50,0	70,83	28,46
Cycle 20 Day 1	Local	5	41,7	5	100,0	63,33	29,81
	Central	4	16,0	4	100,0	75,00	31,91
Cycle 21 Day 1	Local	4	33,3	2	50,0	58,33	35,36
	Central	3	12,0	2	66,7	58,33	11,79
Cycle 22 Day 1	Local	4	33,3	1	25,0	83,33	-
	Central	3	12,0	1	33,3	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	83,33	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	83,33	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	83,33	23,57
	Central	8	32,0	3	37,5	61,11	38,49

BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	82,81	20,07
	No	2	100,0	2	100,0	66,67	0,00
Cycle 2 Day 1	Yes	32	91,4	28	87,5	77,98	20,81
	No	1	50,0	1	100,0	50,00	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	73,56	21,60
	No	1	50,0	1	100,0	16,67	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	82,10	19,02
	No	1	50,0	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	76,19	21,48
	No	1	50,0	1	100,0	100,00	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	75,60	15,37
	No	1	50,0	1	100,0	50,00	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	77,56	16,96
	No	1	50,0	1	100,0	16,67	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	76,39	21,93
	No	1	50,0	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	81,25	19,85
	No	1	50,0	1	100,0	66,67	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	81,16	21,50
	No	1	50,0	1	100,0	83,33	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	81,16	20,29
	No	1	50,0	1	100,0	50,00	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	76,67	16,58
	No	1	50,0	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	78,33	22,36
	No	1	50,0	1	100,0	33,33	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	77,78	21,94
	No	1	50,0	1	100,0	33,33	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	76,67	21,22
	No	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	78,57	20,07
	No	1	50,0	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	78,21	19,70
	No	1	50,0	1	100,0	83,33	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	71,43	23,00
	No	1	50,0	1	100,0	66,67	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	64,29	26,23
	No	1	50,0	1	100,0	0,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	72,92	28,08
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	58,33	21,52
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	58,33	35,36
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	83,33	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	83,33	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	70,00	32,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	83,33	0,00
	No	33	100,0	31	93,9	81,72	20,80
Cycle 2 Day 1	Yes	2	50,0	1	50,0	100,00	-
	No	31	93,9	28	90,3	76,19	21,00
Cycle 3 Day 1	Yes	2	50,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	70,83	23,84
Cycle 4 Day 1	Yes	2	50,0	2	100,0	83,33	23,57
	No	30	90,9	26	86,7	80,77	19,83
Cycle 5 Day 1	Yes	2	50,0	2	100,0	66,67	23,57
	No	29	87,9	27	93,1	77,78	21,68
Cycle 6 Day 1	Yes	2	50,0	2	100,0	75,00	11,79
	No	29	87,9	27	93,1	74,69	16,26
Cycle 7 Day 1	Yes	2	50,0	2	100,0	58,33	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	76,67	19,25
Cycle 8 Day 1	Yes	2	50,0	2	100,0	33,33	23,57
	No	26	78,8	23	88,5	77,54	21,68
Cycle 9 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	24	72,7	24	100,0	81,25	19,85
Cycle 10 Day 1	Yes	1	25,0	1	100,0	50,00	-
	No	24	72,7	23	95,8	82,61	20,40
Cycle 11 Day 1	Yes	1	25,0	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	81,16	20,29
Cycle 12 Day 1	Yes	1	25,0	1	100,0	50,00	-
	No	23	69,7	20	87,0	75,00	20,59
Cycle 13 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	21	63,6	20	95,2	76,67	24,42
Cycle 14 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	21	100,0	77,78	21,94
Cycle 15 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	75,00	25,65
Cycle 16 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	20	60,6	14	70,0	77,38	21,29
Cycle 17 Day 1	Yes	1	25,0	1	100,0	83,33	-
	No	17	51,5	13	76,5	78,21	19,70
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	70,83	21,36
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	56,25	33,26
Cycle 20 Day 1	No	9	27,3	9	100,0	68,52	29,40
Cycle 21 Day 1	No	7	21,2	4	57,1	58,33	21,52
Cycle 22 Day 1	No	7	21,2	2	28,6	58,33	35,36
Cycle 23 Day 1	No	4	12,1	1	25,0	83,33	-
Cycle 24 Day 1	No	1	3,0	1	100,0	83,33	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	83,33	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CF_SG.xls
07SEP2019 19:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	20,59	29,60
Cycle 2 Day 1	All	33	89,2	29	87,9	47,13	35,09
Cycle 3 Day 1	All	32	86,5	30	93,8	51,11	31,24
Cycle 4 Day 1	All	32	86,5	28	87,5	38,10	34,80
Cycle 5 Day 1	All	31	83,8	29	93,5	39,08	30,95
Cycle 6 Day 1	All	31	83,8	29	93,5	35,63	28,07
Cycle 7 Day 1	All	30	81,1	27	90,0	32,10	29,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	33,33	30,43
Cycle 9 Day 1	All	25	67,6	25	100,0	33,33	21,52
Cycle 10 Day 1	All	25	67,6	24	96,0	27,78	21,23
Cycle 11 Day 1	All	24	64,9	24	100,0	27,78	21,23
Cycle 12 Day 1	All	24	64,9	21	87,5	25,40	23,34
Cycle 13 Day 1	All	22	59,5	21	95,5	25,40	23,34
Cycle 14 Day 1	All	22	59,5	22	100,0	34,85	31,67
Cycle 15 Day 1	All	22	59,5	21	95,5	34,92	28,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	35,56	34,43
Cycle 17 Day 1	All	18	48,6	14	77,8	38,10	28,81
Cycle 18 Day 1	All	15	40,5	8	53,3	20,83	24,80
Cycle 19 Day 1	All	13	35,1	8	61,5	41,67	29,55
Cycle 20 Day 1	All	9	24,3	9	100,0	29,63	26,06
Cycle 21 Day 1	All	7	18,9	4	57,1	33,33	38,49
Cycle 22 Day 1	All	7	18,9	2	28,6	16,67	23,57
Cycle 23 Day 1	All	4	10,8	1	25,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	0,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	13,33	18,26
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	23,08	34,39
	Female	23	100,0	21	91,3	19,05	27,02
Cycle 2 Day 1	Male	13	92,9	12	92,3	47,22	30,01
	Female	20	87,0	17	85,0	47,06	39,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	44,44	21,71
	Female	20	87,0	18	90,0	55,56	36,16
Cycle 4 Day 1	Male	12	85,7	11	91,7	36,36	37,87
	Female	20	87,0	17	85,0	39,22	33,82
Cycle 5 Day 1	Male	12	85,7	11	91,7	39,39	29,13
	Female	19	82,6	18	94,7	38,89	32,84
Cycle 6 Day 1	Male	12	85,7	11	91,7	36,36	27,71
	Female	19	82,6	18	94,7	35,19	29,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	33,33	29,81
	Female	19	82,6	16	84,2	31,25	30,96
Cycle 8 Day 1	Male	10	71,4	9	90,0	29,63	35,14
	Female	18	78,3	16	88,9	35,42	28,46
Cycle 9 Day 1	Male	8	57,1	8	100,0	33,33	25,20
	Female	17	73,9	17	100,0	33,33	20,41
Cycle 10 Day 1	Male	8	57,1	8	100,0	29,17	21,36
	Female	17	73,9	16	94,1	27,08	21,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	25,00	15,43
	Female	16	69,6	16	100,0	29,17	23,96
Cycle 12 Day 1	Male	8	57,1	8	100,0	25,00	23,57
	Female	16	69,6	13	81,3	25,64	24,17
Cycle 13 Day 1	Male	8	57,1	8	100,0	25,00	15,43
	Female	14	60,9	13	92,9	25,64	27,74
Cycle 14 Day 1	Male	8	57,1	8	100,0	29,17	33,03
	Female	14	60,9	14	100,0	38,10	31,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	25,00	29,55
	Female	14	60,9	13	92,9	41,03	27,74
Cycle 16 Day 1	Male	8	57,1	5	62,5	33,33	23,57
	Female	13	56,5	10	76,9	36,67	39,91
Cycle 17 Day 1	Male	6	42,9	2	33,3	50,00	23,57
	Female	12	52,2	12	100,0	36,11	30,01
Cycle 18 Day 1	Male	3	21,4	2	66,7	16,67	23,57
	Female	12	52,2	6	50,0	22,22	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	66,67	0,00
	Female	11	47,8	6	54,5	33,33	29,81
Cycle 20 Day 1	Male	2	14,3	2	100,0	50,00	23,57
	Female	7	30,4	7	100,0	23,81	25,20
Cycle 21 Day 1	Male	1	7,1	1	100,0	66,67	-
	Female	6	26,1	3	50,0	22,22	38,49
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	0,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	0,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	16,67	23,57
	Female	7	30,4	3	42,9	11,11	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	17,28	29,77
	65-74	8	100,0	7	87,5	33,33	27,22
Cycle 2 Day 1	18-64	27	93,1	24	88,9	45,83	36,53
	65-74	6	75,0	5	83,3	53,33	29,81
Cycle 3 Day 1	18-64	26	89,7	24	92,3	48,61	31,05
	65-74	6	75,0	6	100,0	61,11	32,77
Cycle 4 Day 1	18-64	26	89,7	23	88,5	37,68	36,66
	65-74	6	75,0	5	83,3	40,00	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	33,33	30,15
	65-74	6	75,0	6	100,0	61,11	25,09
Cycle 6 Day 1	18-64	25	86,2	24	96,0	34,72	30,26
	65-74	6	75,0	5	83,3	40,00	14,91
Cycle 7 Day 1	18-64	25	86,2	23	92,0	33,33	31,78
	65-74	5	62,5	4	80,0	25,00	16,67
Cycle 8 Day 1	18-64	23	79,3	20	87,0	31,67	29,57
	65-74	5	62,5	5	100,0	40,00	36,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	30,00	21,36
	65-74	5	62,5	5	100,0	46,67	18,26
Cycle 10 Day 1	18-64	20	69,0	19	95,0	28,07	20,07
	65-74	5	62,5	5	100,0	26,67	27,89
Cycle 11 Day 1	18-64	19	65,5	19	100,0	28,07	20,07
	65-74	5	62,5	5	100,0	26,67	27,89
Cycle 12 Day 1	18-64	19	65,5	17	89,5	25,49	22,14
	65-74	5	62,5	4	80,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	22,92	23,47
	65-74	5	62,5	5	100,0	33,33	23,57
Cycle 14 Day 1	18-64	17	58,6	17	100,0	31,37	32,21
	65-74	5	62,5	5	100,0	46,67	29,81
Cycle 15 Day 1	18-64	17	58,6	16	94,1	31,25	25,73
	65-74	5	62,5	5	100,0	46,67	38,01
Cycle 16 Day 1	18-64	17	58,6	13	76,5	30,77	31,80
	65-74	4	50,0	2	50,0	66,67	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	38,89	31,25
	65-74	3	37,5	2	66,7	33,33	0,00
Cycle 18 Day 1	18-64	13	44,8	8	61,5	20,83	24,80
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	38,10	29,99
	65-74	2	25,0	1	50,0	66,67	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	29,17	27,82
	65-74	1	12,5	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	33,33	38,49
Cycle 22 Day 1	18-64	7	24,1	2	28,6	16,67	23,57
Cycle 23 Day 1	18-64	4	13,8	1	25,0	0,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	0,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	11,11	19,25
	65-74	6	75,0	2	33,3	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	31,37	34,30
	Other	17	100,0	17	100,0	9,80	19,60
Cycle 2 Day 1	White	19	95,0	16	84,2	39,58	27,81
	Other	14	82,4	13	92,9	56,41	41,69
Cycle 3 Day 1	White	18	90,0	16	88,9	43,75	31,55
	Other	14	82,4	14	100,0	59,52	29,75
Cycle 4 Day 1	White	18	90,0	15	83,3	26,67	28,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	51,28	37,55
Cycle 5 Day 1	White	18	90,0	17	94,4	27,45	21,20
	Other	13	76,5	12	92,3	55,56	35,77
Cycle 6 Day 1	White	18	90,0	16	88,9	31,25	28,46
	Other	13	76,5	13	100,0	41,03	27,74
Cycle 7 Day 1	White	17	85,0	15	88,2	22,22	16,27
	Other	13	76,5	12	92,3	44,44	38,49
Cycle 8 Day 1	White	17	85,0	14	82,4	28,57	22,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	39,39	38,92
Cycle 9 Day 1	White	16	80,0	16	100,0	33,33	24,34
	Other	9	52,9	9	100,0	33,33	16,67
Cycle 10 Day 1	White	16	80,0	15	93,8	31,11	19,79
	Other	9	52,9	9	100,0	22,22	23,57
Cycle 11 Day 1	White	16	80,0	16	100,0	27,08	18,13
	Other	8	47,1	8	100,0	29,17	27,82
Cycle 12 Day 1	White	16	80,0	13	81,3	30,77	25,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	16,67	17,82
Cycle 13 Day 1	White	14	70,0	13	92,9	17,95	22,01
	Other	8	47,1	8	100,0	37,50	21,36
Cycle 14 Day 1	White	14	70,0	14	100,0	33,33	32,03
	Other	8	47,1	8	100,0	37,50	33,03
Cycle 15 Day 1	White	14	70,0	13	92,9	35,90	28,74
	Other	8	47,1	8	100,0	33,33	30,86
Cycle 16 Day 1	White	14	70,0	9	64,3	37,04	35,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	33,33	36,51
Cycle 17 Day 1	White	13	65,0	10	76,9	33,33	22,22
	Other	5	29,4	4	80,0	50,00	43,03
Cycle 18 Day 1	White	11	55,0	4	36,4	16,67	19,25
	Other	4	23,5	4	100,0	25,00	31,91
Cycle 19 Day 1	White	9	45,0	5	55,6	46,67	29,81
	Other	4	23,5	3	75,0	33,33	33,33
Cycle 20 Day 1	White	5	25,0	5	100,0	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	25,00	31,91
Cycle 21 Day 1	White	3	15,0	2	66,7	33,33	47,14
	Other	4	23,5	2	50,0	33,33	47,14
Cycle 22 Day 1	White	3	15,0	1	33,3	33,33	-
	Other	4	23,5	1	25,0	0,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	0,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	22,22	19,25
	Other	9	52,9	2	22,2	0,00	0,00
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	30,56	33,21
	Europe (EU)	10	100,0	8	80,0	20,83	35,36
	Asia (AS)	15	100,0	14	93,3	11,90	21,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	37,04	30,93
	Europe (EU)	9	90,0	8	88,9	50,00	35,63
	Asia (AS)	13	86,7	12	92,3	52,78	38,82
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	45,45	30,81
	Europe (EU)	8	80,0	6	75,0	61,11	38,97
	Asia (AS)	13	86,7	13	100,0	51,28	29,24
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	30,30	27,71
	Europe (EU)	8	80,0	4	50,0	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	48,72	42,20
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	30,30	31,46
	Europe (EU)	8	80,0	7	87,5	38,10	23,00
	Asia (AS)	12	80,0	11	91,7	48,48	34,52
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	27,27	29,13
	Europe (EU)	8	80,0	7	87,5	38,10	23,00
	Asia (AS)	12	80,0	11	91,7	42,42	30,15
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	28,57	12,60
	Asia (AS)	11	73,3	10	90,9	53,33	35,83
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	26,67	34,43
	Europe (EU)	8	80,0	6	75,0	22,22	17,21
	Asia (AS)	9	60,0	9	100,0	48,15	29,40
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	24,24	21,56
	Europe (EU)	7	70,0	7	100,0	42,86	25,20
	Asia (AS)	7	46,7	7	100,0	38,10	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	16,67	17,57
	Europe (EU)	7	70,0	7	100,0	38,10	23,00
	Asia (AS)	7	46,7	7	100,0	33,33	19,25
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	15,15	17,41
	Europe (EU)	7	70,0	7	100,0	33,33	19,25
	Asia (AS)	6	40,0	6	100,0	44,44	17,21
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	20,00	23,31
	Europe (EU)	7	70,0	5	71,4	46,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	16,67	18,26
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	20,00	17,21
	Europe (EU)	6	60,0	5	83,3	26,67	27,89
	Asia (AS)	6	40,0	6	100,0	33,33	29,81
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	26,67	30,63
	Europe (EU)	6	60,0	6	100,0	33,33	36,51
	Asia (AS)	6	40,0	6	100,0	50,00	27,89
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	23,33	22,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	40,00	43,46
	Asia (AS)	6	40,0	6	100,0	50,00	18,26
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	28,57	29,99
	Europe (EU)	6	60,0	2	33,3	66,67	47,14
	Asia (AS)	6	40,0	6	100,0	33,33	36,51
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	27,78	25,09
	Europe (EU)	4	40,0	3	75,0	22,22	19,25
	Asia (AS)	5	33,3	5	100,0	60,00	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	13,33	18,26
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	33,33	33,33
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	41,67	31,91
	Europe (EU)	3	30,0	1	33,3	66,67	-
	Asia (AS)	4	26,7	3	75,0	33,33	33,33
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	26,67	27,89
	Europe (EU)	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	33,33	33,33
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	22,22	38,49
	Asia (AS)	3	20,0	1	33,3	66,67	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	16,67	23,57
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	0,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	11,11	19,25
	Europe (EU)	2	20,0	1	50,0	33,33	-
	Asia (AS)	7	46,7	1	14,3	0,00	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	13,89	22,29
	1	17	100,0	17	100,0	23,53	34,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	26,67	27,89
Cycle 2 Day 1	0	15	100,0	12	80,0	36,11	33,21
	1	15	88,2	14	93,3	57,14	33,15
	2	3	60,0	3	100,0	44,44	50,92
Cycle 3 Day 1	0	15	100,0	14	93,3	47,62	31,25
	1	14	82,4	13	92,9	51,28	25,88
	2	3	60,0	3	100,0	66,67	57,74
Cycle 4 Day 1	0	15	100,0	14	93,3	33,33	32,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	41,67	40,51
	2	3	60,0	2	66,7	50,00	23,57
Cycle 5 Day 1	0	15	100,0	15	100,0	37,78	30,52
	1	14	82,4	12	85,7	41,67	35,18
	2	2	40,0	2	100,0	33,33	0,00
Cycle 6 Day 1	0	15	100,0	15	100,0	26,67	22,54
	1	14	82,4	12	85,7	47,22	33,21
	2	2	40,0	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	21,43	16,57
	1	13	76,5	11	84,6	45,45	40,20
	2	2	40,0	2	100,0	33,33	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	33,33	30,43
	1	11	64,7	10	90,9	36,67	33,15
	2	2	40,0	2	100,0	16,67	23,57
Cycle 9 Day 1	0	14	93,3	14	100,0	33,33	26,15
	1	10	58,8	10	100,0	33,33	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	33,33	-
Cycle 10 Day 1	0	14	93,3	14	100,0	26,19	23,31
	1	10	58,8	9	90,0	29,63	20,03
	2	1	20,0	1	100,0	33,33	-
Cycle 11 Day 1	0	14	93,3	14	100,0	21,43	21,11
	1	9	52,9	9	100,0	37,04	20,03
	2	1	20,0	1	100,0	33,33	-
Cycle 12 Day 1	0	14	93,3	12	85,7	22,22	25,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	25,00	15,43
	2	1	20,0	1	100,0	66,67	-
Cycle 13 Day 1	0	14	93,3	13	92,9	20,51	21,68
	1	8	47,1	8	100,0	33,33	25,20
Cycle 14 Day 1	0	14	93,3	14	100,0	30,95	33,24
	1	8	47,1	8	100,0	41,67	29,55
Cycle 15 Day 1	0	14	93,3	14	100,0	33,33	32,03
	1	8	47,1	7	87,5	38,10	23,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	37,50	37,53
	1	8	47,1	7	87,5	33,33	33,33
Cycle 17 Day 1	0	12	80,0	8	66,7	25,00	23,57
	1	6	35,3	6	100,0	55,56	27,22
Cycle 18 Day 1	0	9	60,0	4	44,4	8,33	16,67
	1	6	35,3	4	66,7	33,33	27,22
Cycle 19 Day 1	0	8	53,3	4	50,0	50,00	33,33
	1	5	29,4	4	80,0	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	33,33	23,57
	1	4	23,5	4	100,0	25,00	31,91
Cycle 21 Day 1	0	3	20,0	3	100,0	22,22	38,49
	1	4	23,5	1	25,0	66,67	-
Cycle 22 Day 1	0	3	20,0	2	66,7	16,67	23,57
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	0,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	22,22	19,25
	1	7	41,2	2	28,6	0,00	0,00
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	15,38	22,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	33,33	47,14
	2 or More	21	100,0	19	90,5	22,81	33,43
Cycle 2 Day 1	None	14	100,0	12	85,7	41,67	37,94
	1	1	50,0	1	100,0	33,33	-
	2 or More	18	85,7	16	88,9	52,08	34,36
Cycle 3 Day 1	None	14	100,0	13	92,9	48,72	35,00
	1	1	50,0	1	100,0	33,33	-
	2 or More	17	81,0	16	94,1	54,17	29,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	36,11	38,82
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	42,22	32,04
Cycle 5 Day 1	None	14	100,0	14	100,0	35,71	33,24
	1	1	50,0	1	100,0	33,33	-
	2 or More	16	76,2	14	87,5	42,86	30,46
Cycle 6 Day 1	None	14	100,0	14	100,0	28,57	25,68
	1	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	42,86	30,46
Cycle 7 Day 1	None	14	100,0	13	92,9	23,08	28,50
	1	1	50,0	1	100,0	33,33	-
	2 or More	15	71,4	13	86,7	41,03	30,89
Cycle 8 Day 1	None	14	100,0	13	92,9	35,90	37,17
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	30,56	22,29
Cycle 9 Day 1	None	13	92,9	13	100,0	25,64	19,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	33,33	-
	2 or More	11	52,4	11	100,0	42,42	21,56
Cycle 10 Day 1	None	13	92,9	12	92,3	19,44	17,16
	1	1	50,0	1	100,0	33,33	-
	2 or More	11	52,4	11	100,0	36,36	23,35
Cycle 11 Day 1	None	13	92,9	13	100,0	20,51	16,88
	1	1	50,0	1	100,0	33,33	-
	2 or More	10	47,6	10	100,0	36,67	24,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	22,22	25,95
	1	1	50,0	1	100,0	33,33	-
	2 or More	10	47,6	8	80,0	29,17	21,36
Cycle 13 Day 1	None	12	85,7	11	91,7	21,21	16,82
	1	1	50,0	1	100,0	33,33	-
	2 or More	9	42,9	9	100,0	29,63	30,93
Cycle 14 Day 1	None	12	85,7	12	100,0	30,56	36,12
	1	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	40,74	27,78
Cycle 15 Day 1	None	12	85,7	12	100,0	19,44	22,29
	1	1	50,0	1	100,0	33,33	-
	2 or More	9	42,9	8	88,9	58,33	23,57
Cycle 16 Day 1	None	11	78,6	8	72,7	25,00	34,50
	1	1	50,0	1	100,0	66,67	-
	2 or More	9	42,9	6	66,7	44,44	34,43
Cycle 17 Day 1	None	10	71,4	7	70,0	38,10	35,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	33,33	-
	2 or More	7	33,3	6	85,7	38,89	25,09
Cycle 18 Day 1	None	8	57,1	4	50,0	8,33	16,67
	1	1	50,0	1	100,0	33,33	-
	2 or More	6	28,6	3	50,0	33,33	33,33
Cycle 19 Day 1	None	7	50,0	3	42,9	55,56	19,25
	1	1	50,0	1	100,0	66,67	-
	2 or More	5	23,8	4	80,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	33,33	38,49
	1	1	50,0	1	100,0	33,33	-
	2 or More	4	19,0	4	100,0	25,00	16,67
Cycle 21 Day 1	None	4	28,6	2	50,0	33,33	47,14
	2 or More	3	14,3	2	66,7	33,33	47,14
Cycle 22 Day 1	None	4	28,6	1	25,0	0,00	-
	2 or More	3	14,3	1	33,3	33,33	-
Cycle 23 Day 1	None	2	14,3	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	0,00	-
	1	2	100,0	1	50,0	33,33	-
	2 or More	9	42,9	3	33,3	11,11	19,25
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	15,38	22,01
	Previously Treated	23	100,0	21	91,3	23,81	33,57
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	41,67	37,94
	Previously Treated	19	82,6	17	89,5	50,98	33,58
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	48,72	35,00
	Previously Treated	18	78,3	17	94,4	52,94	29,01
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	36,11	38,82
	Previously Treated	18	78,3	16	88,9	39,58	32,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	35,71	33,24
	Previously Treated	17	73,9	15	88,2	42,22	29,46
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	28,57	25,68
	Previously Treated	17	73,9	15	88,2	42,22	29,46
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	23,08	28,50
	Previously Treated	16	69,6	14	87,5	40,48	29,75
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	35,90	37,17
	Previously Treated	14	60,9	12	85,7	30,56	22,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	25,64	19,97
	Previously Treated	12	52,2	12	100,0	41,67	20,72
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	19,44	17,16
	Previously Treated	12	52,2	12	100,0	36,11	22,29
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	20,51	16,88
	Previously Treated	11	47,8	11	100,0	36,36	23,35
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	22,22	25,95
	Previously Treated	11	47,8	9	81,8	29,63	20,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	21,21	16,82
	Previously Treated	10	43,5	10	100,0	30,00	29,19
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	30,56	36,12
	Previously Treated	10	43,5	10	100,0	40,00	26,29
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	19,44	22,29
	Previously Treated	10	43,5	9	90,0	55,56	23,57
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	25,00	34,50
	Previously Treated	10	43,5	7	70,0	47,62	32,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	38,10	35,63
	Previously Treated	8	34,8	7	87,5	38,10	23,00
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	8,33	16,67
	Previously Treated	7	30,4	4	57,1	33,33	27,22
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	55,56	19,25
	Previously Treated	6	26,1	5	83,3	33,33	33,33
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	33,33	38,49
	Previously Treated	5	21,7	5	100,0	26,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	33,33	47,14
	Previously Treated	3	13,0	2	66,7	33,33	47,14
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	0,00	-
	Previously Treated	3	13,0	1	33,3	33,33	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	11	47,8	4	36,4	16,67	19,25
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	27,78	34,33
	Central	25	100,0	22	88,0	16,67	26,73
Cycle 2 Day 1	Local	11	91,7	10	90,9	43,33	38,65
	Central	22	88,0	19	86,4	49,12	34,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	48,48	34,52
	Central	21	84,0	19	90,5	52,63	30,05
Cycle 4 Day 1	Local	11	91,7	10	90,9	26,67	34,43
	Central	21	84,0	18	85,7	44,44	34,30
Cycle 5 Day 1	Local	11	91,7	10	90,9	23,33	27,44
	Central	20	80,0	19	95,0	47,37	30,05
Cycle 6 Day 1	Local	11	91,7	11	100,0	30,30	31,46
	Central	20	80,0	18	90,0	38,89	26,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	18,18	22,92
	Central	19	76,0	16	84,2	41,67	31,03
Cycle 8 Day 1	Local	10	83,3	10	100,0	16,67	23,57
	Central	18	72,0	15	83,3	44,44	29,99
Cycle 9 Day 1	Local	10	83,3	10	100,0	26,67	26,29
	Central	15	60,0	15	100,0	37,78	17,21
Cycle 10 Day 1	Local	10	83,3	9	90,0	22,22	23,57
	Central	15	60,0	15	100,0	31,11	19,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	22,22	23,57
	Central	15	60,0	15	100,0	31,11	19,79
Cycle 12 Day 1	Local	9	75,0	8	88,9	25,00	29,55
	Central	15	60,0	13	86,7	25,64	19,97
Cycle 13 Day 1	Local	8	66,7	8	100,0	25,00	23,57
	Central	14	56,0	13	92,9	25,64	24,17
Cycle 14 Day 1	Local	8	66,7	8	100,0	45,83	46,93
	Central	14	56,0	14	100,0	28,57	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	29,17	37,53
	Central	14	56,0	13	92,9	38,46	22,96
Cycle 16 Day 1	Local	8	66,7	6	75,0	44,44	45,54
	Central	13	52,0	9	69,2	29,63	26,06
Cycle 17 Day 1	Local	8	66,7	5	62,5	46,67	38,01
	Central	10	40,0	9	90,0	33,33	23,57
Cycle 18 Day 1	Local	6	50,0	4	66,7	8,33	16,67
	Central	9	36,0	4	44,4	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	58,33	16,67
	Central	8	32,0	4	50,0	25,00	31,91
Cycle 20 Day 1	Local	5	41,7	5	100,0	33,33	33,33
	Central	4	16,0	4	100,0	25,00	16,67
Cycle 21 Day 1	Local	4	33,3	2	50,0	33,33	47,14
	Central	3	12,0	2	66,7	33,33	47,14
Cycle 22 Day 1	Local	4	33,3	1	25,0	0,00	-
	Central	3	12,0	1	33,3	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	0,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	0,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	16,67	23,57
	Central	8	32,0	3	37,5	11,11	19,25
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	19,79	29,16
	No	2	100,0	2	100,0	33,33	47,14
Cycle 2 Day 1	Yes	32	91,4	28	87,5	45,24	34,20
	No	1	50,0	1	100,0	100,00	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	49,43	30,37
	No	1	50,0	1	100,0	100,00	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	39,51	34,64
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	39,29	31,50
	No	1	50,0	1	100,0	33,33	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	35,71	28,59
	No	1	50,0	1	100,0	33,33	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	32,05	30,52
	No	1	50,0	1	100,0	33,33	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	33,33	31,08
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	33,33	21,98
	No	1	50,0	1	100,0	33,33	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	27,54	21,68
	No	1	50,0	1	100,0	33,33	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	27,54	21,68
	No	1	50,0	1	100,0	33,33	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	25,00	23,88
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	25,00	23,88
	No	1	50,0	1	100,0	33,33	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	31,75	28,82
	No	1	50,0	1	100,0	100,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	33,33	28,61
	No	1	50,0	1	100,0	66,67	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	30,95	30,56
	No	1	50,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	33,33	23,57
	No	1	50,0	1	100,0	100,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	23,81	25,20
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	38,10	29,99
	No	1	50,0	1	100,0	66,67	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	25,00	23,57
	No	1	50,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	33,33	38,49
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	16,67	23,57
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	0,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	0,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	11,11	19,25
	No	33	100,0	31	93,9	21,51	30,49
Cycle 2 Day 1	Yes	2	50,0	1	50,0	66,67	-
	No	31	93,9	28	90,3	46,43	35,53
Cycle 3 Day 1	Yes	2	50,0	2	100,0	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	51,19	32,05
Cycle 4 Day 1	Yes	2	50,0	2	100,0	100,00	0,00
	No	30	90,9	26	86,7	33,33	31,27
Cycle 5 Day 1	Yes	2	50,0	2	100,0	66,67	47,14
	No	29	87,9	27	93,1	37,04	29,72
Cycle 6 Day 1	Yes	2	50,0	2	100,0	66,67	47,14
	No	29	87,9	27	93,1	33,33	26,15
Cycle 7 Day 1	Yes	2	50,0	2	100,0	66,67	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	29,33	27,76
Cycle 8 Day 1	Yes	2	50,0	2	100,0	83,33	23,57
	No	26	78,8	23	88,5	28,99	27,16
Cycle 9 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	24	100,0	33,33	21,98
Cycle 10 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	23	95,8	27,54	21,68
Cycle 11 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	27,54	21,68
Cycle 12 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	23	69,7	20	87,0	26,67	23,20
Cycle 13 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	20	95,2	26,67	23,20
Cycle 14 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	21	100,0	34,92	32,45
Cycle 15 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	35,00	29,57
Cycle 16 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	20	60,6	14	70,0	38,10	34,24
Cycle 17 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	17	51,5	13	76,5	38,46	29,96
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	20,83	24,80
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	41,67	29,55
Cycle 20 Day 1	No	9	27,3	9	100,0	29,63	26,06
Cycle 21 Day 1	No	7	21,2	4	57,1	33,33	38,49
Cycle 22 Day 1	No	7	21,2	2	28,6	16,67	23,57
Cycle 23 Day 1	No	4	12,1	1	25,0	0,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	0,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30CO_SG.xls
07SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	6,86	13,68
Cycle 2 Day 1	All	33	89,2	29	87,9	10,34	18,05
Cycle 3 Day 1	All	32	86,5	30	93,8	12,22	18,54
Cycle 4 Day 1	All	32	86,5	28	87,5	16,67	21,28
Cycle 5 Day 1	All	31	83,8	29	93,5	16,09	19,15
Cycle 6 Day 1	All	31	83,8	29	93,5	17,24	26,16
Cycle 7 Day 1	All	30	81,1	27	90,0	16,05	23,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	25,33	30,85
Cycle 9 Day 1	All	25	67,6	25	100,0	22,67	23,01
Cycle 10 Day 1	All	25	67,6	24	96,0	23,61	25,02
Cycle 11 Day 1	All	24	64,9	24	100,0	23,61	26,88
Cycle 12 Day 1	All	24	64,9	21	87,5	26,98	29,10
Cycle 13 Day 1	All	22	59,5	21	95,5	19,05	27,02
Cycle 14 Day 1	All	22	59,5	22	100,0	24,24	31,17
Cycle 15 Day 1	All	22	59,5	21	95,5	17,46	22,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	20,00	21,08
Cycle 17 Day 1	All	18	48,6	14	77,8	23,81	35,63
Cycle 18 Day 1	All	15	40,5	8	53,3	25,00	34,50
Cycle 19 Day 1	All	13	35,1	8	61,5	33,33	35,63
Cycle 20 Day 1	All	9	24,3	9	100,0	33,33	37,27
Cycle 21 Day 1	All	7	18,9	4	57,1	33,33	47,14
Cycle 22 Day 1	All	7	18,9	2	28,6	16,67	23,57
Cycle 23 Day 1	All	4	10,8	1	25,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	0,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	20,00	18,26
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	12,82	16,88
	Female	23	100,0	21	91,3	3,17	10,03
Cycle 2 Day 1	Male	13	92,9	12	92,3	8,33	15,08
	Female	20	87,0	17	85,0	11,76	20,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	13,89	17,16
	Female	20	87,0	18	90,0	11,11	19,80
Cycle 4 Day 1	Male	12	85,7	11	91,7	18,18	22,92
	Female	20	87,0	17	85,0	15,69	20,81
Cycle 5 Day 1	Male	12	85,7	11	91,7	15,15	17,41
	Female	19	82,6	18	94,7	16,67	20,61
Cycle 6 Day 1	Male	12	85,7	11	91,7	15,15	27,34
	Female	19	82,6	18	94,7	18,52	26,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	18,18	27,34
	Female	19	82,6	16	84,2	14,58	20,97
Cycle 8 Day 1	Male	10	71,4	9	90,0	25,93	32,39
	Female	18	78,3	16	88,9	25,00	31,03
Cycle 9 Day 1	Male	8	57,1	8	100,0	29,17	33,03
	Female	17	73,9	17	100,0	19,61	16,91
Cycle 10 Day 1	Male	8	57,1	8	100,0	29,17	33,03
	Female	17	73,9	16	94,1	20,83	20,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	20,83	35,36
	Female	16	69,6	16	100,0	25,00	22,77
Cycle 12 Day 1	Male	8	57,1	8	100,0	33,33	35,63
	Female	16	69,6	13	81,3	23,08	25,04
Cycle 13 Day 1	Male	8	57,1	8	100,0	20,83	35,36
	Female	14	60,9	13	92,9	17,95	22,01
Cycle 14 Day 1	Male	8	57,1	8	100,0	33,33	35,63
	Female	14	60,9	14	100,0	19,05	28,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	16,67	17,82
	Female	14	60,9	13	92,9	17,95	25,88
Cycle 16 Day 1	Male	8	57,1	5	62,5	13,33	18,26
	Female	13	56,5	10	76,9	23,33	22,50
Cycle 17 Day 1	Male	6	42,9	2	33,3	66,67	47,14
	Female	12	52,2	12	100,0	16,67	30,15
Cycle 18 Day 1	Male	3	21,4	2	66,7	66,67	47,14
	Female	12	52,2	6	50,0	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	66,67	47,14
	Female	11	47,8	6	54,5	22,22	27,22
Cycle 20 Day 1	Male	2	14,3	2	100,0	66,67	47,14
	Female	7	30,4	7	100,0	23,81	31,71
Cycle 21 Day 1	Male	1	7,1	1	100,0	100,00	-
	Female	6	26,1	3	50,0	11,11	19,25
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	0,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	0,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	33,33	0,00
	Female	7	30,4	3	42,9	11,11	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	7,41	14,12
	65-74	8	100,0	7	87,5	4,76	12,60
Cycle 2 Day 1	18-64	27	93,1	24	88,9	12,50	19,19
	65-74	6	75,0	5	83,3	0,00	0,00
Cycle 3 Day 1	18-64	26	89,7	24	92,3	9,72	15,48
	65-74	6	75,0	6	100,0	22,22	27,22
Cycle 4 Day 1	18-64	26	89,7	23	88,5	14,49	22,08
	65-74	6	75,0	5	83,3	26,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	15,94	19,77
	65-74	6	75,0	6	100,0	16,67	18,26
Cycle 6 Day 1	18-64	25	86,2	24	96,0	20,83	27,47
	65-74	6	75,0	5	83,3	0,00	0,00
Cycle 7 Day 1	18-64	25	86,2	23	92,0	18,84	24,26
	65-74	5	62,5	4	80,0	0,00	0,00
Cycle 8 Day 1	18-64	23	79,3	20	87,0	30,00	32,26
	65-74	5	62,5	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	23,33	24,42
	65-74	5	62,5	5	100,0	20,00	18,26
Cycle 10 Day 1	18-64	20	69,0	19	95,0	26,32	26,24
	65-74	5	62,5	5	100,0	13,33	18,26
Cycle 11 Day 1	18-64	19	65,5	19	100,0	22,81	27,34
	65-74	5	62,5	5	100,0	26,67	27,89
Cycle 12 Day 1	18-64	19	65,5	17	89,5	31,37	29,98
	65-74	5	62,5	4	80,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	22,92	29,11
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 14 Day 1	18-64	17	58,6	17	100,0	27,45	33,82
	65-74	5	62,5	5	100,0	13,33	18,26
Cycle 15 Day 1	18-64	17	58,6	16	94,1	18,75	24,25
	65-74	5	62,5	5	100,0	13,33	18,26
Cycle 16 Day 1	18-64	17	58,6	13	76,5	20,51	21,68
	65-74	4	50,0	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	27,78	37,15
	65-74	3	37,5	2	66,7	0,00	0,00
Cycle 18 Day 1	18-64	13	44,8	8	61,5	25,00	34,50
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	38,10	35,63
	65-74	2	25,0	1	50,0	0,00	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	37,50	37,53
	65-74	1	12,5	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	33,33	47,14
Cycle 22 Day 1	18-64	7	24,1	2	28,6	16,67	23,57
Cycle 23 Day 1	18-64	4	13,8	1	25,0	0,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	0,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	22,22	19,25
	65-74	6	75,0	2	33,3	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	3,92	11,07
	Other	17	100,0	17	100,0	9,80	15,66
Cycle 2 Day 1	White	19	95,0	16	84,2	10,42	20,07
	Other	14	82,4	13	92,9	10,26	16,01
Cycle 3 Day 1	White	18	90,0	16	88,9	12,50	20,64
	Other	14	82,4	14	100,0	11,90	16,57
Cycle 4 Day 1	White	18	90,0	15	83,3	17,78	24,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	15,38	17,30
Cycle 5 Day 1	White	18	90,0	17	94,4	15,69	20,81
	Other	13	76,5	12	92,3	16,67	17,41
Cycle 6 Day 1	White	18	90,0	16	88,9	18,75	29,74
	Other	13	76,5	13	100,0	15,38	22,01
Cycle 7 Day 1	White	17	85,0	15	88,2	15,56	24,77
	Other	13	76,5	12	92,3	16,67	22,47
Cycle 8 Day 1	White	17	85,0	14	82,4	26,19	35,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	24,24	26,21
Cycle 9 Day 1	White	16	80,0	16	100,0	22,92	26,44
	Other	9	52,9	9	100,0	22,22	16,67
Cycle 10 Day 1	White	16	80,0	15	93,8	22,22	27,22
	Other	9	52,9	9	100,0	25,93	22,22
Cycle 11 Day 1	White	16	80,0	16	100,0	16,67	27,22
	Other	8	47,1	8	100,0	37,50	21,36
Cycle 12 Day 1	White	16	80,0	13	81,3	30,77	34,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	20,83	17,25
Cycle 13 Day 1	White	14	70,0	13	92,9	28,21	29,96
	Other	8	47,1	8	100,0	4,17	11,79
Cycle 14 Day 1	White	14	70,0	14	100,0	28,57	34,24
	Other	8	47,1	8	100,0	16,67	25,20
Cycle 15 Day 1	White	14	70,0	13	92,9	15,38	22,01
	Other	8	47,1	8	100,0	20,83	24,80
Cycle 16 Day 1	White	14	70,0	9	64,3	22,22	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	16,67	18,26
Cycle 17 Day 1	White	13	65,0	10	76,9	26,67	40,98
	Other	5	29,4	4	80,0	16,67	19,25
Cycle 18 Day 1	White	11	55,0	4	36,4	41,67	41,94
	Other	4	23,5	4	100,0	8,33	16,67
Cycle 19 Day 1	White	9	45,0	5	55,6	46,67	38,01
	Other	4	23,5	3	75,0	11,11	19,25
Cycle 20 Day 1	White	5	25,0	5	100,0	40,00	43,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	25,00	31,91
Cycle 21 Day 1	White	3	15,0	2	66,7	50,00	70,71
	Other	4	23,5	2	50,0	16,67	23,57
Cycle 22 Day 1	White	3	15,0	1	33,3	33,33	-
	Other	4	23,5	1	25,0	0,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	0,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	11,11	19,25
	Other	9	52,9	2	22,2	33,33	0,00
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	0,00	0,00
	Europe (EU)	10	100,0	8	80,0	8,33	15,43
	Asia (AS)	15	100,0	14	93,3	11,90	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	7,41	14,70
	Europe (EU)	9	90,0	8	88,9	8,33	15,43
	Asia (AS)	13	86,7	12	92,3	13,89	22,29
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	12,12	16,82
	Europe (EU)	8	80,0	6	75,0	16,67	27,89
	Asia (AS)	13	86,7	13	100,0	10,26	16,01
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	15,15	22,92
	Europe (EU)	8	80,0	4	50,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	15,38	17,30
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	12,12	22,47
	Europe (EU)	8	80,0	7	87,5	9,52	16,27
	Asia (AS)	12	80,0	11	91,7	24,24	15,57
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	18,18	27,34
	Europe (EU)	8	80,0	7	87,5	9,52	25,20
	Asia (AS)	12	80,0	11	91,7	21,21	26,97
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	20,00	23,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	14,29	26,23
	Asia (AS)	11	73,3	10	90,9	13,33	23,31
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	23,33	27,44
	Europe (EU)	8	80,0	6	75,0	27,78	44,31
	Asia (AS)	9	60,0	9	100,0	25,93	27,78
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	24,24	30,15
	Europe (EU)	7	70,0	7	100,0	19,05	17,82
	Asia (AS)	7	46,7	7	100,0	23,81	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	23,33	31,62
	Europe (EU)	7	70,0	7	100,0	19,05	17,82
	Asia (AS)	7	46,7	7	100,0	28,57	23,00
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	24,24	33,63
	Europe (EU)	7	70,0	7	100,0	14,29	17,82
	Asia (AS)	6	40,0	6	100,0	33,33	21,08
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	26,67	34,43
	Europe (EU)	7	70,0	5	71,4	26,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	27,78	25,09
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	23,33	31,62
	Europe (EU)	6	60,0	5	83,3	20,00	18,26
	Asia (AS)	6	40,0	6	100,0	11,11	27,22
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	30,00	39,91
	Europe (EU)	6	60,0	6	100,0	27,78	25,09
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	20,00	18,26
	Asia (AS)	6	40,0	6	100,0	16,67	27,89
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	23,81	25,20
	Europe (EU)	6	60,0	2	33,3	33,33	0,00
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	50,00	40,82
	Europe (EU)	4	40,0	3	75,0	0,00	0,00
	Asia (AS)	5	33,3	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	33,33	40,82
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	11,11	19,25
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	58,33	31,91
	Europe (EU)	3	30,0	1	33,3	0,00	-
	Asia (AS)	4	26,7	3	75,0	11,11	19,25
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	46,67	38,01
	Europe (EU)	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	22,22	38,49
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	44,44	50,92
	Asia (AS)	3	20,0	1	33,3	0,00	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	16,67	23,57
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	0,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	22,22	19,25
	Europe (EU)	2	20,0	1	50,0	0,00	-
	Asia (AS)	7	46,7	1	14,3	33,33	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	2,78	9,62
	1	17	100,0	17	100,0	9,80	15,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	6,67	14,91
Cycle 2 Day 1	0	15	100,0	12	80,0	8,33	15,08
	1	15	88,2	14	93,3	14,29	21,54
	2	3	60,0	3	100,0	0,00	0,00
Cycle 3 Day 1	0	15	100,0	14	93,3	14,29	21,54
	1	14	82,4	13	92,9	10,26	16,01
	2	3	60,0	3	100,0	11,11	19,25
Cycle 4 Day 1	0	15	100,0	14	93,3	19,05	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	11,11	16,41
	2	3	60,0	2	66,7	33,33	0,00
Cycle 5 Day 1	0	15	100,0	15	100,0	15,56	21,33
	1	14	82,4	12	85,7	19,44	17,16
	2	2	40,0	2	100,0	0,00	0,00
Cycle 6 Day 1	0	15	100,0	15	100,0	17,78	27,79
	1	14	82,4	12	85,7	19,44	26,43
	2	2	40,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	16,67	25,32
	1	13	76,5	11	84,6	18,18	22,92
	2	2	40,0	2	100,0	0,00	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	20,51	28,99
	1	11	64,7	10	90,9	26,67	26,29
	2	2	40,0	2	100,0	50,00	70,71
Cycle 9 Day 1	0	14	93,3	14	100,0	21,43	28,06
	1	10	58,8	10	100,0	26,67	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	0,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	21,43	28,06
	1	10	58,8	9	90,0	29,63	20,03
	2	1	20,0	1	100,0	0,00	-
Cycle 11 Day 1	0	14	93,3	14	100,0	21,43	30,96
	1	9	52,9	9	100,0	25,93	22,22
	2	1	20,0	1	100,0	33,33	-
Cycle 12 Day 1	0	14	93,3	12	85,7	27,78	34,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	29,17	21,36
	2	1	20,0	1	100,0	0,00	-
Cycle 13 Day 1	0	14	93,3	13	92,9	20,51	28,99
	1	8	47,1	8	100,0	16,67	25,20
Cycle 14 Day 1	0	14	93,3	14	100,0	26,19	35,03
	1	8	47,1	8	100,0	20,83	24,80
Cycle 15 Day 1	0	14	93,3	14	100,0	16,67	21,68
	1	8	47,1	7	87,5	19,05	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	20,83	24,80
	1	8	47,1	7	87,5	19,05	17,82
Cycle 17 Day 1	0	12	80,0	8	66,7	33,33	43,64
	1	6	35,3	6	100,0	11,11	17,21
Cycle 18 Day 1	0	9	60,0	4	44,4	41,67	41,94
	1	6	35,3	4	66,7	8,33	16,67
Cycle 19 Day 1	0	8	53,3	4	50,0	50,00	43,03
	1	5	29,4	4	80,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	46,67	38,01
	1	4	23,5	4	100,0	16,67	33,33
Cycle 21 Day 1	0	3	20,0	3	100,0	44,44	50,92
	1	4	23,5	1	25,0	0,00	-
Cycle 22 Day 1	0	3	20,0	2	66,7	16,67	23,57
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	0,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	22,22	19,25
	1	7	41,2	2	28,6	16,67	23,57
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	2,56	9,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	0,00	0,00
	2 or More	21	100,0	19	90,5	10,53	15,92
Cycle 2 Day 1	None	14	100,0	12	85,7	8,33	15,08
	1	1	50,0	1	100,0	0,00	-
	2 or More	18	85,7	16	88,9	12,50	20,64
Cycle 3 Day 1	None	14	100,0	13	92,9	12,82	16,88
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	16	94,1	12,50	20,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	11,11	16,41
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	22,22	24,12
Cycle 5 Day 1	None	14	100,0	14	100,0	7,14	14,19
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	26,19	19,30
Cycle 6 Day 1	None	14	100,0	14	100,0	11,90	21,11
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	23,81	30,46
Cycle 7 Day 1	None	14	100,0	13	92,9	15,38	22,01
	1	1	50,0	1	100,0	33,33	-
	2 or More	15	71,4	13	86,7	15,38	25,88
Cycle 8 Day 1	None	14	100,0	13	92,9	17,95	25,88
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	33,33	34,82
Cycle 9 Day 1	None	13	92,9	13	100,0	17,95	29,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	33,33	-
	2 or More	11	52,4	11	100,0	27,27	13,48
Cycle 10 Day 1	None	13	92,9	12	92,3	19,44	30,01
	1	1	50,0	1	100,0	33,33	-
	2 or More	11	52,4	11	100,0	27,27	20,10
Cycle 11 Day 1	None	13	92,9	13	100,0	25,64	30,89
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	10	100,0	23,33	22,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	19,44	30,01
	1	1	50,0	1	100,0	33,33	-
	2 or More	10	47,6	8	80,0	37,50	27,82
Cycle 13 Day 1	None	12	85,7	11	91,7	15,15	31,14
	1	1	50,0	1	100,0	33,33	-
	2 or More	9	42,9	9	100,0	22,22	23,57
Cycle 14 Day 1	None	12	85,7	12	100,0	19,44	33,21
	1	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	29,63	30,93
Cycle 15 Day 1	None	12	85,7	12	100,0	8,33	15,08
	1	1	50,0	1	100,0	33,33	-
	2 or More	9	42,9	8	88,9	29,17	27,82
Cycle 16 Day 1	None	11	78,6	8	72,7	16,67	17,82
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	27,78	25,09
Cycle 17 Day 1	None	10	71,4	7	70,0	23,81	37,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	33,33	-
	2 or More	7	33,3	6	85,7	22,22	40,37
Cycle 18 Day 1	None	8	57,1	4	50,0	25,00	50,00
	1	1	50,0	1	100,0	33,33	-
	2 or More	6	28,6	3	50,0	22,22	19,25
Cycle 19 Day 1	None	7	50,0	3	42,9	44,44	50,92
	1	1	50,0	1	100,0	33,33	-
	2 or More	5	23,8	4	80,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	33,33	47,14
	1	1	50,0	1	100,0	33,33	-
	2 or More	4	19,0	4	100,0	33,33	38,49
Cycle 21 Day 1	None	4	28,6	2	50,0	66,67	47,14
	2 or More	3	14,3	2	66,7	0,00	0,00
Cycle 22 Day 1	None	4	28,6	1	25,0	0,00	-
	2 or More	3	14,3	1	33,3	33,33	-
Cycle 23 Day 1	None	2	14,3	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	33,33	-
	1	2	100,0	1	50,0	33,33	-
	2 or More	9	42,9	3	33,3	11,11	19,25
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	2,56	9,25
	Previously Treated	23	100,0	21	91,3	9,52	15,43
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	8,33	15,08
	Previously Treated	19	82,6	17	89,5	11,76	20,21
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	12,82	16,88
	Previously Treated	18	78,3	17	94,4	11,76	20,21
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	11,11	16,41
	Previously Treated	18	78,3	16	88,9	20,83	23,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	7,14	14,19
	Previously Treated	17	73,9	15	88,2	24,44	19,79
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	11,90	21,11
	Previously Treated	17	73,9	15	88,2	22,22	29,99
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	15,38	22,01
	Previously Treated	16	69,6	14	87,5	16,67	25,32
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	17,95	25,88
	Previously Treated	14	60,9	12	85,7	33,33	34,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	17,95	29,24
	Previously Treated	12	52,2	12	100,0	27,78	12,97
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	19,44	30,01
	Previously Treated	12	52,2	12	100,0	27,78	19,25
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	25,64	30,89
	Previously Treated	11	47,8	11	100,0	21,21	22,47
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	19,44	30,01
	Previously Treated	11	47,8	9	81,8	37,04	26,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	15,15	31,14
	Previously Treated	10	43,5	10	100,0	23,33	22,50
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	19,44	33,21
	Previously Treated	10	43,5	10	100,0	30,00	29,19
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	8,33	15,08
	Previously Treated	10	43,5	9	90,0	29,63	26,06
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	16,67	17,82
	Previously Treated	10	43,5	7	70,0	23,81	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	23,81	37,09
	Previously Treated	8	34,8	7	87,5	23,81	37,09
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	25,00	50,00
	Previously Treated	7	30,4	4	57,1	25,00	16,67
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	44,44	50,92
	Previously Treated	6	26,1	5	83,3	26,67	27,89
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	33,33	47,14
	Previously Treated	5	21,7	5	100,0	33,33	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	66,67	47,14
	Previously Treated	3	13,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	0,00	-
	Previously Treated	3	13,0	1	33,3	33,33	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	11	47,8	4	36,4	16,67	19,25
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	2,78	9,62
	Central	25	100,0	22	88,0	9,09	15,19
Cycle 2 Day 1	Local	11	91,7	10	90,9	10,00	16,10
	Central	22	88,0	19	86,4	10,53	19,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	12,12	22,47
	Central	21	84,0	19	90,5	12,28	16,52
Cycle 4 Day 1	Local	11	91,7	10	90,9	10,00	16,10
	Central	21	84,0	18	85,7	20,37	23,26
Cycle 5 Day 1	Local	11	91,7	10	90,9	13,33	17,21
	Central	20	80,0	19	95,0	17,54	20,39
Cycle 6 Day 1	Local	11	91,7	11	100,0	15,15	22,92
	Central	20	80,0	18	90,0	18,52	28,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	15,15	22,92
	Central	19	76,0	16	84,2	16,67	24,34
Cycle 8 Day 1	Local	10	83,3	10	100,0	16,67	23,57
	Central	18	72,0	15	83,3	31,11	34,43
Cycle 9 Day 1	Local	10	83,3	10	100,0	20,00	32,20
	Central	15	60,0	15	100,0	24,44	15,26
Cycle 10 Day 1	Local	10	83,3	9	90,0	22,22	33,33
	Central	15	60,0	15	100,0	24,44	19,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	22,22	33,33
	Central	15	60,0	15	100,0	24,44	23,46
Cycle 12 Day 1	Local	9	75,0	8	88,9	20,83	35,36
	Central	15	60,0	13	86,7	30,77	25,32
Cycle 13 Day 1	Local	8	66,7	8	100,0	20,83	35,36
	Central	14	56,0	13	92,9	17,95	22,01
Cycle 14 Day 1	Local	8	66,7	8	100,0	20,83	35,36
	Central	14	56,0	14	100,0	26,19	29,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	8,33	15,43
	Central	14	56,0	13	92,9	23,08	25,04
Cycle 16 Day 1	Local	8	66,7	6	75,0	16,67	18,26
	Central	13	52,0	9	69,2	22,22	23,57
Cycle 17 Day 1	Local	8	66,7	5	62,5	26,67	43,46
	Central	10	40,0	9	90,0	22,22	33,33
Cycle 18 Day 1	Local	6	50,0	4	66,7	25,00	50,00
	Central	9	36,0	4	44,4	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	33,33	47,14
	Central	8	32,0	4	50,0	33,33	27,22
Cycle 20 Day 1	Local	5	41,7	5	100,0	26,67	43,46
	Central	4	16,0	4	100,0	41,67	31,91
Cycle 21 Day 1	Local	4	33,3	2	50,0	66,67	47,14
	Central	3	12,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Local	4	33,3	1	25,0	0,00	-
	Central	3	12,0	1	33,3	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	0,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	0,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	0,00	0,00
	Central	8	32,0	3	37,5	33,33	0,00
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	7,29	14,00
	No	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	Yes	32	91,4	28	87,5	10,71	18,27
	No	1	50,0	1	100,0	0,00	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	12,64	18,72
	No	1	50,0	1	100,0	0,00	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	16,05	21,42
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	15,48	19,21
	No	1	50,0	1	100,0	33,33	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	16,67	26,45
	No	1	50,0	1	100,0	33,33	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	15,38	23,53
	No	1	50,0	1	100,0	33,33	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	25,00	31,47
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	22,22	23,40
	No	1	50,0	1	100,0	33,33	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	23,19	25,49
	No	1	50,0	1	100,0	33,33	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	23,19	27,40
	No	1	50,0	1	100,0	33,33	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	26,67	29,81
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	20,00	27,36
	No	1	50,0	1	100,0	0,00	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	25,40	31,46
	No	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	18,33	22,88
	No	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	21,43	21,11
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	25,64	36,40
	No	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	28,57	35,63
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	38,10	35,63
	No	1	50,0	1	100,0	0,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	37,50	37,53
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	33,33	47,14
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	16,67	23,57
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	0,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	0,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	11,11	19,25
	No	33	100,0	31	93,9	6,45	13,39
Cycle 2 Day 1	Yes	2	50,0	1	50,0	0,00	-
	No	31	93,9	28	90,3	10,71	18,27
Cycle 3 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	13,10	18,90
Cycle 4 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	30	90,9	26	86,7	17,95	21,56
Cycle 5 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	27	93,1	17,28	19,33
Cycle 6 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	27	93,1	18,52	26,69
Cycle 7 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	17,33	23,80
Cycle 8 Day 1	Yes	2	50,0	2	100,0	33,33	47,14
	No	26	78,8	23	88,5	24,64	30,51
Cycle 9 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	24	100,0	23,61	23,01
Cycle 10 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	23	95,8	24,64	25,06
Cycle 11 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	24,64	27,00
Cycle 12 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	23	69,7	20	87,0	28,33	29,17
Cycle 13 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	20	95,2	20,00	27,36
Cycle 14 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	21	100,0	25,40	31,46
Cycle 15 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	18,33	22,88
Cycle 16 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	20	60,6	14	70,0	21,43	21,11
Cycle 17 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	17	51,5	13	76,5	25,64	36,40
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	25,00	34,50
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	33,33	35,63
Cycle 20 Day 1	No	9	27,3	9	100,0	33,33	37,27
Cycle 21 Day 1	No	7	21,2	4	57,1	33,33	47,14
Cycle 22 Day 1	No	7	21,2	2	28,6	16,67	23,57
Cycle 23 Day 1	No	4	12,1	1	25,0	0,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	0,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DI_SG.xls
07SEP2019 19:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	44,12	34,54
Cycle 2 Day 1	All	33	89,2	29	87,9	25,29	29,08
Cycle 3 Day 1	All	32	86,5	30	93,8	24,44	23,05
Cycle 4 Day 1	All	32	86,5	28	87,5	17,86	19,21
Cycle 5 Day 1	All	31	83,8	29	93,5	26,44	24,20
Cycle 6 Day 1	All	31	83,8	29	93,5	22,99	25,36
Cycle 7 Day 1	All	30	81,1	27	90,0	29,63	26,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	28,00	24,87
Cycle 9 Day 1	All	25	67,6	25	100,0	29,33	22,19
Cycle 10 Day 1	All	25	67,6	24	96,0	27,78	16,05
Cycle 11 Day 1	All	24	64,9	24	100,0	20,83	19,19
Cycle 12 Day 1	All	24	64,9	21	87,5	23,81	15,43
Cycle 13 Day 1	All	22	59,5	21	95,5	23,81	23,90
Cycle 14 Day 1	All	22	59,5	22	100,0	27,27	30,23
Cycle 15 Day 1	All	22	59,5	21	95,5	25,40	20,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	33,33	25,20
Cycle 17 Day 1	All	18	48,6	14	77,8	28,57	22,10
Cycle 18 Day 1	All	15	40,5	8	53,3	20,83	17,25
Cycle 19 Day 1	All	13	35,1	8	61,5	33,33	17,82
Cycle 20 Day 1	All	9	24,3	9	100,0	25,93	22,22
Cycle 21 Day 1	All	7	18,9	4	57,1	41,67	16,67
Cycle 22 Day 1	All	7	18,9	2	28,6	66,67	47,14
Cycle 23 Day 1	All	4	10,8	1	25,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	33,33	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	60,00	27,89
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	48,72	35,00
	Female	23	100,0	21	91,3	41,27	34,81
Cycle 2 Day 1	Male	13	92,9	12	92,3	36,11	36,12
	Female	20	87,0	17	85,0	17,65	20,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	25,00	20,72
	Female	20	87,0	18	90,0	24,07	25,06
Cycle 4 Day 1	Male	12	85,7	11	91,7	15,15	22,92
	Female	20	87,0	17	85,0	19,61	16,91
Cycle 5 Day 1	Male	12	85,7	11	91,7	24,24	21,56
	Female	19	82,6	18	94,7	27,78	26,20
Cycle 6 Day 1	Male	12	85,7	11	91,7	15,15	22,92
	Female	19	82,6	18	94,7	27,78	26,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	24,24	26,21
	Female	19	82,6	16	84,2	33,33	27,22
Cycle 8 Day 1	Male	10	71,4	9	90,0	33,33	28,87
	Female	18	78,3	16	88,9	25,00	22,77
Cycle 9 Day 1	Male	8	57,1	8	100,0	29,17	21,36
	Female	17	73,9	17	100,0	29,41	23,22
Cycle 10 Day 1	Male	8	57,1	8	100,0	25,00	15,43
	Female	17	73,9	16	94,1	29,17	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	16,67	25,20
	Female	16	69,6	16	100,0	22,92	15,96
Cycle 12 Day 1	Male	8	57,1	8	100,0	20,83	17,25
	Female	16	69,6	13	81,3	25,64	14,62
Cycle 13 Day 1	Male	8	57,1	8	100,0	16,67	17,82
	Female	14	60,9	13	92,9	28,21	26,69
Cycle 14 Day 1	Male	8	57,1	8	100,0	33,33	35,63
	Female	14	60,9	14	100,0	23,81	27,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	25,00	23,57
	Female	14	60,9	13	92,9	25,64	19,97
Cycle 16 Day 1	Male	8	57,1	5	62,5	33,33	23,57
	Female	13	56,5	10	76,9	33,33	27,22
Cycle 17 Day 1	Male	6	42,9	2	33,3	16,67	23,57
	Female	12	52,2	12	100,0	30,56	22,29
Cycle 18 Day 1	Male	3	21,4	2	66,7	16,67	23,57
	Female	12	52,2	6	50,0	22,22	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	33,33	0,00
	Female	11	47,8	6	54,5	33,33	21,08
Cycle 20 Day 1	Male	2	14,3	2	100,0	33,33	0,00
	Female	7	30,4	7	100,0	23,81	25,20
Cycle 21 Day 1	Male	1	7,1	1	100,0	33,33	-
	Female	6	26,1	3	50,0	44,44	19,25
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	66,67	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	33,33	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	33,33	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	83,33	23,57
	Female	7	30,4	3	42,9	44,44	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	43,21	35,58
	65-74	8	100,0	7	87,5	47,62	32,53
Cycle 2 Day 1	18-64	27	93,1	24	88,9	22,22	25,38
	65-74	6	75,0	5	83,3	40,00	43,46
Cycle 3 Day 1	18-64	26	89,7	24	92,3	23,61	18,33
	65-74	6	75,0	6	100,0	27,78	38,97
Cycle 4 Day 1	18-64	26	89,7	23	88,5	15,94	17,03
	65-74	6	75,0	5	83,3	26,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	24,64	22,96
	65-74	6	75,0	6	100,0	33,33	29,81
Cycle 6 Day 1	18-64	25	86,2	24	96,0	22,22	25,38
	65-74	6	75,0	5	83,3	26,67	27,89
Cycle 7 Day 1	18-64	25	86,2	23	92,0	30,43	26,43
	65-74	5	62,5	4	80,0	25,00	31,91
Cycle 8 Day 1	18-64	23	79,3	20	87,0	30,00	26,27
	65-74	5	62,5	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	26,67	17,44
	65-74	5	62,5	5	100,0	40,00	36,51
Cycle 10 Day 1	18-64	20	69,0	19	95,0	26,32	13,96
	65-74	5	62,5	5	100,0	33,33	23,57
Cycle 11 Day 1	18-64	19	65,5	19	100,0	22,81	19,41
	65-74	5	62,5	5	100,0	13,33	18,26
Cycle 12 Day 1	18-64	19	65,5	17	89,5	23,53	15,66
	65-74	5	62,5	4	80,0	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	20,83	16,67
	65-74	5	62,5	5	100,0	33,33	40,82
Cycle 14 Day 1	18-64	17	58,6	17	100,0	25,49	27,71
	65-74	5	62,5	5	100,0	33,33	40,82
Cycle 15 Day 1	18-64	17	58,6	16	94,1	25,00	19,25
	65-74	5	62,5	5	100,0	26,67	27,89
Cycle 16 Day 1	18-64	17	58,6	13	76,5	33,33	27,22
	65-74	4	50,0	2	50,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	30,56	22,29
	65-74	3	37,5	2	66,7	16,67	23,57
Cycle 18 Day 1	18-64	13	44,8	8	61,5	20,83	17,25
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	28,57	12,60
	65-74	2	25,0	1	50,0	66,67	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	20,83	17,25
	65-74	1	12,5	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	41,67	16,67
Cycle 22 Day 1	18-64	7	24,1	2	28,6	66,67	47,14
Cycle 23 Day 1	18-64	4	13,8	1	25,0	33,33	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	33,33	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	66,67	33,33
	65-74	6	75,0	2	33,3	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	49,02	35,59
	Other	17	100,0	17	100,0	39,22	33,82
Cycle 2 Day 1	White	19	95,0	16	84,2	31,25	33,26
	Other	14	82,4	13	92,9	17,95	22,01
Cycle 3 Day 1	White	18	90,0	16	88,9	27,08	27,81
	Other	14	82,4	14	100,0	21,43	16,57
Cycle 4 Day 1	White	18	90,0	15	83,3	15,56	21,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	20,51	16,88
Cycle 5 Day 1	White	18	90,0	17	94,4	27,45	29,43
	Other	13	76,5	12	92,3	25,00	15,08
Cycle 6 Day 1	White	18	90,0	16	88,9	20,83	29,50
	Other	13	76,5	13	100,0	25,64	19,97
Cycle 7 Day 1	White	17	85,0	15	88,2	26,67	28,73
	Other	13	76,5	12	92,3	33,33	24,62
Cycle 8 Day 1	White	17	85,0	14	82,4	21,43	24,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	36,36	23,35
Cycle 9 Day 1	White	16	80,0	16	100,0	27,08	25,00
	Other	9	52,9	9	100,0	33,33	16,67
Cycle 10 Day 1	White	16	80,0	15	93,8	24,44	19,79
	Other	9	52,9	9	100,0	33,33	0,00
Cycle 11 Day 1	White	16	80,0	16	100,0	18,75	17,08
	Other	8	47,1	8	100,0	25,00	23,57
Cycle 12 Day 1	White	16	80,0	13	81,3	25,64	14,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	20,83	17,25
Cycle 13 Day 1	White	14	70,0	13	92,9	23,08	28,50
	Other	8	47,1	8	100,0	25,00	15,43
Cycle 14 Day 1	White	14	70,0	14	100,0	23,81	30,46
	Other	8	47,1	8	100,0	33,33	30,86
Cycle 15 Day 1	White	14	70,0	13	92,9	25,64	24,17
	Other	8	47,1	8	100,0	25,00	15,43
Cycle 16 Day 1	White	14	70,0	9	64,3	25,93	22,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	44,44	27,22
Cycle 17 Day 1	White	13	65,0	10	76,9	23,33	22,50
	Other	5	29,4	4	80,0	41,67	16,67
Cycle 18 Day 1	White	11	55,0	4	36,4	16,67	19,25
	Other	4	23,5	4	100,0	25,00	16,67
Cycle 19 Day 1	White	9	45,0	5	55,6	33,33	23,57
	Other	4	23,5	3	75,0	33,33	0,00
Cycle 20 Day 1	White	5	25,0	5	100,0	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	16,67	19,25
Cycle 21 Day 1	White	3	15,0	2	66,7	50,00	23,57
	Other	4	23,5	2	50,0	33,33	0,00
Cycle 22 Day 1	White	3	15,0	1	33,3	100,00	-
	Other	4	23,5	1	25,0	33,33	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	33,33	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	55,56	19,25
	Other	9	52,9	2	22,2	66,67	47,14
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	33,33	34,82
	Europe (EU)	10	100,0	8	80,0	75,00	29,55
	Asia (AS)	15	100,0	14	93,3	35,71	27,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	14,81	17,57
	Europe (EU)	9	90,0	8	88,9	37,50	37,53
	Asia (AS)	13	86,7	12	92,3	25,00	28,87
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	15,15	17,41
	Europe (EU)	8	80,0	6	75,0	38,89	38,97
	Asia (AS)	13	86,7	13	100,0	25,64	14,62
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	15,15	17,41
	Europe (EU)	8	80,0	4	50,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	23,08	21,01
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	18,18	17,41
	Europe (EU)	8	80,0	7	87,5	23,81	25,20
	Asia (AS)	12	80,0	11	91,7	36,36	27,71
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	12,12	16,82
	Europe (EU)	8	80,0	7	87,5	28,57	29,99
	Asia (AS)	12	80,0	11	91,7	30,30	27,71
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	26,67	30,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	33,33	33,33
	Asia (AS)	11	73,3	10	90,9	30,00	18,92
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	20,00	23,31
	Europe (EU)	8	80,0	6	75,0	38,89	25,09
	Asia (AS)	9	60,0	9	100,0	29,63	26,06
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	21,21	16,82
	Europe (EU)	7	70,0	7	100,0	42,86	31,71
	Asia (AS)	7	46,7	7	100,0	28,57	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	23,33	16,10
	Europe (EU)	7	70,0	7	100,0	28,57	23,00
	Asia (AS)	7	46,7	7	100,0	33,33	0,00
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	15,15	17,41
	Europe (EU)	7	70,0	7	100,0	28,57	23,00
	Asia (AS)	6	40,0	6	100,0	22,22	17,21
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	20,00	17,21
	Europe (EU)	7	70,0	5	71,4	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	22,22	17,21
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	13,33	17,21
	Europe (EU)	6	60,0	5	83,3	40,00	36,51
	Asia (AS)	6	40,0	6	100,0	27,78	13,61
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	16,67	17,57
	Europe (EU)	6	60,0	6	100,0	50,00	45,95
	Asia (AS)	6	40,0	6	100,0	22,22	17,21
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	20,00	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	33,33	33,33
	Asia (AS)	6	40,0	6	100,0	27,78	13,61
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	19,05	17,82
	Europe (EU)	6	60,0	2	33,3	50,00	23,57
	Asia (AS)	6	40,0	6	100,0	44,44	27,22
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	27,78	25,09
	Europe (EU)	4	40,0	3	75,0	11,11	19,25
	Asia (AS)	5	33,3	5	100,0	40,00	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	20,00	18,26
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	22,22	19,25
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	25,00	16,67
	Europe (EU)	3	30,0	1	33,3	66,67	-
	Asia (AS)	4	26,7	3	75,0	33,33	0,00
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	26,67	14,91
	Europe (EU)	1	10,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	11,11	19,25
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	44,44	19,25
	Asia (AS)	3	20,0	1	33,3	33,33	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	66,67	47,14
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	33,33	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	44,44	19,25
	Europe (EU)	2	20,0	1	50,0	66,67	-
	Asia (AS)	7	46,7	1	14,3	100,00	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	30,56	22,29
	1	17	100,0	17	100,0	47,06	35,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	66,67	47,14
Cycle 2 Day 1	0	15	100,0	12	80,0	16,67	22,47
	1	15	88,2	14	93,3	33,33	34,59
	2	3	60,0	3	100,0	22,22	19,25
Cycle 3 Day 1	0	15	100,0	14	93,3	26,19	29,75
	1	14	82,4	13	92,9	23,08	16,01
	2	3	60,0	3	100,0	22,22	19,25
Cycle 4 Day 1	0	15	100,0	14	93,3	11,90	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	25,00	20,72
	2	3	60,0	2	66,7	16,67	23,57
Cycle 5 Day 1	0	15	100,0	15	100,0	22,22	20,57
	1	14	82,4	12	85,7	33,33	28,43
	2	2	40,0	2	100,0	16,67	23,57
Cycle 6 Day 1	0	15	100,0	15	100,0	20,00	21,08
	1	14	82,4	12	85,7	27,78	31,25
	2	2	40,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	26,19	26,73
	1	13	76,5	11	84,6	33,33	25,82
	2	2	40,0	2	100,0	33,33	47,14
Cycle 8 Day 1	0	15	100,0	13	86,7	25,64	27,74
	1	11	64,7	10	90,9	26,67	21,08
	2	2	40,0	2	100,0	50,00	23,57
Cycle 9 Day 1	0	14	93,3	14	100,0	30,95	24,33
	1	10	58,8	10	100,0	26,67	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	33,33	-
Cycle 10 Day 1	0	14	93,3	14	100,0	26,19	19,30
	1	10	58,8	9	90,0	29,63	11,11
	2	1	20,0	1	100,0	33,33	-
Cycle 11 Day 1	0	14	93,3	14	100,0	14,29	17,12
	1	9	52,9	9	100,0	29,63	20,03
	2	1	20,0	1	100,0	33,33	-
Cycle 12 Day 1	0	14	93,3	12	85,7	25,00	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	20,83	17,25
	2	1	20,0	1	100,0	33,33	-
Cycle 13 Day 1	0	14	93,3	13	92,9	25,64	27,74
	1	8	47,1	8	100,0	20,83	17,25
Cycle 14 Day 1	0	14	93,3	14	100,0	28,57	28,81
	1	8	47,1	8	100,0	25,00	34,50
Cycle 15 Day 1	0	14	93,3	14	100,0	26,19	23,31
	1	8	47,1	7	87,5	23,81	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	29,17	21,36
	1	8	47,1	7	87,5	38,10	29,99
Cycle 17 Day 1	0	12	80,0	8	66,7	25,00	23,57
	1	6	35,3	6	100,0	33,33	21,08
Cycle 18 Day 1	0	9	60,0	4	44,4	25,00	16,67
	1	6	35,3	4	66,7	16,67	19,25
Cycle 19 Day 1	0	8	53,3	4	50,0	41,67	16,67
	1	5	29,4	4	80,0	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	40,00	14,91
	1	4	23,5	4	100,0	8,33	16,67
Cycle 21 Day 1	0	3	20,0	3	100,0	44,44	19,25
	1	4	23,5	1	25,0	33,33	-
Cycle 22 Day 1	0	3	20,0	2	66,7	66,67	47,14
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	33,33	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	33,33	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	55,56	19,25
	1	7	41,2	2	28,6	66,67	47,14
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	43,59	34,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	50,00	70,71
	2 or More	21	100,0	19	90,5	43,86	33,43
Cycle 2 Day 1	None	14	100,0	12	85,7	22,22	21,71
	1	1	50,0	1	100,0	0,00	-
	2 or More	18	85,7	16	88,9	29,17	34,16
Cycle 3 Day 1	None	14	100,0	13	92,9	23,08	16,01
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	16	94,1	27,08	27,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	13,89	17,16
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	22,22	20,57
Cycle 5 Day 1	None	14	100,0	14	100,0	21,43	16,57
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	33,33	29,24
Cycle 6 Day 1	None	14	100,0	14	100,0	16,67	21,68
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	30,95	27,62
Cycle 7 Day 1	None	14	100,0	13	92,9	30,77	28,74
	1	1	50,0	1	100,0	0,00	-
	2 or More	15	71,4	13	86,7	30,77	25,32
Cycle 8 Day 1	None	14	100,0	13	92,9	23,08	25,04
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	33,33	24,62
Cycle 9 Day 1	None	13	92,9	13	100,0	25,64	19,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	33,33	-
	2 or More	11	52,4	11	100,0	33,33	25,82
Cycle 10 Day 1	None	13	92,9	12	92,3	22,22	16,41
	1	1	50,0	1	100,0	33,33	-
	2 or More	11	52,4	11	100,0	33,33	14,91
Cycle 11 Day 1	None	13	92,9	13	100,0	20,51	21,68
	1	1	50,0	1	100,0	33,33	-
	2 or More	10	47,6	10	100,0	20,00	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	22,22	16,41
	1	1	50,0	1	100,0	33,33	-
	2 or More	10	47,6	8	80,0	25,00	15,43
Cycle 13 Day 1	None	12	85,7	11	91,7	18,18	17,41
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	33,33	28,87
Cycle 14 Day 1	None	12	85,7	12	100,0	19,44	30,01
	1	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	37,04	30,93
Cycle 15 Day 1	None	12	85,7	12	100,0	16,67	17,41
	1	1	50,0	1	100,0	33,33	-
	2 or More	9	42,9	8	88,9	37,50	21,36
Cycle 16 Day 1	None	11	78,6	8	72,7	37,50	27,82
	1	1	50,0	1	100,0	33,33	-
	2 or More	9	42,9	6	66,7	27,78	25,09
Cycle 17 Day 1	None	10	71,4	7	70,0	28,57	23,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	7	33,3	6	85,7	33,33	21,08
Cycle 18 Day 1	None	8	57,1	4	50,0	16,67	19,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	6	28,6	3	50,0	33,33	0,00
Cycle 19 Day 1	None	7	50,0	3	42,9	22,22	19,25
	1	1	50,0	1	100,0	33,33	-
	2 or More	5	23,8	4	80,0	41,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	16,67	19,25
	1	1	50,0	1	100,0	33,33	-
	2 or More	4	19,0	4	100,0	33,33	27,22
Cycle 21 Day 1	None	4	28,6	2	50,0	33,33	0,00
	2 or More	3	14,3	2	66,7	50,00	23,57
Cycle 22 Day 1	None	4	28,6	1	25,0	33,33	-
	2 or More	3	14,3	1	33,3	100,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	33,33	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	33,33	-
	1	2	100,0	1	50,0	66,67	-
	2 or More	9	42,9	3	33,3	66,67	33,33
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	43,59	34,39
	Previously Treated	23	100,0	21	91,3	44,44	35,49
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	22,22	21,71
	Previously Treated	19	82,6	17	89,5	27,45	33,82
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	23,08	16,01
	Previously Treated	18	78,3	17	94,4	25,49	27,71
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	13,89	17,16
	Previously Treated	18	78,3	16	88,9	20,83	20,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	21,43	16,57
	Previously Treated	17	73,9	15	88,2	31,11	29,46
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	16,67	21,68
	Previously Treated	17	73,9	15	88,2	28,89	27,79
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	30,77	28,74
	Previously Treated	16	69,6	14	87,5	28,57	25,68
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	23,08	25,04
	Previously Treated	14	60,9	12	85,7	33,33	24,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	25,64	19,97
	Previously Treated	12	52,2	12	100,0	33,33	24,62
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	22,22	16,41
	Previously Treated	12	52,2	12	100,0	33,33	14,21
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	20,51	21,68
	Previously Treated	11	47,8	11	100,0	21,21	16,82
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	22,22	16,41
	Previously Treated	11	47,8	9	81,8	25,93	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	18,18	17,41
	Previously Treated	10	43,5	10	100,0	30,00	29,19
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	19,44	30,01
	Previously Treated	10	43,5	10	100,0	36,67	29,19
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	16,67	17,41
	Previously Treated	10	43,5	9	90,0	37,04	20,03
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	37,50	27,82
	Previously Treated	10	43,5	7	70,0	28,57	23,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	28,57	23,00
	Previously Treated	8	34,8	7	87,5	28,57	23,00
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	16,67	19,25
	Previously Treated	7	30,4	4	57,1	25,00	16,67
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	22,22	19,25
	Previously Treated	6	26,1	5	83,3	40,00	14,91
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	16,67	19,25
	Previously Treated	5	21,7	5	100,0	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	33,33	0,00
	Previously Treated	3	13,0	2	66,7	50,00	23,57
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	33,33	-
	Previously Treated	3	13,0	1	33,3	100,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	33,33	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	11	47,8	4	36,4	66,67	27,22
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	44,44	29,59
	Central	25	100,0	22	88,0	43,94	37,64
Cycle 2 Day 1	Local	11	91,7	10	90,9	23,33	22,50
	Central	22	88,0	19	86,4	26,32	32,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	30,30	27,71
	Central	21	84,0	19	90,5	21,05	19,91
Cycle 4 Day 1	Local	11	91,7	10	90,9	16,67	17,57
	Central	21	84,0	18	85,7	18,52	20,52
Cycle 5 Day 1	Local	11	91,7	10	90,9	26,67	21,08
	Central	20	80,0	19	95,0	26,32	26,24
Cycle 6 Day 1	Local	11	91,7	11	100,0	18,18	22,92
	Central	20	80,0	18	90,0	25,93	26,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	30,30	27,71
	Central	19	76,0	16	84,2	29,17	26,87
Cycle 8 Day 1	Local	10	83,3	10	100,0	26,67	21,08
	Central	18	72,0	15	83,3	28,89	27,79
Cycle 9 Day 1	Local	10	83,3	10	100,0	30,00	29,19
	Central	15	60,0	15	100,0	28,89	17,21
Cycle 10 Day 1	Local	10	83,3	9	90,0	29,63	20,03
	Central	15	60,0	15	100,0	26,67	13,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	18,52	17,57
	Central	15	60,0	15	100,0	22,22	20,57
Cycle 12 Day 1	Local	9	75,0	8	88,9	20,83	17,25
	Central	15	60,0	13	86,7	25,64	14,62
Cycle 13 Day 1	Local	8	66,7	8	100,0	25,00	34,50
	Central	14	56,0	13	92,9	23,08	16,01
Cycle 14 Day 1	Local	8	66,7	8	100,0	20,83	35,36
	Central	14	56,0	14	100,0	30,95	27,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	20,83	24,80
	Central	14	56,0	13	92,9	28,21	18,49
Cycle 16 Day 1	Local	8	66,7	6	75,0	33,33	21,08
	Central	13	52,0	9	69,2	33,33	28,87
Cycle 17 Day 1	Local	8	66,7	5	62,5	33,33	23,57
	Central	10	40,0	9	90,0	25,93	22,22
Cycle 18 Day 1	Local	6	50,0	4	66,7	16,67	19,25
	Central	9	36,0	4	44,4	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	33,33	27,22
	Central	8	32,0	4	50,0	33,33	0,00
Cycle 20 Day 1	Local	5	41,7	5	100,0	26,67	27,89
	Central	4	16,0	4	100,0	25,00	16,67
Cycle 21 Day 1	Local	4	33,3	2	50,0	33,33	0,00
	Central	3	12,0	2	66,7	50,00	23,57
Cycle 22 Day 1	Local	4	33,3	1	25,0	33,33	-
	Central	3	12,0	1	33,3	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	33,33	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	33,33	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	50,00	23,57
	Central	8	32,0	3	37,5	66,67	33,33
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	42,71	34,11
	No	2	100,0	2	100,0	66,67	47,14
Cycle 2 Day 1	Yes	32	91,4	28	87,5	25,00	29,57
	No	1	50,0	1	100,0	33,33	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	24,14	23,40
	No	1	50,0	1	100,0	33,33	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	17,28	19,33
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	26,19	24,61
	No	1	50,0	1	100,0	33,33	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	22,62	25,75
	No	1	50,0	1	100,0	33,33	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	29,49	27,21
	No	1	50,0	1	100,0	33,33	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	27,78	25,38
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	29,17	22,66
	No	1	50,0	1	100,0	33,33	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	27,54	16,37
	No	1	50,0	1	100,0	33,33	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	20,29	19,43
	No	1	50,0	1	100,0	33,33	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	23,33	15,67
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	23,33	24,42
	No	1	50,0	1	100,0	33,33	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	28,57	30,34
	No	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	26,67	20,52
	No	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	30,95	24,33
	No	1	50,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	25,64	19,97
	No	1	50,0	1	100,0	66,67	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	23,81	16,27
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	33,33	19,25
	No	1	50,0	1	100,0	33,33	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	29,17	21,36
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	41,67	16,67
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	66,67	47,14
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	33,33	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	33,33	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	60,00	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	66,67	33,33
	No	33	100,0	31	93,9	41,94	34,39
Cycle 2 Day 1	Yes	2	50,0	1	50,0	33,33	-
	No	31	93,9	28	90,3	25,00	29,57
Cycle 3 Day 1	Yes	2	50,0	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	23,81	23,76
Cycle 4 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	30	90,9	26	86,7	17,95	19,39
Cycle 5 Day 1	Yes	2	50,0	2	100,0	33,33	0,00
	No	29	87,9	27	93,1	25,93	25,04
Cycle 6 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	29	87,9	27	93,1	23,46	25,84
Cycle 7 Day 1	Yes	2	50,0	2	100,0	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	28,00	26,67
Cycle 8 Day 1	Yes	2	50,0	2	100,0	33,33	47,14
	No	26	78,8	23	88,5	27,54	23,89
Cycle 9 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	24	100,0	29,17	22,66
Cycle 10 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	23	95,8	27,54	16,37
Cycle 11 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	20,29	19,43
Cycle 12 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	23	69,7	20	87,0	23,33	15,67
Cycle 13 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	20	95,2	23,33	24,42
Cycle 14 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	21	100,0	26,98	30,95
Cycle 15 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	25,00	21,29
Cycle 16 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	20	60,6	14	70,0	30,95	24,33
Cycle 17 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	17	51,5	13	76,5	28,21	22,96
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	20,83	17,25
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	33,33	17,82
Cycle 20 Day 1	No	9	27,3	9	100,0	25,93	22,22
Cycle 21 Day 1	No	7	21,2	4	57,1	41,67	16,67
Cycle 22 Day 1	No	7	21,2	2	28,6	66,67	47,14
Cycle 23 Day 1	No	4	12,1	1	25,0	33,33	-
Cycle 24 Day 1	No	1	3,0	1	100,0	33,33	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	50,00	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30DY_SG.xls
07SEP2019 19:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	73,04	22,10
Cycle 2 Day 1	All	33	89,2	29	87,9	80,46	22,96
Cycle 3 Day 1	All	32	86,5	30	93,8	81,11	19,57
Cycle 4 Day 1	All	32	86,5	28	87,5	86,61	11,86
Cycle 5 Day 1	All	31	83,8	29	93,5	81,03	18,22
Cycle 6 Day 1	All	31	83,8	29	93,5	79,89	15,51
Cycle 7 Day 1	All	30	81,1	27	90,0	78,70	14,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	77,00	21,95
Cycle 9 Day 1	All	25	67,6	25	100,0	81,00	16,58
Cycle 10 Day 1	All	25	67,6	24	96,0	78,13	21,11
Cycle 11 Day 1	All	24	64,9	24	100,0	81,94	18,17
Cycle 12 Day 1	All	24	64,9	21	87,5	82,54	17,26
Cycle 13 Day 1	All	22	59,5	21	95,5	80,16	20,49
Cycle 14 Day 1	All	22	59,5	22	100,0	78,03	22,79
Cycle 15 Day 1	All	22	59,5	21	95,5	79,37	16,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	78,33	20,12
Cycle 17 Day 1	All	18	48,6	14	77,8	78,57	17,52
Cycle 18 Day 1	All	15	40,5	8	53,3	75,00	19,42
Cycle 19 Day 1	All	13	35,1	8	61,5	81,25	20,29
Cycle 20 Day 1	All	9	24,3	9	100,0	75,93	19,74
Cycle 21 Day 1	All	7	18,9	4	57,1	60,42	12,50
Cycle 22 Day 1	All	7	18,9	2	28,6	58,33	35,36
Cycle 23 Day 1	All	4	10,8	1	25,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	66,67	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	68,33	19,90
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	69,23	24,15
	Female	23	100,0	21	91,3	75,40	21,00
Cycle 2 Day 1	Male	13	92,9	12	92,3	72,22	29,37
	Female	20	87,0	17	85,0	86,27	15,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	80,56	17,88
	Female	20	87,0	18	90,0	81,48	21,11
Cycle 4 Day 1	Male	12	85,7	11	91,7	86,36	11,35
	Female	20	87,0	17	85,0	86,76	12,52
Cycle 5 Day 1	Male	12	85,7	11	91,7	79,55	16,82
	Female	19	82,6	18	94,7	81,94	19,44
Cycle 6 Day 1	Male	12	85,7	11	91,7	84,85	13,85
	Female	19	82,6	18	94,7	76,85	16,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	83,33	13,94
	Female	19	82,6	16	84,2	75,52	15,05
Cycle 8 Day 1	Male	10	71,4	9	90,0	71,30	32,03
	Female	18	78,3	16	88,9	80,21	13,90
Cycle 9 Day 1	Male	8	57,1	8	100,0	85,42	13,91
	Female	17	73,9	17	100,0	78,92	17,71
Cycle 10 Day 1	Male	8	57,1	8	100,0	80,21	23,54
	Female	17	73,9	16	94,1	77,08	20,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	84,38	19,64
	Female	16	69,6	16	100,0	80,73	17,93
Cycle 12 Day 1	Male	8	57,1	8	100,0	81,25	20,77
	Female	16	69,6	13	81,3	83,33	15,59
Cycle 13 Day 1	Male	8	57,1	8	100,0	88,54	14,04
	Female	14	60,9	13	92,9	75,00	22,57
Cycle 14 Day 1	Male	8	57,1	8	100,0	81,25	19,80
	Female	14	60,9	14	100,0	76,19	24,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	82,29	16,33
	Female	14	60,9	13	92,9	77,56	17,14
Cycle 16 Day 1	Male	8	57,1	5	62,5	83,33	19,54
	Female	13	56,5	10	76,9	75,83	20,95
Cycle 17 Day 1	Male	6	42,9	2	33,3	75,00	23,57
	Female	12	52,2	12	100,0	79,17	17,59
Cycle 18 Day 1	Male	3	21,4	2	66,7	75,00	23,57
	Female	12	52,2	6	50,0	75,00	20,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	70,83	29,46
	Female	11	47,8	6	54,5	84,72	18,57
Cycle 20 Day 1	Male	2	14,3	2	100,0	66,67	35,36
	Female	7	30,4	7	100,0	78,57	16,57
Cycle 21 Day 1	Male	1	7,1	1	100,0	41,67	-
	Female	6	26,1	3	50,0	66,67	0,00
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	58,33	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	66,67	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	66,67	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	62,50	29,46
	Female	7	30,4	3	42,9	72,22	17,35
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	73,77	22,61
	65-74	8	100,0	7	87,5	70,24	21,44
Cycle 2 Day 1	18-64	27	93,1	24	88,9	80,21	24,43
	65-74	6	75,0	5	83,3	81,67	16,03
Cycle 3 Day 1	18-64	26	89,7	24	92,3	80,56	16,79
	65-74	6	75,0	6	100,0	83,33	30,28
Cycle 4 Day 1	18-64	26	89,7	23	88,5	86,96	11,74
	65-74	6	75,0	5	83,3	85,00	13,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	83,33	15,49
	65-74	6	75,0	6	100,0	72,22	26,18
Cycle 6 Day 1	18-64	25	86,2	24	96,0	80,56	14,26
	65-74	6	75,0	5	83,3	76,67	22,36
Cycle 7 Day 1	18-64	25	86,2	23	92,0	78,62	11,47
	65-74	5	62,5	4	80,0	79,17	30,81
Cycle 8 Day 1	18-64	23	79,3	20	87,0	75,83	22,77
	65-74	5	62,5	5	100,0	81,67	19,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	82,50	13,76
	65-74	5	62,5	5	100,0	75,00	26,35
Cycle 10 Day 1	18-64	20	69,0	19	95,0	79,82	17,64
	65-74	5	62,5	5	100,0	71,67	33,12
Cycle 11 Day 1	18-64	19	65,5	19	100,0	82,02	17,63
	65-74	5	62,5	5	100,0	81,67	22,36
Cycle 12 Day 1	18-64	19	65,5	17	89,5	85,29	15,74
	65-74	5	62,5	4	80,0	70,83	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	83,85	15,36
	65-74	5	62,5	5	100,0	68,33	31,40
Cycle 14 Day 1	18-64	17	58,6	17	100,0	80,88	15,52
	65-74	5	62,5	5	100,0	68,33	40,14
Cycle 15 Day 1	18-64	17	58,6	16	94,1	80,21	12,87
	65-74	5	62,5	5	100,0	76,67	27,26
Cycle 16 Day 1	18-64	17	58,6	13	76,5	78,21	19,99
	65-74	4	50,0	2	50,0	79,17	29,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	77,78	18,58
	65-74	3	37,5	2	66,7	83,33	11,79
Cycle 18 Day 1	18-64	13	44,8	8	61,5	75,00	19,42
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	84,52	19,50
	65-74	2	25,0	1	50,0	58,33	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	78,13	19,89
	65-74	1	12,5	1	100,0	58,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	60,42	12,50
Cycle 22 Day 1	18-64	7	24,1	2	28,6	58,33	35,36
Cycle 23 Day 1	18-64	4	13,8	1	25,0	66,67	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	66,67	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	72,22	26,79
	65-74	6	75,0	2	33,3	62,50	5,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	77,45	18,11
	Other	17	100,0	17	100,0	68,63	25,26
Cycle 2 Day 1	White	19	95,0	16	84,2	78,13	27,87
	Other	14	82,4	13	92,9	83,33	15,59
Cycle 3 Day 1	White	18	90,0	16	88,9	82,29	23,74
	Other	14	82,4	14	100,0	79,76	14,14
Cycle 4 Day 1	White	18	90,0	15	83,3	90,00	10,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	82,69	12,94
Cycle 5 Day 1	White	18	90,0	17	94,4	82,35	21,22
	Other	13	76,5	12	92,3	79,17	13,53
Cycle 6 Day 1	White	18	90,0	16	88,9	82,29	15,18
	Other	13	76,5	13	100,0	76,92	16,01
Cycle 7 Day 1	White	17	85,0	15	88,2	79,44	16,63
	Other	13	76,5	12	92,3	77,78	12,97
Cycle 8 Day 1	White	17	85,0	14	82,4	79,17	18,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	74,24	26,21
Cycle 9 Day 1	White	16	80,0	16	100,0	84,38	17,97
	Other	9	52,9	9	100,0	75,00	12,50
Cycle 10 Day 1	White	16	80,0	15	93,8	80,00	24,56
	Other	9	52,9	9	100,0	75,00	14,43
Cycle 11 Day 1	White	16	80,0	16	100,0	85,42	17,87
	Other	8	47,1	8	100,0	75,00	17,82
Cycle 12 Day 1	White	16	80,0	13	81,3	82,69	19,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	82,29	14,39
Cycle 13 Day 1	White	14	70,0	13	92,9	78,21	23,70
	Other	8	47,1	8	100,0	83,33	14,77
Cycle 14 Day 1	White	14	70,0	14	100,0	75,60	26,85
	Other	8	47,1	8	100,0	82,29	13,68
Cycle 15 Day 1	White	14	70,0	13	92,9	76,92	17,73
	Other	8	47,1	8	100,0	83,33	14,77
Cycle 16 Day 1	White	14	70,0	9	64,3	78,70	20,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	77,78	22,15
Cycle 17 Day 1	White	13	65,0	10	76,9	80,00	18,51
	Other	5	29,4	4	80,0	75,00	16,67
Cycle 18 Day 1	White	11	55,0	4	36,4	79,17	19,84
	Other	4	23,5	4	100,0	70,83	20,97
Cycle 19 Day 1	White	9	45,0	5	55,6	76,67	21,57
	Other	4	23,5	3	75,0	88,89	19,25
Cycle 20 Day 1	White	5	25,0	5	100,0	66,67	18,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	87,50	15,96
Cycle 21 Day 1	White	3	15,0	2	66,7	54,17	17,68
	Other	4	23,5	2	50,0	66,67	0,00
Cycle 22 Day 1	White	3	15,0	1	33,3	33,33	-
	Other	4	23,5	1	25,0	83,33	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	66,67	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	77,78	17,35
	Other	9	52,9	2	22,2	54,17	17,68
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	84,03	15,27
	Europe (EU)	10	100,0	8	80,0	69,79	17,22
	Asia (AS)	15	100,0	14	93,3	65,48	26,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	83,33	22,05
	Europe (EU)	9	90,0	8	88,9	71,88	32,10
	Asia (AS)	13	86,7	12	92,3	84,03	16,07
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	83,33	20,07
	Europe (EU)	8	80,0	6	75,0	75,00	27,89
	Asia (AS)	13	86,7	13	100,0	82,05	15,53
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	84,09	13,15
	Europe (EU)	8	80,0	4	50,0	87,50	4,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	88,46	12,52
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	84,09	16,85
	Europe (EU)	8	80,0	7	87,5	78,57	25,85
	Asia (AS)	12	80,0	11	91,7	79,55	15,08
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	84,85	11,07
	Europe (EU)	8	80,0	7	87,5	75,00	18,00
	Asia (AS)	12	80,0	11	91,7	78,03	17,59
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	84,17	12,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	70,24	18,54
	Asia (AS)	11	73,3	10	90,9	79,17	12,58
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	79,17	16,78
	Europe (EU)	8	80,0	6	75,0	79,17	21,57
	Asia (AS)	9	60,0	9	100,0	73,15	28,50
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	83,33	14,91
	Europe (EU)	7	70,0	7	100,0	78,57	21,44
	Asia (AS)	7	46,7	7	100,0	79,76	15,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	83,33	20,79
	Europe (EU)	7	70,0	7	100,0	69,05	25,33
	Asia (AS)	7	46,7	7	100,0	79,76	16,57
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	84,85	17,41
	Europe (EU)	7	70,0	7	100,0	80,95	19,67
	Asia (AS)	6	40,0	6	100,0	77,78	20,18
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	78,33	18,51
	Europe (EU)	7	70,0	5	71,4	80,00	20,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	91,67	9,13
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	78,33	16,76
	Europe (EU)	6	60,0	5	83,3	71,67	31,51
	Asia (AS)	6	40,0	6	100,0	90,28	13,35
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	79,17	18,53
	Europe (EU)	6	60,0	6	100,0	66,67	33,75
	Asia (AS)	6	40,0	6	100,0	87,50	12,64
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	80,83	14,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	70,00	22,52
	Asia (AS)	6	40,0	6	100,0	84,72	13,35
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	80,95	16,47
	Europe (EU)	6	60,0	2	33,3	70,83	17,68
	Asia (AS)	6	40,0	6	100,0	77,78	26,70
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	72,22	21,52
	Europe (EU)	4	40,0	3	75,0	83,33	8,33
	Asia (AS)	5	33,3	5	100,0	83,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	76,67	18,07
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	72,22	25,46
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	81,25	21,92
	Europe (EU)	3	30,0	1	33,3	58,33	-
	Asia (AS)	4	26,7	3	75,0	88,89	19,25
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	71,67	19,18
	Europe (EU)	1	10,0	1	100,0	58,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	88,89	19,25
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	58,33	14,43
	Asia (AS)	3	20,0	1	33,3	66,67	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	58,33	35,36
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	66,67	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	80,56	12,73
	Europe (EU)	2	20,0	1	50,0	58,33	-
	Asia (AS)	7	46,7	1	14,3	41,67	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	76,39	16,60
	1	17	100,0	17	100,0	72,06	26,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	68,33	22,36
Cycle 2 Day 1	0	15	100,0	12	80,0	77,08	19,18
	1	15	88,2	14	93,3	81,55	27,77
	2	3	60,0	3	100,0	88,89	12,73
Cycle 3 Day 1	0	15	100,0	14	93,3	78,57	24,18
	1	14	82,4	13	92,9	84,62	14,37
	2	3	60,0	3	100,0	77,78	19,25
Cycle 4 Day 1	0	15	100,0	14	93,3	84,52	11,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	90,28	11,14
	2	3	60,0	2	66,7	79,17	17,68
Cycle 5 Day 1	0	15	100,0	15	100,0	78,89	21,33
	1	14	82,4	12	85,7	82,64	14,85
	2	2	40,0	2	100,0	87,50	17,68
Cycle 6 Day 1	0	15	100,0	15	100,0	80,56	15,64
	1	14	82,4	12	85,7	77,08	15,94
	2	2	40,0	2	100,0	91,67	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	78,57	18,70
	1	13	76,5	11	84,6	78,79	10,78
	2	2	40,0	2	100,0	79,17	5,89
Cycle 8 Day 1	0	15	100,0	13	86,7	73,72	20,93
	1	11	64,7	10	90,9	79,17	24,92
	2	2	40,0	2	100,0	87,50	17,68
Cycle 9 Day 1	0	14	93,3	14	100,0	79,17	18,13
	1	10	58,8	10	100,0	83,33	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	83,33	-
Cycle 10 Day 1	0	14	93,3	14	100,0	77,38	25,41
	1	10	58,8	9	90,0	77,78	14,43
	2	1	20,0	1	100,0	91,67	-
Cycle 11 Day 1	0	14	93,3	14	100,0	80,95	18,90
	1	9	52,9	9	100,0	81,48	18,06
	2	1	20,0	1	100,0	100,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	75,00	18,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	91,67	7,72
	2	1	20,0	1	100,0	100,00	-
Cycle 13 Day 1	0	14	93,3	13	92,9	75,64	23,19
	1	8	47,1	8	100,0	87,50	13,36
Cycle 14 Day 1	0	14	93,3	14	100,0	73,81	26,93
	1	8	47,1	8	100,0	85,42	10,68
Cycle 15 Day 1	0	14	93,3	14	100,0	77,38	18,32
	1	8	47,1	7	87,5	83,33	12,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	81,25	19,80
	1	8	47,1	7	87,5	75,00	21,52
Cycle 17 Day 1	0	12	80,0	8	66,7	73,96	17,50
	1	6	35,3	6	100,0	84,72	17,01
Cycle 18 Day 1	0	9	60,0	4	44,4	70,83	14,43
	1	6	35,3	4	66,7	79,17	25,00
Cycle 19 Day 1	0	8	53,3	4	50,0	75,00	24,53
	1	5	29,4	4	80,0	87,50	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	68,33	19,90
	1	4	23,5	4	100,0	85,42	17,18
Cycle 21 Day 1	0	3	20,0	3	100,0	58,33	14,43
	1	4	23,5	1	25,0	66,67	-
Cycle 22 Day 1	0	3	20,0	2	66,7	58,33	35,36
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	66,67	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	66,67	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	69,44	12,73
	1	7	41,2	2	28,6	66,67	35,36
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	73,08	21,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	95,83	5,89
	2 or More	21	100,0	19	90,5	70,61	22,97
Cycle 2 Day 1	None	14	100,0	12	85,7	86,11	19,89
	1	1	50,0	1	100,0	91,67	-
	2 or More	18	85,7	16	88,9	75,52	25,18
Cycle 3 Day 1	None	14	100,0	13	92,9	86,54	17,85
	1	1	50,0	1	100,0	91,67	-
	2 or More	17	81,0	16	94,1	76,04	20,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	85,42	12,87
	1	1	50,0	1	100,0	91,67	-
	2 or More	17	81,0	15	88,2	87,22	11,73
Cycle 5 Day 1	None	14	100,0	14	100,0	86,31	15,19
	1	1	50,0	1	100,0	91,67	-
	2 or More	16	76,2	14	87,5	75,00	20,15
Cycle 6 Day 1	None	14	100,0	14	100,0	85,71	10,56
	1	1	50,0	1	100,0	91,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	73,21	17,66
Cycle 7 Day 1	None	14	100,0	13	92,9	83,97	10,46
	1	1	50,0	1	100,0	91,67	-
	2 or More	15	71,4	13	86,7	72,44	16,80
Cycle 8 Day 1	None	14	100,0	13	92,9	76,28	23,78
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	77,78	20,82
Cycle 9 Day 1	None	13	92,9	13	100,0	81,41	13,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	91,67	-
	2 or More	11	52,4	11	100,0	79,55	20,54
Cycle 10 Day 1	None	13	92,9	12	92,3	78,47	17,57
	1	1	50,0	1	100,0	100,00	-
	2 or More	11	52,4	11	100,0	75,76	25,13
Cycle 11 Day 1	None	13	92,9	13	100,0	81,41	15,65
	1	1	50,0	1	100,0	91,67	-
	2 or More	10	47,6	10	100,0	81,67	22,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	81,25	17,81
	1	1	50,0	1	100,0	91,67	-
	2 or More	10	47,6	8	80,0	83,33	18,37
Cycle 13 Day 1	None	12	85,7	11	91,7	81,06	13,99
	1	1	50,0	1	100,0	100,00	-
	2 or More	9	42,9	9	100,0	76,85	27,25
Cycle 14 Day 1	None	12	85,7	12	100,0	81,25	15,54
	1	1	50,0	1	100,0	91,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	72,22	30,90
Cycle 15 Day 1	None	12	85,7	12	100,0	80,56	13,45
	1	1	50,0	1	100,0	91,67	-
	2 or More	9	42,9	8	88,9	76,04	21,56
Cycle 16 Day 1	None	11	78,6	8	72,7	83,33	17,25
	1	1	50,0	1	100,0	91,67	-
	2 or More	9	42,9	6	66,7	69,44	23,37
Cycle 17 Day 1	None	10	71,4	7	70,0	76,19	13,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	91,67	-
	2 or More	7	33,3	6	85,7	79,17	22,82
Cycle 18 Day 1	None	8	57,1	4	50,0	81,25	21,92
	1	1	50,0	1	100,0	91,67	-
	2 or More	6	28,6	3	50,0	61,11	9,62
Cycle 19 Day 1	None	7	50,0	3	42,9	77,78	25,46
	1	1	50,0	1	100,0	91,67	-
	2 or More	5	23,8	4	80,0	81,25	21,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	75,00	24,53
	1	1	50,0	1	100,0	91,67	-
	2 or More	4	19,0	4	100,0	72,92	18,48
Cycle 21 Day 1	None	4	28,6	2	50,0	54,17	17,68
	2 or More	3	14,3	2	66,7	66,67	0,00
Cycle 22 Day 1	None	4	28,6	1	25,0	83,33	-
	2 or More	3	14,3	1	33,3	33,33	-
Cycle 23 Day 1	None	2	14,3	1	50,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	66,67	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	66,67	-
	1	2	100,0	1	50,0	83,33	-
	2 or More	9	42,9	3	33,3	63,89	25,46
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	73,08	21,29
	Previously Treated	23	100,0	21	91,3	73,02	23,11
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	86,11	19,89
	Previously Treated	19	82,6	17	89,5	76,47	24,69
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	86,54	17,85
	Previously Treated	18	78,3	17	94,4	76,96	20,31
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	85,42	12,87
	Previously Treated	18	78,3	16	88,9	87,50	11,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	86,31	15,19
	Previously Treated	17	73,9	15	88,2	76,11	19,89
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	85,71	10,56
	Previously Treated	17	73,9	15	88,2	74,44	17,67
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	83,97	10,46
	Previously Treated	16	69,6	14	87,5	73,81	16,94
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	76,28	23,78
	Previously Treated	14	60,9	12	85,7	77,78	20,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	81,41	13,67
	Previously Treated	12	52,2	12	100,0	80,56	19,89
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	78,47	17,57
	Previously Treated	12	52,2	12	100,0	77,78	24,96
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	81,41	15,65
	Previously Treated	11	47,8	11	100,0	82,58	21,56
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	81,25	17,81
	Previously Treated	11	47,8	9	81,8	84,26	17,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	81,06	13,99
	Previously Treated	10	43,5	10	100,0	79,17	26,72
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	81,25	15,54
	Previously Treated	10	43,5	10	100,0	74,17	29,78
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	80,56	13,45
	Previously Treated	10	43,5	9	90,0	77,78	20,83
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	83,33	17,25
	Previously Treated	10	43,5	7	70,0	72,62	22,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	76,19	13,97
	Previously Treated	8	34,8	7	87,5	80,95	21,36
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	81,25	21,92
	Previously Treated	7	30,4	4	57,1	68,75	17,18
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	77,78	25,46
	Previously Treated	6	26,1	5	83,3	83,33	19,54
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	75,00	24,53
	Previously Treated	5	21,7	5	100,0	76,67	18,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	54,17	17,68
	Previously Treated	3	13,0	2	66,7	66,67	0,00
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	83,33	-
	Previously Treated	3	13,0	1	33,3	33,33	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	66,67	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	66,67	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	66,67	-
	Previously Treated	11	47,8	4	36,4	68,75	22,95
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	73,61	23,26
	Central	25	100,0	22	88,0	72,73	22,00
Cycle 2 Day 1	Local	11	91,7	10	90,9	78,33	22,29
	Central	22	88,0	19	86,4	81,58	23,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	78,79	26,45
	Central	21	84,0	19	90,5	82,46	14,93
Cycle 4 Day 1	Local	11	91,7	10	90,9	86,67	14,27
	Central	21	84,0	18	85,7	86,57	10,75
Cycle 5 Day 1	Local	11	91,7	10	90,9	75,83	24,67
	Central	20	80,0	19	95,0	83,77	13,74
Cycle 6 Day 1	Local	11	91,7	11	100,0	82,58	16,85
	Central	20	80,0	18	90,0	78,24	14,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	79,55	18,40
	Central	19	76,0	16	84,2	78,13	12,50
Cycle 8 Day 1	Local	10	83,3	10	100,0	76,67	19,16
	Central	18	72,0	15	83,3	77,22	24,29
Cycle 9 Day 1	Local	10	83,3	10	100,0	76,67	20,34
	Central	15	60,0	15	100,0	83,89	13,54
Cycle 10 Day 1	Local	10	83,3	9	90,0	71,30	28,29
	Central	15	60,0	15	100,0	82,22	15,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	77,78	20,83
	Central	15	60,0	15	100,0	84,44	16,63
Cycle 12 Day 1	Local	9	75,0	8	88,9	72,92	20,29
	Central	15	60,0	13	86,7	88,46	12,52
Cycle 13 Day 1	Local	8	66,7	8	100,0	71,88	26,70
	Central	14	56,0	13	92,9	85,26	14,50
Cycle 14 Day 1	Local	8	66,7	8	100,0	71,88	34,20
	Central	14	56,0	14	100,0	81,55	13,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	70,83	20,41
	Central	14	56,0	13	92,9	84,62	11,71
Cycle 16 Day 1	Local	8	66,7	6	75,0	76,39	20,69
	Central	13	52,0	9	69,2	79,63	20,88
Cycle 17 Day 1	Local	8	66,7	5	62,5	73,33	16,03
	Central	10	40,0	9	90,0	81,48	18,53
Cycle 18 Day 1	Local	6	50,0	4	66,7	81,25	21,92
	Central	9	36,0	4	44,4	68,75	17,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	72,92	22,95
	Central	8	32,0	4	50,0	89,58	15,77
Cycle 20 Day 1	Local	5	41,7	5	100,0	71,67	22,52
	Central	4	16,0	4	100,0	81,25	17,18
Cycle 21 Day 1	Local	4	33,3	2	50,0	54,17	17,68
	Central	3	12,0	2	66,7	66,67	0,00
Cycle 22 Day 1	Local	4	33,3	1	25,0	83,33	-
	Central	3	12,0	1	33,3	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	66,67	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	66,67	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	75,00	23,57
	Central	8	32,0	3	37,5	63,89	20,97
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	71,35	21,68
	No	2	100,0	2	100,0	100,00	0,00
Cycle 2 Day 1	Yes	32	91,4	28	87,5	79,76	23,07
	No	1	50,0	1	100,0	100,00	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	80,46	19,58
	No	1	50,0	1	100,0	100,00	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	86,11	11,79
	No	1	50,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	80,95	18,54
	No	1	50,0	1	100,0	83,33	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	79,46	15,63
	No	1	50,0	1	100,0	91,67	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	78,21	14,92
	No	1	50,0	1	100,0	91,67	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	76,74	22,38
	No	1	50,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	81,25	16,89
	No	1	50,0	1	100,0	75,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	77,90	21,56
	No	1	50,0	1	100,0	83,33	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	82,61	18,28
	No	1	50,0	1	100,0	66,67	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	82,50	17,71
	No	1	50,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	79,58	20,85
	No	1	50,0	1	100,0	91,67	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	77,38	23,15
	No	1	50,0	1	100,0	91,67	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	79,58	16,99
	No	1	50,0	1	100,0	75,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	76,79	19,93
	No	1	50,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	79,49	17,88
	No	1	50,0	1	100,0	66,67	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	71,43	17,91
	No	1	50,0	1	100,0	100,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	78,57	20,33
	No	1	50,0	1	100,0	100,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	72,92	18,77
	No	1	50,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	60,42	12,50
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	58,33	35,36
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	66,67	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	66,67	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	68,33	19,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	63,89	33,68
	No	33	100,0	31	93,9	73,92	21,27
Cycle 2 Day 1	Yes	2	50,0	1	50,0	91,67	-
	No	31	93,9	28	90,3	80,06	23,28
Cycle 3 Day 1	Yes	2	50,0	2	100,0	91,67	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	80,36	19,93
Cycle 4 Day 1	Yes	2	50,0	2	100,0	91,67	11,79
	No	30	90,9	26	86,7	86,22	12,01
Cycle 5 Day 1	Yes	2	50,0	2	100,0	91,67	0,00
	No	29	87,9	27	93,1	80,25	18,66
Cycle 6 Day 1	Yes	2	50,0	2	100,0	87,50	5,89
	No	29	87,9	27	93,1	79,32	15,91
Cycle 7 Day 1	Yes	2	50,0	2	100,0	87,50	5,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	78,00	15,19
Cycle 8 Day 1	Yes	2	50,0	2	100,0	45,83	41,25
	No	26	78,8	23	88,5	79,71	18,77
Cycle 9 Day 1	Yes	1	25,0	1	100,0	75,00	-
	No	24	72,7	24	100,0	81,25	16,89
Cycle 10 Day 1	Yes	1	25,0	1	100,0	83,33	-
	No	24	72,7	23	95,8	77,90	21,56
Cycle 11 Day 1	Yes	1	25,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	81,88	18,57
Cycle 12 Day 1	Yes	1	25,0	1	100,0	83,33	-
	No	23	69,7	20	87,0	82,50	17,71
Cycle 13 Day 1	Yes	1	25,0	1	100,0	83,33	-
	No	21	63,6	20	95,2	80,00	21,01
Cycle 14 Day 1	Yes	1	25,0	1	100,0	83,33	-
	No	21	63,6	21	100,0	77,78	23,32
Cycle 15 Day 1	Yes	1	25,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	79,17	16,99
Cycle 16 Day 1	Yes	1	25,0	1	100,0	100,00	-
	No	20	60,6	14	70,0	76,79	19,93
Cycle 17 Day 1	Yes	1	25,0	1	100,0	83,33	-
	No	17	51,5	13	76,5	78,21	18,17
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	75,00	19,42
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	81,25	20,29
Cycle 20 Day 1	No	9	27,3	9	100,0	75,93	19,74
Cycle 21 Day 1	No	7	21,2	4	57,1	60,42	12,50
Cycle 22 Day 1	No	7	21,2	2	28,6	58,33	35,36
Cycle 23 Day 1	No	4	12,1	1	25,0	66,67	-
Cycle 24 Day 1	No	1	3,0	1	100,0	66,67	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	41,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	75,00	15,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30EF_SG.xls
07SEP2019 19:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	43,79	25,80
Cycle 2 Day 1	All	33	89,2	29	87,9	37,16	22,08
Cycle 3 Day 1	All	32	86,5	30	93,8	35,19	25,28
Cycle 4 Day 1	All	32	86,5	28	87,5	27,38	20,17
Cycle 5 Day 1	All	31	83,8	29	93,5	28,74	17,94
Cycle 6 Day 1	All	31	83,8	29	93,5	27,59	15,89
Cycle 7 Day 1	All	30	81,1	27	90,0	31,69	19,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	31,11	19,51
Cycle 9 Day 1	All	25	67,6	25	100,0	27,11	18,45
Cycle 10 Day 1	All	25	67,6	24	96,0	29,17	16,32
Cycle 11 Day 1	All	24	64,9	24	100,0	24,07	14,90
Cycle 12 Day 1	All	24	64,9	21	87,5	29,63	21,18
Cycle 13 Day 1	All	22	59,5	21	95,5	30,69	21,92
Cycle 14 Day 1	All	22	59,5	22	100,0	31,82	27,92
Cycle 15 Day 1	All	22	59,5	21	95,5	30,16	20,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	30,37	15,41
Cycle 17 Day 1	All	18	48,6	14	77,8	26,98	20,77
Cycle 18 Day 1	All	15	40,5	8	53,3	26,39	20,52
Cycle 19 Day 1	All	13	35,1	8	61,5	27,78	15,71
Cycle 20 Day 1	All	9	24,3	9	100,0	29,63	20,03
Cycle 21 Day 1	All	7	18,9	4	57,1	41,67	24,64
Cycle 22 Day 1	All	7	18,9	2	28,6	66,67	47,14
Cycle 23 Day 1	All	4	10,8	1	25,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	33,33	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	46,67	25,34
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	43,59	25,84
	Female	23	100,0	21	91,3	43,92	26,41
Cycle 2 Day 1	Male	13	92,9	12	92,3	33,33	22,22
	Female	20	87,0	17	85,0	39,87	22,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	25,00	12,65
	Female	20	87,0	18	90,0	41,98	29,41
Cycle 4 Day 1	Male	12	85,7	11	91,7	19,19	14,13
	Female	20	87,0	17	85,0	32,68	22,04
Cycle 5 Day 1	Male	12	85,7	11	91,7	29,29	15,93
	Female	19	82,6	18	94,7	28,40	19,52
Cycle 6 Day 1	Male	12	85,7	11	91,7	22,22	17,21
	Female	19	82,6	18	94,7	30,86	14,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	27,27	18,83
	Female	19	82,6	16	84,2	34,72	20,64
Cycle 8 Day 1	Male	10	71,4	9	90,0	29,63	27,22
	Female	18	78,3	16	88,9	31,94	14,56
Cycle 9 Day 1	Male	8	57,1	8	100,0	23,61	17,25
	Female	17	73,9	17	100,0	28,76	19,27
Cycle 10 Day 1	Male	8	57,1	8	100,0	22,22	15,71
	Female	17	73,9	16	94,1	32,64	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	20,83	15,07
	Female	16	69,6	16	100,0	25,69	15,03
Cycle 12 Day 1	Male	8	57,1	8	100,0	23,61	17,25
	Female	16	69,6	13	81,3	33,33	23,13
Cycle 13 Day 1	Male	8	57,1	8	100,0	25,00	17,57
	Female	14	60,9	13	92,9	34,19	24,20
Cycle 14 Day 1	Male	8	57,1	8	100,0	29,17	29,06
	Female	14	60,9	14	100,0	33,33	28,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	33,33	18,78
	Female	14	60,9	13	92,9	28,21	22,04
Cycle 16 Day 1	Male	8	57,1	5	62,5	28,89	18,59
	Female	13	56,5	10	76,9	31,11	14,63
Cycle 17 Day 1	Male	6	42,9	2	33,3	27,78	7,86
	Female	12	52,2	12	100,0	26,85	22,45
Cycle 18 Day 1	Male	3	21,4	2	66,7	22,22	15,71
	Female	12	52,2	6	50,0	27,78	23,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	22,22	15,71
	Female	11	47,8	6	54,5	29,63	16,73
Cycle 20 Day 1	Male	2	14,3	2	100,0	16,67	7,86
	Female	7	30,4	7	100,0	33,33	21,28
Cycle 21 Day 1	Male	1	7,1	1	100,0	22,22	-
	Female	6	26,1	3	50,0	48,15	25,66
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	66,67	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	33,33	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	33,33	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	55,56	47,14
	Female	7	30,4	3	42,9	40,74	6,42
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	43,21	26,92
	65-74	8	100,0	7	87,5	46,03	22,62
Cycle 2 Day 1	18-64	27	93,1	24	88,9	34,72	21,31
	65-74	6	75,0	5	83,3	48,89	24,34
Cycle 3 Day 1	18-64	26	89,7	24	92,3	33,80	24,18
	65-74	6	75,0	6	100,0	40,74	31,16
Cycle 4 Day 1	18-64	26	89,7	23	88,5	27,54	19,78
	65-74	6	75,0	5	83,3	26,67	24,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	26,57	18,27
	65-74	6	75,0	6	100,0	37,04	15,18
Cycle 6 Day 1	18-64	25	86,2	24	96,0	27,31	17,02
	65-74	6	75,0	5	83,3	28,89	9,94
Cycle 7 Day 1	18-64	25	86,2	23	92,0	32,37	21,43
	65-74	5	62,5	4	80,0	27,78	6,42
Cycle 8 Day 1	18-64	23	79,3	20	87,0	32,22	21,30
	65-74	5	62,5	5	100,0	26,67	9,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	22,78	15,91
	65-74	5	62,5	5	100,0	44,44	19,25
Cycle 10 Day 1	18-64	20	69,0	19	95,0	27,49	15,87
	65-74	5	62,5	5	100,0	35,56	18,26
Cycle 11 Day 1	18-64	19	65,5	19	100,0	23,39	14,77
	65-74	5	62,5	5	100,0	26,67	16,85
Cycle 12 Day 1	18-64	19	65,5	17	89,5	28,76	23,59
	65-74	5	62,5	4	80,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	27,08	16,71
	65-74	5	62,5	5	100,0	42,22	33,70
Cycle 14 Day 1	18-64	17	58,6	17	100,0	28,10	26,68
	65-74	5	62,5	5	100,0	44,44	31,43
Cycle 15 Day 1	18-64	17	58,6	16	94,1	28,47	18,58
	65-74	5	62,5	5	100,0	35,56	27,67
Cycle 16 Day 1	18-64	17	58,6	13	76,5	29,91	16,60
	65-74	4	50,0	2	50,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	27,78	21,97
	65-74	3	37,5	2	66,7	22,22	15,71
Cycle 18 Day 1	18-64	13	44,8	8	61,5	26,39	20,52
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	25,40	15,33
	65-74	2	25,0	1	50,0	44,44	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	29,17	21,36
	65-74	1	12,5	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	41,67	24,64
Cycle 22 Day 1	18-64	7	24,1	2	28,6	66,67	47,14
Cycle 23 Day 1	18-64	4	13,8	1	25,0	33,33	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	33,33	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	51,85	33,95
	65-74	6	75,0	2	33,3	38,89	7,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	44,44	30,17
	Other	17	100,0	17	100,0	43,14	21,47
Cycle 2 Day 1	White	19	95,0	16	84,2	40,28	23,96
	Other	14	82,4	13	92,9	33,33	19,77
Cycle 3 Day 1	White	18	90,0	16	88,9	39,58	31,16
	Other	14	82,4	14	100,0	30,16	15,97
Cycle 4 Day 1	White	18	90,0	15	83,3	21,48	20,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	34,19	17,84
Cycle 5 Day 1	White	18	90,0	17	94,4	27,45	23,28
	Other	13	76,5	12	92,3	30,56	5,03
Cycle 6 Day 1	White	18	90,0	16	88,9	26,39	18,54
	Other	13	76,5	13	100,0	29,06	12,45
Cycle 7 Day 1	White	17	85,0	15	88,2	28,89	20,05
	Other	13	76,5	12	92,3	35,19	20,01
Cycle 8 Day 1	White	17	85,0	14	82,4	26,98	15,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	36,36	23,35
Cycle 9 Day 1	White	16	80,0	16	100,0	25,00	21,66
	Other	9	52,9	9	100,0	30,86	10,80
Cycle 10 Day 1	White	16	80,0	15	93,8	28,15	20,08
	Other	9	52,9	9	100,0	30,86	7,41
Cycle 11 Day 1	White	16	80,0	16	100,0	23,61	16,67
	Other	8	47,1	8	100,0	25,00	11,50
Cycle 12 Day 1	White	16	80,0	13	81,3	28,21	27,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	31,94	3,93
Cycle 13 Day 1	White	14	70,0	13	92,9	30,77	27,27
	Other	8	47,1	8	100,0	30,56	9,85
Cycle 14 Day 1	White	14	70,0	14	100,0	29,37	31,00
	Other	8	47,1	8	100,0	36,11	22,81
Cycle 15 Day 1	White	14	70,0	13	92,9	29,91	23,74
	Other	8	47,1	8	100,0	30,56	15,43
Cycle 16 Day 1	White	14	70,0	9	64,3	27,16	15,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	35,19	14,77
Cycle 17 Day 1	White	13	65,0	10	76,9	25,56	24,60
	Other	5	29,4	4	80,0	30,56	5,56
Cycle 18 Day 1	White	11	55,0	4	36,4	30,56	26,25
	Other	4	23,5	4	100,0	22,22	15,71
Cycle 19 Day 1	White	9	45,0	5	55,6	26,67	20,18
	Other	4	23,5	3	75,0	29,63	6,42
Cycle 20 Day 1	White	5	25,0	5	100,0	33,33	26,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	25,00	10,64
Cycle 21 Day 1	White	3	15,0	2	66,7	50,00	39,28
	Other	4	23,5	2	50,0	33,33	0,00
Cycle 22 Day 1	White	3	15,0	1	33,3	100,00	-
	Other	4	23,5	1	25,0	33,33	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	33,33	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	37,04	12,83
	Other	9	52,9	2	22,2	61,11	39,28
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	36,11	26,43
	Europe (EU)	10	100,0	8	80,0	59,72	28,44
	Asia (AS)	15	100,0	14	93,3	41,27	21,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	34,57	16,14
	Europe (EU)	9	90,0	8	88,9	44,44	30,28
	Asia (AS)	13	86,7	12	92,3	34,26	20,36
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	33,33	22,22
	Europe (EU)	8	80,0	6	75,0	53,70	37,46
	Asia (AS)	13	86,7	13	100,0	28,21	17,92
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	25,25	23,88
	Europe (EU)	8	80,0	4	50,0	22,22	25,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	30,77	15,81
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	23,23	18,23
	Europe (EU)	8	80,0	7	87,5	31,75	23,51
	Asia (AS)	12	80,0	11	91,7	32,32	13,57
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	18,18	13,40
	Europe (EU)	8	80,0	7	87,5	33,33	16,97
	Asia (AS)	12	80,0	11	91,7	33,33	14,05
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	25,56	20,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	31,75	14,95
	Asia (AS)	11	73,3	10	90,9	37,78	21,72
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	21,11	14,30
	Europe (EU)	8	80,0	6	75,0	37,04	9,07
	Asia (AS)	9	60,0	9	100,0	38,27	25,53
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	25,25	17,98
	Europe (EU)	7	70,0	7	100,0	34,92	23,51
	Asia (AS)	7	46,7	7	100,0	22,22	12,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	27,78	19,07
	Europe (EU)	7	70,0	7	100,0	36,51	15,33
	Asia (AS)	7	46,7	7	100,0	23,81	11,88
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	22,22	17,21
	Europe (EU)	7	70,0	7	100,0	28,57	14,14
	Asia (AS)	6	40,0	6	100,0	22,22	12,17
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	27,78	28,81
	Europe (EU)	7	70,0	5	71,4	37,78	6,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	25,93	13,46
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	24,44	18,74
	Europe (EU)	6	60,0	5	83,3	46,67	29,81
	Asia (AS)	6	40,0	6	100,0	27,78	15,32
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	26,67	25,77
	Europe (EU)	6	60,0	6	100,0	48,15	38,92
	Asia (AS)	6	40,0	6	100,0	24,07	10,92
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	23,33	17,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	44,44	29,40
	Asia (AS)	6	40,0	6	100,0	29,63	11,48
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	22,22	14,34
	Europe (EU)	6	60,0	2	33,3	44,44	15,71
	Asia (AS)	6	40,0	6	100,0	35,19	12,99
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	35,19	27,59
	Europe (EU)	4	40,0	3	75,0	14,81	16,97
	Asia (AS)	5	33,3	5	100,0	24,44	9,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	31,11	22,77
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	18,52	16,97
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	22,22	20,29
	Europe (EU)	3	30,0	1	33,3	44,44	-
	Asia (AS)	4	26,7	3	75,0	29,63	6,42
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	31,11	26,53
	Europe (EU)	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	25,93	12,83
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	44,44	29,40
	Asia (AS)	3	20,0	1	33,3	33,33	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	66,67	47,14
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	33,33	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	33,33	11,11
	Europe (EU)	2	20,0	1	50,0	44,44	-
	Asia (AS)	7	46,7	1	14,3	88,89	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	26,85	10,00
	1	17	100,0	17	100,0	48,37	24,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	68,89	32,77
Cycle 2 Day 1	0	15	100,0	12	80,0	31,48	20,56
	1	15	88,2	14	93,3	37,30	20,72
	2	3	60,0	3	100,0	59,26	27,96
Cycle 3 Day 1	0	15	100,0	14	93,3	35,71	23,54
	1	14	82,4	13	92,9	27,35	21,09
	2	3	60,0	3	100,0	66,67	33,33
Cycle 4 Day 1	0	15	100,0	14	93,3	23,02	23,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	26,85	8,81
	2	3	60,0	2	66,7	61,11	23,57
Cycle 5 Day 1	0	15	100,0	15	100,0	25,93	13,72
	1	14	82,4	12	85,7	27,78	18,65
	2	2	40,0	2	100,0	55,56	31,43
Cycle 6 Day 1	0	15	100,0	15	100,0	23,70	17,75
	1	14	82,4	12	85,7	31,48	14,08
	2	2	40,0	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	27,78	18,87
	1	13	76,5	11	84,6	35,35	22,67
	2	2	40,0	2	100,0	38,89	7,86
Cycle 8 Day 1	0	15	100,0	13	86,7	27,35	17,92
	1	11	64,7	10	90,9	33,33	22,22
	2	2	40,0	2	100,0	44,44	15,71
Cycle 9 Day 1	0	14	93,3	14	100,0	28,57	20,77
	1	10	58,8	10	100,0	24,44	16,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	33,33	-
Cycle 10 Day 1	0	14	93,3	14	100,0	27,78	16,16
	1	10	58,8	9	90,0	30,86	18,24
	2	1	20,0	1	100,0	33,33	-
Cycle 11 Day 1	0	14	93,3	14	100,0	23,81	15,01
	1	9	52,9	9	100,0	23,46	16,14
	2	1	20,0	1	100,0	33,33	-
Cycle 12 Day 1	0	14	93,3	12	85,7	32,41	25,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	23,61	12,51
	2	1	20,0	1	100,0	44,44	-
Cycle 13 Day 1	0	14	93,3	13	92,9	35,04	24,78
	1	8	47,1	8	100,0	23,61	15,07
Cycle 14 Day 1	0	14	93,3	14	100,0	33,33	29,88
	1	8	47,1	8	100,0	29,17	25,85
Cycle 15 Day 1	0	14	93,3	14	100,0	34,13	20,19
	1	8	47,1	7	87,5	22,22	20,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	30,56	12,94
	1	8	47,1	7	87,5	30,16	18,94
Cycle 17 Day 1	0	12	80,0	8	66,7	30,56	26,39
	1	6	35,3	6	100,0	22,22	9,94
Cycle 18 Day 1	0	9	60,0	4	44,4	36,11	22,91
	1	6	35,3	4	66,7	16,67	14,34
Cycle 19 Day 1	0	8	53,3	4	50,0	33,33	15,71
	1	5	29,4	4	80,0	22,22	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	33,33	26,06
	1	4	23,5	4	100,0	25,00	10,64
Cycle 21 Day 1	0	3	20,0	3	100,0	44,44	29,40
	1	4	23,5	1	25,0	33,33	-
Cycle 22 Day 1	0	3	20,0	2	66,7	66,67	47,14
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	33,33	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	33,33	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	33,33	11,11
	1	7	41,2	2	28,6	66,67	31,43
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	38,46	25,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	50,00	55,00
	2 or More	21	100,0	19	90,5	46,78	24,17
Cycle 2 Day 1	None	14	100,0	12	85,7	32,41	16,04
	1	1	50,0	1	100,0	11,11	-
	2 or More	18	85,7	16	88,9	42,36	25,08
Cycle 3 Day 1	None	14	100,0	13	92,9	29,06	16,06
	1	1	50,0	1	100,0	11,11	-
	2 or More	17	81,0	16	94,1	41,67	30,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	22,22	18,95
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	33,33	19,70
Cycle 5 Day 1	None	14	100,0	14	100,0	23,02	13,41
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	36,51	18,71
Cycle 6 Day 1	None	14	100,0	14	100,0	20,63	13,68
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	36,51	12,65
Cycle 7 Day 1	None	14	100,0	13	92,9	24,79	20,36
	1	1	50,0	1	100,0	33,33	-
	2 or More	15	71,4	13	86,7	38,46	18,49
Cycle 8 Day 1	None	14	100,0	13	92,9	29,06	22,47
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	33,33	16,41
Cycle 9 Day 1	None	13	92,9	13	100,0	24,79	16,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	11,11	-
	2 or More	11	52,4	11	100,0	31,31	20,98
Cycle 10 Day 1	None	13	92,9	12	92,3	27,78	13,81
	1	1	50,0	1	100,0	22,22	-
	2 or More	11	52,4	11	100,0	31,31	19,76
Cycle 11 Day 1	None	13	92,9	13	100,0	19,66	14,45
	1	1	50,0	1	100,0	33,33	-
	2 or More	10	47,6	10	100,0	28,89	15,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	25,93	14,47
	1	1	50,0	1	100,0	11,11	-
	2 or More	10	47,6	8	80,0	37,50	28,44
Cycle 13 Day 1	None	12	85,7	11	91,7	26,26	18,10
	1	1	50,0	1	100,0	22,22	-
	2 or More	9	42,9	9	100,0	37,04	26,64
Cycle 14 Day 1	None	12	85,7	12	100,0	27,78	23,45
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	40,74	32,39
Cycle 15 Day 1	None	12	85,7	12	100,0	24,07	20,01
	1	1	50,0	1	100,0	33,33	-
	2 or More	9	42,9	8	88,9	38,89	20,57
Cycle 16 Day 1	None	11	78,6	8	72,7	29,17	16,73
	1	1	50,0	1	100,0	11,11	-
	2 or More	9	42,9	6	66,7	35,19	12,99
Cycle 17 Day 1	None	10	71,4	7	70,0	22,22	12,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	22,22	-
	2 or More	7	33,3	6	85,7	33,33	28,97
Cycle 18 Day 1	None	8	57,1	4	50,0	19,44	16,67
	1	1	50,0	1	100,0	11,11	-
	2 or More	6	28,6	3	50,0	40,74	23,13
Cycle 19 Day 1	None	7	50,0	3	42,9	22,22	19,25
	1	1	50,0	1	100,0	11,11	-
	2 or More	5	23,8	4	80,0	36,11	10,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	25,00	5,56
	1	1	50,0	1	100,0	11,11	-
	2 or More	4	19,0	4	100,0	38,89	27,96
Cycle 21 Day 1	None	4	28,6	2	50,0	27,78	7,86
	2 or More	3	14,3	2	66,7	55,56	31,43
Cycle 22 Day 1	None	4	28,6	1	25,0	33,33	-
	2 or More	3	14,3	1	33,3	100,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	33,33	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	33,33	-
	1	2	100,0	1	50,0	22,22	-
	2 or More	9	42,9	3	33,3	59,26	25,66
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	38,46	25,51
	Previously Treated	23	100,0	21	91,3	47,09	26,04
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	32,41	16,04
	Previously Treated	19	82,6	17	89,5	40,52	25,44
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	29,06	16,06
	Previously Treated	18	78,3	17	94,4	39,87	30,19
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	22,22	18,95
	Previously Treated	18	78,3	16	88,9	31,25	20,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	23,02	13,41
	Previously Treated	17	73,9	15	88,2	34,07	20,34
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	20,63	13,68
	Previously Treated	17	73,9	15	88,2	34,07	15,41
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	24,79	20,36
	Previously Treated	16	69,6	14	87,5	38,10	17,82
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	29,06	22,47
	Previously Treated	14	60,9	12	85,7	33,33	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	24,79	16,45
	Previously Treated	12	52,2	12	100,0	29,63	20,83
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	27,78	13,81
	Previously Treated	12	52,2	12	100,0	30,56	19,03
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	19,66	14,45
	Previously Treated	11	47,8	11	100,0	29,29	14,29
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	25,93	14,47
	Previously Treated	11	47,8	9	81,8	34,57	28,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	26,26	18,10
	Previously Treated	10	43,5	10	100,0	35,56	25,55
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	27,78	23,45
	Previously Treated	10	43,5	10	100,0	36,67	33,15
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	24,07	20,01
	Previously Treated	10	43,5	9	90,0	38,27	19,33
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	29,17	16,73
	Previously Treated	10	43,5	7	70,0	31,75	14,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	22,22	12,83
	Previously Treated	8	34,8	7	87,5	31,75	26,78
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	19,44	16,67
	Previously Treated	7	30,4	4	57,1	33,33	24,00
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	22,22	19,25
	Previously Treated	6	26,1	5	83,3	31,11	14,49
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	25,00	5,56
	Previously Treated	5	21,7	5	100,0	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	27,78	7,86
	Previously Treated	3	13,0	2	66,7	55,56	31,43
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	33,33	-
	Previously Treated	3	13,0	1	33,3	100,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	33,33	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	11	47,8	4	36,4	50,00	27,96
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	37,96	26,15
	Central	25	100,0	22	88,0	46,97	25,64
Cycle 2 Day 1	Local	11	91,7	10	90,9	32,22	17,72
	Central	22	88,0	19	86,4	39,77	24,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	30,30	27,71
	Central	21	84,0	19	90,5	38,01	24,09
Cycle 4 Day 1	Local	11	91,7	10	90,9	21,11	13,30
	Central	21	84,0	18	85,7	30,86	22,72
Cycle 5 Day 1	Local	11	91,7	10	90,9	25,56	11,77
	Central	20	80,0	19	95,0	30,41	20,57
Cycle 6 Day 1	Local	11	91,7	11	100,0	24,24	13,89
	Central	20	80,0	18	90,0	29,63	17,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	29,29	23,45
	Central	19	76,0	16	84,2	33,33	17,68
Cycle 8 Day 1	Local	10	83,3	10	100,0	22,22	19,60
	Central	18	72,0	15	83,3	37,04	17,65
Cycle 9 Day 1	Local	10	83,3	10	100,0	28,89	24,68
	Central	15	60,0	15	100,0	25,93	13,72
Cycle 10 Day 1	Local	10	83,3	9	90,0	32,10	23,86
	Central	15	60,0	15	100,0	27,41	10,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	23,46	19,60
	Central	15	60,0	15	100,0	24,44	12,03
Cycle 12 Day 1	Local	9	75,0	8	88,9	22,22	15,71
	Central	15	60,0	13	86,7	34,19	23,33
Cycle 13 Day 1	Local	8	66,7	8	100,0	33,33	33,07
	Central	14	56,0	13	92,9	29,06	12,45
Cycle 14 Day 1	Local	8	66,7	8	100,0	31,94	30,54
	Central	14	56,0	14	100,0	31,75	27,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	29,17	25,15
	Central	14	56,0	13	92,9	30,77	18,23
Cycle 16 Day 1	Local	8	66,7	6	75,0	25,93	11,48
	Central	13	52,0	9	69,2	33,33	17,57
Cycle 17 Day 1	Local	8	66,7	5	62,5	24,44	12,17
	Central	10	40,0	9	90,0	28,40	24,91
Cycle 18 Day 1	Local	6	50,0	4	66,7	19,44	16,67
	Central	9	36,0	4	44,4	33,33	24,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	27,78	19,25
	Central	8	32,0	4	50,0	27,78	14,34
Cycle 20 Day 1	Local	5	41,7	5	100,0	26,67	6,09
	Central	4	16,0	4	100,0	33,33	31,43
Cycle 21 Day 1	Local	4	33,3	2	50,0	27,78	7,86
	Central	3	12,0	2	66,7	55,56	31,43
Cycle 22 Day 1	Local	4	33,3	1	25,0	33,33	-
	Central	3	12,0	1	33,3	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	33,33	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	33,33	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	44,44	0,00
	Central	8	32,0	3	37,5	48,15	35,72

BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	43,40	24,66
	No	2	100,0	2	100,0	50,00	55,00
Cycle 2 Day 1	Yes	32	91,4	28	87,5	37,30	22,47
	No	1	50,0	1	100,0	33,33	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	35,25	25,73
	No	1	50,0	1	100,0	33,33	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	27,16	20,52
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	28,57	18,25
	No	1	50,0	1	100,0	33,33	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	27,78	16,14
	No	1	50,0	1	100,0	22,22	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	30,34	19,00
	No	1	50,0	1	100,0	66,67	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	29,63	18,44
	No	1	50,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	26,85	18,80
	No	1	50,0	1	100,0	33,33	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	28,99	16,66
	No	1	50,0	1	100,0	33,33	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	24,15	15,22
	No	1	50,0	1	100,0	22,22	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	29,44	21,71
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	30,56	22,48
	No	1	50,0	1	100,0	33,33	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	31,75	28,61
	No	1	50,0	1	100,0	33,33	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	30,00	21,05
	No	1	50,0	1	100,0	33,33	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	30,16	15,97
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	26,50	21,53
	No	1	50,0	1	100,0	33,33	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	30,16	18,94
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	26,98	16,80
	No	1	50,0	1	100,0	33,33	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	29,17	21,36
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	41,67	24,64
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	66,67	47,14
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	33,33	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	33,33	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	46,67	25,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	59,26	33,95
	No	33	100,0	31	93,9	42,29	25,08
Cycle 2 Day 1	Yes	2	50,0	1	50,0	22,22	-
	No	31	93,9	28	90,3	37,70	22,29
Cycle 3 Day 1	Yes	2	50,0	2	100,0	22,22	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	36,11	25,77
Cycle 4 Day 1	Yes	2	50,0	2	100,0	27,78	7,86
	No	30	90,9	26	86,7	27,35	20,90
Cycle 5 Day 1	Yes	2	50,0	2	100,0	33,33	0,00
	No	29	87,9	27	93,1	28,40	18,58
Cycle 6 Day 1	Yes	2	50,0	2	100,0	33,33	15,71
	No	29	87,9	27	93,1	27,16	16,11
Cycle 7 Day 1	Yes	2	50,0	2	100,0	33,33	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	31,56	20,46
Cycle 8 Day 1	Yes	2	50,0	2	100,0	55,56	31,43
	No	26	78,8	23	88,5	28,99	17,64
Cycle 9 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	24	100,0	26,85	18,80
Cycle 10 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	23	95,8	28,99	16,66
Cycle 11 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	23,67	15,10
Cycle 12 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	23	69,7	20	87,0	29,44	21,71
Cycle 13 Day 1	Yes	1	25,0	1	100,0	44,44	-
	No	21	63,6	20	95,2	30,00	22,25
Cycle 14 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	21	100,0	31,75	28,61
Cycle 15 Day 1	Yes	1	25,0	1	100,0	44,44	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	29,44	20,79
Cycle 16 Day 1	Yes	1	25,0	1	100,0	44,44	-
	No	20	60,6	14	70,0	29,37	15,47
Cycle 17 Day 1	Yes	1	25,0	1	100,0	22,22	-
	No	17	51,5	13	76,5	27,35	21,57
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	26,39	20,52
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	27,78	15,71
Cycle 20 Day 1	No	9	27,3	9	100,0	29,63	20,03
Cycle 21 Day 1	No	7	21,2	4	57,1	41,67	24,64
Cycle 22 Day 1	No	7	21,2	2	28,6	66,67	47,14
Cycle 23 Day 1	No	4	12,1	1	25,0	33,33	-
Cycle 24 Day 1	No	1	3,0	1	100,0	33,33	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	88,89	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	36,11	10,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30FA_SG.xls
07SEP2019 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	11,27	17,75
Cycle 2 Day 1	All	33	89,2	29	87,9	5,17	10,06
Cycle 3 Day 1	All	32	86,5	30	93,8	5,56	15,98
Cycle 4 Day 1	All	32	86,5	28	87,5	3,57	8,31
Cycle 5 Day 1	All	31	83,8	29	93,5	4,60	9,86
Cycle 6 Day 1	All	31	83,8	29	93,5	6,32	12,13
Cycle 7 Day 1	All	30	81,1	27	90,0	6,17	11,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	4,67	10,23
Cycle 9 Day 1	All	25	67,6	25	100,0	5,33	15,00
Cycle 10 Day 1	All	25	67,6	24	96,0	6,25	10,78
Cycle 11 Day 1	All	24	64,9	24	100,0	5,56	10,62
Cycle 12 Day 1	All	24	64,9	21	87,5	7,94	13,56
Cycle 13 Day 1	All	22	59,5	21	95,5	3,97	11,67
Cycle 14 Day 1	All	22	59,5	22	100,0	4,55	14,71
Cycle 15 Day 1	All	22	59,5	21	95,5	4,76	9,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	13,33	18,04
Cycle 17 Day 1	All	18	48,6	14	77,8	7,14	26,73
Cycle 18 Day 1	All	15	40,5	8	53,3	2,08	5,89
Cycle 19 Day 1	All	13	35,1	8	61,5	4,17	11,79
Cycle 20 Day 1	All	9	24,3	9	100,0	1,85	5,56
Cycle 21 Day 1	All	7	18,9	4	57,1	4,17	8,33
Cycle 22 Day 1	All	7	18,9	2	28,6	25,00	35,36
Cycle 23 Day 1	All	4	10,8	1	25,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	0,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	10,00	14,91
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	15,38	24,96
	Female	23	100,0	21	91,3	8,73	11,33
Cycle 2 Day 1	Male	13	92,9	12	92,3	1,39	4,81
	Female	20	87,0	17	85,0	7,84	11,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	1,39	4,81
	Female	20	87,0	18	90,0	8,33	20,01
Cycle 4 Day 1	Male	12	85,7	11	91,7	1,52	5,03
	Female	20	87,0	17	85,0	4,90	9,80
Cycle 5 Day 1	Male	12	85,7	11	91,7	1,52	5,03
	Female	19	82,6	18	94,7	6,48	11,63
Cycle 6 Day 1	Male	12	85,7	11	91,7	4,55	15,08
	Female	19	82,6	18	94,7	7,41	10,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	4,55	10,78
	Female	19	82,6	16	84,2	7,29	12,12
Cycle 8 Day 1	Male	10	71,4	9	90,0	7,41	12,11
	Female	18	78,3	16	88,9	3,13	9,07
Cycle 9 Day 1	Male	8	57,1	8	100,0	8,33	23,57
	Female	17	73,9	17	100,0	3,92	9,37
Cycle 10 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	17	73,9	16	94,1	7,29	10,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	16	69,6	16	100,0	6,25	10,32
Cycle 12 Day 1	Male	8	57,1	8	100,0	6,25	17,68
	Female	16	69,6	13	81,3	8,97	11,00
Cycle 13 Day 1	Male	8	57,1	8	100,0	2,08	5,89
	Female	14	60,9	13	92,9	5,13	14,25
Cycle 14 Day 1	Male	8	57,1	8	100,0	2,08	5,89
	Female	14	60,9	14	100,0	5,95	18,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	2,08	5,89
	Female	14	60,9	13	92,9	6,41	10,84
Cycle 16 Day 1	Male	8	57,1	5	62,5	6,67	14,91
	Female	13	56,5	10	76,9	16,67	19,25
Cycle 17 Day 1	Male	6	42,9	2	33,3	0,00	0,00
	Female	12	52,2	12	100,0	8,33	28,87
Cycle 18 Day 1	Male	3	21,4	2	66,7	0,00	0,00
	Female	12	52,2	6	50,0	2,78	6,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	11	47,8	6	54,5	5,56	13,61
Cycle 20 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	7	30,4	7	100,0	2,38	6,30
Cycle 21 Day 1	Male	1	7,1	1	100,0	0,00	-
	Female	6	26,1	3	50,0	5,56	9,62
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	25,00	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	0,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	0,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	8,33	11,79
	Female	7	30,4	3	42,9	11,11	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	10,49	13,19
	65-74	8	100,0	7	87,5	14,29	31,07
Cycle 2 Day 1	18-64	27	93,1	24	88,9	4,17	8,86
	65-74	6	75,0	5	83,3	10,00	14,91
Cycle 3 Day 1	18-64	26	89,7	24	92,3	3,47	6,91
	65-74	6	75,0	6	100,0	13,89	34,02
Cycle 4 Day 1	18-64	26	89,7	23	88,5	3,62	8,64
	65-74	6	75,0	5	83,3	3,33	7,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	3,62	8,64
	65-74	6	75,0	6	100,0	8,33	13,94
Cycle 6 Day 1	18-64	25	86,2	24	96,0	5,56	11,70
	65-74	6	75,0	5	83,3	10,00	14,91
Cycle 7 Day 1	18-64	25	86,2	23	92,0	5,80	10,79
	65-74	5	62,5	4	80,0	8,33	16,67
Cycle 8 Day 1	18-64	23	79,3	20	87,0	4,17	9,17
	65-74	5	62,5	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	5,00	15,39
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 10 Day 1	18-64	20	69,0	19	95,0	6,14	9,95
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 11 Day 1	18-64	19	65,5	19	100,0	4,39	9,37
	65-74	5	62,5	5	100,0	10,00	14,91
Cycle 12 Day 1	18-64	19	65,5	17	89,5	7,84	13,33
	65-74	5	62,5	4	80,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	2,08	5,69
	65-74	5	62,5	5	100,0	10,00	22,36
Cycle 14 Day 1	18-64	17	58,6	17	100,0	1,96	5,54
	65-74	5	62,5	5	100,0	13,33	29,81
Cycle 15 Day 1	18-64	17	58,6	16	94,1	4,17	7,45
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 16 Day 1	18-64	17	58,6	13	76,5	12,82	18,20
	65-74	4	50,0	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	8,33	28,87
	65-74	3	37,5	2	66,7	0,00	0,00
Cycle 18 Day 1	18-64	13	44,8	8	61,5	2,08	5,89
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	0,00	0,00
	65-74	2	25,0	1	50,0	33,33	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	2,08	5,89
	65-74	1	12,5	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	4,17	8,33
Cycle 22 Day 1	18-64	7	24,1	2	28,6	25,00	35,36
Cycle 23 Day 1	18-64	4	13,8	1	25,0	0,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	0,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	5,56	9,62
	65-74	6	75,0	2	33,3	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	12,75	20,86
	Other	17	100,0	17	100,0	9,80	14,50
Cycle 2 Day 1	White	19	95,0	16	84,2	6,25	11,98
	Other	14	82,4	13	92,9	3,85	7,31
Cycle 3 Day 1	White	18	90,0	16	88,9	8,33	21,08
	Other	14	82,4	14	100,0	2,38	6,05
Cycle 4 Day 1	White	18	90,0	15	83,3	3,33	6,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	3,85	9,99
Cycle 5 Day 1	White	18	90,0	17	94,4	6,86	11,87
	Other	13	76,5	12	92,3	1,39	4,81
Cycle 6 Day 1	White	18	90,0	16	88,9	8,33	14,91
	Other	13	76,5	13	100,0	3,85	7,31
Cycle 7 Day 1	White	17	85,0	15	88,2	6,67	12,28
	Other	13	76,5	12	92,3	5,56	10,86
Cycle 8 Day 1	White	17	85,0	14	82,4	4,76	10,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	4,55	10,78
Cycle 9 Day 1	White	16	80,0	16	100,0	8,33	18,26
	Other	9	52,9	9	100,0	0,00	0,00
Cycle 10 Day 1	White	16	80,0	15	93,8	7,78	12,39
	Other	9	52,9	9	100,0	3,70	7,35
Cycle 11 Day 1	White	16	80,0	16	100,0	5,21	11,74
	Other	8	47,1	8	100,0	6,25	8,63
Cycle 12 Day 1	White	16	80,0	13	81,3	11,54	15,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	2,08	5,89
Cycle 13 Day 1	White	14	70,0	13	92,9	5,13	14,25
	Other	8	47,1	8	100,0	2,08	5,89
Cycle 14 Day 1	White	14	70,0	14	100,0	5,95	18,03
	Other	8	47,1	8	100,0	2,08	5,89
Cycle 15 Day 1	White	14	70,0	13	92,9	5,13	10,51
	Other	8	47,1	8	100,0	4,17	7,72
Cycle 16 Day 1	White	14	70,0	9	64,3	16,67	20,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	8,33	13,94
Cycle 17 Day 1	White	13	65,0	10	76,9	10,00	31,62
	Other	5	29,4	4	80,0	0,00	0,00
Cycle 18 Day 1	White	11	55,0	4	36,4	0,00	0,00
	Other	4	23,5	4	100,0	4,17	8,33
Cycle 19 Day 1	White	9	45,0	5	55,6	6,67	14,91
	Other	4	23,5	3	75,0	0,00	0,00
Cycle 20 Day 1	White	5	25,0	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	4,17	8,33
Cycle 21 Day 1	White	3	15,0	2	66,7	0,00	0,00
	Other	4	23,5	2	50,0	8,33	11,79
Cycle 22 Day 1	White	3	15,0	1	33,3	50,00	-
	Other	4	23,5	1	25,0	0,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	0,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	11,11	19,25
	Other	9	52,9	2	22,2	8,33	11,79
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	5,56	8,21
	Europe (EU)	10	100,0	8	80,0	6,25	8,63
	Asia (AS)	15	100,0	14	93,3	19,05	24,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	5,56	11,79
	Europe (EU)	9	90,0	8	88,9	6,25	12,40
	Asia (AS)	13	86,7	12	92,3	4,17	7,54
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	0,00	0,00
	Europe (EU)	8	80,0	6	75,0	19,44	32,35
	Asia (AS)	13	86,7	13	100,0	3,85	7,31
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	4,55	7,78
	Europe (EU)	8	80,0	4	50,0	4,17	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	2,56	9,25
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	4,55	7,78
	Europe (EU)	8	80,0	7	87,5	11,90	15,85
	Asia (AS)	12	80,0	11	91,7	0,00	0,00
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	4,55	7,78
	Europe (EU)	8	80,0	7	87,5	16,67	19,25
	Asia (AS)	12	80,0	11	91,7	1,52	5,03
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	1,67	5,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	14,29	15,00
	Asia (AS)	11	73,3	10	90,9	5,00	11,25
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	0,00	0,00
	Europe (EU)	8	80,0	6	75,0	8,33	13,94
	Asia (AS)	9	60,0	9	100,0	7,41	12,11
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	1,52	5,03
	Europe (EU)	7	70,0	7	100,0	14,29	26,23
	Asia (AS)	7	46,7	7	100,0	2,38	6,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	5,00	8,05
	Europe (EU)	7	70,0	7	100,0	11,90	15,85
	Asia (AS)	7	46,7	7	100,0	2,38	6,30
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	3,03	6,74
	Europe (EU)	7	70,0	7	100,0	9,52	16,27
	Asia (AS)	6	40,0	6	100,0	5,56	8,61
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	5,00	8,05
	Europe (EU)	7	70,0	5	71,4	20,00	21,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	2,78	6,80
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	0,00	0,00
	Europe (EU)	6	60,0	5	83,3	13,33	21,73
	Asia (AS)	6	40,0	6	100,0	2,78	6,80
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	0,00	0,00
	Europe (EU)	6	60,0	6	100,0	13,89	26,70
	Asia (AS)	6	40,0	6	100,0	2,78	6,80
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	3,33	7,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	10,00	14,91
	Asia (AS)	6	40,0	6	100,0	2,78	6,80
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	7,14	13,11
	Europe (EU)	6	60,0	2	33,3	16,67	23,57
	Asia (AS)	6	40,0	6	100,0	19,44	22,15
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	16,67	40,82
	Europe (EU)	4	40,0	3	75,0	0,00	0,00
	Asia (AS)	5	33,3	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	0,00	0,00
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	5,56	9,62
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	0,00	0,00
	Europe (EU)	3	30,0	1	33,3	33,33	-
	Asia (AS)	4	26,7	3	75,0	0,00	0,00
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	3,33	7,45
	Europe (EU)	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	0,00	0,00
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	5,56	9,62
	Asia (AS)	3	20,0	1	33,3	0,00	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	25,00	35,36
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	0,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	0,00	0,00
	Europe (EU)	2	20,0	1	50,0	33,33	-
	Asia (AS)	7	46,7	1	14,3	16,67	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	4,17	7,54
	1	17	100,0	17	100,0	19,61	21,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	0,00	0,00
Cycle 2 Day 1	0	15	100,0	12	80,0	5,56	10,86
	1	15	88,2	14	93,3	5,95	10,56
	2	3	60,0	3	100,0	0,00	0,00
Cycle 3 Day 1	0	15	100,0	14	93,3	7,14	22,37
	1	14	82,4	13	92,9	2,56	6,26
	2	3	60,0	3	100,0	11,11	9,62
Cycle 4 Day 1	0	15	100,0	14	93,3	3,57	7,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	1,39	4,81
	2	3	60,0	2	66,7	16,67	23,57
Cycle 5 Day 1	0	15	100,0	15	100,0	5,56	10,29
	1	14	82,4	12	85,7	1,39	4,81
	2	2	40,0	2	100,0	16,67	23,57
Cycle 6 Day 1	0	15	100,0	15	100,0	7,78	15,26
	1	14	82,4	12	85,7	2,78	6,49
	2	2	40,0	2	100,0	16,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	5,95	12,42
	1	13	76,5	11	84,6	4,55	10,78
	2	2	40,0	2	100,0	16,67	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	5,13	10,51
	1	11	64,7	10	90,9	5,00	11,25
	2	2	40,0	2	100,0	0,00	0,00
Cycle 9 Day 1	0	14	93,3	14	100,0	7,14	19,30
	1	10	58,8	10	100,0	3,33	7,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	0,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	5,95	12,42
	1	10	58,8	9	90,0	5,56	8,33
	2	1	20,0	1	100,0	16,67	-
Cycle 11 Day 1	0	14	93,3	14	100,0	7,14	12,60
	1	9	52,9	9	100,0	3,70	7,35
	2	1	20,0	1	100,0	0,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	9,72	16,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	4,17	7,72
	2	1	20,0	1	100,0	16,67	-
Cycle 13 Day 1	0	14	93,3	13	92,9	5,13	14,25
	1	8	47,1	8	100,0	2,08	5,89
Cycle 14 Day 1	0	14	93,3	14	100,0	5,95	18,03
	1	8	47,1	8	100,0	2,08	5,89
Cycle 15 Day 1	0	14	93,3	14	100,0	4,76	10,19
	1	8	47,1	7	87,5	4,76	8,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	14,58	16,52
	1	8	47,1	7	87,5	11,90	20,89
Cycle 17 Day 1	0	12	80,0	8	66,7	12,50	35,36
	1	6	35,3	6	100,0	0,00	0,00
Cycle 18 Day 1	0	9	60,0	4	44,4	0,00	0,00
	1	6	35,3	4	66,7	4,17	8,33
Cycle 19 Day 1	0	8	53,3	4	50,0	8,33	16,67
	1	5	29,4	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	3,33	7,45
	1	4	23,5	4	100,0	0,00	0,00
Cycle 21 Day 1	0	3	20,0	3	100,0	5,56	9,62
	1	4	23,5	1	25,0	0,00	-
Cycle 22 Day 1	0	3	20,0	2	66,7	25,00	35,36
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	0,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	11,11	19,25
	1	7	41,2	2	28,6	8,33	11,79
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	6,41	10,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	0,00	0,00
	2 or More	21	100,0	19	90,5	15,79	21,14
Cycle 2 Day 1	None	14	100,0	12	85,7	1,39	4,81
	1	1	50,0	1	100,0	0,00	-
	2 or More	18	85,7	16	88,9	8,33	12,17
Cycle 3 Day 1	None	14	100,0	13	92,9	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	16	94,1	10,42	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	1,39	4,81
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	5,56	10,29
Cycle 5 Day 1	None	14	100,0	14	100,0	1,19	4,45
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	8,33	12,66
Cycle 6 Day 1	None	14	100,0	14	100,0	4,76	7,81
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	8,33	15,68
Cycle 7 Day 1	None	14	100,0	13	92,9	2,56	6,26
	1	1	50,0	1	100,0	0,00	-
	2 or More	15	71,4	13	86,7	10,26	14,50
Cycle 8 Day 1	None	14	100,0	13	92,9	2,56	9,25
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	6,94	11,14
Cycle 9 Day 1	None	13	92,9	13	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	12,12	21,20
Cycle 10 Day 1	None	13	92,9	12	92,3	4,17	7,54
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	9,09	13,67
Cycle 11 Day 1	None	13	92,9	13	100,0	3,85	7,31
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	10	100,0	8,33	14,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	4,17	7,54
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	8	80,0	14,58	18,77
Cycle 13 Day 1	None	12	85,7	11	91,7	1,52	5,03
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	7,41	16,90
Cycle 14 Day 1	None	12	85,7	12	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	11,11	22,05
Cycle 15 Day 1	None	12	85,7	12	100,0	4,17	7,54
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	8	88,9	6,25	12,40
Cycle 16 Day 1	None	11	78,6	8	72,7	10,42	15,27
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	19,44	22,15
Cycle 17 Day 1	None	10	71,4	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	7	33,3	6	85,7	16,67	40,82
Cycle 18 Day 1	None	8	57,1	4	50,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	6	28,6	3	50,0	5,56	9,62
Cycle 19 Day 1	None	7	50,0	3	42,9	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	5	23,8	4	80,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	4,17	8,33
	1	1	50,0	1	100,0	0,00	-
	2 or More	4	19,0	4	100,0	0,00	0,00
Cycle 21 Day 1	None	4	28,6	2	50,0	8,33	11,79
	2 or More	3	14,3	2	66,7	0,00	0,00
Cycle 22 Day 1	None	4	28,6	1	25,0	0,00	-
	2 or More	3	14,3	1	33,3	50,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	0,00	-
	1	2	100,0	1	50,0	0,00	-
	2 or More	9	42,9	3	33,3	16,67	16,67
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	6,41	10,84
	Previously Treated	23	100,0	21	91,3	14,29	20,61
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	1,39	4,81
	Previously Treated	19	82,6	17	89,5	7,84	11,96
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	0,00	0,00
	Previously Treated	18	78,3	17	94,4	9,80	20,46
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	1,39	4,81
	Previously Treated	18	78,3	16	88,9	5,21	10,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	1,19	4,45
	Previously Treated	17	73,9	15	88,2	7,78	12,39
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	4,76	7,81
	Previously Treated	17	73,9	15	88,2	7,78	15,26
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	2,56	6,26
	Previously Treated	16	69,6	14	87,5	9,52	14,19
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	2,56	9,25
	Previously Treated	14	60,9	12	85,7	6,94	11,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	0,00	0,00
	Previously Treated	12	52,2	12	100,0	11,11	20,52
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	4,17	7,54
	Previously Treated	12	52,2	12	100,0	8,33	13,30
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	3,85	7,31
	Previously Treated	11	47,8	11	100,0	7,58	13,67
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	4,17	7,54
	Previously Treated	11	47,8	9	81,8	12,96	18,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	1,52	5,03
	Previously Treated	10	43,5	10	100,0	6,67	16,10
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	0,00	0,00
	Previously Treated	10	43,5	10	100,0	10,00	21,08
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	4,17	7,54
	Previously Treated	10	43,5	9	90,0	5,56	11,79
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	10,42	15,27
	Previously Treated	10	43,5	7	70,0	16,67	21,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	0,00	0,00
	Previously Treated	8	34,8	7	87,5	14,29	37,80
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	0,00	0,00
	Previously Treated	7	30,4	4	57,1	4,17	8,33
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	0,00	0,00
	Previously Treated	6	26,1	5	83,3	6,67	14,91
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	4,17	8,33
	Previously Treated	5	21,7	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	8,33	11,79
	Previously Treated	3	13,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	0,00	-
	Previously Treated	3	13,0	1	33,3	50,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	11	47,8	4	36,4	12,50	15,96
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	8,33	11,24
	Central	25	100,0	22	88,0	12,88	20,53
Cycle 2 Day 1	Local	11	91,7	10	90,9	6,67	14,05
	Central	22	88,0	19	86,4	4,39	7,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	7,58	25,13
	Central	21	84,0	19	90,5	4,39	7,54
Cycle 4 Day 1	Local	11	91,7	10	90,9	1,67	5,27
	Central	21	84,0	18	85,7	4,63	9,58
Cycle 5 Day 1	Local	11	91,7	10	90,9	5,00	11,25
	Central	20	80,0	19	95,0	4,39	9,37
Cycle 6 Day 1	Local	11	91,7	11	100,0	4,55	10,78
	Central	20	80,0	18	90,0	7,41	13,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	6,06	11,24
	Central	19	76,0	16	84,2	6,25	11,98
Cycle 8 Day 1	Local	10	83,3	10	100,0	3,33	10,54
	Central	18	72,0	15	83,3	5,56	10,29
Cycle 9 Day 1	Local	10	83,3	10	100,0	5,00	11,25
	Central	15	60,0	15	100,0	5,56	17,44
Cycle 10 Day 1	Local	10	83,3	9	90,0	7,41	12,11
	Central	15	60,0	15	100,0	5,56	10,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	7,41	12,11
	Central	15	60,0	15	100,0	4,44	9,89
Cycle 12 Day 1	Local	9	75,0	8	88,9	8,33	12,60
	Central	15	60,0	13	86,7	7,69	14,62
Cycle 13 Day 1	Local	8	66,7	8	100,0	8,33	17,82
	Central	14	56,0	13	92,9	1,28	4,62
Cycle 14 Day 1	Local	8	66,7	8	100,0	8,33	23,57
	Central	14	56,0	14	100,0	2,38	6,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	10,42	12,40
	Central	14	56,0	13	92,9	1,28	4,62
Cycle 16 Day 1	Local	8	66,7	6	75,0	13,89	16,39
	Central	13	52,0	9	69,2	12,96	20,03
Cycle 17 Day 1	Local	8	66,7	5	62,5	0,00	0,00
	Central	10	40,0	9	90,0	11,11	33,33
Cycle 18 Day 1	Local	6	50,0	4	66,7	0,00	0,00
	Central	9	36,0	4	44,4	4,17	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	8,33	16,67
	Central	8	32,0	4	50,0	0,00	0,00
Cycle 20 Day 1	Local	5	41,7	5	100,0	3,33	7,45
	Central	4	16,0	4	100,0	0,00	0,00
Cycle 21 Day 1	Local	4	33,3	2	50,0	8,33	11,79
	Central	3	12,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Local	4	33,3	1	25,0	0,00	-
	Central	3	12,0	1	33,3	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	0,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	0,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	16,67	23,57
	Central	8	32,0	3	37,5	5,56	9,62
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	11,98	18,08
	No	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	Yes	32	91,4	28	87,5	5,36	10,20
	No	1	50,0	1	100,0	0,00	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	5,75	16,23
	No	1	50,0	1	100,0	0,00	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	3,70	8,44
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	4,76	10,00
	No	1	50,0	1	100,0	0,00	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	6,55	12,29
	No	1	50,0	1	100,0	0,00	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	6,41	11,62
	No	1	50,0	1	100,0	0,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	4,86	10,40
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	5,56	15,28
	No	1	50,0	1	100,0	0,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	6,52	10,94
	No	1	50,0	1	100,0	0,00	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	5,07	10,58
	No	1	50,0	1	100,0	16,67	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	8,33	13,79
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	3,33	11,60
	No	1	50,0	1	100,0	16,67	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	4,76	15,04
	No	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	4,17	9,17
	No	1	50,0	1	100,0	16,67	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	14,29	18,32
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	7,69	27,74
	No	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	2,38	6,30
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	4,76	12,60
	No	1	50,0	1	100,0	0,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	2,08	5,89
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	4,17	8,33
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	25,00	35,36
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	0,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	0,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	10,00	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	27,78	9,62
	No	33	100,0	31	93,9	9,68	17,62
Cycle 2 Day 1	Yes	2	50,0	1	50,0	0,00	-
	No	31	93,9	28	90,3	5,36	10,20
Cycle 3 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	5,95	16,49
Cycle 4 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	30	90,9	26	86,7	3,85	8,57
Cycle 5 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	27	93,1	4,94	10,14
Cycle 6 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	27	93,1	6,79	12,45
Cycle 7 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	6,67	11,79
Cycle 8 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	26	78,8	23	88,5	3,62	8,64
Cycle 9 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	24	100,0	5,56	15,28
Cycle 10 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	23	95,8	6,52	10,94
Cycle 11 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	5,80	10,79
Cycle 12 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	23	69,7	20	87,0	8,33	13,79
Cycle 13 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	20	95,2	4,17	11,94
Cycle 14 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	21	100,0	4,76	15,04
Cycle 15 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	5,00	9,52
Cycle 16 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	20	60,6	14	70,0	11,90	17,82
Cycle 17 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	17	51,5	13	76,5	7,69	27,74
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	2,08	5,89
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	4,17	11,79
Cycle 20 Day 1	No	9	27,3	9	100,0	1,85	5,56
Cycle 21 Day 1	No	7	21,2	4	57,1	4,17	8,33
Cycle 22 Day 1	No	7	21,2	2	28,6	25,00	35,36
Cycle 23 Day 1	No	4	12,1	1	25,0	0,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	0,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30NV_SG.xls
07SEP2019 20:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	35,29	33,53
Cycle 2 Day 1	All	33	89,2	29	87,9	16,67	20,41
Cycle 3 Day 1	All	32	86,5	30	93,8	15,56	22,71
Cycle 4 Day 1	All	32	86,5	28	87,5	11,31	21,30
Cycle 5 Day 1	All	31	83,8	29	93,5	13,79	21,85
Cycle 6 Day 1	All	31	83,8	29	93,5	13,22	18,57
Cycle 7 Day 1	All	30	81,1	27	90,0	17,28	21,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	17,33	25,22
Cycle 9 Day 1	All	25	67,6	25	100,0	15,33	25,87
Cycle 10 Day 1	All	25	67,6	24	96,0	15,97	22,24
Cycle 11 Day 1	All	24	64,9	24	100,0	11,11	18,17
Cycle 12 Day 1	All	24	64,9	21	87,5	17,46	27,12
Cycle 13 Day 1	All	22	59,5	21	95,5	19,05	29,48
Cycle 14 Day 1	All	22	59,5	22	100,0	18,94	28,77
Cycle 15 Day 1	All	22	59,5	21	95,5	16,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	21,11	27,07
Cycle 17 Day 1	All	18	48,6	14	77,8	19,05	26,84
Cycle 18 Day 1	All	15	40,5	8	53,3	16,67	34,50
Cycle 19 Day 1	All	13	35,1	8	61,5	20,83	29,21
Cycle 20 Day 1	All	9	24,3	9	100,0	18,52	32,75
Cycle 21 Day 1	All	7	18,9	4	57,1	33,33	45,13
Cycle 22 Day 1	All	7	18,9	2	28,6	50,00	70,71
Cycle 23 Day 1	All	4	10,8	1	25,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	33,33	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	40,00	34,56
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	32,05	33,65
	Female	23	100,0	21	91,3	37,30	34,12
Cycle 2 Day 1	Male	13	92,9	12	92,3	22,22	22,84
	Female	20	87,0	17	85,0	12,75	18,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	5,56	10,86
	Female	20	87,0	18	90,0	22,22	26,20
Cycle 4 Day 1	Male	12	85,7	11	91,7	6,06	11,24
	Female	20	87,0	17	85,0	14,71	25,61
Cycle 5 Day 1	Male	12	85,7	11	91,7	6,06	13,48
	Female	19	82,6	18	94,7	18,52	24,85
Cycle 6 Day 1	Male	12	85,7	11	91,7	7,58	17,26
	Female	19	82,6	18	94,7	16,67	18,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	16,67	25,82
	Female	19	82,6	16	84,2	17,71	18,73
Cycle 8 Day 1	Male	10	71,4	9	90,0	24,07	30,17
	Female	18	78,3	16	88,9	13,54	22,13
Cycle 9 Day 1	Male	8	57,1	8	100,0	8,33	17,82
	Female	17	73,9	17	100,0	18,63	28,80
Cycle 10 Day 1	Male	8	57,1	8	100,0	6,25	12,40
	Female	17	73,9	16	94,1	20,83	24,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	8,33	17,82
	Female	16	69,6	16	100,0	12,50	18,76
Cycle 12 Day 1	Male	8	57,1	8	100,0	8,33	17,82
	Female	16	69,6	13	81,3	23,08	30,84
Cycle 13 Day 1	Male	8	57,1	8	100,0	8,33	8,91
	Female	14	60,9	13	92,9	25,64	35,76
Cycle 14 Day 1	Male	8	57,1	8	100,0	4,17	7,72
	Female	14	60,9	14	100,0	27,38	33,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	6,25	8,63
	Female	14	60,9	13	92,9	23,08	33,71
Cycle 16 Day 1	Male	8	57,1	5	62,5	13,33	21,73
	Female	13	56,5	10	76,9	25,00	29,66
Cycle 17 Day 1	Male	6	42,9	2	33,3	8,33	11,79
	Female	12	52,2	12	100,0	20,83	28,54
Cycle 18 Day 1	Male	3	21,4	2	66,7	8,33	11,79
	Female	12	52,2	6	50,0	19,44	40,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	8,33	11,79
	Female	11	47,8	6	54,5	25,00	32,91
Cycle 20 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	7	30,4	7	100,0	23,81	35,82
Cycle 21 Day 1	Male	1	7,1	1	100,0	16,67	-
	Female	6	26,1	3	50,0	38,89	53,58
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	50,00	70,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	0,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	33,33	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	41,67	58,93
	Female	7	30,4	3	42,9	38,89	25,46
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	37,65	34,15
	65-74	8	100,0	7	87,5	26,19	31,71
Cycle 2 Day 1	18-64	27	93,1	24	88,9	18,06	21,38
	65-74	6	75,0	5	83,3	10,00	14,91
Cycle 3 Day 1	18-64	26	89,7	24	92,3	16,67	21,98
	65-74	6	75,0	6	100,0	11,11	27,22
Cycle 4 Day 1	18-64	26	89,7	23	88,5	12,32	23,15
	65-74	6	75,0	5	83,3	6,67	9,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	15,22	23,52
	65-74	6	75,0	6	100,0	8,33	13,94
Cycle 6 Day 1	18-64	25	86,2	24	96,0	13,19	19,65
	65-74	6	75,0	5	83,3	13,33	13,94
Cycle 7 Day 1	18-64	25	86,2	23	92,0	18,84	22,08
	65-74	5	62,5	4	80,0	8,33	16,67
Cycle 8 Day 1	18-64	23	79,3	20	87,0	16,67	26,49
	65-74	5	62,5	5	100,0	20,00	21,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	13,33	20,66
	65-74	5	62,5	5	100,0	23,33	43,46
Cycle 10 Day 1	18-64	20	69,0	19	95,0	14,91	18,34
	65-74	5	62,5	5	100,0	20,00	36,13
Cycle 11 Day 1	18-64	19	65,5	19	100,0	8,77	15,08
	65-74	5	62,5	5	100,0	20,00	27,39
Cycle 12 Day 1	18-64	19	65,5	17	89,5	15,69	26,66
	65-74	5	62,5	4	80,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	15,63	26,15
	65-74	5	62,5	5	100,0	30,00	39,79
Cycle 14 Day 1	18-64	17	58,6	17	100,0	16,67	25,00
	65-74	5	62,5	5	100,0	26,67	41,83
Cycle 15 Day 1	18-64	17	58,6	16	94,1	16,67	25,82
	65-74	5	62,5	5	100,0	16,67	37,27
Cycle 16 Day 1	18-64	17	58,6	13	76,5	21,79	28,37
	65-74	4	50,0	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	18,06	28,83
	65-74	3	37,5	2	66,7	25,00	11,79
Cycle 18 Day 1	18-64	13	44,8	8	61,5	16,67	34,50
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	19,05	31,07
	65-74	2	25,0	1	50,0	33,33	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	18,75	35,00
	65-74	1	12,5	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	33,33	45,13
Cycle 22 Day 1	18-64	7	24,1	2	28,6	50,00	70,71
Cycle 23 Day 1	18-64	4	13,8	1	25,0	0,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	33,33	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	33,33	44,10
	65-74	6	75,0	2	33,3	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	33,33	36,32
	Other	17	100,0	17	100,0	37,25	31,47
Cycle 2 Day 1	White	19	95,0	16	84,2	19,79	22,13
	Other	14	82,4	13	92,9	12,82	18,20
Cycle 3 Day 1	White	18	90,0	16	88,9	19,79	25,25
	Other	14	82,4	14	100,0	10,71	19,18
Cycle 4 Day 1	White	18	90,0	15	83,3	11,11	19,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	11,54	23,94
Cycle 5 Day 1	White	18	90,0	17	94,4	14,71	26,27
	Other	13	76,5	12	92,3	12,50	14,43
Cycle 6 Day 1	White	18	90,0	16	88,9	13,54	17,45
	Other	13	76,5	13	100,0	12,82	20,59
Cycle 7 Day 1	White	17	85,0	15	88,2	15,56	19,38
	Other	13	76,5	12	92,3	19,44	24,45
Cycle 8 Day 1	White	17	85,0	14	82,4	15,48	20,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	19,70	31,46
Cycle 9 Day 1	White	16	80,0	16	100,0	18,75	29,74
	Other	9	52,9	9	100,0	9,26	16,90
Cycle 10 Day 1	White	16	80,0	15	93,8	20,00	25,35
	Other	9	52,9	9	100,0	9,26	14,70
Cycle 11 Day 1	White	16	80,0	16	100,0	14,58	20,97
	Other	8	47,1	8	100,0	4,17	7,72
Cycle 12 Day 1	White	16	80,0	13	81,3	24,36	31,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	6,25	12,40
Cycle 13 Day 1	White	14	70,0	13	92,9	23,08	36,35
	Other	8	47,1	8	100,0	12,50	11,79
Cycle 14 Day 1	White	14	70,0	14	100,0	26,19	33,79
	Other	8	47,1	8	100,0	6,25	8,63
Cycle 15 Day 1	White	14	70,0	13	92,9	23,08	33,01
	Other	8	47,1	8	100,0	6,25	12,40
Cycle 16 Day 1	White	14	70,0	9	64,3	20,37	27,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	22,22	29,19
Cycle 17 Day 1	White	13	65,0	10	76,9	23,33	30,63
	Other	5	29,4	4	80,0	8,33	9,62
Cycle 18 Day 1	White	11	55,0	4	36,4	29,17	47,87
	Other	4	23,5	4	100,0	4,17	8,33
Cycle 19 Day 1	White	9	45,0	5	55,6	26,67	34,56
	Other	4	23,5	3	75,0	11,11	19,25
Cycle 20 Day 1	White	5	25,0	5	100,0	23,33	43,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	12,50	15,96
Cycle 21 Day 1	White	3	15,0	2	66,7	58,33	58,93
	Other	4	23,5	2	50,0	8,33	11,79
Cycle 22 Day 1	White	3	15,0	1	33,3	100,00	-
	Other	4	23,5	1	25,0	0,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	0,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	27,78	34,69
	Other	9	52,9	2	22,2	58,33	35,36
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	26,39	32,92
	Europe (EU)	10	100,0	8	80,0	41,67	40,82
	Asia (AS)	15	100,0	14	93,3	39,29	30,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	18,52	17,57
	Europe (EU)	9	90,0	8	88,9	22,92	25,10
	Asia (AS)	13	86,7	12	92,3	11,11	19,25
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	13,64	23,35
	Europe (EU)	8	80,0	6	75,0	25,00	29,34
	Asia (AS)	13	86,7	13	100,0	12,82	19,43
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	9,09	21,56
	Europe (EU)	8	80,0	4	50,0	12,50	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	12,82	23,72
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	15,15	30,23
	Europe (EU)	8	80,0	7	87,5	9,52	16,27
	Asia (AS)	12	80,0	11	91,7	15,15	15,73
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	12,12	15,08
	Europe (EU)	8	80,0	7	87,5	14,29	20,25
	Asia (AS)	12	80,0	11	91,7	13,64	22,13
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	15,00	18,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	11,90	20,89
	Asia (AS)	11	73,3	10	90,9	23,33	25,09
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	18,33	24,15
	Europe (EU)	8	80,0	6	75,0	8,33	13,94
	Asia (AS)	9	60,0	9	100,0	22,22	32,27
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	10,61	20,10
	Europe (EU)	7	70,0	7	100,0	28,57	39,34
	Asia (AS)	7	46,7	7	100,0	9,52	13,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	10,00	17,92
	Europe (EU)	7	70,0	7	100,0	28,57	29,99
	Asia (AS)	7	46,7	7	100,0	11,90	15,85
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	6,06	11,24
	Europe (EU)	7	70,0	7	100,0	23,81	26,97
	Asia (AS)	6	40,0	6	100,0	5,56	8,61
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	15,00	31,87
	Europe (EU)	7	70,0	5	71,4	30,00	29,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	11,11	13,61
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	16,67	30,43
	Europe (EU)	6	60,0	5	83,3	30,00	41,50
	Asia (AS)	6	40,0	6	100,0	13,89	16,39
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	16,67	30,43
	Europe (EU)	6	60,0	6	100,0	27,78	37,52
	Asia (AS)	6	40,0	6	100,0	13,89	16,39
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	15,00	30,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	20,00	36,13
	Asia (AS)	6	40,0	6	100,0	16,67	18,26
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	14,29	31,07
	Europe (EU)	6	60,0	2	33,3	41,67	11,79
	Asia (AS)	6	40,0	6	100,0	22,22	25,09
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	27,78	37,52
	Europe (EU)	4	40,0	3	75,0	16,67	16,67
	Asia (AS)	5	33,3	5	100,0	10,00	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	23,33	43,46
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	5,56	9,62
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	25,00	39,67
	Europe (EU)	3	30,0	1	33,3	33,33	-
	Asia (AS)	4	26,7	3	75,0	11,11	19,25
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	20,00	44,72
	Europe (EU)	1	10,0	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	16,67	16,67
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	38,89	53,58
	Asia (AS)	3	20,0	1	33,3	16,67	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	50,00	70,71
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	0,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	16,67	16,67
	Europe (EU)	2	20,0	1	50,0	66,67	-
	Asia (AS)	7	46,7	1	14,3	83,33	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	12,50	14,43
	1	17	100,0	17	100,0	46,08	35,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	53,33	36,13
Cycle 2 Day 1	0	15	100,0	12	80,0	19,44	18,58
	1	15	88,2	14	93,3	13,10	18,70
	2	3	60,0	3	100,0	22,22	38,49
Cycle 3 Day 1	0	15	100,0	14	93,3	15,48	23,99
	1	14	82,4	13	92,9	10,26	16,01
	2	3	60,0	3	100,0	38,89	34,69
Cycle 4 Day 1	0	15	100,0	14	93,3	9,52	19,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	8,33	13,30
	2	3	60,0	2	66,7	41,67	58,93
Cycle 5 Day 1	0	15	100,0	15	100,0	14,44	20,77
	1	14	82,4	12	85,7	15,28	25,08
	2	2	40,0	2	100,0	0,00	0,00
Cycle 6 Day 1	0	15	100,0	15	100,0	16,67	17,82
	1	14	82,4	12	85,7	11,11	20,52
	2	2	40,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	19,05	21,54
	1	13	76,5	11	84,6	18,18	22,92
	2	2	40,0	2	100,0	0,00	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	24,36	24,17
	1	11	64,7	10	90,9	11,67	27,27
	2	2	40,0	2	100,0	0,00	0,00
Cycle 9 Day 1	0	14	93,3	14	100,0	21,43	30,96
	1	10	58,8	10	100,0	8,33	16,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	0,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	19,05	25,20
	1	10	58,8	9	90,0	11,11	18,63
	2	1	20,0	1	100,0	16,67	-
Cycle 11 Day 1	0	14	93,3	14	100,0	14,29	21,54
	1	9	52,9	9	100,0	7,41	12,11
	2	1	20,0	1	100,0	0,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	25,00	32,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	8,33	12,60
	2	1	20,0	1	100,0	0,00	-
Cycle 13 Day 1	0	14	93,3	13	92,9	25,64	34,44
	1	8	47,1	8	100,0	8,33	15,43
Cycle 14 Day 1	0	14	93,3	14	100,0	22,62	34,35
	1	8	47,1	8	100,0	12,50	14,77
Cycle 15 Day 1	0	14	93,3	14	100,0	20,24	32,14
	1	8	47,1	7	87,5	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	20,83	29,21
	1	8	47,1	7	87,5	21,43	26,73
Cycle 17 Day 1	0	12	80,0	8	66,7	27,08	32,04
	1	6	35,3	6	100,0	8,33	13,94
Cycle 18 Day 1	0	9	60,0	4	44,4	29,17	47,87
	1	6	35,3	4	66,7	4,17	8,33
Cycle 19 Day 1	0	8	53,3	4	50,0	33,33	36,00
	1	5	29,4	4	80,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	23,33	43,46
	1	4	23,5	4	100,0	12,50	15,96
Cycle 21 Day 1	0	3	20,0	3	100,0	38,89	53,58
	1	4	23,5	1	25,0	16,67	-
Cycle 22 Day 1	0	3	20,0	2	66,7	50,00	70,71
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	0,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	33,33	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	33,33	33,33
	1	7	41,2	2	28,6	50,00	47,14
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	17,95	22,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	41,67	58,93
	2 or More	21	100,0	19	90,5	46,49	34,51
Cycle 2 Day 1	None	14	100,0	12	85,7	13,89	15,62
	1	1	50,0	1	100,0	16,67	-
	2 or More	18	85,7	16	88,9	18,75	24,25
Cycle 3 Day 1	None	14	100,0	13	92,9	3,85	7,31
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	16	94,1	26,04	26,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	21,11	25,56
Cycle 5 Day 1	None	14	100,0	14	100,0	5,95	12,42
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	22,62	26,64
Cycle 6 Day 1	None	14	100,0	14	100,0	7,14	12,60
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	20,24	21,86
Cycle 7 Day 1	None	14	100,0	13	92,9	7,69	12,94
	1	1	50,0	1	100,0	0,00	-
	2 or More	15	71,4	13	86,7	28,21	23,94
Cycle 8 Day 1	None	14	100,0	13	92,9	15,38	25,88
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	19,44	25,46
Cycle 9 Day 1	None	13	92,9	13	100,0	6,41	16,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	27,27	31,86
Cycle 10 Day 1	None	13	92,9	12	92,3	8,33	13,30
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	25,76	27,25
Cycle 11 Day 1	None	13	92,9	13	100,0	2,56	6,26
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	10	100,0	23,33	22,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	6,94	13,22
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	8	80,0	35,42	35,00
Cycle 13 Day 1	None	12	85,7	11	91,7	9,09	11,46
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	33,33	39,97
Cycle 14 Day 1	None	12	85,7	12	100,0	8,33	11,24
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	35,19	38,59
Cycle 15 Day 1	None	12	85,7	12	100,0	6,94	11,14
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	8	88,9	33,33	38,83
Cycle 16 Day 1	None	11	78,6	8	72,7	14,58	18,77
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	33,33	34,96
Cycle 17 Day 1	None	10	71,4	7	70,0	14,29	15,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	7	33,3	6	85,7	27,78	37,52
Cycle 18 Day 1	None	8	57,1	4	50,0	4,17	8,33
	1	1	50,0	1	100,0	0,00	-
	2 or More	6	28,6	3	50,0	38,89	53,58
Cycle 19 Day 1	None	7	50,0	3	42,9	5,56	9,62
	1	1	50,0	1	100,0	0,00	-
	2 or More	5	23,8	4	80,0	37,50	34,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	4	19,0	4	100,0	41,67	39,67
Cycle 21 Day 1	None	4	28,6	2	50,0	8,33	11,79
	2 or More	3	14,3	2	66,7	58,33	58,93
Cycle 22 Day 1	None	4	28,6	1	25,0	0,00	-
	2 or More	3	14,3	1	33,3	100,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	33,33	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	33,33	-
	1	2	100,0	1	50,0	0,00	-
	2 or More	9	42,9	3	33,3	55,56	34,69
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	17,95	22,01
	Previously Treated	23	100,0	21	91,3	46,03	35,32
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	13,89	15,62
	Previously Treated	19	82,6	17	89,5	18,63	23,48
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	3,85	7,31
	Previously Treated	18	78,3	17	94,4	24,51	26,43
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	0,00	0,00
	Previously Treated	18	78,3	16	88,9	19,79	25,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	5,95	12,42
	Previously Treated	17	73,9	15	88,2	21,11	26,33
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	7,14	12,60
	Previously Treated	17	73,9	15	88,2	18,89	21,70
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	7,69	12,94
	Previously Treated	16	69,6	14	87,5	26,19	24,21
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	15,38	25,88
	Previously Treated	14	60,9	12	85,7	19,44	25,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	6,41	16,01
	Previously Treated	12	52,2	12	100,0	25,00	31,38
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	8,33	13,30
	Previously Treated	12	52,2	12	100,0	23,61	27,02
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	2,56	6,26
	Previously Treated	11	47,8	11	100,0	21,21	22,47
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	6,94	13,22
	Previously Treated	11	47,8	9	81,8	31,48	34,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	9,09	11,46
	Previously Treated	10	43,5	10	100,0	30,00	39,13
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	8,33	11,24
	Previously Treated	10	43,5	10	100,0	31,67	38,05
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	6,94	11,14
	Previously Treated	10	43,5	9	90,0	29,63	37,99
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	14,58	18,77
	Previously Treated	10	43,5	7	70,0	28,57	34,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	14,29	15,00
	Previously Treated	8	34,8	7	87,5	23,81	35,82
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	4,17	8,33
	Previously Treated	7	30,4	4	57,1	29,17	47,87
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	5,56	9,62
	Previously Treated	6	26,1	5	83,3	30,00	34,16
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	0,00	0,00
	Previously Treated	5	21,7	5	100,0	33,33	39,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	8,33	11,79
	Previously Treated	3	13,0	2	66,7	58,33	58,93
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	0,00	-
	Previously Treated	3	13,0	1	33,3	100,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	33,33	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	11	47,8	4	36,4	41,67	39,67
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	33,33	36,24
	Central	25	100,0	22	88,0	36,36	32,79
Cycle 2 Day 1	Local	11	91,7	10	90,9	16,67	19,25
	Central	22	88,0	19	86,4	16,67	21,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	13,64	23,35
	Central	21	84,0	19	90,5	16,67	22,91
Cycle 4 Day 1	Local	11	91,7	10	90,9	3,33	10,54
	Central	21	84,0	18	85,7	15,74	24,57
Cycle 5 Day 1	Local	11	91,7	10	90,9	15,00	27,72
	Central	20	80,0	19	95,0	13,16	18,90
Cycle 6 Day 1	Local	11	91,7	11	100,0	12,12	15,08
	Central	20	80,0	18	90,0	13,89	20,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	19,70	20,84
	Central	19	76,0	16	84,2	15,63	22,33
Cycle 8 Day 1	Local	10	83,3	10	100,0	10,00	14,05
	Central	18	72,0	15	83,3	22,22	29,99
Cycle 9 Day 1	Local	10	83,3	10	100,0	16,67	33,33
	Central	15	60,0	15	100,0	14,44	20,77
Cycle 10 Day 1	Local	10	83,3	9	90,0	18,52	28,19
	Central	15	60,0	15	100,0	14,44	18,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	9,26	22,22
	Central	15	60,0	15	100,0	12,22	16,02
Cycle 12 Day 1	Local	9	75,0	8	88,9	10,42	23,46
	Central	15	60,0	13	86,7	21,79	29,17
Cycle 13 Day 1	Local	8	66,7	8	100,0	18,75	33,85
	Central	14	56,0	13	92,9	19,23	27,93
Cycle 14 Day 1	Local	8	66,7	8	100,0	18,75	33,85
	Central	14	56,0	14	100,0	19,05	26,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	16,67	28,17
	Central	14	56,0	13	92,9	16,67	28,87
Cycle 16 Day 1	Local	8	66,7	6	75,0	11,11	13,61
	Central	13	52,0	9	69,2	27,78	32,27
Cycle 17 Day 1	Local	8	66,7	5	62,5	13,33	13,94
	Central	10	40,0	9	90,0	22,22	32,27
Cycle 18 Day 1	Local	6	50,0	4	66,7	4,17	8,33
	Central	9	36,0	4	44,4	29,17	47,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	12,50	15,96
	Central	8	32,0	4	50,0	29,17	39,38
Cycle 20 Day 1	Local	5	41,7	5	100,0	3,33	7,45
	Central	4	16,0	4	100,0	37,50	43,83
Cycle 21 Day 1	Local	4	33,3	2	50,0	8,33	11,79
	Central	3	12,0	2	66,7	58,33	58,93
Cycle 22 Day 1	Local	4	33,3	1	25,0	0,00	-
	Central	3	12,0	1	33,3	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	0,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	33,33	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	41,67	35,36
	Central	8	32,0	3	37,5	38,89	41,94
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	34,90	32,89
	No	2	100,0	2	100,0	41,67	58,93
Cycle 2 Day 1	Yes	32	91,4	28	87,5	17,26	20,53
	No	1	50,0	1	100,0	0,00	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	16,09	22,92
	No	1	50,0	1	100,0	0,00	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	11,73	21,59
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	13,10	21,92
	No	1	50,0	1	100,0	33,33	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	13,69	18,73
	No	1	50,0	1	100,0	0,00	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	17,95	21,56
	No	1	50,0	1	100,0	0,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	18,06	25,50
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	15,97	26,23
	No	1	50,0	1	100,0	0,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	16,67	22,47
	No	1	50,0	1	100,0	0,00	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	11,59	18,42
	No	1	50,0	1	100,0	0,00	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	18,33	27,52
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	20,00	29,91
	No	1	50,0	1	100,0	0,00	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	19,84	29,16
	No	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	17,50	28,34
	No	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	21,43	28,06
	No	1	50,0	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	20,51	27,35
	No	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	19,05	36,55
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	23,81	30,21
	No	1	50,0	1	100,0	0,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	20,83	34,21
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	33,33	45,13
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	50,00	70,71
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	0,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	33,33	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	40,00	34,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	44,44	34,69
	No	33	100,0	31	93,9	34,41	33,87
Cycle 2 Day 1	Yes	2	50,0	1	50,0	16,67	-
	No	31	93,9	28	90,3	16,67	20,79
Cycle 3 Day 1	Yes	2	50,0	2	100,0	8,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	16,07	23,34
Cycle 4 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	30	90,9	26	86,7	12,18	21,89
Cycle 5 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	29	87,9	27	93,1	13,58	22,19
Cycle 6 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	29	87,9	27	93,1	12,96	18,68
Cycle 7 Day 1	Yes	2	50,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	17,33	21,77
Cycle 8 Day 1	Yes	2	50,0	2	100,0	58,33	35,36
	No	26	78,8	23	88,5	13,77	21,70
Cycle 9 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	24	100,0	14,58	26,15
Cycle 10 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	23	95,8	15,22	22,42
Cycle 11 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	11,59	18,42
Cycle 12 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	23	69,7	20	87,0	16,67	27,57
Cycle 13 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	20	95,2	18,33	30,06
Cycle 14 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	21	100,0	18,25	29,30
Cycle 15 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	15,83	28,34
Cycle 16 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	20	60,6	14	70,0	20,24	27,87
Cycle 17 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	17	51,5	13	76,5	17,95	27,61
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	16,67	34,50
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	20,83	29,21
Cycle 20 Day 1	No	9	27,3	9	100,0	18,52	32,75
Cycle 21 Day 1	No	7	21,2	4	57,1	33,33	45,13
Cycle 22 Day 1	No	7	21,2	2	28,6	50,00	70,71
Cycle 23 Day 1	No	4	12,1	1	25,0	0,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	33,33	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	29,17	28,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PA_SG.xls
07SEP2019 20:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	68,87	23,89
Cycle 2 Day 1	All	33	89,2	29	87,9	77,24	20,20
Cycle 3 Day 1	All	32	86,5	30	93,8	77,33	22,67
Cycle 4 Day 1	All	32	86,5	28	87,5	81,43	21,34
Cycle 5 Day 1	All	31	83,8	29	93,5	78,39	21,13
Cycle 6 Day 1	All	31	83,8	29	93,5	80,69	20,50
Cycle 7 Day 1	All	30	81,1	27	90,0	77,28	17,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	76,00	22,44
Cycle 9 Day 1	All	25	67,6	25	100,0	83,73	18,06
Cycle 10 Day 1	All	25	67,6	24	96,0	81,67	15,76
Cycle 11 Day 1	All	24	64,9	24	100,0	81,94	14,77
Cycle 12 Day 1	All	24	64,9	21	87,5	79,68	19,49
Cycle 13 Day 1	All	22	59,5	21	95,5	80,00	21,71
Cycle 14 Day 1	All	22	59,5	22	100,0	77,88	24,81
Cycle 15 Day 1	All	22	59,5	21	95,5	79,68	21,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	73,33	25,94
Cycle 17 Day 1	All	18	48,6	14	77,8	83,33	18,07
Cycle 18 Day 1	All	15	40,5	8	53,3	85,00	24,36
Cycle 19 Day 1	All	13	35,1	8	61,5	75,83	25,93
Cycle 20 Day 1	All	9	24,3	9	100,0	80,00	24,72
Cycle 21 Day 1	All	7	18,9	4	57,1	73,33	36,11
Cycle 22 Day 1	All	7	18,9	2	28,6	53,33	47,14
Cycle 23 Day 1	All	4	10,8	1	25,0	86,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	86,67	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	53,33	31,27
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	67,69	25,07
	Female	23	100,0	21	91,3	69,60	23,73
Cycle 2 Day 1	Male	13	92,9	12	92,3	82,22	14,31
	Female	20	87,0	17	85,0	73,73	23,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	84,44	14,59
	Female	20	87,0	18	90,0	72,59	26,06
Cycle 4 Day 1	Male	12	85,7	11	91,7	89,70	12,78
	Female	20	87,0	17	85,0	76,08	24,27
Cycle 5 Day 1	Male	12	85,7	11	91,7	81,21	19,05
	Female	19	82,6	18	94,7	76,67	22,67
Cycle 6 Day 1	Male	12	85,7	11	91,7	86,67	14,91
	Female	19	82,6	18	94,7	77,04	22,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	82,42	14,69
	Female	19	82,6	16	84,2	73,75	18,77
Cycle 8 Day 1	Male	10	71,4	9	90,0	75,56	25,17
	Female	18	78,3	16	88,9	76,25	21,63
Cycle 9 Day 1	Male	8	57,1	8	100,0	91,67	14,58
	Female	17	73,9	17	100,0	80,00	18,71
Cycle 10 Day 1	Male	8	57,1	8	100,0	87,50	14,88
	Female	17	73,9	16	94,1	78,75	15,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	88,33	13,21
	Female	16	69,6	16	100,0	78,75	14,85
Cycle 12 Day 1	Male	8	57,1	8	100,0	89,17	12,31
	Female	16	69,6	13	81,3	73,85	21,16
Cycle 13 Day 1	Male	8	57,1	8	100,0	92,50	9,04
	Female	14	60,9	13	92,9	72,31	23,86
Cycle 14 Day 1	Male	8	57,1	8	100,0	83,33	22,54
	Female	14	60,9	14	100,0	74,76	26,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	85,00	18,77
	Female	14	60,9	13	92,9	76,41	23,67
Cycle 16 Day 1	Male	8	57,1	5	62,5	81,33	24,68
	Female	13	56,5	10	76,9	69,33	26,89
Cycle 17 Day 1	Male	6	42,9	2	33,3	96,67	4,71
	Female	12	52,2	12	100,0	81,11	18,60
Cycle 18 Day 1	Male	3	21,4	2	66,7	96,67	4,71
	Female	12	52,2	6	50,0	81,11	27,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	90,00	14,14
	Female	11	47,8	6	54,5	71,11	28,18
Cycle 20 Day 1	Male	2	14,3	2	100,0	93,33	0,00
	Female	7	30,4	7	100,0	76,19	27,18
Cycle 21 Day 1	Male	1	7,1	1	100,0	100,00	-
	Female	6	26,1	3	50,0	64,44	38,49
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	53,33	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	86,67	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	86,67	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	33,33	47,14
	Female	7	30,4	3	42,9	66,67	13,33
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	68,95	23,40
	65-74	8	100,0	7	87,5	68,57	27,68
Cycle 2 Day 1	18-64	27	93,1	24	88,9	78,33	21,65
	65-74	6	75,0	5	83,3	72,00	10,95
Cycle 3 Day 1	18-64	26	89,7	24	92,3	77,78	23,40
	65-74	6	75,0	6	100,0	75,56	21,36
Cycle 4 Day 1	18-64	26	89,7	23	88,5	81,16	23,24
	65-74	6	75,0	5	83,3	82,67	10,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	80,58	20,78
	65-74	6	75,0	6	100,0	70,00	22,21
Cycle 6 Day 1	18-64	25	86,2	24	96,0	80,28	21,67
	65-74	6	75,0	5	83,3	82,67	15,35
Cycle 7 Day 1	18-64	25	86,2	23	92,0	76,52	18,41
	65-74	5	62,5	4	80,0	81,67	11,39
Cycle 8 Day 1	18-64	23	79,3	20	87,0	74,33	24,69
	65-74	5	62,5	5	100,0	82,67	7,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	86,00	14,81
	65-74	5	62,5	5	100,0	74,67	28,05
Cycle 10 Day 1	18-64	20	69,0	19	95,0	83,86	13,39
	65-74	5	62,5	5	100,0	73,33	22,61
Cycle 11 Day 1	18-64	19	65,5	19	100,0	83,16	14,12
	65-74	5	62,5	5	100,0	77,33	18,01
Cycle 12 Day 1	18-64	19	65,5	17	89,5	80,78	20,40
	65-74	5	62,5	4	80,0	75,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	83,33	18,70
	65-74	5	62,5	5	100,0	69,33	29,29
Cycle 14 Day 1	18-64	17	58,6	17	100,0	80,78	22,72
	65-74	5	62,5	5	100,0	68,00	31,76
Cycle 15 Day 1	18-64	17	58,6	16	94,1	81,25	21,39
	65-74	5	62,5	5	100,0	74,67	25,12
Cycle 16 Day 1	18-64	17	58,6	13	76,5	73,85	27,68
	65-74	4	50,0	2	50,0	70,00	14,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	83,33	19,59
	65-74	3	37,5	2	66,7	83,33	4,71
Cycle 18 Day 1	18-64	13	44,8	8	61,5	85,00	24,36
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	78,10	27,14
	65-74	2	25,0	1	50,0	60,00	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	81,67	25,88
	65-74	1	12,5	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	73,33	36,11
Cycle 22 Day 1	18-64	7	24,1	2	28,6	53,33	47,14
Cycle 23 Day 1	18-64	4	13,8	1	25,0	86,67	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	86,67	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	44,44	38,49
	65-74	6	75,0	2	33,3	66,67	18,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	71,47	25,81
	Other	17	100,0	17	100,0	66,27	22,29
Cycle 2 Day 1	White	19	95,0	16	84,2	74,58	24,61
	Other	14	82,4	13	92,9	80,51	13,18
Cycle 3 Day 1	White	18	90,0	16	88,9	70,42	27,75
	Other	14	82,4	14	100,0	85,24	11,45
Cycle 4 Day 1	White	18	90,0	15	83,3	80,00	24,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	83,08	18,18
Cycle 5 Day 1	White	18	90,0	17	94,4	76,86	26,89
	Other	13	76,5	12	92,3	80,56	8,74
Cycle 6 Day 1	White	18	90,0	16	88,9	78,75	26,24
	Other	13	76,5	13	100,0	83,08	10,40
Cycle 7 Day 1	White	17	85,0	15	88,2	78,67	21,26
	Other	13	76,5	12	92,3	75,56	11,84
Cycle 8 Day 1	White	17	85,0	14	82,4	77,62	25,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	73,94	19,65
Cycle 9 Day 1	White	16	80,0	16	100,0	84,58	20,33
	Other	9	52,9	9	100,0	82,22	14,14
Cycle 10 Day 1	White	16	80,0	15	93,8	80,00	18,86
	Other	9	52,9	9	100,0	84,44	8,82
Cycle 11 Day 1	White	16	80,0	16	100,0	83,33	16,69
	Other	8	47,1	8	100,0	79,17	10,35
Cycle 12 Day 1	White	16	80,0	13	81,3	78,97	24,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	80,83	9,72
Cycle 13 Day 1	White	14	70,0	13	92,9	79,49	27,28
	Other	8	47,1	8	100,0	80,83	8,31
Cycle 14 Day 1	White	14	70,0	14	100,0	78,57	28,31
	Other	8	47,1	8	100,0	76,67	18,86
Cycle 15 Day 1	White	14	70,0	13	92,9	80,00	26,25
	Other	8	47,1	8	100,0	79,17	13,54
Cycle 16 Day 1	White	14	70,0	9	64,3	79,26	24,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	64,44	27,86
Cycle 17 Day 1	White	13	65,0	10	76,9	83,33	21,60
	Other	5	29,4	4	80,0	83,33	3,85
Cycle 18 Day 1	White	11	55,0	4	36,4	80,00	35,69
	Other	4	23,5	4	100,0	90,00	6,67
Cycle 19 Day 1	White	9	45,0	5	55,6	72,00	33,47
	Other	4	23,5	3	75,0	82,22	3,85
Cycle 20 Day 1	White	5	25,0	5	100,0	74,67	33,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	86,67	7,70
Cycle 21 Day 1	White	3	15,0	2	66,7	60,00	56,57
	Other	4	23,5	2	50,0	86,67	0,00
Cycle 22 Day 1	White	3	15,0	1	33,3	20,00	-
	Other	4	23,5	1	25,0	86,67	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	86,67	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	86,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	62,22	7,70
	Other	9	52,9	2	22,2	40,00	56,57
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	79,03	26,92
	Europe (EU)	10	100,0	8	80,0	57,50	24,93
	Asia (AS)	15	100,0	14	93,3	66,67	17,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	85,93	15,07
	Europe (EU)	9	90,0	8	88,9	64,17	28,72
	Asia (AS)	13	86,7	12	92,3	79,44	12,54
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	83,03	18,22
	Europe (EU)	8	80,0	6	75,0	51,11	31,46
	Asia (AS)	13	86,7	13	100,0	84,62	11,02
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	87,27	15,90
	Europe (EU)	8	80,0	4	50,0	65,00	37,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	81,54	18,69
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	89,70	9,60
	Europe (EU)	8	80,0	7	87,5	66,67	32,66
	Asia (AS)	12	80,0	11	91,7	74,55	16,28
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	89,09	12,74
	Europe (EU)	8	80,0	7	87,5	65,71	33,65
	Asia (AS)	12	80,0	11	91,7	81,82	9,93
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	84,00	15,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	66,67	25,24
	Asia (AS)	11	73,3	10	90,9	78,00	8,92
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	86,00	18,18
	Europe (EU)	8	80,0	6	75,0	63,33	26,25
	Asia (AS)	9	60,0	9	100,0	73,33	21,34
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	87,27	18,25
	Europe (EU)	7	70,0	7	100,0	74,29	23,86
	Asia (AS)	7	46,7	7	100,0	87,62	6,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	87,33	14,56
	Europe (EU)	7	70,0	7	100,0	68,57	17,52
	Asia (AS)	7	46,7	7	100,0	86,67	6,67
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	86,06	17,50
	Europe (EU)	7	70,0	7	100,0	77,14	15,80
	Asia (AS)	6	40,0	6	100,0	80,00	4,22
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	85,33	24,50
	Europe (EU)	7	70,0	5	71,4	65,33	9,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	82,22	9,11
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	85,33	23,05
	Europe (EU)	6	60,0	5	83,3	70,67	30,77
	Asia (AS)	6	40,0	6	100,0	78,89	5,02
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	84,67	24,56
	Europe (EU)	6	60,0	6	100,0	61,11	31,67
	Asia (AS)	6	40,0	6	100,0	83,33	5,58
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	85,33	24,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	66,67	26,67
	Asia (AS)	6	40,0	6	100,0	81,11	5,02
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	84,76	23,64
	Europe (EU)	6	60,0	2	33,3	50,00	14,14
	Asia (AS)	6	40,0	6	100,0	67,78	27,13
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	81,11	27,78
	Europe (EU)	4	40,0	3	75,0	88,89	10,18
	Asia (AS)	5	33,3	5	100,0	82,67	3,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	81,33	31,06
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	91,11	7,70
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	75,00	37,86
	Europe (EU)	3	30,0	1	33,3	60,00	-
	Asia (AS)	4	26,7	3	75,0	82,22	3,85
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	80,00	33,67
	Europe (EU)	1	10,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	84,44	7,70
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	68,89	42,86
	Asia (AS)	3	20,0	1	33,3	86,67	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	53,33	47,14
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	86,67	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	86,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	71,11	7,70
	Europe (EU)	2	20,0	1	50,0	53,33	-
	Asia (AS)	7	46,7	1	14,3	0,00	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	87,36	8,97
	1	17	100,0	17	100,0	63,53	23,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	42,67	18,62
Cycle 2 Day 1	0	15	100,0	12	80,0	83,89	13,77
	1	15	88,2	14	93,3	77,62	14,47
	2	3	60,0	3	100,0	48,89	42,86
Cycle 3 Day 1	0	15	100,0	14	93,3	79,52	20,50
	1	14	82,4	13	92,9	83,59	13,50
	2	3	60,0	3	100,0	40,00	35,28
Cycle 4 Day 1	0	15	100,0	14	93,3	87,62	15,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	84,44	9,57
	2	3	60,0	2	66,7	20,00	9,43
Cycle 5 Day 1	0	15	100,0	15	100,0	84,44	13,01
	1	14	82,4	12	85,7	76,67	17,41
	2	2	40,0	2	100,0	43,33	61,28
Cycle 6 Day 1	0	15	100,0	15	100,0	85,78	15,09
	1	14	82,4	12	85,7	80,56	12,21
	2	2	40,0	2	100,0	43,33	61,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	82,86	14,73
	1	13	76,5	11	84,6	75,15	11,58
	2	2	40,0	2	100,0	50,00	42,43
Cycle 8 Day 1	0	15	100,0	13	86,7	79,49	19,71
	1	11	64,7	10	90,9	76,67	18,92
	2	2	40,0	2	100,0	50,00	51,85
Cycle 9 Day 1	0	14	93,3	14	100,0	82,86	21,99
	1	10	58,8	10	100,0	84,67	12,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	86,67	-
Cycle 10 Day 1	0	14	93,3	14	100,0	80,95	19,19
	1	10	58,8	9	90,0	82,96	10,60
	2	1	20,0	1	100,0	80,00	-
Cycle 11 Day 1	0	14	93,3	14	100,0	82,38	16,66
	1	9	52,9	9	100,0	80,74	13,10
	2	1	20,0	1	100,0	86,67	-
Cycle 12 Day 1	0	14	93,3	12	85,7	79,44	23,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	81,67	14,14
	2	1	20,0	1	100,0	66,67	-
Cycle 13 Day 1	0	14	93,3	13	92,9	78,46	26,69
	1	8	47,1	8	100,0	82,50	10,65
Cycle 14 Day 1	0	14	93,3	14	100,0	77,62	27,75
	1	8	47,1	8	100,0	78,33	20,39
Cycle 15 Day 1	0	14	93,3	14	100,0	79,05	25,20
	1	8	47,1	7	87,5	80,95	14,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	75,00	23,84
	1	8	47,1	7	87,5	71,43	29,99
Cycle 17 Day 1	0	12	80,0	8	66,7	82,50	23,62
	1	6	35,3	6	100,0	84,44	8,07
Cycle 18 Day 1	0	9	60,0	4	44,4	76,67	33,77
	1	6	35,3	4	66,7	93,33	7,70
Cycle 19 Day 1	0	8	53,3	4	50,0	65,00	34,16
	1	5	29,4	4	80,0	86,67	9,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	73,33	31,97
	1	4	23,5	4	100,0	88,33	10,00
Cycle 21 Day 1	0	3	20,0	3	100,0	68,89	42,86
	1	4	23,5	1	25,0	86,67	-
Cycle 22 Day 1	0	3	20,0	2	66,7	53,33	47,14
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	86,67	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	86,67	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	66,67	13,33
	1	7	41,2	2	28,6	33,33	47,14
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	77,44	23,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	63,33	51,85
	2 or More	21	100,0	19	90,5	63,60	20,94
Cycle 2 Day 1	None	14	100,0	12	85,7	84,44	12,50
	1	1	50,0	1	100,0	100,00	-
	2 or More	18	85,7	16	88,9	70,42	22,83
Cycle 3 Day 1	None	14	100,0	13	92,9	86,67	10,18
	1	1	50,0	1	100,0	100,00	-
	2 or More	17	81,0	16	94,1	68,33	26,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	93,33	6,36
	1	1	50,0	1	100,0	100,00	-
	2 or More	17	81,0	15	88,2	70,67	24,01
Cycle 5 Day 1	None	14	100,0	14	100,0	86,67	11,69
	1	1	50,0	1	100,0	100,00	-
	2 or More	16	76,2	14	87,5	68,57	24,73
Cycle 6 Day 1	None	14	100,0	14	100,0	88,10	11,75
	1	1	50,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	71,90	24,42
Cycle 7 Day 1	None	14	100,0	13	92,9	82,56	15,53
	1	1	50,0	1	100,0	93,33	-
	2 or More	15	71,4	13	86,7	70,77	17,96
Cycle 8 Day 1	None	14	100,0	13	92,9	83,08	19,17
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	68,33	23,97
Cycle 9 Day 1	None	13	92,9	13	100,0	88,21	14,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	100,00	-
	2 or More	11	52,4	11	100,0	76,97	20,95
Cycle 10 Day 1	None	13	92,9	12	92,3	86,67	9,85
	1	1	50,0	1	100,0	100,00	-
	2 or More	11	52,4	11	100,0	74,55	18,58
Cycle 11 Day 1	None	13	92,9	13	100,0	87,18	13,46
	1	1	50,0	1	100,0	100,00	-
	2 or More	10	47,6	10	100,0	73,33	12,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	85,00	12,75
	1	1	50,0	1	100,0	100,00	-
	2 or More	10	47,6	8	80,0	69,17	24,41
Cycle 13 Day 1	None	12	85,7	11	91,7	86,67	11,93
	1	1	50,0	1	100,0	100,00	-
	2 or More	9	42,9	9	100,0	69,63	27,71
Cycle 14 Day 1	None	12	85,7	12	100,0	85,00	19,10
	1	1	50,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	65,93	28,57
Cycle 15 Day 1	None	12	85,7	12	100,0	87,22	14,90
	1	1	50,0	1	100,0	93,33	-
	2 or More	9	42,9	8	88,9	66,67	26,43
Cycle 16 Day 1	None	11	78,6	8	72,7	78,33	21,60
	1	1	50,0	1	100,0	100,00	-
	2 or More	9	42,9	6	66,7	62,22	30,01
Cycle 17 Day 1	None	10	71,4	7	70,0	89,52	8,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	100,00	-
	2 or More	7	33,3	6	85,7	73,33	23,09
Cycle 18 Day 1	None	8	57,1	4	50,0	95,00	6,38
	1	1	50,0	1	100,0	100,00	-
	2 or More	6	28,6	3	50,0	66,67	34,64
Cycle 19 Day 1	None	7	50,0	3	42,9	86,67	11,55
	1	1	50,0	1	100,0	100,00	-
	2 or More	5	23,8	4	80,0	61,67	30,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	91,67	8,39
	1	1	50,0	1	100,0	93,33	-
	2 or More	4	19,0	4	100,0	65,00	31,91
Cycle 21 Day 1	None	4	28,6	2	50,0	93,33	9,43
	2 or More	3	14,3	2	66,7	53,33	47,14
Cycle 22 Day 1	None	4	28,6	1	25,0	86,67	-
	2 or More	3	14,3	1	33,3	20,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	86,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	86,67	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	80,00	-
	1	2	100,0	1	50,0	66,67	-
	2 or More	9	42,9	3	33,3	40,00	35,28
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	77,44	23,65
	Previously Treated	23	100,0	21	91,3	63,57	23,00
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	84,44	12,50
	Previously Treated	19	82,6	17	89,5	72,16	23,24
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	86,67	10,18
	Previously Treated	18	78,3	17	94,4	70,20	26,99
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	93,33	6,36
	Previously Treated	18	78,3	16	88,9	72,50	24,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	86,67	11,69
	Previously Treated	17	73,9	15	88,2	70,67	25,17
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	88,10	11,75
	Previously Treated	17	73,9	15	88,2	73,78	24,62
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	82,56	15,53
	Previously Treated	16	69,6	14	87,5	72,38	18,28
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	83,08	19,17
	Previously Treated	14	60,9	12	85,7	68,33	23,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	88,21	14,18
	Previously Treated	12	52,2	12	100,0	78,89	21,05
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	86,67	9,85
	Previously Treated	12	52,2	12	100,0	76,67	19,17
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	87,18	13,46
	Previously Treated	11	47,8	11	100,0	75,76	14,38
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	85,00	12,75
	Previously Treated	11	47,8	9	81,8	72,59	25,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	86,67	11,93
	Previously Treated	10	43,5	10	100,0	72,67	27,84
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	85,00	19,10
	Previously Treated	10	43,5	10	100,0	69,33	29,01
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	87,22	14,90
	Previously Treated	10	43,5	9	90,0	69,63	26,27
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	78,33	21,60
	Previously Treated	10	43,5	7	70,0	67,62	30,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	89,52	8,48
	Previously Treated	8	34,8	7	87,5	77,14	23,37
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	95,00	6,38
	Previously Treated	7	30,4	4	57,1	75,00	32,83
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	86,67	11,55
	Previously Treated	6	26,1	5	83,3	69,33	31,13
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	91,67	8,39
	Previously Treated	5	21,7	5	100,0	70,67	30,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	93,33	9,43
	Previously Treated	3	13,0	2	66,7	53,33	47,14
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	86,67	-
	Previously Treated	3	13,0	1	33,3	20,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	86,67	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	86,67	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	80,00	-
	Previously Treated	11	47,8	4	36,4	46,67	31,74
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	73,33	25,90
	Central	25	100,0	22	88,0	66,44	22,98
Cycle 2 Day 1	Local	11	91,7	10	90,9	82,00	16,35
	Central	22	88,0	19	86,4	74,74	21,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	81,82	21,72
	Central	21	84,0	19	90,5	74,74	23,37
Cycle 4 Day 1	Local	11	91,7	10	90,9	90,00	8,46
	Central	21	84,0	18	85,7	76,67	24,87
Cycle 5 Day 1	Local	11	91,7	10	90,9	84,67	16,35
	Central	20	80,0	19	95,0	75,09	22,97
Cycle 6 Day 1	Local	11	91,7	11	100,0	87,88	12,93
	Central	20	80,0	18	90,0	76,30	23,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	81,82	14,33
	Central	19	76,0	16	84,2	74,17	19,15
Cycle 8 Day 1	Local	10	83,3	10	100,0	86,67	13,70
	Central	18	72,0	15	83,3	68,89	24,65
Cycle 9 Day 1	Local	10	83,3	10	100,0	82,67	24,79
	Central	15	60,0	15	100,0	84,44	12,77
Cycle 10 Day 1	Local	10	83,3	9	90,0	83,70	20,58
	Central	15	60,0	15	100,0	80,44	12,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	84,44	17,00
	Central	15	60,0	15	100,0	80,44	13,68
Cycle 12 Day 1	Local	9	75,0	8	88,9	88,33	15,84
	Central	15	60,0	13	86,7	74,36	20,16
Cycle 13 Day 1	Local	8	66,7	8	100,0	82,50	26,89
	Central	14	56,0	13	92,9	78,46	18,89
Cycle 14 Day 1	Local	8	66,7	8	100,0	80,83	29,05
	Central	14	56,0	14	100,0	76,19	23,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	85,83	23,21
	Central	14	56,0	13	92,9	75,90	21,00
Cycle 16 Day 1	Local	8	66,7	6	75,0	84,44	15,59
	Central	13	52,0	9	69,2	65,93	29,52
Cycle 17 Day 1	Local	8	66,7	5	62,5	89,33	7,60
	Central	10	40,0	9	90,0	80,00	21,60
Cycle 18 Day 1	Local	6	50,0	4	66,7	95,00	6,38
	Central	9	36,0	4	44,4	75,00	32,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	80,00	16,33
	Central	8	32,0	4	50,0	71,67	35,43
Cycle 20 Day 1	Local	5	41,7	5	100,0	86,67	13,33
	Central	4	16,0	4	100,0	71,67	35,01
Cycle 21 Day 1	Local	4	33,3	2	50,0	93,33	9,43
	Central	3	12,0	2	66,7	53,33	47,14
Cycle 22 Day 1	Local	4	33,3	1	25,0	86,67	-
	Central	3	12,0	1	33,3	20,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	86,67	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	86,67	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	60,00	9,43
	Central	8	32,0	3	37,5	48,89	42,86

BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	70,05	23,41
	No	2	100,0	2	100,0	50,00	33,00
Cycle 2 Day 1	Yes	32	91,4	28	87,5	77,86	20,29
	No	1	50,0	1	100,0	60,00	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	76,78	22,86
	No	1	50,0	1	100,0	93,33	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	81,23	21,72
	No	1	50,0	1	100,0	86,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	79,05	21,22
	No	1	50,0	1	100,0	60,00	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	80,95	20,82
	No	1	50,0	1	100,0	73,33	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	77,95	17,46
	No	1	50,0	1	100,0	60,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	76,67	22,67
	No	1	50,0	1	100,0	60,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	83,89	18,43
	No	1	50,0	1	100,0	80,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	81,45	16,08
	No	1	50,0	1	100,0	86,67	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	82,03	15,10
	No	1	50,0	1	100,0	80,00	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	79,67	20,00
	No	1	50,0	1	100,0	80,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	80,33	22,21
	No	1	50,0	1	100,0	73,33	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	78,10	25,40
	No	1	50,0	1	100,0	73,33	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	80,00	22,37
	No	1	50,0	1	100,0	73,33	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	73,33	26,92
	No	1	50,0	1	100,0	73,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	83,59	18,78
	No	1	50,0	1	100,0	80,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	82,86	25,49
	No	1	50,0	1	100,0	100,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	75,24	27,95
	No	1	50,0	1	100,0	80,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	80,00	26,43
	No	1	50,0	1	100,0	80,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	73,33	36,11
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	53,33	47,14
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	86,67	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	86,67	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	53,33	31,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	51,11	20,37
	No	33	100,0	31	93,9	70,59	23,78
Cycle 2 Day 1	Yes	2	50,0	1	50,0	93,33	-
	No	31	93,9	28	90,3	76,67	20,33
Cycle 3 Day 1	Yes	2	50,0	2	100,0	90,00	4,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	76,43	23,20
Cycle 4 Day 1	Yes	2	50,0	2	100,0	96,67	4,71
	No	30	90,9	26	86,7	80,26	21,70
Cycle 5 Day 1	Yes	2	50,0	2	100,0	83,33	4,71
	No	29	87,9	27	93,1	78,02	21,86
Cycle 6 Day 1	Yes	2	50,0	2	100,0	86,67	0,00
	No	29	87,9	27	93,1	80,25	21,20
Cycle 7 Day 1	Yes	2	50,0	2	100,0	80,00	9,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	77,07	18,06
Cycle 8 Day 1	Yes	2	50,0	2	100,0	60,00	37,71
	No	26	78,8	23	88,5	77,39	21,44
Cycle 9 Day 1	Yes	1	25,0	1	100,0	86,67	-
	No	24	72,7	24	100,0	83,61	18,44
Cycle 10 Day 1	Yes	1	25,0	1	100,0	80,00	-
	No	24	72,7	23	95,8	81,74	16,11
Cycle 11 Day 1	Yes	1	25,0	1	100,0	73,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	82,32	14,99
Cycle 12 Day 1	Yes	1	25,0	1	100,0	73,33	-
	No	23	69,7	20	87,0	80,00	19,94
Cycle 13 Day 1	Yes	1	25,0	1	100,0	73,33	-
	No	21	63,6	20	95,2	80,33	22,21
Cycle 14 Day 1	Yes	1	25,0	1	100,0	86,67	-
	No	21	63,6	21	100,0	77,46	25,34
Cycle 15 Day 1	Yes	1	25,0	1	100,0	80,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	79,67	22,42
Cycle 16 Day 1	Yes	1	25,0	1	100,0	53,33	-
	No	20	60,6	14	70,0	74,76	26,30
Cycle 17 Day 1	Yes	1	25,0	1	100,0	86,67	-
	No	17	51,5	13	76,5	83,08	18,78
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	85,00	24,36
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	75,83	25,93
Cycle 20 Day 1	No	9	27,3	9	100,0	80,00	24,72
Cycle 21 Day 1	No	7	21,2	4	57,1	73,33	36,11
Cycle 22 Day 1	No	7	21,2	2	28,6	53,33	47,14
Cycle 23 Day 1	No	4	12,1	1	25,0	86,67	-
Cycle 24 Day 1	No	1	3,0	1	100,0	86,67	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	66,67	10,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30PF_SG.xls
07SEP2019 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	57,84	26,74
Cycle 2 Day 1	All	33	89,2	29	87,9	63,22	23,20
Cycle 3 Day 1	All	32	86,5	30	93,8	64,44	24,07
Cycle 4 Day 1	All	32	86,5	28	87,5	73,81	15,33
Cycle 5 Day 1	All	31	83,8	29	93,5	69,54	19,95
Cycle 6 Day 1	All	31	83,8	29	93,5	70,11	19,10
Cycle 7 Day 1	All	30	81,1	27	90,0	71,91	14,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	72,00	17,82
Cycle 9 Day 1	All	25	67,6	25	100,0	72,33	18,28
Cycle 10 Day 1	All	25	67,6	24	96,0	70,83	18,55
Cycle 11 Day 1	All	24	64,9	24	100,0	76,04	16,17
Cycle 12 Day 1	All	24	64,9	21	87,5	69,84	23,49
Cycle 13 Day 1	All	22	59,5	21	95,5	69,84	24,79
Cycle 14 Day 1	All	22	59,5	22	100,0	72,73	24,83
Cycle 15 Day 1	All	22	59,5	21	95,5	72,22	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	67,78	18,86
Cycle 17 Day 1	All	18	48,6	14	77,8	72,62	21,29
Cycle 18 Day 1	All	15	40,5	8	53,3	69,79	19,38
Cycle 19 Day 1	All	13	35,1	8	61,5	62,50	20,89
Cycle 20 Day 1	All	9	24,3	9	100,0	62,96	19,59
Cycle 21 Day 1	All	7	18,9	4	57,1	56,25	28,36
Cycle 22 Day 1	All	7	18,9	2	28,6	41,67	58,93
Cycle 23 Day 1	All	4	10,8	1	25,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	83,33	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	48,33	23,12
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	59,62	29,82
	Female	23	100,0	21	91,3	56,75	25,36
Cycle 2 Day 1	Male	13	92,9	12	92,3	66,67	20,41
	Female	20	87,0	17	85,0	60,78	25,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	71,53	21,75
	Female	20	87,0	18	90,0	59,72	24,96
Cycle 4 Day 1	Male	12	85,7	11	91,7	78,03	17,59
	Female	20	87,0	17	85,0	71,08	13,54
Cycle 5 Day 1	Male	12	85,7	11	91,7	68,18	23,81
	Female	19	82,6	18	94,7	70,37	17,90
Cycle 6 Day 1	Male	12	85,7	11	91,7	75,00	18,26
	Female	19	82,6	18	94,7	67,13	19,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	79,55	14,61
	Female	19	82,6	16	84,2	66,67	12,17
Cycle 8 Day 1	Male	10	71,4	9	90,0	74,07	21,02
	Female	18	78,3	16	88,9	70,83	16,39
Cycle 9 Day 1	Male	8	57,1	8	100,0	80,21	12,55
	Female	17	73,9	17	100,0	68,63	19,66
Cycle 10 Day 1	Male	8	57,1	8	100,0	84,38	12,15
	Female	17	73,9	16	94,1	64,06	17,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	81,25	9,71
	Female	16	69,6	16	100,0	73,44	18,31
Cycle 12 Day 1	Male	8	57,1	8	100,0	83,33	9,96
	Female	16	69,6	13	81,3	61,54	25,81
Cycle 13 Day 1	Male	8	57,1	8	100,0	83,33	15,43
	Female	14	60,9	13	92,9	61,54	26,25
Cycle 14 Day 1	Male	8	57,1	8	100,0	80,21	15,39
	Female	14	60,9	14	100,0	68,45	28,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	78,13	14,73
	Female	14	60,9	13	92,9	68,59	23,85
Cycle 16 Day 1	Male	8	57,1	5	62,5	75,00	8,33
	Female	13	56,5	10	76,9	64,17	21,89
Cycle 17 Day 1	Male	6	42,9	2	33,3	79,17	5,89
	Female	12	52,2	12	100,0	71,53	22,88
Cycle 18 Day 1	Male	3	21,4	2	66,7	83,33	11,79
	Female	12	52,2	6	50,0	65,28	20,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	75,00	11,79
	Female	11	47,8	6	54,5	58,33	22,36
Cycle 20 Day 1	Male	2	14,3	2	100,0	70,83	5,89
	Female	7	30,4	7	100,0	60,71	21,90
Cycle 21 Day 1	Male	1	7,1	1	100,0	66,67	-
	Female	6	26,1	3	50,0	52,78	33,68
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	41,67	58,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	83,33	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	83,33	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	33,33	35,36
	Female	7	30,4	3	42,9	58,33	8,33
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	57,10	27,61
	65-74	8	100,0	7	87,5	60,71	24,87
Cycle 2 Day 1	18-64	27	93,1	24	88,9	63,19	24,81
	65-74	6	75,0	5	83,3	63,33	15,14
Cycle 3 Day 1	18-64	26	89,7	24	92,3	63,54	22,63
	65-74	6	75,0	6	100,0	68,06	31,37
Cycle 4 Day 1	18-64	26	89,7	23	88,5	73,55	16,60
	65-74	6	75,0	5	83,3	75,00	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	70,65	19,60
	65-74	6	75,0	6	100,0	65,28	22,62
Cycle 6 Day 1	18-64	25	86,2	24	96,0	71,18	17,37
	65-74	6	75,0	5	83,3	65,00	27,89
Cycle 7 Day 1	18-64	25	86,2	23	92,0	70,65	15,05
	65-74	5	62,5	4	80,0	79,17	8,33
Cycle 8 Day 1	18-64	23	79,3	20	87,0	72,08	18,59
	65-74	5	62,5	5	100,0	71,67	16,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	74,17	17,71
	65-74	5	62,5	5	100,0	65,00	20,75
Cycle 10 Day 1	18-64	20	69,0	19	95,0	73,68	15,03
	65-74	5	62,5	5	100,0	60,00	27,89
Cycle 11 Day 1	18-64	19	65,5	19	100,0	77,19	16,40
	65-74	5	62,5	5	100,0	71,67	16,24
Cycle 12 Day 1	18-64	19	65,5	17	89,5	70,59	24,85
	65-74	5	62,5	4	80,0	66,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	71,35	23,37
	65-74	5	62,5	5	100,0	65,00	31,40
Cycle 14 Day 1	18-64	17	58,6	17	100,0	75,49	21,14
	65-74	5	62,5	5	100,0	63,33	36,13
Cycle 15 Day 1	18-64	17	58,6	16	94,1	71,88	22,95
	65-74	5	62,5	5	100,0	73,33	14,91
Cycle 16 Day 1	18-64	17	58,6	13	76,5	66,03	19,68
	65-74	4	50,0	2	50,0	79,17	5,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	70,83	22,61
	65-74	3	37,5	2	66,7	83,33	0,00
Cycle 18 Day 1	18-64	13	44,8	8	61,5	69,79	19,38
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	61,90	22,49
	65-74	2	25,0	1	50,0	66,67	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	62,50	20,89
	65-74	1	12,5	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	56,25	28,36
Cycle 22 Day 1	18-64	7	24,1	2	28,6	41,67	58,93
Cycle 23 Day 1	18-64	4	13,8	1	25,0	83,33	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	83,33	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	41,67	28,87
	65-74	6	75,0	2	33,3	58,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	54,90	30,63
	Other	17	100,0	17	100,0	60,78	22,78
Cycle 2 Day 1	White	19	95,0	16	84,2	60,42	25,73
	Other	14	82,4	13	92,9	66,67	20,13
Cycle 3 Day 1	White	18	90,0	16	88,9	58,85	28,46
	Other	14	82,4	14	100,0	70,83	16,59
Cycle 4 Day 1	White	18	90,0	15	83,3	77,22	16,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	69,87	13,84
Cycle 5 Day 1	White	18	90,0	17	94,4	68,14	23,43
	Other	13	76,5	12	92,3	71,53	14,42
Cycle 6 Day 1	White	18	90,0	16	88,9	72,92	21,41
	Other	13	76,5	13	100,0	66,67	15,96
Cycle 7 Day 1	White	17	85,0	15	88,2	73,33	15,81
	Other	13	76,5	12	92,3	70,14	13,04
Cycle 8 Day 1	White	17	85,0	14	82,4	72,62	20,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	71,21	15,53
Cycle 9 Day 1	White	16	80,0	16	100,0	75,52	20,52
	Other	9	52,9	9	100,0	66,67	12,50
Cycle 10 Day 1	White	16	80,0	15	93,8	71,67	22,67
	Other	9	52,9	9	100,0	69,44	9,32
Cycle 11 Day 1	White	16	80,0	16	100,0	78,13	17,45
	Other	8	47,1	8	100,0	71,88	13,32
Cycle 12 Day 1	White	16	80,0	13	81,3	71,15	26,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	67,71	18,06
Cycle 13 Day 1	White	14	70,0	13	92,9	67,95	28,64
	Other	8	47,1	8	100,0	72,92	18,23
Cycle 14 Day 1	White	14	70,0	14	100,0	72,02	29,16
	Other	8	47,1	8	100,0	73,96	16,33
Cycle 15 Day 1	White	14	70,0	13	92,9	72,44	24,15
	Other	8	47,1	8	100,0	71,88	16,02
Cycle 16 Day 1	White	14	70,0	9	64,3	68,52	23,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	66,67	11,79
Cycle 17 Day 1	White	13	65,0	10	76,9	75,83	22,72
	Other	5	29,4	4	80,0	64,58	17,18
Cycle 18 Day 1	White	11	55,0	4	36,4	72,92	21,92
	Other	4	23,5	4	100,0	66,67	19,25
Cycle 19 Day 1	White	9	45,0	5	55,6	63,33	27,39
	Other	4	23,5	3	75,0	61,11	4,81
Cycle 20 Day 1	White	5	25,0	5	100,0	60,00	24,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	66,67	13,61
Cycle 21 Day 1	White	3	15,0	2	66,7	41,67	35,36
	Other	4	23,5	2	50,0	70,83	17,68
Cycle 22 Day 1	White	3	15,0	1	33,3	0,00	-
	Other	4	23,5	1	25,0	83,33	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	83,33	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	55,56	4,81
	Other	9	52,9	2	22,2	37,50	41,25
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	72,92	24,13
	Europe (EU)	10	100,0	8	80,0	38,54	28,50
	Asia (AS)	15	100,0	14	93,3	55,95	21,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	62,04	27,99
	Europe (EU)	9	90,0	8	88,9	63,54	26,70
	Asia (AS)	13	86,7	12	92,3	63,89	18,58
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	68,18	26,83
	Europe (EU)	8	80,0	6	75,0	45,83	26,74
	Asia (AS)	13	86,7	13	100,0	69,87	16,85
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	80,30	16,78
	Europe (EU)	8	80,0	4	50,0	70,83	10,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	69,23	14,18
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	78,03	23,06
	Europe (EU)	8	80,0	7	87,5	63,10	19,16
	Asia (AS)	12	80,0	11	91,7	65,15	15,28
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	81,82	15,73
	Europe (EU)	8	80,0	7	87,5	63,10	22,49
	Asia (AS)	12	80,0	11	91,7	62,88	15,08
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	80,00	16,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	66,67	9,62
	Asia (AS)	11	73,3	10	90,9	67,50	12,70
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	77,50	16,22
	Europe (EU)	8	80,0	6	75,0	63,89	19,48
	Asia (AS)	9	60,0	9	100,0	71,30	18,22
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	75,76	19,88
	Europe (EU)	7	70,0	7	100,0	71,43	18,54
	Asia (AS)	7	46,7	7	100,0	67,86	16,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	77,50	16,22
	Europe (EU)	7	70,0	7	100,0	59,52	21,75
	Asia (AS)	7	46,7	7	100,0	72,62	15,00
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	76,52	17,41
	Europe (EU)	7	70,0	7	100,0	76,19	15,54
	Asia (AS)	6	40,0	6	100,0	75,00	17,48
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	75,00	29,40
	Europe (EU)	7	70,0	5	71,4	63,33	9,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	66,67	21,73
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	80,00	26,70
	Europe (EU)	6	60,0	5	83,3	53,33	21,73
	Asia (AS)	6	40,0	6	100,0	66,67	17,48
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	80,00	24,28
	Europe (EU)	6	60,0	6	100,0	58,33	31,18
	Asia (AS)	6	40,0	6	100,0	75,00	13,94
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	76,67	25,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	66,67	16,67
	Asia (AS)	6	40,0	6	100,0	69,44	16,39
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	73,81	18,90
	Europe (EU)	6	60,0	2	33,3	75,00	11,79
	Asia (AS)	6	40,0	6	100,0	58,33	19,00
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	70,83	28,26
	Europe (EU)	4	40,0	3	75,0	83,33	0,00
	Asia (AS)	5	33,3	5	100,0	68,33	19,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	75,00	19,54
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	61,11	19,25
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	62,50	31,55
	Europe (EU)	3	30,0	1	33,3	66,67	-
	Asia (AS)	4	26,7	3	75,0	61,11	4,81
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	63,33	26,74
	Europe (EU)	1	10,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	61,11	9,62
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	55,56	34,69
	Asia (AS)	3	20,0	1	33,3	58,33	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	41,67	58,93
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	83,33	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	61,11	4,81
	Europe (EU)	2	20,0	1	50,0	50,00	-
	Asia (AS)	7	46,7	1	14,3	8,33	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	75,69	18,28
	1	17	100,0	17	100,0	52,45	24,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	33,33	26,35
Cycle 2 Day 1	0	15	100,0	12	80,0	65,97	22,60
	1	15	88,2	14	93,3	64,29	19,46
	2	3	60,0	3	100,0	47,22	42,76
Cycle 3 Day 1	0	15	100,0	14	93,3	63,10	27,09
	1	14	82,4	13	92,9	70,51	21,14
	2	3	60,0	3	100,0	44,44	9,62
Cycle 4 Day 1	0	15	100,0	14	93,3	75,60	17,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	71,53	13,97
	2	3	60,0	2	66,7	75,00	11,79
Cycle 5 Day 1	0	15	100,0	15	100,0	69,44	22,20
	1	14	82,4	12	85,7	70,83	17,23
	2	2	40,0	2	100,0	62,50	29,46
Cycle 6 Day 1	0	15	100,0	15	100,0	71,67	21,32
	1	14	82,4	12	85,7	67,36	17,93
	2	2	40,0	2	100,0	75,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	75,60	15,49
	1	13	76,5	11	84,6	69,70	12,51
	2	2	40,0	2	100,0	58,33	11,79
Cycle 8 Day 1	0	15	100,0	13	86,7	71,15	18,82
	1	11	64,7	10	90,9	72,50	15,24
	2	2	40,0	2	100,0	75,00	35,36
Cycle 9 Day 1	0	14	93,3	14	100,0	70,83	19,27
	1	10	58,8	10	100,0	73,33	18,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	83,33	-
Cycle 10 Day 1	0	14	93,3	14	100,0	70,83	22,11
	1	10	58,8	9	90,0	69,44	13,18
	2	1	20,0	1	100,0	83,33	-
Cycle 11 Day 1	0	14	93,3	14	100,0	76,79	12,73
	1	9	52,9	9	100,0	72,22	19,98
	2	1	20,0	1	100,0	100,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	69,44	27,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	70,83	19,42
	2	1	20,0	1	100,0	66,67	-
Cycle 13 Day 1	0	14	93,3	13	92,9	68,59	28,09
	1	8	47,1	8	100,0	71,88	19,89
Cycle 14 Day 1	0	14	93,3	14	100,0	71,43	28,63
	1	8	47,1	8	100,0	75,00	17,82
Cycle 15 Day 1	0	14	93,3	14	100,0	72,02	23,25
	1	8	47,1	7	87,5	72,62	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	66,67	23,99
	1	8	47,1	7	87,5	69,05	12,47
Cycle 17 Day 1	0	12	80,0	8	66,7	70,83	22,71
	1	6	35,3	6	100,0	75,00	21,08
Cycle 18 Day 1	0	9	60,0	4	44,4	72,92	21,92
	1	6	35,3	4	66,7	66,67	19,25
Cycle 19 Day 1	0	8	53,3	4	50,0	58,33	28,87
	1	5	29,4	4	80,0	66,67	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	61,67	26,09
	1	4	23,5	4	100,0	64,58	10,49
Cycle 21 Day 1	0	3	20,0	3	100,0	55,56	34,69
	1	4	23,5	1	25,0	58,33	-
Cycle 22 Day 1	0	3	20,0	2	66,7	41,67	58,93
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	83,33	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	83,33	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	58,33	8,33
	1	7	41,2	2	28,6	33,33	35,36
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	71,15	22,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	62,50	41,25
	2 or More	21	100,0	19	90,5	48,25	25,24
Cycle 2 Day 1	None	14	100,0	12	85,7	65,97	24,74
	1	1	50,0	1	100,0	91,67	-
	2 or More	18	85,7	16	88,9	59,38	21,92
Cycle 3 Day 1	None	14	100,0	13	92,9	66,67	23,07
	1	1	50,0	1	100,0	100,00	-
	2 or More	17	81,0	16	94,1	60,42	24,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	79,86	13,51
	1	1	50,0	1	100,0	100,00	-
	2 or More	17	81,0	15	88,2	67,22	13,54
Cycle 5 Day 1	None	14	100,0	14	100,0	74,40	20,27
	1	1	50,0	1	100,0	100,00	-
	2 or More	16	76,2	14	87,5	62,50	17,22
Cycle 6 Day 1	None	14	100,0	14	100,0	81,55	12,31
	1	1	50,0	1	100,0	91,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	57,14	16,62
Cycle 7 Day 1	None	14	100,0	13	92,9	77,56	13,77
	1	1	50,0	1	100,0	83,33	-
	2 or More	15	71,4	13	86,7	65,38	13,11
Cycle 8 Day 1	None	14	100,0	13	92,9	79,49	13,87
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	63,89	18,58
Cycle 9 Day 1	None	13	92,9	13	100,0	77,56	14,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	83,33	-
	2 or More	11	52,4	11	100,0	65,15	20,69
Cycle 10 Day 1	None	13	92,9	12	92,3	75,69	13,51
	1	1	50,0	1	100,0	91,67	-
	2 or More	11	52,4	11	100,0	63,64	21,50
Cycle 11 Day 1	None	13	92,9	13	100,0	80,77	13,77
	1	1	50,0	1	100,0	83,33	-
	2 or More	10	47,6	10	100,0	69,17	18,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	77,08	15,94
	1	1	50,0	1	100,0	83,33	-
	2 or More	10	47,6	8	80,0	57,29	29,69
Cycle 13 Day 1	None	12	85,7	11	91,7	78,79	18,01
	1	1	50,0	1	100,0	100,00	-
	2 or More	9	42,9	9	100,0	55,56	26,02
Cycle 14 Day 1	None	12	85,7	12	100,0	81,94	14,58
	1	1	50,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	59,26	31,30
Cycle 15 Day 1	None	12	85,7	12	100,0	78,47	13,97
	1	1	50,0	1	100,0	83,33	-
	2 or More	9	42,9	8	88,9	61,46	27,07
Cycle 16 Day 1	None	11	78,6	8	72,7	67,71	21,10
	1	1	50,0	1	100,0	83,33	-
	2 or More	9	42,9	6	66,7	65,28	17,81
Cycle 17 Day 1	None	10	71,4	7	70,0	75,00	15,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	83,33	-
	2 or More	7	33,3	6	85,7	68,06	29,07
Cycle 18 Day 1	None	8	57,1	4	50,0	81,25	4,17
	1	1	50,0	1	100,0	91,67	-
	2 or More	6	28,6	3	50,0	47,22	4,81
Cycle 19 Day 1	None	7	50,0	3	42,9	69,44	12,73
	1	1	50,0	1	100,0	83,33	-
	2 or More	5	23,8	4	80,0	52,08	23,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	75,00	6,80
	1	1	50,0	1	100,0	66,67	-
	2 or More	4	19,0	4	100,0	50,00	23,57
Cycle 21 Day 1	None	4	28,6	2	50,0	75,00	11,79
	2 or More	3	14,3	2	66,7	37,50	29,46
Cycle 22 Day 1	None	4	28,6	1	25,0	83,33	-
	2 or More	3	14,3	1	33,3	0,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	83,33	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	66,67	-
	1	2	100,0	1	50,0	58,33	-
	2 or More	9	42,9	3	33,3	38,89	26,79
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	71,15	22,98
	Previously Treated	23	100,0	21	91,3	49,60	26,02
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	65,97	24,74
	Previously Treated	19	82,6	17	89,5	61,27	22,62
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	66,67	23,07
	Previously Treated	18	78,3	17	94,4	62,75	25,36
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	79,86	13,51
	Previously Treated	18	78,3	16	88,9	69,27	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	74,40	20,27
	Previously Treated	17	73,9	15	88,2	65,00	19,21
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	81,55	12,31
	Previously Treated	17	73,9	15	88,2	59,44	18,33
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	77,56	13,77
	Previously Treated	16	69,6	14	87,5	66,67	13,48
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	79,49	13,87
	Previously Treated	14	60,9	12	85,7	63,89	18,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	77,56	14,98
	Previously Treated	12	52,2	12	100,0	66,67	20,41
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	75,69	13,51
	Previously Treated	12	52,2	12	100,0	65,97	22,04
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	80,77	13,77
	Previously Treated	11	47,8	11	100,0	70,45	17,62
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	77,08	15,94
	Previously Treated	11	47,8	9	81,8	60,19	29,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	78,79	18,01
	Previously Treated	10	43,5	10	100,0	60,00	28,27
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	81,94	14,58
	Previously Treated	10	43,5	10	100,0	61,67	30,48
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	78,47	13,97
	Previously Treated	10	43,5	9	90,0	63,89	26,35
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	67,71	21,10
	Previously Treated	10	43,5	7	70,0	67,86	17,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	75,00	15,21
	Previously Treated	8	34,8	7	87,5	70,24	27,16
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	81,25	4,17
	Previously Treated	7	30,4	4	57,1	58,33	22,57
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	69,44	12,73
	Previously Treated	6	26,1	5	83,3	58,33	25,00
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	75,00	6,80
	Previously Treated	5	21,7	5	100,0	53,33	21,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	75,00	11,79
	Previously Treated	3	13,0	2	66,7	37,50	29,46
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	83,33	-
	Previously Treated	3	13,0	1	33,3	0,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	83,33	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	83,33	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	66,67	-
	Previously Treated	11	47,8	4	36,4	43,75	23,94
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	67,36	25,49
	Central	25	100,0	22	88,0	52,65	26,53
Cycle 2 Day 1	Local	11	91,7	10	90,9	60,83	26,37
	Central	22	88,0	19	86,4	64,47	22,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	68,94	28,16
	Central	21	84,0	19	90,5	61,84	21,75
Cycle 4 Day 1	Local	11	91,7	10	90,9	80,00	14,27
	Central	21	84,0	18	85,7	70,37	15,18
Cycle 5 Day 1	Local	11	91,7	10	90,9	70,00	26,99
	Central	20	80,0	19	95,0	69,30	15,97
Cycle 6 Day 1	Local	11	91,7	11	100,0	76,52	17,41
	Central	20	80,0	18	90,0	66,20	19,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	81,06	12,41
	Central	19	76,0	16	84,2	65,63	12,50
Cycle 8 Day 1	Local	10	83,3	10	100,0	78,33	15,32
	Central	18	72,0	15	83,3	67,78	18,60
Cycle 9 Day 1	Local	10	83,3	10	100,0	72,50	21,89
	Central	15	60,0	15	100,0	72,22	16,27
Cycle 10 Day 1	Local	10	83,3	9	90,0	71,30	25,04
	Central	15	60,0	15	100,0	70,56	14,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	77,78	19,98
	Central	15	60,0	15	100,0	75,00	14,09
Cycle 12 Day 1	Local	9	75,0	8	88,9	82,29	15,06
	Central	15	60,0	13	86,7	62,18	24,91
Cycle 13 Day 1	Local	8	66,7	8	100,0	77,08	28,08
	Central	14	56,0	13	92,9	65,38	22,53
Cycle 14 Day 1	Local	8	66,7	8	100,0	79,17	32,73
	Central	14	56,0	14	100,0	69,05	19,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	77,08	18,23
	Central	14	56,0	13	92,9	69,23	22,67
Cycle 16 Day 1	Local	8	66,7	6	75,0	75,00	13,94
	Central	13	52,0	9	69,2	62,96	20,88
Cycle 17 Day 1	Local	8	66,7	5	62,5	76,67	18,07
	Central	10	40,0	9	90,0	70,37	23,61
Cycle 18 Day 1	Local	6	50,0	4	66,7	81,25	4,17
	Central	9	36,0	4	44,4	58,33	22,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	68,75	10,49
	Central	8	32,0	4	50,0	56,25	28,36
Cycle 20 Day 1	Local	5	41,7	5	100,0	73,33	6,97
	Central	4	16,0	4	100,0	50,00	23,57
Cycle 21 Day 1	Local	4	33,3	2	50,0	75,00	11,79
	Central	3	12,0	2	66,7	37,50	29,46
Cycle 22 Day 1	Local	4	33,3	1	25,0	83,33	-
	Central	3	12,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	83,33	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	83,33	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	54,17	5,89
	Central	8	32,0	3	37,5	44,44	31,55

BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	57,81	26,85
	No	2	100,0	2	100,0	58,33	35,36
Cycle 2 Day 1	Yes	32	91,4	28	87,5	64,29	22,89
	No	1	50,0	1	100,0	33,33	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	64,37	24,49
	No	1	50,0	1	100,0	66,67	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	74,38	15,32
	No	1	50,0	1	100,0	58,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	70,24	19,96
	No	1	50,0	1	100,0	50,00	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	70,24	19,43
	No	1	50,0	1	100,0	66,67	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	72,12	14,71
	No	1	50,0	1	100,0	66,67	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	72,22	18,17
	No	1	50,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	73,26	18,05
	No	1	50,0	1	100,0	50,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	71,38	18,77
	No	1	50,0	1	100,0	58,33	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	75,72	16,46
	No	1	50,0	1	100,0	83,33	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	69,58	24,07
	No	1	50,0	1	100,0	75,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	70,00	25,42
	No	1	50,0	1	100,0	66,67	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	72,22	25,32
	No	1	50,0	1	100,0	83,33	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	73,33	20,87
	No	1	50,0	1	100,0	50,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	69,05	18,90
	No	1	50,0	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	74,36	21,10
	No	1	50,0	1	100,0	50,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	67,86	20,09
	No	1	50,0	1	100,0	83,33	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	63,10	22,49
	No	1	50,0	1	100,0	58,33	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	62,50	20,89
	No	1	50,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	56,25	28,36
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	41,67	58,93
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	83,33	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	83,33	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	48,33	23,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	38,89	9,62
	No	33	100,0	31	93,9	59,68	27,22
Cycle 2 Day 1	Yes	2	50,0	1	50,0	83,33	-
	No	31	93,9	28	90,3	62,50	23,30
Cycle 3 Day 1	Yes	2	50,0	2	100,0	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	64,29	24,52
Cycle 4 Day 1	Yes	2	50,0	2	100,0	75,00	11,79
	No	30	90,9	26	86,7	73,72	15,76
Cycle 5 Day 1	Yes	2	50,0	2	100,0	70,83	5,89
	No	29	87,9	27	93,1	69,44	20,67
Cycle 6 Day 1	Yes	2	50,0	2	100,0	75,00	11,79
	No	29	87,9	27	93,1	69,75	19,63
Cycle 7 Day 1	Yes	2	50,0	2	100,0	75,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	71,67	14,83
Cycle 8 Day 1	Yes	2	50,0	2	100,0	70,83	5,89
	No	26	78,8	23	88,5	72,10	18,57
Cycle 9 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	24	72,7	24	100,0	72,57	18,63
Cycle 10 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	24	72,7	23	95,8	71,01	18,95
Cycle 11 Day 1	Yes	1	25,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	76,45	16,41
Cycle 12 Day 1	Yes	1	25,0	1	100,0	50,00	-
	No	23	69,7	20	87,0	70,83	23,65
Cycle 13 Day 1	Yes	1	25,0	1	100,0	50,00	-
	No	21	63,6	20	95,2	70,83	25,00
Cycle 14 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	21	63,6	21	100,0	73,02	25,40
Cycle 15 Day 1	Yes	1	25,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	72,50	21,48
Cycle 16 Day 1	Yes	1	25,0	1	100,0	25,00	-
	No	20	60,6	14	70,0	70,83	15,24
Cycle 17 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	17	51,5	13	76,5	73,08	22,09
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	69,79	19,38
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	62,50	20,89
Cycle 20 Day 1	No	9	27,3	9	100,0	62,96	19,59
Cycle 21 Day 1	No	7	21,2	4	57,1	56,25	28,36
Cycle 22 Day 1	No	7	21,2	2	28,6	41,67	58,93
Cycle 23 Day 1	No	4	12,1	1	25,0	83,33	-
Cycle 24 Day 1	No	1	3,0	1	100,0	83,33	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	8,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	58,33	6,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30QL_SG.xls
07SEP2019 20:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	60,29	30,98
Cycle 2 Day 1	All	33	89,2	29	87,9	66,67	33,92
Cycle 3 Day 1	All	32	86,5	30	93,8	69,44	30,03
Cycle 4 Day 1	All	32	86,5	28	87,5	75,00	23,79
Cycle 5 Day 1	All	31	83,8	29	93,5	71,26	25,55
Cycle 6 Day 1	All	31	83,8	29	93,5	73,56	26,55
Cycle 7 Day 1	All	30	81,1	27	90,0	73,46	24,13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	68,67	25,60
Cycle 9 Day 1	All	25	67,6	25	100,0	76,00	24,57
Cycle 10 Day 1	All	25	67,6	24	96,0	74,31	23,04
Cycle 11 Day 1	All	24	64,9	24	100,0	75,00	23,05
Cycle 12 Day 1	All	24	64,9	21	87,5	71,43	24,80
Cycle 13 Day 1	All	22	59,5	21	95,5	75,40	31,01
Cycle 14 Day 1	All	22	59,5	22	100,0	70,45	27,18
Cycle 15 Day 1	All	22	59,5	21	95,5	73,81	30,54

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	73,33	28,03
Cycle 17 Day 1	All	18	48,6	14	77,8	78,57	28,06
Cycle 18 Day 1	All	15	40,5	8	53,3	72,92	28,08
Cycle 19 Day 1	All	13	35,1	8	61,5	70,83	37,53
Cycle 20 Day 1	All	9	24,3	9	100,0	70,37	32,03
Cycle 21 Day 1	All	7	18,9	4	57,1	66,67	45,13
Cycle 22 Day 1	All	7	18,9	2	28,6	50,00	70,71
Cycle 23 Day 1	All	4	10,8	1	25,0	100,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	100,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	46,67	21,73
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	57,69	37,03
	Female	23	100,0	21	91,3	61,90	27,46
Cycle 2 Day 1	Male	13	92,9	12	92,3	65,28	37,91
	Female	20	87,0	17	85,0	67,65	31,99

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	75,00	28,87
	Female	20	87,0	18	90,0	65,74	31,03
Cycle 4 Day 1	Male	12	85,7	11	91,7	81,82	22,92
	Female	20	87,0	17	85,0	70,59	23,96
Cycle 5 Day 1	Male	12	85,7	11	91,7	77,27	25,03
	Female	19	82,6	18	94,7	67,59	25,87
Cycle 6 Day 1	Male	12	85,7	11	91,7	86,36	19,46
	Female	19	82,6	18	94,7	65,74	27,70

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	78,79	25,92
	Female	19	82,6	16	84,2	69,79	22,95
Cycle 8 Day 1	Male	10	71,4	9	90,0	70,37	23,24
	Female	18	78,3	16	88,9	67,71	27,53
Cycle 9 Day 1	Male	8	57,1	8	100,0	85,42	18,77
	Female	17	73,9	17	100,0	71,57	26,20
Cycle 10 Day 1	Male	8	57,1	8	100,0	83,33	19,92
	Female	17	73,9	16	94,1	69,79	23,74

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	81,25	24,30
	Female	16	69,6	16	100,0	71,88	22,54
Cycle 12 Day 1	Male	8	57,1	8	100,0	79,17	19,42
	Female	16	69,6	13	81,3	66,67	27,22
Cycle 13 Day 1	Male	8	57,1	8	100,0	89,58	19,80
	Female	14	60,9	13	92,9	66,67	34,02
Cycle 14 Day 1	Male	8	57,1	8	100,0	75,00	21,82
	Female	14	60,9	14	100,0	67,86	30,29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	83,33	19,92
	Female	14	60,9	13	92,9	67,95	35,00
Cycle 16 Day 1	Male	8	57,1	5	62,5	76,67	27,89
	Female	13	56,5	10	76,9	71,67	29,45
Cycle 17 Day 1	Male	6	42,9	2	33,3	100,00	0,00
	Female	12	52,2	12	100,0	75,00	28,87
Cycle 18 Day 1	Male	3	21,4	2	66,7	83,33	23,57
	Female	12	52,2	6	50,0	69,44	30,58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	100,00	0,00
	Female	11	47,8	6	54,5	61,11	38,97
Cycle 20 Day 1	Male	2	14,3	2	100,0	91,67	11,79
	Female	7	30,4	7	100,0	64,29	33,92
Cycle 21 Day 1	Male	1	7,1	1	100,0	83,33	-
	Female	6	26,1	3	50,0	61,11	53,58
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	50,00	70,71

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	100,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	100,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	41,67	35,36
	Female	7	30,4	3	42,9	50,00	16,67
Age							

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	59,26	31,12
	65-74	8	100,0	7	87,5	64,29	32,53
Cycle 2 Day 1	18-64	27	93,1	24	88,9	70,14	34,75
	65-74	6	75,0	5	83,3	50,00	26,35
Cycle 3 Day 1	18-64	26	89,7	24	92,3	71,53	28,44
	65-74	6	75,0	6	100,0	61,11	37,52
Cycle 4 Day 1	18-64	26	89,7	23	88,5	76,81	23,96
	65-74	6	75,0	5	83,3	66,67	23,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	72,46	26,40
	65-74	6	75,0	6	100,0	66,67	23,57
Cycle 6 Day 1	18-64	25	86,2	24	96,0	75,00	27,36
	65-74	6	75,0	5	83,3	66,67	23,57
Cycle 7 Day 1	18-64	25	86,2	23	92,0	74,64	24,03
	65-74	5	62,5	4	80,0	66,67	27,22
Cycle 8 Day 1	18-64	23	79,3	20	87,0	68,33	28,56
	65-74	5	62,5	5	100,0	70,00	7,45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	80,00	19,94
	65-74	5	62,5	5	100,0	60,00	36,51
Cycle 10 Day 1	18-64	20	69,0	19	95,0	76,32	23,12
	65-74	5	62,5	5	100,0	66,67	23,57
Cycle 11 Day 1	18-64	19	65,5	19	100,0	77,19	23,05
	65-74	5	62,5	5	100,0	66,67	23,57
Cycle 12 Day 1	18-64	19	65,5	17	89,5	72,55	24,96
	65-74	5	62,5	4	80,0	66,67	27,22

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	80,21	28,69
	65-74	5	62,5	5	100,0	60,00	36,51
Cycle 14 Day 1	18-64	17	58,6	17	100,0	73,53	24,34
	65-74	5	62,5	5	100,0	60,00	36,51
Cycle 15 Day 1	18-64	17	58,6	16	94,1	78,13	28,36
	65-74	5	62,5	5	100,0	60,00	36,51
Cycle 16 Day 1	18-64	17	58,6	13	76,5	76,92	27,67
	65-74	4	50,0	2	50,0	50,00	23,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	80,56	30,01
	65-74	3	37,5	2	66,7	66,67	0,00
Cycle 18 Day 1	18-64	13	44,8	8	61,5	72,92	28,08
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	76,19	37,09
	65-74	2	25,0	1	50,0	33,33	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	72,92	33,26
	65-74	1	12,5	1	100,0	50,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	66,67	45,13
Cycle 22 Day 1	18-64	7	24,1	2	28,6	50,00	70,71
Cycle 23 Day 1	18-64	4	13,8	1	25,0	100,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	100,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	44,44	25,46
	65-74	6	75,0	2	33,3	50,00	23,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	56,86	32,31
	Other	17	100,0	17	100,0	63,73	30,18
Cycle 2 Day 1	White	19	95,0	16	84,2	59,38	39,43
	Other	14	82,4	13	92,9	75,64	24,17
Cycle 3 Day 1	White	18	90,0	16	88,9	58,33	34,43
	Other	14	82,4	14	100,0	82,14	17,86
Cycle 4 Day 1	White	18	90,0	15	83,3	73,33	26,58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	76,92	21,01
Cycle 5 Day 1	White	18	90,0	17	94,4	70,59	29,77
	Other	13	76,5	12	92,3	72,22	19,25
Cycle 6 Day 1	White	18	90,0	16	88,9	71,88	31,46
	Other	13	76,5	13	100,0	75,64	19,97
Cycle 7 Day 1	White	17	85,0	15	88,2	71,11	27,07
	Other	13	76,5	12	92,3	76,39	20,67
Cycle 8 Day 1	White	17	85,0	14	82,4	70,24	28,63

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	66,67	22,36
Cycle 9 Day 1	White	16	80,0	16	100,0	78,13	27,70
	Other	9	52,9	9	100,0	72,22	18,63
Cycle 10 Day 1	White	16	80,0	15	93,8	72,22	25,72
	Other	9	52,9	9	100,0	77,78	18,63
Cycle 11 Day 1	White	16	80,0	16	100,0	79,17	24,72
	Other	8	47,1	8	100,0	66,67	17,82
Cycle 12 Day 1	White	16	80,0	13	81,3	69,23	28,74

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	75,00	17,82
Cycle 13 Day 1	White	14	70,0	13	92,9	75,64	37,65
	Other	8	47,1	8	100,0	75,00	17,82
Cycle 14 Day 1	White	14	70,0	14	100,0	69,05	30,56
	Other	8	47,1	8	100,0	72,92	21,71
Cycle 15 Day 1	White	14	70,0	13	92,9	71,79	36,25
	Other	8	47,1	8	100,0	77,08	19,80
Cycle 16 Day 1	White	14	70,0	9	64,3	77,78	27,64

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	66,67	29,81
Cycle 17 Day 1	White	13	65,0	10	76,9	80,00	32,20
	Other	5	29,4	4	80,0	75,00	16,67
Cycle 18 Day 1	White	11	55,0	4	36,4	70,83	39,38
	Other	4	23,5	4	100,0	75,00	16,67
Cycle 19 Day 1	White	9	45,0	5	55,6	66,67	47,14
	Other	4	23,5	3	75,0	77,78	19,25
Cycle 20 Day 1	White	5	25,0	5	100,0	66,67	42,49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	75,00	16,67
Cycle 21 Day 1	White	3	15,0	2	66,7	41,67	58,93
	Other	4	23,5	2	50,0	91,67	11,79
Cycle 22 Day 1	White	3	15,0	1	33,3	0,00	-
	Other	4	23,5	1	25,0	100,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	100,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	100,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	50,00	16,67
	Other	9	52,9	2	22,2	41,67	35,36
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	72,22	30,43
	Europe (EU)	10	100,0	8	80,0	39,58	25,10
	Asia (AS)	15	100,0	14	93,3	61,90	30,26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	68,52	42,04
	Europe (EU)	9	90,0	8	88,9	54,17	30,54
	Asia (AS)	13	86,7	12	92,3	73,61	29,69
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	77,27	25,03
	Europe (EU)	8	80,0	6	75,0	33,33	31,62
	Asia (AS)	13	86,7	13	100,0	79,49	20,59
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	83,33	22,36
	Europe (EU)	8	80,0	4	50,0	66,67	27,22

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	70,51	23,72
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	81,82	24,10
	Europe (EU)	8	80,0	7	87,5	59,52	34,50
	Asia (AS)	12	80,0	11	91,7	68,18	17,41
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	87,88	18,40
	Europe (EU)	8	80,0	7	87,5	54,76	31,50
	Asia (AS)	12	80,0	11	91,7	71,21	23,68
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	81,67	25,40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	54,76	24,93
	Asia (AS)	11	73,3	10	90,9	78,33	15,81
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	83,33	22,22
	Europe (EU)	8	80,0	6	75,0	52,78	19,48
	Asia (AS)	9	60,0	9	100,0	62,96	26,06
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	83,33	21,08
	Europe (EU)	7	70,0	7	100,0	61,90	32,93
	Asia (AS)	7	46,7	7	100,0	78,57	15,85

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	83,33	27,22
	Europe (EU)	7	70,0	7	100,0	57,14	13,11
	Asia (AS)	7	46,7	7	100,0	78,57	15,85
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	81,82	24,10
	Europe (EU)	7	70,0	7	100,0	66,67	27,22
	Asia (AS)	6	40,0	6	100,0	72,22	13,61
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	78,33	30,48
	Europe (EU)	7	70,0	5	71,4	53,33	13,94

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	75,00	13,94
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	85,00	31,87
	Europe (EU)	6	60,0	5	83,3	53,33	36,13
	Asia (AS)	6	40,0	6	100,0	77,78	17,21
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	81,67	26,59
	Europe (EU)	6	60,0	6	100,0	55,56	34,43
	Asia (AS)	6	40,0	6	100,0	66,67	10,54
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	85,00	31,87

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	56,67	36,51
	Asia (AS)	6	40,0	6	100,0	69,44	16,39
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	88,10	24,93
	Europe (EU)	6	60,0	2	33,3	33,33	0,00
	Asia (AS)	6	40,0	6	100,0	69,44	22,15
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	83,33	40,82
	Europe (EU)	4	40,0	3	75,0	77,78	19,25
	Asia (AS)	5	33,3	5	100,0	73,33	14,91

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	76,67	36,51
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	66,67	0,00
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	75,00	50,00
	Europe (EU)	3	30,0	1	33,3	33,33	-
	Asia (AS)	4	26,7	3	75,0	77,78	19,25
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	76,67	43,46
	Europe (EU)	1	10,0	1	100,0	50,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	66,67	0,00
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	61,11	53,58
	Asia (AS)	3	20,0	1	33,3	83,33	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	50,00	70,71
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	100,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	100,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	61,11	9,62
	Europe (EU)	2	20,0	1	50,0	33,33	-
	Asia (AS)	7	46,7	1	14,3	16,67	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	81,94	16,60
	1	17	100,0	17	100,0	50,00	30,62

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	43,33	34,56
Cycle 2 Day 1	0	15	100,0	12	80,0	72,22	31,25
	1	15	88,2	14	93,3	64,29	39,15
	2	3	60,0	3	100,0	55,56	19,25
Cycle 3 Day 1	0	15	100,0	14	93,3	71,43	31,64
	1	14	82,4	13	92,9	76,92	22,09
	2	3	60,0	3	100,0	27,78	25,46
Cycle 4 Day 1	0	15	100,0	14	93,3	79,76	22,81

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	76,39	20,67
	2	3	60,0	2	66,7	33,33	0,00
Cycle 5 Day 1	0	15	100,0	15	100,0	75,56	23,46
	1	14	82,4	12	85,7	70,83	21,47
	2	2	40,0	2	100,0	41,67	58,93
Cycle 6 Day 1	0	15	100,0	15	100,0	77,78	23,29
	1	14	82,4	12	85,7	75,00	24,10
	2	2	40,0	2	100,0	33,33	47,14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	73,81	25,91
	1	13	76,5	11	84,6	77,27	21,44
	2	2	40,0	2	100,0	50,00	23,57
Cycle 8 Day 1	0	15	100,0	13	86,7	70,51	22,72
	1	11	64,7	10	90,9	71,67	27,27
	2	2	40,0	2	100,0	41,67	35,36
Cycle 9 Day 1	0	14	93,3	14	100,0	72,62	27,43
	1	10	58,8	10	100,0	78,33	20,86

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	100,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	73,81	25,91
	1	10	58,8	9	90,0	75,93	20,60
	2	1	20,0	1	100,0	66,67	-
Cycle 11 Day 1	0	14	93,3	14	100,0	75,00	23,34
	1	9	52,9	9	100,0	72,22	23,57
	2	1	20,0	1	100,0	100,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	69,44	29,16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	75,00	19,92
	2	1	20,0	1	100,0	66,67	-
Cycle 13 Day 1	0	14	93,3	13	92,9	73,08	35,71
	1	8	47,1	8	100,0	79,17	23,15
Cycle 14 Day 1	0	14	93,3	14	100,0	69,05	30,56
	1	8	47,1	8	100,0	72,92	21,71
Cycle 15 Day 1	0	14	93,3	14	100,0	71,43	34,86
	1	8	47,1	7	87,5	78,57	20,89

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	72,92	28,08
	1	8	47,1	7	87,5	73,81	30,21
Cycle 17 Day 1	0	12	80,0	8	66,7	75,00	34,50
	1	6	35,3	6	100,0	83,33	18,26
Cycle 18 Day 1	0	9	60,0	4	44,4	70,83	39,38
	1	6	35,3	4	66,7	75,00	16,67
Cycle 19 Day 1	0	8	53,3	4	50,0	58,33	50,00
	1	5	29,4	4	80,0	83,33	19,25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	66,67	42,49
	1	4	23,5	4	100,0	75,00	16,67
Cycle 21 Day 1	0	3	20,0	3	100,0	61,11	53,58
	1	4	23,5	1	25,0	83,33	-
Cycle 22 Day 1	0	3	20,0	2	66,7	50,00	70,71
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	100,00	-
	1	1	5,9	0	0,0	-	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	100,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	55,56	19,25
	1	7	41,2	2	28,6	33,33	23,57
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	70,51	27,35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	66,67	47,14
	2 or More	21	100,0	19	90,5	52,63	31,56
Cycle 2 Day 1	None	14	100,0	12	85,7	72,22	34,33
	1	1	50,0	1	100,0	100,00	-
	2 or More	18	85,7	16	88,9	60,42	33,82
Cycle 3 Day 1	None	14	100,0	13	92,9	75,64	25,11
	1	1	50,0	1	100,0	100,00	-
	2 or More	17	81,0	16	94,1	62,50	33,05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	86,11	18,58
	1	1	50,0	1	100,0	100,00	-
	2 or More	17	81,0	15	88,2	64,44	23,46
Cycle 5 Day 1	None	14	100,0	14	100,0	79,76	25,47
	1	1	50,0	1	100,0	100,00	-
	2 or More	16	76,2	14	87,5	60,71	22,27
Cycle 6 Day 1	None	14	100,0	14	100,0	84,52	16,62
	1	1	50,0	1	100,0	100,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	60,71	29,68
Cycle 7 Day 1	None	14	100,0	13	92,9	82,05	23,04
	1	1	50,0	1	100,0	100,00	-
	2 or More	15	71,4	13	86,7	62,82	21,68
Cycle 8 Day 1	None	14	100,0	13	92,9	73,08	27,67
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	63,89	23,39
Cycle 9 Day 1	None	13	92,9	13	100,0	83,33	20,41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	83,33	-
	2 or More	11	52,4	11	100,0	66,67	27,89
Cycle 10 Day 1	None	13	92,9	12	92,3	81,94	19,41
	1	1	50,0	1	100,0	83,33	-
	2 or More	11	52,4	11	100,0	65,15	25,23
Cycle 11 Day 1	None	13	92,9	13	100,0	83,33	21,52
	1	1	50,0	1	100,0	100,00	-
	2 or More	10	47,6	10	100,0	61,67	19,33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	79,17	17,59
	1	1	50,0	1	100,0	83,33	-
	2 or More	10	47,6	8	80,0	58,33	30,86
Cycle 13 Day 1	None	12	85,7	11	91,7	84,85	18,94
	1	1	50,0	1	100,0	100,00	-
	2 or More	9	42,9	9	100,0	61,11	39,09
Cycle 14 Day 1	None	12	85,7	12	100,0	80,56	23,39
	1	1	50,0	1	100,0	83,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	55,56	27,64
Cycle 15 Day 1	None	12	85,7	12	100,0	86,11	21,12
	1	1	50,0	1	100,0	83,33	-
	2 or More	9	42,9	8	88,9	54,17	35,36
Cycle 16 Day 1	None	11	78,6	8	72,7	83,33	25,20
	1	1	50,0	1	100,0	83,33	-
	2 or More	9	42,9	6	66,7	58,33	29,34
Cycle 17 Day 1	None	10	71,4	7	70,0	90,48	16,27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	100,00	-
	2 or More	7	33,3	6	85,7	61,11	32,77
Cycle 18 Day 1	None	8	57,1	4	50,0	83,33	19,25
	1	1	50,0	1	100,0	100,00	-
	2 or More	6	28,6	3	50,0	50,00	28,87
Cycle 19 Day 1	None	7	50,0	3	42,9	88,89	19,25
	1	1	50,0	1	100,0	100,00	-
	2 or More	5	23,8	4	80,0	50,00	43,03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	91,67	16,67
	1	1	50,0	1	100,0	83,33	-
	2 or More	4	19,0	4	100,0	45,83	31,55
Cycle 21 Day 1	None	4	28,6	2	50,0	91,67	11,79
	2 or More	3	14,3	2	66,7	41,67	58,93
Cycle 22 Day 1	None	4	28,6	1	25,0	100,00	-
	2 or More	3	14,3	1	33,3	0,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	100,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	100,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	66,67	-
	1	2	100,0	1	50,0	66,67	-
	2 or More	9	42,9	3	33,3	33,33	16,67
Prior Treatment							

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	70,51	27,35
	Previously Treated	23	100,0	21	91,3	53,97	32,02
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	72,22	34,33
	Previously Treated	19	82,6	17	89,5	62,75	34,12
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	75,64	25,11
	Previously Treated	18	78,3	17	94,4	64,71	33,27
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	86,11	18,58
	Previously Treated	18	78,3	16	88,9	66,67	24,34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	79,76	25,47
	Previously Treated	17	73,9	15	88,2	63,33	23,74
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	84,52	16,62
	Previously Treated	17	73,9	15	88,2	63,33	30,34
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	82,05	23,04
	Previously Treated	16	69,6	14	87,5	65,48	23,08
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	73,08	27,67
	Previously Treated	14	60,9	12	85,7	63,89	23,39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	83,33	20,41
	Previously Treated	12	52,2	12	100,0	68,06	27,02
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	81,94	19,41
	Previously Treated	12	52,2	12	100,0	66,67	24,62
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	83,33	21,52
	Previously Treated	11	47,8	11	100,0	65,15	21,67
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	79,17	17,59
	Previously Treated	11	47,8	9	81,8	61,11	30,05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	84,85	18,94
	Previously Treated	10	43,5	10	100,0	65,00	38,85
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	80,56	23,39
	Previously Treated	10	43,5	10	100,0	58,33	27,50
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	86,11	21,12
	Previously Treated	10	43,5	9	90,0	57,41	34,47
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	83,33	25,20
	Previously Treated	10	43,5	7	70,0	61,90	28,41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	90,48	16,27
	Previously Treated	8	34,8	7	87,5	66,67	33,33
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	83,33	19,25
	Previously Treated	7	30,4	4	57,1	62,50	34,36
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	88,89	19,25
	Previously Treated	6	26,1	5	83,3	60,00	43,46
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	91,67	16,67
	Previously Treated	5	21,7	5	100,0	53,33	32,06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	91,67	11,79
	Previously Treated	3	13,0	2	66,7	41,67	58,93
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	100,00	-
	Previously Treated	3	13,0	1	33,3	0,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	100,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	100,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	66,67	-
	Previously Treated	11	47,8	4	36,4	41,67	21,52
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	66,67	30,98
	Central	25	100,0	22	88,0	56,82	31,14
Cycle 2 Day 1	Local	11	91,7	10	90,9	60,00	42,46
	Central	22	88,0	19	86,4	70,18	29,18

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	74,24	32,80
	Central	21	84,0	19	90,5	66,67	28,87
Cycle 4 Day 1	Local	11	91,7	10	90,9	83,33	17,57
	Central	21	84,0	18	85,7	70,37	25,92
Cycle 5 Day 1	Local	11	91,7	10	90,9	73,33	29,61
	Central	20	80,0	19	95,0	70,18	23,95
Cycle 6 Day 1	Local	11	91,7	11	100,0	84,85	22,92
	Central	20	80,0	18	90,0	66,67	26,81

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	75,76	22,81
	Central	19	76,0	16	84,2	71,88	25,62
Cycle 8 Day 1	Local	10	83,3	10	100,0	80,00	21,94
	Central	18	72,0	15	83,3	61,11	25,72
Cycle 9 Day 1	Local	10	83,3	10	100,0	78,33	33,38
	Central	15	60,0	15	100,0	74,44	17,67
Cycle 10 Day 1	Local	10	83,3	9	90,0	83,33	23,57
	Central	15	60,0	15	100,0	68,89	21,70

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	77,78	25,00
	Central	15	60,0	15	100,0	73,33	22,54
Cycle 12 Day 1	Local	9	75,0	8	88,9	81,25	24,30
	Central	15	60,0	13	86,7	65,38	24,02
Cycle 13 Day 1	Local	8	66,7	8	100,0	81,25	35,00
	Central	14	56,0	13	92,9	71,79	29,17
Cycle 14 Day 1	Local	8	66,7	8	100,0	77,08	34,43
	Central	14	56,0	14	100,0	66,67	22,65

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	83,33	35,63
	Central	14	56,0	13	92,9	67,95	26,75
Cycle 16 Day 1	Local	8	66,7	6	75,0	83,33	27,89
	Central	13	52,0	9	69,2	66,67	27,64
Cycle 17 Day 1	Local	8	66,7	5	62,5	86,67	18,26
	Central	10	40,0	9	90,0	74,07	32,39
Cycle 18 Day 1	Local	6	50,0	4	66,7	83,33	19,25
	Central	9	36,0	4	44,4	62,50	34,36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	75,00	31,91
	Central	8	32,0	4	50,0	66,67	47,14
Cycle 20 Day 1	Local	5	41,7	5	100,0	83,33	23,57
	Central	4	16,0	4	100,0	54,17	36,96
Cycle 21 Day 1	Local	4	33,3	2	50,0	91,67	11,79
	Central	3	12,0	2	66,7	41,67	58,93
Cycle 22 Day 1	Local	4	33,3	1	25,0	100,00	-
	Central	3	12,0	1	33,3	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	100,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	100,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	41,67	11,79
	Central	8	32,0	3	37,5	50,00	28,87
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	60,42	31,32
	No	2	100,0	2	100,0	58,33	35,36
Cycle 2 Day 1	Yes	32	91,4	28	87,5	68,45	33,13
	No	1	50,0	1	100,0	16,67	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	68,97	30,45
	No	1	50,0	1	100,0	83,33	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	75,31	24,18
	No	1	50,0	1	100,0	66,67	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	72,62	24,93
	No	1	50,0	1	100,0	33,33	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	73,81	27,00
	No	1	50,0	1	100,0	66,67	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	73,08	24,53
	No	1	50,0	1	100,0	83,33	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	70,14	25,05
	No	1	50,0	1	100,0	33,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	76,39	25,02
	No	1	50,0	1	100,0	66,67	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	74,64	23,50
	No	1	50,0	1	100,0	66,67	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	75,36	23,50
	No	1	50,0	1	100,0	66,67	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	71,67	25,42
	No	1	50,0	1	100,0	66,67	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	75,83	31,75
	No	1	50,0	1	100,0	66,67	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	70,63	27,84
	No	1	50,0	1	100,0	66,67	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	74,17	31,29
	No	1	50,0	1	100,0	66,67	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	73,81	29,03
	No	1	50,0	1	100,0	66,67	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	79,49	28,99
	No	1	50,0	1	100,0	66,67	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	73,81	30,21
	No	1	50,0	1	100,0	66,67	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	71,43	40,50
	No	1	50,0	1	100,0	66,67	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	70,83	34,21
	No	1	50,0	1	100,0	66,67	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	66,67	45,13
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	50,00	70,71
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	100,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	100,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	46,67	21,73

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	44,44	38,49
	No	33	100,0	31	93,9	61,83	30,49
Cycle 2 Day 1	Yes	2	50,0	1	50,0	100,00	-
	No	31	93,9	28	90,3	65,48	33,92
Cycle 3 Day 1	Yes	2	50,0	2	100,0	83,33	23,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	68,45	30,54
Cycle 4 Day 1	Yes	2	50,0	2	100,0	75,00	35,36
	No	30	90,9	26	86,7	75,00	23,69
Cycle 5 Day 1	Yes	2	50,0	2	100,0	83,33	23,57
	No	29	87,9	27	93,1	70,37	25,88
Cycle 6 Day 1	Yes	2	50,0	2	100,0	83,33	23,57
	No	29	87,9	27	93,1	72,84	27,01
Cycle 7 Day 1	Yes	2	50,0	2	100,0	83,33	23,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	72,67	24,48
Cycle 8 Day 1	Yes	2	50,0	2	100,0	33,33	0,00
	No	26	78,8	23	88,5	71,74	24,33
Cycle 9 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	24	72,7	24	100,0	76,39	25,02
Cycle 10 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	24	72,7	23	95,8	74,64	23,50
Cycle 11 Day 1	Yes	1	25,0	1	100,0	66,67	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	75,36	23,50
Cycle 12 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	23	69,7	20	87,0	71,67	25,42
Cycle 13 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	21	63,6	20	95,2	75,83	31,75
Cycle 14 Day 1	Yes	1	25,0	1	100,0	50,00	-
	No	21	63,6	21	100,0	71,43	27,46
Cycle 15 Day 1	Yes	1	25,0	1	100,0	50,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	75,00	30,83
Cycle 16 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	20	60,6	14	70,0	73,81	29,03
Cycle 17 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	17	51,5	13	76,5	79,49	28,99
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	72,92	28,08
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	70,83	37,53
Cycle 20 Day 1	No	9	27,3	9	100,0	70,37	32,03
Cycle 21 Day 1	No	7	21,2	4	57,1	66,67	45,13
Cycle 22 Day 1	No	7	21,2	2	28,6	50,00	70,71
Cycle 23 Day 1	No	4	12,1	1	25,0	100,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	100,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	16,67	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	54,17	15,96

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	63,24	31,19
Cycle 2 Day 1	All	33	89,2	29	87,9	71,84	27,85
Cycle 3 Day 1	All	32	86,5	30	93,8	72,22	27,80
Cycle 4 Day 1	All	32	86,5	28	87,5	80,95	26,34
Cycle 5 Day 1	All	31	83,8	29	93,5	74,71	28,74
Cycle 6 Day 1	All	31	83,8	29	93,5	79,31	24,26
Cycle 7 Day 1	All	30	81,1	27	90,0	75,93	28,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	76,00	28,09
Cycle 9 Day 1	All	25	67,6	25	100,0	80,00	20,97
Cycle 10 Day 1	All	25	67,6	24	96,0	79,17	22,12
Cycle 11 Day 1	All	24	64,9	24	100,0	80,56	22,88
Cycle 12 Day 1	All	24	64,9	21	87,5	76,19	28,17
Cycle 13 Day 1	All	22	59,5	21	95,5	76,98	30,04
Cycle 14 Day 1	All	22	59,5	22	100,0	75,76	34,78
Cycle 15 Day 1	All	22	59,5	21	95,5	75,40	29,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	75,56	30,12
Cycle 17 Day 1	All	18	48,6	14	77,8	80,95	27,62
Cycle 18 Day 1	All	15	40,5	8	53,3	75,00	34,50
Cycle 19 Day 1	All	13	35,1	8	61,5	70,83	37,53
Cycle 20 Day 1	All	9	24,3	9	100,0	74,07	36,43
Cycle 21 Day 1	All	7	18,9	4	57,1	66,67	47,14
Cycle 22 Day 1	All	7	18,9	2	28,6	50,00	70,71
Cycle 23 Day 1	All	4	10,8	1	25,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	100,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	56,67	22,36
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	61,54	29,96
	Female	23	100,0	21	91,3	64,29	32,61
Cycle 2 Day 1	Male	13	92,9	12	92,3	68,06	33,68
	Female	20	87,0	17	85,0	74,51	23,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	77,78	28,72
	Female	20	87,0	18	90,0	68,52	27,35
Cycle 4 Day 1	Male	12	85,7	11	91,7	96,97	10,05
	Female	20	87,0	17	85,0	70,59	28,58
Cycle 5 Day 1	Male	12	85,7	11	91,7	71,21	31,70
	Female	19	82,6	18	94,7	76,85	27,50
Cycle 6 Day 1	Male	12	85,7	11	91,7	81,82	24,10
	Female	19	82,6	18	94,7	77,78	24,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	83,33	26,87
	Female	19	82,6	16	84,2	70,83	29,50
Cycle 8 Day 1	Male	10	71,4	9	90,0	75,93	26,50
	Female	18	78,3	16	88,9	76,04	29,79
Cycle 9 Day 1	Male	8	57,1	8	100,0	83,33	23,57
	Female	17	73,9	17	100,0	78,43	20,21
Cycle 10 Day 1	Male	8	57,1	8	100,0	83,33	23,57
	Female	17	73,9	16	94,1	77,08	21,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	83,33	25,20
	Female	16	69,6	16	100,0	79,17	22,36
Cycle 12 Day 1	Male	8	57,1	8	100,0	85,42	24,30
	Female	16	69,6	13	81,3	70,51	29,78
Cycle 13 Day 1	Male	8	57,1	8	100,0	89,58	17,68
	Female	14	60,9	13	92,9	69,23	33,92
Cycle 14 Day 1	Male	8	57,1	8	100,0	83,33	35,63
	Female	14	60,9	14	100,0	71,43	34,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	85,42	24,30
	Female	14	60,9	13	92,9	69,23	31,07
Cycle 16 Day 1	Male	8	57,1	5	62,5	86,67	29,81
	Female	13	56,5	10	76,9	70,00	30,23
Cycle 17 Day 1	Male	6	42,9	2	33,3	100,00	0,00
	Female	12	52,2	12	100,0	77,78	28,72
Cycle 18 Day 1	Male	3	21,4	2	66,7	83,33	23,57
	Female	12	52,2	6	50,0	72,22	38,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	100,00	0,00
	Female	11	47,8	6	54,5	61,11	38,97
Cycle 20 Day 1	Male	2	14,3	2	100,0	100,00	0,00
	Female	7	30,4	7	100,0	66,67	38,49
Cycle 21 Day 1	Male	1	7,1	1	100,0	100,00	-
	Female	6	26,1	3	50,0	55,56	50,92
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	50,00	70,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	100,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	100,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	58,33	35,36
	Female	7	30,4	3	42,9	55,56	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	62,96	31,80
	65-74	8	100,0	7	87,5	64,29	31,07
Cycle 2 Day 1	18-64	27	93,1	24	88,9	72,92	29,41
	65-74	6	75,0	5	83,3	66,67	20,41
Cycle 3 Day 1	18-64	26	89,7	24	92,3	73,61	25,97
	65-74	6	75,0	6	100,0	66,67	36,51
Cycle 4 Day 1	18-64	26	89,7	23	88,5	79,71	27,96
	65-74	6	75,0	5	83,3	86,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	76,81	28,75
	65-74	6	75,0	6	100,0	66,67	29,81
Cycle 6 Day 1	18-64	25	86,2	24	96,0	80,56	23,91
	65-74	6	75,0	5	83,3	73,33	27,89
Cycle 7 Day 1	18-64	25	86,2	23	92,0	76,09	28,79
	65-74	5	62,5	4	80,0	75,00	31,91
Cycle 8 Day 1	18-64	23	79,3	20	87,0	74,17	29,85
	65-74	5	62,5	5	100,0	83,33	20,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	82,50	19,85
	65-74	5	62,5	5	100,0	70,00	24,72
Cycle 10 Day 1	18-64	20	69,0	19	95,0	80,70	21,70
	65-74	5	62,5	5	100,0	73,33	25,28
Cycle 11 Day 1	18-64	19	65,5	19	100,0	79,82	24,58
	65-74	5	62,5	5	100,0	83,33	16,67
Cycle 12 Day 1	18-64	19	65,5	17	89,5	76,47	28,30
	65-74	5	62,5	4	80,0	75,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	80,21	27,36
	65-74	5	62,5	5	100,0	66,67	39,09
Cycle 14 Day 1	18-64	17	58,6	17	100,0	78,43	33,73
	65-74	5	62,5	5	100,0	66,67	40,82
Cycle 15 Day 1	18-64	17	58,6	16	94,1	77,08	28,46
	65-74	5	62,5	5	100,0	70,00	34,16
Cycle 16 Day 1	18-64	17	58,6	13	76,5	74,36	31,63
	65-74	4	50,0	2	50,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	81,94	29,69
	65-74	3	37,5	2	66,7	75,00	11,79
Cycle 18 Day 1	18-64	13	44,8	8	61,5	75,00	34,50
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	76,19	37,09
	65-74	2	25,0	1	50,0	33,33	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	79,17	35,36
	65-74	1	12,5	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	66,67	47,14
Cycle 22 Day 1	18-64	7	24,1	2	28,6	50,00	70,71
Cycle 23 Day 1	18-64	4	13,8	1	25,0	100,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	100,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	61,11	25,46
	65-74	6	75,0	2	33,3	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	60,78	33,30
	Other	17	100,0	17	100,0	65,69	29,74
Cycle 2 Day 1	White	19	95,0	16	84,2	66,67	32,20
	Other	14	82,4	13	92,9	78,21	20,84
Cycle 3 Day 1	White	18	90,0	16	88,9	64,58	31,55
	Other	14	82,4	14	100,0	80,95	20,52
Cycle 4 Day 1	White	18	90,0	15	83,3	77,78	29,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	84,62	22,01
Cycle 5 Day 1	White	18	90,0	17	94,4	70,59	31,47
	Other	13	76,5	12	92,3	80,56	24,45
Cycle 6 Day 1	White	18	90,0	16	88,9	80,21	24,51
	Other	13	76,5	13	100,0	78,21	24,89
Cycle 7 Day 1	White	17	85,0	15	88,2	76,67	32,00
	Other	13	76,5	12	92,3	75,00	25,13
Cycle 8 Day 1	White	17	85,0	14	82,4	76,19	30,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	75,76	26,21
Cycle 9 Day 1	White	16	80,0	16	100,0	82,29	21,49
	Other	9	52,9	9	100,0	75,93	20,60
Cycle 10 Day 1	White	16	80,0	15	93,8	80,00	22,89
	Other	9	52,9	9	100,0	77,78	22,05
Cycle 11 Day 1	White	16	80,0	16	100,0	84,38	19,69
	Other	8	47,1	8	100,0	72,92	28,08
Cycle 12 Day 1	White	16	80,0	13	81,3	75,64	30,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	77,08	26,63
Cycle 13 Day 1	White	14	70,0	13	92,9	75,64	35,76
	Other	8	47,1	8	100,0	79,17	19,42
Cycle 14 Day 1	White	14	70,0	14	100,0	77,38	35,57
	Other	8	47,1	8	100,0	72,92	35,57
Cycle 15 Day 1	White	14	70,0	13	92,9	73,08	32,30
	Other	8	47,1	8	100,0	79,17	24,80
Cycle 16 Day 1	White	14	70,0	9	64,3	75,93	32,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	75,00	29,34
Cycle 17 Day 1	White	13	65,0	10	76,9	81,67	31,87
	Other	5	29,4	4	80,0	79,17	15,96
Cycle 18 Day 1	White	11	55,0	4	36,4	66,67	47,14
	Other	4	23,5	4	100,0	83,33	19,25
Cycle 19 Day 1	White	9	45,0	5	55,6	66,67	47,14
	Other	4	23,5	3	75,0	77,78	19,25
Cycle 20 Day 1	White	5	25,0	5	100,0	66,67	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	83,33	19,25
Cycle 21 Day 1	White	3	15,0	2	66,7	50,00	70,71
	Other	4	23,5	2	50,0	83,33	23,57
Cycle 22 Day 1	White	3	15,0	1	33,3	0,00	-
	Other	4	23,5	1	25,0	100,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	100,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	61,11	25,46
	Other	9	52,9	2	22,2	50,00	23,57
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	69,44	28,28
	Europe (EU)	10	100,0	8	80,0	50,00	35,63
	Asia (AS)	15	100,0	14	93,3	65,48	30,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	74,07	29,00
	Europe (EU)	9	90,0	8	88,9	60,42	33,26
	Asia (AS)	13	86,7	12	92,3	77,78	22,84
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	75,76	31,06
	Europe (EU)	8	80,0	6	75,0	50,00	27,89
	Asia (AS)	13	86,7	13	100,0	79,49	20,59
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	84,85	22,92
	Europe (EU)	8	80,0	4	50,0	58,33	41,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	84,62	22,01
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	81,82	24,10
	Europe (EU)	8	80,0	7	87,5	54,76	39,34
	Asia (AS)	12	80,0	11	91,7	80,30	20,84
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	90,91	13,67
	Europe (EU)	8	80,0	7	87,5	59,52	30,21
	Asia (AS)	12	80,0	11	91,7	80,30	22,13
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	90,00	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	54,76	39,34
	Asia (AS)	11	73,3	10	90,9	76,67	17,92
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	90,00	21,08
	Europe (EU)	8	80,0	6	75,0	55,56	31,03
	Asia (AS)	9	60,0	9	100,0	74,07	26,50
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	84,85	17,41
	Europe (EU)	7	70,0	7	100,0	69,05	27,94
	Asia (AS)	7	46,7	7	100,0	83,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	85,00	19,95
	Europe (EU)	7	70,0	7	100,0	69,05	27,94
	Asia (AS)	7	46,7	7	100,0	80,95	17,82
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	83,33	21,08
	Europe (EU)	7	70,0	7	100,0	78,57	24,93
	Asia (AS)	6	40,0	6	100,0	77,78	27,22
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	83,33	31,43
	Europe (EU)	7	70,0	5	71,4	56,67	22,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	80,56	22,15
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	81,67	30,88
	Europe (EU)	6	60,0	5	83,3	60,00	38,37
	Asia (AS)	6	40,0	6	100,0	83,33	18,26
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	85,00	31,87
	Europe (EU)	6	60,0	6	100,0	55,56	45,54
	Asia (AS)	6	40,0	6	100,0	80,56	22,15
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	83,33	31,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	56,67	32,49
	Asia (AS)	6	40,0	6	100,0	77,78	17,21
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	83,33	37,27
	Europe (EU)	6	60,0	2	33,3	50,00	23,57
	Asia (AS)	6	40,0	6	100,0	75,00	20,41
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	80,56	40,02
	Europe (EU)	4	40,0	3	75,0	83,33	16,67
	Asia (AS)	5	33,3	5	100,0	80,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	73,33	43,46
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	77,78	19,25
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	75,00	50,00
	Europe (EU)	3	30,0	1	33,3	33,33	-
	Asia (AS)	4	26,7	3	75,0	77,78	19,25
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	80,00	44,72
	Europe (EU)	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	77,78	19,25
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	66,67	57,74
	Asia (AS)	3	20,0	1	33,3	66,67	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	50,00	70,71
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	100,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	72,22	9,62
	Europe (EU)	2	20,0	1	50,0	33,33	-
	Asia (AS)	7	46,7	1	14,3	33,33	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	77,78	20,52
	1	17	100,0	17	100,0	57,84	32,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	46,67	38,01
Cycle 2 Day 1	0	15	100,0	12	80,0	76,39	27,02
	1	15	88,2	14	93,3	69,05	29,13
	2	3	60,0	3	100,0	66,67	33,33
Cycle 3 Day 1	0	15	100,0	14	93,3	69,05	33,88
	1	14	82,4	13	92,9	82,05	15,90
	2	3	60,0	3	100,0	44,44	19,25
Cycle 4 Day 1	0	15	100,0	14	93,3	85,71	21,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	86,11	17,16
	2	3	60,0	2	66,7	16,67	23,57
Cycle 5 Day 1	0	15	100,0	15	100,0	74,44	24,29
	1	14	82,4	12	85,7	79,17	27,64
	2	2	40,0	2	100,0	50,00	70,71
Cycle 6 Day 1	0	15	100,0	15	100,0	80,00	22,00
	1	14	82,4	12	85,7	80,56	25,46
	2	2	40,0	2	100,0	66,67	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	79,76	24,62
	1	13	76,5	11	84,6	75,76	26,21
	2	2	40,0	2	100,0	50,00	70,71
Cycle 8 Day 1	0	15	100,0	13	86,7	78,21	22,96
	1	11	64,7	10	90,9	80,00	26,99
	2	2	40,0	2	100,0	41,67	58,93
Cycle 9 Day 1	0	14	93,3	14	100,0	78,57	21,11
	1	10	58,8	10	100,0	80,00	21,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	100,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	79,76	23,73
	1	10	58,8	9	90,0	75,93	20,60
	2	1	20,0	1	100,0	100,00	-
Cycle 11 Day 1	0	14	93,3	14	100,0	80,95	20,52
	1	9	52,9	9	100,0	77,78	27,64
	2	1	20,0	1	100,0	100,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	76,39	32,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	75,00	25,20
	2	1	20,0	1	100,0	83,33	-
Cycle 13 Day 1	0	14	93,3	13	92,9	75,64	35,76
	1	8	47,1	8	100,0	79,17	19,42
Cycle 14 Day 1	0	14	93,3	14	100,0	76,19	35,63
	1	8	47,1	8	100,0	75,00	35,63
Cycle 15 Day 1	0	14	93,3	14	100,0	76,19	32,50
	1	8	47,1	7	87,5	73,81	23,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	79,17	35,36
	1	8	47,1	7	87,5	71,43	24,93
Cycle 17 Day 1	0	12	80,0	8	66,7	75,00	33,33
	1	6	35,3	6	100,0	88,89	17,21
Cycle 18 Day 1	0	9	60,0	4	44,4	66,67	47,14
	1	6	35,3	4	66,7	83,33	19,25
Cycle 19 Day 1	0	8	53,3	4	50,0	58,33	50,00
	1	5	29,4	4	80,0	83,33	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	66,67	47,14
	1	4	23,5	4	100,0	83,33	19,25
Cycle 21 Day 1	0	3	20,0	3	100,0	66,67	57,74
	1	4	23,5	1	25,0	66,67	-
Cycle 22 Day 1	0	3	20,0	2	66,7	50,00	70,71
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	100,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	100,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	61,11	25,46
	1	7	41,2	2	28,6	50,00	23,57
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	74,36	22,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	66,67	47,14
	2 or More	21	100,0	19	90,5	55,26	34,27
Cycle 2 Day 1	None	14	100,0	12	85,7	80,56	25,46
	1	1	50,0	1	100,0	100,00	-
	2 or More	18	85,7	16	88,9	63,54	28,03
Cycle 3 Day 1	None	14	100,0	13	92,9	78,21	28,37
	1	1	50,0	1	100,0	100,00	-
	2 or More	17	81,0	16	94,1	65,63	26,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	91,67	15,08
	1	1	50,0	1	100,0	100,00	-
	2 or More	17	81,0	15	88,2	71,11	30,52
Cycle 5 Day 1	None	14	100,0	14	100,0	79,76	27,87
	1	1	50,0	1	100,0	100,00	-
	2 or More	16	76,2	14	87,5	67,86	29,57
Cycle 6 Day 1	None	14	100,0	14	100,0	88,10	20,07
	1	1	50,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	69,05	25,20
Cycle 7 Day 1	None	14	100,0	13	92,9	85,90	24,39
	1	1	50,0	1	100,0	100,00	-
	2 or More	15	71,4	13	86,7	64,10	29,54
Cycle 8 Day 1	None	14	100,0	13	92,9	80,77	23,42
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	70,83	32,66
Cycle 9 Day 1	None	13	92,9	13	100,0	83,33	20,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	100,00	-
	2 or More	11	52,4	11	100,0	74,24	21,56
Cycle 10 Day 1	None	13	92,9	12	92,3	83,33	20,10
	1	1	50,0	1	100,0	100,00	-
	2 or More	11	52,4	11	100,0	72,73	23,89
Cycle 11 Day 1	None	13	92,9	13	100,0	82,05	20,93
	1	1	50,0	1	100,0	100,00	-
	2 or More	10	47,6	10	100,0	76,67	26,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	80,56	22,29
	1	1	50,0	1	100,0	100,00	-
	2 or More	10	47,6	8	80,0	66,67	35,63
Cycle 13 Day 1	None	12	85,7	11	91,7	81,82	17,41
	1	1	50,0	1	100,0	100,00	-
	2 or More	9	42,9	9	100,0	68,52	41,20
Cycle 14 Day 1	None	12	85,7	12	100,0	81,94	29,69
	1	1	50,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	64,81	41,20
Cycle 15 Day 1	None	12	85,7	12	100,0	83,33	21,32
	1	1	50,0	1	100,0	100,00	-
	2 or More	9	42,9	8	88,9	60,42	35,57
Cycle 16 Day 1	None	11	78,6	8	72,7	81,25	24,30
	1	1	50,0	1	100,0	100,00	-
	2 or More	9	42,9	6	66,7	63,89	37,14
Cycle 17 Day 1	None	10	71,4	7	70,0	88,10	15,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	100,00	-
	2 or More	7	33,3	6	85,7	69,44	37,14
Cycle 18 Day 1	None	8	57,1	4	50,0	83,33	19,25
	1	1	50,0	1	100,0	100,00	-
	2 or More	6	28,6	3	50,0	55,56	50,92
Cycle 19 Day 1	None	7	50,0	3	42,9	88,89	19,25
	1	1	50,0	1	100,0	100,00	-
	2 or More	5	23,8	4	80,0	50,00	43,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	91,67	16,67
	1	1	50,0	1	100,0	100,00	-
	2 or More	4	19,0	4	100,0	50,00	43,03
Cycle 21 Day 1	None	4	28,6	2	50,0	100,00	0,00
	2 or More	3	14,3	2	66,7	33,33	47,14
Cycle 22 Day 1	None	4	28,6	1	25,0	100,00	-
	2 or More	3	14,3	1	33,3	0,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	100,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	66,67	-
	1	2	100,0	1	50,0	83,33	-
	2 or More	9	42,9	3	33,3	44,44	19,25
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	74,36	22,17
	Previously Treated	23	100,0	21	91,3	56,35	34,35
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	80,56	25,46
	Previously Treated	19	82,6	17	89,5	65,69	28,55
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	78,21	28,37
	Previously Treated	18	78,3	17	94,4	67,65	27,30
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	91,67	15,08
	Previously Treated	18	78,3	16	88,9	72,92	30,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	79,76	27,87
	Previously Treated	17	73,9	15	88,2	70,00	29,68
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	88,10	20,07
	Previously Treated	17	73,9	15	88,2	71,11	25,56
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	85,90	24,39
	Previously Treated	16	69,6	14	87,5	66,67	29,96
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	80,77	23,42
	Previously Treated	14	60,9	12	85,7	70,83	32,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	83,33	20,41
	Previously Treated	12	52,2	12	100,0	76,39	21,86
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	83,33	20,10
	Previously Treated	12	52,2	12	100,0	75,00	24,10
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	82,05	20,93
	Previously Treated	11	47,8	11	100,0	78,79	25,92
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	80,56	22,29
	Previously Treated	11	47,8	9	81,8	70,37	35,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	81,82	17,41
	Previously Treated	10	43,5	10	100,0	71,67	40,10
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	81,94	29,69
	Previously Treated	10	43,5	10	100,0	68,33	40,41
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	83,33	21,32
	Previously Treated	10	43,5	9	90,0	64,81	35,79
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	81,25	24,30
	Previously Treated	10	43,5	7	70,0	69,05	36,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	88,10	15,85
	Previously Treated	8	34,8	7	87,5	73,81	35,82
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	83,33	19,25
	Previously Treated	7	30,4	4	57,1	66,67	47,14
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	88,89	19,25
	Previously Treated	6	26,1	5	83,3	60,00	43,46
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	91,67	16,67
	Previously Treated	5	21,7	5	100,0	60,00	43,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	100,00	0,00
	Previously Treated	3	13,0	2	66,7	33,33	47,14
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	100,00	-
	Previously Treated	3	13,0	1	33,3	0,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	100,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	100,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	66,67	-
	Previously Treated	11	47,8	4	36,4	54,17	25,00
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	58,33	34,45
	Central	25	100,0	22	88,0	65,91	29,76
Cycle 2 Day 1	Local	11	91,7	10	90,9	68,33	26,59
	Central	22	88,0	19	86,4	73,68	29,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	72,73	38,20
	Central	21	84,0	19	90,5	71,93	20,83
Cycle 4 Day 1	Local	11	91,7	10	90,9	93,33	14,05
	Central	21	84,0	18	85,7	74,07	29,27
Cycle 5 Day 1	Local	11	91,7	10	90,9	76,67	26,29
	Central	20	80,0	19	95,0	73,68	30,59
Cycle 6 Day 1	Local	11	91,7	11	100,0	87,88	21,20
	Central	20	80,0	18	90,0	74,07	25,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	83,33	22,36
	Central	19	76,0	16	84,2	70,83	31,91
Cycle 8 Day 1	Local	10	83,3	10	100,0	85,00	21,44
	Central	18	72,0	15	83,3	70,00	30,99
Cycle 9 Day 1	Local	10	83,3	10	100,0	80,00	20,49
	Central	15	60,0	15	100,0	80,00	22,00
Cycle 10 Day 1	Local	10	83,3	9	90,0	79,63	21,70
	Central	15	60,0	15	100,0	78,89	23,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	85,19	15,47
	Central	15	60,0	15	100,0	77,78	26,48
Cycle 12 Day 1	Local	9	75,0	8	88,9	83,33	26,73
	Central	15	60,0	13	86,7	71,79	29,17
Cycle 13 Day 1	Local	8	66,7	8	100,0	79,17	34,21
	Central	14	56,0	13	92,9	75,64	28,56
Cycle 14 Day 1	Local	8	66,7	8	100,0	83,33	35,63
	Central	14	56,0	14	100,0	71,43	34,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	83,33	29,55
	Central	14	56,0	13	92,9	70,51	28,99
Cycle 16 Day 1	Local	8	66,7	6	75,0	88,89	17,21
	Central	13	52,0	9	69,2	66,67	34,36
Cycle 17 Day 1	Local	8	66,7	5	62,5	83,33	16,67
	Central	10	40,0	9	90,0	79,63	33,10
Cycle 18 Day 1	Local	6	50,0	4	66,7	83,33	19,25
	Central	9	36,0	4	44,4	66,67	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	75,00	31,91
	Central	8	32,0	4	50,0	66,67	47,14
Cycle 20 Day 1	Local	5	41,7	5	100,0	80,00	29,81
	Central	4	16,0	4	100,0	66,67	47,14
Cycle 21 Day 1	Local	4	33,3	2	50,0	100,00	0,00
	Central	3	12,0	2	66,7	33,33	47,14
Cycle 22 Day 1	Local	4	33,3	1	25,0	100,00	-
	Central	3	12,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	100,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	100,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	50,00	23,57
	Central	8	32,0	3	37,5	61,11	25,46

BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	63,02	31,03
	No	2	100,0	2	100,0	66,67	47,14
Cycle 2 Day 1	Yes	32	91,4	28	87,5	71,43	28,28
	No	1	50,0	1	100,0	83,33	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	71,26	27,78
	No	1	50,0	1	100,0	100,00	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	80,25	26,57
	No	1	50,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	75,00	29,22
	No	1	50,0	1	100,0	66,67	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	78,57	24,37
	No	1	50,0	1	100,0	100,00	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	76,28	29,13
	No	1	50,0	1	100,0	66,67	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	77,08	28,15
	No	1	50,0	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	80,56	21,23
	No	1	50,0	1	100,0	66,67	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	79,71	22,45
	No	1	50,0	1	100,0	66,67	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	81,16	23,19
	No	1	50,0	1	100,0	66,67	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	77,50	28,24
	No	1	50,0	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	77,50	30,72
	No	1	50,0	1	100,0	66,67	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	76,19	35,58
	No	1	50,0	1	100,0	66,67	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	75,83	29,85
	No	1	50,0	1	100,0	66,67	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	76,19	31,16
	No	1	50,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	82,05	28,43
	No	1	50,0	1	100,0	66,67	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	76,19	37,09
	No	1	50,0	1	100,0	66,67	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	71,43	40,50
	No	1	50,0	1	100,0	66,67	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	75,00	38,83
	No	1	50,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	66,67	47,14
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	50,00	70,71
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	100,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	100,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	56,67	22,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	66,67	0,00
	No	33	100,0	31	93,9	62,90	32,69
Cycle 2 Day 1	Yes	2	50,0	1	50,0	100,00	-
	No	31	93,9	28	90,3	70,83	27,82
Cycle 3 Day 1	Yes	2	50,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	71,43	28,28
Cycle 4 Day 1	Yes	2	50,0	2	100,0	83,33	23,57
	No	30	90,9	26	86,7	80,77	26,95
Cycle 5 Day 1	Yes	2	50,0	2	100,0	83,33	23,57
	No	29	87,9	27	93,1	74,07	29,36
Cycle 6 Day 1	Yes	2	50,0	2	100,0	83,33	23,57
	No	29	87,9	27	93,1	79,01	24,72
Cycle 7 Day 1	Yes	2	50,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	75,33	29,31
Cycle 8 Day 1	Yes	2	50,0	2	100,0	50,00	23,57
	No	26	78,8	23	88,5	78,26	27,72
Cycle 9 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	24	72,7	24	100,0	80,56	21,23
Cycle 10 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	24	72,7	23	95,8	79,71	22,45
Cycle 11 Day 1	Yes	1	25,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	81,16	23,19
Cycle 12 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	23	69,7	20	87,0	76,67	28,82
Cycle 13 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	21	63,6	20	95,2	77,50	30,72
Cycle 14 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	21	63,6	21	100,0	76,19	35,58
Cycle 15 Day 1	Yes	1	25,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	75,83	29,85
Cycle 16 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	20	60,6	14	70,0	76,19	31,16
Cycle 17 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	17	51,5	13	76,5	82,05	28,43
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	75,00	34,50
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	70,83	37,53
Cycle 20 Day 1	No	9	27,3	9	100,0	74,07	36,43
Cycle 21 Day 1	No	7	21,2	4	57,1	66,67	47,14
Cycle 22 Day 1	No	7	21,2	2	28,6	50,00	70,71
Cycle 23 Day 1	No	4	12,1	1	25,0	100,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	100,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	62,50	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SF_SG.xls
07SEP2019 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	34	91,9	39,22	28,98
Cycle 2 Day 1	All	33	89,2	29	87,9	14,94	19,08
Cycle 3 Day 1	All	32	86,5	30	93,8	11,11	20,22
Cycle 4 Day 1	All	32	86,5	28	87,5	11,90	22,62
Cycle 5 Day 1	All	31	83,8	29	93,5	11,49	20,46
Cycle 6 Day 1	All	31	83,8	29	93,5	16,09	21,12
Cycle 7 Day 1	All	30	81,1	27	90,0	7,41	16,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	18,67	25,60
Cycle 9 Day 1	All	25	67,6	25	100,0	14,67	21,69
Cycle 10 Day 1	All	25	67,6	24	96,0	13,89	19,45
Cycle 11 Day 1	All	24	64,9	24	100,0	11,11	18,82
Cycle 12 Day 1	All	24	64,9	21	87,5	12,70	19,65
Cycle 13 Day 1	All	22	59,5	21	95,5	15,87	29,10
Cycle 14 Day 1	All	22	59,5	22	100,0	18,18	30,39
Cycle 15 Day 1	All	22	59,5	21	95,5	19,05	24,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	13,33	21,08
Cycle 17 Day 1	All	18	48,6	14	77,8	7,14	14,19
Cycle 18 Day 1	All	15	40,5	8	53,3	12,50	17,25
Cycle 19 Day 1	All	13	35,1	8	61,5	20,83	30,54
Cycle 20 Day 1	All	9	24,3	9	100,0	14,81	24,22
Cycle 21 Day 1	All	7	18,9	4	57,1	16,67	19,25
Cycle 22 Day 1	All	7	18,9	2	28,6	50,00	70,71
Cycle 23 Day 1	All	4	10,8	1	25,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	0,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	53,33	29,81
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	35,90	25,32
	Female	23	100,0	21	91,3	41,27	31,46
Cycle 2 Day 1	Male	13	92,9	12	92,3	13,89	17,16
	Female	20	87,0	17	85,0	15,69	20,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	8,33	20,72
	Female	20	87,0	18	90,0	12,96	20,26
Cycle 4 Day 1	Male	12	85,7	11	91,7	9,09	21,56
	Female	20	87,0	17	85,0	13,73	23,74
Cycle 5 Day 1	Male	12	85,7	11	91,7	9,09	15,57
	Female	19	82,6	18	94,7	12,96	23,26
Cycle 6 Day 1	Male	12	85,7	11	91,7	15,15	22,92
	Female	19	82,6	18	94,7	16,67	20,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	6,06	13,48
	Female	19	82,6	16	84,2	8,33	19,25
Cycle 8 Day 1	Male	10	71,4	9	90,0	18,52	33,79
	Female	18	78,3	16	88,9	18,75	20,97
Cycle 9 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	17	73,9	17	100,0	19,61	23,74
Cycle 10 Day 1	Male	8	57,1	8	100,0	8,33	15,43
	Female	17	73,9	16	94,1	16,67	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	16	69,6	16	100,0	14,58	20,97
Cycle 12 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	16	69,6	13	81,3	17,95	22,01
Cycle 13 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	14	60,9	13	92,9	23,08	34,39
Cycle 14 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	14	60,9	14	100,0	26,19	35,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	14	60,9	13	92,9	28,21	26,69
Cycle 16 Day 1	Male	8	57,1	5	62,5	6,67	14,91
	Female	13	56,5	10	76,9	16,67	23,57
Cycle 17 Day 1	Male	6	42,9	2	33,3	0,00	0,00
	Female	12	52,2	12	100,0	8,33	15,08
Cycle 18 Day 1	Male	3	21,4	2	66,7	0,00	0,00
	Female	12	52,2	6	50,0	16,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	11	47,8	6	54,5	27,78	32,77
Cycle 20 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	7	30,4	7	100,0	19,05	26,23
Cycle 21 Day 1	Male	1	7,1	1	100,0	0,00	-
	Female	6	26,1	3	50,0	22,22	19,25
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	50,00	70,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	0,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	0,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	66,67	47,14
	Female	7	30,4	3	42,9	44,44	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	27	93,1	38,27	31,63
	65-74	8	100,0	7	87,5	42,86	16,27
Cycle 2 Day 1	18-64	27	93,1	24	88,9	12,50	16,48
	65-74	6	75,0	5	83,3	26,67	27,89
Cycle 3 Day 1	18-64	26	89,7	24	92,3	9,72	18,33
	65-74	6	75,0	6	100,0	16,67	27,89
Cycle 4 Day 1	18-64	26	89,7	23	88,5	13,04	24,08
	65-74	6	75,0	5	83,3	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	10,14	18,63
	65-74	6	75,0	6	100,0	16,67	27,89
Cycle 6 Day 1	18-64	25	86,2	24	96,0	16,67	21,98
	65-74	6	75,0	5	83,3	13,33	18,26
Cycle 7 Day 1	18-64	25	86,2	23	92,0	7,25	17,28
	65-74	5	62,5	4	80,0	8,33	16,67
Cycle 8 Day 1	18-64	23	79,3	20	87,0	18,33	27,52
	65-74	5	62,5	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	11,67	19,57
	65-74	5	62,5	5	100,0	26,67	27,89
Cycle 10 Day 1	18-64	20	69,0	19	95,0	10,53	15,92
	65-74	5	62,5	5	100,0	26,67	27,89
Cycle 11 Day 1	18-64	19	65,5	19	100,0	10,53	19,41
	65-74	5	62,5	5	100,0	13,33	18,26
Cycle 12 Day 1	18-64	19	65,5	17	89,5	9,80	19,60
	65-74	5	62,5	4	80,0	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	10,42	23,47
	65-74	5	62,5	5	100,0	33,33	40,82
Cycle 14 Day 1	18-64	17	58,6	17	100,0	15,69	26,66
	65-74	5	62,5	5	100,0	26,67	43,46
Cycle 15 Day 1	18-64	17	58,6	16	94,1	16,67	21,08
	65-74	5	62,5	5	100,0	26,67	36,51
Cycle 16 Day 1	18-64	17	58,6	13	76,5	12,82	21,68
	65-74	4	50,0	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	5,56	12,97
	65-74	3	37,5	2	66,7	16,67	23,57
Cycle 18 Day 1	18-64	13	44,8	8	61,5	12,50	17,25
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	14,29	26,23
	65-74	2	25,0	1	50,0	66,67	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	8,33	15,43
	65-74	1	12,5	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	16,67	19,25
Cycle 22 Day 1	18-64	7	24,1	2	28,6	50,00	70,71
Cycle 23 Day 1	18-64	4	13,8	1	25,0	0,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	0,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	66,67	33,33
	65-74	6	75,0	2	33,3	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	17	85,0	37,25	33,09
	Other	17	100,0	17	100,0	41,18	25,08
Cycle 2 Day 1	White	19	95,0	16	84,2	14,58	20,97
	Other	14	82,4	13	92,9	15,38	17,30
Cycle 3 Day 1	White	18	90,0	16	88,9	12,50	23,96
	Other	14	82,4	14	100,0	9,52	15,63
Cycle 4 Day 1	White	18	90,0	15	83,3	13,33	27,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	10,26	16,01
Cycle 5 Day 1	White	18	90,0	17	94,4	15,69	23,91
	Other	13	76,5	12	92,3	5,56	12,97
Cycle 6 Day 1	White	18	90,0	16	88,9	16,67	24,34
	Other	13	76,5	13	100,0	15,38	17,30
Cycle 7 Day 1	White	17	85,0	15	88,2	11,11	20,57
	Other	13	76,5	12	92,3	2,78	9,62
Cycle 8 Day 1	White	17	85,0	14	82,4	19,05	21,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	18,18	31,14
Cycle 9 Day 1	White	16	80,0	16	100,0	14,58	24,25
	Other	9	52,9	9	100,0	14,81	17,57
Cycle 10 Day 1	White	16	80,0	15	93,8	8,89	19,79
	Other	9	52,9	9	100,0	22,22	16,67
Cycle 11 Day 1	White	16	80,0	16	100,0	12,50	20,64
	Other	8	47,1	8	100,0	8,33	15,43
Cycle 12 Day 1	White	16	80,0	13	81,3	10,26	21,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	16,67	17,82
Cycle 13 Day 1	White	14	70,0	13	92,9	17,95	35,00
	Other	8	47,1	8	100,0	12,50	17,25
Cycle 14 Day 1	White	14	70,0	14	100,0	21,43	36,06
	Other	8	47,1	8	100,0	12,50	17,25
Cycle 15 Day 1	White	14	70,0	13	92,9	15,38	22,01
	Other	8	47,1	8	100,0	25,00	29,55
Cycle 16 Day 1	White	14	70,0	9	64,3	11,11	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	16,67	18,26
Cycle 17 Day 1	White	13	65,0	10	76,9	6,67	14,05
	Other	5	29,4	4	80,0	8,33	16,67
Cycle 18 Day 1	White	11	55,0	4	36,4	16,67	19,25
	Other	4	23,5	4	100,0	8,33	16,67
Cycle 19 Day 1	White	9	45,0	5	55,6	26,67	36,51
	Other	4	23,5	3	75,0	11,11	19,25
Cycle 20 Day 1	White	5	25,0	5	100,0	20,00	29,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	8,33	16,67
Cycle 21 Day 1	White	3	15,0	2	66,7	16,67	23,57
	Other	4	23,5	2	50,0	16,67	23,57
Cycle 22 Day 1	White	3	15,0	1	33,3	100,00	-
	Other	4	23,5	1	25,0	0,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	0,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	44,44	19,25
	Other	9	52,9	2	22,2	66,67	47,14
Region							
Cycle 1 Day 1	America (AM)	12	100,0	12	100,0	33,33	31,78
	Europe (EU)	10	100,0	8	80,0	54,17	24,80
	Asia (AS)	15	100,0	14	93,3	35,71	27,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	11,11	16,67
	Europe (EU)	9	90,0	8	88,9	25,00	23,57
	Asia (AS)	13	86,7	12	92,3	11,11	16,41
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	6,06	13,48
	Europe (EU)	8	80,0	6	75,0	27,78	32,77
	Asia (AS)	13	86,7	13	100,0	7,69	14,62
Cycle 4 Day 1	America (AM)	11	91,7	11	100,0	9,09	21,56
	Europe (EU)	8	80,0	4	50,0	33,33	38,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	7,69	14,62
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	12,12	22,47
	Europe (EU)	8	80,0	7	87,5	19,05	26,23
	Asia (AS)	12	80,0	11	91,7	6,06	13,48
Cycle 6 Day 1	America (AM)	11	91,7	11	100,0	15,15	22,92
	Europe (EU)	8	80,0	7	87,5	23,81	25,20
	Asia (AS)	12	80,0	11	91,7	12,12	16,82
Cycle 7 Day 1	America (AM)	11	91,7	10	90,9	6,67	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	14,29	17,82
	Asia (AS)	11	73,3	10	90,9	3,33	10,54
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	13,33	23,31
	Europe (EU)	8	80,0	6	75,0	22,22	17,21
	Asia (AS)	9	60,0	9	100,0	22,22	33,33
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	21,21	22,47
	Europe (EU)	7	70,0	7	100,0	14,29	26,23
	Asia (AS)	7	46,7	7	100,0	4,76	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	13,33	17,21
	Europe (EU)	7	70,0	7	100,0	14,29	26,23
	Asia (AS)	7	46,7	7	100,0	14,29	17,82
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	12,12	22,47
	Europe (EU)	7	70,0	7	100,0	9,52	16,27
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	13,33	23,31
	Europe (EU)	7	70,0	5	71,4	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	16,67	18,26
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	13,33	23,31
	Europe (EU)	6	60,0	5	83,3	20,00	44,72
	Asia (AS)	6	40,0	6	100,0	16,67	27,89
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	16,67	32,39
	Europe (EU)	6	60,0	6	100,0	22,22	40,37
	Asia (AS)	6	40,0	6	100,0	16,67	18,26
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	10,00	22,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	20,00	29,81
	Asia (AS)	6	40,0	6	100,0	33,33	21,08
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	0,00	0,00
	Europe (EU)	6	60,0	2	33,3	33,33	0,00
	Asia (AS)	6	40,0	6	100,0	22,22	27,22
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	5,56	13,61
	Europe (EU)	4	40,0	3	75,0	11,11	19,25
	Asia (AS)	5	33,3	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	20,00	18,26
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	0,00	0,00
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	16,67	33,33
	Europe (EU)	3	30,0	1	33,3	66,67	-
	Asia (AS)	4	26,7	3	75,0	11,11	19,25
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	6,67	14,91
	Europe (EU)	1	10,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	11,11	19,25
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	11,11	19,25
	Asia (AS)	3	20,0	1	33,3	33,33	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	50,00	70,71
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	0,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	44,44	19,25
	Europe (EU)	2	20,0	1	50,0	33,33	-
	Asia (AS)	7	46,7	1	14,3	100,00	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	12	80,0	33,33	24,62
	1	17	100,0	17	100,0	39,22	31,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	53,33	29,81
Cycle 2 Day 1	0	15	100,0	12	80,0	22,22	21,71
	1	15	88,2	14	93,3	9,52	15,63
	2	3	60,0	3	100,0	11,11	19,25
Cycle 3 Day 1	0	15	100,0	14	93,3	14,29	25,20
	1	14	82,4	13	92,9	5,13	12,52
	2	3	60,0	3	100,0	22,22	19,25
Cycle 4 Day 1	0	15	100,0	14	93,3	11,90	24,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	5,56	12,97
	2	3	60,0	2	66,7	50,00	23,57
Cycle 5 Day 1	0	15	100,0	15	100,0	13,33	24,56
	1	14	82,4	12	85,7	8,33	15,08
	2	2	40,0	2	100,0	16,67	23,57
Cycle 6 Day 1	0	15	100,0	15	100,0	20,00	24,56
	1	14	82,4	12	85,7	11,11	16,41
	2	2	40,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	14,29	21,54
	1	13	76,5	11	84,6	0,00	0,00
	2	2	40,0	2	100,0	0,00	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	20,51	21,68
	1	11	64,7	10	90,9	16,67	32,39
	2	2	40,0	2	100,0	16,67	23,57
Cycle 9 Day 1	0	14	93,3	14	100,0	19,05	25,20
	1	10	58,8	10	100,0	10,00	16,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	0,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	16,67	21,68
	1	10	58,8	9	90,0	11,11	16,67
	2	1	20,0	1	100,0	0,00	-
Cycle 11 Day 1	0	14	93,3	14	100,0	11,90	16,57
	1	9	52,9	9	100,0	11,11	23,57
	2	1	20,0	1	100,0	0,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	16,67	22,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	8,33	15,43
	2	1	20,0	1	100,0	0,00	-
Cycle 13 Day 1	0	14	93,3	13	92,9	23,08	34,39
	1	8	47,1	8	100,0	4,17	11,79
Cycle 14 Day 1	0	14	93,3	14	100,0	19,05	36,31
	1	8	47,1	8	100,0	16,67	17,82
Cycle 15 Day 1	0	14	93,3	14	100,0	16,67	25,32
	1	8	47,1	7	87,5	23,81	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	4,17	11,79
	1	8	47,1	7	87,5	23,81	25,20
Cycle 17 Day 1	0	12	80,0	8	66,7	8,33	15,43
	1	6	35,3	6	100,0	5,56	13,61
Cycle 18 Day 1	0	9	60,0	4	44,4	16,67	19,25
	1	6	35,3	4	66,7	8,33	16,67
Cycle 19 Day 1	0	8	53,3	4	50,0	33,33	38,49
	1	5	29,4	4	80,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	20,00	29,81
	1	4	23,5	4	100,0	8,33	16,67
Cycle 21 Day 1	0	3	20,0	3	100,0	11,11	19,25
	1	4	23,5	1	25,0	33,33	-
Cycle 22 Day 1	0	3	20,0	2	66,7	50,00	70,71
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	0,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	33,33	0,00
	1	7	41,2	2	28,6	83,33	23,57
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	35,90	31,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	16,67	23,57
	2 or More	21	100,0	19	90,5	43,86	27,34
Cycle 2 Day 1	None	14	100,0	12	85,7	13,89	17,16
	1	1	50,0	1	100,0	0,00	-
	2 or More	18	85,7	16	88,9	16,67	21,08
Cycle 3 Day 1	None	14	100,0	13	92,9	7,69	14,62
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	16	94,1	14,58	24,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	12	85,7	5,56	12,97
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	17,78	27,79
Cycle 5 Day 1	None	14	100,0	14	100,0	4,76	12,10
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	19,05	25,20
Cycle 6 Day 1	None	14	100,0	14	100,0	11,90	16,57
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	14	87,5	21,43	24,83
Cycle 7 Day 1	None	14	100,0	13	92,9	2,56	9,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	15	71,4	13	86,7	12,82	21,68
Cycle 8 Day 1	None	14	100,0	13	92,9	12,82	28,99
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	25,00	20,72
Cycle 9 Day 1	None	13	92,9	13	100,0	15,38	17,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	15,15	27,34
Cycle 10 Day 1	None	13	92,9	12	92,3	8,33	15,08
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	21,21	22,47
Cycle 11 Day 1	None	13	92,9	13	100,0	10,26	21,01
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	10	100,0	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	11,11	16,41
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	8	80,0	16,67	25,20
Cycle 13 Day 1	None	12	85,7	11	91,7	12,12	22,47
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	22,22	37,27
Cycle 14 Day 1	None	12	85,7	12	100,0	5,56	12,97
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	37,04	38,89
Cycle 15 Day 1	None	12	85,7	12	100,0	11,11	21,71
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	8	88,9	33,33	25,20
Cycle 16 Day 1	None	11	78,6	8	72,7	8,33	15,43
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	22,22	27,22
Cycle 17 Day 1	None	10	71,4	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	7	33,3	6	85,7	16,67	18,26
Cycle 18 Day 1	None	8	57,1	4	50,0	16,67	19,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	6	28,6	3	50,0	11,11	19,25
Cycle 19 Day 1	None	7	50,0	3	42,9	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	5	23,8	4	80,0	41,67	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	4	19,0	4	100,0	33,33	27,22
Cycle 21 Day 1	None	4	28,6	2	50,0	0,00	0,00
	2 or More	3	14,3	2	66,7	33,33	0,00
Cycle 22 Day 1	None	4	28,6	1	25,0	0,00	-
	2 or More	3	14,3	1	33,3	100,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	33,33	-
	1	2	100,0	1	50,0	33,33	-
	2 or More	9	42,9	3	33,3	66,67	33,33
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	35,90	31,80
	Previously Treated	23	100,0	21	91,3	41,27	27,70
Cycle 2 Day 1	Naïve	14	100,0	12	85,7	13,89	17,16
	Previously Treated	19	82,6	17	89,5	15,69	20,81
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	7,69	14,62
	Previously Treated	18	78,3	17	94,4	13,73	23,74
Cycle 4 Day 1	Naïve	14	100,0	12	85,7	5,56	12,97
	Previously Treated	18	78,3	16	88,9	16,67	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	4,76	12,10
	Previously Treated	17	73,9	15	88,2	17,78	24,77
Cycle 6 Day 1	Naïve	14	100,0	14	100,0	11,90	16,57
	Previously Treated	17	73,9	15	88,2	20,00	24,56
Cycle 7 Day 1	Naïve	14	100,0	13	92,9	2,56	9,25
	Previously Treated	16	69,6	14	87,5	11,90	21,11
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	12,82	28,99
	Previously Treated	14	60,9	12	85,7	25,00	20,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	15,38	17,30
	Previously Treated	12	52,2	12	100,0	13,89	26,43
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	8,33	15,08
	Previously Treated	12	52,2	12	100,0	19,44	22,29
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	10,26	21,01
	Previously Treated	11	47,8	11	100,0	12,12	16,82
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	11,11	16,41
	Previously Treated	11	47,8	9	81,8	14,81	24,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	12,12	22,47
	Previously Treated	10	43,5	10	100,0	20,00	35,83
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	5,56	12,97
	Previously Treated	10	43,5	10	100,0	33,33	38,49
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	11,11	21,71
	Previously Treated	10	43,5	9	90,0	29,63	26,06
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	8,33	15,43
	Previously Treated	10	43,5	7	70,0	19,05	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	0,00	0,00
	Previously Treated	8	34,8	7	87,5	14,29	17,82
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	16,67	19,25
	Previously Treated	7	30,4	4	57,1	8,33	16,67
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	0,00	0,00
	Previously Treated	6	26,1	5	83,3	33,33	33,33
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	0,00	0,00
	Previously Treated	5	21,7	5	100,0	26,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	0,00	0,00
	Previously Treated	3	13,0	2	66,7	33,33	0,00
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	0,00	-
	Previously Treated	3	13,0	1	33,3	100,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	11	47,8	4	36,4	58,33	31,91
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	38,89	31,25
	Central	25	100,0	22	88,0	39,39	28,43
Cycle 2 Day 1	Local	11	91,7	10	90,9	16,67	23,57
	Central	22	88,0	19	86,4	14,04	16,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	11	100,0	6,06	20,10
	Central	21	84,0	19	90,5	14,04	20,23
Cycle 4 Day 1	Local	11	91,7	10	90,9	0,00	0,00
	Central	21	84,0	18	85,7	18,52	26,13
Cycle 5 Day 1	Local	11	91,7	10	90,9	13,33	23,31
	Central	20	80,0	19	95,0	10,53	19,41
Cycle 6 Day 1	Local	11	91,7	11	100,0	9,09	15,57
	Central	20	80,0	18	90,0	20,37	23,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	3,03	10,05
	Central	19	76,0	16	84,2	10,42	20,07
Cycle 8 Day 1	Local	10	83,3	10	100,0	6,67	14,05
	Central	18	72,0	15	83,3	26,67	28,73
Cycle 9 Day 1	Local	10	83,3	10	100,0	23,33	22,50
	Central	15	60,0	15	100,0	8,89	19,79
Cycle 10 Day 1	Local	10	83,3	9	90,0	18,52	24,22
	Central	15	60,0	15	100,0	11,11	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	11,11	23,57
	Central	15	60,0	15	100,0	11,11	16,27
Cycle 12 Day 1	Local	9	75,0	8	88,9	12,50	17,25
	Central	15	60,0	13	86,7	12,82	21,68
Cycle 13 Day 1	Local	8	66,7	8	100,0	16,67	35,63
	Central	14	56,0	13	92,9	15,38	25,88
Cycle 14 Day 1	Local	8	66,7	8	100,0	16,67	35,63
	Central	14	56,0	14	100,0	19,05	28,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	12,50	24,80
	Central	14	56,0	13	92,9	23,08	25,04
Cycle 16 Day 1	Local	8	66,7	6	75,0	11,11	17,21
	Central	13	52,0	9	69,2	14,81	24,22
Cycle 17 Day 1	Local	8	66,7	5	62,5	6,67	14,91
	Central	10	40,0	9	90,0	7,41	14,70
Cycle 18 Day 1	Local	6	50,0	4	66,7	16,67	19,25
	Central	9	36,0	4	44,4	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	16,67	33,33
	Central	8	32,0	4	50,0	25,00	31,91
Cycle 20 Day 1	Local	5	41,7	5	100,0	13,33	29,81
	Central	4	16,0	4	100,0	16,67	19,25
Cycle 21 Day 1	Local	4	33,3	2	50,0	0,00	0,00
	Central	3	12,0	2	66,7	33,33	0,00
Cycle 22 Day 1	Local	4	33,3	1	25,0	0,00	-
	Central	3	12,0	1	33,3	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	0,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	0,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	50,00	23,57
	Central	8	32,0	3	37,5	55,56	38,49
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	32	91,4	40,63	29,00
	No	2	100,0	2	100,0	16,67	23,57
Cycle 2 Day 1	Yes	32	91,4	28	87,5	15,48	19,21
	No	1	50,0	1	100,0	0,00	-
Cycle 3 Day 1	Yes	31	88,6	29	93,5	11,49	20,46
	No	1	50,0	1	100,0	0,00	-
Cycle 4 Day 1	Yes	31	88,6	27	87,1	12,35	22,92
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	11,90	20,72
	No	1	50,0	1	100,0	0,00	-
Cycle 6 Day 1	Yes	30	85,7	28	93,3	16,67	21,28
	No	1	50,0	1	100,0	0,00	-
Cycle 7 Day 1	Yes	29	82,9	26	89,7	7,69	17,15
	No	1	50,0	1	100,0	0,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	19,44	25,85
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	13,89	21,80
	No	1	50,0	1	100,0	33,33	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	14,49	19,66
	No	1	50,0	1	100,0	0,00	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	11,59	19,09
	No	1	50,0	1	100,0	0,00	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	11,67	19,57
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	16,67	29,62
	No	1	50,0	1	100,0	0,00	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	19,05	30,86
	No	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	18,33	25,31
	No	1	50,0	1	100,0	33,33	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	11,90	21,11
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	7,69	14,62
	No	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	14,29	17,82
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	23,81	31,71
	No	1	50,0	1	100,0	0,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	16,67	25,20
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	16,67	19,25
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	50,00	70,71
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	0,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	0,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	53,33	29,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	44,44	19,25
	No	33	100,0	31	93,9	38,71	29,93
Cycle 2 Day 1	Yes	2	50,0	1	50,0	0,00	-
	No	31	93,9	28	90,3	15,48	19,21
Cycle 3 Day 1	Yes	2	50,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	28	93,3	10,71	20,39
Cycle 4 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	30	90,9	26	86,7	11,54	22,98
Cycle 5 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	29	87,9	27	93,1	11,11	20,67
Cycle 6 Day 1	Yes	2	50,0	2	100,0	33,33	0,00
	No	29	87,9	27	93,1	14,81	21,35
Cycle 7 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	25	89,3	8,00	17,43
Cycle 8 Day 1	Yes	2	50,0	2	100,0	66,67	47,14
	No	26	78,8	23	88,5	14,49	19,66
Cycle 9 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	24	100,0	15,28	21,93
Cycle 10 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	23	95,8	14,49	19,66
Cycle 11 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	10,14	18,63
Cycle 12 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	23	69,7	20	87,0	11,67	19,57
Cycle 13 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	21	63,6	20	95,2	13,33	27,36
Cycle 14 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	21	100,0	19,05	30,86
Cycle 15 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	18,33	25,31
Cycle 16 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	20	60,6	14	70,0	14,29	21,54
Cycle 17 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	17	51,5	13	76,5	7,69	14,62
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	12,50	17,25
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	20,83	30,54
Cycle 20 Day 1	No	9	27,3	9	100,0	14,81	24,22
Cycle 21 Day 1	No	7	21,2	4	57,1	16,67	19,25
Cycle 22 Day 1	No	7	21,2	2	28,6	50,00	70,71
Cycle 23 Day 1	No	4	12,1	1	25,0	0,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	0,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	41,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_C30SL_SG.xls
07SEP2019 20:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	33,76	34,19
Cycle 2 Day 1	All	72	92,3	65	90,3	13,85	21,96
Cycle 3 Day 1	All	68	87,2	64	94,1	9,90	20,30
Cycle 4 Day 1	All	67	85,9	64	95,5	8,33	17,82
Cycle 5 Day 1	All	65	83,3	64	98,5	5,21	17,03
Cycle 6 Day 1	All	63	80,8	60	95,2	5,56	13,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	4,68	11,68
Cycle 8 Day 1	All	56	71,8	52	92,9	7,05	16,62
Cycle 9 Day 1	All	51	65,4	51	100,0	4,58	13,37
Cycle 10 Day 1	All	51	65,4	50	98,0	4,00	10,94
Cycle 11 Day 1	All	50	64,1	50	100,0	4,67	11,68
Cycle 12 Day 1	All	49	62,8	45	91,8	5,19	12,22
Cycle 13 Day 1	All	46	59,0	45	97,8	6,67	15,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	6,82	16,98
Cycle 15 Day 1	All	44	56,4	44	100,0	3,03	9,69
Cycle 16 Day 1	All	41	52,6	39	95,1	6,84	15,63
Cycle 17 Day 1	All	39	50,0	39	100,0	7,69	19,44
Cycle 18 Day 1	All	38	48,7	35	92,1	6,67	13,53
Cycle 19 Day 1	All	36	46,2	33	91,7	7,07	13,84
Cycle 20 Day 1	All	36	46,2	32	88,9	2,08	8,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	8,97	17,78
Cycle 22 Day 1	All	29	37,2	25	86,2	9,33	22,61
Cycle 23 Day 1	All	21	26,9	18	85,7	7,41	24,40
Cycle 24 Day 1	All	20	25,6	18	90,0	5,56	12,78
Cycle 25 Day 1	All	15	19,2	13	86,7	5,13	12,52
Cycle 26 Day 1	All	14	17,9	12	85,7	5,56	12,97
Cycle 27 Day 1	All	11	14,1	8	72,7	8,33	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	11,11	16,67
Cycle 29 Day 1	All	9	11,5	7	77,8	4,76	12,60
Cycle 30 Day 1	All	7	9,0	5	71,4	6,67	14,91
Cycle 31 Day 1	All	7	9,0	5	71,4	6,67	14,91
Cycle 32 Day 1	All	6	7,7	5	83,3	0,00	0,00
Cycle 33 Day 1	All	2	2,6	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	22,62	27,30
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	41,38	34,10
	Female	49	100,0	49	100,0	29,25	33,77
Cycle 2 Day 1	Male	27	93,1	25	92,6	12,00	18,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	15,00	23,81
Cycle 3 Day 1	Male	25	86,2	23	92,0	7,25	17,28
	Female	43	87,8	41	95,3	11,38	21,87
Cycle 4 Day 1	Male	25	86,2	25	100,0	6,67	16,67
	Female	42	85,7	39	92,9	9,40	18,65
Cycle 5 Day 1	Male	25	86,2	25	100,0	9,33	24,57
	Female	40	81,6	39	97,5	2,56	9,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	8,70	14,97
	Female	38	77,6	37	97,4	3,60	13,11
Cycle 7 Day 1	Male	23	79,3	23	100,0	10,14	15,68
	Female	37	75,5	34	91,9	0,98	5,72
Cycle 8 Day 1	Male	21	72,4	19	90,5	8,77	21,78
	Female	35	71,4	33	94,3	6,06	13,06
Cycle 9 Day 1	Male	18	62,1	18	100,0	3,70	10,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	5,05	14,72
Cycle 10 Day 1	Male	18	62,1	18	100,0	5,56	12,78
	Female	33	67,3	32	97,0	3,13	9,87
Cycle 11 Day 1	Male	18	62,1	18	100,0	5,56	12,78
	Female	32	65,3	32	100,0	4,17	11,20
Cycle 12 Day 1	Male	17	58,6	17	100,0	5,88	13,10
	Female	32	65,3	28	87,5	4,76	11,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	5,88	13,10
	Female	29	59,2	28	96,6	7,14	16,62
Cycle 14 Day 1	Male	17	58,6	16	94,1	4,17	11,39
	Female	28	57,1	28	100,0	8,33	19,51
Cycle 15 Day 1	Male	16	55,2	16	100,0	4,17	11,39
	Female	28	57,1	28	100,0	2,38	8,74
Cycle 16 Day 1	Male	14	48,3	14	100,0	7,14	19,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	6,67	13,61
Cycle 17 Day 1	Male	12	41,4	12	100,0	2,78	9,62
	Female	27	55,1	27	100,0	9,88	22,29
Cycle 18 Day 1	Male	11	37,9	10	90,9	10,00	16,10
	Female	27	55,1	25	92,6	5,33	12,47
Cycle 19 Day 1	Male	10	34,5	10	100,0	10,00	16,10
	Female	26	53,1	23	88,5	5,80	12,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	0,00	0,00
	Female	26	53,1	23	88,5	2,90	9,60
Cycle 21 Day 1	Male	8	27,6	8	100,0	12,50	17,25
	Female	21	42,9	18	85,7	7,41	18,28
Cycle 22 Day 1	Male	8	27,6	6	75,0	0,00	0,00
	Female	21	42,9	19	90,5	12,28	25,36
Cycle 23 Day 1	Male	5	17,2	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	9,52	27,51
Cycle 24 Day 1	Male	5	17,2	4	80,0	0,00	0,00
	Female	15	30,6	14	93,3	7,14	14,19
Cycle 25 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	12	24,5	11	91,7	6,06	13,48
Cycle 26 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	11	22,4	10	90,9	6,67	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	8	16,3	6	75,0	11,11	17,21
Cycle 28 Day 1	Male	2	6,9	2	100,0	0,00	0,00
	Female	8	16,3	7	87,5	14,29	17,82
Cycle 29 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	8	16,3	6	75,0	5,56	13,61
Cycle 30 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	8,33	16,67
Cycle 31 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	8,33	16,67
Cycle 32 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	5	10,2	4	80,0	0,00	0,00
Cycle 33 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	1	2,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	26,67	25,82
	Female	21	42,9	13	61,9	17,95	29,24
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	31,72	32,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	47,62	38,60
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	18-64	59	95,2	53	89,8	11,95	20,77
	65-74	11	78,6	10	90,9	26,67	26,29
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 3 Day 1	18-64	56	90,3	52	92,9	9,62	20,17
	65-74	10	71,4	10	100,0	13,33	23,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 4 Day 1	18-64	55	88,7	53	96,4	8,81	18,66
	65-74	10	71,4	9	90,0	7,41	14,70
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 5 Day 1	18-64	53	85,5	52	98,1	5,13	17,94
	65-74	10	71,4	10	100,0	6,67	14,05
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	4,08	11,04
	65-74	10	71,4	9	90,0	14,81	24,22
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 7 Day 1	18-64	49	79,0	47	95,9	4,96	12,00
	65-74	9	64,3	8	88,9	4,17	11,79
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 8 Day 1	18-64	45	72,6	41	91,1	6,50	17,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	11,11	16,67
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 9 Day 1	18-64	40	64,5	40	100,0	2,50	8,89
	65-74	9	64,3	9	100,0	11,11	23,57
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 10 Day 1	18-64	40	64,5	39	97,5	2,56	9,00
	65-74	9	64,3	9	100,0	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 11 Day 1	18-64	39	62,9	39	100,0	5,13	12,18
	65-74	9	64,3	9	100,0	3,70	11,11
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 12 Day 1	18-64	38	61,3	35	92,1	4,76	11,83
	65-74	9	64,3	8	88,9	8,33	15,43
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	3,92	10,90
	65-74	9	64,3	9	100,0	14,81	24,22
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 14 Day 1	18-64	35	56,5	35	100,0	3,81	10,76
	65-74	9	64,3	8	88,9	20,83	30,54
	>=75	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	1,90	7,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	8,33	15,43
	>=75	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	6,25	15,70
	65-74	7	50,0	6	85,7	5,56	13,61
	>=75	1	50,0	1	100,0	33,33	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	7,29	20,27
	65-74	6	42,9	6	100,0	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	33,33	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	3,45	10,33
	65-74	6	42,9	5	83,3	20,00	18,26
	>=75	1	50,0	1	100,0	33,33	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	7,14	13,93
	65-74	5	35,7	4	80,0	0,00	0,00
	>=75	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	2,56	9,06
	65-74	5	35,7	5	100,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	4,76	11,95
	65-74	4	28,6	4	100,0	25,00	31,91
	>=75	1	50,0	1	100,0	33,33	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	10,00	24,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	8,33	16,67
	>=75	1	50,0	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	8,33	25,82
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	6,25	13,44
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	22,6	12	85,7	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	5,56	12,97
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	8,33	15,43
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	11,11	16,67
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	4,76	12,60
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	6,67	14,91
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	6,67	14,91
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	0,00	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	23,33	28,82
	65-74	10	71,4	7	70,0	23,81	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	0,00	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	36,19	38,24
	Other	43	100,0	43	100,0	31,78	30,82
Cycle 2 Day 1	White	33	94,3	29	87,9	14,94	22,86
	Other	39	90,7	36	92,3	12,96	21,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	12,35	24,72
	Other	37	86,0	37	100,0	8,11	16,49
Cycle 4 Day 1	White	31	88,6	28	90,3	5,95	13,00
	Other	36	83,7	36	100,0	10,19	20,81
Cycle 5 Day 1	White	31	88,6	30	96,8	4,44	14,47
	Other	34	79,1	34	100,0	5,88	19,19
Cycle 6 Day 1	White	30	85,7	28	93,3	5,95	15,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	5,21	12,30
Cycle 7 Day 1	White	29	82,9	27	93,1	3,70	10,68
	Other	31	72,1	30	96,8	5,56	12,63
Cycle 8 Day 1	White	28	80,0	24	85,7	5,56	12,69
	Other	28	65,1	28	100,0	8,33	19,51
Cycle 9 Day 1	White	26	74,3	26	100,0	7,69	17,15
	Other	25	58,1	25	100,0	1,33	6,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	6,67	13,61
	Other	25	58,1	25	100,0	1,33	6,67
Cycle 11 Day 1	White	26	74,3	26	100,0	2,56	9,06
	Other	24	55,8	24	100,0	6,94	13,83
Cycle 12 Day 1	White	26	74,3	22	84,6	1,52	7,11
	Other	23	53,5	23	100,0	8,70	14,97
Cycle 13 Day 1	White	24	68,6	23	95,8	8,70	18,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	4,55	11,71
Cycle 14 Day 1	White	24	68,6	24	100,0	5,56	16,05
	Other	21	48,8	20	95,2	8,33	18,34
Cycle 15 Day 1	White	24	68,6	24	100,0	4,17	11,26
	Other	20	46,5	20	100,0	1,67	7,45
Cycle 16 Day 1	White	22	62,9	20	90,9	11,67	19,57
	Other	19	44,2	19	100,0	1,75	7,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	10,61	23,87
	Other	17	39,5	17	100,0	3,92	11,07
Cycle 18 Day 1	White	21	60,0	18	85,7	5,56	12,78
	Other	17	39,5	17	100,0	7,84	14,57
Cycle 19 Day 1	White	20	57,1	20	100,0	8,33	14,81
	Other	16	37,2	13	81,3	5,13	12,52
Cycle 20 Day 1	White	20	57,1	17	85,0	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	2,22	8,61
Cycle 21 Day 1	White	16	45,7	14	87,5	9,52	15,63
	Other	13	30,2	12	92,3	8,33	20,72
Cycle 22 Day 1	White	16	45,7	13	81,3	12,82	28,99
	Other	13	30,2	12	92,3	5,56	12,97
Cycle 23 Day 1	White	12	34,3	10	83,3	13,33	32,20
	Other	9	20,9	8	88,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	10,00	16,10
	Other	9	20,9	8	88,9	0,00	0,00
Cycle 25 Day 1	White	10	28,6	8	80,0	8,33	15,43
	Other	5	11,6	5	100,0	0,00	0,00
Cycle 26 Day 1	White	10	28,6	8	80,0	8,33	15,43
	Other	4	9,3	4	100,0	0,00	0,00
Cycle 27 Day 1	White	8	22,9	5	62,5	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	11,11	19,25
Cycle 28 Day 1	White	7	20,0	6	85,7	5,56	13,61
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 29 Day 1	White	6	17,1	4	66,7	8,33	16,67
	Other	3	7,0	3	100,0	0,00	0,00
Cycle 30 Day 1	White	4	11,4	2	50,0	0,00	0,00
	Other	3	7,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	0,00	0,00
	Other	3	7,0	3	100,0	11,11	19,25
Cycle 32 Day 1	White	4	11,4	3	75,0	0,00	0,00
	Other	2	4,7	2	100,0	0,00	0,00
Cycle 33 Day 1	White	2	5,7	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	16,67	17,41
	Other	24	55,8	16	66,7	27,08	32,70
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	27,27	35,09
	Europe (EU)	17	100,0	17	100,0	35,29	39,91
	Asia (AS)	39	100,0	39	100,0	36,75	31,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	11,76	20,21
	Europe (EU)	16	94,1	13	81,3	10,26	21,01
	Asia (AS)	36	92,3	35	97,2	16,19	23,39
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	10,53	15,92
	Europe (EU)	15	88,2	12	80,0	16,67	33,33
	Asia (AS)	33	84,6	33	100,0	7,07	16,15
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	8,33	14,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	2,78	9,62
	Asia (AS)	32	82,1	32	100,0	10,42	21,48
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	5,00	16,31
	Europe (EU)	15	88,2	14	93,3	4,76	12,10
	Asia (AS)	30	76,9	30	100,0	5,56	19,74
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	5,00	12,21
	Europe (EU)	14	82,4	13	92,9	7,69	19,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	4,94	12,07
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	3,70	10,78
	Europe (EU)	14	82,4	13	92,9	5,13	12,52
	Asia (AS)	27	69,2	26	96,3	5,13	12,26
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	5,88	13,10
	Europe (EU)	14	82,4	11	78,6	3,03	10,05
	Asia (AS)	24	61,5	24	100,0	9,72	20,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	5,56	12,78
	Europe (EU)	12	70,6	12	100,0	8,33	20,72
	Asia (AS)	21	53,8	21	100,0	1,59	7,27
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	5,88	13,10
	Europe (EU)	12	70,6	12	100,0	8,33	15,08
	Asia (AS)	21	53,8	21	100,0	0,00	0,00
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	5,56	12,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	0,00	0,00
	Asia (AS)	20	51,3	20	100,0	6,67	13,68
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	5,88	13,10
	Europe (EU)	12	70,6	9	75,0	0,00	0,00
	Asia (AS)	19	48,7	19	100,0	7,02	13,96
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	7,84	14,57
	Europe (EU)	11	64,7	10	90,9	10,00	22,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	3,70	10,78
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	5,88	13,10
	Europe (EU)	11	64,7	11	100,0	6,06	20,10
	Asia (AS)	17	43,6	16	94,1	8,33	19,25
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	5,88	13,10
	Europe (EU)	11	64,7	11	100,0	3,03	10,05
	Asia (AS)	16	41,0	16	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	2,38	8,91
	Europe (EU)	11	64,7	9	81,8	14,81	24,22
	Asia (AS)	16	41,0	16	100,0	6,25	13,44
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	9,52	27,51
	Europe (EU)	10	58,8	10	100,0	6,67	14,05
	Asia (AS)	15	38,5	15	100,0	6,67	13,80
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	4,76	12,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	5,56	13,61
	Asia (AS)	15	38,5	15	100,0	8,89	15,26
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	7,69	14,62
	Europe (EU)	9	52,9	9	100,0	7,41	14,70
	Asia (AS)	14	35,9	11	78,6	6,06	13,48
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	2,56	9,25
	Europe (EU)	9	52,9	6	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	2,56	9,25
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	10,00	16,10
	Europe (EU)	7	41,2	6	85,7	11,11	17,21
	Asia (AS)	11	28,2	10	90,9	6,67	21,08
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	16,67	32,39
	Europe (EU)	7	41,2	5	71,4	0,00	0,00
	Asia (AS)	11	28,2	10	90,9	6,67	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	14,81	33,79
	Europe (EU)	5	29,4	3	60,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	0,00	0,00
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	8,33	15,43
	Europe (EU)	5	29,4	4	80,0	8,33	16,67
	Asia (AS)	7	17,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	0,00	0,00
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	11,11	17,21
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	0,00	0,00
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	8,33	16,67
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	8,33	16,67
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	8,33	16,67
	Europe (EU)	2	11,8	1	50,0	0,00	-
	Asia (AS)	4	10,3	4	100,0	16,67	19,25
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	11,11	19,25
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	11,11	19,25
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	11,11	19,25
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	0,00	-
	Asia (AS)	3	7,7	2	66,7	0,00	0,00
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	0,00	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	21,21	16,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	0,00	0,00
	Asia (AS)	21	53,8	13	61,9	30,77	34,59
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	20,00	27,12
	1	38	100,0	38	100,0	42,98	34,58
	2	10	100,0	10	100,0	40,00	40,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	27	90,0	9,88	22,29
	1	36	94,7	32	88,9	14,58	20,63
	2	6	60,0	6	100,0	27,78	25,09
Cycle 3 Day 1	0	29	96,7	27	93,1	11,11	18,49
	1	34	89,5	32	94,1	5,21	14,93
	2	5	50,0	5	100,0	33,33	40,82
Cycle 4 Day 1	0	29	96,7	28	96,6	4,76	11,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	7,29	16,36
	2	5	50,0	4	80,0	41,67	31,91
Cycle 5 Day 1	0	29	96,7	29	100,0	3,45	10,33
	1	33	86,8	32	97,0	6,25	21,48
	2	3	30,0	3	100,0	11,11	19,25
Cycle 6 Day 1	0	29	96,7	29	100,0	5,75	15,61
	1	31	81,6	28	90,3	5,95	13,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	0,00	0,00
Cycle 7 Day 1	0	29	96,7	28	96,6	3,57	10,50
	1	28	73,7	26	92,9	6,41	13,40
	2	3	30,0	3	100,0	0,00	0,00
Cycle 8 Day 1	0	28	93,3	26	92,9	7,69	17,15
	1	25	65,8	23	92,0	7,25	17,28
	2	3	30,0	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	3,85	14,38
	1	23	60,5	23	100,0	5,80	12,92
	2	2	20,0	2	100,0	0,00	0,00
Cycle 10 Day 1	0	26	86,7	26	100,0	5,13	12,26
	1	23	60,5	22	95,7	3,03	9,81
	2	2	20,0	2	100,0	0,00	0,00
Cycle 11 Day 1	0	26	86,7	26	100,0	2,56	9,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	7,58	14,30
	2	2	20,0	2	100,0	0,00	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	6,06	13,16
	1	22	57,9	21	95,5	4,76	11,95
	2	2	20,0	2	100,0	0,00	0,00
Cycle 13 Day 1	0	25	83,3	24	96,0	8,33	17,72
	1	20	52,6	20	100,0	5,00	12,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	9,72	20,80
	1	19	50,0	19	100,0	3,51	10,51
	2	1	10,0	1	100,0	0,00	-
Cycle 15 Day 1	0	24	80,0	24	100,0	2,78	9,41
	1	19	50,0	19	100,0	3,51	10,51
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	6,67	17,44
	1	18	47,4	18	100,0	7,41	14,26
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	6,35	22,65
	1	17	44,7	17	100,0	9,80	15,66
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	3,70	10,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	10,42	15,96
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	5,26	12,49
	1	15	39,5	13	86,7	10,26	16,01
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	1,96	8,08
	1	15	39,5	14	93,3	2,38	8,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	9,52	20,37
	1	13	34,2	11	84,6	9,09	15,57
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	11,11	29,59
	1	13	34,2	12	92,3	8,33	15,08
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	11,11	33,33
	1	9	23,7	8	88,9	4,17	11,79
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	7,41	14,70
	1	9	23,7	8	88,9	4,17	11,79
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	4,76	12,60
Cycle 26 Day 1	0	8	26,7	6	75,0	5,56	13,61
	1	6	15,8	6	100,0	5,56	13,61
Cycle 27 Day 1	0	6	20,0	3	50,0	0,00	0,00
	1	5	13,2	5	100,0	13,33	18,26
Cycle 28 Day 1	0	5	16,7	4	80,0	0,00	0,00
	1	5	13,2	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	0,00	0,00
	1	5	13,2	5	100,0	6,67	14,91
Cycle 30 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	8,33	16,67
Cycle 31 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	8,33	16,67
Cycle 32 Day 1	0	3	10,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	0,00	0,00
Cycle 33 Day 1	0	2	6,7	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	19,05	21,54
	1	20	52,6	12	60,0	25,00	35,18
	2	4	40,0	2	50,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	22,58	29,04
	1	3	100,0	3	100,0	33,33	33,33
	2 or More	44	100,0	44	100,0	41,67	36,03
Cycle 2 Day 1	None	30	96,8	27	90,0	12,35	20,98
	1	2	66,7	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	15,32	23,03
Cycle 3 Day 1	None	30	96,8	28	93,3	8,33	14,70
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	35	97,2	11,43	24,18
Cycle 4 Day 1	None	30	96,8	29	96,7	8,05	17,03
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	35	79,5	33	94,3	9,09	19,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	7,78	22,63
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	33	75,0	32	97,0	3,13	9,87
Cycle 6 Day 1	None	29	93,5	28	96,6	4,76	11,88
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	32	72,7	30	93,8	6,67	16,14
Cycle 7 Day 1	None	27	87,1	26	96,3	2,56	9,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	31	70,5	29	93,5	5,75	12,81
Cycle 8 Day 1	None	26	83,9	25	96,2	8,00	17,43
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	6,17	16,11
Cycle 9 Day 1	None	25	80,6	25	100,0	2,67	9,23
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	6,67	16,67
Cycle 10 Day 1	None	25	80,6	24	96,0	2,78	9,41
	1	1	33,3	1	100,0	0,00	-
	2 or More	25	56,8	25	100,0	5,33	12,47
Cycle 11 Day 1	None	25	80,6	25	100,0	6,67	13,61
	1	1	33,3	1	100,0	0,00	-
	2 or More	24	54,5	24	100,0	2,78	9,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	6,94	13,83
	1	1	33,3	1	100,0	0,00	-
	2 or More	23	52,3	20	87,0	3,33	10,26
Cycle 13 Day 1	None	24	77,4	23	95,8	5,80	12,92
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	7,94	17,97
Cycle 14 Day 1	None	23	74,2	23	100,0	5,80	12,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	20	95,2	8,33	21,29
Cycle 15 Day 1	None	23	74,2	23	100,0	4,35	11,48
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	20	100,0	1,67	7,45
Cycle 16 Day 1	None	20	64,5	19	95,0	3,51	10,51
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	10,53	19,41
Cycle 17 Day 1	None	19	61,3	19	100,0	3,51	10,51
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	19	100,0	12,28	25,36
Cycle 18 Day 1	None	18	58,1	17	94,4	5,88	13,10
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	17	89,5	7,84	14,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	7,84	14,57
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	6,67	13,80
Cycle 20 Day 1	None	17	54,8	16	94,1	4,17	11,39
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	0,00	0,00
Cycle 21 Day 1	None	15	48,4	13	86,7	7,69	14,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	10,26	21,01
Cycle 22 Day 1	None	15	48,4	13	86,7	5,13	12,52
	2 or More	14	31,8	12	85,7	13,89	30,01
Cycle 23 Day 1	None	10	32,3	9	90,0	3,70	11,11
	2 or More	11	25,0	9	81,8	11,11	33,33
Cycle 24 Day 1	None	10	32,3	10	100,0	3,33	10,54
	2 or More	10	22,7	8	80,0	8,33	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	4,17	11,79
	2 or More	6	13,6	5	83,3	6,67	14,91
Cycle 26 Day 1	None	8	25,8	8	100,0	4,17	11,79
	2 or More	6	13,6	4	66,7	8,33	16,67
Cycle 27 Day 1	None	7	22,6	6	85,7	5,56	13,61
	2 or More	4	9,1	2	50,0	16,67	23,57
Cycle 28 Day 1	None	7	22,6	7	100,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	19,4	5	83,3	6,67	14,91
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	12,9	3	75,0	0,00	0,00
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 31 Day 1	None	4	12,9	3	75,0	0,00	0,00
	2 or More	3	6,8	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	0,00	0,00
	2 or More	2	4,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	3,2	1	100,0	0,00	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	16,67	17,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	33,33	-
	2 or More	24	54,5	15	62,5	26,67	33,81
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	22,58	29,04
	Previously Treated	47	100,0	47	100,0	41,13	35,59
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	12,35	20,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	14,91	22,86
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	8,33	14,70
	Previously Treated	38	80,9	36	94,7	11,11	23,90
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	8,05	17,03
	Previously Treated	37	78,7	35	94,6	8,57	18,69
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	7,78	22,63
	Previously Treated	35	74,5	34	97,1	2,94	9,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	4,76	11,88
	Previously Treated	34	72,3	32	94,1	6,25	15,70
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	2,56	9,06
	Previously Treated	33	70,2	31	93,9	6,45	13,39
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	8,00	17,43
	Previously Treated	30	63,8	27	90,0	6,17	16,11
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	2,67	9,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	6,41	16,38
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	2,78	9,41
	Previously Treated	26	55,3	26	100,0	5,13	12,26
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	6,67	13,61
	Previously Treated	25	53,2	25	100,0	2,67	9,23
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	6,94	13,83
	Previously Treated	24	51,1	21	87,5	3,17	10,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	5,80	12,92
	Previously Treated	22	46,8	22	100,0	7,58	17,61
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	5,80	12,92
	Previously Treated	22	46,8	21	95,5	7,94	20,83
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	4,35	11,48
	Previously Treated	21	44,7	21	100,0	1,59	7,27
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	3,51	10,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	10,00	19,04
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	3,51	10,51
	Previously Treated	20	42,6	20	100,0	11,67	24,84
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	5,88	13,10
	Previously Treated	20	42,6	18	90,0	7,41	14,26
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	7,84	14,57
	Previously Treated	19	40,4	16	84,2	6,25	13,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	4,17	11,39
	Previously Treated	19	40,4	16	84,2	0,00	0,00
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	7,69	14,62
	Previously Treated	14	29,8	13	92,9	10,26	21,01
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	5,13	12,52
	Previously Treated	14	29,8	12	85,7	13,89	30,01
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	11,11	33,33
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	3,33	10,54
	Previously Treated	10	21,3	8	80,0	8,33	15,43
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	4,17	11,79
	Previously Treated	6	12,8	5	83,3	6,67	14,91
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	4,17	11,79
	Previously Treated	6	12,8	4	66,7	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	5,56	13,61
	Previously Treated	4	8,5	2	50,0	16,67	23,57
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	9,52	16,27
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	6,67	14,91
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	0,00	0,00
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	0,00	0,00
	Previously Treated	2	4,3	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	0,00	-
	Previously Treated	1	2,1	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	16,67	17,41
	Previously Treated	26	55,3	16	61,5	27,08	32,70
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	33,33	35,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	34,11	33,72
Cycle 2 Day 1	Local	32	91,4	30	93,8	7,78	16,80
	Central	40	93,0	35	87,5	19,05	24,64
Cycle 3 Day 1	Local	29	82,9	28	96,6	9,52	17,82
	Central	39	90,7	36	92,3	10,19	22,28
Cycle 4 Day 1	Local	28	80,0	27	96,4	6,17	16,11
	Central	39	90,7	37	94,9	9,91	19,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	4,94	15,20
	Central	38	88,4	37	97,4	5,41	18,45
Cycle 6 Day 1	Local	27	77,1	27	100,0	6,17	16,11
	Central	36	83,7	33	91,7	5,05	12,14
Cycle 7 Day 1	Local	27	77,1	27	100,0	3,70	10,68
	Central	33	76,7	30	90,9	5,56	12,63
Cycle 8 Day 1	Local	26	74,3	26	100,0	3,85	10,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	10,26	20,59
Cycle 9 Day 1	Local	25	71,4	25	100,0	6,67	16,67
	Central	26	60,5	26	100,0	2,56	9,06
Cycle 10 Day 1	Local	25	71,4	24	96,0	4,17	11,26
	Central	26	60,5	26	100,0	3,85	10,86
Cycle 11 Day 1	Local	24	68,6	24	100,0	2,78	9,41
	Central	26	60,5	26	100,0	6,41	13,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	3,03	9,81
	Central	26	60,5	23	88,5	7,25	14,06
Cycle 13 Day 1	Local	22	62,9	22	100,0	6,06	16,70
	Central	24	55,8	23	95,8	7,25	14,06
Cycle 14 Day 1	Local	22	62,9	22	100,0	4,55	15,59
	Central	23	53,5	22	95,7	9,09	18,35
Cycle 15 Day 1	Local	22	62,9	22	100,0	4,55	11,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	1,52	7,11
Cycle 16 Day 1	Local	20	57,1	20	100,0	1,67	7,45
	Central	21	48,8	19	90,5	12,28	19,91
Cycle 17 Day 1	Local	20	57,1	20	100,0	1,67	7,45
	Central	19	44,2	19	100,0	14,04	25,62
Cycle 18 Day 1	Local	20	57,1	19	95,0	3,51	10,51
	Central	18	41,9	16	88,9	10,42	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	3,92	11,07
	Central	17	39,5	16	94,1	10,42	15,96
Cycle 20 Day 1	Local	19	54,3	17	89,5	0,00	0,00
	Central	17	39,5	15	88,2	4,44	11,73
Cycle 21 Day 1	Local	14	40,0	12	85,7	5,56	12,97
	Central	15	34,9	14	93,3	11,90	21,11
Cycle 22 Day 1	Local	14	40,0	12	85,7	8,33	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	10,26	28,50
Cycle 23 Day 1	Local	11	31,4	10	90,9	0,00	0,00
	Central	10	23,3	8	80,0	16,67	35,63
Cycle 24 Day 1	Local	11	31,4	10	90,9	3,33	10,54
	Central	9	20,9	8	88,9	8,33	15,43
Cycle 25 Day 1	Local	7	20,0	7	100,0	4,76	12,60
	Central	8	18,6	6	75,0	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	5,56	13,61
	Central	8	18,6	6	75,0	5,56	13,61
Cycle 27 Day 1	Local	4	11,4	4	100,0	0,00	0,00
	Central	7	16,3	4	57,1	16,67	19,25
Cycle 28 Day 1	Local	4	11,4	4	100,0	8,33	16,67
	Central	6	14,0	5	83,3	13,33	18,26
Cycle 29 Day 1	Local	3	8,6	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	8,33	16,67
Cycle 30 Day 1	Local	3	8,6	3	100,0	0,00	0,00
	Central	4	9,3	2	50,0	16,67	23,57
Cycle 31 Day 1	Local	3	8,6	3	100,0	0,00	0,00
	Central	4	9,3	2	50,0	16,67	23,57
Cycle 32 Day 1	Local	3	8,6	3	100,0	0,00	0,00
	Central	3	7,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	0,00	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	19,05	28,39
	Central	21	48,8	14	66,7	26,19	26,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	33,33	34,01
	No	4	100,0	4	100,0	41,67	41,94
Cycle 2 Day 1	Yes	70	94,6	63	90,0	13,23	21,20
	No	2	50,0	2	100,0	33,33	47,14
Cycle 3 Day 1	Yes	66	89,2	62	93,9	10,22	20,55
	No	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	8,60	18,04
	No	2	50,0	2	100,0	0,00	0,00
Cycle 5 Day 1	Yes	63	85,1	62	98,4	5,38	17,28
	No	2	50,0	2	100,0	0,00	0,00
Cycle 6 Day 1	Yes	61	82,4	58	95,1	5,17	13,68
	No	2	50,0	2	100,0	16,67	23,57
Cycle 7 Day 1	Yes	58	78,4	55	94,8	4,85	11,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 8 Day 1	Yes	54	73,0	50	92,6	6,67	16,50
	No	2	50,0	2	100,0	16,67	23,57
Cycle 9 Day 1	Yes	49	66,2	49	100,0	4,76	13,61
	No	2	50,0	2	100,0	0,00	0,00
Cycle 10 Day 1	Yes	49	66,2	48	98,0	4,17	11,14
	No	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	4,86	11,89
	No	2	50,0	2	100,0	0,00	0,00
Cycle 12 Day 1	Yes	47	63,5	43	91,5	5,43	12,45
	No	2	50,0	2	100,0	0,00	0,00
Cycle 13 Day 1	Yes	44	59,5	43	97,7	6,20	15,01
	No	2	50,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	43	58,1	42	97,7	5,56	14,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	47,14
Cycle 15 Day 1	Yes	42	56,8	42	100,0	3,17	9,90
	No	2	50,0	2	100,0	0,00	0,00
Cycle 16 Day 1	Yes	39	52,7	37	94,9	7,21	15,98
	No	2	50,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	37	50,0	37	100,0	6,31	18,98
	No	2	50,0	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	6,06	13,06
	No	2	50,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	7,29	14,00
	No	2	50,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	2,22	8,46
	No	2	50,0	2	100,0	0,00	0,00
Cycle 21 Day 1	Yes	27	36,5	24	88,9	6,94	13,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	47,14
Cycle 22 Day 1	Yes	27	36,5	23	85,2	8,70	22,96
	No	2	50,0	2	100,0	16,67	23,57
Cycle 23 Day 1	Yes	20	27,0	17	85,0	7,84	25,08
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	5,88	13,10
	No	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	5,56	12,97
	No	1	25,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	6,06	13,48
	No	1	25,0	1	100,0	0,00	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	9,52	16,27
	No	1	25,0	1	100,0	0,00	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	8,33	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	5,56	13,61
	No	1	25,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	8,33	16,67
	No	1	25,0	1	100,0	0,00	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	8,33	16,67
	No	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	22,62	27,30
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	33,33	25,20
	No	70	100,0	70	100,0	33,81	35,21
Cycle 2 Day 1	Yes	5	62,5	5	100,0	20,00	29,81
	No	67	95,7	60	89,6	13,33	21,44
Cycle 3 Day 1	Yes	5	62,5	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	9,60	20,58
Cycle 4 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	62	88,6	59	95,2	8,47	18,15
Cycle 5 Day 1	Yes	5	62,5	5	100,0	13,33	29,81
	No	60	85,7	59	98,3	4,52	15,73
Cycle 6 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	58	82,9	55	94,8	5,45	14,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	55	78,6	52	94,5	4,49	11,49
Cycle 8 Day 1	Yes	5	62,5	5	100,0	26,67	27,89
	No	51	72,9	47	92,2	4,96	13,86
Cycle 9 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	47	67,1	47	100,0	4,26	13,22
Cycle 10 Day 1	Yes	4	50,0	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	4,35	11,35
Cycle 11 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	46	65,7	46	100,0	3,62	10,49
Cycle 12 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	45	64,3	41	91,1	5,69	12,70
Cycle 13 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	42	60,0	41	97,6	6,50	15,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	41	58,6	40	97,6	7,50	17,68
Cycle 15 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	40	57,1	40	100,0	2,50	8,89
Cycle 16 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	38	54,3	36	94,7	6,48	15,57
Cycle 17 Day 1	Yes	3	37,5	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	8,33	20,12
Cycle 18 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	35	50,0	32	91,4	7,29	14,00
Cycle 19 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	30	90,9	7,78	14,34
Cycle 20 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	29	87,9	2,30	8,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	24	88,9	9,72	18,33
Cycle 22 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	23	85,2	10,14	23,43
Cycle 23 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	19	27,1	16	84,2	8,33	25,82
Cycle 24 Day 1	Yes	2	25,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	6,25	13,44
Cycle 25 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	13	18,6	11	84,6	6,06	13,48
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	6,06	13,48
Cycle 27 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	10	14,3	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	9	12,9	8	88,9	12,50	17,25
Cycle 29 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	8	11,4	6	75,0	5,56	13,61
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	6,67	14,91
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	6,67	14,91
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	0,00	0,00
Cycle 33 Day 1	No	2	2,9	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	20,51	26,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30AP_SG.xls
28NOV2019 10:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	81,84	18,45
Cycle 2 Day 1	All	72	92,3	64	88,9	79,69	20,67
Cycle 3 Day 1	All	68	87,2	64	94,1	75,52	22,02
Cycle 4 Day 1	All	67	85,9	64	95,5	79,95	19,29
Cycle 5 Day 1	All	65	83,3	64	98,5	78,65	18,42
Cycle 6 Day 1	All	63	80,8	60	95,2	77,50	16,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	79,82	18,29
Cycle 8 Day 1	All	56	71,8	52	92,9	77,24	22,39
Cycle 9 Day 1	All	51	65,4	51	100,0	79,41	19,32
Cycle 10 Day 1	All	51	65,4	50	98,0	80,00	18,13
Cycle 11 Day 1	All	50	64,1	50	100,0	79,67	16,60
Cycle 12 Day 1	All	49	62,8	45	91,8	79,63	18,77
Cycle 13 Day 1	All	46	59,0	45	97,8	81,48	20,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	79,55	21,22
Cycle 15 Day 1	All	44	56,4	44	100,0	77,65	22,43
Cycle 16 Day 1	All	41	52,6	39	95,1	80,77	18,55
Cycle 17 Day 1	All	39	50,0	39	100,0	82,91	17,72
Cycle 18 Day 1	All	38	48,7	35	92,1	79,05	19,11
Cycle 19 Day 1	All	36	46,2	33	91,7	76,77	24,27
Cycle 20 Day 1	All	36	46,2	32	88,9	77,60	22,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	75,00	20,14
Cycle 22 Day 1	All	29	37,2	25	86,2	76,67	21,52
Cycle 23 Day 1	All	21	26,9	18	85,7	81,48	18,86
Cycle 24 Day 1	All	20	25,6	18	90,0	79,63	23,26
Cycle 25 Day 1	All	15	19,2	13	86,7	70,51	27,35
Cycle 26 Day 1	All	14	17,9	12	85,7	70,83	26,71
Cycle 27 Day 1	All	11	14,1	8	72,7	64,58	27,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	59,26	26,50
Cycle 29 Day 1	All	9	11,5	7	77,8	57,14	28,64
Cycle 30 Day 1	All	7	9,0	5	71,4	63,33	18,26
Cycle 31 Day 1	All	7	9,0	5	71,4	70,00	13,94
Cycle 32 Day 1	All	6	7,7	5	83,3	66,67	16,67
Cycle 33 Day 1	All	2	2,6	2	100,0	66,67	23,57
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	74,40	20,02
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	81,03	22,59
	Female	49	100,0	49	100,0	82,31	15,74
Cycle 2 Day 1	Male	27	93,1	24	88,9	79,17	19,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	80,00	21,75
Cycle 3 Day 1	Male	25	86,2	23	92,0	79,71	21,29
	Female	43	87,8	41	95,3	73,17	22,32
Cycle 4 Day 1	Male	25	86,2	25	100,0	83,33	16,67
	Female	42	85,7	39	92,9	77,78	20,71
Cycle 5 Day 1	Male	25	86,2	25	100,0	79,33	16,86
	Female	40	81,6	39	97,5	78,21	19,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	78,26	13,70
	Female	38	77,6	37	97,4	77,03	18,57
Cycle 7 Day 1	Male	23	79,3	23	100,0	78,99	12,53
	Female	37	75,5	34	91,9	80,39	21,51
Cycle 8 Day 1	Male	21	72,4	19	90,5	76,32	24,42
	Female	35	71,4	33	94,3	77,78	21,52
Cycle 9 Day 1	Male	18	62,1	18	100,0	81,48	20,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	78,28	18,86
Cycle 10 Day 1	Male	18	62,1	18	100,0	76,85	20,72
	Female	33	67,3	32	97,0	81,77	16,59
Cycle 11 Day 1	Male	18	62,1	18	100,0	78,70	18,79
	Female	32	65,3	32	100,0	80,21	15,52
Cycle 12 Day 1	Male	17	58,6	17	100,0	81,37	17,56
	Female	32	65,3	28	87,5	78,57	19,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	86,27	16,91
	Female	29	59,2	28	96,6	78,57	22,16
Cycle 14 Day 1	Male	17	58,6	16	94,1	83,33	19,25
	Female	28	57,1	28	100,0	77,38	22,32
Cycle 15 Day 1	Male	16	55,2	16	100,0	81,25	18,13
	Female	28	57,1	28	100,0	75,60	24,63
Cycle 16 Day 1	Male	14	48,3	14	100,0	82,14	19,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	80,00	18,63
Cycle 17 Day 1	Male	12	41,4	12	100,0	87,50	17,59
	Female	27	55,1	27	100,0	80,86	17,73
Cycle 18 Day 1	Male	11	37,9	10	90,9	83,33	22,22
	Female	27	55,1	25	92,6	77,33	17,92
Cycle 19 Day 1	Male	10	34,5	10	100,0	76,67	22,50
	Female	26	53,1	23	88,5	76,81	25,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	81,48	25,61
	Female	26	53,1	23	88,5	76,09	21,80
Cycle 21 Day 1	Male	8	27,6	8	100,0	75,00	23,57
	Female	21	42,9	18	85,7	75,00	19,17
Cycle 22 Day 1	Male	8	27,6	6	75,0	77,78	25,09
	Female	21	42,9	19	90,5	76,32	21,02
Cycle 23 Day 1	Male	5	17,2	4	80,0	75,00	21,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	83,33	18,49
Cycle 24 Day 1	Male	5	17,2	4	80,0	62,50	28,46
	Female	15	30,6	14	93,3	84,52	20,11
Cycle 25 Day 1	Male	3	10,3	2	66,7	66,67	47,14
	Female	12	24,5	11	91,7	71,21	25,92
Cycle 26 Day 1	Male	3	10,3	2	66,7	66,67	47,14
	Female	11	22,4	10	90,9	71,67	24,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	75,00	35,36
	Female	8	16,3	6	75,0	61,11	27,22
Cycle 28 Day 1	Male	2	6,9	2	100,0	66,67	47,14
	Female	8	16,3	7	87,5	57,14	23,29
Cycle 29 Day 1	Male	1	3,4	1	100,0	33,33	-
	Female	8	16,3	6	75,0	61,11	29,19
Cycle 30 Day 1	Male	1	3,4	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	66,67	19,25
Cycle 31 Day 1	Male	1	3,4	1	100,0	66,67	-
	Female	6	12,2	4	66,7	70,83	15,96
Cycle 32 Day 1	Male	1	3,4	1	100,0	50,00	-
	Female	5	10,2	4	80,0	70,83	15,96
Cycle 33 Day 1	Male	1	3,4	1	100,0	50,00	-
	Female	1	2,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	72,22	20,57
	Female	21	42,9	13	61,9	76,92	19,88
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	83,87	18,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	71,43	17,82
	>=75	2	100,0	2	100,0	91,67	11,79
Cycle 2 Day 1	18-64	59	95,2	52	88,1	82,05	18,33
	65-74	11	78,6	10	90,9	63,33	25,82
	>=75	2	100,0	2	100,0	100,00	0,00
Cycle 3 Day 1	18-64	56	90,3	52	92,9	76,60	21,96
	65-74	10	71,4	10	100,0	68,33	22,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 4 Day 1	18-64	55	88,7	53	96,4	81,13	19,62
	65-74	10	71,4	9	90,0	70,37	16,20
	>=75	2	100,0	2	100,0	91,67	11,79
Cycle 5 Day 1	18-64	53	85,5	52	98,1	80,45	18,29
	65-74	10	71,4	10	100,0	70,00	18,92
	>=75	2	100,0	2	100,0	75,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	79,25	16,15
	65-74	10	71,4	9	90,0	66,67	18,63
	>=75	2	100,0	2	100,0	83,33	0,00
Cycle 7 Day 1	18-64	49	79,0	47	95,9	80,85	18,71
	65-74	9	64,3	8	88,9	72,92	15,27
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 8 Day 1	18-64	45	72,6	41	91,1	78,46	21,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	66,67	23,57
	>=75	2	100,0	2	100,0	100,00	0,00
Cycle 9 Day 1	18-64	40	64,5	40	100,0	81,67	18,02
	65-74	9	64,3	9	100,0	66,67	22,05
	>=75	2	100,0	2	100,0	91,67	11,79
Cycle 10 Day 1	18-64	40	64,5	39	97,5	81,62	19,04
	65-74	9	64,3	9	100,0	74,07	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	75,00	11,79
Cycle 11 Day 1	18-64	39	62,9	39	100,0	79,49	17,30
	65-74	9	64,3	9	100,0	79,63	16,20
	>=75	2	100,0	2	100,0	83,33	0,00
Cycle 12 Day 1	18-64	38	61,3	35	92,1	79,52	20,25
	65-74	9	64,3	8	88,9	75,00	8,91
	>=75	2	100,0	2	100,0	100,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	83,33	18,80
	65-74	9	64,3	9	100,0	70,37	24,69
	>=75	2	100,0	2	100,0	100,00	0,00
Cycle 14 Day 1	18-64	35	56,5	35	100,0	79,52	21,04
	65-74	9	64,3	8	88,9	77,08	23,46
	>=75	1	50,0	1	100,0	100,00	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	78,57	22,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	72,92	23,46
	>=75	1	50,0	1	100,0	83,33	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	80,21	19,14
	65-74	7	50,0	6	85,7	80,56	16,39
	>=75	1	50,0	1	100,0	100,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	83,33	17,96
	65-74	6	42,9	6	100,0	80,56	19,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	83,33	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	80,46	18,40
	65-74	6	42,9	5	83,3	66,67	20,41
	>=75	1	50,0	1	100,0	100,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	76,79	25,39
	65-74	5	35,7	4	80,0	75,00	21,52
	>=75	1	50,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	78,85	23,83
	65-74	5	35,7	5	100,0	66,67	11,79
	>=75	1	50,0	1	100,0	100,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	76,98	20,05
	65-74	4	28,6	4	100,0	66,67	23,57
	>=75	1	50,0	1	100,0	66,67	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	78,33	21,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	66,67	23,57
	>=75	1	50,0	1	100,0	83,33	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	81,25	20,07
	65-74	2	14,3	2	100,0	83,33	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	80,21	24,51
	65-74	2	14,3	2	100,0	75,00	11,79
Cycle 25 Day 1	18-64	14	22,6	12	85,7	69,44	28,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	83,33	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	70,83	26,71
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	64,58	27,37
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	59,26	26,50
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	57,14	28,64
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	63,33	18,26
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	70,00	13,94
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	62,50	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	83,33	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	50,00	-
	65-74	1	7,1	1	100,0	83,33	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	75,83	22,60
	65-74	10	71,4	7	70,0	71,43	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	66,67	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	84,29	16,14
	Other	43	100,0	43	100,0	79,84	20,10
Cycle 2 Day 1	White	33	94,3	28	84,8	82,14	19,74
	Other	39	90,7	36	92,3	77,78	21,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	75,93	22,33
	Other	37	86,0	37	100,0	75,23	22,09
Cycle 4 Day 1	White	31	88,6	28	90,3	85,12	15,27
	Other	36	83,7	36	100,0	75,93	21,25
Cycle 5 Day 1	White	31	88,6	30	96,8	78,89	20,50
	Other	34	79,1	34	100,0	78,43	16,68
Cycle 6 Day 1	White	30	85,7	28	93,3	80,95	14,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	74,48	17,95
Cycle 7 Day 1	White	29	82,9	27	93,1	82,10	17,86
	Other	31	72,1	30	96,8	77,78	18,74
Cycle 8 Day 1	White	28	80,0	24	85,7	83,33	16,30
	Other	28	65,1	28	100,0	72,02	25,68
Cycle 9 Day 1	White	26	74,3	26	100,0	82,05	19,39
	Other	25	58,1	25	100,0	76,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	84,00	18,93
	Other	25	58,1	25	100,0	76,00	16,72
Cycle 11 Day 1	White	26	74,3	26	100,0	83,33	17,64
	Other	24	55,8	24	100,0	75,69	14,73
Cycle 12 Day 1	White	26	74,3	22	84,6	81,82	17,75
	Other	23	53,5	23	100,0	77,54	19,85
Cycle 13 Day 1	White	24	68,6	23	95,8	86,23	21,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	76,52	19,01
Cycle 14 Day 1	White	24	68,6	24	100,0	81,94	21,38
	Other	21	48,8	20	95,2	76,67	21,22
Cycle 15 Day 1	White	24	68,6	24	100,0	80,56	20,66
	Other	20	46,5	20	100,0	74,17	24,47
Cycle 16 Day 1	White	22	62,9	20	90,9	84,17	15,74
	Other	19	44,2	19	100,0	77,19	20,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	85,61	15,68
	Other	17	39,5	17	100,0	79,41	20,01
Cycle 18 Day 1	White	21	60,0	18	85,7	82,41	19,36
	Other	17	39,5	17	100,0	75,49	18,74
Cycle 19 Day 1	White	20	57,1	20	100,0	77,50	19,70
	Other	16	37,2	13	81,3	75,64	30,89
Cycle 20 Day 1	White	20	57,1	17	85,0	79,41	22,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	75,56	23,46
Cycle 21 Day 1	White	16	45,7	14	87,5	77,38	21,29
	Other	13	30,2	12	92,3	72,22	19,25
Cycle 22 Day 1	White	16	45,7	13	81,3	82,05	18,59
	Other	13	30,2	12	92,3	70,83	23,70
Cycle 23 Day 1	White	12	34,3	10	83,3	85,00	14,59
	Other	9	20,9	8	88,9	77,08	23,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	80,00	21,94
	Other	9	20,9	8	88,9	79,17	26,35
Cycle 25 Day 1	White	10	28,6	8	80,0	75,00	21,82
	Other	5	11,6	5	100,0	63,33	36,13
Cycle 26 Day 1	White	10	28,6	8	80,0	72,92	26,63
	Other	4	9,3	4	100,0	66,67	30,43
Cycle 27 Day 1	White	8	22,9	5	62,5	66,67	26,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	61,11	34,69
Cycle 28 Day 1	White	7	20,0	6	85,7	69,44	26,70
	Other	3	7,0	3	100,0	38,89	9,62
Cycle 29 Day 1	White	6	17,1	4	66,7	45,83	28,46
	Other	3	7,0	3	100,0	72,22	25,46
Cycle 30 Day 1	White	4	11,4	2	50,0	66,67	23,57
	Other	3	7,0	3	100,0	61,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	75,00	11,79
	Other	3	7,0	3	100,0	66,67	16,67
Cycle 32 Day 1	White	4	11,4	3	75,0	72,22	19,25
	Other	2	4,7	2	100,0	58,33	11,79
Cycle 33 Day 1	White	2	5,7	2	100,0	66,67	23,57
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	80,56	15,62
	Other	24	55,8	16	66,7	69,79	22,13
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	80,30	18,99
	Europe (EU)	17	100,0	17	100,0	91,18	8,57
	Asia (AS)	39	100,0	39	100,0	78,63	20,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	16	80,0	78,13	22,54
	Europe (EU)	16	94,1	13	81,3	87,18	13,87
	Asia (AS)	36	92,3	35	97,2	77,62	21,75
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	76,32	22,44
	Europe (EU)	15	88,2	12	80,0	81,94	18,06
	Asia (AS)	33	84,6	33	100,0	72,73	23,13
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	82,50	17,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	91,67	11,24
	Asia (AS)	32	82,1	32	100,0	73,96	20,71
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	78,33	19,57
	Europe (EU)	15	88,2	14	93,3	82,14	20,11
	Asia (AS)	30	76,9	30	100,0	77,22	17,22
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	83,33	14,31
	Europe (EU)	14	82,4	13	92,9	78,21	17,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	72,84	17,39
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	87,04	14,64
	Europe (EU)	14	82,4	13	92,9	79,49	15,45
	Asia (AS)	27	69,2	26	96,3	75,00	20,68
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	82,35	18,13
	Europe (EU)	14	82,4	11	78,6	80,30	16,36
	Asia (AS)	24	61,5	24	100,0	72,22	26,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	81,48	17,98
	Europe (EU)	12	70,6	12	100,0	81,94	19,41
	Asia (AS)	21	53,8	21	100,0	76,19	20,80
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	83,33	20,41
	Europe (EU)	12	70,6	12	100,0	80,56	13,91
	Asia (AS)	21	53,8	21	100,0	76,98	18,62
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	82,41	18,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	83,33	14,21
	Asia (AS)	20	51,3	20	100,0	75,00	15,77
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	82,35	16,11
	Europe (EU)	12	70,6	9	75,0	77,78	16,67
	Asia (AS)	19	48,7	19	100,0	78,07	22,26
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	85,29	17,56
	Europe (EU)	11	64,7	10	90,9	83,33	26,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	76,85	19,92
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	83,33	17,68
	Europe (EU)	11	64,7	11	100,0	83,33	18,26
	Asia (AS)	17	43,6	16	94,1	72,92	25,73
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	84,31	16,11
	Europe (EU)	11	64,7	11	100,0	80,30	20,84
	Asia (AS)	16	41,0	16	100,0	68,75	27,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	85,71	15,82
	Europe (EU)	11	64,7	9	81,8	81,48	15,47
	Asia (AS)	16	41,0	16	100,0	76,04	21,92
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	83,33	19,61
	Europe (EU)	10	58,8	10	100,0	90,00	8,61
	Asia (AS)	15	38,5	15	100,0	77,78	19,59
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	82,14	20,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	88,89	8,61
	Asia (AS)	15	38,5	15	100,0	72,22	19,59
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	78,21	22,96
	Europe (EU)	9	52,9	9	100,0	79,63	13,89
	Asia (AS)	14	35,9	11	78,6	72,73	32,72
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	80,77	25,32
	Europe (EU)	9	52,9	6	66,7	80,56	12,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	73,08	24,09
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	75,00	22,57
	Europe (EU)	7	41,2	6	85,7	83,33	14,91
	Asia (AS)	11	28,2	10	90,9	70,00	20,49
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	81,67	21,44
	Europe (EU)	7	41,2	5	71,4	86,67	7,45
	Asia (AS)	11	28,2	10	90,9	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	85,19	13,03
	Europe (EU)	5	29,4	3	60,0	94,44	9,62
	Asia (AS)	7	17,9	6	85,7	69,44	24,53
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	75,00	21,82
	Europe (EU)	5	29,4	4	80,0	95,83	8,33
	Asia (AS)	7	17,9	6	85,7	75,00	29,34
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	76,19	23,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	91,67	11,79
	Asia (AS)	4	10,3	4	100,0	50,00	30,43
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	69,44	24,53
	Europe (EU)	4	23,5	2	50,0	100,00	0,00
	Asia (AS)	4	10,3	4	100,0	58,33	28,87
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	75,00	21,52
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	54,17	31,55
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	66,67	27,22
	Europe (EU)	2	11,8	1	50,0	100,00	-
	Asia (AS)	4	10,3	4	100,0	41,67	9,62
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	55,56	25,46
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	58,33	34,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	66,67	23,57
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	61,11	19,25
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	75,00	11,79
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	66,67	16,67
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	83,33	-
	Asia (AS)	3	7,7	2	66,7	58,33	11,79
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	50,00	-
	Europe (EU)	1	5,9	1	100,0	83,33	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	78,79	16,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	79,17	15,96
	Asia (AS)	21	53,8	13	61,9	69,23	23,42
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	87,22	14,96
	1	38	100,0	38	100,0	80,26	20,81
	2	10	100,0	10	100,0	71,67	13,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	26	86,7	79,49	25,08
	1	36	94,7	32	88,9	80,21	18,18
	2	6	60,0	6	100,0	77,78	13,61
Cycle 3 Day 1	0	29	96,7	27	93,1	79,63	19,79
	1	34	89,5	32	94,1	73,44	23,89
	2	5	50,0	5	100,0	66,67	20,41
Cycle 4 Day 1	0	29	96,7	28	96,6	81,55	17,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	81,77	17,12
	2	5	50,0	4	80,0	54,17	31,55
Cycle 5 Day 1	0	29	96,7	29	100,0	77,59	20,06
	1	33	86,8	32	97,0	80,21	16,63
	2	3	30,0	3	100,0	72,22	25,46
Cycle 6 Day 1	0	29	96,7	29	100,0	79,89	16,89
	1	31	81,6	28	90,3	75,60	16,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	72,22	25,46
Cycle 7 Day 1	0	29	96,7	28	96,6	82,14	19,21
	1	28	73,7	26	92,9	77,56	18,22
	2	3	30,0	3	100,0	77,78	9,62
Cycle 8 Day 1	0	28	93,3	26	92,9	78,21	20,96
	1	25	65,8	23	92,0	75,36	25,06
	2	3	30,0	3	100,0	83,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	79,49	19,61
	1	23	60,5	23	100,0	78,99	19,60
	2	2	20,0	2	100,0	83,33	23,57
Cycle 10 Day 1	0	26	86,7	26	100,0	77,56	18,22
	1	23	60,5	22	95,7	81,82	18,48
	2	2	20,0	2	100,0	91,67	11,79
Cycle 11 Day 1	0	26	86,7	26	100,0	79,49	18,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	78,79	14,71
	2	2	20,0	2	100,0	91,67	11,79
Cycle 12 Day 1	0	25	83,3	22	88,0	79,55	15,37
	1	22	57,9	21	95,5	80,95	21,91
	2	2	20,0	2	100,0	66,67	23,57
Cycle 13 Day 1	0	25	83,3	24	96,0	82,64	22,24
	1	20	52,6	20	100,0	80,83	18,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	66,67	-
Cycle 14 Day 1	0	25	83,3	24	96,0	77,08	22,42
	1	19	50,0	19	100,0	82,46	20,39
	2	1	10,0	1	100,0	83,33	-
Cycle 15 Day 1	0	24	80,0	24	100,0	77,78	21,80
	1	19	50,0	19	100,0	77,19	24,35
	2	1	10,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	80,00	17,61
	1	18	47,4	18	100,0	81,48	20,52
	2	1	10,0	1	100,0	83,33	-
Cycle 17 Day 1	0	21	70,0	21	100,0	82,54	17,06
	1	17	44,7	17	100,0	83,33	19,54
	2	1	10,0	1	100,0	83,33	-
Cycle 18 Day 1	0	21	70,0	18	85,7	77,78	20,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	79,17	17,74
	2	1	10,0	1	100,0	100,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	78,07	19,29
	1	15	39,5	13	86,7	74,36	31,63
	2	1	10,0	1	100,0	83,33	-
Cycle 20 Day 1	0	20	66,7	17	85,0	75,49	22,14
	1	15	39,5	14	93,3	79,76	24,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	83,33	-
Cycle 21 Day 1	0	15	50,0	14	93,3	75,00	23,34
	1	13	34,2	11	84,6	74,24	17,26
	2	1	10,0	1	100,0	83,33	-
Cycle 22 Day 1	0	15	50,0	12	80,0	75,00	23,03
	1	13	34,2	12	92,3	77,78	21,71
	2	1	10,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	81,48	13,03
	1	9	23,7	8	88,9	81,25	25,88
	2	1	10,0	1	100,0	83,33	-
Cycle 24 Day 1	0	10	33,3	9	90,0	77,78	22,05
	1	9	23,7	8	88,9	79,17	26,35
	2	1	10,0	1	100,0	100,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	72,22	22,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	69,05	32,53
Cycle 26 Day 1	0	8	26,7	6	75,0	69,44	28,71
	1	6	15,8	6	100,0	72,22	27,22
Cycle 27 Day 1	0	6	20,0	3	50,0	61,11	34,69
	1	5	13,2	5	100,0	66,67	26,35
Cycle 28 Day 1	0	5	16,7	4	80,0	70,83	34,36
	1	5	13,2	5	100,0	50,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	25,00	11,79
	1	5	13,2	5	100,0	70,00	21,73
Cycle 30 Day 1	0	3	10,0	1	33,3	50,00	-
	1	4	10,5	4	100,0	66,67	19,25
Cycle 31 Day 1	0	3	10,0	1	33,3	66,67	-
	1	4	10,5	4	100,0	70,83	15,96
Cycle 32 Day 1	0	3	10,0	2	66,7	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	66,67	16,67
Cycle 33 Day 1	0	2	6,7	2	100,0	66,67	23,57
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	77,38	14,03
	1	20	52,6	12	60,0	75,00	24,10
	2	4	40,0	2	50,0	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	82,80	16,93
	1	3	100,0	3	100,0	83,33	16,67
	2 or More	44	100,0	44	100,0	81,06	19,88
Cycle 2 Day 1	None	30	96,8	26	86,7	80,77	21,44
	1	2	66,7	1	50,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	78,38	20,36
Cycle 3 Day 1	None	30	96,8	28	93,3	79,17	22,96
	1	2	66,7	1	50,0	100,00	-
	2 or More	36	81,8	35	97,2	71,90	20,92
Cycle 4 Day 1	None	30	96,8	29	96,7	82,18	17,78
	1	2	66,7	2	100,0	100,00	0,00
	2 or More	35	79,5	33	94,3	76,77	20,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	82,22	18,54
	1	2	66,7	2	100,0	91,67	11,79
	2 or More	33	75,0	32	97,0	74,48	17,95
Cycle 6 Day 1	None	29	93,5	28	96,6	81,55	15,27
	1	2	66,7	2	100,0	91,67	11,79
	2 or More	32	72,7	30	93,8	72,78	17,22
Cycle 7 Day 1	None	27	87,1	26	96,3	82,69	21,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	83,33	0,00
	2 or More	31	70,5	29	93,5	77,01	15,69
Cycle 8 Day 1	None	26	83,9	25	96,2	75,33	25,06
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	79,01	19,93
Cycle 9 Day 1	None	25	80,6	25	100,0	82,67	17,66
	1	1	33,3	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	76,00	21,02
Cycle 10 Day 1	None	25	80,6	24	96,0	81,25	19,23
	1	1	33,3	1	100,0	100,00	-
	2 or More	25	56,8	25	100,0	78,00	17,16
Cycle 11 Day 1	None	25	80,6	25	100,0	78,67	19,56
	1	1	33,3	1	100,0	100,00	-
	2 or More	24	54,5	24	100,0	79,86	12,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	77,08	22,42
	1	1	33,3	1	100,0	83,33	-
	2 or More	23	52,3	20	87,0	82,50	13,76
Cycle 13 Day 1	None	24	77,4	23	95,8	81,16	19,66
	1	1	33,3	1	100,0	100,00	-
	2 or More	21	47,7	21	100,0	80,95	21,91
Cycle 14 Day 1	None	23	74,2	23	100,0	78,26	22,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	83,33	-
	2 or More	21	47,7	20	95,2	80,83	20,43
Cycle 15 Day 1	None	23	74,2	23	100,0	76,09	25,54
	1	1	33,3	1	100,0	83,33	-
	2 or More	20	45,5	20	100,0	79,17	19,40
Cycle 16 Day 1	None	20	64,5	19	95,0	80,70	18,64
	1	1	33,3	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	80,70	19,45
Cycle 17 Day 1	None	19	61,3	19	100,0	87,72	12,22
	1	1	33,3	1	100,0	100,00	-
	2 or More	19	43,2	19	100,0	77,19	20,94
Cycle 18 Day 1	None	18	58,1	17	94,4	80,39	18,85
	1	1	33,3	1	100,0	100,00	-
	2 or More	19	43,2	17	89,5	76,47	19,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	78,43	28,11
	1	1	33,3	1	100,0	83,33	-
	2 or More	18	40,9	15	83,3	74,44	20,77
Cycle 20 Day 1	None	17	54,8	16	94,1	81,25	22,67
	1	1	33,3	1	100,0	100,00	-
	2 or More	18	40,9	15	83,3	72,22	22,42
Cycle 21 Day 1	None	15	48,4	13	86,7	80,77	20,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	69,23	19,06
Cycle 22 Day 1	None	15	48,4	13	86,7	83,33	15,21
	2 or More	14	31,8	12	85,7	69,44	25,46
Cycle 23 Day 1	None	10	32,3	9	90,0	85,19	13,03
	2 or More	11	25,0	9	81,8	77,78	23,57
Cycle 24 Day 1	None	10	32,3	10	100,0	80,00	21,94
	2 or More	10	22,7	8	80,0	79,17	26,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	68,75	30,13
	2 or More	6	13,6	5	83,3	73,33	25,28
Cycle 26 Day 1	None	8	25,8	8	100,0	68,75	27,37
	2 or More	6	13,6	4	66,7	75,00	28,87
Cycle 27 Day 1	None	7	22,6	6	85,7	61,11	27,22
	2 or More	4	9,1	2	50,0	75,00	35,36
Cycle 28 Day 1	None	7	22,6	7	100,0	64,29	27,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	41,67	11,79
Cycle 29 Day 1	None	6	19,4	5	83,3	50,00	26,35
	2 or More	3	6,8	2	66,7	75,00	35,36
Cycle 30 Day 1	None	4	12,9	3	75,0	61,11	19,25
	2 or More	3	6,8	2	66,7	66,67	23,57
Cycle 31 Day 1	None	4	12,9	3	75,0	72,22	9,62
	2 or More	3	6,8	2	66,7	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	66,67	16,67
	2 or More	2	4,5	2	100,0	66,67	23,57
Cycle 33 Day 1	None	1	3,2	1	100,0	50,00	-
	2 or More	1	2,3	1	100,0	83,33	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	77,78	14,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	83,33	-
	2 or More	24	54,5	15	62,5	71,11	23,96
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	82,80	16,93
	Previously Treated	47	100,0	47	100,0	81,21	19,54
Cycle 2 Day 1	Naïve	30	96,8	26	86,7	80,77	21,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	78,95	20,39
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	79,17	22,96
	Previously Treated	38	80,9	36	94,7	72,69	21,14
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	82,18	17,78
	Previously Treated	37	78,7	35	94,6	78,10	20,52
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	82,22	18,54
	Previously Treated	35	74,5	34	97,1	75,49	18,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	81,55	15,27
	Previously Treated	34	72,3	32	94,1	73,96	17,42
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	82,69	21,33
	Previously Treated	33	70,2	31	93,9	77,42	15,24
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	75,33	25,06
	Previously Treated	30	63,8	27	90,0	79,01	19,93
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	82,67	17,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	76,28	20,64
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	81,25	19,23
	Previously Treated	26	55,3	26	100,0	78,85	17,36
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	78,67	19,56
	Previously Treated	25	53,2	25	100,0	80,67	13,33
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	77,08	22,42
	Previously Treated	24	51,1	21	87,5	82,54	13,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	81,16	19,66
	Previously Treated	22	46,8	22	100,0	81,82	21,77
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	78,26	22,72
	Previously Treated	22	46,8	21	95,5	80,95	19,92
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	76,09	25,54
	Previously Treated	21	44,7	21	100,0	79,37	18,93
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	80,70	18,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	80,83	18,95
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	87,72	12,22
	Previously Treated	20	42,6	20	100,0	78,33	21,01
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	80,39	18,85
	Previously Treated	20	42,6	18	90,0	77,78	19,80
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	78,43	28,11
	Previously Treated	19	40,4	16	84,2	75,00	20,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	81,25	22,67
	Previously Treated	19	40,4	16	84,2	73,96	22,75
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	80,77	20,24
	Previously Treated	14	29,8	13	92,9	69,23	19,06
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	83,33	15,21
	Previously Treated	14	29,8	12	85,7	69,44	25,46
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	85,19	13,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	77,78	23,57
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	80,00	21,94
	Previously Treated	10	21,3	8	80,0	79,17	26,35
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	68,75	30,13
	Previously Treated	6	12,8	5	83,3	73,33	25,28
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	68,75	27,37
	Previously Treated	6	12,8	4	66,7	75,00	28,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	61,11	27,22
	Previously Treated	4	8,5	2	50,0	75,00	35,36
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	64,29	27,94
	Previously Treated	3	6,4	2	66,7	41,67	11,79
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	50,00	26,35
	Previously Treated	3	6,4	2	66,7	75,00	35,36
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	61,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	66,67	23,57
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	72,22	9,62
	Previously Treated	3	6,4	2	66,7	66,67	23,57
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	66,67	16,67
	Previously Treated	2	4,3	2	100,0	66,67	23,57
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	50,00	-
	Previously Treated	1	2,1	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	77,78	14,79
	Previously Treated	26	55,3	16	61,5	71,88	23,35
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	80,00	20,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	83,33	16,67
Cycle 2 Day 1	Local	32	91,4	29	90,6	79,31	19,24
	Central	40	93,0	35	87,5	80,00	22,07
Cycle 3 Day 1	Local	29	82,9	28	96,6	75,00	25,05
	Central	39	90,7	36	92,3	75,93	19,70
Cycle 4 Day 1	Local	28	80,0	27	96,4	79,63	20,32
	Central	39	90,7	37	94,9	80,18	18,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	79,63	20,32
	Central	38	88,4	37	97,4	77,93	17,15
Cycle 6 Day 1	Local	27	77,1	27	100,0	78,40	17,18
	Central	36	83,7	33	91,7	76,77	16,64
Cycle 7 Day 1	Local	27	77,1	27	100,0	82,10	19,57
	Central	33	76,7	30	90,9	77,78	17,14
Cycle 8 Day 1	Local	26	74,3	26	100,0	78,21	22,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	76,28	22,69
Cycle 9 Day 1	Local	25	71,4	25	100,0	78,00	20,25
	Central	26	60,5	26	100,0	80,77	18,67
Cycle 10 Day 1	Local	25	71,4	24	96,0	80,56	18,17
	Central	26	60,5	26	100,0	79,49	18,44
Cycle 11 Day 1	Local	24	68,6	24	100,0	79,17	17,20
	Central	26	60,5	26	100,0	80,13	16,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	79,55	21,78
	Central	26	60,5	23	88,5	79,71	15,86
Cycle 13 Day 1	Local	22	62,9	22	100,0	77,27	23,31
	Central	24	55,8	23	95,8	85,51	16,90
Cycle 14 Day 1	Local	22	62,9	22	100,0	80,30	20,98
	Central	23	53,5	22	95,7	78,79	21,93
Cycle 15 Day 1	Local	22	62,9	22	100,0	77,27	25,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	78,03	19,51
Cycle 16 Day 1	Local	20	57,1	20	100,0	80,83	18,16
	Central	21	48,8	19	90,5	80,70	19,45
Cycle 17 Day 1	Local	20	57,1	20	100,0	83,33	17,10
	Central	19	44,2	19	100,0	82,46	18,82
Cycle 18 Day 1	Local	20	57,1	19	95,0	80,70	18,64
	Central	18	41,9	16	88,9	77,08	20,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	75,49	29,53
	Central	17	39,5	16	94,1	78,13	17,97
Cycle 20 Day 1	Local	19	54,3	17	89,5	77,45	25,65
	Central	17	39,5	15	88,2	77,78	19,59
Cycle 21 Day 1	Local	14	40,0	12	85,7	75,00	21,90
	Central	15	34,9	14	93,3	75,00	19,34
Cycle 22 Day 1	Local	14	40,0	12	85,7	79,17	21,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	74,36	22,17
Cycle 23 Day 1	Local	11	31,4	10	90,9	81,67	16,57
	Central	10	23,3	8	80,0	81,25	22,60
Cycle 24 Day 1	Local	11	31,4	10	90,9	78,33	23,64
	Central	9	20,9	8	88,9	81,25	24,30
Cycle 25 Day 1	Local	7	20,0	7	100,0	69,05	32,53
	Central	8	18,6	6	75,0	72,22	22,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	63,89	28,71
	Central	8	18,6	6	75,0	77,78	25,09
Cycle 27 Day 1	Local	4	11,4	4	100,0	66,67	30,43
	Central	7	16,3	4	57,1	62,50	28,46
Cycle 28 Day 1	Local	4	11,4	4	100,0	58,33	31,91
	Central	6	14,0	5	83,3	60,00	25,28
Cycle 29 Day 1	Local	3	8,6	3	100,0	61,11	25,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	54,17	34,36
Cycle 30 Day 1	Local	3	8,6	3	100,0	61,11	19,25
	Central	4	9,3	2	50,0	66,67	23,57
Cycle 31 Day 1	Local	3	8,6	3	100,0	72,22	9,62
	Central	4	9,3	2	50,0	66,67	23,57
Cycle 32 Day 1	Local	3	8,6	3	100,0	66,67	16,67
	Central	3	7,0	2	66,7	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	50,00	-
	Central	1	2,3	1	100,0	83,33	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	76,19	19,30
	Central	21	48,8	14	66,7	72,62	21,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	82,66	18,39
	No	4	100,0	4	100,0	66,67	13,61
Cycle 2 Day 1	Yes	70	94,6	62	88,6	81,18	18,96
	No	2	50,0	2	100,0	33,33	23,57
Cycle 3 Day 1	Yes	66	89,2	62	93,9	76,61	21,01
	No	2	50,0	2	100,0	41,67	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	80,91	18,81
	No	2	50,0	2	100,0	50,00	0,00
Cycle 5 Day 1	Yes	63	85,1	62	98,4	78,76	18,15
	No	2	50,0	2	100,0	75,00	35,36
Cycle 6 Day 1	Yes	61	82,4	58	95,1	78,74	15,55
	No	2	50,0	2	100,0	41,67	11,79
Cycle 7 Day 1	Yes	58	78,4	55	94,8	81,52	15,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	23,57
Cycle 8 Day 1	Yes	54	73,0	50	92,6	79,33	20,08
	No	2	50,0	2	100,0	25,00	11,79
Cycle 9 Day 1	Yes	49	66,2	49	100,0	80,61	18,43
	No	2	50,0	2	100,0	50,00	23,57
Cycle 10 Day 1	Yes	49	66,2	48	98,0	80,21	18,40
	No	2	50,0	2	100,0	75,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	80,56	16,25
	No	2	50,0	2	100,0	58,33	11,79
Cycle 12 Day 1	Yes	47	63,5	43	91,5	81,40	16,35
	No	2	50,0	2	100,0	41,67	35,36
Cycle 13 Day 1	Yes	44	59,5	43	97,7	83,33	18,90
	No	2	50,0	2	100,0	41,67	11,79
Cycle 14 Day 1	Yes	43	58,1	42	97,7	81,75	19,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	0,00
Cycle 15 Day 1	Yes	42	56,8	42	100,0	80,16	18,86
	No	2	50,0	2	100,0	25,00	35,36
Cycle 16 Day 1	Yes	39	52,7	37	94,9	81,98	18,16
	No	2	50,0	2	100,0	58,33	11,79
Cycle 17 Day 1	Yes	37	50,0	37	100,0	83,78	17,34
	No	2	50,0	2	100,0	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	80,81	17,74
	No	2	50,0	2	100,0	50,00	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	79,17	20,30
	No	2	50,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	80,00	21,17
	No	2	50,0	2	100,0	41,67	11,79
Cycle 21 Day 1	Yes	27	36,5	24	88,9	77,08	18,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	50,00	23,57
Cycle 22 Day 1	Yes	27	36,5	23	85,2	79,71	19,43
	No	2	50,0	2	100,0	41,67	11,79
Cycle 23 Day 1	Yes	20	27,0	17	85,0	81,37	19,44
	No	1	25,0	1	100,0	83,33	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	78,43	23,40
	No	1	25,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	75,00	23,03
	No	1	25,0	1	100,0	16,67	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	74,24	25,13
	No	1	25,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	69,05	26,23
	No	1	25,0	1	100,0	33,33	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	62,50	26,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	55,56	31,03
	No	1	25,0	1	100,0	66,67	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	66,67	19,25
	No	1	25,0	1	100,0	50,00	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	70,83	15,96
	No	1	25,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	66,67	19,25
	No	1	25,0	1	100,0	66,67	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	66,67	23,57
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	74,40	20,02
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	83,33	15,43
	No	70	100,0	70	100,0	81,67	18,85
Cycle 2 Day 1	Yes	5	62,5	5	100,0	90,00	14,91
	No	67	95,7	59	88,1	78,81	20,95
Cycle 3 Day 1	Yes	5	62,5	5	100,0	86,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	74,58	22,18
Cycle 4 Day 1	Yes	5	62,5	5	100,0	86,67	18,26
	No	62	88,6	59	95,2	79,38	19,41
Cycle 5 Day 1	Yes	5	62,5	5	100,0	76,67	25,28
	No	60	85,7	59	98,3	78,81	18,00
Cycle 6 Day 1	Yes	5	62,5	5	100,0	83,33	16,67
	No	58	82,9	55	94,8	76,97	16,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	76,67	27,89
	No	55	78,6	52	94,5	80,13	17,48
Cycle 8 Day 1	Yes	5	62,5	5	100,0	66,67	35,36
	No	51	72,9	47	92,2	78,37	20,83
Cycle 9 Day 1	Yes	4	50,0	4	100,0	79,17	25,00
	No	47	67,1	47	100,0	79,43	19,10
Cycle 10 Day 1	Yes	4	50,0	4	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	79,71	17,89
Cycle 11 Day 1	Yes	4	50,0	4	100,0	79,17	25,00
	No	46	65,7	46	100,0	79,71	16,07
Cycle 12 Day 1	Yes	4	50,0	4	100,0	79,17	25,00
	No	45	64,3	41	91,1	79,67	18,45
Cycle 13 Day 1	Yes	4	50,0	4	100,0	83,33	19,25
	No	42	60,0	41	97,6	81,30	20,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	75,00	31,91
	No	41	58,6	40	97,6	80,00	20,39
Cycle 15 Day 1	Yes	4	50,0	4	100,0	75,00	31,91
	No	40	57,1	40	100,0	77,92	21,81
Cycle 16 Day 1	Yes	3	37,5	3	100,0	88,89	19,25
	No	38	54,3	36	94,7	80,09	18,61
Cycle 17 Day 1	Yes	3	37,5	3	100,0	94,44	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	81,94	17,98
Cycle 18 Day 1	Yes	3	37,5	3	100,0	88,89	19,25
	No	35	50,0	32	91,4	78,13	19,14
Cycle 19 Day 1	Yes	3	37,5	3	100,0	88,89	19,25
	No	33	47,1	30	90,9	75,56	24,66
Cycle 20 Day 1	Yes	3	37,5	3	100,0	88,89	19,25
	No	33	47,1	29	87,9	76,44	22,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	66,67	0,00
	No	27	38,6	24	88,9	75,69	20,84
Cycle 22 Day 1	Yes	2	25,0	2	100,0	83,33	23,57
	No	27	38,6	23	85,2	76,09	21,80
Cycle 23 Day 1	Yes	2	25,0	2	100,0	83,33	23,57
	No	19	27,1	16	84,2	81,25	19,12
Cycle 24 Day 1	Yes	2	25,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	79,17	23,96
Cycle 25 Day 1	Yes	2	25,0	2	100,0	83,33	23,57
	No	13	18,6	11	84,6	68,18	28,34
Cycle 26 Day 1	Yes	1	12,5	1	100,0	50,00	-
	No	13	18,6	11	84,6	72,73	27,15
Cycle 27 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	10	14,3	7	70,0	69,05	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	50,00	-
	No	9	12,9	8	88,9	60,42	28,08
Cycle 29 Day 1	Yes	1	12,5	1	100,0	16,67	-
	No	8	11,4	6	75,0	63,89	24,53
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	63,33	18,26
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	70,00	13,94
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	66,67	16,67
Cycle 33 Day 1	No	2	2,9	2	100,0	66,67	23,57
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	41,67	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	76,92	17,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CF_SG.xls
28NOV2019 10:29

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	17,95	26,69
Cycle 2 Day 1	All	72	92,3	65	90,3	41,03	31,05
Cycle 3 Day 1	All	68	87,2	64	94,1	38,54	32,10
Cycle 4 Day 1	All	67	85,9	64	95,5	33,33	30,28
Cycle 5 Day 1	All	65	83,3	64	98,5	34,38	27,84
Cycle 6 Day 1	All	63	80,8	60	95,2	31,67	27,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	30,99	31,41
Cycle 8 Day 1	All	56	71,8	52	92,9	30,77	28,66
Cycle 9 Day 1	All	51	65,4	51	100,0	31,37	26,17
Cycle 10 Day 1	All	51	65,4	50	98,0	27,33	23,03
Cycle 11 Day 1	All	50	64,1	50	100,0	28,67	25,21
Cycle 12 Day 1	All	49	62,8	45	91,8	25,93	25,51
Cycle 13 Day 1	All	46	59,0	45	97,8	27,41	22,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	30,30	28,59
Cycle 15 Day 1	All	44	56,4	44	100,0	31,82	29,60
Cycle 16 Day 1	All	41	52,6	39	95,1	26,50	31,70
Cycle 17 Day 1	All	39	50,0	39	100,0	29,06	27,76
Cycle 18 Day 1	All	38	48,7	35	92,1	22,86	27,74
Cycle 19 Day 1	All	36	46,2	33	91,7	27,27	29,41
Cycle 20 Day 1	All	36	46,2	32	88,9	25,00	29,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	29,49	28,79
Cycle 22 Day 1	All	29	37,2	25	86,2	29,33	27,76
Cycle 23 Day 1	All	21	26,9	18	85,7	31,48	33,28
Cycle 24 Day 1	All	20	25,6	18	90,0	24,07	25,06
Cycle 25 Day 1	All	15	19,2	13	86,7	28,21	29,96
Cycle 26 Day 1	All	14	17,9	12	85,7	22,22	32,82
Cycle 27 Day 1	All	11	14,1	8	72,7	33,33	35,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	18,52	24,22
Cycle 29 Day 1	All	9	11,5	7	77,8	38,10	23,00
Cycle 30 Day 1	All	7	9,0	5	71,4	33,33	23,57
Cycle 31 Day 1	All	7	9,0	5	71,4	33,33	23,57
Cycle 32 Day 1	All	6	7,7	5	83,3	40,00	14,91
Cycle 33 Day 1	All	2	2,6	2	100,0	50,00	23,57
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	22,62	22,32
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	20,69	31,39
	Female	49	100,0	49	100,0	16,33	23,69
Cycle 2 Day 1	Male	27	93,1	25	92,6	49,33	27,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	35,83	32,37
Cycle 3 Day 1	Male	25	86,2	23	92,0	40,58	28,35
	Female	43	87,8	41	95,3	37,40	34,31
Cycle 4 Day 1	Male	25	86,2	25	100,0	34,67	29,63
	Female	42	85,7	39	92,9	32,48	31,05
Cycle 5 Day 1	Male	25	86,2	25	100,0	36,00	27,08
	Female	40	81,6	39	97,5	33,33	28,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	33,33	26,59
	Female	38	77,6	37	97,4	30,63	27,64
Cycle 7 Day 1	Male	23	79,3	23	100,0	36,23	34,69
	Female	37	75,5	34	91,9	27,45	28,98
Cycle 8 Day 1	Male	21	72,4	19	90,5	35,09	30,38
	Female	35	71,4	33	94,3	28,28	27,79
Cycle 9 Day 1	Male	18	62,1	18	100,0	38,89	28,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	27,27	24,23
Cycle 10 Day 1	Male	18	62,1	18	100,0	33,33	22,87
	Female	33	67,3	32	97,0	23,96	22,77
Cycle 11 Day 1	Male	18	62,1	18	100,0	33,33	28,01
	Female	32	65,3	32	100,0	26,04	23,55
Cycle 12 Day 1	Male	17	58,6	17	100,0	29,41	26,04
	Female	32	65,3	28	87,5	23,81	25,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	31,37	21,96
	Female	29	59,2	28	96,6	25,00	23,35
Cycle 14 Day 1	Male	17	58,6	16	94,1	29,17	29,50
	Female	28	57,1	28	100,0	30,95	28,59
Cycle 15 Day 1	Male	16	55,2	16	100,0	31,25	33,26
	Female	28	57,1	28	100,0	32,14	27,94
Cycle 16 Day 1	Male	14	48,3	14	100,0	33,33	29,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	22,67	32,94
Cycle 17 Day 1	Male	12	41,4	12	100,0	27,78	27,83
	Female	27	55,1	27	100,0	29,63	28,24
Cycle 18 Day 1	Male	11	37,9	10	90,9	23,33	27,44
	Female	27	55,1	25	92,6	22,67	28,41
Cycle 19 Day 1	Male	10	34,5	10	100,0	40,00	37,84
	Female	26	53,1	23	88,5	21,74	23,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	29,63	38,89
	Female	26	53,1	23	88,5	23,19	25,49
Cycle 21 Day 1	Male	8	27,6	8	100,0	41,67	38,83
	Female	21	42,9	18	85,7	24,07	22,30
Cycle 22 Day 1	Male	8	27,6	6	75,0	33,33	42,16
	Female	21	42,9	19	90,5	28,07	22,94
Cycle 23 Day 1	Male	5	17,2	4	80,0	41,67	41,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	28,57	31,64
Cycle 24 Day 1	Male	5	17,2	4	80,0	41,67	31,91
	Female	15	30,6	14	93,3	19,05	21,54
Cycle 25 Day 1	Male	3	10,3	2	66,7	33,33	47,14
	Female	12	24,5	11	91,7	27,27	29,13
Cycle 26 Day 1	Male	3	10,3	2	66,7	33,33	47,14
	Female	11	22,4	10	90,9	20,00	32,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	16,67	23,57
	Female	8	16,3	6	75,0	38,89	38,97
Cycle 28 Day 1	Male	2	6,9	2	100,0	33,33	47,14
	Female	8	16,3	7	87,5	14,29	17,82
Cycle 29 Day 1	Male	1	3,4	1	100,0	66,67	-
	Female	8	16,3	6	75,0	33,33	21,08
Cycle 30 Day 1	Male	1	3,4	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	25,00	16,67
Cycle 31 Day 1	Male	1	3,4	1	100,0	66,67	-
	Female	6	12,2	4	66,7	25,00	16,67
Cycle 32 Day 1	Male	1	3,4	1	100,0	66,67	-
	Female	5	10,2	4	80,0	33,33	0,00
Cycle 33 Day 1	Male	1	3,4	1	100,0	66,67	-
	Female	1	2,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	24,44	23,46
	Female	21	42,9	13	61,9	20,51	21,68
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	16,13	25,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	26,19	32,50
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 2 Day 1	18-64	59	95,2	53	89,8	39,62	32,06
	65-74	11	78,6	10	90,9	53,33	23,31
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 3 Day 1	18-64	56	90,3	52	92,9	37,18	32,78
	65-74	10	71,4	10	100,0	50,00	28,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 4 Day 1	18-64	55	88,7	53	96,4	33,33	32,03
	65-74	10	71,4	9	90,0	37,04	20,03
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 5 Day 1	18-64	53	85,5	52	98,1	32,05	27,19
	65-74	10	71,4	10	100,0	43,33	31,62
	>=75	2	100,0	2	100,0	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	33,33	28,05
	65-74	10	71,4	9	90,0	29,63	20,03
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 7 Day 1	18-64	49	79,0	47	95,9	32,62	32,96
	65-74	9	64,3	8	88,9	29,17	21,36
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 8 Day 1	18-64	45	72,6	41	91,1	30,89	29,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	37,04	26,06
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 9 Day 1	18-64	40	64,5	40	100,0	29,17	27,41
	65-74	9	64,3	9	100,0	44,44	16,67
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 10 Day 1	18-64	40	64,5	39	97,5	28,21	22,35
	65-74	9	64,3	9	100,0	25,93	27,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 11 Day 1	18-64	39	62,9	39	100,0	30,77	24,64
	65-74	9	64,3	9	100,0	25,93	27,78
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 12 Day 1	18-64	38	61,3	35	92,1	28,57	25,75
	65-74	9	64,3	8	88,9	20,83	24,80
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	26,47	22,89
	65-74	9	64,3	9	100,0	29,63	26,06
	>=75	2	100,0	2	100,0	33,33	0,00
Cycle 14 Day 1	18-64	35	56,5	35	100,0	28,57	28,17
	65-74	9	64,3	8	88,9	37,50	33,03
	>=75	1	50,0	1	100,0	33,33	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	31,43	27,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	37,50	37,53
	>=75	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	23,96	30,80
	65-74	7	50,0	6	85,7	44,44	34,43
	>=75	1	50,0	1	100,0	0,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	30,21	28,54
	65-74	6	42,9	6	100,0	27,78	25,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	21,84	28,56
	65-74	6	42,9	5	83,3	33,33	23,57
	>=75	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	27,38	30,16
	65-74	5	35,7	4	80,0	33,33	27,22
	>=75	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	25,64	30,27
	65-74	5	35,7	5	100,0	26,67	27,89
	>=75	1	50,0	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	31,75	30,69
	65-74	4	28,6	4	100,0	25,00	16,67
	>=75	1	50,0	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	31,67	29,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	25,00	16,67
	>=75	1	50,0	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	31,25	35,42
	65-74	2	14,3	2	100,0	33,33	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	22,92	26,44
	65-74	2	14,3	2	100,0	33,33	0,00
Cycle 25 Day 1	18-64	14	22,6	12	85,7	27,78	31,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	33,33	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	22,22	32,82
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	33,33	35,63
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	18,52	24,22
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	38,10	23,00
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	33,33	23,57
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	33,33	23,57
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	41,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	33,33	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	66,67	-
	65-74	1	7,1	1	100,0	33,33	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	20,00	22,69
	65-74	10	71,4	7	70,0	28,57	23,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	33,33	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	23,81	31,90
	Other	43	100,0	43	100,0	13,18	20,75
Cycle 2 Day 1	White	33	94,3	29	87,9	35,63	26,62
	Other	39	90,7	36	92,3	45,37	33,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	38,27	31,63
	Other	37	86,0	37	100,0	38,74	32,88
Cycle 4 Day 1	White	31	88,6	28	90,3	29,76	29,17
	Other	36	83,7	36	100,0	36,11	31,24
Cycle 5 Day 1	White	31	88,6	30	96,8	28,89	22,71
	Other	34	79,1	34	100,0	39,22	31,22
Cycle 6 Day 1	White	30	85,7	28	93,3	32,14	27,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	31,25	26,69
Cycle 7 Day 1	White	29	82,9	27	93,1	25,93	26,69
	Other	31	72,1	30	96,8	35,56	34,94
Cycle 8 Day 1	White	28	80,0	24	85,7	29,17	26,58
	Other	28	65,1	28	100,0	32,14	30,74
Cycle 9 Day 1	White	26	74,3	26	100,0	29,49	23,71
	Other	25	58,1	25	100,0	33,33	28,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	29,33	22,19
	Other	25	58,1	25	100,0	25,33	24,11
Cycle 11 Day 1	White	26	74,3	26	100,0	30,77	20,92
	Other	24	55,8	24	100,0	26,39	29,45
Cycle 12 Day 1	White	26	74,3	22	84,6	33,33	29,10
	Other	23	53,5	23	100,0	18,84	19,66
Cycle 13 Day 1	White	24	68,6	23	95,8	24,64	20,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	30,30	25,01
Cycle 14 Day 1	White	24	68,6	24	100,0	30,56	27,66
	Other	21	48,8	20	95,2	30,00	30,40
Cycle 15 Day 1	White	24	68,6	24	100,0	33,33	27,80
	Other	20	46,5	20	100,0	30,00	32,26
Cycle 16 Day 1	White	22	62,9	20	90,9	23,33	30,78
	Other	19	44,2	19	100,0	29,82	33,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	27,27	24,42
	Other	17	39,5	17	100,0	31,37	32,21
Cycle 18 Day 1	White	21	60,0	18	85,7	20,37	28,33
	Other	17	39,5	17	100,0	25,49	27,71
Cycle 19 Day 1	White	20	57,1	20	100,0	28,33	27,09
	Other	16	37,2	13	81,3	25,64	33,76
Cycle 20 Day 1	White	20	57,1	17	85,0	21,57	23,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	28,89	35,34
Cycle 21 Day 1	White	16	45,7	14	87,5	26,19	26,73
	Other	13	30,2	12	92,3	33,33	31,78
Cycle 22 Day 1	White	16	45,7	13	81,3	25,64	24,17
	Other	13	30,2	12	92,3	33,33	31,78
Cycle 23 Day 1	White	12	34,3	10	83,3	30,00	33,15
	Other	9	20,9	8	88,9	33,33	35,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	20,00	23,31
	Other	9	20,9	8	88,9	29,17	27,82
Cycle 25 Day 1	White	10	28,6	8	80,0	25,00	23,57
	Other	5	11,6	5	100,0	33,33	40,82
Cycle 26 Day 1	White	10	28,6	8	80,0	16,67	25,20
	Other	4	9,3	4	100,0	33,33	47,14
Cycle 27 Day 1	White	8	22,9	5	62,5	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	55,56	50,92
Cycle 28 Day 1	White	7	20,0	6	85,7	16,67	27,89
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 29 Day 1	White	6	17,1	4	66,7	33,33	27,22
	Other	3	7,0	3	100,0	44,44	19,25
Cycle 30 Day 1	White	4	11,4	2	50,0	50,00	23,57
	Other	3	7,0	3	100,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	50,00	23,57
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 32 Day 1	White	4	11,4	3	75,0	44,44	19,25
	Other	2	4,7	2	100,0	33,33	0,00
Cycle 33 Day 1	White	2	5,7	2	100,0	50,00	23,57
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	27,78	23,92
	Other	24	55,8	16	66,7	18,75	20,97
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	19,70	28,47
	Europe (EU)	17	100,0	17	100,0	17,65	29,15
	Asia (AS)	39	100,0	39	100,0	17,09	25,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	33,33	28,87
	Europe (EU)	16	94,1	13	81,3	43,59	31,58
	Asia (AS)	36	92,3	35	97,2	43,81	32,11
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	36,84	31,22
	Europe (EU)	15	88,2	12	80,0	44,44	38,49
	Asia (AS)	33	84,6	33	100,0	37,37	30,91
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	30,00	26,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	27,78	27,83
	Asia (AS)	32	82,1	32	100,0	37,50	33,60
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	28,33	27,09
	Europe (EU)	15	88,2	14	93,3	35,71	24,33
	Asia (AS)	30	76,9	30	100,0	37,78	29,99
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	26,67	29,81
	Europe (EU)	14	82,4	13	92,9	30,77	25,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	35,80	26,03
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	20,37	25,92
	Europe (EU)	14	82,4	13	92,9	28,21	26,69
	Asia (AS)	27	69,2	26	96,3	39,74	35,30
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	27,45	31,70
	Europe (EU)	14	82,4	11	78,6	24,24	26,21
	Asia (AS)	24	61,5	24	100,0	36,11	27,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	24,07	22,30
	Europe (EU)	12	70,6	12	100,0	33,33	24,62
	Asia (AS)	21	53,8	21	100,0	36,51	29,64
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	17,65	20,81
	Europe (EU)	12	70,6	12	100,0	33,33	24,62
	Asia (AS)	21	53,8	21	100,0	31,75	22,30
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	18,52	20,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	36,11	22,29
	Asia (AS)	20	51,3	20	100,0	33,33	28,61
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	19,61	23,74
	Europe (EU)	12	70,6	9	75,0	48,15	29,40
	Asia (AS)	19	48,7	19	100,0	21,05	19,91
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	21,57	20,21
	Europe (EU)	11	64,7	10	90,9	26,67	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	33,33	25,57
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	19,61	26,51
	Europe (EU)	11	64,7	11	100,0	36,36	27,71
	Asia (AS)	17	43,6	16	94,1	37,50	29,50
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	23,53	22,87
	Europe (EU)	11	64,7	11	100,0	33,33	36,51
	Asia (AS)	16	41,0	16	100,0	39,58	30,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	19,05	25,20
	Europe (EU)	11	64,7	9	81,8	29,63	35,14
	Asia (AS)	16	41,0	16	100,0	31,25	35,42
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	16,67	21,68
	Europe (EU)	10	58,8	10	100,0	30,00	24,60
	Asia (AS)	15	38,5	15	100,0	40,00	31,37
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	11,90	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	27,78	25,09
	Asia (AS)	15	38,5	15	100,0	31,11	34,43
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	23,08	25,04
	Europe (EU)	9	52,9	9	100,0	33,33	28,87
	Asia (AS)	14	35,9	11	78,6	27,27	35,96
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	17,95	22,01
	Europe (EU)	9	52,9	6	66,7	22,22	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	33,33	36,00
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	20,00	23,31
	Europe (EU)	7	41,2	6	85,7	33,33	29,81
	Asia (AS)	11	28,2	10	90,9	36,67	33,15
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	23,33	22,50
	Europe (EU)	7	41,2	5	71,4	26,67	27,89
	Asia (AS)	11	28,2	10	90,9	36,67	33,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	29,63	35,14
	Europe (EU)	5	29,4	3	60,0	22,22	19,25
	Asia (AS)	7	17,9	6	85,7	38,89	38,97
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	16,67	25,20
	Europe (EU)	5	29,4	4	80,0	16,67	19,25
	Asia (AS)	7	17,9	6	85,7	38,89	25,09
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	23,81	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	16,67	23,57
	Asia (AS)	4	10,3	4	100,0	41,67	41,94
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	16,67	27,89
	Europe (EU)	4	23,5	2	50,0	16,67	23,57
	Asia (AS)	4	10,3	4	100,0	33,33	47,14
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	16,67	19,25
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	50,00	43,03
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	25,00	31,91
	Europe (EU)	2	11,8	1	50,0	0,00	-
	Asia (AS)	4	10,3	4	100,0	16,67	19,25
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	33,33	33,33
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	41,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	50,00	23,57
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	22,22	19,25
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	50,00	23,57
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	22,22	19,25
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	33,33	-
	Asia (AS)	3	7,7	2	66,7	33,33	0,00
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	66,67	-
	Europe (EU)	1	5,9	1	100,0	33,33	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	18,18	22,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	16,67	19,25
	Asia (AS)	21	53,8	13	61,9	28,21	22,96
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	11,11	20,22
	1	38	100,0	38	100,0	20,18	28,52
	2	10	100,0	10	100,0	30,00	33,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	27	90,0	35,80	27,62
	1	36	94,7	32	88,9	44,79	33,45
	2	6	60,0	6	100,0	44,44	34,43
Cycle 3 Day 1	0	29	96,7	27	93,1	37,04	31,12
	1	34	89,5	32	94,1	37,50	31,40
	2	5	50,0	5	100,0	53,33	44,72
Cycle 4 Day 1	0	29	96,7	28	96,6	34,52	29,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	32,29	32,22
	2	5	50,0	4	80,0	33,33	27,22
Cycle 5 Day 1	0	29	96,7	29	100,0	34,48	28,84
	1	33	86,8	32	97,0	35,42	28,00
	2	3	30,0	3	100,0	22,22	19,25
Cycle 6 Day 1	0	29	96,7	29	100,0	26,44	22,50
	1	31	81,6	28	90,3	36,90	31,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	33,33	0,00
Cycle 7 Day 1	0	29	96,7	28	96,6	28,57	26,78
	1	28	73,7	26	92,9	33,33	37,71
	2	3	30,0	3	100,0	33,33	0,00
Cycle 8 Day 1	0	28	93,3	26	92,9	30,77	29,70
	1	25	65,8	23	92,0	31,88	29,26
	2	3	30,0	3	100,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	32,05	29,03
	1	23	60,5	23	100,0	31,88	23,52
	2	2	20,0	2	100,0	16,67	23,57
Cycle 10 Day 1	0	26	86,7	26	100,0	28,21	26,15
	1	23	60,5	22	95,7	27,27	19,62
	2	2	20,0	2	100,0	16,67	23,57
Cycle 11 Day 1	0	26	86,7	26	100,0	28,21	22,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	30,30	28,93
	2	2	20,0	2	100,0	16,67	23,57
Cycle 12 Day 1	0	25	83,3	22	88,0	27,27	28,43
	1	22	57,9	21	95,5	23,81	21,46
	2	2	20,0	2	100,0	33,33	47,14
Cycle 13 Day 1	0	25	83,3	24	96,0	23,61	23,01
	1	20	52,6	20	100,0	33,33	21,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	27,78	30,56
	1	19	50,0	19	100,0	35,09	26,00
	2	1	10,0	1	100,0	0,00	-
Cycle 15 Day 1	0	24	80,0	24	100,0	31,94	28,62
	1	19	50,0	19	100,0	33,33	31,43
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	26,67	29,81
	1	18	47,4	18	100,0	27,78	34,77
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	22,22	24,34
	1	17	44,7	17	100,0	39,22	29,43
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	18,52	23,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	29,17	31,91
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	26,32	28,50
	1	15	39,5	13	86,7	30,77	31,80
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	23,53	25,72
	1	15	39,5	14	93,3	28,57	34,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	26,19	26,73
	1	13	34,2	11	84,6	36,36	31,46
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	22,22	21,71
	1	13	34,2	12	92,3	38,89	31,25
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	29,63	35,14
	1	9	23,7	8	88,9	37,50	33,03
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	18,52	24,22
	1	9	23,7	8	88,9	33,33	25,20
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	22,22	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	33,33	33,33
Cycle 26 Day 1	0	8	26,7	6	75,0	11,11	27,22
	1	6	15,8	6	100,0	33,33	36,51
Cycle 27 Day 1	0	6	20,0	3	50,0	22,22	19,25
	1	5	13,2	5	100,0	40,00	43,46
Cycle 28 Day 1	0	5	16,7	4	80,0	16,67	33,33
	1	5	13,2	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	50,00	23,57
	1	5	13,2	5	100,0	33,33	23,57
Cycle 30 Day 1	0	3	10,0	1	33,3	66,67	-
	1	4	10,5	4	100,0	25,00	16,67
Cycle 31 Day 1	0	3	10,0	1	33,3	66,67	-
	1	4	10,5	4	100,0	25,00	16,67
Cycle 32 Day 1	0	3	10,0	2	66,7	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	33,33	0,00
Cycle 33 Day 1	0	2	6,7	2	100,0	50,00	23,57
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	19,05	21,54
	1	20	52,6	12	60,0	22,22	21,71
	2	4	40,0	2	50,0	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	11,83	20,27
	1	3	100,0	3	100,0	22,22	38,49
	2 or More	44	100,0	44	100,0	21,97	29,59
Cycle 2 Day 1	None	30	96,8	27	90,0	37,04	35,00
	1	2	66,7	1	50,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	44,14	28,39
Cycle 3 Day 1	None	30	96,8	28	93,3	40,48	33,16
	1	2	66,7	1	50,0	33,33	-
	2 or More	36	81,8	35	97,2	37,14	32,11
Cycle 4 Day 1	None	30	96,8	29	96,7	36,78	34,90
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	35	79,5	33	94,3	32,32	25,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	36,67	29,49
	1	2	66,7	2	100,0	33,33	0,00
	2 or More	33	75,0	32	97,0	32,29	27,41
Cycle 6 Day 1	None	29	93,5	28	96,6	28,57	25,20
	1	2	66,7	2	100,0	33,33	0,00
	2 or More	32	72,7	30	93,8	34,44	29,66
Cycle 7 Day 1	None	27	87,1	26	96,3	30,77	33,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	31	70,5	29	93,5	32,18	30,19
Cycle 8 Day 1	None	26	83,9	25	96,2	36,00	33,22
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	25,93	23,27
Cycle 9 Day 1	None	25	80,6	25	100,0	30,67	25,31
	1	1	33,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	32,00	28,02
Cycle 10 Day 1	None	25	80,6	24	96,0	23,61	20,80
	1	1	33,3	1	100,0	33,33	-
	2 or More	25	56,8	25	100,0	30,67	25,31
Cycle 11 Day 1	None	25	80,6	25	100,0	26,67	23,57
	1	1	33,3	1	100,0	33,33	-
	2 or More	24	54,5	24	100,0	30,56	27,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	29,17	30,00
	1	1	33,3	1	100,0	33,33	-
	2 or More	23	52,3	20	87,0	21,67	19,57
Cycle 13 Day 1	None	24	77,4	23	95,8	26,09	19,99
	1	1	33,3	1	100,0	33,33	-
	2 or More	21	47,7	21	100,0	28,57	26,43
Cycle 14 Day 1	None	23	74,2	23	100,0	27,54	31,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	33,33	-
	2 or More	21	47,7	20	95,2	33,33	26,49
Cycle 15 Day 1	None	23	74,2	23	100,0	26,09	24,53
	1	1	33,3	1	100,0	33,33	-
	2 or More	20	45,5	20	100,0	38,33	34,67
Cycle 16 Day 1	None	20	64,5	19	95,0	22,81	27,34
	1	1	33,3	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	28,07	35,60
Cycle 17 Day 1	None	19	61,3	19	100,0	28,07	29,94
	1	1	33,3	1	100,0	33,33	-
	2 or More	19	43,2	19	100,0	29,82	26,98
Cycle 18 Day 1	None	18	58,1	17	94,4	17,65	23,91
	1	1	33,3	1	100,0	33,33	-
	2 or More	19	43,2	17	89,5	27,45	31,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	25,49	27,71
	1	1	33,3	1	100,0	66,67	-
	2 or More	18	40,9	15	83,3	26,67	31,37
Cycle 20 Day 1	None	17	54,8	16	94,1	22,92	29,11
	1	1	33,3	1	100,0	33,33	-
	2 or More	18	40,9	15	83,3	26,67	31,37
Cycle 21 Day 1	None	15	48,4	13	86,7	28,21	26,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	30,77	31,80
Cycle 22 Day 1	None	15	48,4	13	86,7	28,21	26,69
	2 or More	14	31,8	12	85,7	30,56	30,01
Cycle 23 Day 1	None	10	32,3	9	90,0	18,52	24,22
	2 or More	11	25,0	9	81,8	44,44	37,27
Cycle 24 Day 1	None	10	32,3	10	100,0	20,00	23,31
	2 or More	10	22,7	8	80,0	29,17	27,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	20,83	24,80
	2 or More	6	13,6	5	83,3	40,00	36,51
Cycle 26 Day 1	None	8	25,8	8	100,0	25,00	38,83
	2 or More	6	13,6	4	66,7	16,67	19,25
Cycle 27 Day 1	None	7	22,6	6	85,7	33,33	36,51
	2 or More	4	9,1	2	50,0	33,33	47,14
Cycle 28 Day 1	None	7	22,6	7	100,0	19,05	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	19,4	5	83,3	33,33	23,57
	2 or More	3	6,8	2	66,7	50,00	23,57
Cycle 30 Day 1	None	4	12,9	3	75,0	44,44	19,25
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 31 Day 1	None	4	12,9	3	75,0	44,44	19,25
	2 or More	3	6,8	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	44,44	19,25
	2 or More	2	4,5	2	100,0	33,33	0,00
Cycle 33 Day 1	None	1	3,2	1	100,0	66,67	-
	2 or More	1	2,3	1	100,0	33,33	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	22,22	21,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	33,33	-
	2 or More	24	54,5	15	62,5	22,22	24,12
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	11,83	20,27
	Previously Treated	47	100,0	47	100,0	21,99	29,71
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	37,04	35,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	43,86	28,06
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	40,48	33,16
	Previously Treated	38	80,9	36	94,7	37,04	31,65
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	36,78	34,90
	Previously Treated	37	78,7	35	94,6	30,48	26,04
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	36,67	29,49
	Previously Treated	35	74,5	34	97,1	32,35	26,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	28,57	25,20
	Previously Treated	34	72,3	32	94,1	34,38	28,69
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	30,77	33,89
	Previously Treated	33	70,2	31	93,9	31,18	29,73
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	36,00	33,22
	Previously Treated	30	63,8	27	90,0	25,93	23,27
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	30,67	25,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	32,05	27,46
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	23,61	20,80
	Previously Treated	26	55,3	26	100,0	30,77	24,81
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	26,67	23,57
	Previously Treated	25	53,2	25	100,0	30,67	27,08
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	29,17	30,00
	Previously Treated	24	51,1	21	87,5	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	26,09	19,99
	Previously Treated	22	46,8	22	100,0	28,79	25,81
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	27,54	31,22
	Previously Treated	22	46,8	21	95,5	33,33	25,82
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	26,09	24,53
	Previously Treated	21	44,7	21	100,0	38,10	33,81
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	22,81	27,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	30,00	35,71
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	28,07	29,94
	Previously Treated	20	42,6	20	100,0	30,00	26,27
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	17,65	23,91
	Previously Treated	20	42,6	18	90,0	27,78	30,78
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	25,49	27,71
	Previously Treated	19	40,4	16	84,2	29,17	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	22,92	29,11
	Previously Treated	19	40,4	16	84,2	27,08	30,35
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	28,21	26,69
	Previously Treated	14	29,8	13	92,9	30,77	31,80
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	28,21	26,69
	Previously Treated	14	29,8	12	85,7	30,56	30,01
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	18,52	24,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	44,44	37,27
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	20,00	23,31
	Previously Treated	10	21,3	8	80,0	29,17	27,82
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	20,83	24,80
	Previously Treated	6	12,8	5	83,3	40,00	36,51
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	25,00	38,83
	Previously Treated	6	12,8	4	66,7	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	33,33	36,51
	Previously Treated	4	8,5	2	50,0	33,33	47,14
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	19,05	26,23
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	33,33	23,57
	Previously Treated	3	6,4	2	66,7	50,00	23,57
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	44,44	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	44,44	19,25
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	44,44	19,25
	Previously Treated	2	4,3	2	100,0	33,33	0,00
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	66,67	-
	Previously Treated	1	2,1	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	22,22	21,71
	Previously Treated	26	55,3	16	61,5	22,92	23,47
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	20,00	28,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	16,28	25,59
Cycle 2 Day 1	Local	32	91,4	30	93,8	37,78	29,99
	Central	40	93,0	35	87,5	43,81	32,11
Cycle 3 Day 1	Local	29	82,9	28	96,6	33,33	33,95
	Central	39	90,7	36	92,3	42,59	30,46
Cycle 4 Day 1	Local	28	80,0	27	96,4	24,69	25,47
	Central	39	90,7	37	94,9	39,64	32,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	20,99	26,39
	Central	38	88,4	37	97,4	44,14	24,91
Cycle 6 Day 1	Local	27	77,1	27	100,0	28,40	30,25
	Central	36	83,7	33	91,7	34,34	24,27
Cycle 7 Day 1	Local	27	77,1	27	100,0	23,46	28,96
	Central	33	76,7	30	90,9	37,78	32,44
Cycle 8 Day 1	Local	26	74,3	26	100,0	24,36	25,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	37,18	30,30
Cycle 9 Day 1	Local	25	71,4	25	100,0	24,00	28,09
	Central	26	60,5	26	100,0	38,46	22,49
Cycle 10 Day 1	Local	25	71,4	24	96,0	22,22	25,38
	Central	26	60,5	26	100,0	32,05	19,96
Cycle 11 Day 1	Local	24	68,6	24	100,0	23,61	26,88
	Central	26	60,5	26	100,0	33,33	23,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	19,70	24,47
	Central	26	60,5	23	88,5	31,88	25,58
Cycle 13 Day 1	Local	22	62,9	22	100,0	25,76	22,84
	Central	24	55,8	23	95,8	28,99	23,15
Cycle 14 Day 1	Local	22	62,9	22	100,0	27,27	35,09
	Central	23	53,5	22	95,7	33,33	20,57
Cycle 15 Day 1	Local	22	62,9	22	100,0	27,27	33,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	36,36	25,01
Cycle 16 Day 1	Local	20	57,1	20	100,0	25,00	37,27
	Central	21	48,8	19	90,5	28,07	25,49
Cycle 17 Day 1	Local	20	57,1	20	100,0	25,00	30,35
	Central	19	44,2	19	100,0	33,33	24,85
Cycle 18 Day 1	Local	20	57,1	19	95,0	14,04	20,23
	Central	18	41,9	16	88,9	33,33	32,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	25,49	32,34
	Central	17	39,5	16	94,1	29,17	26,87
Cycle 20 Day 1	Local	19	54,3	17	89,5	23,53	32,84
	Central	17	39,5	15	88,2	26,67	25,82
Cycle 21 Day 1	Local	14	40,0	12	85,7	25,00	32,18
	Central	15	34,9	14	93,3	33,33	26,15
Cycle 22 Day 1	Local	14	40,0	12	85,7	22,22	29,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	35,90	25,32
Cycle 23 Day 1	Local	11	31,4	10	90,9	33,33	35,14
	Central	10	23,3	8	80,0	29,17	33,03
Cycle 24 Day 1	Local	11	31,4	10	90,9	23,33	27,44
	Central	9	20,9	8	88,9	25,00	23,57
Cycle 25 Day 1	Local	7	20,0	7	100,0	23,81	25,20
	Central	8	18,6	6	75,0	33,33	36,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	33,33	42,16
	Central	8	18,6	6	75,0	11,11	17,21
Cycle 27 Day 1	Local	4	11,4	4	100,0	41,67	41,94
	Central	7	16,3	4	57,1	25,00	31,91
Cycle 28 Day 1	Local	4	11,4	4	100,0	33,33	27,22
	Central	6	14,0	5	83,3	6,67	14,91
Cycle 29 Day 1	Local	3	8,6	3	100,0	44,44	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	33,33	27,22
Cycle 30 Day 1	Local	3	8,6	3	100,0	44,44	19,25
	Central	4	9,3	2	50,0	16,67	23,57
Cycle 31 Day 1	Local	3	8,6	3	100,0	44,44	19,25
	Central	4	9,3	2	50,0	16,67	23,57
Cycle 32 Day 1	Local	3	8,6	3	100,0	44,44	19,25
	Central	3	7,0	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	66,67	-
	Central	1	2,3	1	100,0	33,33	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	26,19	26,73
	Central	21	48,8	14	66,7	19,05	17,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	18,02	26,57
	No	4	100,0	4	100,0	16,67	33,33
Cycle 2 Day 1	Yes	70	94,6	63	90,0	39,68	30,44
	No	2	50,0	2	100,0	83,33	23,57
Cycle 3 Day 1	Yes	66	89,2	62	93,9	37,63	31,64
	No	2	50,0	2	100,0	66,67	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	33,87	30,47
	No	2	50,0	2	100,0	16,67	23,57
Cycle 5 Day 1	Yes	63	85,1	62	98,4	34,41	28,29
	No	2	50,0	2	100,0	33,33	0,00
Cycle 6 Day 1	Yes	61	82,4	58	95,1	31,61	27,52
	No	2	50,0	2	100,0	33,33	0,00
Cycle 7 Day 1	Yes	58	78,4	55	94,8	30,30	31,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	50,00	23,57
Cycle 8 Day 1	Yes	54	73,0	50	92,6	30,67	29,23
	No	2	50,0	2	100,0	33,33	0,00
Cycle 9 Day 1	Yes	49	66,2	49	100,0	31,29	26,71
	No	2	50,0	2	100,0	33,33	0,00
Cycle 10 Day 1	Yes	49	66,2	48	98,0	26,39	22,76
	No	2	50,0	2	100,0	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	27,78	25,11
	No	2	50,0	2	100,0	50,00	23,57
Cycle 12 Day 1	Yes	47	63,5	43	91,5	25,58	26,06
	No	2	50,0	2	100,0	33,33	0,00
Cycle 13 Day 1	Yes	44	59,5	43	97,7	26,36	22,49
	No	2	50,0	2	100,0	50,00	23,57
Cycle 14 Day 1	Yes	43	58,1	42	97,7	27,78	26,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	83,33	23,57
Cycle 15 Day 1	Yes	42	56,8	42	100,0	30,16	29,27
	No	2	50,0	2	100,0	66,67	0,00
Cycle 16 Day 1	Yes	39	52,7	37	94,9	23,42	29,26
	No	2	50,0	2	100,0	83,33	23,57
Cycle 17 Day 1	Yes	37	50,0	37	100,0	26,13	25,01
	No	2	50,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	22,22	27,22
	No	2	50,0	2	100,0	33,33	47,14
Cycle 19 Day 1	Yes	34	45,9	32	94,1	26,04	29,00
	No	2	50,0	1	50,0	66,67	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	22,22	28,14
	No	2	50,0	2	100,0	66,67	0,00
Cycle 21 Day 1	Yes	27	36,5	24	88,9	29,17	30,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	0,00
Cycle 22 Day 1	Yes	27	36,5	23	85,2	28,99	28,96
	No	2	50,0	2	100,0	33,33	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	29,41	33,09
	No	1	25,0	1	100,0	66,67	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	23,53	25,72
	No	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	27,78	31,25
	No	1	25,0	1	100,0	33,33	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	15,15	22,92
	No	1	25,0	1	100,0	100,00	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	23,81	25,20
	No	1	25,0	1	100,0	100,00	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	16,67	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	38,89	25,09
	No	1	25,0	1	100,0	33,33	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	33,33	27,22
	No	1	25,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	33,33	27,22
	No	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	41,67	16,67
	No	1	25,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	50,00	23,57
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	22,62	22,32
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	8,33	15,43
	No	70	100,0	70	100,0	19,05	27,55
Cycle 2 Day 1	Yes	5	62,5	5	100,0	33,33	33,33
	No	67	95,7	60	89,6	41,67	31,07
Cycle 3 Day 1	Yes	5	62,5	5	100,0	26,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	39,55	32,44
Cycle 4 Day 1	Yes	5	62,5	5	100,0	46,67	50,55
	No	62	88,6	59	95,2	32,20	28,34
Cycle 5 Day 1	Yes	5	62,5	5	100,0	33,33	40,82
	No	60	85,7	59	98,3	34,46	26,96
Cycle 6 Day 1	Yes	5	62,5	5	100,0	33,33	40,82
	No	58	82,9	55	94,8	31,52	25,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	33,33	40,82
	No	55	78,6	52	94,5	30,77	30,85
Cycle 8 Day 1	Yes	5	62,5	5	100,0	40,00	43,46
	No	51	72,9	47	92,2	29,79	27,13
Cycle 9 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	47	67,1	47	100,0	32,62	26,46
Cycle 10 Day 1	Yes	4	50,0	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	28,26	23,27
Cycle 11 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	46	65,7	46	100,0	29,71	25,56
Cycle 12 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	45	64,3	41	91,1	27,64	25,71
Cycle 13 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	42	60,0	41	97,6	28,46	23,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	41	58,6	40	97,6	31,67	29,19
Cycle 15 Day 1	Yes	4	50,0	4	100,0	25,00	31,91
	No	40	57,1	40	100,0	32,50	29,71
Cycle 16 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	38	54,3	36	94,7	28,70	32,02
Cycle 17 Day 1	Yes	3	37,5	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	30,56	28,03
Cycle 18 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	35	50,0	32	91,4	25,00	28,08
Cycle 19 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	30	90,9	30,00	29,49
Cycle 20 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	29	87,9	27,59	29,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	24	88,9	31,94	28,62
Cycle 22 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	23	85,2	31,88	27,48
Cycle 23 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	19	27,1	16	84,2	35,42	33,26
Cycle 24 Day 1	Yes	2	25,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	25,00	25,82
Cycle 25 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	13	18,6	11	84,6	33,33	29,81
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	24,24	33,63
Cycle 27 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	10	14,3	7	70,0	33,33	38,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	9	12,9	8	88,9	20,83	24,80
Cycle 29 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	8	11,4	6	75,0	38,89	25,09
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	33,33	23,57
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	33,33	23,57
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	40,00	14,91
Cycle 33 Day 1	No	2	2,9	2	100,0	50,00	23,57
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	23,08	22,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30CO_SG.xls
28NOV2019 10:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	6,41	13,22
Cycle 2 Day 1	All	72	92,3	64	88,9	15,10	22,17
Cycle 3 Day 1	All	68	87,2	64	94,1	15,10	22,17
Cycle 4 Day 1	All	67	85,9	64	95,5	15,63	19,67
Cycle 5 Day 1	All	65	83,3	64	98,5	15,10	20,51
Cycle 6 Day 1	All	63	80,8	60	95,2	17,22	24,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	16,37	21,01
Cycle 8 Day 1	All	56	71,8	52	92,9	20,51	26,53
Cycle 9 Day 1	All	51	65,4	51	100,0	21,57	24,79
Cycle 10 Day 1	All	51	65,4	50	98,0	20,00	23,33
Cycle 11 Day 1	All	50	64,1	50	100,0	20,00	23,33
Cycle 12 Day 1	All	49	62,8	45	91,8	20,00	25,03
Cycle 13 Day 1	All	46	59,0	45	97,8	18,52	24,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	20,45	27,10
Cycle 15 Day 1	All	44	56,4	44	100,0	17,42	19,67
Cycle 16 Day 1	All	41	52,6	39	95,1	17,09	21,46
Cycle 17 Day 1	All	39	50,0	39	100,0	17,95	26,32
Cycle 18 Day 1	All	38	48,7	35	92,1	15,24	23,35
Cycle 19 Day 1	All	36	46,2	33	91,7	22,22	28,46
Cycle 20 Day 1	All	36	46,2	32	88,9	22,92	29,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	16,67	27,08
Cycle 22 Day 1	All	29	37,2	25	86,2	13,33	21,52
Cycle 23 Day 1	All	21	26,9	18	85,7	18,52	28,52
Cycle 24 Day 1	All	20	25,6	18	90,0	18,52	30,73
Cycle 25 Day 1	All	15	19,2	13	86,7	20,51	28,99
Cycle 26 Day 1	All	14	17,9	12	85,7	19,44	30,01
Cycle 27 Day 1	All	11	14,1	8	72,7	25,00	29,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	18,52	24,22
Cycle 29 Day 1	All	9	11,5	7	77,8	14,29	26,23
Cycle 30 Day 1	All	7	9,0	5	71,4	40,00	36,51
Cycle 31 Day 1	All	7	9,0	5	71,4	33,33	23,57
Cycle 32 Day 1	All	6	7,7	5	83,3	20,00	18,26
Cycle 33 Day 1	All	2	2,6	2	100,0	33,33	47,14
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	23,81	27,00
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	9,20	15,16
	Female	49	100,0	49	100,0	4,76	11,79
Cycle 2 Day 1	Male	27	93,1	24	88,9	9,72	18,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	18,33	23,81
Cycle 3 Day 1	Male	25	86,2	23	92,0	15,94	19,77
	Female	43	87,8	41	95,3	14,63	23,63
Cycle 4 Day 1	Male	25	86,2	25	100,0	14,67	21,69
	Female	42	85,7	39	92,9	16,24	18,53
Cycle 5 Day 1	Male	25	86,2	25	100,0	14,67	21,69
	Female	40	81,6	39	97,5	15,38	20,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	15,94	24,35
	Female	38	77,6	37	97,4	18,02	25,57
Cycle 7 Day 1	Male	23	79,3	23	100,0	14,49	22,08
	Female	37	75,5	34	91,9	17,65	20,49
Cycle 8 Day 1	Male	21	72,4	19	90,5	22,81	27,34
	Female	35	71,4	33	94,3	19,19	26,39
Cycle 9 Day 1	Male	18	62,1	18	100,0	24,07	27,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	20,20	23,48
Cycle 10 Day 1	Male	18	62,1	18	100,0	27,78	28,58
	Female	33	67,3	32	97,0	15,63	18,90
Cycle 11 Day 1	Male	18	62,1	18	100,0	20,37	28,33
	Female	32	65,3	32	100,0	19,79	20,49
Cycle 12 Day 1	Male	17	58,6	17	100,0	23,53	30,65
	Female	32	65,3	28	87,5	17,86	21,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	19,61	31,31
	Female	29	59,2	28	96,6	17,86	19,21
Cycle 14 Day 1	Male	17	58,6	16	94,1	20,83	29,50
	Female	28	57,1	28	100,0	20,24	26,20
Cycle 15 Day 1	Male	16	55,2	16	100,0	14,58	17,08
	Female	28	57,1	28	100,0	19,05	21,14
Cycle 16 Day 1	Male	14	48,3	14	100,0	16,67	25,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	17,33	19,53
Cycle 17 Day 1	Male	12	41,4	12	100,0	25,00	32,18
	Female	27	55,1	27	100,0	14,81	23,27
Cycle 18 Day 1	Male	11	37,9	10	90,9	20,00	35,83
	Female	27	55,1	25	92,6	13,33	16,67
Cycle 19 Day 1	Male	10	34,5	10	100,0	30,00	42,89
	Female	26	53,1	23	88,5	18,84	19,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	29,63	42,31
	Female	26	53,1	23	88,5	20,29	24,08
Cycle 21 Day 1	Male	8	27,6	8	100,0	29,17	41,55
	Female	21	42,9	18	85,7	11,11	16,17
Cycle 22 Day 1	Male	8	27,6	6	75,0	11,11	27,22
	Female	21	42,9	19	90,5	14,04	20,23
Cycle 23 Day 1	Male	5	17,2	4	80,0	41,67	50,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	11,90	16,57
Cycle 24 Day 1	Male	5	17,2	4	80,0	41,67	50,00
	Female	15	30,6	14	93,3	11,90	21,11
Cycle 25 Day 1	Male	3	10,3	2	66,7	50,00	70,71
	Female	12	24,5	11	91,7	15,15	17,41
Cycle 26 Day 1	Male	3	10,3	2	66,7	50,00	70,71
	Female	11	22,4	10	90,9	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	16,67	23,57
	Female	8	16,3	6	75,0	27,78	32,77
Cycle 28 Day 1	Male	2	6,9	2	100,0	33,33	47,14
	Female	8	16,3	7	87,5	14,29	17,82
Cycle 29 Day 1	Male	1	3,4	1	100,0	66,67	-
	Female	8	16,3	6	75,0	5,56	13,61
Cycle 30 Day 1	Male	1	3,4	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	41,67	41,94
Cycle 31 Day 1	Male	1	3,4	1	100,0	66,67	-
	Female	6	12,2	4	66,7	25,00	16,67
Cycle 32 Day 1	Male	1	3,4	1	100,0	33,33	-
	Female	5	10,2	4	80,0	16,67	19,25
Cycle 33 Day 1	Male	1	3,4	1	100,0	66,67	-
	Female	1	2,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	20,00	24,56
	Female	21	42,9	13	61,9	28,21	29,96
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	7,53	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	2,38	8,91
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	18-64	59	95,2	52	88,1	16,67	20,35
	65-74	11	78,6	10	90,9	10,00	31,62
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 3 Day 1	18-64	56	90,3	52	92,9	15,38	22,35
	65-74	10	71,4	10	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 4 Day 1	18-64	55	88,7	53	96,4	14,47	19,07
	65-74	10	71,4	9	90,0	25,93	22,22
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 5 Day 1	18-64	53	85,5	52	98,1	15,38	20,30
	65-74	10	71,4	10	100,0	16,67	23,57
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	18,37	25,51
	65-74	10	71,4	9	90,0	14,81	24,22
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 7 Day 1	18-64	49	79,0	47	95,9	17,02	20,70
	65-74	9	64,3	8	88,9	16,67	25,20
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 8 Day 1	18-64	45	72,6	41	91,1	21,95	28,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	14,81	17,57
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 9 Day 1	18-64	40	64,5	40	100,0	23,33	26,37
	65-74	9	64,3	9	100,0	18,52	17,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 10 Day 1	18-64	40	64,5	39	97,5	21,37	23,55
	65-74	9	64,3	9	100,0	18,52	24,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 11 Day 1	18-64	39	62,9	39	100,0	18,80	22,68
	65-74	9	64,3	9	100,0	29,63	26,06
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 12 Day 1	18-64	38	61,3	35	92,1	21,90	25,49
	65-74	9	64,3	8	88,9	16,67	25,20
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	19,61	24,78
	65-74	9	64,3	9	100,0	18,52	24,22
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 14 Day 1	18-64	35	56,5	35	100,0	22,86	28,89
	65-74	9	64,3	8	88,9	12,50	17,25
	>=75	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	18,10	20,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	16,67	17,82
	>=75	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	19,79	22,17
	65-74	7	50,0	6	85,7	5,56	13,61
	>=75	1	50,0	1	100,0	0,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	19,79	27,90
	65-74	6	42,9	6	100,0	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	17,24	24,59
	65-74	6	42,9	5	83,3	6,67	14,91
	>=75	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	26,19	29,20
	65-74	5	35,7	4	80,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	25,64	30,27
	65-74	5	35,7	5	100,0	13,33	29,81
	>=75	1	50,0	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	20,63	28,82
	65-74	4	28,6	4	100,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	16,67	22,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	20,83	29,50
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	20,83	31,91
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	22,6	12	85,7	22,22	29,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	19,44	30,01
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	25,00	29,55
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	18,52	24,22
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	14,29	26,23
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	40,00	36,51
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	33,33	23,57
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	66,67	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	28,33	27,09
	65-74	10	71,4	7	70,0	14,29	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	0,00	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	2,86	9,47
	Other	43	100,0	43	100,0	9,30	15,13
Cycle 2 Day 1	White	33	94,3	28	84,8	13,10	20,96
	Other	39	90,7	36	92,3	16,67	23,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	14,81	21,35
	Other	37	86,0	37	100,0	15,32	23,03
Cycle 4 Day 1	White	31	88,6	28	90,3	14,29	21,14
	Other	36	83,7	36	100,0	16,67	18,69
Cycle 5 Day 1	White	31	88,6	30	96,8	12,22	18,54
	Other	34	79,1	34	100,0	17,65	22,07
Cycle 6 Day 1	White	30	85,7	28	93,3	14,29	24,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	19,79	25,20
Cycle 7 Day 1	White	29	82,9	27	93,1	14,81	21,35
	Other	31	72,1	30	96,8	17,78	20,96
Cycle 8 Day 1	White	28	80,0	24	85,7	20,83	29,18
	Other	28	65,1	28	100,0	20,24	24,58
Cycle 9 Day 1	White	26	74,3	26	100,0	19,23	25,25
	Other	25	58,1	25	100,0	24,00	24,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	17,33	23,80
	Other	25	58,1	25	100,0	22,67	23,01
Cycle 11 Day 1	White	26	74,3	26	100,0	15,38	23,53
	Other	24	55,8	24	100,0	25,00	22,52
Cycle 12 Day 1	White	26	74,3	22	84,6	22,73	29,79
	Other	23	53,5	23	100,0	17,39	19,77
Cycle 13 Day 1	White	24	68,6	23	95,8	20,29	26,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	16,67	22,42
Cycle 14 Day 1	White	24	68,6	24	100,0	22,22	30,56
	Other	21	48,8	20	95,2	18,33	22,88
Cycle 15 Day 1	White	24	68,6	24	100,0	13,89	19,45
	Other	20	46,5	20	100,0	21,67	19,57
Cycle 16 Day 1	White	22	62,9	20	90,9	18,33	22,88
	Other	19	44,2	19	100,0	15,79	20,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	19,70	31,97
	Other	17	39,5	17	100,0	15,69	17,15
Cycle 18 Day 1	White	21	60,0	18	85,7	20,37	25,92
	Other	17	39,5	17	100,0	9,80	19,60
Cycle 19 Day 1	White	20	57,1	20	100,0	25,00	28,36
	Other	16	37,2	13	81,3	17,95	29,24
Cycle 20 Day 1	White	20	57,1	17	85,0	21,57	28,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	24,44	32,04
Cycle 21 Day 1	White	16	45,7	14	87,5	19,05	31,25
	Other	13	30,2	12	92,3	13,89	22,29
Cycle 22 Day 1	White	16	45,7	13	81,3	12,82	21,68
	Other	13	30,2	12	92,3	13,89	22,29
Cycle 23 Day 1	White	12	34,3	10	83,3	16,67	23,57
	Other	9	20,9	8	88,9	20,83	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	23,33	35,31
	Other	9	20,9	8	88,9	12,50	24,80
Cycle 25 Day 1	White	10	28,6	8	80,0	20,83	35,36
	Other	5	11,6	5	100,0	20,00	18,26
Cycle 26 Day 1	White	10	28,6	8	80,0	25,00	34,50
	Other	4	9,3	4	100,0	8,33	16,67
Cycle 27 Day 1	White	8	22,9	5	62,5	20,00	29,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	33,33	33,33
Cycle 28 Day 1	White	7	20,0	6	85,7	16,67	27,89
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 29 Day 1	White	6	17,1	4	66,7	25,00	31,91
	Other	3	7,0	3	100,0	0,00	0,00
Cycle 30 Day 1	White	4	11,4	2	50,0	16,67	23,57
	Other	3	7,0	3	100,0	55,56	38,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	33,33	47,14
	Other	3	7,0	3	100,0	33,33	0,00
Cycle 32 Day 1	White	4	11,4	3	75,0	11,11	19,25
	Other	2	4,7	2	100,0	33,33	0,00
Cycle 33 Day 1	White	2	5,7	2	100,0	33,33	47,14
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	25,00	32,18
	Other	24	55,8	16	66,7	22,92	23,47
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	4,55	11,71
	Europe (EU)	17	100,0	17	100,0	3,92	11,07
	Asia (AS)	39	100,0	39	100,0	8,55	14,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	16	80,0	8,33	14,91
	Europe (EU)	16	94,1	13	81,3	15,38	22,01
	Asia (AS)	36	92,3	35	97,2	18,10	24,71
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	10,53	15,92
	Europe (EU)	15	88,2	12	80,0	16,67	26,59
	Asia (AS)	33	84,6	33	100,0	17,17	23,75
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	15,00	22,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	13,89	22,29
	Asia (AS)	32	82,1	32	100,0	16,67	16,93
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	11,67	22,36
	Europe (EU)	15	88,2	14	93,3	7,14	14,19
	Asia (AS)	30	76,9	30	100,0	21,11	20,50
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	18,33	25,31
	Europe (EU)	14	82,4	13	92,9	5,13	18,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	22,22	26,15
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	16,67	20,61
	Europe (EU)	14	82,4	13	92,9	12,82	21,68
	Asia (AS)	27	69,2	26	96,3	17,95	21,56
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	17,65	23,91
	Europe (EU)	14	82,4	11	78,6	24,24	33,63
	Asia (AS)	24	61,5	24	100,0	20,83	25,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	22,22	28,01
	Europe (EU)	12	70,6	12	100,0	13,89	17,16
	Asia (AS)	21	53,8	21	100,0	25,40	25,61
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	21,57	28,73
	Europe (EU)	12	70,6	12	100,0	13,89	17,16
	Asia (AS)	21	53,8	21	100,0	22,22	21,94
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	22,22	30,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	13,89	17,16
	Asia (AS)	20	51,3	20	100,0	21,67	19,57
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	23,53	30,65
	Europe (EU)	12	70,6	9	75,0	18,52	24,22
	Asia (AS)	19	48,7	19	100,0	17,54	20,39
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	19,61	29,01
	Europe (EU)	11	64,7	10	90,9	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	20,37	23,26
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	23,53	34,89
	Europe (EU)	11	64,7	11	100,0	21,21	22,47
	Asia (AS)	17	43,6	16	94,1	16,67	21,08
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	15,69	20,81
	Europe (EU)	11	64,7	11	100,0	18,18	17,41
	Asia (AS)	16	41,0	16	100,0	18,75	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	19,05	21,54
	Europe (EU)	11	64,7	9	81,8	18,52	24,22
	Asia (AS)	16	41,0	16	100,0	14,58	20,97
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	26,19	35,03
	Europe (EU)	10	58,8	10	100,0	13,33	23,31
	Asia (AS)	15	38,5	15	100,0	13,33	16,90
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	16,67	28,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	11,11	17,21
	Asia (AS)	15	38,5	15	100,0	15,56	21,33
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	28,21	29,96
	Europe (EU)	9	52,9	9	100,0	14,81	24,22
	Asia (AS)	14	35,9	11	78,6	21,21	30,81
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	25,64	30,89
	Europe (EU)	9	52,9	6	66,7	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	25,64	33,76
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	16,67	32,39
	Europe (EU)	7	41,2	6	85,7	11,11	27,22
	Asia (AS)	11	28,2	10	90,9	20,00	23,31
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	13,33	23,31
	Europe (EU)	7	41,2	5	71,4	6,67	14,91
	Asia (AS)	11	28,2	10	90,9	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	14,81	24,22
	Europe (EU)	5	29,4	3	60,0	11,11	19,25
	Asia (AS)	7	17,9	6	85,7	27,78	38,97
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	25,00	38,83
	Europe (EU)	5	29,4	4	80,0	8,33	16,67
	Asia (AS)	7	17,9	6	85,7	16,67	27,89
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	23,81	37,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	16,67	23,57
	Asia (AS)	4	10,3	4	100,0	16,67	19,25
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	27,78	38,97
	Europe (EU)	4	23,5	2	50,0	16,67	23,57
	Asia (AS)	4	10,3	4	100,0	8,33	16,67
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	25,00	31,91
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	25,00	31,91
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	25,00	31,91
	Europe (EU)	2	11,8	1	50,0	0,00	-
	Asia (AS)	4	10,3	4	100,0	16,67	19,25
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	33,33	33,33
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	55,56	38,49
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	33,33	47,14
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	33,33	0,00
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	0,00	-
	Asia (AS)	3	7,7	2	66,7	33,33	0,00
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	66,67	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	24,24	33,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	33,33	27,22
	Asia (AS)	21	53,8	13	61,9	20,51	21,68
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	4,44	11,52
	1	38	100,0	38	100,0	8,77	14,88
	2	10	100,0	10	100,0	3,33	10,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	26	86,7	17,95	25,35
	1	36	94,7	32	88,9	13,54	20,49
	2	6	60,0	6	100,0	11,11	17,21
Cycle 3 Day 1	0	29	96,7	27	93,1	20,99	26,39
	1	34	89,5	32	94,1	11,46	18,18
	2	5	50,0	5	100,0	6,67	14,91
Cycle 4 Day 1	0	29	96,7	28	96,6	21,43	22,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	9,38	15,23
	2	5	50,0	4	80,0	25,00	16,67
Cycle 5 Day 1	0	29	96,7	29	100,0	17,24	22,92
	1	33	86,8	32	97,0	13,54	18,66
	2	3	30,0	3	100,0	11,11	19,25
Cycle 6 Day 1	0	29	96,7	29	100,0	22,99	28,32
	1	31	81,6	28	90,3	11,90	20,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	11,11	19,25
Cycle 7 Day 1	0	29	96,7	28	96,6	20,24	22,84
	1	28	73,7	26	92,9	12,82	19,04
	2	3	30,0	3	100,0	11,11	19,25
Cycle 8 Day 1	0	28	93,3	26	92,9	21,79	24,84
	1	25	65,8	23	92,0	17,39	24,35
	2	3	30,0	3	100,0	33,33	57,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	24,36	30,63
	1	23	60,5	23	100,0	18,84	16,90
	2	2	20,0	2	100,0	16,67	23,57
Cycle 10 Day 1	0	26	86,7	26	100,0	20,51	25,08
	1	23	60,5	22	95,7	19,70	22,20
	2	2	20,0	2	100,0	16,67	23,57
Cycle 11 Day 1	0	26	86,7	26	100,0	21,79	26,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	16,67	19,92
	2	2	20,0	2	100,0	33,33	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	24,24	29,42
	1	22	57,9	21	95,5	15,87	20,05
	2	2	20,0	2	100,0	16,67	23,57
Cycle 13 Day 1	0	25	83,3	24	96,0	22,22	25,38
	1	20	52,6	20	100,0	15,00	22,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	26,39	31,05
	1	19	50,0	19	100,0	14,04	20,23
	2	1	10,0	1	100,0	0,00	-
Cycle 15 Day 1	0	24	80,0	24	100,0	20,83	19,19
	1	19	50,0	19	100,0	12,28	19,91
	2	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	20,00	22,69
	1	18	47,4	18	100,0	12,96	20,26
	2	1	10,0	1	100,0	33,33	-
Cycle 17 Day 1	0	21	70,0	21	100,0	23,81	31,87
	1	17	44,7	17	100,0	11,76	16,42
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	18,52	26,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	12,50	20,64
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	21,05	29,84
	1	15	39,5	13	86,7	23,08	28,50
	2	1	10,0	1	100,0	33,33	-
Cycle 20 Day 1	0	20	66,7	17	85,0	27,45	29,43
	1	15	39,5	14	93,3	16,67	31,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	33,33	-
Cycle 21 Day 1	0	15	50,0	14	93,3	19,05	31,25
	1	13	34,2	11	84,6	12,12	22,47
	2	1	10,0	1	100,0	33,33	-
Cycle 22 Day 1	0	15	50,0	12	80,0	8,33	15,08
	1	13	34,2	12	92,3	16,67	26,59
	2	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	11,11	23,57
	1	9	23,7	8	88,9	29,17	33,03
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	18,52	37,68
	1	9	23,7	8	88,9	20,83	24,80
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	22,22	40,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	19,05	17,82
Cycle 26 Day 1	0	8	26,7	6	75,0	22,22	40,37
	1	6	15,8	6	100,0	16,67	18,26
Cycle 27 Day 1	0	6	20,0	3	50,0	11,11	19,25
	1	5	13,2	5	100,0	33,33	33,33
Cycle 28 Day 1	0	5	16,7	4	80,0	16,67	33,33
	1	5	13,2	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	33,33	47,14
	1	5	13,2	5	100,0	6,67	14,91
Cycle 30 Day 1	0	3	10,0	1	33,3	33,33	-
	1	4	10,5	4	100,0	41,67	41,94
Cycle 31 Day 1	0	3	10,0	1	33,3	66,67	-
	1	4	10,5	4	100,0	25,00	16,67
Cycle 32 Day 1	0	3	10,0	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	22,22	19,25
Cycle 33 Day 1	0	2	6,7	2	100,0	33,33	47,14
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	23,81	30,46
	1	20	52,6	12	60,0	25,00	25,13
	2	4	40,0	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	5,38	12,46
	1	3	100,0	3	100,0	0,00	0,00
	2 or More	44	100,0	44	100,0	7,58	14,13
Cycle 2 Day 1	None	30	96,8	26	86,7	15,38	21,56
	1	2	66,7	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	15,32	23,03
Cycle 3 Day 1	None	30	96,8	28	93,3	16,67	24,85
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	35	97,2	14,29	20,27
Cycle 4 Day 1	None	30	96,8	29	96,7	11,49	18,42
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	35	79,5	33	94,3	20,20	20,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	8,89	19,44
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	33	75,0	32	97,0	21,88	20,05
Cycle 6 Day 1	None	29	93,5	28	96,6	15,48	26,42
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	32	72,7	30	93,8	20,00	24,13
Cycle 7 Day 1	None	27	87,1	26	96,3	15,38	19,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	31	70,5	29	93,5	17,24	22,92
Cycle 8 Day 1	None	26	83,9	25	96,2	12,00	21,26
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	28,40	28,80
Cycle 9 Day 1	None	25	80,6	25	100,0	20,00	28,87
	1	1	33,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	22,67	20,91
Cycle 10 Day 1	None	25	80,6	24	96,0	16,67	26,01
	1	1	33,3	1	100,0	33,33	-
	2 or More	25	56,8	25	100,0	22,67	20,91
Cycle 11 Day 1	None	25	80,6	25	100,0	20,00	27,22
	1	1	33,3	1	100,0	0,00	-
	2 or More	24	54,5	24	100,0	20,83	19,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	15,28	25,97
	1	1	33,3	1	100,0	33,33	-
	2 or More	23	52,3	20	87,0	25,00	23,88
Cycle 13 Day 1	None	24	77,4	23	95,8	14,49	26,26
	1	1	33,3	1	100,0	33,33	-
	2 or More	21	47,7	21	100,0	22,22	21,94
Cycle 14 Day 1	None	23	74,2	23	100,0	15,94	28,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	33,33	-
	2 or More	21	47,7	20	95,2	25,00	26,21
Cycle 15 Day 1	None	23	74,2	23	100,0	8,70	14,97
	1	1	33,3	1	100,0	33,33	-
	2 or More	20	45,5	20	100,0	26,67	20,52
Cycle 16 Day 1	None	20	64,5	19	95,0	12,28	16,52
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	22,81	24,98
Cycle 17 Day 1	None	19	61,3	19	100,0	14,04	25,62
	1	1	33,3	1	100,0	33,33	-
	2 or More	19	43,2	19	100,0	21,05	27,69
Cycle 18 Day 1	None	18	58,1	17	94,4	13,73	26,51
	1	1	33,3	1	100,0	33,33	-
	2 or More	19	43,2	17	89,5	15,69	20,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	17,65	26,66
	1	1	33,3	1	100,0	33,33	-
	2 or More	18	40,9	15	83,3	26,67	31,37
Cycle 20 Day 1	None	17	54,8	16	94,1	14,58	27,13
	1	1	33,3	1	100,0	33,33	-
	2 or More	18	40,9	15	83,3	31,11	32,04
Cycle 21 Day 1	None	15	48,4	13	86,7	15,38	29,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	17,95	25,88
Cycle 22 Day 1	None	15	48,4	13	86,7	7,69	19,97
	2 or More	14	31,8	12	85,7	19,44	22,29
Cycle 23 Day 1	None	10	32,3	9	90,0	11,11	23,57
	2 or More	11	25,0	9	81,8	25,93	32,39
Cycle 24 Day 1	None	10	32,3	10	100,0	13,33	32,20
	2 or More	10	22,7	8	80,0	25,00	29,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	25,00	34,50
	2 or More	6	13,6	5	83,3	13,33	18,26
Cycle 26 Day 1	None	8	25,8	8	100,0	16,67	35,63
	2 or More	6	13,6	4	66,7	25,00	16,67
Cycle 27 Day 1	None	7	22,6	6	85,7	22,22	27,22
	2 or More	4	9,1	2	50,0	33,33	47,14
Cycle 28 Day 1	None	7	22,6	7	100,0	19,05	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	19,4	5	83,3	20,00	29,81
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	12,9	3	75,0	22,22	19,25
	2 or More	3	6,8	2	66,7	66,67	47,14
Cycle 31 Day 1	None	4	12,9	3	75,0	33,33	33,33
	2 or More	3	6,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	22,22	19,25
	2 or More	2	4,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	3,2	1	100,0	66,67	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	22,22	25,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	33,33	-
	2 or More	24	54,5	15	62,5	24,44	29,46
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	5,38	12,46
	Previously Treated	47	100,0	47	100,0	7,09	13,79
Cycle 2 Day 1	Naïve	30	96,8	26	86,7	15,38	21,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	14,91	22,86
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	16,67	24,85
	Previously Treated	38	80,9	36	94,7	13,89	20,12
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	11,49	18,42
	Previously Treated	37	78,7	35	94,6	19,05	20,27
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	8,89	19,44
	Previously Treated	35	74,5	34	97,1	20,59	20,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	15,48	26,42
	Previously Treated	34	72,3	32	94,1	18,75	23,85
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	15,38	19,39
	Previously Treated	33	70,2	31	93,9	17,20	22,56
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	12,00	21,26
	Previously Treated	30	63,8	27	90,0	28,40	28,80
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	20,00	28,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	23,08	20,59
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	16,67	26,01
	Previously Treated	26	55,3	26	100,0	23,08	20,59
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	20,00	27,22
	Previously Treated	25	53,2	25	100,0	20,00	19,25
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	15,28	25,97
	Previously Treated	24	51,1	21	87,5	25,40	23,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	14,49	26,26
	Previously Treated	22	46,8	22	100,0	22,73	21,54
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	15,94	28,19
	Previously Treated	22	46,8	21	95,5	25,40	25,61
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	8,70	14,97
	Previously Treated	21	44,7	21	100,0	26,98	20,05
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	12,28	16,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	21,67	24,84
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	14,04	25,62
	Previously Treated	20	42,6	20	100,0	21,67	27,09
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	13,73	26,51
	Previously Treated	20	42,6	18	90,0	16,67	20,61
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	17,65	26,66
	Previously Treated	19	40,4	16	84,2	27,08	30,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	14,58	27,13
	Previously Treated	19	40,4	16	84,2	31,25	30,96
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	15,38	29,24
	Previously Treated	14	29,8	13	92,9	17,95	25,88
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	7,69	19,97
	Previously Treated	14	29,8	12	85,7	19,44	22,29
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	11,11	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	25,93	32,39
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	13,33	32,20
	Previously Treated	10	21,3	8	80,0	25,00	29,55
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	25,00	34,50
	Previously Treated	6	12,8	5	83,3	13,33	18,26
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	16,67	35,63
	Previously Treated	6	12,8	4	66,7	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	22,22	27,22
	Previously Treated	4	8,5	2	50,0	33,33	47,14
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	19,05	26,23
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	20,00	29,81
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	66,67	47,14
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	33,33	33,33
	Previously Treated	3	6,4	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	22,22	19,25
	Previously Treated	2	4,3	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	66,67	-
	Previously Treated	1	2,1	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	22,22	25,95
	Previously Treated	26	55,3	16	61,5	25,00	28,54
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	5,71	12,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	6,98	13,72
Cycle 2 Day 1	Local	32	91,4	29	90,6	14,94	16,87
	Central	40	93,0	35	87,5	15,24	26,00
Cycle 3 Day 1	Local	29	82,9	28	96,6	13,10	20,96
	Central	39	90,7	36	92,3	16,67	23,23
Cycle 4 Day 1	Local	28	80,0	27	96,4	16,05	19,33
	Central	39	90,7	37	94,9	15,32	20,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	19,75	21,20
	Central	38	88,4	37	97,4	11,71	19,59
Cycle 6 Day 1	Local	27	77,1	27	100,0	17,28	21,42
	Central	36	83,7	33	91,7	17,17	27,79
Cycle 7 Day 1	Local	27	77,1	27	100,0	16,05	19,33
	Central	33	76,7	30	90,9	16,67	22,74
Cycle 8 Day 1	Local	26	74,3	26	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	24,36	29,15
Cycle 9 Day 1	Local	25	71,4	25	100,0	20,00	27,22
	Central	26	60,5	26	100,0	23,08	22,65
Cycle 10 Day 1	Local	25	71,4	24	96,0	22,22	27,22
	Central	26	60,5	26	100,0	17,95	19,39
Cycle 11 Day 1	Local	24	68,6	24	100,0	20,83	25,66
	Central	26	60,5	26	100,0	19,23	21,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	18,18	26,68
	Central	26	60,5	23	88,5	21,74	23,80
Cycle 13 Day 1	Local	22	62,9	22	100,0	21,21	28,26
	Central	24	55,8	23	95,8	15,94	19,77
Cycle 14 Day 1	Local	22	62,9	22	100,0	18,18	26,68
	Central	23	53,5	22	95,7	22,73	27,96
Cycle 15 Day 1	Local	22	62,9	22	100,0	13,64	16,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	21,21	21,93
Cycle 16 Day 1	Local	20	57,1	20	100,0	16,67	20,23
	Central	21	48,8	19	90,5	17,54	23,22
Cycle 17 Day 1	Local	20	57,1	20	100,0	15,00	25,31
	Central	19	44,2	19	100,0	21,05	27,69
Cycle 18 Day 1	Local	20	57,1	19	95,0	14,04	27,92
	Central	18	41,9	16	88,9	16,67	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	25,49	32,34
	Central	17	39,5	16	94,1	18,75	24,25
Cycle 20 Day 1	Local	19	54,3	17	89,5	19,61	33,46
	Central	17	39,5	15	88,2	26,67	25,82
Cycle 21 Day 1	Local	14	40,0	12	85,7	19,44	33,21
	Central	15	34,9	14	93,3	14,29	21,54
Cycle 22 Day 1	Local	14	40,0	12	85,7	11,11	21,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	15,38	22,01
Cycle 23 Day 1	Local	11	31,4	10	90,9	20,00	35,83
	Central	10	23,3	8	80,0	16,67	17,82
Cycle 24 Day 1	Local	11	31,4	10	90,9	23,33	38,65
	Central	9	20,9	8	88,9	12,50	17,25
Cycle 25 Day 1	Local	7	20,0	7	100,0	23,81	37,09
	Central	8	18,6	6	75,0	16,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	22,22	40,37
	Central	8	18,6	6	75,0	16,67	18,26
Cycle 27 Day 1	Local	4	11,4	4	100,0	16,67	19,25
	Central	7	16,3	4	57,1	33,33	38,49
Cycle 28 Day 1	Local	4	11,4	4	100,0	25,00	31,91
	Central	6	14,0	5	83,3	13,33	18,26
Cycle 29 Day 1	Local	3	8,6	3	100,0	22,22	38,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	8,33	16,67
Cycle 30 Day 1	Local	3	8,6	3	100,0	22,22	19,25
	Central	4	9,3	2	50,0	66,67	47,14
Cycle 31 Day 1	Local	3	8,6	3	100,0	33,33	33,33
	Central	4	9,3	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	8,6	3	100,0	22,22	19,25
	Central	3	7,0	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	66,67	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	16,67	25,32
	Central	21	48,8	14	66,7	30,95	27,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	6,76	13,49
	No	4	100,0	4	100,0	0,00	0,00
Cycle 2 Day 1	Yes	70	94,6	62	88,6	13,98	19,60
	No	2	50,0	2	100,0	50,00	70,71
Cycle 3 Day 1	Yes	66	89,2	62	93,9	15,59	22,35
	No	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	15,05	19,72
	No	2	50,0	2	100,0	33,33	0,00
Cycle 5 Day 1	Yes	63	85,1	62	98,4	15,05	20,63
	No	2	50,0	2	100,0	16,67	23,57
Cycle 6 Day 1	Yes	61	82,4	58	95,1	16,67	25,17
	No	2	50,0	2	100,0	33,33	0,00
Cycle 7 Day 1	Yes	58	78,4	55	94,8	15,15	20,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	50,00	23,57
Cycle 8 Day 1	Yes	54	73,0	50	92,6	20,00	26,94
	No	2	50,0	2	100,0	33,33	0,00
Cycle 9 Day 1	Yes	49	66,2	49	100,0	21,77	25,05
	No	2	50,0	2	100,0	16,67	23,57
Cycle 10 Day 1	Yes	49	66,2	48	98,0	20,14	23,56
	No	2	50,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	19,44	23,65
	No	2	50,0	2	100,0	33,33	0,00
Cycle 12 Day 1	Yes	47	63,5	43	91,5	20,16	25,34
	No	2	50,0	2	100,0	16,67	23,57
Cycle 13 Day 1	Yes	44	59,5	43	97,7	18,60	24,45
	No	2	50,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	43	58,1	42	97,7	21,43	27,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 15 Day 1	Yes	42	56,8	42	100,0	17,46	19,81
	No	2	50,0	2	100,0	16,67	23,57
Cycle 16 Day 1	Yes	39	52,7	37	94,9	18,02	21,65
	No	2	50,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	37	50,0	37	100,0	18,02	26,75
	No	2	50,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	15,15	23,70
	No	2	50,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	22,92	28,63
	No	2	50,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	22,22	29,47
	No	2	50,0	2	100,0	33,33	47,14
Cycle 21 Day 1	Yes	27	36,5	24	88,9	18,06	27,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 22 Day 1	Yes	27	36,5	23	85,2	14,49	22,08
	No	2	50,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	19,61	29,01
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	19,61	31,31
	No	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	19,44	30,01
	No	1	25,0	1	100,0	33,33	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	21,21	30,81
	No	1	25,0	1	100,0	0,00	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	23,81	31,71
	No	1	25,0	1	100,0	33,33	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	16,67	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	16,67	27,89
	No	1	25,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	41,67	41,94
	No	1	25,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	33,33	27,22
	No	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	16,67	19,25
	No	1	25,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	33,33	47,14
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	23,81	27,00
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	8,33	15,43
	No	70	100,0	70	100,0	6,19	13,06
Cycle 2 Day 1	Yes	5	62,5	5	100,0	13,33	18,26
	No	67	95,7	59	88,1	15,25	22,59
Cycle 3 Day 1	Yes	5	62,5	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	15,82	22,62
Cycle 4 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	62	88,6	59	95,2	16,38	19,94
Cycle 5 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	60	85,7	59	98,3	15,82	20,86
Cycle 6 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	58	82,9	55	94,8	18,18	25,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	55	78,6	52	94,5	17,31	21,38
Cycle 8 Day 1	Yes	5	62,5	5	100,0	13,33	29,81
	No	51	72,9	47	92,2	21,28	26,40
Cycle 9 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	47	67,1	47	100,0	23,40	24,98
Cycle 10 Day 1	Yes	4	50,0	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	21,01	23,68
Cycle 11 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	46	65,7	46	100,0	21,74	23,54
Cycle 12 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	45	64,3	41	91,1	21,95	25,40
Cycle 13 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	42	60,0	41	97,6	19,51	24,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	41	58,6	40	97,6	22,50	27,62
Cycle 15 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	40	57,1	40	100,0	19,17	19,81
Cycle 16 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	38	54,3	36	94,7	18,52	21,74
Cycle 17 Day 1	Yes	3	37,5	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	19,44	26,87
Cycle 18 Day 1	Yes	3	37,5	3	100,0	22,22	19,25
	No	35	50,0	32	91,4	14,58	23,85
Cycle 19 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	33	47,1	30	90,9	23,33	29,23
Cycle 20 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	33	47,1	29	87,9	24,14	30,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	27	38,6	24	88,9	16,67	27,80
Cycle 22 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	23	85,2	14,49	22,08
Cycle 23 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	19	27,1	16	84,2	20,83	29,50
Cycle 24 Day 1	Yes	2	25,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	20,83	31,91
Cycle 25 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	13	18,6	11	84,6	24,24	30,15
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	21,21	30,81
Cycle 27 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	10	14,3	7	70,0	28,57	29,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	9	12,9	8	88,9	20,83	24,80
Cycle 29 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	8	11,4	6	75,0	16,67	27,89
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	40,00	36,51
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	33,33	23,57
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	20,00	18,26
Cycle 33 Day 1	No	2	2,9	2	100,0	33,33	47,14
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	24,36	27,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DI_SG.xls
29NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	39,74	30,89
Cycle 2 Day 1	All	72	92,3	65	90,3	27,69	28,61
Cycle 3 Day 1	All	68	87,2	64	94,1	26,04	23,36
Cycle 4 Day 1	All	67	85,9	64	95,5	25,00	25,20
Cycle 5 Day 1	All	65	83,3	64	98,5	29,69	26,64
Cycle 6 Day 1	All	63	80,8	60	95,2	23,33	22,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	28,65	25,54
Cycle 8 Day 1	All	56	71,8	52	92,9	25,00	22,75
Cycle 9 Day 1	All	51	65,4	51	100,0	26,80	24,06
Cycle 10 Day 1	All	51	65,4	50	98,0	28,67	17,83
Cycle 11 Day 1	All	50	64,1	50	100,0	26,00	22,63
Cycle 12 Day 1	All	49	62,8	45	91,8	22,96	19,88
Cycle 13 Day 1	All	46	59,0	45	97,8	21,48	22,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	25,76	25,78
Cycle 15 Day 1	All	44	56,4	44	100,0	24,24	20,79
Cycle 16 Day 1	All	41	52,6	39	95,1	26,50	23,17
Cycle 17 Day 1	All	39	50,0	39	100,0	26,50	24,40
Cycle 18 Day 1	All	38	48,7	35	92,1	21,90	21,30
Cycle 19 Day 1	All	36	46,2	32	88,9	26,04	21,97
Cycle 20 Day 1	All	36	46,2	32	88,9	20,83	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	26,92	21,12
Cycle 22 Day 1	All	29	37,2	25	86,2	26,67	25,46
Cycle 23 Day 1	All	21	26,9	18	85,7	20,37	25,92
Cycle 24 Day 1	All	20	25,6	18	90,0	25,93	18,28
Cycle 25 Day 1	All	15	19,2	13	86,7	23,08	16,01
Cycle 26 Day 1	All	14	17,9	12	85,7	33,33	34,82
Cycle 27 Day 1	All	11	14,1	8	72,7	25,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	22,22	23,57
Cycle 29 Day 1	All	9	11,5	7	77,8	33,33	0,00
Cycle 30 Day 1	All	7	9,0	5	71,4	26,67	14,91
Cycle 31 Day 1	All	7	9,0	5	71,4	33,33	0,00
Cycle 32 Day 1	All	6	7,7	5	83,3	26,67	14,91
Cycle 33 Day 1	All	2	2,6	2	100,0	16,67	23,57
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	46,43	24,58
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	42,53	30,73
	Female	49	100,0	49	100,0	38,10	31,18
Cycle 2 Day 1	Male	27	93,1	25	92,6	32,00	29,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	25,00	27,99
Cycle 3 Day 1	Male	25	86,2	23	92,0	27,54	23,89
	Female	43	87,8	41	95,3	25,20	23,31
Cycle 4 Day 1	Male	25	86,2	25	100,0	26,67	25,46
	Female	42	85,7	39	92,9	23,93	25,30
Cycle 5 Day 1	Male	25	86,2	25	100,0	32,00	26,32
	Female	40	81,6	39	97,5	28,21	27,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	21,74	21,58
	Female	38	77,6	37	97,4	24,32	23,11
Cycle 7 Day 1	Male	23	79,3	23	100,0	28,99	23,15
	Female	37	75,5	34	91,9	28,43	27,38
Cycle 8 Day 1	Male	21	72,4	19	90,5	28,07	22,94
	Female	35	71,4	33	94,3	23,23	22,80
Cycle 9 Day 1	Male	18	62,1	18	100,0	27,78	20,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	26,26	26,03
Cycle 10 Day 1	Male	18	62,1	18	100,0	33,33	19,80
	Female	33	67,3	32	97,0	26,04	16,36
Cycle 11 Day 1	Male	18	62,1	18	100,0	29,63	22,55
	Female	32	65,3	32	100,0	23,96	22,77
Cycle 12 Day 1	Male	17	58,6	17	100,0	23,53	19,60
	Female	32	65,3	28	87,5	22,62	20,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	23,53	22,87
	Female	29	59,2	28	96,6	20,24	22,84
Cycle 14 Day 1	Male	17	58,6	16	94,1	33,33	27,22
	Female	28	57,1	28	100,0	21,43	24,37
Cycle 15 Day 1	Male	16	55,2	16	100,0	27,08	21,84
	Female	28	57,1	28	100,0	22,62	20,39
Cycle 16 Day 1	Male	14	48,3	14	100,0	26,19	23,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	26,67	23,57
Cycle 17 Day 1	Male	12	41,4	12	100,0	22,22	21,71
	Female	27	55,1	27	100,0	28,40	25,66
Cycle 18 Day 1	Male	11	37,9	10	90,9	23,33	27,44
	Female	27	55,1	25	92,6	21,33	18,95
Cycle 19 Day 1	Male	10	34,5	9	90,0	29,63	20,03
	Female	26	53,1	23	88,5	24,64	22,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	22,22	28,87
	Female	26	53,1	23	88,5	20,29	21,88
Cycle 21 Day 1	Male	8	27,6	8	100,0	20,83	17,25
	Female	21	42,9	18	85,7	29,63	22,55
Cycle 22 Day 1	Male	8	27,6	6	75,0	33,33	21,08
	Female	21	42,9	19	90,5	24,56	26,86
Cycle 23 Day 1	Male	5	17,2	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	26,19	26,73
Cycle 24 Day 1	Male	5	17,2	4	80,0	25,00	16,67
	Female	15	30,6	14	93,3	26,19	19,30
Cycle 25 Day 1	Male	3	10,3	2	66,7	16,67	23,57
	Female	12	24,5	11	91,7	24,24	15,57
Cycle 26 Day 1	Male	3	10,3	2	66,7	16,67	23,57
	Female	11	22,4	10	90,9	36,67	36,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	16,67	23,57
	Female	8	16,3	6	75,0	27,78	25,09
Cycle 28 Day 1	Male	2	6,9	2	100,0	16,67	23,57
	Female	8	16,3	7	87,5	23,81	25,20
Cycle 29 Day 1	Male	1	3,4	1	100,0	33,33	-
	Female	8	16,3	6	75,0	33,33	0,00
Cycle 30 Day 1	Male	1	3,4	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	25,00	16,67
Cycle 31 Day 1	Male	1	3,4	1	100,0	33,33	-
	Female	6	12,2	4	66,7	33,33	0,00
Cycle 32 Day 1	Male	1	3,4	1	100,0	33,33	-
	Female	5	10,2	4	80,0	25,00	16,67
Cycle 33 Day 1	Male	1	3,4	1	100,0	33,33	-
	Female	1	2,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	55,56	27,22
	Female	21	42,9	13	61,9	35,90	16,45
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	40,32	30,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	40,48	32,50
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 2 Day 1	18-64	59	95,2	53	89,8	24,53	25,45
	65-74	11	78,6	10	90,9	50,00	36,00
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 3 Day 1	18-64	56	90,3	52	92,9	24,36	22,01
	65-74	10	71,4	10	100,0	33,33	31,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	33,33	0,00
Cycle 4 Day 1	18-64	55	88,7	53	96,4	21,38	22,73
	65-74	10	71,4	9	90,0	40,74	32,39
	>=75	2	100,0	2	100,0	50,00	23,57
Cycle 5 Day 1	18-64	53	85,5	52	98,1	26,28	24,99
	65-74	10	71,4	10	100,0	43,33	31,62
	>=75	2	100,0	2	100,0	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	21,77	22,10
	65-74	10	71,4	9	90,0	33,33	23,57
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 7 Day 1	18-64	49	79,0	47	95,9	26,95	24,71
	65-74	9	64,3	8	88,9	37,50	33,03
	>=75	2	100,0	2	100,0	33,33	0,00
Cycle 8 Day 1	18-64	45	72,6	41	91,1	24,39	23,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	29,63	20,03
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 9 Day 1	18-64	40	64,5	40	100,0	21,67	19,32
	65-74	9	64,3	9	100,0	48,15	33,79
	>=75	2	100,0	2	100,0	33,33	0,00
Cycle 10 Day 1	18-64	40	64,5	39	97,5	26,50	17,40
	65-74	9	64,3	9	100,0	33,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	50,00	23,57
Cycle 11 Day 1	18-64	39	62,9	39	100,0	26,50	23,17
	65-74	9	64,3	9	100,0	25,93	22,22
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 12 Day 1	18-64	38	61,3	35	92,1	20,00	20,13
	65-74	9	64,3	8	88,9	33,33	17,82
	>=75	2	100,0	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	18,63	18,70
	65-74	9	64,3	9	100,0	25,93	32,39
	>=75	2	100,0	2	100,0	50,00	23,57
Cycle 14 Day 1	18-64	35	56,5	35	100,0	22,86	23,94
	65-74	9	64,3	8	88,9	37,50	33,03
	>=75	1	50,0	1	100,0	33,33	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	21,90	19,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	33,33	25,20
	>=75	1	50,0	1	100,0	33,33	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	25,00	23,95
	65-74	7	50,0	6	85,7	33,33	21,08
	>=75	1	50,0	1	100,0	33,33	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	25,00	22,40
	65-74	6	42,9	6	100,0	33,33	36,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	33,33	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	19,54	18,93
	65-74	6	42,9	5	83,3	33,33	33,33
	>=75	1	50,0	1	100,0	33,33	-
Cycle 19 Day 1	18-64	30	48,4	27	90,0	24,69	21,86
	65-74	5	35,7	4	80,0	33,33	27,22
	>=75	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	17,95	19,39
	65-74	5	35,7	5	100,0	26,67	36,51
	>=75	1	50,0	1	100,0	66,67	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	26,98	20,05
	65-74	4	28,6	4	100,0	25,00	31,91
	>=75	1	50,0	1	100,0	33,33	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	26,67	25,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	25,00	31,91
	>=75	1	50,0	1	100,0	33,33	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	22,92	26,44
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	27,08	18,13
	65-74	2	14,3	2	100,0	16,67	23,57
Cycle 25 Day 1	18-64	14	22,6	12	85,7	25,00	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	33,33	34,82
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	25,00	23,57
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	22,22	23,57
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	33,33	0,00
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	26,67	14,91
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	33,33	0,00
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	33,33	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	46,67	27,36
	65-74	10	71,4	7	70,0	47,62	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	33,33	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	40,95	30,34
	Other	43	100,0	43	100,0	38,76	31,65
Cycle 2 Day 1	White	33	94,3	29	87,9	29,89	30,01
	Other	39	90,7	36	92,3	25,93	27,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	24,69	23,74
	Other	37	86,0	37	100,0	27,03	23,36
Cycle 4 Day 1	White	31	88,6	28	90,3	17,86	19,21
	Other	36	83,7	36	100,0	30,56	28,03
Cycle 5 Day 1	White	31	88,6	30	96,8	28,89	28,68
	Other	34	79,1	34	100,0	30,39	25,12
Cycle 6 Day 1	White	30	85,7	28	93,3	23,81	25,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	22,92	19,74
Cycle 7 Day 1	White	29	82,9	27	93,1	27,16	26,21
	Other	31	72,1	30	96,8	30,00	25,30
Cycle 8 Day 1	White	28	80,0	24	85,7	23,61	23,01
	Other	28	65,1	28	100,0	26,19	22,87
Cycle 9 Day 1	White	26	74,3	26	100,0	25,64	23,68
	Other	25	58,1	25	100,0	28,00	24,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	29,33	22,19
	Other	25	58,1	25	100,0	28,00	12,47
Cycle 11 Day 1	White	26	74,3	26	100,0	23,08	18,30
	Other	24	55,8	24	100,0	29,17	26,58
Cycle 12 Day 1	White	26	74,3	22	84,6	22,73	15,89
	Other	23	53,5	23	100,0	23,19	23,43
Cycle 13 Day 1	White	24	68,6	23	95,8	27,54	25,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	15,15	16,99
Cycle 14 Day 1	White	24	68,6	24	100,0	25,00	24,57
	Other	21	48,8	20	95,2	26,67	27,78
Cycle 15 Day 1	White	24	68,6	24	100,0	27,78	21,23
	Other	20	46,5	20	100,0	20,00	19,94
Cycle 16 Day 1	White	22	62,9	20	90,9	21,67	19,57
	Other	19	44,2	19	100,0	31,58	26,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	24,24	21,04
	Other	17	39,5	17	100,0	29,41	28,58
Cycle 18 Day 1	White	21	60,0	18	85,7	16,67	17,15
	Other	17	39,5	17	100,0	27,45	24,25
Cycle 19 Day 1	White	20	57,1	19	95,0	26,32	23,78
	Other	16	37,2	13	81,3	25,64	19,97
Cycle 20 Day 1	White	20	57,1	17	85,0	25,49	22,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	15,56	24,77
Cycle 21 Day 1	White	16	45,7	14	87,5	30,95	20,52
	Other	13	30,2	12	92,3	22,22	21,71
Cycle 22 Day 1	White	16	45,7	13	81,3	25,64	27,74
	Other	13	30,2	12	92,3	27,78	23,92
Cycle 23 Day 1	White	12	34,3	10	83,3	26,67	30,63
	Other	9	20,9	8	88,9	12,50	17,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	26,67	21,08
	Other	9	20,9	8	88,9	25,00	15,43
Cycle 25 Day 1	White	10	28,6	8	80,0	20,83	17,25
	Other	5	11,6	5	100,0	26,67	14,91
Cycle 26 Day 1	White	10	28,6	8	80,0	33,33	43,64
	Other	4	9,3	4	100,0	33,33	0,00
Cycle 27 Day 1	White	8	22,9	5	62,5	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	33,33	33,33
Cycle 28 Day 1	White	7	20,0	6	85,7	16,67	18,26
	Other	3	7,0	3	100,0	33,33	33,33
Cycle 29 Day 1	White	6	17,1	4	66,7	33,33	0,00
	Other	3	7,0	3	100,0	33,33	0,00
Cycle 30 Day 1	White	4	11,4	2	50,0	33,33	0,00
	Other	3	7,0	3	100,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	33,33	0,00
	Other	3	7,0	3	100,0	33,33	0,00
Cycle 32 Day 1	White	4	11,4	3	75,0	22,22	19,25
	Other	2	4,7	2	100,0	33,33	0,00
Cycle 33 Day 1	White	2	5,7	2	100,0	16,67	23,57
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	47,22	22,29
	Other	24	55,8	16	66,7	45,83	26,87
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	39,39	31,93
	Europe (EU)	17	100,0	17	100,0	52,94	33,46
	Asia (AS)	39	100,0	39	100,0	34,19	28,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	25,49	27,71
	Europe (EU)	16	94,1	13	81,3	33,33	33,33
	Asia (AS)	36	92,3	35	97,2	26,67	27,77
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	22,81	19,41
	Europe (EU)	15	88,2	12	80,0	30,56	30,01
	Asia (AS)	33	84,6	33	100,0	26,26	23,21
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	20,00	19,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	22,22	21,71
	Asia (AS)	32	82,1	32	100,0	29,17	29,02
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	26,67	23,20
	Europe (EU)	15	88,2	14	93,3	26,19	23,31
	Asia (AS)	30	76,9	30	100,0	33,33	30,32
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	20,00	19,94
	Europe (EU)	14	82,4	13	92,9	28,21	22,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	23,46	24,13
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	31,48	26,75
	Europe (EU)	14	82,4	13	92,9	28,21	26,69
	Asia (AS)	27	69,2	26	96,3	26,92	24,98
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	23,53	19,60
	Europe (EU)	14	82,4	11	78,6	36,36	23,35
	Asia (AS)	24	61,5	24	100,0	20,83	23,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	24,07	19,15
	Europe (EU)	12	70,6	12	100,0	33,33	28,43
	Asia (AS)	21	53,8	21	100,0	25,40	25,61
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	29,41	20,01
	Europe (EU)	12	70,6	12	100,0	30,56	22,29
	Asia (AS)	21	53,8	21	100,0	26,98	13,41
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	27,78	26,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	27,78	19,25
	Asia (AS)	20	51,3	20	100,0	23,33	21,90
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	21,57	16,42
	Europe (EU)	12	70,6	9	75,0	25,93	14,70
	Asia (AS)	19	48,7	19	100,0	22,81	24,98
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	17,65	20,81
	Europe (EU)	11	64,7	10	90,9	36,67	29,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	16,67	17,15
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	21,57	16,42
	Europe (EU)	11	64,7	11	100,0	39,39	35,96
	Asia (AS)	17	43,6	16	94,1	20,83	23,96
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	23,53	19,60
	Europe (EU)	11	64,7	11	100,0	30,30	23,35
	Asia (AS)	16	41,0	16	100,0	20,83	20,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	19,05	17,12
	Europe (EU)	11	64,7	9	81,8	29,63	20,03
	Asia (AS)	16	41,0	16	100,0	31,25	28,46
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	26,19	23,31
	Europe (EU)	10	58,8	10	100,0	23,33	16,10
	Asia (AS)	15	38,5	15	100,0	28,89	30,52
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	19,05	21,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	16,67	18,26
	Asia (AS)	15	38,5	15	100,0	26,67	22,54
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	25,64	19,97
	Europe (EU)	9	52,9	8	88,9	33,33	25,20
	Asia (AS)	14	35,9	11	78,6	21,21	22,47
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	15,38	17,30
	Europe (EU)	9	52,9	6	66,7	38,89	25,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	17,95	25,88
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	30,00	18,92
	Europe (EU)	7	41,2	6	85,7	33,33	21,08
	Asia (AS)	11	28,2	10	90,9	20,00	23,31
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	30,00	29,19
	Europe (EU)	7	41,2	5	71,4	20,00	18,26
	Asia (AS)	11	28,2	10	90,9	26,67	26,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	25,93	32,39
	Europe (EU)	5	29,4	3	60,0	22,22	19,25
	Asia (AS)	7	17,9	6	85,7	11,11	17,21
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	33,33	17,82
	Europe (EU)	5	29,4	4	80,0	16,67	19,25
	Asia (AS)	7	17,9	6	85,7	22,22	17,21
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	23,81	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	16,67	23,57
	Asia (AS)	4	10,3	4	100,0	25,00	16,67
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	44,44	45,54
	Europe (EU)	4	23,5	2	50,0	16,67	23,57
	Asia (AS)	4	10,3	4	100,0	25,00	16,67
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	16,67	19,25
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	33,33	27,22
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	16,67	19,25
	Europe (EU)	2	11,8	1	50,0	0,00	-
	Asia (AS)	4	10,3	4	100,0	33,33	27,22
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	33,33	0,00
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	33,33	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	22,22	19,25
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	33,33	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	33,33	0,00
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	0,00	-
	Asia (AS)	3	7,7	2	66,7	33,33	0,00
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	33,33	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	42,42	21,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	66,67	27,22
	Asia (AS)	21	53,8	13	61,9	43,59	25,04
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	32,22	23,95
	1	38	100,0	38	100,0	44,74	32,21
	2	10	100,0	10	100,0	43,33	41,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	27	90,0	20,99	24,72
	1	36	94,7	32	88,9	33,33	31,68
	2	6	60,0	6	100,0	27,78	25,09
Cycle 3 Day 1	0	29	96,7	27	93,1	23,46	24,13
	1	34	89,5	32	94,1	29,17	23,57
	2	5	50,0	5	100,0	20,00	18,26
Cycle 4 Day 1	0	29	96,7	28	96,6	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	34,38	27,41
	2	5	50,0	4	80,0	8,33	16,67
Cycle 5 Day 1	0	29	96,7	29	100,0	24,14	21,63
	1	33	86,8	32	97,0	36,46	29,77
	2	3	30,0	3	100,0	11,11	19,25
Cycle 6 Day 1	0	29	96,7	29	100,0	21,84	18,42
	1	31	81,6	28	90,3	26,19	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	11,11	19,25
Cycle 7 Day 1	0	29	96,7	28	96,6	25,00	23,35
	1	28	73,7	26	92,9	33,33	26,67
	2	3	30,0	3	100,0	22,22	38,49
Cycle 8 Day 1	0	28	93,3	26	92,9	26,92	24,98
	1	25	65,8	23	92,0	21,74	19,09
	2	3	30,0	3	100,0	33,33	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	26,92	23,13
	1	23	60,5	23	100,0	27,54	25,92
	2	2	20,0	2	100,0	16,67	23,57
Cycle 10 Day 1	0	26	86,7	26	100,0	26,92	18,90
	1	23	60,5	22	95,7	31,82	16,19
	2	2	20,0	2	100,0	16,67	23,57
Cycle 11 Day 1	0	26	86,7	26	100,0	20,51	19,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	33,33	25,20
	2	2	20,0	2	100,0	16,67	23,57
Cycle 12 Day 1	0	25	83,3	22	88,0	24,24	18,35
	1	22	57,9	21	95,5	22,22	21,94
	2	2	20,0	2	100,0	16,67	23,57
Cycle 13 Day 1	0	25	83,3	24	96,0	23,61	25,02
	1	20	52,6	20	100,0	20,00	19,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	27,78	25,38
	1	19	50,0	19	100,0	24,56	26,86
	2	1	10,0	1	100,0	0,00	-
Cycle 15 Day 1	0	24	80,0	24	100,0	25,00	22,52
	1	19	50,0	19	100,0	24,56	18,73
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	25,00	21,29
	1	18	47,4	18	100,0	29,63	25,28
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	25,40	27,70
	1	17	44,7	17	100,0	29,41	20,01
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	22,22	22,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	20,83	20,64
	2	1	10,0	1	100,0	33,33	-
Cycle 19 Day 1	0	20	66,7	18	90,0	27,78	23,57
	1	15	39,5	13	86,7	25,64	19,97
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	25,49	22,14
	1	15	39,5	14	93,3	16,67	25,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	30,95	24,33
	1	13	34,2	11	84,6	24,24	15,57
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	33,33	28,43
	1	13	34,2	12	92,3	22,22	21,71
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	25,93	32,39
	1	9	23,7	8	88,9	16,67	17,82
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	25,93	22,22
	1	9	23,7	8	88,9	25,00	15,43
	2	1	10,0	1	100,0	33,33	-
Cycle 25 Day 1	0	8	26,7	6	75,0	22,22	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	23,81	16,27
Cycle 26 Day 1	0	8	26,7	6	75,0	27,78	38,97
	1	6	15,8	6	100,0	38,89	32,77
Cycle 27 Day 1	0	6	20,0	3	50,0	22,22	19,25
	1	5	13,2	5	100,0	26,67	27,89
Cycle 28 Day 1	0	5	16,7	4	80,0	16,67	19,25
	1	5	13,2	5	100,0	26,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	33,33	0,00
	1	5	13,2	5	100,0	33,33	0,00
Cycle 30 Day 1	0	3	10,0	1	33,3	33,33	-
	1	4	10,5	4	100,0	25,00	16,67
Cycle 31 Day 1	0	3	10,0	1	33,3	33,33	-
	1	4	10,5	4	100,0	33,33	0,00
Cycle 32 Day 1	0	3	10,0	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	33,33	0,00
Cycle 33 Day 1	0	2	6,7	2	100,0	16,67	23,57
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	40,48	19,30
	1	20	52,6	12	60,0	50,00	30,15
	2	4	40,0	2	50,0	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	45,16	30,49
	1	3	100,0	3	100,0	44,44	50,92
	2 or More	44	100,0	44	100,0	35,61	29,99
Cycle 2 Day 1	None	30	96,8	27	90,0	25,93	26,69
	1	2	66,7	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	29,73	30,21
Cycle 3 Day 1	None	30	96,8	28	93,3	23,81	23,76
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	35	97,2	28,57	23,07
Cycle 4 Day 1	None	30	96,8	29	96,7	22,99	26,88
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	35	79,5	33	94,3	27,27	24,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	26,67	25,37
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	33	75,0	32	97,0	33,33	28,08
Cycle 6 Day 1	None	29	93,5	28	96,6	17,86	21,24
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	32	72,7	30	93,8	28,89	22,71
Cycle 7 Day 1	None	27	87,1	26	96,3	28,21	26,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	31	70,5	29	93,5	29,89	25,73
Cycle 8 Day 1	None	26	83,9	25	96,2	20,00	21,52
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	29,63	23,27
Cycle 9 Day 1	None	25	80,6	25	100,0	24,00	20,46
	1	1	33,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	29,33	27,76
Cycle 10 Day 1	None	25	80,6	24	96,0	26,39	19,61
	1	1	33,3	1	100,0	33,33	-
	2 or More	25	56,8	25	100,0	30,67	16,44
Cycle 11 Day 1	None	25	80,6	25	100,0	25,33	27,69
	1	1	33,3	1	100,0	33,33	-
	2 or More	24	54,5	24	100,0	26,39	16,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	20,83	19,19
	1	1	33,3	1	100,0	33,33	-
	2 or More	23	52,3	20	87,0	25,00	21,29
Cycle 13 Day 1	None	24	77,4	23	95,8	18,84	19,66
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	25,40	25,61
Cycle 14 Day 1	None	23	74,2	23	100,0	20,29	26,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	33,33	-
	2 or More	21	47,7	20	95,2	31,67	25,31
Cycle 15 Day 1	None	23	74,2	23	100,0	18,84	19,66
	1	1	33,3	1	100,0	33,33	-
	2 or More	20	45,5	20	100,0	30,00	21,36
Cycle 16 Day 1	None	20	64,5	19	95,0	22,81	27,34
	1	1	33,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	29,82	18,90
Cycle 17 Day 1	None	19	61,3	19	100,0	21,05	22,80
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	19	100,0	33,33	24,85
Cycle 18 Day 1	None	18	58,1	17	94,4	15,69	23,91
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	17	89,5	29,41	16,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	17,65	20,81
	1	1	33,3	1	100,0	33,33	-
	2 or More	18	40,9	14	77,8	35,71	20,52
Cycle 20 Day 1	None	17	54,8	16	94,1	16,67	21,08
	1	1	33,3	1	100,0	33,33	-
	2 or More	18	40,9	15	83,3	24,44	26,63
Cycle 21 Day 1	None	15	48,4	13	86,7	23,08	16,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	30,77	25,32
Cycle 22 Day 1	None	15	48,4	13	86,7	25,64	19,97
	2 or More	14	31,8	12	85,7	27,78	31,25
Cycle 23 Day 1	None	10	32,3	9	90,0	14,81	17,57
	2 or More	11	25,0	9	81,8	25,93	32,39
Cycle 24 Day 1	None	10	32,3	10	100,0	23,33	16,10
	2 or More	10	22,7	8	80,0	29,17	21,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	25,00	15,43
	2 or More	6	13,6	5	83,3	20,00	18,26
Cycle 26 Day 1	None	8	25,8	8	100,0	25,00	34,50
	2 or More	6	13,6	4	66,7	50,00	33,33
Cycle 27 Day 1	None	7	22,6	6	85,7	27,78	25,09
	2 or More	4	9,1	2	50,0	16,67	23,57
Cycle 28 Day 1	None	7	22,6	7	100,0	23,81	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	19,4	5	83,3	33,33	0,00
	2 or More	3	6,8	2	66,7	33,33	0,00
Cycle 30 Day 1	None	4	12,9	3	75,0	33,33	0,00
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 31 Day 1	None	4	12,9	3	75,0	33,33	0,00
	2 or More	3	6,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	33,33	0,00
	2 or More	2	4,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	3,2	1	100,0	33,33	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	50,00	26,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	66,67	-
	2 or More	24	54,5	15	62,5	42,22	23,46
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	45,16	30,49
	Previously Treated	47	100,0	47	100,0	36,17	30,95
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	25,93	26,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	28,95	30,19
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	23,81	23,76
	Previously Treated	38	80,9	36	94,7	27,78	23,23
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	22,99	26,88
	Previously Treated	37	78,7	35	94,6	26,67	23,98
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	26,67	25,37
	Previously Treated	35	74,5	34	97,1	32,35	27,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	17,86	21,24
	Previously Treated	34	72,3	32	94,1	28,13	22,58
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	28,21	26,15
	Previously Treated	33	70,2	31	93,9	29,03	25,45
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	20,00	21,52
	Previously Treated	30	63,8	27	90,0	29,63	23,27
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	24,00	20,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	29,49	27,21
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	26,39	19,61
	Previously Treated	26	55,3	26	100,0	30,77	16,12
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	25,33	27,69
	Previously Treated	25	53,2	25	100,0	26,67	16,67
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	20,83	19,19
	Previously Treated	24	51,1	21	87,5	25,40	20,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	18,84	19,66
	Previously Treated	22	46,8	22	100,0	24,24	25,58
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	20,29	26,09
	Previously Treated	22	46,8	21	95,5	31,75	24,67
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	18,84	19,66
	Previously Treated	21	44,7	21	100,0	30,16	20,83
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	22,81	27,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	30,00	18,42
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	21,05	22,80
	Previously Treated	20	42,6	20	100,0	31,67	25,31
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	15,69	23,91
	Previously Treated	20	42,6	18	90,0	27,78	17,15
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	17,65	20,81
	Previously Treated	19	40,4	15	78,9	35,56	19,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	16,67	21,08
	Previously Treated	19	40,4	16	84,2	25,00	25,82
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	23,08	16,01
	Previously Treated	14	29,8	13	92,9	30,77	25,32
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	25,64	19,97
	Previously Treated	14	29,8	12	85,7	27,78	31,25
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	14,81	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	25,93	32,39
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	23,33	16,10
	Previously Treated	10	21,3	8	80,0	29,17	21,36
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	25,00	15,43
	Previously Treated	6	12,8	5	83,3	20,00	18,26
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	25,00	34,50
	Previously Treated	6	12,8	4	66,7	50,00	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	27,78	25,09
	Previously Treated	4	8,5	2	50,0	16,67	23,57
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	23,81	25,20
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	33,33	0,00
	Previously Treated	3	6,4	2	66,7	33,33	0,00
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	33,33	0,00
	Previously Treated	3	6,4	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	33,33	0,00
	Previously Treated	2	4,3	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	33,33	-
	Previously Treated	1	2,1	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	50,00	26,59
	Previously Treated	26	55,3	16	61,5	43,75	23,47
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	39,05	27,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	40,31	33,77
Cycle 2 Day 1	Local	32	91,4	30	93,8	26,67	26,84
	Central	40	93,0	35	87,5	28,57	30,40
Cycle 3 Day 1	Local	29	82,9	28	96,6	27,38	22,32
	Central	39	90,7	36	92,3	25,00	24,40
Cycle 4 Day 1	Local	28	80,0	27	96,4	20,99	22,92
	Central	39	90,7	37	94,9	27,93	26,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	28,40	27,27
	Central	38	88,4	37	97,4	30,63	26,50
Cycle 6 Day 1	Local	27	77,1	27	100,0	20,99	22,92
	Central	36	83,7	33	91,7	25,25	22,10
Cycle 7 Day 1	Local	27	77,1	27	100,0	28,40	27,27
	Central	33	76,7	30	90,9	28,89	24,34
Cycle 8 Day 1	Local	26	74,3	26	100,0	21,79	18,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	28,21	26,15
Cycle 9 Day 1	Local	25	71,4	25	100,0	26,67	28,87
	Central	26	60,5	26	100,0	26,92	18,90
Cycle 10 Day 1	Local	25	71,4	24	96,0	29,17	20,41
	Central	26	60,5	26	100,0	28,21	15,47
Cycle 11 Day 1	Local	24	68,6	24	100,0	27,78	23,40
	Central	26	60,5	26	100,0	24,36	22,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	18,18	16,99
	Central	26	60,5	23	88,5	27,54	21,68
Cycle 13 Day 1	Local	22	62,9	22	100,0	18,18	26,68
	Central	24	55,8	23	95,8	24,64	18,03
Cycle 14 Day 1	Local	22	62,9	22	100,0	21,21	24,22
	Central	23	53,5	22	95,7	30,30	27,04
Cycle 15 Day 1	Local	22	62,9	22	100,0	21,21	21,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	27,27	19,62
Cycle 16 Day 1	Local	20	57,1	20	100,0	23,33	19,04
	Central	21	48,8	19	90,5	29,82	26,98
Cycle 17 Day 1	Local	20	57,1	20	100,0	23,33	21,90
	Central	19	44,2	19	100,0	29,82	26,98
Cycle 18 Day 1	Local	20	57,1	19	95,0	21,05	19,91
	Central	18	41,9	16	88,9	22,92	23,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	27,45	24,25
	Central	17	39,5	15	88,2	24,44	19,79
Cycle 20 Day 1	Local	19	54,3	17	89,5	11,76	20,21
	Central	17	39,5	15	88,2	31,11	23,46
Cycle 21 Day 1	Local	14	40,0	12	85,7	16,67	17,41
	Central	15	34,9	14	93,3	35,71	20,52
Cycle 22 Day 1	Local	14	40,0	12	85,7	19,44	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	33,33	30,43
Cycle 23 Day 1	Local	11	31,4	10	90,9	10,00	16,10
	Central	10	23,3	8	80,0	33,33	30,86
Cycle 24 Day 1	Local	11	31,4	10	90,9	30,00	18,92
	Central	9	20,9	8	88,9	20,83	17,25
Cycle 25 Day 1	Local	7	20,0	7	100,0	23,81	16,27
	Central	8	18,6	6	75,0	22,22	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	33,33	36,51
	Central	8	18,6	6	75,0	33,33	36,51
Cycle 27 Day 1	Local	4	11,4	4	100,0	33,33	27,22
	Central	7	16,3	4	57,1	16,67	19,25
Cycle 28 Day 1	Local	4	11,4	4	100,0	33,33	27,22
	Central	6	14,0	5	83,3	13,33	18,26
Cycle 29 Day 1	Local	3	8,6	3	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	33,33	0,00
Cycle 30 Day 1	Local	3	8,6	3	100,0	33,33	0,00
	Central	4	9,3	2	50,0	16,67	23,57
Cycle 31 Day 1	Local	3	8,6	3	100,0	33,33	0,00
	Central	4	9,3	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	8,6	3	100,0	33,33	0,00
	Central	3	7,0	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	33,33	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	42,86	24,21
	Central	21	48,8	14	66,7	50,00	25,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	39,19	30,40
	No	4	100,0	4	100,0	50,00	43,03
Cycle 2 Day 1	Yes	70	94,6	63	90,0	26,46	27,54
	No	2	50,0	2	100,0	66,67	47,14
Cycle 3 Day 1	Yes	66	89,2	62	93,9	25,81	23,70
	No	2	50,0	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	24,19	25,01
	No	2	50,0	2	100,0	50,00	23,57
Cycle 5 Day 1	Yes	63	85,1	62	98,4	29,03	26,64
	No	2	50,0	2	100,0	50,00	23,57
Cycle 6 Day 1	Yes	61	82,4	58	95,1	22,99	22,69
	No	2	50,0	2	100,0	33,33	0,00
Cycle 7 Day 1	Yes	58	78,4	55	94,8	28,48	25,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	0,00
Cycle 8 Day 1	Yes	54	73,0	50	92,6	24,00	22,38
	No	2	50,0	2	100,0	50,00	23,57
Cycle 9 Day 1	Yes	49	66,2	49	100,0	25,85	23,83
	No	2	50,0	2	100,0	50,00	23,57
Cycle 10 Day 1	Yes	49	66,2	48	98,0	28,47	18,18
	No	2	50,0	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	25,00	22,28
	No	2	50,0	2	100,0	50,00	23,57
Cycle 12 Day 1	Yes	47	63,5	43	91,5	21,71	19,08
	No	2	50,0	2	100,0	50,00	23,57
Cycle 13 Day 1	Yes	44	59,5	43	97,7	20,93	23,03
	No	2	50,0	2	100,0	33,33	0,00
Cycle 14 Day 1	Yes	43	58,1	42	97,7	25,40	25,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	47,14
Cycle 15 Day 1	Yes	42	56,8	42	100,0	23,81	19,87
	No	2	50,0	2	100,0	33,33	47,14
Cycle 16 Day 1	Yes	39	52,7	37	94,9	24,32	21,73
	No	2	50,0	2	100,0	66,67	0,00
Cycle 17 Day 1	Yes	37	50,0	37	100,0	23,42	20,59
	No	2	50,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	21,21	20,10
	No	2	50,0	2	100,0	33,33	47,14
Cycle 19 Day 1	Yes	34	45,9	31	91,2	25,81	22,29
	No	2	50,0	1	50,0	33,33	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	20,00	22,49
	No	2	50,0	2	100,0	33,33	47,14
Cycle 21 Day 1	Yes	27	36,5	24	88,9	26,39	19,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	47,14
Cycle 22 Day 1	Yes	27	36,5	23	85,2	24,64	25,06
	No	2	50,0	2	100,0	50,00	23,57
Cycle 23 Day 1	Yes	20	27,0	17	85,0	21,57	26,20
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	27,45	17,62
	No	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	22,22	16,41
	No	1	25,0	1	100,0	33,33	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	33,33	36,51
	No	1	25,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	19,05	17,82
	No	1	25,0	1	100,0	66,67	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	16,67	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	66,67	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	33,33	0,00
	No	1	25,0	1	100,0	33,33	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	25,00	16,67
	No	1	25,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	33,33	0,00
	No	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	25,00	16,67
	No	1	25,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	16,67	23,57
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	46,43	24,58
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	50,00	35,63
	No	70	100,0	70	100,0	38,57	30,37
Cycle 2 Day 1	Yes	5	62,5	5	100,0	33,33	40,82
	No	67	95,7	60	89,6	27,22	27,78
Cycle 3 Day 1	Yes	5	62,5	5	100,0	26,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	25,99	24,03
Cycle 4 Day 1	Yes	5	62,5	5	100,0	13,33	18,26
	No	62	88,6	59	95,2	25,99	25,57
Cycle 5 Day 1	Yes	5	62,5	5	100,0	40,00	36,51
	No	60	85,7	59	98,3	28,81	25,86
Cycle 6 Day 1	Yes	5	62,5	5	100,0	20,00	29,81
	No	58	82,9	55	94,8	23,64	21,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	40,00	27,89
	No	55	78,6	52	94,5	27,56	25,33
Cycle 8 Day 1	Yes	5	62,5	5	100,0	26,67	27,89
	No	51	72,9	47	92,2	24,82	22,49
Cycle 9 Day 1	Yes	4	50,0	4	100,0	33,33	27,22
	No	47	67,1	47	100,0	26,24	24,01
Cycle 10 Day 1	Yes	4	50,0	4	100,0	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	28,26	17,17
Cycle 11 Day 1	Yes	4	50,0	4	100,0	50,00	43,03
	No	46	65,7	46	100,0	23,91	19,45
Cycle 12 Day 1	Yes	4	50,0	4	100,0	25,00	16,67
	No	45	64,3	41	91,1	22,76	20,33
Cycle 13 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	42	60,0	41	97,6	21,95	23,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	41	58,6	40	97,6	26,67	26,37
Cycle 15 Day 1	Yes	4	50,0	4	100,0	25,00	31,91
	No	40	57,1	40	100,0	24,17	19,95
Cycle 16 Day 1	Yes	3	37,5	3	100,0	33,33	33,33
	No	38	54,3	36	94,7	25,93	22,69
Cycle 17 Day 1	Yes	3	37,5	3	100,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	26,85	24,97
Cycle 18 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	35	50,0	32	91,4	22,92	21,48
Cycle 19 Day 1	Yes	3	37,5	3	100,0	22,22	19,25
	No	33	47,1	29	87,9	26,44	22,50
Cycle 20 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	33	47,1	29	87,9	21,84	24,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	33,33	0,00
	No	27	38,6	24	88,9	26,39	21,93
Cycle 22 Day 1	Yes	2	25,0	2	100,0	33,33	0,00
	No	27	38,6	23	85,2	26,09	26,51
Cycle 23 Day 1	Yes	2	25,0	2	100,0	33,33	0,00
	No	19	27,1	16	84,2	18,75	27,13
Cycle 24 Day 1	Yes	2	25,0	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	25,00	19,25
Cycle 25 Day 1	Yes	2	25,0	2	100,0	33,33	0,00
	No	13	18,6	11	84,6	21,21	16,82
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	36,36	34,82
Cycle 27 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	10	14,3	7	70,0	23,81	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	9	12,9	8	88,9	20,83	24,80
Cycle 29 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	8	11,4	6	75,0	33,33	0,00
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	26,67	14,91
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	33,33	0,00
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	26,67	14,91
Cycle 33 Day 1	No	2	2,9	2	100,0	16,67	23,57
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	43,59	22,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30DY_SG.xls
28NOV2019 10:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	75,21	17,71
Cycle 2 Day 1	All	72	92,3	64	88,9	79,95	20,23
Cycle 3 Day 1	All	68	87,2	64	94,1	82,29	16,83
Cycle 4 Day 1	All	67	85,9	64	95,5	83,59	14,92
Cycle 5 Day 1	All	65	83,3	64	98,5	83,20	17,79
Cycle 6 Day 1	All	63	80,8	60	95,2	81,67	16,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	81,29	15,37
Cycle 8 Day 1	All	56	71,8	52	92,9	82,69	18,88
Cycle 9 Day 1	All	51	65,4	51	100,0	82,19	17,16
Cycle 10 Day 1	All	51	65,4	50	98,0	81,83	18,57
Cycle 11 Day 1	All	50	64,1	50	100,0	83,00	15,79
Cycle 12 Day 1	All	49	62,8	45	91,8	83,70	15,28
Cycle 13 Day 1	All	46	59,0	45	97,8	83,70	17,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	80,30	20,18
Cycle 15 Day 1	All	44	56,4	44	100,0	83,33	15,67
Cycle 16 Day 1	All	41	52,6	39	95,1	80,98	16,77
Cycle 17 Day 1	All	39	50,0	39	100,0	81,84	18,62
Cycle 18 Day 1	All	38	48,7	35	92,1	83,10	16,97
Cycle 19 Day 1	All	36	46,2	33	91,7	85,10	14,55
Cycle 20 Day 1	All	36	46,2	32	88,9	83,33	16,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	81,41	16,38
Cycle 22 Day 1	All	29	37,2	25	86,2	82,00	17,63
Cycle 23 Day 1	All	21	26,9	18	85,7	79,63	24,12
Cycle 24 Day 1	All	20	25,6	18	90,0	80,56	18,08
Cycle 25 Day 1	All	15	19,2	13	86,7	78,21	14,65
Cycle 26 Day 1	All	14	17,9	12	85,7	81,94	18,06
Cycle 27 Day 1	All	11	14,1	8	72,7	77,08	13,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	69,44	23,20
Cycle 29 Day 1	All	9	11,5	7	77,8	70,24	19,75
Cycle 30 Day 1	All	7	9,0	5	71,4	65,00	9,13
Cycle 31 Day 1	All	7	9,0	5	71,4	71,67	7,45
Cycle 32 Day 1	All	6	7,7	5	83,3	73,33	27,26
Cycle 33 Day 1	All	2	2,6	2	100,0	75,00	35,36
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	72,92	18,79
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	72,41	17,83
	Female	49	100,0	49	100,0	76,87	17,62
Cycle 2 Day 1	Male	27	93,1	24	88,9	73,26	23,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	83,96	17,34
Cycle 3 Day 1	Male	25	86,2	23	92,0	81,16	16,33
	Female	43	87,8	41	95,3	82,93	17,28
Cycle 4 Day 1	Male	25	86,2	25	100,0	81,67	14,43
	Female	42	85,7	39	92,9	84,83	15,28
Cycle 5 Day 1	Male	25	86,2	25	100,0	80,33	17,66
	Female	40	81,6	39	97,5	85,04	17,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	79,71	16,82
	Female	38	77,6	37	97,4	82,88	16,66
Cycle 7 Day 1	Male	23	79,3	23	100,0	80,07	15,64
	Female	37	75,5	34	91,9	82,11	15,37
Cycle 8 Day 1	Male	21	72,4	19	90,5	77,63	24,85
	Female	35	71,4	33	94,3	85,61	14,02
Cycle 9 Day 1	Male	18	62,1	18	100,0	80,09	18,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	83,33	16,54
Cycle 10 Day 1	Male	18	62,1	18	100,0	82,87	18,85
	Female	33	67,3	32	97,0	81,25	18,69
Cycle 11 Day 1	Male	18	62,1	18	100,0	83,33	16,42
	Female	32	65,3	32	100,0	82,81	15,69
Cycle 12 Day 1	Male	17	58,6	17	100,0	82,35	16,89
	Female	32	65,3	28	87,5	84,52	14,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	85,78	14,36
	Female	29	59,2	28	96,6	82,44	18,89
Cycle 14 Day 1	Male	17	58,6	16	94,1	78,65	17,47
	Female	28	57,1	28	100,0	81,25	21,83
Cycle 15 Day 1	Male	16	55,2	16	100,0	81,77	14,66
	Female	28	57,1	28	100,0	84,23	16,41
Cycle 16 Day 1	Male	14	48,3	14	100,0	79,17	14,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	82,00	17,95
Cycle 17 Day 1	Male	12	41,4	12	100,0	81,25	21,36
	Female	27	55,1	27	100,0	82,10	17,71
Cycle 18 Day 1	Male	11	37,9	10	90,9	84,17	15,93
	Female	27	55,1	25	92,6	82,67	17,66
Cycle 19 Day 1	Male	10	34,5	10	100,0	80,83	16,69
	Female	26	53,1	23	88,5	86,96	13,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	81,48	18,99
	Female	26	53,1	23	88,5	84,06	15,87
Cycle 21 Day 1	Male	8	27,6	8	100,0	77,08	20,77
	Female	21	42,9	18	85,7	83,33	14,29
Cycle 22 Day 1	Male	8	27,6	6	75,0	86,11	15,52
	Female	21	42,9	19	90,5	80,70	18,44
Cycle 23 Day 1	Male	5	17,2	4	80,0	87,50	14,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	77,38	26,24
Cycle 24 Day 1	Male	5	17,2	4	80,0	66,67	24,53
	Female	15	30,6	14	93,3	84,52	14,57
Cycle 25 Day 1	Male	3	10,3	2	66,7	79,17	17,68
	Female	12	24,5	11	91,7	78,03	15,03
Cycle 26 Day 1	Male	3	10,3	2	66,7	75,00	23,57
	Female	11	22,4	10	90,9	83,33	18,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	75,00	23,57
	Female	8	16,3	6	75,0	77,78	11,39
Cycle 28 Day 1	Male	2	6,9	2	100,0	70,83	29,46
	Female	8	16,3	7	87,5	69,05	23,92
Cycle 29 Day 1	Male	1	3,4	1	100,0	41,67	-
	Female	8	16,3	6	75,0	75,00	16,67
Cycle 30 Day 1	Male	1	3,4	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	68,75	4,17
Cycle 31 Day 1	Male	1	3,4	1	100,0	66,67	-
	Female	6	12,2	4	66,7	72,92	7,98
Cycle 32 Day 1	Male	1	3,4	1	100,0	33,33	-
	Female	5	10,2	4	80,0	83,33	18,00
Cycle 33 Day 1	Male	1	3,4	1	100,0	50,00	-
	Female	1	2,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	72,22	21,75
	Female	21	42,9	13	61,9	73,72	15,53
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	75,81	18,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	73,81	17,25
	>=75	2	100,0	2	100,0	66,67	11,79
Cycle 2 Day 1	18-64	59	95,2	52	88,1	80,77	20,11
	65-74	11	78,6	10	90,9	75,83	21,32
	>=75	2	100,0	2	100,0	79,17	29,46
Cycle 3 Day 1	18-64	56	90,3	52	92,9	82,05	15,34
	65-74	10	71,4	10	100,0	83,33	24,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 4 Day 1	18-64	55	88,7	53	96,4	84,43	13,58
	65-74	10	71,4	9	90,0	78,70	21,29
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 5 Day 1	18-64	53	85,5	52	98,1	85,26	15,36
	65-74	10	71,4	10	100,0	74,17	24,67
	>=75	2	100,0	2	100,0	75,00	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	83,16	15,07
	65-74	10	71,4	9	90,0	75,00	21,25
	>=75	2	100,0	2	100,0	75,00	35,36
Cycle 7 Day 1	18-64	49	79,0	47	95,9	81,38	13,82
	65-74	9	64,3	8	88,9	80,21	23,54
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 8 Day 1	18-64	45	72,6	41	91,1	82,93	19,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	81,48	17,57
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 9 Day 1	18-64	40	64,5	40	100,0	83,96	14,66
	65-74	9	64,3	9	100,0	76,85	22,35
	>=75	2	100,0	2	100,0	70,83	41,25
Cycle 10 Day 1	18-64	40	64,5	39	97,5	82,91	16,77
	65-74	9	64,3	9	100,0	76,85	25,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 11 Day 1	18-64	39	62,9	39	100,0	83,33	15,77
	65-74	9	64,3	9	100,0	81,48	16,55
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 12 Day 1	18-64	38	61,3	35	92,1	85,24	14,02
	65-74	9	64,3	8	88,9	77,08	19,29
	>=75	2	100,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	86,03	14,02
	65-74	9	64,3	9	100,0	75,00	25,34
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 14 Day 1	18-64	35	56,5	35	100,0	82,62	16,09
	65-74	9	64,3	8	88,9	70,83	33,33
	>=75	1	50,0	1	100,0	75,00	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	85,00	13,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	77,08	23,46
	>=75	1	50,0	1	100,0	75,00	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	81,77	17,25
	65-74	7	50,0	6	85,7	79,17	15,59
	>=75	1	50,0	1	100,0	66,67	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	82,03	18,34
	65-74	6	42,9	6	100,0	83,33	22,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	66,67	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	84,48	15,22
	65-74	6	42,9	5	83,3	76,67	27,26
	>=75	1	50,0	1	100,0	75,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	86,90	14,24
	65-74	5	35,7	4	80,0	75,00	15,21
	>=75	1	50,0	1	100,0	75,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	85,26	16,38
	65-74	5	35,7	5	100,0	75,00	17,68
	>=75	1	50,0	1	100,0	75,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	82,54	16,44
	65-74	4	28,6	4	100,0	81,25	15,77
	>=75	1	50,0	1	100,0	58,33	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	83,75	17,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	77,08	18,48
	>=75	1	50,0	1	100,0	66,67	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	77,08	24,44
	65-74	2	14,3	2	100,0	100,00	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	81,25	19,12
	65-74	2	14,3	2	100,0	75,00	0,00
Cycle 25 Day 1	18-64	14	22,6	12	85,7	77,08	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	91,67	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	81,94	18,06
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	77,08	13,18
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	69,44	23,20
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	70,24	19,75
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	65,00	9,13
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	71,67	7,45
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	68,75	29,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	91,67	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	50,00	-
	65-74	1	7,1	1	100,0	100,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	68,33	18,06
	65-74	10	71,4	7	70,0	82,14	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	100,00	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	76,67	15,10
	Other	43	100,0	43	100,0	74,03	19,69
Cycle 2 Day 1	White	33	94,3	28	84,8	80,36	24,13
	Other	39	90,7	36	92,3	79,63	16,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	83,64	19,95
	Other	37	86,0	37	100,0	81,31	14,35
Cycle 4 Day 1	White	31	88,6	28	90,3	86,31	13,84
	Other	36	83,7	36	100,0	81,48	15,57
Cycle 5 Day 1	White	31	88,6	30	96,8	83,33	20,29
	Other	34	79,1	34	100,0	83,09	15,55
Cycle 6 Day 1	White	30	85,7	28	93,3	82,74	17,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	80,73	16,04
Cycle 7 Day 1	White	29	82,9	27	93,1	80,56	16,98
	Other	31	72,1	30	96,8	81,94	14,03
Cycle 8 Day 1	White	28	80,0	24	85,7	82,64	17,01
	Other	28	65,1	28	100,0	82,74	20,65
Cycle 9 Day 1	White	26	74,3	26	100,0	82,69	19,71
	Other	25	58,1	25	100,0	81,67	14,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	81,00	21,98
	Other	25	58,1	25	100,0	82,67	14,81
Cycle 11 Day 1	White	26	74,3	26	100,0	84,62	16,95
	Other	24	55,8	24	100,0	81,25	14,59
Cycle 12 Day 1	White	26	74,3	22	84,6	81,82	17,18
	Other	23	53,5	23	100,0	85,51	13,35
Cycle 13 Day 1	White	24	68,6	23	95,8	81,88	20,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	85,61	13,16
Cycle 14 Day 1	White	24	68,6	24	100,0	80,56	23,40
	Other	21	48,8	20	95,2	80,00	16,09
Cycle 15 Day 1	White	24	68,6	24	100,0	81,94	16,79
	Other	20	46,5	20	100,0	85,00	14,46
Cycle 16 Day 1	White	22	62,9	20	90,9	80,00	18,02
	Other	19	44,2	19	100,0	82,02	15,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	80,68	19,82
	Other	17	39,5	17	100,0	83,33	17,43
Cycle 18 Day 1	White	21	60,0	18	85,7	87,04	13,47
	Other	17	39,5	17	100,0	78,92	19,57
Cycle 19 Day 1	White	20	57,1	20	100,0	83,33	15,29
	Other	16	37,2	13	81,3	87,82	13,44
Cycle 20 Day 1	White	20	57,1	17	85,0	82,35	17,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	84,44	15,39
Cycle 21 Day 1	White	16	45,7	14	87,5	80,95	18,03
	Other	13	30,2	12	92,3	81,94	15,01
Cycle 22 Day 1	White	16	45,7	13	81,3	83,33	18,94
	Other	13	30,2	12	92,3	80,56	16,79
Cycle 23 Day 1	White	12	34,3	10	83,3	76,67	28,81
	Other	9	20,9	8	88,9	83,33	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	80,83	20,05
	Other	9	20,9	8	88,9	80,21	16,63
Cycle 25 Day 1	White	10	28,6	8	80,0	80,21	15,39
	Other	5	11,6	5	100,0	75,00	14,43
Cycle 26 Day 1	White	10	28,6	8	80,0	81,25	18,77
	Other	4	9,3	4	100,0	83,33	19,25
Cycle 27 Day 1	White	8	22,9	5	62,5	75,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	80,56	17,35
Cycle 28 Day 1	White	7	20,0	6	85,7	75,00	19,72
	Other	3	7,0	3	100,0	58,33	30,05
Cycle 29 Day 1	White	6	17,1	4	66,7	60,42	17,18
	Other	3	7,0	3	100,0	83,33	16,67
Cycle 30 Day 1	White	4	11,4	2	50,0	62,50	17,68
	Other	3	7,0	3	100,0	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	75,00	11,79
	Other	3	7,0	3	100,0	69,44	4,81
Cycle 32 Day 1	White	4	11,4	3	75,0	69,44	31,55
	Other	2	4,7	2	100,0	79,17	29,46
Cycle 33 Day 1	White	2	5,7	2	100,0	75,00	35,36
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	71,53	20,24
	Other	24	55,8	16	66,7	73,96	18,23
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	81,82	14,46
	Europe (EU)	17	100,0	17	100,0	70,59	14,47
	Asia (AS)	39	100,0	39	100,0	73,50	19,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	16	80,0	85,94	20,12
	Europe (EU)	16	94,1	13	81,3	74,36	27,31
	Asia (AS)	36	92,3	35	97,2	79,29	16,95
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	86,40	16,72
	Europe (EU)	15	88,2	12	80,0	77,08	21,06
	Asia (AS)	33	84,6	33	100,0	81,82	15,09
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	85,42	15,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	81,25	10,13
	Asia (AS)	32	82,1	32	100,0	83,33	16,26
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	85,42	17,29
	Europe (EU)	15	88,2	14	93,3	80,95	22,03
	Asia (AS)	30	76,9	30	100,0	82,78	16,37
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	87,92	12,82
	Europe (EU)	14	82,4	13	92,9	73,72	20,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	80,86	15,98
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	86,11	12,78
	Europe (EU)	14	82,4	13	92,9	72,44	18,75
	Asia (AS)	27	69,2	26	96,3	82,37	13,81
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	84,31	16,11
	Europe (EU)	14	82,4	11	78,6	79,55	18,01
	Asia (AS)	24	61,5	24	100,0	82,99	21,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	83,33	17,15
	Europe (EU)	12	70,6	12	100,0	77,78	21,71
	Asia (AS)	21	53,8	21	100,0	83,73	14,55
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	85,29	17,81
	Europe (EU)	12	70,6	12	100,0	72,22	23,39
	Asia (AS)	21	53,8	21	100,0	84,52	14,74
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	86,11	16,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	79,86	17,57
	Asia (AS)	20	51,3	20	100,0	82,08	14,63
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	82,84	16,79
	Europe (EU)	12	70,6	9	75,0	75,93	16,37
	Asia (AS)	19	48,7	19	100,0	88,16	12,21
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	83,82	15,72
	Europe (EU)	11	64,7	10	90,9	75,83	24,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	87,96	12,53
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	84,31	17,65
	Europe (EU)	11	64,7	11	100,0	73,48	27,34
	Asia (AS)	17	43,6	16	94,1	80,73	16,87
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	85,29	14,29
	Europe (EU)	11	64,7	11	100,0	77,27	19,40
	Asia (AS)	16	41,0	16	100,0	85,42	14,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	82,74	15,83
	Europe (EU)	11	64,7	9	81,8	77,78	16,14
	Asia (AS)	16	41,0	16	100,0	81,25	18,63
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	84,52	20,37
	Europe (EU)	10	58,8	10	100,0	77,50	19,66
	Asia (AS)	15	38,5	15	100,0	82,22	16,92
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	86,31	15,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	87,50	13,69
	Asia (AS)	15	38,5	15	100,0	78,33	19,11
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	83,33	16,32
	Europe (EU)	9	52,9	9	100,0	82,41	14,70
	Asia (AS)	14	35,9	11	78,6	89,39	12,41
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	80,13	18,49
	Europe (EU)	9	52,9	6	66,7	86,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	85,26	14,89
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	80,83	18,86
	Europe (EU)	7	41,2	6	85,7	84,72	16,17
	Asia (AS)	11	28,2	10	90,9	80,00	15,32
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	81,67	21,44
	Europe (EU)	7	41,2	5	71,4	88,33	13,94
	Asia (AS)	11	28,2	10	90,9	79,17	15,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	72,22	29,46
	Europe (EU)	5	29,4	3	60,0	97,22	4,81
	Asia (AS)	7	17,9	6	85,7	81,94	17,01
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	75,00	20,89
	Europe (EU)	5	29,4	4	80,0	87,50	10,76
	Asia (AS)	7	17,9	6	85,7	83,33	18,26
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	75,00	15,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	95,83	5,89
	Asia (AS)	4	10,3	4	100,0	75,00	11,79
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	70,83	15,59
	Europe (EU)	4	23,5	2	50,0	100,00	0,00
	Asia (AS)	4	10,3	4	100,0	89,58	15,77
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	75,00	13,61
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	79,17	14,43
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	70,83	19,84
	Europe (EU)	2	11,8	1	50,0	100,00	-
	Asia (AS)	4	10,3	4	100,0	60,42	24,88
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	61,11	20,97
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	77,08	18,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	62,50	17,68
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	66,67	0,00
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	75,00	11,79
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	69,44	4,81
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	58,33	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	91,67	-
	Asia (AS)	3	7,7	2	66,7	79,17	29,46
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	50,00	-
	Europe (EU)	1	5,9	1	100,0	100,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	74,24	14,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	54,17	14,43
	Asia (AS)	21	53,8	13	61,9	77,56	20,52
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	77,78	12,63
	1	38	100,0	38	100,0	72,59	20,31
	2	10	100,0	10	100,0	77,50	20,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	26	86,7	80,13	19,45
	1	36	94,7	32	88,9	78,91	22,00
	2	6	60,0	6	100,0	84,72	15,29
Cycle 3 Day 1	0	29	96,7	27	93,1	82,10	19,43
	1	34	89,5	32	94,1	83,59	14,59
	2	5	50,0	5	100,0	75,00	16,67
Cycle 4 Day 1	0	29	96,7	28	96,6	84,52	15,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	83,07	14,74
	2	5	50,0	4	80,0	81,25	12,50
Cycle 5 Day 1	0	29	96,7	29	100,0	83,05	19,98
	1	33	86,8	32	97,0	82,55	16,17
	2	3	30,0	3	100,0	91,67	14,43
Cycle 6 Day 1	0	29	96,7	29	100,0	82,47	16,11
	1	31	81,6	28	90,3	79,76	17,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	91,67	8,33
Cycle 7 Day 1	0	29	96,7	28	96,6	83,33	16,97
	1	28	73,7	26	92,9	79,49	14,38
	2	3	30,0	3	100,0	77,78	4,81
Cycle 8 Day 1	0	28	93,3	26	92,9	82,05	19,10
	1	25	65,8	23	92,0	82,25	19,51
	2	3	30,0	3	100,0	91,67	14,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	82,37	17,37
	1	23	60,5	23	100,0	81,16	17,63
	2	2	20,0	2	100,0	91,67	11,79
Cycle 10 Day 1	0	26	86,7	26	100,0	81,73	22,24
	1	23	60,5	22	95,7	80,68	13,94
	2	2	20,0	2	100,0	95,83	5,89
Cycle 11 Day 1	0	26	86,7	26	100,0	82,37	16,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	82,58	15,62
	2	2	20,0	2	100,0	95,83	5,89
Cycle 12 Day 1	0	25	83,3	22	88,0	78,79	17,39
	1	22	57,9	21	95,5	87,70	11,67
	2	2	20,0	2	100,0	95,83	5,89
Cycle 13 Day 1	0	25	83,3	24	96,0	80,56	19,91
	1	20	52,6	20	100,0	86,67	13,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	100,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	78,47	23,81
	1	19	50,0	19	100,0	81,58	14,85
	2	1	10,0	1	100,0	100,00	-
Cycle 15 Day 1	0	24	80,0	24	100,0	81,60	17,72
	1	19	50,0	19	100,0	84,65	12,81
	2	1	10,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	80,42	16,51
	1	18	47,4	18	100,0	80,56	17,39
	2	1	10,0	1	100,0	100,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	80,95	19,03
	1	17	44,7	17	100,0	81,86	18,69
	2	1	10,0	1	100,0	100,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	81,48	18,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	83,85	15,36
	2	1	10,0	1	100,0	100,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	83,77	15,58
	1	15	39,5	13	86,7	85,90	13,34
	2	1	10,0	1	100,0	100,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	79,41	17,46
	1	15	39,5	14	93,3	86,90	14,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	100,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	81,55	17,04
	1	13	34,2	11	84,6	79,55	15,97
	2	1	10,0	1	100,0	100,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	83,33	21,32
	1	13	34,2	12	92,3	79,17	13,53
	2	1	10,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	77,78	31,18
	1	9	23,7	8	88,9	79,17	15,43
	2	1	10,0	1	100,0	100,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	77,78	21,25
	1	9	23,7	8	88,9	81,25	14,60
	2	1	10,0	1	100,0	100,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	77,78	15,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	78,57	15,11
Cycle 26 Day 1	0	8	26,7	6	75,0	76,39	20,69
	1	6	15,8	6	100,0	87,50	14,67
Cycle 27 Day 1	0	6	20,0	3	50,0	75,00	16,67
	1	5	13,2	5	100,0	78,33	12,64
Cycle 28 Day 1	0	5	16,7	4	80,0	77,08	22,95
	1	5	13,2	5	100,0	63,33	24,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	50,00	11,79
	1	5	13,2	5	100,0	78,33	16,24
Cycle 30 Day 1	0	3	10,0	1	33,3	50,00	-
	1	4	10,5	4	100,0	68,75	4,17
Cycle 31 Day 1	0	3	10,0	1	33,3	66,67	-
	1	4	10,5	4	100,0	72,92	7,98
Cycle 32 Day 1	0	3	10,0	2	66,7	62,50	41,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	80,56	20,97
Cycle 33 Day 1	0	2	6,7	2	100,0	75,00	35,36
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	76,19	16,30
	1	20	52,6	12	60,0	68,75	21,65
	2	4	40,0	2	50,0	75,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	75,81	16,99
	1	3	100,0	3	100,0	86,11	17,35
	2 or More	44	100,0	44	100,0	74,05	18,35
Cycle 2 Day 1	None	30	96,8	26	86,7	86,22	17,63
	1	2	66,7	1	50,0	91,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	75,23	21,11
Cycle 3 Day 1	None	30	96,8	28	93,3	86,61	14,58
	1	2	66,7	1	50,0	91,67	-
	2 or More	36	81,8	35	97,2	78,57	18,00
Cycle 4 Day 1	None	30	96,8	29	96,7	83,91	13,90
	1	2	66,7	2	100,0	87,50	5,89
	2 or More	35	79,5	33	94,3	83,08	16,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	86,11	15,37
	1	2	66,7	2	100,0	95,83	5,89
	2 or More	33	75,0	32	97,0	79,69	19,74
Cycle 6 Day 1	None	29	93,5	28	96,6	86,61	14,41
	1	2	66,7	2	100,0	83,33	11,79
	2 or More	32	72,7	30	93,8	76,94	17,87
Cycle 7 Day 1	None	27	87,1	26	96,3	85,58	11,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	70,83	29,46
	2 or More	31	70,5	29	93,5	78,16	16,88
Cycle 8 Day 1	None	26	83,9	25	96,2	82,67	20,12
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	82,72	18,04
Cycle 9 Day 1	None	25	80,6	25	100,0	83,67	15,86
	1	1	33,3	1	100,0	91,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	80,33	18,77
Cycle 10 Day 1	None	25	80,6	24	96,0	84,72	15,67
	1	1	33,3	1	100,0	100,00	-
	2 or More	25	56,8	25	100,0	78,33	20,83
Cycle 11 Day 1	None	25	80,6	25	100,0	84,33	14,50
	1	1	33,3	1	100,0	91,67	-
	2 or More	24	54,5	24	100,0	81,25	17,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	85,76	15,04
	1	1	33,3	1	100,0	91,67	-
	2 or More	23	52,3	20	87,0	80,83	15,79
Cycle 13 Day 1	None	24	77,4	23	95,8	85,51	13,58
	1	1	33,3	1	100,0	100,00	-
	2 or More	21	47,7	21	100,0	80,95	20,61
Cycle 14 Day 1	None	23	74,2	23	100,0	82,61	15,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	91,67	-
	2 or More	21	47,7	20	95,2	77,08	24,76
Cycle 15 Day 1	None	23	74,2	23	100,0	85,14	13,75
	1	1	33,3	1	100,0	91,67	-
	2 or More	20	45,5	20	100,0	80,83	17,95
Cycle 16 Day 1	None	20	64,5	19	95,0	85,53	14,39
	1	1	33,3	1	100,0	91,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	75,88	18,19
Cycle 17 Day 1	None	19	61,3	19	100,0	85,53	18,39
	1	1	33,3	1	100,0	91,67	-
	2 or More	19	43,2	19	100,0	77,63	18,85
Cycle 18 Day 1	None	18	58,1	17	94,4	88,73	14,11
	1	1	33,3	1	100,0	91,67	-
	2 or More	19	43,2	17	89,5	76,96	18,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	86,76	14,15
	1	1	33,3	1	100,0	91,67	-
	2 or More	18	40,9	15	83,3	82,78	15,58
Cycle 20 Day 1	None	17	54,8	16	94,1	84,90	16,73
	1	1	33,3	1	100,0	91,67	-
	2 or More	18	40,9	15	83,3	81,11	17,10
Cycle 21 Day 1	None	15	48,4	13	86,7	85,26	17,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	77,56	14,59
Cycle 22 Day 1	None	15	48,4	13	86,7	89,10	13,34
	2 or More	14	31,8	12	85,7	74,31	18,96
Cycle 23 Day 1	None	10	32,3	9	90,0	87,04	13,89
	2 or More	11	25,0	9	81,8	72,22	30,33
Cycle 24 Day 1	None	10	32,3	10	100,0	82,50	20,95
	2 or More	10	22,7	8	80,0	78,13	14,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	78,13	14,04
	2 or More	6	13,6	5	83,3	78,33	17,28
Cycle 26 Day 1	None	8	25,8	8	100,0	83,33	15,43
	2 or More	6	13,6	4	66,7	79,17	25,00
Cycle 27 Day 1	None	7	22,6	6	85,7	79,17	14,67
	2 or More	4	9,1	2	50,0	70,83	5,89
Cycle 28 Day 1	None	7	22,6	7	100,0	76,19	18,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	45,83	29,46
Cycle 29 Day 1	None	6	19,4	5	83,3	65,00	18,07
	2 or More	3	6,8	2	66,7	83,33	23,57
Cycle 30 Day 1	None	4	12,9	3	75,0	63,89	12,73
	2 or More	3	6,8	2	66,7	66,67	0,00
Cycle 31 Day 1	None	4	12,9	3	75,0	72,22	9,62
	2 or More	3	6,8	2	66,7	70,83	5,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	72,22	34,69
	2 or More	2	4,5	2	100,0	75,00	23,57
Cycle 33 Day 1	None	1	3,2	1	100,0	50,00	-
	2 or More	1	2,3	1	100,0	100,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	69,44	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	83,33	-
	2 or More	24	54,5	15	62,5	75,00	19,16
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	75,81	16,99
	Previously Treated	47	100,0	47	100,0	74,82	18,35
Cycle 2 Day 1	Naïve	30	96,8	26	86,7	86,22	17,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	75,66	20,99
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	86,61	14,58
	Previously Treated	38	80,9	36	94,7	78,94	17,87
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	83,91	13,90
	Previously Treated	37	78,7	35	94,6	83,33	15,91
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	86,11	15,37
	Previously Treated	35	74,5	34	97,1	80,64	19,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	86,61	14,41
	Previously Treated	34	72,3	32	94,1	77,34	17,48
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	85,58	11,68
	Previously Treated	33	70,2	31	93,9	77,69	17,27
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	82,67	20,12
	Previously Treated	30	63,8	27	90,0	82,72	18,04
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	83,67	15,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	80,77	18,52
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	84,72	15,67
	Previously Treated	26	55,3	26	100,0	79,17	20,85
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	84,33	14,50
	Previously Treated	25	53,2	25	100,0	81,67	17,18
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	85,76	15,04
	Previously Treated	24	51,1	21	87,5	81,35	15,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	85,51	13,58
	Previously Treated	22	46,8	22	100,0	81,82	20,52
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	82,61	15,67
	Previously Treated	22	46,8	21	95,5	77,78	24,34
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	85,14	13,75
	Previously Treated	21	44,7	21	100,0	81,35	17,66
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	85,53	14,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	76,67	18,06
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	85,53	18,39
	Previously Treated	20	42,6	20	100,0	78,33	18,61
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	88,73	14,11
	Previously Treated	20	42,6	18	90,0	77,78	18,08
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	86,76	14,15
	Previously Treated	19	40,4	16	84,2	83,33	15,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	84,90	16,73
	Previously Treated	19	40,4	16	84,2	81,77	16,73
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	85,26	17,73
	Previously Treated	14	29,8	13	92,9	77,56	14,59
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	89,10	13,34
	Previously Treated	14	29,8	12	85,7	74,31	18,96
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	87,04	13,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	72,22	30,33
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	82,50	20,95
	Previously Treated	10	21,3	8	80,0	78,13	14,73
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	78,13	14,04
	Previously Treated	6	12,8	5	83,3	78,33	17,28
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	83,33	15,43
	Previously Treated	6	12,8	4	66,7	79,17	25,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	79,17	14,67
	Previously Treated	4	8,5	2	50,0	70,83	5,89
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	76,19	18,28
	Previously Treated	3	6,4	2	66,7	45,83	29,46
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	65,00	18,07
	Previously Treated	3	6,4	2	66,7	83,33	23,57
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	63,89	12,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	66,67	0,00
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	72,22	9,62
	Previously Treated	3	6,4	2	66,7	70,83	5,89
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	72,22	34,69
	Previously Treated	2	4,3	2	100,0	75,00	23,57
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	50,00	-
	Previously Treated	1	2,1	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	69,44	19,25
	Previously Treated	26	55,3	16	61,5	75,52	18,63
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	79,29	16,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	71,90	17,82
Cycle 2 Day 1	Local	32	91,4	29	90,6	79,60	18,17
	Central	40	93,0	35	87,5	80,24	22,06
Cycle 3 Day 1	Local	29	82,9	28	96,6	83,63	20,60
	Central	39	90,7	36	92,3	81,25	13,42
Cycle 4 Day 1	Local	28	80,0	27	96,4	84,88	16,02
	Central	39	90,7	37	94,9	82,66	14,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	83,64	20,73
	Central	38	88,4	37	97,4	82,88	15,58
Cycle 6 Day 1	Local	27	77,1	27	100,0	84,57	16,29
	Central	36	83,7	33	91,7	79,29	16,81
Cycle 7 Day 1	Local	27	77,1	27	100,0	83,64	15,93
	Central	33	76,7	30	90,9	79,17	14,80
Cycle 8 Day 1	Local	26	74,3	26	100,0	83,97	16,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	81,41	20,99
Cycle 9 Day 1	Local	25	71,4	25	100,0	81,33	18,21
	Central	26	60,5	26	100,0	83,01	16,41
Cycle 10 Day 1	Local	25	71,4	24	96,0	79,51	22,11
	Central	26	60,5	26	100,0	83,97	14,71
Cycle 11 Day 1	Local	24	68,6	24	100,0	82,29	17,26
	Central	26	60,5	26	100,0	83,65	14,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	81,82	16,99
	Central	26	60,5	23	88,5	85,51	13,58
Cycle 13 Day 1	Local	22	62,9	22	100,0	82,20	19,97
	Central	24	55,8	23	95,8	85,14	14,42
Cycle 14 Day 1	Local	22	62,9	22	100,0	81,06	24,69
	Central	23	53,5	22	95,7	79,55	14,94
Cycle 15 Day 1	Local	22	62,9	22	100,0	81,82	18,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	84,85	13,02
Cycle 16 Day 1	Local	20	57,1	20	100,0	81,25	16,64
	Central	21	48,8	19	90,5	80,70	17,36
Cycle 17 Day 1	Local	20	57,1	20	100,0	84,58	16,51
	Central	19	44,2	19	100,0	78,95	20,67
Cycle 18 Day 1	Local	20	57,1	19	95,0	86,40	15,52
	Central	18	41,9	16	88,9	79,17	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	82,84	17,05
	Central	17	39,5	16	94,1	87,50	11,39
Cycle 20 Day 1	Local	19	54,3	17	89,5	83,33	18,87
	Central	17	39,5	15	88,2	83,33	14,09
Cycle 21 Day 1	Local	14	40,0	12	85,7	83,33	18,12
	Central	15	34,9	14	93,3	79,76	15,23
Cycle 22 Day 1	Local	14	40,0	12	85,7	84,03	15,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	80,13	19,70
Cycle 23 Day 1	Local	11	31,4	10	90,9	84,17	18,19
	Central	10	23,3	8	80,0	73,96	30,35
Cycle 24 Day 1	Local	11	31,4	10	90,9	79,17	21,61
	Central	9	20,9	8	88,9	82,29	13,68
Cycle 25 Day 1	Local	7	20,0	7	100,0	75,00	15,21
	Central	8	18,6	6	75,0	81,94	14,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	75,00	19,72
	Central	8	18,6	6	75,0	88,89	14,59
Cycle 27 Day 1	Local	4	11,4	4	100,0	81,25	18,48
	Central	7	16,3	4	57,1	72,92	4,17
Cycle 28 Day 1	Local	4	11,4	4	100,0	70,83	19,84
	Central	6	14,0	5	83,3	68,33	27,89
Cycle 29 Day 1	Local	3	8,6	3	100,0	69,44	24,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	70,83	19,84
Cycle 30 Day 1	Local	3	8,6	3	100,0	63,89	12,73
	Central	4	9,3	2	50,0	66,67	0,00
Cycle 31 Day 1	Local	3	8,6	3	100,0	72,22	9,62
	Central	4	9,3	2	50,0	70,83	5,89
Cycle 32 Day 1	Local	3	8,6	3	100,0	72,22	34,69
	Central	3	7,0	2	66,7	75,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	50,00	-
	Central	1	2,3	1	100,0	100,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	76,19	14,19
	Central	21	48,8	14	66,7	69,64	22,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	74,55	17,50
	No	4	100,0	4	100,0	87,50	19,84
Cycle 2 Day 1	Yes	70	94,6	62	88,6	80,51	19,14
	No	2	50,0	2	100,0	62,50	53,03
Cycle 3 Day 1	Yes	66	89,2	62	93,9	82,26	16,84
	No	2	50,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	84,14	13,56
	No	2	50,0	2	100,0	66,67	47,14
Cycle 5 Day 1	Yes	63	85,1	62	98,4	83,87	17,26
	No	2	50,0	2	100,0	62,50	29,46
Cycle 6 Day 1	Yes	61	82,4	58	95,1	82,04	16,36
	No	2	50,0	2	100,0	70,83	29,46
Cycle 7 Day 1	Yes	58	78,4	55	94,8	81,52	15,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	75,00	23,57
Cycle 8 Day 1	Yes	54	73,0	50	92,6	83,00	19,12
	No	2	50,0	2	100,0	75,00	11,79
Cycle 9 Day 1	Yes	49	66,2	49	100,0	82,82	17,13
	No	2	50,0	2	100,0	66,67	11,79
Cycle 10 Day 1	Yes	49	66,2	48	98,0	82,12	18,83
	No	2	50,0	2	100,0	75,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	83,51	15,89
	No	2	50,0	2	100,0	70,83	5,89
Cycle 12 Day 1	Yes	47	63,5	43	91,5	84,30	15,13
	No	2	50,0	2	100,0	70,83	17,68
Cycle 13 Day 1	Yes	44	59,5	43	97,7	83,91	17,38
	No	2	50,0	2	100,0	79,17	17,68
Cycle 14 Day 1	Yes	43	58,1	42	97,7	80,75	20,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	70,83	29,46
Cycle 15 Day 1	Yes	42	56,8	42	100,0	84,13	15,49
	No	2	50,0	2	100,0	66,67	11,79
Cycle 16 Day 1	Yes	39	52,7	37	94,9	80,86	16,77
	No	2	50,0	2	100,0	83,33	23,57
Cycle 17 Day 1	Yes	37	50,0	37	100,0	83,33	17,68
	No	2	50,0	2	100,0	54,17	17,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	84,09	14,78
	No	2	50,0	2	100,0	66,67	47,14
Cycle 19 Day 1	Yes	34	45,9	32	94,1	84,64	14,53
	No	2	50,0	1	50,0	100,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	83,61	16,15
	No	2	50,0	2	100,0	79,17	29,46
Cycle 21 Day 1	Yes	27	36,5	24	88,9	82,99	16,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	62,50	5,89
Cycle 22 Day 1	Yes	27	36,5	23	85,2	83,70	17,31
	No	2	50,0	2	100,0	62,50	5,89
Cycle 23 Day 1	Yes	20	27,0	17	85,0	78,43	24,31
	No	1	25,0	1	100,0	100,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	79,41	17,95
	No	1	25,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	79,17	14,86
	No	1	25,0	1	100,0	66,67	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	80,30	17,98
	No	1	25,0	1	100,0	100,00	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	73,81	10,12
	No	1	25,0	1	100,0	100,00	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	67,71	24,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	83,33	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	68,06	20,69
	No	1	25,0	1	100,0	83,33	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	64,58	10,49
	No	1	25,0	1	100,0	66,67	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	72,92	7,98
	No	1	25,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	66,67	26,35
	No	1	25,0	1	100,0	100,00	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	75,00	35,36
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	72,92	18,79
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	81,25	24,70
	No	70	100,0	70	100,0	74,52	16,84
Cycle 2 Day 1	Yes	5	62,5	5	100,0	83,33	21,25
	No	67	95,7	59	88,1	79,66	20,31
Cycle 3 Day 1	Yes	5	62,5	5	100,0	96,67	7,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	81,07	16,87
Cycle 4 Day 1	Yes	5	62,5	5	100,0	86,67	21,73
	No	62	88,6	59	95,2	83,33	14,43
Cycle 5 Day 1	Yes	5	62,5	5	100,0	86,67	20,92
	No	60	85,7	59	98,3	82,91	17,67
Cycle 6 Day 1	Yes	5	62,5	5	100,0	91,67	8,33
	No	58	82,9	55	94,8	80,76	16,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	88,33	13,94
	No	55	78,6	52	94,5	80,61	15,46
Cycle 8 Day 1	Yes	5	62,5	5	100,0	75,00	34,36
	No	51	72,9	47	92,2	83,51	16,89
Cycle 9 Day 1	Yes	4	50,0	4	100,0	81,25	23,94
	No	47	67,1	47	100,0	82,27	16,81
Cycle 10 Day 1	Yes	4	50,0	4	100,0	91,67	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	80,98	18,98
Cycle 11 Day 1	Yes	4	50,0	4	100,0	89,58	12,50
	No	46	65,7	46	100,0	82,43	16,03
Cycle 12 Day 1	Yes	4	50,0	4	100,0	91,67	9,62
	No	45	64,3	41	91,1	82,93	15,58
Cycle 13 Day 1	Yes	4	50,0	4	100,0	91,67	9,62
	No	42	60,0	41	97,6	82,93	17,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	87,50	15,96
	No	41	58,6	40	97,6	79,58	20,58
Cycle 15 Day 1	Yes	4	50,0	4	100,0	89,58	12,50
	No	40	57,1	40	100,0	82,71	15,94
Cycle 16 Day 1	Yes	3	37,5	3	100,0	100,00	0,00
	No	38	54,3	36	94,7	79,40	16,49
Cycle 17 Day 1	Yes	3	37,5	3	100,0	94,44	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	80,79	18,88
Cycle 18 Day 1	Yes	3	37,5	3	100,0	97,22	4,81
	No	35	50,0	32	91,4	81,77	17,12
Cycle 19 Day 1	Yes	3	37,5	3	100,0	97,22	4,81
	No	33	47,1	30	90,9	83,89	14,67
Cycle 20 Day 1	Yes	3	37,5	3	100,0	94,44	9,62
	No	33	47,1	29	87,9	82,18	16,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	91,67	11,79
	No	27	38,6	24	88,9	80,56	16,61
Cycle 22 Day 1	Yes	2	25,0	2	100,0	95,83	5,89
	No	27	38,6	23	85,2	80,80	17,84
Cycle 23 Day 1	Yes	2	25,0	2	100,0	95,83	5,89
	No	19	27,1	16	84,2	77,60	24,85
Cycle 24 Day 1	Yes	2	25,0	2	100,0	100,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	78,13	17,71
Cycle 25 Day 1	Yes	2	25,0	2	100,0	95,83	5,89
	No	13	18,6	11	84,6	75,00	13,44
Cycle 26 Day 1	Yes	1	12,5	1	100,0	91,67	-
	No	13	18,6	11	84,6	81,06	18,67
Cycle 27 Day 1	Yes	1	12,5	1	100,0	75,00	-
	No	10	14,3	7	70,0	77,38	14,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	66,67	-
	No	9	12,9	8	88,9	69,79	24,78
Cycle 29 Day 1	Yes	1	12,5	1	100,0	58,33	-
	No	8	11,4	6	75,0	72,22	20,86
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	65,00	9,13
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	71,67	7,45
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	73,33	27,26
Cycle 33 Day 1	No	2	2,9	2	100,0	75,00	35,36
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	54,17	17,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	74,36	18,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30EF_SG.xls
28NOV2019 10:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	41,88	23,14
Cycle 2 Day 1	All	72	92,3	65	90,3	38,12	21,96
Cycle 3 Day 1	All	68	87,2	64	94,1	31,77	21,58
Cycle 4 Day 1	All	67	85,9	64	95,5	26,22	19,43
Cycle 5 Day 1	All	65	83,3	64	98,5	27,78	20,09
Cycle 6 Day 1	All	63	80,8	60	95,2	27,22	17,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	27,88	19,37
Cycle 8 Day 1	All	56	71,8	52	92,9	26,28	18,93
Cycle 9 Day 1	All	51	65,4	51	100,0	25,49	18,09
Cycle 10 Day 1	All	51	65,4	50	98,0	27,78	18,95
Cycle 11 Day 1	All	50	64,1	50	100,0	25,33	16,95
Cycle 12 Day 1	All	49	62,8	45	91,8	27,90	18,75
Cycle 13 Day 1	All	46	59,0	45	97,8	26,17	20,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	28,54	23,53
Cycle 15 Day 1	All	44	56,4	44	100,0	27,78	18,33
Cycle 16 Day 1	All	41	52,6	39	95,1	27,92	16,49
Cycle 17 Day 1	All	39	50,0	39	100,0	26,50	18,84
Cycle 18 Day 1	All	38	48,7	35	92,1	22,22	18,08
Cycle 19 Day 1	All	36	46,2	33	91,7	27,61	19,07
Cycle 20 Day 1	All	36	46,2	32	88,9	24,65	17,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	27,78	18,12
Cycle 22 Day 1	All	29	37,2	25	86,2	28,44	20,31
Cycle 23 Day 1	All	21	26,9	18	85,7	27,16	24,47
Cycle 24 Day 1	All	20	25,6	18	90,0	25,93	19,43
Cycle 25 Day 1	All	15	19,2	13	86,7	31,62	18,06
Cycle 26 Day 1	All	14	17,9	12	85,7	28,70	21,43
Cycle 27 Day 1	All	11	14,1	8	72,7	22,22	8,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	28,40	24,29
Cycle 29 Day 1	All	9	11,5	7	77,8	30,16	17,82
Cycle 30 Day 1	All	7	9,0	5	71,4	20,00	14,49
Cycle 31 Day 1	All	7	9,0	5	71,4	26,67	9,94
Cycle 32 Day 1	All	6	7,7	5	83,3	22,22	15,71
Cycle 33 Day 1	All	2	2,6	2	100,0	27,78	7,86
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	48,41	26,57
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	46,36	22,24
	Female	49	100,0	49	100,0	39,23	23,47
Cycle 2 Day 1	Male	27	93,1	25	92,6	40,00	22,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	36,94	21,85
Cycle 3 Day 1	Male	25	86,2	23	92,0	27,54	14,55
	Female	43	87,8	41	95,3	34,15	24,52
Cycle 4 Day 1	Male	25	86,2	25	100,0	26,67	18,98
	Female	42	85,7	39	92,9	25,93	19,96
Cycle 5 Day 1	Male	25	86,2	25	100,0	34,67	22,98
	Female	40	81,6	39	97,5	23,36	16,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	30,43	19,88
	Female	38	77,6	37	97,4	25,23	14,96
Cycle 7 Day 1	Male	23	79,3	23	100,0	32,85	18,80
	Female	37	75,5	34	91,9	24,51	19,30
Cycle 8 Day 1	Male	21	72,4	19	90,5	29,82	22,85
	Female	35	71,4	33	94,3	24,24	16,30
Cycle 9 Day 1	Male	18	62,1	18	100,0	29,01	17,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	23,57	18,16
Cycle 10 Day 1	Male	18	62,1	18	100,0	33,33	21,89
	Female	33	67,3	32	97,0	24,65	16,63
Cycle 11 Day 1	Male	18	62,1	18	100,0	30,86	17,69
	Female	32	65,3	32	100,0	22,22	15,96
Cycle 12 Day 1	Male	17	58,6	17	100,0	30,07	18,33
	Female	32	65,3	28	87,5	26,59	19,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	28,76	18,03
	Female	29	59,2	28	96,6	24,60	22,50
Cycle 14 Day 1	Male	17	58,6	16	94,1	29,86	23,91
	Female	28	57,1	28	100,0	27,78	23,72
Cycle 15 Day 1	Male	16	55,2	16	100,0	31,94	19,82
	Female	28	57,1	28	100,0	25,40	17,33
Cycle 16 Day 1	Male	14	48,3	14	100,0	30,16	15,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	26,67	17,27
Cycle 17 Day 1	Male	12	41,4	12	100,0	29,63	19,15
	Female	27	55,1	27	100,0	25,10	18,89
Cycle 18 Day 1	Male	11	37,9	10	90,9	23,33	18,48
	Female	27	55,1	25	92,6	21,78	18,28
Cycle 19 Day 1	Male	10	34,5	10	100,0	28,89	25,23
	Female	26	53,1	23	88,5	27,05	16,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	22,22	19,25
	Female	26	53,1	23	88,5	25,60	16,56
Cycle 21 Day 1	Male	8	27,6	8	100,0	27,78	17,82
	Female	21	42,9	18	85,7	27,78	18,77
Cycle 22 Day 1	Male	8	27,6	6	75,0	33,33	9,94
	Female	21	42,9	19	90,5	26,90	22,62
Cycle 23 Day 1	Male	5	17,2	4	80,0	27,78	14,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	26,98	27,12
Cycle 24 Day 1	Male	5	17,2	4	80,0	30,56	5,56
	Female	15	30,6	14	93,3	24,60	21,87
Cycle 25 Day 1	Male	3	10,3	2	66,7	27,78	7,86
	Female	12	24,5	11	91,7	32,32	19,53
Cycle 26 Day 1	Male	3	10,3	2	66,7	27,78	7,86
	Female	11	22,4	10	90,9	28,89	23,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	22,22	0,00
	Female	8	16,3	6	75,0	22,22	9,94
Cycle 28 Day 1	Male	2	6,9	2	100,0	27,78	7,86
	Female	8	16,3	7	87,5	28,57	27,86
Cycle 29 Day 1	Male	1	3,4	1	100,0	44,44	-
	Female	8	16,3	6	75,0	27,78	18,26
Cycle 30 Day 1	Male	1	3,4	1	100,0	22,22	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	19,44	16,67
Cycle 31 Day 1	Male	1	3,4	1	100,0	22,22	-
	Female	6	12,2	4	66,7	27,78	11,11
Cycle 32 Day 1	Male	1	3,4	1	100,0	11,11	-
	Female	5	10,2	4	80,0	25,00	16,67
Cycle 33 Day 1	Male	1	3,4	1	100,0	33,33	-
	Female	1	2,0	1	100,0	22,22	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	54,07	22,95
	Female	21	42,9	13	61,9	41,88	29,80
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	40,86	21,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	46,83	27,62
	>=75	2	100,0	2	100,0	38,89	39,28
Cycle 2 Day 1	18-64	59	95,2	53	89,8	35,22	20,29
	65-74	11	78,6	10	90,9	56,67	21,24
	>=75	2	100,0	2	100,0	22,22	31,43
Cycle 3 Day 1	18-64	56	90,3	52	92,9	31,20	21,11
	65-74	10	71,4	10	100,0	36,67	24,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	22,22	31,43
Cycle 4 Day 1	18-64	55	88,7	53	96,4	25,79	19,34
	65-74	10	71,4	9	90,0	30,86	20,62
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 5 Day 1	18-64	53	85,5	52	98,1	25,43	20,56
	65-74	10	71,4	10	100,0	37,78	14,05
	>=75	2	100,0	2	100,0	38,89	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	26,53	17,69
	65-74	10	71,4	9	90,0	30,86	7,41
	>=75	2	100,0	2	100,0	27,78	39,28
Cycle 7 Day 1	18-64	49	79,0	47	95,9	27,42	19,77
	65-74	9	64,3	8	88,9	30,56	14,24
	>=75	2	100,0	2	100,0	27,78	39,28
Cycle 8 Day 1	18-64	45	72,6	41	91,1	24,12	19,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	33,33	12,42
	>=75	2	100,0	2	100,0	38,89	39,28
Cycle 9 Day 1	18-64	40	64,5	40	100,0	21,67	15,70
	65-74	9	64,3	9	100,0	40,74	14,70
	>=75	2	100,0	2	100,0	33,33	47,14
Cycle 10 Day 1	18-64	40	64,5	39	97,5	25,07	16,85
	65-74	9	64,3	9	100,0	38,27	20,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	33,33	47,14
Cycle 11 Day 1	18-64	39	62,9	39	100,0	25,07	16,66
	65-74	9	64,3	9	100,0	27,16	17,67
	>=75	2	100,0	2	100,0	22,22	31,43
Cycle 12 Day 1	18-64	38	61,3	35	92,1	25,71	19,76
	65-74	9	64,3	8	88,9	37,50	13,20
	>=75	2	100,0	2	100,0	27,78	7,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	22,88	17,92
	65-74	9	64,3	9	100,0	38,27	25,53
	>=75	2	100,0	2	100,0	27,78	39,28
Cycle 14 Day 1	18-64	35	56,5	35	100,0	25,08	22,11
	65-74	9	64,3	8	88,9	41,67	27,05
	>=75	1	50,0	1	100,0	44,44	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	26,03	17,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	33,33	21,41
	>=75	1	50,0	1	100,0	44,44	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	25,35	16,27
	65-74	7	50,0	6	85,7	38,89	13,61
	>=75	1	50,0	1	100,0	44,44	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	25,69	19,44
	65-74	6	42,9	6	100,0	27,78	16,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	44,44	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	19,16	17,03
	65-74	6	42,9	5	83,3	35,56	18,26
	>=75	1	50,0	1	100,0	44,44	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	25,40	19,56
	65-74	5	35,7	4	80,0	36,11	5,56
	>=75	1	50,0	1	100,0	55,56	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	23,08	18,03
	65-74	5	35,7	5	100,0	28,89	9,94
	>=75	1	50,0	1	100,0	44,44	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	25,40	18,64
	65-74	4	28,6	4	100,0	33,33	9,07
	>=75	1	50,0	1	100,0	55,56	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	27,22	22,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	30,56	5,56
	>=75	1	50,0	1	100,0	44,44	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	27,08	25,97
	65-74	2	14,3	2	100,0	27,78	7,86
Cycle 24 Day 1	18-64	18	29,0	16	88,9	25,00	20,49
	65-74	2	14,3	2	100,0	33,33	0,00
Cycle 25 Day 1	18-64	14	22,6	12	85,7	31,48	18,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	33,33	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	28,70	21,43
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	22,22	8,40
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	28,40	24,29
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	30,16	17,82
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	20,00	14,49
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	26,67	9,94
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	19,44	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	33,33	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	33,33	-
	65-74	1	7,1	1	100,0	22,22	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	50,56	29,17
	65-74	10	71,4	7	70,0	47,62	15,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	11,11	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	44,44	25,71
	Other	43	100,0	43	100,0	39,79	20,89
Cycle 2 Day 1	White	33	94,3	29	87,9	38,70	24,24
	Other	39	90,7	36	92,3	37,65	20,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	34,98	27,16
	Other	37	86,0	37	100,0	29,43	16,40
Cycle 4 Day 1	White	31	88,6	28	90,3	20,63	17,56
	Other	36	83,7	36	100,0	30,56	19,94
Cycle 5 Day 1	White	31	88,6	30	96,8	24,81	22,35
	Other	34	79,1	34	100,0	30,39	17,79
Cycle 6 Day 1	White	30	85,7	28	93,3	27,78	20,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	26,74	13,49
Cycle 7 Day 1	White	29	82,9	27	93,1	27,16	20,75
	Other	31	72,1	30	96,8	28,52	18,38
Cycle 8 Day 1	White	28	80,0	24	85,7	24,07	17,85
	Other	28	65,1	28	100,0	28,17	19,94
Cycle 9 Day 1	White	26	74,3	26	100,0	24,36	22,00
	Other	25	58,1	25	100,0	26,67	13,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	28,00	22,25
	Other	25	58,1	25	100,0	27,56	15,42
Cycle 11 Day 1	White	26	74,3	26	100,0	24,79	19,20
	Other	24	55,8	24	100,0	25,93	14,53
Cycle 12 Day 1	White	26	74,3	22	84,6	25,25	22,79
	Other	23	53,5	23	100,0	30,43	13,90
Cycle 13 Day 1	White	24	68,6	23	95,8	25,12	25,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	27,27	15,61
Cycle 14 Day 1	White	24	68,6	24	100,0	25,00	26,26
	Other	21	48,8	20	95,2	32,78	19,57
Cycle 15 Day 1	White	24	68,6	24	100,0	27,31	21,23
	Other	20	46,5	20	100,0	28,33	14,63
Cycle 16 Day 1	White	22	62,9	20	90,9	24,44	16,36
	Other	19	44,2	19	100,0	31,58	16,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	25,76	20,68
	Other	17	39,5	17	100,0	27,45	16,72
Cycle 18 Day 1	White	21	60,0	18	85,7	21,60	18,07
	Other	17	39,5	17	100,0	22,88	18,62
Cycle 19 Day 1	White	20	57,1	20	100,0	27,78	22,37
	Other	16	37,2	13	81,3	27,35	13,31
Cycle 20 Day 1	White	20	57,1	17	85,0	23,53	19,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	25,93	14,95
Cycle 21 Day 1	White	16	45,7	14	87,5	27,78	22,54
	Other	13	30,2	12	92,3	27,78	12,08
Cycle 22 Day 1	White	16	45,7	13	81,3	28,21	26,69
	Other	13	30,2	12	92,3	28,70	11,07
Cycle 23 Day 1	White	12	34,3	10	83,3	33,33	28,21
	Other	9	20,9	8	88,9	19,44	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	28,89	23,54
	Other	9	20,9	8	88,9	22,22	13,28
Cycle 25 Day 1	White	10	28,6	8	80,0	33,33	22,22
	Other	5	11,6	5	100,0	28,89	9,94
Cycle 26 Day 1	White	10	28,6	8	80,0	29,17	26,52
	Other	4	9,3	4	100,0	27,78	6,42
Cycle 27 Day 1	White	8	22,9	5	62,5	22,22	7,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	22,22	11,11
Cycle 28 Day 1	White	7	20,0	6	85,7	24,07	23,74
	Other	3	7,0	3	100,0	37,04	27,96
Cycle 29 Day 1	White	6	17,1	4	66,7	33,33	24,00
	Other	3	7,0	3	100,0	25,93	6,42
Cycle 30 Day 1	White	4	11,4	2	50,0	11,11	15,71
	Other	3	7,0	3	100,0	25,93	12,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	16,67	7,86
	Other	3	7,0	3	100,0	33,33	0,00
Cycle 32 Day 1	White	4	11,4	3	75,0	14,81	16,97
	Other	2	4,7	2	100,0	33,33	0,00
Cycle 33 Day 1	White	2	5,7	2	100,0	27,78	7,86
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	44,44	26,80
	Other	24	55,8	16	66,7	51,39	26,87
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	42,93	26,40
	Europe (EU)	17	100,0	17	100,0	47,06	25,92
	Asia (AS)	39	100,0	39	100,0	39,03	19,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	34,64	17,52
	Europe (EU)	16	94,1	13	81,3	41,88	26,51
	Asia (AS)	36	92,3	35	97,2	38,41	22,44
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	33,33	18,52
	Europe (EU)	15	88,2	12	80,0	41,67	32,18
	Asia (AS)	33	84,6	33	100,0	27,27	17,59
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	22,78	19,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	23,15	17,38
	Asia (AS)	32	82,1	32	100,0	29,51	19,88
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	23,33	19,71
	Europe (EU)	15	88,2	14	93,3	27,78	21,24
	Asia (AS)	30	76,9	30	100,0	30,74	19,94
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	20,00	16,36
	Europe (EU)	14	82,4	13	92,9	35,04	19,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	28,81	14,86
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	24,07	21,30
	Europe (EU)	14	82,4	13	92,9	31,62	18,06
	Asia (AS)	27	69,2	26	96,3	28,63	18,90
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	19,61	16,45
	Europe (EU)	14	82,4	11	78,6	33,33	17,21
	Asia (AS)	24	61,5	24	100,0	27,78	20,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	24,69	17,69
	Europe (EU)	12	70,6	12	100,0	31,48	23,61
	Asia (AS)	21	53,8	21	100,0	22,75	14,69
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	27,45	21,20
	Europe (EU)	12	70,6	12	100,0	36,11	20,72
	Asia (AS)	21	53,8	21	100,0	23,28	14,87
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	25,31	18,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	29,63	15,95
	Asia (AS)	20	51,3	20	100,0	22,78	15,91
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	26,14	25,74
	Europe (EU)	12	70,6	9	75,0	33,33	9,62
	Asia (AS)	19	48,7	19	100,0	26,90	14,49
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	20,92	19,60
	Europe (EU)	11	64,7	10	90,9	36,67	26,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	25,31	17,38
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	24,84	23,42
	Europe (EU)	11	64,7	11	100,0	36,36	32,62
	Asia (AS)	17	43,6	16	94,1	27,08	15,16
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	22,22	18,84
	Europe (EU)	11	64,7	11	100,0	36,36	21,14
	Asia (AS)	16	41,0	16	100,0	27,78	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	21,43	14,10
	Europe (EU)	11	64,7	9	81,8	30,86	17,37
	Asia (AS)	16	41,0	16	100,0	31,94	17,15
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	26,19	21,62
	Europe (EU)	10	58,8	10	100,0	26,67	18,29
	Asia (AS)	15	38,5	15	100,0	26,67	17,72
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	19,05	19,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	25,93	15,18
	Asia (AS)	15	38,5	15	100,0	23,70	18,72
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	22,22	18,70
	Europe (EU)	9	52,9	9	100,0	34,57	23,86
	Asia (AS)	14	35,9	11	78,6	28,28	14,37
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	23,93	20,21
	Europe (EU)	9	52,9	6	66,7	24,07	16,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	25,64	15,31
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	28,89	22,95
	Europe (EU)	7	41,2	6	85,7	29,63	18,14
	Asia (AS)	11	28,2	10	90,9	25,56	13,91
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	32,22	27,94
	Europe (EU)	7	41,2	5	71,4	22,22	17,57
	Asia (AS)	11	28,2	10	90,9	27,78	12,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	32,10	31,15
	Europe (EU)	5	29,4	3	60,0	25,93	12,83
	Asia (AS)	7	17,9	6	85,7	20,37	17,80
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	34,72	21,77
	Europe (EU)	5	29,4	4	80,0	13,89	16,67
	Asia (AS)	7	17,9	6	85,7	22,22	14,05
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	31,75	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	27,78	7,86
	Asia (AS)	4	10,3	4	100,0	33,33	0,00
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	37,04	25,98
	Europe (EU)	4	23,5	2	50,0	5,56	7,86
	Asia (AS)	4	10,3	4	100,0	27,78	6,42
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	22,22	9,07
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	22,22	9,07
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	19,44	10,64
	Europe (EU)	2	11,8	1	50,0	0,00	-
	Asia (AS)	4	10,3	4	100,0	44,44	27,22
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	25,93	23,13
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	33,33	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	11,11	15,71
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	25,93	12,83
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	16,67	7,86
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	33,33	0,00
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	5,56	7,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	33,33	-
	Asia (AS)	3	7,7	2	66,7	33,33	0,00
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	33,33	-
	Europe (EU)	1	5,9	1	100,0	22,22	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	44,44	25,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	58,33	29,22
	Asia (AS)	21	53,8	13	61,9	48,72	28,16
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	30,37	15,42
	1	38	100,0	38	100,0	45,32	21,98
	2	10	100,0	10	100,0	63,33	28,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	27	90,0	36,63	23,02
	1	36	94,7	32	88,9	36,81	20,44
	2	6	60,0	6	100,0	51,85	24,00
Cycle 3 Day 1	0	29	96,7	27	93,1	30,04	19,93
	1	34	89,5	32	94,1	29,51	19,88
	2	5	50,0	5	100,0	55,56	30,43
Cycle 4 Day 1	0	29	96,7	28	96,6	20,63	19,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	29,17	16,64
	2	5	50,0	4	80,0	41,67	31,91
Cycle 5 Day 1	0	29	96,7	29	100,0	22,61	15,85
	1	33	86,8	32	97,0	31,25	21,57
	2	3	30,0	3	100,0	40,74	33,95
Cycle 6 Day 1	0	29	96,7	29	100,0	22,99	15,41
	1	31	81,6	28	90,3	31,35	18,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	29,63	6,42
Cycle 7 Day 1	0	29	96,7	28	96,6	25,00	17,79
	1	28	73,7	26	92,9	30,77	21,39
	2	3	30,0	3	100,0	29,63	16,97
Cycle 8 Day 1	0	28	93,3	26	92,9	25,21	17,65
	1	25	65,8	23	92,0	27,05	20,05
	2	3	30,0	3	100,0	29,63	27,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	26,07	17,48
	1	23	60,5	23	100,0	25,60	19,08
	2	2	20,0	2	100,0	16,67	23,57
Cycle 10 Day 1	0	26	86,7	26	100,0	26,07	17,76
	1	23	60,5	22	95,7	30,30	20,91
	2	2	20,0	2	100,0	22,22	15,71
Cycle 11 Day 1	0	26	86,7	26	100,0	25,21	15,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	26,26	18,64
	2	2	20,0	2	100,0	16,67	23,57
Cycle 12 Day 1	0	25	83,3	22	88,0	30,81	21,94
	1	22	57,9	21	95,5	25,40	14,12
	2	2	20,0	2	100,0	22,22	31,43
Cycle 13 Day 1	0	25	83,3	24	96,0	29,17	22,42
	1	20	52,6	20	100,0	23,89	18,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	30,56	26,26
	1	19	50,0	19	100,0	26,90	20,39
	2	1	10,0	1	100,0	11,11	-
Cycle 15 Day 1	0	24	80,0	24	100,0	30,09	18,38
	1	19	50,0	19	100,0	25,73	18,54
	2	1	10,0	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	28,89	17,06
	1	18	47,4	18	100,0	27,78	16,28
	2	1	10,0	1	100,0	11,11	-
Cycle 17 Day 1	0	21	70,0	21	100,0	26,98	20,36
	1	17	44,7	17	100,0	27,45	16,72
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	24,69	19,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	20,14	16,84
	2	1	10,0	1	100,0	11,11	-
Cycle 19 Day 1	0	20	66,7	19	95,0	27,49	21,07
	1	15	39,5	13	86,7	29,06	16,69
	2	1	10,0	1	100,0	11,11	-
Cycle 20 Day 1	0	20	66,7	17	85,0	25,49	19,55
	1	15	39,5	14	93,3	25,40	13,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	30,16	21,09
	1	13	34,2	11	84,6	27,27	12,54
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	33,33	25,07
	1	13	34,2	12	92,3	25,93	12,83
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	33,33	26,64
	1	9	23,7	8	88,9	23,61	21,77
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	28,40	20,12
	1	9	23,7	8	88,9	25,00	20,36
	2	1	10,0	1	100,0	11,11	-
Cycle 25 Day 1	0	8	26,7	6	75,0	38,89	19,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	25,40	15,33
Cycle 26 Day 1	0	8	26,7	6	75,0	31,48	21,56
	1	6	15,8	6	100,0	25,93	22,95
Cycle 27 Day 1	0	6	20,0	3	50,0	22,22	0,00
	1	5	13,2	5	100,0	22,22	11,11
Cycle 28 Day 1	0	5	16,7	4	80,0	30,56	27,78
	1	5	13,2	5	100,0	26,67	24,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	50,00	7,86
	1	5	13,2	5	100,0	22,22	13,61
Cycle 30 Day 1	0	3	10,0	1	33,3	22,22	-
	1	4	10,5	4	100,0	19,44	16,67
Cycle 31 Day 1	0	3	10,0	1	33,3	22,22	-
	1	4	10,5	4	100,0	27,78	11,11
Cycle 32 Day 1	0	3	10,0	2	66,7	22,22	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	22,22	19,25
Cycle 33 Day 1	0	2	6,7	2	100,0	27,78	7,86
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	42,06	22,72
	1	20	52,6	12	60,0	51,85	30,83
	2	4	40,0	2	50,0	72,22	7,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	39,43	22,74
	1	3	100,0	3	100,0	48,15	39,02
	2 or More	44	100,0	44	100,0	43,18	22,76
Cycle 2 Day 1	None	30	96,8	27	90,0	35,80	23,13
	1	2	66,7	1	50,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	40,54	20,99
Cycle 3 Day 1	None	30	96,8	28	93,3	28,97	16,93
	1	2	66,7	1	50,0	11,11	-
	2 or More	36	81,8	35	97,2	34,60	24,66
Cycle 4 Day 1	None	30	96,8	29	96,7	22,22	19,70
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	35	79,5	33	94,3	30,30	18,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	24,81	22,16
	1	2	66,7	2	100,0	11,11	15,71
	2 or More	33	75,0	32	97,0	31,60	17,65
Cycle 6 Day 1	None	29	93,5	28	96,6	20,24	18,90
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	32	72,7	30	93,8	34,44	11,43
Cycle 7 Day 1	None	27	87,1	26	96,3	22,65	20,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	44,44	15,71
	2 or More	31	70,5	29	93,5	31,42	18,08
Cycle 8 Day 1	None	26	83,9	25	96,2	22,67	21,15
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	29,63	16,31
Cycle 9 Day 1	None	25	80,6	25	100,0	22,22	17,57
	1	1	33,3	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	29,33	18,39
Cycle 10 Day 1	None	25	80,6	24	96,0	25,46	20,59
	1	1	33,3	1	100,0	22,22	-
	2 or More	25	56,8	25	100,0	30,22	17,72
Cycle 11 Day 1	None	25	80,6	25	100,0	23,56	19,59
	1	1	33,3	1	100,0	33,33	-
	2 or More	24	54,5	24	100,0	26,85	14,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	25,00	17,41
	1	1	33,3	1	100,0	11,11	-
	2 or More	23	52,3	20	87,0	32,22	20,04
Cycle 13 Day 1	None	24	77,4	23	95,8	22,22	20,38
	1	1	33,3	1	100,0	22,22	-
	2 or More	21	47,7	21	100,0	30,69	21,35
Cycle 14 Day 1	None	23	74,2	23	100,0	27,05	22,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	20	95,2	31,67	25,05
Cycle 15 Day 1	None	23	74,2	23	100,0	25,12	19,88
	1	1	33,3	1	100,0	33,33	-
	2 or More	20	45,5	20	100,0	30,56	16,86
Cycle 16 Day 1	None	20	64,5	19	95,0	25,15	16,91
	1	1	33,3	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	31,58	15,83
Cycle 17 Day 1	None	19	61,3	19	100,0	23,39	17,72
	1	1	33,3	1	100,0	22,22	-
	2 or More	19	43,2	19	100,0	29,82	20,30
Cycle 18 Day 1	None	18	58,1	17	94,4	15,03	16,17
	1	1	33,3	1	100,0	11,11	-
	2 or More	19	43,2	17	89,5	30,07	17,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	20,92	17,52
	1	1	33,3	1	100,0	11,11	-
	2 or More	18	40,9	15	83,3	36,30	18,05
Cycle 20 Day 1	None	17	54,8	16	94,1	23,61	16,17
	1	1	33,3	1	100,0	11,11	-
	2 or More	18	40,9	15	83,3	26,67	18,69
Cycle 21 Day 1	None	15	48,4	13	86,7	18,80	11,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	36,75	19,45
Cycle 22 Day 1	None	15	48,4	13	86,7	22,22	12,00
	2 or More	14	31,8	12	85,7	35,19	25,44
Cycle 23 Day 1	None	10	32,3	9	90,0	19,75	19,07
	2 or More	11	25,0	9	81,8	34,57	28,02
Cycle 24 Day 1	None	10	32,3	10	100,0	24,44	20,15
	2 or More	10	22,7	8	80,0	27,78	19,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	26,39	14,47
	2 or More	6	13,6	5	83,3	40,00	21,66
Cycle 26 Day 1	None	8	25,8	8	100,0	26,39	21,36
	2 or More	6	13,6	4	66,7	33,33	24,00
Cycle 27 Day 1	None	7	22,6	6	85,7	22,22	7,03
	2 or More	4	9,1	2	50,0	22,22	15,71
Cycle 28 Day 1	None	7	22,6	7	100,0	30,16	27,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	22,22	15,71
Cycle 29 Day 1	None	6	19,4	5	83,3	31,11	21,37
	2 or More	3	6,8	2	66,7	27,78	7,86
Cycle 30 Day 1	None	4	12,9	3	75,0	18,52	16,97
	2 or More	3	6,8	2	66,7	22,22	15,71
Cycle 31 Day 1	None	4	12,9	3	75,0	22,22	11,11
	2 or More	3	6,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	14,81	16,97
	2 or More	2	4,5	2	100,0	33,33	0,00
Cycle 33 Day 1	None	1	3,2	1	100,0	33,33	-
	2 or More	1	2,3	1	100,0	22,22	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	44,44	25,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	22,22	-
	2 or More	24	54,5	15	62,5	53,33	27,60
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	39,43	22,74
	Previously Treated	47	100,0	47	100,0	43,50	23,49
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	35,80	23,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	39,77	21,24
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	28,97	16,93
	Previously Treated	38	80,9	36	94,7	33,95	24,62
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	22,22	19,70
	Previously Treated	37	78,7	35	94,6	29,52	18,85
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	24,81	22,16
	Previously Treated	35	74,5	34	97,1	30,39	18,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	20,24	18,90
	Previously Treated	34	72,3	32	94,1	33,33	12,62
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	22,65	20,00
	Previously Treated	33	70,2	31	93,9	32,26	18,00
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	22,67	21,15
	Previously Treated	30	63,8	27	90,0	29,63	16,31
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	22,22	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	28,63	18,37
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	25,46	20,59
	Previously Treated	26	55,3	26	100,0	29,91	17,43
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	23,56	19,59
	Previously Treated	25	53,2	25	100,0	27,11	14,01
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	25,00	17,41
	Previously Treated	24	51,1	21	87,5	31,22	20,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	22,22	20,38
	Previously Treated	22	46,8	22	100,0	30,30	20,91
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	27,05	22,18
	Previously Treated	22	46,8	21	95,5	30,16	25,37
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	25,12	19,88
	Previously Treated	21	44,7	21	100,0	30,69	16,44
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	25,15	16,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	30,56	16,07
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	23,39	17,72
	Previously Treated	20	42,6	20	100,0	29,44	19,84
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	15,03	16,17
	Previously Treated	20	42,6	18	90,0	29,01	17,52
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	20,92	17,52
	Previously Treated	19	40,4	16	84,2	34,72	18,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	23,61	16,17
	Previously Treated	19	40,4	16	84,2	25,69	18,47
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	18,80	11,46
	Previously Treated	14	29,8	13	92,9	36,75	19,45
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	22,22	12,00
	Previously Treated	14	29,8	12	85,7	35,19	25,44
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	19,75	19,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	34,57	28,02
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	24,44	20,15
	Previously Treated	10	21,3	8	80,0	27,78	19,70
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	26,39	14,47
	Previously Treated	6	12,8	5	83,3	40,00	21,66
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	26,39	21,36
	Previously Treated	6	12,8	4	66,7	33,33	24,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	22,22	7,03
	Previously Treated	4	8,5	2	50,0	22,22	15,71
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	30,16	27,00
	Previously Treated	3	6,4	2	66,7	22,22	15,71
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	31,11	21,37
	Previously Treated	3	6,4	2	66,7	27,78	7,86
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	18,52	16,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	22,22	15,71
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	22,22	11,11
	Previously Treated	3	6,4	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	14,81	16,97
	Previously Treated	2	4,3	2	100,0	33,33	0,00
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	33,33	-
	Previously Treated	1	2,1	1	100,0	22,22	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	44,44	25,51
	Previously Treated	26	55,3	16	61,5	51,39	27,78
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	40,95	22,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	42,64	23,62
Cycle 2 Day 1	Local	32	91,4	30	93,8	31,48	17,28
	Central	40	93,0	35	87,5	43,81	24,09
Cycle 3 Day 1	Local	29	82,9	28	96,6	26,98	21,04
	Central	39	90,7	36	92,3	35,49	21,55
Cycle 4 Day 1	Local	28	80,0	27	96,4	22,22	16,31
	Central	39	90,7	37	94,9	29,13	21,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	23,87	15,62
	Central	38	88,4	37	97,4	30,63	22,59
Cycle 6 Day 1	Local	27	77,1	27	100,0	24,69	15,20
	Central	36	83,7	33	91,7	29,29	18,39
Cycle 7 Day 1	Local	27	77,1	27	100,0	24,69	20,05
	Central	33	76,7	30	90,9	30,74	18,61
Cycle 8 Day 1	Local	26	74,3	26	100,0	20,94	17,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	31,62	19,29
Cycle 9 Day 1	Local	25	71,4	25	100,0	25,33	20,16
	Central	26	60,5	26	100,0	25,64	16,26
Cycle 10 Day 1	Local	25	71,4	24	96,0	27,78	20,72
	Central	26	60,5	26	100,0	27,78	17,57
Cycle 11 Day 1	Local	24	68,6	24	100,0	25,00	18,32
	Central	26	60,5	26	100,0	25,64	15,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	22,73	17,31
	Central	26	60,5	23	88,5	32,85	19,09
Cycle 13 Day 1	Local	22	62,9	22	100,0	23,74	24,80
	Central	24	55,8	23	95,8	28,50	16,35
Cycle 14 Day 1	Local	22	62,9	22	100,0	25,25	22,79
	Central	23	53,5	22	95,7	31,82	24,32
Cycle 15 Day 1	Local	22	62,9	22	100,0	23,74	20,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	31,82	15,82
Cycle 16 Day 1	Local	20	57,1	20	100,0	23,33	12,95
	Central	21	48,8	19	90,5	32,75	18,69
Cycle 17 Day 1	Local	20	57,1	20	100,0	20,56	13,13
	Central	19	44,2	19	100,0	32,75	22,06
Cycle 18 Day 1	Local	20	57,1	19	95,0	16,96	13,54
	Central	18	41,9	16	88,9	28,47	21,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	24,18	19,34
	Central	17	39,5	16	94,1	31,25	18,69
Cycle 20 Day 1	Local	19	54,3	17	89,5	19,61	12,75
	Central	17	39,5	15	88,2	30,37	19,91
Cycle 21 Day 1	Local	14	40,0	12	85,7	23,15	16,72
	Central	15	34,9	14	93,3	31,75	18,93
Cycle 22 Day 1	Local	14	40,0	12	85,7	25,00	16,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	31,62	23,50
Cycle 23 Day 1	Local	11	31,4	10	90,9	17,78	17,53
	Central	10	23,3	8	80,0	38,89	27,86
Cycle 24 Day 1	Local	11	31,4	10	90,9	25,56	18,92
	Central	9	20,9	8	88,9	26,39	21,36
Cycle 25 Day 1	Local	7	20,0	7	100,0	30,16	24,61
	Central	8	18,6	6	75,0	33,33	7,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	29,63	21,85
	Central	8	18,6	6	75,0	27,78	23,04
Cycle 27 Day 1	Local	4	11,4	4	100,0	19,44	5,56
	Central	7	16,3	4	57,1	25,00	10,64
Cycle 28 Day 1	Local	4	11,4	4	100,0	33,33	24,00
	Central	6	14,0	5	83,3	24,44	26,53
Cycle 29 Day 1	Local	3	8,6	3	100,0	22,22	22,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	36,11	13,98
Cycle 30 Day 1	Local	3	8,6	3	100,0	18,52	16,97
	Central	4	9,3	2	50,0	22,22	15,71
Cycle 31 Day 1	Local	3	8,6	3	100,0	22,22	11,11
	Central	4	9,3	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	8,6	3	100,0	14,81	16,97
	Central	3	7,0	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	33,33	-
	Central	1	2,3	1	100,0	22,22	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	49,21	21,22
	Central	21	48,8	14	66,7	47,62	31,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	41,29	21,49
	No	4	100,0	4	100,0	52,78	48,33
Cycle 2 Day 1	Yes	70	94,6	63	90,0	37,39	21,34
	No	2	50,0	2	100,0	61,11	39,28
Cycle 3 Day 1	Yes	66	89,2	62	93,9	31,90	21,90
	No	2	50,0	2	100,0	27,78	7,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	26,16	19,72
	No	2	50,0	2	100,0	27,78	7,86
Cycle 5 Day 1	Yes	63	85,1	62	98,4	27,42	20,29
	No	2	50,0	2	100,0	38,89	7,86
Cycle 6 Day 1	Yes	61	82,4	58	95,1	27,20	17,31
	No	2	50,0	2	100,0	27,78	7,86
Cycle 7 Day 1	Yes	58	78,4	55	94,8	27,47	18,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	38,89	39,28
Cycle 8 Day 1	Yes	54	73,0	50	92,6	25,11	18,21
	No	2	50,0	2	100,0	55,56	15,71
Cycle 9 Day 1	Yes	49	66,2	49	100,0	25,17	18,39
	No	2	50,0	2	100,0	33,33	0,00
Cycle 10 Day 1	Yes	49	66,2	48	98,0	28,01	19,18
	No	2	50,0	2	100,0	22,22	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	25,93	16,89
	No	2	50,0	2	100,0	11,11	15,71
Cycle 12 Day 1	Yes	47	63,5	43	91,5	27,65	19,15
	No	2	50,0	2	100,0	33,33	0,00
Cycle 13 Day 1	Yes	44	59,5	43	97,7	25,58	21,07
	No	2	50,0	2	100,0	38,89	7,86
Cycle 14 Day 1	Yes	43	58,1	42	97,7	28,04	23,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	38,89	7,86
Cycle 15 Day 1	Yes	42	56,8	42	100,0	27,51	18,73
	No	2	50,0	2	100,0	33,33	0,00
Cycle 16 Day 1	Yes	39	52,7	37	94,9	26,73	15,60
	No	2	50,0	2	100,0	50,00	23,57
Cycle 17 Day 1	Yes	37	50,0	37	100,0	25,53	18,68
	No	2	50,0	2	100,0	44,44	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	21,55	16,42
	No	2	50,0	2	100,0	33,33	47,14
Cycle 19 Day 1	Yes	34	45,9	32	94,1	27,43	19,34
	No	2	50,0	1	50,0	33,33	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	24,07	17,53
	No	2	50,0	2	100,0	33,33	0,00
Cycle 21 Day 1	Yes	27	36,5	24	88,9	27,31	18,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	15,71
Cycle 22 Day 1	Yes	27	36,5	23	85,2	28,02	21,15
	No	2	50,0	2	100,0	33,33	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	28,76	24,23
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	27,45	18,89
	No	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	31,48	18,85
	No	1	25,0	1	100,0	33,33	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	29,29	22,37
	No	1	25,0	1	100,0	22,22	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	22,22	9,07
	No	1	25,0	1	100,0	22,22	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	23,61	20,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	66,67	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	31,48	19,14
	No	1	25,0	1	100,0	22,22	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	16,67	14,34
	No	1	25,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	25,00	10,64
	No	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	19,44	16,67
	No	1	25,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	27,78	7,86
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	48,41	26,57
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	43,06	24,80
	No	70	100,0	70	100,0	41,75	23,12
Cycle 2 Day 1	Yes	5	62,5	5	100,0	33,33	28,33
	No	67	95,7	60	89,6	38,52	21,60
Cycle 3 Day 1	Yes	5	62,5	5	100,0	22,22	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	32,58	21,92
Cycle 4 Day 1	Yes	5	62,5	5	100,0	17,78	16,85
	No	62	88,6	59	95,2	26,93	19,60
Cycle 5 Day 1	Yes	5	62,5	5	100,0	28,89	25,58
	No	60	85,7	59	98,3	27,68	19,83
Cycle 6 Day 1	Yes	5	62,5	5	100,0	26,67	28,97
	No	58	82,9	55	94,8	27,27	15,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	24,44	25,34
	No	55	78,6	52	94,5	28,21	18,99
Cycle 8 Day 1	Yes	5	62,5	5	100,0	28,89	32,01
	No	51	72,9	47	92,2	26,00	17,53
Cycle 9 Day 1	Yes	4	50,0	4	100,0	27,78	23,13
	No	47	67,1	47	100,0	25,30	17,90
Cycle 10 Day 1	Yes	4	50,0	4	100,0	25,00	24,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	28,02	18,70
Cycle 11 Day 1	Yes	4	50,0	4	100,0	33,33	27,22
	No	46	65,7	46	100,0	24,64	16,04
Cycle 12 Day 1	Yes	4	50,0	4	100,0	19,44	16,67
	No	45	64,3	41	91,1	28,73	18,92
Cycle 13 Day 1	Yes	4	50,0	4	100,0	22,22	25,66
	No	42	60,0	41	97,6	26,56	20,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	25,00	18,98
	No	41	58,6	40	97,6	28,89	24,11
Cycle 15 Day 1	Yes	4	50,0	4	100,0	30,56	24,64
	No	40	57,1	40	100,0	27,50	17,97
Cycle 16 Day 1	Yes	3	37,5	3	100,0	22,22	22,22
	No	38	54,3	36	94,7	28,40	16,25
Cycle 17 Day 1	Yes	3	37,5	3	100,0	14,81	12,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	27,47	19,06
Cycle 18 Day 1	Yes	3	37,5	3	100,0	7,41	12,83
	No	35	50,0	32	91,4	23,61	18,02
Cycle 19 Day 1	Yes	3	37,5	3	100,0	18,52	16,97
	No	33	47,1	30	90,9	28,52	19,29
Cycle 20 Day 1	Yes	3	37,5	3	100,0	14,81	6,42
	No	33	47,1	29	87,9	25,67	17,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	16,67	7,86
	No	27	38,6	24	88,9	28,70	18,51
Cycle 22 Day 1	Yes	2	25,0	2	100,0	22,22	0,00
	No	27	38,6	23	85,2	28,99	21,12
Cycle 23 Day 1	Yes	2	25,0	2	100,0	11,11	15,71
	No	19	27,1	16	84,2	29,17	24,97
Cycle 24 Day 1	Yes	2	25,0	2	100,0	22,22	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	26,39	20,24
Cycle 25 Day 1	Yes	2	25,0	2	100,0	22,22	15,71
	No	13	18,6	11	84,6	33,33	18,59
Cycle 26 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	13	18,6	11	84,6	28,28	22,42
Cycle 27 Day 1	Yes	1	12,5	1	100,0	22,22	-
	No	10	14,3	7	70,0	22,22	9,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	66,67	-
	No	9	12,9	8	88,9	23,61	20,95
Cycle 29 Day 1	Yes	1	12,5	1	100,0	55,56	-
	No	8	11,4	6	75,0	25,93	15,18
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	20,00	14,49
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	26,67	9,94
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	22,22	15,71
Cycle 33 Day 1	No	2	2,9	2	100,0	27,78	7,86
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	72,22	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	46,58	26,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30FA_SG.xls
28NOV2019 10:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	12,61	17,86
Cycle 2 Day 1	All	72	92,3	65	90,3	7,69	12,87
Cycle 3 Day 1	All	68	87,2	64	94,1	6,25	15,29
Cycle 4 Day 1	All	67	85,9	64	95,5	4,69	10,06
Cycle 5 Day 1	All	65	83,3	64	98,5	3,91	9,27
Cycle 6 Day 1	All	63	80,8	60	95,2	4,72	10,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	4,68	9,84
Cycle 8 Day 1	All	56	71,8	52	92,9	3,21	8,76
Cycle 9 Day 1	All	51	65,4	51	100,0	3,59	12,61
Cycle 10 Day 1	All	51	65,4	50	98,0	4,33	9,41
Cycle 11 Day 1	All	50	64,1	50	100,0	3,67	9,09
Cycle 12 Day 1	All	49	62,8	45	91,8	4,81	11,02
Cycle 13 Day 1	All	46	59,0	45	97,8	2,96	8,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	4,55	13,62
Cycle 15 Day 1	All	44	56,4	44	100,0	2,65	7,14
Cycle 16 Day 1	All	41	52,6	39	95,1	6,41	13,58
Cycle 17 Day 1	All	39	50,0	39	100,0	5,56	18,07
Cycle 18 Day 1	All	38	48,7	35	92,1	2,38	7,17
Cycle 19 Day 1	All	36	46,2	33	91,7	4,55	11,24
Cycle 20 Day 1	All	36	46,2	32	88,9	2,60	7,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	1,92	5,43
Cycle 22 Day 1	All	29	37,2	25	86,2	4,00	11,06
Cycle 23 Day 1	All	21	26,9	18	85,7	4,63	13,77
Cycle 24 Day 1	All	20	25,6	18	90,0	2,78	8,57
Cycle 25 Day 1	All	15	19,2	13	86,7	3,85	9,99
Cycle 26 Day 1	All	14	17,9	12	85,7	2,78	6,49
Cycle 27 Day 1	All	11	14,1	8	72,7	6,25	12,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	3,70	7,35
Cycle 29 Day 1	All	9	11,5	7	77,8	4,76	8,13
Cycle 30 Day 1	All	7	9,0	5	71,4	10,00	9,13
Cycle 31 Day 1	All	7	9,0	5	71,4	6,67	9,13
Cycle 32 Day 1	All	6	7,7	5	83,3	3,33	7,45
Cycle 33 Day 1	All	2	2,6	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	14,29	21,14
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	13,79	21,85
	Female	49	100,0	49	100,0	11,90	15,21
Cycle 2 Day 1	Male	27	93,1	25	92,6	6,00	12,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	8,75	13,07
Cycle 3 Day 1	Male	25	86,2	23	92,0	2,90	8,18
	Female	43	87,8	41	95,3	8,13	17,92
Cycle 4 Day 1	Male	25	86,2	25	100,0	3,33	8,33
	Female	42	85,7	39	92,9	5,56	11,04
Cycle 5 Day 1	Male	25	86,2	25	100,0	4,00	9,95
	Female	40	81,6	39	97,5	3,85	8,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	4,35	12,53
	Female	38	77,6	37	97,4	4,95	9,51
Cycle 7 Day 1	Male	23	79,3	23	100,0	2,90	8,18
	Female	37	75,5	34	91,9	5,88	10,76
Cycle 8 Day 1	Male	21	72,4	19	90,5	4,39	9,37
	Female	35	71,4	33	94,3	2,53	8,46
Cycle 9 Day 1	Male	18	62,1	18	100,0	3,70	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	3,54	10,83
Cycle 10 Day 1	Male	18	62,1	18	100,0	2,78	8,57
	Female	33	67,3	32	97,0	5,21	9,87
Cycle 11 Day 1	Male	18	62,1	18	100,0	1,85	7,86
	Female	32	65,3	32	100,0	4,69	9,69
Cycle 12 Day 1	Male	17	58,6	17	100,0	2,94	12,13
	Female	32	65,3	28	87,5	5,95	10,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	1,96	5,54
	Female	29	59,2	28	96,6	3,57	10,50
Cycle 14 Day 1	Male	17	58,6	16	94,1	1,04	4,17
	Female	28	57,1	28	100,0	6,55	16,57
Cycle 15 Day 1	Male	16	55,2	16	100,0	1,04	4,17
	Female	28	57,1	28	100,0	3,57	8,31
Cycle 16 Day 1	Male	14	48,3	14	100,0	4,76	12,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	7,33	14,50
Cycle 17 Day 1	Male	12	41,4	12	100,0	2,78	6,49
	Female	27	55,1	27	100,0	6,79	21,31
Cycle 18 Day 1	Male	11	37,9	10	90,9	3,33	10,54
	Female	27	55,1	25	92,6	2,00	5,53
Cycle 19 Day 1	Male	10	34,5	10	100,0	3,33	10,54
	Female	26	53,1	23	88,5	5,07	11,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	0,00	0,00
	Female	26	53,1	23	88,5	3,62	8,64
Cycle 21 Day 1	Male	8	27,6	8	100,0	0,00	0,00
	Female	21	42,9	18	85,7	2,78	6,39
Cycle 22 Day 1	Male	8	27,6	6	75,0	0,00	0,00
	Female	21	42,9	19	90,5	5,26	12,49
Cycle 23 Day 1	Male	5	17,2	4	80,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	3,57	13,36
Cycle 24 Day 1	Male	5	17,2	4	80,0	0,00	0,00
	Female	15	30,6	14	93,3	3,57	9,65
Cycle 25 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	12	24,5	11	91,7	4,55	10,78
Cycle 26 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	11	22,4	10	90,9	3,33	7,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	8	16,3	6	75,0	8,33	13,94
Cycle 28 Day 1	Male	2	6,9	2	100,0	0,00	0,00
	Female	8	16,3	7	87,5	4,76	8,13
Cycle 29 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	8	16,3	6	75,0	5,56	8,61
Cycle 30 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	12,50	8,33
Cycle 31 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	8,33	9,62
Cycle 32 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	5	10,2	4	80,0	4,17	8,33
Cycle 33 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	1	2,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	11,11	13,61
	Female	21	42,9	13	61,9	17,95	27,61
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	12,37	15,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	15,48	25,71
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	18-64	59	95,2	53	89,8	6,29	10,95
	65-74	11	78,6	10	90,9	13,33	18,92
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 3 Day 1	18-64	56	90,3	52	92,9	6,09	12,80
	65-74	10	71,4	10	100,0	8,33	26,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 4 Day 1	18-64	55	88,7	53	96,4	5,03	10,63
	65-74	10	71,4	9	90,0	3,70	7,35
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 5 Day 1	18-64	53	85,5	52	98,1	3,85	9,11
	65-74	10	71,4	10	100,0	5,00	11,25
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	4,76	10,76
	65-74	10	71,4	9	90,0	5,56	11,79
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 7 Day 1	18-64	49	79,0	47	95,9	3,90	8,66
	65-74	9	64,3	8	88,9	8,33	15,43
	>=75	2	100,0	2	100,0	8,33	11,79
Cycle 8 Day 1	18-64	45	72,6	41	91,1	3,25	8,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	3,70	11,11
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 9 Day 1	18-64	40	64,5	40	100,0	3,75	13,34
	65-74	9	64,3	9	100,0	3,70	11,11
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 10 Day 1	18-64	40	64,5	39	97,5	4,70	9,33
	65-74	9	64,3	9	100,0	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 11 Day 1	18-64	39	62,9	39	100,0	3,42	8,70
	65-74	9	64,3	9	100,0	5,56	11,79
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 12 Day 1	18-64	38	61,3	35	92,1	5,24	11,27
	65-74	9	64,3	8	88,9	4,17	11,79
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	2,45	5,99
	65-74	9	64,3	9	100,0	5,56	16,67
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 14 Day 1	18-64	35	56,5	35	100,0	3,81	10,76
	65-74	9	64,3	8	88,9	8,33	23,57
	>=75	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	2,38	5,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	4,17	11,79
	>=75	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	6,77	13,95
	65-74	7	50,0	6	85,7	5,56	13,61
	>=75	1	50,0	1	100,0	0,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	6,25	19,74
	65-74	6	42,9	6	100,0	2,78	6,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	2,87	7,80
	65-74	6	42,9	5	83,3	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	4,17	10,76
	65-74	5	35,7	4	80,0	8,33	16,67
	>=75	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	1,92	5,43
	65-74	5	35,7	5	100,0	6,67	14,91
	>=75	1	50,0	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	2,38	5,98
	65-74	4	28,6	4	100,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	5,00	12,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	5,21	14,55
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	3,13	9,07
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	22,6	12	85,7	4,17	10,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	2,78	6,49
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	6,25	12,40
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	3,70	7,35
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	4,76	8,13
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	10,00	9,13
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	6,67	9,13
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	4,17	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	0,00	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	16,67	22,94
	65-74	10	71,4	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	0,00	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	15,24	20,36
	Other	43	100,0	43	100,0	10,47	15,44
Cycle 2 Day 1	White	33	94,3	29	87,9	9,20	13,79
	Other	39	90,7	36	92,3	6,48	12,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	7,41	18,10
	Other	37	86,0	37	100,0	5,41	13,06
Cycle 4 Day 1	White	31	88,6	28	90,3	4,76	10,00
	Other	36	83,7	36	100,0	4,63	10,24
Cycle 5 Day 1	White	31	88,6	30	96,8	5,00	9,93
	Other	34	79,1	34	100,0	2,94	8,68
Cycle 6 Day 1	White	30	85,7	28	93,3	6,55	13,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	3,13	7,85
Cycle 7 Day 1	White	29	82,9	27	93,1	4,94	10,14
	Other	31	72,1	30	96,8	4,44	9,72
Cycle 8 Day 1	White	28	80,0	24	85,7	4,17	10,13
	Other	28	65,1	28	100,0	2,38	7,47
Cycle 9 Day 1	White	26	74,3	26	100,0	7,05	17,11
	Other	25	58,1	25	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	6,00	11,67
	Other	25	58,1	25	100,0	2,67	6,24
Cycle 11 Day 1	White	26	74,3	26	100,0	5,13	11,32
	Other	24	55,8	24	100,0	2,08	5,63
Cycle 12 Day 1	White	26	74,3	22	84,6	8,33	14,32
	Other	23	53,5	23	100,0	1,45	4,80
Cycle 13 Day 1	White	24	68,6	23	95,8	3,62	11,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	2,27	5,85
Cycle 14 Day 1	White	24	68,6	24	100,0	5,56	16,79
	Other	21	48,8	20	95,2	3,33	8,72
Cycle 15 Day 1	White	24	68,6	24	100,0	2,78	8,03
	Other	20	46,5	20	100,0	2,50	6,11
Cycle 16 Day 1	White	22	62,9	20	90,9	10,00	16,58
	Other	19	44,2	19	100,0	2,63	8,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	7,58	23,42
	Other	17	39,5	17	100,0	2,94	6,55
Cycle 18 Day 1	White	21	60,0	18	85,7	0,93	3,93
	Other	17	39,5	17	100,0	3,92	9,37
Cycle 19 Day 1	White	20	57,1	20	100,0	6,67	13,68
	Other	16	37,2	13	81,3	1,28	4,62
Cycle 20 Day 1	White	20	57,1	17	85,0	0,98	4,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	4,44	9,89
Cycle 21 Day 1	White	16	45,7	14	87,5	2,38	6,05
	Other	13	30,2	12	92,3	1,39	4,81
Cycle 22 Day 1	White	16	45,7	13	81,3	6,41	14,50
	Other	13	30,2	12	92,3	1,39	4,81
Cycle 23 Day 1	White	12	34,3	10	83,3	5,00	15,81
	Other	9	20,9	8	88,9	4,17	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	5,00	11,25
	Other	9	20,9	8	88,9	0,00	0,00
Cycle 25 Day 1	White	10	28,6	8	80,0	4,17	11,79
	Other	5	11,6	5	100,0	3,33	7,45
Cycle 26 Day 1	White	10	28,6	8	80,0	2,08	5,89
	Other	4	9,3	4	100,0	4,17	8,33
Cycle 27 Day 1	White	8	22,9	5	62,5	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	5,56	9,62
Cycle 28 Day 1	White	7	20,0	6	85,7	0,00	0,00
	Other	3	7,0	3	100,0	11,11	9,62
Cycle 29 Day 1	White	6	17,1	4	66,7	0,00	0,00
	Other	3	7,0	3	100,0	11,11	9,62
Cycle 30 Day 1	White	4	11,4	2	50,0	8,33	11,79
	Other	3	7,0	3	100,0	11,11	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	0,00	0,00
	Other	3	7,0	3	100,0	11,11	9,62
Cycle 32 Day 1	White	4	11,4	3	75,0	0,00	0,00
	Other	2	4,7	2	100,0	8,33	11,79
Cycle 33 Day 1	White	2	5,7	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	18,06	25,08
	Other	24	55,8	16	66,7	11,46	17,97
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	9,09	16,85
	Europe (EU)	17	100,0	17	100,0	7,84	10,40
	Asia (AS)	39	100,0	39	100,0	16,67	20,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	6,86	11,87
	Europe (EU)	16	94,1	13	81,3	8,97	14,62
	Asia (AS)	36	92,3	35	97,2	7,62	13,00
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	4,39	10,89
	Europe (EU)	15	88,2	12	80,0	9,72	24,06
	Asia (AS)	33	84,6	33	100,0	6,06	13,70
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	6,67	11,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	1,39	4,81
	Asia (AS)	32	82,1	32	100,0	4,69	10,57
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	4,17	7,40
	Europe (EU)	15	88,2	14	93,3	5,95	12,42
	Asia (AS)	30	76,9	30	100,0	2,78	8,84
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	5,00	9,52
	Europe (EU)	14	82,4	13	92,9	8,97	16,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	2,47	7,60
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	2,78	6,39
	Europe (EU)	14	82,4	13	92,9	7,69	12,94
	Asia (AS)	27	69,2	26	96,3	4,49	10,06
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	1,96	8,08
	Europe (EU)	14	82,4	11	78,6	4,55	10,78
	Asia (AS)	24	61,5	24	100,0	3,47	8,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	3,70	12,20
	Europe (EU)	12	70,6	12	100,0	8,33	20,72
	Asia (AS)	21	53,8	21	100,0	0,79	3,64
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	4,90	9,80
	Europe (EU)	12	70,6	12	100,0	6,94	13,22
	Asia (AS)	21	53,8	21	100,0	2,38	5,98
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	3,70	9,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	6,94	13,22
	Asia (AS)	20	51,3	20	100,0	1,67	5,13
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	4,90	9,80
	Europe (EU)	12	70,6	9	75,0	11,11	18,63
	Asia (AS)	19	48,7	19	100,0	1,75	5,26
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	0,00	0,00
	Europe (EU)	11	64,7	10	90,9	8,33	16,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	2,78	6,39
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	2,94	12,13
	Europe (EU)	11	64,7	11	100,0	7,58	20,23
	Asia (AS)	17	43,6	16	94,1	4,17	9,62
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	1,96	5,54
	Europe (EU)	11	64,7	11	100,0	4,55	10,78
	Asia (AS)	16	41,0	16	100,0	2,08	5,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	3,57	9,65
	Europe (EU)	11	64,7	9	81,8	9,26	14,70
	Asia (AS)	16	41,0	16	100,0	7,29	16,07
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	10,71	28,95
	Europe (EU)	10	58,8	10	100,0	1,67	5,27
	Asia (AS)	15	38,5	15	100,0	3,33	6,90
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	0,00	0,00
	Asia (AS)	15	38,5	15	100,0	5,56	10,29
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	6,41	12,80
	Europe (EU)	9	52,9	9	100,0	7,41	14,70
	Asia (AS)	14	35,9	11	78,6	0,00	0,00
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	1,28	4,62
	Europe (EU)	9	52,9	6	66,7	2,78	6,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	3,85	9,99
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	1,67	5,27
	Europe (EU)	7	41,2	6	85,7	2,78	6,80
	Asia (AS)	11	28,2	10	90,9	1,67	5,27
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	6,67	16,10
	Europe (EU)	7	41,2	5	71,4	3,33	7,45
	Asia (AS)	11	28,2	10	90,9	1,67	5,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	5,56	16,67
	Europe (EU)	5	29,4	3	60,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	5,56	13,61
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	4,17	11,79
	Europe (EU)	5	29,4	4	80,0	4,17	8,33
	Asia (AS)	7	17,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	7,14	13,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	0,00	0,00
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	2,78	6,80
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	4,17	8,33
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	0,00	0,00
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	12,50	15,96
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	0,00	0,00
	Europe (EU)	2	11,8	1	50,0	0,00	-
	Asia (AS)	4	10,3	4	100,0	8,33	9,62
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	0,00	0,00
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	8,33	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	8,33	11,79
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	11,11	9,62
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	11,11	9,62
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	0,00	-
	Asia (AS)	3	7,7	2	66,7	8,33	11,79
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	0,00	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	12,12	25,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	16,67	13,61
	Asia (AS)	21	53,8	13	61,9	15,38	19,79
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	10,56	16,66
	1	38	100,0	38	100,0	14,04	18,79
	2	10	100,0	10	100,0	13,33	18,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	27	90,0	6,79	13,28
	1	36	94,7	32	88,9	8,33	12,70
	2	6	60,0	6	100,0	8,33	13,94
Cycle 3 Day 1	0	29	96,7	27	93,1	6,79	18,06
	1	34	89,5	32	94,1	3,65	8,18
	2	5	50,0	5	100,0	20,00	27,39
Cycle 4 Day 1	0	29	96,7	28	96,6	4,17	8,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	3,65	9,21
	2	5	50,0	4	80,0	16,67	19,25
Cycle 5 Day 1	0	29	96,7	29	100,0	4,02	8,52
	1	33	86,8	32	97,0	3,13	8,92
	2	3	30,0	3	100,0	11,11	19,25
Cycle 6 Day 1	0	29	96,7	29	100,0	5,75	12,81
	1	31	81,6	28	90,3	2,98	7,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	11,11	9,62
Cycle 7 Day 1	0	29	96,7	28	96,6	4,76	10,98
	1	28	73,7	26	92,9	3,85	8,57
	2	3	30,0	3	100,0	11,11	9,62
Cycle 8 Day 1	0	28	93,3	26	92,9	2,56	7,73
	1	25	65,8	23	92,0	4,35	10,32
	2	3	30,0	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	5,77	16,96
	1	23	60,5	23	100,0	1,45	4,80
	2	2	20,0	2	100,0	0,00	0,00
Cycle 10 Day 1	0	26	86,7	26	100,0	5,13	11,32
	1	23	60,5	22	95,7	3,03	6,58
	2	2	20,0	2	100,0	8,33	11,79
Cycle 11 Day 1	0	26	86,7	26	100,0	5,77	11,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	1,52	4,90
	2	2	20,0	2	100,0	0,00	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	6,82	14,23
	1	22	57,9	21	95,5	2,38	5,98
	2	2	20,0	2	100,0	8,33	11,79
Cycle 13 Day 1	0	25	83,3	24	96,0	3,47	10,97
	1	20	52,6	20	100,0	2,50	6,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	6,25	16,89
	1	19	50,0	19	100,0	2,63	8,36
	2	1	10,0	1	100,0	0,00	-
Cycle 15 Day 1	0	24	80,0	24	100,0	2,78	8,03
	1	19	50,0	19	100,0	2,63	6,24
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	7,50	13,76
	1	18	47,4	18	100,0	5,56	14,00
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	8,73	23,93
	1	17	44,7	17	100,0	1,96	5,54
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	0,93	3,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	4,17	9,62
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	6,14	12,68
	1	15	39,5	13	86,7	2,56	9,25
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	4,90	9,80
	1	15	39,5	14	93,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	2,38	6,05
	1	13	34,2	11	84,6	1,52	5,03
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	6,94	15,01
	1	13	34,2	12	92,3	1,39	4,81
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	5,56	16,67
	1	9	23,7	8	88,9	4,17	11,79
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	5,56	11,79
	1	9	23,7	8	88,9	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	2,38	6,30
Cycle 26 Day 1	0	8	26,7	6	75,0	2,78	6,80
	1	6	15,8	6	100,0	2,78	6,80
Cycle 27 Day 1	0	6	20,0	3	50,0	11,11	19,25
	1	5	13,2	5	100,0	3,33	7,45
Cycle 28 Day 1	0	5	16,7	4	80,0	0,00	0,00
	1	5	13,2	5	100,0	6,67	9,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	0,00	0,00
	1	5	13,2	5	100,0	6,67	9,13
Cycle 30 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	12,50	8,33
Cycle 31 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	8,33	9,62
Cycle 32 Day 1	0	3	10,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	5,56	9,62
Cycle 33 Day 1	0	2	6,7	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	11,90	23,96
	1	20	52,6	12	60,0	12,50	16,09
	2	4	40,0	2	50,0	41,67	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	6,45	14,71
	1	3	100,0	3	100,0	5,56	9,62
	2 or More	44	100,0	44	100,0	17,42	19,00
Cycle 2 Day 1	None	30	96,8	27	90,0	4,32	8,76
	1	2	66,7	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	10,36	14,88
Cycle 3 Day 1	None	30	96,8	28	93,3	2,38	7,47
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	35	97,2	9,52	19,08
Cycle 4 Day 1	None	30	96,8	29	96,7	3,45	9,32
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	35	79,5	33	94,3	6,06	10,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	2,22	7,24
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	33	75,0	32	97,0	5,73	10,88
Cycle 6 Day 1	None	29	93,5	28	96,6	2,98	6,50
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	32	72,7	30	93,8	6,67	13,56
Cycle 7 Day 1	None	27	87,1	26	96,3	3,21	6,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	31	70,5	29	93,5	6,32	12,13
Cycle 8 Day 1	None	26	83,9	25	96,2	2,67	9,23
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	3,70	8,44
Cycle 9 Day 1	None	25	80,6	25	100,0	0,00	0,00
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	7,33	17,40
Cycle 10 Day 1	None	25	80,6	24	96,0	2,08	5,63
	1	1	33,3	1	100,0	0,00	-
	2 or More	25	56,8	25	100,0	6,67	11,79
Cycle 11 Day 1	None	25	80,6	25	100,0	2,00	5,53
	1	1	33,3	1	100,0	0,00	-
	2 or More	24	54,5	24	100,0	5,56	11,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	2,08	5,63
	1	1	33,3	1	100,0	0,00	-
	2 or More	23	52,3	20	87,0	8,33	14,81
Cycle 13 Day 1	None	24	77,4	23	95,8	1,45	4,80
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	4,76	11,95
Cycle 14 Day 1	None	23	74,2	23	100,0	0,72	3,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	20	95,2	9,17	19,10
Cycle 15 Day 1	None	23	74,2	23	100,0	2,17	5,74
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	20	100,0	3,33	8,72
Cycle 16 Day 1	None	20	64,5	19	95,0	4,39	10,89
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	8,77	16,07
Cycle 17 Day 1	None	19	61,3	19	100,0	0,00	0,00
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	19	100,0	11,40	24,88
Cycle 18 Day 1	None	18	58,1	17	94,4	2,94	8,81
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	17	89,5	1,96	5,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	2,94	8,81
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	6,67	13,80
Cycle 20 Day 1	None	17	54,8	16	94,1	3,13	6,72
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	2,22	8,61
Cycle 21 Day 1	None	15	48,4	13	86,7	1,28	4,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	2,56	6,26
Cycle 22 Day 1	None	15	48,4	13	86,7	1,28	4,62
	2 or More	14	31,8	12	85,7	6,94	15,01
Cycle 23 Day 1	None	10	32,3	9	90,0	0,00	0,00
	2 or More	11	25,0	9	81,8	9,26	18,84
Cycle 24 Day 1	None	10	32,3	10	100,0	0,00	0,00
	2 or More	10	22,7	8	80,0	6,25	12,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	2,08	5,89
	2 or More	6	13,6	5	83,3	6,67	14,91
Cycle 26 Day 1	None	8	25,8	8	100,0	2,08	5,89
	2 or More	6	13,6	4	66,7	4,17	8,33
Cycle 27 Day 1	None	7	22,6	6	85,7	5,56	13,61
	2 or More	4	9,1	2	50,0	8,33	11,79
Cycle 28 Day 1	None	7	22,6	7	100,0	2,38	6,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	8,33	11,79
Cycle 29 Day 1	None	6	19,4	5	83,3	3,33	7,45
	2 or More	3	6,8	2	66,7	8,33	11,79
Cycle 30 Day 1	None	4	12,9	3	75,0	11,11	9,62
	2 or More	3	6,8	2	66,7	8,33	11,79
Cycle 31 Day 1	None	4	12,9	3	75,0	5,56	9,62
	2 or More	3	6,8	2	66,7	8,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	5,56	9,62
	2 or More	2	4,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	3,2	1	100,0	0,00	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	9,72	13,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	0,00	-
	2 or More	24	54,5	15	62,5	18,89	25,87
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	6,45	14,71
	Previously Treated	47	100,0	47	100,0	16,67	18,71
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	4,32	8,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	10,09	14,78
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	2,38	7,47
	Previously Treated	38	80,9	36	94,7	9,26	18,87
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	3,45	9,32
	Previously Treated	37	78,7	35	94,6	5,71	10,65
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	2,22	7,24
	Previously Treated	35	74,5	34	97,1	5,39	10,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	2,98	6,50
	Previously Treated	34	72,3	32	94,1	6,25	13,22
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	3,21	6,70
	Previously Treated	33	70,2	31	93,9	5,91	11,82
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	2,67	9,23
	Previously Treated	30	63,8	27	90,0	3,70	8,44
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	7,05	17,11
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	2,08	5,63
	Previously Treated	26	55,3	26	100,0	6,41	11,62
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	2,00	5,53
	Previously Treated	25	53,2	25	100,0	5,33	11,51
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	2,08	5,63
	Previously Treated	24	51,1	21	87,5	7,94	14,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	1,45	4,80
	Previously Treated	22	46,8	22	100,0	4,55	11,71
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	0,72	3,48
	Previously Treated	22	46,8	21	95,5	8,73	18,72
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	2,17	5,74
	Previously Treated	21	44,7	21	100,0	3,17	8,53
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	4,39	10,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	8,33	15,77
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	0,00	0,00
	Previously Treated	20	42,6	20	100,0	10,83	24,35
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	2,94	8,81
	Previously Treated	20	42,6	18	90,0	1,85	5,39
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	2,94	8,81
	Previously Treated	19	40,4	16	84,2	6,25	13,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	3,13	6,72
	Previously Treated	19	40,4	16	84,2	2,08	8,33
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	1,28	4,62
	Previously Treated	14	29,8	13	92,9	2,56	6,26
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	1,28	4,62
	Previously Treated	14	29,8	12	85,7	6,94	15,01
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	9,26	18,84
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	0,00	0,00
	Previously Treated	10	21,3	8	80,0	6,25	12,40
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	2,08	5,89
	Previously Treated	6	12,8	5	83,3	6,67	14,91
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	2,08	5,89
	Previously Treated	6	12,8	4	66,7	4,17	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	5,56	13,61
	Previously Treated	4	8,5	2	50,0	8,33	11,79
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	2,38	6,30
	Previously Treated	3	6,4	2	66,7	8,33	11,79
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	3,33	7,45
	Previously Treated	3	6,4	2	66,7	8,33	11,79
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	11,11	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	8,33	11,79
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	5,56	9,62
	Previously Treated	3	6,4	2	66,7	8,33	11,79
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	5,56	9,62
	Previously Treated	2	4,3	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	0,00	-
	Previously Treated	1	2,1	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	9,72	13,22
	Previously Treated	26	55,3	16	61,5	17,71	25,44
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	15,71	18,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	10,08	17,50
Cycle 2 Day 1	Local	32	91,4	30	93,8	7,78	12,93
	Central	40	93,0	35	87,5	7,62	13,00
Cycle 3 Day 1	Local	29	82,9	28	96,6	8,33	20,54
	Central	39	90,7	36	92,3	4,63	9,44
Cycle 4 Day 1	Local	28	80,0	27	96,4	4,94	11,15
	Central	39	90,7	37	94,9	4,50	9,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	3,09	8,06
	Central	38	88,4	37	97,4	4,50	10,13
Cycle 6 Day 1	Local	27	77,1	27	100,0	3,70	9,62
	Central	36	83,7	33	91,7	5,56	11,54
Cycle 7 Day 1	Local	27	77,1	27	100,0	3,09	8,06
	Central	33	76,7	30	90,9	6,11	11,14
Cycle 8 Day 1	Local	26	74,3	26	100,0	3,21	9,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	3,21	8,19
Cycle 9 Day 1	Local	25	71,4	25	100,0	4,00	12,06
	Central	26	60,5	26	100,0	3,21	13,35
Cycle 10 Day 1	Local	25	71,4	24	96,0	5,56	10,62
	Central	26	60,5	26	100,0	3,21	8,19
Cycle 11 Day 1	Local	24	68,6	24	100,0	4,17	10,13
	Central	26	60,5	26	100,0	3,21	8,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	4,55	10,52
	Central	26	60,5	23	88,5	5,07	11,72
Cycle 13 Day 1	Local	22	62,9	22	100,0	4,55	11,71
	Central	24	55,8	23	95,8	1,45	4,80
Cycle 14 Day 1	Local	22	62,9	22	100,0	6,82	18,30
	Central	23	53,5	22	95,7	2,27	5,85
Cycle 15 Day 1	Local	22	62,9	22	100,0	4,55	9,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	0,76	3,55
Cycle 16 Day 1	Local	20	57,1	20	100,0	4,17	10,64
	Central	21	48,8	19	90,5	8,77	16,07
Cycle 17 Day 1	Local	20	57,1	20	100,0	4,17	11,94
	Central	19	44,2	19	100,0	7,02	23,12
Cycle 18 Day 1	Local	20	57,1	19	95,0	0,00	0,00
	Central	18	41,9	16	88,9	5,21	10,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	6,86	13,25
	Central	17	39,5	16	94,1	2,08	8,33
Cycle 20 Day 1	Local	19	54,3	17	89,5	0,98	4,04
	Central	17	39,5	15	88,2	4,44	9,89
Cycle 21 Day 1	Local	14	40,0	12	85,7	1,39	4,81
	Central	15	34,9	14	93,3	2,38	6,05
Cycle 22 Day 1	Local	14	40,0	12	85,7	1,39	4,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	6,41	14,50
Cycle 23 Day 1	Local	11	31,4	10	90,9	3,33	10,54
	Central	10	23,3	8	80,0	6,25	17,68
Cycle 24 Day 1	Local	11	31,4	10	90,9	3,33	10,54
	Central	9	20,9	8	88,9	2,08	5,89
Cycle 25 Day 1	Local	7	20,0	7	100,0	7,14	13,11
	Central	8	18,6	6	75,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	5,56	8,61
	Central	8	18,6	6	75,0	0,00	0,00
Cycle 27 Day 1	Local	4	11,4	4	100,0	0,00	0,00
	Central	7	16,3	4	57,1	12,50	15,96
Cycle 28 Day 1	Local	4	11,4	4	100,0	4,17	8,33
	Central	6	14,0	5	83,3	3,33	7,45
Cycle 29 Day 1	Local	3	8,6	3	100,0	5,56	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	4,17	8,33
Cycle 30 Day 1	Local	3	8,6	3	100,0	11,11	9,62
	Central	4	9,3	2	50,0	8,33	11,79
Cycle 31 Day 1	Local	3	8,6	3	100,0	5,56	9,62
	Central	4	9,3	2	50,0	8,33	11,79
Cycle 32 Day 1	Local	3	8,6	3	100,0	5,56	9,62
	Central	3	7,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	0,00	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	14,29	20,52
	Central	21	48,8	14	66,7	14,29	22,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	12,84	17,99
	No	4	100,0	4	100,0	8,33	16,67
Cycle 2 Day 1	Yes	70	94,6	63	90,0	7,14	11,87
	No	2	50,0	2	100,0	25,00	35,36
Cycle 3 Day 1	Yes	66	89,2	62	93,9	6,45	15,49
	No	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	4,57	10,09
	No	2	50,0	2	100,0	8,33	11,79
Cycle 5 Day 1	Yes	63	85,1	62	98,4	4,03	9,39
	No	2	50,0	2	100,0	0,00	0,00
Cycle 6 Day 1	Yes	61	82,4	58	95,1	4,89	10,82
	No	2	50,0	2	100,0	0,00	0,00
Cycle 7 Day 1	Yes	58	78,4	55	94,8	4,24	9,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 8 Day 1	Yes	54	73,0	50	92,6	3,33	8,91
	No	2	50,0	2	100,0	0,00	0,00
Cycle 9 Day 1	Yes	49	66,2	49	100,0	3,74	12,85
	No	2	50,0	2	100,0	0,00	0,00
Cycle 10 Day 1	Yes	49	66,2	48	98,0	4,51	9,56
	No	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	3,47	9,07
	No	2	50,0	2	100,0	8,33	11,79
Cycle 12 Day 1	Yes	47	63,5	43	91,5	5,04	11,23
	No	2	50,0	2	100,0	0,00	0,00
Cycle 13 Day 1	Yes	44	59,5	43	97,7	2,71	8,86
	No	2	50,0	2	100,0	8,33	11,79
Cycle 14 Day 1	Yes	43	58,1	42	97,7	4,76	13,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 15 Day 1	Yes	42	56,8	42	100,0	2,38	6,96
	No	2	50,0	2	100,0	8,33	11,79
Cycle 16 Day 1	Yes	39	52,7	37	94,9	6,76	13,87
	No	2	50,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	37	50,0	37	100,0	5,41	18,45
	No	2	50,0	2	100,0	8,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	2,53	7,36
	No	2	50,0	2	100,0	0,00	0,00
Cycle 19 Day 1	Yes	34	45,9	32	94,1	4,69	11,39
	No	2	50,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	1,67	5,09
	No	2	50,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	36,5	24	88,9	2,08	5,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 22 Day 1	Yes	27	36,5	23	85,2	4,35	11,48
	No	2	50,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	4,90	14,15
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	2,94	8,81
	No	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	4,17	10,36
	No	1	25,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	1,52	5,03
	No	1	25,0	1	100,0	16,67	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	7,14	13,11
	No	1	25,0	1	100,0	0,00	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	2,08	5,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	16,67	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	2,78	6,80
	No	1	25,0	1	100,0	16,67	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	8,33	9,62
	No	1	25,0	1	100,0	16,67	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	4,17	8,33
	No	1	25,0	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	0,00	0,00
	No	1	25,0	1	100,0	16,67	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	14,29	21,14
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	16,67	15,43
	No	70	100,0	70	100,0	12,14	18,15
Cycle 2 Day 1	Yes	5	62,5	5	100,0	6,67	9,13
	No	67	95,7	60	89,6	7,78	13,19
Cycle 3 Day 1	Yes	5	62,5	5	100,0	3,33	7,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	6,50	15,79
Cycle 4 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	62	88,6	59	95,2	5,08	10,38
Cycle 5 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	60	85,7	59	98,3	4,24	9,59
Cycle 6 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	58	82,9	55	94,8	5,15	11,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	55	78,6	52	94,5	5,13	10,19
Cycle 8 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	51	72,9	47	92,2	2,84	8,02
Cycle 9 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	47	67,1	47	100,0	3,90	13,10
Cycle 10 Day 1	Yes	4	50,0	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	4,71	9,73
Cycle 11 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	46	65,7	46	100,0	3,99	9,42
Cycle 12 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	45	64,3	41	91,1	5,28	11,45
Cycle 13 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	42	60,0	41	97,6	3,25	9,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	41	58,6	40	97,6	5,00	14,22
Cycle 15 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	40	57,1	40	100,0	2,92	7,44
Cycle 16 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	38	54,3	36	94,7	6,02	13,31
Cycle 17 Day 1	Yes	3	37,5	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	6,02	18,75
Cycle 18 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	35	50,0	32	91,4	2,60	7,46
Cycle 19 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	30	90,9	5,00	11,70
Cycle 20 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	29	87,9	2,87	7,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	24	88,9	2,08	5,63
Cycle 22 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	23	85,2	4,35	11,48
Cycle 23 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	19	27,1	16	84,2	5,21	14,55
Cycle 24 Day 1	Yes	2	25,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	3,13	9,07
Cycle 25 Day 1	Yes	2	25,0	2	100,0	8,33	11,79
	No	13	18,6	11	84,6	3,03	10,05
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	3,03	6,74
Cycle 27 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	10	14,3	7	70,0	2,38	6,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	9	12,9	8	88,9	4,17	7,72
Cycle 29 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	8	11,4	6	75,0	5,56	8,61
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	10,00	9,13
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	6,67	9,13
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	3,33	7,45
Cycle 33 Day 1	No	2	2,9	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	8,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	14,74	21,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30NV_SG.xls
28NOV2019 10:39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	32,48	27,90
Cycle 2 Day 1	All	72	92,3	65	90,3	18,21	22,38
Cycle 3 Day 1	All	68	87,2	64	94,1	15,63	18,52
Cycle 4 Day 1	All	67	85,9	64	95,5	14,58	21,10
Cycle 5 Day 1	All	65	83,3	64	98,5	13,80	21,53
Cycle 6 Day 1	All	63	80,8	60	95,2	13,06	16,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	15,20	17,90
Cycle 8 Day 1	All	56	71,8	52	92,9	13,46	20,09
Cycle 9 Day 1	All	51	65,4	51	100,0	16,01	23,32
Cycle 10 Day 1	All	51	65,4	50	98,0	14,33	18,45
Cycle 11 Day 1	All	50	64,1	50	100,0	13,00	16,60
Cycle 12 Day 1	All	49	62,8	45	91,8	15,19	21,27
Cycle 13 Day 1	All	46	59,0	45	97,8	16,67	22,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	16,67	23,84
Cycle 15 Day 1	All	44	56,4	44	100,0	17,05	22,01
Cycle 16 Day 1	All	41	52,6	39	95,1	20,51	22,77
Cycle 17 Day 1	All	39	50,0	39	100,0	18,38	21,90
Cycle 18 Day 1	All	38	48,7	35	92,1	15,24	21,53
Cycle 19 Day 1	All	36	46,2	33	91,7	17,68	22,41
Cycle 20 Day 1	All	36	46,2	32	88,9	20,31	23,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	21,79	23,93
Cycle 22 Day 1	All	29	37,2	25	86,2	20,67	24,66
Cycle 23 Day 1	All	21	26,9	18	85,7	23,15	28,09
Cycle 24 Day 1	All	20	25,6	18	90,0	18,52	21,30
Cycle 25 Day 1	All	15	19,2	13	86,7	19,23	14,98
Cycle 26 Day 1	All	14	17,9	12	85,7	20,83	28,54
Cycle 27 Day 1	All	11	14,1	8	72,7	29,17	33,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	29,63	21,70
Cycle 29 Day 1	All	9	11,5	7	77,8	23,81	23,29
Cycle 30 Day 1	All	7	9,0	5	71,4	23,33	14,91
Cycle 31 Day 1	All	7	9,0	5	71,4	16,67	11,79
Cycle 32 Day 1	All	6	7,7	5	83,3	20,00	7,45
Cycle 33 Day 1	All	2	2,6	2	100,0	8,33	11,79
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	27,98	27,61
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	32,18	29,19
	Female	49	100,0	49	100,0	32,65	27,42
Cycle 2 Day 1	Male	27	93,1	25	92,6	22,67	23,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	15,42	21,48
Cycle 3 Day 1	Male	25	86,2	23	92,0	11,59	13,70
	Female	43	87,8	41	95,3	17,89	20,54
Cycle 4 Day 1	Male	25	86,2	25	100,0	14,00	21,88
	Female	42	85,7	39	92,9	14,96	20,87
Cycle 5 Day 1	Male	25	86,2	25	100,0	15,33	24,02
	Female	40	81,6	39	97,5	12,82	20,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	13,04	16,63
	Female	38	77,6	37	97,4	13,06	16,73
Cycle 7 Day 1	Male	23	79,3	23	100,0	16,67	20,10
	Female	37	75,5	34	91,9	14,22	16,48
Cycle 8 Day 1	Male	21	72,4	19	90,5	19,30	23,08
	Female	35	71,4	33	94,3	10,10	17,65
Cycle 9 Day 1	Male	18	62,1	18	100,0	13,89	21,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	17,17	24,47
Cycle 10 Day 1	Male	18	62,1	18	100,0	11,11	15,12
	Female	33	67,3	32	97,0	16,15	20,07
Cycle 11 Day 1	Male	18	62,1	18	100,0	14,81	17,04
	Female	32	65,3	32	100,0	11,98	16,52
Cycle 12 Day 1	Male	17	58,6	17	100,0	12,75	17,21
	Female	32	65,3	28	87,5	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	14,71	14,29
	Female	29	59,2	28	96,6	17,86	26,81
Cycle 14 Day 1	Male	17	58,6	16	94,1	11,46	18,97
	Female	28	57,1	28	100,0	19,64	26,08
Cycle 15 Day 1	Male	16	55,2	16	100,0	12,50	15,52
	Female	28	57,1	28	100,0	19,64	24,87
Cycle 16 Day 1	Male	14	48,3	14	100,0	20,24	24,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	20,67	22,19
Cycle 17 Day 1	Male	12	41,4	12	100,0	22,22	20,52
	Female	27	55,1	27	100,0	16,67	22,65
Cycle 18 Day 1	Male	11	37,9	10	90,9	15,00	22,84
	Female	27	55,1	25	92,6	15,33	21,47
Cycle 19 Day 1	Male	10	34,5	10	100,0	21,67	26,12
	Female	26	53,1	23	88,5	15,94	21,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	22,22	25,00
	Female	26	53,1	23	88,5	19,57	22,84
Cycle 21 Day 1	Male	8	27,6	8	100,0	25,00	21,82
	Female	21	42,9	18	85,7	20,37	25,28
Cycle 22 Day 1	Male	8	27,6	6	75,0	25,00	20,41
	Female	21	42,9	19	90,5	19,30	26,21
Cycle 23 Day 1	Male	5	17,2	4	80,0	12,50	25,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	26,19	29,03
Cycle 24 Day 1	Male	5	17,2	4	80,0	12,50	15,96
	Female	15	30,6	14	93,3	20,24	22,81
Cycle 25 Day 1	Male	3	10,3	2	66,7	8,33	11,79
	Female	12	24,5	11	91,7	21,21	15,08
Cycle 26 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	11	22,4	10	90,9	25,00	29,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	8,33	11,79
	Female	8	16,3	6	75,0	36,11	35,62
Cycle 28 Day 1	Male	2	6,9	2	100,0	8,33	11,79
	Female	8	16,3	7	87,5	35,71	20,25
Cycle 29 Day 1	Male	1	3,4	1	100,0	16,67	-
	Female	8	16,3	6	75,0	25,00	25,28
Cycle 30 Day 1	Male	1	3,4	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	25,00	16,67
Cycle 31 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	20,83	8,33
Cycle 32 Day 1	Male	1	3,4	1	100,0	16,67	-
	Female	5	10,2	4	80,0	20,83	8,33
Cycle 33 Day 1	Male	1	3,4	1	100,0	16,67	-
	Female	1	2,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	26,67	30,08
	Female	21	42,9	13	61,9	29,49	25,60
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	34,95	27,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	25,00	27,54
	>=75	2	100,0	2	100,0	8,33	11,79
Cycle 2 Day 1	18-64	59	95,2	53	89,8	18,87	21,94
	65-74	11	78,6	10	90,9	16,67	27,22
	>=75	2	100,0	2	100,0	8,33	11,79
Cycle 3 Day 1	18-64	56	90,3	52	92,9	15,71	18,20
	65-74	10	71,4	10	100,0	11,67	20,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	33,33	0,00
Cycle 4 Day 1	18-64	55	88,7	53	96,4	15,41	22,37
	65-74	10	71,4	9	90,0	9,26	12,11
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 5 Day 1	18-64	53	85,5	52	98,1	14,10	22,48
	65-74	10	71,4	10	100,0	10,00	14,05
	>=75	2	100,0	2	100,0	25,00	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	12,59	17,19
	65-74	10	71,4	9	90,0	11,11	11,79
	>=75	2	100,0	2	100,0	33,33	0,00
Cycle 7 Day 1	18-64	49	79,0	47	95,9	15,60	18,52
	65-74	9	64,3	8	88,9	10,42	15,27
	>=75	2	100,0	2	100,0	25,00	11,79
Cycle 8 Day 1	18-64	45	72,6	41	91,1	12,60	20,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	16,67	18,63
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 9 Day 1	18-64	40	64,5	40	100,0	14,17	19,81
	65-74	9	64,3	9	100,0	20,37	33,10
	>=75	2	100,0	2	100,0	33,33	47,14
Cycle 10 Day 1	18-64	40	64,5	39	97,5	14,10	16,46
	65-74	9	64,3	9	100,0	14,81	28,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	16,67	0,00
Cycle 11 Day 1	18-64	39	62,9	39	100,0	11,11	14,97
	65-74	9	64,3	9	100,0	16,67	22,05
	>=75	2	100,0	2	100,0	33,33	0,00
Cycle 12 Day 1	18-64	38	61,3	35	92,1	14,29	21,06
	65-74	9	64,3	8	88,9	16,67	25,20
	>=75	2	100,0	2	100,0	25,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	14,22	20,16
	65-74	9	64,3	9	100,0	22,22	31,18
	>=75	2	100,0	2	100,0	33,33	23,57
Cycle 14 Day 1	18-64	35	56,5	35	100,0	14,76	20,12
	65-74	9	64,3	8	88,9	18,75	33,85
	>=75	1	50,0	1	100,0	66,67	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	16,19	20,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	16,67	29,55
	>=75	1	50,0	1	100,0	50,00	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	20,83	23,57
	65-74	7	50,0	6	85,7	13,89	16,39
	>=75	1	50,0	1	100,0	50,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	17,19	20,95
	65-74	6	42,9	6	100,0	16,67	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	66,67	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	14,37	20,76
	65-74	6	42,9	5	83,3	10,00	14,91
	>=75	1	50,0	1	100,0	66,67	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	15,48	21,72
	65-74	5	35,7	4	80,0	20,83	15,96
	>=75	1	50,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	19,23	23,42
	65-74	5	35,7	5	100,0	16,67	11,79
	>=75	1	50,0	1	100,0	66,67	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	19,84	24,51
	65-74	4	28,6	4	100,0	20,83	8,33
	>=75	1	50,0	1	100,0	66,67	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	18,33	24,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	25,00	28,87
	>=75	1	50,0	1	100,0	50,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	26,04	28,52
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	19,79	22,13
	65-74	2	14,3	2	100,0	8,33	11,79
Cycle 25 Day 1	18-64	14	22,6	12	85,7	20,83	14,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	20,83	28,54
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	29,17	33,03
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	29,63	21,70
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	23,81	23,29
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	23,33	14,91
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	16,67	11,79
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	20,83	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	16,67	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	16,67	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	32,50	28,34
	65-74	10	71,4	7	70,0	16,67	25,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	16,67	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	33,33	28,30
	Other	43	100,0	43	100,0	31,78	27,89
Cycle 2 Day 1	White	33	94,3	29	87,9	17,24	21,59
	Other	39	90,7	36	92,3	18,98	23,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	16,05	21,92
	Other	37	86,0	37	100,0	15,32	15,90
Cycle 4 Day 1	White	31	88,6	28	90,3	12,50	17,35
	Other	36	83,7	36	100,0	16,20	23,73
Cycle 5 Day 1	White	31	88,6	30	96,8	12,78	22,61
	Other	34	79,1	34	100,0	14,71	20,83
Cycle 6 Day 1	White	30	85,7	28	93,3	13,10	16,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	13,02	16,79
Cycle 7 Day 1	White	29	82,9	27	93,1	12,96	17,50
	Other	31	72,1	30	96,8	17,22	18,30
Cycle 8 Day 1	White	28	80,0	24	85,7	11,11	17,49
	Other	28	65,1	28	100,0	15,48	22,19
Cycle 9 Day 1	White	26	74,3	26	100,0	16,03	27,68
	Other	25	58,1	25	100,0	16,00	18,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	18,00	21,47
	Other	25	58,1	25	100,0	10,67	14,34
Cycle 11 Day 1	White	26	74,3	26	100,0	14,10	19,26
	Other	24	55,8	24	100,0	11,81	13,44
Cycle 12 Day 1	White	26	74,3	22	84,6	17,42	26,47
	Other	23	53,5	23	100,0	13,04	15,04
Cycle 13 Day 1	White	24	68,6	23	95,8	18,12	29,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	15,15	12,50
Cycle 14 Day 1	White	24	68,6	24	100,0	20,14	29,89
	Other	21	48,8	20	95,2	12,50	13,11
Cycle 15 Day 1	White	24	68,6	24	100,0	20,83	27,03
	Other	20	46,5	20	100,0	12,50	13,11
Cycle 16 Day 1	White	22	62,9	20	90,9	22,50	24,94
	Other	19	44,2	19	100,0	18,42	20,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	20,45	25,68
	Other	17	39,5	17	100,0	15,69	16,11
Cycle 18 Day 1	White	21	60,0	18	85,7	18,52	26,75
	Other	17	39,5	17	100,0	11,76	14,15
Cycle 19 Day 1	White	20	57,1	20	100,0	20,00	26,27
	Other	16	37,2	13	81,3	14,10	14,98
Cycle 20 Day 1	White	20	57,1	17	85,0	19,61	27,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	21,11	17,21
Cycle 21 Day 1	White	16	45,7	14	87,5	26,19	29,75
	Other	13	30,2	12	92,3	16,67	14,21
Cycle 22 Day 1	White	16	45,7	13	81,3	23,08	27,67
	Other	13	30,2	12	92,3	18,06	21,86
Cycle 23 Day 1	White	12	34,3	10	83,3	30,00	32,20
	Other	9	20,9	8	88,9	14,58	20,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	25,00	23,90
	Other	9	20,9	8	88,9	10,42	15,27
Cycle 25 Day 1	White	10	28,6	8	80,0	18,75	16,52
	Other	5	11,6	5	100,0	20,00	13,94
Cycle 26 Day 1	White	10	28,6	8	80,0	18,75	35,00
	Other	4	9,3	4	100,0	25,00	9,62
Cycle 27 Day 1	White	8	22,9	5	62,5	26,67	41,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	33,33	16,67
Cycle 28 Day 1	White	7	20,0	6	85,7	19,44	16,39
	Other	3	7,0	3	100,0	50,00	16,67
Cycle 29 Day 1	White	6	17,1	4	66,7	16,67	13,61
	Other	3	7,0	3	100,0	33,33	33,33
Cycle 30 Day 1	White	4	11,4	2	50,0	8,33	11,79
	Other	3	7,0	3	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	8,33	11,79
	Other	3	7,0	3	100,0	22,22	9,62
Cycle 32 Day 1	White	4	11,4	3	75,0	16,67	0,00
	Other	2	4,7	2	100,0	25,00	11,79
Cycle 33 Day 1	White	2	5,7	2	100,0	8,33	11,79
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	29,17	25,75
	Other	24	55,8	16	66,7	27,08	29,74
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	28,79	27,78
	Europe (EU)	17	100,0	17	100,0	36,27	30,75
	Asia (AS)	39	100,0	39	100,0	32,91	27,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	17,65	20,81
	Europe (EU)	16	94,1	13	81,3	17,95	22,01
	Asia (AS)	36	92,3	35	97,2	18,57	23,84
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	13,16	20,47
	Europe (EU)	15	88,2	12	80,0	16,67	23,57
	Asia (AS)	33	84,6	33	100,0	16,67	15,59
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	8,33	17,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	16,67	15,89
	Asia (AS)	32	82,1	32	100,0	17,71	24,30
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	10,00	23,82
	Europe (EU)	15	88,2	14	93,3	11,90	17,82
	Asia (AS)	30	76,9	30	100,0	17,22	21,66
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	10,00	14,71
	Europe (EU)	14	82,4	13	92,9	14,10	17,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	14,81	17,50
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	11,11	16,17
	Europe (EU)	14	82,4	13	92,9	12,82	18,20
	Asia (AS)	27	69,2	26	96,3	19,23	18,67
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	12,75	20,01
	Europe (EU)	14	82,4	11	78,6	7,58	13,67
	Asia (AS)	24	61,5	24	100,0	16,67	22,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	13,89	23,04
	Europe (EU)	12	70,6	12	100,0	22,22	35,06
	Asia (AS)	21	53,8	21	100,0	14,29	14,23
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	11,76	17,45
	Europe (EU)	12	70,6	12	100,0	20,83	24,75
	Asia (AS)	21	53,8	21	100,0	12,70	14,82
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	6,48	11,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	22,22	22,84
	Asia (AS)	20	51,3	20	100,0	13,33	13,89
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	11,76	25,53
	Europe (EU)	12	70,6	9	75,0	22,22	25,00
	Asia (AS)	19	48,7	19	100,0	14,91	14,59
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	12,75	24,67
	Europe (EU)	11	64,7	10	90,9	21,67	32,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	17,59	13,37
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	13,73	25,16
	Europe (EU)	11	64,7	11	100,0	22,73	32,72
	Asia (AS)	17	43,6	16	94,1	15,63	14,23
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	12,75	24,67
	Europe (EU)	11	64,7	11	100,0	24,24	26,21
	Asia (AS)	16	41,0	16	100,0	16,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	15,48	27,32
	Europe (EU)	11	64,7	9	81,8	27,78	20,41
	Asia (AS)	16	41,0	16	100,0	20,83	19,72
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	15,48	27,32
	Europe (EU)	10	58,8	10	100,0	23,33	21,08
	Asia (AS)	15	38,5	15	100,0	17,78	17,21
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	9,52	26,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	25,00	22,97
	Asia (AS)	15	38,5	15	100,0	16,67	14,09
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	12,82	23,72
	Europe (EU)	9	52,9	9	100,0	29,63	26,06
	Asia (AS)	14	35,9	11	78,6	13,64	14,56
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	16,67	29,66
	Europe (EU)	9	52,9	6	66,7	25,00	22,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	21,79	15,79
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	21,67	30,48
	Europe (EU)	7	41,2	6	85,7	33,33	23,57
	Asia (AS)	11	28,2	10	90,9	15,00	14,59
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	16,67	30,43
	Europe (EU)	7	41,2	5	71,4	26,67	19,00
	Asia (AS)	11	28,2	10	90,9	21,67	22,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	25,93	35,46
	Europe (EU)	5	29,4	3	60,0	22,22	19,25
	Asia (AS)	7	17,9	6	85,7	19,44	22,15
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	16,67	28,17
	Europe (EU)	5	29,4	4	80,0	20,83	15,96
	Asia (AS)	7	17,9	6	85,7	19,44	16,39
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	19,05	15,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	16,67	23,57
	Asia (AS)	4	10,3	4	100,0	20,83	15,96
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	22,22	38,97
	Europe (EU)	4	23,5	2	50,0	16,67	23,57
	Asia (AS)	4	10,3	4	100,0	20,83	15,96
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	29,17	47,87
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	29,17	15,96
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	20,83	15,96
	Europe (EU)	2	11,8	1	50,0	0,00	-
	Asia (AS)	4	10,3	4	100,0	45,83	15,96
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	11,11	9,62
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	8,33	11,79
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	33,33	0,00
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	8,33	11,79
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	22,22	9,62
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	16,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	16,67	-
	Asia (AS)	3	7,7	2	66,7	25,00	11,79
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	16,67	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	24,24	23,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	45,83	15,96
	Asia (AS)	21	53,8	13	61,9	25,64	32,36
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	17,22	15,46
	1	38	100,0	38	100,0	42,11	29,44
	2	10	100,0	10	100,0	41,67	32,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	27	90,0	17,28	23,33
	1	36	94,7	32	88,9	19,27	21,21
	2	6	60,0	6	100,0	16,67	27,89
Cycle 3 Day 1	0	29	96,7	27	93,1	11,73	18,95
	1	34	89,5	32	94,1	16,15	15,55
	2	5	50,0	5	100,0	33,33	26,35
Cycle 4 Day 1	0	29	96,7	28	96,6	9,52	16,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	16,67	20,74
	2	5	50,0	4	80,0	33,33	40,82
Cycle 5 Day 1	0	29	96,7	29	100,0	10,92	17,41
	1	33	86,8	32	97,0	17,71	25,02
	2	3	30,0	3	100,0	0,00	0,00
Cycle 6 Day 1	0	29	96,7	29	100,0	11,49	15,50
	1	31	81,6	28	90,3	16,07	17,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	0,00	0,00
Cycle 7 Day 1	0	29	96,7	28	96,6	14,88	18,34
	1	28	73,7	26	92,9	17,31	17,94
	2	3	30,0	3	100,0	0,00	0,00
Cycle 8 Day 1	0	28	93,3	26	92,9	17,31	20,27
	1	25	65,8	23	92,0	10,87	20,48
	2	3	30,0	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	15,38	24,91
	1	23	60,5	23	100,0	18,12	22,42
	2	2	20,0	2	100,0	0,00	0,00
Cycle 10 Day 1	0	26	86,7	26	100,0	13,46	20,56
	1	23	60,5	22	95,7	15,91	16,65
	2	2	20,0	2	100,0	8,33	11,79
Cycle 11 Day 1	0	26	86,7	26	100,0	13,46	18,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	13,64	15,12
	2	2	20,0	2	100,0	0,00	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	18,94	26,87
	1	22	57,9	21	95,5	12,70	13,85
	2	2	20,0	2	100,0	0,00	0,00
Cycle 13 Day 1	0	25	83,3	24	96,0	18,75	27,50
	1	20	52,6	20	100,0	15,00	16,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	16,67	27,80
	1	19	50,0	19	100,0	17,54	18,82
	2	1	10,0	1	100,0	0,00	-
Cycle 15 Day 1	0	24	80,0	24	100,0	18,75	26,15
	1	19	50,0	19	100,0	15,79	16,17
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	23,33	24,42
	1	18	47,4	18	100,0	18,52	21,30
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	19,84	23,93
	1	17	44,7	17	100,0	17,65	19,96
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	16,67	24,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	14,58	19,12
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	19,30	23,74
	1	15	39,5	13	86,7	16,67	21,52
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	21,57	25,53
	1	15	39,5	14	93,3	20,24	20,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	19,05	27,62
	1	13	34,2	11	84,6	27,27	18,67
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	19,44	27,37
	1	13	34,2	12	92,3	23,61	22,98
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	24,07	32,39
	1	9	23,7	8	88,9	25,00	25,20
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	12,96	13,89
	1	9	23,7	8	88,9	27,08	26,63
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	11,11	8,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	26,19	16,27
Cycle 26 Day 1	0	8	26,7	6	75,0	5,56	8,61
	1	6	15,8	6	100,0	36,11	34,02
Cycle 27 Day 1	0	6	20,0	3	50,0	11,11	9,62
	1	5	13,2	5	100,0	40,00	38,37
Cycle 28 Day 1	0	5	16,7	4	80,0	12,50	15,96
	1	5	13,2	5	100,0	43,33	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	25,00	11,79
	1	5	13,2	5	100,0	23,33	27,89
Cycle 30 Day 1	0	3	10,0	1	33,3	16,67	-
	1	4	10,5	4	100,0	25,00	16,67
Cycle 31 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	20,83	8,33
Cycle 32 Day 1	0	3	10,0	2	66,7	16,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	22,22	9,62
Cycle 33 Day 1	0	2	6,7	2	100,0	8,33	11,79
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	21,43	25,68
	1	20	52,6	12	60,0	37,50	29,41
	2	4	40,0	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	23,66	19,14
	1	3	100,0	3	100,0	50,00	44,10
	2 or More	44	100,0	44	100,0	37,50	30,74
Cycle 2 Day 1	None	30	96,8	27	90,0	19,14	22,98
	1	2	66,7	1	50,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	17,57	22,55
Cycle 3 Day 1	None	30	96,8	28	93,3	9,52	13,17
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	35	97,2	20,95	20,75
Cycle 4 Day 1	None	30	96,8	29	96,7	10,92	21,49
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	35	79,5	33	94,3	17,68	20,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	10,56	21,66
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	33	75,0	32	97,0	17,71	21,56
Cycle 6 Day 1	None	29	93,5	28	96,6	9,52	13,93
	1	2	66,7	2	100,0	8,33	11,79
	2 or More	32	72,7	30	93,8	16,67	18,57
Cycle 7 Day 1	None	27	87,1	26	96,3	8,97	12,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	31	70,5	29	93,5	20,69	20,24
Cycle 8 Day 1	None	26	83,9	25	96,2	10,67	20,34
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	16,05	19,87
Cycle 9 Day 1	None	25	80,6	25	100,0	10,67	19,77
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	22,00	25,78
Cycle 10 Day 1	None	25	80,6	24	96,0	9,72	13,83
	1	1	33,3	1	100,0	0,00	-
	2 or More	25	56,8	25	100,0	19,33	21,34
Cycle 11 Day 1	None	25	80,6	25	100,0	8,00	12,84
	1	1	33,3	1	100,0	0,00	-
	2 or More	24	54,5	24	100,0	18,75	18,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	7,64	12,98
	1	1	33,3	1	100,0	0,00	-
	2 or More	23	52,3	20	87,0	25,00	25,65
Cycle 13 Day 1	None	24	77,4	23	95,8	10,87	11,90
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	23,81	29,61
Cycle 14 Day 1	None	23	74,2	23	100,0	10,14	13,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	20	95,2	25,00	30,83
Cycle 15 Day 1	None	23	74,2	23	100,0	8,70	12,17
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	20	100,0	27,50	26,64
Cycle 16 Day 1	None	20	64,5	19	95,0	13,16	21,21
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	28,95	22,11
Cycle 17 Day 1	None	19	61,3	19	100,0	13,16	15,29
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	19	100,0	24,56	26,28
Cycle 18 Day 1	None	18	58,1	17	94,4	7,84	13,33
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	17	89,5	23,53	25,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	8,82	11,96
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	28,89	27,07
Cycle 20 Day 1	None	17	54,8	16	94,1	11,46	15,77
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	31,11	25,87
Cycle 21 Day 1	None	15	48,4	13	86,7	12,82	13,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	30,77	28,74
Cycle 22 Day 1	None	15	48,4	13	86,7	7,69	8,65
	2 or More	14	31,8	12	85,7	34,72	28,83
Cycle 23 Day 1	None	10	32,3	9	90,0	16,67	23,57
	2 or More	11	25,0	9	81,8	29,63	32,03
Cycle 24 Day 1	None	10	32,3	10	100,0	15,00	26,59
	2 or More	10	22,7	8	80,0	22,92	12,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	16,67	15,43
	2 or More	6	13,6	5	83,3	23,33	14,91
Cycle 26 Day 1	None	8	25,8	8	100,0	18,75	35,00
	2 or More	6	13,6	4	66,7	25,00	9,62
Cycle 27 Day 1	None	7	22,6	6	85,7	30,56	38,61
	2 or More	4	9,1	2	50,0	25,00	11,79
Cycle 28 Day 1	None	7	22,6	7	100,0	23,81	18,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	50,00	23,57
Cycle 29 Day 1	None	6	19,4	5	83,3	26,67	25,28
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 30 Day 1	None	4	12,9	3	75,0	16,67	16,67
	2 or More	3	6,8	2	66,7	33,33	0,00
Cycle 31 Day 1	None	4	12,9	3	75,0	11,11	9,62
	2 or More	3	6,8	2	66,7	25,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	16,67	0,00
	2 or More	2	4,5	2	100,0	25,00	11,79
Cycle 33 Day 1	None	1	3,2	1	100,0	16,67	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	30,56	24,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	0,00	-
	2 or More	24	54,5	15	62,5	27,78	30,65
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	23,66	19,14
	Previously Treated	47	100,0	47	100,0	38,30	31,26
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	19,14	22,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	17,54	22,24
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	9,52	13,17
	Previously Treated	38	80,9	36	94,7	20,37	20,74
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	10,92	21,49
	Previously Treated	37	78,7	35	94,6	17,62	20,59
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	10,56	21,66
	Previously Treated	35	74,5	34	97,1	16,67	21,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	9,52	13,93
	Previously Treated	34	72,3	32	94,1	16,15	18,20
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	8,97	12,68
	Previously Treated	33	70,2	31	93,9	20,43	20,05
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	10,67	20,34
	Previously Treated	30	63,8	27	90,0	16,05	19,87
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	10,67	19,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	21,15	25,63
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	9,72	13,83
	Previously Treated	26	55,3	26	100,0	18,59	21,25
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	8,00	12,84
	Previously Treated	25	53,2	25	100,0	18,00	18,58
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	7,64	12,98
	Previously Treated	24	51,1	21	87,5	23,81	25,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	10,87	11,90
	Previously Treated	22	46,8	22	100,0	22,73	29,34
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	10,14	13,05
	Previously Treated	22	46,8	21	95,5	23,81	30,54
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	8,70	12,17
	Previously Treated	21	44,7	21	100,0	26,19	26,65
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	13,16	21,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	27,50	22,47
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	13,16	15,29
	Previously Treated	20	42,6	20	100,0	23,33	26,16
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	7,84	13,33
	Previously Treated	20	42,6	18	90,0	22,22	25,57
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	8,82	11,96
	Previously Treated	19	40,4	16	84,2	27,08	27,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	11,46	15,77
	Previously Treated	19	40,4	16	84,2	29,17	26,18
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	12,82	13,87
	Previously Treated	14	29,8	13	92,9	30,77	28,74
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	7,69	8,65
	Previously Treated	14	29,8	12	85,7	34,72	28,83
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	29,63	32,03
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	15,00	26,59
	Previously Treated	10	21,3	8	80,0	22,92	12,40
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	16,67	15,43
	Previously Treated	6	12,8	5	83,3	23,33	14,91
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	18,75	35,00
	Previously Treated	6	12,8	4	66,7	25,00	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	30,56	38,61
	Previously Treated	4	8,5	2	50,0	25,00	11,79
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	23,81	18,90
	Previously Treated	3	6,4	2	66,7	50,00	23,57
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	26,67	25,28
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	16,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	33,33	0,00
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	11,11	9,62
	Previously Treated	3	6,4	2	66,7	25,00	11,79
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	16,67	0,00
	Previously Treated	2	4,3	2	100,0	25,00	11,79
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	16,67	-
	Previously Treated	1	2,1	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	30,56	24,45
	Previously Treated	26	55,3	16	61,5	26,04	30,41
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	28,57	27,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	35,66	28,31
Cycle 2 Day 1	Local	32	91,4	30	93,8	12,22	16,91
	Central	40	93,0	35	87,5	23,33	25,31
Cycle 3 Day 1	Local	29	82,9	28	96,6	13,10	18,35
	Central	39	90,7	36	92,3	17,59	18,66
Cycle 4 Day 1	Local	28	80,0	27	96,4	6,17	13,19
	Central	39	90,7	37	94,9	20,72	23,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	11,11	20,15
	Central	38	88,4	37	97,4	15,77	22,55
Cycle 6 Day 1	Local	27	77,1	27	100,0	9,88	14,81
	Central	36	83,7	33	91,7	15,66	17,65
Cycle 7 Day 1	Local	27	77,1	27	100,0	11,73	17,18
	Central	33	76,7	30	90,9	18,33	18,23
Cycle 8 Day 1	Local	26	74,3	26	100,0	8,97	12,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	17,95	24,91
Cycle 9 Day 1	Local	25	71,4	25	100,0	16,67	26,35
	Central	26	60,5	26	100,0	15,38	20,51
Cycle 10 Day 1	Local	25	71,4	24	96,0	15,97	21,13
	Central	26	60,5	26	100,0	12,82	15,85
Cycle 11 Day 1	Local	24	68,6	24	100,0	8,33	17,03
	Central	26	60,5	26	100,0	17,31	15,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	10,61	17,48
	Central	26	60,5	23	88,5	19,57	23,92
Cycle 13 Day 1	Local	22	62,9	22	100,0	13,64	22,79
	Central	24	55,8	23	95,8	19,57	22,84
Cycle 14 Day 1	Local	22	62,9	22	100,0	13,64	23,37
	Central	23	53,5	22	95,7	19,70	24,47
Cycle 15 Day 1	Local	22	62,9	22	100,0	14,39	19,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	19,70	24,47
Cycle 16 Day 1	Local	20	57,1	20	100,0	15,00	17,85
	Central	21	48,8	19	90,5	26,32	26,24
Cycle 17 Day 1	Local	20	57,1	20	100,0	10,83	13,55
	Central	19	44,2	19	100,0	26,32	26,24
Cycle 18 Day 1	Local	20	57,1	19	95,0	6,14	9,95
	Central	18	41,9	16	88,9	26,04	26,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	10,78	14,36
	Central	17	39,5	16	94,1	25,00	27,22
Cycle 20 Day 1	Local	19	54,3	17	89,5	11,76	16,42
	Central	17	39,5	15	88,2	30,00	26,13
Cycle 21 Day 1	Local	14	40,0	12	85,7	13,89	15,62
	Central	15	34,9	14	93,3	28,57	28,06
Cycle 22 Day 1	Local	14	40,0	12	85,7	13,89	22,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	26,92	25,94
Cycle 23 Day 1	Local	11	31,4	10	90,9	11,67	17,66
	Central	10	23,3	8	80,0	37,50	33,03
Cycle 24 Day 1	Local	11	31,4	10	90,9	8,33	11,79
	Central	9	20,9	8	88,9	31,25	24,30
Cycle 25 Day 1	Local	7	20,0	7	100,0	11,90	8,13
	Central	8	18,6	6	75,0	27,78	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	11,11	13,61
	Central	8	18,6	6	75,0	30,56	37,14
Cycle 27 Day 1	Local	4	11,4	4	100,0	16,67	23,57
	Central	7	16,3	4	57,1	41,67	39,67
Cycle 28 Day 1	Local	4	11,4	4	100,0	25,00	21,52
	Central	6	14,0	5	83,3	33,33	23,57
Cycle 29 Day 1	Local	3	8,6	3	100,0	27,78	34,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	20,83	15,96
Cycle 30 Day 1	Local	3	8,6	3	100,0	16,67	16,67
	Central	4	9,3	2	50,0	33,33	0,00
Cycle 31 Day 1	Local	3	8,6	3	100,0	11,11	9,62
	Central	4	9,3	2	50,0	25,00	11,79
Cycle 32 Day 1	Local	3	8,6	3	100,0	16,67	0,00
	Central	3	7,0	2	66,7	25,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	16,67	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	26,19	29,75
	Central	21	48,8	14	66,7	29,76	26,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	31,98	27,41
	No	4	100,0	4	100,0	41,67	39,67
Cycle 2 Day 1	Yes	70	94,6	63	90,0	17,46	21,05
	No	2	50,0	2	100,0	41,67	58,93
Cycle 3 Day 1	Yes	66	89,2	62	93,9	15,86	18,71
	No	2	50,0	2	100,0	8,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	14,52	21,23
	No	2	50,0	2	100,0	16,67	23,57
Cycle 5 Day 1	Yes	63	85,1	62	98,4	13,17	21,58
	No	2	50,0	2	100,0	33,33	0,00
Cycle 6 Day 1	Yes	61	82,4	58	95,1	13,22	16,74
	No	2	50,0	2	100,0	8,33	11,79
Cycle 7 Day 1	Yes	58	78,4	55	94,8	15,15	17,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 8 Day 1	Yes	54	73,0	50	92,6	13,67	20,40
	No	2	50,0	2	100,0	8,33	11,79
Cycle 9 Day 1	Yes	49	66,2	49	100,0	15,99	23,56
	No	2	50,0	2	100,0	16,67	23,57
Cycle 10 Day 1	Yes	49	66,2	48	98,0	14,24	18,51
	No	2	50,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	13,19	16,83
	No	2	50,0	2	100,0	8,33	11,79
Cycle 12 Day 1	Yes	47	63,5	43	91,5	15,12	21,46
	No	2	50,0	2	100,0	16,67	23,57
Cycle 13 Day 1	Yes	44	59,5	43	97,7	16,67	23,00
	No	2	50,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	43	58,1	42	97,7	17,06	24,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	8,33	11,79
Cycle 15 Day 1	Yes	42	56,8	42	100,0	17,06	22,24
	No	2	50,0	2	100,0	16,67	23,57
Cycle 16 Day 1	Yes	39	52,7	37	94,9	20,27	23,29
	No	2	50,0	2	100,0	25,00	11,79
Cycle 17 Day 1	Yes	37	50,0	37	100,0	18,02	21,65
	No	2	50,0	2	100,0	25,00	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	15,15	21,80
	No	2	50,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	18,23	22,54
	No	2	50,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	20,56	23,44
	No	2	50,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	36,5	24	88,9	22,92	24,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	8,33	11,79
Cycle 22 Day 1	Yes	27	36,5	23	85,2	22,46	24,93
	No	2	50,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	24,51	28,33
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	19,61	21,44
	No	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	20,83	14,43
	No	1	25,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	19,70	29,64
	No	1	25,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	26,19	34,50
	No	1	25,0	1	100,0	50,00	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	27,08	21,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	50,00	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	16,67	14,91
	No	1	25,0	1	100,0	66,67	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	20,83	15,96
	No	1	25,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	16,67	13,61
	No	1	25,0	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	20,83	8,33
	No	1	25,0	1	100,0	16,67	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	8,33	11,79
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	27,98	27,61
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	31,25	24,30
	No	70	100,0	70	100,0	32,62	28,44
Cycle 2 Day 1	Yes	5	62,5	5	100,0	23,33	14,91
	No	67	95,7	60	89,6	17,78	22,94
Cycle 3 Day 1	Yes	5	62,5	5	100,0	10,00	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	16,10	18,82
Cycle 4 Day 1	Yes	5	62,5	5	100,0	3,33	7,45
	No	62	88,6	59	95,2	15,54	21,63
Cycle 5 Day 1	Yes	5	62,5	5	100,0	13,33	18,26
	No	60	85,7	59	98,3	13,84	21,92
Cycle 6 Day 1	Yes	5	62,5	5	100,0	13,33	18,26
	No	58	82,9	55	94,8	13,03	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	55	78,6	52	94,5	16,03	18,07
Cycle 8 Day 1	Yes	5	62,5	5	100,0	26,67	34,56
	No	51	72,9	47	92,2	12,06	17,96
Cycle 9 Day 1	Yes	4	50,0	4	100,0	37,50	28,46
	No	47	67,1	47	100,0	14,18	22,25
Cycle 10 Day 1	Yes	4	50,0	4	100,0	20,83	25,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	13,77	18,02
Cycle 11 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	46	65,7	46	100,0	13,41	16,71
Cycle 12 Day 1	Yes	4	50,0	4	100,0	12,50	15,96
	No	45	64,3	41	91,1	15,45	21,86
Cycle 13 Day 1	Yes	4	50,0	4	100,0	20,83	15,96
	No	42	60,0	41	97,6	16,26	23,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	25,00	16,67
	No	41	58,6	40	97,6	15,83	24,45
Cycle 15 Day 1	Yes	4	50,0	4	100,0	20,83	15,96
	No	40	57,1	40	100,0	16,67	22,65
Cycle 16 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	38	54,3	36	94,7	21,30	23,10
Cycle 17 Day 1	Yes	3	37,5	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	18,98	22,24
Cycle 18 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	35	50,0	32	91,4	15,63	21,97
Cycle 19 Day 1	Yes	3	37,5	3	100,0	16,67	16,67
	No	33	47,1	30	90,9	17,78	23,13
Cycle 20 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	33	47,1	29	87,9	21,26	23,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	27	38,6	24	88,9	22,22	24,41
Cycle 22 Day 1	Yes	2	25,0	2	100,0	8,33	11,79
	No	27	38,6	23	85,2	21,74	25,34
Cycle 23 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	19	27,1	16	84,2	23,96	29,17
Cycle 24 Day 1	Yes	2	25,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	18,75	21,84
Cycle 25 Day 1	Yes	2	25,0	2	100,0	16,67	0,00
	No	13	18,6	11	84,6	19,70	16,36
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	22,73	29,13
Cycle 27 Day 1	Yes	1	12,5	1	100,0	16,67	-
	No	10	14,3	7	70,0	30,95	35,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	9	12,9	8	88,9	29,17	23,15
Cycle 29 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	8	11,4	6	75,0	22,22	25,09
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	23,33	14,91
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	16,67	11,79
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	20,00	7,45
Cycle 33 Day 1	No	2	2,9	2	100,0	8,33	11,79
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	25,00	25,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PA_SG.xls
28NOV2019 10:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	68,06	22,60
Cycle 2 Day 1	All	72	92,3	65	90,3	76,31	20,98
Cycle 3 Day 1	All	68	87,2	64	94,1	77,71	19,23
Cycle 4 Day 1	All	67	85,9	64	95,5	80,63	19,03
Cycle 5 Day 1	All	65	83,3	64	98,5	79,90	19,28
Cycle 6 Day 1	All	63	80,8	60	95,2	82,22	18,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	79,42	17,29
Cycle 8 Day 1	All	56	71,8	52	92,9	80,64	19,77
Cycle 9 Day 1	All	51	65,4	51	100,0	84,05	18,04
Cycle 10 Day 1	All	51	65,4	50	98,0	81,47	16,78
Cycle 11 Day 1	All	50	64,1	50	100,0	82,27	15,80
Cycle 12 Day 1	All	49	62,8	45	91,8	79,26	17,99
Cycle 13 Day 1	All	46	59,0	45	97,8	81,48	18,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	79,24	21,43
Cycle 15 Day 1	All	44	56,4	44	100,0	80,15	18,66
Cycle 16 Day 1	All	41	52,6	39	95,1	78,80	20,17
Cycle 17 Day 1	All	39	50,0	39	100,0	82,39	16,15
Cycle 18 Day 1	All	38	48,7	35	92,1	82,86	18,10
Cycle 19 Day 1	All	36	46,2	33	91,7	81,21	18,52
Cycle 20 Day 1	All	36	46,2	32	88,9	80,00	20,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	80,00	17,99
Cycle 22 Day 1	All	29	37,2	25	86,2	78,93	19,31
Cycle 23 Day 1	All	21	26,9	18	85,7	78,52	20,52
Cycle 24 Day 1	All	20	25,6	18	90,0	78,89	22,43
Cycle 25 Day 1	All	15	19,2	13	86,7	79,49	18,35
Cycle 26 Day 1	All	14	17,9	12	85,7	73,89	29,74
Cycle 27 Day 1	All	11	14,1	8	72,7	77,50	25,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	77,04	25,84
Cycle 29 Day 1	All	9	11,5	7	77,8	83,81	13,25
Cycle 30 Day 1	All	7	9,0	5	71,4	80,00	14,91
Cycle 31 Day 1	All	7	9,0	5	71,4	82,67	17,38
Cycle 32 Day 1	All	6	7,7	5	83,3	82,67	15,35
Cycle 33 Day 1	All	2	2,6	2	100,0	86,67	9,43
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	63,33	28,20
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	65,06	24,08
	Female	49	100,0	49	100,0	69,83	21,74
Cycle 2 Day 1	Male	27	93,1	25	92,6	79,47	16,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	74,33	23,41
Cycle 3 Day 1	Male	25	86,2	23	92,0	82,32	14,72
	Female	43	87,8	41	95,3	75,12	21,08
Cycle 4 Day 1	Male	25	86,2	25	100,0	85,60	13,84
	Female	42	85,7	39	92,9	77,44	21,28
Cycle 5 Day 1	Male	25	86,2	25	100,0	79,20	19,47
	Female	40	81,6	39	97,5	80,34	19,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	84,64	14,42
	Female	38	77,6	37	97,4	80,72	20,05
Cycle 7 Day 1	Male	23	79,3	23	100,0	80,58	14,76
	Female	37	75,5	34	91,9	78,63	18,98
Cycle 8 Day 1	Male	21	72,4	19	90,5	80,35	21,02
	Female	35	71,4	33	94,3	80,81	19,35
Cycle 9 Day 1	Male	18	62,1	18	100,0	86,67	16,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	82,63	19,00
Cycle 10 Day 1	Male	18	62,1	18	100,0	81,85	17,68
	Female	33	67,3	32	97,0	81,25	16,54
Cycle 11 Day 1	Male	18	62,1	18	100,0	85,19	16,89
	Female	32	65,3	32	100,0	80,63	15,18
Cycle 12 Day 1	Male	17	58,6	17	100,0	80,78	18,09
	Female	32	65,3	28	87,5	78,33	18,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	85,49	14,76
	Female	29	59,2	28	96,6	79,05	19,69
Cycle 14 Day 1	Male	17	58,6	16	94,1	79,58	21,01
	Female	28	57,1	28	100,0	79,05	22,05
Cycle 15 Day 1	Male	16	55,2	16	100,0	82,08	16,46
	Female	28	57,1	28	100,0	79,05	20,02
Cycle 16 Day 1	Male	14	48,3	14	100,0	81,90	18,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	77,07	21,44
Cycle 17 Day 1	Male	12	41,4	12	100,0	85,56	15,53
	Female	27	55,1	27	100,0	80,99	16,51
Cycle 18 Day 1	Male	11	37,9	10	90,9	88,00	16,87
	Female	27	55,1	25	92,6	80,80	18,49
Cycle 19 Day 1	Male	10	34,5	10	100,0	83,33	19,94
	Female	26	53,1	23	88,5	80,29	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	83,70	21,89
	Female	26	53,1	23	88,5	78,55	20,20
Cycle 21 Day 1	Male	8	27,6	8	100,0	90,00	12,85
	Female	21	42,9	18	85,7	75,56	18,44
Cycle 22 Day 1	Male	8	27,6	6	75,0	87,78	17,08
	Female	21	42,9	19	90,5	76,14	19,54
Cycle 23 Day 1	Male	5	17,2	4	80,0	98,33	3,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	72,86	19,82
Cycle 24 Day 1	Male	5	17,2	4	80,0	100,00	0,00
	Female	15	30,6	14	93,3	72,86	21,95
Cycle 25 Day 1	Male	3	10,3	2	66,7	100,00	0,00
	Female	12	24,5	11	91,7	75,76	17,45
Cycle 26 Day 1	Male	3	10,3	2	66,7	100,00	0,00
	Female	11	22,4	10	90,9	68,67	29,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	93,33	9,43
	Female	8	16,3	6	75,0	72,22	27,46
Cycle 28 Day 1	Male	2	6,9	2	100,0	90,00	4,71
	Female	8	16,3	7	87,5	73,33	28,54
Cycle 29 Day 1	Male	1	3,4	1	100,0	100,00	-
	Female	8	16,3	6	75,0	81,11	12,23
Cycle 30 Day 1	Male	1	3,4	1	100,0	86,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	78,33	16,67
Cycle 31 Day 1	Male	1	3,4	1	100,0	100,00	-
	Female	6	12,2	4	66,7	78,33	16,67
Cycle 32 Day 1	Male	1	3,4	1	100,0	93,33	-
	Female	5	10,2	4	80,0	80,00	16,33
Cycle 33 Day 1	Male	1	3,4	1	100,0	93,33	-
	Female	1	2,0	1	100,0	80,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	56,89	28,83
	Female	21	42,9	13	61,9	70,77	26,60
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	69,27	20,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	62,86	32,00
	>=75	2	100,0	2	100,0	66,67	9,43
Cycle 2 Day 1	18-64	59	95,2	53	89,8	79,12	18,17
	65-74	11	78,6	10	90,9	58,67	28,07
	>=75	2	100,0	2	100,0	90,00	4,71
Cycle 3 Day 1	18-64	56	90,3	52	92,9	78,85	19,75
	65-74	10	71,4	10	100,0	73,33	17,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	70,00	14,14
Cycle 4 Day 1	18-64	55	88,7	53	96,4	81,64	19,65
	65-74	10	71,4	9	90,0	74,81	16,92
	>=75	2	100,0	2	100,0	80,00	9,43
Cycle 5 Day 1	18-64	53	85,5	52	98,1	81,79	19,18
	65-74	10	71,4	10	100,0	70,67	18,38
	>=75	2	100,0	2	100,0	76,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	82,72	18,85
	65-74	10	71,4	9	90,0	80,00	14,91
	>=75	2	100,0	2	100,0	80,00	18,86
Cycle 7 Day 1	18-64	49	79,0	47	95,9	79,72	18,07
	65-74	9	64,3	8	88,9	79,17	10,95
	>=75	2	100,0	2	100,0	73,33	28,28
Cycle 8 Day 1	18-64	45	72,6	41	91,1	80,81	21,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	79,26	8,46
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 9 Day 1	18-64	40	64,5	40	100,0	86,67	15,25
	65-74	9	64,3	9	100,0	74,07	24,60
	>=75	2	100,0	2	100,0	76,67	33,00
Cycle 10 Day 1	18-64	40	64,5	39	97,5	83,42	15,74
	65-74	9	64,3	9	100,0	74,81	16,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	73,33	37,71
Cycle 11 Day 1	18-64	39	62,9	39	100,0	83,93	15,35
	65-74	9	64,3	9	100,0	77,78	14,14
	>=75	2	100,0	2	100,0	70,00	33,00
Cycle 12 Day 1	18-64	38	61,3	35	92,1	81,71	18,10
	65-74	9	64,3	8	88,9	70,83	15,09
	>=75	2	100,0	2	100,0	70,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	84,90	16,36
	65-74	9	64,3	9	100,0	71,11	21,60
	>=75	2	100,0	2	100,0	70,00	14,14
Cycle 14 Day 1	18-64	35	56,5	35	100,0	82,10	20,18
	65-74	9	64,3	8	88,9	69,17	25,18
	>=75	1	50,0	1	100,0	60,00	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	81,71	18,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	75,00	20,39
	>=75	1	50,0	1	100,0	66,67	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	79,79	21,32
	65-74	7	50,0	6	85,7	76,67	13,82
	>=75	1	50,0	1	100,0	60,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	83,54	16,42
	65-74	6	42,9	6	100,0	78,89	15,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	66,67	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	85,75	16,88
	65-74	6	42,9	5	83,3	70,67	20,33
	>=75	1	50,0	1	100,0	60,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	83,10	18,81
	65-74	5	35,7	4	80,0	75,00	11,39
	>=75	1	50,0	1	100,0	53,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	82,05	20,72
	65-74	5	35,7	5	100,0	76,00	15,35
	>=75	1	50,0	1	100,0	46,67	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	81,59	18,96
	65-74	4	28,6	4	100,0	75,00	13,74
	>=75	1	50,0	1	100,0	66,67	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	79,67	20,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	80,00	16,33
	>=75	1	50,0	1	100,0	60,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	77,92	21,46
	65-74	2	14,3	2	100,0	83,33	14,14
Cycle 24 Day 1	18-64	18	29,0	16	88,9	77,08	23,09
	65-74	2	14,3	2	100,0	93,33	9,43
Cycle 25 Day 1	18-64	14	22,6	12	85,7	78,89	19,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	86,67	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	73,89	29,74
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	77,50	25,43
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	77,04	25,84
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	83,81	13,25
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	80,00	14,91
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	82,67	17,38
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	83,33	17,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	80,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	93,33	-
	65-74	1	7,1	1	100,0	80,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	61,67	30,04
	65-74	10	71,4	7	70,0	64,76	24,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	86,67	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	66,14	24,82
	Other	43	100,0	43	100,0	69,61	20,79
Cycle 2 Day 1	White	33	94,3	29	87,9	76,55	21,87
	Other	39	90,7	36	92,3	76,11	20,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	73,83	24,17
	Other	37	86,0	37	100,0	80,54	14,35
Cycle 4 Day 1	White	31	88,6	28	90,3	81,19	20,53
	Other	36	83,7	36	100,0	80,19	18,06
Cycle 5 Day 1	White	31	88,6	30	96,8	79,33	23,32
	Other	34	79,1	34	100,0	80,39	15,21
Cycle 6 Day 1	White	30	85,7	28	93,3	80,48	21,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	83,75	14,46
Cycle 7 Day 1	White	29	82,9	27	93,1	80,00	19,04
	Other	31	72,1	30	96,8	78,89	15,86
Cycle 8 Day 1	White	28	80,0	24	85,7	81,11	21,51
	Other	28	65,1	28	100,0	80,24	18,55
Cycle 9 Day 1	White	26	74,3	26	100,0	84,36	18,76
	Other	25	58,1	25	100,0	83,73	17,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	79,73	18,31
	Other	25	58,1	25	100,0	83,20	15,29
Cycle 11 Day 1	White	26	74,3	26	100,0	82,82	17,81
	Other	24	55,8	24	100,0	81,67	13,66
Cycle 12 Day 1	White	26	74,3	22	84,6	80,61	21,27
	Other	23	53,5	23	100,0	77,97	14,56
Cycle 13 Day 1	White	24	68,6	23	95,8	80,87	22,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	82,12	12,24
Cycle 14 Day 1	White	24	68,6	24	100,0	80,56	24,47
	Other	21	48,8	20	95,2	77,67	17,61
Cycle 15 Day 1	White	24	68,6	24	100,0	80,56	21,07
	Other	20	46,5	20	100,0	79,67	15,82
Cycle 16 Day 1	White	22	62,9	20	90,9	80,67	18,08
	Other	19	44,2	19	100,0	76,84	22,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	82,73	17,42
	Other	17	39,5	17	100,0	81,96	14,86
Cycle 18 Day 1	White	21	60,0	18	85,7	82,96	19,16
	Other	17	39,5	17	100,0	82,75	17,49
Cycle 19 Day 1	White	20	57,1	20	100,0	78,67	22,12
	Other	16	37,2	13	81,3	85,13	10,59
Cycle 20 Day 1	White	20	57,1	17	85,0	80,39	21,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	79,56	19,43
Cycle 21 Day 1	White	16	45,7	14	87,5	78,10	21,47
	Other	13	30,2	12	92,3	82,22	13,43
Cycle 22 Day 1	White	16	45,7	13	81,3	77,95	22,83
	Other	13	30,2	12	92,3	80,00	15,57
Cycle 23 Day 1	White	12	34,3	10	83,3	72,00	25,10
	Other	9	20,9	8	88,9	86,67	8,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	78,00	23,53
	Other	9	20,9	8	88,9	80,00	22,54
Cycle 25 Day 1	White	10	28,6	8	80,0	83,33	15,53
	Other	5	11,6	5	100,0	73,33	22,61
Cycle 26 Day 1	White	10	28,6	8	80,0	73,33	36,51
	Other	4	9,3	4	100,0	75,00	11,39
Cycle 27 Day 1	White	8	22,9	5	62,5	77,33	33,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	77,78	7,70
Cycle 28 Day 1	White	7	20,0	6	85,7	88,89	10,89
	Other	3	7,0	3	100,0	53,33	33,33
Cycle 29 Day 1	White	6	17,1	4	66,7	90,00	12,77
	Other	3	7,0	3	100,0	75,56	10,18
Cycle 30 Day 1	White	4	11,4	2	50,0	93,33	9,43
	Other	3	7,0	3	100,0	71,11	10,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	100,00	0,00
	Other	3	7,0	3	100,0	71,11	10,18
Cycle 32 Day 1	White	4	11,4	3	75,0	91,11	10,18
	Other	2	4,7	2	100,0	70,00	14,14
Cycle 33 Day 1	White	2	5,7	2	100,0	86,67	9,43
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	60,56	24,53
	Other	24	55,8	16	66,7	65,42	31,29
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	68,26	26,68
	Europe (EU)	17	100,0	17	100,0	65,10	19,37
	Asia (AS)	39	100,0	39	100,0	69,23	21,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	80,78	17,30
	Europe (EU)	16	94,1	13	81,3	71,28	25,00
	Asia (AS)	36	92,3	35	97,2	76,00	21,16
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	80,70	16,46
	Europe (EU)	15	88,2	12	80,0	65,00	29,56
	Asia (AS)	33	84,6	33	100,0	80,61	14,18
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	85,00	15,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	75,56	25,00
	Asia (AS)	32	82,1	32	100,0	79,79	18,74
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	87,00	14,10
	Europe (EU)	15	88,2	14	93,3	74,29	25,87
	Asia (AS)	30	76,9	30	100,0	77,78	17,97
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	87,00	13,42
	Europe (EU)	14	82,4	13	92,9	73,85	26,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	82,72	15,28
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	82,22	14,64
	Europe (EU)	14	82,4	13	92,9	73,33	21,94
	Asia (AS)	27	69,2	26	96,3	80,51	16,32
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	84,31	17,31
	Europe (EU)	14	82,4	11	78,6	73,94	23,56
	Asia (AS)	24	61,5	24	100,0	81,11	19,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	86,30	16,56
	Europe (EU)	12	70,6	12	100,0	78,33	21,30
	Asia (AS)	21	53,8	21	100,0	85,40	17,46
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	83,53	16,01
	Europe (EU)	12	70,6	12	100,0	72,22	17,71
	Asia (AS)	21	53,8	21	100,0	85,08	15,62
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	84,07	18,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	77,78	16,90
	Asia (AS)	20	51,3	20	100,0	83,33	13,07
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	81,96	21,44
	Europe (EU)	12	70,6	9	75,0	72,59	16,48
	Asia (AS)	19	48,7	19	100,0	80,00	15,23
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	84,31	20,13
	Europe (EU)	11	64,7	10	90,9	76,00	23,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	81,85	12,06
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	83,14	21,62
	Europe (EU)	11	64,7	11	100,0	70,30	27,06
	Asia (AS)	17	43,6	16	94,1	81,25	15,82
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	83,14	20,15
	Europe (EU)	11	64,7	11	100,0	73,94	20,10
	Asia (AS)	16	41,0	16	100,0	81,25	16,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	85,24	17,18
	Europe (EU)	11	64,7	9	81,8	72,59	17,46
	Asia (AS)	16	41,0	16	100,0	76,67	23,35
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	83,81	19,52
	Europe (EU)	10	58,8	10	100,0	80,67	12,75
	Asia (AS)	15	38,5	15	100,0	82,22	15,67
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	85,24	20,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	78,89	13,61
	Asia (AS)	15	38,5	15	100,0	82,22	17,58
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	82,56	22,20
	Europe (EU)	9	52,9	9	100,0	74,07	19,28
	Asia (AS)	14	35,9	11	78,6	85,45	11,86
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	82,56	23,65
	Europe (EU)	9	52,9	6	66,7	71,11	17,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	81,54	18,49
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	81,33	24,30
	Europe (EU)	7	41,2	6	85,7	75,56	13,11
	Asia (AS)	11	28,2	10	90,9	81,33	13,98
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	82,67	24,59
	Europe (EU)	7	41,2	5	71,4	74,67	16,60
	Asia (AS)	11	28,2	10	90,9	77,33	15,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	78,52	26,41
	Europe (EU)	5	29,4	3	60,0	64,44	10,18
	Asia (AS)	7	17,9	6	85,7	85,56	9,81
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	82,50	23,35
	Europe (EU)	5	29,4	4	80,0	76,67	22,77
	Asia (AS)	7	17,9	6	85,7	75,56	24,46
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	85,71	15,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	76,67	14,14
	Asia (AS)	4	10,3	4	100,0	70,00	24,65
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	71,11	41,88
	Europe (EU)	4	23,5	2	50,0	86,67	18,86
	Asia (AS)	4	10,3	4	100,0	71,67	8,39
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	76,67	38,30
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	78,33	6,38
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	88,33	11,39
	Europe (EU)	2	11,8	1	50,0	100,00	-
	Asia (AS)	4	10,3	4	100,0	60,00	30,31
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	95,56	7,70
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	75,00	8,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	93,33	9,43
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	71,11	10,18
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	100,00	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	71,11	10,18
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	96,67	4,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	80,00	-
	Asia (AS)	3	7,7	2	66,7	70,00	14,14
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	93,33	-
	Europe (EU)	1	5,9	1	100,0	80,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	64,85	27,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	53,33	33,99
	Asia (AS)	21	53,8	13	61,9	65,13	28,82
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	82,50	12,52
	1	38	100,0	38	100,0	65,26	19,12
	2	10	100,0	10	100,0	35,33	21,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	27	90,0	81,48	20,03
	1	36	94,7	32	88,9	76,88	16,76
	2	6	60,0	6	100,0	50,00	28,83
Cycle 3 Day 1	0	29	96,7	27	93,1	81,98	16,93
	1	34	89,5	32	94,1	79,38	14,99
	2	5	50,0	5	100,0	44,00	25,65
Cycle 4 Day 1	0	29	96,7	28	96,6	86,67	15,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	81,46	12,98
	2	5	50,0	4	80,0	31,67	14,78
Cycle 5 Day 1	0	29	96,7	29	100,0	85,75	12,56
	1	33	86,8	32	97,0	78,13	17,86
	2	3	30,0	3	100,0	42,22	43,38
Cycle 6 Day 1	0	29	96,7	29	100,0	87,13	13,33
	1	31	81,6	28	90,3	81,67	12,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	40,00	43,72
Cycle 7 Day 1	0	29	96,7	28	96,6	85,00	12,52
	1	28	73,7	26	92,9	77,69	14,48
	2	3	30,0	3	100,0	42,22	32,89
Cycle 8 Day 1	0	28	93,3	26	92,9	84,36	16,21
	1	25	65,8	23	92,0	81,16	16,78
	2	3	30,0	3	100,0	44,44	37,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	86,41	17,23
	1	23	60,5	23	100,0	83,19	17,51
	2	2	20,0	2	100,0	63,33	33,00
Cycle 10 Day 1	0	26	86,7	26	100,0	83,85	15,34
	1	23	60,5	22	95,7	81,21	15,07
	2	2	20,0	2	100,0	53,33	37,71
Cycle 11 Day 1	0	26	86,7	26	100,0	85,64	14,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	79,70	16,00
	2	2	20,0	2	100,0	66,67	28,28
Cycle 12 Day 1	0	25	83,3	22	88,0	81,21	19,80
	1	22	57,9	21	95,5	79,05	15,96
	2	2	20,0	2	100,0	60,00	9,43
Cycle 13 Day 1	0	25	83,3	24	96,0	81,67	21,10
	1	20	52,6	20	100,0	82,33	13,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	60,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	80,83	23,29
	1	19	50,0	19	100,0	78,95	18,49
	2	1	10,0	1	100,0	46,67	-
Cycle 15 Day 1	0	24	80,0	24	100,0	81,67	20,55
	1	19	50,0	19	100,0	80,35	14,14
	2	1	10,0	1	100,0	40,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	81,33	17,78
	1	18	47,4	18	100,0	78,15	21,43
	2	1	10,0	1	100,0	40,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	83,17	18,57
	1	17	44,7	17	100,0	82,35	13,11
	2	1	10,0	1	100,0	66,67	-
Cycle 18 Day 1	0	21	70,0	18	85,7	82,22	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	85,42	13,16
	2	1	10,0	1	100,0	53,33	-
Cycle 19 Day 1	0	20	66,7	19	95,0	82,11	21,67
	1	15	39,5	13	86,7	81,03	13,84
	2	1	10,0	1	100,0	66,67	-
Cycle 20 Day 1	0	20	66,7	17	85,0	80,00	22,11
	1	15	39,5	14	93,3	83,33	14,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	33,33	-
Cycle 21 Day 1	0	15	50,0	14	93,3	80,48	22,56
	1	13	34,2	11	84,6	81,21	10,25
	2	1	10,0	1	100,0	60,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	79,44	24,53
	1	13	34,2	12	92,3	81,11	10,57
	2	1	10,0	1	100,0	46,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	74,81	25,77
	1	9	23,7	8	88,9	83,33	14,69
	2	1	10,0	1	100,0	73,33	-
Cycle 24 Day 1	0	10	33,3	9	90,0	82,96	21,89
	1	9	23,7	8	88,9	79,17	20,91
	2	1	10,0	1	100,0	40,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	86,67	12,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	73,33	21,08
Cycle 26 Day 1	0	8	26,7	6	75,0	83,33	23,76
	1	6	15,8	6	100,0	64,44	34,17
Cycle 27 Day 1	0	6	20,0	3	50,0	88,89	10,18
	1	5	13,2	5	100,0	70,67	30,40
Cycle 28 Day 1	0	5	16,7	4	80,0	90,00	8,61
	1	5	13,2	5	100,0	66,67	31,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	86,67	18,86
	1	5	13,2	5	100,0	82,67	13,00
Cycle 30 Day 1	0	3	10,0	1	33,3	86,67	-
	1	4	10,5	4	100,0	78,33	16,67
Cycle 31 Day 1	0	3	10,0	1	33,3	100,00	-
	1	4	10,5	4	100,0	78,33	16,67
Cycle 32 Day 1	0	3	10,0	2	66,7	86,67	9,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	80,00	20,00
Cycle 33 Day 1	0	2	6,7	2	100,0	86,67	9,43
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	69,52	25,58
	1	20	52,6	12	60,0	61,11	30,99
	2	4	40,0	2	50,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	69,89	20,50
	1	3	100,0	3	100,0	64,44	36,72
	2 or More	44	100,0	44	100,0	67,01	23,55
Cycle 2 Day 1	None	30	96,8	27	90,0	80,99	15,55
	1	2	66,7	1	50,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	72,25	23,65
Cycle 3 Day 1	None	30	96,8	28	93,3	83,10	13,99
	1	2	66,7	1	50,0	100,00	-
	2 or More	36	81,8	35	97,2	72,76	21,59
Cycle 4 Day 1	None	30	96,8	29	96,7	87,36	14,40
	1	2	66,7	2	100,0	90,00	14,14
	2 or More	35	79,5	33	94,3	74,14	20,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	84,44	17,18
	1	2	66,7	2	100,0	96,67	4,71
	2 or More	33	75,0	32	97,0	74,58	20,28
Cycle 6 Day 1	None	29	93,5	28	96,6	87,86	12,31
	1	2	66,7	2	100,0	90,00	14,14
	2 or More	32	72,7	30	93,8	76,44	21,14
Cycle 7 Day 1	None	27	87,1	26	96,3	84,10	14,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	83,33	14,14
	2 or More	31	70,5	29	93,5	74,94	18,91
Cycle 8 Day 1	None	26	83,9	25	96,2	85,07	16,92
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	76,54	21,59
Cycle 9 Day 1	None	25	80,6	25	100,0	88,80	13,84
	1	1	33,3	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	78,67	20,55
Cycle 10 Day 1	None	25	80,6	24	96,0	84,72	13,11
	1	1	33,3	1	100,0	100,00	-
	2 or More	25	56,8	25	100,0	77,60	19,23
Cycle 11 Day 1	None	25	80,6	25	100,0	86,93	14,84
	1	1	33,3	1	100,0	100,00	-
	2 or More	24	54,5	24	100,0	76,67	15,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	83,61	15,48
	1	1	33,3	1	100,0	100,00	-
	2 or More	23	52,3	20	87,0	73,00	19,28
Cycle 13 Day 1	None	24	77,4	23	95,8	86,09	13,32
	1	1	33,3	1	100,0	100,00	-
	2 or More	21	47,7	21	100,0	75,56	21,12
Cycle 14 Day 1	None	23	74,2	23	100,0	84,35	18,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	100,00	-
	2 or More	21	47,7	20	95,2	72,33	23,42
Cycle 15 Day 1	None	23	74,2	23	100,0	85,80	14,26
	1	1	33,3	1	100,0	93,33	-
	2 or More	20	45,5	20	100,0	73,00	21,24
Cycle 16 Day 1	None	20	64,5	19	95,0	84,21	16,36
	1	1	33,3	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	72,28	22,14
Cycle 17 Day 1	None	19	61,3	19	100,0	89,12	12,21
	1	1	33,3	1	100,0	100,00	-
	2 or More	19	43,2	19	100,0	74,74	16,57
Cycle 18 Day 1	None	18	58,1	17	94,4	90,98	12,00
	1	1	33,3	1	100,0	100,00	-
	2 or More	19	43,2	17	89,5	73,73	19,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	89,80	10,83
	1	1	33,3	1	100,0	100,00	-
	2 or More	18	40,9	15	83,3	70,22	20,14
Cycle 20 Day 1	None	17	54,8	16	94,1	91,25	8,33
	1	1	33,3	1	100,0	93,33	-
	2 or More	18	40,9	15	83,3	67,11	22,74
Cycle 21 Day 1	None	15	48,4	13	86,7	90,26	9,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	69,74	18,98
Cycle 22 Day 1	None	15	48,4	13	86,7	89,74	10,75
	2 or More	14	31,8	12	85,7	67,22	19,99
Cycle 23 Day 1	None	10	32,3	9	90,0	88,15	13,24
	2 or More	11	25,0	9	81,8	68,89	22,61
Cycle 24 Day 1	None	10	32,3	10	100,0	89,33	17,27
	2 or More	10	22,7	8	80,0	65,83	22,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	87,50	12,05
	2 or More	6	13,6	5	83,3	66,67	20,55
Cycle 26 Day 1	None	8	25,8	8	100,0	77,50	34,72
	2 or More	6	13,6	4	66,7	66,67	18,05
Cycle 27 Day 1	None	7	22,6	6	85,7	76,67	29,74
	2 or More	4	9,1	2	50,0	80,00	9,43
Cycle 28 Day 1	None	7	22,6	7	100,0	83,81	16,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	53,33	47,14
Cycle 29 Day 1	None	6	19,4	5	83,3	85,33	15,20
	2 or More	3	6,8	2	66,7	80,00	9,43
Cycle 30 Day 1	None	4	12,9	3	75,0	82,22	20,37
	2 or More	3	6,8	2	66,7	76,67	4,71
Cycle 31 Day 1	None	4	12,9	3	75,0	91,11	15,40
	2 or More	3	6,8	2	66,7	70,00	14,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	84,44	21,43
	2 or More	2	4,5	2	100,0	80,00	0,00
Cycle 33 Day 1	None	1	3,2	1	100,0	93,33	-
	2 or More	1	2,3	1	100,0	80,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	66,11	27,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	66,67	-
	2 or More	24	54,5	15	62,5	60,89	30,74
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	69,89	20,50
	Previously Treated	47	100,0	47	100,0	66,84	24,03
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	80,99	15,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	72,98	23,76
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	83,10	13,99
	Previously Treated	38	80,9	36	94,7	73,52	21,76
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	87,36	14,40
	Previously Treated	37	78,7	35	94,6	75,05	20,73
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	84,44	17,18
	Previously Treated	35	74,5	34	97,1	75,88	20,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	87,86	12,31
	Previously Treated	34	72,3	32	94,1	77,29	20,87
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	84,10	14,62
	Previously Treated	33	70,2	31	93,9	75,48	18,57
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	85,07	16,92
	Previously Treated	30	63,8	27	90,0	76,54	21,59
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	88,80	13,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	79,49	20,56
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	84,72	13,11
	Previously Treated	26	55,3	26	100,0	78,46	19,35
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	86,93	14,84
	Previously Treated	25	53,2	25	100,0	77,60	15,62
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	83,61	15,48
	Previously Treated	24	51,1	21	87,5	74,29	19,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	86,09	13,32
	Previously Treated	22	46,8	22	100,0	76,67	21,26
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	84,35	18,27
	Previously Treated	22	46,8	21	95,5	73,65	23,62
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	85,80	14,26
	Previously Treated	21	44,7	21	100,0	73,97	21,18
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	84,21	16,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	73,67	22,42
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	89,12	12,21
	Previously Treated	20	42,6	20	100,0	76,00	17,09
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	90,98	12,00
	Previously Treated	20	42,6	18	90,0	75,19	19,78
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	89,80	10,83
	Previously Treated	19	40,4	16	84,2	72,08	20,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	91,25	8,33
	Previously Treated	19	40,4	16	84,2	68,75	22,93
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	90,26	9,28
	Previously Treated	14	29,8	13	92,9	69,74	18,98
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	89,74	10,75
	Previously Treated	14	29,8	12	85,7	67,22	19,99
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	88,15	13,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	68,89	22,61
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	89,33	17,27
	Previously Treated	10	21,3	8	80,0	65,83	22,09
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	87,50	12,05
	Previously Treated	6	12,8	5	83,3	66,67	20,55
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	77,50	34,72
	Previously Treated	6	12,8	4	66,7	66,67	18,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	76,67	29,74
	Previously Treated	4	8,5	2	50,0	80,00	9,43
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	83,81	16,71
	Previously Treated	3	6,4	2	66,7	53,33	47,14
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	85,33	15,20
	Previously Treated	3	6,4	2	66,7	80,00	9,43
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	82,22	20,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	76,67	4,71
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	91,11	15,40
	Previously Treated	3	6,4	2	66,7	70,00	14,14
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	84,44	21,43
	Previously Treated	2	4,3	2	100,0	80,00	0,00
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	93,33	-
	Previously Treated	1	2,1	1	100,0	80,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	66,11	27,04
	Previously Treated	26	55,3	16	61,5	61,25	29,74
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	66,10	26,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	69,65	19,11
Cycle 2 Day 1	Local	32	91,4	30	93,8	77,33	19,78
	Central	40	93,0	35	87,5	75,43	22,22
Cycle 3 Day 1	Local	29	82,9	28	96,6	79,52	18,76
	Central	39	90,7	36	92,3	76,30	19,74
Cycle 4 Day 1	Local	28	80,0	27	96,4	83,46	16,88
	Central	39	90,7	37	94,9	78,56	20,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	82,72	17,17
	Central	38	88,4	37	97,4	77,84	20,67
Cycle 6 Day 1	Local	27	77,1	27	100,0	85,19	16,47
	Central	36	83,7	33	91,7	79,80	19,18
Cycle 7 Day 1	Local	27	77,1	27	100,0	81,48	17,96
	Central	33	76,7	30	90,9	77,56	16,75
Cycle 8 Day 1	Local	26	74,3	26	100,0	84,62	17,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	76,67	21,60
Cycle 9 Day 1	Local	25	71,4	25	100,0	82,13	21,83
	Central	26	60,5	26	100,0	85,90	13,64
Cycle 10 Day 1	Local	25	71,4	24	96,0	81,11	20,11
	Central	26	60,5	26	100,0	81,79	13,41
Cycle 11 Day 1	Local	24	68,6	24	100,0	83,06	17,47
	Central	26	60,5	26	100,0	81,54	14,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	82,42	16,91
	Central	26	60,5	23	88,5	76,23	18,84
Cycle 13 Day 1	Local	22	62,9	22	100,0	83,33	19,92
	Central	24	55,8	23	95,8	79,71	16,39
Cycle 14 Day 1	Local	22	62,9	22	100,0	81,82	22,18
	Central	23	53,5	22	95,7	76,67	20,85
Cycle 15 Day 1	Local	22	62,9	22	100,0	83,03	19,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	77,27	18,13
Cycle 16 Day 1	Local	20	57,1	20	100,0	84,33	15,49
	Central	21	48,8	19	90,5	72,98	23,14
Cycle 17 Day 1	Local	20	57,1	20	100,0	86,67	11,45
	Central	19	44,2	19	100,0	77,89	19,25
Cycle 18 Day 1	Local	20	57,1	19	95,0	87,02	15,47
	Central	18	41,9	16	88,9	77,92	20,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	84,31	13,93
	Central	17	39,5	16	94,1	77,92	22,41
Cycle 20 Day 1	Local	19	54,3	17	89,5	83,53	19,60
	Central	17	39,5	15	88,2	76,00	21,35
Cycle 21 Day 1	Local	14	40,0	12	85,7	85,56	14,17
	Central	15	34,9	14	93,3	75,24	19,99
Cycle 22 Day 1	Local	14	40,0	12	85,7	84,44	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	73,85	20,99
Cycle 23 Day 1	Local	11	31,4	10	90,9	89,33	12,25
	Central	10	23,3	8	80,0	65,00	21,31
Cycle 24 Day 1	Local	11	31,4	10	90,9	85,33	23,26
	Central	9	20,9	8	88,9	70,83	19,82
Cycle 25 Day 1	Local	7	20,0	7	100,0	88,57	12,60
	Central	8	18,6	6	75,0	68,89	19,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	81,11	25,44
	Central	8	18,6	6	75,0	66,67	34,25
Cycle 27 Day 1	Local	4	11,4	4	100,0	90,00	12,77
	Central	7	16,3	4	57,1	65,00	30,49
Cycle 28 Day 1	Local	4	11,4	4	100,0	83,33	20,73
	Central	6	14,0	5	83,3	72,00	30,70
Cycle 29 Day 1	Local	3	8,6	3	100,0	88,89	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	80,00	7,70
Cycle 30 Day 1	Local	3	8,6	3	100,0	82,22	20,37
	Central	4	9,3	2	50,0	76,67	4,71
Cycle 31 Day 1	Local	3	8,6	3	100,0	91,11	15,40
	Central	4	9,3	2	50,0	70,00	14,14
Cycle 32 Day 1	Local	3	8,6	3	100,0	84,44	21,43
	Central	3	7,0	2	66,7	80,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	93,33	-
	Central	1	2,3	1	100,0	80,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	66,19	24,45
	Central	21	48,8	14	66,7	60,48	32,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	69,21	21,73
	No	4	100,0	4	100,0	46,67	31,27
Cycle 2 Day 1	Yes	70	94,6	63	90,0	77,78	18,82
	No	2	50,0	2	100,0	30,00	42,43
Cycle 3 Day 1	Yes	66	89,2	62	93,9	77,74	19,31
	No	2	50,0	2	100,0	76,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	81,08	18,82
	No	2	50,0	2	100,0	66,67	28,28
Cycle 5 Day 1	Yes	63	85,1	62	98,4	80,65	19,11
	No	2	50,0	2	100,0	56,67	4,71
Cycle 6 Day 1	Yes	61	82,4	58	95,1	82,76	18,10
	No	2	50,0	2	100,0	66,67	9,43
Cycle 7 Day 1	Yes	58	78,4	55	94,8	79,76	17,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	70,00	14,14
Cycle 8 Day 1	Yes	54	73,0	50	92,6	81,20	19,92
	No	2	50,0	2	100,0	66,67	9,43
Cycle 9 Day 1	Yes	49	66,2	49	100,0	84,35	18,34
	No	2	50,0	2	100,0	76,67	4,71
Cycle 10 Day 1	Yes	49	66,2	48	98,0	81,39	17,12
	No	2	50,0	2	100,0	83,33	4,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	82,64	15,96
	No	2	50,0	2	100,0	73,33	9,43
Cycle 12 Day 1	Yes	47	63,5	43	91,5	79,69	18,17
	No	2	50,0	2	100,0	70,00	14,14
Cycle 13 Day 1	Yes	44	59,5	43	97,7	82,02	18,32
	No	2	50,0	2	100,0	70,00	4,71
Cycle 14 Day 1	Yes	43	58,1	42	97,7	79,84	21,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	66,67	9,43
Cycle 15 Day 1	Yes	42	56,8	42	100,0	80,79	18,81
	No	2	50,0	2	100,0	66,67	9,43
Cycle 16 Day 1	Yes	39	52,7	37	94,9	79,28	20,60
	No	2	50,0	2	100,0	70,00	4,71
Cycle 17 Day 1	Yes	37	50,0	37	100,0	83,24	15,84
	No	2	50,0	2	100,0	66,67	18,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	83,43	17,25
	No	2	50,0	2	100,0	73,33	37,71
Cycle 19 Day 1	Yes	34	45,9	32	94,1	81,25	18,81
	No	2	50,0	1	50,0	80,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	80,67	20,81
	No	2	50,0	2	100,0	70,00	14,14
Cycle 21 Day 1	Yes	27	36,5	24	88,9	80,56	18,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	73,33	18,86
Cycle 22 Day 1	Yes	27	36,5	23	85,2	80,00	19,69
	No	2	50,0	2	100,0	66,67	9,43
Cycle 23 Day 1	Yes	20	27,0	17	85,0	77,65	20,81
	No	1	25,0	1	100,0	93,33	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	77,65	22,48
	No	1	25,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	78,89	19,03
	No	1	25,0	1	100,0	86,67	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	75,15	30,85
	No	1	25,0	1	100,0	60,00	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	78,10	27,41
	No	1	25,0	1	100,0	73,33	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	80,00	25,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	53,33	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	86,67	11,93
	No	1	25,0	1	100,0	66,67	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	85,00	11,39
	No	1	25,0	1	100,0	60,00	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	85,00	19,15
	No	1	25,0	1	100,0	73,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	88,33	10,00
	No	1	25,0	1	100,0	60,00	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	86,67	9,43
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	63,33	28,20
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	55,00	20,08
	No	70	100,0	70	100,0	69,55	22,52
Cycle 2 Day 1	Yes	5	62,5	5	100,0	77,33	24,31
	No	67	95,7	60	89,6	76,22	20,92
Cycle 3 Day 1	Yes	5	62,5	5	100,0	81,33	17,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	77,40	19,50
Cycle 4 Day 1	Yes	5	62,5	5	100,0	92,00	14,45
	No	62	88,6	59	95,2	79,66	19,16
Cycle 5 Day 1	Yes	5	62,5	5	100,0	78,67	22,80
	No	60	85,7	59	98,3	80,00	19,18
Cycle 6 Day 1	Yes	5	62,5	5	100,0	82,67	17,38
	No	58	82,9	55	94,8	82,18	18,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	80,00	17,64
	No	55	78,6	52	94,5	79,36	17,43
Cycle 8 Day 1	Yes	5	62,5	5	100,0	70,67	26,92
	No	51	72,9	47	92,2	81,70	18,93
Cycle 9 Day 1	Yes	4	50,0	4	100,0	81,67	19,91
	No	47	67,1	47	100,0	84,26	18,09
Cycle 10 Day 1	Yes	4	50,0	4	100,0	75,00	22,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	82,03	16,44
Cycle 11 Day 1	Yes	4	50,0	4	100,0	70,00	22,77
	No	46	65,7	46	100,0	83,33	14,92
Cycle 12 Day 1	Yes	4	50,0	4	100,0	78,33	19,91
	No	45	64,3	41	91,1	79,35	18,06
Cycle 13 Day 1	Yes	4	50,0	4	100,0	81,67	22,69
	No	42	60,0	41	97,6	81,46	17,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	80,00	23,09
	No	41	58,6	40	97,6	79,17	21,57
Cycle 15 Day 1	Yes	4	50,0	4	100,0	76,67	19,25
	No	40	57,1	40	100,0	80,50	18,82
Cycle 16 Day 1	Yes	3	37,5	3	100,0	77,78	23,41
	No	38	54,3	36	94,7	78,89	20,25
Cycle 17 Day 1	Yes	3	37,5	3	100,0	88,89	10,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	81,85	16,53
Cycle 18 Day 1	Yes	3	37,5	3	100,0	86,67	13,33
	No	35	50,0	32	91,4	82,50	18,61
Cycle 19 Day 1	Yes	3	37,5	3	100,0	88,89	10,18
	No	33	47,1	30	90,9	80,44	19,09
Cycle 20 Day 1	Yes	3	37,5	3	100,0	86,67	11,55
	No	33	47,1	29	87,9	79,31	21,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	76,67	4,71
	No	27	38,6	24	88,9	80,28	18,70
Cycle 22 Day 1	Yes	2	25,0	2	100,0	80,00	0,00
	No	27	38,6	23	85,2	78,84	20,17
Cycle 23 Day 1	Yes	2	25,0	2	100,0	80,00	0,00
	No	19	27,1	16	84,2	78,33	21,84
Cycle 24 Day 1	Yes	2	25,0	2	100,0	80,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	78,75	23,88
Cycle 25 Day 1	Yes	2	25,0	2	100,0	80,00	0,00
	No	13	18,6	11	84,6	79,39	20,10
Cycle 26 Day 1	Yes	1	12,5	1	100,0	73,33	-
	No	13	18,6	11	84,6	73,94	31,19
Cycle 27 Day 1	Yes	1	12,5	1	100,0	80,00	-
	No	10	14,3	7	70,0	77,14	27,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	80,00	-
	No	9	12,9	8	88,9	76,67	27,60
Cycle 29 Day 1	Yes	1	12,5	1	100,0	73,33	-
	No	8	11,4	6	75,0	85,56	13,61
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	80,00	14,91
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	82,67	17,38
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	82,67	15,35
Cycle 33 Day 1	No	2	2,9	2	100,0	86,67	9,43
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	23,33	33,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	66,41	26,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30PF_SG.xls
28NOV2019 10:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	54,91	24,78
Cycle 2 Day 1	All	72	92,3	64	88,9	60,29	21,45
Cycle 3 Day 1	All	68	87,2	64	94,1	64,71	19,57
Cycle 4 Day 1	All	67	85,9	64	95,5	68,75	19,36
Cycle 5 Day 1	All	65	83,3	64	98,5	70,31	19,24
Cycle 6 Day 1	All	63	80,8	60	95,2	68,75	18,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	69,74	17,08
Cycle 8 Day 1	All	56	71,8	52	92,9	71,47	15,94
Cycle 9 Day 1	All	51	65,4	51	100,0	72,55	16,27
Cycle 10 Day 1	All	51	65,4	50	98,0	71,17	17,43
Cycle 11 Day 1	All	50	64,1	50	100,0	72,67	15,62
Cycle 12 Day 1	All	49	62,8	45	91,8	70,19	19,34
Cycle 13 Day 1	All	46	59,0	45	97,8	72,04	19,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	72,92	19,28
Cycle 15 Day 1	All	44	56,4	44	100,0	71,59	16,99
Cycle 16 Day 1	All	41	52,6	39	95,1	69,87	15,72
Cycle 17 Day 1	All	39	50,0	39	100,0	73,08	16,05
Cycle 18 Day 1	All	38	48,7	35	92,1	70,71	14,06
Cycle 19 Day 1	All	36	46,2	33	91,7	69,70	16,90
Cycle 20 Day 1	All	36	46,2	32	88,9	71,61	15,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	64,10	20,11
Cycle 22 Day 1	All	29	37,2	25	86,2	68,67	21,69
Cycle 23 Day 1	All	21	26,9	18	85,7	66,67	21,77
Cycle 24 Day 1	All	20	25,6	18	90,0	67,59	18,05
Cycle 25 Day 1	All	15	19,2	13	86,7	66,67	17,35
Cycle 26 Day 1	All	14	17,9	12	85,7	65,97	25,49
Cycle 27 Day 1	All	11	14,1	8	72,7	57,29	24,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	56,48	29,10
Cycle 29 Day 1	All	9	11,5	7	77,8	61,90	18,54
Cycle 30 Day 1	All	7	9,0	5	71,4	61,67	13,94
Cycle 31 Day 1	All	7	9,0	5	71,4	66,67	15,59
Cycle 32 Day 1	All	6	7,7	5	83,3	61,67	20,07
Cycle 33 Day 1	All	2	2,6	2	100,0	79,17	5,89
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	52,08	22,41
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	52,87	24,43
	Female	49	100,0	49	100,0	56,12	25,16
Cycle 2 Day 1	Male	27	93,1	24	88,9	57,64	20,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	61,88	22,08
Cycle 3 Day 1	Male	25	86,2	23	92,0	66,30	20,33
	Female	43	87,8	41	95,3	63,82	19,33
Cycle 4 Day 1	Male	25	86,2	25	100,0	65,00	24,41
	Female	42	85,7	39	92,9	71,15	15,16
Cycle 5 Day 1	Male	25	86,2	25	100,0	65,67	23,97
	Female	40	81,6	39	97,5	73,29	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	68,12	20,67
	Female	38	77,6	37	97,4	69,14	17,11
Cycle 7 Day 1	Male	23	79,3	23	100,0	70,29	21,73
	Female	37	75,5	34	91,9	69,36	13,41
Cycle 8 Day 1	Male	21	72,4	19	90,5	71,49	18,28
	Female	35	71,4	33	94,3	71,46	14,74
Cycle 9 Day 1	Male	18	62,1	18	100,0	74,54	15,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	71,46	16,80
Cycle 10 Day 1	Male	18	62,1	18	100,0	73,61	19,23
	Female	33	67,3	32	97,0	69,79	16,50
Cycle 11 Day 1	Male	18	62,1	18	100,0	73,61	16,48
	Female	32	65,3	32	100,0	72,14	15,35
Cycle 12 Day 1	Male	17	58,6	17	100,0	77,45	12,42
	Female	32	65,3	28	87,5	65,77	21,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	76,96	15,18
	Female	29	59,2	28	96,6	69,05	22,09
Cycle 14 Day 1	Male	17	58,6	16	94,1	76,04	14,23
	Female	28	57,1	28	100,0	71,13	21,69
Cycle 15 Day 1	Male	16	55,2	16	100,0	72,92	15,96
	Female	28	57,1	28	100,0	70,83	17,79
Cycle 16 Day 1	Male	14	48,3	14	100,0	71,43	11,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	69,00	17,92
Cycle 17 Day 1	Male	12	41,4	12	100,0	71,53	14,85
	Female	27	55,1	27	100,0	73,77	16,78
Cycle 18 Day 1	Male	11	37,9	10	90,9	71,67	16,76
	Female	27	55,1	25	92,6	70,33	13,19
Cycle 19 Day 1	Male	10	34,5	10	100,0	71,67	15,81
	Female	26	53,1	23	88,5	68,84	17,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	75,93	11,37
	Female	26	53,1	23	88,5	69,93	17,18
Cycle 21 Day 1	Male	8	27,6	8	100,0	75,00	15,43
	Female	21	42,9	18	85,7	59,26	20,39
Cycle 22 Day 1	Male	8	27,6	6	75,0	73,61	18,57
	Female	21	42,9	19	90,5	67,11	22,82
Cycle 23 Day 1	Male	5	17,2	4	80,0	79,17	17,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	63,10	22,10
Cycle 24 Day 1	Male	5	17,2	4	80,0	77,08	12,50
	Female	15	30,6	14	93,3	64,88	18,83
Cycle 25 Day 1	Male	3	10,3	2	66,7	70,83	17,68
	Female	12	24,5	11	91,7	65,91	18,05
Cycle 26 Day 1	Male	3	10,3	2	66,7	79,17	5,89
	Female	11	22,4	10	90,9	63,33	27,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	75,00	11,79
	Female	8	16,3	6	75,0	51,39	26,04
Cycle 28 Day 1	Male	2	6,9	2	100,0	70,83	17,68
	Female	8	16,3	7	87,5	52,38	31,44
Cycle 29 Day 1	Male	1	3,4	1	100,0	66,67	-
	Female	8	16,3	6	75,0	61,11	20,18
Cycle 30 Day 1	Male	1	3,4	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	60,42	15,77
Cycle 31 Day 1	Male	1	3,4	1	100,0	66,67	-
	Female	6	12,2	4	66,7	66,67	18,00
Cycle 32 Day 1	Male	1	3,4	1	100,0	50,00	-
	Female	5	10,2	4	80,0	64,58	21,92
Cycle 33 Day 1	Male	1	3,4	1	100,0	75,00	-
	Female	1	2,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	48,89	25,56
	Female	21	42,9	13	61,9	55,77	18,44
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	55,78	23,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	49,40	29,14
	>=75	2	100,0	2	100,0	66,67	23,57
Cycle 2 Day 1	18-64	59	95,2	52	88,1	61,22	21,13
	65-74	11	78,6	10	90,9	51,67	22,84
	>=75	2	100,0	2	100,0	79,17	5,89
Cycle 3 Day 1	18-64	56	90,3	52	92,9	65,54	18,38
	65-74	10	71,4	10	100,0	61,67	26,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	58,33	11,79
Cycle 4 Day 1	18-64	55	88,7	53	96,4	68,71	19,54
	65-74	10	71,4	9	90,0	69,44	13,82
	>=75	2	100,0	2	100,0	66,67	47,14
Cycle 5 Day 1	18-64	53	85,5	52	98,1	71,47	18,70
	65-74	10	71,4	10	100,0	64,17	19,27
	>=75	2	100,0	2	100,0	70,83	41,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	70,58	17,44
	65-74	10	71,4	9	90,0	63,89	22,05
	>=75	2	100,0	2	100,0	45,83	5,89
Cycle 7 Day 1	18-64	49	79,0	47	95,9	70,74	16,20
	65-74	9	64,3	8	88,9	67,71	16,93
	>=75	2	100,0	2	100,0	54,17	41,25
Cycle 8 Day 1	18-64	45	72,6	41	91,1	73,17	15,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	66,67	13,82
	>=75	2	100,0	2	100,0	58,33	35,36
Cycle 9 Day 1	18-64	40	64,5	40	100,0	75,00	15,68
	65-74	9	64,3	9	100,0	62,96	15,65
	>=75	2	100,0	2	100,0	66,67	23,57
Cycle 10 Day 1	18-64	40	64,5	39	97,5	73,72	15,59
	65-74	9	64,3	9	100,0	62,96	20,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	58,33	35,36
Cycle 11 Day 1	18-64	39	62,9	39	100,0	74,15	16,31
	65-74	9	64,3	9	100,0	69,44	11,79
	>=75	2	100,0	2	100,0	58,33	11,79
Cycle 12 Day 1	18-64	38	61,3	35	92,1	70,95	20,35
	65-74	9	64,3	8	88,9	67,71	15,71
	>=75	2	100,0	2	100,0	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	74,51	18,68
	65-74	9	64,3	9	100,0	66,67	23,94
	>=75	2	100,0	2	100,0	54,17	17,68
Cycle 14 Day 1	18-64	35	56,5	35	100,0	75,48	16,54
	65-74	9	64,3	8	88,9	63,54	28,15
	>=75	1	50,0	1	100,0	58,33	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	72,62	17,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	68,75	13,91
	>=75	1	50,0	1	100,0	58,33	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	69,01	16,56
	65-74	7	50,0	6	85,7	76,39	9,74
	>=75	1	50,0	1	100,0	58,33	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	72,66	16,56
	65-74	6	42,9	6	100,0	79,17	10,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	50,00	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	72,70	13,16
	65-74	6	42,9	5	83,3	61,67	17,28
	>=75	1	50,0	1	100,0	58,33	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	69,64	16,39
	65-74	5	35,7	4	80,0	75,00	21,52
	>=75	1	50,0	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	72,44	16,46
	65-74	5	35,7	5	100,0	68,33	14,91
	>=75	1	50,0	1	100,0	66,67	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	67,46	18,80
	65-74	4	28,6	4	100,0	50,00	24,53
	>=75	1	50,0	1	100,0	50,00	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	70,42	21,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	64,58	23,94
	>=75	1	50,0	1	100,0	50,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	64,58	21,41
	65-74	2	14,3	2	100,0	83,33	23,57
Cycle 24 Day 1	18-64	18	29,0	16	88,9	65,10	17,54
	65-74	2	14,3	2	100,0	87,50	5,89
Cycle 25 Day 1	18-64	14	22,6	12	85,7	65,28	17,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	83,33	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	65,97	25,49
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	57,29	24,98
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	56,48	29,10
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	61,90	18,54
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	61,67	13,94
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	66,67	15,59
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	56,25	18,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	83,33	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	75,00	-
	65-74	1	7,1	1	100,0	83,33	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	49,17	23,55
	65-74	10	71,4	7	70,0	58,33	19,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	66,67	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	53,81	24,86
	Other	43	100,0	43	100,0	55,81	24,97
Cycle 2 Day 1	White	33	94,3	28	84,8	59,23	22,72
	Other	39	90,7	36	92,3	61,11	20,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	63,58	24,04
	Other	37	86,0	37	100,0	65,54	15,86
Cycle 4 Day 1	White	31	88,6	28	90,3	71,73	17,91
	Other	36	83,7	36	100,0	66,44	20,36
Cycle 5 Day 1	White	31	88,6	30	96,8	69,17	21,68
	Other	34	79,1	34	100,0	71,32	17,06
Cycle 6 Day 1	White	30	85,7	28	93,3	69,94	21,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	67,71	15,80
Cycle 7 Day 1	White	29	82,9	27	93,1	70,68	18,97
	Other	31	72,1	30	96,8	68,89	15,46
Cycle 8 Day 1	White	28	80,0	24	85,7	72,22	18,50
	Other	28	65,1	28	100,0	70,83	13,70
Cycle 9 Day 1	White	26	74,3	26	100,0	74,36	19,43
	Other	25	58,1	25	100,0	70,67	12,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	69,33	22,53
	Other	25	58,1	25	100,0	73,00	10,29
Cycle 11 Day 1	White	26	74,3	26	100,0	74,68	18,18
	Other	24	55,8	24	100,0	70,49	12,28
Cycle 12 Day 1	White	26	74,3	22	84,6	70,08	22,37
	Other	23	53,5	23	100,0	70,29	16,44
Cycle 13 Day 1	White	24	68,6	23	95,8	71,01	23,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	73,11	15,84
Cycle 14 Day 1	White	24	68,6	24	100,0	72,92	23,22
	Other	21	48,8	20	95,2	72,92	13,75
Cycle 15 Day 1	White	24	68,6	24	100,0	71,53	20,10
	Other	20	46,5	20	100,0	71,67	12,80
Cycle 16 Day 1	White	22	62,9	20	90,9	69,58	17,79
	Other	19	44,2	19	100,0	70,18	13,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	74,24	18,17
	Other	17	39,5	17	100,0	71,57	13,20
Cycle 18 Day 1	White	21	60,0	18	85,7	73,61	12,54
	Other	17	39,5	17	100,0	67,65	15,28
Cycle 19 Day 1	White	20	57,1	20	100,0	69,58	17,79
	Other	16	37,2	13	81,3	69,87	16,15
Cycle 20 Day 1	White	20	57,1	17	85,0	74,51	17,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	68,33	13,80
Cycle 21 Day 1	White	16	45,7	14	87,5	64,88	22,69
	Other	13	30,2	12	92,3	63,19	17,57
Cycle 22 Day 1	White	16	45,7	13	81,3	69,87	26,25
	Other	13	30,2	12	92,3	67,36	16,46
Cycle 23 Day 1	White	12	34,3	10	83,3	61,67	25,22
	Other	9	20,9	8	88,9	72,92	15,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	63,33	20,11
	Other	9	20,9	8	88,9	72,92	14,60
Cycle 25 Day 1	White	10	28,6	8	80,0	65,63	19,64
	Other	5	11,6	5	100,0	68,33	14,91
Cycle 26 Day 1	White	10	28,6	8	80,0	66,67	29,88
	Other	4	9,3	4	100,0	64,58	17,18
Cycle 27 Day 1	White	8	22,9	5	62,5	58,33	32,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	55,56	9,62
Cycle 28 Day 1	White	7	20,0	6	85,7	69,44	22,77
	Other	3	7,0	3	100,0	30,56	24,06
Cycle 29 Day 1	White	6	17,1	4	66,7	66,67	18,00
	Other	3	7,0	3	100,0	55,56	20,97
Cycle 30 Day 1	White	4	11,4	2	50,0	75,00	11,79
	Other	3	7,0	3	100,0	52,78	4,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	79,17	17,68
	Other	3	7,0	3	100,0	58,33	8,33
Cycle 32 Day 1	White	4	11,4	3	75,0	72,22	19,25
	Other	2	4,7	2	100,0	45,83	5,89
Cycle 33 Day 1	White	2	5,7	2	100,0	79,17	5,89
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	52,78	17,88
	Other	24	55,8	16	66,7	51,56	25,86
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	64,39	27,12
	Europe (EU)	17	100,0	17	100,0	47,55	22,59
	Asia (AS)	39	100,0	39	100,0	52,78	23,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	16	80,0	61,98	23,56
	Europe (EU)	16	94,1	13	81,3	62,18	25,37
	Asia (AS)	36	92,3	35	97,2	58,81	19,38
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	65,79	22,72
	Europe (EU)	15	88,2	12	80,0	57,64	24,22
	Asia (AS)	33	84,6	33	100,0	66,67	15,45
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	75,83	19,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	63,19	15,27
	Asia (AS)	32	82,1	32	100,0	66,41	20,13
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	74,58	22,70
	Europe (EU)	15	88,2	14	93,3	67,26	17,13
	Asia (AS)	30	76,9	30	100,0	68,89	17,77
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	77,50	19,89
	Europe (EU)	14	82,4	13	92,9	64,10	19,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	64,51	14,73
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	73,61	20,46
	Europe (EU)	14	82,4	13	92,9	66,03	15,01
	Asia (AS)	27	69,2	26	96,3	68,91	15,56
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	77,45	14,06
	Europe (EU)	14	82,4	11	78,6	63,64	17,98
	Asia (AS)	24	61,5	24	100,0	70,83	15,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	74,07	19,15
	Europe (EU)	12	70,6	12	100,0	72,22	16,41
	Asia (AS)	21	53,8	21	100,0	71,43	14,09
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	74,02	17,89
	Europe (EU)	12	70,6	12	100,0	61,81	22,32
	Asia (AS)	21	53,8	21	100,0	74,21	12,05
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	74,54	17,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	71,53	15,67
	Asia (AS)	20	51,3	20	100,0	71,67	14,15
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	75,49	23,66
	Europe (EU)	12	70,6	9	75,0	62,04	8,45
	Asia (AS)	19	48,7	19	100,0	69,30	18,01
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	80,39	21,84
	Europe (EU)	11	64,7	10	90,9	60,83	19,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	70,37	15,18
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	78,92	19,79
	Europe (EU)	11	64,7	11	100,0	64,39	23,89
	Asia (AS)	17	43,6	16	94,1	72,40	13,17
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	73,53	22,29
	Europe (EU)	11	64,7	11	100,0	69,70	13,06
	Asia (AS)	16	41,0	16	100,0	70,83	13,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	76,19	15,63
	Europe (EU)	11	64,7	9	81,8	67,59	10,58
	Asia (AS)	16	41,0	16	100,0	65,63	17,18
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	76,19	20,11
	Europe (EU)	10	58,8	10	100,0	72,50	13,64
	Asia (AS)	15	38,5	15	100,0	70,56	13,68
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	77,38	15,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	68,06	6,27
	Asia (AS)	15	38,5	15	100,0	65,56	12,94
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	73,08	21,01
	Europe (EU)	9	52,9	9	100,0	70,37	13,89
	Asia (AS)	14	35,9	11	78,6	65,15	13,85
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	74,36	19,38
	Europe (EU)	9	52,9	6	66,7	76,39	8,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	66,67	14,03
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	69,17	24,23
	Europe (EU)	7	41,2	6	85,7	66,67	14,91
	Asia (AS)	11	28,2	10	90,9	57,50	18,19
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	74,17	29,25
	Europe (EU)	7	41,2	5	71,4	71,67	13,94
	Asia (AS)	11	28,2	10	90,9	61,67	14,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	70,37	30,08
	Europe (EU)	5	29,4	3	60,0	66,67	0,00
	Asia (AS)	7	17,9	6	85,7	61,11	10,09
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	70,83	21,82
	Europe (EU)	5	29,4	4	80,0	70,83	15,96
	Asia (AS)	7	17,9	6	85,7	61,11	14,59
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	72,62	16,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	75,00	11,79
	Asia (AS)	4	10,3	4	100,0	52,08	14,23
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	63,89	31,03
	Europe (EU)	4	23,5	2	50,0	91,67	11,79
	Asia (AS)	4	10,3	4	100,0	56,25	12,50
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	64,58	33,59
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	50,00	13,61
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	68,75	17,18
	Europe (EU)	2	11,8	1	50,0	100,00	-
	Asia (AS)	4	10,3	4	100,0	33,33	20,41
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	69,44	20,97
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	56,25	17,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	75,00	11,79
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	52,78	4,81
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	79,17	17,68
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	58,33	8,33
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	83,33	-
	Asia (AS)	3	7,7	2	66,7	45,83	5,89
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	75,00	-
	Europe (EU)	1	5,9	1	100,0	83,33	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	57,58	22,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	39,58	28,36
	Asia (AS)	21	53,8	13	61,9	51,28	20,65
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	68,06	17,24
	1	38	100,0	38	100,0	51,54	24,34
	2	10	100,0	10	100,0	28,33	21,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	26	86,7	60,58	21,29
	1	36	94,7	32	88,9	62,50	20,30
	2	6	60,0	6	100,0	47,22	27,22
Cycle 3 Day 1	0	29	96,7	27	93,1	64,81	22,80
	1	34	89,5	32	94,1	66,15	16,79
	2	5	50,0	5	100,0	55,00	18,26
Cycle 4 Day 1	0	29	96,7	28	96,6	72,62	17,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	66,67	20,52
	2	5	50,0	4	80,0	58,33	21,52
Cycle 5 Day 1	0	29	96,7	29	100,0	72,70	18,08
	1	33	86,8	32	97,0	69,27	20,13
	2	3	30,0	3	100,0	58,33	22,05
Cycle 6 Day 1	0	29	96,7	29	100,0	73,28	17,16
	1	31	81,6	28	90,3	64,29	19,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	66,67	16,67
Cycle 7 Day 1	0	29	96,7	28	96,6	73,21	16,72
	1	28	73,7	26	92,9	66,99	17,71
	2	3	30,0	3	100,0	61,11	9,62
Cycle 8 Day 1	0	28	93,3	26	92,9	71,79	16,17
	1	25	65,8	23	92,0	71,38	15,04
	2	3	30,0	3	100,0	69,44	26,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	71,47	16,36
	1	23	60,5	23	100,0	72,83	16,90
	2	2	20,0	2	100,0	83,33	0,00
Cycle 10 Day 1	0	26	86,7	26	100,0	71,79	18,72
	1	23	60,5	22	95,7	70,08	16,80
	2	2	20,0	2	100,0	75,00	11,79
Cycle 11 Day 1	0	26	86,7	26	100,0	75,32	12,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	68,18	17,56
	2	2	20,0	2	100,0	87,50	17,68
Cycle 12 Day 1	0	25	83,3	22	88,0	70,08	21,77
	1	22	57,9	21	95,5	69,84	17,77
	2	2	20,0	2	100,0	75,00	11,79
Cycle 13 Day 1	0	25	83,3	24	96,0	70,49	21,98
	1	20	52,6	20	100,0	73,75	18,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	75,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	72,22	23,14
	1	19	50,0	19	100,0	73,68	14,24
	2	1	10,0	1	100,0	75,00	-
Cycle 15 Day 1	0	24	80,0	24	100,0	71,88	18,36
	1	19	50,0	19	100,0	71,49	16,03
	2	1	10,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	67,92	19,17
	1	18	47,4	18	100,0	71,30	11,15
	2	1	10,0	1	100,0	83,33	-
Cycle 17 Day 1	0	21	70,0	21	100,0	74,21	15,79
	1	17	44,7	17	100,0	71,08	16,96
	2	1	10,0	1	100,0	83,33	-
Cycle 18 Day 1	0	21	70,0	18	85,7	72,22	14,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	68,23	13,68
	2	1	10,0	1	100,0	83,33	-
Cycle 19 Day 1	0	20	66,7	19	95,0	70,18	19,90
	1	15	39,5	13	86,7	67,95	12,19
	2	1	10,0	1	100,0	83,33	-
Cycle 20 Day 1	0	20	66,7	17	85,0	71,57	19,11
	1	15	39,5	14	93,3	70,83	11,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	83,33	-
Cycle 21 Day 1	0	15	50,0	14	93,3	66,07	24,12
	1	13	34,2	11	84,6	61,36	15,49
	2	1	10,0	1	100,0	66,67	-
Cycle 22 Day 1	0	15	50,0	12	80,0	70,14	26,22
	1	13	34,2	12	92,3	65,97	17,57
	2	1	10,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	65,74	28,40
	1	9	23,7	8	88,9	67,71	15,06
	2	1	10,0	1	100,0	66,67	-
Cycle 24 Day 1	0	10	33,3	9	90,0	69,44	19,98
	1	9	23,7	8	88,9	65,63	18,06
	2	1	10,0	1	100,0	66,67	-
Cycle 25 Day 1	0	8	26,7	6	75,0	65,28	21,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	67,86	14,77
Cycle 26 Day 1	0	8	26,7	6	75,0	70,83	24,58
	1	6	15,8	6	100,0	61,11	27,72
Cycle 27 Day 1	0	6	20,0	3	50,0	61,11	25,46
	1	5	13,2	5	100,0	55,00	27,39
Cycle 28 Day 1	0	5	16,7	4	80,0	70,83	25,91
	1	5	13,2	5	100,0	45,00	28,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	62,50	5,89
	1	5	13,2	5	100,0	61,67	22,52
Cycle 30 Day 1	0	3	10,0	1	33,3	66,67	-
	1	4	10,5	4	100,0	60,42	15,77
Cycle 31 Day 1	0	3	10,0	1	33,3	66,67	-
	1	4	10,5	4	100,0	66,67	18,00
Cycle 32 Day 1	0	3	10,0	2	66,7	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	58,33	22,05
Cycle 33 Day 1	0	2	6,7	2	100,0	79,17	5,89
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	61,31	20,04
	1	20	52,6	12	60,0	43,75	23,06
	2	4	40,0	2	50,0	37,50	5,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	62,63	23,16
	1	3	100,0	3	100,0	58,33	30,05
	2 or More	44	100,0	44	100,0	49,24	24,63
Cycle 2 Day 1	None	30	96,8	26	86,7	61,86	23,94
	1	2	66,7	1	50,0	91,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	58,33	19,34
Cycle 3 Day 1	None	30	96,8	28	93,3	66,96	18,91
	1	2	66,7	1	50,0	100,00	-
	2 or More	36	81,8	35	97,2	61,90	19,42
Cycle 4 Day 1	None	30	96,8	29	96,7	71,55	21,99
	1	2	66,7	2	100,0	83,33	23,57
	2 or More	35	79,5	33	94,3	65,40	16,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	71,67	21,84
	1	2	66,7	2	100,0	91,67	11,79
	2 or More	33	75,0	32	97,0	67,71	16,22
Cycle 6 Day 1	None	29	93,5	28	96,6	75,30	18,35
	1	2	66,7	2	100,0	79,17	17,68
	2 or More	32	72,7	30	93,8	61,94	16,33
Cycle 7 Day 1	None	27	87,1	26	96,3	72,12	17,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	75,00	11,79
	2 or More	31	70,5	29	93,5	67,24	17,38
Cycle 8 Day 1	None	26	83,9	25	96,2	77,00	13,88
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	66,36	16,26
Cycle 9 Day 1	None	25	80,6	25	100,0	76,00	15,65
	1	1	33,3	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	68,67	16,54
Cycle 10 Day 1	None	25	80,6	24	96,0	72,92	15,40
	1	1	33,3	1	100,0	91,67	-
	2 or More	25	56,8	25	100,0	68,67	19,14
Cycle 11 Day 1	None	25	80,6	25	100,0	74,67	17,09
	1	1	33,3	1	100,0	83,33	-
	2 or More	24	54,5	24	100,0	70,14	14,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	75,69	14,10
	1	1	33,3	1	100,0	83,33	-
	2 or More	23	52,3	20	87,0	62,92	22,86
Cycle 13 Day 1	None	24	77,4	23	95,8	77,54	16,56
	1	1	33,3	1	100,0	100,00	-
	2 or More	21	47,7	21	100,0	64,68	21,07
Cycle 14 Day 1	None	23	74,2	23	100,0	78,26	14,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	83,33	-
	2 or More	21	47,7	20	95,2	66,25	22,86
Cycle 15 Day 1	None	23	74,2	23	100,0	74,28	14,63
	1	1	33,3	1	100,0	83,33	-
	2 or More	20	45,5	20	100,0	67,92	19,36
Cycle 16 Day 1	None	20	64,5	19	95,0	71,93	18,47
	1	1	33,3	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	67,11	12,57
Cycle 17 Day 1	None	19	61,3	19	100,0	76,75	14,32
	1	1	33,3	1	100,0	83,33	-
	2 or More	19	43,2	19	100,0	68,86	17,31
Cycle 18 Day 1	None	18	58,1	17	94,4	75,00	13,50
	1	1	33,3	1	100,0	91,67	-
	2 or More	19	43,2	17	89,5	65,20	12,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	75,98	14,09
	1	1	33,3	1	100,0	83,33	-
	2 or More	18	40,9	15	83,3	61,67	17,19
Cycle 20 Day 1	None	17	54,8	16	94,1	76,56	12,99
	1	1	33,3	1	100,0	66,67	-
	2 or More	18	40,9	15	83,3	66,67	17,82
Cycle 21 Day 1	None	15	48,4	13	86,7	73,72	17,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	54,49	18,51
Cycle 22 Day 1	None	15	48,4	13	86,7	80,13	12,52
	2 or More	14	31,8	12	85,7	56,25	23,06
Cycle 23 Day 1	None	10	32,3	9	90,0	76,85	17,07
	2 or More	11	25,0	9	81,8	56,48	21,96
Cycle 24 Day 1	None	10	32,3	10	100,0	73,33	19,95
	2 or More	10	22,7	8	80,0	60,42	13,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	69,79	19,38
	2 or More	6	13,6	5	83,3	61,67	13,94
Cycle 26 Day 1	None	8	25,8	8	100,0	71,88	26,70
	2 or More	6	13,6	4	66,7	54,17	20,97
Cycle 27 Day 1	None	7	22,6	6	85,7	59,72	29,07
	2 or More	4	9,1	2	50,0	50,00	0,00
Cycle 28 Day 1	None	7	22,6	7	100,0	61,90	28,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	37,50	29,46
Cycle 29 Day 1	None	6	19,4	5	83,3	60,00	21,57
	2 or More	3	6,8	2	66,7	66,67	11,79
Cycle 30 Day 1	None	4	12,9	3	75,0	66,67	16,67
	2 or More	3	6,8	2	66,7	54,17	5,89
Cycle 31 Day 1	None	4	12,9	3	75,0	69,44	20,97
	2 or More	3	6,8	2	66,7	62,50	5,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	61,11	19,25
	2 or More	2	4,5	2	100,0	62,50	29,46
Cycle 33 Day 1	None	1	3,2	1	100,0	75,00	-
	2 or More	1	2,3	1	100,0	83,33	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	56,25	25,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	58,33	-
	2 or More	24	54,5	15	62,5	48,33	20,70
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	62,63	23,16
	Previously Treated	47	100,0	47	100,0	49,82	24,73
Cycle 2 Day 1	Naïve	30	96,8	26	86,7	61,86	23,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	59,21	19,83
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	66,96	18,91
	Previously Treated	38	80,9	36	94,7	62,96	20,16
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	71,55	21,99
	Previously Treated	37	78,7	35	94,6	66,43	16,85
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	71,67	21,84
	Previously Treated	35	74,5	34	97,1	69,12	16,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	75,30	18,35
	Previously Treated	34	72,3	32	94,1	63,02	16,66
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	72,12	17,15
	Previously Treated	33	70,2	31	93,9	67,74	17,04
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	77,00	13,88
	Previously Treated	30	63,8	27	90,0	66,36	16,26
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	76,00	15,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	69,23	16,46
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	72,92	15,40
	Previously Treated	26	55,3	26	100,0	69,55	19,28
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	74,67	17,09
	Previously Treated	25	53,2	25	100,0	70,67	14,05
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	75,69	14,10
	Previously Treated	24	51,1	21	87,5	63,89	22,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	77,54	16,56
	Previously Treated	22	46,8	22	100,0	66,29	21,89
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	78,26	14,16
	Previously Treated	22	46,8	21	95,5	67,06	22,59
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	74,28	14,63
	Previously Treated	21	44,7	21	100,0	68,65	19,17
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	71,93	18,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	67,92	12,76
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	76,75	14,32
	Previously Treated	20	42,6	20	100,0	69,58	17,16
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	75,00	13,50
	Previously Treated	20	42,6	18	90,0	66,67	13,71
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	75,98	14,09
	Previously Treated	19	40,4	16	84,2	63,02	17,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	76,56	12,99
	Previously Treated	19	40,4	16	84,2	66,67	17,21
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	73,72	17,30
	Previously Treated	14	29,8	13	92,9	54,49	18,51
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	80,13	12,52
	Previously Treated	14	29,8	12	85,7	56,25	23,06
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	76,85	17,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	56,48	21,96
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	73,33	19,95
	Previously Treated	10	21,3	8	80,0	60,42	13,18
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	69,79	19,38
	Previously Treated	6	12,8	5	83,3	61,67	13,94
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	71,88	26,70
	Previously Treated	6	12,8	4	66,7	54,17	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	59,72	29,07
	Previously Treated	4	8,5	2	50,0	50,00	0,00
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	61,90	28,81
	Previously Treated	3	6,4	2	66,7	37,50	29,46
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	60,00	21,57
	Previously Treated	3	6,4	2	66,7	66,67	11,79
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	66,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	54,17	5,89
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	69,44	20,97
	Previously Treated	3	6,4	2	66,7	62,50	5,89
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	61,11	19,25
	Previously Treated	2	4,3	2	100,0	62,50	29,46
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	75,00	-
	Previously Treated	1	2,1	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	56,25	25,41
	Previously Treated	26	55,3	16	61,5	48,96	20,16
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	56,67	27,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	53,49	22,51
Cycle 2 Day 1	Local	32	91,4	29	90,6	61,21	19,32
	Central	40	93,0	35	87,5	59,52	23,32
Cycle 3 Day 1	Local	29	82,9	28	96,6	66,37	20,09
	Central	39	90,7	36	92,3	63,43	19,34
Cycle 4 Day 1	Local	28	80,0	27	96,4	69,75	20,30
	Central	39	90,7	37	94,9	68,02	18,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	70,99	21,60
	Central	38	88,4	37	97,4	69,82	17,61
Cycle 6 Day 1	Local	27	77,1	27	100,0	72,53	18,75
	Central	36	83,7	33	91,7	65,66	17,77
Cycle 7 Day 1	Local	27	77,1	27	100,0	76,23	16,13
	Central	33	76,7	30	90,9	63,89	15,98
Cycle 8 Day 1	Local	26	74,3	26	100,0	75,96	13,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	66,99	17,40
Cycle 9 Day 1	Local	25	71,4	25	100,0	73,00	17,39
	Central	26	60,5	26	100,0	72,12	15,45
Cycle 10 Day 1	Local	25	71,4	24	96,0	72,57	18,95
	Central	26	60,5	26	100,0	69,87	16,17
Cycle 11 Day 1	Local	24	68,6	24	100,0	75,35	16,20
	Central	26	60,5	26	100,0	70,19	14,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	77,65	13,94
	Central	26	60,5	23	88,5	63,04	21,29
Cycle 13 Day 1	Local	22	62,9	22	100,0	77,65	19,31
	Central	24	55,8	23	95,8	66,67	19,46
Cycle 14 Day 1	Local	22	62,9	22	100,0	77,27	20,60
	Central	23	53,5	22	95,7	68,56	17,24
Cycle 15 Day 1	Local	22	62,9	22	100,0	73,11	15,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	70,08	18,30
Cycle 16 Day 1	Local	20	57,1	20	100,0	75,83	11,44
	Central	21	48,8	19	90,5	63,60	17,39
Cycle 17 Day 1	Local	20	57,1	20	100,0	77,08	12,35
	Central	19	44,2	19	100,0	68,86	18,60
Cycle 18 Day 1	Local	20	57,1	19	95,0	75,44	12,57
	Central	18	41,9	16	88,9	65,10	14,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	73,04	13,67
	Central	17	39,5	16	94,1	66,15	19,60
Cycle 20 Day 1	Local	19	54,3	17	89,5	76,47	11,12
	Central	17	39,5	15	88,2	66,11	18,76
Cycle 21 Day 1	Local	14	40,0	12	85,7	68,75	20,14
	Central	15	34,9	14	93,3	60,12	19,93
Cycle 22 Day 1	Local	14	40,0	12	85,7	76,39	19,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	61,54	22,19
Cycle 23 Day 1	Local	11	31,4	10	90,9	78,33	12,55
	Central	10	23,3	8	80,0	52,08	22,60
Cycle 24 Day 1	Local	11	31,4	10	90,9	75,00	14,70
	Central	9	20,9	8	88,9	58,33	18,37
Cycle 25 Day 1	Local	7	20,0	7	100,0	73,81	15,54
	Central	8	18,6	6	75,0	58,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	73,61	20,69
	Central	8	18,6	6	75,0	58,33	29,34
Cycle 27 Day 1	Local	4	11,4	4	100,0	77,08	12,50
	Central	7	16,3	4	57,1	37,50	15,96
Cycle 28 Day 1	Local	4	11,4	4	100,0	60,42	31,46
	Central	6	14,0	5	83,3	53,33	30,39
Cycle 29 Day 1	Local	3	8,6	3	100,0	63,89	29,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	60,42	10,49
Cycle 30 Day 1	Local	3	8,6	3	100,0	66,67	16,67
	Central	4	9,3	2	50,0	54,17	5,89
Cycle 31 Day 1	Local	3	8,6	3	100,0	69,44	20,97
	Central	4	9,3	2	50,0	62,50	5,89
Cycle 32 Day 1	Local	3	8,6	3	100,0	61,11	19,25
	Central	3	7,0	2	66,7	62,50	29,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	75,00	-
	Central	1	2,3	1	100,0	83,33	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	55,95	19,46
	Central	21	48,8	14	66,7	48,21	25,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	55,52	24,26
	No	4	100,0	4	100,0	43,75	35,60
Cycle 2 Day 1	Yes	70	94,6	62	88,6	61,69	20,04
	No	2	50,0	2	100,0	16,67	23,57
Cycle 3 Day 1	Yes	66	89,2	62	93,9	65,05	19,66
	No	2	50,0	2	100,0	54,17	17,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	69,09	19,58
	No	2	50,0	2	100,0	58,33	0,00
Cycle 5 Day 1	Yes	63	85,1	62	98,4	70,97	19,19
	No	2	50,0	2	100,0	50,00	0,00
Cycle 6 Day 1	Yes	61	82,4	58	95,1	69,11	18,54
	No	2	50,0	2	100,0	58,33	11,79
Cycle 7 Day 1	Yes	58	78,4	55	94,8	69,85	17,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	66,67	0,00
Cycle 8 Day 1	Yes	54	73,0	50	92,6	71,83	16,14
	No	2	50,0	2	100,0	62,50	5,89
Cycle 9 Day 1	Yes	49	66,2	49	100,0	73,47	15,93
	No	2	50,0	2	100,0	50,00	0,00
Cycle 10 Day 1	Yes	49	66,2	48	98,0	71,53	17,68
	No	2	50,0	2	100,0	62,50	5,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	72,57	15,84
	No	2	50,0	2	100,0	75,00	11,79
Cycle 12 Day 1	Yes	47	63,5	43	91,5	70,16	19,77
	No	2	50,0	2	100,0	70,83	5,89
Cycle 13 Day 1	Yes	44	59,5	43	97,7	72,29	20,39
	No	2	50,0	2	100,0	66,67	0,00
Cycle 14 Day 1	Yes	43	58,1	42	97,7	73,21	19,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	66,67	23,57
Cycle 15 Day 1	Yes	42	56,8	42	100,0	72,22	17,04
	No	2	50,0	2	100,0	58,33	11,79
Cycle 16 Day 1	Yes	39	52,7	37	94,9	70,50	15,79
	No	2	50,0	2	100,0	58,33	11,79
Cycle 17 Day 1	Yes	37	50,0	37	100,0	73,87	15,98
	No	2	50,0	2	100,0	58,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	70,71	14,15
	No	2	50,0	2	100,0	70,83	17,68
Cycle 19 Day 1	Yes	34	45,9	32	94,1	70,05	17,05
	No	2	50,0	1	50,0	58,33	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	72,22	16,13
	No	2	50,0	2	100,0	62,50	5,89
Cycle 21 Day 1	Yes	27	36,5	24	88,9	64,93	20,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	54,17	17,68
Cycle 22 Day 1	Yes	27	36,5	23	85,2	69,20	22,53
	No	2	50,0	2	100,0	62,50	5,89
Cycle 23 Day 1	Yes	20	27,0	17	85,0	66,18	22,34
	No	1	25,0	1	100,0	75,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	66,67	18,16
	No	1	25,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	66,67	18,12
	No	1	25,0	1	100,0	66,67	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	65,15	26,57
	No	1	25,0	1	100,0	75,00	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	55,95	26,66
	No	1	25,0	1	100,0	66,67	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	61,46	26,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	16,67	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	66,67	14,91
	No	1	25,0	1	100,0	33,33	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	64,58	14,23
	No	1	25,0	1	100,0	50,00	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	70,83	14,43
	No	1	25,0	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	64,58	21,92
	No	1	25,0	1	100,0	50,00	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	79,17	5,89
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	52,08	22,41
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	53,13	26,70
	No	70	100,0	70	100,0	55,12	24,75
Cycle 2 Day 1	Yes	5	62,5	5	100,0	73,33	22,36
	No	67	95,7	59	88,1	59,18	21,20
Cycle 3 Day 1	Yes	5	62,5	5	100,0	66,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	64,55	19,91
Cycle 4 Day 1	Yes	5	62,5	5	100,0	73,33	25,28
	No	62	88,6	59	95,2	68,36	19,00
Cycle 5 Day 1	Yes	5	62,5	5	100,0	65,00	27,89
	No	60	85,7	59	98,3	70,76	18,59
Cycle 6 Day 1	Yes	5	62,5	5	100,0	70,00	32,06
	No	58	82,9	55	94,8	68,64	17,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	61,67	24,72
	No	55	78,6	52	94,5	70,51	16,29
Cycle 8 Day 1	Yes	5	62,5	5	100,0	71,67	9,50
	No	51	72,9	47	92,2	71,45	16,55
Cycle 9 Day 1	Yes	4	50,0	4	100,0	64,58	21,92
	No	47	67,1	47	100,0	73,23	15,82
Cycle 10 Day 1	Yes	4	50,0	4	100,0	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	71,56	17,09
Cycle 11 Day 1	Yes	4	50,0	4	100,0	62,50	20,97
	No	46	65,7	46	100,0	73,55	15,04
Cycle 12 Day 1	Yes	4	50,0	4	100,0	70,83	15,96
	No	45	64,3	41	91,1	70,12	19,81
Cycle 13 Day 1	Yes	4	50,0	4	100,0	75,00	21,52
	No	42	60,0	41	97,6	71,75	20,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	70,83	15,96
	No	41	58,6	40	97,6	73,13	19,75
Cycle 15 Day 1	Yes	4	50,0	4	100,0	64,58	21,92
	No	40	57,1	40	100,0	72,29	16,60
Cycle 16 Day 1	Yes	3	37,5	3	100,0	63,89	33,68
	No	38	54,3	36	94,7	70,37	14,15
Cycle 17 Day 1	Yes	3	37,5	3	100,0	77,78	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	72,69	16,50
Cycle 18 Day 1	Yes	3	37,5	3	100,0	75,00	14,43
	No	35	50,0	32	91,4	70,31	14,19
Cycle 19 Day 1	Yes	3	37,5	3	100,0	75,00	14,43
	No	33	47,1	30	90,9	69,17	17,25
Cycle 20 Day 1	Yes	3	37,5	3	100,0	72,22	9,62
	No	33	47,1	29	87,9	71,55	16,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	41,67	11,79
	No	27	38,6	24	88,9	65,97	19,65
Cycle 22 Day 1	Yes	2	25,0	2	100,0	70,83	17,68
	No	27	38,6	23	85,2	68,48	22,33
Cycle 23 Day 1	Yes	2	25,0	2	100,0	66,67	23,57
	No	19	27,1	16	84,2	66,67	22,36
Cycle 24 Day 1	Yes	2	25,0	2	100,0	62,50	29,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	68,23	17,54
Cycle 25 Day 1	Yes	2	25,0	2	100,0	58,33	35,36
	No	13	18,6	11	84,6	68,18	14,82
Cycle 26 Day 1	Yes	1	12,5	1	100,0	50,00	-
	No	13	18,6	11	84,6	67,42	26,21
Cycle 27 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	10	14,3	7	70,0	60,71	24,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	41,67	-
	No	9	12,9	8	88,9	58,33	30,54
Cycle 29 Day 1	Yes	1	12,5	1	100,0	58,33	-
	No	8	11,4	6	75,0	62,50	20,24
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	61,67	13,94
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	66,67	15,59
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	61,67	20,07
Cycle 33 Day 1	No	2	2,9	2	100,0	79,17	5,89
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	20,83	17,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	54,49	21,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30QL_SG.xls
28NOV2019 10:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	60,68	28,17
Cycle 2 Day 1	All	72	92,3	65	90,3	66,92	30,12
Cycle 3 Day 1	All	68	87,2	64	94,1	70,83	25,02
Cycle 4 Day 1	All	67	85,9	64	95,5	74,74	23,00
Cycle 5 Day 1	All	65	83,3	64	98,5	72,66	23,45
Cycle 6 Day 1	All	63	80,8	60	95,2	74,44	22,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	74,56	21,62
Cycle 8 Day 1	All	56	71,8	52	92,9	72,12	23,51
Cycle 9 Day 1	All	51	65,4	51	100,0	75,82	22,44
Cycle 10 Day 1	All	51	65,4	50	98,0	76,67	22,34
Cycle 11 Day 1	All	50	64,1	50	100,0	75,67	21,35
Cycle 12 Day 1	All	49	62,8	45	91,8	73,33	21,73
Cycle 13 Day 1	All	46	59,0	45	97,8	78,15	25,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	71,59	25,56
Cycle 15 Day 1	All	44	56,4	44	100,0	71,59	26,31
Cycle 16 Day 1	All	41	52,6	39	95,1	73,93	22,23
Cycle 17 Day 1	All	39	50,0	39	100,0	73,50	23,79
Cycle 18 Day 1	All	38	48,7	35	92,1	75,71	21,14
Cycle 19 Day 1	All	36	46,2	33	91,7	72,73	25,62
Cycle 20 Day 1	All	36	46,2	32	88,9	71,88	23,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	71,79	21,99
Cycle 22 Day 1	All	29	37,2	25	86,2	70,00	24,06
Cycle 23 Day 1	All	21	26,9	18	85,7	73,15	26,90
Cycle 24 Day 1	All	20	25,6	18	90,0	70,37	27,75
Cycle 25 Day 1	All	15	19,2	13	86,7	70,51	28,99
Cycle 26 Day 1	All	14	17,9	12	85,7	72,22	27,83
Cycle 27 Day 1	All	11	14,1	8	72,7	68,75	32,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	68,52	33,79
Cycle 29 Day 1	All	9	11,5	7	77,8	73,81	21,21
Cycle 30 Day 1	All	7	9,0	5	71,4	76,67	22,36
Cycle 31 Day 1	All	7	9,0	5	71,4	73,33	14,91
Cycle 32 Day 1	All	6	7,7	5	83,3	80,00	18,26
Cycle 33 Day 1	All	2	2,6	2	100,0	83,33	23,57
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	52,98	34,86
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	56,90	30,38
	Female	49	100,0	49	100,0	62,93	26,85
Cycle 2 Day 1	Male	27	93,1	25	92,6	62,67	30,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	69,58	29,93
Cycle 3 Day 1	Male	25	86,2	23	92,0	75,36	25,56
	Female	43	87,8	41	95,3	68,29	24,67
Cycle 4 Day 1	Male	25	86,2	25	100,0	74,00	25,95
	Female	42	85,7	39	92,9	75,21	21,24
Cycle 5 Day 1	Male	25	86,2	25	100,0	73,33	25,46
	Female	40	81,6	39	97,5	72,22	22,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	78,99	21,45
	Female	38	77,6	37	97,4	71,62	22,86
Cycle 7 Day 1	Male	23	79,3	23	100,0	73,91	23,48
	Female	37	75,5	34	91,9	75,00	20,62
Cycle 8 Day 1	Male	21	72,4	19	90,5	71,93	22,26
	Female	35	71,4	33	94,3	72,22	24,53
Cycle 9 Day 1	Male	18	62,1	18	100,0	76,85	22,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	75,25	22,49
Cycle 10 Day 1	Male	18	62,1	18	100,0	77,78	22,87
	Female	33	67,3	32	97,0	76,04	22,38
Cycle 11 Day 1	Male	18	62,1	18	100,0	75,00	25,08
	Female	32	65,3	32	100,0	76,04	19,37
Cycle 12 Day 1	Male	17	58,6	17	100,0	73,53	21,29
	Female	32	65,3	28	87,5	73,21	22,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	81,37	22,73
	Female	29	59,2	28	96,6	76,19	26,62
Cycle 14 Day 1	Male	17	58,6	16	94,1	70,83	23,96
	Female	28	57,1	28	100,0	72,02	26,86
Cycle 15 Day 1	Male	16	55,2	16	100,0	77,08	20,97
	Female	28	57,1	28	100,0	68,45	28,81
Cycle 16 Day 1	Male	14	48,3	14	100,0	75,00	20,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	73,33	23,57
Cycle 17 Day 1	Male	12	41,4	12	100,0	79,17	23,70
	Female	27	55,1	27	100,0	70,99	23,84
Cycle 18 Day 1	Male	11	37,9	10	90,9	80,00	23,31
	Female	27	55,1	25	92,6	74,00	20,46
Cycle 19 Day 1	Male	10	34,5	10	100,0	71,67	29,45
	Female	26	53,1	23	88,5	73,19	24,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	75,93	22,22
	Female	26	53,1	23	88,5	70,29	24,08
Cycle 21 Day 1	Male	8	27,6	8	100,0	77,08	23,46
	Female	21	42,9	18	85,7	69,44	21,58
Cycle 22 Day 1	Male	8	27,6	6	75,0	66,67	29,81
	Female	21	42,9	19	90,5	71,05	22,80
Cycle 23 Day 1	Male	5	17,2	4	80,0	87,50	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	69,05	28,39
Cycle 24 Day 1	Male	5	17,2	4	80,0	91,67	16,67
	Female	15	30,6	14	93,3	64,29	27,62
Cycle 25 Day 1	Male	3	10,3	2	66,7	91,67	11,79
	Female	12	24,5	11	91,7	66,67	29,81
Cycle 26 Day 1	Male	3	10,3	2	66,7	100,00	0,00
	Female	11	22,4	10	90,9	66,67	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	91,67	11,79
	Female	8	16,3	6	75,0	61,11	34,43
Cycle 28 Day 1	Male	2	6,9	2	100,0	75,00	11,79
	Female	8	16,3	7	87,5	66,67	38,49
Cycle 29 Day 1	Male	1	3,4	1	100,0	100,00	-
	Female	8	16,3	6	75,0	69,44	19,48
Cycle 30 Day 1	Male	1	3,4	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	70,83	20,97
Cycle 31 Day 1	Male	1	3,4	1	100,0	100,00	-
	Female	6	12,2	4	66,7	66,67	0,00
Cycle 32 Day 1	Male	1	3,4	1	100,0	100,00	-
	Female	5	10,2	4	80,0	75,00	16,67
Cycle 33 Day 1	Male	1	3,4	1	100,0	100,00	-
	Female	1	2,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	46,67	34,62
	Female	21	42,9	13	61,9	60,26	35,05
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	60,48	26,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	58,33	36,25
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 2 Day 1	18-64	59	95,2	53	89,8	70,13	29,66
	65-74	11	78,6	10	90,9	48,33	27,72
	>=75	2	100,0	2	100,0	75,00	35,36
Cycle 3 Day 1	18-64	56	90,3	52	92,9	71,79	23,92
	65-74	10	71,4	10	100,0	65,00	30,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	75,00	35,36
Cycle 4 Day 1	18-64	55	88,7	53	96,4	74,84	23,26
	65-74	10	71,4	9	90,0	72,22	23,57
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 5 Day 1	18-64	53	85,5	52	98,1	73,40	24,31
	65-74	10	71,4	10	100,0	68,33	18,34
	>=75	2	100,0	2	100,0	75,00	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	75,17	23,35
	65-74	10	71,4	9	90,0	68,52	17,57
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 7 Day 1	18-64	49	79,0	47	95,9	75,89	21,37
	65-74	9	64,3	8	88,9	64,58	22,60
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 8 Day 1	18-64	45	72,6	41	91,1	72,36	24,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	72,22	11,79
	>=75	2	100,0	2	100,0	66,67	47,14
Cycle 9 Day 1	18-64	40	64,5	40	100,0	78,75	19,24
	65-74	9	64,3	9	100,0	64,81	29,40
	>=75	2	100,0	2	100,0	66,67	47,14
Cycle 10 Day 1	18-64	40	64,5	39	97,5	77,35	21,79
	65-74	9	64,3	9	100,0	75,93	22,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	66,67	47,14
Cycle 11 Day 1	18-64	39	62,9	39	100,0	77,35	20,41
	65-74	9	64,3	9	100,0	70,37	21,70
	>=75	2	100,0	2	100,0	66,67	47,14
Cycle 12 Day 1	18-64	38	61,3	35	92,1	74,29	22,27
	65-74	9	64,3	8	88,9	66,67	19,92
	>=75	2	100,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	80,88	23,62
	65-74	9	64,3	9	100,0	68,52	29,40
	>=75	2	100,0	2	100,0	75,00	35,36
Cycle 14 Day 1	18-64	35	56,5	35	100,0	74,76	24,71
	65-74	9	64,3	8	88,9	60,42	28,08
	>=75	1	50,0	1	100,0	50,00	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	74,76	25,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	58,33	29,55
	>=75	1	50,0	1	100,0	66,67	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	76,56	21,94
	65-74	7	50,0	6	85,7	63,89	22,15
	>=75	1	50,0	1	100,0	50,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	75,52	24,31
	65-74	6	42,9	6	100,0	69,44	16,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	33,33	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	78,16	20,46
	65-74	6	42,9	5	83,3	70,00	18,26
	>=75	1	50,0	1	100,0	33,33	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	76,19	25,43
	65-74	5	35,7	4	80,0	58,33	16,67
	>=75	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	75,64	22,72
	65-74	5	35,7	5	100,0	60,00	19,00
	>=75	1	50,0	1	100,0	33,33	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	73,02	22,03
	65-74	4	28,6	4	100,0	75,00	16,67
	>=75	1	50,0	1	100,0	33,33	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	72,50	25,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	66,67	0,00
	>=75	1	50,0	1	100,0	33,33	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	72,92	28,46
	65-74	2	14,3	2	100,0	75,00	11,79
Cycle 24 Day 1	18-64	18	29,0	16	88,9	68,75	28,46
	65-74	2	14,3	2	100,0	83,33	23,57
Cycle 25 Day 1	18-64	14	22,6	12	85,7	70,83	30,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	66,67	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	72,22	27,83
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	68,75	32,66
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	68,52	33,79
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	73,81	21,21
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	76,67	22,36
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	73,33	14,91
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	83,33	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	66,67	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	100,00	-
	65-74	1	7,1	1	100,0	66,67	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	50,00	36,27
	65-74	10	71,4	7	70,0	54,76	29,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	100,00	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	56,19	28,61
	Other	43	100,0	43	100,0	64,34	27,60
Cycle 2 Day 1	White	33	94,3	29	87,9	62,64	35,54
	Other	39	90,7	36	92,3	70,37	24,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	64,81	30,78
	Other	37	86,0	37	100,0	75,23	19,09
Cycle 4 Day 1	White	31	88,6	28	90,3	76,19	22,87
	Other	36	83,7	36	100,0	73,61	23,36
Cycle 5 Day 1	White	31	88,6	30	96,8	74,44	28,28
	Other	34	79,1	34	100,0	71,08	18,49
Cycle 6 Day 1	White	30	85,7	28	93,3	73,81	26,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	75,00	18,45
Cycle 7 Day 1	White	29	82,9	27	93,1	75,31	24,18
	Other	31	72,1	30	96,8	73,89	19,42
Cycle 8 Day 1	White	28	80,0	24	85,7	74,31	26,91
	Other	28	65,1	28	100,0	70,24	20,47
Cycle 9 Day 1	White	26	74,3	26	100,0	78,21	26,99
	Other	25	58,1	25	100,0	73,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	74,00	25,50
	Other	25	58,1	25	100,0	79,33	18,81
Cycle 11 Day 1	White	26	74,3	26	100,0	78,21	24,84
	Other	24	55,8	24	100,0	72,92	16,89
Cycle 12 Day 1	White	26	74,3	22	84,6	74,24	26,59
	Other	23	53,5	23	100,0	72,46	16,37
Cycle 13 Day 1	White	24	68,6	23	95,8	78,26	31,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	78,03	15,76
Cycle 14 Day 1	White	24	68,6	24	100,0	73,61	29,86
	Other	21	48,8	20	95,2	69,17	19,70
Cycle 15 Day 1	White	24	68,6	24	100,0	74,31	30,29
	Other	20	46,5	20	100,0	68,33	20,87
Cycle 16 Day 1	White	22	62,9	20	90,9	79,17	22,21
	Other	19	44,2	19	100,0	68,42	21,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	75,00	27,58
	Other	17	39,5	17	100,0	71,57	18,41
Cycle 18 Day 1	White	21	60,0	18	85,7	78,70	24,79
	Other	17	39,5	17	100,0	72,55	16,61
Cycle 19 Day 1	White	20	57,1	20	100,0	73,33	29,81
	Other	16	37,2	13	81,3	71,79	18,49
Cycle 20 Day 1	White	20	57,1	17	85,0	75,49	28,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	67,78	14,73
Cycle 21 Day 1	White	16	45,7	14	87,5	70,24	27,87
	Other	13	30,2	12	92,3	73,61	13,22
Cycle 22 Day 1	White	16	45,7	13	81,3	71,79	30,72
	Other	13	30,2	12	92,3	68,06	15,01
Cycle 23 Day 1	White	12	34,3	10	83,3	70,00	30,23
	Other	9	20,9	8	88,9	77,08	23,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	70,00	29,19
	Other	9	20,9	8	88,9	70,83	27,82
Cycle 25 Day 1	White	10	28,6	8	80,0	72,92	21,71
	Other	5	11,6	5	100,0	66,67	40,82
Cycle 26 Day 1	White	10	28,6	8	80,0	72,92	32,04
	Other	4	9,3	4	100,0	70,83	20,97
Cycle 27 Day 1	White	8	22,9	5	62,5	66,67	42,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	72,22	9,62
Cycle 28 Day 1	White	7	20,0	6	85,7	86,11	16,39
	Other	3	7,0	3	100,0	33,33	33,33
Cycle 29 Day 1	White	6	17,1	4	66,7	83,33	19,25
	Other	3	7,0	3	100,0	61,11	19,25
Cycle 30 Day 1	White	4	11,4	2	50,0	100,00	0,00
	Other	3	7,0	3	100,0	61,11	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	83,33	23,57
	Other	3	7,0	3	100,0	66,67	0,00
Cycle 32 Day 1	White	4	11,4	3	75,0	88,89	19,25
	Other	2	4,7	2	100,0	66,67	0,00
Cycle 33 Day 1	White	2	5,7	2	100,0	83,33	23,57
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	48,61	28,83
	Other	24	55,8	16	66,7	56,25	39,38
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	66,67	29,55
	Europe (EU)	17	100,0	17	100,0	49,02	22,42
	Asia (AS)	39	100,0	39	100,0	62,39	28,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	74,51	33,39
	Europe (EU)	16	94,1	13	81,3	58,97	28,56
	Asia (AS)	36	92,3	35	97,2	66,19	29,00
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	74,56	20,31
	Europe (EU)	15	88,2	12	80,0	54,17	36,32
	Asia (AS)	33	84,6	33	100,0	74,75	20,46
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	80,83	21,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	72,22	20,52
	Asia (AS)	32	82,1	32	100,0	71,88	24,48
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	80,83	25,52
	Europe (EU)	15	88,2	14	93,3	69,05	29,13
	Asia (AS)	30	76,9	30	100,0	68,89	17,90
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	81,67	20,87
	Europe (EU)	14	82,4	13	92,9	66,67	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	72,84	20,23
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	81,48	23,49
	Europe (EU)	14	82,4	13	92,9	66,67	24,53
	Asia (AS)	27	69,2	26	96,3	73,72	17,75
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	83,33	20,41
	Europe (EU)	14	82,4	11	78,6	62,12	24,82
	Asia (AS)	24	61,5	24	100,0	68,75	22,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	81,48	22,06
	Europe (EU)	12	70,6	12	100,0	66,67	30,15
	Asia (AS)	21	53,8	21	100,0	76,19	16,31
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	81,37	25,61
	Europe (EU)	12	70,6	12	100,0	62,50	18,97
	Asia (AS)	21	53,8	21	100,0	80,95	18,47
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	79,63	24,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	68,06	25,08
	Asia (AS)	20	51,3	20	100,0	76,67	14,71
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	76,47	27,68
	Europe (EU)	12	70,6	9	75,0	66,67	22,05
	Asia (AS)	19	48,7	19	100,0	73,68	15,03
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	84,31	28,55
	Europe (EU)	11	64,7	10	90,9	66,67	31,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	78,70	14,91
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	80,39	27,79
	Europe (EU)	11	64,7	11	100,0	65,15	30,23
	Asia (AS)	17	43,6	16	94,1	66,67	17,21
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	82,35	28,55
	Europe (EU)	11	64,7	11	100,0	65,15	27,34
	Asia (AS)	16	41,0	16	100,0	64,58	20,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	86,90	20,86
	Europe (EU)	11	64,7	9	81,8	64,81	22,74
	Asia (AS)	16	41,0	16	100,0	67,71	18,73
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	83,33	28,50
	Europe (EU)	10	58,8	10	100,0	65,00	21,44
	Asia (AS)	15	38,5	15	100,0	70,00	18,04
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	84,52	24,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	69,44	22,15
	Asia (AS)	15	38,5	15	100,0	70,00	14,36
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	80,77	27,93
	Europe (EU)	9	52,9	9	100,0	64,81	29,40
	Asia (AS)	14	35,9	11	78,6	69,70	17,98
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	78,21	27,54
	Europe (EU)	9	52,9	6	66,7	66,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	67,95	15,90
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	78,33	31,48
	Europe (EU)	7	41,2	6	85,7	66,67	21,08
	Asia (AS)	11	28,2	10	90,9	68,33	5,27
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	78,33	31,48
	Europe (EU)	7	41,2	5	71,4	63,33	24,72
	Asia (AS)	11	28,2	10	90,9	65,00	12,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	74,07	33,45
	Europe (EU)	5	29,4	3	60,0	72,22	9,62
	Asia (AS)	7	17,9	6	85,7	72,22	25,09
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	79,17	30,54
	Europe (EU)	5	29,4	4	80,0	66,67	27,22
	Asia (AS)	7	17,9	6	85,7	61,11	25,09
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	78,57	24,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	66,67	0,00
	Asia (AS)	4	10,3	4	100,0	58,33	41,94
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	77,78	36,00
	Europe (EU)	4	23,5	2	50,0	75,00	35,36
	Asia (AS)	4	10,3	4	100,0	62,50	8,33
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	70,83	47,87
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	66,67	13,61
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	87,50	15,96
	Europe (EU)	2	11,8	1	50,0	100,00	-
	Asia (AS)	4	10,3	4	100,0	41,67	31,91
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	88,89	19,25
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	62,50	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	100,00	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	61,11	9,62
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	83,33	23,57
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	66,67	0,00
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	100,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	66,67	-
	Asia (AS)	3	7,7	2	66,7	66,67	0,00
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	100,00	-
	Europe (EU)	1	5,9	1	100,0	66,67	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	56,06	35,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	33,33	27,22
	Asia (AS)	21	53,8	13	61,9	56,41	36,35
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	75,00	19,94
	1	38	100,0	38	100,0	56,58	26,72
	2	10	100,0	10	100,0	33,33	31,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	27	90,0	69,75	31,02
	1	36	94,7	32	88,9	66,15	31,25
	2	6	60,0	6	100,0	58,33	20,41
Cycle 3 Day 1	0	29	96,7	27	93,1	76,54	26,25
	1	34	89,5	32	94,1	70,31	21,05
	2	5	50,0	5	100,0	43,33	27,89
Cycle 4 Day 1	0	29	96,7	28	96,6	82,14	20,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	71,35	21,68
	2	5	50,0	4	80,0	50,00	33,33
Cycle 5 Day 1	0	29	96,7	29	100,0	79,31	19,75
	1	33	86,8	32	97,0	69,79	22,17
	2	3	30,0	3	100,0	38,89	41,94
Cycle 6 Day 1	0	29	96,7	29	100,0	79,89	19,10
	1	31	81,6	28	90,3	72,62	21,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	38,89	34,69
Cycle 7 Day 1	0	29	96,7	28	96,6	77,38	22,32
	1	28	73,7	26	92,9	73,72	20,64
	2	3	30,0	3	100,0	55,56	19,25
Cycle 8 Day 1	0	28	93,3	26	92,9	76,92	20,59
	1	25	65,8	23	92,0	71,74	22,15
	2	3	30,0	3	100,0	33,33	28,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	76,28	23,65
	1	23	60,5	23	100,0	74,64	21,83
	2	2	20,0	2	100,0	83,33	23,57
Cycle 10 Day 1	0	26	86,7	26	100,0	80,13	22,12
	1	23	60,5	22	95,7	75,00	21,67
	2	2	20,0	2	100,0	50,00	23,57
Cycle 11 Day 1	0	26	86,7	26	100,0	79,49	20,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	70,45	21,78
	2	2	20,0	2	100,0	83,33	23,57
Cycle 12 Day 1	0	25	83,3	22	88,0	73,48	23,94
	1	22	57,9	21	95,5	74,60	20,15
	2	2	20,0	2	100,0	58,33	11,79
Cycle 13 Day 1	0	25	83,3	24	96,0	77,78	28,09
	1	20	52,6	20	100,0	79,17	22,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	66,67	-
Cycle 14 Day 1	0	25	83,3	24	96,0	75,69	27,35
	1	19	50,0	19	100,0	68,42	22,15
	2	1	10,0	1	100,0	33,33	-
Cycle 15 Day 1	0	24	80,0	24	100,0	73,61	29,45
	1	19	50,0	19	100,0	71,93	19,29
	2	1	10,0	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	76,67	21,90
	1	18	47,4	18	100,0	73,15	21,50
	2	1	10,0	1	100,0	33,33	-
Cycle 17 Day 1	0	21	70,0	21	100,0	75,40	23,93
	1	17	44,7	17	100,0	73,53	22,87
	2	1	10,0	1	100,0	33,33	-
Cycle 18 Day 1	0	21	70,0	18	85,7	78,70	23,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	73,96	18,23
	2	1	10,0	1	100,0	50,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	73,68	29,04
	1	15	39,5	13	86,7	71,79	21,93
	2	1	10,0	1	100,0	66,67	-
Cycle 20 Day 1	0	20	66,7	17	85,0	73,53	27,68
	1	15	39,5	14	93,3	71,43	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	50,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	75,00	26,75
	1	13	34,2	11	84,6	68,18	15,73
	2	1	10,0	1	100,0	66,67	-
Cycle 22 Day 1	0	15	50,0	12	80,0	73,61	27,94
	1	13	34,2	12	92,3	66,67	21,32
	2	1	10,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	74,07	31,30
	1	9	23,7	8	88,9	77,08	19,80
	2	1	10,0	1	100,0	33,33	-
Cycle 24 Day 1	0	10	33,3	9	90,0	81,48	24,22
	1	9	23,7	8	88,9	62,50	27,82
	2	1	10,0	1	100,0	33,33	-
Cycle 25 Day 1	0	8	26,7	6	75,0	75,00	25,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	66,67	33,33
Cycle 26 Day 1	0	8	26,7	6	75,0	86,11	22,15
	1	6	15,8	6	100,0	58,33	27,39
Cycle 27 Day 1	0	6	20,0	3	50,0	77,78	25,46
	1	5	13,2	5	100,0	63,33	38,01
Cycle 28 Day 1	0	5	16,7	4	80,0	79,17	15,96
	1	5	13,2	5	100,0	60,00	43,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	83,33	23,57
	1	5	13,2	5	100,0	70,00	21,73
Cycle 30 Day 1	0	3	10,0	1	33,3	100,00	-
	1	4	10,5	4	100,0	70,83	20,97
Cycle 31 Day 1	0	3	10,0	1	33,3	100,00	-
	1	4	10,5	4	100,0	66,67	0,00
Cycle 32 Day 1	0	3	10,0	2	66,7	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	77,78	19,25
Cycle 33 Day 1	0	2	6,7	2	100,0	83,33	23,57
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	63,10	32,80
	1	20	52,6	12	60,0	44,44	37,83
	2	4	40,0	2	50,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	64,52	23,47
	1	3	100,0	3	100,0	66,67	33,33
	2 or More	44	100,0	44	100,0	57,58	31,02
Cycle 2 Day 1	None	30	96,8	27	90,0	69,14	31,59
	1	2	66,7	1	50,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	64,41	29,18
Cycle 3 Day 1	None	30	96,8	28	93,3	75,60	21,51
	1	2	66,7	1	50,0	100,00	-
	2 or More	36	81,8	35	97,2	66,19	26,96
Cycle 4 Day 1	None	30	96,8	29	96,7	78,74	24,76
	1	2	66,7	2	100,0	83,33	23,57
	2 or More	35	79,5	33	94,3	70,71	21,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	77,22	25,70
	1	2	66,7	2	100,0	91,67	11,79
	2 or More	33	75,0	32	97,0	67,19	20,52
Cycle 6 Day 1	None	29	93,5	28	96,6	82,74	18,42
	1	2	66,7	2	100,0	83,33	23,57
	2 or More	32	72,7	30	93,8	66,11	23,36
Cycle 7 Day 1	None	27	87,1	26	96,3	82,69	20,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	83,33	23,57
	2 or More	31	70,5	29	93,5	66,67	19,92
Cycle 8 Day 1	None	26	83,9	25	96,2	76,67	23,07
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	67,90	23,54
Cycle 9 Day 1	None	25	80,6	25	100,0	80,67	20,79
	1	1	33,3	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	70,67	23,71
Cycle 10 Day 1	None	25	80,6	24	96,0	81,94	20,21
	1	1	33,3	1	100,0	83,33	-
	2 or More	25	56,8	25	100,0	71,33	23,82
Cycle 11 Day 1	None	25	80,6	25	100,0	80,67	21,88
	1	1	33,3	1	100,0	100,00	-
	2 or More	24	54,5	24	100,0	69,44	19,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	80,56	20,66
	1	1	33,3	1	100,0	83,33	-
	2 or More	23	52,3	20	87,0	64,17	20,43
Cycle 13 Day 1	None	24	77,4	23	95,8	84,06	19,77
	1	1	33,3	1	100,0	100,00	-
	2 or More	21	47,7	21	100,0	70,63	28,82
Cycle 14 Day 1	None	23	74,2	23	100,0	78,99	24,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	83,33	-
	2 or More	21	47,7	20	95,2	62,50	25,29
Cycle 15 Day 1	None	23	74,2	23	100,0	81,16	21,50
	1	1	33,3	1	100,0	83,33	-
	2 or More	20	45,5	20	100,0	60,00	27,78
Cycle 16 Day 1	None	20	64,5	19	95,0	82,46	19,62
	1	1	33,3	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	64,91	22,15
Cycle 17 Day 1	None	19	61,3	19	100,0	82,46	17,98
	1	1	33,3	1	100,0	100,00	-
	2 or More	19	43,2	19	100,0	63,16	25,20
Cycle 18 Day 1	None	18	58,1	17	94,4	86,27	16,91
	1	1	33,3	1	100,0	100,00	-
	2 or More	19	43,2	17	89,5	63,73	18,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	81,37	19,44
	1	1	33,3	1	100,0	100,00	-
	2 or More	18	40,9	15	83,3	61,11	27,94
Cycle 20 Day 1	None	17	54,8	16	94,1	84,38	15,48
	1	1	33,3	1	100,0	83,33	-
	2 or More	18	40,9	15	83,3	57,78	23,46
Cycle 21 Day 1	None	15	48,4	13	86,7	83,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	60,26	21,01
Cycle 22 Day 1	None	15	48,4	13	86,7	82,05	20,93
	2 or More	14	31,8	12	85,7	56,94	20,67
Cycle 23 Day 1	None	10	32,3	9	90,0	85,19	19,44
	2 or More	11	25,0	9	81,8	61,11	28,87
Cycle 24 Day 1	None	10	32,3	10	100,0	86,67	23,31
	2 or More	10	22,7	8	80,0	50,00	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	85,42	16,52
	2 or More	6	13,6	5	83,3	46,67	29,81
Cycle 26 Day 1	None	8	25,8	8	100,0	79,17	31,81
	2 or More	6	13,6	4	66,7	58,33	9,62
Cycle 27 Day 1	None	7	22,6	6	85,7	69,44	38,61
	2 or More	4	9,1	2	50,0	66,67	0,00
Cycle 28 Day 1	None	7	22,6	7	100,0	78,57	24,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	33,33	47,14
Cycle 29 Day 1	None	6	19,4	5	83,3	76,67	22,36
	2 or More	3	6,8	2	66,7	66,67	23,57
Cycle 30 Day 1	None	4	12,9	3	75,0	88,89	19,25
	2 or More	3	6,8	2	66,7	58,33	11,79
Cycle 31 Day 1	None	4	12,9	3	75,0	77,78	19,25
	2 or More	3	6,8	2	66,7	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	88,89	19,25
	2 or More	2	4,5	2	100,0	66,67	0,00
Cycle 33 Day 1	None	1	3,2	1	100,0	100,00	-
	2 or More	1	2,3	1	100,0	66,67	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	54,17	39,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	66,67	-
	2 or More	24	54,5	15	62,5	51,11	33,61
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	64,52	23,47
	Previously Treated	47	100,0	47	100,0	58,16	30,86
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	69,14	31,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	65,35	29,35
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	75,60	21,51
	Previously Treated	38	80,9	36	94,7	67,13	27,16
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	78,74	24,76
	Previously Treated	37	78,7	35	94,6	71,43	21,23
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	77,22	25,70
	Previously Treated	35	74,5	34	97,1	68,63	20,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	82,74	18,42
	Previously Treated	34	72,3	32	94,1	67,19	23,37
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	82,69	20,81
	Previously Treated	33	70,2	31	93,9	67,74	20,15
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	76,67	23,07
	Previously Treated	30	63,8	27	90,0	67,90	23,54
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	80,67	20,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	71,15	23,36
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	81,94	20,21
	Previously Treated	26	55,3	26	100,0	71,79	23,46
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	80,67	21,88
	Previously Treated	25	53,2	25	100,0	70,67	20,00
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	80,56	20,66
	Previously Treated	24	51,1	21	87,5	65,08	20,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	84,06	19,77
	Previously Treated	22	46,8	22	100,0	71,97	28,82
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	78,99	24,21
	Previously Treated	22	46,8	21	95,5	63,49	25,07
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	81,16	21,50
	Previously Treated	21	44,7	21	100,0	61,11	27,55
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	82,46	19,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	65,83	21,95
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	82,46	17,98
	Previously Treated	20	42,6	20	100,0	65,00	25,88
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	86,27	16,91
	Previously Treated	20	42,6	18	90,0	65,74	20,19
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	81,37	19,44
	Previously Treated	19	40,4	16	84,2	63,54	28,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	84,38	15,48
	Previously Treated	19	40,4	16	84,2	59,38	23,55
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	83,33	16,67
	Previously Treated	14	29,8	13	92,9	60,26	21,01
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	82,05	20,93
	Previously Treated	14	29,8	12	85,7	56,94	20,67
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	85,19	19,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	61,11	28,87
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	86,67	23,31
	Previously Treated	10	21,3	8	80,0	50,00	17,82
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	85,42	16,52
	Previously Treated	6	12,8	5	83,3	46,67	29,81
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	79,17	31,81
	Previously Treated	6	12,8	4	66,7	58,33	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	69,44	38,61
	Previously Treated	4	8,5	2	50,0	66,67	0,00
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	78,57	24,93
	Previously Treated	3	6,4	2	66,7	33,33	47,14
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	76,67	22,36
	Previously Treated	3	6,4	2	66,7	66,67	23,57
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	88,89	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	58,33	11,79
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	77,78	19,25
	Previously Treated	3	6,4	2	66,7	66,67	0,00
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	88,89	19,25
	Previously Treated	2	4,3	2	100,0	66,67	0,00
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	100,00	-
	Previously Treated	1	2,1	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	54,17	39,01
	Previously Treated	26	55,3	16	61,5	52,08	32,70
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	61,90	29,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	59,69	27,03
Cycle 2 Day 1	Local	32	91,4	30	93,8	70,00	30,76
	Central	40	93,0	35	87,5	64,29	29,74
Cycle 3 Day 1	Local	29	82,9	28	96,6	73,81	23,32
	Central	39	90,7	36	92,3	68,52	26,36
Cycle 4 Day 1	Local	28	80,0	27	96,4	78,40	20,05
	Central	39	90,7	37	94,9	72,07	24,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	74,69	25,89
	Central	38	88,4	37	97,4	71,17	21,75
Cycle 6 Day 1	Local	27	77,1	27	100,0	79,01	20,98
	Central	36	83,7	33	91,7	70,71	23,21
Cycle 7 Day 1	Local	27	77,1	27	100,0	75,93	19,79
	Central	33	76,7	30	90,9	73,33	23,41
Cycle 8 Day 1	Local	26	74,3	26	100,0	76,28	21,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	67,95	24,91
Cycle 9 Day 1	Local	25	71,4	25	100,0	77,33	25,40
	Central	26	60,5	26	100,0	74,36	19,57
Cycle 10 Day 1	Local	25	71,4	24	96,0	79,86	23,04
	Central	26	60,5	26	100,0	73,72	21,69
Cycle 11 Day 1	Local	24	68,6	24	100,0	76,39	21,93
	Central	26	60,5	26	100,0	75,00	21,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	75,00	21,67
	Central	26	60,5	23	88,5	71,74	22,15
Cycle 13 Day 1	Local	22	62,9	22	100,0	80,30	25,53
	Central	24	55,8	23	95,8	76,09	25,04
Cycle 14 Day 1	Local	22	62,9	22	100,0	73,48	28,94
	Central	23	53,5	22	95,7	69,70	22,20
Cycle 15 Day 1	Local	22	62,9	22	100,0	75,76	28,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	67,42	23,28
Cycle 16 Day 1	Local	20	57,1	20	100,0	78,33	22,36
	Central	21	48,8	19	90,5	69,30	21,70
Cycle 17 Day 1	Local	20	57,1	20	100,0	80,00	19,94
	Central	19	44,2	19	100,0	66,67	26,06
Cycle 18 Day 1	Local	20	57,1	19	95,0	79,82	18,07
	Central	18	41,9	16	88,9	70,83	23,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	77,45	20,36
	Central	17	39,5	16	94,1	67,71	30,10
Cycle 20 Day 1	Local	19	54,3	17	89,5	78,43	18,41
	Central	17	39,5	15	88,2	64,44	26,63
Cycle 21 Day 1	Local	14	40,0	12	85,7	79,17	16,09
	Central	15	34,9	14	93,3	65,48	24,86
Cycle 22 Day 1	Local	14	40,0	12	85,7	80,56	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	60,26	25,94
Cycle 23 Day 1	Local	11	31,4	10	90,9	81,67	22,84
	Central	10	23,3	8	80,0	62,50	29,21
Cycle 24 Day 1	Local	11	31,4	10	90,9	80,00	28,11
	Central	9	20,9	8	88,9	58,33	23,57
Cycle 25 Day 1	Local	7	20,0	7	100,0	83,33	25,46
	Central	8	18,6	6	75,0	55,56	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	83,33	25,82
	Central	8	18,6	6	75,0	61,11	27,22
Cycle 27 Day 1	Local	4	11,4	4	100,0	91,67	9,62
	Central	7	16,3	4	57,1	45,83	31,55
Cycle 28 Day 1	Local	4	11,4	4	100,0	70,83	28,46
	Central	6	14,0	5	83,3	66,67	40,82
Cycle 29 Day 1	Local	3	8,6	3	100,0	83,33	28,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	66,67	13,61
Cycle 30 Day 1	Local	3	8,6	3	100,0	88,89	19,25
	Central	4	9,3	2	50,0	58,33	11,79
Cycle 31 Day 1	Local	3	8,6	3	100,0	77,78	19,25
	Central	4	9,3	2	50,0	66,67	0,00
Cycle 32 Day 1	Local	3	8,6	3	100,0	88,89	19,25
	Central	3	7,0	2	66,7	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	100,00	-
	Central	1	2,3	1	100,0	66,67	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	55,95	37,33
	Central	21	48,8	14	66,7	50,00	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	61,04	27,35
	No	4	100,0	4	100,0	54,17	45,90
Cycle 2 Day 1	Yes	70	94,6	63	90,0	68,78	28,63
	No	2	50,0	2	100,0	8,33	11,79
Cycle 3 Day 1	Yes	66	89,2	62	93,9	70,97	25,24
	No	2	50,0	2	100,0	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	74,46	23,13
	No	2	50,0	2	100,0	83,33	23,57
Cycle 5 Day 1	Yes	63	85,1	62	98,4	73,39	23,27
	No	2	50,0	2	100,0	50,00	23,57
Cycle 6 Day 1	Yes	61	82,4	58	95,1	74,71	22,78
	No	2	50,0	2	100,0	66,67	0,00
Cycle 7 Day 1	Yes	58	78,4	55	94,8	75,15	21,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	58,33	35,36
Cycle 8 Day 1	Yes	54	73,0	50	92,6	73,00	23,30
	No	2	50,0	2	100,0	50,00	23,57
Cycle 9 Day 1	Yes	49	66,2	49	100,0	76,53	22,55
	No	2	50,0	2	100,0	58,33	11,79
Cycle 10 Day 1	Yes	49	66,2	48	98,0	76,39	22,50
	No	2	50,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	75,35	21,47
	No	2	50,0	2	100,0	83,33	23,57
Cycle 12 Day 1	Yes	47	63,5	43	91,5	73,64	22,19
	No	2	50,0	2	100,0	66,67	0,00
Cycle 13 Day 1	Yes	44	59,5	43	97,7	78,68	25,54
	No	2	50,0	2	100,0	66,67	0,00
Cycle 14 Day 1	Yes	43	58,1	42	97,7	72,22	25,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	58,33	11,79
Cycle 15 Day 1	Yes	42	56,8	42	100,0	72,62	26,24
	No	2	50,0	2	100,0	50,00	23,57
Cycle 16 Day 1	Yes	39	52,7	37	94,9	74,77	22,44
	No	2	50,0	2	100,0	58,33	11,79
Cycle 17 Day 1	Yes	37	50,0	37	100,0	74,32	24,09
	No	2	50,0	2	100,0	58,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	76,77	21,22
	No	2	50,0	2	100,0	58,33	11,79
Cycle 19 Day 1	Yes	34	45,9	32	94,1	72,92	26,01
	No	2	50,0	1	50,0	66,67	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	73,33	22,99
	No	2	50,0	2	100,0	50,00	23,57
Cycle 21 Day 1	Yes	27	36,5	24	88,9	72,22	22,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	66,67	0,00
Cycle 22 Day 1	Yes	27	36,5	23	85,2	70,29	25,10
	No	2	50,0	2	100,0	66,67	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	71,57	26,85
	No	1	25,0	1	100,0	100,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	68,63	27,56
	No	1	25,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	68,06	28,83
	No	1	25,0	1	100,0	100,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	74,24	28,25
	No	1	25,0	1	100,0	50,00	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	66,67	34,69
	No	1	25,0	1	100,0	83,33	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	72,92	33,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	77,78	20,18
	No	1	25,0	1	100,0	50,00	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	79,17	25,00
	No	1	25,0	1	100,0	66,67	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	75,00	16,67
	No	1	25,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	83,33	19,25
	No	1	25,0	1	100,0	66,67	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	83,33	23,57
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	52,98	34,86
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	54,17	29,21
	No	70	100,0	70	100,0	61,43	28,17
Cycle 2 Day 1	Yes	5	62,5	5	100,0	73,33	43,46
	No	67	95,7	60	89,6	66,39	29,19
Cycle 3 Day 1	Yes	5	62,5	5	100,0	80,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	70,06	25,48
Cycle 4 Day 1	Yes	5	62,5	5	100,0	80,00	27,39
	No	62	88,6	59	95,2	74,29	22,81
Cycle 5 Day 1	Yes	5	62,5	5	100,0	70,00	34,16
	No	60	85,7	59	98,3	72,88	22,72
Cycle 6 Day 1	Yes	5	62,5	5	100,0	80,00	29,81
	No	58	82,9	55	94,8	73,94	21,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	80,00	29,81
	No	55	78,6	52	94,5	74,04	20,98
Cycle 8 Day 1	Yes	5	62,5	5	100,0	60,00	30,28
	No	51	72,9	47	92,2	73,40	22,70
Cycle 9 Day 1	Yes	4	50,0	4	100,0	66,67	27,22
	No	47	67,1	47	100,0	76,60	22,16
Cycle 10 Day 1	Yes	4	50,0	4	100,0	66,67	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	77,54	22,00
Cycle 11 Day 1	Yes	4	50,0	4	100,0	66,67	27,22
	No	46	65,7	46	100,0	76,45	20,96
Cycle 12 Day 1	Yes	4	50,0	4	100,0	75,00	31,91
	No	45	64,3	41	91,1	73,17	21,04
Cycle 13 Day 1	Yes	4	50,0	4	100,0	75,00	31,91
	No	42	60,0	41	97,6	78,46	24,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	58,33	34,69
	No	41	58,6	40	97,6	72,92	24,66
Cycle 15 Day 1	Yes	4	50,0	4	100,0	62,50	28,46
	No	40	57,1	40	100,0	72,50	26,30
Cycle 16 Day 1	Yes	3	37,5	3	100,0	77,78	19,25
	No	38	54,3	36	94,7	73,61	22,67
Cycle 17 Day 1	Yes	3	37,5	3	100,0	77,78	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	73,15	24,33
Cycle 18 Day 1	Yes	3	37,5	3	100,0	77,78	19,25
	No	35	50,0	32	91,4	75,52	21,58
Cycle 19 Day 1	Yes	3	37,5	3	100,0	77,78	19,25
	No	33	47,1	30	90,9	72,22	26,38
Cycle 20 Day 1	Yes	3	37,5	3	100,0	77,78	19,25
	No	33	47,1	29	87,9	71,26	23,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	66,67	0,00
	No	27	38,6	24	88,9	72,22	22,88
Cycle 22 Day 1	Yes	2	25,0	2	100,0	66,67	0,00
	No	27	38,6	23	85,2	70,29	25,10
Cycle 23 Day 1	Yes	2	25,0	2	100,0	66,67	0,00
	No	19	27,1	16	84,2	73,96	28,52
Cycle 24 Day 1	Yes	2	25,0	2	100,0	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	70,83	29,50
Cycle 25 Day 1	Yes	2	25,0	2	100,0	66,67	0,00
	No	13	18,6	11	84,6	71,21	31,70
Cycle 26 Day 1	Yes	1	12,5	1	100,0	66,67	-
	No	13	18,6	11	84,6	72,73	29,13
Cycle 27 Day 1	Yes	1	12,5	1	100,0	50,00	-
	No	10	14,3	7	70,0	71,43	34,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	66,67	-
	No	9	12,9	8	88,9	68,75	36,12
Cycle 29 Day 1	Yes	1	12,5	1	100,0	66,67	-
	No	8	11,4	6	75,0	75,00	22,97
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	76,67	22,36
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	73,33	14,91
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	80,00	18,26
Cycle 33 Day 1	No	2	2,9	2	100,0	83,33	23,57
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	16,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	55,77	34,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30RF_SG.xls
28NOV2019 10:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	63,68	27,88
Cycle 2 Day 1	All	72	92,3	64	88,9	69,01	26,04
Cycle 3 Day 1	All	68	87,2	64	94,1	75,00	25,02
Cycle 4 Day 1	All	67	85,9	64	95,5	80,47	22,53
Cycle 5 Day 1	All	65	83,3	64	98,5	77,34	26,12
Cycle 6 Day 1	All	63	80,8	60	95,2	80,28	21,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	76,90	24,75
Cycle 8 Day 1	All	56	71,8	52	92,9	81,73	22,93
Cycle 9 Day 1	All	51	65,4	51	100,0	81,37	21,25
Cycle 10 Day 1	All	51	65,4	50	98,0	79,33	21,97
Cycle 11 Day 1	All	50	64,1	50	100,0	81,33	21,47
Cycle 12 Day 1	All	49	62,8	45	91,8	78,89	23,68
Cycle 13 Day 1	All	46	59,0	45	97,8	80,37	24,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	77,27	27,16
Cycle 15 Day 1	All	44	56,4	44	100,0	78,03	23,78
Cycle 16 Day 1	All	41	52,6	39	95,1	76,07	23,51
Cycle 17 Day 1	All	39	50,0	39	100,0	79,49	21,78
Cycle 18 Day 1	All	38	48,7	35	92,1	77,62	22,85
Cycle 19 Day 1	All	36	46,2	33	91,7	77,27	24,23
Cycle 20 Day 1	All	36	46,2	32	88,9	76,04	22,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	75,00	23,21
Cycle 22 Day 1	All	29	37,2	25	86,2	75,33	25,51
Cycle 23 Day 1	All	21	26,9	18	85,7	74,07	28,71
Cycle 24 Day 1	All	20	25,6	18	90,0	80,56	20,01
Cycle 25 Day 1	All	15	19,2	13	86,7	80,77	21,35
Cycle 26 Day 1	All	14	17,9	12	85,7	76,39	27,94
Cycle 27 Day 1	All	11	14,1	8	72,7	83,33	19,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	87,04	16,20
Cycle 29 Day 1	All	9	11,5	7	77,8	83,33	16,67
Cycle 30 Day 1	All	7	9,0	5	71,4	70,00	24,72
Cycle 31 Day 1	All	7	9,0	5	71,4	80,00	18,26
Cycle 32 Day 1	All	6	7,7	5	83,3	80,00	18,26
Cycle 33 Day 1	All	2	2,6	2	100,0	83,33	23,57
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	63,69	32,73
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	58,62	26,96
	Female	49	100,0	49	100,0	66,67	28,26
Cycle 2 Day 1	Male	27	93,1	24	88,9	61,81	29,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	73,33	23,20
Cycle 3 Day 1	Male	25	86,2	23	92,0	76,09	27,90
	Female	43	87,8	41	95,3	74,39	23,60
Cycle 4 Day 1	Male	25	86,2	25	100,0	85,33	20,59
	Female	42	85,7	39	92,9	77,35	23,41
Cycle 5 Day 1	Male	25	86,2	25	100,0	71,33	30,63
	Female	40	81,6	39	97,5	81,20	22,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	78,99	22,60
	Female	38	77,6	37	97,4	81,08	20,47
Cycle 7 Day 1	Male	23	79,3	23	100,0	77,54	25,92
	Female	37	75,5	34	91,9	76,47	24,31
Cycle 8 Day 1	Male	21	72,4	19	90,5	82,46	22,55
	Female	35	71,4	33	94,3	81,31	23,48
Cycle 9 Day 1	Male	18	62,1	18	100,0	83,33	25,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	80,30	18,84
Cycle 10 Day 1	Male	18	62,1	18	100,0	78,70	25,44
	Female	33	67,3	32	97,0	79,69	20,18
Cycle 11 Day 1	Male	18	62,1	18	100,0	82,41	21,75
	Female	32	65,3	32	100,0	80,73	21,63
Cycle 12 Day 1	Male	17	58,6	17	100,0	83,33	21,25
	Female	32	65,3	28	87,5	76,19	25,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	85,29	20,31
	Female	29	59,2	28	96,6	77,38	26,53
Cycle 14 Day 1	Male	17	58,6	16	94,1	80,21	29,32
	Female	28	57,1	28	100,0	75,60	26,25
Cycle 15 Day 1	Male	16	55,2	16	100,0	80,21	22,95
	Female	28	57,1	28	100,0	76,79	24,57
Cycle 16 Day 1	Male	14	48,3	14	100,0	76,19	25,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	76,00	22,61
Cycle 17 Day 1	Male	12	41,4	12	100,0	80,56	21,12
	Female	27	55,1	27	100,0	79,01	22,45
Cycle 18 Day 1	Male	11	37,9	10	90,9	81,67	18,34
	Female	27	55,1	25	92,6	76,00	24,57
Cycle 19 Day 1	Male	10	34,5	10	100,0	80,00	23,31
	Female	26	53,1	23	88,5	76,09	25,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	85,19	17,57
	Female	26	53,1	23	88,5	72,46	23,89
Cycle 21 Day 1	Male	8	27,6	8	100,0	77,08	25,10
	Female	21	42,9	18	85,7	74,07	23,02
Cycle 22 Day 1	Male	8	27,6	6	75,0	72,22	25,09
	Female	21	42,9	19	90,5	76,32	26,24
Cycle 23 Day 1	Male	5	17,2	4	80,0	75,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	73,81	29,03
Cycle 24 Day 1	Male	5	17,2	4	80,0	70,83	28,46
	Female	15	30,6	14	93,3	83,33	17,30
Cycle 25 Day 1	Male	3	10,3	2	66,7	100,00	0,00
	Female	12	24,5	11	91,7	77,27	21,44
Cycle 26 Day 1	Male	3	10,3	2	66,7	100,00	0,00
	Female	11	22,4	10	90,9	71,67	28,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	100,00	0,00
	Female	8	16,3	6	75,0	77,78	20,18
Cycle 28 Day 1	Male	2	6,9	2	100,0	100,00	0,00
	Female	8	16,3	7	87,5	83,33	16,67
Cycle 29 Day 1	Male	1	3,4	1	100,0	100,00	-
	Female	8	16,3	6	75,0	80,56	16,39
Cycle 30 Day 1	Male	1	3,4	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	79,17	15,96
Cycle 31 Day 1	Male	1	3,4	1	100,0	100,00	-
	Female	6	12,2	4	66,7	75,00	16,67
Cycle 32 Day 1	Male	1	3,4	1	100,0	100,00	-
	Female	5	10,2	4	80,0	75,00	16,67
Cycle 33 Day 1	Male	1	3,4	1	100,0	100,00	-
	Female	1	2,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	56,67	32,00
	Female	21	42,9	13	61,9	71,79	32,90
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	63,71	26,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	60,71	33,72
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 2 Day 1	18-64	59	95,2	52	88,1	71,15	26,22
	65-74	11	78,6	10	90,9	60,00	26,29
	>=75	2	100,0	2	100,0	58,33	11,79
Cycle 3 Day 1	18-64	56	90,3	52	92,9	75,64	23,91
	65-74	10	71,4	10	100,0	68,33	31,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	91,67	11,79
Cycle 4 Day 1	18-64	55	88,7	53	96,4	80,50	23,28
	65-74	10	71,4	9	90,0	79,63	20,03
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 5 Day 1	18-64	53	85,5	52	98,1	78,53	25,85
	65-74	10	71,4	10	100,0	73,33	26,29
	>=75	2	100,0	2	100,0	66,67	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	81,63	21,31
	65-74	10	71,4	9	90,0	75,93	22,22
	>=75	2	100,0	2	100,0	66,67	0,00
Cycle 7 Day 1	18-64	49	79,0	47	95,9	76,60	24,98
	65-74	9	64,3	8	88,9	79,17	24,80
	>=75	2	100,0	2	100,0	75,00	35,36
Cycle 8 Day 1	18-64	45	72,6	41	91,1	80,89	24,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	83,33	16,67
	>=75	2	100,0	2	100,0	91,67	11,79
Cycle 9 Day 1	18-64	40	64,5	40	100,0	83,33	19,97
	65-74	9	64,3	9	100,0	75,93	22,22
	>=75	2	100,0	2	100,0	66,67	47,14
Cycle 10 Day 1	18-64	40	64,5	39	97,5	80,77	20,78
	65-74	9	64,3	9	100,0	75,93	23,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	66,67	47,14
Cycle 11 Day 1	18-64	39	62,9	39	100,0	80,77	22,79
	65-74	9	64,3	9	100,0	81,48	17,57
	>=75	2	100,0	2	100,0	91,67	11,79
Cycle 12 Day 1	18-64	38	61,3	35	92,1	78,57	24,11
	65-74	9	64,3	8	88,9	79,17	24,80
	>=75	2	100,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	81,37	23,12
	65-74	9	64,3	9	100,0	75,93	31,30
	>=75	2	100,0	2	100,0	83,33	23,57
Cycle 14 Day 1	18-64	35	56,5	35	100,0	79,52	26,53
	65-74	9	64,3	8	88,9	68,75	31,42
	>=75	1	50,0	1	100,0	66,67	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	80,00	23,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	70,83	26,35
	>=75	1	50,0	1	100,0	66,67	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	76,04	25,38
	65-74	7	50,0	6	85,7	77,78	13,61
	>=75	1	50,0	1	100,0	66,67	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	81,25	21,06
	65-74	6	42,9	6	100,0	77,78	20,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	33,33	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	80,46	22,74
	65-74	6	42,9	5	83,3	66,67	20,41
	>=75	1	50,0	1	100,0	50,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	80,95	23,00
	65-74	5	35,7	4	80,0	62,50	20,97
	>=75	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	79,49	22,76
	65-74	5	35,7	5	100,0	60,00	19,00
	>=75	1	50,0	1	100,0	66,67	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	76,98	23,85
	65-74	4	28,6	4	100,0	75,00	9,62
	>=75	1	50,0	1	100,0	33,33	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	79,17	25,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	66,67	13,61
	>=75	1	50,0	1	100,0	33,33	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	75,00	30,43
	65-74	2	14,3	2	100,0	66,67	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	81,25	20,97
	65-74	2	14,3	2	100,0	75,00	11,79
Cycle 25 Day 1	18-64	14	22,6	12	85,7	81,94	21,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	66,67	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	76,39	27,94
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	83,33	19,92
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	87,04	16,20
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	83,33	16,67
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	70,00	24,72
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	80,00	18,26
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	83,33	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	66,67	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	100,00	-
	65-74	1	7,1	1	100,0	66,67	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	62,50	35,41
	65-74	10	71,4	7	70,0	61,90	24,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	100,00	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	60,95	28,57
	Other	43	100,0	43	100,0	65,89	27,45
Cycle 2 Day 1	White	33	94,3	28	84,8	66,07	27,77
	Other	39	90,7	36	92,3	71,30	24,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	72,22	27,35
	Other	37	86,0	37	100,0	77,03	23,36
Cycle 4 Day 1	White	31	88,6	28	90,3	80,95	25,14
	Other	36	83,7	36	100,0	80,09	20,63
Cycle 5 Day 1	White	31	88,6	30	96,8	76,11	29,26
	Other	34	79,1	34	100,0	78,43	23,40
Cycle 6 Day 1	White	30	85,7	28	93,3	80,95	23,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	79,69	19,74
Cycle 7 Day 1	White	29	82,9	27	93,1	77,78	28,50
	Other	31	72,1	30	96,8	76,11	21,30
Cycle 8 Day 1	White	28	80,0	24	85,7	79,86	26,00
	Other	28	65,1	28	100,0	83,33	20,29
Cycle 9 Day 1	White	26	74,3	26	100,0	81,41	24,19
	Other	25	58,1	25	100,0	81,33	18,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	78,67	23,82
	Other	25	58,1	25	100,0	80,00	20,41
Cycle 11 Day 1	White	26	74,3	26	100,0	82,05	22,07
	Other	24	55,8	24	100,0	80,56	21,23
Cycle 12 Day 1	White	26	74,3	22	84,6	78,03	27,88
	Other	23	53,5	23	100,0	79,71	19,43
Cycle 13 Day 1	White	24	68,6	23	95,8	79,71	30,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	81,06	16,50
Cycle 14 Day 1	White	24	68,6	24	100,0	79,86	30,29
	Other	21	48,8	20	95,2	74,17	23,24
Cycle 15 Day 1	White	24	68,6	24	100,0	77,78	28,09
	Other	20	46,5	20	100,0	78,33	18,02
Cycle 16 Day 1	White	22	62,9	20	90,9	75,00	27,84
	Other	19	44,2	19	100,0	77,19	18,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	81,06	25,87
	Other	17	39,5	17	100,0	77,45	15,52
Cycle 18 Day 1	White	21	60,0	18	85,7	79,63	26,54
	Other	17	39,5	17	100,0	75,49	18,74
Cycle 19 Day 1	White	20	57,1	20	100,0	77,50	29,26
	Other	16	37,2	13	81,3	76,92	14,50
Cycle 20 Day 1	White	20	57,1	17	85,0	77,45	28,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	74,44	15,26
Cycle 21 Day 1	White	16	45,7	14	87,5	73,81	29,03
	Other	13	30,2	12	92,3	76,39	15,01
Cycle 22 Day 1	White	16	45,7	13	81,3	75,64	32,36
	Other	13	30,2	12	92,3	75,00	16,67
Cycle 23 Day 1	White	12	34,3	10	83,3	71,67	33,38
	Other	9	20,9	8	88,9	77,08	23,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	80,00	17,21
	Other	9	20,9	8	88,9	81,25	24,30
Cycle 25 Day 1	White	10	28,6	8	80,0	77,08	23,46
	Other	5	11,6	5	100,0	86,67	18,26
Cycle 26 Day 1	White	10	28,6	8	80,0	75,00	30,86
	Other	4	9,3	4	100,0	79,17	25,00
Cycle 27 Day 1	White	8	22,9	5	62,5	90,00	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	72,22	25,46
Cycle 28 Day 1	White	7	20,0	6	85,7	91,67	13,94
	Other	3	7,0	3	100,0	77,78	19,25
Cycle 29 Day 1	White	6	17,1	4	66,7	87,50	15,96
	Other	3	7,0	3	100,0	77,78	19,25
Cycle 30 Day 1	White	4	11,4	2	50,0	66,67	47,14
	Other	3	7,0	3	100,0	72,22	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	100,00	0,00
	Other	3	7,0	3	100,0	66,67	0,00
Cycle 32 Day 1	White	4	11,4	3	75,0	88,89	19,25
	Other	2	4,7	2	100,0	66,67	0,00
Cycle 33 Day 1	White	2	5,7	2	100,0	83,33	23,57
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	56,94	31,35
	Other	24	55,8	16	66,7	68,75	33,82
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	64,39	27,36
	Europe (EU)	17	100,0	17	100,0	61,76	28,11
	Asia (AS)	39	100,0	39	100,0	64,10	28,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	16	80,0	75,00	24,34
	Europe (EU)	16	94,1	13	81,3	62,82	28,99
	Asia (AS)	36	92,3	35	97,2	68,57	25,81
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	74,56	25,68
	Europe (EU)	15	88,2	12	80,0	70,83	29,41
	Asia (AS)	33	84,6	33	100,0	76,77	23,55
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	81,67	22,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	75,00	29,73
	Asia (AS)	32	82,1	32	100,0	81,77	20,02
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	80,83	23,12
	Europe (EU)	15	88,2	14	93,3	70,24	35,91
	Asia (AS)	30	76,9	30	100,0	78,33	22,81
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	87,50	18,63
	Europe (EU)	14	82,4	13	92,9	70,51	27,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	79,63	18,10
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	82,41	23,90
	Europe (EU)	14	82,4	13	92,9	67,95	34,33
	Asia (AS)	27	69,2	26	96,3	77,56	18,82
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	86,27	20,61
	Europe (EU)	14	82,4	11	78,6	72,73	30,07
	Asia (AS)	24	61,5	24	100,0	82,64	20,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	84,26	21,75
	Europe (EU)	12	70,6	12	100,0	75,00	27,98
	Asia (AS)	21	53,8	21	100,0	82,54	16,22
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	84,31	19,96
	Europe (EU)	12	70,6	12	100,0	69,44	27,37
	Asia (AS)	21	53,8	21	100,0	80,95	19,21
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	81,48	22,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	79,17	22,61
	Asia (AS)	20	51,3	20	100,0	82,50	20,57
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	81,37	29,39
	Europe (EU)	12	70,6	9	75,0	70,37	24,69
	Asia (AS)	19	48,7	19	100,0	80,70	16,91
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	83,33	27,64
	Europe (EU)	11	64,7	10	90,9	73,33	31,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	81,48	16,06
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	83,33	28,26
	Europe (EU)	11	64,7	11	100,0	68,18	36,86
	Asia (AS)	17	43,6	16	94,1	77,08	15,96
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	84,31	27,93
	Europe (EU)	11	64,7	11	100,0	71,21	27,98
	Asia (AS)	16	41,0	16	100,0	76,04	13,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	80,95	29,86
	Europe (EU)	11	64,7	9	81,8	68,52	24,22
	Asia (AS)	16	41,0	16	100,0	76,04	16,07
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	82,14	28,09
	Europe (EU)	10	58,8	10	100,0	78,33	20,86
	Asia (AS)	15	38,5	15	100,0	77,78	16,27
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	83,33	27,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	75,00	20,41
	Asia (AS)	15	38,5	15	100,0	73,33	18,69
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	82,05	30,02
	Europe (EU)	9	52,9	9	100,0	72,22	26,35
	Asia (AS)	14	35,9	11	78,6	75,76	13,67
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	80,77	28,74
	Europe (EU)	9	52,9	6	66,7	72,22	25,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	73,08	14,50
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	78,33	30,48
	Europe (EU)	7	41,2	6	85,7	66,67	21,08
	Asia (AS)	11	28,2	10	90,9	76,67	16,10
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	78,33	33,38
	Europe (EU)	7	41,2	5	71,4	73,33	27,89
	Asia (AS)	11	28,2	10	90,9	73,33	16,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	70,37	35,14
	Europe (EU)	5	29,4	3	60,0	77,78	19,25
	Asia (AS)	7	17,9	6	85,7	77,78	25,09
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	81,25	16,52
	Europe (EU)	5	29,4	4	80,0	83,33	19,25
	Asia (AS)	7	17,9	6	85,7	77,78	27,22
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	80,95	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	66,67	0,00
	Asia (AS)	4	10,3	4	100,0	87,50	15,96
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	77,78	36,00
	Europe (EU)	4	23,5	2	50,0	83,33	23,57
	Asia (AS)	4	10,3	4	100,0	70,83	20,97
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	95,83	8,33
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	70,83	20,97
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	95,83	8,33
	Europe (EU)	2	11,8	1	50,0	100,00	-
	Asia (AS)	4	10,3	4	100,0	75,00	16,67
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	94,44	9,62
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	75,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	66,67	47,14
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	72,22	9,62
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	100,00	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	66,67	0,00
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	100,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	66,67	-
	Asia (AS)	3	7,7	2	66,7	66,67	0,00
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	100,00	-
	Europe (EU)	1	5,9	1	100,0	66,67	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	57,58	32,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	41,67	31,91
	Asia (AS)	21	53,8	13	61,9	75,64	30,14
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	75,56	18,43
	1	38	100,0	38	100,0	60,53	28,85
	2	10	100,0	10	100,0	40,00	31,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	26	86,7	72,44	26,22
	1	36	94,7	32	88,9	66,67	26,77
	2	6	60,0	6	100,0	66,67	23,57
Cycle 3 Day 1	0	29	96,7	27	93,1	75,31	28,63
	1	34	89,5	32	94,1	77,08	21,06
	2	5	50,0	5	100,0	60,00	27,89
Cycle 4 Day 1	0	29	96,7	28	96,6	86,90	19,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	78,13	19,14
	2	5	50,0	4	80,0	54,17	45,90
Cycle 5 Day 1	0	29	96,7	29	100,0	81,61	21,52
	1	33	86,8	32	97,0	75,52	27,10
	2	3	30,0	3	100,0	55,56	50,92
Cycle 6 Day 1	0	29	96,7	29	100,0	83,33	18,90
	1	31	81,6	28	90,3	77,98	22,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	72,22	34,69
Cycle 7 Day 1	0	29	96,7	28	96,6	82,14	21,24
	1	28	73,7	26	92,9	73,72	24,12
	2	3	30,0	3	100,0	55,56	50,92
Cycle 8 Day 1	0	28	93,3	26	92,9	84,62	19,39
	1	25	65,8	23	92,0	81,88	21,85
	2	3	30,0	3	100,0	55,56	48,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	82,69	19,71
	1	23	60,5	23	100,0	79,71	23,55
	2	2	20,0	2	100,0	83,33	23,57
Cycle 10 Day 1	0	26	86,7	26	100,0	80,77	21,44
	1	23	60,5	22	95,7	77,27	23,31
	2	2	20,0	2	100,0	83,33	23,57
Cycle 11 Day 1	0	26	86,7	26	100,0	82,05	21,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	78,79	21,93
	2	2	20,0	2	100,0	100,00	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	78,79	27,30
	1	22	57,9	21	95,5	79,37	21,02
	2	2	20,0	2	100,0	75,00	11,79
Cycle 13 Day 1	0	25	83,3	24	96,0	80,56	28,09
	1	20	52,6	20	100,0	80,83	20,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	66,67	-
Cycle 14 Day 1	0	25	83,3	24	96,0	78,47	28,44
	1	19	50,0	19	100,0	76,32	26,83
	2	1	10,0	1	100,0	66,67	-
Cycle 15 Day 1	0	24	80,0	24	100,0	79,86	26,46
	1	19	50,0	19	100,0	76,32	21,02
	2	1	10,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	75,83	27,82
	1	18	47,4	18	100,0	75,00	18,30
	2	1	10,0	1	100,0	100,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	78,57	24,23
	1	17	44,7	17	100,0	80,39	19,75
	2	1	10,0	1	100,0	83,33	-
Cycle 18 Day 1	0	21	70,0	18	85,7	76,85	26,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	77,08	18,13
	2	1	10,0	1	100,0	100,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	77,19	27,89
	1	15	39,5	13	86,7	76,92	19,88
	2	1	10,0	1	100,0	83,33	-
Cycle 20 Day 1	0	20	66,7	17	85,0	75,49	28,94
	1	15	39,5	14	93,3	76,19	14,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	83,33	-
Cycle 21 Day 1	0	15	50,0	14	93,3	77,38	27,43
	1	13	34,2	11	84,6	71,21	18,40
	2	1	10,0	1	100,0	83,33	-
Cycle 22 Day 1	0	15	50,0	12	80,0	75,00	29,73
	1	13	34,2	12	92,3	73,61	21,86
	2	1	10,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	72,22	35,36
	1	9	23,7	8	88,9	75,00	23,57
	2	1	10,0	1	100,0	83,33	-
Cycle 24 Day 1	0	10	33,3	9	90,0	83,33	16,67
	1	9	23,7	8	88,9	75,00	23,57
	2	1	10,0	1	100,0	100,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	80,56	26,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	80,95	17,82
Cycle 26 Day 1	0	8	26,7	6	75,0	80,56	34,02
	1	6	15,8	6	100,0	72,22	22,77
Cycle 27 Day 1	0	6	20,0	3	50,0	88,89	19,25
	1	5	13,2	5	100,0	80,00	21,73
Cycle 28 Day 1	0	5	16,7	4	80,0	91,67	16,67
	1	5	13,2	5	100,0	83,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	83,33	23,57
	1	5	13,2	5	100,0	83,33	16,67
Cycle 30 Day 1	0	3	10,0	1	33,3	33,33	-
	1	4	10,5	4	100,0	79,17	15,96
Cycle 31 Day 1	0	3	10,0	1	33,3	100,00	-
	1	4	10,5	4	100,0	75,00	16,67
Cycle 32 Day 1	0	3	10,0	2	66,7	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	77,78	19,25
Cycle 33 Day 1	0	2	6,7	2	100,0	83,33	23,57
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	66,67	31,35
	1	20	52,6	12	60,0	63,89	36,81
	2	4	40,0	2	50,0	41,67	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	68,82	21,41
	1	3	100,0	3	100,0	66,67	33,33
	2 or More	44	100,0	44	100,0	59,85	31,40
Cycle 2 Day 1	None	30	96,8	26	86,7	72,44	25,36
	1	2	66,7	1	50,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	65,77	26,34
Cycle 3 Day 1	None	30	96,8	28	93,3	77,38	25,34
	1	2	66,7	1	50,0	100,00	-
	2 or More	36	81,8	35	97,2	72,38	24,90
Cycle 4 Day 1	None	30	96,8	29	96,7	83,33	19,42
	1	2	66,7	2	100,0	100,00	0,00
	2 or More	35	79,5	33	94,3	76,77	24,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	78,89	25,87
	1	2	66,7	2	100,0	100,00	0,00
	2 or More	33	75,0	32	97,0	74,48	26,77
Cycle 6 Day 1	None	29	93,5	28	96,6	84,52	19,74
	1	2	66,7	2	100,0	100,00	0,00
	2 or More	32	72,7	30	93,8	75,00	21,77
Cycle 7 Day 1	None	27	87,1	26	96,3	80,77	23,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	83,33	23,57
	2 or More	31	70,5	29	93,5	72,99	26,13
Cycle 8 Day 1	None	26	83,9	25	96,2	85,33	20,59
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	78,40	24,81
Cycle 9 Day 1	None	25	80,6	25	100,0	86,67	20,41
	1	1	33,3	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	75,33	21,04
Cycle 10 Day 1	None	25	80,6	24	96,0	83,33	20,26
	1	1	33,3	1	100,0	100,00	-
	2 or More	25	56,8	25	100,0	74,67	23,13
Cycle 11 Day 1	None	25	80,6	25	100,0	83,33	19,84
	1	1	33,3	1	100,0	100,00	-
	2 or More	24	54,5	24	100,0	78,47	23,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	84,72	19,61
	1	1	33,3	1	100,0	100,00	-
	2 or More	23	52,3	20	87,0	70,83	26,42
Cycle 13 Day 1	None	24	77,4	23	95,8	84,78	18,74
	1	1	33,3	1	100,0	100,00	-
	2 or More	21	47,7	21	100,0	74,60	29,16
Cycle 14 Day 1	None	23	74,2	23	100,0	82,61	25,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	100,00	-
	2 or More	21	47,7	20	95,2	70,00	28,41
Cycle 15 Day 1	None	23	74,2	23	100,0	83,33	20,72
	1	1	33,3	1	100,0	100,00	-
	2 or More	20	45,5	20	100,0	70,83	25,86
Cycle 16 Day 1	None	20	64,5	19	95,0	81,58	20,71
	1	1	33,3	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	69,30	25,01
Cycle 17 Day 1	None	19	61,3	19	100,0	85,96	14,97
	1	1	33,3	1	100,0	100,00	-
	2 or More	19	43,2	19	100,0	71,93	25,49
Cycle 18 Day 1	None	18	58,1	17	94,4	85,29	15,46
	1	1	33,3	1	100,0	100,00	-
	2 or More	19	43,2	17	89,5	68,63	26,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	85,29	16,54
	1	1	33,3	1	100,0	100,00	-
	2 or More	18	40,9	15	83,3	66,67	28,17
Cycle 20 Day 1	None	17	54,8	16	94,1	82,29	16,63
	1	1	33,3	1	100,0	100,00	-
	2 or More	18	40,9	15	83,3	67,78	26,33
Cycle 21 Day 1	None	15	48,4	13	86,7	87,18	13,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	62,82	24,68
Cycle 22 Day 1	None	15	48,4	13	86,7	84,62	17,30
	2 or More	14	31,8	12	85,7	65,28	29,69
Cycle 23 Day 1	None	10	32,3	9	90,0	87,04	16,20
	2 or More	11	25,0	9	81,8	61,11	33,33
Cycle 24 Day 1	None	10	32,3	10	100,0	85,00	16,57
	2 or More	10	22,7	8	80,0	75,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	89,58	15,27
	2 or More	6	13,6	5	83,3	66,67	23,57
Cycle 26 Day 1	None	8	25,8	8	100,0	83,33	23,57
	2 or More	6	13,6	4	66,7	62,50	34,36
Cycle 27 Day 1	None	7	22,6	6	85,7	83,33	21,08
	2 or More	4	9,1	2	50,0	83,33	23,57
Cycle 28 Day 1	None	7	22,6	7	100,0	88,10	15,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	83,33	23,57
Cycle 29 Day 1	None	6	19,4	5	83,3	83,33	16,67
	2 or More	3	6,8	2	66,7	83,33	23,57
Cycle 30 Day 1	None	4	12,9	3	75,0	66,67	33,33
	2 or More	3	6,8	2	66,7	75,00	11,79
Cycle 31 Day 1	None	4	12,9	3	75,0	88,89	19,25
	2 or More	3	6,8	2	66,7	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	88,89	19,25
	2 or More	2	4,5	2	100,0	66,67	0,00
Cycle 33 Day 1	None	1	3,2	1	100,0	100,00	-
	2 or More	1	2,3	1	100,0	66,67	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	58,33	32,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	83,33	-
	2 or More	24	54,5	15	62,5	66,67	33,92
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	68,82	21,41
	Previously Treated	47	100,0	47	100,0	60,28	31,19
Cycle 2 Day 1	Naïve	30	96,8	26	86,7	72,44	25,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	66,67	26,57
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	77,38	25,34
	Previously Treated	38	80,9	36	94,7	73,15	24,97
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	83,33	19,42
	Previously Treated	37	78,7	35	94,6	78,10	24,84
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	78,89	25,87
	Previously Treated	35	74,5	34	97,1	75,98	26,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	84,52	19,74
	Previously Treated	34	72,3	32	94,1	76,56	21,94
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	80,77	23,42
	Previously Treated	33	70,2	31	93,9	73,66	25,74
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	85,33	20,59
	Previously Treated	30	63,8	27	90,0	78,40	24,81
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	86,67	20,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	76,28	21,17
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	83,33	20,26
	Previously Treated	26	55,3	26	100,0	75,64	23,20
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	83,33	19,84
	Previously Treated	25	53,2	25	100,0	79,33	23,21
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	84,72	19,61
	Previously Treated	24	51,1	21	87,5	72,22	26,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	84,78	18,74
	Previously Treated	22	46,8	22	100,0	75,76	28,97
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	82,61	25,37
	Previously Treated	22	46,8	21	95,5	71,43	28,45
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	83,33	20,72
	Previously Treated	21	44,7	21	100,0	72,22	26,00
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	81,58	20,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	70,83	25,29
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	85,96	14,97
	Previously Treated	20	42,6	20	100,0	73,33	25,59
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	85,29	15,46
	Previously Treated	20	42,6	18	90,0	70,37	26,54
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	85,29	16,54
	Previously Treated	19	40,4	16	84,2	68,75	28,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	82,29	16,63
	Previously Treated	19	40,4	16	84,2	69,79	26,68
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	87,18	13,87
	Previously Treated	14	29,8	13	92,9	62,82	24,68
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	84,62	17,30
	Previously Treated	14	29,8	12	85,7	65,28	29,69
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	87,04	16,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	61,11	33,33
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	85,00	16,57
	Previously Treated	10	21,3	8	80,0	75,00	23,57
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	89,58	15,27
	Previously Treated	6	12,8	5	83,3	66,67	23,57
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	83,33	23,57
	Previously Treated	6	12,8	4	66,7	62,50	34,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	83,33	21,08
	Previously Treated	4	8,5	2	50,0	83,33	23,57
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	88,10	15,85
	Previously Treated	3	6,4	2	66,7	83,33	23,57
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	83,33	16,67
	Previously Treated	3	6,4	2	66,7	83,33	23,57
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	66,67	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	75,00	11,79
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	88,89	19,25
	Previously Treated	3	6,4	2	66,7	66,67	0,00
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	88,89	19,25
	Previously Treated	2	4,3	2	100,0	66,67	0,00
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	100,00	-
	Previously Treated	1	2,1	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	58,33	32,95
	Previously Treated	26	55,3	16	61,5	67,71	33,04
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	59,52	30,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	67,05	25,59
Cycle 2 Day 1	Local	32	91,4	29	90,6	72,99	23,32
	Central	40	93,0	35	87,5	65,71	27,99
Cycle 3 Day 1	Local	29	82,9	28	96,6	79,17	26,69
	Central	39	90,7	36	92,3	71,76	23,51
Cycle 4 Day 1	Local	28	80,0	27	96,4	86,42	17,92
	Central	39	90,7	37	94,9	76,13	24,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	79,63	24,17
	Central	38	88,4	37	97,4	75,68	27,66
Cycle 6 Day 1	Local	27	77,1	27	100,0	86,42	20,17
	Central	36	83,7	33	91,7	75,25	20,88
Cycle 7 Day 1	Local	27	77,1	27	100,0	80,86	20,52
	Central	33	76,7	30	90,9	73,33	27,89
Cycle 8 Day 1	Local	26	74,3	26	100,0	83,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	80,13	27,09
Cycle 9 Day 1	Local	25	71,4	25	100,0	80,00	20,97
	Central	26	60,5	26	100,0	82,69	21,85
Cycle 10 Day 1	Local	25	71,4	24	96,0	79,86	20,25
	Central	26	60,5	26	100,0	78,85	23,83
Cycle 11 Day 1	Local	24	68,6	24	100,0	81,94	18,98
	Central	26	60,5	26	100,0	80,77	23,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	80,30	23,37
	Central	26	60,5	23	88,5	77,54	24,42
Cycle 13 Day 1	Local	22	62,9	22	100,0	80,30	25,53
	Central	24	55,8	23	95,8	80,43	23,92
Cycle 14 Day 1	Local	22	62,9	22	100,0	80,30	25,53
	Central	23	53,5	22	95,7	74,24	28,97
Cycle 15 Day 1	Local	22	62,9	22	100,0	81,06	23,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	75,00	24,53
Cycle 16 Day 1	Local	20	57,1	20	100,0	80,83	18,95
	Central	21	48,8	19	90,5	71,05	27,13
Cycle 17 Day 1	Local	20	57,1	20	100,0	82,50	15,74
	Central	19	44,2	19	100,0	76,32	26,83
Cycle 18 Day 1	Local	20	57,1	19	95,0	82,46	17,10
	Central	18	41,9	16	88,9	71,88	27,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	82,35	20,81
	Central	17	39,5	16	94,1	71,88	27,02
Cycle 20 Day 1	Local	19	54,3	17	89,5	80,39	19,75
	Central	17	39,5	15	88,2	71,11	25,56
Cycle 21 Day 1	Local	14	40,0	12	85,7	81,94	16,60
	Central	15	34,9	14	93,3	69,05	26,84
Cycle 22 Day 1	Local	14	40,0	12	85,7	80,56	21,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	70,51	28,99
Cycle 23 Day 1	Local	11	31,4	10	90,9	78,33	27,27
	Central	10	23,3	8	80,0	68,75	31,42
Cycle 24 Day 1	Local	11	31,4	10	90,9	81,67	22,84
	Central	9	20,9	8	88,9	79,17	17,25
Cycle 25 Day 1	Local	7	20,0	7	100,0	85,71	26,23
	Central	8	18,6	6	75,0	75,00	13,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	77,78	36,00
	Central	8	18,6	6	75,0	75,00	20,41
Cycle 27 Day 1	Local	4	11,4	4	100,0	87,50	25,00
	Central	7	16,3	4	57,1	79,17	15,96
Cycle 28 Day 1	Local	4	11,4	4	100,0	91,67	16,67
	Central	6	14,0	5	83,3	83,33	16,67
Cycle 29 Day 1	Local	3	8,6	3	100,0	88,89	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	79,17	15,96
Cycle 30 Day 1	Local	3	8,6	3	100,0	66,67	33,33
	Central	4	9,3	2	50,0	75,00	11,79
Cycle 31 Day 1	Local	3	8,6	3	100,0	88,89	19,25
	Central	4	9,3	2	50,0	66,67	0,00
Cycle 32 Day 1	Local	3	8,6	3	100,0	88,89	19,25
	Central	3	7,0	2	66,7	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	100,00	-
	Central	1	2,3	1	100,0	66,67	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	64,29	31,25
	Central	21	48,8	14	66,7	63,10	35,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	63,74	27,22
	No	4	100,0	4	100,0	62,50	43,83
Cycle 2 Day 1	Yes	70	94,6	62	88,6	69,89	24,86
	No	2	50,0	2	100,0	41,67	58,93
Cycle 3 Day 1	Yes	66	89,2	62	93,9	75,27	24,65
	No	2	50,0	2	100,0	66,67	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	80,38	22,69
	No	2	50,0	2	100,0	83,33	23,57
Cycle 5 Day 1	Yes	63	85,1	62	98,4	77,69	26,47
	No	2	50,0	2	100,0	66,67	0,00
Cycle 6 Day 1	Yes	61	82,4	58	95,1	80,17	21,28
	No	2	50,0	2	100,0	83,33	23,57
Cycle 7 Day 1	Yes	58	78,4	55	94,8	77,27	25,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	66,67	0,00
Cycle 8 Day 1	Yes	54	73,0	50	92,6	82,67	22,83
	No	2	50,0	2	100,0	58,33	11,79
Cycle 9 Day 1	Yes	49	66,2	49	100,0	81,97	21,47
	No	2	50,0	2	100,0	66,67	0,00
Cycle 10 Day 1	Yes	49	66,2	48	98,0	80,21	21,92
	No	2	50,0	2	100,0	58,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	82,29	21,31
	No	2	50,0	2	100,0	58,33	11,79
Cycle 12 Day 1	Yes	47	63,5	43	91,5	79,84	23,73
	No	2	50,0	2	100,0	58,33	11,79
Cycle 13 Day 1	Yes	44	59,5	43	97,7	81,01	24,82
	No	2	50,0	2	100,0	66,67	0,00
Cycle 14 Day 1	Yes	43	58,1	42	97,7	77,78	27,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	66,67	0,00
Cycle 15 Day 1	Yes	42	56,8	42	100,0	78,57	24,22
	No	2	50,0	2	100,0	66,67	0,00
Cycle 16 Day 1	Yes	39	52,7	37	94,9	76,58	24,04
	No	2	50,0	2	100,0	66,67	0,00
Cycle 17 Day 1	Yes	37	50,0	37	100,0	80,63	21,70
	No	2	50,0	2	100,0	58,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	79,29	22,06
	No	2	50,0	2	100,0	50,00	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	77,60	24,54
	No	2	50,0	1	50,0	66,67	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	77,22	22,95
	No	2	50,0	2	100,0	58,33	11,79
Cycle 21 Day 1	Yes	27	36,5	24	88,9	75,69	24,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	66,67	0,00
Cycle 22 Day 1	Yes	27	36,5	23	85,2	75,36	26,53
	No	2	50,0	2	100,0	75,00	11,79
Cycle 23 Day 1	Yes	20	27,0	17	85,0	72,55	28,83
	No	1	25,0	1	100,0	100,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	79,41	20,01
	No	1	25,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	79,17	21,47
	No	1	25,0	1	100,0	100,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	78,79	27,98
	No	1	25,0	1	100,0	50,00	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	88,10	15,85
	No	1	25,0	1	100,0	50,00	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	89,58	15,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	66,67	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	86,11	16,39
	No	1	25,0	1	100,0	66,67	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	70,83	28,46
	No	1	25,0	1	100,0	66,67	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	83,33	19,25
	No	1	25,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	83,33	19,25
	No	1	25,0	1	100,0	66,67	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	83,33	23,57
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	63,69	32,73
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	62,50	14,77
	No	70	100,0	70	100,0	63,81	29,07
Cycle 2 Day 1	Yes	5	62,5	5	100,0	76,67	32,49
	No	67	95,7	59	88,1	68,36	25,65
Cycle 3 Day 1	Yes	5	62,5	5	100,0	86,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	74,01	25,38
Cycle 4 Day 1	Yes	5	62,5	5	100,0	83,33	23,57
	No	62	88,6	59	95,2	80,23	22,63
Cycle 5 Day 1	Yes	5	62,5	5	100,0	73,33	27,89
	No	60	85,7	59	98,3	77,68	26,19
Cycle 6 Day 1	Yes	5	62,5	5	100,0	80,00	29,81
	No	58	82,9	55	94,8	80,30	20,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	73,33	27,89
	No	55	78,6	52	94,5	77,24	24,70
Cycle 8 Day 1	Yes	5	62,5	5	100,0	70,00	29,81
	No	51	72,9	47	92,2	82,98	22,11
Cycle 9 Day 1	Yes	4	50,0	4	100,0	75,00	31,91
	No	47	67,1	47	100,0	81,91	20,51
Cycle 10 Day 1	Yes	4	50,0	4	100,0	79,17	25,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	79,35	21,99
Cycle 11 Day 1	Yes	4	50,0	4	100,0	75,00	21,52
	No	46	65,7	46	100,0	81,88	21,61
Cycle 12 Day 1	Yes	4	50,0	4	100,0	79,17	25,00
	No	45	64,3	41	91,1	78,86	23,87
Cycle 13 Day 1	Yes	4	50,0	4	100,0	75,00	31,91
	No	42	60,0	41	97,6	80,89	24,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	70,83	28,46
	No	41	58,6	40	97,6	77,92	27,32
Cycle 15 Day 1	Yes	4	50,0	4	100,0	75,00	31,91
	No	40	57,1	40	100,0	78,33	23,33
Cycle 16 Day 1	Yes	3	37,5	3	100,0	83,33	16,67
	No	38	54,3	36	94,7	75,46	24,07
Cycle 17 Day 1	Yes	3	37,5	3	100,0	77,78	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	79,63	22,22
Cycle 18 Day 1	Yes	3	37,5	3	100,0	77,78	19,25
	No	35	50,0	32	91,4	77,60	23,42
Cycle 19 Day 1	Yes	3	37,5	3	100,0	77,78	19,25
	No	33	47,1	30	90,9	77,22	24,95
Cycle 20 Day 1	Yes	3	37,5	3	100,0	77,78	19,25
	No	33	47,1	29	87,9	75,86	23,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	83,33	23,57
	No	27	38,6	24	88,9	74,31	23,56
Cycle 22 Day 1	Yes	2	25,0	2	100,0	66,67	0,00
	No	27	38,6	23	85,2	76,09	26,51
Cycle 23 Day 1	Yes	2	25,0	2	100,0	75,00	11,79
	No	19	27,1	16	84,2	73,96	30,41
Cycle 24 Day 1	Yes	2	25,0	2	100,0	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	82,29	20,61
Cycle 25 Day 1	Yes	2	25,0	2	100,0	75,00	11,79
	No	13	18,6	11	84,6	81,82	22,92
Cycle 26 Day 1	Yes	1	12,5	1	100,0	66,67	-
	No	13	18,6	11	84,6	77,27	29,13
Cycle 27 Day 1	Yes	1	12,5	1	100,0	66,67	-
	No	10	14,3	7	70,0	85,71	20,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	66,67	-
	No	9	12,9	8	88,9	89,58	15,27
Cycle 29 Day 1	Yes	1	12,5	1	100,0	66,67	-
	No	8	11,4	6	75,0	86,11	16,39
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	70,00	24,72
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	80,00	18,26
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	80,00	18,26
Cycle 33 Day 1	No	2	2,9	2	100,0	83,33	23,57
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	25,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	66,67	31,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D180_REE_C30SF_SG.xls
28NOV2019 10:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	78	100,0	34,19	27,90
Cycle 2 Day 1	All	72	92,3	65	90,3	18,46	22,85
Cycle 3 Day 1	All	68	87,2	64	94,1	14,58	20,47
Cycle 4 Day 1	All	67	85,9	64	95,5	14,06	23,61
Cycle 5 Day 1	All	65	83,3	64	98,5	13,02	20,24
Cycle 6 Day 1	All	63	80,8	60	95,2	12,22	18,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	60	76,9	57	95,0	12,28	19,55
Cycle 8 Day 1	All	56	71,8	52	92,9	14,10	21,23
Cycle 9 Day 1	All	51	65,4	51	100,0	9,80	18,01
Cycle 10 Day 1	All	51	65,4	50	98,0	9,33	16,55
Cycle 11 Day 1	All	50	64,1	50	100,0	11,33	18,58
Cycle 12 Day 1	All	49	62,8	45	91,8	12,59	19,19
Cycle 13 Day 1	All	46	59,0	45	97,8	11,11	22,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	45	57,7	44	97,8	12,88	24,08
Cycle 15 Day 1	All	44	56,4	44	100,0	12,12	21,68
Cycle 16 Day 1	All	41	52,6	39	95,1	10,26	17,36
Cycle 17 Day 1	All	39	50,0	39	100,0	6,84	13,64
Cycle 18 Day 1	All	38	48,7	35	92,1	8,57	14,78
Cycle 19 Day 1	All	36	46,2	33	91,7	14,14	23,61
Cycle 20 Day 1	All	36	46,2	32	88,9	10,42	17,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	37,2	26	89,7	12,82	16,54
Cycle 22 Day 1	All	29	37,2	25	86,2	13,33	25,46
Cycle 23 Day 1	All	21	26,9	18	85,7	9,26	15,36
Cycle 24 Day 1	All	20	25,6	18	90,0	7,41	14,26
Cycle 25 Day 1	All	15	19,2	13	86,7	20,51	25,60
Cycle 26 Day 1	All	14	17,9	12	85,7	19,44	26,43
Cycle 27 Day 1	All	11	14,1	8	72,7	33,33	30,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	12,8	9	90,0	7,41	14,70
Cycle 29 Day 1	All	9	11,5	7	77,8	28,57	35,63
Cycle 30 Day 1	All	7	9,0	5	71,4	13,33	18,26
Cycle 31 Day 1	All	7	9,0	5	71,4	13,33	18,26
Cycle 32 Day 1	All	6	7,7	5	83,3	0,00	0,00
Cycle 33 Day 1	All	2	2,6	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	30,95	27,11
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	32,18	20,86
	Female	49	100,0	49	100,0	35,37	31,48
Cycle 2 Day 1	Male	27	93,1	25	92,6	18,67	19,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	45	91,8	40	88,9	18,33	24,98
Cycle 3 Day 1	Male	25	86,2	23	92,0	15,94	22,18
	Female	43	87,8	41	95,3	13,82	19,69
Cycle 4 Day 1	Male	25	86,2	25	100,0	16,00	27,42
	Female	42	85,7	39	92,9	12,82	21,10
Cycle 5 Day 1	Male	25	86,2	25	100,0	16,00	21,77
	Female	40	81,6	39	97,5	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	25	86,2	23	92,0	13,04	19,43
	Female	38	77,6	37	97,4	11,71	17,94
Cycle 7 Day 1	Male	23	79,3	23	100,0	18,84	22,08
	Female	37	75,5	34	91,9	7,84	16,53
Cycle 8 Day 1	Male	21	72,4	19	90,5	17,54	25,74
	Female	35	71,4	33	94,3	12,12	18,29
Cycle 9 Day 1	Male	18	62,1	18	100,0	7,41	14,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	11,11	19,84
Cycle 10 Day 1	Male	18	62,1	18	100,0	9,26	15,36
	Female	33	67,3	32	97,0	9,38	17,42
Cycle 11 Day 1	Male	18	62,1	18	100,0	11,11	16,17
	Female	32	65,3	32	100,0	11,46	20,05
Cycle 12 Day 1	Male	17	58,6	17	100,0	9,80	19,60
	Female	32	65,3	28	87,5	14,29	19,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	17	58,6	17	100,0	7,84	14,57
	Female	29	59,2	28	96,6	13,10	26,20
Cycle 14 Day 1	Male	17	58,6	16	94,1	8,33	14,91
	Female	28	57,1	28	100,0	15,48	27,94
Cycle 15 Day 1	Male	16	55,2	16	100,0	8,33	19,25
	Female	28	57,1	28	100,0	14,29	23,00
Cycle 16 Day 1	Male	14	48,3	14	100,0	9,52	15,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	25	92,6	10,67	18,56
Cycle 17 Day 1	Male	12	41,4	12	100,0	8,33	15,08
	Female	27	55,1	27	100,0	6,17	13,19
Cycle 18 Day 1	Male	11	37,9	10	90,9	10,00	16,10
	Female	27	55,1	25	92,6	8,00	14,53
Cycle 19 Day 1	Male	10	34,5	10	100,0	20,00	28,11
	Female	26	53,1	23	88,5	11,59	21,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	34,5	9	90,0	11,11	16,67
	Female	26	53,1	23	88,5	10,14	18,63
Cycle 21 Day 1	Male	8	27,6	8	100,0	20,83	17,25
	Female	21	42,9	18	85,7	9,26	15,36
Cycle 22 Day 1	Male	8	27,6	6	75,0	16,67	27,89
	Female	21	42,9	19	90,5	12,28	25,36
Cycle 23 Day 1	Male	5	17,2	4	80,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	32,7	14	87,5	9,52	15,63
Cycle 24 Day 1	Male	5	17,2	4	80,0	16,67	19,25
	Female	15	30,6	14	93,3	4,76	12,10
Cycle 25 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	12	24,5	11	91,7	24,24	26,21
Cycle 26 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	11	22,4	10	90,9	23,33	27,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	10,3	2	66,7	16,67	23,57
	Female	8	16,3	6	75,0	38,89	32,77
Cycle 28 Day 1	Male	2	6,9	2	100,0	0,00	0,00
	Female	8	16,3	7	87,5	9,52	16,27
Cycle 29 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	8	16,3	6	75,0	33,33	36,51
Cycle 30 Day 1	Male	1	3,4	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	12,2	4	66,7	8,33	16,67
Cycle 31 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	16,67	19,25
Cycle 32 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	5	10,2	4	80,0	0,00	0,00
Cycle 33 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	1	2,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	28,89	30,52
	Female	21	42,9	13	61,9	33,33	23,57
Age							
Cycle 1 Day 1	18-64	62	100,0	62	100,0	33,33	28,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	40,48	26,73
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 2 Day 1	18-64	59	95,2	53	89,8	16,35	22,29
	65-74	11	78,6	10	90,9	26,67	26,29
	>=75	2	100,0	2	100,0	33,33	0,00
Cycle 3 Day 1	18-64	56	90,3	52	92,9	14,10	20,18
	65-74	10	71,4	10	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 4 Day 1	18-64	55	88,7	53	96,4	14,47	24,03
	65-74	10	71,4	9	90,0	14,81	24,22
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 5 Day 1	18-64	53	85,5	52	98,1	12,18	19,83
	65-74	10	71,4	10	100,0	16,67	23,57
	>=75	2	100,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	51	82,3	49	96,1	11,56	18,70
	65-74	10	71,4	9	90,0	14,81	17,57
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 7 Day 1	18-64	49	79,0	47	95,9	9,93	19,55
	65-74	9	64,3	8	88,9	20,83	17,25
	>=75	2	100,0	2	100,0	33,33	0,00
Cycle 8 Day 1	18-64	45	72,6	41	91,1	13,01	22,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	18,52	17,57
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 9 Day 1	18-64	40	64,5	40	100,0	7,50	15,99
	65-74	9	64,3	9	100,0	18,52	24,22
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 10 Day 1	18-64	40	64,5	39	97,5	6,84	13,64
	65-74	9	64,3	9	100,0	22,22	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 11 Day 1	18-64	39	62,9	39	100,0	10,26	18,97
	65-74	9	64,3	9	100,0	14,81	17,57
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 12 Day 1	18-64	38	61,3	35	92,1	10,48	19,42
	65-74	9	64,3	8	88,9	25,00	15,43
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	35	56,5	34	97,1	7,84	18,46
	65-74	9	64,3	9	100,0	18,52	33,79
	>=75	2	100,0	2	100,0	33,33	0,00
Cycle 14 Day 1	18-64	35	56,5	35	100,0	11,43	21,30
	65-74	9	64,3	8	88,9	16,67	35,63
	>=75	1	50,0	1	100,0	33,33	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	10,48	19,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	57,1	8	100,0	16,67	30,86
	>=75	1	50,0	1	100,0	33,33	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	9,38	17,42
	65-74	7	50,0	6	85,7	16,67	18,26
	>=75	1	50,0	1	100,0	0,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	4,17	11,20
	65-74	6	42,9	6	100,0	16,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	33,33	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	6,90	13,74
	65-74	6	42,9	5	83,3	13,33	18,26
	>=75	1	50,0	1	100,0	33,33	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	11,90	22,62
	65-74	5	35,7	4	80,0	25,00	31,91
	>=75	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	7,69	14,32
	65-74	5	35,7	5	100,0	20,00	29,81
	>=75	1	50,0	1	100,0	33,33	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	11,11	16,10
	65-74	4	28,6	4	100,0	16,67	19,25
	>=75	1	50,0	1	100,0	33,33	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	13,33	27,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	28,6	4	100,0	16,67	19,25
	>=75	1	50,0	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	10,42	15,96
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	6,25	13,44
	65-74	2	14,3	2	100,0	16,67	23,57
Cycle 25 Day 1	18-64	14	22,6	12	85,7	22,22	25,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	19,44	26,43
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	33,33	30,86
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	7,41	14,70
	65-74	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	12,9	7	87,5	28,57	35,63
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	13,33	18,26
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	13,33	18,26
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	0,00	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	33,33	30,59
	65-74	10	71,4	7	70,0	23,81	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	1	50,0	33,33	-
Race							
Cycle 1 Day 1	White	35	100,0	35	100,0	34,29	29,69
	Other	43	100,0	43	100,0	34,11	26,71
Cycle 2 Day 1	White	33	94,3	29	87,9	14,94	21,06
	Other	39	90,7	36	92,3	21,30	24,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	31	88,6	27	87,1	11,11	20,67
	Other	37	86,0	37	100,0	17,12	20,22
Cycle 4 Day 1	White	31	88,6	28	90,3	9,52	21,96
	Other	36	83,7	36	100,0	17,59	24,54
Cycle 5 Day 1	White	31	88,6	30	96,8	14,44	22,63
	Other	34	79,1	34	100,0	11,76	18,13
Cycle 6 Day 1	White	30	85,7	28	93,3	13,10	20,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	33	76,7	32	97,0	11,46	16,09
Cycle 7 Day 1	White	29	82,9	27	93,1	13,58	21,20
	Other	31	72,1	30	96,8	11,11	18,22
Cycle 8 Day 1	White	28	80,0	24	85,7	13,89	19,45
	Other	28	65,1	28	100,0	14,29	23,00
Cycle 9 Day 1	White	26	74,3	26	100,0	10,26	20,59
	Other	25	58,1	25	100,0	9,33	15,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	5,33	15,75
	Other	25	58,1	25	100,0	13,33	16,67
Cycle 11 Day 1	White	26	74,3	26	100,0	12,82	21,24
	Other	24	55,8	24	100,0	9,72	15,48
Cycle 12 Day 1	White	26	74,3	22	84,6	9,09	18,35
	Other	23	53,5	23	100,0	15,94	19,77
Cycle 13 Day 1	White	24	68,6	23	95,8	13,04	27,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	22	51,2	22	100,0	9,09	15,19
Cycle 14 Day 1	White	24	68,6	24	100,0	15,28	29,45
	Other	21	48,8	20	95,2	10,00	15,67
Cycle 15 Day 1	White	24	68,6	24	100,0	9,72	18,33
	Other	20	46,5	20	100,0	15,00	25,31
Cycle 16 Day 1	White	22	62,9	20	90,9	6,67	17,44
	Other	19	44,2	19	100,0	14,04	16,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	22	62,9	22	100,0	4,55	11,71
	Other	17	39,5	17	100,0	9,80	15,66
Cycle 18 Day 1	White	21	60,0	18	85,7	7,41	14,26
	Other	17	39,5	17	100,0	9,80	15,66
Cycle 19 Day 1	White	20	57,1	20	100,0	15,00	25,31
	Other	16	37,2	13	81,3	12,82	21,68
Cycle 20 Day 1	White	20	57,1	17	85,0	9,80	19,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	37,2	15	93,8	11,11	16,27
Cycle 21 Day 1	White	16	45,7	14	87,5	11,90	16,57
	Other	13	30,2	12	92,3	13,89	17,16
Cycle 22 Day 1	White	16	45,7	13	81,3	12,82	28,99
	Other	13	30,2	12	92,3	13,89	22,29
Cycle 23 Day 1	White	12	34,3	10	83,3	6,67	14,05
	Other	9	20,9	8	88,9	12,50	17,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	31,4	10	90,9	6,67	14,05
	Other	9	20,9	8	88,9	8,33	15,43
Cycle 25 Day 1	White	10	28,6	8	80,0	20,83	24,80
	Other	5	11,6	5	100,0	20,00	29,81
Cycle 26 Day 1	White	10	28,6	8	80,0	20,83	30,54
	Other	4	9,3	4	100,0	16,67	19,25
Cycle 27 Day 1	White	8	22,9	5	62,5	33,33	40,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	7,0	3	100,0	33,33	0,00
Cycle 28 Day 1	White	7	20,0	6	85,7	5,56	13,61
	Other	3	7,0	3	100,0	11,11	19,25
Cycle 29 Day 1	White	6	17,1	4	66,7	41,67	41,94
	Other	3	7,0	3	100,0	11,11	19,25
Cycle 30 Day 1	White	4	11,4	2	50,0	16,67	23,57
	Other	3	7,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	11,4	2	50,0	0,00	0,00
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 32 Day 1	White	4	11,4	3	75,0	0,00	0,00
	Other	2	4,7	2	100,0	0,00	0,00
Cycle 33 Day 1	White	2	5,7	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	15	42,9	12	80,0	27,78	23,92
	Other	24	55,8	16	66,7	33,33	29,81
Region							
Cycle 1 Day 1	America (AM)	22	100,0	22	100,0	37,88	31,36
	Europe (EU)	17	100,0	17	100,0	37,25	26,04
	Asia (AS)	39	100,0	39	100,0	30,77	26,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	9,80	19,60
	Europe (EU)	16	94,1	13	81,3	20,51	21,68
	Asia (AS)	36	92,3	35	97,2	21,90	24,18
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	7,02	13,96
	Europe (EU)	15	88,2	12	80,0	22,22	25,95
	Asia (AS)	33	84,6	33	100,0	16,16	20,62
Cycle 4 Day 1	America (AM)	20	90,9	20	100,0	13,33	22,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	88,2	12	80,0	13,89	26,43
	Asia (AS)	32	82,1	32	100,0	14,58	23,85
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	13,33	22,69
	Europe (EU)	15	88,2	14	93,3	14,29	21,54
	Asia (AS)	30	76,9	30	100,0	12,22	18,54
Cycle 6 Day 1	America (AM)	20	90,9	20	100,0	11,67	19,57
	Europe (EU)	14	82,4	13	92,9	15,38	22,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	74,4	27	93,1	11,11	16,01
Cycle 7 Day 1	America (AM)	19	86,4	18	94,7	9,26	19,15
	Europe (EU)	14	82,4	13	92,9	17,95	22,01
	Asia (AS)	27	69,2	26	96,3	11,54	18,72
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	9,80	19,60
	Europe (EU)	14	82,4	11	78,6	18,18	17,41
	Asia (AS)	24	61,5	24	100,0	15,28	24,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	14,81	20,52
	Europe (EU)	12	70,6	12	100,0	11,11	21,71
	Asia (AS)	21	53,8	21	100,0	4,76	11,95
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	9,80	15,66
	Europe (EU)	12	70,6	12	100,0	8,33	20,72
	Asia (AS)	21	53,8	21	100,0	9,52	15,43
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	12,96	23,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	12	70,6	12	100,0	11,11	16,41
	Asia (AS)	20	51,3	20	100,0	10,00	15,67
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	11,76	20,21
	Europe (EU)	12	70,6	9	75,0	7,41	14,70
	Asia (AS)	19	48,7	19	100,0	15,79	20,39
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	7,84	18,74
	Europe (EU)	11	64,7	10	90,9	16,67	32,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	18	46,2	18	100,0	11,11	19,80
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	11,76	26,20
	Europe (EU)	11	64,7	11	100,0	15,15	31,14
	Asia (AS)	17	43,6	16	94,1	12,50	16,67
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	5,88	17,62
	Europe (EU)	11	64,7	11	100,0	12,12	22,47
	Asia (AS)	16	41,0	16	100,0	18,75	24,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	2,38	8,91
	Europe (EU)	11	64,7	9	81,8	11,11	16,67
	Asia (AS)	16	41,0	16	100,0	16,67	21,08
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	4,76	12,10
	Europe (EU)	10	58,8	10	100,0	6,67	14,05
	Asia (AS)	15	38,5	15	100,0	8,89	15,26
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	11,90	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	9	52,9	6	66,7	5,56	13,61
	Asia (AS)	15	38,5	15	100,0	6,67	13,80
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	12,82	21,68
	Europe (EU)	9	52,9	9	100,0	18,52	29,40
	Asia (AS)	14	35,9	11	78,6	12,12	22,47
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	7,69	14,62
	Europe (EU)	9	52,9	6	66,7	16,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	10,26	16,01
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	13,33	17,21
	Europe (EU)	7	41,2	6	85,7	16,67	18,26
	Asia (AS)	11	28,2	10	90,9	10,00	16,10
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	20,00	32,20
	Europe (EU)	7	41,2	5	71,4	0,00	0,00
	Asia (AS)	11	28,2	10	90,9	13,33	23,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	3,70	11,11
	Europe (EU)	5	29,4	3	60,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	22,22	17,21
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	12,50	17,25
	Europe (EU)	5	29,4	4	80,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	5,56	13,61
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	19,05	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	33,33	27,22
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	27,78	32,77
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	16,67	19,25
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	33,33	47,14
	Europe (EU)	3	17,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	33,33	0,00
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	0,00	0,00
	Europe (EU)	2	11,8	1	50,0	0,00	-
	Asia (AS)	4	10,3	4	100,0	16,67	19,25
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	22,22	19,25
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	33,33	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	11,11	19,25
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	22,22	19,25
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	1	100,0	0,00	-
	Asia (AS)	3	7,7	2	66,7	0,00	0,00
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	0,00	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	30,30	23,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	35,3	4	66,7	41,67	16,67
	Asia (AS)	21	53,8	13	61,9	28,21	32,90
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	30	100,0	24,44	24,66
	1	38	100,0	38	100,0	36,84	27,72
	2	10	100,0	10	100,0	53,33	28,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	30	100,0	27	90,0	17,28	23,33
	1	36	94,7	32	88,9	16,67	20,74
	2	6	60,0	6	100,0	33,33	29,81
Cycle 3 Day 1	0	29	96,7	27	93,1	11,11	20,67
	1	34	89,5	32	94,1	14,58	18,81
	2	5	50,0	5	100,0	33,33	23,57
Cycle 4 Day 1	0	29	96,7	28	96,6	9,52	21,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	14,58	22,30
	2	5	50,0	4	80,0	41,67	31,91
Cycle 5 Day 1	0	29	96,7	29	100,0	10,34	20,13
	1	33	86,8	32	97,0	15,63	20,71
	2	3	30,0	3	100,0	11,11	19,25
Cycle 6 Day 1	0	29	96,7	29	100,0	13,79	20,93
	1	31	81,6	28	90,3	10,71	15,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	3	30,0	3	100,0	11,11	19,25
Cycle 7 Day 1	0	29	96,7	28	96,6	13,10	18,90
	1	28	73,7	26	92,9	12,82	21,24
	2	3	30,0	3	100,0	0,00	0,00
Cycle 8 Day 1	0	28	93,3	26	92,9	15,38	19,39
	1	25	65,8	23	92,0	13,04	24,08
	2	3	30,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	26	86,7	26	100,0	11,54	20,96
	1	23	60,5	23	100,0	8,70	14,97
	2	2	20,0	2	100,0	0,00	0,00
Cycle 10 Day 1	0	26	86,7	26	100,0	11,54	18,72
	1	23	60,5	22	95,7	7,58	14,30
	2	2	20,0	2	100,0	0,00	0,00
Cycle 11 Day 1	0	26	86,7	26	100,0	12,82	19,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	22	100,0	10,61	18,93
	2	2	20,0	2	100,0	0,00	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	18,18	19,86
	1	22	57,9	21	95,5	7,94	17,97
	2	2	20,0	2	100,0	0,00	0,00
Cycle 13 Day 1	0	25	83,3	24	96,0	13,89	27,66
	1	20	52,6	20	100,0	8,33	14,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	12,50	29,18
	1	19	50,0	19	100,0	14,04	16,91
	2	1	10,0	1	100,0	0,00	-
Cycle 15 Day 1	0	24	80,0	24	100,0	9,72	20,80
	1	19	50,0	19	100,0	15,79	23,22
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	22	73,3	20	90,9	6,67	13,68
	1	18	47,4	18	100,0	14,81	20,52
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	7,94	14,55
	1	17	44,7	17	100,0	5,88	13,10
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	11,11	16,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	16	42,1	16	100,0	6,25	13,44
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	15,79	25,74
	1	15	39,5	13	86,7	12,82	21,68
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	13,73	20,61
	1	15	39,5	14	93,3	7,14	14,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	9,52	15,63
	1	13	34,2	11	84,6	18,18	17,41
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	13,89	30,01
	1	13	34,2	12	92,3	13,89	22,29
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	3,70	11,11
	1	9	23,7	8	88,9	16,67	17,82
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	7,41	14,70
	1	9	23,7	8	88,9	8,33	15,43
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	16,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	18,4	7	100,0	23,81	25,20
Cycle 26 Day 1	0	8	26,7	6	75,0	11,11	27,22
	1	6	15,8	6	100,0	27,78	25,09
Cycle 27 Day 1	0	6	20,0	3	50,0	22,22	19,25
	1	5	13,2	5	100,0	40,00	36,51
Cycle 28 Day 1	0	5	16,7	4	80,0	8,33	16,67
	1	5	13,2	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	13,3	2	50,0	50,00	70,71
	1	5	13,2	5	100,0	20,00	18,26
Cycle 30 Day 1	0	3	10,0	1	33,3	33,33	-
	1	4	10,5	4	100,0	8,33	16,67
Cycle 31 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	16,67	19,25
Cycle 32 Day 1	0	3	10,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	7,9	3	100,0	0,00	0,00
Cycle 33 Day 1	0	2	6,7	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	23,81	20,37
	1	20	52,6	12	60,0	38,89	34,33
	2	4	40,0	2	50,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	31,18	25,73
	1	3	100,0	3	100,0	22,22	19,25
	2 or More	44	100,0	44	100,0	37,12	29,83
Cycle 2 Day 1	None	30	96,8	27	90,0	16,05	21,42
	1	2	66,7	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	40	90,9	37	92,5	20,72	24,03
Cycle 3 Day 1	None	30	96,8	28	93,3	10,71	18,27
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	35	97,2	18,10	21,91
Cycle 4 Day 1	None	30	96,8	29	96,7	13,79	24,43
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	35	79,5	33	94,3	15,15	23,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	30	96,8	30	100,0	11,11	20,22
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	33	75,0	32	97,0	15,63	20,71
Cycle 6 Day 1	None	29	93,5	28	96,6	10,71	15,85
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	32	72,7	30	93,8	14,44	20,87
Cycle 7 Day 1	None	27	87,1	26	96,3	10,26	18,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	33,33	47,14
	2 or More	31	70,5	29	93,5	12,64	18,72
Cycle 8 Day 1	None	26	83,9	25	96,2	12,00	23,33
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	16,05	19,33
Cycle 9 Day 1	None	25	80,6	25	100,0	10,67	15,87
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	9,33	20,46
Cycle 10 Day 1	None	25	80,6	24	96,0	6,94	13,83
	1	1	33,3	1	100,0	0,00	-
	2 or More	25	56,8	25	100,0	12,00	18,95
Cycle 11 Day 1	None	25	80,6	25	100,0	10,67	18,56
	1	1	33,3	1	100,0	0,00	-
	2 or More	24	54,5	24	100,0	12,50	19,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	25	80,6	24	96,0	12,50	19,19
	1	1	33,3	1	100,0	0,00	-
	2 or More	23	52,3	20	87,0	13,33	19,94
Cycle 13 Day 1	None	24	77,4	23	95,8	11,59	19,09
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	11,11	26,53
Cycle 14 Day 1	None	23	74,2	23	100,0	7,25	14,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	20	95,2	20,00	31,34
Cycle 15 Day 1	None	23	74,2	23	100,0	8,70	20,64
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	20	100,0	16,67	22,94
Cycle 16 Day 1	None	20	64,5	19	95,0	8,77	15,08
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	20	45,5	19	95,0	12,28	19,91
Cycle 17 Day 1	None	19	61,3	19	100,0	5,26	12,49
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	19	100,0	8,77	15,08
Cycle 18 Day 1	None	18	58,1	17	94,4	9,80	15,66
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	17	89,5	7,84	14,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	54,8	17	100,0	9,80	19,60
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	20,00	27,60
Cycle 20 Day 1	None	17	54,8	16	94,1	8,33	14,91
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	13,33	21,08
Cycle 21 Day 1	None	15	48,4	13	86,7	10,26	16,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	31,8	13	92,9	15,38	17,30
Cycle 22 Day 1	None	15	48,4	13	86,7	15,38	22,01
	2 or More	14	31,8	12	85,7	11,11	29,59
Cycle 23 Day 1	None	10	32,3	9	90,0	7,41	14,70
	2 or More	11	25,0	9	81,8	11,11	16,67
Cycle 24 Day 1	None	10	32,3	10	100,0	10,00	16,10
	2 or More	10	22,7	8	80,0	4,17	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	29,0	8	88,9	12,50	17,25
	2 or More	6	13,6	5	83,3	33,33	33,33
Cycle 26 Day 1	None	8	25,8	8	100,0	12,50	24,80
	2 or More	6	13,6	4	66,7	33,33	27,22
Cycle 27 Day 1	None	7	22,6	6	85,7	33,33	36,51
	2 or More	4	9,1	2	50,0	33,33	0,00
Cycle 28 Day 1	None	7	22,6	7	100,0	4,76	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	19,4	5	83,3	33,33	40,82
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 30 Day 1	None	4	12,9	3	75,0	11,11	19,25
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 31 Day 1	None	4	12,9	3	75,0	0,00	0,00
	2 or More	3	6,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	0,00	0,00
	2 or More	2	4,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	3,2	1	100,0	0,00	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	30,56	22,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	1	50,0	33,33	-
	2 or More	24	54,5	15	62,5	31,11	32,04
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	31,18	25,73
	Previously Treated	47	100,0	47	100,0	36,17	29,35
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	16,05	21,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	89,4	38	90,5	20,18	23,94
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	10,71	18,27
	Previously Treated	38	80,9	36	94,7	17,59	21,80
Cycle 4 Day 1	Naïve	30	96,8	29	96,7	13,79	24,43
	Previously Treated	37	78,7	35	94,6	14,29	23,27
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	11,11	20,22
	Previously Treated	35	74,5	34	97,1	14,71	20,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	29	93,5	28	96,6	10,71	15,85
	Previously Treated	34	72,3	32	94,1	13,54	20,49
Cycle 7 Day 1	Naïve	27	87,1	26	96,3	10,26	18,30
	Previously Treated	33	70,2	31	93,9	13,98	20,68
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	12,00	23,33
	Previously Treated	30	63,8	27	90,0	16,05	19,33
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	10,67	15,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	26	100,0	8,97	20,13
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	6,94	13,83
	Previously Treated	26	55,3	26	100,0	11,54	18,72
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	10,67	18,56
	Previously Treated	25	53,2	25	100,0	12,00	18,95
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	12,50	19,19
	Previously Treated	24	51,1	21	87,5	12,70	19,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	11,59	19,09
	Previously Treated	22	46,8	22	100,0	10,61	26,00
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	7,25	14,06
	Previously Treated	22	46,8	21	95,5	19,05	30,86
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	8,70	20,64
	Previously Treated	21	44,7	21	100,0	15,87	22,65
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	8,77	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	20	95,2	11,67	19,57
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	5,26	12,49
	Previously Treated	20	42,6	20	100,0	8,33	14,81
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	9,80	15,66
	Previously Treated	20	42,6	18	90,0	7,41	14,26
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	9,80	19,60
	Previously Treated	19	40,4	16	84,2	18,75	27,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	8,33	14,91
	Previously Treated	19	40,4	16	84,2	12,50	20,64
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	10,26	16,01
	Previously Treated	14	29,8	13	92,9	15,38	17,30
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	15,38	22,01
	Previously Treated	14	29,8	12	85,7	11,11	29,59
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	11,11	16,67
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	10,00	16,10
	Previously Treated	10	21,3	8	80,0	4,17	11,79
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	12,50	17,25
	Previously Treated	6	12,8	5	83,3	33,33	33,33
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	12,50	24,80
	Previously Treated	6	12,8	4	66,7	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	33,33	36,51
	Previously Treated	4	8,5	2	50,0	33,33	0,00
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	4,76	12,60
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	33,33	40,82
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	0,00	0,00
	Previously Treated	3	6,4	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	0,00	0,00
	Previously Treated	2	4,3	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	0,00	-
	Previously Treated	1	2,1	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	30,56	22,29
	Previously Treated	26	55,3	16	61,5	31,25	30,96
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	33,33	28,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	43	100,0	43	100,0	34,88	28,13
Cycle 2 Day 1	Local	32	91,4	30	93,8	13,33	22,49
	Central	40	93,0	35	87,5	22,86	22,54
Cycle 3 Day 1	Local	29	82,9	28	96,6	11,90	20,72
	Central	39	90,7	36	92,3	16,67	20,31
Cycle 4 Day 1	Local	28	80,0	27	96,4	8,64	19,81
	Central	39	90,7	37	94,9	18,02	25,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	27	77,1	27	100,0	11,11	20,67
	Central	38	88,4	37	97,4	14,41	20,09
Cycle 6 Day 1	Local	27	77,1	27	100,0	6,17	13,19
	Central	36	83,7	33	91,7	17,17	20,62
Cycle 7 Day 1	Local	27	77,1	27	100,0	6,17	13,19
	Central	33	76,7	30	90,9	17,78	22,71
Cycle 8 Day 1	Local	26	74,3	26	100,0	6,41	13,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	30	69,8	26	86,7	21,79	24,84
Cycle 9 Day 1	Local	25	71,4	25	100,0	10,67	18,56
	Central	26	60,5	26	100,0	8,97	17,78
Cycle 10 Day 1	Local	25	71,4	24	96,0	9,72	18,33
	Central	26	60,5	26	100,0	8,97	15,08
Cycle 11 Day 1	Local	24	68,6	24	100,0	9,72	20,80
	Central	26	60,5	26	100,0	12,82	16,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	23	65,7	22	95,7	9,09	15,19
	Central	26	60,5	23	88,5	15,94	22,18
Cycle 13 Day 1	Local	22	62,9	22	100,0	6,06	22,15
	Central	24	55,8	23	95,8	15,94	22,18
Cycle 14 Day 1	Local	22	62,9	22	100,0	9,09	23,42
	Central	23	53,5	22	95,7	16,67	24,67
Cycle 15 Day 1	Local	22	62,9	22	100,0	6,06	16,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	18,18	24,62
Cycle 16 Day 1	Local	20	57,1	20	100,0	8,33	14,81
	Central	21	48,8	19	90,5	12,28	19,91
Cycle 17 Day 1	Local	20	57,1	20	100,0	3,33	10,26
	Central	19	44,2	19	100,0	10,53	15,92
Cycle 18 Day 1	Local	20	57,1	19	95,0	7,02	13,96
	Central	18	41,9	16	88,9	10,42	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	54,3	17	89,5	9,80	19,60
	Central	17	39,5	16	94,1	18,75	27,13
Cycle 20 Day 1	Local	19	54,3	17	89,5	7,84	18,74
	Central	17	39,5	15	88,2	13,33	16,90
Cycle 21 Day 1	Local	14	40,0	12	85,7	8,33	15,08
	Central	15	34,9	14	93,3	16,67	17,30
Cycle 22 Day 1	Local	14	40,0	12	85,7	8,33	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	34,9	13	86,7	17,95	32,25
Cycle 23 Day 1	Local	11	31,4	10	90,9	6,67	14,05
	Central	10	23,3	8	80,0	12,50	17,25
Cycle 24 Day 1	Local	11	31,4	10	90,9	6,67	14,05
	Central	9	20,9	8	88,9	8,33	15,43
Cycle 25 Day 1	Local	7	20,0	7	100,0	14,29	26,23
	Central	8	18,6	6	75,0	27,78	25,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	17,1	6	100,0	16,67	27,89
	Central	8	18,6	6	75,0	22,22	27,22
Cycle 27 Day 1	Local	4	11,4	4	100,0	16,67	19,25
	Central	7	16,3	4	57,1	50,00	33,33
Cycle 28 Day 1	Local	4	11,4	4	100,0	0,00	0,00
	Central	6	14,0	5	83,3	13,33	18,26
Cycle 29 Day 1	Local	3	8,6	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	14,0	4	66,7	41,67	41,94
Cycle 30 Day 1	Local	3	8,6	3	100,0	11,11	19,25
	Central	4	9,3	2	50,0	16,67	23,57
Cycle 31 Day 1	Local	3	8,6	3	100,0	0,00	0,00
	Central	4	9,3	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	8,6	3	100,0	0,00	0,00
	Central	3	7,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	2,9	1	100,0	0,00	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	26,19	23,31
	Central	21	48,8	14	66,7	35,71	30,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	74	100,0	34,23	27,01
	No	4	100,0	4	100,0	33,33	47,14
Cycle 2 Day 1	Yes	70	94,6	63	90,0	17,99	22,26
	No	2	50,0	2	100,0	33,33	47,14
Cycle 3 Day 1	Yes	66	89,2	62	93,9	15,05	20,63
	No	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	65	87,8	62	95,4	14,52	23,86
	No	2	50,0	2	100,0	0,00	0,00
Cycle 5 Day 1	Yes	63	85,1	62	98,4	12,90	20,34
	No	2	50,0	2	100,0	16,67	23,57
Cycle 6 Day 1	Yes	61	82,4	58	95,1	12,07	18,42
	No	2	50,0	2	100,0	16,67	23,57
Cycle 7 Day 1	Yes	58	78,4	55	94,8	12,12	19,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 8 Day 1	Yes	54	73,0	50	92,6	14,00	21,39
	No	2	50,0	2	100,0	16,67	23,57
Cycle 9 Day 1	Yes	49	66,2	49	100,0	9,52	18,00
	No	2	50,0	2	100,0	16,67	23,57
Cycle 10 Day 1	Yes	49	66,2	48	98,0	9,72	16,78
	No	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	48	64,9	48	100,0	11,81	18,82
	No	2	50,0	2	100,0	0,00	0,00
Cycle 12 Day 1	Yes	47	63,5	43	91,5	11,63	19,08
	No	2	50,0	2	100,0	33,33	0,00
Cycle 13 Day 1	Yes	44	59,5	43	97,7	11,63	22,87
	No	2	50,0	2	100,0	0,00	0,00
Cycle 14 Day 1	Yes	43	58,1	42	97,7	13,49	24,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 15 Day 1	Yes	42	56,8	42	100,0	11,90	21,87
	No	2	50,0	2	100,0	16,67	23,57
Cycle 16 Day 1	Yes	39	52,7	37	94,9	9,91	17,33
	No	2	50,0	2	100,0	16,67	23,57
Cycle 17 Day 1	Yes	37	50,0	37	100,0	6,31	13,24
	No	2	50,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	36	48,6	33	91,7	8,08	14,51
	No	2	50,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	14,58	23,85
	No	2	50,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	11,11	18,22
	No	2	50,0	2	100,0	0,00	0,00
Cycle 21 Day 1	Yes	27	36,5	24	88,9	13,89	16,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 22 Day 1	Yes	27	36,5	23	85,2	14,49	26,26
	No	2	50,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	9,80	15,66
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	7,84	14,57
	No	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	18,9	12	85,7	22,22	25,95
	No	1	25,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	21,21	26,97
	No	1	25,0	1	100,0	0,00	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	33,33	33,33
	No	1	25,0	1	100,0	33,33	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	8,33	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	33,33	36,51
	No	1	25,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	16,67	19,25
	No	1	25,0	1	100,0	0,00	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	16,67	19,25
	No	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	6,8	4	80,0	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	30,95	27,11
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	33,33	17,82
	No	70	100,0	70	100,0	34,29	28,92
Cycle 2 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	67	95,7	60	89,6	19,44	23,20
Cycle 3 Day 1	Yes	5	62,5	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	63	90,0	59	93,7	14,69	20,78
Cycle 4 Day 1	Yes	5	62,5	5	100,0	13,33	18,26
	No	62	88,6	59	95,2	14,12	24,14
Cycle 5 Day 1	Yes	5	62,5	5	100,0	26,67	27,89
	No	60	85,7	59	98,3	11,86	19,34
Cycle 6 Day 1	Yes	5	62,5	5	100,0	20,00	18,26
	No	58	82,9	55	94,8	11,52	18,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	55	78,6	52	94,5	12,82	19,97
Cycle 8 Day 1	Yes	5	62,5	5	100,0	26,67	43,46
	No	51	72,9	47	92,2	12,77	17,79
Cycle 9 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	47	67,1	47	100,0	10,64	18,53
Cycle 10 Day 1	Yes	4	50,0	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	47	67,1	46	97,9	10,14	17,03
Cycle 11 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	46	65,7	46	100,0	11,59	18,88
Cycle 12 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	45	64,3	41	91,1	13,01	19,55
Cycle 13 Day 1	Yes	4	50,0	4	100,0	16,67	33,33
	No	42	60,0	41	97,6	10,57	21,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	41	58,6	40	97,6	13,33	24,81
Cycle 15 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	40	57,1	40	100,0	12,50	22,25
Cycle 16 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	38	54,3	36	94,7	11,11	17,82
Cycle 17 Day 1	Yes	3	37,5	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	36	51,4	36	100,0	7,41	14,05
Cycle 18 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	35	50,0	32	91,4	9,38	15,23
Cycle 19 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	30	90,9	15,56	24,34
Cycle 20 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	29	87,9	11,49	18,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	27	38,6	24	88,9	12,50	16,48
Cycle 22 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	23	85,2	14,49	26,26
Cycle 23 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	19	27,1	16	84,2	8,33	14,91
Cycle 24 Day 1	Yes	2	25,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	25,7	16	88,9	8,33	14,91
Cycle 25 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	13	18,6	11	84,6	21,21	26,97
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	21,21	26,97
Cycle 27 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	10	14,3	7	70,0	33,33	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	9	12,9	8	88,9	4,17	11,79
Cycle 29 Day 1	Yes	1	12,5	1	100,0	100,00	-
	No	8	11,4	6	75,0	16,67	18,26
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	13,33	18,26
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	8,6	5	83,3	13,33	18,26
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	0,00	0,00
Cycle 33 Day 1	No	2	2,9	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	50,00	70,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	37	52,9	26	70,3	29,49	23,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
80_REE_C30SL_SG.xls
28NOV2019 10:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	29,58	31,54
Cycle 2 Day 1	All	136	93,8	126	92,6	11,64	21,22
Cycle 3 Day 1	All	131	90,3	118	90,1	9,89	20,58
Cycle 4 Day 1	All	128	88,3	120	93,8	6,94	17,23
Cycle 5 Day 1	All	124	85,5	118	95,2	4,80	14,63
Cycle 6 Day 1	All	121	83,4	112	92,6	4,46	12,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	6,29	16,01
Cycle 8 Day 1	All	106	73,1	97	91,5	6,19	16,19
Cycle 9 Day 1	All	98	67,6	96	98,0	5,56	14,24
Cycle 10 Day 1	All	89	61,4	86	96,6	5,43	12,38
Cycle 11 Day 1	All	80	55,2	78	97,5	5,98	13,95
Cycle 12 Day 1	All	76	52,4	69	90,8	5,80	13,95
Cycle 13 Day 1	All	66	45,5	62	93,9	6,45	15,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	7,02	17,52
Cycle 15 Day 1	All	57	39,3	54	94,7	3,70	10,57
Cycle 16 Day 1	All	50	34,5	47	94,0	7,09	16,93
Cycle 17 Day 1	All	45	31,0	44	97,8	8,33	19,19
Cycle 18 Day 1	All	41	28,3	37	90,2	6,31	13,24
Cycle 19 Day 1	All	36	24,8	33	91,7	7,07	13,84
Cycle 20 Day 1	All	36	24,8	32	88,9	2,08	8,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	8,97	17,78
Cycle 22 Day 1	All	29	20,0	25	86,2	9,33	22,61
Cycle 23 Day 1	All	21	14,5	18	85,7	7,41	24,40
Cycle 24 Day 1	All	20	13,8	18	90,0	5,56	12,78
Cycle 25 Day 1	All	15	10,3	13	86,7	5,13	12,52
Cycle 26 Day 1	All	14	9,7	12	85,7	5,56	12,97
Cycle 27 Day 1	All	11	7,6	8	72,7	8,33	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	11,11	16,67
Cycle 29 Day 1	All	9	6,2	7	77,8	4,76	12,60
Cycle 30 Day 1	All	7	4,8	5	71,4	6,67	14,91
Cycle 31 Day 1	All	7	4,8	5	71,4	6,67	14,91
Cycle 32 Day 1	All	6	4,1	5	83,3	0,00	0,00
Cycle 33 Day 1	All	2	1,4	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	21,21	27,93
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	28,76	31,99
	Female	93	100,0	91	97,8	30,04	31,45
Cycle 2 Day 1	Male	50	96,2	47	94,0	10,64	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	12,24	21,47
Cycle 3 Day 1	Male	47	90,4	42	89,4	7,14	15,68
	Female	84	90,3	76	90,5	11,40	22,81
Cycle 4 Day 1	Male	46	88,5	45	97,8	8,15	20,30
	Female	82	88,2	75	91,5	6,22	15,20
Cycle 5 Day 1	Male	45	86,5	43	95,6	6,98	20,00
	Female	79	84,9	75	94,9	3,56	10,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	6,50	13,37
	Female	76	81,7	71	93,4	3,29	11,48
Cycle 7 Day 1	Male	40	76,9	39	97,5	11,11	22,08
	Female	73	78,5	67	91,8	3,48	10,27
Cycle 8 Day 1	Male	37	71,2	34	91,9	4,90	16,68
	Female	69	74,2	63	91,3	6,88	16,02
Cycle 9 Day 1	Male	33	63,5	33	100,0	6,06	15,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	5,29	13,66
Cycle 10 Day 1	Male	30	57,7	30	100,0	7,78	14,34
	Female	59	63,4	56	94,9	4,17	11,12
Cycle 11 Day 1	Male	29	55,8	29	100,0	5,75	12,81
	Female	51	54,8	49	96,1	6,12	14,71
Cycle 12 Day 1	Male	27	51,9	26	96,3	6,41	13,40
	Female	49	52,7	43	87,8	5,43	14,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	7,25	17,28
	Female	41	44,1	39	95,1	5,98	15,05
Cycle 14 Day 1	Male	23	44,2	21	91,3	3,17	10,03
	Female	37	39,8	36	97,3	9,26	20,49
Cycle 15 Day 1	Male	21	40,4	20	95,2	3,33	10,26
	Female	36	38,7	34	94,4	3,92	10,90
Cycle 16 Day 1	Male	16	30,8	16	100,0	6,25	18,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	7,53	16,58
Cycle 17 Day 1	Male	13	25,0	13	100,0	2,56	9,25
	Female	32	34,4	31	96,9	10,75	21,75
Cycle 18 Day 1	Male	12	23,1	11	91,7	9,09	15,57
	Female	29	31,2	26	89,7	5,13	12,26
Cycle 19 Day 1	Male	10	19,2	10	100,0	10,00	16,10
	Female	26	28,0	23	88,5	5,80	12,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	0,00	0,00
	Female	26	28,0	23	88,5	2,90	9,60
Cycle 21 Day 1	Male	8	15,4	8	100,0	12,50	17,25
	Female	21	22,6	18	85,7	7,41	18,28
Cycle 22 Day 1	Male	8	15,4	6	75,0	0,00	0,00
	Female	21	22,6	19	90,5	12,28	25,36
Cycle 23 Day 1	Male	5	9,6	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	9,52	27,51
Cycle 24 Day 1	Male	5	9,6	4	80,0	0,00	0,00
	Female	15	16,1	14	93,3	7,14	14,19
Cycle 25 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	12	12,9	11	91,7	6,06	13,48
Cycle 26 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	11	11,8	10	90,9	6,67	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	8	8,6	6	75,0	11,11	17,21
Cycle 28 Day 1	Male	2	3,8	2	100,0	0,00	0,00
	Female	8	8,6	7	87,5	14,29	17,82
Cycle 29 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	8	8,6	6	75,0	5,56	13,61
Cycle 30 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	8,33	16,67
Cycle 31 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	8,33	16,67
Cycle 32 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	5	5,4	4	80,0	0,00	0,00
Cycle 33 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	1	1,1	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	25,40	29,64
	Female	37	39,8	23	62,2	17,39	26,34
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	27,36	30,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	40,23	37,14
	>=75	7	100,0	7	100,0	19,05	17,82
Cycle 2 Day 1	18-64	103	94,5	94	91,3	8,87	19,66
	65-74	26	89,7	25	96,2	18,67	23,73
	>=75	7	100,0	7	100,0	23,81	25,20
Cycle 3 Day 1	18-64	99	90,8	87	87,9	8,05	18,30
	65-74	25	86,2	24	96,0	11,11	18,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	28,57	40,50
Cycle 4 Day 1	18-64	98	89,9	92	93,9	6,88	18,18
	65-74	23	79,3	21	91,3	7,94	14,55
	>=75	7	100,0	7	100,0	4,76	12,60
Cycle 5 Day 1	18-64	95	87,2	90	94,7	3,70	14,52
	65-74	22	75,9	22	100,0	7,58	14,30
	>=75	7	100,0	6	85,7	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	2,78	9,27
	65-74	22	75,9	21	95,5	11,11	19,25
	>=75	7	100,0	7	100,0	4,76	12,60
Cycle 7 Day 1	18-64	86	78,9	81	94,2	6,17	16,76
	65-74	20	69,0	19	95,0	7,02	13,96
	>=75	7	100,0	6	85,7	5,56	13,61
Cycle 8 Day 1	18-64	80	73,4	72	90,0	4,63	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	10,53	19,41
	>=75	7	100,0	6	85,7	11,11	27,22
Cycle 9 Day 1	18-64	74	67,9	73	98,6	4,57	12,81
	65-74	18	62,1	18	100,0	9,26	19,15
	>=75	6	85,7	5	83,3	6,67	14,91
Cycle 10 Day 1	18-64	69	63,3	66	95,7	5,05	12,04
	65-74	15	51,7	15	100,0	4,44	11,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	13,33	18,26
Cycle 11 Day 1	18-64	61	56,0	59	96,7	7,34	15,25
	65-74	15	51,7	15	100,0	2,22	8,61
	>=75	4	57,1	4	100,0	0,00	0,00
Cycle 12 Day 1	18-64	57	52,3	51	89,5	6,54	14,94
	65-74	15	51,7	14	93,3	4,76	12,10
	>=75	4	57,1	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	5,07	14,00
	65-74	13	44,8	12	92,3	11,11	21,71
	>=75	4	57,1	4	100,0	8,33	16,67
Cycle 14 Day 1	18-64	45	41,3	44	97,8	5,30	14,28
	65-74	13	44,8	11	84,6	15,15	27,34
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 15 Day 1	18-64	43	39,4	41	95,3	2,44	8,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	6,06	13,48
	>=75	2	28,6	2	100,0	16,67	23,57
Cycle 16 Day 1	18-64	38	34,9	36	94,7	7,41	18,01
	65-74	10	34,5	9	90,0	3,70	11,11
	>=75	2	28,6	2	100,0	16,67	23,57
Cycle 17 Day 1	18-64	36	33,0	35	97,2	8,57	20,36
	65-74	8	27,6	8	100,0	4,17	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	33,33	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	3,33	10,17
	65-74	7	24,1	6	85,7	16,67	18,26
	>=75	1	14,3	1	100,0	33,33	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	7,14	13,93
	65-74	5	17,2	4	80,0	0,00	0,00
	>=75	1	14,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	2,56	9,06
	65-74	5	17,2	5	100,0	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	4,76	11,95
	65-74	4	13,8	4	100,0	25,00	31,91
	>=75	1	14,3	1	100,0	33,33	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	10,00	24,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	8,33	16,67
	>=75	1	14,3	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	8,33	25,82
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	6,25	13,44
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	12,8	12	85,7	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	5,56	12,97
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	8,33	15,43
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	11,11	16,67
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	4,76	12,60
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	6,67	14,91
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	6,67	14,91
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	0,00	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	21,57	29,45
	65-74	15	51,7	8	53,3	20,83	24,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	16,67	23,57
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	31,61	34,44
	Other	85	100,0	84	98,8	28,17	29,50
Cycle 2 Day 1	White	57	95,0	51	89,5	11,11	19,63
	Other	79	92,9	75	94,9	12,00	22,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	11,36	22,67
	Other	77	90,6	74	96,1	9,01	19,35
Cycle 4 Day 1	White	53	88,3	47	88,7	7,80	18,67
	Other	75	88,2	73	97,3	6,39	16,35
Cycle 5 Day 1	White	52	86,7	48	92,3	4,86	13,73
	Other	72	84,7	70	97,2	4,76	15,32
Cycle 6 Day 1	White	50	83,3	44	88,0	4,55	13,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	4,41	11,38
Cycle 7 Day 1	White	47	78,3	42	89,4	3,97	10,93
	Other	66	77,6	64	97,0	7,81	18,54
Cycle 8 Day 1	White	45	75,0	39	86,7	5,98	15,05
	Other	61	71,8	58	95,1	6,32	17,05
Cycle 9 Day 1	White	42	70,0	41	97,6	4,88	14,07
	Other	56	65,9	55	98,2	6,06	14,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	5,13	12,18
	Other	48	56,5	47	97,9	5,67	12,66
Cycle 11 Day 1	White	37	61,7	37	100,0	1,80	7,64
	Other	43	50,6	41	95,3	9,76	17,07
Cycle 12 Day 1	White	37	61,7	33	89,2	1,01	5,80
	Other	39	45,9	36	92,3	10,19	17,49
Cycle 13 Day 1	White	32	53,3	30	93,8	6,67	16,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	6,25	15,70
Cycle 14 Day 1	White	31	51,7	30	96,8	4,44	14,47
	Other	29	34,1	27	93,1	9,88	20,29
Cycle 15 Day 1	White	30	50,0	28	93,3	3,57	10,50
	Other	27	31,8	26	96,3	3,85	10,86
Cycle 16 Day 1	White	26	43,3	24	92,3	12,50	21,56
	Other	24	28,2	23	95,8	1,45	6,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	11,11	23,40
	Other	21	24,7	20	95,2	5,00	12,21
Cycle 18 Day 1	White	22	36,7	19	86,4	5,26	12,49
	Other	19	22,4	18	94,7	7,41	14,26
Cycle 19 Day 1	White	20	33,3	20	100,0	8,33	14,81
	Other	16	18,8	13	81,3	5,13	12,52
Cycle 20 Day 1	White	20	33,3	17	85,0	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	2,22	8,61
Cycle 21 Day 1	White	16	26,7	14	87,5	9,52	15,63
	Other	13	15,3	12	92,3	8,33	20,72
Cycle 22 Day 1	White	16	26,7	13	81,3	12,82	28,99
	Other	13	15,3	12	92,3	5,56	12,97
Cycle 23 Day 1	White	12	20,0	10	83,3	13,33	32,20
	Other	9	10,6	8	88,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	10,00	16,10
	Other	9	10,6	8	88,9	0,00	0,00
Cycle 25 Day 1	White	10	16,7	8	80,0	8,33	15,43
	Other	5	5,9	5	100,0	0,00	0,00
Cycle 26 Day 1	White	10	16,7	8	80,0	8,33	15,43
	Other	4	4,7	4	100,0	0,00	0,00
Cycle 27 Day 1	White	8	13,3	5	62,5	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	11,11	19,25
Cycle 28 Day 1	White	7	11,7	6	85,7	5,56	13,61
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 29 Day 1	White	6	10,0	4	66,7	8,33	16,67
	Other	3	3,5	3	100,0	0,00	0,00
Cycle 30 Day 1	White	4	6,7	2	50,0	0,00	0,00
	Other	3	3,5	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	0,00	0,00
	Other	3	3,5	3	100,0	11,11	19,25
Cycle 32 Day 1	White	4	6,7	3	75,0	0,00	0,00
	Other	2	2,4	2	100,0	0,00	0,00
Cycle 33 Day 1	White	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	17,65	26,66
	Other	39	45,9	27	69,2	23,46	28,96
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	25,00	29,96
	Europe (EU)	34	100,0	31	91,2	31,18	37,45
	Asia (AS)	71	100,0	71	100,0	31,46	29,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	33	86,8	11,11	19,84
	Europe (EU)	32	94,1	28	87,5	10,71	24,09
	Asia (AS)	66	93,0	65	98,5	12,31	20,89
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	12,12	21,76
	Europe (EU)	31	91,2	22	71,0	10,61	26,00
	Asia (AS)	63	88,7	63	100,0	8,47	17,93
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	6,86	13,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	2,67	9,23
	Asia (AS)	61	85,9	61	100,0	8,74	21,00
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	4,76	14,33
	Europe (EU)	30	88,2	26	86,7	5,13	12,26
	Asia (AS)	57	80,3	57	100,0	4,68	15,98
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	3,81	10,76
	Europe (EU)	28	82,4	25	89,3	4,00	14,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	5,13	12,14
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	6,25	19,74
	Europe (EU)	28	82,4	25	89,3	6,67	16,67
	Asia (AS)	50	70,4	49	98,0	6,12	13,04
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	3,70	10,68
	Europe (EU)	28	82,4	23	82,1	2,90	9,60
	Asia (AS)	47	66,2	47	100,0	9,22	20,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	4,76	11,88
	Europe (EU)	26	76,5	25	96,2	6,67	19,25
	Asia (AS)	43	60,6	43	100,0	5,43	12,45
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	4,17	11,26
	Europe (EU)	25	73,5	25	100,0	8,00	14,53
	Asia (AS)	37	52,1	37	100,0	4,50	11,55
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	5,80	12,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	1,52	7,11
	Asia (AS)	33	46,5	33	100,0	9,09	17,23
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	4,35	11,48
	Europe (EU)	23	67,6	18	78,3	1,85	7,86
	Asia (AS)	29	40,8	28	96,6	9,52	17,82
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	6,06	13,16
	Europe (EU)	18	52,9	15	83,3	11,11	24,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	4,00	11,06
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	6,35	13,41
	Europe (EU)	17	50,0	16	94,1	4,17	16,67
	Asia (AS)	21	29,6	20	95,2	10,00	21,90
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	6,67	13,68
	Europe (EU)	15	44,1	14	93,3	2,38	8,91
	Asia (AS)	20	28,2	20	100,0	1,67	7,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	5,88	17,62
	Europe (EU)	14	41,2	11	78,6	12,12	22,47
	Asia (AS)	19	26,8	19	100,0	5,26	12,49
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	10,42	26,44
	Europe (EU)	13	38,2	12	92,3	5,56	12,97
	Asia (AS)	16	22,5	16	100,0	8,33	14,91
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	4,76	12,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	4,76	12,60
	Asia (AS)	16	22,5	16	100,0	8,33	14,91
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	7,69	14,62
	Europe (EU)	9	26,5	9	100,0	7,41	14,70
	Asia (AS)	14	19,7	11	78,6	6,06	13,48
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	2,56	9,25
	Europe (EU)	9	26,5	6	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	2,56	9,25
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	10,00	16,10
	Europe (EU)	7	20,6	6	85,7	11,11	17,21
	Asia (AS)	11	15,5	10	90,9	6,67	21,08
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	16,67	32,39
	Europe (EU)	7	20,6	5	71,4	0,00	0,00
	Asia (AS)	11	15,5	10	90,9	6,67	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	14,81	33,79
	Europe (EU)	5	14,7	3	60,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	0,00	0,00
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	8,33	15,43
	Europe (EU)	5	14,7	4	80,0	8,33	16,67
	Asia (AS)	7	9,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	0,00	0,00
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	11,11	17,21
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	0,00	0,00
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	8,33	16,67
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	8,33	16,67
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	8,33	16,67
	Europe (EU)	2	5,9	1	50,0	0,00	-
	Asia (AS)	4	5,6	4	100,0	16,67	19,25
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	11,11	19,25
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	11,11	19,25
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	11,11	19,25
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	0,00	-
	Asia (AS)	3	4,2	2	66,7	0,00	0,00
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	0,00	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	15,69	17,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	0,00	0,00
	Asia (AS)	34	47,9	22	64,7	30,30	33,98
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	15,56	22,52
	1	69	100,0	67	97,1	38,31	32,44
	2	15	100,0	15	100,0	46,67	37,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	56	94,9	8,93	22,47
	1	67	97,1	60	89,6	13,33	19,60
	2	10	66,7	10	100,0	16,67	23,57
Cycle 3 Day 1	0	57	93,4	51	89,5	9,15	20,09
	1	65	94,2	58	89,2	9,20	18,52
	2	9	60,0	9	100,0	18,52	33,79
Cycle 4 Day 1	0	57	93,4	54	94,7	5,56	16,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	5,75	14,15
	2	9	60,0	8	88,9	25,00	29,55
Cycle 5 Day 1	0	56	91,8	53	94,6	3,14	9,84
	1	62	89,9	59	95,2	6,21	18,02
	2	6	40,0	6	100,0	5,56	13,61
Cycle 6 Day 1	0	56	91,8	54	96,4	3,70	12,40
	1	59	85,5	53	89,8	5,66	12,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	0,00	0,00
Cycle 7 Day 1	0	54	88,5	51	94,4	4,58	13,37
	1	54	78,3	50	92,6	8,67	18,82
	2	5	33,3	5	100,0	0,00	0,00
Cycle 8 Day 1	0	52	85,2	48	92,3	4,86	13,73
	1	49	71,0	44	89,8	6,82	16,98
	2	5	33,3	5	100,0	13,33	29,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	4,76	15,21
	1	44	63,8	43	97,7	6,20	13,12
	2	4	26,7	4	100,0	8,33	16,67
Cycle 10 Day 1	0	46	75,4	46	100,0	6,52	13,37
	1	40	58,0	37	92,5	4,50	11,55
	2	3	20,0	3	100,0	0,00	0,00
Cycle 11 Day 1	0	43	70,5	41	95,3	3,25	10,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	9,80	17,46
	2	3	20,0	3	100,0	0,00	0,00
Cycle 12 Day 1	0	42	68,9	36	85,7	6,48	13,38
	1	31	44,9	30	96,8	5,56	15,37
	2	3	20,0	3	100,0	0,00	0,00
Cycle 13 Day 1	0	38	62,3	34	89,5	7,84	18,46
	1	27	39,1	27	100,0	4,94	12,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	7,29	18,42
	1	24	34,8	24	100,0	6,94	16,97
	2	1	6,7	1	100,0	0,00	-
Cycle 15 Day 1	0	33	54,1	30	90,9	3,33	10,17
	1	23	33,3	23	100,0	4,35	11,48
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	8,00	19,91
	1	21	30,4	21	100,0	6,35	13,41
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	5,80	21,68
	1	20	29,0	20	100,0	11,67	16,31
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	3,51	10,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	9,80	15,66
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	5,26	12,49
	1	15	21,7	13	86,7	10,26	16,01
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	1,96	8,08
	1	15	21,7	14	93,3	2,38	8,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	9,52	20,37
	1	13	18,8	11	84,6	9,09	15,57
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	11,11	29,59
	1	13	18,8	12	92,3	8,33	15,08
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	11,11	33,33
	1	9	13,0	8	88,9	4,17	11,79
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	7,41	14,70
	1	9	13,0	8	88,9	4,17	11,79
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	4,76	12,60
Cycle 26 Day 1	0	8	13,1	6	75,0	5,56	13,61
	1	6	8,7	6	100,0	5,56	13,61
Cycle 27 Day 1	0	6	9,8	3	50,0	0,00	0,00
	1	5	7,2	5	100,0	13,33	18,26
Cycle 28 Day 1	0	5	8,2	4	80,0	0,00	0,00
	1	5	7,2	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	0,00	0,00
	1	5	7,2	5	100,0	6,67	14,91
Cycle 30 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	8,33	16,67
Cycle 31 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	8,33	16,67
Cycle 32 Day 1	0	3	4,9	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	0,00	0,00
Cycle 33 Day 1	0	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	19,05	27,02
	1	34	49,3	20	58,8	23,33	30,78
	2	7	46,7	3	42,9	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	24,44	29,98
	1	4	100,0	4	100,0	33,33	27,22
	2 or More	79	100,0	78	98,7	33,33	32,68
Cycle 2 Day 1	None	60	96,8	55	91,7	12,12	21,62
	1	3	75,0	2	66,7	33,33	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	10,63	20,21
Cycle 3 Day 1	None	59	95,2	53	89,8	9,43	16,51
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	69	87,3	63	91,3	10,58	23,82
Cycle 4 Day 1	None	59	95,2	56	94,9	8,33	19,33
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	66	83,5	62	93,9	5,91	15,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	7,14	18,76
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	63	79,7	59	93,7	2,82	9,36
Cycle 6 Day 1	None	57	91,9	52	91,2	4,49	11,49
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	61	77,2	57	93,4	4,68	13,27
Cycle 7 Day 1	None	52	83,9	50	96,2	7,33	19,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	11,11	19,25
	2 or More	58	73,4	53	91,4	5,03	12,05
Cycle 8 Day 1	None	50	80,6	46	92,0	7,25	17,09
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	5,33	15,59
Cycle 9 Day 1	None	48	77,4	47	97,9	5,67	14,44
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	5,56	14,31
Cycle 10 Day 1	None	43	69,4	41	95,3	3,25	10,01
	1	1	25,0	1	100,0	0,00	-
	2 or More	45	57,0	44	97,8	7,58	14,13
Cycle 11 Day 1	None	37	59,7	35	94,6	6,67	13,53
	1	1	25,0	1	100,0	0,00	-
	2 or More	42	53,2	42	100,0	5,56	14,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	5,88	12,90
	1	1	25,0	1	100,0	0,00	-
	2 or More	38	48,1	34	89,5	5,88	15,29
Cycle 13 Day 1	None	34	54,8	30	88,2	6,67	16,14
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	6,45	15,91
Cycle 14 Day 1	None	31	50,0	29	93,5	5,75	12,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	28	35,4	27	96,4	8,64	21,86
Cycle 15 Day 1	None	30	48,4	28	93,3	4,76	11,88
	1	1	25,0	1	100,0	0,00	-
	2 or More	26	32,9	25	96,2	2,67	9,23
Cycle 16 Day 1	None	25	40,3	23	92,0	2,90	9,60
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	11,59	21,58
Cycle 17 Day 1	None	23	37,1	22	95,7	3,03	9,81
	1	1	25,0	1	100,0	0,00	-
	2 or More	21	26,6	21	100,0	14,29	24,88
Cycle 18 Day 1	None	20	32,3	18	90,0	5,56	12,78
	1	1	25,0	1	100,0	0,00	-
	2 or More	20	25,3	18	90,0	7,41	14,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	7,84	14,57
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	6,67	13,80
Cycle 20 Day 1	None	17	27,4	16	94,1	4,17	11,39
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	0,00	0,00
Cycle 21 Day 1	None	15	24,2	13	86,7	7,69	14,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	10,26	21,01
Cycle 22 Day 1	None	15	24,2	13	86,7	5,13	12,52
	2 or More	14	17,7	12	85,7	13,89	30,01
Cycle 23 Day 1	None	10	16,1	9	90,0	3,70	11,11
	2 or More	11	13,9	9	81,8	11,11	33,33
Cycle 24 Day 1	None	10	16,1	10	100,0	3,33	10,54
	2 or More	10	12,7	8	80,0	8,33	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	4,17	11,79
	2 or More	6	7,6	5	83,3	6,67	14,91
Cycle 26 Day 1	None	8	12,9	8	100,0	4,17	11,79
	2 or More	6	7,6	4	66,7	8,33	16,67
Cycle 27 Day 1	None	7	11,3	6	85,7	5,56	13,61
	2 or More	4	5,1	2	50,0	16,67	23,57
Cycle 28 Day 1	None	7	11,3	7	100,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	9,7	5	83,3	6,67	14,91
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	6,5	3	75,0	0,00	0,00
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 31 Day 1	None	4	6,5	3	75,0	0,00	0,00
	2 or More	3	3,8	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	0,00	0,00
	2 or More	2	2,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	1,6	1	100,0	0,00	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	21,05	27,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	33,33	-
	2 or More	39	49,4	24	61,5	20,83	29,18
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	24,44	29,98
	Previously Treated	83	100,0	82	98,8	33,33	32,29
Cycle 2 Day 1	Naïve	60	96,8	55	91,7	12,12	21,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	11,27	21,04
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	9,43	16,51
	Previously Treated	72	86,7	65	90,3	10,26	23,51
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	8,33	19,33
	Previously Treated	69	83,1	64	92,8	5,73	15,21
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	7,14	18,76
	Previously Treated	66	79,5	62	93,9	2,69	9,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	4,49	11,49
	Previously Treated	64	77,1	60	93,8	4,44	12,97
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	7,33	19,39
	Previously Treated	61	73,5	56	91,8	5,36	12,35
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	7,25	17,09
	Previously Treated	56	67,5	51	91,1	5,23	15,45
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	5,67	14,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	5,44	14,19
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	3,25	10,01
	Previously Treated	46	55,4	45	97,8	7,41	14,01
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	6,67	13,53
	Previously Treated	43	51,8	43	100,0	5,43	14,42
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	5,88	12,90
	Previously Treated	39	47,0	35	89,7	5,71	15,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	6,67	16,14
	Previously Treated	32	38,6	32	100,0	6,25	15,70
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	5,75	12,81
	Previously Treated	29	34,9	28	96,6	8,33	21,52
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	4,76	11,88
	Previously Treated	27	32,5	26	96,3	2,56	9,06
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	2,90	9,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	11,11	21,23
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	3,03	9,81
	Previously Treated	22	26,5	22	100,0	13,64	24,47
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	5,56	12,78
	Previously Treated	21	25,3	19	90,5	7,02	13,96
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	7,84	14,57
	Previously Treated	19	22,9	16	84,2	6,25	13,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	4,17	11,39
	Previously Treated	19	22,9	16	84,2	0,00	0,00
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	7,69	14,62
	Previously Treated	14	16,9	13	92,9	10,26	21,01
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	5,13	12,52
	Previously Treated	14	16,9	12	85,7	13,89	30,01
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	11,11	33,33
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	3,33	10,54
	Previously Treated	10	12,0	8	80,0	8,33	15,43
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	4,17	11,79
	Previously Treated	6	7,2	5	83,3	6,67	14,91
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	4,17	11,79
	Previously Treated	6	7,2	4	66,7	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	5,56	13,61
	Previously Treated	4	4,8	2	50,0	16,67	23,57
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	9,52	16,27
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	6,67	14,91
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	0,00	0,00
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	0,00	0,00
	Previously Treated	2	2,4	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	0,00	-
	Previously Treated	1	1,2	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	21,05	27,69
	Previously Treated	42	50,6	25	59,5	21,33	28,67
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	29,78	30,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	29,35	32,58
Cycle 2 Day 1	Local	71	94,7	67	94,4	9,95	20,93
	Central	65	92,9	59	90,8	13,56	21,55
Cycle 3 Day 1	Local	67	89,3	62	92,5	8,60	19,02
	Central	64	91,4	56	87,5	11,31	22,27
Cycle 4 Day 1	Local	65	86,7	61	93,8	4,37	12,87
	Central	63	90,0	59	93,7	9,60	20,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	5,08	13,58
	Central	61	87,1	59	96,7	4,52	15,73
Cycle 6 Day 1	Local	63	84,0	61	96,8	4,37	12,87
	Central	58	82,9	51	87,9	4,58	11,58
Cycle 7 Day 1	Local	61	81,3	59	96,7	7,34	18,64
	Central	52	74,3	47	90,4	4,96	12,00
Cycle 8 Day 1	Local	57	76,0	55	96,5	4,24	12,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	8,73	19,56
Cycle 9 Day 1	Local	54	72,0	53	98,1	6,29	14,70
	Central	44	62,9	43	97,7	4,65	13,77
Cycle 10 Day 1	Local	48	64,0	46	95,8	7,25	13,90
	Central	41	58,6	40	97,6	3,33	10,13
Cycle 11 Day 1	Local	40	53,3	38	95,0	7,02	15,80
	Central	40	57,1	40	100,0	5,00	12,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	3,03	9,73
	Central	40	57,1	36	90,0	8,33	16,67
Cycle 13 Day 1	Local	30	40,0	29	96,7	4,60	14,70
	Central	36	51,4	33	91,7	8,08	16,73
Cycle 14 Day 1	Local	27	36,0	27	100,0	3,70	14,12
	Central	33	47,1	30	90,9	10,00	19,87
Cycle 15 Day 1	Local	26	34,7	25	96,2	5,33	12,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	2,30	8,60
Cycle 16 Day 1	Local	24	32,0	24	100,0	4,17	14,95
	Central	26	37,1	23	88,5	10,14	18,63
Cycle 17 Day 1	Local	22	29,3	22	100,0	3,03	9,81
	Central	23	32,9	22	95,7	13,64	24,47
Cycle 18 Day 1	Local	20	26,7	19	95,0	3,51	10,51
	Central	21	30,0	18	85,7	9,26	15,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	3,92	11,07
	Central	17	24,3	16	94,1	10,42	15,96
Cycle 20 Day 1	Local	19	25,3	17	89,5	0,00	0,00
	Central	17	24,3	15	88,2	4,44	11,73
Cycle 21 Day 1	Local	14	18,7	12	85,7	5,56	12,97
	Central	15	21,4	14	93,3	11,90	21,11
Cycle 22 Day 1	Local	14	18,7	12	85,7	8,33	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	10,26	28,50
Cycle 23 Day 1	Local	11	14,7	10	90,9	0,00	0,00
	Central	10	14,3	8	80,0	16,67	35,63
Cycle 24 Day 1	Local	11	14,7	10	90,9	3,33	10,54
	Central	9	12,9	8	88,9	8,33	15,43
Cycle 25 Day 1	Local	7	9,3	7	100,0	4,76	12,60
	Central	8	11,4	6	75,0	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	5,56	13,61
	Central	8	11,4	6	75,0	5,56	13,61
Cycle 27 Day 1	Local	4	5,3	4	100,0	0,00	0,00
	Central	7	10,0	4	57,1	16,67	19,25
Cycle 28 Day 1	Local	4	5,3	4	100,0	8,33	16,67
	Central	6	8,6	5	83,3	13,33	18,26
Cycle 29 Day 1	Local	3	4,0	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	8,33	16,67
Cycle 30 Day 1	Local	3	4,0	3	100,0	0,00	0,00
	Central	4	5,7	2	50,0	16,67	23,57
Cycle 31 Day 1	Local	3	4,0	3	100,0	0,00	0,00
	Central	4	5,7	2	50,0	16,67	23,57
Cycle 32 Day 1	Local	3	4,0	3	100,0	0,00	0,00
	Central	3	4,3	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	0,00	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	15,28	24,04
	Central	32	45,7	20	62,5	28,33	31,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	28,79	31,58
	No	10	100,0	10	100,0	40,00	30,63
Cycle 2 Day 1	Yes	129	95,6	119	92,2	11,20	20,94
	No	7	70,0	7	100,0	19,05	26,23
Cycle 3 Day 1	Yes	124	91,9	112	90,3	9,82	20,81
	No	7	70,0	6	85,7	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	7,08	17,51
	No	7	70,0	7	100,0	4,76	12,60
Cycle 5 Day 1	Yes	117	86,7	112	95,7	4,17	14,24
	No	7	70,0	6	85,7	16,67	18,26
Cycle 6 Day 1	Yes	114	84,4	105	92,1	4,44	12,29
	No	7	70,0	7	100,0	4,76	12,60
Cycle 7 Day 1	Yes	106	78,5	99	93,4	5,39	13,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	19,05	37,80
Cycle 8 Day 1	Yes	100	74,1	91	91,0	5,86	16,17
	No	6	60,0	6	100,0	11,11	17,21
Cycle 9 Day 1	Yes	92	68,1	90	97,8	5,56	14,35
	No	6	60,0	6	100,0	5,56	13,61
Cycle 10 Day 1	Yes	83	61,5	80	96,4	5,42	12,37
	No	6	60,0	6	100,0	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	6,31	14,26
	No	4	40,0	4	100,0	0,00	0,00
Cycle 12 Day 1	Yes	72	53,3	65	90,3	6,15	14,30
	No	4	40,0	4	100,0	0,00	0,00
Cycle 13 Day 1	Yes	64	47,4	60	93,8	6,11	15,64
	No	2	20,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	58	43,0	55	94,8	6,06	15,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	33,33	47,14
Cycle 15 Day 1	Yes	55	40,7	52	94,5	3,85	10,75
	No	2	20,0	2	100,0	0,00	0,00
Cycle 16 Day 1	Yes	48	35,6	45	93,8	7,41	17,25
	No	2	20,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	43	31,9	42	97,7	7,14	18,82
	No	2	20,0	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	5,71	12,75
	No	2	20,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	7,29	14,00
	No	2	20,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	2,22	8,46
	No	2	20,0	2	100,0	0,00	0,00
Cycle 21 Day 1	Yes	27	20,0	24	88,9	6,94	13,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	33,33	47,14
Cycle 22 Day 1	Yes	27	20,0	23	85,2	8,70	22,96
	No	2	20,0	2	100,0	16,67	23,57
Cycle 23 Day 1	Yes	20	14,8	17	85,0	7,84	25,08
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	5,88	13,10
	No	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	5,56	12,97
	No	1	10,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	6,06	13,48
	No	1	10,0	1	100,0	0,00	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	9,52	16,27
	No	1	10,0	1	100,0	0,00	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	8,33	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	5,56	13,61
	No	1	10,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	8,33	16,67
	No	1	10,0	1	100,0	0,00	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	8,33	16,67
	No	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	21,71	28,06
	No	2	20,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	36,36	27,71
	No	134	100,0	131	97,8	29,01	31,86
Cycle 2 Day 1	Yes	7	63,6	7	100,0	14,29	26,23
	No	129	96,3	119	92,2	11,48	21,01
Cycle 3 Day 1	Yes	7	63,6	7	100,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	9,91	20,89
Cycle 4 Day 1	Yes	7	63,6	7	100,0	4,76	12,60
	No	121	90,3	113	93,4	7,08	17,51
Cycle 5 Day 1	Yes	7	63,6	7	100,0	9,52	25,20
	No	117	87,3	111	94,9	4,50	13,84
Cycle 6 Day 1	Yes	7	63,6	7	100,0	4,76	12,60
	No	114	85,1	105	92,1	4,44	12,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	4,76	12,60
	No	106	79,1	99	93,4	6,40	16,27
Cycle 8 Day 1	Yes	7	63,6	7	100,0	19,05	26,23
	No	99	73,9	90	90,9	5,19	14,92
Cycle 9 Day 1	Yes	6	54,5	6	100,0	5,56	13,61
	No	92	68,7	90	97,8	5,56	14,35
Cycle 10 Day 1	Yes	6	54,5	6	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	5,83	12,75
Cycle 11 Day 1	Yes	6	54,5	6	100,0	11,11	17,21
	No	74	55,2	72	97,3	5,56	13,70
Cycle 12 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	70	52,2	63	90,0	6,35	14,49
Cycle 13 Day 1	Yes	5	45,5	5	100,0	6,67	14,91
	No	61	45,5	57	93,4	6,43	15,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	0,00	0,00
	No	55	41,0	52	94,5	7,69	18,22
Cycle 15 Day 1	Yes	4	36,4	4	100,0	8,33	16,67
	No	53	39,6	50	94,3	3,33	10,10
Cycle 16 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	47	35,1	44	93,6	6,82	16,98
Cycle 17 Day 1	Yes	3	27,3	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	8,94	19,75
Cycle 18 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	38	28,4	34	89,5	6,86	13,68
Cycle 19 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	30	90,9	7,78	14,34
Cycle 20 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	29	87,9	2,30	8,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	24	88,9	9,72	18,33
Cycle 22 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	23	85,2	10,14	23,43
Cycle 23 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	19	14,2	16	84,2	8,33	25,82
Cycle 24 Day 1	Yes	2	18,2	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	6,25	13,44
Cycle 25 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	13	9,7	11	84,6	6,06	13,48
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	6,06	13,48
Cycle 27 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	10	7,5	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	9	6,7	8	88,9	12,50	17,25
Cycle 29 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	8	6,0	6	75,0	5,56	13,61
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	6,67	14,91
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	6,67	14,91
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	0,00	0,00
Cycle 33 Day 1	No	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	33,33	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	20,33	27,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30AP_SG.xls
24JUN2020 20:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	82,75	17,58
Cycle 2 Day 1	All	136	93,8	125	91,9	79,47	21,18
Cycle 3 Day 1	All	131	90,3	118	90,1	75,00	21,87
Cycle 4 Day 1	All	128	88,3	120	93,8	79,44	19,89
Cycle 5 Day 1	All	124	85,5	118	95,2	77,68	18,26
Cycle 6 Day 1	All	121	83,4	112	92,6	76,93	19,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	77,04	20,89
Cycle 8 Day 1	All	106	73,1	97	91,5	76,80	20,63
Cycle 9 Day 1	All	98	67,6	96	98,0	77,60	20,78
Cycle 10 Day 1	All	89	61,4	86	96,6	76,55	20,51
Cycle 11 Day 1	All	80	55,2	78	97,5	79,49	17,60
Cycle 12 Day 1	All	76	52,4	69	90,8	79,95	20,53
Cycle 13 Day 1	All	66	45,5	62	93,9	80,65	19,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	77,49	21,93
Cycle 15 Day 1	All	57	39,3	54	94,7	78,09	21,92
Cycle 16 Day 1	All	50	34,5	47	94,0	80,14	18,92
Cycle 17 Day 1	All	45	31,0	44	97,8	82,20	18,81
Cycle 18 Day 1	All	41	28,3	37	90,2	78,38	18,78
Cycle 19 Day 1	All	36	24,8	33	91,7	76,77	24,27
Cycle 20 Day 1	All	36	24,8	32	88,9	77,60	22,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	75,00	20,14
Cycle 22 Day 1	All	29	20,0	25	86,2	76,67	21,52
Cycle 23 Day 1	All	21	14,5	18	85,7	81,48	18,86
Cycle 24 Day 1	All	20	13,8	18	90,0	79,63	23,26
Cycle 25 Day 1	All	15	10,3	13	86,7	70,51	27,35
Cycle 26 Day 1	All	14	9,7	12	85,7	70,83	26,71
Cycle 27 Day 1	All	11	7,6	8	72,7	64,58	27,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	59,26	26,50
Cycle 29 Day 1	All	9	6,2	7	77,8	57,14	28,64
Cycle 30 Day 1	All	7	4,8	5	71,4	63,33	18,26
Cycle 31 Day 1	All	7	4,8	5	71,4	70,00	13,94
Cycle 32 Day 1	All	6	4,1	5	83,3	66,67	16,67
Cycle 33 Day 1	All	2	1,4	2	100,0	66,67	23,57
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	73,48	17,36
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	85,62	19,73
	Female	93	100,0	91	97,8	81,14	16,14
Cycle 2 Day 1	Male	50	96,2	46	92,0	81,88	18,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	78,06	22,42
Cycle 3 Day 1	Male	47	90,4	42	89,4	80,16	22,76
	Female	84	90,3	76	90,5	72,15	20,97
Cycle 4 Day 1	Male	46	88,5	45	97,8	83,70	17,58
	Female	82	88,2	75	91,5	76,89	20,85
Cycle 5 Day 1	Male	45	86,5	43	95,6	78,68	16,80
	Female	79	84,9	75	94,9	77,11	19,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	80,49	17,04
	Female	76	81,7	71	93,4	74,88	20,09
Cycle 7 Day 1	Male	40	76,9	39	97,5	77,78	19,62
	Female	73	78,5	67	91,8	76,62	21,72
Cycle 8 Day 1	Male	37	71,2	34	91,9	77,94	20,40
	Female	69	74,2	63	91,3	76,19	20,89
Cycle 9 Day 1	Male	33	63,5	33	100,0	82,32	19,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	75,13	21,14
Cycle 10 Day 1	Male	30	57,7	30	100,0	75,56	19,93
	Female	59	63,4	56	94,9	77,08	20,98
Cycle 11 Day 1	Male	29	55,8	29	100,0	79,31	18,72
	Female	51	54,8	49	96,1	79,59	17,10
Cycle 12 Day 1	Male	27	51,9	26	96,3	83,33	18,86
	Female	49	52,7	43	87,8	77,91	21,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	81,88	20,05
	Female	41	44,1	39	95,1	79,91	19,93
Cycle 14 Day 1	Male	23	44,2	21	91,3	77,78	23,77
	Female	37	39,8	36	97,3	77,31	21,14
Cycle 15 Day 1	Male	21	40,4	20	95,2	79,17	19,40
	Female	36	38,7	34	94,4	77,45	23,53
Cycle 16 Day 1	Male	16	30,8	16	100,0	81,25	20,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	79,57	18,61
Cycle 17 Day 1	Male	13	25,0	13	100,0	87,18	16,88
	Female	32	34,4	31	96,9	80,11	19,45
Cycle 18 Day 1	Male	12	23,1	11	91,7	81,82	21,67
	Female	29	31,2	26	89,7	76,92	17,69
Cycle 19 Day 1	Male	10	19,2	10	100,0	76,67	22,50
	Female	26	28,0	23	88,5	76,81	25,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	81,48	25,61
	Female	26	28,0	23	88,5	76,09	21,80
Cycle 21 Day 1	Male	8	15,4	8	100,0	75,00	23,57
	Female	21	22,6	18	85,7	75,00	19,17
Cycle 22 Day 1	Male	8	15,4	6	75,0	77,78	25,09
	Female	21	22,6	19	90,5	76,32	21,02
Cycle 23 Day 1	Male	5	9,6	4	80,0	75,00	21,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	83,33	18,49
Cycle 24 Day 1	Male	5	9,6	4	80,0	62,50	28,46
	Female	15	16,1	14	93,3	84,52	20,11
Cycle 25 Day 1	Male	3	5,8	2	66,7	66,67	47,14
	Female	12	12,9	11	91,7	71,21	25,92
Cycle 26 Day 1	Male	3	5,8	2	66,7	66,67	47,14
	Female	11	11,8	10	90,9	71,67	24,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	75,00	35,36
	Female	8	8,6	6	75,0	61,11	27,22
Cycle 28 Day 1	Male	2	3,8	2	100,0	66,67	47,14
	Female	8	8,6	7	87,5	57,14	23,29
Cycle 29 Day 1	Male	1	1,9	1	100,0	33,33	-
	Female	8	8,6	6	75,0	61,11	29,19
Cycle 30 Day 1	Male	1	1,9	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	66,67	19,25
Cycle 31 Day 1	Male	1	1,9	1	100,0	66,67	-
	Female	6	6,5	4	66,7	70,83	15,96
Cycle 32 Day 1	Male	1	1,9	1	100,0	50,00	-
	Female	5	5,4	4	80,0	70,83	15,96
Cycle 33 Day 1	Male	1	1,9	1	100,0	50,00	-
	Female	1	1,1	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	73,02	18,62
	Female	37	39,8	23	62,2	73,91	16,53
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	84,75	17,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	75,86	16,42
	>=75	7	100,0	7	100,0	80,95	17,82
Cycle 2 Day 1	18-64	103	94,5	93	90,3	81,90	18,82
	65-74	26	89,7	25	96,2	72,00	25,78
	>=75	7	100,0	7	100,0	73,81	28,64
Cycle 3 Day 1	18-64	99	90,8	87	87,9	75,86	21,38
	65-74	25	86,2	24	96,0	73,61	25,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	69,05	17,82
Cycle 4 Day 1	18-64	98	89,9	92	93,9	80,25	20,66
	65-74	23	79,3	21	91,3	76,19	18,69
	>=75	7	100,0	7	100,0	78,57	12,60
Cycle 5 Day 1	18-64	95	87,2	90	94,7	78,52	18,23
	65-74	22	75,9	22	100,0	75,00	20,41
	>=75	7	100,0	6	85,7	75,00	9,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	78,77	19,07
	65-74	22	75,9	21	95,5	71,43	21,18
	>=75	7	100,0	7	100,0	71,43	8,13
Cycle 7 Day 1	18-64	86	78,9	81	94,2	76,95	22,45
	65-74	20	69,0	19	95,0	78,07	14,75
	>=75	7	100,0	6	85,7	75,00	17,48
Cycle 8 Day 1	18-64	80	73,4	72	90,0	77,08	21,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	74,56	21,06
	>=75	7	100,0	6	85,7	80,56	16,39
Cycle 9 Day 1	18-64	74	67,9	73	98,6	78,08	21,13
	65-74	18	62,1	18	100,0	74,07	21,56
	>=75	6	85,7	5	83,3	83,33	11,79
Cycle 10 Day 1	18-64	69	63,3	66	95,7	77,53	21,78
	65-74	15	51,7	15	100,0	72,22	17,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	76,67	9,13
Cycle 11 Day 1	18-64	61	56,0	59	96,7	79,10	18,46
	65-74	15	51,7	15	100,0	82,22	16,02
	>=75	4	57,1	4	100,0	75,00	9,62
Cycle 12 Day 1	18-64	57	52,3	51	89,5	79,74	22,44
	65-74	15	51,7	14	93,3	77,38	14,03
	>=75	4	57,1	4	100,0	91,67	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	82,97	18,08
	65-74	13	44,8	12	92,3	69,44	24,45
	>=75	4	57,1	4	100,0	87,50	15,96
Cycle 14 Day 1	18-64	45	41,3	44	97,8	78,79	20,76
	65-74	13	44,8	11	84,6	71,21	26,97
	>=75	2	28,6	2	100,0	83,33	23,57
Cycle 15 Day 1	18-64	43	39,4	41	95,3	78,46	22,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	75,76	23,99
	>=75	2	28,6	2	100,0	83,33	0,00
Cycle 16 Day 1	18-64	38	34,9	36	94,7	79,17	19,26
	65-74	10	34,5	9	90,0	81,48	19,44
	>=75	2	28,6	2	100,0	91,67	11,79
Cycle 17 Day 1	18-64	36	33,0	35	97,2	81,90	19,54
	65-74	8	27,6	8	100,0	83,33	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	83,33	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	80,00	18,26
	65-74	7	24,1	6	85,7	66,67	18,26
	>=75	1	14,3	1	100,0	100,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	76,79	25,39
	65-74	5	17,2	4	80,0	75,00	21,52
	>=75	1	14,3	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	78,85	23,83
	65-74	5	17,2	5	100,0	66,67	11,79
	>=75	1	14,3	1	100,0	100,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	76,98	20,05
	65-74	4	13,8	4	100,0	66,67	23,57
	>=75	1	14,3	1	100,0	66,67	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	78,33	21,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	66,67	23,57
	>=75	1	14,3	1	100,0	83,33	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	81,25	20,07
	65-74	2	6,9	2	100,0	83,33	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	80,21	24,51
	65-74	2	6,9	2	100,0	75,00	11,79
Cycle 25 Day 1	18-64	14	12,8	12	85,7	69,44	28,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	83,33	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	70,83	26,71
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	64,58	27,37
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	59,26	26,50
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	57,14	28,64
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	63,33	18,26
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	70,00	13,94
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	62,50	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	83,33	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	50,00	-
	65-74	1	3,4	1	100,0	83,33	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	75,00	18,46
	65-74	15	51,7	8	53,3	70,83	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	58,33	11,79
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	83,62	18,07
	Other	85	100,0	84	98,8	82,14	17,31
Cycle 2 Day 1	White	57	95,0	50	87,7	80,00	22,34
	Other	79	92,9	75	94,9	79,11	20,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	73,11	22,51
	Other	77	90,6	74	96,1	76,13	21,56
Cycle 4 Day 1	White	53	88,3	47	88,7	83,33	17,38
	Other	75	88,2	73	97,3	76,94	21,09
Cycle 5 Day 1	White	52	86,7	48	92,3	78,82	18,75
	Other	72	84,7	70	97,2	76,90	18,01
Cycle 6 Day 1	White	50	83,3	44	88,0	78,41	15,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	75,98	21,04
Cycle 7 Day 1	White	47	78,3	42	89,4	80,56	17,23
	Other	66	77,6	64	97,0	74,74	22,81
Cycle 8 Day 1	White	45	75,0	39	86,7	80,77	16,01
	Other	61	71,8	58	95,1	74,14	22,98
Cycle 9 Day 1	White	42	70,0	41	97,6	80,89	18,84
	Other	56	65,9	55	98,2	75,15	21,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	81,20	18,41
	Other	48	56,5	47	97,9	72,70	21,54
Cycle 11 Day 1	White	37	61,7	37	100,0	81,98	16,84
	Other	43	50,6	41	95,3	77,24	18,16
Cycle 12 Day 1	White	37	61,7	33	89,2	82,83	17,91
	Other	39	45,9	36	92,3	77,31	22,59
Cycle 13 Day 1	White	32	53,3	30	93,8	83,33	21,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	78,13	18,18
Cycle 14 Day 1	White	31	51,7	30	96,8	78,89	23,13
	Other	29	34,1	27	93,1	75,93	20,84
Cycle 15 Day 1	White	30	50,0	28	93,3	79,76	21,45
	Other	27	31,8	26	96,3	76,28	22,69
Cycle 16 Day 1	White	26	43,3	24	92,3	83,33	17,03
	Other	24	28,2	23	95,8	76,81	20,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	86,11	15,28
	Other	21	24,7	20	95,2	77,50	21,81
Cycle 18 Day 1	White	22	36,7	19	86,4	81,58	19,16
	Other	19	22,4	18	94,7	75,00	18,30
Cycle 19 Day 1	White	20	33,3	20	100,0	77,50	19,70
	Other	16	18,8	13	81,3	75,64	30,89
Cycle 20 Day 1	White	20	33,3	17	85,0	79,41	22,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	75,56	23,46
Cycle 21 Day 1	White	16	26,7	14	87,5	77,38	21,29
	Other	13	15,3	12	92,3	72,22	19,25
Cycle 22 Day 1	White	16	26,7	13	81,3	82,05	18,59
	Other	13	15,3	12	92,3	70,83	23,70
Cycle 23 Day 1	White	12	20,0	10	83,3	85,00	14,59
	Other	9	10,6	8	88,9	77,08	23,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	80,00	21,94
	Other	9	10,6	8	88,9	79,17	26,35
Cycle 25 Day 1	White	10	16,7	8	80,0	75,00	21,82
	Other	5	5,9	5	100,0	63,33	36,13
Cycle 26 Day 1	White	10	16,7	8	80,0	72,92	26,63
	Other	4	4,7	4	100,0	66,67	30,43
Cycle 27 Day 1	White	8	13,3	5	62,5	66,67	26,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	61,11	34,69
Cycle 28 Day 1	White	7	11,7	6	85,7	69,44	26,70
	Other	3	3,5	3	100,0	38,89	9,62
Cycle 29 Day 1	White	6	10,0	4	66,7	45,83	28,46
	Other	3	3,5	3	100,0	72,22	25,46
Cycle 30 Day 1	White	4	6,7	2	50,0	66,67	23,57
	Other	3	3,5	3	100,0	61,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	75,00	11,79
	Other	3	3,5	3	100,0	66,67	16,67
Cycle 32 Day 1	White	4	6,7	3	75,0	72,22	19,25
	Other	2	2,4	2	100,0	58,33	11,79
Cycle 33 Day 1	White	2	3,3	2	100,0	66,67	23,57
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	79,41	15,06
	Other	39	45,9	27	69,2	69,75	17,92
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	83,33	18,10
	Europe (EU)	34	100,0	31	91,2	88,71	15,15
	Asia (AS)	71	100,0	71	100,0	79,81	17,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	75,00	23,95
	Europe (EU)	32	94,1	28	87,5	85,71	15,53
	Asia (AS)	66	93,0	65	98,5	78,97	21,51
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	74,75	21,70
	Europe (EU)	31	91,2	22	71,0	74,24	21,66
	Asia (AS)	63	88,7	63	100,0	75,40	22,37
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	80,39	18,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	87,33	18,18
	Asia (AS)	61	85,9	61	100,0	75,68	20,77
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	76,67	17,24
	Europe (EU)	30	88,2	26	86,7	81,41	20,72
	Asia (AS)	57	80,3	57	100,0	76,61	17,78
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	80,48	16,90
	Europe (EU)	28	82,4	25	89,3	78,00	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	74,04	20,98
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	78,65	23,28
	Europe (EU)	28	82,4	25	89,3	79,33	19,41
	Asia (AS)	50	70,4	49	98,0	74,83	20,16
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	79,01	18,83
	Europe (EU)	28	82,4	23	82,1	81,16	14,48
	Asia (AS)	47	66,2	47	100,0	73,40	23,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	77,98	18,73
	Europe (EU)	26	76,5	25	96,2	83,33	17,35
	Asia (AS)	43	60,6	43	100,0	74,03	23,37
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	81,25	21,03
	Europe (EU)	25	73,5	25	100,0	76,00	14,50
	Asia (AS)	37	52,1	37	100,0	73,87	23,42
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	83,33	18,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	82,58	15,83
	Asia (AS)	33	46,5	33	100,0	74,75	17,74
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	83,33	15,89
	Europe (EU)	23	67,6	18	78,3	83,33	16,17
	Asia (AS)	29	40,8	28	96,6	75,00	25,46
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	84,09	17,43
	Europe (EU)	18	52,9	15	83,3	81,11	22,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	77,33	20,34
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	83,33	17,48
	Europe (EU)	17	50,0	16	94,1	79,17	17,74
	Asia (AS)	21	29,6	20	95,2	70,00	27,36
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	85,00	16,13
	Europe (EU)	15	44,1	14	93,3	80,95	21,54
	Asia (AS)	20	28,2	20	100,0	69,17	24,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	83,33	17,68
	Europe (EU)	14	41,2	11	78,6	84,85	15,73
	Asia (AS)	19	26,8	19	100,0	74,56	21,06
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	83,33	19,25
	Europe (EU)	13	38,2	12	92,3	90,28	8,58
	Asia (AS)	16	22,5	16	100,0	75,00	21,94
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	82,14	20,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	85,71	11,50
	Asia (AS)	16	22,5	16	100,0	71,88	18,97
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	78,21	22,96
	Europe (EU)	9	26,5	9	100,0	79,63	13,89
	Asia (AS)	14	19,7	11	78,6	72,73	32,72
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	80,77	25,32
	Europe (EU)	9	26,5	6	66,7	80,56	12,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	73,08	24,09
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	75,00	22,57
	Europe (EU)	7	20,6	6	85,7	83,33	14,91
	Asia (AS)	11	15,5	10	90,9	70,00	20,49
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	81,67	21,44
	Europe (EU)	7	20,6	5	71,4	86,67	7,45
	Asia (AS)	11	15,5	10	90,9	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	85,19	13,03
	Europe (EU)	5	14,7	3	60,0	94,44	9,62
	Asia (AS)	7	9,9	6	85,7	69,44	24,53
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	75,00	21,82
	Europe (EU)	5	14,7	4	80,0	95,83	8,33
	Asia (AS)	7	9,9	6	85,7	75,00	29,34
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	76,19	23,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	91,67	11,79
	Asia (AS)	4	5,6	4	100,0	50,00	30,43
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	69,44	24,53
	Europe (EU)	4	11,8	2	50,0	100,00	0,00
	Asia (AS)	4	5,6	4	100,0	58,33	28,87
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	75,00	21,52
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	54,17	31,55
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	66,67	27,22
	Europe (EU)	2	5,9	1	50,0	100,00	-
	Asia (AS)	4	5,6	4	100,0	41,67	9,62
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	55,56	25,46
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	58,33	34,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	66,67	23,57
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	61,11	19,25
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	75,00	11,79
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	66,67	16,67
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	83,33	-
	Asia (AS)	3	4,2	2	66,7	58,33	11,79
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	50,00	-
	Europe (EU)	1	2,9	1	100,0	83,33	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	74,51	15,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	76,67	14,91
	Asia (AS)	34	47,9	22	64,7	71,97	19,51
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	88,33	14,16
	1	69	100,0	67	97,1	81,09	18,55
	2	15	100,0	15	100,0	67,78	16,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	55	93,2	83,03	20,41
	1	67	97,1	60	89,6	75,56	22,44
	2	10	66,7	10	100,0	83,33	13,61
Cycle 3 Day 1	0	57	93,4	51	89,5	79,74	20,90
	1	65	94,2	58	89,2	71,26	22,68
	2	9	60,0	9	100,0	72,22	18,63
Cycle 4 Day 1	0	57	93,4	54	94,7	80,56	19,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	80,17	19,11
	2	9	60,0	8	88,9	66,67	26,73
Cycle 5 Day 1	0	56	91,8	53	94,6	77,36	19,91
	1	62	89,9	59	95,2	78,53	16,97
	2	6	40,0	6	100,0	72,22	17,21
Cycle 6 Day 1	0	56	91,8	54	96,4	79,01	18,93
	1	59	85,5	53	89,8	75,16	19,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	73,33	19,00
Cycle 7 Day 1	0	54	88,5	51	94,4	78,43	22,18
	1	54	78,3	50	92,6	76,00	20,53
	2	5	33,3	5	100,0	73,33	9,13
Cycle 8 Day 1	0	52	85,2	48	92,3	78,82	19,67
	1	49	71,0	44	89,8	74,24	22,29
	2	5	33,3	5	100,0	80,00	13,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	80,61	19,05
	1	44	63,8	43	97,7	74,42	22,81
	2	4	26,7	4	100,0	75,00	16,67
Cycle 10 Day 1	0	46	75,4	46	100,0	75,00	20,11
	1	40	58,0	37	92,5	77,93	21,54
	2	3	20,0	3	100,0	83,33	16,67
Cycle 11 Day 1	0	43	70,5	41	95,3	79,27	18,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	79,41	16,44
	2	3	20,0	3	100,0	83,33	16,67
Cycle 12 Day 1	0	42	68,9	36	85,7	81,02	16,97
	1	31	44,9	30	96,8	80,00	24,53
	2	3	20,0	3	100,0	66,67	16,67
Cycle 13 Day 1	0	38	62,3	34	89,5	79,90	22,01
	1	27	39,1	27	100,0	82,10	17,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	66,67	-
Cycle 14 Day 1	0	35	57,4	32	91,4	73,44	23,13
	1	24	34,8	24	100,0	82,64	19,95
	2	1	6,7	1	100,0	83,33	-
Cycle 15 Day 1	0	33	54,1	30	90,9	76,67	21,26
	1	23	33,3	23	100,0	79,71	23,55
	2	1	6,7	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	78,00	18,46
	1	21	30,4	21	100,0	82,54	20,05
	2	1	6,7	1	100,0	83,33	-
Cycle 17 Day 1	0	24	39,3	23	95,8	81,88	16,60
	1	20	29,0	20	100,0	82,50	21,95
	2	1	6,7	1	100,0	83,33	-
Cycle 18 Day 1	0	23	37,7	19	82,6	77,19	20,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	78,43	17,45
	2	1	6,7	1	100,0	100,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	78,07	19,29
	1	15	21,7	13	86,7	74,36	31,63
	2	1	6,7	1	100,0	83,33	-
Cycle 20 Day 1	0	20	32,8	17	85,0	75,49	22,14
	1	15	21,7	14	93,3	79,76	24,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	83,33	-
Cycle 21 Day 1	0	15	24,6	14	93,3	75,00	23,34
	1	13	18,8	11	84,6	74,24	17,26
	2	1	6,7	1	100,0	83,33	-
Cycle 22 Day 1	0	15	24,6	12	80,0	75,00	23,03
	1	13	18,8	12	92,3	77,78	21,71
	2	1	6,7	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	81,48	13,03
	1	9	13,0	8	88,9	81,25	25,88
	2	1	6,7	1	100,0	83,33	-
Cycle 24 Day 1	0	10	16,4	9	90,0	77,78	22,05
	1	9	13,0	8	88,9	79,17	26,35
	2	1	6,7	1	100,0	100,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	72,22	22,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	69,05	32,53
Cycle 26 Day 1	0	8	13,1	6	75,0	69,44	28,71
	1	6	8,7	6	100,0	72,22	27,22
Cycle 27 Day 1	0	6	9,8	3	50,0	61,11	34,69
	1	5	7,2	5	100,0	66,67	26,35
Cycle 28 Day 1	0	5	8,2	4	80,0	70,83	34,36
	1	5	7,2	5	100,0	50,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	25,00	11,79
	1	5	7,2	5	100,0	70,00	21,73
Cycle 30 Day 1	0	3	4,9	1	33,3	50,00	-
	1	4	5,8	4	100,0	66,67	19,25
Cycle 31 Day 1	0	3	4,9	1	33,3	66,67	-
	1	4	5,8	4	100,0	70,83	15,96
Cycle 32 Day 1	0	3	4,9	2	66,7	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	66,67	16,67
Cycle 33 Day 1	0	2	3,3	2	100,0	66,67	23,57
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	75,40	14,55
	1	34	49,3	20	58,8	74,17	19,10
	2	7	46,7	3	42,9	55,56	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	83,06	17,22
	1	4	100,0	4	100,0	83,33	13,61
	2 or More	79	100,0	78	98,7	82,48	18,20
Cycle 2 Day 1	None	60	96,8	54	90,0	78,70	20,84
	1	3	75,0	2	66,7	100,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	79,47	21,61
Cycle 3 Day 1	None	59	95,2	53	89,8	75,47	21,58
	1	3	75,0	2	66,7	91,67	11,79
	2 or More	69	87,3	63	91,3	74,07	22,36
Cycle 4 Day 1	None	59	95,2	56	94,9	80,06	18,37
	1	3	75,0	2	66,7	100,00	0,00
	2 or More	66	83,5	62	93,9	78,23	21,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	78,27	18,78
	1	3	75,0	3	100,0	94,44	9,62
	2 or More	63	79,7	59	93,7	76,27	17,83
Cycle 6 Day 1	None	57	91,9	52	91,2	78,21	17,63
	1	3	75,0	3	100,0	94,44	9,62
	2 or More	61	77,2	57	93,4	74,85	20,44
Cycle 7 Day 1	None	52	83,9	50	96,2	77,33	23,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	88,89	9,62
	2 or More	58	73,4	53	91,4	76,10	18,35
Cycle 8 Day 1	None	50	80,6	46	92,0	75,72	21,86
	1	3	75,0	1	33,3	83,33	-
	2 or More	53	67,1	50	94,3	77,67	19,81
Cycle 9 Day 1	None	48	77,4	47	97,9	80,14	17,94
	1	1	25,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	75,00	23,32
Cycle 10 Day 1	None	43	69,4	41	95,3	77,24	20,33
	1	1	25,0	1	100,0	100,00	-
	2 or More	45	57,0	44	97,8	75,38	20,80
Cycle 11 Day 1	None	37	59,7	35	94,6	80,48	19,59
	1	1	25,0	1	100,0	100,00	-
	2 or More	42	53,2	42	100,0	78,17	15,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	78,92	21,05
	1	1	25,0	1	100,0	83,33	-
	2 or More	38	48,1	34	89,5	80,88	20,57
Cycle 13 Day 1	None	34	54,8	30	88,2	78,33	20,60
	1	1	25,0	1	100,0	100,00	-
	2 or More	31	39,2	31	100,0	82,26	19,21
Cycle 14 Day 1	None	31	50,0	29	93,5	75,29	24,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	83,33	-
	2 or More	28	35,4	27	96,4	79,63	19,79
Cycle 15 Day 1	None	30	48,4	28	93,3	77,38	24,93
	1	1	25,0	1	100,0	83,33	-
	2 or More	26	32,9	25	96,2	78,67	18,95
Cycle 16 Day 1	None	25	40,3	23	92,0	79,71	20,07
	1	1	25,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	80,43	18,57
Cycle 17 Day 1	None	23	37,1	22	95,7	87,12	12,53
	1	1	25,0	1	100,0	100,00	-
	2 or More	21	26,6	21	100,0	76,19	22,71
Cycle 18 Day 1	None	20	32,3	18	90,0	79,63	18,57
	1	1	25,0	1	100,0	100,00	-
	2 or More	20	25,3	18	90,0	75,93	19,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	78,43	28,11
	1	1	25,0	1	100,0	83,33	-
	2 or More	18	22,8	15	83,3	74,44	20,77
Cycle 20 Day 1	None	17	27,4	16	94,1	81,25	22,67
	1	1	25,0	1	100,0	100,00	-
	2 or More	18	22,8	15	83,3	72,22	22,42
Cycle 21 Day 1	None	15	24,2	13	86,7	80,77	20,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	69,23	19,06
Cycle 22 Day 1	None	15	24,2	13	86,7	83,33	15,21
	2 or More	14	17,7	12	85,7	69,44	25,46
Cycle 23 Day 1	None	10	16,1	9	90,0	85,19	13,03
	2 or More	11	13,9	9	81,8	77,78	23,57
Cycle 24 Day 1	None	10	16,1	10	100,0	80,00	21,94
	2 or More	10	12,7	8	80,0	79,17	26,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	68,75	30,13
	2 or More	6	7,6	5	83,3	73,33	25,28
Cycle 26 Day 1	None	8	12,9	8	100,0	68,75	27,37
	2 or More	6	7,6	4	66,7	75,00	28,87
Cycle 27 Day 1	None	7	11,3	6	85,7	61,11	27,22
	2 or More	4	5,1	2	50,0	75,00	35,36
Cycle 28 Day 1	None	7	11,3	7	100,0	64,29	27,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	41,67	11,79
Cycle 29 Day 1	None	6	9,7	5	83,3	50,00	26,35
	2 or More	3	3,8	2	66,7	75,00	35,36
Cycle 30 Day 1	None	4	6,5	3	75,0	61,11	19,25
	2 or More	3	3,8	2	66,7	66,67	23,57
Cycle 31 Day 1	None	4	6,5	3	75,0	72,22	9,62
	2 or More	3	3,8	2	66,7	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	66,67	16,67
	2 or More	2	2,5	2	100,0	66,67	23,57
Cycle 33 Day 1	None	1	1,6	1	100,0	50,00	-
	2 or More	1	1,3	1	100,0	83,33	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	76,32	13,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	83,33	-
	2 or More	39	49,4	24	61,5	70,83	19,81
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	83,06	17,22
	Previously Treated	83	100,0	82	98,8	82,52	17,94
Cycle 2 Day 1	Naïve	60	96,8	54	90,0	78,70	20,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	80,05	21,57
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	75,47	21,58
	Previously Treated	72	86,7	65	90,3	74,62	22,26
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	80,06	18,37
	Previously Treated	69	83,1	64	92,8	78,91	21,26
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	78,27	18,78
	Previously Treated	66	79,5	62	93,9	77,15	17,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	78,21	17,63
	Previously Treated	64	77,1	60	93,8	75,83	20,45
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	77,33	23,75
	Previously Treated	61	73,5	56	91,8	76,79	18,17
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	75,72	21,86
	Previously Treated	56	67,5	51	91,1	77,78	19,63
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	80,14	17,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	75,17	23,10
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	77,24	20,33
	Previously Treated	46	55,4	45	97,8	75,93	20,89
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	80,48	19,59
	Previously Treated	43	51,8	43	100,0	78,68	15,99
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	78,92	21,05
	Previously Treated	39	47,0	35	89,7	80,95	20,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	78,33	20,60
	Previously Treated	32	38,6	32	100,0	82,81	19,16
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	75,29	24,24
	Previously Treated	29	34,9	28	96,6	79,76	19,43
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	77,38	24,93
	Previously Treated	27	32,5	26	96,3	78,85	18,59
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	79,71	20,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	80,56	18,17
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	87,12	12,53
	Previously Treated	22	26,5	22	100,0	77,27	22,74
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	79,63	18,57
	Previously Treated	21	25,3	19	90,5	77,19	19,41
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	78,43	28,11
	Previously Treated	19	22,9	16	84,2	75,00	20,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	81,25	22,67
	Previously Treated	19	22,9	16	84,2	73,96	22,75
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	80,77	20,24
	Previously Treated	14	16,9	13	92,9	69,23	19,06
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	83,33	15,21
	Previously Treated	14	16,9	12	85,7	69,44	25,46
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	85,19	13,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	77,78	23,57
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	80,00	21,94
	Previously Treated	10	12,0	8	80,0	79,17	26,35
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	68,75	30,13
	Previously Treated	6	7,2	5	83,3	73,33	25,28
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	68,75	27,37
	Previously Treated	6	7,2	4	66,7	75,00	28,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	61,11	27,22
	Previously Treated	4	4,8	2	50,0	75,00	35,36
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	64,29	27,94
	Previously Treated	3	3,6	2	66,7	41,67	11,79
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	50,00	26,35
	Previously Treated	3	3,6	2	66,7	75,00	35,36
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	61,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	66,67	23,57
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	72,22	9,62
	Previously Treated	3	3,6	2	66,7	66,67	23,57
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	66,67	16,67
	Previously Treated	2	2,4	2	100,0	66,67	23,57
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	50,00	-
	Previously Treated	1	1,2	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	76,32	13,96
	Previously Treated	42	50,6	25	59,5	71,33	19,56
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	82,44	18,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	83,08	17,04
Cycle 2 Day 1	Local	71	94,7	66	93,0	78,54	21,24
	Central	65	92,9	59	90,8	80,51	21,25
Cycle 3 Day 1	Local	67	89,3	62	92,5	73,92	21,89
	Central	64	91,4	56	87,5	76,19	21,99
Cycle 4 Day 1	Local	65	86,7	61	93,8	79,51	21,17
	Central	63	90,0	59	93,7	79,38	18,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	76,84	19,58
	Central	61	87,1	59	96,7	78,53	16,97
Cycle 6 Day 1	Local	63	84,0	61	96,8	77,32	18,77
	Central	58	82,9	51	87,9	76,47	19,77
Cycle 7 Day 1	Local	61	81,3	59	96,7	76,27	23,41
	Central	52	74,3	47	90,4	78,01	17,41
Cycle 8 Day 1	Local	57	76,0	55	96,5	76,36	20,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	77,38	21,41
Cycle 9 Day 1	Local	54	72,0	53	98,1	76,42	20,00
	Central	44	62,9	43	97,7	79,07	21,85
Cycle 10 Day 1	Local	48	64,0	46	95,8	75,36	20,71
	Central	41	58,6	40	97,6	77,92	20,46
Cycle 11 Day 1	Local	40	53,3	38	95,0	76,32	17,17
	Central	40	57,1	40	100,0	82,50	17,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	78,28	19,76
	Central	40	57,1	36	90,0	81,48	21,37
Cycle 13 Day 1	Local	30	40,0	29	96,7	77,01	21,09
	Central	36	51,4	33	91,7	83,84	18,39
Cycle 14 Day 1	Local	27	36,0	27	100,0	78,40	20,58
	Central	33	47,1	30	90,9	76,67	23,41
Cycle 15 Day 1	Local	26	34,7	25	96,2	78,00	24,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	78,16	19,97
Cycle 16 Day 1	Local	24	32,0	24	100,0	79,86	18,38
	Central	26	37,1	23	88,5	80,43	19,88
Cycle 17 Day 1	Local	22	29,3	22	100,0	83,33	17,06
	Central	23	32,9	22	95,7	81,06	20,76
Cycle 18 Day 1	Local	20	26,7	19	95,0	80,70	18,64
	Central	21	30,0	18	85,7	75,93	19,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	75,49	29,53
	Central	17	24,3	16	94,1	78,13	17,97
Cycle 20 Day 1	Local	19	25,3	17	89,5	77,45	25,65
	Central	17	24,3	15	88,2	77,78	19,59
Cycle 21 Day 1	Local	14	18,7	12	85,7	75,00	21,90
	Central	15	21,4	14	93,3	75,00	19,34
Cycle 22 Day 1	Local	14	18,7	12	85,7	79,17	21,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	74,36	22,17
Cycle 23 Day 1	Local	11	14,7	10	90,9	81,67	16,57
	Central	10	14,3	8	80,0	81,25	22,60
Cycle 24 Day 1	Local	11	14,7	10	90,9	78,33	23,64
	Central	9	12,9	8	88,9	81,25	24,30
Cycle 25 Day 1	Local	7	9,3	7	100,0	69,05	32,53
	Central	8	11,4	6	75,0	72,22	22,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	63,89	28,71
	Central	8	11,4	6	75,0	77,78	25,09
Cycle 27 Day 1	Local	4	5,3	4	100,0	66,67	30,43
	Central	7	10,0	4	57,1	62,50	28,46
Cycle 28 Day 1	Local	4	5,3	4	100,0	58,33	31,91
	Central	6	8,6	5	83,3	60,00	25,28
Cycle 29 Day 1	Local	3	4,0	3	100,0	61,11	25,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	54,17	34,36
Cycle 30 Day 1	Local	3	4,0	3	100,0	61,11	19,25
	Central	4	5,7	2	50,0	66,67	23,57
Cycle 31 Day 1	Local	3	4,0	3	100,0	72,22	9,62
	Central	4	5,7	2	50,0	66,67	23,57
Cycle 32 Day 1	Local	3	4,0	3	100,0	66,67	16,67
	Central	3	4,3	2	66,7	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	50,00	-
	Central	1	1,4	1	100,0	83,33	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	72,92	16,16
	Central	32	45,7	20	62,5	74,17	19,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	83,21	17,04
	No	10	100,0	10	100,0	76,67	23,83
Cycle 2 Day 1	Yes	129	95,6	118	91,5	80,23	20,55
	No	7	70,0	7	100,0	66,67	28,87
Cycle 3 Day 1	Yes	124	91,9	112	90,3	75,60	21,57
	No	7	70,0	6	85,7	63,89	26,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	79,50	19,92
	No	7	70,0	7	100,0	78,57	20,89
Cycle 5 Day 1	Yes	117	86,7	112	95,7	77,83	18,37
	No	7	70,0	6	85,7	75,00	17,48
Cycle 6 Day 1	Yes	114	84,4	105	92,1	77,78	18,87
	No	7	70,0	7	100,0	64,29	20,25
Cycle 7 Day 1	Yes	106	78,5	99	93,4	78,45	18,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	57,14	37,09
Cycle 8 Day 1	Yes	100	74,1	91	91,0	78,02	19,70
	No	6	60,0	6	100,0	58,33	27,39
Cycle 9 Day 1	Yes	92	68,1	90	97,8	78,15	20,70
	No	6	60,0	6	100,0	69,44	22,15
Cycle 10 Day 1	Yes	83	61,5	80	96,4	76,67	21,15
	No	6	60,0	6	100,0	75,00	9,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	80,18	17,59
	No	4	40,0	4	100,0	66,67	13,61
Cycle 12 Day 1	Yes	72	53,3	65	90,3	81,03	19,29
	No	4	40,0	4	100,0	62,50	34,36
Cycle 13 Day 1	Yes	64	47,4	60	93,8	81,94	18,74
	No	2	20,0	2	100,0	41,67	11,79
Cycle 14 Day 1	Yes	58	43,0	55	94,8	79,09	20,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	33,33	0,00
Cycle 15 Day 1	Yes	55	40,7	52	94,5	80,13	18,97
	No	2	20,0	2	100,0	25,00	35,36
Cycle 16 Day 1	Yes	48	35,6	45	93,8	81,11	18,67
	No	2	20,0	2	100,0	58,33	11,79
Cycle 17 Day 1	Yes	43	31,9	42	97,7	82,94	18,58
	No	2	20,0	2	100,0	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	80,00	17,53
	No	2	20,0	2	100,0	50,00	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	79,17	20,30
	No	2	20,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	80,00	21,17
	No	2	20,0	2	100,0	41,67	11,79
Cycle 21 Day 1	Yes	27	20,0	24	88,9	77,08	18,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	50,00	23,57
Cycle 22 Day 1	Yes	27	20,0	23	85,2	79,71	19,43
	No	2	20,0	2	100,0	41,67	11,79
Cycle 23 Day 1	Yes	20	14,8	17	85,0	81,37	19,44
	No	1	10,0	1	100,0	83,33	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	78,43	23,40
	No	1	10,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	75,00	23,03
	No	1	10,0	1	100,0	16,67	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	74,24	25,13
	No	1	10,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	69,05	26,23
	No	1	10,0	1	100,0	33,33	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	62,50	26,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	55,56	31,03
	No	1	10,0	1	100,0	66,67	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	66,67	19,25
	No	1	10,0	1	100,0	50,00	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	70,83	15,96
	No	1	10,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	66,67	19,25
	No	1	10,0	1	100,0	66,67	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	66,67	23,57
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	73,64	17,53
	No	2	20,0	1	50,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	78,79	21,20
	No	134	100,0	131	97,8	83,08	17,29
Cycle 2 Day 1	Yes	7	63,6	7	100,0	88,10	12,60
	No	129	96,3	118	91,5	78,95	21,51
Cycle 3 Day 1	Yes	7	63,6	7	100,0	76,19	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	74,92	21,77
Cycle 4 Day 1	Yes	7	63,6	7	100,0	85,71	17,82
	No	121	90,3	113	93,4	79,06	20,02
Cycle 5 Day 1	Yes	7	63,6	7	100,0	76,19	21,21
	No	117	87,3	111	94,9	77,78	18,16
Cycle 6 Day 1	Yes	7	63,6	7	100,0	80,95	15,00
	No	114	85,1	105	92,1	76,67	19,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	76,19	23,29
	No	106	79,1	99	93,4	77,10	20,84
Cycle 8 Day 1	Yes	7	63,6	7	100,0	69,05	29,55
	No	99	73,9	90	90,9	77,41	19,88
Cycle 9 Day 1	Yes	6	54,5	6	100,0	77,78	20,18
	No	92	68,7	90	97,8	77,59	20,93
Cycle 10 Day 1	Yes	6	54,5	6	100,0	80,56	19,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	76,25	20,67
Cycle 11 Day 1	Yes	6	54,5	6	100,0	77,78	20,18
	No	74	55,2	72	97,3	79,63	17,52
Cycle 12 Day 1	Yes	6	54,5	6	100,0	80,56	22,15
	No	70	52,2	63	90,0	79,89	20,56
Cycle 13 Day 1	Yes	5	45,5	5	100,0	83,33	16,67
	No	61	45,5	57	93,4	80,41	20,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	76,67	27,89
	No	55	41,0	52	94,5	77,56	21,61
Cycle 15 Day 1	Yes	4	36,4	4	100,0	75,00	31,91
	No	53	39,6	50	94,3	78,33	21,36
Cycle 16 Day 1	Yes	3	27,3	3	100,0	88,89	19,25
	No	47	35,1	44	93,6	79,55	18,97
Cycle 17 Day 1	Yes	3	27,3	3	100,0	94,44	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	81,30	19,07
Cycle 18 Day 1	Yes	3	27,3	3	100,0	88,89	19,25
	No	38	28,4	34	89,5	77,45	18,75
Cycle 19 Day 1	Yes	3	27,3	3	100,0	88,89	19,25
	No	33	24,6	30	90,9	75,56	24,66
Cycle 20 Day 1	Yes	3	27,3	3	100,0	88,89	19,25
	No	33	24,6	29	87,9	76,44	22,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	66,67	0,00
	No	27	20,1	24	88,9	75,69	20,84
Cycle 22 Day 1	Yes	2	18,2	2	100,0	83,33	23,57
	No	27	20,1	23	85,2	76,09	21,80
Cycle 23 Day 1	Yes	2	18,2	2	100,0	83,33	23,57
	No	19	14,2	16	84,2	81,25	19,12
Cycle 24 Day 1	Yes	2	18,2	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	79,17	23,96
Cycle 25 Day 1	Yes	2	18,2	2	100,0	83,33	23,57
	No	13	9,7	11	84,6	68,18	28,34
Cycle 26 Day 1	Yes	1	9,1	1	100,0	50,00	-
	No	13	9,7	11	84,6	72,73	27,15
Cycle 27 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	10	7,5	7	70,0	69,05	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	50,00	-
	No	9	6,7	8	88,9	60,42	28,08
Cycle 29 Day 1	Yes	1	9,1	1	100,0	16,67	-
	No	8	6,0	6	75,0	63,89	24,53
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	63,33	18,26
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	70,00	13,94
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	66,67	16,67
Cycle 33 Day 1	No	2	1,5	2	100,0	66,67	23,57
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	50,00	28,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	75,20	15,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CF_SG.xls
24JUN2020 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	16,67	24,71
Cycle 2 Day 1	All	136	93,8	126	92,6	37,04	31,05
Cycle 3 Day 1	All	131	90,3	118	90,1	38,14	30,59
Cycle 4 Day 1	All	128	88,3	120	93,8	34,17	30,39
Cycle 5 Day 1	All	124	85,5	118	95,2	34,46	28,56
Cycle 6 Day 1	All	121	83,4	112	92,6	34,23	28,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	34,91	29,95
Cycle 8 Day 1	All	106	73,1	97	91,5	30,93	28,16
Cycle 9 Day 1	All	98	67,6	96	98,0	31,25	26,85
Cycle 10 Day 1	All	89	61,4	86	96,6	28,68	25,65
Cycle 11 Day 1	All	80	55,2	78	97,5	26,92	25,80
Cycle 12 Day 1	All	76	52,4	69	90,8	24,15	25,49
Cycle 13 Day 1	All	66	45,5	62	93,9	27,42	23,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	29,82	29,33
Cycle 15 Day 1	All	57	39,3	54	94,7	30,25	29,15
Cycle 16 Day 1	All	50	34,5	47	94,0	25,53	29,66
Cycle 17 Day 1	All	45	31,0	44	97,8	28,03	27,79
Cycle 18 Day 1	All	41	28,3	37	90,2	24,32	27,94
Cycle 19 Day 1	All	36	24,8	33	91,7	27,27	29,41
Cycle 20 Day 1	All	36	24,8	32	88,9	25,00	29,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	29,49	28,79
Cycle 22 Day 1	All	29	20,0	25	86,2	29,33	27,76
Cycle 23 Day 1	All	21	14,5	18	85,7	31,48	33,28
Cycle 24 Day 1	All	20	13,8	18	90,0	24,07	25,06
Cycle 25 Day 1	All	15	10,3	13	86,7	28,21	29,96
Cycle 26 Day 1	All	14	9,7	12	85,7	22,22	32,82
Cycle 27 Day 1	All	11	7,6	8	72,7	33,33	35,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	18,52	24,22
Cycle 29 Day 1	All	9	6,2	7	77,8	38,10	23,00
Cycle 30 Day 1	All	7	4,8	5	71,4	33,33	23,57
Cycle 31 Day 1	All	7	4,8	5	71,4	33,33	23,57
Cycle 32 Day 1	All	6	4,1	5	83,3	40,00	14,91
Cycle 33 Day 1	All	2	1,4	2	100,0	50,00	23,57
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	25,76	22,58
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	15,69	26,12
	Female	93	100,0	91	97,8	17,22	24,02
Cycle 2 Day 1	Male	50	96,2	47	94,0	41,84	32,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	34,18	29,71
Cycle 3 Day 1	Male	47	90,4	42	89,4	38,89	30,28
	Female	84	90,3	76	90,5	37,72	30,96
Cycle 4 Day 1	Male	46	88,5	45	97,8	34,81	30,94
	Female	82	88,2	75	91,5	33,78	30,26
Cycle 5 Day 1	Male	45	86,5	43	95,6	36,43	27,04
	Female	79	84,9	75	94,9	33,33	29,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	37,40	30,91
	Female	76	81,7	71	93,4	32,39	27,59
Cycle 7 Day 1	Male	40	76,9	39	97,5	37,61	32,61
	Female	73	78,5	67	91,8	33,33	28,43
Cycle 8 Day 1	Male	37	71,2	34	91,9	33,33	30,70
	Female	69	74,2	63	91,3	29,63	26,85
Cycle 9 Day 1	Male	33	63,5	33	100,0	34,34	26,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	29,63	26,85
Cycle 10 Day 1	Male	30	57,7	30	100,0	31,11	27,59
	Female	59	63,4	56	94,9	27,38	24,71
Cycle 11 Day 1	Male	29	55,8	29	100,0	28,74	27,78
	Female	51	54,8	49	96,1	25,85	24,78
Cycle 12 Day 1	Male	27	51,9	26	96,3	29,49	28,79
	Female	49	52,7	43	87,8	20,93	23,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	33,33	24,62
	Female	41	44,1	39	95,1	23,93	22,88
Cycle 14 Day 1	Male	23	44,2	21	91,3	31,75	32,45
	Female	37	39,8	36	97,3	28,70	27,78
Cycle 15 Day 1	Male	21	40,4	20	95,2	31,67	31,48
	Female	36	38,7	34	94,4	29,41	28,15
Cycle 16 Day 1	Male	16	30,8	16	100,0	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	21,51	30,49
Cycle 17 Day 1	Male	13	25,0	13	100,0	30,77	28,74
	Female	32	34,4	31	96,9	26,88	27,78
Cycle 18 Day 1	Male	12	23,1	11	91,7	27,27	29,13
	Female	29	31,2	26	89,7	23,08	27,92
Cycle 19 Day 1	Male	10	19,2	10	100,0	40,00	37,84
	Female	26	28,0	23	88,5	21,74	23,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	29,63	38,89
	Female	26	28,0	23	88,5	23,19	25,49
Cycle 21 Day 1	Male	8	15,4	8	100,0	41,67	38,83
	Female	21	22,6	18	85,7	24,07	22,30
Cycle 22 Day 1	Male	8	15,4	6	75,0	33,33	42,16
	Female	21	22,6	19	90,5	28,07	22,94
Cycle 23 Day 1	Male	5	9,6	4	80,0	41,67	41,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	28,57	31,64
Cycle 24 Day 1	Male	5	9,6	4	80,0	41,67	31,91
	Female	15	16,1	14	93,3	19,05	21,54
Cycle 25 Day 1	Male	3	5,8	2	66,7	33,33	47,14
	Female	12	12,9	11	91,7	27,27	29,13
Cycle 26 Day 1	Male	3	5,8	2	66,7	33,33	47,14
	Female	11	11,8	10	90,9	20,00	32,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	16,67	23,57
	Female	8	8,6	6	75,0	38,89	38,97
Cycle 28 Day 1	Male	2	3,8	2	100,0	33,33	47,14
	Female	8	8,6	7	87,5	14,29	17,82
Cycle 29 Day 1	Male	1	1,9	1	100,0	66,67	-
	Female	8	8,6	6	75,0	33,33	21,08
Cycle 30 Day 1	Male	1	1,9	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	25,00	16,67
Cycle 31 Day 1	Male	1	1,9	1	100,0	66,67	-
	Female	6	6,5	4	66,7	25,00	16,67
Cycle 32 Day 1	Male	1	1,9	1	100,0	66,67	-
	Female	5	5,4	4	80,0	33,33	0,00
Cycle 33 Day 1	Male	1	1,9	1	100,0	66,67	-
	Female	1	1,1	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	28,57	24,23
	Female	37	39,8	23	62,2	23,19	21,17
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	15,09	24,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	19,54	26,00
	>=75	7	100,0	7	100,0	28,57	12,60
Cycle 2 Day 1	18-64	103	94,5	94	91,3	37,94	33,37
	65-74	26	89,7	25	96,2	37,33	24,19
	>=75	7	100,0	7	100,0	23,81	16,27
Cycle 3 Day 1	18-64	99	90,8	87	87,9	37,55	31,25
	65-74	25	86,2	24	96,0	40,28	29,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	38,10	29,99
Cycle 4 Day 1	18-64	98	89,9	92	93,9	33,33	31,25
	65-74	23	79,3	21	91,3	36,51	27,70
	>=75	7	100,0	7	100,0	38,10	29,99
Cycle 5 Day 1	18-64	95	87,2	90	94,7	34,07	28,26
	65-74	22	75,9	22	100,0	33,33	29,10
	>=75	7	100,0	6	85,7	44,44	34,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	34,92	30,13
	65-74	22	75,9	21	95,5	30,16	20,83
	>=75	7	100,0	7	100,0	38,10	35,63
Cycle 7 Day 1	18-64	86	78,9	81	94,2	36,63	31,00
	65-74	20	69,0	19	95,0	28,07	20,07
	>=75	7	100,0	6	85,7	33,33	42,16
Cycle 8 Day 1	18-64	80	73,4	72	90,0	31,94	30,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	29,82	21,93
	>=75	7	100,0	6	85,7	22,22	17,21
Cycle 9 Day 1	18-64	74	67,9	73	98,6	29,68	28,63
	65-74	18	62,1	18	100,0	37,04	19,43
	>=75	6	85,7	5	83,3	33,33	23,57
Cycle 10 Day 1	18-64	69	63,3	66	95,7	28,79	26,07
	65-74	15	51,7	15	100,0	26,67	25,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	33,33	23,57
Cycle 11 Day 1	18-64	61	56,0	59	96,7	27,12	25,88
	65-74	15	51,7	15	100,0	28,89	27,79
	>=75	4	57,1	4	100,0	16,67	19,25
Cycle 12 Day 1	18-64	57	52,3	51	89,5	24,84	25,68
	65-74	15	51,7	14	93,3	23,81	27,51
	>=75	4	57,1	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	24,64	22,70
	65-74	13	44,8	12	92,3	33,33	28,43
	>=75	4	57,1	4	100,0	41,67	16,67
Cycle 14 Day 1	18-64	45	41,3	44	97,8	25,76	26,77
	65-74	13	44,8	11	84,6	42,42	36,79
	>=75	2	28,6	2	100,0	50,00	23,57
Cycle 15 Day 1	18-64	43	39,4	41	95,3	28,46	27,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	36,36	34,82
	>=75	2	28,6	2	100,0	33,33	47,14
Cycle 16 Day 1	18-64	38	34,9	36	94,7	23,15	29,62
	65-74	10	34,5	9	90,0	37,04	30,93
	>=75	2	28,6	2	100,0	16,67	23,57
Cycle 17 Day 1	18-64	36	33,0	35	97,2	28,57	28,17
	65-74	8	27,6	8	100,0	29,17	27,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	0,00	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	22,22	28,14
	65-74	7	24,1	6	85,7	38,89	25,09
	>=75	1	14,3	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	27,38	30,16
	65-74	5	17,2	4	80,0	33,33	27,22
	>=75	1	14,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	25,64	30,27
	65-74	5	17,2	5	100,0	26,67	27,89
	>=75	1	14,3	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	31,75	30,69
	65-74	4	13,8	4	100,0	25,00	16,67
	>=75	1	14,3	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	31,67	29,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	25,00	16,67
	>=75	1	14,3	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	31,25	35,42
	65-74	2	6,9	2	100,0	33,33	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	22,92	26,44
	65-74	2	6,9	2	100,0	33,33	0,00
Cycle 25 Day 1	18-64	14	12,8	12	85,7	27,78	31,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	33,33	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	22,22	32,82
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	33,33	35,63
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	18,52	24,22
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	38,10	23,00
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	33,33	23,57
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	33,33	23,57
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	41,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	33,33	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	66,67	-
	65-74	1	3,4	1	100,0	33,33	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	25,49	23,30
	65-74	15	51,7	8	53,3	29,17	21,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	16,67	23,57
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	17,82	27,37
	Other	85	100,0	84	98,8	15,87	22,84
Cycle 2 Day 1	White	57	95,0	51	89,5	31,37	27,82
	Other	79	92,9	75	94,9	40,89	32,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	37,88	28,39
	Other	77	90,6	74	96,1	38,29	32,02
Cycle 4 Day 1	White	53	88,3	47	88,7	30,50	27,65
	Other	75	88,2	73	97,3	36,53	31,99
Cycle 5 Day 1	White	52	86,7	48	92,3	29,17	23,44
	Other	72	84,7	70	97,2	38,10	31,23
Cycle 6 Day 1	White	50	83,3	44	88,0	33,33	25,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	34,80	30,71
Cycle 7 Day 1	White	47	78,3	42	89,4	27,78	26,46
	Other	66	77,6	64	97,0	39,58	31,36
Cycle 8 Day 1	White	45	75,0	39	86,7	27,35	22,78
	Other	61	71,8	58	95,1	33,33	31,22
Cycle 9 Day 1	White	42	70,0	41	97,6	29,27	22,60
	Other	56	65,9	55	98,2	32,73	29,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	27,35	21,46
	Other	48	56,5	47	97,9	29,79	28,85
Cycle 11 Day 1	White	37	61,7	37	100,0	28,83	22,45
	Other	43	50,6	41	95,3	25,20	28,66
Cycle 12 Day 1	White	37	61,7	33	89,2	29,29	28,57
	Other	39	45,9	36	92,3	19,44	21,64
Cycle 13 Day 1	White	32	53,3	30	93,8	27,78	21,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	27,08	26,01
Cycle 14 Day 1	White	31	51,7	30	96,8	32,22	29,66
	Other	29	34,1	27	93,1	27,16	29,29
Cycle 15 Day 1	White	30	50,0	28	93,3	33,33	27,22
	Other	27	31,8	26	96,3	26,92	31,30
Cycle 16 Day 1	White	26	43,3	24	92,3	23,61	28,62
	Other	24	28,2	23	95,8	27,54	31,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	27,78	25,38
	Other	21	24,7	20	95,2	28,33	31,11
Cycle 18 Day 1	White	22	36,7	19	86,4	22,81	29,51
	Other	19	22,4	18	94,7	25,93	26,95
Cycle 19 Day 1	White	20	33,3	20	100,0	28,33	27,09
	Other	16	18,8	13	81,3	25,64	33,76
Cycle 20 Day 1	White	20	33,3	17	85,0	21,57	23,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	28,89	35,34
Cycle 21 Day 1	White	16	26,7	14	87,5	26,19	26,73
	Other	13	15,3	12	92,3	33,33	31,78
Cycle 22 Day 1	White	16	26,7	13	81,3	25,64	24,17
	Other	13	15,3	12	92,3	33,33	31,78
Cycle 23 Day 1	White	12	20,0	10	83,3	30,00	33,15
	Other	9	10,6	8	88,9	33,33	35,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	20,00	23,31
	Other	9	10,6	8	88,9	29,17	27,82
Cycle 25 Day 1	White	10	16,7	8	80,0	25,00	23,57
	Other	5	5,9	5	100,0	33,33	40,82
Cycle 26 Day 1	White	10	16,7	8	80,0	16,67	25,20
	Other	4	4,7	4	100,0	33,33	47,14
Cycle 27 Day 1	White	8	13,3	5	62,5	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	55,56	50,92
Cycle 28 Day 1	White	7	11,7	6	85,7	16,67	27,89
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 29 Day 1	White	6	10,0	4	66,7	33,33	27,22
	Other	3	3,5	3	100,0	44,44	19,25
Cycle 30 Day 1	White	4	6,7	2	50,0	50,00	23,57
	Other	3	3,5	3	100,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	50,00	23,57
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 32 Day 1	White	4	6,7	3	75,0	44,44	19,25
	Other	2	2,4	2	100,0	33,33	0,00
Cycle 33 Day 1	White	2	3,3	2	100,0	50,00	23,57
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	27,45	21,20
	Other	39	45,9	27	69,2	24,69	23,74
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	15,83	23,86
	Europe (EU)	34	100,0	31	91,2	11,83	23,65
	Asia (AS)	71	100,0	71	100,0	19,25	25,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	33	86,8	36,36	29,30
	Europe (EU)	32	94,1	28	87,5	32,14	32,05
	Asia (AS)	66	93,0	65	98,5	39,49	31,67
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	40,40	32,01
	Europe (EU)	31	91,2	22	71,0	36,36	32,38
	Asia (AS)	63	88,7	63	100,0	37,57	29,63
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	30,39	25,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	29,33	29,38
	Asia (AS)	61	85,9	61	100,0	38,25	33,24
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	31,43	27,94
	Europe (EU)	30	88,2	26	86,7	33,33	23,09
	Asia (AS)	57	80,3	57	100,0	36,84	31,30
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	33,33	29,15
	Europe (EU)	28	82,4	25	89,3	29,33	24,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	37,18	30,72
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	30,21	27,25
	Europe (EU)	28	82,4	25	89,3	28,00	28,35
	Asia (AS)	50	70,4	49	98,0	41,50	31,57
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	28,40	27,27
	Europe (EU)	28	82,4	23	82,1	23,19	23,43
	Asia (AS)	47	66,2	47	100,0	36,17	30,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	25,00	21,52
	Europe (EU)	26	76,5	25	96,2	29,33	22,19
	Asia (AS)	43	60,6	43	100,0	36,43	31,55
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	16,67	19,66
	Europe (EU)	25	73,5	25	100,0	25,33	24,11
	Asia (AS)	37	52,1	37	100,0	38,74	26,66
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	18,84	19,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	28,79	25,81
	Asia (AS)	33	46,5	33	100,0	31,31	28,79
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	18,84	22,08
	Europe (EU)	23	67,6	18	78,3	29,63	32,11
	Asia (AS)	29	40,8	28	96,6	25,00	23,35
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	21,21	19,37
	Europe (EU)	18	52,9	15	83,3	26,67	22,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	33,33	27,22
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	19,05	24,88
	Europe (EU)	17	50,0	16	94,1	33,33	27,22
	Asia (AS)	21	29,6	20	95,2	38,33	32,94
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	21,67	22,36
	Europe (EU)	15	44,1	14	93,3	33,33	34,59
	Asia (AS)	20	28,2	20	100,0	36,67	30,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	19,61	23,74
	Europe (EU)	14	41,2	11	78,6	27,27	32,72
	Asia (AS)	19	26,8	19	100,0	29,82	33,14
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	16,67	21,08
	Europe (EU)	13	38,2	12	92,3	30,56	26,43
	Asia (AS)	16	22,5	16	100,0	37,50	31,91
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	11,90	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	33,33	27,22
	Asia (AS)	16	22,5	16	100,0	31,25	33,26
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	23,08	25,04
	Europe (EU)	9	26,5	9	100,0	33,33	28,87
	Asia (AS)	14	19,7	11	78,6	27,27	35,96
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	17,95	22,01
	Europe (EU)	9	26,5	6	66,7	22,22	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	33,33	36,00
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	20,00	23,31
	Europe (EU)	7	20,6	6	85,7	33,33	29,81
	Asia (AS)	11	15,5	10	90,9	36,67	33,15
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	23,33	22,50
	Europe (EU)	7	20,6	5	71,4	26,67	27,89
	Asia (AS)	11	15,5	10	90,9	36,67	33,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	29,63	35,14
	Europe (EU)	5	14,7	3	60,0	22,22	19,25
	Asia (AS)	7	9,9	6	85,7	38,89	38,97
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	16,67	25,20
	Europe (EU)	5	14,7	4	80,0	16,67	19,25
	Asia (AS)	7	9,9	6	85,7	38,89	25,09
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	23,81	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	16,67	23,57
	Asia (AS)	4	5,6	4	100,0	41,67	41,94
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	16,67	27,89
	Europe (EU)	4	11,8	2	50,0	16,67	23,57
	Asia (AS)	4	5,6	4	100,0	33,33	47,14
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	16,67	19,25
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	50,00	43,03
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	25,00	31,91
	Europe (EU)	2	5,9	1	50,0	0,00	-
	Asia (AS)	4	5,6	4	100,0	16,67	19,25
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	33,33	33,33
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	41,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	50,00	23,57
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	22,22	19,25
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	50,00	23,57
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	22,22	19,25
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	33,33	-
	Asia (AS)	3	4,2	2	66,7	33,33	0,00
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	66,67	-
	Europe (EU)	1	2,9	1	100,0	33,33	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	25,49	25,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	20,00	18,26
	Asia (AS)	34	47,9	22	64,7	27,27	22,15
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	12,78	21,34
	1	69	100,0	67	97,1	18,41	26,13
	2	15	100,0	15	100,0	24,44	29,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	56	94,9	37,50	33,07
	1	67	97,1	60	89,6	37,22	29,49
	2	10	66,7	10	100,0	33,33	31,43
Cycle 3 Day 1	0	57	93,4	51	89,5	39,87	31,28
	1	65	94,2	58	89,2	36,21	29,48
	2	9	60,0	9	100,0	40,74	36,43
Cycle 4 Day 1	0	57	93,4	54	94,7	36,42	30,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	33,33	31,22
	2	9	60,0	8	88,9	25,00	23,57
Cycle 5 Day 1	0	56	91,8	53	94,6	38,36	28,04
	1	62	89,9	59	95,2	32,20	29,66
	2	6	40,0	6	100,0	22,22	17,21
Cycle 6 Day 1	0	56	91,8	54	96,4	33,33	29,67
	1	59	85,5	53	89,8	35,85	29,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	26,67	14,91
Cycle 7 Day 1	0	54	88,5	51	94,4	33,33	29,06
	1	54	78,3	50	92,6	38,00	31,59
	2	5	33,3	5	100,0	20,00	18,26
Cycle 8 Day 1	0	52	85,2	48	92,3	31,94	28,32
	1	49	71,0	44	89,8	31,82	28,71
	2	5	33,3	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	32,65	27,63
	1	44	63,8	43	97,7	31,01	26,62
	2	4	26,7	4	100,0	16,67	19,25
Cycle 10 Day 1	0	46	75,4	46	100,0	30,43	27,96
	1	40	58,0	37	92,5	27,93	22,92
	2	3	20,0	3	100,0	11,11	19,25
Cycle 11 Day 1	0	43	70,5	41	95,3	26,83	22,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	28,43	29,74
	2	3	20,0	3	100,0	11,11	19,25
Cycle 12 Day 1	0	42	68,9	36	85,7	27,78	28,17
	1	31	44,9	30	96,8	20,00	20,72
	2	3	20,0	3	100,0	22,22	38,49
Cycle 13 Day 1	0	38	62,3	34	89,5	27,45	25,25
	1	27	39,1	27	100,0	28,40	22,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	31,25	31,61
	1	24	34,8	24	100,0	29,17	26,58
	2	1	6,7	1	100,0	0,00	-
Cycle 15 Day 1	0	33	54,1	30	90,9	33,33	27,68
	1	23	33,3	23	100,0	27,54	31,22
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	28,00	26,67
	1	21	30,4	21	100,0	23,81	33,57
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	24,64	25,06
	1	20	29,0	20	100,0	33,33	30,59
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	21,05	25,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	29,41	30,92
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	26,32	28,50
	1	15	21,7	13	86,7	30,77	31,80
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	23,53	25,72
	1	15	21,7	14	93,3	28,57	34,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	26,19	26,73
	1	13	18,8	11	84,6	36,36	31,46
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	22,22	21,71
	1	13	18,8	12	92,3	38,89	31,25
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	29,63	35,14
	1	9	13,0	8	88,9	37,50	33,03
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	18,52	24,22
	1	9	13,0	8	88,9	33,33	25,20
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	22,22	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	33,33	33,33
Cycle 26 Day 1	0	8	13,1	6	75,0	11,11	27,22
	1	6	8,7	6	100,0	33,33	36,51
Cycle 27 Day 1	0	6	9,8	3	50,0	22,22	19,25
	1	5	7,2	5	100,0	40,00	43,46
Cycle 28 Day 1	0	5	8,2	4	80,0	16,67	33,33
	1	5	7,2	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	50,00	23,57
	1	5	7,2	5	100,0	33,33	23,57
Cycle 30 Day 1	0	3	4,9	1	33,3	66,67	-
	1	4	5,8	4	100,0	25,00	16,67
Cycle 31 Day 1	0	3	4,9	1	33,3	66,67	-
	1	4	5,8	4	100,0	25,00	16,67
Cycle 32 Day 1	0	3	4,9	2	66,7	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	33,33	0,00
Cycle 33 Day 1	0	2	3,3	2	100,0	50,00	23,57
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	23,81	23,90
	1	34	49,3	20	58,8	25,00	21,29
	2	7	46,7	3	42,9	44,44	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	12,22	19,38
	1	4	100,0	4	100,0	25,00	31,91
	2 or More	79	100,0	78	98,7	19,66	27,62
Cycle 2 Day 1	None	60	96,8	55	91,7	32,73	32,39
	1	3	75,0	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	40,58	30,18
Cycle 3 Day 1	None	59	95,2	53	89,8	36,48	29,43
	1	3	75,0	2	66,7	33,33	0,00
	2 or More	69	87,3	63	91,3	39,68	32,16
Cycle 4 Day 1	None	59	95,2	56	94,9	36,31	31,96
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	66	83,5	62	93,9	33,33	28,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	34,52	27,68
	1	3	75,0	3	100,0	22,22	19,25
	2 or More	63	79,7	59	93,7	35,03	29,96
Cycle 6 Day 1	None	57	91,9	52	91,2	31,41	25,06
	1	3	75,0	3	100,0	33,33	0,00
	2 or More	61	77,2	57	93,4	36,84	32,54
Cycle 7 Day 1	None	52	83,9	50	96,2	32,67	30,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	22,22	19,25
	2 or More	58	73,4	53	91,4	37,74	29,98
Cycle 8 Day 1	None	50	80,6	46	92,0	31,16	28,46
	1	3	75,0	1	33,3	33,33	-
	2 or More	53	67,1	50	94,3	30,67	28,44
Cycle 9 Day 1	None	48	77,4	47	97,9	26,95	22,67
	1	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	35,42	30,29
Cycle 10 Day 1	None	43	69,4	41	95,3	23,58	21,40
	1	1	25,0	1	100,0	33,33	-
	2 or More	45	57,0	44	97,8	33,33	28,76
Cycle 11 Day 1	None	37	59,7	35	94,6	26,67	23,98
	1	1	25,0	1	100,0	33,33	-
	2 or More	42	53,2	42	100,0	26,98	27,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	27,45	28,98
	1	1	25,0	1	100,0	33,33	-
	2 or More	38	48,1	34	89,5	20,59	21,73
Cycle 13 Day 1	None	34	54,8	30	88,2	26,67	22,15
	1	1	25,0	1	100,0	33,33	-
	2 or More	31	39,2	31	100,0	27,96	25,96
Cycle 14 Day 1	None	31	50,0	29	93,5	29,89	32,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	33,33	-
	2 or More	28	35,4	27	96,4	29,63	26,69
Cycle 15 Day 1	None	30	48,4	28	93,3	26,19	24,61
	1	1	25,0	1	100,0	33,33	-
	2 or More	26	32,9	25	96,2	34,67	33,99
Cycle 16 Day 1	None	25	40,3	23	92,0	23,19	25,49
	1	1	25,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	26,09	33,27
Cycle 17 Day 1	None	23	37,1	22	95,7	28,79	29,63
	1	1	25,0	1	100,0	33,33	-
	2 or More	21	26,6	21	100,0	26,98	27,12
Cycle 18 Day 1	None	20	32,3	18	90,0	20,37	25,92
	1	1	25,0	1	100,0	33,33	-
	2 or More	20	25,3	18	90,0	27,78	30,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	25,49	27,71
	1	1	25,0	1	100,0	66,67	-
	2 or More	18	22,8	15	83,3	26,67	31,37
Cycle 20 Day 1	None	17	27,4	16	94,1	22,92	29,11
	1	1	25,0	1	100,0	33,33	-
	2 or More	18	22,8	15	83,3	26,67	31,37
Cycle 21 Day 1	None	15	24,2	13	86,7	28,21	26,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	30,77	31,80
Cycle 22 Day 1	None	15	24,2	13	86,7	28,21	26,69
	2 or More	14	17,7	12	85,7	30,56	30,01
Cycle 23 Day 1	None	10	16,1	9	90,0	18,52	24,22
	2 or More	11	13,9	9	81,8	44,44	37,27
Cycle 24 Day 1	None	10	16,1	10	100,0	20,00	23,31
	2 or More	10	12,7	8	80,0	29,17	27,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	20,83	24,80
	2 or More	6	7,6	5	83,3	40,00	36,51
Cycle 26 Day 1	None	8	12,9	8	100,0	25,00	38,83
	2 or More	6	7,6	4	66,7	16,67	19,25
Cycle 27 Day 1	None	7	11,3	6	85,7	33,33	36,51
	2 or More	4	5,1	2	50,0	33,33	47,14
Cycle 28 Day 1	None	7	11,3	7	100,0	19,05	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	9,7	5	83,3	33,33	23,57
	2 or More	3	3,8	2	66,7	50,00	23,57
Cycle 30 Day 1	None	4	6,5	3	75,0	44,44	19,25
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 31 Day 1	None	4	6,5	3	75,0	44,44	19,25
	2 or More	3	3,8	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	44,44	19,25
	2 or More	2	2,5	2	100,0	33,33	0,00
Cycle 33 Day 1	None	1	1,6	1	100,0	66,67	-
	2 or More	1	1,3	1	100,0	33,33	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	22,81	22,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	33,33	-
	2 or More	39	49,4	24	61,5	27,78	23,40
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	12,22	19,38
	Previously Treated	83	100,0	82	98,8	19,92	27,65
Cycle 2 Day 1	Naïve	60	96,8	55	91,7	32,73	32,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	40,38	29,77
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	36,48	29,43
	Previously Treated	72	86,7	65	90,3	39,49	31,67
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	36,31	31,96
	Previously Treated	69	83,1	64	92,8	32,29	29,08
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	34,52	27,68
	Previously Treated	66	79,5	62	93,9	34,41	29,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	31,41	25,06
	Previously Treated	64	77,1	60	93,8	36,67	31,71
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	32,67	30,48
	Previously Treated	61	73,5	56	91,8	36,90	29,60
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	31,16	28,46
	Previously Treated	56	67,5	51	91,1	30,72	28,16
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	26,95	22,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	35,37	29,98
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	23,58	21,40
	Previously Treated	46	55,4	45	97,8	33,33	28,43
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	26,67	23,98
	Previously Treated	43	51,8	43	100,0	27,13	27,46
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	27,45	28,98
	Previously Treated	39	47,0	35	89,7	20,95	21,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	26,67	22,15
	Previously Treated	32	38,6	32	100,0	28,13	25,55
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	29,89	32,54
	Previously Treated	29	34,9	28	96,6	29,76	26,20
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	26,19	24,61
	Previously Treated	27	32,5	26	96,3	34,62	33,31
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	23,19	25,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	27,78	33,57
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	28,79	29,63
	Previously Treated	22	26,5	22	100,0	27,27	26,50
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	20,37	25,92
	Previously Treated	21	25,3	19	90,5	28,07	29,94
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	25,49	27,71
	Previously Treated	19	22,9	16	84,2	29,17	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	22,92	29,11
	Previously Treated	19	22,9	16	84,2	27,08	30,35
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	28,21	26,69
	Previously Treated	14	16,9	13	92,9	30,77	31,80
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	28,21	26,69
	Previously Treated	14	16,9	12	85,7	30,56	30,01
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	18,52	24,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	44,44	37,27
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	20,00	23,31
	Previously Treated	10	12,0	8	80,0	29,17	27,82
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	20,83	24,80
	Previously Treated	6	7,2	5	83,3	40,00	36,51
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	25,00	38,83
	Previously Treated	6	7,2	4	66,7	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	33,33	36,51
	Previously Treated	4	4,8	2	50,0	33,33	47,14
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	19,05	26,23
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	33,33	23,57
	Previously Treated	3	3,6	2	66,7	50,00	23,57
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	44,44	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	44,44	19,25
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	44,44	19,25
	Previously Treated	2	2,4	2	100,0	33,33	0,00
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	66,67	-
	Previously Treated	1	1,2	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	22,81	22,37
	Previously Treated	42	50,6	25	59,5	28,00	22,93
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	18,67	25,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	14,43	23,37
Cycle 2 Day 1	Local	71	94,7	67	94,4	34,83	29,83
	Central	65	92,9	59	90,8	39,55	32,44
Cycle 3 Day 1	Local	67	89,3	62	92,5	36,02	32,11
	Central	64	91,4	56	87,5	40,48	28,93
Cycle 4 Day 1	Local	65	86,7	61	93,8	29,51	29,25
	Central	63	90,0	59	93,7	38,98	31,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	29,94	30,76
	Central	61	87,1	59	96,7	38,98	25,64
Cycle 6 Day 1	Local	63	84,0	61	96,8	35,52	32,13
	Central	58	82,9	51	87,9	32,68	24,49
Cycle 7 Day 1	Local	61	81,3	59	96,7	32,20	29,66
	Central	52	74,3	47	90,4	38,30	30,28
Cycle 8 Day 1	Local	57	76,0	55	96,5	30,30	28,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	31,75	27,50
Cycle 9 Day 1	Local	54	72,0	53	98,1	30,82	29,12
	Central	44	62,9	43	97,7	31,78	24,07
Cycle 10 Day 1	Local	48	64,0	46	95,8	28,99	28,64
	Central	41	58,6	40	97,6	28,33	22,07
Cycle 11 Day 1	Local	40	53,3	38	95,0	24,56	27,60
	Central	40	57,1	40	100,0	29,17	24,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	22,22	23,07
	Central	40	57,1	36	90,0	25,93	27,73
Cycle 13 Day 1	Local	30	40,0	29	96,7	28,74	23,10
	Central	36	51,4	33	91,7	26,26	24,66
Cycle 14 Day 1	Local	27	36,0	27	100,0	28,40	32,95
	Central	33	47,1	30	90,9	31,11	26,16
Cycle 15 Day 1	Local	26	34,7	25	96,2	28,00	32,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	32,18	25,95
Cycle 16 Day 1	Local	24	32,0	24	100,0	25,00	34,40
	Central	26	37,1	23	88,5	26,09	24,53
Cycle 17 Day 1	Local	22	29,3	22	100,0	24,24	29,42
	Central	23	32,9	22	95,7	31,82	26,18
Cycle 18 Day 1	Local	20	26,7	19	95,0	14,04	20,23
	Central	21	30,0	18	85,7	35,19	31,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	25,49	32,34
	Central	17	24,3	16	94,1	29,17	26,87
Cycle 20 Day 1	Local	19	25,3	17	89,5	23,53	32,84
	Central	17	24,3	15	88,2	26,67	25,82
Cycle 21 Day 1	Local	14	18,7	12	85,7	25,00	32,18
	Central	15	21,4	14	93,3	33,33	26,15
Cycle 22 Day 1	Local	14	18,7	12	85,7	22,22	29,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	35,90	25,32
Cycle 23 Day 1	Local	11	14,7	10	90,9	33,33	35,14
	Central	10	14,3	8	80,0	29,17	33,03
Cycle 24 Day 1	Local	11	14,7	10	90,9	23,33	27,44
	Central	9	12,9	8	88,9	25,00	23,57
Cycle 25 Day 1	Local	7	9,3	7	100,0	23,81	25,20
	Central	8	11,4	6	75,0	33,33	36,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	33,33	42,16
	Central	8	11,4	6	75,0	11,11	17,21
Cycle 27 Day 1	Local	4	5,3	4	100,0	41,67	41,94
	Central	7	10,0	4	57,1	25,00	31,91
Cycle 28 Day 1	Local	4	5,3	4	100,0	33,33	27,22
	Central	6	8,6	5	83,3	6,67	14,91
Cycle 29 Day 1	Local	3	4,0	3	100,0	44,44	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	33,33	27,22
Cycle 30 Day 1	Local	3	4,0	3	100,0	44,44	19,25
	Central	4	5,7	2	50,0	16,67	23,57
Cycle 31 Day 1	Local	3	4,0	3	100,0	44,44	19,25
	Central	4	5,7	2	50,0	16,67	23,57
Cycle 32 Day 1	Local	3	4,0	3	100,0	44,44	19,25
	Central	3	4,3	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	66,67	-
	Central	1	1,4	1	100,0	33,33	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	30,56	23,91
	Central	32	45,7	20	62,5	20,00	19,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	16,67	24,88
	No	10	100,0	10	100,0	16,67	23,57
Cycle 2 Day 1	Yes	129	95,6	119	92,2	35,85	30,43
	No	7	70,0	7	100,0	57,14	37,09
Cycle 3 Day 1	Yes	124	91,9	112	90,3	37,50	30,06
	No	7	70,0	6	85,7	50,00	40,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	34,22	30,69
	No	7	70,0	7	100,0	33,33	27,22
Cycle 5 Day 1	Yes	117	86,7	112	95,7	34,23	28,81
	No	7	70,0	6	85,7	38,89	25,09
Cycle 6 Day 1	Yes	114	84,4	105	92,1	33,33	28,87
	No	7	70,0	7	100,0	47,62	26,23
Cycle 7 Day 1	Yes	106	78,5	99	93,4	34,01	30,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	47,62	26,23
Cycle 8 Day 1	Yes	100	74,1	91	91,0	31,50	28,70
	No	6	60,0	6	100,0	22,22	17,21
Cycle 9 Day 1	Yes	92	68,1	90	97,8	31,48	27,53
	No	6	60,0	6	100,0	27,78	13,61
Cycle 10 Day 1	Yes	83	61,5	80	96,4	28,33	26,04
	No	6	60,0	6	100,0	33,33	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	26,13	25,45
	No	4	40,0	4	100,0	41,67	31,91
Cycle 12 Day 1	Yes	72	53,3	65	90,3	24,10	26,03
	No	4	40,0	4	100,0	25,00	16,67
Cycle 13 Day 1	Yes	64	47,4	60	93,8	26,67	23,61
	No	2	20,0	2	100,0	50,00	23,57
Cycle 14 Day 1	Yes	58	43,0	55	94,8	27,88	27,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	83,33	23,57
Cycle 15 Day 1	Yes	55	40,7	52	94,5	28,85	28,79
	No	2	20,0	2	100,0	66,67	0,00
Cycle 16 Day 1	Yes	48	35,6	45	93,8	22,96	27,36
	No	2	20,0	2	100,0	83,33	23,57
Cycle 17 Day 1	Yes	43	31,9	42	97,7	25,40	25,30
	No	2	20,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	23,81	27,50
	No	2	20,0	2	100,0	33,33	47,14
Cycle 19 Day 1	Yes	34	25,2	32	94,1	26,04	29,00
	No	2	20,0	1	50,0	66,67	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	22,22	28,14
	No	2	20,0	2	100,0	66,67	0,00
Cycle 21 Day 1	Yes	27	20,0	24	88,9	29,17	30,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	33,33	0,00
Cycle 22 Day 1	Yes	27	20,0	23	85,2	28,99	28,96
	No	2	20,0	2	100,0	33,33	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	29,41	33,09
	No	1	10,0	1	100,0	66,67	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	23,53	25,72
	No	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	27,78	31,25
	No	1	10,0	1	100,0	33,33	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	15,15	22,92
	No	1	10,0	1	100,0	100,00	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	23,81	25,20
	No	1	10,0	1	100,0	100,00	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	16,67	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	38,89	25,09
	No	1	10,0	1	100,0	33,33	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	33,33	27,22
	No	1	10,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	33,33	27,22
	No	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	41,67	16,67
	No	1	10,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	50,00	23,57
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	24,81	21,93
	No	2	20,0	1	50,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	6,06	13,48
	No	134	100,0	131	97,8	17,56	25,26
Cycle 2 Day 1	Yes	7	63,6	7	100,0	28,57	29,99
	No	129	96,3	119	92,2	37,54	31,16
Cycle 3 Day 1	Yes	7	63,6	7	100,0	28,57	23,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	38,74	30,99
Cycle 4 Day 1	Yes	7	63,6	7	100,0	42,86	41,79
	No	121	90,3	113	93,4	33,63	29,71
Cycle 5 Day 1	Yes	7	63,6	7	100,0	33,33	33,33
	No	117	87,3	111	94,9	34,53	28,40
Cycle 6 Day 1	Yes	7	63,6	7	100,0	33,33	33,33
	No	114	85,1	105	92,1	34,29	28,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	28,57	35,63
	No	106	79,1	99	93,4	35,35	29,67
Cycle 8 Day 1	Yes	7	63,6	7	100,0	33,33	38,49
	No	99	73,9	90	90,9	30,74	27,47
Cycle 9 Day 1	Yes	6	54,5	6	100,0	16,67	18,26
	No	92	68,7	90	97,8	32,22	27,12
Cycle 10 Day 1	Yes	6	54,5	6	100,0	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	30,00	25,77
Cycle 11 Day 1	Yes	6	54,5	6	100,0	11,11	17,21
	No	74	55,2	72	97,3	28,24	26,04
Cycle 12 Day 1	Yes	6	54,5	6	100,0	5,56	13,61
	No	70	52,2	63	90,0	25,93	25,71
Cycle 13 Day 1	Yes	5	45,5	5	100,0	20,00	18,26
	No	61	45,5	57	93,4	28,07	24,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	20,00	18,26
	No	55	41,0	52	94,5	30,77	30,14
Cycle 15 Day 1	Yes	4	36,4	4	100,0	25,00	31,91
	No	53	39,6	50	94,3	30,67	29,23
Cycle 16 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	47	35,1	44	93,6	27,27	29,88
Cycle 17 Day 1	Yes	3	27,3	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	29,27	28,08
Cycle 18 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	38	28,4	34	89,5	26,47	28,16
Cycle 19 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	30	90,9	30,00	29,49
Cycle 20 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	29	87,9	27,59	29,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	24	88,9	31,94	28,62
Cycle 22 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	23	85,2	31,88	27,48
Cycle 23 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	19	14,2	16	84,2	35,42	33,26
Cycle 24 Day 1	Yes	2	18,2	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	25,00	25,82
Cycle 25 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	13	9,7	11	84,6	33,33	29,81
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	24,24	33,63
Cycle 27 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	10	7,5	7	70,0	33,33	38,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	9	6,7	8	88,9	20,83	24,80
Cycle 29 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	8	6,0	6	75,0	38,89	25,09
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	33,33	23,57
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	33,33	23,57
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	40,00	14,91
Cycle 33 Day 1	No	2	1,5	2	100,0	50,00	23,57
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	26,02	22,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30CO_SG.xls
24JUN2020 20:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	8,22	15,97
Cycle 2 Day 1	All	136	93,8	125	91,9	12,53	20,15
Cycle 3 Day 1	All	131	90,3	118	90,1	13,84	20,13
Cycle 4 Day 1	All	128	88,3	120	93,8	17,22	21,60
Cycle 5 Day 1	All	124	85,5	118	95,2	15,54	20,29
Cycle 6 Day 1	All	121	83,4	112	92,6	14,58	22,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	14,78	20,10
Cycle 8 Day 1	All	106	73,1	97	91,5	17,87	23,10
Cycle 9 Day 1	All	98	67,6	96	98,0	18,06	23,65
Cycle 10 Day 1	All	89	61,4	86	96,6	17,83	22,11
Cycle 11 Day 1	All	80	55,2	78	97,5	17,95	22,60
Cycle 12 Day 1	All	76	52,4	69	90,8	17,39	22,59
Cycle 13 Day 1	All	66	45,5	62	93,9	17,20	23,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	17,54	25,28
Cycle 15 Day 1	All	57	39,3	54	94,7	16,05	19,14
Cycle 16 Day 1	All	50	34,5	47	94,0	16,31	21,84
Cycle 17 Day 1	All	45	31,0	44	97,8	16,67	25,42
Cycle 18 Day 1	All	41	28,3	37	90,2	14,41	22,96
Cycle 19 Day 1	All	36	24,8	33	91,7	22,22	28,46
Cycle 20 Day 1	All	36	24,8	32	88,9	22,92	29,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	16,67	27,08
Cycle 22 Day 1	All	29	20,0	25	86,2	13,33	21,52
Cycle 23 Day 1	All	21	14,5	18	85,7	18,52	28,52
Cycle 24 Day 1	All	20	13,8	18	90,0	18,52	30,73
Cycle 25 Day 1	All	15	10,3	13	86,7	20,51	28,99
Cycle 26 Day 1	All	14	9,7	12	85,7	19,44	30,01
Cycle 27 Day 1	All	11	7,6	8	72,7	25,00	29,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	18,52	24,22
Cycle 29 Day 1	All	9	6,2	7	77,8	14,29	26,23
Cycle 30 Day 1	All	7	4,8	5	71,4	40,00	36,51
Cycle 31 Day 1	All	7	4,8	5	71,4	33,33	23,57
Cycle 32 Day 1	All	6	4,1	5	83,3	20,00	18,26
Cycle 33 Day 1	All	2	1,4	2	100,0	33,33	47,14
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	25,00	28,87
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	7,84	14,28
	Female	93	100,0	91	97,8	8,42	16,92
Cycle 2 Day 1	Male	50	96,2	46	92,0	7,97	16,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	15,19	21,88
Cycle 3 Day 1	Male	47	90,4	42	89,4	11,90	17,76
	Female	84	90,3	76	90,5	14,91	21,36
Cycle 4 Day 1	Male	46	88,5	45	97,8	18,52	25,18
	Female	82	88,2	75	91,5	16,44	19,28
Cycle 5 Day 1	Male	45	86,5	43	95,6	13,95	19,56
	Female	79	84,9	75	94,9	16,44	20,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	14,63	24,78
	Female	76	81,7	71	93,4	14,55	21,63
Cycle 7 Day 1	Male	40	76,9	39	97,5	16,24	21,46
	Female	73	78,5	67	91,8	13,93	19,38
Cycle 8 Day 1	Male	37	71,2	34	91,9	20,59	24,64
	Female	69	74,2	63	91,3	16,40	22,30
Cycle 9 Day 1	Male	33	63,5	33	100,0	22,22	24,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	15,87	23,08
Cycle 10 Day 1	Male	30	57,7	30	100,0	26,67	26,84
	Female	59	63,4	56	94,9	13,10	17,61
Cycle 11 Day 1	Male	29	55,8	29	100,0	18,39	26,10
	Female	51	54,8	49	96,1	17,69	20,53
Cycle 12 Day 1	Male	27	51,9	26	96,3	19,23	26,95
	Female	49	52,7	43	87,8	16,28	19,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	17,39	29,93
	Female	41	44,1	39	95,1	17,09	20,05
Cycle 14 Day 1	Male	23	44,2	21	91,3	17,46	27,12
	Female	37	39,8	36	97,3	17,59	24,54
Cycle 15 Day 1	Male	21	40,4	20	95,2	15,00	17,01
	Female	36	38,7	34	94,4	16,67	20,52
Cycle 16 Day 1	Male	16	30,8	16	100,0	16,67	24,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	16,13	20,85
Cycle 17 Day 1	Male	13	25,0	13	100,0	23,08	31,58
	Female	32	34,4	31	96,9	13,98	22,40
Cycle 18 Day 1	Male	12	23,1	11	91,7	18,18	34,52
	Female	29	31,2	26	89,7	12,82	16,54
Cycle 19 Day 1	Male	10	19,2	10	100,0	30,00	42,89
	Female	26	28,0	23	88,5	18,84	19,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	29,63	42,31
	Female	26	28,0	23	88,5	20,29	24,08
Cycle 21 Day 1	Male	8	15,4	8	100,0	29,17	41,55
	Female	21	22,6	18	85,7	11,11	16,17
Cycle 22 Day 1	Male	8	15,4	6	75,0	11,11	27,22
	Female	21	22,6	19	90,5	14,04	20,23
Cycle 23 Day 1	Male	5	9,6	4	80,0	41,67	50,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	11,90	16,57
Cycle 24 Day 1	Male	5	9,6	4	80,0	41,67	50,00
	Female	15	16,1	14	93,3	11,90	21,11
Cycle 25 Day 1	Male	3	5,8	2	66,7	50,00	70,71
	Female	12	12,9	11	91,7	15,15	17,41
Cycle 26 Day 1	Male	3	5,8	2	66,7	50,00	70,71
	Female	11	11,8	10	90,9	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	16,67	23,57
	Female	8	8,6	6	75,0	27,78	32,77
Cycle 28 Day 1	Male	2	3,8	2	100,0	33,33	47,14
	Female	8	8,6	7	87,5	14,29	17,82
Cycle 29 Day 1	Male	1	1,9	1	100,0	66,67	-
	Female	8	8,6	6	75,0	5,56	13,61
Cycle 30 Day 1	Male	1	1,9	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	41,67	41,94
Cycle 31 Day 1	Male	1	1,9	1	100,0	66,67	-
	Female	6	6,5	4	66,7	25,00	16,67
Cycle 32 Day 1	Male	1	1,9	1	100,0	33,33	-
	Female	5	5,4	4	80,0	16,67	19,25
Cycle 33 Day 1	Male	1	1,9	1	100,0	66,67	-
	Female	1	1,1	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	23,81	26,13
	Female	37	39,8	23	62,2	26,09	31,71
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	8,18	14,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	6,90	13,74
	>=75	7	100,0	7	100,0	14,29	37,80
Cycle 2 Day 1	18-64	103	94,5	93	90,3	13,98	19,24
	65-74	26	89,7	25	96,2	8,00	22,11
	>=75	7	100,0	7	100,0	9,52	25,20
Cycle 3 Day 1	18-64	99	90,8	87	87,9	13,41	19,99
	65-74	25	86,2	24	96,0	15,28	19,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	14,29	26,23
Cycle 4 Day 1	18-64	98	89,9	92	93,9	16,30	21,25
	65-74	23	79,3	21	91,3	22,22	24,34
	>=75	7	100,0	7	100,0	14,29	17,82
Cycle 5 Day 1	18-64	95	87,2	90	94,7	16,67	20,14
	65-74	22	75,9	22	100,0	12,12	19,37
	>=75	7	100,0	6	85,7	11,11	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	15,08	23,94
	65-74	22	75,9	21	95,5	12,70	19,65
	>=75	7	100,0	7	100,0	14,29	17,82
Cycle 7 Day 1	18-64	86	78,9	81	94,2	15,23	19,76
	65-74	20	69,0	19	95,0	12,28	19,91
	>=75	7	100,0	6	85,7	16,67	27,89
Cycle 8 Day 1	18-64	80	73,4	72	90,0	19,44	24,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	10,53	15,92
	>=75	7	100,0	6	85,7	22,22	17,21
Cycle 9 Day 1	18-64	74	67,9	73	98,6	20,09	25,30
	65-74	18	62,1	18	100,0	12,96	16,72
	>=75	6	85,7	5	83,3	6,67	14,91
Cycle 10 Day 1	18-64	69	63,3	66	95,7	19,19	22,69
	65-74	15	51,7	15	100,0	15,56	21,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	6,67	14,91
Cycle 11 Day 1	18-64	61	56,0	59	96,7	18,08	21,73
	65-74	15	51,7	15	100,0	17,78	24,77
	>=75	4	57,1	4	100,0	16,67	33,33
Cycle 12 Day 1	18-64	57	52,3	51	89,5	19,61	23,26
	65-74	15	51,7	14	93,3	11,90	21,11
	>=75	4	57,1	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	16,67	23,04
	65-74	13	44,8	12	92,3	19,44	26,43
	>=75	4	57,1	4	100,0	16,67	33,33
Cycle 14 Day 1	18-64	45	41,3	44	97,8	19,70	27,20
	65-74	13	44,8	11	84,6	12,12	16,82
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 15 Day 1	18-64	43	39,4	41	95,3	17,07	19,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	15,15	17,41
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 16 Day 1	18-64	38	34,9	36	94,7	19,44	23,06
	65-74	10	34,5	9	90,0	7,41	14,70
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 17 Day 1	18-64	36	33,0	35	97,2	19,05	27,16
	65-74	8	27,6	8	100,0	8,33	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	0,00	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	16,67	24,37
	65-74	7	24,1	6	85,7	5,56	13,61
	>=75	1	14,3	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	26,19	29,20
	65-74	5	17,2	4	80,0	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	25,64	30,27
	65-74	5	17,2	5	100,0	13,33	29,81
	>=75	1	14,3	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	20,63	28,82
	65-74	4	13,8	4	100,0	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	16,67	22,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	20,83	29,50
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	20,83	31,91
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	12,8	12	85,7	22,22	29,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	19,44	30,01
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	25,00	29,55
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	18,52	24,22
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	14,29	26,23
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	40,00	36,51
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	33,33	23,57
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	66,67	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	28,43	29,74
	65-74	15	51,7	8	53,3	16,67	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	0,00	0,00
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	6,32	17,05
	Other	85	100,0	84	98,8	9,52	15,15
Cycle 2 Day 1	White	57	95,0	50	87,7	13,33	21,30
	Other	79	92,9	75	94,9	12,00	19,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	14,39	20,83
	Other	77	90,6	74	96,1	13,51	19,83
Cycle 4 Day 1	White	53	88,3	47	88,7	20,57	24,63
	Other	75	88,2	73	97,3	15,07	19,28
Cycle 5 Day 1	White	52	86,7	48	92,3	15,97	21,73
	Other	72	84,7	70	97,2	15,24	19,40
Cycle 6 Day 1	White	50	83,3	44	88,0	12,12	21,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	16,18	23,39
Cycle 7 Day 1	White	47	78,3	42	89,4	15,08	21,08
	Other	66	77,6	64	97,0	14,58	19,59
Cycle 8 Day 1	White	45	75,0	39	86,7	19,66	25,04
	Other	61	71,8	58	95,1	16,67	21,85
Cycle 9 Day 1	White	42	70,0	41	97,6	19,51	24,69
	Other	56	65,9	55	98,2	16,97	23,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	17,09	22,78
	Other	48	56,5	47	97,9	18,44	21,77
Cycle 11 Day 1	White	37	61,7	37	100,0	15,32	23,03
	Other	43	50,6	41	95,3	20,33	22,21
Cycle 12 Day 1	White	37	61,7	33	89,2	19,19	26,39
	Other	39	45,9	36	92,3	15,74	18,66
Cycle 13 Day 1	White	32	53,3	30	93,8	22,22	26,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	12,50	20,30
Cycle 14 Day 1	White	31	51,7	30	96,8	21,11	28,34
	Other	29	34,1	27	93,1	13,58	21,20
Cycle 15 Day 1	White	30	50,0	28	93,3	14,29	19,09
	Other	27	31,8	26	96,3	17,95	19,39
Cycle 16 Day 1	White	26	43,3	24	92,3	19,44	23,91
	Other	24	28,2	23	95,8	13,04	19,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	18,06	31,05
	Other	21	24,7	20	95,2	15,00	17,01
Cycle 18 Day 1	White	22	36,7	19	86,4	19,30	25,62
	Other	19	22,4	18	94,7	9,26	19,15
Cycle 19 Day 1	White	20	33,3	20	100,0	25,00	28,36
	Other	16	18,8	13	81,3	17,95	29,24
Cycle 20 Day 1	White	20	33,3	17	85,0	21,57	28,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	24,44	32,04
Cycle 21 Day 1	White	16	26,7	14	87,5	19,05	31,25
	Other	13	15,3	12	92,3	13,89	22,29
Cycle 22 Day 1	White	16	26,7	13	81,3	12,82	21,68
	Other	13	15,3	12	92,3	13,89	22,29
Cycle 23 Day 1	White	12	20,0	10	83,3	16,67	23,57
	Other	9	10,6	8	88,9	20,83	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	23,33	35,31
	Other	9	10,6	8	88,9	12,50	24,80
Cycle 25 Day 1	White	10	16,7	8	80,0	20,83	35,36
	Other	5	5,9	5	100,0	20,00	18,26
Cycle 26 Day 1	White	10	16,7	8	80,0	25,00	34,50
	Other	4	4,7	4	100,0	8,33	16,67
Cycle 27 Day 1	White	8	13,3	5	62,5	20,00	29,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	33,33	33,33
Cycle 28 Day 1	White	7	11,7	6	85,7	16,67	27,89
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 29 Day 1	White	6	10,0	4	66,7	25,00	31,91
	Other	3	3,5	3	100,0	0,00	0,00
Cycle 30 Day 1	White	4	6,7	2	50,0	16,67	23,57
	Other	3	3,5	3	100,0	55,56	38,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	33,33	47,14
	Other	3	3,5	3	100,0	33,33	0,00
Cycle 32 Day 1	White	4	6,7	3	75,0	11,11	19,25
	Other	2	2,4	2	100,0	33,33	0,00
Cycle 33 Day 1	White	2	3,3	2	100,0	33,33	47,14
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	23,53	30,65
	Other	39	45,9	27	69,2	25,93	28,24
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	5,00	12,05
	Europe (EU)	34	100,0	31	91,2	7,53	14,17
	Asia (AS)	71	100,0	71	100,0	10,33	18,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	9,38	17,42
	Europe (EU)	32	94,1	28	87,5	15,48	21,24
	Asia (AS)	66	93,0	65	98,5	12,82	20,99
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	11,11	15,96
	Europe (EU)	31	91,2	22	71,0	12,12	21,93
	Asia (AS)	63	88,7	63	100,0	15,87	21,47
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	15,69	23,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	17,33	21,77
	Asia (AS)	61	85,9	61	100,0	18,03	20,70
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	17,14	23,39
	Europe (EU)	30	88,2	26	86,7	11,54	18,72
	Asia (AS)	57	80,3	57	100,0	16,37	19,03
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	13,33	21,69
	Europe (EU)	28	82,4	25	89,3	10,67	24,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	17,31	22,38
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	13,54	18,66
	Europe (EU)	28	82,4	25	89,3	12,00	18,95
	Asia (AS)	50	70,4	49	98,0	17,01	21,65
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	14,81	21,35
	Europe (EU)	28	82,4	23	82,1	20,29	26,09
	Asia (AS)	47	66,2	47	100,0	18,44	22,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	20,24	26,20
	Europe (EU)	26	76,5	25	96,2	12,00	18,95
	Asia (AS)	43	60,6	43	100,0	20,16	24,28
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	19,44	25,85
	Europe (EU)	25	73,5	25	100,0	13,33	19,25
	Asia (AS)	37	52,1	37	100,0	19,82	21,46
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	23,19	29,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	12,12	16,41
	Asia (AS)	33	46,5	33	100,0	18,18	20,57
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	21,74	27,72
	Europe (EU)	23	67,6	18	78,3	12,96	20,26
	Asia (AS)	29	40,8	28	96,6	16,67	19,25
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	19,70	28,47
	Europe (EU)	18	52,9	15	83,3	11,11	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	18,67	23,73
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	20,63	32,45
	Europe (EU)	17	50,0	16	94,1	16,67	21,08
	Asia (AS)	21	29,6	20	95,2	15,00	20,16
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	15,00	20,16
	Europe (EU)	15	44,1	14	93,3	16,67	17,30
	Asia (AS)	20	28,2	20	100,0	16,67	20,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	19,61	23,74
	Europe (EU)	14	41,2	11	78,6	15,15	22,92
	Asia (AS)	19	26,8	19	100,0	14,04	20,23
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	25,00	33,33
	Europe (EU)	13	38,2	12	92,3	11,11	21,71
	Asia (AS)	16	22,5	16	100,0	12,50	16,67
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	16,67	28,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	9,52	16,27
	Asia (AS)	16	22,5	16	100,0	14,58	20,97
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	28,21	29,96
	Europe (EU)	9	26,5	9	100,0	14,81	24,22
	Asia (AS)	14	19,7	11	78,6	21,21	30,81
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	25,64	30,89
	Europe (EU)	9	26,5	6	66,7	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	25,64	33,76
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	16,67	32,39
	Europe (EU)	7	20,6	6	85,7	11,11	27,22
	Asia (AS)	11	15,5	10	90,9	20,00	23,31
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	13,33	23,31
	Europe (EU)	7	20,6	5	71,4	6,67	14,91
	Asia (AS)	11	15,5	10	90,9	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	14,81	24,22
	Europe (EU)	5	14,7	3	60,0	11,11	19,25
	Asia (AS)	7	9,9	6	85,7	27,78	38,97
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	25,00	38,83
	Europe (EU)	5	14,7	4	80,0	8,33	16,67
	Asia (AS)	7	9,9	6	85,7	16,67	27,89
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	23,81	37,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	16,67	23,57
	Asia (AS)	4	5,6	4	100,0	16,67	19,25
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	27,78	38,97
	Europe (EU)	4	11,8	2	50,0	16,67	23,57
	Asia (AS)	4	5,6	4	100,0	8,33	16,67
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	25,00	31,91
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	25,00	31,91
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	25,00	31,91
	Europe (EU)	2	5,9	1	50,0	0,00	-
	Asia (AS)	4	5,6	4	100,0	16,67	19,25
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	33,33	33,33
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	55,56	38,49
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	33,33	47,14
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	33,33	0,00
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	0,00	-
	Asia (AS)	3	4,2	2	66,7	33,33	0,00
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	66,67	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	19,61	31,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	26,67	27,89
	Asia (AS)	34	47,9	22	64,7	28,79	27,78
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	6,67	13,45
	1	69	100,0	67	97,1	9,45	18,17
	2	15	100,0	15	100,0	8,89	15,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	55	93,2	12,12	20,65
	1	67	97,1	60	89,6	13,33	20,54
	2	10	66,7	10	100,0	10,00	16,10
Cycle 3 Day 1	0	57	93,4	51	89,5	15,69	22,46
	1	65	94,2	58	89,2	13,22	18,67
	2	9	60,0	9	100,0	7,41	14,70
Cycle 4 Day 1	0	57	93,4	54	94,7	22,22	24,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	12,07	18,42
	2	9	60,0	8	88,9	20,83	17,25
Cycle 5 Day 1	0	56	91,8	53	94,6	16,35	20,28
	1	62	89,9	59	95,2	14,69	20,78
	2	6	40,0	6	100,0	16,67	18,26
Cycle 6 Day 1	0	56	91,8	54	96,4	18,52	26,44
	1	59	85,5	53	89,8	10,69	18,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	13,33	18,26
Cycle 7 Day 1	0	54	88,5	51	94,4	18,30	21,41
	1	54	78,3	50	92,6	12,00	18,76
	2	5	33,3	5	100,0	6,67	14,91
Cycle 8 Day 1	0	52	85,2	48	92,3	20,14	22,53
	1	49	71,0	44	89,8	15,15	20,90
	2	5	33,3	5	100,0	20,00	44,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	21,09	26,95
	1	44	63,8	43	97,7	15,50	19,72
	2	4	26,7	4	100,0	8,33	16,67
Cycle 10 Day 1	0	46	75,4	46	100,0	21,01	23,68
	1	40	58,0	37	92,5	14,41	20,09
	2	3	20,0	3	100,0	11,11	19,25
Cycle 11 Day 1	0	43	70,5	41	95,3	18,70	24,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	16,67	20,52
	2	3	20,0	3	100,0	22,22	19,25
Cycle 12 Day 1	0	42	68,9	36	85,7	20,37	25,55
	1	31	44,9	30	96,8	14,44	18,94
	2	3	20,0	3	100,0	11,11	19,25
Cycle 13 Day 1	0	38	62,3	34	89,5	18,63	24,88
	1	27	39,1	27	100,0	16,05	23,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	21,88	28,85
	1	24	34,8	24	100,0	12,50	19,19
	2	1	6,7	1	100,0	0,00	-
Cycle 15 Day 1	0	33	54,1	30	90,9	18,89	18,94
	1	23	33,3	23	100,0	11,59	19,09
	2	1	6,7	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	20,00	23,57
	1	21	30,4	21	100,0	11,11	19,25
	2	1	6,7	1	100,0	33,33	-
Cycle 17 Day 1	0	24	39,3	23	95,8	23,19	30,87
	1	20	29,0	20	100,0	10,00	15,67
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	17,54	25,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	11,76	20,21
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	21,05	29,84
	1	15	21,7	13	86,7	23,08	28,50
	2	1	6,7	1	100,0	33,33	-
Cycle 20 Day 1	0	20	32,8	17	85,0	27,45	29,43
	1	15	21,7	14	93,3	16,67	31,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	33,33	-
Cycle 21 Day 1	0	15	24,6	14	93,3	19,05	31,25
	1	13	18,8	11	84,6	12,12	22,47
	2	1	6,7	1	100,0	33,33	-
Cycle 22 Day 1	0	15	24,6	12	80,0	8,33	15,08
	1	13	18,8	12	92,3	16,67	26,59
	2	1	6,7	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	11,11	23,57
	1	9	13,0	8	88,9	29,17	33,03
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	18,52	37,68
	1	9	13,0	8	88,9	20,83	24,80
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	22,22	40,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	19,05	17,82
Cycle 26 Day 1	0	8	13,1	6	75,0	22,22	40,37
	1	6	8,7	6	100,0	16,67	18,26
Cycle 27 Day 1	0	6	9,8	3	50,0	11,11	19,25
	1	5	7,2	5	100,0	33,33	33,33
Cycle 28 Day 1	0	5	8,2	4	80,0	16,67	33,33
	1	5	7,2	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	33,33	47,14
	1	5	7,2	5	100,0	6,67	14,91
Cycle 30 Day 1	0	3	4,9	1	33,3	33,33	-
	1	4	5,8	4	100,0	41,67	41,94
Cycle 31 Day 1	0	3	4,9	1	33,3	66,67	-
	1	4	5,8	4	100,0	25,00	16,67
Cycle 32 Day 1	0	3	4,9	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	22,22	19,25
Cycle 33 Day 1	0	2	3,3	2	100,0	33,33	47,14
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	26,98	29,10
	1	34	49,3	20	58,8	25,00	30,35
	2	7	46,7	3	42,9	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	7,22	13,85
	1	4	100,0	4	100,0	8,33	16,67
	2 or More	79	100,0	78	98,7	8,97	17,55
Cycle 2 Day 1	None	60	96,8	54	90,0	12,96	19,87
	1	3	75,0	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	12,08	20,59
Cycle 3 Day 1	None	59	95,2	53	89,8	15,72	21,29
	1	3	75,0	2	66,7	16,67	23,57
	2 or More	69	87,3	63	91,3	12,17	19,22
Cycle 4 Day 1	None	59	95,2	56	94,9	16,07	22,91
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	66	83,5	62	93,9	18,82	20,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	13,69	19,88
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	63	79,7	59	93,7	18,08	20,83
Cycle 6 Day 1	None	57	91,9	52	91,2	15,38	25,10
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	61	77,2	57	93,4	14,62	20,91
Cycle 7 Day 1	None	52	83,9	50	96,2	13,33	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	11,11	19,25
	2 or More	58	73,4	53	91,4	16,35	22,29
Cycle 8 Day 1	None	50	80,6	46	92,0	13,77	19,34
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	22,00	25,74
Cycle 9 Day 1	None	48	77,4	47	97,9	15,60	25,87
	1	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	20,14	21,46
Cycle 10 Day 1	None	43	69,4	41	95,3	14,63	22,42
	1	1	25,0	1	100,0	33,33	-
	2 or More	45	57,0	44	97,8	20,45	21,82
Cycle 11 Day 1	None	37	59,7	35	94,6	18,10	26,00
	1	1	25,0	1	100,0	0,00	-
	2 or More	42	53,2	42	100,0	18,25	19,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	14,71	23,49
	1	1	25,0	1	100,0	33,33	-
	2 or More	38	48,1	34	89,5	19,61	21,89
Cycle 13 Day 1	None	34	54,8	30	88,2	15,56	27,31
	1	1	25,0	1	100,0	33,33	-
	2 or More	31	39,2	31	100,0	18,28	20,80
Cycle 14 Day 1	None	31	50,0	29	93,5	13,79	26,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	33,33	-
	2 or More	28	35,4	27	96,4	20,99	24,72
Cycle 15 Day 1	None	30	48,4	28	93,3	9,52	15,33
	1	1	25,0	1	100,0	33,33	-
	2 or More	26	32,9	25	96,2	22,67	20,91
Cycle 16 Day 1	None	25	40,3	23	92,0	11,59	16,23
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	21,74	25,84
Cycle 17 Day 1	None	23	37,1	22	95,7	13,64	24,47
	1	1	25,0	1	100,0	33,33	-
	2 or More	21	26,6	21	100,0	19,05	27,02
Cycle 18 Day 1	None	20	32,3	18	90,0	12,96	25,92
	1	1	25,0	1	100,0	33,33	-
	2 or More	20	25,3	18	90,0	14,81	20,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	17,65	26,66
	1	1	25,0	1	100,0	33,33	-
	2 or More	18	22,8	15	83,3	26,67	31,37
Cycle 20 Day 1	None	17	27,4	16	94,1	14,58	27,13
	1	1	25,0	1	100,0	33,33	-
	2 or More	18	22,8	15	83,3	31,11	32,04
Cycle 21 Day 1	None	15	24,2	13	86,7	15,38	29,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	17,95	25,88
Cycle 22 Day 1	None	15	24,2	13	86,7	7,69	19,97
	2 or More	14	17,7	12	85,7	19,44	22,29
Cycle 23 Day 1	None	10	16,1	9	90,0	11,11	23,57
	2 or More	11	13,9	9	81,8	25,93	32,39
Cycle 24 Day 1	None	10	16,1	10	100,0	13,33	32,20
	2 or More	10	12,7	8	80,0	25,00	29,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	25,00	34,50
	2 or More	6	7,6	5	83,3	13,33	18,26
Cycle 26 Day 1	None	8	12,9	8	100,0	16,67	35,63
	2 or More	6	7,6	4	66,7	25,00	16,67
Cycle 27 Day 1	None	7	11,3	6	85,7	22,22	27,22
	2 or More	4	5,1	2	50,0	33,33	47,14
Cycle 28 Day 1	None	7	11,3	7	100,0	19,05	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	9,7	5	83,3	20,00	29,81
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	6,5	3	75,0	22,22	19,25
	2 or More	3	3,8	2	66,7	66,67	47,14
Cycle 31 Day 1	None	4	6,5	3	75,0	33,33	33,33
	2 or More	3	3,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	22,22	19,25
	2 or More	2	2,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	1,6	1	100,0	66,67	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	24,56	29,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	33,33	-
	2 or More	39	49,4	24	61,5	25,00	29,90
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	7,22	13,85
	Previously Treated	83	100,0	82	98,8	8,94	17,41
Cycle 2 Day 1	Naïve	60	96,8	54	90,0	12,96	19,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	12,21	20,50
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	15,72	21,29
	Previously Treated	72	86,7	65	90,3	12,31	19,16
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	16,07	22,91
	Previously Treated	69	83,1	64	92,8	18,23	20,51
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	13,69	19,88
	Previously Treated	66	79,5	62	93,9	17,20	20,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	15,38	25,10
	Previously Treated	64	77,1	60	93,8	13,89	20,62
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	13,33	17,82
	Previously Treated	61	73,5	56	91,8	16,07	22,01
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	13,77	19,34
	Previously Treated	56	67,5	51	91,1	21,57	25,67
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	15,60	25,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	20,41	21,32
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	14,63	22,42
	Previously Treated	46	55,4	45	97,8	20,74	21,66
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	18,10	26,00
	Previously Treated	43	51,8	43	100,0	17,83	19,72
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	14,71	23,49
	Previously Treated	39	47,0	35	89,7	20,00	21,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	15,56	27,31
	Previously Treated	32	38,6	32	100,0	18,75	20,63
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	13,79	26,00
	Previously Treated	29	34,9	28	96,6	21,43	24,37
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	9,52	15,33
	Previously Treated	27	32,5	26	96,3	23,08	20,59
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	11,59	16,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	20,83	25,66
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	13,64	24,47
	Previously Treated	22	26,5	22	100,0	19,70	26,55
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	12,96	25,92
	Previously Treated	21	25,3	19	90,5	15,79	20,39
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	17,65	26,66
	Previously Treated	19	22,9	16	84,2	27,08	30,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	14,58	27,13
	Previously Treated	19	22,9	16	84,2	31,25	30,96
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	15,38	29,24
	Previously Treated	14	16,9	13	92,9	17,95	25,88
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	7,69	19,97
	Previously Treated	14	16,9	12	85,7	19,44	22,29
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	11,11	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	25,93	32,39
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	13,33	32,20
	Previously Treated	10	12,0	8	80,0	25,00	29,55
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	25,00	34,50
	Previously Treated	6	7,2	5	83,3	13,33	18,26
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	16,67	35,63
	Previously Treated	6	7,2	4	66,7	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	22,22	27,22
	Previously Treated	4	4,8	2	50,0	33,33	47,14
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	19,05	26,23
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	20,00	29,81
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	66,67	47,14
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	33,33	33,33
	Previously Treated	3	3,6	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	22,22	19,25
	Previously Treated	2	2,4	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	66,67	-
	Previously Treated	1	1,2	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	24,56	29,06
	Previously Treated	42	50,6	25	59,5	25,33	29,31
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	7,56	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	8,96	17,96
Cycle 2 Day 1	Local	71	94,7	66	93,0	13,13	17,42
	Central	65	92,9	59	90,8	11,86	22,96
Cycle 3 Day 1	Local	67	89,3	62	92,5	10,75	17,88
	Central	64	91,4	56	87,5	17,26	22,01
Cycle 4 Day 1	Local	65	86,7	61	93,8	15,85	19,82
	Central	63	90,0	59	93,7	18,64	23,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	17,51	20,86
	Central	61	87,1	59	96,7	13,56	19,69
Cycle 6 Day 1	Local	63	84,0	61	96,8	13,66	21,41
	Central	58	82,9	51	87,9	15,69	24,36
Cycle 7 Day 1	Local	61	81,3	59	96,7	13,56	17,64
	Central	52	74,3	47	90,4	16,31	22,92
Cycle 8 Day 1	Local	57	76,0	55	96,5	14,55	20,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	22,22	26,20
Cycle 9 Day 1	Local	54	72,0	53	98,1	16,98	24,13
	Central	44	62,9	43	97,7	19,38	23,27
Cycle 10 Day 1	Local	48	64,0	46	95,8	18,84	23,99
	Central	41	58,6	40	97,6	16,67	19,97
Cycle 11 Day 1	Local	40	53,3	38	95,0	18,42	24,13
	Central	40	57,1	40	100,0	17,50	21,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	17,17	23,75
	Central	40	57,1	36	90,0	17,59	21,80
Cycle 13 Day 1	Local	30	40,0	29	96,7	20,69	27,33
	Central	36	51,4	33	91,7	14,14	20,46
Cycle 14 Day 1	Local	27	36,0	27	100,0	16,05	25,10
	Central	33	47,1	30	90,9	18,89	25,80
Cycle 15 Day 1	Local	26	34,7	25	96,2	12,00	16,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	19,54	20,93
Cycle 16 Day 1	Local	24	32,0	24	100,0	16,67	21,98
	Central	26	37,1	23	88,5	15,94	22,18
Cycle 17 Day 1	Local	22	29,3	22	100,0	15,15	24,62
	Central	23	32,9	22	95,7	18,18	26,68
Cycle 18 Day 1	Local	20	26,7	19	95,0	14,04	27,92
	Central	21	30,0	18	85,7	14,81	17,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	25,49	32,34
	Central	17	24,3	16	94,1	18,75	24,25
Cycle 20 Day 1	Local	19	25,3	17	89,5	19,61	33,46
	Central	17	24,3	15	88,2	26,67	25,82
Cycle 21 Day 1	Local	14	18,7	12	85,7	19,44	33,21
	Central	15	21,4	14	93,3	14,29	21,54
Cycle 22 Day 1	Local	14	18,7	12	85,7	11,11	21,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	15,38	22,01
Cycle 23 Day 1	Local	11	14,7	10	90,9	20,00	35,83
	Central	10	14,3	8	80,0	16,67	17,82
Cycle 24 Day 1	Local	11	14,7	10	90,9	23,33	38,65
	Central	9	12,9	8	88,9	12,50	17,25
Cycle 25 Day 1	Local	7	9,3	7	100,0	23,81	37,09
	Central	8	11,4	6	75,0	16,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	22,22	40,37
	Central	8	11,4	6	75,0	16,67	18,26
Cycle 27 Day 1	Local	4	5,3	4	100,0	16,67	19,25
	Central	7	10,0	4	57,1	33,33	38,49
Cycle 28 Day 1	Local	4	5,3	4	100,0	25,00	31,91
	Central	6	8,6	5	83,3	13,33	18,26
Cycle 29 Day 1	Local	3	4,0	3	100,0	22,22	38,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	8,33	16,67
Cycle 30 Day 1	Local	3	4,0	3	100,0	22,22	19,25
	Central	4	5,7	2	50,0	66,67	47,14
Cycle 31 Day 1	Local	3	4,0	3	100,0	33,33	33,33
	Central	4	5,7	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	4,0	3	100,0	22,22	19,25
	Central	3	4,3	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	66,67	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	18,06	27,77
	Central	32	45,7	20	62,5	33,33	28,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	8,33	16,15
	No	10	100,0	10	100,0	6,67	14,05
Cycle 2 Day 1	Yes	129	95,6	118	91,5	12,15	18,83
	No	7	70,0	7	100,0	19,05	37,80
Cycle 3 Day 1	Yes	124	91,9	112	90,3	14,58	20,40
	No	7	70,0	6	85,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	17,11	21,87
	No	7	70,0	7	100,0	19,05	17,82
Cycle 5 Day 1	Yes	117	86,7	112	95,7	16,07	20,50
	No	7	70,0	6	85,7	5,56	13,61
Cycle 6 Day 1	Yes	114	84,4	105	92,1	14,60	23,08
	No	7	70,0	7	100,0	14,29	17,82
Cycle 7 Day 1	Yes	106	78,5	99	93,4	14,48	19,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	19,05	26,23
Cycle 8 Day 1	Yes	100	74,1	91	91,0	17,58	23,49
	No	6	60,0	6	100,0	22,22	17,21
Cycle 9 Day 1	Yes	92	68,1	90	97,8	18,52	24,02
	No	6	60,0	6	100,0	11,11	17,21
Cycle 10 Day 1	Yes	83	61,5	80	96,4	17,92	21,83
	No	6	60,0	6	100,0	16,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	17,57	22,90
	No	4	40,0	4	100,0	25,00	16,67
Cycle 12 Day 1	Yes	72	53,3	65	90,3	17,44	22,90
	No	4	40,0	4	100,0	16,67	19,25
Cycle 13 Day 1	Yes	64	47,4	60	93,8	17,22	24,16
	No	2	20,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	58	43,0	55	94,8	18,18	25,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	0,00	0,00
Cycle 15 Day 1	Yes	55	40,7	52	94,5	16,03	19,23
	No	2	20,0	2	100,0	16,67	23,57
Cycle 16 Day 1	Yes	48	35,6	45	93,8	17,04	22,04
	No	2	20,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	43	31,9	42	97,7	16,67	25,77
	No	2	20,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	14,29	23,27
	No	2	20,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	22,92	28,63
	No	2	20,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	22,22	29,47
	No	2	20,0	2	100,0	33,33	47,14
Cycle 21 Day 1	Yes	27	20,0	24	88,9	18,06	27,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	0,00	0,00
Cycle 22 Day 1	Yes	27	20,0	23	85,2	14,49	22,08
	No	2	20,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	19,61	29,01
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	19,61	31,31
	No	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	19,44	30,01
	No	1	10,0	1	100,0	33,33	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	21,21	30,81
	No	1	10,0	1	100,0	0,00	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	23,81	31,71
	No	1	10,0	1	100,0	33,33	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	16,67	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	16,67	27,89
	No	1	10,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	41,67	41,94
	No	1	10,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	33,33	27,22
	No	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	16,67	19,25
	No	1	10,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	33,33	47,14
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	25,58	28,95
	No	2	20,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	12,12	16,82
	No	134	100,0	131	97,8	7,89	15,92
Cycle 2 Day 1	Yes	7	63,6	7	100,0	14,29	17,82
	No	129	96,3	118	91,5	12,43	20,35
Cycle 3 Day 1	Yes	7	63,6	7	100,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	14,11	20,38
Cycle 4 Day 1	Yes	7	63,6	7	100,0	14,29	26,23
	No	121	90,3	113	93,4	17,40	21,41
Cycle 5 Day 1	Yes	7	63,6	7	100,0	14,29	26,23
	No	117	87,3	111	94,9	15,62	20,01
Cycle 6 Day 1	Yes	7	63,6	7	100,0	4,76	12,60
	No	114	85,1	105	92,1	15,24	23,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	4,76	12,60
	No	106	79,1	99	93,4	15,49	20,38
Cycle 8 Day 1	Yes	7	63,6	7	100,0	14,29	26,23
	No	99	73,9	90	90,9	18,15	22,99
Cycle 9 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	92	68,7	90	97,8	19,26	23,95
Cycle 10 Day 1	Yes	6	54,5	6	100,0	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	18,75	22,40
Cycle 11 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	74	55,2	72	97,3	19,44	22,90
Cycle 12 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	70	52,2	63	90,0	19,05	22,97
Cycle 13 Day 1	Yes	5	45,5	5	100,0	13,33	18,26
	No	61	45,5	57	93,4	17,54	24,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	6,67	14,91
	No	55	41,0	52	94,5	18,59	25,92
Cycle 15 Day 1	Yes	4	36,4	4	100,0	0,00	0,00
	No	53	39,6	50	94,3	17,33	19,33
Cycle 16 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	47	35,1	44	93,6	17,42	22,14
Cycle 17 Day 1	Yes	3	27,3	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	17,89	25,92
Cycle 18 Day 1	Yes	3	27,3	3	100,0	22,22	19,25
	No	38	28,4	34	89,5	13,73	23,38
Cycle 19 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	33	24,6	30	90,9	23,33	29,23
Cycle 20 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	33	24,6	29	87,9	24,14	30,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	27	20,1	24	88,9	16,67	27,80
Cycle 22 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	23	85,2	14,49	22,08
Cycle 23 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	19	14,2	16	84,2	20,83	29,50
Cycle 24 Day 1	Yes	2	18,2	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	20,83	31,91
Cycle 25 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	13	9,7	11	84,6	24,24	30,15
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	21,21	30,81
Cycle 27 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	10	7,5	7	70,0	28,57	29,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	9	6,7	8	88,9	20,83	24,80
Cycle 29 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	8	6,0	6	75,0	16,67	27,89
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	40,00	36,51
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	33,33	23,57
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	20,00	18,26
Cycle 33 Day 1	No	2	1,5	2	100,0	33,33	47,14
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	26,02	29,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DI_SG.xls
24JUN2020 20:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	36,15	31,13
Cycle 2 Day 1	All	136	93,8	126	92,6	26,19	26,54
Cycle 3 Day 1	All	131	90,3	118	90,1	24,58	21,98
Cycle 4 Day 1	All	128	88,3	120	93,8	23,89	24,89
Cycle 5 Day 1	All	124	85,5	118	95,2	25,14	24,24
Cycle 6 Day 1	All	121	83,4	112	92,6	24,40	25,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	26,42	25,91
Cycle 8 Day 1	All	106	73,1	97	91,5	24,05	22,43
Cycle 9 Day 1	All	98	67,6	96	98,0	22,57	22,94
Cycle 10 Day 1	All	89	61,4	86	96,6	24,81	21,80
Cycle 11 Day 1	All	80	55,2	78	97,5	23,93	22,08
Cycle 12 Day 1	All	76	52,4	69	90,8	21,26	20,59
Cycle 13 Day 1	All	66	45,5	62	93,9	21,51	23,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	24,56	24,01
Cycle 15 Day 1	All	57	39,3	54	94,7	22,84	20,30
Cycle 16 Day 1	All	50	34,5	47	94,0	26,24	22,99
Cycle 17 Day 1	All	45	31,0	44	97,8	24,24	24,23
Cycle 18 Day 1	All	41	28,3	37	90,2	20,72	21,30
Cycle 19 Day 1	All	36	24,8	32	88,9	26,04	21,97
Cycle 20 Day 1	All	36	24,8	32	88,9	20,83	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	26,92	21,12
Cycle 22 Day 1	All	29	20,0	25	86,2	26,67	25,46
Cycle 23 Day 1	All	21	14,5	18	85,7	20,37	25,92
Cycle 24 Day 1	All	20	13,8	18	90,0	25,93	18,28
Cycle 25 Day 1	All	15	10,3	13	86,7	23,08	16,01
Cycle 26 Day 1	All	14	9,7	12	85,7	33,33	34,82
Cycle 27 Day 1	All	11	7,6	8	72,7	25,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	22,22	23,57
Cycle 29 Day 1	All	9	6,2	7	77,8	33,33	0,00
Cycle 30 Day 1	All	7	4,8	5	71,4	26,67	14,91
Cycle 31 Day 1	All	7	4,8	5	71,4	33,33	0,00
Cycle 32 Day 1	All	6	4,1	5	83,3	26,67	14,91
Cycle 33 Day 1	All	2	1,4	2	100,0	16,67	23,57
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	44,70	24,84
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	36,60	30,74
	Female	93	100,0	91	97,8	35,90	31,52
Cycle 2 Day 1	Male	50	96,2	47	94,0	28,37	28,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	24,89	25,30
Cycle 3 Day 1	Male	47	90,4	42	89,4	26,19	22,73
	Female	84	90,3	76	90,5	23,68	21,65
Cycle 4 Day 1	Male	46	88,5	45	97,8	24,44	26,01
	Female	82	88,2	75	91,5	23,56	24,37
Cycle 5 Day 1	Male	45	86,5	43	95,6	27,91	24,05
	Female	79	84,9	75	94,9	23,56	24,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	26,02	26,37
	Female	76	81,7	71	93,4	23,47	25,44
Cycle 7 Day 1	Male	40	76,9	39	97,5	29,91	26,26
	Female	73	78,5	67	91,8	24,38	25,68
Cycle 8 Day 1	Male	37	71,2	34	91,9	27,45	22,43
	Female	69	74,2	63	91,3	22,22	22,40
Cycle 9 Day 1	Male	33	63,5	33	100,0	24,24	22,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	21,69	23,31
Cycle 10 Day 1	Male	30	57,7	30	100,0	30,00	25,30
	Female	59	63,4	56	94,9	22,02	19,36
Cycle 11 Day 1	Male	29	55,8	29	100,0	25,29	22,98
	Female	51	54,8	49	96,1	23,13	21,74
Cycle 12 Day 1	Male	27	51,9	26	96,3	23,08	20,59
	Female	49	52,7	43	87,8	20,16	20,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	21,74	23,80
	Female	41	44,1	39	95,1	21,37	23,55
Cycle 14 Day 1	Male	23	44,2	21	91,3	28,57	26,43
	Female	37	39,8	36	97,3	22,22	22,54
Cycle 15 Day 1	Male	21	40,4	20	95,2	25,00	21,29
	Female	36	38,7	34	94,4	21,57	19,90
Cycle 16 Day 1	Male	16	30,8	16	100,0	25,00	22,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	26,88	23,44
Cycle 17 Day 1	Male	13	25,0	13	100,0	20,51	21,68
	Female	32	34,4	31	96,9	25,81	25,40
Cycle 18 Day 1	Male	12	23,1	11	91,7	21,21	26,97
	Female	29	31,2	26	89,7	20,51	19,04
Cycle 19 Day 1	Male	10	19,2	9	90,0	29,63	20,03
	Female	26	28,0	23	88,5	24,64	22,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	22,22	28,87
	Female	26	28,0	23	88,5	20,29	21,88
Cycle 21 Day 1	Male	8	15,4	8	100,0	20,83	17,25
	Female	21	22,6	18	85,7	29,63	22,55
Cycle 22 Day 1	Male	8	15,4	6	75,0	33,33	21,08
	Female	21	22,6	19	90,5	24,56	26,86
Cycle 23 Day 1	Male	5	9,6	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	26,19	26,73
Cycle 24 Day 1	Male	5	9,6	4	80,0	25,00	16,67
	Female	15	16,1	14	93,3	26,19	19,30
Cycle 25 Day 1	Male	3	5,8	2	66,7	16,67	23,57
	Female	12	12,9	11	91,7	24,24	15,57
Cycle 26 Day 1	Male	3	5,8	2	66,7	16,67	23,57
	Female	11	11,8	10	90,9	36,67	36,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	16,67	23,57
	Female	8	8,6	6	75,0	27,78	25,09
Cycle 28 Day 1	Male	2	3,8	2	100,0	16,67	23,57
	Female	8	8,6	7	87,5	23,81	25,20
Cycle 29 Day 1	Male	1	1,9	1	100,0	33,33	-
	Female	8	8,6	6	75,0	33,33	0,00
Cycle 30 Day 1	Male	1	1,9	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	25,00	16,67
Cycle 31 Day 1	Male	1	1,9	1	100,0	33,33	-
	Female	6	6,5	4	66,7	33,33	0,00
Cycle 32 Day 1	Male	1	1,9	1	100,0	33,33	-
	Female	5	5,4	4	80,0	25,00	16,67
Cycle 33 Day 1	Male	1	1,9	1	100,0	33,33	-
	Female	1	1,1	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	53,97	28,82
	Female	37	39,8	23	62,2	36,23	17,15
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	37,74	31,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	31,03	33,25
	>=75	7	100,0	7	100,0	33,33	19,25
Cycle 2 Day 1	18-64	103	94,5	94	91,3	24,11	24,64
	65-74	26	89,7	25	96,2	34,67	29,63
	>=75	7	100,0	7	100,0	23,81	37,09
Cycle 3 Day 1	18-64	99	90,8	87	87,9	22,99	21,15
	65-74	25	86,2	24	96,0	26,39	25,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	38,10	12,60
Cycle 4 Day 1	18-64	98	89,9	92	93,9	21,01	24,57
	65-74	23	79,3	21	91,3	30,16	25,61
	>=75	7	100,0	7	100,0	42,86	16,27
Cycle 5 Day 1	18-64	95	87,2	90	94,7	23,33	23,14
	65-74	22	75,9	22	100,0	27,27	28,43
	>=75	7	100,0	6	85,7	44,44	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	22,22	25,52
	65-74	22	75,9	21	95,5	28,57	24,23
	>=75	7	100,0	7	100,0	38,10	29,99
Cycle 7 Day 1	18-64	86	78,9	81	94,2	25,51	25,43
	65-74	20	69,0	19	95,0	29,82	29,18
	>=75	7	100,0	6	85,7	27,78	25,09
Cycle 8 Day 1	18-64	80	73,4	72	90,0	24,54	22,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	24,56	21,78
	>=75	7	100,0	6	85,7	16,67	27,89
Cycle 9 Day 1	18-64	74	67,9	73	98,6	19,63	19,90
	65-74	18	62,1	18	100,0	33,33	30,25
	>=75	6	85,7	5	83,3	26,67	27,89
Cycle 10 Day 1	18-64	69	63,3	66	95,7	23,23	21,85
	65-74	15	51,7	15	100,0	28,89	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	33,33	33,33
Cycle 11 Day 1	18-64	61	56,0	59	96,7	24,86	22,82
	65-74	15	51,7	15	100,0	22,22	20,57
	>=75	4	57,1	4	100,0	16,67	19,25
Cycle 12 Day 1	18-64	57	52,3	51	89,5	19,61	20,20
	65-74	15	51,7	14	93,3	26,19	23,31
	>=75	4	57,1	4	100,0	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	18,84	20,67
	65-74	13	44,8	12	92,3	27,78	31,25
	>=75	4	57,1	4	100,0	33,33	27,22
Cycle 14 Day 1	18-64	45	41,3	44	97,8	21,97	22,67
	65-74	13	44,8	11	84,6	33,33	29,81
	>=75	2	28,6	2	100,0	33,33	0,00
Cycle 15 Day 1	18-64	43	39,4	41	95,3	20,33	19,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	30,30	23,35
	>=75	2	28,6	2	100,0	33,33	0,00
Cycle 16 Day 1	18-64	38	34,9	36	94,7	25,00	24,40
	65-74	10	34,5	9	90,0	29,63	20,03
	>=75	2	28,6	2	100,0	33,33	0,00
Cycle 17 Day 1	18-64	36	33,0	35	97,2	22,86	22,54
	65-74	8	27,6	8	100,0	29,17	33,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	33,33	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	18,89	18,94
	65-74	7	24,1	6	85,7	27,78	32,77
	>=75	1	14,3	1	100,0	33,33	-
Cycle 19 Day 1	18-64	30	27,5	27	90,0	24,69	21,86
	65-74	5	17,2	4	80,0	33,33	27,22
	>=75	1	14,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	17,95	19,39
	65-74	5	17,2	5	100,0	26,67	36,51
	>=75	1	14,3	1	100,0	66,67	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	26,98	20,05
	65-74	4	13,8	4	100,0	25,00	31,91
	>=75	1	14,3	1	100,0	33,33	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	26,67	25,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	25,00	31,91
	>=75	1	14,3	1	100,0	33,33	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	22,92	26,44
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	27,08	18,13
	65-74	2	6,9	2	100,0	16,67	23,57
Cycle 25 Day 1	18-64	14	12,8	12	85,7	25,00	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	33,33	34,82
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	25,00	23,57
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	22,22	23,57
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	33,33	0,00
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	26,67	14,91
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	33,33	0,00
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	33,33	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	44,12	26,87
	65-74	15	51,7	8	53,3	45,83	17,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	50,00	23,57
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	40,23	31,07
	Other	85	100,0	84	98,8	33,33	31,05
Cycle 2 Day 1	White	57	95,0	51	89,5	30,07	30,74
	Other	79	92,9	75	94,9	23,56	23,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	25,00	22,87
	Other	77	90,6	74	96,1	24,32	21,58
Cycle 4 Day 1	White	53	88,3	47	88,7	20,57	22,58
	Other	75	88,2	73	97,3	26,03	26,20
Cycle 5 Day 1	White	52	86,7	48	92,3	26,39	25,69
	Other	72	84,7	70	97,2	24,29	23,34
Cycle 6 Day 1	White	50	83,3	44	88,0	25,00	26,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	24,02	25,66
Cycle 7 Day 1	White	47	78,3	42	89,4	26,19	26,07
	Other	66	77,6	64	97,0	26,56	26,01
Cycle 8 Day 1	White	45	75,0	39	86,7	20,51	21,10
	Other	61	71,8	58	95,1	26,44	23,16
Cycle 9 Day 1	White	42	70,0	41	97,6	22,76	21,65
	Other	56	65,9	55	98,2	22,42	24,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	23,08	21,84
	Other	48	56,5	47	97,9	26,24	21,91
Cycle 11 Day 1	White	37	61,7	37	100,0	20,72	18,17
	Other	43	50,6	41	95,3	26,83	24,97
Cycle 12 Day 1	White	37	61,7	33	89,2	19,19	16,73
	Other	39	45,9	36	92,3	23,15	23,66
Cycle 13 Day 1	White	32	53,3	30	93,8	26,67	25,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	16,67	20,74
Cycle 14 Day 1	White	31	51,7	30	96,8	23,33	23,41
	Other	29	34,1	27	93,1	25,93	25,04
Cycle 15 Day 1	White	30	50,0	28	93,3	25,00	21,52
	Other	27	31,8	26	96,3	20,51	19,04
Cycle 16 Day 1	White	26	43,3	24	92,3	22,22	21,23
	Other	24	28,2	23	95,8	30,43	24,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	22,22	21,23
	Other	21	24,7	20	95,2	26,67	27,78
Cycle 18 Day 1	White	22	36,7	19	86,4	15,79	17,10
	Other	19	22,4	18	94,7	25,93	24,40
Cycle 19 Day 1	White	20	33,3	19	95,0	26,32	23,78
	Other	16	18,8	13	81,3	25,64	19,97
Cycle 20 Day 1	White	20	33,3	17	85,0	25,49	22,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	15,56	24,77
Cycle 21 Day 1	White	16	26,7	14	87,5	30,95	20,52
	Other	13	15,3	12	92,3	22,22	21,71
Cycle 22 Day 1	White	16	26,7	13	81,3	25,64	27,74
	Other	13	15,3	12	92,3	27,78	23,92
Cycle 23 Day 1	White	12	20,0	10	83,3	26,67	30,63
	Other	9	10,6	8	88,9	12,50	17,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	26,67	21,08
	Other	9	10,6	8	88,9	25,00	15,43
Cycle 25 Day 1	White	10	16,7	8	80,0	20,83	17,25
	Other	5	5,9	5	100,0	26,67	14,91
Cycle 26 Day 1	White	10	16,7	8	80,0	33,33	43,64
	Other	4	4,7	4	100,0	33,33	0,00
Cycle 27 Day 1	White	8	13,3	5	62,5	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	33,33	33,33
Cycle 28 Day 1	White	7	11,7	6	85,7	16,67	18,26
	Other	3	3,5	3	100,0	33,33	33,33
Cycle 29 Day 1	White	6	10,0	4	66,7	33,33	0,00
	Other	3	3,5	3	100,0	33,33	0,00
Cycle 30 Day 1	White	4	6,7	2	50,0	33,33	0,00
	Other	3	3,5	3	100,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	33,33	0,00
	Other	3	3,5	3	100,0	33,33	0,00
Cycle 32 Day 1	White	4	6,7	3	75,0	22,22	19,25
	Other	2	2,4	2	100,0	33,33	0,00
Cycle 33 Day 1	White	2	3,3	2	100,0	16,67	23,57
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	49,02	20,81
	Other	39	45,9	27	69,2	41,98	27,10
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	35,00	30,15
	Europe (EU)	34	100,0	31	91,2	43,01	34,63
	Asia (AS)	71	100,0	71	100,0	33,80	30,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	33	86,8	31,31	27,56
	Europe (EU)	32	94,1	28	87,5	21,43	27,54
	Asia (AS)	66	93,0	65	98,5	25,64	25,53
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	26,26	18,18
	Europe (EU)	31	91,2	22	71,0	24,24	29,42
	Asia (AS)	63	88,7	63	100,0	23,81	21,11
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	25,49	24,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	14,67	19,44
	Asia (AS)	61	85,9	61	100,0	26,78	26,40
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	25,71	21,52
	Europe (EU)	30	88,2	26	86,7	23,08	22,65
	Asia (AS)	57	80,3	57	100,0	25,73	26,74
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	26,67	27,77
	Europe (EU)	28	82,4	25	89,3	24,00	22,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	23,08	26,02
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	33,33	28,08
	Europe (EU)	28	82,4	25	89,3	20,00	23,57
	Asia (AS)	50	70,4	49	98,0	25,17	25,03
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	22,22	18,49
	Europe (EU)	28	82,4	23	82,1	26,09	24,53
	Asia (AS)	47	66,2	47	100,0	24,11	23,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	21,43	18,62
	Europe (EU)	26	76,5	25	96,2	24,00	24,57
	Asia (AS)	43	60,6	43	100,0	22,48	24,90
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	26,39	19,61
	Europe (EU)	25	73,5	25	100,0	21,33	27,01
	Asia (AS)	37	52,1	37	100,0	26,13	19,46
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	23,19	25,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	22,73	18,93
	Asia (AS)	33	46,5	33	100,0	25,25	22,10
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	18,84	16,90
	Europe (EU)	23	67,6	18	78,3	22,22	19,80
	Asia (AS)	29	40,8	28	96,6	22,62	24,09
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	18,18	19,86
	Europe (EU)	18	52,9	15	83,3	33,33	30,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	17,33	19,53
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	22,22	16,10
	Europe (EU)	17	50,0	16	94,1	31,25	33,26
	Asia (AS)	21	29,6	20	95,2	21,67	22,36
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	21,67	19,57
	Europe (EU)	15	44,1	14	93,3	26,19	23,31
	Asia (AS)	20	28,2	20	100,0	21,67	19,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	19,61	20,61
	Europe (EU)	14	41,2	11	78,6	27,27	20,10
	Asia (AS)	19	26,8	19	100,0	31,58	26,00
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	22,92	23,47
	Europe (EU)	13	38,2	12	92,3	22,22	16,41
	Asia (AS)	16	22,5	16	100,0	27,08	30,35
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	19,05	21,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	14,29	17,82
	Asia (AS)	16	22,5	16	100,0	25,00	22,77
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	25,64	19,97
	Europe (EU)	9	26,5	8	88,9	33,33	25,20
	Asia (AS)	14	19,7	11	78,6	21,21	22,47
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	15,38	17,30
	Europe (EU)	9	26,5	6	66,7	38,89	25,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	17,95	25,88
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	30,00	18,92
	Europe (EU)	7	20,6	6	85,7	33,33	21,08
	Asia (AS)	11	15,5	10	90,9	20,00	23,31
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	30,00	29,19
	Europe (EU)	7	20,6	5	71,4	20,00	18,26
	Asia (AS)	11	15,5	10	90,9	26,67	26,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	25,93	32,39
	Europe (EU)	5	14,7	3	60,0	22,22	19,25
	Asia (AS)	7	9,9	6	85,7	11,11	17,21
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	33,33	17,82
	Europe (EU)	5	14,7	4	80,0	16,67	19,25
	Asia (AS)	7	9,9	6	85,7	22,22	17,21
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	23,81	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	16,67	23,57
	Asia (AS)	4	5,6	4	100,0	25,00	16,67
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	44,44	45,54
	Europe (EU)	4	11,8	2	50,0	16,67	23,57
	Asia (AS)	4	5,6	4	100,0	25,00	16,67
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	16,67	19,25
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	33,33	27,22
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	16,67	19,25
	Europe (EU)	2	5,9	1	50,0	0,00	-
	Asia (AS)	4	5,6	4	100,0	33,33	27,22
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	33,33	0,00
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	33,33	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	22,22	19,25
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	33,33	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	33,33	0,00
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	0,00	-
	Asia (AS)	3	4,2	2	66,7	33,33	0,00
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	33,33	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	47,06	26,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	60,00	27,89
	Asia (AS)	34	47,9	22	64,7	39,39	22,15
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	27,78	25,43
	1	69	100,0	67	97,1	40,30	32,07
	2	15	100,0	15	100,0	51,11	39,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	56	94,9	19,64	25,25
	1	67	97,1	60	89,6	32,22	27,42
	2	10	66,7	10	100,0	26,67	21,08
Cycle 3 Day 1	0	57	93,4	51	89,5	22,22	22,77
	1	65	94,2	58	89,2	27,59	21,75
	2	9	60,0	9	100,0	18,52	17,57
Cycle 4 Day 1	0	57	93,4	54	94,7	18,52	23,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	29,31	25,80
	2	9	60,0	8	88,9	20,83	24,80
Cycle 5 Day 1	0	56	91,8	53	94,6	23,90	21,06
	1	62	89,9	59	95,2	26,55	27,53
	2	6	40,0	6	100,0	22,22	17,21
Cycle 6 Day 1	0	56	91,8	54	96,4	25,93	25,63
	1	59	85,5	53	89,8	23,90	26,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	13,33	18,26
Cycle 7 Day 1	0	54	88,5	51	94,4	23,53	23,38
	1	54	78,3	50	92,6	30,00	27,97
	2	5	33,3	5	100,0	20,00	29,81
Cycle 8 Day 1	0	52	85,2	48	92,3	25,69	25,02
	1	49	71,0	44	89,8	21,21	19,14
	2	5	33,3	5	100,0	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	23,13	22,78
	1	44	63,8	43	97,7	22,48	23,82
	2	4	26,7	4	100,0	16,67	19,25
Cycle 10 Day 1	0	46	75,4	46	100,0	24,64	23,76
	1	40	58,0	37	92,5	26,13	19,46
	2	3	20,0	3	100,0	11,11	19,25
Cycle 11 Day 1	0	43	70,5	41	95,3	20,33	19,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	28,43	24,80
	2	3	20,0	3	100,0	22,22	19,25
Cycle 12 Day 1	0	42	68,9	36	85,7	23,15	19,22
	1	31	44,9	30	96,8	18,89	22,63
	2	3	20,0	3	100,0	22,22	19,25
Cycle 13 Day 1	0	38	62,3	34	89,5	21,57	24,46
	1	27	39,1	27	100,0	22,22	22,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	26,04	23,55
	1	24	34,8	24	100,0	23,61	25,02
	2	1	6,7	1	100,0	0,00	-
Cycle 15 Day 1	0	33	54,1	30	90,9	23,33	21,71
	1	23	33,3	23	100,0	23,19	18,63
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	25,33	22,11
	1	21	30,4	21	100,0	28,57	24,23
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	23,19	27,40
	1	20	29,0	20	100,0	26,67	20,52
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	21,05	22,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	19,61	20,61
	2	1	6,7	1	100,0	33,33	-
Cycle 19 Day 1	0	20	32,8	18	90,0	27,78	23,57
	1	15	21,7	13	86,7	25,64	19,97
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	25,49	22,14
	1	15	21,7	14	93,3	16,67	25,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	30,95	24,33
	1	13	18,8	11	84,6	24,24	15,57
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	33,33	28,43
	1	13	18,8	12	92,3	22,22	21,71
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	25,93	32,39
	1	9	13,0	8	88,9	16,67	17,82
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	25,93	22,22
	1	9	13,0	8	88,9	25,00	15,43
	2	1	6,7	1	100,0	33,33	-
Cycle 25 Day 1	0	8	13,1	6	75,0	22,22	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	23,81	16,27
Cycle 26 Day 1	0	8	13,1	6	75,0	27,78	38,97
	1	6	8,7	6	100,0	38,89	32,77
Cycle 27 Day 1	0	6	9,8	3	50,0	22,22	19,25
	1	5	7,2	5	100,0	26,67	27,89
Cycle 28 Day 1	0	5	8,2	4	80,0	16,67	19,25
	1	5	7,2	5	100,0	26,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	33,33	0,00
	1	5	7,2	5	100,0	33,33	0,00
Cycle 30 Day 1	0	3	4,9	1	33,3	33,33	-
	1	4	5,8	4	100,0	25,00	16,67
Cycle 31 Day 1	0	3	4,9	1	33,3	33,33	-
	1	4	5,8	4	100,0	33,33	0,00
Cycle 32 Day 1	0	3	4,9	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	33,33	0,00
Cycle 33 Day 1	0	2	3,3	2	100,0	16,67	23,57
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	46,03	22,30
	1	34	49,3	20	58,8	41,67	28,36
	2	7	46,7	3	42,9	55,56	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	40,00	32,36
	1	4	100,0	4	100,0	33,33	47,14
	2 or More	79	100,0	78	98,7	33,33	29,42
Cycle 2 Day 1	None	60	96,8	55	91,7	27,88	27,04
	1	3	75,0	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	25,12	26,45
Cycle 3 Day 1	None	59	95,2	53	89,8	23,27	23,19
	1	3	75,0	2	66,7	16,67	23,57
	2 or More	69	87,3	63	91,3	25,93	21,12
Cycle 4 Day 1	None	59	95,2	56	94,9	22,62	24,71
	1	3	75,0	2	66,7	16,67	23,57
	2 or More	66	83,5	62	93,9	25,27	25,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	24,40	22,47
	1	3	75,0	3	100,0	11,11	19,25
	2 or More	63	79,7	59	93,7	26,55	26,10
Cycle 6 Day 1	None	57	91,9	52	91,2	20,51	23,01
	1	3	75,0	3	100,0	11,11	19,25
	2 or More	61	77,2	57	93,4	28,65	27,77
Cycle 7 Day 1	None	52	83,9	50	96,2	26,67	26,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	11,11	19,25
	2 or More	58	73,4	53	91,4	27,04	26,20
Cycle 8 Day 1	None	50	80,6	46	92,0	21,74	22,46
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	26,67	22,34
Cycle 9 Day 1	None	48	77,4	47	97,9	19,86	19,24
	1	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	25,00	26,18
Cycle 10 Day 1	None	43	69,4	41	95,3	23,58	22,66
	1	1	25,0	1	100,0	33,33	-
	2 or More	45	57,0	44	97,8	25,76	21,40
Cycle 11 Day 1	None	37	59,7	35	94,6	20,95	25,67
	1	1	25,0	1	100,0	33,33	-
	2 or More	42	53,2	42	100,0	26,19	18,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	19,61	20,30
	1	1	25,0	1	100,0	33,33	-
	2 or More	38	48,1	34	89,5	22,55	21,27
Cycle 13 Day 1	None	34	54,8	30	88,2	18,89	20,87
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	24,73	25,77
Cycle 14 Day 1	None	31	50,0	29	93,5	20,69	24,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	33,33	-
	2 or More	28	35,4	27	96,4	28,40	23,94
Cycle 15 Day 1	None	30	48,4	28	93,3	19,05	19,09
	1	1	25,0	1	100,0	33,33	-
	2 or More	26	32,9	25	96,2	26,67	21,52
Cycle 16 Day 1	None	25	40,3	23	92,0	21,74	25,84
	1	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	30,43	19,88
Cycle 17 Day 1	None	23	37,1	22	95,7	19,70	22,20
	1	1	25,0	1	100,0	0,00	-
	2 or More	21	26,6	21	100,0	30,16	25,61
Cycle 18 Day 1	None	20	32,3	18	90,0	14,81	23,49
	1	1	25,0	1	100,0	0,00	-
	2 or More	20	25,3	18	90,0	27,78	17,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	17,65	20,81
	1	1	25,0	1	100,0	33,33	-
	2 or More	18	22,8	14	77,8	35,71	20,52
Cycle 20 Day 1	None	17	27,4	16	94,1	16,67	21,08
	1	1	25,0	1	100,0	33,33	-
	2 or More	18	22,8	15	83,3	24,44	26,63
Cycle 21 Day 1	None	15	24,2	13	86,7	23,08	16,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	30,77	25,32
Cycle 22 Day 1	None	15	24,2	13	86,7	25,64	19,97
	2 or More	14	17,7	12	85,7	27,78	31,25
Cycle 23 Day 1	None	10	16,1	9	90,0	14,81	17,57
	2 or More	11	13,9	9	81,8	25,93	32,39
Cycle 24 Day 1	None	10	16,1	10	100,0	23,33	16,10
	2 or More	10	12,7	8	80,0	29,17	21,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	25,00	15,43
	2 or More	6	7,6	5	83,3	20,00	18,26
Cycle 26 Day 1	None	8	12,9	8	100,0	25,00	34,50
	2 or More	6	7,6	4	66,7	50,00	33,33
Cycle 27 Day 1	None	7	11,3	6	85,7	27,78	25,09
	2 or More	4	5,1	2	50,0	16,67	23,57
Cycle 28 Day 1	None	7	11,3	7	100,0	23,81	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	9,7	5	83,3	33,33	0,00
	2 or More	3	3,8	2	66,7	33,33	0,00
Cycle 30 Day 1	None	4	6,5	3	75,0	33,33	0,00
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 31 Day 1	None	4	6,5	3	75,0	33,33	0,00
	2 or More	3	3,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	33,33	0,00
	2 or More	2	2,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	1,6	1	100,0	33,33	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	43,86	24,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	66,67	-
	2 or More	39	49,4	24	61,5	44,44	25,38
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	40,00	32,36
	Previously Treated	83	100,0	82	98,8	33,33	30,09
Cycle 2 Day 1	Naïve	60	96,8	55	91,7	27,88	27,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	24,88	26,26
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	23,27	23,19
	Previously Treated	72	86,7	65	90,3	25,64	21,06
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	22,62	24,71
	Previously Treated	69	83,1	64	92,8	25,00	25,20
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	24,40	22,47
	Previously Treated	66	79,5	62	93,9	25,81	25,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	20,51	23,01
	Previously Treated	64	77,1	60	93,8	27,78	27,56
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	26,67	26,08
	Previously Treated	61	73,5	56	91,8	26,19	25,99
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	21,74	22,46
	Previously Treated	56	67,5	51	91,1	26,14	22,42
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	19,86	19,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	25,17	25,94
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	23,58	22,66
	Previously Treated	46	55,4	45	97,8	25,93	21,19
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	20,95	25,67
	Previously Treated	43	51,8	43	100,0	26,36	18,63
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	19,61	20,30
	Previously Treated	39	47,0	35	89,7	22,86	21,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	18,89	20,87
	Previously Treated	32	38,6	32	100,0	23,96	25,73
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	20,69	24,26
	Previously Treated	29	34,9	28	96,6	28,57	23,51
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	19,05	19,09
	Previously Treated	27	32,5	26	96,3	26,92	21,12
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	21,74	25,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	30,56	19,45
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	19,70	22,20
	Previously Treated	22	26,5	22	100,0	28,79	25,81
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	14,81	23,49
	Previously Treated	21	25,3	19	90,5	26,32	17,84
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	17,65	20,81
	Previously Treated	19	22,9	15	78,9	35,56	19,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	16,67	21,08
	Previously Treated	19	22,9	16	84,2	25,00	25,82
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	23,08	16,01
	Previously Treated	14	16,9	13	92,9	30,77	25,32
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	25,64	19,97
	Previously Treated	14	16,9	12	85,7	27,78	31,25
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	14,81	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	25,93	32,39
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	23,33	16,10
	Previously Treated	10	12,0	8	80,0	29,17	21,36
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	25,00	15,43
	Previously Treated	6	7,2	5	83,3	20,00	18,26
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	25,00	34,50
	Previously Treated	6	7,2	4	66,7	50,00	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	27,78	25,09
	Previously Treated	4	4,8	2	50,0	16,67	23,57
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	23,81	25,20
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	33,33	0,00
	Previously Treated	3	3,6	2	66,7	33,33	0,00
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	33,33	0,00
	Previously Treated	3	3,6	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	33,33	0,00
	Previously Treated	2	2,4	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	33,33	-
	Previously Treated	1	1,2	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	43,86	24,98
	Previously Treated	42	50,6	25	59,5	45,33	25,24
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	36,89	29,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	35,32	33,27
Cycle 2 Day 1	Local	71	94,7	67	94,4	25,37	24,68
	Central	65	92,9	59	90,8	27,12	28,68
Cycle 3 Day 1	Local	67	89,3	62	92,5	24,73	20,85
	Central	64	91,4	56	87,5	24,40	23,35
Cycle 4 Day 1	Local	65	86,7	61	93,8	24,04	25,19
	Central	63	90,0	59	93,7	23,73	24,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	24,86	24,44
	Central	61	87,1	59	96,7	25,42	24,24
Cycle 6 Day 1	Local	63	84,0	61	96,8	27,32	28,22
	Central	58	82,9	51	87,9	20,92	22,07
Cycle 7 Day 1	Local	61	81,3	59	96,7	28,25	27,55
	Central	52	74,3	47	90,4	24,11	23,78
Cycle 8 Day 1	Local	57	76,0	55	96,5	24,24	20,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	23,81	24,73
Cycle 9 Day 1	Local	54	72,0	53	98,1	23,27	25,81
	Central	44	62,9	43	97,7	21,71	19,08
Cycle 10 Day 1	Local	48	64,0	46	95,8	26,81	24,96
	Central	41	58,6	40	97,6	22,50	17,52
Cycle 11 Day 1	Local	40	53,3	38	95,0	27,19	23,06
	Central	40	57,1	40	100,0	20,83	20,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	19,19	18,69
	Central	40	57,1	36	90,0	23,15	22,28
Cycle 13 Day 1	Local	30	40,0	29	96,7	19,54	26,00
	Central	36	51,4	33	91,7	23,23	21,22
Cycle 14 Day 1	Local	27	36,0	27	100,0	20,99	22,92
	Central	33	47,1	30	90,9	27,78	24,89
Cycle 15 Day 1	Local	26	34,7	25	96,2	20,00	21,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	25,29	19,22
Cycle 16 Day 1	Local	24	32,0	24	100,0	23,61	20,80
	Central	26	37,1	23	88,5	28,99	25,23
Cycle 17 Day 1	Local	22	29,3	22	100,0	21,21	21,93
	Central	23	32,9	22	95,7	27,27	26,50
Cycle 18 Day 1	Local	20	26,7	19	95,0	21,05	19,91
	Central	21	30,0	18	85,7	20,37	23,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	27,45	24,25
	Central	17	24,3	15	88,2	24,44	19,79
Cycle 20 Day 1	Local	19	25,3	17	89,5	11,76	20,21
	Central	17	24,3	15	88,2	31,11	23,46
Cycle 21 Day 1	Local	14	18,7	12	85,7	16,67	17,41
	Central	15	21,4	14	93,3	35,71	20,52
Cycle 22 Day 1	Local	14	18,7	12	85,7	19,44	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	33,33	30,43
Cycle 23 Day 1	Local	11	14,7	10	90,9	10,00	16,10
	Central	10	14,3	8	80,0	33,33	30,86
Cycle 24 Day 1	Local	11	14,7	10	90,9	30,00	18,92
	Central	9	12,9	8	88,9	20,83	17,25
Cycle 25 Day 1	Local	7	9,3	7	100,0	23,81	16,27
	Central	8	11,4	6	75,0	22,22	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	33,33	36,51
	Central	8	11,4	6	75,0	33,33	36,51
Cycle 27 Day 1	Local	4	5,3	4	100,0	33,33	27,22
	Central	7	10,0	4	57,1	16,67	19,25
Cycle 28 Day 1	Local	4	5,3	4	100,0	33,33	27,22
	Central	6	8,6	5	83,3	13,33	18,26
Cycle 29 Day 1	Local	3	4,0	3	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	33,33	0,00
Cycle 30 Day 1	Local	3	4,0	3	100,0	33,33	0,00
	Central	4	5,7	2	50,0	16,67	23,57
Cycle 31 Day 1	Local	3	4,0	3	100,0	33,33	0,00
	Central	4	5,7	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	4,0	3	100,0	33,33	0,00
	Central	3	4,3	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	33,33	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	43,06	26,88
	Central	32	45,7	20	62,5	46,67	22,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	35,35	31,03
	No	10	100,0	10	100,0	46,67	32,20
Cycle 2 Day 1	Yes	129	95,6	119	92,2	25,49	26,29
	No	7	70,0	7	100,0	38,10	29,99
Cycle 3 Day 1	Yes	124	91,9	112	90,3	23,81	21,66
	No	7	70,0	6	85,7	38,89	25,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	23,01	24,43
	No	7	70,0	7	100,0	38,10	29,99
Cycle 5 Day 1	Yes	117	86,7	112	95,7	24,11	23,76
	No	7	70,0	6	85,7	44,44	27,22
Cycle 6 Day 1	Yes	114	84,4	105	92,1	22,54	24,68
	No	7	70,0	7	100,0	52,38	26,23
Cycle 7 Day 1	Yes	106	78,5	99	93,4	25,59	25,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	38,10	35,63
Cycle 8 Day 1	Yes	100	74,1	91	91,0	23,81	22,38
	No	6	60,0	6	100,0	27,78	25,09
Cycle 9 Day 1	Yes	92	68,1	90	97,8	22,22	22,90
	No	6	60,0	6	100,0	27,78	25,09
Cycle 10 Day 1	Yes	83	61,5	80	96,4	25,42	22,02
	No	6	60,0	6	100,0	16,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	23,42	21,88
	No	4	40,0	4	100,0	33,33	27,22
Cycle 12 Day 1	Yes	72	53,3	65	90,3	20,51	20,15
	No	4	40,0	4	100,0	33,33	27,22
Cycle 13 Day 1	Yes	64	47,4	60	93,8	21,11	23,74
	No	2	20,0	2	100,0	33,33	0,00
Cycle 14 Day 1	Yes	58	43,0	55	94,8	24,24	23,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	33,33	47,14
Cycle 15 Day 1	Yes	55	40,7	52	94,5	22,44	19,49
	No	2	20,0	2	100,0	33,33	47,14
Cycle 16 Day 1	Yes	48	35,6	45	93,8	24,44	21,79
	No	2	20,0	2	100,0	66,67	0,00
Cycle 17 Day 1	Yes	43	31,9	42	97,7	21,43	20,59
	No	2	20,0	2	100,0	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	20,00	20,13
	No	2	20,0	2	100,0	33,33	47,14
Cycle 19 Day 1	Yes	34	25,2	31	91,2	25,81	22,29
	No	2	20,0	1	50,0	33,33	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	20,00	22,49
	No	2	20,0	2	100,0	33,33	47,14
Cycle 21 Day 1	Yes	27	20,0	24	88,9	26,39	19,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	33,33	47,14
Cycle 22 Day 1	Yes	27	20,0	23	85,2	24,64	25,06
	No	2	20,0	2	100,0	50,00	23,57
Cycle 23 Day 1	Yes	20	14,8	17	85,0	21,57	26,20
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	27,45	17,62
	No	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	22,22	16,41
	No	1	10,0	1	100,0	33,33	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	33,33	36,51
	No	1	10,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	19,05	17,82
	No	1	10,0	1	100,0	66,67	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	16,67	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	66,67	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	33,33	0,00
	No	1	10,0	1	100,0	33,33	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	25,00	16,67
	No	1	10,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	33,33	0,00
	No	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	25,00	16,67
	No	1	10,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	16,67	23,57
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	43,41	23,61
	No	2	20,0	1	50,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	45,45	34,23
	No	134	100,0	131	97,8	35,37	30,87
Cycle 2 Day 1	Yes	7	63,6	7	100,0	23,81	37,09
	No	129	96,3	119	92,2	26,33	25,99
Cycle 3 Day 1	Yes	7	63,6	7	100,0	23,81	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	24,62	22,34
Cycle 4 Day 1	Yes	7	63,6	7	100,0	9,52	16,27
	No	121	90,3	113	93,4	24,78	25,11
Cycle 5 Day 1	Yes	7	63,6	7	100,0	33,33	33,33
	No	117	87,3	111	94,9	24,62	23,66
Cycle 6 Day 1	Yes	7	63,6	7	100,0	14,29	26,23
	No	114	85,1	105	92,1	25,08	25,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	28,57	29,99
	No	106	79,1	99	93,4	26,26	25,76
Cycle 8 Day 1	Yes	7	63,6	7	100,0	23,81	25,20
	No	99	73,9	90	90,9	24,07	22,36
Cycle 9 Day 1	Yes	6	54,5	6	100,0	33,33	21,08
	No	92	68,7	90	97,8	21,85	22,99
Cycle 10 Day 1	Yes	6	54,5	6	100,0	22,22	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	25,00	21,54
Cycle 11 Day 1	Yes	6	54,5	6	100,0	44,44	34,43
	No	74	55,2	72	97,3	22,22	20,17
Cycle 12 Day 1	Yes	6	54,5	6	100,0	22,22	17,21
	No	70	52,2	63	90,0	21,16	21,00
Cycle 13 Day 1	Yes	5	45,5	5	100,0	26,67	27,89
	No	61	45,5	57	93,4	21,05	23,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	20,00	18,26
	No	55	41,0	52	94,5	25,00	24,59
Cycle 15 Day 1	Yes	4	36,4	4	100,0	25,00	31,91
	No	53	39,6	50	94,3	22,67	19,56
Cycle 16 Day 1	Yes	3	27,3	3	100,0	33,33	33,33
	No	47	35,1	44	93,6	25,76	22,58
Cycle 17 Day 1	Yes	3	27,3	3	100,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	24,39	24,75
Cycle 18 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	38	28,4	34	89,5	21,57	21,53
Cycle 19 Day 1	Yes	3	27,3	3	100,0	22,22	19,25
	No	33	24,6	29	87,9	26,44	22,50
Cycle 20 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	33	24,6	29	87,9	21,84	24,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	33,33	0,00
	No	27	20,1	24	88,9	26,39	21,93
Cycle 22 Day 1	Yes	2	18,2	2	100,0	33,33	0,00
	No	27	20,1	23	85,2	26,09	26,51
Cycle 23 Day 1	Yes	2	18,2	2	100,0	33,33	0,00
	No	19	14,2	16	84,2	18,75	27,13
Cycle 24 Day 1	Yes	2	18,2	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	25,00	19,25
Cycle 25 Day 1	Yes	2	18,2	2	100,0	33,33	0,00
	No	13	9,7	11	84,6	21,21	16,82
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	36,36	34,82
Cycle 27 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	10	7,5	7	70,0	23,81	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	9	6,7	8	88,9	20,83	24,80
Cycle 29 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	8	6,0	6	75,0	33,33	0,00
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	26,67	14,91
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	33,33	0,00
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	26,67	14,91
Cycle 33 Day 1	No	2	1,5	2	100,0	16,67	23,57
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	66,67	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	43,09	23,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30DY_SG.xls
24JUN2020 20:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	74,77	19,06
Cycle 2 Day 1	All	136	93,8	125	91,9	80,20	19,90
Cycle 3 Day 1	All	131	90,3	118	90,1	82,27	17,11
Cycle 4 Day 1	All	128	88,3	120	93,8	81,74	17,73
Cycle 5 Day 1	All	124	85,5	118	95,2	82,34	17,40
Cycle 6 Day 1	All	121	83,4	112	92,6	80,21	16,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	80,90	18,58
Cycle 8 Day 1	All	106	73,1	97	91,5	82,73	17,40
Cycle 9 Day 1	All	98	67,6	96	98,0	83,07	15,83
Cycle 10 Day 1	All	89	61,4	86	96,6	82,75	17,89
Cycle 11 Day 1	All	80	55,2	78	97,5	82,59	16,57
Cycle 12 Day 1	All	76	52,4	69	90,8	83,09	16,17
Cycle 13 Day 1	All	66	45,5	62	93,9	83,06	18,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	79,97	20,46
Cycle 15 Day 1	All	57	39,3	54	94,7	84,41	15,53
Cycle 16 Day 1	All	50	34,5	47	94,0	80,50	17,49
Cycle 17 Day 1	All	45	31,0	44	97,8	82,20	18,29
Cycle 18 Day 1	All	41	28,3	37	90,2	83,11	16,95
Cycle 19 Day 1	All	36	24,8	33	91,7	85,10	14,55
Cycle 20 Day 1	All	36	24,8	32	88,9	83,33	16,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	81,41	16,38
Cycle 22 Day 1	All	29	20,0	25	86,2	82,00	17,63
Cycle 23 Day 1	All	21	14,5	18	85,7	79,63	24,12
Cycle 24 Day 1	All	20	13,8	18	90,0	80,56	18,08
Cycle 25 Day 1	All	15	10,3	13	86,7	78,21	14,65
Cycle 26 Day 1	All	14	9,7	12	85,7	81,94	18,06
Cycle 27 Day 1	All	11	7,6	8	72,7	77,08	13,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	69,44	23,20
Cycle 29 Day 1	All	9	6,2	7	77,8	70,24	19,75
Cycle 30 Day 1	All	7	4,8	5	71,4	65,00	9,13
Cycle 31 Day 1	All	7	4,8	5	71,4	71,67	7,45
Cycle 32 Day 1	All	6	4,1	5	83,3	73,33	27,26
Cycle 33 Day 1	All	2	1,4	2	100,0	75,00	35,36
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	71,02	17,75
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	75,00	18,86
	Female	93	100,0	91	97,8	74,63	19,28
Cycle 2 Day 1	Male	50	96,2	46	92,0	75,36	24,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	83,02	16,26
Cycle 3 Day 1	Male	47	90,4	42	89,4	82,54	18,39
	Female	84	90,3	76	90,5	82,13	16,48
Cycle 4 Day 1	Male	46	88,5	45	97,8	79,63	20,14
	Female	82	88,2	75	91,5	83,00	16,12
Cycle 5 Day 1	Male	45	86,5	43	95,6	80,23	19,07
	Female	79	84,9	75	94,9	83,56	16,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	78,66	17,97
	Female	76	81,7	71	93,4	81,10	16,30
Cycle 7 Day 1	Male	40	76,9	39	97,5	79,06	22,53
	Female	73	78,5	67	91,8	81,97	15,93
Cycle 8 Day 1	Male	37	71,2	34	91,9	82,84	20,92
	Female	69	74,2	63	91,3	82,67	15,36
Cycle 9 Day 1	Male	33	63,5	33	100,0	84,09	16,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	82,54	15,61
Cycle 10 Day 1	Male	30	57,7	30	100,0	85,28	16,76
	Female	59	63,4	56	94,9	81,40	18,46
Cycle 11 Day 1	Male	29	55,8	29	100,0	83,91	14,59
	Female	51	54,8	49	96,1	81,80	17,73
Cycle 12 Day 1	Male	27	51,9	26	96,3	83,01	15,72
	Female	49	52,7	43	87,8	83,14	16,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	82,97	18,37
	Female	41	44,1	39	95,1	83,12	18,48
Cycle 14 Day 1	Male	23	44,2	21	91,3	76,19	20,63
	Female	37	39,8	36	97,3	82,18	20,33
Cycle 15 Day 1	Male	21	40,4	20	95,2	80,83	14,58
	Female	36	38,7	34	94,4	86,52	15,89
Cycle 16 Day 1	Male	16	30,8	16	100,0	78,65	13,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	81,45	19,21
Cycle 17 Day 1	Male	13	25,0	13	100,0	80,13	20,84
	Female	32	34,4	31	96,9	83,06	17,41
Cycle 18 Day 1	Male	12	23,1	11	91,7	82,58	16,01
	Female	29	31,2	26	89,7	83,33	17,64
Cycle 19 Day 1	Male	10	19,2	10	100,0	80,83	16,69
	Female	26	28,0	23	88,5	86,96	13,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	81,48	18,99
	Female	26	28,0	23	88,5	84,06	15,87
Cycle 21 Day 1	Male	8	15,4	8	100,0	77,08	20,77
	Female	21	22,6	18	85,7	83,33	14,29
Cycle 22 Day 1	Male	8	15,4	6	75,0	86,11	15,52
	Female	21	22,6	19	90,5	80,70	18,44
Cycle 23 Day 1	Male	5	9,6	4	80,0	87,50	14,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	77,38	26,24
Cycle 24 Day 1	Male	5	9,6	4	80,0	66,67	24,53
	Female	15	16,1	14	93,3	84,52	14,57
Cycle 25 Day 1	Male	3	5,8	2	66,7	79,17	17,68
	Female	12	12,9	11	91,7	78,03	15,03
Cycle 26 Day 1	Male	3	5,8	2	66,7	75,00	23,57
	Female	11	11,8	10	90,9	83,33	18,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	75,00	23,57
	Female	8	8,6	6	75,0	77,78	11,39
Cycle 28 Day 1	Male	2	3,8	2	100,0	70,83	29,46
	Female	8	8,6	7	87,5	69,05	23,92
Cycle 29 Day 1	Male	1	1,9	1	100,0	41,67	-
	Female	8	8,6	6	75,0	75,00	16,67
Cycle 30 Day 1	Male	1	1,9	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	68,75	4,17
Cycle 31 Day 1	Male	1	1,9	1	100,0	66,67	-
	Female	6	6,5	4	66,7	72,92	7,98
Cycle 32 Day 1	Male	1	1,9	1	100,0	33,33	-
	Female	5	5,4	4	80,0	83,33	18,00
Cycle 33 Day 1	Male	1	1,9	1	100,0	50,00	-
	Female	1	1,1	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	71,83	19,45
	Female	37	39,8	23	62,2	70,29	16,44
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	75,24	19,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	74,71	18,02
	>=75	7	100,0	7	100,0	67,86	18,90
Cycle 2 Day 1	18-64	103	94,5	93	90,3	80,82	19,88
	65-74	26	89,7	25	96,2	76,67	21,25
	>=75	7	100,0	7	100,0	84,52	15,54
Cycle 3 Day 1	18-64	99	90,8	87	87,9	82,28	16,66
	65-74	25	86,2	24	96,0	84,38	18,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	75,00	19,25
Cycle 4 Day 1	18-64	98	89,9	92	93,9	81,61	17,84
	65-74	23	79,3	21	91,3	80,56	19,25
	>=75	7	100,0	7	100,0	86,90	11,64
Cycle 5 Day 1	18-64	95	87,2	90	94,7	82,96	16,85
	65-74	22	75,9	22	100,0	80,30	19,68
	>=75	7	100,0	6	85,7	80,56	19,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	80,65	16,67
	65-74	22	75,9	21	95,5	78,97	17,80
	>=75	7	100,0	7	100,0	78,57	19,16
Cycle 7 Day 1	18-64	86	78,9	81	94,2	80,14	18,75
	65-74	20	69,0	19	95,0	82,46	19,02
	>=75	7	100,0	6	85,7	86,11	16,39
Cycle 8 Day 1	18-64	80	73,4	72	90,0	82,99	18,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	81,58	14,85
	>=75	7	100,0	6	85,7	83,33	15,81
Cycle 9 Day 1	18-64	74	67,9	73	98,6	83,90	14,46
	65-74	18	62,1	18	100,0	79,17	18,80
	>=75	6	85,7	5	83,3	85,00	24,58
Cycle 10 Day 1	18-64	69	63,3	66	95,7	83,08	17,05
	65-74	15	51,7	15	100,0	79,44	22,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	88,33	13,94
Cycle 11 Day 1	18-64	61	56,0	59	96,7	82,06	16,65
	65-74	15	51,7	15	100,0	82,22	16,63
	>=75	4	57,1	4	100,0	91,67	16,67
Cycle 12 Day 1	18-64	57	52,3	51	89,5	83,50	15,68
	65-74	15	51,7	14	93,3	79,17	17,83
	>=75	4	57,1	4	100,0	91,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	84,78	16,79
	65-74	13	44,8	12	92,3	74,31	22,88
	>=75	4	57,1	4	100,0	89,58	15,77
Cycle 14 Day 1	18-64	45	41,3	44	97,8	81,82	17,82
	65-74	13	44,8	11	84,6	71,97	29,64
	>=75	2	28,6	2	100,0	83,33	11,79
Cycle 15 Day 1	18-64	43	39,4	41	95,3	86,18	13,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	77,27	21,44
	>=75	2	28,6	2	100,0	87,50	17,68
Cycle 16 Day 1	18-64	38	34,9	36	94,7	80,56	18,58
	65-74	10	34,5	9	90,0	79,63	13,25
	>=75	2	28,6	2	100,0	83,33	23,57
Cycle 17 Day 1	18-64	36	33,0	35	97,2	82,38	18,05
	65-74	8	27,6	8	100,0	83,33	20,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	66,67	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	85,00	15,23
	65-74	7	24,1	6	85,7	75,00	24,72
	>=75	1	14,3	1	100,0	75,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	86,90	14,24
	65-74	5	17,2	4	80,0	75,00	15,21
	>=75	1	14,3	1	100,0	75,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	85,26	16,38
	65-74	5	17,2	5	100,0	75,00	17,68
	>=75	1	14,3	1	100,0	75,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	82,54	16,44
	65-74	4	13,8	4	100,0	81,25	15,77
	>=75	1	14,3	1	100,0	58,33	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	83,75	17,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	77,08	18,48
	>=75	1	14,3	1	100,0	66,67	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	77,08	24,44
	65-74	2	6,9	2	100,0	100,00	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	81,25	19,12
	65-74	2	6,9	2	100,0	75,00	0,00
Cycle 25 Day 1	18-64	14	12,8	12	85,7	77,08	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	91,67	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	81,94	18,06
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	77,08	13,18
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	69,44	23,20
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	70,24	19,75
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	65,00	9,13
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	71,67	7,45
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	68,75	29,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	91,67	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	50,00	-
	65-74	1	3,4	1	100,0	100,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	68,63	16,67
	65-74	15	51,7	8	53,3	81,25	15,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	70,83	41,25
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	72,84	18,64
	Other	85	100,0	84	98,8	76,09	19,35
Cycle 2 Day 1	White	57	95,0	50	87,7	79,17	20,01
	Other	79	92,9	75	94,9	80,89	19,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	82,01	18,41
	Other	77	90,6	74	96,1	82,43	16,41
Cycle 4 Day 1	White	53	88,3	47	88,7	82,98	15,63
	Other	75	88,2	73	97,3	80,94	19,02
Cycle 5 Day 1	White	52	86,7	48	92,3	81,60	18,27
	Other	72	84,7	70	97,2	82,86	16,90
Cycle 6 Day 1	White	50	83,3	44	88,0	79,73	16,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	80,51	17,01
Cycle 7 Day 1	White	47	78,3	42	89,4	79,76	16,17
	Other	66	77,6	64	97,0	81,64	20,10
Cycle 8 Day 1	White	45	75,0	39	86,7	79,70	17,50
	Other	61	71,8	58	95,1	84,77	17,18
Cycle 9 Day 1	White	42	70,0	41	97,6	81,71	17,99
	Other	56	65,9	55	98,2	84,09	14,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	79,06	21,11
	Other	48	56,5	47	97,9	85,82	14,21
Cycle 11 Day 1	White	37	61,7	37	100,0	81,98	19,59
	Other	43	50,6	41	95,3	83,13	13,50
Cycle 12 Day 1	White	37	61,7	33	89,2	80,30	18,84
	Other	39	45,9	36	92,3	85,65	13,00
Cycle 13 Day 1	White	32	53,3	30	93,8	80,83	19,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	85,16	16,63
Cycle 14 Day 1	White	31	51,7	30	96,8	80,00	22,17
	Other	29	34,1	27	93,1	79,94	18,81
Cycle 15 Day 1	White	30	50,0	28	93,3	81,25	16,45
	Other	27	31,8	26	96,3	87,82	13,99
Cycle 16 Day 1	White	26	43,3	24	92,3	78,47	19,49
	Other	24	28,2	23	95,8	82,61	15,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	80,90	19,58
	Other	21	24,7	20	95,2	83,75	16,99
Cycle 18 Day 1	White	22	36,7	19	86,4	85,96	13,90
	Other	19	22,4	18	94,7	80,09	19,62
Cycle 19 Day 1	White	20	33,3	20	100,0	83,33	15,29
	Other	16	18,8	13	81,3	87,82	13,44
Cycle 20 Day 1	White	20	33,3	17	85,0	82,35	17,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	84,44	15,39
Cycle 21 Day 1	White	16	26,7	14	87,5	80,95	18,03
	Other	13	15,3	12	92,3	81,94	15,01
Cycle 22 Day 1	White	16	26,7	13	81,3	83,33	18,94
	Other	13	15,3	12	92,3	80,56	16,79
Cycle 23 Day 1	White	12	20,0	10	83,3	76,67	28,81
	Other	9	10,6	8	88,9	83,33	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	80,83	20,05
	Other	9	10,6	8	88,9	80,21	16,63
Cycle 25 Day 1	White	10	16,7	8	80,0	80,21	15,39
	Other	5	5,9	5	100,0	75,00	14,43
Cycle 26 Day 1	White	10	16,7	8	80,0	81,25	18,77
	Other	4	4,7	4	100,0	83,33	19,25
Cycle 27 Day 1	White	8	13,3	5	62,5	75,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	80,56	17,35
Cycle 28 Day 1	White	7	11,7	6	85,7	75,00	19,72
	Other	3	3,5	3	100,0	58,33	30,05
Cycle 29 Day 1	White	6	10,0	4	66,7	60,42	17,18
	Other	3	3,5	3	100,0	83,33	16,67
Cycle 30 Day 1	White	4	6,7	2	50,0	62,50	17,68
	Other	3	3,5	3	100,0	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	75,00	11,79
	Other	3	3,5	3	100,0	69,44	4,81
Cycle 32 Day 1	White	4	6,7	3	75,0	69,44	31,55
	Other	2	2,4	2	100,0	79,17	29,46
Cycle 33 Day 1	White	2	3,3	2	100,0	75,00	35,36
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	68,63	19,21
	Other	39	45,9	27	69,2	72,53	16,96
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	78,54	16,97
	Europe (EU)	34	100,0	31	91,2	70,16	19,46
	Asia (AS)	71	100,0	71	100,0	74,65	19,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	83,59	17,26
	Europe (EU)	32	94,1	28	87,5	73,21	26,58
	Asia (AS)	66	93,0	65	98,5	81,54	17,21
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	82,32	17,77
	Europe (EU)	31	91,2	22	71,0	76,14	22,46
	Asia (AS)	63	88,7	63	100,0	84,39	14,16
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	82,84	17,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	76,00	21,56
	Asia (AS)	61	85,9	61	100,0	83,47	15,77
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	82,62	16,71
	Europe (EU)	30	88,2	26	86,7	79,81	22,13
	Asia (AS)	57	80,3	57	100,0	83,33	15,51
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	83,10	15,72
	Europe (EU)	28	82,4	25	89,3	72,67	20,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	81,89	15,19
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	80,99	19,54
	Europe (EU)	28	82,4	25	89,3	72,67	21,85
	Asia (AS)	50	70,4	49	98,0	85,03	14,73
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	84,57	15,28
	Europe (EU)	28	82,4	23	82,1	77,90	18,05
	Asia (AS)	47	66,2	47	100,0	84,04	18,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	84,52	15,83
	Europe (EU)	26	76,5	25	96,2	80,00	17,68
	Asia (AS)	43	60,6	43	100,0	83,91	14,82
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	86,46	16,27
	Europe (EU)	25	73,5	25	100,0	76,67	22,69
	Asia (AS)	37	52,1	37	100,0	84,46	14,32
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	86,59	16,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	78,03	19,84
	Asia (AS)	33	46,5	33	100,0	82,83	13,97
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	84,42	16,15
	Europe (EU)	23	67,6	18	78,3	75,46	19,06
	Asia (AS)	29	40,8	28	96,6	86,90	12,71
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	84,85	15,14
	Europe (EU)	18	52,9	15	83,3	73,33	24,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	87,33	14,46
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	84,92	17,00
	Europe (EU)	17	50,0	16	94,1	73,44	27,42
	Asia (AS)	21	29,6	20	95,2	80,00	16,53
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	86,67	13,89
	Europe (EU)	15	44,1	14	93,3	77,98	18,38
	Asia (AS)	20	28,2	20	100,0	86,67	14,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	80,88	19,27
	Europe (EU)	14	41,2	11	78,6	78,79	15,08
	Asia (AS)	19	26,8	19	100,0	81,14	17,97
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	85,94	19,42
	Europe (EU)	13	38,2	12	92,3	78,47	19,29
	Asia (AS)	16	22,5	16	100,0	81,25	16,80
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	86,31	15,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	84,52	14,77
	Asia (AS)	16	22,5	16	100,0	79,69	19,24
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	83,33	16,32
	Europe (EU)	9	26,5	9	100,0	82,41	14,70
	Asia (AS)	14	19,7	11	78,6	89,39	12,41
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	80,13	18,49
	Europe (EU)	9	26,5	6	66,7	86,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	85,26	14,89
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	80,83	18,86
	Europe (EU)	7	20,6	6	85,7	84,72	16,17
	Asia (AS)	11	15,5	10	90,9	80,00	15,32
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	81,67	21,44
	Europe (EU)	7	20,6	5	71,4	88,33	13,94
	Asia (AS)	11	15,5	10	90,9	79,17	15,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	72,22	29,46
	Europe (EU)	5	14,7	3	60,0	97,22	4,81
	Asia (AS)	7	9,9	6	85,7	81,94	17,01
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	75,00	20,89
	Europe (EU)	5	14,7	4	80,0	87,50	10,76
	Asia (AS)	7	9,9	6	85,7	83,33	18,26
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	75,00	15,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	95,83	5,89
	Asia (AS)	4	5,6	4	100,0	75,00	11,79
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	70,83	15,59
	Europe (EU)	4	11,8	2	50,0	100,00	0,00
	Asia (AS)	4	5,6	4	100,0	89,58	15,77
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	75,00	13,61
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	79,17	14,43
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	70,83	19,84
	Europe (EU)	2	5,9	1	50,0	100,00	-
	Asia (AS)	4	5,6	4	100,0	60,42	24,88
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	61,11	20,97
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	77,08	18,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	62,50	17,68
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	66,67	0,00
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	75,00	11,79
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	69,44	4,81
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	58,33	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	91,67	-
	Asia (AS)	3	4,2	2	66,7	79,17	29,46
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	50,00	-
	Europe (EU)	1	2,9	1	100,0	100,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	70,10	15,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	50,00	15,59
	Asia (AS)	34	47,9	22	64,7	76,52	16,99
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	79,17	14,60
	1	69	100,0	67	97,1	72,76	20,24
	2	15	100,0	15	100,0	66,11	25,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	55	93,2	80,61	20,67
	1	67	97,1	60	89,6	79,03	20,21
	2	10	66,7	10	100,0	85,00	13,49
Cycle 3 Day 1	0	57	93,4	51	89,5	83,17	19,68
	1	65	94,2	58	89,2	81,75	14,85
	2	9	60,0	9	100,0	80,56	16,67
Cycle 4 Day 1	0	57	93,4	54	94,7	81,94	19,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	81,47	16,23
	2	9	60,0	8	88,9	82,29	14,39
Cycle 5 Day 1	0	56	91,8	53	94,6	82,86	19,84
	1	62	89,9	59	95,2	81,50	15,25
	2	6	40,0	6	100,0	86,11	16,39
Cycle 6 Day 1	0	56	91,8	54	96,4	80,71	17,50
	1	59	85,5	53	89,8	79,25	16,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	85,00	20,75
Cycle 7 Day 1	0	54	88,5	51	94,4	83,33	19,22
	1	54	78,3	50	92,6	78,50	18,37
	2	5	33,3	5	100,0	80,00	12,64
Cycle 8 Day 1	0	52	85,2	48	92,3	84,72	16,96
	1	49	71,0	44	89,8	81,06	16,80
	2	5	33,3	5	100,0	78,33	27,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	84,52	15,87
	1	44	63,8	43	97,7	81,40	16,15
	2	4	26,7	4	100,0	83,33	13,61
Cycle 10 Day 1	0	46	75,4	46	100,0	83,51	19,12
	1	40	58,0	37	92,5	82,43	14,80
	2	3	20,0	3	100,0	75,00	36,32
Cycle 11 Day 1	0	43	70,5	41	95,3	82,93	15,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	82,11	17,90
	2	3	20,0	3	100,0	83,33	22,05
Cycle 12 Day 1	0	42	68,9	36	85,7	80,56	16,31
	1	31	44,9	30	96,8	86,94	13,07
	2	3	20,0	3	100,0	75,00	36,32
Cycle 13 Day 1	0	38	62,3	34	89,5	80,39	20,50
	1	27	39,1	27	100,0	85,80	14,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	100,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	77,08	23,67
	1	24	34,8	24	100,0	82,99	15,04
	2	1	6,7	1	100,0	100,00	-
Cycle 15 Day 1	0	33	54,1	30	90,9	81,67	17,01
	1	23	33,3	23	100,0	87,32	13,02
	2	1	6,7	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	79,00	18,02
	1	21	30,4	21	100,0	81,35	17,06
	2	1	6,7	1	100,0	100,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	80,80	18,54
	1	20	29,0	20	100,0	82,92	18,43
	2	1	6,7	1	100,0	100,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	80,70	18,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	84,80	15,38
	2	1	6,7	1	100,0	100,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	83,77	15,58
	1	15	21,7	13	86,7	85,90	13,34
	2	1	6,7	1	100,0	100,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	79,41	17,46
	1	15	21,7	14	93,3	86,90	14,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	100,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	81,55	17,04
	1	13	18,8	11	84,6	79,55	15,97
	2	1	6,7	1	100,0	100,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	83,33	21,32
	1	13	18,8	12	92,3	79,17	13,53
	2	1	6,7	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	77,78	31,18
	1	9	13,0	8	88,9	79,17	15,43
	2	1	6,7	1	100,0	100,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	77,78	21,25
	1	9	13,0	8	88,9	81,25	14,60
	2	1	6,7	1	100,0	100,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	77,78	15,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	78,57	15,11
Cycle 26 Day 1	0	8	13,1	6	75,0	76,39	20,69
	1	6	8,7	6	100,0	87,50	14,67
Cycle 27 Day 1	0	6	9,8	3	50,0	75,00	16,67
	1	5	7,2	5	100,0	78,33	12,64
Cycle 28 Day 1	0	5	8,2	4	80,0	77,08	22,95
	1	5	7,2	5	100,0	63,33	24,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	50,00	11,79
	1	5	7,2	5	100,0	78,33	16,24
Cycle 30 Day 1	0	3	4,9	1	33,3	50,00	-
	1	4	5,8	4	100,0	68,75	4,17
Cycle 31 Day 1	0	3	4,9	1	33,3	66,67	-
	1	4	5,8	4	100,0	72,92	7,98
Cycle 32 Day 1	0	3	4,9	2	66,7	62,50	41,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	80,56	20,97
Cycle 33 Day 1	0	2	3,3	2	100,0	75,00	35,36
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	72,22	16,10
	1	34	49,3	20	58,8	71,25	18,23
	2	7	46,7	3	42,9	61,11	29,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	74,03	18,29
	1	4	100,0	4	100,0	81,25	17,18
	2 or More	79	100,0	78	98,7	75,00	19,88
Cycle 2 Day 1	None	60	96,8	54	90,0	81,48	20,65
	1	3	75,0	2	66,7	91,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	78,86	19,57
Cycle 3 Day 1	None	59	95,2	53	89,8	84,59	16,21
	1	3	75,0	2	66,7	91,67	0,00
	2 or More	69	87,3	63	91,3	80,03	17,87
Cycle 4 Day 1	None	59	95,2	56	94,9	80,51	18,62
	1	3	75,0	2	66,7	87,50	5,89
	2 or More	66	83,5	62	93,9	82,66	17,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	83,78	16,00
	1	3	75,0	3	100,0	97,22	4,81
	2 or More	63	79,7	59	93,7	80,23	18,69
Cycle 6 Day 1	None	57	91,9	52	91,2	82,53	16,61
	1	3	75,0	3	100,0	80,56	9,62
	2 or More	61	77,2	57	93,4	78,07	17,37
Cycle 7 Day 1	None	52	83,9	50	96,2	81,50	19,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	69,44	20,97
	2 or More	58	73,4	53	91,4	80,97	17,25
Cycle 8 Day 1	None	50	80,6	46	92,0	82,61	17,02
	1	3	75,0	1	33,3	66,67	-
	2 or More	53	67,1	50	94,3	83,17	17,94
Cycle 9 Day 1	None	48	77,4	47	97,9	83,33	14,95
	1	1	25,0	1	100,0	91,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	82,64	16,92
Cycle 10 Day 1	None	43	69,4	41	95,3	85,77	15,17
	1	1	25,0	1	100,0	100,00	-
	2 or More	45	57,0	44	97,8	79,55	19,81
Cycle 11 Day 1	None	37	59,7	35	94,6	84,05	14,20
	1	1	25,0	1	100,0	91,67	-
	2 or More	42	53,2	42	100,0	81,15	18,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	84,80	15,00
	1	1	25,0	1	100,0	91,67	-
	2 or More	38	48,1	34	89,5	81,13	17,45
Cycle 13 Day 1	None	34	54,8	30	88,2	83,06	16,59
	1	1	25,0	1	100,0	100,00	-
	2 or More	31	39,2	31	100,0	82,53	20,11
Cycle 14 Day 1	None	31	50,0	29	93,5	80,46	18,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	91,67	-
	2 or More	28	35,4	27	96,4	79,01	22,57
Cycle 15 Day 1	None	30	48,4	28	93,3	84,82	13,99
	1	1	25,0	1	100,0	91,67	-
	2 or More	26	32,9	25	96,2	83,67	17,59
Cycle 16 Day 1	None	25	40,3	23	92,0	84,78	13,45
	1	1	25,0	1	100,0	91,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	75,72	20,24
Cycle 17 Day 1	None	23	37,1	22	95,7	85,61	17,85
	1	1	25,0	1	100,0	91,67	-
	2 or More	21	26,6	21	100,0	78,17	18,72
Cycle 18 Day 1	None	20	32,3	18	90,0	87,50	14,64
	1	1	25,0	1	100,0	91,67	-
	2 or More	20	25,3	18	90,0	78,24	18,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	86,76	14,15
	1	1	25,0	1	100,0	91,67	-
	2 or More	18	22,8	15	83,3	82,78	15,58
Cycle 20 Day 1	None	17	27,4	16	94,1	84,90	16,73
	1	1	25,0	1	100,0	91,67	-
	2 or More	18	22,8	15	83,3	81,11	17,10
Cycle 21 Day 1	None	15	24,2	13	86,7	85,26	17,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	77,56	14,59
Cycle 22 Day 1	None	15	24,2	13	86,7	89,10	13,34
	2 or More	14	17,7	12	85,7	74,31	18,96
Cycle 23 Day 1	None	10	16,1	9	90,0	87,04	13,89
	2 or More	11	13,9	9	81,8	72,22	30,33
Cycle 24 Day 1	None	10	16,1	10	100,0	82,50	20,95
	2 or More	10	12,7	8	80,0	78,13	14,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	78,13	14,04
	2 or More	6	7,6	5	83,3	78,33	17,28
Cycle 26 Day 1	None	8	12,9	8	100,0	83,33	15,43
	2 or More	6	7,6	4	66,7	79,17	25,00
Cycle 27 Day 1	None	7	11,3	6	85,7	79,17	14,67
	2 or More	4	5,1	2	50,0	70,83	5,89
Cycle 28 Day 1	None	7	11,3	7	100,0	76,19	18,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	45,83	29,46
Cycle 29 Day 1	None	6	9,7	5	83,3	65,00	18,07
	2 or More	3	3,8	2	66,7	83,33	23,57
Cycle 30 Day 1	None	4	6,5	3	75,0	63,89	12,73
	2 or More	3	3,8	2	66,7	66,67	0,00
Cycle 31 Day 1	None	4	6,5	3	75,0	72,22	9,62
	2 or More	3	3,8	2	66,7	70,83	5,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	72,22	34,69
	2 or More	2	2,5	2	100,0	75,00	23,57
Cycle 33 Day 1	None	1	1,6	1	100,0	50,00	-
	2 or More	1	1,3	1	100,0	100,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	71,49	16,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	83,33	-
	2 or More	39	49,4	24	61,5	70,14	19,49
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	74,03	18,29
	Previously Treated	83	100,0	82	98,8	75,30	19,70
Cycle 2 Day 1	Naïve	60	96,8	54	90,0	81,48	20,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	79,23	19,41
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	84,59	16,21
	Previously Treated	72	86,7	65	90,3	80,38	17,70
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	80,51	18,62
	Previously Treated	69	83,1	64	92,8	82,81	16,99
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	83,78	16,00
	Previously Treated	66	79,5	62	93,9	81,05	18,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	82,53	16,61
	Previously Treated	64	77,1	60	93,8	78,19	17,02
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	81,50	19,94
	Previously Treated	61	73,5	56	91,8	80,36	17,44
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	82,61	17,02
	Previously Treated	56	67,5	51	91,1	82,84	17,90
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	83,33	14,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	82,82	16,79
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	85,77	15,17
	Previously Treated	46	55,4	45	97,8	80,00	19,82
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	84,05	14,20
	Previously Treated	43	51,8	43	100,0	81,40	18,35
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	84,80	15,00
	Previously Treated	39	47,0	35	89,7	81,43	17,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	83,06	16,59
	Previously Treated	32	38,6	32	100,0	83,07	20,02
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	80,46	18,93
	Previously Treated	29	34,9	28	96,6	79,46	22,28
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	84,82	13,99
	Previously Treated	27	32,5	26	96,3	83,97	17,31
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	84,78	13,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	76,39	20,06
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	85,61	17,85
	Previously Treated	22	26,5	22	100,0	78,79	18,50
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	87,50	14,64
	Previously Treated	21	25,3	19	90,5	78,95	18,29
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	86,76	14,15
	Previously Treated	19	22,9	16	84,2	83,33	15,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	84,90	16,73
	Previously Treated	19	22,9	16	84,2	81,77	16,73
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	85,26	17,73
	Previously Treated	14	16,9	13	92,9	77,56	14,59
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	89,10	13,34
	Previously Treated	14	16,9	12	85,7	74,31	18,96
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	87,04	13,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	72,22	30,33
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	82,50	20,95
	Previously Treated	10	12,0	8	80,0	78,13	14,73
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	78,13	14,04
	Previously Treated	6	7,2	5	83,3	78,33	17,28
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	83,33	15,43
	Previously Treated	6	7,2	4	66,7	79,17	25,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	79,17	14,67
	Previously Treated	4	4,8	2	50,0	70,83	5,89
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	76,19	18,28
	Previously Treated	3	3,6	2	66,7	45,83	29,46
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	65,00	18,07
	Previously Treated	3	3,6	2	66,7	83,33	23,57
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	63,89	12,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	66,67	0,00
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	72,22	9,62
	Previously Treated	3	3,6	2	66,7	70,83	5,89
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	72,22	34,69
	Previously Treated	2	2,4	2	100,0	75,00	23,57
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	50,00	-
	Previously Treated	1	1,2	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	71,49	16,03
	Previously Treated	42	50,6	25	59,5	70,67	19,26
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	75,22	19,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	74,25	18,28
Cycle 2 Day 1	Local	71	94,7	66	93,0	80,43	19,42
	Central	65	92,9	59	90,8	79,94	20,59
Cycle 3 Day 1	Local	67	89,3	62	92,5	81,99	19,34
	Central	64	91,4	56	87,5	82,59	14,41
Cycle 4 Day 1	Local	65	86,7	61	93,8	81,97	19,96
	Central	63	90,0	59	93,7	81,50	15,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	81,92	18,06
	Central	61	87,1	59	96,7	82,77	16,87
Cycle 6 Day 1	Local	63	84,0	61	96,8	80,33	16,53
	Central	58	82,9	51	87,9	80,07	17,49
Cycle 7 Day 1	Local	61	81,3	59	96,7	81,07	18,69
	Central	52	74,3	47	90,4	80,67	18,64
Cycle 8 Day 1	Local	57	76,0	55	96,5	83,48	16,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	81,75	18,88
Cycle 9 Day 1	Local	54	72,0	53	98,1	83,33	15,85
	Central	44	62,9	43	97,7	82,75	16,00
Cycle 10 Day 1	Local	48	64,0	46	95,8	80,98	19,69
	Central	41	58,6	40	97,6	84,79	15,55
Cycle 11 Day 1	Local	40	53,3	38	95,0	81,36	16,60
	Central	40	57,1	40	100,0	83,75	16,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	81,31	18,05
	Central	40	57,1	36	90,0	84,72	14,30
Cycle 13 Day 1	Local	30	40,0	29	96,7	83,91	18,36
	Central	36	51,4	33	91,7	82,32	18,49
Cycle 14 Day 1	Local	27	36,0	27	100,0	79,63	25,25
	Central	33	47,1	30	90,9	80,28	15,39
Cycle 15 Day 1	Local	26	34,7	25	96,2	83,33	17,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	85,34	13,67
Cycle 16 Day 1	Local	24	32,0	24	100,0	80,90	18,95
	Central	26	37,1	23	88,5	80,07	16,23
Cycle 17 Day 1	Local	22	29,3	22	100,0	85,61	16,10
	Central	23	32,9	22	95,7	78,79	20,04
Cycle 18 Day 1	Local	20	26,7	19	95,0	86,40	15,52
	Central	21	30,0	18	85,7	79,63	18,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	82,84	17,05
	Central	17	24,3	16	94,1	87,50	11,39
Cycle 20 Day 1	Local	19	25,3	17	89,5	83,33	18,87
	Central	17	24,3	15	88,2	83,33	14,09
Cycle 21 Day 1	Local	14	18,7	12	85,7	83,33	18,12
	Central	15	21,4	14	93,3	79,76	15,23
Cycle 22 Day 1	Local	14	18,7	12	85,7	84,03	15,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	80,13	19,70
Cycle 23 Day 1	Local	11	14,7	10	90,9	84,17	18,19
	Central	10	14,3	8	80,0	73,96	30,35
Cycle 24 Day 1	Local	11	14,7	10	90,9	79,17	21,61
	Central	9	12,9	8	88,9	82,29	13,68
Cycle 25 Day 1	Local	7	9,3	7	100,0	75,00	15,21
	Central	8	11,4	6	75,0	81,94	14,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	75,00	19,72
	Central	8	11,4	6	75,0	88,89	14,59
Cycle 27 Day 1	Local	4	5,3	4	100,0	81,25	18,48
	Central	7	10,0	4	57,1	72,92	4,17
Cycle 28 Day 1	Local	4	5,3	4	100,0	70,83	19,84
	Central	6	8,6	5	83,3	68,33	27,89
Cycle 29 Day 1	Local	3	4,0	3	100,0	69,44	24,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	70,83	19,84
Cycle 30 Day 1	Local	3	4,0	3	100,0	63,89	12,73
	Central	4	5,7	2	50,0	66,67	0,00
Cycle 31 Day 1	Local	3	4,0	3	100,0	72,22	9,62
	Central	4	5,7	2	50,0	70,83	5,89
Cycle 32 Day 1	Local	3	4,0	3	100,0	72,22	34,69
	Central	3	4,3	2	66,7	75,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	50,00	-
	Central	1	1,4	1	100,0	100,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	70,83	16,67
	Central	32	45,7	20	62,5	71,25	19,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	75,00	18,73
	No	10	100,0	10	100,0	71,67	23,96
Cycle 2 Day 1	Yes	129	95,6	118	91,5	80,30	19,54
	No	7	70,0	7	100,0	78,57	27,16
Cycle 3 Day 1	Yes	124	91,9	112	90,3	82,37	17,32
	No	7	70,0	6	85,7	80,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	81,93	17,32
	No	7	70,0	7	100,0	78,57	24,93
Cycle 5 Day 1	Yes	117	86,7	112	95,7	83,26	17,02
	No	7	70,0	6	85,7	65,28	17,01
Cycle 6 Day 1	Yes	114	84,4	105	92,1	80,87	16,94
	No	7	70,0	7	100,0	70,24	13,49
Cycle 7 Day 1	Yes	106	78,5	99	93,4	82,24	17,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	61,90	25,85
Cycle 8 Day 1	Yes	100	74,1	91	91,0	83,15	17,79
	No	6	60,0	6	100,0	76,39	8,19
Cycle 9 Day 1	Yes	92	68,1	90	97,8	83,43	15,88
	No	6	60,0	6	100,0	77,78	15,52
Cycle 10 Day 1	Yes	83	61,5	80	96,4	82,71	18,17
	No	6	60,0	6	100,0	83,33	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	83,00	16,75
	No	4	40,0	4	100,0	75,00	11,79
Cycle 12 Day 1	Yes	72	53,3	65	90,3	83,59	16,20
	No	4	40,0	4	100,0	75,00	15,21
Cycle 13 Day 1	Yes	64	47,4	60	93,8	83,19	18,44
	No	2	20,0	2	100,0	79,17	17,68
Cycle 14 Day 1	Yes	58	43,0	55	94,8	80,30	20,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	70,83	29,46
Cycle 15 Day 1	Yes	55	40,7	52	94,5	85,10	15,33
	No	2	20,0	2	100,0	66,67	11,79
Cycle 16 Day 1	Yes	48	35,6	45	93,8	80,37	17,51
	No	2	20,0	2	100,0	83,33	23,57
Cycle 17 Day 1	Yes	43	31,9	42	97,7	83,53	17,41
	No	2	20,0	2	100,0	54,17	17,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	84,05	14,90
	No	2	20,0	2	100,0	66,67	47,14
Cycle 19 Day 1	Yes	34	25,2	32	94,1	84,64	14,53
	No	2	20,0	1	50,0	100,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	83,61	16,15
	No	2	20,0	2	100,0	79,17	29,46
Cycle 21 Day 1	Yes	27	20,0	24	88,9	82,99	16,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	62,50	5,89
Cycle 22 Day 1	Yes	27	20,0	23	85,2	83,70	17,31
	No	2	20,0	2	100,0	62,50	5,89
Cycle 23 Day 1	Yes	20	14,8	17	85,0	78,43	24,31
	No	1	10,0	1	100,0	100,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	79,41	17,95
	No	1	10,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	79,17	14,86
	No	1	10,0	1	100,0	66,67	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	80,30	17,98
	No	1	10,0	1	100,0	100,00	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	73,81	10,12
	No	1	10,0	1	100,0	100,00	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	67,71	24,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	83,33	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	68,06	20,69
	No	1	10,0	1	100,0	83,33	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	64,58	10,49
	No	1	10,0	1	100,0	66,67	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	72,92	7,98
	No	1	10,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	66,67	26,35
	No	1	10,0	1	100,0	100,00	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	75,00	35,36
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	71,51	17,65
	No	2	20,0	1	50,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	70,45	29,43
	No	134	100,0	131	97,8	75,13	18,05
Cycle 2 Day 1	Yes	7	63,6	7	100,0	79,76	18,54
	No	129	96,3	118	91,5	80,23	20,05
Cycle 3 Day 1	Yes	7	63,6	7	100,0	84,52	22,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	82,13	16,81
Cycle 4 Day 1	Yes	7	63,6	7	100,0	78,57	22,49
	No	121	90,3	113	93,4	81,93	17,50
Cycle 5 Day 1	Yes	7	63,6	7	100,0	79,76	20,89
	No	117	87,3	111	94,9	82,51	17,26
Cycle 6 Day 1	Yes	7	63,6	7	100,0	84,52	16,96
	No	114	85,1	105	92,1	79,92	16,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	79,76	19,16
	No	106	79,1	99	93,4	80,98	18,64
Cycle 8 Day 1	Yes	7	63,6	7	100,0	66,67	32,27
	No	99	73,9	90	90,9	83,98	15,31
Cycle 9 Day 1	Yes	6	54,5	6	100,0	76,39	20,01
	No	92	68,7	90	97,8	83,52	15,55
Cycle 10 Day 1	Yes	6	54,5	6	100,0	75,00	27,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	83,33	17,08
Cycle 11 Day 1	Yes	6	54,5	6	100,0	73,61	28,59
	No	74	55,2	72	97,3	83,33	15,26
Cycle 12 Day 1	Yes	6	54,5	6	100,0	76,39	26,04
	No	70	52,2	63	90,0	83,73	15,07
Cycle 13 Day 1	Yes	5	45,5	5	100,0	85,00	17,08
	No	61	45,5	57	93,4	82,89	18,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	85,00	14,91
	No	55	41,0	52	94,5	79,49	20,97
Cycle 15 Day 1	Yes	4	36,4	4	100,0	89,58	12,50
	No	53	39,6	50	94,3	84,00	15,78
Cycle 16 Day 1	Yes	3	27,3	3	100,0	100,00	0,00
	No	47	35,1	44	93,6	79,17	17,29
Cycle 17 Day 1	Yes	3	27,3	3	100,0	94,44	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	81,30	18,52
Cycle 18 Day 1	Yes	3	27,3	3	100,0	97,22	4,81
	No	38	28,4	34	89,5	81,86	17,10
Cycle 19 Day 1	Yes	3	27,3	3	100,0	97,22	4,81
	No	33	24,6	30	90,9	83,89	14,67
Cycle 20 Day 1	Yes	3	27,3	3	100,0	94,44	9,62
	No	33	24,6	29	87,9	82,18	16,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	91,67	11,79
	No	27	20,1	24	88,9	80,56	16,61
Cycle 22 Day 1	Yes	2	18,2	2	100,0	95,83	5,89
	No	27	20,1	23	85,2	80,80	17,84
Cycle 23 Day 1	Yes	2	18,2	2	100,0	95,83	5,89
	No	19	14,2	16	84,2	77,60	24,85
Cycle 24 Day 1	Yes	2	18,2	2	100,0	100,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	78,13	17,71
Cycle 25 Day 1	Yes	2	18,2	2	100,0	95,83	5,89
	No	13	9,7	11	84,6	75,00	13,44
Cycle 26 Day 1	Yes	1	9,1	1	100,0	91,67	-
	No	13	9,7	11	84,6	81,06	18,67
Cycle 27 Day 1	Yes	1	9,1	1	100,0	75,00	-
	No	10	7,5	7	70,0	77,38	14,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	66,67	-
	No	9	6,7	8	88,9	69,79	24,78
Cycle 29 Day 1	Yes	1	9,1	1	100,0	58,33	-
	No	8	6,0	6	75,0	72,22	20,86
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	65,00	9,13
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	71,67	7,45
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	73,33	27,26
Cycle 33 Day 1	No	2	1,5	2	100,0	75,00	35,36
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	47,22	17,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	72,76	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30EF_SG.xls
24JUN2020 20:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	38,89	23,21
Cycle 2 Day 1	All	136	93,8	126	92,6	34,13	20,85
Cycle 3 Day 1	All	131	90,3	118	90,1	30,79	19,57
Cycle 4 Day 1	All	128	88,3	120	93,8	27,13	19,04
Cycle 5 Day 1	All	124	85,5	118	95,2	26,55	19,16
Cycle 6 Day 1	All	121	83,4	112	92,6	26,98	18,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	26,83	19,87
Cycle 8 Day 1	All	106	73,1	97	91,5	25,20	17,46
Cycle 9 Day 1	All	98	67,6	96	98,0	23,73	17,85
Cycle 10 Day 1	All	89	61,4	86	96,6	27,52	18,80
Cycle 11 Day 1	All	80	55,2	78	97,5	25,64	19,97
Cycle 12 Day 1	All	76	52,4	69	90,8	25,93	18,04
Cycle 13 Day 1	All	66	45,5	62	93,9	26,16	22,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	27,68	23,01
Cycle 15 Day 1	All	57	39,3	54	94,7	26,54	17,59
Cycle 16 Day 1	All	50	34,5	47	94,0	28,13	18,07
Cycle 17 Day 1	All	45	31,0	44	97,8	26,01	18,86
Cycle 18 Day 1	All	41	28,3	37	90,2	21,62	17,94
Cycle 19 Day 1	All	36	24,8	33	91,7	27,61	19,07
Cycle 20 Day 1	All	36	24,8	32	88,9	24,65	17,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	27,78	18,12
Cycle 22 Day 1	All	29	20,0	25	86,2	28,44	20,31
Cycle 23 Day 1	All	21	14,5	18	85,7	27,16	24,47
Cycle 24 Day 1	All	20	13,8	18	90,0	25,93	19,43
Cycle 25 Day 1	All	15	10,3	13	86,7	31,62	18,06
Cycle 26 Day 1	All	14	9,7	12	85,7	28,70	21,43
Cycle 27 Day 1	All	11	7,6	8	72,7	22,22	8,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	28,40	24,29
Cycle 29 Day 1	All	9	6,2	7	77,8	30,16	17,82
Cycle 30 Day 1	All	7	4,8	5	71,4	20,00	14,49
Cycle 31 Day 1	All	7	4,8	5	71,4	26,67	9,94
Cycle 32 Day 1	All	6	4,1	5	83,3	22,22	15,71
Cycle 33 Day 1	All	2	1,4	2	100,0	27,78	7,86
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	47,47	24,83
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	38,78	25,37
	Female	93	100,0	91	97,8	38,95	22,06
Cycle 2 Day 1	Male	50	96,2	47	94,0	35,93	21,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	33,05	20,36
Cycle 3 Day 1	Male	47	90,4	42	89,4	28,04	15,95
	Female	84	90,3	76	90,5	32,31	21,25
Cycle 4 Day 1	Male	46	88,5	45	97,8	28,64	20,03
	Female	82	88,2	75	91,5	26,22	18,51
Cycle 5 Day 1	Male	45	86,5	43	95,6	32,82	21,68
	Female	79	84,9	75	94,9	22,96	16,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	28,73	20,63
	Female	76	81,7	71	93,4	25,98	17,81
Cycle 7 Day 1	Male	40	76,9	39	97,5	29,91	21,50
	Female	73	78,5	67	91,8	25,04	18,79
Cycle 8 Day 1	Male	37	71,2	34	91,9	26,14	19,32
	Female	69	74,2	63	91,3	24,69	16,51
Cycle 9 Day 1	Male	33	63,5	33	100,0	23,91	18,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	23,63	17,45
Cycle 10 Day 1	Male	30	57,7	30	100,0	32,22	22,10
	Female	59	63,4	56	94,9	25,00	16,45
Cycle 11 Day 1	Male	29	55,8	29	100,0	29,12	18,88
	Female	51	54,8	49	96,1	23,58	20,49
Cycle 12 Day 1	Male	27	51,9	26	96,3	27,78	18,39
	Female	49	52,7	43	87,8	24,81	17,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	30,92	20,64
	Female	41	44,1	39	95,1	23,36	22,63
Cycle 14 Day 1	Male	23	44,2	21	91,3	27,51	22,67
	Female	37	39,8	36	97,3	27,78	23,53
Cycle 15 Day 1	Male	21	40,4	20	95,2	30,00	19,11
	Female	36	38,7	34	94,4	24,51	16,59
Cycle 16 Day 1	Male	16	30,8	16	100,0	29,17	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	27,60	19,00
Cycle 17 Day 1	Male	13	25,0	13	100,0	28,21	19,04
	Female	32	34,4	31	96,9	25,09	19,02
Cycle 18 Day 1	Male	12	23,1	11	91,7	21,21	18,89
	Female	29	31,2	26	89,7	21,79	17,91
Cycle 19 Day 1	Male	10	19,2	10	100,0	28,89	25,23
	Female	26	28,0	23	88,5	27,05	16,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	22,22	19,25
	Female	26	28,0	23	88,5	25,60	16,56
Cycle 21 Day 1	Male	8	15,4	8	100,0	27,78	17,82
	Female	21	22,6	18	85,7	27,78	18,77
Cycle 22 Day 1	Male	8	15,4	6	75,0	33,33	9,94
	Female	21	22,6	19	90,5	26,90	22,62
Cycle 23 Day 1	Male	5	9,6	4	80,0	27,78	14,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	26,98	27,12
Cycle 24 Day 1	Male	5	9,6	4	80,0	30,56	5,56
	Female	15	16,1	14	93,3	24,60	21,87
Cycle 25 Day 1	Male	3	5,8	2	66,7	27,78	7,86
	Female	12	12,9	11	91,7	32,32	19,53
Cycle 26 Day 1	Male	3	5,8	2	66,7	27,78	7,86
	Female	11	11,8	10	90,9	28,89	23,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	22,22	0,00
	Female	8	8,6	6	75,0	22,22	9,94
Cycle 28 Day 1	Male	2	3,8	2	100,0	27,78	7,86
	Female	8	8,6	7	87,5	28,57	27,86
Cycle 29 Day 1	Male	1	1,9	1	100,0	44,44	-
	Female	8	8,6	6	75,0	27,78	18,26
Cycle 30 Day 1	Male	1	1,9	1	100,0	22,22	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	19,44	16,67
Cycle 31 Day 1	Male	1	1,9	1	100,0	22,22	-
	Female	6	6,5	4	66,7	27,78	11,11
Cycle 32 Day 1	Male	1	1,9	1	100,0	11,11	-
	Female	5	5,4	4	80,0	25,00	16,67
Cycle 33 Day 1	Male	1	1,9	1	100,0	33,33	-
	Female	1	1,1	1	100,0	22,22	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	52,91	22,75
	Female	37	39,8	23	62,2	42,51	26,09
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	38,99	22,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	38,31	26,82
	>=75	7	100,0	7	100,0	39,68	17,98
Cycle 2 Day 1	18-64	103	94,5	94	91,3	32,15	18,82
	65-74	26	89,7	25	96,2	41,78	25,92
	>=75	7	100,0	7	100,0	33,33	24,00
Cycle 3 Day 1	18-64	99	90,8	87	87,9	30,27	19,30
	65-74	25	86,2	24	96,0	31,02	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	36,51	19,99
Cycle 4 Day 1	18-64	98	89,9	92	93,9	27,78	19,46
	65-74	23	79,3	21	91,3	24,34	19,44
	>=75	7	100,0	7	100,0	26,98	12,60
Cycle 5 Day 1	18-64	95	87,2	90	94,7	25,68	19,89
	65-74	22	75,9	22	100,0	28,28	16,35
	>=75	7	100,0	6	85,7	33,33	18,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	26,19	19,41
	65-74	22	75,9	21	95,5	26,98	14,30
	>=75	7	100,0	7	100,0	36,51	23,76
Cycle 7 Day 1	18-64	86	78,9	81	94,2	26,89	20,78
	65-74	20	69,0	19	95,0	25,15	15,20
	>=75	7	100,0	6	85,7	31,48	22,68
Cycle 8 Day 1	18-64	80	73,4	72	90,0	23,15	17,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	29,24	14,91
	>=75	7	100,0	6	85,7	37,04	25,01
Cycle 9 Day 1	18-64	74	67,9	73	98,6	21,16	16,37
	65-74	18	62,1	18	100,0	32,10	19,01
	>=75	6	85,7	5	83,3	31,11	26,53
Cycle 10 Day 1	18-64	69	63,3	66	95,7	25,93	18,42
	65-74	15	51,7	15	100,0	32,59	18,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	33,33	24,85
Cycle 11 Day 1	18-64	61	56,0	59	96,7	26,74	20,65
	65-74	15	51,7	15	100,0	23,70	17,25
	>=75	4	57,1	4	100,0	16,67	21,28
Cycle 12 Day 1	18-64	57	52,3	51	89,5	24,84	18,80
	65-74	15	51,7	14	93,3	30,95	16,98
	>=75	4	57,1	4	100,0	22,22	9,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	23,43	20,32
	65-74	13	44,8	12	92,3	37,04	26,09
	>=75	4	57,1	4	100,0	25,00	24,64
Cycle 14 Day 1	18-64	45	41,3	44	97,8	24,49	22,43
	65-74	13	44,8	11	84,6	38,38	24,53
	>=75	2	28,6	2	100,0	38,89	7,86
Cycle 15 Day 1	18-64	43	39,4	41	95,3	25,20	17,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	29,29	20,65
	>=75	2	28,6	2	100,0	38,89	7,86
Cycle 16 Day 1	18-64	38	34,9	36	94,7	25,93	18,40
	65-74	10	34,5	9	90,0	34,57	17,07
	>=75	2	28,6	2	100,0	38,89	7,86
Cycle 17 Day 1	18-64	36	33,0	35	97,2	25,71	19,76
	65-74	8	27,6	8	100,0	25,00	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	44,44	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	19,26	16,75
	65-74	7	24,1	6	85,7	29,63	21,85
	>=75	1	14,3	1	100,0	44,44	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	25,40	19,56
	65-74	5	17,2	4	80,0	36,11	5,56
	>=75	1	14,3	1	100,0	55,56	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	23,08	18,03
	65-74	5	17,2	5	100,0	28,89	9,94
	>=75	1	14,3	1	100,0	44,44	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	25,40	18,64
	65-74	4	13,8	4	100,0	33,33	9,07
	>=75	1	14,3	1	100,0	55,56	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	27,22	22,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	30,56	5,56
	>=75	1	14,3	1	100,0	44,44	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	27,08	25,97
	65-74	2	6,9	2	100,0	27,78	7,86
Cycle 24 Day 1	18-64	18	16,5	16	88,9	25,00	20,49
	65-74	2	6,9	2	100,0	33,33	0,00
Cycle 25 Day 1	18-64	14	12,8	12	85,7	31,48	18,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	33,33	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	28,70	21,43
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	22,22	8,40
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	28,40	24,29
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	30,16	17,82
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	20,00	14,49
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	26,67	9,94
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	19,44	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	33,33	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	33,33	-
	65-74	1	3,4	1	100,0	22,22	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	48,04	25,47
	65-74	15	51,7	8	53,3	44,44	16,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	50,00	55,00
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	43,49	25,68
	Other	85	100,0	84	98,8	35,71	20,92
Cycle 2 Day 1	White	57	95,0	51	89,5	36,60	22,69
	Other	79	92,9	75	94,9	32,44	19,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	34,85	24,03
	Other	77	90,6	74	96,1	28,38	16,05
Cycle 4 Day 1	White	53	88,3	47	88,7	25,06	19,03
	Other	75	88,2	73	97,3	28,46	19,06
Cycle 5 Day 1	White	52	86,7	48	92,3	25,00	20,69
	Other	72	84,7	70	97,2	27,62	18,12
Cycle 6 Day 1	White	50	83,3	44	88,0	27,53	21,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	26,63	17,40
Cycle 7 Day 1	White	47	78,3	42	89,4	26,46	19,00
	Other	66	77,6	64	97,0	27,08	20,56
Cycle 8 Day 1	White	45	75,0	39	86,7	24,22	16,49
	Other	61	71,8	58	95,1	25,86	18,19
Cycle 9 Day 1	White	42	70,0	41	97,6	23,04	19,47
	Other	56	65,9	55	98,2	24,24	16,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	27,35	19,72
	Other	48	56,5	47	97,9	27,66	18,22
Cycle 11 Day 1	White	37	61,7	37	100,0	24,92	22,28
	Other	43	50,6	41	95,3	26,29	17,87
Cycle 12 Day 1	White	37	61,7	33	89,2	22,56	21,42
	Other	39	45,9	36	92,3	29,01	13,87
Cycle 13 Day 1	White	32	53,3	30	93,8	24,07	24,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	28,13	19,34
Cycle 14 Day 1	White	31	51,7	30	96,8	24,81	25,38
	Other	29	34,1	27	93,1	30,86	20,05
Cycle 15 Day 1	White	30	50,0	28	93,3	25,79	20,96
	Other	27	31,8	26	96,3	27,35	13,42
Cycle 16 Day 1	White	26	43,3	24	92,3	25,46	20,32
	Other	24	28,2	23	95,8	30,92	15,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	26,39	20,93
	Other	21	24,7	20	95,2	25,56	16,56
Cycle 18 Day 1	White	22	36,7	19	86,4	20,47	18,24
	Other	19	22,4	18	94,7	22,84	18,07
Cycle 19 Day 1	White	20	33,3	20	100,0	27,78	22,37
	Other	16	18,8	13	81,3	27,35	13,31
Cycle 20 Day 1	White	20	33,3	17	85,0	23,53	19,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	25,93	14,95
Cycle 21 Day 1	White	16	26,7	14	87,5	27,78	22,54
	Other	13	15,3	12	92,3	27,78	12,08
Cycle 22 Day 1	White	16	26,7	13	81,3	28,21	26,69
	Other	13	15,3	12	92,3	28,70	11,07
Cycle 23 Day 1	White	12	20,0	10	83,3	33,33	28,21
	Other	9	10,6	8	88,9	19,44	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	28,89	23,54
	Other	9	10,6	8	88,9	22,22	13,28
Cycle 25 Day 1	White	10	16,7	8	80,0	33,33	22,22
	Other	5	5,9	5	100,0	28,89	9,94
Cycle 26 Day 1	White	10	16,7	8	80,0	29,17	26,52
	Other	4	4,7	4	100,0	27,78	6,42
Cycle 27 Day 1	White	8	13,3	5	62,5	22,22	7,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	22,22	11,11
Cycle 28 Day 1	White	7	11,7	6	85,7	24,07	23,74
	Other	3	3,5	3	100,0	37,04	27,96
Cycle 29 Day 1	White	6	10,0	4	66,7	33,33	24,00
	Other	3	3,5	3	100,0	25,93	6,42
Cycle 30 Day 1	White	4	6,7	2	50,0	11,11	15,71
	Other	3	3,5	3	100,0	25,93	12,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	16,67	7,86
	Other	3	3,5	3	100,0	33,33	0,00
Cycle 32 Day 1	White	4	6,7	3	75,0	14,81	16,97
	Other	2	2,4	2	100,0	33,33	0,00
Cycle 33 Day 1	White	2	3,3	2	100,0	27,78	7,86
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	44,44	26,35
	Other	39	45,9	27	69,2	49,38	24,13
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	39,44	22,92
	Europe (EU)	34	100,0	31	91,2	42,65	26,46
	Asia (AS)	71	100,0	71	100,0	36,93	21,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	33	86,8	36,03	18,22
	Europe (EU)	32	94,1	28	87,5	31,75	22,97
	Asia (AS)	66	93,0	65	98,5	34,19	21,36
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	34,68	16,84
	Europe (EU)	31	91,2	22	71,0	34,34	27,41
	Asia (AS)	63	88,7	63	100,0	27,51	17,27
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	27,78	20,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	23,11	15,02
	Asia (AS)	61	85,9	61	100,0	28,42	19,72
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	26,67	20,73
	Europe (EU)	30	88,2	26	86,7	23,93	18,51
	Asia (AS)	57	80,3	57	100,0	27,68	18,68
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	22,22	19,43
	Europe (EU)	28	82,4	25	89,3	32,44	19,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	27,56	17,67
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	25,35	22,08
	Europe (EU)	28	82,4	25	89,3	25,33	17,43
	Asia (AS)	50	70,4	49	98,0	28,57	19,77
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	18,93	15,35
	Europe (EU)	28	82,4	23	82,1	27,54	15,30
	Asia (AS)	47	66,2	47	100,0	27,66	18,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	22,22	16,29
	Europe (EU)	26	76,5	25	96,2	22,67	20,41
	Asia (AS)	43	60,6	43	100,0	25,32	17,54
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	23,15	20,18
	Europe (EU)	25	73,5	25	100,0	33,78	18,28
	Asia (AS)	37	52,1	37	100,0	26,13	17,61
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	24,64	25,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	23,23	17,11
	Asia (AS)	33	46,5	33	100,0	27,95	18,03
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	22,22	23,69
	Europe (EU)	23	67,6	18	78,3	25,93	14,76
	Asia (AS)	29	40,8	28	96,6	28,97	14,29
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	19,19	18,52
	Europe (EU)	18	52,9	15	83,3	33,33	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	28,00	21,31
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	24,34	22,94
	Europe (EU)	17	50,0	16	94,1	29,86	29,74
	Asia (AS)	21	29,6	20	95,2	29,44	17,01
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	21,11	18,35
	Europe (EU)	15	44,1	14	93,3	32,54	21,11
	Asia (AS)	20	28,2	20	100,0	27,78	12,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	22,88	19,83
	Europe (EU)	14	41,2	11	78,6	28,28	18,16
	Asia (AS)	19	26,8	19	100,0	32,75	15,92
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	26,39	22,54
	Europe (EU)	13	38,2	12	92,3	25,00	17,16
	Asia (AS)	16	22,5	16	100,0	26,39	17,15
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	19,05	19,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	22,22	16,97
	Asia (AS)	16	22,5	16	100,0	23,61	18,09
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	22,22	18,70
	Europe (EU)	9	26,5	9	100,0	34,57	23,86
	Asia (AS)	14	19,7	11	78,6	28,28	14,37
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	23,93	20,21
	Europe (EU)	9	26,5	6	66,7	24,07	16,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	25,64	15,31
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	28,89	22,95
	Europe (EU)	7	20,6	6	85,7	29,63	18,14
	Asia (AS)	11	15,5	10	90,9	25,56	13,91
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	32,22	27,94
	Europe (EU)	7	20,6	5	71,4	22,22	17,57
	Asia (AS)	11	15,5	10	90,9	27,78	12,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	32,10	31,15
	Europe (EU)	5	14,7	3	60,0	25,93	12,83
	Asia (AS)	7	9,9	6	85,7	20,37	17,80
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	34,72	21,77
	Europe (EU)	5	14,7	4	80,0	13,89	16,67
	Asia (AS)	7	9,9	6	85,7	22,22	14,05
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	31,75	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	27,78	7,86
	Asia (AS)	4	5,6	4	100,0	33,33	0,00
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	37,04	25,98
	Europe (EU)	4	11,8	2	50,0	5,56	7,86
	Asia (AS)	4	5,6	4	100,0	27,78	6,42
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	22,22	9,07
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	22,22	9,07
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	19,44	10,64
	Europe (EU)	2	5,9	1	50,0	0,00	-
	Asia (AS)	4	5,6	4	100,0	44,44	27,22
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	25,93	23,13
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	33,33	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	11,11	15,71
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	25,93	12,83
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	16,67	7,86
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	33,33	0,00
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	5,56	7,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	33,33	-
	Asia (AS)	3	4,2	2	66,7	33,33	0,00
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	33,33	-
	Europe (EU)	1	2,9	1	100,0	22,22	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	45,10	26,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	55,56	26,06
	Asia (AS)	34	47,9	22	64,7	47,47	23,80
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	29,63	18,71
	1	69	100,0	67	97,1	41,29	20,81
	2	15	100,0	15	100,0	65,19	27,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	56	94,9	32,54	21,28
	1	67	97,1	60	89,6	34,26	20,18
	2	10	66,7	10	100,0	42,22	22,71
Cycle 3 Day 1	0	57	93,4	51	89,5	29,85	19,56
	1	65	94,2	58	89,2	30,27	17,76
	2	9	60,0	9	100,0	39,51	29,46
Cycle 4 Day 1	0	57	93,4	54	94,7	24,69	21,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	28,93	15,71
	2	9	60,0	8	88,9	30,56	26,39
Cycle 5 Day 1	0	56	91,8	53	94,6	23,69	17,71
	1	62	89,9	59	95,2	28,63	19,60
	2	6	40,0	6	100,0	31,48	26,68
Cycle 6 Day 1	0	56	91,8	54	96,4	25,72	19,88
	1	59	85,5	53	89,8	27,67	17,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	33,33	20,79
Cycle 7 Day 1	0	54	88,5	51	94,4	23,97	19,16
	1	54	78,3	50	92,6	29,33	21,03
	2	5	33,3	5	100,0	31,11	12,17
Cycle 8 Day 1	0	52	85,2	48	92,3	24,54	18,04
	1	49	71,0	44	89,8	25,51	16,87
	2	5	33,3	5	100,0	28,89	20,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	23,36	18,87
	1	44	63,8	43	97,7	24,29	17,19
	2	4	26,7	4	100,0	22,22	15,71
Cycle 10 Day 1	0	46	75,4	46	100,0	27,29	19,84
	1	40	58,0	37	92,5	27,93	18,26
	2	3	20,0	3	100,0	25,93	12,83
Cycle 11 Day 1	0	43	70,5	41	95,3	26,56	21,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	24,84	18,36
	2	3	20,0	3	100,0	22,22	19,25
Cycle 12 Day 1	0	42	68,9	36	85,7	27,78	19,96
	1	31	44,9	30	96,8	23,70	15,37
	2	3	20,0	3	100,0	25,93	23,13
Cycle 13 Day 1	0	38	62,3	34	89,5	29,08	23,05
	1	27	39,1	27	100,0	23,46	20,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	29,17	24,56
	1	24	34,8	24	100,0	26,39	21,44
	2	1	6,7	1	100,0	11,11	-
Cycle 15 Day 1	0	33	54,1	30	90,9	28,52	17,67
	1	23	33,3	23	100,0	24,64	17,71
	2	1	6,7	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	29,78	19,70
	1	21	30,4	21	100,0	26,98	16,32
	2	1	6,7	1	100,0	11,11	-
Cycle 17 Day 1	0	24	39,3	23	95,8	25,12	20,44
	1	20	29,0	20	100,0	28,33	16,71
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	23,39	19,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	20,26	16,31
	2	1	6,7	1	100,0	11,11	-
Cycle 19 Day 1	0	20	32,8	19	95,0	27,49	21,07
	1	15	21,7	13	86,7	29,06	16,69
	2	1	6,7	1	100,0	11,11	-
Cycle 20 Day 1	0	20	32,8	17	85,0	25,49	19,55
	1	15	21,7	14	93,3	25,40	13,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	30,16	21,09
	1	13	18,8	11	84,6	27,27	12,54
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	33,33	25,07
	1	13	18,8	12	92,3	25,93	12,83
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	33,33	26,64
	1	9	13,0	8	88,9	23,61	21,77
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	28,40	20,12
	1	9	13,0	8	88,9	25,00	20,36
	2	1	6,7	1	100,0	11,11	-
Cycle 25 Day 1	0	8	13,1	6	75,0	38,89	19,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	25,40	15,33
Cycle 26 Day 1	0	8	13,1	6	75,0	31,48	21,56
	1	6	8,7	6	100,0	25,93	22,95
Cycle 27 Day 1	0	6	9,8	3	50,0	22,22	0,00
	1	5	7,2	5	100,0	22,22	11,11
Cycle 28 Day 1	0	5	8,2	4	80,0	30,56	27,78
	1	5	7,2	5	100,0	26,67	24,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	50,00	7,86
	1	5	7,2	5	100,0	22,22	13,61
Cycle 30 Day 1	0	3	4,9	1	33,3	22,22	-
	1	4	5,8	4	100,0	19,44	16,67
Cycle 31 Day 1	0	3	4,9	1	33,3	22,22	-
	1	4	5,8	4	100,0	27,78	11,11
Cycle 32 Day 1	0	3	4,9	2	66,7	22,22	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	22,22	19,25
Cycle 33 Day 1	0	2	3,3	2	100,0	27,78	7,86
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	47,09	23,81
	1	34	49,3	20	58,8	45,56	26,95
	2	7	46,7	3	42,9	62,96	16,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	39,81	25,16
	1	4	100,0	4	100,0	41,67	34,40
	2 or More	79	100,0	78	98,7	38,03	21,30
Cycle 2 Day 1	None	60	96,8	55	91,7	34,75	20,18
	1	3	75,0	2	66,7	11,11	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	34,30	21,45
Cycle 3 Day 1	None	59	95,2	53	89,8	29,77	15,68
	1	3	75,0	2	66,7	16,67	7,86
	2 or More	69	87,3	63	91,3	32,10	22,50
Cycle 4 Day 1	None	59	95,2	56	94,9	25,60	18,22
	1	3	75,0	2	66,7	16,67	23,57
	2 or More	66	83,5	62	93,9	28,85	19,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	24,80	19,19
	1	3	75,0	3	100,0	7,41	12,83
	2 or More	63	79,7	59	93,7	29,19	18,90
Cycle 6 Day 1	None	57	91,9	52	91,2	23,50	17,96
	1	3	75,0	3	100,0	14,81	16,97
	2 or More	61	77,2	57	93,4	30,80	19,13
Cycle 7 Day 1	None	52	83,9	50	96,2	24,89	20,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	33,33	22,22
	2 or More	58	73,4	53	91,4	28,30	19,07
Cycle 8 Day 1	None	50	80,6	46	92,0	24,40	18,09
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	26,44	16,78
Cycle 9 Day 1	None	48	77,4	47	97,9	21,99	18,17
	1	1	25,0	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	25,69	17,63
Cycle 10 Day 1	None	43	69,4	41	95,3	25,20	19,57
	1	1	25,0	1	100,0	22,22	-
	2 or More	45	57,0	44	97,8	29,80	18,21
Cycle 11 Day 1	None	37	59,7	35	94,6	20,32	18,96
	1	1	25,0	1	100,0	33,33	-
	2 or More	42	53,2	42	100,0	29,89	20,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	22,88	16,85
	1	1	25,0	1	100,0	11,11	-
	2 or More	38	48,1	34	89,5	29,41	18,93
Cycle 13 Day 1	None	34	54,8	30	88,2	23,70	22,17
	1	1	25,0	1	100,0	22,22	-
	2 or More	31	39,2	31	100,0	28,67	22,37
Cycle 14 Day 1	None	31	50,0	29	93,5	25,67	21,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	28	35,4	27	96,4	30,86	24,91
Cycle 15 Day 1	None	30	48,4	28	93,3	24,21	18,90
	1	1	25,0	1	100,0	33,33	-
	2 or More	26	32,9	25	96,2	28,89	16,36
Cycle 16 Day 1	None	25	40,3	23	92,0	24,64	17,07
	1	1	25,0	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	32,37	18,63
Cycle 17 Day 1	None	23	37,1	22	95,7	21,72	17,31
	1	1	25,0	1	100,0	22,22	-
	2 or More	21	26,6	21	100,0	30,69	20,16
Cycle 18 Day 1	None	20	32,3	18	90,0	14,20	16,08
	1	1	25,0	1	100,0	11,11	-
	2 or More	20	25,3	18	90,0	29,63	17,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	20,92	17,52
	1	1	25,0	1	100,0	11,11	-
	2 or More	18	22,8	15	83,3	36,30	18,05
Cycle 20 Day 1	None	17	27,4	16	94,1	23,61	16,17
	1	1	25,0	1	100,0	11,11	-
	2 or More	18	22,8	15	83,3	26,67	18,69
Cycle 21 Day 1	None	15	24,2	13	86,7	18,80	11,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	36,75	19,45
Cycle 22 Day 1	None	15	24,2	13	86,7	22,22	12,00
	2 or More	14	17,7	12	85,7	35,19	25,44
Cycle 23 Day 1	None	10	16,1	9	90,0	19,75	19,07
	2 or More	11	13,9	9	81,8	34,57	28,02
Cycle 24 Day 1	None	10	16,1	10	100,0	24,44	20,15
	2 or More	10	12,7	8	80,0	27,78	19,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	26,39	14,47
	2 or More	6	7,6	5	83,3	40,00	21,66
Cycle 26 Day 1	None	8	12,9	8	100,0	26,39	21,36
	2 or More	6	7,6	4	66,7	33,33	24,00
Cycle 27 Day 1	None	7	11,3	6	85,7	22,22	7,03
	2 or More	4	5,1	2	50,0	22,22	15,71
Cycle 28 Day 1	None	7	11,3	7	100,0	30,16	27,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	22,22	15,71
Cycle 29 Day 1	None	6	9,7	5	83,3	31,11	21,37
	2 or More	3	3,8	2	66,7	27,78	7,86
Cycle 30 Day 1	None	4	6,5	3	75,0	18,52	16,97
	2 or More	3	3,8	2	66,7	22,22	15,71
Cycle 31 Day 1	None	4	6,5	3	75,0	22,22	11,11
	2 or More	3	3,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	14,81	16,97
	2 or More	2	2,5	2	100,0	33,33	0,00
Cycle 33 Day 1	None	1	1,6	1	100,0	33,33	-
	2 or More	1	1,3	1	100,0	22,22	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	42,69	24,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	22,22	-
	2 or More	39	49,4	24	61,5	52,31	24,62
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	39,81	25,16
	Previously Treated	83	100,0	82	98,8	38,21	21,81
Cycle 2 Day 1	Naïve	60	96,8	55	91,7	34,75	20,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	33,65	21,49
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	29,77	15,68
	Previously Treated	72	86,7	65	90,3	31,62	22,33
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	25,60	18,22
	Previously Treated	69	83,1	64	92,8	28,47	19,78
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	24,80	19,19
	Previously Treated	66	79,5	62	93,9	28,14	19,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	23,50	17,96
	Previously Treated	64	77,1	60	93,8	30,00	19,22
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	24,89	20,76
	Previously Treated	61	73,5	56	91,8	28,57	19,05
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	24,40	18,09
	Previously Treated	56	67,5	51	91,1	25,93	17,02
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	21,99	18,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	25,40	17,57
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	25,20	19,57
	Previously Treated	46	55,4	45	97,8	29,63	18,04
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	20,32	18,96
	Previously Treated	43	51,8	43	100,0	29,97	19,93
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	22,88	16,85
	Previously Treated	39	47,0	35	89,7	28,89	18,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	23,70	22,17
	Previously Treated	32	38,6	32	100,0	28,47	22,03
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	25,67	21,02
	Previously Treated	29	34,9	28	96,6	29,76	25,13
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	24,21	18,90
	Previously Treated	27	32,5	26	96,3	29,06	16,05
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	24,64	17,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	31,48	18,73
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	21,72	17,31
	Previously Treated	22	26,5	22	100,0	30,30	19,75
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	14,20	16,08
	Previously Treated	21	25,3	19	90,5	28,65	17,10
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	20,92	17,52
	Previously Treated	19	22,9	16	84,2	34,72	18,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	23,61	16,17
	Previously Treated	19	22,9	16	84,2	25,69	18,47
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	18,80	11,46
	Previously Treated	14	16,9	13	92,9	36,75	19,45
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	22,22	12,00
	Previously Treated	14	16,9	12	85,7	35,19	25,44
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	19,75	19,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	34,57	28,02
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	24,44	20,15
	Previously Treated	10	12,0	8	80,0	27,78	19,70
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	26,39	14,47
	Previously Treated	6	7,2	5	83,3	40,00	21,66
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	26,39	21,36
	Previously Treated	6	7,2	4	66,7	33,33	24,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	22,22	7,03
	Previously Treated	4	4,8	2	50,0	22,22	15,71
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	30,16	27,00
	Previously Treated	3	3,6	2	66,7	22,22	15,71
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	31,11	21,37
	Previously Treated	3	3,6	2	66,7	27,78	7,86
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	18,52	16,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	22,22	15,71
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	22,22	11,11
	Previously Treated	3	3,6	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	14,81	16,97
	Previously Treated	2	2,4	2	100,0	33,33	0,00
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	33,33	-
	Previously Treated	1	1,2	1	100,0	22,22	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	42,69	24,64
	Previously Treated	42	50,6	25	59,5	51,11	24,85
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	38,81	21,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	38,97	24,87
Cycle 2 Day 1	Local	71	94,7	67	94,4	30,51	17,87
	Central	65	92,9	59	90,8	38,23	23,28
Cycle 3 Day 1	Local	67	89,3	62	92,5	28,14	19,06
	Central	64	91,4	56	87,5	33,73	19,87
Cycle 4 Day 1	Local	65	86,7	61	93,8	25,68	18,43
	Central	63	90,0	59	93,7	28,63	19,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	25,42	18,23
	Central	61	87,1	59	96,7	27,68	20,15
Cycle 6 Day 1	Local	63	84,0	61	96,8	26,23	20,19
	Central	58	82,9	51	87,9	27,89	17,27
Cycle 7 Day 1	Local	61	81,3	59	96,7	24,86	20,77
	Central	52	74,3	47	90,4	29,31	18,60
Cycle 8 Day 1	Local	57	76,0	55	96,5	21,62	16,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	29,89	17,44
Cycle 9 Day 1	Local	54	72,0	53	98,1	23,27	18,52
	Central	44	62,9	43	97,7	24,29	17,19
Cycle 10 Day 1	Local	48	64,0	46	95,8	29,95	20,13
	Central	41	58,6	40	97,6	24,72	16,97
Cycle 11 Day 1	Local	40	53,3	38	95,0	28,65	22,91
	Central	40	57,1	40	100,0	22,78	16,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	22,22	16,43
	Central	40	57,1	36	90,0	29,32	19,00
Cycle 13 Day 1	Local	30	40,0	29	96,7	22,61	23,09
	Central	36	51,4	33	91,7	29,29	20,94
Cycle 14 Day 1	Local	27	36,0	27	100,0	24,28	22,65
	Central	33	47,1	30	90,9	30,74	23,29
Cycle 15 Day 1	Local	26	34,7	25	96,2	22,67	19,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	29,89	15,17
Cycle 16 Day 1	Local	24	32,0	24	100,0	24,54	17,33
	Central	26	37,1	23	88,5	31,88	18,44
Cycle 17 Day 1	Local	22	29,3	22	100,0	21,21	15,30
	Central	23	32,9	22	95,7	30,81	21,12
Cycle 18 Day 1	Local	20	26,7	19	95,0	16,96	13,54
	Central	21	30,0	18	85,7	26,54	20,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	24,18	19,34
	Central	17	24,3	16	94,1	31,25	18,69
Cycle 20 Day 1	Local	19	25,3	17	89,5	19,61	12,75
	Central	17	24,3	15	88,2	30,37	19,91
Cycle 21 Day 1	Local	14	18,7	12	85,7	23,15	16,72
	Central	15	21,4	14	93,3	31,75	18,93
Cycle 22 Day 1	Local	14	18,7	12	85,7	25,00	16,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	31,62	23,50
Cycle 23 Day 1	Local	11	14,7	10	90,9	17,78	17,53
	Central	10	14,3	8	80,0	38,89	27,86
Cycle 24 Day 1	Local	11	14,7	10	90,9	25,56	18,92
	Central	9	12,9	8	88,9	26,39	21,36
Cycle 25 Day 1	Local	7	9,3	7	100,0	30,16	24,61
	Central	8	11,4	6	75,0	33,33	7,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	29,63	21,85
	Central	8	11,4	6	75,0	27,78	23,04
Cycle 27 Day 1	Local	4	5,3	4	100,0	19,44	5,56
	Central	7	10,0	4	57,1	25,00	10,64
Cycle 28 Day 1	Local	4	5,3	4	100,0	33,33	24,00
	Central	6	8,6	5	83,3	24,44	26,53
Cycle 29 Day 1	Local	3	4,0	3	100,0	22,22	22,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	36,11	13,98
Cycle 30 Day 1	Local	3	4,0	3	100,0	18,52	16,97
	Central	4	5,7	2	50,0	22,22	15,71
Cycle 31 Day 1	Local	3	4,0	3	100,0	22,22	11,11
	Central	4	5,7	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	4,0	3	100,0	14,81	16,97
	Central	3	4,3	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	33,33	-
	Central	1	1,4	1	100,0	22,22	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	47,69	21,85
	Central	32	45,7	20	62,5	47,22	28,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	37,88	22,05
	No	10	100,0	10	100,0	52,22	33,97
Cycle 2 Day 1	Yes	129	95,6	119	92,2	34,08	20,70
	No	7	70,0	7	100,0	34,92	25,20
Cycle 3 Day 1	Yes	124	91,9	112	90,3	30,65	19,91
	No	7	70,0	6	85,7	33,33	12,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	26,55	19,16
	No	7	70,0	7	100,0	36,51	15,33
Cycle 5 Day 1	Yes	117	86,7	112	95,7	25,50	18,79
	No	7	70,0	6	85,7	46,30	16,36
Cycle 6 Day 1	Yes	114	84,4	105	92,1	26,77	18,98
	No	7	70,0	7	100,0	30,16	17,82
Cycle 7 Day 1	Yes	106	78,5	99	93,4	26,04	18,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	38,10	30,67
Cycle 8 Day 1	Yes	100	74,1	91	91,0	24,66	17,12
	No	6	60,0	6	100,0	33,33	22,22
Cycle 9 Day 1	Yes	92	68,1	90	97,8	23,70	18,26
	No	6	60,0	6	100,0	24,07	10,92
Cycle 10 Day 1	Yes	83	61,5	80	96,4	27,36	19,28
	No	6	60,0	6	100,0	29,63	11,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	26,28	20,03
	No	4	40,0	4	100,0	13,89	16,67
Cycle 12 Day 1	Yes	72	53,3	65	90,3	25,98	18,24
	No	4	40,0	4	100,0	25,00	16,67
Cycle 13 Day 1	Yes	64	47,4	60	93,8	25,74	22,27
	No	2	20,0	2	100,0	38,89	7,86
Cycle 14 Day 1	Yes	58	43,0	55	94,8	27,27	23,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	38,89	7,86
Cycle 15 Day 1	Yes	55	40,7	52	94,5	26,28	17,88
	No	2	20,0	2	100,0	33,33	0,00
Cycle 16 Day 1	Yes	48	35,6	45	93,8	27,16	17,50
	No	2	20,0	2	100,0	50,00	23,57
Cycle 17 Day 1	Yes	43	31,9	42	97,7	25,13	18,70
	No	2	20,0	2	100,0	44,44	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	20,95	16,34
	No	2	20,0	2	100,0	33,33	47,14
Cycle 19 Day 1	Yes	34	25,2	32	94,1	27,43	19,34
	No	2	20,0	1	50,0	33,33	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	24,07	17,53
	No	2	20,0	2	100,0	33,33	0,00
Cycle 21 Day 1	Yes	27	20,0	24	88,9	27,31	18,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	33,33	15,71
Cycle 22 Day 1	Yes	27	20,0	23	85,2	28,02	21,15
	No	2	20,0	2	100,0	33,33	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	28,76	24,23
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	27,45	18,89
	No	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	31,48	18,85
	No	1	10,0	1	100,0	33,33	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	29,29	22,37
	No	1	10,0	1	100,0	22,22	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	22,22	9,07
	No	1	10,0	1	100,0	22,22	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	23,61	20,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	66,67	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	31,48	19,14
	No	1	10,0	1	100,0	22,22	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	16,67	14,34
	No	1	10,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	25,00	10,64
	No	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	19,44	16,67
	No	1	10,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	27,78	7,86
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	47,03	24,94
	No	2	20,0	1	50,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	45,45	26,04
	No	134	100,0	131	97,8	38,34	22,99
Cycle 2 Day 1	Yes	7	63,6	7	100,0	26,98	25,55
	No	129	96,3	119	92,2	34,55	20,60
Cycle 3 Day 1	Yes	7	63,6	7	100,0	23,81	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	31,23	19,74
Cycle 4 Day 1	Yes	7	63,6	7	100,0	15,87	14,14
	No	121	90,3	113	93,4	27,83	19,14
Cycle 5 Day 1	Yes	7	63,6	7	100,0	20,63	25,20
	No	117	87,3	111	94,9	26,93	18,81
Cycle 6 Day 1	Yes	7	63,6	7	100,0	30,16	29,20
	No	114	85,1	105	92,1	26,77	18,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	22,22	23,13
	No	106	79,1	99	93,4	27,16	19,71
Cycle 8 Day 1	Yes	7	63,6	7	100,0	25,40	27,00
	No	99	73,9	90	90,9	25,19	16,72
Cycle 9 Day 1	Yes	6	54,5	6	100,0	24,07	19,14
	No	92	68,7	90	97,8	23,70	17,88
Cycle 10 Day 1	Yes	6	54,5	6	100,0	24,07	20,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	27,78	18,79
Cycle 11 Day 1	Yes	6	54,5	6	100,0	29,63	22,95
	No	74	55,2	72	97,3	25,31	19,84
Cycle 12 Day 1	Yes	6	54,5	6	100,0	18,52	16,73
	No	70	52,2	63	90,0	26,63	18,13
Cycle 13 Day 1	Yes	5	45,5	5	100,0	17,78	24,34
	No	61	45,5	57	93,4	26,90	21,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	20,00	19,88
	No	55	41,0	52	94,5	28,42	23,33
Cycle 15 Day 1	Yes	4	36,4	4	100,0	30,56	24,64
	No	53	39,6	50	94,3	26,22	17,21
Cycle 16 Day 1	Yes	3	27,3	3	100,0	22,22	22,22
	No	47	35,1	44	93,6	28,54	18,00
Cycle 17 Day 1	Yes	3	27,3	3	100,0	14,81	12,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	26,83	19,08
Cycle 18 Day 1	Yes	3	27,3	3	100,0	7,41	12,83
	No	38	28,4	34	89,5	22,88	17,92
Cycle 19 Day 1	Yes	3	27,3	3	100,0	18,52	16,97
	No	33	24,6	30	90,9	28,52	19,29
Cycle 20 Day 1	Yes	3	27,3	3	100,0	14,81	6,42
	No	33	24,6	29	87,9	25,67	17,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	16,67	7,86
	No	27	20,1	24	88,9	28,70	18,51
Cycle 22 Day 1	Yes	2	18,2	2	100,0	22,22	0,00
	No	27	20,1	23	85,2	28,99	21,12
Cycle 23 Day 1	Yes	2	18,2	2	100,0	11,11	15,71
	No	19	14,2	16	84,2	29,17	24,97
Cycle 24 Day 1	Yes	2	18,2	2	100,0	22,22	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	26,39	20,24
Cycle 25 Day 1	Yes	2	18,2	2	100,0	22,22	15,71
	No	13	9,7	11	84,6	33,33	18,59
Cycle 26 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	13	9,7	11	84,6	28,28	22,42
Cycle 27 Day 1	Yes	1	9,1	1	100,0	22,22	-
	No	10	7,5	7	70,0	22,22	9,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	66,67	-
	No	9	6,7	8	88,9	23,61	20,95
Cycle 29 Day 1	Yes	1	9,1	1	100,0	55,56	-
	No	8	6,0	6	75,0	25,93	15,18
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	20,00	14,49
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	26,67	9,94
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	22,22	15,71
Cycle 33 Day 1	No	2	1,5	2	100,0	27,78	7,86
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	62,96	23,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	46,34	24,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30FA_SG.xls
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	11,97	17,68
Cycle 2 Day 1	All	136	93,8	126	92,6	7,54	12,76
Cycle 3 Day 1	All	131	90,3	118	90,1	6,36	14,11
Cycle 4 Day 1	All	128	88,3	120	93,8	5,56	11,50
Cycle 5 Day 1	All	124	85,5	118	95,2	3,95	9,42
Cycle 6 Day 1	All	121	83,4	112	92,6	5,65	10,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	4,40	9,00
Cycle 8 Day 1	All	106	73,1	97	91,5	3,44	8,31
Cycle 9 Day 1	All	98	67,6	96	98,0	3,47	10,52
Cycle 10 Day 1	All	89	61,4	86	96,6	5,04	12,80
Cycle 11 Day 1	All	80	55,2	78	97,5	4,70	11,68
Cycle 12 Day 1	All	76	52,4	69	90,8	4,35	10,56
Cycle 13 Day 1	All	66	45,5	62	93,9	2,42	7,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	3,80	12,21
Cycle 15 Day 1	All	57	39,3	54	94,7	2,47	6,80
Cycle 16 Day 1	All	50	34,5	47	94,0	6,03	12,73
Cycle 17 Day 1	All	45	31,0	44	97,8	5,68	17,22
Cycle 18 Day 1	All	41	28,3	37	90,2	2,70	7,36
Cycle 19 Day 1	All	36	24,8	33	91,7	4,55	11,24
Cycle 20 Day 1	All	36	24,8	32	88,9	2,60	7,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	1,92	5,43
Cycle 22 Day 1	All	29	20,0	25	86,2	4,00	11,06
Cycle 23 Day 1	All	21	14,5	18	85,7	4,63	13,77
Cycle 24 Day 1	All	20	13,8	18	90,0	2,78	8,57
Cycle 25 Day 1	All	15	10,3	13	86,7	3,85	9,99
Cycle 26 Day 1	All	14	9,7	12	85,7	2,78	6,49
Cycle 27 Day 1	All	11	7,6	8	72,7	6,25	12,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	3,70	7,35
Cycle 29 Day 1	All	9	6,2	7	77,8	4,76	8,13
Cycle 30 Day 1	All	7	4,8	5	71,4	10,00	9,13
Cycle 31 Day 1	All	7	4,8	5	71,4	6,67	9,13
Cycle 32 Day 1	All	6	4,1	5	83,3	3,33	7,45
Cycle 33 Day 1	All	2	1,4	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	10,98	17,95
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	9,80	18,01
	Female	93	100,0	91	97,8	13,19	17,48
Cycle 2 Day 1	Male	50	96,2	47	94,0	4,96	11,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	9,07	13,29
Cycle 3 Day 1	Male	47	90,4	42	89,4	2,78	8,16
	Female	84	90,3	76	90,5	8,33	16,22
Cycle 4 Day 1	Male	46	88,5	45	97,8	4,44	11,46
	Female	82	88,2	75	91,5	6,22	11,55
Cycle 5 Day 1	Male	45	86,5	43	95,6	3,49	9,31
	Female	79	84,9	75	94,9	4,22	9,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	5,69	12,70
	Female	76	81,7	71	93,4	5,63	9,74
Cycle 7 Day 1	Male	40	76,9	39	97,5	2,99	7,52
	Female	73	78,5	67	91,8	5,22	9,71
Cycle 8 Day 1	Male	37	71,2	34	91,9	2,45	7,26
	Female	69	74,2	63	91,3	3,97	8,84
Cycle 9 Day 1	Male	33	63,5	33	100,0	3,03	12,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	3,70	9,67
Cycle 10 Day 1	Male	30	57,7	30	100,0	4,44	13,79
	Female	59	63,4	56	94,9	5,36	12,35
Cycle 11 Day 1	Male	29	55,8	29	100,0	1,72	6,82
	Female	51	54,8	49	96,1	6,46	13,53
Cycle 12 Day 1	Male	27	51,9	26	96,3	1,92	9,81
	Female	49	52,7	43	87,8	5,81	10,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	1,45	4,80
	Female	41	44,1	39	95,1	2,99	9,27
Cycle 14 Day 1	Male	23	44,2	21	91,3	0,79	3,64
	Female	37	39,8	36	97,3	5,56	14,91
Cycle 15 Day 1	Male	21	40,4	20	95,2	1,67	5,13
	Female	36	38,7	34	94,4	2,94	7,64
Cycle 16 Day 1	Male	16	30,8	16	100,0	4,17	11,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	6,99	13,45
Cycle 17 Day 1	Male	13	25,0	13	100,0	2,56	6,26
	Female	32	34,4	31	96,9	6,99	20,08
Cycle 18 Day 1	Male	12	23,1	11	91,7	3,03	10,05
	Female	29	31,2	26	89,7	2,56	6,13
Cycle 19 Day 1	Male	10	19,2	10	100,0	3,33	10,54
	Female	26	28,0	23	88,5	5,07	11,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	0,00	0,00
	Female	26	28,0	23	88,5	3,62	8,64
Cycle 21 Day 1	Male	8	15,4	8	100,0	0,00	0,00
	Female	21	22,6	18	85,7	2,78	6,39
Cycle 22 Day 1	Male	8	15,4	6	75,0	0,00	0,00
	Female	21	22,6	19	90,5	5,26	12,49
Cycle 23 Day 1	Male	5	9,6	4	80,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	3,57	13,36
Cycle 24 Day 1	Male	5	9,6	4	80,0	0,00	0,00
	Female	15	16,1	14	93,3	3,57	9,65
Cycle 25 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	12	12,9	11	91,7	4,55	10,78
Cycle 26 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	11	11,8	10	90,9	3,33	7,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	8	8,6	6	75,0	8,33	13,94
Cycle 28 Day 1	Male	2	3,8	2	100,0	0,00	0,00
	Female	8	8,6	7	87,5	4,76	8,13
Cycle 29 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	8	8,6	6	75,0	5,56	8,61
Cycle 30 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	12,50	8,33
Cycle 31 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	8,33	9,62
Cycle 32 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	5	5,4	4	80,0	4,17	8,33
Cycle 33 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	1	1,1	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	10,32	12,33
	Female	37	39,8	23	62,2	11,59	22,15
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	12,26	17,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	12,64	20,73
	>=75	7	100,0	7	100,0	4,76	8,13
Cycle 2 Day 1	18-64	103	94,5	94	91,3	5,67	10,53
	65-74	26	89,7	25	96,2	12,00	17,69
	>=75	7	100,0	7	100,0	16,67	13,61
Cycle 3 Day 1	18-64	99	90,8	87	87,9	5,36	12,05
	65-74	25	86,2	24	96,0	7,64	19,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	14,29	15,00
Cycle 4 Day 1	18-64	98	89,9	92	93,9	5,07	10,70
	65-74	23	79,3	21	91,3	5,56	12,17
	>=75	7	100,0	7	100,0	11,90	18,54
Cycle 5 Day 1	18-64	95	87,2	90	94,7	3,52	8,47
	65-74	22	75,9	22	100,0	3,03	8,35
	>=75	7	100,0	6	85,7	13,89	19,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	5,16	10,34
	65-74	22	75,9	21	95,5	5,56	12,17
	>=75	7	100,0	7	100,0	11,90	12,60
Cycle 7 Day 1	18-64	86	78,9	81	94,2	3,91	8,02
	65-74	20	69,0	19	95,0	4,39	10,89
	>=75	7	100,0	6	85,7	11,11	13,61
Cycle 8 Day 1	18-64	80	73,4	72	90,0	3,01	8,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	4,39	9,37
	>=75	7	100,0	6	85,7	5,56	8,61
Cycle 9 Day 1	18-64	74	67,9	73	98,6	3,65	10,85
	65-74	18	62,1	18	100,0	3,70	10,78
	>=75	6	85,7	5	83,3	0,00	0,00
Cycle 10 Day 1	18-64	69	63,3	66	95,7	6,06	13,91
	65-74	15	51,7	15	100,0	2,22	8,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	0,00	0,00
Cycle 11 Day 1	18-64	61	56,0	59	96,7	5,37	12,55
	65-74	15	51,7	15	100,0	3,33	9,34
	>=75	4	57,1	4	100,0	0,00	0,00
Cycle 12 Day 1	18-64	57	52,3	51	89,5	5,23	11,30
	65-74	15	51,7	14	93,3	2,38	8,91
	>=75	4	57,1	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	2,17	5,68
	65-74	13	44,8	12	92,3	4,17	14,43
	>=75	4	57,1	4	100,0	0,00	0,00
Cycle 14 Day 1	18-64	45	41,3	44	97,8	3,41	9,90
	65-74	13	44,8	11	84,6	6,06	20,10
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 15 Day 1	18-64	43	39,4	41	95,3	2,44	5,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	3,03	10,05
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 16 Day 1	18-64	38	34,9	36	94,7	6,94	13,44
	65-74	10	34,5	9	90,0	3,70	11,11
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 17 Day 1	18-64	36	33,0	35	97,2	6,67	19,05
	65-74	8	27,6	8	100,0	2,08	5,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	0,00	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	3,33	8,07
	65-74	7	24,1	6	85,7	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	4,17	10,76
	65-74	5	17,2	4	80,0	8,33	16,67
	>=75	1	14,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	1,92	5,43
	65-74	5	17,2	5	100,0	6,67	14,91
	>=75	1	14,3	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	2,38	5,98
	65-74	4	13,8	4	100,0	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	5,00	12,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	5,21	14,55
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	3,13	9,07
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	12,8	12	85,7	4,17	10,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	2,78	6,49
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	6,25	12,40
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	3,70	7,35
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	4,76	8,13
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	10,00	9,13
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	6,67	9,13
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	4,17	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	0,00	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	11,76	19,04
	65-74	15	51,7	8	53,3	10,42	15,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	0,00	0,00
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	14,66	21,87
	Other	85	100,0	84	98,8	10,12	13,94
Cycle 2 Day 1	White	57	95,0	51	89,5	7,52	12,61
	Other	79	92,9	75	94,9	7,56	12,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	6,82	15,80
	Other	77	90,6	74	96,1	6,08	13,11
Cycle 4 Day 1	White	53	88,3	47	88,7	4,96	10,38
	Other	75	88,2	73	97,3	5,94	12,23
Cycle 5 Day 1	White	52	86,7	48	92,3	5,21	9,82
	Other	72	84,7	70	97,2	3,10	9,10
Cycle 6 Day 1	White	50	83,3	44	88,0	7,20	12,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	4,66	9,48
Cycle 7 Day 1	White	47	78,3	42	89,4	4,37	9,06
	Other	66	77,6	64	97,0	4,43	9,03
Cycle 8 Day 1	White	45	75,0	39	86,7	3,85	8,94
	Other	61	71,8	58	95,1	3,16	7,93
Cycle 9 Day 1	White	42	70,0	41	97,6	4,88	14,07
	Other	56	65,9	55	98,2	2,42	6,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	5,98	14,04
	Other	48	56,5	47	97,9	4,26	11,77
Cycle 11 Day 1	White	37	61,7	37	100,0	4,05	9,94
	Other	43	50,6	41	95,3	5,28	13,14
Cycle 12 Day 1	White	37	61,7	33	89,2	5,56	12,27
	Other	39	45,9	36	92,3	3,24	8,75
Cycle 13 Day 1	White	32	53,3	30	93,8	3,33	10,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	1,56	4,94
Cycle 14 Day 1	White	31	51,7	30	96,8	4,44	15,12
	Other	29	34,1	27	93,1	3,09	8,06
Cycle 15 Day 1	White	30	50,0	28	93,3	2,98	7,93
	Other	27	31,8	26	96,3	1,92	5,43
Cycle 16 Day 1	White	26	43,3	24	92,3	9,03	15,53
	Other	24	28,2	23	95,8	2,90	8,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	6,94	22,48
	Other	21	24,7	20	95,2	4,17	7,40
Cycle 18 Day 1	White	22	36,7	19	86,4	0,88	3,82
	Other	19	22,4	18	94,7	4,63	9,58
Cycle 19 Day 1	White	20	33,3	20	100,0	6,67	13,68
	Other	16	18,8	13	81,3	1,28	4,62
Cycle 20 Day 1	White	20	33,3	17	85,0	0,98	4,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	4,44	9,89
Cycle 21 Day 1	White	16	26,7	14	87,5	2,38	6,05
	Other	13	15,3	12	92,3	1,39	4,81
Cycle 22 Day 1	White	16	26,7	13	81,3	6,41	14,50
	Other	13	15,3	12	92,3	1,39	4,81
Cycle 23 Day 1	White	12	20,0	10	83,3	5,00	15,81
	Other	9	10,6	8	88,9	4,17	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	5,00	11,25
	Other	9	10,6	8	88,9	0,00	0,00
Cycle 25 Day 1	White	10	16,7	8	80,0	4,17	11,79
	Other	5	5,9	5	100,0	3,33	7,45
Cycle 26 Day 1	White	10	16,7	8	80,0	2,08	5,89
	Other	4	4,7	4	100,0	4,17	8,33
Cycle 27 Day 1	White	8	13,3	5	62,5	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	5,56	9,62
Cycle 28 Day 1	White	7	11,7	6	85,7	0,00	0,00
	Other	3	3,5	3	100,0	11,11	9,62
Cycle 29 Day 1	White	6	10,0	4	66,7	0,00	0,00
	Other	3	3,5	3	100,0	11,11	9,62
Cycle 30 Day 1	White	4	6,7	2	50,0	8,33	11,79
	Other	3	3,5	3	100,0	11,11	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	0,00	0,00
	Other	3	3,5	3	100,0	11,11	9,62
Cycle 32 Day 1	White	4	6,7	3	75,0	0,00	0,00
	Other	2	2,4	2	100,0	8,33	11,79
Cycle 33 Day 1	White	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	15,69	21,63
	Other	39	45,9	27	69,2	8,02	14,89
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	10,42	20,22
	Europe (EU)	34	100,0	31	91,2	10,75	15,24
	Asia (AS)	71	100,0	71	100,0	13,38	17,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	33	86,8	8,59	13,26
	Europe (EU)	32	94,1	28	87,5	5,95	12,18
	Asia (AS)	66	93,0	65	98,5	7,69	12,87
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	5,56	11,54
	Europe (EU)	31	91,2	22	71,0	6,06	18,22
	Asia (AS)	63	88,7	63	100,0	6,88	13,92
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	5,39	10,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	1,33	4,61
	Asia (AS)	61	85,9	61	100,0	7,38	13,45
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	4,29	8,42
	Europe (EU)	30	88,2	26	86,7	4,49	10,06
	Asia (AS)	57	80,3	57	100,0	3,51	9,83
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	5,71	9,85
	Europe (EU)	28	82,4	25	89,3	7,33	13,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	4,81	10,08
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	2,60	6,15
	Europe (EU)	28	82,4	25	89,3	5,33	10,45
	Asia (AS)	50	70,4	49	98,0	5,10	9,74
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	1,85	7,06
	Europe (EU)	28	82,4	23	82,1	3,62	8,64
	Asia (AS)	47	66,2	47	100,0	4,26	8,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	2,98	10,20
	Europe (EU)	26	76,5	25	96,2	4,67	14,84
	Asia (AS)	43	60,6	43	100,0	3,10	7,50
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	3,47	8,48
	Europe (EU)	25	73,5	25	100,0	7,33	16,02
	Asia (AS)	37	52,1	37	100,0	4,50	12,82
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	3,62	8,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	3,79	10,20
	Asia (AS)	33	46,5	33	100,0	6,06	14,32
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	4,35	9,01
	Europe (EU)	23	67,6	18	78,3	5,56	14,00
	Asia (AS)	29	40,8	28	96,6	3,57	9,47
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	0,76	3,55
	Europe (EU)	18	52,9	15	83,3	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	2,00	5,53
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	3,17	11,33
	Europe (EU)	17	50,0	16	94,1	5,21	16,91
	Asia (AS)	21	29,6	20	95,2	3,33	8,72
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	1,67	5,13
	Europe (EU)	15	44,1	14	93,3	4,76	10,19
	Asia (AS)	20	28,2	20	100,0	1,67	5,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	3,92	9,37
	Europe (EU)	14	41,2	11	78,6	7,58	13,67
	Asia (AS)	19	26,8	19	100,0	7,02	15,03
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	10,42	27,13
	Europe (EU)	13	38,2	12	92,3	1,39	4,81
	Asia (AS)	16	22,5	16	100,0	4,17	7,45
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	0,00	0,00
	Asia (AS)	16	22,5	16	100,0	6,25	10,32
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	6,41	12,80
	Europe (EU)	9	26,5	9	100,0	7,41	14,70
	Asia (AS)	14	19,7	11	78,6	0,00	0,00
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	1,28	4,62
	Europe (EU)	9	26,5	6	66,7	2,78	6,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	3,85	9,99
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	1,67	5,27
	Europe (EU)	7	20,6	6	85,7	2,78	6,80
	Asia (AS)	11	15,5	10	90,9	1,67	5,27
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	6,67	16,10
	Europe (EU)	7	20,6	5	71,4	3,33	7,45
	Asia (AS)	11	15,5	10	90,9	1,67	5,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	5,56	16,67
	Europe (EU)	5	14,7	3	60,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	5,56	13,61
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	4,17	11,79
	Europe (EU)	5	14,7	4	80,0	4,17	8,33
	Asia (AS)	7	9,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	7,14	13,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	0,00	0,00
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	2,78	6,80
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	4,17	8,33
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	0,00	0,00
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	12,50	15,96
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	0,00	0,00
	Europe (EU)	2	5,9	1	50,0	0,00	-
	Asia (AS)	4	5,6	4	100,0	8,33	9,62
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	0,00	0,00
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	8,33	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	8,33	11,79
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	11,11	9,62
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	11,11	9,62
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	0,00	-
	Asia (AS)	3	4,2	2	66,7	8,33	11,79
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	0,00	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	9,80	21,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	13,33	13,94
	Asia (AS)	34	47,9	22	64,7	11,36	16,58
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	8,61	14,55
	1	69	100,0	67	97,1	14,43	20,08
	2	15	100,0	15	100,0	14,44	16,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	56	94,9	5,65	11,14
	1	67	97,1	60	89,6	9,72	14,16
	2	10	66,7	10	100,0	5,00	11,25
Cycle 3 Day 1	0	57	93,4	51	89,5	5,88	14,84
	1	65	94,2	58	89,2	6,03	11,97
	2	9	60,0	9	100,0	11,11	22,05
Cycle 4 Day 1	0	57	93,4	54	94,7	6,17	12,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	4,60	9,77
	2	9	60,0	8	88,9	8,33	15,43
Cycle 5 Day 1	0	56	91,8	53	94,6	5,35	10,73
	1	62	89,9	59	95,2	2,54	7,46
	2	6	40,0	6	100,0	5,56	13,61
Cycle 6 Day 1	0	56	91,8	54	96,4	6,79	12,75
	1	59	85,5	53	89,8	4,40	8,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	6,67	9,13
Cycle 7 Day 1	0	54	88,5	51	94,4	4,25	9,91
	1	54	78,3	50	92,6	4,33	8,12
	2	5	33,3	5	100,0	6,67	9,13
Cycle 8 Day 1	0	52	85,2	48	92,3	2,78	7,94
	1	49	71,0	44	89,8	4,55	9,07
	2	5	33,3	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	4,08	12,97
	1	44	63,8	43	97,7	3,10	7,50
	2	4	26,7	4	100,0	0,00	0,00
Cycle 10 Day 1	0	46	75,4	46	100,0	6,16	13,77
	1	40	58,0	37	92,5	3,60	11,87
	2	3	20,0	3	100,0	5,56	9,62
Cycle 11 Day 1	0	43	70,5	41	95,3	4,47	9,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	5,39	14,05
	2	3	20,0	3	100,0	0,00	0,00
Cycle 12 Day 1	0	42	68,9	36	85,7	5,56	12,60
	1	31	44,9	30	96,8	2,78	7,69
	2	3	20,0	3	100,0	5,56	9,62
Cycle 13 Day 1	0	38	62,3	34	89,5	2,94	9,60
	1	27	39,1	27	100,0	1,85	5,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	4,69	14,81
	1	24	34,8	24	100,0	2,78	8,03
	2	1	6,7	1	100,0	0,00	-
Cycle 15 Day 1	0	33	54,1	30	90,9	2,78	7,69
	1	23	33,3	23	100,0	2,17	5,74
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	6,67	12,73
	1	21	30,4	21	100,0	5,56	13,26
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	8,70	22,96
	1	20	29,0	20	100,0	2,50	6,11
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	0,88	3,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	4,90	9,80
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	6,14	12,68
	1	15	21,7	13	86,7	2,56	9,25
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	4,90	9,80
	1	15	21,7	14	93,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	2,38	6,05
	1	13	18,8	11	84,6	1,52	5,03
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	6,94	15,01
	1	13	18,8	12	92,3	1,39	4,81
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	5,56	16,67
	1	9	13,0	8	88,9	4,17	11,79
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	5,56	11,79
	1	9	13,0	8	88,9	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	2,38	6,30
Cycle 26 Day 1	0	8	13,1	6	75,0	2,78	6,80
	1	6	8,7	6	100,0	2,78	6,80
Cycle 27 Day 1	0	6	9,8	3	50,0	11,11	19,25
	1	5	7,2	5	100,0	3,33	7,45
Cycle 28 Day 1	0	5	8,2	4	80,0	0,00	0,00
	1	5	7,2	5	100,0	6,67	9,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	0,00	0,00
	1	5	7,2	5	100,0	6,67	9,13
Cycle 30 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	12,50	8,33
Cycle 31 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	8,33	9,62
Cycle 32 Day 1	0	3	4,9	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	5,56	9,62
Cycle 33 Day 1	0	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	10,32	20,05
	1	34	49,3	20	58,8	9,17	13,76
	2	7	46,7	3	42,9	27,78	25,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	9,72	19,23
	1	4	100,0	4	100,0	8,33	9,62
	2 or More	79	100,0	78	98,7	13,89	16,65
Cycle 2 Day 1	None	60	96,8	55	91,7	5,76	10,25
	1	3	75,0	2	66,7	25,00	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	8,45	13,60
Cycle 3 Day 1	None	59	95,2	53	89,8	3,77	9,61
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	69	87,3	63	91,3	8,73	16,90
Cycle 4 Day 1	None	59	95,2	56	94,9	4,76	10,88
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	66	83,5	62	93,9	6,45	12,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	2,68	6,95
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	63	79,7	59	93,7	5,37	11,35
Cycle 6 Day 1	None	57	91,9	52	91,2	4,17	8,65
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	61	77,2	57	93,4	7,31	12,61
Cycle 7 Day 1	None	52	83,9	50	96,2	3,33	6,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	58	73,4	53	91,4	5,66	10,81
Cycle 8 Day 1	None	50	80,6	46	92,0	2,54	7,83
	1	3	75,0	1	33,3	16,67	-
	2 or More	53	67,1	50	94,3	4,00	8,62
Cycle 9 Day 1	None	48	77,4	47	97,9	1,42	5,85
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	5,56	13,46
Cycle 10 Day 1	None	43	69,4	41	95,3	2,44	5,96
	1	1	25,0	1	100,0	0,00	-
	2 or More	45	57,0	44	97,8	7,58	16,65
Cycle 11 Day 1	None	37	59,7	35	94,6	1,43	4,73
	1	1	25,0	1	100,0	0,00	-
	2 or More	42	53,2	42	100,0	7,54	14,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	1,96	5,45
	1	1	25,0	1	100,0	0,00	-
	2 or More	38	48,1	34	89,5	6,86	13,68
Cycle 13 Day 1	None	34	54,8	30	88,2	1,11	4,23
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	3,76	10,28
Cycle 14 Day 1	None	31	50,0	29	93,5	1,15	4,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	28	35,4	27	96,4	6,79	16,83
Cycle 15 Day 1	None	30	48,4	28	93,3	1,79	5,25
	1	1	25,0	1	100,0	0,00	-
	2 or More	26	32,9	25	96,2	3,33	8,33
Cycle 16 Day 1	None	25	40,3	23	92,0	3,62	10,00
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	8,70	14,97
Cycle 17 Day 1	None	23	37,1	22	95,7	0,76	3,55
	1	1	25,0	1	100,0	0,00	-
	2 or More	21	26,6	21	100,0	11,11	23,77
Cycle 18 Day 1	None	20	32,3	18	90,0	2,78	8,57
	1	1	25,0	1	100,0	0,00	-
	2 or More	20	25,3	18	90,0	2,78	6,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	2,94	8,81
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	6,67	13,80
Cycle 20 Day 1	None	17	27,4	16	94,1	3,13	6,72
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	2,22	8,61
Cycle 21 Day 1	None	15	24,2	13	86,7	1,28	4,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	2,56	6,26
Cycle 22 Day 1	None	15	24,2	13	86,7	1,28	4,62
	2 or More	14	17,7	12	85,7	6,94	15,01
Cycle 23 Day 1	None	10	16,1	9	90,0	0,00	0,00
	2 or More	11	13,9	9	81,8	9,26	18,84
Cycle 24 Day 1	None	10	16,1	10	100,0	0,00	0,00
	2 or More	10	12,7	8	80,0	6,25	12,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	2,08	5,89
	2 or More	6	7,6	5	83,3	6,67	14,91
Cycle 26 Day 1	None	8	12,9	8	100,0	2,08	5,89
	2 or More	6	7,6	4	66,7	4,17	8,33
Cycle 27 Day 1	None	7	11,3	6	85,7	5,56	13,61
	2 or More	4	5,1	2	50,0	8,33	11,79
Cycle 28 Day 1	None	7	11,3	7	100,0	2,38	6,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	8,33	11,79
Cycle 29 Day 1	None	6	9,7	5	83,3	3,33	7,45
	2 or More	3	3,8	2	66,7	8,33	11,79
Cycle 30 Day 1	None	4	6,5	3	75,0	11,11	9,62
	2 or More	3	3,8	2	66,7	8,33	11,79
Cycle 31 Day 1	None	4	6,5	3	75,0	5,56	9,62
	2 or More	3	3,8	2	66,7	8,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	5,56	9,62
	2 or More	2	2,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	1,6	1	100,0	0,00	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	8,77	11,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	0,00	-
	2 or More	39	49,4	24	61,5	13,19	21,97
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	9,72	19,23
	Previously Treated	83	100,0	82	98,8	13,62	16,38
Cycle 2 Day 1	Naïve	60	96,8	55	91,7	5,76	10,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	8,92	14,32
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	3,77	9,61
	Previously Treated	72	86,7	65	90,3	8,46	16,70
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	4,76	10,88
	Previously Treated	69	83,1	64	92,8	6,25	12,06
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	2,68	6,95
	Previously Treated	66	79,5	62	93,9	5,11	11,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	4,17	8,65
	Previously Treated	64	77,1	60	93,8	6,94	12,39
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	3,33	6,73
	Previously Treated	61	73,5	56	91,8	5,36	10,59
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	2,54	7,83
	Previously Treated	56	67,5	51	91,1	4,25	8,72
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	1,42	5,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	5,44	13,35
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	2,44	5,96
	Previously Treated	46	55,4	45	97,8	7,41	16,50
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	1,43	4,73
	Previously Treated	43	51,8	43	100,0	7,36	14,68
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	1,96	5,45
	Previously Treated	39	47,0	35	89,7	6,67	13,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	1,11	4,23
	Previously Treated	32	38,6	32	100,0	3,65	10,14
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	1,15	4,30
	Previously Treated	29	34,9	28	96,6	6,55	16,57
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	1,79	5,25
	Previously Treated	27	32,5	26	96,3	3,21	8,19
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	3,62	10,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	8,33	14,74
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	0,76	3,55
	Previously Treated	22	26,5	22	100,0	10,61	23,31
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	2,78	8,57
	Previously Treated	21	25,3	19	90,5	2,63	6,24
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	2,94	8,81
	Previously Treated	19	22,9	16	84,2	6,25	13,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	3,13	6,72
	Previously Treated	19	22,9	16	84,2	2,08	8,33
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	1,28	4,62
	Previously Treated	14	16,9	13	92,9	2,56	6,26
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	1,28	4,62
	Previously Treated	14	16,9	12	85,7	6,94	15,01
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	9,26	18,84
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	0,00	0,00
	Previously Treated	10	12,0	8	80,0	6,25	12,40
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	2,08	5,89
	Previously Treated	6	7,2	5	83,3	6,67	14,91
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	2,08	5,89
	Previously Treated	6	7,2	4	66,7	4,17	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	5,56	13,61
	Previously Treated	4	4,8	2	50,0	8,33	11,79
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	2,38	6,30
	Previously Treated	3	3,6	2	66,7	8,33	11,79
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	3,33	7,45
	Previously Treated	3	3,6	2	66,7	8,33	11,79
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	11,11	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	8,33	11,79
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	5,56	9,62
	Previously Treated	3	3,6	2	66,7	8,33	11,79
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	5,56	9,62
	Previously Treated	2	2,4	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	0,00	-
	Previously Treated	1	1,2	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	8,77	11,61
	Previously Treated	42	50,6	25	59,5	12,67	21,67
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	14,22	19,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	9,45	15,68
Cycle 2 Day 1	Local	71	94,7	67	94,4	7,96	13,09
	Central	65	92,9	59	90,8	7,06	12,46
Cycle 3 Day 1	Local	67	89,3	62	92,5	7,80	17,00
	Central	64	91,4	56	87,5	4,76	9,91
Cycle 4 Day 1	Local	65	86,7	61	93,8	5,74	11,74
	Central	63	90,0	59	93,7	5,37	11,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	4,24	10,07
	Central	61	87,1	59	96,7	3,67	8,79
Cycle 6 Day 1	Local	63	84,0	61	96,8	6,01	10,99
	Central	58	82,9	51	87,9	5,23	10,80
Cycle 7 Day 1	Local	61	81,3	59	96,7	3,67	8,23
	Central	52	74,3	47	90,4	5,32	9,89
Cycle 8 Day 1	Local	57	76,0	55	96,5	3,64	8,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	3,17	7,58
Cycle 9 Day 1	Local	54	72,0	53	98,1	3,46	10,00
	Central	44	62,9	43	97,7	3,49	11,24
Cycle 10 Day 1	Local	48	64,0	46	95,8	6,88	15,94
	Central	41	58,6	40	97,6	2,92	7,44
Cycle 11 Day 1	Local	40	53,3	38	95,0	6,58	14,26
	Central	40	57,1	40	100,0	2,92	8,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	4,55	10,44
	Central	40	57,1	36	90,0	4,17	10,82
Cycle 13 Day 1	Local	30	40,0	29	96,7	4,02	10,59
	Central	36	51,4	33	91,7	1,01	4,04
Cycle 14 Day 1	Local	27	36,0	27	100,0	5,56	16,67
	Central	33	47,1	30	90,9	2,22	5,76
Cycle 15 Day 1	Local	26	34,7	25	96,2	4,00	8,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	1,15	4,30
Cycle 16 Day 1	Local	24	32,0	24	100,0	4,17	10,13
	Central	26	37,1	23	88,5	7,97	14,97
Cycle 17 Day 1	Local	22	29,3	22	100,0	4,55	11,71
	Central	23	32,9	22	95,7	6,82	21,61
Cycle 18 Day 1	Local	20	26,7	19	95,0	0,00	0,00
	Central	21	30,0	18	85,7	5,56	9,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	6,86	13,25
	Central	17	24,3	16	94,1	2,08	8,33
Cycle 20 Day 1	Local	19	25,3	17	89,5	0,98	4,04
	Central	17	24,3	15	88,2	4,44	9,89
Cycle 21 Day 1	Local	14	18,7	12	85,7	1,39	4,81
	Central	15	21,4	14	93,3	2,38	6,05
Cycle 22 Day 1	Local	14	18,7	12	85,7	1,39	4,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	6,41	14,50
Cycle 23 Day 1	Local	11	14,7	10	90,9	3,33	10,54
	Central	10	14,3	8	80,0	6,25	17,68
Cycle 24 Day 1	Local	11	14,7	10	90,9	3,33	10,54
	Central	9	12,9	8	88,9	2,08	5,89
Cycle 25 Day 1	Local	7	9,3	7	100,0	7,14	13,11
	Central	8	11,4	6	75,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	5,56	8,61
	Central	8	11,4	6	75,0	0,00	0,00
Cycle 27 Day 1	Local	4	5,3	4	100,0	0,00	0,00
	Central	7	10,0	4	57,1	12,50	15,96
Cycle 28 Day 1	Local	4	5,3	4	100,0	4,17	8,33
	Central	6	8,6	5	83,3	3,33	7,45
Cycle 29 Day 1	Local	3	4,0	3	100,0	5,56	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	4,17	8,33
Cycle 30 Day 1	Local	3	4,0	3	100,0	11,11	9,62
	Central	4	5,7	2	50,0	8,33	11,79
Cycle 31 Day 1	Local	3	4,0	3	100,0	5,56	9,62
	Central	4	5,7	2	50,0	8,33	11,79
Cycle 32 Day 1	Local	3	4,0	3	100,0	5,56	9,62
	Central	3	4,3	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	0,00	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	9,72	16,97
	Central	32	45,7	20	62,5	12,50	19,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	11,87	17,78
	No	10	100,0	10	100,0	13,33	17,21
Cycle 2 Day 1	Yes	129	95,6	119	92,2	7,28	12,20
	No	7	70,0	7	100,0	11,90	20,89
Cycle 3 Day 1	Yes	124	91,9	112	90,3	6,55	14,39
	No	7	70,0	6	85,7	2,78	6,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	5,60	11,70
	No	7	70,0	7	100,0	4,76	8,13
Cycle 5 Day 1	Yes	117	86,7	112	95,7	4,02	9,56
	No	7	70,0	6	85,7	2,78	6,80
Cycle 6 Day 1	Yes	114	84,4	105	92,1	5,56	10,76
	No	7	70,0	7	100,0	7,14	13,11
Cycle 7 Day 1	Yes	106	78,5	99	93,4	4,04	8,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	9,52	13,11
Cycle 8 Day 1	Yes	100	74,1	91	91,0	3,48	8,43
	No	6	60,0	6	100,0	2,78	6,80
Cycle 9 Day 1	Yes	92	68,1	90	97,8	3,70	10,83
	No	6	60,0	6	100,0	0,00	0,00
Cycle 10 Day 1	Yes	83	61,5	80	96,4	4,58	11,24
	No	6	60,0	6	100,0	11,11	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	4,73	11,87
	No	4	40,0	4	100,0	4,17	8,33
Cycle 12 Day 1	Yes	72	53,3	65	90,3	4,62	10,83
	No	4	40,0	4	100,0	0,00	0,00
Cycle 13 Day 1	Yes	64	47,4	60	93,8	2,22	7,80
	No	2	20,0	2	100,0	8,33	11,79
Cycle 14 Day 1	Yes	58	43,0	55	94,8	3,94	12,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	0,00	0,00
Cycle 15 Day 1	Yes	55	40,7	52	94,5	2,24	6,62
	No	2	20,0	2	100,0	8,33	11,79
Cycle 16 Day 1	Yes	48	35,6	45	93,8	6,30	12,95
	No	2	20,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	43	31,9	42	97,7	5,56	17,53
	No	2	20,0	2	100,0	8,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	2,86	7,55
	No	2	20,0	2	100,0	0,00	0,00
Cycle 19 Day 1	Yes	34	25,2	32	94,1	4,69	11,39
	No	2	20,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	1,67	5,09
	No	2	20,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	20,0	24	88,9	2,08	5,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	0,00	0,00
Cycle 22 Day 1	Yes	27	20,0	23	85,2	4,35	11,48
	No	2	20,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	4,90	14,15
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	2,94	8,81
	No	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	4,17	10,36
	No	1	10,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	1,52	5,03
	No	1	10,0	1	100,0	16,67	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	7,14	13,11
	No	1	10,0	1	100,0	0,00	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	2,08	5,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	16,67	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	2,78	6,80
	No	1	10,0	1	100,0	16,67	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	8,33	9,62
	No	1	10,0	1	100,0	16,67	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	4,17	8,33
	No	1	10,0	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	0,00	0,00
	No	1	10,0	1	100,0	16,67	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	11,24	18,08
	No	2	20,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	16,67	14,91
	No	134	100,0	131	97,8	11,58	17,89
Cycle 2 Day 1	Yes	7	63,6	7	100,0	4,76	8,13
	No	129	96,3	119	92,2	7,70	12,98
Cycle 3 Day 1	Yes	7	63,6	7	100,0	2,38	6,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	6,61	14,44
Cycle 4 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	121	90,3	113	93,4	5,90	11,77
Cycle 5 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	117	87,3	111	94,9	4,20	9,66
Cycle 6 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	114	85,1	105	92,1	6,03	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	2,38	6,30
	No	106	79,1	99	93,4	4,55	9,17
Cycle 8 Day 1	Yes	7	63,6	7	100,0	7,14	13,11
	No	99	73,9	90	90,9	3,15	7,86
Cycle 9 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	92	68,7	90	97,8	3,70	10,83
Cycle 10 Day 1	Yes	6	54,5	6	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	5,42	13,20
Cycle 11 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	74	55,2	72	97,3	5,09	12,08
Cycle 12 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	70	52,2	63	90,0	4,76	10,97
Cycle 13 Day 1	Yes	5	45,5	5	100,0	0,00	0,00
	No	61	45,5	57	93,4	2,63	8,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	0,00	0,00
	No	55	41,0	52	94,5	4,17	12,73
Cycle 15 Day 1	Yes	4	36,4	4	100,0	0,00	0,00
	No	53	39,6	50	94,3	2,67	7,03
Cycle 16 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	47	35,1	44	93,6	5,68	12,42
Cycle 17 Day 1	Yes	3	27,3	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	6,10	17,78
Cycle 18 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	38	28,4	34	89,5	2,94	7,64
Cycle 19 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	30	90,9	5,00	11,70
Cycle 20 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	29	87,9	2,87	7,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	24	88,9	2,08	5,63
Cycle 22 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	23	85,2	4,35	11,48
Cycle 23 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	19	14,2	16	84,2	5,21	14,55
Cycle 24 Day 1	Yes	2	18,2	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	3,13	9,07
Cycle 25 Day 1	Yes	2	18,2	2	100,0	8,33	11,79
	No	13	9,7	11	84,6	3,03	10,05
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	3,03	6,74
Cycle 27 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	10	7,5	7	70,0	2,38	6,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	9	6,7	8	88,9	4,17	7,72
Cycle 29 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	8	6,0	6	75,0	5,56	8,61
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	10,00	9,13
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	6,67	9,13
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	3,33	7,45
Cycle 33 Day 1	No	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	5,56	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	11,38	18,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30NV_SG.xls
24JUN2020 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	28,76	27,37
Cycle 2 Day 1	All	136	93,8	126	92,6	16,80	22,16
Cycle 3 Day 1	All	131	90,3	118	90,1	14,41	20,32
Cycle 4 Day 1	All	128	88,3	120	93,8	14,72	21,52
Cycle 5 Day 1	All	124	85,5	118	95,2	13,42	19,76
Cycle 6 Day 1	All	121	83,4	112	92,6	13,54	16,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	16,19	19,71
Cycle 8 Day 1	All	106	73,1	97	91,5	12,89	18,40
Cycle 9 Day 1	All	98	67,6	96	98,0	14,76	21,20
Cycle 10 Day 1	All	89	61,4	86	96,6	13,76	17,93
Cycle 11 Day 1	All	80	55,2	78	97,5	12,61	16,38
Cycle 12 Day 1	All	76	52,4	69	90,8	14,98	21,42
Cycle 13 Day 1	All	66	45,5	62	93,9	17,74	23,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	18,13	25,84
Cycle 15 Day 1	All	57	39,3	54	94,7	14,51	20,99
Cycle 16 Day 1	All	50	34,5	47	94,0	20,21	24,80
Cycle 17 Day 1	All	45	31,0	44	97,8	19,32	24,63
Cycle 18 Day 1	All	41	28,3	37	90,2	15,32	21,29
Cycle 19 Day 1	All	36	24,8	33	91,7	17,68	22,41
Cycle 20 Day 1	All	36	24,8	32	88,9	20,31	23,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	21,79	23,93
Cycle 22 Day 1	All	29	20,0	25	86,2	20,67	24,66
Cycle 23 Day 1	All	21	14,5	18	85,7	23,15	28,09
Cycle 24 Day 1	All	20	13,8	18	90,0	18,52	21,30
Cycle 25 Day 1	All	15	10,3	13	86,7	19,23	14,98
Cycle 26 Day 1	All	14	9,7	12	85,7	20,83	28,54
Cycle 27 Day 1	All	11	7,6	8	72,7	29,17	33,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	29,63	21,70
Cycle 29 Day 1	All	9	6,2	7	77,8	23,81	23,29
Cycle 30 Day 1	All	7	4,8	5	71,4	23,33	14,91
Cycle 31 Day 1	All	7	4,8	5	71,4	16,67	11,79
Cycle 32 Day 1	All	6	4,1	5	83,3	20,00	7,45
Cycle 33 Day 1	All	2	1,4	2	100,0	8,33	11,79
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	27,65	24,89
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	26,14	27,94
	Female	93	100,0	91	97,8	30,22	27,09
Cycle 2 Day 1	Male	50	96,2	47	94,0	21,28	22,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	14,14	21,37
Cycle 3 Day 1	Male	47	90,4	42	89,4	11,51	18,95
	Female	84	90,3	76	90,5	16,01	20,98
Cycle 4 Day 1	Male	46	88,5	45	97,8	12,59	22,80
	Female	82	88,2	75	91,5	16,00	20,77
Cycle 5 Day 1	Male	45	86,5	43	95,6	13,95	20,87
	Female	79	84,9	75	94,9	13,11	19,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	12,60	15,71
	Female	76	81,7	71	93,4	14,08	16,58
Cycle 7 Day 1	Male	40	76,9	39	97,5	17,95	22,09
	Female	73	78,5	67	91,8	15,17	18,29
Cycle 8 Day 1	Male	37	71,2	34	91,9	14,71	20,00
	Female	69	74,2	63	91,3	11,90	17,56
Cycle 9 Day 1	Male	33	63,5	33	100,0	11,11	18,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	16,67	22,60
Cycle 10 Day 1	Male	30	57,7	30	100,0	10,00	14,25
	Female	59	63,4	56	94,9	15,77	19,44
Cycle 11 Day 1	Male	29	55,8	29	100,0	13,79	16,10
	Female	51	54,8	49	96,1	11,90	16,67
Cycle 12 Day 1	Male	27	51,9	26	96,3	12,18	15,32
	Female	49	52,7	43	87,8	16,67	24,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	15,22	15,00
	Female	41	44,1	39	95,1	19,23	27,18
Cycle 14 Day 1	Male	23	44,2	21	91,3	14,29	25,97
	Female	37	39,8	36	97,3	20,37	25,85
Cycle 15 Day 1	Male	21	40,4	20	95,2	10,00	14,71
	Female	36	38,7	34	94,4	17,16	23,74
Cycle 16 Day 1	Male	16	30,8	16	100,0	18,75	23,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	20,97	25,81
Cycle 17 Day 1	Male	13	25,0	13	100,0	20,51	20,59
	Female	32	34,4	31	96,9	18,82	26,44
Cycle 18 Day 1	Male	12	23,1	11	91,7	13,64	22,13
	Female	29	31,2	26	89,7	16,03	21,33
Cycle 19 Day 1	Male	10	19,2	10	100,0	21,67	26,12
	Female	26	28,0	23	88,5	15,94	21,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	22,22	25,00
	Female	26	28,0	23	88,5	19,57	22,84
Cycle 21 Day 1	Male	8	15,4	8	100,0	25,00	21,82
	Female	21	22,6	18	85,7	20,37	25,28
Cycle 22 Day 1	Male	8	15,4	6	75,0	25,00	20,41
	Female	21	22,6	19	90,5	19,30	26,21
Cycle 23 Day 1	Male	5	9,6	4	80,0	12,50	25,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	26,19	29,03
Cycle 24 Day 1	Male	5	9,6	4	80,0	12,50	15,96
	Female	15	16,1	14	93,3	20,24	22,81
Cycle 25 Day 1	Male	3	5,8	2	66,7	8,33	11,79
	Female	12	12,9	11	91,7	21,21	15,08
Cycle 26 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	11	11,8	10	90,9	25,00	29,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	8,33	11,79
	Female	8	8,6	6	75,0	36,11	35,62
Cycle 28 Day 1	Male	2	3,8	2	100,0	8,33	11,79
	Female	8	8,6	7	87,5	35,71	20,25
Cycle 29 Day 1	Male	1	1,9	1	100,0	16,67	-
	Female	8	8,6	6	75,0	25,00	25,28
Cycle 30 Day 1	Male	1	1,9	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	25,00	16,67
Cycle 31 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	20,83	8,33
Cycle 32 Day 1	Male	1	1,9	1	100,0	16,67	-
	Female	5	5,4	4	80,0	20,83	8,33
Cycle 33 Day 1	Male	1	1,9	1	100,0	16,67	-
	Female	1	1,1	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	26,98	27,12
	Female	37	39,8	23	62,2	28,26	23,27
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	31,60	27,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	21,84	28,21
	>=75	7	100,0	7	100,0	14,29	15,00
Cycle 2 Day 1	18-64	103	94,5	94	91,3	18,44	21,37
	65-74	26	89,7	25	96,2	14,67	26,49
	>=75	7	100,0	7	100,0	2,38	6,30
Cycle 3 Day 1	18-64	99	90,8	87	87,9	14,94	19,36
	65-74	25	86,2	24	96,0	9,72	16,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	23,81	37,09
Cycle 4 Day 1	18-64	98	89,9	92	93,9	15,76	22,69
	65-74	23	79,3	21	91,3	13,49	17,97
	>=75	7	100,0	7	100,0	4,76	12,60
Cycle 5 Day 1	18-64	95	87,2	90	94,7	14,63	21,17
	65-74	22	75,9	22	100,0	9,85	12,24
	>=75	7	100,0	6	85,7	8,33	20,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	13,29	16,92
	65-74	22	75,9	21	95,5	14,29	13,21
	>=75	7	100,0	7	100,0	14,29	17,82
Cycle 7 Day 1	18-64	86	78,9	81	94,2	16,87	20,33
	65-74	20	69,0	19	95,0	14,91	19,16
	>=75	7	100,0	6	85,7	11,11	13,61
Cycle 8 Day 1	18-64	80	73,4	72	90,0	13,43	19,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	12,28	16,52
	>=75	7	100,0	6	85,7	8,33	13,94
Cycle 9 Day 1	18-64	74	67,9	73	98,6	14,16	19,38
	65-74	18	62,1	18	100,0	17,59	26,49
	>=75	6	85,7	5	83,3	13,33	29,81
Cycle 10 Day 1	18-64	69	63,3	66	95,7	15,15	17,23
	65-74	15	51,7	15	100,0	10,00	22,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	6,67	9,13
Cycle 11 Day 1	18-64	61	56,0	59	96,7	12,43	15,96
	65-74	15	51,7	15	100,0	11,11	18,54
	>=75	4	57,1	4	100,0	20,83	15,96
Cycle 12 Day 1	18-64	57	52,3	51	89,5	15,36	22,32
	65-74	15	51,7	14	93,3	14,29	20,52
	>=75	4	57,1	4	100,0	12,50	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	17,03	22,63
	65-74	13	44,8	12	92,3	20,83	27,64
	>=75	4	57,1	4	100,0	16,67	23,57
Cycle 14 Day 1	18-64	45	41,3	44	97,8	18,18	24,59
	65-74	13	44,8	11	84,6	15,15	29,30
	>=75	2	28,6	2	100,0	33,33	47,14
Cycle 15 Day 1	18-64	43	39,4	41	95,3	14,63	19,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	12,12	25,92
	>=75	2	28,6	2	100,0	25,00	35,36
Cycle 16 Day 1	18-64	38	34,9	36	94,7	22,22	26,43
	65-74	10	34,5	9	90,0	11,11	14,43
	>=75	2	28,6	2	100,0	25,00	35,36
Cycle 17 Day 1	18-64	36	33,0	35	97,2	19,52	24,75
	65-74	8	27,6	8	100,0	12,50	19,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	66,67	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	15,00	20,69
	65-74	7	24,1	6	85,7	8,33	13,94
	>=75	1	14,3	1	100,0	66,67	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	15,48	21,72
	65-74	5	17,2	4	80,0	20,83	15,96
	>=75	1	14,3	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	19,23	23,42
	65-74	5	17,2	5	100,0	16,67	11,79
	>=75	1	14,3	1	100,0	66,67	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	19,84	24,51
	65-74	4	13,8	4	100,0	20,83	8,33
	>=75	1	14,3	1	100,0	66,67	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	18,33	24,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	25,00	28,87
	>=75	1	14,3	1	100,0	50,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	26,04	28,52
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	19,79	22,13
	65-74	2	6,9	2	100,0	8,33	11,79
Cycle 25 Day 1	18-64	14	12,8	12	85,7	20,83	14,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	20,83	28,54
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	29,17	33,03
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	29,63	21,70
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	23,81	23,29
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	23,33	14,91
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	16,67	11,79
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	20,83	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	16,67	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	16,67	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	30,39	25,45
	65-74	15	51,7	8	53,3	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	25,00	11,79
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	32,76	28,09
	Other	85	100,0	84	98,8	25,99	26,68
Cycle 2 Day 1	White	57	95,0	51	89,5	17,32	21,59
	Other	79	92,9	75	94,9	16,44	22,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	15,91	20,32
	Other	77	90,6	74	96,1	13,51	20,40
Cycle 4 Day 1	White	53	88,3	47	88,7	12,06	17,27
	Other	75	88,2	73	97,3	16,44	23,81
Cycle 5 Day 1	White	52	86,7	48	92,3	13,19	20,62
	Other	72	84,7	70	97,2	13,57	19,31
Cycle 6 Day 1	White	50	83,3	44	88,0	14,77	16,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	12,75	15,80
Cycle 7 Day 1	White	47	78,3	42	89,4	15,08	19,06
	Other	66	77,6	64	97,0	16,93	20,25
Cycle 8 Day 1	White	45	75,0	39	86,7	13,68	17,04
	Other	61	71,8	58	95,1	12,36	19,39
Cycle 9 Day 1	White	42	70,0	41	97,6	15,04	24,38
	Other	56	65,9	55	98,2	14,55	18,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	17,52	20,57
	Other	48	56,5	47	97,9	10,64	14,92
Cycle 11 Day 1	White	37	61,7	37	100,0	13,06	18,06
	Other	43	50,6	41	95,3	12,20	14,92
Cycle 12 Day 1	White	37	61,7	33	89,2	15,15	22,96
	Other	39	45,9	36	92,3	14,81	20,23
Cycle 13 Day 1	White	32	53,3	30	93,8	17,78	26,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	17,71	19,83
Cycle 14 Day 1	White	31	51,7	30	96,8	18,89	27,59
	Other	29	34,1	27	93,1	17,28	24,23
Cycle 15 Day 1	White	30	50,0	28	93,3	17,86	26,03
	Other	27	31,8	26	96,3	10,90	13,29
Cycle 16 Day 1	White	26	43,3	24	92,3	23,61	28,62
	Other	24	28,2	23	95,8	16,67	20,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	22,92	29,82
	Other	21	24,7	20	95,2	15,00	16,13
Cycle 18 Day 1	White	22	36,7	19	86,4	17,54	26,34
	Other	19	22,4	18	94,7	12,96	14,64
Cycle 19 Day 1	White	20	33,3	20	100,0	20,00	26,27
	Other	16	18,8	13	81,3	14,10	14,98
Cycle 20 Day 1	White	20	33,3	17	85,0	19,61	27,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	21,11	17,21
Cycle 21 Day 1	White	16	26,7	14	87,5	26,19	29,75
	Other	13	15,3	12	92,3	16,67	14,21
Cycle 22 Day 1	White	16	26,7	13	81,3	23,08	27,67
	Other	13	15,3	12	92,3	18,06	21,86
Cycle 23 Day 1	White	12	20,0	10	83,3	30,00	32,20
	Other	9	10,6	8	88,9	14,58	20,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	25,00	23,90
	Other	9	10,6	8	88,9	10,42	15,27
Cycle 25 Day 1	White	10	16,7	8	80,0	18,75	16,52
	Other	5	5,9	5	100,0	20,00	13,94
Cycle 26 Day 1	White	10	16,7	8	80,0	18,75	35,00
	Other	4	4,7	4	100,0	25,00	9,62
Cycle 27 Day 1	White	8	13,3	5	62,5	26,67	41,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	33,33	16,67
Cycle 28 Day 1	White	7	11,7	6	85,7	19,44	16,39
	Other	3	3,5	3	100,0	50,00	16,67
Cycle 29 Day 1	White	6	10,0	4	66,7	16,67	13,61
	Other	3	3,5	3	100,0	33,33	33,33
Cycle 30 Day 1	White	4	6,7	2	50,0	8,33	11,79
	Other	3	3,5	3	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	8,33	11,79
	Other	3	3,5	3	100,0	22,22	9,62
Cycle 32 Day 1	White	4	6,7	3	75,0	16,67	0,00
	Other	2	2,4	2	100,0	25,00	11,79
Cycle 33 Day 1	White	2	3,3	2	100,0	8,33	11,79
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	28,43	24,84
	Other	39	45,9	27	69,2	27,16	25,38
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	27,92	25,98
	Europe (EU)	34	100,0	31	91,2	32,80	29,34
	Asia (AS)	71	100,0	71	100,0	27,46	27,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	33	86,8	16,67	21,65
	Europe (EU)	32	94,1	28	87,5	17,26	21,98
	Asia (AS)	66	93,0	65	98,5	16,67	22,82
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	15,15	24,07
	Europe (EU)	31	91,2	22	71,0	18,94	27,36
	Asia (AS)	63	88,7	63	100,0	12,43	14,66
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	9,80	16,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	19,33	24,38
	Asia (AS)	61	85,9	61	100,0	15,57	22,54
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	10,95	21,37
	Europe (EU)	30	88,2	26	86,7	12,82	17,20
	Asia (AS)	57	80,3	57	100,0	15,20	19,99
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	10,95	14,54
	Europe (EU)	28	82,4	25	89,3	15,33	17,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	14,42	16,51
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	13,54	17,68
	Europe (EU)	28	82,4	25	89,3	16,67	24,53
	Asia (AS)	50	70,4	49	98,0	17,69	18,45
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	12,35	18,25
	Europe (EU)	28	82,4	23	82,1	13,77	16,40
	Asia (AS)	47	66,2	47	100,0	12,77	19,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	14,88	22,83
	Europe (EU)	26	76,5	25	96,2	17,33	26,99
	Asia (AS)	43	60,6	43	100,0	13,18	16,08
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	11,11	16,05
	Europe (EU)	25	73,5	25	100,0	16,67	22,57
	Asia (AS)	37	52,1	37	100,0	13,51	15,63
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	6,52	10,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	17,42	20,88
	Asia (AS)	33	46,5	33	100,0	13,64	15,28
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	10,14	22,88
	Europe (EU)	23	67,6	18	78,3	16,67	19,80
	Asia (AS)	29	40,8	28	96,6	17,86	21,24
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	13,64	22,79
	Europe (EU)	18	52,9	15	83,3	20,00	27,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	20,00	21,52
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	15,08	24,67
	Europe (EU)	17	50,0	16	94,1	23,96	34,94
	Asia (AS)	21	29,6	20	95,2	16,67	17,93
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	10,83	23,12
	Europe (EU)	15	44,1	14	93,3	19,05	25,20
	Asia (AS)	20	28,2	20	100,0	15,00	15,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	18,63	32,75
	Europe (EU)	14	41,2	11	78,6	22,73	21,44
	Asia (AS)	19	26,8	19	100,0	20,18	18,90
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	19,79	33,45
	Europe (EU)	13	38,2	12	92,3	19,44	21,12
	Asia (AS)	16	22,5	16	100,0	18,75	17,08
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	9,52	26,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	21,43	23,00
	Asia (AS)	16	22,5	16	100,0	17,71	14,23
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	12,82	23,72
	Europe (EU)	9	26,5	9	100,0	29,63	26,06
	Asia (AS)	14	19,7	11	78,6	13,64	14,56
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	16,67	29,66
	Europe (EU)	9	26,5	6	66,7	25,00	22,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	21,79	15,79
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	21,67	30,48
	Europe (EU)	7	20,6	6	85,7	33,33	23,57
	Asia (AS)	11	15,5	10	90,9	15,00	14,59
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	16,67	30,43
	Europe (EU)	7	20,6	5	71,4	26,67	19,00
	Asia (AS)	11	15,5	10	90,9	21,67	22,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	25,93	35,46
	Europe (EU)	5	14,7	3	60,0	22,22	19,25
	Asia (AS)	7	9,9	6	85,7	19,44	22,15
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	16,67	28,17
	Europe (EU)	5	14,7	4	80,0	20,83	15,96
	Asia (AS)	7	9,9	6	85,7	19,44	16,39
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	19,05	15,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	16,67	23,57
	Asia (AS)	4	5,6	4	100,0	20,83	15,96
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	22,22	38,97
	Europe (EU)	4	11,8	2	50,0	16,67	23,57
	Asia (AS)	4	5,6	4	100,0	20,83	15,96
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	29,17	47,87
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	29,17	15,96
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	20,83	15,96
	Europe (EU)	2	5,9	1	50,0	0,00	-
	Asia (AS)	4	5,6	4	100,0	45,83	15,96
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	11,11	9,62
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	8,33	11,79
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	33,33	0,00
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	8,33	11,79
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	22,22	9,62
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	16,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	16,67	-
	Asia (AS)	3	4,2	2	66,7	25,00	11,79
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	16,67	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	22,55	20,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	40,00	19,00
	Asia (AS)	34	47,9	22	64,7	28,79	28,72
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	18,89	20,69
	1	69	100,0	67	97,1	35,57	29,57
	2	15	100,0	15	100,0	37,78	29,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	56	94,9	16,96	21,20
	1	67	97,1	60	89,6	17,78	23,14
	2	10	66,7	10	100,0	10,00	22,50
Cycle 3 Day 1	0	57	93,4	51	89,5	14,05	24,12
	1	65	94,2	58	89,2	13,79	15,65
	2	9	60,0	9	100,0	20,37	24,69
Cycle 4 Day 1	0	57	93,4	54	94,7	11,11	19,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	16,95	21,51
	2	9	60,0	8	88,9	22,92	30,78
Cycle 5 Day 1	0	56	91,8	53	94,6	11,95	17,41
	1	62	89,9	59	95,2	15,54	22,29
	2	6	40,0	6	100,0	5,56	8,61
Cycle 6 Day 1	0	56	91,8	54	96,4	13,27	16,31
	1	59	85,5	53	89,8	14,78	16,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	3,33	7,45
Cycle 7 Day 1	0	54	88,5	51	94,4	15,69	20,66
	1	54	78,3	50	92,6	18,33	19,12
	2	5	33,3	5	100,0	0,00	0,00
Cycle 8 Day 1	0	52	85,2	48	92,3	15,97	18,82
	1	49	71,0	44	89,8	10,98	18,31
	2	5	33,3	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	13,61	21,16
	1	44	63,8	43	97,7	17,05	21,97
	2	4	26,7	4	100,0	4,17	8,33
Cycle 10 Day 1	0	46	75,4	46	100,0	13,04	18,89
	1	40	58,0	37	92,5	14,86	17,47
	2	3	20,0	3	100,0	11,11	9,62
Cycle 11 Day 1	0	43	70,5	41	95,3	12,20	16,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	14,22	16,48
	2	3	20,0	3	100,0	0,00	0,00
Cycle 12 Day 1	0	42	68,9	36	85,7	16,20	22,71
	1	31	44,9	30	96,8	15,00	20,69
	2	3	20,0	3	100,0	0,00	0,00
Cycle 13 Day 1	0	38	62,3	34	89,5	17,16	24,78
	1	27	39,1	27	100,0	19,14	22,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	17,19	29,17
	1	24	34,8	24	100,0	20,14	21,41
	2	1	6,7	1	100,0	0,00	-
Cycle 15 Day 1	0	33	54,1	30	90,9	15,00	24,51
	1	23	33,3	23	100,0	14,49	16,13
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	23,33	28,05
	1	21	30,4	21	100,0	17,46	20,73
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	18,12	23,52
	1	20	29,0	20	100,0	21,67	26,55
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	15,79	23,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	15,69	19,07
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	19,30	23,74
	1	15	21,7	13	86,7	16,67	21,52
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	21,57	25,53
	1	15	21,7	14	93,3	20,24	20,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	19,05	27,62
	1	13	18,8	11	84,6	27,27	18,67
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	19,44	27,37
	1	13	18,8	12	92,3	23,61	22,98
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	24,07	32,39
	1	9	13,0	8	88,9	25,00	25,20
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	12,96	13,89
	1	9	13,0	8	88,9	27,08	26,63
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	11,11	8,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	26,19	16,27
Cycle 26 Day 1	0	8	13,1	6	75,0	5,56	8,61
	1	6	8,7	6	100,0	36,11	34,02
Cycle 27 Day 1	0	6	9,8	3	50,0	11,11	9,62
	1	5	7,2	5	100,0	40,00	38,37
Cycle 28 Day 1	0	5	8,2	4	80,0	12,50	15,96
	1	5	7,2	5	100,0	43,33	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	25,00	11,79
	1	5	7,2	5	100,0	23,33	27,89
Cycle 30 Day 1	0	3	4,9	1	33,3	16,67	-
	1	4	5,8	4	100,0	25,00	16,67
Cycle 31 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	20,83	8,33
Cycle 32 Day 1	0	3	4,9	2	66,7	16,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	22,22	9,62
Cycle 33 Day 1	0	2	3,3	2	100,0	8,33	11,79
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	21,43	24,23
	1	34	49,3	20	58,8	35,83	24,94
	2	7	46,7	3	42,9	16,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	26,39	24,98
	1	4	100,0	4	100,0	37,50	43,83
	2 or More	79	100,0	78	98,7	30,13	28,43
Cycle 2 Day 1	None	60	96,8	55	91,7	17,58	24,30
	1	3	75,0	2	66,7	8,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	16,43	20,71
Cycle 3 Day 1	None	59	95,2	53	89,8	11,95	18,31
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	69	87,3	63	91,3	16,93	21,89
Cycle 4 Day 1	None	59	95,2	56	94,9	14,88	23,72
	1	3	75,0	2	66,7	16,67	23,57
	2 or More	66	83,5	62	93,9	14,52	19,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	11,01	18,61
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	63	79,7	59	93,7	16,38	20,87
Cycle 6 Day 1	None	57	91,9	52	91,2	11,22	14,28
	1	3	75,0	3	100,0	5,56	9,62
	2 or More	61	77,2	57	93,4	16,08	17,81
Cycle 7 Day 1	None	52	83,9	50	96,2	14,33	19,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	11,11	19,25
	2 or More	58	73,4	53	91,4	18,24	19,68
Cycle 8 Day 1	None	50	80,6	46	92,0	11,23	17,93
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	14,67	18,94
Cycle 9 Day 1	None	48	77,4	47	97,9	12,77	19,72
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	17,01	22,67
Cycle 10 Day 1	None	43	69,4	41	95,3	8,54	12,98
	1	1	25,0	1	100,0	0,00	-
	2 or More	45	57,0	44	97,8	18,94	20,52
Cycle 11 Day 1	None	37	59,7	35	94,6	7,62	12,36
	1	1	25,0	1	100,0	0,00	-
	2 or More	42	53,2	42	100,0	17,06	18,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	7,84	12,47
	1	1	25,0	1	100,0	0,00	-
	2 or More	38	48,1	34	89,5	22,55	25,91
Cycle 13 Day 1	None	34	54,8	30	88,2	12,22	13,08
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	23,66	29,43
Cycle 14 Day 1	None	31	50,0	29	93,5	13,79	21,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	28	35,4	27	96,4	23,46	29,33
Cycle 15 Day 1	None	30	48,4	28	93,3	7,14	11,50
	1	1	25,0	1	100,0	0,00	-
	2 or More	26	32,9	25	96,2	23,33	25,91
Cycle 16 Day 1	None	25	40,3	23	92,0	11,59	19,74
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	29,71	26,57
Cycle 17 Day 1	None	23	37,1	22	95,7	11,36	14,90
	1	1	25,0	1	100,0	0,00	-
	2 or More	21	26,6	21	100,0	28,57	29,88
Cycle 18 Day 1	None	20	32,3	18	90,0	7,41	13,06
	1	1	25,0	1	100,0	0,00	-
	2 or More	20	25,3	18	90,0	24,07	25,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	8,82	11,96
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	28,89	27,07
Cycle 20 Day 1	None	17	27,4	16	94,1	11,46	15,77
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	31,11	25,87
Cycle 21 Day 1	None	15	24,2	13	86,7	12,82	13,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	30,77	28,74
Cycle 22 Day 1	None	15	24,2	13	86,7	7,69	8,65
	2 or More	14	17,7	12	85,7	34,72	28,83
Cycle 23 Day 1	None	10	16,1	9	90,0	16,67	23,57
	2 or More	11	13,9	9	81,8	29,63	32,03
Cycle 24 Day 1	None	10	16,1	10	100,0	15,00	26,59
	2 or More	10	12,7	8	80,0	22,92	12,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	16,67	15,43
	2 or More	6	7,6	5	83,3	23,33	14,91
Cycle 26 Day 1	None	8	12,9	8	100,0	18,75	35,00
	2 or More	6	7,6	4	66,7	25,00	9,62
Cycle 27 Day 1	None	7	11,3	6	85,7	30,56	38,61
	2 or More	4	5,1	2	50,0	25,00	11,79
Cycle 28 Day 1	None	7	11,3	7	100,0	23,81	18,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	50,00	23,57
Cycle 29 Day 1	None	6	9,7	5	83,3	26,67	25,28
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 30 Day 1	None	4	6,5	3	75,0	16,67	16,67
	2 or More	3	3,8	2	66,7	33,33	0,00
Cycle 31 Day 1	None	4	6,5	3	75,0	11,11	9,62
	2 or More	3	3,8	2	66,7	25,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	16,67	0,00
	2 or More	2	2,5	2	100,0	25,00	11,79
Cycle 33 Day 1	None	1	1,6	1	100,0	16,67	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	33,33	22,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	0,00	-
	2 or More	39	49,4	24	61,5	24,31	26,46
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	26,39	24,98
	Previously Treated	83	100,0	82	98,8	30,49	29,02
Cycle 2 Day 1	Naïve	60	96,8	55	91,7	17,58	24,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	16,20	20,50
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	11,95	18,31
	Previously Treated	72	86,7	65	90,3	16,41	21,75
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	14,88	23,72
	Previously Treated	69	83,1	64	92,8	14,58	19,59
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	11,01	18,61
	Previously Treated	66	79,5	62	93,9	15,59	20,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	11,22	14,28
	Previously Treated	64	77,1	60	93,8	15,56	17,59
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	14,33	19,92
	Previously Treated	61	73,5	56	91,8	17,86	19,55
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	11,23	17,93
	Previously Treated	56	67,5	51	91,1	14,38	18,86
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	12,77	19,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	16,67	22,57
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	8,54	12,98
	Previously Treated	46	55,4	45	97,8	18,52	20,48
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	7,62	12,36
	Previously Treated	43	51,8	43	100,0	16,67	18,18
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	7,84	12,47
	Previously Treated	39	47,0	35	89,7	21,90	25,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	12,22	13,08
	Previously Treated	32	38,6	32	100,0	22,92	29,25
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	13,79	21,85
	Previously Treated	29	34,9	28	96,6	22,62	29,12
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	7,14	11,50
	Previously Treated	27	32,5	26	96,3	22,44	25,80
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	11,59	19,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	28,47	26,68
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	11,36	14,90
	Previously Treated	22	26,5	22	100,0	27,27	29,79
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	7,41	13,06
	Previously Treated	21	25,3	19	90,5	22,81	24,98
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	8,82	11,96
	Previously Treated	19	22,9	16	84,2	27,08	27,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	11,46	15,77
	Previously Treated	19	22,9	16	84,2	29,17	26,18
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	12,82	13,87
	Previously Treated	14	16,9	13	92,9	30,77	28,74
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	7,69	8,65
	Previously Treated	14	16,9	12	85,7	34,72	28,83
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	29,63	32,03
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	15,00	26,59
	Previously Treated	10	12,0	8	80,0	22,92	12,40
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	16,67	15,43
	Previously Treated	6	7,2	5	83,3	23,33	14,91
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	18,75	35,00
	Previously Treated	6	7,2	4	66,7	25,00	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	30,56	38,61
	Previously Treated	4	4,8	2	50,0	25,00	11,79
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	23,81	18,90
	Previously Treated	3	3,6	2	66,7	50,00	23,57
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	26,67	25,28
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	16,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	33,33	0,00
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	11,11	9,62
	Previously Treated	3	3,6	2	66,7	25,00	11,79
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	16,67	0,00
	Previously Treated	2	2,4	2	100,0	25,00	11,79
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	16,67	-
	Previously Treated	1	1,2	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	33,33	22,22
	Previously Treated	42	50,6	25	59,5	23,33	26,35
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	28,00	28,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	29,60	26,72
Cycle 2 Day 1	Local	71	94,7	67	94,4	13,93	20,84
	Central	65	92,9	59	90,8	20,06	23,32
Cycle 3 Day 1	Local	67	89,3	62	92,5	14,25	22,35
	Central	64	91,4	56	87,5	14,58	18,00
Cycle 4 Day 1	Local	65	86,7	61	93,8	12,30	19,46
	Central	63	90,0	59	93,7	17,23	23,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	11,58	18,11
	Central	61	87,1	59	96,7	15,25	21,28
Cycle 6 Day 1	Local	63	84,0	61	96,8	12,02	15,25
	Central	58	82,9	51	87,9	15,36	17,27
Cycle 7 Day 1	Local	61	81,3	59	96,7	16,10	21,21
	Central	52	74,3	47	90,4	16,31	17,89
Cycle 8 Day 1	Local	57	76,0	55	96,5	10,30	15,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	16,27	21,62
Cycle 9 Day 1	Local	54	72,0	53	98,1	14,15	21,78
	Central	44	62,9	43	97,7	15,50	20,70
Cycle 10 Day 1	Local	48	64,0	46	95,8	14,49	18,79
	Central	41	58,6	40	97,6	12,92	17,08
Cycle 11 Day 1	Local	40	53,3	38	95,0	10,96	16,11
	Central	40	57,1	40	100,0	14,17	16,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	12,12	16,81
	Central	40	57,1	36	90,0	17,59	24,86
Cycle 13 Day 1	Local	30	40,0	29	96,7	13,79	20,93
	Central	36	51,4	33	91,7	21,21	25,09
Cycle 14 Day 1	Local	27	36,0	27	100,0	16,05	27,53
	Central	33	47,1	30	90,9	20,00	24,53
Cycle 15 Day 1	Local	26	34,7	25	96,2	12,67	18,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	16,09	22,92
Cycle 16 Day 1	Local	24	32,0	24	100,0	16,67	24,57
	Central	26	37,1	23	88,5	23,91	25,04
Cycle 17 Day 1	Local	22	29,3	22	100,0	14,39	23,17
	Central	23	32,9	22	95,7	24,24	25,58
Cycle 18 Day 1	Local	20	26,7	19	95,0	6,14	9,95
	Central	21	30,0	18	85,7	25,00	25,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	10,78	14,36
	Central	17	24,3	16	94,1	25,00	27,22
Cycle 20 Day 1	Local	19	25,3	17	89,5	11,76	16,42
	Central	17	24,3	15	88,2	30,00	26,13
Cycle 21 Day 1	Local	14	18,7	12	85,7	13,89	15,62
	Central	15	21,4	14	93,3	28,57	28,06
Cycle 22 Day 1	Local	14	18,7	12	85,7	13,89	22,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	26,92	25,94
Cycle 23 Day 1	Local	11	14,7	10	90,9	11,67	17,66
	Central	10	14,3	8	80,0	37,50	33,03
Cycle 24 Day 1	Local	11	14,7	10	90,9	8,33	11,79
	Central	9	12,9	8	88,9	31,25	24,30
Cycle 25 Day 1	Local	7	9,3	7	100,0	11,90	8,13
	Central	8	11,4	6	75,0	27,78	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	11,11	13,61
	Central	8	11,4	6	75,0	30,56	37,14
Cycle 27 Day 1	Local	4	5,3	4	100,0	16,67	23,57
	Central	7	10,0	4	57,1	41,67	39,67
Cycle 28 Day 1	Local	4	5,3	4	100,0	25,00	21,52
	Central	6	8,6	5	83,3	33,33	23,57
Cycle 29 Day 1	Local	3	4,0	3	100,0	27,78	34,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	20,83	15,96
Cycle 30 Day 1	Local	3	4,0	3	100,0	16,67	16,67
	Central	4	5,7	2	50,0	33,33	0,00
Cycle 31 Day 1	Local	3	4,0	3	100,0	11,11	9,62
	Central	4	5,7	2	50,0	25,00	11,79
Cycle 32 Day 1	Local	3	4,0	3	100,0	16,67	0,00
	Central	3	4,3	2	66,7	25,00	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	16,67	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	24,31	24,56
	Central	32	45,7	20	62,5	31,67	25,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	28,28	27,00
	No	10	100,0	10	100,0	35,00	32,82
Cycle 2 Day 1	Yes	129	95,6	119	92,2	16,53	21,64
	No	7	70,0	7	100,0	21,43	31,50
Cycle 3 Day 1	Yes	124	91,9	112	90,3	14,73	20,59
	No	7	70,0	6	85,7	8,33	13,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	14,90	21,63
	No	7	70,0	7	100,0	11,90	20,89
Cycle 5 Day 1	Yes	117	86,7	112	95,7	13,10	19,69
	No	7	70,0	6	85,7	19,44	22,15
Cycle 6 Day 1	Yes	114	84,4	105	92,1	13,49	16,36
	No	7	70,0	7	100,0	14,29	15,00
Cycle 7 Day 1	Yes	106	78,5	99	93,4	15,49	18,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	26,19	30,21
Cycle 8 Day 1	Yes	100	74,1	91	91,0	12,82	18,61
	No	6	60,0	6	100,0	13,89	16,39
Cycle 9 Day 1	Yes	92	68,1	90	97,8	15,19	21,59
	No	6	60,0	6	100,0	8,33	13,94
Cycle 10 Day 1	Yes	83	61,5	80	96,4	14,38	18,13
	No	6	60,0	6	100,0	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	12,61	16,74
	No	4	40,0	4	100,0	12,50	8,33
Cycle 12 Day 1	Yes	72	53,3	65	90,3	14,62	21,75
	No	4	40,0	4	100,0	20,83	15,96
Cycle 13 Day 1	Yes	64	47,4	60	93,8	17,78	23,54
	No	2	20,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	58	43,0	55	94,8	18,48	26,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	8,33	11,79
Cycle 15 Day 1	Yes	55	40,7	52	94,5	14,42	21,14
	No	2	20,0	2	100,0	16,67	23,57
Cycle 16 Day 1	Yes	48	35,6	45	93,8	20,00	25,28
	No	2	20,0	2	100,0	25,00	11,79
Cycle 17 Day 1	Yes	43	31,9	42	97,7	19,05	24,58
	No	2	20,0	2	100,0	25,00	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	15,24	21,53
	No	2	20,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	18,23	22,54
	No	2	20,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	20,56	23,44
	No	2	20,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	20,0	24	88,9	22,92	24,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	8,33	11,79
Cycle 22 Day 1	Yes	27	20,0	23	85,2	22,46	24,93
	No	2	20,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	24,51	28,33
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	19,61	21,44
	No	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	20,83	14,43
	No	1	10,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	19,70	29,64
	No	1	10,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	26,19	34,50
	No	1	10,0	1	100,0	50,00	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	27,08	21,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	50,00	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	16,67	14,91
	No	1	10,0	1	100,0	66,67	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	20,83	15,96
	No	1	10,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	16,67	13,61
	No	1	10,0	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	20,83	8,33
	No	1	10,0	1	100,0	16,67	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	8,33	11,79
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	27,91	25,12
	No	2	20,0	1	50,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	34,85	24,10
	No	134	100,0	131	97,8	28,24	27,65
Cycle 2 Day 1	Yes	7	63,6	7	100,0	23,81	18,90
	No	129	96,3	119	92,2	16,39	22,34
Cycle 3 Day 1	Yes	7	63,6	7	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	14,26	20,46
Cycle 4 Day 1	Yes	7	63,6	7	100,0	11,90	18,54
	No	121	90,3	113	93,4	14,90	21,75
Cycle 5 Day 1	Yes	7	63,6	7	100,0	19,05	20,25
	No	117	87,3	111	94,9	13,06	19,77
Cycle 6 Day 1	Yes	7	63,6	7	100,0	16,67	21,52
	No	114	85,1	105	92,1	13,33	15,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	11,90	20,89
	No	106	79,1	99	93,4	16,50	19,71
Cycle 8 Day 1	Yes	7	63,6	7	100,0	23,81	30,21
	No	99	73,9	90	90,9	12,04	17,13
Cycle 9 Day 1	Yes	6	54,5	6	100,0	33,33	27,89
	No	92	68,7	90	97,8	13,52	20,28
Cycle 10 Day 1	Yes	6	54,5	6	100,0	27,78	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	12,71	16,82
Cycle 11 Day 1	Yes	6	54,5	6	100,0	13,89	22,15
	No	74	55,2	72	97,3	12,50	16,01
Cycle 12 Day 1	Yes	6	54,5	6	100,0	11,11	13,61
	No	70	52,2	63	90,0	15,34	22,06
Cycle 13 Day 1	Yes	5	45,5	5	100,0	23,33	14,91
	No	61	45,5	57	93,4	17,25	23,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	26,67	14,91
	No	55	41,0	52	94,5	17,31	26,60
Cycle 15 Day 1	Yes	4	36,4	4	100,0	20,83	15,96
	No	53	39,6	50	94,3	14,00	21,39
Cycle 16 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	47	35,1	44	93,6	20,83	25,19
Cycle 17 Day 1	Yes	3	27,3	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	19,92	25,06
Cycle 18 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	38	28,4	34	89,5	15,69	21,69
Cycle 19 Day 1	Yes	3	27,3	3	100,0	16,67	16,67
	No	33	24,6	30	90,9	17,78	23,13
Cycle 20 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	33	24,6	29	87,9	21,26	23,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	27	20,1	24	88,9	22,22	24,41
Cycle 22 Day 1	Yes	2	18,2	2	100,0	8,33	11,79
	No	27	20,1	23	85,2	21,74	25,34
Cycle 23 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	19	14,2	16	84,2	23,96	29,17
Cycle 24 Day 1	Yes	2	18,2	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	18,75	21,84
Cycle 25 Day 1	Yes	2	18,2	2	100,0	16,67	0,00
	No	13	9,7	11	84,6	19,70	16,36
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	22,73	29,13
Cycle 27 Day 1	Yes	1	9,1	1	100,0	16,67	-
	No	10	7,5	7	70,0	30,95	35,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	9	6,7	8	88,9	29,17	23,15
Cycle 29 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	8	6,0	6	75,0	22,22	25,09
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	23,33	14,91
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	16,67	11,79
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	20,00	7,45
Cycle 33 Day 1	No	2	1,5	2	100,0	8,33	11,79
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	50,00	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	26,02	23,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PA_SG.xls
24JUN2020 20:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	71,51	24,06
Cycle 2 Day 1	All	136	93,8	126	92,6	77,46	20,02
Cycle 3 Day 1	All	131	90,3	118	90,1	78,98	19,72
Cycle 4 Day 1	All	128	88,3	120	93,8	80,06	18,96
Cycle 5 Day 1	All	124	85,5	118	95,2	81,81	17,16
Cycle 6 Day 1	All	121	83,4	112	92,6	82,02	17,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	81,32	17,30
Cycle 8 Day 1	All	106	73,1	97	91,5	83,02	16,97
Cycle 9 Day 1	All	98	67,6	96	98,0	84,10	16,37
Cycle 10 Day 1	All	89	61,4	86	96,6	82,40	15,71
Cycle 11 Day 1	All	80	55,2	78	97,5	81,28	16,89
Cycle 12 Day 1	All	76	52,4	69	90,8	80,97	17,76
Cycle 13 Day 1	All	66	45,5	62	93,9	81,83	18,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	78,83	20,97
Cycle 15 Day 1	All	57	39,3	54	94,7	80,86	17,52
Cycle 16 Day 1	All	50	34,5	47	94,0	79,57	19,48
Cycle 17 Day 1	All	45	31,0	44	97,8	81,67	16,46
Cycle 18 Day 1	All	41	28,3	37	90,2	82,70	17,67
Cycle 19 Day 1	All	36	24,8	33	91,7	81,21	18,52
Cycle 20 Day 1	All	36	24,8	32	88,9	80,00	20,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	80,00	17,99
Cycle 22 Day 1	All	29	20,0	25	86,2	78,93	19,31
Cycle 23 Day 1	All	21	14,5	18	85,7	78,52	20,52
Cycle 24 Day 1	All	20	13,8	18	90,0	78,89	22,43
Cycle 25 Day 1	All	15	10,3	13	86,7	79,49	18,35
Cycle 26 Day 1	All	14	9,7	12	85,7	73,89	29,74
Cycle 27 Day 1	All	11	7,6	8	72,7	77,50	25,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	77,04	25,84
Cycle 29 Day 1	All	9	6,2	7	77,8	83,81	13,25
Cycle 30 Day 1	All	7	4,8	5	71,4	80,00	14,91
Cycle 31 Day 1	All	7	4,8	5	71,4	82,67	17,38
Cycle 32 Day 1	All	6	4,1	5	83,3	82,67	15,35
Cycle 33 Day 1	All	2	1,4	2	100,0	86,67	9,43
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	63,03	26,41
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	72,94	24,92
	Female	93	100,0	91	97,8	70,71	23,66
Cycle 2 Day 1	Male	50	96,2	47	94,0	80,71	19,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	75,53	20,36
Cycle 3 Day 1	Male	47	90,4	42	89,4	82,86	19,15
	Female	84	90,3	76	90,5	76,84	19,82
Cycle 4 Day 1	Male	46	88,5	45	97,8	84,74	15,61
	Female	82	88,2	75	91,5	77,24	20,30
Cycle 5 Day 1	Male	45	86,5	43	95,6	82,48	18,23
	Female	79	84,9	75	94,9	81,42	16,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	84,07	14,75
	Female	76	81,7	71	93,4	80,85	18,31
Cycle 7 Day 1	Male	40	76,9	39	97,5	81,88	17,57
	Female	73	78,5	67	91,8	81,00	17,26
Cycle 8 Day 1	Male	37	71,2	34	91,9	84,12	17,45
	Female	69	74,2	63	91,3	82,43	16,82
Cycle 9 Day 1	Male	33	63,5	33	100,0	87,47	13,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	82,33	17,40
Cycle 10 Day 1	Male	30	57,7	30	100,0	83,78	15,13
	Female	59	63,4	56	94,9	81,67	16,09
Cycle 11 Day 1	Male	29	55,8	29	100,0	83,91	14,86
	Female	51	54,8	49	96,1	79,73	17,95
Cycle 12 Day 1	Male	27	51,9	26	96,3	82,56	16,77
	Female	49	52,7	43	87,8	80,00	18,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	83,77	14,61
	Female	41	44,1	39	95,1	80,68	20,34
Cycle 14 Day 1	Male	23	44,2	21	91,3	79,68	18,91
	Female	37	39,8	36	97,3	78,33	22,33
Cycle 15 Day 1	Male	21	40,4	20	95,2	82,00	14,84
	Female	36	38,7	34	94,4	80,20	19,10
Cycle 16 Day 1	Male	16	30,8	16	100,0	82,92	17,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	77,85	20,54
Cycle 17 Day 1	Male	13	25,0	13	100,0	85,64	14,87
	Female	32	34,4	31	96,9	80,00	17,04
Cycle 18 Day 1	Male	12	23,1	11	91,7	87,88	16,01
	Female	29	31,2	26	89,7	80,51	18,18
Cycle 19 Day 1	Male	10	19,2	10	100,0	83,33	19,94
	Female	26	28,0	23	88,5	80,29	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	83,70	21,89
	Female	26	28,0	23	88,5	78,55	20,20
Cycle 21 Day 1	Male	8	15,4	8	100,0	90,00	12,85
	Female	21	22,6	18	85,7	75,56	18,44
Cycle 22 Day 1	Male	8	15,4	6	75,0	87,78	17,08
	Female	21	22,6	19	90,5	76,14	19,54
Cycle 23 Day 1	Male	5	9,6	4	80,0	98,33	3,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	72,86	19,82
Cycle 24 Day 1	Male	5	9,6	4	80,0	100,00	0,00
	Female	15	16,1	14	93,3	72,86	21,95
Cycle 25 Day 1	Male	3	5,8	2	66,7	100,00	0,00
	Female	12	12,9	11	91,7	75,76	17,45
Cycle 26 Day 1	Male	3	5,8	2	66,7	100,00	0,00
	Female	11	11,8	10	90,9	68,67	29,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	93,33	9,43
	Female	8	8,6	6	75,0	72,22	27,46
Cycle 28 Day 1	Male	2	3,8	2	100,0	90,00	4,71
	Female	8	8,6	7	87,5	73,33	28,54
Cycle 29 Day 1	Male	1	1,9	1	100,0	100,00	-
	Female	8	8,6	6	75,0	81,11	12,23
Cycle 30 Day 1	Male	1	1,9	1	100,0	86,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	78,33	16,67
Cycle 31 Day 1	Male	1	1,9	1	100,0	100,00	-
	Female	6	6,5	4	66,7	78,33	16,67
Cycle 32 Day 1	Male	1	1,9	1	100,0	93,33	-
	Female	5	5,4	4	80,0	80,00	16,33
Cycle 33 Day 1	Male	1	1,9	1	100,0	93,33	-
	Female	1	1,1	1	100,0	80,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	57,78	26,86
	Female	37	39,8	23	62,2	67,83	25,64
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	72,09	23,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	69,43	28,81
	>=75	7	100,0	7	100,0	71,43	15,74
Cycle 2 Day 1	18-64	103	94,5	94	91,3	80,35	16,69
	65-74	26	89,7	25	96,2	66,40	27,99
	>=75	7	100,0	7	100,0	78,10	16,20
Cycle 3 Day 1	18-64	99	90,8	87	87,9	80,46	18,57
	65-74	25	86,2	24	96,0	76,67	22,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	68,57	22,01
Cycle 4 Day 1	18-64	98	89,9	92	93,9	80,94	19,90
	65-74	23	79,3	21	91,3	77,78	16,78
	>=75	7	100,0	7	100,0	75,24	11,36
Cycle 5 Day 1	18-64	95	87,2	90	94,7	83,11	17,26
	65-74	22	75,9	22	100,0	77,58	17,76
	>=75	7	100,0	6	85,7	77,78	11,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	83,33	17,15
	65-74	22	75,9	21	95,5	79,05	15,68
	>=75	7	100,0	7	100,0	75,24	20,26
Cycle 7 Day 1	18-64	86	78,9	81	94,2	81,23	18,38
	65-74	20	69,0	19	95,0	81,40	13,07
	>=75	7	100,0	6	85,7	82,22	16,15
Cycle 8 Day 1	18-64	80	73,4	72	90,0	83,80	18,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	79,65	13,05
	>=75	7	100,0	6	85,7	84,44	13,77
Cycle 9 Day 1	18-64	74	67,9	73	98,6	85,84	15,03
	65-74	18	62,1	18	100,0	78,52	20,01
	>=75	6	85,7	5	83,3	78,67	19,09
Cycle 10 Day 1	18-64	69	63,3	66	95,7	83,43	15,52
	65-74	15	51,7	15	100,0	79,11	14,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	78,67	22,31
Cycle 11 Day 1	18-64	61	56,0	59	96,7	81,92	17,60
	65-74	15	51,7	15	100,0	79,11	12,57
	>=75	4	57,1	4	100,0	80,00	23,73
Cycle 12 Day 1	18-64	57	52,3	51	89,5	82,09	18,21
	65-74	15	51,7	14	93,3	77,14	16,68
	>=75	4	57,1	4	100,0	80,00	18,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	84,49	18,00
	65-74	13	44,8	12	92,3	72,22	18,82
	>=75	4	57,1	4	100,0	80,00	14,40
Cycle 14 Day 1	18-64	45	41,3	44	97,8	81,36	20,71
	65-74	13	44,8	11	84,6	70,30	21,78
	>=75	2	28,6	2	100,0	70,00	14,14
Cycle 15 Day 1	18-64	43	39,4	41	95,3	82,28	17,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	76,97	17,73
	>=75	2	28,6	2	100,0	73,33	9,43
Cycle 16 Day 1	18-64	38	34,9	36	94,7	79,63	21,08
	65-74	10	34,5	9	90,0	80,74	13,52
	>=75	2	28,6	2	100,0	73,33	18,86
Cycle 17 Day 1	18-64	36	33,0	35	97,2	82,67	17,20
	65-74	8	27,6	8	100,0	79,17	13,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	66,67	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	85,33	16,74
	65-74	7	24,1	6	85,7	73,33	19,32
	>=75	1	14,3	1	100,0	60,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	83,10	18,81
	65-74	5	17,2	4	80,0	75,00	11,39
	>=75	1	14,3	1	100,0	53,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	82,05	20,72
	65-74	5	17,2	5	100,0	76,00	15,35
	>=75	1	14,3	1	100,0	46,67	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	81,59	18,96
	65-74	4	13,8	4	100,0	75,00	13,74
	>=75	1	14,3	1	100,0	66,67	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	79,67	20,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	80,00	16,33
	>=75	1	14,3	1	100,0	60,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	77,92	21,46
	65-74	2	6,9	2	100,0	83,33	14,14
Cycle 24 Day 1	18-64	18	16,5	16	88,9	77,08	23,09
	65-74	2	6,9	2	100,0	93,33	9,43
Cycle 25 Day 1	18-64	14	12,8	12	85,7	78,89	19,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	86,67	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	73,89	29,74
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	77,50	25,43
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	77,04	25,84
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	83,81	13,25
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	80,00	14,91
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	82,67	17,38
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	83,33	17,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	80,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	93,33	-
	65-74	1	3,4	1	100,0	80,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	63,14	26,88
	65-74	15	51,7	8	53,3	65,00	23,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	53,33	47,14
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	65,66	26,79
	Other	85	100,0	84	98,8	75,56	21,22
Cycle 2 Day 1	White	57	95,0	51	89,5	76,21	19,74
	Other	79	92,9	75	94,9	78,31	20,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	75,76	21,38
	Other	77	90,6	74	96,1	80,90	18,54
Cycle 4 Day 1	White	53	88,3	47	88,7	79,43	18,17
	Other	75	88,2	73	97,3	80,46	19,57
Cycle 5 Day 1	White	52	86,7	48	92,3	80,42	19,57
	Other	72	84,7	70	97,2	82,76	15,37
Cycle 6 Day 1	White	50	83,3	44	88,0	80,76	19,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	82,84	15,81
Cycle 7 Day 1	White	47	78,3	42	89,4	80,63	17,10
	Other	66	77,6	64	97,0	81,77	17,55
Cycle 8 Day 1	White	45	75,0	39	86,7	82,22	18,18
	Other	61	71,8	58	95,1	83,56	16,24
Cycle 9 Day 1	White	42	70,0	41	97,6	84,55	15,23
	Other	56	65,9	55	98,2	83,76	17,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	81,71	15,65
	Other	48	56,5	47	97,9	82,98	15,90
Cycle 11 Day 1	White	37	61,7	37	100,0	81,62	19,33
	Other	43	50,6	41	95,3	80,98	14,57
Cycle 12 Day 1	White	37	61,7	33	89,2	83,23	18,72
	Other	39	45,9	36	92,3	78,89	16,83
Cycle 13 Day 1	White	32	53,3	30	93,8	81,56	20,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	82,08	16,80
Cycle 14 Day 1	White	31	51,7	30	96,8	80,22	22,45
	Other	29	34,1	27	93,1	77,28	19,50
Cycle 15 Day 1	White	30	50,0	28	93,3	80,95	19,69
	Other	27	31,8	26	96,3	80,77	15,24
Cycle 16 Day 1	White	26	43,3	24	92,3	80,83	18,05
	Other	24	28,2	23	95,8	78,26	21,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	81,39	18,23
	Other	21	24,7	20	95,2	82,00	14,53
Cycle 18 Day 1	White	22	36,7	19	86,4	83,16	18,64
	Other	19	22,4	18	94,7	82,22	17,11
Cycle 19 Day 1	White	20	33,3	20	100,0	78,67	22,12
	Other	16	18,8	13	81,3	85,13	10,59
Cycle 20 Day 1	White	20	33,3	17	85,0	80,39	21,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	79,56	19,43
Cycle 21 Day 1	White	16	26,7	14	87,5	78,10	21,47
	Other	13	15,3	12	92,3	82,22	13,43
Cycle 22 Day 1	White	16	26,7	13	81,3	77,95	22,83
	Other	13	15,3	12	92,3	80,00	15,57
Cycle 23 Day 1	White	12	20,0	10	83,3	72,00	25,10
	Other	9	10,6	8	88,9	86,67	8,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	78,00	23,53
	Other	9	10,6	8	88,9	80,00	22,54
Cycle 25 Day 1	White	10	16,7	8	80,0	83,33	15,53
	Other	5	5,9	5	100,0	73,33	22,61
Cycle 26 Day 1	White	10	16,7	8	80,0	73,33	36,51
	Other	4	4,7	4	100,0	75,00	11,39
Cycle 27 Day 1	White	8	13,3	5	62,5	77,33	33,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	77,78	7,70
Cycle 28 Day 1	White	7	11,7	6	85,7	88,89	10,89
	Other	3	3,5	3	100,0	53,33	33,33
Cycle 29 Day 1	White	6	10,0	4	66,7	90,00	12,77
	Other	3	3,5	3	100,0	75,56	10,18
Cycle 30 Day 1	White	4	6,7	2	50,0	93,33	9,43
	Other	3	3,5	3	100,0	71,11	10,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	100,00	0,00
	Other	3	3,5	3	100,0	71,11	10,18
Cycle 32 Day 1	White	4	6,7	3	75,0	91,11	10,18
	Other	2	2,4	2	100,0	70,00	14,14
Cycle 33 Day 1	White	2	3,3	2	100,0	86,67	9,43
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	61,57	22,55
	Other	39	45,9	27	69,2	63,95	28,96
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	72,71	23,82
	Europe (EU)	34	100,0	31	91,2	67,31	26,35
	Asia (AS)	71	100,0	71	100,0	72,68	23,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	33	86,8	80,81	16,14
	Europe (EU)	32	94,1	28	87,5	75,48	21,16
	Asia (AS)	66	93,0	65	98,5	76,62	21,35
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	79,60	16,91
	Europe (EU)	31	91,2	22	71,0	73,33	26,59
	Asia (AS)	63	88,7	63	100,0	80,63	18,23
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	80,78	16,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	81,33	20,55
	Asia (AS)	61	85,9	61	100,0	79,13	19,79
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	84,57	14,80
	Europe (EU)	30	88,2	26	86,7	80,00	21,58
	Asia (AS)	57	80,3	57	100,0	80,94	16,35
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	83,81	15,78
	Europe (EU)	28	82,4	25	89,3	78,40	21,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	82,56	15,63
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	81,04	18,48
	Europe (EU)	28	82,4	25	89,3	80,00	19,15
	Asia (AS)	50	70,4	49	98,0	82,18	15,78
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	87,16	14,55
	Europe (EU)	28	82,4	23	82,1	78,55	19,17
	Asia (AS)	47	66,2	47	100,0	82,84	16,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	86,67	14,05
	Europe (EU)	26	76,5	25	96,2	83,47	16,68
	Asia (AS)	43	60,6	43	100,0	82,79	17,71
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	86,11	14,83
	Europe (EU)	25	73,5	25	100,0	79,47	15,74
	Asia (AS)	37	52,1	37	100,0	81,98	16,17
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	82,03	22,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	80,30	14,76
	Asia (AS)	33	46,5	33	100,0	81,41	14,31
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	84,93	19,20
	Europe (EU)	23	67,6	18	78,3	80,74	15,99
	Asia (AS)	29	40,8	28	96,6	77,86	17,60
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	86,36	18,11
	Europe (EU)	18	52,9	15	83,3	79,11	19,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	79,47	17,52
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	83,49	20,18
	Europe (EU)	17	50,0	16	94,1	74,58	23,12
	Asia (AS)	21	29,6	20	95,2	77,33	20,10
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	85,00	19,09
	Europe (EU)	15	44,1	14	93,3	76,19	18,25
	Asia (AS)	20	28,2	20	100,0	80,00	15,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	84,71	17,91
	Europe (EU)	14	41,2	11	78,6	76,36	17,98
	Asia (AS)	19	26,8	19	100,0	76,84	21,59
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	82,50	20,92
	Europe (EU)	13	38,2	12	92,3	80,56	11,88
	Asia (AS)	16	22,5	16	100,0	81,67	15,30
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	85,24	20,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	80,00	12,77
	Asia (AS)	16	22,5	16	100,0	81,67	17,13
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	82,56	22,20
	Europe (EU)	9	26,5	9	100,0	74,07	19,28
	Asia (AS)	14	19,7	11	78,6	85,45	11,86
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	82,56	23,65
	Europe (EU)	9	26,5	6	66,7	71,11	17,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	81,54	18,49
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	81,33	24,30
	Europe (EU)	7	20,6	6	85,7	75,56	13,11
	Asia (AS)	11	15,5	10	90,9	81,33	13,98
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	82,67	24,59
	Europe (EU)	7	20,6	5	71,4	74,67	16,60
	Asia (AS)	11	15,5	10	90,9	77,33	15,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	78,52	26,41
	Europe (EU)	5	14,7	3	60,0	64,44	10,18
	Asia (AS)	7	9,9	6	85,7	85,56	9,81
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	82,50	23,35
	Europe (EU)	5	14,7	4	80,0	76,67	22,77
	Asia (AS)	7	9,9	6	85,7	75,56	24,46
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	85,71	15,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	76,67	14,14
	Asia (AS)	4	5,6	4	100,0	70,00	24,65
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	71,11	41,88
	Europe (EU)	4	11,8	2	50,0	86,67	18,86
	Asia (AS)	4	5,6	4	100,0	71,67	8,39
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	76,67	38,30
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	78,33	6,38
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	88,33	11,39
	Europe (EU)	2	5,9	1	50,0	100,00	-
	Asia (AS)	4	5,6	4	100,0	60,00	30,31
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	95,56	7,70
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	75,00	8,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	93,33	9,43
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	71,11	10,18
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	100,00	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	71,11	10,18
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	96,67	4,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	80,00	-
	Asia (AS)	3	4,2	2	66,7	70,00	14,14
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	93,33	-
	Europe (EU)	1	2,9	1	100,0	80,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	62,75	26,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	58,67	31,76
	Asia (AS)	34	47,9	22	64,7	64,24	26,07
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	84,47	15,15
	1	69	100,0	67	97,1	68,16	20,88
	2	15	100,0	15	100,0	34,67	24,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	56	94,9	83,33	16,33
	1	67	97,1	60	89,6	74,22	20,11
	2	10	66,7	10	100,0	64,00	28,32
Cycle 3 Day 1	0	57	93,4	51	89,5	82,75	18,29
	1	65	94,2	58	89,2	78,16	18,22
	2	9	60,0	9	100,0	62,96	29,08
Cycle 4 Day 1	0	57	93,4	54	94,7	85,19	18,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	78,74	14,64
	2	9	60,0	8	88,9	55,00	28,89
Cycle 5 Day 1	0	56	91,8	53	94,6	86,16	14,13
	1	62	89,9	59	95,2	79,66	15,68
	2	6	40,0	6	100,0	64,44	36,68
Cycle 6 Day 1	0	56	91,8	54	96,4	85,43	14,71
	1	59	85,5	53	89,8	80,75	14,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	58,67	40,11
Cycle 7 Day 1	0	54	88,5	51	94,4	86,01	13,94
	1	54	78,3	50	92,6	78,40	16,31
	2	5	33,3	5	100,0	62,67	36,70
Cycle 8 Day 1	0	52	85,2	48	92,3	85,69	14,68
	1	49	71,0	44	89,8	82,42	15,02
	2	5	33,3	5	100,0	62,67	36,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	87,48	15,13
	1	44	63,8	43	97,7	80,93	16,50
	2	4	26,7	4	100,0	76,67	24,65
Cycle 10 Day 1	0	46	75,4	46	100,0	84,78	14,65
	1	40	58,0	37	92,5	80,90	14,75
	2	3	20,0	3	100,0	64,44	32,89
Cycle 11 Day 1	0	43	70,5	41	95,3	82,93	17,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	80,00	15,31
	2	3	20,0	3	100,0	73,33	23,09
Cycle 12 Day 1	0	42	68,9	36	85,7	82,96	17,71
	1	31	44,9	30	96,8	79,78	17,90
	2	3	20,0	3	100,0	68,89	16,78
Cycle 13 Day 1	0	38	62,3	34	89,5	82,55	19,07
	1	27	39,1	27	100,0	81,73	17,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	60,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	80,83	20,93
	1	24	34,8	24	100,0	77,50	20,69
	2	1	6,7	1	100,0	46,67	-
Cycle 15 Day 1	0	33	54,1	30	90,9	82,22	18,72
	1	23	33,3	23	100,0	80,87	14,11
	2	1	6,7	1	100,0	40,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	81,87	17,69
	1	21	30,4	21	100,0	78,73	20,29
	2	1	6,7	1	100,0	40,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	84,06	18,06
	1	20	29,0	20	100,0	79,67	14,59
	2	1	6,7	1	100,0	66,67	-
Cycle 18 Day 1	0	23	37,7	19	82,6	82,46	20,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	84,71	13,07
	2	1	6,7	1	100,0	53,33	-
Cycle 19 Day 1	0	20	32,8	19	95,0	82,11	21,67
	1	15	21,7	13	86,7	81,03	13,84
	2	1	6,7	1	100,0	66,67	-
Cycle 20 Day 1	0	20	32,8	17	85,0	80,00	22,11
	1	15	21,7	14	93,3	83,33	14,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	33,33	-
Cycle 21 Day 1	0	15	24,6	14	93,3	80,48	22,56
	1	13	18,8	11	84,6	81,21	10,25
	2	1	6,7	1	100,0	60,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	79,44	24,53
	1	13	18,8	12	92,3	81,11	10,57
	2	1	6,7	1	100,0	46,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	74,81	25,77
	1	9	13,0	8	88,9	83,33	14,69
	2	1	6,7	1	100,0	73,33	-
Cycle 24 Day 1	0	10	16,4	9	90,0	82,96	21,89
	1	9	13,0	8	88,9	79,17	20,91
	2	1	6,7	1	100,0	40,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	86,67	12,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	73,33	21,08
Cycle 26 Day 1	0	8	13,1	6	75,0	83,33	23,76
	1	6	8,7	6	100,0	64,44	34,17
Cycle 27 Day 1	0	6	9,8	3	50,0	88,89	10,18
	1	5	7,2	5	100,0	70,67	30,40
Cycle 28 Day 1	0	5	8,2	4	80,0	90,00	8,61
	1	5	7,2	5	100,0	66,67	31,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	86,67	18,86
	1	5	7,2	5	100,0	82,67	13,00
Cycle 30 Day 1	0	3	4,9	1	33,3	86,67	-
	1	4	5,8	4	100,0	78,33	16,67
Cycle 31 Day 1	0	3	4,9	1	33,3	100,00	-
	1	4	5,8	4	100,0	78,33	16,67
Cycle 32 Day 1	0	3	4,9	2	66,7	86,67	9,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	80,00	20,00
Cycle 33 Day 1	0	2	3,3	2	100,0	86,67	9,43
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	64,76	26,26
	1	34	49,3	20	58,8	63,33	27,23
	2	7	46,7	3	42,9	48,89	26,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	70,89	26,27
	1	4	100,0	4	100,0	68,33	30,97
	2 or More	79	100,0	78	98,7	72,16	22,20
Cycle 2 Day 1	None	60	96,8	55	91,7	79,76	15,71
	1	3	75,0	2	66,7	93,33	9,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	75,17	22,86
Cycle 3 Day 1	None	59	95,2	53	89,8	83,40	14,36
	1	3	75,0	2	66,7	93,33	9,43
	2 or More	69	87,3	63	91,3	74,81	22,76
Cycle 4 Day 1	None	59	95,2	56	94,9	84,05	16,06
	1	3	75,0	2	66,7	90,00	14,14
	2 or More	66	83,5	62	93,9	76,13	20,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	85,24	15,19
	1	3	75,0	3	100,0	93,33	6,67
	2 or More	63	79,7	59	93,7	77,97	18,46
Cycle 6 Day 1	None	57	91,9	52	91,2	85,13	14,44
	1	3	75,0	3	100,0	91,11	10,18
	2 or More	61	77,2	57	93,4	78,71	19,00
Cycle 7 Day 1	None	52	83,9	50	96,2	84,40	16,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	84,44	10,18
	2 or More	58	73,4	53	91,4	78,24	18,12
Cycle 8 Day 1	None	50	80,6	46	92,0	84,35	16,10
	1	3	75,0	1	33,3	86,67	-
	2 or More	53	67,1	50	94,3	81,73	17,96
Cycle 9 Day 1	None	48	77,4	47	97,9	86,81	13,73
	1	1	25,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	81,11	18,31
Cycle 10 Day 1	None	43	69,4	41	95,3	85,69	13,04
	1	1	25,0	1	100,0	100,00	-
	2 or More	45	57,0	44	97,8	78,94	17,31
Cycle 11 Day 1	None	37	59,7	35	94,6	85,90	14,17
	1	1	25,0	1	100,0	100,00	-
	2 or More	42	53,2	42	100,0	76,98	17,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	85,10	14,78
	1	1	25,0	1	100,0	100,00	-
	2 or More	38	48,1	34	89,5	76,27	19,50
Cycle 13 Day 1	None	34	54,8	30	88,2	86,44	12,92
	1	1	25,0	1	100,0	100,00	-
	2 or More	31	39,2	31	100,0	76,77	21,56
Cycle 14 Day 1	None	31	50,0	29	93,5	83,68	17,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	100,00	-
	2 or More	28	35,4	27	96,4	72,84	23,46
Cycle 15 Day 1	None	30	48,4	28	93,3	86,19	13,45
	1	1	25,0	1	100,0	93,33	-
	2 or More	26	32,9	25	96,2	74,40	19,78
Cycle 16 Day 1	None	25	40,3	23	92,0	85,51	15,52
	1	1	25,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	72,75	21,17
Cycle 17 Day 1	None	23	37,1	22	95,7	88,79	12,06
	1	1	25,0	1	100,0	100,00	-
	2 or More	21	26,6	21	100,0	73,33	16,87
Cycle 18 Day 1	None	20	32,3	18	90,0	90,74	11,69
	1	1	25,0	1	100,0	100,00	-
	2 or More	20	25,3	18	90,0	73,70	18,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	89,80	10,83
	1	1	25,0	1	100,0	100,00	-
	2 or More	18	22,8	15	83,3	70,22	20,14
Cycle 20 Day 1	None	17	27,4	16	94,1	91,25	8,33
	1	1	25,0	1	100,0	93,33	-
	2 or More	18	22,8	15	83,3	67,11	22,74
Cycle 21 Day 1	None	15	24,2	13	86,7	90,26	9,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	69,74	18,98
Cycle 22 Day 1	None	15	24,2	13	86,7	89,74	10,75
	2 or More	14	17,7	12	85,7	67,22	19,99
Cycle 23 Day 1	None	10	16,1	9	90,0	88,15	13,24
	2 or More	11	13,9	9	81,8	68,89	22,61
Cycle 24 Day 1	None	10	16,1	10	100,0	89,33	17,27
	2 or More	10	12,7	8	80,0	65,83	22,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	87,50	12,05
	2 or More	6	7,6	5	83,3	66,67	20,55
Cycle 26 Day 1	None	8	12,9	8	100,0	77,50	34,72
	2 or More	6	7,6	4	66,7	66,67	18,05
Cycle 27 Day 1	None	7	11,3	6	85,7	76,67	29,74
	2 or More	4	5,1	2	50,0	80,00	9,43
Cycle 28 Day 1	None	7	11,3	7	100,0	83,81	16,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	53,33	47,14
Cycle 29 Day 1	None	6	9,7	5	83,3	85,33	15,20
	2 or More	3	3,8	2	66,7	80,00	9,43
Cycle 30 Day 1	None	4	6,5	3	75,0	82,22	20,37
	2 or More	3	3,8	2	66,7	76,67	4,71
Cycle 31 Day 1	None	4	6,5	3	75,0	91,11	15,40
	2 or More	3	3,8	2	66,7	70,00	14,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	84,44	21,43
	2 or More	2	2,5	2	100,0	80,00	0,00
Cycle 33 Day 1	None	1	1,6	1	100,0	93,33	-
	2 or More	1	1,3	1	100,0	80,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	65,61	24,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	66,67	-
	2 or More	39	49,4	24	61,5	60,83	28,78
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	70,89	26,27
	Previously Treated	83	100,0	82	98,8	71,97	22,46
Cycle 2 Day 1	Naïve	60	96,8	55	91,7	79,76	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	75,68	22,76
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	83,40	14,36
	Previously Treated	72	86,7	65	90,3	75,38	22,67
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	84,05	16,06
	Previously Treated	69	83,1	64	92,8	76,56	20,68
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	85,24	15,19
	Previously Treated	66	79,5	62	93,9	78,71	18,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	85,13	14,44
	Previously Treated	64	77,1	60	93,8	79,33	18,80
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	84,40	16,36
	Previously Treated	61	73,5	56	91,8	78,57	17,78
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	84,35	16,10
	Previously Treated	56	67,5	51	91,1	81,83	17,79
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	86,81	13,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	81,50	18,32
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	85,69	13,04
	Previously Treated	46	55,4	45	97,8	79,41	17,40
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	85,90	14,17
	Previously Treated	43	51,8	43	100,0	77,52	18,11
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	85,10	14,78
	Previously Treated	39	47,0	35	89,7	76,95	19,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	86,44	12,92
	Previously Treated	32	38,6	32	100,0	77,50	21,60
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	83,68	17,14
	Previously Treated	29	34,9	28	96,6	73,81	23,58
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	86,19	13,45
	Previously Treated	27	32,5	26	96,3	75,13	19,74
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	85,51	15,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	73,89	21,44
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	88,79	12,06
	Previously Treated	22	26,5	22	100,0	74,55	17,41
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	90,74	11,69
	Previously Treated	21	25,3	19	90,5	75,09	19,22
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	89,80	10,83
	Previously Treated	19	22,9	16	84,2	72,08	20,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	91,25	8,33
	Previously Treated	19	22,9	16	84,2	68,75	22,93
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	90,26	9,28
	Previously Treated	14	16,9	13	92,9	69,74	18,98
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	89,74	10,75
	Previously Treated	14	16,9	12	85,7	67,22	19,99
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	88,15	13,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	68,89	22,61
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	89,33	17,27
	Previously Treated	10	12,0	8	80,0	65,83	22,09
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	87,50	12,05
	Previously Treated	6	7,2	5	83,3	66,67	20,55
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	77,50	34,72
	Previously Treated	6	7,2	4	66,7	66,67	18,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	76,67	29,74
	Previously Treated	4	4,8	2	50,0	80,00	9,43
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	83,81	16,71
	Previously Treated	3	3,6	2	66,7	53,33	47,14
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	85,33	15,20
	Previously Treated	3	3,6	2	66,7	80,00	9,43
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	82,22	20,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	76,67	4,71
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	91,11	15,40
	Previously Treated	3	3,6	2	66,7	70,00	14,14
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	84,44	21,43
	Previously Treated	2	2,4	2	100,0	80,00	0,00
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	93,33	-
	Previously Treated	1	1,2	1	100,0	80,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	65,61	24,37
	Previously Treated	42	50,6	25	59,5	61,07	28,20
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	70,49	24,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	72,66	23,70
Cycle 2 Day 1	Local	71	94,7	67	94,4	78,11	18,23
	Central	65	92,9	59	90,8	76,72	22,02
Cycle 3 Day 1	Local	67	89,3	62	92,5	78,92	18,94
	Central	64	91,4	56	87,5	79,05	20,71
Cycle 4 Day 1	Local	65	86,7	61	93,8	80,00	19,05
	Central	63	90,0	59	93,7	80,11	19,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	81,92	16,61
	Central	61	87,1	59	96,7	81,69	17,84
Cycle 6 Day 1	Local	63	84,0	61	96,8	82,40	17,17
	Central	58	82,9	51	87,9	81,57	17,16
Cycle 7 Day 1	Local	61	81,3	59	96,7	81,81	18,69
	Central	52	74,3	47	90,4	80,71	15,56
Cycle 8 Day 1	Local	57	76,0	55	96,5	85,21	15,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	80,16	18,77
Cycle 9 Day 1	Local	54	72,0	53	98,1	83,77	18,23
	Central	44	62,9	43	97,7	84,50	13,93
Cycle 10 Day 1	Local	48	64,0	46	95,8	81,30	17,53
	Central	41	58,6	40	97,6	83,67	13,41
Cycle 11 Day 1	Local	40	53,3	38	95,0	79,65	19,54
	Central	40	57,1	40	100,0	82,83	13,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	83,03	15,37
	Central	40	57,1	36	90,0	79,07	19,72
Cycle 13 Day 1	Local	30	40,0	29	96,7	84,37	18,37
	Central	36	51,4	33	91,7	79,60	18,33
Cycle 14 Day 1	Local	27	36,0	27	100,0	82,47	20,60
	Central	33	47,1	30	90,9	75,56	21,11
Cycle 15 Day 1	Local	26	34,7	25	96,2	84,00	18,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	78,16	16,61
Cycle 16 Day 1	Local	24	32,0	24	100,0	84,17	15,95
	Central	26	37,1	23	88,5	74,78	21,92
Cycle 17 Day 1	Local	22	29,3	22	100,0	85,45	14,20
	Central	23	32,9	22	95,7	77,88	17,98
Cycle 18 Day 1	Local	20	26,7	19	95,0	87,02	15,47
	Central	21	30,0	18	85,7	78,15	19,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	84,31	13,93
	Central	17	24,3	16	94,1	77,92	22,41
Cycle 20 Day 1	Local	19	25,3	17	89,5	83,53	19,60
	Central	17	24,3	15	88,2	76,00	21,35
Cycle 21 Day 1	Local	14	18,7	12	85,7	85,56	14,17
	Central	15	21,4	14	93,3	75,24	19,99
Cycle 22 Day 1	Local	14	18,7	12	85,7	84,44	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	73,85	20,99
Cycle 23 Day 1	Local	11	14,7	10	90,9	89,33	12,25
	Central	10	14,3	8	80,0	65,00	21,31
Cycle 24 Day 1	Local	11	14,7	10	90,9	85,33	23,26
	Central	9	12,9	8	88,9	70,83	19,82
Cycle 25 Day 1	Local	7	9,3	7	100,0	88,57	12,60
	Central	8	11,4	6	75,0	68,89	19,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	81,11	25,44
	Central	8	11,4	6	75,0	66,67	34,25
Cycle 27 Day 1	Local	4	5,3	4	100,0	90,00	12,77
	Central	7	10,0	4	57,1	65,00	30,49
Cycle 28 Day 1	Local	4	5,3	4	100,0	83,33	20,73
	Central	6	8,6	5	83,3	72,00	30,70
Cycle 29 Day 1	Local	3	4,0	3	100,0	88,89	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	80,00	7,70
Cycle 30 Day 1	Local	3	4,0	3	100,0	82,22	20,37
	Central	4	5,7	2	50,0	76,67	4,71
Cycle 31 Day 1	Local	3	4,0	3	100,0	91,11	15,40
	Central	4	5,7	2	50,0	70,00	14,14
Cycle 32 Day 1	Local	3	4,0	3	100,0	84,44	21,43
	Central	3	4,3	2	66,7	80,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	93,33	-
	Central	1	1,4	1	100,0	80,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	64,44	24,76
	Central	32	45,7	20	62,5	61,33	28,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	73,14	22,80
	No	10	100,0	10	100,0	50,00	30,83
Cycle 2 Day 1	Yes	129	95,6	119	92,2	78,26	18,87
	No	7	70,0	7	100,0	63,81	33,52
Cycle 3 Day 1	Yes	124	91,9	112	90,3	79,64	19,48
	No	7	70,0	6	85,7	66,67	21,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	81,00	18,54
	No	7	70,0	7	100,0	64,76	20,63
Cycle 5 Day 1	Yes	117	86,7	112	95,7	83,04	16,38
	No	7	70,0	6	85,7	58,89	16,56
Cycle 6 Day 1	Yes	114	84,4	105	92,1	83,11	16,54
	No	7	70,0	7	100,0	65,71	18,23
Cycle 7 Day 1	Yes	106	78,5	99	93,4	82,63	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	62,86	25,49
Cycle 8 Day 1	Yes	100	74,1	91	91,0	83,52	16,96
	No	6	60,0	6	100,0	75,56	16,69
Cycle 9 Day 1	Yes	92	68,1	90	97,8	84,22	16,83
	No	6	60,0	6	100,0	82,22	6,89
Cycle 10 Day 1	Yes	83	61,5	80	96,4	82,25	16,05
	No	6	60,0	6	100,0	84,44	10,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	81,44	17,18
	No	4	40,0	4	100,0	78,33	11,39
Cycle 12 Day 1	Yes	72	53,3	65	90,3	81,23	18,02
	No	4	40,0	4	100,0	76,67	13,88
Cycle 13 Day 1	Yes	64	47,4	60	93,8	82,22	18,52
	No	2	20,0	2	100,0	70,00	4,71
Cycle 14 Day 1	Yes	58	43,0	55	94,8	79,27	21,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	66,67	9,43
Cycle 15 Day 1	Yes	55	40,7	52	94,5	81,41	17,58
	No	2	20,0	2	100,0	66,67	9,43
Cycle 16 Day 1	Yes	48	35,6	45	93,8	80,00	19,80
	No	2	20,0	2	100,0	70,00	4,71
Cycle 17 Day 1	Yes	43	31,9	42	97,7	82,38	16,25
	No	2	20,0	2	100,0	66,67	18,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	83,24	16,83
	No	2	20,0	2	100,0	73,33	37,71
Cycle 19 Day 1	Yes	34	25,2	32	94,1	81,25	18,81
	No	2	20,0	1	50,0	80,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	80,67	20,81
	No	2	20,0	2	100,0	70,00	14,14
Cycle 21 Day 1	Yes	27	20,0	24	88,9	80,56	18,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	73,33	18,86
Cycle 22 Day 1	Yes	27	20,0	23	85,2	80,00	19,69
	No	2	20,0	2	100,0	66,67	9,43
Cycle 23 Day 1	Yes	20	14,8	17	85,0	77,65	20,81
	No	1	10,0	1	100,0	93,33	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	77,65	22,48
	No	1	10,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	78,89	19,03
	No	1	10,0	1	100,0	86,67	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	75,15	30,85
	No	1	10,0	1	100,0	60,00	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	78,10	27,41
	No	1	10,0	1	100,0	73,33	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	80,00	25,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	53,33	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	86,67	11,93
	No	1	10,0	1	100,0	66,67	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	85,00	11,39
	No	1	10,0	1	100,0	60,00	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	85,00	19,15
	No	1	10,0	1	100,0	73,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	88,33	10,00
	No	1	10,0	1	100,0	60,00	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	86,67	9,43
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	63,72	26,32
	No	2	20,0	1	50,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	51,52	26,35
	No	134	100,0	131	97,8	73,19	23,19
Cycle 2 Day 1	Yes	7	63,6	7	100,0	80,00	20,37
	No	129	96,3	119	92,2	77,31	20,08
Cycle 3 Day 1	Yes	7	63,6	7	100,0	82,86	14,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	78,74	20,03
Cycle 4 Day 1	Yes	7	63,6	7	100,0	90,48	12,08
	No	121	90,3	113	93,4	79,41	19,16
Cycle 5 Day 1	Yes	7	63,6	7	100,0	80,95	19,02
	No	117	87,3	111	94,9	81,86	17,13
Cycle 6 Day 1	Yes	7	63,6	7	100,0	82,86	14,33
	No	114	85,1	105	92,1	81,97	17,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	81,90	14,76
	No	106	79,1	99	93,4	81,28	17,53
Cycle 8 Day 1	Yes	7	63,6	7	100,0	76,19	23,99
	No	99	73,9	90	90,9	83,56	16,37
Cycle 9 Day 1	Yes	6	54,5	6	100,0	83,33	15,63
	No	92	68,7	90	97,8	84,15	16,50
Cycle 10 Day 1	Yes	6	54,5	6	100,0	80,00	18,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	82,58	15,57
Cycle 11 Day 1	Yes	6	54,5	6	100,0	75,56	19,63
	No	74	55,2	72	97,3	81,76	16,71
Cycle 12 Day 1	Yes	6	54,5	6	100,0	82,22	16,69
	No	70	52,2	63	90,0	80,85	17,98
Cycle 13 Day 1	Yes	5	45,5	5	100,0	82,67	19,78
	No	61	45,5	57	93,4	81,75	18,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	81,33	20,22
	No	55	41,0	52	94,5	78,59	21,22
Cycle 15 Day 1	Yes	4	36,4	4	100,0	76,67	19,25
	No	53	39,6	50	94,3	81,20	17,55
Cycle 16 Day 1	Yes	3	27,3	3	100,0	77,78	23,41
	No	47	35,1	44	93,6	79,70	19,50
Cycle 17 Day 1	Yes	3	27,3	3	100,0	88,89	10,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	81,14	16,79
Cycle 18 Day 1	Yes	3	27,3	3	100,0	86,67	13,33
	No	38	28,4	34	89,5	82,35	18,12
Cycle 19 Day 1	Yes	3	27,3	3	100,0	88,89	10,18
	No	33	24,6	30	90,9	80,44	19,09
Cycle 20 Day 1	Yes	3	27,3	3	100,0	86,67	11,55
	No	33	24,6	29	87,9	79,31	21,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	76,67	4,71
	No	27	20,1	24	88,9	80,28	18,70
Cycle 22 Day 1	Yes	2	18,2	2	100,0	80,00	0,00
	No	27	20,1	23	85,2	78,84	20,17
Cycle 23 Day 1	Yes	2	18,2	2	100,0	80,00	0,00
	No	19	14,2	16	84,2	78,33	21,84
Cycle 24 Day 1	Yes	2	18,2	2	100,0	80,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	78,75	23,88
Cycle 25 Day 1	Yes	2	18,2	2	100,0	80,00	0,00
	No	13	9,7	11	84,6	79,39	20,10
Cycle 26 Day 1	Yes	1	9,1	1	100,0	73,33	-
	No	13	9,7	11	84,6	73,94	31,19
Cycle 27 Day 1	Yes	1	9,1	1	100,0	80,00	-
	No	10	7,5	7	70,0	77,14	27,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	80,00	-
	No	9	6,7	8	88,9	76,67	27,60
Cycle 29 Day 1	Yes	1	9,1	1	100,0	73,33	-
	No	8	6,0	6	75,0	85,56	13,61
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	80,00	14,91
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	82,67	17,38
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	82,67	15,35
Cycle 33 Day 1	No	2	1,5	2	100,0	86,67	9,43
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	42,22	40,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	64,55	25,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30PF_SG.xls
24JUN2020 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	56,04	24,97
Cycle 2 Day 1	All	136	93,8	125	91,9	62,73	20,43
Cycle 3 Day 1	All	131	90,3	118	90,1	62,78	20,20
Cycle 4 Day 1	All	128	88,3	120	93,8	67,43	20,15
Cycle 5 Day 1	All	124	85,5	118	95,2	68,15	19,14
Cycle 6 Day 1	All	121	83,4	112	92,6	69,20	18,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	69,26	17,94
Cycle 8 Day 1	All	106	73,1	97	91,5	70,45	17,39
Cycle 9 Day 1	All	98	67,6	96	98,0	70,66	16,80
Cycle 10 Day 1	All	89	61,4	86	96,6	67,93	19,15
Cycle 11 Day 1	All	80	55,2	78	97,5	70,83	17,45
Cycle 12 Day 1	All	76	52,4	69	90,8	68,72	19,25
Cycle 13 Day 1	All	66	45,5	62	93,9	70,16	20,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	70,76	20,36
Cycle 15 Day 1	All	57	39,3	54	94,7	72,22	16,19
Cycle 16 Day 1	All	50	34,5	47	94,0	70,74	15,63
Cycle 17 Day 1	All	45	31,0	44	97,8	70,83	18,02
Cycle 18 Day 1	All	41	28,3	37	90,2	69,59	14,46
Cycle 19 Day 1	All	36	24,8	33	91,7	69,70	16,90
Cycle 20 Day 1	All	36	24,8	32	88,9	71,61	15,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	64,10	20,11
Cycle 22 Day 1	All	29	20,0	25	86,2	68,67	21,69
Cycle 23 Day 1	All	21	14,5	18	85,7	66,67	21,77
Cycle 24 Day 1	All	20	13,8	18	90,0	67,59	18,05
Cycle 25 Day 1	All	15	10,3	13	86,7	66,67	17,35
Cycle 26 Day 1	All	14	9,7	12	85,7	65,97	25,49
Cycle 27 Day 1	All	11	7,6	8	72,7	57,29	24,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	56,48	29,10
Cycle 29 Day 1	All	9	6,2	7	77,8	61,90	18,54
Cycle 30 Day 1	All	7	4,8	5	71,4	61,67	13,94
Cycle 31 Day 1	All	7	4,8	5	71,4	66,67	15,59
Cycle 32 Day 1	All	6	4,1	5	83,3	61,67	20,07
Cycle 33 Day 1	All	2	1,4	2	100,0	79,17	5,89
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	49,62	21,41
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	59,15	25,89
	Female	93	100,0	91	97,8	54,30	24,42
Cycle 2 Day 1	Male	50	96,2	46	92,0	60,51	21,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	64,03	19,91
Cycle 3 Day 1	Male	47	90,4	42	89,4	64,88	21,97
	Female	84	90,3	76	90,5	61,62	19,20
Cycle 4 Day 1	Male	46	88,5	45	97,8	65,56	25,29
	Female	82	88,2	75	91,5	68,56	16,42
Cycle 5 Day 1	Male	45	86,5	43	95,6	65,50	22,68
	Female	79	84,9	75	94,9	69,67	16,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	69,72	19,96
	Female	76	81,7	71	93,4	68,90	17,65
Cycle 7 Day 1	Male	40	76,9	39	97,5	69,23	21,47
	Female	73	78,5	67	91,8	69,28	15,71
Cycle 8 Day 1	Male	37	71,2	34	91,9	72,79	17,32
	Female	69	74,2	63	91,3	69,18	17,43
Cycle 9 Day 1	Male	33	63,5	33	100,0	75,51	14,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	68,12	17,62
Cycle 10 Day 1	Male	30	57,7	30	100,0	70,56	18,54
	Female	59	63,4	56	94,9	66,52	19,49
Cycle 11 Day 1	Male	29	55,8	29	100,0	71,84	17,31
	Female	51	54,8	49	96,1	70,24	17,68
Cycle 12 Day 1	Male	27	51,9	26	96,3	75,32	11,66
	Female	49	52,7	43	87,8	64,73	21,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	71,01	17,92
	Female	41	44,1	39	95,1	69,66	22,74
Cycle 14 Day 1	Male	23	44,2	21	91,3	72,22	17,15
	Female	37	39,8	36	97,3	69,91	22,21
Cycle 15 Day 1	Male	21	40,4	20	95,2	72,08	14,38
	Female	36	38,7	34	94,4	72,30	17,37
Cycle 16 Day 1	Male	16	30,8	16	100,0	71,88	10,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	70,16	17,71
Cycle 17 Day 1	Male	13	25,0	13	100,0	71,15	14,28
	Female	32	34,4	31	96,9	70,70	19,59
Cycle 18 Day 1	Male	12	23,1	11	91,7	69,70	17,19
	Female	29	31,2	26	89,7	69,55	13,53
Cycle 19 Day 1	Male	10	19,2	10	100,0	71,67	15,81
	Female	26	28,0	23	88,5	68,84	17,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	75,93	11,37
	Female	26	28,0	23	88,5	69,93	17,18
Cycle 21 Day 1	Male	8	15,4	8	100,0	75,00	15,43
	Female	21	22,6	18	85,7	59,26	20,39
Cycle 22 Day 1	Male	8	15,4	6	75,0	73,61	18,57
	Female	21	22,6	19	90,5	67,11	22,82
Cycle 23 Day 1	Male	5	9,6	4	80,0	79,17	17,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	63,10	22,10
Cycle 24 Day 1	Male	5	9,6	4	80,0	77,08	12,50
	Female	15	16,1	14	93,3	64,88	18,83
Cycle 25 Day 1	Male	3	5,8	2	66,7	70,83	17,68
	Female	12	12,9	11	91,7	65,91	18,05
Cycle 26 Day 1	Male	3	5,8	2	66,7	79,17	5,89
	Female	11	11,8	10	90,9	63,33	27,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	75,00	11,79
	Female	8	8,6	6	75,0	51,39	26,04
Cycle 28 Day 1	Male	2	3,8	2	100,0	70,83	17,68
	Female	8	8,6	7	87,5	52,38	31,44
Cycle 29 Day 1	Male	1	1,9	1	100,0	66,67	-
	Female	8	8,6	6	75,0	61,11	20,18
Cycle 30 Day 1	Male	1	1,9	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	60,42	15,77
Cycle 31 Day 1	Male	1	1,9	1	100,0	66,67	-
	Female	6	6,5	4	66,7	66,67	18,00
Cycle 32 Day 1	Male	1	1,9	1	100,0	50,00	-
	Female	5	5,4	4	80,0	64,58	21,92
Cycle 33 Day 1	Male	1	1,9	1	100,0	75,00	-
	Female	1	1,1	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	45,24	23,06
	Female	37	39,8	23	62,2	53,62	19,43
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	56,37	23,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	53,16	30,33
	>=75	7	100,0	7	100,0	63,10	17,91
Cycle 2 Day 1	18-64	103	94,5	93	90,3	63,35	20,08
	65-74	26	89,7	25	96,2	60,00	22,31
	>=75	7	100,0	7	100,0	64,29	20,25
Cycle 3 Day 1	18-64	99	90,8	87	87,9	64,08	18,56
	65-74	25	86,2	24	96,0	61,11	25,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	52,38	19,07
Cycle 4 Day 1	18-64	98	89,9	92	93,9	67,48	20,53
	65-74	23	79,3	21	91,3	67,46	18,80
	>=75	7	100,0	7	100,0	66,67	22,05
Cycle 5 Day 1	18-64	95	87,2	90	94,7	68,61	19,03
	65-74	22	75,9	22	100,0	68,18	19,69
	>=75	7	100,0	6	85,7	61,11	20,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	70,63	18,13
	65-74	22	75,9	21	95,5	67,46	18,99
	>=75	7	100,0	7	100,0	57,14	18,28
Cycle 7 Day 1	18-64	86	78,9	81	94,2	69,65	17,79
	65-74	20	69,0	19	95,0	68,42	17,91
	>=75	7	100,0	6	85,7	66,67	22,97
Cycle 8 Day 1	18-64	80	73,4	72	90,0	72,11	17,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	66,23	15,58
	>=75	7	100,0	6	85,7	63,89	18,76
Cycle 9 Day 1	18-64	74	67,9	73	98,6	72,26	16,84
	65-74	18	62,1	18	100,0	64,35	16,62
	>=75	6	85,7	5	83,3	70,00	13,94
Cycle 10 Day 1	18-64	69	63,3	66	95,7	68,81	19,08
	65-74	15	51,7	15	100,0	63,89	19,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	68,33	20,75
Cycle 11 Day 1	18-64	61	56,0	59	96,7	71,47	18,19
	65-74	15	51,7	15	100,0	68,33	15,49
	>=75	4	57,1	4	100,0	70,83	15,96
Cycle 12 Day 1	18-64	57	52,3	51	89,5	69,77	19,51
	65-74	15	51,7	14	93,3	67,86	14,19
	>=75	4	57,1	4	100,0	58,33	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	71,92	21,33
	65-74	13	44,8	12	92,3	65,28	20,97
	>=75	4	57,1	4	100,0	64,58	17,18
Cycle 14 Day 1	18-64	45	41,3	44	97,8	72,54	19,65
	65-74	13	44,8	11	84,6	63,64	23,65
	>=75	2	28,6	2	100,0	70,83	17,68
Cycle 15 Day 1	18-64	43	39,4	41	95,3	73,37	17,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	68,18	11,68
	>=75	2	28,6	2	100,0	70,83	17,68
Cycle 16 Day 1	18-64	38	34,9	36	94,7	69,68	16,92
	65-74	10	34,5	9	90,0	75,00	9,32
	>=75	2	28,6	2	100,0	70,83	17,68
Cycle 17 Day 1	18-64	36	33,0	35	97,2	70,71	18,89
	65-74	8	27,6	8	100,0	73,96	13,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	50,00	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	71,94	13,58
	65-74	7	24,1	6	85,7	59,72	16,17
	>=75	1	14,3	1	100,0	58,33	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	69,64	16,39
	65-74	5	17,2	4	80,0	75,00	21,52
	>=75	1	14,3	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	72,44	16,46
	65-74	5	17,2	5	100,0	68,33	14,91
	>=75	1	14,3	1	100,0	66,67	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	67,46	18,80
	65-74	4	13,8	4	100,0	50,00	24,53
	>=75	1	14,3	1	100,0	50,00	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	70,42	21,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	64,58	23,94
	>=75	1	14,3	1	100,0	50,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	64,58	21,41
	65-74	2	6,9	2	100,0	83,33	23,57
Cycle 24 Day 1	18-64	18	16,5	16	88,9	65,10	17,54
	65-74	2	6,9	2	100,0	87,50	5,89
Cycle 25 Day 1	18-64	14	12,8	12	85,7	65,28	17,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	83,33	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	65,97	25,49
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	57,29	24,98
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	56,48	29,10
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	61,90	18,54
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	61,67	13,94
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	66,67	15,59
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	56,25	18,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	83,33	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	75,00	-
	65-74	1	3,4	1	100,0	83,33	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	48,53	21,76
	65-74	15	51,7	8	53,3	55,21	20,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	45,83	29,46
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	53,30	24,43
	Other	85	100,0	84	98,8	57,94	25,31
Cycle 2 Day 1	White	57	95,0	50	87,7	59,17	20,29
	Other	79	92,9	75	94,9	65,11	20,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	60,42	22,09
	Other	77	90,6	74	96,1	64,19	19,00
Cycle 4 Day 1	White	53	88,3	47	88,7	67,20	17,41
	Other	75	88,2	73	97,3	67,58	21,85
Cycle 5 Day 1	White	52	86,7	48	92,3	66,67	19,14
	Other	72	84,7	70	97,2	69,17	19,21
Cycle 6 Day 1	White	50	83,3	44	88,0	68,37	20,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	69,73	17,09
Cycle 7 Day 1	White	47	78,3	42	89,4	68,65	17,15
	Other	66	77,6	64	97,0	69,66	18,57
Cycle 8 Day 1	White	45	75,0	39	86,7	69,02	17,41
	Other	61	71,8	58	95,1	71,41	17,46
Cycle 9 Day 1	White	42	70,0	41	97,6	71,54	17,38
	Other	56	65,9	55	98,2	70,00	16,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	69,02	19,86
	Other	48	56,5	47	97,9	67,02	18,71
Cycle 11 Day 1	White	37	61,7	37	100,0	72,75	20,47
	Other	43	50,6	41	95,3	69,11	14,22
Cycle 12 Day 1	White	37	61,7	33	89,2	69,19	20,25
	Other	39	45,9	36	92,3	68,29	18,56
Cycle 13 Day 1	White	32	53,3	30	93,8	68,61	21,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	71,61	20,51
Cycle 14 Day 1	White	31	51,7	30	96,8	71,94	21,83
	Other	29	34,1	27	93,1	69,44	18,92
Cycle 15 Day 1	White	30	50,0	28	93,3	71,43	18,76
	Other	27	31,8	26	96,3	73,08	13,19
Cycle 16 Day 1	White	26	43,3	24	92,3	69,79	17,17
	Other	24	28,2	23	95,8	71,74	14,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	71,53	20,98
	Other	21	24,7	20	95,2	70,00	14,15
Cycle 18 Day 1	White	22	36,7	19	86,4	72,37	13,34
	Other	19	22,4	18	94,7	66,67	15,39
Cycle 19 Day 1	White	20	33,3	20	100,0	69,58	17,79
	Other	16	18,8	13	81,3	69,87	16,15
Cycle 20 Day 1	White	20	33,3	17	85,0	74,51	17,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	68,33	13,80
Cycle 21 Day 1	White	16	26,7	14	87,5	64,88	22,69
	Other	13	15,3	12	92,3	63,19	17,57
Cycle 22 Day 1	White	16	26,7	13	81,3	69,87	26,25
	Other	13	15,3	12	92,3	67,36	16,46
Cycle 23 Day 1	White	12	20,0	10	83,3	61,67	25,22
	Other	9	10,6	8	88,9	72,92	15,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	63,33	20,11
	Other	9	10,6	8	88,9	72,92	14,60
Cycle 25 Day 1	White	10	16,7	8	80,0	65,63	19,64
	Other	5	5,9	5	100,0	68,33	14,91
Cycle 26 Day 1	White	10	16,7	8	80,0	66,67	29,88
	Other	4	4,7	4	100,0	64,58	17,18
Cycle 27 Day 1	White	8	13,3	5	62,5	58,33	32,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	55,56	9,62
Cycle 28 Day 1	White	7	11,7	6	85,7	69,44	22,77
	Other	3	3,5	3	100,0	30,56	24,06
Cycle 29 Day 1	White	6	10,0	4	66,7	66,67	18,00
	Other	3	3,5	3	100,0	55,56	20,97
Cycle 30 Day 1	White	4	6,7	2	50,0	75,00	11,79
	Other	3	3,5	3	100,0	52,78	4,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	79,17	17,68
	Other	3	3,5	3	100,0	58,33	8,33
Cycle 32 Day 1	White	4	6,7	3	75,0	72,22	19,25
	Other	2	2,4	2	100,0	45,83	5,89
Cycle 33 Day 1	White	2	3,3	2	100,0	79,17	5,89
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	52,45	19,04
	Other	39	45,9	27	69,2	47,84	22,95
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	63,96	24,12
	Europe (EU)	34	100,0	31	91,2	52,42	24,07
	Asia (AS)	71	100,0	71	100,0	53,17	25,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	63,54	21,66
	Europe (EU)	32	94,1	28	87,5	61,61	21,20
	Asia (AS)	66	93,0	65	98,5	62,82	19,77
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	63,38	21,14
	Europe (EU)	31	91,2	22	71,0	58,71	21,28
	Asia (AS)	63	88,7	63	100,0	63,89	19,46
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	70,34	19,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	62,67	18,34
	Asia (AS)	61	85,9	61	100,0	67,76	21,05
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	70,24	21,61
	Europe (EU)	30	88,2	26	86,7	66,67	15,28
	Asia (AS)	57	80,3	57	100,0	67,54	19,33
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	74,29	19,74
	Europe (EU)	28	82,4	25	89,3	63,67	17,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	68,43	17,18
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	72,92	20,19
	Europe (EU)	28	82,4	25	89,3	64,67	14,88
	Asia (AS)	50	70,4	49	98,0	69,22	17,61
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	77,16	14,36
	Europe (EU)	28	82,4	23	82,1	65,22	18,57
	Asia (AS)	47	66,2	47	100,0	69,15	17,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	74,11	17,32
	Europe (EU)	26	76,5	25	96,2	70,00	13,61
	Asia (AS)	43	60,6	43	100,0	68,80	18,10
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	75,00	15,73
	Europe (EU)	25	73,5	25	100,0	60,33	18,21
	Asia (AS)	37	52,1	37	100,0	68,47	20,33
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	75,36	20,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	70,45	15,80
	Asia (AS)	33	46,5	33	100,0	67,93	16,02
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	77,17	21,94
	Europe (EU)	23	67,6	18	78,3	64,35	11,72
	Asia (AS)	29	40,8	28	96,6	64,58	19,06
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	79,92	20,52
	Europe (EU)	18	52,9	15	83,3	58,89	18,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	68,33	19,54
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	78,17	19,45
	Europe (EU)	17	50,0	16	94,1	61,98	21,94
	Asia (AS)	21	29,6	20	95,2	70,00	17,81
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	74,58	21,71
	Europe (EU)	15	44,1	14	93,3	69,05	11,52
	Asia (AS)	20	28,2	20	100,0	72,08	12,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	76,47	16,73
	Europe (EU)	14	41,2	11	78,6	68,94	10,60
	Asia (AS)	19	26,8	19	100,0	66,67	16,20
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	72,92	24,06
	Europe (EU)	13	38,2	12	92,3	70,14	13,97
	Asia (AS)	16	22,5	16	100,0	69,27	14,18
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	77,38	15,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	65,48	8,91
	Asia (AS)	16	22,5	16	100,0	64,58	13,09
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	73,08	21,01
	Europe (EU)	9	26,5	9	100,0	70,37	13,89
	Asia (AS)	14	19,7	11	78,6	65,15	13,85
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	74,36	19,38
	Europe (EU)	9	26,5	6	66,7	76,39	8,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	66,67	14,03
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	69,17	24,23
	Europe (EU)	7	20,6	6	85,7	66,67	14,91
	Asia (AS)	11	15,5	10	90,9	57,50	18,19
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	74,17	29,25
	Europe (EU)	7	20,6	5	71,4	71,67	13,94
	Asia (AS)	11	15,5	10	90,9	61,67	14,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	70,37	30,08
	Europe (EU)	5	14,7	3	60,0	66,67	0,00
	Asia (AS)	7	9,9	6	85,7	61,11	10,09
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	70,83	21,82
	Europe (EU)	5	14,7	4	80,0	70,83	15,96
	Asia (AS)	7	9,9	6	85,7	61,11	14,59
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	72,62	16,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	75,00	11,79
	Asia (AS)	4	5,6	4	100,0	52,08	14,23
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	63,89	31,03
	Europe (EU)	4	11,8	2	50,0	91,67	11,79
	Asia (AS)	4	5,6	4	100,0	56,25	12,50
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	64,58	33,59
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	50,00	13,61
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	68,75	17,18
	Europe (EU)	2	5,9	1	50,0	100,00	-
	Asia (AS)	4	5,6	4	100,0	33,33	20,41
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	69,44	20,97
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	56,25	17,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	75,00	11,79
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	52,78	4,81
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	79,17	17,68
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	58,33	8,33
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	83,33	-
	Asia (AS)	3	4,2	2	66,7	45,83	5,89
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	75,00	-
	Europe (EU)	1	2,9	1	100,0	83,33	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	54,90	21,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	41,67	25,00
	Asia (AS)	34	47,9	22	64,7	47,35	20,64
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	68,47	20,65
	1	69	100,0	67	97,1	51,12	22,84
	2	15	100,0	15	100,0	28,33	20,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	55	93,2	65,61	20,42
	1	67	97,1	60	89,6	61,25	19,88
	2	10	66,7	10	100,0	55,83	23,26
Cycle 3 Day 1	0	57	93,4	51	89,5	63,89	23,25
	1	65	94,2	58	89,2	62,36	18,22
	2	9	60,0	9	100,0	59,26	14,10
Cycle 4 Day 1	0	57	93,4	54	94,7	70,52	22,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	65,23	18,54
	2	9	60,0	8	88,9	62,50	17,25
Cycle 5 Day 1	0	56	91,8	53	94,6	69,97	20,76
	1	62	89,9	59	95,2	67,09	17,81
	2	6	40,0	6	100,0	62,50	18,07
Cycle 6 Day 1	0	56	91,8	54	96,4	72,53	18,22
	1	59	85,5	53	89,8	66,35	18,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	63,33	21,73
Cycle 7 Day 1	0	54	88,5	51	94,4	73,37	18,86
	1	54	78,3	50	92,6	65,50	16,75
	2	5	33,3	5	100,0	65,00	12,36
Cycle 8 Day 1	0	52	85,2	48	92,3	73,78	17,70
	1	49	71,0	44	89,8	67,42	16,36
	2	5	33,3	5	100,0	65,00	20,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	72,45	16,42
	1	44	63,8	43	97,7	68,02	17,62
	2	4	26,7	4	100,0	77,08	7,98
Cycle 10 Day 1	0	46	75,4	46	100,0	68,84	21,26
	1	40	58,0	37	92,5	66,44	17,07
	2	3	20,0	3	100,0	72,22	9,62
Cycle 11 Day 1	0	43	70,5	41	95,3	73,78	15,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	66,42	18,52
	2	3	20,0	3	100,0	80,56	17,35
Cycle 12 Day 1	0	42	68,9	36	85,7	68,98	20,95
	1	31	44,9	30	96,8	68,61	17,87
	2	3	20,0	3	100,0	66,67	16,67
Cycle 13 Day 1	0	38	62,3	34	89,5	69,36	21,88
	1	27	39,1	27	100,0	70,99	20,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	75,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	70,57	22,20
	1	24	34,8	24	100,0	70,83	18,55
	2	1	6,7	1	100,0	75,00	-
Cycle 15 Day 1	0	33	54,1	30	90,9	72,78	17,36
	1	23	33,3	23	100,0	71,74	15,23
	2	1	6,7	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	69,67	19,08
	1	21	30,4	21	100,0	71,43	10,73
	2	1	6,7	1	100,0	83,33	-
Cycle 17 Day 1	0	24	39,3	23	95,8	74,28	15,27
	1	20	29,0	20	100,0	66,25	20,50
	2	1	6,7	1	100,0	83,33	-
Cycle 18 Day 1	0	23	37,7	19	82,6	71,05	15,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	67,16	13,97
	2	1	6,7	1	100,0	83,33	-
Cycle 19 Day 1	0	20	32,8	19	95,0	70,18	19,90
	1	15	21,7	13	86,7	67,95	12,19
	2	1	6,7	1	100,0	83,33	-
Cycle 20 Day 1	0	20	32,8	17	85,0	71,57	19,11
	1	15	21,7	14	93,3	70,83	11,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	83,33	-
Cycle 21 Day 1	0	15	24,6	14	93,3	66,07	24,12
	1	13	18,8	11	84,6	61,36	15,49
	2	1	6,7	1	100,0	66,67	-
Cycle 22 Day 1	0	15	24,6	12	80,0	70,14	26,22
	1	13	18,8	12	92,3	65,97	17,57
	2	1	6,7	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	65,74	28,40
	1	9	13,0	8	88,9	67,71	15,06
	2	1	6,7	1	100,0	66,67	-
Cycle 24 Day 1	0	10	16,4	9	90,0	69,44	19,98
	1	9	13,0	8	88,9	65,63	18,06
	2	1	6,7	1	100,0	66,67	-
Cycle 25 Day 1	0	8	13,1	6	75,0	65,28	21,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	67,86	14,77
Cycle 26 Day 1	0	8	13,1	6	75,0	70,83	24,58
	1	6	8,7	6	100,0	61,11	27,72
Cycle 27 Day 1	0	6	9,8	3	50,0	61,11	25,46
	1	5	7,2	5	100,0	55,00	27,39
Cycle 28 Day 1	0	5	8,2	4	80,0	70,83	25,91
	1	5	7,2	5	100,0	45,00	28,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	62,50	5,89
	1	5	7,2	5	100,0	61,67	22,52
Cycle 30 Day 1	0	3	4,9	1	33,3	66,67	-
	1	4	5,8	4	100,0	60,42	15,77
Cycle 31 Day 1	0	3	4,9	1	33,3	66,67	-
	1	4	5,8	4	100,0	66,67	18,00
Cycle 32 Day 1	0	3	4,9	2	66,7	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	58,33	22,05
Cycle 33 Day 1	0	2	3,3	2	100,0	79,17	5,89
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	53,97	22,76
	1	34	49,3	20	58,8	46,25	21,03
	2	7	46,7	3	42,9	41,67	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	57,22	26,37
	1	4	100,0	4	100,0	60,42	24,88
	2 or More	79	100,0	78	98,7	54,91	24,12
Cycle 2 Day 1	None	60	96,8	54	90,0	62,96	20,46
	1	3	75,0	2	66,7	83,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	61,96	20,49
Cycle 3 Day 1	None	59	95,2	53	89,8	63,52	18,14
	1	3	75,0	2	66,7	83,33	23,57
	2 or More	69	87,3	63	91,3	61,51	21,66
Cycle 4 Day 1	None	59	95,2	56	94,9	66,82	22,22
	1	3	75,0	2	66,7	83,33	23,57
	2 or More	66	83,5	62	93,9	67,47	18,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	69,49	19,15
	1	3	75,0	3	100,0	88,89	9,62
	2 or More	63	79,7	59	93,7	65,82	18,93
Cycle 6 Day 1	None	57	91,9	52	91,2	72,12	17,69
	1	3	75,0	3	100,0	80,56	12,73
	2 or More	61	77,2	57	93,4	65,94	18,92
Cycle 7 Day 1	None	52	83,9	50	96,2	70,00	17,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	80,56	12,73
	2 or More	58	73,4	53	91,4	67,92	18,15
Cycle 8 Day 1	None	50	80,6	46	92,0	73,37	16,44
	1	3	75,0	1	33,3	83,33	-
	2 or More	53	67,1	50	94,3	67,50	18,00
Cycle 9 Day 1	None	48	77,4	47	97,9	71,45	17,61
	1	1	25,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	69,62	16,17
Cycle 10 Day 1	None	43	69,4	41	95,3	70,93	16,57
	1	1	25,0	1	100,0	91,67	-
	2 or More	45	57,0	44	97,8	64,58	20,89
Cycle 11 Day 1	None	37	59,7	35	94,6	74,76	16,60
	1	1	25,0	1	100,0	83,33	-
	2 or More	42	53,2	42	100,0	67,26	17,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	75,98	14,33
	1	1	25,0	1	100,0	83,33	-
	2 or More	38	48,1	34	89,5	61,03	20,89
Cycle 13 Day 1	None	34	54,8	30	88,2	75,28	18,24
	1	1	25,0	1	100,0	100,00	-
	2 or More	31	39,2	31	100,0	64,25	21,86
Cycle 14 Day 1	None	31	50,0	29	93,5	74,43	16,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	83,33	-
	2 or More	28	35,4	27	96,4	66,36	23,40
Cycle 15 Day 1	None	30	48,4	28	93,3	73,81	14,65
	1	1	25,0	1	100,0	83,33	-
	2 or More	26	32,9	25	96,2	70,00	18,00
Cycle 16 Day 1	None	25	40,3	23	92,0	73,19	17,94
	1	1	25,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	67,75	12,89
Cycle 17 Day 1	None	23	37,1	22	95,7	75,38	14,66
	1	1	25,0	1	100,0	83,33	-
	2 or More	21	26,6	21	100,0	65,48	20,29
Cycle 18 Day 1	None	20	32,3	18	90,0	73,61	14,36
	1	1	25,0	1	100,0	91,67	-
	2 or More	20	25,3	18	90,0	64,35	12,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	75,98	14,09
	1	1	25,0	1	100,0	83,33	-
	2 or More	18	22,8	15	83,3	61,67	17,19
Cycle 20 Day 1	None	17	27,4	16	94,1	76,56	12,99
	1	1	25,0	1	100,0	66,67	-
	2 or More	18	22,8	15	83,3	66,67	17,82
Cycle 21 Day 1	None	15	24,2	13	86,7	73,72	17,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	54,49	18,51
Cycle 22 Day 1	None	15	24,2	13	86,7	80,13	12,52
	2 or More	14	17,7	12	85,7	56,25	23,06
Cycle 23 Day 1	None	10	16,1	9	90,0	76,85	17,07
	2 or More	11	13,9	9	81,8	56,48	21,96
Cycle 24 Day 1	None	10	16,1	10	100,0	73,33	19,95
	2 or More	10	12,7	8	80,0	60,42	13,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	69,79	19,38
	2 or More	6	7,6	5	83,3	61,67	13,94
Cycle 26 Day 1	None	8	12,9	8	100,0	71,88	26,70
	2 or More	6	7,6	4	66,7	54,17	20,97
Cycle 27 Day 1	None	7	11,3	6	85,7	59,72	29,07
	2 or More	4	5,1	2	50,0	50,00	0,00
Cycle 28 Day 1	None	7	11,3	7	100,0	61,90	28,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	37,50	29,46
Cycle 29 Day 1	None	6	9,7	5	83,3	60,00	21,57
	2 or More	3	3,8	2	66,7	66,67	11,79
Cycle 30 Day 1	None	4	6,5	3	75,0	66,67	16,67
	2 or More	3	3,8	2	66,7	54,17	5,89
Cycle 31 Day 1	None	4	6,5	3	75,0	69,44	20,97
	2 or More	3	3,8	2	66,7	62,50	5,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	61,11	19,25
	2 or More	2	2,5	2	100,0	62,50	29,46
Cycle 33 Day 1	None	1	1,6	1	100,0	75,00	-
	2 or More	1	1,3	1	100,0	83,33	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	51,32	23,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	58,33	-
	2 or More	39	49,4	24	61,5	47,92	20,74
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	57,22	26,37
	Previously Treated	83	100,0	82	98,8	55,18	24,03
Cycle 2 Day 1	Naïve	60	96,8	54	90,0	62,96	20,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	62,56	20,55
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	63,52	18,14
	Previously Treated	72	86,7	65	90,3	62,18	21,85
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	66,82	22,22
	Previously Treated	69	83,1	64	92,8	67,97	18,32
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	69,49	19,15
	Previously Treated	66	79,5	62	93,9	66,94	19,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	72,12	17,69
	Previously Treated	64	77,1	60	93,8	66,67	18,85
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	70,00	17,98
	Previously Treated	61	73,5	56	91,8	68,60	18,05
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	73,37	16,44
	Previously Treated	56	67,5	51	91,1	67,81	17,95
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	71,45	17,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	69,90	16,12
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	70,93	16,57
	Previously Treated	46	55,4	45	97,8	65,19	21,04
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	74,76	16,60
	Previously Treated	43	51,8	43	100,0	67,64	17,65
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	75,98	14,33
	Previously Treated	39	47,0	35	89,7	61,67	20,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	75,28	18,24
	Previously Treated	32	38,6	32	100,0	65,36	22,41
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	74,43	16,80
	Previously Treated	29	34,9	28	96,6	66,96	23,18
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	73,81	14,65
	Previously Treated	27	32,5	26	96,3	70,51	17,83
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	73,19	17,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	68,40	13,00
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	75,38	14,66
	Previously Treated	22	26,5	22	100,0	66,29	20,16
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	73,61	14,36
	Previously Treated	21	25,3	19	90,5	65,79	13,86
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	75,98	14,09
	Previously Treated	19	22,9	16	84,2	63,02	17,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	76,56	12,99
	Previously Treated	19	22,9	16	84,2	66,67	17,21
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	73,72	17,30
	Previously Treated	14	16,9	13	92,9	54,49	18,51
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	80,13	12,52
	Previously Treated	14	16,9	12	85,7	56,25	23,06
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	76,85	17,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	56,48	21,96
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	73,33	19,95
	Previously Treated	10	12,0	8	80,0	60,42	13,18
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	69,79	19,38
	Previously Treated	6	7,2	5	83,3	61,67	13,94
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	71,88	26,70
	Previously Treated	6	7,2	4	66,7	54,17	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	59,72	29,07
	Previously Treated	4	4,8	2	50,0	50,00	0,00
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	61,90	28,81
	Previously Treated	3	3,6	2	66,7	37,50	29,46
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	60,00	21,57
	Previously Treated	3	3,6	2	66,7	66,67	11,79
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	66,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	54,17	5,89
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	69,44	20,97
	Previously Treated	3	3,6	2	66,7	62,50	5,89
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	61,11	19,25
	Previously Treated	2	2,4	2	100,0	62,50	29,46
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	75,00	-
	Previously Treated	1	1,2	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	51,32	23,12
	Previously Treated	42	50,6	25	59,5	48,33	20,41
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	56,00	26,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	56,09	23,15
Cycle 2 Day 1	Local	71	94,7	66	93,0	62,50	19,90
	Central	65	92,9	59	90,8	62,99	21,18
Cycle 3 Day 1	Local	67	89,3	62	92,5	64,11	20,11
	Central	64	91,4	56	87,5	61,31	20,38
Cycle 4 Day 1	Local	65	86,7	61	93,8	66,53	21,27
	Central	63	90,0	59	93,7	68,36	19,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	66,67	21,27
	Central	61	87,1	59	96,7	69,63	16,79
Cycle 6 Day 1	Local	63	84,0	61	96,8	70,90	19,34
	Central	58	82,9	51	87,9	67,16	17,27
Cycle 7 Day 1	Local	61	81,3	59	96,7	72,46	18,52
	Central	52	74,3	47	90,4	65,25	16,51
Cycle 8 Day 1	Local	57	76,0	55	96,5	73,64	17,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	66,27	17,06
Cycle 9 Day 1	Local	54	72,0	53	98,1	72,48	16,14
	Central	44	62,9	43	97,7	68,41	17,50
Cycle 10 Day 1	Local	48	64,0	46	95,8	68,48	18,75
	Central	41	58,6	40	97,6	67,29	19,83
Cycle 11 Day 1	Local	40	53,3	38	95,0	70,83	18,86
	Central	40	57,1	40	100,0	70,83	16,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	72,98	18,52
	Central	40	57,1	36	90,0	64,81	19,33
Cycle 13 Day 1	Local	30	40,0	29	96,7	76,44	19,04
	Central	36	51,4	33	91,7	64,65	21,25
Cycle 14 Day 1	Local	27	36,0	27	100,0	75,93	21,97
	Central	33	47,1	30	90,9	66,11	17,90
Cycle 15 Day 1	Local	26	34,7	25	96,2	75,00	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	69,83	16,28
Cycle 16 Day 1	Local	24	32,0	24	100,0	76,39	12,93
	Central	26	37,1	23	88,5	64,86	16,28
Cycle 17 Day 1	Local	22	29,3	22	100,0	74,62	17,53
	Central	23	32,9	22	95,7	67,05	18,09
Cycle 18 Day 1	Local	20	26,7	19	95,0	75,44	12,57
	Central	21	30,0	18	85,7	63,43	14,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	73,04	13,67
	Central	17	24,3	16	94,1	66,15	19,60
Cycle 20 Day 1	Local	19	25,3	17	89,5	76,47	11,12
	Central	17	24,3	15	88,2	66,11	18,76
Cycle 21 Day 1	Local	14	18,7	12	85,7	68,75	20,14
	Central	15	21,4	14	93,3	60,12	19,93
Cycle 22 Day 1	Local	14	18,7	12	85,7	76,39	19,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	61,54	22,19
Cycle 23 Day 1	Local	11	14,7	10	90,9	78,33	12,55
	Central	10	14,3	8	80,0	52,08	22,60
Cycle 24 Day 1	Local	11	14,7	10	90,9	75,00	14,70
	Central	9	12,9	8	88,9	58,33	18,37
Cycle 25 Day 1	Local	7	9,3	7	100,0	73,81	15,54
	Central	8	11,4	6	75,0	58,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	73,61	20,69
	Central	8	11,4	6	75,0	58,33	29,34
Cycle 27 Day 1	Local	4	5,3	4	100,0	77,08	12,50
	Central	7	10,0	4	57,1	37,50	15,96
Cycle 28 Day 1	Local	4	5,3	4	100,0	60,42	31,46
	Central	6	8,6	5	83,3	53,33	30,39
Cycle 29 Day 1	Local	3	4,0	3	100,0	63,89	29,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	60,42	10,49
Cycle 30 Day 1	Local	3	4,0	3	100,0	66,67	16,67
	Central	4	5,7	2	50,0	54,17	5,89
Cycle 31 Day 1	Local	3	4,0	3	100,0	69,44	20,97
	Central	4	5,7	2	50,0	62,50	5,89
Cycle 32 Day 1	Local	3	4,0	3	100,0	61,11	19,25
	Central	3	4,3	2	66,7	62,50	29,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	75,00	-
	Central	1	1,4	1	100,0	83,33	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	53,47	19,65
	Central	32	45,7	20	62,5	45,00	23,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	56,63	24,79
	No	10	100,0	10	100,0	48,33	27,44
Cycle 2 Day 1	Yes	129	95,6	118	91,5	63,77	19,74
	No	7	70,0	7	100,0	45,24	25,39
Cycle 3 Day 1	Yes	124	91,9	112	90,3	63,62	20,13
	No	7	70,0	6	85,7	47,22	15,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	68,14	20,39
	No	7	70,0	7	100,0	55,95	11,50
Cycle 5 Day 1	Yes	117	86,7	112	95,7	69,35	18,79
	No	7	70,0	6	85,7	45,83	10,21
Cycle 6 Day 1	Yes	114	84,4	105	92,1	70,24	18,08
	No	7	70,0	7	100,0	53,57	17,91
Cycle 7 Day 1	Yes	106	78,5	99	93,4	69,95	17,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	59,52	16,27
Cycle 8 Day 1	Yes	100	74,1	91	91,0	71,06	17,54
	No	6	60,0	6	100,0	61,11	12,55
Cycle 9 Day 1	Yes	92	68,1	90	97,8	70,93	16,96
	No	6	60,0	6	100,0	66,67	14,91
Cycle 10 Day 1	Yes	83	61,5	80	96,4	68,54	19,62
	No	6	60,0	6	100,0	59,72	8,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	70,83	17,62
	No	4	40,0	4	100,0	70,83	15,96
Cycle 12 Day 1	Yes	72	53,3	65	90,3	68,72	19,60
	No	4	40,0	4	100,0	68,75	14,23
Cycle 13 Day 1	Yes	64	47,4	60	93,8	70,28	21,28
	No	2	20,0	2	100,0	66,67	0,00
Cycle 14 Day 1	Yes	58	43,0	55	94,8	70,91	20,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	66,67	23,57
Cycle 15 Day 1	Yes	55	40,7	52	94,5	72,76	16,18
	No	2	20,0	2	100,0	58,33	11,79
Cycle 16 Day 1	Yes	48	35,6	45	93,8	71,30	15,65
	No	2	20,0	2	100,0	58,33	11,79
Cycle 17 Day 1	Yes	43	31,9	42	97,7	71,43	18,14
	No	2	20,0	2	100,0	58,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	69,52	14,57
	No	2	20,0	2	100,0	70,83	17,68
Cycle 19 Day 1	Yes	34	25,2	32	94,1	70,05	17,05
	No	2	20,0	1	50,0	58,33	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	72,22	16,13
	No	2	20,0	2	100,0	62,50	5,89
Cycle 21 Day 1	Yes	27	20,0	24	88,9	64,93	20,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	54,17	17,68
Cycle 22 Day 1	Yes	27	20,0	23	85,2	69,20	22,53
	No	2	20,0	2	100,0	62,50	5,89
Cycle 23 Day 1	Yes	20	14,8	17	85,0	66,18	22,34
	No	1	10,0	1	100,0	75,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	66,67	18,16
	No	1	10,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	66,67	18,12
	No	1	10,0	1	100,0	66,67	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	65,15	26,57
	No	1	10,0	1	100,0	75,00	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	55,95	26,66
	No	1	10,0	1	100,0	66,67	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	61,46	26,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	16,67	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	66,67	14,91
	No	1	10,0	1	100,0	33,33	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	64,58	14,23
	No	1	10,0	1	100,0	50,00	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	70,83	14,43
	No	1	10,0	1	100,0	50,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	64,58	21,92
	No	1	10,0	1	100,0	50,00	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	79,17	5,89
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	50,00	21,52
	No	2	20,0	1	50,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	50,76	23,41
	No	134	100,0	131	97,8	56,49	25,13
Cycle 2 Day 1	Yes	7	63,6	7	100,0	69,05	20,25
	No	129	96,3	118	91,5	62,36	20,46
Cycle 3 Day 1	Yes	7	63,6	7	100,0	61,90	18,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	62,84	20,37
Cycle 4 Day 1	Yes	7	63,6	7	100,0	70,24	21,44
	No	121	90,3	113	93,4	67,26	20,16
Cycle 5 Day 1	Yes	7	63,6	7	100,0	63,10	23,50
	No	117	87,3	111	94,9	68,47	18,92
Cycle 6 Day 1	Yes	7	63,6	7	100,0	63,10	29,60
	No	114	85,1	105	92,1	69,60	17,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	60,71	20,25
	No	106	79,1	99	93,4	69,87	17,73
Cycle 8 Day 1	Yes	7	63,6	7	100,0	66,67	11,79
	No	99	73,9	90	90,9	70,74	17,77
Cycle 9 Day 1	Yes	6	54,5	6	100,0	62,50	18,07
	No	92	68,7	90	97,8	71,20	16,67
Cycle 10 Day 1	Yes	6	54,5	6	100,0	62,50	20,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	68,33	19,10
Cycle 11 Day 1	Yes	6	54,5	6	100,0	58,33	20,41
	No	74	55,2	72	97,3	71,88	16,93
Cycle 12 Day 1	Yes	6	54,5	6	100,0	63,89	16,39
	No	70	52,2	63	90,0	69,18	19,55
Cycle 13 Day 1	Yes	5	45,5	5	100,0	68,33	23,86
	No	61	45,5	57	93,4	70,32	20,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	68,33	14,91
	No	55	41,0	52	94,5	70,99	20,91
Cycle 15 Day 1	Yes	4	36,4	4	100,0	64,58	21,92
	No	53	39,6	50	94,3	72,83	15,78
Cycle 16 Day 1	Yes	3	27,3	3	100,0	63,89	33,68
	No	47	35,1	44	93,6	71,21	14,32
Cycle 17 Day 1	Yes	3	27,3	3	100,0	77,78	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	70,33	18,45
Cycle 18 Day 1	Yes	3	27,3	3	100,0	75,00	14,43
	No	38	28,4	34	89,5	69,12	14,58
Cycle 19 Day 1	Yes	3	27,3	3	100,0	75,00	14,43
	No	33	24,6	30	90,9	69,17	17,25
Cycle 20 Day 1	Yes	3	27,3	3	100,0	72,22	9,62
	No	33	24,6	29	87,9	71,55	16,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	41,67	11,79
	No	27	20,1	24	88,9	65,97	19,65
Cycle 22 Day 1	Yes	2	18,2	2	100,0	70,83	17,68
	No	27	20,1	23	85,2	68,48	22,33
Cycle 23 Day 1	Yes	2	18,2	2	100,0	66,67	23,57
	No	19	14,2	16	84,2	66,67	22,36
Cycle 24 Day 1	Yes	2	18,2	2	100,0	62,50	29,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	68,23	17,54
Cycle 25 Day 1	Yes	2	18,2	2	100,0	58,33	35,36
	No	13	9,7	11	84,6	68,18	14,82
Cycle 26 Day 1	Yes	1	9,1	1	100,0	50,00	-
	No	13	9,7	11	84,6	67,42	26,21
Cycle 27 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	10	7,5	7	70,0	60,71	24,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	41,67	-
	No	9	6,7	8	88,9	58,33	30,54
Cycle 29 Day 1	Yes	1	9,1	1	100,0	58,33	-
	No	8	6,0	6	75,0	62,50	20,24
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	61,67	13,94
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	66,67	15,59
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	61,67	20,07
Cycle 33 Day 1	No	2	1,5	2	100,0	79,17	5,89
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	30,56	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	51,02	21,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30QL_SG.xls
24JUN2020 20:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	62,44	29,47
Cycle 2 Day 1	All	136	93,8	126	92,6	67,59	27,11
Cycle 3 Day 1	All	131	90,3	118	90,1	69,63	26,30
Cycle 4 Day 1	All	128	88,3	120	93,8	72,78	26,19
Cycle 5 Day 1	All	124	85,5	118	95,2	72,74	24,52
Cycle 6 Day 1	All	121	83,4	112	92,6	73,81	23,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	75,94	22,31
Cycle 8 Day 1	All	106	73,1	97	91,5	75,09	22,19
Cycle 9 Day 1	All	98	67,6	96	98,0	76,39	21,85
Cycle 10 Day 1	All	89	61,4	86	96,6	77,71	22,08
Cycle 11 Day 1	All	80	55,2	78	97,5	74,79	23,22
Cycle 12 Day 1	All	76	52,4	69	90,8	76,57	21,64
Cycle 13 Day 1	All	66	45,5	62	93,9	77,42	25,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	70,18	27,23
Cycle 15 Day 1	All	57	39,3	54	94,7	72,84	25,14
Cycle 16 Day 1	All	50	34,5	47	94,0	73,76	23,76
Cycle 17 Day 1	All	45	31,0	44	97,8	72,73	23,60
Cycle 18 Day 1	All	41	28,3	37	90,2	75,23	20,65
Cycle 19 Day 1	All	36	24,8	33	91,7	72,73	25,62
Cycle 20 Day 1	All	36	24,8	32	88,9	71,88	23,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	71,79	21,99
Cycle 22 Day 1	All	29	20,0	25	86,2	70,00	24,06
Cycle 23 Day 1	All	21	14,5	18	85,7	73,15	26,90
Cycle 24 Day 1	All	20	13,8	18	90,0	70,37	27,75
Cycle 25 Day 1	All	15	10,3	13	86,7	70,51	28,99
Cycle 26 Day 1	All	14	9,7	12	85,7	72,22	27,83
Cycle 27 Day 1	All	11	7,6	8	72,7	68,75	32,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	68,52	33,79
Cycle 29 Day 1	All	9	6,2	7	77,8	73,81	21,21
Cycle 30 Day 1	All	7	4,8	5	71,4	76,67	22,36
Cycle 31 Day 1	All	7	4,8	5	71,4	73,33	14,91
Cycle 32 Day 1	All	6	4,1	5	83,3	80,00	18,26
Cycle 33 Day 1	All	2	1,4	2	100,0	83,33	23,57
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	53,41	32,66
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	60,78	31,59
	Female	93	100,0	91	97,8	63,37	28,35
Cycle 2 Day 1	Male	50	96,2	47	94,0	63,48	27,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	70,04	26,87
Cycle 3 Day 1	Male	47	90,4	42	89,4	72,22	28,91
	Female	84	90,3	76	90,5	68,20	24,82
Cycle 4 Day 1	Male	46	88,5	45	97,8	72,59	28,24
	Female	82	88,2	75	91,5	72,89	25,08
Cycle 5 Day 1	Male	45	86,5	43	95,6	72,48	24,90
	Female	79	84,9	75	94,9	72,89	24,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	72,36	27,03
	Female	76	81,7	71	93,4	74,65	22,16
Cycle 7 Day 1	Male	40	76,9	39	97,5	74,79	25,33
	Female	73	78,5	67	91,8	76,62	20,53
Cycle 8 Day 1	Male	37	71,2	34	91,9	73,53	20,56
	Female	69	74,2	63	91,3	75,93	23,14
Cycle 9 Day 1	Male	33	63,5	33	100,0	75,76	21,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	76,72	22,11
Cycle 10 Day 1	Male	30	57,7	30	100,0	76,11	23,44
	Female	59	63,4	56	94,9	78,57	21,49
Cycle 11 Day 1	Male	29	55,8	29	100,0	75,29	22,10
	Female	51	54,8	49	96,1	74,49	24,08
Cycle 12 Day 1	Male	27	51,9	26	96,3	76,28	20,64
	Female	49	52,7	43	87,8	76,74	22,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	77,54	22,81
	Female	41	44,1	39	95,1	77,35	27,96
Cycle 14 Day 1	Male	23	44,2	21	91,3	67,46	22,65
	Female	37	39,8	36	97,3	71,76	29,77
Cycle 15 Day 1	Male	21	40,4	20	95,2	74,17	19,85
	Female	36	38,7	34	94,4	72,06	28,05
Cycle 16 Day 1	Male	16	30,8	16	100,0	76,04	20,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	72,58	25,66
Cycle 17 Day 1	Male	13	25,0	13	100,0	78,21	22,96
	Female	32	34,4	31	96,9	70,43	23,85
Cycle 18 Day 1	Male	12	23,1	11	91,7	78,79	22,47
	Female	29	31,2	26	89,7	73,72	20,10
Cycle 19 Day 1	Male	10	19,2	10	100,0	71,67	29,45
	Female	26	28,0	23	88,5	73,19	24,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	75,93	22,22
	Female	26	28,0	23	88,5	70,29	24,08
Cycle 21 Day 1	Male	8	15,4	8	100,0	77,08	23,46
	Female	21	22,6	18	85,7	69,44	21,58
Cycle 22 Day 1	Male	8	15,4	6	75,0	66,67	29,81
	Female	21	22,6	19	90,5	71,05	22,80
Cycle 23 Day 1	Male	5	9,6	4	80,0	87,50	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	69,05	28,39
Cycle 24 Day 1	Male	5	9,6	4	80,0	91,67	16,67
	Female	15	16,1	14	93,3	64,29	27,62
Cycle 25 Day 1	Male	3	5,8	2	66,7	91,67	11,79
	Female	12	12,9	11	91,7	66,67	29,81
Cycle 26 Day 1	Male	3	5,8	2	66,7	100,00	0,00
	Female	11	11,8	10	90,9	66,67	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	91,67	11,79
	Female	8	8,6	6	75,0	61,11	34,43
Cycle 28 Day 1	Male	2	3,8	2	100,0	75,00	11,79
	Female	8	8,6	7	87,5	66,67	38,49
Cycle 29 Day 1	Male	1	1,9	1	100,0	100,00	-
	Female	8	8,6	6	75,0	69,44	19,48
Cycle 30 Day 1	Male	1	1,9	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	70,83	20,97
Cycle 31 Day 1	Male	1	1,9	1	100,0	100,00	-
	Female	6	6,5	4	66,7	66,67	0,00
Cycle 32 Day 1	Male	1	1,9	1	100,0	100,00	-
	Female	5	5,4	4	80,0	75,00	16,67
Cycle 33 Day 1	Male	1	1,9	1	100,0	100,00	-
	Female	1	1,1	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	46,03	32,45
	Female	37	39,8	23	62,2	60,14	32,07
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	60,69	28,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	66,09	34,06
	>=75	7	100,0	7	100,0	73,81	18,90
Cycle 2 Day 1	18-64	103	94,5	94	91,3	69,15	26,55
	65-74	26	89,7	25	96,2	59,33	29,69
	>=75	7	100,0	7	100,0	76,19	21,21
Cycle 3 Day 1	18-64	99	90,8	87	87,9	71,07	24,70
	65-74	25	86,2	24	96,0	65,97	29,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	64,29	35,26
Cycle 4 Day 1	18-64	98	89,9	92	93,9	71,74	27,49
	65-74	23	79,3	21	91,3	74,60	22,74
	>=75	7	100,0	7	100,0	80,95	17,82
Cycle 5 Day 1	18-64	95	87,2	90	94,7	72,22	25,84
	65-74	22	75,9	22	100,0	73,48	20,35
	>=75	7	100,0	6	85,7	77,78	20,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	73,61	25,38
	65-74	22	75,9	21	95,5	75,40	17,97
	>=75	7	100,0	7	100,0	71,43	24,93
Cycle 7 Day 1	18-64	86	78,9	81	94,2	75,72	22,37
	65-74	20	69,0	19	95,0	73,68	23,78
	>=75	7	100,0	6	85,7	86,11	16,39
Cycle 8 Day 1	18-64	80	73,4	72	90,0	74,07	22,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	77,19	20,19
	>=75	7	100,0	6	85,7	80,56	24,53
Cycle 9 Day 1	18-64	74	67,9	73	98,6	77,85	19,46
	65-74	18	62,1	18	100,0	69,44	28,73
	>=75	6	85,7	5	83,3	80,00	27,39
Cycle 10 Day 1	18-64	69	63,3	66	95,7	77,53	22,17
	65-74	15	51,7	15	100,0	77,78	21,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	80,00	27,39
Cycle 11 Day 1	18-64	61	56,0	59	96,7	74,29	23,64
	65-74	15	51,7	15	100,0	75,56	20,77
	>=75	4	57,1	4	100,0	79,17	31,55
Cycle 12 Day 1	18-64	57	52,3	51	89,5	75,82	21,68
	65-74	15	51,7	14	93,3	75,00	22,41
	>=75	4	57,1	4	100,0	91,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	78,99	25,20
	65-74	13	44,8	12	92,3	68,06	28,83
	>=75	4	57,1	4	100,0	87,50	25,00
Cycle 14 Day 1	18-64	45	41,3	44	97,8	72,73	27,40
	65-74	13	44,8	11	84,6	62,12	27,98
	>=75	2	28,6	2	100,0	58,33	11,79
Cycle 15 Day 1	18-64	43	39,4	41	95,3	75,20	24,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	62,12	27,98
	>=75	2	28,6	2	100,0	83,33	23,57
Cycle 16 Day 1	18-64	38	34,9	36	94,7	74,54	24,39
	65-74	10	34,5	9	90,0	72,22	23,57
	>=75	2	28,6	2	100,0	66,67	23,57
Cycle 17 Day 1	18-64	36	33,0	35	97,2	74,76	24,71
	65-74	8	27,6	8	100,0	68,75	13,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	33,33	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	77,78	20,22
	65-74	7	24,1	6	85,7	69,44	16,39
	>=75	1	14,3	1	100,0	33,33	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	76,19	25,43
	65-74	5	17,2	4	80,0	58,33	16,67
	>=75	1	14,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	75,64	22,72
	65-74	5	17,2	5	100,0	60,00	19,00
	>=75	1	14,3	1	100,0	33,33	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	73,02	22,03
	65-74	4	13,8	4	100,0	75,00	16,67
	>=75	1	14,3	1	100,0	33,33	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	72,50	25,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	66,67	0,00
	>=75	1	14,3	1	100,0	33,33	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	72,92	28,46
	65-74	2	6,9	2	100,0	75,00	11,79
Cycle 24 Day 1	18-64	18	16,5	16	88,9	68,75	28,46
	65-74	2	6,9	2	100,0	83,33	23,57
Cycle 25 Day 1	18-64	14	12,8	12	85,7	70,83	30,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	66,67	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	72,22	27,83
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	68,75	32,66
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	68,52	33,79
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	73,81	21,21
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	76,67	22,36
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	73,33	14,91
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	83,33	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	66,67	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	100,00	-
	65-74	1	3,4	1	100,0	66,67	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	52,45	32,34
	65-74	15	51,7	8	53,3	58,33	29,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	50,00	70,71
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	52,87	29,64
	Other	85	100,0	84	98,8	69,05	27,64
Cycle 2 Day 1	White	57	95,0	51	89,5	61,44	31,00
	Other	79	92,9	75	94,9	71,78	23,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	63,26	28,89
	Other	77	90,6	74	96,1	73,42	24,04
Cycle 4 Day 1	White	53	88,3	47	88,7	71,28	25,94
	Other	75	88,2	73	97,3	73,74	26,49
Cycle 5 Day 1	White	52	86,7	48	92,3	72,57	26,52
	Other	72	84,7	70	97,2	72,86	23,26
Cycle 6 Day 1	White	50	83,3	44	88,0	72,35	24,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	74,75	23,48
Cycle 7 Day 1	White	47	78,3	42	89,4	73,41	23,59
	Other	66	77,6	64	97,0	77,60	21,46
Cycle 8 Day 1	White	45	75,0	39	86,7	73,93	24,12
	Other	61	71,8	58	95,1	75,86	20,98
Cycle 9 Day 1	White	42	70,0	41	97,6	76,83	25,52
	Other	56	65,9	55	98,2	76,06	18,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	73,50	23,79
	Other	48	56,5	47	97,9	81,21	20,15
Cycle 11 Day 1	White	37	61,7	37	100,0	75,23	26,53
	Other	43	50,6	41	95,3	74,39	20,10
Cycle 12 Day 1	White	37	61,7	33	89,2	75,76	24,33
	Other	39	45,9	36	92,3	77,31	19,17
Cycle 13 Day 1	White	32	53,3	30	93,8	77,22	30,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	77,60	21,42
Cycle 14 Day 1	White	31	51,7	30	96,8	71,67	30,37
	Other	29	34,1	27	93,1	68,52	23,72
Cycle 15 Day 1	White	30	50,0	28	93,3	73,81	28,84
	Other	27	31,8	26	96,3	71,79	20,96
Cycle 16 Day 1	White	26	43,3	24	92,3	77,08	24,48
	Other	24	28,2	23	95,8	70,29	23,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	72,92	27,72
	Other	21	24,7	20	95,2	72,50	18,16
Cycle 18 Day 1	White	22	36,7	19	86,4	78,07	24,25
	Other	19	22,4	18	94,7	72,22	16,17
Cycle 19 Day 1	White	20	33,3	20	100,0	73,33	29,81
	Other	16	18,8	13	81,3	71,79	18,49
Cycle 20 Day 1	White	20	33,3	17	85,0	75,49	28,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	67,78	14,73
Cycle 21 Day 1	White	16	26,7	14	87,5	70,24	27,87
	Other	13	15,3	12	92,3	73,61	13,22
Cycle 22 Day 1	White	16	26,7	13	81,3	71,79	30,72
	Other	13	15,3	12	92,3	68,06	15,01
Cycle 23 Day 1	White	12	20,0	10	83,3	70,00	30,23
	Other	9	10,6	8	88,9	77,08	23,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	70,00	29,19
	Other	9	10,6	8	88,9	70,83	27,82
Cycle 25 Day 1	White	10	16,7	8	80,0	72,92	21,71
	Other	5	5,9	5	100,0	66,67	40,82
Cycle 26 Day 1	White	10	16,7	8	80,0	72,92	32,04
	Other	4	4,7	4	100,0	70,83	20,97
Cycle 27 Day 1	White	8	13,3	5	62,5	66,67	42,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	72,22	9,62
Cycle 28 Day 1	White	7	11,7	6	85,7	86,11	16,39
	Other	3	3,5	3	100,0	33,33	33,33
Cycle 29 Day 1	White	6	10,0	4	66,7	83,33	19,25
	Other	3	3,5	3	100,0	61,11	19,25
Cycle 30 Day 1	White	4	6,7	2	50,0	100,00	0,00
	Other	3	3,5	3	100,0	61,11	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	83,33	23,57
	Other	3	3,5	3	100,0	66,67	0,00
Cycle 32 Day 1	White	4	6,7	3	75,0	88,89	19,25
	Other	2	2,4	2	100,0	66,67	0,00
Cycle 33 Day 1	White	2	3,3	2	100,0	83,33	23,57
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	49,02	30,32
	Other	39	45,9	27	69,2	56,17	34,33
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	61,67	30,48
	Europe (EU)	34	100,0	31	91,2	56,45	27,78
	Asia (AS)	71	100,0	71	100,0	65,49	29,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	33	86,8	70,71	27,33
	Europe (EU)	32	94,1	28	87,5	61,31	26,86
	Asia (AS)	66	93,0	65	98,5	68,72	27,08
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	66,67	25,34
	Europe (EU)	31	91,2	22	71,0	58,33	33,63
	Asia (AS)	63	88,7	63	100,0	75,13	22,57
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	73,53	28,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	70,67	24,66
	Asia (AS)	61	85,9	61	100,0	73,22	26,05
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	75,71	27,52
	Europe (EU)	30	88,2	26	86,7	70,51	25,08
	Asia (AS)	57	80,3	57	100,0	71,93	22,53
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	76,67	27,18
	Europe (EU)	28	82,4	25	89,3	68,00	26,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	74,68	19,94
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	77,60	27,31
	Europe (EU)	28	82,4	25	89,3	73,33	24,06
	Asia (AS)	50	70,4	49	98,0	76,19	17,68
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	83,95	19,87
	Europe (EU)	28	82,4	23	82,1	68,84	22,08
	Asia (AS)	47	66,2	47	100,0	73,05	22,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	81,55	21,44
	Europe (EU)	26	76,5	25	96,2	74,00	25,95
	Asia (AS)	43	60,6	43	100,0	74,42	19,36
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	82,64	24,81
	Europe (EU)	25	73,5	25	100,0	70,67	21,13
	Asia (AS)	37	52,1	37	100,0	79,28	20,19
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	78,99	28,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	72,73	23,87
	Asia (AS)	33	46,5	33	100,0	73,23	18,61
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	79,71	26,09
	Europe (EU)	23	67,6	18	78,3	75,93	20,79
	Asia (AS)	29	40,8	28	96,6	74,40	18,42
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	85,61	26,87
	Europe (EU)	18	52,9	15	83,3	68,89	26,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	75,33	23,63
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	79,37	29,30
	Europe (EU)	17	50,0	16	94,1	68,75	27,81
	Asia (AS)	21	29,6	20	95,2	61,67	22,36
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	83,33	27,04
	Europe (EU)	15	44,1	14	93,3	67,86	25,71
	Asia (AS)	20	28,2	20	100,0	65,83	19,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	83,33	25,69
	Europe (EU)	14	41,2	11	78,6	71,21	24,82
	Asia (AS)	19	26,8	19	100,0	66,67	19,25
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	81,25	29,74
	Europe (EU)	13	38,2	12	92,3	65,28	19,41
	Asia (AS)	16	22,5	16	100,0	69,79	17,45
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	84,52	24,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	69,05	20,25
	Asia (AS)	16	22,5	16	100,0	69,79	13,90
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	80,77	27,93
	Europe (EU)	9	26,5	9	100,0	64,81	29,40
	Asia (AS)	14	19,7	11	78,6	69,70	17,98
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	78,21	27,54
	Europe (EU)	9	26,5	6	66,7	66,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	67,95	15,90
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	78,33	31,48
	Europe (EU)	7	20,6	6	85,7	66,67	21,08
	Asia (AS)	11	15,5	10	90,9	68,33	5,27
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	78,33	31,48
	Europe (EU)	7	20,6	5	71,4	63,33	24,72
	Asia (AS)	11	15,5	10	90,9	65,00	12,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	74,07	33,45
	Europe (EU)	5	14,7	3	60,0	72,22	9,62
	Asia (AS)	7	9,9	6	85,7	72,22	25,09
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	79,17	30,54
	Europe (EU)	5	14,7	4	80,0	66,67	27,22
	Asia (AS)	7	9,9	6	85,7	61,11	25,09
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	78,57	24,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	66,67	0,00
	Asia (AS)	4	5,6	4	100,0	58,33	41,94
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	77,78	36,00
	Europe (EU)	4	11,8	2	50,0	75,00	35,36
	Asia (AS)	4	5,6	4	100,0	62,50	8,33
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	70,83	47,87
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	66,67	13,61
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	87,50	15,96
	Europe (EU)	2	5,9	1	50,0	100,00	-
	Asia (AS)	4	5,6	4	100,0	41,67	31,91
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	88,89	19,25
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	62,50	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	100,00	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	61,11	9,62
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	83,33	23,57
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	66,67	0,00
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	100,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	66,67	-
	Asia (AS)	3	4,2	2	66,7	66,67	0,00
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	100,00	-
	Europe (EU)	1	2,9	1	100,0	66,67	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	52,94	34,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	40,00	27,89
	Asia (AS)	34	47,9	22	64,7	56,82	32,80
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	75,00	24,06
	1	69	100,0	67	97,1	57,96	27,58
	2	15	100,0	15	100,0	32,22	31,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	56	94,9	70,83	26,45
	1	67	97,1	60	89,6	65,56	29,09
	2	10	66,7	10	100,0	61,67	15,81
Cycle 3 Day 1	0	57	93,4	51	89,5	72,88	30,36
	1	65	94,2	58	89,2	68,97	21,50
	2	9	60,0	9	100,0	55,56	27,64
Cycle 4 Day 1	0	57	93,4	54	94,7	77,47	26,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	69,25	24,94
	2	9	60,0	8	88,9	66,67	28,17
Cycle 5 Day 1	0	56	91,8	53	94,6	76,73	23,65
	1	62	89,9	59	95,2	70,34	23,58
	2	6	40,0	6	100,0	61,11	37,52
Cycle 6 Day 1	0	56	91,8	54	96,4	75,31	24,81
	1	59	85,5	53	89,8	74,21	21,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	53,33	32,06
Cycle 7 Day 1	0	54	88,5	51	94,4	79,74	22,44
	1	54	78,3	50	92,6	73,67	22,10
	2	5	33,3	5	100,0	60,00	14,91
Cycle 8 Day 1	0	52	85,2	48	92,3	77,08	20,81
	1	49	71,0	44	89,8	75,38	21,11
	2	5	33,3	5	100,0	53,33	36,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	78,23	22,62
	1	44	63,8	43	97,7	74,03	21,61
	2	4	26,7	4	100,0	79,17	15,96
Cycle 10 Day 1	0	46	75,4	46	100,0	79,71	22,75
	1	40	58,0	37	92,5	77,03	20,92
	2	3	20,0	3	100,0	55,56	19,25
Cycle 11 Day 1	0	43	70,5	41	95,3	77,24	23,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	71,57	23,40
	2	3	20,0	3	100,0	77,78	19,25
Cycle 12 Day 1	0	42	68,9	36	85,7	76,85	22,64
	1	31	44,9	30	96,8	77,78	21,14
	2	3	20,0	3	100,0	61,11	9,62
Cycle 13 Day 1	0	38	62,3	34	89,5	76,96	26,60
	1	27	39,1	27	100,0	78,40	26,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	66,67	-
Cycle 14 Day 1	0	35	57,4	32	91,4	71,35	27,51
	1	24	34,8	24	100,0	70,14	26,91
	2	1	6,7	1	100,0	33,33	-
Cycle 15 Day 1	0	33	54,1	30	90,9	73,89	27,57
	1	23	33,3	23	100,0	73,91	19,35
	2	1	6,7	1	100,0	16,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	76,00	24,09
	1	21	30,4	21	100,0	73,02	22,65
	2	1	6,7	1	100,0	33,33	-
Cycle 17 Day 1	0	24	39,3	23	95,8	76,09	23,48
	1	20	29,0	20	100,0	70,83	22,86
	2	1	6,7	1	100,0	33,33	-
Cycle 18 Day 1	0	23	37,7	19	82,6	78,07	22,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	73,53	17,74
	2	1	6,7	1	100,0	50,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	73,68	29,04
	1	15	21,7	13	86,7	71,79	21,93
	2	1	6,7	1	100,0	66,67	-
Cycle 20 Day 1	0	20	32,8	17	85,0	73,53	27,68
	1	15	21,7	14	93,3	71,43	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	50,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	75,00	26,75
	1	13	18,8	11	84,6	68,18	15,73
	2	1	6,7	1	100,0	66,67	-
Cycle 22 Day 1	0	15	24,6	12	80,0	73,61	27,94
	1	13	18,8	12	92,3	66,67	21,32
	2	1	6,7	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	74,07	31,30
	1	9	13,0	8	88,9	77,08	19,80
	2	1	6,7	1	100,0	33,33	-
Cycle 24 Day 1	0	10	16,4	9	90,0	81,48	24,22
	1	9	13,0	8	88,9	62,50	27,82
	2	1	6,7	1	100,0	33,33	-
Cycle 25 Day 1	0	8	13,1	6	75,0	75,00	25,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	66,67	33,33
Cycle 26 Day 1	0	8	13,1	6	75,0	86,11	22,15
	1	6	8,7	6	100,0	58,33	27,39
Cycle 27 Day 1	0	6	9,8	3	50,0	77,78	25,46
	1	5	7,2	5	100,0	63,33	38,01
Cycle 28 Day 1	0	5	8,2	4	80,0	79,17	15,96
	1	5	7,2	5	100,0	60,00	43,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	83,33	23,57
	1	5	7,2	5	100,0	70,00	21,73
Cycle 30 Day 1	0	3	4,9	1	33,3	100,00	-
	1	4	5,8	4	100,0	70,83	20,97
Cycle 31 Day 1	0	3	4,9	1	33,3	100,00	-
	1	4	5,8	4	100,0	66,67	0,00
Cycle 32 Day 1	0	3	4,9	2	66,7	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	77,78	19,25
Cycle 33 Day 1	0	2	3,3	2	100,0	83,33	23,57
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	57,14	35,19
	1	34	49,3	20	58,8	50,83	32,21
	2	7	46,7	3	42,9	44,44	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	62,78	29,33
	1	4	100,0	4	100,0	66,67	27,22
	2 or More	79	100,0	78	98,7	61,97	30,02
Cycle 2 Day 1	None	60	96,8	55	91,7	70,00	26,14
	1	3	75,0	2	66,7	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	65,22	27,97
Cycle 3 Day 1	None	59	95,2	53	89,8	72,01	22,83
	1	3	75,0	2	66,7	83,33	23,57
	2 or More	69	87,3	63	91,3	67,20	29,02
Cycle 4 Day 1	None	59	95,2	56	94,9	74,70	26,40
	1	3	75,0	2	66,7	83,33	23,57
	2 or More	66	83,5	62	93,9	70,70	26,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	76,49	24,57
	1	3	75,0	3	100,0	94,44	9,62
	2 or More	63	79,7	59	93,7	68,08	24,03
Cycle 6 Day 1	None	57	91,9	52	91,2	78,21	23,23
	1	3	75,0	3	100,0	88,89	19,25
	2 or More	61	77,2	57	93,4	69,01	24,08
Cycle 7 Day 1	None	52	83,9	50	96,2	81,00	22,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	88,89	19,25
	2 or More	58	73,4	53	91,4	70,44	21,09
Cycle 8 Day 1	None	50	80,6	46	92,0	77,54	22,28
	1	3	75,0	1	33,3	100,00	-
	2 or More	53	67,1	50	94,3	72,33	21,98
Cycle 9 Day 1	None	48	77,4	47	97,9	79,08	23,17
	1	1	25,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	73,61	20,58
Cycle 10 Day 1	None	43	69,4	41	95,3	83,33	19,72
	1	1	25,0	1	100,0	83,33	-
	2 or More	45	57,0	44	97,8	72,35	23,28
Cycle 11 Day 1	None	37	59,7	35	94,6	82,86	20,41
	1	1	25,0	1	100,0	100,00	-
	2 or More	42	53,2	42	100,0	67,46	23,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	83,33	20,10
	1	1	25,0	1	100,0	83,33	-
	2 or More	38	48,1	34	89,5	69,61	21,51
Cycle 13 Day 1	None	34	54,8	30	88,2	83,33	20,99
	1	1	25,0	1	100,0	100,00	-
	2 or More	31	39,2	31	100,0	70,97	29,18
Cycle 14 Day 1	None	31	50,0	29	93,5	77,59	24,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	83,33	-
	2 or More	28	35,4	27	96,4	61,73	28,43
Cycle 15 Day 1	None	30	48,4	28	93,3	80,36	21,30
	1	1	25,0	1	100,0	83,33	-
	2 or More	26	32,9	25	96,2	64,00	27,08
Cycle 16 Day 1	None	25	40,3	23	92,0	84,06	19,12
	1	1	25,0	1	100,0	83,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	63,04	24,08
Cycle 17 Day 1	None	23	37,1	22	95,7	81,82	17,75
	1	1	25,0	1	100,0	100,00	-
	2 or More	21	26,6	21	100,0	61,90	24,80
Cycle 18 Day 1	None	20	32,3	18	90,0	85,19	17,04
	1	1	25,0	1	100,0	100,00	-
	2 or More	20	25,3	18	90,0	63,89	18,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	81,37	19,44
	1	1	25,0	1	100,0	100,00	-
	2 or More	18	22,8	15	83,3	61,11	27,94
Cycle 20 Day 1	None	17	27,4	16	94,1	84,38	15,48
	1	1	25,0	1	100,0	83,33	-
	2 or More	18	22,8	15	83,3	57,78	23,46
Cycle 21 Day 1	None	15	24,2	13	86,7	83,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	60,26	21,01
Cycle 22 Day 1	None	15	24,2	13	86,7	82,05	20,93
	2 or More	14	17,7	12	85,7	56,94	20,67
Cycle 23 Day 1	None	10	16,1	9	90,0	85,19	19,44
	2 or More	11	13,9	9	81,8	61,11	28,87
Cycle 24 Day 1	None	10	16,1	10	100,0	86,67	23,31
	2 or More	10	12,7	8	80,0	50,00	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	85,42	16,52
	2 or More	6	7,6	5	83,3	46,67	29,81
Cycle 26 Day 1	None	8	12,9	8	100,0	79,17	31,81
	2 or More	6	7,6	4	66,7	58,33	9,62
Cycle 27 Day 1	None	7	11,3	6	85,7	69,44	38,61
	2 or More	4	5,1	2	50,0	66,67	0,00
Cycle 28 Day 1	None	7	11,3	7	100,0	78,57	24,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	33,33	47,14
Cycle 29 Day 1	None	6	9,7	5	83,3	76,67	22,36
	2 or More	3	3,8	2	66,7	66,67	23,57
Cycle 30 Day 1	None	4	6,5	3	75,0	88,89	19,25
	2 or More	3	3,8	2	66,7	58,33	11,79
Cycle 31 Day 1	None	4	6,5	3	75,0	77,78	19,25
	2 or More	3	3,8	2	66,7	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	88,89	19,25
	2 or More	2	2,5	2	100,0	66,67	0,00
Cycle 33 Day 1	None	1	1,6	1	100,0	100,00	-
	2 or More	1	1,3	1	100,0	66,67	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	57,02	35,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	66,67	-
	2 or More	39	49,4	24	61,5	50,00	31,08
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	62,78	29,33
	Previously Treated	83	100,0	82	98,8	62,20	29,75
Cycle 2 Day 1	Naïve	60	96,8	55	91,7	70,00	26,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	65,73	27,87
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	72,01	22,83
	Previously Treated	72	86,7	65	90,3	67,69	28,85
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	74,70	26,40
	Previously Treated	69	83,1	64	92,8	71,09	26,10
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	76,49	24,57
	Previously Treated	66	79,5	62	93,9	69,35	24,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	78,21	23,23
	Previously Treated	64	77,1	60	93,8	70,00	24,12
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	81,00	22,59
	Previously Treated	61	73,5	56	91,8	71,43	21,25
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	77,54	22,28
	Previously Treated	56	67,5	51	91,1	72,88	22,10
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	79,08	23,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	73,81	20,41
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	83,33	19,72
	Previously Treated	46	55,4	45	97,8	72,59	23,07
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	82,86	20,41
	Previously Treated	43	51,8	43	100,0	68,22	23,52
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	83,33	20,10
	Previously Treated	39	47,0	35	89,7	70,00	21,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	83,33	20,99
	Previously Treated	32	38,6	32	100,0	71,88	29,16
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	77,59	24,51
	Previously Treated	29	34,9	28	96,6	62,50	28,19
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	80,36	21,30
	Previously Treated	27	32,5	26	96,3	64,74	26,80
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	84,06	19,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	63,89	23,91
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	81,82	17,75
	Previously Treated	22	26,5	22	100,0	63,64	25,53
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	85,19	17,04
	Previously Treated	21	25,3	19	90,5	65,79	19,62
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	81,37	19,44
	Previously Treated	19	22,9	16	84,2	63,54	28,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	84,38	15,48
	Previously Treated	19	22,9	16	84,2	59,38	23,55
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	83,33	16,67
	Previously Treated	14	16,9	13	92,9	60,26	21,01
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	82,05	20,93
	Previously Treated	14	16,9	12	85,7	56,94	20,67
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	85,19	19,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	61,11	28,87
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	86,67	23,31
	Previously Treated	10	12,0	8	80,0	50,00	17,82
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	85,42	16,52
	Previously Treated	6	7,2	5	83,3	46,67	29,81
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	79,17	31,81
	Previously Treated	6	7,2	4	66,7	58,33	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	69,44	38,61
	Previously Treated	4	4,8	2	50,0	66,67	0,00
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	78,57	24,93
	Previously Treated	3	3,6	2	66,7	33,33	47,14
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	76,67	22,36
	Previously Treated	3	3,6	2	66,7	66,67	23,57
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	88,89	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	58,33	11,79
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	77,78	19,25
	Previously Treated	3	3,6	2	66,7	66,67	0,00
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	88,89	19,25
	Previously Treated	2	2,4	2	100,0	66,67	0,00
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	100,00	-
	Previously Treated	1	1,2	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	57,02	35,71
	Previously Treated	42	50,6	25	59,5	50,67	30,61
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	62,00	28,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	62,94	30,40
Cycle 2 Day 1	Local	71	94,7	67	94,4	68,41	26,29
	Central	65	92,9	59	90,8	66,67	28,20
Cycle 3 Day 1	Local	67	89,3	62	92,5	68,01	26,19
	Central	64	91,4	56	87,5	71,43	26,54
Cycle 4 Day 1	Local	65	86,7	61	93,8	71,86	27,48
	Central	63	90,0	59	93,7	73,73	24,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	72,60	27,29
	Central	61	87,1	59	96,7	72,88	21,64
Cycle 6 Day 1	Local	63	84,0	61	96,8	75,14	25,57
	Central	58	82,9	51	87,9	72,22	22,03
Cycle 7 Day 1	Local	61	81,3	59	96,7	75,71	22,81
	Central	52	74,3	47	90,4	76,24	21,91
Cycle 8 Day 1	Local	57	76,0	55	96,5	78,18	21,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	71,03	23,01
Cycle 9 Day 1	Local	54	72,0	53	98,1	78,30	22,78
	Central	44	62,9	43	97,7	74,03	20,67
Cycle 10 Day 1	Local	48	64,0	46	95,8	77,90	23,06
	Central	41	58,6	40	97,6	77,50	21,20
Cycle 11 Day 1	Local	40	53,3	38	95,0	73,25	25,27
	Central	40	57,1	40	100,0	76,25	21,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	77,27	20,76
	Central	40	57,1	36	90,0	75,93	22,69
Cycle 13 Day 1	Local	30	40,0	29	96,7	82,18	24,37
	Central	36	51,4	33	91,7	73,23	26,98
Cycle 14 Day 1	Local	27	36,0	27	100,0	72,22	29,60
	Central	33	47,1	30	90,9	68,33	25,28
Cycle 15 Day 1	Local	26	34,7	25	96,2	78,67	28,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	67,82	21,33
Cycle 16 Day 1	Local	24	32,0	24	100,0	77,08	24,48
	Central	26	37,1	23	88,5	70,29	23,00
Cycle 17 Day 1	Local	22	29,3	22	100,0	78,79	21,93
	Central	23	32,9	22	95,7	66,67	24,12
Cycle 18 Day 1	Local	20	26,7	19	95,0	79,82	18,07
	Central	21	30,0	18	85,7	70,37	22,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	77,45	20,36
	Central	17	24,3	16	94,1	67,71	30,10
Cycle 20 Day 1	Local	19	25,3	17	89,5	78,43	18,41
	Central	17	24,3	15	88,2	64,44	26,63
Cycle 21 Day 1	Local	14	18,7	12	85,7	79,17	16,09
	Central	15	21,4	14	93,3	65,48	24,86
Cycle 22 Day 1	Local	14	18,7	12	85,7	80,56	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	60,26	25,94
Cycle 23 Day 1	Local	11	14,7	10	90,9	81,67	22,84
	Central	10	14,3	8	80,0	62,50	29,21
Cycle 24 Day 1	Local	11	14,7	10	90,9	80,00	28,11
	Central	9	12,9	8	88,9	58,33	23,57
Cycle 25 Day 1	Local	7	9,3	7	100,0	83,33	25,46
	Central	8	11,4	6	75,0	55,56	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	83,33	25,82
	Central	8	11,4	6	75,0	61,11	27,22
Cycle 27 Day 1	Local	4	5,3	4	100,0	91,67	9,62
	Central	7	10,0	4	57,1	45,83	31,55
Cycle 28 Day 1	Local	4	5,3	4	100,0	70,83	28,46
	Central	6	8,6	5	83,3	66,67	40,82
Cycle 29 Day 1	Local	3	4,0	3	100,0	83,33	28,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	66,67	13,61
Cycle 30 Day 1	Local	3	4,0	3	100,0	88,89	19,25
	Central	4	5,7	2	50,0	58,33	11,79
Cycle 31 Day 1	Local	3	4,0	3	100,0	77,78	19,25
	Central	4	5,7	2	50,0	66,67	0,00
Cycle 32 Day 1	Local	3	4,0	3	100,0	88,89	19,25
	Central	3	4,3	2	66,7	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	100,00	-
	Central	1	1,4	1	100,0	66,67	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	53,47	32,96
	Central	32	45,7	20	62,5	53,33	33,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	63,38	29,01
	No	10	100,0	10	100,0	50,00	34,25
Cycle 2 Day 1	Yes	129	95,6	119	92,2	69,05	26,51
	No	7	70,0	7	100,0	42,86	26,97
Cycle 3 Day 1	Yes	124	91,9	112	90,3	70,39	26,54
	No	7	70,0	6	85,7	55,56	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	73,60	26,04
	No	7	70,0	7	100,0	59,52	26,97
Cycle 5 Day 1	Yes	117	86,7	112	95,7	74,40	23,67
	No	7	70,0	6	85,7	41,67	20,41
Cycle 6 Day 1	Yes	114	84,4	105	92,1	75,40	23,24
	No	7	70,0	7	100,0	50,00	23,57
Cycle 7 Day 1	Yes	106	78,5	99	93,4	77,61	20,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	52,38	36,55
Cycle 8 Day 1	Yes	100	74,1	91	91,0	76,37	21,81
	No	6	60,0	6	100,0	55,56	20,18
Cycle 9 Day 1	Yes	92	68,1	90	97,8	77,41	21,68
	No	6	60,0	6	100,0	61,11	20,18
Cycle 10 Day 1	Yes	83	61,5	80	96,4	78,54	21,90
	No	6	60,0	6	100,0	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	74,55	23,61
	No	4	40,0	4	100,0	79,17	15,96
Cycle 12 Day 1	Yes	72	53,3	65	90,3	76,92	22,18
	No	4	40,0	4	100,0	70,83	8,33
Cycle 13 Day 1	Yes	64	47,4	60	93,8	77,78	26,34
	No	2	20,0	2	100,0	66,67	0,00
Cycle 14 Day 1	Yes	58	43,0	55	94,8	70,61	27,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	58,33	11,79
Cycle 15 Day 1	Yes	55	40,7	52	94,5	73,72	24,99
	No	2	20,0	2	100,0	50,00	23,57
Cycle 16 Day 1	Yes	48	35,6	45	93,8	74,44	23,99
	No	2	20,0	2	100,0	58,33	11,79
Cycle 17 Day 1	Yes	43	31,9	42	97,7	73,41	23,87
	No	2	20,0	2	100,0	58,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	76,19	20,72
	No	2	20,0	2	100,0	58,33	11,79
Cycle 19 Day 1	Yes	34	25,2	32	94,1	72,92	26,01
	No	2	20,0	1	50,0	66,67	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	73,33	22,99
	No	2	20,0	2	100,0	50,00	23,57
Cycle 21 Day 1	Yes	27	20,0	24	88,9	72,22	22,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	66,67	0,00
Cycle 22 Day 1	Yes	27	20,0	23	85,2	70,29	25,10
	No	2	20,0	2	100,0	66,67	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	71,57	26,85
	No	1	10,0	1	100,0	100,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	68,63	27,56
	No	1	10,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	68,06	28,83
	No	1	10,0	1	100,0	100,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	74,24	28,25
	No	1	10,0	1	100,0	50,00	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	66,67	34,69
	No	1	10,0	1	100,0	83,33	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	72,92	33,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	77,78	20,18
	No	1	10,0	1	100,0	50,00	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	79,17	25,00
	No	1	10,0	1	100,0	66,67	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	75,00	16,67
	No	1	10,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	83,33	19,25
	No	1	10,0	1	100,0	66,67	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	83,33	23,57
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	53,88	32,90
	No	2	20,0	1	50,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	48,48	30,23
	No	134	100,0	131	97,8	63,61	29,22
Cycle 2 Day 1	Yes	7	63,6	7	100,0	66,67	38,49
	No	129	96,3	119	92,2	67,65	26,51
Cycle 3 Day 1	Yes	7	63,6	7	100,0	73,81	18,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	69,37	26,74
Cycle 4 Day 1	Yes	7	63,6	7	100,0	76,19	25,20
	No	121	90,3	113	93,4	72,57	26,34
Cycle 5 Day 1	Yes	7	63,6	7	100,0	69,05	29,55
	No	117	87,3	111	94,9	72,97	24,31
Cycle 6 Day 1	Yes	7	63,6	7	100,0	76,19	25,20
	No	114	85,1	105	92,1	73,65	23,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	73,81	26,97
	No	106	79,1	99	93,4	76,09	22,10
Cycle 8 Day 1	Yes	7	63,6	7	100,0	61,90	24,93
	No	99	73,9	90	90,9	76,11	21,79
Cycle 9 Day 1	Yes	6	54,5	6	100,0	66,67	21,08
	No	92	68,7	90	97,8	77,04	21,86
Cycle 10 Day 1	Yes	6	54,5	6	100,0	66,67	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	78,54	22,06
Cycle 11 Day 1	Yes	6	54,5	6	100,0	61,11	25,09
	No	74	55,2	72	97,3	75,93	22,88
Cycle 12 Day 1	Yes	6	54,5	6	100,0	75,00	25,28
	No	70	52,2	63	90,0	76,72	21,49
Cycle 13 Day 1	Yes	5	45,5	5	100,0	73,33	27,89
	No	61	45,5	57	93,4	77,78	26,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	66,67	35,36
	No	55	41,0	52	94,5	70,51	26,74
Cycle 15 Day 1	Yes	4	36,4	4	100,0	62,50	28,46
	No	53	39,6	50	94,3	73,67	24,99
Cycle 16 Day 1	Yes	3	27,3	3	100,0	77,78	19,25
	No	47	35,1	44	93,6	73,48	24,20
Cycle 17 Day 1	Yes	3	27,3	3	100,0	77,78	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	72,36	24,04
Cycle 18 Day 1	Yes	3	27,3	3	100,0	77,78	19,25
	No	38	28,4	34	89,5	75,00	21,02
Cycle 19 Day 1	Yes	3	27,3	3	100,0	77,78	19,25
	No	33	24,6	30	90,9	72,22	26,38
Cycle 20 Day 1	Yes	3	27,3	3	100,0	77,78	19,25
	No	33	24,6	29	87,9	71,26	23,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	66,67	0,00
	No	27	20,1	24	88,9	72,22	22,88
Cycle 22 Day 1	Yes	2	18,2	2	100,0	66,67	0,00
	No	27	20,1	23	85,2	70,29	25,10
Cycle 23 Day 1	Yes	2	18,2	2	100,0	66,67	0,00
	No	19	14,2	16	84,2	73,96	28,52
Cycle 24 Day 1	Yes	2	18,2	2	100,0	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	70,83	29,50
Cycle 25 Day 1	Yes	2	18,2	2	100,0	66,67	0,00
	No	13	9,7	11	84,6	71,21	31,70
Cycle 26 Day 1	Yes	1	9,1	1	100,0	66,67	-
	No	13	9,7	11	84,6	72,73	29,13
Cycle 27 Day 1	Yes	1	9,1	1	100,0	50,00	-
	No	10	7,5	7	70,0	71,43	34,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	66,67	-
	No	9	6,7	8	88,9	68,75	36,12
Cycle 29 Day 1	Yes	1	9,1	1	100,0	66,67	-
	No	8	6,0	6	75,0	75,00	22,97
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	76,67	22,36
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	73,33	14,91
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	80,00	18,26
Cycle 33 Day 1	No	2	1,5	2	100,0	83,33	23,57
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	33,33	28,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	54,88	32,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30RF_SG.xls
24JUN2020 20:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	65,02	28,79
Cycle 2 Day 1	All	136	93,8	125	91,9	70,93	25,21
Cycle 3 Day 1	All	131	90,3	118	90,1	74,58	24,14
Cycle 4 Day 1	All	128	88,3	120	93,8	77,08	24,92
Cycle 5 Day 1	All	124	85,5	118	95,2	76,55	24,48
Cycle 6 Day 1	All	121	83,4	112	92,6	78,57	21,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	76,89	26,28
Cycle 8 Day 1	All	106	73,1	97	91,5	83,16	21,31
Cycle 9 Day 1	All	98	67,6	96	98,0	80,73	21,94
Cycle 10 Day 1	All	89	61,4	86	96,6	80,04	21,82
Cycle 11 Day 1	All	80	55,2	78	97,5	82,05	22,60
Cycle 12 Day 1	All	76	52,4	69	90,8	78,74	24,40
Cycle 13 Day 1	All	66	45,5	62	93,9	80,11	23,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	75,44	26,93
Cycle 15 Day 1	All	57	39,3	54	94,7	79,63	22,59
Cycle 16 Day 1	All	50	34,5	47	94,0	76,60	25,22
Cycle 17 Day 1	All	45	31,0	44	97,8	79,17	23,33
Cycle 18 Day 1	All	41	28,3	37	90,2	77,48	22,30
Cycle 19 Day 1	All	36	24,8	33	91,7	77,27	24,23
Cycle 20 Day 1	All	36	24,8	32	88,9	76,04	22,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	75,00	23,21
Cycle 22 Day 1	All	29	20,0	25	86,2	75,33	25,51
Cycle 23 Day 1	All	21	14,5	18	85,7	74,07	28,71
Cycle 24 Day 1	All	20	13,8	18	90,0	80,56	20,01
Cycle 25 Day 1	All	15	10,3	13	86,7	80,77	21,35
Cycle 26 Day 1	All	14	9,7	12	85,7	76,39	27,94
Cycle 27 Day 1	All	11	7,6	8	72,7	83,33	19,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	87,04	16,20
Cycle 29 Day 1	All	9	6,2	7	77,8	83,33	16,67
Cycle 30 Day 1	All	7	4,8	5	71,4	70,00	24,72
Cycle 31 Day 1	All	7	4,8	5	71,4	80,00	18,26
Cycle 32 Day 1	All	6	4,1	5	83,3	80,00	18,26
Cycle 33 Day 1	All	2	1,4	2	100,0	83,33	23,57
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	63,26	29,98
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	64,05	29,13
	Female	93	100,0	91	97,8	65,57	28,74
Cycle 2 Day 1	Male	50	96,2	46	92,0	68,48	26,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	72,36	24,30
Cycle 3 Day 1	Male	47	90,4	42	89,4	76,19	26,58
	Female	84	90,3	76	90,5	73,68	22,81
Cycle 4 Day 1	Male	46	88,5	45	97,8	78,52	27,44
	Female	82	88,2	75	91,5	76,22	23,44
Cycle 5 Day 1	Male	45	86,5	43	95,6	71,71	27,59
	Female	79	84,9	75	94,9	79,33	22,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	76,83	21,04
	Female	76	81,7	71	93,4	79,58	21,49
Cycle 7 Day 1	Male	40	76,9	39	97,5	76,07	28,56
	Female	73	78,5	67	91,8	77,36	25,08
Cycle 8 Day 1	Male	37	71,2	34	91,9	85,29	19,58
	Female	69	74,2	63	91,3	82,01	22,26
Cycle 9 Day 1	Male	33	63,5	33	100,0	83,33	21,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	79,37	22,14
Cycle 10 Day 1	Male	30	57,7	30	100,0	77,78	22,88
	Female	59	63,4	56	94,9	81,25	21,33
Cycle 11 Day 1	Male	29	55,8	29	100,0	84,48	19,38
	Female	51	54,8	49	96,1	80,61	24,38
Cycle 12 Day 1	Male	27	51,9	26	96,3	82,69	20,27
	Female	49	52,7	43	87,8	76,36	26,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	83,33	20,10
	Female	41	44,1	39	95,1	78,21	25,98
Cycle 14 Day 1	Male	23	44,2	21	91,3	75,40	28,20
	Female	37	39,8	36	97,3	75,46	26,57
Cycle 15 Day 1	Male	21	40,4	20	95,2	80,00	21,36
	Female	36	38,7	34	94,4	79,41	23,59
Cycle 16 Day 1	Male	16	30,8	16	100,0	78,13	24,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	75,81	25,76
Cycle 17 Day 1	Male	13	25,0	13	100,0	82,05	20,93
	Female	32	34,4	31	96,9	77,96	24,49
Cycle 18 Day 1	Male	12	23,1	11	91,7	81,82	17,41
	Female	29	31,2	26	89,7	75,64	24,14
Cycle 19 Day 1	Male	10	19,2	10	100,0	80,00	23,31
	Female	26	28,0	23	88,5	76,09	25,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	85,19	17,57
	Female	26	28,0	23	88,5	72,46	23,89
Cycle 21 Day 1	Male	8	15,4	8	100,0	77,08	25,10
	Female	21	22,6	18	85,7	74,07	23,02
Cycle 22 Day 1	Male	8	15,4	6	75,0	72,22	25,09
	Female	21	22,6	19	90,5	76,32	26,24
Cycle 23 Day 1	Male	5	9,6	4	80,0	75,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	73,81	29,03
Cycle 24 Day 1	Male	5	9,6	4	80,0	70,83	28,46
	Female	15	16,1	14	93,3	83,33	17,30
Cycle 25 Day 1	Male	3	5,8	2	66,7	100,00	0,00
	Female	12	12,9	11	91,7	77,27	21,44
Cycle 26 Day 1	Male	3	5,8	2	66,7	100,00	0,00
	Female	11	11,8	10	90,9	71,67	28,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	100,00	0,00
	Female	8	8,6	6	75,0	77,78	20,18
Cycle 28 Day 1	Male	2	3,8	2	100,0	100,00	0,00
	Female	8	8,6	7	87,5	83,33	16,67
Cycle 29 Day 1	Male	1	1,9	1	100,0	100,00	-
	Female	8	8,6	6	75,0	80,56	16,39
Cycle 30 Day 1	Male	1	1,9	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	79,17	15,96
Cycle 31 Day 1	Male	1	1,9	1	100,0	100,00	-
	Female	6	6,5	4	66,7	75,00	16,67
Cycle 32 Day 1	Male	1	1,9	1	100,0	100,00	-
	Female	5	5,4	4	80,0	75,00	16,67
Cycle 33 Day 1	Male	1	1,9	1	100,0	100,00	-
	Female	1	1,1	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	54,76	30,80
	Female	37	39,8	23	62,2	71,01	27,62
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	63,36	28,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	69,54	30,23
	>=75	7	100,0	7	100,0	71,43	29,99
Cycle 2 Day 1	18-64	103	94,5	93	90,3	71,15	25,67
	65-74	26	89,7	25	96,2	70,67	25,13
	>=75	7	100,0	7	100,0	69,05	22,42
Cycle 3 Day 1	18-64	99	90,8	87	87,9	75,10	23,00
	65-74	25	86,2	24	96,0	72,22	28,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	76,19	23,29
Cycle 4 Day 1	18-64	98	89,9	92	93,9	76,27	25,82
	65-74	23	79,3	21	91,3	80,16	21,49
	>=75	7	100,0	7	100,0	78,57	24,93
Cycle 5 Day 1	18-64	95	87,2	90	94,7	75,56	25,01
	65-74	22	75,9	22	100,0	80,30	22,20
	>=75	7	100,0	6	85,7	77,78	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	78,37	22,22
	65-74	22	75,9	21	95,5	80,16	19,45
	>=75	7	100,0	7	100,0	76,19	16,27
Cycle 7 Day 1	18-64	86	78,9	81	94,2	74,90	26,76
	65-74	20	69,0	19	95,0	85,09	19,95
	>=75	7	100,0	6	85,7	77,78	36,00
Cycle 8 Day 1	18-64	80	73,4	72	90,0	81,25	23,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	88,60	14,75
	>=75	7	100,0	6	85,7	88,89	13,61
Cycle 9 Day 1	18-64	74	67,9	73	98,6	80,14	22,34
	65-74	18	62,1	18	100,0	83,33	19,80
	>=75	6	85,7	5	83,3	80,00	27,39
Cycle 10 Day 1	18-64	69	63,3	66	95,7	79,55	21,84
	65-74	15	51,7	15	100,0	82,22	21,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	80,00	27,39
Cycle 11 Day 1	18-64	61	56,0	59	96,7	79,94	24,13
	65-74	15	51,7	15	100,0	86,67	16,90
	>=75	4	57,1	4	100,0	95,83	8,33
Cycle 12 Day 1	18-64	57	52,3	51	89,5	76,80	25,18
	65-74	15	51,7	14	93,3	82,14	23,08
	>=75	4	57,1	4	100,0	91,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	80,07	23,21
	65-74	13	44,8	12	92,3	76,39	28,83
	>=75	4	57,1	4	100,0	91,67	16,67
Cycle 14 Day 1	18-64	45	41,3	44	97,8	75,76	27,25
	65-74	13	44,8	11	84,6	72,73	28,16
	>=75	2	28,6	2	100,0	83,33	23,57
Cycle 15 Day 1	18-64	43	39,4	41	95,3	80,08	22,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	77,27	25,03
	>=75	2	28,6	2	100,0	83,33	23,57
Cycle 16 Day 1	18-64	38	34,9	36	94,7	74,54	27,45
	65-74	10	34,5	9	90,0	83,33	14,43
	>=75	2	28,6	2	100,0	83,33	23,57
Cycle 17 Day 1	18-64	36	33,0	35	97,2	79,52	23,25
	65-74	8	27,6	8	100,0	83,33	19,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	33,33	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	80,00	22,49
	65-74	7	24,1	6	85,7	69,44	19,48
	>=75	1	14,3	1	100,0	50,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	80,95	23,00
	65-74	5	17,2	4	80,0	62,50	20,97
	>=75	1	14,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	79,49	22,76
	65-74	5	17,2	5	100,0	60,00	19,00
	>=75	1	14,3	1	100,0	66,67	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	76,98	23,85
	65-74	4	13,8	4	100,0	75,00	9,62
	>=75	1	14,3	1	100,0	33,33	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	79,17	25,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	66,67	13,61
	>=75	1	14,3	1	100,0	33,33	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	75,00	30,43
	65-74	2	6,9	2	100,0	66,67	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	81,25	20,97
	65-74	2	6,9	2	100,0	75,00	11,79
Cycle 25 Day 1	18-64	14	12,8	12	85,7	81,94	21,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	66,67	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	76,39	27,94
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	83,33	19,92
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	87,04	16,20
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	83,33	16,67
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	70,00	24,72
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	80,00	18,26
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	83,33	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	66,67	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	100,00	-
	65-74	1	3,4	1	100,0	66,67	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	62,75	31,26
	65-74	15	51,7	8	53,3	64,58	24,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	66,67	47,14
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	59,20	29,48
	Other	85	100,0	84	98,8	69,05	27,76
Cycle 2 Day 1	White	57	95,0	50	87,7	64,67	26,22
	Other	79	92,9	75	94,9	75,11	23,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	71,59	25,31
	Other	77	90,6	74	96,1	76,35	23,41
Cycle 4 Day 1	White	53	88,3	47	88,7	74,11	27,32
	Other	75	88,2	73	97,3	79,00	23,25
Cycle 5 Day 1	White	52	86,7	48	92,3	75,35	26,41
	Other	72	84,7	70	97,2	77,38	23,23
Cycle 6 Day 1	White	50	83,3	44	88,0	79,92	22,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	77,70	20,89
Cycle 7 Day 1	White	47	78,3	42	89,4	76,98	27,53
	Other	66	77,6	64	97,0	76,82	25,65
Cycle 8 Day 1	White	45	75,0	39	86,7	79,91	23,31
	Other	61	71,8	58	95,1	85,34	19,76
Cycle 9 Day 1	White	42	70,0	41	97,6	80,89	22,22
	Other	56	65,9	55	98,2	80,61	21,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	76,92	24,07
	Other	48	56,5	47	97,9	82,62	19,65
Cycle 11 Day 1	White	37	61,7	37	100,0	81,08	25,81
	Other	43	50,6	41	95,3	82,93	19,54
Cycle 12 Day 1	White	37	61,7	33	89,2	78,79	26,77
	Other	39	45,9	36	92,3	78,70	22,40
Cycle 13 Day 1	White	32	53,3	30	93,8	78,33	29,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	81,77	18,14
Cycle 14 Day 1	White	31	51,7	30	96,8	77,78	28,81
	Other	29	34,1	27	93,1	72,84	24,96
Cycle 15 Day 1	White	30	50,0	28	93,3	79,17	26,69
	Other	27	31,8	26	96,3	80,13	17,65
Cycle 16 Day 1	White	26	43,3	24	92,3	73,61	30,26
	Other	24	28,2	23	95,8	79,71	18,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	79,17	28,34
	Other	21	24,7	20	95,2	79,17	16,11
Cycle 18 Day 1	White	22	36,7	19	86,4	79,82	25,81
	Other	19	22,4	18	94,7	75,00	18,30
Cycle 19 Day 1	White	20	33,3	20	100,0	77,50	29,26
	Other	16	18,8	13	81,3	76,92	14,50
Cycle 20 Day 1	White	20	33,3	17	85,0	77,45	28,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	74,44	15,26
Cycle 21 Day 1	White	16	26,7	14	87,5	73,81	29,03
	Other	13	15,3	12	92,3	76,39	15,01
Cycle 22 Day 1	White	16	26,7	13	81,3	75,64	32,36
	Other	13	15,3	12	92,3	75,00	16,67
Cycle 23 Day 1	White	12	20,0	10	83,3	71,67	33,38
	Other	9	10,6	8	88,9	77,08	23,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	80,00	17,21
	Other	9	10,6	8	88,9	81,25	24,30
Cycle 25 Day 1	White	10	16,7	8	80,0	77,08	23,46
	Other	5	5,9	5	100,0	86,67	18,26
Cycle 26 Day 1	White	10	16,7	8	80,0	75,00	30,86
	Other	4	4,7	4	100,0	79,17	25,00
Cycle 27 Day 1	White	8	13,3	5	62,5	90,00	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	72,22	25,46
Cycle 28 Day 1	White	7	11,7	6	85,7	91,67	13,94
	Other	3	3,5	3	100,0	77,78	19,25
Cycle 29 Day 1	White	6	10,0	4	66,7	87,50	15,96
	Other	3	3,5	3	100,0	77,78	19,25
Cycle 30 Day 1	White	4	6,7	2	50,0	66,67	47,14
	Other	3	3,5	3	100,0	72,22	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	100,00	0,00
	Other	3	3,5	3	100,0	66,67	0,00
Cycle 32 Day 1	White	4	6,7	3	75,0	88,89	19,25
	Other	2	2,4	2	100,0	66,67	0,00
Cycle 33 Day 1	White	2	3,3	2	100,0	83,33	23,57
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	55,88	31,70
	Other	39	45,9	27	69,2	67,90	28,47
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	61,67	28,29
	Europe (EU)	34	100,0	31	91,2	69,35	27,59
	Asia (AS)	71	100,0	71	100,0	65,02	29,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	70,83	25,75
	Europe (EU)	32	94,1	28	87,5	70,24	26,59
	Asia (AS)	66	93,0	65	98,5	71,28	24,74
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	71,72	24,82
	Europe (EU)	31	91,2	22	71,0	73,48	24,48
	Asia (AS)	63	88,7	63	100,0	76,46	23,88
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	75,98	23,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	75,33	28,10
	Asia (AS)	61	85,9	61	100,0	78,42	24,60
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	77,62	23,55
	Europe (EU)	30	88,2	26	86,7	73,08	29,84
	Asia (AS)	57	80,3	57	100,0	77,49	22,60
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	82,86	21,57
	Europe (EU)	28	82,4	25	89,3	74,00	23,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	77,88	20,00
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	77,60	27,31
	Europe (EU)	28	82,4	25	89,3	75,33	31,59
	Asia (AS)	50	70,4	49	98,0	77,21	23,00
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	88,27	19,51
	Europe (EU)	28	82,4	23	82,1	78,99	24,73
	Asia (AS)	47	66,2	47	100,0	82,27	20,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	83,33	21,28
	Europe (EU)	26	76,5	25	96,2	81,33	22,22
	Asia (AS)	43	60,6	43	100,0	78,68	22,52
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	84,03	21,13
	Europe (EU)	25	73,5	25	100,0	73,33	25,46
	Asia (AS)	37	52,1	37	100,0	81,98	18,99
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	79,71	27,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	84,09	22,70
	Asia (AS)	33	46,5	33	100,0	82,32	19,07
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	81,88	27,94
	Europe (EU)	23	67,6	18	78,3	77,78	22,87
	Asia (AS)	29	40,8	28	96,6	76,79	22,83
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	83,33	26,23
	Europe (EU)	18	52,9	15	83,3	75,56	28,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	80,00	19,25
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	81,75	28,34
	Europe (EU)	17	50,0	16	94,1	68,75	32,70
	Asia (AS)	21	29,6	20	95,2	74,17	19,10
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	85,83	26,09
	Europe (EU)	15	44,1	14	93,3	75,00	26,75
	Asia (AS)	20	28,2	20	100,0	76,67	13,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	77,45	33,82
	Europe (EU)	14	41,2	11	78,6	74,24	25,13
	Asia (AS)	19	26,8	19	100,0	77,19	15,92
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	79,17	31,33
	Europe (EU)	13	38,2	12	92,3	81,94	20,67
	Asia (AS)	16	22,5	16	100,0	77,08	15,96
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	83,33	27,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	76,19	18,90
	Asia (AS)	16	22,5	16	100,0	72,92	18,13
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	82,05	30,02
	Europe (EU)	9	26,5	9	100,0	72,22	26,35
	Asia (AS)	14	19,7	11	78,6	75,76	13,67
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	80,77	28,74
	Europe (EU)	9	26,5	6	66,7	72,22	25,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	73,08	14,50
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	78,33	30,48
	Europe (EU)	7	20,6	6	85,7	66,67	21,08
	Asia (AS)	11	15,5	10	90,9	76,67	16,10
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	78,33	33,38
	Europe (EU)	7	20,6	5	71,4	73,33	27,89
	Asia (AS)	11	15,5	10	90,9	73,33	16,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	70,37	35,14
	Europe (EU)	5	14,7	3	60,0	77,78	19,25
	Asia (AS)	7	9,9	6	85,7	77,78	25,09
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	81,25	16,52
	Europe (EU)	5	14,7	4	80,0	83,33	19,25
	Asia (AS)	7	9,9	6	85,7	77,78	27,22
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	80,95	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	66,67	0,00
	Asia (AS)	4	5,6	4	100,0	87,50	15,96
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	77,78	36,00
	Europe (EU)	4	11,8	2	50,0	83,33	23,57
	Asia (AS)	4	5,6	4	100,0	70,83	20,97
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	95,83	8,33
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	70,83	20,97
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	95,83	8,33
	Europe (EU)	2	5,9	1	50,0	100,00	-
	Asia (AS)	4	5,6	4	100,0	75,00	16,67
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	94,44	9,62
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	75,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	66,67	47,14
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	72,22	9,62
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	100,00	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	66,67	0,00
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	100,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	66,67	-
	Asia (AS)	3	4,2	2	66,7	66,67	0,00
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	100,00	-
	Europe (EU)	1	2,9	1	100,0	66,67	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	56,86	29,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	46,67	29,81
	Asia (AS)	34	47,9	22	64,7	71,97	28,82
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	76,94	21,72
	1	69	100,0	67	97,1	60,70	28,97
	2	15	100,0	15	100,0	36,67	29,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	55	93,2	74,85	27,57
	1	67	97,1	60	89,6	67,78	23,74
	2	10	66,7	10	100,0	68,33	18,34
Cycle 3 Day 1	0	57	93,4	51	89,5	76,14	26,93
	1	65	94,2	58	89,2	75,00	21,91
	2	9	60,0	9	100,0	62,96	20,03
Cycle 4 Day 1	0	57	93,4	54	94,7	78,40	27,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	77,30	20,16
	2	9	60,0	8	88,9	66,67	34,50
Cycle 5 Day 1	0	56	91,8	53	94,6	79,25	22,86
	1	62	89,9	59	95,2	75,42	24,83
	2	6	40,0	6	100,0	63,89	34,02
Cycle 6 Day 1	0	56	91,8	54	96,4	78,40	21,87
	1	59	85,5	53	89,8	78,93	20,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	76,67	27,89
Cycle 7 Day 1	0	54	88,5	51	94,4	81,05	23,57
	1	54	78,3	50	92,6	74,00	27,39
	2	5	33,3	5	100,0	63,33	38,01
Cycle 8 Day 1	0	52	85,2	48	92,3	85,07	20,12
	1	49	71,0	44	89,8	83,33	20,01
	2	5	33,3	5	100,0	63,33	36,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	82,99	20,55
	1	44	63,8	43	97,7	77,91	23,77
	2	4	26,7	4	100,0	83,33	19,25
Cycle 10 Day 1	0	46	75,4	46	100,0	80,07	22,39
	1	40	58,0	37	92,5	80,18	21,81
	2	3	20,0	3	100,0	77,78	19,25
Cycle 11 Day 1	0	43	70,5	41	95,3	82,52	23,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	80,88	22,15
	2	3	20,0	3	100,0	88,89	19,25
Cycle 12 Day 1	0	42	68,9	36	85,7	79,17	25,00
	1	31	44,9	30	96,8	78,89	25,12
	2	3	20,0	3	100,0	72,22	9,62
Cycle 13 Day 1	0	38	62,3	34	89,5	80,88	25,99
	1	27	39,1	27	100,0	79,63	21,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	66,67	-
Cycle 14 Day 1	0	35	57,4	32	91,4	75,52	28,08
	1	24	34,8	24	100,0	75,69	26,46
	2	1	6,7	1	100,0	66,67	-
Cycle 15 Day 1	0	33	54,1	30	90,9	81,11	24,66
	1	23	33,3	23	100,0	78,26	20,37
	2	1	6,7	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	76,00	30,46
	1	21	30,4	21	100,0	76,19	17,93
	2	1	6,7	1	100,0	100,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	80,43	23,92
	1	20	29,0	20	100,0	77,50	23,74
	2	1	6,7	1	100,0	83,33	-
Cycle 18 Day 1	0	23	37,7	19	82,6	77,19	26,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	76,47	17,74
	2	1	6,7	1	100,0	100,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	77,19	27,89
	1	15	21,7	13	86,7	76,92	19,88
	2	1	6,7	1	100,0	83,33	-
Cycle 20 Day 1	0	20	32,8	17	85,0	75,49	28,94
	1	15	21,7	14	93,3	76,19	14,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	83,33	-
Cycle 21 Day 1	0	15	24,6	14	93,3	77,38	27,43
	1	13	18,8	11	84,6	71,21	18,40
	2	1	6,7	1	100,0	83,33	-
Cycle 22 Day 1	0	15	24,6	12	80,0	75,00	29,73
	1	13	18,8	12	92,3	73,61	21,86
	2	1	6,7	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	72,22	35,36
	1	9	13,0	8	88,9	75,00	23,57
	2	1	6,7	1	100,0	83,33	-
Cycle 24 Day 1	0	10	16,4	9	90,0	83,33	16,67
	1	9	13,0	8	88,9	75,00	23,57
	2	1	6,7	1	100,0	100,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	80,56	26,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	80,95	17,82
Cycle 26 Day 1	0	8	13,1	6	75,0	80,56	34,02
	1	6	8,7	6	100,0	72,22	22,77
Cycle 27 Day 1	0	6	9,8	3	50,0	88,89	19,25
	1	5	7,2	5	100,0	80,00	21,73
Cycle 28 Day 1	0	5	8,2	4	80,0	91,67	16,67
	1	5	7,2	5	100,0	83,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	83,33	23,57
	1	5	7,2	5	100,0	83,33	16,67
Cycle 30 Day 1	0	3	4,9	1	33,3	33,33	-
	1	4	5,8	4	100,0	79,17	15,96
Cycle 31 Day 1	0	3	4,9	1	33,3	100,00	-
	1	4	5,8	4	100,0	75,00	16,67
Cycle 32 Day 1	0	3	4,9	2	66,7	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	77,78	19,25
Cycle 33 Day 1	0	2	3,3	2	100,0	83,33	23,57
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	62,70	32,45
	1	34	49,3	20	58,8	65,83	29,36
	2	7	46,7	3	42,9	50,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	66,39	27,53
	1	4	100,0	4	100,0	70,83	28,46
	2 or More	79	100,0	78	98,7	63,68	30,00
Cycle 2 Day 1	None	60	96,8	54	90,0	72,22	24,66
	1	3	75,0	2	66,7	83,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	69,57	25,88
Cycle 3 Day 1	None	59	95,2	53	89,8	76,10	22,29
	1	3	75,0	2	66,7	83,33	23,57
	2 or More	69	87,3	63	91,3	73,02	25,82
Cycle 4 Day 1	None	59	95,2	56	94,9	77,38	24,91
	1	3	75,0	2	66,7	100,00	0,00
	2 or More	66	83,5	62	93,9	76,08	25,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	77,98	23,59
	1	3	75,0	3	100,0	94,44	9,62
	2 or More	63	79,7	59	93,7	74,29	25,58
Cycle 6 Day 1	None	57	91,9	52	91,2	81,41	20,25
	1	3	75,0	3	100,0	94,44	9,62
	2 or More	61	77,2	57	93,4	75,15	22,08
Cycle 7 Day 1	None	52	83,9	50	96,2	79,67	26,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	88,89	19,25
	2 or More	58	73,4	53	91,4	73,58	26,64
Cycle 8 Day 1	None	50	80,6	46	92,0	85,87	19,87
	1	3	75,0	1	33,3	100,00	-
	2 or More	53	67,1	50	94,3	80,33	22,51
Cycle 9 Day 1	None	48	77,4	47	97,9	85,11	20,33
	1	1	25,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	76,04	22,78
Cycle 10 Day 1	None	43	69,4	41	95,3	84,15	19,70
	1	1	25,0	1	100,0	100,00	-
	2 or More	45	57,0	44	97,8	75,76	23,14
Cycle 11 Day 1	None	37	59,7	35	94,6	86,19	18,74
	1	1	25,0	1	100,0	100,00	-
	2 or More	42	53,2	42	100,0	78,17	25,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	85,78	18,86
	1	1	25,0	1	100,0	100,00	-
	2 or More	38	48,1	34	89,5	71,08	27,31
Cycle 13 Day 1	None	34	54,8	30	88,2	85,00	18,75
	1	1	25,0	1	100,0	100,00	-
	2 or More	31	39,2	31	100,0	74,73	27,51
Cycle 14 Day 1	None	31	50,0	29	93,5	81,03	25,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	100,00	-
	2 or More	28	35,4	27	96,4	68,52	27,86
Cycle 15 Day 1	None	30	48,4	28	93,3	85,12	19,43
	1	1	25,0	1	100,0	100,00	-
	2 or More	26	32,9	25	96,2	72,67	24,48
Cycle 16 Day 1	None	25	40,3	23	92,0	84,06	19,77
	1	1	25,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	68,12	27,94
Cycle 17 Day 1	None	23	37,1	22	95,7	87,88	14,71
	1	1	25,0	1	100,0	100,00	-
	2 or More	21	26,6	21	100,0	69,05	27,02
Cycle 18 Day 1	None	20	32,3	18	90,0	85,19	15,00
	1	1	25,0	1	100,0	100,00	-
	2 or More	20	25,3	18	90,0	68,52	25,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	85,29	16,54
	1	1	25,0	1	100,0	100,00	-
	2 or More	18	22,8	15	83,3	66,67	28,17
Cycle 20 Day 1	None	17	27,4	16	94,1	82,29	16,63
	1	1	25,0	1	100,0	100,00	-
	2 or More	18	22,8	15	83,3	67,78	26,33
Cycle 21 Day 1	None	15	24,2	13	86,7	87,18	13,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	62,82	24,68
Cycle 22 Day 1	None	15	24,2	13	86,7	84,62	17,30
	2 or More	14	17,7	12	85,7	65,28	29,69
Cycle 23 Day 1	None	10	16,1	9	90,0	87,04	16,20
	2 or More	11	13,9	9	81,8	61,11	33,33
Cycle 24 Day 1	None	10	16,1	10	100,0	85,00	16,57
	2 or More	10	12,7	8	80,0	75,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	89,58	15,27
	2 or More	6	7,6	5	83,3	66,67	23,57
Cycle 26 Day 1	None	8	12,9	8	100,0	83,33	23,57
	2 or More	6	7,6	4	66,7	62,50	34,36
Cycle 27 Day 1	None	7	11,3	6	85,7	83,33	21,08
	2 or More	4	5,1	2	50,0	83,33	23,57
Cycle 28 Day 1	None	7	11,3	7	100,0	88,10	15,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	83,33	23,57
Cycle 29 Day 1	None	6	9,7	5	83,3	83,33	16,67
	2 or More	3	3,8	2	66,7	83,33	23,57
Cycle 30 Day 1	None	4	6,5	3	75,0	66,67	33,33
	2 or More	3	3,8	2	66,7	75,00	11,79
Cycle 31 Day 1	None	4	6,5	3	75,0	88,89	19,25
	2 or More	3	3,8	2	66,7	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	88,89	19,25
	2 or More	2	2,5	2	100,0	66,67	0,00
Cycle 33 Day 1	None	1	1,6	1	100,0	100,00	-
	2 or More	1	1,3	1	100,0	66,67	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	60,53	31,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	83,33	-
	2 or More	39	49,4	24	61,5	64,58	29,62
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	66,39	27,53
	Previously Treated	83	100,0	82	98,8	64,02	29,80
Cycle 2 Day 1	Naïve	60	96,8	54	90,0	72,22	24,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	69,95	25,76
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	76,10	22,29
	Previously Treated	72	86,7	65	90,3	73,33	25,65
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	77,38	24,91
	Previously Treated	69	83,1	64	92,8	76,82	25,13
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	77,98	23,59
	Previously Treated	66	79,5	62	93,9	75,27	25,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	81,41	20,25
	Previously Treated	64	77,1	60	93,8	76,11	21,99
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	79,67	26,14
	Previously Treated	61	73,5	56	91,8	74,40	26,39
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	85,87	19,87
	Previously Treated	56	67,5	51	91,1	80,72	22,45
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	85,11	20,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	76,53	22,80
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	84,15	19,70
	Previously Treated	46	55,4	45	97,8	76,30	23,16
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	86,19	18,74
	Previously Treated	43	51,8	43	100,0	78,68	25,02
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	85,78	18,86
	Previously Treated	39	47,0	35	89,7	71,90	27,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	85,00	18,75
	Previously Treated	32	38,6	32	100,0	75,52	27,43
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	81,03	25,09
	Previously Treated	29	34,9	28	96,6	69,64	27,98
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	85,12	19,43
	Previously Treated	27	32,5	26	96,3	73,72	24,57
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	84,06	19,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	69,44	28,09
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	87,88	14,71
	Previously Treated	22	26,5	22	100,0	70,45	27,18
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	85,19	15,00
	Previously Treated	21	25,3	19	90,5	70,18	25,81
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	85,29	16,54
	Previously Treated	19	22,9	16	84,2	68,75	28,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	82,29	16,63
	Previously Treated	19	22,9	16	84,2	69,79	26,68
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	87,18	13,87
	Previously Treated	14	16,9	13	92,9	62,82	24,68
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	84,62	17,30
	Previously Treated	14	16,9	12	85,7	65,28	29,69
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	87,04	16,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	61,11	33,33
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	85,00	16,57
	Previously Treated	10	12,0	8	80,0	75,00	23,57
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	89,58	15,27
	Previously Treated	6	7,2	5	83,3	66,67	23,57
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	83,33	23,57
	Previously Treated	6	7,2	4	66,7	62,50	34,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	83,33	21,08
	Previously Treated	4	4,8	2	50,0	83,33	23,57
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	88,10	15,85
	Previously Treated	3	3,6	2	66,7	83,33	23,57
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	83,33	16,67
	Previously Treated	3	3,6	2	66,7	83,33	23,57
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	66,67	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	75,00	11,79
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	88,89	19,25
	Previously Treated	3	3,6	2	66,7	66,67	0,00
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	88,89	19,25
	Previously Treated	2	2,4	2	100,0	66,67	0,00
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	100,00	-
	Previously Treated	1	1,2	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	60,53	31,53
	Previously Treated	42	50,6	25	59,5	65,33	29,23
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	61,56	28,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	68,91	28,26
Cycle 2 Day 1	Local	71	94,7	66	93,0	72,73	23,32
	Central	65	92,9	59	90,8	68,93	27,24
Cycle 3 Day 1	Local	67	89,3	62	92,5	77,15	23,62
	Central	64	91,4	56	87,5	71,73	24,60
Cycle 4 Day 1	Local	65	86,7	61	93,8	80,33	23,28
	Central	63	90,0	59	93,7	73,73	26,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	77,12	23,75
	Central	61	87,1	59	96,7	75,99	25,38
Cycle 6 Day 1	Local	63	84,0	61	96,8	80,60	21,98
	Central	58	82,9	51	87,9	76,14	20,35
Cycle 7 Day 1	Local	61	81,3	59	96,7	79,38	24,04
	Central	52	74,3	47	90,4	73,76	28,81
Cycle 8 Day 1	Local	57	76,0	55	96,5	85,15	18,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	80,56	24,39
Cycle 9 Day 1	Local	54	72,0	53	98,1	80,19	22,42
	Central	44	62,9	43	97,7	81,40	21,58
Cycle 10 Day 1	Local	48	64,0	46	95,8	80,07	20,37
	Central	41	58,6	40	97,6	80,00	23,63
Cycle 11 Day 1	Local	40	53,3	38	95,0	81,58	22,86
	Central	40	57,1	40	100,0	82,50	22,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	81,31	22,73
	Central	40	57,1	36	90,0	76,39	25,93
Cycle 13 Day 1	Local	30	40,0	29	96,7	82,18	24,37
	Central	36	51,4	33	91,7	78,28	23,75
Cycle 14 Day 1	Local	27	36,0	27	100,0	79,01	27,19
	Central	33	47,1	30	90,9	72,22	26,74
Cycle 15 Day 1	Local	26	34,7	25	96,2	83,33	22,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	76,44	22,50
Cycle 16 Day 1	Local	24	32,0	24	100,0	79,17	24,70
	Central	26	37,1	23	88,5	73,91	26,03
Cycle 17 Day 1	Local	22	29,3	22	100,0	80,30	20,98
	Central	23	32,9	22	95,7	78,03	25,92
Cycle 18 Day 1	Local	20	26,7	19	95,0	82,46	17,10
	Central	21	30,0	18	85,7	72,22	26,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	82,35	20,81
	Central	17	24,3	16	94,1	71,88	27,02
Cycle 20 Day 1	Local	19	25,3	17	89,5	80,39	19,75
	Central	17	24,3	15	88,2	71,11	25,56
Cycle 21 Day 1	Local	14	18,7	12	85,7	81,94	16,60
	Central	15	21,4	14	93,3	69,05	26,84
Cycle 22 Day 1	Local	14	18,7	12	85,7	80,56	21,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	70,51	28,99
Cycle 23 Day 1	Local	11	14,7	10	90,9	78,33	27,27
	Central	10	14,3	8	80,0	68,75	31,42
Cycle 24 Day 1	Local	11	14,7	10	90,9	81,67	22,84
	Central	9	12,9	8	88,9	79,17	17,25
Cycle 25 Day 1	Local	7	9,3	7	100,0	85,71	26,23
	Central	8	11,4	6	75,0	75,00	13,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	77,78	36,00
	Central	8	11,4	6	75,0	75,00	20,41
Cycle 27 Day 1	Local	4	5,3	4	100,0	87,50	25,00
	Central	7	10,0	4	57,1	79,17	15,96
Cycle 28 Day 1	Local	4	5,3	4	100,0	91,67	16,67
	Central	6	8,6	5	83,3	83,33	16,67
Cycle 29 Day 1	Local	3	4,0	3	100,0	88,89	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	79,17	15,96
Cycle 30 Day 1	Local	3	4,0	3	100,0	66,67	33,33
	Central	4	5,7	2	50,0	75,00	11,79
Cycle 31 Day 1	Local	3	4,0	3	100,0	88,89	19,25
	Central	4	5,7	2	50,0	66,67	0,00
Cycle 32 Day 1	Local	3	4,0	3	100,0	88,89	19,25
	Central	3	4,3	2	66,7	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	100,00	-
	Central	1	1,4	1	100,0	66,67	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	63,19	26,91
	Central	32	45,7	20	62,5	63,33	34,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	65,03	28,67
	No	10	100,0	10	100,0	65,00	31,87
Cycle 2 Day 1	Yes	129	95,6	118	91,5	71,47	24,85
	No	7	70,0	7	100,0	61,90	31,50
Cycle 3 Day 1	Yes	124	91,9	112	90,3	74,70	24,20
	No	7	70,0	6	85,7	72,22	25,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	76,99	25,13
	No	7	70,0	7	100,0	78,57	23,00
Cycle 5 Day 1	Yes	117	86,7	112	95,7	77,38	24,29
	No	7	70,0	6	85,7	61,11	25,09
Cycle 6 Day 1	Yes	114	84,4	105	92,1	78,73	21,12
	No	7	70,0	7	100,0	76,19	25,20
Cycle 7 Day 1	Yes	106	78,5	99	93,4	77,61	25,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	66,67	38,49
Cycle 8 Day 1	Yes	100	74,1	91	91,0	83,70	21,51
	No	6	60,0	6	100,0	75,00	17,48
Cycle 9 Day 1	Yes	92	68,1	90	97,8	80,93	22,42
	No	6	60,0	6	100,0	77,78	13,61
Cycle 10 Day 1	Yes	83	61,5	80	96,4	81,04	21,50
	No	6	60,0	6	100,0	66,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	82,21	22,64
	No	4	40,0	4	100,0	79,17	25,00
Cycle 12 Day 1	Yes	72	53,3	65	90,3	78,72	24,56
	No	4	40,0	4	100,0	79,17	25,00
Cycle 13 Day 1	Yes	64	47,4	60	93,8	80,56	24,19
	No	2	20,0	2	100,0	66,67	0,00
Cycle 14 Day 1	Yes	58	43,0	55	94,8	75,76	27,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	66,67	0,00
Cycle 15 Day 1	Yes	55	40,7	52	94,5	80,13	22,88
	No	2	20,0	2	100,0	66,67	0,00
Cycle 16 Day 1	Yes	48	35,6	45	93,8	77,04	25,69
	No	2	20,0	2	100,0	66,67	0,00
Cycle 17 Day 1	Yes	43	31,9	42	97,7	80,16	23,35
	No	2	20,0	2	100,0	58,33	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	79,05	21,52
	No	2	20,0	2	100,0	50,00	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	77,60	24,54
	No	2	20,0	1	50,0	66,67	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	77,22	22,95
	No	2	20,0	2	100,0	58,33	11,79
Cycle 21 Day 1	Yes	27	20,0	24	88,9	75,69	24,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	66,67	0,00
Cycle 22 Day 1	Yes	27	20,0	23	85,2	75,36	26,53
	No	2	20,0	2	100,0	75,00	11,79
Cycle 23 Day 1	Yes	20	14,8	17	85,0	72,55	28,83
	No	1	10,0	1	100,0	100,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	79,41	20,01
	No	1	10,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	79,17	21,47
	No	1	10,0	1	100,0	100,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	78,79	27,98
	No	1	10,0	1	100,0	50,00	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	88,10	15,85
	No	1	10,0	1	100,0	50,00	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	89,58	15,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	66,67	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	86,11	16,39
	No	1	10,0	1	100,0	66,67	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	70,83	28,46
	No	1	10,0	1	100,0	66,67	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	83,33	19,25
	No	1	10,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	83,33	19,25
	No	1	10,0	1	100,0	66,67	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	83,33	23,57
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	63,95	29,98
	No	2	20,0	1	50,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	57,58	17,26
	No	134	100,0	131	97,8	65,65	29,51
Cycle 2 Day 1	Yes	7	63,6	7	100,0	69,05	31,07
	No	129	96,3	118	91,5	71,05	24,98
Cycle 3 Day 1	Yes	7	63,6	7	100,0	78,57	20,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	74,32	24,39
Cycle 4 Day 1	Yes	7	63,6	7	100,0	78,57	23,00
	No	121	90,3	113	93,4	76,99	25,13
Cycle 5 Day 1	Yes	7	63,6	7	100,0	66,67	27,22
	No	117	87,3	111	94,9	77,18	24,30
Cycle 6 Day 1	Yes	7	63,6	7	100,0	76,19	25,20
	No	114	85,1	105	92,1	78,73	21,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	69,05	24,40
	No	106	79,1	99	93,4	77,44	26,44
Cycle 8 Day 1	Yes	7	63,6	7	100,0	69,05	24,40
	No	99	73,9	90	90,9	84,26	20,81
Cycle 9 Day 1	Yes	6	54,5	6	100,0	72,22	25,09
	No	92	68,7	90	97,8	81,30	21,76
Cycle 10 Day 1	Yes	6	54,5	6	100,0	69,44	26,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	80,83	21,40
Cycle 11 Day 1	Yes	6	54,5	6	100,0	66,67	23,57
	No	74	55,2	72	97,3	83,33	22,20
Cycle 12 Day 1	Yes	6	54,5	6	100,0	72,22	22,77
	No	70	52,2	63	90,0	79,37	24,63
Cycle 13 Day 1	Yes	5	45,5	5	100,0	70,00	29,81
	No	61	45,5	57	93,4	80,99	23,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	70,00	24,72
	No	55	41,0	52	94,5	75,96	27,30
Cycle 15 Day 1	Yes	4	36,4	4	100,0	75,00	31,91
	No	53	39,6	50	94,3	80,00	22,08
Cycle 16 Day 1	Yes	3	27,3	3	100,0	83,33	16,67
	No	47	35,1	44	93,6	76,14	25,77
Cycle 17 Day 1	Yes	3	27,3	3	100,0	77,78	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	79,27	23,80
Cycle 18 Day 1	Yes	3	27,3	3	100,0	77,78	19,25
	No	38	28,4	34	89,5	77,45	22,80
Cycle 19 Day 1	Yes	3	27,3	3	100,0	77,78	19,25
	No	33	24,6	30	90,9	77,22	24,95
Cycle 20 Day 1	Yes	3	27,3	3	100,0	77,78	19,25
	No	33	24,6	29	87,9	75,86	23,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	83,33	23,57
	No	27	20,1	24	88,9	74,31	23,56
Cycle 22 Day 1	Yes	2	18,2	2	100,0	66,67	0,00
	No	27	20,1	23	85,2	76,09	26,51
Cycle 23 Day 1	Yes	2	18,2	2	100,0	75,00	11,79
	No	19	14,2	16	84,2	73,96	30,41
Cycle 24 Day 1	Yes	2	18,2	2	100,0	66,67	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	82,29	20,61
Cycle 25 Day 1	Yes	2	18,2	2	100,0	75,00	11,79
	No	13	9,7	11	84,6	81,82	22,92
Cycle 26 Day 1	Yes	1	9,1	1	100,0	66,67	-
	No	13	9,7	11	84,6	77,27	29,13
Cycle 27 Day 1	Yes	1	9,1	1	100,0	66,67	-
	No	10	7,5	7	70,0	85,71	20,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	66,67	-
	No	9	6,7	8	88,9	89,58	15,27
Cycle 29 Day 1	Yes	1	9,1	1	100,0	66,67	-
	No	8	6,0	6	75,0	86,11	16,39
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	70,00	24,72
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	80,00	18,26
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	80,00	18,26
Cycle 33 Day 1	No	2	1,5	2	100,0	83,33	23,57
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	38,89	25,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	65,04	29,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D194_REE_C30SF_SG.xls
24JUN2020 20:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	142	97,9	32,39	27,20
Cycle 2 Day 1	All	136	93,8	126	92,6	16,93	23,00
Cycle 3 Day 1	All	131	90,3	118	90,1	10,73	18,43
Cycle 4 Day 1	All	128	88,3	120	93,8	12,50	21,20
Cycle 5 Day 1	All	124	85,5	118	95,2	12,43	20,81
Cycle 6 Day 1	All	121	83,4	112	92,6	10,42	18,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	All	113	77,9	106	93,8	11,01	20,94
Cycle 8 Day 1	All	106	73,1	97	91,5	11,34	20,35
Cycle 9 Day 1	All	98	67,6	96	98,0	7,99	15,85
Cycle 10 Day 1	All	89	61,4	86	96,6	8,91	17,28
Cycle 11 Day 1	All	80	55,2	78	97,5	10,26	18,06
Cycle 12 Day 1	All	76	52,4	69	90,8	11,59	18,81
Cycle 13 Day 1	All	66	45,5	62	93,9	9,14	20,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	All	60	41,4	57	95,0	11,70	23,14
Cycle 15 Day 1	All	57	39,3	54	94,7	11,11	20,48
Cycle 16 Day 1	All	50	34,5	47	94,0	9,93	16,90
Cycle 17 Day 1	All	45	31,0	44	97,8	6,82	13,60
Cycle 18 Day 1	All	41	28,3	37	90,2	8,11	14,50
Cycle 19 Day 1	All	36	24,8	33	91,7	14,14	23,61
Cycle 20 Day 1	All	36	24,8	32	88,9	10,42	17,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	All	29	20,0	26	89,7	12,82	16,54
Cycle 22 Day 1	All	29	20,0	25	86,2	13,33	25,46
Cycle 23 Day 1	All	21	14,5	18	85,7	9,26	15,36
Cycle 24 Day 1	All	20	13,8	18	90,0	7,41	14,26
Cycle 25 Day 1	All	15	10,3	13	86,7	20,51	25,60
Cycle 26 Day 1	All	14	9,7	12	85,7	19,44	26,43
Cycle 27 Day 1	All	11	7,6	8	72,7	33,33	30,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	All	10	6,9	9	90,0	7,41	14,70
Cycle 29 Day 1	All	9	6,2	7	77,8	28,57	35,63
Cycle 30 Day 1	All	7	4,8	5	71,4	13,33	18,26
Cycle 31 Day 1	All	7	4,8	5	71,4	13,33	18,26
Cycle 32 Day 1	All	6	4,1	5	83,3	0,00	0,00
Cycle 33 Day 1	All	2	1,4	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	31,06	26,31
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	32,03	24,91
	Female	93	100,0	91	97,8	32,60	28,54
Cycle 2 Day 1	Male	50	96,2	47	94,0	16,31	22,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	86	92,5	79	91,9	17,30	23,18
Cycle 3 Day 1	Male	47	90,4	42	89,4	11,11	19,01
	Female	84	90,3	76	90,5	10,53	18,23
Cycle 4 Day 1	Male	46	88,5	45	97,8	12,59	23,88
	Female	82	88,2	75	91,5	12,44	19,59
Cycle 5 Day 1	Male	45	86,5	43	95,6	16,28	22,27
	Female	79	84,9	75	94,9	10,22	19,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Male	45	86,5	41	91,1	11,38	17,65
	Female	76	81,7	71	93,4	9,86	19,02
Cycle 7 Day 1	Male	40	76,9	39	97,5	12,82	19,67
	Female	73	78,5	67	91,8	9,95	21,72
Cycle 8 Day 1	Male	37	71,2	34	91,9	11,76	21,53
	Female	69	74,2	63	91,3	11,11	19,86
Cycle 9 Day 1	Male	33	63,5	33	100,0	6,06	13,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	63	96,9	8,99	17,15
Cycle 10 Day 1	Male	30	57,7	30	100,0	8,89	17,36
	Female	59	63,4	56	94,9	8,93	17,40
Cycle 11 Day 1	Male	29	55,8	29	100,0	9,20	15,16
	Female	51	54,8	49	96,1	10,88	19,71
Cycle 12 Day 1	Male	27	51,9	26	96,3	10,26	18,30
	Female	49	52,7	43	87,8	12,40	19,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Male	25	48,1	23	92,0	5,80	12,92
	Female	41	44,1	39	95,1	11,11	23,36
Cycle 14 Day 1	Male	23	44,2	21	91,3	6,35	13,41
	Female	37	39,8	36	97,3	14,81	26,96
Cycle 15 Day 1	Male	21	40,4	20	95,2	8,33	18,34
	Female	36	38,7	34	94,4	12,75	21,73
Cycle 16 Day 1	Male	16	30,8	16	100,0	8,33	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	34	36,6	31	91,2	10,75	18,03
Cycle 17 Day 1	Male	13	25,0	13	100,0	7,69	14,62
	Female	32	34,4	31	96,9	6,45	13,39
Cycle 18 Day 1	Male	12	23,1	11	91,7	9,09	15,57
	Female	29	31,2	26	89,7	7,69	14,32
Cycle 19 Day 1	Male	10	19,2	10	100,0	20,00	28,11
	Female	26	28,0	23	88,5	11,59	21,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Male	10	19,2	9	90,0	11,11	16,67
	Female	26	28,0	23	88,5	10,14	18,63
Cycle 21 Day 1	Male	8	15,4	8	100,0	20,83	17,25
	Female	21	22,6	18	85,7	9,26	15,36
Cycle 22 Day 1	Male	8	15,4	6	75,0	16,67	27,89
	Female	21	22,6	19	90,5	12,28	25,36
Cycle 23 Day 1	Male	5	9,6	4	80,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	16	17,2	14	87,5	9,52	15,63
Cycle 24 Day 1	Male	5	9,6	4	80,0	16,67	19,25
	Female	15	16,1	14	93,3	4,76	12,10
Cycle 25 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	12	12,9	11	91,7	24,24	26,21
Cycle 26 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	11	11,8	10	90,9	23,33	27,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Male	3	5,8	2	66,7	16,67	23,57
	Female	8	8,6	6	75,0	38,89	32,77
Cycle 28 Day 1	Male	2	3,8	2	100,0	0,00	0,00
	Female	8	8,6	7	87,5	9,52	16,27
Cycle 29 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	8	8,6	6	75,0	33,33	36,51
Cycle 30 Day 1	Male	1	1,9	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	6	6,5	4	66,7	8,33	16,67
Cycle 31 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	16,67	19,25
Cycle 32 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	5	5,4	4	80,0	0,00	0,00
Cycle 33 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	1	1,1	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	30,16	25,61
	Female	37	39,8	23	62,2	31,88	27,48
Age							
Cycle 1 Day 1	18-64	109	100,0	106	97,2	32,08	27,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	31,03	25,09
	>=75	7	100,0	7	100,0	42,86	37,09
Cycle 2 Day 1	18-64	103	94,5	94	91,3	15,25	21,12
	65-74	26	89,7	25	96,2	20,00	28,87
	>=75	7	100,0	7	100,0	28,57	23,00
Cycle 3 Day 1	18-64	99	90,8	87	87,9	10,34	17,84
	65-74	25	86,2	24	96,0	8,33	17,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	23,81	25,20
Cycle 4 Day 1	18-64	98	89,9	92	93,9	13,04	21,52
	65-74	23	79,3	21	91,3	7,94	17,97
	>=75	7	100,0	7	100,0	19,05	26,23
Cycle 5 Day 1	18-64	95	87,2	90	94,7	11,85	19,55
	65-74	22	75,9	22	100,0	12,12	19,37
	>=75	7	100,0	6	85,7	22,22	40,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	18-64	92	84,4	84	91,3	9,13	16,65
	65-74	22	75,9	21	95,5	12,70	16,59
	>=75	7	100,0	7	100,0	19,05	37,80
Cycle 7 Day 1	18-64	86	78,9	81	94,2	9,47	19,88
	65-74	20	69,0	19	95,0	12,28	16,52
	>=75	7	100,0	6	85,7	27,78	38,97
Cycle 8 Day 1	18-64	80	73,4	72	90,0	9,72	18,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	19	65,5	19	100,0	12,28	16,52
	>=75	7	100,0	6	85,7	27,78	38,97
Cycle 9 Day 1	18-64	74	67,9	73	98,6	5,94	13,99
	65-74	18	62,1	18	100,0	14,81	20,52
	>=75	6	85,7	5	83,3	13,33	18,26
Cycle 10 Day 1	18-64	69	63,3	66	95,7	8,08	16,60
	65-74	15	51,7	15	100,0	13,33	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	5	71,4	5	100,0	6,67	14,91
Cycle 11 Day 1	18-64	61	56,0	59	96,7	9,60	18,62
	65-74	15	51,7	15	100,0	11,11	16,27
	>=75	4	57,1	4	100,0	16,67	19,25
Cycle 12 Day 1	18-64	57	52,3	51	89,5	11,11	19,63
	65-74	15	51,7	14	93,3	16,67	17,30
	>=75	4	57,1	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	49	45,0	46	93,9	7,25	17,09
	65-74	13	44,8	12	92,3	13,89	30,01
	>=75	4	57,1	4	100,0	16,67	19,25
Cycle 14 Day 1	18-64	45	41,3	44	97,8	11,36	21,50
	65-74	13	44,8	11	84,6	12,12	30,81
	>=75	2	28,6	2	100,0	16,67	23,57
Cycle 15 Day 1	18-64	43	39,4	41	95,3	9,76	18,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	12	41,4	11	91,7	12,12	26,97
	>=75	2	28,6	2	100,0	33,33	0,00
Cycle 16 Day 1	18-64	38	34,9	36	94,7	10,19	17,49
	65-74	10	34,5	9	90,0	11,11	16,67
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 17 Day 1	18-64	36	33,0	35	97,2	4,76	11,83
	65-74	8	27,6	8	100,0	12,50	17,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	33,33	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	6,67	13,56
	65-74	7	24,1	6	85,7	11,11	17,21
	>=75	1	14,3	1	100,0	33,33	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	11,90	22,62
	65-74	5	17,2	4	80,0	25,00	31,91
	>=75	1	14,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	7,69	14,32
	65-74	5	17,2	5	100,0	20,00	29,81
	>=75	1	14,3	1	100,0	33,33	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	11,11	16,10
	65-74	4	13,8	4	100,0	16,67	19,25
	>=75	1	14,3	1	100,0	33,33	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	13,33	27,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	4	13,8	4	100,0	16,67	19,25
	>=75	1	14,3	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	10,42	15,96
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	6,25	13,44
	65-74	2	6,9	2	100,0	16,67	23,57
Cycle 25 Day 1	18-64	14	12,8	12	85,7	22,22	25,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	19,44	26,43
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	33,33	30,86
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	7,41	14,70
	65-74	1	3,4	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	18-64	8	7,3	7	87,5	28,57	35,63
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	13,33	18,26
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	13,33	18,26
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	0,00	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	30,39	26,42
	65-74	15	51,7	8	53,3	25,00	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	4	57,1	2	50,0	66,67	47,14
Race							
Cycle 1 Day 1	White	60	100,0	58	96,7	34,48	29,26
	Other	85	100,0	84	98,8	30,95	25,76
Cycle 2 Day 1	White	57	95,0	51	89,5	16,99	22,48
	Other	79	92,9	75	94,9	16,89	23,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	White	54	90,0	44	81,5	9,85	19,79
	Other	77	90,6	74	96,1	11,26	17,69
Cycle 4 Day 1	White	53	88,3	47	88,7	10,64	20,97
	Other	75	88,2	73	97,3	13,70	21,40
Cycle 5 Day 1	White	52	86,7	48	92,3	12,50	23,44
	Other	72	84,7	70	97,2	12,38	18,97
Cycle 6 Day 1	White	50	83,3	44	88,0	12,88	22,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	71	83,5	68	95,8	8,82	14,82
Cycle 7 Day 1	White	47	78,3	42	89,4	12,70	23,23
	Other	66	77,6	64	97,0	9,90	19,41
Cycle 8 Day 1	White	45	75,0	39	86,7	14,53	22,68
	Other	61	71,8	58	95,1	9,20	18,52
Cycle 9 Day 1	White	42	70,0	41	97,6	8,13	17,92
	Other	56	65,9	55	98,2	7,88	14,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	5,13	16,29
	Other	48	56,5	47	97,9	12,06	17,62
Cycle 11 Day 1	White	37	61,7	37	100,0	11,71	19,59
	Other	43	50,6	41	95,3	8,94	16,71
Cycle 12 Day 1	White	37	61,7	33	89,2	8,08	16,73
	Other	39	45,9	36	92,3	14,81	20,23
Cycle 13 Day 1	White	32	53,3	30	93,8	11,11	25,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	34	40,0	32	94,1	7,29	14,00
Cycle 14 Day 1	White	31	51,7	30	96,8	13,33	27,12
	Other	29	34,1	27	93,1	9,88	18,06
Cycle 15 Day 1	White	30	50,0	28	93,3	9,52	17,82
	Other	27	31,8	26	96,3	12,82	23,24
Cycle 16 Day 1	White	26	43,3	24	92,3	6,94	16,97
	Other	24	28,2	23	95,8	13,04	16,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	White	24	40,0	24	100,0	4,17	11,26
	Other	21	24,7	20	95,2	10,00	15,67
Cycle 18 Day 1	White	22	36,7	19	86,4	7,02	13,96
	Other	19	22,4	18	94,7	9,26	15,36
Cycle 19 Day 1	White	20	33,3	20	100,0	15,00	25,31
	Other	16	18,8	13	81,3	12,82	21,68
Cycle 20 Day 1	White	20	33,3	17	85,0	9,80	19,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	16	18,8	15	93,8	11,11	16,27
Cycle 21 Day 1	White	16	26,7	14	87,5	11,90	16,57
	Other	13	15,3	12	92,3	13,89	17,16
Cycle 22 Day 1	White	16	26,7	13	81,3	12,82	28,99
	Other	13	15,3	12	92,3	13,89	22,29
Cycle 23 Day 1	White	12	20,0	10	83,3	6,67	14,05
	Other	9	10,6	8	88,9	12,50	17,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	White	11	18,3	10	90,9	6,67	14,05
	Other	9	10,6	8	88,9	8,33	15,43
Cycle 25 Day 1	White	10	16,7	8	80,0	20,83	24,80
	Other	5	5,9	5	100,0	20,00	29,81
Cycle 26 Day 1	White	10	16,7	8	80,0	20,83	30,54
	Other	4	4,7	4	100,0	16,67	19,25
Cycle 27 Day 1	White	8	13,3	5	62,5	33,33	40,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	3	3,5	3	100,0	33,33	0,00
Cycle 28 Day 1	White	7	11,7	6	85,7	5,56	13,61
	Other	3	3,5	3	100,0	11,11	19,25
Cycle 29 Day 1	White	6	10,0	4	66,7	41,67	41,94
	Other	3	3,5	3	100,0	11,11	19,25
Cycle 30 Day 1	White	4	6,7	2	50,0	16,67	23,57
	Other	3	3,5	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 31 Day 1	White	4	6,7	2	50,0	0,00	0,00
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 32 Day 1	White	4	6,7	3	75,0	0,00	0,00
	Other	2	2,4	2	100,0	0,00	0,00
Cycle 33 Day 1	White	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	White	25	41,7	17	68,0	27,45	21,20
	Other	39	45,9	27	69,2	33,33	29,24
Region							
Cycle 1 Day 1	America (AM)	40	100,0	40	100,0	34,17	30,65
	Europe (EU)	34	100,0	31	91,2	32,26	23,54
	Asia (AS)	71	100,0	71	100,0	31,46	26,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	33	86,8	14,14	22,10
	Europe (EU)	32	94,1	28	87,5	16,67	21,28
	Asia (AS)	66	93,0	65	98,5	18,46	24,32
Cycle 3 Day 1	America (AM)	37	92,5	33	89,2	9,09	15,08
	Europe (EU)	31	91,2	22	71,0	12,12	21,93
	Asia (AS)	63	88,7	63	100,0	11,11	18,93
Cycle 4 Day 1	America (AM)	37	92,5	34	91,9	13,73	21,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	30	88,2	25	83,3	9,33	20,46
	Asia (AS)	61	85,9	61	100,0	13,11	21,33
Cycle 5 Day 1	America (AM)	37	92,5	35	94,6	14,29	23,27
	Europe (EU)	30	88,2	26	86,7	7,69	17,15
	Asia (AS)	57	80,3	57	100,0	13,45	20,76
Cycle 6 Day 1	America (AM)	37	92,5	35	94,6	9,52	17,29
	Europe (EU)	28	82,4	25	89,3	10,67	18,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	56	78,9	52	92,9	10,90	19,49
Cycle 7 Day 1	America (AM)	35	87,5	32	91,4	7,29	16,36
	Europe (EU)	28	82,4	25	89,3	12,00	18,95
	Asia (AS)	50	70,4	49	98,0	12,93	24,36
Cycle 8 Day 1	America (AM)	31	77,5	27	87,1	9,88	18,06
	Europe (EU)	28	82,4	23	82,1	13,04	16,63
	Asia (AS)	47	66,2	47	100,0	11,35	23,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	America (AM)	29	72,5	28	96,6	11,90	18,62
	Europe (EU)	26	76,5	25	96,2	8,00	17,43
	Asia (AS)	43	60,6	43	100,0	5,43	12,45
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	6,94	13,83
	Europe (EU)	25	73,5	25	100,0	8,00	19,91
	Asia (AS)	37	52,1	37	100,0	10,81	17,66
Cycle 11 Day 1	America (AM)	24	60,0	23	95,8	13,04	21,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	23	67,6	22	95,7	6,06	13,16
	Asia (AS)	33	46,5	33	100,0	11,11	18,00
Cycle 12 Day 1	America (AM)	24	60,0	23	95,8	10,14	18,63
	Europe (EU)	23	67,6	18	78,3	5,56	12,78
	Asia (AS)	29	40,8	28	96,6	16,67	21,28
Cycle 13 Day 1	America (AM)	23	57,5	22	95,7	7,58	17,61
	Europe (EU)	18	52,9	15	83,3	11,11	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	25	35,2	25	100,0	9,33	18,05
Cycle 14 Day 1	America (AM)	22	55,0	21	95,5	11,11	24,34
	Europe (EU)	17	50,0	16	94,1	10,42	26,44
	Asia (AS)	21	29,6	20	95,2	13,33	19,94
Cycle 15 Day 1	America (AM)	22	55,0	20	90,9	5,00	16,31
	Europe (EU)	15	44,1	14	93,3	11,90	21,11
	Asia (AS)	20	28,2	20	100,0	16,67	22,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	3,92	11,07
	Europe (EU)	14	41,2	11	78,6	9,09	15,57
	Asia (AS)	19	26,8	19	100,0	15,79	20,39
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	4,17	11,39
	Europe (EU)	13	38,2	12	92,3	5,56	12,97
	Asia (AS)	16	22,5	16	100,0	10,42	15,96
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	11,90	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	32,4	7	63,6	4,76	12,60
	Asia (AS)	16	22,5	16	100,0	6,25	13,44
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	12,82	21,68
	Europe (EU)	9	26,5	9	100,0	18,52	29,40
	Asia (AS)	14	19,7	11	78,6	12,12	22,47
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	7,69	14,62
	Europe (EU)	9	26,5	6	66,7	16,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	10,26	16,01
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	13,33	17,21
	Europe (EU)	7	20,6	6	85,7	16,67	18,26
	Asia (AS)	11	15,5	10	90,9	10,00	16,10
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	20,00	32,20
	Europe (EU)	7	20,6	5	71,4	0,00	0,00
	Asia (AS)	11	15,5	10	90,9	13,33	23,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	3,70	11,11
	Europe (EU)	5	14,7	3	60,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	22,22	17,21
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	12,50	17,25
	Europe (EU)	5	14,7	4	80,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	5,56	13,61
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	19,05	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	33,33	27,22
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	27,78	32,77
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	16,67	19,25
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	33,33	47,14
	Europe (EU)	3	8,8	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	33,33	0,00
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	0,00	0,00
	Europe (EU)	2	5,9	1	50,0	0,00	-
	Asia (AS)	4	5,6	4	100,0	16,67	19,25
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	22,22	19,25
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	33,33	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	11,11	19,25
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	22,22	19,25
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	1	100,0	0,00	-
	Asia (AS)	3	4,2	2	66,7	0,00	0,00
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	0,00	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	33,33	26,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	10	29,4	5	50,0	40,00	14,91
	Asia (AS)	34	47,9	22	64,7	27,27	28,43
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	60	98,4	28,89	25,65
	1	69	100,0	67	97,1	31,84	28,09
	2	15	100,0	15	100,0	48,89	24,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	0	59	96,7	56	94,9	16,07	23,78
	1	67	97,1	60	89,6	17,22	21,69
	2	10	66,7	10	100,0	20,00	28,11
Cycle 3 Day 1	0	57	93,4	51	89,5	8,50	17,44
	1	65	94,2	58	89,2	11,49	18,26
	2	9	60,0	9	100,0	18,52	24,22
Cycle 4 Day 1	0	57	93,4	54	94,7	9,26	19,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	58	93,5	13,79	20,74
	2	9	60,0	8	88,9	25,00	29,55
Cycle 5 Day 1	0	56	91,8	53	94,6	11,32	19,55
	1	62	89,9	59	95,2	14,12	22,49
	2	6	40,0	6	100,0	5,56	13,61
Cycle 6 Day 1	0	56	91,8	54	96,4	11,11	18,31
	1	59	85,5	53	89,8	10,06	19,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	6	40,0	5	83,3	6,67	14,91
Cycle 7 Day 1	0	54	88,5	51	94,4	11,11	20,73
	1	54	78,3	50	92,6	12,00	22,09
	2	5	33,3	5	100,0	0,00	0,00
Cycle 8 Day 1	0	52	85,2	48	92,3	11,11	17,30
	1	49	71,0	44	89,8	12,12	23,94
	2	5	33,3	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	0	50	82,0	49	98,0	9,52	18,00
	1	44	63,8	43	97,7	6,98	13,72
	2	4	26,7	4	100,0	0,00	0,00
Cycle 10 Day 1	0	46	75,4	46	100,0	10,87	18,66
	1	40	58,0	37	92,5	7,21	15,98
	2	3	20,0	3	100,0	0,00	0,00
Cycle 11 Day 1	0	43	70,5	41	95,3	9,76	17,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	34	49,3	34	100,0	11,76	19,90
	2	3	20,0	3	100,0	0,00	0,00
Cycle 12 Day 1	0	42	68,9	36	85,7	15,74	18,66
	1	31	44,9	30	96,8	7,78	18,94
	2	3	20,0	3	100,0	0,00	0,00
Cycle 13 Day 1	0	38	62,3	34	89,5	10,78	24,23
	1	27	39,1	27	100,0	7,41	14,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	10,42	26,01
	1	24	34,8	24	100,0	13,89	19,45
	2	1	6,7	1	100,0	0,00	-
Cycle 15 Day 1	0	33	54,1	30	90,9	10,00	19,87
	1	23	33,3	23	100,0	13,04	21,88
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	28	45,9	25	89,3	6,67	13,61
	1	21	30,4	21	100,0	14,29	19,92
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	7,25	14,06
	1	20	29,0	20	100,0	6,67	13,68
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	10,53	15,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	17	24,6	17	100,0	5,88	13,10
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	15,79	25,74
	1	15	21,7	13	86,7	12,82	21,68
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	13,73	20,61
	1	15	21,7	14	93,3	7,14	14,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	9,52	15,63
	1	13	18,8	11	84,6	18,18	17,41
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	13,89	30,01
	1	13	18,8	12	92,3	13,89	22,29
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	3,70	11,11
	1	9	13,0	8	88,9	16,67	17,82
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	7,41	14,70
	1	9	13,0	8	88,9	8,33	15,43
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	16,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	7	10,1	7	100,0	23,81	25,20
Cycle 26 Day 1	0	8	13,1	6	75,0	11,11	27,22
	1	6	8,7	6	100,0	27,78	25,09
Cycle 27 Day 1	0	6	9,8	3	50,0	22,22	19,25
	1	5	7,2	5	100,0	40,00	36,51
Cycle 28 Day 1	0	5	8,2	4	80,0	8,33	16,67
	1	5	7,2	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 29 Day 1	0	4	6,6	2	50,0	50,00	70,71
	1	5	7,2	5	100,0	20,00	18,26
Cycle 30 Day 1	0	3	4,9	1	33,3	33,33	-
	1	4	5,8	4	100,0	8,33	16,67
Cycle 31 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	16,67	19,25
Cycle 32 Day 1	0	3	4,9	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	4,3	3	100,0	0,00	0,00
Cycle 33 Day 1	0	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	28,57	24,23
	1	34	49,3	20	58,8	33,33	30,59
	2	7	46,7	3	42,9	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	60	96,8	32,78	24,92
	1	4	100,0	4	100,0	25,00	16,67
	2 or More	79	100,0	78	98,7	32,48	29,41
Cycle 2 Day 1	None	60	96,8	55	91,7	16,97	23,89
	1	3	75,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	73	92,4	69	94,5	17,39	22,59
Cycle 3 Day 1	None	59	95,2	53	89,8	8,18	15,89
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	69	87,3	63	91,3	13,23	20,34
Cycle 4 Day 1	None	59	95,2	56	94,9	10,12	20,02
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	66	83,5	62	93,9	15,05	22,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	None	58	93,5	56	96,6	11,90	19,52
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	63	79,7	59	93,7	13,56	22,42
Cycle 6 Day 1	None	57	91,9	52	91,2	10,90	15,79
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	61	77,2	57	93,4	10,53	21,04
Cycle 7 Day 1	None	52	83,9	50	96,2	9,33	16,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	3	100,0	22,22	38,49
	2 or More	58	73,4	53	91,4	11,95	23,66
Cycle 8 Day 1	None	50	80,6	46	92,0	11,59	20,14
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	11,33	20,88
Cycle 9 Day 1	None	48	77,4	47	97,9	10,64	15,71
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	5,56	15,88
Cycle 10 Day 1	None	43	69,4	41	95,3	5,69	12,70
	1	1	25,0	1	100,0	0,00	-
	2 or More	45	57,0	44	97,8	12,12	20,45
Cycle 11 Day 1	None	37	59,7	35	94,6	9,52	17,29
	1	1	25,0	1	100,0	0,00	-
	2 or More	42	53,2	42	100,0	11,11	19,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	37	59,7	34	91,9	10,78	17,83
	1	1	25,0	1	100,0	0,00	-
	2 or More	38	48,1	34	89,5	12,75	20,13
Cycle 13 Day 1	None	34	54,8	30	88,2	8,89	17,36
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	9,68	23,08
Cycle 14 Day 1	None	31	50,0	29	93,5	5,75	12,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	28	35,4	27	96,4	18,52	29,72
Cycle 15 Day 1	None	30	48,4	28	93,3	7,14	18,94
	1	1	25,0	1	100,0	0,00	-
	2 or More	26	32,9	25	96,2	16,00	21,77
Cycle 16 Day 1	None	25	40,3	23	92,0	7,25	14,06
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	30,4	23	95,8	13,04	19,43
Cycle 17 Day 1	None	23	37,1	22	95,7	4,55	11,71
	1	1	25,0	1	100,0	0,00	-
	2 or More	21	26,6	21	100,0	9,52	15,43
Cycle 18 Day 1	None	20	32,3	18	90,0	9,26	15,36
	1	1	25,0	1	100,0	0,00	-
	2 or More	20	25,3	18	90,0	7,41	14,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	None	17	27,4	17	100,0	9,80	19,60
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	20,00	27,60
Cycle 20 Day 1	None	17	27,4	16	94,1	8,33	14,91
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	13,33	21,08
Cycle 21 Day 1	None	15	24,2	13	86,7	10,26	16,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	14	17,7	13	92,9	15,38	17,30
Cycle 22 Day 1	None	15	24,2	13	86,7	15,38	22,01
	2 or More	14	17,7	12	85,7	11,11	29,59
Cycle 23 Day 1	None	10	16,1	9	90,0	7,41	14,70
	2 or More	11	13,9	9	81,8	11,11	16,67
Cycle 24 Day 1	None	10	16,1	10	100,0	10,00	16,10
	2 or More	10	12,7	8	80,0	4,17	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	None	9	14,5	8	88,9	12,50	17,25
	2 or More	6	7,6	5	83,3	33,33	33,33
Cycle 26 Day 1	None	8	12,9	8	100,0	12,50	24,80
	2 or More	6	7,6	4	66,7	33,33	27,22
Cycle 27 Day 1	None	7	11,3	6	85,7	33,33	36,51
	2 or More	4	5,1	2	50,0	33,33	0,00
Cycle 28 Day 1	None	7	11,3	7	100,0	4,76	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	9,7	5	83,3	33,33	40,82
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 30 Day 1	None	4	6,5	3	75,0	11,11	19,25
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 31 Day 1	None	4	6,5	3	75,0	0,00	0,00
	2 or More	3	3,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	0,00	0,00
	2 or More	2	2,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	1,6	1	100,0	0,00	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	28,07	20,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	1	33,3	33,33	-
	2 or More	39	49,4	24	61,5	33,33	31,08
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	60	96,8	32,78	24,92
	Previously Treated	83	100,0	82	98,8	32,11	28,90
Cycle 2 Day 1	Naïve	60	96,8	55	91,7	16,97	23,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	76	91,6	71	93,4	16,90	22,45
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	8,18	15,89
	Previously Treated	72	86,7	65	90,3	12,82	20,15
Cycle 4 Day 1	Naïve	59	95,2	56	94,9	10,12	20,02
	Previously Treated	69	83,1	64	92,8	14,58	22,12
Cycle 5 Day 1	Naïve	58	93,5	56	96,6	11,90	19,52
	Previously Treated	66	79,5	62	93,9	12,90	22,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	Naïve	57	91,9	52	91,2	10,90	15,79
	Previously Treated	64	77,1	60	93,8	10,00	20,63
Cycle 7 Day 1	Naïve	52	83,9	50	96,2	9,33	16,55
	Previously Treated	61	73,5	56	91,8	12,50	24,26
Cycle 8 Day 1	Naïve	50	80,6	46	92,0	11,59	20,14
	Previously Treated	56	67,5	51	91,1	11,11	20,73
Cycle 9 Day 1	Naïve	48	77,4	47	97,9	10,64	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	50	60,2	49	98,0	5,44	15,73
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	5,69	12,70
	Previously Treated	46	55,4	45	97,8	11,85	20,30
Cycle 11 Day 1	Naïve	37	59,7	35	94,6	9,52	17,29
	Previously Treated	43	51,8	43	100,0	10,85	18,86
Cycle 12 Day 1	Naïve	37	59,7	34	91,9	10,78	17,83
	Previously Treated	39	47,0	35	89,7	12,38	19,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	34	54,8	30	88,2	8,89	17,36
	Previously Treated	32	38,6	32	100,0	9,38	22,77
Cycle 14 Day 1	Naïve	31	50,0	29	93,5	5,75	12,81
	Previously Treated	29	34,9	28	96,6	17,86	29,37
Cycle 15 Day 1	Naïve	30	48,4	28	93,3	7,14	18,94
	Previously Treated	27	32,5	26	96,3	15,38	21,56
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	7,25	14,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	30,1	24	96,0	12,50	19,19
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	4,55	11,71
	Previously Treated	22	26,5	22	100,0	9,09	15,19
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	9,26	15,36
	Previously Treated	21	25,3	19	90,5	7,02	13,96
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	9,80	19,60
	Previously Treated	19	22,9	16	84,2	18,75	27,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	8,33	14,91
	Previously Treated	19	22,9	16	84,2	12,50	20,64
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	10,26	16,01
	Previously Treated	14	16,9	13	92,9	15,38	17,30
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	15,38	22,01
	Previously Treated	14	16,9	12	85,7	11,11	29,59
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	11,11	16,67
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	10,00	16,10
	Previously Treated	10	12,0	8	80,0	4,17	11,79
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	12,50	17,25
	Previously Treated	6	7,2	5	83,3	33,33	33,33
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	12,50	24,80
	Previously Treated	6	7,2	4	66,7	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	33,33	36,51
	Previously Treated	4	4,8	2	50,0	33,33	0,00
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	4,76	12,60
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	33,33	40,82
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	0,00	0,00
	Previously Treated	3	3,6	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	0,00	0,00
	Previously Treated	2	2,4	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	0,00	-
	Previously Treated	1	1,2	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	28,07	20,07
	Previously Treated	42	50,6	25	59,5	33,33	30,43
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	31,56	27,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	70	100,0	67	95,7	33,33	27,22
Cycle 2 Day 1	Local	71	94,7	67	94,4	13,93	21,83
	Central	65	92,9	59	90,8	20,34	23,99
Cycle 3 Day 1	Local	67	89,3	62	92,5	8,60	17,00
	Central	64	91,4	56	87,5	13,10	19,78
Cycle 4 Day 1	Local	65	86,7	61	93,8	9,29	18,39
	Central	63	90,0	59	93,7	15,82	23,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Local	63	84,0	59	93,7	10,73	20,00
	Central	61	87,1	59	96,7	14,12	21,62
Cycle 6 Day 1	Local	63	84,0	61	96,8	5,46	12,44
	Central	58	82,9	51	87,9	16,34	22,48
Cycle 7 Day 1	Local	61	81,3	59	96,7	6,78	17,26
	Central	52	74,3	47	90,4	16,31	23,95
Cycle 8 Day 1	Local	57	76,0	55	96,5	7,27	13,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	49	70,0	42	85,7	16,67	25,77
Cycle 9 Day 1	Local	54	72,0	53	98,1	8,18	15,89
	Central	44	62,9	43	97,7	7,75	16,00
Cycle 10 Day 1	Local	48	64,0	46	95,8	10,14	19,71
	Central	41	58,6	40	97,6	7,50	14,10
Cycle 11 Day 1	Local	40	53,3	38	95,0	10,53	20,66
	Central	40	57,1	40	100,0	10,00	15,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Local	36	48,0	33	91,7	8,08	14,51
	Central	40	57,1	36	90,0	14,81	21,74
Cycle 13 Day 1	Local	30	40,0	29	96,7	5,75	20,06
	Central	36	51,4	33	91,7	12,12	20,10
Cycle 14 Day 1	Local	27	36,0	27	100,0	8,64	21,86
	Central	33	47,1	30	90,9	14,44	24,26
Cycle 15 Day 1	Local	26	34,7	25	96,2	6,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	29	93,5	14,94	22,86
Cycle 16 Day 1	Local	24	32,0	24	100,0	8,33	14,74
	Central	26	37,1	23	88,5	11,59	19,09
Cycle 17 Day 1	Local	22	29,3	22	100,0	3,03	9,81
	Central	23	32,9	22	95,7	10,61	15,89
Cycle 18 Day 1	Local	20	26,7	19	95,0	7,02	13,96
	Central	21	30,0	18	85,7	9,26	15,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	19	25,3	17	89,5	9,80	19,60
	Central	17	24,3	16	94,1	18,75	27,13
Cycle 20 Day 1	Local	19	25,3	17	89,5	7,84	18,74
	Central	17	24,3	15	88,2	13,33	16,90
Cycle 21 Day 1	Local	14	18,7	12	85,7	8,33	15,08
	Central	15	21,4	14	93,3	16,67	17,30
Cycle 22 Day 1	Local	14	18,7	12	85,7	8,33	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	15	21,4	13	86,7	17,95	32,25
Cycle 23 Day 1	Local	11	14,7	10	90,9	6,67	14,05
	Central	10	14,3	8	80,0	12,50	17,25
Cycle 24 Day 1	Local	11	14,7	10	90,9	6,67	14,05
	Central	9	12,9	8	88,9	8,33	15,43
Cycle 25 Day 1	Local	7	9,3	7	100,0	14,29	26,23
	Central	8	11,4	6	75,0	27,78	25,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	Local	6	8,0	6	100,0	16,67	27,89
	Central	8	11,4	6	75,0	22,22	27,22
Cycle 27 Day 1	Local	4	5,3	4	100,0	16,67	19,25
	Central	7	10,0	4	57,1	50,00	33,33
Cycle 28 Day 1	Local	4	5,3	4	100,0	0,00	0,00
	Central	6	8,6	5	83,3	13,33	18,26
Cycle 29 Day 1	Local	3	4,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	6	8,6	4	66,7	41,67	41,94
Cycle 30 Day 1	Local	3	4,0	3	100,0	11,11	19,25
	Central	4	5,7	2	50,0	16,67	23,57
Cycle 31 Day 1	Local	3	4,0	3	100,0	0,00	0,00
	Central	4	5,7	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	4,0	3	100,0	0,00	0,00
	Central	3	4,3	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 33 Day 1	Local	1	1,3	1	100,0	0,00	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	30,56	25,85
	Central	32	45,7	20	62,5	31,67	27,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	132	97,8	32,83	27,00
	No	10	100,0	10	100,0	26,67	30,63
Cycle 2 Day 1	Yes	129	95,6	119	92,2	17,09	22,91
	No	7	70,0	7	100,0	14,29	26,23
Cycle 3 Day 1	Yes	124	91,9	112	90,3	11,01	18,66
	No	7	70,0	6	85,7	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	121	89,6	113	93,4	12,68	21,04
	No	7	70,0	7	100,0	9,52	25,20
Cycle 5 Day 1	Yes	117	86,7	112	95,7	11,61	19,86
	No	7	70,0	6	85,7	27,78	32,77
Cycle 6 Day 1	Yes	114	84,4	105	92,1	10,16	18,56
	No	7	70,0	7	100,0	14,29	17,82
Cycle 7 Day 1	Yes	106	78,5	99	93,4	10,77	21,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	14,29	17,82
Cycle 8 Day 1	Yes	100	74,1	91	91,0	10,99	20,52
	No	6	60,0	6	100,0	16,67	18,26
Cycle 9 Day 1	Yes	92	68,1	90	97,8	8,15	16,05
	No	6	60,0	6	100,0	5,56	13,61
Cycle 10 Day 1	Yes	83	61,5	80	96,4	8,75	16,56
	No	6	60,0	6	100,0	11,11	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Yes	76	56,3	74	97,4	10,81	18,39
	No	4	40,0	4	100,0	0,00	0,00
Cycle 12 Day 1	Yes	72	53,3	65	90,3	11,28	18,89
	No	4	40,0	4	100,0	16,67	19,25
Cycle 13 Day 1	Yes	64	47,4	60	93,8	9,44	20,44
	No	2	20,0	2	100,0	0,00	0,00
Cycle 14 Day 1	Yes	58	43,0	55	94,8	12,12	23,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	0,00	0,00
Cycle 15 Day 1	Yes	55	40,7	52	94,5	10,90	20,58
	No	2	20,0	2	100,0	16,67	23,57
Cycle 16 Day 1	Yes	48	35,6	45	93,8	9,63	16,85
	No	2	20,0	2	100,0	16,67	23,57
Cycle 17 Day 1	Yes	43	31,9	42	97,7	6,35	13,25
	No	2	20,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	Yes	39	28,9	35	89,7	7,62	14,20
	No	2	20,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	14,58	23,85
	No	2	20,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	11,11	18,22
	No	2	20,0	2	100,0	0,00	0,00
Cycle 21 Day 1	Yes	27	20,0	24	88,9	13,89	16,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	0,00	0,00
Cycle 22 Day 1	Yes	27	20,0	23	85,2	14,49	26,26
	No	2	20,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	9,80	15,66
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	7,84	14,57
	No	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Yes	14	10,4	12	85,7	22,22	25,95
	No	1	10,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	21,21	26,97
	No	1	10,0	1	100,0	0,00	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	33,33	33,33
	No	1	10,0	1	100,0	33,33	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	8,33	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	33,33	36,51
	No	1	10,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	16,67	19,25
	No	1	10,0	1	100,0	0,00	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	16,67	19,25
	No	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	5	3,7	4	80,0	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	31,01	26,62
	No	2	20,0	1	50,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	33,33	14,91
	No	134	100,0	131	97,8	32,32	28,02
Cycle 2 Day 1	Yes	7	63,6	7	100,0	9,52	16,27
	No	129	96,3	119	92,2	17,37	23,31
Cycle 3 Day 1	Yes	7	63,6	7	100,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	124	92,5	111	89,5	10,81	18,62
Cycle 4 Day 1	Yes	7	63,6	7	100,0	14,29	17,82
	No	121	90,3	113	93,4	12,39	21,45
Cycle 5 Day 1	Yes	7	63,6	7	100,0	19,05	26,23
	No	117	87,3	111	94,9	12,01	20,50
Cycle 6 Day 1	Yes	7	63,6	7	100,0	14,29	17,82
	No	114	85,1	105	92,1	10,16	18,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Yes	7	63,6	7	100,0	4,76	12,60
	No	106	79,1	99	93,4	11,45	21,38
Cycle 8 Day 1	Yes	7	63,6	7	100,0	19,05	37,80
	No	99	73,9	90	90,9	10,74	18,58
Cycle 9 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	92	68,7	90	97,8	8,52	16,24
Cycle 10 Day 1	Yes	6	54,5	6	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	83	61,9	80	96,4	9,58	17,74
Cycle 11 Day 1	Yes	6	54,5	6	100,0	5,56	13,61
	No	74	55,2	72	97,3	10,65	18,41
Cycle 12 Day 1	Yes	6	54,5	6	100,0	5,56	13,61
	No	70	52,2	63	90,0	12,17	19,22
Cycle 13 Day 1	Yes	5	45,5	5	100,0	13,33	29,81
	No	61	45,5	57	93,4	8,77	19,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	Yes	5	45,5	5	100,0	6,67	14,91
	No	55	41,0	52	94,5	12,18	23,83
Cycle 15 Day 1	Yes	4	36,4	4	100,0	8,33	16,67
	No	53	39,6	50	94,3	11,33	20,88
Cycle 16 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	47	35,1	44	93,6	10,61	17,27
Cycle 17 Day 1	Yes	3	27,3	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	42	31,3	41	97,6	7,32	13,97
Cycle 18 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	38	28,4	34	89,5	8,82	14,93
Cycle 19 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	30	90,9	15,56	24,34
Cycle 20 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	29	87,9	11,49	18,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	27	20,1	24	88,9	12,50	16,48
Cycle 22 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	23	85,2	14,49	26,26
Cycle 23 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	19	14,2	16	84,2	8,33	14,91
Cycle 24 Day 1	Yes	2	18,2	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	18	13,4	16	88,9	8,33	14,91
Cycle 25 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	13	9,7	11	84,6	21,21	26,97
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	21,21	26,97
Cycle 27 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	10	7,5	7	70,0	33,33	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	9	6,7	8	88,9	4,17	11,79
Cycle 29 Day 1	Yes	1	9,1	1	100,0	100,00	-
	No	8	6,0	6	75,0	16,67	18,26
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	13,33	18,26
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	6	4,5	5	83,3	13,33	18,26
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	0,00	0,00
Cycle 33 Day 1	No	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	44,44	50,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	61	45,5	41	67,2	30,08	24,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D1
94_REE_C30SL_SG.xls
24JUN2020 20:46

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30AP.p
10SEP2019 13:34

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30CF.
10SEP2019 13:48

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30CO.
10SEP2019 14:0(

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30DI.
10SEP2019 14:14

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30DY.
10SEP2019 14:28

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30EF.p
10SEP2019 14:37

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30FA.p
10SEP2019 15:08

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30NV.p
10SEP2019 15:57

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30PA.
10SEP2019 16:37

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30PF.
10SEP2019 17:15

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30QL.
10SEP2019 17:39

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30RF.
10SEP2019 17:55

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30SF.
10SEP2019 18:12

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_C30SL.
10SEP2019 18:27

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30AP.
28NOV2019 11:07

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30CF.
28NOV2019 11:14

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30CO
28NOV2019 11:21

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30DI
28NOV2019 11:27

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30DY.
28NOV2019 11:34

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30EF.
28NOV2019 11:41

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30FA.
28NOV2019 11:48

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30NV.
28NOV2019 12:01

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30PA.
28NOV2019 12:08

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30PF.
28NOV2019 12:14

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30QL
28NOV2019 12:21

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30RF.
29NOV2019 13:19

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30SF.
28NOV2019 12:31

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_C30SL.
28NOV2019 12:38

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30AP.
24JUN2020 21:18

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30CF.
24JUN2020 21:25

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30CO
24JUN2020 21:3

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30DI
24JUN2020 21:3

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30DY.
24JUN2020 21:4(

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30EF.
24JUN2020 21:53

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30FA.
24JUN2020 21:5

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30NV.
24JUN2020 22:13

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30PA.
24JUN2020 22:19

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30PF.
24JUN2020 22:25

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30QL
24JUN2020 22:32

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30RF.
24JUN2020 22:38

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30SF.
24JUN2020 22:4

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_C30SL.
24JUN2020 22:5(

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	10	27,0	27	73,0	6,41	1,87	NE	18,04	14,72	NE
Sex	Male	14	37,8	3	21,4	11	78,6	18,04	6,41	NE	18,04	18,04	NE
	Female	23	62,2	7	30,4	16	69,6	2,83	0,95	NE	NE	3,68	NE
Age	18-64	29	78,4	8	27,6	21	72,4	14,72	1,97	NE	18,04	14,72	NE
	65-74	8	21,6	2	25,0	6	75,0	1,81	0,95	NE	NE	1,81	NE
Race	White	20	54,1	5	25,0	15	75,0	18,04	1,87	NE	18,04	18,04	NE
	Other	17	45,9	5	29,4	12	70,6	6,41	0,95	NE	14,72	6,41	NE
Region	America (AM)	12	32,4	4	33,3	8	66,7	3,68	0,95	NE	18,04	3,68	NE
	Europe (EU)	10	27,0	2	20,0	8	80,0	NE	1,81	NE	NE	1,97	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30AP_SG.xls
07SEP2019 18:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	4	26,7	11	73,3	6,41	0,95	NE	NE	6,41	NE
ECOG Performance Status	0	15	40,5	6	40,0	9	60,0	3,68	1,81	NE	18,04	6,41	NE
	1	17	45,9	2	11,8	15	88,2	14,72	14,72	NE	NE	14,72	NE
	2	5	13,5	2	40,0	3	60,0	0,95	0,95	NE	1,97	0,95	NE
Number of Prior Anticancer Therapies	None	14	37,8	3	21,4	11	78,6	14,72	1,87	NE	NE	14,72	NE
	1	2	5,4	1	50,0	1	50,0	18,04	NE	NE	18,04	NE	NE
	2 or More	21	56,8	6	28,6	15	71,4	3,68	0,95	NE	NE	3,68	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30AP_SG.xls
07SEP2019 18:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	3	21,4	11	78,6	14,72	1,87	NE	NE	14,72	NE
	Previously Treated	23	62,2	7	30,4	16	69,6	3,68	0,95	18,04	18,04	6,41	18,04
Molecular Testing Results	Local	12	32,4	3	25,0	9	75,0	14,72	1,81	NE	NE	14,72	NE
	Central	25	67,6	7	28,0	18	72,0	6,41	0,95	18,04	18,04	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30AP_SG.xls
07SEP2019 18:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	9	25,7	26	74,3	6,41	1,87	NE	18,04	18,04	NE
	No	2	5,4	1	50,0	1	50,0	14,72	NE	NE	14,72	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8			4	100,0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30AP_SG.xls
07SEP2019 18:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	10	30,3	23	69,7	6,41	1,81	NE	18,04	14,72	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30AP_SG.xls
07SEP2019 18:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	27	73,0	10	27,0	1,02	0,95	1,87	3,25	1,48	4,63
Sex	Male	14	37,8	10	71,4	4	28,6	1,05	0,92	4,63	4,37	1,05	6,47
	Female	23	62,2	17	73,9	6	26,1	0,99	0,95	1,84	1,86	1,02	4,63
Age	18-64	29	78,4	23	79,3	6	20,7	1,02	0,95	1,87	2,38	1,48	4,63
	65-74	8	21,6	4	50,0	4	50,0	0,95	0,95	4,63	4,37	0,95	NE
Race	White	20	54,1	14	70,0	6	30,0	1,48	0,95	3,71	3,71	1,84	10,18
	Other	17	45,9	13	76,5	4	23,5	0,95	0,95	1,81	1,81	0,95	4,63
Region	America (AM)	12	32,4	8	66,7	4	33,3	1,02	0,95	2,79	2,79	1,02	NE
	Europe (EU)	10	27,0	7	70,0	3	30,0	1,05	0,92	7,56	1,97	1,05	10,18

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30CF_SG.xls
07SEP2019 18:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	12	80,0	3	20,0	0,95	0,95	4,11	3,91	0,95	6,41
ECOG Performance Status	0	15	40,5	10	66,7	5	33,3	1,48	0,95	4,63	4,63	1,87	NE
	1	17	45,9	14	82,4	3	17,6	0,95	0,92	1,05	1,45	0,95	4,63
	2	5	13,5	3	60,0	2	40,0	1,81	1,81	10,18	1,97	1,81	10,18
Number of Prior Anticancer Therapies	None	14	37,8	11	78,6	3	21,4	1,02	0,95	2,79	2,32	1,02	10,18
	1	2	5,4	1	50,0	1	50,0	3,71	NE	NE	3,71	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30CF_SG.xls
07SEP2019 18:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	21	56,8	15	71,4	6	28,6	0,95	0,95	3,71	3,71	1,02	6,41
Prior Treatment	Naïve	14	37,8	11	78,6	3	21,4	1,02	0,95	2,79	2,32	1,02	10,18
	Previously Treated	23	62,2	16	69,6	7	30,4	0,99	0,95	3,71	3,71	1,02	6,41
Molecular Testing Results	Local	12	32,4	7	58,3	5	41,7	0,95	0,95	3,71	3,71	0,95	NE
	Central	25	67,6	20	80,0	5	20,0	1,02	0,95	1,87	1,97	1,48	4,63

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30CF_SG.xls
07SEP2019 18:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	26	74,3	9	25,7	1,02	0,95	1,87	3,71	1,81	4,63
	No	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8	2	50,0	2	50,0	0,85	0,85	NE	6,47	0,85	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30CF_SG.xls
07SEP2019 18:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	25	75,8	8	24,2	1,02	0,95	1,87	2,79	1,48	4,63

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30CF_SG.xls
07SEP2019 18:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	24	64,9	13	35,1	0,95	0,95	1,05	1,87	0,95	8,31
Sex	Male	14	37,8	10	71,4	4	28,6	0,95	0,95	1,87	1,46	0,95	8,31
	Female	23	62,2	14	60,9	9	39,1	0,95	0,95	1,87	1,89	0,95	14,75
Age	18-64	29	78,4	20	69,0	9	31,0	0,95	0,95	1,87	1,87	1,02	8,31
	65-74	8	21,6	4	50,0	4	50,0	0,95	0,95	3,75	2,35	0,95	NE
Race	White	20	54,1	11	55,0	9	45,0	1,87	0,95	8,31	8,31	1,87	NE
	Other	17	45,9	13	76,5	4	23,5	0,95	NE	NE	0,95	0,95	1,87
Region	America (AM)	12	32,4	8	66,7	4	33,3	0,95	0,95	3,75	3,75	0,95	NE
	Europe (EU)	10	27,0	5	50,0	5	50,0	1,05	0,95	7,56	5,65	1,05	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30CO_SG.xls
07SEP2019 18:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	11	73,3	4	26,7	0,95	NE	NE	0,95	0,95	1,91
ECOG Performance Status	0	15	40,5	10	66,7	5	33,3	0,95	0,95	3,75	3,75	0,95	NE
	1	17	45,9	11	64,7	6	35,3	0,95	0,95	1,87	1,46	0,95	14,75
	2	5	13,5	3	60,0	2	40,0	0,95	0,95	3,75	1,05	0,95	3,75
Number of Prior Anticancer Therapies	None	14	37,8	10	71,4	4	28,6	0,95	0,95	3,75	3,75	0,95	NE
	1	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE
	2 or More	21	56,8	13	61,9	8	38,1	0,95	0,95	1,87	1,87	0,95	14,75

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30CO_SG.xls
07SEP2019 18:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	10	71,4	4	28,6	0,95	0,95	3,75	3,75	0,95	NE
	Previously Treated	23	62,2	14	60,9	9	39,1	0,95	0,95	1,05	1,46	0,95	7,56
Molecular Testing Results	Local	12	32,4	9	75,0	3	25,0	0,95	0,95	1,91	1,91	0,95	11,99
	Central	25	67,6	15	60,0	10	40,0	0,95	0,95	1,05	1,87	0,95	14,75

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30CO_SG.xls
07SEP2019 18:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	23	65,7	12	34,3	0,95	0,95	1,87	1,87	1,02	8,31
	No	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30CO_SG.xls
07SEP2019 18:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	0,95	0,95	NE	NE	0,95	NE
	No	33	89,2	23	69,7	10	30,3	0,95	0,95	1,05	1,87	0,95	7,56

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30CO_SG.xls
07SEP2019 18:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	24	64,9	13	35,1	1,81	1,02	3,68	4,19	1,87	7,56
Sex	Male	14	37,8	7	50,0	7	50,0	3,27	1,87	6,47	6,47	3,75	NE
	Female	23	62,2	17	73,9	6	26,1	1,64	0,95	2,79	3,24	1,81	6,41
Age	18-64	29	78,4	20	69,0	9	31,0	1,81	0,95	3,68	5,13	1,87	7,56
	65-74	8	21,6	4	50,0	4	50,0	1,81	1,81	3,75	3,27	1,81	NE
Race	White	20	54,1	13	65,0	7	35,0	1,81	0,95	5,62	5,62	1,84	16,49
	Other	17	45,9	11	64,7	6	35,3	1,81	0,95	3,75	3,71	1,81	6,47
Region	America (AM)	12	32,4	10	83,3	2	16,7	1,81	0,95	3,68	3,68	1,81	5,62
	Europe (EU)	10	27,0	6	60,0	4	40,0	4,11	1,48	9,26	8,41	1,81	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30DI_SG.xls
07SEP2019 18:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	8	53,3	7	46,7	1,81	0,95	3,68	3,68	1,81	NE
ECOG Performance Status	0	15	40,5	10	66,7	5	33,3	1,81	1,48	3,75	3,75	1,87	NE
	1	17	45,9	11	64,7	6	35,3	1,02	0,95	6,47	5,08	1,02	11,93
	2	5	13,5	3	60,0	2	40,0	1,81	1,81	9,26	6,41	1,81	9,26
Number of Prior Anticancer Therapies	None	14	37,8	12	85,7	2	14,3	1,84	1,48	4,63	4,19	1,84	11,93
	1	2	5,4	1	50,0	1	50,0	5,62	NE	NE	5,62	NE	NE
	2 or More	21	56,8	11	52,4	10	47,6	1,81	0,95	3,68	3,68	1,81	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30DI_SG.xls
07SEP2019 18:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	12	85,7	2	14,3	1,84	1,48	4,63	4,19	1,84	11,93
	Previously Treated	23	62,2	12	52,2	11	47,8	1,81	0,95	3,68	4,65	1,81	7,56
Molecular Testing Results	Local	12	32,4	9	75,0	3	25,0	1,02	0,95	2,79	2,79	1,02	16,49
	Central	25	67,6	15	60,0	10	40,0	1,84	1,48	5,62	6,41	2,79	9,26

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30DI_SG.xls
07SEP2019 18:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	23	65,7	12	34,3	1,81	1,02	3,68	4,63	1,87	7,56
	No	2	5,4	1	50,0	1	50,0	2,79	NE	NE	2,79	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30DI_SG.xls
07SEP2019 18:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	6,47	6,47	NE	NE	6,47	NE
	No	33	89,2	23	69,7	10	30,3	1,81	0,95	2,79	3,71	1,84	7,56

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30DI_SG.xls
07SEP2019 18:13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	12	32,4	25	67,6	6,54	3,68	NE	NE	13,90	NE
Sex	Male	14	37,8	4	28,6	10	71,4	6,54	1,31	NE	NE	6,54	NE
	Female	23	62,2	8	34,8	15	65,2	5,08	3,68	NE	NE	5,55	NE
Age	18-64	29	78,4	9	31,0	20	69,0	7,39	3,71	NE	NE	13,90	NE
	65-74	8	21,6	3	37,5	5	62,5	1,81	1,31	NE	NE	1,81	NE
Race	White	20	54,1	6	30,0	14	70,0	7,39	1,81	NE	NE	14,72	NE
	Other	17	45,9	6	35,3	11	64,7	5,55	0,95	NE	13,90	5,55	NE
Region	America (AM)	12	32,4	5	41,7	7	58,3	6,54	3,68	NE	14,72	6,54	NE
	Europe (EU)	10	27,0	1	10,0	9	90,0	NE	1,81	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30DY_SG.xls
07SEP2019 18:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	6	40,0	9	60,0	3,71	0,95	NE	13,90	3,71	NE
ECOG Performance Status	0	15	40,5	5	33,3	10	66,7	6,54	3,68	NE	NE	6,54	NE
	1	17	45,9	6	35,3	11	64,7	4,60	1,31	14,72	14,72	13,90	NE
	2	5	13,5	1	20,0	4	80,0	0,95	0,95	NE	NE	0,95	NE
Number of Prior Anticancer Therapies	None	14	37,8	4	28,6	10	71,4	13,90	6,54	NE	NE	13,90	NE
	1	2	5,4	1	50,0	1	50,0	7,39	NE	NE	7,39	NE	NE
	2 or More	21	56,8	7	33,3	14	66,7	3,68	0,95	NE	NE	3,71	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30DY_SG.xls
07SEP2019 18:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	4	28,6	10	71,4	13,90	6,54	NE	NE	13,90	NE
	Previously Treated	23	62,2	8	34,8	15	65,2	3,68	1,31	NE	NE	3,71	NE
Molecular Testing Results	Local	12	32,4	4	33,3	8	66,7	6,54	1,81	NE	13,90	6,54	NE
	Central	25	67,6	8	32,0	17	68,0	4,60	1,31	NE	NE	7,39	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30DY_SG.xls
07SEP2019 18:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	11	31,4	24	68,6	5,55	3,68	NE	NE	7,39	NE
	No	2	5,4	1	50,0	1	50,0	13,90	NE	NE	13,90	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30DY_SG.xls
07SEP2019 18:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	0,85	0,85	NE	NE	0,85	NE
	No	33	89,2	11	33,3	22	66,7	6,54	3,68	NE	14,72	13,90	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30DY_SG.xls
07SEP2019 18:16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	16	43,2	21	56,8	2,83	1,81	9,26	13,83	6,54	NE
Sex	Male	14	37,8	5	35,7	9	64,3	6,41	0,92	NE	NE	6,41	NE
	Female	23	62,2	11	47,8	12	52,2	2,79	1,81	13,83	13,83	2,83	15,61
Age	18-64	29	78,4	15	51,7	14	48,3	2,79	0,95	6,54	9,26	6,41	NE
	65-74	8	21,6	1	12,5	7	87,5	NE	1,81	NE	NE	NE	NE
Race	White	20	54,1	9	45,0	11	55,0	2,76	1,81	13,83	13,83	6,54	NE
	Other	17	45,9	7	41,2	10	58,8	2,83	0,95	15,61	15,61	3,71	15,61
Region	America (AM)	12	32,4	7	58,3	5	41,7	2,76	0,95	6,54	6,54	2,76	NE
	Europe (EU)	10	27,0	2	20,0	8	80,0	NE	0,92	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30EF_SG.xls
07SEP2019 18:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	7	46,7	8	53,3	3,71	0,95	15,61	13,83	3,71	15,61
ECOG Performance Status	0	15	40,5	6	40,0	9	60,0	2,83	1,81	NE	NE	6,41	NE
	1	17	45,9	9	52,9	8	47,1	3,24	0,92	13,83	9,26	3,71	15,61
	2	5	13,5	1	20,0	4	80,0	1,81	1,81	NE	NE	1,81	NE
Number of Prior Anticancer Therapies	None	14	37,8	6	42,9	8	57,1	3,71	2,76	NE	NE	3,71	NE
	1	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
	2 or More	21	56,8	10	47,6	11	52,4	1,81	0,95	13,83	13,83	1,87	15,61

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30EF_SG.xls
07SEP2019 18:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	6	42,9	8	57,1	3,71	2,76	NE	NE	3,71	NE
	Previously Treated	23	62,2	10	43,5	13	56,5	1,84	0,95	13,83	13,83	1,87	NE
Molecular Testing Results	Local	12	32,4	7	58,3	5	41,7	2,83	0,95	6,54	6,54	2,83	NE
	Central	25	67,6	9	36,0	16	64,0	2,76	0,95	15,61	15,61	6,41	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30EF_SG.xls
07SEP2019 18:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	15	42,9	20	57,1	2,83	1,81	13,83	15,61	6,54	NE
	No	2	5,4	1	50,0	1	50,0	3,71	NE	NE	3,71	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	0,85	0,85	NE	NE	0,85	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30EF_SG.xls
07SEP2019 18:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	15	45,5	18	54,5	2,83	1,81	9,26	13,83	6,54	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30EF_SG.xls
07SEP2019 18:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	17	45,9	20	54,1	0,95	0,95	5,49	11,93	1,87	NE
Sex	Male	14	37,8	8	57,1	6	42,9	1,87	0,95	6,41	6,41	1,87	NE
	Female	23	62,2	9	39,1	14	60,9	0,95	0,95	NE	NE	0,95	NE
Age	18-64	29	78,4	15	51,7	14	48,3	0,95	0,95	5,49	6,41	1,84	NE
	65-74	8	21,6	2	25,0	6	75,0	0,95	0,95	NE	NE	0,95	NE
Race	White	20	54,1	8	40,0	12	60,0	1,84	0,95	NE	NE	1,87	NE
	Other	17	45,9	9	52,9	8	47,1	0,95	0,95	6,41	6,41	0,95	NE
Region	America (AM)	12	32,4	7	58,3	5	41,7	0,95	0,95	1,87	1,87	0,95	NE
	Europe (EU)	10	27,0	2	20,0	8	80,0	11,93	0,95	NE	NE	11,93	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30FA_SG.xls
07SEP2019 18:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	8	53,3	7	46,7	0,95	0,95	6,41	5,49	0,95	NE
ECOG Performance Status	0	15	40,5	8	53,3	7	46,7	0,95	0,95	6,41	6,41	1,87	NE
	1	17	45,9	8	47,1	9	52,9	0,95	0,95	11,93	11,93	1,02	NE
	2	5	13,5	1	20,0	4	80,0	0,95	0,95	NE	NE	0,95	NE
Number of Prior Anticancer Therapies	None	14	37,8	7	50,0	7	50,0	0,95	0,95	NE	11,93	0,95	NE
	1	2	5,4	1	50,0	1	50,0	5,62	NE	NE	5,62	NE	NE
	2 or More	21	56,8	9	42,9	12	57,1	0,95	0,95	6,41	6,41	1,02	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30FA_SG.xls
07SEP2019 18:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	7	50,0	7	50,0	0,95	0,95	NE	11,93	0,95	NE
	Previously Treated	23	62,2	10	43,5	13	56,5	0,95	0,95	5,62	6,41	1,02	NE
Molecular Testing Results	Local	12	32,4	6	50,0	6	50,0	0,95	0,95	5,49	5,49	0,95	NE
	Central	25	67,6	11	44,0	14	56,0	1,02	0,95	11,93	11,93	1,84	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30FA_SG.xls
07SEP2019 18:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	16	45,7	19	54,3	1,02	0,95	5,62	11,93	1,87	NE
	No	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30FA_SG.xls
07SEP2019 18:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	0,85	0,85	NE	NE	0,85	NE
	No	33	89,2	16	48,5	17	51,5	0,95	0,95	5,49	6,41	1,84	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30FA_SG.xls
07SEP2019 18:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	14	37,8	23	62,2	4,67	1,81	13,83	13,83	9,23	NE
Sex	Male	14	37,8	2	14,3	12	85,7	13,83	6,41	NE	NE	13,83	NE
	Female	23	62,2	12	52,2	11	47,8	1,89	0,95	9,23	9,23	1,97	NE
Age	18-64	29	78,4	12	41,4	17	58,6	5,52	1,97	13,83	13,83	9,23	NE
	65-74	8	21,6	2	25,0	6	75,0	0,95	0,95	NE	NE	0,95	NE
Race	White	20	54,1	8	40,0	12	60,0	4,67	1,02	NE	NE	10,15	NE
	Other	17	45,9	6	35,3	11	64,7	5,52	0,95	NE	NE	5,52	NE
Region	America (AM)	12	32,4	5	41,7	7	58,3	3,68	0,95	NE	NE	3,68	NE
	Europe (EU)	10	27,0	3	30,0	7	70,0	3,32	0,95	NE	NE	1,97	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30NV_SG.xls
07SEP2019 18:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	6	40,0	9	60,0	6,41	1,81	13,83	13,83	6,41	NE
ECOG Performance Status	0	15	40,5	5	33,3	10	66,7	6,41	0,95	NE	NE	13,83	NE
	1	17	45,9	6	35,3	11	64,7	9,23	1,02	13,83	13,83	9,23	NE
	2	5	13,5	3	60,0	2	40,0	1,81	1,81	4,67	1,97	1,81	4,67
Number of Prior Anticancer Therapies	None	14	37,8	5	35,7	9	64,3	10,15	4,67	NE	NE	10,15	NE
	1	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
	2 or More	21	56,8	9	42,9	12	57,1	1,97	0,95	13,83	13,83	1,97	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30NV_SG.xls
07SEP2019 18:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	5	35,7	9	64,3	10,15	4,67	NE	NE	10,15	NE
	Previously Treated	23	62,2	9	39,1	14	60,9	1,97	0,95	13,83	13,83	3,68	NE
Molecular Testing Results	Local	12	32,4	5	41,7	7	58,3	9,23	0,95	NE	13,83	9,23	NE
	Central	25	67,6	9	36,0	16	64,0	4,67	1,81	NE	NE	5,52	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30NV_SG.xls
07SEP2019 18:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	13	37,1	22	62,9	4,67	1,81	13,83	NE	10,15	NE
	No	2	5,4	1	50,0	1	50,0	9,23	NE	NE	9,23	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8			4	100,0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30NV_SG.xls
07SEP2019 18:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	14	42,4	19	57,6	4,67	1,02	13,83	13,83	6,41	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30NV_SG.xls
07SEP2019 18:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	17	45,9	20	54,1	5,55	0,95	11,04	11,99	6,47	NE
Sex	Male	14	37,8	8	57,1	6	42,9	5,55	0,95	9,30	6,47	5,55	13,77
	Female	23	62,2	9	39,1	14	60,9	5,55	0,95	14,72	14,72	7,39	NE
Age	18-64	29	78,4	14	48,3	15	51,7	5,55	0,95	11,04	11,99	7,39	NE
	65-74	8	21,6	3	37,5	5	62,5	0,95	0,95	NE	6,47	0,95	NE
Race	White	20	54,1	8	40,0	12	60,0	6,47	0,95	14,72	14,72	6,47	NE
	Other	17	45,9	9	52,9	8	47,1	3,71	0,95	11,04	7,39	5,55	13,77
Region	America (AM)	12	32,4	8	66,7	4	33,3	0,95	0,95	7,39	7,39	0,95	14,72
	Europe (EU)	10	27,0	2	20,0	8	80,0	13,77	0,95	NE	NE	13,77	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30PA_SG.xls
07SEP2019 18:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	7	46,7	8	53,3	5,55	0,95	11,99	11,04	5,55	NE
ECOG Performance Status	0	15	40,5	10	66,7	5	33,3	0,95	0,95	6,47	6,47	1,87	NE
	1	17	45,9	6	35,3	11	64,7	11,04	3,71	14,72	13,77	11,04	NE
	2	5	13,5	1	20,0	4	80,0	0,95	0,95	NE	NE	0,95	NE
Number of Prior Anticancer Therapies	None	14	37,8	8	57,1	6	42,9	6,47	0,95	13,77	13,77	6,47	NE
	1	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE
	2 or More	21	56,8	8	38,1	13	61,9	5,55	0,95	11,99	11,99	5,55	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30PA_SG.xls
07SEP2019 18:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	8	57,1	6	42,9	6,47	0,95	13,77	13,77	6,47	NE
	Previously Treated	23	62,2	9	39,1	14	60,9	1,87	0,95	11,99	11,04	5,55	NE
Molecular Testing Results	Local	12	32,4	6	50,0	6	50,0	3,71	0,95	9,30	9,30	3,71	NE
	Central	25	67,6	11	44,0	14	56,0	5,55	0,95	13,77	13,77	6,47	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30PA_SG.xls
07SEP2019 18:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	16	45,7	19	54,3	5,55	0,95	11,04	11,99	7,39	NE
	No	2	5,4	1	50,0	1	50,0	3,71	NE	NE	3,71	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30PA_SG.xls
07SEP2019 18:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	0,85	0,85	NE	NE	0,85	NE
	No	33	89,2	16	48,5	17	51,5	5,55	0,95	11,04	11,99	6,47	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30PA_SG.xls
07SEP2019 18:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	14	37,8	23	62,2	3,71	0,95	18,04	18,04	6,41	NE
Sex	Male	14	37,8	5	35,7	9	64,3	11,93	4,37	NE	18,04	11,93	NE
	Female	23	62,2	9	39,1	14	60,9	1,43	0,95	NE	NE	1,81	NE
Age	18-64	29	78,4	11	37,9	18	62,1	3,71	1,05	18,04	18,04	6,41	NE
	65-74	8	21,6	3	37,5	5	62,5	0,95	0,95	NE	NE	0,95	NE
Race	White	20	54,1	6	30,0	14	70,0	4,37	1,05	NE	18,04	18,04	NE
	Other	17	45,9	8	47,1	9	52,9	0,95	0,95	11,93	9,17	1,81	NE
Region	America (AM)	12	32,4	4	33,3	8	66,7	5,55	0,95	NE	18,04	5,55	NE
	Europe (EU)	10	27,0	3	30,0	7	70,0	6,49	0,95	NE	NE	1,05	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30PF_SG.xls
07SEP2019 18:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	7	46,7	8	53,3	1,81	0,95	NE	6,41	1,81	NE
ECOG Performance Status	0	15	40,5	6	40,0	9	60,0	5,55	0,95	NE	18,04	6,41	NE
	1	17	45,9	6	35,3	11	64,7	3,71	0,95	NE	NE	4,37	NE
	2	5	13,5	2	40,0	3	60,0	1,05	1,05	NE	1,81	1,05	NE
Number of Prior Anticancer Therapies	None	14	37,8	4	28,6	10	71,4	11,93	0,95	NE	NE	11,93	NE
	1	2	5,4	1	50,0	1	50,0	18,04	NE	NE	18,04	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30PF_SG.xls
07SEP2019 18:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	21	56,8	9	42,9	12	57,1	1,81	0,95	6,41	6,41	1,87	NE
Prior Treatment	Naïve	14	37,8	4	28,6	10	71,4	11,93	0,95	NE	NE	11,93	NE
	Previously Treated	23	62,2	10	43,5	13	56,5	1,81	0,95	6,41	18,04	1,87	18,04
Molecular Testing Results	Local	12	32,4	3	25,0	9	75,0	5,55	0,95	NE	NE	5,55	NE
	Central	25	67,6	11	44,0	14	56,0	1,87	0,95	11,93	18,04	3,71	18,04

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30PF_SG.xls
07SEP2019 18:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	13	37,1	22	62,9	4,37	1,05	18,04	18,04	6,41	NE
	No	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	0,85	0,85	NE	NE	0,85	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30PF_SG.xls
07SEP2019 18:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	13	39,4	20	60,6	3,71	0,95	18,04	18,04	5,55	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30PF_SG.xls
07SEP2019 18:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	17	45,9	20	54,1	1,84	0,95	7,39	15,61	4,63	17,54
Sex	Male	14	37,8	6	42,9	8	57,1	4,63	0,95	17,54	17,54	4,63	17,54
	Female	23	62,2	11	47,8	12	52,2	1,81	0,95	11,30	11,30	1,81	NE
Age	18-64	29	78,4	14	48,3	15	51,7	1,84	0,95	11,30	15,61	4,57	17,54
	65-74	8	21,6	3	37,5	5	62,5	1,81	0,95	NE	7,39	1,81	NE
Race	White	20	54,1	8	40,0	12	60,0	1,87	0,95	17,54	17,54	4,63	17,54
	Other	17	45,9	9	52,9	8	47,1	0,95	0,95	7,39	7,39	1,81	15,61
Region	America (AM)	12	32,4	7	58,3	5	41,7	1,84	0,95	4,63	4,63	1,84	17,54
	Europe (EU)	10	27,0	2	20,0	8	80,0	11,30	1,81	NE	NE	11,30	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30QL_SG.xls
07SEP2019 18:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	8	53,3	7	46,7	0,95	0,95	7,39	7,39	0,95	15,61
ECOG Performance Status	0	15	40,5	8	53,3	7	46,7	1,87	0,95	17,54	17,54	4,63	17,54
	1	17	45,9	8	47,1	9	52,9	0,95	0,95	15,61	11,30	1,84	NE
	2	5	13,5	1	20,0	4	80,0	1,81	1,81	NE	NE	1,81	NE
Number of Prior Anticancer Therapies	None	14	37,8	6	42,9	8	57,1	1,84	0,95	NE	NE	1,84	NE
	1	2	5,4	1	50,0	1	50,0	17,54	NE	NE	17,54	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30QL_SG.xls
07SEP2019 18:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	21	56,8	10	47,6	11	52,4	1,81	0,95	11,30	11,30	1,87	15,61
Prior Treatment	Naïve	14	37,8	6	42,9	8	57,1	1,84	0,95	NE	NE	1,84	NE
	Previously Treated	23	62,2	11	47,8	12	52,2	1,81	0,95	11,30	11,30	1,87	17,54
Molecular Testing Results	Local	12	32,4	6	50,0	6	50,0	1,81	0,95	4,63	4,63	1,81	NE
	Central	25	67,6	11	44,0	14	56,0	1,84	0,95	15,61	15,61	1,87	17,54

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30QL_SG.xls
07SEP2019 18:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	16	45,7	19	54,3	1,87	0,95	11,30	15,61	4,63	17,54
	No	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	0,85	0,85	NE	NE	0,85	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30QL_SG.xls
07SEP2019 18:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	16	48,5	17	51,5	1,84	0,95	7,39	11,30	4,57	17,54

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30QL_SG.xls
07SEP2019 18:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	17	45,9	20	54,1	1,97	0,95	6,47	7,39	3,71	NE
Sex	Male	14	37,8	7	50,0	7	50,0	2,79	0,95	7,39	6,54	2,79	NE
	Female	23	62,2	10	43,5	13	56,5	1,92	0,95	13,80	13,80	1,97	NE
Age	18-64	29	78,4	13	44,8	16	55,2	2,79	0,95	7,39	13,80	3,71	NE
	65-74	8	21,6	4	50,0	4	50,0	0,95	0,95	6,54	3,75	0,95	NE
Race	White	20	54,1	8	40,0	12	60,0	1,97	0,95	NE	NE	2,79	NE
	Other	17	45,9	9	52,9	8	47,1	0,95	0,95	6,54	6,47	0,95	13,80
Region	America (AM)	12	32,4	7	58,3	5	41,7	1,87	0,95	6,54	6,54	1,87	NE
	Europe (EU)	10	27,0	3	30,0	7	70,0	1,97	0,92	NE	NE	1,97	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30RF_SG.xls
07SEP2019 18:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	7	46,7	8	53,3	3,71	0,95	13,80	6,47	3,71	NE
ECOG Performance Status	0	15	40,5	9	60,0	6	40,0	0,95	0,95	6,54	6,54	1,87	NE
	1	17	45,9	6	35,3	11	64,7	4,60	0,95	NE	13,80	4,60	NE
	2	5	13,5	2	40,0	3	60,0	0,95	0,95	NE	1,97	0,95	NE
Number of Prior Anticancer Therapies	None	14	37,8	7	50,0	7	50,0	2,79	0,95	NE	NE	2,79	NE
	1	2	5,4	1	50,0	1	50,0	7,39	NE	NE	7,39	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30RF_SG.xls
07SEP2019 18:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	21	56,8	9	42,9	12	57,1	1,87	0,95	13,80	13,80	1,97	NE
Prior Treatment	Naïve	14	37,8	7	50,0	7	50,0	2,79	0,95	NE	NE	2,79	NE
	Previously Treated	23	62,2	10	43,5	13	56,5	1,87	0,95	7,39	13,80	1,97	NE
Molecular Testing Results	Local	12	32,4	6	50,0	6	50,0	0,95	0,95	6,54	6,54	0,95	NE
	Central	25	67,6	11	44,0	14	56,0	1,97	0,95	7,39	13,80	3,71	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30RF_SG.xls
07SEP2019 18:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	16	45,7	19	54,3	2,38	0,95	6,54	13,80	3,71	NE
	No	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	6,47	6,47	NE	NE	6,47	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30RF_SG.xls
07SEP2019 18:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	16	48,5	17	51,5	1,87	0,95	6,54	13,80	3,71	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30RF_SG.xls
07SEP2019 18:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	18	48,6	19	51,4	1,84	0,95	7,46	9,30	6,41	NE
Sex	Male	14	37,8	9	64,3	5	35,7	3,65	0,92	7,46	7,46	3,65	18,04
	Female	23	62,2	9	39,1	14	60,9	1,82	0,95	12,91	NE	1,84	NE
Age	18-64	29	78,4	15	51,7	14	48,3	1,86	0,95	7,56	12,91	6,41	NE
	65-74	8	21,6	3	37,5	5	62,5	1,81	0,95	NE	7,46	1,81	NE
Race	White	20	54,1	9	45,0	11	55,0	1,87	1,81	18,04	18,04	7,56	18,04
	Other	17	45,9	9	52,9	8	47,1	0,95	0,95	6,47	6,47	0,95	NE
Region	America (AM)	12	32,4	7	58,3	5	41,7	1,84	0,95	9,30	9,30	1,84	NE
	Europe (EU)	10	27,0	4	40,0	6	60,0	3,65	0,92	NE	NE	3,65	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30SF_SG.xls
07SEP2019 18:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	7	46,7	8	53,3	0,95	0,95	12,91	12,91	0,95	NE
ECOG Performance Status	0	15	40,5	8	53,3	7	46,7	1,87	0,95	18,04	18,04	6,41	NE
	1	17	45,9	9	52,9	8	47,1	1,40	0,92	7,56	7,56	1,84	NE
	2	5	13,5	1	20,0	4	80,0	0,95	0,95	NE	NE	0,95	NE
Number of Prior Anticancer Therapies	None	14	37,8	8	57,1	6	42,9	1,84	0,95	9,30	8,38	1,84	NE
	1	2	5,4	1	50,0	1	50,0	18,04	NE	NE	18,04	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30SF_SG.xls
07SEP2019 18:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	21	56,8	9	42,9	12	57,1	1,81	0,95	12,91	12,91	1,87	NE
Prior Treatment	Naïve	14	37,8	8	57,1	6	42,9	1,84	0,95	9,30	8,38	1,84	NE
	Previously Treated	23	62,2	10	43,5	13	56,5	1,84	0,95	12,91	12,91	1,87	18,04
Molecular Testing Results	Local	12	32,4	5	41,7	7	58,3	1,81	0,95	NE	9,30	1,81	NE
	Central	25	67,6	13	52,0	12	48,0	1,84	0,95	7,56	7,56	3,65	18,04

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30SF_SG.xls
07SEP2019 18:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	17	48,6	18	51,4	1,87	0,95	7,56	12,91	6,41	NE
	No	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8	2	50,0	2	50,0	0,85	0,85	NE	6,47	0,85	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30SF_SG.xls
07SEP2019 18:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	16	48,5	17	51,5	1,84	0,95	7,56	12,91	6,41	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30SF_SG.xls
07SEP2019 18:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	13	35,1	24	64,9	11,07	7,39	13,11	18,04	11,96	NE
Sex	Male	14	37,8	5	35,7	9	64,3	6,47	0,95	18,04	18,04	6,47	18,04
	Female	23	62,2	8	34,8	15	65,2	11,96	7,39	13,11	13,11	11,96	NE
Age	18-64	29	78,4	11	37,9	18	62,1	9,26	6,47	12,88	18,04	11,96	NE
	65-74	8	21,6	2	25,0	6	75,0	13,11	11,07	NE	NE	11,07	NE
Race	White	20	54,1	7	35,0	13	65,0	11,07	9,26	18,04	18,04	11,96	18,04
	Other	17	45,9	6	35,3	11	64,7	7,39	0,95	NE	13,11	7,39	NE
Region	America (AM)	12	32,4	6	50,0	6	50,0	9,30	0,95	18,04	13,11	9,30	NE
	Europe (EU)	10	27,0	1	10,0	9	90,0	NE	11,07	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30SL_SG.xls
07SEP2019 18:52

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	6	40,0	9	60,0	6,47	0,95	12,88	11,99	6,47	NE
ECOG Performance Status	0	15	40,5	6	40,0	9	60,0	11,96	9,30	NE	18,04	11,96	NE
	1	17	45,9	7	41,2	10	58,8	7,39	0,95	12,88	11,99	7,39	NE
	2	5	13,5			5	100,0	NE	NE	NE	NE	NE	NE
Number of Prior Anticancer Therapies	None	14	37,8	6	42,9	8	57,1	9,26	6,47	NE	NE	9,26	NE
	1	2	5,4	1	50,0	1	50,0	18,04	NE	NE	18,04	NE	NE
	2 or More	21	56,8	6	28,6	15	71,4	11,96	0,95	NE	12,88	11,96	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30SL_SG.xls
07SEP2019 18:52

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	6	42,9	8	57,1	9,26	6,47	NE	NE	9,26	NE
	Previously Treated	23	62,2	7	30,4	16	69,6	11,96	11,07	18,04	12,88	11,96	18,04
Molecular Testing Results	Local	12	32,4	5	41,7	7	58,3	9,26	0,95	NE	11,07	9,26	NE
	Central	25	67,6	8	32,0	17	68,0	11,99	6,47	18,04	18,04	12,88	18,04

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30SL_SG.xls
07SEP2019 18:52

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	12	34,3	23	65,7	11,07	6,47	13,11	18,04	11,99	NE
	No	2	5,4	1	50,0	1	50,0	7,39	NE	NE	7,39	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8	2	50,0	2	50,0	0,85	0,85	NE	6,47	0,85	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30SL_SG.xls
07SEP2019 18:52

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	11	33,3	22	66,7	11,96	9,26	18,04	18,04	11,99	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_C30SL_SG.xls
07SEP2019 18:52

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	25	32,1	53	67,9	6,41	2,07	18,04	23,95	18,04	NE
Sex	Male	29	37,2	9	31,0	20	69,0	7,39	3,65	20,27	20,27	14,62	NE
	Female	49	62,8	16	32,7	33	67,3	2,10	1,81	NE	NE	15,87	NE
Age	18-64	62	79,5	20	32,3	42	67,7	6,41	2,07	20,27	23,95	18,04	NE
	65-74	14	17,9	4	28,6	10	71,4	1,81	0,92	NE	NE	1,81	NE
	>=75	2	2,6	1	50,0	1	50,0	7,39	7,39	NE	NE	7,39	NE
Race	White	35	44,9	11	31,4	24	68,6	7,39	1,97	NE	NE	18,04	NE
	Other	43	55,1	14	32,6	29	67,4	2,79	1,87	23,95	23,95	14,62	NE
Region	America (AM)	22	28,2	9	40,9	13	59,1	2,87	1,87	20,27	20,27	3,65	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30AP_SG.xls
28NOV2019 9:18

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	4	23,5	13	76,5	7,39	1,87	NE	NE	7,39	NE
	Asia (AS)	39	50,0	12	30,8	27	69,2	14,62	1,87	23,95	23,95	14,72	23,95
ECOG Performance Status	0	30	38,5	13	43,3	17	56,7	3,68	1,81	18,04	20,27	14,62	NE
	1	38	48,7	9	23,7	29	76,3	14,72	2,79	NE	23,95	23,95	NE
	2	10	12,8	3	30,0	7	70,0	0,95	0,92	NE	1,97	0,95	NE
Number of Prior Anticancer Therapies	None	31	39,7	11	35,5	20	64,5	3,65	1,87	NE	NE	15,87	NE
	1	3	3,8	1	33,3	2	66,7	18,04	NE	NE	18,04	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30AP_SG.xls
28NOV2019 9:18

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	13	29,5	31	70,5	6,41	1,87	23,95	23,95	14,62	23,95
Prior Treatment	Naïve	31	39,7	11	35,5	20	64,5	3,65	1,87	NE	NE	15,87	NE
	Previously Treated	47	60,3	14	29,8	33	70,2	6,41	1,87	23,95	23,95	14,62	23,95
Molecular Testing Results	Local	35	44,9	8	22,9	27	77,1	20,27	2,10	NE	NE	20,27	NE
	Central	43	55,1	17	39,5	26	60,5	2,79	1,87	15,87	18,04	7,39	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30AP_SG.xls
28NOV2019 9:18

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	23	31,1	51	68,9	6,41	2,07	20,27	23,95	20,27	NE
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	14,72	7,82	0,92	14,72
Investigator Measurable CNS Disease	Yes	8	10,3	3	37,5	5	62,5	3,65	2,10	NE	15,87	2,10	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30AP_SG.xls
28NOV2019 9:18

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	70	89,7	22	31,4	48	68,6	6,41	1,97	20,27	23,95	20,27	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30AP_SG.xls
28NOV2019 9:18

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	54	69,2	24	30,8	1,02	0,95	1,84	2,79	1,87	4,63
Sex	Male	29	37,2	19	65,5	10	34,5	1,02	0,95	2,79	3,71	2,79	6,47
	Female	49	62,8	35	71,4	14	28,6	1,02	0,95	1,84	2,14	1,84	4,63
Age	18-64	62	79,5	44	71,0	18	29,0	1,02	0,95	1,84	2,79	1,87	5,49
	65-74	14	17,9	8	57,1	6	42,9	0,95	0,92	2,79	2,79	0,95	4,63
	>=75	2	2,6	2	100,0			1,84	1,84	3,71	2,78	1,84	3,71
Race	White	35	44,9	24	68,6	11	31,4	1,84	0,95	2,69	3,71	1,87	7,39
	Other	43	55,1	30	69,8	13	30,2	0,95	0,95	1,84	2,79	1,81	4,63
Region	America (AM)	22	28,2	13	59,1	9	40,9	1,84	0,95	3,71	3,76	1,84	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30CF_SG.xls
28NOV2019 9:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	13	76,5	4	23,5	1,02	0,95	1,97	2,33	1,05	7,56
	Asia (AS)	39	50,0	28	71,8	11	28,2	0,95	0,95	1,87	2,79	1,81	4,63
ECOG Performance Status	0	30	38,5	22	73,3	8	26,7	1,84	0,95	2,79	3,81	1,91	6,41
	1	38	48,7	27	71,1	11	28,9	0,95	0,95	1,84	2,79	1,02	4,63
	2	10	12,8	5	50,0	5	50,0	1,81	1,81	2,73	1,97	1,81	10,18
Number of Prior Anticancer Therapies	None	31	39,7	22	71,0	9	29,0	1,05	0,95	2,79	3,30	1,84	10,18
	1	3	3,8	1	33,3	2	66,7	3,71	3,71	NE	NE	3,71	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30CF_SG.xls
28NOV2019 9:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	31	70,5	13	29,5	0,95	0,95	1,87	2,14	1,81	4,63
Prior Treatment	Naïve	31	39,7	22	71,0	9	29,0	1,05	0,95	2,79	3,30	1,84	10,18
	Previously Treated	47	60,3	32	68,1	15	31,9	0,95	0,95	1,87	2,73	1,84	4,63
Molecular Testing Results	Local	35	44,9	18	51,4	17	48,6	1,81	0,95	2,79	3,71	2,14	NE
	Central	43	55,1	36	83,7	7	16,3	0,99	0,95	1,84	1,97	1,81	4,11

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30CF_SG.xls
28NOV2019 9:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	52	70,3	22	29,7	1,05	0,95	1,87	2,79	1,91	4,63
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	0,95	0,94	0,92	0,95
Investigator Measurable CNS Disease	Yes	8	10,3	5	62,5	3	37,5	0,89	0,85	6,47	5,98	0,89	18,43
	No	70	89,7	49	70,0	21	30,0	1,02	0,95	1,84	2,79	1,87	4,11

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30CF_SG.xls
28NOV2019 9:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30CF_SG.xls
28NOV2019 9:20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	56	71,8	22	28,2	0,95	NE	NE	1,81	0,99	2,14
Sex	Male	29	37,2	23	79,3	6	20,7	0,95	NE	NE	0,95	0,95	2,73
	Female	49	62,8	33	67,3	16	32,7	0,95	0,95	1,05	1,87	0,99	3,78
Age	18-64	62	79,5	46	74,2	16	25,8	0,95	NE	NE	1,81	0,95	2,73
	65-74	14	17,9	9	64,3	5	35,7	0,95	0,92	0,99	0,99	0,95	7,39
	>=75	2	2,6	1	50,0	1	50,0	1,84	1,84	NE	NE	1,84	NE
Race	White	35	44,9	24	68,6	11	31,4	0,99	0,95	1,87	2,73	1,81	8,31
	Other	43	55,1	32	74,4	11	25,6	0,95	NE	NE	0,95	0,95	1,84
Region	America (AM)	22	28,2	17	77,3	5	22,7	0,95	0,95	1,87	2,30	0,95	8,31

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30CO_SG.xls
28NOV2019 9:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	11	64,7	6	35,3	0,99	0,95	1,81	1,81	0,99	7,56
	Asia (AS)	39	50,0	28	71,8	11	28,2	0,95	NE	NE	0,99	0,95	1,87
ECOG Performance Status	0	30	38,5	26	86,7	4	13,3	0,95	NE	NE	0,99	0,95	1,87
	1	38	48,7	27	71,1	11	28,9	0,95	0,95	0,99	1,84	0,95	3,78
	2	10	12,8	3	30,0	7	70,0	1,05	0,95	NE	3,75	1,05	NE
Number of Prior Anticancer Therapies	None	31	39,7	25	80,6	6	19,4	0,95	0,95	1,05	1,82	0,95	3,75
	1	3	3,8	2	66,7	1	33,3	0,95	0,95	3,65	2,30	0,95	3,65

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30CO_SG.xls
28NOV2019 9:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	29	65,9	15	34,1	0,95	0,95	0,99	1,05	0,95	4,60
Prior Treatment	Naïve	31	39,7	25	80,6	6	19,4	0,95	0,95	1,05	1,82	0,95	3,75
	Previously Treated	47	60,3	31	66,0	16	34,0	0,95	0,95	0,99	1,05	0,95	3,65
Molecular Testing Results	Local	35	44,9	24	68,6	11	31,4	0,95	0,95	0,99	1,91	0,95	3,78
	Central	43	55,1	32	74,4	11	25,6	0,95	0,95	0,99	1,05	0,95	1,87

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30CO_SG.xls
28NOV2019 9:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	54	73,0	20	27,0	0,95	NE	NE	1,81	0,99	2,73
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	0,95	0,94	0,92	0,95
Investigator Measurable CNS Disease	Yes	8	10,3	4	50,0	4	50,0	0,95	0,89	3,78	1,81	0,89	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30CO_SG.xls
28NOV2019 9:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	70	89,7	52	74,3	18	25,7	0,95	NE	NE	1,81	0,95	2,14

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30CO_SG.xls
28NOV2019 9:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	51	65,4	27	34,6	1,48	0,95	1,87	2,79	1,87	5,49
Sex	Male	29	37,2	17	58,6	12	41,4	1,94	1,81	3,75	3,75	2,79	11,93
	Female	49	62,8	34	69,4	15	30,6	0,99	0,95	1,81	1,87	1,81	4,63
Age	18-64	62	79,5	43	69,4	19	30,6	1,02	0,95	1,87	2,79	1,87	5,62
	65-74	14	17,9	7	50,0	7	50,0	1,81	0,92	2,79	2,79	1,81	NE
	>=75	2	2,6	1	50,0	1	50,0	6,47	6,47	NE	NE	6,47	NE
Race	White	35	44,9	24	68,6	11	31,4	1,05	0,99	2,79	3,75	1,84	7,56
	Other	43	55,1	27	62,8	16	37,2	1,81	0,95	1,94	2,79	1,87	4,63
Region	America (AM)	22	28,2	15	68,2	7	31,8	1,84	1,05	3,68	3,71	1,84	5,62

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30DI_SG.xls
28NOV2019 9:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	12	70,6	5	29,4	1,48	0,95	6,41	6,41	1,81	9,26
	Asia (AS)	39	50,0	24	61,5	15	38,5	0,95	0,95	1,87	1,94	1,81	6,47
ECOG Performance Status	0	30	38,5	24	80,0	6	20,0	1,05	0,95	1,87	2,79	1,81	3,75
	1	38	48,7	22	57,9	16	42,1	1,84	0,99	2,79	5,49	1,87	11,93
	2	10	12,8	5	50,0	5	50,0	0,95	0,92	6,41	1,81	0,95	9,26
Number of Prior Anticancer Therapies	None	31	39,7	22	71,0	9	29,0	1,81	0,99	2,79	3,75	1,84	11,93
	1	3	3,8	1	33,3	2	66,7	5,62	NE	NE	5,62	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30DI_SG.xls
28NOV2019 9:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	28	63,6	16	36,4	0,99	0,95	1,87	2,76	1,84	3,68
Prior Treatment	Naïve	31	39,7	22	71,0	9	29,0	1,81	0,99	2,79	3,75	1,84	11,93
	Previously Treated	47	60,3	29	61,7	18	38,3	1,02	0,95	1,87	2,79	1,84	5,62
Molecular Testing Results	Local	35	44,9	22	62,9	13	37,1	0,99	0,95	1,87	1,87	1,81	4,63
	Central	43	55,1	29	67,4	14	32,6	1,81	0,99	2,79	3,68	1,94	6,47

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30DI_SG.xls
28NOV2019 9:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	49	66,2	25	33,8	1,48	0,99	1,87	2,83	1,87	5,62
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	2,79	1,86	0,92	2,79
Investigator Measurable CNS Disease	Yes	8	10,3	3	37,5	5	62,5	6,47	0,99	NE	15,84	0,99	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30DI_SG.xls
28NOV2019 9:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	70	89,7	48	68,6	22	31,4	1,48	0,95	1,87	2,79	1,87	4,63

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30DI_SG.xls
28NOV2019 9:26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	36	46,2	42	53,8	2,79	1,87	5,55	14,72	5,68	NE
Sex	Male	29	37,2	14	48,3	15	51,7	1,87	0,99	7,39	8,34	3,65	NE
	Female	49	62,8	22	44,9	27	55,1	3,68	2,07	5,68	14,72	4,60	NE
Age	18-64	62	79,5	26	41,9	36	58,1	3,71	2,07	8,34	15,61	8,34	NE
	65-74	14	17,9	8	57,1	6	42,9	0,95	0,92	2,79	2,79	0,95	16,59
	>=75	2	2,6	2	100,0			1,87	1,87	2,79	2,33	1,87	2,79
Race	White	35	44,9	17	48,6	18	51,4	3,66	1,81	14,72	14,72	3,75	NE
	Other	43	55,1	19	44,2	24	55,8	2,79	1,87	6,54	13,90	4,60	NE
Region	America (AM)	22	28,2	10	45,5	12	54,5	6,11	3,68	20,27	20,27	6,54	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30DY_SG.xls
28NOV2019 9:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	6	35,3	11	64,7	1,87	1,81	NE	NE	3,75	NE
	Asia (AS)	39	50,0	20	51,3	19	48,7	1,87	0,95	3,71	8,34	2,79	NE
ECOG Performance Status	0	30	38,5	15	50,0	15	50,0	3,75	1,81	14,72	16,59	5,68	NE
	1	38	48,7	17	44,7	21	55,3	2,79	1,87	8,34	13,90	3,71	NE
	2	10	12,8	4	40,0	6	60,0	0,95	0,95	15,61	9,64	0,95	15,61
Number of Prior Anticancer Therapies	None	31	39,7	13	41,9	18	58,1	5,55	1,87	20,27	20,27	6,54	NE
	1	3	3,8	1	33,3	2	66,7	7,39	NE	NE	7,39	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30DY_SG.xls
28NOV2019 9:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	22	50,0	22	50,0	1,87	1,31	3,71	8,34	3,68	16,59
Prior Treatment	Naïve	31	39,7	13	41,9	18	58,1	5,55	1,87	20,27	20,27	6,54	NE
	Previously Treated	47	60,3	23	48,9	24	51,1	2,79	1,31	3,75	8,34	3,71	16,59
Molecular Testing Results	Local	35	44,9	13	37,1	22	62,9	6,54	2,79	15,61	20,27	13,90	NE
	Central	43	55,1	23	53,5	20	46,5	1,87	0,99	3,71	5,68	3,68	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30DY_SG.xls
28NOV2019 9:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	34	45,9	40	54,1	3,65	1,87	5,55	15,61	5,68	NE
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	13,90	7,41	0,92	13,90
Investigator Measurable CNS Disease	Yes	8	10,3	3	37,5	5	62,5	1,81	0,85	NE	NE	1,81	NE
	No	70	89,7	33	47,1	37	52,9	3,68	1,87	5,68	14,72	5,68	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30DY_SG.xls
28NOV2019 9:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30DY_SG.xls
28NOV2019 9:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	37	47,4	41	52,6	3,81	1,81	6,54	13,83	6,54	25,00
Sex	Male	29	37,2	16	55,2	13	44,8	4,63	0,95	6,54	7,46	5,49	NE
	Female	49	62,8	21	42,9	28	57,1	2,83	1,81	13,83	19,32	6,54	NE
Age	18-64	62	79,5	31	50,0	31	50,0	3,71	1,81	6,54	13,83	6,54	25,00
	65-74	14	17,9	5	35,7	9	64,3	4,63	0,92	19,32	19,32	4,63	NE
	>=75	2	2,6	1	50,0	1	50,0	7,39	7,39	NE	NE	7,39	NE
Race	White	35	44,9	18	51,4	17	48,6	4,63	1,87	7,46	13,83	6,54	NE
	Other	43	55,1	19	44,2	24	55,8	2,83	0,95	11,99	15,61	5,55	NE
Region	America (AM)	22	28,2	11	50,0	11	50,0	3,32	1,87	9,26	9,26	3,81	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30EF_SG.xls
29NOV2019 18:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	8	47,1	9	52,9	4,67	1,81	20,04	20,04	5,49	NE
	Asia (AS)	39	50,0	18	46,2	21	53,8	2,14	0,95	11,99	15,61	5,55	25,00
ECOG Performance Status	0	30	38,5	13	43,3	17	56,7	4,67	1,87	25,00	25,00	6,54	NE
	1	38	48,7	21	55,3	17	44,7	4,63	0,95	7,39	11,99	5,49	19,32
	2	10	12,8	3	30,0	7	70,0	1,81	0,95	NE	1,81	1,81	NE
Number of Prior Anticancer Therapies	None	31	39,7	14	45,2	17	54,8	4,63	2,83	20,04	20,04	6,54	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30EF_SG.xls
29NOV2019 18:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	3	3,8	1	33,3	2	66,7	5,49	5,49	NE	NE	5,49	NE
	2 or More	44	56,4	22	50,0	22	50,0	1,81	0,95	6,54	13,83	5,55	19,32
Prior Treatment	Naïve	31	39,7	14	45,2	17	54,8	4,63	2,83	20,04	20,04	6,54	NE
	Previously Treated	47	60,3	23	48,9	24	51,1	1,87	0,95	6,54	13,83	5,55	19,32
Molecular Testing Results	Local	35	44,9	16	45,7	19	54,3	2,14	0,95	6,54	13,83	3,71	NE
	Central	43	55,1	21	48,8	22	51,2	4,63	1,87	7,46	13,83	6,41	25,00

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30EF_SG.xls
29NOV2019 18:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	35	47,3	39	52,7	4,63	1,87	6,54	15,61	7,39	25,00
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	3,71	2,32	0,92	3,71
Investigator Measurable CNS Disease	Yes	8	10,3	3	37,5	5	62,5	0,89	0,85	25,00	25,00	0,89	25,00
	No	70	89,7	34	48,6	36	51,4	4,63	1,87	6,54	13,83	6,54	20,04

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30EF_SG.xls
29NOV2019 18:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30EF_SG.xls
29NOV2019 18:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	40	51,3	38	48,7	1,02	0,95	1,87	11,93	3,65	22,11
Sex	Male	29	37,2	16	55,2	13	44,8	1,87	0,95	5,49	5,62	3,65	NE
	Female	49	62,8	24	49,0	25	51,0	1,00	0,95	1,87	15,87	1,81	NE
Age	18-64	62	79,5	33	53,2	29	46,8	1,05	0,95	2,14	11,93	2,14	22,11
	65-74	14	17,9	6	42,9	8	57,1	0,95	0,92	14,62	14,62	0,95	NE
	>=75	2	2,6	1	50,0	1	50,0	3,71	3,71	NE	NE	3,71	NE
Race	White	35	44,9	18	51,4	17	48,6	1,81	0,99	5,49	12,81	1,87	NE
	Other	43	55,1	22	51,2	21	48,8	0,95	0,95	3,65	11,93	1,61	NE
Region	America (AM)	22	28,2	11	50,0	11	50,0	1,45	0,95	5,62	5,62	1,84	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30FA_SG.xls
29NOV2019 18:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	8	47,1	9	52,9	1,81	0,99	12,81	12,81	1,87	NE
	Asia (AS)	39	50,0	21	53,8	18	46,2	0,95	0,92	3,65	6,41	1,61	22,11
ECOG Performance Status	0	30	38,5	19	63,3	11	36,7	0,95	0,95	1,87	6,41	1,05	16,56
	1	38	48,7	19	50,0	19	50,0	1,81	0,95	3,71	11,93	3,65	NE
	2	10	12,8	2	20,0	8	80,0	0,95	0,92	NE	NE	0,95	NE
Number of Prior Anticancer Therapies	None	31	39,7	17	54,8	14	45,2	1,05	0,95	3,65	11,93	1,84	NE
	1	3	3,8	2	66,7	1	33,3	5,49	5,49	5,62	5,55	5,49	5,62

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30FA_SG.xls
29NOV2019 18:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	21	47,7	23	52,3	0,95	0,95	2,14	14,62	1,87	NE
Prior Treatment	Naïve	31	39,7	17	54,8	14	45,2	1,05	0,95	3,65	11,93	1,84	NE
	Previously Treated	47	60,3	23	48,9	24	51,1	0,99	0,95	5,49	6,41	1,87	NE
Molecular Testing Results	Local	35	44,9	14	40,0	21	60,0	1,02	0,95	5,49	NE	2,14	NE
	Central	43	55,1	26	60,5	17	39,5	1,02	0,95	3,65	5,62	1,87	14,62

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30FA_SG.xls
29NOV2019 18:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	38	51,4	36	48,6	1,05	0,95	2,14	12,81	3,65	NE
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	0,95	0,94	0,92	0,95
Investigator Measurable CNS Disease	Yes	8	10,3	4	50,0	4	50,0	1,02	0,85	15,87	9,76	1,02	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30FA_SG.xls
29NOV2019 18:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	70	89,7	36	51,4	34	48,6	1,02	0,95	1,87	11,93	2,14	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30FA_SG.xls
29NOV2019 18:48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	36	46,2	42	53,8	2,73	1,05	5,55	13,83	6,41	NE
Sex	Male	29	37,2	10	34,5	19	65,5	6,41	2,79	20,27	20,27	13,83	NE
	Female	49	62,8	26	53,1	23	46,9	1,81	1,02	5,52	9,23	3,68	NE
Age	18-64	62	79,5	31	50,0	31	50,0	2,79	1,81	6,41	13,83	6,41	NE
	65-74	14	17,9	3	21,4	11	78,6	0,95	0,92	NE	NE	0,95	NE
	>=75	2	2,6	2	100,0			0,95	0,95	5,55	3,25	0,95	5,55
Race	White	35	44,9	16	45,7	19	54,3	3,68	1,05	10,97	13,83	7,36	NE
	Other	43	55,1	20	46,5	23	53,5	1,87	0,95	6,41	10,15	4,63	NE
Region	America (AM)	22	28,2	9	40,9	13	59,1	3,20	1,02	NE	NE	3,68	NE
	Europe (EU)	17	21,8	8	47,1	9	52,9	1,97	0,95	20,04	10,97	4,67	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30NV_SG.xls
28NOV2019 9:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	39	50,0	19	48,7	20	51,3	2,14	0,95	6,41	10,15	5,52	NE
ECOG Performance Status	0	30	38,5	13	43,3	17	56,7	5,55	0,95	13,96	NE	7,36	NE
	1	38	48,7	19	50,0	19	50,0	2,73	0,99	9,23	10,15	5,52	20,27
	2	10	12,8	4	40,0	6	60,0	1,81	1,81	4,67	1,97	1,81	NE
Number of Prior Anticancer Therapies	None	31	39,7	17	54,8	14	45,2	2,79	1,02	10,15	13,83	4,67	NE
	1	3	3,8			3	100,0	NE	NE	NE	NE	NE	NE
	2 or More	44	56,4	19	43,2	25	56,8	1,97	0,95	6,41	13,83	5,52	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30NV_SG.xls
28NOV2019 9:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	31	39,7	17	54,8	14	45,2	2,79	1,02	10,15	13,83	4,67	NE
	Previously Treated	47	60,3	19	40,4	28	59,6	1,97	0,95	7,36	13,83	5,55	NE
Molecular Testing Results	Local	35	44,9	12	34,3	23	65,7	7,36	1,81	20,27	NE	10,15	NE
	Central	43	55,1	24	55,8	19	44,2	1,87	0,95	5,52	6,41	4,63	20,04

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30NV_SG.xls
28NOV2019 9:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	34	45,9	40	54,1	2,73	1,81	5,55	13,83	6,41	NE
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	9,23	5,08	0,92	9,23
Investigator Measurable CNS Disease	Yes	8	10,3	2	25,0	6	75,0	13,96	1,02	NE	13,96	1,02	NE
	No	70	89,7	34	48,6	36	51,4	2,73	1,05	5,55	10,97	5,55	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30NV_SG.xls
28NOV2019 9:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30NV_SG.xls
28NOV2019 9:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	42	53,8	36	46,2	1,91	0,95	6,47	9,30	6,47	14,72
Sex	Male	29	37,2	16	55,2	13	44,8	0,95	0,95	6,47	6,47	1,91	NE
	Female	49	62,8	26	53,1	23	46,9	2,83	1,81	7,39	11,99	7,36	19,38
Age	18-64	62	79,5	33	53,2	29	46,8	3,71	1,81	7,39	11,99	7,39	19,38
	65-74	14	17,9	7	50,0	7	50,0	0,95	0,92	6,47	6,47	0,95	NE
	>=75	2	2,6	2	100,0			1,84	1,84	1,87	1,86	1,84	1,87
Race	White	35	44,9	18	51,4	17	48,6	2,83	1,05	9,30	12,78	7,33	24,77
	Other	43	55,1	24	55,8	19	44,2	1,84	0,95	5,59	7,39	3,71	13,83
Region	America (AM)	22	28,2	14	63,6	8	36,4	3,73	0,95	7,39	7,39	5,59	24,77

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30PA_SG.xls
28NOV2019 9:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	7	41,2	10	58,8	2,83	0,95	19,38	19,38	12,78	NE
	Asia (AS)	39	50,0	21	53,8	18	46,2	1,84	0,95	5,55	7,36	3,65	22,11
ECOG Performance Status	0	30	38,5	22	73,3	8	26,7	1,05	0,95	3,71	5,59	1,91	12,78
	1	38	48,7	17	44,7	21	55,3	7,36	1,87	11,99	13,77	8,25	24,77
	2	10	12,8	3	30,0	7	70,0	0,95	0,95	NE	1,81	0,95	NE
Number of Prior Anticancer Therapies	None	31	39,7	19	61,3	12	38,7	3,71	0,95	7,39	9,30	6,47	24,77
	1	3	3,8	1	33,3	2	66,7	0,95	0,95	NE	NE	0,95	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30PA_SG.xls
28NOV2019 9:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	22	50,0	22	50,0	1,87	0,95	6,47	11,04	5,55	22,11
Prior Treatment	Naïve	31	39,7	19	61,3	12	38,7	3,71	0,95	7,39	9,30	6,47	24,77
	Previously Treated	47	60,3	23	48,9	24	51,1	1,87	0,95	5,59	11,04	5,55	19,38
Molecular Testing Results	Local	35	44,9	17	48,6	18	51,4	5,59	1,81	7,39	9,30	7,33	24,77
	Central	43	55,1	25	58,1	18	41,9	1,84	0,95	5,55	11,04	3,65	14,72

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30PA_SG.xls
28NOV2019 9:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	40	54,1	34	45,9	2,14	1,05	6,47	11,04	6,47	14,72
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	3,71	2,32	0,92	3,71
Investigator Measurable CNS Disease	Yes	8	10,3	4	50,0	4	50,0	3,65	0,85	7,39	7,33	3,65	NE
	No	70	89,7	38	54,3	32	45,7	1,91	0,95	6,47	11,04	6,47	14,72

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30PA_SG.xls
28NOV2019 9:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30PA_SG.xls
28NOV2019 9:37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	36	46,2	42	53,8	3,71	1,81	8,31	18,04	9,17	21,16
Sex	Male	29	37,2	14	48,3	15	51,7	5,59	1,87	14,62	16,36	8,31	NE
	Female	49	62,8	22	44,9	27	55,1	1,87	1,05	9,17	20,24	5,55	NE
Age	18-64	62	79,5	26	41,9	36	58,1	5,55	1,87	11,93	20,27	9,23	NE
	65-74	14	17,9	9	64,3	5	35,7	0,95	0,92	4,37	4,37	0,95	14,62
	>=75	2	2,6	1	50,0	1	50,0	8,31	8,31	NE	NE	8,31	NE
Race	White	35	44,9	15	42,9	20	57,1	8,31	1,87	20,24	20,27	12,02	NE
	Other	43	55,1	21	48,8	22	51,2	1,87	0,95	5,59	11,93	5,55	NE
Region	America (AM)	22	28,2	9	40,9	13	59,1	16,36	5,55	20,27	20,27	18,04	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30PF_SG.xls
28NOV2019 9:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	8	47,1	9	52,9	1,87	1,05	12,02	12,02	8,31	NE
	Asia (AS)	39	50,0	19	48,7	20	51,3	1,87	0,95	5,55	9,17	3,71	NE
ECOG Performance Status	0	30	38,5	18	60,0	12	40,0	5,55	0,95	12,02	14,62	6,41	21,16
	1	38	48,7	15	39,5	23	60,5	3,71	1,81	20,24	20,24	8,31	NE
	2	10	12,8	3	30,0	7	70,0	1,81	1,05	NE	1,81	1,05	NE
Number of Prior Anticancer Therapies	None	31	39,7	11	35,5	20	64,5	11,93	3,65	20,27	20,27	16,36	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30PF_SG.xls
28NOV2019 9:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	3	3,8	1	33,3	2	66,7	18,04	NE	NE	18,04	NE	NE
	2 or More	44	56,4	24	54,5	20	45,5	1,87	0,99	4,37	8,31	3,71	21,13
Prior Treatment	Naïve	31	39,7	11	35,5	20	64,5	11,93	3,65	20,27	20,27	16,36	NE
	Previously Treated	47	60,3	25	53,2	22	46,8	1,87	0,99	4,37	9,23	3,71	21,13
Molecular Testing Results	Local	35	44,9	11	31,4	24	68,6	5,59	1,81	NE	NE	16,36	NE
	Central	43	55,1	25	58,1	18	41,9	1,87	1,05	6,41	9,23	5,55	18,04

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30PF_SG.xls
28NOV2019 9:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	34	45,9	40	54,1	3,71	1,87	9,17	18,04	9,23	21,16
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	0,95	0,94	0,92	0,95
Investigator Measurable CNS Disease	Yes	8	10,3	2	25,0	6	75,0	9,17	0,85	NE	NE	9,17	NE
	No	70	89,7	34	48,6	36	51,4	3,65	1,81	8,31	16,36	8,31	21,13

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30PF_SG.xls
28NOV2019 9:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30PF_SG.xls
28NOV2019 9:40

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	39	50,0	39	50,0	1,84	0,99	2,73	11,30	2,79	20,04
Sex	Male	29	37,2	16	55,2	13	44,8	1,87	0,95	4,57	7,39	2,79	20,04
	Female	49	62,8	23	46,9	26	53,1	1,82	0,99	2,14	13,83	1,87	NE
Age	18-64	62	79,5	31	50,0	31	50,0	1,87	1,05	2,79	13,83	2,79	NE
	65-74	14	17,9	6	42,9	8	57,1	0,95	0,92	7,39	4,67	0,95	NE
	>=75	2	2,6	2	100,0			1,84	1,84	2,79	2,32	1,84	2,79
Race	White	35	44,9	16	45,7	19	54,3	1,84	1,81	4,67	11,30	2,73	NE
	Other	43	55,1	23	53,5	20	46,5	1,81	0,95	2,79	7,39	2,10	20,04
Region	America (AM)	22	28,2	12	54,5	10	45,5	1,84	0,95	4,63	4,63	1,84	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30QL_SG.xls
28NOV2019 9:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	7	41,2	10	58,8	2,79	1,81	20,04	20,04	4,67	NE
	Asia (AS)	39	50,0	20	51,3	19	48,7	1,81	0,95	2,79	7,39	1,87	NE
ECOG Performance Status	0	30	38,5	19	63,3	11	36,7	1,81	0,95	2,83	4,63	1,84	17,54
	1	38	48,7	19	50,0	19	50,0	1,87	0,99	2,79	11,30	2,73	NE
	2	10	12,8	1	10,0	9	90,0	NE	1,81	NE	NE	1,81	NE
Number of Prior Anticancer Therapies	None	31	39,7	15	48,4	16	51,6	1,84	0,99	4,63	20,04	2,73	NE
	1	3	3,8	1	33,3	2	66,7	17,54	NE	NE	17,54	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30QL_SG.xls
28NOV2019 9:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	23	52,3	21	47,7	1,81	0,95	2,14	4,57	1,87	NE
Prior Treatment	Naïve	31	39,7	15	48,4	16	51,6	1,84	0,99	4,63	20,04	2,73	NE
	Previously Treated	47	60,3	24	51,1	23	48,9	1,84	0,95	2,79	4,67	1,87	17,54
Molecular Testing Results	Local	35	44,9	15	42,9	20	57,1	1,87	0,99	4,57	4,63	2,73	NE
	Central	43	55,1	24	55,8	19	44,2	1,84	0,95	2,79	11,30	1,87	17,54

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30QL_SG.xls
28NOV2019 9:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	37	50,0	37	50,0	1,87	1,81	2,79	11,30	2,83	NE
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	0,95	0,94	0,92	0,95
Investigator Measurable CNS Disease	Yes	8	10,3	4	50,0	4	50,0	1,81	0,85	2,73	2,41	1,81	NE
	No	70	89,7	35	50,0	35	50,0	1,84	0,99	2,79	11,30	2,83	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30QL_SG.xls
28NOV2019 9:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30QL_SG.xls
28NOV2019 9:42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	43	55,1	35	44,9	1,84	0,95	2,79	7,39	3,68	20,04
Sex	Male	29	37,2	18	62,1	11	37,9	0,95	0,95	2,79	6,47	1,87	16,36
	Female	49	62,8	25	51,0	24	49,0	1,87	0,95	4,60	15,31	3,71	21,13
Age	18-64	62	79,5	35	56,5	27	43,5	1,97	1,81	3,71	10,18	3,71	20,04
	65-74	14	17,9	7	50,0	7	50,0	0,95	0,92	6,54	6,54	0,95	NE
	>=75	2	2,6	1	50,0	1	50,0	0,95	0,95	NE	NE	0,95	NE
Race	White	35	44,9	19	54,3	16	45,7	1,87	0,99	3,71	15,31	2,73	27,63
	Other	43	55,1	24	55,8	19	44,2	0,95	0,95	4,60	6,54	3,68	20,04
Region	America (AM)	22	28,2	14	63,6	8	36,4	2,41	1,84	7,39	7,39	2,73	20,24

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30RF_SG.xls
28NOV2019 9:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	10	58,8	7	41,2	1,40	0,95	15,31	15,31	1,81	NE
	Asia (AS)	39	50,0	19	48,7	20	51,3	0,95	0,95	4,60	6,47	2,79	NE
ECOG Performance Status	0	30	38,5	19	63,3	11	36,7	0,95	0,95	2,79	6,54	1,87	19,38
	1	38	48,7	20	52,6	18	47,4	2,10	0,95	13,80	15,31	4,60	21,13
	2	10	12,8	4	40,0	6	60,0	1,97	0,95	6,41	3,68	1,97	NE
Number of Prior Anticancer Therapies	None	31	39,7	19	61,3	12	38,7	2,10	0,95	3,71	6,54	2,73	20,24

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30RF_SG.xls
28NOV2019 9:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	3	3,8	1	33,3	2	66,7	7,39	NE	NE	7,39	NE	NE
	2 or More	44	56,4	23	52,3	21	47,7	1,84	0,95	3,71	10,18	1,97	19,38
Prior Treatment	Naïve	31	39,7	19	61,3	12	38,7	2,10	0,95	3,71	6,54	2,73	20,24
	Previously Treated	47	60,3	24	51,1	23	48,9	1,84	0,95	4,60	10,18	3,68	19,38
Molecular Testing Results	Local	35	44,9	17	48,6	18	51,4	2,10	0,95	6,41	10,18	2,79	27,63
	Central	43	55,1	26	60,5	17	39,5	1,40	0,95	3,71	7,39	2,73	20,04

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30RF_SG.xls
28NOV2019 9:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	41	55,4	33	44,6	1,87	0,95	3,68	10,18	3,71	20,04
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	0,95	0,94	0,92	0,95
Investigator Measurable CNS Disease	Yes	8	10,3	4	50,0	4	50,0	2,73	2,10	6,47	2,73	2,10	NE
	No	70	89,7	39	55,7	31	44,3	1,84	0,95	3,68	13,80	3,71	20,04

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30RF_SG.xls
28NOV2019 9:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30RF_SG.xls
28NOV2019 9:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	37	47,4	41	52,6	1,87	0,95	5,68	14,62	6,41	NE
Sex	Male	29	37,2	17	58,6	12	41,4	3,65	0,95	6,47	7,46	3,71	18,04
	Female	49	62,8	20	40,8	29	59,2	1,84	0,95	7,56	19,32	5,68	NE
Age	18-64	62	79,5	27	43,5	35	56,5	3,65	0,99	6,47	18,04	6,47	NE
	65-74	14	17,9	8	57,1	6	42,9	0,99	0,92	14,62	7,46	0,99	16,36
	>=75	2	2,6	2	100,0			0,92	0,92	3,71	2,32	0,92	3,71
Race	White	35	44,9	17	48,6	18	51,4	3,65	1,81	9,30	12,91	5,55	NE
	Other	43	55,1	20	46,5	23	53,5	0,95	0,95	6,47	14,62	3,78	NE
Region	America (AM)	22	28,2	12	54,5	10	45,5	2,76	1,84	9,30	9,30	3,65	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30SF_SG.xls
28NOV2019 9:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	8	47,1	9	52,9	2,73	0,99	7,56	7,56	3,65	NE
	Asia (AS)	39	50,0	17	43,6	22	56,4	2,30	0,95	12,91	14,62	6,41	NE
ECOG Performance Status	0	30	38,5	17	56,7	13	43,3	1,87	0,95	9,30	15,87	5,68	NE
	1	38	48,7	18	47,4	20	52,6	3,65	0,95	6,47	12,91	3,71	NE
	2	10	12,8	2	20,0	8	80,0	3,68	0,95	NE	NE	3,68	NE
Number of Prior Anticancer Therapies	None	31	39,7	18	58,1	13	41,9	1,84	0,95	5,68	7,46	3,65	NE
	1	3	3,8	1	33,3	2	66,7	18,04	NE	NE	18,04	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30SF_SG.xls
28NOV2019 9:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	18	40,9	26	59,1	1,87	0,95	12,91	14,62	6,41	NE
Prior Treatment	Naïve	31	39,7	18	58,1	13	41,9	1,84	0,95	5,68	7,46	3,65	NE
	Previously Treated	47	60,3	19	40,4	28	59,6	3,68	0,99	12,91	18,04	6,41	NE
Molecular Testing Results	Local	35	44,9	12	34,3	23	65,7	3,78	1,81	19,32	19,32	9,30	NE
	Central	43	55,1	25	58,1	18	41,9	0,99	0,95	5,55	6,47	3,65	15,87

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30SF_SG.xls
28NOV2019 9:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	35	47,3	39	52,7	3,65	0,99	6,41	14,62	6,47	NE
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	0,95	0,94	0,92	0,95
Investigator Measurable CNS Disease	Yes	8	10,3	5	62,5	3	37,5	3,65	0,85	6,47	5,13	3,65	15,87
	No	70	89,7	32	45,7	38	54,3	1,87	0,95	6,41	16,36	6,41	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30SF_SG.xls
28NOV2019 9:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30SF_SG.xls
28NOV2019 9:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	30	38,5	48	61,5	6,47	2,79	11,96	18,04	11,96	NE
Sex	Male	29	37,2	13	44,8	16	55,2	2,79	0,95	9,30	18,04	3,81	NE
	Female	49	62,8	17	34,7	32	65,3	9,82	6,47	13,11	18,40	11,99	NE
Age	18-64	62	79,5	24	38,7	38	61,3	6,47	3,65	11,99	18,04	11,96	NE
	65-74	14	17,9	5	35,7	9	64,3	2,79	0,92	NE	13,11	2,79	NE
	>=75	2	2,6	1	50,0	1	50,0	0,95	0,95	NE	NE	0,95	NE
Race	White	35	44,9	15	42,9	20	57,1	9,26	3,65	11,99	18,04	9,82	NE
	Other	43	55,1	15	34,9	28	65,1	6,47	1,81	13,11	NE	12,88	NE
Region	America (AM)	22	28,2	10	45,5	12	54,5	9,26	3,65	18,04	18,04	9,30	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30SL_SG.xls
28NOV2019 9:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	6	35,3	11	64,7	5,49	0,99	NE	NE	5,49	NE
	Asia (AS)	39	50,0	14	35,9	25	64,1	6,47	0,95	12,88	15,67	7,39	NE
ECOG Performance Status	0	30	38,5	15	50,0	15	50,0	6,47	1,87	11,96	15,67	9,82	NE
	1	38	48,7	14	36,8	24	63,2	6,47	1,81	18,40	18,40	9,26	NE
	2	10	12,8	1	10,0	9	90,0	NE	0,92	NE	NE	NE	NE
Number of Prior Anticancer Therapies	None	31	39,7	15	48,4	16	51,6	6,47	2,79	13,11	15,67	9,26	NE
	1	3	3,8	2	66,7	1	33,3	5,49	5,49	18,04	11,76	5,49	18,04

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30SL_SG.xls
28NOV2019 9:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	13	29,5	31	70,5	11,07	0,99	NE	NE	11,96	NE
Prior Treatment	Naïve	31	39,7	15	48,4	16	51,6	6,47	2,79	13,11	15,67	9,26	NE
	Previously Treated	47	60,3	15	31,9	32	68,1	5,49	0,99	18,04	18,04	11,96	NE
Molecular Testing Results	Local	35	44,9	10	28,6	25	71,4	9,26	2,79	NE	NE	11,07	NE
	Central	43	55,1	20	46,5	23	53,5	5,49	0,99	11,99	13,11	9,82	18,40

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30SL_SG.xls
28NOV2019 9:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	28	37,8	46	62,2	6,47	3,65	11,99	18,40	11,99	NE
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	7,39	4,16	0,92	7,39
Investigator Measurable CNS Disease	Yes	8	10,3	4	50,0	4	50,0	3,65	0,85	6,47	5,52	3,65	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30SL_SG.xls
28NOV2019 9:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	70	89,7	26	37,1	44	62,9	9,26	2,79	12,88	18,04	11,99	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_C30SL_SG.xls
28NOV2019 9:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	46	31,7	99	68,3	5,59	2,10	14,62	23,95	18,04	NE
Sex	Male	52	35,9	17	32,7	35	67,3	6,41	2,79	20,27	20,27	14,62	NE
	Female	93	64,1	29	31,2	64	68,8	3,68	1,87	15,87	23,95	15,87	NE
Age	18-64	109	75,2	34	31,2	75	68,8	8,31	2,79	15,87	23,95	18,04	NE
	65-74	29	20,0	7	24,1	22	75,9	14,62	0,95	NE	NE	14,62	NE
	>=75	7	4,8	5	71,4	2	28,6	0,95	0,95	7,39	2,10	0,95	NE
Race	White	60	41,4	17	28,3	43	71,7	8,31	2,10	20,27	NE	18,04	NE
	Other	85	58,6	29	34,1	56	65,9	2,79	1,87	14,62	23,95	14,62	NE
Region	America (AM)	40	27,6	17	42,5	23	57,5	2,79	1,81	13,83	20,27	5,55	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30AP_SG.xls
24JUN2020 19:00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	6	17,6	28	82,4	NE	1,97	NE	NE	NE	NE
	Asia (AS)	71	49,0	23	32,4	48	67,6	5,59	1,87	14,72	23,95	14,62	23,95
ECOG Performance Status	0	61	42,1	23	37,7	38	62,3	3,68	1,87	15,87	20,27	14,62	NE
	1	69	47,6	20	29,0	49	71,0	8,38	2,14	NE	23,95	23,95	NE
	2	15	10,3	3	20,0	12	80,0	1,97	0,92	NE	NE	1,97	NE
Number of Prior Anticancer Therapies	None	62	42,8	20	32,3	42	67,7	5,55	1,94	20,27	NE	15,87	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30AP_SG.xls
24JUN2020 19:00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	2	50,0	2	50,0	0,95	0,95	18,04	18,04	0,95	18,04
	2 or More	79	54,5	24	30,4	55	69,6	6,41	1,97	14,62	23,95	14,62	23,95
Prior Treatment	Naïve	62	42,8	20	32,3	42	67,7	5,55	1,94	20,27	NE	15,87	NE
	Previously Treated	83	57,2	26	31,3	57	68,7	5,59	1,97	14,62	23,95	14,62	23,95
Molecular Testing Results	Local	75	51,7	21	28,0	54	72,0	8,31	2,14	NE	NE	20,27	NE
	Central	70	48,3	25	35,7	45	64,3	3,68	1,87	15,87	23,95	14,62	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30AP_SG.xls
24JUN2020 19:00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	42	31,1	93	68,9	5,59	2,07	15,87	23,95	18,04	NE
	No	10	6,9	4	40,0	6	60,0	5,55	0,92	14,72	8,31	5,55	14,72
Investigator Measurable CNS Disease	Yes	11	7,6	3	27,3	8	72,7	3,65	2,10	NE	15,87	3,65	NE
	No	134	92,4	43	32,1	91	67,9	5,59	1,97	14,62	23,95	18,04	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30AP_SG.xls
24JUN2020 19:00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30AP_SG.xls
24JUN2020 19:00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	101	69,7	44	30,3	1,02	0,95	1,84	2,83	2,00	4,60
Sex	Male	52	35,9	38	73,1	14	26,9	1,05	0,95	2,79	3,71	2,79	4,67
	Female	93	64,1	63	67,7	30	32,3	1,02	0,95	1,84	2,69	1,87	4,63
Age	18-64	109	75,2	78	71,6	31	28,4	1,05	0,95	1,84	2,83	1,97	4,63
	65-74	29	20,0	17	58,6	12	41,4	0,99	0,92	2,79	2,79	1,91	8,31
	>=75	7	4,8	6	85,7	1	14,3	1,02	0,95	3,71	1,84	1,02	4,60
Race	White	60	41,4	40	66,7	20	33,3	1,18	0,99	2,00	3,75	2,00	5,55
	Other	85	58,6	61	71,8	24	28,2	0,95	0,95	1,84	2,79	1,87	4,60
Region	America (AM)	40	27,6	29	72,5	11	27,5	1,02	0,95	1,87	2,79	1,84	4,67

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30CF_SG.xls
24JUN2020 19:04

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	24	70,6	10	29,4	1,05	0,95	2,00	2,74	1,77	7,39
	Asia (AS)	71	49,0	48	67,6	23	32,4	0,99	0,95	1,94	3,58	1,94	4,63
ECOG Performance Status	0	61	42,1	48	78,7	13	21,3	1,81	0,95	2,76	3,71	2,76	4,63
	1	69	47,6	48	69,6	21	30,4	0,95	0,95	1,05	1,94	1,18	4,63
	2	15	10,3	5	33,3	10	66,7	1,97	1,81	10,18	10,18	1,97	NE
Number of Prior Anticancer Therapies	None	62	42,8	44	71,0	18	29,0	1,03	0,95	1,94	2,79	1,94	5,55

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30CF_SG.xls
24JUN2020 19:04

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	1	25,0	3	75,0	3,71	3,71	NE	NE	3,71	NE
	2 or More	79	54,5	56	70,9	23	29,1	0,99	0,95	1,84	2,79	1,87	4,11
Prior Treatment	Naïve	62	42,8	44	71,0	18	29,0	1,03	0,95	1,94	2,79	1,94	5,55
	Previously Treated	83	57,2	57	68,7	26	31,3	1,02	0,95	1,87	2,83	1,91	4,11
Molecular Testing Results	Local	75	51,7	48	64,0	27	36,0	1,05	0,95	1,87	2,79	1,94	4,67
	Central	70	48,3	53	75,7	17	24,3	0,99	0,95	1,87	3,58	1,91	4,63

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30CF_SG.xls
24JUN2020 19:04

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	95	70,4	40	29,6	1,05	0,95	1,84	3,58	2,14	4,60
	No	10	6,9	6	60,0	4	40,0	0,95	0,92	2,76	1,02	0,95	6,47
Investigator Measurable CNS Disease	Yes	11	7,6	6	54,5	5	45,5	0,92	0,85	6,47	5,98	0,89	18,43
	No	134	92,4	95	70,9	39	29,1	1,05	0,95	1,84	2,79	2,00	4,11

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30CF_SG.xls
24JUN2020 19:04

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30CF_SG.xls
24JUN2020 19:04

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	105	72,4	40	27,6	0,95	0,95	0,99	1,81	1,02	2,33
Sex	Male	52	35,9	42	80,8	10	19,2	0,95	NE	NE	0,99	0,95	1,87
	Female	93	64,1	63	67,7	30	32,3	0,95	0,95	1,02	1,87	1,18	3,65
Age	18-64	109	75,2	81	74,3	28	25,7	0,95	0,95	0,99	1,81	1,02	2,14
	65-74	29	20,0	19	65,5	10	34,5	0,95	0,92	0,99	0,99	0,95	3,75
	>=75	7	4,8	5	71,4	2	28,6	1,84	1,81	5,78	4,73	1,84	NE
Race	White	60	41,4	42	70,0	18	30,0	0,99	0,95	1,81	2,33	1,81	4,60
	Other	85	58,6	63	74,1	22	25,9	0,95	NE	NE	0,99	0,95	1,91
Region	America (AM)	40	27,6	33	82,5	7	17,5	0,95	0,95	1,18	1,87	0,99	3,75

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30CO_SG.xls
24JUN2020 19:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	22	64,7	12	35,3	0,99	0,95	1,87	2,53	1,05	7,56
	Asia (AS)	71	49,0	50	70,4	21	29,6	0,95	NE	NE	1,02	0,95	1,91
ECOG Performance Status	0	61	42,1	50	82,0	11	18,0	0,95	0,95	0,99	1,02	0,99	1,87
	1	69	47,6	50	72,5	19	27,5	0,95	0,95	0,99	1,87	1,02	4,73
	2	15	10,3	5	33,3	10	66,7	1,05	0,95	NE	3,75	1,05	NE
Number of Prior Anticancer Therapies	None	62	42,8	47	75,8	15	24,2	0,95	0,95	1,05	1,87	1,05	3,65

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30CO_SG.xls
24JUN2020 19:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	2	50,0	2	50,0	0,95	0,95	NE	3,65	0,95	NE
	2 or More	79	54,5	56	70,9	23	29,1	0,95	0,95	0,99	1,02	0,99	1,91
Prior Treatment	Naïve	62	42,8	47	75,8	15	24,2	0,95	0,95	1,05	1,87	1,05	3,65
	Previously Treated	83	57,2	58	69,9	25	30,1	0,95	0,95	0,99	1,02	0,99	1,94
Molecular Testing Results	Local	75	51,7	55	73,3	20	26,7	0,95	0,95	0,99	1,94	0,99	3,65
	Central	70	48,3	50	71,4	20	28,6	0,95	0,95	0,99	1,81	0,99	1,87

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30CO_SG.xls
24JUN2020 19:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	99	73,3	36	26,7	0,95	0,95	0,99	1,81	1,02	2,33
	No	10	6,9	6	60,0	4	40,0	0,92	0,92	2,83	0,95	0,92	5,55
Investigator Measurable CNS Disease	Yes	11	7,6	6	54,5	5	45,5	0,95	0,89	1,87	1,81	0,95	3,78
	No	134	92,4	99	73,9	35	26,1	0,95	0,95	0,99	1,81	1,02	2,53

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30CO_SG.xls
24JUN2020 19:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30CO_SG.xls
24JUN2020 19:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	90	62,1	55	37,9	1,84	1,02	2,10	3,75	2,79	6,34
Sex	Male	52	35,9	31	59,6	21	40,4	2,33	1,87	2,83	5,62	2,79	8,31
	Female	93	64,1	59	63,4	34	36,6	1,05	0,95	1,87	2,86	2,76	6,34
Age	18-64	109	75,2	71	65,1	38	34,9	1,05	0,99	1,87	3,68	2,79	6,34
	65-74	29	20,0	15	51,7	14	48,3	2,33	1,81	2,83	3,75	2,76	NE
	>=75	7	4,8	4	57,1	3	42,9	2,76	0,95	NE	6,47	2,76	NE
Race	White	60	41,4	40	66,7	20	33,3	1,84	1,02	2,79	3,68	2,79	6,47
	Other	85	58,6	50	58,8	35	41,2	1,81	0,95	2,76	3,75	2,79	9,23
Region	America (AM)	40	27,6	26	65,0	14	35,0	2,10	1,81	2,83	3,68	2,79	9,23

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30DI_SG.xls
24JUN2020 19:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	21	61,8	13	38,2	1,87	1,02	6,28	6,41	3,75	8,31
	Asia (AS)	71	49,0	43	60,6	28	39,4	1,02	0,95	1,87	2,79	1,87	6,47
ECOG Performance Status	0	61	42,1	45	73,8	16	26,2	1,48	0,95	2,76	2,83	2,76	4,63
	1	69	47,6	38	55,1	31	44,9	1,87	1,02	2,79	6,47	2,83	11,93
	2	15	10,3	7	46,7	8	53,3	1,81	0,92	6,41	2,73	1,81	9,26
Number of Prior Anticancer Therapies	None	62	42,8	43	69,4	19	30,6	1,84	1,02	2,79	3,75	2,79	7,52

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30DI_SG.xls
24JUN2020 19:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	1	25,0	3	75,0	5,62	5,62	NE	NE	5,62	NE
	2 or More	79	54,5	46	58,2	33	41,8	1,81	0,95	2,10	3,68	2,76	6,47
Prior Treatment	Naïve	62	42,8	43	69,4	19	30,6	1,84	1,02	2,79	3,75	2,79	7,52
	Previously Treated	83	57,2	47	56,6	36	43,4	1,81	0,95	2,76	3,71	2,79	6,47
Molecular Testing Results	Local	75	51,7	46	61,3	29	38,7	1,81	0,95	2,76	3,65	2,79	6,28
	Central	70	48,3	44	62,9	26	37,1	1,87	1,05	2,76	5,62	2,79	9,23

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30DI_SG.xls
24JUN2020 19:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	85	63,0	50	37,0	1,84	1,02	1,94	3,71	2,79	6,34
	No	10	6,9	5	50,0	5	50,0	2,79	0,92	8,31	6,28	2,79	NE
Investigator Measurable CNS Disease	Yes	11	7,6	4	36,4	7	63,6	1,87	0,99	15,84	15,84	1,87	NE
	No	134	92,4	86	64,2	48	35,8	1,84	1,02	2,10	3,68	2,79	5,62

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30DI_SG.xls
24JUN2020 19:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30DI_SG.xls
24JUN2020 19:09

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	67	46,2	78	53,8	2,07	1,87	3,71	13,90	5,68	20,27
Sex	Male	52	35,9	25	48,1	27	51,9	1,91	1,31	5,55	8,34	4,63	NE
	Female	93	64,1	42	45,2	51	54,8	2,73	1,81	3,71	14,72	4,60	NE
Age	18-64	109	75,2	46	42,2	63	57,8	3,65	1,94	5,55	14,72	8,34	NE
	65-74	29	20,0	16	55,2	13	44,8	0,95	0,92	1,84	2,79	1,31	16,59
	>=75	7	4,8	5	71,4	2	28,6	1,87	0,95	4,63	4,60	1,87	NE
Race	White	60	41,4	26	43,3	34	56,7	3,65	1,81	7,39	14,72	5,68	NE
	Other	85	58,6	41	48,2	44	51,8	1,94	1,02	3,68	8,34	4,60	NE
Region	America (AM)	40	27,6	23	57,5	17	42,5	3,02	1,87	5,55	7,39	4,60	20,27

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30DY_SG.xls
24JUN2020 19:12

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	11	32,4	23	67,6	3,75	1,87	NE	NE	6,47	NE
	Asia (AS)	71	49,0	33	46,5	38	53,5	1,81	0,95	3,68	13,90	3,71	NE
ECOG Performance Status	0	61	42,1	32	52,5	29	47,5	2,79	1,87	5,55	13,83	5,55	20,27
	1	69	47,6	31	44,9	38	55,1	1,87	1,18	3,02	13,90	3,65	NE
	2	15	10,3	4	26,7	11	73,3	3,68	0,95	15,61	15,61	3,68	15,61
Number of Prior Anticancer Therapies	None	62	42,8	27	43,5	35	56,5	2,73	1,02	6,47	20,27	6,47	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30DY_SG.xls
24JUN2020 19:12

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	2	50,0	2	50,0	0,95	0,95	7,39	7,39	0,95	7,39
	2 or More	79	54,5	38	48,1	41	51,9	1,94	1,87	3,71	8,34	4,60	16,59
Prior Treatment	Naïve	62	42,8	27	43,5	35	56,5	2,73	1,02	6,47	20,27	6,47	NE
	Previously Treated	83	57,2	40	48,2	43	51,8	1,91	1,81	3,71	8,34	4,60	16,59
Molecular Testing Results	Local	75	51,7	32	42,7	43	57,3	3,65	2,79	6,51	14,72	6,54	NE
	Central	70	48,3	35	50,0	35	50,0	1,84	0,95	2,79	5,68	3,68	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30DY_SG.xls
24JUN2020 19:12

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	62	45,9	73	54,1	1,94	1,84	3,71	14,72	6,47	NE
	No	10	6,9	5	50,0	5	50,0	2,79	0,92	13,90	4,63	2,79	13,90
Investigator Measurable CNS Disease	Yes	11	7,6	4	36,4	7	63,6	1,84	0,85	NE	NE	1,81	NE
	No	134	92,4	63	47,0	71	53,0	2,73	1,87	3,71	13,90	5,68	20,27

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30DY_SG.xls
24JUN2020 19:12

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30DY_SG.xls
24JUN2020 19:12

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	60	41,4	85	58,6	3,71	1,87	5,55	15,61	11,99	25,00
Sex	Male	52	35,9	24	46,2	28	53,8	4,63	1,87	7,39	11,99	6,54	NE
	Female	93	64,1	36	38,7	57	61,3	2,86	1,84	9,26	19,32	13,83	NE
Age	18-64	109	75,2	47	43,1	62	56,9	3,81	2,76	6,54	13,83	9,26	25,00
	65-74	29	20,0	10	34,5	19	65,5	3,71	1,05	NE	19,32	4,63	NE
	>=75	7	4,8	3	42,9	4	57,1	1,81	0,95	NE	NE	1,81	NE
Race	White	60	41,4	25	41,7	35	58,3	4,67	2,76	9,26	13,83	7,46	NE
	Other	85	58,6	35	41,2	50	58,8	2,83	1,81	4,67	15,61	9,26	NE
Region	America (AM)	40	27,6	19	47,5	21	52,5	3,71	1,87	6,54	13,83	4,63	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30EF_SG.xls
24JUN2020 19:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	12	35,3	22	64,7	5,49	1,87	20,04	20,04	12,98	NE
	Asia (AS)	71	49,0	29	40,8	42	59,2	2,86	1,81	9,26	15,61	9,26	25,00
ECOG Performance Status	0	61	42,1	22	36,1	39	63,9	6,41	3,71	13,83	25,00	13,83	NE
	1	69	47,6	35	50,7	34	49,3	2,76	1,05	4,63	11,99	5,49	19,32
	2	15	10,3	3	20,0	12	80,0	1,81	0,95	NE	NE	1,81	NE
Number of Prior Anticancer Therapies	None	62	42,8	22	35,5	40	64,5	4,63	2,83	20,04	25,00	11,99	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30EF_SG.xls
24JUN2020 19:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	1	25,0	3	75,0	5,49	5,49	NE	NE	5,49	NE
	2 or More	79	54,5	37	46,8	42	53,2	2,76	1,81	5,55	12,98	6,41	15,61
Prior Treatment	Naïve	62	42,8	22	35,5	40	64,5	4,63	2,83	20,04	25,00	11,99	NE
	Previously Treated	83	57,2	38	45,8	45	54,2	2,76	1,81	5,55	13,83	6,54	19,32
Molecular Testing Results	Local	75	51,7	29	38,7	46	61,3	3,71	1,81	6,54	19,32	9,26	NE
	Central	70	48,3	31	44,3	39	55,7	4,63	1,87	7,46	13,83	7,46	25,00

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30EF_SG.xls
24JUN2020 19:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	57	42,2	78	57,8	3,71	1,87	6,41	15,61	11,99	25,00
	No	10	6,9	3	30,0	7	70,0	3,71	0,92	NE	NE	3,71	NE
Investigator Measurable CNS Disease	Yes	11	7,6	4	36,4	7	63,6	1,38	0,85	25,00	25,00	0,89	25,00
	No	134	92,4	56	41,8	78	58,2	3,81	2,76	6,41	13,83	9,26	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30EF_SG.xls
24JUN2020 19:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30EF_SG.xls
24JUN2020 19:15

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	77	53,1	68	46,9	0,99	0,95	1,81	5,62	3,48	14,82
Sex	Male	52	35,9	31	59,6	21	40,4	0,99	0,95	2,33	5,49	1,87	11,93
	Female	93	64,1	46	49,5	47	50,5	1,02	0,95	1,87	12,81	2,86	22,11
Age	18-64	109	75,2	58	53,2	51	46,8	1,02	0,95	1,87	8,31	3,48	15,87
	65-74	29	20,0	14	48,3	15	51,7	0,95	0,95	1,81	2,33	0,99	NE
	>=75	7	4,8	5	71,4	2	28,6	1,81	0,95	4,60	3,94	1,81	NE
Race	White	60	41,4	34	56,7	26	43,3	1,05	0,99	1,87	5,49	1,87	15,87
	Other	85	58,6	43	50,6	42	49,4	0,97	0,95	1,87	9,23	2,79	22,11
Region	America (AM)	40	27,6	26	65,0	14	35,0	0,99	0,95	1,84	1,87	1,81	14,82

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30FA_SG.xls
24JUN2020 19:18

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	15	44,1	19	55,9	1,87	0,99	8,31	12,81	4,47	NE
	Asia (AS)	71	49,0	36	50,7	35	49,3	0,99	0,95	2,86	6,41	3,65	22,11
ECOG Performance Status	0	61	42,1	38	62,3	23	37,7	0,95	0,95	1,81	2,79	1,81	14,62
	1	69	47,6	36	52,2	33	47,8	1,61	0,95	3,48	9,23	3,65	NE
	2	15	10,3	3	20,0	12	80,0	4,47	0,92	NE	NE	4,47	NE
Number of Prior Anticancer Therapies	None	62	42,8	31	50,0	31	50,0	1,00	0,95	2,33	11,93	2,33	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30FA_SG.xls
24JUN2020 19:18

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	2	50,0	2	50,0	5,49	5,49	NE	5,62	5,49	NE
	2 or More	79	54,5	44	55,7	35	44,3	0,99	0,95	1,87	4,60	1,87	14,82
Prior Treatment	Naïve	62	42,8	31	50,0	31	50,0	1,00	0,95	2,33	11,93	2,33	NE
	Previously Treated	83	57,2	46	55,4	37	44,6	0,99	0,95	1,87	5,49	2,14	14,82
Molecular Testing Results	Local	75	51,7	38	50,7	37	49,3	1,02	0,95	2,14	8,31	2,76	NE
	Central	70	48,3	39	55,7	31	44,3	0,99	0,95	1,87	5,62	1,87	14,62

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30FA_SG.xls
24JUN2020 19:18

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	72	53,3	63	46,7	1,02	0,95	1,81	5,62	3,48	15,87
	No	10	6,9	5	50,0	5	50,0	0,95	0,92	8,31	2,76	0,95	NE
Investigator Measurable CNS Disease	Yes	11	7,6	6	54,5	5	45,5	1,45	0,85	4,47	4,06	1,02	15,87
	No	134	92,4	71	53,0	63	47,0	0,99	0,95	1,81	6,41	2,86	14,82

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30FA_SG.xls
24JUN2020 19:18

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30FA_SG.xls
24JUN2020 19:18

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	64	44,1	81	55,9	2,73	1,18	4,73	13,83	7,36	NE
Sex	Male	52	35,9	18	34,6	34	65,4	5,55	2,79	20,04	20,04	13,83	NE
	Female	93	64,1	46	49,5	47	50,5	1,84	1,02	3,68	10,15	4,73	13,96
Age	18-64	109	75,2	50	45,9	59	54,1	3,68	1,87	5,55	12,98	7,36	20,27
	65-74	29	20,0	8	27,6	21	72,4	0,95	0,95	NE	NE	NE	NE
	>=75	7	4,8	6	85,7	1	14,3	0,95	0,95	2,10	1,02	0,95	5,55
Race	White	60	41,4	26	43,3	34	56,7	3,68	1,18	7,36	13,83	7,36	NE
	Other	85	58,6	38	44,7	47	55,3	1,84	0,95	5,52	11,99	5,55	NE
Region	America (AM)	40	27,6	19	47,5	21	52,5	1,18	0,99	7,36	11,99	4,63	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30NV_SG.xls
24JUN2020 19:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	12	35,3	22	64,7	5,55	1,97	20,04	20,04	10,97	NE
	Asia (AS)	71	49,0	33	46,5	38	53,5	2,10	0,99	5,52	10,15	5,52	NE
ECOG Performance Status	0	61	42,1	23	37,7	38	62,3	4,63	1,05	12,98	NE	12,98	NE
	1	69	47,6	37	53,6	32	46,4	1,84	0,99	4,63	9,23	4,73	20,04
	2	15	10,3	4	26,7	11	73,3	1,97	1,81	NE	NE	1,97	NE
Number of Prior Anticancer Therapies	None	62	42,8	28	45,2	34	54,8	2,79	1,02	9,23	13,83	9,23	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30NV_SG.xls
24JUN2020 19:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	1	25,0	3	75,0	0,95	0,95	NE	NE	0,95	NE
	2 or More	79	54,5	35	44,3	44	55,7	2,10	1,18	4,73	12,98	5,55	NE
Prior Treatment	Naïve	62	42,8	28	45,2	34	54,8	2,79	1,02	9,23	13,83	9,23	NE
	Previously Treated	83	57,2	36	43,4	47	56,6	2,10	1,18	4,73	12,98	5,55	NE
Molecular Testing Results	Local	75	51,7	31	41,3	44	58,7	2,14	1,02	5,55	20,27	6,54	NE
	Central	70	48,3	33	47,1	37	52,9	2,79	1,05	5,55	11,99	5,55	20,04

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30NV_SG.xls
24JUN2020 19:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	59	43,7	76	56,3	2,73	1,81	5,52	13,83	10,15	NE
	No	10	6,9	5	50,0	5	50,0	1,02	0,92	9,23	5,55	1,02	NE
Investigator Measurable CNS Disease	Yes	11	7,6	3	27,3	8	72,7	5,55	1,02	NE	13,96	5,55	NE
	No	134	92,4	61	45,5	73	54,5	2,14	1,18	4,67	12,98	6,54	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30NV_SG.xls
24JUN2020 19:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30NV_SG.xls
24JUN2020 19:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	72	49,7	73	50,3	2,76	1,81	4,73	9,30	7,33	13,83
Sex	Male	52	35,9	29	55,8	23	44,2	0,99	0,95	5,55	6,47	4,73	13,77
	Female	93	64,1	43	46,2	50	53,8	2,86	1,87	7,39	11,99	7,39	19,38
Age	18-64	109	75,2	55	50,5	54	49,5	2,86	1,81	6,47	11,04	7,39	14,72
	65-74	29	20,0	14	48,3	15	51,7	2,76	0,95	4,73	6,44	2,83	NE
	>=75	7	4,8	3	42,9	4	57,1	1,84	1,81	NE	NE	1,84	NE
Race	White	60	41,4	25	41,7	35	58,3	4,73	1,87	11,99	14,72	9,30	24,77
	Other	85	58,6	47	55,3	38	44,7	1,91	0,99	3,71	7,36	5,55	11,04
Region	America (AM)	40	27,6	22	55,0	18	45,0	2,79	1,81	7,39	8,25	6,47	14,82

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30PA_SG.xls
24JUN2020 19:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	14	41,2	20	58,8	4,73	0,95	12,78	13,77	7,03	NE
	Asia (AS)	71	49,0	36	50,7	35	49,3	1,91	0,95	3,71	8,38	4,57	13,83
ECOG Performance Status	0	61	42,1	37	60,7	24	39,3	1,05	0,95	2,86	6,47	2,86	12,78
	1	69	47,6	31	44,9	38	55,1	6,44	2,76	8,31	11,99	8,25	22,11
	2	15	10,3	4	26,7	11	73,3	1,81	0,95	NE	NE	1,81	NE
Number of Prior Anticancer Therapies	None	62	42,8	33	53,2	29	46,8	3,65	1,05	7,03	9,30	7,03	24,77

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30PA_SG.xls
24JUN2020 19:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	1	25,0	3	75,0	0,95	0,95	NE	NE	0,95	NE
	2 or More	79	54,5	38	48,1	41	51,9	1,87	1,02	5,59	10,18	5,59	19,38
Prior Treatment	Naïve	62	42,8	33	53,2	29	46,8	3,65	1,05	7,03	9,30	7,03	24,77
	Previously Treated	83	57,2	39	47,0	44	53,0	1,87	0,99	5,59	10,18	5,59	19,38
Molecular Testing Results	Local	75	51,7	33	44,0	42	56,0	2,86	1,87	7,33	12,78	7,36	24,77
	Central	70	48,3	39	55,7	31	44,3	1,87	0,95	4,73	8,38	5,55	13,77

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30PA_SG.xls
24JUN2020 19:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	68	50,4	67	49,6	2,76	1,81	5,59	10,18	7,36	14,72
	No	10	6,9	4	40,0	6	60,0	0,95	0,92	NE	3,71	0,95	NE
Investigator Measurable CNS Disease	Yes	11	7,6	5	45,5	6	54,5	5,49	0,85	8,31	7,39	3,65	NE
	No	134	92,4	67	50,0	67	50,0	2,76	1,81	4,73	10,18	7,03	14,72

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30PA_SG.xls
24JUN2020 19:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Pain

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30PA_SG.xls
24JUN2020 19:27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	71	49,0	74	51,0	2,14	1,81	3,75	12,02	7,43	20,24
Sex	Male	52	35,9	28	53,8	24	46,2	3,65	1,08	5,59	11,93	4,73	18,04
	Female	93	64,1	43	46,2	50	53,8	1,87	1,05	3,71	12,02	6,44	21,16
Age	18-64	109	75,2	49	45,0	60	55,0	2,86	1,87	5,55	18,04	9,17	21,16
	65-74	29	20,0	18	62,1	11	37,9	0,99	0,95	4,37	4,73	2,33	12,16
	>=75	7	4,8	4	57,1	3	42,9	0,95	0,95	8,31	8,31	0,95	NE
Race	White	60	41,4	25	41,7	35	58,3	4,37	1,87	12,02	20,24	9,23	NE
	Other	85	58,6	46	54,1	39	45,9	1,84	0,95	2,86	6,44	3,75	16,36
Region	America (AM)	40	27,6	21	52,5	19	47,5	2,76	1,81	9,23	18,04	5,55	21,16

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30PF_SG.xls
24JUN2020 19:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	14	41,2	20	58,8	2,53	1,05	11,93	12,02	8,31	NE
	Asia (AS)	71	49,0	36	50,7	35	49,3	1,84	0,95	3,71	9,17	3,75	21,13
ECOG Performance Status	0	61	42,1	38	62,3	23	37,7	1,87	0,95	4,73	9,23	4,73	16,36
	1	69	47,6	30	43,5	39	56,5	2,86	1,81	7,46	20,24	7,46	NE
	2	15	10,3	3	20,0	12	80,0	1,81	1,05	NE	NE	1,81	NE
Number of Prior Anticancer Therapies	None	62	42,8	28	45,2	34	54,8	3,25	1,08	7,46	16,36	7,46	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30PF_SG.xls
24JUN2020 19:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	1	25,0	3	75,0	18,04	NE	NE	18,04	NE	NE
	2 or More	79	54,5	42	53,2	37	46,8	1,87	1,05	3,71	8,31	3,71	14,62
Prior Treatment	Naïve	62	42,8	28	45,2	34	54,8	3,25	1,08	7,46	16,36	7,46	NE
	Previously Treated	83	57,2	43	51,8	40	48,2	1,87	1,05	3,71	9,23	3,75	18,04
Molecular Testing Results	Local	75	51,7	31	41,3	44	58,7	2,76	1,08	5,59	20,27	7,43	NE
	Central	70	48,3	40	57,1	30	42,9	1,87	0,99	4,37	9,17	4,73	14,62

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30PF_SG.xls
24JUN2020 19:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	67	49,6	68	50,4	2,33	1,81	4,37	12,02	7,46	20,24
	No	10	6,9	4	40,0	6	60,0	0,95	0,92	NE	4,53	0,95	NE
Investigator Measurable CNS Disease	Yes	11	7,6	2	18,2	9	81,8	9,17	0,85	NE	NE	9,17	NE
	No	134	92,4	69	51,5	65	48,5	1,94	1,81	3,71	11,93	6,41	18,04

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30PF_SG.xls
24JUN2020 19:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Physical Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30PF_SG.xls
24JUN2020 19:30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	68	46,9	77	53,1	1,87	1,81	2,79	11,30	6,44	17,54
Sex	Male	52	35,9	28	53,8	24	46,2	1,84	0,95	2,79	6,54	2,73	20,04
	Female	93	64,1	40	43,0	53	57,0	1,87	1,81	4,67	13,83	8,28	NE
Age	18-64	109	75,2	51	46,8	58	53,2	1,87	1,81	3,71	11,30	7,46	20,04
	65-74	29	20,0	11	37,9	18	62,1	1,81	0,95	7,39	NE	1,87	NE
	>=75	7	4,8	6	85,7	1	14,3	1,81	0,95	2,79	2,10	1,81	3,68
Race	White	60	41,4	26	43,3	34	56,7	1,87	1,81	4,67	14,82	4,63	NE
	Other	85	58,6	42	49,4	43	50,6	1,87	0,99	2,83	9,23	4,57	20,04
Region	America (AM)	40	27,6	22	55,0	18	45,0	1,84	0,99	3,48	4,63	1,87	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30QL_SG.xls
24JUN2020 19:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	12	35,3	22	64,7	4,67	1,81	20,04	20,04	6,54	NE
	Asia (AS)	71	49,0	34	47,9	37	52,1	1,87	0,99	2,83	9,23	3,68	NE
ECOG Performance Status	0	61	42,1	35	57,4	26	42,6	1,81	0,95	1,91	6,54	1,91	17,54
	1	69	47,6	32	46,4	37	53,6	2,10	1,81	6,44	11,30	6,44	20,04
	2	15	10,3	1	6,7	14	93,3	NE	1,81	NE	NE	NE	NE
Number of Prior Anticancer Therapies	None	62	42,8	23	37,1	39	62,9	2,73	1,81	13,83	20,04	13,83	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30QL_SG.xls
24JUN2020 19:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	1	25,0	3	75,0	17,54	NE	NE	17,54	NE	NE
	2 or More	79	54,5	44	55,7	35	44,3	1,81	0,99	1,94	6,54	2,10	11,30
Prior Treatment	Naïve	62	42,8	23	37,1	39	62,9	2,73	1,81	13,83	20,04	13,83	NE
	Previously Treated	83	57,2	45	54,2	38	45,8	1,81	0,99	1,94	7,39	2,79	11,30
Molecular Testing Results	Local	75	51,7	31	41,3	44	58,7	1,94	1,81	3,71	14,82	4,57	NE
	Central	70	48,3	37	52,9	33	47,1	1,84	0,99	2,79	8,28	4,67	15,61

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30QL_SG.xls
24JUN2020 19:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	63	46,7	72	53,3	1,87	1,81	2,83	11,30	7,39	20,04
	No	10	6,9	5	50,0	5	50,0	0,95	0,92	3,71	1,84	0,95	NE
Investigator Measurable CNS Disease	Yes	11	7,6	4	36,4	7	63,6	1,95	0,85	NE	NE	1,81	NE
	No	134	92,4	64	47,8	70	52,2	1,87	1,81	2,83	10,15	6,54	17,54

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30QL_SG.xls
24JUN2020 19:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30QL_SG.xls
24JUN2020 19:33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	77	53,1	68	46,9	1,81	0,95	2,33	9,23	3,71	16,36
Sex	Male	52	35,9	32	61,5	20	38,5	0,99	0,95	2,73	4,67	2,33	10,18
	Female	93	64,1	45	48,4	48	51,6	1,87	1,05	2,86	13,80	4,57	20,24
Age	18-64	109	75,2	58	53,2	51	46,8	1,87	1,02	2,73	9,23	3,71	19,38
	65-74	29	20,0	16	55,2	13	44,8	0,95	0,92	2,79	4,57	0,99	16,36
	>=75	7	4,8	3	42,9	4	57,1	0,95	0,95	NE	NE	0,95	NE
Race	White	60	41,4	27	45,0	33	55,0	1,87	1,05	2,79	19,38	2,79	27,63
	Other	85	58,6	50	58,8	35	41,2	0,99	0,95	2,10	6,41	2,76	10,18
Region	America (AM)	40	27,6	22	55,0	18	45,0	1,87	1,81	3,71	10,18	2,73	20,24

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30RF_SG.xls
24JUN2020 19:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	18	52,9	16	47,1	1,02	0,95	2,79	13,17	1,87	20,04
	Asia (AS)	71	49,0	37	52,1	34	47,9	0,99	0,95	2,79	6,47	2,86	21,13
ECOG Performance Status	0	61	42,1	37	60,7	24	39,3	0,95	0,95	1,87	2,79	1,87	10,18
	1	69	47,6	35	50,7	34	49,3	1,87	0,99	4,60	13,80	6,47	20,24
	2	15	10,3	5	33,3	10	66,7	1,97	0,89	NE	6,41	1,97	NE
Number of Prior Anticancer Therapies	None	62	42,8	32	51,6	30	48,4	2,10	0,95	2,86	16,36	2,86	20,24

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30RF_SG.xls
24JUN2020 19:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	1	25,0	3	75,0	7,39	NE	NE	7,39	NE	NE
	2 or More	79	54,5	44	55,7	35	44,3	1,05	0,95	1,87	4,67	1,94	13,80
Prior Treatment	Naïve	62	42,8	32	51,6	30	48,4	2,10	0,95	2,86	16,36	2,86	20,24
	Previously Treated	83	57,2	45	54,2	38	45,8	1,05	0,95	1,87	6,41	1,97	13,80
Molecular Testing Results	Local	75	51,7	36	48,0	39	52,0	1,84	0,95	2,76	10,18	2,79	27,63
	Central	70	48,3	41	58,6	29	41,4	1,81	0,95	2,73	6,47	2,79	15,31

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30RF_SG.xls
24JUN2020 19:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	72	53,3	63	46,7	1,84	0,99	2,73	9,23	4,57	16,36
	No	10	6,9	5	50,0	5	50,0	0,95	0,92	2,76	1,87	0,95	NE
Investigator Measurable CNS Disease	Yes	11	7,6	5	45,5	6	54,5	2,10	0,95	6,47	2,73	2,10	NE
	No	134	92,4	72	53,7	62	46,3	1,81	0,95	2,33	9,23	3,71	16,36

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30RF_SG.xls
24JUN2020 19:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Role Functioning

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30RF_SG.xls
24JUN2020 19:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	72	49,7	73	50,3	1,84	0,99	3,65	9,30	5,68	16,36
Sex	Male	52	35,9	32	61,5	20	38,5	0,99	0,95	4,63	6,47	3,71	14,62
	Female	93	64,1	40	43,0	53	57,0	1,84	0,99	3,68	14,82	6,60	NE
Age	18-64	109	75,2	51	46,8	58	53,2	2,53	0,99	3,78	10,15	6,47	NE
	65-74	29	20,0	17	58,6	12	41,4	0,99	0,95	4,70	4,73	1,81	16,36
	>=75	7	4,8	4	57,1	3	42,9	0,95	0,92	NE	3,71	0,95	NE
Race	White	60	41,4	29	48,3	31	51,7	1,87	0,99	5,68	12,91	5,68	NE
	Other	85	58,6	43	50,6	42	49,4	1,81	0,95	3,65	7,43	3,68	19,32
Region	America (AM)	40	27,6	21	52,5	19	47,5	1,87	0,99	7,46	10,15	3,65	18,04

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30SF_SG.xls
24JUN2020 19:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	19	55,9	15	44,1	1,79	0,99	3,71	5,55	2,53	NE
	Asia (AS)	71	49,0	32	45,1	39	54,9	1,87	0,95	4,70	12,91	6,41	NE
ECOG Performance Status	0	61	42,1	38	62,3	23	37,7	1,81	0,95	2,86	6,54	2,86	14,62
	1	69	47,6	32	46,4	37	53,6	1,84	0,95	3,71	12,91	3,78	NE
	2	15	10,3	2	13,3	13	86,7	NE	0,95	NE	NE	3,68	NE
Number of Prior Anticancer Therapies	None	62	42,8	34	54,8	28	45,2	1,77	0,95	3,65	7,46	3,65	16,36

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30SF_SG.xls
24JUN2020 19:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	2	50,0	2	50,0	0,95	0,95	18,04	18,04	0,95	18,04
	2 or More	79	54,5	36	45,6	43	54,4	2,76	0,99	4,70	12,91	6,41	19,32
Prior Treatment	Naïve	62	42,8	34	54,8	28	45,2	1,77	0,95	3,65	7,46	3,65	16,36
	Previously Treated	83	57,2	38	45,8	45	54,2	1,87	0,99	4,70	12,91	6,41	19,32
Molecular Testing Results	Local	75	51,7	32	42,7	43	57,3	2,86	1,81	7,36	14,82	7,43	NE
	Central	70	48,3	40	57,1	30	42,9	0,99	0,95	2,53	6,41	3,65	14,62

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30SF_SG.xls
24JUN2020 19:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	66	48,9	69	51,1	1,87	0,99	3,71	10,15	6,54	18,04
	No	10	6,9	6	60,0	4	40,0	0,95	0,92	2,76	0,95	0,95	2,83
Investigator Measurable CNS Disease	Yes	11	7,6	6	54,5	5	45,5	2,30	0,85	6,47	5,13	0,95	15,87
	No	134	92,4	66	49,3	68	50,7	1,84	0,99	3,65	9,30	6,41	18,04

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30SF_SG.xls
24JUN2020 19:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30SF_SG.xls
24JUN2020 19:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	43	29,7	102	70,3	9,26	5,49	11,99	NE	15,67	NE
Sex	Male	52	35,9	18	34,6	34	65,4	3,81	2,76	18,04	18,04	9,30	NE
	Female	93	64,1	25	26,9	68	73,1	10,09	7,36	13,11	NE	12,88	NE
Age	18-64	109	75,2	32	29,4	77	70,6	9,26	5,49	15,67	NE	15,67	NE
	65-74	29	20,0	8	27,6	21	72,4	7,36	1,05	NE	NE	11,07	NE
	>=75	7	4,8	3	42,9	4	57,1	0,95	0,95	NE	10,09	0,95	NE
Race	White	60	41,4	19	31,7	41	68,3	9,30	5,36	18,04	18,40	11,96	NE
	Other	85	58,6	24	28,2	61	71,8	7,36	3,71	15,67	NE	13,11	NE
Region	America (AM)	40	27,6	15	37,5	25	62,5	9,26	3,71	18,04	18,40	10,09	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30SL_SG.xls
24JUN2020 19:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	9	26,5	25	73,5	9,82	5,49	NE	NE	11,07	NE
	Asia (AS)	71	49,0	19	26,8	52	73,2	7,39	2,76	NE	NE	12,88	NE
ECOG Performance Status	0	61	42,1	21	34,4	40	65,6	9,30	4,57	13,11	18,04	11,96	NE
	1	69	47,6	21	30,4	48	69,6	7,36	2,76	18,40	NE	12,88	NE
	2	15	10,3	1	6,7	14	93,3	NE	0,92	NE	NE	NE	NE
Number of Prior Anticancer Therapies	None	62	42,8	19	30,6	43	69,4	9,26	6,47	18,40	NE	13,11	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30SL_SG.xls
24JUN2020 19:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia

MODEL: --

STUDY: STARTRK-2

Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	1	4	2,8	2	50,0	2	50,0	5,49	5,49	18,04	18,04	5,49	18,04
	2 or More	79	54,5	22	27,8	57	72,2	8,31	2,76	12,88	NE	11,99	NE
Prior Treatment	Naïve	62	42,8	19	30,6	43	69,4	9,26	6,47	18,40	NE	13,11	NE
	Previously Treated	83	57,2	24	28,9	59	71,1	8,31	2,76	12,88	NE	11,99	NE
Molecular Testing Results	Local	75	51,7	20	26,7	55	73,3	9,26	3,81	NE	NE	NE	NE
	Central	70	48,3	23	32,9	47	67,1	7,36	4,57	13,11	15,67	12,88	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30SL_SG.xls
24JUN2020 19:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	38	28,1	97	71,9	9,82	5,62	13,11	NE	15,67	NE
	No	10	6,9	5	50,0	5	50,0	2,76	0,92	8,31	7,39	2,76	NE
Investigator Measurable CNS Disease	Yes	11	7,6	4	36,4	7	63,6	4,11	0,85	NE	NE	3,65	NE
	No	134	92,4	39	29,1	95	70,9	9,30	5,62	12,88	NE	15,67	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30SL_SG.xls
24JUN2020 19:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_C30SL_SG.xls
24JUN2020 19:41

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	26	25	22	20	19	17	11	5	3	1	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	5	5	8	9	10	12	18	23	25	26	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30AP_SG1.pdf
10SEP2019 17:03

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	18	15	10	7	7	5	2	NE	NE	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	3	3	4	4	4	5	8	NE	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30CF_SG1.pdf
10SEP2019 17:43

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	14	12	11	10	9	7	6	1	1	1	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	5	5	6	6	6	7	8	12	12	12	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30CO_SG1.pdf
10SEP2019 18:10

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	21	16	11	7	6	5	3	1	NE	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	5	5	8	9	9	9	11	13	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30DI_SG1.pdf
10SEP2019 18:38

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	29	27	23	18	17	15	7	3	1	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	4	4	6	9	10	12	19	22	24	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30DY_SG1.pdf
10SEP2019 19:00

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	27	24	21	16	14	13	5	1	1	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	3	3	6	8	9	10	17	20	20	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30EF_SG1.pdf
10SEP2019 19:22

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	20	20	17	14	13	10	6	3	1	1	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	4	4	5	7	8	10	14	17	19	19	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30FA_SG1.pdf
10SEP2019 19:44

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	26	25	21	19	17	16	7	3	3	1	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	5	5	7	8	9	9	16	20	20	22	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30NV_SG1.pdf
10SEP2019 20:27

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	26	25	21	16	14	10	6	2	NE	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	4	4	7	9	10	12	15	18	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30PA_SG1.pdf
10SEP2019 20:49

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	25	24	20	18	17	14	8	4	2	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	4	4	6	7	8	10	16	20	22	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30PF_SG1.pdf
10SEP2019 21:11

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	23	23	18	14	13	10	6	2	NE	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	4	4	6	9	10	12	16	19	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30QL_SG1.pdf
10SEP2019 21:32

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	24	21	18	14	13	11	6	2	NE	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	4	4	6	7	8	10	14	18	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30RF_SG1.pdf
10SEP2019 21:53

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	24	23	20	15	13	11	7	4	2	1	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	3	3	6	7	8	10	13	16	18	18	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30SF_SG1.pdf
10SEP2019 22:14

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	30	29	26	22	19	14	6	2	2	1	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	4	5	8	10	11	13	19	23	23	23	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_C30SL_SG1.pdf
10SEP2019 22:36

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	53	45	39	33	30	20	13	4	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	10	16	20	26	27	36	41	49	51	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30AP_SG1.pdf
28NOV2019 8:32

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	33	19	14	10	9	4	2	1	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	8	12	13	15	16	21	22	23	NE	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30CF_SG1.pdf
28NOV2019 8:43

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	24	14	10	8	7	6	4	1	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	10	15	15	16	16	17	18	21	NE	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30CO_SG1.pdf
28NOV2019 8:54

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	32	20	14	11	9	5	2	NE	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	10	15	17	18	20	22	25	NE	NE	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30DI_SG1.pdf
29NOV2019 19:29

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	51	38	30	27	21	13	7	5	3	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	9	13	18	21	24	30	35	37	39	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30DY_SG1.pdf
28NOV2019 9:07

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	54	41	32	25	20	13	7	3	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	8	13	17	22	25	31	35	39	NE	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30EF_SG1.pdf
29NOV2019 19:44

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	43	33	27	23	20	13	9	2	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	8	12	17	20	21	26	30	36	37	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30FA_SG1.pdf
29NOV2019 20:01

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	49	38	33	27	21	15	10	4	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	10	15	18	20	23	29	32	38	41	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30NV_SG1.pdf
28NOV2019 9:24

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	49	38	26	20	15	9	7	2	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	9	15	20	23	24	30	31	35	NE	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30PA_SG1.pdf
28NOV2019 9:36

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	53	41	35	27	23	17	11	4	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	9	14	18	23	25	30	33	38	40	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30PF_SG1.pdf
28NOV2019 9:47

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	41	29	24	20	18	12	7	3	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	8	16	20	23	24	28	32	36	38	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30QL_SG1.pdf
28NOV2019 9:58

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	43	35	26	21	19	12	6	3	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	9	13	18	22	23	28	31	33	35	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30RF_SG1.pdf
28NOV2019 10:10

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	51	37	29	23	20	12	8	4	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	9	15	19	24	25	31	33	37	39	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30SF_SG1.pdf
28NOV2019 10:22

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	56	47	38	26	22	15	9	1	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	10	15	21	27	29	35	39	47	NE	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_C30SL_SG1.pdf
28NOV2019 10:34

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Appetite Loss
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	100	85	62	41	31	20	13	4	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	16	27	46	65	72	82	87	95	97	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30AP_SG1.pdf
24JUN2020 18:05

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Cognitive Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	65	36	20	10	9	4	2	1	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	11	19	27	35	36	41	42	43	NE	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30CF_SG1.pdf
24JUN2020 18:18

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Constipation
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	45	28	15	10	7	6	4	1	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	15	22	29	33	34	35	36	39	NE	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30CO_SG1.pdf
24JUN2020 18:31

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Diarrhoea
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	68	48	28	14	10	5	2	NE	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	15	22	34	43	47	50	53	NE	NE	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30DI_SG1.pdf
24JUN2020 18:44

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Dyspnoea
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	90	67	43	31	22	13	7	5	3	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	15	23	42	54	59	66	71	73	75	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30DY_SG1.pdf
24JUN2020 18:57

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Emotional Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	102	77	53	33	21	13	7	3	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	13	24	43	60	68	75	79	83	NE	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30EF_SG1.pdf
24JUN2020 19:09

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Fatigue
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	76	57	39	26	20	13	9	2	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	13	21	37	48	51	56	60	66	67	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30FA_SG1.pdf
24JUN2020 19:21

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Nausea and Vomiting
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	92	71	54	35	22	15	10	4	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	16	24	38	52	61	68	71	77	80	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30NV_SG1.pdf
24JUN2020 19:47

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Pain
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	92	72	40	25	15	9	7	2	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	15	25	45	56	61	67	68	72	NE	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30PA_SG1.pdf
24JUN2020 19:58

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Physical Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	93	73	50	31	23	17	11	4	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	12	20	38	52	57	62	65	70	72	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30PF_SG1.pdf
24JUN2020 20:10

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Global Health Status/QoL
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	85	64	40	23	18	12	7	3	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	13	27	46	59	62	66	70	74	76	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30QL_SG1.pdf
24JUN2020 20:22

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Role Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	78	63	40	25	19	12	6	3	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	13	22	40	51	56	61	64	66	68	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30RF_SG1.pdf
24JUN2020 20:33

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Social Functioning
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	88	65	41	26	20	12	8	4	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	14	25	41	54	57	63	65	69	71	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30SF_SG1.pdf
24JUN2020 20:45

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-C30 Insomnia
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	110	92	62	36	23	15	9	1	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	16	27	52	71	82	89	93	101	NE	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_C30SL_SG1.pdf
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	33	89,2	44,44	23,07
Cycle 2 Day 1	All	33	89,2	30	90,9	25,56	22,63
Cycle 3 Day 1	All	32	86,5	29	90,6	11,49	16,12
Cycle 4 Day 1	All	32	86,5	27	84,4	16,05	23,33
Cycle 5 Day 1	All	31	83,8	29	93,5	24,14	21,63
Cycle 6 Day 1	All	31	83,8	26	83,9	17,95	19,39
Cycle 7 Day 1	All	30	81,1	26	86,7	17,95	25,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	25,33	19,91
Cycle 9 Day 1	All	25	67,6	25	100,0	17,33	21,77
Cycle 10 Day 1	All	25	67,6	24	96,0	20,83	21,56
Cycle 11 Day 1	All	24	64,9	24	100,0	16,67	17,03
Cycle 12 Day 1	All	24	64,9	21	87,5	20,63	16,59
Cycle 13 Day 1	All	22	59,5	21	95,5	19,05	19,92
Cycle 14 Day 1	All	22	59,5	22	100,0	19,70	19,68
Cycle 15 Day 1	All	22	59,5	21	95,5	17,46	17,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	22,22	24,12
Cycle 17 Day 1	All	18	48,6	14	77,8	16,67	17,30
Cycle 18 Day 1	All	15	40,5	8	53,3	16,67	25,20
Cycle 19 Day 1	All	13	35,1	8	61,5	20,83	17,25
Cycle 20 Day 1	All	9	24,3	9	100,0	18,52	17,57
Cycle 21 Day 1	All	7	18,9	4	57,1	16,67	19,25
Cycle 22 Day 1	All	7	18,9	2	28,6	33,33	0,00
Cycle 23 Day 1	All	4	10,8	1	25,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	0,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	46,67	18,26
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	48,72	22,01
	Female	23	100,0	20	87,0	41,67	23,88
Cycle 2 Day 1	Male	13	92,9	13	100,0	30,77	28,74
	Female	20	87,0	17	85,0	21,57	16,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	11,11	16,41
	Female	20	87,0	17	85,0	11,76	16,42
Cycle 4 Day 1	Male	12	85,7	10	83,3	23,33	31,62
	Female	20	87,0	17	85,0	11,76	16,42
Cycle 5 Day 1	Male	12	85,7	11	91,7	27,27	25,03
	Female	19	82,6	18	94,7	22,22	19,80
Cycle 6 Day 1	Male	12	85,7	11	91,7	24,24	15,57
	Female	19	82,6	15	78,9	13,33	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	21,21	22,47
	Female	19	82,6	15	78,9	15,56	27,79
Cycle 8 Day 1	Male	10	71,4	9	90,0	29,63	20,03
	Female	18	78,3	16	88,9	22,92	20,07
Cycle 9 Day 1	Male	8	57,1	8	100,0	20,83	24,80
	Female	17	73,9	17	100,0	15,69	20,81
Cycle 10 Day 1	Male	8	57,1	8	100,0	25,00	23,57
	Female	17	73,9	16	94,1	18,75	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	20,83	17,25
	Female	16	69,6	16	100,0	14,58	17,08
Cycle 12 Day 1	Male	8	57,1	8	100,0	25,00	15,43
	Female	16	69,6	13	81,3	17,95	17,30
Cycle 13 Day 1	Male	8	57,1	8	100,0	16,67	17,82
	Female	14	60,9	13	92,9	20,51	21,68
Cycle 14 Day 1	Male	8	57,1	8	100,0	20,83	17,25
	Female	14	60,9	14	100,0	19,05	21,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	20,83	17,25
	Female	14	60,9	13	92,9	15,38	17,30
Cycle 16 Day 1	Male	8	57,1	5	62,5	20,00	29,81
	Female	13	56,5	10	76,9	23,33	22,50
Cycle 17 Day 1	Male	6	42,9	2	33,3	33,33	0,00
	Female	12	52,2	12	100,0	13,89	17,16
Cycle 18 Day 1	Male	3	21,4	2	66,7	33,33	47,14
	Female	12	52,2	6	50,0	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	33,33	0,00
	Female	11	47,8	6	54,5	16,67	18,26
Cycle 20 Day 1	Male	2	14,3	2	100,0	33,33	0,00
	Female	7	30,4	7	100,0	14,29	17,82
Cycle 21 Day 1	Male	1	7,1	1	100,0	33,33	-
	Female	6	26,1	3	50,0	11,11	19,25
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	33,33	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	0,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	50,00	23,57
	Female	7	30,4	3	42,9	44,44	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	26	89,7	44,87	22,98
	65-74	8	100,0	7	87,5	42,86	25,20
Cycle 2 Day 1	18-64	27	93,1	24	88,9	27,78	23,40
	65-74	6	75,0	6	100,0	16,67	18,26
Cycle 3 Day 1	18-64	26	89,7	24	92,3	13,89	16,79
	65-74	6	75,0	5	83,3	0,00	0,00
Cycle 4 Day 1	18-64	26	89,7	22	84,6	16,67	24,67
	65-74	6	75,0	5	83,3	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	23,19	18,63
	65-74	6	75,0	6	100,0	27,78	32,77
Cycle 6 Day 1	18-64	25	86,2	21	84,0	17,46	20,05
	65-74	6	75,0	5	83,3	20,00	18,26
Cycle 7 Day 1	18-64	25	86,2	22	88,0	19,70	26,55
	65-74	5	62,5	4	80,0	8,33	16,67
Cycle 8 Day 1	18-64	23	79,3	20	87,0	26,67	20,52
	65-74	5	62,5	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	20,00	22,69
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 10 Day 1	18-64	20	69,0	19	95,0	21,05	22,80
	65-74	5	62,5	5	100,0	20,00	18,26
Cycle 11 Day 1	18-64	19	65,5	19	100,0	17,54	17,10
	65-74	5	62,5	5	100,0	13,33	18,26
Cycle 12 Day 1	18-64	19	65,5	17	89,5	19,61	16,91
	65-74	5	62,5	4	80,0	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	16,67	17,21
	65-74	5	62,5	5	100,0	26,67	27,89
Cycle 14 Day 1	18-64	17	58,6	17	100,0	17,65	17,15
	65-74	5	62,5	5	100,0	26,67	27,89
Cycle 15 Day 1	18-64	17	58,6	16	94,1	16,67	17,21
	65-74	5	62,5	5	100,0	20,00	18,26
Cycle 16 Day 1	18-64	17	58,6	13	76,5	23,08	25,04
	65-74	4	50,0	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	16,67	17,41
	65-74	3	37,5	2	66,7	16,67	23,57
Cycle 18 Day 1	18-64	13	44,8	8	61,5	16,67	25,20
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	19,05	17,82
	65-74	2	25,0	1	50,0	33,33	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	16,67	17,82
	65-74	1	12,5	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	16,67	19,25
Cycle 22 Day 1	18-64	7	24,1	2	28,6	33,33	0,00
Cycle 23 Day 1	18-64	4	13,8	1	25,0	33,33	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	0,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	55,56	19,25
	65-74	6	75,0	2	33,3	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	16	80,0	50,00	24,34
	Other	17	100,0	17	100,0	39,22	21,20
Cycle 2 Day 1	White	19	95,0	16	84,2	29,17	23,96
	Other	14	82,4	14	100,0	21,43	21,11
Cycle 3 Day 1	White	18	90,0	15	83,3	11,11	16,27
	Other	14	82,4	14	100,0	11,90	16,57
Cycle 4 Day 1	White	18	90,0	14	77,8	11,90	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	20,51	28,99
Cycle 5 Day 1	White	18	90,0	17	94,4	23,53	22,87
	Other	13	76,5	12	92,3	25,00	20,72
Cycle 6 Day 1	White	18	90,0	13	72,2	15,38	17,30
	Other	13	76,5	13	100,0	20,51	21,68
Cycle 7 Day 1	White	17	85,0	14	82,4	19,05	28,39
	Other	13	76,5	12	92,3	16,67	22,47
Cycle 8 Day 1	White	17	85,0	14	82,4	21,43	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	30,30	23,35
Cycle 9 Day 1	White	16	80,0	16	100,0	16,67	21,08
	Other	9	52,9	9	100,0	18,52	24,22
Cycle 10 Day 1	White	16	80,0	15	93,8	20,00	21,08
	Other	9	52,9	9	100,0	22,22	23,57
Cycle 11 Day 1	White	16	80,0	16	100,0	16,67	17,21
	Other	8	47,1	8	100,0	16,67	17,82
Cycle 12 Day 1	White	16	80,0	13	81,3	20,51	16,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	20,83	17,25
Cycle 13 Day 1	White	14	70,0	13	92,9	20,51	21,68
	Other	8	47,1	8	100,0	16,67	17,82
Cycle 14 Day 1	White	14	70,0	14	100,0	19,05	21,54
	Other	8	47,1	8	100,0	20,83	17,25
Cycle 15 Day 1	White	14	70,0	13	92,9	15,38	17,30
	Other	8	47,1	8	100,0	20,83	17,25
Cycle 16 Day 1	White	14	70,0	9	64,3	25,93	27,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	16,67	18,26
Cycle 17 Day 1	White	13	65,0	10	76,9	23,33	16,10
	Other	5	29,4	4	80,0	0,00	0,00
Cycle 18 Day 1	White	11	55,0	4	36,4	25,00	31,91
	Other	4	23,5	4	100,0	8,33	16,67
Cycle 19 Day 1	White	9	45,0	5	55,6	26,67	14,91
	Other	4	23,5	3	75,0	11,11	19,25
Cycle 20 Day 1	White	5	25,0	5	100,0	26,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	8,33	16,67
Cycle 21 Day 1	White	3	15,0	2	66,7	16,67	23,57
	Other	4	23,5	2	50,0	16,67	23,57
Cycle 22 Day 1	White	3	15,0	1	33,3	33,33	-
	Other	4	23,5	1	25,0	33,33	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	33,33	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	44,44	19,25
	Other	9	52,9	2	22,2	50,00	23,57
Region							
Cycle 1 Day 1	America (AM)	12	100,0	11	91,7	36,36	10,05
	Europe (EU)	10	100,0	8	80,0	66,67	25,20
	Asia (AS)	15	100,0	14	93,3	38,10	22,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	10	90,9	26,67	14,05
	Europe (EU)	9	90,0	8	88,9	37,50	33,03
	Asia (AS)	13	86,7	12	92,3	16,67	17,41
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	9,09	15,57
	Europe (EU)	8	80,0	5	62,5	20,00	18,26
	Asia (AS)	13	86,7	13	100,0	10,26	16,01
Cycle 4 Day 1	America (AM)	11	91,7	10	90,9	13,33	17,21
	Europe (EU)	8	80,0	4	50,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	20,51	28,99
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	18,18	17,41
	Europe (EU)	8	80,0	7	87,5	23,81	25,20
	Asia (AS)	12	80,0	11	91,7	30,30	23,35
Cycle 6 Day 1	America (AM)	11	91,7	9	81,8	22,22	16,67
	Europe (EU)	8	80,0	6	75,0	16,67	18,26
	Asia (AS)	12	80,0	11	91,7	15,15	22,92
Cycle 7 Day 1	America (AM)	11	91,7	9	81,8	25,93	32,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	14,29	17,82
	Asia (AS)	11	73,3	10	90,9	13,33	23,31
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	26,67	21,08
	Europe (EU)	8	80,0	6	75,0	27,78	13,61
	Asia (AS)	9	60,0	9	100,0	22,22	23,57
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	12,12	22,47
	Europe (EU)	7	70,0	7	100,0	23,81	16,27
	Asia (AS)	7	46,7	7	100,0	19,05	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	13,33	17,21
	Europe (EU)	7	70,0	7	100,0	33,33	27,22
	Asia (AS)	7	46,7	7	100,0	19,05	17,82
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	12,12	16,82
	Europe (EU)	7	70,0	7	100,0	23,81	16,27
	Asia (AS)	6	40,0	6	100,0	16,67	18,26
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	23,33	16,10
	Europe (EU)	7	70,0	5	71,4	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	5,56	13,61
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	13,33	17,21
	Europe (EU)	6	60,0	5	83,3	33,33	23,57
	Asia (AS)	6	40,0	6	100,0	16,67	18,26
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	23,33	16,10
	Europe (EU)	6	60,0	6	100,0	22,22	27,22
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	20,00	18,26
	Asia (AS)	6	40,0	6	100,0	22,22	17,21
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	19,05	26,23
	Europe (EU)	6	60,0	2	33,3	33,33	0,00
	Asia (AS)	6	40,0	6	100,0	22,22	27,22
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	22,22	17,21
	Europe (EU)	4	40,0	3	75,0	11,11	19,25
	Asia (AS)	5	33,3	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	26,67	27,89
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	0,00	0,00
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	25,00	16,67
	Europe (EU)	3	30,0	1	33,3	33,33	-
	Asia (AS)	4	26,7	3	75,0	11,11	19,25
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	20,00	18,26
	Europe (EU)	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	11,11	19,25
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	22,22	19,25
	Asia (AS)	3	20,0	1	33,3	0,00	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	33,33	0,00
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	33,33	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	44,44	19,25
	Europe (EU)	2	20,0	1	50,0	33,33	-
	Asia (AS)	7	46,7	1	14,3	66,67	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	11	73,3	45,45	22,47
	1	17	100,0	17	100,0	47,06	23,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	33,33	23,57
Cycle 2 Day 1	0	15	100,0	13	86,7	20,51	16,88
	1	15	88,2	14	93,3	28,57	28,81
	2	3	60,0	3	100,0	33,33	0,00
Cycle 3 Day 1	0	15	100,0	13	86,7	12,82	16,88
	1	14	82,4	13	92,9	10,26	16,01
	2	3	60,0	3	100,0	11,11	19,25
Cycle 4 Day 1	0	15	100,0	13	86,7	15,38	17,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	16,67	30,15
	2	3	60,0	2	66,7	16,67	23,57
Cycle 5 Day 1	0	15	100,0	15	100,0	22,22	20,57
	1	14	82,4	12	85,7	27,78	23,92
	2	2	40,0	2	100,0	16,67	23,57
Cycle 6 Day 1	0	15	100,0	14	93,3	21,43	16,57
	1	14	82,4	11	78,6	15,15	22,92
	2	2	40,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	26,19	29,75
	1	13	76,5	10	76,9	10,00	16,10
	2	2	40,0	2	100,0	0,00	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	28,21	22,96
	1	11	64,7	10	90,9	20,00	17,21
	2	2	40,0	2	100,0	33,33	0,00
Cycle 9 Day 1	0	14	93,3	14	100,0	16,67	21,68
	1	10	58,8	10	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	33,33	-
Cycle 10 Day 1	0	14	93,3	14	100,0	19,05	17,12
	1	10	58,8	9	90,0	22,22	28,87
	2	1	20,0	1	100,0	33,33	-
Cycle 11 Day 1	0	14	93,3	14	100,0	16,67	17,30
	1	9	52,9	9	100,0	14,81	17,57
	2	1	20,0	1	100,0	33,33	-
Cycle 12 Day 1	0	14	93,3	12	85,7	25,00	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	12,50	17,25
	2	1	20,0	1	100,0	33,33	-
Cycle 13 Day 1	0	14	93,3	13	92,9	20,51	21,68
	1	8	47,1	8	100,0	16,67	17,82
Cycle 14 Day 1	0	14	93,3	14	100,0	23,81	20,37
	1	8	47,1	8	100,0	12,50	17,25
Cycle 15 Day 1	0	14	93,3	14	100,0	19,05	17,12
	1	8	47,1	7	87,5	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	25,00	29,55
	1	8	47,1	7	87,5	19,05	17,82
Cycle 17 Day 1	0	12	80,0	8	66,7	20,83	17,25
	1	6	35,3	6	100,0	11,11	17,21
Cycle 18 Day 1	0	9	60,0	4	44,4	25,00	31,91
	1	6	35,3	4	66,7	8,33	16,67
Cycle 19 Day 1	0	8	53,3	4	50,0	25,00	16,67
	1	5	29,4	4	80,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	20,00	18,26
	1	4	23,5	4	100,0	16,67	19,25
Cycle 21 Day 1	0	3	20,0	3	100,0	22,22	19,25
	1	4	23,5	1	25,0	0,00	-
Cycle 22 Day 1	0	3	20,0	2	66,7	33,33	0,00
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	33,33	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	33,33	0,00
	1	7	41,2	2	28,6	66,67	0,00
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	46,15	16,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	33,33	0,00
	2 or More	21	100,0	18	85,7	44,44	28,01
Cycle 2 Day 1	None	14	100,0	13	92,9	25,64	19,97
	1	1	50,0	1	100,0	0,00	-
	2 or More	18	85,7	16	88,9	27,08	25,00
Cycle 3 Day 1	None	14	100,0	13	92,9	12,82	16,88
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	11,11	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	11	78,6	18,18	31,14
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	15,56	17,21
Cycle 5 Day 1	None	14	100,0	14	100,0	23,81	20,37
	1	1	50,0	1	100,0	33,33	-
	2 or More	16	76,2	14	87,5	23,81	24,21
Cycle 6 Day 1	None	14	100,0	12	85,7	19,44	17,16
	1	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	13	81,3	15,38	22,01
Cycle 7 Day 1	None	14	100,0	12	85,7	11,11	16,41
	1	1	50,0	1	100,0	33,33	-
	2 or More	15	71,4	13	86,7	23,08	31,58
Cycle 8 Day 1	None	14	100,0	13	92,9	28,21	18,49
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	22,22	21,71
Cycle 9 Day 1	None	13	92,9	13	100,0	17,95	22,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	18,18	22,92
Cycle 10 Day 1	None	13	92,9	12	92,3	22,22	21,71
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	21,21	22,47
Cycle 11 Day 1	None	13	92,9	13	100,0	17,95	17,30
	1	1	50,0	1	100,0	33,33	-
	2 or More	10	47,6	10	100,0	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	22,22	16,41
	1	1	50,0	1	100,0	33,33	-
	2 or More	10	47,6	8	80,0	16,67	17,82
Cycle 13 Day 1	None	12	85,7	11	91,7	18,18	17,41
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	22,22	23,57
Cycle 14 Day 1	None	12	85,7	12	100,0	22,22	16,41
	1	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	14,81	24,22
Cycle 15 Day 1	None	12	85,7	12	100,0	16,67	17,41
	1	1	50,0	1	100,0	33,33	-
	2 or More	9	42,9	8	88,9	16,67	17,82
Cycle 16 Day 1	None	11	78,6	8	72,7	29,17	27,82
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	16,67	18,26
Cycle 17 Day 1	None	10	71,4	7	70,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	33,33	-
	2 or More	7	33,3	6	85,7	16,67	18,26
Cycle 18 Day 1	None	8	57,1	4	50,0	33,33	27,22
	1	1	50,0	1	100,0	0,00	-
	2 or More	6	28,6	3	50,0	0,00	0,00
Cycle 19 Day 1	None	7	50,0	3	42,9	22,22	19,25
	1	1	50,0	1	100,0	33,33	-
	2 or More	5	23,8	4	80,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	16,67	19,25
	1	1	50,0	1	100,0	33,33	-
	2 or More	4	19,0	4	100,0	16,67	19,25
Cycle 21 Day 1	None	4	28,6	2	50,0	33,33	0,00
	2 or More	3	14,3	2	66,7	0,00	0,00
Cycle 22 Day 1	None	4	28,6	1	25,0	33,33	-
	2 or More	3	14,3	1	33,3	33,33	-
Cycle 23 Day 1	None	2	14,3	1	50,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	33,33	-
	1	2	100,0	1	50,0	33,33	-
	2 or More	9	42,9	3	33,3	55,56	19,25
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	46,15	16,88
	Previously Treated	23	100,0	20	87,0	43,33	26,71
Cycle 2 Day 1	Naïve	14	100,0	13	92,9	25,64	19,97
	Previously Treated	19	82,6	17	89,5	25,49	25,08
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	12,82	16,88
	Previously Treated	18	78,3	16	88,9	10,42	15,96
Cycle 4 Day 1	Naïve	14	100,0	11	78,6	18,18	31,14
	Previously Treated	18	78,3	16	88,9	14,58	17,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	23,81	20,37
	Previously Treated	17	73,9	15	88,2	24,44	23,46
Cycle 6 Day 1	Naïve	14	100,0	12	85,7	19,44	17,16
	Previously Treated	17	73,9	14	82,4	16,67	21,68
Cycle 7 Day 1	Naïve	14	100,0	12	85,7	11,11	16,41
	Previously Treated	16	69,6	14	87,5	23,81	30,46
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	28,21	18,49
	Previously Treated	14	60,9	12	85,7	22,22	21,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	17,95	22,01
	Previously Treated	12	52,2	12	100,0	16,67	22,47
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	22,22	21,71
	Previously Treated	12	52,2	12	100,0	19,44	22,29
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	17,95	17,30
	Previously Treated	11	47,8	11	100,0	15,15	17,41
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	22,22	16,41
	Previously Treated	11	47,8	9	81,8	18,52	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	18,18	17,41
	Previously Treated	10	43,5	10	100,0	20,00	23,31
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	22,22	16,41
	Previously Treated	10	43,5	10	100,0	16,67	23,57
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	16,67	17,41
	Previously Treated	10	43,5	9	90,0	18,52	17,57
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	29,17	27,82
	Previously Treated	10	43,5	7	70,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	14,29	17,82
	Previously Treated	8	34,8	7	87,5	19,05	17,82
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	33,33	27,22
	Previously Treated	7	30,4	4	57,1	0,00	0,00
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	22,22	19,25
	Previously Treated	6	26,1	5	83,3	20,00	18,26
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	16,67	19,25
	Previously Treated	5	21,7	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	33,33	0,00
	Previously Treated	3	13,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	33,33	-
	Previously Treated	3	13,0	1	33,3	33,33	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	11	47,8	4	36,4	50,00	19,25
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	44,44	21,71
	Central	25	100,0	21	84,0	44,44	24,34
Cycle 2 Day 1	Local	11	91,7	11	100,0	27,27	13,48
	Central	22	88,0	19	86,4	24,56	26,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	10	90,9	13,33	17,21
	Central	21	84,0	19	90,5	10,53	15,92
Cycle 4 Day 1	Local	11	91,7	9	81,8	11,11	16,67
	Central	21	84,0	18	85,7	18,52	26,13
Cycle 5 Day 1	Local	11	91,7	10	90,9	23,33	22,50
	Central	20	80,0	19	95,0	24,56	21,78
Cycle 6 Day 1	Local	11	91,7	11	100,0	15,15	17,41
	Central	20	80,0	15	75,0	20,00	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	15,15	17,41
	Central	19	76,0	15	78,9	20,00	30,34
Cycle 8 Day 1	Local	10	83,3	10	100,0	26,67	21,08
	Central	18	72,0	15	83,3	24,44	19,79
Cycle 9 Day 1	Local	10	83,3	10	100,0	20,00	23,31
	Central	15	60,0	15	100,0	15,56	21,33
Cycle 10 Day 1	Local	10	83,3	9	90,0	18,52	17,57
	Central	15	60,0	15	100,0	22,22	24,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	18,52	17,57
	Central	15	60,0	15	100,0	15,56	17,21
Cycle 12 Day 1	Local	9	75,0	8	88,9	25,00	15,43
	Central	15	60,0	13	86,7	17,95	17,30
Cycle 13 Day 1	Local	8	66,7	8	100,0	20,83	24,80
	Central	14	56,0	13	92,9	17,95	17,30
Cycle 14 Day 1	Local	8	66,7	8	100,0	25,00	23,57
	Central	14	56,0	14	100,0	16,67	17,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	16,67	17,82
	Central	14	56,0	13	92,9	17,95	17,30
Cycle 16 Day 1	Local	8	66,7	6	75,0	22,22	27,22
	Central	13	52,0	9	69,2	22,22	23,57
Cycle 17 Day 1	Local	8	66,7	5	62,5	13,33	18,26
	Central	10	40,0	9	90,0	18,52	17,57
Cycle 18 Day 1	Local	6	50,0	4	66,7	33,33	27,22
	Central	9	36,0	4	44,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	25,00	16,67
	Central	8	32,0	4	50,0	16,67	19,25
Cycle 20 Day 1	Local	5	41,7	5	100,0	20,00	18,26
	Central	4	16,0	4	100,0	16,67	19,25
Cycle 21 Day 1	Local	4	33,3	2	50,0	33,33	0,00
	Central	3	12,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Local	4	33,3	1	25,0	33,33	-
	Central	3	12,0	1	33,3	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	33,33	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	0,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	50,00	23,57
	Central	8	32,0	3	37,5	44,44	19,25

BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	31	88,6	44,09	23,39
	No	2	100,0	2	100,0	50,00	23,57
Cycle 2 Day 1	Yes	32	91,4	29	90,6	26,44	22,50
	No	1	50,0	1	100,0	0,00	-
Cycle 3 Day 1	Yes	31	88,6	28	90,3	10,71	15,85
	No	1	50,0	1	100,0	33,33	-
Cycle 4 Day 1	Yes	31	88,6	26	83,9	16,67	23,57
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	23,81	21,96
	No	1	50,0	1	100,0	33,33	-
Cycle 6 Day 1	Yes	30	85,7	25	83,3	18,67	19,44
	No	1	50,0	1	100,0	0,00	-
Cycle 7 Day 1	Yes	29	82,9	25	86,2	18,67	25,60
	No	1	50,0	1	100,0	0,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	25,00	20,26
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	18,06	21,93
	No	1	50,0	1	100,0	0,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	21,74	21,58
	No	1	50,0	1	100,0	0,00	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	15,94	17,03
	No	1	50,0	1	100,0	33,33	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	20,00	16,75
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	18,33	20,16
	No	1	50,0	1	100,0	33,33	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	19,05	19,92
	No	1	50,0	1	100,0	33,33	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	16,67	17,10
	No	1	50,0	1	100,0	33,33	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	23,81	24,21
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	17,95	17,30
	No	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	19,05	26,23
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	23,81	16,27
	No	1	50,0	1	100,0	0,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	20,83	17,25
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	16,67	19,25
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	33,33	0,00
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	33,33	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	0,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	46,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	55,56	19,25
	No	33	100,0	30	90,9	43,33	23,41
Cycle 2 Day 1	Yes	2	50,0	1	50,0	0,00	-
	No	31	93,9	29	93,5	26,44	22,50
Cycle 3 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	27	90,0	12,35	16,40
Cycle 4 Day 1	Yes	2	50,0	2	100,0	50,00	70,71
	No	30	90,9	25	83,3	13,33	16,67
Cycle 5 Day 1	Yes	2	50,0	2	100,0	50,00	23,57
	No	29	87,9	27	93,1	22,22	20,67
Cycle 6 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	29	87,9	24	82,8	18,06	19,61
Cycle 7 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	24	85,7	19,44	25,85
Cycle 8 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	26	78,8	23	88,5	26,09	19,99
Cycle 9 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	24	100,0	18,06	21,93
Cycle 10 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	23	95,8	20,29	21,88
Cycle 11 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	15,94	17,03
Cycle 12 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	23	69,7	20	87,0	21,67	16,31
Cycle 13 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	20	95,2	18,33	20,16
Cycle 14 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	21	100,0	19,05	19,92
Cycle 15 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	16,67	17,10
Cycle 16 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	20	60,6	14	70,0	19,05	21,54
Cycle 17 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	17	51,5	13	76,5	15,38	17,30
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	16,67	25,20
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	20,83	17,25
Cycle 20 Day 1	No	9	27,3	9	100,0	18,52	17,57
Cycle 21 Day 1	No	7	21,2	4	57,1	16,67	19,25
Cycle 22 Day 1	No	7	21,2	2	28,6	33,33	0,00
Cycle 23 Day 1	No	4	12,1	1	25,0	33,33	-
Cycle 24 Day 1	No	1	3,0	1	100,0	0,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	41,67	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13CO_SG.xls
07SEP2019 20:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	33	89,2	9,09	25,38
Cycle 2 Day 1	All	33	89,2	30	90,9	18,89	24,26
Cycle 3 Day 1	All	32	86,5	29	90,6	13,79	16,71
Cycle 4 Day 1	All	32	86,5	27	84,4	9,88	15,51
Cycle 5 Day 1	All	31	83,8	29	93,5	8,05	17,03
Cycle 6 Day 1	All	31	83,8	26	83,9	8,97	17,78
Cycle 7 Day 1	All	30	81,1	26	86,7	8,97	17,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	9,33	15,28
Cycle 9 Day 1	All	25	67,6	25	100,0	9,33	15,28
Cycle 10 Day 1	All	25	67,6	24	96,0	13,89	19,45
Cycle 11 Day 1	All	24	64,9	24	100,0	12,50	19,19
Cycle 12 Day 1	All	24	64,9	21	87,5	12,70	16,59
Cycle 13 Day 1	All	22	59,5	21	95,5	12,70	16,59
Cycle 14 Day 1	All	22	59,5	22	100,0	10,61	18,93
Cycle 15 Day 1	All	22	59,5	21	95,5	9,52	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	8,89	15,26
Cycle 17 Day 1	All	18	48,6	14	77,8	9,52	15,63
Cycle 18 Day 1	All	15	40,5	8	53,3	0,00	0,00
Cycle 19 Day 1	All	13	35,1	8	61,5	12,50	35,36
Cycle 20 Day 1	All	9	24,3	9	100,0	7,41	22,22
Cycle 21 Day 1	All	7	18,9	4	57,1	0,00	0,00
Cycle 22 Day 1	All	7	18,9	2	28,6	0,00	0,00
Cycle 23 Day 1	All	4	10,8	1	25,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	0,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	6,67	14,91
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	17,95	37,55
	Female	23	100,0	20	87,0	3,33	10,26
Cycle 2 Day 1	Male	13	92,9	13	100,0	23,08	31,58
	Female	20	87,0	17	85,0	15,69	17,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	13,89	17,16
	Female	20	87,0	17	85,0	13,73	16,91
Cycle 4 Day 1	Male	12	85,7	10	83,3	3,33	10,54
	Female	20	87,0	17	85,0	13,73	16,91
Cycle 5 Day 1	Male	12	85,7	11	91,7	6,06	20,10
	Female	19	82,6	18	94,7	9,26	15,36
Cycle 6 Day 1	Male	12	85,7	11	91,7	6,06	13,48
	Female	19	82,6	15	78,9	11,11	20,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	9,09	15,57
	Female	19	82,6	15	78,9	8,89	19,79
Cycle 8 Day 1	Male	10	71,4	9	90,0	11,11	16,67
	Female	18	78,3	16	88,9	8,33	14,91
Cycle 9 Day 1	Male	8	57,1	8	100,0	8,33	15,43
	Female	17	73,9	17	100,0	9,80	15,66
Cycle 10 Day 1	Male	8	57,1	8	100,0	16,67	25,20
	Female	17	73,9	16	94,1	12,50	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	20,83	24,80
	Female	16	69,6	16	100,0	8,33	14,91
Cycle 12 Day 1	Male	8	57,1	8	100,0	12,50	17,25
	Female	16	69,6	13	81,3	12,82	16,88
Cycle 13 Day 1	Male	8	57,1	8	100,0	8,33	15,43
	Female	14	60,9	13	92,9	15,38	17,30
Cycle 14 Day 1	Male	8	57,1	8	100,0	8,33	15,43
	Female	14	60,9	14	100,0	11,90	21,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	8,33	15,43
	Female	14	60,9	13	92,9	10,26	16,01
Cycle 16 Day 1	Male	8	57,1	5	62,5	6,67	14,91
	Female	13	56,5	10	76,9	10,00	16,10
Cycle 17 Day 1	Male	6	42,9	2	33,3	0,00	0,00
	Female	12	52,2	12	100,0	11,11	16,41
Cycle 18 Day 1	Male	3	21,4	2	66,7	0,00	0,00
	Female	12	52,2	6	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	11	47,8	6	54,5	16,67	40,82
Cycle 20 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	7	30,4	7	100,0	9,52	25,20
Cycle 21 Day 1	Male	1	7,1	1	100,0	0,00	-
	Female	6	26,1	3	50,0	0,00	0,00
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	0,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	0,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	0,00	0,00
	Female	7	30,4	3	42,9	11,11	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	26	89,7	7,69	21,72
	65-74	8	100,0	7	87,5	14,29	37,80
Cycle 2 Day 1	18-64	27	93,1	24	88,9	19,44	25,85
	65-74	6	75,0	6	100,0	16,67	18,26
Cycle 3 Day 1	18-64	26	89,7	24	92,3	13,89	16,79
	65-74	6	75,0	5	83,3	13,33	18,26
Cycle 4 Day 1	18-64	26	89,7	22	84,6	9,09	15,19
	65-74	6	75,0	5	83,3	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	7,25	17,28
	65-74	6	75,0	6	100,0	11,11	17,21
Cycle 6 Day 1	18-64	25	86,2	21	84,0	7,94	14,55
	65-74	6	75,0	5	83,3	13,33	29,81
Cycle 7 Day 1	18-64	25	86,2	22	88,0	9,09	18,35
	65-74	5	62,5	4	80,0	8,33	16,67
Cycle 8 Day 1	18-64	23	79,3	20	87,0	8,33	14,81
	65-74	5	62,5	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	10,00	15,67
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 10 Day 1	18-64	20	69,0	19	95,0	14,04	20,23
	65-74	5	62,5	5	100,0	13,33	18,26
Cycle 11 Day 1	18-64	19	65,5	19	100,0	14,04	20,23
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 12 Day 1	18-64	19	65,5	17	89,5	11,76	16,42
	65-74	5	62,5	4	80,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	12,50	16,67
	65-74	5	62,5	5	100,0	13,33	18,26
Cycle 14 Day 1	18-64	17	58,6	17	100,0	9,80	15,66
	65-74	5	62,5	5	100,0	13,33	29,81
Cycle 15 Day 1	18-64	17	58,6	16	94,1	10,42	15,96
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 16 Day 1	18-64	17	58,6	13	76,5	10,26	16,01
	65-74	4	50,0	2	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	11,11	16,41
	65-74	3	37,5	2	66,7	0,00	0,00
Cycle 18 Day 1	18-64	13	44,8	8	61,5	0,00	0,00
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	14,29	37,80
	65-74	2	25,0	1	50,0	0,00	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	8,33	23,57
	65-74	1	12,5	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	0,00	0,00
Cycle 22 Day 1	18-64	7	24,1	2	28,6	0,00	0,00
Cycle 23 Day 1	18-64	4	13,8	1	25,0	0,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	0,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	0,00	0,00
	65-74	6	75,0	2	33,3	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	16	80,0	16,67	34,43
	Other	17	100,0	17	100,0	1,96	8,08
Cycle 2 Day 1	White	19	95,0	16	84,2	18,75	29,74
	Other	14	82,4	14	100,0	19,05	17,12
Cycle 3 Day 1	White	18	90,0	15	83,3	15,56	17,21
	Other	14	82,4	14	100,0	11,90	16,57
Cycle 4 Day 1	White	18	90,0	14	77,8	9,52	15,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	10,26	16,01
Cycle 5 Day 1	White	18	90,0	17	94,4	5,88	13,10
	Other	13	76,5	12	92,3	11,11	21,71
Cycle 6 Day 1	White	18	90,0	13	72,2	12,82	21,68
	Other	13	76,5	13	100,0	5,13	12,52
Cycle 7 Day 1	White	17	85,0	14	82,4	11,90	21,11
	Other	13	76,5	12	92,3	5,56	12,97
Cycle 8 Day 1	White	17	85,0	14	82,4	11,90	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	6,06	13,48
Cycle 9 Day 1	White	16	80,0	16	100,0	8,33	14,91
	Other	9	52,9	9	100,0	11,11	16,67
Cycle 10 Day 1	White	16	80,0	15	93,8	17,78	21,33
	Other	9	52,9	9	100,0	7,41	14,70
Cycle 11 Day 1	White	16	80,0	16	100,0	14,58	20,97
	Other	8	47,1	8	100,0	8,33	15,43
Cycle 12 Day 1	White	16	80,0	13	81,3	15,38	17,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	8,33	15,43
Cycle 13 Day 1	White	14	70,0	13	92,9	12,82	16,88
	Other	8	47,1	8	100,0	12,50	17,25
Cycle 14 Day 1	White	14	70,0	14	100,0	14,29	21,54
	Other	8	47,1	8	100,0	4,17	11,79
Cycle 15 Day 1	White	14	70,0	13	92,9	10,26	16,01
	Other	8	47,1	8	100,0	8,33	15,43
Cycle 16 Day 1	White	14	70,0	9	64,3	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	11,11	17,21
Cycle 17 Day 1	White	13	65,0	10	76,9	10,00	16,10
	Other	5	29,4	4	80,0	8,33	16,67
Cycle 18 Day 1	White	11	55,0	4	36,4	0,00	0,00
	Other	4	23,5	4	100,0	0,00	0,00
Cycle 19 Day 1	White	9	45,0	5	55,6	0,00	0,00
	Other	4	23,5	3	75,0	33,33	57,74
Cycle 20 Day 1	White	5	25,0	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	16,67	33,33
Cycle 21 Day 1	White	3	15,0	2	66,7	0,00	0,00
	Other	4	23,5	2	50,0	0,00	0,00
Cycle 22 Day 1	White	3	15,0	1	33,3	0,00	-
	Other	4	23,5	1	25,0	0,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	0,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	11,11	19,25
	Other	9	52,9	2	22,2	0,00	0,00
Region							
Cycle 1 Day 1	America (AM)	12	100,0	11	91,7	0,00	0,00
	Europe (EU)	10	100,0	8	80,0	20,83	35,36
	Asia (AS)	15	100,0	14	93,3	9,52	27,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	10	90,9	20,00	23,31
	Europe (EU)	9	90,0	8	88,9	20,83	35,36
	Asia (AS)	13	86,7	12	92,3	16,67	17,41
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	12,12	16,82
	Europe (EU)	8	80,0	5	62,5	13,33	18,26
	Asia (AS)	13	86,7	13	100,0	15,38	17,30
Cycle 4 Day 1	America (AM)	11	91,7	10	90,9	10,00	16,10
	Europe (EU)	8	80,0	4	50,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	10,26	16,01
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	3,03	10,05
	Europe (EU)	8	80,0	7	87,5	14,29	26,23
	Asia (AS)	12	80,0	11	91,7	9,09	15,57
Cycle 6 Day 1	America (AM)	11	91,7	9	81,8	0,00	0,00
	Europe (EU)	8	80,0	6	75,0	22,22	27,22
	Asia (AS)	12	80,0	11	91,7	9,09	15,57
Cycle 7 Day 1	America (AM)	11	91,7	9	81,8	7,41	22,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	14,29	17,82
	Asia (AS)	11	73,3	10	90,9	6,67	14,05
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	3,33	10,54
	Europe (EU)	8	80,0	6	75,0	16,67	18,26
	Asia (AS)	9	60,0	9	100,0	11,11	16,67
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	3,03	10,05
	Europe (EU)	7	70,0	7	100,0	9,52	16,27
	Asia (AS)	7	46,7	7	100,0	19,05	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	10,00	22,50
	Europe (EU)	7	70,0	7	100,0	19,05	17,82
	Asia (AS)	7	46,7	7	100,0	14,29	17,82
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	9,09	15,57
	Europe (EU)	7	70,0	7	100,0	19,05	26,23
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	6,67	14,05
	Europe (EU)	7	70,0	5	71,4	26,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	6,67	14,05
	Europe (EU)	6	60,0	5	83,3	20,00	18,26
	Asia (AS)	6	40,0	6	100,0	16,67	18,26
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	3,33	10,54
	Europe (EU)	6	60,0	6	100,0	22,22	27,22
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	20,00	18,26
	Asia (AS)	6	40,0	6	100,0	16,67	18,26
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	4,76	12,60
	Europe (EU)	6	60,0	2	33,3	16,67	23,57
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	5,56	13,61
	Europe (EU)	4	40,0	3	75,0	0,00	0,00
	Asia (AS)	5	33,3	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	0,00	0,00
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	0,00	0,00
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	0,00	0,00
	Europe (EU)	3	30,0	1	33,3	0,00	-
	Asia (AS)	4	26,7	3	75,0	33,33	57,74
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	0,00	0,00
	Europe (EU)	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	22,22	38,49
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	0,00	0,00
	Asia (AS)	3	20,0	1	33,3	0,00	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	0,00	0,00
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	0,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	0,00	0,00
	Europe (EU)	2	20,0	1	50,0	33,33	-
	Asia (AS)	7	46,7	1	14,3	0,00	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	11	73,3	0,00	0,00
	1	17	100,0	17	100,0	17,65	33,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	0,00	0,00
Cycle 2 Day 1	0	15	100,0	13	86,7	15,38	22,01
	1	15	88,2	14	93,3	26,19	26,73
	2	3	60,0	3	100,0	0,00	0,00
Cycle 3 Day 1	0	15	100,0	13	86,7	10,26	16,01
	1	14	82,4	13	92,9	20,51	16,88
	2	3	60,0	3	100,0	0,00	0,00
Cycle 4 Day 1	0	15	100,0	13	86,7	10,26	16,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	11,11	16,41
	2	3	60,0	2	66,7	0,00	0,00
Cycle 5 Day 1	0	15	100,0	15	100,0	6,67	13,80
	1	14	82,4	12	85,7	11,11	21,71
	2	2	40,0	2	100,0	0,00	0,00
Cycle 6 Day 1	0	15	100,0	14	93,3	9,52	20,37
	1	14	82,4	11	78,6	9,09	15,57
	2	2	40,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	11,90	21,11
	1	13	76,5	10	76,9	6,67	14,05
	2	2	40,0	2	100,0	0,00	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	10,26	16,01
	1	11	64,7	10	90,9	10,00	16,10
	2	2	40,0	2	100,0	0,00	0,00
Cycle 9 Day 1	0	14	93,3	14	100,0	7,14	14,19
	1	10	58,8	10	100,0	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	0,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	14,29	21,54
	1	10	58,8	9	90,0	14,81	17,57
	2	1	20,0	1	100,0	0,00	-
Cycle 11 Day 1	0	14	93,3	14	100,0	14,29	21,54
	1	9	52,9	9	100,0	11,11	16,67
	2	1	20,0	1	100,0	0,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	11,11	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	16,67	17,82
	2	1	20,0	1	100,0	0,00	-
Cycle 13 Day 1	0	14	93,3	13	92,9	7,69	14,62
	1	8	47,1	8	100,0	20,83	17,25
Cycle 14 Day 1	0	14	93,3	14	100,0	9,52	20,37
	1	8	47,1	8	100,0	12,50	17,25
Cycle 15 Day 1	0	14	93,3	14	100,0	7,14	14,19
	1	8	47,1	7	87,5	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	0,00	0,00
	1	8	47,1	7	87,5	19,05	17,82
Cycle 17 Day 1	0	12	80,0	8	66,7	4,17	11,79
	1	6	35,3	6	100,0	16,67	18,26
Cycle 18 Day 1	0	9	60,0	4	44,4	0,00	0,00
	1	6	35,3	4	66,7	0,00	0,00
Cycle 19 Day 1	0	8	53,3	4	50,0	0,00	0,00
	1	5	29,4	4	80,0	25,00	50,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	0,00	0,00
	1	4	23,5	4	100,0	16,67	33,33
Cycle 21 Day 1	0	3	20,0	3	100,0	0,00	0,00
	1	4	23,5	1	25,0	0,00	-
Cycle 22 Day 1	0	3	20,0	2	66,7	0,00	0,00
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	0,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	11,11	19,25
	1	7	41,2	2	28,6	0,00	0,00
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	2,56	9,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	0,00	0,00
	2 or More	21	100,0	18	85,7	14,81	32,78
Cycle 2 Day 1	None	14	100,0	13	92,9	17,95	22,01
	1	1	50,0	1	100,0	0,00	-
	2 or More	18	85,7	16	88,9	20,83	26,87
Cycle 3 Day 1	None	14	100,0	13	92,9	15,38	17,30
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	13,33	16,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	11	78,6	12,12	16,82
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	8,89	15,26
Cycle 5 Day 1	None	14	100,0	14	100,0	11,90	21,11
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	4,76	12,10
Cycle 6 Day 1	None	14	100,0	12	85,7	8,33	15,08
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	13	81,3	10,26	21,01
Cycle 7 Day 1	None	14	100,0	12	85,7	5,56	12,97
	1	1	50,0	1	100,0	0,00	-
	2 or More	15	71,4	13	86,7	12,82	21,68
Cycle 8 Day 1	None	14	100,0	13	92,9	7,69	14,62
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	11,11	16,41
Cycle 9 Day 1	None	13	92,9	13	100,0	10,26	16,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	9,09	15,57
Cycle 10 Day 1	None	13	92,9	12	92,3	16,67	22,47
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	12,12	16,82
Cycle 11 Day 1	None	13	92,9	13	100,0	12,82	16,88
	1	1	50,0	1	100,0	33,33	-
	2 or More	10	47,6	10	100,0	10,00	22,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	11,11	16,41
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	8	80,0	16,67	17,82
Cycle 13 Day 1	None	12	85,7	11	91,7	15,15	17,41
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	11,11	16,67
Cycle 14 Day 1	None	12	85,7	12	100,0	8,33	15,08
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	14,81	24,22
Cycle 15 Day 1	None	12	85,7	12	100,0	8,33	15,08
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	8	88,9	12,50	17,25
Cycle 16 Day 1	None	11	78,6	8	72,7	8,33	15,43
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	11,11	17,21
Cycle 17 Day 1	None	10	71,4	7	70,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	7	33,3	6	85,7	5,56	13,61
Cycle 18 Day 1	None	8	57,1	4	50,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	6	28,6	3	50,0	0,00	0,00
Cycle 19 Day 1	None	7	50,0	3	42,9	33,33	57,74
	1	1	50,0	1	100,0	0,00	-
	2 or More	5	23,8	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	16,67	33,33
	1	1	50,0	1	100,0	0,00	-
	2 or More	4	19,0	4	100,0	0,00	0,00
Cycle 21 Day 1	None	4	28,6	2	50,0	0,00	0,00
	2 or More	3	14,3	2	66,7	0,00	0,00
Cycle 22 Day 1	None	4	28,6	1	25,0	0,00	-
	2 or More	3	14,3	1	33,3	0,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	0,00	-
	1	2	100,0	1	50,0	0,00	-
	2 or More	9	42,9	3	33,3	11,11	19,25
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	2,56	9,25
	Previously Treated	23	100,0	20	87,0	13,33	31,34
Cycle 2 Day 1	Naïve	14	100,0	13	92,9	17,95	22,01
	Previously Treated	19	82,6	17	89,5	19,61	26,51
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	15,38	17,30
	Previously Treated	18	78,3	16	88,9	12,50	16,67
Cycle 4 Day 1	Naïve	14	100,0	11	78,6	12,12	16,82
	Previously Treated	18	78,3	16	88,9	8,33	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	11,90	21,11
	Previously Treated	17	73,9	15	88,2	4,44	11,73
Cycle 6 Day 1	Naïve	14	100,0	12	85,7	8,33	15,08
	Previously Treated	17	73,9	14	82,4	9,52	20,37
Cycle 7 Day 1	Naïve	14	100,0	12	85,7	5,56	12,97
	Previously Treated	16	69,6	14	87,5	11,90	21,11
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	7,69	14,62
	Previously Treated	14	60,9	12	85,7	11,11	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	10,26	16,01
	Previously Treated	12	52,2	12	100,0	8,33	15,08
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	16,67	22,47
	Previously Treated	12	52,2	12	100,0	11,11	16,41
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	12,82	16,88
	Previously Treated	11	47,8	11	100,0	12,12	22,47
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	11,11	16,41
	Previously Treated	11	47,8	9	81,8	14,81	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	15,15	17,41
	Previously Treated	10	43,5	10	100,0	10,00	16,10
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	8,33	15,08
	Previously Treated	10	43,5	10	100,0	13,33	23,31
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	8,33	15,08
	Previously Treated	10	43,5	9	90,0	11,11	16,67
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	8,33	15,43
	Previously Treated	10	43,5	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	14,29	17,82
	Previously Treated	8	34,8	7	87,5	4,76	12,60
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	0,00	0,00
	Previously Treated	7	30,4	4	57,1	0,00	0,00
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	33,33	57,74
	Previously Treated	6	26,1	5	83,3	0,00	0,00
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	16,67	33,33
	Previously Treated	5	21,7	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	0,00	0,00
	Previously Treated	3	13,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	0,00	-
	Previously Treated	3	13,0	1	33,3	0,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	11	47,8	4	36,4	8,33	16,67
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	0,00	0,00
	Central	25	100,0	21	84,0	14,29	30,86
Cycle 2 Day 1	Local	11	91,7	11	100,0	27,27	20,10
	Central	22	88,0	19	86,4	14,04	25,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	10	90,9	16,67	17,57
	Central	21	84,0	19	90,5	12,28	16,52
Cycle 4 Day 1	Local	11	91,7	9	81,8	11,11	16,67
	Central	21	84,0	18	85,7	9,26	15,36
Cycle 5 Day 1	Local	11	91,7	10	90,9	6,67	14,05
	Central	20	80,0	19	95,0	8,77	18,73
Cycle 6 Day 1	Local	11	91,7	11	100,0	9,09	21,56
	Central	20	80,0	15	75,0	8,89	15,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	6,06	13,48
	Central	19	76,0	15	78,9	11,11	20,57
Cycle 8 Day 1	Local	10	83,3	10	100,0	3,33	10,54
	Central	18	72,0	15	83,3	13,33	16,90
Cycle 9 Day 1	Local	10	83,3	10	100,0	10,00	16,10
	Central	15	60,0	15	100,0	8,89	15,26
Cycle 10 Day 1	Local	10	83,3	9	90,0	14,81	24,22
	Central	15	60,0	15	100,0	13,33	16,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	7,41	14,70
	Central	15	60,0	15	100,0	15,56	21,33
Cycle 12 Day 1	Local	9	75,0	8	88,9	8,33	15,43
	Central	15	60,0	13	86,7	15,38	17,30
Cycle 13 Day 1	Local	8	66,7	8	100,0	12,50	17,25
	Central	14	56,0	13	92,9	12,82	16,88
Cycle 14 Day 1	Local	8	66,7	8	100,0	8,33	23,57
	Central	14	56,0	14	100,0	11,90	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	8,33	15,43
	Central	14	56,0	13	92,9	10,26	16,01
Cycle 16 Day 1	Local	8	66,7	6	75,0	0,00	0,00
	Central	13	52,0	9	69,2	14,81	17,57
Cycle 17 Day 1	Local	8	66,7	5	62,5	6,67	14,91
	Central	10	40,0	9	90,0	11,11	16,67
Cycle 18 Day 1	Local	6	50,0	4	66,7	0,00	0,00
	Central	9	36,0	4	44,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	25,00	50,00
	Central	8	32,0	4	50,0	0,00	0,00
Cycle 20 Day 1	Local	5	41,7	5	100,0	13,33	29,81
	Central	4	16,0	4	100,0	0,00	0,00
Cycle 21 Day 1	Local	4	33,3	2	50,0	0,00	0,00
	Central	3	12,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Local	4	33,3	1	25,0	0,00	-
	Central	3	12,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	0,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	0,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	16,67	23,57
	Central	8	32,0	3	37,5	0,00	0,00
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	31	88,6	9,68	26,10
	No	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	Yes	32	91,4	29	90,6	18,39	24,54
	No	1	50,0	1	100,0	33,33	-
Cycle 3 Day 1	Yes	31	88,6	28	90,3	13,10	16,58
	No	1	50,0	1	100,0	33,33	-
Cycle 4 Day 1	Yes	31	88,6	26	83,9	10,26	15,69
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	7,14	16,62
	No	1	50,0	1	100,0	33,33	-
Cycle 6 Day 1	Yes	30	85,7	25	83,3	8,00	17,43
	No	1	50,0	1	100,0	33,33	-
Cycle 7 Day 1	Yes	29	82,9	25	86,2	9,33	18,05
	No	1	50,0	1	100,0	0,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	9,72	15,48
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	8,33	14,74
	No	1	50,0	1	100,0	33,33	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	13,04	19,43
	No	1	50,0	1	100,0	33,33	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	11,59	19,09
	No	1	50,0	1	100,0	33,33	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	13,33	16,75
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	11,67	16,31
	No	1	50,0	1	100,0	33,33	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	11,11	19,25
	No	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	8,33	14,81
	No	1	50,0	1	100,0	33,33	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	9,52	15,63
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	7,69	14,62
	No	1	50,0	1	100,0	33,33	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	0,00	0,00
	No	1	50,0	1	100,0	100,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	0,00	0,00
	No	1	50,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	0,00	0,00
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	0,00	0,00
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	0,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	0,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	0,00	0,00
	No	33	100,0	30	90,9	10,00	26,48
Cycle 2 Day 1	Yes	2	50,0	1	50,0	0,00	-
	No	31	93,9	29	93,5	19,54	24,43
Cycle 3 Day 1	Yes	2	50,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	27	90,0	13,58	16,69
Cycle 4 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	30	90,9	25	83,3	9,33	15,28
Cycle 5 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	29	87,9	27	93,1	7,41	16,88
Cycle 6 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	29	87,9	24	82,8	8,33	17,72
Cycle 7 Day 1	Yes	2	50,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	24	85,7	8,33	17,72
Cycle 8 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	26	78,8	23	88,5	8,70	14,97
Cycle 9 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	24	100,0	8,33	14,74
Cycle 10 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	23	95,8	13,04	19,43
Cycle 11 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	11,59	19,09
Cycle 12 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	23	69,7	20	87,0	11,67	16,31
Cycle 13 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	20	95,2	11,67	16,31
Cycle 14 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	21	100,0	9,52	18,69
Cycle 15 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	8,33	14,81
Cycle 16 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	20	60,6	14	70,0	9,52	15,63
Cycle 17 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	17	51,5	13	76,5	7,69	14,62
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	0,00	0,00
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	12,50	35,36
Cycle 20 Day 1	No	9	27,3	9	100,0	7,41	22,22
Cycle 21 Day 1	No	7	21,2	4	57,1	0,00	0,00
Cycle 22 Day 1	No	7	21,2	2	28,6	0,00	0,00
Cycle 23 Day 1	No	4	12,1	1	25,0	0,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	0,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DS_SG.xls
07SEP2019 20:23

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	33	89,2	38,05	29,00
Cycle 2 Day 1	All	33	89,2	29	87,9	23,75	23,33
Cycle 3 Day 1	All	32	86,5	29	90,6	22,61	19,36
Cycle 4 Day 1	All	32	86,5	27	84,4	20,99	20,05
Cycle 5 Day 1	All	31	83,8	29	93,5	24,90	17,23
Cycle 6 Day 1	All	31	83,8	26	83,9	24,36	19,88
Cycle 7 Day 1	All	30	81,1	26	86,7	26,92	17,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	27,56	20,82
Cycle 9 Day 1	All	25	67,6	25	100,0	25,33	20,16
Cycle 10 Day 1	All	25	67,6	24	96,0	23,61	16,48
Cycle 11 Day 1	All	24	64,9	24	100,0	21,76	14,83
Cycle 12 Day 1	All	24	64,9	21	87,5	22,75	16,66
Cycle 13 Day 1	All	22	59,5	21	95,5	22,22	20,49
Cycle 14 Day 1	All	22	59,5	22	100,0	28,28	27,59
Cycle 15 Day 1	All	22	59,5	21	95,5	22,22	16,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	34,81	27,50
Cycle 17 Day 1	All	18	48,6	14	77,8	24,60	22,72
Cycle 18 Day 1	All	15	40,5	8	53,3	25,00	14,24
Cycle 19 Day 1	All	13	35,1	8	61,5	27,78	18,78
Cycle 20 Day 1	All	9	24,3	9	100,0	27,16	19,33
Cycle 21 Day 1	All	7	18,9	4	57,1	33,33	15,71
Cycle 22 Day 1	All	7	18,9	2	28,6	44,44	47,14
Cycle 23 Day 1	All	4	10,8	1	25,0	22,22	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	11,11	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	60,00	27,89
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	42,74	31,70
	Female	23	100,0	20	87,0	35,00	27,52
Cycle 2 Day 1	Male	13	92,9	12	92,3	30,56	26,43
	Female	20	87,0	17	85,0	18,95	20,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	19,44	16,50
	Female	20	87,0	17	85,0	24,84	21,35
Cycle 4 Day 1	Male	12	85,7	10	83,3	14,44	16,60
	Female	20	87,0	17	85,0	24,84	21,35
Cycle 5 Day 1	Male	12	85,7	11	91,7	21,21	12,62
	Female	19	82,6	18	94,7	27,16	19,52
Cycle 6 Day 1	Male	12	85,7	11	91,7	17,17	19,48
	Female	19	82,6	15	78,9	29,63	19,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	21,21	16,82
	Female	19	82,6	15	78,9	31,11	17,42
Cycle 8 Day 1	Male	10	71,4	9	90,0	32,10	26,90
	Female	18	78,3	16	88,9	25,00	16,97
Cycle 9 Day 1	Male	8	57,1	8	100,0	20,83	16,20
	Female	17	73,9	17	100,0	27,45	21,91
Cycle 10 Day 1	Male	8	57,1	8	100,0	19,44	16,53
	Female	17	73,9	16	94,1	25,69	16,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	18,06	17,76
	Female	16	69,6	16	100,0	23,61	13,38
Cycle 12 Day 1	Male	8	57,1	8	100,0	19,44	17,57
	Female	16	69,6	13	81,3	24,79	16,45
Cycle 13 Day 1	Male	8	57,1	8	100,0	15,28	15,64
	Female	14	60,9	13	92,9	26,50	22,47
Cycle 14 Day 1	Male	8	57,1	8	100,0	29,17	31,39
	Female	14	60,9	14	100,0	27,78	26,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	16,67	15,71
	Female	14	60,9	13	92,9	25,64	16,60
Cycle 16 Day 1	Male	8	57,1	5	62,5	31,11	29,81
	Female	13	56,5	10	76,9	36,67	27,74
Cycle 17 Day 1	Male	6	42,9	2	33,3	22,22	15,71
	Female	12	52,2	12	100,0	25,00	24,22
Cycle 18 Day 1	Male	3	21,4	2	66,7	16,67	7,86
	Female	12	52,2	6	50,0	27,78	15,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	22,22	15,71
	Female	11	47,8	6	54,5	29,63	20,69
Cycle 20 Day 1	Male	2	14,3	2	100,0	16,67	7,86
	Female	7	30,4	7	100,0	30,16	21,00
Cycle 21 Day 1	Male	1	7,1	1	100,0	22,22	-
	Female	6	26,1	3	50,0	37,04	16,97
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	44,44	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	22,22	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	11,11	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	83,33	23,57
	Female	7	30,4	3	42,9	44,44	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	26	89,7	36,75	31,23
	65-74	8	100,0	7	87,5	42,86	19,70
Cycle 2 Day 1	18-64	27	93,1	23	85,2	23,67	23,28
	65-74	6	75,0	6	100,0	24,07	25,74
Cycle 3 Day 1	18-64	26	89,7	24	92,3	24,54	20,19
	65-74	6	75,0	5	83,3	13,33	12,17
Cycle 4 Day 1	18-64	26	89,7	22	84,6	21,21	21,93
	65-74	6	75,0	5	83,3	20,00	9,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	24,15	17,93
	65-74	6	75,0	6	100,0	27,78	15,32
Cycle 6 Day 1	18-64	25	86,2	21	84,0	22,75	19,08
	65-74	6	75,0	5	83,3	31,11	24,09
Cycle 7 Day 1	18-64	25	86,2	22	88,0	25,76	18,59
	65-74	5	62,5	4	80,0	33,33	9,07
Cycle 8 Day 1	18-64	23	79,3	20	87,0	29,44	22,01
	65-74	5	62,5	5	100,0	20,00	14,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	21,67	16,71
	65-74	5	62,5	5	100,0	40,00	27,89
Cycle 10 Day 1	18-64	20	69,0	19	95,0	21,64	15,03
	65-74	5	62,5	5	100,0	31,11	21,37
Cycle 11 Day 1	18-64	19	65,5	19	100,0	22,22	15,27
	65-74	5	62,5	5	100,0	20,00	14,49
Cycle 12 Day 1	18-64	19	65,5	17	89,5	20,92	17,52
	65-74	5	62,5	4	80,0	30,56	10,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	20,14	17,32
	65-74	5	62,5	5	100,0	28,89	30,02
Cycle 14 Day 1	18-64	17	58,6	17	100,0	27,45	28,09
	65-74	5	62,5	5	100,0	31,11	28,76
Cycle 15 Day 1	18-64	17	58,6	16	94,1	21,53	15,96
	65-74	5	62,5	5	100,0	24,44	19,88
Cycle 16 Day 1	18-64	17	58,6	13	76,5	35,04	29,69
	65-74	4	50,0	2	50,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	25,93	24,31
	65-74	3	37,5	2	66,7	16,67	7,86
Cycle 18 Day 1	18-64	13	44,8	8	61,5	25,00	14,24
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	23,81	16,27
	65-74	2	25,0	1	50,0	55,56	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	25,00	19,47
	65-74	1	12,5	1	100,0	44,44	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	33,33	15,71
Cycle 22 Day 1	18-64	7	24,1	2	28,6	44,44	47,14
Cycle 23 Day 1	18-64	4	13,8	1	25,0	22,22	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	11,11	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	66,67	33,33
	65-74	6	75,0	2	33,3	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	16	80,0	38,19	32,45
	Other	17	100,0	17	100,0	37,91	26,37
Cycle 2 Day 1	White	19	95,0	15	78,9	28,89	29,04
	Other	14	82,4	14	100,0	18,25	14,19
Cycle 3 Day 1	White	18	90,0	15	83,3	22,22	24,49
	Other	14	82,4	14	100,0	23,02	12,68
Cycle 4 Day 1	White	18	90,0	14	77,8	15,08	18,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	27,35	20,60
Cycle 5 Day 1	White	18	90,0	17	94,4	24,18	19,73
	Other	13	76,5	12	92,3	25,93	13,68
Cycle 6 Day 1	White	18	90,0	13	72,2	25,64	25,00
	Other	13	76,5	13	100,0	23,08	13,95
Cycle 7 Day 1	White	17	85,0	14	82,4	23,81	21,29
	Other	13	76,5	12	92,3	30,56	11,73
Cycle 8 Day 1	White	17	85,0	14	82,4	19,84	18,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	37,37	20,65
Cycle 9 Day 1	White	16	80,0	16	100,0	23,61	23,96
	Other	9	52,9	9	100,0	28,40	11,26
Cycle 10 Day 1	White	16	80,0	15	93,8	21,48	19,00
	Other	9	52,9	9	100,0	27,16	11,26
Cycle 11 Day 1	White	16	80,0	16	100,0	18,75	14,47
	Other	8	47,1	8	100,0	27,78	14,55
Cycle 12 Day 1	White	16	80,0	13	81,3	20,51	18,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	26,39	14,47
Cycle 13 Day 1	White	14	70,0	13	92,9	20,51	24,78
	Other	8	47,1	8	100,0	25,00	11,50
Cycle 14 Day 1	White	14	70,0	14	100,0	23,02	27,72
	Other	8	47,1	8	100,0	37,50	26,52
Cycle 15 Day 1	White	14	70,0	13	92,9	18,80	18,36
	Other	8	47,1	8	100,0	27,78	11,88
Cycle 16 Day 1	White	14	70,0	9	64,3	25,93	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	48,15	29,54
Cycle 17 Day 1	White	13	65,0	10	76,9	24,44	24,46
	Other	5	29,4	4	80,0	25,00	21,03
Cycle 18 Day 1	White	11	55,0	4	36,4	22,22	15,71
	Other	4	23,5	4	100,0	27,78	14,34
Cycle 19 Day 1	White	9	45,0	5	55,6	28,89	23,04
	Other	4	23,5	3	75,0	25,93	12,83
Cycle 20 Day 1	White	5	25,0	5	100,0	31,11	24,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	22,22	12,83
Cycle 21 Day 1	White	3	15,0	2	66,7	38,89	23,57
	Other	4	23,5	2	50,0	27,78	7,86
Cycle 22 Day 1	White	3	15,0	1	33,3	77,78	-
	Other	4	23,5	1	25,0	11,11	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	22,22	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	55,56	19,25
	Other	9	52,9	2	22,2	66,67	47,14
Region							
Cycle 1 Day 1	America (AM)	12	100,0	11	91,7	25,25	27,26
	Europe (EU)	10	100,0	8	80,0	61,11	26,56
	Asia (AS)	15	100,0	14	93,3	34,92	25,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	9	81,8	14,81	7,86
	Europe (EU)	9	90,0	8	88,9	41,67	36,49
	Asia (AS)	13	86,7	12	92,3	18,52	12,83
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	16,16	16,75
	Europe (EU)	8	80,0	5	62,5	40,00	28,97
	Asia (AS)	13	86,7	13	100,0	21,37	13,95
Cycle 4 Day 1	America (AM)	11	91,7	10	90,9	14,44	13,91
	Europe (EU)	8	80,0	4	50,0	27,78	27,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	23,93	21,68
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	17,17	12,54
	Europe (EU)	8	80,0	7	87,5	34,92	21,69
	Asia (AS)	12	80,0	11	91,7	26,26	15,93
Cycle 6 Day 1	America (AM)	11	91,7	9	81,8	13,58	15,49
	Europe (EU)	8	80,0	6	75,0	38,89	25,09
	Asia (AS)	12	80,0	11	91,7	25,25	15,78
Cycle 7 Day 1	America (AM)	11	91,7	9	81,8	18,52	21,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	34,92	16,27
	Asia (AS)	11	73,3	10	90,9	28,89	11,94
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	16,67	14,10
	Europe (EU)	8	80,0	6	75,0	31,48	19,14
	Asia (AS)	9	60,0	9	100,0	37,04	24,22
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	20,20	17,79
	Europe (EU)	7	70,0	7	100,0	36,51	27,75
	Asia (AS)	7	46,7	7	100,0	22,22	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	20,00	15,54
	Europe (EU)	7	70,0	7	100,0	33,33	20,29
	Asia (AS)	7	46,7	7	100,0	19,05	10,57
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	18,18	14,29
	Europe (EU)	7	70,0	7	100,0	26,98	15,53
	Asia (AS)	6	40,0	6	100,0	22,22	15,71
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	18,89	18,18
	Europe (EU)	7	70,0	5	71,4	37,78	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	16,67	6,09
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	15,56	19,03
	Europe (EU)	6	60,0	5	83,3	35,56	28,76
	Asia (AS)	6	40,0	6	100,0	22,22	9,94
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	24,44	28,59
	Europe (EU)	6	60,0	6	100,0	37,04	36,29
	Asia (AS)	6	40,0	6	100,0	25,93	16,73
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	15,56	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	28,89	23,04
	Asia (AS)	6	40,0	6	100,0	27,78	11,65
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	20,63	19,70
	Europe (EU)	6	60,0	2	33,3	55,56	31,43
	Asia (AS)	6	40,0	6	100,0	44,44	29,81
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	29,63	30,36
	Europe (EU)	4	40,0	3	75,0	11,11	11,11
	Asia (AS)	5	33,3	5	100,0	26,67	16,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	22,22	13,61
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	29,63	16,97
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	22,22	20,29
	Europe (EU)	3	30,0	1	33,3	55,56	-
	Asia (AS)	4	26,7	3	75,0	25,93	12,83
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	24,44	24,09
	Europe (EU)	1	10,0	1	100,0	44,44	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	25,93	12,83
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	33,33	19,25
	Asia (AS)	3	20,0	1	33,3	33,33	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	44,44	47,14
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	22,22	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	44,44	19,25
	Europe (EU)	2	20,0	1	50,0	66,67	-
	Asia (AS)	7	46,7	1	14,3	100,00	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	11	73,3	24,24	15,57
	1	17	100,0	17	100,0	41,18	31,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	57,78	33,70
Cycle 2 Day 1	0	15	100,0	12	80,0	17,59	18,63
	1	15	88,2	14	93,3	26,19	26,01
	2	3	60,0	3	100,0	37,04	27,96
Cycle 3 Day 1	0	15	100,0	13	86,7	17,95	15,41
	1	14	82,4	13	92,9	20,51	17,48
	2	3	60,0	3	100,0	51,85	23,13
Cycle 4 Day 1	0	15	100,0	13	86,7	14,53	12,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	20,37	18,85
	2	3	60,0	2	66,7	66,67	0,00
Cycle 5 Day 1	0	15	100,0	15	100,0	20,74	15,06
	1	14	82,4	12	85,7	25,93	16,64
	2	2	40,0	2	100,0	50,00	23,57
Cycle 6 Day 1	0	15	100,0	14	93,3	23,02	21,56
	1	14	82,4	11	78,6	23,23	16,82
	2	2	40,0	1	50,0	55,56	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	24,60	20,52
	1	13	76,5	10	76,9	27,78	14,10
	2	2	40,0	2	100,0	38,89	7,86
Cycle 8 Day 1	0	15	100,0	13	86,7	22,22	16,36
	1	11	64,7	10	90,9	32,22	25,36
	2	2	40,0	2	100,0	38,89	23,57
Cycle 9 Day 1	0	14	93,3	14	100,0	25,40	22,40
	1	10	58,8	10	100,0	25,56	18,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	22,22	-
Cycle 10 Day 1	0	14	93,3	14	100,0	22,22	18,49
	1	10	58,8	9	90,0	24,69	14,46
	2	1	20,0	1	100,0	33,33	-
Cycle 11 Day 1	0	14	93,3	14	100,0	18,25	14,19
	1	9	52,9	9	100,0	25,93	15,71
	2	1	20,0	1	100,0	33,33	-
Cycle 12 Day 1	0	14	93,3	12	85,7	24,07	16,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	20,83	19,19
	2	1	20,0	1	100,0	22,22	-
Cycle 13 Day 1	0	14	93,3	13	92,9	22,22	23,13
	1	8	47,1	8	100,0	22,22	16,80
Cycle 14 Day 1	0	14	93,3	14	100,0	28,57	27,12
	1	8	47,1	8	100,0	27,78	30,28
Cycle 15 Day 1	0	14	93,3	14	100,0	20,63	17,35
	1	8	47,1	7	87,5	25,40	15,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	31,94	21,77
	1	8	47,1	7	87,5	38,10	34,46
Cycle 17 Day 1	0	12	80,0	8	66,7	25,00	27,70
	1	6	35,3	6	100,0	24,07	16,36
Cycle 18 Day 1	0	9	60,0	4	44,4	25,00	13,98
	1	6	35,3	4	66,7	25,00	16,67
Cycle 19 Day 1	0	8	53,3	4	50,0	36,11	18,98
	1	5	29,4	4	80,0	19,44	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	31,11	24,09
	1	4	23,5	4	100,0	22,22	12,83
Cycle 21 Day 1	0	3	20,0	3	100,0	33,33	19,25
	1	4	23,5	1	25,0	33,33	-
Cycle 22 Day 1	0	3	20,0	2	66,7	44,44	47,14
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	22,22	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	11,11	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	55,56	19,25
	1	7	41,2	2	28,6	66,67	47,14
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	29,91	26,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	44,44	47,14
	2 or More	21	100,0	18	85,7	43,21	29,74
Cycle 2 Day 1	None	14	100,0	13	92,9	17,09	14,07
	1	1	50,0	0	0,0	-	-
	2 or More	18	85,7	16	88,9	29,17	28,07
Cycle 3 Day 1	None	14	100,0	13	92,9	19,66	12,13
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	26,67	23,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	11	78,6	19,19	21,14
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	23,70	19,64
Cycle 5 Day 1	None	14	100,0	14	100,0	21,43	15,99
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	30,16	17,12
Cycle 6 Day 1	None	14	100,0	12	85,7	18,52	16,64
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	13	81,3	31,62	20,71
Cycle 7 Day 1	None	14	100,0	12	85,7	21,30	18,02
	1	1	50,0	1	100,0	0,00	-
	2 or More	15	71,4	13	86,7	34,19	13,95
Cycle 8 Day 1	None	14	100,0	13	92,9	23,93	25,19
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	31,48	14,86
Cycle 9 Day 1	None	13	92,9	13	100,0	18,80	15,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	11,11	-
	2 or More	11	52,4	11	100,0	34,34	23,02
Cycle 10 Day 1	None	13	92,9	12	92,3	20,37	16,97
	1	1	50,0	1	100,0	11,11	-
	2 or More	11	52,4	11	100,0	28,28	16,00
Cycle 11 Day 1	None	13	92,9	13	100,0	18,80	15,31
	1	1	50,0	1	100,0	11,11	-
	2 or More	10	47,6	10	100,0	26,67	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	20,37	16,30
	1	1	50,0	1	100,0	11,11	-
	2 or More	10	47,6	8	80,0	27,78	17,82
Cycle 13 Day 1	None	12	85,7	11	91,7	17,17	15,21
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	30,86	24,07
Cycle 14 Day 1	None	12	85,7	12	100,0	28,70	29,38
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	30,86	26,51
Cycle 15 Day 1	None	12	85,7	12	100,0	17,59	16,04
	1	1	50,0	1	100,0	11,11	-
	2 or More	9	42,9	8	88,9	30,56	15,43
Cycle 16 Day 1	None	11	78,6	8	72,7	36,11	30,72
	1	1	50,0	1	100,0	11,11	-
	2 or More	9	42,9	6	66,7	37,04	25,98
Cycle 17 Day 1	None	10	71,4	7	70,0	22,22	18,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	11,11	-
	2 or More	7	33,3	6	85,7	29,63	29,54
Cycle 18 Day 1	None	8	57,1	4	50,0	22,22	9,07
	1	1	50,0	1	100,0	11,11	-
	2 or More	6	28,6	3	50,0	33,33	19,25
Cycle 19 Day 1	None	7	50,0	3	42,9	22,22	19,25
	1	1	50,0	1	100,0	11,11	-
	2 or More	5	23,8	4	80,0	36,11	18,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	11,11	0,00
	1	1	50,0	1	100,0	22,22	-
	2 or More	4	19,0	4	100,0	44,44	15,71
Cycle 21 Day 1	None	4	28,6	2	50,0	22,22	0,00
	2 or More	3	14,3	2	66,7	44,44	15,71
Cycle 22 Day 1	None	4	28,6	1	25,0	11,11	-
	2 or More	3	14,3	1	33,3	77,78	-
Cycle 23 Day 1	None	2	14,3	1	50,0	22,22	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	11,11	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	33,33	-
	1	2	100,0	1	50,0	66,67	-
	2 or More	9	42,9	3	33,3	66,67	33,33
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	29,91	26,21
	Previously Treated	23	100,0	20	87,0	43,33	30,14
Cycle 2 Day 1	Naïve	14	100,0	13	92,9	17,09	14,07
	Previously Treated	19	82,6	16	84,2	29,17	28,07
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	19,66	12,13
	Previously Treated	18	78,3	16	88,9	25,00	23,83
Cycle 4 Day 1	Naïve	14	100,0	11	78,6	19,19	21,14
	Previously Treated	18	78,3	16	88,9	22,22	19,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	21,43	15,99
	Previously Treated	17	73,9	15	88,2	28,15	18,24
Cycle 6 Day 1	Naïve	14	100,0	12	85,7	18,52	16,64
	Previously Treated	17	73,9	14	82,4	29,37	21,62
Cycle 7 Day 1	Naïve	14	100,0	12	85,7	21,30	18,02
	Previously Treated	16	69,6	14	87,5	31,75	16,22
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	23,93	25,19
	Previously Treated	14	60,9	12	85,7	31,48	14,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	18,80	15,31
	Previously Treated	12	52,2	12	100,0	32,41	22,95
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	20,37	16,97
	Previously Treated	12	52,2	12	100,0	26,85	16,04
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	18,80	15,31
	Previously Treated	11	47,8	11	100,0	25,25	14,13
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	20,37	16,30
	Previously Treated	11	47,8	9	81,8	25,93	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	17,17	15,21
	Previously Treated	10	43,5	10	100,0	27,78	24,71
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	28,70	29,38
	Previously Treated	10	43,5	10	100,0	27,78	26,84
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	17,59	16,04
	Previously Treated	10	43,5	9	90,0	28,40	15,82
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	36,11	30,72
	Previously Treated	10	43,5	7	70,0	33,33	25,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	22,22	18,14
	Previously Treated	8	34,8	7	87,5	26,98	27,86
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	22,22	9,07
	Previously Treated	7	30,4	4	57,1	27,78	19,25
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	22,22	19,25
	Previously Treated	6	26,1	5	83,3	31,11	19,88
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	11,11	0,00
	Previously Treated	5	21,7	5	100,0	40,00	16,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	22,22	0,00
	Previously Treated	3	13,0	2	66,7	44,44	15,71
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	11,11	-
	Previously Treated	3	13,0	1	33,3	77,78	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	22,22	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	11,11	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	11	47,8	4	36,4	66,67	27,22
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	36,11	28,48
	Central	25	100,0	21	84,0	39,15	29,94
Cycle 2 Day 1	Local	11	91,7	11	100,0	20,20	17,79
	Central	22	88,0	18	81,8	25,93	26,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	10	90,9	20,00	16,40
	Central	21	84,0	19	90,5	23,98	21,04
Cycle 4 Day 1	Local	11	91,7	9	81,8	18,52	16,67
	Central	21	84,0	18	85,7	22,22	21,89
Cycle 5 Day 1	Local	11	91,7	10	90,9	26,67	17,53
	Central	20	80,0	19	95,0	23,98	17,48
Cycle 6 Day 1	Local	11	91,7	11	100,0	20,20	22,12
	Central	20	80,0	15	75,0	27,41	18,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	22,22	17,21
	Central	19	76,0	15	78,9	30,37	17,55
Cycle 8 Day 1	Local	10	83,3	10	100,0	23,33	16,93
	Central	18	72,0	15	83,3	30,37	23,18
Cycle 9 Day 1	Local	10	83,3	10	100,0	27,78	27,34
	Central	15	60,0	15	100,0	23,70	14,47
Cycle 10 Day 1	Local	10	83,3	9	90,0	25,93	20,79
	Central	15	60,0	15	100,0	22,22	13,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	19,75	13,35
	Central	15	60,0	15	100,0	22,96	15,97
Cycle 12 Day 1	Local	9	75,0	8	88,9	19,44	15,43
	Central	15	60,0	13	86,7	24,79	17,66
Cycle 13 Day 1	Local	8	66,7	8	100,0	20,83	25,50
	Central	14	56,0	13	92,9	23,08	17,84
Cycle 14 Day 1	Local	8	66,7	8	100,0	29,17	26,52
	Central	14	56,0	14	100,0	27,78	29,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	22,22	20,57
	Central	14	56,0	13	92,9	22,22	14,34
Cycle 16 Day 1	Local	8	66,7	6	75,0	29,63	21,85
	Central	13	52,0	9	69,2	38,27	31,48
Cycle 17 Day 1	Local	8	66,7	5	62,5	26,67	18,59
	Central	10	40,0	9	90,0	23,46	25,73
Cycle 18 Day 1	Local	6	50,0	4	66,7	22,22	9,07
	Central	9	36,0	4	44,4	27,78	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	30,56	22,91
	Central	8	32,0	4	50,0	25,00	16,67
Cycle 20 Day 1	Local	5	41,7	5	100,0	17,78	14,91
	Central	4	16,0	4	100,0	38,89	19,25
Cycle 21 Day 1	Local	4	33,3	2	50,0	22,22	0,00
	Central	3	12,0	2	66,7	44,44	15,71
Cycle 22 Day 1	Local	4	33,3	1	25,0	11,11	-
	Central	3	12,0	1	33,3	77,78	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	22,22	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	11,11	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	50,00	23,57
	Central	8	32,0	3	37,5	66,67	33,33
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	31	88,6	36,92	29,03
	No	2	100,0	2	100,0	55,56	31,43
Cycle 2 Day 1	Yes	32	91,4	28	87,5	23,81	23,76
	No	1	50,0	1	100,0	22,22	-
Cycle 3 Day 1	Yes	31	88,6	28	90,3	22,22	19,60
	No	1	50,0	1	100,0	33,33	-
Cycle 4 Day 1	Yes	31	88,6	26	83,9	19,66	19,20
	No	1	50,0	1	100,0	55,56	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	23,81	16,48
	No	1	50,0	1	100,0	55,56	-
Cycle 6 Day 1	Yes	30	85,7	25	83,3	23,56	19,86
	No	1	50,0	1	100,0	44,44	-
Cycle 7 Day 1	Yes	29	82,9	25	86,2	25,78	16,89
	No	1	50,0	1	100,0	55,56	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	26,39	20,41
	No	1	50,0	1	100,0	55,56	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	25,00	20,53
	No	1	50,0	1	100,0	33,33	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	23,19	16,72
	No	1	50,0	1	100,0	33,33	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	21,74	15,16
	No	1	50,0	1	100,0	22,22	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	22,78	17,09
	No	1	50,0	1	100,0	22,22	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	22,22	21,02
	No	1	50,0	1	100,0	22,22	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	26,98	27,57
	No	1	50,0	1	100,0	55,56	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	21,11	16,08
	No	1	50,0	1	100,0	44,44	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	32,54	27,03
	No	1	50,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	22,22	21,75
	No	1	50,0	1	100,0	55,56	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	23,81	14,95
	No	1	50,0	1	100,0	33,33	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	26,98	20,14
	No	1	50,0	1	100,0	33,33	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	29,17	19,64
	No	1	50,0	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	33,33	15,71
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	44,44	47,14
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	22,22	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	11,11	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	60,00	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	55,56	29,40
	No	33	100,0	30	90,9	36,30	28,88
Cycle 2 Day 1	Yes	2	50,0	1	50,0	22,22	-
	No	31	93,9	28	90,3	23,81	23,76
Cycle 3 Day 1	Yes	2	50,0	2	100,0	22,22	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	27	90,0	22,63	20,09
Cycle 4 Day 1	Yes	2	50,0	2	100,0	33,33	31,43
	No	30	90,9	25	83,3	20,00	19,51
Cycle 5 Day 1	Yes	2	50,0	2	100,0	22,22	15,71
	No	29	87,9	27	93,1	25,10	17,59
Cycle 6 Day 1	Yes	2	50,0	2	100,0	16,67	7,86
	No	29	87,9	24	82,8	25,00	20,53
Cycle 7 Day 1	Yes	2	50,0	2	100,0	22,22	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	24	85,7	27,31	18,24
Cycle 8 Day 1	Yes	2	50,0	2	100,0	50,00	55,00
	No	26	78,8	23	88,5	25,60	16,90
Cycle 9 Day 1	Yes	1	25,0	1	100,0	22,22	-
	No	24	72,7	24	100,0	25,46	20,59
Cycle 10 Day 1	Yes	1	25,0	1	100,0	11,11	-
	No	24	72,7	23	95,8	24,15	16,63
Cycle 11 Day 1	Yes	1	25,0	1	100,0	22,22	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	21,74	15,16
Cycle 12 Day 1	Yes	1	25,0	1	100,0	22,22	-
	No	23	69,7	20	87,0	22,78	17,09
Cycle 13 Day 1	Yes	1	25,0	1	100,0	22,22	-
	No	21	63,6	20	95,2	22,22	21,02
Cycle 14 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	21	100,0	28,04	28,24
Cycle 15 Day 1	Yes	1	25,0	1	100,0	22,22	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	22,22	16,91
Cycle 16 Day 1	Yes	1	25,0	1	100,0	66,67	-
	No	20	60,6	14	70,0	32,54	27,03
Cycle 17 Day 1	Yes	1	25,0	1	100,0	22,22	-
	No	17	51,5	13	76,5	24,79	23,64
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	25,00	14,24
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	27,78	18,78
Cycle 20 Day 1	No	9	27,3	9	100,0	27,16	19,33
Cycle 21 Day 1	No	7	21,2	4	57,1	33,33	15,71
Cycle 22 Day 1	No	7	21,2	2	28,6	44,44	47,14
Cycle 23 Day 1	No	4	12,1	1	25,0	22,22	-
Cycle 24 Day 1	No	1	3,0	1	100,0	11,11	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	50,00	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13DY_SG.xls
07SEP2019 20:25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	33	89,2	2,02	8,08
Cycle 2 Day 1	All	33	89,2	30	90,9	0,00	0,00
Cycle 3 Day 1	All	32	86,5	29	90,6	1,15	6,19
Cycle 4 Day 1	All	32	86,5	27	84,4	1,23	6,42
Cycle 5 Day 1	All	31	83,8	29	93,5	2,30	8,60
Cycle 6 Day 1	All	31	83,8	26	83,9	2,56	9,06
Cycle 7 Day 1	All	30	81,1	26	86,7	2,56	13,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	0,00	0,00
Cycle 9 Day 1	All	25	67,6	25	100,0	0,00	0,00
Cycle 10 Day 1	All	25	67,6	24	96,0	1,39	6,80
Cycle 11 Day 1	All	24	64,9	24	100,0	0,00	0,00
Cycle 12 Day 1	All	24	64,9	21	87,5	1,59	7,27
Cycle 13 Day 1	All	22	59,5	21	95,5	0,00	0,00
Cycle 14 Day 1	All	22	59,5	22	100,0	0,00	0,00
Cycle 15 Day 1	All	22	59,5	21	95,5	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	0,00	0,00
Cycle 17 Day 1	All	18	48,6	14	77,8	0,00	0,00
Cycle 18 Day 1	All	15	40,5	8	53,3	0,00	0,00
Cycle 19 Day 1	All	13	35,1	8	61,5	0,00	0,00
Cycle 20 Day 1	All	9	24,3	9	100,0	0,00	0,00
Cycle 21 Day 1	All	7	18,9	4	57,1	0,00	0,00
Cycle 22 Day 1	All	7	18,9	2	28,6	0,00	0,00
Cycle 23 Day 1	All	4	10,8	1	25,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	0,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	6,67	14,91
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	2,56	9,25
	Female	23	100,0	20	87,0	1,67	7,45
Cycle 2 Day 1	Male	13	92,9	13	100,0	0,00	0,00
	Female	20	87,0	17	85,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	2,78	9,62
	Female	20	87,0	17	85,0	0,00	0,00
Cycle 4 Day 1	Male	12	85,7	10	83,3	3,33	10,54
	Female	20	87,0	17	85,0	0,00	0,00
Cycle 5 Day 1	Male	12	85,7	11	91,7	6,06	13,48
	Female	19	82,6	18	94,7	0,00	0,00
Cycle 6 Day 1	Male	12	85,7	11	91,7	6,06	13,48
	Female	19	82,6	15	78,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	6,06	20,10
	Female	19	82,6	15	78,9	0,00	0,00
Cycle 8 Day 1	Male	10	71,4	9	90,0	0,00	0,00
	Female	18	78,3	16	88,9	0,00	0,00
Cycle 9 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	17	73,9	17	100,0	0,00	0,00
Cycle 10 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	17	73,9	16	94,1	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	16	69,6	16	100,0	0,00	0,00
Cycle 12 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	16	69,6	13	81,3	0,00	0,00
Cycle 13 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	14	60,9	13	92,9	0,00	0,00
Cycle 14 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	14	60,9	14	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	14	60,9	13	92,9	0,00	0,00
Cycle 16 Day 1	Male	8	57,1	5	62,5	0,00	0,00
	Female	13	56,5	10	76,9	0,00	0,00
Cycle 17 Day 1	Male	6	42,9	2	33,3	0,00	0,00
	Female	12	52,2	12	100,0	0,00	0,00
Cycle 18 Day 1	Male	3	21,4	2	66,7	0,00	0,00
	Female	12	52,2	6	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	11	47,8	6	54,5	0,00	0,00
Cycle 20 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	7	30,4	7	100,0	0,00	0,00
Cycle 21 Day 1	Male	1	7,1	1	100,0	0,00	-
	Female	6	26,1	3	50,0	0,00	0,00
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	0,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	0,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	0,00	0,00
	Female	7	30,4	3	42,9	11,11	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	26	89,7	2,56	9,06
	65-74	8	100,0	7	87,5	0,00	0,00
Cycle 2 Day 1	18-64	27	93,1	24	88,9	0,00	0,00
	65-74	6	75,0	6	100,0	0,00	0,00
Cycle 3 Day 1	18-64	26	89,7	24	92,3	1,39	6,80
	65-74	6	75,0	5	83,3	0,00	0,00
Cycle 4 Day 1	18-64	26	89,7	22	84,6	1,52	7,11
	65-74	6	75,0	5	83,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	2,90	9,60
	65-74	6	75,0	6	100,0	0,00	0,00
Cycle 6 Day 1	18-64	25	86,2	21	84,0	3,17	10,03
	65-74	6	75,0	5	83,3	0,00	0,00
Cycle 7 Day 1	18-64	25	86,2	22	88,0	3,03	14,21
	65-74	5	62,5	4	80,0	0,00	0,00
Cycle 8 Day 1	18-64	23	79,3	20	87,0	0,00	0,00
	65-74	5	62,5	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	0,00	0,00
	65-74	5	62,5	5	100,0	0,00	0,00
Cycle 10 Day 1	18-64	20	69,0	19	95,0	1,75	7,65
	65-74	5	62,5	5	100,0	0,00	0,00
Cycle 11 Day 1	18-64	19	65,5	19	100,0	0,00	0,00
	65-74	5	62,5	5	100,0	0,00	0,00
Cycle 12 Day 1	18-64	19	65,5	17	89,5	1,96	8,08
	65-74	5	62,5	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	0,00	0,00
	65-74	5	62,5	5	100,0	0,00	0,00
Cycle 14 Day 1	18-64	17	58,6	17	100,0	0,00	0,00
	65-74	5	62,5	5	100,0	0,00	0,00
Cycle 15 Day 1	18-64	17	58,6	16	94,1	0,00	0,00
	65-74	5	62,5	5	100,0	0,00	0,00
Cycle 16 Day 1	18-64	17	58,6	13	76,5	0,00	0,00
	65-74	4	50,0	2	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	0,00	0,00
	65-74	3	37,5	2	66,7	0,00	0,00
Cycle 18 Day 1	18-64	13	44,8	8	61,5	0,00	0,00
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	0,00	0,00
	65-74	2	25,0	1	50,0	0,00	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	0,00	0,00
	65-74	1	12,5	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	0,00	0,00
Cycle 22 Day 1	18-64	7	24,1	2	28,6	0,00	0,00
Cycle 23 Day 1	18-64	4	13,8	1	25,0	0,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	0,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	11,11	19,25
	65-74	6	75,0	2	33,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	16	80,0	2,08	8,33
	Other	17	100,0	17	100,0	1,96	8,08
Cycle 2 Day 1	White	19	95,0	16	84,2	0,00	0,00
	Other	14	82,4	14	100,0	0,00	0,00
Cycle 3 Day 1	White	18	90,0	15	83,3	2,22	8,61
	Other	14	82,4	14	100,0	0,00	0,00
Cycle 4 Day 1	White	18	90,0	14	77,8	2,38	8,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	0,00	0,00
Cycle 5 Day 1	White	18	90,0	17	94,4	1,96	8,08
	Other	13	76,5	12	92,3	2,78	9,62
Cycle 6 Day 1	White	18	90,0	13	72,2	2,56	9,25
	Other	13	76,5	13	100,0	2,56	9,25
Cycle 7 Day 1	White	17	85,0	14	82,4	0,00	0,00
	Other	13	76,5	12	92,3	5,56	19,25
Cycle 8 Day 1	White	17	85,0	14	82,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	0,00	0,00
Cycle 9 Day 1	White	16	80,0	16	100,0	0,00	0,00
	Other	9	52,9	9	100,0	0,00	0,00
Cycle 10 Day 1	White	16	80,0	15	93,8	2,22	8,61
	Other	9	52,9	9	100,0	0,00	0,00
Cycle 11 Day 1	White	16	80,0	16	100,0	0,00	0,00
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 12 Day 1	White	16	80,0	13	81,3	2,56	9,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 13 Day 1	White	14	70,0	13	92,9	0,00	0,00
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 14 Day 1	White	14	70,0	14	100,0	0,00	0,00
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 15 Day 1	White	14	70,0	13	92,9	0,00	0,00
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 16 Day 1	White	14	70,0	9	64,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	0,00	0,00
Cycle 17 Day 1	White	13	65,0	10	76,9	0,00	0,00
	Other	5	29,4	4	80,0	0,00	0,00
Cycle 18 Day 1	White	11	55,0	4	36,4	0,00	0,00
	Other	4	23,5	4	100,0	0,00	0,00
Cycle 19 Day 1	White	9	45,0	5	55,6	0,00	0,00
	Other	4	23,5	3	75,0	0,00	0,00
Cycle 20 Day 1	White	5	25,0	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	0,00	0,00
Cycle 21 Day 1	White	3	15,0	2	66,7	0,00	0,00
	Other	4	23,5	2	50,0	0,00	0,00
Cycle 22 Day 1	White	3	15,0	1	33,3	0,00	-
	Other	4	23,5	1	25,0	0,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	0,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	11,11	19,25
	Other	9	52,9	2	22,2	0,00	0,00
Region							
Cycle 1 Day 1	America (AM)	12	100,0	11	91,7	3,03	10,05
	Europe (EU)	10	100,0	8	80,0	0,00	0,00
	Asia (AS)	15	100,0	14	93,3	2,38	8,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	10	90,9	0,00	0,00
	Europe (EU)	9	90,0	8	88,9	0,00	0,00
	Asia (AS)	13	86,7	12	92,3	0,00	0,00
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	0,00	0,00
	Europe (EU)	8	80,0	5	62,5	6,67	14,91
	Asia (AS)	13	86,7	13	100,0	0,00	0,00
Cycle 4 Day 1	America (AM)	11	91,7	10	90,9	0,00	0,00
	Europe (EU)	8	80,0	4	50,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	0,00	0,00
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	0,00	0,00
	Europe (EU)	8	80,0	7	87,5	4,76	12,60
	Asia (AS)	12	80,0	11	91,7	3,03	10,05
Cycle 6 Day 1	America (AM)	11	91,7	9	81,8	0,00	0,00
	Europe (EU)	8	80,0	6	75,0	5,56	13,61
	Asia (AS)	12	80,0	11	91,7	3,03	10,05
Cycle 7 Day 1	America (AM)	11	91,7	9	81,8	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	0,00	0,00
	Asia (AS)	11	73,3	10	90,9	6,67	21,08
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	0,00	0,00
	Europe (EU)	8	80,0	6	75,0	0,00	0,00
	Asia (AS)	9	60,0	9	100,0	0,00	0,00
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	0,00	0,00
	Europe (EU)	7	70,0	7	100,0	0,00	0,00
	Asia (AS)	7	46,7	7	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	0,00	0,00
	Europe (EU)	7	70,0	7	100,0	4,76	12,60
	Asia (AS)	7	46,7	7	100,0	0,00	0,00
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	0,00	0,00
	Europe (EU)	7	70,0	7	100,0	0,00	0,00
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	0,00	0,00
	Europe (EU)	7	70,0	5	71,4	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	0,00	0,00
	Europe (EU)	6	60,0	5	83,3	0,00	0,00
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	0,00	0,00
	Europe (EU)	6	60,0	6	100,0	0,00	0,00
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	0,00	0,00
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	0,00	0,00
	Europe (EU)	6	60,0	2	33,3	0,00	0,00
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	0,00	0,00
	Europe (EU)	4	40,0	3	75,0	0,00	0,00
	Asia (AS)	5	33,3	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	0,00	0,00
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	0,00	0,00
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	0,00	0,00
	Europe (EU)	3	30,0	1	33,3	0,00	-
	Asia (AS)	4	26,7	3	75,0	0,00	0,00
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	0,00	0,00
	Europe (EU)	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	0,00	0,00
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	0,00	0,00
	Asia (AS)	3	20,0	1	33,3	0,00	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	0,00	0,00
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	0,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	11,11	19,25
	Europe (EU)	2	20,0	1	50,0	0,00	-
	Asia (AS)	7	46,7	1	14,3	0,00	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	11	73,3	3,03	10,05
	1	17	100,0	17	100,0	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	0,00	0,00
Cycle 2 Day 1	0	15	100,0	13	86,7	0,00	0,00
	1	15	88,2	14	93,3	0,00	0,00
	2	3	60,0	3	100,0	0,00	0,00
Cycle 3 Day 1	0	15	100,0	13	86,7	2,56	9,25
	1	14	82,4	13	92,9	0,00	0,00
	2	3	60,0	3	100,0	0,00	0,00
Cycle 4 Day 1	0	15	100,0	13	86,7	2,56	9,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	0,00	0,00
	2	3	60,0	2	66,7	0,00	0,00
Cycle 5 Day 1	0	15	100,0	15	100,0	4,44	11,73
	1	14	82,4	12	85,7	0,00	0,00
	2	2	40,0	2	100,0	0,00	0,00
Cycle 6 Day 1	0	15	100,0	14	93,3	4,76	12,10
	1	14	82,4	11	78,6	0,00	0,00
	2	2	40,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	4,76	17,82
	1	13	76,5	10	76,9	0,00	0,00
	2	2	40,0	2	100,0	0,00	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	0,00	0,00
	1	11	64,7	10	90,9	0,00	0,00
	2	2	40,0	2	100,0	0,00	0,00
Cycle 9 Day 1	0	14	93,3	14	100,0	0,00	0,00
	1	10	58,8	10	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	0,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	2,38	8,91
	1	10	58,8	9	90,0	0,00	0,00
	2	1	20,0	1	100,0	0,00	-
Cycle 11 Day 1	0	14	93,3	14	100,0	0,00	0,00
	1	9	52,9	9	100,0	0,00	0,00
	2	1	20,0	1	100,0	0,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	2,78	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	0,00	0,00
	2	1	20,0	1	100,0	0,00	-
Cycle 13 Day 1	0	14	93,3	13	92,9	0,00	0,00
	1	8	47,1	8	100,0	0,00	0,00
Cycle 14 Day 1	0	14	93,3	14	100,0	0,00	0,00
	1	8	47,1	8	100,0	0,00	0,00
Cycle 15 Day 1	0	14	93,3	14	100,0	0,00	0,00
	1	8	47,1	7	87,5	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	0,00	0,00
	1	8	47,1	7	87,5	0,00	0,00
Cycle 17 Day 1	0	12	80,0	8	66,7	0,00	0,00
	1	6	35,3	6	100,0	0,00	0,00
Cycle 18 Day 1	0	9	60,0	4	44,4	0,00	0,00
	1	6	35,3	4	66,7	0,00	0,00
Cycle 19 Day 1	0	8	53,3	4	50,0	0,00	0,00
	1	5	29,4	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	0,00	0,00
	1	4	23,5	4	100,0	0,00	0,00
Cycle 21 Day 1	0	3	20,0	3	100,0	0,00	0,00
	1	4	23,5	1	25,0	0,00	-
Cycle 22 Day 1	0	3	20,0	2	66,7	0,00	0,00
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	0,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	0,00	0,00
	1	7	41,2	2	28,6	16,67	23,57
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	0,00	0,00
	2 or More	21	100,0	18	85,7	3,70	10,78
Cycle 2 Day 1	None	14	100,0	13	92,9	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	18	85,7	16	88,9	0,00	0,00
Cycle 3 Day 1	None	14	100,0	13	92,9	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	2,22	8,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	11	78,6	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	2,22	8,61
Cycle 5 Day 1	None	14	100,0	14	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	4,76	12,10
Cycle 6 Day 1	None	14	100,0	12	85,7	0,00	0,00
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	13	81,3	5,13	12,52
Cycle 7 Day 1	None	14	100,0	12	85,7	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	15	71,4	13	86,7	5,13	18,49
Cycle 8 Day 1	None	14	100,0	13	92,9	0,00	0,00
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	0,00	0,00
Cycle 9 Day 1	None	13	92,9	13	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	0,00	0,00
Cycle 10 Day 1	None	13	92,9	12	92,3	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	3,03	10,05
Cycle 11 Day 1	None	13	92,9	13	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	10	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	8	80,0	4,17	11,79
Cycle 13 Day 1	None	12	85,7	11	91,7	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	0,00	0,00
Cycle 14 Day 1	None	12	85,7	12	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	0,00	0,00
Cycle 15 Day 1	None	12	85,7	12	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	8	88,9	0,00	0,00
Cycle 16 Day 1	None	11	78,6	8	72,7	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	0,00	0,00
Cycle 17 Day 1	None	10	71,4	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	7	33,3	6	85,7	0,00	0,00
Cycle 18 Day 1	None	8	57,1	4	50,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	6	28,6	3	50,0	0,00	0,00
Cycle 19 Day 1	None	7	50,0	3	42,9	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	5	23,8	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	4	19,0	4	100,0	0,00	0,00
Cycle 21 Day 1	None	4	28,6	2	50,0	0,00	0,00
	2 or More	3	14,3	2	66,7	0,00	0,00
Cycle 22 Day 1	None	4	28,6	1	25,0	0,00	-
	2 or More	3	14,3	1	33,3	0,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	0,00	-
	1	2	100,0	1	50,0	0,00	-
	2 or More	9	42,9	3	33,3	11,11	19,25
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	0,00	0,00
	Previously Treated	23	100,0	20	87,0	3,33	10,26
Cycle 2 Day 1	Naïve	14	100,0	13	92,9	0,00	0,00
	Previously Treated	19	82,6	17	89,5	0,00	0,00
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	0,00	0,00
	Previously Treated	18	78,3	16	88,9	2,08	8,33
Cycle 4 Day 1	Naïve	14	100,0	11	78,6	0,00	0,00
	Previously Treated	18	78,3	16	88,9	2,08	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	0,00	0,00
	Previously Treated	17	73,9	15	88,2	4,44	11,73
Cycle 6 Day 1	Naïve	14	100,0	12	85,7	0,00	0,00
	Previously Treated	17	73,9	14	82,4	4,76	12,10
Cycle 7 Day 1	Naïve	14	100,0	12	85,7	0,00	0,00
	Previously Treated	16	69,6	14	87,5	4,76	17,82
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	0,00	0,00
	Previously Treated	14	60,9	12	85,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	0,00	0,00
	Previously Treated	12	52,2	12	100,0	0,00	0,00
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	0,00	0,00
	Previously Treated	12	52,2	12	100,0	2,78	9,62
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	0,00	0,00
	Previously Treated	11	47,8	11	100,0	0,00	0,00
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	0,00	0,00
	Previously Treated	11	47,8	9	81,8	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	0,00	0,00
	Previously Treated	10	43,5	10	100,0	0,00	0,00
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	0,00	0,00
	Previously Treated	10	43,5	10	100,0	0,00	0,00
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	0,00	0,00
	Previously Treated	10	43,5	9	90,0	0,00	0,00
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	0,00	0,00
	Previously Treated	10	43,5	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	0,00	0,00
	Previously Treated	8	34,8	7	87,5	0,00	0,00
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	0,00	0,00
	Previously Treated	7	30,4	4	57,1	0,00	0,00
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	0,00	0,00
	Previously Treated	6	26,1	5	83,3	0,00	0,00
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	0,00	0,00
	Previously Treated	5	21,7	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	0,00	0,00
	Previously Treated	3	13,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	0,00	-
	Previously Treated	3	13,0	1	33,3	0,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	11	47,8	4	36,4	8,33	16,67
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	2,78	9,62
	Central	25	100,0	21	84,0	1,59	7,27
Cycle 2 Day 1	Local	11	91,7	11	100,0	0,00	0,00
	Central	22	88,0	19	86,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	10	90,9	0,00	0,00
	Central	21	84,0	19	90,5	1,75	7,65
Cycle 4 Day 1	Local	11	91,7	9	81,8	0,00	0,00
	Central	21	84,0	18	85,7	1,85	7,86
Cycle 5 Day 1	Local	11	91,7	10	90,9	0,00	0,00
	Central	20	80,0	19	95,0	3,51	10,51
Cycle 6 Day 1	Local	11	91,7	11	100,0	0,00	0,00
	Central	20	80,0	15	75,0	4,44	11,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	0,00	0,00
	Central	19	76,0	15	78,9	4,44	17,21
Cycle 8 Day 1	Local	10	83,3	10	100,0	0,00	0,00
	Central	18	72,0	15	83,3	0,00	0,00
Cycle 9 Day 1	Local	10	83,3	10	100,0	0,00	0,00
	Central	15	60,0	15	100,0	0,00	0,00
Cycle 10 Day 1	Local	10	83,3	9	90,0	0,00	0,00
	Central	15	60,0	15	100,0	2,22	8,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	0,00	0,00
	Central	15	60,0	15	100,0	0,00	0,00
Cycle 12 Day 1	Local	9	75,0	8	88,9	0,00	0,00
	Central	15	60,0	13	86,7	2,56	9,25
Cycle 13 Day 1	Local	8	66,7	8	100,0	0,00	0,00
	Central	14	56,0	13	92,9	0,00	0,00
Cycle 14 Day 1	Local	8	66,7	8	100,0	0,00	0,00
	Central	14	56,0	14	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	0,00	0,00
	Central	14	56,0	13	92,9	0,00	0,00
Cycle 16 Day 1	Local	8	66,7	6	75,0	0,00	0,00
	Central	13	52,0	9	69,2	0,00	0,00
Cycle 17 Day 1	Local	8	66,7	5	62,5	0,00	0,00
	Central	10	40,0	9	90,0	0,00	0,00
Cycle 18 Day 1	Local	6	50,0	4	66,7	0,00	0,00
	Central	9	36,0	4	44,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	0,00	0,00
	Central	8	32,0	4	50,0	0,00	0,00
Cycle 20 Day 1	Local	5	41,7	5	100,0	0,00	0,00
	Central	4	16,0	4	100,0	0,00	0,00
Cycle 21 Day 1	Local	4	33,3	2	50,0	0,00	0,00
	Central	3	12,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Local	4	33,3	1	25,0	0,00	-
	Central	3	12,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	0,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	0,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	16,67	23,57
	Central	8	32,0	3	37,5	0,00	0,00
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	31	88,6	2,15	8,32
	No	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	Yes	32	91,4	29	90,6	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 3 Day 1	Yes	31	88,6	28	90,3	1,19	6,30
	No	1	50,0	1	100,0	0,00	-
Cycle 4 Day 1	Yes	31	88,6	26	83,9	1,28	6,54
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	2,38	8,74
	No	1	50,0	1	100,0	0,00	-
Cycle 6 Day 1	Yes	30	85,7	25	83,3	2,67	9,23
	No	1	50,0	1	100,0	0,00	-
Cycle 7 Day 1	Yes	29	82,9	25	86,2	2,67	13,33
	No	1	50,0	1	100,0	0,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	0,00	0,00
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	1,45	6,95
	No	1	50,0	1	100,0	0,00	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	1,67	7,45
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	0,00	0,00
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	0,00	0,00
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	0,00	0,00
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	0,00	0,00
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	0,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	0,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	0,00	0,00
	No	33	100,0	30	90,9	2,22	8,46
Cycle 2 Day 1	Yes	2	50,0	1	50,0	0,00	-
	No	31	93,9	29	93,5	0,00	0,00
Cycle 3 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	27	90,0	1,23	6,42
Cycle 4 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	30	90,9	25	83,3	1,33	6,67
Cycle 5 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	27	93,1	2,47	8,90
Cycle 6 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	24	82,8	2,78	9,41
Cycle 7 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	24	85,7	2,78	13,61
Cycle 8 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	26	78,8	23	88,5	0,00	0,00
Cycle 9 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	24	100,0	0,00	0,00
Cycle 10 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	23	95,8	1,45	6,95
Cycle 11 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	0,00	0,00
Cycle 12 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	23	69,7	20	87,0	1,67	7,45
Cycle 13 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	20	95,2	0,00	0,00
Cycle 14 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	21	100,0	0,00	0,00
Cycle 15 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	0,00	0,00
Cycle 16 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	20	60,6	14	70,0	0,00	0,00
Cycle 17 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	17	51,5	13	76,5	0,00	0,00
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	0,00	0,00
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	0,00	0,00
Cycle 20 Day 1	No	9	27,3	9	100,0	0,00	0,00
Cycle 21 Day 1	No	7	21,2	4	57,1	0,00	0,00
Cycle 22 Day 1	No	7	21,2	2	28,6	0,00	0,00
Cycle 23 Day 1	No	4	12,1	1	25,0	0,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	0,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HA_SG.xls
07SEP2019 20:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	33	89,2	7,07	20,00
Cycle 2 Day 1	All	33	89,2	30	90,9	10,00	26,48
Cycle 3 Day 1	All	32	86,5	29	90,6	8,05	22,98
Cycle 4 Day 1	All	32	86,5	27	84,4	6,17	20,75
Cycle 5 Day 1	All	31	83,8	29	93,5	4,60	19,36
Cycle 6 Day 1	All	31	83,8	26	83,9	2,56	9,06
Cycle 7 Day 1	All	30	81,1	26	86,7	1,28	6,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	4,00	11,06
Cycle 9 Day 1	All	25	67,6	25	100,0	4,00	11,06
Cycle 10 Day 1	All	25	67,6	24	96,0	5,56	16,05
Cycle 11 Day 1	All	24	64,9	24	100,0	2,78	9,41
Cycle 12 Day 1	All	24	64,9	21	87,5	11,11	19,25
Cycle 13 Day 1	All	22	59,5	21	95,5	11,11	24,34
Cycle 14 Day 1	All	22	59,5	22	100,0	6,06	22,15
Cycle 15 Day 1	All	22	59,5	21	95,5	3,17	10,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	8,89	26,63
Cycle 17 Day 1	All	18	48,6	14	77,8	11,90	28,06
Cycle 18 Day 1	All	15	40,5	8	53,3	0,00	0,00
Cycle 19 Day 1	All	13	35,1	8	61,5	4,17	11,79
Cycle 20 Day 1	All	9	24,3	9	100,0	3,70	11,11
Cycle 21 Day 1	All	7	18,9	4	57,1	0,00	0,00
Cycle 22 Day 1	All	7	18,9	2	28,6	0,00	0,00
Cycle 23 Day 1	All	4	10,8	1	25,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	0,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	6,67	14,91
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	2,56	9,25
	Female	23	100,0	20	87,0	10,00	24,42
Cycle 2 Day 1	Male	13	92,9	13	100,0	2,56	9,25
	Female	20	87,0	17	85,0	15,69	33,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	0,00	0,00
	Female	20	87,0	17	85,0	13,73	29,01
Cycle 4 Day 1	Male	12	85,7	10	83,3	3,33	10,54
	Female	20	87,0	17	85,0	7,84	25,08
Cycle 5 Day 1	Male	12	85,7	11	91,7	0,00	0,00
	Female	19	82,6	18	94,7	7,41	24,40
Cycle 6 Day 1	Male	12	85,7	11	91,7	3,03	10,05
	Female	19	82,6	15	78,9	2,22	8,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	0,00	0,00
	Female	19	82,6	15	78,9	2,22	8,61
Cycle 8 Day 1	Male	10	71,4	9	90,0	3,70	11,11
	Female	18	78,3	16	88,9	4,17	11,39
Cycle 9 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	17	73,9	17	100,0	5,88	13,10
Cycle 10 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	17	73,9	16	94,1	6,25	18,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	16	69,6	16	100,0	2,08	8,33
Cycle 12 Day 1	Male	8	57,1	8	100,0	12,50	17,25
	Female	16	69,6	13	81,3	10,26	21,01
Cycle 13 Day 1	Male	8	57,1	8	100,0	8,33	15,43
	Female	14	60,9	13	92,9	12,82	28,99
Cycle 14 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	14	60,9	14	100,0	9,52	27,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	14	60,9	13	92,9	5,13	12,52
Cycle 16 Day 1	Male	8	57,1	5	62,5	0,00	0,00
	Female	13	56,5	10	76,9	13,33	32,20
Cycle 17 Day 1	Male	6	42,9	2	33,3	0,00	0,00
	Female	12	52,2	12	100,0	13,89	30,01
Cycle 18 Day 1	Male	3	21,4	2	66,7	0,00	0,00
	Female	12	52,2	6	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	11	47,8	6	54,5	5,56	13,61
Cycle 20 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	7	30,4	7	100,0	4,76	12,60
Cycle 21 Day 1	Male	1	7,1	1	100,0	0,00	-
	Female	6	26,1	3	50,0	0,00	0,00
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	0,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	0,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	0,00	0,00
	Female	7	30,4	3	42,9	11,11	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	26	89,7	7,69	21,72
	65-74	8	100,0	7	87,5	4,76	12,60
Cycle 2 Day 1	18-64	27	93,1	24	88,9	12,50	29,18
	65-74	6	75,0	6	100,0	0,00	0,00
Cycle 3 Day 1	18-64	26	89,7	24	92,3	9,72	25,02
	65-74	6	75,0	5	83,3	0,00	0,00
Cycle 4 Day 1	18-64	26	89,7	22	84,6	6,06	22,15
	65-74	6	75,0	5	83,3	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	4,35	20,85
	65-74	6	75,0	6	100,0	5,56	13,61
Cycle 6 Day 1	18-64	25	86,2	21	84,0	1,59	7,27
	65-74	6	75,0	5	83,3	6,67	14,91
Cycle 7 Day 1	18-64	25	86,2	22	88,0	0,00	0,00
	65-74	5	62,5	4	80,0	8,33	16,67
Cycle 8 Day 1	18-64	23	79,3	20	87,0	3,33	10,26
	65-74	5	62,5	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	1,67	7,45
	65-74	5	62,5	5	100,0	13,33	18,26
Cycle 10 Day 1	18-64	20	69,0	19	95,0	5,26	16,72
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 11 Day 1	18-64	19	65,5	19	100,0	1,75	7,65
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 12 Day 1	18-64	19	65,5	17	89,5	9,80	19,60
	65-74	5	62,5	4	80,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	10,42	26,44
	65-74	5	62,5	5	100,0	13,33	18,26
Cycle 14 Day 1	18-64	17	58,6	17	100,0	5,88	24,25
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 15 Day 1	18-64	17	58,6	16	94,1	0,00	0,00
	65-74	5	62,5	5	100,0	13,33	18,26
Cycle 16 Day 1	18-64	17	58,6	13	76,5	7,69	27,74
	65-74	4	50,0	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	11,11	29,59
	65-74	3	37,5	2	66,7	16,67	23,57
Cycle 18 Day 1	18-64	13	44,8	8	61,5	0,00	0,00
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	0,00	0,00
	65-74	2	25,0	1	50,0	33,33	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	0,00	0,00
	65-74	1	12,5	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	0,00	0,00
Cycle 22 Day 1	18-64	7	24,1	2	28,6	0,00	0,00
Cycle 23 Day 1	18-64	4	13,8	1	25,0	0,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	0,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	0,00	0,00
	65-74	6	75,0	2	33,3	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	16	80,0	8,33	25,82
	Other	17	100,0	17	100,0	5,88	13,10
Cycle 2 Day 1	White	19	95,0	16	84,2	14,58	34,36
	Other	14	82,4	14	100,0	4,76	12,10
Cycle 3 Day 1	White	18	90,0	15	83,3	8,89	26,63
	Other	14	82,4	14	100,0	7,14	19,30
Cycle 4 Day 1	White	18	90,0	14	77,8	7,14	26,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	5,13	12,52
Cycle 5 Day 1	White	18	90,0	17	94,4	7,84	25,08
	Other	13	76,5	12	92,3	0,00	0,00
Cycle 6 Day 1	White	18	90,0	13	72,2	5,13	12,52
	Other	13	76,5	13	100,0	0,00	0,00
Cycle 7 Day 1	White	17	85,0	14	82,4	2,38	8,91
	Other	13	76,5	12	92,3	0,00	0,00
Cycle 8 Day 1	White	17	85,0	14	82,4	2,38	8,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	6,06	13,48
Cycle 9 Day 1	White	16	80,0	16	100,0	6,25	13,44
	Other	9	52,9	9	100,0	0,00	0,00
Cycle 10 Day 1	White	16	80,0	15	93,8	8,89	19,79
	Other	9	52,9	9	100,0	0,00	0,00
Cycle 11 Day 1	White	16	80,0	16	100,0	4,17	11,39
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 12 Day 1	White	16	80,0	13	81,3	15,38	22,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	4,17	11,79
Cycle 13 Day 1	White	14	70,0	13	92,9	12,82	28,99
	Other	8	47,1	8	100,0	8,33	15,43
Cycle 14 Day 1	White	14	70,0	14	100,0	9,52	27,51
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 15 Day 1	White	14	70,0	13	92,9	2,56	9,25
	Other	8	47,1	8	100,0	4,17	11,79
Cycle 16 Day 1	White	14	70,0	9	64,3	14,81	33,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	0,00	0,00
Cycle 17 Day 1	White	13	65,0	10	76,9	16,67	32,39
	Other	5	29,4	4	80,0	0,00	0,00
Cycle 18 Day 1	White	11	55,0	4	36,4	0,00	0,00
	Other	4	23,5	4	100,0	0,00	0,00
Cycle 19 Day 1	White	9	45,0	5	55,6	6,67	14,91
	Other	4	23,5	3	75,0	0,00	0,00
Cycle 20 Day 1	White	5	25,0	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	0,00	0,00
Cycle 21 Day 1	White	3	15,0	2	66,7	0,00	0,00
	Other	4	23,5	2	50,0	0,00	0,00
Cycle 22 Day 1	White	3	15,0	1	33,3	0,00	-
	Other	4	23,5	1	25,0	0,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	0,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	11,11	19,25
	Other	9	52,9	2	22,2	0,00	0,00
Region							
Cycle 1 Day 1	America (AM)	12	100,0	11	91,7	9,09	30,15
	Europe (EU)	10	100,0	8	80,0	4,17	11,79
	Asia (AS)	15	100,0	14	93,3	7,14	14,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	10	90,9	23,33	41,72
	Europe (EU)	9	90,0	8	88,9	0,00	0,00
	Asia (AS)	13	86,7	12	92,3	5,56	12,97
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	12,12	30,81
	Europe (EU)	8	80,0	5	62,5	0,00	0,00
	Asia (AS)	13	86,7	13	100,0	7,69	19,97
Cycle 4 Day 1	America (AM)	11	91,7	10	90,9	13,33	32,20
	Europe (EU)	8	80,0	4	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	2,56	9,25
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	9,09	30,15
	Europe (EU)	8	80,0	7	87,5	4,76	12,60
	Asia (AS)	12	80,0	11	91,7	0,00	0,00
Cycle 6 Day 1	America (AM)	11	91,7	9	81,8	0,00	0,00
	Europe (EU)	8	80,0	6	75,0	11,11	17,21
	Asia (AS)	12	80,0	11	91,7	0,00	0,00
Cycle 7 Day 1	America (AM)	11	91,7	9	81,8	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	4,76	12,60
	Asia (AS)	11	73,3	10	90,9	0,00	0,00
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	0,00	0,00
	Europe (EU)	8	80,0	6	75,0	5,56	13,61
	Asia (AS)	9	60,0	9	100,0	7,41	14,70
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	3,03	10,05
	Europe (EU)	7	70,0	7	100,0	9,52	16,27
	Asia (AS)	7	46,7	7	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	6,67	21,08
	Europe (EU)	7	70,0	7	100,0	9,52	16,27
	Asia (AS)	7	46,7	7	100,0	0,00	0,00
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	0,00	0,00
	Europe (EU)	7	70,0	7	100,0	9,52	16,27
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	10,00	16,10
	Europe (EU)	7	70,0	5	71,4	26,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	16,67	32,39
	Europe (EU)	6	60,0	5	83,3	6,67	14,91
	Asia (AS)	6	40,0	6	100,0	5,56	13,61
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	10,00	31,62
	Europe (EU)	6	60,0	6	100,0	5,56	13,61
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	3,33	10,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	6,67	14,91
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	0,00	0,00
	Europe (EU)	6	60,0	2	33,3	16,67	23,57
	Asia (AS)	6	40,0	6	100,0	16,67	40,82
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	5,56	13,61
	Europe (EU)	4	40,0	3	75,0	11,11	19,25
	Asia (AS)	5	33,3	5	100,0	20,00	44,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	0,00	0,00
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	0,00	0,00
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	0,00	0,00
	Europe (EU)	3	30,0	1	33,3	33,33	-
	Asia (AS)	4	26,7	3	75,0	0,00	0,00
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	0,00	0,00
	Europe (EU)	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	0,00	0,00
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	0,00	0,00
	Asia (AS)	3	20,0	1	33,3	0,00	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	0,00	0,00
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	0,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	0,00	0,00
	Europe (EU)	2	20,0	1	50,0	33,33	-
	Asia (AS)	7	46,7	1	14,3	0,00	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	11	73,3	0,00	0,00
	1	17	100,0	17	100,0	11,76	26,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	6,67	14,91
Cycle 2 Day 1	0	15	100,0	13	86,7	2,56	9,25
	1	15	88,2	14	93,3	16,67	36,40
	2	3	60,0	3	100,0	11,11	19,25
Cycle 3 Day 1	0	15	100,0	13	86,7	2,56	9,25
	1	14	82,4	13	92,9	10,26	28,50
	2	3	60,0	3	100,0	22,22	38,49
Cycle 4 Day 1	0	15	100,0	13	86,7	2,56	9,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	8,33	28,87
	2	3	60,0	2	66,7	16,67	23,57
Cycle 5 Day 1	0	15	100,0	15	100,0	2,22	8,61
	1	14	82,4	12	85,7	8,33	28,87
	2	2	40,0	2	100,0	0,00	0,00
Cycle 6 Day 1	0	15	100,0	14	93,3	4,76	12,10
	1	14	82,4	11	78,6	0,00	0,00
	2	2	40,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	2,38	8,91
	1	13	76,5	10	76,9	0,00	0,00
	2	2	40,0	2	100,0	0,00	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	2,56	9,25
	1	11	64,7	10	90,9	6,67	14,05
	2	2	40,0	2	100,0	0,00	0,00
Cycle 9 Day 1	0	14	93,3	14	100,0	7,14	14,19
	1	10	58,8	10	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	0,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	4,76	12,10
	1	10	58,8	9	90,0	7,41	22,22
	2	1	20,0	1	100,0	0,00	-
Cycle 11 Day 1	0	14	93,3	14	100,0	4,76	12,10
	1	9	52,9	9	100,0	0,00	0,00
	2	1	20,0	1	100,0	0,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	11,11	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	4,17	11,79
	2	1	20,0	1	100,0	66,67	-
Cycle 13 Day 1	0	14	93,3	13	92,9	7,69	14,62
	1	8	47,1	8	100,0	16,67	35,63
Cycle 14 Day 1	0	14	93,3	14	100,0	2,38	8,91
	1	8	47,1	8	100,0	12,50	35,36
Cycle 15 Day 1	0	14	93,3	14	100,0	4,76	12,10
	1	8	47,1	7	87,5	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	4,17	11,79
	1	8	47,1	7	87,5	14,29	37,80
Cycle 17 Day 1	0	12	80,0	8	66,7	4,17	11,79
	1	6	35,3	6	100,0	22,22	40,37
Cycle 18 Day 1	0	9	60,0	4	44,4	0,00	0,00
	1	6	35,3	4	66,7	0,00	0,00
Cycle 19 Day 1	0	8	53,3	4	50,0	8,33	16,67
	1	5	29,4	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	6,67	14,91
	1	4	23,5	4	100,0	0,00	0,00
Cycle 21 Day 1	0	3	20,0	3	100,0	0,00	0,00
	1	4	23,5	1	25,0	0,00	-
Cycle 22 Day 1	0	3	20,0	2	66,7	0,00	0,00
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	0,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	11,11	19,25
	1	7	41,2	2	28,6	0,00	0,00
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	7,69	27,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	0,00	0,00
	2 or More	21	100,0	18	85,7	7,41	14,26
Cycle 2 Day 1	None	14	100,0	13	92,9	10,26	28,50
	1	1	50,0	1	100,0	0,00	-
	2 or More	18	85,7	16	88,9	10,42	26,44
Cycle 3 Day 1	None	14	100,0	13	92,9	7,69	27,74
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	8,89	19,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	11	78,6	12,12	30,81
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	2,22	8,61
Cycle 5 Day 1	None	14	100,0	14	100,0	7,14	26,73
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	2,38	8,91
Cycle 6 Day 1	None	14	100,0	12	85,7	0,00	0,00
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	13	81,3	5,13	12,52
Cycle 7 Day 1	None	14	100,0	12	85,7	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	15	71,4	13	86,7	2,56	9,25
Cycle 8 Day 1	None	14	100,0	13	92,9	2,56	9,25
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	5,56	12,97
Cycle 9 Day 1	None	13	92,9	13	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	9,09	15,57
Cycle 10 Day 1	None	13	92,9	12	92,3	5,56	19,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	6,06	13,48
Cycle 11 Day 1	None	13	92,9	13	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	10	100,0	6,67	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	11,11	21,71
	1	1	50,0	1	100,0	33,33	-
	2 or More	10	47,6	8	80,0	8,33	15,43
Cycle 13 Day 1	None	12	85,7	11	91,7	12,12	30,81
	1	1	50,0	1	100,0	33,33	-
	2 or More	9	42,9	9	100,0	7,41	14,70
Cycle 14 Day 1	None	12	85,7	12	100,0	8,33	28,87
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	3,70	11,11
Cycle 15 Day 1	None	12	85,7	12	100,0	2,78	9,62
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	8	88,9	4,17	11,79
Cycle 16 Day 1	None	11	78,6	8	72,7	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	22,22	40,37
Cycle 17 Day 1	None	10	71,4	7	70,0	4,76	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	7	33,3	6	85,7	22,22	40,37
Cycle 18 Day 1	None	8	57,1	4	50,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	6	28,6	3	50,0	0,00	0,00
Cycle 19 Day 1	None	7	50,0	3	42,9	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	5	23,8	4	80,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	4	19,0	4	100,0	8,33	16,67
Cycle 21 Day 1	None	4	28,6	2	50,0	0,00	0,00
	2 or More	3	14,3	2	66,7	0,00	0,00
Cycle 22 Day 1	None	4	28,6	1	25,0	0,00	-
	2 or More	3	14,3	1	33,3	0,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	0,00	-
	1	2	100,0	1	50,0	0,00	-
	2 or More	9	42,9	3	33,3	11,11	19,25
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	7,69	27,74
	Previously Treated	23	100,0	20	87,0	6,67	13,68
Cycle 2 Day 1	Naïve	14	100,0	13	92,9	10,26	28,50
	Previously Treated	19	82,6	17	89,5	9,80	25,72
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	7,69	27,74
	Previously Treated	18	78,3	16	88,9	8,33	19,25
Cycle 4 Day 1	Naïve	14	100,0	11	78,6	12,12	30,81
	Previously Treated	18	78,3	16	88,9	2,08	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	7,14	26,73
	Previously Treated	17	73,9	15	88,2	2,22	8,61
Cycle 6 Day 1	Naïve	14	100,0	12	85,7	0,00	0,00
	Previously Treated	17	73,9	14	82,4	4,76	12,10
Cycle 7 Day 1	Naïve	14	100,0	12	85,7	0,00	0,00
	Previously Treated	16	69,6	14	87,5	2,38	8,91
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	2,56	9,25
	Previously Treated	14	60,9	12	85,7	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	0,00	0,00
	Previously Treated	12	52,2	12	100,0	8,33	15,08
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	5,56	19,25
	Previously Treated	12	52,2	12	100,0	5,56	12,97
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	0,00	0,00
	Previously Treated	11	47,8	11	100,0	6,06	13,48
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	11,11	21,71
	Previously Treated	11	47,8	9	81,8	11,11	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	12,12	30,81
	Previously Treated	10	43,5	10	100,0	10,00	16,10
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	8,33	28,87
	Previously Treated	10	43,5	10	100,0	3,33	10,54
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	2,78	9,62
	Previously Treated	10	43,5	9	90,0	3,70	11,11
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	0,00	0,00
	Previously Treated	10	43,5	7	70,0	19,05	37,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	4,76	12,60
	Previously Treated	8	34,8	7	87,5	19,05	37,80
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	0,00	0,00
	Previously Treated	7	30,4	4	57,1	0,00	0,00
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	0,00	0,00
	Previously Treated	6	26,1	5	83,3	6,67	14,91
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	0,00	0,00
	Previously Treated	5	21,7	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	0,00	0,00
	Previously Treated	3	13,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	0,00	-
	Previously Treated	3	13,0	1	33,3	0,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	11	47,8	4	36,4	8,33	16,67
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	0,00	0,00
	Central	25	100,0	21	84,0	11,11	24,34
Cycle 2 Day 1	Local	11	91,7	11	100,0	12,12	30,81
	Central	22	88,0	19	86,4	8,77	24,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	10	90,9	3,33	10,54
	Central	21	84,0	19	90,5	10,53	27,34
Cycle 4 Day 1	Local	11	91,7	9	81,8	3,70	11,11
	Central	21	84,0	18	85,7	7,41	24,40
Cycle 5 Day 1	Local	11	91,7	10	90,9	3,33	10,54
	Central	20	80,0	19	95,0	5,26	22,94
Cycle 6 Day 1	Local	11	91,7	11	100,0	3,03	10,05
	Central	20	80,0	15	75,0	2,22	8,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	3,03	10,05
	Central	19	76,0	15	78,9	0,00	0,00
Cycle 8 Day 1	Local	10	83,3	10	100,0	6,67	14,05
	Central	18	72,0	15	83,3	2,22	8,61
Cycle 9 Day 1	Local	10	83,3	10	100,0	3,33	10,54
	Central	15	60,0	15	100,0	4,44	11,73
Cycle 10 Day 1	Local	10	83,3	9	90,0	3,70	11,11
	Central	15	60,0	15	100,0	6,67	18,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	3,70	11,11
	Central	15	60,0	15	100,0	2,22	8,61
Cycle 12 Day 1	Local	9	75,0	8	88,9	8,33	15,43
	Central	15	60,0	13	86,7	12,82	21,68
Cycle 13 Day 1	Local	8	66,7	8	100,0	8,33	15,43
	Central	14	56,0	13	92,9	12,82	28,99
Cycle 14 Day 1	Local	8	66,7	8	100,0	4,17	11,79
	Central	14	56,0	14	100,0	7,14	26,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	4,17	11,79
	Central	14	56,0	13	92,9	2,56	9,25
Cycle 16 Day 1	Local	8	66,7	6	75,0	5,56	13,61
	Central	13	52,0	9	69,2	11,11	33,33
Cycle 17 Day 1	Local	8	66,7	5	62,5	6,67	14,91
	Central	10	40,0	9	90,0	14,81	33,79
Cycle 18 Day 1	Local	6	50,0	4	66,7	0,00	0,00
	Central	9	36,0	4	44,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	8,33	16,67
	Central	8	32,0	4	50,0	0,00	0,00
Cycle 20 Day 1	Local	5	41,7	5	100,0	6,67	14,91
	Central	4	16,0	4	100,0	0,00	0,00
Cycle 21 Day 1	Local	4	33,3	2	50,0	0,00	0,00
	Central	3	12,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Local	4	33,3	1	25,0	0,00	-
	Central	3	12,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	0,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	0,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	16,67	23,57
	Central	8	32,0	3	37,5	0,00	0,00
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	31	88,6	7,53	20,57
	No	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	Yes	32	91,4	29	90,6	10,34	26,88
	No	1	50,0	1	100,0	0,00	-
Cycle 3 Day 1	Yes	31	88,6	28	90,3	8,33	23,35
	No	1	50,0	1	100,0	0,00	-
Cycle 4 Day 1	Yes	31	88,6	26	83,9	6,41	21,12
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	4,76	19,70
	No	1	50,0	1	100,0	0,00	-
Cycle 6 Day 1	Yes	30	85,7	25	83,3	2,67	9,23
	No	1	50,0	1	100,0	0,00	-
Cycle 7 Day 1	Yes	29	82,9	25	86,2	1,33	6,67
	No	1	50,0	1	100,0	0,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	4,17	11,26
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	4,17	11,26
	No	1	50,0	1	100,0	0,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	5,80	16,37
	No	1	50,0	1	100,0	0,00	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	2,90	9,60
	No	1	50,0	1	100,0	0,00	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	11,67	19,57
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	11,67	24,84
	No	1	50,0	1	100,0	0,00	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	6,35	22,65
	No	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	3,33	10,26
	No	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	9,52	27,51
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	12,82	28,99
	No	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	4,76	12,60
	No	1	50,0	1	100,0	0,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	4,17	11,79
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	0,00	0,00
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	0,00	0,00
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	0,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	0,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	22,22	19,25
	No	33	100,0	30	90,9	5,56	19,74
Cycle 2 Day 1	Yes	2	50,0	1	50,0	0,00	-
	No	31	93,9	29	93,5	10,34	26,88
Cycle 3 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	27	90,0	8,64	23,74
Cycle 4 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	30	90,9	25	83,3	6,67	21,52
Cycle 5 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	27	93,1	4,94	20,05
Cycle 6 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	24	82,8	2,78	9,41
Cycle 7 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	24	85,7	1,39	6,80
Cycle 8 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	26	78,8	23	88,5	2,90	9,60
Cycle 9 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	24	100,0	4,17	11,26
Cycle 10 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	23	95,8	5,80	16,37
Cycle 11 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	2,90	9,60
Cycle 12 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	23	69,7	20	87,0	11,67	19,57
Cycle 13 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	20	95,2	11,67	24,84
Cycle 14 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	21	100,0	6,35	22,65
Cycle 15 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	3,33	10,26
Cycle 16 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	20	60,6	14	70,0	9,52	27,51
Cycle 17 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	17	51,5	13	76,5	12,82	28,99
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	0,00	0,00
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	4,17	11,79
Cycle 20 Day 1	No	9	27,3	9	100,0	3,70	11,11
Cycle 21 Day 1	No	7	21,2	4	57,1	0,00	0,00
Cycle 22 Day 1	No	7	21,2	2	28,6	0,00	0,00
Cycle 23 Day 1	No	4	12,1	1	25,0	0,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	0,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13HR_SG.xls
07SEP2019 20:34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	33	89,2	18,18	22,19
Cycle 2 Day 1	All	33	89,2	30	90,9	12,22	18,54
Cycle 3 Day 1	All	32	86,5	29	90,6	4,60	11,70
Cycle 4 Day 1	All	32	86,5	27	84,4	12,35	22,92
Cycle 5 Day 1	All	31	83,8	29	93,5	5,75	15,61
Cycle 6 Day 1	All	31	83,8	26	83,9	7,69	19,57
Cycle 7 Day 1	All	30	81,1	26	86,7	6,41	13,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	10,67	15,87
Cycle 9 Day 1	All	25	67,6	25	100,0	8,00	14,53
Cycle 10 Day 1	All	25	67,6	24	96,0	6,94	13,83
Cycle 11 Day 1	All	24	64,9	24	100,0	5,56	16,05
Cycle 12 Day 1	All	24	64,9	21	87,5	9,52	15,43
Cycle 13 Day 1	All	22	59,5	21	95,5	11,11	19,25
Cycle 14 Day 1	All	22	59,5	22	100,0	10,61	21,54
Cycle 15 Day 1	All	22	59,5	21	95,5	9,52	18,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	8,89	15,26
Cycle 17 Day 1	All	18	48,6	14	77,8	7,14	14,19
Cycle 18 Day 1	All	15	40,5	8	53,3	12,50	17,25
Cycle 19 Day 1	All	13	35,1	8	61,5	12,50	17,25
Cycle 20 Day 1	All	9	24,3	9	100,0	14,81	17,57
Cycle 21 Day 1	All	7	18,9	4	57,1	16,67	19,25
Cycle 22 Day 1	All	7	18,9	2	28,6	16,67	23,57
Cycle 23 Day 1	All	4	10,8	1	25,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	33,33	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	20,00	29,81
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	10,26	21,01
	Female	23	100,0	20	87,0	23,33	21,90
Cycle 2 Day 1	Male	13	92,9	13	100,0	12,82	16,88
	Female	20	87,0	17	85,0	11,76	20,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	2,78	9,62
	Female	20	87,0	17	85,0	5,88	13,10
Cycle 4 Day 1	Male	12	85,7	10	83,3	6,67	14,05
	Female	20	87,0	17	85,0	15,69	26,66
Cycle 5 Day 1	Male	12	85,7	11	91,7	3,03	10,05
	Female	19	82,6	18	94,7	7,41	18,28
Cycle 6 Day 1	Male	12	85,7	11	91,7	6,06	13,48
	Female	19	82,6	15	78,9	8,89	23,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	6,06	13,48
	Female	19	82,6	15	78,9	6,67	13,80
Cycle 8 Day 1	Male	10	71,4	9	90,0	7,41	14,70
	Female	18	78,3	16	88,9	12,50	16,67
Cycle 9 Day 1	Male	8	57,1	8	100,0	8,33	15,43
	Female	17	73,9	17	100,0	7,84	14,57
Cycle 10 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	17	73,9	16	94,1	8,33	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	8,33	23,57
	Female	16	69,6	16	100,0	4,17	11,39
Cycle 12 Day 1	Male	8	57,1	8	100,0	8,33	15,43
	Female	16	69,6	13	81,3	10,26	16,01
Cycle 13 Day 1	Male	8	57,1	8	100,0	8,33	15,43
	Female	14	60,9	13	92,9	12,82	21,68
Cycle 14 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	14	60,9	14	100,0	14,29	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	14	60,9	13	92,9	15,38	22,01
Cycle 16 Day 1	Male	8	57,1	5	62,5	0,00	0,00
	Female	13	56,5	10	76,9	13,33	17,21
Cycle 17 Day 1	Male	6	42,9	2	33,3	0,00	0,00
	Female	12	52,2	12	100,0	8,33	15,08
Cycle 18 Day 1	Male	3	21,4	2	66,7	0,00	0,00
	Female	12	52,2	6	50,0	16,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	11	47,8	6	54,5	16,67	18,26
Cycle 20 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	7	30,4	7	100,0	19,05	17,82
Cycle 21 Day 1	Male	1	7,1	1	100,0	0,00	-
	Female	6	26,1	3	50,0	22,22	19,25
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	33,33	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	33,33	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	16,67	23,57
	Female	7	30,4	3	42,9	22,22	38,49
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	26	89,7	19,23	23,42
	65-74	8	100,0	7	87,5	14,29	17,82
Cycle 2 Day 1	18-64	27	93,1	24	88,9	11,11	18,82
	65-74	6	75,0	6	100,0	16,67	18,26
Cycle 3 Day 1	18-64	26	89,7	24	92,3	5,56	12,69
	65-74	6	75,0	5	83,3	0,00	0,00
Cycle 4 Day 1	18-64	26	89,7	22	84,6	12,12	24,22
	65-74	6	75,0	5	83,3	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	2,90	9,60
	65-74	6	75,0	6	100,0	16,67	27,89
Cycle 6 Day 1	18-64	25	86,2	21	84,0	4,76	15,94
	65-74	6	75,0	5	83,3	20,00	29,81
Cycle 7 Day 1	18-64	25	86,2	22	88,0	6,06	13,16
	65-74	5	62,5	4	80,0	8,33	16,67
Cycle 8 Day 1	18-64	23	79,3	20	87,0	10,00	15,67
	65-74	5	62,5	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	5,00	12,21
	65-74	5	62,5	5	100,0	20,00	18,26
Cycle 10 Day 1	18-64	20	69,0	19	95,0	7,02	13,96
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 11 Day 1	18-64	19	65,5	19	100,0	5,26	16,72
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 12 Day 1	18-64	19	65,5	17	89,5	7,84	14,57
	65-74	5	62,5	4	80,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	10,42	15,96
	65-74	5	62,5	5	100,0	13,33	29,81
Cycle 14 Day 1	18-64	17	58,6	17	100,0	7,84	18,74
	65-74	5	62,5	5	100,0	20,00	29,81
Cycle 15 Day 1	18-64	17	58,6	16	94,1	10,42	20,07
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 16 Day 1	18-64	17	58,6	13	76,5	7,69	14,62
	65-74	4	50,0	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	5,56	12,97
	65-74	3	37,5	2	66,7	16,67	23,57
Cycle 18 Day 1	18-64	13	44,8	8	61,5	12,50	17,25
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	9,52	16,27
	65-74	2	25,0	1	50,0	33,33	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	12,50	17,25
	65-74	1	12,5	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	16,67	19,25
Cycle 22 Day 1	18-64	7	24,1	2	28,6	16,67	23,57
Cycle 23 Day 1	18-64	4	13,8	1	25,0	33,33	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	33,33	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	11,11	19,25
	65-74	6	75,0	2	33,3	33,33	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	16	80,0	14,58	20,97
	Other	17	100,0	17	100,0	21,57	23,40
Cycle 2 Day 1	White	19	95,0	16	84,2	6,25	13,44
	Other	14	82,4	14	100,0	19,05	21,54
Cycle 3 Day 1	White	18	90,0	15	83,3	4,44	11,73
	Other	14	82,4	14	100,0	4,76	12,10
Cycle 4 Day 1	White	18	90,0	14	77,8	7,14	14,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	17,95	29,24
Cycle 5 Day 1	White	18	90,0	17	94,4	3,92	11,07
	Other	13	76,5	12	92,3	8,33	20,72
Cycle 6 Day 1	White	18	90,0	13	72,2	7,69	19,97
	Other	13	76,5	13	100,0	7,69	19,97
Cycle 7 Day 1	White	17	85,0	14	82,4	4,76	12,10
	Other	13	76,5	12	92,3	8,33	15,08
Cycle 8 Day 1	White	17	85,0	14	82,4	9,52	15,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	12,12	16,82
Cycle 9 Day 1	White	16	80,0	16	100,0	4,17	11,39
	Other	9	52,9	9	100,0	14,81	17,57
Cycle 10 Day 1	White	16	80,0	15	93,8	4,44	11,73
	Other	9	52,9	9	100,0	11,11	16,67
Cycle 11 Day 1	White	16	80,0	16	100,0	6,25	18,13
	Other	8	47,1	8	100,0	4,17	11,79
Cycle 12 Day 1	White	16	80,0	13	81,3	7,69	14,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	12,50	17,25
Cycle 13 Day 1	White	14	70,0	13	92,9	10,26	21,01
	Other	8	47,1	8	100,0	12,50	17,25
Cycle 14 Day 1	White	14	70,0	14	100,0	9,52	24,21
	Other	8	47,1	8	100,0	12,50	17,25
Cycle 15 Day 1	White	14	70,0	13	92,9	10,26	21,01
	Other	8	47,1	8	100,0	8,33	15,43
Cycle 16 Day 1	White	14	70,0	9	64,3	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	11,11	17,21
Cycle 17 Day 1	White	13	65,0	10	76,9	6,67	14,05
	Other	5	29,4	4	80,0	8,33	16,67
Cycle 18 Day 1	White	11	55,0	4	36,4	8,33	16,67
	Other	4	23,5	4	100,0	16,67	19,25
Cycle 19 Day 1	White	9	45,0	5	55,6	13,33	18,26
	Other	4	23,5	3	75,0	11,11	19,25
Cycle 20 Day 1	White	5	25,0	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	25,00	16,67
Cycle 21 Day 1	White	3	15,0	2	66,7	0,00	0,00
	Other	4	23,5	2	50,0	33,33	0,00
Cycle 22 Day 1	White	3	15,0	1	33,3	0,00	-
	Other	4	23,5	1	25,0	33,33	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	33,33	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	22,22	38,49
	Other	9	52,9	2	22,2	16,67	23,57
Region							
Cycle 1 Day 1	America (AM)	12	100,0	11	91,7	12,12	16,82
	Europe (EU)	10	100,0	8	80,0	25,00	23,57
	Asia (AS)	15	100,0	14	93,3	19,05	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	10	90,9	3,33	10,54
	Europe (EU)	9	90,0	8	88,9	12,50	17,25
	Asia (AS)	13	86,7	12	92,3	19,44	22,29
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	0,00	0,00
	Europe (EU)	8	80,0	5	62,5	13,33	18,26
	Asia (AS)	13	86,7	13	100,0	5,13	12,52
Cycle 4 Day 1	America (AM)	11	91,7	10	90,9	6,67	14,05
	Europe (EU)	8	80,0	4	50,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	15,38	29,24
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	9,09	21,56
	Europe (EU)	8	80,0	7	87,5	9,52	16,27
	Asia (AS)	12	80,0	11	91,7	0,00	0,00
Cycle 6 Day 1	America (AM)	11	91,7	9	81,8	7,41	22,22
	Europe (EU)	8	80,0	6	75,0	16,67	27,89
	Asia (AS)	12	80,0	11	91,7	3,03	10,05
Cycle 7 Day 1	America (AM)	11	91,7	9	81,8	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	9,52	16,27
	Asia (AS)	11	73,3	10	90,9	6,67	14,05
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	13,33	17,21
	Europe (EU)	8	80,0	6	75,0	16,67	18,26
	Asia (AS)	9	60,0	9	100,0	3,70	11,11
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	3,03	10,05
	Europe (EU)	7	70,0	7	100,0	9,52	16,27
	Asia (AS)	7	46,7	7	100,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	3,33	10,54
	Europe (EU)	7	70,0	7	100,0	9,52	16,27
	Asia (AS)	7	46,7	7	100,0	9,52	16,27
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	0,00	0,00
	Europe (EU)	7	70,0	7	100,0	14,29	26,23
	Asia (AS)	6	40,0	6	100,0	5,56	13,61
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	10,00	16,10
	Europe (EU)	7	70,0	5	71,4	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	3,33	10,54
	Europe (EU)	6	60,0	5	83,3	26,67	27,89
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	3,33	10,54
	Europe (EU)	6	60,0	6	100,0	16,67	27,89
	Asia (AS)	6	40,0	6	100,0	16,67	27,89
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	3,33	10,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	6,67	14,91
	Asia (AS)	6	40,0	6	100,0	22,22	27,22
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	4,76	12,60
	Europe (EU)	6	60,0	2	33,3	16,67	23,57
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	5,56	13,61
	Europe (EU)	4	40,0	3	75,0	11,11	19,25
	Asia (AS)	5	33,3	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	13,33	18,26
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	11,11	19,25
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	8,33	16,67
	Europe (EU)	3	30,0	1	33,3	33,33	-
	Asia (AS)	4	26,7	3	75,0	11,11	19,25
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	6,67	14,91
	Europe (EU)	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	22,22	19,25
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	11,11	19,25
	Asia (AS)	3	20,0	1	33,3	33,33	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	16,67	23,57
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	33,33	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	0,00	0,00
	Europe (EU)	2	20,0	1	50,0	66,67	-
	Asia (AS)	7	46,7	1	14,3	33,33	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	11	73,3	6,06	13,48
	1	17	100,0	17	100,0	21,57	23,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	33,33	23,57
Cycle 2 Day 1	0	15	100,0	13	86,7	7,69	14,62
	1	15	88,2	14	93,3	16,67	21,68
	2	3	60,0	3	100,0	11,11	19,25
Cycle 3 Day 1	0	15	100,0	13	86,7	2,56	9,25
	1	14	82,4	13	92,9	5,13	12,52
	2	3	60,0	3	100,0	11,11	19,25
Cycle 4 Day 1	0	15	100,0	13	86,7	7,69	14,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	11,11	16,41
	2	3	60,0	2	66,7	50,00	70,71
Cycle 5 Day 1	0	15	100,0	15	100,0	11,11	20,57
	1	14	82,4	12	85,7	0,00	0,00
	2	2	40,0	2	100,0	0,00	0,00
Cycle 6 Day 1	0	15	100,0	14	93,3	14,29	25,20
	1	14	82,4	11	78,6	0,00	0,00
	2	2	40,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	7,14	14,19
	1	13	76,5	10	76,9	6,67	14,05
	2	2	40,0	2	100,0	0,00	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	10,26	16,01
	1	11	64,7	10	90,9	13,33	17,21
	2	2	40,0	2	100,0	0,00	0,00
Cycle 9 Day 1	0	14	93,3	14	100,0	9,52	15,63
	1	10	58,8	10	100,0	6,67	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	0,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	7,14	14,19
	1	10	58,8	9	90,0	7,41	14,70
	2	1	20,0	1	100,0	0,00	-
Cycle 11 Day 1	0	14	93,3	14	100,0	7,14	19,30
	1	9	52,9	9	100,0	3,70	11,11
	2	1	20,0	1	100,0	0,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	13,89	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	4,17	11,79
	2	1	20,0	1	100,0	0,00	-
Cycle 13 Day 1	0	14	93,3	13	92,9	12,82	21,68
	1	8	47,1	8	100,0	8,33	15,43
Cycle 14 Day 1	0	14	93,3	14	100,0	7,14	19,30
	1	8	47,1	8	100,0	16,67	25,20
Cycle 15 Day 1	0	14	93,3	14	100,0	7,14	14,19
	1	8	47,1	7	87,5	14,29	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	8,33	15,43
	1	8	47,1	7	87,5	9,52	16,27
Cycle 17 Day 1	0	12	80,0	8	66,7	8,33	15,43
	1	6	35,3	6	100,0	5,56	13,61
Cycle 18 Day 1	0	9	60,0	4	44,4	8,33	16,67
	1	6	35,3	4	66,7	16,67	19,25
Cycle 19 Day 1	0	8	53,3	4	50,0	8,33	16,67
	1	5	29,4	4	80,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	13,33	18,26
	1	4	23,5	4	100,0	16,67	19,25
Cycle 21 Day 1	0	3	20,0	3	100,0	11,11	19,25
	1	4	23,5	1	25,0	33,33	-
Cycle 22 Day 1	0	3	20,0	2	66,7	16,67	23,57
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	33,33	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	33,33	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	22,22	38,49
	1	7	41,2	2	28,6	16,67	23,57
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	17,95	22,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	16,67	23,57
	2 or More	21	100,0	18	85,7	18,52	23,49
Cycle 2 Day 1	None	14	100,0	13	92,9	7,69	14,62
	1	1	50,0	1	100,0	0,00	-
	2 or More	18	85,7	16	88,9	16,67	21,08
Cycle 3 Day 1	None	14	100,0	13	92,9	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	8,89	15,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	11	78,6	9,09	15,57
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	15,56	27,79
Cycle 5 Day 1	None	14	100,0	14	100,0	7,14	19,30
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	4,76	12,10
Cycle 6 Day 1	None	14	100,0	12	85,7	5,56	19,25
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	13	81,3	10,26	21,01
Cycle 7 Day 1	None	14	100,0	12	85,7	2,78	9,62
	1	1	50,0	1	100,0	0,00	-
	2 or More	15	71,4	13	86,7	10,26	16,01
Cycle 8 Day 1	None	14	100,0	13	92,9	12,82	16,88
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	8,33	15,08
Cycle 9 Day 1	None	13	92,9	13	100,0	2,56	9,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	15,15	17,41
Cycle 10 Day 1	None	13	92,9	12	92,3	2,78	9,62
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	12,12	16,82
Cycle 11 Day 1	None	13	92,9	13	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	10	100,0	13,33	23,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	8,33	15,08
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	8	80,0	12,50	17,25
Cycle 13 Day 1	None	12	85,7	11	91,7	9,09	15,57
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	14,81	24,22
Cycle 14 Day 1	None	12	85,7	12	100,0	5,56	12,97
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	18,52	29,40
Cycle 15 Day 1	None	12	85,7	12	100,0	5,56	12,97
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	8	88,9	16,67	25,20
Cycle 16 Day 1	None	11	78,6	8	72,7	4,17	11,79
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	16,67	18,26
Cycle 17 Day 1	None	10	71,4	7	70,0	4,76	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	7	33,3	6	85,7	11,11	17,21
Cycle 18 Day 1	None	8	57,1	4	50,0	16,67	19,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	6	28,6	3	50,0	11,11	19,25
Cycle 19 Day 1	None	7	50,0	3	42,9	11,11	19,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	5	23,8	4	80,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	8,33	16,67
	1	1	50,0	1	100,0	0,00	-
	2 or More	4	19,0	4	100,0	25,00	16,67
Cycle 21 Day 1	None	4	28,6	2	50,0	16,67	23,57
	2 or More	3	14,3	2	66,7	16,67	23,57
Cycle 22 Day 1	None	4	28,6	1	25,0	33,33	-
	2 or More	3	14,3	1	33,3	0,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	33,33	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	0,00	-
	1	2	100,0	1	50,0	0,00	-
	2 or More	9	42,9	3	33,3	33,33	33,33
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	17,95	22,01
	Previously Treated	23	100,0	20	87,0	18,33	22,88
Cycle 2 Day 1	Naïve	14	100,0	13	92,9	7,69	14,62
	Previously Treated	19	82,6	17	89,5	15,69	20,81
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	0,00	0,00
	Previously Treated	18	78,3	16	88,9	8,33	14,91
Cycle 4 Day 1	Naïve	14	100,0	11	78,6	9,09	15,57
	Previously Treated	18	78,3	16	88,9	14,58	27,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	7,14	19,30
	Previously Treated	17	73,9	15	88,2	4,44	11,73
Cycle 6 Day 1	Naïve	14	100,0	12	85,7	5,56	19,25
	Previously Treated	17	73,9	14	82,4	9,52	20,37
Cycle 7 Day 1	Naïve	14	100,0	12	85,7	2,78	9,62
	Previously Treated	16	69,6	14	87,5	9,52	15,63
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	12,82	16,88
	Previously Treated	14	60,9	12	85,7	8,33	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	2,56	9,25
	Previously Treated	12	52,2	12	100,0	13,89	17,16
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	2,78	9,62
	Previously Treated	12	52,2	12	100,0	11,11	16,41
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	0,00	0,00
	Previously Treated	11	47,8	11	100,0	12,12	22,47
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	8,33	15,08
	Previously Treated	11	47,8	9	81,8	11,11	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	9,09	15,57
	Previously Treated	10	43,5	10	100,0	13,33	23,31
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	5,56	12,97
	Previously Treated	10	43,5	10	100,0	16,67	28,33
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	5,56	12,97
	Previously Treated	10	43,5	9	90,0	14,81	24,22
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	4,17	11,79
	Previously Treated	10	43,5	7	70,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	4,76	12,60
	Previously Treated	8	34,8	7	87,5	9,52	16,27
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	16,67	19,25
	Previously Treated	7	30,4	4	57,1	8,33	16,67
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	11,11	19,25
	Previously Treated	6	26,1	5	83,3	13,33	18,26
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	8,33	16,67
	Previously Treated	5	21,7	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	16,67	23,57
	Previously Treated	3	13,0	2	66,7	16,67	23,57
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	33,33	-
	Previously Treated	3	13,0	1	33,3	0,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	33,33	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	11	47,8	4	36,4	25,00	31,91
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	13,89	17,16
	Central	25	100,0	21	84,0	20,63	24,67
Cycle 2 Day 1	Local	11	91,7	11	100,0	6,06	13,48
	Central	22	88,0	19	86,4	15,79	20,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	10	90,9	0,00	0,00
	Central	21	84,0	19	90,5	7,02	13,96
Cycle 4 Day 1	Local	11	91,7	9	81,8	3,70	11,11
	Central	21	84,0	18	85,7	16,67	26,20
Cycle 5 Day 1	Local	11	91,7	10	90,9	6,67	14,05
	Central	20	80,0	19	95,0	5,26	16,72
Cycle 6 Day 1	Local	11	91,7	11	100,0	12,12	26,97
	Central	20	80,0	15	75,0	4,44	11,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	9,09	15,57
	Central	19	76,0	15	78,9	4,44	11,73
Cycle 8 Day 1	Local	10	83,3	10	100,0	10,00	16,10
	Central	18	72,0	15	83,3	11,11	16,27
Cycle 9 Day 1	Local	10	83,3	10	100,0	6,67	14,05
	Central	15	60,0	15	100,0	8,89	15,26
Cycle 10 Day 1	Local	10	83,3	9	90,0	11,11	16,67
	Central	15	60,0	15	100,0	4,44	11,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	3,70	11,11
	Central	15	60,0	15	100,0	6,67	18,69
Cycle 12 Day 1	Local	9	75,0	8	88,9	8,33	15,43
	Central	15	60,0	13	86,7	10,26	16,01
Cycle 13 Day 1	Local	8	66,7	8	100,0	12,50	24,80
	Central	14	56,0	13	92,9	10,26	16,01
Cycle 14 Day 1	Local	8	66,7	8	100,0	8,33	23,57
	Central	14	56,0	14	100,0	11,90	21,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	8,33	15,43
	Central	14	56,0	13	92,9	10,26	21,01
Cycle 16 Day 1	Local	8	66,7	6	75,0	11,11	17,21
	Central	13	52,0	9	69,2	7,41	14,70
Cycle 17 Day 1	Local	8	66,7	5	62,5	13,33	18,26
	Central	10	40,0	9	90,0	3,70	11,11
Cycle 18 Day 1	Local	6	50,0	4	66,7	16,67	19,25
	Central	9	36,0	4	44,4	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	16,67	19,25
	Central	8	32,0	4	50,0	8,33	16,67
Cycle 20 Day 1	Local	5	41,7	5	100,0	13,33	18,26
	Central	4	16,0	4	100,0	16,67	19,25
Cycle 21 Day 1	Local	4	33,3	2	50,0	16,67	23,57
	Central	3	12,0	2	66,7	16,67	23,57
Cycle 22 Day 1	Local	4	33,3	1	25,0	33,33	-
	Central	3	12,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	33,33	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	33,33	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	33,33	47,14
	Central	8	32,0	3	37,5	11,11	19,25
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	31	88,6	18,28	22,51
	No	2	100,0	2	100,0	16,67	23,57
Cycle 2 Day 1	Yes	32	91,4	29	90,6	12,64	18,72
	No	1	50,0	1	100,0	0,00	-
Cycle 3 Day 1	Yes	31	88,6	28	90,3	4,76	11,88
	No	1	50,0	1	100,0	0,00	-
Cycle 4 Day 1	Yes	31	88,6	26	83,9	12,82	23,24
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	5,95	15,85
	No	1	50,0	1	100,0	0,00	-
Cycle 6 Day 1	Yes	30	85,7	25	83,3	8,00	19,91
	No	1	50,0	1	100,0	0,00	-
Cycle 7 Day 1	Yes	29	82,9	25	86,2	6,67	13,61
	No	1	50,0	1	100,0	0,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	11,11	16,05
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	8,33	14,74
	No	1	50,0	1	100,0	0,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	7,25	14,06
	No	1	50,0	1	100,0	0,00	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	5,80	16,37
	No	1	50,0	1	100,0	0,00	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	10,00	15,67
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	11,67	19,57
	No	1	50,0	1	100,0	0,00	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	11,11	21,94
	No	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	10,00	19,04
	No	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	9,52	15,63
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	7,69	14,62
	No	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	14,29	17,82
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	14,29	17,82
	No	1	50,0	1	100,0	0,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	16,67	17,82
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	16,67	19,25
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	16,67	23,57
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	33,33	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	33,33	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	20,00	29,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	22,22	38,49
	No	33	100,0	30	90,9	17,78	20,96
Cycle 2 Day 1	Yes	2	50,0	1	50,0	33,33	-
	No	31	93,9	29	93,5	11,49	18,42
Cycle 3 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	27	90,0	4,94	12,07
Cycle 4 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	30	90,9	25	83,3	12,00	23,33
Cycle 5 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	27	93,1	6,17	16,11
Cycle 6 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	24	82,8	8,33	20,26
Cycle 7 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	24	85,7	6,94	13,83
Cycle 8 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	26	78,8	23	88,5	11,59	16,23
Cycle 9 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	24	100,0	8,33	14,74
Cycle 10 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	23	95,8	7,25	14,06
Cycle 11 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	5,80	16,37
Cycle 12 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	23	69,7	20	87,0	10,00	15,67
Cycle 13 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	20	95,2	10,00	19,04
Cycle 14 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	21	100,0	11,11	21,94
Cycle 15 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	8,33	18,34
Cycle 16 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	20	60,6	14	70,0	9,52	15,63
Cycle 17 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	17	51,5	13	76,5	7,69	14,62
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	12,50	17,25
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	12,50	17,25
Cycle 20 Day 1	No	9	27,3	9	100,0	14,81	17,57
Cycle 21 Day 1	No	7	21,2	4	57,1	16,67	19,25
Cycle 22 Day 1	No	7	21,2	2	28,6	16,67	23,57
Cycle 23 Day 1	No	4	12,1	1	25,0	33,33	-
Cycle 24 Day 1	No	1	3,0	1	100,0	33,33	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	16,67	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PA_SG.xls
07SEP2019 20:36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	33	89,2	17,17	20,62
Cycle 2 Day 1	All	33	89,2	30	90,9	13,33	18,77
Cycle 3 Day 1	All	32	86,5	29	90,6	4,60	11,70
Cycle 4 Day 1	All	32	86,5	27	84,4	6,17	13,19
Cycle 5 Day 1	All	31	83,8	29	93,5	6,90	13,74
Cycle 6 Day 1	All	31	83,8	26	83,9	5,13	15,47
Cycle 7 Day 1	All	30	81,1	26	86,7	14,10	25,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	8,00	14,53
Cycle 9 Day 1	All	25	67,6	25	100,0	8,00	17,43
Cycle 10 Day 1	All	25	67,6	24	96,0	6,94	16,97
Cycle 11 Day 1	All	24	64,9	24	100,0	5,56	12,69
Cycle 12 Day 1	All	24	64,9	21	87,5	4,76	11,95
Cycle 13 Day 1	All	22	59,5	21	95,5	7,94	17,97
Cycle 14 Day 1	All	22	59,5	22	100,0	6,06	16,70
Cycle 15 Day 1	All	22	59,5	21	95,5	6,35	13,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	15,56	24,77
Cycle 17 Day 1	All	18	48,6	14	77,8	2,38	8,91
Cycle 18 Day 1	All	15	40,5	8	53,3	8,33	15,43
Cycle 19 Day 1	All	13	35,1	8	61,5	12,50	24,80
Cycle 20 Day 1	All	9	24,3	9	100,0	14,81	17,57
Cycle 21 Day 1	All	7	18,9	4	57,1	16,67	19,25
Cycle 22 Day 1	All	7	18,9	2	28,6	0,00	0,00
Cycle 23 Day 1	All	4	10,8	1	25,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	0,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	20,00	18,26
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	17,95	25,88
	Female	23	100,0	20	87,0	16,67	17,10
Cycle 2 Day 1	Male	13	92,9	13	100,0	12,82	21,68
	Female	20	87,0	17	85,0	13,73	16,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	5,56	12,97
	Female	20	87,0	17	85,0	3,92	11,07
Cycle 4 Day 1	Male	12	85,7	10	83,3	6,67	14,05
	Female	20	87,0	17	85,0	5,88	13,10
Cycle 5 Day 1	Male	12	85,7	11	91,7	6,06	13,48
	Female	19	82,6	18	94,7	7,41	14,26
Cycle 6 Day 1	Male	12	85,7	11	91,7	6,06	13,48
	Female	19	82,6	15	78,9	4,44	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	15,15	27,34
	Female	19	82,6	15	78,9	13,33	24,56
Cycle 8 Day 1	Male	10	71,4	9	90,0	11,11	16,67
	Female	18	78,3	16	88,9	6,25	13,44
Cycle 9 Day 1	Male	8	57,1	8	100,0	8,33	15,43
	Female	17	73,9	17	100,0	7,84	18,74
Cycle 10 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	17	73,9	16	94,1	8,33	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	16	69,6	16	100,0	6,25	13,44
Cycle 12 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	16	69,6	13	81,3	5,13	12,52
Cycle 13 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	14	60,9	13	92,9	10,26	21,01
Cycle 14 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	14	60,9	14	100,0	7,14	19,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	14	60,9	13	92,9	10,26	16,01
Cycle 16 Day 1	Male	8	57,1	5	62,5	0,00	0,00
	Female	13	56,5	10	76,9	23,33	27,44
Cycle 17 Day 1	Male	6	42,9	2	33,3	0,00	0,00
	Female	12	52,2	12	100,0	2,78	9,62
Cycle 18 Day 1	Male	3	21,4	2	66,7	0,00	0,00
	Female	12	52,2	6	50,0	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	11	47,8	6	54,5	16,67	27,89
Cycle 20 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	7	30,4	7	100,0	19,05	17,82
Cycle 21 Day 1	Male	1	7,1	1	100,0	0,00	-
	Female	6	26,1	3	50,0	22,22	19,25
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	0,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	0,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	16,67	23,57
	Female	7	30,4	3	42,9	22,22	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	26	89,7	14,10	19,26
	65-74	8	100,0	7	87,5	28,57	23,00
Cycle 2 Day 1	18-64	27	93,1	24	88,9	12,50	19,19
	65-74	6	75,0	6	100,0	16,67	18,26
Cycle 3 Day 1	18-64	26	89,7	24	92,3	5,56	12,69
	65-74	6	75,0	5	83,3	0,00	0,00
Cycle 4 Day 1	18-64	26	89,7	22	84,6	7,58	14,30
	65-74	6	75,0	5	83,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	7,25	14,06
	65-74	6	75,0	6	100,0	5,56	13,61
Cycle 6 Day 1	18-64	25	86,2	21	84,0	3,17	10,03
	65-74	6	75,0	5	83,3	13,33	29,81
Cycle 7 Day 1	18-64	25	86,2	22	88,0	13,64	24,47
	65-74	5	62,5	4	80,0	16,67	33,33
Cycle 8 Day 1	18-64	23	79,3	20	87,0	6,67	13,68
	65-74	5	62,5	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	5,00	12,21
	65-74	5	62,5	5	100,0	20,00	29,81
Cycle 10 Day 1	18-64	20	69,0	19	95,0	5,26	12,49
	65-74	5	62,5	5	100,0	13,33	29,81
Cycle 11 Day 1	18-64	19	65,5	19	100,0	5,26	12,49
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 12 Day 1	18-64	19	65,5	17	89,5	3,92	11,07
	65-74	5	62,5	4	80,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	2,08	8,33
	65-74	5	62,5	5	100,0	26,67	27,89
Cycle 14 Day 1	18-64	17	58,6	17	100,0	3,92	11,07
	65-74	5	62,5	5	100,0	13,33	29,81
Cycle 15 Day 1	18-64	17	58,6	16	94,1	6,25	13,44
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 16 Day 1	18-64	17	58,6	13	76,5	15,38	25,88
	65-74	4	50,0	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	0,00	0,00
	65-74	3	37,5	2	66,7	16,67	23,57
Cycle 18 Day 1	18-64	13	44,8	8	61,5	8,33	15,43
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	9,52	25,20
	65-74	2	25,0	1	50,0	33,33	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	12,50	17,25
	65-74	1	12,5	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	16,67	19,25
Cycle 22 Day 1	18-64	7	24,1	2	28,6	0,00	0,00
Cycle 23 Day 1	18-64	4	13,8	1	25,0	0,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	0,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	22,22	19,25
	65-74	6	75,0	2	33,3	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	16	80,0	12,50	20,64
	Other	17	100,0	17	100,0	21,57	20,21
Cycle 2 Day 1	White	19	95,0	16	84,2	14,58	20,97
	Other	14	82,4	14	100,0	11,90	16,57
Cycle 3 Day 1	White	18	90,0	15	83,3	4,44	11,73
	Other	14	82,4	14	100,0	4,76	12,10
Cycle 4 Day 1	White	18	90,0	14	77,8	4,76	12,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	7,69	14,62
Cycle 5 Day 1	White	18	90,0	17	94,4	5,88	13,10
	Other	13	76,5	12	92,3	8,33	15,08
Cycle 6 Day 1	White	18	90,0	13	72,2	7,69	19,97
	Other	13	76,5	13	100,0	2,56	9,25
Cycle 7 Day 1	White	17	85,0	14	82,4	11,90	24,83
	Other	13	76,5	12	92,3	16,67	26,59
Cycle 8 Day 1	White	17	85,0	14	82,4	9,52	15,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	6,06	13,48
Cycle 9 Day 1	White	16	80,0	16	100,0	10,42	20,07
	Other	9	52,9	9	100,0	3,70	11,11
Cycle 10 Day 1	White	16	80,0	15	93,8	11,11	20,57
	Other	9	52,9	9	100,0	0,00	0,00
Cycle 11 Day 1	White	16	80,0	16	100,0	8,33	14,91
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 12 Day 1	White	16	80,0	13	81,3	7,69	14,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 13 Day 1	White	14	70,0	13	92,9	5,13	18,49
	Other	8	47,1	8	100,0	12,50	17,25
Cycle 14 Day 1	White	14	70,0	14	100,0	9,52	20,37
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 15 Day 1	White	14	70,0	13	92,9	7,69	14,62
	Other	8	47,1	8	100,0	4,17	11,79
Cycle 16 Day 1	White	14	70,0	9	64,3	11,11	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	22,22	27,22
Cycle 17 Day 1	White	13	65,0	10	76,9	3,33	10,54
	Other	5	29,4	4	80,0	0,00	0,00
Cycle 18 Day 1	White	11	55,0	4	36,4	0,00	0,00
	Other	4	23,5	4	100,0	16,67	19,25
Cycle 19 Day 1	White	9	45,0	5	55,6	6,67	14,91
	Other	4	23,5	3	75,0	22,22	38,49
Cycle 20 Day 1	White	5	25,0	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	16,67	19,25
Cycle 21 Day 1	White	3	15,0	2	66,7	0,00	0,00
	Other	4	23,5	2	50,0	33,33	0,00
Cycle 22 Day 1	White	3	15,0	1	33,3	0,00	-
	Other	4	23,5	1	25,0	0,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	0,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	22,22	19,25
	Other	9	52,9	2	22,2	16,67	23,57
Region							
Cycle 1 Day 1	America (AM)	12	100,0	11	91,7	15,15	17,41
	Europe (EU)	10	100,0	8	80,0	12,50	17,25
	Asia (AS)	15	100,0	14	93,3	21,43	24,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	10	90,9	16,67	17,57
	Europe (EU)	9	90,0	8	88,9	20,83	24,80
	Asia (AS)	13	86,7	12	92,3	5,56	12,97
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	3,03	10,05
	Europe (EU)	8	80,0	5	62,5	6,67	14,91
	Asia (AS)	13	86,7	13	100,0	5,13	12,52
Cycle 4 Day 1	America (AM)	11	91,7	10	90,9	3,33	10,54
	Europe (EU)	8	80,0	4	50,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	7,69	14,62
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	3,03	10,05
	Europe (EU)	8	80,0	7	87,5	9,52	16,27
	Asia (AS)	12	80,0	11	91,7	9,09	15,57
Cycle 6 Day 1	America (AM)	11	91,7	9	81,8	0,00	0,00
	Europe (EU)	8	80,0	6	75,0	16,67	27,89
	Asia (AS)	12	80,0	11	91,7	3,03	10,05
Cycle 7 Day 1	America (AM)	11	91,7	9	81,8	11,11	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	14,29	26,23
	Asia (AS)	11	73,3	10	90,9	16,67	28,33
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	3,33	10,54
	Europe (EU)	8	80,0	6	75,0	16,67	18,26
	Asia (AS)	9	60,0	9	100,0	7,41	14,70
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	6,06	13,48
	Europe (EU)	7	70,0	7	100,0	14,29	26,23
	Asia (AS)	7	46,7	7	100,0	4,76	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	0,00	0,00
	Europe (EU)	7	70,0	7	100,0	23,81	25,20
	Asia (AS)	7	46,7	7	100,0	0,00	0,00
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	3,03	10,05
	Europe (EU)	7	70,0	7	100,0	9,52	16,27
	Asia (AS)	6	40,0	6	100,0	5,56	13,61
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	3,33	10,54
	Europe (EU)	7	70,0	5	71,4	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	6,67	14,05
	Europe (EU)	6	60,0	5	83,3	13,33	29,81
	Asia (AS)	6	40,0	6	100,0	5,56	13,61
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	3,33	10,54
	Europe (EU)	6	60,0	6	100,0	16,67	27,89
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	6,67	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	6,67	14,91
	Asia (AS)	6	40,0	6	100,0	5,56	13,61
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	14,29	26,23
	Europe (EU)	6	60,0	2	33,3	16,67	23,57
	Asia (AS)	6	40,0	6	100,0	16,67	27,89
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	0,00	0,00
	Europe (EU)	4	40,0	3	75,0	11,11	19,25
	Asia (AS)	5	33,3	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	6,67	14,91
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	11,11	19,25
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	0,00	0,00
	Europe (EU)	3	30,0	1	33,3	33,33	-
	Asia (AS)	4	26,7	3	75,0	22,22	38,49
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	6,67	14,91
	Europe (EU)	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	22,22	19,25
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	11,11	19,25
	Asia (AS)	3	20,0	1	33,3	33,33	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	0,00	0,00
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	0,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	11,11	19,25
	Europe (EU)	2	20,0	1	50,0	33,33	-
	Asia (AS)	7	46,7	1	14,3	33,33	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	11	73,3	15,15	22,92
	1	17	100,0	17	100,0	19,61	20,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	13,33	18,26
Cycle 2 Day 1	0	15	100,0	13	86,7	17,95	17,30
	1	15	88,2	14	93,3	9,52	20,37
	2	3	60,0	3	100,0	11,11	19,25
Cycle 3 Day 1	0	15	100,0	13	86,7	5,13	12,52
	1	14	82,4	13	92,9	2,56	9,25
	2	3	60,0	3	100,0	11,11	19,25
Cycle 4 Day 1	0	15	100,0	13	86,7	5,13	12,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	5,56	12,97
	2	3	60,0	2	66,7	16,67	23,57
Cycle 5 Day 1	0	15	100,0	15	100,0	6,67	13,80
	1	14	82,4	12	85,7	8,33	15,08
	2	2	40,0	2	100,0	0,00	0,00
Cycle 6 Day 1	0	15	100,0	14	93,3	9,52	20,37
	1	14	82,4	11	78,6	0,00	0,00
	2	2	40,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	19,05	28,39
	1	13	76,5	10	76,9	10,00	22,50
	2	2	40,0	2	100,0	0,00	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	10,26	16,01
	1	11	64,7	10	90,9	3,33	10,54
	2	2	40,0	2	100,0	16,67	23,57
Cycle 9 Day 1	0	14	93,3	14	100,0	9,52	20,37
	1	10	58,8	10	100,0	6,67	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	0,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	7,14	19,30
	1	10	58,8	9	90,0	3,70	11,11
	2	1	20,0	1	100,0	33,33	-
Cycle 11 Day 1	0	14	93,3	14	100,0	4,76	12,10
	1	9	52,9	9	100,0	7,41	14,70
	2	1	20,0	1	100,0	0,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	4,17	11,79
	2	1	20,0	1	100,0	0,00	-
Cycle 13 Day 1	0	14	93,3	13	92,9	12,82	21,68
	1	8	47,1	8	100,0	0,00	0,00
Cycle 14 Day 1	0	14	93,3	14	100,0	7,14	19,30
	1	8	47,1	8	100,0	4,17	11,79
Cycle 15 Day 1	0	14	93,3	14	100,0	7,14	14,19
	1	8	47,1	7	87,5	4,76	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	8,33	15,43
	1	8	47,1	7	87,5	23,81	31,71
Cycle 17 Day 1	0	12	80,0	8	66,7	4,17	11,79
	1	6	35,3	6	100,0	0,00	0,00
Cycle 18 Day 1	0	9	60,0	4	44,4	8,33	16,67
	1	6	35,3	4	66,7	8,33	16,67
Cycle 19 Day 1	0	8	53,3	4	50,0	8,33	16,67
	1	5	29,4	4	80,0	16,67	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	6,67	14,91
	1	4	23,5	4	100,0	25,00	16,67
Cycle 21 Day 1	0	3	20,0	3	100,0	11,11	19,25
	1	4	23,5	1	25,0	33,33	-
Cycle 22 Day 1	0	3	20,0	2	66,7	0,00	0,00
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	0,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	11,11	19,25
	1	7	41,2	2	28,6	33,33	0,00
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	10,26	16,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	16,67	23,57
	2 or More	21	100,0	18	85,7	22,22	22,87
Cycle 2 Day 1	None	14	100,0	13	92,9	12,82	16,88
	1	1	50,0	1	100,0	0,00	-
	2 or More	18	85,7	16	88,9	14,58	20,97
Cycle 3 Day 1	None	14	100,0	13	92,9	2,56	9,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	6,67	13,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	11	78,6	3,03	10,05
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	8,89	15,26
Cycle 5 Day 1	None	14	100,0	14	100,0	4,76	12,10
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	9,52	15,63
Cycle 6 Day 1	None	14	100,0	12	85,7	0,00	0,00
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	13	81,3	10,26	21,01
Cycle 7 Day 1	None	14	100,0	12	85,7	2,78	9,62
	1	1	50,0	1	100,0	0,00	-
	2 or More	15	71,4	13	86,7	25,64	30,89
Cycle 8 Day 1	None	14	100,0	13	92,9	5,13	12,52
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	11,11	16,41
Cycle 9 Day 1	None	13	92,9	13	100,0	2,56	9,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	15,15	22,92
Cycle 10 Day 1	None	13	92,9	12	92,3	2,78	9,62
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	12,12	22,47
Cycle 11 Day 1	None	13	92,9	13	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	10	100,0	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	2,78	9,62
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	8	80,0	8,33	15,43
Cycle 13 Day 1	None	12	85,7	11	91,7	6,06	13,48
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	11,11	23,57
Cycle 14 Day 1	None	12	85,7	12	100,0	2,78	9,62
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	11,11	23,57
Cycle 15 Day 1	None	12	85,7	12	100,0	8,33	15,08
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	8	88,9	4,17	11,79
Cycle 16 Day 1	None	11	78,6	8	72,7	16,67	25,20
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	16,67	27,89
Cycle 17 Day 1	None	10	71,4	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	7	33,3	6	85,7	5,56	13,61
Cycle 18 Day 1	None	8	57,1	4	50,0	8,33	16,67
	1	1	50,0	1	100,0	0,00	-
	2 or More	6	28,6	3	50,0	11,11	19,25
Cycle 19 Day 1	None	7	50,0	3	42,9	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	5	23,8	4	80,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	8,33	16,67
	1	1	50,0	1	100,0	0,00	-
	2 or More	4	19,0	4	100,0	25,00	16,67
Cycle 21 Day 1	None	4	28,6	2	50,0	16,67	23,57
	2 or More	3	14,3	2	66,7	16,67	23,57
Cycle 22 Day 1	None	4	28,6	1	25,0	0,00	-
	2 or More	3	14,3	1	33,3	0,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	0,00	-
	1	2	100,0	1	50,0	0,00	-
	2 or More	9	42,9	3	33,3	33,33	0,00
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	10,26	16,01
	Previously Treated	23	100,0	20	87,0	21,67	22,36
Cycle 2 Day 1	Naïve	14	100,0	13	92,9	12,82	16,88
	Previously Treated	19	82,6	17	89,5	13,73	20,61
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	2,56	9,25
	Previously Treated	18	78,3	16	88,9	6,25	13,44
Cycle 4 Day 1	Naïve	14	100,0	11	78,6	3,03	10,05
	Previously Treated	18	78,3	16	88,9	8,33	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	4,76	12,10
	Previously Treated	17	73,9	15	88,2	8,89	15,26
Cycle 6 Day 1	Naïve	14	100,0	12	85,7	0,00	0,00
	Previously Treated	17	73,9	14	82,4	9,52	20,37
Cycle 7 Day 1	Naïve	14	100,0	12	85,7	2,78	9,62
	Previously Treated	16	69,6	14	87,5	23,81	30,46
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	5,13	12,52
	Previously Treated	14	60,9	12	85,7	11,11	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	2,56	9,25
	Previously Treated	12	52,2	12	100,0	13,89	22,29
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	2,78	9,62
	Previously Treated	12	52,2	12	100,0	11,11	21,71
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	0,00	0,00
	Previously Treated	11	47,8	11	100,0	12,12	16,82
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	2,78	9,62
	Previously Treated	11	47,8	9	81,8	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	6,06	13,48
	Previously Treated	10	43,5	10	100,0	10,00	22,50
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	2,78	9,62
	Previously Treated	10	43,5	10	100,0	10,00	22,50
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	8,33	15,08
	Previously Treated	10	43,5	9	90,0	3,70	11,11
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	16,67	25,20
	Previously Treated	10	43,5	7	70,0	14,29	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	0,00	0,00
	Previously Treated	8	34,8	7	87,5	4,76	12,60
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	8,33	16,67
	Previously Treated	7	30,4	4	57,1	8,33	16,67
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	0,00	0,00
	Previously Treated	6	26,1	5	83,3	20,00	29,81
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	8,33	16,67
	Previously Treated	5	21,7	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	16,67	23,57
	Previously Treated	3	13,0	2	66,7	16,67	23,57
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	0,00	-
	Previously Treated	3	13,0	1	33,3	0,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	11	47,8	4	36,4	25,00	16,67
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	22,22	16,41
	Central	25	100,0	21	84,0	14,29	22,54
Cycle 2 Day 1	Local	11	91,7	11	100,0	15,15	17,41
	Central	22	88,0	19	86,4	12,28	19,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	10	90,9	3,33	10,54
	Central	21	84,0	19	90,5	5,26	12,49
Cycle 4 Day 1	Local	11	91,7	9	81,8	3,70	11,11
	Central	21	84,0	18	85,7	7,41	14,26
Cycle 5 Day 1	Local	11	91,7	10	90,9	10,00	16,10
	Central	20	80,0	19	95,0	5,26	12,49
Cycle 6 Day 1	Local	11	91,7	11	100,0	6,06	20,10
	Central	20	80,0	15	75,0	4,44	11,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	18,18	27,34
	Central	19	76,0	15	78,9	11,11	24,12
Cycle 8 Day 1	Local	10	83,3	10	100,0	6,67	14,05
	Central	18	72,0	15	83,3	8,89	15,26
Cycle 9 Day 1	Local	10	83,3	10	100,0	13,33	23,31
	Central	15	60,0	15	100,0	4,44	11,73
Cycle 10 Day 1	Local	10	83,3	9	90,0	7,41	22,22
	Central	15	60,0	15	100,0	6,67	13,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	7,41	14,70
	Central	15	60,0	15	100,0	4,44	11,73
Cycle 12 Day 1	Local	9	75,0	8	88,9	8,33	15,43
	Central	15	60,0	13	86,7	2,56	9,25
Cycle 13 Day 1	Local	8	66,7	8	100,0	12,50	24,80
	Central	14	56,0	13	92,9	5,13	12,52
Cycle 14 Day 1	Local	8	66,7	8	100,0	12,50	24,80
	Central	14	56,0	14	100,0	2,38	8,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	12,50	17,25
	Central	14	56,0	13	92,9	2,56	9,25
Cycle 16 Day 1	Local	8	66,7	6	75,0	27,78	25,09
	Central	13	52,0	9	69,2	7,41	22,22
Cycle 17 Day 1	Local	8	66,7	5	62,5	6,67	14,91
	Central	10	40,0	9	90,0	0,00	0,00
Cycle 18 Day 1	Local	6	50,0	4	66,7	8,33	16,67
	Central	9	36,0	4	44,4	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	8,33	16,67
	Central	8	32,0	4	50,0	16,67	33,33
Cycle 20 Day 1	Local	5	41,7	5	100,0	13,33	18,26
	Central	4	16,0	4	100,0	16,67	19,25
Cycle 21 Day 1	Local	4	33,3	2	50,0	16,67	23,57
	Central	3	12,0	2	66,7	16,67	23,57
Cycle 22 Day 1	Local	4	33,3	1	25,0	0,00	-
	Central	3	12,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	0,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	0,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	33,33	0,00
	Central	8	32,0	3	37,5	11,11	19,25
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	31	88,6	17,20	20,85
	No	2	100,0	2	100,0	16,67	23,57
Cycle 2 Day 1	Yes	32	91,4	29	90,6	13,79	18,93
	No	1	50,0	1	100,0	0,00	-
Cycle 3 Day 1	Yes	31	88,6	28	90,3	4,76	11,88
	No	1	50,0	1	100,0	0,00	-
Cycle 4 Day 1	Yes	31	88,6	26	83,9	6,41	13,40
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	5,95	13,00
	No	1	50,0	1	100,0	33,33	-
Cycle 6 Day 1	Yes	30	85,7	25	83,3	5,33	15,75
	No	1	50,0	1	100,0	0,00	-
Cycle 7 Day 1	Yes	29	82,9	25	86,2	14,67	25,60
	No	1	50,0	1	100,0	0,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	8,33	14,74
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	8,33	17,72
	No	1	50,0	1	100,0	0,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	7,25	17,28
	No	1	50,0	1	100,0	0,00	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	5,80	12,92
	No	1	50,0	1	100,0	0,00	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	5,00	12,21
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	8,33	18,34
	No	1	50,0	1	100,0	0,00	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	6,35	17,06
	No	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	6,67	13,68
	No	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	14,29	25,20
	No	1	50,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	2,56	9,25
	No	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	9,52	16,27
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	14,29	26,23
	No	1	50,0	1	100,0	0,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	16,67	17,82
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	16,67	19,25
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	0,00	0,00
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	0,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	0,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	0,00	0,00
	No	33	100,0	30	90,9	18,89	20,87
Cycle 2 Day 1	Yes	2	50,0	1	50,0	0,00	-
	No	31	93,9	29	93,5	13,79	18,93
Cycle 3 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	27	90,0	4,94	12,07
Cycle 4 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	30	90,9	25	83,3	6,67	13,61
Cycle 5 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	27	93,1	7,41	14,12
Cycle 6 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	24	82,8	5,56	16,05
Cycle 7 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	24	85,7	15,28	25,97
Cycle 8 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	26	78,8	23	88,5	8,70	14,97
Cycle 9 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	24	100,0	8,33	17,72
Cycle 10 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	23	95,8	7,25	17,28
Cycle 11 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	5,80	12,92
Cycle 12 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	23	69,7	20	87,0	5,00	12,21
Cycle 13 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	20	95,2	8,33	18,34
Cycle 14 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	21	100,0	6,35	17,06
Cycle 15 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	5,00	12,21
Cycle 16 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	20	60,6	14	70,0	16,67	25,32
Cycle 17 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	17	51,5	13	76,5	2,56	9,25
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	8,33	15,43
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	12,50	24,80
Cycle 20 Day 1	No	9	27,3	9	100,0	14,81	17,57
Cycle 21 Day 1	No	7	21,2	4	57,1	16,67	19,25
Cycle 22 Day 1	No	7	21,2	2	28,6	0,00	0,00
Cycle 23 Day 1	No	4	12,1	1	25,0	0,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	0,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PC_SG.xls
07SEP2019 20:38

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	33	89,2	15,15	23,70
Cycle 2 Day 1	All	33	89,2	30	90,9	16,67	22,74
Cycle 3 Day 1	All	32	86,5	29	90,6	17,24	21,12
Cycle 4 Day 1	All	32	86,5	27	84,4	16,05	21,42
Cycle 5 Day 1	All	31	83,8	29	93,5	20,69	25,84
Cycle 6 Day 1	All	31	83,8	26	83,9	23,08	27,92
Cycle 7 Day 1	All	30	81,1	26	86,7	23,08	27,92

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	24,00	28,09
Cycle 9 Day 1	All	25	67,6	25	100,0	25,33	25,96
Cycle 10 Day 1	All	25	67,6	24	96,0	25,00	24,57
Cycle 11 Day 1	All	24	64,9	24	100,0	19,44	21,80
Cycle 12 Day 1	All	24	64,9	21	87,5	22,22	19,25
Cycle 13 Day 1	All	22	59,5	21	95,5	23,81	18,69
Cycle 14 Day 1	All	22	59,5	22	100,0	19,70	22,20
Cycle 15 Day 1	All	22	59,5	21	95,5	19,05	24,88

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	15,56	17,21
Cycle 17 Day 1	All	18	48,6	14	77,8	16,67	21,68
Cycle 18 Day 1	All	15	40,5	8	53,3	12,50	17,25
Cycle 19 Day 1	All	13	35,1	8	61,5	12,50	17,25
Cycle 20 Day 1	All	9	24,3	9	100,0	14,81	17,57
Cycle 21 Day 1	All	7	18,9	4	57,1	8,33	16,67
Cycle 22 Day 1	All	7	18,9	2	28,6	16,67	23,57
Cycle 23 Day 1	All	4	10,8	1	25,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	33,33	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	20,00	29,81
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	20,51	32,03
	Female	23	100,0	20	87,0	11,67	16,31
Cycle 2 Day 1	Male	13	92,9	13	100,0	23,08	28,50
	Female	20	87,0	17	85,0	11,76	16,42

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	13,89	17,16
	Female	20	87,0	17	85,0	19,61	23,74
Cycle 4 Day 1	Male	12	85,7	10	83,3	16,67	23,57
	Female	20	87,0	17	85,0	15,69	20,81
Cycle 5 Day 1	Male	12	85,7	11	91,7	18,18	22,92
	Female	19	82,6	18	94,7	22,22	28,01
Cycle 6 Day 1	Male	12	85,7	11	91,7	15,15	17,41
	Female	19	82,6	15	78,9	28,89	33,01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	21,21	34,23
	Female	19	82,6	15	78,9	24,44	23,46
Cycle 8 Day 1	Male	10	71,4	9	90,0	14,81	24,22
	Female	18	78,3	16	88,9	29,17	29,50
Cycle 9 Day 1	Male	8	57,1	8	100,0	20,83	24,80
	Female	17	73,9	17	100,0	27,45	26,97
Cycle 10 Day 1	Male	8	57,1	8	100,0	25,00	29,55
	Female	17	73,9	16	94,1	25,00	22,77

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	29,17	27,82
	Female	16	69,6	16	100,0	14,58	17,08
Cycle 12 Day 1	Male	8	57,1	8	100,0	16,67	17,82
	Female	16	69,6	13	81,3	25,64	19,97
Cycle 13 Day 1	Male	8	57,1	8	100,0	16,67	17,82
	Female	14	60,9	13	92,9	28,21	18,49
Cycle 14 Day 1	Male	8	57,1	8	100,0	16,67	17,82
	Female	14	60,9	14	100,0	21,43	24,83

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	12,50	24,80
	Female	14	60,9	13	92,9	23,08	25,04
Cycle 16 Day 1	Male	8	57,1	5	62,5	6,67	14,91
	Female	13	56,5	10	76,9	20,00	17,21
Cycle 17 Day 1	Male	6	42,9	2	33,3	0,00	0,00
	Female	12	52,2	12	100,0	19,44	22,29
Cycle 18 Day 1	Male	3	21,4	2	66,7	16,67	23,57
	Female	12	52,2	6	50,0	11,11	17,21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	11	47,8	6	54,5	16,67	18,26
Cycle 20 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	7	30,4	7	100,0	19,05	17,82
Cycle 21 Day 1	Male	1	7,1	1	100,0	0,00	-
	Female	6	26,1	3	50,0	11,11	19,25
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	16,67	23,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	0,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	33,33	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	0,00	0,00
	Female	7	30,4	3	42,9	33,33	33,33
Age							

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	26	89,7	15,38	25,35
	65-74	8	100,0	7	87,5	14,29	17,82
Cycle 2 Day 1	18-64	27	93,1	24	88,9	19,44	23,91
	65-74	6	75,0	6	100,0	5,56	13,61
Cycle 3 Day 1	18-64	26	89,7	24	92,3	16,67	19,66
	65-74	6	75,0	5	83,3	20,00	29,81
Cycle 4 Day 1	18-64	26	89,7	22	84,6	13,64	19,68
	65-74	6	75,0	5	83,3	26,67	27,89

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	18,84	22,08
	65-74	6	75,0	6	100,0	27,78	38,97
Cycle 6 Day 1	18-64	25	86,2	21	84,0	19,05	22,54
	65-74	6	75,0	5	83,3	40,00	43,46
Cycle 7 Day 1	18-64	25	86,2	22	88,0	24,24	29,42
	65-74	5	62,5	4	80,0	16,67	19,25
Cycle 8 Day 1	18-64	23	79,3	20	87,0	21,67	22,36
	65-74	5	62,5	5	100,0	33,33	47,14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	23,33	21,90
	65-74	5	62,5	5	100,0	33,33	40,82
Cycle 10 Day 1	18-64	20	69,0	19	95,0	22,81	22,37
	65-74	5	62,5	5	100,0	33,33	33,33
Cycle 11 Day 1	18-64	19	65,5	19	100,0	21,05	22,80
	65-74	5	62,5	5	100,0	13,33	18,26
Cycle 12 Day 1	18-64	19	65,5	17	89,5	21,57	20,21
	65-74	5	62,5	4	80,0	25,00	16,67

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	22,92	15,96
	65-74	5	62,5	5	100,0	26,67	27,89
Cycle 14 Day 1	18-64	17	58,6	17	100,0	17,65	20,81
	65-74	5	62,5	5	100,0	26,67	27,89
Cycle 15 Day 1	18-64	17	58,6	16	94,1	20,83	23,96
	65-74	5	62,5	5	100,0	13,33	29,81
Cycle 16 Day 1	18-64	17	58,6	13	76,5	15,38	17,30
	65-74	4	50,0	2	50,0	16,67	23,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	16,67	22,47
	65-74	3	37,5	2	66,7	16,67	23,57
Cycle 18 Day 1	18-64	13	44,8	8	61,5	12,50	17,25
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	9,52	16,27
	65-74	2	25,0	1	50,0	33,33	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	12,50	17,25
	65-74	1	12,5	1	100,0	33,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	8,33	16,67
Cycle 22 Day 1	18-64	7	24,1	2	28,6	16,67	23,57
Cycle 23 Day 1	18-64	4	13,8	1	25,0	0,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	33,33	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	0,00	0,00
	65-74	6	75,0	2	33,3	50,00	23,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	16	80,0	12,50	29,50
	Other	17	100,0	17	100,0	17,65	17,15
Cycle 2 Day 1	White	19	95,0	16	84,2	20,83	26,87
	Other	14	82,4	14	100,0	11,90	16,57
Cycle 3 Day 1	White	18	90,0	15	83,3	15,56	21,33
	Other	14	82,4	14	100,0	19,05	21,54
Cycle 4 Day 1	White	18	90,0	14	77,8	11,90	16,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	20,51	25,60
Cycle 5 Day 1	White	18	90,0	17	94,4	17,65	20,81
	Other	13	76,5	12	92,3	25,00	32,18
Cycle 6 Day 1	White	18	90,0	13	72,2	23,08	28,50
	Other	13	76,5	13	100,0	23,08	28,50
Cycle 7 Day 1	White	17	85,0	14	82,4	23,81	30,46
	Other	13	76,5	12	92,3	22,22	25,95
Cycle 8 Day 1	White	17	85,0	14	82,4	19,05	25,20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	30,30	31,46
Cycle 9 Day 1	White	16	80,0	16	100,0	22,92	29,11
	Other	9	52,9	9	100,0	29,63	20,03
Cycle 10 Day 1	White	16	80,0	15	93,8	20,00	24,56
	Other	9	52,9	9	100,0	33,33	23,57
Cycle 11 Day 1	White	16	80,0	16	100,0	18,75	20,97
	Other	8	47,1	8	100,0	20,83	24,80
Cycle 12 Day 1	White	16	80,0	13	81,3	20,51	21,68

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	25,00	15,43
Cycle 13 Day 1	White	14	70,0	13	92,9	20,51	21,68
	Other	8	47,1	8	100,0	29,17	11,79
Cycle 14 Day 1	White	14	70,0	14	100,0	16,67	21,68
	Other	8	47,1	8	100,0	25,00	23,57
Cycle 15 Day 1	White	14	70,0	13	92,9	17,95	25,88
	Other	8	47,1	8	100,0	20,83	24,80
Cycle 16 Day 1	White	14	70,0	9	64,3	11,11	16,67

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	22,22	17,21
Cycle 17 Day 1	White	13	65,0	10	76,9	10,00	16,10
	Other	5	29,4	4	80,0	33,33	27,22
Cycle 18 Day 1	White	11	55,0	4	36,4	16,67	19,25
	Other	4	23,5	4	100,0	8,33	16,67
Cycle 19 Day 1	White	9	45,0	5	55,6	6,67	14,91
	Other	4	23,5	3	75,0	22,22	19,25
Cycle 20 Day 1	White	5	25,0	5	100,0	13,33	18,26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	16,67	19,25
Cycle 21 Day 1	White	3	15,0	2	66,7	0,00	0,00
	Other	4	23,5	2	50,0	16,67	23,57
Cycle 22 Day 1	White	3	15,0	1	33,3	33,33	-
	Other	4	23,5	1	25,0	0,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	0,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	33,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	22,22	38,49
	Other	9	52,9	2	22,2	16,67	23,57
Region							
Cycle 1 Day 1	America (AM)	12	100,0	11	91,7	24,24	30,15
	Europe (EU)	10	100,0	8	80,0	8,33	23,57
	Asia (AS)	15	100,0	14	93,3	11,90	16,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	10	90,9	20,00	17,21
	Europe (EU)	9	90,0	8	88,9	25,00	34,50
	Asia (AS)	13	86,7	12	92,3	8,33	15,08
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	21,21	26,97
	Europe (EU)	8	80,0	5	62,5	20,00	18,26
	Asia (AS)	13	86,7	13	100,0	12,82	16,88
Cycle 4 Day 1	America (AM)	11	91,7	10	90,9	16,67	23,57
	Europe (EU)	8	80,0	4	50,0	16,67	19,25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	15,38	22,01
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	24,24	30,15
	Europe (EU)	8	80,0	7	87,5	28,57	29,99
	Asia (AS)	12	80,0	11	91,7	12,12	16,82
Cycle 6 Day 1	America (AM)	11	91,7	9	81,8	33,33	33,33
	Europe (EU)	8	80,0	6	75,0	22,22	27,22
	Asia (AS)	12	80,0	11	91,7	15,15	22,92
Cycle 7 Day 1	America (AM)	11	91,7	9	81,8	22,22	23,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	33,33	38,49
	Asia (AS)	11	73,3	10	90,9	16,67	23,57
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	16,67	32,39
	Europe (EU)	8	80,0	6	75,0	38,89	32,77
	Asia (AS)	9	60,0	9	100,0	22,22	16,67
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	18,18	17,41
	Europe (EU)	7	70,0	7	100,0	42,86	37,09
	Asia (AS)	7	46,7	7	100,0	19,05	17,82

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	16,67	23,57
	Europe (EU)	7	70,0	7	100,0	38,10	29,99
	Asia (AS)	7	46,7	7	100,0	23,81	16,27
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	15,15	17,41
	Europe (EU)	7	70,0	7	100,0	33,33	27,22
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	13,33	17,21
	Europe (EU)	7	70,0	5	71,4	40,00	14,91

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	22,22	17,21
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	16,67	17,57
	Europe (EU)	6	60,0	5	83,3	33,33	23,57
	Asia (AS)	6	40,0	6	100,0	27,78	13,61
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	13,33	17,21
	Europe (EU)	6	60,0	6	100,0	27,78	25,09
	Asia (AS)	6	40,0	6	100,0	22,22	27,22
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	3,33	10,54

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	33,33	33,33
	Asia (AS)	6	40,0	6	100,0	33,33	21,08
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	9,52	16,27
	Europe (EU)	6	60,0	2	33,3	33,33	0,00
	Asia (AS)	6	40,0	6	100,0	16,67	18,26
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	11,11	17,21
	Europe (EU)	4	40,0	3	75,0	11,11	19,25
	Asia (AS)	5	33,3	5	100,0	26,67	27,89

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	20,00	18,26
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	0,00	0,00
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	0,00	0,00
	Europe (EU)	3	30,0	1	33,3	33,33	-
	Asia (AS)	4	26,7	3	75,0	22,22	19,25
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	6,67	14,91
	Europe (EU)	1	10,0	1	100,0	33,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	22,22	19,25
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	0,00	0,00
	Asia (AS)	3	20,0	1	33,3	33,33	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	16,67	23,57
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	0,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	33,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	11,11	19,25
	Europe (EU)	2	20,0	1	50,0	66,67	-
	Asia (AS)	7	46,7	1	14,3	0,00	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	11	73,3	18,18	31,14
	1	17	100,0	17	100,0	15,69	20,81

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	6,67	14,91
Cycle 2 Day 1	0	15	100,0	13	86,7	15,38	17,30
	1	15	88,2	14	93,3	21,43	28,06
	2	3	60,0	3	100,0	0,00	0,00
Cycle 3 Day 1	0	15	100,0	13	86,7	15,38	22,01
	1	14	82,4	13	92,9	17,95	22,01
	2	3	60,0	3	100,0	22,22	19,25
Cycle 4 Day 1	0	15	100,0	13	86,7	17,95	22,01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	13,89	22,29
	2	3	60,0	2	66,7	16,67	23,57
Cycle 5 Day 1	0	15	100,0	15	100,0	20,00	27,60
	1	14	82,4	12	85,7	19,44	22,29
	2	2	40,0	2	100,0	33,33	47,14
Cycle 6 Day 1	0	15	100,0	14	93,3	21,43	30,96
	1	14	82,4	11	78,6	27,27	25,03
	2	2	40,0	1	50,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	19,05	28,39
	1	13	76,5	10	76,9	30,00	29,19
	2	2	40,0	2	100,0	16,67	23,57
Cycle 8 Day 1	0	15	100,0	13	86,7	20,51	32,03
	1	11	64,7	10	90,9	26,67	21,08
	2	2	40,0	2	100,0	33,33	47,14
Cycle 9 Day 1	0	14	93,3	14	100,0	21,43	28,06
	1	10	58,8	10	100,0	26,67	21,08

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	66,67	-
Cycle 10 Day 1	0	14	93,3	14	100,0	23,81	27,51
	1	10	58,8	9	90,0	25,93	22,22
	2	1	20,0	1	100,0	33,33	-
Cycle 11 Day 1	0	14	93,3	14	100,0	19,05	21,54
	1	9	52,9	9	100,0	18,52	24,22
	2	1	20,0	1	100,0	33,33	-
Cycle 12 Day 1	0	14	93,3	12	85,7	19,44	17,16

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	20,83	17,25
	2	1	20,0	1	100,0	66,67	-
Cycle 13 Day 1	0	14	93,3	13	92,9	20,51	21,68
	1	8	47,1	8	100,0	29,17	11,79
Cycle 14 Day 1	0	14	93,3	14	100,0	16,67	21,68
	1	8	47,1	8	100,0	25,00	23,57
Cycle 15 Day 1	0	14	93,3	14	100,0	11,90	24,83
	1	8	47,1	7	87,5	33,33	19,25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	12,50	17,25
	1	8	47,1	7	87,5	19,05	17,82
Cycle 17 Day 1	0	12	80,0	8	66,7	12,50	17,25
	1	6	35,3	6	100,0	22,22	27,22
Cycle 18 Day 1	0	9	60,0	4	44,4	16,67	19,25
	1	6	35,3	4	66,7	8,33	16,67
Cycle 19 Day 1	0	8	53,3	4	50,0	8,33	16,67
	1	5	29,4	4	80,0	16,67	19,25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	6,67	14,91
	1	4	23,5	4	100,0	25,00	16,67
Cycle 21 Day 1	0	3	20,0	3	100,0	0,00	0,00
	1	4	23,5	1	25,0	33,33	-
Cycle 22 Day 1	0	3	20,0	2	66,7	16,67	23,57
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	0,00	-
	1	1	5,9	0	0,0	-	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	33,33	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	33,33	33,33
	1	7	41,2	2	28,6	0,00	0,00
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	15,38	29,24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	16,67	23,57
	2 or More	21	100,0	18	85,7	14,81	20,52
Cycle 2 Day 1	None	14	100,0	13	92,9	12,82	16,88
	1	1	50,0	1	100,0	33,33	-
	2 or More	18	85,7	16	88,9	18,75	27,13
Cycle 3 Day 1	None	14	100,0	13	92,9	17,95	22,01
	1	1	50,0	1	100,0	33,33	-
	2 or More	17	81,0	15	88,2	15,56	21,33

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	11	78,6	21,21	26,97
	1	1	50,0	1	100,0	33,33	-
	2 or More	17	81,0	15	88,2	11,11	16,27
Cycle 5 Day 1	None	14	100,0	14	100,0	28,57	31,64
	1	1	50,0	1	100,0	33,33	-
	2 or More	16	76,2	14	87,5	11,90	16,57
Cycle 6 Day 1	None	14	100,0	12	85,7	27,78	31,25
	1	1	50,0	1	100,0	33,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	13	81,3	17,95	25,88
Cycle 7 Day 1	None	14	100,0	12	85,7	25,00	25,13
	1	1	50,0	1	100,0	33,33	-
	2 or More	15	71,4	13	86,7	20,51	32,03
Cycle 8 Day 1	None	14	100,0	13	92,9	30,77	31,80
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	16,67	22,47
Cycle 9 Day 1	None	13	92,9	13	100,0	25,64	24,17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	33,33	-
	2 or More	11	52,4	11	100,0	24,24	30,15
Cycle 10 Day 1	None	13	92,9	12	92,3	25,00	25,13
	1	1	50,0	1	100,0	33,33	-
	2 or More	11	52,4	11	100,0	24,24	26,21
Cycle 11 Day 1	None	13	92,9	13	100,0	23,08	21,01
	1	1	50,0	1	100,0	33,33	-
	2 or More	10	47,6	10	100,0	13,33	23,31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	22,22	21,71
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	8	80,0	25,00	15,43
Cycle 13 Day 1	None	12	85,7	11	91,7	24,24	15,57
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	25,93	22,22
Cycle 14 Day 1	None	12	85,7	12	100,0	19,44	22,29
	1	1	50,0	1	100,0	33,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	18,52	24,22
Cycle 15 Day 1	None	12	85,7	12	100,0	13,89	22,29
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	8	88,9	29,17	27,82
Cycle 16 Day 1	None	11	78,6	8	72,7	16,67	17,82
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	16,67	18,26
Cycle 17 Day 1	None	10	71,4	7	70,0	23,81	25,20

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	7	33,3	6	85,7	11,11	17,21
Cycle 18 Day 1	None	8	57,1	4	50,0	16,67	19,25
	1	1	50,0	1	100,0	33,33	-
	2 or More	6	28,6	3	50,0	0,00	0,00
Cycle 19 Day 1	None	7	50,0	3	42,9	11,11	19,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	5	23,8	4	80,0	16,67	19,25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	8,33	16,67
	1	1	50,0	1	100,0	0,00	-
	2 or More	4	19,0	4	100,0	25,00	16,67
Cycle 21 Day 1	None	4	28,6	2	50,0	0,00	0,00
	2 or More	3	14,3	2	66,7	16,67	23,57
Cycle 22 Day 1	None	4	28,6	1	25,0	0,00	-
	2 or More	3	14,3	1	33,3	33,33	-
Cycle 23 Day 1	None	2	14,3	1	50,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	33,33	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	33,33	-
	1	2	100,0	1	50,0	0,00	-
	2 or More	9	42,9	3	33,3	22,22	38,49
Prior Treatment							

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	15,38	29,24
	Previously Treated	23	100,0	20	87,0	15,00	20,16
Cycle 2 Day 1	Naïve	14	100,0	13	92,9	12,82	16,88
	Previously Treated	19	82,6	17	89,5	19,61	26,51
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	17,95	22,01
	Previously Treated	18	78,3	16	88,9	16,67	21,08
Cycle 4 Day 1	Naïve	14	100,0	11	78,6	21,21	26,97
	Previously Treated	18	78,3	16	88,9	12,50	16,67

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	28,57	31,64
	Previously Treated	17	73,9	15	88,2	13,33	16,90
Cycle 6 Day 1	Naïve	14	100,0	12	85,7	27,78	31,25
	Previously Treated	17	73,9	14	82,4	19,05	25,20
Cycle 7 Day 1	Naïve	14	100,0	12	85,7	25,00	25,13
	Previously Treated	16	69,6	14	87,5	21,43	30,96
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	30,77	31,80
	Previously Treated	14	60,9	12	85,7	16,67	22,47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	25,64	24,17
	Previously Treated	12	52,2	12	100,0	25,00	28,87
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	25,00	25,13
	Previously Treated	12	52,2	12	100,0	25,00	25,13
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	23,08	21,01
	Previously Treated	11	47,8	11	100,0	15,15	22,92
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	22,22	21,71
	Previously Treated	11	47,8	9	81,8	22,22	16,67

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	24,24	15,57
	Previously Treated	10	43,5	10	100,0	23,33	22,50
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	19,44	22,29
	Previously Treated	10	43,5	10	100,0	20,00	23,31
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	13,89	22,29
	Previously Treated	10	43,5	9	90,0	25,93	27,78
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	16,67	17,82
	Previously Treated	10	43,5	7	70,0	14,29	17,82

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	23,81	25,20
	Previously Treated	8	34,8	7	87,5	9,52	16,27
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	16,67	19,25
	Previously Treated	7	30,4	4	57,1	8,33	16,67
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	11,11	19,25
	Previously Treated	6	26,1	5	83,3	13,33	18,26
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	8,33	16,67
	Previously Treated	5	21,7	5	100,0	20,00	18,26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	0,00	0,00
	Previously Treated	3	13,0	2	66,7	16,67	23,57
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	0,00	-
	Previously Treated	3	13,0	1	33,3	33,33	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	33,33	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	11	47,8	4	36,4	16,67	33,33
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	22,22	29,59
	Central	25	100,0	21	84,0	11,11	19,25
Cycle 2 Day 1	Local	11	91,7	11	100,0	21,21	16,82
	Central	22	88,0	19	86,4	14,04	25,62

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	10	90,9	10,00	22,50
	Central	21	84,0	19	90,5	21,05	19,91
Cycle 4 Day 1	Local	11	91,7	9	81,8	11,11	16,67
	Central	21	84,0	18	85,7	18,52	23,49
Cycle 5 Day 1	Local	11	91,7	10	90,9	16,67	17,57
	Central	20	80,0	19	95,0	22,81	29,51
Cycle 6 Day 1	Local	11	91,7	11	100,0	24,24	26,21
	Central	20	80,0	15	75,0	22,22	29,99

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	21,21	22,47
	Central	19	76,0	15	78,9	24,44	32,04
Cycle 8 Day 1	Local	10	83,3	10	100,0	20,00	23,31
	Central	18	72,0	15	83,3	26,67	31,37
Cycle 9 Day 1	Local	10	83,3	10	100,0	30,00	29,19
	Central	15	60,0	15	100,0	22,22	24,12
Cycle 10 Day 1	Local	10	83,3	9	90,0	18,52	24,22
	Central	15	60,0	15	100,0	28,89	24,77

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	22,22	16,67
	Central	15	60,0	15	100,0	17,78	24,77
Cycle 12 Day 1	Local	9	75,0	8	88,9	16,67	17,82
	Central	15	60,0	13	86,7	25,64	19,97
Cycle 13 Day 1	Local	8	66,7	8	100,0	29,17	21,36
	Central	14	56,0	13	92,9	20,51	16,88
Cycle 14 Day 1	Local	8	66,7	8	100,0	25,00	29,55
	Central	14	56,0	14	100,0	16,67	17,30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	20,83	30,54
	Central	14	56,0	13	92,9	17,95	22,01
Cycle 16 Day 1	Local	8	66,7	6	75,0	16,67	18,26
	Central	13	52,0	9	69,2	14,81	17,57
Cycle 17 Day 1	Local	8	66,7	5	62,5	33,33	23,57
	Central	10	40,0	9	90,0	7,41	14,70
Cycle 18 Day 1	Local	6	50,0	4	66,7	16,67	19,25
	Central	9	36,0	4	44,4	8,33	16,67

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	16,67	19,25
	Central	8	32,0	4	50,0	8,33	16,67
Cycle 20 Day 1	Local	5	41,7	5	100,0	13,33	18,26
	Central	4	16,0	4	100,0	16,67	19,25
Cycle 21 Day 1	Local	4	33,3	2	50,0	0,00	0,00
	Central	3	12,0	2	66,7	16,67	23,57
Cycle 22 Day 1	Local	4	33,3	1	25,0	0,00	-
	Central	3	12,0	1	33,3	33,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	0,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	33,33	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	33,33	47,14
	Central	8	32,0	3	37,5	11,11	19,25
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	31	88,6	15,05	24,10
	No	2	100,0	2	100,0	16,67	23,57
Cycle 2 Day 1	Yes	32	91,4	29	90,6	17,24	22,92
	No	1	50,0	1	100,0	0,00	-
Cycle 3 Day 1	Yes	31	88,6	28	90,3	17,86	21,24
	No	1	50,0	1	100,0	0,00	-
Cycle 4 Day 1	Yes	31	88,6	26	83,9	15,38	21,56
	No	1	50,0	1	100,0	33,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	20,24	26,20
	No	1	50,0	1	100,0	33,33	-
Cycle 6 Day 1	Yes	30	85,7	25	83,3	22,67	28,41
	No	1	50,0	1	100,0	33,33	-
Cycle 7 Day 1	Yes	29	82,9	25	86,2	22,67	28,41
	No	1	50,0	1	100,0	33,33	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	23,61	28,62
	No	1	50,0	1	100,0	33,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	25,00	26,47
	No	1	50,0	1	100,0	33,33	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	24,64	25,06
	No	1	50,0	1	100,0	33,33	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	18,84	22,08
	No	1	50,0	1	100,0	33,33	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	21,67	19,57
	No	1	50,0	1	100,0	33,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	23,33	19,04
	No	1	50,0	1	100,0	33,33	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	17,46	20,05
	No	1	50,0	1	100,0	66,67	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	16,67	22,94
	No	1	50,0	1	100,0	66,67	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	16,67	17,30
	No	1	50,0	1	100,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	12,82	16,88
	No	1	50,0	1	100,0	66,67	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	14,29	17,82
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	9,52	16,27
	No	1	50,0	1	100,0	33,33	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	16,67	17,82
	No	1	50,0	1	100,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	8,33	16,67
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	16,67	23,57
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	0,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	33,33	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	20,00	29,81

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	11,11	19,25
	No	33	100,0	30	90,9	15,56	24,34
Cycle 2 Day 1	Yes	2	50,0	1	50,0	0,00	-
	No	31	93,9	29	93,5	17,24	22,92
Cycle 3 Day 1	Yes	2	50,0	2	100,0	33,33	0,00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	27	90,0	16,05	21,42
Cycle 4 Day 1	Yes	2	50,0	2	100,0	50,00	23,57
	No	30	90,9	25	83,3	13,33	19,25
Cycle 5 Day 1	Yes	2	50,0	2	100,0	33,33	0,00
	No	29	87,9	27	93,1	19,75	26,57
Cycle 6 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	29	87,9	24	82,8	23,61	28,62
Cycle 7 Day 1	Yes	2	50,0	2	100,0	16,67	23,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	24	85,7	23,61	28,62
Cycle 8 Day 1	Yes	2	50,0	2	100,0	33,33	0,00
	No	26	78,8	23	88,5	23,19	29,19
Cycle 9 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	24	100,0	25,00	26,47
Cycle 10 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	23	95,8	24,64	25,06
Cycle 11 Day 1	Yes	1	25,0	1	100,0	33,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	18,84	22,08
Cycle 12 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	23	69,7	20	87,0	21,67	19,57
Cycle 13 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	20	95,2	23,33	19,04
Cycle 14 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	21	100,0	19,05	22,54
Cycle 15 Day 1	Yes	1	25,0	1	100,0	33,33	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	18,33	25,31
Cycle 16 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	20	60,6	14	70,0	14,29	17,12
Cycle 17 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	17	51,5	13	76,5	15,38	22,01
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	12,50	17,25
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	12,50	17,25
Cycle 20 Day 1	No	9	27,3	9	100,0	14,81	17,57
Cycle 21 Day 1	No	7	21,2	4	57,1	8,33	16,67
Cycle 22 Day 1	No	7	21,2	2	28,6	16,67	23,57
Cycle 23 Day 1	No	4	12,1	1	25,0	0,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	33,33	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	25,00	31,91

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	33	89,2	32,32	32,79
Cycle 2 Day 1	All	33	89,2	30	90,9	25,56	27,24
Cycle 3 Day 1	All	32	86,5	29	90,6	17,24	27,63
Cycle 4 Day 1	All	32	86,5	27	84,4	14,81	25,04
Cycle 5 Day 1	All	31	83,8	29	93,5	18,39	24,54
Cycle 6 Day 1	All	31	83,8	26	83,9	16,67	25,39
Cycle 7 Day 1	All	30	81,1	26	86,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	17,33	23,80
Cycle 9 Day 1	All	25	67,6	25	100,0	21,33	28,67
Cycle 10 Day 1	All	25	67,6	24	96,0	16,67	26,01
Cycle 11 Day 1	All	24	64,9	24	100,0	22,22	27,22
Cycle 12 Day 1	All	24	64,9	21	87,5	28,57	33,81
Cycle 13 Day 1	All	22	59,5	21	95,5	22,22	30,43
Cycle 14 Day 1	All	22	59,5	22	100,0	24,24	32,82
Cycle 15 Day 1	All	22	59,5	21	95,5	20,63	26,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	17,78	17,21
Cycle 17 Day 1	All	18	48,6	14	77,8	21,43	28,06
Cycle 18 Day 1	All	15	40,5	8	53,3	25,00	34,50
Cycle 19 Day 1	All	13	35,1	8	61,5	25,00	34,50
Cycle 20 Day 1	All	9	24,3	9	100,0	22,22	33,33
Cycle 21 Day 1	All	7	18,9	4	57,1	41,67	41,94
Cycle 22 Day 1	All	7	18,9	2	28,6	66,67	47,14
Cycle 23 Day 1	All	4	10,8	1	25,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	33,33	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	33,33	23,57
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	23,08	36,98
	Female	23	100,0	20	87,0	38,33	29,17
Cycle 2 Day 1	Male	13	92,9	13	100,0	28,21	29,96
	Female	20	87,0	17	85,0	23,53	25,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	11,11	16,41
	Female	20	87,0	17	85,0	21,57	33,21
Cycle 4 Day 1	Male	12	85,7	10	83,3	13,33	17,21
	Female	20	87,0	17	85,0	15,69	29,15
Cycle 5 Day 1	Male	12	85,7	11	91,7	21,21	22,47
	Female	19	82,6	18	94,7	16,67	26,20
Cycle 6 Day 1	Male	12	85,7	11	91,7	9,09	15,57
	Female	19	82,6	15	78,9	22,22	29,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	12,12	22,47
	Female	19	82,6	15	78,9	20,00	24,56
Cycle 8 Day 1	Male	10	71,4	9	90,0	18,52	17,57
	Female	18	78,3	16	88,9	16,67	27,22
Cycle 9 Day 1	Male	8	57,1	8	100,0	8,33	15,43
	Female	17	73,9	17	100,0	27,45	31,70
Cycle 10 Day 1	Male	8	57,1	8	100,0	8,33	15,43
	Female	17	73,9	16	94,1	20,83	29,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	12,50	24,80
	Female	16	69,6	16	100,0	27,08	27,81
Cycle 12 Day 1	Male	8	57,1	8	100,0	16,67	30,86
	Female	16	69,6	13	81,3	35,90	34,59
Cycle 13 Day 1	Male	8	57,1	8	100,0	12,50	17,25
	Female	14	60,9	13	92,9	28,21	35,61
Cycle 14 Day 1	Male	8	57,1	8	100,0	16,67	30,86
	Female	14	60,9	14	100,0	28,57	34,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	8,33	15,43
	Female	14	60,9	13	92,9	28,21	29,96
Cycle 16 Day 1	Male	8	57,1	5	62,5	13,33	18,26
	Female	13	56,5	10	76,9	20,00	17,21
Cycle 17 Day 1	Male	6	42,9	2	33,3	16,67	23,57
	Female	12	52,2	12	100,0	22,22	29,59
Cycle 18 Day 1	Male	3	21,4	2	66,7	16,67	23,57
	Female	12	52,2	6	50,0	27,78	38,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	16,67	23,57
	Female	11	47,8	6	54,5	27,78	38,97
Cycle 20 Day 1	Male	2	14,3	2	100,0	16,67	23,57
	Female	7	30,4	7	100,0	23,81	37,09
Cycle 21 Day 1	Male	1	7,1	1	100,0	33,33	-
	Female	6	26,1	3	50,0	44,44	50,92
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	66,67	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	0,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	33,33	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	16,67	23,57
	Female	7	30,4	3	42,9	44,44	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	26	89,7	34,62	33,31
	65-74	8	100,0	7	87,5	23,81	31,71
Cycle 2 Day 1	18-64	27	93,1	24	88,9	29,17	28,34
	65-74	6	75,0	6	100,0	11,11	17,21
Cycle 3 Day 1	18-64	26	89,7	24	92,3	19,44	29,35
	65-74	6	75,0	5	83,3	6,67	14,91
Cycle 4 Day 1	18-64	26	89,7	22	84,6	16,67	26,73
	65-74	6	75,0	5	83,3	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	18,84	26,26
	65-74	6	75,0	6	100,0	16,67	18,26
Cycle 6 Day 1	18-64	25	86,2	21	84,0	17,46	27,12
	65-74	6	75,0	5	83,3	13,33	18,26
Cycle 7 Day 1	18-64	25	86,2	22	88,0	18,18	24,62
	65-74	5	62,5	4	80,0	8,33	16,67
Cycle 8 Day 1	18-64	23	79,3	20	87,0	18,33	25,31
	65-74	5	62,5	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	18,33	25,31
	65-74	5	62,5	5	100,0	33,33	40,82
Cycle 10 Day 1	18-64	20	69,0	19	95,0	15,79	20,39
	65-74	5	62,5	5	100,0	20,00	44,72
Cycle 11 Day 1	18-64	19	65,5	19	100,0	21,05	22,80
	65-74	5	62,5	5	100,0	26,67	43,46
Cycle 12 Day 1	18-64	19	65,5	17	89,5	27,45	31,70
	65-74	5	62,5	4	80,0	33,33	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	20,83	26,87
	65-74	5	62,5	5	100,0	26,67	43,46
Cycle 14 Day 1	18-64	17	58,6	17	100,0	23,53	30,65
	65-74	5	62,5	5	100,0	26,67	43,46
Cycle 15 Day 1	18-64	17	58,6	16	94,1	20,83	26,87
	65-74	5	62,5	5	100,0	20,00	29,81
Cycle 16 Day 1	18-64	17	58,6	13	76,5	17,95	17,30
	65-74	4	50,0	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	22,22	29,59
	65-74	3	37,5	2	66,7	16,67	23,57
Cycle 18 Day 1	18-64	13	44,8	8	61,5	25,00	34,50
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	23,81	37,09
	65-74	2	25,0	1	50,0	33,33	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	20,83	35,36
	65-74	1	12,5	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	41,67	41,94
Cycle 22 Day 1	18-64	7	24,1	2	28,6	66,67	47,14
Cycle 23 Day 1	18-64	4	13,8	1	25,0	0,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	33,33	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	22,22	19,25
	65-74	6	75,0	2	33,3	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	16	80,0	29,17	34,16
	Other	17	100,0	17	100,0	35,29	32,21
Cycle 2 Day 1	White	19	95,0	16	84,2	25,00	28,54
	Other	14	82,4	14	100,0	26,19	26,73
Cycle 3 Day 1	White	18	90,0	15	83,3	11,11	27,22
	Other	14	82,4	14	100,0	23,81	27,51
Cycle 4 Day 1	White	18	90,0	14	77,8	11,90	21,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	17,95	29,24
Cycle 5 Day 1	White	18	90,0	17	94,4	15,69	26,66
	Other	13	76,5	12	92,3	22,22	21,71
Cycle 6 Day 1	White	18	90,0	13	72,2	12,82	21,68
	Other	13	76,5	13	100,0	20,51	28,99
Cycle 7 Day 1	White	17	85,0	14	82,4	19,05	25,20
	Other	13	76,5	12	92,3	13,89	22,29
Cycle 8 Day 1	White	17	85,0	14	82,4	23,81	27,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	9,09	15,57
Cycle 9 Day 1	White	16	80,0	16	100,0	22,92	31,55
	Other	9	52,9	9	100,0	18,52	24,22
Cycle 10 Day 1	White	16	80,0	15	93,8	22,22	29,99
	Other	9	52,9	9	100,0	7,41	14,70
Cycle 11 Day 1	White	16	80,0	16	100,0	27,08	30,35
	Other	8	47,1	8	100,0	12,50	17,25
Cycle 12 Day 1	White	16	80,0	13	81,3	38,46	38,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	12,50	17,25
Cycle 13 Day 1	White	14	70,0	13	92,9	25,64	36,40
	Other	8	47,1	8	100,0	16,67	17,82
Cycle 14 Day 1	White	14	70,0	14	100,0	30,95	38,04
	Other	8	47,1	8	100,0	12,50	17,25
Cycle 15 Day 1	White	14	70,0	13	92,9	25,64	30,89
	Other	8	47,1	8	100,0	12,50	17,25
Cycle 16 Day 1	White	14	70,0	9	64,3	18,52	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	16,67	18,26
Cycle 17 Day 1	White	13	65,0	10	76,9	23,33	31,62
	Other	5	29,4	4	80,0	16,67	19,25
Cycle 18 Day 1	White	11	55,0	4	36,4	33,33	47,14
	Other	4	23,5	4	100,0	16,67	19,25
Cycle 19 Day 1	White	9	45,0	5	55,6	33,33	40,82
	Other	4	23,5	3	75,0	11,11	19,25
Cycle 20 Day 1	White	5	25,0	5	100,0	33,33	40,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	8,33	16,67
Cycle 21 Day 1	White	3	15,0	2	66,7	66,67	47,14
	Other	4	23,5	2	50,0	16,67	23,57
Cycle 22 Day 1	White	3	15,0	1	33,3	100,00	-
	Other	4	23,5	1	25,0	33,33	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	0,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	33,33	33,33
	Other	9	52,9	2	22,2	33,33	0,00
Region							
Cycle 1 Day 1	America (AM)	12	100,0	11	91,7	24,24	26,21
	Europe (EU)	10	100,0	8	80,0	41,67	38,83
	Asia (AS)	15	100,0	14	93,3	33,33	34,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	10	90,9	26,67	21,08
	Europe (EU)	9	90,0	8	88,9	29,17	33,03
	Asia (AS)	13	86,7	12	92,3	22,22	29,59
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	18,18	31,14
	Europe (EU)	8	80,0	5	62,5	6,67	14,91
	Asia (AS)	13	86,7	13	100,0	20,51	28,99
Cycle 4 Day 1	America (AM)	11	91,7	10	90,9	16,67	23,57
	Europe (EU)	8	80,0	4	50,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	15,38	29,24
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	18,18	31,14
	Europe (EU)	8	80,0	7	87,5	19,05	26,23
	Asia (AS)	12	80,0	11	91,7	18,18	17,41
Cycle 6 Day 1	America (AM)	11	91,7	9	81,8	14,81	24,22
	Europe (EU)	8	80,0	6	75,0	11,11	17,21
	Asia (AS)	12	80,0	11	91,7	21,21	30,81
Cycle 7 Day 1	America (AM)	11	91,7	9	81,8	14,81	24,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	14,29	26,23
	Asia (AS)	11	73,3	10	90,9	20,00	23,31
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	26,67	30,63
	Europe (EU)	8	80,0	6	75,0	16,67	18,26
	Asia (AS)	9	60,0	9	100,0	7,41	14,70
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	21,21	26,97
	Europe (EU)	7	70,0	7	100,0	28,57	40,50
	Asia (AS)	7	46,7	7	100,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	16,67	23,57
	Europe (EU)	7	70,0	7	100,0	23,81	37,09
	Asia (AS)	7	46,7	7	100,0	9,52	16,27
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	21,21	22,47
	Europe (EU)	7	70,0	7	100,0	28,57	40,50
	Asia (AS)	6	40,0	6	100,0	16,67	18,26
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	26,67	34,43
	Europe (EU)	7	70,0	5	71,4	46,67	44,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	16,67	18,26
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	20,00	32,20
	Europe (EU)	6	60,0	5	83,3	40,00	36,51
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	26,67	34,43
	Europe (EU)	6	60,0	6	100,0	33,33	42,16
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	26,67	30,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	20,00	29,81
	Asia (AS)	6	40,0	6	100,0	11,11	17,21
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	14,29	17,82
	Europe (EU)	6	60,0	2	33,3	33,33	0,00
	Asia (AS)	6	40,0	6	100,0	16,67	18,26
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	33,33	36,51
	Europe (EU)	4	40,0	3	75,0	11,11	19,25
	Asia (AS)	5	33,3	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	33,33	40,82
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	11,11	19,25
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	33,33	47,14
	Europe (EU)	3	30,0	1	33,3	33,33	-
	Asia (AS)	4	26,7	3	75,0	11,11	19,25
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	26,67	43,46
	Europe (EU)	1	10,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	11,11	19,25
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	44,44	50,92
	Asia (AS)	3	20,0	1	33,3	33,33	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	66,67	47,14
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	0,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	22,22	19,25
	Europe (EU)	2	20,0	1	50,0	66,67	-
	Asia (AS)	7	46,7	1	14,3	33,33	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	11	73,3	12,12	16,82
	1	17	100,0	17	100,0	37,25	35,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	60,00	27,89
Cycle 2 Day 1	0	15	100,0	13	86,7	23,08	21,01
	1	15	88,2	14	93,3	23,81	27,51
	2	3	60,0	3	100,0	44,44	50,92
Cycle 3 Day 1	0	15	100,0	13	86,7	15,38	29,24
	1	14	82,4	13	92,9	15,38	17,30
	2	3	60,0	3	100,0	33,33	57,74
Cycle 4 Day 1	0	15	100,0	13	86,7	15,38	22,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	8,33	15,08
	2	3	60,0	2	66,7	50,00	70,71
Cycle 5 Day 1	0	15	100,0	15	100,0	17,78	27,79
	1	14	82,4	12	85,7	22,22	21,71
	2	2	40,0	2	100,0	0,00	0,00
Cycle 6 Day 1	0	15	100,0	14	93,3	14,29	17,12
	1	14	82,4	11	78,6	21,21	34,23
	2	2	40,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	16,67	25,32
	1	13	76,5	10	76,9	20,00	23,31
	2	2	40,0	2	100,0	0,00	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	25,64	27,74
	1	11	64,7	10	90,9	10,00	16,10
	2	2	40,0	2	100,0	0,00	0,00
Cycle 9 Day 1	0	14	93,3	14	100,0	26,19	32,50
	1	10	58,8	10	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	0,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	21,43	30,96
	1	10	58,8	9	90,0	11,11	16,67
	2	1	20,0	1	100,0	0,00	-
Cycle 11 Day 1	0	14	93,3	14	100,0	26,19	32,50
	1	9	52,9	9	100,0	18,52	17,57
	2	1	20,0	1	100,0	0,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	36,11	38,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	20,83	24,80
	2	1	20,0	1	100,0	0,00	-
Cycle 13 Day 1	0	14	93,3	13	92,9	28,21	35,61
	1	8	47,1	8	100,0	12,50	17,25
Cycle 14 Day 1	0	14	93,3	14	100,0	30,95	38,04
	1	8	47,1	8	100,0	12,50	17,25
Cycle 15 Day 1	0	14	93,3	14	100,0	23,81	30,46
	1	8	47,1	7	87,5	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	16,67	17,82
	1	8	47,1	7	87,5	19,05	17,82
Cycle 17 Day 1	0	12	80,0	8	66,7	29,17	33,03
	1	6	35,3	6	100,0	11,11	17,21
Cycle 18 Day 1	0	9	60,0	4	44,4	41,67	41,94
	1	6	35,3	4	66,7	8,33	16,67
Cycle 19 Day 1	0	8	53,3	4	50,0	41,67	41,94
	1	5	29,4	4	80,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	33,33	40,82
	1	4	23,5	4	100,0	8,33	16,67
Cycle 21 Day 1	0	3	20,0	3	100,0	44,44	50,92
	1	4	23,5	1	25,0	33,33	-
Cycle 22 Day 1	0	3	20,0	2	66,7	66,67	47,14
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	0,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	33,33	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	33,33	33,33
	1	7	41,2	2	28,6	33,33	0,00
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	25,64	27,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	33,33	47,14
	2 or More	21	100,0	18	85,7	37,04	35,95
Cycle 2 Day 1	None	14	100,0	13	92,9	23,08	21,01
	1	1	50,0	1	100,0	33,33	-
	2 or More	18	85,7	16	88,9	27,08	32,70
Cycle 3 Day 1	None	14	100,0	13	92,9	10,26	16,01
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	24,44	34,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	11	78,6	9,09	15,57
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	20,00	30,34
Cycle 5 Day 1	None	14	100,0	14	100,0	14,29	21,54
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	23,81	27,51
Cycle 6 Day 1	None	14	100,0	12	85,7	8,33	15,08
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	13	81,3	25,64	30,89
Cycle 7 Day 1	None	14	100,0	12	85,7	5,56	12,97
	1	1	50,0	1	100,0	0,00	-
	2 or More	15	71,4	13	86,7	28,21	26,69
Cycle 8 Day 1	None	14	100,0	13	92,9	15,38	17,30
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	19,44	30,01
Cycle 9 Day 1	None	13	92,9	13	100,0	12,82	21,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	33,33	33,33
Cycle 10 Day 1	None	13	92,9	12	92,3	11,11	16,41
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	24,24	33,63
Cycle 11 Day 1	None	13	92,9	13	100,0	12,82	16,88
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	10	100,0	36,67	33,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	16,67	22,47
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	8	80,0	50,00	39,84
Cycle 13 Day 1	None	12	85,7	11	91,7	15,15	17,41
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	33,33	40,82
Cycle 14 Day 1	None	12	85,7	12	100,0	16,67	22,47
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	37,04	42,31
Cycle 15 Day 1	None	12	85,7	12	100,0	16,67	17,41
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	8	88,9	29,17	37,53
Cycle 16 Day 1	None	11	78,6	8	72,7	20,83	17,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	16,67	18,26
Cycle 17 Day 1	None	10	71,4	7	70,0	19,05	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	7	33,3	6	85,7	27,78	38,97
Cycle 18 Day 1	None	8	57,1	4	50,0	16,67	19,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	6	28,6	3	50,0	44,44	50,92
Cycle 19 Day 1	None	7	50,0	3	42,9	11,11	19,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	5	23,8	4	80,0	41,67	41,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	8,33	16,67
	1	1	50,0	1	100,0	0,00	-
	2 or More	4	19,0	4	100,0	41,67	41,94
Cycle 21 Day 1	None	4	28,6	2	50,0	16,67	23,57
	2 or More	3	14,3	2	66,7	66,67	47,14
Cycle 22 Day 1	None	4	28,6	1	25,0	33,33	-
	2 or More	3	14,3	1	33,3	100,00	-
Cycle 23 Day 1	None	2	14,3	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	33,33	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	33,33	-
	1	2	100,0	1	50,0	0,00	-
	2 or More	9	42,9	3	33,3	44,44	19,25
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	25,64	27,74
	Previously Treated	23	100,0	20	87,0	36,67	35,71
Cycle 2 Day 1	Naïve	14	100,0	13	92,9	23,08	21,01
	Previously Treated	19	82,6	17	89,5	27,45	31,70
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	10,26	16,01
	Previously Treated	18	78,3	16	88,9	22,92	33,82
Cycle 4 Day 1	Naïve	14	100,0	11	78,6	9,09	15,57
	Previously Treated	18	78,3	16	88,9	18,75	29,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	14,29	21,54
	Previously Treated	17	73,9	15	88,2	22,22	27,22
Cycle 6 Day 1	Naïve	14	100,0	12	85,7	8,33	15,08
	Previously Treated	17	73,9	14	82,4	23,81	30,46
Cycle 7 Day 1	Naïve	14	100,0	12	85,7	5,56	12,97
	Previously Treated	16	69,6	14	87,5	26,19	26,73
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	15,38	17,30
	Previously Treated	14	60,9	12	85,7	19,44	30,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	12,82	21,68
	Previously Treated	12	52,2	12	100,0	30,56	33,21
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	11,11	16,41
	Previously Treated	12	52,2	12	100,0	22,22	32,82
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	12,82	16,88
	Previously Treated	11	47,8	11	100,0	33,33	33,33
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	16,67	22,47
	Previously Treated	11	47,8	9	81,8	44,44	40,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	15,15	17,41
	Previously Treated	10	43,5	10	100,0	30,00	39,91
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	16,67	22,47
	Previously Treated	10	43,5	10	100,0	33,33	41,57
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	16,67	17,41
	Previously Treated	10	43,5	9	90,0	25,93	36,43
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	20,83	17,25
	Previously Treated	10	43,5	7	70,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	19,05	17,82
	Previously Treated	8	34,8	7	87,5	23,81	37,09
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	16,67	19,25
	Previously Treated	7	30,4	4	57,1	33,33	47,14
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	11,11	19,25
	Previously Treated	6	26,1	5	83,3	33,33	40,82
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	8,33	16,67
	Previously Treated	5	21,7	5	100,0	33,33	40,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	16,67	23,57
	Previously Treated	3	13,0	2	66,7	66,67	47,14
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	33,33	-
	Previously Treated	3	13,0	1	33,3	100,00	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	33,33	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	33,33	-
	Previously Treated	11	47,8	4	36,4	33,33	27,22
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	19,44	26,43
	Central	25	100,0	21	84,0	39,68	34,35
Cycle 2 Day 1	Local	11	91,7	11	100,0	21,21	22,47
	Central	22	88,0	19	86,4	28,07	29,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	10	90,9	10,00	16,10
	Central	21	84,0	19	90,5	21,05	31,84
Cycle 4 Day 1	Local	11	91,7	9	81,8	7,41	14,70
	Central	21	84,0	18	85,7	18,52	28,52
Cycle 5 Day 1	Local	11	91,7	10	90,9	13,33	17,21
	Central	20	80,0	19	95,0	21,05	27,69
Cycle 6 Day 1	Local	11	91,7	11	100,0	15,15	22,92
	Central	20	80,0	15	75,0	17,78	27,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	15,15	17,41
	Central	19	76,0	15	78,9	17,78	27,79
Cycle 8 Day 1	Local	10	83,3	10	100,0	13,33	17,21
	Central	18	72,0	15	83,3	20,00	27,60
Cycle 9 Day 1	Local	10	83,3	10	100,0	23,33	35,31
	Central	15	60,0	15	100,0	20,00	24,56
Cycle 10 Day 1	Local	10	83,3	9	90,0	22,22	33,33
	Central	15	60,0	15	100,0	13,33	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	22,22	33,33
	Central	15	60,0	15	100,0	22,22	24,12
Cycle 12 Day 1	Local	9	75,0	8	88,9	25,00	38,83
	Central	15	60,0	13	86,7	30,77	31,80
Cycle 13 Day 1	Local	8	66,7	8	100,0	20,83	35,36
	Central	14	56,0	13	92,9	23,08	28,50
Cycle 14 Day 1	Local	8	66,7	8	100,0	25,00	38,83
	Central	14	56,0	14	100,0	23,81	30,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	20,83	24,80
	Central	14	56,0	13	92,9	20,51	28,99
Cycle 16 Day 1	Local	8	66,7	6	75,0	16,67	18,26
	Central	13	52,0	9	69,2	18,52	17,57
Cycle 17 Day 1	Local	8	66,7	5	62,5	20,00	18,26
	Central	10	40,0	9	90,0	22,22	33,33
Cycle 18 Day 1	Local	6	50,0	4	66,7	16,67	19,25
	Central	9	36,0	4	44,4	33,33	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	16,67	19,25
	Central	8	32,0	4	50,0	33,33	47,14
Cycle 20 Day 1	Local	5	41,7	5	100,0	13,33	18,26
	Central	4	16,0	4	100,0	33,33	47,14
Cycle 21 Day 1	Local	4	33,3	2	50,0	16,67	23,57
	Central	3	12,0	2	66,7	66,67	47,14
Cycle 22 Day 1	Local	4	33,3	1	25,0	33,33	-
	Central	3	12,0	1	33,3	100,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	0,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	33,33	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	50,00	23,57
	Central	8	32,0	3	37,5	22,22	19,25
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	31	88,6	32,26	32,75
	No	2	100,0	2	100,0	33,33	47,14
Cycle 2 Day 1	Yes	32	91,4	29	90,6	26,44	27,28
	No	1	50,0	1	100,0	0,00	-
Cycle 3 Day 1	Yes	31	88,6	28	90,3	17,86	27,94
	No	1	50,0	1	100,0	0,00	-
Cycle 4 Day 1	Yes	31	88,6	26	83,9	15,38	25,35
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	17,86	24,82
	No	1	50,0	1	100,0	33,33	-
Cycle 6 Day 1	Yes	30	85,7	25	83,3	17,33	25,68
	No	1	50,0	1	100,0	0,00	-
Cycle 7 Day 1	Yes	29	82,9	25	86,2	17,33	23,80
	No	1	50,0	1	100,0	0,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	18,06	24,04
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	22,22	28,94
	No	1	50,0	1	100,0	0,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	17,39	26,34
	No	1	50,0	1	100,0	0,00	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	23,19	27,40
	No	1	50,0	1	100,0	0,00	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	30,00	34,03
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	23,33	30,78
	No	1	50,0	1	100,0	0,00	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	25,40	33,17
	No	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	21,67	27,09
	No	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	19,05	17,12
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	23,08	28,50
	No	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	28,57	35,63
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	28,57	35,63
	No	1	50,0	1	100,0	0,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	25,00	34,50
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	41,67	41,94
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	66,67	47,14
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	0,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	33,33	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	55,56	38,49
	No	33	100,0	30	90,9	30,00	31,98
Cycle 2 Day 1	Yes	2	50,0	1	50,0	33,33	-
	No	31	93,9	29	93,5	25,29	27,68
Cycle 3 Day 1	Yes	2	50,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	27	90,0	17,28	28,30
Cycle 4 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	30	90,9	25	83,3	14,67	25,60
Cycle 5 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	29	87,9	27	93,1	18,52	25,04
Cycle 6 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	29	87,9	24	82,8	16,67	26,01
Cycle 7 Day 1	Yes	2	50,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	24	85,7	16,67	24,08
Cycle 8 Day 1	Yes	2	50,0	2	100,0	16,67	23,57
	No	26	78,8	23	88,5	17,39	24,35
Cycle 9 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	24	100,0	20,83	29,18
Cycle 10 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	24	72,7	23	95,8	15,94	26,34
Cycle 11 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	21,74	27,72
Cycle 12 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	23	69,7	20	87,0	28,33	34,67
Cycle 13 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	20	95,2	21,67	31,11
Cycle 14 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	21	63,6	21	100,0	23,81	33,57
Cycle 15 Day 1	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	20,00	27,36
Cycle 16 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	20	60,6	14	70,0	16,67	17,30
Cycle 17 Day 1	Yes	1	25,0	1	100,0	33,33	-
	No	17	51,5	13	76,5	20,51	28,99
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	25,00	34,50
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	25,00	34,50
Cycle 20 Day 1	No	9	27,3	9	100,0	22,22	33,33
Cycle 21 Day 1	No	7	21,2	4	57,1	41,67	41,94
Cycle 22 Day 1	No	7	21,2	2	28,6	66,67	47,14
Cycle 23 Day 1	No	4	12,1	1	25,0	0,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	33,33	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13PO_SG.xls
07SEP2019 20:41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	37	100,0	33	89,2	4,04	11,05
Cycle 2 Day 1	All	33	89,2	30	90,9	5,56	12,63
Cycle 3 Day 1	All	32	86,5	29	90,6	3,45	10,33
Cycle 4 Day 1	All	32	86,5	27	84,4	0,00	0,00
Cycle 5 Day 1	All	31	83,8	29	93,5	3,45	10,33
Cycle 6 Day 1	All	31	83,8	26	83,9	5,13	12,26
Cycle 7 Day 1	All	30	81,1	26	86,7	1,28	6,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	28	75,7	25	89,3	4,00	11,06
Cycle 9 Day 1	All	25	67,6	25	100,0	2,67	9,23
Cycle 10 Day 1	All	25	67,6	24	96,0	6,94	16,97
Cycle 11 Day 1	All	24	64,9	24	100,0	2,78	9,41
Cycle 12 Day 1	All	24	64,9	21	87,5	1,59	7,27
Cycle 13 Day 1	All	22	59,5	21	95,5	3,17	10,03
Cycle 14 Day 1	All	22	59,5	22	100,0	3,03	9,81
Cycle 15 Day 1	All	22	59,5	21	95,5	4,76	11,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	21	56,8	15	71,4	2,22	8,61
Cycle 17 Day 1	All	18	48,6	14	77,8	2,38	8,91
Cycle 18 Day 1	All	15	40,5	8	53,3	0,00	0,00
Cycle 19 Day 1	All	13	35,1	8	61,5	0,00	0,00
Cycle 20 Day 1	All	9	24,3	9	100,0	0,00	0,00
Cycle 21 Day 1	All	7	18,9	4	57,1	0,00	0,00
Cycle 22 Day 1	All	7	18,9	2	28,6	16,67	23,57
Cycle 23 Day 1	All	4	10,8	1	25,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	1	2,7	1	100,0	0,00	-
Cycle 25 Day 1	All	1	2,7	0	0,0	-	-
End Of Treatment	All	13	35,1	5	38,5	6,67	14,91
Sex							
Cycle 1 Day 1	Male	14	100,0	13	92,9	5,13	12,52
	Female	23	100,0	20	87,0	3,33	10,26
Cycle 2 Day 1	Male	13	92,9	13	100,0	2,56	9,25
	Female	20	87,0	17	85,0	7,84	14,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Male	12	85,7	12	100,0	0,00	0,00
	Female	20	87,0	17	85,0	5,88	13,10
Cycle 4 Day 1	Male	12	85,7	10	83,3	0,00	0,00
	Female	20	87,0	17	85,0	0,00	0,00
Cycle 5 Day 1	Male	12	85,7	11	91,7	0,00	0,00
	Female	19	82,6	18	94,7	5,56	12,78
Cycle 6 Day 1	Male	12	85,7	11	91,7	3,03	10,05
	Female	19	82,6	15	78,9	6,67	13,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Male	11	78,6	11	100,0	0,00	0,00
	Female	19	82,6	15	78,9	2,22	8,61
Cycle 8 Day 1	Male	10	71,4	9	90,0	3,70	11,11
	Female	18	78,3	16	88,9	4,17	11,39
Cycle 9 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	17	73,9	17	100,0	3,92	11,07
Cycle 10 Day 1	Male	8	57,1	8	100,0	12,50	24,80
	Female	17	73,9	16	94,1	4,17	11,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	16	69,6	16	100,0	2,08	8,33
Cycle 12 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	16	69,6	13	81,3	2,56	9,25
Cycle 13 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	14	60,9	13	92,9	5,13	12,52
Cycle 14 Day 1	Male	8	57,1	8	100,0	0,00	0,00
	Female	14	60,9	14	100,0	4,76	12,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Male	8	57,1	8	100,0	4,17	11,79
	Female	14	60,9	13	92,9	5,13	12,52
Cycle 16 Day 1	Male	8	57,1	5	62,5	0,00	0,00
	Female	13	56,5	10	76,9	3,33	10,54
Cycle 17 Day 1	Male	6	42,9	2	33,3	0,00	0,00
	Female	12	52,2	12	100,0	2,78	9,62
Cycle 18 Day 1	Male	3	21,4	2	66,7	0,00	0,00
	Female	12	52,2	6	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	11	47,8	6	54,5	0,00	0,00
Cycle 20 Day 1	Male	2	14,3	2	100,0	0,00	0,00
	Female	7	30,4	7	100,0	0,00	0,00
Cycle 21 Day 1	Male	1	7,1	1	100,0	0,00	-
	Female	6	26,1	3	50,0	0,00	0,00
Cycle 22 Day 1	Male	1	7,1	0	0,0	-	-
	Female	6	26,1	2	33,3	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Male	1	7,1	0	0,0	-	-
	Female	3	13,0	1	33,3	0,00	-
Cycle 24 Day 1	Female	1	4,3	1	100,0	0,00	-
Cycle 25 Day 1	Female	1	4,3	0	0,0	-	-
End Of Treatment	Male	6	42,9	2	33,3	0,00	0,00
	Female	7	30,4	3	42,9	11,11	19,25
Age							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	18-64	29	100,0	26	89,7	2,56	9,06
	65-74	8	100,0	7	87,5	9,52	16,27
Cycle 2 Day 1	18-64	27	93,1	24	88,9	4,17	11,26
	65-74	6	75,0	6	100,0	11,11	17,21
Cycle 3 Day 1	18-64	26	89,7	24	92,3	2,78	9,41
	65-74	6	75,0	5	83,3	6,67	14,91
Cycle 4 Day 1	18-64	26	89,7	22	84,6	0,00	0,00
	65-74	6	75,0	5	83,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	18-64	25	86,2	23	92,0	2,90	9,60
	65-74	6	75,0	6	100,0	5,56	13,61
Cycle 6 Day 1	18-64	25	86,2	21	84,0	4,76	11,95
	65-74	6	75,0	5	83,3	6,67	14,91
Cycle 7 Day 1	18-64	25	86,2	22	88,0	0,00	0,00
	65-74	5	62,5	4	80,0	8,33	16,67
Cycle 8 Day 1	18-64	23	79,3	20	87,0	3,33	10,26
	65-74	5	62,5	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	18-64	20	69,0	20	100,0	1,67	7,45
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 10 Day 1	18-64	20	69,0	19	95,0	7,02	17,84
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 11 Day 1	18-64	19	65,5	19	100,0	3,51	10,51
	65-74	5	62,5	5	100,0	0,00	0,00
Cycle 12 Day 1	18-64	19	65,5	17	89,5	0,00	0,00
	65-74	5	62,5	4	80,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	18-64	17	58,6	16	94,1	2,08	8,33
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 14 Day 1	18-64	17	58,6	17	100,0	1,96	8,08
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 15 Day 1	18-64	17	58,6	16	94,1	4,17	11,39
	65-74	5	62,5	5	100,0	6,67	14,91
Cycle 16 Day 1	18-64	17	58,6	13	76,5	2,56	9,25
	65-74	4	50,0	2	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	18-64	15	51,7	12	80,0	2,78	9,62
	65-74	3	37,5	2	66,7	0,00	0,00
Cycle 18 Day 1	18-64	13	44,8	8	61,5	0,00	0,00
	65-74	2	25,0	0	0,0	-	-
Cycle 19 Day 1	18-64	11	37,9	7	63,6	0,00	0,00
	65-74	2	25,0	1	50,0	0,00	-
Cycle 20 Day 1	18-64	8	27,6	8	100,0	0,00	0,00
	65-74	1	12,5	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	18-64	7	24,1	4	57,1	0,00	0,00
Cycle 22 Day 1	18-64	7	24,1	2	28,6	16,67	23,57
Cycle 23 Day 1	18-64	4	13,8	1	25,0	0,00	-
Cycle 24 Day 1	18-64	1	3,4	1	100,0	0,00	-
Cycle 25 Day 1	18-64	1	3,4	0	0,0	-	-
End Of Treatment	18-64	7	24,1	3	42,9	0,00	0,00
	65-74	6	75,0	2	33,3	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Race							
Cycle 1 Day 1	White	20	100,0	16	80,0	2,08	8,33
	Other	17	100,0	17	100,0	5,88	13,10
Cycle 2 Day 1	White	19	95,0	16	84,2	6,25	13,44
	Other	14	82,4	14	100,0	4,76	12,10
Cycle 3 Day 1	White	18	90,0	15	83,3	4,44	11,73
	Other	14	82,4	14	100,0	2,38	8,91
Cycle 4 Day 1	White	18	90,0	14	77,8	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	14	82,4	13	92,9	0,00	0,00
Cycle 5 Day 1	White	18	90,0	17	94,4	5,88	13,10
	Other	13	76,5	12	92,3	0,00	0,00
Cycle 6 Day 1	White	18	90,0	13	72,2	7,69	14,62
	Other	13	76,5	13	100,0	2,56	9,25
Cycle 7 Day 1	White	17	85,0	14	82,4	2,38	8,91
	Other	13	76,5	12	92,3	0,00	0,00
Cycle 8 Day 1	White	17	85,0	14	82,4	4,76	12,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	11	64,7	11	100,0	3,03	10,05
Cycle 9 Day 1	White	16	80,0	16	100,0	4,17	11,39
	Other	9	52,9	9	100,0	0,00	0,00
Cycle 10 Day 1	White	16	80,0	15	93,8	11,11	20,57
	Other	9	52,9	9	100,0	0,00	0,00
Cycle 11 Day 1	White	16	80,0	16	100,0	4,17	11,39
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 12 Day 1	White	16	80,0	13	81,3	2,56	9,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 13 Day 1	White	14	70,0	13	92,9	5,13	12,52
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 14 Day 1	White	14	70,0	14	100,0	4,76	12,10
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 15 Day 1	White	14	70,0	13	92,9	7,69	14,62
	Other	8	47,1	8	100,0	0,00	0,00
Cycle 16 Day 1	White	14	70,0	9	64,3	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	7	41,2	6	85,7	0,00	0,00
Cycle 17 Day 1	White	13	65,0	10	76,9	3,33	10,54
	Other	5	29,4	4	80,0	0,00	0,00
Cycle 18 Day 1	White	11	55,0	4	36,4	0,00	0,00
	Other	4	23,5	4	100,0	0,00	0,00
Cycle 19 Day 1	White	9	45,0	5	55,6	0,00	0,00
	Other	4	23,5	3	75,0	0,00	0,00
Cycle 20 Day 1	White	5	25,0	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Other	4	23,5	4	100,0	0,00	0,00
Cycle 21 Day 1	White	3	15,0	2	66,7	0,00	0,00
	Other	4	23,5	2	50,0	0,00	0,00
Cycle 22 Day 1	White	3	15,0	1	33,3	33,33	-
	Other	4	23,5	1	25,0	0,00	-
Cycle 23 Day 1	White	2	10,0	0	0,0	-	-
	Other	2	11,8	1	50,0	0,00	-
Cycle 24 Day 1	Other	1	5,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	Other	1	5,9	0	0,0	-	-
End Of Treatment	White	4	20,0	3	75,0	11,11	19,25
	Other	9	52,9	2	22,2	0,00	0,00
Region							
Cycle 1 Day 1	America (AM)	12	100,0	11	91,7	3,03	10,05
	Europe (EU)	10	100,0	8	80,0	8,33	15,43
	Asia (AS)	15	100,0	14	93,3	2,38	8,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	11	91,7	10	90,9	6,67	14,05
	Europe (EU)	9	90,0	8	88,9	12,50	17,25
	Asia (AS)	13	86,7	12	92,3	0,00	0,00
Cycle 3 Day 1	America (AM)	11	91,7	11	100,0	3,03	10,05
	Europe (EU)	8	80,0	5	62,5	6,67	14,91
	Asia (AS)	13	86,7	13	100,0	2,56	9,25
Cycle 4 Day 1	America (AM)	11	91,7	10	90,9	0,00	0,00
	Europe (EU)	8	80,0	4	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	13	86,7	13	100,0	0,00	0,00
Cycle 5 Day 1	America (AM)	11	91,7	11	100,0	0,00	0,00
	Europe (EU)	8	80,0	7	87,5	9,52	16,27
	Asia (AS)	12	80,0	11	91,7	3,03	10,05
Cycle 6 Day 1	America (AM)	11	91,7	9	81,8	0,00	0,00
	Europe (EU)	8	80,0	6	75,0	11,11	17,21
	Asia (AS)	12	80,0	11	91,7	6,06	13,48
Cycle 7 Day 1	America (AM)	11	91,7	9	81,8	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	8	80,0	7	87,5	4,76	12,60
	Asia (AS)	11	73,3	10	90,9	0,00	0,00
Cycle 8 Day 1	America (AM)	11	91,7	10	90,9	0,00	0,00
	Europe (EU)	8	80,0	6	75,0	16,67	18,26
	Asia (AS)	9	60,0	9	100,0	0,00	0,00
Cycle 9 Day 1	America (AM)	11	91,7	11	100,0	0,00	0,00
	Europe (EU)	7	70,0	7	100,0	4,76	12,60
	Asia (AS)	7	46,7	7	100,0	4,76	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	11	91,7	10	90,9	6,67	21,08
	Europe (EU)	7	70,0	7	100,0	9,52	16,27
	Asia (AS)	7	46,7	7	100,0	4,76	12,60
Cycle 11 Day 1	America (AM)	11	91,7	11	100,0	0,00	0,00
	Europe (EU)	7	70,0	7	100,0	4,76	12,60
	Asia (AS)	6	40,0	6	100,0	5,56	13,61
Cycle 12 Day 1	America (AM)	11	91,7	10	90,9	0,00	0,00
	Europe (EU)	7	70,0	5	71,4	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	6	40,0	6	100,0	0,00	0,00
Cycle 13 Day 1	America (AM)	10	83,3	10	100,0	0,00	0,00
	Europe (EU)	6	60,0	5	83,3	6,67	14,91
	Asia (AS)	6	40,0	6	100,0	5,56	13,61
Cycle 14 Day 1	America (AM)	10	83,3	10	100,0	0,00	0,00
	Europe (EU)	6	60,0	6	100,0	5,56	13,61
	Asia (AS)	6	40,0	6	100,0	5,56	13,61
Cycle 15 Day 1	America (AM)	10	83,3	10	100,0	3,33	10,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	6	60,0	5	83,3	6,67	14,91
	Asia (AS)	6	40,0	6	100,0	5,56	13,61
Cycle 16 Day 1	America (AM)	9	75,0	7	77,8	0,00	0,00
	Europe (EU)	6	60,0	2	33,3	0,00	0,00
	Asia (AS)	6	40,0	6	100,0	5,56	13,61
Cycle 17 Day 1	America (AM)	9	75,0	6	66,7	0,00	0,00
	Europe (EU)	4	40,0	3	75,0	0,00	0,00
	Asia (AS)	5	33,3	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	7	58,3	5	71,4	0,00	0,00
	Europe (EU)	3	30,0	0	0,0	-	-
	Asia (AS)	5	33,3	3	60,0	0,00	0,00
Cycle 19 Day 1	America (AM)	6	50,0	4	66,7	0,00	0,00
	Europe (EU)	3	30,0	1	33,3	0,00	-
	Asia (AS)	4	26,7	3	75,0	0,00	0,00
Cycle 20 Day 1	America (AM)	5	41,7	5	100,0	0,00	0,00
	Europe (EU)	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	3	20,0	3	100,0	0,00	0,00
Cycle 21 Day 1	America (AM)	4	33,3	3	75,0	0,00	0,00
	Asia (AS)	3	20,0	1	33,3	0,00	-
Cycle 22 Day 1	America (AM)	4	33,3	2	50,0	16,67	23,57
	Asia (AS)	3	20,0	0	0,0	-	-
Cycle 23 Day 1	America (AM)	3	25,0	1	33,3	0,00	-
	Asia (AS)	1	6,7	0	0,0	-	-
Cycle 24 Day 1	America (AM)	1	8,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 25 Day 1	America (AM)	1	8,3	0	0,0	-	-
End Of Treatment	America (AM)	4	33,3	3	75,0	0,00	0,00
	Europe (EU)	2	20,0	1	50,0	33,33	-
	Asia (AS)	7	46,7	1	14,3	0,00	-
ECOG Performance Status							
Cycle 1 Day 1	0	15	100,0	11	73,3	3,03	10,05
	1	17	100,0	17	100,0	3,92	11,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	5	100,0	5	100,0	6,67	14,91
Cycle 2 Day 1	0	15	100,0	13	86,7	10,26	16,01
	1	15	88,2	14	93,3	0,00	0,00
	2	3	60,0	3	100,0	11,11	19,25
Cycle 3 Day 1	0	15	100,0	13	86,7	2,56	9,25
	1	14	82,4	13	92,9	5,13	12,52
	2	3	60,0	3	100,0	0,00	0,00
Cycle 4 Day 1	0	15	100,0	13	86,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	14	82,4	12	85,7	0,00	0,00
	2	3	60,0	2	66,7	0,00	0,00
Cycle 5 Day 1	0	15	100,0	15	100,0	2,22	8,61
	1	14	82,4	12	85,7	2,78	9,62
	2	2	40,0	2	100,0	16,67	23,57
Cycle 6 Day 1	0	15	100,0	14	93,3	4,76	12,10
	1	14	82,4	11	78,6	6,06	13,48
	2	2	40,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	15	100,0	14	93,3	2,38	8,91
	1	13	76,5	10	76,9	0,00	0,00
	2	2	40,0	2	100,0	0,00	0,00
Cycle 8 Day 1	0	15	100,0	13	86,7	2,56	9,25
	1	11	64,7	10	90,9	3,33	10,54
	2	2	40,0	2	100,0	16,67	23,57
Cycle 9 Day 1	0	14	93,3	14	100,0	2,38	8,91
	1	10	58,8	10	100,0	3,33	10,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	20,0	1	100,0	0,00	-
Cycle 10 Day 1	0	14	93,3	14	100,0	9,52	20,37
	1	10	58,8	9	90,0	3,70	11,11
	2	1	20,0	1	100,0	0,00	-
Cycle 11 Day 1	0	14	93,3	14	100,0	2,38	8,91
	1	9	52,9	9	100,0	3,70	11,11
	2	1	20,0	1	100,0	0,00	-
Cycle 12 Day 1	0	14	93,3	12	85,7	2,78	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	9	52,9	8	88,9	0,00	0,00
	2	1	20,0	1	100,0	0,00	-
Cycle 13 Day 1	0	14	93,3	13	92,9	2,56	9,25
	1	8	47,1	8	100,0	4,17	11,79
Cycle 14 Day 1	0	14	93,3	14	100,0	2,38	8,91
	1	8	47,1	8	100,0	4,17	11,79
Cycle 15 Day 1	0	14	93,3	14	100,0	4,76	12,10
	1	8	47,1	7	87,5	4,76	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	0	13	86,7	8	61,5	0,00	0,00
	1	8	47,1	7	87,5	4,76	12,60
Cycle 17 Day 1	0	12	80,0	8	66,7	0,00	0,00
	1	6	35,3	6	100,0	5,56	13,61
Cycle 18 Day 1	0	9	60,0	4	44,4	0,00	0,00
	1	6	35,3	4	66,7	0,00	0,00
Cycle 19 Day 1	0	8	53,3	4	50,0	0,00	0,00
	1	5	29,4	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	0	5	33,3	5	100,0	0,00	0,00
	1	4	23,5	4	100,0	0,00	0,00
Cycle 21 Day 1	0	3	20,0	3	100,0	0,00	0,00
	1	4	23,5	1	25,0	0,00	-
Cycle 22 Day 1	0	3	20,0	2	66,7	16,67	23,57
	1	4	23,5	0	0,0	-	-
Cycle 23 Day 1	0	3	20,0	1	33,3	0,00	-
	1	1	5,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	0	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	1	6,7	0	0,0	-	-
End Of Treatment	0	4	26,7	3	75,0	11,11	19,25
	1	7	41,2	2	28,6	0,00	0,00
	2	2	40,0	0	0,0	-	-
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	14	100,0	13	92,9	5,13	12,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	100,0	2	100,0	0,00	0,00
	2 or More	21	100,0	18	85,7	3,70	10,78
Cycle 2 Day 1	None	14	100,0	13	92,9	10,26	16,01
	1	1	50,0	1	100,0	0,00	-
	2 or More	18	85,7	16	88,9	2,08	8,33
Cycle 3 Day 1	None	14	100,0	13	92,9	2,56	9,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	4,44	11,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	None	14	100,0	11	78,6	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	17	81,0	15	88,2	0,00	0,00
Cycle 5 Day 1	None	14	100,0	14	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	16	76,2	14	87,5	7,14	14,19
Cycle 6 Day 1	None	14	100,0	12	85,7	0,00	0,00
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	16	76,2	13	81,3	10,26	16,01
Cycle 7 Day 1	None	14	100,0	12	85,7	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	15	71,4	13	86,7	2,56	9,25
Cycle 8 Day 1	None	14	100,0	13	92,9	2,56	9,25
	1	1	50,0	0	0,0	-	-
	2 or More	13	61,9	12	92,3	5,56	12,97
Cycle 9 Day 1	None	13	92,9	13	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	6,06	13,48
Cycle 10 Day 1	None	13	92,9	12	92,3	5,56	19,25
	1	1	50,0	1	100,0	0,00	-
	2 or More	11	52,4	11	100,0	9,09	15,57
Cycle 11 Day 1	None	13	92,9	13	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	10	100,0	6,67	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	None	13	92,9	12	92,3	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	10	47,6	8	80,0	4,17	11,79
Cycle 13 Day 1	None	12	85,7	11	91,7	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	9	100,0	7,41	14,70
Cycle 14 Day 1	None	12	85,7	12	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	9	42,9	9	100,0	7,41	14,70
Cycle 15 Day 1	None	12	85,7	12	100,0	2,78	9,62
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	8	88,9	8,33	15,43
Cycle 16 Day 1	None	11	78,6	8	72,7	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	9	42,9	6	66,7	5,56	13,61
Cycle 17 Day 1	None	10	71,4	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	50,0	1	100,0	0,00	-
	2 or More	7	33,3	6	85,7	5,56	13,61
Cycle 18 Day 1	None	8	57,1	4	50,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	6	28,6	3	50,0	0,00	0,00
Cycle 19 Day 1	None	7	50,0	3	42,9	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	5	23,8	4	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	None	4	28,6	4	100,0	0,00	0,00
	1	1	50,0	1	100,0	0,00	-
	2 or More	4	19,0	4	100,0	0,00	0,00
Cycle 21 Day 1	None	4	28,6	2	50,0	0,00	0,00
	2 or More	3	14,3	2	66,7	0,00	0,00
Cycle 22 Day 1	None	4	28,6	1	25,0	0,00	-
	2 or More	3	14,3	1	33,3	33,33	-
Cycle 23 Day 1	None	2	14,3	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	2	9,5	0	0,0	-	-
Cycle 24 Day 1	None	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	None	1	7,1	0	0,0	-	-
End Of Treatment	None	2	14,3	1	50,0	0,00	-
	1	2	100,0	1	50,0	0,00	-
	2 or More	9	42,9	3	33,3	11,11	19,25
Prior Treatment							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Naïve	14	100,0	13	92,9	5,13	12,52
	Previously Treated	23	100,0	20	87,0	3,33	10,26
Cycle 2 Day 1	Naïve	14	100,0	13	92,9	10,26	16,01
	Previously Treated	19	82,6	17	89,5	1,96	8,08
Cycle 3 Day 1	Naïve	14	100,0	13	92,9	2,56	9,25
	Previously Treated	18	78,3	16	88,9	4,17	11,39
Cycle 4 Day 1	Naïve	14	100,0	11	78,6	0,00	0,00
	Previously Treated	18	78,3	16	88,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Naïve	14	100,0	14	100,0	0,00	0,00
	Previously Treated	17	73,9	15	88,2	6,67	13,80
Cycle 6 Day 1	Naïve	14	100,0	12	85,7	0,00	0,00
	Previously Treated	17	73,9	14	82,4	9,52	15,63
Cycle 7 Day 1	Naïve	14	100,0	12	85,7	0,00	0,00
	Previously Treated	16	69,6	14	87,5	2,38	8,91
Cycle 8 Day 1	Naïve	14	100,0	13	92,9	2,56	9,25
	Previously Treated	14	60,9	12	85,7	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Naïve	13	92,9	13	100,0	0,00	0,00
	Previously Treated	12	52,2	12	100,0	5,56	12,97
Cycle 10 Day 1	Naïve	13	92,9	12	92,3	5,56	19,25
	Previously Treated	12	52,2	12	100,0	8,33	15,08
Cycle 11 Day 1	Naïve	13	92,9	13	100,0	0,00	0,00
	Previously Treated	11	47,8	11	100,0	6,06	13,48
Cycle 12 Day 1	Naïve	13	92,9	12	92,3	0,00	0,00
	Previously Treated	11	47,8	9	81,8	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Naïve	12	85,7	11	91,7	0,00	0,00
	Previously Treated	10	43,5	10	100,0	6,67	14,05
Cycle 14 Day 1	Naïve	12	85,7	12	100,0	0,00	0,00
	Previously Treated	10	43,5	10	100,0	6,67	14,05
Cycle 15 Day 1	Naïve	12	85,7	12	100,0	2,78	9,62
	Previously Treated	10	43,5	9	90,0	7,41	14,70
Cycle 16 Day 1	Naïve	11	78,6	8	72,7	0,00	0,00
	Previously Treated	10	43,5	7	70,0	4,76	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Naïve	10	71,4	7	70,0	0,00	0,00
	Previously Treated	8	34,8	7	87,5	4,76	12,60
Cycle 18 Day 1	Naïve	8	57,1	4	50,0	0,00	0,00
	Previously Treated	7	30,4	4	57,1	0,00	0,00
Cycle 19 Day 1	Naïve	7	50,0	3	42,9	0,00	0,00
	Previously Treated	6	26,1	5	83,3	0,00	0,00
Cycle 20 Day 1	Naïve	4	28,6	4	100,0	0,00	0,00
	Previously Treated	5	21,7	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Naïve	4	28,6	2	50,0	0,00	0,00
	Previously Treated	3	13,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Naïve	4	28,6	1	25,0	0,00	-
	Previously Treated	3	13,0	1	33,3	33,33	-
Cycle 23 Day 1	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	2	8,7	0	0,0	-	-
Cycle 24 Day 1	Naïve	1	7,1	1	100,0	0,00	-
Cycle 25 Day 1	Naïve	1	7,1	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
End Of Treatment	Naïve	2	14,3	1	50,0	0,00	-
	Previously Treated	11	47,8	4	36,4	8,33	16,67
Molecular Testing Results							
Cycle 1 Day 1	Local	12	100,0	12	100,0	2,78	9,62
	Central	25	100,0	21	84,0	4,76	11,95
Cycle 2 Day 1	Local	11	91,7	11	100,0	9,09	15,57
	Central	22	88,0	19	86,4	3,51	10,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 3 Day 1	Local	11	91,7	10	90,9	0,00	0,00
	Central	21	84,0	19	90,5	5,26	12,49
Cycle 4 Day 1	Local	11	91,7	9	81,8	0,00	0,00
	Central	21	84,0	18	85,7	0,00	0,00
Cycle 5 Day 1	Local	11	91,7	10	90,9	3,33	10,54
	Central	20	80,0	19	95,0	3,51	10,51
Cycle 6 Day 1	Local	11	91,7	11	100,0	3,03	10,05
	Central	20	80,0	15	75,0	6,67	13,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	Local	11	91,7	11	100,0	3,03	10,05
	Central	19	76,0	15	78,9	0,00	0,00
Cycle 8 Day 1	Local	10	83,3	10	100,0	3,33	10,54
	Central	18	72,0	15	83,3	4,44	11,73
Cycle 9 Day 1	Local	10	83,3	10	100,0	3,33	10,54
	Central	15	60,0	15	100,0	2,22	8,61
Cycle 10 Day 1	Local	10	83,3	9	90,0	11,11	23,57
	Central	15	60,0	15	100,0	4,44	11,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 11 Day 1	Local	9	75,0	9	100,0	0,00	0,00
	Central	15	60,0	15	100,0	4,44	11,73
Cycle 12 Day 1	Local	9	75,0	8	88,9	4,17	11,79
	Central	15	60,0	13	86,7	0,00	0,00
Cycle 13 Day 1	Local	8	66,7	8	100,0	4,17	11,79
	Central	14	56,0	13	92,9	2,56	9,25
Cycle 14 Day 1	Local	8	66,7	8	100,0	4,17	11,79
	Central	14	56,0	14	100,0	2,38	8,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	Local	8	66,7	8	100,0	8,33	15,43
	Central	14	56,0	13	92,9	2,56	9,25
Cycle 16 Day 1	Local	8	66,7	6	75,0	0,00	0,00
	Central	13	52,0	9	69,2	3,70	11,11
Cycle 17 Day 1	Local	8	66,7	5	62,5	0,00	0,00
	Central	10	40,0	9	90,0	3,70	11,11
Cycle 18 Day 1	Local	6	50,0	4	66,7	0,00	0,00
	Central	9	36,0	4	44,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 19 Day 1	Local	5	41,7	4	80,0	0,00	0,00
	Central	8	32,0	4	50,0	0,00	0,00
Cycle 20 Day 1	Local	5	41,7	5	100,0	0,00	0,00
	Central	4	16,0	4	100,0	0,00	0,00
Cycle 21 Day 1	Local	4	33,3	2	50,0	0,00	0,00
	Central	3	12,0	2	66,7	0,00	0,00
Cycle 22 Day 1	Local	4	33,3	1	25,0	0,00	-
	Central	3	12,0	1	33,3	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	Local	2	16,7	1	50,0	0,00	-
	Central	2	8,0	0	0,0	-	-
Cycle 24 Day 1	Local	1	8,3	1	100,0	0,00	-
Cycle 25 Day 1	Local	1	8,3	0	0,0	-	-
End Of Treatment	Local	5	41,7	2	40,0	16,67	23,57
	Central	8	32,0	3	37,5	0,00	0,00
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 1 Day 1	Yes	35	100,0	31	88,6	4,30	11,36
	No	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	Yes	32	91,4	29	90,6	5,75	12,81
	No	1	50,0	1	100,0	0,00	-
Cycle 3 Day 1	Yes	31	88,6	28	90,3	3,57	10,50
	No	1	50,0	1	100,0	0,00	-
Cycle 4 Day 1	Yes	31	88,6	26	83,9	0,00	0,00
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 5 Day 1	Yes	30	85,7	28	93,3	3,57	10,50
	No	1	50,0	1	100,0	0,00	-
Cycle 6 Day 1	Yes	30	85,7	25	83,3	5,33	12,47
	No	1	50,0	1	100,0	0,00	-
Cycle 7 Day 1	Yes	29	82,9	25	86,2	1,33	6,67
	No	1	50,0	1	100,0	0,00	-
Cycle 8 Day 1	Yes	27	77,1	24	88,9	4,17	11,26
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 9 Day 1	Yes	24	68,6	24	100,0	2,78	9,41
	No	1	50,0	1	100,0	0,00	-
Cycle 10 Day 1	Yes	24	68,6	23	95,8	7,25	17,28
	No	1	50,0	1	100,0	0,00	-
Cycle 11 Day 1	Yes	23	65,7	23	100,0	2,90	9,60
	No	1	50,0	1	100,0	0,00	-
Cycle 12 Day 1	Yes	23	65,7	20	87,0	1,67	7,45
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 13 Day 1	Yes	21	60,0	20	95,2	3,33	10,26
	No	1	50,0	1	100,0	0,00	-
Cycle 14 Day 1	Yes	21	60,0	21	100,0	3,17	10,03
	No	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	Yes	21	60,0	20	95,2	5,00	12,21
	No	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	Yes	20	57,1	14	70,0	2,38	8,91
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 17 Day 1	Yes	17	48,6	13	76,5	2,56	9,25
	No	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	Yes	14	40,0	7	50,0	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	Yes	12	34,3	7	58,3	0,00	0,00
	No	1	50,0	1	100,0	0,00	-
Cycle 20 Day 1	Yes	8	22,9	8	100,0	0,00	0,00
	No	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 21 Day 1	Yes	6	17,1	4	66,7	0,00	0,00
	No	1	50,0	0	0,0	-	-
Cycle 22 Day 1	Yes	6	17,1	2	33,3	16,67	23,57
	No	1	50,0	0	0,0	-	-
Cycle 23 Day 1	Yes	4	11,4	1	25,0	0,00	-
Cycle 24 Day 1	Yes	1	2,9	1	100,0	0,00	-
Cycle 25 Day 1	Yes	1	2,9	0	0,0	-	-
End Of Treatment	Yes	12	34,3	5	41,7	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	50,0	0	0,0	-	-
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	4	100,0	3	75,0	11,11	19,25
	No	33	100,0	30	90,9	3,33	10,17
Cycle 2 Day 1	Yes	2	50,0	1	50,0	0,00	-
	No	31	93,9	29	93,5	5,75	12,81
Cycle 3 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	30	90,9	27	90,0	3,70	10,68
Cycle 4 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	30	90,9	25	83,3	0,00	0,00
Cycle 5 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	27	93,1	3,70	10,68
Cycle 6 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	29	87,9	24	82,8	5,56	12,69
Cycle 7 Day 1	Yes	2	50,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	28	84,8	24	85,7	1,39	6,80
Cycle 8 Day 1	Yes	2	50,0	2	100,0	0,00	0,00
	No	26	78,8	23	88,5	4,35	11,48
Cycle 9 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	24	100,0	2,78	9,41
Cycle 10 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	24	72,7	23	95,8	7,25	17,28
Cycle 11 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	23	69,7	23	100,0	2,90	9,60
Cycle 12 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	23	69,7	20	87,0	1,67	7,45
Cycle 13 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	20	95,2	3,33	10,26
Cycle 14 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	21	63,6	21	100,0	3,17	10,03
Cycle 15 Day 1	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	21	63,6	20	95,2	5,00	12,21
Cycle 16 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	20	60,6	14	70,0	2,38	8,91
Cycle 17 Day 1	Yes	1	25,0	1	100,0	0,00	-
	No	17	51,5	13	76,5	2,56	9,25
Cycle 18 Day 1	Yes	1	25,0	0	0,0	-	-
	No	14	42,4	8	57,1	0,00	0,00
Cycle 19 Day 1	Yes	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	8	66,7	0,00	0,00
Cycle 20 Day 1	No	9	27,3	9	100,0	0,00	0,00
Cycle 21 Day 1	No	7	21,2	4	57,1	0,00	0,00
Cycle 22 Day 1	No	7	21,2	2	28,6	16,67	23,57
Cycle 23 Day 1	No	4	12,1	1	25,0	0,00	-
Cycle 24 Day 1	No	1	3,0	1	100,0	0,00	-
Cycle 25 Day 1	No	1	3,0	0	0,0	-	-
End Of Treatment	Yes	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	12	36,4	4	33,3	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 31MAY2018

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_mean_NDA_REE_LC13SM_SG.xls
07SEP2019 20:45

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	77	98,7	38,53	26,53
Cycle 2 Day 1	All	72	92,3	65	90,3	24,62	21,47
Cycle 3 Day 1	All	68	87,2	63	92,6	14,81	17,74
Cycle 4 Day 1	All	67	85,9	61	91,0	18,03	21,58
Cycle 5 Day 1	All	65	83,3	63	96,9	21,16	20,13
Cycle 6 Day 1	All	63	80,8	57	90,5	19,30	19,87
Cycle 7 Day 1	All	60	76,9	56	93,3	19,05	24,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	56	71,8	52	92,9	19,87	21,14
Cycle 9 Day 1	All	51	65,4	51	100,0	16,34	20,41
Cycle 10 Day 1	All	51	65,4	50	98,0	21,33	21,04
Cycle 11 Day 1	All	50	64,1	50	100,0	18,67	19,24
Cycle 12 Day 1	All	49	62,8	45	91,8	17,04	18,29
Cycle 13 Day 1	All	46	59,0	45	97,8	16,30	20,87
Cycle 14 Day 1	All	45	57,7	44	97,8	19,70	19,45
Cycle 15 Day 1	All	44	56,4	44	100,0	16,67	18,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	41	52,6	39	95,1	17,95	21,42
Cycle 17 Day 1	All	39	50,0	39	100,0	13,68	16,61
Cycle 18 Day 1	All	38	48,7	35	92,1	12,38	18,23
Cycle 19 Day 1	All	36	46,2	33	91,7	14,14	18,69
Cycle 20 Day 1	All	36	46,2	32	88,9	14,58	16,80
Cycle 21 Day 1	All	29	37,2	26	89,7	11,54	16,17
Cycle 22 Day 1	All	29	37,2	25	86,2	8,00	14,53
Cycle 23 Day 1	All	21	26,9	18	85,7	7,41	14,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	25,6	18	90,0	11,11	25,57
Cycle 25 Day 1	All	15	19,2	13	86,7	10,26	16,01
Cycle 26 Day 1	All	14	17,9	12	85,7	13,89	22,29
Cycle 27 Day 1	All	11	14,1	8	72,7	12,50	17,25
Cycle 28 Day 1	All	10	12,8	9	90,0	29,63	35,14
Cycle 29 Day 1	All	9	11,5	7	77,8	19,05	17,82
Cycle 30 Day 1	All	7	9,0	5	71,4	13,33	18,26
Cycle 31 Day 1	All	7	9,0	5	71,4	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	7,7	5	83,3	20,00	18,26
Cycle 33 Day 1	All	2	2,6	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	38,10	26,78
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	42,53	26,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	49	100,0	48	98,0	36,11	26,48
Cycle 2 Day 1	Male	27	93,1	25	92,6	28,00	26,67
	Female	45	91,8	40	88,9	22,50	17,52
Cycle 3 Day 1	Male	25	86,2	24	96,0	15,28	16,97
	Female	43	87,8	39	90,7	14,53	18,41
Cycle 4 Day 1	Male	25	86,2	23	92,0	21,74	23,80
	Female	42	85,7	38	90,5	15,79	20,12
Cycle 5 Day 1	Male	25	86,2	24	96,0	25,00	22,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	40	81,6	39	97,5	18,80	18,41
Cycle 6 Day 1	Male	25	86,2	23	92,0	20,29	19,43
	Female	38	77,6	34	89,5	18,63	20,42
Cycle 7 Day 1	Male	23	79,3	23	100,0	21,74	25,84
	Female	37	75,5	33	89,2	17,17	23,75
Cycle 8 Day 1	Male	21	72,4	19	90,5	22,81	24,98
	Female	35	71,4	33	94,3	18,18	18,80
Cycle 9 Day 1	Male	18	62,1	18	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	16,16	18,86
Cycle 10 Day 1	Male	18	62,1	18	100,0	24,07	25,06
	Female	33	67,3	32	97,0	19,79	18,66
Cycle 11 Day 1	Male	18	62,1	18	100,0	20,37	20,26
	Female	32	65,3	32	100,0	17,71	18,90
Cycle 12 Day 1	Male	17	58,6	17	100,0	19,61	20,61
	Female	32	65,3	28	87,5	15,48	16,93
Cycle 13 Day 1	Male	17	58,6	17	100,0	17,65	20,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	29	59,2	28	96,6	15,48	21,24
Cycle 14 Day 1	Male	17	58,6	16	94,1	20,83	16,67
	Female	28	57,1	28	100,0	19,05	21,14
Cycle 15 Day 1	Male	16	55,2	16	100,0	20,83	20,64
	Female	28	57,1	28	100,0	14,29	16,80
Cycle 16 Day 1	Male	14	48,3	14	100,0	21,43	24,83
	Female	27	55,1	25	92,6	16,00	19,53
Cycle 17 Day 1	Male	12	41,4	12	100,0	13,89	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	27	100,0	13,58	16,69
Cycle 18 Day 1	Male	11	37,9	10	90,9	16,67	23,57
	Female	27	55,1	25	92,6	10,67	15,87
Cycle 19 Day 1	Male	10	34,5	10	100,0	13,33	17,21
	Female	26	53,1	23	88,5	14,49	19,66
Cycle 20 Day 1	Male	10	34,5	9	90,0	14,81	17,57
	Female	26	53,1	23	88,5	14,49	16,90
Cycle 21 Day 1	Male	8	27,6	8	100,0	12,50	17,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	42,9	18	85,7	11,11	16,17
Cycle 22 Day 1	Male	8	27,6	6	75,0	5,56	13,61
	Female	21	42,9	19	90,5	8,77	15,08
Cycle 23 Day 1	Male	5	17,2	4	80,0	0,00	0,00
	Female	16	32,7	14	87,5	9,52	15,63
Cycle 24 Day 1	Male	5	17,2	4	80,0	8,33	16,67
	Female	15	30,6	14	93,3	11,90	28,06
Cycle 25 Day 1	Male	3	10,3	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	24,5	11	91,7	12,12	16,82
Cycle 26 Day 1	Male	3	10,3	2	66,7	16,67	23,57
	Female	11	22,4	10	90,9	13,33	23,31
Cycle 27 Day 1	Male	3	10,3	2	66,7	16,67	23,57
	Female	8	16,3	6	75,0	11,11	17,21
Cycle 28 Day 1	Male	2	6,9	2	100,0	16,67	23,57
	Female	8	16,3	7	87,5	33,33	38,49
Cycle 29 Day 1	Male	1	3,4	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	16,3	6	75,0	16,67	18,26
Cycle 30 Day 1	Male	1	3,4	1	100,0	33,33	-
	Female	6	12,2	4	66,7	8,33	16,67
Cycle 31 Day 1	Male	1	3,4	1	100,0	66,67	-
	Female	6	12,2	4	66,7	25,00	16,67
Cycle 32 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	5	10,2	4	80,0	25,00	16,67
Cycle 33 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	2,0	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	44,44	27,22
	Female	21	42,9	13	61,9	30,77	25,32
Age							
Cycle 1 Day 1	18-64	62	100,0	61	98,4	38,25	25,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	42,86	30,46
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 2 Day 1	18-64	59	95,2	52	88,1	25,00	21,77
	65-74	11	78,6	11	100,0	21,21	22,47
	>=75	2	100,0	2	100,0	33,33	0,00
Cycle 3 Day 1	18-64	56	90,3	52	92,9	14,10	16,63
	65-74	10	71,4	9	90,0	18,52	24,22
	>=75	2	100,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	55	88,7	50	90,9	18,67	22,50
	65-74	10	71,4	9	90,0	18,52	17,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 5 Day 1	18-64	53	85,5	52	98,1	19,87	18,97
	65-74	10	71,4	10	100,0	30,00	24,60
	>=75	2	100,0	1	50,0	0,00	-
Cycle 6 Day 1	18-64	51	82,3	46	90,2	19,57	20,58
	65-74	10	71,4	9	90,0	22,22	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 7 Day 1	18-64	49	79,0	46	93,9	18,84	25,00
	65-74	9	64,3	8	88,9	25,00	23,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 8 Day 1	18-64	45	72,6	41	91,1	19,51	21,05
	65-74	9	64,3	9	100,0	22,22	23,57
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 9 Day 1	18-64	40	64,5	40	100,0	17,50	21,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	14,81	17,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 10 Day 1	18-64	40	64,5	39	97,5	22,22	22,08
	65-74	9	64,3	9	100,0	22,22	16,67
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 11 Day 1	18-64	39	62,9	39	100,0	19,66	19,82
	65-74	9	64,3	9	100,0	18,52	17,57
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	38	61,3	35	92,1	17,14	18,74
	65-74	9	64,3	8	88,9	20,83	17,25
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 13 Day 1	18-64	35	56,5	34	97,1	13,73	18,56
	65-74	9	64,3	9	100,0	29,63	26,06
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 14 Day 1	18-64	35	56,5	35	100,0	16,19	16,90
	65-74	9	64,3	8	88,9	33,33	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	33,33	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	15,24	18,69
	65-74	8	57,1	8	100,0	25,00	15,43
	>=75	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	15,63	20,71
	65-74	7	50,0	6	85,7	22,22	17,21
	>=75	1	50,0	1	100,0	66,67	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	12,50	16,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	6	42,9	6	100,0	22,22	17,21
	>=75	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	11,49	18,42
	65-74	6	42,9	5	83,3	20,00	18,26
	>=75	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	14,29	19,09
	65-74	5	35,7	4	80,0	16,67	19,25
	>=75	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	14,10	16,79
	65-74	5	35,7	5	100,0	20,00	18,26
	>=75	1	50,0	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	9,52	15,43
	65-74	4	28,6	4	100,0	25,00	16,67
	>=75	1	50,0	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	6,67	13,68
	65-74	4	28,6	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	8,33	14,91
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	10,42	26,44
	65-74	2	14,3	2	100,0	16,67	23,57
Cycle 25 Day 1	18-64	14	22,6	12	85,7	11,11	16,41
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	13,89	22,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	12,50	17,25
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	29,63	35,14
	65-74	1	7,1	0	0,0	-	-
Cycle 29 Day 1	18-64	8	12,9	7	87,5	19,05	17,82
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	33,33	23,57
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	16,67	19,25
	65-74	1	7,1	1	100,0	33,33	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	0,00	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	40,00	27,78
	65-74	10	71,4	7	70,0	38,10	23,00
	>=75	2	100,0	1	50,0	0,00	-
Race							
Cycle 1 Day 1	White	35	100,0	34	97,1	43,14	30,18
	Other	43	100,0	43	100,0	34,88	22,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	33	94,3	28	84,8	28,57	23,51
	Other	39	90,7	37	94,9	21,62	19,59
Cycle 3 Day 1	White	31	88,6	27	87,1	14,81	16,88
	Other	37	86,0	36	97,3	14,81	18,59
Cycle 4 Day 1	White	31	88,6	26	83,9	16,67	17,00
	Other	36	83,7	35	97,2	19,05	24,64
Cycle 5 Day 1	White	31	88,6	29	93,5	22,99	22,01
	Other	34	79,1	34	100,0	19,61	18,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	30	85,7	25	83,3	20,00	19,25
	Other	33	76,7	32	97,0	18,75	20,63
Cycle 7 Day 1	White	29	82,9	26	89,7	23,08	27,92
	Other	31	72,1	30	96,8	15,56	20,96
Cycle 8 Day 1	White	28	80,0	24	85,7	19,44	19,45
	Other	28	65,1	28	100,0	20,24	22,84
Cycle 9 Day 1	White	26	74,3	26	100,0	17,95	21,56
	Other	25	58,1	25	100,0	14,67	19,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	22,67	23,01
	Other	25	58,1	25	100,0	20,00	19,25
Cycle 11 Day 1	White	26	74,3	26	100,0	17,95	19,39
	Other	24	55,8	24	100,0	19,44	19,45
Cycle 12 Day 1	White	26	74,3	22	84,6	19,70	19,68
	Other	23	53,5	23	100,0	14,49	16,90
Cycle 13 Day 1	White	24	68,6	23	95,8	15,94	19,77
	Other	22	51,2	22	100,0	16,67	22,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	24	68,6	24	100,0	18,06	19,61
	Other	21	48,8	20	95,2	21,67	19,57
Cycle 15 Day 1	White	24	68,6	24	100,0	16,67	19,66
	Other	20	46,5	20	100,0	16,67	17,10
Cycle 16 Day 1	White	22	62,9	20	90,9	20,00	25,13
	Other	19	44,2	19	100,0	15,79	17,10
Cycle 17 Day 1	White	22	62,9	22	100,0	16,67	17,06
	Other	17	39,5	17	100,0	9,80	15,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	21	60,0	18	85,7	9,26	19,15
	Other	17	39,5	17	100,0	15,69	17,15
Cycle 19 Day 1	White	20	57,1	20	100,0	18,33	20,16
	Other	16	37,2	13	81,3	7,69	14,62
Cycle 20 Day 1	White	20	57,1	17	85,0	15,69	17,15
	Other	16	37,2	15	93,8	13,33	16,90
Cycle 21 Day 1	White	16	45,7	14	87,5	14,29	17,12
	Other	13	30,2	12	92,3	8,33	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	45,7	13	81,3	10,26	16,01
	Other	13	30,2	12	92,3	5,56	12,97
Cycle 23 Day 1	White	12	34,3	10	83,3	13,33	17,21
	Other	9	20,9	8	88,9	0,00	0,00
Cycle 24 Day 1	White	11	31,4	10	90,9	16,67	32,39
	Other	9	20,9	8	88,9	4,17	11,79
Cycle 25 Day 1	White	10	28,6	8	80,0	12,50	17,25
	Other	5	11,6	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	28,6	8	80,0	16,67	25,20
	Other	4	9,3	4	100,0	8,33	16,67
Cycle 27 Day 1	White	8	22,9	5	62,5	13,33	18,26
	Other	3	7,0	3	100,0	11,11	19,25
Cycle 28 Day 1	White	7	20,0	6	85,7	16,67	18,26
	Other	3	7,0	3	100,0	55,56	50,92
Cycle 29 Day 1	White	6	17,1	4	66,7	33,33	0,00
	Other	3	7,0	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	11,4	2	50,0	33,33	0,00
	Other	3	7,0	3	100,0	0,00	0,00
Cycle 31 Day 1	White	4	11,4	2	50,0	50,00	23,57
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 32 Day 1	White	4	11,4	3	75,0	22,22	19,25
	Other	2	4,7	2	100,0	16,67	23,57
Cycle 33 Day 1	White	2	5,7	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-
End Of Treatment	White	15	42,9	12	80,0	47,22	22,29
	Other	24	55,8	16	66,7	31,25	28,46
Region							
Cycle 1 Day 1	America (AM)	22	100,0	21	95,5	44,44	21,94
	Europe (EU)	17	100,0	17	100,0	47,06	35,47
	Asia (AS)	39	100,0	39	100,0	31,62	22,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	27,45	17,62
	Europe (EU)	16	94,1	13	81,3	35,90	28,74
	Asia (AS)	36	92,3	35	97,2	19,05	18,59
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	15,79	17,10
	Europe (EU)	15	88,2	11	73,3	21,21	16,82
	Asia (AS)	33	84,6	33	100,0	12,12	18,29
Cycle 4 Day 1	America (AM)	20	90,9	19	95,0	19,30	16,91
	Europe (EU)	15	88,2	11	73,3	15,15	17,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	32	82,1	31	96,9	18,28	25,59
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	20,00	19,94
	Europe (EU)	15	88,2	13	86,7	23,08	21,01
	Asia (AS)	30	76,9	30	100,0	21,11	20,50
Cycle 6 Day 1	America (AM)	20	90,9	18	90,0	24,07	19,15
	Europe (EU)	14	82,4	12	85,7	19,44	17,16
	Asia (AS)	29	74,4	27	93,1	16,05	21,42
Cycle 7 Day 1	America (AM)	19	86,4	17	89,5	29,41	30,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	14	82,4	13	92,9	17,95	22,01
	Asia (AS)	27	69,2	26	96,3	12,82	19,04
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	27,45	24,25
	Europe (EU)	14	82,4	11	78,6	18,18	17,41
	Asia (AS)	24	61,5	24	100,0	15,28	19,61
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	16,67	23,57
	Europe (EU)	12	70,6	12	100,0	19,44	17,16
	Asia (AS)	21	53,8	21	100,0	14,29	19,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	17,65	20,81
	Europe (EU)	12	70,6	12	100,0	30,56	26,43
	Asia (AS)	21	53,8	21	100,0	19,05	16,90
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	18,52	23,49
	Europe (EU)	12	70,6	12	100,0	22,22	16,41
	Asia (AS)	20	51,3	20	100,0	16,67	17,10
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	21,57	20,21
	Europe (EU)	12	70,6	9	75,0	25,93	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	19	48,7	19	100,0	8,77	15,08
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	13,73	20,61
	Europe (EU)	11	64,7	10	90,9	23,33	22,50
	Asia (AS)	18	46,2	18	100,0	14,81	20,52
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	23,53	15,66
	Europe (EU)	11	64,7	11	100,0	18,18	22,92
	Asia (AS)	17	43,6	16	94,1	16,67	21,08
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	17,65	20,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	64,7	11	100,0	15,15	17,41
	Asia (AS)	16	41,0	16	100,0	16,67	17,21
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	14,29	21,54
	Europe (EU)	11	64,7	9	81,8	25,93	22,22
	Asia (AS)	16	41,0	16	100,0	16,67	21,08
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	14,29	17,12
	Europe (EU)	10	58,8	10	100,0	13,33	17,21
	Asia (AS)	15	38,5	15	100,0	13,33	16,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	16,67	21,68
	Europe (EU)	9	52,9	6	66,7	5,56	13,61
	Asia (AS)	15	38,5	15	100,0	11,11	16,27
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	15,38	17,30
	Europe (EU)	9	52,9	9	100,0	22,22	23,57
	Asia (AS)	14	35,9	11	78,6	6,06	13,48
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	17,95	17,30
	Europe (EU)	9	52,9	6	66,7	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	12,82	16,88
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	16,67	17,57
	Europe (EU)	7	41,2	6	85,7	16,67	18,26
	Asia (AS)	11	28,2	10	90,9	3,33	10,54
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	13,33	17,21
	Europe (EU)	7	41,2	5	71,4	13,33	18,26
	Asia (AS)	11	28,2	10	90,9	0,00	0,00
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	14,81	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	29,4	3	60,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	0,00	0,00
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	12,50	17,25
	Europe (EU)	5	29,4	4	80,0	25,00	50,00
	Asia (AS)	7	17,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	14,29	17,82
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	22,22	27,22
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	8,33	16,67
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	16,67	19,25
	Europe (EU)	3	17,6	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	8,33	16,67
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	16,67	19,25
	Europe (EU)	2	11,8	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	50,00	43,03
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	33,33	0,00
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	8,33	16,67
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	33,33	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	0,00	0,00
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	22,22	19,25
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57
	Europe (EU)	1	5,9	1	100,0	33,33	-
	Asia (AS)	3	7,7	2	66,7	16,67	23,57
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	0,00	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	45,45	22,47
	Europe (EU)	6	35,3	4	66,7	58,33	16,67
	Asia (AS)	21	53,8	13	61,9	25,64	27,74
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	29	96,7	39,08	28,27
	1	38	100,0	38	100,0	38,60	26,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	10	100,0	10	100,0	36,67	24,60
Cycle 2 Day 1	0	30	100,0	27	90,0	22,22	18,49
	1	36	94,7	32	88,9	26,04	25,02
	2	6	60,0	6	100,0	27,78	13,61
Cycle 3 Day 1	0	29	96,7	27	93,1	14,81	16,88
	1	34	89,5	31	91,2	15,05	18,93
	2	5	50,0	5	100,0	13,33	18,26
Cycle 4 Day 1	0	29	96,7	25	86,2	17,33	17,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	17,71	23,92
	2	5	50,0	4	80,0	25,00	31,91
Cycle 5 Day 1	0	29	96,7	29	100,0	18,39	19,08
	1	33	86,8	31	93,9	24,73	21,03
	2	3	30,0	3	100,0	11,11	19,25
Cycle 6 Day 1	0	29	96,7	28	96,6	20,24	16,58
	1	31	81,6	27	87,1	18,52	23,27
	2	3	30,0	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	29	96,7	28	96,6	25,00	26,64
	1	28	73,7	25	89,3	14,67	21,69
	2	3	30,0	3	100,0	0,00	0,00
Cycle 8 Day 1	0	28	93,3	26	92,9	20,51	23,24
	1	25	65,8	23	92,0	18,84	19,66
	2	3	30,0	3	100,0	22,22	19,25
Cycle 9 Day 1	0	26	86,7	26	100,0	16,67	19,44
	1	23	60,5	23	100,0	15,94	22,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	2	20,0	2	100,0	16,67	23,57
Cycle 10 Day 1	0	26	86,7	26	100,0	19,23	16,79
	1	23	60,5	22	95,7	24,24	25,58
	2	2	20,0	2	100,0	16,67	23,57
Cycle 11 Day 1	0	26	86,7	26	100,0	19,23	16,79
	1	22	57,9	22	100,0	16,67	22,42
	2	2	20,0	2	100,0	33,33	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	21,21	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	21	95,5	12,70	19,65
	2	2	20,0	2	100,0	16,67	23,57
Cycle 13 Day 1	0	25	83,3	24	96,0	20,83	23,70
	1	20	52,6	20	100,0	11,67	16,31
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	25,00	20,26
	1	19	50,0	19	100,0	14,04	16,91
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	24	80,0	24	100,0	19,44	16,79
	1	19	50,0	19	100,0	14,04	20,23
	2	1	10,0	1	100,0	0,00	-
Cycle 16 Day 1	0	22	73,3	20	90,9	18,33	22,88
	1	18	47,4	18	100,0	18,52	20,52
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	17,46	17,06
	1	17	44,7	17	100,0	9,80	15,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	14,81	20,52
	1	16	42,1	16	100,0	10,42	15,96
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	17,54	20,39
	1	15	39,5	13	86,7	10,26	16,01
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	23,53	15,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	39,5	14	93,3	4,76	12,10
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	16,67	17,30
	1	13	34,2	11	84,6	6,06	13,48
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	16,67	17,41
	1	13	34,2	12	92,3	0,00	0,00
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	7,41	14,70
	1	9	23,7	8	88,9	8,33	15,43
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	18,52	33,79
	1	9	23,7	8	88,9	4,17	11,79
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	5,56	13,61
	1	7	18,4	7	100,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	26,7	6	75,0	16,67	27,89
	1	6	15,8	6	100,0	11,11	17,21
Cycle 27 Day 1	0	6	20,0	3	50,0	11,11	19,25
	1	5	13,2	5	100,0	13,33	18,26
Cycle 28 Day 1	0	5	16,7	4	80,0	16,67	19,25
	1	5	13,2	5	100,0	40,00	43,46
Cycle 29 Day 1	0	4	13,3	2	50,0	33,33	0,00
	1	5	13,2	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	10,0	1	33,3	33,33	-
	1	4	10,5	4	100,0	8,33	16,67
Cycle 31 Day 1	0	3	10,0	1	33,3	66,67	-
	1	4	10,5	4	100,0	25,00	16,67
Cycle 32 Day 1	0	3	10,0	2	66,7	16,67	23,57
	1	3	7,9	3	100,0	22,22	19,25
Cycle 33 Day 1	0	2	6,7	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	40,48	23,31
	1	20	52,6	12	60,0	36,11	30,01
	2	4	40,0	2	50,0	33,33	47,14
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	43,01	26,10
	1	3	100,0	3	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	44	100,0	43	97,7	35,66	27,60
Cycle 2 Day 1	None	30	96,8	27	90,0	27,16	20,75
	1	2	66,7	1	50,0	0,00	-
	2 or More	40	90,9	37	92,5	23,42	22,03
Cycle 3 Day 1	None	30	96,8	28	93,3	17,86	16,93
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	34	94,4	12,75	18,38
Cycle 4 Day 1	None	30	96,8	28	93,3	17,86	23,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	35	79,5	31	88,6	18,28	20,80
Cycle 5 Day 1	None	30	96,8	30	100,0	23,33	19,87
	1	2	66,7	2	100,0	33,33	0,00
	2 or More	33	75,0	31	93,9	18,28	20,80
Cycle 6 Day 1	None	29	93,5	26	89,7	23,08	18,30
	1	2	66,7	2	100,0	33,33	0,00
	2 or More	32	72,7	29	90,6	14,94	21,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	27	87,1	25	92,6	17,33	23,80
	1	2	66,7	2	100,0	50,00	23,57
	2 or More	31	70,5	29	93,5	18,39	24,54
Cycle 8 Day 1	None	26	83,9	25	96,2	25,33	22,11
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	14,81	19,25
Cycle 9 Day 1	None	25	80,6	25	100,0	17,33	21,77
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	16,00	19,53
Cycle 10 Day 1	None	25	80,6	24	96,0	25,00	22,52
	1	1	33,3	1	100,0	0,00	-
	2 or More	25	56,8	25	100,0	18,67	19,44
Cycle 11 Day 1	None	25	80,6	25	100,0	22,67	20,91
	1	1	33,3	1	100,0	33,33	-
	2 or More	24	54,5	24	100,0	13,89	16,79
Cycle 12 Day 1	None	25	80,6	24	96,0	18,06	19,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	33,33	-
	2 or More	23	52,3	20	87,0	15,00	17,01
Cycle 13 Day 1	None	24	77,4	23	95,8	17,39	22,18
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	15,87	20,05
Cycle 14 Day 1	None	23	74,2	23	100,0	17,39	17,03
	1	1	33,3	1	100,0	33,33	-
	2 or More	21	47,7	20	95,2	21,67	22,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	23	74,2	23	100,0	17,39	19,77
	1	1	33,3	1	100,0	33,33	-
	2 or More	20	45,5	20	100,0	15,00	17,01
Cycle 16 Day 1	None	20	64,5	19	95,0	19,30	23,08
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	19	95,0	17,54	20,39
Cycle 17 Day 1	None	19	61,3	19	100,0	10,53	15,92
	1	1	33,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	19	43,2	19	100,0	15,79	17,10
Cycle 18 Day 1	None	18	58,1	17	94,4	15,69	20,81
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	17	89,5	9,80	15,66
Cycle 19 Day 1	None	17	54,8	17	100,0	11,76	16,42
	1	1	33,3	1	100,0	33,33	-
	2 or More	18	40,9	15	83,3	15,56	21,33
Cycle 20 Day 1	None	17	54,8	16	94,1	18,75	17,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	33,33	-
	2 or More	18	40,9	15	83,3	8,89	15,26
Cycle 21 Day 1	None	15	48,4	13	86,7	10,26	16,01
	2 or More	14	31,8	13	92,9	12,82	16,88
Cycle 22 Day 1	None	15	48,4	13	86,7	7,69	14,62
	2 or More	14	31,8	12	85,7	8,33	15,08
Cycle 23 Day 1	None	10	32,3	9	90,0	7,41	14,70
	2 or More	11	25,0	9	81,8	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	32,3	10	100,0	6,67	14,05
	2 or More	10	22,7	8	80,0	16,67	35,63
Cycle 25 Day 1	None	9	29,0	8	88,9	12,50	17,25
	2 or More	6	13,6	5	83,3	6,67	14,91
Cycle 26 Day 1	None	8	25,8	8	100,0	12,50	17,25
	2 or More	6	13,6	4	66,7	16,67	33,33
Cycle 27 Day 1	None	7	22,6	6	85,7	16,67	18,26
	2 or More	4	9,1	2	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	22,6	7	100,0	23,81	25,20
	2 or More	3	6,8	2	66,7	50,00	70,71
Cycle 29 Day 1	None	6	19,4	5	83,3	26,67	14,91
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	12,9	3	75,0	22,22	19,25
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 31 Day 1	None	4	12,9	3	75,0	44,44	19,25
	2 or More	3	6,8	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	22,22	19,25
	2 or More	2	4,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	3,2	1	100,0	0,00	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	44,44	25,95
	1	2	66,7	1	50,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	54,5	15	62,5	33,33	28,17
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	43,01	26,10
	Previously Treated	47	100,0	46	97,9	35,51	26,67
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	27,16	20,75
	Previously Treated	42	89,4	38	90,5	22,81	22,06
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	17,86	16,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	38	80,9	35	92,1	12,38	18,23
Cycle 4 Day 1	Naïve	30	96,8	28	93,3	17,86	23,10
	Previously Treated	37	78,7	33	89,2	18,18	20,57
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	23,33	19,87
	Previously Treated	35	74,5	33	94,3	19,19	20,46
Cycle 6 Day 1	Naïve	29	93,5	26	89,7	23,08	18,30
	Previously Treated	34	72,3	31	91,2	16,13	20,85
Cycle 7 Day 1	Naïve	27	87,1	25	92,6	17,33	23,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	33	70,2	31	93,9	20,43	25,35
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	25,33	22,11
	Previously Treated	30	63,8	27	90,0	14,81	19,25
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	17,33	21,77
	Previously Treated	26	55,3	26	100,0	15,38	19,39
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	25,00	22,52
	Previously Treated	26	55,3	26	100,0	17,95	19,39
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	22,67	20,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	53,2	25	100,0	14,67	16,89
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	18,06	19,61
	Previously Treated	24	51,1	21	87,5	15,87	17,06
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	17,39	22,18
	Previously Treated	22	46,8	22	100,0	15,15	19,86
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	17,39	17,03
	Previously Treated	22	46,8	21	95,5	22,22	21,94
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	17,39	19,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	21	100,0	15,87	17,06
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	19,30	23,08
	Previously Treated	21	44,7	20	95,2	16,67	20,23
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	10,53	15,92
	Previously Treated	20	42,6	20	100,0	16,67	17,10
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	15,69	20,81
	Previously Treated	20	42,6	18	90,0	9,26	15,36
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	11,76	16,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	40,4	16	84,2	16,67	21,08
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	18,75	17,08
	Previously Treated	19	40,4	16	84,2	10,42	15,96
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	10,26	16,01
	Previously Treated	14	29,8	13	92,9	12,82	16,88
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	7,69	14,62
	Previously Treated	14	29,8	12	85,7	8,33	15,08
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	7,41	14,70
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	6,67	14,05
	Previously Treated	10	21,3	8	80,0	16,67	35,63
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	12,50	17,25
	Previously Treated	6	12,8	5	83,3	6,67	14,91
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	12,50	17,25
	Previously Treated	6	12,8	4	66,7	16,67	33,33
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	16,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	8,5	2	50,0	0,00	0,00
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	23,81	25,20
	Previously Treated	3	6,4	2	66,7	50,00	70,71
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	26,67	14,91
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	22,22	19,25
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	44,44	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	22,22	19,25
	Previously Treated	2	4,3	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	0,00	-
	Previously Treated	1	2,1	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	44,44	25,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	16	61,5	33,33	27,22
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	40,95	28,11
	Central	43	100,0	42	97,7	36,51	25,30
Cycle 2 Day 1	Local	32	91,4	30	93,8	21,11	18,54
	Central	40	93,0	35	87,5	27,62	23,55
Cycle 3 Day 1	Local	29	82,9	27	93,1	14,81	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	39	90,7	36	92,3	14,81	16,80
Cycle 4 Day 1	Local	28	80,0	24	85,7	19,44	19,45
	Central	39	90,7	37	94,9	17,12	23,07
Cycle 5 Day 1	Local	27	77,1	27	100,0	18,52	21,35
	Central	38	88,4	36	94,7	23,15	19,22
Cycle 6 Day 1	Local	27	77,1	27	100,0	17,28	19,33
	Central	36	83,7	30	83,3	21,11	20,50
Cycle 7 Day 1	Local	27	77,1	27	100,0	17,28	21,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	33	76,7	29	87,9	20,69	27,33
Cycle 8 Day 1	Local	26	74,3	26	100,0	21,79	22,98
	Central	30	69,8	26	86,7	17,95	19,39
Cycle 9 Day 1	Local	25	71,4	25	100,0	18,67	21,69
	Central	26	60,5	26	100,0	14,10	19,26
Cycle 10 Day 1	Local	25	71,4	24	96,0	20,83	19,19
	Central	26	60,5	26	100,0	21,79	22,98
Cycle 11 Day 1	Local	24	68,6	24	100,0	19,44	21,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	26	60,5	26	100,0	17,95	16,95
Cycle 12 Day 1	Local	23	65,7	22	95,7	18,18	19,86
	Central	26	60,5	23	88,5	15,94	17,03
Cycle 13 Day 1	Local	22	62,9	22	100,0	15,15	22,37
	Central	24	55,8	23	95,8	17,39	19,77
Cycle 14 Day 1	Local	22	62,9	22	100,0	22,73	18,93
	Central	23	53,5	22	95,7	16,67	19,92
Cycle 15 Day 1	Local	22	62,9	22	100,0	18,18	19,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	15,15	16,99
Cycle 16 Day 1	Local	20	57,1	20	100,0	16,67	20,23
	Central	21	48,8	19	90,5	19,30	23,08
Cycle 17 Day 1	Local	20	57,1	20	100,0	11,67	16,31
	Central	19	44,2	19	100,0	15,79	17,10
Cycle 18 Day 1	Local	20	57,1	19	95,0	19,30	20,23
	Central	18	41,9	16	88,9	4,17	11,39
Cycle 19 Day 1	Local	19	54,3	17	89,5	15,69	20,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	39,5	16	94,1	12,50	16,67
Cycle 20 Day 1	Local	19	54,3	17	89,5	13,73	16,91
	Central	17	39,5	15	88,2	15,56	17,21
Cycle 21 Day 1	Local	14	40,0	12	85,7	13,89	17,16
	Central	15	34,9	14	93,3	9,52	15,63
Cycle 22 Day 1	Local	14	40,0	12	85,7	8,33	15,08
	Central	15	34,9	13	86,7	7,69	14,62
Cycle 23 Day 1	Local	11	31,4	10	90,9	6,67	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	23,3	8	80,0	8,33	15,43
Cycle 24 Day 1	Local	11	31,4	10	90,9	10,00	16,10
	Central	9	20,9	8	88,9	12,50	35,36
Cycle 25 Day 1	Local	7	20,0	7	100,0	14,29	17,82
	Central	8	18,6	6	75,0	5,56	13,61
Cycle 26 Day 1	Local	6	17,1	6	100,0	27,78	25,09
	Central	8	18,6	6	75,0	0,00	0,00
Cycle 27 Day 1	Local	4	11,4	4	100,0	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	16,3	4	57,1	0,00	0,00
Cycle 28 Day 1	Local	4	11,4	4	100,0	25,00	31,91
	Central	6	14,0	5	83,3	33,33	40,82
Cycle 29 Day 1	Local	3	8,6	3	100,0	22,22	19,25
	Central	6	14,0	4	66,7	16,67	19,25
Cycle 30 Day 1	Local	3	8,6	3	100,0	22,22	19,25
	Central	4	9,3	2	50,0	0,00	0,00
Cycle 31 Day 1	Local	3	8,6	3	100,0	44,44	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	9,3	2	50,0	16,67	23,57
Cycle 32 Day 1	Local	3	8,6	3	100,0	22,22	19,25
	Central	3	7,0	2	66,7	16,67	23,57
Cycle 33 Day 1	Local	1	2,9	1	100,0	0,00	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	38,10	31,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	21	48,8	14	66,7	38,10	22,10
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	73	98,6	37,90	26,83
	No	4	100,0	4	100,0	50,00	19,25
Cycle 2 Day 1	Yes	70	94,6	63	90,0	24,34	20,92
	No	2	50,0	2	100,0	33,33	47,14
Cycle 3 Day 1	Yes	66	89,2	61	92,4	14,21	17,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	0,00
Cycle 4 Day 1	Yes	65	87,8	59	90,8	18,08	21,73
	No	2	50,0	2	100,0	16,67	23,57
Cycle 5 Day 1	Yes	63	85,1	61	96,8	20,77	20,33
	No	2	50,0	2	100,0	33,33	0,00
Cycle 6 Day 1	Yes	61	82,4	55	90,2	19,39	19,97
	No	2	50,0	2	100,0	16,67	23,57
Cycle 7 Day 1	Yes	58	78,4	54	93,1	19,14	24,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 8 Day 1	Yes	54	73,0	50	92,6	20,00	21,30
	No	2	50,0	2	100,0	16,67	23,57
Cycle 9 Day 1	Yes	49	66,2	49	100,0	16,33	20,55
	No	2	50,0	2	100,0	16,67	23,57
Cycle 10 Day 1	Yes	49	66,2	48	98,0	21,53	21,18
	No	2	50,0	2	100,0	16,67	23,57
Cycle 11 Day 1	Yes	48	64,9	48	100,0	18,06	19,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	0,00
Cycle 12 Day 1	Yes	47	63,5	43	91,5	16,28	18,36
	No	2	50,0	2	100,0	33,33	0,00
Cycle 13 Day 1	Yes	44	59,5	43	97,7	15,50	21,02
	No	2	50,0	2	100,0	33,33	0,00
Cycle 14 Day 1	Yes	43	58,1	42	97,7	18,25	18,34
	No	2	50,0	2	100,0	50,00	23,57
Cycle 15 Day 1	Yes	42	56,8	42	100,0	15,87	18,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	0,00
Cycle 16 Day 1	Yes	39	52,7	37	94,9	18,92	21,57
	No	2	50,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	37	50,0	37	100,0	13,51	16,59
	No	2	50,0	2	100,0	16,67	23,57
Cycle 18 Day 1	Yes	36	48,6	33	91,7	12,12	18,29
	No	2	50,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	14,58	18,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	14,44	16,80
	No	2	50,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	36,5	24	88,9	11,11	16,05
	No	2	50,0	2	100,0	16,67	23,57
Cycle 22 Day 1	Yes	27	36,5	23	85,2	8,70	14,97
	No	2	50,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	7,84	14,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	11,76	26,20
	No	1	25,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	18,9	12	85,7	8,33	15,08
	No	1	25,0	1	100,0	33,33	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	12,12	22,47
	No	1	25,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	33,33	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	25,00	34,50
	No	1	25,0	1	100,0	66,67	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	22,22	17,21
	No	1	25,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	16,67	19,25
	No	1	25,0	1	100,0	0,00	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	33,33	-
Cycle 32 Day 1	Yes	5	6,8	4	80,0	16,67	19,25
	No	1	25,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	38,10	26,78
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	37,50	27,82
	No	70	100,0	69	98,6	38,65	26,58
Cycle 2 Day 1	Yes	5	62,5	5	100,0	13,33	29,81
	No	67	95,7	60	89,6	25,56	20,69
Cycle 3 Day 1	Yes	5	62,5	4	80,0	8,33	16,67
	No	63	90,0	59	93,7	15,25	17,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	5	62,5	5	100,0	26,67	43,46
	No	62	88,6	56	90,3	17,26	19,06
Cycle 5 Day 1	Yes	5	62,5	5	100,0	33,33	33,33
	No	60	85,7	58	96,7	20,11	18,67
Cycle 6 Day 1	Yes	5	62,5	5	100,0	20,00	29,81
	No	58	82,9	52	89,7	19,23	19,07
Cycle 7 Day 1	Yes	5	62,5	5	100,0	13,33	29,81
	No	55	78,6	51	92,7	19,61	24,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	5	62,5	5	100,0	20,00	29,81
	No	51	72,9	47	92,2	19,86	20,45
Cycle 9 Day 1	Yes	4	50,0	4	100,0	16,67	33,33
	No	47	67,1	47	100,0	16,31	19,50
Cycle 10 Day 1	Yes	4	50,0	4	100,0	25,00	31,91
	No	47	67,1	46	97,9	21,01	20,32
Cycle 11 Day 1	Yes	4	50,0	4	100,0	41,67	31,91
	No	46	65,7	46	100,0	16,67	16,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	4	50,0	4	100,0	16,67	33,33
	No	45	64,3	41	91,1	17,07	16,87
Cycle 13 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	42	60,0	41	97,6	16,26	21,24
Cycle 14 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	41	58,6	40	97,6	20,00	19,68
Cycle 15 Day 1	Yes	4	50,0	4	100,0	25,00	31,91
	No	40	57,1	40	100,0	15,83	16,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	37,5	3	100,0	22,22	38,49
	No	38	54,3	36	94,7	17,59	20,29
Cycle 17 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	36	51,4	36	100,0	13,89	16,67
Cycle 18 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	35	50,0	32	91,4	13,54	18,66
Cycle 19 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	30	90,9	15,56	19,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	33	47,1	29	87,9	14,94	16,87
Cycle 21 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	24	88,9	12,50	16,48
Cycle 22 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	23	85,2	8,70	14,97
Cycle 23 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	19	27,1	16	84,2	8,33	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	18	25,7	16	88,9	12,50	26,87
Cycle 25 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	13	18,6	11	84,6	12,12	16,82
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	15,15	22,92
Cycle 27 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	10	14,3	7	70,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	9	12,9	8	88,9	29,17	37,53
Cycle 29 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	8	11,4	6	75,0	16,67	18,26
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	13,33	18,26
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	20,00	18,26
Cycle 33 Day 1	No	2	2,9	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	66,67	0,00
	No	37	52,9	26	70,3	35,90	26,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13CO_SG.xls
28NOV2019 10:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	77	98,7	6,93	18,99
Cycle 2 Day 1	All	72	92,3	65	90,3	17,95	22,88
Cycle 3 Day 1	All	68	87,2	63	92,6	11,11	15,84
Cycle 4 Day 1	All	67	85,9	61	91,0	13,11	19,51
Cycle 5 Day 1	All	65	83,3	63	96,9	7,94	16,63
Cycle 6 Day 1	All	63	80,8	57	90,5	7,60	15,45
Cycle 7 Day 1	All	60	76,9	56	93,3	8,33	15,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	56	71,8	52	92,9	8,97	14,93
Cycle 9 Day 1	All	51	65,4	51	100,0	9,15	15,02
Cycle 10 Day 1	All	51	65,4	50	98,0	9,33	16,55
Cycle 11 Day 1	All	50	64,1	50	100,0	10,67	17,09
Cycle 12 Day 1	All	49	62,8	45	91,8	9,63	15,28
Cycle 13 Day 1	All	46	59,0	45	97,8	10,37	15,61
Cycle 14 Day 1	All	45	57,7	44	97,8	9,09	16,65
Cycle 15 Day 1	All	44	56,4	44	100,0	9,85	15,38

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	41	52,6	39	95,1	9,40	17,01
Cycle 17 Day 1	All	39	50,0	39	100,0	9,40	17,01
Cycle 18 Day 1	All	38	48,7	35	92,1	8,57	16,85
Cycle 19 Day 1	All	36	46,2	33	91,7	8,08	20,46
Cycle 20 Day 1	All	36	46,2	32	88,9	8,33	16,93
Cycle 21 Day 1	All	29	37,2	26	89,7	7,69	17,15
Cycle 22 Day 1	All	29	37,2	25	86,2	4,00	11,06
Cycle 23 Day 1	All	21	26,9	18	85,7	7,41	14,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	25,6	18	90,0	5,56	12,78
Cycle 25 Day 1	All	15	19,2	13	86,7	5,13	12,52
Cycle 26 Day 1	All	14	17,9	12	85,7	8,33	15,08
Cycle 27 Day 1	All	11	14,1	8	72,7	12,50	17,25
Cycle 28 Day 1	All	10	12,8	9	90,0	14,81	24,22
Cycle 29 Day 1	All	9	11,5	7	77,8	19,05	26,23
Cycle 30 Day 1	All	7	9,0	5	71,4	6,67	14,91
Cycle 31 Day 1	All	7	9,0	5	71,4	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	7,7	5	83,3	6,67	14,91
Cycle 33 Day 1	All	2	2,6	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	14,29	16,80
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	12,64	27,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	49	100,0	48	98,0	3,47	10,29
Cycle 2 Day 1	Male	27	93,1	25	92,6	20,00	25,46
	Female	45	91,8	40	88,9	16,67	21,35
Cycle 3 Day 1	Male	25	86,2	24	96,0	9,72	15,48
	Female	43	87,8	39	90,7	11,97	16,20
Cycle 4 Day 1	Male	25	86,2	23	92,0	10,14	18,63
	Female	42	85,7	38	90,5	14,91	20,06
Cycle 5 Day 1	Male	25	86,2	24	96,0	8,33	20,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	40	81,6	39	97,5	7,69	14,23
Cycle 6 Day 1	Male	25	86,2	23	92,0	7,25	14,06
	Female	38	77,6	34	89,5	7,84	16,53
Cycle 7 Day 1	Male	23	79,3	23	100,0	10,14	15,68
	Female	37	75,5	33	89,2	7,07	16,15
Cycle 8 Day 1	Male	21	72,4	19	90,5	10,53	15,92
	Female	35	71,4	33	94,3	8,08	14,51
Cycle 9 Day 1	Male	18	62,1	18	100,0	9,26	15,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	9,09	15,08
Cycle 10 Day 1	Male	18	62,1	18	100,0	11,11	19,80
	Female	33	67,3	32	97,0	8,33	14,66
Cycle 11 Day 1	Male	18	62,1	18	100,0	16,67	20,61
	Female	32	65,3	32	100,0	7,29	14,00
Cycle 12 Day 1	Male	17	58,6	17	100,0	9,80	15,66
	Female	32	65,3	28	87,5	9,52	15,33
Cycle 13 Day 1	Male	17	58,6	17	100,0	11,76	16,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	29	59,2	28	96,6	9,52	15,33
Cycle 14 Day 1	Male	17	58,6	16	94,1	8,33	14,91
	Female	28	57,1	28	100,0	9,52	17,82
Cycle 15 Day 1	Male	16	55,2	16	100,0	12,50	16,67
	Female	28	57,1	28	100,0	8,33	14,70
Cycle 16 Day 1	Male	14	48,3	14	100,0	14,29	21,54
	Female	27	55,1	25	92,6	6,67	13,61
Cycle 17 Day 1	Male	12	41,4	12	100,0	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	27	100,0	11,11	18,49
Cycle 18 Day 1	Male	11	37,9	10	90,9	6,67	14,05
	Female	27	55,1	25	92,6	9,33	18,05
Cycle 19 Day 1	Male	10	34,5	10	100,0	10,00	16,10
	Female	26	53,1	23	88,5	7,25	22,38
Cycle 20 Day 1	Male	10	34,5	9	90,0	7,41	14,70
	Female	26	53,1	23	88,5	8,70	18,03
Cycle 21 Day 1	Male	8	27,6	8	100,0	16,67	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	42,9	18	85,7	3,70	10,78
Cycle 22 Day 1	Male	8	27,6	6	75,0	11,11	17,21
	Female	21	42,9	19	90,5	1,75	7,65
Cycle 23 Day 1	Male	5	17,2	4	80,0	8,33	16,67
	Female	16	32,7	14	87,5	7,14	14,19
Cycle 24 Day 1	Male	5	17,2	4	80,0	8,33	16,67
	Female	15	30,6	14	93,3	4,76	12,10
Cycle 25 Day 1	Male	3	10,3	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	24,5	11	91,7	3,03	10,05
Cycle 26 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	11	22,4	10	90,9	10,00	16,10
Cycle 27 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	8	16,3	6	75,0	16,67	18,26
Cycle 28 Day 1	Male	2	6,9	2	100,0	0,00	0,00
	Female	8	16,3	7	87,5	19,05	26,23
Cycle 29 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	16,3	6	75,0	22,22	27,22
Cycle 30 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	8,33	16,67
Cycle 31 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	16,67	19,25
Cycle 32 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	5	10,2	4	80,0	8,33	16,67
Cycle 33 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	2,0	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	17,78	17,21
	Female	21	42,9	13	61,9	10,26	16,01
Age							
Cycle 1 Day 1	18-64	62	100,0	61	98,4	7,10	17,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	7,14	26,73
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	18-64	59	95,2	52	88,1	17,31	24,24
	65-74	11	78,6	11	100,0	21,21	16,82
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 3 Day 1	18-64	56	90,3	52	92,9	11,54	16,01
	65-74	10	71,4	9	90,0	11,11	16,67
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	55	88,7	50	90,9	13,33	20,20
	65-74	10	71,4	9	90,0	14,81	17,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 5 Day 1	18-64	53	85,5	52	98,1	7,69	16,98
	65-74	10	71,4	10	100,0	10,00	16,10
	>=75	2	100,0	1	50,0	0,00	-
Cycle 6 Day 1	18-64	51	82,3	46	90,2	7,25	13,90
	65-74	10	71,4	9	90,0	11,11	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 7 Day 1	18-64	49	79,0	46	93,9	7,97	16,00
	65-74	9	64,3	8	88,9	12,50	17,25
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 8 Day 1	18-64	45	72,6	41	91,1	7,32	13,97
	65-74	9	64,3	9	100,0	18,52	17,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 9 Day 1	18-64	40	64,5	40	100,0	7,50	14,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	18,52	17,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 10 Day 1	18-64	40	64,5	39	97,5	9,40	17,01
	65-74	9	64,3	9	100,0	11,11	16,67
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 11 Day 1	18-64	39	62,9	39	100,0	11,11	17,66
	65-74	9	64,3	9	100,0	11,11	16,67
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	38	61,3	35	92,1	8,57	14,78
	65-74	9	64,3	8	88,9	16,67	17,82
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 13 Day 1	18-64	35	56,5	34	97,1	8,82	14,93
	65-74	9	64,3	9	100,0	18,52	17,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 14 Day 1	18-64	35	56,5	35	100,0	7,62	14,20
	65-74	9	64,3	8	88,9	16,67	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	8,57	14,78
	65-74	8	57,1	8	100,0	12,50	17,25
	>=75	1	50,0	1	100,0	33,33	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	8,33	16,93
	65-74	7	50,0	6	85,7	16,67	18,26
	>=75	1	50,0	1	100,0	0,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	8,33	14,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	6	42,9	6	100,0	16,67	27,89
	>=75	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	8,05	17,03
	65-74	6	42,9	5	83,3	13,33	18,26
	>=75	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	8,33	21,52
	65-74	5	35,7	4	80,0	8,33	16,67
	>=75	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	8,97	17,78
	65-74	5	35,7	5	100,0	6,67	14,91
	>=75	1	50,0	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	7,94	17,97
	65-74	4	28,6	4	100,0	8,33	16,67
	>=75	1	50,0	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	3,33	10,26
	65-74	4	28,6	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	6,25	13,44
	65-74	2	14,3	2	100,0	16,67	23,57
Cycle 24 Day 1	18-64	18	29,0	16	88,9	4,17	11,39
	65-74	2	14,3	2	100,0	16,67	23,57
Cycle 25 Day 1	18-64	14	22,6	12	85,7	5,56	12,97
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	8,33	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	12,50	17,25
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	14,81	24,22
	65-74	1	7,1	0	0,0	-	-
Cycle 29 Day 1	18-64	8	12,9	7	87,5	19,05	26,23
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	13,33	18,26
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	8,33	16,67
	65-74	1	7,1	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	0,00	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	15,00	17,01
	65-74	10	71,4	7	70,0	14,29	17,82
	>=75	2	100,0	1	50,0	0,00	-
Race							
Cycle 1 Day 1	White	35	100,0	34	97,1	9,80	25,33
	Other	43	100,0	43	100,0	4,65	11,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	33	94,3	28	84,8	13,10	24,58
	Other	39	90,7	37	94,9	21,62	21,11
Cycle 3 Day 1	White	31	88,6	27	87,1	8,64	14,89
	Other	37	86,0	36	97,3	12,96	16,48
Cycle 4 Day 1	White	31	88,6	26	83,9	6,41	13,40
	Other	36	83,7	35	97,2	18,10	21,91
Cycle 5 Day 1	White	31	88,6	29	93,5	4,60	11,70
	Other	34	79,1	34	100,0	10,78	19,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	30	85,7	25	83,3	8,00	17,43
	Other	33	76,7	32	97,0	7,29	14,00
Cycle 7 Day 1	White	29	82,9	26	89,7	6,41	16,38
	Other	31	72,1	30	96,8	10,00	15,54
Cycle 8 Day 1	White	28	80,0	24	85,7	6,94	13,83
	Other	28	65,1	28	100,0	10,71	15,85
Cycle 9 Day 1	White	26	74,3	26	100,0	5,13	12,26
	Other	25	58,1	25	100,0	13,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	10,67	18,56
	Other	25	58,1	25	100,0	8,00	14,53
Cycle 11 Day 1	White	26	74,3	26	100,0	8,97	17,78
	Other	24	55,8	24	100,0	12,50	16,48
Cycle 12 Day 1	White	26	74,3	22	84,6	9,09	15,19
	Other	23	53,5	23	100,0	10,14	15,68
Cycle 13 Day 1	White	24	68,6	23	95,8	8,70	14,97
	Other	22	51,2	22	100,0	12,12	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	24	68,6	24	100,0	8,33	17,72
	Other	21	48,8	20	95,2	10,00	15,67
Cycle 15 Day 1	White	24	68,6	24	100,0	9,72	15,48
	Other	20	46,5	20	100,0	10,00	15,67
Cycle 16 Day 1	White	22	62,9	20	90,9	6,67	17,44
	Other	19	44,2	19	100,0	12,28	16,52
Cycle 17 Day 1	White	22	62,9	22	100,0	7,58	14,30
	Other	17	39,5	17	100,0	11,76	20,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	21	60,0	18	85,7	7,41	18,28
	Other	17	39,5	17	100,0	9,80	15,66
Cycle 19 Day 1	White	20	57,1	20	100,0	5,00	12,21
	Other	16	37,2	13	81,3	12,82	28,99
Cycle 20 Day 1	White	20	57,1	17	85,0	5,88	13,10
	Other	16	37,2	15	93,8	11,11	20,57
Cycle 21 Day 1	White	16	45,7	14	87,5	9,52	20,37
	Other	13	30,2	12	92,3	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	45,7	13	81,3	2,56	9,25
	Other	13	30,2	12	92,3	5,56	12,97
Cycle 23 Day 1	White	12	34,3	10	83,3	10,00	16,10
	Other	9	20,9	8	88,9	4,17	11,79
Cycle 24 Day 1	White	11	31,4	10	90,9	6,67	14,05
	Other	9	20,9	8	88,9	4,17	11,79
Cycle 25 Day 1	White	10	28,6	8	80,0	8,33	15,43
	Other	5	11,6	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	28,6	8	80,0	8,33	15,43
	Other	4	9,3	4	100,0	8,33	16,67
Cycle 27 Day 1	White	8	22,9	5	62,5	13,33	18,26
	Other	3	7,0	3	100,0	11,11	19,25
Cycle 28 Day 1	White	7	20,0	6	85,7	16,67	27,89
	Other	3	7,0	3	100,0	11,11	19,25
Cycle 29 Day 1	White	6	17,1	4	66,7	25,00	31,91
	Other	3	7,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	11,4	2	50,0	0,00	0,00
	Other	3	7,0	3	100,0	11,11	19,25
Cycle 31 Day 1	White	4	11,4	2	50,0	0,00	0,00
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 32 Day 1	White	4	11,4	3	75,0	0,00	0,00
	Other	2	4,7	2	100,0	16,67	23,57
Cycle 33 Day 1	White	2	5,7	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-
End Of Treatment	White	15	42,9	12	80,0	11,11	16,41
	Other	24	55,8	16	66,7	16,67	17,21
Region							
Cycle 1 Day 1	America (AM)	22	100,0	21	95,5	1,59	7,27
	Europe (EU)	17	100,0	17	100,0	11,76	26,20
	Asia (AS)	39	100,0	39	100,0	7,69	19,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	15,69	20,81
	Europe (EU)	16	94,1	13	81,3	17,95	29,24
	Asia (AS)	36	92,3	35	97,2	19,05	21,82
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	7,02	13,96
	Europe (EU)	15	88,2	11	73,3	6,06	13,48
	Asia (AS)	33	84,6	33	100,0	15,15	16,85
Cycle 4 Day 1	America (AM)	20	90,9	19	95,0	7,02	13,96
	Europe (EU)	15	88,2	11	73,3	9,09	15,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	32	82,1	31	96,9	18,28	22,51
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	1,67	7,45
	Europe (EU)	15	88,2	13	86,7	7,69	19,97
	Asia (AS)	30	76,9	30	100,0	12,22	18,54
Cycle 6 Day 1	America (AM)	20	90,9	18	90,0	1,85	7,86
	Europe (EU)	14	82,4	12	85,7	13,89	22,29
	Asia (AS)	29	74,4	27	93,1	8,64	14,89
Cycle 7 Day 1	America (AM)	19	86,4	17	89,5	5,88	17,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	14	82,4	13	92,9	7,69	14,62
	Asia (AS)	27	69,2	26	96,3	10,26	15,69
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	3,92	11,07
	Europe (EU)	14	82,4	11	78,6	9,09	15,57
	Asia (AS)	24	61,5	24	100,0	12,50	16,48
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	3,70	10,78
	Europe (EU)	12	70,6	12	100,0	5,56	12,97
	Asia (AS)	21	53,8	21	100,0	15,87	17,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	5,88	17,62
	Europe (EU)	12	70,6	12	100,0	11,11	16,41
	Asia (AS)	21	53,8	21	100,0	11,11	16,10
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	9,26	15,36
	Europe (EU)	12	70,6	12	100,0	11,11	21,71
	Asia (AS)	20	51,3	20	100,0	11,67	16,31
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	5,88	13,10
	Europe (EU)	12	70,6	9	75,0	14,81	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	19	48,7	19	100,0	10,53	15,92
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	9,80	15,66
	Europe (EU)	11	64,7	10	90,9	10,00	16,10
	Asia (AS)	18	46,2	18	100,0	11,11	16,17
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	5,88	13,10
	Europe (EU)	11	64,7	11	100,0	12,12	22,47
	Asia (AS)	17	43,6	16	94,1	10,42	15,96
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	5,88	13,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	64,7	11	100,0	15,15	17,41
	Asia (AS)	16	41,0	16	100,0	10,42	15,96
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	9,52	15,63
	Europe (EU)	11	64,7	9	81,8	11,11	23,57
	Asia (AS)	16	41,0	16	100,0	8,33	14,91
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	4,76	12,10
	Europe (EU)	10	58,8	10	100,0	6,67	14,05
	Asia (AS)	15	38,5	15	100,0	15,56	21,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	2,38	8,91
	Europe (EU)	9	52,9	6	66,7	5,56	13,61
	Asia (AS)	15	38,5	15	100,0	15,56	21,33
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	2,56	9,25
	Europe (EU)	9	52,9	9	100,0	7,41	14,70
	Asia (AS)	14	35,9	11	78,6	15,15	31,14
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	5,13	12,52
	Europe (EU)	9	52,9	6	66,7	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	12,82	21,68
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	6,67	14,05
	Europe (EU)	7	41,2	6	85,7	11,11	27,22
	Asia (AS)	11	28,2	10	90,9	6,67	14,05
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	3,33	10,54
	Europe (EU)	7	41,2	5	71,4	0,00	0,00
	Asia (AS)	11	28,2	10	90,9	6,67	14,05
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	29,4	3	60,0	11,11	19,25
	Asia (AS)	7	17,9	6	85,7	5,56	13,61
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	8,33	15,43
	Europe (EU)	5	29,4	4	80,0	8,33	16,67
	Asia (AS)	7	17,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	4,76	12,60
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	5,56	13,61
	Europe (EU)	4	23,5	2	50,0	16,67	23,57
	Asia (AS)	4	10,3	4	100,0	8,33	16,67
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	8,33	16,67
	Europe (EU)	3	17,6	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	16,67	19,25
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	8,33	16,67
	Europe (EU)	2	11,8	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	25,00	31,91
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	11,11	19,25
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	25,00	31,91
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	11,11	19,25
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	22,22	19,25
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00
	Europe (EU)	1	5,9	1	100,0	0,00	-
	Asia (AS)	3	7,7	2	66,7	16,67	23,57
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	0,00	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	12,12	16,82
	Europe (EU)	6	35,3	4	66,7	16,67	19,25
	Asia (AS)	21	53,8	13	61,9	15,38	17,30
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	29	96,7	3,45	10,33
	1	38	100,0	38	100,0	11,40	24,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	10	100,0	10	100,0	0,00	0,00
Cycle 2 Day 1	0	30	100,0	27	90,0	17,28	19,33
	1	36	94,7	32	88,9	21,88	26,25
	2	6	60,0	6	100,0	0,00	0,00
Cycle 3 Day 1	0	29	96,7	27	93,1	9,88	15,51
	1	34	89,5	31	91,2	12,90	16,50
	2	5	50,0	5	100,0	6,67	14,91
Cycle 4 Day 1	0	29	96,7	25	86,2	10,67	15,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	14,58	20,63
	2	5	50,0	4	80,0	16,67	33,33
Cycle 5 Day 1	0	29	96,7	29	100,0	5,75	12,81
	1	33	86,8	31	93,9	10,75	19,98
	2	3	30,0	3	100,0	0,00	0,00
Cycle 6 Day 1	0	29	96,7	28	96,6	9,52	17,82
	1	31	81,6	27	87,1	6,17	13,19
	2	3	30,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	29	96,7	28	96,6	11,90	18,62
	1	28	73,7	25	89,3	5,33	12,47
	2	3	30,0	3	100,0	0,00	0,00
Cycle 8 Day 1	0	28	93,3	26	92,9	12,82	16,54
	1	25	65,8	23	92,0	5,80	12,92
	2	3	30,0	3	100,0	0,00	0,00
Cycle 9 Day 1	0	26	86,7	26	100,0	10,26	15,69
	1	23	60,5	23	100,0	8,70	14,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	2	20,0	2	100,0	0,00	0,00
Cycle 10 Day 1	0	26	86,7	26	100,0	12,82	19,04
	1	23	60,5	22	95,7	6,06	13,16
	2	2	20,0	2	100,0	0,00	0,00
Cycle 11 Day 1	0	26	86,7	26	100,0	14,10	19,26
	1	22	57,9	22	100,0	7,58	14,30
	2	2	20,0	2	100,0	0,00	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	12,12	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	21	95,5	7,94	14,55
	2	2	20,0	2	100,0	0,00	0,00
Cycle 13 Day 1	0	25	83,3	24	96,0	12,50	16,48
	1	20	52,6	20	100,0	8,33	14,81
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	11,11	18,82
	1	19	50,0	19	100,0	7,02	13,96
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	24	80,0	24	100,0	11,11	16,05
	1	19	50,0	19	100,0	8,77	15,08
	2	1	10,0	1	100,0	0,00	-
Cycle 16 Day 1	0	22	73,3	20	90,9	10,00	19,04
	1	18	47,4	18	100,0	9,26	15,36
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	9,52	18,69
	1	17	44,7	17	100,0	9,80	15,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	7,41	14,26
	1	16	42,1	16	100,0	10,42	20,07
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	5,26	12,49
	1	15	39,5	13	86,7	12,82	28,99
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	5,88	13,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	39,5	14	93,3	11,90	21,11
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	9,52	20,37
	1	13	34,2	11	84,6	6,06	13,48
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	5,56	12,97
	1	13	34,2	12	92,3	2,78	9,62
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	7,41	14,70
	1	9	23,7	8	88,9	8,33	15,43
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	7,41	14,70
	1	9	23,7	8	88,9	4,17	11,79
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	11,11	17,21
	1	7	18,4	7	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	26,7	6	75,0	0,00	0,00
	1	6	15,8	6	100,0	16,67	18,26
Cycle 27 Day 1	0	6	20,0	3	50,0	11,11	19,25
	1	5	13,2	5	100,0	13,33	18,26
Cycle 28 Day 1	0	5	16,7	4	80,0	16,67	33,33
	1	5	13,2	5	100,0	13,33	18,26
Cycle 29 Day 1	0	4	13,3	2	50,0	33,33	47,14
	1	5	13,2	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	8,33	16,67
Cycle 31 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	16,67	19,25
Cycle 32 Day 1	0	3	10,0	2	66,7	0,00	0,00
	1	3	7,9	3	100,0	11,11	19,25
Cycle 33 Day 1	0	2	6,7	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	14,29	17,12
	1	20	52,6	12	60,0	16,67	17,41
	2	4	40,0	2	50,0	0,00	0,00
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	4,30	11,36
	1	3	100,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	44	100,0	43	97,7	8,53	23,11
Cycle 2 Day 1	None	30	96,8	27	90,0	14,81	19,25
	1	2	66,7	1	50,0	0,00	-
	2 or More	40	90,9	37	92,5	20,72	25,28
Cycle 3 Day 1	None	30	96,8	28	93,3	10,71	15,85
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	34	94,4	11,76	16,17
Cycle 4 Day 1	None	30	96,8	28	93,3	14,29	19,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	35	79,5	31	88,6	12,90	20,51
Cycle 5 Day 1	None	30	96,8	30	100,0	10,00	19,87
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	33	75,0	31	93,9	6,45	13,39
Cycle 6 Day 1	None	29	93,5	26	89,7	7,69	14,32
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	32	72,7	29	90,6	8,05	17,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	27	87,1	25	92,6	6,67	13,61
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	31	70,5	29	93,5	10,34	18,05
Cycle 8 Day 1	None	26	83,9	25	96,2	8,00	14,53
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	9,88	15,51
Cycle 9 Day 1	None	25	80,6	25	100,0	8,00	14,53
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	10,67	15,87
Cycle 10 Day 1	None	25	80,6	24	96,0	11,11	18,82
	1	1	33,3	1	100,0	0,00	-
	2 or More	25	56,8	25	100,0	8,00	14,53
Cycle 11 Day 1	None	25	80,6	25	100,0	9,33	15,28
	1	1	33,3	1	100,0	33,33	-
	2 or More	24	54,5	24	100,0	11,11	18,82
Cycle 12 Day 1	None	25	80,6	24	96,0	9,72	15,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	23	52,3	20	87,0	10,00	15,67
Cycle 13 Day 1	None	24	77,4	23	95,8	11,59	16,23
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	9,52	15,43
Cycle 14 Day 1	None	23	74,2	23	100,0	7,25	14,06
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	20	95,2	11,67	19,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	23	74,2	23	100,0	8,70	14,97
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	20	100,0	11,67	16,31
Cycle 16 Day 1	None	20	64,5	19	95,0	7,02	13,96
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	19	95,0	12,28	19,91
Cycle 17 Day 1	None	19	61,3	19	100,0	8,77	15,08
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	19	43,2	19	100,0	10,53	19,41
Cycle 18 Day 1	None	18	58,1	17	94,4	7,84	14,57
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	17	89,5	9,80	19,60
Cycle 19 Day 1	None	17	54,8	17	100,0	11,76	26,20
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	4,44	11,73
Cycle 20 Day 1	None	17	54,8	16	94,1	14,58	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	2,22	8,61
Cycle 21 Day 1	None	15	48,4	13	86,7	10,26	16,01
	2 or More	14	31,8	13	92,9	5,13	18,49
Cycle 22 Day 1	None	15	48,4	13	86,7	7,69	14,62
	2 or More	14	31,8	12	85,7	0,00	0,00
Cycle 23 Day 1	None	10	32,3	9	90,0	11,11	16,67
	2 or More	11	25,0	9	81,8	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	32,3	10	100,0	3,33	10,54
	2 or More	10	22,7	8	80,0	8,33	15,43
Cycle 25 Day 1	None	9	29,0	8	88,9	8,33	15,43
	2 or More	6	13,6	5	83,3	0,00	0,00
Cycle 26 Day 1	None	8	25,8	8	100,0	8,33	15,43
	2 or More	6	13,6	4	66,7	8,33	16,67
Cycle 27 Day 1	None	7	22,6	6	85,7	16,67	18,26
	2 or More	4	9,1	2	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	22,6	7	100,0	19,05	26,23
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 29 Day 1	None	6	19,4	5	83,3	26,67	27,89
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	12,9	3	75,0	11,11	19,25
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 31 Day 1	None	4	12,9	3	75,0	11,11	19,25
	2 or More	3	6,8	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	11,11	19,25
	2 or More	2	4,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	3,2	1	100,0	0,00	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	16,67	17,41
	1	2	66,7	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	54,5	15	62,5	13,33	16,90
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	4,30	11,36
	Previously Treated	47	100,0	46	97,9	8,70	22,70
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	14,81	19,25
	Previously Treated	42	89,4	38	90,5	20,18	25,16
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	10,71	15,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	38	80,9	35	92,1	11,43	16,05
Cycle 4 Day 1	Naïve	30	96,8	28	93,3	14,29	19,09
	Previously Treated	37	78,7	33	89,2	12,12	20,10
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	10,00	19,87
	Previously Treated	35	74,5	33	94,3	6,06	13,06
Cycle 6 Day 1	Naïve	29	93,5	26	89,7	7,69	14,32
	Previously Treated	34	72,3	31	91,2	7,53	16,58
Cycle 7 Day 1	Naïve	27	87,1	25	92,6	6,67	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	33	70,2	31	93,9	9,68	17,62
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	8,00	14,53
	Previously Treated	30	63,8	27	90,0	9,88	15,51
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	8,00	14,53
	Previously Treated	26	55,3	26	100,0	10,26	15,69
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	11,11	18,82
	Previously Treated	26	55,3	26	100,0	7,69	14,32
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	9,33	15,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	53,2	25	100,0	12,00	18,95
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	9,72	15,48
	Previously Treated	24	51,1	21	87,5	9,52	15,43
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	11,59	16,23
	Previously Treated	22	46,8	22	100,0	9,09	15,19
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	7,25	14,06
	Previously Treated	22	46,8	21	95,5	11,11	19,25
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	8,70	14,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	21	100,0	11,11	16,10
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	7,02	13,96
	Previously Treated	21	44,7	20	95,2	11,67	19,57
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	8,77	15,08
	Previously Treated	20	42,6	20	100,0	10,00	19,04
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	7,84	14,57
	Previously Treated	20	42,6	18	90,0	9,26	19,15
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	11,76	26,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	40,4	16	84,2	4,17	11,39
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	14,58	20,97
	Previously Treated	19	40,4	16	84,2	2,08	8,33
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	10,26	16,01
	Previously Treated	14	29,8	13	92,9	5,13	18,49
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	7,69	14,62
	Previously Treated	14	29,8	12	85,7	0,00	0,00
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	11,11	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	3,70	11,11
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	3,33	10,54
	Previously Treated	10	21,3	8	80,0	8,33	15,43
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	8,33	15,43
	Previously Treated	6	12,8	5	83,3	0,00	0,00
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	8,33	15,43
	Previously Treated	6	12,8	4	66,7	8,33	16,67
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	16,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	8,5	2	50,0	0,00	0,00
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	19,05	26,23
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	26,67	27,89
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	11,11	19,25
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	11,11	19,25
	Previously Treated	2	4,3	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	0,00	-
	Previously Treated	1	2,1	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	16,67	17,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	16	61,5	12,50	16,67
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	2,86	9,47
	Central	43	100,0	42	97,7	10,32	23,84
Cycle 2 Day 1	Local	32	91,4	30	93,8	16,67	19,08
	Central	40	93,0	35	87,5	19,05	25,93
Cycle 3 Day 1	Local	29	82,9	27	93,1	9,88	15,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	39	90,7	36	92,3	12,04	16,24
Cycle 4 Day 1	Local	28	80,0	24	85,7	11,11	18,82
	Central	39	90,7	37	94,9	14,41	20,09
Cycle 5 Day 1	Local	27	77,1	27	100,0	4,94	12,07
	Central	38	88,4	36	94,7	10,19	19,22
Cycle 6 Day 1	Local	27	77,1	27	100,0	7,41	16,88
	Central	36	83,7	30	83,3	7,78	14,34
Cycle 7 Day 1	Local	27	77,1	27	100,0	4,94	12,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	33	76,7	29	87,9	11,49	18,42
Cycle 8 Day 1	Local	26	74,3	26	100,0	5,13	12,26
	Central	30	69,8	26	86,7	12,82	16,54
Cycle 9 Day 1	Local	25	71,4	25	100,0	9,33	15,28
	Central	26	60,5	26	100,0	8,97	15,08
Cycle 10 Day 1	Local	25	71,4	24	96,0	6,94	16,97
	Central	26	60,5	26	100,0	11,54	16,17
Cycle 11 Day 1	Local	24	68,6	24	100,0	8,33	14,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	26	60,5	26	100,0	12,82	19,04
Cycle 12 Day 1	Local	23	65,7	22	95,7	6,06	13,16
	Central	26	60,5	23	88,5	13,04	16,63
Cycle 13 Day 1	Local	22	62,9	22	100,0	9,09	15,19
	Central	24	55,8	23	95,8	11,59	16,23
Cycle 14 Day 1	Local	22	62,9	22	100,0	7,58	17,61
	Central	23	53,5	22	95,7	10,61	15,89
Cycle 15 Day 1	Local	22	62,9	22	100,0	7,58	14,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	12,12	16,41
Cycle 16 Day 1	Local	20	57,1	20	100,0	6,67	13,68
	Central	21	48,8	19	90,5	12,28	19,91
Cycle 17 Day 1	Local	20	57,1	20	100,0	5,00	12,21
	Central	19	44,2	19	100,0	14,04	20,23
Cycle 18 Day 1	Local	20	57,1	19	95,0	3,51	10,51
	Central	18	41,9	16	88,9	14,58	20,97
Cycle 19 Day 1	Local	19	54,3	17	89,5	7,84	25,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	39,5	16	94,1	8,33	14,91
Cycle 20 Day 1	Local	19	54,3	17	89,5	5,88	17,62
	Central	17	39,5	15	88,2	11,11	16,27
Cycle 21 Day 1	Local	14	40,0	12	85,7	2,78	9,62
	Central	15	34,9	14	93,3	11,90	21,11
Cycle 22 Day 1	Local	14	40,0	12	85,7	2,78	9,62
	Central	15	34,9	13	86,7	5,13	12,52
Cycle 23 Day 1	Local	11	31,4	10	90,9	3,33	10,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	23,3	8	80,0	12,50	17,25
Cycle 24 Day 1	Local	11	31,4	10	90,9	6,67	14,05
	Central	9	20,9	8	88,9	4,17	11,79
Cycle 25 Day 1	Local	7	20,0	7	100,0	4,76	12,60
	Central	8	18,6	6	75,0	5,56	13,61
Cycle 26 Day 1	Local	6	17,1	6	100,0	5,56	13,61
	Central	8	18,6	6	75,0	11,11	17,21
Cycle 27 Day 1	Local	4	11,4	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	16,3	4	57,1	16,67	19,25
Cycle 28 Day 1	Local	4	11,4	4	100,0	8,33	16,67
	Central	6	14,0	5	83,3	20,00	29,81
Cycle 29 Day 1	Local	3	8,6	3	100,0	11,11	19,25
	Central	6	14,0	4	66,7	25,00	31,91
Cycle 30 Day 1	Local	3	8,6	3	100,0	11,11	19,25
	Central	4	9,3	2	50,0	0,00	0,00
Cycle 31 Day 1	Local	3	8,6	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	9,3	2	50,0	16,67	23,57
Cycle 32 Day 1	Local	3	8,6	3	100,0	11,11	19,25
	Central	3	7,0	2	66,7	0,00	0,00
Cycle 33 Day 1	Local	1	2,9	1	100,0	0,00	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	19,05	17,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	21	48,8	14	66,7	9,52	15,63
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	73	98,6	7,31	19,44
	No	4	100,0	4	100,0	0,00	0,00
Cycle 2 Day 1	Yes	70	94,6	63	90,0	17,46	23,08
	No	2	50,0	2	100,0	33,33	0,00
Cycle 3 Day 1	Yes	66	89,2	61	92,4	10,38	15,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	0,00
Cycle 4 Day 1	Yes	65	87,8	59	90,8	13,56	19,69
	No	2	50,0	2	100,0	0,00	0,00
Cycle 5 Day 1	Yes	63	85,1	61	96,8	7,65	16,55
	No	2	50,0	2	100,0	16,67	23,57
Cycle 6 Day 1	Yes	61	82,4	55	90,2	7,27	15,30
	No	2	50,0	2	100,0	16,67	23,57
Cycle 7 Day 1	Yes	58	78,4	54	93,1	8,64	16,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 8 Day 1	Yes	54	73,0	50	92,6	8,67	14,77
	No	2	50,0	2	100,0	16,67	23,57
Cycle 9 Day 1	Yes	49	66,2	49	100,0	8,16	14,48
	No	2	50,0	2	100,0	33,33	0,00
Cycle 10 Day 1	Yes	49	66,2	48	98,0	9,03	16,47
	No	2	50,0	2	100,0	16,67	23,57
Cycle 11 Day 1	Yes	48	64,9	48	100,0	10,42	17,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 12 Day 1	Yes	47	63,5	43	91,5	10,08	15,49
	No	2	50,0	2	100,0	0,00	0,00
Cycle 13 Day 1	Yes	44	59,5	43	97,7	9,30	15,13
	No	2	50,0	2	100,0	33,33	0,00
Cycle 14 Day 1	Yes	43	58,1	42	97,7	8,73	16,56
	No	2	50,0	2	100,0	16,67	23,57
Cycle 15 Day 1	Yes	42	56,8	42	100,0	8,73	14,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	0,00
Cycle 16 Day 1	Yes	39	52,7	37	94,9	9,01	16,94
	No	2	50,0	2	100,0	16,67	23,57
Cycle 17 Day 1	Yes	37	50,0	37	100,0	7,21	13,91
	No	2	50,0	2	100,0	50,00	23,57
Cycle 18 Day 1	Yes	36	48,6	33	91,7	8,08	16,73
	No	2	50,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	5,21	12,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	1	50,0	100,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	6,67	13,56
	No	2	50,0	2	100,0	33,33	47,14
Cycle 21 Day 1	Yes	27	36,5	24	88,9	8,33	17,72
	No	2	50,0	2	100,0	0,00	0,00
Cycle 22 Day 1	Yes	27	36,5	23	85,2	4,35	11,48
	No	2	50,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	7,84	14,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	5,88	13,10
	No	1	25,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	18,9	12	85,7	5,56	12,97
	No	1	25,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	6,06	13,48
	No	1	25,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	33,33	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	12,50	24,80
	No	1	25,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	16,67	27,89
	No	1	25,0	1	100,0	33,33	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	0,00	0,00
	No	1	25,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	33,33	-
Cycle 32 Day 1	Yes	5	6,8	4	80,0	0,00	0,00
	No	1	25,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	14,29	16,80
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	0,00	0,00
	No	70	100,0	69	98,6	7,73	19,92
Cycle 2 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	67	95,7	60	89,6	19,44	23,20
Cycle 3 Day 1	Yes	5	62,5	4	80,0	8,33	16,67
	No	63	90,0	59	93,7	11,30	15,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	62	88,6	56	90,3	13,69	19,88
Cycle 5 Day 1	Yes	5	62,5	5	100,0	13,33	18,26
	No	60	85,7	58	96,7	7,47	16,57
Cycle 6 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	58	82,9	52	89,7	7,69	15,64
Cycle 7 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	55	78,6	51	92,7	8,50	16,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	51	72,9	47	92,2	9,22	15,07
Cycle 9 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	47	67,1	47	100,0	9,22	15,07
Cycle 10 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	47	67,1	46	97,9	9,42	16,72
Cycle 11 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	46	65,7	46	100,0	10,87	17,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	45	64,3	41	91,1	9,76	15,35
Cycle 13 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	42	60,0	41	97,6	10,57	15,70
Cycle 14 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	41	58,6	40	97,6	9,17	16,86
Cycle 15 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	40	57,1	40	100,0	10,00	15,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	38	54,3	36	94,7	10,19	17,49
Cycle 17 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	36	51,4	36	100,0	9,26	17,11
Cycle 18 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	35	50,0	32	91,4	8,33	16,93
Cycle 19 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	33	47,1	30	90,9	7,78	20,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	33	47,1	29	87,9	8,05	17,03
Cycle 21 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	27	38,6	24	88,9	6,94	16,97
Cycle 22 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	27	38,6	23	85,2	2,90	9,60
Cycle 23 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	19	27,1	16	84,2	6,25	13,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	18	25,7	16	88,9	6,25	13,44
Cycle 25 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	13	18,6	11	84,6	3,03	10,05
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	9,09	15,57
Cycle 27 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	10	14,3	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	66,67	-
	No	9	12,9	8	88,9	8,33	15,43
Cycle 29 Day 1	Yes	1	12,5	1	100,0	66,67	-
	No	8	11,4	6	75,0	11,11	17,21
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	6,67	14,91
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	6,67	14,91
Cycle 33 Day 1	No	2	2,9	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	0,00	0,00
	No	37	52,9	26	70,3	15,38	16,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DS_SG.xls
28NOV2019 10:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	77	98,7	35,93	25,10
Cycle 2 Day 1	All	72	92,3	64	88,9	23,61	22,09
Cycle 3 Day 1	All	68	87,2	63	92,6	22,75	20,10
Cycle 4 Day 1	All	67	85,9	61	91,0	23,68	21,03
Cycle 5 Day 1	All	65	83,3	63	96,9	24,69	19,39
Cycle 6 Day 1	All	63	80,8	57	90,5	22,22	18,78
Cycle 7 Day 1	All	60	76,9	56	93,3	24,80	18,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	56	71,8	52	92,9	23,50	19,88
Cycle 9 Day 1	All	51	65,4	51	100,0	22,44	18,52
Cycle 10 Day 1	All	51	65,4	50	98,0	24,44	17,96
Cycle 11 Day 1	All	50	64,1	50	100,0	22,22	17,39
Cycle 12 Day 1	All	49	62,8	45	91,8	22,47	18,73
Cycle 13 Day 1	All	46	59,0	45	97,8	21,73	17,40
Cycle 14 Day 1	All	45	57,7	44	97,8	24,75	23,83
Cycle 15 Day 1	All	44	56,4	44	100,0	20,45	18,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	41	52,6	39	95,1	26,50	23,59
Cycle 17 Day 1	All	39	50,0	39	100,0	21,94	23,29
Cycle 18 Day 1	All	38	48,7	35	92,1	20,95	17,83
Cycle 19 Day 1	All	36	46,2	33	91,7	21,55	18,62
Cycle 20 Day 1	All	36	46,2	32	88,9	20,83	17,57
Cycle 21 Day 1	All	29	37,2	26	89,7	25,64	22,61
Cycle 22 Day 1	All	29	37,2	25	86,2	26,67	20,03
Cycle 23 Day 1	All	21	26,9	18	85,7	23,46	23,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	25,6	18	90,0	24,07	16,28
Cycle 25 Day 1	All	15	19,2	13	86,7	21,37	15,36
Cycle 26 Day 1	All	14	17,9	12	85,7	26,85	25,71
Cycle 27 Day 1	All	11	14,1	8	72,7	25,00	22,02
Cycle 28 Day 1	All	10	12,8	9	90,0	32,10	34,00
Cycle 29 Day 1	All	9	11,5	7	77,8	28,57	12,60
Cycle 30 Day 1	All	7	9,0	5	71,4	28,89	9,94
Cycle 31 Day 1	All	7	9,0	5	71,4	31,11	14,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	7,7	5	83,3	26,67	12,67
Cycle 33 Day 1	All	2	2,6	2	100,0	16,67	7,86
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	42,86	22,57
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	42,15	24,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	49	100,0	48	98,0	32,18	25,13
Cycle 2 Day 1	Male	27	93,1	24	88,9	31,48	23,55
	Female	45	91,8	40	88,9	18,89	20,00
Cycle 3 Day 1	Male	25	86,2	24	96,0	20,83	18,62
	Female	43	87,8	39	90,7	23,93	21,10
Cycle 4 Day 1	Male	25	86,2	23	92,0	19,81	18,94
	Female	42	85,7	38	90,5	26,02	22,11
Cycle 5 Day 1	Male	25	86,2	24	96,0	24,07	20,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	40	81,6	39	97,5	25,07	18,86
Cycle 6 Day 1	Male	25	86,2	23	92,0	19,81	18,94
	Female	38	77,6	34	89,5	23,86	18,78
Cycle 7 Day 1	Male	23	79,3	23	100,0	25,12	18,42
	Female	37	75,5	33	89,2	24,58	18,16
Cycle 8 Day 1	Male	21	72,4	19	90,5	26,90	23,81
	Female	35	71,4	33	94,3	21,55	17,33
Cycle 9 Day 1	Male	18	62,1	18	100,0	23,46	17,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	21,89	19,14
Cycle 10 Day 1	Male	18	62,1	18	100,0	29,01	21,27
	Female	33	67,3	32	97,0	21,88	15,58
Cycle 11 Day 1	Male	18	62,1	18	100,0	22,84	17,24
	Female	32	65,3	32	100,0	21,88	17,73
Cycle 12 Day 1	Male	17	58,6	17	100,0	24,84	20,98
	Female	32	65,3	28	87,5	21,03	17,46
Cycle 13 Day 1	Male	17	58,6	17	100,0	20,92	15,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	29	59,2	28	96,6	22,22	18,89
Cycle 14 Day 1	Male	17	58,6	16	94,1	27,78	26,91
	Female	28	57,1	28	100,0	23,02	22,21
Cycle 15 Day 1	Male	16	55,2	16	100,0	22,92	20,87
	Female	28	57,1	28	100,0	19,05	16,80
Cycle 16 Day 1	Male	14	48,3	14	100,0	27,78	25,69
	Female	27	55,1	25	92,6	25,78	22,84
Cycle 17 Day 1	Male	12	41,4	12	100,0	19,44	19,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	27	100,0	23,05	25,21
Cycle 18 Day 1	Male	11	37,9	10	90,9	18,89	22,86
	Female	27	55,1	25	92,6	21,78	15,87
Cycle 19 Day 1	Male	10	34,5	10	100,0	23,33	19,91
	Female	26	53,1	23	88,5	20,77	18,44
Cycle 20 Day 1	Male	10	34,5	9	90,0	13,58	14,46
	Female	26	53,1	23	88,5	23,67	18,14
Cycle 21 Day 1	Male	8	27,6	8	100,0	19,44	14,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	42,9	18	85,7	28,40	25,34
Cycle 22 Day 1	Male	8	27,6	6	75,0	22,22	15,71
	Female	21	42,9	19	90,5	28,07	21,39
Cycle 23 Day 1	Male	5	17,2	4	80,0	8,33	10,64
	Female	16	32,7	14	87,5	27,78	24,56
Cycle 24 Day 1	Male	5	17,2	4	80,0	19,44	13,98
	Female	15	30,6	14	93,3	25,40	17,12
Cycle 25 Day 1	Male	3	10,3	2	66,7	11,11	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	24,5	11	91,7	23,23	15,28
Cycle 26 Day 1	Male	3	10,3	2	66,7	5,56	7,86
	Female	11	22,4	10	90,9	31,11	26,08
Cycle 27 Day 1	Male	3	10,3	2	66,7	11,11	15,71
	Female	8	16,3	6	75,0	29,63	22,95
Cycle 28 Day 1	Male	2	6,9	2	100,0	11,11	15,71
	Female	8	16,3	7	87,5	38,10	36,21
Cycle 29 Day 1	Male	1	3,4	1	100,0	22,22	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	16,3	6	75,0	29,63	13,46
Cycle 30 Day 1	Male	1	3,4	1	100,0	22,22	-
	Female	6	12,2	4	66,7	30,56	10,64
Cycle 31 Day 1	Male	1	3,4	1	100,0	33,33	-
	Female	6	12,2	4	66,7	30,56	16,67
Cycle 32 Day 1	Male	1	3,4	1	100,0	22,22	-
	Female	5	10,2	4	80,0	27,78	14,34
Cycle 33 Day 1	Male	1	3,4	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	2,0	1	100,0	22,22	-
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	50,37	22,95
	Female	21	42,9	13	61,9	34,19	19,49
Age							
Cycle 1 Day 1	18-64	62	100,0	61	98,4	36,25	26,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	34,13	21,99
	>=75	2	100,0	2	100,0	38,89	7,86
Cycle 2 Day 1	18-64	59	95,2	51	86,4	21,57	20,54
	65-74	11	78,6	11	100,0	35,35	27,13
	>=75	2	100,0	2	100,0	11,11	15,71
Cycle 3 Day 1	18-64	56	90,3	52	92,9	22,86	20,92
	65-74	10	71,4	9	90,0	23,46	17,95
	>=75	2	100,0	2	100,0	16,67	7,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	55	88,7	50	90,9	21,56	19,75
	65-74	10	71,4	9	90,0	34,57	26,32
	>=75	2	100,0	2	100,0	27,78	23,57
Cycle 5 Day 1	18-64	53	85,5	52	98,1	22,86	19,61
	65-74	10	71,4	10	100,0	32,22	16,93
	>=75	2	100,0	1	50,0	44,44	-
Cycle 6 Day 1	18-64	51	82,3	46	90,2	20,53	18,44
	65-74	10	71,4	9	90,0	33,33	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	11,11	0,00
Cycle 7 Day 1	18-64	49	79,0	46	93,9	22,22	18,14
	65-74	9	64,3	8	88,9	37,50	13,20
	>=75	2	100,0	2	100,0	33,33	15,71
Cycle 8 Day 1	18-64	45	72,6	41	91,1	22,22	20,34
	65-74	9	64,3	9	100,0	28,40	18,52
	>=75	2	100,0	2	100,0	27,78	23,57
Cycle 9 Day 1	18-64	40	64,5	40	100,0	18,89	16,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	35,80	22,76
	>=75	2	100,0	2	100,0	33,33	15,71
Cycle 10 Day 1	18-64	40	64,5	39	97,5	21,94	17,19
	65-74	9	64,3	9	100,0	35,80	19,07
	>=75	2	100,0	2	100,0	22,22	15,71
Cycle 11 Day 1	18-64	39	62,9	39	100,0	22,22	18,38
	65-74	9	64,3	9	100,0	23,46	12,96
	>=75	2	100,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	38	61,3	35	92,1	20,00	19,40
	65-74	9	64,3	8	88,9	30,56	14,24
	>=75	2	100,0	2	100,0	33,33	15,71
Cycle 13 Day 1	18-64	35	56,5	34	97,1	18,63	14,91
	65-74	9	64,3	9	100,0	29,63	23,57
	>=75	2	100,0	2	100,0	38,89	7,86
Cycle 14 Day 1	18-64	35	56,5	35	100,0	22,22	23,34
	65-74	9	64,3	8	88,9	33,33	25,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	44,44	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	17,78	17,09
	65-74	8	57,1	8	100,0	27,78	18,78
	>=75	1	50,0	1	100,0	55,56	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	25,00	25,24
	65-74	7	50,0	6	85,7	35,19	12,99
	>=75	1	50,0	1	100,0	22,22	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	19,44	20,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	6	42,9	6	100,0	31,48	35,43
	>=75	1	50,0	1	100,0	44,44	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	17,62	14,70
	65-74	6	42,9	5	83,3	37,78	26,76
	>=75	1	50,0	1	100,0	33,33	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	19,44	17,79
	65-74	5	35,7	4	80,0	27,78	19,25
	>=75	1	50,0	1	100,0	55,56	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	17,52	16,97
	65-74	5	35,7	5	100,0	35,56	14,49
	>=75	1	50,0	1	100,0	33,33	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	22,22	18,59
	65-74	4	28,6	4	100,0	41,67	38,89
	>=75	1	50,0	1	100,0	33,33	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	27,22	22,36
	65-74	4	28,6	4	100,0	22,22	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	33,33	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	23,61	24,97
	65-74	2	14,3	2	100,0	22,22	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	24,31	17,32
	65-74	2	14,3	2	100,0	22,22	0,00
Cycle 25 Day 1	18-64	14	22,6	12	85,7	21,30	16,04
	65-74	1	7,1	1	100,0	22,22	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	26,85	25,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	25,00	22,02
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	32,10	34,00
	65-74	1	7,1	0	0,0	-	-
Cycle 29 Day 1	18-64	8	12,9	7	87,5	28,57	12,60
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	28,89	9,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	31,11	14,49
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	27,78	14,34
	65-74	1	7,1	1	100,0	22,22	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	11,11	-
	65-74	1	7,1	1	100,0	22,22	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	43,33	25,21
	65-74	10	71,4	7	70,0	44,44	14,34
	>=75	2	100,0	1	50,0	22,22	-
Race							
Cycle 1 Day 1	White	35	100,0	34	97,1	34,97	27,51
	Other	43	100,0	43	100,0	36,69	23,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	33	94,3	27	81,8	26,75	24,70
	Other	39	90,7	37	94,9	21,32	20,01
Cycle 3 Day 1	White	31	88,6	27	87,1	21,40	20,66
	Other	37	86,0	36	97,3	23,77	19,90
Cycle 4 Day 1	White	31	88,6	26	83,9	17,09	18,39
	Other	36	83,7	35	97,2	28,57	21,77
Cycle 5 Day 1	White	31	88,6	29	93,5	23,75	21,36
	Other	34	79,1	34	100,0	25,49	17,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	30	85,7	25	83,3	24,89	22,29
	Other	33	76,7	32	97,0	20,14	15,57
Cycle 7 Day 1	White	29	82,9	26	89,7	24,36	20,61
	Other	31	72,1	30	96,8	25,19	15,96
Cycle 8 Day 1	White	28	80,0	24	85,7	20,37	19,01
	Other	28	65,1	28	100,0	26,19	20,56
Cycle 9 Day 1	White	26	74,3	26	100,0	23,93	21,93
	Other	25	58,1	25	100,0	20,89	14,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	24,44	20,54
	Other	25	58,1	25	100,0	24,44	15,38
Cycle 11 Day 1	White	26	74,3	26	100,0	21,37	15,69
	Other	24	55,8	24	100,0	23,15	19,36
Cycle 12 Day 1	White	26	74,3	22	84,6	22,73	19,84
	Other	23	53,5	23	100,0	22,22	18,04
Cycle 13 Day 1	White	24	68,6	23	95,8	22,22	20,38
	Other	22	51,2	22	100,0	21,21	14,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	24	68,6	24	100,0	23,15	24,28
	Other	21	48,8	20	95,2	26,67	23,75
Cycle 15 Day 1	White	24	68,6	24	100,0	21,30	19,08
	Other	20	46,5	20	100,0	19,44	17,61
Cycle 16 Day 1	White	22	62,9	20	90,9	23,89	21,41
	Other	19	44,2	19	100,0	29,24	25,98
Cycle 17 Day 1	White	22	62,9	22	100,0	23,23	21,11
	Other	17	39,5	17	100,0	20,26	26,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	21	60,0	18	85,7	19,14	14,16
	Other	17	39,5	17	100,0	22,88	21,33
Cycle 19 Day 1	White	20	57,1	20	100,0	24,44	21,20
	Other	16	37,2	13	81,3	17,09	13,31
Cycle 20 Day 1	White	20	57,1	17	85,0	21,57	19,43
	Other	16	37,2	15	93,8	20,00	15,83
Cycle 21 Day 1	White	16	45,7	14	87,5	26,19	19,78
	Other	13	30,2	12	92,3	25,00	26,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	45,7	13	81,3	29,06	25,47
	Other	13	30,2	12	92,3	24,07	12,38
Cycle 23 Day 1	White	12	34,3	10	83,3	32,22	26,94
	Other	9	20,9	8	88,9	12,50	12,51
Cycle 24 Day 1	White	11	31,4	10	90,9	23,33	19,21
	Other	9	20,9	8	88,9	25,00	12,94
Cycle 25 Day 1	White	10	28,6	8	80,0	20,83	18,25
	Other	5	11,6	5	100,0	22,22	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	28,6	8	80,0	18,06	22,95
	Other	4	9,3	4	100,0	44,44	24,00
Cycle 27 Day 1	White	8	22,9	5	62,5	13,33	12,17
	Other	3	7,0	3	100,0	44,44	22,22
Cycle 28 Day 1	White	7	20,0	6	85,7	12,96	14,77
	Other	3	7,0	3	100,0	70,37	27,96
Cycle 29 Day 1	White	6	17,1	4	66,7	22,22	9,07
	Other	3	7,0	3	100,0	37,04	12,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	11,4	2	50,0	22,22	0,00
	Other	3	7,0	3	100,0	33,33	11,11
Cycle 31 Day 1	White	4	11,4	2	50,0	22,22	15,71
	Other	3	7,0	3	100,0	37,04	12,83
Cycle 32 Day 1	White	4	11,4	3	75,0	18,52	6,42
	Other	2	4,7	2	100,0	38,89	7,86
Cycle 33 Day 1	White	2	5,7	2	100,0	16,67	7,86
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-
End Of Treatment	White	15	42,9	12	80,0	42,59	17,62
	Other	24	55,8	16	66,7	43,06	26,25
Region							
Cycle 1 Day 1	America (AM)	22	100,0	21	95,5	34,92	28,17
	Europe (EU)	17	100,0	17	100,0	45,10	26,49
	Asia (AS)	39	100,0	39	100,0	32,48	22,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	16	80,0	22,92	17,90
	Europe (EU)	16	94,1	13	81,3	34,19	30,58
	Asia (AS)	36	92,3	35	97,2	20,00	19,40
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	21,05	19,21
	Europe (EU)	15	88,2	11	73,3	28,28	24,02
	Asia (AS)	33	84,6	33	100,0	21,89	19,54
Cycle 4 Day 1	America (AM)	20	90,9	19	95,0	19,30	18,46
	Europe (EU)	15	88,2	11	73,3	22,22	20,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	32	82,1	31	96,9	26,88	22,73
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	21,11	18,70
	Europe (EU)	15	88,2	13	86,7	27,35	20,60
	Asia (AS)	30	76,9	30	100,0	25,93	19,65
Cycle 6 Day 1	America (AM)	20	90,9	18	90,0	19,75	19,64
	Europe (EU)	14	82,4	12	85,7	28,70	21,43
	Asia (AS)	29	74,4	27	93,1	20,99	16,97
Cycle 7 Day 1	America (AM)	19	86,4	17	89,5	22,22	20,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	14	82,4	13	92,9	29,91	17,20
	Asia (AS)	27	69,2	26	96,3	23,93	17,12
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	20,26	17,23
	Europe (EU)	14	82,4	11	78,6	25,25	19,30
	Asia (AS)	24	61,5	24	100,0	25,00	22,28
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	21,60	18,46
	Europe (EU)	12	70,6	12	100,0	30,56	23,75
	Asia (AS)	21	53,8	21	100,0	18,52	14,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	26,14	18,40
	Europe (EU)	12	70,6	12	100,0	31,48	21,10
	Asia (AS)	21	53,8	21	100,0	19,05	14,55
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	25,93	22,22
	Europe (EU)	12	70,6	12	100,0	25,93	12,83
	Asia (AS)	20	51,3	20	100,0	16,67	13,73
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	20,26	20,50
	Europe (EU)	12	70,6	9	75,0	32,10	17,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	19	48,7	19	100,0	19,88	17,20
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	18,95	17,02
	Europe (EU)	11	64,7	10	90,9	30,00	21,63
	Asia (AS)	18	46,2	18	100,0	19,75	14,54
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	24,18	24,92
	Europe (EU)	11	64,7	11	100,0	30,30	28,58
	Asia (AS)	17	43,6	16	94,1	21,53	19,65
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	17,65	17,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	64,7	11	100,0	26,26	19,42
	Asia (AS)	16	41,0	16	100,0	19,44	18,37
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	19,84	17,53
	Europe (EU)	11	64,7	9	81,8	34,57	24,50
	Asia (AS)	16	41,0	16	100,0	27,78	27,22
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	22,22	25,04
	Europe (EU)	10	58,8	10	100,0	22,22	14,81
	Asia (AS)	15	38,5	15	100,0	21,48	27,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	19,05	18,71
	Europe (EU)	9	52,9	6	66,7	24,07	12,99
	Asia (AS)	15	38,5	15	100,0	21,48	19,46
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	18,80	18,36
	Europe (EU)	9	52,9	9	100,0	33,33	19,25
	Asia (AS)	14	35,9	11	78,6	15,15	15,13
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	17,95	18,45
	Europe (EU)	9	52,9	6	66,7	29,63	16,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	19,66	17,07
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	20,00	20,82
	Europe (EU)	7	41,2	6	85,7	31,48	14,77
	Asia (AS)	11	28,2	10	90,9	27,78	28,33
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	24,44	26,60
	Europe (EU)	7	41,2	5	71,4	33,33	17,57
	Asia (AS)	11	28,2	10	90,9	25,56	13,91
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	27,16	27,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	29,4	3	60,0	37,04	16,97
	Asia (AS)	7	17,9	6	85,7	11,11	14,05
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	25,00	19,47
	Europe (EU)	5	29,4	4	80,0	19,44	13,98
	Asia (AS)	7	17,9	6	85,7	25,93	15,18
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	15,87	19,09
	Europe (EU)	4	23,5	2	50,0	27,78	7,86
	Asia (AS)	4	10,3	4	100,0	27,78	6,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	18,52	25,01
	Europe (EU)	4	23,5	2	50,0	16,67	23,57
	Asia (AS)	4	10,3	4	100,0	44,44	24,00
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	11,11	12,83
	Europe (EU)	3	17,6	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	38,89	21,28
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	11,11	12,83
	Europe (EU)	2	11,8	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	61,11	29,40
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	22,22	11,11
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	33,33	12,83
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	22,22	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	33,33	11,11
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	22,22	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	37,04	12,83
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	16,67	7,86
	Europe (EU)	1	5,9	1	100,0	22,22	-
	Asia (AS)	3	7,7	2	66,7	38,89	7,86
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	11,11	-
	Europe (EU)	1	5,9	1	100,0	22,22	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	40,40	17,41
	Europe (EU)	6	35,3	4	66,7	58,33	27,78
	Asia (AS)	21	53,8	13	61,9	40,17	24,65
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	29	96,7	27,20	17,96
	1	38	100,0	38	100,0	41,81	26,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	10	100,0	10	100,0	38,89	32,39
Cycle 2 Day 1	0	30	100,0	26	86,7	20,09	22,45
	1	36	94,7	32	88,9	25,00	22,22
	2	6	60,0	6	100,0	31,48	20,39
Cycle 3 Day 1	0	29	96,7	27	93,1	17,70	16,38
	1	34	89,5	31	91,2	24,01	20,10
	2	5	50,0	5	100,0	42,22	28,76
Cycle 4 Day 1	0	29	96,7	25	86,2	17,78	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	25,35	20,40
	2	5	50,0	4	80,0	47,22	22,91
Cycle 5 Day 1	0	29	96,7	29	100,0	19,54	15,33
	1	33	86,8	31	93,9	27,96	21,44
	2	3	30,0	3	100,0	40,74	23,13
Cycle 6 Day 1	0	29	96,7	28	96,6	21,83	19,24
	1	31	81,6	27	87,1	22,22	17,70
	2	3	30,0	2	66,7	27,78	39,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	29	96,7	28	96,6	21,83	18,01
	1	28	73,7	25	89,3	27,11	18,72
	2	3	30,0	3	100,0	33,33	11,11
Cycle 8 Day 1	0	28	93,3	26	92,9	19,23	15,57
	1	25	65,8	23	92,0	28,02	22,94
	2	3	30,0	3	100,0	25,93	27,96
Cycle 9 Day 1	0	26	86,7	26	100,0	22,22	19,37
	1	23	60,5	23	100,0	23,19	18,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	2	20,0	2	100,0	16,67	7,86
Cycle 10 Day 1	0	26	86,7	26	100,0	23,08	18,03
	1	23	60,5	22	95,7	26,26	18,64
	2	2	20,0	2	100,0	22,22	15,71
Cycle 11 Day 1	0	26	86,7	26	100,0	19,23	12,40
	1	22	57,9	22	100,0	25,76	22,06
	2	2	20,0	2	100,0	22,22	15,71
Cycle 12 Day 1	0	25	83,3	22	88,0	21,72	16,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	21	95,5	23,28	21,63
	2	2	20,0	2	100,0	22,22	0,00
Cycle 13 Day 1	0	25	83,3	24	96,0	22,22	19,11
	1	20	52,6	20	100,0	21,67	15,91
	2	1	10,0	1	100,0	11,11	-
Cycle 14 Day 1	0	25	83,3	24	96,0	24,54	24,07
	1	19	50,0	19	100,0	25,73	24,58
	2	1	10,0	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	24	80,0	24	100,0	18,98	17,18
	1	19	50,0	19	100,0	23,39	19,56
	2	1	10,0	1	100,0	0,00	-
Cycle 16 Day 1	0	22	73,3	20	90,9	26,67	22,34
	1	18	47,4	18	100,0	27,16	25,91
	2	1	10,0	1	100,0	11,11	-
Cycle 17 Day 1	0	21	70,0	21	100,0	22,22	28,54
	1	17	44,7	17	100,0	22,88	15,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	21,60	21,04
	1	16	42,1	16	100,0	20,83	14,56
	2	1	10,0	1	100,0	11,11	-
Cycle 19 Day 1	0	20	66,7	19	95,0	21,64	19,76
	1	15	39,5	13	86,7	22,22	18,14
	2	1	10,0	1	100,0	11,11	-
Cycle 20 Day 1	0	20	66,7	17	85,0	21,57	20,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	39,5	14	93,3	20,63	15,01
	2	1	10,0	1	100,0	11,11	-
Cycle 21 Day 1	0	15	50,0	14	93,3	29,37	28,45
	1	13	34,2	11	84,6	23,23	11,61
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	28,70	25,27
	1	13	34,2	12	92,3	25,93	14,47
	2	1	10,0	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	32,10	28,57
	1	9	23,7	8	88,9	16,67	13,28
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	23,46	19,60
	1	9	23,7	8	88,9	23,61	13,85
	2	1	10,0	1	100,0	33,33	-
Cycle 25 Day 1	0	8	26,7	6	75,0	22,22	18,59
	1	7	18,4	7	100,0	20,63	13,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	26,7	6	75,0	20,37	24,76
	1	6	15,8	6	100,0	33,33	27,22
Cycle 27 Day 1	0	6	20,0	3	50,0	14,81	12,83
	1	5	13,2	5	100,0	31,11	25,34
Cycle 28 Day 1	0	5	16,7	4	80,0	13,89	16,67
	1	5	13,2	5	100,0	46,67	38,81
Cycle 29 Day 1	0	4	13,3	2	50,0	22,22	0,00
	1	5	13,2	5	100,0	31,11	14,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	10,0	1	33,3	22,22	-
	1	4	10,5	4	100,0	30,56	10,64
Cycle 31 Day 1	0	3	10,0	1	33,3	33,33	-
	1	4	10,5	4	100,0	30,56	16,67
Cycle 32 Day 1	0	3	10,0	2	66,7	22,22	0,00
	1	3	7,9	3	100,0	29,63	16,97
Cycle 33 Day 1	0	2	6,7	2	100,0	16,67	7,86
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	40,48	18,80
	1	20	52,6	12	60,0	47,22	28,08
	2	4	40,0	2	50,0	33,33	0,00
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	35,48	25,41
	1	3	100,0	3	100,0	44,44	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	44	100,0	43	97,7	35,66	24,91
Cycle 2 Day 1	None	30	96,8	27	90,0	20,99	19,81
	1	2	66,7	0	0,0	-	-
	2 or More	40	90,9	37	92,5	25,53	23,70
Cycle 3 Day 1	None	30	96,8	28	93,3	21,03	19,44
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	34	94,4	24,84	20,66
Cycle 4 Day 1	None	30	96,8	28	93,3	21,43	20,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	11,11	15,71
	2 or More	35	79,5	31	88,6	26,52	21,60
Cycle 5 Day 1	None	30	96,8	30	100,0	22,59	21,54
	1	2	66,7	2	100,0	11,11	15,71
	2 or More	33	75,0	31	93,9	27,60	17,18
Cycle 6 Day 1	None	29	93,5	26	89,7	19,23	19,00
	1	2	66,7	2	100,0	11,11	15,71
	2 or More	32	72,7	29	90,6	25,67	18,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	27	87,1	25	92,6	20,89	18,23
	1	2	66,7	2	100,0	22,22	31,43
	2 or More	31	70,5	29	93,5	28,35	17,21
Cycle 8 Day 1	None	26	83,9	25	96,2	20,89	22,53
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	25,93	17,16
Cycle 9 Day 1	None	25	80,6	25	100,0	19,11	16,52
	1	1	33,3	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	26,22	20,26
Cycle 10 Day 1	None	25	80,6	24	96,0	24,54	21,48
	1	1	33,3	1	100,0	11,11	-
	2 or More	25	56,8	25	100,0	24,89	14,44
Cycle 11 Day 1	None	25	80,6	25	100,0	21,78	21,63
	1	1	33,3	1	100,0	11,11	-
	2 or More	24	54,5	24	100,0	23,15	12,22
Cycle 12 Day 1	None	25	80,6	24	96,0	20,37	19,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	11,11	-
	2 or More	23	52,3	20	87,0	25,56	18,06
Cycle 13 Day 1	None	24	77,4	23	95,8	17,87	14,50
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	26,98	19,11
Cycle 14 Day 1	None	23	74,2	23	100,0	25,12	24,89
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	20	95,2	25,56	23,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	23	74,2	23	100,0	17,39	18,60
	1	1	33,3	1	100,0	11,11	-
	2 or More	20	45,5	20	100,0	24,44	17,88
Cycle 16 Day 1	None	20	64,5	19	95,0	25,15	25,62
	1	1	33,3	1	100,0	11,11	-
	2 or More	20	45,5	19	95,0	28,65	22,32
Cycle 17 Day 1	None	19	61,3	19	100,0	16,37	17,52
	1	1	33,3	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	19	43,2	19	100,0	28,07	27,56
Cycle 18 Day 1	None	18	58,1	17	94,4	16,99	18,05
	1	1	33,3	1	100,0	11,11	-
	2 or More	19	43,2	17	89,5	25,49	17,46
Cycle 19 Day 1	None	17	54,8	17	100,0	13,07	15,33
	1	1	33,3	1	100,0	11,11	-
	2 or More	18	40,9	15	83,3	31,85	17,75
Cycle 20 Day 1	None	17	54,8	16	94,1	11,81	11,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	22,22	-
	2 or More	18	40,9	15	83,3	30,37	19,00
Cycle 21 Day 1	None	15	48,4	13	86,7	13,68	11,25
	2 or More	14	31,8	13	92,9	37,61	25,07
Cycle 22 Day 1	None	15	48,4	13	86,7	16,24	13,31
	2 or More	14	31,8	12	85,7	37,96	20,36
Cycle 23 Day 1	None	10	32,3	9	90,0	13,58	9,26
	2 or More	11	25,0	9	81,8	33,33	29,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	32,3	10	100,0	15,56	11,94
	2 or More	10	22,7	8	80,0	34,72	15,07
Cycle 25 Day 1	None	9	29,0	8	88,9	13,89	11,50
	2 or More	6	13,6	5	83,3	33,33	13,61
Cycle 26 Day 1	None	8	25,8	8	100,0	18,06	25,85
	2 or More	6	13,6	4	66,7	44,44	15,71
Cycle 27 Day 1	None	7	22,6	6	85,7	22,22	24,34
	2 or More	4	9,1	2	50,0	33,33	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	22,6	7	100,0	20,63	24,37
	2 or More	3	6,8	2	66,7	72,22	39,28
Cycle 29 Day 1	None	6	19,4	5	83,3	26,67	12,67
	2 or More	3	6,8	2	66,7	33,33	15,71
Cycle 30 Day 1	None	4	12,9	3	75,0	25,93	6,42
	2 or More	3	6,8	2	66,7	33,33	15,71
Cycle 31 Day 1	None	4	12,9	3	75,0	22,22	11,11
	2 or More	3	6,8	2	66,7	44,44	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	22,22	11,11
	2 or More	2	4,5	2	100,0	33,33	15,71
Cycle 33 Day 1	None	1	3,2	1	100,0	11,11	-
	2 or More	1	2,3	1	100,0	22,22	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	42,59	21,62
	1	2	66,7	1	50,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	54,5	15	62,5	41,48	23,93
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	35,48	25,41
	Previously Treated	47	100,0	46	97,9	36,23	25,17
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	20,99	19,81
	Previously Treated	42	89,4	37	88,1	25,53	23,70
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	21,03	19,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	38	80,9	35	92,1	24,13	20,78
Cycle 4 Day 1	Naïve	30	96,8	28	93,3	21,43	20,72
	Previously Treated	37	78,7	33	89,2	25,59	21,42
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	22,59	21,54
	Previously Treated	35	74,5	33	94,3	26,60	17,33
Cycle 6 Day 1	Naïve	29	93,5	26	89,7	19,23	19,00
	Previously Treated	34	72,3	31	91,2	24,73	18,53
Cycle 7 Day 1	Naïve	27	87,1	25	92,6	20,89	18,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	33	70,2	31	93,9	27,96	17,65
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	20,89	22,53
	Previously Treated	30	63,8	27	90,0	25,93	17,16
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	19,11	16,52
	Previously Treated	26	55,3	26	100,0	25,64	20,07
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	24,54	21,48
	Previously Treated	26	55,3	26	100,0	24,36	14,41
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	21,78	21,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	53,2	25	100,0	22,67	12,21
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	20,37	19,57
	Previously Treated	24	51,1	21	87,5	24,87	17,88
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	17,87	14,50
	Previously Treated	22	46,8	22	100,0	25,76	19,51
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	25,12	24,89
	Previously Treated	22	46,8	21	95,5	24,34	23,21
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	17,39	18,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	21	100,0	23,81	17,67
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	25,15	25,62
	Previously Treated	21	44,7	20	95,2	27,78	22,08
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	16,37	17,52
	Previously Treated	20	42,6	20	100,0	27,22	27,09
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	16,99	18,05
	Previously Treated	20	42,6	18	90,0	24,69	17,28
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	13,07	15,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	40,4	16	84,2	30,56	17,92
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	11,81	11,09
	Previously Treated	19	40,4	16	84,2	29,86	18,47
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	13,68	11,25
	Previously Treated	14	29,8	13	92,9	37,61	25,07
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	16,24	13,31
	Previously Treated	14	29,8	12	85,7	37,96	20,36
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	13,58	9,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	33,33	29,40
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	15,56	11,94
	Previously Treated	10	21,3	8	80,0	34,72	15,07
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	13,89	11,50
	Previously Treated	6	12,8	5	83,3	33,33	13,61
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	18,06	25,85
	Previously Treated	6	12,8	4	66,7	44,44	15,71
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	22,22	24,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	8,5	2	50,0	33,33	15,71
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	20,63	24,37
	Previously Treated	3	6,4	2	66,7	72,22	39,28
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	26,67	12,67
	Previously Treated	3	6,4	2	66,7	33,33	15,71
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	25,93	6,42
	Previously Treated	3	6,4	2	66,7	33,33	15,71
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	22,22	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	44,44	0,00
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	22,22	11,11
	Previously Treated	2	4,3	2	100,0	33,33	15,71
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	11,11	-
	Previously Treated	1	2,1	1	100,0	22,22	-
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	42,59	21,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	16	61,5	43,06	23,96
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	35,24	24,33
	Central	43	100,0	42	97,7	36,51	26,00
Cycle 2 Day 1	Local	32	91,4	30	93,8	20,74	18,39
	Central	40	93,0	34	85,0	26,14	24,90
Cycle 3 Day 1	Local	29	82,9	27	93,1	19,34	17,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	39	90,7	36	92,3	25,31	21,84
Cycle 4 Day 1	Local	28	80,0	24	85,7	20,83	19,74
	Central	39	90,7	37	94,9	25,53	21,89
Cycle 5 Day 1	Local	27	77,1	27	100,0	24,69	20,75
	Central	38	88,4	36	94,7	24,69	18,61
Cycle 6 Day 1	Local	27	77,1	27	100,0	19,34	19,87
	Central	36	83,7	30	83,3	24,81	17,67
Cycle 7 Day 1	Local	27	77,1	27	100,0	20,99	18,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	33	76,7	29	87,9	28,35	17,71
Cycle 8 Day 1	Local	26	74,3	26	100,0	20,94	18,14
	Central	30	69,8	26	86,7	26,07	21,53
Cycle 9 Day 1	Local	25	71,4	25	100,0	21,33	21,74
	Central	26	60,5	26	100,0	23,50	15,18
Cycle 10 Day 1	Local	25	71,4	24	96,0	24,54	18,82
	Central	26	60,5	26	100,0	24,36	17,50
Cycle 11 Day 1	Local	24	68,6	24	100,0	22,69	20,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	26	60,5	26	100,0	21,79	14,90
Cycle 12 Day 1	Local	23	65,7	22	95,7	18,69	17,94
	Central	26	60,5	23	88,5	26,09	19,13
Cycle 13 Day 1	Local	22	62,9	22	100,0	19,19	17,88
	Central	24	55,8	23	95,8	24,15	16,97
Cycle 14 Day 1	Local	22	62,9	22	100,0	21,72	21,27
	Central	23	53,5	22	95,7	27,78	26,28
Cycle 15 Day 1	Local	22	62,9	22	100,0	17,68	18,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	23,23	17,79
Cycle 16 Day 1	Local	20	57,1	20	100,0	19,44	17,24
	Central	21	48,8	19	90,5	33,92	27,34
Cycle 17 Day 1	Local	20	57,1	20	100,0	16,67	17,48
	Central	19	44,2	19	100,0	27,49	27,56
Cycle 18 Day 1	Local	20	57,1	19	95,0	16,96	16,72
	Central	18	41,9	16	88,9	25,69	18,47
Cycle 19 Day 1	Local	19	54,3	17	89,5	20,26	18,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	39,5	16	94,1	22,92	19,65
Cycle 20 Day 1	Local	19	54,3	17	89,5	15,03	13,57
	Central	17	39,5	15	88,2	27,41	19,64
Cycle 21 Day 1	Local	14	40,0	12	85,7	16,67	15,35
	Central	15	34,9	14	93,3	33,33	25,41
Cycle 22 Day 1	Local	14	40,0	12	85,7	20,37	16,30
	Central	15	34,9	13	86,7	32,48	21,97
Cycle 23 Day 1	Local	11	31,4	10	90,9	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	23,3	8	80,0	36,11	25,02
Cycle 24 Day 1	Local	11	31,4	10	90,9	23,33	19,21
	Central	9	20,9	8	88,9	25,00	12,94
Cycle 25 Day 1	Local	7	20,0	7	100,0	20,63	18,62
	Central	8	18,6	6	75,0	22,22	12,17
Cycle 26 Day 1	Local	6	17,1	6	100,0	31,48	32,52
	Central	8	18,6	6	75,0	22,22	18,59
Cycle 27 Day 1	Local	4	11,4	4	100,0	27,78	27,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	16,3	4	57,1	22,22	18,14
Cycle 28 Day 1	Local	4	11,4	4	100,0	27,78	27,96
	Central	6	14,0	5	83,3	35,56	41,13
Cycle 29 Day 1	Local	3	8,6	3	100,0	25,93	16,97
	Central	6	14,0	4	66,7	30,56	10,64
Cycle 30 Day 1	Local	3	8,6	3	100,0	25,93	6,42
	Central	4	9,3	2	50,0	33,33	15,71
Cycle 31 Day 1	Local	3	8,6	3	100,0	22,22	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	9,3	2	50,0	44,44	0,00
Cycle 32 Day 1	Local	3	8,6	3	100,0	22,22	11,11
	Central	3	7,0	2	66,7	33,33	15,71
Cycle 33 Day 1	Local	1	2,9	1	100,0	11,11	-
	Central	1	2,3	1	100,0	22,22	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	37,30	16,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	21	48,8	14	66,7	48,41	26,73
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	73	98,6	35,92	24,95
	No	4	100,0	4	100,0	36,11	31,91
Cycle 2 Day 1	Yes	70	94,6	62	88,6	22,58	20,81
	No	2	50,0	2	100,0	55,56	47,14
Cycle 3 Day 1	Yes	66	89,2	61	92,4	22,04	19,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	44,44	15,71
Cycle 4 Day 1	Yes	65	87,8	59	90,8	22,03	19,08
	No	2	50,0	2	100,0	72,22	23,57
Cycle 5 Day 1	Yes	63	85,1	61	96,8	23,68	18,86
	No	2	50,0	2	100,0	55,56	0,00
Cycle 6 Day 1	Yes	61	82,4	55	90,2	21,21	18,30
	No	2	50,0	2	100,0	50,00	7,86
Cycle 7 Day 1	Yes	58	78,4	54	93,1	23,66	17,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	55,56	0,00
Cycle 8 Day 1	Yes	54	73,0	50	92,6	22,22	19,18
	No	2	50,0	2	100,0	55,56	0,00
Cycle 9 Day 1	Yes	49	66,2	49	100,0	21,54	18,20
	No	2	50,0	2	100,0	44,44	15,71
Cycle 10 Day 1	Yes	49	66,2	48	98,0	23,61	17,70
	No	2	50,0	2	100,0	44,44	15,71
Cycle 11 Day 1	Yes	48	64,9	48	100,0	21,76	17,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	15,71
Cycle 12 Day 1	Yes	47	63,5	43	91,5	21,71	18,46
	No	2	50,0	2	100,0	38,89	23,57
Cycle 13 Day 1	Yes	44	59,5	43	97,7	20,93	17,01
	No	2	50,0	2	100,0	38,89	23,57
Cycle 14 Day 1	Yes	43	58,1	42	97,7	23,02	22,94
	No	2	50,0	2	100,0	61,11	7,86
Cycle 15 Day 1	Yes	42	56,8	42	100,0	19,05	17,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	50,00	7,86
Cycle 16 Day 1	Yes	39	52,7	37	94,9	24,62	22,70
	No	2	50,0	2	100,0	61,11	7,86
Cycle 17 Day 1	Yes	37	50,0	37	100,0	18,92	19,04
	No	2	50,0	2	100,0	77,78	31,43
Cycle 18 Day 1	Yes	36	48,6	33	91,7	19,19	16,26
	No	2	50,0	2	100,0	50,00	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	21,18	18,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	1	50,0	33,33	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	20,00	16,86
	No	2	50,0	2	100,0	33,33	31,43
Cycle 21 Day 1	Yes	27	36,5	24	88,9	22,69	17,49
	No	2	50,0	2	100,0	61,11	55,00
Cycle 22 Day 1	Yes	27	36,5	23	85,2	27,05	20,87
	No	2	50,0	2	100,0	22,22	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	24,84	23,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	25,49	15,60
	No	1	25,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	18,9	12	85,7	20,37	15,59
	No	1	25,0	1	100,0	33,33	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	22,22	21,08
	No	1	25,0	1	100,0	77,78	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	19,05	15,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	66,67	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	27,78	33,60
	No	1	25,0	1	100,0	66,67	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	25,93	11,48
	No	1	25,0	1	100,0	44,44	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	27,78	11,11
	No	1	25,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	33,33	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	22,22	-
Cycle 32 Day 1	Yes	5	6,8	4	80,0	25,00	13,98
	No	1	25,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	16,67	7,86
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	42,86	22,57
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	44,44	26,56
	No	70	100,0	69	98,6	34,94	24,94
Cycle 2 Day 1	Yes	5	62,5	5	100,0	24,44	27,67
	No	67	95,7	59	88,1	23,54	21,84
Cycle 3 Day 1	Yes	5	62,5	4	80,0	19,44	13,98
	No	63	90,0	59	93,7	22,98	20,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	5	62,5	5	100,0	26,67	32,01
	No	62	88,6	56	90,3	23,41	20,18
Cycle 5 Day 1	Yes	5	62,5	5	100,0	28,89	35,66
	No	60	85,7	58	96,7	24,33	17,84
Cycle 6 Day 1	Yes	5	62,5	5	100,0	22,22	26,06
	No	58	82,9	52	89,7	22,22	18,28
Cycle 7 Day 1	Yes	5	62,5	5	100,0	26,67	24,34
	No	55	78,6	51	92,7	24,62	17,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	5	62,5	5	100,0	40,00	37,35
	No	51	72,9	47	92,2	21,75	16,86
Cycle 9 Day 1	Yes	4	50,0	4	100,0	25,00	29,22
	No	47	67,1	47	100,0	22,22	17,80
Cycle 10 Day 1	Yes	4	50,0	4	100,0	27,78	29,40
	No	47	67,1	46	97,9	24,15	17,10
Cycle 11 Day 1	Yes	4	50,0	4	100,0	44,44	40,57
	No	46	65,7	46	100,0	20,29	13,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	4	50,0	4	100,0	22,22	31,43
	No	45	64,3	41	91,1	22,49	17,65
Cycle 13 Day 1	Yes	4	50,0	4	100,0	16,67	21,28
	No	42	60,0	41	97,6	22,22	17,21
Cycle 14 Day 1	Yes	4	50,0	4	100,0	30,56	27,78
	No	41	58,6	40	97,6	24,17	23,72
Cycle 15 Day 1	Yes	4	50,0	4	100,0	22,22	31,43
	No	40	57,1	40	100,0	20,28	17,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	37,5	3	100,0	29,63	33,95
	No	38	54,3	36	94,7	26,23	23,18
Cycle 17 Day 1	Yes	3	37,5	3	100,0	14,81	12,83
	No	36	51,4	36	100,0	22,53	23,98
Cycle 18 Day 1	Yes	3	37,5	3	100,0	14,81	12,83
	No	35	50,0	32	91,4	21,53	18,28
Cycle 19 Day 1	Yes	3	37,5	3	100,0	11,11	11,11
	No	33	47,1	30	90,9	22,59	19,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	37,5	3	100,0	14,81	12,83
	No	33	47,1	29	87,9	21,46	18,05
Cycle 21 Day 1	Yes	2	25,0	2	100,0	16,67	7,86
	No	27	38,6	24	88,9	26,39	23,36
Cycle 22 Day 1	Yes	2	25,0	2	100,0	27,78	7,86
	No	27	38,6	23	85,2	26,57	20,85
Cycle 23 Day 1	Yes	2	25,0	2	100,0	22,22	0,00
	No	19	27,1	16	84,2	23,61	24,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	25,0	2	100,0	22,22	0,00
	No	18	25,7	16	88,9	24,31	17,32
Cycle 25 Day 1	Yes	2	25,0	2	100,0	16,67	7,86
	No	13	18,6	11	84,6	22,22	16,48
Cycle 26 Day 1	Yes	1	12,5	1	100,0	22,22	-
	No	13	18,6	11	84,6	27,27	26,93
Cycle 27 Day 1	Yes	1	12,5	1	100,0	22,22	-
	No	10	14,3	7	70,0	25,40	23,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	9	12,9	8	88,9	31,94	36,34
Cycle 29 Day 1	Yes	1	12,5	1	100,0	22,22	-
	No	8	11,4	6	75,0	29,63	13,46
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	28,89	9,94
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	31,11	14,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	26,67	12,67
Cycle 33 Day 1	No	2	2,9	2	100,0	16,67	7,86
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	72,22	39,28
	No	37	52,9	26	70,3	40,60	20,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13DY_SG.xls
29NOV2019 14:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	77	98,7	2,16	8,27
Cycle 2 Day 1	All	72	92,3	65	90,3	0,51	4,13
Cycle 3 Day 1	All	68	87,2	63	92,6	0,53	4,20
Cycle 4 Day 1	All	67	85,9	61	91,0	1,09	5,99
Cycle 5 Day 1	All	65	83,3	63	96,9	1,06	5,89
Cycle 6 Day 1	All	63	80,8	57	90,5	1,17	6,19
Cycle 7 Day 1	All	60	76,9	56	93,3	1,79	9,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	56	71,8	52	92,9	0,00	0,00
Cycle 9 Day 1	All	51	65,4	51	100,0	0,00	0,00
Cycle 10 Day 1	All	51	65,4	50	98,0	0,67	4,71
Cycle 11 Day 1	All	50	64,1	50	100,0	0,00	0,00
Cycle 12 Day 1	All	49	62,8	45	91,8	0,74	4,97
Cycle 13 Day 1	All	46	59,0	45	97,8	0,00	0,00
Cycle 14 Day 1	All	45	57,7	44	97,8	0,00	0,00
Cycle 15 Day 1	All	44	56,4	44	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	41	52,6	39	95,1	0,00	0,00
Cycle 17 Day 1	All	39	50,0	39	100,0	0,00	0,00
Cycle 18 Day 1	All	38	48,7	35	92,1	0,00	0,00
Cycle 19 Day 1	All	36	46,2	33	91,7	0,00	0,00
Cycle 20 Day 1	All	36	46,2	32	88,9	0,00	0,00
Cycle 21 Day 1	All	29	37,2	26	89,7	0,00	0,00
Cycle 22 Day 1	All	29	37,2	25	86,2	0,00	0,00
Cycle 23 Day 1	All	21	26,9	18	85,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	25,6	18	90,0	0,00	0,00
Cycle 25 Day 1	All	15	19,2	13	86,7	0,00	0,00
Cycle 26 Day 1	All	14	17,9	12	85,7	0,00	0,00
Cycle 27 Day 1	All	11	14,1	8	72,7	0,00	0,00
Cycle 28 Day 1	All	10	12,8	9	90,0	11,11	33,33
Cycle 29 Day 1	All	9	11,5	7	77,8	0,00	0,00
Cycle 30 Day 1	All	7	9,0	5	71,4	0,00	0,00
Cycle 31 Day 1	All	7	9,0	5	71,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	7,7	5	83,3	0,00	0,00
Cycle 33 Day 1	All	2	2,6	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	5,95	13,00
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	2,30	8,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	49	100,0	48	98,0	2,08	8,15
Cycle 2 Day 1	Male	27	93,1	25	92,6	1,33	6,67
	Female	45	91,8	40	88,9	0,00	0,00
Cycle 3 Day 1	Male	25	86,2	24	96,0	1,39	6,80
	Female	43	87,8	39	90,7	0,00	0,00
Cycle 4 Day 1	Male	25	86,2	23	92,0	2,90	9,60
	Female	42	85,7	38	90,5	0,00	0,00
Cycle 5 Day 1	Male	25	86,2	24	96,0	2,78	9,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	40	81,6	39	97,5	0,00	0,00
Cycle 6 Day 1	Male	25	86,2	23	92,0	2,90	9,60
	Female	38	77,6	34	89,5	0,00	0,00
Cycle 7 Day 1	Male	23	79,3	23	100,0	4,35	15,26
	Female	37	75,5	33	89,2	0,00	0,00
Cycle 8 Day 1	Male	21	72,4	19	90,5	0,00	0,00
	Female	35	71,4	33	94,3	0,00	0,00
Cycle 9 Day 1	Male	18	62,1	18	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	0,00	0,00
Cycle 10 Day 1	Male	18	62,1	18	100,0	1,85	7,86
	Female	33	67,3	32	97,0	0,00	0,00
Cycle 11 Day 1	Male	18	62,1	18	100,0	0,00	0,00
	Female	32	65,3	32	100,0	0,00	0,00
Cycle 12 Day 1	Male	17	58,6	17	100,0	1,96	8,08
	Female	32	65,3	28	87,5	0,00	0,00
Cycle 13 Day 1	Male	17	58,6	17	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	29	59,2	28	96,6	0,00	0,00
Cycle 14 Day 1	Male	17	58,6	16	94,1	0,00	0,00
	Female	28	57,1	28	100,0	0,00	0,00
Cycle 15 Day 1	Male	16	55,2	16	100,0	0,00	0,00
	Female	28	57,1	28	100,0	0,00	0,00
Cycle 16 Day 1	Male	14	48,3	14	100,0	0,00	0,00
	Female	27	55,1	25	92,6	0,00	0,00
Cycle 17 Day 1	Male	12	41,4	12	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	27	100,0	0,00	0,00
Cycle 18 Day 1	Male	11	37,9	10	90,9	0,00	0,00
	Female	27	55,1	25	92,6	0,00	0,00
Cycle 19 Day 1	Male	10	34,5	10	100,0	0,00	0,00
	Female	26	53,1	23	88,5	0,00	0,00
Cycle 20 Day 1	Male	10	34,5	9	90,0	0,00	0,00
	Female	26	53,1	23	88,5	0,00	0,00
Cycle 21 Day 1	Male	8	27,6	8	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	42,9	18	85,7	0,00	0,00
Cycle 22 Day 1	Male	8	27,6	6	75,0	0,00	0,00
	Female	21	42,9	19	90,5	0,00	0,00
Cycle 23 Day 1	Male	5	17,2	4	80,0	0,00	0,00
	Female	16	32,7	14	87,5	0,00	0,00
Cycle 24 Day 1	Male	5	17,2	4	80,0	0,00	0,00
	Female	15	30,6	14	93,3	0,00	0,00
Cycle 25 Day 1	Male	3	10,3	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	24,5	11	91,7	0,00	0,00
Cycle 26 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	11	22,4	10	90,9	0,00	0,00
Cycle 27 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	8	16,3	6	75,0	0,00	0,00
Cycle 28 Day 1	Male	2	6,9	2	100,0	0,00	0,00
	Female	8	16,3	7	87,5	14,29	37,80
Cycle 29 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	16,3	6	75,0	0,00	0,00
Cycle 30 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	0,00	0,00
Cycle 31 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	0,00	0,00
Cycle 32 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	5	10,2	4	80,0	0,00	0,00
Cycle 33 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	2,0	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	4,44	11,73
	Female	21	42,9	13	61,9	7,69	14,62
Age							
Cycle 1 Day 1	18-64	62	100,0	61	98,4	2,73	9,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	0,00	0,00
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	18-64	59	95,2	52	88,1	0,64	4,62
	65-74	11	78,6	11	100,0	0,00	0,00
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 3 Day 1	18-64	56	90,3	52	92,9	0,64	4,62
	65-74	10	71,4	9	90,0	0,00	0,00
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	55	88,7	50	90,9	1,33	6,60
	65-74	10	71,4	9	90,0	0,00	0,00
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 5 Day 1	18-64	53	85,5	52	98,1	1,28	6,47
	65-74	10	71,4	10	100,0	0,00	0,00
	>=75	2	100,0	1	50,0	0,00	-
Cycle 6 Day 1	18-64	51	82,3	46	90,2	1,45	6,87
	65-74	10	71,4	9	90,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 7 Day 1	18-64	49	79,0	46	93,9	2,17	10,89
	65-74	9	64,3	8	88,9	0,00	0,00
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 8 Day 1	18-64	45	72,6	41	91,1	0,00	0,00
	65-74	9	64,3	9	100,0	0,00	0,00
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 9 Day 1	18-64	40	64,5	40	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	0,00	0,00
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 10 Day 1	18-64	40	64,5	39	97,5	0,85	5,34
	65-74	9	64,3	9	100,0	0,00	0,00
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 11 Day 1	18-64	39	62,9	39	100,0	0,00	0,00
	65-74	9	64,3	9	100,0	0,00	0,00
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	38	61,3	35	92,1	0,95	5,63
	65-74	9	64,3	8	88,9	0,00	0,00
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 13 Day 1	18-64	35	56,5	34	97,1	0,00	0,00
	65-74	9	64,3	9	100,0	0,00	0,00
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 14 Day 1	18-64	35	56,5	35	100,0	0,00	0,00
	65-74	9	64,3	8	88,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	0,00	0,00
	65-74	8	57,1	8	100,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	0,00	0,00
	65-74	7	50,0	6	85,7	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	6	42,9	6	100,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	0,00	0,00
	65-74	6	42,9	5	83,3	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	0,00	0,00
	65-74	5	35,7	4	80,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	0,00	0,00
	65-74	5	35,7	5	100,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	0,00	0,00
	65-74	4	28,6	4	100,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	0,00	0,00
	65-74	4	28,6	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	0,00	0,00
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	0,00	0,00
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	22,6	12	85,7	0,00	0,00
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	0,00	0,00
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	11,11	33,33
	65-74	1	7,1	0	0,0	-	-
Cycle 29 Day 1	18-64	8	12,9	7	87,5	0,00	0,00
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	0,00	0,00
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	0,00	0,00
	65-74	1	7,1	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	0,00	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	8,33	14,81
	65-74	10	71,4	7	70,0	0,00	0,00
	>=75	2	100,0	1	50,0	0,00	-
Race							
Cycle 1 Day 1	White	35	100,0	34	97,1	2,94	9,60
	Other	43	100,0	43	100,0	1,55	7,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	33	94,3	28	84,8	1,19	6,30
	Other	39	90,7	37	94,9	0,00	0,00
Cycle 3 Day 1	White	31	88,6	27	87,1	1,23	6,42
	Other	37	86,0	36	97,3	0,00	0,00
Cycle 4 Day 1	White	31	88,6	26	83,9	1,28	6,54
	Other	36	83,7	35	97,2	0,95	5,63
Cycle 5 Day 1	White	31	88,6	29	93,5	1,15	6,19
	Other	34	79,1	34	100,0	0,98	5,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	30	85,7	25	83,3	1,33	6,67
	Other	33	76,7	32	97,0	1,04	5,89
Cycle 7 Day 1	White	29	82,9	26	89,7	1,28	6,54
	Other	31	72,1	30	96,8	2,22	12,17
Cycle 8 Day 1	White	28	80,0	24	85,7	0,00	0,00
	Other	28	65,1	28	100,0	0,00	0,00
Cycle 9 Day 1	White	26	74,3	26	100,0	0,00	0,00
	Other	25	58,1	25	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	1,33	6,67
	Other	25	58,1	25	100,0	0,00	0,00
Cycle 11 Day 1	White	26	74,3	26	100,0	0,00	0,00
	Other	24	55,8	24	100,0	0,00	0,00
Cycle 12 Day 1	White	26	74,3	22	84,6	1,52	7,11
	Other	23	53,5	23	100,0	0,00	0,00
Cycle 13 Day 1	White	24	68,6	23	95,8	0,00	0,00
	Other	22	51,2	22	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	24	68,6	24	100,0	0,00	0,00
	Other	21	48,8	20	95,2	0,00	0,00
Cycle 15 Day 1	White	24	68,6	24	100,0	0,00	0,00
	Other	20	46,5	20	100,0	0,00	0,00
Cycle 16 Day 1	White	22	62,9	20	90,9	0,00	0,00
	Other	19	44,2	19	100,0	0,00	0,00
Cycle 17 Day 1	White	22	62,9	22	100,0	0,00	0,00
	Other	17	39,5	17	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	21	60,0	18	85,7	0,00	0,00
	Other	17	39,5	17	100,0	0,00	0,00
Cycle 19 Day 1	White	20	57,1	20	100,0	0,00	0,00
	Other	16	37,2	13	81,3	0,00	0,00
Cycle 20 Day 1	White	20	57,1	17	85,0	0,00	0,00
	Other	16	37,2	15	93,8	0,00	0,00
Cycle 21 Day 1	White	16	45,7	14	87,5	0,00	0,00
	Other	13	30,2	12	92,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	45,7	13	81,3	0,00	0,00
	Other	13	30,2	12	92,3	0,00	0,00
Cycle 23 Day 1	White	12	34,3	10	83,3	0,00	0,00
	Other	9	20,9	8	88,9	0,00	0,00
Cycle 24 Day 1	White	11	31,4	10	90,9	0,00	0,00
	Other	9	20,9	8	88,9	0,00	0,00
Cycle 25 Day 1	White	10	28,6	8	80,0	0,00	0,00
	Other	5	11,6	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	28,6	8	80,0	0,00	0,00
	Other	4	9,3	4	100,0	0,00	0,00
Cycle 27 Day 1	White	8	22,9	5	62,5	0,00	0,00
	Other	3	7,0	3	100,0	0,00	0,00
Cycle 28 Day 1	White	7	20,0	6	85,7	0,00	0,00
	Other	3	7,0	3	100,0	33,33	57,74
Cycle 29 Day 1	White	6	17,1	4	66,7	0,00	0,00
	Other	3	7,0	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	11,4	2	50,0	0,00	0,00
	Other	3	7,0	3	100,0	0,00	0,00
Cycle 31 Day 1	White	4	11,4	2	50,0	0,00	0,00
	Other	3	7,0	3	100,0	0,00	0,00
Cycle 32 Day 1	White	4	11,4	3	75,0	0,00	0,00
	Other	2	4,7	2	100,0	0,00	0,00
Cycle 33 Day 1	White	2	5,7	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-
End Of Treatment	White	15	42,9	12	80,0	8,33	15,08
	Other	24	55,8	16	66,7	4,17	11,39
Region							
Cycle 1 Day 1	America (AM)	22	100,0	21	95,5	3,17	10,03
	Europe (EU)	17	100,0	17	100,0	0,00	0,00
	Asia (AS)	39	100,0	39	100,0	2,56	9,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	0,00	0,00
	Europe (EU)	16	94,1	13	81,3	2,56	9,25
	Asia (AS)	36	92,3	35	97,2	0,00	0,00
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	0,00	0,00
	Europe (EU)	15	88,2	11	73,3	3,03	10,05
	Asia (AS)	33	84,6	33	100,0	0,00	0,00
Cycle 4 Day 1	America (AM)	20	90,9	19	95,0	0,00	0,00
	Europe (EU)	15	88,2	11	73,3	3,03	10,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	32	82,1	31	96,9	1,08	5,99
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	0,00	0,00
	Europe (EU)	15	88,2	13	86,7	2,56	9,25
	Asia (AS)	30	76,9	30	100,0	1,11	6,09
Cycle 6 Day 1	America (AM)	20	90,9	18	90,0	0,00	0,00
	Europe (EU)	14	82,4	12	85,7	2,78	9,62
	Asia (AS)	29	74,4	27	93,1	1,23	6,42
Cycle 7 Day 1	America (AM)	19	86,4	17	89,5	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	14	82,4	13	92,9	2,56	9,25
	Asia (AS)	27	69,2	26	96,3	2,56	13,07
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	0,00	0,00
	Europe (EU)	14	82,4	11	78,6	0,00	0,00
	Asia (AS)	24	61,5	24	100,0	0,00	0,00
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	0,00	0,00
	Europe (EU)	12	70,6	12	100,0	0,00	0,00
	Asia (AS)	21	53,8	21	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	0,00	0,00
	Europe (EU)	12	70,6	12	100,0	2,78	9,62
	Asia (AS)	21	53,8	21	100,0	0,00	0,00
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	0,00	0,00
	Europe (EU)	12	70,6	12	100,0	0,00	0,00
	Asia (AS)	20	51,3	20	100,0	0,00	0,00
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	0,00	0,00
	Europe (EU)	12	70,6	9	75,0	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	19	48,7	19	100,0	0,00	0,00
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	0,00	0,00
	Europe (EU)	11	64,7	10	90,9	0,00	0,00
	Asia (AS)	18	46,2	18	100,0	0,00	0,00
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	0,00	0,00
	Europe (EU)	11	64,7	11	100,0	0,00	0,00
	Asia (AS)	17	43,6	16	94,1	0,00	0,00
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	64,7	11	100,0	0,00	0,00
	Asia (AS)	16	41,0	16	100,0	0,00	0,00
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	0,00	0,00
	Europe (EU)	11	64,7	9	81,8	0,00	0,00
	Asia (AS)	16	41,0	16	100,0	0,00	0,00
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	0,00	0,00
	Europe (EU)	10	58,8	10	100,0	0,00	0,00
	Asia (AS)	15	38,5	15	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	0,00	0,00
	Europe (EU)	9	52,9	6	66,7	0,00	0,00
	Asia (AS)	15	38,5	15	100,0	0,00	0,00
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	0,00	0,00
	Europe (EU)	9	52,9	9	100,0	0,00	0,00
	Asia (AS)	14	35,9	11	78,6	0,00	0,00
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	0,00	0,00
	Europe (EU)	9	52,9	6	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	0,00	0,00
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	0,00	0,00
	Europe (EU)	7	41,2	6	85,7	0,00	0,00
	Asia (AS)	11	28,2	10	90,9	0,00	0,00
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	0,00	0,00
	Europe (EU)	7	41,2	5	71,4	0,00	0,00
	Asia (AS)	11	28,2	10	90,9	0,00	0,00
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	29,4	3	60,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	0,00	0,00
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	0,00	0,00
	Europe (EU)	5	29,4	4	80,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	0,00	0,00
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	0,00	0,00
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	0,00	0,00
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	0,00	0,00
	Europe (EU)	3	17,6	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	0,00	0,00
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	0,00	0,00
	Europe (EU)	2	11,8	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	25,00	50,00
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	0,00	0,00
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	0,00	0,00
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	0,00	0,00
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	0,00	0,00
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00
	Europe (EU)	1	5,9	1	100,0	0,00	-
	Asia (AS)	3	7,7	2	66,7	0,00	0,00
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	0,00	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	6,06	13,48
	Europe (EU)	6	35,3	4	66,7	8,33	16,67
	Asia (AS)	21	53,8	13	61,9	5,13	12,52
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	29	96,7	3,45	10,33
	1	38	100,0	38	100,0	1,75	7,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	10	100,0	10	100,0	0,00	0,00
Cycle 2 Day 1	0	30	100,0	27	90,0	0,00	0,00
	1	36	94,7	32	88,9	1,04	5,89
	2	6	60,0	6	100,0	0,00	0,00
Cycle 3 Day 1	0	29	96,7	27	93,1	1,23	6,42
	1	34	89,5	31	91,2	0,00	0,00
	2	5	50,0	5	100,0	0,00	0,00
Cycle 4 Day 1	0	29	96,7	25	86,2	1,33	6,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	1,04	5,89
	2	5	50,0	4	80,0	0,00	0,00
Cycle 5 Day 1	0	29	96,7	29	100,0	2,30	8,60
	1	33	86,8	31	93,9	0,00	0,00
	2	3	30,0	3	100,0	0,00	0,00
Cycle 6 Day 1	0	29	96,7	28	96,6	2,38	8,74
	1	31	81,6	27	87,1	0,00	0,00
	2	3	30,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	29	96,7	28	96,6	2,38	12,60
	1	28	73,7	25	89,3	1,33	6,67
	2	3	30,0	3	100,0	0,00	0,00
Cycle 8 Day 1	0	28	93,3	26	92,9	0,00	0,00
	1	25	65,8	23	92,0	0,00	0,00
	2	3	30,0	3	100,0	0,00	0,00
Cycle 9 Day 1	0	26	86,7	26	100,0	0,00	0,00
	1	23	60,5	23	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	2	20,0	2	100,0	0,00	0,00
Cycle 10 Day 1	0	26	86,7	26	100,0	1,28	6,54
	1	23	60,5	22	95,7	0,00	0,00
	2	2	20,0	2	100,0	0,00	0,00
Cycle 11 Day 1	0	26	86,7	26	100,0	0,00	0,00
	1	22	57,9	22	100,0	0,00	0,00
	2	2	20,0	2	100,0	0,00	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	1,52	7,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	21	95,5	0,00	0,00
	2	2	20,0	2	100,0	0,00	0,00
Cycle 13 Day 1	0	25	83,3	24	96,0	0,00	0,00
	1	20	52,6	20	100,0	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	0,00	0,00
	1	19	50,0	19	100,0	0,00	0,00
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	24	80,0	24	100,0	0,00	0,00
	1	19	50,0	19	100,0	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 16 Day 1	0	22	73,3	20	90,9	0,00	0,00
	1	18	47,4	18	100,0	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	0,00	0,00
	1	17	44,7	17	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	0,00	0,00
	1	16	42,1	16	100,0	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	0,00	0,00
	1	15	39,5	13	86,7	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	39,5	14	93,3	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	0,00	0,00
	1	13	34,2	11	84,6	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	0,00	0,00
	1	13	34,2	12	92,3	0,00	0,00
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	0,00	0,00
	1	9	23,7	8	88,9	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	0,00	0,00
	1	9	23,7	8	88,9	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	0,00	0,00
	1	7	18,4	7	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	26,7	6	75,0	0,00	0,00
	1	6	15,8	6	100,0	0,00	0,00
Cycle 27 Day 1	0	6	20,0	3	50,0	0,00	0,00
	1	5	13,2	5	100,0	0,00	0,00
Cycle 28 Day 1	0	5	16,7	4	80,0	0,00	0,00
	1	5	13,2	5	100,0	20,00	44,72
Cycle 29 Day 1	0	4	13,3	2	50,0	0,00	0,00
	1	5	13,2	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	0,00	0,00
Cycle 31 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	0,00	0,00
Cycle 32 Day 1	0	3	10,0	2	66,7	0,00	0,00
	1	3	7,9	3	100,0	0,00	0,00
Cycle 33 Day 1	0	2	6,7	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	2,38	8,91
	1	20	52,6	12	60,0	8,33	15,08
	2	4	40,0	2	50,0	16,67	23,57
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	3,23	10,02
	1	3	100,0	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	44	100,0	43	97,7	1,55	7,10
Cycle 2 Day 1	None	30	96,8	27	90,0	1,23	6,42
	1	2	66,7	1	50,0	0,00	-
	2 or More	40	90,9	37	92,5	0,00	0,00
Cycle 3 Day 1	None	30	96,8	28	93,3	0,00	0,00
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	34	94,4	0,98	5,72
Cycle 4 Day 1	None	30	96,8	28	93,3	1,19	6,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	35	79,5	31	88,6	1,08	5,99
Cycle 5 Day 1	None	30	96,8	30	100,0	0,00	0,00
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	33	75,0	31	93,9	2,15	8,32
Cycle 6 Day 1	None	29	93,5	26	89,7	0,00	0,00
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	32	72,7	29	90,6	2,30	8,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	27	87,1	25	92,6	0,00	0,00
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	31	70,5	29	93,5	2,30	12,38
Cycle 8 Day 1	None	26	83,9	25	96,2	0,00	0,00
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	0,00	0,00
Cycle 9 Day 1	None	25	80,6	25	100,0	0,00	0,00
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	0,00	0,00
Cycle 10 Day 1	None	25	80,6	24	96,0	0,00	0,00
	1	1	33,3	1	100,0	0,00	-
	2 or More	25	56,8	25	100,0	1,33	6,67
Cycle 11 Day 1	None	25	80,6	25	100,0	0,00	0,00
	1	1	33,3	1	100,0	0,00	-
	2 or More	24	54,5	24	100,0	0,00	0,00
Cycle 12 Day 1	None	25	80,6	24	96,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	23	52,3	20	87,0	1,67	7,45
Cycle 13 Day 1	None	24	77,4	23	95,8	0,00	0,00
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	0,00	0,00
Cycle 14 Day 1	None	23	74,2	23	100,0	0,00	0,00
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	20	95,2	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	23	74,2	23	100,0	0,00	0,00
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	20	100,0	0,00	0,00
Cycle 16 Day 1	None	20	64,5	19	95,0	0,00	0,00
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	19	95,0	0,00	0,00
Cycle 17 Day 1	None	19	61,3	19	100,0	0,00	0,00
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	19	43,2	19	100,0	0,00	0,00
Cycle 18 Day 1	None	18	58,1	17	94,4	0,00	0,00
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	17	89,5	0,00	0,00
Cycle 19 Day 1	None	17	54,8	17	100,0	0,00	0,00
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	0,00	0,00
Cycle 20 Day 1	None	17	54,8	16	94,1	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	0,00	0,00
Cycle 21 Day 1	None	15	48,4	13	86,7	0,00	0,00
	2 or More	14	31,8	13	92,9	0,00	0,00
Cycle 22 Day 1	None	15	48,4	13	86,7	0,00	0,00
	2 or More	14	31,8	12	85,7	0,00	0,00
Cycle 23 Day 1	None	10	32,3	9	90,0	0,00	0,00
	2 or More	11	25,0	9	81,8	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	32,3	10	100,0	0,00	0,00
	2 or More	10	22,7	8	80,0	0,00	0,00
Cycle 25 Day 1	None	9	29,0	8	88,9	0,00	0,00
	2 or More	6	13,6	5	83,3	0,00	0,00
Cycle 26 Day 1	None	8	25,8	8	100,0	0,00	0,00
	2 or More	6	13,6	4	66,7	0,00	0,00
Cycle 27 Day 1	None	7	22,6	6	85,7	0,00	0,00
	2 or More	4	9,1	2	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	22,6	7	100,0	0,00	0,00
	2 or More	3	6,8	2	66,7	50,00	70,71
Cycle 29 Day 1	None	6	19,4	5	83,3	0,00	0,00
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	12,9	3	75,0	0,00	0,00
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 31 Day 1	None	4	12,9	3	75,0	0,00	0,00
	2 or More	3	6,8	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	0,00	0,00
	2 or More	2	4,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	3,2	1	100,0	0,00	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	5,56	12,97
	1	2	66,7	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	54,5	15	62,5	6,67	13,80
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	3,23	10,02
	Previously Treated	47	100,0	46	97,9	1,45	6,87
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	1,23	6,42
	Previously Treated	42	89,4	38	90,5	0,00	0,00
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	38	80,9	35	92,1	0,95	5,63
Cycle 4 Day 1	Naïve	30	96,8	28	93,3	1,19	6,30
	Previously Treated	37	78,7	33	89,2	1,01	5,80
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	0,00	0,00
	Previously Treated	35	74,5	33	94,3	2,02	8,08
Cycle 6 Day 1	Naïve	29	93,5	26	89,7	0,00	0,00
	Previously Treated	34	72,3	31	91,2	2,15	8,32
Cycle 7 Day 1	Naïve	27	87,1	25	92,6	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	33	70,2	31	93,9	3,23	13,21
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	0,00	0,00
	Previously Treated	30	63,8	27	90,0	0,00	0,00
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	0,00	0,00
	Previously Treated	26	55,3	26	100,0	0,00	0,00
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	0,00	0,00
	Previously Treated	26	55,3	26	100,0	1,28	6,54
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	53,2	25	100,0	0,00	0,00
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	0,00	0,00
	Previously Treated	24	51,1	21	87,5	1,59	7,27
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	0,00	0,00
	Previously Treated	22	46,8	22	100,0	0,00	0,00
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	0,00	0,00
	Previously Treated	22	46,8	21	95,5	0,00	0,00
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	21	100,0	0,00	0,00
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	0,00	0,00
	Previously Treated	21	44,7	20	95,2	0,00	0,00
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	0,00	0,00
	Previously Treated	20	42,6	20	100,0	0,00	0,00
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	0,00	0,00
	Previously Treated	20	42,6	18	90,0	0,00	0,00
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	40,4	16	84,2	0,00	0,00
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	0,00	0,00
	Previously Treated	19	40,4	16	84,2	0,00	0,00
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	0,00	0,00
	Previously Treated	14	29,8	13	92,9	0,00	0,00
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	0,00	0,00
	Previously Treated	14	29,8	12	85,7	0,00	0,00
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	0,00	0,00
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	0,00	0,00
	Previously Treated	10	21,3	8	80,0	0,00	0,00
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	0,00	0,00
	Previously Treated	6	12,8	5	83,3	0,00	0,00
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	0,00	0,00
	Previously Treated	6	12,8	4	66,7	0,00	0,00
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	8,5	2	50,0	0,00	0,00
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	0,00	0,00
	Previously Treated	3	6,4	2	66,7	50,00	70,71
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	0,00	0,00
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	0,00	0,00
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	0,00	0,00
	Previously Treated	2	4,3	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	0,00	-
	Previously Treated	1	2,1	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	16	61,5	6,25	13,44
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	2,86	9,47
	Central	43	100,0	42	97,7	1,59	7,18
Cycle 2 Day 1	Local	32	91,4	30	93,8	0,00	0,00
	Central	40	93,0	35	87,5	0,95	5,63
Cycle 3 Day 1	Local	29	82,9	27	93,1	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	39	90,7	36	92,3	0,93	5,56
Cycle 4 Day 1	Local	28	80,0	24	85,7	0,00	0,00
	Central	39	90,7	37	94,9	1,80	7,64
Cycle 5 Day 1	Local	27	77,1	27	100,0	0,00	0,00
	Central	38	88,4	36	94,7	1,85	7,74
Cycle 6 Day 1	Local	27	77,1	27	100,0	0,00	0,00
	Central	36	83,7	30	83,3	2,22	8,46
Cycle 7 Day 1	Local	27	77,1	27	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	33	76,7	29	87,9	3,45	13,64
Cycle 8 Day 1	Local	26	74,3	26	100,0	0,00	0,00
	Central	30	69,8	26	86,7	0,00	0,00
Cycle 9 Day 1	Local	25	71,4	25	100,0	0,00	0,00
	Central	26	60,5	26	100,0	0,00	0,00
Cycle 10 Day 1	Local	25	71,4	24	96,0	0,00	0,00
	Central	26	60,5	26	100,0	1,28	6,54
Cycle 11 Day 1	Local	24	68,6	24	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	26	60,5	26	100,0	0,00	0,00
Cycle 12 Day 1	Local	23	65,7	22	95,7	0,00	0,00
	Central	26	60,5	23	88,5	1,45	6,95
Cycle 13 Day 1	Local	22	62,9	22	100,0	0,00	0,00
	Central	24	55,8	23	95,8	0,00	0,00
Cycle 14 Day 1	Local	22	62,9	22	100,0	0,00	0,00
	Central	23	53,5	22	95,7	0,00	0,00
Cycle 15 Day 1	Local	22	62,9	22	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	0,00	0,00
Cycle 16 Day 1	Local	20	57,1	20	100,0	0,00	0,00
	Central	21	48,8	19	90,5	0,00	0,00
Cycle 17 Day 1	Local	20	57,1	20	100,0	0,00	0,00
	Central	19	44,2	19	100,0	0,00	0,00
Cycle 18 Day 1	Local	20	57,1	19	95,0	0,00	0,00
	Central	18	41,9	16	88,9	0,00	0,00
Cycle 19 Day 1	Local	19	54,3	17	89,5	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	39,5	16	94,1	0,00	0,00
Cycle 20 Day 1	Local	19	54,3	17	89,5	0,00	0,00
	Central	17	39,5	15	88,2	0,00	0,00
Cycle 21 Day 1	Local	14	40,0	12	85,7	0,00	0,00
	Central	15	34,9	14	93,3	0,00	0,00
Cycle 22 Day 1	Local	14	40,0	12	85,7	0,00	0,00
	Central	15	34,9	13	86,7	0,00	0,00
Cycle 23 Day 1	Local	11	31,4	10	90,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	23,3	8	80,0	0,00	0,00
Cycle 24 Day 1	Local	11	31,4	10	90,9	0,00	0,00
	Central	9	20,9	8	88,9	0,00	0,00
Cycle 25 Day 1	Local	7	20,0	7	100,0	0,00	0,00
	Central	8	18,6	6	75,0	0,00	0,00
Cycle 26 Day 1	Local	6	17,1	6	100,0	0,00	0,00
	Central	8	18,6	6	75,0	0,00	0,00
Cycle 27 Day 1	Local	4	11,4	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	16,3	4	57,1	0,00	0,00
Cycle 28 Day 1	Local	4	11,4	4	100,0	0,00	0,00
	Central	6	14,0	5	83,3	20,00	44,72
Cycle 29 Day 1	Local	3	8,6	3	100,0	0,00	0,00
	Central	6	14,0	4	66,7	0,00	0,00
Cycle 30 Day 1	Local	3	8,6	3	100,0	0,00	0,00
	Central	4	9,3	2	50,0	0,00	0,00
Cycle 31 Day 1	Local	3	8,6	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	9,3	2	50,0	0,00	0,00
Cycle 32 Day 1	Local	3	8,6	3	100,0	0,00	0,00
	Central	3	7,0	2	66,7	0,00	0,00
Cycle 33 Day 1	Local	1	2,9	1	100,0	0,00	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	9,52	15,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	21	48,8	14	66,7	2,38	8,91
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	73	98,6	2,28	8,48
	No	4	100,0	4	100,0	0,00	0,00
Cycle 2 Day 1	Yes	70	94,6	63	90,0	0,53	4,20
	No	2	50,0	2	100,0	0,00	0,00
Cycle 3 Day 1	Yes	66	89,2	61	92,4	0,55	4,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 4 Day 1	Yes	65	87,8	59	90,8	1,13	6,08
	No	2	50,0	2	100,0	0,00	0,00
Cycle 5 Day 1	Yes	63	85,1	61	96,8	1,09	5,99
	No	2	50,0	2	100,0	0,00	0,00
Cycle 6 Day 1	Yes	61	82,4	55	90,2	1,21	6,30
	No	2	50,0	2	100,0	0,00	0,00
Cycle 7 Day 1	Yes	58	78,4	54	93,1	1,85	10,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 8 Day 1	Yes	54	73,0	50	92,6	0,00	0,00
	No	2	50,0	2	100,0	0,00	0,00
Cycle 9 Day 1	Yes	49	66,2	49	100,0	0,00	0,00
	No	2	50,0	2	100,0	0,00	0,00
Cycle 10 Day 1	Yes	49	66,2	48	98,0	0,69	4,81
	No	2	50,0	2	100,0	0,00	0,00
Cycle 11 Day 1	Yes	48	64,9	48	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 12 Day 1	Yes	47	63,5	43	91,5	0,78	5,08
	No	2	50,0	2	100,0	0,00	0,00
Cycle 13 Day 1	Yes	44	59,5	43	97,7	0,00	0,00
	No	2	50,0	2	100,0	0,00	0,00
Cycle 14 Day 1	Yes	43	58,1	42	97,7	0,00	0,00
	No	2	50,0	2	100,0	0,00	0,00
Cycle 15 Day 1	Yes	42	56,8	42	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 16 Day 1	Yes	39	52,7	37	94,9	0,00	0,00
	No	2	50,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	37	50,0	37	100,0	0,00	0,00
	No	2	50,0	2	100,0	0,00	0,00
Cycle 18 Day 1	Yes	36	48,6	33	91,7	0,00	0,00
	No	2	50,0	2	100,0	0,00	0,00
Cycle 19 Day 1	Yes	34	45,9	32	94,1	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	0,00	0,00
	No	2	50,0	2	100,0	0,00	0,00
Cycle 21 Day 1	Yes	27	36,5	24	88,9	0,00	0,00
	No	2	50,0	2	100,0	0,00	0,00
Cycle 22 Day 1	Yes	27	36,5	23	85,2	0,00	0,00
	No	2	50,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	18,9	12	85,7	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	12,50	35,36
	No	1	25,0	1	100,0	0,00	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 32 Day 1	Yes	5	6,8	4	80,0	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	5,95	13,00
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	4,17	11,79
	No	70	100,0	69	98,6	1,93	7,85
Cycle 2 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	67	95,7	60	89,6	0,56	4,30
Cycle 3 Day 1	Yes	5	62,5	4	80,0	0,00	0,00
	No	63	90,0	59	93,7	0,56	4,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	62	88,6	56	90,3	1,19	6,24
Cycle 5 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	60	85,7	58	96,7	1,15	6,14
Cycle 6 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	58	82,9	52	89,7	1,28	6,47
Cycle 7 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	55	78,6	51	92,7	1,96	10,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	51	72,9	47	92,2	0,00	0,00
Cycle 9 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	47	67,1	47	100,0	0,00	0,00
Cycle 10 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	47	67,1	46	97,9	0,72	4,91
Cycle 11 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	46	65,7	46	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	45	64,3	41	91,1	0,81	5,21
Cycle 13 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	42	60,0	41	97,6	0,00	0,00
Cycle 14 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	41	58,6	40	97,6	0,00	0,00
Cycle 15 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	40	57,1	40	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	38	54,3	36	94,7	0,00	0,00
Cycle 17 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	36	51,4	36	100,0	0,00	0,00
Cycle 18 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	35	50,0	32	91,4	0,00	0,00
Cycle 19 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	30	90,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	29	87,9	0,00	0,00
Cycle 21 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	24	88,9	0,00	0,00
Cycle 22 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	23	85,2	0,00	0,00
Cycle 23 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	19	27,1	16	84,2	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	18	25,7	16	88,9	0,00	0,00
Cycle 25 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	13	18,6	11	84,6	0,00	0,00
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	0,00	0,00
Cycle 27 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	10	14,3	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	9	12,9	8	88,9	12,50	35,36
Cycle 29 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	8	11,4	6	75,0	0,00	0,00
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	0,00	0,00
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	0,00	0,00
Cycle 33 Day 1	No	2	2,9	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	0,00	0,00
	No	37	52,9	26	70,3	6,41	13,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HA_SG.xls
28NOV2019 10:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	77	98,7	9,09	21,38
Cycle 2 Day 1	All	72	92,3	65	90,3	8,21	21,27
Cycle 3 Day 1	All	68	87,2	63	92,6	7,94	18,66
Cycle 4 Day 1	All	67	85,9	61	91,0	7,10	18,37
Cycle 5 Day 1	All	65	83,3	63	96,9	7,94	21,35
Cycle 6 Day 1	All	63	80,8	57	90,5	5,85	15,59
Cycle 7 Day 1	All	60	76,9	56	93,3	6,55	18,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	56	71,8	52	92,9	7,69	19,38
Cycle 9 Day 1	All	51	65,4	51	100,0	7,19	19,22
Cycle 10 Day 1	All	51	65,4	50	98,0	6,00	16,06
Cycle 11 Day 1	All	50	64,1	50	100,0	4,67	13,49
Cycle 12 Day 1	All	49	62,8	45	91,8	9,63	16,85
Cycle 13 Day 1	All	46	59,0	45	97,8	8,15	19,01
Cycle 14 Day 1	All	45	57,7	44	97,8	4,55	17,00
Cycle 15 Day 1	All	44	56,4	44	100,0	3,03	12,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	41	52,6	39	95,1	5,98	18,53
Cycle 17 Day 1	All	39	50,0	39	100,0	5,98	18,53
Cycle 18 Day 1	All	38	48,7	35	92,1	5,71	15,09
Cycle 19 Day 1	All	36	46,2	33	91,7	3,03	9,73
Cycle 20 Day 1	All	36	46,2	32	88,9	6,25	13,22
Cycle 21 Day 1	All	29	37,2	26	89,7	3,85	10,86
Cycle 22 Day 1	All	29	37,2	25	86,2	6,67	13,61
Cycle 23 Day 1	All	21	26,9	18	85,7	1,85	7,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	25,6	18	90,0	0,00	0,00
Cycle 25 Day 1	All	15	19,2	13	86,7	7,69	27,74
Cycle 26 Day 1	All	14	17,9	12	85,7	8,33	20,72
Cycle 27 Day 1	All	11	14,1	8	72,7	8,33	15,43
Cycle 28 Day 1	All	10	12,8	9	90,0	14,81	33,79
Cycle 29 Day 1	All	9	11,5	7	77,8	4,76	12,60
Cycle 30 Day 1	All	7	9,0	5	71,4	6,67	14,91
Cycle 31 Day 1	All	7	9,0	5	71,4	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	7,7	5	83,3	0,00	0,00
Cycle 33 Day 1	All	2	2,6	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	9,52	21,96
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	2,30	8,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	49	100,0	48	98,0	13,19	25,49
Cycle 2 Day 1	Male	27	93,1	25	92,6	2,67	9,23
	Female	45	91,8	40	88,9	11,67	25,65
Cycle 3 Day 1	Male	25	86,2	24	96,0	4,17	11,26
	Female	43	87,8	39	90,7	10,26	21,84
Cycle 4 Day 1	Male	25	86,2	23	92,0	2,90	9,60
	Female	42	85,7	38	90,5	9,65	21,79
Cycle 5 Day 1	Male	25	86,2	24	96,0	6,94	16,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	40	81,6	39	97,5	8,55	23,84
Cycle 6 Day 1	Male	25	86,2	23	92,0	7,25	17,28
	Female	38	77,6	34	89,5	4,90	14,52
Cycle 7 Day 1	Male	23	79,3	23	100,0	5,80	16,37
	Female	37	75,5	33	89,2	7,07	20,00
Cycle 8 Day 1	Male	21	72,4	19	90,5	10,53	24,98
	Female	35	71,4	33	94,3	6,06	15,49
Cycle 9 Day 1	Male	18	62,1	18	100,0	5,56	17,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	8,08	20,46
Cycle 10 Day 1	Male	18	62,1	18	100,0	7,41	18,28
	Female	33	67,3	32	97,0	5,21	14,93
Cycle 11 Day 1	Male	18	62,1	18	100,0	3,70	10,78
	Female	32	65,3	32	100,0	5,21	14,93
Cycle 12 Day 1	Male	17	58,6	17	100,0	11,76	16,42
	Female	32	65,3	28	87,5	8,33	17,27
Cycle 13 Day 1	Male	17	58,6	17	100,0	7,84	14,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	29	59,2	28	96,6	8,33	21,52
Cycle 14 Day 1	Male	17	58,6	16	94,1	2,08	8,33
	Female	28	57,1	28	100,0	5,95	20,39
Cycle 15 Day 1	Male	16	55,2	16	100,0	0,00	0,00
	Female	28	57,1	28	100,0	4,76	14,95
Cycle 16 Day 1	Male	14	48,3	14	100,0	4,76	12,10
	Female	27	55,1	25	92,6	6,67	21,52
Cycle 17 Day 1	Male	12	41,4	12	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	27	100,0	8,64	21,86
Cycle 18 Day 1	Male	11	37,9	10	90,9	3,33	10,54
	Female	27	55,1	25	92,6	6,67	16,67
Cycle 19 Day 1	Male	10	34,5	10	100,0	6,67	14,05
	Female	26	53,1	23	88,5	1,45	6,95
Cycle 20 Day 1	Male	10	34,5	9	90,0	7,41	14,70
	Female	26	53,1	23	88,5	5,80	12,92
Cycle 21 Day 1	Male	8	27,6	8	100,0	4,17	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	42,9	18	85,7	3,70	10,78
Cycle 22 Day 1	Male	8	27,6	6	75,0	11,11	17,21
	Female	21	42,9	19	90,5	5,26	12,49
Cycle 23 Day 1	Male	5	17,2	4	80,0	0,00	0,00
	Female	16	32,7	14	87,5	2,38	8,91
Cycle 24 Day 1	Male	5	17,2	4	80,0	0,00	0,00
	Female	15	30,6	14	93,3	0,00	0,00
Cycle 25 Day 1	Male	3	10,3	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	24,5	11	91,7	9,09	30,15
Cycle 26 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	11	22,4	10	90,9	10,00	22,50
Cycle 27 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	8	16,3	6	75,0	11,11	17,21
Cycle 28 Day 1	Male	2	6,9	2	100,0	0,00	0,00
	Female	8	16,3	7	87,5	19,05	37,80
Cycle 29 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	16,3	6	75,0	5,56	13,61
Cycle 30 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	8,33	16,67
Cycle 31 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	16,67	19,25
Cycle 32 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	5	10,2	4	80,0	0,00	0,00
Cycle 33 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	2,0	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	6,67	13,80
	Female	21	42,9	13	61,9	12,82	28,99
Age							
Cycle 1 Day 1	18-64	62	100,0	61	98,4	9,29	22,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	9,52	15,63
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	18-64	59	95,2	52	88,1	8,97	22,98
	65-74	11	78,6	11	100,0	6,06	13,48
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 3 Day 1	18-64	56	90,3	52	92,9	8,33	19,66
	65-74	10	71,4	9	90,0	7,41	14,70
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	55	88,7	50	90,9	6,67	19,05
	65-74	10	71,4	9	90,0	11,11	16,67
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 5 Day 1	18-64	53	85,5	52	98,1	7,69	22,50
	65-74	10	71,4	10	100,0	10,00	16,10
	>=75	2	100,0	1	50,0	0,00	-
Cycle 6 Day 1	18-64	51	82,3	46	90,2	5,07	15,66
	65-74	10	71,4	9	90,0	11,11	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 7 Day 1	18-64	49	79,0	46	93,9	5,80	18,99
	65-74	9	64,3	8	88,9	12,50	17,25
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 8 Day 1	18-64	45	72,6	41	91,1	6,50	20,03
	65-74	9	64,3	9	100,0	14,81	17,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 9 Day 1	18-64	40	64,5	40	100,0	5,83	19,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	14,81	17,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 10 Day 1	18-64	40	64,5	39	97,5	5,98	16,88
	65-74	9	64,3	9	100,0	7,41	14,70
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 11 Day 1	18-64	39	62,9	39	100,0	3,42	12,78
	65-74	9	64,3	9	100,0	11,11	16,67
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	38	61,3	35	92,1	7,62	16,34
	65-74	9	64,3	8	88,9	20,83	17,25
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 13 Day 1	18-64	35	56,5	34	97,1	5,88	19,19
	65-74	9	64,3	9	100,0	18,52	17,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 14 Day 1	18-64	35	56,5	35	100,0	2,86	16,90
	65-74	9	64,3	8	88,9	8,33	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	33,33	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	0,00	0,00
	65-74	8	57,1	8	100,0	16,67	25,20
	>=75	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	3,13	17,68
	65-74	7	50,0	6	85,7	22,22	17,21
	>=75	1	50,0	1	100,0	0,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	5,21	19,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	6	42,9	6	100,0	11,11	17,21
	>=75	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	4,60	14,70
	65-74	6	42,9	5	83,3	13,33	18,26
	>=75	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	1,19	6,30
	65-74	5	35,7	4	80,0	16,67	19,25
	>=75	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	3,85	10,86
	65-74	5	35,7	5	100,0	20,00	18,26
	>=75	1	50,0	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	3,17	10,03
	65-74	4	28,6	4	100,0	8,33	16,67
	>=75	1	50,0	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	5,00	12,21
	65-74	4	28,6	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	2,08	8,33
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	0,00	0,00
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	22,6	12	85,7	8,33	28,87
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	8,33	20,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	8,33	15,43
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	14,81	33,79
	65-74	1	7,1	0	0,0	-	-
Cycle 29 Day 1	18-64	8	12,9	7	87,5	4,76	12,60
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	13,33	18,26
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	0,00	0,00
	65-74	1	7,1	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	0,00	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	10,00	24,42
	65-74	10	71,4	7	70,0	9,52	16,27
	>=75	2	100,0	1	50,0	0,00	-
Race							
Cycle 1 Day 1	White	35	100,0	34	97,1	8,82	25,04
	Other	43	100,0	43	100,0	9,30	18,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	33	94,3	28	84,8	8,33	26,64
	Other	39	90,7	37	94,9	8,11	16,49
Cycle 3 Day 1	White	31	88,6	27	87,1	4,94	20,05
	Other	37	86,0	36	97,3	10,19	17,49
Cycle 4 Day 1	White	31	88,6	26	83,9	5,13	20,42
	Other	36	83,7	35	97,2	8,57	16,85
Cycle 5 Day 1	White	31	88,6	29	93,5	9,20	26,57
	Other	34	79,1	34	100,0	6,86	15,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	30	85,7	25	83,3	6,67	16,67
	Other	33	76,7	32	97,0	5,21	14,93
Cycle 7 Day 1	White	29	82,9	26	89,7	7,69	21,72
	Other	31	72,1	30	96,8	5,56	15,37
Cycle 8 Day 1	White	28	80,0	24	85,7	1,39	6,80
	Other	28	65,1	28	100,0	13,10	24,58
Cycle 9 Day 1	White	26	74,3	26	100,0	5,13	12,26
	Other	25	58,1	25	100,0	9,33	24,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	5,33	15,75
	Other	25	58,1	25	100,0	6,67	16,67
Cycle 11 Day 1	White	26	74,3	26	100,0	2,56	9,06
	Other	24	55,8	24	100,0	6,94	16,97
Cycle 12 Day 1	White	26	74,3	22	84,6	9,09	18,35
	Other	23	53,5	23	100,0	10,14	15,68
Cycle 13 Day 1	White	24	68,6	23	95,8	7,25	22,38
	Other	22	51,2	22	100,0	9,09	15,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	24	68,6	24	100,0	6,94	21,93
	Other	21	48,8	20	95,2	1,67	7,45
Cycle 15 Day 1	White	24	68,6	24	100,0	1,39	6,80
	Other	20	46,5	20	100,0	5,00	16,31
Cycle 16 Day 1	White	22	62,9	20	90,9	6,67	23,20
	Other	19	44,2	19	100,0	5,26	12,49
Cycle 17 Day 1	White	22	62,9	22	100,0	9,09	23,42
	Other	17	39,5	17	100,0	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	21	60,0	18	85,7	7,41	18,28
	Other	17	39,5	17	100,0	3,92	11,07
Cycle 19 Day 1	White	20	57,1	20	100,0	1,67	7,45
	Other	16	37,2	13	81,3	5,13	12,52
Cycle 20 Day 1	White	20	57,1	17	85,0	5,88	13,10
	Other	16	37,2	15	93,8	6,67	13,80
Cycle 21 Day 1	White	16	45,7	14	87,5	2,38	8,91
	Other	13	30,2	12	92,3	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	45,7	13	81,3	5,13	12,52
	Other	13	30,2	12	92,3	8,33	15,08
Cycle 23 Day 1	White	12	34,3	10	83,3	3,33	10,54
	Other	9	20,9	8	88,9	0,00	0,00
Cycle 24 Day 1	White	11	31,4	10	90,9	0,00	0,00
	Other	9	20,9	8	88,9	0,00	0,00
Cycle 25 Day 1	White	10	28,6	8	80,0	0,00	0,00
	Other	5	11,6	5	100,0	20,00	44,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	28,6	8	80,0	0,00	0,00
	Other	4	9,3	4	100,0	25,00	31,91
Cycle 27 Day 1	White	8	22,9	5	62,5	0,00	0,00
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 28 Day 1	White	7	20,0	6	85,7	0,00	0,00
	Other	3	7,0	3	100,0	44,44	50,92
Cycle 29 Day 1	White	6	17,1	4	66,7	0,00	0,00
	Other	3	7,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	11,4	2	50,0	0,00	0,00
	Other	3	7,0	3	100,0	11,11	19,25
Cycle 31 Day 1	White	4	11,4	2	50,0	0,00	0,00
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 32 Day 1	White	4	11,4	3	75,0	0,00	0,00
	Other	2	4,7	2	100,0	0,00	0,00
Cycle 33 Day 1	White	2	5,7	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-
End Of Treatment	White	15	42,9	12	80,0	13,89	30,01
	Other	24	55,8	16	66,7	6,25	13,44
Region							
Cycle 1 Day 1	America (AM)	22	100,0	21	95,5	9,52	23,90
	Europe (EU)	17	100,0	17	100,0	1,96	8,08
	Asia (AS)	39	100,0	39	100,0	11,97	23,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	13,73	33,46
	Europe (EU)	16	94,1	13	81,3	0,00	0,00
	Asia (AS)	36	92,3	35	97,2	8,57	16,85
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	8,77	24,45
	Europe (EU)	15	88,2	11	73,3	0,00	0,00
	Asia (AS)	33	84,6	33	100,0	10,10	17,65
Cycle 4 Day 1	America (AM)	20	90,9	19	95,0	8,77	24,45
	Europe (EU)	15	88,2	11	73,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	32	82,1	31	96,9	8,60	17,14
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	13,33	31,34
	Europe (EU)	15	88,2	13	86,7	2,56	9,25
	Asia (AS)	30	76,9	30	100,0	6,67	16,14
Cycle 6 Day 1	America (AM)	20	90,9	18	90,0	9,26	19,15
	Europe (EU)	14	82,4	12	85,7	5,56	12,97
	Asia (AS)	29	74,4	27	93,1	3,70	14,12
Cycle 7 Day 1	America (AM)	19	86,4	17	89,5	11,76	26,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	14	82,4	13	92,9	2,56	9,25
	Asia (AS)	27	69,2	26	96,3	5,13	15,47
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	5,88	17,62
	Europe (EU)	14	82,4	11	78,6	3,03	10,05
	Asia (AS)	24	61,5	24	100,0	11,11	23,40
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	11,11	25,57
	Europe (EU)	12	70,6	12	100,0	5,56	12,97
	Asia (AS)	21	53,8	21	100,0	4,76	15,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	7,84	18,74
	Europe (EU)	12	70,6	12	100,0	5,56	12,97
	Asia (AS)	21	53,8	21	100,0	4,76	15,94
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	5,56	17,15
	Europe (EU)	12	70,6	12	100,0	5,56	12,97
	Asia (AS)	20	51,3	20	100,0	3,33	10,26
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	9,80	15,66
	Europe (EU)	12	70,6	9	75,0	14,81	24,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	19	48,7	19	100,0	7,02	13,96
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	13,73	26,51
	Europe (EU)	11	64,7	10	90,9	3,33	10,54
	Asia (AS)	18	46,2	18	100,0	5,56	12,78
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	5,88	24,25
	Europe (EU)	11	64,7	11	100,0	6,06	13,48
	Asia (AS)	17	43,6	16	94,1	2,08	8,33
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	64,7	11	100,0	3,03	10,05
	Asia (AS)	16	41,0	16	100,0	4,17	16,67
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	4,76	12,10
	Europe (EU)	11	64,7	9	81,8	3,70	11,11
	Asia (AS)	16	41,0	16	100,0	8,33	25,82
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	2,38	8,91
	Europe (EU)	10	58,8	10	100,0	3,33	10,54
	Asia (AS)	15	38,5	15	100,0	11,11	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	4,76	12,10
	Europe (EU)	9	52,9	6	66,7	0,00	0,00
	Asia (AS)	15	38,5	15	100,0	8,89	19,79
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	2,56	9,25
	Europe (EU)	9	52,9	9	100,0	3,70	11,11
	Asia (AS)	14	35,9	11	78,6	3,03	10,05
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	5,13	12,52
	Europe (EU)	9	52,9	6	66,7	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	7,69	14,62
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	3,33	10,54
	Europe (EU)	7	41,2	6	85,7	0,00	0,00
	Asia (AS)	11	28,2	10	90,9	6,67	14,05
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	10,00	16,10
	Europe (EU)	7	41,2	5	71,4	0,00	0,00
	Asia (AS)	11	28,2	10	90,9	6,67	14,05
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	29,4	3	60,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	0,00	0,00
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	0,00	0,00
	Europe (EU)	5	29,4	4	80,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	0,00	0,00
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	25,00	50,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	0,00	0,00
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	25,00	31,91
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	0,00	0,00
	Europe (EU)	3	17,6	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	16,67	19,25
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	0,00	0,00
	Europe (EU)	2	11,8	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	33,33	47,14
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	0,00	0,00
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	8,33	16,67
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	11,11	19,25
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	22,22	19,25
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00
	Europe (EU)	1	5,9	1	100,0	0,00	-
	Asia (AS)	3	7,7	2	66,7	0,00	0,00
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	0,00	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	12,12	30,81
	Europe (EU)	6	35,3	4	66,7	8,33	16,67
	Asia (AS)	21	53,8	13	61,9	7,69	14,62
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	29	96,7	8,05	21,19
	1	38	100,0	38	100,0	9,65	23,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	10	100,0	10	100,0	10,00	16,10
Cycle 2 Day 1	0	30	100,0	27	90,0	3,70	10,68
	1	36	94,7	32	88,9	11,46	27,58
	2	6	60,0	6	100,0	11,11	17,21
Cycle 3 Day 1	0	29	96,7	27	93,1	3,70	10,68
	1	34	89,5	31	91,2	9,68	21,42
	2	5	50,0	5	100,0	20,00	29,81
Cycle 4 Day 1	0	29	96,7	25	86,2	4,00	11,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	7,29	20,27
	2	5	50,0	4	80,0	25,00	31,91
Cycle 5 Day 1	0	29	96,7	29	100,0	8,05	21,19
	1	33	86,8	31	93,9	8,60	22,72
	2	3	30,0	3	100,0	0,00	0,00
Cycle 6 Day 1	0	29	96,7	28	96,6	8,33	17,27
	1	31	81,6	27	87,1	3,70	14,12
	2	3	30,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	29	96,7	28	96,6	8,33	21,52
	1	28	73,7	25	89,3	5,33	15,75
	2	3	30,0	3	100,0	0,00	0,00
Cycle 8 Day 1	0	28	93,3	26	92,9	3,85	10,86
	1	25	65,8	23	92,0	13,04	26,09
	2	3	30,0	3	100,0	0,00	0,00
Cycle 9 Day 1	0	26	86,7	26	100,0	7,69	14,32
	1	23	60,5	23	100,0	7,25	24,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	2	20,0	2	100,0	0,00	0,00
Cycle 10 Day 1	0	26	86,7	26	100,0	3,85	10,86
	1	23	60,5	22	95,7	9,09	21,04
	2	2	20,0	2	100,0	0,00	0,00
Cycle 11 Day 1	0	26	86,7	26	100,0	5,13	12,26
	1	22	57,9	22	100,0	4,55	15,59
	2	2	20,0	2	100,0	0,00	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	10,61	15,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	21	95,5	6,35	13,41
	2	2	20,0	2	100,0	33,33	47,14
Cycle 13 Day 1	0	25	83,3	24	96,0	8,33	14,74
	1	20	52,6	20	100,0	8,33	23,88
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	2,78	9,41
	1	19	50,0	19	100,0	7,02	23,78
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	24	80,0	24	100,0	5,56	16,05
	1	19	50,0	19	100,0	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 16 Day 1	0	22	73,3	20	90,9	6,67	13,68
	1	18	47,4	18	100,0	5,56	23,57
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	3,17	10,03
	1	17	44,7	17	100,0	9,80	25,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	3,70	10,78
	1	16	42,1	16	100,0	8,33	19,25
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	3,51	10,51
	1	15	39,5	13	86,7	2,56	9,25
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	5,88	13,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	39,5	14	93,3	7,14	14,19
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	2,38	8,91
	1	13	34,2	11	84,6	6,06	13,48
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	5,56	12,97
	1	13	34,2	12	92,3	8,33	15,08
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	0,00	0,00
	1	9	23,7	8	88,9	4,17	11,79
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	0,00	0,00
	1	9	23,7	8	88,9	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	0,00	0,00
	1	7	18,4	7	100,0	14,29	37,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	26,7	6	75,0	0,00	0,00
	1	6	15,8	6	100,0	16,67	27,89
Cycle 27 Day 1	0	6	20,0	3	50,0	0,00	0,00
	1	5	13,2	5	100,0	13,33	18,26
Cycle 28 Day 1	0	5	16,7	4	80,0	0,00	0,00
	1	5	13,2	5	100,0	26,67	43,46
Cycle 29 Day 1	0	4	13,3	2	50,0	0,00	0,00
	1	5	13,2	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	8,33	16,67
Cycle 31 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	16,67	19,25
Cycle 32 Day 1	0	3	10,0	2	66,7	0,00	0,00
	1	3	7,9	3	100,0	0,00	0,00
Cycle 33 Day 1	0	2	6,7	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	14,29	28,39
	1	20	52,6	12	60,0	5,56	12,97
	2	4	40,0	2	50,0	0,00	0,00
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	8,60	25,77
	1	3	100,0	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	44	100,0	43	97,7	10,08	18,59
Cycle 2 Day 1	None	30	96,8	27	90,0	4,94	20,05
	1	2	66,7	1	50,0	0,00	-
	2 or More	40	90,9	37	92,5	10,81	22,30
Cycle 3 Day 1	None	30	96,8	28	93,3	5,95	20,39
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	34	94,4	9,80	17,46
Cycle 4 Day 1	None	30	96,8	28	93,3	7,14	21,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	35	79,5	31	88,6	7,53	16,58
Cycle 5 Day 1	None	30	96,8	30	100,0	12,22	28,34
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	33	75,0	31	93,9	4,30	11,36
Cycle 6 Day 1	None	29	93,5	26	89,7	8,97	20,13
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	32	72,7	29	90,6	3,45	10,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	27	87,1	25	92,6	12,00	25,24
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	31	70,5	29	93,5	2,30	8,60
Cycle 8 Day 1	None	26	83,9	25	96,2	9,33	24,57
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	6,17	13,19
Cycle 9 Day 1	None	25	80,6	25	100,0	8,00	24,11
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	6,67	13,61
Cycle 10 Day 1	None	25	80,6	24	96,0	8,33	20,26
	1	1	33,3	1	100,0	0,00	-
	2 or More	25	56,8	25	100,0	4,00	11,06
Cycle 11 Day 1	None	25	80,6	25	100,0	4,00	14,66
	1	1	33,3	1	100,0	0,00	-
	2 or More	24	54,5	24	100,0	5,56	12,69
Cycle 12 Day 1	None	25	80,6	24	96,0	9,72	18,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	33,33	-
	2 or More	23	52,3	20	87,0	8,33	14,81
Cycle 13 Day 1	None	24	77,4	23	95,8	8,70	22,96
	1	1	33,3	1	100,0	33,33	-
	2 or More	21	47,7	21	100,0	6,35	13,41
Cycle 14 Day 1	None	23	74,2	23	100,0	4,35	20,85
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	20	95,2	5,00	12,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	23	74,2	23	100,0	1,45	6,95
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	20	100,0	5,00	16,31
Cycle 16 Day 1	None	20	64,5	19	95,0	3,51	10,51
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	19	95,0	8,77	24,45
Cycle 17 Day 1	None	19	61,3	19	100,0	3,51	10,51
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	19	43,2	19	100,0	8,77	24,45
Cycle 18 Day 1	None	18	58,1	17	94,4	5,88	13,10
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	17	89,5	5,88	17,62
Cycle 19 Day 1	None	17	54,8	17	100,0	3,92	11,07
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	2,22	8,61
Cycle 20 Day 1	None	17	54,8	16	94,1	8,33	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	4,44	11,73
Cycle 21 Day 1	None	15	48,4	13	86,7	5,13	12,52
	2 or More	14	31,8	13	92,9	2,56	9,25
Cycle 22 Day 1	None	15	48,4	13	86,7	10,26	16,01
	2 or More	14	31,8	12	85,7	2,78	9,62
Cycle 23 Day 1	None	10	32,3	9	90,0	3,70	11,11
	2 or More	11	25,0	9	81,8	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	32,3	10	100,0	0,00	0,00
	2 or More	10	22,7	8	80,0	0,00	0,00
Cycle 25 Day 1	None	9	29,0	8	88,9	0,00	0,00
	2 or More	6	13,6	5	83,3	20,00	44,72
Cycle 26 Day 1	None	8	25,8	8	100,0	4,17	11,79
	2 or More	6	13,6	4	66,7	16,67	33,33
Cycle 27 Day 1	None	7	22,6	6	85,7	5,56	13,61
	2 or More	4	9,1	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	22,6	7	100,0	4,76	12,60
	2 or More	3	6,8	2	66,7	50,00	70,71
Cycle 29 Day 1	None	6	19,4	5	83,3	6,67	14,91
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	12,9	3	75,0	11,11	19,25
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 31 Day 1	None	4	12,9	3	75,0	11,11	19,25
	2 or More	3	6,8	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	0,00	0,00
	2 or More	2	4,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	3,2	1	100,0	0,00	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	13,89	30,01
	1	2	66,7	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	54,5	15	62,5	6,67	13,80
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	8,60	25,77
	Previously Treated	47	100,0	46	97,9	9,42	18,14
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	4,94	20,05
	Previously Treated	42	89,4	38	90,5	10,53	22,06
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	5,95	20,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	38	80,9	35	92,1	9,52	17,29
Cycle 4 Day 1	Naïve	30	96,8	28	93,3	7,14	21,00
	Previously Treated	37	78,7	33	89,2	7,07	16,15
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	12,22	28,34
	Previously Treated	35	74,5	33	94,3	4,04	11,05
Cycle 6 Day 1	Naïve	29	93,5	26	89,7	8,97	20,13
	Previously Treated	34	72,3	31	91,2	3,23	10,02
Cycle 7 Day 1	Naïve	27	87,1	25	92,6	12,00	25,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	33	70,2	31	93,9	2,15	8,32
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	9,33	24,57
	Previously Treated	30	63,8	27	90,0	6,17	13,19
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	8,00	24,11
	Previously Treated	26	55,3	26	100,0	6,41	13,40
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	8,33	20,26
	Previously Treated	26	55,3	26	100,0	3,85	10,86
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	4,00	14,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	53,2	25	100,0	5,33	12,47
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	9,72	18,33
	Previously Treated	24	51,1	21	87,5	9,52	15,43
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	8,70	22,96
	Previously Treated	22	46,8	22	100,0	7,58	14,30
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	4,35	20,85
	Previously Treated	22	46,8	21	95,5	4,76	11,95
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	1,45	6,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	21	100,0	4,76	15,94
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	3,51	10,51
	Previously Treated	21	44,7	20	95,2	8,33	23,88
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	3,51	10,51
	Previously Treated	20	42,6	20	100,0	8,33	23,88
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	5,88	13,10
	Previously Treated	20	42,6	18	90,0	5,56	17,15
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	3,92	11,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	40,4	16	84,2	2,08	8,33
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	8,33	14,91
	Previously Treated	19	40,4	16	84,2	4,17	11,39
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	5,13	12,52
	Previously Treated	14	29,8	13	92,9	2,56	9,25
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	10,26	16,01
	Previously Treated	14	29,8	12	85,7	2,78	9,62
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	0,00	0,00
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	0,00	0,00
	Previously Treated	10	21,3	8	80,0	0,00	0,00
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	0,00	0,00
	Previously Treated	6	12,8	5	83,3	20,00	44,72
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	4,17	11,79
	Previously Treated	6	12,8	4	66,7	16,67	33,33
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	8,5	2	50,0	16,67	23,57
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	4,76	12,60
	Previously Treated	3	6,4	2	66,7	50,00	70,71
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	6,67	14,91
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	11,11	19,25
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	0,00	0,00
	Previously Treated	2	4,3	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	0,00	-
	Previously Treated	1	2,1	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	13,89	30,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	16	61,5	6,25	13,44
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	4,76	14,33
	Central	43	100,0	42	97,7	12,70	25,45
Cycle 2 Day 1	Local	32	91,4	30	93,8	7,78	20,87
	Central	40	93,0	35	87,5	8,57	21,91
Cycle 3 Day 1	Local	29	82,9	27	93,1	4,94	12,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	39	90,7	36	92,3	10,19	22,28
Cycle 4 Day 1	Local	28	80,0	24	85,7	6,94	16,97
	Central	39	90,7	37	94,9	7,21	19,46
Cycle 5 Day 1	Local	27	77,1	27	100,0	6,17	13,19
	Central	38	88,4	36	94,7	9,26	25,96
Cycle 6 Day 1	Local	27	77,1	27	100,0	4,94	12,07
	Central	36	83,7	30	83,3	6,67	18,36
Cycle 7 Day 1	Local	27	77,1	27	100,0	6,17	13,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	33	76,7	29	87,9	6,90	22,50
Cycle 8 Day 1	Local	26	74,3	26	100,0	8,97	17,78
	Central	30	69,8	26	86,7	6,41	21,12
Cycle 9 Day 1	Local	25	71,4	25	100,0	8,00	22,11
	Central	26	60,5	26	100,0	6,41	16,38
Cycle 10 Day 1	Local	25	71,4	24	96,0	4,17	11,26
	Central	26	60,5	26	100,0	7,69	19,57
Cycle 11 Day 1	Local	24	68,6	24	100,0	5,56	16,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	26	60,5	26	100,0	3,85	10,86
Cycle 12 Day 1	Local	23	65,7	22	95,7	6,06	13,16
	Central	26	60,5	23	88,5	13,04	19,43
Cycle 13 Day 1	Local	22	62,9	22	100,0	6,06	13,16
	Central	24	55,8	23	95,8	10,14	23,43
Cycle 14 Day 1	Local	22	62,9	22	100,0	1,52	7,11
	Central	23	53,5	22	95,7	7,58	22,84
Cycle 15 Day 1	Local	22	62,9	22	100,0	1,52	7,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	4,55	15,59
Cycle 16 Day 1	Local	20	57,1	20	100,0	5,00	12,21
	Central	21	48,8	19	90,5	7,02	23,78
Cycle 17 Day 1	Local	20	57,1	20	100,0	3,33	10,26
	Central	19	44,2	19	100,0	8,77	24,45
Cycle 18 Day 1	Local	20	57,1	19	95,0	3,51	10,51
	Central	18	41,9	16	88,9	8,33	19,25
Cycle 19 Day 1	Local	19	54,3	17	89,5	3,92	11,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	39,5	16	94,1	2,08	8,33
Cycle 20 Day 1	Local	19	54,3	17	89,5	5,88	13,10
	Central	17	39,5	15	88,2	6,67	13,80
Cycle 21 Day 1	Local	14	40,0	12	85,7	0,00	0,00
	Central	15	34,9	14	93,3	7,14	14,19
Cycle 22 Day 1	Local	14	40,0	12	85,7	5,56	12,97
	Central	15	34,9	13	86,7	7,69	14,62
Cycle 23 Day 1	Local	11	31,4	10	90,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	23,3	8	80,0	4,17	11,79
Cycle 24 Day 1	Local	11	31,4	10	90,9	0,00	0,00
	Central	9	20,9	8	88,9	0,00	0,00
Cycle 25 Day 1	Local	7	20,0	7	100,0	0,00	0,00
	Central	8	18,6	6	75,0	16,67	40,82
Cycle 26 Day 1	Local	6	17,1	6	100,0	5,56	13,61
	Central	8	18,6	6	75,0	11,11	27,22
Cycle 27 Day 1	Local	4	11,4	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	16,3	4	57,1	8,33	16,67
Cycle 28 Day 1	Local	4	11,4	4	100,0	8,33	16,67
	Central	6	14,0	5	83,3	20,00	44,72
Cycle 29 Day 1	Local	3	8,6	3	100,0	11,11	19,25
	Central	6	14,0	4	66,7	0,00	0,00
Cycle 30 Day 1	Local	3	8,6	3	100,0	11,11	19,25
	Central	4	9,3	2	50,0	0,00	0,00
Cycle 31 Day 1	Local	3	8,6	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	9,3	2	50,0	16,67	23,57
Cycle 32 Day 1	Local	3	8,6	3	100,0	0,00	0,00
	Central	3	7,0	2	66,7	0,00	0,00
Cycle 33 Day 1	Local	1	2,9	1	100,0	0,00	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	7,14	14,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	21	48,8	14	66,7	11,90	28,06
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	73	98,6	8,68	21,54
	No	4	100,0	4	100,0	16,67	19,25
Cycle 2 Day 1	Yes	70	94,6	63	90,0	7,94	21,35
	No	2	50,0	2	100,0	16,67	23,57
Cycle 3 Day 1	Yes	66	89,2	61	92,4	7,65	18,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 4 Day 1	Yes	65	87,8	59	90,8	6,78	18,34
	No	2	50,0	2	100,0	16,67	23,57
Cycle 5 Day 1	Yes	63	85,1	61	96,8	7,65	21,42
	No	2	50,0	2	100,0	16,67	23,57
Cycle 6 Day 1	Yes	61	82,4	55	90,2	5,45	15,40
	No	2	50,0	2	100,0	16,67	23,57
Cycle 7 Day 1	Yes	58	78,4	54	93,1	6,17	18,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 8 Day 1	Yes	54	73,0	50	92,6	7,33	19,39
	No	2	50,0	2	100,0	16,67	23,57
Cycle 9 Day 1	Yes	49	66,2	49	100,0	6,80	19,22
	No	2	50,0	2	100,0	16,67	23,57
Cycle 10 Day 1	Yes	49	66,2	48	98,0	6,25	16,35
	No	2	50,0	2	100,0	0,00	0,00
Cycle 11 Day 1	Yes	48	64,9	48	100,0	4,17	13,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 12 Day 1	Yes	47	63,5	43	91,5	9,30	16,79
	No	2	50,0	2	100,0	16,67	23,57
Cycle 13 Day 1	Yes	44	59,5	43	97,7	7,75	19,02
	No	2	50,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	43	58,1	42	97,7	3,97	16,79
	No	2	50,0	2	100,0	16,67	23,57
Cycle 15 Day 1	Yes	42	56,8	42	100,0	1,59	7,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	47,14
Cycle 16 Day 1	Yes	39	52,7	37	94,9	5,41	18,45
	No	2	50,0	2	100,0	16,67	23,57
Cycle 17 Day 1	Yes	37	50,0	37	100,0	5,41	18,45
	No	2	50,0	2	100,0	16,67	23,57
Cycle 18 Day 1	Yes	36	48,6	33	91,7	5,05	14,72
	No	2	50,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	3,13	9,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	5,56	12,63
	No	2	50,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	36,5	24	88,9	2,78	9,41
	No	2	50,0	2	100,0	16,67	23,57
Cycle 22 Day 1	Yes	27	36,5	23	85,2	5,80	12,92
	No	2	50,0	2	100,0	16,67	23,57
Cycle 23 Day 1	Yes	20	27,0	17	85,0	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	18,9	12	85,7	8,33	28,87
	No	1	25,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	6,06	20,10
	No	1	25,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	4,76	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	33,33	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	12,50	35,36
	No	1	25,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	0,00	0,00
	No	1	25,0	1	100,0	33,33	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	0,00	0,00
	No	1	25,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	33,33	-
Cycle 32 Day 1	Yes	5	6,8	4	80,0	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	9,52	21,96
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	20,83	35,36
	No	70	100,0	69	98,6	7,73	19,08
Cycle 2 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	67	95,7	60	89,6	8,89	22,01
Cycle 3 Day 1	Yes	5	62,5	4	80,0	0,00	0,00
	No	63	90,0	59	93,7	8,47	19,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	62	88,6	56	90,3	7,74	19,06
Cycle 5 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	60	85,7	58	96,7	8,62	22,13
Cycle 6 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	58	82,9	52	89,7	5,77	15,79
Cycle 7 Day 1	Yes	5	62,5	5	100,0	13,33	18,26
	No	55	78,6	51	92,7	5,88	18,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	5	62,5	5	100,0	20,00	29,81
	No	51	72,9	47	92,2	6,38	17,91
Cycle 9 Day 1	Yes	4	50,0	4	100,0	25,00	50,00
	No	47	67,1	47	100,0	5,67	14,44
Cycle 10 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	47	67,1	46	97,9	5,80	16,18
Cycle 11 Day 1	Yes	4	50,0	4	100,0	16,67	33,33
	No	46	65,7	46	100,0	3,62	10,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	45	64,3	41	91,1	9,76	17,07
Cycle 13 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	42	60,0	41	97,6	8,13	19,41
Cycle 14 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	41	58,6	40	97,6	5,00	17,78
Cycle 15 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	40	57,1	40	100,0	3,33	12,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	38	54,3	36	94,7	6,48	19,22
Cycle 17 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	36	51,4	36	100,0	5,56	18,69
Cycle 18 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	35	50,0	32	91,4	5,21	14,93
Cycle 19 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	30	90,9	3,33	10,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	33	47,1	29	87,9	5,75	12,81
Cycle 21 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	24	88,9	4,17	11,26
Cycle 22 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	23	85,2	7,25	14,06
Cycle 23 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	19	27,1	16	84,2	2,08	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	18	25,7	16	88,9	0,00	0,00
Cycle 25 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	13	18,6	11	84,6	9,09	30,15
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	9,09	21,56
Cycle 27 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	10	14,3	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	9	12,9	8	88,9	16,67	35,63
Cycle 29 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	8	11,4	6	75,0	5,56	13,61
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	6,67	14,91
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	0,00	0,00
Cycle 33 Day 1	No	2	2,9	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	0,00	0,00
	No	37	52,9	26	70,3	10,26	22,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13HR_SG.xls
28NOV2019 10:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	77	98,7	17,75	23,93
Cycle 2 Day 1	All	72	92,3	65	90,3	12,31	17,25
Cycle 3 Day 1	All	68	87,2	63	92,6	8,47	16,90
Cycle 4 Day 1	All	67	85,9	61	91,0	11,48	20,08
Cycle 5 Day 1	All	65	83,3	63	96,9	10,58	19,70
Cycle 6 Day 1	All	63	80,8	57	90,5	11,11	19,25
Cycle 7 Day 1	All	60	76,9	56	93,3	7,74	14,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	56	71,8	52	92,9	10,26	19,29
Cycle 9 Day 1	All	51	65,4	51	100,0	9,80	16,73
Cycle 10 Day 1	All	51	65,4	50	98,0	10,00	16,84
Cycle 11 Day 1	All	50	64,1	50	100,0	10,00	19,34
Cycle 12 Day 1	All	49	62,8	45	91,8	11,85	17,63
Cycle 13 Day 1	All	46	59,0	45	97,8	11,85	20,30
Cycle 14 Day 1	All	45	57,7	44	97,8	12,12	21,68
Cycle 15 Day 1	All	44	56,4	44	100,0	9,85	18,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	41	52,6	39	95,1	10,26	17,36
Cycle 17 Day 1	All	39	50,0	39	100,0	9,40	17,01
Cycle 18 Day 1	All	38	48,7	35	92,1	9,52	15,28
Cycle 19 Day 1	All	36	46,2	33	91,7	11,11	19,84
Cycle 20 Day 1	All	36	46,2	32	88,9	11,46	18,18
Cycle 21 Day 1	All	29	37,2	26	89,7	8,97	17,78
Cycle 22 Day 1	All	29	37,2	25	86,2	9,33	15,28
Cycle 23 Day 1	All	21	26,9	18	85,7	11,11	16,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	25,6	18	90,0	11,11	16,17
Cycle 25 Day 1	All	15	19,2	13	86,7	7,69	14,62
Cycle 26 Day 1	All	14	17,9	12	85,7	11,11	16,41
Cycle 27 Day 1	All	11	14,1	8	72,7	16,67	25,20
Cycle 28 Day 1	All	10	12,8	9	90,0	14,81	17,57
Cycle 29 Day 1	All	9	11,5	7	77,8	14,29	17,82
Cycle 30 Day 1	All	7	9,0	5	71,4	20,00	18,26
Cycle 31 Day 1	All	7	9,0	5	71,4	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	7,7	5	83,3	13,33	18,26
Cycle 33 Day 1	All	2	2,6	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	15,48	19,21
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	9,20	17,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	49	100,0	48	98,0	22,92	25,87
Cycle 2 Day 1	Male	27	93,1	25	92,6	12,00	16,33
	Female	45	91,8	40	88,9	12,50	18,00
Cycle 3 Day 1	Male	25	86,2	24	96,0	9,72	18,33
	Female	43	87,8	39	90,7	7,69	16,15
Cycle 4 Day 1	Male	25	86,2	23	92,0	10,14	15,68
	Female	42	85,7	38	90,5	12,28	22,49
Cycle 5 Day 1	Male	25	86,2	24	96,0	6,94	16,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	40	81,6	39	97,5	12,82	21,10
Cycle 6 Day 1	Male	25	86,2	23	92,0	8,70	14,97
	Female	38	77,6	34	89,5	12,75	21,73
Cycle 7 Day 1	Male	23	79,3	23	100,0	5,80	12,92
	Female	37	75,5	33	89,2	9,09	15,08
Cycle 8 Day 1	Male	21	72,4	19	90,5	7,02	13,96
	Female	35	71,4	33	94,3	12,12	21,76
Cycle 9 Day 1	Male	18	62,1	18	100,0	5,56	12,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	12,12	18,29
Cycle 10 Day 1	Male	18	62,1	18	100,0	7,41	14,26
	Female	33	67,3	32	97,0	11,46	18,18
Cycle 11 Day 1	Male	18	62,1	18	100,0	12,96	23,26
	Female	32	65,3	32	100,0	8,33	16,93
Cycle 12 Day 1	Male	17	58,6	17	100,0	9,80	15,66
	Female	32	65,3	28	87,5	13,10	18,90
Cycle 13 Day 1	Male	17	58,6	17	100,0	11,76	20,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	29	59,2	28	96,6	11,90	20,72
Cycle 14 Day 1	Male	17	58,6	16	94,1	8,33	14,91
	Female	28	57,1	28	100,0	14,29	24,73
Cycle 15 Day 1	Male	16	55,2	16	100,0	6,25	13,44
	Female	28	57,1	28	100,0	11,90	20,72
Cycle 16 Day 1	Male	14	48,3	14	100,0	7,14	14,19
	Female	27	55,1	25	92,6	12,00	18,95
Cycle 17 Day 1	Male	12	41,4	12	100,0	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	27	100,0	11,11	18,49
Cycle 18 Day 1	Male	11	37,9	10	90,9	6,67	14,05
	Female	27	55,1	25	92,6	10,67	15,87
Cycle 19 Day 1	Male	10	34,5	10	100,0	10,00	22,50
	Female	26	53,1	23	88,5	11,59	19,09
Cycle 20 Day 1	Male	10	34,5	9	90,0	7,41	14,70
	Female	26	53,1	23	88,5	13,04	19,43
Cycle 21 Day 1	Male	8	27,6	8	100,0	12,50	24,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	42,9	18	85,7	7,41	14,26
Cycle 22 Day 1	Male	8	27,6	6	75,0	22,22	17,21
	Female	21	42,9	19	90,5	5,26	12,49
Cycle 23 Day 1	Male	5	17,2	4	80,0	16,67	19,25
	Female	16	32,7	14	87,5	9,52	15,63
Cycle 24 Day 1	Male	5	17,2	4	80,0	8,33	16,67
	Female	15	30,6	14	93,3	11,90	16,57
Cycle 25 Day 1	Male	3	10,3	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	24,5	11	91,7	9,09	15,57
Cycle 26 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	11	22,4	10	90,9	13,33	17,21
Cycle 27 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	8	16,3	6	75,0	22,22	27,22
Cycle 28 Day 1	Male	2	6,9	2	100,0	0,00	0,00
	Female	8	16,3	7	87,5	19,05	17,82
Cycle 29 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	16,3	6	75,0	16,67	18,26
Cycle 30 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	25,00	16,67
Cycle 31 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	25,00	16,67
Cycle 32 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	5	10,2	4	80,0	16,67	19,25
Cycle 33 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	2,0	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	11,11	16,27
	Female	21	42,9	13	61,9	20,51	21,68
Age							
Cycle 1 Day 1	18-64	62	100,0	61	98,4	19,67	25,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	11,90	16,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	18-64	59	95,2	52	88,1	12,82	17,66
	65-74	11	78,6	11	100,0	12,12	16,82
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 3 Day 1	18-64	56	90,3	52	92,9	8,33	17,31
	65-74	10	71,4	9	90,0	7,41	14,70
	>=75	2	100,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	55	88,7	50	90,9	12,00	21,04
	65-74	10	71,4	9	90,0	11,11	16,67
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 5 Day 1	18-64	53	85,5	52	98,1	10,26	19,29
	65-74	10	71,4	10	100,0	10,00	22,50
	>=75	2	100,0	1	50,0	33,33	-
Cycle 6 Day 1	18-64	51	82,3	46	90,2	10,14	18,42
	65-74	10	71,4	9	90,0	14,81	24,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 7 Day 1	18-64	49	79,0	46	93,9	7,97	14,38
	65-74	9	64,3	8	88,9	8,33	15,43
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 8 Day 1	18-64	45	72,6	41	91,1	10,57	20,33
	65-74	9	64,3	9	100,0	11,11	16,67
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 9 Day 1	18-64	40	64,5	40	100,0	8,33	16,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	14,81	17,57
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 10 Day 1	18-64	40	64,5	39	97,5	11,11	17,66
	65-74	9	64,3	9	100,0	3,70	11,11
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 11 Day 1	18-64	39	62,9	39	100,0	9,40	20,16
	65-74	9	64,3	9	100,0	7,41	14,70
	>=75	2	100,0	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	38	61,3	35	92,1	11,43	17,97
	65-74	9	64,3	8	88,9	12,50	17,25
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 13 Day 1	18-64	35	56,5	34	97,1	11,76	19,90
	65-74	9	64,3	9	100,0	11,11	23,57
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 14 Day 1	18-64	35	56,5	35	100,0	10,48	21,04
	65-74	9	64,3	8	88,9	16,67	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	33,33	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	8,57	18,69
	65-74	8	57,1	8	100,0	12,50	17,25
	>=75	1	50,0	1	100,0	33,33	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	11,46	18,18
	65-74	7	50,0	6	85,7	5,56	13,61
	>=75	1	50,0	1	100,0	0,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	9,38	17,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	6	42,9	6	100,0	11,11	17,21
	>=75	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	9,20	15,16
	65-74	6	42,9	5	83,3	13,33	18,26
	>=75	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	11,90	20,72
	65-74	5	35,7	4	80,0	8,33	16,67
	>=75	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	11,54	18,72
	65-74	5	35,7	5	100,0	13,33	18,26
	>=75	1	50,0	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	9,52	18,69
	65-74	4	28,6	4	100,0	8,33	16,67
	>=75	1	50,0	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	10,00	15,67
	65-74	4	28,6	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	33,33	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	10,42	15,96
	65-74	2	14,3	2	100,0	16,67	23,57
Cycle 24 Day 1	18-64	18	29,0	16	88,9	12,50	16,67
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	22,6	12	85,7	8,33	15,08
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	11,11	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	16,67	25,20
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	14,81	17,57
	65-74	1	7,1	0	0,0	-	-
Cycle 29 Day 1	18-64	8	12,9	7	87,5	14,29	17,82
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	20,00	18,26
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	16,67	19,25
	65-74	1	7,1	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	0,00	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	16,67	17,10
	65-74	10	71,4	7	70,0	9,52	25,20
	>=75	2	100,0	1	50,0	33,33	-
Race							
Cycle 1 Day 1	White	35	100,0	34	97,1	13,73	21,89
	Other	43	100,0	43	100,0	20,93	25,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	33	94,3	28	84,8	4,76	11,88
	Other	39	90,7	37	94,9	18,02	18,58
Cycle 3 Day 1	White	31	88,6	27	87,1	4,94	12,07
	Other	37	86,0	36	97,3	11,11	19,52
Cycle 4 Day 1	White	31	88,6	26	83,9	6,41	13,40
	Other	36	83,7	35	97,2	15,24	23,35
Cycle 5 Day 1	White	31	88,6	29	93,5	6,90	16,38
	Other	34	79,1	34	100,0	13,73	21,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	30	85,7	25	83,3	9,33	18,05
	Other	33	76,7	32	97,0	12,50	20,30
Cycle 7 Day 1	White	29	82,9	26	89,7	5,13	12,26
	Other	31	72,1	30	96,8	10,00	15,54
Cycle 8 Day 1	White	28	80,0	24	85,7	8,33	14,74
	Other	28	65,1	28	100,0	11,90	22,62
Cycle 9 Day 1	White	26	74,3	26	100,0	5,13	12,26
	Other	25	58,1	25	100,0	14,67	19,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	6,67	13,61
	Other	25	58,1	25	100,0	13,33	19,25
Cycle 11 Day 1	White	26	74,3	26	100,0	6,41	16,38
	Other	24	55,8	24	100,0	13,89	21,80
Cycle 12 Day 1	White	26	74,3	22	84,6	7,58	14,30
	Other	23	53,5	23	100,0	15,94	19,77
Cycle 13 Day 1	White	24	68,6	23	95,8	8,70	18,03
	Other	22	51,2	22	100,0	15,15	22,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	24	68,6	24	100,0	8,33	20,26
	Other	21	48,8	20	95,2	16,67	22,94
Cycle 15 Day 1	White	24	68,6	24	100,0	8,33	17,72
	Other	20	46,5	20	100,0	11,67	19,57
Cycle 16 Day 1	White	22	62,9	20	90,9	8,33	14,81
	Other	19	44,2	19	100,0	12,28	19,91
Cycle 17 Day 1	White	22	62,9	22	100,0	4,55	11,71
	Other	17	39,5	17	100,0	15,69	20,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	21	60,0	18	85,7	3,70	10,78
	Other	17	39,5	17	100,0	15,69	17,15
Cycle 19 Day 1	White	20	57,1	20	100,0	8,33	14,81
	Other	16	37,2	13	81,3	15,38	25,88
Cycle 20 Day 1	White	20	57,1	17	85,0	3,92	11,07
	Other	16	37,2	15	93,8	20,00	21,08
Cycle 21 Day 1	White	16	45,7	14	87,5	2,38	8,91
	Other	13	30,2	12	92,3	16,67	22,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	45,7	13	81,3	5,13	12,52
	Other	13	30,2	12	92,3	13,89	17,16
Cycle 23 Day 1	White	12	34,3	10	83,3	6,67	14,05
	Other	9	20,9	8	88,9	16,67	17,82
Cycle 24 Day 1	White	11	31,4	10	90,9	6,67	14,05
	Other	9	20,9	8	88,9	16,67	17,82
Cycle 25 Day 1	White	10	28,6	8	80,0	0,00	0,00
	Other	5	11,6	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	28,6	8	80,0	4,17	11,79
	Other	4	9,3	4	100,0	25,00	16,67
Cycle 27 Day 1	White	8	22,9	5	62,5	0,00	0,00
	Other	3	7,0	3	100,0	44,44	19,25
Cycle 28 Day 1	White	7	20,0	6	85,7	5,56	13,61
	Other	3	7,0	3	100,0	33,33	0,00
Cycle 29 Day 1	White	6	17,1	4	66,7	16,67	19,25
	Other	3	7,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	11,4	2	50,0	16,67	23,57
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 31 Day 1	White	4	11,4	2	50,0	16,67	23,57
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 32 Day 1	White	4	11,4	3	75,0	11,11	19,25
	Other	2	4,7	2	100,0	16,67	23,57
Cycle 33 Day 1	White	2	5,7	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-
End Of Treatment	White	15	42,9	12	80,0	13,89	22,29
	Other	24	55,8	16	66,7	16,67	17,21
Region							
Cycle 1 Day 1	America (AM)	22	100,0	21	95,5	14,29	19,92
	Europe (EU)	17	100,0	17	100,0	13,73	20,61
	Asia (AS)	39	100,0	39	100,0	21,37	27,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	3,92	11,07
	Europe (EU)	16	94,1	13	81,3	7,69	14,62
	Asia (AS)	36	92,3	35	97,2	18,10	18,69
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	0,00	0,00
	Europe (EU)	15	88,2	11	73,3	12,12	16,82
	Asia (AS)	33	84,6	33	100,0	12,12	20,10
Cycle 4 Day 1	America (AM)	20	90,9	19	95,0	5,26	12,49
	Europe (EU)	15	88,2	11	73,3	12,12	16,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	32	82,1	31	96,9	15,05	24,10
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	10,00	21,90
	Europe (EU)	15	88,2	13	86,7	7,69	14,62
	Asia (AS)	30	76,9	30	100,0	12,22	20,50
Cycle 6 Day 1	America (AM)	20	90,9	18	90,0	7,41	18,28
	Europe (EU)	14	82,4	12	85,7	13,89	22,29
	Asia (AS)	29	74,4	27	93,1	12,35	18,83
Cycle 7 Day 1	America (AM)	19	86,4	17	89,5	3,92	11,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	14	82,4	13	92,9	7,69	14,62
	Asia (AS)	27	69,2	26	96,3	10,26	15,69
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	7,84	14,57
	Europe (EU)	14	82,4	11	78,6	15,15	17,41
	Asia (AS)	24	61,5	24	100,0	9,72	23,01
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	3,70	10,78
	Europe (EU)	12	70,6	12	100,0	8,33	15,08
	Asia (AS)	21	53,8	21	100,0	15,87	20,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	3,92	11,07
	Europe (EU)	12	70,6	12	100,0	11,11	16,41
	Asia (AS)	21	53,8	21	100,0	14,29	19,92
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	0,00	0,00
	Europe (EU)	12	70,6	12	100,0	13,89	22,29
	Asia (AS)	20	51,3	20	100,0	16,67	22,94
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	5,88	13,10
	Europe (EU)	12	70,6	9	75,0	18,52	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	19	48,7	19	100,0	14,04	20,23
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	1,96	8,08
	Europe (EU)	11	64,7	10	90,9	20,00	23,31
	Asia (AS)	18	46,2	18	100,0	16,67	23,57
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	5,88	17,62
	Europe (EU)	11	64,7	11	100,0	15,15	22,92
	Asia (AS)	17	43,6	16	94,1	16,67	24,34
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	64,7	11	100,0	9,09	15,57
	Asia (AS)	16	41,0	16	100,0	18,75	24,25
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	2,38	8,91
	Europe (EU)	11	64,7	9	81,8	14,81	17,57
	Asia (AS)	16	41,0	16	100,0	14,58	20,97
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	2,38	8,91
	Europe (EU)	10	58,8	10	100,0	6,67	14,05
	Asia (AS)	15	38,5	15	100,0	17,78	21,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	4,76	12,10
	Europe (EU)	9	52,9	6	66,7	5,56	13,61
	Asia (AS)	15	38,5	15	100,0	15,56	17,21
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	5,13	12,52
	Europe (EU)	9	52,9	9	100,0	11,11	16,67
	Asia (AS)	14	35,9	11	78,6	18,18	27,34
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	2,56	9,25
	Europe (EU)	9	52,9	6	66,7	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	23,08	21,01
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	3,33	10,54
	Europe (EU)	7	41,2	6	85,7	5,56	13,61
	Asia (AS)	11	28,2	10	90,9	16,67	23,57
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	6,67	14,05
	Europe (EU)	7	41,2	5	71,4	6,67	14,91
	Asia (AS)	11	28,2	10	90,9	13,33	17,21
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	14,81	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	29,4	3	60,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	11,11	17,21
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	12,50	17,25
	Europe (EU)	5	29,4	4	80,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	16,67	18,26
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	4,76	12,60
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	11,11	17,21
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	16,67	19,25
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	0,00	0,00
	Europe (EU)	3	17,6	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	33,33	27,22
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	8,33	16,67
	Europe (EU)	2	11,8	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	25,00	16,67
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	22,22	19,25
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	8,33	16,67
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	22,22	19,25
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	22,22	19,25
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57
	Europe (EU)	1	5,9	1	100,0	0,00	-
	Asia (AS)	3	7,7	2	66,7	16,67	23,57
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	0,00	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	9,09	15,57
	Europe (EU)	6	35,3	4	66,7	33,33	27,22
	Asia (AS)	21	53,8	13	61,9	15,38	17,30
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	29	96,7	12,64	20,73
	1	38	100,0	38	100,0	20,18	26,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	10	100,0	10	100,0	23,33	22,50
Cycle 2 Day 1	0	30	100,0	27	90,0	7,41	14,12
	1	36	94,7	32	88,9	15,63	18,90
	2	6	60,0	6	100,0	16,67	18,26
Cycle 3 Day 1	0	29	96,7	27	93,1	8,64	17,52
	1	34	89,5	31	91,2	8,60	17,14
	2	5	50,0	5	100,0	6,67	14,91
Cycle 4 Day 1	0	29	96,7	25	86,2	9,33	18,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	10,42	15,70
	2	5	50,0	4	80,0	33,33	47,14
Cycle 5 Day 1	0	29	96,7	29	100,0	12,64	22,56
	1	33	86,8	31	93,9	8,60	17,14
	2	3	30,0	3	100,0	11,11	19,25
Cycle 6 Day 1	0	29	96,7	28	96,6	13,10	22,84
	1	31	81,6	27	87,1	8,64	14,89
	2	3	30,0	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	29	96,7	28	96,6	8,33	14,70
	1	28	73,7	25	89,3	8,00	14,53
	2	3	30,0	3	100,0	0,00	0,00
Cycle 8 Day 1	0	28	93,3	26	92,9	10,26	22,65
	1	25	65,8	23	92,0	11,59	16,23
	2	3	30,0	3	100,0	0,00	0,00
Cycle 9 Day 1	0	26	86,7	26	100,0	11,54	18,72
	1	23	60,5	23	100,0	8,70	14,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	2	20,0	2	100,0	0,00	0,00
Cycle 10 Day 1	0	26	86,7	26	100,0	8,97	17,78
	1	23	60,5	22	95,7	12,12	16,41
	2	2	20,0	2	100,0	0,00	0,00
Cycle 11 Day 1	0	26	86,7	26	100,0	8,97	20,13
	1	22	57,9	22	100,0	12,12	19,37
	2	2	20,0	2	100,0	0,00	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	13,64	19,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	21	95,5	11,11	16,10
	2	2	20,0	2	100,0	0,00	0,00
Cycle 13 Day 1	0	25	83,3	24	96,0	12,50	21,56
	1	20	52,6	20	100,0	11,67	19,57
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	8,33	20,26
	1	19	50,0	19	100,0	17,54	23,22
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	24	80,0	24	100,0	8,33	17,72
	1	19	50,0	19	100,0	12,28	19,91
	2	1	10,0	1	100,0	0,00	-
Cycle 16 Day 1	0	22	73,3	20	90,9	11,67	19,57
	1	18	47,4	18	100,0	9,26	15,36
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	11,11	19,25
	1	17	44,7	17	100,0	7,84	14,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	9,26	15,36
	1	16	42,1	16	100,0	10,42	15,96
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	12,28	19,91
	1	15	39,5	13	86,7	10,26	21,01
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	13,73	20,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	39,5	14	93,3	9,52	15,63
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	9,52	15,63
	1	13	34,2	11	84,6	9,09	21,56
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	8,33	15,08
	1	13	34,2	12	92,3	11,11	16,41
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	7,41	14,70
	1	9	23,7	8	88,9	16,67	17,82
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	3,70	11,11
	1	9	23,7	8	88,9	20,83	17,25
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	5,56	13,61
	1	7	18,4	7	100,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	26,7	6	75,0	5,56	13,61
	1	6	15,8	6	100,0	16,67	18,26
Cycle 27 Day 1	0	6	20,0	3	50,0	0,00	0,00
	1	5	13,2	5	100,0	26,67	27,89
Cycle 28 Day 1	0	5	16,7	4	80,0	0,00	0,00
	1	5	13,2	5	100,0	26,67	14,91
Cycle 29 Day 1	0	4	13,3	2	50,0	0,00	0,00
	1	5	13,2	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	25,00	16,67
Cycle 31 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	25,00	16,67
Cycle 32 Day 1	0	3	10,0	2	66,7	0,00	0,00
	1	3	7,9	3	100,0	22,22	19,25
Cycle 33 Day 1	0	2	6,7	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	11,90	21,11
	1	20	52,6	12	60,0	19,44	17,16
	2	4	40,0	2	50,0	16,67	23,57
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	17,20	22,56
	1	3	100,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	44	100,0	43	97,7	18,60	25,51
Cycle 2 Day 1	None	30	96,8	27	90,0	8,64	14,89
	1	2	66,7	1	50,0	0,00	-
	2 or More	40	90,9	37	92,5	15,32	18,58
Cycle 3 Day 1	None	30	96,8	28	93,3	7,14	18,94
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	34	94,4	9,80	15,42
Cycle 4 Day 1	None	30	96,8	28	93,3	11,90	18,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	35	79,5	31	88,6	11,83	22,02
Cycle 5 Day 1	None	30	96,8	30	100,0	14,44	24,26
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	33	75,0	31	93,9	7,53	14,17
Cycle 6 Day 1	None	29	93,5	26	89,7	11,54	20,96
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	32	72,7	29	90,6	11,49	18,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	27	87,1	25	92,6	6,67	13,61
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	31	70,5	29	93,5	9,20	15,16
Cycle 8 Day 1	None	26	83,9	25	96,2	12,00	23,33
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	8,64	14,89
Cycle 9 Day 1	None	25	80,6	25	100,0	9,33	18,05
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	10,67	15,87
Cycle 10 Day 1	None	25	80,6	24	96,0	9,72	18,33
	1	1	33,3	1	100,0	0,00	-
	2 or More	25	56,8	25	100,0	10,67	15,87
Cycle 11 Day 1	None	25	80,6	25	100,0	9,33	20,46
	1	1	33,3	1	100,0	0,00	-
	2 or More	24	54,5	24	100,0	11,11	18,82
Cycle 12 Day 1	None	25	80,6	24	96,0	11,11	18,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	23	52,3	20	87,0	13,33	16,75
Cycle 13 Day 1	None	24	77,4	23	95,8	11,59	19,09
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	12,70	22,30
Cycle 14 Day 1	None	23	74,2	23	100,0	10,14	21,17
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	20	95,2	15,00	22,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	23	74,2	23	100,0	7,25	17,28
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	20	100,0	13,33	19,94
Cycle 16 Day 1	None	20	64,5	19	95,0	8,77	18,73
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	19	95,0	12,28	16,52
Cycle 17 Day 1	None	19	61,3	19	100,0	8,77	18,73
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	19	43,2	19	100,0	10,53	15,92
Cycle 18 Day 1	None	18	58,1	17	94,4	9,80	15,66
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	17	89,5	9,80	15,66
Cycle 19 Day 1	None	17	54,8	17	100,0	9,80	19,60
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	13,33	21,08
Cycle 20 Day 1	None	17	54,8	16	94,1	12,50	20,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	11,11	16,27
Cycle 21 Day 1	None	15	48,4	13	86,7	5,13	12,52
	2 or More	14	31,8	13	92,9	12,82	21,68
Cycle 22 Day 1	None	15	48,4	13	86,7	10,26	16,01
	2 or More	14	31,8	12	85,7	8,33	15,08
Cycle 23 Day 1	None	10	32,3	9	90,0	14,81	17,57
	2 or More	11	25,0	9	81,8	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	32,3	10	100,0	10,00	16,10
	2 or More	10	22,7	8	80,0	12,50	17,25
Cycle 25 Day 1	None	9	29,0	8	88,9	4,17	11,79
	2 or More	6	13,6	5	83,3	13,33	18,26
Cycle 26 Day 1	None	8	25,8	8	100,0	12,50	17,25
	2 or More	6	13,6	4	66,7	8,33	16,67
Cycle 27 Day 1	None	7	22,6	6	85,7	11,11	27,22
	2 or More	4	9,1	2	50,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	22,6	7	100,0	9,52	16,27
	2 or More	3	6,8	2	66,7	33,33	0,00
Cycle 29 Day 1	None	6	19,4	5	83,3	13,33	18,26
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 30 Day 1	None	4	12,9	3	75,0	22,22	19,25
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 31 Day 1	None	4	12,9	3	75,0	11,11	19,25
	2 or More	3	6,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	11,11	19,25
	2 or More	2	4,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	3,2	1	100,0	0,00	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	19,44	17,16
	1	2	66,7	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	54,5	15	62,5	13,33	21,08
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	17,20	22,56
	Previously Treated	47	100,0	46	97,9	18,12	25,05
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	8,64	14,89
	Previously Treated	42	89,4	38	90,5	14,91	18,50
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	7,14	18,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	38	80,9	35	92,1	9,52	15,28
Cycle 4 Day 1	Naïve	30	96,8	28	93,3	11,90	18,62
	Previously Treated	37	78,7	33	89,2	11,11	21,52
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	14,44	24,26
	Previously Treated	35	74,5	33	94,3	7,07	13,84
Cycle 6 Day 1	Naïve	29	93,5	26	89,7	11,54	20,96
	Previously Treated	34	72,3	31	91,2	10,75	18,03
Cycle 7 Day 1	Naïve	27	87,1	25	92,6	6,67	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	33	70,2	31	93,9	8,60	14,83
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	12,00	23,33
	Previously Treated	30	63,8	27	90,0	8,64	14,89
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	9,33	18,05
	Previously Treated	26	55,3	26	100,0	10,26	15,69
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	9,72	18,33
	Previously Treated	26	55,3	26	100,0	10,26	15,69
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	9,33	20,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	53,2	25	100,0	10,67	18,56
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	11,11	18,82
	Previously Treated	24	51,1	21	87,5	12,70	16,59
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	11,59	19,09
	Previously Treated	22	46,8	22	100,0	12,12	21,93
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	10,14	21,17
	Previously Treated	22	46,8	21	95,5	14,29	22,54
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	7,25	17,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	21	100,0	12,70	19,65
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	8,77	18,73
	Previously Treated	21	44,7	20	95,2	11,67	16,31
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	8,77	18,73
	Previously Treated	20	42,6	20	100,0	10,00	15,67
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	9,80	15,66
	Previously Treated	20	42,6	18	90,0	9,26	15,36
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	9,80	19,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	40,4	16	84,2	12,50	20,64
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	12,50	20,64
	Previously Treated	19	40,4	16	84,2	10,42	15,96
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	5,13	12,52
	Previously Treated	14	29,8	13	92,9	12,82	21,68
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	10,26	16,01
	Previously Treated	14	29,8	12	85,7	8,33	15,08
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	14,81	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	7,41	14,70
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	10,00	16,10
	Previously Treated	10	21,3	8	80,0	12,50	17,25
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	4,17	11,79
	Previously Treated	6	12,8	5	83,3	13,33	18,26
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	12,50	17,25
	Previously Treated	6	12,8	4	66,7	8,33	16,67
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	11,11	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	8,5	2	50,0	33,33	0,00
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	9,52	16,27
	Previously Treated	3	6,4	2	66,7	33,33	0,00
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	13,33	18,26
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	22,22	19,25
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	11,11	19,25
	Previously Treated	2	4,3	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	0,00	-
	Previously Treated	1	2,1	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	19,44	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	16	61,5	12,50	20,64
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	15,24	20,36
	Central	43	100,0	42	97,7	19,84	26,61
Cycle 2 Day 1	Local	32	91,4	30	93,8	8,89	14,99
	Central	40	93,0	35	87,5	15,24	18,69
Cycle 3 Day 1	Local	29	82,9	27	93,1	2,47	8,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	39	90,7	36	92,3	12,96	19,96
Cycle 4 Day 1	Local	28	80,0	24	85,7	4,17	11,26
	Central	39	90,7	37	94,9	16,22	23,07
Cycle 5 Day 1	Local	27	77,1	27	100,0	8,64	14,89
	Central	38	88,4	36	94,7	12,04	22,75
Cycle 6 Day 1	Local	27	77,1	27	100,0	11,11	20,67
	Central	36	83,7	30	83,3	11,11	18,22
Cycle 7 Day 1	Local	27	77,1	27	100,0	7,41	14,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	33	76,7	29	87,9	8,05	14,52
Cycle 8 Day 1	Local	26	74,3	26	100,0	7,69	14,32
	Central	30	69,8	26	86,7	12,82	23,24
Cycle 9 Day 1	Local	25	71,4	25	100,0	5,33	12,47
	Central	26	60,5	26	100,0	14,10	19,26
Cycle 10 Day 1	Local	25	71,4	24	96,0	9,72	15,48
	Central	26	60,5	26	100,0	10,26	18,30
Cycle 11 Day 1	Local	24	68,6	24	100,0	2,78	9,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	26	60,5	26	100,0	16,67	23,57
Cycle 12 Day 1	Local	23	65,7	22	95,7	7,58	14,30
	Central	26	60,5	23	88,5	15,94	19,77
Cycle 13 Day 1	Local	22	62,9	22	100,0	9,09	21,04
	Central	24	55,8	23	95,8	14,49	19,66
Cycle 14 Day 1	Local	22	62,9	22	100,0	9,09	21,04
	Central	23	53,5	22	95,7	15,15	22,37
Cycle 15 Day 1	Local	22	62,9	22	100,0	6,06	13,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	13,64	22,20
Cycle 16 Day 1	Local	20	57,1	20	100,0	8,33	14,81
	Central	21	48,8	19	90,5	12,28	19,91
Cycle 17 Day 1	Local	20	57,1	20	100,0	8,33	14,81
	Central	19	44,2	19	100,0	10,53	19,41
Cycle 18 Day 1	Local	20	57,1	19	95,0	8,77	15,08
	Central	18	41,9	16	88,9	10,42	15,96
Cycle 19 Day 1	Local	19	54,3	17	89,5	11,76	20,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	39,5	16	94,1	10,42	20,07
Cycle 20 Day 1	Local	19	54,3	17	89,5	5,88	13,10
	Central	17	39,5	15	88,2	17,78	21,33
Cycle 21 Day 1	Local	14	40,0	12	85,7	8,33	20,72
	Central	15	34,9	14	93,3	9,52	15,63
Cycle 22 Day 1	Local	14	40,0	12	85,7	8,33	15,08
	Central	15	34,9	13	86,7	10,26	16,01
Cycle 23 Day 1	Local	11	31,4	10	90,9	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	23,3	8	80,0	8,33	15,43
Cycle 24 Day 1	Local	11	31,4	10	90,9	10,00	16,10
	Central	9	20,9	8	88,9	12,50	17,25
Cycle 25 Day 1	Local	7	20,0	7	100,0	4,76	12,60
	Central	8	18,6	6	75,0	11,11	17,21
Cycle 26 Day 1	Local	6	17,1	6	100,0	16,67	18,26
	Central	8	18,6	6	75,0	5,56	13,61
Cycle 27 Day 1	Local	4	11,4	4	100,0	16,67	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	16,3	4	57,1	16,67	19,25
Cycle 28 Day 1	Local	4	11,4	4	100,0	16,67	19,25
	Central	6	14,0	5	83,3	13,33	18,26
Cycle 29 Day 1	Local	3	8,6	3	100,0	11,11	19,25
	Central	6	14,0	4	66,7	16,67	19,25
Cycle 30 Day 1	Local	3	8,6	3	100,0	22,22	19,25
	Central	4	9,3	2	50,0	16,67	23,57
Cycle 31 Day 1	Local	3	8,6	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	9,3	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	8,6	3	100,0	11,11	19,25
	Central	3	7,0	2	66,7	16,67	23,57
Cycle 33 Day 1	Local	1	2,9	1	100,0	0,00	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	14,29	21,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	21	48,8	14	66,7	16,67	17,30
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	73	98,6	17,81	24,27
	No	4	100,0	4	100,0	16,67	19,25
Cycle 2 Day 1	Yes	70	94,6	63	90,0	12,17	17,25
	No	2	50,0	2	100,0	16,67	23,57
Cycle 3 Day 1	Yes	66	89,2	61	92,4	8,20	16,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 4 Day 1	Yes	65	87,8	59	90,8	11,30	20,16
	No	2	50,0	2	100,0	16,67	23,57
Cycle 5 Day 1	Yes	63	85,1	61	96,8	10,93	19,93
	No	2	50,0	2	100,0	0,00	0,00
Cycle 6 Day 1	Yes	61	82,4	55	90,2	10,91	19,30
	No	2	50,0	2	100,0	16,67	23,57
Cycle 7 Day 1	Yes	58	78,4	54	93,1	7,41	13,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 8 Day 1	Yes	54	73,0	50	92,6	10,67	19,56
	No	2	50,0	2	100,0	0,00	0,00
Cycle 9 Day 1	Yes	49	66,2	49	100,0	9,52	16,67
	No	2	50,0	2	100,0	16,67	23,57
Cycle 10 Day 1	Yes	49	66,2	48	98,0	10,42	17,06
	No	2	50,0	2	100,0	0,00	0,00
Cycle 11 Day 1	Yes	48	64,9	48	100,0	9,72	19,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 12 Day 1	Yes	47	63,5	43	91,5	11,63	17,64
	No	2	50,0	2	100,0	16,67	23,57
Cycle 13 Day 1	Yes	44	59,5	43	97,7	11,63	20,42
	No	2	50,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	43	58,1	42	97,7	11,90	21,87
	No	2	50,0	2	100,0	16,67	23,57
Cycle 15 Day 1	Yes	42	56,8	42	100,0	9,52	18,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 16 Day 1	Yes	39	52,7	37	94,9	10,81	17,66
	No	2	50,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	37	50,0	37	100,0	9,01	16,94
	No	2	50,0	2	100,0	16,67	23,57
Cycle 18 Day 1	Yes	36	48,6	33	91,7	9,09	15,08
	No	2	50,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	11,46	20,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	11,11	18,22
	No	2	50,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	36,5	24	88,9	8,33	17,72
	No	2	50,0	2	100,0	16,67	23,57
Cycle 22 Day 1	Yes	27	36,5	23	85,2	10,14	15,68
	No	2	50,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	11,76	16,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	11,76	16,42
	No	1	25,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	18,9	12	85,7	8,33	15,08
	No	1	25,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	9,09	15,57
	No	1	25,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	66,67	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	12,50	17,25
	No	1	25,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	16,67	18,26
	No	1	25,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	16,67	19,25
	No	1	25,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 32 Day 1	Yes	5	6,8	4	80,0	16,67	19,25
	No	1	25,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	15,48	19,21
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	16,67	30,86
	No	70	100,0	69	98,6	17,87	23,28
Cycle 2 Day 1	Yes	5	62,5	5	100,0	13,33	18,26
	No	67	95,7	60	89,6	12,22	17,32
Cycle 3 Day 1	Yes	5	62,5	4	80,0	0,00	0,00
	No	63	90,0	59	93,7	9,04	17,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	62	88,6	56	90,3	11,90	20,53
Cycle 5 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	60	85,7	58	96,7	11,49	20,28
Cycle 6 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	58	82,9	52	89,7	11,54	19,68
Cycle 7 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	55	78,6	51	92,7	8,50	14,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	51	72,9	47	92,2	11,35	20,00
Cycle 9 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	47	67,1	47	100,0	10,64	17,18
Cycle 10 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	47	67,1	46	97,9	10,87	17,29
Cycle 11 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	46	65,7	46	100,0	10,87	19,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	45	64,3	41	91,1	13,01	18,07
Cycle 13 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	42	60,0	41	97,6	12,20	20,76
Cycle 14 Day 1	Yes	4	50,0	4	100,0	16,67	33,33
	No	41	58,6	40	97,6	11,67	20,74
Cycle 15 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	40	57,1	40	100,0	10,00	18,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	38	54,3	36	94,7	11,11	17,82
Cycle 17 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	36	51,4	36	100,0	10,19	17,49
Cycle 18 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	35	50,0	32	91,4	10,42	15,70
Cycle 19 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	33	47,1	30	90,9	11,11	20,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	33	47,1	29	87,9	11,49	18,42
Cycle 21 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	24	88,9	9,72	18,33
Cycle 22 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	23	85,2	10,14	15,68
Cycle 23 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	19	27,1	16	84,2	12,50	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	18	25,7	16	88,9	12,50	16,67
Cycle 25 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	13	18,6	11	84,6	9,09	15,57
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	12,12	16,82
Cycle 27 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	10	14,3	7	70,0	19,05	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	9	12,9	8	88,9	16,67	17,82
Cycle 29 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	8	11,4	6	75,0	16,67	18,26
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	20,00	18,26
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	13,33	18,26
Cycle 33 Day 1	No	2	2,9	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	16,67	23,57
	No	37	52,9	26	70,3	15,38	19,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PA_SG.xls
28NOV2019 10:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	77	98,7	18,18	22,00
Cycle 2 Day 1	All	72	92,3	65	90,3	10,26	16,59
Cycle 3 Day 1	All	68	87,2	63	92,6	7,41	13,97
Cycle 4 Day 1	All	67	85,9	61	91,0	8,20	17,90
Cycle 5 Day 1	All	65	83,3	63	96,9	7,94	14,31
Cycle 6 Day 1	All	63	80,8	57	90,5	6,43	14,69
Cycle 7 Day 1	All	60	76,9	56	93,3	10,71	20,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	56	71,8	52	92,9	8,33	14,57
Cycle 9 Day 1	All	51	65,4	51	100,0	5,88	14,46
Cycle 10 Day 1	All	51	65,4	50	98,0	6,00	14,58
Cycle 11 Day 1	All	50	64,1	50	100,0	8,00	14,38
Cycle 12 Day 1	All	49	62,8	45	91,8	5,93	12,89
Cycle 13 Day 1	All	46	59,0	45	97,8	7,41	15,71
Cycle 14 Day 1	All	45	57,7	44	97,8	6,06	14,86
Cycle 15 Day 1	All	44	56,4	44	100,0	6,06	13,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	41	52,6	39	95,1	11,11	19,25
Cycle 17 Day 1	All	39	50,0	39	100,0	6,84	13,64
Cycle 18 Day 1	All	38	48,7	35	92,1	6,67	13,53
Cycle 19 Day 1	All	36	46,2	33	91,7	5,05	14,72
Cycle 20 Day 1	All	36	46,2	32	88,9	11,46	21,77
Cycle 21 Day 1	All	29	37,2	26	89,7	6,41	13,40
Cycle 22 Day 1	All	29	37,2	25	86,2	5,33	12,47
Cycle 23 Day 1	All	21	26,9	18	85,7	3,70	10,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	25,6	18	90,0	7,41	18,28
Cycle 25 Day 1	All	15	19,2	13	86,7	5,13	12,52
Cycle 26 Day 1	All	14	17,9	12	85,7	5,56	12,97
Cycle 27 Day 1	All	11	14,1	8	72,7	12,50	17,25
Cycle 28 Day 1	All	10	12,8	9	90,0	14,81	24,22
Cycle 29 Day 1	All	9	11,5	7	77,8	4,76	12,60
Cycle 30 Day 1	All	7	9,0	5	71,4	13,33	18,26
Cycle 31 Day 1	All	7	9,0	5	71,4	26,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	7,7	5	83,3	13,33	18,26
Cycle 33 Day 1	All	2	2,6	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	15,48	16,93
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	21,84	24,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	49	100,0	48	98,0	15,97	20,62
Cycle 2 Day 1	Male	27	93,1	25	92,6	10,67	18,56
	Female	45	91,8	40	88,9	10,00	15,47
Cycle 3 Day 1	Male	25	86,2	24	96,0	8,33	14,74
	Female	43	87,8	39	90,7	6,84	13,64
Cycle 4 Day 1	Male	25	86,2	23	92,0	13,04	24,08
	Female	42	85,7	38	90,5	5,26	12,32
Cycle 5 Day 1	Male	25	86,2	24	96,0	8,33	14,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	40	81,6	39	97,5	7,69	14,23
Cycle 6 Day 1	Male	25	86,2	23	92,0	7,25	14,06
	Female	38	77,6	34	89,5	5,88	15,29
Cycle 7 Day 1	Male	23	79,3	23	100,0	10,14	21,17
	Female	37	75,5	33	89,2	11,11	19,84
Cycle 8 Day 1	Male	21	72,4	19	90,5	8,77	15,08
	Female	35	71,4	33	94,3	8,08	14,51
Cycle 9 Day 1	Male	18	62,1	18	100,0	5,56	12,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	6,06	15,49
Cycle 10 Day 1	Male	18	62,1	18	100,0	3,70	10,78
	Female	33	67,3	32	97,0	7,29	16,36
Cycle 11 Day 1	Male	18	62,1	18	100,0	5,56	12,78
	Female	32	65,3	32	100,0	9,38	15,23
Cycle 12 Day 1	Male	17	58,6	17	100,0	1,96	8,08
	Female	32	65,3	28	87,5	8,33	14,70
Cycle 13 Day 1	Male	17	58,6	17	100,0	5,88	13,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	29	59,2	28	96,6	8,33	17,27
Cycle 14 Day 1	Male	17	58,6	16	94,1	2,08	8,33
	Female	28	57,1	28	100,0	8,33	17,27
Cycle 15 Day 1	Male	16	55,2	16	100,0	2,08	8,33
	Female	28	57,1	28	100,0	8,33	14,70
Cycle 16 Day 1	Male	14	48,3	14	100,0	2,38	8,91
	Female	27	55,1	25	92,6	16,00	21,77
Cycle 17 Day 1	Male	12	41,4	12	100,0	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	27	100,0	7,41	14,12
Cycle 18 Day 1	Male	11	37,9	10	90,9	3,33	10,54
	Female	27	55,1	25	92,6	8,00	14,53
Cycle 19 Day 1	Male	10	34,5	10	100,0	3,33	10,54
	Female	26	53,1	23	88,5	5,80	16,37
Cycle 20 Day 1	Male	10	34,5	9	90,0	0,00	0,00
	Female	26	53,1	23	88,5	15,94	24,35
Cycle 21 Day 1	Male	8	27,6	8	100,0	8,33	15,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	42,9	18	85,7	5,56	12,78
Cycle 22 Day 1	Male	8	27,6	6	75,0	0,00	0,00
	Female	21	42,9	19	90,5	7,02	13,96
Cycle 23 Day 1	Male	5	17,2	4	80,0	0,00	0,00
	Female	16	32,7	14	87,5	4,76	12,10
Cycle 24 Day 1	Male	5	17,2	4	80,0	0,00	0,00
	Female	15	30,6	14	93,3	9,52	20,37
Cycle 25 Day 1	Male	3	10,3	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	24,5	11	91,7	6,06	13,48
Cycle 26 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	11	22,4	10	90,9	6,67	14,05
Cycle 27 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	8	16,3	6	75,0	16,67	18,26
Cycle 28 Day 1	Male	2	6,9	2	100,0	0,00	0,00
	Female	8	16,3	7	87,5	19,05	26,23
Cycle 29 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	16,3	6	75,0	5,56	13,61
Cycle 30 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	16,67	19,25
Cycle 31 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	33,33	27,22
Cycle 32 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	5	10,2	4	80,0	16,67	19,25
Cycle 33 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	2,0	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	15,56	17,21
	Female	21	42,9	13	61,9	15,38	17,30
Age							
Cycle 1 Day 1	18-64	62	100,0	61	98,4	18,03	22,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	21,43	21,11
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	18-64	59	95,2	52	88,1	10,26	16,88
	65-74	11	78,6	11	100,0	12,12	16,82
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 3 Day 1	18-64	56	90,3	52	92,9	8,33	14,57
	65-74	10	71,4	9	90,0	3,70	11,11
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	55	88,7	50	90,9	10,00	19,34
	65-74	10	71,4	9	90,0	0,00	0,00
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 5 Day 1	18-64	53	85,5	52	98,1	8,33	14,57
	65-74	10	71,4	10	100,0	6,67	14,05
	>=75	2	100,0	1	50,0	0,00	-
Cycle 6 Day 1	18-64	51	82,3	46	90,2	5,07	12,11
	65-74	10	71,4	9	90,0	14,81	24,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 7 Day 1	18-64	49	79,0	46	93,9	10,14	19,71
	65-74	9	64,3	8	88,9	16,67	25,20
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 8 Day 1	18-64	45	72,6	41	91,1	6,50	13,37
	65-74	9	64,3	9	100,0	18,52	17,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 9 Day 1	18-64	40	64,5	40	100,0	4,17	11,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	14,81	24,22
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 10 Day 1	18-64	40	64,5	39	97,5	5,13	12,18
	65-74	9	64,3	9	100,0	11,11	23,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 11 Day 1	18-64	39	62,9	39	100,0	7,69	14,23
	65-74	9	64,3	9	100,0	11,11	16,67
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	38	61,3	35	92,1	5,71	12,75
	65-74	9	64,3	8	88,9	8,33	15,43
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 13 Day 1	18-64	35	56,5	34	97,1	3,92	10,90
	65-74	9	64,3	9	100,0	22,22	23,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 14 Day 1	18-64	35	56,5	35	100,0	4,76	11,83
	65-74	9	64,3	8	88,9	12,50	24,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	5,71	12,75
	65-74	8	57,1	8	100,0	8,33	15,43
	>=75	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	11,46	20,05
	65-74	7	50,0	6	85,7	11,11	17,21
	>=75	1	50,0	1	100,0	0,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	6,25	13,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	6	42,9	6	100,0	11,11	17,21
	>=75	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	6,90	13,74
	65-74	6	42,9	5	83,3	6,67	14,91
	>=75	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	4,76	14,95
	65-74	5	35,7	4	80,0	8,33	16,67
	>=75	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	11,54	22,98
	65-74	5	35,7	5	100,0	13,33	18,26
	>=75	1	50,0	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	6,35	13,41
	65-74	4	28,6	4	100,0	8,33	16,67
	>=75	1	50,0	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	6,67	13,68
	65-74	4	28,6	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	4,17	11,39
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	8,33	19,25
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	22,6	12	85,7	5,56	12,97
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	12,50	17,25
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	14,81	24,22
	65-74	1	7,1	0	0,0	-	-
Cycle 29 Day 1	18-64	8	12,9	7	87,5	4,76	12,60
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	26,67	27,89
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	16,67	19,25
	65-74	1	7,1	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	0,00	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	18,33	17,01
	65-74	10	71,4	7	70,0	9,52	16,27
	>=75	2	100,0	1	50,0	0,00	-
Race							
Cycle 1 Day 1	White	35	100,0	34	97,1	12,75	18,38
	Other	43	100,0	43	100,0	22,48	23,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	33	94,3	28	84,8	9,52	17,82
	Other	39	90,7	37	94,9	10,81	15,82
Cycle 3 Day 1	White	31	88,6	27	87,1	2,47	8,90
	Other	37	86,0	36	97,3	11,11	15,94
Cycle 4 Day 1	White	31	88,6	26	83,9	2,56	9,06
	Other	36	83,7	35	97,2	12,38	21,52
Cycle 5 Day 1	White	31	88,6	29	93,5	5,75	12,81
	Other	34	79,1	34	100,0	9,80	15,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	30	85,7	25	83,3	4,00	14,66
	Other	33	76,7	32	97,0	8,33	14,66
Cycle 7 Day 1	White	29	82,9	26	89,7	7,69	19,57
	Other	31	72,1	30	96,8	13,33	20,72
Cycle 8 Day 1	White	28	80,0	24	85,7	6,94	13,83
	Other	28	65,1	28	100,0	9,52	15,33
Cycle 9 Day 1	White	26	74,3	26	100,0	6,41	16,38
	Other	25	58,1	25	100,0	5,33	12,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	9,33	18,05
	Other	25	58,1	25	100,0	2,67	9,23
Cycle 11 Day 1	White	26	74,3	26	100,0	7,69	14,32
	Other	24	55,8	24	100,0	8,33	14,74
Cycle 12 Day 1	White	26	74,3	22	84,6	6,06	13,16
	Other	23	53,5	23	100,0	5,80	12,92
Cycle 13 Day 1	White	24	68,6	23	95,8	4,35	15,26
	Other	22	51,2	22	100,0	10,61	15,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	24	68,6	24	100,0	5,56	16,05
	Other	21	48,8	20	95,2	6,67	13,68
Cycle 15 Day 1	White	24	68,6	24	100,0	6,94	13,83
	Other	20	46,5	20	100,0	5,00	12,21
Cycle 16 Day 1	White	22	62,9	20	90,9	8,33	18,34
	Other	19	44,2	19	100,0	14,04	20,23
Cycle 17 Day 1	White	22	62,9	22	100,0	4,55	11,71
	Other	17	39,5	17	100,0	9,80	15,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	21	60,0	18	85,7	1,85	7,86
	Other	17	39,5	17	100,0	11,76	16,42
Cycle 19 Day 1	White	20	57,1	20	100,0	5,00	12,21
	Other	16	37,2	13	81,3	5,13	18,49
Cycle 20 Day 1	White	20	57,1	17	85,0	3,92	11,07
	Other	16	37,2	15	93,8	20,00	27,60
Cycle 21 Day 1	White	16	45,7	14	87,5	2,38	8,91
	Other	13	30,2	12	92,3	11,11	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	45,7	13	81,3	5,13	12,52
	Other	13	30,2	12	92,3	5,56	12,97
Cycle 23 Day 1	White	12	34,3	10	83,3	3,33	10,54
	Other	9	20,9	8	88,9	4,17	11,79
Cycle 24 Day 1	White	11	31,4	10	90,9	6,67	14,05
	Other	9	20,9	8	88,9	8,33	23,57
Cycle 25 Day 1	White	10	28,6	8	80,0	4,17	11,79
	Other	5	11,6	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	28,6	8	80,0	4,17	11,79
	Other	4	9,3	4	100,0	8,33	16,67
Cycle 27 Day 1	White	8	22,9	5	62,5	6,67	14,91
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 28 Day 1	White	7	20,0	6	85,7	11,11	27,22
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 29 Day 1	White	6	17,1	4	66,7	0,00	0,00
	Other	3	7,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	11,4	2	50,0	0,00	0,00
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 31 Day 1	White	4	11,4	2	50,0	16,67	23,57
	Other	3	7,0	3	100,0	33,33	33,33
Cycle 32 Day 1	White	4	11,4	3	75,0	11,11	19,25
	Other	2	4,7	2	100,0	16,67	23,57
Cycle 33 Day 1	White	2	5,7	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-
End Of Treatment	White	15	42,9	12	80,0	19,44	17,16
	Other	24	55,8	16	66,7	12,50	16,67
Region							
Cycle 1 Day 1	America (AM)	22	100,0	21	95,5	14,29	19,92
	Europe (EU)	17	100,0	17	100,0	13,73	16,91
	Asia (AS)	39	100,0	39	100,0	22,22	24,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	9,80	15,66
	Europe (EU)	16	94,1	13	81,3	15,38	22,01
	Asia (AS)	36	92,3	35	97,2	8,57	14,78
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	3,51	10,51
	Europe (EU)	15	88,2	11	73,3	3,03	10,05
	Asia (AS)	33	84,6	33	100,0	11,11	15,96
Cycle 4 Day 1	America (AM)	20	90,9	19	95,0	3,51	10,51
	Europe (EU)	15	88,2	11	73,3	6,06	13,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	32	82,1	31	96,9	11,83	22,02
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	3,33	10,26
	Europe (EU)	15	88,2	13	86,7	7,69	14,62
	Asia (AS)	30	76,9	30	100,0	11,11	15,98
Cycle 6 Day 1	America (AM)	20	90,9	18	90,0	0,00	0,00
	Europe (EU)	14	82,4	12	85,7	8,33	20,72
	Asia (AS)	29	74,4	27	93,1	9,88	15,51
Cycle 7 Day 1	America (AM)	19	86,4	17	89,5	5,88	17,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	14	82,4	13	92,9	10,26	21,01
	Asia (AS)	27	69,2	26	96,3	14,10	21,44
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	1,96	8,08
	Europe (EU)	14	82,4	11	78,6	12,12	16,82
	Asia (AS)	24	61,5	24	100,0	11,11	16,05
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	3,70	10,78
	Europe (EU)	12	70,6	12	100,0	8,33	20,72
	Asia (AS)	21	53,8	21	100,0	6,35	13,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	0,00	0,00
	Europe (EU)	12	70,6	12	100,0	19,44	22,29
	Asia (AS)	21	53,8	21	100,0	3,17	10,03
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	1,85	7,86
	Europe (EU)	12	70,6	12	100,0	11,11	16,41
	Asia (AS)	20	51,3	20	100,0	11,67	16,31
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	1,96	8,08
	Europe (EU)	12	70,6	9	75,0	11,11	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	19	48,7	19	100,0	7,02	13,96
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	5,88	13,10
	Europe (EU)	11	64,7	10	90,9	6,67	21,08
	Asia (AS)	18	46,2	18	100,0	9,26	15,36
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	1,96	8,08
	Europe (EU)	11	64,7	11	100,0	9,09	21,56
	Asia (AS)	17	43,6	16	94,1	8,33	14,91
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	5,88	13,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	64,7	11	100,0	6,06	13,48
	Asia (AS)	16	41,0	16	100,0	6,25	13,44
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	7,14	19,30
	Europe (EU)	11	64,7	9	81,8	11,11	16,67
	Asia (AS)	16	41,0	16	100,0	14,58	20,97
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	0,00	0,00
	Europe (EU)	10	58,8	10	100,0	10,00	16,10
	Asia (AS)	15	38,5	15	100,0	11,11	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	2,38	8,91
	Europe (EU)	9	52,9	6	66,7	5,56	13,61
	Asia (AS)	15	38,5	15	100,0	11,11	16,27
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	0,00	0,00
	Europe (EU)	9	52,9	9	100,0	11,11	16,67
	Asia (AS)	14	35,9	11	78,6	6,06	20,10
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	12,82	28,99
	Europe (EU)	9	52,9	6	66,7	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	12,82	16,88
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	0,00	0,00
	Europe (EU)	7	41,2	6	85,7	5,56	13,61
	Asia (AS)	11	28,2	10	90,9	13,33	17,21
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	3,33	10,54
	Europe (EU)	7	41,2	5	71,4	0,00	0,00
	Asia (AS)	11	28,2	10	90,9	10,00	16,10
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	29,4	3	60,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	5,56	13,61
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	8,33	15,43
	Europe (EU)	5	29,4	4	80,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	11,11	27,22
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	4,76	12,60
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	5,56	13,61
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	8,33	16,67
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	8,33	16,67
	Europe (EU)	3	17,6	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	16,67	19,25
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	16,67	33,33
	Europe (EU)	2	11,8	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	16,67	19,25
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	0,00	0,00
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	8,33	16,67
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	22,22	19,25
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	33,33	33,33
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57
	Europe (EU)	1	5,9	1	100,0	0,00	-
	Asia (AS)	3	7,7	2	66,7	16,67	23,57
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	0,00	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	9,09	15,57
	Europe (EU)	6	35,3	4	66,7	33,33	0,00
	Asia (AS)	21	53,8	13	61,9	15,38	17,30
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	29	96,7	11,49	18,42
	1	38	100,0	38	100,0	22,81	23,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	10	100,0	10	100,0	20,00	23,31
Cycle 2 Day 1	0	30	100,0	27	90,0	11,11	16,01
	1	36	94,7	32	88,9	9,38	17,42
	2	6	60,0	6	100,0	11,11	17,21
Cycle 3 Day 1	0	29	96,7	27	93,1	6,17	13,19
	1	34	89,5	31	91,2	7,53	14,17
	2	5	50,0	5	100,0	13,33	18,26
Cycle 4 Day 1	0	29	96,7	25	86,2	2,67	9,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	12,50	22,00
	2	5	50,0	4	80,0	8,33	16,67
Cycle 5 Day 1	0	29	96,7	29	100,0	6,90	13,74
	1	33	86,8	31	93,9	9,68	15,38
	2	3	30,0	3	100,0	0,00	0,00
Cycle 6 Day 1	0	29	96,7	28	96,6	8,33	17,27
	1	31	81,6	27	87,1	4,94	12,07
	2	3	30,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	29	96,7	28	96,6	14,29	23,00
	1	28	73,7	25	89,3	8,00	17,43
	2	3	30,0	3	100,0	0,00	0,00
Cycle 8 Day 1	0	28	93,3	26	92,9	10,26	15,69
	1	25	65,8	23	92,0	5,80	12,92
	2	3	30,0	3	100,0	11,11	19,25
Cycle 9 Day 1	0	26	86,7	26	100,0	6,41	16,38
	1	23	60,5	23	100,0	5,80	12,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	2	20,0	2	100,0	0,00	0,00
Cycle 10 Day 1	0	26	86,7	26	100,0	6,41	16,38
	1	23	60,5	22	95,7	4,55	11,71
	2	2	20,0	2	100,0	16,67	23,57
Cycle 11 Day 1	0	26	86,7	26	100,0	7,69	14,32
	1	22	57,9	22	100,0	9,09	15,19
	2	2	20,0	2	100,0	0,00	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	6,06	13,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	21	95,5	6,35	13,41
	2	2	20,0	2	100,0	0,00	0,00
Cycle 13 Day 1	0	25	83,3	24	96,0	11,11	18,82
	1	20	52,6	20	100,0	3,33	10,26
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	6,94	16,97
	1	19	50,0	19	100,0	5,26	12,49
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	24	80,0	24	100,0	6,94	13,83
	1	19	50,0	19	100,0	5,26	12,49
	2	1	10,0	1	100,0	0,00	-
Cycle 16 Day 1	0	22	73,3	20	90,9	8,33	14,81
	1	18	47,4	18	100,0	14,81	23,49
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	7,94	14,55
	1	17	44,7	17	100,0	5,88	13,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	5,56	12,78
	1	16	42,1	16	100,0	8,33	14,91
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	5,26	12,49
	1	15	39,5	13	86,7	5,13	18,49
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	7,84	14,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	39,5	14	93,3	16,67	28,50
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	7,14	14,19
	1	13	34,2	11	84,6	6,06	13,48
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	5,56	12,97
	1	13	34,2	12	92,3	5,56	12,97
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	3,70	11,11
	1	9	23,7	8	88,9	4,17	11,79
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	3,70	11,11
	1	9	23,7	8	88,9	12,50	24,80
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	0,00	0,00
	1	7	18,4	7	100,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	26,7	6	75,0	5,56	13,61
	1	6	15,8	6	100,0	5,56	13,61
Cycle 27 Day 1	0	6	20,0	3	50,0	0,00	0,00
	1	5	13,2	5	100,0	20,00	18,26
Cycle 28 Day 1	0	5	16,7	4	80,0	0,00	0,00
	1	5	13,2	5	100,0	26,67	27,89
Cycle 29 Day 1	0	4	13,3	2	50,0	0,00	0,00
	1	5	13,2	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	16,67	19,25
Cycle 31 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	33,33	27,22
Cycle 32 Day 1	0	3	10,0	2	66,7	0,00	0,00
	1	3	7,9	3	100,0	22,22	19,25
Cycle 33 Day 1	0	2	6,7	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	11,90	16,57
	1	20	52,6	12	60,0	19,44	17,16
	2	4	40,0	2	50,0	16,67	23,57
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	13,98	20,68
	1	3	100,0	3	100,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	44	100,0	43	97,7	20,93	23,03
Cycle 2 Day 1	None	30	96,8	27	90,0	8,64	14,89
	1	2	66,7	1	50,0	0,00	-
	2 or More	40	90,9	37	92,5	11,71	17,94
Cycle 3 Day 1	None	30	96,8	28	93,3	7,14	13,93
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	34	94,4	7,84	14,35
Cycle 4 Day 1	None	30	96,8	28	93,3	8,33	21,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	35	79,5	31	88,6	8,60	14,83
Cycle 5 Day 1	None	30	96,8	30	100,0	6,67	13,56
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	33	75,0	31	93,9	9,68	15,38
Cycle 6 Day 1	None	29	93,5	26	89,7	2,56	9,06
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	32	72,7	29	90,6	10,34	18,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	27	87,1	25	92,6	2,67	9,23
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	31	70,5	29	93,5	18,39	24,54
Cycle 8 Day 1	None	26	83,9	25	96,2	4,00	11,06
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	12,35	16,40
Cycle 9 Day 1	None	25	80,6	25	100,0	2,67	9,23
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	9,33	18,05
Cycle 10 Day 1	None	25	80,6	24	96,0	2,78	9,41
	1	1	33,3	1	100,0	0,00	-
	2 or More	25	56,8	25	100,0	9,33	18,05
Cycle 11 Day 1	None	25	80,6	25	100,0	2,67	9,23
	1	1	33,3	1	100,0	0,00	-
	2 or More	24	54,5	24	100,0	13,89	16,79
Cycle 12 Day 1	None	25	80,6	24	96,0	1,39	6,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	23	52,3	20	87,0	11,67	16,31
Cycle 13 Day 1	None	24	77,4	23	95,8	5,80	12,92
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	9,52	18,69
Cycle 14 Day 1	None	23	74,2	23	100,0	2,90	9,60
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	20	95,2	10,00	19,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	23	74,2	23	100,0	5,80	12,92
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	20	100,0	6,67	13,68
Cycle 16 Day 1	None	20	64,5	19	95,0	10,53	19,41
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	19	95,0	12,28	19,91
Cycle 17 Day 1	None	19	61,3	19	100,0	1,75	7,65
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	19	43,2	19	100,0	12,28	16,52
Cycle 18 Day 1	None	18	58,1	17	94,4	1,96	8,08
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	17	89,5	11,76	16,42
Cycle 19 Day 1	None	17	54,8	17	100,0	0,00	0,00
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	11,11	20,57
Cycle 20 Day 1	None	17	54,8	16	94,1	12,50	26,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	11,11	16,27
Cycle 21 Day 1	None	15	48,4	13	86,7	2,56	9,25
	2 or More	14	31,8	13	92,9	10,26	16,01
Cycle 22 Day 1	None	15	48,4	13	86,7	7,69	14,62
	2 or More	14	31,8	12	85,7	2,78	9,62
Cycle 23 Day 1	None	10	32,3	9	90,0	0,00	0,00
	2 or More	11	25,0	9	81,8	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	32,3	10	100,0	3,33	10,54
	2 or More	10	22,7	8	80,0	12,50	24,80
Cycle 25 Day 1	None	9	29,0	8	88,9	4,17	11,79
	2 or More	6	13,6	5	83,3	6,67	14,91
Cycle 26 Day 1	None	8	25,8	8	100,0	0,00	0,00
	2 or More	6	13,6	4	66,7	16,67	19,25
Cycle 27 Day 1	None	7	22,6	6	85,7	5,56	13,61
	2 or More	4	9,1	2	50,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	22,6	7	100,0	9,52	25,20
	2 or More	3	6,8	2	66,7	33,33	0,00
Cycle 29 Day 1	None	6	19,4	5	83,3	0,00	0,00
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 30 Day 1	None	4	12,9	3	75,0	11,11	19,25
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 31 Day 1	None	4	12,9	3	75,0	11,11	19,25
	2 or More	3	6,8	2	66,7	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	11,11	19,25
	2 or More	2	4,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	3,2	1	100,0	0,00	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	13,89	17,16
	1	2	66,7	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	54,5	15	62,5	17,78	17,21
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	13,98	20,68
	Previously Treated	47	100,0	46	97,9	21,01	22,62
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	8,64	14,89
	Previously Treated	42	89,4	38	90,5	11,40	17,80
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	7,14	13,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	38	80,9	35	92,1	7,62	14,20
Cycle 4 Day 1	Naïve	30	96,8	28	93,3	8,33	21,52
	Previously Treated	37	78,7	33	89,2	8,08	14,51
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	6,67	13,56
	Previously Treated	35	74,5	33	94,3	9,09	15,08
Cycle 6 Day 1	Naïve	29	93,5	26	89,7	2,56	9,06
	Previously Treated	34	72,3	31	91,2	9,68	17,62
Cycle 7 Day 1	Naïve	27	87,1	25	92,6	2,67	9,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	33	70,2	31	93,9	17,20	24,15
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	4,00	11,06
	Previously Treated	30	63,8	27	90,0	12,35	16,40
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	2,67	9,23
	Previously Treated	26	55,3	26	100,0	8,97	17,78
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	2,78	9,41
	Previously Treated	26	55,3	26	100,0	8,97	17,78
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	2,67	9,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	53,2	25	100,0	13,33	16,67
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	1,39	6,80
	Previously Treated	24	51,1	21	87,5	11,11	16,10
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	5,80	12,92
	Previously Treated	22	46,8	22	100,0	9,09	18,35
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	2,90	9,60
	Previously Treated	22	46,8	21	95,5	9,52	18,69
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	5,80	12,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	21	100,0	6,35	13,41
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	10,53	19,41
	Previously Treated	21	44,7	20	95,2	11,67	19,57
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	1,75	7,65
	Previously Treated	20	42,6	20	100,0	11,67	16,31
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	1,96	8,08
	Previously Treated	20	42,6	18	90,0	11,11	16,17
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	40,4	16	84,2	10,42	20,07
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	12,50	26,87
	Previously Treated	19	40,4	16	84,2	10,42	15,96
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	2,56	9,25
	Previously Treated	14	29,8	13	92,9	10,26	16,01
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	7,69	14,62
	Previously Treated	14	29,8	12	85,7	2,78	9,62
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	7,41	14,70
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	3,33	10,54
	Previously Treated	10	21,3	8	80,0	12,50	24,80
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	4,17	11,79
	Previously Treated	6	12,8	5	83,3	6,67	14,91
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	0,00	0,00
	Previously Treated	6	12,8	4	66,7	16,67	19,25
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	8,5	2	50,0	33,33	0,00
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	9,52	25,20
	Previously Treated	3	6,4	2	66,7	33,33	0,00
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	0,00	0,00
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	11,11	19,25
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	50,00	23,57
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	11,11	19,25
	Previously Treated	2	4,3	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	0,00	-
	Previously Treated	1	2,1	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	13,89	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	16	61,5	16,67	17,21
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	18,10	18,69
	Central	43	100,0	42	97,7	18,25	24,64
Cycle 2 Day 1	Local	32	91,4	30	93,8	8,89	14,99
	Central	40	93,0	35	87,5	11,43	17,97
Cycle 3 Day 1	Local	29	82,9	27	93,1	4,94	12,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	39	90,7	36	92,3	9,26	15,14
Cycle 4 Day 1	Local	28	80,0	24	85,7	5,56	12,69
	Central	39	90,7	37	94,9	9,91	20,59
Cycle 5 Day 1	Local	27	77,1	27	100,0	8,64	14,89
	Central	38	88,4	36	94,7	7,41	14,05
Cycle 6 Day 1	Local	27	77,1	27	100,0	4,94	15,20
	Central	36	83,7	30	83,3	7,78	14,34
Cycle 7 Day 1	Local	27	77,1	27	100,0	11,11	20,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	33	76,7	29	87,9	10,34	20,13
Cycle 8 Day 1	Local	26	74,3	26	100,0	7,69	14,32
	Central	30	69,8	26	86,7	8,97	15,08
Cycle 9 Day 1	Local	25	71,4	25	100,0	6,67	16,67
	Central	26	60,5	26	100,0	5,13	12,26
Cycle 10 Day 1	Local	25	71,4	24	96,0	5,56	16,05
	Central	26	60,5	26	100,0	6,41	13,40
Cycle 11 Day 1	Local	24	68,6	24	100,0	6,94	13,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	26	60,5	26	100,0	8,97	15,08
Cycle 12 Day 1	Local	23	65,7	22	95,7	7,58	14,30
	Central	26	60,5	23	88,5	4,35	11,48
Cycle 13 Day 1	Local	22	62,9	22	100,0	7,58	17,61
	Central	24	55,8	23	95,8	7,25	14,06
Cycle 14 Day 1	Local	22	62,9	22	100,0	7,58	17,61
	Central	23	53,5	22	95,7	4,55	11,71
Cycle 15 Day 1	Local	22	62,9	22	100,0	9,09	15,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	3,03	9,81
Cycle 16 Day 1	Local	20	57,1	20	100,0	13,33	19,94
	Central	21	48,8	19	90,5	8,77	18,73
Cycle 17 Day 1	Local	20	57,1	20	100,0	8,33	14,81
	Central	19	44,2	19	100,0	5,26	12,49
Cycle 18 Day 1	Local	20	57,1	19	95,0	8,77	15,08
	Central	18	41,9	16	88,9	4,17	11,39
Cycle 19 Day 1	Local	19	54,3	17	89,5	3,92	11,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	39,5	16	94,1	6,25	18,13
Cycle 20 Day 1	Local	19	54,3	17	89,5	13,73	26,51
	Central	17	39,5	15	88,2	8,89	15,26
Cycle 21 Day 1	Local	14	40,0	12	85,7	2,78	9,62
	Central	15	34,9	14	93,3	9,52	15,63
Cycle 22 Day 1	Local	14	40,0	12	85,7	2,78	9,62
	Central	15	34,9	13	86,7	7,69	14,62
Cycle 23 Day 1	Local	11	31,4	10	90,9	3,33	10,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	23,3	8	80,0	4,17	11,79
Cycle 24 Day 1	Local	11	31,4	10	90,9	6,67	14,05
	Central	9	20,9	8	88,9	8,33	23,57
Cycle 25 Day 1	Local	7	20,0	7	100,0	4,76	12,60
	Central	8	18,6	6	75,0	5,56	13,61
Cycle 26 Day 1	Local	6	17,1	6	100,0	5,56	13,61
	Central	8	18,6	6	75,0	5,56	13,61
Cycle 27 Day 1	Local	4	11,4	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	16,3	4	57,1	16,67	19,25
Cycle 28 Day 1	Local	4	11,4	4	100,0	16,67	33,33
	Central	6	14,0	5	83,3	13,33	18,26
Cycle 29 Day 1	Local	3	8,6	3	100,0	0,00	0,00
	Central	6	14,0	4	66,7	8,33	16,67
Cycle 30 Day 1	Local	3	8,6	3	100,0	11,11	19,25
	Central	4	9,3	2	50,0	16,67	23,57
Cycle 31 Day 1	Local	3	8,6	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	9,3	2	50,0	50,00	23,57
Cycle 32 Day 1	Local	3	8,6	3	100,0	11,11	19,25
	Central	3	7,0	2	66,7	16,67	23,57
Cycle 33 Day 1	Local	1	2,9	1	100,0	0,00	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	11,90	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	21	48,8	14	66,7	19,05	17,12
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	73	98,6	18,72	22,21
	No	4	100,0	4	100,0	8,33	16,67
Cycle 2 Day 1	Yes	70	94,6	63	90,0	10,58	16,75
	No	2	50,0	2	100,0	0,00	0,00
Cycle 3 Day 1	Yes	66	89,2	61	92,4	7,65	14,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 4 Day 1	Yes	65	87,8	59	90,8	8,47	18,15
	No	2	50,0	2	100,0	0,00	0,00
Cycle 5 Day 1	Yes	63	85,1	61	96,8	7,10	13,76
	No	2	50,0	2	100,0	33,33	0,00
Cycle 6 Day 1	Yes	61	82,4	55	90,2	6,06	14,47
	No	2	50,0	2	100,0	16,67	23,57
Cycle 7 Day 1	Yes	58	78,4	54	93,1	10,49	20,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 8 Day 1	Yes	54	73,0	50	92,6	8,00	14,38
	No	2	50,0	2	100,0	16,67	23,57
Cycle 9 Day 1	Yes	49	66,2	49	100,0	5,44	14,19
	No	2	50,0	2	100,0	16,67	23,57
Cycle 10 Day 1	Yes	49	66,2	48	98,0	5,56	14,31
	No	2	50,0	2	100,0	16,67	23,57
Cycle 11 Day 1	Yes	48	64,9	48	100,0	7,64	14,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 12 Day 1	Yes	47	63,5	43	91,5	5,43	12,45
	No	2	50,0	2	100,0	16,67	23,57
Cycle 13 Day 1	Yes	44	59,5	43	97,7	6,98	15,53
	No	2	50,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	43	58,1	42	97,7	5,56	14,57
	No	2	50,0	2	100,0	16,67	23,57
Cycle 15 Day 1	Yes	42	56,8	42	100,0	5,56	12,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 16 Day 1	Yes	39	52,7	37	94,9	9,91	19,03
	No	2	50,0	2	100,0	33,33	0,00
Cycle 17 Day 1	Yes	37	50,0	37	100,0	6,31	13,24
	No	2	50,0	2	100,0	16,67	23,57
Cycle 18 Day 1	Yes	36	48,6	33	91,7	6,06	13,06
	No	2	50,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	5,21	14,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	11,11	22,03
	No	2	50,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	36,5	24	88,9	5,56	12,69
	No	2	50,0	2	100,0	16,67	23,57
Cycle 22 Day 1	Yes	27	36,5	23	85,2	5,80	12,92
	No	2	50,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	3,92	11,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	7,84	18,74
	No	1	25,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	18,9	12	85,7	5,56	12,97
	No	1	25,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	6,06	13,48
	No	1	25,0	1	100,0	0,00	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	16,67	25,20
	No	1	25,0	1	100,0	0,00	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	5,56	13,61
	No	1	25,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	8,33	16,67
	No	1	25,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 32 Day 1	Yes	5	6,8	4	80,0	16,67	19,25
	No	1	25,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	15,48	16,93
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	8,33	15,43
	No	70	100,0	69	98,6	19,32	22,44
Cycle 2 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	67	95,7	60	89,6	11,11	16,99
Cycle 3 Day 1	Yes	5	62,5	4	80,0	0,00	0,00
	No	63	90,0	59	93,7	7,91	14,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	62	88,6	56	90,3	8,93	18,52
Cycle 5 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	60	85,7	58	96,7	8,05	14,39
Cycle 6 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	58	82,9	52	89,7	7,05	15,25
Cycle 7 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	55	78,6	51	92,7	11,76	20,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	51	72,9	47	92,2	9,22	15,07
Cycle 9 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	47	67,1	47	100,0	6,38	14,97
Cycle 10 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	47	67,1	46	97,9	6,52	15,10
Cycle 11 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	46	65,7	46	100,0	8,70	14,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	45	64,3	41	91,1	6,50	13,37
Cycle 13 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	42	60,0	41	97,6	7,32	15,83
Cycle 14 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	41	58,6	40	97,6	6,67	15,47
Cycle 15 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	40	57,1	40	100,0	5,00	12,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	38	54,3	36	94,7	12,04	19,76
Cycle 17 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	36	51,4	36	100,0	7,41	14,05
Cycle 18 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	35	50,0	32	91,4	7,29	14,00
Cycle 19 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	30	90,9	5,56	15,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	37,5	3	100,0	33,33	57,74
	No	33	47,1	29	87,9	9,20	15,16
Cycle 21 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	24	88,9	6,94	13,83
Cycle 22 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	27	38,6	23	85,2	4,35	11,48
Cycle 23 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	19	27,1	16	84,2	4,17	11,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	18	25,7	16	88,9	8,33	19,25
Cycle 25 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	13	18,6	11	84,6	6,06	13,48
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	6,06	13,48
Cycle 27 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	10	14,3	7	70,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	9	12,9	8	88,9	16,67	25,20
Cycle 29 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	8	11,4	6	75,0	5,56	13,61
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	13,33	18,26
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	26,67	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	13,33	18,26
Cycle 33 Day 1	No	2	2,9	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	16,67	23,57
	No	37	52,9	26	70,3	15,38	16,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PC_SG.xls
29NOV2019 14:32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	77	98,7	16,88	26,83
Cycle 2 Day 1	All	72	92,3	65	90,3	23,08	26,30
Cycle 3 Day 1	All	68	87,2	63	92,6	19,05	24,48
Cycle 4 Day 1	All	67	85,9	61	91,0	21,31	27,24
Cycle 5 Day 1	All	65	83,3	63	96,9	20,11	25,78
Cycle 6 Day 1	All	63	80,8	57	90,5	21,05	26,45
Cycle 7 Day 1	All	60	76,9	56	93,3	20,24	24,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	56	71,8	52	92,9	22,44	26,99
Cycle 9 Day 1	All	51	65,4	51	100,0	20,92	22,07
Cycle 10 Day 1	All	51	65,4	50	98,0	20,00	22,34
Cycle 11 Day 1	All	50	64,1	50	100,0	17,33	19,33
Cycle 12 Day 1	All	49	62,8	45	91,8	19,26	21,89
Cycle 13 Day 1	All	46	59,0	45	97,8	20,00	19,33
Cycle 14 Day 1	All	45	57,7	44	97,8	18,94	20,83
Cycle 15 Day 1	All	44	56,4	44	100,0	19,70	23,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	41	52,6	39	95,1	18,80	19,93
Cycle 17 Day 1	All	39	50,0	39	100,0	17,09	21,46
Cycle 18 Day 1	All	38	48,7	35	92,1	12,38	16,34
Cycle 19 Day 1	All	36	46,2	33	91,7	14,14	16,73
Cycle 20 Day 1	All	36	46,2	32	88,9	16,67	20,74
Cycle 21 Day 1	All	29	37,2	26	89,7	17,95	23,53
Cycle 22 Day 1	All	29	37,2	25	86,2	16,00	17,00
Cycle 23 Day 1	All	21	26,9	18	85,7	12,96	16,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	25,6	18	90,0	14,81	23,49
Cycle 25 Day 1	All	15	19,2	13	86,7	10,26	16,01
Cycle 26 Day 1	All	14	17,9	12	85,7	13,89	22,29
Cycle 27 Day 1	All	11	14,1	8	72,7	25,00	23,57
Cycle 28 Day 1	All	10	12,8	9	90,0	18,52	24,22
Cycle 29 Day 1	All	9	11,5	7	77,8	33,33	27,22
Cycle 30 Day 1	All	7	9,0	5	71,4	26,67	14,91
Cycle 31 Day 1	All	7	9,0	5	71,4	26,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	7,7	5	83,3	20,00	18,26
Cycle 33 Day 1	All	2	2,6	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	25,00	23,35
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	17,24	30,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	49	100,0	48	98,0	16,67	24,79
Cycle 2 Day 1	Male	27	93,1	25	92,6	26,67	28,87
	Female	45	91,8	40	88,9	20,83	24,68
Cycle 3 Day 1	Male	25	86,2	24	96,0	20,83	27,47
	Female	43	87,8	39	90,7	17,95	22,74
Cycle 4 Day 1	Male	25	86,2	23	92,0	27,54	31,22
	Female	42	85,7	38	90,5	17,54	24,18
Cycle 5 Day 1	Male	25	86,2	24	96,0	19,44	21,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	40	81,6	39	97,5	20,51	28,22
Cycle 6 Day 1	Male	25	86,2	23	92,0	23,19	25,49
	Female	38	77,6	34	89,5	19,61	27,36
Cycle 7 Day 1	Male	23	79,3	23	100,0	23,19	27,40
	Female	37	75,5	33	89,2	18,18	22,19
Cycle 8 Day 1	Male	21	72,4	19	90,5	22,81	29,51
	Female	35	71,4	33	94,3	22,22	25,91
Cycle 9 Day 1	Male	18	62,1	18	100,0	22,22	19,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	20,20	23,48
Cycle 10 Day 1	Male	18	62,1	18	100,0	20,37	23,26
	Female	33	67,3	32	97,0	19,79	22,17
Cycle 11 Day 1	Male	18	62,1	18	100,0	27,78	20,61
	Female	32	65,3	32	100,0	11,46	16,09
Cycle 12 Day 1	Male	17	58,6	17	100,0	21,57	23,40
	Female	32	65,3	28	87,5	17,86	21,24
Cycle 13 Day 1	Male	17	58,6	17	100,0	21,57	16,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	29	59,2	28	96,6	19,05	21,14
Cycle 14 Day 1	Male	17	58,6	16	94,1	18,75	17,08
	Female	28	57,1	28	100,0	19,05	23,00
Cycle 15 Day 1	Male	16	55,2	16	100,0	16,67	21,08
	Female	28	57,1	28	100,0	21,43	24,37
Cycle 16 Day 1	Male	14	48,3	14	100,0	16,67	17,30
	Female	27	55,1	25	92,6	20,00	21,52
Cycle 17 Day 1	Male	12	41,4	12	100,0	19,44	22,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	27	100,0	16,05	21,42
Cycle 18 Day 1	Male	11	37,9	10	90,9	16,67	17,57
	Female	27	55,1	25	92,6	10,67	15,87
Cycle 19 Day 1	Male	10	34,5	10	100,0	16,67	17,57
	Female	26	53,1	23	88,5	13,04	16,63
Cycle 20 Day 1	Male	10	34,5	9	90,0	14,81	17,57
	Female	26	53,1	23	88,5	17,39	22,18
Cycle 21 Day 1	Male	8	27,6	8	100,0	16,67	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	42,9	18	85,7	18,52	26,13
Cycle 22 Day 1	Male	8	27,6	6	75,0	16,67	18,26
	Female	21	42,9	19	90,5	15,79	17,10
Cycle 23 Day 1	Male	5	17,2	4	80,0	16,67	19,25
	Female	16	32,7	14	87,5	11,90	16,57
Cycle 24 Day 1	Male	5	17,2	4	80,0	16,67	19,25
	Female	15	30,6	14	93,3	14,29	25,20
Cycle 25 Day 1	Male	3	10,3	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	24,5	11	91,7	12,12	16,82
Cycle 26 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	11	22,4	10	90,9	16,67	23,57
Cycle 27 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	8	16,3	6	75,0	33,33	21,08
Cycle 28 Day 1	Male	2	6,9	2	100,0	0,00	0,00
	Female	8	16,3	7	87,5	23,81	25,20
Cycle 29 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	16,3	6	75,0	38,89	25,09
Cycle 30 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	33,33	0,00
Cycle 31 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	33,33	0,00
Cycle 32 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	5	10,2	4	80,0	25,00	16,67
Cycle 33 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	2,0	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	31,11	23,46
	Female	21	42,9	13	61,9	17,95	22,01
Age							
Cycle 1 Day 1	18-64	62	100,0	61	98,4	16,94	27,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	19,05	25,20
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	18-64	59	95,2	52	88,1	26,28	27,48
	65-74	11	78,6	11	100,0	12,12	16,82
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 3 Day 1	18-64	56	90,3	52	92,9	19,23	25,00
	65-74	10	71,4	9	90,0	18,52	24,22
	>=75	2	100,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	55	88,7	50	90,9	20,67	27,68
	65-74	10	71,4	9	90,0	25,93	27,78
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 5 Day 1	18-64	53	85,5	52	98,1	19,23	24,11
	65-74	10	71,4	10	100,0	26,67	34,43
	>=75	2	100,0	1	50,0	0,00	-
Cycle 6 Day 1	18-64	51	82,3	46	90,2	20,29	24,82
	65-74	10	71,4	9	90,0	29,63	35,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 7 Day 1	18-64	49	79,0	46	93,9	20,29	24,82
	65-74	9	64,3	8	88,9	25,00	23,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 8 Day 1	18-64	45	72,6	41	91,1	21,95	25,40
	65-74	9	64,3	9	100,0	29,63	35,14
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 9 Day 1	18-64	40	64,5	40	100,0	20,83	19,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	25,93	32,39
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 10 Day 1	18-64	40	64,5	39	97,5	18,80	19,93
	65-74	9	64,3	9	100,0	29,63	30,93
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 11 Day 1	18-64	39	62,9	39	100,0	17,95	20,01
	65-74	9	64,3	9	100,0	14,81	17,57
	>=75	2	100,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	38	61,3	35	92,1	19,05	21,82
	65-74	9	64,3	8	88,9	25,00	23,57
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 13 Day 1	18-64	35	56,5	34	97,1	19,61	16,65
	65-74	9	64,3	9	100,0	25,93	27,78
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 14 Day 1	18-64	35	56,5	35	100,0	18,10	18,69
	65-74	9	64,3	8	88,9	25,00	29,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	20,95	21,52
	65-74	8	57,1	8	100,0	16,67	30,86
	>=75	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	18,75	18,81
	65-74	7	50,0	6	85,7	22,22	27,22
	>=75	1	50,0	1	100,0	0,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	17,71	20,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	6	42,9	6	100,0	16,67	27,89
	>=75	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	12,64	16,46
	65-74	6	42,9	5	83,3	13,33	18,26
	>=75	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	13,10	16,58
	65-74	5	35,7	4	80,0	25,00	16,67
	>=75	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	15,38	19,39
	65-74	5	35,7	5	100,0	26,67	27,89
	>=75	1	50,0	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	15,87	17,06
	65-74	4	28,6	4	100,0	33,33	47,14
	>=75	1	50,0	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	16,67	17,10
	65-74	4	28,6	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	12,50	16,67
	65-74	2	14,3	2	100,0	16,67	23,57
Cycle 24 Day 1	18-64	18	29,0	16	88,9	14,58	24,25
	65-74	2	14,3	2	100,0	16,67	23,57
Cycle 25 Day 1	18-64	14	22,6	12	85,7	11,11	16,41
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	13,89	22,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	25,00	23,57
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	18,52	24,22
	65-74	1	7,1	0	0,0	-	-
Cycle 29 Day 1	18-64	8	12,9	7	87,5	33,33	27,22
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	26,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	26,67	14,91
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	25,00	16,67
	65-74	1	7,1	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	0,00	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	21,67	24,84
	65-74	10	71,4	7	70,0	33,33	19,25
	>=75	2	100,0	1	50,0	33,33	-
Race							
Cycle 1 Day 1	White	35	100,0	34	97,1	13,73	27,36
	Other	43	100,0	43	100,0	19,38	26,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	33	94,3	28	84,8	22,62	27,30
	Other	39	90,7	37	94,9	23,42	25,90
Cycle 3 Day 1	White	31	88,6	27	87,1	14,81	21,35
	Other	37	86,0	36	97,3	22,22	26,43
Cycle 4 Day 1	White	31	88,6	26	83,9	16,67	23,57
	Other	36	83,7	35	97,2	24,76	29,53
Cycle 5 Day 1	White	31	88,6	29	93,5	19,54	22,74
	Other	34	79,1	34	100,0	20,59	28,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	30	85,7	25	83,3	24,00	29,69
	Other	33	76,7	32	97,0	18,75	23,85
Cycle 7 Day 1	White	29	82,9	26	89,7	20,51	26,79
	Other	31	72,1	30	96,8	20,00	22,49
Cycle 8 Day 1	White	28	80,0	24	85,7	16,67	24,08
	Other	28	65,1	28	100,0	27,38	28,77
Cycle 9 Day 1	White	26	74,3	26	100,0	19,23	25,25
	Other	25	58,1	25	100,0	22,67	18,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	16,00	21,77
	Other	25	58,1	25	100,0	24,00	22,61
Cycle 11 Day 1	White	26	74,3	26	100,0	16,67	19,44
	Other	24	55,8	24	100,0	18,06	19,61
Cycle 12 Day 1	White	26	74,3	22	84,6	18,18	22,37
	Other	23	53,5	23	100,0	20,29	21,88
Cycle 13 Day 1	White	24	68,6	23	95,8	17,39	19,77
	Other	22	51,2	22	100,0	22,73	18,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	24	68,6	24	100,0	16,67	19,66
	Other	21	48,8	20	95,2	21,67	22,36
Cycle 15 Day 1	White	24	68,6	24	100,0	19,44	21,80
	Other	20	46,5	20	100,0	20,00	25,13
Cycle 16 Day 1	White	22	62,9	20	90,9	15,00	17,01
	Other	19	44,2	19	100,0	22,81	22,37
Cycle 17 Day 1	White	22	62,9	22	100,0	10,61	15,89
	Other	17	39,5	17	100,0	25,49	25,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	21	60,0	18	85,7	7,41	14,26
	Other	17	39,5	17	100,0	17,65	17,15
Cycle 19 Day 1	White	20	57,1	20	100,0	11,67	16,31
	Other	16	37,2	13	81,3	17,95	17,30
Cycle 20 Day 1	White	20	57,1	17	85,0	11,76	20,21
	Other	16	37,2	15	93,8	22,22	20,57
Cycle 21 Day 1	White	16	45,7	14	87,5	9,52	15,63
	Other	13	30,2	12	92,3	27,78	27,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	45,7	13	81,3	12,82	16,88
	Other	13	30,2	12	92,3	19,44	17,16
Cycle 23 Day 1	White	12	34,3	10	83,3	6,67	14,05
	Other	9	20,9	8	88,9	20,83	17,25
Cycle 24 Day 1	White	11	31,4	10	90,9	10,00	22,50
	Other	9	20,9	8	88,9	20,83	24,80
Cycle 25 Day 1	White	10	28,6	8	80,0	8,33	15,43
	Other	5	11,6	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	28,6	8	80,0	16,67	25,20
	Other	4	9,3	4	100,0	8,33	16,67
Cycle 27 Day 1	White	8	22,9	5	62,5	13,33	18,26
	Other	3	7,0	3	100,0	44,44	19,25
Cycle 28 Day 1	White	7	20,0	6	85,7	16,67	27,89
	Other	3	7,0	3	100,0	22,22	19,25
Cycle 29 Day 1	White	6	17,1	4	66,7	16,67	19,25
	Other	3	7,0	3	100,0	55,56	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	11,4	2	50,0	16,67	23,57
	Other	3	7,0	3	100,0	33,33	0,00
Cycle 31 Day 1	White	4	11,4	2	50,0	16,67	23,57
	Other	3	7,0	3	100,0	33,33	0,00
Cycle 32 Day 1	White	4	11,4	3	75,0	11,11	19,25
	Other	2	4,7	2	100,0	33,33	0,00
Cycle 33 Day 1	White	2	5,7	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-
End Of Treatment	White	15	42,9	12	80,0	19,44	22,29
	Other	24	55,8	16	66,7	29,17	23,96
Region							
Cycle 1 Day 1	America (AM)	22	100,0	21	95,5	23,81	31,87
	Europe (EU)	17	100,0	17	100,0	7,84	18,74
	Asia (AS)	39	100,0	39	100,0	17,09	26,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	21,57	20,21
	Europe (EU)	16	94,1	13	81,3	20,51	32,03
	Asia (AS)	36	92,3	35	97,2	24,76	27,23
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	19,30	25,62
	Europe (EU)	15	88,2	11	73,3	18,18	22,92
	Asia (AS)	33	84,6	33	100,0	19,19	25,04
Cycle 4 Day 1	America (AM)	20	90,9	19	95,0	17,54	28,04
	Europe (EU)	15	88,2	11	73,3	24,24	30,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	32	82,1	31	96,9	22,58	26,37
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	25,00	30,35
	Europe (EU)	15	88,2	13	86,7	28,21	29,96
	Asia (AS)	30	76,9	30	100,0	13,33	18,77
Cycle 6 Day 1	America (AM)	20	90,9	18	90,0	27,78	26,20
	Europe (EU)	14	82,4	12	85,7	25,00	35,18
	Asia (AS)	29	74,4	27	93,1	14,81	21,35
Cycle 7 Day 1	America (AM)	19	86,4	17	89,5	17,65	20,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	14	82,4	13	92,9	28,21	32,90
	Asia (AS)	27	69,2	26	96,3	17,95	21,56
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	17,65	33,58
	Europe (EU)	14	82,4	11	78,6	30,30	31,46
	Asia (AS)	24	61,5	24	100,0	22,22	18,82
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	16,67	17,15
	Europe (EU)	12	70,6	12	100,0	30,56	33,21
	Asia (AS)	21	53,8	21	100,0	19,05	16,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	13,73	20,61
	Europe (EU)	12	70,6	12	100,0	27,78	27,83
	Asia (AS)	21	53,8	21	100,0	20,63	19,65
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	12,96	16,72
	Europe (EU)	12	70,6	12	100,0	27,78	23,92
	Asia (AS)	20	51,3	20	100,0	15,00	17,01
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	11,76	16,42
	Europe (EU)	12	70,6	9	75,0	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	19	48,7	19	100,0	19,30	23,08
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	15,69	17,15
	Europe (EU)	11	64,7	10	90,9	23,33	22,50
	Asia (AS)	18	46,2	18	100,0	22,22	19,80
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	11,76	16,42
	Europe (EU)	11	64,7	11	100,0	24,24	21,56
	Asia (AS)	17	43,6	16	94,1	22,92	23,47
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	9,80	15,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	64,7	11	100,0	27,27	25,03
	Asia (AS)	16	41,0	16	100,0	25,00	25,82
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	11,90	16,57
	Europe (EU)	11	64,7	9	81,8	25,93	14,70
	Asia (AS)	16	41,0	16	100,0	20,83	23,96
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	9,52	15,63
	Europe (EU)	10	58,8	10	100,0	13,33	17,21
	Asia (AS)	15	38,5	15	100,0	26,67	25,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	11,90	16,57
	Europe (EU)	9	52,9	6	66,7	5,56	13,61
	Asia (AS)	15	38,5	15	100,0	15,56	17,21
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	5,13	12,52
	Europe (EU)	9	52,9	9	100,0	22,22	16,67
	Asia (AS)	14	35,9	11	78,6	18,18	17,41
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	12,82	21,68
	Europe (EU)	9	52,9	6	66,7	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	23,08	21,01
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	6,67	14,05
	Europe (EU)	7	41,2	6	85,7	11,11	17,21
	Asia (AS)	11	28,2	10	90,9	33,33	27,22
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	13,33	17,21
	Europe (EU)	7	41,2	5	71,4	6,67	14,91
	Asia (AS)	11	28,2	10	90,9	23,33	16,10
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	11,11	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	29,4	3	60,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	22,22	17,21
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	8,33	15,43
	Europe (EU)	5	29,4	4	80,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	33,33	29,81
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	4,76	12,60
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	16,67	27,89
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	16,67	19,25
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	8,33	16,67
	Europe (EU)	3	17,6	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	41,67	16,67
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	8,33	16,67
	Europe (EU)	2	11,8	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	33,33	27,22
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	11,11	19,25
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	50,00	19,25
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	33,33	0,00
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	33,33	0,00
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57
	Europe (EU)	1	5,9	1	100,0	0,00	-
	Asia (AS)	3	7,7	2	66,7	33,33	0,00
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	0,00	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	18,18	17,41
	Europe (EU)	6	35,3	4	66,7	41,67	31,91
	Asia (AS)	21	53,8	13	61,9	25,64	24,17
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	29	96,7	14,94	26,10
	1	38	100,0	38	100,0	19,30	29,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	10	100,0	10	100,0	13,33	17,21
Cycle 2 Day 1	0	30	100,0	27	90,0	24,69	23,74
	1	36	94,7	32	88,9	23,96	29,61
	2	6	60,0	6	100,0	11,11	17,21
Cycle 3 Day 1	0	29	96,7	27	93,1	17,28	23,33
	1	34	89,5	31	91,2	20,43	26,77
	2	5	50,0	5	100,0	20,00	18,26
Cycle 4 Day 1	0	29	96,7	25	86,2	22,67	26,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	18,75	25,31
	2	5	50,0	4	80,0	33,33	47,14
Cycle 5 Day 1	0	29	96,7	29	100,0	19,54	26,00
	1	33	86,8	31	93,9	20,43	25,35
	2	3	30,0	3	100,0	22,22	38,49
Cycle 6 Day 1	0	29	96,7	28	96,6	21,43	26,00
	1	31	81,6	27	87,1	22,22	27,74
	2	3	30,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	29	96,7	28	96,6	19,05	24,73
	1	28	73,7	25	89,3	22,67	24,94
	2	3	30,0	3	100,0	11,11	19,25
Cycle 8 Day 1	0	28	93,3	26	92,9	23,08	30,94
	1	25	65,8	23	92,0	21,74	21,58
	2	3	30,0	3	100,0	22,22	38,49
Cycle 9 Day 1	0	26	86,7	26	100,0	19,23	23,42
	1	23	60,5	23	100,0	21,74	19,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	2	20,0	2	100,0	33,33	47,14
Cycle 10 Day 1	0	26	86,7	26	100,0	21,79	24,84
	1	23	60,5	22	95,7	18,18	19,86
	2	2	20,0	2	100,0	16,67	23,57
Cycle 11 Day 1	0	26	86,7	26	100,0	19,23	19,26
	1	22	57,9	22	100,0	15,15	19,86
	2	2	20,0	2	100,0	16,67	23,57
Cycle 12 Day 1	0	25	83,3	22	88,0	19,70	19,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	21	95,5	17,46	22,65
	2	2	20,0	2	100,0	33,33	47,14
Cycle 13 Day 1	0	25	83,3	24	96,0	20,83	21,56
	1	20	52,6	20	100,0	20,00	16,75
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	18,06	21,93
	1	19	50,0	19	100,0	21,05	19,91
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	24	80,0	24	100,0	19,44	25,85
	1	19	50,0	19	100,0	21,05	19,91
	2	1	10,0	1	100,0	0,00	-
Cycle 16 Day 1	0	22	73,3	20	90,9	21,67	22,36
	1	18	47,4	18	100,0	16,67	17,15
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	15,87	20,05
	1	17	44,7	17	100,0	19,61	23,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	14,81	17,04
	1	16	42,1	16	100,0	10,42	15,96
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	15,79	17,10
	1	15	39,5	13	86,7	12,82	16,88
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	19,61	23,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	39,5	14	93,3	14,29	17,12
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	21,43	28,06
	1	13	34,2	11	84,6	15,15	17,41
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	13,89	17,16
	1	13	34,2	12	92,3	19,44	17,16
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	14,81	17,57
	1	9	23,7	8	88,9	12,50	17,25
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	11,11	23,57
	1	9	23,7	8	88,9	20,83	24,80
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	5,56	13,61
	1	7	18,4	7	100,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	26,7	6	75,0	16,67	27,89
	1	6	15,8	6	100,0	11,11	17,21
Cycle 27 Day 1	0	6	20,0	3	50,0	11,11	19,25
	1	5	13,2	5	100,0	33,33	23,57
Cycle 28 Day 1	0	5	16,7	4	80,0	16,67	33,33
	1	5	13,2	5	100,0	20,00	18,26
Cycle 29 Day 1	0	4	13,3	2	50,0	16,67	23,57
	1	5	13,2	5	100,0	40,00	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	33,33	0,00
Cycle 31 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	33,33	0,00
Cycle 32 Day 1	0	3	10,0	2	66,7	0,00	0,00
	1	3	7,9	3	100,0	33,33	0,00
Cycle 33 Day 1	0	2	6,7	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	21,43	21,11
	1	20	52,6	12	60,0	30,56	26,43
	2	4	40,0	2	50,0	16,67	23,57
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	15,05	28,33
	1	3	100,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	44	100,0	43	97,7	18,60	26,53
Cycle 2 Day 1	None	30	96,8	27	90,0	17,28	23,33
	1	2	66,7	1	50,0	33,33	-
	2 or More	40	90,9	37	92,5	27,03	28,15
Cycle 3 Day 1	None	30	96,8	28	93,3	14,29	21,14
	1	2	66,7	1	50,0	33,33	-
	2 or More	36	81,8	34	94,4	22,55	26,87
Cycle 4 Day 1	None	30	96,8	28	93,3	21,43	27,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	35	79,5	31	88,6	21,51	27,95
Cycle 5 Day 1	None	30	96,8	30	100,0	23,33	30,51
	1	2	66,7	2	100,0	33,33	0,00
	2 or More	33	75,0	31	93,9	16,13	20,85
Cycle 6 Day 1	None	29	93,5	26	89,7	24,36	30,63
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	32	72,7	29	90,6	18,39	22,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	27	87,1	25	92,6	20,00	23,57
	1	2	66,7	2	100,0	33,33	0,00
	2 or More	31	70,5	29	93,5	19,54	26,00
Cycle 8 Day 1	None	26	83,9	25	96,2	25,33	29,31
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	19,75	24,91
Cycle 9 Day 1	None	25	80,6	25	100,0	20,00	21,52
	1	1	33,3	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	21,33	23,33
Cycle 10 Day 1	None	25	80,6	24	96,0	18,06	21,93
	1	1	33,3	1	100,0	33,33	-
	2 or More	25	56,8	25	100,0	21,33	23,33
Cycle 11 Day 1	None	25	80,6	25	100,0	17,33	19,53
	1	1	33,3	1	100,0	33,33	-
	2 or More	24	54,5	24	100,0	16,67	19,66
Cycle 12 Day 1	None	25	80,6	24	96,0	19,44	23,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	23	52,3	20	87,0	20,00	19,94
Cycle 13 Day 1	None	24	77,4	23	95,8	18,84	16,90
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	22,22	21,94
Cycle 14 Day 1	None	23	74,2	23	100,0	17,39	19,77
	1	1	33,3	1	100,0	33,33	-
	2 or More	21	47,7	20	95,2	20,00	22,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	23	74,2	23	100,0	15,94	22,18
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	20	100,0	25,00	23,88
Cycle 16 Day 1	None	20	64,5	19	95,0	17,54	20,39
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	19	95,0	21,05	19,91
Cycle 17 Day 1	None	19	61,3	19	100,0	17,54	23,22
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	19	43,2	19	100,0	17,54	20,39
Cycle 18 Day 1	None	18	58,1	17	94,4	11,76	16,42
	1	1	33,3	1	100,0	33,33	-
	2 or More	19	43,2	17	89,5	11,76	16,42
Cycle 19 Day 1	None	17	54,8	17	100,0	11,76	16,42
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	17,78	17,21
Cycle 20 Day 1	None	17	54,8	16	94,1	12,50	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	22,22	24,12
Cycle 21 Day 1	None	15	48,4	13	86,7	15,38	17,30
	2 or More	14	31,8	13	92,9	20,51	28,99
Cycle 22 Day 1	None	15	48,4	13	86,7	12,82	16,88
	2 or More	14	31,8	12	85,7	19,44	17,16
Cycle 23 Day 1	None	10	32,3	9	90,0	11,11	16,67
	2 or More	11	25,0	9	81,8	14,81	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	32,3	10	100,0	13,33	23,31
	2 or More	10	22,7	8	80,0	16,67	25,20
Cycle 25 Day 1	None	9	29,0	8	88,9	8,33	15,43
	2 or More	6	13,6	5	83,3	13,33	18,26
Cycle 26 Day 1	None	8	25,8	8	100,0	12,50	17,25
	2 or More	6	13,6	4	66,7	16,67	33,33
Cycle 27 Day 1	None	7	22,6	6	85,7	22,22	27,22
	2 or More	4	9,1	2	50,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	22,6	7	100,0	19,05	26,23
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	19,4	5	83,3	26,67	27,89
	2 or More	3	6,8	2	66,7	50,00	23,57
Cycle 30 Day 1	None	4	12,9	3	75,0	22,22	19,25
	2 or More	3	6,8	2	66,7	33,33	0,00
Cycle 31 Day 1	None	4	12,9	3	75,0	22,22	19,25
	2 or More	3	6,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	22,22	19,25
	2 or More	2	4,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	3,2	1	100,0	0,00	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	33,33	20,10
	1	2	66,7	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	54,5	15	62,5	20,00	24,56
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	15,05	28,33
	Previously Treated	47	100,0	46	97,9	18,12	26,02
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	17,28	23,33
	Previously Treated	42	89,4	38	90,5	27,19	27,79
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	14,29	21,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	38	80,9	35	92,1	22,86	26,53
Cycle 4 Day 1	Naïve	30	96,8	28	93,3	21,43	27,54
	Previously Treated	37	78,7	33	89,2	21,21	27,41
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	23,33	30,51
	Previously Treated	35	74,5	33	94,3	17,17	20,62
Cycle 6 Day 1	Naïve	29	93,5	26	89,7	24,36	30,63
	Previously Treated	34	72,3	31	91,2	18,28	22,51
Cycle 7 Day 1	Naïve	27	87,1	25	92,6	20,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	33	70,2	31	93,9	20,43	25,35
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	25,33	29,31
	Previously Treated	30	63,8	27	90,0	19,75	24,91
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	20,00	21,52
	Previously Treated	26	55,3	26	100,0	21,79	22,98
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	18,06	21,93
	Previously Treated	26	55,3	26	100,0	21,79	22,98
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	17,33	19,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	53,2	25	100,0	17,33	19,53
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	19,44	23,91
	Previously Treated	24	51,1	21	87,5	19,05	19,92
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	18,84	16,90
	Previously Treated	22	46,8	22	100,0	21,21	21,93
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	17,39	19,77
	Previously Treated	22	46,8	21	95,5	20,63	22,30
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	15,94	22,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	21	100,0	23,81	23,90
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	17,54	20,39
	Previously Treated	21	44,7	20	95,2	20,00	19,94
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	17,54	23,22
	Previously Treated	20	42,6	20	100,0	16,67	20,23
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	11,76	16,42
	Previously Treated	20	42,6	18	90,0	12,96	16,72
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	11,76	16,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	40,4	16	84,2	16,67	17,21
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	12,50	16,67
	Previously Treated	19	40,4	16	84,2	20,83	23,96
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	15,38	17,30
	Previously Treated	14	29,8	13	92,9	20,51	28,99
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	12,82	16,88
	Previously Treated	14	29,8	12	85,7	19,44	17,16
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	11,11	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	14,81	17,57
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	13,33	23,31
	Previously Treated	10	21,3	8	80,0	16,67	25,20
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	8,33	15,43
	Previously Treated	6	12,8	5	83,3	13,33	18,26
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	12,50	17,25
	Previously Treated	6	12,8	4	66,7	16,67	33,33
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	22,22	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	8,5	2	50,0	33,33	0,00
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	19,05	26,23
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	26,67	27,89
	Previously Treated	3	6,4	2	66,7	50,00	23,57
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	22,22	19,25
	Previously Treated	3	6,4	2	66,7	33,33	0,00
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	22,22	19,25
	Previously Treated	2	4,3	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	0,00	-
	Previously Treated	1	2,1	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	33,33	20,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	16	61,5	18,75	24,25
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	20,00	28,24
	Central	43	100,0	42	97,7	14,29	25,65
Cycle 2 Day 1	Local	32	91,4	30	93,8	26,67	25,37
	Central	40	93,0	35	87,5	20,00	27,06
Cycle 3 Day 1	Local	29	82,9	27	93,1	17,28	28,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	39	90,7	36	92,3	20,37	21,50
Cycle 4 Day 1	Local	28	80,0	24	85,7	18,06	29,45
	Central	39	90,7	37	94,9	23,42	25,90
Cycle 5 Day 1	Local	27	77,1	27	100,0	14,81	19,25
	Central	38	88,4	36	94,7	24,07	29,40
Cycle 6 Day 1	Local	27	77,1	27	100,0	19,75	23,13
	Central	36	83,7	30	83,3	22,22	29,47
Cycle 7 Day 1	Local	27	77,1	27	100,0	17,28	19,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	33	76,7	29	87,9	22,99	28,32
Cycle 8 Day 1	Local	26	74,3	26	100,0	17,95	25,35
	Central	30	69,8	26	86,7	26,92	28,31
Cycle 9 Day 1	Local	25	71,4	25	100,0	21,33	23,33
	Central	26	60,5	26	100,0	20,51	21,24
Cycle 10 Day 1	Local	25	71,4	24	96,0	13,89	19,45
	Central	26	60,5	26	100,0	25,64	23,68
Cycle 11 Day 1	Local	24	68,6	24	100,0	15,28	16,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	26	60,5	26	100,0	19,23	21,44
Cycle 12 Day 1	Local	23	65,7	22	95,7	10,61	15,89
	Central	26	60,5	23	88,5	27,54	23,89
Cycle 13 Day 1	Local	22	62,9	22	100,0	19,70	19,68
	Central	24	55,8	23	95,8	20,29	19,43
Cycle 14 Day 1	Local	22	62,9	22	100,0	18,18	22,37
	Central	23	53,5	22	95,7	19,70	19,68
Cycle 15 Day 1	Local	22	62,9	22	100,0	16,67	22,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	22,73	23,87
Cycle 16 Day 1	Local	20	57,1	20	100,0	15,00	17,01
	Central	21	48,8	19	90,5	22,81	22,37
Cycle 17 Day 1	Local	20	57,1	20	100,0	18,33	20,16
	Central	19	44,2	19	100,0	15,79	23,22
Cycle 18 Day 1	Local	20	57,1	19	95,0	14,04	16,91
	Central	18	41,9	16	88,9	10,42	15,96
Cycle 19 Day 1	Local	19	54,3	17	89,5	11,76	16,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	39,5	16	94,1	16,67	17,21
Cycle 20 Day 1	Local	19	54,3	17	89,5	15,69	20,81
	Central	17	39,5	15	88,2	17,78	21,33
Cycle 21 Day 1	Local	14	40,0	12	85,7	11,11	16,41
	Central	15	34,9	14	93,3	23,81	27,51
Cycle 22 Day 1	Local	14	40,0	12	85,7	13,89	17,16
	Central	15	34,9	13	86,7	17,95	17,30
Cycle 23 Day 1	Local	11	31,4	10	90,9	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	23,3	8	80,0	12,50	17,25
Cycle 24 Day 1	Local	11	31,4	10	90,9	10,00	16,10
	Central	9	20,9	8	88,9	20,83	30,54
Cycle 25 Day 1	Local	7	20,0	7	100,0	4,76	12,60
	Central	8	18,6	6	75,0	16,67	18,26
Cycle 26 Day 1	Local	6	17,1	6	100,0	22,22	27,22
	Central	8	18,6	6	75,0	5,56	13,61
Cycle 27 Day 1	Local	4	11,4	4	100,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	16,3	4	57,1	25,00	16,67
Cycle 28 Day 1	Local	4	11,4	4	100,0	16,67	19,25
	Central	6	14,0	5	83,3	20,00	29,81
Cycle 29 Day 1	Local	3	8,6	3	100,0	33,33	33,33
	Central	6	14,0	4	66,7	33,33	27,22
Cycle 30 Day 1	Local	3	8,6	3	100,0	22,22	19,25
	Central	4	9,3	2	50,0	33,33	0,00
Cycle 31 Day 1	Local	3	8,6	3	100,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	9,3	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	8,6	3	100,0	22,22	19,25
	Central	3	7,0	2	66,7	16,67	23,57
Cycle 33 Day 1	Local	1	2,9	1	100,0	0,00	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	21,43	21,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	21	48,8	14	66,7	28,57	25,68
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	73	98,6	15,98	26,71
	No	4	100,0	4	100,0	33,33	27,22
Cycle 2 Day 1	Yes	70	94,6	63	90,0	23,28	26,53
	No	2	50,0	2	100,0	16,67	23,57
Cycle 3 Day 1	Yes	66	89,2	61	92,4	19,13	24,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 4 Day 1	Yes	65	87,8	59	90,8	20,34	26,99
	No	2	50,0	2	100,0	50,00	23,57
Cycle 5 Day 1	Yes	63	85,1	61	96,8	19,13	25,43
	No	2	50,0	2	100,0	50,00	23,57
Cycle 6 Day 1	Yes	61	82,4	55	90,2	20,61	26,83
	No	2	50,0	2	100,0	33,33	0,00
Cycle 7 Day 1	Yes	58	78,4	54	93,1	19,14	23,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	50,00	23,57
Cycle 8 Day 1	Yes	54	73,0	50	92,6	22,00	27,45
	No	2	50,0	2	100,0	33,33	0,00
Cycle 9 Day 1	Yes	49	66,2	49	100,0	20,41	22,38
	No	2	50,0	2	100,0	33,33	0,00
Cycle 10 Day 1	Yes	49	66,2	48	98,0	18,75	21,64
	No	2	50,0	2	100,0	50,00	23,57
Cycle 11 Day 1	Yes	48	64,9	48	100,0	16,67	19,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	33,33	0,00
Cycle 12 Day 1	Yes	47	63,5	43	91,5	17,83	21,02
	No	2	50,0	2	100,0	50,00	23,57
Cycle 13 Day 1	Yes	44	59,5	43	97,7	18,60	18,26
	No	2	50,0	2	100,0	50,00	23,57
Cycle 14 Day 1	Yes	43	58,1	42	97,7	16,67	18,41
	No	2	50,0	2	100,0	66,67	0,00
Cycle 15 Day 1	Yes	42	56,8	42	100,0	17,46	21,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	66,67	0,00
Cycle 16 Day 1	Yes	39	52,7	37	94,9	18,02	18,58
	No	2	50,0	2	100,0	33,33	47,14
Cycle 17 Day 1	Yes	37	50,0	37	100,0	14,41	18,49
	No	2	50,0	2	100,0	66,67	0,00
Cycle 18 Day 1	Yes	36	48,6	33	91,7	12,12	16,28
	No	2	50,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	13,54	16,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	1	50,0	33,33	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	15,56	19,04
	No	2	50,0	2	100,0	33,33	47,14
Cycle 21 Day 1	Yes	27	36,5	24	88,9	13,89	16,79
	No	2	50,0	2	100,0	66,67	47,14
Cycle 22 Day 1	Yes	27	36,5	23	85,2	14,49	16,90
	No	2	50,0	2	100,0	33,33	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	13,73	16,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	15,69	23,91
	No	1	25,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	18,9	12	85,7	11,11	16,41
	No	1	25,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	12,12	22,47
	No	1	25,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	19,05	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	66,67	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	16,67	25,20
	No	1	25,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	27,78	25,09
	No	1	25,0	1	100,0	66,67	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	25,00	16,67
	No	1	25,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	33,33	-
Cycle 32 Day 1	Yes	5	6,8	4	80,0	16,67	19,25
	No	1	25,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	25,00	23,35
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	33,33	35,63
	No	70	100,0	69	98,6	14,98	25,27
Cycle 2 Day 1	Yes	5	62,5	5	100,0	20,00	29,81
	No	67	95,7	60	89,6	23,33	26,25
Cycle 3 Day 1	Yes	5	62,5	4	80,0	16,67	19,25
	No	63	90,0	59	93,7	19,21	24,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	5	62,5	5	100,0	33,33	23,57
	No	62	88,6	56	90,3	20,24	27,47
Cycle 5 Day 1	Yes	5	62,5	5	100,0	13,33	18,26
	No	60	85,7	58	96,7	20,69	26,36
Cycle 6 Day 1	Yes	5	62,5	5	100,0	13,33	18,26
	No	58	82,9	52	89,7	21,79	27,12
Cycle 7 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	55	78,6	51	92,7	21,57	24,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	5	62,5	5	100,0	13,33	18,26
	No	51	72,9	47	92,2	23,40	27,73
Cycle 9 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	47	67,1	47	100,0	21,28	22,44
Cycle 10 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	47	67,1	46	97,9	21,01	22,62
Cycle 11 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	46	65,7	46	100,0	18,12	19,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	45	64,3	41	91,1	19,51	22,33
Cycle 13 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	42	60,0	41	97,6	20,33	19,55
Cycle 14 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	41	58,6	40	97,6	19,17	21,20
Cycle 15 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	40	57,1	40	100,0	20,00	23,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	38	54,3	36	94,7	19,44	20,12
Cycle 17 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	36	51,4	36	100,0	17,59	21,80
Cycle 18 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	35	50,0	32	91,4	12,50	16,40
Cycle 19 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	33	47,1	30	90,9	14,44	16,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	33	47,1	29	87,9	17,24	21,12
Cycle 21 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	27	38,6	24	88,9	18,06	24,04
Cycle 22 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	27	38,6	23	85,2	15,94	17,03
Cycle 23 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	19	27,1	16	84,2	12,50	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	25,0	2	100,0	33,33	47,14
	No	18	25,7	16	88,9	12,50	20,64
Cycle 25 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	13	18,6	11	84,6	9,09	15,57
Cycle 26 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	13	18,6	11	84,6	12,12	22,47
Cycle 27 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	10	14,3	7	70,0	23,81	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	66,67	-
	No	9	12,9	8	88,9	12,50	17,25
Cycle 29 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	8	11,4	6	75,0	33,33	29,81
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	26,67	14,91
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	26,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	20,00	18,26
Cycle 33 Day 1	No	2	2,9	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	16,67	23,57
	No	37	52,9	26	70,3	25,64	23,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PN_SG.xls
28NOV2019 11:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	76	97,4	28,95	27,94
Cycle 2 Day 1	All	72	92,3	65	90,3	23,59	24,10
Cycle 3 Day 1	All	68	87,2	63	92,6	15,34	22,26
Cycle 4 Day 1	All	67	85,9	61	91,0	15,30	21,58
Cycle 5 Day 1	All	65	83,3	63	96,9	15,34	23,82
Cycle 6 Day 1	All	63	80,8	57	90,5	12,28	20,54
Cycle 7 Day 1	All	60	76,9	56	93,3	14,88	21,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	56	71,8	52	92,9	12,18	19,83
Cycle 9 Day 1	All	51	65,4	51	100,0	18,30	26,09
Cycle 10 Day 1	All	51	65,4	50	98,0	14,67	22,50
Cycle 11 Day 1	All	50	64,1	50	100,0	18,67	22,50
Cycle 12 Day 1	All	49	62,8	45	91,8	20,74	27,79
Cycle 13 Day 1	All	46	59,0	45	97,8	17,78	24,20
Cycle 14 Day 1	All	45	57,7	44	97,8	21,97	26,84
Cycle 15 Day 1	All	44	56,4	44	100,0	18,94	23,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	41	52,6	39	95,1	22,22	20,71
Cycle 17 Day 1	All	39	50,0	39	100,0	21,37	23,55
Cycle 18 Day 1	All	38	48,7	35	92,1	20,00	23,15
Cycle 19 Day 1	All	36	46,2	33	91,7	20,20	24,92
Cycle 20 Day 1	All	36	46,2	32	88,9	19,79	23,74
Cycle 21 Day 1	All	29	37,2	26	89,7	26,92	24,98
Cycle 22 Day 1	All	29	37,2	25	86,2	26,67	28,87
Cycle 23 Day 1	All	21	26,9	18	85,7	31,48	26,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	25,6	18	90,0	24,07	25,06
Cycle 25 Day 1	All	15	19,2	13	86,7	25,64	19,97
Cycle 26 Day 1	All	14	17,9	12	85,7	19,44	17,16
Cycle 27 Day 1	All	11	14,1	8	72,7	33,33	35,63
Cycle 28 Day 1	All	10	12,8	9	90,0	14,81	17,57
Cycle 29 Day 1	All	9	11,5	7	77,8	23,81	25,20
Cycle 30 Day 1	All	7	9,0	5	71,4	33,33	23,57
Cycle 31 Day 1	All	7	9,0	5	71,4	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	7,7	5	83,3	20,00	18,26
Cycle 33 Day 1	All	2	2,6	2	100,0	16,67	23,57
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	26,19	22,87
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	26,44	33,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	49	100,0	47	95,9	30,50	23,91
Cycle 2 Day 1	Male	27	93,1	25	92,6	26,67	25,46
	Female	45	91,8	40	88,9	21,67	23,33
Cycle 3 Day 1	Male	25	86,2	24	96,0	15,28	16,97
	Female	43	87,8	39	90,7	15,38	25,18
Cycle 4 Day 1	Male	25	86,2	23	92,0	17,39	17,03
	Female	42	85,7	38	90,5	14,04	24,05
Cycle 5 Day 1	Male	25	86,2	24	96,0	20,83	25,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	40	81,6	39	97,5	11,97	22,28
Cycle 6 Day 1	Male	25	86,2	23	92,0	10,14	15,68
	Female	38	77,6	34	89,5	13,73	23,38
Cycle 7 Day 1	Male	23	79,3	23	100,0	17,39	22,18
	Female	37	75,5	33	89,2	13,13	21,95
Cycle 8 Day 1	Male	21	72,4	19	90,5	14,04	16,91
	Female	35	71,4	33	94,3	11,11	21,52
Cycle 9 Day 1	Male	18	62,1	18	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	19,19	27,68
Cycle 10 Day 1	Male	18	62,1	18	100,0	16,67	20,61
	Female	33	67,3	32	97,0	13,54	23,74
Cycle 11 Day 1	Male	18	62,1	18	100,0	16,67	20,61
	Female	32	65,3	32	100,0	19,79	23,74
Cycle 12 Day 1	Male	17	58,6	17	100,0	19,61	26,51
	Female	32	65,3	28	87,5	21,43	28,99
Cycle 13 Day 1	Male	17	58,6	17	100,0	13,73	16,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	29	59,2	28	96,6	20,24	27,72
Cycle 14 Day 1	Male	17	58,6	16	94,1	22,92	26,44
	Female	28	57,1	28	100,0	21,43	27,54
Cycle 15 Day 1	Male	16	55,2	16	100,0	14,58	17,08
	Female	28	57,1	28	100,0	21,43	26,00
Cycle 16 Day 1	Male	14	48,3	14	100,0	28,57	25,68
	Female	27	55,1	25	92,6	18,67	16,89
Cycle 17 Day 1	Male	12	41,4	12	100,0	27,78	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	27	100,0	18,52	25,04
Cycle 18 Day 1	Male	11	37,9	10	90,9	23,33	22,50
	Female	27	55,1	25	92,6	18,67	23,73
Cycle 19 Day 1	Male	10	34,5	10	100,0	23,33	22,50
	Female	26	53,1	23	88,5	18,84	26,26
Cycle 20 Day 1	Male	10	34,5	9	90,0	22,22	23,57
	Female	26	53,1	23	88,5	18,84	24,26
Cycle 21 Day 1	Male	8	27,6	8	100,0	25,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	42,9	18	85,7	27,78	26,20
Cycle 22 Day 1	Male	8	27,6	6	75,0	22,22	27,22
	Female	21	42,9	19	90,5	28,07	29,94
Cycle 23 Day 1	Male	5	17,2	4	80,0	33,33	0,00
	Female	16	32,7	14	87,5	30,95	30,56
Cycle 24 Day 1	Male	5	17,2	4	80,0	25,00	16,67
	Female	15	30,6	14	93,3	23,81	27,51
Cycle 25 Day 1	Male	3	10,3	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	24,5	11	91,7	27,27	20,10
Cycle 26 Day 1	Male	3	10,3	2	66,7	16,67	23,57
	Female	11	22,4	10	90,9	20,00	17,21
Cycle 27 Day 1	Male	3	10,3	2	66,7	16,67	23,57
	Female	8	16,3	6	75,0	38,89	38,97
Cycle 28 Day 1	Male	2	6,9	2	100,0	16,67	23,57
	Female	8	16,3	7	87,5	14,29	17,82
Cycle 29 Day 1	Male	1	3,4	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	16,3	6	75,0	22,22	27,22
Cycle 30 Day 1	Male	1	3,4	1	100,0	33,33	-
	Female	6	12,2	4	66,7	33,33	27,22
Cycle 31 Day 1	Male	1	3,4	1	100,0	33,33	-
	Female	6	12,2	4	66,7	33,33	0,00
Cycle 32 Day 1	Male	1	3,4	1	100,0	33,33	-
	Female	5	10,2	4	80,0	16,67	19,25
Cycle 33 Day 1	Male	1	3,4	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	2,0	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	22,22	24,12
	Female	21	42,9	13	61,9	30,77	21,35
Age							
Cycle 1 Day 1	18-64	62	100,0	61	98,4	31,15	27,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	13	92,9	23,08	28,50
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	18-64	59	95,2	52	88,1	26,28	24,99
	65-74	11	78,6	11	100,0	15,15	17,41
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 3 Day 1	18-64	56	90,3	52	92,9	16,03	23,33
	65-74	10	71,4	9	90,0	11,11	16,67
	>=75	2	100,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	55	88,7	50	90,9	17,33	22,58
	65-74	10	71,4	9	90,0	3,70	11,11
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 5 Day 1	18-64	53	85,5	52	98,1	14,74	24,18
	65-74	10	71,4	10	100,0	16,67	23,57
	>=75	2	100,0	1	50,0	33,33	-
Cycle 6 Day 1	18-64	51	82,3	46	90,2	12,32	21,50
	65-74	10	71,4	9	90,0	11,11	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 7 Day 1	18-64	49	79,0	46	93,9	15,22	21,89
	65-74	9	64,3	8	88,9	8,33	15,43
	>=75	2	100,0	2	100,0	33,33	47,14
Cycle 8 Day 1	18-64	45	72,6	41	91,1	13,01	20,92
	65-74	9	64,3	9	100,0	11,11	16,67
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 9 Day 1	18-64	40	64,5	40	100,0	15,83	23,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	25,93	32,39
	>=75	2	100,0	2	100,0	33,33	47,14
Cycle 10 Day 1	18-64	40	64,5	39	97,5	14,53	19,93
	65-74	9	64,3	9	100,0	14,81	33,79
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 11 Day 1	18-64	39	62,9	39	100,0	18,80	19,93
	65-74	9	64,3	9	100,0	22,22	33,33
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	38	61,3	35	92,1	19,05	25,93
	65-74	9	64,3	8	88,9	25,00	34,50
	>=75	2	100,0	2	100,0	33,33	47,14
Cycle 13 Day 1	18-64	35	56,5	34	97,1	17,65	22,07
	65-74	9	64,3	9	100,0	18,52	33,79
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 14 Day 1	18-64	35	56,5	35	100,0	20,95	24,37
	65-74	9	64,3	8	88,9	20,83	35,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	66,67	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	19,05	23,27
	65-74	8	57,1	8	100,0	16,67	25,20
	>=75	1	50,0	1	100,0	33,33	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	20,83	20,30
	65-74	7	50,0	6	85,7	22,22	17,21
	>=75	1	50,0	1	100,0	66,67	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	20,83	22,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	6	42,9	6	100,0	16,67	27,89
	>=75	1	50,0	1	100,0	66,67	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	19,54	22,74
	65-74	6	42,9	5	83,3	13,33	18,26
	>=75	1	50,0	1	100,0	66,67	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	20,24	24,58
	65-74	5	35,7	4	80,0	8,33	16,67
	>=75	1	50,0	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	20,51	25,08
	65-74	5	35,7	5	100,0	13,33	18,26
	>=75	1	50,0	1	100,0	33,33	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	26,98	24,99
	65-74	4	28,6	4	100,0	16,67	19,25
	>=75	1	50,0	1	100,0	66,67	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	25,00	28,36
	65-74	4	28,6	4	100,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	66,67	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	33,33	27,22
	65-74	2	14,3	2	100,0	16,67	23,57
Cycle 24 Day 1	18-64	18	29,0	16	88,9	27,08	25,00
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	22,6	12	85,7	27,78	19,25
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	19,44	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	33,33	35,63
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	14,81	17,57
	65-74	1	7,1	0	0,0	-	-
Cycle 29 Day 1	18-64	8	12,9	7	87,5	23,81	25,20
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	33,33	0,00
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	25,00	16,67
	65-74	1	7,1	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	33,33	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	30,00	21,36
	65-74	10	71,4	7	70,0	19,05	26,23
	>=75	2	100,0	1	50,0	0,00	-
Race							
Cycle 1 Day 1	White	35	100,0	33	94,3	29,29	30,91
	Other	43	100,0	43	100,0	28,68	25,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	33	94,3	28	84,8	20,24	26,20
	Other	39	90,7	37	94,9	26,13	22,41
Cycle 3 Day 1	White	31	88,6	27	87,1	11,11	22,65
	Other	37	86,0	36	97,3	18,52	21,74
Cycle 4 Day 1	White	31	88,6	26	83,9	12,82	19,04
	Other	36	83,7	35	97,2	17,14	23,39
Cycle 5 Day 1	White	31	88,6	29	93,5	10,34	22,01
	Other	34	79,1	34	100,0	19,61	24,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	30	85,7	25	83,3	12,00	18,95
	Other	33	76,7	32	97,0	12,50	22,00
Cycle 7 Day 1	White	29	82,9	26	89,7	14,10	23,42
	Other	31	72,1	30	96,8	15,56	20,96
Cycle 8 Day 1	White	28	80,0	24	85,7	15,28	24,04
	Other	28	65,1	28	100,0	9,52	15,33
Cycle 9 Day 1	White	26	74,3	26	100,0	19,23	30,07
	Other	25	58,1	25	100,0	17,33	21,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	20,00	27,22
	Other	25	58,1	25	100,0	9,33	15,28
Cycle 11 Day 1	White	26	74,3	26	100,0	21,79	26,57
	Other	24	55,8	24	100,0	15,28	16,97
Cycle 12 Day 1	White	26	74,3	22	84,6	28,79	34,57
	Other	23	53,5	23	100,0	13,04	16,63
Cycle 13 Day 1	White	24	68,6	23	95,8	20,29	29,71
	Other	22	51,2	22	100,0	15,15	16,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	24	68,6	24	100,0	26,39	32,57
	Other	21	48,8	20	95,2	16,67	17,10
Cycle 15 Day 1	White	24	68,6	24	100,0	22,22	25,38
	Other	20	46,5	20	100,0	15,00	20,16
Cycle 16 Day 1	White	22	62,9	20	90,9	23,33	21,90
	Other	19	44,2	19	100,0	21,05	19,91
Cycle 17 Day 1	White	22	62,9	22	100,0	22,73	26,00
	Other	17	39,5	17	100,0	19,61	20,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	21	60,0	18	85,7	20,37	28,33
	Other	17	39,5	17	100,0	19,61	16,91
Cycle 19 Day 1	White	20	57,1	20	100,0	25,00	28,36
	Other	16	37,2	13	81,3	12,82	16,88
Cycle 20 Day 1	White	20	57,1	17	85,0	19,61	26,51
	Other	16	37,2	15	93,8	20,00	21,08
Cycle 21 Day 1	White	16	45,7	14	87,5	33,33	29,24
	Other	13	30,2	12	92,3	19,44	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	45,7	13	81,3	30,77	34,59
	Other	13	30,2	12	92,3	22,22	21,71
Cycle 23 Day 1	White	12	34,3	10	83,3	43,33	27,44
	Other	9	20,9	8	88,9	16,67	17,82
Cycle 24 Day 1	White	11	31,4	10	90,9	33,33	27,22
	Other	9	20,9	8	88,9	12,50	17,25
Cycle 25 Day 1	White	10	28,6	8	80,0	20,83	17,25
	Other	5	11,6	5	100,0	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	28,6	8	80,0	12,50	17,25
	Other	4	9,3	4	100,0	33,33	0,00
Cycle 27 Day 1	White	8	22,9	5	62,5	33,33	40,82
	Other	3	7,0	3	100,0	33,33	33,33
Cycle 28 Day 1	White	7	20,0	6	85,7	16,67	18,26
	Other	3	7,0	3	100,0	11,11	19,25
Cycle 29 Day 1	White	6	17,1	4	66,7	16,67	19,25
	Other	3	7,0	3	100,0	33,33	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	11,4	2	50,0	16,67	23,57
	Other	3	7,0	3	100,0	44,44	19,25
Cycle 31 Day 1	White	4	11,4	2	50,0	33,33	0,00
	Other	3	7,0	3	100,0	33,33	0,00
Cycle 32 Day 1	White	4	11,4	3	75,0	11,11	19,25
	Other	2	4,7	2	100,0	33,33	0,00
Cycle 33 Day 1	White	2	5,7	2	100,0	16,67	23,57
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-
End Of Treatment	White	15	42,9	12	80,0	36,11	26,43
	Other	24	55,8	16	66,7	18,75	17,08
Region							
Cycle 1 Day 1	America (AM)	22	100,0	21	95,5	22,22	28,54
	Europe (EU)	17	100,0	16	94,1	37,50	29,50
	Asia (AS)	39	100,0	39	100,0	29,06	26,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	25,49	22,14
	Europe (EU)	16	94,1	13	81,3	23,08	28,50
	Asia (AS)	36	92,3	35	97,2	22,86	23,94
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	15,79	25,74
	Europe (EU)	15	88,2	11	73,3	9,09	15,57
	Asia (AS)	33	84,6	33	100,0	17,17	22,24
Cycle 4 Day 1	America (AM)	20	90,9	19	95,0	12,28	19,91
	Europe (EU)	15	88,2	11	73,3	15,15	17,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	32	82,1	31	96,9	17,20	24,15
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	13,33	25,13
	Europe (EU)	15	88,2	13	86,7	10,26	21,01
	Asia (AS)	30	76,9	30	100,0	18,89	24,26
Cycle 6 Day 1	America (AM)	20	90,9	18	90,0	11,11	19,80
	Europe (EU)	14	82,4	12	85,7	11,11	16,41
	Asia (AS)	29	74,4	27	93,1	13,58	23,13
Cycle 7 Day 1	America (AM)	19	86,4	17	89,5	9,80	19,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	14	82,4	13	92,9	15,38	25,88
	Asia (AS)	27	69,2	26	96,3	17,95	21,56
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	17,65	26,66
	Europe (EU)	14	82,4	11	78,6	9,09	15,57
	Asia (AS)	24	61,5	24	100,0	9,72	15,48
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	24,07	27,55
	Europe (EU)	12	70,6	12	100,0	22,22	35,77
	Asia (AS)	21	53,8	21	100,0	11,11	16,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	19,61	23,74
	Europe (EU)	12	70,6	12	100,0	19,44	30,01
	Asia (AS)	21	53,8	21	100,0	7,94	14,55
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	16,67	20,61
	Europe (EU)	12	70,6	12	100,0	25,00	32,18
	Asia (AS)	20	51,3	20	100,0	16,67	17,10
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	17,65	29,15
	Europe (EU)	12	70,6	9	75,0	40,74	36,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	19	48,7	19	100,0	14,04	16,91
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	15,69	26,66
	Europe (EU)	11	64,7	10	90,9	26,67	30,63
	Asia (AS)	18	46,2	18	100,0	14,81	17,04
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	19,61	29,01
	Europe (EU)	11	64,7	11	100,0	33,33	33,33
	Asia (AS)	17	43,6	16	94,1	16,67	17,21
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	21,57	26,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	64,7	11	100,0	21,21	22,47
	Asia (AS)	16	41,0	16	100,0	14,58	20,97
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	19,05	21,54
	Europe (EU)	11	64,7	9	81,8	29,63	20,03
	Asia (AS)	16	41,0	16	100,0	20,83	20,64
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	21,43	28,06
	Europe (EU)	10	58,8	10	100,0	23,33	22,50
	Asia (AS)	15	38,5	15	100,0	20,00	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	19,05	28,39
	Europe (EU)	9	52,9	6	66,7	22,22	27,22
	Asia (AS)	15	38,5	15	100,0	20,00	16,90
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	20,51	32,03
	Europe (EU)	9	52,9	9	100,0	25,93	22,22
	Asia (AS)	14	35,9	11	78,6	15,15	17,41
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	23,08	31,58
	Europe (EU)	9	52,9	6	66,7	16,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	17,95	17,30
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	26,67	30,63
	Europe (EU)	7	41,2	6	85,7	33,33	29,81
	Asia (AS)	11	28,2	10	90,9	23,33	16,10
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	20,00	35,83
	Europe (EU)	7	41,2	5	71,4	33,33	33,33
	Asia (AS)	11	28,2	10	90,9	30,00	18,92
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	40,74	27,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	29,4	3	60,0	33,33	33,33
	Asia (AS)	7	17,9	6	85,7	16,67	18,26
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	25,00	23,57
	Europe (EU)	5	29,4	4	80,0	33,33	38,49
	Asia (AS)	7	17,9	6	85,7	16,67	18,26
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	28,57	12,60
	Europe (EU)	4	23,5	2	50,0	16,67	23,57
	Asia (AS)	4	10,3	4	100,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	11,11	17,21
	Europe (EU)	4	23,5	2	50,0	16,67	23,57
	Asia (AS)	4	10,3	4	100,0	33,33	0,00
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	33,33	47,14
	Europe (EU)	3	17,6	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	33,33	27,22
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	16,67	19,25
	Europe (EU)	2	11,8	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	16,67	19,25
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	11,11	19,25
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	33,33	27,22
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	44,44	19,25
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	33,33	0,00
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	16,67	23,57
	Europe (EU)	1	5,9	1	100,0	0,00	-
	Asia (AS)	3	7,7	2	66,7	33,33	0,00
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	33,33	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	30,30	23,35
	Europe (EU)	6	35,3	4	66,7	50,00	19,25
	Asia (AS)	21	53,8	13	61,9	15,38	17,30
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	28	93,3	17,86	16,93
	1	38	100,0	38	100,0	32,46	30,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	10	100,0	10	100,0	46,67	32,20
Cycle 2 Day 1	0	30	100,0	27	90,0	20,99	20,98
	1	36	94,7	32	88,9	25,00	23,95
	2	6	60,0	6	100,0	27,78	38,97
Cycle 3 Day 1	0	29	96,7	27	93,1	14,81	23,27
	1	34	89,5	31	91,2	13,98	16,72
	2	5	50,0	5	100,0	26,67	43,46
Cycle 4 Day 1	0	29	96,7	25	86,2	8,00	17,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	17,71	16,90
	2	5	50,0	4	80,0	41,67	50,00
Cycle 5 Day 1	0	29	96,7	29	100,0	13,79	24,43
	1	33	86,8	31	93,9	18,28	24,10
	2	3	30,0	3	100,0	0,00	0,00
Cycle 6 Day 1	0	29	96,7	28	96,6	9,52	15,33
	1	31	81,6	27	87,1	16,05	25,10
	2	3	30,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	29	96,7	28	96,6	11,90	20,72
	1	28	73,7	25	89,3	20,00	23,57
	2	3	30,0	3	100,0	0,00	0,00
Cycle 8 Day 1	0	28	93,3	26	92,9	14,10	23,42
	1	25	65,8	23	92,0	11,59	16,23
	2	3	30,0	3	100,0	0,00	0,00
Cycle 9 Day 1	0	26	86,7	26	100,0	20,51	26,79
	1	23	60,5	23	100,0	17,39	26,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	2	20,0	2	100,0	0,00	0,00
Cycle 10 Day 1	0	26	86,7	26	100,0	15,38	25,35
	1	23	60,5	22	95,7	15,15	19,86
	2	2	20,0	2	100,0	0,00	0,00
Cycle 11 Day 1	0	26	86,7	26	100,0	23,08	26,28
	1	22	57,9	22	100,0	15,15	16,99
	2	2	20,0	2	100,0	0,00	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	25,76	32,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	21	95,5	17,46	22,65
	2	2	20,0	2	100,0	0,00	0,00
Cycle 13 Day 1	0	25	83,3	24	96,0	20,83	29,18
	1	20	52,6	20	100,0	15,00	17,01
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	26,39	31,05
	1	19	50,0	19	100,0	17,54	20,39
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	24	80,0	24	100,0	23,61	26,88
	1	19	50,0	19	100,0	14,04	16,91
	2	1	10,0	1	100,0	0,00	-
Cycle 16 Day 1	0	22	73,3	20	90,9	23,33	19,04
	1	18	47,4	18	100,0	22,22	22,87
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	23,81	26,13
	1	17	44,7	17	100,0	19,61	20,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	22,22	25,57
	1	16	42,1	16	100,0	18,75	20,97
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	22,81	27,34
	1	15	39,5	13	86,7	17,95	22,01
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	23,53	28,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	39,5	14	93,3	16,67	17,30
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	28,57	28,81
	1	13	34,2	11	84,6	27,27	20,10
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	25,00	32,18
	1	13	34,2	12	92,3	30,56	26,43
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	40,74	27,78
	1	9	23,7	8	88,9	25,00	23,57
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	22,22	23,57
	1	9	23,7	8	88,9	29,17	27,82
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	16,67	18,26
	1	7	18,4	7	100,0	33,33	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	26,7	6	75,0	16,67	18,26
	1	6	15,8	6	100,0	22,22	17,21
Cycle 27 Day 1	0	6	20,0	3	50,0	22,22	19,25
	1	5	13,2	5	100,0	40,00	43,46
Cycle 28 Day 1	0	5	16,7	4	80,0	16,67	19,25
	1	5	13,2	5	100,0	13,33	18,26
Cycle 29 Day 1	0	4	13,3	2	50,0	33,33	0,00
	1	5	13,2	5	100,0	20,00	29,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	10,0	1	33,3	33,33	-
	1	4	10,5	4	100,0	33,33	27,22
Cycle 31 Day 1	0	3	10,0	1	33,3	33,33	-
	1	4	10,5	4	100,0	33,33	0,00
Cycle 32 Day 1	0	3	10,0	2	66,7	16,67	23,57
	1	3	7,9	3	100,0	22,22	19,25
Cycle 33 Day 1	0	2	6,7	2	100,0	16,67	23,57
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	26,19	26,73
	1	20	52,6	12	60,0	27,78	19,25
	2	4	40,0	2	50,0	16,67	23,57
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	23,66	26,10
	1	3	100,0	3	100,0	44,44	38,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	44	100,0	42	95,5	31,75	28,47
Cycle 2 Day 1	None	30	96,8	27	90,0	23,46	22,29
	1	2	66,7	1	50,0	33,33	-
	2 or More	40	90,9	37	92,5	23,42	25,90
Cycle 3 Day 1	None	30	96,8	28	93,3	10,71	15,85
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	34	94,4	19,61	26,10
Cycle 4 Day 1	None	30	96,8	28	93,3	13,10	16,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	35	79,5	31	88,6	18,28	25,59
Cycle 5 Day 1	None	30	96,8	30	100,0	13,33	24,13
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	33	75,0	31	93,9	18,28	24,10
Cycle 6 Day 1	None	29	93,5	26	89,7	7,69	14,32
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	32	72,7	29	90,6	17,24	24,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	27	87,1	25	92,6	5,33	12,47
	1	2	66,7	2	100,0	16,67	23,57
	2 or More	31	70,5	29	93,5	22,99	25,36
Cycle 8 Day 1	None	26	83,9	25	96,2	12,00	16,33
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	12,35	22,92
Cycle 9 Day 1	None	25	80,6	25	100,0	16,00	23,80
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	21,33	28,67
Cycle 10 Day 1	None	25	80,6	24	96,0	13,89	19,45
	1	1	33,3	1	100,0	0,00	-
	2 or More	25	56,8	25	100,0	16,00	25,68
Cycle 11 Day 1	None	25	80,6	25	100,0	13,33	16,67
	1	1	33,3	1	100,0	0,00	-
	2 or More	24	54,5	24	100,0	25,00	26,47
Cycle 12 Day 1	None	25	80,6	24	96,0	11,11	18,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	23	52,3	20	87,0	33,33	32,44
Cycle 13 Day 1	None	24	77,4	23	95,8	13,04	16,63
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	23,81	30,08
Cycle 14 Day 1	None	23	74,2	23	100,0	15,94	19,77
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	20	95,2	30,00	32,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	23	74,2	23	100,0	17,39	19,77
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	20	100,0	21,67	27,09
Cycle 16 Day 1	None	20	64,5	19	95,0	21,05	22,80
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	19	95,0	24,56	18,73
Cycle 17 Day 1	None	19	61,3	19	100,0	15,79	17,10
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	19	43,2	19	100,0	28,07	27,81
Cycle 18 Day 1	None	18	58,1	17	94,4	15,69	17,15
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	17	89,5	25,49	27,71
Cycle 19 Day 1	None	17	54,8	17	100,0	9,80	15,66
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	33,33	28,17
Cycle 20 Day 1	None	17	54,8	16	94,1	14,58	17,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	26,67	28,73
Cycle 21 Day 1	None	15	48,4	13	86,7	17,95	17,30
	2 or More	14	31,8	13	92,9	35,90	28,74
Cycle 22 Day 1	None	15	48,4	13	86,7	12,82	21,68
	2 or More	14	31,8	12	85,7	41,67	28,87
Cycle 23 Day 1	None	10	32,3	9	90,0	29,63	20,03
	2 or More	11	25,0	9	81,8	33,33	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	32,3	10	100,0	23,33	22,50
	2 or More	10	22,7	8	80,0	25,00	29,55
Cycle 25 Day 1	None	9	29,0	8	88,9	29,17	21,36
	2 or More	6	13,6	5	83,3	20,00	18,26
Cycle 26 Day 1	None	8	25,8	8	100,0	16,67	17,82
	2 or More	6	13,6	4	66,7	25,00	16,67
Cycle 27 Day 1	None	7	22,6	6	85,7	38,89	38,97
	2 or More	4	9,1	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	22,6	7	100,0	14,29	17,82
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	19,4	5	83,3	26,67	27,89
	2 or More	3	6,8	2	66,7	16,67	23,57
Cycle 30 Day 1	None	4	12,9	3	75,0	22,22	19,25
	2 or More	3	6,8	2	66,7	50,00	23,57
Cycle 31 Day 1	None	4	12,9	3	75,0	33,33	0,00
	2 or More	3	6,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	22,22	19,25
	2 or More	2	4,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	3,2	1	100,0	33,33	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	30,56	22,29
	1	2	66,7	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	54,5	15	62,5	24,44	23,46
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	23,66	26,10
	Previously Treated	47	100,0	45	95,7	32,59	28,86
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	23,46	22,29
	Previously Treated	42	89,4	38	90,5	23,68	25,60
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	10,71	15,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	38	80,9	35	92,1	19,05	25,93
Cycle 4 Day 1	Naïve	30	96,8	28	93,3	13,10	16,58
	Previously Treated	37	78,7	33	89,2	17,17	25,17
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	13,33	24,13
	Previously Treated	35	74,5	33	94,3	17,17	23,75
Cycle 6 Day 1	Naïve	29	93,5	26	89,7	7,69	14,32
	Previously Treated	34	72,3	31	91,2	16,13	24,15
Cycle 7 Day 1	Naïve	27	87,1	25	92,6	5,33	12,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	33	70,2	31	93,9	22,58	24,93
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	12,00	16,33
	Previously Treated	30	63,8	27	90,0	12,35	22,92
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	16,00	23,80
	Previously Treated	26	55,3	26	100,0	20,51	28,40
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	13,89	19,45
	Previously Treated	26	55,3	26	100,0	15,38	25,35
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	13,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	53,2	25	100,0	24,00	26,39
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	11,11	18,82
	Previously Treated	24	51,1	21	87,5	31,75	32,45
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	13,04	16,63
	Previously Treated	22	46,8	22	100,0	22,73	29,79
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	15,94	19,77
	Previously Treated	22	46,8	21	95,5	28,57	32,12
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	17,39	19,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	21	100,0	20,63	26,82
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	21,05	22,80
	Previously Treated	21	44,7	20	95,2	23,33	19,04
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	15,79	17,10
	Previously Treated	20	42,6	20	100,0	26,67	27,78
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	15,69	17,15
	Previously Treated	20	42,6	18	90,0	24,07	27,55
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	9,80	15,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	40,4	16	84,2	31,25	28,46
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	14,58	17,08
	Previously Treated	19	40,4	16	84,2	25,00	28,54
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	17,95	17,30
	Previously Treated	14	29,8	13	92,9	35,90	28,74
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	12,82	21,68
	Previously Treated	14	29,8	12	85,7	41,67	28,87
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	29,63	20,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	33,33	33,33
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	23,33	22,50
	Previously Treated	10	21,3	8	80,0	25,00	29,55
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	29,17	21,36
	Previously Treated	6	12,8	5	83,3	20,00	18,26
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	16,67	17,82
	Previously Treated	6	12,8	4	66,7	25,00	16,67
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	38,89	38,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	8,5	2	50,0	16,67	23,57
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	14,29	17,82
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	26,67	27,89
	Previously Treated	3	6,4	2	66,7	16,67	23,57
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	22,22	19,25
	Previously Treated	3	6,4	2	66,7	50,00	23,57
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	22,22	19,25
	Previously Treated	2	4,3	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	33,33	-
	Previously Treated	1	2,1	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	30,56	22,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	16	61,5	22,92	23,47
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	23,81	27,50
	Central	43	100,0	41	95,3	33,33	27,89
Cycle 2 Day 1	Local	32	91,4	30	93,8	17,78	19,04
	Central	40	93,0	35	87,5	28,57	26,99
Cycle 3 Day 1	Local	29	82,9	27	93,1	11,11	16,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	39	90,7	36	92,3	18,52	25,75
Cycle 4 Day 1	Local	28	80,0	24	85,7	12,50	19,19
	Central	39	90,7	37	94,9	17,12	23,07
Cycle 5 Day 1	Local	27	77,1	27	100,0	11,11	16,01
	Central	38	88,4	36	94,7	18,52	28,11
Cycle 6 Day 1	Local	27	77,1	27	100,0	11,11	18,49
	Central	36	83,7	30	83,3	13,33	22,49
Cycle 7 Day 1	Local	27	77,1	27	100,0	12,35	18,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	33	76,7	29	87,9	17,24	24,59
Cycle 8 Day 1	Local	26	74,3	26	100,0	10,26	15,69
	Central	30	69,8	26	86,7	14,10	23,42
Cycle 9 Day 1	Local	25	71,4	25	100,0	18,67	29,00
	Central	26	60,5	26	100,0	17,95	23,53
Cycle 10 Day 1	Local	25	71,4	24	96,0	18,06	25,97
	Central	26	60,5	26	100,0	11,54	18,72
Cycle 11 Day 1	Local	24	68,6	24	100,0	13,89	23,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	26	60,5	26	100,0	23,08	20,59
Cycle 12 Day 1	Local	23	65,7	22	95,7	13,64	26,55
	Central	26	60,5	23	88,5	27,54	27,80
Cycle 13 Day 1	Local	22	62,9	22	100,0	16,67	24,67
	Central	24	55,8	23	95,8	18,84	24,26
Cycle 14 Day 1	Local	22	62,9	22	100,0	16,67	26,73
	Central	23	53,5	22	95,7	27,27	26,50
Cycle 15 Day 1	Local	22	62,9	22	100,0	12,12	19,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	25,76	25,05
Cycle 16 Day 1	Local	20	57,1	20	100,0	18,33	20,16
	Central	21	48,8	19	90,5	26,32	21,02
Cycle 17 Day 1	Local	20	57,1	20	100,0	15,00	17,01
	Central	19	44,2	19	100,0	28,07	27,81
Cycle 18 Day 1	Local	20	57,1	19	95,0	10,53	15,92
	Central	18	41,9	16	88,9	31,25	25,73
Cycle 19 Day 1	Local	19	54,3	17	89,5	13,73	20,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	39,5	16	94,1	27,08	27,81
Cycle 20 Day 1	Local	19	54,3	17	89,5	15,69	20,81
	Central	17	39,5	15	88,2	24,44	26,63
Cycle 21 Day 1	Local	14	40,0	12	85,7	16,67	17,41
	Central	15	34,9	14	93,3	35,71	27,62
Cycle 22 Day 1	Local	14	40,0	12	85,7	11,11	21,71
	Central	15	34,9	13	86,7	41,03	27,74
Cycle 23 Day 1	Local	11	31,4	10	90,9	23,33	16,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	23,3	8	80,0	41,67	34,50
Cycle 24 Day 1	Local	11	31,4	10	90,9	16,67	17,57
	Central	9	20,9	8	88,9	33,33	30,86
Cycle 25 Day 1	Local	7	20,0	7	100,0	33,33	19,25
	Central	8	18,6	6	75,0	16,67	18,26
Cycle 26 Day 1	Local	6	17,1	6	100,0	16,67	18,26
	Central	8	18,6	6	75,0	22,22	17,21
Cycle 27 Day 1	Local	4	11,4	4	100,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	16,3	4	57,1	41,67	41,94
Cycle 28 Day 1	Local	4	11,4	4	100,0	8,33	16,67
	Central	6	14,0	5	83,3	20,00	18,26
Cycle 29 Day 1	Local	3	8,6	3	100,0	33,33	33,33
	Central	6	14,0	4	66,7	16,67	19,25
Cycle 30 Day 1	Local	3	8,6	3	100,0	22,22	19,25
	Central	4	9,3	2	50,0	50,00	23,57
Cycle 31 Day 1	Local	3	8,6	3	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	9,3	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	8,6	3	100,0	22,22	19,25
	Central	3	7,0	2	66,7	16,67	23,57
Cycle 33 Day 1	Local	1	2,9	1	100,0	33,33	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	26,19	23,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	21	48,8	14	66,7	26,19	23,31
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	72	97,3	29,17	27,94
	No	4	100,0	4	100,0	25,00	31,91
Cycle 2 Day 1	Yes	70	94,6	63	90,0	23,81	24,27
	No	2	50,0	2	100,0	16,67	23,57
Cycle 3 Day 1	Yes	66	89,2	61	92,4	15,30	22,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 4 Day 1	Yes	65	87,8	59	90,8	15,82	21,76
	No	2	50,0	2	100,0	0,00	0,00
Cycle 5 Day 1	Yes	63	85,1	61	96,8	14,21	23,14
	No	2	50,0	2	100,0	50,00	23,57
Cycle 6 Day 1	Yes	61	82,4	55	90,2	12,12	20,65
	No	2	50,0	2	100,0	16,67	23,57
Cycle 7 Day 1	Yes	58	78,4	54	93,1	15,43	22,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 8 Day 1	Yes	54	73,0	50	92,6	12,67	20,08
	No	2	50,0	2	100,0	0,00	0,00
Cycle 9 Day 1	Yes	49	66,2	49	100,0	18,37	26,41
	No	2	50,0	2	100,0	16,67	23,57
Cycle 10 Day 1	Yes	49	66,2	48	98,0	15,28	22,76
	No	2	50,0	2	100,0	0,00	0,00
Cycle 11 Day 1	Yes	48	64,9	48	100,0	18,75	22,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 12 Day 1	Yes	47	63,5	43	91,5	20,93	28,19
	No	2	50,0	2	100,0	16,67	23,57
Cycle 13 Day 1	Yes	44	59,5	43	97,7	17,83	24,50
	No	2	50,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	43	58,1	42	97,7	22,22	27,22
	No	2	50,0	2	100,0	16,67	23,57
Cycle 15 Day 1	Yes	42	56,8	42	100,0	19,05	23,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	16,67	23,57
Cycle 16 Day 1	Yes	39	52,7	37	94,9	22,52	20,87
	No	2	50,0	2	100,0	16,67	23,57
Cycle 17 Day 1	Yes	37	50,0	37	100,0	20,72	22,70
	No	2	50,0	2	100,0	33,33	47,14
Cycle 18 Day 1	Yes	36	48,6	33	91,7	20,20	23,48
	No	2	50,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	45,9	32	94,1	20,83	25,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	20,00	24,13
	No	2	50,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	36,5	24	88,9	27,78	25,38
	No	2	50,0	2	100,0	16,67	23,57
Cycle 22 Day 1	Yes	27	36,5	23	85,2	27,54	29,56
	No	2	50,0	2	100,0	16,67	23,57
Cycle 23 Day 1	Yes	20	27,0	17	85,0	33,33	26,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	25,49	25,08
	No	1	25,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	18,9	12	85,7	22,22	16,41
	No	1	25,0	1	100,0	66,67	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	18,18	17,41
	No	1	25,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	28,57	35,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	66,67	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	16,67	17,82
	No	1	25,0	1	100,0	0,00	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	16,67	18,26
	No	1	25,0	1	100,0	66,67	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	33,33	27,22
	No	1	25,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	33,33	-
Cycle 32 Day 1	Yes	5	6,8	4	80,0	16,67	19,25
	No	1	25,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	16,67	23,57
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	26,19	22,87
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	37,50	41,55
	No	70	100,0	68	97,1	27,94	26,15
Cycle 2 Day 1	Yes	5	62,5	5	100,0	20,00	18,26
	No	67	95,7	60	89,6	23,89	24,62
Cycle 3 Day 1	Yes	5	62,5	4	80,0	16,67	19,25
	No	63	90,0	59	93,7	15,25	22,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	5	62,5	5	100,0	20,00	18,26
	No	62	88,6	56	90,3	14,88	21,95
Cycle 5 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	60	85,7	58	96,7	16,09	24,38
Cycle 6 Day 1	Yes	5	62,5	5	100,0	13,33	18,26
	No	58	82,9	52	89,7	12,18	20,90
Cycle 7 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	55	78,6	51	92,7	15,69	22,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	5	62,5	5	100,0	13,33	18,26
	No	51	72,9	47	92,2	12,06	20,17
Cycle 9 Day 1	Yes	4	50,0	4	100,0	41,67	31,91
	No	47	67,1	47	100,0	16,31	24,94
Cycle 10 Day 1	Yes	4	50,0	4	100,0	25,00	31,91
	No	47	67,1	46	97,9	13,77	21,75
Cycle 11 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	46	65,7	46	100,0	18,84	22,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	45	64,3	41	91,1	21,95	28,49
Cycle 13 Day 1	Yes	4	50,0	4	100,0	25,00	16,67
	No	42	60,0	41	97,6	17,07	24,86
Cycle 14 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	41	58,6	40	97,6	22,50	27,62
Cycle 15 Day 1	Yes	4	50,0	4	100,0	16,67	19,25
	No	40	57,1	40	100,0	19,17	23,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	38	54,3	36	94,7	23,15	20,81
Cycle 17 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	36	51,4	36	100,0	22,22	23,90
Cycle 18 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	35	50,0	32	91,4	20,83	23,57
Cycle 19 Day 1	Yes	3	37,5	3	100,0	11,11	19,25
	No	33	47,1	30	90,9	21,11	25,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	37,5	3	100,0	22,22	19,25
	No	33	47,1	29	87,9	19,54	24,43
Cycle 21 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	27	38,6	24	88,9	27,78	25,38
Cycle 22 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	27	38,6	23	85,2	27,54	29,56
Cycle 23 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	19	27,1	16	84,2	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	18	25,7	16	88,9	25,00	25,82
Cycle 25 Day 1	Yes	2	25,0	2	100,0	16,67	23,57
	No	13	18,6	11	84,6	27,27	20,10
Cycle 26 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	13	18,6	11	84,6	18,18	17,41
Cycle 27 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	10	14,3	7	70,0	33,33	38,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	9	12,9	8	88,9	12,50	17,25
Cycle 29 Day 1	Yes	1	12,5	1	100,0	33,33	-
	No	8	11,4	6	75,0	22,22	27,22
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	33,33	23,57
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	20,00	18,26
Cycle 33 Day 1	No	2	2,9	2	100,0	16,67	23,57
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	33,33	0,00
	No	37	52,9	26	70,3	25,64	23,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13PO_SG.xls
28NOV2019 11:02

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	78	100,0	77	98,7	6,49	15,33
Cycle 2 Day 1	All	72	92,3	65	90,3	6,15	13,03
Cycle 3 Day 1	All	68	87,2	63	92,6	4,76	11,76
Cycle 4 Day 1	All	67	85,9	61	91,0	2,73	9,22
Cycle 5 Day 1	All	65	83,3	63	96,9	4,76	11,76
Cycle 6 Day 1	All	63	80,8	57	90,5	4,09	11,04
Cycle 7 Day 1	All	60	76,9	56	93,3	4,17	11,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	56	71,8	52	92,9	3,85	10,75
Cycle 9 Day 1	All	51	65,4	51	100,0	3,92	10,85
Cycle 10 Day 1	All	51	65,4	50	98,0	6,00	14,58
Cycle 11 Day 1	All	50	64,1	50	100,0	4,67	11,68
Cycle 12 Day 1	All	49	62,8	45	91,8	2,22	8,41
Cycle 13 Day 1	All	46	59,0	45	97,8	4,44	11,46
Cycle 14 Day 1	All	45	57,7	44	97,8	3,79	10,70
Cycle 15 Day 1	All	44	56,4	44	100,0	3,03	9,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	41	52,6	39	95,1	3,42	12,78
Cycle 17 Day 1	All	39	50,0	39	100,0	2,56	9,00
Cycle 18 Day 1	All	38	48,7	35	92,1	3,81	10,76
Cycle 19 Day 1	All	36	46,2	33	91,7	2,02	8,08
Cycle 20 Day 1	All	36	46,2	32	88,9	2,08	8,20
Cycle 21 Day 1	All	29	37,2	26	89,7	1,28	6,54
Cycle 22 Day 1	All	29	37,2	25	86,2	2,67	9,23
Cycle 23 Day 1	All	21	26,9	18	85,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	25,6	18	90,0	0,00	0,00
Cycle 25 Day 1	All	15	19,2	13	86,7	0,00	0,00
Cycle 26 Day 1	All	14	17,9	12	85,7	5,56	19,25
Cycle 27 Day 1	All	11	14,1	8	72,7	0,00	0,00
Cycle 28 Day 1	All	10	12,8	9	90,0	0,00	0,00
Cycle 29 Day 1	All	9	11,5	7	77,8	0,00	0,00
Cycle 30 Day 1	All	7	9,0	5	71,4	0,00	0,00
Cycle 31 Day 1	All	7	9,0	5	71,4	13,33	29,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	7,7	5	83,3	0,00	0,00
Cycle 33 Day 1	All	2	2,6	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	1,3	0	0,0	-	-
Cycle 35 Day 1	All	1	1,3	0	0,0	-	-
End Of Treatment	All	39	50,0	28	71,8	11,90	20,72
Sex							
Cycle 1 Day 1	Male	29	100,0	29	100,0	6,90	13,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	49	100,0	48	98,0	6,25	16,35
Cycle 2 Day 1	Male	27	93,1	25	92,6	9,33	15,28
	Female	45	91,8	40	88,9	4,17	11,16
Cycle 3 Day 1	Male	25	86,2	24	96,0	5,56	12,69
	Female	43	87,8	39	90,7	4,27	11,29
Cycle 4 Day 1	Male	25	86,2	23	92,0	4,35	11,48
	Female	42	85,7	38	90,5	1,75	7,54
Cycle 5 Day 1	Male	25	86,2	24	96,0	5,56	12,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	40	81,6	39	97,5	4,27	11,29
Cycle 6 Day 1	Male	25	86,2	23	92,0	4,35	11,48
	Female	38	77,6	34	89,5	3,92	10,90
Cycle 7 Day 1	Male	23	79,3	23	100,0	2,90	9,60
	Female	37	75,5	33	89,2	5,05	12,14
Cycle 8 Day 1	Male	21	72,4	19	90,5	3,51	10,51
	Female	35	71,4	33	94,3	4,04	11,05
Cycle 9 Day 1	Male	18	62,1	18	100,0	3,70	10,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	33	67,3	33	100,0	4,04	11,05
Cycle 10 Day 1	Male	18	62,1	18	100,0	9,26	19,15
	Female	33	67,3	32	97,0	4,17	11,20
Cycle 11 Day 1	Male	18	62,1	18	100,0	7,41	14,26
	Female	32	65,3	32	100,0	3,13	9,87
Cycle 12 Day 1	Male	17	58,6	17	100,0	1,96	8,08
	Female	32	65,3	28	87,5	2,38	8,74
Cycle 13 Day 1	Male	17	58,6	17	100,0	5,88	13,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	29	59,2	28	96,6	3,57	10,50
Cycle 14 Day 1	Male	17	58,6	16	94,1	4,17	11,39
	Female	28	57,1	28	100,0	3,57	10,50
Cycle 15 Day 1	Male	16	55,2	16	100,0	2,08	8,33
	Female	28	57,1	28	100,0	3,57	10,50
Cycle 16 Day 1	Male	14	48,3	14	100,0	4,76	17,82
	Female	27	55,1	25	92,6	2,67	9,23
Cycle 17 Day 1	Male	12	41,4	12	100,0	2,78	9,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	27	55,1	27	100,0	2,47	8,90
Cycle 18 Day 1	Male	11	37,9	10	90,9	6,67	14,05
	Female	27	55,1	25	92,6	2,67	9,23
Cycle 19 Day 1	Male	10	34,5	10	100,0	6,67	14,05
	Female	26	53,1	23	88,5	0,00	0,00
Cycle 20 Day 1	Male	10	34,5	9	90,0	3,70	11,11
	Female	26	53,1	23	88,5	1,45	6,95
Cycle 21 Day 1	Male	8	27,6	8	100,0	4,17	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	42,9	18	85,7	0,00	0,00
Cycle 22 Day 1	Male	8	27,6	6	75,0	5,56	13,61
	Female	21	42,9	19	90,5	1,75	7,65
Cycle 23 Day 1	Male	5	17,2	4	80,0	0,00	0,00
	Female	16	32,7	14	87,5	0,00	0,00
Cycle 24 Day 1	Male	5	17,2	4	80,0	0,00	0,00
	Female	15	30,6	14	93,3	0,00	0,00
Cycle 25 Day 1	Male	3	10,3	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	24,5	11	91,7	0,00	0,00
Cycle 26 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	11	22,4	10	90,9	6,67	21,08
Cycle 27 Day 1	Male	3	10,3	2	66,7	0,00	0,00
	Female	8	16,3	6	75,0	0,00	0,00
Cycle 28 Day 1	Male	2	6,9	2	100,0	0,00	0,00
	Female	8	16,3	7	87,5	0,00	0,00
Cycle 29 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	16,3	6	75,0	0,00	0,00
Cycle 30 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	0,00	0,00
Cycle 31 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	6	12,2	4	66,7	16,67	33,33
Cycle 32 Day 1	Male	1	3,4	1	100,0	0,00	-
	Female	5	10,2	4	80,0	0,00	0,00
Cycle 33 Day 1	Male	1	3,4	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	2,0	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	3,4	0	0,0	-	-
Cycle 35 Day 1	Male	1	3,4	0	0,0	-	-
End Of Treatment	Male	18	62,1	15	83,3	11,11	20,57
	Female	21	42,9	13	61,9	12,82	21,68
Age							
Cycle 1 Day 1	18-64	62	100,0	61	98,4	6,01	15,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	14	100,0	14	100,0	9,52	15,63
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 2 Day 1	18-64	59	95,2	52	88,1	4,49	11,49
	65-74	11	78,6	11	100,0	12,12	16,82
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 3 Day 1	18-64	56	90,3	52	92,9	3,85	10,75
	65-74	10	71,4	9	90,0	7,41	14,70
	>=75	2	100,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	55	88,7	50	90,9	2,67	9,13
	65-74	10	71,4	9	90,0	3,70	11,11
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 5 Day 1	18-64	53	85,5	52	98,1	4,49	11,49
	65-74	10	71,4	10	100,0	6,67	14,05
	>=75	2	100,0	1	50,0	0,00	-
Cycle 6 Day 1	18-64	51	82,3	46	90,2	4,35	11,35
	65-74	10	71,4	9	90,0	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 7 Day 1	18-64	49	79,0	46	93,9	3,62	10,49
	65-74	9	64,3	8	88,9	4,17	11,79
	>=75	2	100,0	2	100,0	16,67	23,57
Cycle 8 Day 1	18-64	45	72,6	41	91,1	3,25	10,01
	65-74	9	64,3	9	100,0	7,41	14,70
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 9 Day 1	18-64	40	64,5	40	100,0	3,33	10,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	9	64,3	9	100,0	7,41	14,70
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 10 Day 1	18-64	40	64,5	39	97,5	5,98	15,05
	65-74	9	64,3	9	100,0	7,41	14,70
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 11 Day 1	18-64	39	62,9	39	100,0	5,13	12,18
	65-74	9	64,3	9	100,0	3,70	11,11
	>=75	2	100,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	38	61,3	35	92,1	0,95	5,63
	65-74	9	64,3	8	88,9	8,33	15,43
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 13 Day 1	18-64	35	56,5	34	97,1	3,92	10,90
	65-74	9	64,3	9	100,0	7,41	14,70
	>=75	2	100,0	2	100,0	0,00	0,00
Cycle 14 Day 1	18-64	35	56,5	35	100,0	3,81	10,76
	65-74	9	64,3	8	88,9	4,17	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 15 Day 1	18-64	35	56,5	35	100,0	2,86	9,47
	65-74	8	57,1	8	100,0	4,17	11,79
	>=75	1	50,0	1	100,0	0,00	-
Cycle 16 Day 1	18-64	33	53,2	32	97,0	4,17	14,04
	65-74	7	50,0	6	85,7	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 17 Day 1	18-64	32	51,6	32	100,0	3,13	9,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	6	42,9	6	100,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 18 Day 1	18-64	31	50,0	29	93,5	3,45	10,33
	65-74	6	42,9	5	83,3	6,67	14,91
	>=75	1	50,0	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	48,4	28	93,3	1,19	6,30
	65-74	5	35,7	4	80,0	8,33	16,67
	>=75	1	50,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	48,4	26	86,7	2,56	9,06
	65-74	5	35,7	5	100,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	38,7	21	87,5	1,59	7,27
	65-74	4	28,6	4	100,0	0,00	0,00
	>=75	1	50,0	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	38,7	20	83,3	1,67	7,45
	65-74	4	28,6	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	50,0	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	30,6	16	84,2	0,00	0,00
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	29,0	16	88,9	0,00	0,00
	65-74	2	14,3	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	22,6	12	85,7	0,00	0,00
	65-74	1	7,1	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	21,0	12	92,3	5,56	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 27 Day 1	18-64	10	16,1	8	80,0	0,00	0,00
	65-74	1	7,1	0	0,0	-	-
Cycle 28 Day 1	18-64	9	14,5	9	100,0	0,00	0,00
	65-74	1	7,1	0	0,0	-	-
Cycle 29 Day 1	18-64	8	12,9	7	87,5	0,00	0,00
	65-74	1	7,1	0	0,0	-	-
Cycle 30 Day 1	18-64	6	9,7	5	83,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	7,1	0	0,0	-	-
Cycle 31 Day 1	18-64	6	9,7	5	83,3	13,33	29,81
	65-74	1	7,1	0	0,0	-	-
Cycle 32 Day 1	18-64	5	8,1	4	80,0	0,00	0,00
	65-74	1	7,1	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	1,6	1	100,0	0,00	-
	65-74	1	7,1	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	1,6	0	0,0	-	-
End Of Treatment	18-64	27	43,5	20	74,1	13,33	22,69
	65-74	10	71,4	7	70,0	9,52	16,27
	>=75	2	100,0	1	50,0	0,00	-
Race							
Cycle 1 Day 1	White	35	100,0	34	97,1	1,96	7,96
	Other	43	100,0	43	100,0	10,08	18,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	33	94,3	28	84,8	5,95	13,00
	Other	39	90,7	37	94,9	6,31	13,24
Cycle 3 Day 1	White	31	88,6	27	87,1	3,70	10,68
	Other	37	86,0	36	97,3	5,56	12,60
Cycle 4 Day 1	White	31	88,6	26	83,9	0,00	0,00
	Other	36	83,7	35	97,2	4,76	11,83
Cycle 5 Day 1	White	31	88,6	29	93,5	3,45	10,33
	Other	34	79,1	34	100,0	5,88	12,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	30	85,7	25	83,3	4,00	11,06
	Other	33	76,7	32	97,0	4,17	11,20
Cycle 7 Day 1	White	29	82,9	26	89,7	2,56	9,06
	Other	31	72,1	30	96,8	5,56	12,63
Cycle 8 Day 1	White	28	80,0	24	85,7	2,78	9,41
	Other	28	65,1	28	100,0	4,76	11,88
Cycle 9 Day 1	White	26	74,3	26	100,0	3,85	10,86
	Other	25	58,1	25	100,0	4,00	11,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	26	74,3	25	96,2	8,00	17,43
	Other	25	58,1	25	100,0	4,00	11,06
Cycle 11 Day 1	White	26	74,3	26	100,0	3,85	10,86
	Other	24	55,8	24	100,0	5,56	12,69
Cycle 12 Day 1	White	26	74,3	22	84,6	1,52	7,11
	Other	23	53,5	23	100,0	2,90	9,60
Cycle 13 Day 1	White	24	68,6	23	95,8	5,80	12,92
	Other	22	51,2	22	100,0	3,03	9,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	24	68,6	24	100,0	4,17	11,26
	Other	21	48,8	20	95,2	3,33	10,26
Cycle 15 Day 1	White	24	68,6	24	100,0	4,17	11,26
	Other	20	46,5	20	100,0	1,67	7,45
Cycle 16 Day 1	White	22	62,9	20	90,9	5,00	16,31
	Other	19	44,2	19	100,0	1,75	7,65
Cycle 17 Day 1	White	22	62,9	22	100,0	3,03	9,81
	Other	17	39,5	17	100,0	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	21	60,0	18	85,7	1,85	7,86
	Other	17	39,5	17	100,0	5,88	13,10
Cycle 19 Day 1	White	20	57,1	20	100,0	1,67	7,45
	Other	16	37,2	13	81,3	2,56	9,25
Cycle 20 Day 1	White	20	57,1	17	85,0	1,96	8,08
	Other	16	37,2	15	93,8	2,22	8,61
Cycle 21 Day 1	White	16	45,7	14	87,5	2,38	8,91
	Other	13	30,2	12	92,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	45,7	13	81,3	2,56	9,25
	Other	13	30,2	12	92,3	2,78	9,62
Cycle 23 Day 1	White	12	34,3	10	83,3	0,00	0,00
	Other	9	20,9	8	88,9	0,00	0,00
Cycle 24 Day 1	White	11	31,4	10	90,9	0,00	0,00
	Other	9	20,9	8	88,9	0,00	0,00
Cycle 25 Day 1	White	10	28,6	8	80,0	0,00	0,00
	Other	5	11,6	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	28,6	8	80,0	0,00	0,00
	Other	4	9,3	4	100,0	16,67	33,33
Cycle 27 Day 1	White	8	22,9	5	62,5	0,00	0,00
	Other	3	7,0	3	100,0	0,00	0,00
Cycle 28 Day 1	White	7	20,0	6	85,7	0,00	0,00
	Other	3	7,0	3	100,0	0,00	0,00
Cycle 29 Day 1	White	6	17,1	4	66,7	0,00	0,00
	Other	3	7,0	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	11,4	2	50,0	0,00	0,00
	Other	3	7,0	3	100,0	0,00	0,00
Cycle 31 Day 1	White	4	11,4	2	50,0	0,00	0,00
	Other	3	7,0	3	100,0	22,22	38,49
Cycle 32 Day 1	White	4	11,4	3	75,0	0,00	0,00
	Other	2	4,7	2	100,0	0,00	0,00
Cycle 33 Day 1	White	2	5,7	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	2,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	2,9	0	0,0	-	-
End Of Treatment	White	15	42,9	12	80,0	5,56	12,97
	Other	24	55,8	16	66,7	16,67	24,34
Region							
Cycle 1 Day 1	America (AM)	22	100,0	21	95,5	6,35	17,06
	Europe (EU)	17	100,0	17	100,0	3,92	11,07
	Asia (AS)	39	100,0	39	100,0	7,69	16,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	20	90,9	17	85,0	5,88	13,10
	Europe (EU)	16	94,1	13	81,3	10,26	16,01
	Asia (AS)	36	92,3	35	97,2	4,76	11,83
Cycle 3 Day 1	America (AM)	20	90,9	19	95,0	1,75	7,65
	Europe (EU)	15	88,2	11	73,3	6,06	13,48
	Asia (AS)	33	84,6	33	100,0	6,06	13,06
Cycle 4 Day 1	America (AM)	20	90,9	19	95,0	0,00	0,00
	Europe (EU)	15	88,2	11	73,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	32	82,1	31	96,9	5,38	12,46
Cycle 5 Day 1	America (AM)	20	90,9	20	100,0	0,00	0,00
	Europe (EU)	15	88,2	13	86,7	5,13	12,52
	Asia (AS)	30	76,9	30	100,0	7,78	14,34
Cycle 6 Day 1	America (AM)	20	90,9	18	90,0	0,00	0,00
	Europe (EU)	14	82,4	12	85,7	5,56	12,97
	Asia (AS)	29	74,4	27	93,1	6,17	13,19
Cycle 7 Day 1	America (AM)	19	86,4	17	89,5	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	14	82,4	13	92,9	5,13	12,52
	Asia (AS)	27	69,2	26	96,3	6,41	13,40
Cycle 8 Day 1	America (AM)	18	81,8	17	94,4	0,00	0,00
	Europe (EU)	14	82,4	11	78,6	9,09	15,57
	Asia (AS)	24	61,5	24	100,0	4,17	11,26
Cycle 9 Day 1	America (AM)	18	81,8	18	100,0	1,85	7,86
	Europe (EU)	12	70,6	12	100,0	2,78	9,62
	Asia (AS)	21	53,8	21	100,0	6,35	13,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	18	81,8	17	94,4	5,88	17,62
	Europe (EU)	12	70,6	12	100,0	5,56	12,97
	Asia (AS)	21	53,8	21	100,0	6,35	13,41
Cycle 11 Day 1	America (AM)	18	81,8	18	100,0	1,85	7,86
	Europe (EU)	12	70,6	12	100,0	2,78	9,62
	Asia (AS)	20	51,3	20	100,0	8,33	14,81
Cycle 12 Day 1	America (AM)	18	81,8	17	94,4	0,00	0,00
	Europe (EU)	12	70,6	9	75,0	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	19	48,7	19	100,0	3,51	10,51
Cycle 13 Day 1	America (AM)	17	77,3	17	100,0	3,92	11,07
	Europe (EU)	11	64,7	10	90,9	3,33	10,54
	Asia (AS)	18	46,2	18	100,0	5,56	12,78
Cycle 14 Day 1	America (AM)	17	77,3	17	100,0	1,96	8,08
	Europe (EU)	11	64,7	11	100,0	3,03	10,05
	Asia (AS)	17	43,6	16	94,1	6,25	13,44
Cycle 15 Day 1	America (AM)	17	77,3	17	100,0	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	11	64,7	11	100,0	3,03	10,05
	Asia (AS)	16	41,0	16	100,0	4,17	11,39
Cycle 16 Day 1	America (AM)	14	63,6	14	100,0	0,00	0,00
	Europe (EU)	11	64,7	9	81,8	7,41	22,22
	Asia (AS)	16	41,0	16	100,0	4,17	11,39
Cycle 17 Day 1	America (AM)	14	63,6	14	100,0	0,00	0,00
	Europe (EU)	10	58,8	10	100,0	3,33	10,54
	Asia (AS)	15	38,5	15	100,0	4,44	11,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	63,6	14	100,0	2,38	8,91
	Europe (EU)	9	52,9	6	66,7	0,00	0,00
	Asia (AS)	15	38,5	15	100,0	6,67	13,80
Cycle 19 Day 1	America (AM)	13	59,1	13	100,0	2,56	9,25
	Europe (EU)	9	52,9	9	100,0	3,70	11,11
	Asia (AS)	14	35,9	11	78,6	0,00	0,00
Cycle 20 Day 1	America (AM)	13	59,1	13	100,0	2,56	9,25
	Europe (EU)	9	52,9	6	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	35,9	13	92,9	2,56	9,25
Cycle 21 Day 1	America (AM)	11	50,0	10	90,9	0,00	0,00
	Europe (EU)	7	41,2	6	85,7	5,56	13,61
	Asia (AS)	11	28,2	10	90,9	0,00	0,00
Cycle 22 Day 1	America (AM)	11	50,0	10	90,9	6,67	14,05
	Europe (EU)	7	41,2	5	71,4	0,00	0,00
	Asia (AS)	11	28,2	10	90,9	0,00	0,00
Cycle 23 Day 1	America (AM)	9	40,9	9	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	29,4	3	60,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	0,00	0,00
Cycle 24 Day 1	America (AM)	8	36,4	8	100,0	0,00	0,00
	Europe (EU)	5	29,4	4	80,0	0,00	0,00
	Asia (AS)	7	17,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	31,8	7	100,0	0,00	0,00
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	27,3	6	100,0	0,00	0,00
	Europe (EU)	4	23,5	2	50,0	0,00	0,00
	Asia (AS)	4	10,3	4	100,0	16,67	33,33
Cycle 27 Day 1	America (AM)	4	18,2	4	100,0	0,00	0,00
	Europe (EU)	3	17,6	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	0,00	0,00
Cycle 28 Day 1	America (AM)	4	18,2	4	100,0	0,00	0,00
	Europe (EU)	2	11,8	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	10,3	4	100,0	0,00	0,00
Cycle 29 Day 1	America (AM)	3	13,6	3	100,0	0,00	0,00
	Europe (EU)	2	11,8	0	0,0	-	-
	Asia (AS)	4	10,3	4	100,0	0,00	0,00
Cycle 30 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	0,00	0,00
Cycle 31 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	5,9	0	0,0	-	-
	Asia (AS)	4	10,3	3	75,0	22,22	38,49
Cycle 32 Day 1	America (AM)	2	9,1	2	100,0	0,00	0,00
	Europe (EU)	1	5,9	1	100,0	0,00	-
	Asia (AS)	3	7,7	2	66,7	0,00	0,00
Cycle 33 Day 1	America (AM)	1	4,5	1	100,0	0,00	-
	Europe (EU)	1	5,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	4,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	4,5	0	0,0	-	-
End Of Treatment	America (AM)	12	54,5	11	91,7	3,03	10,05
	Europe (EU)	6	35,3	4	66,7	8,33	16,67
	Asia (AS)	21	53,8	13	61,9	20,51	25,60
ECOG Performance Status							
Cycle 1 Day 1	0	30	100,0	29	96,7	4,60	11,70
	1	38	100,0	38	100,0	8,77	18,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	10	100,0	10	100,0	3,33	10,54
Cycle 2 Day 1	0	30	100,0	27	90,0	7,41	14,12
	1	36	94,7	32	88,9	5,21	12,30
	2	6	60,0	6	100,0	5,56	13,61
Cycle 3 Day 1	0	29	96,7	27	93,1	2,47	8,90
	1	34	89,5	31	91,2	6,45	13,39
	2	5	50,0	5	100,0	6,67	14,91
Cycle 4 Day 1	0	29	96,7	25	86,2	2,67	9,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	33	86,8	32	97,0	2,08	8,20
	2	5	50,0	4	80,0	8,33	16,67
Cycle 5 Day 1	0	29	96,7	29	100,0	2,30	8,60
	1	33	86,8	31	93,9	6,45	13,39
	2	3	30,0	3	100,0	11,11	19,25
Cycle 6 Day 1	0	29	96,7	28	96,6	3,57	10,50
	1	31	81,6	27	87,1	4,94	12,07
	2	3	30,0	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	29	96,7	28	96,6	2,38	8,74
	1	28	73,7	25	89,3	6,67	13,61
	2	3	30,0	3	100,0	0,00	0,00
Cycle 8 Day 1	0	28	93,3	26	92,9	2,56	9,06
	1	25	65,8	23	92,0	4,35	11,48
	2	3	30,0	3	100,0	11,11	19,25
Cycle 9 Day 1	0	26	86,7	26	100,0	3,85	10,86
	1	23	60,5	23	100,0	4,35	11,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	2	20,0	2	100,0	0,00	0,00
Cycle 10 Day 1	0	26	86,7	26	100,0	7,69	17,15
	1	23	60,5	22	95,7	4,55	11,71
	2	2	20,0	2	100,0	0,00	0,00
Cycle 11 Day 1	0	26	86,7	26	100,0	5,13	12,26
	1	22	57,9	22	100,0	4,55	11,71
	2	2	20,0	2	100,0	0,00	0,00
Cycle 12 Day 1	0	25	83,3	22	88,0	3,03	9,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	22	57,9	21	95,5	1,59	7,27
	2	2	20,0	2	100,0	0,00	0,00
Cycle 13 Day 1	0	25	83,3	24	96,0	4,17	11,26
	1	20	52,6	20	100,0	5,00	12,21
	2	1	10,0	1	100,0	0,00	-
Cycle 14 Day 1	0	25	83,3	24	96,0	2,78	9,41
	1	19	50,0	19	100,0	5,26	12,49
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	24	80,0	24	100,0	2,78	9,41
	1	19	50,0	19	100,0	3,51	10,51
	2	1	10,0	1	100,0	0,00	-
Cycle 16 Day 1	0	22	73,3	20	90,9	3,33	14,91
	1	18	47,4	18	100,0	3,70	10,78
	2	1	10,0	1	100,0	0,00	-
Cycle 17 Day 1	0	21	70,0	21	100,0	1,59	7,27
	1	17	44,7	17	100,0	3,92	11,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	10,0	1	100,0	0,00	-
Cycle 18 Day 1	0	21	70,0	18	85,7	1,85	7,86
	1	16	42,1	16	100,0	6,25	13,44
	2	1	10,0	1	100,0	0,00	-
Cycle 19 Day 1	0	20	66,7	19	95,0	3,51	10,51
	1	15	39,5	13	86,7	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 20 Day 1	0	20	66,7	17	85,0	3,92	11,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	39,5	14	93,3	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 21 Day 1	0	15	50,0	14	93,3	2,38	8,91
	1	13	34,2	11	84,6	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 22 Day 1	0	15	50,0	12	80,0	5,56	12,97
	1	13	34,2	12	92,3	0,00	0,00
	2	1	10,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	36,7	9	81,8	0,00	0,00
	1	9	23,7	8	88,9	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	0	10	33,3	9	90,0	0,00	0,00
	1	9	23,7	8	88,9	0,00	0,00
	2	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	0	8	26,7	6	75,0	0,00	0,00
	1	7	18,4	7	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	26,7	6	75,0	0,00	0,00
	1	6	15,8	6	100,0	11,11	27,22
Cycle 27 Day 1	0	6	20,0	3	50,0	0,00	0,00
	1	5	13,2	5	100,0	0,00	0,00
Cycle 28 Day 1	0	5	16,7	4	80,0	0,00	0,00
	1	5	13,2	5	100,0	0,00	0,00
Cycle 29 Day 1	0	4	13,3	2	50,0	0,00	0,00
	1	5	13,2	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	0,00	0,00
Cycle 31 Day 1	0	3	10,0	1	33,3	0,00	-
	1	4	10,5	4	100,0	16,67	33,33
Cycle 32 Day 1	0	3	10,0	2	66,7	0,00	0,00
	1	3	7,9	3	100,0	0,00	0,00
Cycle 33 Day 1	0	2	6,7	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	3,3	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	3,3	0	0,0	-	-
End Of Treatment	0	15	50,0	14	93,3	7,14	14,19
	1	20	52,6	12	60,0	16,67	26,59
	2	4	40,0	2	50,0	16,67	23,57
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	31	100,0	31	100,0	6,45	15,91
	1	3	100,0	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	44	100,0	43	97,7	6,98	15,53
Cycle 2 Day 1	None	30	96,8	27	90,0	7,41	14,12
	1	2	66,7	1	50,0	0,00	-
	2 or More	40	90,9	37	92,5	5,41	12,46
Cycle 3 Day 1	None	30	96,8	28	93,3	2,38	8,74
	1	2	66,7	1	50,0	0,00	-
	2 or More	36	81,8	34	94,4	6,86	13,68
Cycle 4 Day 1	None	30	96,8	28	93,3	2,38	8,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	35	79,5	31	88,6	3,23	10,02
Cycle 5 Day 1	None	30	96,8	30	100,0	1,11	6,09
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	33	75,0	31	93,9	8,60	14,83
Cycle 6 Day 1	None	29	93,5	26	89,7	0,00	0,00
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	32	72,7	29	90,6	8,05	14,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	27	87,1	25	92,6	1,33	6,67
	1	2	66,7	2	100,0	0,00	0,00
	2 or More	31	70,5	29	93,5	6,90	13,74
Cycle 8 Day 1	None	26	83,9	25	96,2	1,33	6,67
	1	2	66,7	0	0,0	-	-
	2 or More	28	63,6	27	96,4	6,17	13,19
Cycle 9 Day 1	None	25	80,6	25	100,0	1,33	6,67
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	25	56,8	25	100,0	6,67	13,61
Cycle 10 Day 1	None	25	80,6	24	96,0	4,17	14,95
	1	1	33,3	1	100,0	0,00	-
	2 or More	25	56,8	25	100,0	8,00	14,53
Cycle 11 Day 1	None	25	80,6	25	100,0	1,33	6,67
	1	1	33,3	1	100,0	0,00	-
	2 or More	24	54,5	24	100,0	8,33	14,74
Cycle 12 Day 1	None	25	80,6	24	96,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	23	52,3	20	87,0	5,00	12,21
Cycle 13 Day 1	None	24	77,4	23	95,8	2,90	9,60
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	21	100,0	6,35	13,41
Cycle 14 Day 1	None	23	74,2	23	100,0	1,45	6,95
	1	1	33,3	1	100,0	0,00	-
	2 or More	21	47,7	20	95,2	6,67	13,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	23	74,2	23	100,0	1,45	6,95
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	20	100,0	5,00	12,21
Cycle 16 Day 1	None	20	64,5	19	95,0	0,00	0,00
	1	1	33,3	1	100,0	0,00	-
	2 or More	20	45,5	19	95,0	7,02	17,84
Cycle 17 Day 1	None	19	61,3	19	100,0	0,00	0,00
	1	1	33,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	19	43,2	19	100,0	5,26	12,49
Cycle 18 Day 1	None	18	58,1	17	94,4	1,96	8,08
	1	1	33,3	1	100,0	0,00	-
	2 or More	19	43,2	17	89,5	5,88	13,10
Cycle 19 Day 1	None	17	54,8	17	100,0	1,96	8,08
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	2,22	8,61
Cycle 20 Day 1	None	17	54,8	16	94,1	4,17	11,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	33,3	1	100,0	0,00	-
	2 or More	18	40,9	15	83,3	0,00	0,00
Cycle 21 Day 1	None	15	48,4	13	86,7	0,00	0,00
	2 or More	14	31,8	13	92,9	2,56	9,25
Cycle 22 Day 1	None	15	48,4	13	86,7	2,56	9,25
	2 or More	14	31,8	12	85,7	2,78	9,62
Cycle 23 Day 1	None	10	32,3	9	90,0	0,00	0,00
	2 or More	11	25,0	9	81,8	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	32,3	10	100,0	0,00	0,00
	2 or More	10	22,7	8	80,0	0,00	0,00
Cycle 25 Day 1	None	9	29,0	8	88,9	0,00	0,00
	2 or More	6	13,6	5	83,3	0,00	0,00
Cycle 26 Day 1	None	8	25,8	8	100,0	8,33	23,57
	2 or More	6	13,6	4	66,7	0,00	0,00
Cycle 27 Day 1	None	7	22,6	6	85,7	0,00	0,00
	2 or More	4	9,1	2	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	22,6	7	100,0	0,00	0,00
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 29 Day 1	None	6	19,4	5	83,3	0,00	0,00
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	12,9	3	75,0	0,00	0,00
	2 or More	3	6,8	2	66,7	0,00	0,00
Cycle 31 Day 1	None	4	12,9	3	75,0	0,00	0,00
	2 or More	3	6,8	2	66,7	33,33	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	12,9	3	75,0	0,00	0,00
	2 or More	2	4,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	3,2	1	100,0	0,00	-
	2 or More	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	3,2	0	0,0	-	-
Cycle 35 Day 1	None	1	3,2	0	0,0	-	-
End Of Treatment	None	13	41,9	12	92,3	8,33	20,72
	1	2	66,7	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	24	54,5	15	62,5	15,56	21,33
Prior Treatment							
Cycle 1 Day 1	Naïve	31	100,0	31	100,0	6,45	15,91
	Previously Treated	47	100,0	46	97,9	6,52	15,10
Cycle 2 Day 1	Naïve	30	96,8	27	90,0	7,41	14,12
	Previously Treated	42	89,4	38	90,5	5,26	12,32
Cycle 3 Day 1	Naïve	30	96,8	28	93,3	2,38	8,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	38	80,9	35	92,1	6,67	13,53
Cycle 4 Day 1	Naïve	30	96,8	28	93,3	2,38	8,74
	Previously Treated	37	78,7	33	89,2	3,03	9,73
Cycle 5 Day 1	Naïve	30	96,8	30	100,0	1,11	6,09
	Previously Treated	35	74,5	33	94,3	8,08	14,51
Cycle 6 Day 1	Naïve	29	93,5	26	89,7	0,00	0,00
	Previously Treated	34	72,3	31	91,2	7,53	14,17
Cycle 7 Day 1	Naïve	27	87,1	25	92,6	1,33	6,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	33	70,2	31	93,9	6,45	13,39
Cycle 8 Day 1	Naïve	26	83,9	25	96,2	1,33	6,67
	Previously Treated	30	63,8	27	90,0	6,17	13,19
Cycle 9 Day 1	Naïve	25	80,6	25	100,0	1,33	6,67
	Previously Treated	26	55,3	26	100,0	6,41	13,40
Cycle 10 Day 1	Naïve	25	80,6	24	96,0	4,17	14,95
	Previously Treated	26	55,3	26	100,0	7,69	14,32
Cycle 11 Day 1	Naïve	25	80,6	25	100,0	1,33	6,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	25	53,2	25	100,0	8,00	14,53
Cycle 12 Day 1	Naïve	25	80,6	24	96,0	0,00	0,00
	Previously Treated	24	51,1	21	87,5	4,76	11,95
Cycle 13 Day 1	Naïve	24	77,4	23	95,8	2,90	9,60
	Previously Treated	22	46,8	22	100,0	6,06	13,16
Cycle 14 Day 1	Naïve	23	74,2	23	100,0	1,45	6,95
	Previously Treated	22	46,8	21	95,5	6,35	13,41
Cycle 15 Day 1	Naïve	23	74,2	23	100,0	1,45	6,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	21	44,7	21	100,0	4,76	11,95
Cycle 16 Day 1	Naïve	20	64,5	19	95,0	0,00	0,00
	Previously Treated	21	44,7	20	95,2	6,67	17,44
Cycle 17 Day 1	Naïve	19	61,3	19	100,0	0,00	0,00
	Previously Treated	20	42,6	20	100,0	5,00	12,21
Cycle 18 Day 1	Naïve	18	58,1	17	94,4	1,96	8,08
	Previously Treated	20	42,6	18	90,0	5,56	12,78
Cycle 19 Day 1	Naïve	17	54,8	17	100,0	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	40,4	16	84,2	2,08	8,33
Cycle 20 Day 1	Naïve	17	54,8	16	94,1	4,17	11,39
	Previously Treated	19	40,4	16	84,2	0,00	0,00
Cycle 21 Day 1	Naïve	15	48,4	13	86,7	0,00	0,00
	Previously Treated	14	29,8	13	92,9	2,56	9,25
Cycle 22 Day 1	Naïve	15	48,4	13	86,7	2,56	9,25
	Previously Treated	14	29,8	12	85,7	2,78	9,62
Cycle 23 Day 1	Naïve	10	32,3	9	90,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	23,4	9	81,8	0,00	0,00
Cycle 24 Day 1	Naïve	10	32,3	10	100,0	0,00	0,00
	Previously Treated	10	21,3	8	80,0	0,00	0,00
Cycle 25 Day 1	Naïve	9	29,0	8	88,9	0,00	0,00
	Previously Treated	6	12,8	5	83,3	0,00	0,00
Cycle 26 Day 1	Naïve	8	25,8	8	100,0	8,33	23,57
	Previously Treated	6	12,8	4	66,7	0,00	0,00
Cycle 27 Day 1	Naïve	7	22,6	6	85,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	8,5	2	50,0	0,00	0,00
Cycle 28 Day 1	Naïve	7	22,6	7	100,0	0,00	0,00
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 29 Day 1	Naïve	6	19,4	5	83,3	0,00	0,00
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	12,9	3	75,0	0,00	0,00
	Previously Treated	3	6,4	2	66,7	0,00	0,00
Cycle 31 Day 1	Naïve	4	12,9	3	75,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	6,4	2	66,7	33,33	47,14
Cycle 32 Day 1	Naïve	4	12,9	3	75,0	0,00	0,00
	Previously Treated	2	4,3	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	3,2	1	100,0	0,00	-
	Previously Treated	1	2,1	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	3,2	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	3,2	0	0,0	-	-
End Of Treatment	Naïve	13	41,9	12	92,3	8,33	20,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	26	55,3	16	61,5	14,58	20,97
Molecular Testing Results							
Cycle 1 Day 1	Local	35	100,0	35	100,0	4,76	11,83
	Central	43	100,0	42	97,7	7,94	17,74
Cycle 2 Day 1	Local	32	91,4	30	93,8	6,67	13,56
	Central	40	93,0	35	87,5	5,71	12,75
Cycle 3 Day 1	Local	29	82,9	27	93,1	2,47	8,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	39	90,7	36	92,3	6,48	13,38
Cycle 4 Day 1	Local	28	80,0	24	85,7	1,39	6,80
	Central	39	90,7	37	94,9	3,60	10,49
Cycle 5 Day 1	Local	27	77,1	27	100,0	4,94	12,07
	Central	38	88,4	36	94,7	4,63	11,69
Cycle 6 Day 1	Local	27	77,1	27	100,0	3,70	10,68
	Central	36	83,7	30	83,3	4,44	11,52
Cycle 7 Day 1	Local	27	77,1	27	100,0	3,70	10,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	33	76,7	29	87,9	4,60	11,70
Cycle 8 Day 1	Local	26	74,3	26	100,0	2,56	9,06
	Central	30	69,8	26	86,7	5,13	12,26
Cycle 9 Day 1	Local	25	71,4	25	100,0	4,00	11,06
	Central	26	60,5	26	100,0	3,85	10,86
Cycle 10 Day 1	Local	25	71,4	24	96,0	6,94	16,97
	Central	26	60,5	26	100,0	5,13	12,26
Cycle 11 Day 1	Local	24	68,6	24	100,0	4,17	11,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	26	60,5	26	100,0	5,13	12,26
Cycle 12 Day 1	Local	23	65,7	22	95,7	3,03	9,81
	Central	26	60,5	23	88,5	1,45	6,95
Cycle 13 Day 1	Local	22	62,9	22	100,0	6,06	13,16
	Central	24	55,8	23	95,8	2,90	9,60
Cycle 14 Day 1	Local	22	62,9	22	100,0	6,06	13,16
	Central	23	53,5	22	95,7	1,52	7,11
Cycle 15 Day 1	Local	22	62,9	22	100,0	4,55	11,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	22	51,2	22	100,0	1,52	7,11
Cycle 16 Day 1	Local	20	57,1	20	100,0	1,67	7,45
	Central	21	48,8	19	90,5	5,26	16,72
Cycle 17 Day 1	Local	20	57,1	20	100,0	1,67	7,45
	Central	19	44,2	19	100,0	3,51	10,51
Cycle 18 Day 1	Local	20	57,1	19	95,0	5,26	12,49
	Central	18	41,9	16	88,9	2,08	8,33
Cycle 19 Day 1	Local	19	54,3	17	89,5	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	39,5	16	94,1	2,08	8,33
Cycle 20 Day 1	Local	19	54,3	17	89,5	1,96	8,08
	Central	17	39,5	15	88,2	2,22	8,61
Cycle 21 Day 1	Local	14	40,0	12	85,7	0,00	0,00
	Central	15	34,9	14	93,3	2,38	8,91
Cycle 22 Day 1	Local	14	40,0	12	85,7	2,78	9,62
	Central	15	34,9	13	86,7	2,56	9,25
Cycle 23 Day 1	Local	11	31,4	10	90,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	23,3	8	80,0	0,00	0,00
Cycle 24 Day 1	Local	11	31,4	10	90,9	0,00	0,00
	Central	9	20,9	8	88,9	0,00	0,00
Cycle 25 Day 1	Local	7	20,0	7	100,0	0,00	0,00
	Central	8	18,6	6	75,0	0,00	0,00
Cycle 26 Day 1	Local	6	17,1	6	100,0	11,11	27,22
	Central	8	18,6	6	75,0	0,00	0,00
Cycle 27 Day 1	Local	4	11,4	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	16,3	4	57,1	0,00	0,00
Cycle 28 Day 1	Local	4	11,4	4	100,0	0,00	0,00
	Central	6	14,0	5	83,3	0,00	0,00
Cycle 29 Day 1	Local	3	8,6	3	100,0	0,00	0,00
	Central	6	14,0	4	66,7	0,00	0,00
Cycle 30 Day 1	Local	3	8,6	3	100,0	0,00	0,00
	Central	4	9,3	2	50,0	0,00	0,00
Cycle 31 Day 1	Local	3	8,6	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	9,3	2	50,0	33,33	47,14
Cycle 32 Day 1	Local	3	8,6	3	100,0	0,00	0,00
	Central	3	7,0	2	66,7	0,00	0,00
Cycle 33 Day 1	Local	1	2,9	1	100,0	0,00	-
	Central	1	2,3	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	2,9	0	0,0	-	-
Cycle 35 Day 1	Local	1	2,9	0	0,0	-	-
End Of Treatment	Local	18	51,4	14	77,8	14,29	21,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	21	48,8	14	66,7	9,52	20,37
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	74	100,0	73	98,6	6,85	15,67
	No	4	100,0	4	100,0	0,00	0,00
Cycle 2 Day 1	Yes	70	94,6	63	90,0	6,35	13,19
	No	2	50,0	2	100,0	0,00	0,00
Cycle 3 Day 1	Yes	66	89,2	61	92,4	4,92	11,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 4 Day 1	Yes	65	87,8	59	90,8	2,82	9,36
	No	2	50,0	2	100,0	0,00	0,00
Cycle 5 Day 1	Yes	63	85,1	61	96,8	4,92	11,92
	No	2	50,0	2	100,0	0,00	0,00
Cycle 6 Day 1	Yes	61	82,4	55	90,2	4,24	11,21
	No	2	50,0	2	100,0	0,00	0,00
Cycle 7 Day 1	Yes	58	78,4	54	93,1	4,32	11,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 8 Day 1	Yes	54	73,0	50	92,6	4,00	10,94
	No	2	50,0	2	100,0	0,00	0,00
Cycle 9 Day 1	Yes	49	66,2	49	100,0	4,08	11,04
	No	2	50,0	2	100,0	0,00	0,00
Cycle 10 Day 1	Yes	49	66,2	48	98,0	6,25	14,84
	No	2	50,0	2	100,0	0,00	0,00
Cycle 11 Day 1	Yes	48	64,9	48	100,0	4,86	11,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 12 Day 1	Yes	47	63,5	43	91,5	2,33	8,59
	No	2	50,0	2	100,0	0,00	0,00
Cycle 13 Day 1	Yes	44	59,5	43	97,7	4,65	11,69
	No	2	50,0	2	100,0	0,00	0,00
Cycle 14 Day 1	Yes	43	58,1	42	97,7	3,97	10,93
	No	2	50,0	2	100,0	0,00	0,00
Cycle 15 Day 1	Yes	42	56,8	42	100,0	3,17	9,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	2	100,0	0,00	0,00
Cycle 16 Day 1	Yes	39	52,7	37	94,9	3,60	13,11
	No	2	50,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	37	50,0	37	100,0	2,70	9,22
	No	2	50,0	2	100,0	0,00	0,00
Cycle 18 Day 1	Yes	36	48,6	33	91,7	4,04	11,05
	No	2	50,0	2	100,0	0,00	0,00
Cycle 19 Day 1	Yes	34	45,9	32	94,1	2,08	8,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	50,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	45,9	30	88,2	2,22	8,46
	No	2	50,0	2	100,0	0,00	0,00
Cycle 21 Day 1	Yes	27	36,5	24	88,9	1,39	6,80
	No	2	50,0	2	100,0	0,00	0,00
Cycle 22 Day 1	Yes	27	36,5	23	85,2	2,90	9,60
	No	2	50,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	27,0	17	85,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	25,7	17	89,5	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	18,9	12	85,7	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	17,6	11	84,6	0,00	0,00
	No	1	25,0	1	100,0	66,67	-
Cycle 27 Day 1	Yes	10	13,5	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 28 Day 1	Yes	9	12,2	8	88,9	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 29 Day 1	Yes	8	10,8	6	75,0	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	8,1	4	66,7	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 31 Day 1	Yes	6	8,1	4	66,7	16,67	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	25,0	1	100,0	0,00	-
Cycle 32 Day 1	Yes	5	6,8	4	80,0	0,00	0,00
	No	1	25,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	2,7	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	1,4	0	0,0	-	-
Cycle 35 Day 1	Yes	1	1,4	0	0,0	-	-
End Of Treatment	Yes	38	51,4	28	73,7	11,90	20,72
	No	1	25,0	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	8	100,0	8	100,0	4,17	11,79
	No	70	100,0	69	98,6	6,76	15,74
Cycle 2 Day 1	Yes	5	62,5	5	100,0	6,67	14,91
	No	67	95,7	60	89,6	6,11	13,01
Cycle 3 Day 1	Yes	5	62,5	4	80,0	0,00	0,00
	No	63	90,0	59	93,7	5,08	12,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	62	88,6	56	90,3	2,98	9,59
Cycle 5 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	60	85,7	58	96,7	5,17	12,17
Cycle 6 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	58	82,9	52	89,7	4,49	11,49
Cycle 7 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	55	78,6	51	92,7	4,58	11,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	5	62,5	5	100,0	0,00	0,00
	No	51	72,9	47	92,2	4,26	11,24
Cycle 9 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	47	67,1	47	100,0	4,26	11,24
Cycle 10 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	47	67,1	46	97,9	6,52	15,10
Cycle 11 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	46	65,7	46	100,0	5,07	12,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	45	64,3	41	91,1	2,44	8,79
Cycle 13 Day 1	Yes	4	50,0	4	100,0	8,33	16,67
	No	42	60,0	41	97,6	4,07	11,04
Cycle 14 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	41	58,6	40	97,6	4,17	11,16
Cycle 15 Day 1	Yes	4	50,0	4	100,0	0,00	0,00
	No	40	57,1	40	100,0	3,33	10,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	38	54,3	36	94,7	3,70	13,28
Cycle 17 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	36	51,4	36	100,0	2,78	9,34
Cycle 18 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	35	50,0	32	91,4	4,17	11,20
Cycle 19 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	30	90,9	2,22	8,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	37,5	3	100,0	0,00	0,00
	No	33	47,1	29	87,9	2,30	8,60
Cycle 21 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	24	88,9	1,39	6,80
Cycle 22 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	27	38,6	23	85,2	2,90	9,60
Cycle 23 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	19	27,1	16	84,2	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	18	25,7	16	88,9	0,00	0,00
Cycle 25 Day 1	Yes	2	25,0	2	100,0	0,00	0,00
	No	13	18,6	11	84,6	0,00	0,00
Cycle 26 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	13	18,6	11	84,6	6,06	20,10
Cycle 27 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	10	14,3	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	9	12,9	8	88,9	0,00	0,00
Cycle 29 Day 1	Yes	1	12,5	1	100,0	0,00	-
	No	8	11,4	6	75,0	0,00	0,00
Cycle 30 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	0,00	0,00
Cycle 31 Day 1	Yes	1	12,5	0	0,0	-	-
	No	6	8,6	5	83,3	13,33	29,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	12,5	0	0,0	-	-
	No	5	7,1	5	100,0	0,00	0,00
Cycle 33 Day 1	No	2	2,9	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	1,4	0	0,0	-	-
Cycle 35 Day 1	No	1	1,4	0	0,0	-	-
End Of Treatment	Yes	2	25,0	2	100,0	0,00	0,00
	No	37	52,9	26	70,3	12,82	21,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D180_REE_LC13SM_SG.xls
28NOV2019 11:05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	140	96,6	38,57	27,20
Cycle 2 Day 1	All	136	93,8	124	91,2	23,66	21,99
Cycle 3 Day 1	All	131	90,3	116	88,5	17,82	20,35
Cycle 4 Day 1	All	128	88,3	116	90,6	16,95	20,38
Cycle 5 Day 1	All	124	85,5	115	92,7	18,84	19,31
Cycle 6 Day 1	All	121	83,4	108	89,3	18,52	18,97
Cycle 7 Day 1	All	113	77,9	103	91,2	18,45	22,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	106	73,1	96	90,6	18,75	21,53
Cycle 9 Day 1	All	98	67,6	95	96,9	17,54	23,24
Cycle 10 Day 1	All	89	61,4	86	96,6	21,71	24,93
Cycle 11 Day 1	All	80	55,2	76	95,0	17,54	20,71
Cycle 12 Day 1	All	76	52,4	68	89,5	16,67	18,66
Cycle 13 Day 1	All	66	45,5	60	90,9	16,11	22,54
Cycle 14 Day 1	All	60	41,4	56	93,3	17,86	19,03
Cycle 15 Day 1	All	57	39,3	53	93,0	16,35	19,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	50	34,5	47	94,0	19,15	21,70
Cycle 17 Day 1	All	45	31,0	44	97,8	13,64	16,58
Cycle 18 Day 1	All	41	28,3	37	90,2	11,71	17,94
Cycle 19 Day 1	All	36	24,8	33	91,7	14,14	18,69
Cycle 20 Day 1	All	36	24,8	32	88,9	14,58	16,80
Cycle 21 Day 1	All	29	20,0	26	89,7	11,54	16,17
Cycle 22 Day 1	All	29	20,0	25	86,2	8,00	14,53
Cycle 23 Day 1	All	21	14,5	18	85,7	7,41	14,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	13,8	18	90,0	11,11	25,57
Cycle 25 Day 1	All	15	10,3	13	86,7	10,26	16,01
Cycle 26 Day 1	All	14	9,7	12	85,7	13,89	22,29
Cycle 27 Day 1	All	11	7,6	8	72,7	12,50	17,25
Cycle 28 Day 1	All	10	6,9	9	90,0	29,63	35,14
Cycle 29 Day 1	All	9	6,2	7	77,8	19,05	17,82
Cycle 30 Day 1	All	7	4,8	5	71,4	13,33	18,26
Cycle 31 Day 1	All	7	4,8	5	71,4	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	4,1	5	83,3	20,00	18,26
Cycle 33 Day 1	All	2	1,4	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	34,09	26,40
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	39,22	28,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	93	100,0	89	95,7	38,20	26,38
Cycle 2 Day 1	Male	50	96,2	46	92,0	25,36	23,50
	Female	86	92,5	78	90,7	22,65	21,15
Cycle 3 Day 1	Male	47	90,4	43	91,5	19,38	23,27
	Female	84	90,3	73	86,9	16,89	18,53
Cycle 4 Day 1	Male	46	88,5	43	93,5	22,48	22,68
	Female	82	88,2	73	89,0	13,70	18,29
Cycle 5 Day 1	Male	45	86,5	42	93,3	22,22	21,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	79	84,9	73	92,4	16,89	17,68
Cycle 6 Day 1	Male	45	86,5	41	91,1	20,33	19,55
	Female	76	81,7	67	88,2	17,41	18,68
Cycle 7 Day 1	Male	40	76,9	39	97,5	19,66	23,84
	Female	73	78,5	64	87,7	17,71	22,20
Cycle 8 Day 1	Male	37	71,2	34	91,9	20,59	25,97
	Female	69	74,2	62	89,9	17,74	18,82
Cycle 9 Day 1	Male	33	63,5	33	100,0	12,12	20,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	62	95,4	20,43	24,41
Cycle 10 Day 1	Male	30	57,7	30	100,0	24,44	27,59
	Female	59	63,4	56	94,9	20,24	23,51
Cycle 11 Day 1	Male	29	55,8	28	96,6	17,86	21,24
	Female	51	54,8	48	94,1	17,36	20,62
Cycle 12 Day 1	Male	27	51,9	26	96,3	17,95	21,56
	Female	49	52,7	42	85,7	15,87	16,85
Cycle 13 Day 1	Male	25	48,1	23	92,0	20,29	26,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	41	44,1	37	90,2	13,51	19,97
Cycle 14 Day 1	Male	23	44,2	21	91,3	19,05	16,90
	Female	37	39,8	35	94,6	17,14	20,41
Cycle 15 Day 1	Male	21	40,4	20	95,2	20,00	22,69
	Female	36	38,7	33	91,7	14,14	16,73
Cycle 16 Day 1	Male	16	30,8	16	100,0	22,92	26,44
	Female	34	36,6	31	91,2	17,20	19,00
Cycle 17 Day 1	Male	13	25,0	13	100,0	12,82	16,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	32	34,4	31	96,9	13,98	16,72
Cycle 18 Day 1	Male	12	23,1	11	91,7	15,15	22,92
	Female	29	31,2	26	89,7	10,26	15,69
Cycle 19 Day 1	Male	10	19,2	10	100,0	13,33	17,21
	Female	26	28,0	23	88,5	14,49	19,66
Cycle 20 Day 1	Male	10	19,2	9	90,0	14,81	17,57
	Female	26	28,0	23	88,5	14,49	16,90
Cycle 21 Day 1	Male	8	15,4	8	100,0	12,50	17,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	22,6	18	85,7	11,11	16,17
Cycle 22 Day 1	Male	8	15,4	6	75,0	5,56	13,61
	Female	21	22,6	19	90,5	8,77	15,08
Cycle 23 Day 1	Male	5	9,6	4	80,0	0,00	0,00
	Female	16	17,2	14	87,5	9,52	15,63
Cycle 24 Day 1	Male	5	9,6	4	80,0	8,33	16,67
	Female	15	16,1	14	93,3	11,90	28,06
Cycle 25 Day 1	Male	3	5,8	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	12,9	11	91,7	12,12	16,82
Cycle 26 Day 1	Male	3	5,8	2	66,7	16,67	23,57
	Female	11	11,8	10	90,9	13,33	23,31
Cycle 27 Day 1	Male	3	5,8	2	66,7	16,67	23,57
	Female	8	8,6	6	75,0	11,11	17,21
Cycle 28 Day 1	Male	2	3,8	2	100,0	16,67	23,57
	Female	8	8,6	7	87,5	33,33	38,49
Cycle 29 Day 1	Male	1	1,9	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	8,6	6	75,0	16,67	18,26
Cycle 30 Day 1	Male	1	1,9	1	100,0	33,33	-
	Female	6	6,5	4	66,7	8,33	16,67
Cycle 31 Day 1	Male	1	1,9	1	100,0	66,67	-
	Female	6	6,5	4	66,7	25,00	16,67
Cycle 32 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	5	5,4	4	80,0	25,00	16,67
Cycle 33 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	1,1	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	39,68	27,12
	Female	37	39,8	23	62,2	28,99	25,23
Age							
Cycle 1 Day 1	18-64	109	100,0	104	95,4	39,10	28,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	36,78	25,73
	>=75	7	100,0	7	100,0	38,10	23,00
Cycle 2 Day 1	18-64	103	94,5	91	88,3	24,18	21,70
	65-74	26	89,7	26	100,0	19,23	19,26
	>=75	7	100,0	7	100,0	33,33	33,33
Cycle 3 Day 1	18-64	99	90,8	87	87,9	17,24	20,25
	65-74	25	86,2	23	92,0	18,84	22,08
	>=75	7	100,0	6	85,7	22,22	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	98	89,9	88	89,8	17,05	21,44
	65-74	23	79,3	21	91,3	15,87	17,06
	>=75	7	100,0	7	100,0	19,05	17,82
Cycle 5 Day 1	18-64	95	87,2	88	92,6	18,18	18,85
	65-74	22	75,9	22	100,0	21,21	21,93
	>=75	7	100,0	5	71,4	20,00	18,26
Cycle 6 Day 1	18-64	92	84,4	80	87,0	18,33	19,77
	65-74	22	75,9	21	95,5	19,05	16,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	19,05	17,82
Cycle 7 Day 1	18-64	86	78,9	78	90,7	18,38	23,20
	65-74	20	69,0	19	95,0	19,30	23,08
	>=75	7	100,0	6	85,7	16,67	18,26
Cycle 8 Day 1	18-64	80	73,4	71	88,8	18,31	22,39
	65-74	19	65,5	19	100,0	19,30	20,23
	>=75	7	100,0	6	85,7	22,22	17,21
Cycle 9 Day 1	18-64	74	67,9	72	97,3	18,06	23,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	18	62,1	18	100,0	16,67	26,20
	>=75	6	85,7	5	83,3	13,33	18,26
Cycle 10 Day 1	18-64	69	63,3	66	95,7	21,21	24,56
	65-74	15	51,7	15	100,0	26,67	28,73
	>=75	5	71,4	5	100,0	13,33	18,26
Cycle 11 Day 1	18-64	61	56,0	58	95,1	17,24	20,93
	65-74	15	51,7	14	93,3	19,05	21,54
	>=75	4	57,1	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	57	52,3	50	87,7	16,00	18,12
	65-74	15	51,7	14	93,3	19,05	21,54
	>=75	4	57,1	4	100,0	16,67	19,25
Cycle 13 Day 1	18-64	49	45,0	45	91,8	13,33	21,79
	65-74	13	44,8	11	84,6	27,27	25,03
	>=75	4	57,1	4	100,0	16,67	19,25
Cycle 14 Day 1	18-64	45	41,3	43	95,6	13,95	16,64
	65-74	13	44,8	11	84,6	30,30	23,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	28,6	2	100,0	33,33	0,00
Cycle 15 Day 1	18-64	43	39,4	40	93,0	14,17	18,32
	65-74	12	41,4	11	91,7	24,24	21,56
	>=75	2	28,6	2	100,0	16,67	23,57
Cycle 16 Day 1	18-64	38	34,9	36	94,7	15,74	20,29
	65-74	10	34,5	9	90,0	25,93	22,22
	>=75	2	28,6	2	100,0	50,00	23,57
Cycle 17 Day 1	18-64	36	33,0	35	97,2	13,33	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	27,6	8	100,0	16,67	17,82
	>=75	1	14,3	1	100,0	0,00	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	11,11	18,22
	65-74	7	24,1	6	85,7	16,67	18,26
	>=75	1	14,3	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	14,29	19,09
	65-74	5	17,2	4	80,0	16,67	19,25
	>=75	1	14,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	14,10	16,79
	65-74	5	17,2	5	100,0	20,00	18,26
	>=75	1	14,3	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	9,52	15,43
	65-74	4	13,8	4	100,0	25,00	16,67
	>=75	1	14,3	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	6,67	13,68
	65-74	4	13,8	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	8,33	14,91
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	10,42	26,44
	65-74	2	6,9	2	100,0	16,67	23,57
Cycle 25 Day 1	18-64	14	12,8	12	85,7	11,11	16,41
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	13,89	22,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	12,50	17,25
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	29,63	35,14
	65-74	1	3,4	0	0,0	-	-
Cycle 29 Day 1	18-64	8	7,3	7	87,5	19,05	17,82
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	33,33	23,57
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	16,67	19,25
	65-74	1	3,4	1	100,0	33,33	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	0,00	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	34,31	27,81
	65-74	15	51,7	8	53,3	37,50	21,36
	>=75	4	57,1	2	50,0	16,67	23,57
Race							
Cycle 1 Day 1	White	60	100,0	57	95,0	45,03	29,20
	Other	85	100,0	83	97,6	34,14	24,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	57	95,0	50	87,7	29,33	24,87
	Other	79	92,9	74	93,7	19,82	19,05
Cycle 3 Day 1	White	54	90,0	44	81,5	21,21	22,84
	Other	77	90,6	72	93,5	15,74	18,53
Cycle 4 Day 1	White	53	88,3	45	84,9	17,78	18,26
	Other	75	88,2	71	94,7	16,43	21,73
Cycle 5 Day 1	White	52	86,7	47	90,4	20,57	20,33
	Other	72	84,7	68	94,4	17,65	18,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	50	83,3	41	82,0	18,70	18,33
	Other	71	83,5	67	94,4	18,41	19,49
Cycle 7 Day 1	White	47	78,3	40	85,1	20,83	26,89
	Other	66	77,6	63	95,5	16,93	19,74
Cycle 8 Day 1	White	45	75,0	38	84,4	21,05	22,49
	Other	61	71,8	58	95,1	17,24	20,93
Cycle 9 Day 1	White	42	70,0	41	97,6	18,70	22,42
	Other	56	65,9	54	96,4	16,67	24,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	20,51	22,45
	Other	48	56,5	47	97,9	22,70	27,01
Cycle 11 Day 1	White	37	61,7	36	97,3	16,67	20,31
	Other	43	50,6	40	93,0	18,33	21,28
Cycle 12 Day 1	White	37	61,7	33	89,2	17,17	20,62
	Other	39	45,9	35	89,7	16,19	16,90
Cycle 13 Day 1	White	32	53,3	30	93,8	14,44	18,94
	Other	34	40,0	30	88,2	17,78	25,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	31	51,7	30	96,8	15,56	19,04
	Other	29	34,1	26	89,7	20,51	19,04
Cycle 15 Day 1	White	30	50,0	28	93,3	16,67	21,28
	Other	27	31,8	25	92,6	16,00	17,00
Cycle 16 Day 1	White	26	43,3	24	92,3	20,83	25,66
	Other	24	28,2	23	95,8	17,39	17,03
Cycle 17 Day 1	White	24	40,0	24	100,0	16,67	17,03
	Other	21	24,7	20	95,2	10,00	15,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	22	36,7	19	86,4	8,77	18,73
	Other	19	22,4	18	94,7	14,81	17,04
Cycle 19 Day 1	White	20	33,3	20	100,0	18,33	20,16
	Other	16	18,8	13	81,3	7,69	14,62
Cycle 20 Day 1	White	20	33,3	17	85,0	15,69	17,15
	Other	16	18,8	15	93,8	13,33	16,90
Cycle 21 Day 1	White	16	26,7	14	87,5	14,29	17,12
	Other	13	15,3	12	92,3	8,33	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	26,7	13	81,3	10,26	16,01
	Other	13	15,3	12	92,3	5,56	12,97
Cycle 23 Day 1	White	12	20,0	10	83,3	13,33	17,21
	Other	9	10,6	8	88,9	0,00	0,00
Cycle 24 Day 1	White	11	18,3	10	90,9	16,67	32,39
	Other	9	10,6	8	88,9	4,17	11,79
Cycle 25 Day 1	White	10	16,7	8	80,0	12,50	17,25
	Other	5	5,9	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	16,7	8	80,0	16,67	25,20
	Other	4	4,7	4	100,0	8,33	16,67
Cycle 27 Day 1	White	8	13,3	5	62,5	13,33	18,26
	Other	3	3,5	3	100,0	11,11	19,25
Cycle 28 Day 1	White	7	11,7	6	85,7	16,67	18,26
	Other	3	3,5	3	100,0	55,56	50,92
Cycle 29 Day 1	White	6	10,0	4	66,7	33,33	0,00
	Other	3	3,5	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	6,7	2	50,0	33,33	0,00
	Other	3	3,5	3	100,0	0,00	0,00
Cycle 31 Day 1	White	4	6,7	2	50,0	50,00	23,57
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 32 Day 1	White	4	6,7	3	75,0	22,22	19,25
	Other	2	2,4	2	100,0	16,67	23,57
Cycle 33 Day 1	White	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-
End Of Treatment	White	25	41,7	17	68,0	39,22	24,25
	Other	39	45,9	27	69,2	30,86	27,62
Region							
Cycle 1 Day 1	America (AM)	40	100,0	38	95,0	47,37	25,27
	Europe (EU)	34	100,0	31	91,2	40,86	35,18
	Asia (AS)	71	100,0	71	100,0	32,86	22,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	31,25	22,30
	Europe (EU)	32	94,1	27	84,4	23,46	25,84
	Asia (AS)	66	93,0	65	98,5	20,00	19,36
Cycle 3 Day 1	America (AM)	37	92,5	32	86,5	21,88	20,05
	Europe (EU)	31	91,2	21	67,7	14,29	16,90
	Asia (AS)	63	88,7	63	100,0	16,93	21,48
Cycle 4 Day 1	America (AM)	37	92,5	32	86,5	21,88	18,18
	Europe (EU)	30	88,2	24	80,0	12,50	16,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	61	85,9	60	98,4	16,11	22,54
Cycle 5 Day 1	America (AM)	37	92,5	33	89,2	23,23	19,52
	Europe (EU)	30	88,2	25	83,3	16,00	19,53
	Asia (AS)	57	80,3	57	100,0	17,54	19,01
Cycle 6 Day 1	America (AM)	37	92,5	32	86,5	23,96	19,37
	Europe (EU)	28	82,4	24	85,7	15,28	16,97
	Asia (AS)	56	78,9	52	92,9	16,67	19,25
Cycle 7 Day 1	America (AM)	35	87,5	29	82,9	26,44	27,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	28	82,4	25	89,3	12,00	18,95
	Asia (AS)	50	70,4	49	98,0	17,01	20,55
Cycle 8 Day 1	America (AM)	31	77,5	26	83,9	21,79	22,98
	Europe (EU)	28	82,4	23	82,1	18,84	24,26
	Asia (AS)	47	66,2	47	100,0	17,02	19,50
Cycle 9 Day 1	America (AM)	29	72,5	27	93,1	18,52	25,04
	Europe (EU)	26	76,5	25	96,2	17,33	23,80
	Asia (AS)	43	60,6	43	100,0	17,05	22,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	16,67	19,66
	Europe (EU)	25	73,5	25	100,0	26,67	31,91
	Asia (AS)	37	52,1	37	100,0	21,62	22,52
Cycle 11 Day 1	America (AM)	24	60,0	21	87,5	17,46	22,65
	Europe (EU)	23	67,6	22	95,7	13,64	16,77
	Asia (AS)	33	46,5	33	100,0	20,20	21,95
Cycle 12 Day 1	America (AM)	24	60,0	22	91,7	18,18	19,86
	Europe (EU)	23	67,6	18	78,3	16,67	17,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	40,8	28	96,6	15,48	19,21
Cycle 13 Day 1	America (AM)	23	57,5	21	91,3	12,70	19,65
	Europe (EU)	18	52,9	14	77,8	23,81	30,46
	Asia (AS)	25	35,2	25	100,0	14,67	19,44
Cycle 14 Day 1	America (AM)	22	55,0	20	90,9	20,00	16,75
	Europe (EU)	17	50,0	16	94,1	14,58	20,97
	Asia (AS)	21	29,6	20	95,2	18,33	20,16
Cycle 15 Day 1	America (AM)	22	55,0	19	86,4	15,79	20,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	44,1	14	93,3	11,90	16,57
	Asia (AS)	20	28,2	20	100,0	20,00	19,94
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	13,73	20,61
	Europe (EU)	14	41,2	11	78,6	24,24	21,56
	Asia (AS)	19	26,8	19	100,0	21,05	22,80
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	14,58	17,08
	Europe (EU)	13	38,2	12	92,3	11,11	16,41
	Asia (AS)	16	22,5	16	100,0	14,58	17,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	16,67	21,68
	Europe (EU)	11	32,4	7	63,6	4,76	12,60
	Asia (AS)	16	22,5	16	100,0	10,42	15,96
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	15,38	17,30
	Europe (EU)	9	26,5	9	100,0	22,22	23,57
	Asia (AS)	14	19,7	11	78,6	6,06	13,48
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	17,95	17,30
	Europe (EU)	9	26,5	6	66,7	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	12,82	16,88
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	16,67	17,57
	Europe (EU)	7	20,6	6	85,7	16,67	18,26
	Asia (AS)	11	15,5	10	90,9	3,33	10,54
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	13,33	17,21
	Europe (EU)	7	20,6	5	71,4	13,33	18,26
	Asia (AS)	11	15,5	10	90,9	0,00	0,00
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	14,81	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	14,7	3	60,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	0,00	0,00
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	12,50	17,25
	Europe (EU)	5	14,7	4	80,0	25,00	50,00
	Asia (AS)	7	9,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	14,29	17,82
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	22,22	27,22
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	8,33	16,67
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	16,67	19,25
	Europe (EU)	3	8,8	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	8,33	16,67
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	16,67	19,25
	Europe (EU)	2	5,9	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	50,00	43,03
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	33,33	0,00
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	8,33	16,67
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	33,33	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	0,00	0,00
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	50,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	22,22	19,25
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57
	Europe (EU)	1	2,9	1	100,0	33,33	-
	Asia (AS)	3	4,2	2	66,7	16,67	23,57
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	0,00	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	39,22	24,25
	Europe (EU)	10	29,4	5	50,0	53,33	18,26
	Asia (AS)	34	47,9	22	64,7	25,76	27,08
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	59	96,7	33,33	25,52
	1	69	100,0	66	95,7	41,92	28,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	15	100,0	15	100,0	44,44	27,22
Cycle 2 Day 1	0	59	96,7	55	93,2	20,00	18,81
	1	67	97,1	59	88,1	26,55	25,36
	2	10	66,7	10	100,0	26,67	14,05
Cycle 3 Day 1	0	57	93,4	50	87,7	18,67	22,50
	1	65	94,2	57	87,7	16,96	19,03
	2	9	60,0	9	100,0	18,52	17,57
Cycle 4 Day 1	0	57	93,4	51	89,5	17,65	19,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	57	91,9	15,79	20,99
	2	9	60,0	8	88,9	20,83	24,80
Cycle 5 Day 1	0	56	91,8	52	92,9	17,31	19,23
	1	62	89,9	57	91,9	20,47	19,67
	2	6	40,0	6	100,0	16,67	18,26
Cycle 6 Day 1	0	56	91,8	53	94,6	19,50	17,82
	1	59	85,5	51	86,4	17,65	20,39
	2	6	40,0	4	66,7	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	54	88,5	51	94,4	21,57	23,87
	1	54	78,3	47	87,0	17,02	21,84
	2	5	33,3	5	100,0	0,00	0,00
Cycle 8 Day 1	0	52	85,2	48	92,3	20,83	24,43
	1	49	71,0	43	87,8	15,50	18,33
	2	5	33,3	5	100,0	26,67	14,91
Cycle 9 Day 1	0	50	82,0	49	98,0	15,65	20,53
	1	44	63,8	42	95,5	19,84	26,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	4	26,7	4	100,0	16,67	19,25
Cycle 10 Day 1	0	46	75,4	46	100,0	19,57	21,75
	1	40	58,0	37	92,5	25,23	28,77
	2	3	20,0	3	100,0	11,11	19,25
Cycle 11 Day 1	0	43	70,5	40	93,0	17,50	19,95
	1	34	49,3	33	97,1	16,16	22,24
	2	3	20,0	3	100,0	33,33	0,00
Cycle 12 Day 1	0	42	68,9	36	85,7	18,52	18,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	31	44,9	29	93,5	13,79	18,93
	2	3	20,0	3	100,0	22,22	19,25
Cycle 13 Day 1	0	38	62,3	34	89,5	20,59	25,97
	1	27	39,1	25	92,6	10,67	15,87
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	21,88	20,05
	1	24	34,8	23	95,8	13,04	16,63
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	33	54,1	30	90,9	18,89	18,94
	1	23	33,3	22	95,7	13,64	19,68
	2	1	6,7	1	100,0	0,00	-
Cycle 16 Day 1	0	28	45,9	25	89,3	20,00	23,57
	1	21	30,4	21	100,0	19,05	19,92
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	15,94	17,03
	1	20	29,0	20	100,0	11,67	16,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	14,04	20,23
	1	17	24,6	17	100,0	9,80	15,66
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	17,54	20,39
	1	15	21,7	13	86,7	10,26	16,01
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	23,53	15,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	21,7	14	93,3	4,76	12,10
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	16,67	17,30
	1	13	18,8	11	84,6	6,06	13,48
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	16,67	17,41
	1	13	18,8	12	92,3	0,00	0,00
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	7,41	14,70
	1	9	13,0	8	88,9	8,33	15,43
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	18,52	33,79
	1	9	13,0	8	88,9	4,17	11,79
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	5,56	13,61
	1	7	10,1	7	100,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	13,1	6	75,0	16,67	27,89
	1	6	8,7	6	100,0	11,11	17,21
Cycle 27 Day 1	0	6	9,8	3	50,0	11,11	19,25
	1	5	7,2	5	100,0	13,33	18,26
Cycle 28 Day 1	0	5	8,2	4	80,0	16,67	19,25
	1	5	7,2	5	100,0	40,00	43,46
Cycle 29 Day 1	0	4	6,6	2	50,0	33,33	0,00
	1	5	7,2	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	4,9	1	33,3	33,33	-
	1	4	5,8	4	100,0	8,33	16,67
Cycle 31 Day 1	0	3	4,9	1	33,3	66,67	-
	1	4	5,8	4	100,0	25,00	16,67
Cycle 32 Day 1	0	3	4,9	2	66,7	16,67	23,57
	1	3	4,3	3	100,0	22,22	19,25
Cycle 33 Day 1	0	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	36,51	23,34
	1	34	49,3	20	58,8	31,67	29,57
	2	7	46,7	3	42,9	33,33	33,33
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	59	95,2	43,50	26,45
	1	4	100,0	4	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	79	100,0	77	97,5	35,06	28,04
Cycle 2 Day 1	None	60	96,8	53	88,3	25,16	23,48
	1	3	75,0	2	66,7	16,67	23,57
	2 or More	73	92,4	69	94,5	22,71	21,00
Cycle 3 Day 1	None	59	95,2	53	89,8	19,50	21,12
	1	3	75,0	2	66,7	16,67	23,57
	2 or More	69	87,3	61	88,4	16,39	19,84
Cycle 4 Day 1	None	59	95,2	54	91,5	19,14	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	2	66,7	16,67	23,57
	2 or More	66	83,5	60	90,9	15,00	19,82
Cycle 5 Day 1	None	58	93,5	54	93,1	20,99	18,65
	1	3	75,0	3	100,0	33,33	0,00
	2 or More	63	79,7	58	92,1	16,09	19,98
Cycle 6 Day 1	None	57	91,9	49	86,0	19,73	17,90
	1	3	75,0	3	100,0	33,33	0,00
	2 or More	61	77,2	56	91,8	16,67	20,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	52	83,9	47	90,4	17,02	22,92
	1	3	75,0	3	100,0	44,44	19,25
	2 or More	58	73,4	53	91,4	18,24	22,23
Cycle 8 Day 1	None	50	80,6	45	90,0	21,48	20,30
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	16,67	22,59
Cycle 9 Day 1	None	48	77,4	46	95,8	16,67	23,04
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	18,75	23,73
Cycle 10 Day 1	None	43	69,4	41	95,3	26,02	27,40
	1	1	25,0	1	100,0	0,00	-
	2 or More	45	57,0	44	97,8	18,18	22,10
Cycle 11 Day 1	None	37	59,7	33	89,2	20,20	21,95
	1	1	25,0	1	100,0	33,33	-
	2 or More	42	53,2	42	100,0	15,08	19,76
Cycle 12 Day 1	None	37	59,7	33	89,2	17,17	20,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	33,33	-
	2 or More	38	48,1	34	89,5	15,69	16,89
Cycle 13 Day 1	None	34	54,8	28	82,4	20,24	26,20
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	12,90	18,61
Cycle 14 Day 1	None	31	50,0	28	90,3	16,67	16,97
	1	1	25,0	1	100,0	33,33	-
	2 or More	28	35,4	27	96,4	18,52	21,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	30	48,4	27	90,0	17,28	21,42
	1	1	25,0	1	100,0	33,33	-
	2 or More	26	32,9	25	96,2	14,67	16,89
Cycle 16 Day 1	None	25	40,3	23	92,0	20,29	24,08
	1	1	25,0	1	100,0	0,00	-
	2 or More	24	30,4	23	95,8	18,84	19,66
Cycle 17 Day 1	None	23	37,1	22	95,7	9,09	15,19
	1	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	21	26,6	21	100,0	17,46	17,06
Cycle 18 Day 1	None	20	32,3	18	90,0	14,81	20,52
	1	1	25,0	1	100,0	0,00	-
	2 or More	20	25,3	18	90,0	9,26	15,36
Cycle 19 Day 1	None	17	27,4	17	100,0	11,76	16,42
	1	1	25,0	1	100,0	33,33	-
	2 or More	18	22,8	15	83,3	15,56	21,33
Cycle 20 Day 1	None	17	27,4	16	94,1	18,75	17,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	33,33	-
	2 or More	18	22,8	15	83,3	8,89	15,26
Cycle 21 Day 1	None	15	24,2	13	86,7	10,26	16,01
	2 or More	14	17,7	13	92,9	12,82	16,88
Cycle 22 Day 1	None	15	24,2	13	86,7	7,69	14,62
	2 or More	14	17,7	12	85,7	8,33	15,08
Cycle 23 Day 1	None	10	16,1	9	90,0	7,41	14,70
	2 or More	11	13,9	9	81,8	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	16,1	10	100,0	6,67	14,05
	2 or More	10	12,7	8	80,0	16,67	35,63
Cycle 25 Day 1	None	9	14,5	8	88,9	12,50	17,25
	2 or More	6	7,6	5	83,3	6,67	14,91
Cycle 26 Day 1	None	8	12,9	8	100,0	12,50	17,25
	2 or More	6	7,6	4	66,7	16,67	33,33
Cycle 27 Day 1	None	7	11,3	6	85,7	16,67	18,26
	2 or More	4	5,1	2	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	11,3	7	100,0	23,81	25,20
	2 or More	3	3,8	2	66,7	50,00	70,71
Cycle 29 Day 1	None	6	9,7	5	83,3	26,67	14,91
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	6,5	3	75,0	22,22	19,25
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 31 Day 1	None	4	6,5	3	75,0	44,44	19,25
	2 or More	3	3,8	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	22,22	19,25
	2 or More	2	2,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	1,6	1	100,0	0,00	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	38,60	27,81
	1	3	75,0	1	33,3	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	39	49,4	24	61,5	30,56	25,85
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	59	95,2	43,50	26,45
	Previously Treated	83	100,0	81	97,6	34,98	27,34
Cycle 2 Day 1	Naïve	60	96,8	53	88,3	25,16	23,48
	Previously Treated	76	91,6	71	93,4	22,54	20,91
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	19,50	21,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	72	86,7	63	87,5	16,40	19,74
Cycle 4 Day 1	Naïve	59	95,2	54	91,5	19,14	21,08
	Previously Treated	69	83,1	62	89,9	15,05	19,72
Cycle 5 Day 1	Naïve	58	93,5	54	93,1	20,99	18,65
	Previously Treated	66	79,5	61	92,4	16,94	19,84
Cycle 6 Day 1	Naïve	57	91,9	49	86,0	19,73	17,90
	Previously Treated	64	77,1	59	92,2	17,51	19,92
Cycle 7 Day 1	Naïve	52	83,9	47	90,4	17,02	22,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	61	73,5	56	91,8	19,64	22,72
Cycle 8 Day 1	Naïve	50	80,6	45	90,0	21,48	20,30
	Previously Treated	56	67,5	51	91,1	16,34	22,48
Cycle 9 Day 1	Naïve	48	77,4	46	95,8	16,67	23,04
	Previously Treated	50	60,2	49	98,0	18,37	23,63
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	26,02	27,40
	Previously Treated	46	55,4	45	97,8	17,78	22,02
Cycle 11 Day 1	Naïve	37	59,7	33	89,2	20,20	21,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	43	51,8	43	100,0	15,50	19,72
Cycle 12 Day 1	Naïve	37	59,7	33	89,2	17,17	20,62
	Previously Treated	39	47,0	35	89,7	16,19	16,90
Cycle 13 Day 1	Naïve	34	54,8	28	82,4	20,24	26,20
	Previously Treated	32	38,6	32	100,0	12,50	18,45
Cycle 14 Day 1	Naïve	31	50,0	28	90,3	16,67	16,97
	Previously Treated	29	34,9	28	96,6	19,05	21,14
Cycle 15 Day 1	Naïve	30	48,4	27	90,0	17,28	21,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	27	32,5	26	96,3	15,38	16,95
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	20,29	24,08
	Previously Treated	25	30,1	24	96,0	18,06	19,61
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	9,09	15,19
	Previously Treated	22	26,5	22	100,0	18,18	16,99
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	14,81	20,52
	Previously Treated	21	25,3	19	90,5	8,77	15,08
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	11,76	16,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	22,9	16	84,2	16,67	21,08
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	18,75	17,08
	Previously Treated	19	22,9	16	84,2	10,42	15,96
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	10,26	16,01
	Previously Treated	14	16,9	13	92,9	12,82	16,88
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	7,69	14,62
	Previously Treated	14	16,9	12	85,7	8,33	15,08
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	7,41	14,70
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	6,67	14,05
	Previously Treated	10	12,0	8	80,0	16,67	35,63
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	12,50	17,25
	Previously Treated	6	7,2	5	83,3	6,67	14,91
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	12,50	17,25
	Previously Treated	6	7,2	4	66,7	16,67	33,33
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	16,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	4,8	2	50,0	0,00	0,00
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	23,81	25,20
	Previously Treated	3	3,6	2	66,7	50,00	70,71
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	26,67	14,91
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	22,22	19,25
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	44,44	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	22,22	19,25
	Previously Treated	2	2,4	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	0,00	-
	Previously Treated	1	1,2	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	38,60	27,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	50,6	25	59,5	30,67	25,31
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	40,00	29,51
	Central	70	100,0	65	92,9	36,92	24,38
Cycle 2 Day 1	Local	71	94,7	67	94,4	23,38	21,72
	Central	65	92,9	57	87,7	23,98	22,50
Cycle 3 Day 1	Local	67	89,3	60	89,6	17,22	19,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	64	91,4	56	87,5	18,45	21,00
Cycle 4 Day 1	Local	65	86,7	58	89,2	17,24	18,98
	Central	63	90,0	58	92,1	16,67	21,85
Cycle 5 Day 1	Local	63	84,0	58	92,1	17,82	19,96
	Central	61	87,1	57	93,4	19,88	18,75
Cycle 6 Day 1	Local	63	84,0	61	96,8	17,49	18,86
	Central	58	82,9	47	81,0	19,86	19,24
Cycle 7 Day 1	Local	61	81,3	58	95,1	17,82	19,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	52	74,3	45	86,5	19,26	26,10
Cycle 8 Day 1	Local	57	76,0	54	94,7	20,37	23,72
	Central	49	70,0	42	85,7	16,67	18,41
Cycle 9 Day 1	Local	54	72,0	53	98,1	20,13	23,88
	Central	44	62,9	42	95,5	14,29	22,26
Cycle 10 Day 1	Local	48	64,0	46	95,8	21,01	24,70
	Central	41	58,6	40	97,6	22,50	25,47
Cycle 11 Day 1	Local	40	53,3	38	95,0	19,30	22,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	40	57,1	38	95,0	15,79	18,56
Cycle 12 Day 1	Local	36	48,0	33	91,7	17,17	18,86
	Central	40	57,1	35	87,5	16,19	18,74
Cycle 13 Day 1	Local	30	40,0	29	96,7	13,79	20,93
	Central	36	51,4	31	86,1	18,28	24,10
Cycle 14 Day 1	Local	27	36,0	27	100,0	19,75	19,08
	Central	33	47,1	29	87,9	16,09	19,15
Cycle 15 Day 1	Local	26	34,7	25	96,2	17,33	19,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	28	90,3	15,48	19,21
Cycle 16 Day 1	Local	24	32,0	24	100,0	16,67	19,66
	Central	26	37,1	23	88,5	21,74	23,80
Cycle 17 Day 1	Local	22	29,3	22	100,0	12,12	16,41
	Central	23	32,9	22	95,7	15,15	16,99
Cycle 18 Day 1	Local	20	26,7	19	95,0	19,30	20,23
	Central	21	30,0	18	85,7	3,70	10,78
Cycle 19 Day 1	Local	19	25,3	17	89,5	15,69	20,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	24,3	16	94,1	12,50	16,67
Cycle 20 Day 1	Local	19	25,3	17	89,5	13,73	16,91
	Central	17	24,3	15	88,2	15,56	17,21
Cycle 21 Day 1	Local	14	18,7	12	85,7	13,89	17,16
	Central	15	21,4	14	93,3	9,52	15,63
Cycle 22 Day 1	Local	14	18,7	12	85,7	8,33	15,08
	Central	15	21,4	13	86,7	7,69	14,62
Cycle 23 Day 1	Local	11	14,7	10	90,9	6,67	14,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	14,3	8	80,0	8,33	15,43
Cycle 24 Day 1	Local	11	14,7	10	90,9	10,00	16,10
	Central	9	12,9	8	88,9	12,50	35,36
Cycle 25 Day 1	Local	7	9,3	7	100,0	14,29	17,82
	Central	8	11,4	6	75,0	5,56	13,61
Cycle 26 Day 1	Local	6	8,0	6	100,0	27,78	25,09
	Central	8	11,4	6	75,0	0,00	0,00
Cycle 27 Day 1	Local	4	5,3	4	100,0	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	10,0	4	57,1	0,00	0,00
Cycle 28 Day 1	Local	4	5,3	4	100,0	25,00	31,91
	Central	6	8,6	5	83,3	33,33	40,82
Cycle 29 Day 1	Local	3	4,0	3	100,0	22,22	19,25
	Central	6	8,6	4	66,7	16,67	19,25
Cycle 30 Day 1	Local	3	4,0	3	100,0	22,22	19,25
	Central	4	5,7	2	50,0	0,00	0,00
Cycle 31 Day 1	Local	3	4,0	3	100,0	44,44	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	5,7	2	50,0	16,67	23,57
Cycle 32 Day 1	Local	3	4,0	3	100,0	22,22	19,25
	Central	3	4,3	2	66,7	16,67	23,57
Cycle 33 Day 1	Local	1	1,3	1	100,0	0,00	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	31,94	28,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	32	45,7	20	62,5	36,67	23,94
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	130	96,3	37,18	26,78
	No	10	100,0	10	100,0	56,67	27,44
Cycle 2 Day 1	Yes	129	95,6	117	90,7	23,65	21,91
	No	7	70,0	7	100,0	23,81	25,20
Cycle 3 Day 1	Yes	124	91,9	110	88,7	17,88	20,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	6	85,7	16,67	18,26
Cycle 4 Day 1	Yes	121	89,6	109	90,1	16,51	20,09
	No	7	70,0	7	100,0	23,81	25,20
Cycle 5 Day 1	Yes	117	86,7	109	93,2	18,35	18,97
	No	7	70,0	6	85,7	27,78	25,09
Cycle 6 Day 1	Yes	114	84,4	101	88,6	18,48	18,54
	No	7	70,0	7	100,0	19,05	26,23
Cycle 7 Day 1	Yes	106	78,5	96	90,6	19,10	23,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	9,52	16,27
Cycle 8 Day 1	Yes	100	74,1	90	90,0	18,52	20,06
	No	6	60,0	6	100,0	22,22	40,37
Cycle 9 Day 1	Yes	92	68,1	89	96,7	18,35	23,58
	No	6	60,0	6	100,0	5,56	13,61
Cycle 10 Day 1	Yes	83	61,5	80	96,4	22,50	25,31
	No	6	60,0	6	100,0	11,11	17,21
Cycle 11 Day 1	Yes	76	56,3	72	94,7	17,59	20,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	4	40,0	4	100,0	16,67	19,25
Cycle 12 Day 1	Yes	72	53,3	64	88,9	16,67	18,78
	No	4	40,0	4	100,0	16,67	19,25
Cycle 13 Day 1	Yes	64	47,4	58	90,6	15,52	22,70
	No	2	20,0	2	100,0	33,33	0,00
Cycle 14 Day 1	Yes	58	43,0	54	93,1	16,67	18,03
	No	2	20,0	2	100,0	50,00	23,57
Cycle 15 Day 1	Yes	55	40,7	51	92,7	15,69	19,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	33,33	0,00
Cycle 16 Day 1	Yes	48	35,6	45	93,8	20,00	21,79
	No	2	20,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	43	31,9	42	97,7	13,49	16,56
	No	2	20,0	2	100,0	16,67	23,57
Cycle 18 Day 1	Yes	39	28,9	35	89,7	11,43	17,97
	No	2	20,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	14,58	18,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	14,44	16,80
	No	2	20,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	20,0	24	88,9	11,11	16,05
	No	2	20,0	2	100,0	16,67	23,57
Cycle 22 Day 1	Yes	27	20,0	23	85,2	8,70	14,97
	No	2	20,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	7,84	14,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	11,76	26,20
	No	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	10,4	12	85,7	8,33	15,08
	No	1	10,0	1	100,0	33,33	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	12,12	22,47
	No	1	10,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	33,33	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	25,00	34,50
	No	1	10,0	1	100,0	66,67	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	22,22	17,21
	No	1	10,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	16,67	19,25
	No	1	10,0	1	100,0	0,00	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	33,33	-
Cycle 32 Day 1	Yes	5	3,7	4	80,0	16,67	19,25
	No	1	10,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	33,33	26,23
	No	2	20,0	1	50,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	42,42	33,63
	No	134	100,0	129	96,3	38,24	26,71
Cycle 2 Day 1	Yes	7	63,6	7	100,0	14,29	26,23
	No	129	96,3	117	90,7	24,22	21,72
Cycle 3 Day 1	Yes	7	63,6	6	85,7	11,11	17,21
	No	124	92,5	110	88,7	18,18	20,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	7	63,6	7	100,0	23,81	37,09
	No	121	90,3	109	90,1	16,51	19,04
Cycle 5 Day 1	Yes	7	63,6	7	100,0	28,57	29,99
	No	117	87,3	108	92,3	18,21	18,45
Cycle 6 Day 1	Yes	7	63,6	7	100,0	19,05	26,23
	No	114	85,1	101	88,6	18,48	18,54
Cycle 7 Day 1	Yes	7	63,6	7	100,0	9,52	25,20
	No	106	79,1	96	90,6	19,10	22,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	7	63,6	7	100,0	19,05	26,23
	No	99	73,9	89	89,9	18,73	21,29
Cycle 9 Day 1	Yes	6	54,5	6	100,0	22,22	27,22
	No	92	68,7	89	96,7	17,23	23,09
Cycle 10 Day 1	Yes	6	54,5	6	100,0	22,22	27,22
	No	83	61,9	80	96,4	21,67	24,93
Cycle 11 Day 1	Yes	6	54,5	6	100,0	33,33	29,81
	No	74	55,2	70	94,6	16,19	19,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	6	54,5	6	100,0	16,67	27,89
	No	70	52,2	62	88,6	16,67	17,85
Cycle 13 Day 1	Yes	5	45,5	5	100,0	13,33	18,26
	No	61	45,5	55	90,2	16,36	23,02
Cycle 14 Day 1	Yes	5	45,5	5	100,0	13,33	18,26
	No	55	41,0	51	92,7	18,30	19,22
Cycle 15 Day 1	Yes	4	36,4	4	100,0	25,00	31,91
	No	53	39,6	49	92,5	15,65	18,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	27,3	3	100,0	22,22	38,49
	No	47	35,1	44	93,6	18,94	20,83
Cycle 17 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	42	31,3	41	97,6	13,82	16,63
Cycle 18 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	38	28,4	34	89,5	12,75	18,38
Cycle 19 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	30	90,9	15,56	19,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	33	24,6	29	87,9	14,94	16,87
Cycle 21 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	24	88,9	12,50	16,48
Cycle 22 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	23	85,2	8,70	14,97
Cycle 23 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	19	14,2	16	84,2	8,33	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	18	13,4	16	88,9	12,50	26,87
Cycle 25 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	13	9,7	11	84,6	12,12	16,82
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	15,15	22,92
Cycle 27 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	10	7,5	7	70,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	9	6,7	8	88,9	29,17	37,53
Cycle 29 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	8	6,0	6	75,0	16,67	18,26
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	13,33	18,26
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	20,00	18,26
Cycle 33 Day 1	No	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	55,56	19,25
	No	61	45,5	41	67,2	32,52	26,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13CO_SG.xls
24JUN2020 20:47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	140	96,6	7,14	17,33
Cycle 2 Day 1	All	136	93,8	124	91,2	17,47	23,46
Cycle 3 Day 1	All	131	90,3	116	88,5	11,78	16,60
Cycle 4 Day 1	All	128	88,3	116	90,6	13,22	19,60
Cycle 5 Day 1	All	124	85,5	115	92,7	12,17	19,41
Cycle 6 Day 1	All	121	83,4	108	89,3	12,96	19,78
Cycle 7 Day 1	All	113	77,9	103	91,2	11,00	17,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	106	73,1	96	90,6	11,11	15,80
Cycle 9 Day 1	All	98	67,6	95	96,9	11,23	17,27
Cycle 10 Day 1	All	89	61,4	86	96,6	10,85	16,52
Cycle 11 Day 1	All	80	55,2	76	95,0	12,28	18,73
Cycle 12 Day 1	All	76	52,4	68	89,5	11,27	15,89
Cycle 13 Day 1	All	66	45,5	60	90,9	12,22	16,20
Cycle 14 Day 1	All	60	41,4	56	93,3	11,31	18,29
Cycle 15 Day 1	All	57	39,3	53	93,0	10,06	15,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	50	34,5	47	94,0	9,93	16,90
Cycle 17 Day 1	All	45	31,0	44	97,8	11,36	17,53
Cycle 18 Day 1	All	41	28,3	37	90,2	9,01	16,94
Cycle 19 Day 1	All	36	24,8	33	91,7	8,08	20,46
Cycle 20 Day 1	All	36	24,8	32	88,9	8,33	16,93
Cycle 21 Day 1	All	29	20,0	26	89,7	7,69	17,15
Cycle 22 Day 1	All	29	20,0	25	86,2	4,00	11,06
Cycle 23 Day 1	All	21	14,5	18	85,7	7,41	14,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	13,8	18	90,0	5,56	12,78
Cycle 25 Day 1	All	15	10,3	13	86,7	5,13	12,52
Cycle 26 Day 1	All	14	9,7	12	85,7	8,33	15,08
Cycle 27 Day 1	All	11	7,6	8	72,7	12,50	17,25
Cycle 28 Day 1	All	10	6,9	9	90,0	14,81	24,22
Cycle 29 Day 1	All	9	6,2	7	77,8	19,05	26,23
Cycle 30 Day 1	All	7	4,8	5	71,4	6,67	14,91
Cycle 31 Day 1	All	7	4,8	5	71,4	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	4,1	5	83,3	6,67	14,91
Cycle 33 Day 1	All	2	1,4	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	14,39	18,18
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	9,80	22,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	93	100,0	89	95,7	5,62	13,52
Cycle 2 Day 1	Male	50	96,2	46	92,0	18,12	26,95
	Female	86	92,5	78	90,7	17,09	21,32
Cycle 3 Day 1	Male	47	90,4	43	91,5	11,63	17,64
	Female	84	90,3	73	86,9	11,87	16,07
Cycle 4 Day 1	Male	46	88,5	43	93,5	10,08	18,59
	Female	82	88,2	73	89,0	15,07	20,06
Cycle 5 Day 1	Male	45	86,5	42	93,3	10,32	18,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	79	84,9	73	92,4	13,24	19,83
Cycle 6 Day 1	Male	45	86,5	41	91,1	11,38	17,65
	Female	76	81,7	67	88,2	13,93	21,04
Cycle 7 Day 1	Male	40	76,9	39	97,5	9,40	15,20
	Female	73	78,5	64	87,7	11,98	19,12
Cycle 8 Day 1	Male	37	71,2	34	91,9	10,78	15,83
	Female	69	74,2	62	89,9	11,29	15,90
Cycle 9 Day 1	Male	33	63,5	33	100,0	10,10	19,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	62	95,4	11,83	16,08
Cycle 10 Day 1	Male	30	57,7	30	100,0	11,11	18,22
	Female	59	63,4	56	94,9	10,71	15,71
Cycle 11 Day 1	Male	29	55,8	28	96,6	15,48	21,24
	Female	51	54,8	48	94,1	10,42	17,06
Cycle 12 Day 1	Male	27	51,9	26	96,3	10,26	15,69
	Female	49	52,7	42	85,7	11,90	16,17
Cycle 13 Day 1	Male	25	48,1	23	92,0	13,04	16,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	41	44,1	37	90,2	11,71	16,13
Cycle 14 Day 1	Male	23	44,2	21	91,3	7,94	14,55
	Female	37	39,8	35	94,6	13,33	20,13
Cycle 15 Day 1	Male	21	40,4	20	95,2	11,67	16,31
	Female	36	38,7	33	91,7	9,09	15,08
Cycle 16 Day 1	Male	16	30,8	16	100,0	12,50	20,64
	Female	34	36,6	31	91,2	8,60	14,83
Cycle 17 Day 1	Male	13	25,0	13	100,0	7,69	14,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	32	34,4	31	96,9	12,90	18,61
Cycle 18 Day 1	Male	12	23,1	11	91,7	9,09	15,57
	Female	29	31,2	26	89,7	8,97	17,78
Cycle 19 Day 1	Male	10	19,2	10	100,0	10,00	16,10
	Female	26	28,0	23	88,5	7,25	22,38
Cycle 20 Day 1	Male	10	19,2	9	90,0	7,41	14,70
	Female	26	28,0	23	88,5	8,70	18,03
Cycle 21 Day 1	Male	8	15,4	8	100,0	16,67	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	22,6	18	85,7	3,70	10,78
Cycle 22 Day 1	Male	8	15,4	6	75,0	11,11	17,21
	Female	21	22,6	19	90,5	1,75	7,65
Cycle 23 Day 1	Male	5	9,6	4	80,0	8,33	16,67
	Female	16	17,2	14	87,5	7,14	14,19
Cycle 24 Day 1	Male	5	9,6	4	80,0	8,33	16,67
	Female	15	16,1	14	93,3	4,76	12,10
Cycle 25 Day 1	Male	3	5,8	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	12,9	11	91,7	3,03	10,05
Cycle 26 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	11	11,8	10	90,9	10,00	16,10
Cycle 27 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	8	8,6	6	75,0	16,67	18,26
Cycle 28 Day 1	Male	2	3,8	2	100,0	0,00	0,00
	Female	8	8,6	7	87,5	19,05	26,23
Cycle 29 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	8,6	6	75,0	22,22	27,22
Cycle 30 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	8,33	16,67
Cycle 31 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	16,67	19,25
Cycle 32 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	5	5,4	4	80,0	8,33	16,67
Cycle 33 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	1,1	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	19,05	19,92
	Female	37	39,8	23	62,2	10,14	15,68
Age							
Cycle 1 Day 1	18-64	109	100,0	104	95,4	7,37	16,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	5,75	20,06
	>=75	7	100,0	7	100,0	9,52	16,27
Cycle 2 Day 1	18-64	103	94,5	91	88,3	17,22	23,50
	65-74	26	89,7	26	100,0	17,95	25,35
	>=75	7	100,0	7	100,0	19,05	17,82
Cycle 3 Day 1	18-64	99	90,8	87	87,9	11,11	15,80
	65-74	25	86,2	23	92,0	13,04	19,43
	>=75	7	100,0	6	85,7	16,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	98	89,9	88	89,8	11,74	18,94
	65-74	23	79,3	21	91,3	15,87	20,05
	>=75	7	100,0	7	100,0	23,81	25,20
Cycle 5 Day 1	18-64	95	87,2	88	92,6	12,12	19,69
	65-74	22	75,9	22	100,0	9,09	15,19
	>=75	7	100,0	5	71,4	26,67	27,89
Cycle 6 Day 1	18-64	92	84,4	80	87,0	10,83	16,58
	65-74	22	75,9	21	95,5	14,29	19,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	33,33	38,49
Cycle 7 Day 1	18-64	86	78,9	78	90,7	10,26	17,25
	65-74	20	69,0	19	95,0	10,53	15,92
	>=75	7	100,0	6	85,7	22,22	27,22
Cycle 8 Day 1	18-64	80	73,4	71	88,8	9,39	15,10
	65-74	19	65,5	19	100,0	17,54	17,10
	>=75	7	100,0	6	85,7	11,11	17,21
Cycle 9 Day 1	18-64	74	67,9	72	97,3	10,19	17,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	18	62,1	18	100,0	14,81	17,04
	>=75	6	85,7	5	83,3	13,33	18,26
Cycle 10 Day 1	18-64	69	63,3	66	95,7	10,10	16,51
	65-74	15	51,7	15	100,0	13,33	16,90
	>=75	5	71,4	5	100,0	13,33	18,26
Cycle 11 Day 1	18-64	61	56,0	58	95,1	12,07	19,44
	65-74	15	51,7	14	93,3	11,90	16,57
	>=75	4	57,1	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	57	52,3	50	87,7	10,00	15,43
	65-74	15	51,7	14	93,3	16,67	17,30
	>=75	4	57,1	4	100,0	8,33	16,67
Cycle 13 Day 1	18-64	49	45,0	45	91,8	9,63	15,28
	65-74	13	44,8	11	84,6	21,21	16,82
	>=75	4	57,1	4	100,0	16,67	19,25
Cycle 14 Day 1	18-64	45	41,3	43	95,6	10,08	17,11
	65-74	13	44,8	11	84,6	15,15	22,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	28,6	2	100,0	16,67	23,57
Cycle 15 Day 1	18-64	43	39,4	40	93,0	8,33	14,62
	65-74	12	41,4	11	91,7	12,12	16,82
	>=75	2	28,6	2	100,0	33,33	0,00
Cycle 16 Day 1	18-64	38	34,9	36	94,7	10,19	17,49
	65-74	10	34,5	9	90,0	11,11	16,67
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 17 Day 1	18-64	36	33,0	35	97,2	10,48	15,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	27,6	8	100,0	16,67	25,20
	>=75	1	14,3	1	100,0	0,00	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	7,78	16,80
	65-74	7	24,1	6	85,7	16,67	18,26
	>=75	1	14,3	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	8,33	21,52
	65-74	5	17,2	4	80,0	8,33	16,67
	>=75	1	14,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	8,97	17,78
	65-74	5	17,2	5	100,0	6,67	14,91
	>=75	1	14,3	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	7,94	17,97
	65-74	4	13,8	4	100,0	8,33	16,67
	>=75	1	14,3	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	3,33	10,26
	65-74	4	13,8	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	6,25	13,44
	65-74	2	6,9	2	100,0	16,67	23,57
Cycle 24 Day 1	18-64	18	16,5	16	88,9	4,17	11,39
	65-74	2	6,9	2	100,0	16,67	23,57
Cycle 25 Day 1	18-64	14	12,8	12	85,7	5,56	12,97
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	8,33	15,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	12,50	17,25
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	14,81	24,22
	65-74	1	3,4	0	0,0	-	-
Cycle 29 Day 1	18-64	8	7,3	7	87,5	19,05	26,23
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	13,33	18,26
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	8,33	16,67
	65-74	1	3,4	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	0,00	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	15,69	18,78
	65-74	15	51,7	8	53,3	12,50	17,25
	>=75	4	57,1	2	50,0	0,00	0,00
Race							
Cycle 1 Day 1	White	60	100,0	57	95,0	9,94	22,68
	Other	85	100,0	83	97,6	5,22	12,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	57	95,0	50	87,7	14,67	24,43
	Other	79	92,9	74	93,7	19,37	22,75
Cycle 3 Day 1	White	54	90,0	44	81,5	11,36	15,98
	Other	77	90,6	72	93,5	12,04	17,07
Cycle 4 Day 1	White	53	88,3	45	84,9	9,63	15,28
	Other	75	88,2	71	94,7	15,49	21,70
Cycle 5 Day 1	White	52	86,7	47	90,4	7,80	14,27
	Other	72	84,7	68	94,4	15,20	21,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	50	83,3	41	82,0	12,20	19,37
	Other	71	83,5	67	94,4	13,43	20,15
Cycle 7 Day 1	White	47	78,3	40	85,1	9,17	16,86
	Other	66	77,6	63	95,5	12,17	18,26
Cycle 8 Day 1	White	45	75,0	38	84,4	10,53	15,70
	Other	61	71,8	58	95,1	11,49	15,98
Cycle 9 Day 1	White	42	70,0	41	97,6	8,94	14,95
	Other	56	65,9	54	96,4	12,96	18,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	13,68	18,29
	Other	48	56,5	47	97,9	8,51	14,69
Cycle 11 Day 1	White	37	61,7	36	97,3	12,04	19,76
	Other	43	50,6	40	93,0	12,50	18,00
Cycle 12 Day 1	White	37	61,7	33	89,2	9,09	15,08
	Other	39	45,9	35	89,7	13,33	16,57
Cycle 13 Day 1	White	32	53,3	30	93,8	12,22	16,34
	Other	34	40,0	30	88,2	12,22	16,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	31	51,7	30	96,8	10,00	17,83
	Other	29	34,1	26	89,7	12,82	19,04
Cycle 15 Day 1	White	30	50,0	28	93,3	9,52	15,33
	Other	27	31,8	25	92,6	10,67	15,87
Cycle 16 Day 1	White	26	43,3	24	92,3	6,94	16,97
	Other	24	28,2	23	95,8	13,04	16,63
Cycle 17 Day 1	White	24	40,0	24	100,0	9,72	15,48
	Other	21	24,7	20	95,2	13,33	19,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	22	36,7	19	86,4	8,77	18,73
	Other	19	22,4	18	94,7	9,26	15,36
Cycle 19 Day 1	White	20	33,3	20	100,0	5,00	12,21
	Other	16	18,8	13	81,3	12,82	28,99
Cycle 20 Day 1	White	20	33,3	17	85,0	5,88	13,10
	Other	16	18,8	15	93,8	11,11	20,57
Cycle 21 Day 1	White	16	26,7	14	87,5	9,52	20,37
	Other	13	15,3	12	92,3	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	26,7	13	81,3	2,56	9,25
	Other	13	15,3	12	92,3	5,56	12,97
Cycle 23 Day 1	White	12	20,0	10	83,3	10,00	16,10
	Other	9	10,6	8	88,9	4,17	11,79
Cycle 24 Day 1	White	11	18,3	10	90,9	6,67	14,05
	Other	9	10,6	8	88,9	4,17	11,79
Cycle 25 Day 1	White	10	16,7	8	80,0	8,33	15,43
	Other	5	5,9	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	16,7	8	80,0	8,33	15,43
	Other	4	4,7	4	100,0	8,33	16,67
Cycle 27 Day 1	White	8	13,3	5	62,5	13,33	18,26
	Other	3	3,5	3	100,0	11,11	19,25
Cycle 28 Day 1	White	7	11,7	6	85,7	16,67	27,89
	Other	3	3,5	3	100,0	11,11	19,25
Cycle 29 Day 1	White	6	10,0	4	66,7	25,00	31,91
	Other	3	3,5	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	6,7	2	50,0	0,00	0,00
	Other	3	3,5	3	100,0	11,11	19,25
Cycle 31 Day 1	White	4	6,7	2	50,0	0,00	0,00
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 32 Day 1	White	4	6,7	3	75,0	0,00	0,00
	Other	2	2,4	2	100,0	16,67	23,57
Cycle 33 Day 1	White	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-
End Of Treatment	White	25	41,7	17	68,0	15,69	20,81
	Other	39	45,9	27	69,2	13,58	16,69
Region							
Cycle 1 Day 1	America (AM)	40	100,0	38	95,0	2,63	9,11
	Europe (EU)	34	100,0	31	91,2	9,68	23,08
	Asia (AS)	71	100,0	71	100,0	8,45	17,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	16,67	23,95
	Europe (EU)	32	94,1	27	84,4	16,05	25,10
	Asia (AS)	66	93,0	65	98,5	18,46	22,85
Cycle 3 Day 1	America (AM)	37	92,5	32	86,5	9,38	15,23
	Europe (EU)	31	91,2	21	67,7	6,35	13,41
	Asia (AS)	63	88,7	63	100,0	14,81	17,74
Cycle 4 Day 1	America (AM)	37	92,5	32	86,5	11,46	16,09
	Europe (EU)	30	88,2	24	80,0	6,94	13,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	61	85,9	60	98,4	16,67	22,55
Cycle 5 Day 1	America (AM)	37	92,5	33	89,2	7,07	13,84
	Europe (EU)	30	88,2	25	83,3	8,00	17,43
	Asia (AS)	57	80,3	57	100,0	16,96	21,93
Cycle 6 Day 1	America (AM)	37	92,5	32	86,5	10,42	19,74
	Europe (EU)	28	82,4	24	85,7	15,28	19,61
	Asia (AS)	56	78,9	52	92,9	13,46	20,09
Cycle 7 Day 1	America (AM)	35	87,5	29	82,9	8,05	17,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	28	82,4	25	89,3	9,33	15,28
	Asia (AS)	50	70,4	49	98,0	13,61	19,15
Cycle 8 Day 1	America (AM)	31	77,5	26	83,9	7,69	14,32
	Europe (EU)	28	82,4	23	82,1	11,59	16,23
	Asia (AS)	47	66,2	47	100,0	12,77	16,38
Cycle 9 Day 1	America (AM)	29	72,5	27	93,1	8,64	14,89
	Europe (EU)	26	76,5	25	96,2	6,67	13,61
	Asia (AS)	43	60,6	43	100,0	15,50	19,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	9,72	18,33
	Europe (EU)	25	73,5	25	100,0	10,67	15,87
	Asia (AS)	37	52,1	37	100,0	11,71	16,13
Cycle 11 Day 1	America (AM)	24	60,0	21	87,5	11,11	16,10
	Europe (EU)	23	67,6	22	95,7	12,12	21,93
	Asia (AS)	33	46,5	33	100,0	13,13	18,52
Cycle 12 Day 1	America (AM)	24	60,0	22	91,7	7,58	14,30
	Europe (EU)	23	67,6	18	78,3	11,11	16,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	40,8	28	96,6	14,29	16,80
Cycle 13 Day 1	America (AM)	23	57,5	21	91,3	12,70	16,59
	Europe (EU)	18	52,9	14	77,8	11,90	16,57
	Asia (AS)	25	35,2	25	100,0	12,00	16,33
Cycle 14 Day 1	America (AM)	22	55,0	20	90,9	10,00	19,04
	Europe (EU)	17	50,0	16	94,1	12,50	20,64
	Asia (AS)	21	29,6	20	95,2	11,67	16,31
Cycle 15 Day 1	America (AM)	22	55,0	19	86,4	7,02	13,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	44,1	14	93,3	14,29	17,12
	Asia (AS)	20	28,2	20	100,0	10,00	15,67
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	11,76	16,42
	Europe (EU)	14	41,2	11	78,6	9,09	21,56
	Asia (AS)	19	26,8	19	100,0	8,77	15,08
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	8,33	14,91
	Europe (EU)	13	38,2	12	92,3	8,33	15,08
	Asia (AS)	16	22,5	16	100,0	16,67	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	2,38	8,91
	Europe (EU)	11	32,4	7	63,6	9,52	16,27
	Asia (AS)	16	22,5	16	100,0	14,58	20,97
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	2,56	9,25
	Europe (EU)	9	26,5	9	100,0	7,41	14,70
	Asia (AS)	14	19,7	11	78,6	15,15	31,14
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	5,13	12,52
	Europe (EU)	9	26,5	6	66,7	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	12,82	21,68
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	6,67	14,05
	Europe (EU)	7	20,6	6	85,7	11,11	27,22
	Asia (AS)	11	15,5	10	90,9	6,67	14,05
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	3,33	10,54
	Europe (EU)	7	20,6	5	71,4	0,00	0,00
	Asia (AS)	11	15,5	10	90,9	6,67	14,05
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	14,7	3	60,0	11,11	19,25
	Asia (AS)	7	9,9	6	85,7	5,56	13,61
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	8,33	15,43
	Europe (EU)	5	14,7	4	80,0	8,33	16,67
	Asia (AS)	7	9,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	4,76	12,60
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	5,56	13,61
	Europe (EU)	4	11,8	2	50,0	16,67	23,57
	Asia (AS)	4	5,6	4	100,0	8,33	16,67
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	8,33	16,67
	Europe (EU)	3	8,8	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	16,67	19,25
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	8,33	16,67
	Europe (EU)	2	5,9	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	25,00	31,91
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	11,11	19,25
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	25,00	31,91
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	11,11	19,25
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	22,22	19,25
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00
	Europe (EU)	1	2,9	1	100,0	0,00	-
	Asia (AS)	3	4,2	2	66,7	16,67	23,57
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	0,00	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	15,69	20,81
	Europe (EU)	10	29,4	5	50,0	13,33	18,26
	Asia (AS)	34	47,9	22	64,7	13,64	16,77
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	59	96,7	3,39	10,16
	1	69	100,0	66	95,7	10,61	21,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	15	100,0	15	100,0	6,67	18,69
Cycle 2 Day 1	0	59	96,7	55	93,2	16,97	22,10
	1	67	97,1	59	88,1	20,90	25,44
	2	10	66,7	10	100,0	0,00	0,00
Cycle 3 Day 1	0	57	93,4	50	87,7	12,00	17,51
	1	65	94,2	57	87,7	12,28	16,22
	2	9	60,0	9	100,0	7,41	14,70
Cycle 4 Day 1	0	57	93,4	51	89,5	13,07	20,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	57	91,9	14,04	18,84
	2	9	60,0	8	88,9	8,33	23,57
Cycle 5 Day 1	0	56	91,8	52	92,9	11,54	20,75
	1	62	89,9	57	91,9	13,45	18,75
	2	6	40,0	6	100,0	5,56	13,61
Cycle 6 Day 1	0	56	91,8	53	94,6	15,72	23,21
	1	59	85,5	51	86,4	10,46	15,62
	2	6	40,0	4	66,7	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	54	88,5	51	94,4	11,76	18,65
	1	54	78,3	47	87,0	11,35	17,41
	2	5	33,3	5	100,0	0,00	0,00
Cycle 8 Day 1	0	52	85,2	48	92,3	13,89	16,61
	1	49	71,0	43	87,8	8,53	14,72
	2	5	33,3	5	100,0	6,67	14,91
Cycle 9 Day 1	0	50	82,0	49	98,0	12,24	18,87
	1	44	63,8	42	95,5	11,11	15,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	4	26,7	4	100,0	0,00	0,00
Cycle 10 Day 1	0	46	75,4	46	100,0	14,49	18,12
	1	40	58,0	37	92,5	7,21	13,91
	2	3	20,0	3	100,0	0,00	0,00
Cycle 11 Day 1	0	43	70,5	40	93,0	15,00	19,90
	1	34	49,3	33	97,1	10,10	17,65
	2	3	20,0	3	100,0	0,00	0,00
Cycle 12 Day 1	0	42	68,9	36	85,7	13,89	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	31	44,9	29	93,5	9,20	15,16
	2	3	20,0	3	100,0	0,00	0,00
Cycle 13 Day 1	0	38	62,3	34	89,5	14,71	16,80
	1	27	39,1	25	92,6	9,33	15,28
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	13,54	20,49
	1	24	34,8	23	95,8	8,70	14,97
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	33	54,1	30	90,9	12,22	16,34
	1	23	33,3	22	95,7	7,58	14,30
	2	1	6,7	1	100,0	0,00	-
Cycle 16 Day 1	0	28	45,9	25	89,3	10,67	18,56
	1	21	30,4	21	100,0	9,52	15,43
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	11,59	19,09
	1	20	29,0	20	100,0	11,67	16,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	8,77	15,08
	1	17	24,6	17	100,0	9,80	19,60
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	5,26	12,49
	1	15	21,7	13	86,7	12,82	28,99
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	5,88	13,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	21,7	14	93,3	11,90	21,11
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	9,52	20,37
	1	13	18,8	11	84,6	6,06	13,48
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	5,56	12,97
	1	13	18,8	12	92,3	2,78	9,62
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	7,41	14,70
	1	9	13,0	8	88,9	8,33	15,43
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	7,41	14,70
	1	9	13,0	8	88,9	4,17	11,79
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	11,11	17,21
	1	7	10,1	7	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	13,1	6	75,0	0,00	0,00
	1	6	8,7	6	100,0	16,67	18,26
Cycle 27 Day 1	0	6	9,8	3	50,0	11,11	19,25
	1	5	7,2	5	100,0	13,33	18,26
Cycle 28 Day 1	0	5	8,2	4	80,0	16,67	33,33
	1	5	7,2	5	100,0	13,33	18,26
Cycle 29 Day 1	0	4	6,6	2	50,0	33,33	47,14
	1	5	7,2	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	8,33	16,67
Cycle 31 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	16,67	19,25
Cycle 32 Day 1	0	3	4,9	2	66,7	0,00	0,00
	1	3	4,3	3	100,0	11,11	19,25
Cycle 33 Day 1	0	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	15,87	20,05
	1	34	49,3	20	58,8	15,00	17,01
	2	7	46,7	3	42,9	0,00	0,00
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	59	95,2	6,78	14,88
	1	4	100,0	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	79	100,0	77	97,5	7,36	19,21
Cycle 2 Day 1	None	60	96,8	53	88,3	16,98	22,29
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	73	92,4	69	94,5	18,36	24,61
Cycle 3 Day 1	None	59	95,2	53	89,8	12,58	17,57
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	69	87,3	61	88,4	11,48	15,97
Cycle 4 Day 1	None	59	95,2	54	91,5	14,20	20,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	66	83,5	60	90,9	12,78	19,50
Cycle 5 Day 1	None	58	93,5	54	93,1	12,35	21,76
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	63	79,7	58	92,1	12,64	17,47
Cycle 6 Day 1	None	57	91,9	49	86,0	13,61	16,55
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	61	77,2	56	91,8	13,10	22,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	52	83,9	47	90,4	9,93	15,41
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	58	73,4	53	91,4	12,58	19,86
Cycle 8 Day 1	None	50	80,6	45	90,0	12,59	16,34
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	10,00	15,43
Cycle 9 Day 1	None	48	77,4	46	95,8	10,14	15,51
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	12,50	18,99
Cycle 10 Day 1	None	43	69,4	41	95,3	12,20	17,88
	1	1	25,0	1	100,0	0,00	-
	2 or More	45	57,0	44	97,8	9,85	15,38
Cycle 11 Day 1	None	37	59,7	33	89,2	10,10	15,56
	1	1	25,0	1	100,0	33,33	-
	2 or More	42	53,2	42	100,0	13,49	20,90
Cycle 12 Day 1	None	37	59,7	33	89,2	11,11	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	38	48,1	34	89,5	11,76	16,17
Cycle 13 Day 1	None	34	54,8	28	82,4	14,29	16,80
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	10,75	15,84
Cycle 14 Day 1	None	31	50,0	28	90,3	9,52	17,82
	1	1	25,0	1	100,0	0,00	-
	2 or More	28	35,4	27	96,4	13,58	19,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	30	48,4	27	90,0	9,88	15,51
	1	1	25,0	1	100,0	0,00	-
	2 or More	26	32,9	25	96,2	10,67	15,87
Cycle 16 Day 1	None	25	40,3	23	92,0	7,25	14,06
	1	1	25,0	1	100,0	0,00	-
	2 or More	24	30,4	23	95,8	13,04	19,43
Cycle 17 Day 1	None	23	37,1	22	95,7	10,61	15,89
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	21	26,6	21	100,0	12,70	19,65
Cycle 18 Day 1	None	20	32,3	18	90,0	9,26	15,36
	1	1	25,0	1	100,0	0,00	-
	2 or More	20	25,3	18	90,0	9,26	19,15
Cycle 19 Day 1	None	17	27,4	17	100,0	11,76	26,20
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	4,44	11,73
Cycle 20 Day 1	None	17	27,4	16	94,1	14,58	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	2,22	8,61
Cycle 21 Day 1	None	15	24,2	13	86,7	10,26	16,01
	2 or More	14	17,7	13	92,9	5,13	18,49
Cycle 22 Day 1	None	15	24,2	13	86,7	7,69	14,62
	2 or More	14	17,7	12	85,7	0,00	0,00
Cycle 23 Day 1	None	10	16,1	9	90,0	11,11	16,67
	2 or More	11	13,9	9	81,8	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	16,1	10	100,0	3,33	10,54
	2 or More	10	12,7	8	80,0	8,33	15,43
Cycle 25 Day 1	None	9	14,5	8	88,9	8,33	15,43
	2 or More	6	7,6	5	83,3	0,00	0,00
Cycle 26 Day 1	None	8	12,9	8	100,0	8,33	15,43
	2 or More	6	7,6	4	66,7	8,33	16,67
Cycle 27 Day 1	None	7	11,3	6	85,7	16,67	18,26
	2 or More	4	5,1	2	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	11,3	7	100,0	19,05	26,23
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 29 Day 1	None	6	9,7	5	83,3	26,67	27,89
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	6,5	3	75,0	11,11	19,25
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 31 Day 1	None	4	6,5	3	75,0	11,11	19,25
	2 or More	3	3,8	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	11,11	19,25
	2 or More	2	2,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	1,6	1	100,0	0,00	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	15,79	17,10
	1	3	75,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	39	49,4	24	61,5	13,89	19,45
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	59	95,2	6,78	14,88
	Previously Treated	83	100,0	81	97,6	7,41	19,00
Cycle 2 Day 1	Naïve	60	96,8	53	88,3	16,98	22,29
	Previously Treated	76	91,6	71	93,4	17,84	24,45
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	12,58	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	72	86,7	63	87,5	11,11	15,84
Cycle 4 Day 1	Naïve	59	95,2	54	91,5	14,20	20,06
	Previously Treated	69	83,1	62	89,9	12,37	19,31
Cycle 5 Day 1	Naïve	58	93,5	54	93,1	12,35	21,76
	Previously Treated	66	79,5	61	92,4	12,02	17,25
Cycle 6 Day 1	Naïve	57	91,9	49	86,0	13,61	16,55
	Previously Treated	64	77,1	59	92,2	12,43	22,23
Cycle 7 Day 1	Naïve	52	83,9	47	90,4	9,93	15,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	61	73,5	56	91,8	11,90	19,52
Cycle 8 Day 1	Naïve	50	80,6	45	90,0	12,59	16,34
	Previously Treated	56	67,5	51	91,1	9,80	15,34
Cycle 9 Day 1	Naïve	48	77,4	46	95,8	10,14	15,51
	Previously Treated	50	60,2	49	98,0	12,24	18,87
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	12,20	17,88
	Previously Treated	46	55,4	45	97,8	9,63	15,28
Cycle 11 Day 1	Naïve	37	59,7	33	89,2	10,10	15,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	43	51,8	43	100,0	13,95	20,87
Cycle 12 Day 1	Naïve	37	59,7	33	89,2	11,11	15,96
	Previously Treated	39	47,0	35	89,7	11,43	16,05
Cycle 13 Day 1	Naïve	34	54,8	28	82,4	14,29	16,80
	Previously Treated	32	38,6	32	100,0	10,42	15,70
Cycle 14 Day 1	Naïve	31	50,0	28	90,3	9,52	17,82
	Previously Treated	29	34,9	28	96,6	13,10	18,90
Cycle 15 Day 1	Naïve	30	48,4	27	90,0	9,88	15,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	27	32,5	26	96,3	10,26	15,69
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	7,25	14,06
	Previously Treated	25	30,1	24	96,0	12,50	19,19
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	10,61	15,89
	Previously Treated	22	26,5	22	100,0	12,12	19,37
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	9,26	15,36
	Previously Treated	21	25,3	19	90,5	8,77	18,73
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	11,76	26,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	22,9	16	84,2	4,17	11,39
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	14,58	20,97
	Previously Treated	19	22,9	16	84,2	2,08	8,33
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	10,26	16,01
	Previously Treated	14	16,9	13	92,9	5,13	18,49
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	7,69	14,62
	Previously Treated	14	16,9	12	85,7	0,00	0,00
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	11,11	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	3,70	11,11
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	3,33	10,54
	Previously Treated	10	12,0	8	80,0	8,33	15,43
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	8,33	15,43
	Previously Treated	6	7,2	5	83,3	0,00	0,00
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	8,33	15,43
	Previously Treated	6	7,2	4	66,7	8,33	16,67
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	16,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	4,8	2	50,0	0,00	0,00
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	19,05	26,23
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	26,67	27,89
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	11,11	19,25
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	11,11	19,25
	Previously Treated	2	2,4	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	0,00	-
	Previously Treated	1	1,2	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	15,79	17,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	50,6	25	59,5	13,33	19,25
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	4,44	11,41
	Central	70	100,0	65	92,9	10,26	21,99
Cycle 2 Day 1	Local	71	94,7	67	94,4	15,92	21,21
	Central	65	92,9	57	87,7	19,30	25,93
Cycle 3 Day 1	Local	67	89,3	60	89,6	10,00	15,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	64	91,4	56	87,5	13,69	17,73
Cycle 4 Day 1	Local	65	86,7	58	89,2	10,92	18,08
	Central	63	90,0	58	92,1	15,52	20,91
Cycle 5 Day 1	Local	63	84,0	58	92,1	11,49	17,16
	Central	61	87,1	57	93,4	12,87	21,60
Cycle 6 Day 1	Local	63	84,0	61	96,8	14,21	22,33
	Central	58	82,9	47	81,0	11,35	15,97
Cycle 7 Day 1	Local	61	81,3	58	95,1	9,20	17,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	52	74,3	45	86,5	13,33	17,98
Cycle 8 Day 1	Local	57	76,0	54	94,7	8,64	14,74
	Central	49	70,0	42	85,7	14,29	16,70
Cycle 9 Day 1	Local	54	72,0	53	98,1	11,95	17,41
	Central	44	62,9	42	95,5	10,32	17,25
Cycle 10 Day 1	Local	48	64,0	46	95,8	10,14	17,03
	Central	41	58,6	40	97,6	11,67	16,10
Cycle 11 Day 1	Local	40	53,3	38	95,0	11,40	16,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	40	57,1	38	95,0	13,16	21,28
Cycle 12 Day 1	Local	36	48,0	33	91,7	10,10	15,56
	Central	40	57,1	35	87,5	12,38	16,34
Cycle 13 Day 1	Local	30	40,0	29	96,7	12,64	16,46
	Central	36	51,4	31	86,1	11,83	16,21
Cycle 14 Day 1	Local	27	36,0	27	100,0	11,11	20,67
	Central	33	47,1	29	87,9	11,49	16,12
Cycle 15 Day 1	Local	26	34,7	25	96,2	9,33	15,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	28	90,3	10,71	15,85
Cycle 16 Day 1	Local	24	32,0	24	100,0	8,33	14,74
	Central	26	37,1	23	88,5	11,59	19,09
Cycle 17 Day 1	Local	22	29,3	22	100,0	7,58	14,30
	Central	23	32,9	22	95,7	15,15	19,86
Cycle 18 Day 1	Local	20	26,7	19	95,0	3,51	10,51
	Central	21	30,0	18	85,7	14,81	20,52
Cycle 19 Day 1	Local	19	25,3	17	89,5	7,84	25,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	24,3	16	94,1	8,33	14,91
Cycle 20 Day 1	Local	19	25,3	17	89,5	5,88	17,62
	Central	17	24,3	15	88,2	11,11	16,27
Cycle 21 Day 1	Local	14	18,7	12	85,7	2,78	9,62
	Central	15	21,4	14	93,3	11,90	21,11
Cycle 22 Day 1	Local	14	18,7	12	85,7	2,78	9,62
	Central	15	21,4	13	86,7	5,13	12,52
Cycle 23 Day 1	Local	11	14,7	10	90,9	3,33	10,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	14,3	8	80,0	12,50	17,25
Cycle 24 Day 1	Local	11	14,7	10	90,9	6,67	14,05
	Central	9	12,9	8	88,9	4,17	11,79
Cycle 25 Day 1	Local	7	9,3	7	100,0	4,76	12,60
	Central	8	11,4	6	75,0	5,56	13,61
Cycle 26 Day 1	Local	6	8,0	6	100,0	5,56	13,61
	Central	8	11,4	6	75,0	11,11	17,21
Cycle 27 Day 1	Local	4	5,3	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	10,0	4	57,1	16,67	19,25
Cycle 28 Day 1	Local	4	5,3	4	100,0	8,33	16,67
	Central	6	8,6	5	83,3	20,00	29,81
Cycle 29 Day 1	Local	3	4,0	3	100,0	11,11	19,25
	Central	6	8,6	4	66,7	25,00	31,91
Cycle 30 Day 1	Local	3	4,0	3	100,0	11,11	19,25
	Central	4	5,7	2	50,0	0,00	0,00
Cycle 31 Day 1	Local	3	4,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	5,7	2	50,0	16,67	23,57
Cycle 32 Day 1	Local	3	4,0	3	100,0	11,11	19,25
	Central	3	4,3	2	66,7	0,00	0,00
Cycle 33 Day 1	Local	1	1,3	1	100,0	0,00	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	19,44	19,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	32	45,7	20	62,5	8,33	14,81
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	130	96,3	6,92	16,96
	No	10	100,0	10	100,0	10,00	22,50
Cycle 2 Day 1	Yes	129	95,6	117	90,7	17,38	23,81
	No	7	70,0	7	100,0	19,05	17,82
Cycle 3 Day 1	Yes	124	91,9	110	88,7	11,21	16,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	6	85,7	22,22	17,21
Cycle 4 Day 1	Yes	121	89,6	109	90,1	13,76	19,88
	No	7	70,0	7	100,0	4,76	12,60
Cycle 5 Day 1	Yes	117	86,7	109	93,2	12,23	19,59
	No	7	70,0	6	85,7	11,11	17,21
Cycle 6 Day 1	Yes	114	84,4	101	88,6	12,54	19,92
	No	7	70,0	7	100,0	19,05	17,82
Cycle 7 Day 1	Yes	106	78,5	96	90,6	11,46	17,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	4,76	12,60
Cycle 8 Day 1	Yes	100	74,1	90	90,0	11,11	15,80
	No	6	60,0	6	100,0	11,11	17,21
Cycle 9 Day 1	Yes	92	68,1	89	96,7	10,86	17,24
	No	6	60,0	6	100,0	16,67	18,26
Cycle 10 Day 1	Yes	83	61,5	80	96,4	10,83	16,58
	No	6	60,0	6	100,0	11,11	17,21
Cycle 11 Day 1	Yes	76	56,3	72	94,7	12,04	18,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	4	40,0	4	100,0	16,67	19,25
Cycle 12 Day 1	Yes	72	53,3	64	88,9	11,46	15,96
	No	4	40,0	4	100,0	8,33	16,67
Cycle 13 Day 1	Yes	64	47,4	58	90,6	11,49	15,98
	No	2	20,0	2	100,0	33,33	0,00
Cycle 14 Day 1	Yes	58	43,0	54	93,1	11,11	18,31
	No	2	20,0	2	100,0	16,67	23,57
Cycle 15 Day 1	Yes	55	40,7	51	92,7	9,15	15,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	33,33	0,00
Cycle 16 Day 1	Yes	48	35,6	45	93,8	9,63	16,85
	No	2	20,0	2	100,0	16,67	23,57
Cycle 17 Day 1	Yes	43	31,9	42	97,7	9,52	15,24
	No	2	20,0	2	100,0	50,00	23,57
Cycle 18 Day 1	Yes	39	28,9	35	89,7	8,57	16,85
	No	2	20,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	5,21	12,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	1	50,0	100,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	6,67	13,56
	No	2	20,0	2	100,0	33,33	47,14
Cycle 21 Day 1	Yes	27	20,0	24	88,9	8,33	17,72
	No	2	20,0	2	100,0	0,00	0,00
Cycle 22 Day 1	Yes	27	20,0	23	85,2	4,35	11,48
	No	2	20,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	7,84	14,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	5,88	13,10
	No	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	10,4	12	85,7	5,56	12,97
	No	1	10,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	6,06	13,48
	No	1	10,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	33,33	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	12,50	24,80
	No	1	10,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	16,67	27,89
	No	1	10,0	1	100,0	33,33	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	0,00	0,00
	No	1	10,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	33,33	-
Cycle 32 Day 1	Yes	5	3,7	4	80,0	0,00	0,00
	No	1	10,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	14,73	18,26
	No	2	20,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	6,06	20,10
	No	134	100,0	129	96,3	7,24	17,16
Cycle 2 Day 1	Yes	7	63,6	7	100,0	4,76	12,60
	No	129	96,3	117	90,7	18,23	23,77
Cycle 3 Day 1	Yes	7	63,6	6	85,7	5,56	13,61
	No	124	92,5	110	88,7	12,12	16,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	7	63,6	7	100,0	9,52	16,27
	No	121	90,3	109	90,1	13,46	19,83
Cycle 5 Day 1	Yes	7	63,6	7	100,0	14,29	17,82
	No	117	87,3	108	92,3	12,04	19,58
Cycle 6 Day 1	Yes	7	63,6	7	100,0	9,52	16,27
	No	114	85,1	101	88,6	13,20	20,04
Cycle 7 Day 1	Yes	7	63,6	7	100,0	9,52	16,27
	No	106	79,1	96	90,6	11,11	17,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	7	63,6	7	100,0	9,52	16,27
	No	99	73,9	89	89,9	11,24	15,85
Cycle 9 Day 1	Yes	6	54,5	6	100,0	11,11	17,21
	No	92	68,7	89	96,7	11,24	17,37
Cycle 10 Day 1	Yes	6	54,5	6	100,0	11,11	17,21
	No	83	61,9	80	96,4	10,83	16,58
Cycle 11 Day 1	Yes	6	54,5	6	100,0	16,67	27,89
	No	74	55,2	70	94,6	11,90	17,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	6	54,5	6	100,0	5,56	13,61
	No	70	52,2	62	88,6	11,83	16,08
Cycle 13 Day 1	Yes	5	45,5	5	100,0	13,33	18,26
	No	61	45,5	55	90,2	12,12	16,18
Cycle 14 Day 1	Yes	5	45,5	5	100,0	13,33	18,26
	No	55	41,0	51	92,7	11,11	18,46
Cycle 15 Day 1	Yes	4	36,4	4	100,0	8,33	16,67
	No	53	39,6	49	92,5	10,20	15,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	47	35,1	44	93,6	10,61	17,27
Cycle 17 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	42	31,3	41	97,6	11,38	17,65
Cycle 18 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	38	28,4	34	89,5	8,82	17,03
Cycle 19 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	33	24,6	30	90,9	7,78	20,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	33	24,6	29	87,9	8,05	17,03
Cycle 21 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	27	20,1	24	88,9	6,94	16,97
Cycle 22 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	27	20,1	23	85,2	2,90	9,60
Cycle 23 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	19	14,2	16	84,2	6,25	13,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	18	13,4	16	88,9	6,25	13,44
Cycle 25 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	13	9,7	11	84,6	3,03	10,05
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	9,09	15,57
Cycle 27 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	10	7,5	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	66,67	-
	No	9	6,7	8	88,9	8,33	15,43
Cycle 29 Day 1	Yes	1	9,1	1	100,0	66,67	-
	No	8	6,0	6	75,0	11,11	17,21
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	6,67	14,91
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	6,67	14,91
Cycle 33 Day 1	No	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	0,00	0,00
	No	61	45,5	41	67,2	15,45	18,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DS_SG.xls
24JUN2020 20:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	140	96,6	32,30	24,17
Cycle 2 Day 1	All	136	93,8	123	90,4	21,32	20,94
Cycle 3 Day 1	All	131	90,3	116	88,5	22,41	18,42
Cycle 4 Day 1	All	128	88,3	116	90,6	22,41	19,66
Cycle 5 Day 1	All	124	85,5	115	92,7	23,19	18,82
Cycle 6 Day 1	All	121	83,4	108	89,3	22,02	19,57
Cycle 7 Day 1	All	113	77,9	103	91,2	23,30	20,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	106	73,1	96	90,6	21,99	18,31
Cycle 9 Day 1	All	98	67,6	95	96,9	20,70	17,73
Cycle 10 Day 1	All	89	61,4	86	96,6	23,64	19,04
Cycle 11 Day 1	All	80	55,2	76	95,0	21,05	17,27
Cycle 12 Day 1	All	76	52,4	68	89,5	21,57	18,40
Cycle 13 Day 1	All	66	45,5	60	90,9	20,00	16,97
Cycle 14 Day 1	All	60	41,4	56	93,3	24,01	22,10
Cycle 15 Day 1	All	57	39,3	53	93,0	19,71	17,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	50	34,5	47	94,0	26,00	22,97
Cycle 17 Day 1	All	45	31,0	44	97,8	20,20	22,51
Cycle 18 Day 1	All	41	28,3	37	90,2	20,72	17,40
Cycle 19 Day 1	All	36	24,8	33	91,7	21,55	18,62
Cycle 20 Day 1	All	36	24,8	32	88,9	20,83	17,57
Cycle 21 Day 1	All	29	20,0	26	89,7	25,64	22,61
Cycle 22 Day 1	All	29	20,0	25	86,2	26,67	20,03
Cycle 23 Day 1	All	21	14,5	18	85,7	23,46	23,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	13,8	18	90,0	24,07	16,28
Cycle 25 Day 1	All	15	10,3	13	86,7	21,37	15,36
Cycle 26 Day 1	All	14	9,7	12	85,7	26,85	25,71
Cycle 27 Day 1	All	11	7,6	8	72,7	25,00	22,02
Cycle 28 Day 1	All	10	6,9	9	90,0	32,10	34,00
Cycle 29 Day 1	All	9	6,2	7	77,8	28,57	12,60
Cycle 30 Day 1	All	7	4,8	5	71,4	28,89	9,94
Cycle 31 Day 1	All	7	4,8	5	71,4	31,11	14,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	4,1	5	83,3	26,67	12,67
Cycle 33 Day 1	All	2	1,4	2	100,0	16,67	7,86
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	40,40	21,97
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	34,20	25,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	93	100,0	89	95,7	31,21	23,26
Cycle 2 Day 1	Male	50	96,2	45	90,0	27,41	23,40
	Female	86	92,5	78	90,7	17,81	18,64
Cycle 3 Day 1	Male	47	90,4	43	91,5	22,22	17,98
	Female	84	90,3	73	86,9	22,53	18,79
Cycle 4 Day 1	Male	46	88,5	43	93,5	20,93	19,43
	Female	82	88,2	73	89,0	23,29	19,87
Cycle 5 Day 1	Male	45	86,5	42	93,3	22,49	19,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	79	84,9	73	92,4	23,59	18,33
Cycle 6 Day 1	Male	45	86,5	41	91,1	21,14	20,31
	Female	76	81,7	67	88,2	22,55	19,24
Cycle 7 Day 1	Male	40	76,9	39	97,5	23,36	21,30
	Female	73	78,5	64	87,7	23,26	19,37
Cycle 8 Day 1	Male	37	71,2	34	91,9	22,22	20,10
	Female	69	74,2	62	89,9	21,86	17,42
Cycle 9 Day 1	Male	33	63,5	33	100,0	19,53	17,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	62	95,4	21,33	18,14
Cycle 10 Day 1	Male	30	57,7	30	100,0	26,67	21,95
	Female	59	63,4	56	94,9	22,02	17,28
Cycle 11 Day 1	Male	29	55,8	28	96,6	20,24	16,58
	Female	51	54,8	48	94,1	21,53	17,81
Cycle 12 Day 1	Male	27	51,9	26	96,3	23,08	18,57
	Female	49	52,7	42	85,7	20,63	18,46
Cycle 13 Day 1	Male	25	48,1	23	92,0	19,81	15,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	41	44,1	37	90,2	20,12	17,92
Cycle 14 Day 1	Male	23	44,2	21	91,3	26,46	24,21
	Female	37	39,8	35	94,6	22,54	20,96
Cycle 15 Day 1	Male	21	40,4	20	95,2	21,67	19,57
	Female	36	38,7	33	91,7	18,52	15,63
Cycle 16 Day 1	Male	16	30,8	16	100,0	25,69	24,92
	Female	34	36,6	31	91,2	26,16	22,32
Cycle 17 Day 1	Male	13	25,0	13	100,0	18,80	18,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	32	34,4	31	96,9	20,79	24,30
Cycle 18 Day 1	Male	12	23,1	11	91,7	18,18	21,81
	Female	29	31,2	26	89,7	21,79	15,55
Cycle 19 Day 1	Male	10	19,2	10	100,0	23,33	19,91
	Female	26	28,0	23	88,5	20,77	18,44
Cycle 20 Day 1	Male	10	19,2	9	90,0	13,58	14,46
	Female	26	28,0	23	88,5	23,67	18,14
Cycle 21 Day 1	Male	8	15,4	8	100,0	19,44	14,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	22,6	18	85,7	28,40	25,34
Cycle 22 Day 1	Male	8	15,4	6	75,0	22,22	15,71
	Female	21	22,6	19	90,5	28,07	21,39
Cycle 23 Day 1	Male	5	9,6	4	80,0	8,33	10,64
	Female	16	17,2	14	87,5	27,78	24,56
Cycle 24 Day 1	Male	5	9,6	4	80,0	19,44	13,98
	Female	15	16,1	14	93,3	25,40	17,12
Cycle 25 Day 1	Male	3	5,8	2	66,7	11,11	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	12,9	11	91,7	23,23	15,28
Cycle 26 Day 1	Male	3	5,8	2	66,7	5,56	7,86
	Female	11	11,8	10	90,9	31,11	26,08
Cycle 27 Day 1	Male	3	5,8	2	66,7	11,11	15,71
	Female	8	8,6	6	75,0	29,63	22,95
Cycle 28 Day 1	Male	2	3,8	2	100,0	11,11	15,71
	Female	8	8,6	7	87,5	38,10	36,21
Cycle 29 Day 1	Male	1	1,9	1	100,0	22,22	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	8,6	6	75,0	29,63	13,46
Cycle 30 Day 1	Male	1	1,9	1	100,0	22,22	-
	Female	6	6,5	4	66,7	30,56	10,64
Cycle 31 Day 1	Male	1	1,9	1	100,0	33,33	-
	Female	6	6,5	4	66,7	30,56	16,67
Cycle 32 Day 1	Male	1	1,9	1	100,0	22,22	-
	Female	5	5,4	4	80,0	27,78	14,34
Cycle 33 Day 1	Male	1	1,9	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	1,1	1	100,0	22,22	-
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	48,68	23,69
	Female	37	39,8	23	62,2	32,85	17,56
Age							
Cycle 1 Day 1	18-64	109	100,0	104	95,4	33,23	25,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	27,59	22,54
	>=75	7	100,0	7	100,0	38,10	10,84
Cycle 2 Day 1	18-64	103	94,5	90	87,4	19,51	19,45
	65-74	26	89,7	26	100,0	27,78	25,58
	>=75	7	100,0	7	100,0	20,63	18,62
Cycle 3 Day 1	18-64	99	90,8	87	87,9	21,71	18,71
	65-74	25	86,2	23	92,0	22,22	15,71
	>=75	7	100,0	6	85,7	33,33	23,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	98	89,9	88	89,8	20,96	19,24
	65-74	23	79,3	21	91,3	25,93	22,31
	>=75	7	100,0	7	100,0	30,16	15,33
Cycle 5 Day 1	18-64	95	87,2	88	92,6	23,48	19,53
	65-74	22	75,9	22	100,0	21,21	17,79
	>=75	7	100,0	5	71,4	26,67	9,94
Cycle 6 Day 1	18-64	92	84,4	80	87,0	20,69	19,43
	65-74	22	75,9	21	95,5	25,93	19,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	25,40	23,76
Cycle 7 Day 1	18-64	86	78,9	78	90,7	22,08	21,07
	65-74	20	69,0	19	95,0	26,90	16,28
	>=75	7	100,0	6	85,7	27,78	16,85
Cycle 8 Day 1	18-64	80	73,4	71	88,8	22,07	19,20
	65-74	19	65,5	19	100,0	21,64	17,16
	>=75	7	100,0	6	85,7	22,22	12,17
Cycle 9 Day 1	18-64	74	67,9	72	97,3	19,29	16,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	18	62,1	18	100,0	25,31	21,49
	>=75	6	85,7	5	83,3	24,44	19,88
Cycle 10 Day 1	18-64	69	63,3	66	95,7	22,56	19,09
	65-74	15	51,7	15	100,0	27,41	19,64
	>=75	5	71,4	5	100,0	26,67	18,59
Cycle 11 Day 1	18-64	61	56,0	58	95,1	21,46	18,48
	65-74	15	51,7	14	93,3	20,63	12,97
	>=75	4	57,1	4	100,0	16,67	14,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	57	52,3	50	87,7	20,89	19,26
	65-74	15	51,7	14	93,3	23,81	16,22
	>=75	4	57,1	4	100,0	22,22	18,14
Cycle 13 Day 1	18-64	49	45,0	45	91,8	17,53	15,07
	65-74	13	44,8	11	84,6	27,27	22,97
	>=75	4	57,1	4	100,0	27,78	14,34
Cycle 14 Day 1	18-64	45	41,3	43	95,6	22,22	21,96
	65-74	13	44,8	11	84,6	29,29	23,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	28,6	2	100,0	33,33	15,71
Cycle 15 Day 1	18-64	43	39,4	40	93,0	17,22	16,30
	65-74	12	41,4	11	91,7	25,25	17,28
	>=75	2	28,6	2	100,0	38,89	23,57
Cycle 16 Day 1	18-64	38	34,9	36	94,7	25,93	25,06
	65-74	10	34,5	9	90,0	27,16	16,77
	>=75	2	28,6	2	100,0	22,22	0,00
Cycle 17 Day 1	18-64	36	33,0	35	97,2	18,10	20,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	27,6	8	100,0	26,39	31,39
	>=75	1	14,3	1	100,0	44,44	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	17,78	14,47
	65-74	7	24,1	6	85,7	33,33	26,29
	>=75	1	14,3	1	100,0	33,33	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	19,44	17,79
	65-74	5	17,2	4	80,0	27,78	19,25
	>=75	1	14,3	1	100,0	55,56	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	17,52	16,97
	65-74	5	17,2	5	100,0	35,56	14,49
	>=75	1	14,3	1	100,0	33,33	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	22,22	18,59
	65-74	4	13,8	4	100,0	41,67	38,89
	>=75	1	14,3	1	100,0	33,33	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	27,22	22,36
	65-74	4	13,8	4	100,0	22,22	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	33,33	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	23,61	24,97
	65-74	2	6,9	2	100,0	22,22	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	24,31	17,32
	65-74	2	6,9	2	100,0	22,22	0,00
Cycle 25 Day 1	18-64	14	12,8	12	85,7	21,30	16,04
	65-74	1	3,4	1	100,0	22,22	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	26,85	25,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	25,00	22,02
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	32,10	34,00
	65-74	1	3,4	0	0,0	-	-
Cycle 29 Day 1	18-64	8	7,3	7	87,5	28,57	12,60
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	28,89	9,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	31,11	14,49
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	27,78	14,34
	65-74	1	3,4	1	100,0	22,22	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	11,11	-
	65-74	1	3,4	1	100,0	22,22	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	40,85	23,80
	65-74	15	51,7	8	53,3	41,67	15,43
	>=75	4	57,1	2	50,0	27,78	7,86
Race							
Cycle 1 Day 1	White	60	100,0	57	95,0	34,89	26,43
	Other	85	100,0	83	97,6	30,52	22,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	57	95,0	49	86,0	25,17	23,22
	Other	79	92,9	74	93,7	18,77	19,02
Cycle 3 Day 1	White	54	90,0	44	81,5	23,74	19,55
	Other	77	90,6	72	93,5	21,60	17,78
Cycle 4 Day 1	White	53	88,3	45	84,9	19,75	17,71
	Other	75	88,2	71	94,7	24,10	20,74
Cycle 5 Day 1	White	52	86,7	47	90,4	22,22	18,82
	Other	72	84,7	68	94,4	23,86	18,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	50	83,3	41	82,0	22,76	21,51
	Other	71	83,5	67	94,4	21,56	18,44
Cycle 7 Day 1	White	47	78,3	40	85,1	25,00	19,93
	Other	66	77,6	63	95,5	22,22	20,15
Cycle 8 Day 1	White	45	75,0	38	84,4	19,88	17,36
	Other	61	71,8	58	95,1	23,37	18,93
Cycle 9 Day 1	White	42	70,0	41	97,6	22,49	19,64
	Other	56	65,9	54	96,4	19,34	16,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	22,79	18,02
	Other	48	56,5	47	97,9	24,35	20,02
Cycle 11 Day 1	White	37	61,7	36	97,3	20,99	14,97
	Other	43	50,6	40	93,0	21,11	19,29
Cycle 12 Day 1	White	37	61,7	33	89,2	20,88	18,99
	Other	39	45,9	35	89,7	22,22	18,08
Cycle 13 Day 1	White	32	53,3	30	93,8	21,11	19,21
	Other	34	40,0	30	88,2	18,89	14,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	31	51,7	30	96,8	22,96	22,96
	Other	29	34,1	26	89,7	25,21	21,44
Cycle 15 Day 1	White	30	50,0	28	93,3	21,03	17,98
	Other	27	31,8	25	92,6	18,22	16,32
Cycle 16 Day 1	White	26	43,3	24	92,3	23,61	21,31
	Other	24	28,2	23	95,8	28,50	24,81
Cycle 17 Day 1	White	24	40,0	24	100,0	21,76	20,85
	Other	21	24,7	20	95,2	18,33	24,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	22	36,7	19	86,4	18,71	13,88
	Other	19	22,4	18	94,7	22,84	20,69
Cycle 19 Day 1	White	20	33,3	20	100,0	24,44	21,20
	Other	16	18,8	13	81,3	17,09	13,31
Cycle 20 Day 1	White	20	33,3	17	85,0	21,57	19,43
	Other	16	18,8	15	93,8	20,00	15,83
Cycle 21 Day 1	White	16	26,7	14	87,5	26,19	19,78
	Other	13	15,3	12	92,3	25,00	26,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	26,7	13	81,3	29,06	25,47
	Other	13	15,3	12	92,3	24,07	12,38
Cycle 23 Day 1	White	12	20,0	10	83,3	32,22	26,94
	Other	9	10,6	8	88,9	12,50	12,51
Cycle 24 Day 1	White	11	18,3	10	90,9	23,33	19,21
	Other	9	10,6	8	88,9	25,00	12,94
Cycle 25 Day 1	White	10	16,7	8	80,0	20,83	18,25
	Other	5	5,9	5	100,0	22,22	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	16,7	8	80,0	18,06	22,95
	Other	4	4,7	4	100,0	44,44	24,00
Cycle 27 Day 1	White	8	13,3	5	62,5	13,33	12,17
	Other	3	3,5	3	100,0	44,44	22,22
Cycle 28 Day 1	White	7	11,7	6	85,7	12,96	14,77
	Other	3	3,5	3	100,0	70,37	27,96
Cycle 29 Day 1	White	6	10,0	4	66,7	22,22	9,07
	Other	3	3,5	3	100,0	37,04	12,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	6,7	2	50,0	22,22	0,00
	Other	3	3,5	3	100,0	33,33	11,11
Cycle 31 Day 1	White	4	6,7	2	50,0	22,22	15,71
	Other	3	3,5	3	100,0	37,04	12,83
Cycle 32 Day 1	White	4	6,7	3	75,0	18,52	6,42
	Other	2	2,4	2	100,0	38,89	7,86
Cycle 33 Day 1	White	2	3,3	2	100,0	16,67	7,86
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-
End Of Treatment	White	25	41,7	17	68,0	42,48	15,33
	Other	39	45,9	27	69,2	39,09	25,48
Region							
Cycle 1 Day 1	America (AM)	40	100,0	38	95,0	31,29	24,76
	Europe (EU)	34	100,0	31	91,2	36,20	28,40
	Asia (AS)	71	100,0	71	100,0	31,14	21,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	31	81,6	25,45	19,07
	Europe (EU)	32	94,1	27	84,4	24,69	24,91
	Asia (AS)	66	93,0	65	98,5	17,95	19,71
Cycle 3 Day 1	America (AM)	37	92,5	32	86,5	24,31	16,56
	Europe (EU)	31	91,2	21	67,7	23,28	23,81
	Asia (AS)	63	88,7	63	100,0	21,16	17,48
Cycle 4 Day 1	America (AM)	37	92,5	32	86,5	23,61	19,09
	Europe (EU)	30	88,2	24	80,0	17,13	17,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	61	85,9	60	98,4	23,89	20,64
Cycle 5 Day 1	America (AM)	37	92,5	33	89,2	23,57	18,37
	Europe (EU)	30	88,2	25	83,3	22,22	17,57
	Asia (AS)	57	80,3	57	100,0	23,39	19,89
Cycle 6 Day 1	America (AM)	37	92,5	32	86,5	23,61	22,53
	Europe (EU)	28	82,4	24	85,7	22,69	18,67
	Asia (AS)	56	78,9	52	92,9	20,73	18,28
Cycle 7 Day 1	America (AM)	35	87,5	29	82,9	26,05	24,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	28	82,4	25	89,3	22,67	18,83
	Asia (AS)	50	70,4	49	98,0	22,00	17,93
Cycle 8 Day 1	America (AM)	31	77,5	26	83,9	19,66	17,86
	Europe (EU)	28	82,4	23	82,1	21,26	15,32
	Asia (AS)	47	66,2	47	100,0	23,64	20,01
Cycle 9 Day 1	America (AM)	29	72,5	27	93,1	19,75	18,06
	Europe (EU)	26	76,5	25	96,2	23,11	20,01
	Asia (AS)	43	60,6	43	100,0	19,90	16,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	23,61	17,43
	Europe (EU)	25	73,5	25	100,0	25,78	21,92
	Asia (AS)	37	52,1	37	100,0	22,22	18,33
Cycle 11 Day 1	America (AM)	24	60,0	21	87,5	24,87	21,92
	Europe (EU)	23	67,6	22	95,7	20,20	13,12
	Asia (AS)	33	46,5	33	100,0	19,19	16,50
Cycle 12 Day 1	America (AM)	24	60,0	22	91,7	18,18	21,29
	Europe (EU)	23	67,6	18	78,3	25,31	15,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	40,8	28	96,6	21,83	18,01
Cycle 13 Day 1	America (AM)	23	57,5	21	91,3	17,99	16,28
	Europe (EU)	18	52,9	14	77,8	24,60	21,43
	Asia (AS)	25	35,2	25	100,0	19,11	14,88
Cycle 14 Day 1	America (AM)	22	55,0	20	90,9	23,89	23,99
	Europe (EU)	17	50,0	16	94,1	27,78	24,68
	Asia (AS)	21	29,6	20	95,2	21,11	18,35
Cycle 15 Day 1	America (AM)	22	55,0	19	86,4	17,54	16,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	44,1	14	93,3	23,81	17,89
	Asia (AS)	20	28,2	20	100,0	18,89	17,33
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	20,92	18,38
	Europe (EU)	14	41,2	11	78,6	29,29	24,98
	Asia (AS)	19	26,8	19	100,0	28,65	25,74
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	19,44	24,51
	Europe (EU)	13	38,2	12	92,3	20,37	14,08
	Asia (AS)	16	22,5	16	100,0	20,83	26,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	19,05	18,71
	Europe (EU)	11	32,4	7	63,6	22,22	12,83
	Asia (AS)	16	22,5	16	100,0	21,53	18,80
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	18,80	18,36
	Europe (EU)	9	26,5	9	100,0	33,33	19,25
	Asia (AS)	14	19,7	11	78,6	15,15	15,13
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	17,95	18,45
	Europe (EU)	9	26,5	6	66,7	29,63	16,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	19,66	17,07
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	20,00	20,82
	Europe (EU)	7	20,6	6	85,7	31,48	14,77
	Asia (AS)	11	15,5	10	90,9	27,78	28,33
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	24,44	26,60
	Europe (EU)	7	20,6	5	71,4	33,33	17,57
	Asia (AS)	11	15,5	10	90,9	25,56	13,91
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	27,16	27,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	14,7	3	60,0	37,04	16,97
	Asia (AS)	7	9,9	6	85,7	11,11	14,05
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	25,00	19,47
	Europe (EU)	5	14,7	4	80,0	19,44	13,98
	Asia (AS)	7	9,9	6	85,7	25,93	15,18
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	15,87	19,09
	Europe (EU)	4	11,8	2	50,0	27,78	7,86
	Asia (AS)	4	5,6	4	100,0	27,78	6,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	18,52	25,01
	Europe (EU)	4	11,8	2	50,0	16,67	23,57
	Asia (AS)	4	5,6	4	100,0	44,44	24,00
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	11,11	12,83
	Europe (EU)	3	8,8	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	38,89	21,28
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	11,11	12,83
	Europe (EU)	2	5,9	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	61,11	29,40
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	22,22	11,11
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	33,33	12,83
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	22,22	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	33,33	11,11
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	22,22	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	37,04	12,83
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	16,67	7,86
	Europe (EU)	1	2,9	1	100,0	22,22	-
	Asia (AS)	3	4,2	2	66,7	38,89	7,86
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	11,11	-
	Europe (EU)	1	2,9	1	100,0	22,22	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	41,18	19,94
	Europe (EU)	10	29,4	5	50,0	53,33	26,53
	Asia (AS)	34	47,9	22	64,7	36,87	22,32
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	59	96,7	23,16	19,05
	1	69	100,0	66	95,7	37,37	24,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	15	100,0	15	100,0	45,93	30,24
Cycle 2 Day 1	0	59	96,7	54	91,5	17,28	19,62
	1	67	97,1	59	88,1	24,48	22,01
	2	10	66,7	10	100,0	24,44	19,46
Cycle 3 Day 1	0	57	93,4	50	87,7	18,00	16,48
	1	65	94,2	57	87,7	24,95	18,22
	2	9	60,0	9	100,0	30,86	25,32
Cycle 4 Day 1	0	57	93,4	51	89,5	18,52	19,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	57	91,9	24,37	18,12
	2	9	60,0	8	88,9	33,33	24,49
Cycle 5 Day 1	0	56	91,8	52	92,9	20,09	17,33
	1	62	89,9	57	91,9	25,15	19,87
	2	6	40,0	6	100,0	31,48	19,14
Cycle 6 Day 1	0	56	91,8	53	94,6	23,06	22,10
	1	59	85,5	51	86,4	20,48	16,54
	2	6	40,0	4	66,7	27,78	23,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	54	88,5	51	94,4	20,48	19,55
	1	54	78,3	47	87,0	25,77	20,99
	2	5	33,3	5	100,0	28,89	12,67
Cycle 8 Day 1	0	52	85,2	48	92,3	18,29	16,76
	1	49	71,0	43	87,8	25,58	19,33
	2	5	33,3	5	100,0	26,67	20,18
Cycle 9 Day 1	0	50	82,0	49	98,0	19,95	18,84
	1	44	63,8	42	95,5	21,43	17,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	4	26,7	4	100,0	22,22	9,07
Cycle 10 Day 1	0	46	75,4	46	100,0	22,95	20,47
	1	40	58,0	37	92,5	24,32	17,92
	2	3	20,0	3	100,0	25,93	12,83
Cycle 11 Day 1	0	43	70,5	40	93,0	19,17	14,67
	1	34	49,3	33	97,1	22,90	20,40
	2	3	20,0	3	100,0	25,93	12,83
Cycle 12 Day 1	0	42	68,9	36	85,7	21,91	16,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	31	44,9	29	93,5	20,69	21,36
	2	3	20,0	3	100,0	25,93	6,42
Cycle 13 Day 1	0	38	62,3	34	89,5	20,26	18,45
	1	27	39,1	25	92,6	20,00	15,38
	2	1	6,7	1	100,0	11,11	-
Cycle 14 Day 1	0	35	57,4	32	91,4	24,65	21,63
	1	24	34,8	23	95,8	23,67	23,52
	2	1	6,7	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	33	54,1	30	90,9	18,89	16,02
	1	23	33,3	22	95,7	21,72	18,62
	2	1	6,7	1	100,0	0,00	-
Cycle 16 Day 1	0	28	45,9	25	89,3	25,78	21,69
	1	21	30,4	21	100,0	26,98	25,23
	2	1	6,7	1	100,0	11,11	-
Cycle 17 Day 1	0	24	39,3	23	95,8	20,77	27,69
	1	20	29,0	20	100,0	20,56	15,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	21,05	20,59
	1	17	24,6	17	100,0	20,92	14,10
	2	1	6,7	1	100,0	11,11	-
Cycle 19 Day 1	0	20	32,8	19	95,0	21,64	19,76
	1	15	21,7	13	86,7	22,22	18,14
	2	1	6,7	1	100,0	11,11	-
Cycle 20 Day 1	0	20	32,8	17	85,0	21,57	20,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	21,7	14	93,3	20,63	15,01
	2	1	6,7	1	100,0	11,11	-
Cycle 21 Day 1	0	15	24,6	14	93,3	29,37	28,45
	1	13	18,8	11	84,6	23,23	11,61
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	28,70	25,27
	1	13	18,8	12	92,3	25,93	14,47
	2	1	6,7	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	32,10	28,57
	1	9	13,0	8	88,9	16,67	13,28
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	23,46	19,60
	1	9	13,0	8	88,9	23,61	13,85
	2	1	6,7	1	100,0	33,33	-
Cycle 25 Day 1	0	8	13,1	6	75,0	22,22	18,59
	1	7	10,1	7	100,0	20,63	13,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	13,1	6	75,0	20,37	24,76
	1	6	8,7	6	100,0	33,33	27,22
Cycle 27 Day 1	0	6	9,8	3	50,0	14,81	12,83
	1	5	7,2	5	100,0	31,11	25,34
Cycle 28 Day 1	0	5	8,2	4	80,0	13,89	16,67
	1	5	7,2	5	100,0	46,67	38,81
Cycle 29 Day 1	0	4	6,6	2	50,0	22,22	0,00
	1	5	7,2	5	100,0	31,11	14,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	4,9	1	33,3	22,22	-
	1	4	5,8	4	100,0	30,56	10,64
Cycle 31 Day 1	0	3	4,9	1	33,3	33,33	-
	1	4	5,8	4	100,0	30,56	16,67
Cycle 32 Day 1	0	3	4,9	2	66,7	22,22	0,00
	1	3	4,3	3	100,0	29,63	16,97
Cycle 33 Day 1	0	2	3,3	2	100,0	16,67	7,86
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	40,21	20,93
	1	34	49,3	20	58,8	41,67	24,94
	2	7	46,7	3	42,9	33,33	0,00
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	59	95,2	32,58	25,43
	1	4	100,0	4	100,0	36,11	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	79	100,0	77	97,5	31,89	23,11
Cycle 2 Day 1	None	60	96,8	53	88,3	21,17	18,14
	1	3	75,0	1	33,3	22,22	-
	2 or More	73	92,4	69	94,5	21,42	23,13
Cycle 3 Day 1	None	59	95,2	53	89,8	21,80	18,49
	1	3	75,0	2	66,7	16,67	23,57
	2 or More	69	87,3	61	88,4	23,13	18,51
Cycle 4 Day 1	None	59	95,2	54	91,5	21,60	18,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	2	66,7	11,11	15,71
	2 or More	66	83,5	60	90,9	23,52	20,47
Cycle 5 Day 1	None	58	93,5	54	93,1	21,19	18,60
	1	3	75,0	3	100,0	11,11	11,11
	2 or More	63	79,7	58	92,1	25,67	19,10
Cycle 6 Day 1	None	57	91,9	49	86,0	20,63	17,86
	1	3	75,0	3	100,0	11,11	11,11
	2 or More	61	77,2	56	91,8	23,81	21,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	52	83,9	47	90,4	20,33	20,24
	1	3	75,0	3	100,0	18,52	23,13
	2 or More	58	73,4	53	91,4	26,21	19,62
Cycle 8 Day 1	None	50	80,6	45	90,0	20,25	19,58
	1	3	75,0	1	33,3	22,22	-
	2 or More	53	67,1	50	94,3	23,56	17,34
Cycle 9 Day 1	None	48	77,4	46	95,8	18,36	16,43
	1	1	25,0	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	23,15	18,88
Cycle 10 Day 1	None	43	69,4	41	95,3	22,22	21,37
	1	1	25,0	1	100,0	11,11	-
	2 or More	45	57,0	44	97,8	25,25	16,84
Cycle 11 Day 1	None	37	59,7	33	89,2	19,53	19,84
	1	1	25,0	1	100,0	11,11	-
	2 or More	42	53,2	42	100,0	22,49	15,22
Cycle 12 Day 1	None	37	59,7	33	89,2	18,52	18,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	11,11	-
	2 or More	38	48,1	34	89,5	24,84	18,56
Cycle 13 Day 1	None	34	54,8	28	82,4	16,67	14,34
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	23,66	18,54
Cycle 14 Day 1	None	31	50,0	28	90,3	24,60	23,10
	1	1	25,0	1	100,0	0,00	-
	2 or More	28	35,4	27	96,4	24,28	21,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	30	48,4	27	90,0	17,70	17,50
	1	1	25,0	1	100,0	11,11	-
	2 or More	26	32,9	25	96,2	22,22	16,97
Cycle 16 Day 1	None	25	40,3	23	92,0	22,71	24,04
	1	1	25,0	1	100,0	11,11	-
	2 or More	24	30,4	23	95,8	29,95	22,08
Cycle 17 Day 1	None	23	37,1	22	95,7	15,15	16,64
	1	1	25,0	1	100,0	11,11	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	21	26,6	21	100,0	25,93	27,06
Cycle 18 Day 1	None	20	32,3	18	90,0	16,67	17,57
	1	1	25,0	1	100,0	11,11	-
	2 or More	20	25,3	18	90,0	25,31	16,96
Cycle 19 Day 1	None	17	27,4	17	100,0	13,07	15,33
	1	1	25,0	1	100,0	11,11	-
	2 or More	18	22,8	15	83,3	31,85	17,75
Cycle 20 Day 1	None	17	27,4	16	94,1	11,81	11,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	22,22	-
	2 or More	18	22,8	15	83,3	30,37	19,00
Cycle 21 Day 1	None	15	24,2	13	86,7	13,68	11,25
	2 or More	14	17,7	13	92,9	37,61	25,07
Cycle 22 Day 1	None	15	24,2	13	86,7	16,24	13,31
	2 or More	14	17,7	12	85,7	37,96	20,36
Cycle 23 Day 1	None	10	16,1	9	90,0	13,58	9,26
	2 or More	11	13,9	9	81,8	33,33	29,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	16,1	10	100,0	15,56	11,94
	2 or More	10	12,7	8	80,0	34,72	15,07
Cycle 25 Day 1	None	9	14,5	8	88,9	13,89	11,50
	2 or More	6	7,6	5	83,3	33,33	13,61
Cycle 26 Day 1	None	8	12,9	8	100,0	18,06	25,85
	2 or More	6	7,6	4	66,7	44,44	15,71
Cycle 27 Day 1	None	7	11,3	6	85,7	22,22	24,34
	2 or More	4	5,1	2	50,0	33,33	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	11,3	7	100,0	20,63	24,37
	2 or More	3	3,8	2	66,7	72,22	39,28
Cycle 29 Day 1	None	6	9,7	5	83,3	26,67	12,67
	2 or More	3	3,8	2	66,7	33,33	15,71
Cycle 30 Day 1	None	4	6,5	3	75,0	25,93	6,42
	2 or More	3	3,8	2	66,7	33,33	15,71
Cycle 31 Day 1	None	4	6,5	3	75,0	22,22	11,11
	2 or More	3	3,8	2	66,7	44,44	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	22,22	11,11
	2 or More	2	2,5	2	100,0	33,33	15,71
Cycle 33 Day 1	None	1	1,6	1	100,0	11,11	-
	2 or More	1	1,3	1	100,0	22,22	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	36,84	20,30
	1	3	75,0	1	33,3	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	39	49,4	24	61,5	42,13	23,16
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	59	95,2	32,58	25,43
	Previously Treated	83	100,0	81	97,6	32,10	23,37
Cycle 2 Day 1	Naïve	60	96,8	53	88,3	21,17	18,14
	Previously Treated	76	91,6	70	92,1	21,43	22,96
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	21,80	18,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	72	86,7	63	87,5	22,93	18,49
Cycle 4 Day 1	Naïve	59	95,2	54	91,5	21,60	18,99
	Previously Treated	69	83,1	62	89,9	23,12	20,35
Cycle 5 Day 1	Naïve	58	93,5	54	93,1	21,19	18,60
	Previously Treated	66	79,5	61	92,4	24,95	18,99
Cycle 6 Day 1	Naïve	57	91,9	49	86,0	20,63	17,86
	Previously Treated	64	77,1	59	92,2	23,16	20,97
Cycle 7 Day 1	Naïve	52	83,9	47	90,4	20,33	20,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	61	73,5	56	91,8	25,79	19,66
Cycle 8 Day 1	Naïve	50	80,6	45	90,0	20,25	19,58
	Previously Treated	56	67,5	51	91,1	23,53	17,16
Cycle 9 Day 1	Naïve	48	77,4	46	95,8	18,36	16,43
	Previously Treated	50	60,2	49	98,0	22,90	18,76
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	22,22	21,37
	Previously Treated	46	55,4	45	97,8	24,94	16,78
Cycle 11 Day 1	Naïve	37	59,7	33	89,2	19,53	19,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	43	51,8	43	100,0	22,22	15,14
Cycle 12 Day 1	Naïve	37	59,7	33	89,2	18,52	18,14
	Previously Treated	39	47,0	35	89,7	24,44	18,44
Cycle 13 Day 1	Naïve	34	54,8	28	82,4	16,67	14,34
	Previously Treated	32	38,6	32	100,0	22,92	18,71
Cycle 14 Day 1	Naïve	31	50,0	28	90,3	24,60	23,10
	Previously Treated	29	34,9	28	96,6	23,41	21,46
Cycle 15 Day 1	Naïve	30	48,4	27	90,0	17,70	17,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	27	32,5	26	96,3	21,79	16,77
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	22,71	24,04
	Previously Treated	25	30,1	24	96,0	29,17	21,93
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	15,15	16,64
	Previously Treated	22	26,5	22	100,0	25,25	26,60
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	16,67	17,57
	Previously Treated	21	25,3	19	90,5	24,56	16,80
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	13,07	15,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	22,9	16	84,2	30,56	17,92
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	11,81	11,09
	Previously Treated	19	22,9	16	84,2	29,86	18,47
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	13,68	11,25
	Previously Treated	14	16,9	13	92,9	37,61	25,07
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	16,24	13,31
	Previously Treated	14	16,9	12	85,7	37,96	20,36
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	13,58	9,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	33,33	29,40
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	15,56	11,94
	Previously Treated	10	12,0	8	80,0	34,72	15,07
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	13,89	11,50
	Previously Treated	6	7,2	5	83,3	33,33	13,61
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	18,06	25,85
	Previously Treated	6	7,2	4	66,7	44,44	15,71
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	22,22	24,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	4,8	2	50,0	33,33	15,71
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	20,63	24,37
	Previously Treated	3	3,6	2	66,7	72,22	39,28
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	26,67	12,67
	Previously Treated	3	3,6	2	66,7	33,33	15,71
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	25,93	6,42
	Previously Treated	3	3,6	2	66,7	33,33	15,71
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	22,22	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	44,44	0,00
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	22,22	11,11
	Previously Treated	2	2,4	2	100,0	33,33	15,71
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	11,11	-
	Previously Treated	1	1,2	1	100,0	22,22	-
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	36,84	20,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	50,6	25	59,5	43,11	23,20
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	31,85	23,56
	Central	70	100,0	65	92,9	32,82	25,03
Cycle 2 Day 1	Local	71	94,7	67	94,4	20,07	18,07
	Central	65	92,9	56	86,2	22,82	24,01
Cycle 3 Day 1	Local	67	89,3	60	89,6	20,19	17,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	64	91,4	56	87,5	24,80	19,07
Cycle 4 Day 1	Local	65	86,7	58	89,2	22,22	19,63
	Central	63	90,0	58	92,1	22,61	19,85
Cycle 5 Day 1	Local	63	84,0	58	92,1	23,95	19,50
	Central	61	87,1	57	93,4	22,42	18,24
Cycle 6 Day 1	Local	63	84,0	61	96,8	23,13	20,91
	Central	58	82,9	47	81,0	20,57	17,79
Cycle 7 Day 1	Local	61	81,3	58	95,1	22,80	21,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	52	74,3	45	86,5	23,95	18,34
Cycle 8 Day 1	Local	57	76,0	54	94,7	22,02	17,47
	Central	49	70,0	42	85,7	21,96	19,55
Cycle 9 Day 1	Local	54	72,0	53	98,1	21,80	18,74
	Central	44	62,9	42	95,5	19,31	16,47
Cycle 10 Day 1	Local	48	64,0	46	95,8	26,33	20,33
	Central	41	58,6	40	97,6	20,56	17,17
Cycle 11 Day 1	Local	40	53,3	38	95,0	23,68	19,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	40	57,1	38	95,0	18,42	14,45
Cycle 12 Day 1	Local	36	48,0	33	91,7	19,19	18,69
	Central	40	57,1	35	87,5	23,81	18,11
Cycle 13 Day 1	Local	30	40,0	29	96,7	19,16	17,03
	Central	36	51,4	31	86,1	20,79	17,15
Cycle 14 Day 1	Local	27	36,0	27	100,0	22,22	20,21
	Central	33	47,1	29	87,9	25,67	23,96
Cycle 15 Day 1	Local	26	34,7	25	96,2	17,78	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	28	90,3	21,43	16,82
Cycle 16 Day 1	Local	24	32,0	24	100,0	20,37	17,54
	Central	26	37,1	23	88,5	31,88	26,65
Cycle 17 Day 1	Local	22	29,3	22	100,0	15,15	17,33
	Central	23	32,9	22	95,7	25,25	26,16
Cycle 18 Day 1	Local	20	26,7	19	95,0	16,96	16,72
	Central	21	30,0	18	85,7	24,69	17,69
Cycle 19 Day 1	Local	19	25,3	17	89,5	20,26	18,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	24,3	16	94,1	22,92	19,65
Cycle 20 Day 1	Local	19	25,3	17	89,5	15,03	13,57
	Central	17	24,3	15	88,2	27,41	19,64
Cycle 21 Day 1	Local	14	18,7	12	85,7	16,67	15,35
	Central	15	21,4	14	93,3	33,33	25,41
Cycle 22 Day 1	Local	14	18,7	12	85,7	20,37	16,30
	Central	15	21,4	13	86,7	32,48	21,97
Cycle 23 Day 1	Local	11	14,7	10	90,9	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	14,3	8	80,0	36,11	25,02
Cycle 24 Day 1	Local	11	14,7	10	90,9	23,33	19,21
	Central	9	12,9	8	88,9	25,00	12,94
Cycle 25 Day 1	Local	7	9,3	7	100,0	20,63	18,62
	Central	8	11,4	6	75,0	22,22	12,17
Cycle 26 Day 1	Local	6	8,0	6	100,0	31,48	32,52
	Central	8	11,4	6	75,0	22,22	18,59
Cycle 27 Day 1	Local	4	5,3	4	100,0	27,78	27,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	10,0	4	57,1	22,22	18,14
Cycle 28 Day 1	Local	4	5,3	4	100,0	27,78	27,96
	Central	6	8,6	5	83,3	35,56	41,13
Cycle 29 Day 1	Local	3	4,0	3	100,0	25,93	16,97
	Central	6	8,6	4	66,7	30,56	10,64
Cycle 30 Day 1	Local	3	4,0	3	100,0	25,93	6,42
	Central	4	5,7	2	50,0	33,33	15,71
Cycle 31 Day 1	Local	3	4,0	3	100,0	22,22	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	5,7	2	50,0	44,44	0,00
Cycle 32 Day 1	Local	3	4,0	3	100,0	22,22	11,11
	Central	3	4,3	2	66,7	33,33	15,71
Cycle 33 Day 1	Local	1	1,3	1	100,0	11,11	-
	Central	1	1,4	1	100,0	22,22	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	39,35	18,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	32	45,7	20	62,5	41,67	25,71
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	130	96,3	31,88	24,22
	No	10	100,0	10	100,0	37,78	24,12
Cycle 2 Day 1	Yes	129	95,6	116	89,9	20,31	20,37
	No	7	70,0	7	100,0	38,10	24,73
Cycle 3 Day 1	Yes	124	91,9	110	88,7	21,21	17,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	6	85,7	44,44	23,31
Cycle 4 Day 1	Yes	121	89,6	109	90,1	20,69	18,11
	No	7	70,0	7	100,0	49,21	24,73
Cycle 5 Day 1	Yes	117	86,7	109	93,2	22,02	18,27
	No	7	70,0	6	85,7	44,44	17,21
Cycle 6 Day 1	Yes	114	84,4	101	88,6	20,68	18,99
	No	7	70,0	7	100,0	41,27	18,94
Cycle 7 Day 1	Yes	106	78,5	96	90,6	21,88	18,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	42,86	32,35
Cycle 8 Day 1	Yes	100	74,1	90	90,0	21,23	17,99
	No	6	60,0	6	100,0	33,33	21,08
Cycle 9 Day 1	Yes	92	68,1	89	96,7	20,22	17,77
	No	6	60,0	6	100,0	27,78	16,85
Cycle 10 Day 1	Yes	83	61,5	80	96,4	23,19	19,30
	No	6	60,0	6	100,0	29,63	15,18
Cycle 11 Day 1	Yes	76	56,3	72	94,7	20,99	17,45

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	4	40,0	4	100,0	22,22	15,71
Cycle 12 Day 1	Yes	72	53,3	64	88,9	21,35	18,39
	No	4	40,0	4	100,0	25,00	21,03
Cycle 13 Day 1	Yes	64	47,4	58	90,6	19,35	16,59
	No	2	20,0	2	100,0	38,89	23,57
Cycle 14 Day 1	Yes	58	43,0	54	93,1	22,63	21,25
	No	2	20,0	2	100,0	61,11	7,86
Cycle 15 Day 1	Yes	55	40,7	51	92,7	18,52	16,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	50,00	7,86
Cycle 16 Day 1	Yes	48	35,6	45	93,8	24,44	22,17
	No	2	20,0	2	100,0	61,11	7,86
Cycle 17 Day 1	Yes	43	31,9	42	97,7	17,46	18,39
	No	2	20,0	2	100,0	77,78	31,43
Cycle 18 Day 1	Yes	39	28,9	35	89,7	19,05	15,84
	No	2	20,0	2	100,0	50,00	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	21,18	18,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	1	50,0	33,33	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	20,00	16,86
	No	2	20,0	2	100,0	33,33	31,43
Cycle 21 Day 1	Yes	27	20,0	24	88,9	22,69	17,49
	No	2	20,0	2	100,0	61,11	55,00
Cycle 22 Day 1	Yes	27	20,0	23	85,2	27,05	20,87
	No	2	20,0	2	100,0	22,22	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	24,84	23,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	25,49	15,60
	No	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	10,4	12	85,7	20,37	15,59
	No	1	10,0	1	100,0	33,33	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	22,22	21,08
	No	1	10,0	1	100,0	77,78	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	19,05	15,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	66,67	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	27,78	33,60
	No	1	10,0	1	100,0	66,67	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	25,93	11,48
	No	1	10,0	1	100,0	44,44	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	27,78	11,11
	No	1	10,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	33,33	15,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	22,22	-
Cycle 32 Day 1	Yes	5	3,7	4	80,0	25,00	13,98
	No	1	10,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	16,67	7,86
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	39,28	20,91
	No	2	20,0	1	50,0	88,89	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	44,44	24,34
	No	134	100,0	129	96,3	31,27	23,97
Cycle 2 Day 1	Yes	7	63,6	7	100,0	20,63	23,51
	No	129	96,3	116	89,9	21,36	20,88
Cycle 3 Day 1	Yes	7	63,6	6	85,7	20,37	10,92
	No	124	92,5	110	88,7	22,53	18,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	7	63,6	7	100,0	23,81	26,78
	No	121	90,3	109	90,1	22,32	19,27
Cycle 5 Day 1	Yes	7	63,6	7	100,0	26,98	29,99
	No	117	87,3	108	92,3	22,94	18,06
Cycle 6 Day 1	Yes	7	63,6	7	100,0	19,05	22,87
	No	114	85,1	101	88,6	22,22	19,44
Cycle 7 Day 1	Yes	7	63,6	7	100,0	23,81	22,62
	No	106	79,1	96	90,6	23,26	19,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	7	63,6	7	100,0	34,92	32,35
	No	99	73,9	89	89,9	20,97	16,62
Cycle 9 Day 1	Yes	6	54,5	6	100,0	25,93	22,95
	No	92	68,7	89	96,7	20,35	17,43
Cycle 10 Day 1	Yes	6	54,5	6	100,0	27,78	23,04
	No	83	61,9	80	96,4	23,33	18,84
Cycle 11 Day 1	Yes	6	54,5	6	100,0	38,89	32,77
	No	74	55,2	70	94,6	19,52	14,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	6	54,5	6	100,0	22,22	25,34
	No	70	52,2	62	88,6	21,51	17,87
Cycle 13 Day 1	Yes	5	45,5	5	100,0	20,00	19,88
	No	61	45,5	55	90,2	20,00	16,89
Cycle 14 Day 1	Yes	5	45,5	5	100,0	31,11	24,09
	No	55	41,0	51	92,7	23,31	22,03
Cycle 15 Day 1	Yes	4	36,4	4	100,0	22,22	31,43
	No	53	39,6	49	92,5	19,50	15,96

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	27,3	3	100,0	29,63	33,95
	No	47	35,1	44	93,6	25,76	22,58
Cycle 17 Day 1	Yes	3	27,3	3	100,0	14,81	12,83
	No	42	31,3	41	97,6	20,60	23,12
Cycle 18 Day 1	Yes	3	27,3	3	100,0	14,81	12,83
	No	38	28,4	34	89,5	21,24	17,80
Cycle 19 Day 1	Yes	3	27,3	3	100,0	11,11	11,11
	No	33	24,6	30	90,9	22,59	19,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	27,3	3	100,0	14,81	12,83
	No	33	24,6	29	87,9	21,46	18,05
Cycle 21 Day 1	Yes	2	18,2	2	100,0	16,67	7,86
	No	27	20,1	24	88,9	26,39	23,36
Cycle 22 Day 1	Yes	2	18,2	2	100,0	27,78	7,86
	No	27	20,1	23	85,2	26,57	20,85
Cycle 23 Day 1	Yes	2	18,2	2	100,0	22,22	0,00
	No	19	14,2	16	84,2	23,61	24,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	18,2	2	100,0	22,22	0,00
	No	18	13,4	16	88,9	24,31	17,32
Cycle 25 Day 1	Yes	2	18,2	2	100,0	16,67	7,86
	No	13	9,7	11	84,6	22,22	16,48
Cycle 26 Day 1	Yes	1	9,1	1	100,0	22,22	-
	No	13	9,7	11	84,6	27,27	26,93
Cycle 27 Day 1	Yes	1	9,1	1	100,0	22,22	-
	No	10	7,5	7	70,0	25,40	23,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	9	6,7	8	88,9	31,94	36,34
Cycle 29 Day 1	Yes	1	9,1	1	100,0	22,22	-
	No	8	6,0	6	75,0	29,63	13,46
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	28,89	9,94
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	31,11	14,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	26,67	12,67
Cycle 33 Day 1	No	2	1,5	2	100,0	16,67	7,86
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	59,26	35,72
	No	61	45,5	41	67,2	39,02	20,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13DY_SG.xls
24JUN2020 20:50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	140	96,6	2,62	9,00
Cycle 2 Day 1	All	136	93,8	124	91,2	1,34	6,58
Cycle 3 Day 1	All	131	90,3	116	88,5	0,57	4,36
Cycle 4 Day 1	All	128	88,3	116	90,6	0,86	5,31
Cycle 5 Day 1	All	124	85,5	115	92,7	0,87	5,34
Cycle 6 Day 1	All	121	83,4	108	89,3	1,23	6,32
Cycle 7 Day 1	All	113	77,9	103	91,2	0,97	7,32

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	106	73,1	96	90,6	0,00	0,00
Cycle 9 Day 1	All	98	67,6	95	96,9	0,35	3,42
Cycle 10 Day 1	All	89	61,4	86	96,6	0,39	3,59
Cycle 11 Day 1	All	80	55,2	76	95,0	0,44	3,82
Cycle 12 Day 1	All	76	52,4	68	89,5	0,49	4,04
Cycle 13 Day 1	All	66	45,5	60	90,9	0,00	0,00
Cycle 14 Day 1	All	60	41,4	56	93,3	0,00	0,00
Cycle 15 Day 1	All	57	39,3	53	93,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	50	34,5	47	94,0	0,00	0,00
Cycle 17 Day 1	All	45	31,0	44	97,8	0,00	0,00
Cycle 18 Day 1	All	41	28,3	37	90,2	0,00	0,00
Cycle 19 Day 1	All	36	24,8	33	91,7	0,00	0,00
Cycle 20 Day 1	All	36	24,8	32	88,9	0,00	0,00
Cycle 21 Day 1	All	29	20,0	26	89,7	0,00	0,00
Cycle 22 Day 1	All	29	20,0	25	86,2	0,00	0,00
Cycle 23 Day 1	All	21	14,5	18	85,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	13,8	18	90,0	0,00	0,00
Cycle 25 Day 1	All	15	10,3	13	86,7	0,00	0,00
Cycle 26 Day 1	All	14	9,7	12	85,7	0,00	0,00
Cycle 27 Day 1	All	11	7,6	8	72,7	0,00	0,00
Cycle 28 Day 1	All	10	6,9	9	90,0	11,11	33,33
Cycle 29 Day 1	All	9	6,2	7	77,8	0,00	0,00
Cycle 30 Day 1	All	7	4,8	5	71,4	0,00	0,00
Cycle 31 Day 1	All	7	4,8	5	71,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	4,1	5	83,3	0,00	0,00
Cycle 33 Day 1	All	2	1,4	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	5,30	12,33
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	2,61	9,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	93	100,0	89	95,7	2,62	9,02
Cycle 2 Day 1	Male	50	96,2	46	92,0	2,90	9,50
	Female	86	92,5	78	90,7	0,43	3,77
Cycle 3 Day 1	Male	47	90,4	43	91,5	1,55	7,10
	Female	84	90,3	73	86,9	0,00	0,00
Cycle 4 Day 1	Male	46	88,5	43	93,5	2,33	8,59
	Female	82	88,2	73	89,0	0,00	0,00
Cycle 5 Day 1	Male	45	86,5	42	93,3	1,59	7,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	79	84,9	73	92,4	0,46	3,90
Cycle 6 Day 1	Male	45	86,5	41	91,1	3,25	10,01
	Female	76	81,7	67	88,2	0,00	0,00
Cycle 7 Day 1	Male	40	76,9	39	97,5	2,56	11,81
	Female	73	78,5	64	87,7	0,00	0,00
Cycle 8 Day 1	Male	37	71,2	34	91,9	0,00	0,00
	Female	69	74,2	62	89,9	0,00	0,00
Cycle 9 Day 1	Male	33	63,5	33	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	62	95,4	0,54	4,23
Cycle 10 Day 1	Male	30	57,7	30	100,0	1,11	6,09
	Female	59	63,4	56	94,9	0,00	0,00
Cycle 11 Day 1	Male	29	55,8	28	96,6	0,00	0,00
	Female	51	54,8	48	94,1	0,69	4,81
Cycle 12 Day 1	Male	27	51,9	26	96,3	1,28	6,54
	Female	49	52,7	42	85,7	0,00	0,00
Cycle 13 Day 1	Male	25	48,1	23	92,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	41	44,1	37	90,2	0,00	0,00
Cycle 14 Day 1	Male	23	44,2	21	91,3	0,00	0,00
	Female	37	39,8	35	94,6	0,00	0,00
Cycle 15 Day 1	Male	21	40,4	20	95,2	0,00	0,00
	Female	36	38,7	33	91,7	0,00	0,00
Cycle 16 Day 1	Male	16	30,8	16	100,0	0,00	0,00
	Female	34	36,6	31	91,2	0,00	0,00
Cycle 17 Day 1	Male	13	25,0	13	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	32	34,4	31	96,9	0,00	0,00
Cycle 18 Day 1	Male	12	23,1	11	91,7	0,00	0,00
	Female	29	31,2	26	89,7	0,00	0,00
Cycle 19 Day 1	Male	10	19,2	10	100,0	0,00	0,00
	Female	26	28,0	23	88,5	0,00	0,00
Cycle 20 Day 1	Male	10	19,2	9	90,0	0,00	0,00
	Female	26	28,0	23	88,5	0,00	0,00
Cycle 21 Day 1	Male	8	15,4	8	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	22,6	18	85,7	0,00	0,00
Cycle 22 Day 1	Male	8	15,4	6	75,0	0,00	0,00
	Female	21	22,6	19	90,5	0,00	0,00
Cycle 23 Day 1	Male	5	9,6	4	80,0	0,00	0,00
	Female	16	17,2	14	87,5	0,00	0,00
Cycle 24 Day 1	Male	5	9,6	4	80,0	0,00	0,00
	Female	15	16,1	14	93,3	0,00	0,00
Cycle 25 Day 1	Male	3	5,8	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	12,9	11	91,7	0,00	0,00
Cycle 26 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	11	11,8	10	90,9	0,00	0,00
Cycle 27 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	8	8,6	6	75,0	0,00	0,00
Cycle 28 Day 1	Male	2	3,8	2	100,0	0,00	0,00
	Female	8	8,6	7	87,5	14,29	37,80
Cycle 29 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	8,6	6	75,0	0,00	0,00
Cycle 30 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	0,00	0,00
Cycle 31 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	0,00	0,00
Cycle 32 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	5	5,4	4	80,0	0,00	0,00
Cycle 33 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	1,1	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	4,76	11,95
	Female	37	39,8	23	62,2	5,80	12,92
Age							
Cycle 1 Day 1	18-64	109	100,0	104	95,4	3,21	9,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	1,15	6,19
	>=75	7	100,0	7	100,0	0,00	0,00
Cycle 2 Day 1	18-64	103	94,5	91	88,3	1,47	6,87
	65-74	26	89,7	26	100,0	1,28	6,54
	>=75	7	100,0	7	100,0	0,00	0,00
Cycle 3 Day 1	18-64	99	90,8	87	87,9	0,77	5,02
	65-74	25	86,2	23	92,0	0,00	0,00
	>=75	7	100,0	6	85,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	98	89,9	88	89,8	0,76	5,00
	65-74	23	79,3	21	91,3	1,59	7,27
	>=75	7	100,0	7	100,0	0,00	0,00
Cycle 5 Day 1	18-64	95	87,2	88	92,6	0,76	5,00
	65-74	22	75,9	22	100,0	0,00	0,00
	>=75	7	100,0	5	71,4	6,67	14,91
Cycle 6 Day 1	18-64	92	84,4	80	87,0	1,25	6,37
	65-74	22	75,9	21	95,5	1,59	7,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	0,00	0,00
Cycle 7 Day 1	18-64	86	78,9	78	90,7	1,28	8,40
	65-74	20	69,0	19	95,0	0,00	0,00
	>=75	7	100,0	6	85,7	0,00	0,00
Cycle 8 Day 1	18-64	80	73,4	71	88,8	0,00	0,00
	65-74	19	65,5	19	100,0	0,00	0,00
	>=75	7	100,0	6	85,7	0,00	0,00
Cycle 9 Day 1	18-64	74	67,9	72	97,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	18	62,1	18	100,0	0,00	0,00
	>=75	6	85,7	5	83,3	6,67	14,91
Cycle 10 Day 1	18-64	69	63,3	66	95,7	0,51	4,10
	65-74	15	51,7	15	100,0	0,00	0,00
	>=75	5	71,4	5	100,0	0,00	0,00
Cycle 11 Day 1	18-64	61	56,0	58	95,1	0,57	4,38
	65-74	15	51,7	14	93,3	0,00	0,00
	>=75	4	57,1	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	57	52,3	50	87,7	0,67	4,71
	65-74	15	51,7	14	93,3	0,00	0,00
	>=75	4	57,1	4	100,0	0,00	0,00
Cycle 13 Day 1	18-64	49	45,0	45	91,8	0,00	0,00
	65-74	13	44,8	11	84,6	0,00	0,00
	>=75	4	57,1	4	100,0	0,00	0,00
Cycle 14 Day 1	18-64	45	41,3	43	95,6	0,00	0,00
	65-74	13	44,8	11	84,6	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 15 Day 1	18-64	43	39,4	40	93,0	0,00	0,00
	65-74	12	41,4	11	91,7	0,00	0,00
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 16 Day 1	18-64	38	34,9	36	94,7	0,00	0,00
	65-74	10	34,5	9	90,0	0,00	0,00
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 17 Day 1	18-64	36	33,0	35	97,2	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	27,6	8	100,0	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	0,00	0,00
	65-74	7	24,1	6	85,7	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	0,00	0,00
	65-74	5	17,2	4	80,0	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	0,00	0,00
	65-74	5	17,2	5	100,0	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	0,00	0,00
	65-74	4	13,8	4	100,0	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	0,00	0,00
	65-74	4	13,8	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	0,00	0,00
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	0,00	0,00
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	12,8	12	85,7	0,00	0,00
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	0,00	0,00
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	11,11	33,33
	65-74	1	3,4	0	0,0	-	-
Cycle 29 Day 1	18-64	8	7,3	7	87,5	0,00	0,00
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	0,00	0,00
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	0,00	0,00
	65-74	1	3,4	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	0,00	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	6,86	13,68
	65-74	15	51,7	8	53,3	0,00	0,00
	>=75	4	57,1	2	50,0	0,00	0,00
Race							
Cycle 1 Day 1	White	60	100,0	57	95,0	4,09	11,04
	Other	85	100,0	83	97,6	1,61	7,18

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	57	95,0	50	87,7	2,67	9,13
	Other	79	92,9	74	93,7	0,45	3,87
Cycle 3 Day 1	White	54	90,0	44	81,5	1,52	7,02
	Other	77	90,6	72	93,5	0,00	0,00
Cycle 4 Day 1	White	53	88,3	45	84,9	1,48	6,95
	Other	75	88,2	71	94,7	0,47	3,96
Cycle 5 Day 1	White	52	86,7	47	90,4	1,42	6,80
	Other	72	84,7	68	94,4	0,49	4,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	50	83,3	41	82,0	1,63	7,27
	Other	71	83,5	67	94,4	1,00	5,72
Cycle 7 Day 1	White	47	78,3	40	85,1	0,83	5,27
	Other	66	77,6	63	95,5	1,06	8,40
Cycle 8 Day 1	White	45	75,0	38	84,4	0,00	0,00
	Other	61	71,8	58	95,1	0,00	0,00
Cycle 9 Day 1	White	42	70,0	41	97,6	0,00	0,00
	Other	56	65,9	54	96,4	0,62	4,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	0,85	5,34
	Other	48	56,5	47	97,9	0,00	0,00
Cycle 11 Day 1	White	37	61,7	36	97,3	0,00	0,00
	Other	43	50,6	40	93,0	0,83	5,27
Cycle 12 Day 1	White	37	61,7	33	89,2	1,01	5,80
	Other	39	45,9	35	89,7	0,00	0,00
Cycle 13 Day 1	White	32	53,3	30	93,8	0,00	0,00
	Other	34	40,0	30	88,2	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	31	51,7	30	96,8	0,00	0,00
	Other	29	34,1	26	89,7	0,00	0,00
Cycle 15 Day 1	White	30	50,0	28	93,3	0,00	0,00
	Other	27	31,8	25	92,6	0,00	0,00
Cycle 16 Day 1	White	26	43,3	24	92,3	0,00	0,00
	Other	24	28,2	23	95,8	0,00	0,00
Cycle 17 Day 1	White	24	40,0	24	100,0	0,00	0,00
	Other	21	24,7	20	95,2	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	22	36,7	19	86,4	0,00	0,00
	Other	19	22,4	18	94,7	0,00	0,00
Cycle 19 Day 1	White	20	33,3	20	100,0	0,00	0,00
	Other	16	18,8	13	81,3	0,00	0,00
Cycle 20 Day 1	White	20	33,3	17	85,0	0,00	0,00
	Other	16	18,8	15	93,8	0,00	0,00
Cycle 21 Day 1	White	16	26,7	14	87,5	0,00	0,00
	Other	13	15,3	12	92,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	26,7	13	81,3	0,00	0,00
	Other	13	15,3	12	92,3	0,00	0,00
Cycle 23 Day 1	White	12	20,0	10	83,3	0,00	0,00
	Other	9	10,6	8	88,9	0,00	0,00
Cycle 24 Day 1	White	11	18,3	10	90,9	0,00	0,00
	Other	9	10,6	8	88,9	0,00	0,00
Cycle 25 Day 1	White	10	16,7	8	80,0	0,00	0,00
	Other	5	5,9	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	16,7	8	80,0	0,00	0,00
	Other	4	4,7	4	100,0	0,00	0,00
Cycle 27 Day 1	White	8	13,3	5	62,5	0,00	0,00
	Other	3	3,5	3	100,0	0,00	0,00
Cycle 28 Day 1	White	7	11,7	6	85,7	0,00	0,00
	Other	3	3,5	3	100,0	33,33	57,74
Cycle 29 Day 1	White	6	10,0	4	66,7	0,00	0,00
	Other	3	3,5	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	6,7	2	50,0	0,00	0,00
	Other	3	3,5	3	100,0	0,00	0,00
Cycle 31 Day 1	White	4	6,7	2	50,0	0,00	0,00
	Other	3	3,5	3	100,0	0,00	0,00
Cycle 32 Day 1	White	4	6,7	3	75,0	0,00	0,00
	Other	2	2,4	2	100,0	0,00	0,00
Cycle 33 Day 1	White	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-
End Of Treatment	White	25	41,7	17	68,0	7,84	14,57
	Other	39	45,9	27	69,2	3,70	10,68
Region							
Cycle 1 Day 1	America (AM)	40	100,0	38	95,0	3,51	10,37
	Europe (EU)	34	100,0	31	91,2	2,15	8,32
	Asia (AS)	71	100,0	71	100,0	2,35	8,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	2,08	8,20
	Europe (EU)	32	94,1	27	84,4	1,23	6,42
	Asia (AS)	66	93,0	65	98,5	1,03	5,80
Cycle 3 Day 1	America (AM)	37	92,5	32	86,5	1,04	5,89
	Europe (EU)	31	91,2	21	67,7	1,59	7,27
	Asia (AS)	63	88,7	63	100,0	0,00	0,00
Cycle 4 Day 1	America (AM)	37	92,5	32	86,5	0,00	0,00
	Europe (EU)	30	88,2	24	80,0	1,39	6,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	61	85,9	60	98,4	1,11	6,03
Cycle 5 Day 1	America (AM)	37	92,5	33	89,2	0,00	0,00
	Europe (EU)	30	88,2	25	83,3	1,33	6,67
	Asia (AS)	57	80,3	57	100,0	1,17	6,19
Cycle 6 Day 1	America (AM)	37	92,5	32	86,5	1,04	5,89
	Europe (EU)	28	82,4	24	85,7	1,39	6,80
	Asia (AS)	56	78,9	52	92,9	1,28	6,47
Cycle 7 Day 1	America (AM)	35	87,5	29	82,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	28	82,4	25	89,3	1,33	6,67
	Asia (AS)	50	70,4	49	98,0	1,36	9,52
Cycle 8 Day 1	America (AM)	31	77,5	26	83,9	0,00	0,00
	Europe (EU)	28	82,4	23	82,1	0,00	0,00
	Asia (AS)	47	66,2	47	100,0	0,00	0,00
Cycle 9 Day 1	America (AM)	29	72,5	27	93,1	0,00	0,00
	Europe (EU)	26	76,5	25	96,2	0,00	0,00
	Asia (AS)	43	60,6	43	100,0	0,78	5,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	0,00	0,00
	Europe (EU)	25	73,5	25	100,0	1,33	6,67
	Asia (AS)	37	52,1	37	100,0	0,00	0,00
Cycle 11 Day 1	America (AM)	24	60,0	21	87,5	0,00	0,00
	Europe (EU)	23	67,6	22	95,7	0,00	0,00
	Asia (AS)	33	46,5	33	100,0	1,01	5,80
Cycle 12 Day 1	America (AM)	24	60,0	22	91,7	0,00	0,00
	Europe (EU)	23	67,6	18	78,3	1,85	7,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	40,8	28	96,6	0,00	0,00
Cycle 13 Day 1	America (AM)	23	57,5	21	91,3	0,00	0,00
	Europe (EU)	18	52,9	14	77,8	0,00	0,00
	Asia (AS)	25	35,2	25	100,0	0,00	0,00
Cycle 14 Day 1	America (AM)	22	55,0	20	90,9	0,00	0,00
	Europe (EU)	17	50,0	16	94,1	0,00	0,00
	Asia (AS)	21	29,6	20	95,2	0,00	0,00
Cycle 15 Day 1	America (AM)	22	55,0	19	86,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	44,1	14	93,3	0,00	0,00
	Asia (AS)	20	28,2	20	100,0	0,00	0,00
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	0,00	0,00
	Europe (EU)	14	41,2	11	78,6	0,00	0,00
	Asia (AS)	19	26,8	19	100,0	0,00	0,00
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	0,00	0,00
	Europe (EU)	13	38,2	12	92,3	0,00	0,00
	Asia (AS)	16	22,5	16	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	0,00	0,00
	Europe (EU)	11	32,4	7	63,6	0,00	0,00
	Asia (AS)	16	22,5	16	100,0	0,00	0,00
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	0,00	0,00
	Europe (EU)	9	26,5	9	100,0	0,00	0,00
	Asia (AS)	14	19,7	11	78,6	0,00	0,00
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	0,00	0,00
	Europe (EU)	9	26,5	6	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	0,00	0,00
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	0,00	0,00
	Europe (EU)	7	20,6	6	85,7	0,00	0,00
	Asia (AS)	11	15,5	10	90,9	0,00	0,00
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	0,00	0,00
	Europe (EU)	7	20,6	5	71,4	0,00	0,00
	Asia (AS)	11	15,5	10	90,9	0,00	0,00
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	14,7	3	60,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	0,00	0,00
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	0,00	0,00
	Europe (EU)	5	14,7	4	80,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	0,00	0,00
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	0,00	0,00
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	0,00	0,00
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	0,00	0,00
	Europe (EU)	3	8,8	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	0,00	0,00
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	0,00	0,00
	Europe (EU)	2	5,9	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	25,00	50,00
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	0,00	0,00
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	0,00	0,00
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	0,00	0,00
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	0,00	0,00
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00
	Europe (EU)	1	2,9	1	100,0	0,00	-
	Asia (AS)	3	4,2	2	66,7	0,00	0,00
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	0,00	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	5,88	13,10
	Europe (EU)	10	29,4	5	50,0	6,67	14,91
	Asia (AS)	34	47,9	22	64,7	4,55	11,71
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	59	96,7	2,26	8,45
	1	69	100,0	66	95,7	3,03	9,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	15	100,0	15	100,0	2,22	8,61
Cycle 2 Day 1	0	59	96,7	55	93,2	1,21	6,30
	1	67	97,1	59	88,1	1,69	7,39
	2	10	66,7	10	100,0	0,00	0,00
Cycle 3 Day 1	0	57	93,4	50	87,7	1,33	6,60
	1	65	94,2	57	87,7	0,00	0,00
	2	9	60,0	9	100,0	0,00	0,00
Cycle 4 Day 1	0	57	93,4	51	89,5	1,31	6,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	57	91,9	0,58	4,42
	2	9	60,0	8	88,9	0,00	0,00
Cycle 5 Day 1	0	56	91,8	52	92,9	1,28	6,47
	1	62	89,9	57	91,9	0,58	4,42
	2	6	40,0	6	100,0	0,00	0,00
Cycle 6 Day 1	0	56	91,8	53	94,6	2,52	8,89
	1	59	85,5	51	86,4	0,00	0,00
	2	6	40,0	4	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	54	88,5	51	94,4	1,31	9,34
	1	54	78,3	47	87,0	0,71	4,86
	2	5	33,3	5	100,0	0,00	0,00
Cycle 8 Day 1	0	52	85,2	48	92,3	0,00	0,00
	1	49	71,0	43	87,8	0,00	0,00
	2	5	33,3	5	100,0	0,00	0,00
Cycle 9 Day 1	0	50	82,0	49	98,0	0,68	4,76
	1	44	63,8	42	95,5	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	4	26,7	4	100,0	0,00	0,00
Cycle 10 Day 1	0	46	75,4	46	100,0	0,72	4,91
	1	40	58,0	37	92,5	0,00	0,00
	2	3	20,0	3	100,0	0,00	0,00
Cycle 11 Day 1	0	43	70,5	40	93,0	0,83	5,27
	1	34	49,3	33	97,1	0,00	0,00
	2	3	20,0	3	100,0	0,00	0,00
Cycle 12 Day 1	0	42	68,9	36	85,7	0,93	5,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	31	44,9	29	93,5	0,00	0,00
	2	3	20,0	3	100,0	0,00	0,00
Cycle 13 Day 1	0	38	62,3	34	89,5	0,00	0,00
	1	27	39,1	25	92,6	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	0,00	0,00
	1	24	34,8	23	95,8	0,00	0,00
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	33	54,1	30	90,9	0,00	0,00
	1	23	33,3	22	95,7	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 16 Day 1	0	28	45,9	25	89,3	0,00	0,00
	1	21	30,4	21	100,0	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	0,00	0,00
	1	20	29,0	20	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	0,00	0,00
	1	17	24,6	17	100,0	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	0,00	0,00
	1	15	21,7	13	86,7	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	21,7	14	93,3	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	0,00	0,00
	1	13	18,8	11	84,6	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	0,00	0,00
	1	13	18,8	12	92,3	0,00	0,00
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	0,00	0,00
	1	9	13,0	8	88,9	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	0,00	0,00
	1	9	13,0	8	88,9	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	0,00	0,00
	1	7	10,1	7	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	13,1	6	75,0	0,00	0,00
	1	6	8,7	6	100,0	0,00	0,00
Cycle 27 Day 1	0	6	9,8	3	50,0	0,00	0,00
	1	5	7,2	5	100,0	0,00	0,00
Cycle 28 Day 1	0	5	8,2	4	80,0	0,00	0,00
	1	5	7,2	5	100,0	20,00	44,72
Cycle 29 Day 1	0	4	6,6	2	50,0	0,00	0,00
	1	5	7,2	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	0,00	0,00
Cycle 31 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	0,00	0,00
Cycle 32 Day 1	0	3	4,9	2	66,7	0,00	0,00
	1	3	4,3	3	100,0	0,00	0,00
Cycle 33 Day 1	0	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	3,17	10,03
	1	34	49,3	20	58,8	6,67	13,68
	2	7	46,7	3	42,9	11,11	19,25
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	59	95,2	5,08	12,09
	1	4	100,0	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	79	100,0	77	97,5	0,87	5,34
Cycle 2 Day 1	None	60	96,8	53	88,3	1,89	7,78
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	73	92,4	69	94,5	0,97	5,63
Cycle 3 Day 1	None	59	95,2	53	89,8	0,00	0,00
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	69	87,3	61	88,4	1,09	5,99
Cycle 4 Day 1	None	59	95,2	54	91,5	1,23	6,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	66	83,5	60	90,9	0,56	4,30
Cycle 5 Day 1	None	58	93,5	54	93,1	0,00	0,00
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	63	79,7	58	92,1	1,72	7,45
Cycle 6 Day 1	None	57	91,9	49	86,0	0,68	4,76
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	61	77,2	56	91,8	1,79	7,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	52	83,9	47	90,4	0,00	0,00
	1	3	75,0	3	100,0	11,11	19,25
	2 or More	58	73,4	53	91,4	1,26	9,16
Cycle 8 Day 1	None	50	80,6	45	90,0	0,00	0,00
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	0,00	0,00
Cycle 9 Day 1	None	48	77,4	46	95,8	0,00	0,00
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	0,69	4,81
Cycle 10 Day 1	None	43	69,4	41	95,3	0,00	0,00
	1	1	25,0	1	100,0	0,00	-
	2 or More	45	57,0	44	97,8	0,76	5,03
Cycle 11 Day 1	None	37	59,7	33	89,2	0,00	0,00
	1	1	25,0	1	100,0	0,00	-
	2 or More	42	53,2	42	100,0	0,79	5,14
Cycle 12 Day 1	None	37	59,7	33	89,2	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	38	48,1	34	89,5	0,98	5,72
Cycle 13 Day 1	None	34	54,8	28	82,4	0,00	0,00
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	0,00	0,00
Cycle 14 Day 1	None	31	50,0	28	90,3	0,00	0,00
	1	1	25,0	1	100,0	0,00	-
	2 or More	28	35,4	27	96,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	30	48,4	27	90,0	0,00	0,00
	1	1	25,0	1	100,0	0,00	-
	2 or More	26	32,9	25	96,2	0,00	0,00
Cycle 16 Day 1	None	25	40,3	23	92,0	0,00	0,00
	1	1	25,0	1	100,0	0,00	-
	2 or More	24	30,4	23	95,8	0,00	0,00
Cycle 17 Day 1	None	23	37,1	22	95,7	0,00	0,00
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	21	26,6	21	100,0	0,00	0,00
Cycle 18 Day 1	None	20	32,3	18	90,0	0,00	0,00
	1	1	25,0	1	100,0	0,00	-
	2 or More	20	25,3	18	90,0	0,00	0,00
Cycle 19 Day 1	None	17	27,4	17	100,0	0,00	0,00
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	0,00	0,00
Cycle 20 Day 1	None	17	27,4	16	94,1	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	0,00	0,00
Cycle 21 Day 1	None	15	24,2	13	86,7	0,00	0,00
	2 or More	14	17,7	13	92,9	0,00	0,00
Cycle 22 Day 1	None	15	24,2	13	86,7	0,00	0,00
	2 or More	14	17,7	12	85,7	0,00	0,00
Cycle 23 Day 1	None	10	16,1	9	90,0	0,00	0,00
	2 or More	11	13,9	9	81,8	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	16,1	10	100,0	0,00	0,00
	2 or More	10	12,7	8	80,0	0,00	0,00
Cycle 25 Day 1	None	9	14,5	8	88,9	0,00	0,00
	2 or More	6	7,6	5	83,3	0,00	0,00
Cycle 26 Day 1	None	8	12,9	8	100,0	0,00	0,00
	2 or More	6	7,6	4	66,7	0,00	0,00
Cycle 27 Day 1	None	7	11,3	6	85,7	0,00	0,00
	2 or More	4	5,1	2	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	11,3	7	100,0	0,00	0,00
	2 or More	3	3,8	2	66,7	50,00	70,71
Cycle 29 Day 1	None	6	9,7	5	83,3	0,00	0,00
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	6,5	3	75,0	0,00	0,00
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 31 Day 1	None	4	6,5	3	75,0	0,00	0,00
	2 or More	3	3,8	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	0,00	0,00
	2 or More	2	2,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	1,6	1	100,0	0,00	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	5,26	12,49
	1	3	75,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	39	49,4	24	61,5	5,56	12,69
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	59	95,2	5,08	12,09
	Previously Treated	83	100,0	81	97,6	0,82	5,20
Cycle 2 Day 1	Naïve	60	96,8	53	88,3	1,89	7,78
	Previously Treated	76	91,6	71	93,4	0,94	5,55
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	72	86,7	63	87,5	1,06	5,89
Cycle 4 Day 1	Naïve	59	95,2	54	91,5	1,23	6,35
	Previously Treated	69	83,1	62	89,9	0,54	4,23
Cycle 5 Day 1	Naïve	58	93,5	54	93,1	0,00	0,00
	Previously Treated	66	79,5	61	92,4	1,64	7,27
Cycle 6 Day 1	Naïve	57	91,9	49	86,0	0,68	4,76
	Previously Treated	64	77,1	59	92,2	1,69	7,39
Cycle 7 Day 1	Naïve	52	83,9	47	90,4	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	61	73,5	56	91,8	1,79	9,89
Cycle 8 Day 1	Naïve	50	80,6	45	90,0	0,00	0,00
	Previously Treated	56	67,5	51	91,1	0,00	0,00
Cycle 9 Day 1	Naïve	48	77,4	46	95,8	0,00	0,00
	Previously Treated	50	60,2	49	98,0	0,68	4,76
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	0,00	0,00
	Previously Treated	46	55,4	45	97,8	0,74	4,97
Cycle 11 Day 1	Naïve	37	59,7	33	89,2	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	43	51,8	43	100,0	0,78	5,08
Cycle 12 Day 1	Naïve	37	59,7	33	89,2	0,00	0,00
	Previously Treated	39	47,0	35	89,7	0,95	5,63
Cycle 13 Day 1	Naïve	34	54,8	28	82,4	0,00	0,00
	Previously Treated	32	38,6	32	100,0	0,00	0,00
Cycle 14 Day 1	Naïve	31	50,0	28	90,3	0,00	0,00
	Previously Treated	29	34,9	28	96,6	0,00	0,00
Cycle 15 Day 1	Naïve	30	48,4	27	90,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	27	32,5	26	96,3	0,00	0,00
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	0,00	0,00
	Previously Treated	25	30,1	24	96,0	0,00	0,00
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	0,00	0,00
	Previously Treated	22	26,5	22	100,0	0,00	0,00
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	0,00	0,00
	Previously Treated	21	25,3	19	90,5	0,00	0,00
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	22,9	16	84,2	0,00	0,00
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	0,00	0,00
	Previously Treated	19	22,9	16	84,2	0,00	0,00
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	0,00	0,00
	Previously Treated	14	16,9	13	92,9	0,00	0,00
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	0,00	0,00
	Previously Treated	14	16,9	12	85,7	0,00	0,00
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	0,00	0,00
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	0,00	0,00
	Previously Treated	10	12,0	8	80,0	0,00	0,00
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	0,00	0,00
	Previously Treated	6	7,2	5	83,3	0,00	0,00
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	0,00	0,00
	Previously Treated	6	7,2	4	66,7	0,00	0,00
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	4,8	2	50,0	0,00	0,00
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	0,00	0,00
	Previously Treated	3	3,6	2	66,7	50,00	70,71
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	0,00	0,00
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	0,00	0,00
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	0,00	0,00
	Previously Treated	2	2,4	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	0,00	-
	Previously Treated	1	1,2	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	5,26	12,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	50,6	25	59,5	5,33	12,47
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	2,67	9,10
	Central	70	100,0	65	92,9	2,56	8,95
Cycle 2 Day 1	Local	71	94,7	67	94,4	1,00	5,72
	Central	65	92,9	57	87,7	1,75	7,51
Cycle 3 Day 1	Local	67	89,3	60	89,6	0,56	4,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	64	91,4	56	87,5	0,60	4,45
Cycle 4 Day 1	Local	65	86,7	58	89,2	0,00	0,00
	Central	63	90,0	58	92,1	1,72	7,45
Cycle 5 Day 1	Local	63	84,0	58	92,1	0,00	0,00
	Central	61	87,1	57	93,4	1,75	7,51
Cycle 6 Day 1	Local	63	84,0	61	96,8	0,55	4,27
	Central	58	82,9	47	81,0	2,13	8,24
Cycle 7 Day 1	Local	61	81,3	58	95,1	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	52	74,3	45	86,5	2,22	11,01
Cycle 8 Day 1	Local	57	76,0	54	94,7	0,00	0,00
	Central	49	70,0	42	85,7	0,00	0,00
Cycle 9 Day 1	Local	54	72,0	53	98,1	0,63	4,58
	Central	44	62,9	42	95,5	0,00	0,00
Cycle 10 Day 1	Local	48	64,0	46	95,8	0,00	0,00
	Central	41	58,6	40	97,6	0,83	5,27
Cycle 11 Day 1	Local	40	53,3	38	95,0	0,88	5,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	40	57,1	38	95,0	0,00	0,00
Cycle 12 Day 1	Local	36	48,0	33	91,7	0,00	0,00
	Central	40	57,1	35	87,5	0,95	5,63
Cycle 13 Day 1	Local	30	40,0	29	96,7	0,00	0,00
	Central	36	51,4	31	86,1	0,00	0,00
Cycle 14 Day 1	Local	27	36,0	27	100,0	0,00	0,00
	Central	33	47,1	29	87,9	0,00	0,00
Cycle 15 Day 1	Local	26	34,7	25	96,2	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	28	90,3	0,00	0,00
Cycle 16 Day 1	Local	24	32,0	24	100,0	0,00	0,00
	Central	26	37,1	23	88,5	0,00	0,00
Cycle 17 Day 1	Local	22	29,3	22	100,0	0,00	0,00
	Central	23	32,9	22	95,7	0,00	0,00
Cycle 18 Day 1	Local	20	26,7	19	95,0	0,00	0,00
	Central	21	30,0	18	85,7	0,00	0,00
Cycle 19 Day 1	Local	19	25,3	17	89,5	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	24,3	16	94,1	0,00	0,00
Cycle 20 Day 1	Local	19	25,3	17	89,5	0,00	0,00
	Central	17	24,3	15	88,2	0,00	0,00
Cycle 21 Day 1	Local	14	18,7	12	85,7	0,00	0,00
	Central	15	21,4	14	93,3	0,00	0,00
Cycle 22 Day 1	Local	14	18,7	12	85,7	0,00	0,00
	Central	15	21,4	13	86,7	0,00	0,00
Cycle 23 Day 1	Local	11	14,7	10	90,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	14,3	8	80,0	0,00	0,00
Cycle 24 Day 1	Local	11	14,7	10	90,9	0,00	0,00
	Central	9	12,9	8	88,9	0,00	0,00
Cycle 25 Day 1	Local	7	9,3	7	100,0	0,00	0,00
	Central	8	11,4	6	75,0	0,00	0,00
Cycle 26 Day 1	Local	6	8,0	6	100,0	0,00	0,00
	Central	8	11,4	6	75,0	0,00	0,00
Cycle 27 Day 1	Local	4	5,3	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	10,0	4	57,1	0,00	0,00
Cycle 28 Day 1	Local	4	5,3	4	100,0	0,00	0,00
	Central	6	8,6	5	83,3	20,00	44,72
Cycle 29 Day 1	Local	3	4,0	3	100,0	0,00	0,00
	Central	6	8,6	4	66,7	0,00	0,00
Cycle 30 Day 1	Local	3	4,0	3	100,0	0,00	0,00
	Central	4	5,7	2	50,0	0,00	0,00
Cycle 31 Day 1	Local	3	4,0	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	5,7	2	50,0	0,00	0,00
Cycle 32 Day 1	Local	3	4,0	3	100,0	0,00	0,00
	Central	3	4,3	2	66,7	0,00	0,00
Cycle 33 Day 1	Local	1	1,3	1	100,0	0,00	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	6,94	13,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	32	45,7	20	62,5	3,33	10,26
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	130	96,3	2,31	8,49
	No	10	100,0	10	100,0	6,67	14,05
Cycle 2 Day 1	Yes	129	95,6	117	90,7	1,42	6,77
	No	7	70,0	7	100,0	0,00	0,00
Cycle 3 Day 1	Yes	124	91,9	110	88,7	0,61	4,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	6	85,7	0,00	0,00
Cycle 4 Day 1	Yes	121	89,6	109	90,1	0,92	5,48
	No	7	70,0	7	100,0	0,00	0,00
Cycle 5 Day 1	Yes	117	86,7	109	93,2	0,92	5,48
	No	7	70,0	6	85,7	0,00	0,00
Cycle 6 Day 1	Yes	114	84,4	101	88,6	1,32	6,53
	No	7	70,0	7	100,0	0,00	0,00
Cycle 7 Day 1	Yes	106	78,5	96	90,6	1,04	7,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	0,00	0,00
Cycle 8 Day 1	Yes	100	74,1	90	90,0	0,00	0,00
	No	6	60,0	6	100,0	0,00	0,00
Cycle 9 Day 1	Yes	92	68,1	89	96,7	0,37	3,53
	No	6	60,0	6	100,0	0,00	0,00
Cycle 10 Day 1	Yes	83	61,5	80	96,4	0,42	3,73
	No	6	60,0	6	100,0	0,00	0,00
Cycle 11 Day 1	Yes	76	56,3	72	94,7	0,46	3,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	4	40,0	4	100,0	0,00	0,00
Cycle 12 Day 1	Yes	72	53,3	64	88,9	0,52	4,17
	No	4	40,0	4	100,0	0,00	0,00
Cycle 13 Day 1	Yes	64	47,4	58	90,6	0,00	0,00
	No	2	20,0	2	100,0	0,00	0,00
Cycle 14 Day 1	Yes	58	43,0	54	93,1	0,00	0,00
	No	2	20,0	2	100,0	0,00	0,00
Cycle 15 Day 1	Yes	55	40,7	51	92,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	0,00	0,00
Cycle 16 Day 1	Yes	48	35,6	45	93,8	0,00	0,00
	No	2	20,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	43	31,9	42	97,7	0,00	0,00
	No	2	20,0	2	100,0	0,00	0,00
Cycle 18 Day 1	Yes	39	28,9	35	89,7	0,00	0,00
	No	2	20,0	2	100,0	0,00	0,00
Cycle 19 Day 1	Yes	34	25,2	32	94,1	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	0,00	0,00
	No	2	20,0	2	100,0	0,00	0,00
Cycle 21 Day 1	Yes	27	20,0	24	88,9	0,00	0,00
	No	2	20,0	2	100,0	0,00	0,00
Cycle 22 Day 1	Yes	27	20,0	23	85,2	0,00	0,00
	No	2	20,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	10,4	12	85,7	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	12,50	35,36
	No	1	10,0	1	100,0	0,00	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 32 Day 1	Yes	5	3,7	4	80,0	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	5,43	12,45
	No	2	20,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	6,06	13,48
	No	134	100,0	129	96,3	2,33	8,52
Cycle 2 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	129	96,3	117	90,7	1,42	6,77
Cycle 3 Day 1	Yes	7	63,6	6	85,7	0,00	0,00
	No	124	92,5	110	88,7	0,61	4,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	121	90,3	109	90,1	0,92	5,48
Cycle 5 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	117	87,3	108	92,3	0,93	5,50
Cycle 6 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	114	85,1	101	88,6	1,32	6,53
Cycle 7 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	106	79,1	96	90,6	1,04	7,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	99	73,9	89	89,9	0,00	0,00
Cycle 9 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	92	68,7	89	96,7	0,37	3,53
Cycle 10 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	83	61,9	80	96,4	0,42	3,73
Cycle 11 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	74	55,2	70	94,6	0,48	3,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	70	52,2	62	88,6	0,54	4,23
Cycle 13 Day 1	Yes	5	45,5	5	100,0	0,00	0,00
	No	61	45,5	55	90,2	0,00	0,00
Cycle 14 Day 1	Yes	5	45,5	5	100,0	0,00	0,00
	No	55	41,0	51	92,7	0,00	0,00
Cycle 15 Day 1	Yes	4	36,4	4	100,0	0,00	0,00
	No	53	39,6	49	92,5	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	47	35,1	44	93,6	0,00	0,00
Cycle 17 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	42	31,3	41	97,6	0,00	0,00
Cycle 18 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	38	28,4	34	89,5	0,00	0,00
Cycle 19 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	30	90,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	29	87,9	0,00	0,00
Cycle 21 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	24	88,9	0,00	0,00
Cycle 22 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	23	85,2	0,00	0,00
Cycle 23 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	19	14,2	16	84,2	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	18	13,4	16	88,9	0,00	0,00
Cycle 25 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	13	9,7	11	84,6	0,00	0,00
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	0,00	0,00
Cycle 27 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	10	7,5	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	9	6,7	8	88,9	12,50	35,36
Cycle 29 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	8	6,0	6	75,0	0,00	0,00
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	0,00	0,00
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	0,00	0,00
Cycle 33 Day 1	No	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	0,00	0,00
	No	61	45,5	41	67,2	5,69	12,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HA_SG.xls
24JUN2020 20:57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	140	96,6	9,52	20,50
Cycle 2 Day 1	All	136	93,8	124	91,2	7,53	17,95
Cycle 3 Day 1	All	131	90,3	116	88,5	8,91	17,23
Cycle 4 Day 1	All	128	88,3	116	90,6	6,61	15,98
Cycle 5 Day 1	All	124	85,5	115	92,7	7,54	18,76
Cycle 6 Day 1	All	121	83,4	108	89,3	5,25	13,79
Cycle 7 Day 1	All	113	77,9	103	91,2	7,77	19,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	106	73,1	96	90,6	6,60	16,49
Cycle 9 Day 1	All	98	67,6	95	96,9	8,07	19,28
Cycle 10 Day 1	All	89	61,4	86	96,6	5,81	14,63
Cycle 11 Day 1	All	80	55,2	76	95,0	5,26	13,39
Cycle 12 Day 1	All	76	52,4	68	89,5	8,33	15,64
Cycle 13 Day 1	All	66	45,5	60	90,9	6,67	17,14
Cycle 14 Day 1	All	60	41,4	56	93,3	5,36	16,55
Cycle 15 Day 1	All	57	39,3	53	93,0	4,40	13,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	50	34,5	47	94,0	6,38	17,91
Cycle 17 Day 1	All	45	31,0	44	97,8	6,06	18,00
Cycle 18 Day 1	All	41	28,3	37	90,2	6,31	15,39
Cycle 19 Day 1	All	36	24,8	33	91,7	3,03	9,73
Cycle 20 Day 1	All	36	24,8	32	88,9	6,25	13,22
Cycle 21 Day 1	All	29	20,0	26	89,7	3,85	10,86
Cycle 22 Day 1	All	29	20,0	25	86,2	6,67	13,61
Cycle 23 Day 1	All	21	14,5	18	85,7	1,85	7,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	13,8	18	90,0	0,00	0,00
Cycle 25 Day 1	All	15	10,3	13	86,7	7,69	27,74
Cycle 26 Day 1	All	14	9,7	12	85,7	8,33	20,72
Cycle 27 Day 1	All	11	7,6	8	72,7	8,33	15,43
Cycle 28 Day 1	All	10	6,9	9	90,0	14,81	33,79
Cycle 29 Day 1	All	9	6,2	7	77,8	4,76	12,60
Cycle 30 Day 1	All	7	4,8	5	71,4	6,67	14,91
Cycle 31 Day 1	All	7	4,8	5	71,4	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	4,1	5	83,3	0,00	0,00
Cycle 33 Day 1	All	2	1,4	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	8,33	20,49
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	3,27	10,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	93	100,0	89	95,7	13,11	23,90
Cycle 2 Day 1	Male	50	96,2	46	92,0	4,35	11,35
	Female	86	92,5	78	90,7	9,40	20,74
Cycle 3 Day 1	Male	47	90,4	43	91,5	6,98	13,72
	Female	84	90,3	73	86,9	10,05	18,99
Cycle 4 Day 1	Male	46	88,5	43	93,5	3,10	9,80
	Female	82	88,2	73	89,0	8,68	18,45
Cycle 5 Day 1	Male	45	86,5	42	93,3	6,35	15,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	79	84,9	73	92,4	8,22	20,62
Cycle 6 Day 1	Male	45	86,5	41	91,1	5,69	14,72
	Female	76	81,7	67	88,2	4,98	13,30
Cycle 7 Day 1	Male	40	76,9	39	97,5	5,98	15,05
	Female	73	78,5	64	87,7	8,85	22,41
Cycle 8 Day 1	Male	37	71,2	34	91,9	7,84	20,20
	Female	69	74,2	62	89,9	5,91	14,19
Cycle 9 Day 1	Male	33	63,5	33	100,0	5,05	14,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	62	95,4	9,68	21,24
Cycle 10 Day 1	Male	30	57,7	30	100,0	7,78	16,80
	Female	59	63,4	56	94,9	4,76	13,38
Cycle 11 Day 1	Male	29	55,8	28	96,6	3,57	10,50
	Female	51	54,8	48	94,1	6,25	14,84
Cycle 12 Day 1	Male	27	51,9	26	96,3	10,26	15,69
	Female	49	52,7	42	85,7	7,14	15,68
Cycle 13 Day 1	Male	25	48,1	23	92,0	7,25	14,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	41	44,1	37	90,2	6,31	18,98
Cycle 14 Day 1	Male	23	44,2	21	91,3	3,17	10,03
	Female	37	39,8	35	94,6	6,67	19,47
Cycle 15 Day 1	Male	21	40,4	20	95,2	1,67	7,45
	Female	36	38,7	33	91,7	6,06	15,49
Cycle 16 Day 1	Male	16	30,8	16	100,0	6,25	13,44
	Female	34	36,6	31	91,2	6,45	20,04
Cycle 17 Day 1	Male	13	25,0	13	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	32	34,4	31	96,9	8,60	21,03
Cycle 18 Day 1	Male	12	23,1	11	91,7	3,03	10,05
	Female	29	31,2	26	89,7	7,69	17,15
Cycle 19 Day 1	Male	10	19,2	10	100,0	6,67	14,05
	Female	26	28,0	23	88,5	1,45	6,95
Cycle 20 Day 1	Male	10	19,2	9	90,0	7,41	14,70
	Female	26	28,0	23	88,5	5,80	12,92
Cycle 21 Day 1	Male	8	15,4	8	100,0	4,17	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	22,6	18	85,7	3,70	10,78
Cycle 22 Day 1	Male	8	15,4	6	75,0	11,11	17,21
	Female	21	22,6	19	90,5	5,26	12,49
Cycle 23 Day 1	Male	5	9,6	4	80,0	0,00	0,00
	Female	16	17,2	14	87,5	2,38	8,91
Cycle 24 Day 1	Male	5	9,6	4	80,0	0,00	0,00
	Female	15	16,1	14	93,3	0,00	0,00
Cycle 25 Day 1	Male	3	5,8	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	12,9	11	91,7	9,09	30,15
Cycle 26 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	11	11,8	10	90,9	10,00	22,50
Cycle 27 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	8	8,6	6	75,0	11,11	17,21
Cycle 28 Day 1	Male	2	3,8	2	100,0	0,00	0,00
	Female	8	8,6	7	87,5	19,05	37,80
Cycle 29 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	8,6	6	75,0	5,56	13,61
Cycle 30 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	8,33	16,67
Cycle 31 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	16,67	19,25
Cycle 32 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	5	5,4	4	80,0	0,00	0,00
Cycle 33 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	1,1	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	4,76	11,95
	Female	37	39,8	23	62,2	11,59	25,84
Age							
Cycle 1 Day 1	18-64	109	100,0	104	95,4	9,94	21,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	5,75	12,81
	>=75	7	100,0	7	100,0	19,05	32,53
Cycle 2 Day 1	18-64	103	94,5	91	88,3	8,42	19,62
	65-74	26	89,7	26	100,0	3,85	10,86
	>=75	7	100,0	7	100,0	9,52	16,27
Cycle 3 Day 1	18-64	99	90,8	87	87,9	8,81	17,94
	65-74	25	86,2	23	92,0	8,70	14,97
	>=75	7	100,0	6	85,7	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	98	89,9	88	89,8	5,68	16,16
	65-74	23	79,3	21	91,3	9,52	15,43
	>=75	7	100,0	7	100,0	9,52	16,27
Cycle 5 Day 1	18-64	95	87,2	88	92,6	6,82	19,02
	65-74	22	75,9	22	100,0	10,61	18,93
	>=75	7	100,0	5	71,4	6,67	14,91
Cycle 6 Day 1	18-64	92	84,4	80	87,0	5,00	14,13
	65-74	22	75,9	21	95,5	7,94	14,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	0,00	0,00
Cycle 7 Day 1	18-64	86	78,9	78	90,7	5,98	19,18
	65-74	20	69,0	19	95,0	15,79	23,22
	>=75	7	100,0	6	85,7	5,56	13,61
Cycle 8 Day 1	18-64	80	73,4	71	88,8	5,16	16,57
	65-74	19	65,5	19	100,0	12,28	16,52
	>=75	7	100,0	6	85,7	5,56	13,61
Cycle 9 Day 1	18-64	74	67,9	72	97,3	6,94	20,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	18	62,1	18	100,0	14,81	17,04
	>=75	6	85,7	5	83,3	0,00	0,00
Cycle 10 Day 1	18-64	69	63,3	66	95,7	5,56	15,00
	65-74	15	51,7	15	100,0	8,89	15,26
	>=75	5	71,4	5	100,0	0,00	0,00
Cycle 11 Day 1	18-64	61	56,0	58	95,1	4,02	12,61
	65-74	15	51,7	14	93,3	9,52	15,63
	>=75	4	57,1	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	57	52,3	50	87,7	6,67	15,06
	65-74	15	51,7	14	93,3	16,67	17,30
	>=75	4	57,1	4	100,0	0,00	0,00
Cycle 13 Day 1	18-64	49	45,0	45	91,8	4,44	16,82
	65-74	13	44,8	11	84,6	18,18	17,41
	>=75	4	57,1	4	100,0	0,00	0,00
Cycle 14 Day 1	18-64	45	41,3	43	95,6	3,10	15,96
	65-74	13	44,8	11	84,6	12,12	16,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	28,6	2	100,0	16,67	23,57
Cycle 15 Day 1	18-64	43	39,4	40	93,0	0,83	5,27
	65-74	12	41,4	11	91,7	18,18	22,92
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 16 Day 1	18-64	38	34,9	36	94,7	2,78	16,67
	65-74	10	34,5	9	90,0	22,22	16,67
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 17 Day 1	18-64	36	33,0	35	97,2	5,71	18,94

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	27,6	8	100,0	8,33	15,43
	>=75	1	14,3	1	100,0	0,00	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	5,56	15,37
	65-74	7	24,1	6	85,7	11,11	17,21
	>=75	1	14,3	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	1,19	6,30
	65-74	5	17,2	4	80,0	16,67	19,25
	>=75	1	14,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	3,85	10,86
	65-74	5	17,2	5	100,0	20,00	18,26
	>=75	1	14,3	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	3,17	10,03
	65-74	4	13,8	4	100,0	8,33	16,67
	>=75	1	14,3	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	5,00	12,21
	65-74	4	13,8	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	2,08	8,33
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	0,00	0,00
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	12,8	12	85,7	8,33	28,87
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	8,33	20,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	8,33	15,43
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	14,81	33,79
	65-74	1	3,4	0	0,0	-	-
Cycle 29 Day 1	18-64	8	7,3	7	87,5	4,76	12,60
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	13,33	18,26
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	0,00	0,00
	65-74	1	3,4	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	0,00	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	8,82	22,19
	65-74	15	51,7	8	53,3	8,33	15,43
	>=75	4	57,1	2	50,0	0,00	0,00
Race							
Cycle 1 Day 1	White	60	100,0	57	95,0	9,36	23,36
	Other	85	100,0	83	97,6	9,64	18,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	57	95,0	50	87,7	8,00	21,88
	Other	79	92,9	74	93,7	7,21	14,88
Cycle 3 Day 1	White	54	90,0	44	81,5	8,33	19,19
	Other	77	90,6	72	93,5	9,26	16,04
Cycle 4 Day 1	White	53	88,3	45	84,9	5,19	17,34
	Other	75	88,2	71	94,7	7,51	15,12
Cycle 5 Day 1	White	52	86,7	47	90,4	9,22	23,78
	Other	72	84,7	68	94,4	6,37	14,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	50	83,3	41	82,0	4,88	14,07
	Other	71	83,5	67	94,4	5,47	13,73
Cycle 7 Day 1	White	47	78,3	40	85,1	8,33	21,01
	Other	66	77,6	63	95,5	7,41	19,35
Cycle 8 Day 1	White	45	75,0	38	84,4	3,51	10,37
	Other	61	71,8	58	95,1	8,62	19,31
Cycle 9 Day 1	White	42	70,0	41	97,6	5,69	12,70
	Other	56	65,9	54	96,4	9,88	23,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	6,84	15,63
	Other	48	56,5	47	97,9	4,96	13,86
Cycle 11 Day 1	White	37	61,7	36	97,3	3,70	10,62
	Other	43	50,6	40	93,0	6,67	15,47
Cycle 12 Day 1	White	37	61,7	33	89,2	8,08	16,73
	Other	39	45,9	35	89,7	8,57	14,78
Cycle 13 Day 1	White	32	53,3	30	93,8	6,67	20,34
	Other	34	40,0	30	88,2	6,67	13,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	31	51,7	30	96,8	6,67	20,34
	Other	29	34,1	26	89,7	3,85	10,86
Cycle 15 Day 1	White	30	50,0	28	93,3	2,38	8,74
	Other	27	31,8	25	92,6	6,67	16,67
Cycle 16 Day 1	White	26	43,3	24	92,3	6,94	21,93
	Other	24	28,2	23	95,8	5,80	12,92
Cycle 17 Day 1	White	24	40,0	24	100,0	8,33	22,52
	Other	21	24,7	20	95,2	3,33	10,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	22	36,7	19	86,4	7,02	17,84
	Other	19	22,4	18	94,7	5,56	12,78
Cycle 19 Day 1	White	20	33,3	20	100,0	1,67	7,45
	Other	16	18,8	13	81,3	5,13	12,52
Cycle 20 Day 1	White	20	33,3	17	85,0	5,88	13,10
	Other	16	18,8	15	93,8	6,67	13,80
Cycle 21 Day 1	White	16	26,7	14	87,5	2,38	8,91
	Other	13	15,3	12	92,3	5,56	12,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	26,7	13	81,3	5,13	12,52
	Other	13	15,3	12	92,3	8,33	15,08
Cycle 23 Day 1	White	12	20,0	10	83,3	3,33	10,54
	Other	9	10,6	8	88,9	0,00	0,00
Cycle 24 Day 1	White	11	18,3	10	90,9	0,00	0,00
	Other	9	10,6	8	88,9	0,00	0,00
Cycle 25 Day 1	White	10	16,7	8	80,0	0,00	0,00
	Other	5	5,9	5	100,0	20,00	44,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	16,7	8	80,0	0,00	0,00
	Other	4	4,7	4	100,0	25,00	31,91
Cycle 27 Day 1	White	8	13,3	5	62,5	0,00	0,00
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 28 Day 1	White	7	11,7	6	85,7	0,00	0,00
	Other	3	3,5	3	100,0	44,44	50,92
Cycle 29 Day 1	White	6	10,0	4	66,7	0,00	0,00
	Other	3	3,5	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	6,7	2	50,0	0,00	0,00
	Other	3	3,5	3	100,0	11,11	19,25
Cycle 31 Day 1	White	4	6,7	2	50,0	0,00	0,00
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 32 Day 1	White	4	6,7	3	75,0	0,00	0,00
	Other	2	2,4	2	100,0	0,00	0,00
Cycle 33 Day 1	White	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-
End Of Treatment	White	25	41,7	17	68,0	9,80	25,72
	Other	39	45,9	27	69,2	7,41	16,88
Region							
Cycle 1 Day 1	America (AM)	40	100,0	38	95,0	14,04	25,27
	Europe (EU)	34	100,0	31	91,2	2,15	8,32
	Asia (AS)	71	100,0	71	100,0	10,33	20,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	11,46	26,25
	Europe (EU)	32	94,1	27	84,4	2,47	8,90
	Asia (AS)	66	93,0	65	98,5	7,69	15,33
Cycle 3 Day 1	America (AM)	37	92,5	32	86,5	8,33	20,74
	Europe (EU)	31	91,2	21	67,7	6,35	13,41
	Asia (AS)	63	88,7	63	100,0	10,05	16,54
Cycle 4 Day 1	America (AM)	37	92,5	32	86,5	6,25	19,74
	Europe (EU)	30	88,2	24	80,0	4,17	11,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	61	85,9	60	98,4	7,78	15,49
Cycle 5 Day 1	America (AM)	37	92,5	33	89,2	11,11	25,91
	Europe (EU)	30	88,2	25	83,3	5,33	15,75
	Asia (AS)	57	80,3	57	100,0	6,43	14,69
Cycle 6 Day 1	America (AM)	37	92,5	32	86,5	7,29	16,36
	Europe (EU)	28	82,4	24	85,7	2,78	9,41
	Asia (AS)	56	78,9	52	92,9	5,13	13,82
Cycle 7 Day 1	America (AM)	35	87,5	29	82,9	10,34	23,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	28	82,4	25	89,3	4,00	14,66
	Asia (AS)	50	70,4	49	98,0	8,16	19,87
Cycle 8 Day 1	America (AM)	31	77,5	26	83,9	3,85	14,38
	Europe (EU)	28	82,4	23	82,1	4,35	11,48
	Asia (AS)	47	66,2	47	100,0	9,22	19,29
Cycle 9 Day 1	America (AM)	29	72,5	27	93,1	9,88	22,29
	Europe (EU)	26	76,5	25	96,2	4,00	11,06
	Asia (AS)	43	60,6	43	100,0	9,30	20,99

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	6,94	16,97
	Europe (EU)	25	73,5	25	100,0	5,33	12,47
	Asia (AS)	37	52,1	37	100,0	5,41	14,73
Cycle 11 Day 1	America (AM)	24	60,0	21	87,5	6,35	17,06
	Europe (EU)	23	67,6	22	95,7	4,55	11,71
	Asia (AS)	33	46,5	33	100,0	5,05	12,14
Cycle 12 Day 1	America (AM)	24	60,0	22	91,7	7,58	14,30
	Europe (EU)	23	67,6	18	78,3	9,26	19,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	40,8	28	96,6	8,33	14,70
Cycle 13 Day 1	America (AM)	23	57,5	21	91,3	11,11	24,34
	Europe (EU)	18	52,9	14	77,8	2,38	8,91
	Asia (AS)	25	35,2	25	100,0	5,33	12,47
Cycle 14 Day 1	America (AM)	22	55,0	20	90,9	5,00	22,36
	Europe (EU)	17	50,0	16	94,1	6,25	13,44
	Asia (AS)	21	29,6	20	95,2	5,00	12,21
Cycle 15 Day 1	America (AM)	22	55,0	19	86,4	1,75	7,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	44,1	14	93,3	4,76	12,10
	Asia (AS)	20	28,2	20	100,0	6,67	17,44
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	3,92	11,07
	Europe (EU)	14	41,2	11	78,6	6,06	13,48
	Asia (AS)	19	26,8	19	100,0	8,77	24,45
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	2,08	8,33
	Europe (EU)	13	38,2	12	92,3	2,78	9,62
	Asia (AS)	16	22,5	16	100,0	12,50	26,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	4,76	12,10
	Europe (EU)	11	32,4	7	63,6	0,00	0,00
	Asia (AS)	16	22,5	16	100,0	10,42	20,07
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	2,56	9,25
	Europe (EU)	9	26,5	9	100,0	3,70	11,11
	Asia (AS)	14	19,7	11	78,6	3,03	10,05
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	5,13	12,52
	Europe (EU)	9	26,5	6	66,7	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	7,69	14,62
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	3,33	10,54
	Europe (EU)	7	20,6	6	85,7	0,00	0,00
	Asia (AS)	11	15,5	10	90,9	6,67	14,05
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	10,00	16,10
	Europe (EU)	7	20,6	5	71,4	0,00	0,00
	Asia (AS)	11	15,5	10	90,9	6,67	14,05
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	14,7	3	60,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	0,00	0,00
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	0,00	0,00
	Europe (EU)	5	14,7	4	80,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	0,00	0,00
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	25,00	50,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	0,00	0,00
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	25,00	31,91
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	0,00	0,00
	Europe (EU)	3	8,8	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	16,67	19,25
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	0,00	0,00
	Europe (EU)	2	5,9	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	33,33	47,14
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	0,00	0,00
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	8,33	16,67
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	11,11	19,25
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	22,22	19,25
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00
	Europe (EU)	1	2,9	1	100,0	0,00	-
	Asia (AS)	3	4,2	2	66,7	0,00	0,00
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	0,00	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	7,84	25,08
	Europe (EU)	10	29,4	5	50,0	6,67	14,91
	Asia (AS)	34	47,9	22	64,7	9,09	18,35
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	59	96,7	8,47	20,15
	1	69	100,0	66	95,7	10,61	22,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	15	100,0	15	100,0	8,89	15,26
Cycle 2 Day 1	0	59	96,7	55	93,2	5,45	12,45
	1	67	97,1	59	88,1	9,04	22,17
	2	10	66,7	10	100,0	10,00	16,10
Cycle 3 Day 1	0	57	93,4	50	87,7	7,33	13,95
	1	65	94,2	57	87,7	9,36	18,64
	2	9	60,0	9	100,0	14,81	24,22
Cycle 4 Day 1	0	57	93,4	51	89,5	3,92	10,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	57	91,9	7,60	17,84
	2	9	60,0	8	88,9	16,67	25,20
Cycle 5 Day 1	0	56	91,8	52	92,9	7,69	18,22
	1	62	89,9	57	91,9	7,60	19,94
	2	6	40,0	6	100,0	5,56	13,61
Cycle 6 Day 1	0	56	91,8	53	94,6	6,29	14,70
	1	59	85,5	51	86,4	3,92	12,73
	2	6	40,0	4	66,7	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	54	88,5	51	94,4	6,54	17,66
	1	54	78,3	47	87,0	9,93	22,96
	2	5	33,3	5	100,0	0,00	0,00
Cycle 8 Day 1	0	52	85,2	48	92,3	4,17	11,14
	1	49	71,0	43	87,8	9,30	20,99
	2	5	33,3	5	100,0	6,67	14,91
Cycle 9 Day 1	0	50	82,0	49	98,0	6,80	13,57
	1	44	63,8	42	95,5	9,52	24,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	4	26,7	4	100,0	8,33	16,67
Cycle 10 Day 1	0	46	75,4	46	100,0	5,07	12,11
	1	40	58,0	37	92,5	7,21	17,80
	2	3	20,0	3	100,0	0,00	0,00
Cycle 11 Day 1	0	43	70,5	40	93,0	4,17	11,16
	1	34	49,3	33	97,1	7,07	16,15
	2	3	20,0	3	100,0	0,00	0,00
Cycle 12 Day 1	0	42	68,9	36	85,7	8,33	14,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	31	44,9	29	93,5	6,90	13,74
	2	3	20,0	3	100,0	22,22	38,49
Cycle 13 Day 1	0	38	62,3	34	89,5	6,86	13,68
	1	27	39,1	25	92,6	6,67	21,52
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	3,13	9,87
	1	24	34,8	23	95,8	8,70	22,96
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	33	54,1	30	90,9	5,56	15,37
	1	23	33,3	22	95,7	3,03	9,81
	2	1	6,7	1	100,0	0,00	-
Cycle 16 Day 1	0	28	45,9	25	89,3	6,67	13,61
	1	21	30,4	21	100,0	6,35	22,65
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	2,90	9,60
	1	20	29,0	20	100,0	10,00	24,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	3,51	10,51
	1	17	24,6	17	100,0	9,80	19,60
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	3,51	10,51
	1	15	21,7	13	86,7	2,56	9,25
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	5,88	13,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	21,7	14	93,3	7,14	14,19
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	2,38	8,91
	1	13	18,8	11	84,6	6,06	13,48
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	5,56	12,97
	1	13	18,8	12	92,3	8,33	15,08
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	0,00	0,00
	1	9	13,0	8	88,9	4,17	11,79
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	0,00	0,00
	1	9	13,0	8	88,9	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	0,00	0,00
	1	7	10,1	7	100,0	14,29	37,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	13,1	6	75,0	0,00	0,00
	1	6	8,7	6	100,0	16,67	27,89
Cycle 27 Day 1	0	6	9,8	3	50,0	0,00	0,00
	1	5	7,2	5	100,0	13,33	18,26
Cycle 28 Day 1	0	5	8,2	4	80,0	0,00	0,00
	1	5	7,2	5	100,0	26,67	43,46
Cycle 29 Day 1	0	4	6,6	2	50,0	0,00	0,00
	1	5	7,2	5	100,0	6,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	8,33	16,67
Cycle 31 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	16,67	19,25
Cycle 32 Day 1	0	3	4,9	2	66,7	0,00	0,00
	1	3	4,3	3	100,0	0,00	0,00
Cycle 33 Day 1	0	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	9,52	23,90
	1	34	49,3	20	58,8	8,33	18,34
	2	7	46,7	3	42,9	0,00	0,00
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	59	95,2	7,34	21,50
	1	4	100,0	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	79	100,0	77	97,5	11,69	20,06
Cycle 2 Day 1	None	60	96,8	53	88,3	5,03	16,53
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	73	92,4	69	94,5	9,66	19,05
Cycle 3 Day 1	None	59	95,2	53	89,8	6,92	17,73
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	69	87,3	61	88,4	10,93	16,91
Cycle 4 Day 1	None	59	95,2	54	91,5	7,41	17,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	66	83,5	60	90,9	6,11	14,38
Cycle 5 Day 1	None	58	93,5	54	93,1	10,49	24,08
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	63	79,7	58	92,1	5,17	12,17
Cycle 6 Day 1	None	57	91,9	49	86,0	7,48	17,03
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	61	77,2	56	91,8	3,57	10,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	52	83,9	47	90,4	12,77	26,52
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	58	73,4	53	91,4	3,77	10,66
Cycle 8 Day 1	None	50	80,6	45	90,0	8,15	20,30
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	5,33	12,34
Cycle 9 Day 1	None	48	77,4	46	95,8	10,14	24,21
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	6,25	13,15
Cycle 10 Day 1	None	43	69,4	41	95,3	6,50	17,03
	1	1	25,0	1	100,0	0,00	-
	2 or More	45	57,0	44	97,8	5,30	12,33
Cycle 11 Day 1	None	37	59,7	33	89,2	5,05	14,72
	1	1	25,0	1	100,0	0,00	-
	2 or More	42	53,2	42	100,0	5,56	12,57
Cycle 12 Day 1	None	37	59,7	33	89,2	9,09	17,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	33,33	-
	2 or More	38	48,1	34	89,5	6,86	13,68
Cycle 13 Day 1	None	34	54,8	28	82,4	8,33	21,52
	1	1	25,0	1	100,0	33,33	-
	2 or More	31	39,2	31	100,0	4,30	11,36
Cycle 14 Day 1	None	31	50,0	28	90,3	5,95	20,39
	1	1	25,0	1	100,0	0,00	-
	2 or More	28	35,4	27	96,4	4,94	12,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	30	48,4	27	90,0	3,70	10,68
	1	1	25,0	1	100,0	0,00	-
	2 or More	26	32,9	25	96,2	5,33	15,75
Cycle 16 Day 1	None	25	40,3	23	92,0	5,80	12,92
	1	1	25,0	1	100,0	0,00	-
	2 or More	24	30,4	23	95,8	7,25	22,38
Cycle 17 Day 1	None	23	37,1	22	95,7	3,03	9,81
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	21	26,6	21	100,0	9,52	23,90
Cycle 18 Day 1	None	20	32,3	18	90,0	5,56	12,78
	1	1	25,0	1	100,0	0,00	-
	2 or More	20	25,3	18	90,0	7,41	18,28
Cycle 19 Day 1	None	17	27,4	17	100,0	3,92	11,07
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	2,22	8,61
Cycle 20 Day 1	None	17	27,4	16	94,1	8,33	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	4,44	11,73
Cycle 21 Day 1	None	15	24,2	13	86,7	5,13	12,52
	2 or More	14	17,7	13	92,9	2,56	9,25
Cycle 22 Day 1	None	15	24,2	13	86,7	10,26	16,01
	2 or More	14	17,7	12	85,7	2,78	9,62
Cycle 23 Day 1	None	10	16,1	9	90,0	3,70	11,11
	2 or More	11	13,9	9	81,8	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	16,1	10	100,0	0,00	0,00
	2 or More	10	12,7	8	80,0	0,00	0,00
Cycle 25 Day 1	None	9	14,5	8	88,9	0,00	0,00
	2 or More	6	7,6	5	83,3	20,00	44,72
Cycle 26 Day 1	None	8	12,9	8	100,0	4,17	11,79
	2 or More	6	7,6	4	66,7	16,67	33,33
Cycle 27 Day 1	None	7	11,3	6	85,7	5,56	13,61
	2 or More	4	5,1	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	11,3	7	100,0	4,76	12,60
	2 or More	3	3,8	2	66,7	50,00	70,71
Cycle 29 Day 1	None	6	9,7	5	83,3	6,67	14,91
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	6,5	3	75,0	11,11	19,25
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 31 Day 1	None	4	6,5	3	75,0	11,11	19,25
	2 or More	3	3,8	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	0,00	0,00
	2 or More	2	2,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	1,6	1	100,0	0,00	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	14,04	27,92
	1	3	75,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	39	49,4	24	61,5	4,17	11,26
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	59	95,2	7,34	21,50
	Previously Treated	83	100,0	81	97,6	11,11	19,72
Cycle 2 Day 1	Naïve	60	96,8	53	88,3	5,03	16,53
	Previously Treated	76	91,6	71	93,4	9,39	18,84
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	6,92	17,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	72	86,7	63	87,5	10,58	16,75
Cycle 4 Day 1	Naïve	59	95,2	54	91,5	7,41	17,93
	Previously Treated	69	83,1	62	89,9	5,91	14,19
Cycle 5 Day 1	Naïve	58	93,5	54	93,1	10,49	24,08
	Previously Treated	66	79,5	61	92,4	4,92	11,92
Cycle 6 Day 1	Naïve	57	91,9	49	86,0	7,48	17,03
	Previously Treated	64	77,1	59	92,2	3,39	10,16
Cycle 7 Day 1	Naïve	52	83,9	47	90,4	12,77	26,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	61	73,5	56	91,8	3,57	10,40
Cycle 8 Day 1	Naïve	50	80,6	45	90,0	8,15	20,30
	Previously Treated	56	67,5	51	91,1	5,23	12,24
Cycle 9 Day 1	Naïve	48	77,4	46	95,8	10,14	24,21
	Previously Treated	50	60,2	49	98,0	6,12	13,04
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	6,50	17,03
	Previously Treated	46	55,4	45	97,8	5,19	12,22
Cycle 11 Day 1	Naïve	37	59,7	33	89,2	5,05	14,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	43	51,8	43	100,0	5,43	12,45
Cycle 12 Day 1	Naïve	37	59,7	33	89,2	9,09	17,23
	Previously Treated	39	47,0	35	89,7	7,62	14,20
Cycle 13 Day 1	Naïve	34	54,8	28	82,4	8,33	21,52
	Previously Treated	32	38,6	32	100,0	5,21	12,30
Cycle 14 Day 1	Naïve	31	50,0	28	90,3	5,95	20,39
	Previously Treated	29	34,9	28	96,6	4,76	11,88
Cycle 15 Day 1	Naïve	30	48,4	27	90,0	3,70	10,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	27	32,5	26	96,3	5,13	15,47
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	5,80	12,92
	Previously Treated	25	30,1	24	96,0	6,94	21,93
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	3,03	9,81
	Previously Treated	22	26,5	22	100,0	9,09	23,42
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	5,56	12,78
	Previously Treated	21	25,3	19	90,5	7,02	17,84
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	3,92	11,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	22,9	16	84,2	2,08	8,33
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	8,33	14,91
	Previously Treated	19	22,9	16	84,2	4,17	11,39
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	5,13	12,52
	Previously Treated	14	16,9	13	92,9	2,56	9,25
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	10,26	16,01
	Previously Treated	14	16,9	12	85,7	2,78	9,62
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	3,70	11,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	0,00	0,00
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	0,00	0,00
	Previously Treated	10	12,0	8	80,0	0,00	0,00
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	0,00	0,00
	Previously Treated	6	7,2	5	83,3	20,00	44,72
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	4,17	11,79
	Previously Treated	6	7,2	4	66,7	16,67	33,33
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	4,8	2	50,0	16,67	23,57
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	4,76	12,60
	Previously Treated	3	3,6	2	66,7	50,00	70,71
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	6,67	14,91
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	11,11	19,25
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	0,00	0,00
	Previously Treated	2	2,4	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	0,00	-
	Previously Treated	1	1,2	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	14,04	27,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	50,6	25	59,5	4,00	11,06
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	8,44	18,25
	Central	70	100,0	65	92,9	10,77	22,90
Cycle 2 Day 1	Local	71	94,7	67	94,4	7,96	17,49
	Central	65	92,9	57	87,7	7,02	18,62
Cycle 3 Day 1	Local	67	89,3	60	89,6	7,22	13,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	64	91,4	56	87,5	10,71	20,21
Cycle 4 Day 1	Local	65	86,7	58	89,2	6,32	14,59
	Central	63	90,0	58	92,1	6,90	17,39
Cycle 5 Day 1	Local	63	84,0	58	92,1	7,47	15,35
	Central	61	87,1	57	93,4	7,60	21,84
Cycle 6 Day 1	Local	63	84,0	61	96,8	4,92	11,92
	Central	58	82,9	47	81,0	5,67	16,03
Cycle 7 Day 1	Local	61	81,3	58	95,1	6,90	16,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	52	74,3	45	86,5	8,89	23,99
Cycle 8 Day 1	Local	57	76,0	54	94,7	6,79	15,02
	Central	49	70,0	42	85,7	6,35	18,39
Cycle 9 Day 1	Local	54	72,0	53	98,1	7,55	18,07
	Central	44	62,9	42	95,5	8,73	20,90
Cycle 10 Day 1	Local	48	64,0	46	95,8	5,07	12,11
	Central	41	58,6	40	97,6	6,67	17,21
Cycle 11 Day 1	Local	40	53,3	38	95,0	6,14	15,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	40	57,1	38	95,0	4,39	11,42
Cycle 12 Day 1	Local	36	48,0	33	91,7	5,05	12,14
	Central	40	57,1	35	87,5	11,43	17,97
Cycle 13 Day 1	Local	30	40,0	29	96,7	4,60	11,70
	Central	36	51,4	31	86,1	8,60	21,03
Cycle 14 Day 1	Local	27	36,0	27	100,0	1,23	6,42
	Central	33	47,1	29	87,9	9,20	21,63
Cycle 15 Day 1	Local	26	34,7	25	96,2	1,33	6,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	28	90,3	7,14	16,62
Cycle 16 Day 1	Local	24	32,0	24	100,0	4,17	11,26
	Central	26	37,1	23	88,5	8,70	22,96
Cycle 17 Day 1	Local	22	29,3	22	100,0	3,03	9,81
	Central	23	32,9	22	95,7	9,09	23,42
Cycle 18 Day 1	Local	20	26,7	19	95,0	3,51	10,51
	Central	21	30,0	18	85,7	9,26	19,15
Cycle 19 Day 1	Local	19	25,3	17	89,5	3,92	11,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	24,3	16	94,1	2,08	8,33
Cycle 20 Day 1	Local	19	25,3	17	89,5	5,88	13,10
	Central	17	24,3	15	88,2	6,67	13,80
Cycle 21 Day 1	Local	14	18,7	12	85,7	0,00	0,00
	Central	15	21,4	14	93,3	7,14	14,19
Cycle 22 Day 1	Local	14	18,7	12	85,7	5,56	12,97
	Central	15	21,4	13	86,7	7,69	14,62
Cycle 23 Day 1	Local	11	14,7	10	90,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	14,3	8	80,0	4,17	11,79
Cycle 24 Day 1	Local	11	14,7	10	90,9	0,00	0,00
	Central	9	12,9	8	88,9	0,00	0,00
Cycle 25 Day 1	Local	7	9,3	7	100,0	0,00	0,00
	Central	8	11,4	6	75,0	16,67	40,82
Cycle 26 Day 1	Local	6	8,0	6	100,0	5,56	13,61
	Central	8	11,4	6	75,0	11,11	27,22
Cycle 27 Day 1	Local	4	5,3	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	10,0	4	57,1	8,33	16,67
Cycle 28 Day 1	Local	4	5,3	4	100,0	8,33	16,67
	Central	6	8,6	5	83,3	20,00	44,72
Cycle 29 Day 1	Local	3	4,0	3	100,0	11,11	19,25
	Central	6	8,6	4	66,7	0,00	0,00
Cycle 30 Day 1	Local	3	4,0	3	100,0	11,11	19,25
	Central	4	5,7	2	50,0	0,00	0,00
Cycle 31 Day 1	Local	3	4,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	5,7	2	50,0	16,67	23,57
Cycle 32 Day 1	Local	3	4,0	3	100,0	0,00	0,00
	Central	3	4,3	2	66,7	0,00	0,00
Cycle 33 Day 1	Local	1	1,3	1	100,0	0,00	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	4,17	11,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	32	45,7	20	62,5	13,33	27,36
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	130	96,3	9,23	20,76
	No	10	100,0	10	100,0	13,33	17,21
Cycle 2 Day 1	Yes	129	95,6	117	90,7	7,41	18,11
	No	7	70,0	7	100,0	9,52	16,27
Cycle 3 Day 1	Yes	124	91,9	110	88,7	8,48	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	6	85,7	16,67	18,26
Cycle 4 Day 1	Yes	121	89,6	109	90,1	6,12	15,82
	No	7	70,0	7	100,0	14,29	17,82
Cycle 5 Day 1	Yes	117	86,7	109	93,2	7,03	18,19
	No	7	70,0	6	85,7	16,67	27,89
Cycle 6 Day 1	Yes	114	84,4	101	88,6	5,28	13,93
	No	7	70,0	7	100,0	4,76	12,60
Cycle 7 Day 1	Yes	106	78,5	96	90,6	7,29	19,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	14,29	26,23
Cycle 8 Day 1	Yes	100	74,1	90	90,0	6,30	16,49
	No	6	60,0	6	100,0	11,11	17,21
Cycle 9 Day 1	Yes	92	68,1	89	96,7	7,87	19,48
	No	6	60,0	6	100,0	11,11	17,21
Cycle 10 Day 1	Yes	83	61,5	80	96,4	5,42	14,47
	No	6	60,0	6	100,0	11,11	17,21
Cycle 11 Day 1	Yes	76	56,3	72	94,7	4,63	12,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	4	40,0	4	100,0	16,67	19,25
Cycle 12 Day 1	Yes	72	53,3	64	88,9	7,81	15,42
	No	4	40,0	4	100,0	16,67	19,25
Cycle 13 Day 1	Yes	64	47,4	58	90,6	6,32	17,05
	No	2	20,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	58	43,0	54	93,1	4,94	16,39
	No	2	20,0	2	100,0	16,67	23,57
Cycle 15 Day 1	Yes	55	40,7	51	92,7	3,27	10,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	33,33	47,14
Cycle 16 Day 1	Yes	48	35,6	45	93,8	5,93	17,82
	No	2	20,0	2	100,0	16,67	23,57
Cycle 17 Day 1	Yes	43	31,9	42	97,7	5,56	17,91
	No	2	20,0	2	100,0	16,67	23,57
Cycle 18 Day 1	Yes	39	28,9	35	89,7	5,71	15,09
	No	2	20,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	3,13	9,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	5,56	12,63
	No	2	20,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	20,0	24	88,9	2,78	9,41
	No	2	20,0	2	100,0	16,67	23,57
Cycle 22 Day 1	Yes	27	20,0	23	85,2	5,80	12,92
	No	2	20,0	2	100,0	16,67	23,57
Cycle 23 Day 1	Yes	20	14,8	17	85,0	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	10,4	12	85,7	8,33	28,87
	No	1	10,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	6,06	20,10
	No	1	10,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	4,76	12,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	33,33	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	12,50	35,36
	No	1	10,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	0,00	0,00
	No	1	10,0	1	100,0	33,33	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	0,00	0,00
	No	1	10,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	33,33	-
Cycle 32 Day 1	Yes	5	3,7	4	80,0	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	8,53	20,69
	No	2	20,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	18,18	31,14
	No	134	100,0	129	96,3	8,79	19,33
Cycle 2 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	129	96,3	117	90,7	7,98	18,39
Cycle 3 Day 1	Yes	7	63,6	6	85,7	5,56	13,61
	No	124	92,5	110	88,7	9,09	17,43

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	121	90,3	109	90,1	7,03	16,40
Cycle 5 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	117	87,3	108	92,3	8,02	19,26
Cycle 6 Day 1	Yes	7	63,6	7	100,0	4,76	12,60
	No	114	85,1	101	88,6	5,28	13,93
Cycle 7 Day 1	Yes	7	63,6	7	100,0	9,52	16,27
	No	106	79,1	96	90,6	7,64	20,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	7	63,6	7	100,0	14,29	26,23
	No	99	73,9	89	89,9	5,99	15,54
Cycle 9 Day 1	Yes	6	54,5	6	100,0	16,67	40,82
	No	92	68,7	89	96,7	7,49	17,23
Cycle 10 Day 1	Yes	6	54,5	6	100,0	5,56	13,61
	No	83	61,9	80	96,4	5,83	14,79
Cycle 11 Day 1	Yes	6	54,5	6	100,0	11,11	27,22
	No	74	55,2	70	94,6	4,76	11,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	6	54,5	6	100,0	5,56	13,61
	No	70	52,2	62	88,6	8,60	15,90
Cycle 13 Day 1	Yes	5	45,5	5	100,0	6,67	14,91
	No	61	45,5	55	90,2	6,67	17,45
Cycle 14 Day 1	Yes	5	45,5	5	100,0	0,00	0,00
	No	55	41,0	51	92,7	5,88	17,26
Cycle 15 Day 1	Yes	4	36,4	4	100,0	0,00	0,00
	No	53	39,6	49	92,5	4,76	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	47	35,1	44	93,6	6,82	18,44
Cycle 17 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	42	31,3	41	97,6	5,69	18,11
Cycle 18 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	38	28,4	34	89,5	5,88	15,29
Cycle 19 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	30	90,9	3,33	10,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	33	24,6	29	87,9	5,75	12,81
Cycle 21 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	24	88,9	4,17	11,26
Cycle 22 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	23	85,2	7,25	14,06
Cycle 23 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	19	14,2	16	84,2	2,08	8,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	18	13,4	16	88,9	0,00	0,00
Cycle 25 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	13	9,7	11	84,6	9,09	30,15
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	9,09	21,56
Cycle 27 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	10	7,5	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	9	6,7	8	88,9	16,67	35,63
Cycle 29 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	8	6,0	6	75,0	5,56	13,61
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	6,67	14,91
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	0,00	0,00
Cycle 33 Day 1	No	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	0,00	0,00
	No	61	45,5	41	67,2	8,94	21,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mean_D194_REE_LC13HR_SG.xls
24JUN2020 20:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	140	96,6	18,57	25,37
Cycle 2 Day 1	All	136	93,8	124	91,2	8,60	15,83
Cycle 3 Day 1	All	131	90,3	116	88,5	7,18	16,91
Cycle 4 Day 1	All	128	88,3	116	90,6	9,20	17,90
Cycle 5 Day 1	All	124	85,5	115	92,7	8,99	17,84
Cycle 6 Day 1	All	121	83,4	108	89,3	10,19	19,58
Cycle 7 Day 1	All	113	77,9	103	91,2	6,80	14,28

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	106	73,1	96	90,6	8,33	16,75
Cycle 9 Day 1	All	98	67,6	95	96,9	7,72	14,95
Cycle 10 Day 1	All	89	61,4	86	96,6	7,75	15,06
Cycle 11 Day 1	All	80	55,2	76	95,0	10,53	21,23
Cycle 12 Day 1	All	76	52,4	68	89,5	10,78	16,73
Cycle 13 Day 1	All	66	45,5	60	90,9	12,78	23,04
Cycle 14 Day 1	All	60	41,4	56	93,3	11,90	21,49
Cycle 15 Day 1	All	57	39,3	53	93,0	8,81	17,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	50	34,5	47	94,0	9,93	16,90
Cycle 17 Day 1	All	45	31,0	44	97,8	10,61	18,71
Cycle 18 Day 1	All	41	28,3	37	90,2	9,91	15,45
Cycle 19 Day 1	All	36	24,8	33	91,7	11,11	19,84
Cycle 20 Day 1	All	36	24,8	32	88,9	11,46	18,18
Cycle 21 Day 1	All	29	20,0	26	89,7	8,97	17,78
Cycle 22 Day 1	All	29	20,0	25	86,2	9,33	15,28
Cycle 23 Day 1	All	21	14,5	18	85,7	11,11	16,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	13,8	18	90,0	11,11	16,17
Cycle 25 Day 1	All	15	10,3	13	86,7	7,69	14,62
Cycle 26 Day 1	All	14	9,7	12	85,7	11,11	16,41
Cycle 27 Day 1	All	11	7,6	8	72,7	16,67	25,20
Cycle 28 Day 1	All	10	6,9	9	90,0	14,81	17,57
Cycle 29 Day 1	All	9	6,2	7	77,8	14,29	17,82
Cycle 30 Day 1	All	7	4,8	5	71,4	20,00	18,26
Cycle 31 Day 1	All	7	4,8	5	71,4	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	4,1	5	83,3	13,33	18,26
Cycle 33 Day 1	All	2	1,4	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	12,88	19,31
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	10,46	20,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	93	100,0	89	95,7	23,22	26,78
Cycle 2 Day 1	Male	50	96,2	46	92,0	8,70	16,38
	Female	86	92,5	78	90,7	8,55	15,60
Cycle 3 Day 1	Male	47	90,4	43	91,5	8,53	20,69
	Female	84	90,3	73	86,9	6,39	14,33
Cycle 4 Day 1	Male	46	88,5	43	93,5	8,53	16,42
	Female	82	88,2	73	89,0	9,59	18,82
Cycle 5 Day 1	Male	45	86,5	42	93,3	7,94	16,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	79	84,9	73	92,4	9,59	18,82
Cycle 6 Day 1	Male	45	86,5	41	91,1	9,76	20,06
	Female	76	81,7	67	88,2	10,45	19,43
Cycle 7 Day 1	Male	40	76,9	39	97,5	6,84	15,63
	Female	73	78,5	64	87,7	6,77	13,52
Cycle 8 Day 1	Male	37	71,2	34	91,9	6,86	13,68
	Female	69	74,2	62	89,9	9,14	18,28
Cycle 9 Day 1	Male	33	63,5	33	100,0	4,04	11,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	62	95,4	9,68	16,40
Cycle 10 Day 1	Male	30	57,7	30	100,0	4,44	11,52
	Female	59	63,4	56	94,9	9,52	16,47
Cycle 11 Day 1	Male	29	55,8	28	96,6	15,48	26,42
	Female	51	54,8	48	94,1	7,64	17,18
Cycle 12 Day 1	Male	27	51,9	26	96,3	10,26	15,69
	Female	49	52,7	42	85,7	11,11	17,53
Cycle 13 Day 1	Male	25	48,1	23	92,0	13,04	21,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	41	44,1	37	90,2	12,61	24,03
Cycle 14 Day 1	Male	23	44,2	21	91,3	7,94	14,55
	Female	37	39,8	35	94,6	14,29	24,64
Cycle 15 Day 1	Male	21	40,4	20	95,2	5,00	12,21
	Female	36	38,7	33	91,7	11,11	19,84
Cycle 16 Day 1	Male	16	30,8	16	100,0	8,33	14,91
	Female	34	36,6	31	91,2	10,75	18,03
Cycle 17 Day 1	Male	13	25,0	13	100,0	5,13	12,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	32	34,4	31	96,9	12,90	20,51
Cycle 18 Day 1	Male	12	23,1	11	91,7	6,06	13,48
	Female	29	31,2	26	89,7	11,54	16,17
Cycle 19 Day 1	Male	10	19,2	10	100,0	10,00	22,50
	Female	26	28,0	23	88,5	11,59	19,09
Cycle 20 Day 1	Male	10	19,2	9	90,0	7,41	14,70
	Female	26	28,0	23	88,5	13,04	19,43
Cycle 21 Day 1	Male	8	15,4	8	100,0	12,50	24,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	22,6	18	85,7	7,41	14,26
Cycle 22 Day 1	Male	8	15,4	6	75,0	22,22	17,21
	Female	21	22,6	19	90,5	5,26	12,49
Cycle 23 Day 1	Male	5	9,6	4	80,0	16,67	19,25
	Female	16	17,2	14	87,5	9,52	15,63
Cycle 24 Day 1	Male	5	9,6	4	80,0	8,33	16,67
	Female	15	16,1	14	93,3	11,90	16,57
Cycle 25 Day 1	Male	3	5,8	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	12,9	11	91,7	9,09	15,57
Cycle 26 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	11	11,8	10	90,9	13,33	17,21
Cycle 27 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	8	8,6	6	75,0	22,22	27,22
Cycle 28 Day 1	Male	2	3,8	2	100,0	0,00	0,00
	Female	8	8,6	7	87,5	19,05	17,82
Cycle 29 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	8,6	6	75,0	16,67	18,26
Cycle 30 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	25,00	16,67
Cycle 31 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	25,00	16,67
Cycle 32 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	5	5,4	4	80,0	16,67	19,25
Cycle 33 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	1,1	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	9,52	15,43
	Female	37	39,8	23	62,2	15,94	22,18
Age							
Cycle 1 Day 1	18-64	109	100,0	104	95,4	20,19	27,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	13,79	16,71
	>=75	7	100,0	7	100,0	14,29	17,82
Cycle 2 Day 1	18-64	103	94,5	91	88,3	8,79	15,58
	65-74	26	89,7	26	100,0	10,26	18,30
	>=75	7	100,0	7	100,0	0,00	0,00
Cycle 3 Day 1	18-64	99	90,8	87	87,9	8,05	18,30
	65-74	25	86,2	23	92,0	4,35	11,48
	>=75	7	100,0	6	85,7	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	98	89,9	88	89,8	9,85	19,02
	65-74	23	79,3	21	91,3	7,94	14,55
	>=75	7	100,0	7	100,0	4,76	12,60
Cycle 5 Day 1	18-64	95	87,2	88	92,6	9,47	18,19
	65-74	22	75,9	22	100,0	6,06	16,70
	>=75	7	100,0	5	71,4	13,33	18,26
Cycle 6 Day 1	18-64	92	84,4	80	87,0	10,83	20,39
	65-74	22	75,9	21	95,5	7,94	17,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	9,52	16,27
Cycle 7 Day 1	18-64	86	78,9	78	90,7	7,69	15,12
	65-74	20	69,0	19	95,0	5,26	12,49
	>=75	7	100,0	6	85,7	0,00	0,00
Cycle 8 Day 1	18-64	80	73,4	71	88,8	8,45	17,56
	65-74	19	65,5	19	100,0	8,77	15,08
	>=75	7	100,0	6	85,7	5,56	13,61
Cycle 9 Day 1	18-64	74	67,9	72	97,3	7,41	15,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	18	62,1	18	100,0	9,26	15,36
	>=75	6	85,7	5	83,3	6,67	14,91
Cycle 10 Day 1	18-64	69	63,3	66	95,7	9,09	16,06
	65-74	15	51,7	15	100,0	2,22	8,61
	>=75	5	71,4	5	100,0	6,67	14,91
Cycle 11 Day 1	18-64	61	56,0	58	95,1	10,92	22,85
	65-74	15	51,7	14	93,3	7,14	14,19
	>=75	4	57,1	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	57	52,3	50	87,7	11,33	17,31
	65-74	15	51,7	14	93,3	9,52	15,63
	>=75	4	57,1	4	100,0	8,33	16,67
Cycle 13 Day 1	18-64	49	45,0	45	91,8	12,59	22,80
	65-74	13	44,8	11	84,6	15,15	27,34
	>=75	4	57,1	4	100,0	8,33	16,67
Cycle 14 Day 1	18-64	45	41,3	43	95,6	10,85	21,48
	65-74	13	44,8	11	84,6	15,15	22,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	28,6	2	100,0	16,67	23,57
Cycle 15 Day 1	18-64	43	39,4	40	93,0	8,33	18,10
	65-74	12	41,4	11	91,7	9,09	15,57
	>=75	2	28,6	2	100,0	16,67	23,57
Cycle 16 Day 1	18-64	38	34,9	36	94,7	11,11	17,82
	65-74	10	34,5	9	90,0	7,41	14,70
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 17 Day 1	18-64	36	33,0	35	97,2	11,43	19,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	27,6	8	100,0	8,33	15,43
	>=75	1	14,3	1	100,0	0,00	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	10,00	15,54
	65-74	7	24,1	6	85,7	11,11	17,21
	>=75	1	14,3	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	11,90	20,72
	65-74	5	17,2	4	80,0	8,33	16,67
	>=75	1	14,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	11,54	18,72
	65-74	5	17,2	5	100,0	13,33	18,26
	>=75	1	14,3	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	9,52	18,69
	65-74	4	13,8	4	100,0	8,33	16,67
	>=75	1	14,3	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	10,00	15,67
	65-74	4	13,8	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	33,33	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	10,42	15,96
	65-74	2	6,9	2	100,0	16,67	23,57
Cycle 24 Day 1	18-64	18	16,5	16	88,9	12,50	16,67
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	12,8	12	85,7	8,33	15,08
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	11,11	16,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	16,67	25,20
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	14,81	17,57
	65-74	1	3,4	0	0,0	-	-
Cycle 29 Day 1	18-64	8	7,3	7	87,5	14,29	17,82
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	20,00	18,26
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	16,67	19,25
	65-74	1	3,4	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	0,00	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	13,73	18,56
	65-74	15	51,7	8	53,3	8,33	23,57
	>=75	4	57,1	2	50,0	16,67	23,57
Race							
Cycle 1 Day 1	White	60	100,0	57	95,0	19,88	28,77
	Other	85	100,0	83	97,6	17,67	22,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	57	95,0	50	87,7	4,00	10,94
	Other	79	92,9	74	93,7	11,71	17,82
Cycle 3 Day 1	White	54	90,0	44	81,5	4,55	11,57
	Other	77	90,6	72	93,5	8,80	19,37
Cycle 4 Day 1	White	53	88,3	45	84,9	5,93	12,89
	Other	75	88,2	71	94,7	11,27	20,27
Cycle 5 Day 1	White	52	86,7	47	90,4	7,09	16,93
	Other	72	84,7	68	94,4	10,29	18,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	50	83,3	41	82,0	10,57	18,91
	Other	71	83,5	67	94,4	9,95	20,11
Cycle 7 Day 1	White	47	78,3	40	85,1	4,17	11,16
	Other	66	77,6	63	95,5	8,47	15,80
Cycle 8 Day 1	White	45	75,0	38	84,4	8,77	14,88
	Other	61	71,8	58	95,1	8,05	18,00
Cycle 9 Day 1	White	42	70,0	41	97,6	4,88	11,93
	Other	56	65,9	54	96,4	9,88	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	5,98	12,96
	Other	48	56,5	47	97,9	9,22	16,60
Cycle 11 Day 1	White	37	61,7	36	97,3	5,56	14,91
	Other	43	50,6	40	93,0	15,00	24,98
Cycle 12 Day 1	White	37	61,7	33	89,2	6,06	13,06
	Other	39	45,9	35	89,7	15,24	18,69
Cycle 13 Day 1	White	32	53,3	30	93,8	8,89	19,44
	Other	34	40,0	30	88,2	16,67	25,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	31	51,7	30	96,8	8,89	19,44
	Other	29	34,1	26	89,7	15,38	23,53
Cycle 15 Day 1	White	30	50,0	28	93,3	7,14	16,62
	Other	27	31,8	25	92,6	10,67	18,56
Cycle 16 Day 1	White	26	43,3	24	92,3	8,33	14,74
	Other	24	28,2	23	95,8	11,59	19,09
Cycle 17 Day 1	White	24	40,0	24	100,0	6,94	16,97
	Other	21	24,7	20	95,2	15,00	20,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	22	36,7	19	86,4	3,51	10,51
	Other	19	22,4	18	94,7	16,67	17,15
Cycle 19 Day 1	White	20	33,3	20	100,0	8,33	14,81
	Other	16	18,8	13	81,3	15,38	25,88
Cycle 20 Day 1	White	20	33,3	17	85,0	3,92	11,07
	Other	16	18,8	15	93,8	20,00	21,08
Cycle 21 Day 1	White	16	26,7	14	87,5	2,38	8,91
	Other	13	15,3	12	92,3	16,67	22,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	26,7	13	81,3	5,13	12,52
	Other	13	15,3	12	92,3	13,89	17,16
Cycle 23 Day 1	White	12	20,0	10	83,3	6,67	14,05
	Other	9	10,6	8	88,9	16,67	17,82
Cycle 24 Day 1	White	11	18,3	10	90,9	6,67	14,05
	Other	9	10,6	8	88,9	16,67	17,82
Cycle 25 Day 1	White	10	16,7	8	80,0	0,00	0,00
	Other	5	5,9	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	16,7	8	80,0	4,17	11,79
	Other	4	4,7	4	100,0	25,00	16,67
Cycle 27 Day 1	White	8	13,3	5	62,5	0,00	0,00
	Other	3	3,5	3	100,0	44,44	19,25
Cycle 28 Day 1	White	7	11,7	6	85,7	5,56	13,61
	Other	3	3,5	3	100,0	33,33	0,00
Cycle 29 Day 1	White	6	10,0	4	66,7	16,67	19,25
	Other	3	3,5	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	6,7	2	50,0	16,67	23,57
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 31 Day 1	White	4	6,7	2	50,0	16,67	23,57
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 32 Day 1	White	4	6,7	3	75,0	11,11	19,25
	Other	2	2,4	2	100,0	16,67	23,57
Cycle 33 Day 1	White	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-
End Of Treatment	White	25	41,7	17	68,0	9,80	19,60
	Other	39	45,9	27	69,2	14,81	19,25
Region							
Cycle 1 Day 1	America (AM)	40	100,0	38	95,0	21,05	27,31
	Europe (EU)	34	100,0	31	91,2	13,98	25,49
	Asia (AS)	71	100,0	71	100,0	19,25	24,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	2,08	8,20
	Europe (EU)	32	94,1	27	84,4	6,17	13,19
	Asia (AS)	66	93,0	65	98,5	12,82	18,34
Cycle 3 Day 1	America (AM)	37	92,5	32	86,5	1,04	5,89
	Europe (EU)	31	91,2	21	67,7	12,70	24,67
	Asia (AS)	63	88,7	63	100,0	8,47	16,90
Cycle 4 Day 1	America (AM)	37	92,5	32	86,5	5,21	12,30
	Europe (EU)	30	88,2	24	80,0	11,11	18,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	61	85,9	60	98,4	10,56	19,88
Cycle 5 Day 1	America (AM)	37	92,5	33	89,2	9,09	19,14
	Europe (EU)	30	88,2	25	83,3	8,00	17,43
	Asia (AS)	57	80,3	57	100,0	9,36	17,54
Cycle 6 Day 1	America (AM)	37	92,5	32	86,5	8,33	16,93
	Europe (EU)	28	82,4	24	85,7	13,89	27,66
	Asia (AS)	56	78,9	52	92,9	9,62	16,62
Cycle 7 Day 1	America (AM)	35	87,5	29	82,9	5,75	15,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	28	82,4	25	89,3	5,33	12,47
	Asia (AS)	50	70,4	49	98,0	8,16	14,48
Cycle 8 Day 1	America (AM)	31	77,5	26	83,9	6,41	13,40
	Europe (EU)	28	82,4	23	82,1	10,14	15,68
	Asia (AS)	47	66,2	47	100,0	8,51	18,99
Cycle 9 Day 1	America (AM)	29	72,5	27	93,1	4,94	12,07
	Europe (EU)	26	76,5	25	96,2	5,33	12,47
	Asia (AS)	43	60,6	43	100,0	10,85	17,40

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	4,17	11,26
	Europe (EU)	25	73,5	25	100,0	6,67	13,61
	Asia (AS)	37	52,1	37	100,0	10,81	17,66
Cycle 11 Day 1	America (AM)	24	60,0	21	87,5	0,00	0,00
	Europe (EU)	23	67,6	22	95,7	12,12	26,32
	Asia (AS)	33	46,5	33	100,0	16,16	22,24
Cycle 12 Day 1	America (AM)	24	60,0	22	91,7	4,55	11,71
	Europe (EU)	23	67,6	18	78,3	11,11	16,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	40,8	28	96,6	15,48	19,21
Cycle 13 Day 1	America (AM)	23	57,5	21	91,3	1,59	7,27
	Europe (EU)	18	52,9	14	77,8	14,29	21,54
	Asia (AS)	25	35,2	25	100,0	21,33	28,67
Cycle 14 Day 1	America (AM)	22	55,0	20	90,9	6,67	17,44
	Europe (EU)	17	50,0	16	94,1	10,42	20,07
	Asia (AS)	21	29,6	20	95,2	18,33	25,31
Cycle 15 Day 1	America (AM)	22	55,0	19	86,4	1,75	7,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	44,1	14	93,3	7,14	14,19
	Asia (AS)	20	28,2	20	100,0	16,67	22,94
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	1,96	8,08
	Europe (EU)	14	41,2	11	78,6	12,12	16,82
	Asia (AS)	19	26,8	19	100,0	15,79	20,39
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	6,25	18,13
	Europe (EU)	13	38,2	12	92,3	5,56	12,97
	Asia (AS)	16	22,5	16	100,0	18,75	20,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	4,76	12,10
	Europe (EU)	11	32,4	7	63,6	4,76	12,60
	Asia (AS)	16	22,5	16	100,0	16,67	17,21
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	5,13	12,52
	Europe (EU)	9	26,5	9	100,0	11,11	16,67
	Asia (AS)	14	19,7	11	78,6	18,18	27,34
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	2,56	9,25
	Europe (EU)	9	26,5	6	66,7	5,56	13,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	23,08	21,01
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	3,33	10,54
	Europe (EU)	7	20,6	6	85,7	5,56	13,61
	Asia (AS)	11	15,5	10	90,9	16,67	23,57
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	6,67	14,05
	Europe (EU)	7	20,6	5	71,4	6,67	14,91
	Asia (AS)	11	15,5	10	90,9	13,33	17,21
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	14,81	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	14,7	3	60,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	11,11	17,21
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	12,50	17,25
	Europe (EU)	5	14,7	4	80,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	16,67	18,26
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	4,76	12,60
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	11,11	17,21
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	16,67	19,25
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	0,00	0,00
	Europe (EU)	3	8,8	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	33,33	27,22
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	8,33	16,67
	Europe (EU)	2	5,9	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	25,00	16,67
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	22,22	19,25
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	8,33	16,67
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	22,22	19,25
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	22,22	19,25
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57
	Europe (EU)	1	2,9	1	100,0	0,00	-
	Asia (AS)	3	4,2	2	66,7	16,67	23,57
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	0,00	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	7,84	14,57
	Europe (EU)	10	29,4	5	50,0	26,67	27,89
	Asia (AS)	34	47,9	22	64,7	13,64	19,68
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	59	96,7	16,38	25,05
	1	69	100,0	66	95,7	19,70	26,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	15	100,0	15	100,0	22,22	24,12
Cycle 2 Day 1	0	59	96,7	55	93,2	5,45	12,45
	1	67	97,1	59	88,1	11,30	18,16
	2	10	66,7	10	100,0	10,00	16,10
Cycle 3 Day 1	0	57	93,4	50	87,7	9,33	20,25
	1	65	94,2	57	87,7	5,85	14,26
	2	9	60,0	9	100,0	3,70	11,11
Cycle 4 Day 1	0	57	93,4	51	89,5	8,50	17,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	57	91,9	8,77	14,81
	2	9	60,0	8	88,9	16,67	35,63
Cycle 5 Day 1	0	56	91,8	52	92,9	12,18	20,90
	1	62	89,9	57	91,9	6,43	14,69
	2	6	40,0	6	100,0	5,56	13,61
Cycle 6 Day 1	0	56	91,8	53	94,6	13,21	23,88
	1	59	85,5	51	86,4	7,19	13,85
	2	6	40,0	4	66,7	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	54	88,5	51	94,4	8,50	16,12
	1	54	78,3	47	87,0	5,67	12,66
	2	5	33,3	5	100,0	0,00	0,00
Cycle 8 Day 1	0	52	85,2	48	92,3	9,72	19,40
	1	49	71,0	43	87,8	7,75	14,25
	2	5	33,3	5	100,0	0,00	0,00
Cycle 9 Day 1	0	50	82,0	49	98,0	8,84	16,35
	1	44	63,8	42	95,5	7,14	13,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	4	26,7	4	100,0	0,00	0,00
Cycle 10 Day 1	0	46	75,4	46	100,0	7,25	15,58
	1	40	58,0	37	92,5	9,01	15,01
	2	3	20,0	3	100,0	0,00	0,00
Cycle 11 Day 1	0	43	70,5	40	93,0	12,50	24,68
	1	34	49,3	33	97,1	9,09	17,23
	2	3	20,0	3	100,0	0,00	0,00
Cycle 12 Day 1	0	42	68,9	36	85,7	12,04	18,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	31	44,9	29	93,5	10,34	15,69
	2	3	20,0	3	100,0	0,00	0,00
Cycle 13 Day 1	0	38	62,3	34	89,5	11,76	21,53
	1	27	39,1	25	92,6	14,67	25,60
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	8,33	18,93
	1	24	34,8	23	95,8	17,39	24,35
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	33	54,1	30	90,9	6,67	16,14
	1	23	33,3	22	95,7	12,12	19,37
	2	1	6,7	1	100,0	0,00	-
Cycle 16 Day 1	0	28	45,9	25	89,3	10,67	18,56
	1	21	30,4	21	100,0	9,52	15,43
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	10,14	18,63
	1	20	29,0	20	100,0	11,67	19,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	8,77	15,08
	1	17	24,6	17	100,0	11,76	16,42
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	12,28	19,91
	1	15	21,7	13	86,7	10,26	21,01
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	13,73	20,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	21,7	14	93,3	9,52	15,63
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	9,52	15,63
	1	13	18,8	11	84,6	9,09	21,56
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	8,33	15,08
	1	13	18,8	12	92,3	11,11	16,41
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	7,41	14,70
	1	9	13,0	8	88,9	16,67	17,82
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	3,70	11,11
	1	9	13,0	8	88,9	20,83	17,25
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	5,56	13,61
	1	7	10,1	7	100,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	13,1	6	75,0	5,56	13,61
	1	6	8,7	6	100,0	16,67	18,26
Cycle 27 Day 1	0	6	9,8	3	50,0	0,00	0,00
	1	5	7,2	5	100,0	26,67	27,89
Cycle 28 Day 1	0	5	8,2	4	80,0	0,00	0,00
	1	5	7,2	5	100,0	26,67	14,91
Cycle 29 Day 1	0	4	6,6	2	50,0	0,00	0,00
	1	5	7,2	5	100,0	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	25,00	16,67
Cycle 31 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	25,00	16,67
Cycle 32 Day 1	0	3	4,9	2	66,7	0,00	0,00
	1	3	4,3	3	100,0	22,22	19,25
Cycle 33 Day 1	0	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	9,52	18,69
	1	34	49,3	20	58,8	16,67	20,23
	2	7	46,7	3	42,9	11,11	19,25
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	59	95,2	19,21	26,41
	1	4	100,0	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	79	100,0	77	97,5	18,61	25,07
Cycle 2 Day 1	None	60	96,8	53	88,3	6,29	13,17
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	73	92,4	69	94,5	10,63	17,61
Cycle 3 Day 1	None	59	95,2	53	89,8	8,18	20,57
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	69	87,3	61	88,4	6,56	13,36
Cycle 4 Day 1	None	59	95,2	54	91,5	10,49	18,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	66	83,5	60	90,9	8,33	18,02
Cycle 5 Day 1	None	58	93,5	54	93,1	11,73	21,63
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	63	79,7	58	92,1	6,90	13,62
Cycle 6 Day 1	None	57	91,9	49	86,0	11,56	23,13
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	61	77,2	56	91,8	9,52	16,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	52	83,9	47	90,4	6,38	13,26
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	58	73,4	53	91,4	7,55	15,53
Cycle 8 Day 1	None	50	80,6	45	90,0	9,63	19,62
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	7,33	13,95
Cycle 9 Day 1	None	48	77,4	46	95,8	7,25	15,58
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	8,33	14,59
Cycle 10 Day 1	None	43	69,4	41	95,3	7,32	15,83
	1	1	25,0	1	100,0	0,00	-
	2 or More	45	57,0	44	97,8	8,33	14,60
Cycle 11 Day 1	None	37	59,7	33	89,2	11,11	24,53
	1	1	25,0	1	100,0	0,00	-
	2 or More	42	53,2	42	100,0	10,32	18,75
Cycle 12 Day 1	None	37	59,7	33	89,2	10,10	17,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	38	48,1	34	89,5	11,76	16,17
Cycle 13 Day 1	None	34	54,8	28	82,4	11,90	20,72
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	13,98	25,49
Cycle 14 Day 1	None	31	50,0	28	90,3	9,52	19,99
	1	1	25,0	1	100,0	0,00	-
	2 or More	28	35,4	27	96,4	14,81	23,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	30	48,4	27	90,0	6,17	16,11
	1	1	25,0	1	100,0	0,00	-
	2 or More	26	32,9	25	96,2	12,00	18,95
Cycle 16 Day 1	None	25	40,3	23	92,0	8,70	18,03
	1	1	25,0	1	100,0	0,00	-
	2 or More	24	30,4	23	95,8	11,59	16,23
Cycle 17 Day 1	None	23	37,1	22	95,7	7,58	17,61
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	21	26,6	21	100,0	14,29	19,92
Cycle 18 Day 1	None	20	32,3	18	90,0	9,26	15,36
	1	1	25,0	1	100,0	0,00	-
	2 or More	20	25,3	18	90,0	11,11	16,17
Cycle 19 Day 1	None	17	27,4	17	100,0	9,80	19,60
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	13,33	21,08
Cycle 20 Day 1	None	17	27,4	16	94,1	12,50	20,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	11,11	16,27
Cycle 21 Day 1	None	15	24,2	13	86,7	5,13	12,52
	2 or More	14	17,7	13	92,9	12,82	21,68
Cycle 22 Day 1	None	15	24,2	13	86,7	10,26	16,01
	2 or More	14	17,7	12	85,7	8,33	15,08
Cycle 23 Day 1	None	10	16,1	9	90,0	14,81	17,57
	2 or More	11	13,9	9	81,8	7,41	14,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	16,1	10	100,0	10,00	16,10
	2 or More	10	12,7	8	80,0	12,50	17,25
Cycle 25 Day 1	None	9	14,5	8	88,9	4,17	11,79
	2 or More	6	7,6	5	83,3	13,33	18,26
Cycle 26 Day 1	None	8	12,9	8	100,0	12,50	17,25
	2 or More	6	7,6	4	66,7	8,33	16,67
Cycle 27 Day 1	None	7	11,3	6	85,7	11,11	27,22
	2 or More	4	5,1	2	50,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	11,3	7	100,0	9,52	16,27
	2 or More	3	3,8	2	66,7	33,33	0,00
Cycle 29 Day 1	None	6	9,7	5	83,3	13,33	18,26
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 30 Day 1	None	4	6,5	3	75,0	22,22	19,25
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 31 Day 1	None	4	6,5	3	75,0	11,11	19,25
	2 or More	3	3,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	11,11	19,25
	2 or More	2	2,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	1,6	1	100,0	0,00	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	17,54	20,39
	1	3	75,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	39	49,4	24	61,5	9,72	18,33
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	59	95,2	19,21	26,41
	Previously Treated	83	100,0	81	97,6	18,11	24,75
Cycle 2 Day 1	Naïve	60	96,8	53	88,3	6,29	13,17
	Previously Treated	76	91,6	71	93,4	10,33	17,45
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	8,18	20,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	72	86,7	63	87,5	6,35	13,19
Cycle 4 Day 1	Naïve	59	95,2	54	91,5	10,49	18,11
	Previously Treated	69	83,1	62	89,9	8,06	17,79
Cycle 5 Day 1	Naïve	58	93,5	54	93,1	11,73	21,63
	Previously Treated	66	79,5	61	92,4	6,56	13,36
Cycle 6 Day 1	Naïve	57	91,9	49	86,0	11,56	23,13
	Previously Treated	64	77,1	59	92,2	9,04	16,18
Cycle 7 Day 1	Naïve	52	83,9	47	90,4	6,38	13,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	61	73,5	56	91,8	7,14	15,19
Cycle 8 Day 1	Naïve	50	80,6	45	90,0	9,63	19,62
	Previously Treated	56	67,5	51	91,1	7,19	13,85
Cycle 9 Day 1	Naïve	48	77,4	46	95,8	7,25	15,58
	Previously Treated	50	60,2	49	98,0	8,16	14,48
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	7,32	15,83
	Previously Treated	46	55,4	45	97,8	8,15	14,49
Cycle 11 Day 1	Naïve	37	59,7	33	89,2	11,11	24,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	43	51,8	43	100,0	10,08	18,59
Cycle 12 Day 1	Naïve	37	59,7	33	89,2	10,10	17,65
	Previously Treated	39	47,0	35	89,7	11,43	16,05
Cycle 13 Day 1	Naïve	34	54,8	28	82,4	11,90	20,72
	Previously Treated	32	38,6	32	100,0	13,54	25,20
Cycle 14 Day 1	Naïve	31	50,0	28	90,3	9,52	19,99
	Previously Treated	29	34,9	28	96,6	14,29	23,00
Cycle 15 Day 1	Naïve	30	48,4	27	90,0	6,17	16,11

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	27	32,5	26	96,3	11,54	18,72
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	8,70	18,03
	Previously Treated	25	30,1	24	96,0	11,11	16,05
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	7,58	17,61
	Previously Treated	22	26,5	22	100,0	13,64	19,68
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	9,26	15,36
	Previously Treated	21	25,3	19	90,5	10,53	15,92
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	9,80	19,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	22,9	16	84,2	12,50	20,64
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	12,50	20,64
	Previously Treated	19	22,9	16	84,2	10,42	15,96
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	5,13	12,52
	Previously Treated	14	16,9	13	92,9	12,82	21,68
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	10,26	16,01
	Previously Treated	14	16,9	12	85,7	8,33	15,08
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	14,81	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	7,41	14,70
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	10,00	16,10
	Previously Treated	10	12,0	8	80,0	12,50	17,25
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	4,17	11,79
	Previously Treated	6	7,2	5	83,3	13,33	18,26
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	12,50	17,25
	Previously Treated	6	7,2	4	66,7	8,33	16,67
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	11,11	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	4,8	2	50,0	33,33	0,00
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	9,52	16,27
	Previously Treated	3	3,6	2	66,7	33,33	0,00
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	13,33	18,26
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	22,22	19,25
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	11,11	19,25
	Previously Treated	2	2,4	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	0,00	-
	Previously Treated	1	1,2	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	17,54	20,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	50,6	25	59,5	9,33	18,05
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	18,22	25,29
	Central	70	100,0	65	92,9	18,97	25,66
Cycle 2 Day 1	Local	71	94,7	67	94,4	4,98	11,97
	Central	65	92,9	57	87,7	12,87	18,64
Cycle 3 Day 1	Local	67	89,3	60	89,6	4,44	15,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	64	91,4	56	87,5	10,12	17,89
Cycle 4 Day 1	Local	65	86,7	58	89,2	6,90	14,98
	Central	63	90,0	58	92,1	11,49	20,28
Cycle 5 Day 1	Local	63	84,0	58	92,1	8,05	15,68
	Central	61	87,1	57	93,4	9,94	19,89
Cycle 6 Day 1	Local	63	84,0	61	96,8	10,93	21,71
	Central	58	82,9	47	81,0	9,22	16,60
Cycle 7 Day 1	Local	61	81,3	58	95,1	6,90	14,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	52	74,3	45	86,5	6,67	13,48
Cycle 8 Day 1	Local	57	76,0	54	94,7	6,17	13,07
	Central	49	70,0	42	85,7	11,11	20,38
Cycle 9 Day 1	Local	54	72,0	53	98,1	6,29	13,17
	Central	44	62,9	42	95,5	9,52	16,93
Cycle 10 Day 1	Local	48	64,0	46	95,8	7,97	14,38
	Central	41	58,6	40	97,6	7,50	15,99
Cycle 11 Day 1	Local	40	53,3	38	95,0	7,89	21,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	40	57,1	38	95,0	13,16	21,28
Cycle 12 Day 1	Local	36	48,0	33	91,7	7,07	13,84
	Central	40	57,1	35	87,5	14,29	18,59
Cycle 13 Day 1	Local	30	40,0	29	96,7	9,20	19,71
	Central	36	51,4	31	86,1	16,13	25,63
Cycle 14 Day 1	Local	27	36,0	27	100,0	8,64	19,81
	Central	33	47,1	29	87,9	14,94	22,86
Cycle 15 Day 1	Local	26	34,7	25	96,2	5,33	12,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	28	90,3	11,90	20,72
Cycle 16 Day 1	Local	24	32,0	24	100,0	6,94	13,83
	Central	26	37,1	23	88,5	13,04	19,43
Cycle 17 Day 1	Local	22	29,3	22	100,0	10,61	18,93
	Central	23	32,9	22	95,7	10,61	18,93
Cycle 18 Day 1	Local	20	26,7	19	95,0	8,77	15,08
	Central	21	30,0	18	85,7	11,11	16,17
Cycle 19 Day 1	Local	19	25,3	17	89,5	11,76	20,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	24,3	16	94,1	10,42	20,07
Cycle 20 Day 1	Local	19	25,3	17	89,5	5,88	13,10
	Central	17	24,3	15	88,2	17,78	21,33
Cycle 21 Day 1	Local	14	18,7	12	85,7	8,33	20,72
	Central	15	21,4	14	93,3	9,52	15,63
Cycle 22 Day 1	Local	14	18,7	12	85,7	8,33	15,08
	Central	15	21,4	13	86,7	10,26	16,01
Cycle 23 Day 1	Local	11	14,7	10	90,9	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	14,3	8	80,0	8,33	15,43
Cycle 24 Day 1	Local	11	14,7	10	90,9	10,00	16,10
	Central	9	12,9	8	88,9	12,50	17,25
Cycle 25 Day 1	Local	7	9,3	7	100,0	4,76	12,60
	Central	8	11,4	6	75,0	11,11	17,21
Cycle 26 Day 1	Local	6	8,0	6	100,0	16,67	18,26
	Central	8	11,4	6	75,0	5,56	13,61
Cycle 27 Day 1	Local	4	5,3	4	100,0	16,67	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	10,0	4	57,1	16,67	19,25
Cycle 28 Day 1	Local	4	5,3	4	100,0	16,67	19,25
	Central	6	8,6	5	83,3	13,33	18,26
Cycle 29 Day 1	Local	3	4,0	3	100,0	11,11	19,25
	Central	6	8,6	4	66,7	16,67	19,25
Cycle 30 Day 1	Local	3	4,0	3	100,0	22,22	19,25
	Central	4	5,7	2	50,0	16,67	23,57
Cycle 31 Day 1	Local	3	4,0	3	100,0	11,11	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	5,7	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	4,0	3	100,0	11,11	19,25
	Central	3	4,3	2	66,7	16,67	23,57
Cycle 33 Day 1	Local	1	1,3	1	100,0	0,00	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	9,72	18,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	32	45,7	20	62,5	16,67	20,23
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	130	96,3	18,72	25,59
	No	10	100,0	10	100,0	16,67	23,57
Cycle 2 Day 1	Yes	129	95,6	117	90,7	8,55	15,87
	No	7	70,0	7	100,0	9,52	16,27
Cycle 3 Day 1	Yes	124	91,9	110	88,7	7,27	17,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	6	85,7	5,56	13,61
Cycle 4 Day 1	Yes	121	89,6	109	90,1	9,17	18,07
	No	7	70,0	7	100,0	9,52	16,27
Cycle 5 Day 1	Yes	117	86,7	109	93,2	9,48	18,20
	No	7	70,0	6	85,7	0,00	0,00
Cycle 6 Day 1	Yes	114	84,4	101	88,6	10,56	19,96
	No	7	70,0	7	100,0	4,76	12,60
Cycle 7 Day 1	Yes	106	78,5	96	90,6	6,60	14,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	9,52	16,27
Cycle 8 Day 1	Yes	100	74,1	90	90,0	8,89	17,16
	No	6	60,0	6	100,0	0,00	0,00
Cycle 9 Day 1	Yes	92	68,1	89	96,7	7,87	15,09
	No	6	60,0	6	100,0	5,56	13,61
Cycle 10 Day 1	Yes	83	61,5	80	96,4	8,33	15,46
	No	6	60,0	6	100,0	0,00	0,00
Cycle 11 Day 1	Yes	76	56,3	72	94,7	10,65	21,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	4	40,0	4	100,0	8,33	16,67
Cycle 12 Day 1	Yes	72	53,3	64	88,9	10,94	16,86
	No	4	40,0	4	100,0	8,33	16,67
Cycle 13 Day 1	Yes	64	47,4	58	90,6	12,64	23,22
	No	2	20,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	58	43,0	54	93,1	11,73	21,63
	No	2	20,0	2	100,0	16,67	23,57
Cycle 15 Day 1	Yes	55	40,7	51	92,7	8,50	17,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	16,67	23,57
Cycle 16 Day 1	Yes	48	35,6	45	93,8	10,37	17,15
	No	2	20,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	43	31,9	42	97,7	10,32	18,75
	No	2	20,0	2	100,0	16,67	23,57
Cycle 18 Day 1	Yes	39	28,9	35	89,7	9,52	15,28
	No	2	20,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	11,46	20,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	11,11	18,22
	No	2	20,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	20,0	24	88,9	8,33	17,72
	No	2	20,0	2	100,0	16,67	23,57
Cycle 22 Day 1	Yes	27	20,0	23	85,2	10,14	15,68
	No	2	20,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	11,76	16,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	11,76	16,42
	No	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	10,4	12	85,7	8,33	15,08
	No	1	10,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	9,09	15,57
	No	1	10,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	9,52	16,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	66,67	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	12,50	17,25
	No	1	10,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	16,67	18,26
	No	1	10,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	16,67	19,25
	No	1	10,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 32 Day 1	Yes	5	3,7	4	80,0	16,67	19,25
	No	1	10,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	13,18	19,44
	No	2	20,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	18,18	31,14
	No	134	100,0	129	96,3	18,60	24,97
Cycle 2 Day 1	Yes	7	63,6	7	100,0	14,29	17,82
	No	129	96,3	117	90,7	8,26	15,72
Cycle 3 Day 1	Yes	7	63,6	6	85,7	0,00	0,00
	No	124	92,5	110	88,7	7,58	17,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	7	63,6	7	100,0	4,76	12,60
	No	121	90,3	109	90,1	9,48	18,20
Cycle 5 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	117	87,3	108	92,3	9,57	18,26
Cycle 6 Day 1	Yes	7	63,6	7	100,0	4,76	12,60
	No	114	85,1	101	88,6	10,56	19,96
Cycle 7 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	106	79,1	96	90,6	7,29	14,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	99	73,9	89	89,9	8,99	17,24
Cycle 9 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	92	68,7	89	96,7	8,24	15,31
Cycle 10 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	83	61,9	80	96,4	8,33	15,46
Cycle 11 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	74	55,2	70	94,6	11,43	21,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	70	52,2	62	88,6	11,83	17,17
Cycle 13 Day 1	Yes	5	45,5	5	100,0	6,67	14,91
	No	61	45,5	55	90,2	13,33	23,66
Cycle 14 Day 1	Yes	5	45,5	5	100,0	13,33	29,81
	No	55	41,0	51	92,7	11,76	20,90
Cycle 15 Day 1	Yes	4	36,4	4	100,0	8,33	16,67
	No	53	39,6	49	92,5	8,84	17,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	47	35,1	44	93,6	10,61	17,27
Cycle 17 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	42	31,3	41	97,6	11,38	19,16
Cycle 18 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	38	28,4	34	89,5	10,78	15,83
Cycle 19 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	33	24,6	30	90,9	11,11	20,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	33	24,6	29	87,9	11,49	18,42
Cycle 21 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	24	88,9	9,72	18,33
Cycle 22 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	23	85,2	10,14	15,68
Cycle 23 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	19	14,2	16	84,2	12,50	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	18	13,4	16	88,9	12,50	16,67
Cycle 25 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	13	9,7	11	84,6	9,09	15,57
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	12,12	16,82
Cycle 27 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	10	7,5	7	70,0	19,05	26,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	9	6,7	8	88,9	16,67	17,82
Cycle 29 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	8	6,0	6	75,0	16,67	18,26
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	20,00	18,26
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	20,00	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	13,33	18,26
Cycle 33 Day 1	No	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	11,11	19,25
	No	61	45,5	41	67,2	13,01	19,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PA_SG.xls
24JUN2020 21:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	140	96,6	18,57	23,06
Cycle 2 Day 1	All	136	93,8	124	91,2	8,60	16,93
Cycle 3 Day 1	All	131	90,3	116	88,5	5,75	13,39
Cycle 4 Day 1	All	128	88,3	116	90,6	6,61	15,98
Cycle 5 Day 1	All	124	85,5	115	92,7	6,96	14,30
Cycle 6 Day 1	All	121	83,4	108	89,3	6,48	14,02
Cycle 7 Day 1	All	113	77,9	103	91,2	8,09	17,13

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	106	73,1	96	90,6	7,29	13,85
Cycle 9 Day 1	All	98	67,6	95	96,9	5,61	14,30
Cycle 10 Day 1	All	89	61,4	86	96,6	6,59	15,18
Cycle 11 Day 1	All	80	55,2	76	95,0	7,46	15,00
Cycle 12 Day 1	All	76	52,4	68	89,5	4,90	11,89
Cycle 13 Day 1	All	66	45,5	60	90,9	6,67	14,78
Cycle 14 Day 1	All	60	41,4	56	93,3	5,36	13,89
Cycle 15 Day 1	All	57	39,3	53	93,0	5,66	12,64

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	50	34,5	47	94,0	10,64	18,53
Cycle 17 Day 1	All	45	31,0	44	97,8	7,58	15,85
Cycle 18 Day 1	All	41	28,3	37	90,2	7,21	13,91
Cycle 19 Day 1	All	36	24,8	33	91,7	5,05	14,72
Cycle 20 Day 1	All	36	24,8	32	88,9	11,46	21,77
Cycle 21 Day 1	All	29	20,0	26	89,7	6,41	13,40
Cycle 22 Day 1	All	29	20,0	25	86,2	5,33	12,47
Cycle 23 Day 1	All	21	14,5	18	85,7	3,70	10,78

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	13,8	18	90,0	7,41	18,28
Cycle 25 Day 1	All	15	10,3	13	86,7	5,13	12,52
Cycle 26 Day 1	All	14	9,7	12	85,7	5,56	12,97
Cycle 27 Day 1	All	11	7,6	8	72,7	12,50	17,25
Cycle 28 Day 1	All	10	6,9	9	90,0	14,81	24,22
Cycle 29 Day 1	All	9	6,2	7	77,8	4,76	12,60
Cycle 30 Day 1	All	7	4,8	5	71,4	13,33	18,26
Cycle 31 Day 1	All	7	4,8	5	71,4	26,67	27,89

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	4,1	5	83,3	13,33	18,26
Cycle 33 Day 1	All	2	1,4	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	15,15	16,79
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	18,30	25,22

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	93	100,0	89	95,7	18,73	21,88
Cycle 2 Day 1	Male	50	96,2	46	92,0	10,87	21,15
	Female	86	92,5	78	90,7	7,26	13,85
Cycle 3 Day 1	Male	47	90,4	43	91,5	5,43	12,45
	Female	84	90,3	73	86,9	5,94	13,99
Cycle 4 Day 1	Male	46	88,5	43	93,5	10,08	21,25
	Female	82	88,2	73	89,0	4,57	11,54
Cycle 5 Day 1	Male	45	86,5	42	93,3	7,94	14,37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	79	84,9	73	92,4	6,39	14,33
Cycle 6 Day 1	Male	45	86,5	41	91,1	8,13	14,49
	Female	76	81,7	67	88,2	5,47	13,73
Cycle 7 Day 1	Male	40	76,9	39	97,5	6,84	17,40
	Female	73	78,5	64	87,7	8,85	17,05
Cycle 8 Day 1	Male	37	71,2	34	91,9	6,86	13,68
	Female	69	74,2	62	89,9	7,53	14,05
Cycle 9 Day 1	Male	33	63,5	33	100,0	4,04	11,05

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	62	95,4	6,45	15,78
Cycle 10 Day 1	Male	30	57,7	30	100,0	3,33	10,17
	Female	59	63,4	56	94,9	8,33	17,12
Cycle 11 Day 1	Male	29	55,8	28	96,6	4,76	11,88
	Female	51	54,8	48	94,1	9,03	16,47
Cycle 12 Day 1	Male	27	51,9	26	96,3	2,56	9,06
	Female	49	52,7	42	85,7	6,35	13,25
Cycle 13 Day 1	Male	25	48,1	23	92,0	5,80	12,92

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	41	44,1	37	90,2	7,21	15,98
Cycle 14 Day 1	Male	23	44,2	21	91,3	3,17	10,03
	Female	37	39,8	35	94,6	6,67	15,76
Cycle 15 Day 1	Male	21	40,4	20	95,2	3,33	10,26
	Female	36	38,7	33	91,7	7,07	13,84
Cycle 16 Day 1	Male	16	30,8	16	100,0	2,08	8,33
	Female	34	36,6	31	91,2	15,05	20,80
Cycle 17 Day 1	Male	13	25,0	13	100,0	5,13	12,52

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	32	34,4	31	96,9	8,60	17,14
Cycle 18 Day 1	Male	12	23,1	11	91,7	3,03	10,05
	Female	29	31,2	26	89,7	8,97	15,08
Cycle 19 Day 1	Male	10	19,2	10	100,0	3,33	10,54
	Female	26	28,0	23	88,5	5,80	16,37
Cycle 20 Day 1	Male	10	19,2	9	90,0	0,00	0,00
	Female	26	28,0	23	88,5	15,94	24,35
Cycle 21 Day 1	Male	8	15,4	8	100,0	8,33	15,43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	22,6	18	85,7	5,56	12,78
Cycle 22 Day 1	Male	8	15,4	6	75,0	0,00	0,00
	Female	21	22,6	19	90,5	7,02	13,96
Cycle 23 Day 1	Male	5	9,6	4	80,0	0,00	0,00
	Female	16	17,2	14	87,5	4,76	12,10
Cycle 24 Day 1	Male	5	9,6	4	80,0	0,00	0,00
	Female	15	16,1	14	93,3	9,52	20,37
Cycle 25 Day 1	Male	3	5,8	2	66,7	0,00	0,00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	12,9	11	91,7	6,06	13,48
Cycle 26 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	11	11,8	10	90,9	6,67	14,05
Cycle 27 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	8	8,6	6	75,0	16,67	18,26
Cycle 28 Day 1	Male	2	3,8	2	100,0	0,00	0,00
	Female	8	8,6	7	87,5	19,05	26,23
Cycle 29 Day 1	Male	1	1,9	1	100,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	8,6	6	75,0	5,56	13,61
Cycle 30 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	16,67	19,25
Cycle 31 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	33,33	27,22
Cycle 32 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	5	5,4	4	80,0	16,67	19,25
Cycle 33 Day 1	Male	1	1,9	1	100,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	1,1	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	17,46	17,06
	Female	37	39,8	23	62,2	13,04	16,63
Age							
Cycle 1 Day 1	18-64	109	100,0	104	95,4	20,19	24,32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	13,79	18,93
	>=75	7	100,0	7	100,0	14,29	17,82
Cycle 2 Day 1	18-64	103	94,5	91	88,3	9,16	17,26
	65-74	26	89,7	26	100,0	8,97	17,78
	>=75	7	100,0	7	100,0	0,00	0,00
Cycle 3 Day 1	18-64	99	90,8	87	87,9	7,28	14,75
	65-74	25	86,2	23	92,0	1,45	6,95
	>=75	7	100,0	6	85,7	0,00	0,00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	98	89,9	88	89,8	7,95	17,50
	65-74	23	79,3	21	91,3	3,17	10,03
	>=75	7	100,0	7	100,0	0,00	0,00
Cycle 5 Day 1	18-64	95	87,2	88	92,6	7,58	14,93
	65-74	22	75,9	22	100,0	6,06	13,16
	>=75	7	100,0	5	71,4	0,00	0,00
Cycle 6 Day 1	18-64	92	84,4	80	87,0	6,25	13,09
	65-74	22	75,9	21	95,5	9,52	18,69

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	0,00	0,00
Cycle 7 Day 1	18-64	86	78,9	78	90,7	8,12	17,15
	65-74	20	69,0	19	95,0	10,53	19,41
	>=75	7	100,0	6	85,7	0,00	0,00
Cycle 8 Day 1	18-64	80	73,4	71	88,8	7,51	14,03
	65-74	19	65,5	19	100,0	8,77	15,08
	>=75	7	100,0	6	85,7	0,00	0,00
Cycle 9 Day 1	18-64	74	67,9	72	97,3	4,63	12,89

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	18	62,1	18	100,0	11,11	19,80
	>=75	6	85,7	5	83,3	0,00	0,00
Cycle 10 Day 1	18-64	69	63,3	66	95,7	7,07	14,92
	65-74	15	51,7	15	100,0	6,67	18,69
	>=75	5	71,4	5	100,0	0,00	0,00
Cycle 11 Day 1	18-64	61	56,0	58	95,1	6,90	14,98
	65-74	15	51,7	14	93,3	9,52	15,63
	>=75	4	57,1	4	100,0	8,33	16,67

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	57	52,3	50	87,7	4,67	11,68
	65-74	15	51,7	14	93,3	7,14	14,19
	>=75	4	57,1	4	100,0	0,00	0,00
Cycle 13 Day 1	18-64	49	45,0	45	91,8	3,70	10,59
	65-74	13	44,8	11	84,6	21,21	22,47
	>=75	4	57,1	4	100,0	0,00	0,00
Cycle 14 Day 1	18-64	45	41,3	43	95,6	3,88	10,81
	65-74	13	44,8	11	84,6	12,12	22,47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 15 Day 1	18-64	43	39,4	40	93,0	5,00	12,05
	65-74	12	41,4	11	91,7	9,09	15,57
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 16 Day 1	18-64	38	34,9	36	94,7	12,04	19,76
	65-74	10	34,5	9	90,0	7,41	14,70
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 17 Day 1	18-64	36	33,0	35	97,2	7,62	16,34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	27,6	8	100,0	8,33	15,43
	>=75	1	14,3	1	100,0	0,00	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	7,78	14,34
	65-74	7	24,1	6	85,7	5,56	13,61
	>=75	1	14,3	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	4,76	14,95
	65-74	5	17,2	4	80,0	8,33	16,67
	>=75	1	14,3	1	100,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	11,54	22,98
	65-74	5	17,2	5	100,0	13,33	18,26
	>=75	1	14,3	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	6,35	13,41
	65-74	4	13,8	4	100,0	8,33	16,67
	>=75	1	14,3	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	6,67	13,68
	65-74	4	13,8	4	100,0	0,00	0,00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	4,17	11,39
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	8,33	19,25
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	12,8	12	85,7	5,56	12,97
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	5,56	12,97

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	12,50	17,25
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	14,81	24,22
	65-74	1	3,4	0	0,0	-	-
Cycle 29 Day 1	18-64	8	7,3	7	87,5	4,76	12,60
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	13,33	18,26

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	26,67	27,89
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	16,67	19,25
	65-74	1	3,4	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	0,00	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	15,69	16,89
	65-74	15	51,7	8	53,3	12,50	17,25
	>=75	4	57,1	2	50,0	16,67	23,57
Race							
Cycle 1 Day 1	White	60	100,0	57	95,0	17,54	23,66
	Other	85	100,0	83	97,6	19,28	22,76

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	57	95,0	50	87,7	10,67	19,56
	Other	79	92,9	74	93,7	7,21	14,88
Cycle 3 Day 1	White	54	90,0	44	81,5	4,55	13,62
	Other	77	90,6	72	93,5	6,48	13,28
Cycle 4 Day 1	White	53	88,3	45	84,9	3,70	10,59
	Other	75	88,2	71	94,7	8,45	18,45
Cycle 5 Day 1	White	52	86,7	47	90,4	5,67	12,66
	Other	72	84,7	68	94,4	7,84	15,36

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	50	83,3	41	82,0	6,50	15,31
	Other	71	83,5	67	94,4	6,47	13,28
Cycle 7 Day 1	White	47	78,3	40	85,1	7,50	17,68
	Other	66	77,6	63	95,5	8,47	16,90
Cycle 8 Day 1	White	45	75,0	38	84,4	6,14	13,10
	Other	61	71,8	58	95,1	8,05	14,39
Cycle 9 Day 1	White	42	70,0	41	97,6	7,32	17,50
	Other	56	65,9	54	96,4	4,32	11,30

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	8,55	16,61
	Other	48	56,5	47	97,9	4,96	13,86
Cycle 11 Day 1	White	37	61,7	36	97,3	7,41	14,05
	Other	43	50,6	40	93,0	7,50	15,99
Cycle 12 Day 1	White	37	61,7	33	89,2	5,05	12,14
	Other	39	45,9	35	89,7	4,76	11,83
Cycle 13 Day 1	White	32	53,3	30	93,8	5,56	15,37
	Other	34	40,0	30	88,2	7,78	14,34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	31	51,7	30	96,8	5,56	15,37
	Other	29	34,1	26	89,7	5,13	12,26
Cycle 15 Day 1	White	30	50,0	28	93,3	7,14	13,93
	Other	27	31,8	25	92,6	4,00	11,06
Cycle 16 Day 1	White	26	43,3	24	92,3	9,72	18,33
	Other	24	28,2	23	95,8	11,59	19,09
Cycle 17 Day 1	White	24	40,0	24	100,0	6,94	16,97
	Other	21	24,7	20	95,2	8,33	14,81

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	22	36,7	19	86,4	1,75	7,65
	Other	19	22,4	18	94,7	12,96	16,72
Cycle 19 Day 1	White	20	33,3	20	100,0	5,00	12,21
	Other	16	18,8	13	81,3	5,13	18,49
Cycle 20 Day 1	White	20	33,3	17	85,0	3,92	11,07
	Other	16	18,8	15	93,8	20,00	27,60
Cycle 21 Day 1	White	16	26,7	14	87,5	2,38	8,91
	Other	13	15,3	12	92,3	11,11	16,41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	26,7	13	81,3	5,13	12,52
	Other	13	15,3	12	92,3	5,56	12,97
Cycle 23 Day 1	White	12	20,0	10	83,3	3,33	10,54
	Other	9	10,6	8	88,9	4,17	11,79
Cycle 24 Day 1	White	11	18,3	10	90,9	6,67	14,05
	Other	9	10,6	8	88,9	8,33	23,57
Cycle 25 Day 1	White	10	16,7	8	80,0	4,17	11,79
	Other	5	5,9	5	100,0	6,67	14,91

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	16,7	8	80,0	4,17	11,79
	Other	4	4,7	4	100,0	8,33	16,67
Cycle 27 Day 1	White	8	13,3	5	62,5	6,67	14,91
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 28 Day 1	White	7	11,7	6	85,7	11,11	27,22
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 29 Day 1	White	6	10,0	4	66,7	0,00	0,00
	Other	3	3,5	3	100,0	11,11	19,25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	6,7	2	50,0	0,00	0,00
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 31 Day 1	White	4	6,7	2	50,0	16,67	23,57
	Other	3	3,5	3	100,0	33,33	33,33
Cycle 32 Day 1	White	4	6,7	3	75,0	11,11	19,25
	Other	2	2,4	2	100,0	16,67	23,57
Cycle 33 Day 1	White	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-
End Of Treatment	White	25	41,7	17	68,0	19,61	16,91
	Other	39	45,9	27	69,2	12,35	16,40
Region							
Cycle 1 Day 1	America (AM)	40	100,0	38	95,0	19,30	25,27
	Europe (EU)	34	100,0	31	91,2	13,98	20,68
	Asia (AS)	71	100,0	71	100,0	20,19	22,87

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	10,42	17,84
	Europe (EU)	32	94,1	27	84,4	7,41	16,88
	Asia (AS)	66	93,0	65	98,5	8,21	16,70
Cycle 3 Day 1	America (AM)	37	92,5	32	86,5	6,25	15,70
	Europe (EU)	31	91,2	21	67,7	1,59	7,27
	Asia (AS)	63	88,7	63	100,0	6,88	13,60
Cycle 4 Day 1	America (AM)	37	92,5	32	86,5	7,29	16,36
	Europe (EU)	30	88,2	24	80,0	2,78	9,41

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	61	85,9	60	98,4	7,78	17,75
Cycle 5 Day 1	America (AM)	37	92,5	33	89,2	5,05	12,14
	Europe (EU)	30	88,2	25	83,3	4,00	11,06
	Asia (AS)	57	80,3	57	100,0	9,36	16,37
Cycle 6 Day 1	America (AM)	37	92,5	32	86,5	4,17	11,20
	Europe (EU)	28	82,4	24	85,7	6,94	16,97
	Asia (AS)	56	78,9	52	92,9	7,69	14,18
Cycle 7 Day 1	America (AM)	35	87,5	29	82,9	4,60	14,70

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	28	82,4	25	89,3	6,67	16,67
	Asia (AS)	50	70,4	49	98,0	10,88	18,49
Cycle 8 Day 1	America (AM)	31	77,5	26	83,9	2,56	9,06
	Europe (EU)	28	82,4	23	82,1	7,25	14,06
	Asia (AS)	47	66,2	47	100,0	9,93	15,41
Cycle 9 Day 1	America (AM)	29	72,5	27	93,1	4,94	15,20
	Europe (EU)	26	76,5	25	96,2	5,33	15,75
	Asia (AS)	43	60,6	43	100,0	6,20	13,12

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	2,78	9,41
	Europe (EU)	25	73,5	25	100,0	12,00	18,95
	Asia (AS)	37	52,1	37	100,0	5,41	14,73
Cycle 11 Day 1	America (AM)	24	60,0	21	87,5	3,17	10,03
	Europe (EU)	23	67,6	22	95,7	6,06	13,16
	Asia (AS)	33	46,5	33	100,0	11,11	18,00
Cycle 12 Day 1	America (AM)	24	60,0	22	91,7	1,52	7,11
	Europe (EU)	23	67,6	18	78,3	5,56	12,78

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	40,8	28	96,6	7,14	13,93
Cycle 13 Day 1	America (AM)	23	57,5	21	91,3	6,35	13,41
	Europe (EU)	18	52,9	14	77,8	4,76	17,82
	Asia (AS)	25	35,2	25	100,0	8,00	14,53
Cycle 14 Day 1	America (AM)	22	55,0	20	90,9	1,67	7,45
	Europe (EU)	17	50,0	16	94,1	6,25	18,13
	Asia (AS)	21	29,6	20	95,2	8,33	14,81
Cycle 15 Day 1	America (AM)	22	55,0	19	86,4	5,26	12,49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	44,1	14	93,3	4,76	12,10
	Asia (AS)	20	28,2	20	100,0	6,67	13,68
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	9,80	19,60
	Europe (EU)	14	41,2	11	78,6	9,09	15,57
	Asia (AS)	19	26,8	19	100,0	12,28	19,91
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	4,17	16,67
	Europe (EU)	13	38,2	12	92,3	8,33	15,08
	Asia (AS)	16	22,5	16	100,0	10,42	15,96

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	2,38	8,91
	Europe (EU)	11	32,4	7	63,6	4,76	12,60
	Asia (AS)	16	22,5	16	100,0	12,50	16,67
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	0,00	0,00
	Europe (EU)	9	26,5	9	100,0	11,11	16,67
	Asia (AS)	14	19,7	11	78,6	6,06	20,10
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	12,82	28,99
	Europe (EU)	9	26,5	6	66,7	5,56	13,61

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	12,82	16,88
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	0,00	0,00
	Europe (EU)	7	20,6	6	85,7	5,56	13,61
	Asia (AS)	11	15,5	10	90,9	13,33	17,21
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	3,33	10,54
	Europe (EU)	7	20,6	5	71,4	0,00	0,00
	Asia (AS)	11	15,5	10	90,9	10,00	16,10
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	3,70	11,11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	14,7	3	60,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	5,56	13,61
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	8,33	15,43
	Europe (EU)	5	14,7	4	80,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	11,11	27,22
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	4,76	12,60
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	8,33	16,67

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	5,56	13,61
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	8,33	16,67
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	8,33	16,67
	Europe (EU)	3	8,8	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	16,67	19,25
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	16,67	33,33
	Europe (EU)	2	5,9	1	50,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	16,67	19,25
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	0,00	0,00
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	8,33	16,67
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	22,22	19,25
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	33,33	33,33
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57
	Europe (EU)	1	2,9	1	100,0	0,00	-
	Asia (AS)	3	4,2	2	66,7	16,67	23,57
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	0,00	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	13,73	16,91
	Europe (EU)	10	29,4	5	50,0	26,67	14,91
	Asia (AS)	34	47,9	22	64,7	13,64	16,77
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	59	96,7	13,56	21,55
	1	69	100,0	66	95,7	22,73	23,50

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	15	100,0	15	100,0	20,00	24,56
Cycle 2 Day 1	0	59	96,7	55	93,2	9,70	17,77
	1	67	97,1	59	88,1	7,91	16,77
	2	10	66,7	10	100,0	6,67	14,05
Cycle 3 Day 1	0	57	93,4	50	87,7	6,00	14,58
	1	65	94,2	57	87,7	5,26	12,26
	2	9	60,0	9	100,0	7,41	14,70
Cycle 4 Day 1	0	57	93,4	51	89,5	3,92	10,85

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	57	91,9	9,36	19,67
	2	9	60,0	8	88,9	4,17	11,79
Cycle 5 Day 1	0	56	91,8	52	92,9	8,33	16,00
	1	62	89,9	57	91,9	6,43	13,27
	2	6	40,0	6	100,0	0,00	0,00
Cycle 6 Day 1	0	56	91,8	53	94,6	8,81	16,21
	1	59	85,5	51	86,4	4,58	11,58
	2	6	40,0	4	66,7	0,00	0,00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	54	88,5	51	94,4	10,46	19,43
	1	54	78,3	47	87,0	6,38	14,97
	2	5	33,3	5	100,0	0,00	0,00
Cycle 8 Day 1	0	52	85,2	48	92,3	8,33	14,59
	1	49	71,0	43	87,8	6,20	13,12
	2	5	33,3	5	100,0	6,67	14,91
Cycle 9 Day 1	0	50	82,0	49	98,0	7,48	17,03
	1	44	63,8	42	95,5	3,97	10,93

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	4	26,7	4	100,0	0,00	0,00
Cycle 10 Day 1	0	46	75,4	46	100,0	7,97	17,48
	1	40	58,0	37	92,5	4,50	11,55
	2	3	20,0	3	100,0	11,11	19,25
Cycle 11 Day 1	0	43	70,5	40	93,0	9,17	16,86
	1	34	49,3	33	97,1	6,06	13,06
	2	3	20,0	3	100,0	0,00	0,00
Cycle 12 Day 1	0	42	68,9	36	85,7	5,56	12,60

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	31	44,9	29	93,5	4,60	11,70
	2	3	20,0	3	100,0	0,00	0,00
Cycle 13 Day 1	0	38	62,3	34	89,5	8,82	17,03
	1	27	39,1	25	92,6	4,00	11,06
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	6,25	15,70
	1	24	34,8	23	95,8	4,35	11,48
	2	1	6,7	1	100,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	33	54,1	30	90,9	6,67	13,56
	1	23	33,3	22	95,7	4,55	11,71
	2	1	6,7	1	100,0	0,00	-
Cycle 16 Day 1	0	28	45,9	25	89,3	8,00	14,53
	1	21	30,4	21	100,0	14,29	22,54
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	7,25	14,06
	1	20	29,0	20	100,0	8,33	18,34

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	5,26	12,49
	1	17	24,6	17	100,0	9,80	15,66
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	5,26	12,49
	1	15	21,7	13	86,7	5,13	18,49
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	7,84	14,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	21,7	14	93,3	16,67	28,50
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	7,14	14,19
	1	13	18,8	11	84,6	6,06	13,48
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	5,56	12,97
	1	13	18,8	12	92,3	5,56	12,97
	2	1	6,7	1	100,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	3,70	11,11
	1	9	13,0	8	88,9	4,17	11,79
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	3,70	11,11
	1	9	13,0	8	88,9	12,50	24,80
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	0,00	0,00
	1	7	10,1	7	100,0	9,52	16,27

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	13,1	6	75,0	5,56	13,61
	1	6	8,7	6	100,0	5,56	13,61
Cycle 27 Day 1	0	6	9,8	3	50,0	0,00	0,00
	1	5	7,2	5	100,0	20,00	18,26
Cycle 28 Day 1	0	5	8,2	4	80,0	0,00	0,00
	1	5	7,2	5	100,0	26,67	27,89
Cycle 29 Day 1	0	4	6,6	2	50,0	0,00	0,00
	1	5	7,2	5	100,0	6,67	14,91

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	16,67	19,25
Cycle 31 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	33,33	27,22
Cycle 32 Day 1	0	3	4,9	2	66,7	0,00	0,00
	1	3	4,3	3	100,0	22,22	19,25
Cycle 33 Day 1	0	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	14,29	16,90
	1	34	49,3	20	58,8	16,67	17,10
	2	7	46,7	3	42,9	11,11	19,25
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	59	95,2	18,08	24,23
	1	4	100,0	4	100,0	16,67	19,25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	79	100,0	77	97,5	19,05	22,57
Cycle 2 Day 1	None	60	96,8	53	88,3	8,18	17,18
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	73	92,4	69	94,5	9,18	17,04
Cycle 3 Day 1	None	59	95,2	53	89,8	3,77	10,66
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	69	87,3	61	88,4	7,65	15,39
Cycle 4 Day 1	None	59	95,2	54	91,5	6,79	18,74

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	66	83,5	60	90,9	6,67	13,45
Cycle 5 Day 1	None	58	93,5	54	93,1	6,17	13,07
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	63	79,7	58	92,1	8,05	15,68
Cycle 6 Day 1	None	57	91,9	49	86,0	6,12	13,04
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	61	77,2	56	91,8	7,14	15,19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	52	83,9	47	90,4	4,96	12,00
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	58	73,4	53	91,4	11,32	20,61
Cycle 8 Day 1	None	50	80,6	45	90,0	3,70	10,59
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	10,67	15,71
Cycle 9 Day 1	None	48	77,4	46	95,8	4,35	11,35
	1	1	25,0	1	100,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	6,94	16,78
Cycle 10 Day 1	None	43	69,4	41	95,3	4,07	11,04
	1	1	25,0	1	100,0	0,00	-
	2 or More	45	57,0	44	97,8	9,09	18,13
Cycle 11 Day 1	None	37	59,7	33	89,2	3,03	9,73
	1	1	25,0	1	100,0	0,00	-
	2 or More	42	53,2	42	100,0	11,11	17,53
Cycle 12 Day 1	None	37	59,7	33	89,2	2,02	8,08

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	38	48,1	34	89,5	7,84	14,35
Cycle 13 Day 1	None	34	54,8	28	82,4	5,95	13,00
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	7,53	16,58
Cycle 14 Day 1	None	31	50,0	28	90,3	3,57	10,50
	1	1	25,0	1	100,0	0,00	-
	2 or More	28	35,4	27	96,4	7,41	16,88

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	30	48,4	27	90,0	6,17	13,19
	1	1	25,0	1	100,0	0,00	-
	2 or More	26	32,9	25	96,2	5,33	12,47
Cycle 16 Day 1	None	25	40,3	23	92,0	8,70	18,03
	1	1	25,0	1	100,0	0,00	-
	2 or More	24	30,4	23	95,8	13,04	19,43
Cycle 17 Day 1	None	23	37,1	22	95,7	1,52	7,11
	1	1	25,0	1	100,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	21	26,6	21	100,0	14,29	19,92
Cycle 18 Day 1	None	20	32,3	18	90,0	1,85	7,86
	1	1	25,0	1	100,0	0,00	-
	2 or More	20	25,3	18	90,0	12,96	16,72
Cycle 19 Day 1	None	17	27,4	17	100,0	0,00	0,00
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	11,11	20,57
Cycle 20 Day 1	None	17	27,4	16	94,1	12,50	26,87

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	11,11	16,27
Cycle 21 Day 1	None	15	24,2	13	86,7	2,56	9,25
	2 or More	14	17,7	13	92,9	10,26	16,01
Cycle 22 Day 1	None	15	24,2	13	86,7	7,69	14,62
	2 or More	14	17,7	12	85,7	2,78	9,62
Cycle 23 Day 1	None	10	16,1	9	90,0	0,00	0,00
	2 or More	11	13,9	9	81,8	7,41	14,70

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	16,1	10	100,0	3,33	10,54
	2 or More	10	12,7	8	80,0	12,50	24,80
Cycle 25 Day 1	None	9	14,5	8	88,9	4,17	11,79
	2 or More	6	7,6	5	83,3	6,67	14,91
Cycle 26 Day 1	None	8	12,9	8	100,0	0,00	0,00
	2 or More	6	7,6	4	66,7	16,67	19,25
Cycle 27 Day 1	None	7	11,3	6	85,7	5,56	13,61
	2 or More	4	5,1	2	50,0	33,33	0,00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	11,3	7	100,0	9,52	25,20
	2 or More	3	3,8	2	66,7	33,33	0,00
Cycle 29 Day 1	None	6	9,7	5	83,3	0,00	0,00
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 30 Day 1	None	4	6,5	3	75,0	11,11	19,25
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 31 Day 1	None	4	6,5	3	75,0	11,11	19,25
	2 or More	3	3,8	2	66,7	50,00	23,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	11,11	19,25
	2 or More	2	2,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	1,6	1	100,0	0,00	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	17,54	17,10
	1	3	75,0	1	33,3	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	39	49,4	24	61,5	13,89	16,79
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	59	95,2	18,08	24,23
	Previously Treated	83	100,0	81	97,6	18,93	22,32
Cycle 2 Day 1	Naïve	60	96,8	53	88,3	8,18	17,18
	Previously Treated	76	91,6	71	93,4	8,92	16,86
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	3,77	10,66

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	72	86,7	63	87,5	7,41	15,20
Cycle 4 Day 1	Naïve	59	95,2	54	91,5	6,79	18,74
	Previously Treated	69	83,1	62	89,9	6,45	13,28
Cycle 5 Day 1	Naïve	58	93,5	54	93,1	6,17	13,07
	Previously Treated	66	79,5	61	92,4	7,65	15,39
Cycle 6 Day 1	Naïve	57	91,9	49	86,0	6,12	13,04
	Previously Treated	64	77,1	59	92,2	6,78	14,88
Cycle 7 Day 1	Naïve	52	83,9	47	90,4	4,96	12,00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	61	73,5	56	91,8	10,71	20,21
Cycle 8 Day 1	Naïve	50	80,6	45	90,0	3,70	10,59
	Previously Treated	56	67,5	51	91,1	10,46	15,62
Cycle 9 Day 1	Naïve	48	77,4	46	95,8	4,35	11,35
	Previously Treated	50	60,2	49	98,0	6,80	16,64
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	4,07	11,04
	Previously Treated	46	55,4	45	97,8	8,89	17,98
Cycle 11 Day 1	Naïve	37	59,7	33	89,2	3,03	9,73

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	43	51,8	43	100,0	10,85	17,40
Cycle 12 Day 1	Naïve	37	59,7	33	89,2	2,02	8,08
	Previously Treated	39	47,0	35	89,7	7,62	14,20
Cycle 13 Day 1	Naïve	34	54,8	28	82,4	5,95	13,00
	Previously Treated	32	38,6	32	100,0	7,29	16,36
Cycle 14 Day 1	Naïve	31	50,0	28	90,3	3,57	10,50
	Previously Treated	29	34,9	28	96,6	7,14	16,62
Cycle 15 Day 1	Naïve	30	48,4	27	90,0	6,17	13,19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	27	32,5	26	96,3	5,13	12,26
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	8,70	18,03
	Previously Treated	25	30,1	24	96,0	12,50	19,19
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	1,52	7,11
	Previously Treated	22	26,5	22	100,0	13,64	19,68
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	1,85	7,86
	Previously Treated	21	25,3	19	90,5	12,28	16,52
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	0,00	0,00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	22,9	16	84,2	10,42	20,07
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	12,50	26,87
	Previously Treated	19	22,9	16	84,2	10,42	15,96
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	2,56	9,25
	Previously Treated	14	16,9	13	92,9	10,26	16,01
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	7,69	14,62
	Previously Treated	14	16,9	12	85,7	2,78	9,62
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	0,00	0,00

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	7,41	14,70
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	3,33	10,54
	Previously Treated	10	12,0	8	80,0	12,50	24,80
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	4,17	11,79
	Previously Treated	6	7,2	5	83,3	6,67	14,91
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	0,00	0,00
	Previously Treated	6	7,2	4	66,7	16,67	19,25
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	5,56	13,61

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	4,8	2	50,0	33,33	0,00
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	9,52	25,20
	Previously Treated	3	3,6	2	66,7	33,33	0,00
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	0,00	0,00
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	11,11	19,25
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	11,11	19,25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	50,00	23,57
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	11,11	19,25
	Previously Treated	2	2,4	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	0,00	-
	Previously Treated	1	1,2	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	17,54	17,10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	50,6	25	59,5	13,33	16,67
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	20,00	23,25
	Central	70	100,0	65	92,9	16,92	22,92
Cycle 2 Day 1	Local	71	94,7	67	94,4	6,97	14,84
	Central	65	92,9	57	87,7	10,53	19,06
Cycle 3 Day 1	Local	67	89,3	60	89,6	5,56	13,95

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	64	91,4	56	87,5	5,95	12,88
Cycle 4 Day 1	Local	65	86,7	58	89,2	6,32	14,59
	Central	63	90,0	58	92,1	6,90	17,39
Cycle 5 Day 1	Local	63	84,0	58	92,1	7,47	15,35
	Central	61	87,1	57	93,4	6,43	13,27
Cycle 6 Day 1	Local	63	84,0	61	96,8	6,01	14,28
	Central	58	82,9	47	81,0	7,09	13,79
Cycle 7 Day 1	Local	61	81,3	58	95,1	7,47	16,57

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	52	74,3	45	86,5	8,89	17,98
Cycle 8 Day 1	Local	57	76,0	54	94,7	7,41	13,99
	Central	49	70,0	42	85,7	7,14	13,84
Cycle 9 Day 1	Local	54	72,0	53	98,1	6,29	16,09
	Central	44	62,9	42	95,5	4,76	11,81
Cycle 10 Day 1	Local	48	64,0	46	95,8	7,97	17,48
	Central	41	58,6	40	97,6	5,00	12,05
Cycle 11 Day 1	Local	40	53,3	38	95,0	7,89	16,32

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	40	57,1	38	95,0	7,02	13,77
Cycle 12 Day 1	Local	36	48,0	33	91,7	6,06	13,06
	Central	40	57,1	35	87,5	3,81	10,76
Cycle 13 Day 1	Local	30	40,0	29	96,7	6,90	16,38
	Central	36	51,4	31	86,1	6,45	13,39
Cycle 14 Day 1	Local	27	36,0	27	100,0	6,17	16,11
	Central	33	47,1	29	87,9	4,60	11,70
Cycle 15 Day 1	Local	26	34,7	25	96,2	8,00	14,53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	28	90,3	3,57	10,50
Cycle 16 Day 1	Local	24	32,0	24	100,0	13,89	19,45
	Central	26	37,1	23	88,5	7,25	17,28
Cycle 17 Day 1	Local	22	29,3	22	100,0	10,61	18,93
	Central	23	32,9	22	95,7	4,55	11,71
Cycle 18 Day 1	Local	20	26,7	19	95,0	8,77	15,08
	Central	21	30,0	18	85,7	5,56	12,78
Cycle 19 Day 1	Local	19	25,3	17	89,5	3,92	11,07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	24,3	16	94,1	6,25	18,13
Cycle 20 Day 1	Local	19	25,3	17	89,5	13,73	26,51
	Central	17	24,3	15	88,2	8,89	15,26
Cycle 21 Day 1	Local	14	18,7	12	85,7	2,78	9,62
	Central	15	21,4	14	93,3	9,52	15,63
Cycle 22 Day 1	Local	14	18,7	12	85,7	2,78	9,62
	Central	15	21,4	13	86,7	7,69	14,62
Cycle 23 Day 1	Local	11	14,7	10	90,9	3,33	10,54

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	14,3	8	80,0	4,17	11,79
Cycle 24 Day 1	Local	11	14,7	10	90,9	6,67	14,05
	Central	9	12,9	8	88,9	8,33	23,57
Cycle 25 Day 1	Local	7	9,3	7	100,0	4,76	12,60
	Central	8	11,4	6	75,0	5,56	13,61
Cycle 26 Day 1	Local	6	8,0	6	100,0	5,56	13,61
	Central	8	11,4	6	75,0	5,56	13,61
Cycle 27 Day 1	Local	4	5,3	4	100,0	8,33	16,67

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	10,0	4	57,1	16,67	19,25
Cycle 28 Day 1	Local	4	5,3	4	100,0	16,67	33,33
	Central	6	8,6	5	83,3	13,33	18,26
Cycle 29 Day 1	Local	3	4,0	3	100,0	0,00	0,00
	Central	6	8,6	4	66,7	8,33	16,67
Cycle 30 Day 1	Local	3	4,0	3	100,0	11,11	19,25
	Central	4	5,7	2	50,0	16,67	23,57
Cycle 31 Day 1	Local	3	4,0	3	100,0	11,11	19,25

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	5,7	2	50,0	50,00	23,57
Cycle 32 Day 1	Local	3	4,0	3	100,0	11,11	19,25
	Central	3	4,3	2	66,7	16,67	23,57
Cycle 33 Day 1	Local	1	1,3	1	100,0	0,00	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	12,50	16,48

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	32	45,7	20	62,5	18,33	17,01
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	130	96,3	18,97	23,09
	No	10	100,0	10	100,0	13,33	23,31
Cycle 2 Day 1	Yes	129	95,6	117	90,7	9,12	17,30
	No	7	70,0	7	100,0	0,00	0,00
Cycle 3 Day 1	Yes	124	91,9	110	88,7	6,06	13,68

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	6	85,7	0,00	0,00
Cycle 4 Day 1	Yes	121	89,6	109	90,1	6,42	15,37
	No	7	70,0	7	100,0	9,52	25,20
Cycle 5 Day 1	Yes	117	86,7	109	93,2	6,42	13,96
	No	7	70,0	6	85,7	16,67	18,26
Cycle 6 Day 1	Yes	114	84,4	101	88,6	6,27	13,91
	No	7	70,0	7	100,0	9,52	16,27
Cycle 7 Day 1	Yes	106	78,5	96	90,6	8,33	17,44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	4,76	12,60
Cycle 8 Day 1	Yes	100	74,1	90	90,0	7,04	13,68
	No	6	60,0	6	100,0	11,11	17,21
Cycle 9 Day 1	Yes	92	68,1	89	96,7	5,62	14,42
	No	6	60,0	6	100,0	5,56	13,61
Cycle 10 Day 1	Yes	83	61,5	80	96,4	6,67	15,37
	No	6	60,0	6	100,0	5,56	13,61
Cycle 11 Day 1	Yes	76	56,3	72	94,7	7,41	15,03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	4	40,0	4	100,0	8,33	16,67
Cycle 12 Day 1	Yes	72	53,3	64	88,9	4,69	11,68
	No	4	40,0	4	100,0	8,33	16,67
Cycle 13 Day 1	Yes	64	47,4	58	90,6	6,32	14,59
	No	2	20,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	58	43,0	54	93,1	4,94	13,59
	No	2	20,0	2	100,0	16,67	23,57
Cycle 15 Day 1	Yes	55	40,7	51	92,7	5,23	12,24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	16,67	23,57
Cycle 16 Day 1	Yes	48	35,6	45	93,8	9,63	18,29
	No	2	20,0	2	100,0	33,33	0,00
Cycle 17 Day 1	Yes	43	31,9	42	97,7	7,14	15,68
	No	2	20,0	2	100,0	16,67	23,57
Cycle 18 Day 1	Yes	39	28,9	35	89,7	6,67	13,53
	No	2	20,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	5,21	14,93

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	11,11	22,03
	No	2	20,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	20,0	24	88,9	5,56	12,69
	No	2	20,0	2	100,0	16,67	23,57
Cycle 22 Day 1	Yes	27	20,0	23	85,2	5,80	12,92
	No	2	20,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	3,92	11,07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	7,84	18,74
	No	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	10,4	12	85,7	5,56	12,97
	No	1	10,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	6,06	13,48
	No	1	10,0	1	100,0	0,00	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	14,29	17,82

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	16,67	25,20
	No	1	10,0	1	100,0	0,00	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	5,56	13,61
	No	1	10,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	8,33	16,67
	No	1	10,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	33,33	27,22

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 32 Day 1	Yes	5	3,7	4	80,0	16,67	19,25
	No	1	10,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	15,50	16,82
	No	2	20,0	1	50,0	0,00	-

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	15,15	22,92
	No	134	100,0	129	96,3	18,86	23,14
Cycle 2 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	129	96,3	117	90,7	9,12	17,30
Cycle 3 Day 1	Yes	7	63,6	6	85,7	0,00	0,00
	No	124	92,5	110	88,7	6,06	13,68

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	121	90,3	109	90,1	7,03	16,40
Cycle 5 Day 1	Yes	7	63,6	7	100,0	4,76	12,60
	No	117	87,3	108	92,3	7,10	14,45
Cycle 6 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	114	85,1	101	88,6	6,93	14,39
Cycle 7 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	106	79,1	96	90,6	8,68	17,60

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	99	73,9	89	89,9	7,87	14,23
Cycle 9 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	92	68,7	89	96,7	5,99	14,70
Cycle 10 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	83	61,9	80	96,4	7,08	15,64
Cycle 11 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	74	55,2	70	94,6	8,10	15,47

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	70	52,2	62	88,6	5,38	12,36
Cycle 13 Day 1	Yes	5	45,5	5	100,0	6,67	14,91
	No	61	45,5	55	90,2	6,67	14,91
Cycle 14 Day 1	Yes	5	45,5	5	100,0	0,00	0,00
	No	55	41,0	51	92,7	5,88	14,46
Cycle 15 Day 1	Yes	4	36,4	4	100,0	16,67	19,25
	No	53	39,6	49	92,5	4,76	11,79

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	47	35,1	44	93,6	11,36	18,94
Cycle 17 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	42	31,3	41	97,6	8,13	16,30
Cycle 18 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	38	28,4	34	89,5	7,84	14,35
Cycle 19 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	30	90,9	5,56	15,37

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	27,3	3	100,0	33,33	57,74
	No	33	24,6	29	87,9	9,20	15,16
Cycle 21 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	24	88,9	6,94	13,83
Cycle 22 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	27	20,1	23	85,2	4,35	11,48
Cycle 23 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	19	14,2	16	84,2	4,17	11,39

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest

MODEL: --

STUDY: STARTRK-2

Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	18	13,4	16	88,9	8,33	19,25
Cycle 25 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	13	9,7	11	84,6	6,06	13,48
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	6,06	13,48
Cycle 27 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	10	7,5	7	70,0	14,29	17,82

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	9	6,7	8	88,9	16,67	25,20
Cycle 29 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	8	6,0	6	75,0	5,56	13,61
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	13,33	18,26
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	26,67	27,89

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	13,33	18,26
Cycle 33 Day 1	No	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	11,11	19,25
	No	61	45,5	41	67,2	15,45	16,83

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	140	96,6	14,05	24,34
Cycle 2 Day 1	All	136	93,8	124	91,2	21,24	24,54
Cycle 3 Day 1	All	131	90,3	116	88,5	17,82	22,17
Cycle 4 Day 1	All	128	88,3	116	90,6	20,11	24,82
Cycle 5 Day 1	All	124	85,5	115	92,7	18,84	24,63
Cycle 6 Day 1	All	121	83,4	108	89,3	20,37	25,31
Cycle 7 Day 1	All	113	77,9	103	91,2	20,71	24,31

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	106	73,1	96	90,6	19,44	25,44
Cycle 9 Day 1	All	98	67,6	95	96,9	18,95	21,00
Cycle 10 Day 1	All	89	61,4	86	96,6	18,60	22,64
Cycle 11 Day 1	All	80	55,2	76	95,0	18,86	21,32
Cycle 12 Day 1	All	76	52,4	67	88,2	22,89	23,36
Cycle 13 Day 1	All	66	45,5	60	90,9	21,67	21,10
Cycle 14 Day 1	All	60	41,4	56	93,3	20,24	21,72
Cycle 15 Day 1	All	57	39,3	53	93,0	18,87	23,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	50	34,5	47	94,0	21,28	21,34
Cycle 17 Day 1	All	45	31,0	44	97,8	18,94	23,18
Cycle 18 Day 1	All	41	28,3	37	90,2	13,51	16,59
Cycle 19 Day 1	All	36	24,8	33	91,7	14,14	16,73
Cycle 20 Day 1	All	36	24,8	32	88,9	16,67	20,74
Cycle 21 Day 1	All	29	20,0	26	89,7	17,95	23,53
Cycle 22 Day 1	All	29	20,0	25	86,2	16,00	17,00
Cycle 23 Day 1	All	21	14,5	18	85,7	12,96	16,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	13,8	18	90,0	14,81	23,49
Cycle 25 Day 1	All	15	10,3	13	86,7	10,26	16,01
Cycle 26 Day 1	All	14	9,7	12	85,7	13,89	22,29
Cycle 27 Day 1	All	11	7,6	8	72,7	25,00	23,57
Cycle 28 Day 1	All	10	6,9	9	90,0	18,52	24,22
Cycle 29 Day 1	All	9	6,2	7	77,8	33,33	27,22
Cycle 30 Day 1	All	7	4,8	5	71,4	26,67	14,91
Cycle 31 Day 1	All	7	4,8	5	71,4	26,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	4,1	5	83,3	20,00	18,26
Cycle 33 Day 1	All	2	1,4	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	23,48	23,38
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	13,07	25,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	93	100,0	89	95,7	14,61	24,08
Cycle 2 Day 1	Male	50	96,2	46	92,0	23,19	26,17
	Female	86	92,5	78	90,7	20,09	23,63
Cycle 3 Day 1	Male	47	90,4	43	91,5	17,05	23,43
	Female	84	90,3	73	86,9	18,26	21,55
Cycle 4 Day 1	Male	46	88,5	43	93,5	21,71	27,10
	Female	82	88,2	73	89,0	19,18	23,52
Cycle 5 Day 1	Male	45	86,5	42	93,3	21,43	24,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	79	84,9	73	92,4	17,35	24,91
Cycle 6 Day 1	Male	45	86,5	41	91,1	21,95	24,28
	Female	76	81,7	67	88,2	19,40	26,05
Cycle 7 Day 1	Male	40	76,9	39	97,5	22,22	25,74
	Female	73	78,5	64	87,7	19,79	23,55
Cycle 8 Day 1	Male	37	71,2	34	91,9	16,67	26,27
	Female	69	74,2	62	89,9	20,97	25,06
Cycle 9 Day 1	Male	33	63,5	33	100,0	18,18	20,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	62	95,4	19,35	21,38
Cycle 10 Day 1	Male	30	57,7	30	100,0	15,56	20,96
	Female	59	63,4	56	94,9	20,24	23,51
Cycle 11 Day 1	Male	29	55,8	28	96,6	26,19	22,87
	Female	51	54,8	48	94,1	14,58	19,33
Cycle 12 Day 1	Male	27	51,9	26	96,3	21,79	20,96
	Female	49	52,7	41	83,7	23,58	24,99
Cycle 13 Day 1	Male	25	48,1	23	92,0	20,29	16,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	41	44,1	37	90,2	22,52	23,64
Cycle 14 Day 1	Male	23	44,2	21	91,3	17,46	17,06
	Female	37	39,8	35	94,6	21,90	24,18
Cycle 15 Day 1	Male	21	40,4	20	95,2	16,67	20,23
	Female	36	38,7	33	91,7	20,20	24,92
Cycle 16 Day 1	Male	16	30,8	16	100,0	20,83	20,64
	Female	34	36,6	31	91,2	21,51	22,02
Cycle 17 Day 1	Male	13	25,0	13	100,0	23,08	25,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	32	34,4	31	96,9	17,20	22,56
Cycle 18 Day 1	Male	12	23,1	11	91,7	18,18	17,41
	Female	29	31,2	26	89,7	11,54	16,17
Cycle 19 Day 1	Male	10	19,2	10	100,0	16,67	17,57
	Female	26	28,0	23	88,5	13,04	16,63
Cycle 20 Day 1	Male	10	19,2	9	90,0	14,81	17,57
	Female	26	28,0	23	88,5	17,39	22,18
Cycle 21 Day 1	Male	8	15,4	8	100,0	16,67	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	22,6	18	85,7	18,52	26,13
Cycle 22 Day 1	Male	8	15,4	6	75,0	16,67	18,26
	Female	21	22,6	19	90,5	15,79	17,10
Cycle 23 Day 1	Male	5	9,6	4	80,0	16,67	19,25
	Female	16	17,2	14	87,5	11,90	16,57
Cycle 24 Day 1	Male	5	9,6	4	80,0	16,67	19,25
	Female	15	16,1	14	93,3	14,29	25,20
Cycle 25 Day 1	Male	3	5,8	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	12,9	11	91,7	12,12	16,82
Cycle 26 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	11	11,8	10	90,9	16,67	23,57
Cycle 27 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	8	8,6	6	75,0	33,33	21,08
Cycle 28 Day 1	Male	2	3,8	2	100,0	0,00	0,00
	Female	8	8,6	7	87,5	23,81	25,20
Cycle 29 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	8,6	6	75,0	38,89	25,09
Cycle 30 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	33,33	0,00
Cycle 31 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	33,33	0,00
Cycle 32 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	5	5,4	4	80,0	25,00	16,67
Cycle 33 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	1,1	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	31,75	22,30
	Female	37	39,8	23	62,2	15,94	22,18
Age							
Cycle 1 Day 1	18-64	109	100,0	104	95,4	14,42	25,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	13,79	22,74
	>=75	7	100,0	7	100,0	9,52	16,27
Cycle 2 Day 1	18-64	103	94,5	91	88,3	23,81	25,96
	65-74	26	89,7	26	100,0	15,38	19,39
	>=75	7	100,0	7	100,0	9,52	16,27
Cycle 3 Day 1	18-64	99	90,8	87	87,9	18,77	22,56
	65-74	25	86,2	23	92,0	11,59	19,09
	>=75	7	100,0	6	85,7	27,78	25,09

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	98	89,9	88	89,8	20,08	25,04
	65-74	23	79,3	21	91,3	17,46	24,99
	>=75	7	100,0	7	100,0	28,57	23,00
Cycle 5 Day 1	18-64	95	87,2	88	92,6	19,70	24,57
	65-74	22	75,9	22	100,0	18,18	26,68
	>=75	7	100,0	5	71,4	6,67	14,91
Cycle 6 Day 1	18-64	92	84,4	80	87,0	20,83	25,64
	65-74	22	75,9	21	95,5	17,46	27,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	23,81	16,27
Cycle 7 Day 1	18-64	86	78,9	78	90,7	21,79	24,52
	65-74	20	69,0	19	95,0	19,30	23,08
	>=75	7	100,0	6	85,7	11,11	27,22
Cycle 8 Day 1	18-64	80	73,4	71	88,8	18,31	24,42
	65-74	19	65,5	19	100,0	24,56	29,06
	>=75	7	100,0	6	85,7	16,67	27,89
Cycle 9 Day 1	18-64	74	67,9	72	97,3	19,44	19,98

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	18	62,1	18	100,0	20,37	25,92
	>=75	6	85,7	5	83,3	6,67	14,91
Cycle 10 Day 1	18-64	69	63,3	66	95,7	18,69	21,98
	65-74	15	51,7	15	100,0	22,22	27,22
	>=75	5	71,4	5	100,0	6,67	14,91
Cycle 11 Day 1	18-64	61	56,0	58	95,1	18,97	21,73
	65-74	15	51,7	14	93,3	19,05	21,54
	>=75	4	57,1	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	57	52,3	49	86,0	23,81	24,53
	65-74	15	51,7	14	93,3	21,43	21,11
	>=75	4	57,1	4	100,0	16,67	19,25
Cycle 13 Day 1	18-64	49	45,0	45	91,8	22,22	20,10
	65-74	13	44,8	11	84,6	24,24	26,21
	>=75	4	57,1	4	100,0	8,33	16,67
Cycle 14 Day 1	18-64	45	41,3	43	95,6	19,38	20,87
	65-74	13	44,8	11	84,6	24,24	26,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	28,6	2	100,0	16,67	23,57
Cycle 15 Day 1	18-64	43	39,4	40	93,0	20,83	22,25
	65-74	12	41,4	11	91,7	15,15	27,34
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 16 Day 1	18-64	38	34,9	36	94,7	20,37	19,96
	65-74	10	34,5	9	90,0	25,93	27,78
	>=75	2	28,6	2	100,0	16,67	23,57
Cycle 17 Day 1	18-64	36	33,0	35	97,2	19,05	21,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	27,6	8	100,0	20,83	30,54
	>=75	1	14,3	1	100,0	0,00	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	13,33	16,61
	65-74	7	24,1	6	85,7	16,67	18,26
	>=75	1	14,3	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	13,10	16,58
	65-74	5	17,2	4	80,0	25,00	16,67
	>=75	1	14,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	15,38	19,39
	65-74	5	17,2	5	100,0	26,67	27,89
	>=75	1	14,3	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	15,87	17,06
	65-74	4	13,8	4	100,0	33,33	47,14
	>=75	1	14,3	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	16,67	17,10
	65-74	4	13,8	4	100,0	16,67	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	12,50	16,67
	65-74	2	6,9	2	100,0	16,67	23,57
Cycle 24 Day 1	18-64	18	16,5	16	88,9	14,58	24,25
	65-74	2	6,9	2	100,0	16,67	23,57
Cycle 25 Day 1	18-64	14	12,8	12	85,7	11,11	16,41
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	13,89	22,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	25,00	23,57
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	18,52	24,22
	65-74	1	3,4	0	0,0	-	-
Cycle 29 Day 1	18-64	8	7,3	7	87,5	33,33	27,22
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	26,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	26,67	14,91
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	25,00	16,67
	65-74	1	3,4	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	0,00	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	21,57	24,46
	65-74	15	51,7	8	53,3	29,17	21,36
	>=75	4	57,1	2	50,0	33,33	0,00
Race							
Cycle 1 Day 1	White	60	100,0	57	95,0	15,20	26,78
	Other	85	100,0	83	97,6	13,25	22,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	57	95,0	50	87,7	22,00	27,45
	Other	79	92,9	74	93,7	20,72	22,55
Cycle 3 Day 1	White	54	90,0	44	81,5	18,18	22,10
	Other	77	90,6	72	93,5	17,59	22,36
Cycle 4 Day 1	White	53	88,3	45	84,9	20,74	23,88
	Other	75	88,2	71	94,7	19,72	25,56
Cycle 5 Day 1	White	52	86,7	47	90,4	23,40	22,96
	Other	72	84,7	68	94,4	15,69	25,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	50	83,3	41	82,0	26,83	27,10
	Other	71	83,5	67	94,4	16,42	23,48
Cycle 7 Day 1	White	47	78,3	40	85,1	24,17	26,14
	Other	66	77,6	63	95,5	18,52	23,01
Cycle 8 Day 1	White	45	75,0	38	84,4	20,18	23,94
	Other	61	71,8	58	95,1	18,97	26,57
Cycle 9 Day 1	White	42	70,0	41	97,6	19,51	22,33
	Other	56	65,9	54	96,4	18,52	20,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	18,80	21,35
	Other	48	56,5	47	97,9	18,44	23,88
Cycle 11 Day 1	White	37	61,7	36	97,3	20,37	21,50
	Other	43	50,6	40	93,0	17,50	21,33
Cycle 12 Day 1	White	37	61,7	33	89,2	21,21	20,10
	Other	39	45,9	34	87,2	24,51	26,35
Cycle 13 Day 1	White	32	53,3	30	93,8	20,00	20,72
	Other	34	40,0	30	88,2	23,33	21,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	31	51,7	30	96,8	20,00	20,72
	Other	29	34,1	26	89,7	20,51	23,24
Cycle 15 Day 1	White	30	50,0	28	93,3	19,05	21,14
	Other	27	31,8	25	92,6	18,67	25,60
Cycle 16 Day 1	White	26	43,3	24	92,3	18,06	19,61
	Other	24	28,2	23	95,8	24,64	22,96
Cycle 17 Day 1	White	24	40,0	24	100,0	12,50	19,19
	Other	21	24,7	20	95,2	26,67	25,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	22	36,7	19	86,4	8,77	15,08
	Other	19	22,4	18	94,7	18,52	17,04
Cycle 19 Day 1	White	20	33,3	20	100,0	11,67	16,31
	Other	16	18,8	13	81,3	17,95	17,30
Cycle 20 Day 1	White	20	33,3	17	85,0	11,76	20,21
	Other	16	18,8	15	93,8	22,22	20,57
Cycle 21 Day 1	White	16	26,7	14	87,5	9,52	15,63
	Other	13	15,3	12	92,3	27,78	27,83

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	26,7	13	81,3	12,82	16,88
	Other	13	15,3	12	92,3	19,44	17,16
Cycle 23 Day 1	White	12	20,0	10	83,3	6,67	14,05
	Other	9	10,6	8	88,9	20,83	17,25
Cycle 24 Day 1	White	11	18,3	10	90,9	10,00	22,50
	Other	9	10,6	8	88,9	20,83	24,80
Cycle 25 Day 1	White	10	16,7	8	80,0	8,33	15,43
	Other	5	5,9	5	100,0	13,33	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	16,7	8	80,0	16,67	25,20
	Other	4	4,7	4	100,0	8,33	16,67
Cycle 27 Day 1	White	8	13,3	5	62,5	13,33	18,26
	Other	3	3,5	3	100,0	44,44	19,25
Cycle 28 Day 1	White	7	11,7	6	85,7	16,67	27,89
	Other	3	3,5	3	100,0	22,22	19,25
Cycle 29 Day 1	White	6	10,0	4	66,7	16,67	19,25
	Other	3	3,5	3	100,0	55,56	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	6,7	2	50,0	16,67	23,57
	Other	3	3,5	3	100,0	33,33	0,00
Cycle 31 Day 1	White	4	6,7	2	50,0	16,67	23,57
	Other	3	3,5	3	100,0	33,33	0,00
Cycle 32 Day 1	White	4	6,7	3	75,0	11,11	19,25
	Other	2	2,4	2	100,0	33,33	0,00
Cycle 33 Day 1	White	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-
End Of Treatment	White	25	41,7	17	68,0	21,57	23,40
	Other	39	45,9	27	69,2	24,69	23,74
Region							
Cycle 1 Day 1	America (AM)	40	100,0	38	95,0	19,30	29,64
	Europe (EU)	34	100,0	31	91,2	9,68	19,61
	Asia (AS)	71	100,0	71	100,0	13,15	22,87

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	27,08	24,59
	Europe (EU)	32	94,1	27	84,4	17,28	25,10
	Asia (AS)	66	93,0	65	98,5	20,00	24,15
Cycle 3 Day 1	America (AM)	37	92,5	32	86,5	17,71	22,38
	Europe (EU)	31	91,2	21	67,7	20,63	22,30
	Asia (AS)	63	88,7	63	100,0	16,93	22,30
Cycle 4 Day 1	America (AM)	37	92,5	32	86,5	19,79	23,74
	Europe (EU)	30	88,2	24	80,0	25,00	28,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	61	85,9	60	98,4	18,33	24,10
Cycle 5 Day 1	America (AM)	37	92,5	33	89,2	23,23	26,98
	Europe (EU)	30	88,2	25	83,3	28,00	31,45
	Asia (AS)	57	80,3	57	100,0	12,28	17,40
Cycle 6 Day 1	America (AM)	37	92,5	32	86,5	26,04	25,02
	Europe (EU)	28	82,4	24	85,7	26,39	29,45
	Asia (AS)	56	78,9	52	92,9	14,10	22,23
Cycle 7 Day 1	America (AM)	35	87,5	29	82,9	17,24	19,15

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	28	82,4	25	89,3	30,67	30,31
	Asia (AS)	50	70,4	49	98,0	17,69	22,67
Cycle 8 Day 1	America (AM)	31	77,5	26	83,9	14,10	28,55
	Europe (EU)	28	82,4	23	82,1	23,19	25,49
	Asia (AS)	47	66,2	47	100,0	20,57	23,62
Cycle 9 Day 1	America (AM)	29	72,5	27	93,1	16,05	16,97
	Europe (EU)	26	76,5	25	96,2	24,00	26,39
	Asia (AS)	43	60,6	43	100,0	17,83	19,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	15,28	19,61
	Europe (EU)	25	73,5	25	100,0	24,00	24,57
	Asia (AS)	37	52,1	37	100,0	17,12	23,07
Cycle 11 Day 1	America (AM)	24	60,0	21	87,5	14,29	16,90
	Europe (EU)	23	67,6	22	95,7	24,24	23,42
	Asia (AS)	33	46,5	33	100,0	18,18	22,19
Cycle 12 Day 1	America (AM)	24	60,0	22	91,7	18,18	19,86
	Europe (EU)	23	67,6	17	73,9	29,41	20,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	40,8	28	96,6	22,62	27,30
Cycle 13 Day 1	America (AM)	23	57,5	21	91,3	20,63	22,30
	Europe (EU)	18	52,9	14	77,8	23,81	20,37
	Asia (AS)	25	35,2	25	100,0	21,33	21,26
Cycle 14 Day 1	America (AM)	22	55,0	20	90,9	18,33	22,88
	Europe (EU)	17	50,0	16	94,1	20,83	20,64
	Asia (AS)	21	29,6	20	95,2	21,67	22,36
Cycle 15 Day 1	America (AM)	22	55,0	19	86,4	12,28	19,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	44,1	14	93,3	26,19	23,31
	Asia (AS)	20	28,2	20	100,0	20,00	25,13
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	15,69	20,81
	Europe (EU)	14	41,2	11	78,6	27,27	20,10
	Asia (AS)	19	26,8	19	100,0	22,81	22,37
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	12,50	20,64
	Europe (EU)	13	38,2	12	92,3	16,67	22,47
	Asia (AS)	16	22,5	16	100,0	27,08	25,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	11,90	16,57
	Europe (EU)	11	32,4	7	63,6	9,52	16,27
	Asia (AS)	16	22,5	16	100,0	16,67	17,21
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	5,13	12,52
	Europe (EU)	9	26,5	9	100,0	22,22	16,67
	Asia (AS)	14	19,7	11	78,6	18,18	17,41
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	12,82	21,68
	Europe (EU)	9	26,5	6	66,7	11,11	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	23,08	21,01
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	6,67	14,05
	Europe (EU)	7	20,6	6	85,7	11,11	17,21
	Asia (AS)	11	15,5	10	90,9	33,33	27,22
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	13,33	17,21
	Europe (EU)	7	20,6	5	71,4	6,67	14,91
	Asia (AS)	11	15,5	10	90,9	23,33	16,10
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	11,11	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	14,7	3	60,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	22,22	17,21
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	8,33	15,43
	Europe (EU)	5	14,7	4	80,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	33,33	29,81
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	4,76	12,60
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	16,67	27,89
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	16,67	19,25
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	8,33	16,67
	Europe (EU)	3	8,8	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	41,67	16,67
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	8,33	16,67
	Europe (EU)	2	5,9	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	33,33	27,22
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	11,11	19,25
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	50,00	19,25
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	33,33	0,00
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	33,33	0,00
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57
	Europe (EU)	1	2,9	1	100,0	0,00	-
	Asia (AS)	3	4,2	2	66,7	33,33	0,00
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	0,00	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	21,57	20,21
	Europe (EU)	10	29,4	5	50,0	40,00	27,89
	Asia (AS)	34	47,9	22	64,7	21,21	24,22
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	59	96,7	10,73	20,94
	1	69	100,0	66	95,7	16,67	27,58

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	15	100,0	15	100,0	15,56	21,33
Cycle 2 Day 1	0	59	96,7	55	93,2	21,82	21,49
	1	67	97,1	59	88,1	22,03	28,10
	2	10	66,7	10	100,0	13,33	17,21
Cycle 3 Day 1	0	57	93,4	50	87,7	16,67	20,48
	1	65	94,2	57	87,7	18,13	24,45
	2	9	60,0	9	100,0	22,22	16,67
Cycle 4 Day 1	0	57	93,4	51	89,5	19,61	23,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	57	91,9	19,30	24,35
	2	9	60,0	8	88,9	29,17	37,53
Cycle 5 Day 1	0	56	91,8	52	92,9	19,23	25,86
	1	62	89,9	57	91,9	17,54	22,80
	2	6	40,0	6	100,0	27,78	32,77
Cycle 6 Day 1	0	56	91,8	53	94,6	22,64	25,96
	1	59	85,5	51	86,4	18,30	24,33
	2	6	40,0	4	66,7	16,67	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	54	88,5	51	94,4	21,57	24,79
	1	54	78,3	47	87,0	20,57	24,63
	2	5	33,3	5	100,0	13,33	18,26
Cycle 8 Day 1	0	52	85,2	48	92,3	20,14	28,96
	1	49	71,0	43	87,8	18,60	20,96
	2	5	33,3	5	100,0	20,00	29,81
Cycle 9 Day 1	0	50	82,0	49	98,0	18,37	22,63
	1	44	63,8	42	95,5	19,05	18,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	4	26,7	4	100,0	25,00	31,91
Cycle 10 Day 1	0	46	75,4	46	100,0	21,01	25,68
	1	40	58,0	37	92,5	15,32	18,58
	2	3	20,0	3	100,0	22,22	19,25
Cycle 11 Day 1	0	43	70,5	40	93,0	21,67	22,07
	1	34	49,3	33	97,1	16,16	20,62
	2	3	20,0	3	100,0	11,11	19,25
Cycle 12 Day 1	0	42	68,9	35	83,3	23,81	20,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	31	44,9	29	93,5	20,69	25,84
	2	3	20,0	3	100,0	33,33	33,33
Cycle 13 Day 1	0	38	62,3	34	89,5	21,57	21,53
	1	27	39,1	25	92,6	22,67	20,91
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	20,83	23,57
	1	24	34,8	23	95,8	20,29	19,43
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	33	54,1	30	90,9	20,00	25,67
	1	23	33,3	22	95,7	18,18	19,86
	2	1	6,7	1	100,0	0,00	-
Cycle 16 Day 1	0	28	45,9	25	89,3	26,67	23,57
	1	21	30,4	21	100,0	15,87	17,06
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	20,29	24,08
	1	20	29,0	20	100,0	18,33	22,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	15,79	17,10
	1	17	24,6	17	100,0	11,76	16,42
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	15,79	17,10
	1	15	21,7	13	86,7	12,82	16,88
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	19,61	23,74

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	21,7	14	93,3	14,29	17,12
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	21,43	28,06
	1	13	18,8	11	84,6	15,15	17,41
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	13,89	17,16
	1	13	18,8	12	92,3	19,44	17,16
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	14,81	17,57
	1	9	13,0	8	88,9	12,50	17,25
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	11,11	23,57
	1	9	13,0	8	88,9	20,83	24,80
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	5,56	13,61
	1	7	10,1	7	100,0	14,29	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	13,1	6	75,0	16,67	27,89
	1	6	8,7	6	100,0	11,11	17,21
Cycle 27 Day 1	0	6	9,8	3	50,0	11,11	19,25
	1	5	7,2	5	100,0	33,33	23,57
Cycle 28 Day 1	0	5	8,2	4	80,0	16,67	33,33
	1	5	7,2	5	100,0	20,00	18,26
Cycle 29 Day 1	0	4	6,6	2	50,0	16,67	23,57
	1	5	7,2	5	100,0	40,00	27,89

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	33,33	0,00
Cycle 31 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	33,33	0,00
Cycle 32 Day 1	0	3	4,9	2	66,7	0,00	0,00
	1	3	4,3	3	100,0	33,33	0,00
Cycle 33 Day 1	0	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	25,40	23,34
	1	34	49,3	20	58,8	21,67	24,84
	2	7	46,7	3	42,9	22,22	19,25
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	59	95,2	14,12	24,92
	1	4	100,0	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	79	100,0	77	97,5	14,29	24,44
Cycle 2 Day 1	None	60	96,8	53	88,3	17,61	23,21
	1	3	75,0	2	66,7	33,33	0,00
	2 or More	73	92,4	69	94,5	23,67	25,63
Cycle 3 Day 1	None	59	95,2	53	89,8	14,47	19,07
	1	3	75,0	2	66,7	16,67	23,57
	2 or More	69	87,3	61	88,4	20,77	24,47
Cycle 4 Day 1	None	59	95,2	54	91,5	20,37	24,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	2	66,7	16,67	23,57
	2 or More	66	83,5	60	90,9	20,00	25,45
Cycle 5 Day 1	None	58	93,5	54	93,1	20,37	27,79
	1	3	75,0	3	100,0	22,22	19,25
	2 or More	63	79,7	58	92,1	17,24	21,85
Cycle 6 Day 1	None	57	91,9	49	86,0	21,09	26,08
	1	3	75,0	3	100,0	11,11	19,25
	2 or More	61	77,2	56	91,8	20,24	25,17

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	52	83,9	47	90,4	21,99	24,35
	1	3	75,0	3	100,0	22,22	19,25
	2 or More	58	73,4	53	91,4	19,50	24,84
Cycle 8 Day 1	None	50	80,6	45	90,0	20,74	25,91
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	18,67	25,34
Cycle 9 Day 1	None	48	77,4	46	95,8	16,67	19,56
	1	1	25,0	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	20,83	22,41
Cycle 10 Day 1	None	43	69,4	41	95,3	17,07	21,24
	1	1	25,0	1	100,0	33,33	-
	2 or More	45	57,0	44	97,8	19,70	24,19
Cycle 11 Day 1	None	37	59,7	33	89,2	19,19	20,46
	1	1	25,0	1	100,0	33,33	-
	2 or More	42	53,2	42	100,0	18,25	22,33
Cycle 12 Day 1	None	37	59,7	32	86,5	21,88	23,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	38	48,1	34	89,5	24,51	23,65
Cycle 13 Day 1	None	34	54,8	28	82,4	19,05	19,09
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	24,73	22,72
Cycle 14 Day 1	None	31	50,0	28	90,3	19,05	21,14
	1	1	25,0	1	100,0	33,33	-
	2 or More	28	35,4	27	96,4	20,99	22,92

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	30	48,4	27	90,0	17,28	23,33
	1	1	25,0	1	100,0	0,00	-
	2 or More	26	32,9	25	96,2	21,33	23,33
Cycle 16 Day 1	None	25	40,3	23	92,0	21,74	23,80
	1	1	25,0	1	100,0	0,00	-
	2 or More	24	30,4	23	95,8	21,74	19,09
Cycle 17 Day 1	None	23	37,1	22	95,7	21,21	26,32
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	21	26,6	21	100,0	17,46	20,05
Cycle 18 Day 1	None	20	32,3	18	90,0	12,96	16,72
	1	1	25,0	1	100,0	33,33	-
	2 or More	20	25,3	18	90,0	12,96	16,72
Cycle 19 Day 1	None	17	27,4	17	100,0	11,76	16,42
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	17,78	17,21
Cycle 20 Day 1	None	17	27,4	16	94,1	12,50	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	22,22	24,12
Cycle 21 Day 1	None	15	24,2	13	86,7	15,38	17,30
	2 or More	14	17,7	13	92,9	20,51	28,99
Cycle 22 Day 1	None	15	24,2	13	86,7	12,82	16,88
	2 or More	14	17,7	12	85,7	19,44	17,16
Cycle 23 Day 1	None	10	16,1	9	90,0	11,11	16,67
	2 or More	11	13,9	9	81,8	14,81	17,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	16,1	10	100,0	13,33	23,31
	2 or More	10	12,7	8	80,0	16,67	25,20
Cycle 25 Day 1	None	9	14,5	8	88,9	8,33	15,43
	2 or More	6	7,6	5	83,3	13,33	18,26
Cycle 26 Day 1	None	8	12,9	8	100,0	12,50	17,25
	2 or More	6	7,6	4	66,7	16,67	33,33
Cycle 27 Day 1	None	7	11,3	6	85,7	22,22	27,22
	2 or More	4	5,1	2	50,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	11,3	7	100,0	19,05	26,23
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	9,7	5	83,3	26,67	27,89
	2 or More	3	3,8	2	66,7	50,00	23,57
Cycle 30 Day 1	None	4	6,5	3	75,0	22,22	19,25
	2 or More	3	3,8	2	66,7	33,33	0,00
Cycle 31 Day 1	None	4	6,5	3	75,0	22,22	19,25
	2 or More	3	3,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	22,22	19,25
	2 or More	2	2,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	1,6	1	100,0	0,00	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	24,56	21,78
	1	3	75,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	39	49,4	24	61,5	23,61	25,02
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	59	95,2	14,12	24,92
	Previously Treated	83	100,0	81	97,6	13,99	24,07
Cycle 2 Day 1	Naïve	60	96,8	53	88,3	17,61	23,21
	Previously Treated	76	91,6	71	93,4	23,94	25,31
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	14,47	19,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	72	86,7	63	87,5	20,63	24,27
Cycle 4 Day 1	Naïve	59	95,2	54	91,5	20,37	24,59
	Previously Treated	69	83,1	62	89,9	19,89	25,22
Cycle 5 Day 1	Naïve	58	93,5	54	93,1	20,37	27,79
	Previously Treated	66	79,5	61	92,4	17,49	21,61
Cycle 6 Day 1	Naïve	57	91,9	49	86,0	21,09	26,08
	Previously Treated	64	77,1	59	92,2	19,77	24,85
Cycle 7 Day 1	Naïve	52	83,9	47	90,4	21,99	24,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	61	73,5	56	91,8	19,64	24,43
Cycle 8 Day 1	Naïve	50	80,6	45	90,0	20,74	25,91
	Previously Treated	56	67,5	51	91,1	18,30	25,22
Cycle 9 Day 1	Naïve	48	77,4	46	95,8	16,67	19,56
	Previously Treated	50	60,2	49	98,0	21,09	22,25
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	17,07	21,24
	Previously Treated	46	55,4	45	97,8	20,00	23,99
Cycle 11 Day 1	Naïve	37	59,7	33	89,2	19,19	20,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	43	51,8	43	100,0	18,60	22,19
Cycle 12 Day 1	Naïve	37	59,7	32	86,5	21,88	23,36
	Previously Treated	39	47,0	35	89,7	23,81	23,67
Cycle 13 Day 1	Naïve	34	54,8	28	82,4	19,05	19,09
	Previously Treated	32	38,6	32	100,0	23,96	22,77
Cycle 14 Day 1	Naïve	31	50,0	28	90,3	19,05	21,14
	Previously Treated	29	34,9	28	96,6	21,43	22,62
Cycle 15 Day 1	Naïve	30	48,4	27	90,0	17,28	23,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	27	32,5	26	96,3	20,51	23,24
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	21,74	23,80
	Previously Treated	25	30,1	24	96,0	20,83	19,19
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	21,21	26,32
	Previously Treated	22	26,5	22	100,0	16,67	19,92
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	12,96	16,72
	Previously Treated	21	25,3	19	90,5	14,04	16,91
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	11,76	16,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	22,9	16	84,2	16,67	17,21
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	12,50	16,67
	Previously Treated	19	22,9	16	84,2	20,83	23,96
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	15,38	17,30
	Previously Treated	14	16,9	13	92,9	20,51	28,99
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	12,82	16,88
	Previously Treated	14	16,9	12	85,7	19,44	17,16
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	11,11	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	14,81	17,57
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	13,33	23,31
	Previously Treated	10	12,0	8	80,0	16,67	25,20
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	8,33	15,43
	Previously Treated	6	7,2	5	83,3	13,33	18,26
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	12,50	17,25
	Previously Treated	6	7,2	4	66,7	16,67	33,33
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	22,22	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	4,8	2	50,0	33,33	0,00
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	19,05	26,23
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	26,67	27,89
	Previously Treated	3	3,6	2	66,7	50,00	23,57
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	22,22	19,25
	Previously Treated	3	3,6	2	66,7	33,33	0,00
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	22,22	19,25
	Previously Treated	2	2,4	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	0,00	-
	Previously Treated	1	1,2	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	24,56	21,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	50,6	25	59,5	22,67	24,94
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	14,67	25,26
	Central	70	100,0	65	92,9	13,33	23,42
Cycle 2 Day 1	Local	71	94,7	67	94,4	24,88	24,17
	Central	65	92,9	57	87,7	16,96	24,50
Cycle 3 Day 1	Local	67	89,3	60	89,6	17,22	22,54

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	64	91,4	56	87,5	18,45	21,95
Cycle 4 Day 1	Local	65	86,7	58	89,2	18,39	24,32
	Central	63	90,0	58	92,1	21,84	25,40
Cycle 5 Day 1	Local	63	84,0	58	92,1	14,94	19,91
	Central	61	87,1	57	93,4	22,81	28,28
Cycle 6 Day 1	Local	63	84,0	61	96,8	20,22	24,55
	Central	58	82,9	47	81,0	20,57	26,52
Cycle 7 Day 1	Local	61	81,3	58	95,1	17,82	21,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	52	74,3	45	86,5	24,44	26,97
Cycle 8 Day 1	Local	57	76,0	54	94,7	15,43	23,98
	Central	49	70,0	42	85,7	24,60	26,61
Cycle 9 Day 1	Local	54	72,0	53	98,1	18,24	21,25
	Central	44	62,9	42	95,5	19,84	20,90
Cycle 10 Day 1	Local	48	64,0	46	95,8	15,94	23,03
	Central	41	58,6	40	97,6	21,67	22,07
Cycle 11 Day 1	Local	40	53,3	38	95,0	15,79	18,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	40	57,1	38	95,0	21,93	23,60
Cycle 12 Day 1	Local	36	48,0	33	91,7	18,18	20,57
	Central	40	57,1	34	85,0	27,45	25,25
Cycle 13 Day 1	Local	30	40,0	29	96,7	22,99	22,01
	Central	36	51,4	31	86,1	20,43	20,51
Cycle 14 Day 1	Local	27	36,0	27	100,0	22,22	24,46
	Central	33	47,1	29	87,9	18,39	19,08
Cycle 15 Day 1	Local	26	34,7	25	96,2	17,33	23,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	28	90,3	20,24	22,84
Cycle 16 Day 1	Local	24	32,0	24	100,0	18,06	19,61
	Central	26	37,1	23	88,5	24,64	22,96
Cycle 17 Day 1	Local	22	29,3	22	100,0	19,70	22,20
	Central	23	32,9	22	95,7	18,18	24,62
Cycle 18 Day 1	Local	20	26,7	19	95,0	14,04	16,91
	Central	21	30,0	18	85,7	12,96	16,72
Cycle 19 Day 1	Local	19	25,3	17	89,5	11,76	16,42

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	24,3	16	94,1	16,67	17,21
Cycle 20 Day 1	Local	19	25,3	17	89,5	15,69	20,81
	Central	17	24,3	15	88,2	17,78	21,33
Cycle 21 Day 1	Local	14	18,7	12	85,7	11,11	16,41
	Central	15	21,4	14	93,3	23,81	27,51
Cycle 22 Day 1	Local	14	18,7	12	85,7	13,89	17,16
	Central	15	21,4	13	86,7	17,95	17,30
Cycle 23 Day 1	Local	11	14,7	10	90,9	13,33	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	14,3	8	80,0	12,50	17,25
Cycle 24 Day 1	Local	11	14,7	10	90,9	10,00	16,10
	Central	9	12,9	8	88,9	20,83	30,54
Cycle 25 Day 1	Local	7	9,3	7	100,0	4,76	12,60
	Central	8	11,4	6	75,0	16,67	18,26
Cycle 26 Day 1	Local	6	8,0	6	100,0	22,22	27,22
	Central	8	11,4	6	75,0	5,56	13,61
Cycle 27 Day 1	Local	4	5,3	4	100,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	10,0	4	57,1	25,00	16,67
Cycle 28 Day 1	Local	4	5,3	4	100,0	16,67	19,25
	Central	6	8,6	5	83,3	20,00	29,81
Cycle 29 Day 1	Local	3	4,0	3	100,0	33,33	33,33
	Central	6	8,6	4	66,7	33,33	27,22
Cycle 30 Day 1	Local	3	4,0	3	100,0	22,22	19,25
	Central	4	5,7	2	50,0	33,33	0,00
Cycle 31 Day 1	Local	3	4,0	3	100,0	22,22	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	5,7	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	4,0	3	100,0	22,22	19,25
	Central	3	4,3	2	66,7	16,67	23,57
Cycle 33 Day 1	Local	1	1,3	1	100,0	0,00	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	22,22	21,23

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	32	45,7	20	62,5	25,00	26,21
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	130	96,3	13,33	24,06
	No	10	100,0	10	100,0	23,33	27,44
Cycle 2 Day 1	Yes	129	95,6	117	90,7	21,37	24,94
	No	7	70,0	7	100,0	19,05	17,82
Cycle 3 Day 1	Yes	124	91,9	110	88,7	17,58	22,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	6	85,7	22,22	17,21
Cycle 4 Day 1	Yes	121	89,6	109	90,1	19,88	24,89
	No	7	70,0	7	100,0	23,81	25,20
Cycle 5 Day 1	Yes	117	86,7	109	93,2	18,35	24,63
	No	7	70,0	6	85,7	27,78	25,09
Cycle 6 Day 1	Yes	114	84,4	101	88,6	20,13	25,85
	No	7	70,0	7	100,0	23,81	16,27
Cycle 7 Day 1	Yes	106	78,5	96	90,6	20,49	24,36

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	23,81	25,20
Cycle 8 Day 1	Yes	100	74,1	90	90,0	19,26	25,95
	No	6	60,0	6	100,0	22,22	17,21
Cycle 9 Day 1	Yes	92	68,1	89	96,7	18,73	21,29
	No	6	60,0	6	100,0	22,22	17,21
Cycle 10 Day 1	Yes	83	61,5	80	96,4	18,33	22,44
	No	6	60,0	6	100,0	22,22	27,22
Cycle 11 Day 1	Yes	76	56,3	72	94,7	18,52	21,59

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	4	40,0	4	100,0	25,00	16,67
Cycle 12 Day 1	Yes	72	53,3	63	87,5	22,22	23,19
	No	4	40,0	4	100,0	33,33	27,22
Cycle 13 Day 1	Yes	64	47,4	58	90,6	20,69	20,55
	No	2	20,0	2	100,0	50,00	23,57
Cycle 14 Day 1	Yes	58	43,0	54	93,1	18,52	20,13
	No	2	20,0	2	100,0	66,67	0,00
Cycle 15 Day 1	Yes	55	40,7	51	92,7	16,99	21,47

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	66,67	0,00
Cycle 16 Day 1	Yes	48	35,6	45	93,8	20,74	20,46
	No	2	20,0	2	100,0	33,33	47,14
Cycle 17 Day 1	Yes	43	31,9	42	97,7	16,67	21,15
	No	2	20,0	2	100,0	66,67	0,00
Cycle 18 Day 1	Yes	39	28,9	35	89,7	13,33	16,57
	No	2	20,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	13,54	16,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	1	50,0	33,33	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	15,56	19,04
	No	2	20,0	2	100,0	33,33	47,14
Cycle 21 Day 1	Yes	27	20,0	24	88,9	13,89	16,79
	No	2	20,0	2	100,0	66,67	47,14
Cycle 22 Day 1	Yes	27	20,0	23	85,2	14,49	16,90
	No	2	20,0	2	100,0	33,33	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	13,73	16,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	15,69	23,91
	No	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	10,4	12	85,7	11,11	16,41
	No	1	10,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	12,12	22,47
	No	1	10,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	19,05	17,82

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	66,67	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	16,67	25,20
	No	1	10,0	1	100,0	33,33	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	27,78	25,09
	No	1	10,0	1	100,0	66,67	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	25,00	16,67
	No	1	10,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	25,00	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	33,33	-
Cycle 32 Day 1	Yes	5	3,7	4	80,0	16,67	19,25
	No	1	10,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	23,26	23,61
	No	2	20,0	1	50,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	33,33	33,33
	No	134	100,0	129	96,3	12,40	22,85
Cycle 2 Day 1	Yes	7	63,6	7	100,0	23,81	25,20
	No	129	96,3	117	90,7	21,08	24,60
Cycle 3 Day 1	Yes	7	63,6	6	85,7	27,78	25,09
	No	124	92,5	110	88,7	17,27	22,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	7	63,6	7	100,0	42,86	25,20
	No	121	90,3	109	90,1	18,65	24,19
Cycle 5 Day 1	Yes	7	63,6	7	100,0	28,57	29,99
	No	117	87,3	108	92,3	18,21	24,28
Cycle 6 Day 1	Yes	7	63,6	7	100,0	23,81	25,20
	No	114	85,1	101	88,6	20,13	25,42
Cycle 7 Day 1	Yes	7	63,6	7	100,0	19,05	26,23
	No	106	79,1	96	90,6	20,83	24,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	7	63,6	7	100,0	19,05	17,82
	No	99	73,9	89	89,9	19,48	26,02
Cycle 9 Day 1	Yes	6	54,5	6	100,0	22,22	17,21
	No	92	68,7	89	96,7	18,73	21,29
Cycle 10 Day 1	Yes	6	54,5	6	100,0	16,67	18,26
	No	83	61,9	80	96,4	18,75	23,02
Cycle 11 Day 1	Yes	6	54,5	6	100,0	16,67	27,89
	No	74	55,2	70	94,6	19,05	20,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	6	54,5	6	100,0	22,22	17,21
	No	70	52,2	61	87,1	22,95	23,99
Cycle 13 Day 1	Yes	5	45,5	5	100,0	20,00	18,26
	No	61	45,5	55	90,2	21,82	21,49
Cycle 14 Day 1	Yes	5	45,5	5	100,0	20,00	18,26
	No	55	41,0	51	92,7	20,26	22,19
Cycle 15 Day 1	Yes	4	36,4	4	100,0	16,67	19,25
	No	53	39,6	49	92,5	19,05	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	47	35,1	44	93,6	21,97	21,50
Cycle 17 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	42	31,3	41	97,6	19,51	23,54
Cycle 18 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	38	28,4	34	89,5	13,73	16,65
Cycle 19 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	33	24,6	30	90,9	14,44	16,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	33	24,6	29	87,9	17,24	21,12
Cycle 21 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	27	20,1	24	88,9	18,06	24,04
Cycle 22 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	27	20,1	23	85,2	15,94	17,03
Cycle 23 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	19	14,2	16	84,2	12,50	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	18,2	2	100,0	33,33	47,14
	No	18	13,4	16	88,9	12,50	20,64
Cycle 25 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	13	9,7	11	84,6	9,09	15,57
Cycle 26 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	13	9,7	11	84,6	12,12	22,47
Cycle 27 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	10	7,5	7	70,0	23,81	25,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	66,67	-
	No	9	6,7	8	88,9	12,50	17,25
Cycle 29 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	8	6,0	6	75,0	33,33	29,81
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	26,67	14,91
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	26,67	14,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	20,00	18,26
Cycle 33 Day 1	No	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	22,22	19,25
	No	61	45,5	41	67,2	23,58	23,86

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PN_SG.xls
24JUN2020 21:07

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	139	95,9	24,94	24,77
Cycle 2 Day 1	All	136	93,8	124	91,2	22,04	23,62
Cycle 3 Day 1	All	131	90,3	116	88,5	16,67	22,20
Cycle 4 Day 1	All	128	88,3	116	90,6	17,53	23,45
Cycle 5 Day 1	All	124	85,5	115	92,7	17,68	24,31
Cycle 6 Day 1	All	121	83,4	108	89,3	15,12	20,58
Cycle 7 Day 1	All	113	77,9	103	91,2	18,45	24,13

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	106	73,1	96	90,6	14,93	18,65
Cycle 9 Day 1	All	98	67,6	95	96,9	17,19	24,24
Cycle 10 Day 1	All	89	61,4	86	96,6	15,89	22,13
Cycle 11 Day 1	All	80	55,2	76	95,0	17,98	22,07
Cycle 12 Day 1	All	76	52,4	68	89,5	20,10	27,10
Cycle 13 Day 1	All	66	45,5	60	90,9	18,33	23,31
Cycle 14 Day 1	All	60	41,4	56	93,3	21,43	28,02
Cycle 15 Day 1	All	57	39,3	53	93,0	16,35	22,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	50	34,5	47	94,0	21,99	23,34
Cycle 17 Day 1	All	45	31,0	44	97,8	21,97	25,86
Cycle 18 Day 1	All	41	28,3	37	90,2	20,72	22,70
Cycle 19 Day 1	All	36	24,8	33	91,7	20,20	24,92
Cycle 20 Day 1	All	36	24,8	32	88,9	19,79	23,74
Cycle 21 Day 1	All	29	20,0	26	89,7	26,92	24,98
Cycle 22 Day 1	All	29	20,0	25	86,2	26,67	28,87
Cycle 23 Day 1	All	21	14,5	18	85,7	31,48	26,75

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	13,8	18	90,0	24,07	25,06
Cycle 25 Day 1	All	15	10,3	13	86,7	25,64	19,97
Cycle 26 Day 1	All	14	9,7	12	85,7	19,44	17,16
Cycle 27 Day 1	All	11	7,6	8	72,7	33,33	35,63
Cycle 28 Day 1	All	10	6,9	9	90,0	14,81	17,57
Cycle 29 Day 1	All	9	6,2	7	77,8	23,81	25,20
Cycle 30 Day 1	All	7	4,8	5	71,4	33,33	23,57
Cycle 31 Day 1	All	7	4,8	5	71,4	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	4,1	5	83,3	20,00	18,26
Cycle 33 Day 1	All	2	1,4	2	100,0	16,67	23,57
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	29,55	21,82
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	22,22	28,02

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	93	100,0	88	94,6	26,52	22,69
Cycle 2 Day 1	Male	50	96,2	46	92,0	25,36	24,53
	Female	86	92,5	78	90,7	20,09	23,01
Cycle 3 Day 1	Male	47	90,4	43	91,5	16,28	21,05
	Female	84	90,3	73	86,9	16,89	22,99
Cycle 4 Day 1	Male	46	88,5	43	93,5	16,28	21,05
	Female	82	88,2	73	89,0	18,26	24,87
Cycle 5 Day 1	Male	45	86,5	42	93,3	18,25	22,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	79	84,9	73	92,4	17,35	25,53
Cycle 6 Day 1	Male	45	86,5	41	91,1	14,63	19,79
	Female	76	81,7	67	88,2	15,42	21,18
Cycle 7 Day 1	Male	40	76,9	39	97,5	19,66	23,84
	Female	73	78,5	64	87,7	17,71	24,47
Cycle 8 Day 1	Male	37	71,2	34	91,9	15,69	16,89
	Female	69	74,2	62	89,9	14,52	19,67
Cycle 9 Day 1	Male	33	63,5	33	100,0	14,14	20,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	62	95,4	18,82	26,05
Cycle 10 Day 1	Male	30	57,7	30	100,0	16,67	20,99
	Female	59	63,4	56	94,9	15,48	22,89
Cycle 11 Day 1	Male	29	55,8	28	96,6	15,48	19,21
	Female	51	54,8	48	94,1	19,44	23,65
Cycle 12 Day 1	Male	27	51,9	26	96,3	16,67	23,57
	Female	49	52,7	42	85,7	22,22	29,14
Cycle 13 Day 1	Male	25	48,1	23	92,0	14,49	16,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	41	44,1	37	90,2	20,72	26,47
Cycle 14 Day 1	Male	23	44,2	21	91,3	22,22	30,43
	Female	37	39,8	35	94,6	20,95	26,92
Cycle 15 Day 1	Male	21	40,4	20	95,2	11,67	16,31
	Female	36	38,7	33	91,7	19,19	25,04
Cycle 16 Day 1	Male	16	30,8	16	100,0	27,08	25,00
	Female	34	36,6	31	91,2	19,35	22,40
Cycle 17 Day 1	Male	13	25,0	13	100,0	25,64	19,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	32	34,4	31	96,9	20,43	28,12
Cycle 18 Day 1	Male	12	23,1	11	91,7	24,24	21,56
	Female	29	31,2	26	89,7	19,23	23,42
Cycle 19 Day 1	Male	10	19,2	10	100,0	23,33	22,50
	Female	26	28,0	23	88,5	18,84	26,26
Cycle 20 Day 1	Male	10	19,2	9	90,0	22,22	23,57
	Female	26	28,0	23	88,5	18,84	24,26
Cycle 21 Day 1	Male	8	15,4	8	100,0	25,00	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	22,6	18	85,7	27,78	26,20
Cycle 22 Day 1	Male	8	15,4	6	75,0	22,22	27,22
	Female	21	22,6	19	90,5	28,07	29,94
Cycle 23 Day 1	Male	5	9,6	4	80,0	33,33	0,00
	Female	16	17,2	14	87,5	30,95	30,56
Cycle 24 Day 1	Male	5	9,6	4	80,0	25,00	16,67
	Female	15	16,1	14	93,3	23,81	27,51
Cycle 25 Day 1	Male	3	5,8	2	66,7	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	12,9	11	91,7	27,27	20,10
Cycle 26 Day 1	Male	3	5,8	2	66,7	16,67	23,57
	Female	11	11,8	10	90,9	20,00	17,21
Cycle 27 Day 1	Male	3	5,8	2	66,7	16,67	23,57
	Female	8	8,6	6	75,0	38,89	38,97
Cycle 28 Day 1	Male	2	3,8	2	100,0	16,67	23,57
	Female	8	8,6	7	87,5	14,29	17,82
Cycle 29 Day 1	Male	1	1,9	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	8,6	6	75,0	22,22	27,22
Cycle 30 Day 1	Male	1	1,9	1	100,0	33,33	-
	Female	6	6,5	4	66,7	33,33	27,22
Cycle 31 Day 1	Male	1	1,9	1	100,0	33,33	-
	Female	6	6,5	4	66,7	33,33	0,00
Cycle 32 Day 1	Male	1	1,9	1	100,0	33,33	-
	Female	5	5,4	4	80,0	16,67	19,25
Cycle 33 Day 1	Male	1	1,9	1	100,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	1,1	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	25,40	20,83
	Female	37	39,8	23	62,2	33,33	22,47
Age							
Cycle 1 Day 1	18-64	109	100,0	104	95,4	27,56	24,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	28	96,6	19,05	26,34
	>=75	7	100,0	7	100,0	9,52	16,27
Cycle 2 Day 1	18-64	103	94,5	91	88,3	25,64	23,87
	65-74	26	89,7	26	100,0	14,10	21,44
	>=75	7	100,0	7	100,0	4,76	12,60
Cycle 3 Day 1	18-64	99	90,8	87	87,9	17,62	23,21
	65-74	25	86,2	23	92,0	11,59	19,09
	>=75	7	100,0	6	85,7	22,22	17,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	98	89,9	88	89,8	19,70	24,57
	65-74	23	79,3	21	91,3	11,11	19,25
	>=75	7	100,0	7	100,0	9,52	16,27
Cycle 5 Day 1	18-64	95	87,2	88	92,6	18,56	25,70
	65-74	22	75,9	22	100,0	15,15	19,86
	>=75	7	100,0	5	71,4	13,33	18,26
Cycle 6 Day 1	18-64	92	84,4	80	87,0	15,42	21,83
	65-74	22	75,9	21	95,5	15,87	17,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	9,52	16,27
Cycle 7 Day 1	18-64	86	78,9	78	90,7	19,23	24,33
	65-74	20	69,0	19	95,0	14,04	23,08
	>=75	7	100,0	6	85,7	22,22	27,22
Cycle 8 Day 1	18-64	80	73,4	71	88,8	16,43	19,41
	65-74	19	65,5	19	100,0	10,53	15,92
	>=75	7	100,0	6	85,7	11,11	17,21
Cycle 9 Day 1	18-64	74	67,9	72	97,3	15,74	23,05

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	18	62,1	18	100,0	22,22	28,01
	>=75	6	85,7	5	83,3	20,00	29,81
Cycle 10 Day 1	18-64	69	63,3	66	95,7	16,16	20,46
	65-74	15	51,7	15	100,0	15,56	30,52
	>=75	5	71,4	5	100,0	13,33	18,26
Cycle 11 Day 1	18-64	61	56,0	58	95,1	18,39	20,87
	65-74	15	51,7	14	93,3	19,05	28,39
	>=75	4	57,1	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	57	52,3	50	87,7	20,00	26,94
	65-74	15	51,7	14	93,3	19,05	28,39
	>=75	4	57,1	4	100,0	25,00	31,91
Cycle 13 Day 1	18-64	49	45,0	45	91,8	19,26	21,89
	65-74	13	44,8	11	84,6	18,18	31,14
	>=75	4	57,1	4	100,0	8,33	16,67
Cycle 14 Day 1	18-64	45	41,3	43	95,6	22,48	26,94
	65-74	13	44,8	11	84,6	15,15	31,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	28,6	2	100,0	33,33	47,14
Cycle 15 Day 1	18-64	43	39,4	40	93,0	17,50	22,63
	65-74	12	41,4	11	91,7	12,12	22,47
	>=75	2	28,6	2	100,0	16,67	23,57
Cycle 16 Day 1	18-64	38	34,9	36	94,7	22,22	23,90
	65-74	10	34,5	9	90,0	18,52	17,57
	>=75	2	28,6	2	100,0	33,33	47,14
Cycle 17 Day 1	18-64	36	33,0	35	97,2	22,86	25,27

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	27,6	8	100,0	12,50	24,80
	>=75	1	14,3	1	100,0	66,67	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	20,00	22,49
	65-74	7	24,1	6	85,7	16,67	18,26
	>=75	1	14,3	1	100,0	66,67	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	20,24	24,58
	65-74	5	17,2	4	80,0	8,33	16,67
	>=75	1	14,3	1	100,0	66,67	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	20,51	25,08
	65-74	5	17,2	5	100,0	13,33	18,26
	>=75	1	14,3	1	100,0	33,33	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	26,98	24,99
	65-74	4	13,8	4	100,0	16,67	19,25
	>=75	1	14,3	1	100,0	66,67	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	25,00	28,36
	65-74	4	13,8	4	100,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	66,67	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	33,33	27,22
	65-74	2	6,9	2	100,0	16,67	23,57
Cycle 24 Day 1	18-64	18	16,5	16	88,9	27,08	25,00
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	12,8	12	85,7	27,78	19,25
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	19,44	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	33,33	35,63
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	14,81	17,57
	65-74	1	3,4	0	0,0	-	-
Cycle 29 Day 1	18-64	8	7,3	7	87,5	23,81	25,20
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	33,33	0,00
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	25,00	16,67
	65-74	1	3,4	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	33,33	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	31,37	20,00
	65-74	15	51,7	8	53,3	20,83	24,80
	>=75	4	57,1	2	50,0	33,33	47,14
Race							
Cycle 1 Day 1	White	60	100,0	56	93,3	27,98	26,80
	Other	85	100,0	83	97,6	22,89	23,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	57	95,0	50	87,7	21,33	24,98
	Other	79	92,9	74	93,7	22,52	22,82
Cycle 3 Day 1	White	54	90,0	44	81,5	16,67	23,29
	Other	77	90,6	72	93,5	16,67	21,67
Cycle 4 Day 1	White	53	88,3	45	84,9	15,56	20,84
	Other	75	88,2	71	94,7	18,78	25,03
Cycle 5 Day 1	White	52	86,7	47	90,4	15,60	24,92
	Other	72	84,7	68	94,4	19,12	23,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	50	83,3	41	82,0	14,63	18,33
	Other	71	83,5	67	94,4	15,42	21,96
Cycle 7 Day 1	White	47	78,3	40	85,1	19,17	24,91
	Other	66	77,6	63	95,5	17,99	23,82
Cycle 8 Day 1	White	45	75,0	38	84,4	16,67	21,57
	Other	61	71,8	58	95,1	13,79	16,56
Cycle 9 Day 1	White	42	70,0	41	97,6	18,70	27,94
	Other	56	65,9	54	96,4	16,05	21,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	19,66	25,04
	Other	48	56,5	47	97,9	12,77	19,10
Cycle 11 Day 1	White	37	61,7	36	97,3	21,30	25,39
	Other	43	50,6	40	93,0	15,00	18,41
Cycle 12 Day 1	White	37	61,7	33	89,2	25,25	31,21
	Other	39	45,9	35	89,7	15,24	21,91
Cycle 13 Day 1	White	32	53,3	30	93,8	21,11	28,34
	Other	34	40,0	30	88,2	15,56	16,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	31	51,7	30	96,8	23,33	30,51
	Other	29	34,1	26	89,7	19,23	25,25
Cycle 15 Day 1	White	30	50,0	28	93,3	19,05	24,73
	Other	27	31,8	25	92,6	13,33	19,25
Cycle 16 Day 1	White	26	43,3	24	92,3	25,00	26,47
	Other	24	28,2	23	95,8	18,84	19,66
Cycle 17 Day 1	White	24	40,0	24	100,0	25,00	29,90
	Other	21	24,7	20	95,2	18,33	20,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	22	36,7	19	86,4	21,05	27,69
	Other	19	22,4	18	94,7	20,37	16,72
Cycle 19 Day 1	White	20	33,3	20	100,0	25,00	28,36
	Other	16	18,8	13	81,3	12,82	16,88
Cycle 20 Day 1	White	20	33,3	17	85,0	19,61	26,51
	Other	16	18,8	15	93,8	20,00	21,08
Cycle 21 Day 1	White	16	26,7	14	87,5	33,33	29,24
	Other	13	15,3	12	92,3	19,44	17,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	26,7	13	81,3	30,77	34,59
	Other	13	15,3	12	92,3	22,22	21,71
Cycle 23 Day 1	White	12	20,0	10	83,3	43,33	27,44
	Other	9	10,6	8	88,9	16,67	17,82
Cycle 24 Day 1	White	11	18,3	10	90,9	33,33	27,22
	Other	9	10,6	8	88,9	12,50	17,25
Cycle 25 Day 1	White	10	16,7	8	80,0	20,83	17,25
	Other	5	5,9	5	100,0	33,33	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	16,7	8	80,0	12,50	17,25
	Other	4	4,7	4	100,0	33,33	0,00
Cycle 27 Day 1	White	8	13,3	5	62,5	33,33	40,82
	Other	3	3,5	3	100,0	33,33	33,33
Cycle 28 Day 1	White	7	11,7	6	85,7	16,67	18,26
	Other	3	3,5	3	100,0	11,11	19,25
Cycle 29 Day 1	White	6	10,0	4	66,7	16,67	19,25
	Other	3	3,5	3	100,0	33,33	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	6,7	2	50,0	16,67	23,57
	Other	3	3,5	3	100,0	44,44	19,25
Cycle 31 Day 1	White	4	6,7	2	50,0	33,33	0,00
	Other	3	3,5	3	100,0	33,33	0,00
Cycle 32 Day 1	White	4	6,7	3	75,0	11,11	19,25
	Other	2	2,4	2	100,0	33,33	0,00
Cycle 33 Day 1	White	2	3,3	2	100,0	16,67	23,57
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-
End Of Treatment	White	25	41,7	17	68,0	33,33	23,57
	Other	39	45,9	27	69,2	27,16	20,75
Region							
Cycle 1 Day 1	America (AM)	40	100,0	38	95,0	22,81	23,39
	Europe (EU)	34	100,0	30	88,2	32,22	26,96
	Asia (AS)	71	100,0	71	100,0	23,00	24,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	25,00	22,40
	Europe (EU)	32	94,1	27	84,4	22,22	26,15
	Asia (AS)	66	93,0	65	98,5	20,51	23,34
Cycle 3 Day 1	America (AM)	37	92,5	32	86,5	17,71	23,92
	Europe (EU)	31	91,2	21	67,7	15,87	27,12
	Asia (AS)	63	88,7	63	100,0	16,40	19,74
Cycle 4 Day 1	America (AM)	37	92,5	32	86,5	14,58	20,63
	Europe (EU)	30	88,2	24	80,0	20,83	25,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	61	85,9	60	98,4	17,78	24,14
Cycle 5 Day 1	America (AM)	37	92,5	33	89,2	18,18	25,13
	Europe (EU)	30	88,2	25	83,3	13,33	23,57
	Asia (AS)	57	80,3	57	100,0	19,30	24,35
Cycle 6 Day 1	America (AM)	37	92,5	32	86,5	13,54	20,49
	Europe (EU)	28	82,4	24	85,7	15,28	19,61
	Asia (AS)	56	78,9	52	92,9	16,03	21,38
Cycle 7 Day 1	America (AM)	35	87,5	29	82,9	12,64	18,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	28	82,4	25	89,3	20,00	27,22
	Asia (AS)	50	70,4	49	98,0	21,09	25,18
Cycle 8 Day 1	America (AM)	31	77,5	26	83,9	19,23	23,42
	Europe (EU)	28	82,4	23	82,1	14,49	16,90
	Asia (AS)	47	66,2	47	100,0	12,77	16,38
Cycle 9 Day 1	America (AM)	29	72,5	27	93,1	20,99	26,39
	Europe (EU)	26	76,5	25	96,2	18,67	30,55
	Asia (AS)	43	60,6	43	100,0	13,95	18,16

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	19,44	23,91
	Europe (EU)	25	73,5	25	100,0	20,00	27,22
	Asia (AS)	37	52,1	37	100,0	10,81	15,82
Cycle 11 Day 1	America (AM)	24	60,0	21	87,5	17,46	20,05
	Europe (EU)	23	67,6	22	95,7	19,70	28,47
	Asia (AS)	33	46,5	33	100,0	17,17	18,86
Cycle 12 Day 1	America (AM)	24	60,0	22	91,7	15,15	26,68
	Europe (EU)	23	67,6	18	78,3	27,78	32,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	40,8	28	96,6	19,05	23,00
Cycle 13 Day 1	America (AM)	23	57,5	21	91,3	15,87	24,99
	Europe (EU)	18	52,9	14	77,8	26,19	29,75
	Asia (AS)	25	35,2	25	100,0	16,00	17,00
Cycle 14 Day 1	America (AM)	22	55,0	20	90,9	18,33	27,52
	Europe (EU)	17	50,0	16	94,1	31,25	35,42
	Asia (AS)	21	29,6	20	95,2	16,67	20,23
Cycle 15 Day 1	America (AM)	22	55,0	19	86,4	19,30	25,62

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	44,1	14	93,3	16,67	21,68
	Asia (AS)	20	28,2	20	100,0	13,33	19,94
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	21,57	28,73
	Europe (EU)	14	41,2	11	78,6	24,24	21,56
	Asia (AS)	19	26,8	19	100,0	21,05	19,91
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	25,00	33,33
	Europe (EU)	13	38,2	12	92,3	19,44	22,29
	Asia (AS)	16	22,5	16	100,0	20,83	20,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	19,05	28,39
	Europe (EU)	11	32,4	7	63,6	23,81	25,20
	Asia (AS)	16	22,5	16	100,0	20,83	16,67
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	20,51	32,03
	Europe (EU)	9	26,5	9	100,0	25,93	22,22
	Asia (AS)	14	19,7	11	78,6	15,15	17,41
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	23,08	31,58
	Europe (EU)	9	26,5	6	66,7	16,67	18,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	17,95	17,30
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	26,67	30,63
	Europe (EU)	7	20,6	6	85,7	33,33	29,81
	Asia (AS)	11	15,5	10	90,9	23,33	16,10
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	20,00	35,83
	Europe (EU)	7	20,6	5	71,4	33,33	33,33
	Asia (AS)	11	15,5	10	90,9	30,00	18,92
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	40,74	27,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	14,7	3	60,0	33,33	33,33
	Asia (AS)	7	9,9	6	85,7	16,67	18,26
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	25,00	23,57
	Europe (EU)	5	14,7	4	80,0	33,33	38,49
	Asia (AS)	7	9,9	6	85,7	16,67	18,26
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	28,57	12,60
	Europe (EU)	4	11,8	2	50,0	16,67	23,57
	Asia (AS)	4	5,6	4	100,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	11,11	17,21
	Europe (EU)	4	11,8	2	50,0	16,67	23,57
	Asia (AS)	4	5,6	4	100,0	33,33	0,00
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	33,33	47,14
	Europe (EU)	3	8,8	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	33,33	27,22
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	16,67	19,25
	Europe (EU)	2	5,9	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	16,67	19,25
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	11,11	19,25
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	33,33	27,22
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	44,44	19,25
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	33,33	0,00
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	16,67	23,57
	Europe (EU)	1	2,9	1	100,0	0,00	-
	Asia (AS)	3	4,2	2	66,7	33,33	0,00
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	33,33	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	31,37	21,96
	Europe (EU)	10	29,4	5	50,0	46,67	18,26
	Asia (AS)	34	47,9	22	64,7	24,24	21,04
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	58	95,1	16,67	16,81
	1	69	100,0	66	95,7	29,29	27,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	15	100,0	15	100,0	37,78	30,52
Cycle 2 Day 1	0	59	96,7	55	93,2	21,82	21,49
	1	67	97,1	59	88,1	22,60	24,32
	2	10	66,7	10	100,0	20,00	32,20
Cycle 3 Day 1	0	57	93,4	50	87,7	17,33	24,50
	1	65	94,2	57	87,7	15,79	17,93
	2	9	60,0	9	100,0	18,52	33,79
Cycle 4 Day 1	0	57	93,4	51	89,5	14,38	23,34

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	57	91,9	18,71	20,91
	2	9	60,0	8	88,9	29,17	37,53
Cycle 5 Day 1	0	56	91,8	52	92,9	17,31	25,98
	1	62	89,9	57	91,9	19,30	23,53
	2	6	40,0	6	100,0	5,56	13,61
Cycle 6 Day 1	0	56	91,8	53	94,6	13,21	18,88
	1	59	85,5	51	86,4	17,65	22,46
	2	6	40,0	4	66,7	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	54	88,5	51	94,4	16,34	25,27
	1	54	78,3	47	87,0	21,99	23,34
	2	5	33,3	5	100,0	6,67	14,91
Cycle 8 Day 1	0	52	85,2	48	92,3	16,67	20,63
	1	49	71,0	43	87,8	14,73	16,75
	2	5	33,3	5	100,0	0,00	0,00
Cycle 9 Day 1	0	50	82,0	49	98,0	18,37	23,63
	1	44	63,8	42	95,5	16,67	25,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	4	26,7	4	100,0	8,33	16,67
Cycle 10 Day 1	0	46	75,4	46	100,0	15,22	21,89
	1	40	58,0	37	92,5	17,12	23,07
	2	3	20,0	3	100,0	11,11	19,25
Cycle 11 Day 1	0	43	70,5	40	93,0	20,83	24,68
	1	34	49,3	33	97,1	16,16	18,86
	2	3	20,0	3	100,0	0,00	0,00
Cycle 12 Day 1	0	42	68,9	36	85,7	21,30	27,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	31	44,9	29	93,5	20,69	27,33
	2	3	20,0	3	100,0	0,00	0,00
Cycle 13 Day 1	0	38	62,3	34	89,5	18,63	26,20
	1	27	39,1	25	92,6	18,67	19,44
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	23,96	31,94
	1	24	34,8	23	95,8	18,84	22,08
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	33	54,1	30	90,9	18,89	25,80
	1	23	33,3	22	95,7	13,64	16,77
	2	1	6,7	1	100,0	0,00	-
Cycle 16 Day 1	0	28	45,9	25	89,3	24,00	24,57
	1	21	30,4	21	100,0	20,63	22,30
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	21,74	25,84
	1	20	29,0	20	100,0	23,33	26,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	22,81	24,98
	1	17	24,6	17	100,0	19,61	20,61
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	22,81	27,34
	1	15	21,7	13	86,7	17,95	22,01
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	23,53	28,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	21,7	14	93,3	16,67	17,30
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	28,57	28,81
	1	13	18,8	11	84,6	27,27	20,10
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	25,00	32,18
	1	13	18,8	12	92,3	30,56	26,43
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	40,74	27,78
	1	9	13,0	8	88,9	25,00	23,57
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	22,22	23,57
	1	9	13,0	8	88,9	29,17	27,82
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	16,67	18,26
	1	7	10,1	7	100,0	33,33	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	13,1	6	75,0	16,67	18,26
	1	6	8,7	6	100,0	22,22	17,21
Cycle 27 Day 1	0	6	9,8	3	50,0	22,22	19,25
	1	5	7,2	5	100,0	40,00	43,46
Cycle 28 Day 1	0	5	8,2	4	80,0	16,67	19,25
	1	5	7,2	5	100,0	13,33	18,26
Cycle 29 Day 1	0	4	6,6	2	50,0	33,33	0,00
	1	5	7,2	5	100,0	20,00	29,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	4,9	1	33,3	33,33	-
	1	4	5,8	4	100,0	33,33	27,22
Cycle 31 Day 1	0	3	4,9	1	33,3	33,33	-
	1	4	5,8	4	100,0	33,33	0,00
Cycle 32 Day 1	0	3	4,9	2	66,7	16,67	23,57
	1	3	4,3	3	100,0	22,22	19,25
Cycle 33 Day 1	0	2	3,3	2	100,0	16,67	23,57
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	28,57	24,23
	1	34	49,3	20	58,8	31,67	20,16
	2	7	46,7	3	42,9	22,22	19,25
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	59	95,2	22,03	23,66
	1	4	100,0	4	100,0	33,33	38,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	79	100,0	76	96,2	26,75	24,96
Cycle 2 Day 1	None	60	96,8	53	88,3	23,27	24,09
	1	3	75,0	2	66,7	16,67	23,57
	2 or More	73	92,4	69	94,5	21,26	23,55
Cycle 3 Day 1	None	59	95,2	53	89,8	15,72	21,29
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	69	87,3	61	88,4	18,03	23,23
Cycle 4 Day 1	None	59	95,2	54	91,5	16,67	22,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	66	83,5	60	90,9	18,89	24,83
Cycle 5 Day 1	None	58	93,5	54	93,1	15,43	23,09
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	63	79,7	58	92,1	20,69	25,61
Cycle 6 Day 1	None	57	91,9	49	86,0	14,29	20,41
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	61	77,2	56	91,8	16,67	21,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	52	83,9	47	90,4	12,77	21,48
	1	3	75,0	3	100,0	11,11	19,25
	2 or More	58	73,4	53	91,4	23,90	25,63
Cycle 8 Day 1	None	50	80,6	45	90,0	15,56	16,82
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	14,67	20,38
Cycle 9 Day 1	None	48	77,4	46	95,8	15,22	22,99
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	19,44	25,57
Cycle 10 Day 1	None	43	69,4	41	95,3	15,45	21,21
	1	1	25,0	1	100,0	0,00	-
	2 or More	45	57,0	44	97,8	16,67	23,29
Cycle 11 Day 1	None	37	59,7	33	89,2	14,14	16,73
	1	1	25,0	1	100,0	0,00	-
	2 or More	42	53,2	42	100,0	21,43	25,31
Cycle 12 Day 1	None	37	59,7	33	89,2	10,10	17,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	38	48,1	34	89,5	30,39	31,10
Cycle 13 Day 1	None	34	54,8	28	82,4	13,10	16,58
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	23,66	27,48
Cycle 14 Day 1	None	31	50,0	28	90,3	16,67	24,85
	1	1	25,0	1	100,0	0,00	-
	2 or More	28	35,4	27	96,4	27,16	30,71

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	30	48,4	27	90,0	14,81	19,25
	1	1	25,0	1	100,0	0,00	-
	2 or More	26	32,9	25	96,2	18,67	25,60
Cycle 16 Day 1	None	25	40,3	23	92,0	18,84	22,08
	1	1	25,0	1	100,0	0,00	-
	2 or More	24	30,4	23	95,8	26,09	24,53
Cycle 17 Day 1	None	23	37,1	22	95,7	13,64	16,77
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	21	26,6	21	100,0	31,75	30,69
Cycle 18 Day 1	None	20	32,3	18	90,0	16,67	17,15
	1	1	25,0	1	100,0	0,00	-
	2 or More	20	25,3	18	90,0	25,93	26,95
Cycle 19 Day 1	None	17	27,4	17	100,0	9,80	15,66
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	33,33	28,17
Cycle 20 Day 1	None	17	27,4	16	94,1	14,58	17,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	26,67	28,73
Cycle 21 Day 1	None	15	24,2	13	86,7	17,95	17,30
	2 or More	14	17,7	13	92,9	35,90	28,74
Cycle 22 Day 1	None	15	24,2	13	86,7	12,82	21,68
	2 or More	14	17,7	12	85,7	41,67	28,87
Cycle 23 Day 1	None	10	16,1	9	90,0	29,63	20,03
	2 or More	11	13,9	9	81,8	33,33	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	16,1	10	100,0	23,33	22,50
	2 or More	10	12,7	8	80,0	25,00	29,55
Cycle 25 Day 1	None	9	14,5	8	88,9	29,17	21,36
	2 or More	6	7,6	5	83,3	20,00	18,26
Cycle 26 Day 1	None	8	12,9	8	100,0	16,67	17,82
	2 or More	6	7,6	4	66,7	25,00	16,67
Cycle 27 Day 1	None	7	11,3	6	85,7	38,89	38,97
	2 or More	4	5,1	2	50,0	16,67	23,57

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	11,3	7	100,0	14,29	17,82
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 29 Day 1	None	6	9,7	5	83,3	26,67	27,89
	2 or More	3	3,8	2	66,7	16,67	23,57
Cycle 30 Day 1	None	4	6,5	3	75,0	22,22	19,25
	2 or More	3	3,8	2	66,7	50,00	23,57
Cycle 31 Day 1	None	4	6,5	3	75,0	33,33	0,00
	2 or More	3	3,8	2	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	22,22	19,25
	2 or More	2	2,5	2	100,0	16,67	23,57
Cycle 33 Day 1	None	1	1,6	1	100,0	33,33	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	33,33	19,25
	1	3	75,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	39	49,4	24	61,5	27,78	23,40
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	59	95,2	22,03	23,66
	Previously Treated	83	100,0	80	96,4	27,08	25,49
Cycle 2 Day 1	Naïve	60	96,8	53	88,3	23,27	24,09
	Previously Treated	76	91,6	71	93,4	21,13	23,39
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	15,72	21,29

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	72	86,7	63	87,5	17,46	23,08
Cycle 4 Day 1	Naïve	59	95,2	54	91,5	16,67	22,20
	Previously Treated	69	83,1	62	89,9	18,28	24,65
Cycle 5 Day 1	Naïve	58	93,5	54	93,1	15,43	23,09
	Previously Treated	66	79,5	61	92,4	19,67	25,37
Cycle 6 Day 1	Naïve	57	91,9	49	86,0	14,29	20,41
	Previously Treated	64	77,1	59	92,2	15,82	20,86
Cycle 7 Day 1	Naïve	52	83,9	47	90,4	12,77	21,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	61	73,5	56	91,8	23,21	25,36
Cycle 8 Day 1	Naïve	50	80,6	45	90,0	15,56	16,82
	Previously Treated	56	67,5	51	91,1	14,38	20,28
Cycle 9 Day 1	Naïve	48	77,4	46	95,8	15,22	22,99
	Previously Treated	50	60,2	49	98,0	19,05	25,46
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	15,45	21,21
	Previously Treated	46	55,4	45	97,8	16,30	23,16
Cycle 11 Day 1	Naïve	37	59,7	33	89,2	14,14	16,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	43	51,8	43	100,0	20,93	25,22
Cycle 12 Day 1	Naïve	37	59,7	33	89,2	10,10	17,65
	Previously Treated	39	47,0	35	89,7	29,52	31,07
Cycle 13 Day 1	Naïve	34	54,8	28	82,4	13,10	16,58
	Previously Treated	32	38,6	32	100,0	22,92	27,35
Cycle 14 Day 1	Naïve	31	50,0	28	90,3	16,67	24,85
	Previously Treated	29	34,9	28	96,6	26,19	30,57
Cycle 15 Day 1	Naïve	30	48,4	27	90,0	14,81	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	27	32,5	26	96,3	17,95	25,35
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	18,84	22,08
	Previously Treated	25	30,1	24	96,0	25,00	24,57
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	13,64	16,77
	Previously Treated	22	26,5	22	100,0	30,30	30,70
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	16,67	17,15
	Previously Treated	21	25,3	19	90,5	24,56	26,86
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	9,80	15,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	22,9	16	84,2	31,25	28,46
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	14,58	17,08
	Previously Treated	19	22,9	16	84,2	25,00	28,54
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	17,95	17,30
	Previously Treated	14	16,9	13	92,9	35,90	28,74
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	12,82	21,68
	Previously Treated	14	16,9	12	85,7	41,67	28,87
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	29,63	20,03

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	33,33	33,33
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	23,33	22,50
	Previously Treated	10	12,0	8	80,0	25,00	29,55
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	29,17	21,36
	Previously Treated	6	7,2	5	83,3	20,00	18,26
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	16,67	17,82
	Previously Treated	6	7,2	4	66,7	25,00	16,67
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	38,89	38,97

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	4,8	2	50,0	16,67	23,57
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	14,29	17,82
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	26,67	27,89
	Previously Treated	3	3,6	2	66,7	16,67	23,57
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	22,22	19,25
	Previously Treated	3	3,6	2	66,7	50,00	23,57
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	33,33	0,00
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	22,22	19,25
	Previously Treated	2	2,4	2	100,0	16,67	23,57
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	33,33	-
	Previously Treated	1	1,2	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	33,33	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	50,6	25	59,5	26,67	23,57
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	24,00	22,96
	Central	70	100,0	64	91,4	26,04	26,87
Cycle 2 Day 1	Local	71	94,7	67	94,4	19,40	21,04
	Central	65	92,9	57	87,7	25,15	26,19
Cycle 3 Day 1	Local	67	89,3	60	89,6	17,22	21,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	64	91,4	56	87,5	16,07	22,91
Cycle 4 Day 1	Local	65	86,7	58	89,2	18,97	23,46
	Central	63	90,0	58	92,1	16,09	23,56
Cycle 5 Day 1	Local	63	84,0	58	92,1	17,24	22,72
	Central	61	87,1	57	93,4	18,13	26,03
Cycle 6 Day 1	Local	63	84,0	61	96,8	15,30	19,79
	Central	58	82,9	47	81,0	14,89	21,77
Cycle 7 Day 1	Local	61	81,3	58	95,1	18,39	23,51

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	52	74,3	45	86,5	18,52	25,18
Cycle 8 Day 1	Local	57	76,0	54	94,7	16,05	16,81
	Central	49	70,0	42	85,7	13,49	20,90
Cycle 9 Day 1	Local	54	72,0	53	98,1	16,98	25,00
	Central	44	62,9	42	95,5	17,46	23,56
Cycle 10 Day 1	Local	48	64,0	46	95,8	18,12	22,99
	Central	41	58,6	40	97,6	13,33	21,08
Cycle 11 Day 1	Local	40	53,3	38	95,0	15,79	22,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	40	57,1	38	95,0	20,18	21,28
Cycle 12 Day 1	Local	36	48,0	33	91,7	16,16	23,75
	Central	40	57,1	35	87,5	23,81	29,78
Cycle 13 Day 1	Local	30	40,0	29	96,7	17,24	22,92
	Central	36	51,4	31	86,1	19,35	24,00
Cycle 14 Day 1	Local	27	36,0	27	100,0	18,52	29,72
	Central	33	47,1	29	87,9	24,14	26,57
Cycle 15 Day 1	Local	26	34,7	25	96,2	10,67	18,56

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	28	90,3	21,43	24,37
Cycle 16 Day 1	Local	24	32,0	24	100,0	19,44	25,85
	Central	26	37,1	23	88,5	24,64	20,64
Cycle 17 Day 1	Local	22	29,3	22	100,0	18,18	24,62
	Central	23	32,9	22	95,7	25,76	27,08
Cycle 18 Day 1	Local	20	26,7	19	95,0	10,53	15,92
	Central	21	30,0	18	85,7	31,48	24,18
Cycle 19 Day 1	Local	19	25,3	17	89,5	13,73	20,61

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	24,3	16	94,1	27,08	27,81
Cycle 20 Day 1	Local	19	25,3	17	89,5	15,69	20,81
	Central	17	24,3	15	88,2	24,44	26,63
Cycle 21 Day 1	Local	14	18,7	12	85,7	16,67	17,41
	Central	15	21,4	14	93,3	35,71	27,62
Cycle 22 Day 1	Local	14	18,7	12	85,7	11,11	21,71
	Central	15	21,4	13	86,7	41,03	27,74
Cycle 23 Day 1	Local	11	14,7	10	90,9	23,33	16,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	14,3	8	80,0	41,67	34,50
Cycle 24 Day 1	Local	11	14,7	10	90,9	16,67	17,57
	Central	9	12,9	8	88,9	33,33	30,86
Cycle 25 Day 1	Local	7	9,3	7	100,0	33,33	19,25
	Central	8	11,4	6	75,0	16,67	18,26
Cycle 26 Day 1	Local	6	8,0	6	100,0	16,67	18,26
	Central	8	11,4	6	75,0	22,22	17,21
Cycle 27 Day 1	Local	4	5,3	4	100,0	25,00	31,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	10,0	4	57,1	41,67	41,94
Cycle 28 Day 1	Local	4	5,3	4	100,0	8,33	16,67
	Central	6	8,6	5	83,3	20,00	18,26
Cycle 29 Day 1	Local	3	4,0	3	100,0	33,33	33,33
	Central	6	8,6	4	66,7	16,67	19,25
Cycle 30 Day 1	Local	3	4,0	3	100,0	22,22	19,25
	Central	4	5,7	2	50,0	50,00	23,57
Cycle 31 Day 1	Local	3	4,0	3	100,0	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	5,7	2	50,0	33,33	0,00
Cycle 32 Day 1	Local	3	4,0	3	100,0	22,22	19,25
	Central	3	4,3	2	66,7	16,67	23,57
Cycle 33 Day 1	Local	1	1,3	1	100,0	33,33	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	30,56	21,80

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	32	45,7	20	62,5	28,33	22,36
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	129	95,6	24,81	24,75
	No	10	100,0	10	100,0	26,67	26,29
Cycle 2 Day 1	Yes	129	95,6	117	90,7	22,22	23,97
	No	7	70,0	7	100,0	19,05	17,82
Cycle 3 Day 1	Yes	124	91,9	110	88,7	16,67	22,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	6	85,7	16,67	27,89
Cycle 4 Day 1	Yes	121	89,6	109	90,1	18,04	23,80
	No	7	70,0	7	100,0	9,52	16,27
Cycle 5 Day 1	Yes	117	86,7	109	93,2	17,13	24,26
	No	7	70,0	6	85,7	27,78	25,09
Cycle 6 Day 1	Yes	114	84,4	101	88,6	14,19	20,19
	No	7	70,0	7	100,0	28,57	23,00
Cycle 7 Day 1	Yes	106	78,5	96	90,6	18,06	24,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	23,81	25,20
Cycle 8 Day 1	Yes	100	74,1	90	90,0	14,81	18,77
	No	6	60,0	6	100,0	16,67	18,26
Cycle 9 Day 1	Yes	92	68,1	89	96,7	17,60	24,66
	No	6	60,0	6	100,0	11,11	17,21
Cycle 10 Day 1	Yes	83	61,5	80	96,4	15,83	21,85
	No	6	60,0	6	100,0	16,67	27,89
Cycle 11 Day 1	Yes	76	56,3	72	94,7	18,06	22,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	4	40,0	4	100,0	16,67	19,25
Cycle 12 Day 1	Yes	72	53,3	64	88,9	19,79	27,68
	No	4	40,0	4	100,0	25,00	16,67
Cycle 13 Day 1	Yes	64	47,4	58	90,6	18,39	23,51
	No	2	20,0	2	100,0	16,67	23,57
Cycle 14 Day 1	Yes	58	43,0	54	93,1	21,60	28,34
	No	2	20,0	2	100,0	16,67	23,57
Cycle 15 Day 1	Yes	55	40,7	51	92,7	16,34	22,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	16,67	23,57
Cycle 16 Day 1	Yes	48	35,6	45	93,8	22,22	23,57
	No	2	20,0	2	100,0	16,67	23,57
Cycle 17 Day 1	Yes	43	31,9	42	97,7	21,43	25,31
	No	2	20,0	2	100,0	33,33	47,14
Cycle 18 Day 1	Yes	39	28,9	35	89,7	20,95	22,99
	No	2	20,0	2	100,0	16,67	23,57
Cycle 19 Day 1	Yes	34	25,2	32	94,1	20,83	25,04

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	20,00	24,13
	No	2	20,0	2	100,0	16,67	23,57
Cycle 21 Day 1	Yes	27	20,0	24	88,9	27,78	25,38
	No	2	20,0	2	100,0	16,67	23,57
Cycle 22 Day 1	Yes	27	20,0	23	85,2	27,54	29,56
	No	2	20,0	2	100,0	16,67	23,57
Cycle 23 Day 1	Yes	20	14,8	17	85,0	33,33	26,35

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	25,49	25,08
	No	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	10,4	12	85,7	22,22	16,41
	No	1	10,0	1	100,0	66,67	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	18,18	17,41
	No	1	10,0	1	100,0	33,33	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	28,57	35,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	66,67	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	16,67	17,82
	No	1	10,0	1	100,0	0,00	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	16,67	18,26
	No	1	10,0	1	100,0	66,67	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	33,33	27,22
	No	1	10,0	1	100,0	33,33	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	33,33	-
Cycle 32 Day 1	Yes	5	3,7	4	80,0	16,67	19,25
	No	1	10,0	1	100,0	33,33	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	16,67	23,57
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	29,46	22,07
	No	2	20,0	1	50,0	33,33	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	36,36	37,87
	No	134	100,0	128	95,5	23,96	23,27
Cycle 2 Day 1	Yes	7	63,6	7	100,0	23,81	25,20
	No	129	96,3	117	90,7	21,94	23,64
Cycle 3 Day 1	Yes	7	63,6	6	85,7	16,67	18,26
	No	124	92,5	110	88,7	16,67	22,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	7	63,6	7	100,0	28,57	23,00
	No	121	90,3	109	90,1	16,82	23,41
Cycle 5 Day 1	Yes	7	63,6	7	100,0	19,05	26,23
	No	117	87,3	108	92,3	17,59	24,31
Cycle 6 Day 1	Yes	7	63,6	7	100,0	14,29	17,82
	No	114	85,1	101	88,6	15,18	20,83
Cycle 7 Day 1	Yes	7	63,6	7	100,0	19,05	26,23
	No	106	79,1	96	90,6	18,40	24,12

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	7	63,6	7	100,0	14,29	17,82
	No	99	73,9	89	89,9	14,98	18,81
Cycle 9 Day 1	Yes	6	54,5	6	100,0	38,89	32,77
	No	92	68,7	89	96,7	15,73	23,08
Cycle 10 Day 1	Yes	6	54,5	6	100,0	33,33	29,81
	No	83	61,9	80	96,4	14,58	21,11
Cycle 11 Day 1	Yes	6	54,5	6	100,0	22,22	27,22
	No	74	55,2	70	94,6	17,62	21,77

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	6	54,5	6	100,0	16,67	27,89
	No	70	52,2	62	88,6	20,43	27,23
Cycle 13 Day 1	Yes	5	45,5	5	100,0	33,33	23,57
	No	61	45,5	55	90,2	16,97	23,02
Cycle 14 Day 1	Yes	5	45,5	5	100,0	20,00	18,26
	No	55	41,0	51	92,7	21,57	28,92
Cycle 15 Day 1	Yes	4	36,4	4	100,0	16,67	19,25
	No	53	39,6	49	92,5	16,33	22,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	47	35,1	44	93,6	22,73	23,60
Cycle 17 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	42	31,3	41	97,6	22,76	26,29
Cycle 18 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	38	28,4	34	89,5	21,57	23,04
Cycle 19 Day 1	Yes	3	27,3	3	100,0	11,11	19,25
	No	33	24,6	30	90,9	21,11	25,50

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	27,3	3	100,0	22,22	19,25
	No	33	24,6	29	87,9	19,54	24,43
Cycle 21 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	27	20,1	24	88,9	27,78	25,38
Cycle 22 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	27	20,1	23	85,2	27,54	29,56
Cycle 23 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	19	14,2	16	84,2	33,33	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	18	13,4	16	88,9	25,00	25,82
Cycle 25 Day 1	Yes	2	18,2	2	100,0	16,67	23,57
	No	13	9,7	11	84,6	27,27	20,10
Cycle 26 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	13	9,7	11	84,6	18,18	17,41
Cycle 27 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	10	7,5	7	70,0	33,33	38,49

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	9	6,7	8	88,9	12,50	17,25
Cycle 29 Day 1	Yes	1	9,1	1	100,0	33,33	-
	No	8	6,0	6	75,0	22,22	27,22
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	33,33	23,57
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	33,33	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	20,00	18,26
Cycle 33 Day 1	No	2	1,5	2	100,0	16,67	23,57
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	33,33	0,00
	No	61	45,5	41	67,2	29,27	22,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13PO_SG.xls
24JUN2020 21:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
All							
Cycle 1 Day 1	All	145	100,0	140	96,6	5,48	14,20
Cycle 2 Day 1	All	136	93,8	124	91,2	8,06	14,95
Cycle 3 Day 1	All	131	90,3	116	88,5	6,03	13,62
Cycle 4 Day 1	All	128	88,3	116	90,6	4,89	12,63
Cycle 5 Day 1	All	124	85,5	115	92,7	6,96	14,97
Cycle 6 Day 1	All	121	83,4	108	89,3	6,48	13,25
Cycle 7 Day 1	All	113	77,9	103	91,2	5,83	12,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	All	106	73,1	96	90,6	4,51	11,47
Cycle 9 Day 1	All	98	67,6	95	96,9	4,56	12,50
Cycle 10 Day 1	All	89	61,4	86	96,6	5,43	13,39
Cycle 11 Day 1	All	80	55,2	76	95,0	7,02	16,61
Cycle 12 Day 1	All	76	52,4	68	89,5	4,41	11,38
Cycle 13 Day 1	All	66	45,5	60	90,9	5,56	12,53
Cycle 14 Day 1	All	60	41,4	56	93,3	5,95	14,36
Cycle 15 Day 1	All	57	39,3	53	93,0	3,14	9,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	All	50	34,5	47	94,0	4,96	13,86
Cycle 17 Day 1	All	45	31,0	44	97,8	3,79	10,70
Cycle 18 Day 1	All	41	28,3	37	90,2	5,41	12,46
Cycle 19 Day 1	All	36	24,8	33	91,7	2,02	8,08
Cycle 20 Day 1	All	36	24,8	32	88,9	2,08	8,20
Cycle 21 Day 1	All	29	20,0	26	89,7	1,28	6,54
Cycle 22 Day 1	All	29	20,0	25	86,2	2,67	9,23
Cycle 23 Day 1	All	21	14,5	18	85,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	All	20	13,8	18	90,0	0,00	0,00
Cycle 25 Day 1	All	15	10,3	13	86,7	0,00	0,00
Cycle 26 Day 1	All	14	9,7	12	85,7	5,56	19,25
Cycle 27 Day 1	All	11	7,6	8	72,7	0,00	0,00
Cycle 28 Day 1	All	10	6,9	9	90,0	0,00	0,00
Cycle 29 Day 1	All	9	6,2	7	77,8	0,00	0,00
Cycle 30 Day 1	All	7	4,8	5	71,4	0,00	0,00
Cycle 31 Day 1	All	7	4,8	5	71,4	13,33	29,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	All	6	4,1	5	83,3	0,00	0,00
Cycle 33 Day 1	All	2	1,4	2	100,0	0,00	0,00
Cycle 34 Day 1	All	1	0,7	0	0,0	-	-
Cycle 35 Day 1	All	1	0,7	0	0,0	-	-
End Of Treatment	All	64	44,1	44	68,8	12,12	19,14
Sex							
Cycle 1 Day 1	Male	52	100,0	51	98,1	3,92	10,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	93	100,0	89	95,7	6,37	15,79
Cycle 2 Day 1	Male	50	96,2	46	92,0	9,42	15,17
	Female	86	92,5	78	90,7	7,26	14,86
Cycle 3 Day 1	Male	47	90,4	43	91,5	6,98	13,72
	Female	84	90,3	73	86,9	5,48	13,62
Cycle 4 Day 1	Male	46	88,5	43	93,5	5,43	12,45
	Female	82	88,2	73	89,0	4,57	12,81
Cycle 5 Day 1	Male	45	86,5	42	93,3	7,14	13,84

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	79	84,9	73	92,4	6,85	15,67
Cycle 6 Day 1	Male	45	86,5	41	91,1	7,32	13,97
	Female	76	81,7	67	88,2	5,97	12,88
Cycle 7 Day 1	Male	40	76,9	39	97,5	3,42	10,25
	Female	73	78,5	64	87,7	7,29	13,89
Cycle 8 Day 1	Male	37	71,2	34	91,9	3,92	10,90
	Female	69	74,2	62	89,9	4,84	11,84
Cycle 9 Day 1	Male	33	63,5	33	100,0	5,05	14,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	65	69,9	62	95,4	4,30	11,27
Cycle 10 Day 1	Male	30	57,7	30	100,0	6,67	16,14
	Female	59	63,4	56	94,9	4,76	11,77
Cycle 11 Day 1	Male	29	55,8	28	96,6	8,33	14,70
	Female	51	54,8	48	94,1	6,25	17,74
Cycle 12 Day 1	Male	27	51,9	26	96,3	3,85	10,86
	Female	49	52,7	42	85,7	4,76	11,81
Cycle 13 Day 1	Male	25	48,1	23	92,0	7,25	14,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	41	44,1	37	90,2	4,50	11,55
Cycle 14 Day 1	Male	23	44,2	21	91,3	4,76	11,95
	Female	37	39,8	35	94,6	6,67	15,76
Cycle 15 Day 1	Male	21	40,4	20	95,2	3,33	10,26
	Female	36	38,7	33	91,7	3,03	9,73
Cycle 16 Day 1	Male	16	30,8	16	100,0	6,25	18,13
	Female	34	36,6	31	91,2	4,30	11,36
Cycle 17 Day 1	Male	13	25,0	13	100,0	5,13	12,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	32	34,4	31	96,9	3,23	10,02
Cycle 18 Day 1	Male	12	23,1	11	91,7	9,09	15,57
	Female	29	31,2	26	89,7	3,85	10,86
Cycle 19 Day 1	Male	10	19,2	10	100,0	6,67	14,05
	Female	26	28,0	23	88,5	0,00	0,00
Cycle 20 Day 1	Male	10	19,2	9	90,0	3,70	11,11
	Female	26	28,0	23	88,5	1,45	6,95
Cycle 21 Day 1	Male	8	15,4	8	100,0	4,17	11,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	21	22,6	18	85,7	0,00	0,00
Cycle 22 Day 1	Male	8	15,4	6	75,0	5,56	13,61
	Female	21	22,6	19	90,5	1,75	7,65
Cycle 23 Day 1	Male	5	9,6	4	80,0	0,00	0,00
	Female	16	17,2	14	87,5	0,00	0,00
Cycle 24 Day 1	Male	5	9,6	4	80,0	0,00	0,00
	Female	15	16,1	14	93,3	0,00	0,00
Cycle 25 Day 1	Male	3	5,8	2	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	12	12,9	11	91,7	0,00	0,00
Cycle 26 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	11	11,8	10	90,9	6,67	21,08
Cycle 27 Day 1	Male	3	5,8	2	66,7	0,00	0,00
	Female	8	8,6	6	75,0	0,00	0,00
Cycle 28 Day 1	Male	2	3,8	2	100,0	0,00	0,00
	Female	8	8,6	7	87,5	0,00	0,00
Cycle 29 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	8	8,6	6	75,0	0,00	0,00
Cycle 30 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	0,00	0,00
Cycle 31 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	6	6,5	4	66,7	16,67	33,33
Cycle 32 Day 1	Male	1	1,9	1	100,0	0,00	-
	Female	5	5,4	4	80,0	0,00	0,00
Cycle 33 Day 1	Male	1	1,9	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Female	1	1,1	1	100,0	0,00	-
Cycle 34 Day 1	Male	1	1,9	0	0,0	-	-
Cycle 35 Day 1	Male	1	1,9	0	0,0	-	-
End Of Treatment	Male	27	51,9	21	77,8	11,11	19,25
	Female	37	39,8	23	62,2	13,04	19,43
Age							
Cycle 1 Day 1	18-64	109	100,0	104	95,4	4,17	12,88

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	29	100,0	29	100,0	10,34	18,05
	>=75	7	100,0	7	100,0	4,76	12,60
Cycle 2 Day 1	18-64	103	94,5	91	88,3	6,59	13,35
	65-74	26	89,7	26	100,0	12,82	19,04
	>=75	7	100,0	7	100,0	9,52	16,27
Cycle 3 Day 1	18-64	99	90,8	87	87,9	4,21	11,14
	65-74	25	86,2	23	92,0	8,70	14,97
	>=75	7	100,0	6	85,7	22,22	27,22

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	18-64	98	89,9	88	89,8	3,03	9,64
	65-74	23	79,3	21	91,3	9,52	15,43
	>=75	7	100,0	7	100,0	14,29	26,23
Cycle 5 Day 1	18-64	95	87,2	88	92,6	6,44	15,04
	65-74	22	75,9	22	100,0	7,58	14,30
	>=75	7	100,0	5	71,4	13,33	18,26
Cycle 6 Day 1	18-64	92	84,4	80	87,0	5,42	12,37
	65-74	22	75,9	21	95,5	7,94	14,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	7	100,0	7	100,0	14,29	17,82
Cycle 7 Day 1	18-64	86	78,9	78	90,7	3,85	10,72
	65-74	20	69,0	19	95,0	10,53	15,92
	>=75	7	100,0	6	85,7	16,67	18,26
Cycle 8 Day 1	18-64	80	73,4	71	88,8	2,82	9,34
	65-74	19	65,5	19	100,0	10,53	15,92
	>=75	7	100,0	6	85,7	5,56	13,61
Cycle 9 Day 1	18-64	74	67,9	72	97,3	2,31	8,53

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	18	62,1	18	100,0	12,96	20,26
	>=75	6	85,7	5	83,3	6,67	14,91
Cycle 10 Day 1	18-64	69	63,3	66	95,7	5,05	13,39
	65-74	15	51,7	15	100,0	6,67	13,80
	>=75	5	71,4	5	100,0	6,67	14,91
Cycle 11 Day 1	18-64	61	56,0	58	95,1	6,32	17,05
	65-74	15	51,7	14	93,3	9,52	15,63
	>=75	4	57,1	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	18-64	57	52,3	50	87,7	2,67	9,13
	65-74	15	51,7	14	93,3	9,52	15,63
	>=75	4	57,1	4	100,0	8,33	16,67
Cycle 13 Day 1	18-64	49	45,0	45	91,8	4,44	11,46
	65-74	13	44,8	11	84,6	9,09	15,57
	>=75	4	57,1	4	100,0	8,33	16,67
Cycle 14 Day 1	18-64	45	41,3	43	95,6	4,65	11,69
	65-74	13	44,8	11	84,6	6,06	13,48

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	2	28,6	2	100,0	33,33	47,14
Cycle 15 Day 1	18-64	43	39,4	40	93,0	2,50	8,89
	65-74	12	41,4	11	91,7	6,06	13,48
	>=75	2	28,6	2	100,0	0,00	0,00
Cycle 16 Day 1	18-64	38	34,9	36	94,7	4,63	14,15
	65-74	10	34,5	9	90,0	3,70	11,11
	>=75	2	28,6	2	100,0	16,67	23,57
Cycle 17 Day 1	18-64	36	33,0	35	97,2	3,81	10,76

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	8	27,6	8	100,0	4,17	11,79
	>=75	1	14,3	1	100,0	0,00	-
Cycle 18 Day 1	18-64	33	30,3	30	90,9	4,44	11,52
	65-74	7	24,1	6	85,7	11,11	17,21
	>=75	1	14,3	1	100,0	0,00	-
Cycle 19 Day 1	18-64	30	27,5	28	93,3	1,19	6,30
	65-74	5	17,2	4	80,0	8,33	16,67
	>=75	1	14,3	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	18-64	30	27,5	26	86,7	2,56	9,06
	65-74	5	17,2	5	100,0	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-
Cycle 21 Day 1	18-64	24	22,0	21	87,5	1,59	7,27
	65-74	4	13,8	4	100,0	0,00	0,00
	>=75	1	14,3	1	100,0	0,00	-
Cycle 22 Day 1	18-64	24	22,0	20	83,3	1,67	7,45
	65-74	4	13,8	4	100,0	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	>=75	1	14,3	1	100,0	0,00	-
Cycle 23 Day 1	18-64	19	17,4	16	84,2	0,00	0,00
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 24 Day 1	18-64	18	16,5	16	88,9	0,00	0,00
	65-74	2	6,9	2	100,0	0,00	0,00
Cycle 25 Day 1	18-64	14	12,8	12	85,7	0,00	0,00
	65-74	1	3,4	1	100,0	0,00	-
Cycle 26 Day 1	18-64	13	11,9	12	92,3	5,56	19,25

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 27 Day 1	18-64	10	9,2	8	80,0	0,00	0,00
	65-74	1	3,4	0	0,0	-	-
Cycle 28 Day 1	18-64	9	8,3	9	100,0	0,00	0,00
	65-74	1	3,4	0	0,0	-	-
Cycle 29 Day 1	18-64	8	7,3	7	87,5	0,00	0,00
	65-74	1	3,4	0	0,0	-	-
Cycle 30 Day 1	18-64	6	5,5	5	83,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	65-74	1	3,4	0	0,0	-	-
Cycle 31 Day 1	18-64	6	5,5	5	83,3	13,33	29,81
	65-74	1	3,4	0	0,0	-	-
Cycle 32 Day 1	18-64	5	4,6	4	80,0	0,00	0,00
	65-74	1	3,4	1	100,0	0,00	-
Cycle 33 Day 1	18-64	1	0,9	1	100,0	0,00	-
	65-74	1	3,4	1	100,0	0,00	-
Cycle 34 Day 1	18-64	1	0,9	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	18-64	1	0,9	0	0,0	-	-
End Of Treatment	18-64	45	41,3	34	75,6	11,76	19,90
	65-74	15	51,7	8	53,3	12,50	17,25
	>=75	4	57,1	2	50,0	16,67	23,57
Race							
Cycle 1 Day 1	White	60	100,0	57	95,0	2,34	8,59
	Other	85	100,0	83	97,6	7,63	16,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	White	57	95,0	50	87,7	6,67	13,47
	Other	79	92,9	74	93,7	9,01	15,89
Cycle 3 Day 1	White	54	90,0	44	81,5	3,79	10,70
	Other	77	90,6	72	93,5	7,41	15,03
Cycle 4 Day 1	White	53	88,3	45	84,9	1,48	6,95
	Other	75	88,2	71	94,7	7,04	14,82
Cycle 5 Day 1	White	52	86,7	47	90,4	4,96	13,86
	Other	72	84,7	68	94,4	8,33	15,64

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 6 Day 1	White	50	83,3	41	82,0	6,50	13,37
	Other	71	83,5	67	94,4	6,47	13,28
Cycle 7 Day 1	White	47	78,3	40	85,1	5,00	12,05
	Other	66	77,6	63	95,5	6,35	13,19
Cycle 8 Day 1	White	45	75,0	38	84,4	3,51	10,37
	Other	61	71,8	58	95,1	5,17	12,17
Cycle 9 Day 1	White	42	70,0	41	97,6	4,07	13,32
	Other	56	65,9	54	96,4	4,94	11,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	White	41	68,3	39	95,1	5,98	15,05
	Other	48	56,5	47	97,9	4,96	12,00
Cycle 11 Day 1	White	37	61,7	36	97,3	5,56	12,60
	Other	43	50,6	40	93,0	8,33	19,61
Cycle 12 Day 1	White	37	61,7	33	89,2	3,03	9,73
	Other	39	45,9	35	89,7	5,71	12,75
Cycle 13 Day 1	White	32	53,3	30	93,8	5,56	12,63
	Other	34	40,0	30	88,2	5,56	12,63

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 14 Day 1	White	31	51,7	30	96,8	4,44	11,52
	Other	29	34,1	26	89,7	7,69	17,15
Cycle 15 Day 1	White	30	50,0	28	93,3	4,76	11,88
	Other	27	31,8	25	92,6	1,33	6,67
Cycle 16 Day 1	White	26	43,3	24	92,3	5,56	16,05
	Other	24	28,2	23	95,8	4,35	11,48
Cycle 17 Day 1	White	24	40,0	24	100,0	4,17	11,26
	Other	21	24,7	20	95,2	3,33	10,26

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	White	22	36,7	19	86,4	3,51	10,51
	Other	19	22,4	18	94,7	7,41	14,26
Cycle 19 Day 1	White	20	33,3	20	100,0	1,67	7,45
	Other	16	18,8	13	81,3	2,56	9,25
Cycle 20 Day 1	White	20	33,3	17	85,0	1,96	8,08
	Other	16	18,8	15	93,8	2,22	8,61
Cycle 21 Day 1	White	16	26,7	14	87,5	2,38	8,91
	Other	13	15,3	12	92,3	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 22 Day 1	White	16	26,7	13	81,3	2,56	9,25
	Other	13	15,3	12	92,3	2,78	9,62
Cycle 23 Day 1	White	12	20,0	10	83,3	0,00	0,00
	Other	9	10,6	8	88,9	0,00	0,00
Cycle 24 Day 1	White	11	18,3	10	90,9	0,00	0,00
	Other	9	10,6	8	88,9	0,00	0,00
Cycle 25 Day 1	White	10	16,7	8	80,0	0,00	0,00
	Other	5	5,9	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	White	10	16,7	8	80,0	0,00	0,00
	Other	4	4,7	4	100,0	16,67	33,33
Cycle 27 Day 1	White	8	13,3	5	62,5	0,00	0,00
	Other	3	3,5	3	100,0	0,00	0,00
Cycle 28 Day 1	White	7	11,7	6	85,7	0,00	0,00
	Other	3	3,5	3	100,0	0,00	0,00
Cycle 29 Day 1	White	6	10,0	4	66,7	0,00	0,00
	Other	3	3,5	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	White	4	6,7	2	50,0	0,00	0,00
	Other	3	3,5	3	100,0	0,00	0,00
Cycle 31 Day 1	White	4	6,7	2	50,0	0,00	0,00
	Other	3	3,5	3	100,0	22,22	38,49
Cycle 32 Day 1	White	4	6,7	3	75,0	0,00	0,00
	Other	2	2,4	2	100,0	0,00	0,00
Cycle 33 Day 1	White	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	White	1	1,7	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	White	1	1,7	0	0,0	-	-
End Of Treatment	White	25	41,7	17	68,0	3,92	11,07
	Other	39	45,9	27	69,2	17,28	21,42
Region							
Cycle 1 Day 1	America (AM)	40	100,0	38	95,0	4,39	13,80
	Europe (EU)	34	100,0	31	91,2	3,23	10,02
	Asia (AS)	71	100,0	71	100,0	7,04	15,85

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 2 Day 1	America (AM)	38	95,0	32	84,2	10,42	15,70
	Europe (EU)	32	94,1	27	84,4	6,17	13,19
	Asia (AS)	66	93,0	65	98,5	7,69	15,33
Cycle 3 Day 1	America (AM)	37	92,5	32	86,5	3,13	9,87
	Europe (EU)	31	91,2	21	67,7	4,76	11,95
	Asia (AS)	63	88,7	63	100,0	7,94	15,51
Cycle 4 Day 1	America (AM)	37	92,5	32	86,5	3,13	9,87
	Europe (EU)	30	88,2	24	80,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	61	85,9	60	98,4	7,78	15,49
Cycle 5 Day 1	America (AM)	37	92,5	33	89,2	4,04	13,84
	Europe (EU)	30	88,2	25	83,3	4,00	11,06
	Asia (AS)	57	80,3	57	100,0	9,94	16,62
Cycle 6 Day 1	America (AM)	37	92,5	32	86,5	6,25	13,22
	Europe (EU)	28	82,4	24	85,7	5,56	12,69
	Asia (AS)	56	78,9	52	92,9	7,05	13,75
Cycle 7 Day 1	America (AM)	35	87,5	29	82,9	1,15	6,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	28	82,4	25	89,3	5,33	12,47
	Asia (AS)	50	70,4	49	98,0	8,84	14,87
Cycle 8 Day 1	America (AM)	31	77,5	26	83,9	0,00	0,00
	Europe (EU)	28	82,4	23	82,1	7,25	14,06
	Asia (AS)	47	66,2	47	100,0	5,67	12,66
Cycle 9 Day 1	America (AM)	29	72,5	27	93,1	1,23	6,42
	Europe (EU)	26	76,5	25	96,2	4,00	14,66
	Asia (AS)	43	60,6	43	100,0	6,98	13,72

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 10 Day 1	America (AM)	27	67,5	24	88,9	4,17	14,95
	Europe (EU)	25	73,5	25	100,0	4,00	11,06
	Asia (AS)	37	52,1	37	100,0	7,21	13,91
Cycle 11 Day 1	America (AM)	24	60,0	21	87,5	1,59	7,27
	Europe (EU)	23	67,6	22	95,7	6,06	13,16
	Asia (AS)	33	46,5	33	100,0	11,11	21,52
Cycle 12 Day 1	America (AM)	24	60,0	22	91,7	0,00	0,00
	Europe (EU)	23	67,6	18	78,3	5,56	12,78

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	29	40,8	28	96,6	7,14	13,93
Cycle 13 Day 1	America (AM)	23	57,5	21	91,3	3,17	10,03
	Europe (EU)	18	52,9	14	77,8	4,76	12,10
	Asia (AS)	25	35,2	25	100,0	8,00	14,53
Cycle 14 Day 1	America (AM)	22	55,0	20	90,9	3,33	10,26
	Europe (EU)	17	50,0	16	94,1	4,17	11,39
	Asia (AS)	21	29,6	20	95,2	10,00	19,04
Cycle 15 Day 1	America (AM)	22	55,0	19	86,4	1,75	7,65

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	15	44,1	14	93,3	4,76	12,10
	Asia (AS)	20	28,2	20	100,0	3,33	10,26
Cycle 16 Day 1	America (AM)	17	42,5	17	100,0	0,00	0,00
	Europe (EU)	14	41,2	11	78,6	9,09	21,56
	Asia (AS)	19	26,8	19	100,0	7,02	13,96
Cycle 17 Day 1	America (AM)	16	40,0	16	100,0	0,00	0,00
	Europe (EU)	13	38,2	12	92,3	5,56	12,97
	Asia (AS)	16	22,5	16	100,0	6,25	13,44

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 18 Day 1	America (AM)	14	35,0	14	100,0	2,38	8,91
	Europe (EU)	11	32,4	7	63,6	4,76	12,60
	Asia (AS)	16	22,5	16	100,0	8,33	14,91
Cycle 19 Day 1	America (AM)	13	32,5	13	100,0	2,56	9,25
	Europe (EU)	9	26,5	9	100,0	3,70	11,11
	Asia (AS)	14	19,7	11	78,6	0,00	0,00
Cycle 20 Day 1	America (AM)	13	32,5	13	100,0	2,56	9,25
	Europe (EU)	9	26,5	6	66,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	14	19,7	13	92,9	2,56	9,25
Cycle 21 Day 1	America (AM)	11	27,5	10	90,9	0,00	0,00
	Europe (EU)	7	20,6	6	85,7	5,56	13,61
	Asia (AS)	11	15,5	10	90,9	0,00	0,00
Cycle 22 Day 1	America (AM)	11	27,5	10	90,9	6,67	14,05
	Europe (EU)	7	20,6	5	71,4	0,00	0,00
	Asia (AS)	11	15,5	10	90,9	0,00	0,00
Cycle 23 Day 1	America (AM)	9	22,5	9	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	5	14,7	3	60,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	0,00	0,00
Cycle 24 Day 1	America (AM)	8	20,0	8	100,0	0,00	0,00
	Europe (EU)	5	14,7	4	80,0	0,00	0,00
	Asia (AS)	7	9,9	6	85,7	0,00	0,00
Cycle 25 Day 1	America (AM)	7	17,5	7	100,0	0,00	0,00
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	America (AM)	6	15,0	6	100,0	0,00	0,00
	Europe (EU)	4	11,8	2	50,0	0,00	0,00
	Asia (AS)	4	5,6	4	100,0	16,67	33,33
Cycle 27 Day 1	America (AM)	4	10,0	4	100,0	0,00	0,00
	Europe (EU)	3	8,8	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	0,00	0,00
Cycle 28 Day 1	America (AM)	4	10,0	4	100,0	0,00	0,00
	Europe (EU)	2	5,9	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Asia (AS)	4	5,6	4	100,0	0,00	0,00
Cycle 29 Day 1	America (AM)	3	7,5	3	100,0	0,00	0,00
	Europe (EU)	2	5,9	0	0,0	-	-
	Asia (AS)	4	5,6	4	100,0	0,00	0,00
Cycle 30 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	0,00	0,00
Cycle 31 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Europe (EU)	1	2,9	0	0,0	-	-
	Asia (AS)	4	5,6	3	75,0	22,22	38,49
Cycle 32 Day 1	America (AM)	2	5,0	2	100,0	0,00	0,00
	Europe (EU)	1	2,9	1	100,0	0,00	-
	Asia (AS)	3	4,2	2	66,7	0,00	0,00
Cycle 33 Day 1	America (AM)	1	2,5	1	100,0	0,00	-
	Europe (EU)	1	2,9	1	100,0	0,00	-
Cycle 34 Day 1	America (AM)	1	2,5	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	America (AM)	1	2,5	0	0,0	-	-
End Of Treatment	America (AM)	20	50,0	17	85,0	5,88	13,10
	Europe (EU)	10	29,4	5	50,0	6,67	14,91
	Asia (AS)	34	47,9	22	64,7	18,18	22,37
ECOG Performance Status							
Cycle 1 Day 1	0	61	100,0	59	96,7	2,26	8,45
	1	69	100,0	66	95,7	8,08	16,60

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	15	100,0	15	100,0	6,67	18,69
Cycle 2 Day 1	0	59	96,7	55	93,2	7,88	14,29
	1	67	97,1	59	88,1	8,47	15,89
	2	10	66,7	10	100,0	6,67	14,05
Cycle 3 Day 1	0	57	93,4	50	87,7	5,33	14,06
	1	65	94,2	57	87,7	7,02	13,71
	2	9	60,0	9	100,0	3,70	11,11
Cycle 4 Day 1	0	57	93,4	51	89,5	4,58	13,37

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	62	89,9	57	91,9	4,68	11,68
	2	9	60,0	8	88,9	8,33	15,43
Cycle 5 Day 1	0	56	91,8	52	92,9	6,41	14,82
	1	62	89,9	57	91,9	7,02	15,09
	2	6	40,0	6	100,0	11,11	17,21
Cycle 6 Day 1	0	56	91,8	53	94,6	6,29	13,17
	1	59	85,5	51	86,4	6,54	13,37
	2	6	40,0	4	66,7	8,33	16,67

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	0	54	88,5	51	94,4	3,27	10,01
	1	54	78,3	47	87,0	8,51	14,69
	2	5	33,3	5	100,0	6,67	14,91
Cycle 8 Day 1	0	52	85,2	48	92,3	3,47	10,29
	1	49	71,0	43	87,8	4,65	11,69
	2	5	33,3	5	100,0	13,33	18,26
Cycle 9 Day 1	0	50	82,0	49	98,0	4,76	13,61
	1	44	63,8	42	95,5	3,97	10,93

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	4	26,7	4	100,0	8,33	16,67
Cycle 10 Day 1	0	46	75,4	46	100,0	6,52	15,10
	1	40	58,0	37	92,5	4,50	11,55
	2	3	20,0	3	100,0	0,00	0,00
Cycle 11 Day 1	0	43	70,5	40	93,0	6,67	13,50
	1	34	49,3	33	97,1	8,08	20,46
	2	3	20,0	3	100,0	0,00	0,00
Cycle 12 Day 1	0	42	68,9	36	85,7	4,63	11,69

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	31	44,9	29	93,5	4,60	11,70
	2	3	20,0	3	100,0	0,00	0,00
Cycle 13 Day 1	0	38	62,3	34	89,5	5,88	12,90
	1	27	39,1	25	92,6	5,33	12,47
	2	1	6,7	1	100,0	0,00	-
Cycle 14 Day 1	0	35	57,4	32	91,4	6,25	15,70
	1	24	34,8	23	95,8	5,80	12,92
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	0	33	54,1	30	90,9	3,33	10,17
	1	23	33,3	22	95,7	3,03	9,81
	2	1	6,7	1	100,0	0,00	-
Cycle 16 Day 1	0	28	45,9	25	89,3	5,33	15,75
	1	21	30,4	21	100,0	4,76	11,95
	2	1	6,7	1	100,0	0,00	-
Cycle 17 Day 1	0	24	39,3	23	95,8	2,90	9,60
	1	20	29,0	20	100,0	5,00	12,21

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2	1	6,7	1	100,0	0,00	-
Cycle 18 Day 1	0	23	37,7	19	82,6	3,51	10,51
	1	17	24,6	17	100,0	7,84	14,57
	2	1	6,7	1	100,0	0,00	-
Cycle 19 Day 1	0	20	32,8	19	95,0	3,51	10,51
	1	15	21,7	13	86,7	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 20 Day 1	0	20	32,8	17	85,0	3,92	11,07

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	15	21,7	14	93,3	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 21 Day 1	0	15	24,6	14	93,3	2,38	8,91
	1	13	18,8	11	84,6	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 22 Day 1	0	15	24,6	12	80,0	5,56	12,97
	1	13	18,8	12	92,3	0,00	0,00
	2	1	6,7	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 23 Day 1	0	11	18,0	9	81,8	0,00	0,00
	1	9	13,0	8	88,9	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 24 Day 1	0	10	16,4	9	90,0	0,00	0,00
	1	9	13,0	8	88,9	0,00	0,00
	2	1	6,7	1	100,0	0,00	-
Cycle 25 Day 1	0	8	13,1	6	75,0	0,00	0,00
	1	7	10,1	7	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 26 Day 1	0	8	13,1	6	75,0	0,00	0,00
	1	6	8,7	6	100,0	11,11	27,22
Cycle 27 Day 1	0	6	9,8	3	50,0	0,00	0,00
	1	5	7,2	5	100,0	0,00	0,00
Cycle 28 Day 1	0	5	8,2	4	80,0	0,00	0,00
	1	5	7,2	5	100,0	0,00	0,00
Cycle 29 Day 1	0	4	6,6	2	50,0	0,00	0,00
	1	5	7,2	5	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 30 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	0,00	0,00
Cycle 31 Day 1	0	3	4,9	1	33,3	0,00	-
	1	4	5,8	4	100,0	16,67	33,33
Cycle 32 Day 1	0	3	4,9	2	66,7	0,00	0,00
	1	3	4,3	3	100,0	0,00	0,00
Cycle 33 Day 1	0	2	3,3	2	100,0	0,00	0,00
Cycle 34 Day 1	0	1	1,6	0	0,0	-	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 35 Day 1	0	1	1,6	0	0,0	-	-
End Of Treatment	0	23	37,7	21	91,3	11,11	16,10
	1	34	49,3	20	58,8	13,33	22,69
	2	7	46,7	3	42,9	11,11	19,25
Number of Prior Anticancer Therapies							
Cycle 1 Day 1	None	62	100,0	59	95,2	6,78	16,12
	1	4	100,0	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	79	100,0	77	97,5	4,76	12,93
Cycle 2 Day 1	None	60	96,8	53	88,3	8,81	14,84
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	73	92,4	69	94,5	7,73	15,28
Cycle 3 Day 1	None	59	95,2	53	89,8	3,77	10,66
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	69	87,3	61	88,4	8,20	15,70
Cycle 4 Day 1	None	59	95,2	54	91,5	4,32	11,30

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	3	75,0	2	66,7	0,00	0,00
	2 or More	66	83,5	60	90,9	5,56	13,95
Cycle 5 Day 1	None	58	93,5	54	93,1	4,32	13,03
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	63	79,7	58	92,1	9,77	16,53
Cycle 6 Day 1	None	57	91,9	49	86,0	5,44	12,45
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	61	77,2	56	91,8	7,74	14,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 7 Day 1	None	52	83,9	47	90,4	4,26	11,24
	1	3	75,0	3	100,0	0,00	0,00
	2 or More	58	73,4	53	91,4	7,55	14,08
Cycle 8 Day 1	None	50	80,6	45	90,0	2,96	9,59
	1	3	75,0	1	33,3	0,00	-
	2 or More	53	67,1	50	94,3	6,00	12,94
Cycle 9 Day 1	None	48	77,4	46	95,8	3,62	12,63
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	49	62,0	48	98,0	5,56	12,55
Cycle 10 Day 1	None	43	69,4	41	95,3	4,07	13,32
	1	1	25,0	1	100,0	0,00	-
	2 or More	45	57,0	44	97,8	6,82	13,60
Cycle 11 Day 1	None	37	59,7	33	89,2	5,05	12,14
	1	1	25,0	1	100,0	0,00	-
	2 or More	42	53,2	42	100,0	8,73	19,56
Cycle 12 Day 1	None	37	59,7	33	89,2	2,02	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	38	48,1	34	89,5	6,86	13,68
Cycle 13 Day 1	None	34	54,8	28	82,4	3,57	10,50
	1	1	25,0	1	100,0	0,00	-
	2 or More	31	39,2	31	100,0	7,53	14,17
Cycle 14 Day 1	None	31	50,0	28	90,3	3,57	10,50
	1	1	25,0	1	100,0	0,00	-
	2 or More	28	35,4	27	96,4	8,64	17,52

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 15 Day 1	None	30	48,4	27	90,0	2,47	8,90
	1	1	25,0	1	100,0	0,00	-
	2 or More	26	32,9	25	96,2	4,00	11,06
Cycle 16 Day 1	None	25	40,3	23	92,0	1,45	6,95
	1	1	25,0	1	100,0	0,00	-
	2 or More	24	30,4	23	95,8	8,70	18,03
Cycle 17 Day 1	None	23	37,1	22	95,7	1,52	7,11
	1	1	25,0	1	100,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	21	26,6	21	100,0	6,35	13,41
Cycle 18 Day 1	None	20	32,3	18	90,0	3,70	10,78
	1	1	25,0	1	100,0	0,00	-
	2 or More	20	25,3	18	90,0	7,41	14,26
Cycle 19 Day 1	None	17	27,4	17	100,0	1,96	8,08
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	2,22	8,61
Cycle 20 Day 1	None	17	27,4	16	94,1	4,17	11,39

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	1	1	25,0	1	100,0	0,00	-
	2 or More	18	22,8	15	83,3	0,00	0,00
Cycle 21 Day 1	None	15	24,2	13	86,7	0,00	0,00
	2 or More	14	17,7	13	92,9	2,56	9,25
Cycle 22 Day 1	None	15	24,2	13	86,7	2,56	9,25
	2 or More	14	17,7	12	85,7	2,78	9,62
Cycle 23 Day 1	None	10	16,1	9	90,0	0,00	0,00
	2 or More	11	13,9	9	81,8	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	None	10	16,1	10	100,0	0,00	0,00
	2 or More	10	12,7	8	80,0	0,00	0,00
Cycle 25 Day 1	None	9	14,5	8	88,9	0,00	0,00
	2 or More	6	7,6	5	83,3	0,00	0,00
Cycle 26 Day 1	None	8	12,9	8	100,0	8,33	23,57
	2 or More	6	7,6	4	66,7	0,00	0,00
Cycle 27 Day 1	None	7	11,3	6	85,7	0,00	0,00
	2 or More	4	5,1	2	50,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	None	7	11,3	7	100,0	0,00	0,00
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 29 Day 1	None	6	9,7	5	83,3	0,00	0,00
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 30 Day 1	None	4	6,5	3	75,0	0,00	0,00
	2 or More	3	3,8	2	66,7	0,00	0,00
Cycle 31 Day 1	None	4	6,5	3	75,0	0,00	0,00
	2 or More	3	3,8	2	66,7	33,33	47,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	None	4	6,5	3	75,0	0,00	0,00
	2 or More	2	2,5	2	100,0	0,00	0,00
Cycle 33 Day 1	None	1	1,6	1	100,0	0,00	-
	2 or More	1	1,3	1	100,0	0,00	-
Cycle 34 Day 1	None	1	1,6	0	0,0	-	-
Cycle 35 Day 1	None	1	1,6	0	0,0	-	-
End Of Treatment	None	22	35,5	19	86,4	10,53	19,41
	1	3	75,0	1	33,3	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	2 or More	39	49,4	24	61,5	13,89	19,45
Prior Treatment							
Cycle 1 Day 1	Naïve	62	100,0	59	95,2	6,78	16,12
	Previously Treated	83	100,0	81	97,6	4,53	12,64
Cycle 2 Day 1	Naïve	60	96,8	53	88,3	8,81	14,84
	Previously Treated	76	91,6	71	93,4	7,51	15,12
Cycle 3 Day 1	Naïve	59	95,2	53	89,8	3,77	10,66

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	72	86,7	63	87,5	7,94	15,51
Cycle 4 Day 1	Naïve	59	95,2	54	91,5	4,32	11,30
	Previously Treated	69	83,1	62	89,9	5,38	13,76
Cycle 5 Day 1	Naïve	58	93,5	54	93,1	4,32	13,03
	Previously Treated	66	79,5	61	92,4	9,29	16,25
Cycle 6 Day 1	Naïve	57	91,9	49	86,0	5,44	12,45
	Previously Treated	64	77,1	59	92,2	7,34	13,93
Cycle 7 Day 1	Naïve	52	83,9	47	90,4	4,26	11,24

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	61	73,5	56	91,8	7,14	13,80
Cycle 8 Day 1	Naïve	50	80,6	45	90,0	2,96	9,59
	Previously Treated	56	67,5	51	91,1	5,88	12,83
Cycle 9 Day 1	Naïve	48	77,4	46	95,8	3,62	12,63
	Previously Treated	50	60,2	49	98,0	5,44	12,45
Cycle 10 Day 1	Naïve	43	69,4	41	95,3	4,07	13,32
	Previously Treated	46	55,4	45	97,8	6,67	13,48
Cycle 11 Day 1	Naïve	37	59,7	33	89,2	5,05	12,14

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	43	51,8	43	100,0	8,53	19,37
Cycle 12 Day 1	Naïve	37	59,7	33	89,2	2,02	8,08
	Previously Treated	39	47,0	35	89,7	6,67	13,53
Cycle 13 Day 1	Naïve	34	54,8	28	82,4	3,57	10,50
	Previously Treated	32	38,6	32	100,0	7,29	14,00
Cycle 14 Day 1	Naïve	31	50,0	28	90,3	3,57	10,50
	Previously Treated	29	34,9	28	96,6	8,33	17,27
Cycle 15 Day 1	Naïve	30	48,4	27	90,0	2,47	8,90

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	27	32,5	26	96,3	3,85	10,86
Cycle 16 Day 1	Naïve	25	40,3	23	92,0	1,45	6,95
	Previously Treated	25	30,1	24	96,0	8,33	17,72
Cycle 17 Day 1	Naïve	23	37,1	22	95,7	1,52	7,11
	Previously Treated	22	26,5	22	100,0	6,06	13,16
Cycle 18 Day 1	Naïve	20	32,3	18	90,0	3,70	10,78
	Previously Treated	21	25,3	19	90,5	7,02	13,96
Cycle 19 Day 1	Naïve	17	27,4	17	100,0	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	19	22,9	16	84,2	2,08	8,33
Cycle 20 Day 1	Naïve	17	27,4	16	94,1	4,17	11,39
	Previously Treated	19	22,9	16	84,2	0,00	0,00
Cycle 21 Day 1	Naïve	15	24,2	13	86,7	0,00	0,00
	Previously Treated	14	16,9	13	92,9	2,56	9,25
Cycle 22 Day 1	Naïve	15	24,2	13	86,7	2,56	9,25
	Previously Treated	14	16,9	12	85,7	2,78	9,62
Cycle 23 Day 1	Naïve	10	16,1	9	90,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	11	13,3	9	81,8	0,00	0,00
Cycle 24 Day 1	Naïve	10	16,1	10	100,0	0,00	0,00
	Previously Treated	10	12,0	8	80,0	0,00	0,00
Cycle 25 Day 1	Naïve	9	14,5	8	88,9	0,00	0,00
	Previously Treated	6	7,2	5	83,3	0,00	0,00
Cycle 26 Day 1	Naïve	8	12,9	8	100,0	8,33	23,57
	Previously Treated	6	7,2	4	66,7	0,00	0,00
Cycle 27 Day 1	Naïve	7	11,3	6	85,7	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	4	4,8	2	50,0	0,00	0,00
Cycle 28 Day 1	Naïve	7	11,3	7	100,0	0,00	0,00
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 29 Day 1	Naïve	6	9,7	5	83,3	0,00	0,00
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 30 Day 1	Naïve	4	6,5	3	75,0	0,00	0,00
	Previously Treated	3	3,6	2	66,7	0,00	0,00
Cycle 31 Day 1	Naïve	4	6,5	3	75,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	3	3,6	2	66,7	33,33	47,14
Cycle 32 Day 1	Naïve	4	6,5	3	75,0	0,00	0,00
	Previously Treated	2	2,4	2	100,0	0,00	0,00
Cycle 33 Day 1	Naïve	1	1,6	1	100,0	0,00	-
	Previously Treated	1	1,2	1	100,0	0,00	-
Cycle 34 Day 1	Naïve	1	1,6	0	0,0	-	-
Cycle 35 Day 1	Naïve	1	1,6	0	0,0	-	-
End Of Treatment	Naïve	22	35,5	19	86,4	10,53	19,41

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Previously Treated	42	50,6	25	59,5	13,33	19,25
Molecular Testing Results							
Cycle 1 Day 1	Local	75	100,0	75	100,0	4,44	12,66
	Central	70	100,0	65	92,9	6,67	15,81
Cycle 2 Day 1	Local	71	94,7	67	94,4	9,45	15,14
	Central	65	92,9	57	87,7	6,43	14,69
Cycle 3 Day 1	Local	67	89,3	60	89,6	5,56	13,95

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	64	91,4	56	87,5	6,55	13,36
Cycle 4 Day 1	Local	65	86,7	58	89,2	5,75	14,15
	Central	63	90,0	58	92,1	4,02	10,95
Cycle 5 Day 1	Local	63	84,0	58	92,1	6,90	14,98
	Central	61	87,1	57	93,4	7,02	15,09
Cycle 6 Day 1	Local	63	84,0	61	96,8	8,20	14,47
	Central	58	82,9	47	81,0	4,26	11,24
Cycle 7 Day 1	Local	61	81,3	58	95,1	5,75	12,70

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	52	74,3	45	86,5	5,93	12,89
Cycle 8 Day 1	Local	57	76,0	54	94,7	4,32	11,30
	Central	49	70,0	42	85,7	4,76	11,81
Cycle 9 Day 1	Local	54	72,0	53	98,1	4,40	11,39
	Central	44	62,9	42	95,5	4,76	13,91
Cycle 10 Day 1	Local	48	64,0	46	95,8	6,52	15,10
	Central	41	58,6	40	97,6	4,17	11,16
Cycle 11 Day 1	Local	40	53,3	38	95,0	6,14	13,10

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	40	57,1	38	95,0	7,89	19,66
Cycle 12 Day 1	Local	36	48,0	33	91,7	6,06	13,06
	Central	40	57,1	35	87,5	2,86	9,47
Cycle 13 Day 1	Local	30	40,0	29	96,7	8,05	14,52
	Central	36	51,4	31	86,1	3,23	10,02
Cycle 14 Day 1	Local	27	36,0	27	100,0	8,64	17,52
	Central	33	47,1	29	87,9	3,45	10,33
Cycle 15 Day 1	Local	26	34,7	25	96,2	4,00	11,06

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	31	44,3	28	90,3	2,38	8,74
Cycle 16 Day 1	Local	24	32,0	24	100,0	2,78	9,41
	Central	26	37,1	23	88,5	7,25	17,28
Cycle 17 Day 1	Local	22	29,3	22	100,0	1,52	7,11
	Central	23	32,9	22	95,7	6,06	13,16
Cycle 18 Day 1	Local	20	26,7	19	95,0	5,26	12,49
	Central	21	30,0	18	85,7	5,56	12,78
Cycle 19 Day 1	Local	19	25,3	17	89,5	1,96	8,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	17	24,3	16	94,1	2,08	8,33
Cycle 20 Day 1	Local	19	25,3	17	89,5	1,96	8,08
	Central	17	24,3	15	88,2	2,22	8,61
Cycle 21 Day 1	Local	14	18,7	12	85,7	0,00	0,00
	Central	15	21,4	14	93,3	2,38	8,91
Cycle 22 Day 1	Local	14	18,7	12	85,7	2,78	9,62
	Central	15	21,4	13	86,7	2,56	9,25
Cycle 23 Day 1	Local	11	14,7	10	90,9	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	10	14,3	8	80,0	0,00	0,00
Cycle 24 Day 1	Local	11	14,7	10	90,9	0,00	0,00
	Central	9	12,9	8	88,9	0,00	0,00
Cycle 25 Day 1	Local	7	9,3	7	100,0	0,00	0,00
	Central	8	11,4	6	75,0	0,00	0,00
Cycle 26 Day 1	Local	6	8,0	6	100,0	11,11	27,22
	Central	8	11,4	6	75,0	0,00	0,00
Cycle 27 Day 1	Local	4	5,3	4	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	7	10,0	4	57,1	0,00	0,00
Cycle 28 Day 1	Local	4	5,3	4	100,0	0,00	0,00
	Central	6	8,6	5	83,3	0,00	0,00
Cycle 29 Day 1	Local	3	4,0	3	100,0	0,00	0,00
	Central	6	8,6	4	66,7	0,00	0,00
Cycle 30 Day 1	Local	3	4,0	3	100,0	0,00	0,00
	Central	4	5,7	2	50,0	0,00	0,00
Cycle 31 Day 1	Local	3	4,0	3	100,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	4	5,7	2	50,0	33,33	47,14
Cycle 32 Day 1	Local	3	4,0	3	100,0	0,00	0,00
	Central	3	4,3	2	66,7	0,00	0,00
Cycle 33 Day 1	Local	1	1,3	1	100,0	0,00	-
	Central	1	1,4	1	100,0	0,00	-
Cycle 34 Day 1	Local	1	1,3	0	0,0	-	-
Cycle 35 Day 1	Local	1	1,3	0	0,0	-	-
End Of Treatment	Local	32	42,7	24	75,0	12,50	19,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	Central	32	45,7	20	62,5	11,67	19,57
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib							
Cycle 1 Day 1	Yes	135	100,0	130	96,3	5,64	14,46
	No	10	100,0	10	100,0	3,33	10,54
Cycle 2 Day 1	Yes	129	95,6	117	90,7	7,98	14,94
	No	7	70,0	7	100,0	9,52	16,27
Cycle 3 Day 1	Yes	124	91,9	110	88,7	6,06	13,68

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	6	85,7	5,56	13,61
Cycle 4 Day 1	Yes	121	89,6	109	90,1	5,20	12,97
	No	7	70,0	7	100,0	0,00	0,00
Cycle 5 Day 1	Yes	117	86,7	109	93,2	7,34	15,29
	No	7	70,0	6	85,7	0,00	0,00
Cycle 6 Day 1	Yes	114	84,4	101	88,6	6,27	13,09
	No	7	70,0	7	100,0	9,52	16,27
Cycle 7 Day 1	Yes	106	78,5	96	90,6	5,90	12,79

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	7	70,0	7	100,0	4,76	12,60
Cycle 8 Day 1	Yes	100	74,1	90	90,0	4,44	11,39
	No	6	60,0	6	100,0	5,56	13,61
Cycle 9 Day 1	Yes	92	68,1	89	96,7	4,87	12,86
	No	6	60,0	6	100,0	0,00	0,00
Cycle 10 Day 1	Yes	83	61,5	80	96,4	5,42	13,46
	No	6	60,0	6	100,0	5,56	13,61
Cycle 11 Day 1	Yes	76	56,3	72	94,7	6,94	16,73

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	4	40,0	4	100,0	8,33	16,67
Cycle 12 Day 1	Yes	72	53,3	64	88,9	4,17	11,11
	No	4	40,0	4	100,0	8,33	16,67
Cycle 13 Day 1	Yes	64	47,4	58	90,6	5,75	12,70
	No	2	20,0	2	100,0	0,00	0,00
Cycle 14 Day 1	Yes	58	43,0	54	93,1	6,17	14,59
	No	2	20,0	2	100,0	0,00	0,00
Cycle 15 Day 1	Yes	55	40,7	51	92,7	3,27	10,01

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	2	100,0	0,00	0,00
Cycle 16 Day 1	Yes	48	35,6	45	93,8	5,19	14,13
	No	2	20,0	2	100,0	0,00	0,00
Cycle 17 Day 1	Yes	43	31,9	42	97,7	3,97	10,93
	No	2	20,0	2	100,0	0,00	0,00
Cycle 18 Day 1	Yes	39	28,9	35	89,7	5,71	12,75
	No	2	20,0	2	100,0	0,00	0,00
Cycle 19 Day 1	Yes	34	25,2	32	94,1	2,08	8,20

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	2	20,0	1	50,0	0,00	-
Cycle 20 Day 1	Yes	34	25,2	30	88,2	2,22	8,46
	No	2	20,0	2	100,0	0,00	0,00
Cycle 21 Day 1	Yes	27	20,0	24	88,9	1,39	6,80
	No	2	20,0	2	100,0	0,00	0,00
Cycle 22 Day 1	Yes	27	20,0	23	85,2	2,90	9,60
	No	2	20,0	2	100,0	0,00	0,00
Cycle 23 Day 1	Yes	20	14,8	17	85,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 24 Day 1	Yes	19	14,1	17	89,5	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 25 Day 1	Yes	14	10,4	12	85,7	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 26 Day 1	Yes	13	9,6	11	84,6	0,00	0,00
	No	1	10,0	1	100,0	66,67	-
Cycle 27 Day 1	Yes	10	7,4	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 28 Day 1	Yes	9	6,7	8	88,9	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 29 Day 1	Yes	8	5,9	6	75,0	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 30 Day 1	Yes	6	4,4	4	66,7	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 31 Day 1	Yes	6	4,4	4	66,7	16,67	33,33

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
	No	1	10,0	1	100,0	0,00	-
Cycle 32 Day 1	Yes	5	3,7	4	80,0	0,00	0,00
	No	1	10,0	1	100,0	0,00	-
Cycle 33 Day 1	Yes	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	Yes	1	0,7	0	0,0	-	-
Cycle 35 Day 1	Yes	1	0,7	0	0,0	-	-
End Of Treatment	Yes	62	45,9	43	69,4	12,40	19,28
	No	2	20,0	1	50,0	0,00	-

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Investigator Measurable CNS Disease							
Cycle 1 Day 1	Yes	11	100,0	11	100,0	3,03	10,05
	No	134	100,0	129	96,3	5,68	14,51
Cycle 2 Day 1	Yes	7	63,6	7	100,0	4,76	12,60
	No	129	96,3	117	90,7	8,26	15,10
Cycle 3 Day 1	Yes	7	63,6	6	85,7	0,00	0,00
	No	124	92,5	110	88,7	6,36	13,91

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 4 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	121	90,3	109	90,1	5,20	12,97
Cycle 5 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	117	87,3	108	92,3	7,41	15,34
Cycle 6 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	114	85,1	101	88,6	6,93	13,59
Cycle 7 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	106	79,1	96	90,6	6,25	13,08

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 8 Day 1	Yes	7	63,6	7	100,0	0,00	0,00
	No	99	73,9	89	89,9	4,87	11,84
Cycle 9 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	92	68,7	89	96,7	4,87	12,86
Cycle 10 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	83	61,9	80	96,4	5,83	13,80
Cycle 11 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	74	55,2	70	94,6	7,62	17,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 12 Day 1	Yes	6	54,5	6	100,0	0,00	0,00
	No	70	52,2	62	88,6	4,84	11,84
Cycle 13 Day 1	Yes	5	45,5	5	100,0	6,67	14,91
	No	61	45,5	55	90,2	5,45	12,45
Cycle 14 Day 1	Yes	5	45,5	5	100,0	0,00	0,00
	No	55	41,0	51	92,7	6,54	14,94
Cycle 15 Day 1	Yes	4	36,4	4	100,0	0,00	0,00
	No	53	39,6	49	92,5	3,40	10,19

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 16 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	47	35,1	44	93,6	5,30	14,28
Cycle 17 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	42	31,3	41	97,6	4,07	11,04
Cycle 18 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	38	28,4	34	89,5	5,88	12,90
Cycle 19 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	30	90,9	2,22	8,46

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 20 Day 1	Yes	3	27,3	3	100,0	0,00	0,00
	No	33	24,6	29	87,9	2,30	8,60
Cycle 21 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	24	88,9	1,39	6,80
Cycle 22 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	27	20,1	23	85,2	2,90	9,60
Cycle 23 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	19	14,2	16	84,2	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 24 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	18	13,4	16	88,9	0,00	0,00
Cycle 25 Day 1	Yes	2	18,2	2	100,0	0,00	0,00
	No	13	9,7	11	84,6	0,00	0,00
Cycle 26 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	13	9,7	11	84,6	6,06	20,10
Cycle 27 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	10	7,5	7	70,0	0,00	0,00

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 28 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	9	6,7	8	88,9	0,00	0,00
Cycle 29 Day 1	Yes	1	9,1	1	100,0	0,00	-
	No	8	6,0	6	75,0	0,00	0,00
Cycle 30 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	0,00	0,00
Cycle 31 Day 1	Yes	1	9,1	0	0,0	-	-
	No	6	4,5	5	83,3	13,33	29,81

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)
Cycle 32 Day 1	Yes	1	9,1	0	0,0	-	-
	No	5	3,7	5	100,0	0,00	0,00
Cycle 33 Day 1	No	2	1,5	2	100,0	0,00	0,00
Cycle 34 Day 1	No	1	0,7	0	0,0	-	-
Cycle 35 Day 1	No	1	0,7	0	0,0	-	-
End Of Treatment	Yes	3	27,3	3	100,0	0,00	0,00
	No	61	45,5	41	67,2	13,01	19,55

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Compliance/Mean

		RXDX-101 600 mg/day (N=145)					
		Patients				Statistics	
Name Visit	Level	in study [1]	%	with value [1]	%	mean [2]	SD(mean)

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the
[2] mean: descriptive statistics - absolute values
Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program:
Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_mea
n_D194_REE_LC13SM_SG.xls
24JUN2020 21:14

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_LC13CO.
10SEP2019 18:44

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_LC13DS.
10SEP2019 18:55

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_LC13DY.
10SEP2019 19:07

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_LC13HA.
10SEP2019 19:53

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_LC13HR.
10SEP2019 20:04

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_LC13PA.
10SEP2019 20:16

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_LC13PC.
10SEP2019 20:27

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_LC13PN.
10SEP2019 20:39

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_LC13PO.
10SEP2019 20:51

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/g_eff_mean_NDA_REE_LC13SM.
10SEP2019 21:14

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_LC13CO
28NOV2019 12:44

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_LC13DS.
28NOV2019 12:5(

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_LC13DY.
28NOV2019 12:57

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_LC13HA.
29NOV2019 15:27

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_LC13HR.
28NOV2019 13:18

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_LC13PA.
28NOV2019 13:25

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_LC13PC.
28NOV2019 13:32

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_LC13PN.
28NOV2019 13:41

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_LC13PO.
29NOV2019 15:39

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Mean plot, subgroup: All



Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D180_REE_LC13SM.
28NOV2019 13:56

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_LC13CO
24JUN2020 22:57

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_LC13DS.
24JUN2020 23:0

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_LC13DY.
24JUN2020 23:1(

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_LC13HA.
24JUN2020 23:3(

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_LC13HR.
24JUN2020 23:42

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_LC13PA.
24JUN2020 23:48

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_LC13PC.
24JUN2020 23:54

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_LC13PN.
25JUN2020 0:01

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_LC13PO.
25JUN2020 0:07

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2



Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY201

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/g_eff_mean.s
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/g_eff_mean_D194_REE_LC13SM.
25JUN2020 0:19

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	9	24,3	28	75,7	7,39	4,37	NE	NE	NE	NE
Sex	Male	14	37,8	4	28,6	10	71,4	7,39	2,79	NE	NE	7,39	NE
	Female	23	62,2	5	21,7	18	78,3	10,22	6,47	NE	NE	NE	NE
Age	18-64	29	78,4	8	27,6	21	72,4	7,39	2,79	NE	NE	10,22	NE
	65-74	8	21,6	1	12,5	7	87,5	NE	4,37	NE	NE	NE	NE
Race	White	20	54,1	3	15,0	17	85,0	NE	7,39	NE	NE	NE	NE
	Other	17	45,9	6	35,3	11	64,7	2,79	0,95	NE	NE	6,47	NE
Region	America (AM)	12	32,4	3	25,0	9	75,0	10,22	6,47	NE	NE	10,22	NE
	Europe (EU)	10	27,0			10	100,0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13CO_SG.xls
07SEP2019 18:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	6	40,0	9	60,0	2,79	0,95	NE	NE	2,79	NE
ECOG Performance Status	0	15	40,5	2	13,3	13	86,7	NE	7,39	NE	NE	NE	NE
	1	17	45,9	6	35,3	11	64,7	4,37	1,02	NE	NE	7,39	NE
	2	5	13,5	1	20,0	4	80,0	0,95	0,95	NE	NE	0,95	NE
Number of Prior Anticancer Therapies	None	14	37,8	3	21,4	11	78,6	NE	6,47	NE	NE	NE	NE
	1	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
	2 or More	21	56,8	6	28,6	15	71,4	7,39	0,95	NE	NE	7,39	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13CO_SG.xls
07SEP2019 18:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	3	21,4	11	78,6	NE	6,47	NE	NE	NE	NE
	Previously Treated	23	62,2	6	26,1	17	73,9	7,39	1,02	NE	NE	10,22	NE
Molecular Testing Results	Local	12	32,4	3	25,0	9	75,0	10,22	6,47	NE	NE	10,22	NE
	Central	25	67,6	6	24,0	19	76,0	7,39	1,02	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13CO_SG.xls
07SEP2019 18:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	9	25,7	26	74,3	7,39	4,37	NE	NE	NE	NE
	No	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8	2	50,0	2	50,0	0,85	0,85	NE	2,79	0,85	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13CO_SG.xls
07SEP2019 18:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	7	21,2	26	78,8	10,22	6,47	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13CO_SG.xls
07SEP2019 18:56

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	17	45,9	20	54,1	1,02	0,95	6,47	9,26	2,83	NE
Sex	Male	14	37,8	7	50,0	7	50,0	3,70	0,95	7,39	7,39	3,75	NE
	Female	23	62,2	10	43,5	13	56,5	0,99	0,95	13,80	13,80	1,02	NE
Age	18-64	29	78,4	13	44,8	16	55,2	1,02	0,95	9,26	13,80	2,83	NE
	65-74	8	21,6	4	50,0	4	50,0	0,95	0,95	6,47	5,11	0,95	NE
Race	White	20	54,1	6	30,0	14	70,0	7,39	0,95	NE	NE	7,39	NE
	Other	17	45,9	11	64,7	6	35,3	0,95	0,95	3,65	2,83	0,95	6,47
Region	America (AM)	12	32,4	8	66,7	4	33,3	1,02	0,95	3,75	3,75	1,02	NE
	Europe (EU)	10	27,0	2	20,0	8	80,0	NE	0,95	NE	NE	3,65	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13DS_SG.xls
07SEP2019 18:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	7	46,7	8	53,3	0,95	0,95	13,80	6,47	0,95	NE
ECOG Performance Status	0	15	40,5	8	53,3	7	46,7	2,83	0,95	9,26	9,26	3,75	NE
	1	17	45,9	9	52,9	8	47,1	0,95	0,95	3,65	2,74	0,95	NE
	2	5	13,5			5	100,0	NE	NE	NE	NE	NE	NE
Number of Prior Anticancer Therapies	None	14	37,8	8	57,1	6	42,9	1,84	0,95	7,39	5,57	1,84	NE
	1	2	5,4	1	50,0	1	50,0	9,26	NE	NE	9,26	NE	NE
	2 or More	21	56,8	8	38,1	13	61,9	1,02	0,95	13,80	13,80	1,02	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13DS_SG.xls
07SEP2019 18:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	8	57,1	6	42,9	1,84	0,95	7,39	5,57	1,84	NE
	Previously Treated	23	62,2	9	39,1	14	60,9	1,02	0,95	13,80	11,53	1,02	NE
Molecular Testing Results	Local	12	32,4	9	75,0	3	25,0	0,95	0,95	1,02	1,02	0,95	7,39
	Central	25	67,6	8	32,0	17	68,0	6,47	1,02	NE	NE	6,47	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13DS_SG.xls
07SEP2019 18:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	16	45,7	19	54,3	1,02	0,95	6,47	9,26	3,65	NE
	No	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8			4	100,0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13DS_SG.xls
07SEP2019 18:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	17	51,5	16	48,5	1,02	0,95	3,75	7,39	1,84	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13DS_SG.xls
07SEP2019 18:59

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	17	45,9	20	54,1	1,87	0,95	4,63	12,19	3,71	NE
Sex	Male	14	37,8	6	42,9	8	57,1	4,63	0,95	17,54	17,54	4,63	17,54
	Female	23	62,2	11	47,8	12	52,2	1,87	0,95	4,60	8,39	1,87	NE
Age	18-64	29	78,4	14	48,3	15	51,7	1,87	0,95	4,60	11,93	2,79	NE
	65-74	8	21,6	3	37,5	5	62,5	4,63	0,95	NE	12,19	4,63	NE
Race	White	20	54,1	7	35,0	13	65,0	1,87	0,95	NE	17,54	3,71	NE
	Other	17	45,9	10	58,8	7	41,2	1,87	0,95	4,63	4,63	2,79	12,19
Region	America (AM)	12	32,4	7	58,3	5	41,7	1,02	0,92	12,19	12,19	1,02	NE
	Europe (EU)	10	27,0	2	20,0	8	80,0	11,93	0,95	NE	NE	11,93	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13DY_SG.xls
07SEP2019 19:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	8	53,3	7	46,7	1,87	0,95	4,63	4,60	1,87	NE
ECOG Performance Status	0	15	40,5	7	46,7	8	53,3	3,71	0,95	17,54	17,54	4,63	NE
	1	17	45,9	9	52,9	8	47,1	1,87	0,92	4,60	4,60	1,87	NE
	2	5	13,5	1	20,0	4	80,0	0,95	0,95	NE	NE	0,95	NE
Number of Prior Anticancer Therapies	None	14	37,8	8	57,1	6	42,9	2,79	0,95	12,19	11,93	2,79	NE
	1	2	5,4	1	50,0	1	50,0	17,54	NE	NE	17,54	NE	NE
	2 or More	21	56,8	8	38,1	13	61,9	1,87	0,95	NE	NE	1,87	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13DY_SG.xls
07SEP2019 19:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	8	57,1	6	42,9	2,79	0,95	12,19	11,93	2,79	NE
	Previously Treated	23	62,2	9	39,1	14	60,9	1,87	0,95	17,54	17,54	1,87	NE
Molecular Testing Results	Local	12	32,4	6	50,0	6	50,0	1,02	0,95	3,71	3,71	1,02	NE
	Central	25	67,6	11	44,0	14	56,0	1,87	0,95	12,19	12,19	4,60	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13DY_SG.xls
07SEP2019 19:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	16	45,7	19	54,3	1,87	0,95	11,93	12,19	3,71	NE
	No	2	5,4	1	50,0	1	50,0	2,79	NE	NE	2,79	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13DY_SG.xls
07SEP2019 19:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	0,85	0,85	NE	NE	0,85	NE
	No	33	89,2	16	48,5	17	51,5	1,87	0,95	4,63	12,19	2,83	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13DY_SG.xls
07SEP2019 19:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	1	2,7	36	97,3	NE	NE	NE	NE	NE	NE
Sex	Male	14	37,8	1	7,1	13	92,9	NE	5,55	NE	NE	NE	NE
	Female	23	62,2			23	100,0	NE	NE	NE	NE	NE	NE
Age	18-64	29	78,4	1	3,4	28	96,6	NE	NE	NE	NE	NE	NE
	65-74	8	21,6			8	100,0	NE	NE	NE	NE	NE	NE
Race	White	20	54,1			20	100,0	NE	NE	NE	NE	NE	NE
	Other	17	45,9	1	5,9	16	94,1	NE	5,55	NE	NE	NE	NE
Region	America (AM)	12	32,4			12	100,0	NE	NE	NE	NE	NE	NE
	Europe (EU)	10	27,0			10	100,0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13HA_SG.xls
07SEP2019 19:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	1	6,7	14	93,3	NE	5,55	NE	NE	NE	NE
ECOG Performance Status	0	15	40,5	1	6,7	14	93,3	NE	NE	NE	NE	NE	NE
	1	17	45,9			17	100,0	NE	NE	NE	NE	NE	NE
	2	5	13,5			5	100,0	NE	NE	NE	NE	NE	NE
Number of Prior Anticancer Therapies	None	14	37,8			14	100,0	NE	NE	NE	NE	NE	NE
	1	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
	2 or More	21	56,8	1	4,8	20	95,2	NE	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13HA_SG.xls
07SEP2019 19:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8			14	100,0	NE	NE	NE	NE	NE	NE
	Previously Treated	23	62,2	1	4,3	22	95,7	NE	NE	NE	NE	NE	NE
Molecular Testing Results	Local	12	32,4			12	100,0	NE	NE	NE	NE	NE	NE
	Central	25	67,6	1	4,0	24	96,0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13HA_SG.xls
07SEP2019 19:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	1	2,9	34	97,1	NE	NE	NE	NE	NE	NE
	No	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8			4	100,0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13HA_SG.xls
07SEP2019 19:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	1	3,0	32	97,0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13HA_SG.xls
07SEP2019 19:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	12	32,4	25	67,6	6,47	1,91	NE	NE	13,11	NE
Sex	Male	14	37,8	4	28,6	10	71,4	6,47	3,75	NE	NE	6,47	NE
	Female	23	62,2	8	34,8	15	65,2	6,92	1,02	NE	NE	10,18	NE
Age	18-64	29	78,4	9	31,0	20	69,0	10,18	1,02	NE	NE	10,18	NE
	65-74	8	21,6	3	37,5	5	62,5	3,75	3,65	NE	13,11	3,75	NE
Race	White	20	54,1	6	30,0	14	70,0	10,18	1,02	NE	NE	10,18	NE
	Other	17	45,9	6	35,3	11	64,7	3,75	0,95	NE	NE	3,75	NE
Region	America (AM)	12	32,4	5	41,7	7	58,3	3,75	1,02	NE	NE	3,75	NE
	Europe (EU)	10	27,0	2	20,0	8	80,0	10,18	3,65	NE	NE	10,18	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13HR_SG.xls
07SEP2019 19:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	5	33,3	10	66,7	6,47	0,95	NE	NE	6,47	NE
ECOG Performance Status	0	15	40,5	5	33,3	10	66,7	10,18	3,65	NE	NE	13,11	NE
	1	17	45,9	5	29,4	12	70,6	6,47	1,02	NE	NE	6,47	NE
	2	5	13,5	2	40,0	3	60,0	0,95	0,95	10,18	10,18	0,95	10,18
Number of Prior Anticancer Therapies	None	14	37,8	5	35,7	9	64,3	10,18	3,75	NE	NE	10,18	NE
	1	2	5,4	1	50,0	1	50,0	10,18	NE	NE	10,18	NE	NE
	2 or More	21	56,8	6	28,6	15	71,4	3,65	0,95	NE	NE	3,65	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13HR_SG.xls
07SEP2019 19:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	5	35,7	9	64,3	10,18	3,75	NE	NE	10,18	NE
	Previously Treated	23	62,2	7	30,4	16	69,6	3,65	0,95	NE	NE	10,18	NE
Molecular Testing Results	Local	12	32,4	5	41,7	7	58,3	1,91	1,02	NE	NE	1,91	NE
	Central	25	67,6	7	28,0	18	72,0	10,18	6,47	NE	NE	13,11	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13HR_SG.xls
07SEP2019 19:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	12	34,3	23	65,7	6,47	1,91	NE	NE	10,18	NE
	No	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	6,47	6,47	NE	NE	6,47	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13HR_SG.xls
07SEP2019 19:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	11	33,3	22	66,7	10,18	1,02	NE	NE	13,11	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13HR_SG.xls
07SEP2019 19:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	10	27,0	27	73,0	4,63	1,31	NE	NE	NE	NE
Sex	Male	14	37,8	3	21,4	11	78,6	NE	1,31	NE	NE	NE	NE
	Female	23	62,2	7	30,4	16	69,6	3,81	1,02	NE	NE	3,91	NE
Age	18-64	29	78,4	6	20,7	23	79,3	NE	2,76	NE	NE	NE	NE
	65-74	8	21,6	4	50,0	4	50,0	1,31	0,95	4,63	4,27	1,31	NE
Race	White	20	54,1	4	20,0	16	80,0	NE	1,31	NE	NE	NE	NE
	Other	17	45,9	6	35,3	11	64,7	3,71	0,95	NE	NE	3,91	NE
Region	America (AM)	12	32,4	3	25,0	9	75,0	3,91	2,76	NE	NE	3,91	NE
	Europe (EU)	10	27,0	1	10,0	9	90,0	NE	0,95	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PA_SG.xls
07SEP2019 19:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	6	40,0	9	60,0	1,31	0,95	NE	NE	1,31	NE
ECOG Performance Status	0	15	40,5	4	26,7	11	73,3	4,63	3,71	NE	NE	NE	NE
	1	17	45,9	5	29,4	12	70,6	2,76	1,02	NE	NE	11,99	NE
	2	5	13,5	1	20,0	4	80,0	0,95	0,95	NE	NE	0,95	NE
Number of Prior Anticancer Therapies	None	14	37,8	3	21,4	11	78,6	NE	3,71	NE	NE	NE	NE
	1	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
	2 or More	21	56,8	7	33,3	14	66,7	1,31	0,95	NE	NE	4,63	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PA_SG.xls
07SEP2019 19:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	3	21,4	11	78,6	NE	3,71	NE	NE	NE	NE
	Previously Treated	23	62,2	7	30,4	16	69,6	1,31	0,95	NE	NE	4,63	NE
Molecular Testing Results	Local	12	32,4	2	16,7	10	83,3	NE	0,95	NE	NE	NE	NE
	Central	25	67,6	8	32,0	17	68,0	3,91	1,02	NE	NE	4,63	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PA_SG.xls
07SEP2019 19:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	10	28,6	25	71,4	4,63	1,31	NE	NE	NE	NE
	No	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	0,85	0,85	NE	NE	0,85	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PA_SG.xls
07SEP2019 19:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	9	27,3	24	72,7	4,63	1,31	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PA_SG.xls
07SEP2019 19:24

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	13	35,1	24	64,9	6,47	1,48	13,83	NE	9,23	NE
Sex	Male	14	37,8	4	28,6	10	71,4	6,47	0,92	NE	NE	6,47	NE
	Female	23	62,2	9	39,1	14	60,9	5,54	1,48	13,83	13,83	6,51	NE
Age	18-64	29	78,4	10	34,5	19	65,5	6,51	1,48	NE	NE	13,80	NE
	65-74	8	21,6	3	37,5	5	62,5	4,57	0,95	NE	6,47	4,57	NE
Race	White	20	54,1	6	30,0	14	70,0	9,23	4,57	NE	NE	13,83	NE
	Other	17	45,9	7	41,2	10	58,8	3,71	0,95	13,80	13,80	5,49	NE
Region	America (AM)	12	32,4	2	16,7	10	83,3	NE	0,95	NE	NE	NE	NE
	Europe (EU)	10	27,0	4	40,0	6	60,0	4,57	0,92	NE	NE	4,57	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PC_SG.xls
07SEP2019 19:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	7	46,7	8	53,3	5,49	0,95	13,80	9,23	5,49	NE
ECOG Performance Status	0	15	40,5	4	26,7	11	73,3	6,47	1,48	NE	NE	6,47	NE
	1	17	45,9	7	41,2	10	58,8	5,49	0,92	13,83	13,80	9,23	NE
	2	5	13,5	2	40,0	3	60,0	0,95	0,95	6,51	6,51	0,95	6,51
Number of Prior Anticancer Therapies	None	14	37,8	5	35,7	9	64,3	6,51	1,48	NE	NE	6,51	NE
	1	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
	2 or More	21	56,8	8	38,1	13	61,9	5,49	0,95	13,80	13,80	6,47	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PC_SG.xls
07SEP2019 19:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	5	35,7	9	64,3	6,51	1,48	NE	NE	6,51	NE
	Previously Treated	23	62,2	8	34,8	15	65,2	5,49	0,95	NE	NE	6,47	NE
Molecular Testing Results	Local	12	32,4	4	33,3	8	66,7	5,49	3,71	NE	NE	5,49	NE
	Central	25	67,6	9	36,0	16	64,0	6,47	0,95	NE	NE	6,51	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PC_SG.xls
07SEP2019 19:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	12	34,3	23	65,7	6,47	1,48	NE	NE	13,80	NE
	No	2	5,4	1	50,0	1	50,0	3,71	NE	NE	3,71	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	0,85	0,85	NE	NE	0,85	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PC_SG.xls
07SEP2019 19:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	12	36,4	21	63,6	6,47	3,71	13,83	NE	9,23	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PC_SG.xls
07SEP2019 19:28

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	19	51,4	18	48,6	1,81	0,95	2,79	5,52	1,87	NE
Sex	Male	14	37,8	6	42,9	8	57,1	0,95	0,95	NE	NE	0,95	NE
	Female	23	62,2	13	56,5	10	43,5	1,86	1,81	4,63	5,08	1,87	NE
Age	18-64	29	78,4	17	58,6	12	41,4	1,81	0,95	2,79	4,63	1,87	NE
	65-74	8	21,6	2	25,0	6	75,0	1,81	0,95	NE	NE	1,81	NE
Race	White	20	54,1	12	60,0	8	40,0	0,95	0,95	3,75	3,75	1,02	NE
	Other	17	45,9	7	41,2	10	58,8	1,87	1,81	6,47	6,47	1,87	NE
Region	America (AM)	12	32,4	7	58,3	5	41,7	0,95	0,95	1,84	1,84	0,95	NE
	Europe (EU)	10	27,0	6	60,0	4	40,0	1,05	0,92	7,56	3,75	1,05	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PN_SG.xls
07SEP2019 19:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	6	40,0	9	60,0	4,63	1,87	NE	6,47	4,63	NE
ECOG Performance Status	0	15	40,5	5	33,3	10	66,7	0,95	0,95	NE	NE	1,81	NE
	1	17	45,9	11	64,7	6	35,3	1,84	1,02	4,63	4,63	1,87	7,56
	2	5	13,5	3	60,0	2	40,0	1,81	1,81	3,75	1,97	1,81	3,75
Number of Prior Anticancer Therapies	None	14	37,8	9	64,3	5	35,7	1,05	0,95	2,79	2,33	1,05	NE
	1	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE
	2 or More	21	56,8	9	42,9	12	57,1	1,97	0,95	7,56	7,56	4,63	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PN_SG.xls
07SEP2019 19:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	9	64,3	5	35,7	1,05	0,95	2,79	2,33	1,05	NE
	Previously Treated	23	62,2	10	43,5	13	56,5	1,87	0,95	6,47	6,47	1,97	NE
Molecular Testing Results	Local	12	32,4	7	58,3	5	41,7	0,95	0,95	2,79	2,79	0,95	NE
	Central	25	67,6	12	48,0	13	52,0	1,84	1,05	5,52	5,52	1,87	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PN_SG.xls
07SEP2019 19:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	18	51,4	17	48,6	1,81	0,95	3,75	5,52	1,87	NE
	No	2	5,4	1	50,0	1	50,0	2,79	NE	NE	2,79	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PN_SG.xls
07SEP2019 19:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Investigator Measurable CNS Disease	Yes	4	10,8	1	25,0	3	75,0	1,87	1,87	NE	NE	1,87	NE
	No	33	89,2	18	54,5	15	45,5	1,81	0,95	3,75	5,52	1,87	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PN_SG.xls
07SEP2019 19:31

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	14	37,8	23	62,2	3,68	0,95	7,56	NE	4,57	NE
Sex	Male	14	37,8	8	57,1	6	42,9	2,30	0,95	4,57	4,47	2,73	NE
	Female	23	62,2	6	26,1	17	73,9	7,39	0,95	NE	NE	7,56	NE
Age	18-64	29	78,4	11	37,9	18	62,1	3,65	0,95	NE	NE	4,57	NE
	65-74	8	21,6	3	37,5	5	62,5	4,37	0,95	NE	NE	4,37	NE
Race	White	20	54,1	7	35,0	13	65,0	2,73	0,95	NE	NE	4,37	NE
	Other	17	45,9	7	41,2	10	58,8	3,71	0,95	7,39	7,39	3,71	NE
Region	America (AM)	12	32,4	5	41,7	7	58,3	1,87	0,95	NE	NE	1,87	NE
	Europe (EU)	10	27,0	3	30,0	7	70,0	5,60	0,95	NE	NE	3,65	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PO_SG.xls
07SEP2019 19:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	6	40,0	9	60,0	4,37	0,95	NE	7,39	4,37	NE
ECOG Performance Status	0	15	40,5	7	46,7	8	53,3	1,87	0,95	NE	NE	2,73	NE
	1	17	45,9	6	35,3	11	64,7	4,37	3,65	NE	NE	4,37	NE
	2	5	13,5	1	20,0	4	80,0	0,95	0,95	NE	NE	0,95	NE
Number of Prior Anticancer Therapies	None	14	37,8	6	42,9	8	57,1	3,65	1,87	NE	NE	3,65	NE
	1	2	5,4	1	50,0	1	50,0	0,95	NE	NE	0,95	NE	NE
	2 or More	21	56,8	7	33,3	14	66,7	4,57	0,95	NE	NE	4,57	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PO_SG.xls
07SEP2019 19:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	6	42,9	8	57,1	3,65	1,87	NE	NE	3,65	NE
	Previously Treated	23	62,2	8	34,8	15	65,2	4,37	0,95	NE	NE	4,57	NE
Molecular Testing Results	Local	12	32,4	7	58,3	5	41,7	1,87	0,95	4,57	4,57	1,87	NE
	Central	25	67,6	7	28,0	18	72,0	7,39	0,95	NE	NE	7,39	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PO_SG.xls
07SEP2019 19:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	13	37,1	22	62,9	3,65	0,95	7,56	NE	7,39	NE
	No	2	5,4	1	50,0	1	50,0	3,71	NE	NE	3,71	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8			4	100,0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PO_SG.xls
07SEP2019 19:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	14	42,4	19	57,6	3,65	0,95	7,39	NE	4,37	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13PO_SG.xls
07SEP2019 19:35

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	37	100,0	10	27,0	27	73,0	3,71	1,84	NE	NE	NE	NE
Sex	Male	14	37,8	1	7,1	13	92,9	NE	8,31	NE	NE	NE	NE
	Female	23	62,2	9	39,1	14	60,9	1,86	0,99	NE	NE	1,87	NE
Age	18-64	29	78,4	9	31,0	20	69,0	3,71	1,84	NE	NE	8,31	NE
	65-74	8	21,6	1	12,5	7	87,5	NE	0,95	NE	NE	NE	NE
Race	White	20	54,1	7	35,0	13	65,0	3,65	0,95	NE	NE	3,71	NE
	Other	17	45,9	3	17,6	14	82,4	NE	1,87	NE	NE	NE	NE
Region	America (AM)	12	32,4	3	25,0	9	75,0	8,31	0,99	NE	NE	8,31	NE
	Europe (EU)	10	27,0	4	40,0	6	60,0	1,22	0,95	NE	NE	0,95	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13SM_SG.xls
07SEP2019 19:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	15	40,5	3	20,0	12	80,0	4,60	3,71	NE	NE	4,60	NE
ECOG Performance Status	0	15	40,5	4	26,7	11	73,3	8,31	0,99	NE	NE	8,31	NE
	1	17	45,9	4	23,5	13	76,5	4,60	1,87	NE	NE	4,60	NE
	2	5	13,5	2	40,0	3	60,0	0,95	0,95	3,65	3,65	0,95	3,65
Number of Prior Anticancer Therapies	None	14	37,8	5	35,7	9	64,3	1,84	0,99	NE	NE	1,84	NE
	1	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
	2 or More	21	56,8	5	23,8	16	76,2	4,60	1,87	NE	NE	4,60	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13SM_SG.xls
07SEP2019 19:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	14	37,8	5	35,7	9	64,3	1,84	0,99	NE	NE	1,84	NE
	Previously Treated	23	62,2	5	21,7	18	78,3	4,60	1,87	NE	NE	4,60	NE
Molecular Testing Results	Local	12	32,4	3	25,0	9	75,0	8,31	0,95	NE	NE	8,31	NE
	Central	25	67,6	7	28,0	18	72,0	3,71	1,84	NE	NE	4,60	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13SM_SG.xls
07SEP2019 19:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	35	94,6	10	28,6	25	71,4	3,71	1,84	NE	NE	8,31	NE
	No	2	5,4			2	100,0	NE	NE	NE	NE	NE	NE
Investigator Measurable CNS Disease	Yes	4	10,8			4	100,0	NE	NE	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13SM_SG.xls
07SEP2019 19:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=37)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	33	89,2	10	30,3	23	69,7	3,71	1,48	NE	NE	8,31	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA/prod/output/eff_tte_NDA_REE_LC13SM_SG.xls
07SEP2019 19:43

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	23	29,5	55	70,5	7,39	3,65	23,23	NE	23,23	NE
Sex	Male	29	37,2	8	27,6	21	72,4	7,39	2,79	NE	NE	14,62	NE
	Female	49	62,8	15	30,6	34	69,4	7,39	2,76	23,23	NE	18,43	NE
Age	18-64	62	79,5	18	29,0	44	71,0	7,39	2,79	NE	NE	23,23	NE
	65-74	14	17,9	4	28,6	10	71,4	14,62	0,92	NE	NE	14,62	NE
	>=75	2	2,6	1	50,0	1	50,0	0,95	0,95	NE	NE	0,95	NE
Race	White	35	44,9	11	31,4	24	68,6	7,39	4,37	NE	NE	18,43	NE
	Other	43	55,1	12	27,9	31	72,1	7,39	2,76	NE	NE	14,62	NE
Region	America (AM)	22	28,2	6	27,3	16	72,7	10,22	7,39	NE	NE	23,23	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13CO_SG.xls
28NOV2019 9:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	5	29,4	12	70,6	5,49	0,95	NE	NE	5,49	NE
	Asia (AS)	39	50,0	12	30,8	27	69,2	3,65	1,02	NE	NE	7,39	NE
ECOG Performance Status	0	30	38,5	11	36,7	19	63,3	7,39	1,87	NE	23,23	14,62	NE
	1	38	48,7	11	28,9	27	71,1	7,39	2,76	NE	NE	10,22	NE
	2	10	12,8	1	10,0	9	90,0	NE	0,95	NE	NE	NE	NE
Number of Prior Anticancer Therapies	None	31	39,7	7	22,6	24	77,4	NE	5,68	NE	NE	NE	NE
	1	3	3,8	1	33,3	2	66,7	5,49	5,49	NE	NE	5,49	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13CO_SG.xls
28NOV2019 9:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	15	34,1	29	65,9	4,37	1,02	18,43	23,23	10,22	NE
Prior Treatment	Naïve	31	39,7	7	22,6	24	77,4	NE	5,68	NE	NE	NE	NE
	Previously Treated	47	60,3	16	34,0	31	66,0	4,37	1,02	18,43	23,23	10,22	NE
Molecular Testing Results	Local	35	44,9	7	20,0	28	80,0	23,23	7,39	NE	NE	23,23	NE
	Central	43	55,1	16	37,2	27	62,8	4,37	1,02	18,43	NE	7,39	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13CO_SG.xls
28NOV2019 9:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	22	29,7	52	70,3	7,39	3,65	23,23	NE	23,23	NE
	No	4	5,1	1	25,0	3	75,0	0,92	0,92	NE	NE	0,92	NE
Investigator Measurable CNS Disease	Yes	8	10,3	4	50,0	4	50,0	2,79	0,85	9,23	6,44	2,79	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13CO_SG.xls
28NOV2019 9:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	70	89,7	19	27,1	51	72,9	7,39	5,49	NE	NE	23,23	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13CO_SG.xls
28NOV2019 9:51

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	39	50,0	39	50,0	0,99	0,95	1,87	7,39	2,14	NE
Sex	Male	29	37,2	14	48,3	15	51,7	0,95	0,95	6,47	7,39	2,79	NE
	Female	49	62,8	25	51,0	24	49,0	0,99	0,95	1,84	3,71	1,81	NE
Age	18-64	62	79,5	29	46,8	33	53,2	1,61	0,95	2,83	13,80	2,83	NE
	65-74	14	17,9	9	64,3	5	35,7	0,95	0,92	0,99	0,99	0,95	3,75
	>=75	2	2,6	1	50,0	1	50,0	0,95	0,95	NE	NE	0,95	NE
Race	White	35	44,9	14	40,0	21	60,0	1,87	1,02	15,67	21,16	7,39	NE
	Other	43	55,1	25	58,1	18	41,9	0,95	0,95	1,02	2,46	0,99	13,80
Region	America (AM)	22	28,2	11	50,0	11	50,0	1,43	0,95	9,26	9,26	1,84	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13DS_SG.xls
28NOV2019 9:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	6	35,3	11	64,7	1,87	0,95	NE	NE	2,83	NE
	Asia (AS)	39	50,0	22	56,4	17	43,6	0,95	0,95	1,81	2,79	0,99	15,67
ECOG Performance Status	0	30	38,5	19	63,3	11	36,7	0,95	0,95	2,83	3,75	0,99	21,16
	1	38	48,7	19	50,0	19	50,0	0,99	0,95	2,79	13,80	1,61	NE
	2	10	12,8	1	10,0	9	90,0	NE	1,81	NE	NE	1,81	NE
Number of Prior Anticancer Therapies	None	31	39,7	14	45,2	17	54,8	1,84	0,95	3,75	NE	2,83	NE
	1	3	3,8	1	33,3	2	66,7	9,26	NE	NE	9,26	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13DS_SG.xls
28NOV2019 9:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	24	54,5	20	45,5	0,95	0,95	1,61	2,14	1,02	21,16
Prior Treatment	Naïve	31	39,7	14	45,2	17	54,8	1,84	0,95	3,75	NE	2,83	NE
	Previously Treated	47	60,3	25	53,2	22	46,8	0,95	0,95	1,81	2,83	1,02	21,16
Molecular Testing Results	Local	35	44,9	19	54,3	16	45,7	0,95	0,95	2,14	3,71	1,02	NE
	Central	43	55,1	20	46,5	23	53,5	1,02	0,95	3,65	9,26	2,79	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13DS_SG.xls
28NOV2019 9:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	37	50,0	37	50,0	1,02	0,95	2,14	7,39	2,79	NE
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	0,95	0,94	0,92	0,95
Investigator Measurable CNS Disease	Yes	8	10,3	2	25,0	6	75,0	3,71	1,81	NE	NE	1,81	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13DS_SG.xls
28NOV2019 9:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	70	89,7	37	52,9	33	47,1	0,95	0,95	1,84	6,47	1,87	21,16

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13DS_SG.xls
28NOV2019 9:53

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	42	53,8	36	46,2	1,87	1,05	2,79	8,31	2,83	17,54
Sex	Male	29	37,2	15	51,7	14	48,3	3,71	0,95	12,91	15,67	5,55	21,72
	Female	49	62,8	27	55,1	22	44,9	1,81	1,02	2,79	2,83	2,73	NE
Age	18-64	62	79,5	31	50,0	31	50,0	1,87	1,81	2,79	9,23	2,79	NE
	65-74	14	17,9	9	64,3	5	35,7	0,95	0,92	4,63	4,63	0,95	15,67
	>=75	2	2,6	2	100,0			2,79	2,79	12,91	7,85	2,79	12,91
Race	White	35	44,9	17	48,6	18	51,4	1,81	0,95	3,71	12,91	1,87	NE
	Other	43	55,1	25	58,1	18	41,9	2,73	1,87	2,83	4,67	2,79	15,67
Region	America (AM)	22	28,2	13	59,1	9	40,9	1,56	0,95	12,19	12,19	2,07	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13DY_SG.xls
28NOV2019 9:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	8	47,1	9	52,9	1,87	0,95	12,91	11,93	2,83	NE
	Asia (AS)	39	50,0	21	53,8	18	46,2	1,87	0,95	2,79	4,60	2,76	NE
ECOG Performance Status	0	30	38,5	16	53,3	14	46,7	2,83	0,95	12,19	15,67	3,71	NE
	1	38	48,7	22	57,9	16	42,1	1,87	1,81	2,79	5,55	2,79	12,91
	2	10	12,8	4	40,0	6	60,0	0,95	0,95	2,73	2,27	0,95	NE
Number of Prior Anticancer Therapies	None	31	39,7	20	64,5	11	35,5	1,87	1,02	3,71	8,31	2,79	21,72
	1	3	3,8	1	33,3	2	66,7	17,54	NE	NE	17,54	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13DY_SG.xls
28NOV2019 9:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	21	47,7	23	52,3	1,87	0,95	2,79	4,63	2,76	NE
Prior Treatment	Naïve	31	39,7	20	64,5	11	35,5	1,87	1,02	3,71	8,31	2,79	21,72
	Previously Treated	47	60,3	22	46,8	25	53,2	1,87	0,95	2,83	5,55	2,79	NE
Molecular Testing Results	Local	35	44,9	16	45,7	19	54,3	2,73	0,95	3,71	15,67	2,79	NE
	Central	43	55,1	26	60,5	17	39,5	1,87	1,05	2,83	4,67	2,76	12,91

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13DY_SG.xls
28NOV2019 9:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	40	54,1	34	45,9	1,87	1,81	2,79	9,23	2,83	17,54
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	2,79	1,86	0,92	2,79
Investigator Measurable CNS Disease	Yes	8	10,3	4	50,0	4	50,0	0,89	0,85	9,23	5,52	0,89	NE
	No	70	89,7	38	54,3	32	45,7	1,87	1,81	2,79	8,31	2,83	21,72

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13DY_SG.xls
28NOV2019 9:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13DY_SG.xls
28NOV2019 9:55

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	8	10,3	70	89,7	NE	24,80	NE	NE	NE	NE
Sex	Male	29	37,2	5	17,2	24	82,8	NE	5,49	NE	NE	NE	NE
	Female	49	62,8	3	6,1	46	93,9	NE	24,80	NE	NE	NE	NE
Age	18-64	62	79,5	8	12,9	54	87,1	NE	24,80	NE	NE	NE	NE
	65-74	14	17,9			14	100,0	NE	NE	NE	NE	NE	NE
	>=75	2	2,6			2	100,0	NE	NE	NE	NE	NE	NE
Race	White	35	44,9	3	8,6	32	91,4	NE	NE	NE	NE	NE	NE
	Other	43	55,1	5	11,6	38	88,4	24,80	24,80	NE	NE	24,80	NE
Region	America (AM)	22	28,2			22	100,0	NE	NE	NE	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13HA_SG.xls
28NOV2019 10:04

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	3	17,6	14	82,4	NE	1,87	NE	NE	NE	NE
	Asia (AS)	39	50,0	5	12,8	34	87,2	24,80	24,80	NE	NE	24,80	NE
ECOG Performance Status	0	30	38,5	2	6,7	28	93,3	NE	NE	NE	NE	NE	NE
	1	38	48,7	5	13,2	33	86,8	24,80	24,80	NE	NE	24,80	NE
	2	10	12,8	1	10,0	9	90,0	NE	3,68	NE	NE	3,68	NE
Number of Prior Anticancer Therapies	None	31	39,7	2	6,5	29	93,5	NE	NE	NE	NE	NE	NE
	1	3	3,8	1	33,3	2	66,7	5,49	5,49	NE	NE	5,49	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13HA_SG.xls
28NOV2019 10:04

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	5	11,4	39	88,6	24,80	24,80	NE	24,80	24,80	NE
Prior Treatment	Naïve	31	39,7	2	6,5	29	93,5	NE	NE	NE	NE	NE	NE
	Previously Treated	47	60,3	6	12,8	41	87,2	24,80	5,55	NE	24,80	24,80	NE
Molecular Testing Results	Local	35	44,9	2	5,7	33	94,3	NE	NE	NE	NE	NE	NE
	Central	43	55,1	6	14,0	37	86,0	24,80	5,55	NE	NE	24,80	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13HA_SG.xls
28NOV2019 10:04

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	8	10,8	66	89,2	NE	24,80	NE	NE	NE	NE
	No	4	5,1			4	100,0	NE	NE	NE	NE	NE	NE
Investigator Measurable CNS Disease	Yes	8	10,3			8	100,0	NE	NE	NE	NE	NE	NE
	No	70	89,7	8	11,4	62	88,6	NE	24,80	NE	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13HA_SG.xls
28NOV2019 10:04

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13HA_SG.xls
28NOV2019 10:04

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	32	41,0	46	59,0	4,22	2,79	8,31	22,11	10,18	NE
Sex	Male	29	37,2	11	37,9	18	62,1	3,75	2,79	11,99	NE	5,55	NE
	Female	49	62,8	21	42,9	28	57,1	4,63	2,73	12,91	22,11	8,31	NE
Age	18-64	62	79,5	24	38,7	38	61,3	4,63	2,14	10,18	23,00	10,18	NE
	65-74	14	17,9	7	50,0	7	50,0	3,71	2,79	12,91	7,43	3,71	13,11
	>=75	2	2,6	1	50,0	1	50,0	11,99	11,99	NE	NE	11,99	NE
Race	White	35	44,9	13	37,1	22	62,9	7,36	3,81	13,83	NE	10,18	NE
	Other	43	55,1	19	44,2	24	55,8	2,79	1,91	8,31	13,11	4,63	NE
Region	America (AM)	22	28,2	10	45,5	12	54,5	3,78	3,65	13,11	13,11	3,81	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13HR_SG.xls
28NOV2019 10:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	5	29,4	12	70,6	10,18	5,55	NE	NE	10,18	NE
	Asia (AS)	39	50,0	17	43,6	22	56,4	2,79	1,87	12,91	13,83	6,47	NE
ECOG Performance Status	0	30	38,5	12	40,0	18	60,0	7,36	3,71	NE	NE	10,18	NE
	1	38	48,7	17	44,7	21	55,3	2,79	1,87	11,99	13,83	6,47	NE
	2	10	12,8	3	30,0	7	70,0	2,73	0,95	NE	10,18	2,73	NE
Number of Prior Anticancer Therapies	None	31	39,7	13	41,9	18	58,1	4,63	3,65	23,00	23,00	6,47	NE
	1	3	3,8	1	33,3	2	66,7	10,18	NE	NE	10,18	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13HR_SG.xls
28NOV2019 10:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	18	40,9	26	59,1	3,65	1,91	11,99	13,83	7,36	NE
Prior Treatment	Naïve	31	39,7	13	41,9	18	58,1	4,63	3,65	23,00	23,00	6,47	NE
	Previously Treated	47	60,3	19	40,4	28	59,6	3,65	1,91	10,18	12,91	7,43	NE
Molecular Testing Results	Local	35	44,9	16	45,7	19	54,3	2,79	1,87	4,63	7,36	3,65	NE
	Central	43	55,1	16	37,2	27	62,8	8,31	5,55	13,11	22,11	11,99	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13HR_SG.xls
28NOV2019 10:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	30	40,5	44	59,5	3,81	2,79	8,31	22,11	8,31	NE
	No	4	5,1	2	50,0	2	50,0	12,91	12,91	23,00	17,95	12,91	23,00
Investigator Measurable CNS Disease	Yes	8	10,3	3	37,5	5	62,5	5,59	4,63	NE	6,47	4,63	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13HR_SG.xls
28NOV2019 10:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	70	89,7	29	41,4	41	58,6	3,75	2,79	10,18	22,11	10,18	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13HR_SG.xls
28NOV2019 10:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	32	41,0	46	59,0	3,65	1,81	6,47	20,34	8,34	NE
Sex	Male	29	37,2	13	44,8	16	55,2	1,87	0,95	19,35	19,35	2,69	NE
	Female	49	62,8	19	38,8	30	61,2	3,71	2,76	11,01	23,00	6,47	NE
Age	18-64	62	79,5	21	33,9	41	66,1	6,47	2,69	19,35	NE	12,06	NE
	65-74	14	17,9	9	64,3	5	35,7	1,31	0,92	3,91	3,91	1,31	6,44
	>=75	2	2,6	2	100,0			1,87	1,87	3,71	2,79	1,87	3,71
Race	White	35	44,9	13	37,1	22	62,9	2,83	1,87	19,35	NE	11,01	NE
	Other	43	55,1	19	44,2	24	55,8	3,71	0,95	6,47	12,06	4,63	23,00
Region	America (AM)	22	28,2	9	40,9	13	59,1	3,86	3,65	20,34	20,34	3,91	NE
	Europe (EU)	17	21,8	5	29,4	12	70,6	2,69	0,95	NE	NE	2,83	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PA_SG.xls
28NOV2019 10:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Asia (AS)	39	50,0	18	46,2	21	53,8	1,81	0,95	6,47	11,01	4,63	NE
ECOG Performance Status	0	30	38,5	14	46,7	16	53,3	3,91	1,94	19,35	20,34	6,47	NE
	1	38	48,7	16	42,1	22	57,9	2,69	1,31	11,99	23,00	3,71	NE
	2	10	12,8	2	20,0	8	80,0	0,95	0,95	NE	NE	0,95	NE
Number of Prior Anticancer Therapies	None	31	39,7	15	48,4	16	51,6	3,81	2,76	19,35	20,34	6,47	NE
	1	3	3,8			3	100,0	NE	NE	NE	NE	NE	NE
	2 or More	44	56,4	17	38,6	27	61,4	1,31	0,95	8,34	11,99	4,63	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PA_SG.xls
28NOV2019 10:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
Prior Treatment	Naïve	31	39,7	15	48,4	16	51,6	3,81	2,76	19,35	20,34	6,47	NE
	Previously Treated	47	60,3	17	36,2	30	63,8	1,87	0,95	8,34	NE	4,63	NE
Molecular Testing Results	Local	35	44,9	13	37,1	22	62,9	6,44	0,95	20,34	20,34	12,06	NE
	Central	43	55,1	19	44,2	24	55,8	2,76	1,31	4,63	11,99	3,81	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PA_SG.xls
28NOV2019 10:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	30	40,5	44	59,5	3,65	1,87	6,47	19,35	8,34	NE
	No	4	5,1	2	50,0	2	50,0	0,92	0,92	23,00	11,96	0,92	23,00
Investigator Measurable CNS Disease	Yes	8	10,3	4	50,0	4	50,0	0,89	0,85	12,06	11,01	0,89	NE
	No	70	89,7	28	40,0	42	60,0	3,65	1,87	6,47	20,34	6,47	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PA_SG.xls
28NOV2019 10:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PA_SG.xls
28NOV2019 10:10

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	23	29,5	55	70,5	12,81	5,49	20,27	27,56	20,24	NE
Sex	Male	29	37,2	6	20,7	23	79,3	20,27	5,49	NE	NE	20,27	NE
	Female	49	62,8	17	34,7	32	65,3	6,87	3,71	17,58	27,56	13,80	27,56
Age	18-64	62	79,5	19	30,6	43	69,4	12,81	5,49	20,27	27,56	20,24	NE
	65-74	14	17,9	4	28,6	10	71,4	4,57	0,95	NE	NE	4,57	NE
	>=75	2	2,6			2	100,0	NE	NE	NE	NE	NE	NE
Race	White	35	44,9	10	28,6	25	71,4	13,83	6,51	NE	NE	20,24	NE
	Other	43	55,1	13	30,2	30	69,8	6,47	1,87	27,56	27,56	13,80	27,56
Region	America (AM)	22	28,2	6	27,3	16	72,7	20,24	13,83	NE	NE	20,24	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PC_SG.xls
28NOV2019 10:12

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	4	23,5	13	76,5	6,51	1,48	NE	NE	6,51	NE
	Asia (AS)	39	50,0	13	33,3	26	66,7	6,47	1,87	13,80	27,56	9,23	27,56
ECOG Performance Status	0	30	38,5	10	33,3	20	66,7	12,81	3,71	NE	NE	20,24	NE
	1	38	48,7	11	28,9	27	71,1	13,80	3,71	27,56	27,56	13,83	27,56
	2	10	12,8	2	20,0	8	80,0	6,51	0,95	NE	6,51	6,51	NE
Number of Prior Anticancer Therapies	None	31	39,7	11	35,5	20	64,5	12,81	1,87	20,27	NE	13,83	NE
	1	3	3,8			3	100,0	NE	NE	NE	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PC_SG.xls
28NOV2019 10:12

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	12	27,3	32	72,7	9,23	4,57	27,56	27,56	20,24	27,56
Prior Treatment	Naïve	31	39,7	11	35,5	20	64,5	12,81	1,87	20,27	NE	13,83	NE
	Previously Treated	47	60,3	12	25,5	35	74,5	9,23	4,57	27,56	27,56	20,24	27,56
Molecular Testing Results	Local	35	44,9	8	22,9	27	77,1	17,58	5,49	NE	NE	20,24	NE
	Central	43	55,1	15	34,9	28	65,1	6,51	1,81	27,56	27,56	9,23	27,56

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PC_SG.xls
28NOV2019 10:12

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	21	28,4	53	71,6	13,80	6,47	20,27	27,56	20,24	NE
	No	4	5,1	2	50,0	2	50,0	3,71	NE	NE	3,71	NE	NE
Investigator Measurable CNS Disease	Yes	8	10,3	3	37,5	5	62,5	12,81	0,85	17,58	17,58	12,81	17,58
	No	70	89,7	20	28,6	50	71,4	9,23	5,49	27,56	27,56	20,24	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PC_SG.xls
28NOV2019 10:12

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PC_SG.xls
28NOV2019 10:12

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	51	65,4	27	34,6	1,02	0,95	1,87	3,65	2,69	6,47
Sex	Male	29	37,2	19	65,5	10	34,5	0,95	0,95	1,87	2,69	0,95	15,67
	Female	49	62,8	32	65,3	17	34,7	1,81	0,99	2,79	3,75	2,79	7,56
Age	18-64	62	79,5	42	67,7	20	32,3	0,99	0,95	1,87	2,79	1,87	6,41
	65-74	14	17,9	7	50,0	7	50,0	1,81	0,95	15,67	15,67	1,81	18,50
	>=75	2	2,6	2	100,0			1,87	1,87	11,99	6,93	1,87	11,99
Race	White	35	44,9	26	74,3	9	25,7	1,02	0,95	1,97	2,79	1,87	4,63
	Other	43	55,1	25	58,1	18	41,9	1,05	0,95	2,79	5,52	2,73	18,50
Region	America (AM)	22	28,2	13	59,1	9	40,9	0,99	0,95	1,87	2,76	1,02	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PN_SG.xls
28NOV2019 10:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	14	82,4	3	17,6	1,46	0,95	2,79	2,81	1,87	6,51
	Asia (AS)	39	50,0	24	61,5	15	38,5	0,99	0,95	2,79	5,49	2,73	15,87
ECOG Performance Status	0	30	38,5	21	70,0	9	30,0	0,95	0,95	2,79	2,83	0,99	15,87
	1	38	48,7	25	65,8	13	34,2	1,84	0,95	2,79	4,63	2,69	6,47
	2	10	12,8	5	50,0	5	50,0	1,81	0,95	2,73	2,35	1,81	3,75
Number of Prior Anticancer Therapies	None	31	39,7	22	71,0	9	29,0	1,05	0,95	2,79	3,22	1,84	15,67
	1	3	3,8	2	66,7	1	33,3	0,95	0,95	3,65	2,30	0,95	3,65

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PN_SG.xls
28NOV2019 10:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	27	61,4	17	38,6	0,95	0,95	2,73	4,63	1,87	6,51
Prior Treatment	Naïve	31	39,7	22	71,0	9	29,0	1,05	0,95	2,79	3,22	1,84	15,67
	Previously Treated	47	60,3	29	61,7	18	38,3	0,95	0,95	2,73	4,63	1,87	6,51
Molecular Testing Results	Local	35	44,9	21	60,0	14	40,0	0,95	0,95	1,87	2,79	0,95	6,47
	Central	43	55,1	30	69,8	13	30,2	1,87	1,05	2,83	3,75	2,79	11,99

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PN_SG.xls
28NOV2019 10:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	49	66,2	25	33,8	1,02	0,95	1,87	3,65	1,97	6,47
	No	4	5,1	2	50,0	2	50,0	2,79	2,79	18,50	10,64	2,79	18,50
Investigator Measurable CNS Disease	Yes	8	10,3	3	37,5	5	62,5	2,79	1,87	NE	15,87	1,87	NE
	No	70	89,7	48	68,6	22	31,4	0,99	0,95	1,87	3,65	1,97	6,41

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PN_SG.xls
28NOV2019 10:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PN_SG.xls
28NOV2019 10:14

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	42	53,8	36	46,2	2,83	1,87	4,57	7,56	5,55	19,32
Sex	Male	29	37,2	18	62,1	11	37,9	1,87	0,95	4,37	4,57	2,73	7,39
	Female	49	62,8	24	49,0	25	51,0	3,71	2,73	7,56	16,56	7,39	26,71
Age	18-64	62	79,5	32	51,6	30	48,4	2,83	1,87	5,55	8,25	5,55	19,38
	65-74	14	17,9	8	57,1	6	42,9	3,71	0,92	7,39	7,39	3,71	19,32
	>=75	2	2,6	2	100,0			1,87	1,87	3,71	2,79	1,87	3,71
Race	White	35	44,9	18	51,4	17	48,6	2,79	1,87	7,56	15,28	4,57	19,38
	Other	43	55,1	24	55,8	19	44,2	2,83	0,95	5,55	7,39	3,71	13,90
Region	America (AM)	22	28,2	15	68,2	7	31,8	2,30	0,95	7,39	7,39	2,73	16,56

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PO_SG.xls
28NOV2019 10:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	7	41,2	10	58,8	6,51	1,87	19,38	19,38	6,51	NE
	Asia (AS)	39	50,0	20	51,3	19	48,7	2,79	0,95	4,57	7,39	3,71	26,71
ECOG Performance Status	0	30	38,5	20	66,7	10	33,3	1,91	0,95	6,51	7,39	3,65	16,56
	1	38	48,7	20	52,6	18	47,4	3,71	2,14	7,39	8,25	4,57	19,32
	2	10	12,8	2	20,0	8	80,0	2,73	0,95	NE	NE	2,73	NE
Number of Prior Anticancer Therapies	None	31	39,7	20	64,5	11	35,5	3,65	1,87	7,39	7,39	3,71	15,28
	1	3	3,8	1	33,3	2	66,7	0,95	0,95	NE	NE	0,95	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PO_SG.xls
28NOV2019 10:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	21	47,7	23	52,3	2,73	0,95	6,51	7,56	4,57	26,71
Prior Treatment	Naïve	31	39,7	20	64,5	11	35,5	3,65	1,87	7,39	7,39	3,71	15,28
	Previously Treated	47	60,3	22	46,8	25	53,2	2,14	0,95	6,51	7,56	4,57	26,71
Molecular Testing Results	Local	35	44,9	20	57,1	15	42,9	2,73	1,87	5,55	7,39	3,65	16,56
	Central	43	55,1	22	51,2	21	48,8	3,65	0,95	7,39	12,91	4,57	19,38

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PO_SG.xls
28NOV2019 10:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	40	54,1	34	45,9	2,79	1,87	5,55	7,56	6,51	19,32
	No	4	5,1	2	50,0	2	50,0	3,71	NE	NE	3,71	NE	NE
Investigator Measurable CNS Disease	Yes	8	10,3	3	37,5	5	62,5	4,57	2,79	NE	7,39	2,79	NE
	No	70	89,7	39	55,7	31	44,3	2,83	1,87	4,57	7,56	4,57	19,32

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PO_SG.xls
28NOV2019 10:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13PO_SG.xls
28NOV2019 10:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	78	100,0	28	35,9	50	64,1	4,60	1,91	15,67	23,00	15,67	NE
Sex	Male	29	37,2	10	34,5	19	65,5	8,31	4,63	17,51	17,51	12,02	NE
	Female	49	62,8	18	36,7	31	63,3	3,20	1,84	23,00	27,56	17,51	NE
Age	18-64	62	79,5	24	38,7	38	61,3	4,60	1,87	17,51	23,00	15,51	NE
	65-74	14	17,9	3	21,4	11	78,6	15,67	0,95	NE	NE	15,67	NE
	>=75	2	2,6	1	50,0	1	50,0	0,95	0,95	NE	NE	0,95	NE
Race	White	35	44,9	12	34,3	23	65,7	3,65	1,48	NE	NE	8,31	NE
	Other	43	55,1	16	37,2	27	62,8	4,63	2,14	17,51	23,00	15,51	27,56
Region	America (AM)	22	28,2	6	27,3	16	72,7	15,67	1,84	NE	NE	17,51	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13SM_SG.xls
28NOV2019 10:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	17	21,8	7	41,2	10	58,8	1,48	0,95	NE	NE	1,91	NE
	Asia (AS)	39	50,0	15	38,5	24	61,5	4,60	2,14	17,51	23,00	12,02	27,56
ECOG Performance Status	0	30	38,5	11	36,7	19	63,3	8,31	1,48	NE	NE	15,67	NE
	1	38	48,7	14	36,8	24	63,2	4,60	1,87	23,00	23,00	12,02	NE
	2	10	12,8	3	30,0	7	70,0	1,81	0,95	NE	3,65	1,81	NE
Number of Prior Anticancer Therapies	None	31	39,7	12	38,7	19	61,3	8,31	1,48	23,00	23,00	15,67	NE
	1	3	3,8			3	100,0	NE	NE	NE	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13SM_SG.xls
28NOV2019 10:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	44	56,4	16	36,4	28	63,6	3,71	1,87	15,51	27,56	5,55	27,56
Prior Treatment	Naïve	31	39,7	12	38,7	19	61,3	8,31	1,48	23,00	23,00	15,67	NE
	Previously Treated	47	60,3	16	34,0	31	66,0	3,71	1,87	15,51	27,56	12,02	27,56
Molecular Testing Results	Local	35	44,9	14	40,0	21	60,0	3,71	1,61	17,51	23,00	12,02	NE
	Central	43	55,1	14	32,6	29	67,4	4,60	1,91	27,56	27,56	17,51	27,56

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13SM_SG.xls
28NOV2019 10:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	74	94,9	27	36,5	47	63,5	3,71	1,87	15,67	27,56	15,67	NE
	No	4	5,1	1	25,0	3	75,0	23,00	NE	NE	23,00	NE	NE
Investigator Measurable CNS Disease	Yes	8	10,3	1	12,5	7	87,5	NE	0,89	NE	NE	0,89	NE
	No	70	89,7	27	38,6	43	61,4	3,71	1,91	15,67	23,00	15,51	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13SM_SG.xls
28NOV2019 10:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK
THIS LINE LEFT BLANK

		RXDX-101 600 mg/day (N=78)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D180_REE_LC13SM_SG.xls
28NOV2019 10:21

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	41	28,3	104	71,7	7,39	5,55	14,62	NE	23,23	NE
Sex	Male	52	35,9	16	30,8	36	69,2	5,55	2,76	NE	NE	14,62	NE
	Female	93	64,1	25	26,9	68	73,1	8,38	5,68	23,23	NE	18,43	NE
Age	18-64	109	75,2	31	28,4	78	71,6	7,39	5,55	23,23	NE	23,23	NE
	65-74	29	20,0	8	27,6	21	72,4	5,55	1,87	NE	18,43	14,62	NE
	>=75	7	4,8	2	28,6	5	71,4	0,95	0,95	NE	NE	0,95	NE
Race	White	60	41,4	20	33,3	40	66,7	7,39	3,65	18,43	23,23	10,22	NE
	Other	85	58,6	21	24,7	64	75,3	8,38	5,16	NE	NE	NE	NE
Region	America (AM)	40	27,6	10	25,0	30	75,0	10,22	6,47	NE	NE	23,23	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13CO_SG.xls
24JUN2020 19:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	10	29,4	24	70,6	7,39	1,87	NE	NE	18,43	NE
	Asia (AS)	71	49,0	21	29,6	50	70,4	5,55	2,76	NE	NE	14,62	NE
ECOG Performance Status	0	61	42,1	20	32,8	41	67,2	7,39	5,55	23,23	23,23	18,43	NE
	1	69	47,6	20	29,0	49	71,0	7,39	2,79	NE	NE	NE	NE
	2	15	10,3	1	6,7	14	93,3	NE	0,95	NE	NE	NE	NE
Number of Prior Anticancer Therapies	None	62	42,8	15	24,2	47	75,8	8,38	5,55	NE	NE	NE	NE
	1	4	2,8	1	25,0	3	75,0	5,49	5,49	NE	NE	5,49	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13CO_SG.xls
24JUN2020 19:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	79	54,5	25	31,6	54	68,4	7,39	1,87	14,62	23,23	14,62	NE
Prior Treatment	Naïve	62	42,8	15	24,2	47	75,8	8,38	5,55	NE	NE	NE	NE
	Previously Treated	83	57,2	26	31,3	57	68,7	7,39	2,76	14,62	23,23	14,62	NE
Molecular Testing Results	Local	75	51,7	16	21,3	59	78,7	10,22	7,39	NE	NE	23,23	NE
	Central	70	48,3	25	35,7	45	64,3	5,49	1,87	8,38	NE	8,38	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13CO_SG.xls
24JUN2020 19:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	39	28,9	96	71,1	7,39	5,55	18,43	NE	23,23	NE
	No	10	6,9	2	20,0	8	80,0	0,95	0,92	NE	NE	0,95	NE
Investigator Measurable CNS Disease	Yes	11	7,6	5	45,5	6	54,5	3,22	0,85	9,23	8,31	2,79	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13CO_SG.xls
24JUN2020 19:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	134	92,4	36	26,9	98	73,1	8,38	5,55	23,23	NE	23,23	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13CO_SG.xls
24JUN2020 19:44

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	72	49,7	73	50,3	0,99	0,95	1,87	7,39	3,65	21,16
Sex	Male	52	35,9	25	48,1	27	51,9	1,87	0,95	4,53	7,39	3,75	NE
	Female	93	64,1	47	50,5	46	49,5	0,99	0,95	1,81	5,55	1,87	21,16
Age	18-64	109	75,2	52	47,7	57	52,3	1,05	0,95	1,94	9,26	3,68	NE
	65-74	29	20,0	16	55,2	13	44,8	0,95	0,95	2,83	3,75	0,99	NE
	>=75	7	4,8	4	57,1	3	42,9	0,95	0,95	NE	1,87	0,95	NE
Race	White	60	41,4	26	43,3	34	56,7	1,87	1,02	4,73	15,67	4,67	NE
	Other	85	58,6	46	54,1	39	45,9	0,95	0,95	1,61	3,71	1,87	13,80
Region	America (AM)	40	27,6	24	60,0	16	40,0	1,18	0,95	2,83	4,53	1,87	21,16

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13DS_SG.xls
24JUN2020 19:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	12	35,3	22	64,7	1,87	0,95	NE	NE	4,73	NE
	Asia (AS)	71	49,0	36	50,7	35	49,3	0,95	0,95	1,81	6,47	1,94	NE
ECOG Performance Status	0	61	42,1	36	59,0	25	41,0	0,95	0,95	1,87	4,67	1,87	21,16
	1	69	47,6	35	50,7	34	49,3	1,02	0,95	2,73	8,31	2,76	NE
	2	15	10,3	1	6,7	14	93,3	NE	1,81	NE	NE	NE	NE
Number of Prior Anticancer Therapies	None	62	42,8	29	46,8	33	53,2	1,84	0,95	3,68	7,39	3,68	NE
	1	4	2,8	1	25,0	3	75,0	9,26	NE	NE	9,26	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13DS_SG.xls
24JUN2020 19:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	79	54,5	42	53,2	37	46,8	0,99	0,95	1,18	4,67	1,81	15,67
Prior Treatment	Naïve	62	42,8	29	46,8	33	53,2	1,84	0,95	3,68	7,39	3,68	NE
	Previously Treated	83	57,2	43	51,8	40	48,2	0,99	0,95	1,61	6,47	1,87	15,67
Molecular Testing Results	Local	75	51,7	42	56,0	33	44,0	0,99	0,95	1,87	3,71	1,87	21,16
	Central	70	48,3	30	42,9	40	57,1	1,81	0,95	3,68	13,80	4,73	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13DS_SG.xls
24JUN2020 19:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	68	50,4	67	49,6	1,02	0,95	1,87	7,39	3,65	21,16
	No	10	6,9	4	40,0	6	60,0	0,95	0,92	NE	4,53	0,95	NE
Investigator Measurable CNS Disease	Yes	11	7,6	3	27,3	8	72,7	1,81	0,95	NE	NE	1,81	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13DS_SG.xls
24JUN2020 19:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	134	92,4	69	51,5	65	48,5	0,99	0,95	1,87	6,47	2,83	21,16

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13DS_SG.xls
24JUN2020 19:46

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	82	56,6	63	43,4	1,87	1,08	2,76	5,55	3,65	11,93
Sex	Male	52	35,9	32	61,5	20	38,5	1,08	0,95	2,79	5,55	2,76	15,67
	Female	93	64,1	50	53,8	43	46,2	1,87	1,81	2,79	5,55	2,83	11,99
Age	18-64	109	75,2	56	51,4	53	48,6	1,87	1,81	2,79	8,31	4,24	17,54
	65-74	29	20,0	20	69,0	9	31,0	0,95	0,95	2,33	2,81	1,05	12,19
	>=75	7	4,8	6	85,7	1	14,3	1,91	0,95	4,63	4,60	1,91	12,91
Race	White	60	41,4	31	51,7	29	48,3	1,18	0,95	2,33	8,31	1,91	NE
	Other	85	58,6	51	60,0	34	40,0	1,94	1,81	2,79	4,63	2,83	11,93
Region	America (AM)	40	27,6	27	67,5	13	32,5	1,05	0,95	2,79	5,09	2,33	15,67

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13DY_SG.xls
24JUN2020 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	16	47,1	18	52,9	1,87	0,95	11,07	11,93	3,65	NE
	Asia (AS)	71	49,0	39	54,9	32	45,1	1,87	1,81	2,79	4,63	2,79	8,44
ECOG Performance Status	0	61	42,1	37	60,7	24	39,3	1,81	0,99	2,83	5,49	2,83	15,67
	1	69	47,6	41	59,4	28	40,6	1,87	1,05	2,79	5,55	2,79	11,07
	2	15	10,3	4	26,7	11	73,3	1,81	0,95	NE	NE	1,81	NE
Number of Prior Anticancer Therapies	None	62	42,8	37	59,7	25	40,3	1,84	1,02	2,83	6,44	2,83	12,19
	1	4	2,8	2	50,0	2	50,0	0,95	0,95	17,54	17,54	0,95	17,54

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13DY_SG.xls
24JUN2020 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	79	54,5	43	54,4	36	45,6	1,87	1,05	2,76	5,55	2,79	11,07
Prior Treatment	Naïve	62	42,8	37	59,7	25	40,3	1,84	1,02	2,83	6,44	2,83	12,19
	Previously Treated	83	57,2	45	54,2	38	45,8	1,87	0,99	2,76	5,55	2,79	12,91
Molecular Testing Results	Local	75	51,7	42	56,0	33	44,0	1,91	0,99	2,79	6,44	2,83	15,67
	Central	70	48,3	40	57,1	30	42,9	1,87	1,05	2,33	5,49	2,76	12,19

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13DY_SG.xls
24JUN2020 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	76	56,3	59	43,7	1,87	1,08	2,76	6,44	4,24	11,99
	No	10	6,9	6	60,0	4	40,0	0,95	0,92	2,79	2,76	0,95	2,79
Investigator Measurable CNS Disease	Yes	11	7,6	5	45,5	6	54,5	1,35	0,85	11,07	9,23	0,89	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13DY_SG.xls
24JUN2020 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	134	92,4	77	57,5	57	42,5	1,87	1,08	2,76	5,55	3,55	11,99

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13DY_SG.xls
24JUN2020 19:49

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	16	11,0	129	89,0	NE	24,80	NE	NE	NE	NE
Sex	Male	52	35,9	9	17,3	43	82,7	NE	5,49	NE	NE	NE	NE
	Female	93	64,1	7	7,5	86	92,5	NE	24,80	NE	NE	NE	NE
Age	18-64	109	75,2	11	10,1	98	89,9	NE	24,80	NE	NE	NE	NE
	65-74	29	20,0	3	10,3	26	89,7	NE	4,63	NE	NE	NE	NE
	>=75	7	4,8	2	28,6	5	71,4	7,36	3,94	NE	NE	7,36	NE
Race	White	60	41,4	6	10,0	54	90,0	NE	NE	NE	NE	NE	NE
	Other	85	58,6	10	11,8	75	88,2	24,80	24,80	NE	NE	24,80	NE
Region	America (AM)	40	27,6	1	2,5	39	97,5	NE	NE	NE	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13HA_SG.xls
24JUN2020 19:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	3	8,8	31	91,2	NE	NE	NE	NE	NE	NE
	Asia (AS)	71	49,0	12	16,9	59	83,1	24,80	8,38	NE	NE	24,80	NE
ECOG Performance Status	0	61	42,1	7	11,5	54	88,5	NE	NE	NE	NE	NE	NE
	1	69	47,6	8	11,6	61	88,4	24,80	24,80	NE	NE	24,80	NE
	2	15	10,3	1	6,7	14	93,3	NE	3,68	NE	NE	NE	NE
Number of Prior Anticancer Therapies	None	62	42,8	5	8,1	57	91,9	NE	NE	NE	NE	NE	NE
	1	4	2,8	1	25,0	3	75,0	5,49	5,49	NE	NE	5,49	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13HA_SG.xls
24JUN2020 19:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	79	54,5	10	12,7	69	87,3	24,80	24,80	NE	24,80	24,80	NE
Prior Treatment	Naïve	62	42,8	5	8,1	57	91,9	NE	NE	NE	NE	NE	NE
	Previously Treated	83	57,2	11	13,3	72	86,7	24,80	24,80	NE	24,80	24,80	NE
Molecular Testing Results	Local	75	51,7	5	6,7	70	93,3	NE	NE	NE	NE	NE	NE
	Central	70	48,3	11	15,7	59	84,3	24,80	8,38	NE	NE	24,80	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13HA_SG.xls
24JUN2020 19:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	16	11,9	119	88,1	NE	24,80	NE	NE	NE	NE
	No	10	6,9			10	100,0	NE	NE	NE	NE	NE	NE
Investigator Measurable CNS Disease	Yes	11	7,6			11	100,0	NE	NE	NE	NE	NE	NE
	No	134	92,4	16	11,9	118	88,1	NE	24,80	NE	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13HA_SG.xls
24JUN2020 19:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13HA_SG.xls
24JUN2020 19:58

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	53	36,6	92	63,4	4,63	3,65	8,31	22,11	11,99	NE
Sex	Male	52	35,9	17	32,7	35	67,3	5,55	2,79	11,99	NE	10,18	NE
	Female	93	64,1	36	38,7	57	61,3	4,63	2,79	9,33	22,11	10,18	NE
Age	18-64	109	75,2	36	33,0	73	67,0	5,55	2,99	10,18	23,00	13,83	NE
	65-74	29	20,0	14	48,3	15	51,7	3,71	1,87	7,43	11,96	3,75	13,11
	>=75	7	4,8	3	42,9	4	57,1	9,33	1,02	NE	11,99	9,33	NE
Race	White	60	41,4	22	36,7	38	63,3	5,55	3,65	10,18	NE	9,33	NE
	Other	85	58,6	31	36,5	54	63,5	3,75	2,14	11,96	22,11	11,96	NE
Region	America (AM)	40	27,6	14	35,0	26	65,0	5,52	3,75	13,11	NE	9,33	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13HR_SG.xls
24JUN2020 20:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	13	38,2	21	61,8	5,55	1,87	11,96	NE	8,31	NE
	Asia (AS)	71	49,0	26	36,6	45	63,4	2,79	1,91	12,91	22,11	8,31	NE
ECOG Performance Status	0	61	42,1	22	36,1	39	63,9	5,55	3,65	12,91	NE	10,18	NE
	1	69	47,6	27	39,1	42	60,9	4,63	2,14	9,33	13,83	9,33	NE
	2	15	10,3	4	26,7	11	73,3	2,73	0,92	NE	10,18	2,73	NE
Number of Prior Anticancer Therapies	None	62	42,8	26	41,9	36	58,1	4,57	3,65	9,33	23,00	9,33	NE
	1	4	2,8	1	25,0	3	75,0	10,18	NE	NE	10,18	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13HR_SG.xls
24JUN2020 20:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	79	54,5	26	32,9	53	67,1	7,36	1,94	11,99	22,11	11,99	NE
Prior Treatment	Naïve	62	42,8	26	41,9	36	58,1	4,57	3,65	9,33	23,00	9,33	NE
	Previously Treated	83	57,2	27	32,5	56	67,5	7,36	1,94	11,99	22,11	11,99	NE
Molecular Testing Results	Local	75	51,7	27	36,0	48	64,0	3,65	2,14	8,31	23,00	8,31	NE
	Central	70	48,3	26	37,1	44	62,9	7,39	3,81	11,96	13,83	11,96	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13HR_SG.xls
24JUN2020 20:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	48	35,6	87	64,4	4,63	3,65	8,31	22,11	11,99	NE
	No	10	6,9	5	50,0	5	50,0	1,87	1,02	12,91	12,91	1,87	23,00
Investigator Measurable CNS Disease	Yes	11	7,6	4	36,4	7	63,6	4,63	1,87	NE	6,47	4,63	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13HR_SG.xls
24JUN2020 20:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	134	92,4	49	36,6	85	63,4	4,63	2,99	9,33	22,11	11,99	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13HR_SG.xls
24JUN2020 20:01

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	49	33,8	96	66,2	5,55	3,71	11,01	20,34	11,99	NE
Sex	Male	52	35,9	22	42,3	30	57,7	3,71	1,87	9,26	19,35	8,34	NE
	Female	93	64,1	27	29,0	66	71,0	9,30	3,81	12,06	23,00	12,06	NE
Age	18-64	109	75,2	33	30,3	76	69,7	9,26	3,71	12,06	23,00	12,06	NE
	65-74	29	20,0	12	41,4	17	58,6	3,91	1,31	11,01	11,01	4,63	20,34
	>=75	7	4,8	4	57,1	3	42,9	2,79	1,87	NE	3,94	2,79	NE
Race	White	60	41,4	20	33,3	40	66,7	4,57	2,79	14,82	NE	11,01	NE
	Other	85	58,6	29	34,1	56	65,9	6,44	3,71	10,18	20,34	10,18	NE
Region	America (AM)	40	27,6	14	35,0	26	65,0	5,55	3,71	20,34	20,34	14,82	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PA_SG.xls
24JUN2020 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	9	26,5	25	73,5	2,83	1,87	NE	NE	NE	NE
	Asia (AS)	71	49,0	26	36,6	45	63,4	6,44	1,81	10,18	11,07	9,30	NE
ECOG Performance Status	0	61	42,1	22	36,1	39	63,9	8,34	3,81	11,01	20,34	11,01	NE
	1	69	47,6	25	36,2	44	63,8	3,94	2,69	11,99	14,82	11,99	NE
	2	15	10,3	2	13,3	13	86,7	NE	0,95	NE	NE	NE	NE
Number of Prior Anticancer Therapies	None	62	42,8	22	35,5	40	64,5	6,47	3,71	19,35	20,34	11,01	NE
	1	4	2,8			4	100,0	NE	NE	NE	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PA_SG.xls
24JUN2020 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	79	54,5	27	34,2	52	65,8	3,94	1,31	10,18	14,82	10,18	NE
Prior Treatment	Naïve	62	42,8	22	35,5	40	64,5	6,47	3,71	19,35	20,34	11,01	NE
	Previously Treated	83	57,2	27	32,5	56	67,5	4,63	1,31	11,07	NE	11,07	NE
Molecular Testing Results	Local	75	51,7	22	29,3	53	70,7	9,26	3,71	19,35	20,34	14,82	NE
	Central	70	48,3	27	38,6	43	61,4	3,81	1,87	10,18	11,99	10,18	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PA_SG.xls
24JUN2020 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	45	33,3	90	66,7	6,44	3,71	11,01	20,34	11,99	NE
	No	10	6,9	4	40,0	6	60,0	2,79	0,92	23,00	23,00	2,79	23,00
Investigator Measurable CNS Disease	Yes	11	7,6	5	45,5	6	54,5	0,92	0,85	12,06	11,01	0,89	NE
	No	134	92,4	44	32,8	90	67,2	6,44	3,71	11,01	20,34	14,82	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PA_SG.xls
24JUN2020 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PA_SG.xls
24JUN2020 20:03

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	33	22,8	112	77,2	13,80	8,31	20,27	27,56	20,24	NE
Sex	Male	52	35,9	11	21,2	41	78,8	20,27	5,49	NE	NE	20,27	NE
	Female	93	64,1	22	23,7	71	76,3	13,80	8,31	20,24	27,56	15,61	27,56
Age	18-64	109	75,2	27	24,8	82	75,2	13,80	6,87	20,27	27,56	20,24	NE
	65-74	29	20,0	5	17,2	24	82,8	NE	4,57	NE	NE	NE	NE
	>=75	7	4,8	1	14,3	6	85,7	NE	9,20	NE	NE	9,20	NE
Race	White	60	41,4	14	23,3	46	76,7	13,83	6,87	NE	NE	20,24	NE
	Other	85	58,6	19	22,4	66	77,6	13,80	5,49	27,56	27,56	17,58	27,56
Region	America (AM)	40	27,6	9	22,5	31	77,5	17,58	8,31	NE	NE	20,24	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PC_SG.xls
24JUN2020 20:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	6	17,6	28	82,4	NE	4,63	NE	NE	NE	NE
	Asia (AS)	71	49,0	18	25,4	53	74,6	9,23	5,49	27,56	27,56	13,80	27,56
ECOG Performance Status	0	61	42,1	16	26,2	45	73,8	12,81	4,63	NE	NE	20,24	NE
	1	69	47,6	15	21,7	54	78,3	13,83	9,23	27,56	27,56	15,61	27,56
	2	15	10,3	2	13,3	13	86,7	6,51	0,95	NE	NE	6,51	NE
Number of Prior Anticancer Therapies	None	62	42,8	14	22,6	48	77,4	13,83	6,51	NE	NE	20,27	NE
	1	4	2,8			4	100,0	NE	NE	NE	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PC_SG.xls
24JUN2020 20:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	79	54,5	19	24,1	60	75,9	13,80	6,47	27,56	27,56	15,61	27,56
Prior Treatment	Naïve	62	42,8	14	22,6	48	77,4	13,83	6,51	NE	NE	20,27	NE
	Previously Treated	83	57,2	19	22,9	64	77,1	13,80	6,47	27,56	27,56	20,24	27,56
Molecular Testing Results	Local	75	51,7	15	20,0	60	80,0	17,58	8,31	NE	NE	20,24	NE
	Central	70	48,3	18	25,7	52	74,3	12,81	6,47	27,56	27,56	15,61	27,56

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PC_SG.xls
24JUN2020 20:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	29	21,5	106	78,5	13,83	9,23	27,56	27,56	20,24	NE
	No	10	6,9	4	40,0	6	60,0	3,71	2,79	NE	6,47	3,71	NE
Investigator Measurable CNS Disease	Yes	11	7,6	3	27,3	8	72,7	12,81	0,85	17,58	17,58	12,81	17,58
	No	134	92,4	30	22,4	104	77,6	13,83	6,87	27,56	27,56	20,27	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PC_SG.xls
24JUN2020 20:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PC_SG.xls
24JUN2020 20:06

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	91	62,8	54	37,2	0,99	0,95	1,84	3,75	2,79	6,41
Sex	Male	52	35,9	33	63,5	19	36,5	0,95	0,95	1,87	3,68	1,05	10,15
	Female	93	64,1	58	62,4	35	37,6	1,05	0,95	2,53	4,24	2,79	6,47
Age	18-64	109	75,2	70	64,2	39	35,8	0,99	0,95	1,84	3,68	2,69	5,52
	65-74	29	20,0	15	51,7	14	48,3	1,81	0,95	6,41	10,15	3,68	18,50
	>=75	7	4,8	6	85,7	1	14,3	0,95	0,95	2,89	2,10	0,95	11,99
Race	White	60	41,4	42	70,0	18	30,0	1,02	0,95	1,97	2,89	1,97	4,63
	Other	85	58,6	49	57,6	36	42,4	0,99	0,95	2,53	5,49	2,76	11,99
Region	America (AM)	40	27,6	26	65,0	14	35,0	0,95	0,95	1,05	1,87	0,99	11,07

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PN_SG.xls
24JUN2020 20:08

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	23	67,6	11	32,4	1,77	0,95	2,79	3,65	1,97	7,56
	Asia (AS)	71	49,0	42	59,2	29	40,8	0,99	0,95	2,79	4,70	2,79	11,99
ECOG Performance Status	0	61	42,1	42	68,9	19	31,1	0,95	0,95	1,77	3,68	1,77	10,15
	1	69	47,6	42	60,9	27	39,1	1,84	0,95	2,79	5,49	2,79	7,56
	2	15	10,3	7	46,7	8	53,3	0,95	0,92	2,73	2,35	0,95	NE
Number of Prior Anticancer Therapies	None	62	42,8	39	62,9	23	37,1	1,77	0,95	2,79	4,24	2,79	14,03
	1	4	2,8	3	75,0	1	25,0	0,95	0,95	3,65	0,95	0,95	3,65

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PN_SG.xls
24JUN2020 20:08

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	79	54,5	49	62,0	30	38,0	0,99	0,95	1,87	3,78	1,87	6,41
Prior Treatment	Naïve	62	42,8	39	62,9	23	37,1	1,77	0,95	2,79	4,24	2,79	14,03
	Previously Treated	83	57,2	52	62,7	31	37,3	0,95	0,95	1,81	3,65	1,87	6,41
Molecular Testing Results	Local	75	51,7	46	61,3	29	38,7	0,95	0,95	0,99	2,76	0,99	6,47
	Central	70	48,3	45	64,3	25	35,7	1,97	1,81	3,68	5,52	3,68	10,15

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PN_SG.xls
24JUN2020 20:08

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	86	63,7	49	36,3	0,99	0,95	1,87	3,78	2,79	6,41
	No	10	6,9	5	50,0	5	50,0	0,95	0,92	18,50	2,79	0,95	18,50
Investigator Measurable CNS Disease	Yes	11	7,6	5	45,5	6	54,5	1,87	0,95	15,87	2,79	1,87	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PN_SG.xls
24JUN2020 20:08

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	134	92,4	86	64,2	48	35,8	0,99	0,95	1,81	3,78	2,79	6,41

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PN_SG.xls
24JUN2020 20:08

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	71	49,0	74	51,0	2,76	1,87	3,71	10,09	7,39	16,56
Sex	Male	52	35,9	28	53,8	24	46,2	1,87	0,95	3,68	7,39	3,65	15,28
	Female	93	64,1	43	46,2	50	53,8	3,71	2,14	7,36	14,82	7,39	19,38
Age	18-64	109	75,2	50	45,9	59	54,1	2,79	1,87	5,55	14,82	7,39	19,38
	65-74	29	20,0	15	51,7	14	48,3	3,71	0,99	7,36	7,39	3,71	19,32
	>=75	7	4,8	6	85,7	1	14,3	1,87	0,95	3,71	2,10	1,87	10,09
Race	White	60	41,4	28	46,7	32	53,3	2,79	1,87	6,51	15,28	5,55	19,38
	Other	85	58,6	43	50,6	42	49,4	2,73	0,99	3,71	7,39	5,55	13,90
Region	America (AM)	40	27,6	23	57,5	17	42,5	1,87	0,95	7,39	8,25	3,65	16,56

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PO_SG.xls
24JUN2020 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	11	32,4	23	67,6	7,36	3,68	19,38	19,38	15,28	NE
	Asia (AS)	71	49,0	37	52,1	34	47,9	2,73	1,02	3,71	5,55	3,71	19,32
ECOG Performance Status	0	61	42,1	35	57,4	26	42,6	1,87	0,95	3,71	7,39	3,71	16,56
	1	69	47,6	33	47,8	36	52,2	3,71	2,14	7,36	14,82	7,36	19,32
	2	15	10,3	3	20,0	12	80,0	2,76	0,95	NE	NE	2,76	NE
Number of Prior Anticancer Therapies	None	62	42,8	37	59,7	25	40,3	2,78	1,08	3,71	7,39	3,71	13,90
	1	4	2,8	1	25,0	3	75,0	0,95	0,95	NE	NE	0,95	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PO_SG.xls
24JUN2020 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	79	54,5	33	41,8	46	58,2	2,73	1,87	7,39	16,56	7,39	26,71
Prior Treatment	Naïve	62	42,8	37	59,7	25	40,3	2,78	1,08	3,71	7,39	3,71	13,90
	Previously Treated	83	57,2	34	41,0	49	59,0	2,73	1,87	7,39	16,56	7,39	26,71
Molecular Testing Results	Local	75	51,7	35	46,7	40	53,3	2,73	1,87	4,57	13,90	5,55	19,32
	Central	70	48,3	36	51,4	34	48,6	3,65	1,87	5,55	7,56	5,55	19,38

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PO_SG.xls
24JUN2020 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	68	50,4	67	49,6	2,73	1,87	3,84	8,38	7,36	16,56
	No	10	6,9	3	30,0	7	70,0	3,71	0,95	NE	NE	3,71	NE
Investigator Measurable CNS Disease	Yes	11	7,6	3	27,3	8	72,7	4,57	2,79	NE	NE	4,57	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PO_SG.xls
24JUN2020 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	No	134	92,4	68	50,7	66	49,3	2,73	1,87	3,71	8,38	7,36	16,56

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13PO_SG.xls
24JUN2020 20:11

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	145	100,0	56	38,6	89	61,4	3,71	1,87	5,55	23,00	15,51	NE
Sex	Male	52	35,9	23	44,2	29	55,8	4,53	0,99	9,17	15,51	8,31	NE
	Female	93	64,1	33	35,5	60	64,5	3,71	1,84	9,23	23,00	17,51	NE
Age	18-64	109	75,2	44	40,4	65	59,6	3,71	1,84	8,31	23,00	12,02	NE
	65-74	29	20,0	8	27,6	21	72,4	4,73	1,84	NE	NE	9,17	NE
	>=75	7	4,8	4	57,1	3	42,9	0,95	0,95	NE	4,73	0,95	NE
Race	White	60	41,4	20	33,3	40	66,7	3,75	1,48	17,51	NE	9,17	NE
	Other	85	58,6	36	42,4	49	57,6	2,76	1,81	8,38	15,67	9,23	27,56
Region	America (AM)	40	27,6	18	45,0	22	55,0	1,87	0,99	8,31	17,51	4,63	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13SM_SG.xls
24JUN2020 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	Europe (EU)	34	23,4	9	26,5	25	73,5	5,55	1,91	NE	NE	NE	NE
	Asia (AS)	71	49,0	29	40,8	42	59,2	3,71	1,81	9,17	15,51	9,17	27,56
ECOG Performance Status	0	61	42,1	28	45,9	33	54,1	1,89	0,99	8,31	17,51	8,31	NE
	1	69	47,6	25	36,2	44	63,8	4,60	1,87	12,02	23,00	12,02	NE
	2	15	10,3	3	20,0	12	80,0	3,65	0,95	NE	NE	3,65	NE
Number of Prior Anticancer Therapies	None	62	42,8	24	38,7	38	61,3	4,73	1,87	15,67	17,51	9,23	NE
	1	4	2,8			4	100,0	NE	NE	NE	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13SM_SG.xls
24JUN2020 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
	2 or More	79	54,5	32	40,5	47	59,5	1,91	1,18	4,60	15,51	4,63	27,56
Prior Treatment	Naïve	62	42,8	24	38,7	38	61,3	4,73	1,87	15,67	17,51	9,23	NE
	Previously Treated	83	57,2	32	38,6	51	61,4	1,91	1,18	4,63	27,56	5,55	27,56
Molecular Testing Results	Local	75	51,7	34	45,3	41	54,7	1,84	0,99	4,63	15,67	4,73	NE
	Central	70	48,3	22	31,4	48	68,6	4,73	3,65	27,56	27,56	17,51	27,56

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13SM_SG.xls
24JUN2020 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
BICR-confirmed measurable disease at baseline and have received at least one dose of entrectinib	Yes	135	93,1	53	39,3	82	60,7	3,71	1,84	5,55	17,51	12,02	NE
	No	10	6,9	3	30,0	7	70,0	4,53	0,92	23,00	23,00	4,53	23,00
Investigator Measurable CNS Disease	Yes	11	7,6	1	9,1	10	90,9	NE	0,89	NE	NE	NE	NE
	No	134	92,4	55	41,0	79	59,0	3,71	1,84	4,73	17,51	12,02	27,56

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13SM_SG.xls
24JUN2020 20:17

POPULATION: Efficacy-Evaluable ROS1 Population

ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
Time to event analysis (efficacy)

		RXDX-101 600 mg/day (N=145)											
		Patients		Patients with Event		Censored		Time to event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/program/eff_tte.sas

Output:
root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180/prod/output/eff_tte_D194_REE_LC13SM_SG.xls
24JUN2020 20:17

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	30	29	27	22	21	19	11	6	4	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	4	4	5	7	8	9	17	22	24	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_LC13CO_SG1.pdf
10SEP2019 22:57

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	22	18	17	12	11	10	6	2	1	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	5	6	7	10	10	11	14	18	19	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_LC13DS_SG1.pdf
10SEP2019 23:18

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	24	21	17	14	13	10	5	2	1	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	4	4	6	9	10	12	16	19	19	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_LC13DY_SG1.pdf
10SEP2019 23:39

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	32	31	27	25	24	22	14	9	6	1	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	5	6	9	11	12	14	22	27	30	35	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_LC13HA_SG1.pdf
11SEP2019 1:06

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	27	25	22	20	20	18	10	6	4	1	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	5	5	8	9	9	9	15	19	21	24	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_LC13HR_SG1.pdf
11SEP2019 1:28

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	28	25	23	20	19	16	10	7	4	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	4	4	5	8	9	11	17	20	23	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_LC13PA_SG1.pdf
11SEP2019 1:53

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	29	28	24	19	17	16	8	5	4	1	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	3	3	5	8	9	10	16	19	20	23	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_LC13PC_SG1.pdf
11SEP2019 2:14

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	20	18	14	11	11	11	8	5	4	1	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	4	4	6	7	7	7	10	13	14	17	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_LC13PN_SG1.pdf
11SEP2019 2:37

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	26	23	20	14	13	11	8	3	1	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	5	5	6	9	10	12	15	20	22	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_LC13PO_SG1.pdf
11SEP2019 2:58

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk														
RXDX-101 600 mg/day	37	26	23	20	18	16	15	7	5	2	NE	NE	NE	NE
Patients censored														
RXDX-101 600 mg/day	0	5	6	8	10	11	12	20	22	25	NE	NE	NE	NE

Clinical cut-off: 31MAY2018

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_NDA_STREAM2/prod/output/g_eff_tte_NDA_REE_LC13SM_SG1.pdf
11SEP2019 3:41

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	57	48	40	34	30	22	11	6	3	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	10	15	20	24	27	35	45	49	52	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_LC13CO_SG1.pdf
29NOV2019 21:21

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	38	29	23	19	16	12	10	3	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	10	16	20	23	25	28	30	36	38	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_LC13DS_SG1.pdf
28NOV2019 10:53

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	41	33	27	21	18	11	7	2	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	8	11	16	20	21	26	30	34	NE	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_LC13DY_SG1.pdf
28NOV2019 11:04

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	63	55	49	43	39	30	19	9	4	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	11	16	22	28	32	41	52	62	66	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_LC13HA_SG1.pdf
28NOV2019 11:50

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	56	42	35	29	24	18	13	6	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	10	16	19	22	24	30	35	40	44	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_LC13HR_SG1.pdf
28NOV2019 12:01

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	51	39	30	25	23	17	11	6	4	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	10	16	22	25	26	32	36	40	42	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_LC13PA_SG1.pdf
28NOV2019 12:12

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	61	49	40	34	29	22	12	4	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	9	17	23	28	30	36	44	52	54	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_LC13PC_SG1.pdf
29NOV2019 21:38

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	35	25	20	17	15	11	9	3	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	9	12	13	15	17	18	19	24	25	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_LC13PN_SG1.pdf
28NOV2019 12:30

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	50	36	23	21	17	12	7	3	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	10	15	21	23	25	28	30	34	35	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_LC13PO_SG1.pdf
28NOV2019 12:41

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	78	54	43	36	32	28	19	11	3	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	10	15	21	25	28	33	41	48	49	NE	NE	NE

Enrollment cut-off: 30NOV2017, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D180_REE_LC13SM_SG1.pdf
28NOV2019 13:03

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Coughing
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	109	93	60	41	32	22	11	6	3	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	16	25	49	66	74	84	94	98	101	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_LC13CO_SG1.pdf
24JUN2020 21:11

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Dysphagia
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	75	56	36	23	16	12	10	3	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	15	25	41	53	59	62	64	70	72	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_LC13DS_SG1.pdf
24JUN2020 21:24

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Dyspnoea
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	78	59	39	24	18	11	7	2	NE	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	12	18	33	44	48	53	57	61	NE	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_LC13DY_SG1.pdf
24JUN2020 21:37

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Haemoptysis
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	121	105	77	53	41	30	19	9	4	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	17	28	54	77	89	100	111	121	125	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_LC13HA_SG1.pdf
24JUN2020 22:24

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Alopecia
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	105	80	55	36	25	18	13	6	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	16	28	47	61	69	76	81	86	90	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_LC13HR_SG1.pdf
24JUN2020 22:36

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in arm or shoulder
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	107	83	57	32	23	17	11	6	4	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	15	29	51	69	76	82	86	90	92	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_LC13PA_SG1.pdf
24JUN2020 22:47

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in chest
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	118	97	65	42	31	22	12	4	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	15	30	57	78	86	93	101	109	111	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_LC13PC_SG1.pdf
24JUN2020 22:58

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Peripheral neuropathy
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	70	48	32	21	15	11	9	3	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	14	21	32	39	44	45	46	51	52	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_LC13PN_SG1.pdf
24JUN2020 23:10

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Pain in other parts
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	93	69	40	25	17	12	7	3	1	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	15	25	44	58	63	66	68	72	73	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_LC13PO_SG1.pdf
24JUN2020 23:22

POPULATION: Efficacy-Evaluable ROS1 Population
ENDPOINT: EORTC QLQ-LC13 Sore mouth
MODEL: --
STUDY: STARTRK-2
KM plot, subgroup: All



Patients at risk													
RXDX-101 600 mg/day	145	100	76	56	38	28	19	11	3	2	NE	NE	NE
Patients censored													
RXDX-101 600 mg/day	0	14	25	43	58	67	72	80	87	88	NE	NE	NE

Enrollment cut-off: 31OCT2018, Clinical cut-off: 01MAY2019

Program: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_BASE/prod/program/g_eff_tte.sas
Output: root/clinical_studies/RO7102122/CDT30222/GO40782/data_analysis/ACE_D180_STREAM2/prod/output/g_eff_tte_D194_REE_LC13SM_SG1.pdf
25JUN2020 9:12